A	O
method	O
of	O
catalyzing	O
in	O
vitro	O
reactions	O
using	O
seeds	O
containing	O
enhanced	O
amounts	O
of	O
enzymes	O
is	O
disclosed	O
.	O

The	O
method	O
involves	O
adding	O
transgenic	O
,	O
non	O
-	O
wild	O
type	O
seeds	O
,	O
preferably	O
in	O
a	O
ground	O
form	O
,	O
to	O
a	O
reaction	O
mixture	O
and	O
allowing	O
the	O
enzymes	O
in	O
the	O
seeds	O
to	O
increase	O
the	O
rate	O
of	O
reaction	O
.	O

By	O
directly	O
adding	O
the	O
seeds	O
to	O
the	O
reaction	O
mixture	O
the	O
method	O
provides	O
a	O
solution	O
to	O
the	O
expensive	O
and	O
problematic	O
process	O
of	O
extracting	O
and	O
purifying	O
the	O
enzyme	O
.	O

Methods	O
of	O
treatment	O
are	O
also	O
provided	O
whereby	O
a	O
subject	O
lacking	O
a	O
sufficient	O
supply	O
of	O
an	O
enzyme	O
is	O
administered	O
the	O
enzyme	O
in	O
the	O
form	O
of	O
seeds	O
containing	O
enhanced	O
amounts	O
of	O
the	O
enzyme	O
.	O

Production	O
of	O
enzymes	O
in	O
seeds	O
and	O
their	O
use	O

This	O
invention	O
relates	O
to	O
compositions	O
comprising	O
a	O
tramadol	B
material	O
and	O
any	O
of	O
codeine	B
,	O
oxycodone	B
or	O
hydrocodone	B
,	O
and	O
their	O
use	O
.	O

The	O
compositions	O
are	O
pharmacologically	O
useful	O
in	O
treating	O
pain	O
,	O
diarrhea	O
and	O
tussive	O
conditions	O
.	O

The	O
compositions	O
are	O
also	O
subject	O
to	O
less	O
side	O
-	O
effects	O
as	O
compared	O
to	O
pure	O
opiate	O
based	O
compositions	O
,	O
such	O
as	O
abuse	O
liability	O
,	O
tolerance	O
,	O
constipation	O
and	O
respiratory	O
depression	O
.	O

Furthermore	O
,	O
where	O
the	O
components	O
,	O
i.e.	O
,	O
a	O
tramadol	B
material	O
and	O
any	O
of	O
codeine	B
,	O
oxycodone	B
or	O
hydrocodone	B
,	O
of	O
the	O
compositions	O
are	O
within	O
certain	O
ratios	O
the	O
pharmacological	O
effects	O
of	O
the	O
compositions	O
are	O
superadditive	O
(	O
synergistic	O
)	O
.	O

Compositions	O
comprising	O
a	O
tramadol	B
material	O
and	O
any	O
of	O
codeine	B
,	O
oxycodone	B
or	O
hydrocodone	B
and	O
their	O
use	O

A	O
method	O
of	O
treating	O
a	O
host	O
using	O
taxol	B
comprising	O
administering	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
to	O
the	O
host	O
being	O
treated	O
with	O
taxol	B
.	O

The	O
present	O
inventive	O
method	O
allows	O
for	O
increased	O
levels	O
of	O
taxol	B
to	O
be	O
administered	O
to	O
the	O
host	O
in	O
the	O
treatment	O
of	O
various	O
conditions	O
,	O
particularly	O
with	O
respect	O
to	O
ovarian	O
tumors	O
.	O

Use	O
of	O
g	O
-	O
csf	O
for	O
treating	O
taxol	B
side	O
-	O
effects	O

This	O
invention	O
relates	O
to	O
genetic	O
constructs	O
which	O
comprise	O
an	O
enhancer	O
-	O
promoter	O
region	O
which	O
is	O
responsive	O
to	O
radiation	O
,	O
and	O
at	O
least	O
one	O
structural	O
gene	O
whose	O
expression	O
is	O
controlled	O
by	O
the	O
enhancer	O
-	O
promoter	O
.	O

This	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
destroying	O
,	O
altering	O
,	O
or	O
inactivating	O
cells	O
in	O
target	O
tissue	O
by	O
delivering	O
the	O
genetic	O
constructs	O
to	O
the	O
cells	O
of	O
the	O
tissues	O
and	O
inducing	O
expressing	O
of	O
the	O
structural	O
gene	O
or	O
genes	O
in	O
the	O
construct	O
by	O
exposing	O
the	O
tissues	O
to	O
ionizing	O
radiation	O
.	O

This	O
invention	O
is	O
useful	O
for	O
treating	O
patients	O
with	O
cancer	O
,	O
clotting	O
disorders	O
,	O
myocardial	O
infarction	O
,	O
and	O
other	O
diseases	O
for	O
which	O
target	O
tissues	O
can	O
be	O
identified	O
and	O
for	O
which	O
gene	O
expression	O
of	O
the	O
construct	O
within	O
the	O
target	O
tissues	O
can	O
alleviate	O
the	O
disease	O
or	O
disorder	O
.	O

Control	O
of	O
gene	O
expression	O
by	O
ionizing	O
radiation	O

This	O
invention	O
relates	O
to	O
bis	B
mono-	I
and/or	I
bicyclic	I
aryl	I
and/or	I
heteroaryl	I
compounds	O
exhibiting	O
protein	O
tyrosine	B
kinase	O
inhibition	O
activity	O
.	O

More	O
specifically	O
,	O
it	O
relates	O
to	O
the	O
method	O
of	O
inhibiting	O
abnormal	O
cell	O
proliferation	O
in	O
a	O
patient	O
suffering	O
from	O
a	O
disorder	O
characterized	O
by	O
such	O
proliferation	O
comprising	O
the	O
administration	O
thereto	O
of	O
an	O
EGF	O
and/or	O
PDGF	O
receptor	O
inhibiting	O
effective	O
amount	O
of	O
said	O
bis	B
mono-	I
and/or	I
bicyclic	I
aryl	I
and/or	I
heteroaryl	I
compound	O
and	O
to	O
the	O
preparation	O
of	O
said	O
compounds	O
and	O
their	O
use	O
in	O
pharmaceutical	O
compositions	O
used	O
in	O
this	O
method	O
.	O

Bis	B
mono	I
-	I
and	I
bicyclic	I
aryl	I
and	I
heteroaryl	I
compounds	O
which	O
inhibit	O
egf	O
and/or	O
pdgf	O
receptor	O
tyrosine	O
kinase	O

The	O
invention	O
relates	O
to	O
carbazolone	B
derivatives	O
of	O
the	O
formula	O
wherein	O
A	O
represents	O
a	O
group	O
of	O
formula	O
wherein	O
R	O
represents	O
a	O
hydroxyl	B
or	O
2-methyl-1H	B
-	I
imidazol-1-yl	I
group	O
;	O
B	O
represents	O
a	O
group	O
of	O
formula	O
wherein	O
R1	O
represents	O
hydrogen	B
or	O
a	O
methyl	B
or	O
ethyl	B
group	O
;	O
or	O
A	O
and	O
B	O
together	O
form	O
a	O
group	O
of	O
formula	O
wherein	O
R2	O
means	O
a	O
methyl	B
or	O
ethyl	B
group	O
;	O
or	O
A	O
and	O
B	O
together	O
form	O
a	O
group	O
of	O
formula	O
The	O
above	O
compounds	O
are	O
useful	O
intermediates	O
in	O
the	O
:	O
syn	O
-	O
thesis	O
of	O
ondansetron	B
of	O
formula	O
chemically	O
9-methyl-3-	B
[	I
(	I
2-methyl-1H	I
-	I
imidazol-1-yl	I
)	I
methyl	I
]	I
--1,2,3,9-tetrahydro-4H	I
-	I
carbazol-4-one	I
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
novel	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
A	O
and	O
Bare	O
the	O
same	O
as	O
in	O
formula	O
(	O
I	O
)	O
but	O
B	O
may	O
be	O
also	O
hydrogen	B
.	O

Thus	O
,	O
this	O
novel	O
process	O
is	O
suitable	O
for	O
the	O
preparation	O
of	O
ondansetron	B
itself	O
.	O

Carbazolone	B
derivatives	O
and	O
process	O
for	O
preparing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
oligoribonucleotide	B
analogs	O
with	O
terminal	O
3'-3	O
'	O
and/or	O
5'-5	O
'	O
internucleotide	O
linkages	O
.	O

This	O
modification	O
stabilizes	O
the	O
molecules	O
altered	O
in	O
this	O
way	O
,	O
including	O
ribozymes	O
,	O
without	O
adversely	O
altering	O
their	O
properties	O
,	O
including	O
,	O
where	O
appropriate	O
,	O
catalytic	O
activities	O
.	O

Oligoribonucleotide	B
and	O
ribozyme	O
analogs	O
with	O
terminal	O
3'-3	O
'	O
and/or	O
5'-5	O
'	O
linkages	O

Disclosed	O
are	O
acyclic	B
phosphonomethoxyalkyl	I
substituted	O
,	O
alkenyl	B
and	I
alkynyl	I
purine	I
and	I
pyrimidine	I
derivatives	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
said	O
purine	B
and	O
pyrimidine	B
derivatives	O
.	O

The	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
viral	O
infections	O
,	O
especially	O
those	O
caused	O
by	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Antiviral	O
acyclic	B
phosphonomethoxyalkyl	I
substituted	O
,	O
alkenyl	B
and	I
alkynyl	I
purine	I
and	I
pyrimidine	I
derivatives	O

Aqueous	O
injection	O
solution	O
that	O
is	O
ready	O
-	O
for	O
-	O
injection	O
of	O
a	O
water	O
-	O
soluble	O
,	O
physiologically	O
well	O
-	O
tolerated	O
azosemide	B
salt	O
of	O
an	O
organic	O
amide	B
,	O
which	O
contains	O
an	O
organic	O
solvent	O
and	O
if	O
desired	O
,	O
a	O
physiologically	O
well	O
-	O
tolerated	O
buffer	O
and	O
it	O
concerns	O
a	O
process	O
for	O
the	O
production	O
of	O
such	O
an	O
injection	O
solution	O
in	O
which	O
the	O
salt	O
is	O
dissolved	O
in	O
a	O
mixture	O
which	O
contains	O
water	O
,	O
an	O
organic	O
solvent	O
and	O
,	O
if	O
desired	O
,	O
a	O
physiologically	O
well	O
-	O
tolerated	O
buffer	O
.	O

Injection	O
solutions	O
of	O
azosemide	B
which	O
are	O
ready	O
for	O
injection	O

Disclosed	O
is	O
a	O
method	O
for	O
reducing	O
non	O
-	O
ischemic	O
NMDA	O
receptor	O
-	O
mediated	O
neuronal	O
damage	O
in	O
a	O
mammal	O
by	O
administering	O
to	O
the	O
mammal	O
a	O
compound	O
of	O
the	O
formula	O
shown	O
in	O
Fig.	O
1	O
(	O
or	O
a	O
physiologically	O
-	O
acceptable	O
salt	O
thereof	O
)	O
,	O
wherein	O
R1	O
includes	O
an	O
amino	B
group	O
,	O
R2-R17	O
are	O
independently	O
H	B
or	O
a	O
short	O
chain	O
aliphatic	B
group	O
comprising	O
1	O
-	O
5	O
carbons	B
,	O
and	O
R4	O
and	O
R10	O
also	O
may	O
(	O
independently	O
)	O
be	O
a	O
halogen	B
or	O
an	O
acyl	B
group	O
.	O

Also	O
disclosed	O
is	O
a	O
screen	O
for	O
antagonists	O
of	O
NMDA	O
receptor	O
mediated	O
neurotoxicity	O
which	O
have	O
an	O
enhanced	O
prospect	O
for	O
being	O
clinically	O
tolerated	O
and	O
selective	O
against	O
such	O
neurotoxicity	O
.	O

Method	O
of	O
preventing	O
nmda	O
receptor	O
-	O
mediated	O
neuronal	O
damage	O

Compound	O
having	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
one	O
of	O
X	O
and	O
Y	O
is	O
CH2	B
and	O
the	O
other	O
one	O
is	O
CH2	B
,	O
O	B
or	O
S	B
;	O
R1	O
is	O
an	O
aliphatic	O
hydrocarbon	B
group	O
,	O
arylalkyl	B
,	O
aryl	B
,	O
a	O
sulphonyl	B
group	O
,	O
a	O
carbonate	B
group	O
or	O
R11R12NCO-	B
where	O
R11	O
and	O
R12	O
are	O
selected	O
form	O
hydrogen	B
and	O
a	O
hydrocarbon	B
group	O
;	O
R2	O
is	O
hydrogen	B
or	O
a	O
hydrocarbon	B
group	O
;	O
R3-R5	O
an	O
independently	O
selected	O
from	O
hydrogen	B
,	O
halogen	B
,	O
alkyl	B
,	O
alkoxy	B
,	O
alkylthio	B
,	O
hydroxy	B
,	O
alkylsulphonyl	B
,	O
cyano	B
,	O
trifluoromethyl	B
,	O
cycloalkyl	B
,	O
cycloalkylalkyl	B
or	O
nitro	B
;	O
R6	O
and	O
R7	O
are	O
each	O
hydrogen	B
or	O
lower	O
alkyl	B
or	O
they	O
are	O
linked	O
together	O
to	O
constitute	O
a	O
carbocyclic	B
ring	O
;	O
R8	O
and	O
R9	O
are	O
independently	O
hydrogen	B
,	O
a	O
hydrocarbon	B
group	O
or	O
a	O
group	O
1a	O
wherein	O
R13	O
is	O
hydrogen	B
,	O
or	O
a	O
hydrocarbon	B
group	O
,	O
W	O
is	O
O	B
or	O
S	B
,	O
and	O
r	O
is	O
2	O
-	O
6	O
;	O
R8	O
and	O
R9	O
are	O
linked	O
together	O
thereby	O
forming	O
alkylene	B
group;have	O
effect	O
at	O
central	O
5-HT1A	O
receptors	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
psychosis	O
,	O
anxiety	O
disorders	O
,	O
depression	O
,	O
impulse	O
control	O
disorders	O
,	O
alcohol	B
abuse	O
,	O
aggression	O
,	O
ischaemic	O
diseases	O
,	O
side	O
effects	O
induced	O
by	O
conventional	O
antipsychotic	O
agents	O
or	O
cardiovascular	O
disorders	O
.	O

Aminomethylindans	B
,	O
-benzofurans	O
and	O
-benzothiophenes	O

Compounds	O
of	O
the	O
formula	O
(	O
see	O
formula	O
I	O
)	O
wherein	O
Q	O
is	O
(	O
see	O
formula	O
II	O
)	O
or	O
-XR	O
'	O
;	O
X	O
is	O
oxygen	B
or	O
sulphur	B
;	O
R1	O
is	O
hydrogen	B
,	O
halogen	B
,	O
C1-C4	B
alkyl	I
or	O
C1-C4	B
alkoxy	I
;	O
R2	O
is	O
hydrogen	B
,	O
halogen	B
,	O
C1-C4	B
alkyl	I
,	O
C1-C4	B
alkoxy	I
,	O
C3-C4	B
alkenyloxy	I
,	O
C3-C4	B
alkynyloxy	I
,	O
mono-	B
,	I
di-	I
or	I
tri	I
-	I
halomethyl	I
,	O
trifuluoromethoxy	B
,	O
C1-C4	B
alkylthio	I
,	O
C3-C4	O
branched	O
alkylthio	B
,	O
nitro	B
,	O
or	O
cyano	B
;	O
R3	O
is	O
hydrogen	B
or	O
C1-C4	B
alkyl	I
;	O
R	O
4	O
is	O
C3-C6	B
alkenyl	I
,	O
C3-C6	B
alkynyl	I
,	O
C1-C8	B
haloalkyl	I
,	O
C1-C8	B
alkoxyalkyl	I
,	O
C1-C8	B
alkylthioalkyl	I
,	O
C1-C8	B
hydroxyalkyl	I
,	O
C1-C8	B
acyloxyalkyl	I
,	O
C1-C8	B
aroyloxyalkyl	I
,	O
C1-C8	B
carboxyalkyl	I
,	O
C1-C8	B
alkylcarboxyalkyl	I
,	O
C6-C12	B
arylcarboxyalkyl	I
,	O
C1-C8	B
aminoalkyl	I
,	O
C1-C8	B
alkylaminoalkyl	I
,	O
C1-C8	B
dialkylaminoalkyl	I
,	O
C1-C8	B
trialkylsilylalkyl	I
,	O
wherein	O
each	O
of	O
the	O
aforementioned	O
alkyl	B
moieties	O
may	O
be	O
straight	O
-	O
chain	O
or	O
branched	O
;	O
C3-C8	B
cycloalkyl	I
,	O
C1-C6	B
alkylphenyl	I
,	O
C7-C12	B
arylalkyl	I
,	O
C7-C12	B
alkarylalkyl	I
,	O
or	O
heterocyclylalkyl	B
,	O
wherein	O
the	O
heterocyclic	B
moiety	O
is	O
morpholinyl	B
,	O
piperidinyl	B
,	O
pyrrolidinyl	B
,	O
piperazinyl	B
,	O
oxiranyl	B
,	O
oxetanyl	B
,	O
furanyl	B
,	O
tetrahydropyranyl	B
or	O
tetrahydrofuranyl	B
;	O
R	O
'	O
is	O
C1-C8	B
haloalkyl	I
,	O
C1-C8	B
alkoxyalkyl	I
,	O
C1-C8	B
alkylthioalkyl	I
,	O
C1-C8	B
hydroxyalkyl	I
,	O
C1-C8	B
acyloxyalkyl	I
,	O
C1-C8	B
aroyloxyalkyl	I
,	O
C1-C8	B
aminoalkyl	I
,	O
C1-C8	B
alkylaminoalkyl	I
,	O
C1-C8	B
dialkylaminoalkyl	I
,	O
C1-C8	B
trialkylsilylalkyl	I
,	O
wherein	O
each	O
of	O
the	O
aforementioned	O
alkyl	B
moieties	O
may	O
be	O
straight	O
-	O
chain	O
or	O
branched	O
;	O
C1-C6	B
alkylphenyl	I
,	O
C7-C12	B
arylalkyl	I
,	O
C7-C12	B
alkarylalkyl	I
,	O
or	O
heterocyclylalkyl	B
,	O
wherein	O
the	O
heterocyclic	B
moiety	O
is	O
morpholinyl	B
,	O
piperidinyl	B
,	O
pyrrolidinyl	B
,	O
piperazinyl	B
,	O
oxiranyl	B
,	O
oxetanyl	B
,	O
furanyl	B
,	O
tetrahydropyranyl	B
or	O
tetrahydrofuranyl	B
;	O
R5	O
is	O
hydrogen	B
,	O
halo	B
,	O
methyl	B
,	O
mono-	B
,	I
di-	I
or	I
tri	I
-	I
halomethyl	I
;	O
and	O
R6	O
is	O
an	O
aliphatic	O
or	O
cyclic	O
side	O
chain	O
as	O
defined	O
herein	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
inhibiting	O
the	O
growth	O
or	O
replication	O
of	O
retroviruses	O
such	O
as	O
HIV	O
.	O

Anti	O
-	O
viral	O
aromatic	B
o	O
-	O
alkylated	O
oximes	B
,	O
ethers	B
and	O
thioethers	B

The	O
invention	O
relates	O
to	O
novel	O
1,6-naphthyridonecarboxylic	B
acid	I
derivatives	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
antibacterial	O
compositions	O
and	O
feed	O
additives	O
in	O
which	O
they	O
are	O
present	O
,	O
and	O
to	O
novel	O
intermediates	O
for	O
the	O
preparation	O
of	O
these	O
active	O
compounds	O
.	O

The	O
novel	O
compounds	O
are	O
useful	O
as	O
antibacterial	O
agents	O
and	O
have	O
the	O
structure:	O
(	O
see	O
formula	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
X1	O
and	O
Z	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
.	O

1,6-naphthyridonecarboxylic	B
acid	I
derivatives	O

The	O
present	O
invention	O
is	O
a	O
pharmaceutical	O
composition	O
used	O
as	O
an	O
antiviral	O
agent	O
,	O
a	O
diarrheal	O
remedy	O
,	O
an	O
anti	O
-	O
ulcer	O
agent	O
,	O
an	O
anti	O
-	O
inflammatory	O
agent	O
,	O
an	O
anti	O
-	O
allergic	O
agent	O
and	O
an	O
agent	O
for	O
promoting	O
the	O
proliferation	O
of	O
Bifidobacteria	O
,	O
characterized	O
by	O
containing	O
a	O
sialic	B
acid	I
derivative	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
method	O
for	O
producing	O
a	O
sialic	B
acid	I
derivative	O
of	O
the	O
present	O
invention	O
is	O
characterized	O
in	O
that	O
an	O
almond	O
or	O
apricot	O
seed	O
is	O
added	O
to	O
an	O
avian	O
egg	O
yolk	O
,	O
by	O
which	O
the	O
desired	O
product	O
can	O
easily	O
be	O
obtained	O
in	O
a	O
high	O
yield	O
.	O

Pharmaceutical	O
composition	O
containing	O
sialic	B
acid	I
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
analogues	O
of	O
purine	B
nucleosides	I
containing	O
a	O
ring	O
-	O
expanded	O
(	O
""""	O
fat	O
""""	O
)	O
heterocyclic	B
ring	O
,	O
in	O
place	O
of	O
purine	B
,	O
and	O
an	O
unmodified	O
or	O
modified	O
sugar	B
residue	O
,	O
pharmaceutically	O
acceptable	O
derivatives	O
of	O
such	O
compositions	O
,	O
as	O
well	O
as	O
methods	O
of	O
use	O
thereof	O
.	O

In	O
particular	O
,	O
these	O
compositions	O
may	O
be	O
utilized	O
in	O
the	O
treatment	O
of	O
certain	O
cancers	O
,	O
bacterial	O
,	O
fungal	O
,	O
parasitic	O
,	O
and	O
virai	O
infections	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
and	O
hepatitis	O
.	O

Ring	O
-	O
expanded	O
nucleosides	B
and	O
nucleotides	B

The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
for	O
-	O
mula	O
(	O
I	O
)	O
and	O
their	O
therapeutic	O
use	O
.	O

Alkoxy	B
alkyl	I
carbamates	I
from	O
imidazo	B
(	I
1,2-a	I
)	I
pyridines	I

The	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
A	O
)	O
,	O
or	O
a	O
bioprecursor	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
phosphate	B
ester	I
and/or	O
acyl	B
deriva	O
-	O
tive	O
of	O
either	O
of	O
the	O
foregoing	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
(	O
including	O
prophylaxis	O
)	O
of	O
HHV-7	O
infection	O
.	O

Use	O
of	O
2-amino	B
purine	I
derivatives	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
human	O
herpes	O
virus	O
7	O
infection	O

There	O
are	O
described	O
compounds	O
of	O
the	O
formula	O

I	O
(	O
see	O
formula	O
I	O
)	O
and	O
their	O
pharmaceutically	O
tolerable	O
salts	O
.	O

These	O
are	O
effective	O
inhibitors	O
of	O
the	O
cellular	O
sodium	B
proton	O
antiporter	O
(	O
Na+	B
/	O
H+	B
exchanger	O
)	O
.	O

They	O
are	O
therefore	O
outstandingly	O
suitable	O
for	O
the	O
treatment	O
of	O
all	O
diseases	O
which	O
can	O
be	O
attributed	O
to	O
increased	O
Na+	B
/	O
H+	B
exchange	O
.	O

Substituted	O
benzyloxycarbonylguanidines	B
,	O
process	O
for	O
their	O
preparation	O
,	O
their	O
use	O
as	O
a	O
medicament	O
or	O
diagnostic	O
,	O
and	O
medicament	O
containing	O
them	O

The	O
invention	O
relates	O
to	O
pharmaceutical	O
prepara-	O
tions	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
inflamma-	O
tory	O
bowel	O
disorders	O
and	O
contain	O
at	O
least	O
one	O
compound	O
of	O
the	O
formula	O
I	O
in	O
which	O
R	O
is	O
Ar	B
,	O
cycloalkyl	B
having	O
3	O
-	O
7	O
C	B
atoms	O
or	O
cyclo-	B
alkylalkyl	I
having	O
4	O
-	O
8	O
C	B
atoms	O
,	O
R	O
2	O
is	O
Ar	B
,	O
R1	O
and	O
R2	O
together	O
are	O
also	O
Kappa	O
-	O
opiate	O
agonists	O
for	O
inflammatory	O
bowel	O
disorders	O

This	O
invention	O
provides	O
a	O
sustained	O
release	O
composition	O
comprising	O
a	O
PLGA	B
matrix	O
,	O
a	O
bioactive	O
agent	O
,	O
and	O
a	O
quaternary	B
ammonium	I
surfactant	O
,	O
in	O
which	O
the	O
release	O
profile	O
of	O
the	O
bioactive	O
agent	O
from	O
the	O
PLGA	B
matrix	O
is	O
controlled	O
by	O
the	O
concentration	O
of	O
the	O
quaternary	B
ammonium	I
surfactant	O
.	O

Sustained	O
release	O
composition	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
pteridine	O
derivatives	O
of	O
the	O
formula	O

I	O
in	O
which	O
X	O
is	O
0	O
or	O
NH	B
and	O
R4	O
,	O
for	O
example	O
,	O
is	O
hydrogen	B
,	O
phenyl	B
or	O
the	O
radical	O
R4a	B
-	I
CH2-	I
and	O
R4a	O
,	O
for	O
example	O
,	O
is	O
hydrogen	B
,	O
(	B
C1-C4	I
)	I
-alkylmercapto	I
,	O
the	O
radical	O
-NR11R12	B
or	O
the	O
radical	O
-OR13	B
,	O
and	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R11	O
,	O
R12	O
and	O
R13	O
have	O
the	O
meanings	O
given	O
in	O
claim	O
1	O
,	O
which	O
are	O
nitric	B
oxide	I
synthase	O
inhibitors	O
,	O
for	O
the	O
treatment	O
of	O
diseases	O
which	O
are	O
caused	O
by	O
an	O
increased	O
nitric	B
oxide	I
level	O
.	O

Use	O
of	O
tetrahydropteridine	B
derivatives	O
as	O
no	O
-	O
synthase	O
inhibitors	O

Substituted	O
sulfonimidamides	B
,	O
processes	O
for	O
their	O
preparation	O
,	O
their	O
use	O
as	O
a	O
medicament	O
or	O
diagnostic	O
,	O
and	O
medicament	O
comprising	O
them	O
Sulfonimidamides	B
of	O
the	O
formula	O
I	O
(	O
see	O
formula	O
I	O
)	O
in	O
which	O
at	O
least	O
one	O
of	O
the	O
three	O
substituents	O
R	O
(	O
1	O
)	O
,	O
R	O
(	O
2	O
)	O
and	O
R	O
(	O
3	O
)	O
is	O
a	O
benzoylguanidine	B
,	O
and	O
in	O
which	O
the	O
other	O
substituents	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
claims	O
,	O
are	O
outstandingly	O
suitable	O
as	O
medicaments	O
having	O
action	O
on	O
the	O
cardiovascular	O
system	O
;	O
that	O
is	O
as	O
antiarrhythmic	O
pharmaceuticals	O
having	O
a	O
cardioprotective	O
component	O
as	O
well	O
as	O
for	O
treating	O
ischemically	O
induced	O
damage	O
;	O
also	O
in	O
operative	O
interventions	O
,	O
such	O
as	O
organ	O
transplantation	O
.	O

Substituted	O
sulfonimidamides	B
,	O
processes	O
for	O
their	O
preparation	O
,	O
their	O
use	O
as	O
a	O
medicament	O
or	O
diagnostic	O
,	O
and	O
medicament	O
comprising	O
them	O

A	O
device	O
for	O
delivering	O
a	O
heparinic	O
anticoagulant	O
across	O
a	O
mucosal	O
surface	O
in	O
order	O
to	O
achieve	O
or	O
maintain	O
a	O
therapeutically	O
effective	O
blood	O
level	O
of	O
the	O
heparinic	O
anticoagulant	O
.	O

The	O
device	O
involves	O
a	O
matrix	O
containing	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
heparinic	O
anticoagulant	O
,	O
and	O
a	O
mucoadhesive	O
or	O
other	O
mechanism	O
for	O
maintaining	O
the	O
matrix	O
in	O
contact	O
with	O
the	O
mucosal	O
surface	O
for	O
a	O
time	O
sufficient	O
to	O
allow	O
release	O
of	O
the	O
heparinic	O
anticoagulant	O
to	O
the	O
mucosal	O
surface	O
.	O

Transmucosal	O
delivery	O
system	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
(	O
see	O
formula	O
I	O
)	O
~and	O
the	O
quaternary	O
ammonium	O
derivatives	O
thereof	O
,	O
especially	O
compounds	O
in	O
which	O
L	O
represents	O
a	O
group	O
(	O
see	O
formula	O
II	O
)	O
have	O
tachykinin	O
receptor	O
antagonist	O
activity	O
and	O
exhibit	O
an	O
activity	O
against	O
both	O
the	O
NK1	O
receptors	O
and	O
the	O
NK2	O
receptors	O
.	O

Heterocyclic	O
compounds	O
having	O
tachykinin	O
receptor	O
antagonist	O
activity	O
,	O
their	O
preparation	O
and	O
their	O
use	O

A	O
method	O
of	O
separating	O
the	O
racemate	O
of	O
tramadol	B
is	O
disclosed	O
.	O

A	O
method	O
of	O
separating	O
the	O
racemate	O
of	O
tramadol	B

The	O
invention	O
concerns	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
.	O

These	O
compounds	O
are	O
novel	O
,	O
effective	O
PDE	O
--	O
inhibitors	O
.	O

Dihydrobenzofuranes	B

Compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
their	O
salts	O
and	O
solvates	O
are	O
antifungal	O
agents	O
and	O
as	O
such	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
fungal	O
infections	O
.	O

Pharmaceutical	O
compositions	O
including	O
these	O
compounds	O
and	O
processes	O
for	O
their	O
preparation	O
are	O
also	O
provided	O
.	O

New	O
pyrimidone	B
derivatives	O
with	O
antifungal	O
activity	O

Methods	O
and	O
compositions	O
for	O
treating	O
pathogens	O
in	O
material	O
are	O
described	O
,	O
including	O
methods	O
of	O
decontaminating	O
human	O
fluids	O
prior	O
to	O
processing	O
in	O
the	O
clinical	O
laboratory	O
and	O
methods	O
for	O
decontaminating	O
blood	O
products	O
prior	O
to	O
in	O
vivo	O
use	O
.	O

The	O
techniques	O
handle	O
large	O
volumes	O
of	O
human	O
serum	O
without	O
imparing	O
the	O
testing	O
results	O
.	O

Novel	O
compounds	O
for	O
photodecontaminating	O
biological	O
material	O
are	O
also	O
contemplated	O
which	O
are	O
compatible	O
with	O
clinical	O
testing	O
,	O
in	O
that	O
they	O
do	O
not	O
interfere	O
with	O
serum	O
analytes	O
.	O

Treating	O
red	O
blood	O
cell	O
solutions	O
with	O
anti	O
-	O
viral	O
agents	O

Novel	O
inhibitors	O
of	O
.beta	O
.-	O
glucuronidase	O

Compounds	O
of	O
the	O
formulae	O
I	O
and	O
II	O
Novel	O
inhibitors	O
of	O
.beta	O
.-	O
glucuronidase	O

The	O
present	O
invention	O
relates	O
to	O
facilitating	O
detoxification	O
and	O
treatment	O
of	O
substance	O
addiction	O
.	O

Accordingly	O
,	O
the	O
present	O
invention	O
is	O
broadly	O
directed	O
to	O
a	O
method	O
for	O
treating	O
substance	O
addiction	O
subject	O
comprising	O
administering	O
ketamine	O
in	O
an	O
amount	O
effective	O
to	O
facilitate	O
detoxification	O
or	O
assist	O
in	O
overcoming	O
substance	O
addiction	O
,	O
or	O
both	O
.	O

The	O
present	O
invention	O
is	O
broadly	O
directed	O
to	O
transmucosal	O
administration	O
of	O
ketamine	O
.	O

In	O
a	O
further	O
embodiment	O
,	O
the	O
present	O
invention	O
provides	O
for	O
parenteral	O
administration	O
of	O
ketamine	O
.	O

Treatment	O
with	O
ketamine	O
advantageously	O
allows	O
for	O
patient	O
self	O
administration	O
of	O
the	O
drug	O
,	O
which	O
provides	O
for	O
management	O
or	O
treatment	O
of	O
a	O
substance	O
addiction	O
on	O
an	O
outpatient	O
basis	O
.	O

Moreover	O
,	O
ketamine	O
administration	O
in	O
nasal	O
sprays	O
and	O
inhalers	O
are	O
generally	O
socially	O
acceptable	O
.	O

In	O
a	O
specific	O
example	O
,	O
a	O
dedicated	O
smoker	O
was	O
able	O
to	O
reduce	O
her	O
craving	O
from	O
three	O
packs	O
of	O
ciga	O
rettes	O
a	O
day	O
.	O

Use	O
of	O
ketamine	O
for	O
facilitating	O
detoxification	O
and	O
treatment	O
of	O
smoking	O
addiction	O
,	O
and	O
device	O
therefor	O

The	O
use	O
of	O
a	O
composition	O
comprising	O
2,4-dichlorobenzyl	B
alcohol	I
and	O
amylmetacresol	B
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
HIV	O
viral	O
infections	O
.	O

2,4-dichlorobenzyl	B
alcohol	I
and	O
amylmetacresol	B
against	O
hiv	O
infection	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
(	O
see	O
formula	O
I	O
)	O
which	O
are	O
inhibitors	O
of	O
the	O
adhesion	O
and	O
migration	O
of	O
leucocytes	O
and/or	O
antagonists	O
of	O
the	O
adhesion	O
receptor	O
VLA-4	O
which	O
belongs	O
to	O
the	O
group	O
of	O
integrins	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
the	O
use	O
of	O
compounds	O
of	O
the	O
formula	O
I	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
caused	O
by	O
an	O
undesired	O
extent	O
of	O
leucocyte	O
adhesion	O
and/or	O
leucocyte	O
migration	O
or	O
which	O
are	O
associated	O
therewith	O
or	O
in	O
which	O
cell	O
-	O
cell	O
or	O
cell	O
-	O
matrix	O
interactions	O
which	O
are	O
based	O
on	O
interactions	O
of	O
VLA-4	O
receptors	O
with	O
their	O
ligands	O
play	O
a	O
part	O
,	O
for	O
example	O
of	O
inflammatory	O
processes	O
,	O
of	O
rheumatoid	O
arthritis	O
or	O
of	O
allergic	O
disorders	O
,	O
and	O
also	O
to	O
the	O
use	O
of	O
compounds	O
of	O
the	O
formula	O
I	O
for	O
the	O
production	O
of	O
pharmaceuticals	O
for	O
use	O
in	O
such	O
diseases	O
,	O
and	O
to	O
pharmaceutical	O
preparations	O
which	O
contain	O
the	O
compounds	O
of	O
the	O
formula	O
I.	O
Novel	O
heterocycles	B
as	O
inhibitors	O
of	O
leucocyte	O
adhesion	O
and	O
as	O
vla-4	O
antagonists	O

Aromatic	B
acid	I
diamide	I
compounds	O
with	O
antigastrin	O
activity	O
are	O
described	O
which	O
may	O
be	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
Ar	B
is	O
a	O
phenyl	B
group	O
or	O
an	O
unsubstituted	O
pyridyl	B
group	O
or	O
a	O
pyridyl	B
group	O
mono-	O
or	O
disubstituted	O
with	O
a	O
group	O
selected	O
independently	O
from	O
C1-C4	B
alkyl	I
,	O
C1-C4	B
alkoxy	I
,	O
phenyl	B
,	O
cyano	B
,	O
nitro	B
,	O
amino	B
,	O
hydroxyl	B
,	O
or	O
halogens	B
or	O
a	O
naphthyl	B
group	O
,	O
a	O
quinolinyl	B
group	O
.	O

Aromatic	B
acid	I
diamides	I
with	O
antigastrin	O
activity	O
,	O
a	O
method	O
for	O
their	O
preparation	O
and	O
their	O
pharmaceutical	O
use	O

A	O
compound	O
of	O
the	O
formula	O
(	O
see	O
formula	O
I	O
)	O
where	O
R1	O
is	O
the	O
radical	O
of	O
the	O
formula	O
II	O
or	O
III	O
(	O
see	O
formula	O
II	O
et	O
III	O
)	O
is	O
suitable	O
for	O
the	O
production	O
of	O
a	O
pharmaceutical	O
for	O
the	O
treatment	O
of	O
inflammations	O
,	O
carcinomatous	O
diseases	O
or	O
autoimmune	O
diseases	O
.	O

A	O
compound	O
of	O
the	O
formula	O
IV	O
(	O
see	O
formula	O
IV	O
)	O
is	O
suitable	O
for	O
the	O
production	O
of	O
specific	O
antibodies	O
against	O
a	O
compound	O
of	O
the	O
formula	O
I	O
for	O
the	O
discovery	O
of	O
specific	O
-	O
binding	O
proteins	O
from	O
cell	O
extracts	O
,	O
serum	O
,	O
blood	O
or	O
synovial	O
fluids	O
,	O
for	O
the	O
purification	O
of	O
proteins	O
,	O
for	O
the	O
modification	O
of	O
microtiter	O
plates	O
or	O
for	O
the	O
preparation	O
of	O
chromatography	O
material	O
,	O
in	O
particular	O
of	O
affinity	O
chromatography	O
material	O
,	O
and	O
for	O
use	O
in	O
diagnostics	O
.	O

Isoxazole	B
and	O
crotonamide	B
derivatives	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
and	O
diagnostics	O

The	O
present	O
invention	O
relates	O
to	O
new	O
piperazine	B
derivatives	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
or	O
a	O
R2	O
are	O
the	O
same	O
or	O
different	O
or	O
a	O
each	O
represent	O
a	O
hydrogen	B
atom	O
,	O
a	O
substituted	O
or	O
unsub	O
-	O
stituted	O
C1-C8	B
alkyl	I
group	O
,	O
a	O
substituted	O
or	O
unsub	O
-	O
stituted	O
C3-C6	B
cycloalkyl	I
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
C2-C8	B
unsaturated	I
alkyl	I
.	O

group	O
,	O
a	O
ketone	B
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
aryl	B
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
C1-C4	B
alkoxy	I
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
arylhydroxy	B
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
amino	B
group	O
,	O
a	O
C1-C4	B
ester	I
group	O
,	O
a	O
C1-C4	B
thioester	I
group	O
,	O
a	O
thiol	B
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
carboxyl	B
.	O

group	O
,	O
an	O
epoxy	B
group	O
,	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
C1-C4	B
thio	I
-	I
alkoxy	I
group	O
,	O
or	O
R1	O
or	O
a	O
R2	O
are	O
fused	O
to	O
form	O
a	O
C3-C4	O
saturated	O
or	O
unsaturated	O
chain	O
;	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
or	O
a	O
R7	O
are	O
the	O
same	O
or	O
different	O
or	O
a	O
each	O
represent	O
a	O
hydrogen	B
atom	O
,	O
a	O
halogen	B
atom	O
,	O
a	O
hydroxy	B
group	O
,	O
a	O
nitro	O
group	O
,	O
a	O
C1-C4	B
ester	I
group	O
,	O
a	O
lower	O
alkyl	B
group	O
,	O
a	O
C1-C4	B
thio	I
-	I
alkyl	I
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
C3-C6	B
cycloalkyl	I
group	O
,	O
a	O
lower	O
alkoxy	B
group	O
,	O
a	O
C1-C4	B
thioalkoxy	I
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
aryl	B
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
arylalkoxy	B
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkylamino	B
group	O
,	O
or	O
a	O
lower	O
alkyl	B
substituted	O
or	O
unsubstituted	O
carbamate	B
group	O
;	O
or	O
two	O
adjacent	O
groups	O
among	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
or	O
a	O
R7	O
are	O
bonded	O
with	O
each	O
other	O
to	O
form	O
a	O
1,2-phenylene	B
or	O
2,3-naphthylene	B
group	O
;	O
X	O
is	O
an	O
oxygen	B
or	O
sulfur	B
atom	O
,	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
imino	B
group	O
;	O
Y	O
is	O
bonded	O
at	O
the	O
3-position	O
or	O
4-position	O
of	O
the	O
aromatic	B
ring	O
or	O
a	O
represents	O
an	O
oxygen	B
atom	O
or	O
-NR8-	B
in	O
which	O
R8	O
has	O
the	O
same	O
meaning	O
as	O
R3	O
;	O
Z	O
is	O
a	O
hydroxy	B
group	O
,	O
a	O
lower	O
alkoxy	B
group	O
,	O
a	O
C1-C4	B
thioalkoxy	I
group	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
aryloxy	B
group	O
,	O
a	O
lower	O
alkylamino	B
group	O
,	O
or	O
a	O
substituted	O
or	O
unsubsti	O
-	O
tuted	O
cycloamino	O
containing	O
1	B
-	I
5	I
nitrogen	I
atoms	O
;	O
A	O
is	O
a	O
nitrogen	B
atom	O
or	O
-CH=	B
;	O
or	O
a	O
their	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
i	O
)	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
tumors	O
in	O
mammals	O
.	O

Piperazine	B
derivatives	O
and	O
process	O
for	O
the	O
preparation	O
thereof	O

The	O
invention	O
concerns	O
semi	O
-	O
fluorinated	O
alkanes	O
of	O
the	O
general	O
formulae	O
R	O
F	B
R	O
H	B
and	O
R	O
F	B
R	O
H	B
R	O
F	B
,	O
R	O
F	B
being	O
a	O
linear	O
or	O
branched	O
perfluoroalkyl	B
group	O
and	O
R	O
H	B
being	O
a	O
linear	O
or	O
branched	O
saturated	O
(	B
hydrocarbon	I
)	I
-alkyl	I
group	O
.	O

Semi	O
-	O
fluorinated	O
alkanes	B
and	O
their	O
use	O

The	O
invention	O
provides	O
a	O
dietary	O
supplement	O
comprising	O
at	O
least	O
one	O
flavonoid	B
source	O
and	O
an	O
enzyme	O
,	O
that	O
is	O
effective	O
for	O
inhibiting	O
in	O
vivo	O
platelet	O
activity	O
and	O
LDL	O
cholesterol	B
oxidation	O
in	O
a	O
mammal	O
at	O
a	O
dosage	O
of	O
about	O
30	O
mg	O
/	O
Kg	O
or	O
less	O
.	O

The	O
supplement	O
may	O
contain	O
flavonoid	B
sources	O
found	O
in	O
grape	O
seed	O
extracts	O
,	O
grape	O
skin	O
extracts	O
,	O
bilberry	O
extracts	O
,	O
ginkgo	O
biloba	O
extracts	O
or	O
the	O
flavonoid	B
quercetin	B
.	O

The	O
supplement	O
may	O
also	O
contain	O
fungal	O
proteases	O
,	O
acid	O
stable	O
proteases	O
and	O
bromelain	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
for	O
using	O
the	O
dietary	O
supplement	O
and	O
an	O
article	O
of	O
manufacture	O
containing	O
the	O
supplement	O
.	O

Dietary	O
supplements	O
containing	O
natural	O
ingredients	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
composition	O
for	O
treating	O
burns	O
.	O

The	O
composition	O
comprises	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
weak	O
organic	O
acid	O
compatible	O
with	O
human	O
skin	O
,	O
in	O
a	O
suitable	O
carrier	O
delivered	O
at	O
pH	O
2.5	O
-	O
4.5	O
.	O

The	O
weak	O
organic	O
acid	O
is	O
preferably	O
acetic	B
acid	I
or	O
citric	B
acid	I
and	O
the	O
suitable	O
carrier	O
is	O
preferably	O
an	O
aqueous	O
based	O
carrier	O
,	O
more	O
preferably	O
a	O
gel	O
form	O
,	O
utilizing	O
a	O
Carbopol	O
.	O

TM	O
.	O

as	O
a	O
gelling	O
agent	O
.	O

The	O
composition	O
may	O
also	O
include	O
one	O
or	O
more	O
other	O
agents	O
selected	O
from	O
sun	O
blocking	O
agents	O
,	O
skin	O
moisturizing	O
agents	O
and	O
herb	O
extracts	O
.	O

Compositions	O
for	O
treatment	O
of	O
burns	O

A	O
method	O
for	O
treating	O
urinary	O
incontinence	O
while	O
avoiding	O
concomitant	O
liability	O
of	O
adverse	O
effects	O
associated	O
with	O
racemic	B
oxybutynin	I
is	O
disclosed	O
.	O

The	O
method	O
comprises	O
administering	O
from	O
100	O
mg	O
to	O
1	O
000	O
mg	O
/	O
day	O
of	O
(	B
S	I
)	I
-oxybutynin	I
,	O
(	B
S	I
)	I
-desethyloxybutynin	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
substantially	O
free	O
of	O
the	O
corresponding	O
R	O
enantiomer	O
.	O

Pharmaceutical	O
compositions	O
in	O
the	O
form	O
of	O
tablets	O
soft	O
elastic	O
gelatin	O
capsules	O
and	O
transdermal	O
devices	O
comprising	O
an	O
acceptable	O
corner	O
and	O
up	O
to	O
500	O
mg	O
of	O
(	B
S	I
)	I
-oxybutynin	I
or	O
(	B
S	I
)	I
-desethyloxybutynin	I
are	O
also	O
disclosed	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
urinary	O
incontinence	O
using	O
optically	O
pure	O
(	B
s	I
)	I
-oxybutynin	I

A	O
method	O
of	O
inhibiting	O
the	O
harmful	O
effect	O
of	O
UVR	O
exposure	O
to	O
the	O
human	O
skin	O
comprising	O
topically	O
applying	O
a	O
therapeutically	O
effective	O
amount	O
of	O
genistein	B
to	O
the	O
skin	O
at	O
a	O
time	O
sufficiently	O
close	O
to	O
the	O
time	O
of	O
UVR	O
exposure	O
to	O
inhibit	O
UVR	O
-	O
induced	O
damage	O
to	O
the	O
skin	O
.	O

The	O
genistein	B
appears	O
to	O
act	O
as	O
a	O
chemo	O
preventative	O
agent	O
since	O
it	O
has	O
no	O
appreciable	O
sun	O
blocking	O
effect	O
.	O

The	O
genistein	B
may	O
be	O
mixed	O
with	O
a	O
variety	O
of	O
carriers	O
and	O
skin	O
treatment	O
compositions	O
.	O

Genistein	O
as	O
a	O
preventive	O
against	O
ultraviolet	O
induced	O
skin	O
photodamage	O
and	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
transdermal	O
dosage	O
forms	O
(	O
10	O
)	O
for	O
delivery	O
of	O
androgens	B
.	O

Transdermal	O
administration	O
of	O
ment	O

Compounds	O
of	O
formula	O
(	O
1	O
)	O
where	O
the	O
symbols	O
have	O
the	O
meaning	O
defined	O
in	O
the	O
specification	O
,	O
have	O
retinoid	B
,	O
retinoid	B
antagonist	O
or	O
retinoid	B
inverse	O
agonist	O
-	O
like	O
biological	O
activity	O
.	O

N	B
-	I
aryl	I
substituted	I
tetrahydroquinolines	I
ligands	O
for	O
retinoid	B
receptors	O
having	O
agonist	O
,	O
antagonist	O
or	O
inverse	O
agonist	O
type	O
activity	O

Disclosed	O
are	O
compounds	O
that	O
are	O
highly	O
selective	O
partial	O
agonists	O
or	O
antagonists	O
at	O
human	O
CRF1	O
receptors	O
that	O
are	O
useful	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
treating	O
stress	O
related	O
disorders	O
such	O
as	O
post	O
traumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
as	O
well	O
as	O
depression	O
,	O
headache	O
and	O
anxiety	O
.	O

The	O
compounds	O
have	O
formula	O
(	O
I	O
)	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
wherein	O
Ar	O
,	O
R1	O
,	O
R2	O
.	O

R3	O
,	O
R4	O
and	O
W	O
are	O
various	O
organic	O
and	O
inorganic	O
substituents	O
.	O

Isoquinolinamine	B
and	O
phthalazinamine	B
derivatives	O
which	O
interact	O
with	O
crf	O
receptors	O

The	O
properties	O
of	O
biologically	O
active	O
compounds	O
,	O
for	O
example	O
drugs	O
and	O
agrochemicals	O
,	O
which	O
contain	O
in	O
their	O
molecular	O
structure	O
one	O
or	O
more	O
functional	O
groups	O
selected	O
from	O
alcohol	B
,	O
ether	B
,	O
phenyl	B
,	O
amino	B
,	O
amido	B
,	O
thiol	B
,	O
carboxylic	B
acid	I
and	O
carboxylic	B
acid	I
ester	I
groups	O
are	O
modified	O
by	O
replacing	O
one	O
or	O
more	O
of	O
these	O
functional	O
groups	O
by	O
a	O
lipophilic	O
group	O
selected	O
from	O
those	O
of	O
the	O
formula	O
:	O
RCOO-	B
,	O
RCONH-	B
,	O
RCOS-	B
,	O
RCH2O-	B
,	O
RCH2NH-	B
,	O
-COOCH2R	B
,	O
-CONHCH2R	B
and	O
-SCH2R	B
,	O
wherein	O
R	O
is	O
a	O
lipophilic	O
moiety	O
selected	O
from	O
cis-8-heptadecenyl	B
,	O
trans-8-heptadecenyl	B
,	O
cis-10-nonadecenyl	B
and	O
trans-10-nonadecenyl	B
.	O

New	O
fatty	B
acid	I
derivatives	O

Hydroxyazepanes	B
display	O
inhibitory	O
activity	O
with	O
respect	O
to	O
glycosidase	O
,	O
with	O
K	O
i	O
values	O
from	O
moderate	O
to	O
low	O
micromolar	O
range	O
.	O

Benzyl	B
and	O
3,6-dibenzyl	B
derivatives	O
of	O
hydroxyazepanes	B
display	O
inhibitory	O
activity	O
with	O
respect	O
to	O
HIV	O
protease	O
.	O

These	O
compounds	O
are	O
synthesized	O
either	O
by	O
chemoenzymatic	O
or	O
chemical	O
methodologies	O
.	O

Methods	O
are	O
provided	O
for	O
producing	O
a	O
tetrahydroxyazepane	B
with	O
the	O
formula:	O
(	O
see	O
formula	O
I	O
)	O
Hydroxyazepanes	B
as	O
inhibitors	O
of	O
glycosidase	O
and	O
hiv	O
protease	O

The	O
present	O
invention	O
relates	O
to	O
the	O
determination	O
of	O
an	O
authentic	O
HCV	O
genome	O
RNA	O
sequences	O
,	O
to	O
construction	O
of	O
infectious	O
HCVDNA	O
clones	O
,	O
and	O
to	O
use	O
of	O
the	O
clones	O
,	O
or	O
their	O
derivatives	O
,	O
in	O
therapeutic	O
,	O
vaccine	O
,	O
and	O
diagnostic	O
applications	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
HCV	O
vectors	O
,	O
e.g.	O
,	O
for	O
gene	O
therapy	O
of	O
gene	O
vaccines	O
.	O

Functional	O
dna	O
clone	O
for	O
hepatitis	O
c	O
virus	O
(	O
hcv	O
)	O
and	O
uses	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
substance	O
inhibiting	O
tumorous	O
proliferation	O
in	O
ectoderm	O
derived	O
tissues	O
and	O
to	O
a	O
composition	O
containing	O
such	O
substance	O
.	O

The	O
active	O
substance	O
and	O
composition	O
according	O
to	O
the	O
invention	O
are	O
characterized	O
in	O
that	O
human	O
or	O
animal	O
derived	O
fertilized	O
ovum	O
,	O
preferably	O
derived	O
from	O
sea	O
water	O
fish	O
or	O
fresh	O
water	O
fish	O
or	O
amphibian	O
is	O
subjected	O
to	O
cell	O
wall	O
destruction	O
after	O
24	O
hours	O
at	O
most	O
,	O
preferably	O
after	O
14	O
-	O
16	O
hours	O
after	O
fertilization	O
,	O
then	O
the	O
material	O
is	O
ultracentrifuged	O
,	O
the	O
supernatant	O
is	O
separated	O
,	O
the	O
sediment	O
is	O
homogenized	O
,	O
then	O
ultracentrifuged	O
several	O
times	O
,	O
and	O
each	O
time	O
the	O
supernatant	O
and	O
the	O
sediment	O
are	O
separated	O
,	O
thereafter	O
all	O
supernatant	O
fractions	O
are	O
combined	O
and	O
centrifuged	O
preferably	O
at	O
8,000	O
-	O
15,000	O
rpm	O
,	O
the	O
supernatant	O
obtained	O
is	O
separated	O
and	O
diluted	O
with	O
physiological	O
solution	O
,	O
preferable	O
in	O
1:2	O
ratio	O
by	O
weight	O
,	O
the	O
material	O
is	O
subjected	O
to	O
a	O
series	O
of	O
gel	O
filtration	O
at	O
least	O
twice	O
,	O
then	O
the	O
filtered	O
substance	O
is	O
lyophilized	O
or	O
optionally	O
diluted	O
with	O
a	O
diluent	O
,	O
preferably	O
with	O
physiological	O
saline	O
solution	O
or	O
dextrose	B
solution	O
or	O
sterile	O
distilled	O
water	O
,	O
preferably	O
in	O
1:2	O
ratio	O
by	O
weight	O
.	O

Active	O
substance	O
and	O
composition	O
inhibiting	O
tumorous	O
proliferation	O
in	O
ectoderm	O
derived	O
tissues	O

An	O
ophthalmic	O
solution	O
containing	O
a	O
compound	O
represented	O
by	O
formula	O

I	O
:	O
(	O
see	O
figure	O
I	O
)	O
wherein	O
X	O
represents	O
a	O
halogen	B
atom	O
or	O
a	O
hydrogen	B
atom	O
,	O
is	O
disclosed	O
.	O

Eyedrops	O
containing	O
a	O
loratadine	B
metabolite	O

Covalent	O
compositions	O
of	O
N	O
,	O
O	O
-	O
carboxymethyl	O
chitosan	O
(	O
NOCC	O
)	O
are	O
disclosed	O
.	O

NOCC	O
can	O
be	O
intra-	O
or	O
intermolecularly	O
linked	O
,	O
either	O
through	O
a	O
direct	O
bond	O
or	O
through	O
a	O
bridging	O
moiety	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
preparing	O
and	O
using	O
the	O
covalent	O
NOCC	O
compositions	O
.	O

The	O
NOCC	O
compositions	O
are	O
useful	O
in	O
the	O
administration	O
of	O
therapeutially	O
active	O
compounds	O
and	O
for	O
wound	O
management	O
.	O

Covalently	O
linked	O
n	O
,	O
o	O
-	O
carboxymethylchitosan	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
an	O
evacuant	O
possessing	O
a	O
sufficient	O
evacuating	O
effect	O
in	O
a	O
small	O
dose	O
substantially	O
without	O
accompanying	O
any	O
irritation	O
to	O
bowel	O
,	O
irrespective	O
of	O
whether	O
its	O
preparations	O
are	O
in	O
the	O
form	O
of	O
tablets	O
,	O
liquids	O
or	O
elixirs	O
,	O
and	O
having	O
a	O
suppressing	O
action	O
to	O
odor	O
of	O
feces	O
.	O

This	O
evacuant	O
is	O
characterized	O
by	O
containing	O
an	O
active	O
magnesium	B
oxide	I
which	O
has	O
a	O
BET	O
value	O
(	O
surface	O
area	O
in	O
terms	O
of	O
m2	O
/	O
g	O
)	O
of	O
at	O
least	O
21	O
,	O
preferably	O
21	O
-	O
50	O
,	O
more	O
preferably	O
30	O
-	O
40	O
and	O
is	O
excellent	O
in	O
acid	O
reactivity	O
,	O
and	O
may	O
preferably	O
be	O
incorporated	O
with	O
lactic	B
acid	I
bacteria	O
,	O
a	O
mixture	O
of	O
sporolactobacteria	O
and	O
yeast	O
extracts	O
and/or	O
oligosaccharides	O
.	O

The	O
preparations	O
are	O
preferably	O
in	O
the	O
form	O
of	O
liquids	O
,	O
granules	O
,	O
tablets	O
and	O
capsules	O
.	O

An	O
evacuant	O

A	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
irritable	O
bowel	O
syndrome	O
which	O
composition	O
includes	O
a	O
carrier	O
vehicle	O
and	O
a	O
vanilloid	B
compound	O
is	O
provided	O
.	O

The	O
carrier	O
vehicle	O
enables	O
the	O
vanilloid	B
compound	O
to	O
be	O
released	O
in	O
the	O
lower	O
GI	O
tract	O
.	O

The	O
vanilloid	B
compound	O
has	O
the	O
effect	O
of	O
desensitising	O
nerves	O
in	O
the	O
lower	O
GI	O
tract	O
leading	O
to	O
the	O
relief	O
of	O
symptoms	O
of	O
irritable	O
bowel	O
syndrome	O
.	O

Therapeutically	O
active	O
compositions	O

Novel	O
compounds	O
of	O
Formula	O
(	O
1.0	O
)	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
farnesyl	B
protein	O
transferase	O
function	O
and	O
therefore	O
inhibiting	O
the	O
abnormal	O
growth	O
of	O
cells	O
.	O

The	O
method	O
comprises	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
1.0	O
)	O
to	O
a	O
biological	O
system	O
.	O

In	O
particular	O
,	O
the	O
method	O
inhibits	O
the	O
abnormal	O
growth	O
of	O
cells	O
in	O
a	O
mammal	O
such	O
as	O
a	O
human	O
being	O
.	O

Benzpyrido	B
cycloheptane	I
compounds	O
useful	O
for	O
inhibition	O
of	O
farnesyl	B
protein	O
transferase	O

This	O
invention	O
relates	O
to	O
a	O
palatable	O
elemental	O
nutritional	O
formula	O
that	O
is	O
nutritionally	O
complete	O
for	O
humans	O
with	O
specialized	O
dietary	O
needs	O
.	O

The	O
nutritional	O
of	O
the	O
present	O
invention	O
uses	O
specific	O
free	O
amino	B
acids	I
to	O
provide	O
the	O
source	O
of	O
amino	B
nitrogen	I
(	O
protein	O
equivalents	O
)	O
and	O
a	O
special	O
blend	O
of	O
fats	O
that	O
provides	O
38	O
to	O
50	O
%	O
of	O
the	O
total	O
calories	O
in	O
a	O
pleasant	O
tasting	O
formula	O
.	O

The	O
nutritionally	O
complete	O
formula	O
of	O
this	O
invention	O
is	O
useful	O
for	O
children	O
having	O
multiple	O
protein	O
allergies	O
,	O
short	O
gut	O
syndrome	O
,	O
sick	O
gut	O
,	O
diarrhea	O
and	O
the	O
like	O
.	O

More	O
specifically	O
,	O
the	O
nutritional	O
product	O
,	O
in	O
accordance	O
with	O
this	O
invention	O
,	O
utilizes	O
L	B
-	I
asparagine	I
monohydrochloride	I
and	O
L	B
-	I
glutamine	I
in	O
place	O
of	O
L	B
-	I
aspartic	I
acid	I
and	O
L	B
-	I
glutamic	I
acid	I
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
source	O
of	O
fat	O
comprises	O
soy	O
,	O
fractionated	O
coconut	O
oil	O
(	O
medium	O
chain	O
triglycerides	O
)	O
,	O
high	O
oleic	O
safflower	O
oil	O
and	O
esterified	O
glycerol	O
emulsifiers	O
.	O

The	O
level	O
of	O
fat	O
calories	O
is	O
about	O
38	O
to	O
50	O
%	O
of	O
total	O
calories	O
,	O
which	O
produces	O
a	O
product	O
having	O
a	O
low	O
osmolarity	O
and	O
provides	O
required	O
energy	O
requirements	O
in	O
a	O
small	O
volume	O
.	O

Palatable	O
elemental	O
medical	O
food	O

A	O
chewable	O
dosage	O
form	O
containing	O
a	O
histamine	B
H2-receptor	O
antagonist	O
in	O
an	O
amount	O
which	O
is	O
effective	O
to	O
treat	O
a	O
gastrointestinal	O
disorder	O
is	O
provided	O
in	O
a	O
palatably	O
acceptable	O
form	O
.	O

The	O
dosage	O
form	O
comprises	O
granules	O
containing	O
the	O
histamine	B
H2	O
-	O
-receptor	O
antagonist	O
,	O
which	O
are	O
provided	O
with	O
a	O
taste	O
-	O
masking	O
coating	O
comprising	O
a	O
water	O
-	O
insoluble	O
,	O
water	O
-	O
permeable	O
methacrylate	B
ester	I
copolymer	O
in	O
which	O
the	O
coating	O
is	O
applied	O
to	O
the	O
granules	O
in	O
an	O
amount	O
which	O
provides	O
a	O
taste	O
-	O
masking	O
effect	O
for	O
a	O
relatively	O
short	O
period	O
during	O
which	O
the	O
composition	O
is	O
being	O
chewed	O
by	O
a	O
patient	O
,	O
but	O
which	O
allows	O
substantially	O
immediate	O
release	O
of	O
the	O
histamine	B
H2-receptor	O
antagonist	O
after	O
the	O
composition	O
has	O
been	O
chewed	O
and	O
ingested	O
.	O

Taste	O
-	O
masked	O
pharmaceutical	O
composition	O

Plaster	O
for	O
topical	O
use	O
having	O
an	O
analgesic	O
activity	O
and	O
at	O
the	O
same	O
time	O
being	O
able	O
to	O
re	O
-	O
absorb	O
haematomas	O
,	O
comprising	O
:	O
a	O
substrate	O
layer	O
;	O
an	O
adhesive	O
layer	O
in	O
the	O
form	O
of	O
a	O
hydrogel	O
matrix	O
containing	O
a	O
pharmaceutically	O
acceptable	O
diclofenac	B
salt	O
,	O
heparin	O
,	O
or	O
a	O
heparinoid	O
;	O
a	O
protective	O
film	O
which	O
can	O
be	O
removed	O
at	O
the	O
moment	O
of	O
use	O
.	O

Plaster	O
for	O
topical	O
use	O
containing	O
heparin	O
and	O
diclofenac	B

The	O
data	O
indicates	O
that	O
the	O
growth	O
of	O
endometrial	O
tissue	O
implanted	O
into	O
the	O
abdominal	O
cavity	O
is	O
suppressed	O
by	O
angiogenesis	O
inhibitors	O
.	O

The	O
dose	O
of	O
TNP-470	O
used	O
in	O
this	O
pilot	O
study	O
is	O
1	O
/	O
3	O
of	O
the	O
established	O
tumor	O
dose	O
.	O

Method	O
for	O
regulating	O
size	O
and	O
growth	O
of	O
vascularized	O
normal	O
tissue	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
are	O
selected	O
from	O
lower	O
alkyl	B
groups	O
having	O
1	O
-	O
6	O
carbon	B
atoms	O
,	O
substituted	O
or	O
unsubstituted	O
aryl	B
groups	O
,	O
and	O
unsaturated	O
alkyl	B
groups	O
having	O
1	O
-	O
6	O
carbon	B
atoms	O
;	O
R3	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
group	O
having	O
1	O
-	O
6	O
carbons	B
;	O
and	O
R4	O
is	O
selected	O
from	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
groups	O
having	O
1	O
-	O
6	O
carbon	B
atoms	O
,	O
substituted	O
or	O
unsubstituted	O
aryl	B
groups	O
,	O
and	O
unsaturated	O
alkyl	B
groups	O
having	O
1	O
-	O
6	O
carbon	B
atoms	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
above	O
compound	O
,	O
as	O
well	O
as	O
a	O
method	O
of	O
treating	O
tumor	O
cells	O
with	O
the	O
compound	O
.	O

N	B
,	I
n'-bis	I
(	I
sulfonyl	I
)	I
hydrazines	I
useful	O
as	O
antineoplastic	O
agents	O

The	O
invention	O
concerns	O
a	O
method	O
for	O
accelerating	O
the	O
digestion	O
rate	O
of	O
a	O
protein	O
matter	O
which	O
consists	O
in	O
treating	O
the	O
protein	O
matter	O
with	O
transglutaminase	O
,	O
and	O
in	O
mixing	O
it	O
with	O
anionic	O
polysaccharides	O
.	O

The	O
invention	O
also	O
concerns	O
the	O
use	O
of	O
a	O
protein	O
matter	O
with	O
rapid	O
digestion	O
for	O
preparing	O
a	O
food	O
or	O
pharmaceutical	O
composition	O
to	O
be	O
orally	O
administered	O
to	O
a	O
mammal	O
so	O
as	O
to	O
induce	O
a	O
postprandial	O
peak	O
of	O
plasma	O
increase	O
in	O
amino	B
acids	I
.	O

Said	O
composition	O
is	O
designed	O
for	O
modulating	O
postprandial	O
protein	O
gain	O
,	O
and	O
or	O
limiting	O
problems	O
related	O
to	O
disorders	O
of	O
gastrointestinal	O
motility	O
,	O
and/or	O
limiting	O
postprandial	O
feelings	O
of	O
nausea	O
in	O
pregnant	O
women	O
,	O
and/or	O
limiting	O
postprandial	O
risks	O
of	O
regurgitation	O
and/or	O
gastroesophageal	O
reflux	O
.	O

Finally	O
the	O
invention	O
also	O
concerns	O
a	O
food	O
or	O
pharmaceutical	O
composition	O
comprising	O
anionic	O
polysaccharides	O
and	O
a	O
protein	O
matter	O
treated	O
with	O
transglutaminase	O
.	O

Method	O
for	O
accelerating	O
protein	O
digestion	O
rate	O

The	O
present	O
invention	O
relates	O
to	O
a	O
cyclopentenopyridine	B
derivative	O
represented	O
by	O
general	O
formula	O
[	O
I	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
(	O
see	O
formula	O
I	O
)	O
wherein	O
Ar	B
is	O
a	O
phenyl	B
group	O
or	O
the	O
like	O
,	O
R1	O
is	O
a	O
mono	B
-	I
or	I
di	I
-	I
C1-C6	I
alkylamino	I
group	O
or	O
the	O
like	O
,	O
and	O
R2	O
is	O
a	O
hydroxyl	B
group	O
or	O
the	O
like	O
,	O
a	O
process	O
for	O
its	O
production	O
and	O
its	O
use	O
as	O
endothelin	O
antagonist	O
.	O

Substituted	O
5-	B
(	I
2,2-difluoro-1,3-benzodioxol-5-yl	I
)	I
cyclopentenopyridine	I
derivative	O
as	O
selective	O
endothelin	O
antagonists	O

The	O
present	O
invention	O
provides	O
a	O
single	O
-	O
stranded	O
oligodeoxyribonucleotide	B
,	O
which	O
(	O
i	O
)	O
comprises	O
from	O
about	O
5	O
to	O
11	O
bases	O
,	O
at	O
least	O
one	O
of	O
which	O
is	O
a	O
substituted	O
or	O
an	O
unsubstituted	O
O6-benzylguanine	B
,	O
and	O
(	O
ii	O
)	O
inactivates	O
human	O
AGT	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
single	O
-	O
stranded	O
oligodeoxyribonucleotide	B
,	O
which	O
can	O
inactivate	O
a	O
mutant	O
human	O
AGT	O
,	O
which	O
either	O
is	O
not	O
inactivated	O
by	O
O6-benzylguanine	B
or	O
is	O
less	O
inactivated	O
by	O
O6-benzylguanine	B
than	O
by	O
said	O
single	O
-	O
stranded	O
oligodeoxyribonucleotide	B
.	O

A	O
phosphate	O
of	O
the	O
single	O
-	O
stranded	O
oligodeoxyribonucleotide	B
can	O
be	O
replaced	O
by	O
a	O
methylphosphonate	B
or	O
a	O
phosphorothioate	B
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
composition	O
comprising	O
such	O
an	O
oligodeoxyribonucleotide	B
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
enhancing	O
the	O
effect	O
of	O
an	O
antineoplastic	O
alkylating	O
agent	O
,	O
which	O
alkylates	O
the	O
O6	O
position	O
of	O
guanine	B
residues	O
in	O
DNA	O
,	O
in	O
the	O
chemotherapeutic	O
treatment	O
of	O
cancer	O
in	O
a	O
mammal	O
,	O
which	O
method	O
comprises	O
the	O
co	O
-	O
administration	O
to	O
the	O
mammal	O
of	O
a	O
cancer	O
-	O
treatment	O
effective	O
amount	O
of	O
an	O
antineoplastic	O
alkylating	O
agent	O
and	O
a	O
chemotherapeutic	O
treatment	O
-	O
enhancing	O
amount	O
of	O
a	O
present	O
inventive	O
oligodeoxyribonucleotide	B
or	O
composition	O
thereof	O
.	O

Oligodeoxyribonucleotides	B
comprising	O
o6-benzylguanine	B
and	O
their	O
use	O

The	O
present	O
invention	O
relates	O
to	O
processes	O
for	O
the	O
production	O
of	O
mistletoe	O
lectin	O
polypeptides	O
in	O
homologous	O
and	O
heterologous	O
host	O
systems	O
and	O
mistletoe	O
lectin	O
peptides	O
as	O
such	O
.	O

Further	O
,	O
nucleic	O
acid	O
molecules	O
are	O
provided	O
,	O
which	O
code	O
for	O
these	O
mistletoe	O
lectin	O
polypeptides	O
,	O
and	O
also	O
pharmaceutical	O
compositions	O
which	O
contain	O
these	O
mistletoe	O
lectin	O
polypeptides	O
or	O
mistletoe	O
lectin	O
nucleic	O
acids	O
.	O

In	O
order	O
to	O
produce	O
the	O
many	O
mistletoe	O
lectin	O
isoenzymes	O
contained	O
in	O
the	O
natural	O
mistletoe	O
extract	O
,	O
which	O
can	O
trigger	O
anti	O
-	O
tumorigenic	O
and	O
mood	O
-	O
brightening	O
effects	O
,	O
in	O
sufficient	O
quantities	O
,	O
the	O
present	O
invention	O
provides	O
a	O
process	O
which	O
makes	O
it	O
possible	O
to	O
produce	O
mistletoe	O
lectins	O
in	O
required	O
quantities	O
biotechnologically	O
and	O
at	O
the	O
same	O
time	O
to	O
recreate	O
the	O
diversity	O
of	O
the	O
natural	O
mistletoe	O
extract	O
in	O
mistletoe	O
lectin	O
isoenzymes	O
.	O

Recombinant	O
mistletoe	O
lectins	O

The	O
present	O
invention	O
describes	O
in	O
particular	O
a	O
method	O
for	O
stabilizing	O
a	O
pharmaceutical	O
composition	O
by	O
contacting	O
said	O
composition	O
with	O
a	O
polymeric	O
material	O
comprising	O
an	O
antioxidant	O
.	O

Method	O
for	O
stabilizing	O
pharmaceutical	O
compositions	O
by	O
special	O
use	O
of	O
an	O
antioxidant	O

Food	O
compositions	O
,	O
compositions	O
for	O
the	O
oral	O
cavity	O
and	O
medicinal	O
compositions	O
for	O
preventing	O
or	O
treating	O
periodontosis	O
which	O
contain	O
(	O
A	O
)	O
one	O
or	O
more	O
components	O
selected	O
from	O
among	O
natural	O
polyphenol	B
-	O
containing	O
extracts	O
,	O
and	O
(	O
B	O
)	O
one	O
or	O
more	O
components	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
vitamin	B
C	I
,	O
vitamin	B
E	I
,	O
vitamin	B
A	I
and	O
.beta	O
.-	B
carotene	I
;	O
and	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
periodontosis	O
with	O
the	O
use	O
of	O
these	O
compositions	O
.	O

Food	O
compositions	O
,	O
compositions	O
for	O
oral	O
cavity	O
and	O
medicinal	O
compositions	O
for	O
preventing	O
or	O
treating	O
periodontosis	O
and	O
method	O
for	O
preventing	O
or	O
treating	O
periodontosis	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
having	O
general	O
formula	O
(	O
I	O
)	O
as	O
described	O
hereunder	O
(	O
see	O
formula	O
I	O
)	O
wherein	O
R	O
=	O
CH3	B
(	O
FPB	O
compound	O
)	O
for	O
the	O
preparation	O
of	O
compositions	O
with	O
an	O
antioxidant	O
activity	O
for	O
administering	O
to	O
human	O
beings	O
for	O
therapeu	O
-	O
tic	O
or	O
nutritional	O
purposes	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
prepara	O
-	O
tion	O
of	O
a	O
compound	O
having	O
general	O
formula	O
(	O
I	O
)	O
as	O
defined	O
above	O
characterized	O
in	O
that	O
a	O
cellular	O
culture	O
is	O
ob	O
-	O
tained	O
from	O
an	O
Ajuga	O
reptans	O
plant	O
,	O
said	O
culture	O
being	O
subsequently	O
subjected	O
to	O
cultivation	O
under	O
aerobic	O
con	O
-	O
ditions	O
,	O
in	O
a	O
liquid	O
medium	O
containing	O
assimilable	O
carbon	B
and	O
nitrogen	B
sources	O
,	O
and	O
mineral	O
salts	O
.	O

Compounds	O
with	O
an	O
antioxidant	O
activity	O
,	O
compositions	O
useful	O
as	O
food	O
integrators	O
containing	O
them	O
and	O
process	O
for	O
their	O
preparation	O

An	O
aqueous	O
-	O
based	O
sprayable	O
composition	O
comprises	O
a	O
therapeutic	O
or	O
palliative	O
agent	O
,	O
water	O
and	O
a	O
mixture	O
of	O
microcrystalline	O
cellulose	O
and	O
alkali	O
metal	O
carboxyalkylcellulose	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
composition	O
is	O
a	O
non	O
-	O
Newtonian	O
nasal	O
spray	O
exhibiting	O
a	O
very	O
rapid	O
viscosity	O
recovery	O
upon	O
removal	O
of	O
shear	O
forces	O
.	O

Spray	O
composition	O

The	O
aqueous	O
ophthalmic	O
formulation	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
infections	O
contains	O
ofloxacin	B
as	O
active	O
ingredient	O
and	O
a	O
chitosan	O
having	O
a	O
weight	O
average	O
molecular	O
weight	O
of	O
500,000	O
-	O
5,000,000	O
Daltons	O
and	O
a	O
deacetylation	O
degree	O
of	O
30	O
-	O
90	O
%	O
as	O
solubilizing	O
agent	O
of	O
ofloxacin	B
.	O

Chitosan	O
having	O
a	O
deacetylation	O
degree	O
of	O
30	O
-	O
90	O
%	O
may	O
be	O
also	O
used	O
for	O
solubilizing	O
ofloxacin	B
suspended	O
in	O
an	O
aqueous	O
media	O
having	O
a	O
substantially	O
neutral	O
pH	O
in	O
any	O
other	O
applications	O
.	O

Antibacterial	O
aqueous	O
ophthalmic	O
formulations	O
containing	O
ofloxacin	B
and	O
use	O
of	O
chitosan	O
for	O
solubilizing	O
ofloxacin	B
suspended	O
in	O
an	O
aqueous	O
media	O

The	O
instant	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
modeling	O
post	O
-	O
Amadori	O
AGE	O
formation	O
and	O
the	O
identification	O
and	O
characterization	O
of	O
effective	O
inhibitors	O
of	O
post	O
-	O
Amadori	O
AGE	O
formation	O
,	O
and	O
such	O
identified	O
inhibitor	O
compositions	O
.	O

The	O
instant	O
invention	O
also	O
teaches	O
methods	O
to	O
treat	O
or	O
prevent	O
diabetes	O
associated	O
hyperlipidemia	O
,	O
cellular	O
redox	O
imbalances	O
,	O
hypercholesterolemia	O
,	O
hypertriglyceridemia	O
,	O
and	O
atherosclerosis	O
,	O
comprising	O
administering	O
the	O
compounds	O
of	O
the	O
invention	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O

Methods	O
for	O
inhibiting	O
diabetic	O
complications	O

A	O
food	O
product	O
comprising	O
menaquinone	B
at	O
a	O
level	O
of	O
50	O
to	O
5,000	O
µg	O
per	O
100	O
g	O
of	O
product	O
.	O

Vitamin	B
k2	I
containing	O
food	O
product	O

There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
IA	O
)	O
and	O
of	O
Formula	O
(	O
IB	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
A	O
have	O
meanings	O
given	O
in	O
the	O
description	O
,	O
which	O
are	O
useful	O
in	O
the	O
curative	O
and	O
prophylactic	O
treatment	O
of	O
medical	O
conditions	O
for	O
which	O
inhibition	O
of	O
a	O
cyclic	B
guanosine	I
3',5'-monophosphate	I
phosphodiesterase	O
(	O
e.g.	O
cGMP	O
PDE5	O
)	O
is	O
desired	O
.	O

Pyrazolopyrimidinone	B
cgmp	O
pde5	O
inhibitors	O
for	O
the	O
treatment	O
of	O
sexual	O
dysfunction	O

Process	O
for	O
the	O
manufacturing	O
of	O
slightly	O
soluble	O
or	O
less	O
soluble	O
alkaline	O
salts	O
of	O
substituted	O
sulphinyl	B
heterocycles	I
containing	O
an	O
imidazole	B
moiety	O
with	O
formula	O
(	O
I	O
)	O
,	O
preferably	O
alkaline	O
salts	O
of	O
a	O
proton	O
pump	O
inhibitor	O
compound	O
,	O
wherein	O
the	O
process	O
comprises	O
the	O
step	O
of	O
reacting	O
the	O
substituted	O
sulphinyl	B
heterocycle	I
of	O
formula	O
(	O
I	O
)	O
with	O
a	O
source	O
of	O
the	O
cation	O
in	O
the	O
presence	O
of	O
a	O
base	O
,	O
characterized	O
by	O
a	O
washing	O
step	O
in	O
which	O
the	O
prepared	O
alkaline	O
salt	O
of	O
the	O
substituted	O
sulphinyl	B
compound	O
is	O
washed	O
with	O
a	O
basic	O
aqueous	O
solvent	O
mixture	O
.	O

The	O
obtained	O
bulk	O
drug	O
substance	O
resulting	O
in	O
a	O
bulk	O
product	O
that	O
in	O
an	O
aqueous	O
suspension	O
of	O
the	O
substituted	O
sulphinyl	B
heterocycle	I
having	O
a	O
pH	O
not	O
significantly	O
lower	O
than	O
that	O
of	O
a	O
saturated	O
water	O
solution	O
of	O
the	O
pure	O
compound	O
prepared	O
.	O

Alternatively	O
,	O
the	O
process	O
for	O
manufacturing	O
a	O
pharmaceutical	O
dosage	O
form	O
comprising	O
the	O
active	O
substance	O
could	O
be	O
adjusted	O
.	O

For	O
instance	O
the	O
pH	O
of	O
an	O
aqueous	O
suspension	O
of	O
the	O
active	O
substance	O
is	O
adjusted	O
to	O
a	O
pH	O
not	O
significantly	O
lower	O
than	O
that	O
of	O
a	O
saturated	O
water	O
solution	O
of	O
the	O
pure	O
compound	O
.	O

The	O
processes	O
are	O
preferably	O
useful	O
in	O
the	O
manufacturing	O
of	O
omeprazole	B
magnesium	I
salt	O
or	O
magnesium	B
salt	O
of	O
one	O
of	O
its	O
single	O
enantiomers	O
used	O
in	O
pharmaceutical	O
dosage	O
forms	O
.	O

Process	O
for	O
the	O
manufacturing	O
of	O
alkaline	O
salts	O
of	O
substituted	O
sulphinyl	B
compounds	O
and	O
products	O
prepared	O
thereby	O

A	O
composition	O
and	O
method	O
for	O
treating	O
periodontal	O
disease	O
is	O
provided	O
comprising	O
resveratrol	B
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
composition	O
is	O
particularly	O
useful	O
for	O
administration	O
to	O
individuals	O
at	O
high	O
risk	O
of	O
developing	O
periodontal	O
disease	O
such	O
as	O
those	O
who	O
smoke	O
tobacco	O
products	O
and	O
those	O
exposed	O
to	O
second	O
-	O
hand	O
tobacco	O
smoke	O
or	O
environmental	O
pollutant	O
AhR	O
ligands	O
.	O

A	O
composition	O
useful	O
to	O
treat	O
periodontal	O
disease	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
biochemical	O
substances	O
for	O
a	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
health	O
conditions	O
caused	O
by	O
constriction	O
of	O
smooth	O
muscle	O
cells	O
in	O
organs	O
of	O
the	O
human	O
body	O
like	O
high	O
blood	O
pressure	O
,	O
asthma	O
,	O
glaucoma	O
and	O
tinnitus	O
.	O

Use	O
of	O
biochemical	O
substances	O
for	O
a	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
health	O
conditions	O
caused	O
by	O
constriction	O
of	O
smooth	O
muscle	O
cells	O
in	O
organs	O
of	O
the	O
human	O
body	O

This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
wherein	O
X1	O
,	O
X2	O
,	O
R2	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
and	O
R11	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
are	O
antibacterial	O
and	O
antiprotozoal	O
agents	O
that	O
may	O
be	O
used	O
to	O
treat	O
various	O
bacterial	O
and	O
protozoal	O
infections	O
and	O
disorders	O
related	O
to	O
such	O
infections	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
methods	O
of	O
treating	O
bacterial	O
and	O
protozoal	O
infections	O
by	O
administering	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
.	O

Ketolide	B
antibiotics	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
retinoid	B
antagonists	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
dotted	O
bond	O
is	O
optional	O
;	O
and	O
,	O
when	O
the	O
dotted	O
bond	O
is	O
present	O
,	O
R1	O
is	O
lower	O
alkyl	B
and	O
R2	O
is	O
hydrogen	B
;	O
and	O
,	O
when	O
the	O
dotted	O
bond	O
is	O
absent	O
,	O
R1	O
and	O
R2	O
taken	O
together	O
are	O
methylene	B
to	O
form	O
a	O
cis	O
-	O
substituted	O
cyclopropyl	B
ring	O
;	O
R3	O
is	O
hydroxy	B
or	O
lower	O
alkoxy	B
;	O
R4	O
is	O
alkyl	B
or	O
alkoxy	B
;	O
and	O
R5	O
and	O
R6	O
are	O
,	O
independently	O
,	O
a	O
C4	O
-	O
12	O
alkyl	B
group	O
or	O
a	O
mono-	O
or	O
polycyclic	O
C5	B
-	I
12-hydrocarbon	I
group	O
which	O
are	O
linked	O
to	O
the	O
phenyl	B
ring	O
through	O
a	O
quaternary	B
carbon	I
atom	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
carboxylic	B
acids	I
of	O
formula	O
(	O
I	O
)	O
;	O
the	O
use	O
of	O
retinoid	B
antagonists	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
or	O
pharmaceutically	O
acceptable	O
hydrolyzable	O
esters	B
,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
T	O
-	O
helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
-mediated	O
immune	O
diseases	O
,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
and	O
for	O
use	O
in	O
the	O
treatment	O
of	O
preneoplastic	O
and	O
neoplastic	O
diseases	O
.	O

Retinoid	B
antagonists	O
and	O
use	O
thereof	O

Designed	O
iminocyclitols	B
have	O
potent	O
inhibition	O
activity	O
with	O
respect	O
to	O
hexoaminidases	O
and	O
glycosidases	O
.	O

Iminocyclitol	B
inhibitors	O
of	O
hexoaminidase	O
and	O
glycosidase	O

Isophosphoramide	B
mustard	O
analogs	O
useful	O
for	O
treating	O
cancer	O
are	O
provided	O
.	O

Isophosphoramide	B
mustard	O
analogs	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen	B
or	O
halogen	B
;	O
R2	O
is	O
hydrogen	B
,	O
halogen	B
,	O
lower	O
alkyl	B
or	O
lower	O
alkoxy	B
;	O
R1	O
and	O
R2	O
may	O
be	O
together	O
with	O
the	O
two	O
carbon	B
atoms	O
-CH	B
=	I
CH	I
-	I
CH	I
=	I
CH-	I
;	O
R3	O
is	O
halogen	B
,	O
trifluoromethyl	B
,	O
lower	O
alkyl	B
or	O
lower	O
alkoxy	B
;	O
R4	O
/	O
R4	O
'	O
are	O
independently	O
from	O
each	O
other	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
R5	O
is	O
lower	O
alkyl	B
,	O
lower	O
alkoxy	B
,	O
amino	B
,	O
phenyl	B
,	O
hydroxy	B
-	O
lower	O
alkyl	B
,	O
cyano	B
-	O
lower	O
alkyl	B
,	O
carbamoyl	B
-	O
lower	O
alkyl	B
,	O
pyridyl	B
,	O
pyrimidyl	B
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
piperazinyl	I
,	O
which	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
lower	O
alkyl	B
groups	O
or	O
by	O
hydroxy	B
-	O
lower	O
alkyl	B
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
morpholinyl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
--	O
piperidinyl	B
,	O
-	B
(	I
CH2	I
)	I
n+1-imidazolyl	I
,	O
lower	O
alkyl	B
-	I
sulfanyl	I
,	O
lower	O
alkyl	B
-	I
sulfonyl	I
,	O
benzylamino	B
,	O
-NH-	B
(	I
CH2	I
)	I
n+1N	I
(	I
"R4"""	I
)	I
2	I
,	O
-	B
(	I
CH2	I
)	I
n+1N	I
(	I
"R4"""	I
)	I
2	I
,	O
-O-	B
(	I
CH2	I
)	I
n+1-morpholinyl	I
,	O
-O-	B
(	I
CH2	I
)	I
n+1-piperidinyl	I
or	O
-O-	B
(	I
CH2	I
)	I
n+1N	I
(	I
"R4"""	I
)	I
2	I
,	O
wherein	O
R4	O
""""	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
and	O
n	O
is	O
0-	O
2	O
;	O
X	O
is	O
-C	B
(	I
O	I
)	I
N	I
(	I
"R4"""	I
)	I
-	I
or	O
-N	B
(	I
"R4"""	I
)	I
C	I
(	I
O	I
)	I
-	I
;	O
and	O
to	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
compounds	O
have	O
a	O
good	O
affinity	O
to	O
the	O
NK-1	O
receptor	O
and	O
may	O
therefore	O
be	O
used	O
for	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
this	O
receptor	O
.	O

4-phenyl	B
-	I
pyrimidine	I
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
ribonucleotide	O
oligonucleotides	O
(	O
RNOs	O
)	O
that	O
are	O
specifically	O
designed	O
to	O
inhibit	O
viral	O
replication	O
.	O

The	O
RNOs	O
are	O
capable	O
of	O
binding	O
to	O
both	O
the	O
negative	O
and	O
positive	O
strands	O
of	O
influenza	O
RNA	O
segments	O
,	O
thereby	O
inhibiting	O
the	O
virus	O
'	O
ability	O
to	O
produce	O
various	O
viral	O
components	O
,	O
thus	O
inhibiting	O
viral	O
propagation	O
,	O
and	O
effectively	O
killing	O
the	O
virus	O
at	O
the	O
intracellular	O
sites	O
of	O
infection	O
in	O
the	O
respiratory	O
tract	O
.	O

The	O
RNOs	O
provided	O
may	O
act	O
independently	O
,	O
or	O
in	O
combination	O
to	O
optimize	O
their	O
antiviral	O
activity	O
.	O

In	O
addition	O
,	O
the	O
RNOs	O
provided	O
may	O
be	O
formulated	O
in	O
liposomes	O
,	O
which	O
facilitate	O
their	O
therapeutic	O
delivery	O
to	O
intracellular	O
sites	O
of	O
infection	O
,	O
and	O
additionally	O
increase	O
antiviral	O
efficacies	O
.	O

Therapy	O
of	O
respiratory	O
influenza	O
virus	O
infection	O
using	O
free	O
and	O
liposome	O
-	O
encapsulated	O
ribonucleotides	O

An	O
emulsion	O
is	O
formed	O
by	O
combining	O
two	O
phases	O
in	O
a	O
static	O
mixer	O
(	O
140	O
,	O
235	O
)	O
.	O

The	O
outflow	O
of	O
the	O
blending	O
static	O
mixer	O
(	O
130,230	O
)	O
.	O

The	O
emulsion	O
is	O
conbined	O
with	O
an	O
extraction	O
liquid	O
in	O
a	O
blending	O
static	O
mixer	O
is	O
combined	O
with	O
additional	O
extraction	O
liquid	O
.	O

The	O
additional	O
extraction	O
liquid	O
and	O
the	O
outlfow	O
of	O
the	O
blending	O
static	O
mixer	O
can	O
be	O
combined	O
in	O
a	O
vessel	O
(	O
160	O
)	O
,	O
or	O
through	O
the	O
use	O
of	O
a	O
static	O
mixer	O
manifold	O
(	O
240	O
)	O
that	O
includes	O
a	O
plurality	O
of	O
static	O
mixers	O
.	O

Apparatus	O
and	O
method	O
for	O
preparing	O
microparticles	O
using	O
in	O
-	O
line	O
solvent	O
extraction	O

The	O
present	O
invention	O
relates	O
to	O
6-O	B
-	I
alkyl-2-nor-2-substituted	I
ketolide	I
compound	O
or	O
a	O
derivative	O
thereof	O
,	O
a	O
composi	O
-	O
tion	O
comprising	O
the	O
compound	O
and	O
a	O
suitable	O
carrier	O
,	O
a	O
method	O
of	O
preparing	O
the	O
compound	O
,	O
and	O
a	O
method	O
of	O
treatment	O
and	O
prevention	O
of	O
in	O
mammals	O
comprising	O
administering	O
said	O
compound	O
.	O

6-o	B
-	I
alkyl-2-nor-2-substituted	I
ketolide	I
derivatives	O

A	O
formulation	O
for	O
use	O
in	O
an	O
inhaler	O
device	O
comprises	O
carrier	O
particles	O
having	O
a	O
diameter	O
of	O
at	O
least	O
50	O
µm	O
and	O
a	O
mass	O
median	O
diameter	O
of	O
at	O
least	O
175	O
µm	O
;	O
fine	O
particles	O
of	O
an	O
excipient	O
material	O
having	O
a	O
mass	O
median	O
aerodynamic	O
diameter	O
of	O
not	O
more	O
than	O
20	O
µm	O
;	O
and	O
active	O
particles	O
.	O

The	O
formulation	O
has	O
excellent	O
flowability	O
even	O
at	O
relatively	O
high	O
contents	O
of	O
fine	O
particles	O
.	O

Improvements	O
in	O
or	O
relating	O
to	O
formulations	O
for	O
use	O
in	O
inhaler	O
devices	O

Novel	O
polymeric	O
micelles	O
which	O
are	O
used	O
to	O
deliver	O
therapeutic	O
agents	O
,	O
including	O
anti	O
tumor	O
drugs	O
.	O

Polymeric	O
micelle	O
compositions	O

A	O
long	O
-	O
term	O
storage	O
stable	O
tretinoin	B
and	O
4-hydroxyanisole	B
composition	O
contains	O
low	O
molecular	O
weight	O
polyethylene	B
glycol	I
,	O
antioxidant	O
,	O
a	O
chelating	O
agent	O
,	O
lower	O
alkanol	B
and	O
water	O
.	O

The	O
chelating	O
agent	O
provides	O
at	O
least	O
two	O
of	O
the	O
functions	O
of	O
oxygen	B
scavaging	O
,	O
free	O
radical	O
chain	O
terminating	O
and	O
reducing	O
.	O

The	O
composition	O
has	O
a	O
pH	O
of	O
2.5	O
to	O
5	O
and	O
a	O
water	O
content	O
of	O
at	O
least	O
12	O
%	O
.	O

Storage	O
stable	O
tretinoin	B
and	O
4-hydroxy	B
anisole	I
containing	O
topical	O
composition	O

Inhibitors	O
of	O
serine	B
proteases	O
are	O
provided	O
having	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
as	O
defined	O
herein	O
.	O

In	O
particular	O
,	O
the	O
compounds	O
bind	O
to	O
factor	O
VIIa	O
,	O
tissue	O
factor	O
/	O
factor	O
Xa	O
complex	O
,	O
thrombin	O
,	O
trypsin	O
,	O
plasmin	O
and	O
kallikrein	O
and	O
have	O
anticoagulant	O
activity	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
are	O
useful	O
for	O
inhibiting	O
the	O
formation	O
of	O
veinous	O
and/or	O
arterial	O
thrombi	O
in	O
vivo	O
.	O

Amidine	B
inhibitors	O
of	O
serine	B
proteases	O

An	O
osteoinductive	O
/	O
osteoconductive	O
composition	O
prepared	O
from	O
a	O
quantity	O
of	O
demineralized	O
fibrous	O
bone	O
elements	O
possessing	O
an	O
average	O
surface	O
area	O
to	O
volume	O
ratio	O
of	O
about	O
100:1	O
to	O
about	O
20:1	O
,	O
a	O
quantity	O
of	O
mostly	O
shaped	O
regular	O
non	O
-	O
fibrous	O
bone	O
elements	O
possessing	O
an	O
average	O
surface	O
area	O
to	O
volume	O
ratio	O
of	O
about	O
10:1	O
or	O
less	O
and	O
a	O
sufficient	O
quantity	O
of	O
biocompatible	O
fluid	O
carrier	O
sufficient	O
to	O
provide	O
the	O
composition	O
as	O
a	O
deformable	O
mass	O
is	O
provided	O
herein	O
.	O

Also	O
provided	O
is	O
a	O
method	O
of	O
using	O
the	O
composition	O
to	O
repair	O
a	O
bone	O
defect	O
site	O
.	O

Volume	O
maintaining	O
osteoinductive	O
/	O
oesteoconductive	O
compositions	O

The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
a	O
peroxisome	O
proliferator	O
activated	O
receptor	O
(	O
PPAR	O
)	O
activator	O
and	O
a	O
benzoquinone	B
and	O
their	O
use	O
in	O
treating	O
and/or	O
preventing	O
disorders	O
characterized	O
by	O
endothelial	O
dysfunction	O
,	O
such	O
as	O
cardiovascular	O
disease	O
,	O
strokes	O
and	O
myocardial	O
infarction	O
.	O

According	O
to	O
a	O
preferred	O
embodiment	O
of	O
the	O
invention	O
the	O
benzoquinone	B
or	O
precursor	O
thereof	O
is	O
a	O
ubiquinone	O
or	O
precursor	O
thereof	O
,	O
more	O
preferably	O
,	O
coenzyme	O
Q10	O
or	O
a	O
precursor	O
thereof	O
,	O
and	O
the	O
PPAR	O
activator	O
is	O
a	O
fibrate	O
or	O
a	O
thiazolidinedione	B
,	O
more	O
preferably	O
fenofibrate	B
.	O

Combination	O
of	O
fenofibrate	B
and	O
coenzyme	O
q10	O
for	O
the	O
treatment	O
of	O
endothelial	O
dysfunction	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
and	O
potent	O
tumor	O
antigen	O
capable	O
of	O
causing	O
T	O
cells	O
to	O
elicit	O
an	O
immune	O
response	O
and	O
methods	O
of	O
its	O
use	O
in	O
the	O
detection	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
cancer	O
,	O
preferably	O
melanoma	O
,	O
in	O
mammals	O
.	O

More	O
specifically	O
,	O
this	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
a	O
novel	O
tyrosinase	O
-	O
related	O
protein	O
2	O
(	O
TRP2	O
)	O
,	O
specifically	O
TRP2	O
-	O
6b	O
protein	O
,	O
and	O
peptides	O
derived	O
from	O
said	O
protein	O
.	O

The	O
present	O
invention	O
therefore	O
also	O
relates	O
to	O
nucleic	O
acid	O
sequences	O
that	O
encode	O
the	O
TRP2	O
-	O
6b	O
protein	O
or	O
peptide	O
fragments	O
thereof	O
.	O

A	O
novel	O
trp2	O
isoform	O
containing	O
hla	O
-	O
a2	O
restricted	O
cytotoxic	O
t	O
lymphocyte	O
epitopes	O

Methods	O
of	O
synthesizing	O
an	O
acylanilide	B
include	O
contacting	O
a	O
compound	O
having	O
the	O
structure	O
of	O
Formula	O
I	O
with	O
a	O
compound	O
having	O
the	O
structure	O
of	O
Formula	O
II	O
under	O
conditions	O
sufficient	O
to	O
provide	O
a	O
compound	O
having	O
the	O
structure	O
of	O
Formula	O
III	O
and	O
treating	O
the	O
compound	O
of	O
Formula	O
III	O
under	O
conditions	O
sufficient	O
to	O
provide	O
an	O
acylanilide	B
.	O

The	O
compound	O
of	O
Formula	O
III	O
may	O
be	O
addition	O
reacted	O
with	O
a	O
compound	O
having	O
the	O
structure	O
of	O
Formula	O
IV	O
:	O
under	O
conditions	O
sufficient	O
to	O
provide	O
an	O
acylanilide	B
having	O
the	O
structure	O
of	O
Formula	O
V.	O
Methods	O
of	O
synthesizing	O
acylanilides	B
including	O
bicalutamide	B
and	O
derivatives	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
combination	O
therapy	O
for	O
the	O
treatment	O
of	O
tumors	O
metastases	O
comprising	O
administration	O
of	O
anti	O
-	O
angiogenic	O
agents	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF.alpha	O
.	O
)	O
optionally	O
together	O
with	O
other	O
cytotoxic	O
agents	O
,	O
such	O
as	O
interferon	O
gamma	O
(	O
IFNy	O
)	O
orchemotherapeutic	O
agents	O
such	O
as	O
anti	O
-	O
EGFR	O
antibodies	O
.	O

The	O
method	O
and	O
the	O
pharmaceuticalcompositions	O
comprising	O
said	O
agents	O
can	O
result	O
in	O
a	O
synergistic	O
potentiation	O
of	O
the	O
tumor	O
cell	O
proliferation	O
inhibition	O
effect	O
of	O
each	O
individual	O
therapeutic	O
agent	O
,	O
yielding	O
more	O
effective	O
treatment	O
than	O
found	O
by	O
administering	O
an	O
individual	O
component	O
alone	O
.	O

Combination	O
therapy	O
using	O
anti	O
-	O
angiogenic	O
agents	O
and	O
tnfa	O

The	O
present	O
invention	O
comprises	O
compositions	O
and	O
methods	O
for	O
delivery	O
systems	O
of	O
agents	O
,	O
including	O
therapeutic	O
compounds	O
,	O
pharmaceutical	O
agents	O
,	O
drugs	O
,	O
detection	O
agents	O
,	O
nucleic	O
acid	O
sequences	O
and	O
biological	O
factors	O
.	O

In	O
general	O
,	O
these	O
vector	O
compositions	O
comprise	O
a	O
colloidal	O
metal	O
,	O
derivatized	O
PEG	B
(	O
polyethylene	B
glycol	I
)	O
and	O
an	O
agent	O
.	O

The	O
invention	O
also	O
comprises	O
methods	O
and	O
compositions	O
for	O
making	O
such	O
colloidal	O
metal	O
compositions	O
and	O
for	O
treatment	O
of	O
cancer	O
.	O

Colloidal	O
metal	O
compositions	O
and	O
methods	O

The	O
invention	O
relates	O
to	O
a	O
medicament	O
,	O
for	O
treating	O
and	O
improving	O
the	O
restorative	O
quality	O
of	O
sleep	O
,	O
in	O
a	O
patient	O
suffering	O
from	O
primary	O
insomnia	O
,	O
which	O
comprises	O
at	O
least	O
one	O
compound	O
selected	O
from	O
melatonin	O
,	O
other	O
melatonergic	O
agents	O
,	O
melatonin	B
agonists	O
and	O
melatonin	B
antagonists	O
,	O
in	O
an	O
effective	O
amount	O
within	O
the	O
range	O
of	O
0.0025	O
to	O
50	O
mg	O
,	O
and	O
optionally	O
one	O
or	O
more	O
other	O
therapeutically	O
active	O
agents	O
.	O

Method	O
for	O
treating	O
primary	O
insomnia	O

It	O
is	O
intended	O
to	O
provide	O
an	O
effective	O
method	O
of	O
treating	O
PML	O
(	O
human	O
progressive	O
multifocal	O
leukoencephalopathy	O
)	O
.	O

A	O
method	O
of	O
inhibiting	O
the	O
proliferation	O
of	O
JC	O
virus	O
in	O
JC	O
virus	O
-	O
infected	O
cells	O
by	O
inhibiting	O
the	O
expression	O
of	O
JV	O
virus	O
agno	O
gene	O
;	O
and	O
a	O
method	O
of	O
inhibiting	O
the	O
canceration	O
of	O
JC	O
virus	O
-	O
infected	O
cells	O
.	O

Treatment	O
of	O
pml	O
targeting	O
jc	O
virus	O
agno	O

A	O
method	O
of	O
modulating	O
motor	O
neuron	O
activity	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
the	O
method	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
Müllerian	O
inhibitory	O
substance	O
receptor	O
agonist	O
or	O
antagonist	O
.	O

Method	O
of	O
modulation	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
depressive	O
disorders	O
through	O
the	O
administration	O
of	O
modafinil	B
with	O
antidepressants	O
.	O

Combination	O
of	O
the	O
analeptic	O
modafinil	B
and	O
an	O
antidepressant	O
for	O
the	O
treatment	O
of	O
depression	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
combination	O
of	O
Loxapine	B
and	O
a	O
serotonin	B
reuptake	O
inhibitor	O
(	O
SRI	O
)	O
,	O
for	O
the	O
treatment	O
of	O
depression	O
and	O
other	O
affective	O
disorders	O
.	O

The	O
combination	O
of	O
a	O
serotonin	B
reuptake	O
inhibitor	O
and	O
loxapine	B

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
prostate	O
cancer	O
.	O

The	O
composition	O
comprises	O
a	O
morpholino	B
antisense	O
compound	O
having	O
uncharged	O
phosphorus	B
-	O
containing	O
backbone	O
linkages	O
and	O
a	O
base	O
sequence	O
that	O
is	O
complementary	O
to	O
a	O
target	O
region	O
containing	O
at	O
least	O
12	O
contiguous	O
bases	O
in	O
a	O
preprocessed	O
or	O
processed	O
human	O
androgen	B
receptor	O
transcript	O
.	O

The	O
method	O
is	O
designed	O
for	O
treating	O
prostate	O
cancer	O
in	O
a	O
subject	O
having	O
a	O
hormone	O
-	O
refractory	O
(	O
androgen	B
-	O
independent	O
)	O
prostate	O
cancer	O
.	O

Compound	O
and	O
method	O
for	O
treating	O
androgen	B
-	O
independent	O
prostate	O
cancer	O

The	O
invention	O
provides	O
cells	O
and	O
animals	O
,	O
as	O
well	O
as	O
methods	O
of	O
producing	O
cells	O
and	O
animals	O
,	O
that	O
express	O
at	O
least	O
one	O
interfering	O
RNA	O
molecule	O
to	O
regulate	O
the	O
expression	O
of	O
a	O
specific	O
gene	O
or	O
family	O
of	O
genes	O
.	O

The	O
invention	O
further	O
provides	O
novel	O
iRNA	O
molecules	O
,	O
as	O
well	O
as	O
DNA	O
templates	O
for	O
producing	O
iRNA	O
molecules	O
.	O

Use	O
of	O
interfering	O
rna	O
in	O
the	O
production	O
of	O
transgenic	O
animals	O

A	O
kit	O
,	O
and	O
a	O
method	O
of	O
using	O
same	O
,	O
that	O
comprises	O
first	O
,	O
second	O
and	O
third	O
components	O
wherein	O
the	O
first	O
,	O
second	O
and	O
third	O
components	O
collectively	O
comprise	O
Glycine	B
,	O
Arginine	B
,	O
Leucine	B
,	O
Creatine	B
,	O
Alpha	B
Lipoic	I
Acid	I
,	O
and	O
earth	O
metal	O
salts	O
of	O
Ketoisocaproic	B
Acid	I
.	O

Use	O
of	O
the	O
kit	O
may	O
enhance	O
muscle	O
performance	O
,	O
build	O
muscle	O
,	O
increase	O
muscle	O
strength	O
,	O
increase	O
muscle	O
size	O
and	O
reduce	O
muscle	O
fatigue	O
.	O

The	O
three	O
compositions	O
may	O
be	O
used	O
in	O
synergy	O
so	O
as	O
to	O
promote	O
muscle	O
anabolism	O
,	O
neutralize	O
reactive	O
oxygen	B
species	O
,	O
and	O
improve	O
creatine	B
uptake	O
in	O
muscle	O
tissue	O
.	O

The	O
method	O
may	O
also	O
include	O
a	O
schedule	O
for	O
administering	O
each	O
composition	O
to	O
the	O
user	O
for	O
optimal	O
results	O
.	O

Kit	O
comprising	O
three	O
independent	O
compositions	O
and	O
methods	O
for	O
building	O
muscle	O
,	O
increasing	O
strength	O
,	O
increasing	O
muscle	O
size	O
,	O
increasing	O
muscle	O
performance	O
and	O
reducing	O
muscle	O
fatigue	O

The	O
present	O
invention	O
provides	O
combinations	O
of	O
pharmaceutically	O
active	O
agents	O
(	O
i.e.	O
statins	O
and	O
negatively	O
charged	O
phospholipids	O
)	O
for	O
treating	O
or	O
preventing	O
atherosclerosis	O
or	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
in	O
mammals	O
,	O
and	O
methods	O
therefore	O
.	O

In	O
particular	O
,	O
these	O
combinations	O
and	O
methods	O
find	O
utility	O
for	O
achieving	O
one	O
or	O
more	O
of	O
the	O
following	O
effects	O
in	O
a	O
subject	O
:	O
(	O
1	O
)	O
a	O
reduction	O
in	O
plasma	O
levels	O
of	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B
and	O
very	O
-	O
low	O
--	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
cholesterol	B
;	O
(	O
2	O
)	O
an	O
increase	O
in	O
plasma	O
levels	O
of	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B
;	O
and	O
(	O
3	O
)	O
a	O
reduction	O
in	O
plasma	O
levels	O
of	O
triglycerides	O
.	O

Combinations	O
of	O
hmg	O
coa	O
reductase	O
inhibitors	O
and	O
negatively	O
charged	O
phospholipids	O
and	O
uses	O
thereof	O

A	O
use	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
cathepsin	B
B	I
inhibitor	O
for	O
correcting	O
bone	O
mineralization	O
defect	O
.	O

Methods	O
of	O
correcting	O
bone	O
mineralization	O
defects	O
,	O
kits	O
therefor	O
and	O
compositions	O
therefor	O

Provided	O
are	O
crystalline	O
forms	O
of	O
nateglinide	B
and	O
processes	O
for	O
their	O
preparation	O
.	O

Polymorphic	O
forms	O
of	O
nateglinide	B

A	O
composition	O
for	O
accelerating	O
calcium	B
absorption	O
which	O
contains	O
a	O
less	O
absorbable	O
L	B
-	I
form	I
aldonic	I
acid	I
,	O
a	O
salt	O
thereof	O
,	O
or	O
a	O
less	O
absorbable	O
L	B
-	I
form	I
aldonolactone	I
;	O
and	O
a	O
food	O
or	O
beverage	O
which	O
contains	O
L	B
-	I
arabonic	I
acid	I
,	O
a	O
salt	O
thereof	O
,	O
or	O
L	B
-	I
arabonolactone	I
.	O

Also	O
provided	O
is	O
a	O
process	O
for	O
producing	O
L	B
-	I
arabono-.gamma	I
.-	I
lactone	I
crystals	O
,	O
characterized	O
by	O
dissolving	O
L	B
-	I
arabonic	I
acid	I
in	O
an	O
organic	O
solvent	O
and	O
crystallizing	O
the	O
lactone	B
from	O
the	O
solution	O
.	O

Thus	O
,	O
a	O
food	O
or	O
medicine	O
effective	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
osteoporosis	O
can	O
be	O
provided	O
.	O

Composition	O
for	O
accelerating	O
calcium	B
absorption	O

A	O
process	O
for	O
producing	O
a	O
diacylglycerol	B
-	O
containing	O
fat	O
which	O
contains	O
a	O
highly	O
unsaturated	O
fatty	B
acid	I
as	O
a	O
constituent	O
fatty	B
acid	I
and	O
in	O
which	O
the	O
proportion	O
of	O
the	O
diacylglycerol	B
to	O
all	O
natural	O
lipids	O
is	O
20	O
wt.%	O
or	O
higher	O
,	O
characterized	O
by	O
incubating	O
a	O
microorganism	O
capable	O
of	O
yielding	O
the	O
fat	O
and	O
collecting	O
the	O
fat	O
according	O
to	O
need	O
.	O

Process	O
for	O
production	O
of	O
microbial	O
fat	O
/	O
oil	O
containing	O
discretional	O
amount	O
of	O
diacylglycerol	B
and	O
said	O
fat	O
/	O
oil	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
copper	B
ions	I
to	O
achieve	O
enhanced	O
retention	O
of	O
a	O
therapeutic	O
agent	O
within	O
a	O
liposome	O
.	O

The	O
invention	O
may	O
be	O
employed	O
to	O
more	O
effectively	O
deliver	O
a	O
liposomally	O
encapsulated	O
therapeutic	O
agent	O
to	O
a	O
target	O
site	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
anti	O
-	O
cancer	O
or	O
other	O
therapy	O
.	O

The	O
liposome	O
may	O
comprise	O
an	O
interior	O
buffer	O
solution	O
containing	O
the	O
therapeutic	O
agent	O
,	O
the	O
solution	O
having	O
a	O
pH	O
less	O
than	O
6.5	O
and	O
most	O
preferably	O
approximating	O
pH	O
3.5	O
.	O

At	O
least	O
some	O
of	O
the	O
copper	B
ions	I
are	O
retained	O
within	O
the	O
interior	O
solution	O
.	O

In	O
a	O
particular	O
embodiment	O
the	O
therapeutic	O
agent	O
may	O
be	O
a	O
chemotherapeutic	O
drug	O
,	O
such	O
as	O
irinotecan	B
.	O

The	O
invention	O
may	O
also	O
comprise	O
an	O
ionophore	O
to	O
facilitate	O
loading	O
of	O
drug	O
into	O
the	O
liposome	O
.	O

In	O
one	O
particular	O
embodiment	O
the	O
combination	O
of	O
the	O
ionophore	O
A23187	O
and	O
encapsulated	O
divalent	O
copper	B
(	O
Cu2	B
+	I
)	O
resulted	O
in	O
an	O
irinotecan	O
formulation	O
that	O
exhibited	O
surprisingly	O
improved	O
drug	O
retention	O
attributes	O
.	O

Liposomes	O
with	O
improved	O
drug	O
retention	O
for	O
treatment	O
of	O
cancer	O

Method	O
for	O
treating	O
HIV	O
infection	O
through	O
co	O
-	O
administration	O
of	O
tipranavir	B
and	O
GW873140	O
.	O

Method	O
for	O
treating	O
hiv	O
infection	O
through	O
co	O
-	O
administration	O
of	O
tipranavir	B
and	O
gw873140	O

A	O
composition	O
comprising	O
:	O
(	O
i	O
)	O
an	O
antigen	O
;	O
and	O
(	O
ii	O
)	O
a	O
phosphatidyl	B
serine	I
receptor	O
ligand	O
.	O

Composition	O
comprising	O
phosphatidyl	B
serine	I
and	O
an	O
antigen	O
or	O
allergen	O
and	O
the	O
use	O
thereof	O

Methods	O
of	O
treating	O
,	O
preventing	O
and/or	O
managing	O
an	O
immunodeficiency	O
disease	O
or	O
disorder	O
are	O
disclosed	O
.	O

Specific	O
methods	O
encompass	O
the	O
administration	O
of	O
an	O
immunomodulatory	O
compound	O
alone	O
or	O
in	O
combination	O
with	O
a	O
second	O
active	O
agent	O
.	O

Methods	O
of	O
boosting	O
humoral	O
immunity	O
are	O
also	O
disclosed	O
.	O

Compositions	O
comprising	O
immunomodulatory	O
compounds	O
and	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
immunodeficiency	O
disorders	O

Disclosed	O
are	O
methods	O
of	O
treating	O
cancer	O
,	O
inflammatory	O
conditions	O
,	O
and/or	O
infectious	O
disease	O
in	O
an	O
animal	O
comprising	O
:	O
administering	O
to	O
the	O
animal	O
,	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
heterocyclic	B
compound	O
.	O

The	O
animal	O
is	O
a	O
mammal	O
,	O
preferably	O
a	O
human	O
or	O
a	O
rodent	O
.	O

Methods	O
of	O
using	O
[	B
3.2.0	I
]	I
heterocyclic	I
compounds	O
and	O
analogs	O
thereof	O

Compositions	O
comprising	O
quaternary	B
ammonium	I
halides	I
and	O
methods	O
of	O
using	O
the	O
compositions	O
comprising	O
quaternary	B
ammonium	I
halides	I
to	O
treat	O
and/or	O
prevent	O
infectious	O
conditions	O
in	O
humans	O
are	O
provided	O
.	O

Quaternary	B
ammonium	I
halides	I
for	O
treatment	O
of	O
infectious	O
conditions	O

A	O
nutritional	O
composition	O
comprising	O
at	O
least	O
an	O
effective	O
amount	O
of	O
geranylgeranylacetone	B
or	O
derivative	O
of	O
geranygeranylacetone	B
and/or	O
paeoniflorin	B
or	O
derivative	O
of	O
paeoniflorin	B
and	O
an	O
effective	O
amount	O
of	O
Schisandrin	B
B	I
,	O
wherein	O
the	O
ingredients	O
act	O
substantially	O
simultaneously	O
,	O
via	O
differing	O
mechanism	O
,	O
to	O
enhance	O
the	O
expression	O
of	O
heat	O
shock	O
protein	O
in	O
cells	O
,	O
particularly	O
heat	O
shock	O
protein	O
72	O
in	O
skeletal	O
muscle	O
.	O

A	O
method	O
of	O
same	O
is	O
also	O
provided	O
.	O

Compositions	O
and	O
methods	O
affecting	O
heat	O
shock	O
protein	O
expression	O
for	O
improved	O
muscle	O
building	O

This	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
preventing	O
,	O
treating	O
,	O
reversing	O
,	O
inhibiting	O
,	O
or	O
arresting	O
epileptogenesis	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Formula	O
(	O
I	O
)	O
and	O
Formula	O
(	O
II	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
,	O
:	O
Formula	O
(	O
I	O
)	O
Formula	O
(	O
II	O
)	O
wherein	O
phenyl	O
is	O
substituted	O
at	O
X	O
with	O
one	O
to	O
five	O
halogen	B
atoms	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
fluorine	B
,	O
chlorine	B
,	O
bromine	B
and	O
iodine	B
;	O
and	O
,	O
R	O
-	O
i	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
and	O
CrC4	B
alkyl	I
;	O
wherein	O
C1-C4	B
alkyl	I
is	O
optionally	O
substituted	O
with	O
phenyl	B
(	O
wherein	O
phenyl	B
is	O
optionally	O
substituted	O
with	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	B
,	O
CrC4	B
alkyl	I
,	O
CrC4	B
alkoxy	I
,	O
amino	B
,	O
nitro	B
and	O
cyano	B
)	O
.	O

Methods	O
of	O
treating	O
epileptogenesis	O

The	O
invention	O
provides	O
a	O
process	O
for	O
preparation	O
of	O
tiotropium	B
salts	O
of	O
Formula	O
1	O
(	O
see	O
formula	O
1	O
)	O
wherein	O
a	O
compound	O
of	O
Formula	O
2	O
(	O
see	O
formula	O
2	O
)	O
is	O
reacted	O
in	O
one	O
step	O
with	O
a	O
compound	O
of	O
Formula	O
3	O
(	O
see	O
formula	O
3	O
)	O
in	O
the	O
presence	O
of	O
a	O
solvent	O
and	O
a	O
catalyst	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
zeolites	B
,	O
alkoxides	B
,	O
lipases	O
and	O
tertiary	B
amines	I
to	O
obtain	O
a	O
compound	O
of	O
Formula	O
4	O
(	O
see	O
formula	O
4	O
)	O
and	O
without	O
being	O
isolated	O
,	O
the	O
compound	O
of	O
Formula	O
4	O
is	O
converted	O
to	O
the	O
compound	O
of	O
Formula	O
1	O
with	O
a	O
salt	O
of	O
Formula	O
cat+X-	O
.	O

Method	O
for	O
producing	O
tiotropium	B
salts	O
comprising	O
an	O
esterification	O
reaction	O
of	O
methylscopinium	B
and	O
a	O
dithienyl	B
derivative	O

Dietary	O
supplements	O
,	O
compositions	O
and	O
methods	O
of	O
administering	O
the	O
supplements	O
to	O
reduce	O
pain	O
,	O
inflammation	O
and	O
stiffness	O
in	O
said	O
mammal	O
within	O
a	O
few	O
hours	O
.	O

The	O
supplements	O
and	O
compositions	O
can	O
include	O
a	O
combination	O
of	O
an	O
amino	B
acid	I
,	O
vitamins	O
,	O
herbs	O
and	O
enzymes	O
.	O

The	O
composition	O
/	O
supplement	O
can	O
be	O
put	O
in	O
capsule	O
form	O
and	O
when	O
administered	O
to	O
mammals	O
can	O
reduce	O
these	O
symptoms	O
with	O
approximately	O
two	O
hours	O
.	O

reducing	O
the	O
pain	O
and	O
inflammation	O
associated	O
with	O
chronic	O
joint	O
discomfort	O
,	O
chronic	O
low	O
back	O
pain	O
,	O
muscle	O
strain	O
,	O
arthritis	O
,	O
sports	O
injuries	O
,	O
normal	O
everyday	O
bumps	O
and	O
bruises	O
.	O

The	O
novel	O
composition	O
has	O
also	O
been	O
shown	O
to	O
be	O
very	O
effective	O
in	O
reducing	O
monthly	O
menstrual	O
symptoms	O
(	O
PMS	O
)	O
.	O

The	O
novel	O
composition	O
can	O
also	O
have	O
benefits	O
for	O
other	O
ailments	O
such	O
as	O
but	O
not	O
limited	O
to	O
Osteoarthritis	O
,	O
Cardiovascular	O
disease	O
,	O
Neurological	O
ailments	O
,	O
Alzheimer	O
disease	O
,	O
and	O
Cancer	O
.	O

Supplements	O
for	O
pain	O
management	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
combinations	O
which	O
,	O
besides	O
one	O
or	O
more	O
,	O
preferably	O
one	O
,	O
compound	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
in	O
which	O
the	O
radicals	O
R1	O
,	O
R2	O
and	O
R3	O
have	O
the	O
meanings	O
stated	O
in	O
the	O
claims	O
and	O
in	O
the	O
description	O
,	O
comprise	O
at	O
least	O
one	O
further	O
active	O
ingredient	O
2	O
,	O
method	O
for	O
the	O
manufacture	O
thereof	O
,	O
and	O
the	O
use	O
thereof	O
as	O
pharmaceutical	O
.	O

Novel	O
pharmaceutical	O
combinations	O
for	O
the	O
treatment	O
of	O
respiratory	O
disorders	O

Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
see	O
formula	O
I	O
)	O
wherein	O
R1	O
represents	O
an	O
aryl	B
or	O
heterocyclic	B
group	O
which	O
may	O
be	O
substituted	O
or	O
the	O
like	O
;	O
X1	O
represents	O
a	O
C2-C4	B
alkylene	I
group	O
or	O
the	O
like	O
;	O
X2	O
,	O
X3	O
and	O
X5	O
independently	O
represent	O
NH	B
,	O
a	O
bond	O
or	O
the	O
like	O
;	O
X4	O
represents	O
a	O
lower	O
alkylene	B
group	O
,	O
a	O
bond	O
or	O
the	O
like	O
;	O
Y1	O
represents	O
a	O
bivalent	O
alicyclic	B
hydrocarbon	I
residue	O
which	O
may	O
be	O
substituted	O
or	O
a	O
bivalent	O
alicyclic	B
amine	I
residue	O
which	O
may	O
be	O
substituted	O
;	O
and	O
Z1	O
,	O
Z2	O
,	O
Z3	O
,	O
Z4	O
,	O
Z5	O
and	O
Z6	O
independently	O
represent	O
a	O
nitrogen	B
atom	O
,	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
CH	B
,	O
or	O
the	O
like	O
,	O
provided	O
that	O
at	O
least	O
one	O
of	O
Z3	O
,	O
Z4	O
,	O
Z5	O
and	O
Z6	O
represents	O
a	O
nitrogen	B
atom	O
or	O
a	O
salt	O
thereof	O
,	O
which	O
is	O
useful	O
as	O
an	O
antibacterial	O
agent	O
.	O

Novel	O
heterocyclic	B
compound	O
or	O
salt	O
thereof	O
and	O
intermediate	O
thereof	O

Solution	O
and	O
suspension	O
formulations	O
are	O
provided	O
for	O
administration	O
prior	O
to	O
or	O
after	O
exposure	O
to	O
ionizing	O
radiation	O
for	O
reducing	O
toxic	O
effects	O
of	O
the	O
radiation	O
in	O
a	O
subject	O
which	O
comprises	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
radioprotective	O
.alpha	B
.	I
,	I
.beta	I
.	I

unsaturated	B
aryl	I
sulfone	I
wherein	O
the	O
composition	O
has	O
a	O
pH	O
within	O
the	O
range	O
of	O
about	O
8	O
to	O
about	O
9	O
.	O

Formulations	O
of	O
radioprotective	O
.alpha	B
.	I
,	I
.beta	I
.	I

unsaturated	B
aryl	I
sulfones	I

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
the	O
formula	O
(	O
1	O
)	O
in	O
which	O
X-	O
is	O
a	O
singly	O
negatively	O
charged	O
anion	O
,	O
R	O
is	O
H	B
,	O
methyl	B
or	O
OH	B
,	O
R1	O
and	O
R2	O
are	O
identical	O
or	O
different	O
,	O
phenyl	B
or	O
thienyl	B
,	O
for	O
producing	O
a	O
medicament	O
for	O
killing	O
microorganisms	O
and/or	O
for	O
producing	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
respiratory	O
tract	O
infections	O
caused	O
by	O
microorganisms	O
.	O

Use	O
of	O
a	O
pharmaceutical	O
composition	O
comprising	O
an	O
anticholinergic	O
for	O
killing	O
microorganisms	O
and	O
for	O
treating	O
respiratory	O
tract	O
infections	O

Class	O
A	O
beta	O
-	O
lactamase	O
may	O
be	O
used	O
for	O
reducing	O
side-	O
effects	O
in	O
the	O
intestine	O
associated	O
with	O
antibiotic	O
therapy	O
with	O
a	O
combination	O
of	O
beta	B
-	I
iactam	I
antibiotic	O
and	O
beta-	O
lactamase	O
inhibitor	O
.	O

Use	O
of	O
beta	O
-	O
lactamase	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
4-	B
(	I
Heterocyclyl	I
)	I
alkyl	I
-	I
N-	I
(	I
arylsulfonyl	I
)	I
indole	I
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
above	O
said	O
novel	O
compounds	O
,	O
their	O
derivatives	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
that	O
are	O
related	O
to	O
5-HT6	O
receptor	O
functions	O
.	O

Specifically	O
,	O
the	O
compounds	O
of	O
this	O
invention	O
are	O
also	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
CNS	O
disorders	O
,	O
hematological	O
disorders	O
,	O
eating	O
disorders	O
,	O
diseases	O
associated	O
with	O
pain	O
,	O
respiratory	O
diseases	O
,	O
genito	O
-	O
urological	O
disorders	O
,	O
cardiovascular	O
diseases	O
and	O
cancer	O
.	O

4-	B
(	I
heterocyclyl	I
)	I
alkyl	I
-	I
n-	I
(	I
arylsulfonyl	I
)	I
indole	I
compounds	O
and	O
their	O
use	O
as	O
5-ht6	O
ligands	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
uses	O
thereof	O
for	O
treating	O
cancers	O
which	O
have	O
acquired	O
resistance	O
to	O
a	O
KIT	O
inhibitor	O
by	O
administering	O
effective	O
amounts	O
of	O
DAST	O
(	O
4	B
{	I
4-	I
[	I
3-	I
(	I
4-chloro-3-	I
trifluoromethylphenyf	I
)	I
-ureido	I
]	I
-3-fluorophenoxy	I
}	I
-pyridine	I
-2-carboxylic	I
acid	I
methylamide	I
.	O
)	O

Use	O
of	O
dast	O
for	O
treatment	O
of	O
cancers	O
with	O
acquired	O
resistance	O
to	O
kit	O
inhibitors	O

The	O
present	O
invention	O
provides	O
a	O
composition	O
which	O
comprises	O
olive	O
oil	O
,	O
trimethylglycine	B
and	O
xylitol	B
for	O
the	O
treatment	O
of	O
xerostomy	O
and	O
disorders	O
associated	O
therewith	O
,	O
with	O
very	O
good	O
results	O
of	O
increase	O
in	O
non	O
-	O
stimulated	O
saliva	O
flow	O
,	O
of	O
relief	O
of	O
xerostomy	O
symptoms	O
,	O
including	O
the	O
pain	O
associated	O
with	O
xerostomy	O
and	O
also	O
improvement	O
in	O
the	O
quality	O
of	O
life	O
of	O
affected	O
persons	O
.	O

The	O
composition	O
as	O
per	O
the	O
invention	O
has	O
also	O
been	O
shown	O
to	O
protect	O
dentin	O
from	O
demineralization	O
in	O
acid	O
conditions	O
.	O

Composition	O
for	O
treating	O
xerostomia	O
or	O
dry	O
mouth	O

The	O
invention	O
is	O
a	O
spot	O
treatment	O
cream	O
used	O
once	O
a	O
day	O
that	O
clears	O
acne	O
in	O
one	O
week	O
or	O
less	O
.	O

Benzoyl	B
free	O
formula	O
(	O
bff	O
)	O
acne	O
treatment	O
solution	O

The	O
present	O
invention	O
relates	O
to	O
nucleic	O
acid	O
vaccines	O
encoding	O
multiple	O
CTL	O
and	O
HTL	O
epitopes	O
and	O
MHC	O
targeting	O
sequences	O
.	O

Expression	O
vectors	O
for	O
stimulating	O
an	O
immune	O
response	O
and	O
methods	O
of	O
using	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
series	O
of	O
disaccharides	B
,	O
as	O
well	O
as	O
of	O
compositions	O
containing	O
them	O
,	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
tendon	O
,	O
ligament	O
or	O
bone	O
disease	O
,	O
disorder	O
or	O
injury	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
new	O
compositions	O
comprising	O
a	O
disaccharide	B
in	O
combination	O
with	O
inulin	O
polysulphate	O
,	O
a	O
glycosaminoglycan	O
,	O
a	O
growth	O
factor	O
or	O
cells	O
.	O

The	O
glycosaminoglycan	O
is	O
preferably	O
chondroitin	O
sulphate	O
or	O
hyaluronic	O
acid	O
and	O
the	O
growth	O
factor	O
is	O
IFG-1	O
.	O

Disaccharides	B
for	O
the	O
treatment	O
of	O
tendons	O
,	O
ligaments	O
and	O
bones	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
specific	O
types	O
of	O
compounds	O
acting	O
as	O
pharmacological	O
chaperones	O
having	O
a	O
stabilizing	O
activity	O
op	O
the	O
phenylalanine	B
hydroxylase	O
(	O
PAH	O
)	O
enzyme	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
hyperphenylalaninemia	O
(	O
HPA	O
)	O
and	O
phenylketonuria	O
(	O
PKU	O
)	O
and	O
diseases	O
,	O
disorders	O
and	O
conditions	O
related	O
thereto	O
.	O

Further	O
,	O
the	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
according	O
to	O
the	O
present	O
invention	O
as	O
well	O
as	O
to	O
methods	O
of	O
treatment	O
of	O
HPA	O
,	O
in	O
particular	O
,	O
PKU	O
and	O
diseases	O
,	O
disorders	O
and	O
conditions	O
related	O
thereto	O
.	O

Compositions	O
for	O
the	O
treatment	O
of	O
hyperphenylalaninemia	O

The	O
present	O
invention	O
relates	O
to	O
new	O
dosage	O
forms	O
of	O
cephem	B
compounds	O
,	O
useful	O
for	O
the	O
treatment	O
of	O
bacterial	O
infections	O
.	O

The	O
dosage	O
forms	O
are	O
stable	O
,	O
exhibit	O
enhanced	O
solubility	O
,	O
and	O
are	O
particularly	O
well	O
suited	O
for	O
,	O
e.g.	O
,	O
parenteral	O
administration	O
.	O

Soluble	O
dosage	O
forms	O
containing	O
cephem	B
derivatives	O
suitable	O
for	O
parenteral	O
administration	O

The	O
present	O
invention	O
generally	O
relates	O
to	O
the	O
field	O
of	O
the	O
immune	O
system	O
,	O
in	O
particular	O
to	O
strengthening	O
the	O
immune	O
system	O
of	O
the	O
elderly	O
.	O

One	O
embodiment	O
of	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
food	O
product	O
enriched	O
with	O
sialic	B
acid	I
for	O
the	O
preparation	O
of	O
a	O
composition	O
to	O
strengthen	O
the	O
immune	O
system	O
.	O

Sialic	B
acid	I
to	O
support	O
the	O
immune	O
system	O
in	O
the	O
elderly	O

The	O
claimed	O
invention	O
is	O
directed	O
towards	O
the	O
generation	O
of	O
pluripotent	O
,	O
multipotent	O
,	O
and/or	O
self	O
-	O
renewing	O
cells	O
which	O
are	O
capable	O
of	O
beginning	O
to	O
differentiate	O
in	O
culture	O
into	O
a	O
variety	O
of	O
cell	O
types	O
and	O
capable	O
of	O
further	O
differentiation	O
in	O
vivo	O
.	O

The	O
claimed	O
invention	O
is	O
also	O
directed	O
towards	O
the	O
generation	O
of	O
desirable	O
,	O
differentiating	O
cell	O
populations	O
transplantable	O
to	O
patients	O
,	O
genetic	O
modification	O
of	O
endogenous	O
cells	O
,	O
and	O
the	O
treatment	O
of	O
patients	O
suffering	O
from	O
diseases	O
that	O
may	O
be	O
ameliorated	O
by	O
these	O
methods	O
.	O

This	O
invention	O
also	O
provides	O
methods	O
for	O
preventing	O
,	O
treating	O
,	O
or	O
retarding	O
disease	O
related	O
to	O
immunodeficiency	O
virus	O
(	O
e.g.	O
HIV	O
-	O
I	O
,	O
HIV-2	O
,	O
SIV	O
,	O
FIV	O
,	O
etc	O
.	O
)	O
infection	O
.	O

Methods	O
for	O
production	O
and	O
uses	O
of	O
multipotent	O
cell	O
populations	O
,	O
pluripotent	O
cell	O
populations	O
,	O
neuronal	O
cell	O
populations	O
,	O
and	O
muscle	O
cell	O
populations	O

The	O
disclosed	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
a	O
disorder	O
modulated	O
by	O
blocking	O
angiotensin	B
I1	I
(	O
All	O
)	O
receptors	O
,	O
and	O
particularly	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hypertension	O
,	O
congestive	O
heart	O
failure	O
,	O
renal	O
failure	O
,	O
and	O
combinations	O
thereof	O
,	O
by	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
effective	O
dose	O
of	O
an	O
eprosartan	O
compound	O
.	O

With	O
reference	O
to	O
the	O
Recommended	O
Effective	O
Daily	O
Dose	O
of	O
600	O
mg	O
,	O
calculated	O
on	O
the	O
basis	O
of	O
eprosartan	B
administered	O
in	O
the	O
form	O
of	O
eprosartan	B
mesylate	I
,	O
it	O
has	O
now	O
been	O
found	O
that	O
a	O
lower	O
dose	O
of	O
eprosartan	B
can	O
be	O
administered	O
when	O
the	O
eprosartan	B
compound	O
is	O
eprosartan	B
acid	I
.	O

This	O
dose	O
is	O
in	O
the	O
range	O
of	O
from	O
410	O
to	O
490	O
mg	O
,	O
most	O
preferably	O
about	O
450	O
mg	O
.	O

Eprosartan	B
compositions	O

A	O
method	O
and	O
compound	O
for	O
suppressing	O
an	O
immune	O
response	O
in	O
a	O
mammalian	O
subject	O
,	O
for	O
the	O
treatment	O
or	O
pre	O
-	O
vention	O
of	O
an	O
autoimmune	O
condition	O
or	O
transplantation	O
rejection	O
are	O
disclosed	O
.	O

The	O
compound	O
is	O
an	O
antisense	O
oligonucleotide	O
ana	O
-	O
log	O
compound	O
having	O
a	O
targeting	O
sequence	O
complementary	O
to	O
a	O
preprocessed	O
CTLA	O
4	O
mRNA	O
region	O
identified	O
by	O
SEQ	O
ID	O
NO	O
:	O
22	O
in	O
SEQ	O
ID	O
NO	O

:	O
1	O
,	O
spanning	O
the	O
splice	O
junction	O
between	O
intron	O
1	O
and	O
exon	O
2	O
of	O
the	O
preprocessed	O
mRNA	O
of	O
the	O
subject	O
.	O

The	O
com	O
-	O
pound	O
is	O
effective	O
,	O
when	O
administered	O
to	O
a	O
subject	O
,	O
to	O
form	O
within	O
host	O
cells	O
,	O
a	O
heteroduplex	O
structure	O
(	O
i	O
)	O
composed	O
of	O
the	O
prepro	O
-	O
cessed	O
CTLA	O
4	O
mRNA	O
and	O
the	O
oligonucleotide	O
compound	O
,	O
(	O
ii	O
)	O
characterized	O
by	O
a	O
Tm	O
of	O
dissociation	O
of	O
at	O
least	O
45	O
°	O
C	O
,	O
and	O
(	O
iii	O
)	O
re	O
-	O
sulting	O
in	O
an	O
increased	O
ratio	O
of	O
processed	O
mRNA	O
encoding	O
ligand	O
independent	O
CTLA	O
4	O
to	O
processed	O
mRNA	O
encoding	O
full	O
length	O
CTLA	O
4	O
.	O

Immunosuppression	O
compound	O
and	O
treatment	O
method	O

Disclosed	O
are	O
methods	O
and	O
compositions	O
for	O
modulating	O
the	O
function	O
of	O
transcription	O
factors	O
,	O
especially	O
transcription	O
factors	O
that	O
recruit	O
epigenetic	O
regulators	O
(	O
histone	O
modifying	O
enzymes	O
)	O
to	O
specific	O
DNA	O
promoters	O
.	O

The	O
targeted	O
transcription	O
factors	O
include	O
but	O
are	O
not	O
limited	O
to	O
the	O
myocyte	O
enhancing	O
factor	O
(	O
MEF2	O
)	O
,	O
the	O
forkhead	O
/	O
winged	O
helix	O
transcription	O
factor	O
FOX	O
-	O
P3	O
and	O
the	O
transcription	O
factor	O
GATA3	O
.	O

Also	O
disclosed	O
are	O
small	O
molecule	O
modulators	O
of	O
MEF2	O
and	O
its	O
associated	O
factors	O
that	O
include	O
but	O
not	O
limited	O
to	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
,	O
p300	O
/	O
CBP	O
and	O
Cabin	O
1	O
and	O
the	O
therapeutic	O
applications	O
thereof	O
.	O

Small	O
molecule	O
modulators	O
of	O
epigenetic	O
regulation	O
and	O
their	O
therapeutic	O
applications	O

Dosage	O
regimens	O
for	O
at	O
least	O
one	O
compound	O
chosen	O
from	O
lurasidone	B
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
clathrates	O
,	O
and	O
stereoisomers	O
thereof	O
are	O
disclosed	O
as	O
are	O
kits	O
and	O
methods	O
for	O
treatment	O
and/or	O
prevention	O
of	O
at	O
least	O
one	O
CNS	O
disorder	O
such	O
as	O
,	O
for	O
example	O
,	O
mixed	O
depression	O
and	O
bipolar	O
disorder	O
,	O
and	O
management	O
of	O
at	O
least	O
one	O
CNS	O
disorder	O
,	O
such	O
as	O
improving	O
quality	O
of	O
life	O
and	O
reversing	O
impairment	O
in	O
learning	O
and	O
memory	O
associated	O
with	O
schizophrenia	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
a	O
therapeutically	O
or	O
prophylactically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
chosen	O
from	O
lurasidone	B
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
clathrates	B
,	O
and	O
stereoisomers	O
thereof	O
.	O

Novel	O
dosage	O
regimens	O
and	O
methods	O
for	O
treatment	O
,	O
prevention	O
,	O
and/or	O
management	O
of	O
at	O
least	O
one	O
cns	O
disorder	O

Disclosed	O
are	O
JAK	O
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
where	O
G1	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
and	O
R7	O
are	O
defined	O
in	O
the	O
specification	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
,	O
kits	O
and	O
articles	O
of	O
manufacture	O
which	O
contain	O
the	O
compounds	O
,	O
methods	O
and	O
materials	O
for	O
making	O
the	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
to	O
treat	O
diseases	O
,	O
disorders	O
,	O
and	O
conditions	O
involving	O
the	O
immune	O
system	O
and	O
inflammation	O
,	O
including	O
rheumatoid	O
arthritis	O
,	O
hematological	O
malignancies	O
,	O
epithelial	O
cancers	O
(	O
i.e.	O
,	O
carcinomas	O
)	O
,	O
and	O
other	O
diseases	O
,	O
disorders	O
or	O
conditions	O
associated	O
with	O
JAK	O
.	O

Dihydropyrrolonaphtyridinone	B
compounds	O
as	O
inhibitors	O
of	O
jak	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
benzosulphonamide	B
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
A	O
are	O
as	O
defined	O
in	O
the	O
claims	O
,	O
to	O
methods	O
of	O
preparing	O
said	O
compounds	O
,	O
to	O
pharmaceutical	O
compositions	O
and	O
combinations	O
comprising	O
said	O
compounds	O
and	O
to	O
the	O
use	O
of	O
said	O
compounds	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
disease	O
,	O
in	O
particular	O
of	O
a	O
hyper	O
-	O
proliferative	O
and/or	O
angiogenesis	O
disorder	O
,	O
as	O
a	O
sole	O
agent	O
or	O
in	O
combination	O
with	O
other	O
active	O
ingredients	O
.	O

Substituted	O
benzosulphonamides	B

Fragmented	O
polysaccharide	O
based	O
hydrogel	O
compositions	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
same	O
are	O
provided	O
.	O

The	O
subject	O
polysaccharide	O
based	O
hydrogel	O
compositions	O
are	O
prepared	O
by	O
combining	O
a	O
polysaccharide	O
component	O
with	O
a	O
hydrophilic	O
polymer	O
and	O
a	O
cross	O
-	O
linking	O
agent	O
.	O

Also	O
provided	O
are	O
kits	O
and	O
systems	O
for	O
use	O
in	O
preparing	O
the	O
subject	O
compositions	O
.	O

Fragmented	O
hydrogels	O

The	O
invention	O
comprises	O
a	O
method	O
of	O
treatment	O
of	O
CNS	O
disorders	O
by	O
a	O
pharmaceutical	O
agent	O
exhibiting	O
combined	O
noradrenergic	O
,	O
serotonergic	O
or	O
dopaminergic	O
reuptake	O
transporter	O
inhibitory	O
and	O
µ-opioid	O
agonistic	O
activity	O
.	O

Method	O
of	O
treatment	O
of	O
cns	O
disorders	O

Described	O
herein	O
are	O
compositions	O
comprising	O
shortened	O
fibers	O
of	O
poly	B
-	I
N	I
-	I
acetylglucosamine	I
and/or	O
a	O
derivative	O
thereof	O
(	O
""""	O
sNAG	O
nanofibers	O
""""	O
)	O
and	O
anti	O
-	O
bacterial	O
applications	O
of	O
such	O
compositions	O
.	O

The	O
sNAG	O
nanofibers	O
may	O
be	O
formulated	O
into	O
compositions	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
bacterial	O
infections	O
and	O
diseases	O
associated	O
with	O
such	O
infections	O
.	O

Regimens	O
employing	O
such	O
compositions	O
are	O
also	O
described	O
.	O

Anti	O
-	O
bacterial	O
applications	O
of	O
poly	B
-	I
n	I
-	I
acetylglucosamine	I
nanofibers	O

which	O
include	O
such	O
co	O
-	O
crystals	O
and	O
methods	O
for	O
treating	O
conditions	O
associated	O
with	O
hyper	O
-	O
cholesterolemia	O
Methods	O
for	O
the	O
preparation	O
of	O
Rosuvastatin	B
by	O
co	O
-	O
crystals	O
of	O
Rosuvastatin	B
or	O
intermediates	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
co	O
-	O
crystals	O
,	O
pharmaceutical	O
compositions	O
by	O
administering	O
such	O
compositions	O
.	O

Co	O
-	O
crystal	O
intermediates	O
of	O
rosuvastatin	B
and	O
methods	O
of	O
using	O
same	O

A	O
composition	O
provides	O
an	O
isotonic	O
nasal	O
irrigation	O
solution	O
with	O
pH	O
less	O
than	O
about	O
7Ø	O
The	O
composition	O
may	O
be	O
formed	O
of	O
a	O
salt	O
and	O
a	O
pH	O
buffer	O
and	O
may	O
include	O
an	O
additive	O
.	O

The	O
composition	O
may	O
be	O
mixed	O
with	O
water	O
to	O
form	O
the	O
solution	O
.	O

The	O
composition	O
may	O
aid	O
in	O
the	O
treatment	O
of	O
various	O
nasal	O
or	O
sinus	O
disorders	O
such	O
as	O
,	O
for	O
example	O
,	O
dryness	O
,	O
rhinitis	O
,	O
and	O
sinusitis	O
.	O

The	O
isotonic	O
irrigation	O
solution	O
may	O
also	O
aid	O
in	O
the	O
removal	O
of	O
contaminants	O
from	O
the	O
sinus	O
and	O
nasal	O
cavities	O
such	O
as	O
blood	O
,	O
mucus	O
,	O
dirt	O
,	O
pollen	O
,	O
allergens	O
,	O
viruses	O
,	O
and	O
bacterial	O
.	O

The	O
composition	O
may	O
be	O
liquid	O
or	O
dry	O
.	O

Nasal	O
wash	O
solution	O

The	O
invention	O
provides	O
methods	O
,	O
compositions	O
,	O
and	O
dietary	O
formulations	O
useful	O
for	O
preventing	O
or	O
treating	O
dermatitis	O
,	O
promoting	O
healthy	O
skin	O
,	O
and	O
retarding	O
skin	O
aging	O
.	O

The	O
methods	O
comprise	O
administering	O
to	O
an	O
animal	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
combination	O
of	O
at	O
least	O
two	O
of	O
one	O
or	O
more	O
antioxidants	O
;	O
one	O
or	O
more	O
anti	O
-	O
glycation	O
agents	O
;	O
one	O
or	O
more	O
body	O
fat	O
reducing	O
agents	O
;	O
one	O
or	O
more	O
insulin	O
sensitivity	O
enhancing	O
agents	O
;	O
and	O
one	O
or	O
more	O
anti	O
-	O
inflammatory	O
agents	O
.	O

Methods	O
and	O
compositions	O
suitable	O
for	O
promoting	O
healthy	O
skin	O

Some	O
aspects	O
of	O
the	O
invention	O
provide	O
for	O
a	O
method	O
of	O
treating	O
Wet	O
and/or	O
Dry	O
Age	O
-	O
related	O
Macular	O
Degeneration	O
,	O
Retinitis	O
Pigmentosa	O
,	O
Diabetic	O
Retinopathy	O
,	O
cataracts	O
,	O
and/or	O
Stargardt	O
Disease	O
using	O
polyunsaturated	B
fatty	I
acids	I
which	O
are	O
modified	O
in	O
certain	O
positions	O
to	O
attenuate	O
oxidative	O
damage	O
by	O
Reactive	O
Oxygen	B
Species	O
(	O
ROS	O
)	O
and/or	O
suppress	O
the	O
rate	O
of	O
formation	O
of	O
reactive	O
products	O
and	O
toxic	O
compounds	O
.	O

Oxidative	O
retinal	O
diseases	O

This	O
invention	O
relates	O
to	O
novel	O
compounds	O
suitable	O
for	O
labeling	O
by	O
18F	B
and	O
to	O
the	O
corresponding	O
18F	B
labeled	O
compounds	O
themselves	O
,	O
19F	B
-	O
fluorinated	O
analogues	O
thereof	O
and	O
their	O
use	O
as	O
reference	O
standards	O
,	O
methods	O
of	O
preparing	O
such	O
compounds	O
,	O
compositions	O
comprising	O
such	O
compounds	O
,	O
kits	O
comprising	O
such	O
compounds	O
or	O
compositions	O
and	O
uses	O
of	O
such	O
compounds	O
,	O
compositions	O
or	O
kits	O
for	O
diagnostic	O
imaging	O
by	O
Positron	O
Emission	O
Tomography	O
(	O
PET	O
)	O
.	O

Radiolabeled	O
amino	B
acids	I
for	O
diagnostic	O
imaging	O

An	O
energy	O
tablet	O
and	O
method	O
of	O
manufacturing	O
the	O
same	O
that	O
successfully	O
masks	O
the	O
bitter	O
taste	O
of	O
caffeine	B
which	O
has	O
precluded	O
popularity	O
of	O
chewable	O
energy	O
tablets	O
in	O
the	O
past	O
.	O

Sweet	O
tart	O
energy	O
tablet	O

Provided	O
herein	O
are	O
methods	O
,	O
compounds	O
,	O
and	O
compositions	O
for	O
reducing	O
expression	O
of	O
GCCR	O
mRNA	O
and	O
protein	O
in	O
an	O
animal	O
.	O

Such	O
methods	O
,	O
compounds	O
,	O
and	O
compositions	O
are	O
useful	O
to	O
treat	O
,	O
prevent	O
,	O
delay	O
,	O
or	O
ameliorate	O
metabolic	O
disease	O
,	O
for	O
example	O
,	O
diabetes	O
,	O
or	O
a	O
symptom	O
thereof	O
.	O

Antisense	O
modulation	O
of	O
gccr	O
expression	O

The	O
present	O
invention	O
relates	O
to	O
the	O
combination	O
of	O
memantine	B
and	O
baclofen	B
active	O
ingredients	O
,	O
and	O
also	O
to	O
the	O
method	O
for	O
achieving	O
body	O
weight	O
loss	O
and	O
thereby	O
treating	O
obesity	O
and	O
related	O
co	O
-	O
morbidities	O
by	O
co	O
-	O
administration	O
of	O
baclofen	B
and	O
memantine	B
.	O

Therapeutic	O
combination	O
of	O
memantine	B
and	O
baclofen	B
and	O
pharmaceutical	O
composition	O
containing	O
them	O

The	O
present	O
invention	O
relates	O
to	O
the	O
phytocannabinoid	B
tetrahydrocannabivarin	I
(	O
THCV	B
)	O
for	O
use	O
in	O
the	O
protection	O
of	O
pancreatic	O
islet	O
cells	O
.	O

Preferably	O
the	O
pancreatic	O
islet	O
cells	O
to	O
be	O
protected	O
are	O
beta	O
cells	O
.	O

More	O
preferably	O
the	O
protection	O
of	O
the	O
pancreatic	O
islet	O
cells	O
maintains	O
insulin	O
production	O
at	O
levels	O
which	O
are	O
able	O
to	O
substantially	O
control	O
or	O
improve	O
control	O
of	O
blood	O
glucose	B
levels	O
in	O
a	O
patient	O
.	O

Tetrahydrocannabivarin	B
(	O
thcv	B
)	O
for	O
use	O
in	O
the	O
protection	O
of	O
pancreatic	O
islet	O
cells	O

Provided	O
is	O
a	O
chelating	O
composite	O
micell	O
to	O
be	O
used	O
in	O
a	O
drug	O
carrier	O
,	O
and	O
the	O
chelating	O
composite	O
micell	O
of	O
the	O
present	O
invention	O
can	O
bond	O
to	O
drugs	O
without	O
damaging	O
or	O
changing	O
their	O
structure	O
and	O
extend	O
the	O
half	O
-	O
life	O
of	O
the	O
drugs	O
in	O
the	O
human	O
body	O
.	O

A	O
drug	O
carrier	O
with	O
chelating	O
complex	O
micelles	O
and	O
the	O
application	O
thereof	O

Extracts	O
obtained	O
from	O
the	O
genus	O
Hippophae	O
or	O
other	O
plant	O
sources	O
or	O
compositions	O
produced	O
by	O
chemical	O
or	O
molecular	O
biological	O
techniques	O
each	O
having	O
in	O
common	O
certain	O
moieties	O
in	O
amounts	O
effective	O
when	O
combined	O
with	O
reproductive	O
cells	O
to	O
reduce	O
the	O
loss	O
of	O
function	O
.	O

Reproductive	O
cell	O
maintenance	O
system	O

The	O
present	O
invention	O
relates	O
to	O
an	O
improved	O
process	O
for	O
recovery	O
of	O
nalmefene	B
hydrochloride	I
[	B
17-	I
(	I
cyclopropylmethyl	I
)	I
-4,5-alpha	I
-	I
epoxy-6-methylenemorphinan-3,14-diol	I
hydrochloride	I
]	I
from	O
an	O
aqueous	O
composition	O
containing	O
nalmefene	B
and	O
certain	O
impurities	O
.	O

Process	O
for	O
recovery	O
of	O
nalmefene	B
hydrochloride	I

Citric	B
acid	I
and	O
conjugate	O
bases	O
thereof	O
are	O
useful	O
for	O
stabilizing	O
stabilized	O
chlorine	B
dioxide	I
in	O
the	O
presence	O
of	O
therapeutically	O
active	O
agents	O
and	O
excipients	O
in	O
a	O
composition	O
.	O

Ophthalmic	O
compositions	O
and	O
methods	O
related	O
thereto	O
are	O
also	O
disclosed	O
herein	O
.	O

Stabilized	O
compositions	O
comprising	O
therapeutically	O
active	O
agent	O
,	O
citric	B
acid	I
or	O
conjugated	O
base	O
and	O
chlorine	B
dioxide	I

An	O
injectable	O
pharmaceutical	O
composition	O
for	O
treatment	O
of	O
erectile	O
dysfunction	O
.	O

The	O
composition	O
includes	O
prostaglandin	B
E-1	I
,	O
and	O
optionally	O
further	O
includes	O
levsin	B
and/or	O
additional	O
vasodilators	O
such	O
as	O
diltiazem	B
HC1	I
,	O
veparamill	B
,	O
chlorpromazine	B
,	O
d	B
,	I
L	I
-	I
hyoscyamine	I
,	O
and	O
6,7-dimethoxy-1-veratrylisoquinoline	B
HC1	I
.	O

The	O
composition	O
is	O
effective	O
for	O
long	O
-	O
term	O
restoration	O
of	O
normal	O
erectile	O
function	O
to	O
a	O
patient	O
having	O
erectile	O
dysfunction	O
.	O

The	O
ability	O
to	O
reverse	O
erectile	O
dysfunction	O
may	O
be	O
further	O
enhanced	O
by	O
the	O
inclusion	O
of	O
vitamin	B
B-6	I
,	I
B12	I
,	O
folic	B
acid	I
,	O
and/or	O
TPA	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
treatment	O
and	O
reversal	O
of	O
erectile	O
dysfunction	O
by	O
injecting	O
the	O
pharmaceutical	O
composition	O
into	O
the	O
penis	O
,	O
either	O
by	O
subcutaneous	O
or	O
intracavernosal	O
injection	O
.	O

Injectable	O
pharmaceutical	O
composition	O
for	O
treatment	O
and	O
reversal	O
of	O
erectile	O
dysfunction	O

A	O
process	O
for	O
preparing	O
the	O
capsule	O
used	O
for	O
activating	O
blood	O
and	O
relieving	O
pain	O
includes	O
such	O
steps	O
as	O
supercritical	O
extracting	O
to	O
Chinese	O
angelica	O
root	O
and	O
frankincense	O
to	O
obtain	O
volatile	O
oil	O
,	O
including	O
it	O
with	O
beta	O
-	O
cyclodextrin	O
to	O
obtain	O
the	O
included	O
substance	O
A	O
,	O
including	O
borneol	B
with	O
beta	O
-	O
cyclodextrin	O
to	O
obtain	O
the	O
included	O
substance	O
B	O
,	O
extracting	O
from	O
the	O
dregs	O
generated	O
by	O
said	O
supercritical	O
extracting	O
in	O
alcohol	B
to	O
obtain	O
alcohol	B
extract	O
,	O
extracting	O
from	O
ground	O
beetle	O
and	O
pyrite	O
in	O
water	O
to	O
obtain	O
aquatic	O
extract	O
,	O
pulverizing	O
notoginseng	O
to	O
obtain	O
superfine	O
powder	O
,	O
mixing	O
them	O
together	O
,	O
granulating	O
and	O
filling	O
in	O
capsules	O
.	O

Preparation	O
of	O
blood	O
-	O
activating	O
and	O
pain	O
-	O
stopping	O
capsules	O

Gram	O
Liewei	O
in	O
the	O
preparation	O
tyrosinase	O
inhibitor	O
's	O
application	O
relates	O
to	O
one	O
kind	O
of	O
gram	O
Liewei	O
to	O
be	O
mellow	O
mellowly	O
,	O
which	O
provides	O
one	O
kind	O
to	O
originate	O
from	O
mangrove	O
forest	O
endogenous	O
fungus	O
secondary	O
metabolite	O
gram	O
Liewei	O
mellowly	O
in	O
the	O
preparation	O
tyrosinase	O
inhibitor	O
application	O
.	O

The	O
preparation	O
method	O
is	O
:	O
dwarf	O
rods	O
Aspergillus	O
BYY-1	O
seed	O
culture	O
;	O
submerged	O
fermentation	O
;	O
broth	O
filter	O
strains	O
;	O
concentrated	O
filtrate	O
decompression	O
after	O
repeatedly	O
using	O
organic	O
solvent	O
extraction	O
,	O
collection	O
and	O
decompression	O
organic	O
phase	O
was	O
concentrated	O
extracts	O
;	O
Extracts	O
of	O
the	O
silica	B
gel	I
column	O
chromatography	O
and	O
recrystallization	O
obtained	O
after	O
refining	O
grams	O
Levy	O
alcohol	O
.	O

The	O
pharmacological	O
experiments	O
have	O
confirmed	O
that	O
the	O
compound	O
significantly	O
inhibited	O
the	O
activity	O
of	O
tyrosine	B
,	O
can	O
be	O
used	O
for	O
preparation	O
of	O
tyrosinase	O
inhibitors	O
and	O
applied	O
to	O
pharmaceuticals	O
,	O
cosmetics	O
and	O
food	O
.	O

It	O
may	O
obtain	O
through	O
the	O
fermentation	O
system	O
,	O
raw	O
material	O
is	O
rich	O
,	O
moreover	O
the	O
extraction	O
purification	O
method	O
is	O
simple	O
,	O
suits	O
the	O
formalization	O
production	O
.	O

Use	O
of	O
krev	O
alcohol	B
in	O
preparing	O
tyrosinase	O
inhibitor	O

A	O
snuff	O
for	O
preventing	O
and	O
treating	O
senile	O
dementia	O
,	O
improving	O
memory	O
and	O
regulating	O
the	O
permeability	O
of	O
blood	O
brain	O
barrier	O
is	O
prepared	O
from	O
the	O
active	O
component	O
(	O
s	O
)	O
chosen	O
from	O
eugenol	B
,	O
its	O
salt	O
,	O
itsisomer	O
and	O
their	O
mixture	O
,	O
and	O
selective	O
natural	O
spice	O
.	O

Permeability	O
nose	O
absorption	O
type	O
medicine	O
for	O
treating	O
and	O
preventing	O
senile	O
dementia	O
,	O
improving	O
learning	O
memory	O
faculty	O
and	O
regulating	O
blood	O
brain	O
barrier	O

The	O
invention	O
provides	O
a	O
silybin	B
and	O
phosphatidy	B
lcholine	I
compound	O
which	O
is	O
prepared	O
into	O
capsules	O
with	O
high	O
dissolving	O
degree	O
.	O

The	O
invention	O
also	O
provides	O
a	O
process	O
for	O
preparing	O
the	O
silybin	O
and	O
phosphatidy	B
lcholine	I
compound	O
and	O
its	O
capsule	O
medicament	O
,	O
the	O
preparing	O
process	O
is	O
characterized	O
by	O
simple	O
manufacturing	O
method	O
,	O
high	O
yield	O
and	O
fitting	O
for	O
mass	O
production	O
.	O

Pharmaceutical	O
composition	O
of	O
Silybin	B
and	O
preparation	O
method	O
thereof	O

A	O
medicinal	O
composition	O
for	O
injection	O
,	O
perfusion	O
,	O
or	O
freeze	O
-	O
dried	O
powder	O
injection	O
contains	O
high	O
-	O
purity	O
danshenolic	B
acid	I
A	I
and	O
high	O
-	O
purity	O
danshenolic	B
acid	I
B.	I
Its	O
preparing	O
process	O
and	O
quality	O
control	O
method	O
are	O
also	O
disclosed	O
.	O

Medicine	O
composition	O
used	O
for	O
injection	O
and	O
its	O
preparing	O
method	O

A	O
liquid	O
-	O
phase	O
nano	O
-	O
Se	B
containing	I
VC	I
used	O
as	O
a	O
bioactive	O
health	O
-	O
care	O
product	O
stored	O
in	O
liquid	O
phase	O
is	O
prepared	O
through	O
dropping	O
the	O
solution	O
of	O
selenium	B
oxide	I
or	O
selenite	B
into	O
VC	B
solution	O
while	O
stirring	O
until	O
the	O
red	O
color	O
is	O
not	O
changed	O
.	O

It	O
can	O
be	O
used	O
to	O
prepare	O
medicines	O
.	O

Liquid	O
vitamic	B
C	I
compounded	O
nanometer	O
elementary	O
selenium	B
its	O
preparation	O
method	O
and	O
storage	O
method	O

A	O
microemulsion	O
of	O
hypocrelline	O
for	O
venous	O
injection	O
with	O
high	O
stability	O
,	O
target	O
nature	O
and	O
biodegradability	O
and	O
strong	O
photodynamic	O
function	O
is	O
proportionally	O
prepared	O
from	O
hypocrelline	O
,	O
natural	O
oil	O
,	O
surfactant	O
,	O
water	O
-	O
soluble	O
polyol	O
,	O
and	O
water	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Microemulsion	O
of	O
hypocrellin	O
,	O
and	O
its	O
preparing	O
method	O

An	O
application	O
of	O
the	O
chlorogenic	B
acid	I
along	O
with	O
medicinal	O
carrier	O
and/or	O
excipient	O
in	O
preparing	O
the	O
medicines	O
for	O
preventing	O
and	O
treating	O
amplications	O
of	O
diabetes	O
is	O
disclosed	O
.	O

Application	O
of	O
chlorogenic	B
acid	I
for	O
preparing	O
medicine	O
to	O
treat	O
diabetes	O
complications	O

A	O
series	O
of	O
spherosin	B
medicines	O
in	O
the	O
form	O
of	O
slowly	O
-	O
released	O
tablet	O
,	O
slowly	O
-	O
released	O
capsule	O
,	O
or	O
injection	O
for	O
treating	O
the	O
tumor	O
in	O
digestive	O
tract	O
,	O
leukemia	O
,	O
melanoma	O
and	O
AIDS	O
,	O
and	O
its	O
preparing	O
process	O
are	O
disclosed	O
.	O

Series	O
preparation	O
of	O
swainsonine	B
,	O
preparing	O
method	O
and	O
use	O
thereof	O

An	O
eyedrops	O
of	O
the	O
quinolone	O
medicine	O
for	O
treating	O
bacterial	O
conjunctivitis	O
,	O
keratitis	O
,	O
corneal	O
ulcer	O
,	O
dacryocystitis	O
,	O
trachoma	O
,	O
and	O
the	O
eye	O
infection	O
after	O
operation	O
is	O
prepared	O
from	O
the	O
medicine	O
A	O
and	O
additives	O
.	O

Said	O
medicine	O
A	O
is	O
6-fluoro-	B
1-methyl	I
,	I
4-oxy-7-	I
(	I
1-piperazinyl	I
)	I
-4H-	I
[	I
1	I
,	I
3	I
]	I
thiazine	I
[	I
3	I
,	I
2-a	I
]	I
quinoline-3-	I
carboxylate	I
,	O
or	O
its	O
hydrochloride	B
,	O
or	O
its	O
methanesulfonate	B
.	O

Anti	O
-	O
inflammatory	O
and	O
sterilizing	O
preparation	O

A	O
slowly	O
-	O
released	O
tablet	O
of	O
clarithromycin	B
contains	O
proportionally	O
clarithromycin	B
,	O
high	O
-	O
molecular	O
adhesive	O
,	O
flow	O
-	O
assistant	O
lubricant	O
,	O
pH	O
regulator	O
and	O
sweetening	O
agent	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Slow	O
releace	O
tablets	O
of	O
clarithromycin	B
,	O
and	O
its	O
preparing	O
method	O

A	O
medicine	O
for	O
treating	O
the	O
lichen	O
sclerosus	O
of	O
vulva	O
and	O
hypoestrin	O
vaginitis	O
is	O
prepared	O
from	O
17	O
raw	O
materials	O
including	O
allantoin	B
,	O
VE	O
,	O
concentrated	O
fish	O
liver	O
oil	O
,	O
glycerin	B
borate	I
,	O
and	O
13	O
Chinese	O
-	O
medicinal	O
materials	O
including	O
cloves	O
,	O
liquorice	O
root	O
,	O
borneol	B
,	O
etc	O
.	O

Medicine	O
for	O
treating	O
proganital	O
lichen	O
sclerosus	O
disease	O

This	O
invention	O
relates	O
to	O
quinazoline	B
compounds	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
as	O
shown	O
in	O
general	O
formula	O
I.	O
In	O
the	O
formula	O
,	O
R1	O
,	O
Q1	O
,	O
Q2	O
and	O
m	O
are	O
defined	O
in	O
the	O
invention	O
.	O

This	O
invention	O
also	O
relates	O
to	O
their	O
preparation	O
method	O
,	O
and	O
drug	O
composition	O
containing	O
them	O
with	O
effective	O
dosage	O
.	O

The	O
quinazoline	B
compounds	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
as	O
shown	O
in	O
general	O
formula	O
I	O
can	O
inhibit	O
epidermal	O
growth	O
factor	O
receptor	O
protein	O
on	O
bacteria	O
surface	O
thus	O
can	O
be	O
used	O
to	O
treat	O
hyperplasia	O
diseases	O
such	O
as	O
cancer	O
.	O

Compound	O
in	O
quinazoline	B
class	O
or	O
its	O
pharmaceutical	O
salt	O
preparation	O
method	O
,	O
and	O
medical	O
usage	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
containing	O
mycophenolate	B
mofetil	I
,	O
which	O
can	O
be	O
prepared	O
into	O
dispersible	O
tablets	O
,	O
thereby	O
overcoming	O
the	O
shortcomings	O
of	O
difficult	O
swallowing	O
and	O
weak	O
medicine	O
compliance	O
existed	O
in	O
the	O
conventional	O
dose	O
forms	O
,	O
as	O
a	O
result	O
,	O
the	O
patients	O
can	O
administrate	O
the	O
medicament	O
more	O
easily	O
.	O

The	O
invention	O
relates	O
to	O
the	O
process	O
for	O
preparing	O
compositions	O
containing	O
mycophenolate	B
mofetil	I
.	O

Medicinal	O
composition	O
containing	O
mycophonolate	B
mofetil	I
and	O
its	O
preparation	O
method	O

Disclosed	O
is	O
an	O
water	O
soluble	O
vitamin	O
freeze	O
-	O
drying	O
preparation	O
containing	O
no	O
bacteria	O
inhibitor	O
,	O
wherein	O
each	O
bottle	O
of	O
the	O
preparation	O
comprises	O
constituents	O
of	O
aneurine	B
mononitrate	I
2.79	O
-	O
3.41	O
mg	O
,	O
riboflavin	B
sodium	I
phosphate	I
4.41	O
-	O
5.39	O
mg	O
,	O
nicotinamide	B
36	O
-	O
44	O
mg	O
,	O
chlorhydric	B
pyridoxine	I
4.41	O
-	O
5.39	O
mg	O
,	O
sodium	B
pantothenate	I
14.85	O
-	O
18.15	O
mg	O
,	O
vitamin	B
C	I
sodium	I
101.7	O
-	O
124.3	O
mg	O
,	O
biotin	B
54	O
-	O
66mug	O
,	O
folic	B
acid	I
0.36	O
-	O
0.44	O
mg	O
,	O
vitamin	B
B12	I
4.5	O
-	O
5.5mug	O
,	O
glycine	B
270	O
-	O
330	O
mg	O
,	O
and	O
dium	B
ethylenediamine	I
tetraacetate	I
0.45	O
-	O
0.55	O
mg	O
.	O

Bacteriostat	O
-	O
free	O
water	O
-	O
soluble	O
vitamin	O
freeze	O
-	O
dried	O
preparation	O
for	O
injection	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
controlling	O
quality	O
of	O
turpinia	O
ternata	O
nakai	O
and	O
its	O
preparation	O
,	O
wherein	O
the	O
index	O
includes	O
the	O
constituents	O
of	O
gallic	B
acid	I
,	O
apigenin-7-O	B
-	I
neohesperidoside	I
,	O
apigenin-7-O-2'-isodulcitolrutinoside	B
,	O
apigenin-7-O	B
-	I
beta	I
-	I
D	I
-	I
glucopyranoside	I
and	O
apigenin	B
,	O
and	O
the	O
quality	O
control	O
method	O
includes	O
the	O
fingerprint	O
pattern	O
of	O
turpinia	O
ternate	O
nakai	O
and	O
compositions	O
containing	O
same	O
.	O

Quality	O
control	O
methods	O
of	O
leaves	O
of	O
cordyalis	O
esquirolii	O
and	O
its	O
preparation	O

The	O
invention	O
disclosed	O
a	O
kind	O
of	O
medicine	O
that	O
can	O
treat	O
hemorrhagic	O
shock	O
,	O
especially	O
a	O
kind	O
of	O
blood	O
plasma	O
substitute	O
which	O
contains	O
one	O
active	O
ingredient	O
.	O

The	O
ingredient	O
can	O
not	O
only	O
expand	O
the	O
blood	O
volume	O
,	O
it	O
can	O
also	O
improve	O
the	O
blood	O
rheology	O
and	O
relieve	O
inflamed	O
damage	O
.	O

The	O
blood	O
plasma	O
substitute	O
which	O
has	O
the	O
two	O
functions	O
is	O
provided	O
in	O
the	O
invention	O
.	O

There	O
's	O
also	O
provided	O
a	O
active	O
ingredient	O
which	O
is	O
a	O
physically	O
acceptable	O
polyose	O
high	O
molecular	O
compound	O
.	O

The	O
active	O
ingredient	O
is	O
prepared	O
by	O
raw	O
plant	O
such	O
as	O
astragali	O
radix	O
.	O

The	O
blood	O
plasma	O
substitute	O
in	O
the	O
invention	O
can	O
be	O
used	O
as	O
medicine	O
to	O
treat	O
hemorrhagic	O
shock	O
.	O

A	O
plasma	O
substitute	O
and	O
its	O
application	O
for	O
treating	O
hemorrhagic	O
shock	O

The	O
invention	O
discloses	O
milk	O
with	O
combined	O
formulas	O
and	O
its	O
preparing	O
process	O
,	O
wherein	O
the	O
milk	O
is	O
prepared	O
from	O
conventional	O
milk	O
and	O
L	B
-	I
arginine	I
through	O
homogeneous	O
processes	O
.	O

The	O
milk	O
has	O
the	O
function	O
of	O
adjusting	O
body	O
immunity	O
.	O

Milk	O
for	O
regulating	O
organism	O
immunity	O
and	O
its	O
preparation	O

The	O
invention	O
relates	O
to	O
a	O
non	O
-	O
steroid	O
analgesic	O
-	O
antipyretic	O
acetaminopher	B
which	O
contains	O
carboxy	B
group	O
,	O
nalorphine	B
,	O
antiphon	B
,	O
arfonad	B
,	O
chlorostyrene	B
,	O
cyclobutyrol	B
,	O
chlofenamic	B
acid	I
,	O
or	O
the	O
like	O
,	O
while	O
it	O
can	O
improve	O
the	O
drug	O
stability	O
,	O
reduce	O
excitation	O
on	O
gastrointestinal	O
tract	O
,	O
and	O
effect	O
.	O

Non	O
-	O
steroidal	O
analgesic	O
-	O
antipyretic	O
medicament	O
paracetamol	B
containing	O
carboxyl	B
group	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
doxitasa	O
self	O
-	O
emulsion	O
capsule	O
agent	O
,	O
which	O
comprises	O
doxitasa	O
,	O
oil	O
,	O
emulsifier	O
,	O
and	O
auxiliary	O
emulsifying	O
agent	O
.	O

And	O
the	O
preparation	O
comprises	O
that	O
dissolving	O
the	O
materials	O
into	O
oil	O
via	O
mixing	O
or	O
ultrasonic	O
wave	O
,	O
adding	O
emulsifier	O
and	O
auxiliary	O
emulsifying	O
agent	O
,	O
mixing	O
or	O
using	O
ultrasonic	O
wave	O
to	O
obtain	O
uniform	O
transparent	O
solution	O
;	O
filling	O
into	O
capsule	O
to	O
obtain	O
soft	O
or	O
hard	O
capsule	O
.	O

The	O
invention	O
has	O
simple	O
process	O
,	O
high	O
stability	O
and	O
high	O
utilization	O
.	O

Self	O
-	O
emulsifying	O
capsule	O
of	O
docetaxel	B
and	O
its	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
naristillae	O
or	O
atomizing	O
agent	O
used	O
to	O
treat	O
coryza	O
.	O

The	O
inventive	O
agent	O
is	O
prepared	O
from	O
bupleurum	O
root	O
extractive	O
,	O
baras	O
camphor	B
and	O
medical	O
liquid	O
baras	O
camphor	B
,	O
with	O
anti	O
-	O
inflammation	O
,	O
and	O
antibiosis	O
functions	O
or	O
the	O
like	O
.	O

The	O
inventive	O
drug	O
will	O
not	O
hurt	O
nasal	O
,	O
without	O
excitation	O
.	O

Collunarium	O
or	O
spraying	O
preparation	O
for	O
treating	O
nasal	O
cavity	O
inflammation	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
an	O
externally	O
-	O
used	O
medicinal	O
composition	O
for	O
treating	O
soft	O
tissue	O
injury	O
,	O
wherein	O
the	O
raw	O
materials	O
of	O
the	O
effective	O
constituents	O
comprise	O
(	O
by	O
weight	O
ratio	O
)	O

Sichuan	O
aconite	O
root	O
8	O
-	O
12	O
,	O
safflower	O
8	O
-	O
10	O
,	O
arisaema	O
tuber	O
7	O
-	O
11	O
,	O
Rhododendron	O
molle	O
8	O
-	O
12	O
,	O
Clematis	O
chinensis	O
7	O
-	O
11	O
,	O
rhizome	O
of	O
Sichuan	O
lovage	O
8	O
-	O
12	O
,	O
tetrandra	O
root	O
7	O
-	O
11	O
,	O
corydalis	O
tuber	O
8	O
-	O
12	O
,	O
Tripterygium	O
wilfordii	O
7	O
-	O
11	O
,	O
peach	O
kernel	O
7	O
-	O
11	O
and	O
borneol	B
0.4	O
-	O
0.5	O
.	O

Externally	O
applied	O
medicament	O
for	O
treating	O
soft	O
tissue	O
injury	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
western	O
medicinal	O
preparation	O
,	O
and	O
relates	O
to	O
a	O
preparation	O
with	O
suitable	O
phase	O
variation	O
,	O
detention	O
time	O
prolonging	O
effects	O
and	O
topically	O
administered	O
in	O
nasal	O
cavity	O
,	O
and	O
its	O
preparation	O
method	O
.	O

The	O
method	O
comprises	O
dispersing	O
momestasone	B
furoate	I
or	O
budesonide	B
in	O
hydrophilic	O
gel	O
substrate	O
prepared	O
from	O
acetyl	B
-	O
removed	O
gellan	O
gum	O
and	O
sodium	B
alginate	I
in	O
micro	O
powder	O
form	O
.	O

the	O
gel	O
preparation	O
is	O
prepared	O
and	O
stored	O
in	O
solution	O
from	O
,	O
and	O
administered	O
in	O
solution	O
spraying	O
form	O
;	O
generates	O
phase	O
variation	O
due	O
to	O
the	O
change	O
of	O
environmental	O
ionic	O
strength	O
,	O
pH	O
,	O
or	O
temperature	O
after	O
contacting	O
with	O
tunica	O
mucosa	O
of	O
nasal	O
cavity	O
,	O
and	O
forms	O
gel	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
and	O
accurate	O
administered	O
dose	O
;	O
can	O
prolong	O
the	O
contact	O
time	O
of	O
medicine	O
and	O
schneiderian	O
membrane	O
;	O
and	O
improves	O
therapeutic	O
effect	O
of	O
the	O
medicine	O
to	O
anaphylactic	O
rhinitis	O
.	O

Instant	O
gelling	O
agent	O
for	O
treating	O
allergic	O
rhinitis	O

The	O
invention	O
discloses	O
a	O
new	O
molecule	O
with	O
relative	O
structure	O
of	O
HEPT	O
and	O
pyridinone	B
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
adopting	O
1-í	B
(	I
2-hydroxy	I
ethoxy	I
)	I
-methylí	I
-6-	I
(	I
benzene	I
thio	I
)	I
thymine	I
(	O
HEPT	O
)	O
as	O
reverse	O
transcriptase	O
inhibitor	O
of	O
non	O
-	O
nucleoside	B
HIV-1	O
and	O
4-benzene	B
thiopyridinone	I
as	O
primer	O
;	O
linking	O
each	O
structure	O
and	O
activity	O
to	O
fuse	O
into	O
one	O
molecule	O
;	O
designing	O
a	O
new	O
molecule	O
with	O
general	O
formula	O
as	O
formula	O
I	O
with	O
each	O
group	O
defined	O
as	O
instruction	O
;	O
making	O
new	O
compound	O
connect	O
HIV-1	O
reverse	O
transcriptase	O
conveniently	O
;	O
inhibiting	O
the	O
activity	O
of	O
reverse	O
transcriptase	O
.	O

Preparation	O
of	O
HIV-1	O
reverse	O
transcriptase	O
inhibitor	O
and	O
application	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
phosphorylated	B
polyphenols	I
,	O
preferably	O
tannins	O
that	O
,	O
unlike	O
their	O
unphosphorylated	O
counterparts	O
,	O
do	O
not	O
suffer	O
from	O
relatively	O
low	O
stability	O
,	O
resulting	O
in	O
an	O
activity	O
that	O
is	O
relatively	O
short	O
in	O
time	O
,	O
and/or	O
that	O
do	O
not	O
result	O
in	O
yellowing	O
of	O
materials	O
therewith	O
such	O
as	O
textiles	O
or	O
polymers	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
simple	O
,	O
cheap	O
and	O
environmentally	O
friendly	O
way	O
of	O
preparing	O
these	O
compounds	O
.	O

The	O
phosphorylation	O
process	O
of	O
the	O
invention	O
can	O
be	O
extended	O
to	O
simple	O
phenolic	B
compounds	O
as	O
well	O
,	O
as	O
long	O
as	O
these	O
have	O
at	O
least	O
one	O
accessible	O
hydroxyl	B
group	O
.	O

The	O
phosphorylated	O
compounds	O
according	O
to	O
the	O
invention	O
can	O
be	O
used	O
as	O
antioxidants	O
,	O
as	O
radical	O
scavengers	O
,	O
as	O
complexating	O
agents	O
for	O
metals	O
and	O
proteins	O
,	O
as	O
antibacterials	O
or	O
antiallergenic	O
compounds	O
,	O
and	O
as	O
agents	O
to	O
flock	O
textile	O
.	O

Phosphorylated	B
polyphenols	I
as	O
colour	O
-	O
stable	O
agents	O

The	O
present	O
invention	O
is	O
application	O
of	O
2-phenyl-1	B
,	I
2-benzoisoselenazole-3	I
(	I
2H	I
)	I
-tone	I
in	O
preparing	O
medicine	O
for	O
resisting	O
sports	O
fatigue	O
.	O

Pharmacological	O
experiment	O
proves	O
that	O
active	O
component	O
2-phenyl-1	B
,	I
2-benzoisoselenazole-3	I
(	I
2H	I
)	I
-tone	I
has	O
the	O
effects	O
of	O
resisting	O
the	O
overoxidation	O
of	O
lipid	O
,	O
eliminating	O
free	O
radical	O
caused	O
in	O
overtraining	O
,	O
inhibiting	O
apoptosis	O
during	O
sports	O
and	O
maintaining	O
the	O
normal	O
morphological	O
structure	O
and	O
function	O
of	O
locomotive	O
organs	O
,	O
delaying	O
sports	O
fatigue	O
and	O
raising	O
sport	O
capacity	O
of	O
rat	O
.	O

Application	O
of	O
2-phenyl-1	B
,	I
2-benzoisoselenazole-3	I
(	I
2H	I
)	I
-tone	I
in	O
preparing	O
medicine	O
for	O
resisting	O
sports	O
fatigue	O

The	O
present	O
invention	O
relates	O
to	O
one	O
kind	O
of	O
medicine	O
for	O
treating	O
hepatosis	O
,	O
including	O
fatty	O
liver	O
,	O
alcoholic	O
hepatitis	O
,	O
etc	O
.	O
and	O
reducing	O
blood	O
fat	O
.	O

The	O
medicine	O
consists	O
of	O
amino	O
acid	O
30	O
-	O
60	O
weight	O
portions	O
,	O
vitamin	O
10	O
-	O
30	O
weight	O
portions	O
,	O
and	O
trace	O
elements	O
2	O
-	O
5	O
weight	O
portions	O
.	O

Experiment	O
and	O
clinical	O
application	O
show	O
that	O
the	O
present	O
invention	O
has	O
high	O
curative	O
effect	O
.	O

Medicine	O
for	O
treating	O
fatty	O
liver	O
and	O
alcoholic	O
hepatitis	O
and	O
reducing	O
blood	O
fat	O
and	O
transaminase	O

An	O
application	O
of	O
curcumin	B
in	O
preparing	O
the	O
orally	O
taken	O
medicine	O
for	O
treating	O
acute	O
viral	O
hepatitis	O
or	O
toxic	O
hepatitis	O
is	O
disclosed	O
.	O

Use	O
of	O
curcumin	B
in	O
medicine	O

An	O
instant	O
freeze	O
-	O
dried	O
powder	O
injection	O
of	O
pirarubicin	B
is	O
prepared	O
from	O
pirarubicin	B
,	O
excipient	O
and	O
cosolvent	O
through	O
proportionally	O
dissolving	O
them	O
in	O
the	O
water	O
for	O
injection	O
,	O
aseptic	O
filtering	O
,	O
loading	O
in	O
containers	O
,	O
and	O
freeze	O
-	O
drying	O
.	O

Instant	O
pyrobixi	O
freeze	O
-	O
drying	O
powdery	O
injection	O
and	O
its	O
production	O

An	O
artificial	O
medical	O
snake	O
gall	O
powder	O
is	O
a	O
solid	O
powder	O
mixture	O
prepared	O
by	O
taurocholic	B
acid	I
,	O
chicken	O
bile	O
dry	O
extract	O
,	O
cholesterol	B
,	O
mucoprotein	O
,	O
ZnSO4.7H2O	B
,	O
calcium	B
gluconate	I
,	O
sodium	B
bicarbonate	I
and	O
taurine	B
,	O
and	O
optional	O
taurodeoxycholic	B
acid	I
and/or	O
the	O
extract	O
of	O
rabbit	O
bile	O
dry	O
extract	O
.	O

An	O
artificial	O
medical	O
snake	O
gall	O
liquid	O
is	O
prepared	O
by	O
dissolving	O
the	O
artificial	O
medical	O
snake	O
gall	O
powder	O
in	O
an	O
ethanol	B
solution	O
with	O
the	O
concentration	O
of	O
25%-50	O
%	O
,	O
which	O
has	O
extremely	O
similar	O
compositions	O
and	O
pharmacologic	O
effect	O
with	O
the	O
high	O
-	O
quality	O
natural	O
snake	O
gall	O
,	O
has	O
remarkable	O
antitussive	O
effect	O
,	O
expectorant	O
effect	O
,	O
antiasthmatic	O
effect	O
,	O
anti	O
-	O
inflammatory	O
effect	O
and	O
the	O
like	O
,	O
has	O
no	O
obvious	O
toxic	O
and	O
side	O
effect	O
,	O
and	O
is	O
an	O
ideal	O
substitute	O
for	O
the	O
natural	O
medical	O
snake	O
gall	O
.	O

Snake	O
gallbladder	O
for	O
artificial	O
medicine	O
and	O
its	O
production	O

The	O
present	O
invention	O
relates	O
to	O
the	O
application	O
of	O
azone	O
as	O
active	O
medicine	O
component	O
in	O
preparing	O
externally	O
applied	O
slimming	O
medicine	O
,	O
externally	O
applied	O
slimming	O
health	O
product	O
and	O
slimming	O
cosmetic	O
.	O

The	O
present	O
invention	O
uses	O
azone	O
as	O
active	O
medicine	O
component	O
except	O
being	O
used	O
as	O
permeation	O
assistant	O
.	O

The	O
externally	O
applied	O
slimming	O
preparations	O
with	O
azone	O
as	O
active	O
medicine	O
component	O
has	O
obvious	O
curative	O
effect	O
,	O
fast	O
acting	O
and	O
no	O
toxic	O
side	O
effect	O
,	O
and	O
are	O
prepared	O
preferably	O
as	O
navel	O
administrating	O
preparation	O
,	O
such	O
as	O
navel	O
plaster	O
,	O
drops	O
,	O
etc	O
.	O

External	O
agent	O
for	O
losing	O
weight	O

The	O
present	O
invention	O
discloses	O
the	O
application	O
of	O
asiaticoside	B
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
hepatic	O
fibrosis	O
.	O

By	O
means	O
of	O
the	O
effect	O
of	O
asiaticoside	B
on	O
hepatic	O
fibrosis	O
of	O
rat	O
,	O
the	O
present	O
invention	O
proves	O
the	O
effect	O
of	O
asiaticoside	B
in	O
antagonizing	O
hepatic	O
fibrosis	O
.	O

Therefore	O
,	O
asiaticoside	B
may	O
be	O
used	O
as	O
the	O
active	O
component	O
for	O
medicine	O
to	O
treat	O
hepatic	O
fibrosis	O
.	O

Application	O
of	O
centella	O
triterpenes	B
in	O
the	O
preparing	O
of	O
medicine	O
for	O
preventing	O
and	O
curing	O
liver	O
fibrosis	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
gynura	O
procumbens	O
(	O
Lour	O
.	O
)	O

organic	O
acid	O
and	O
the	O
use	O
thereof	O
.	O

The	O
organic	O
acid	O
total	O
ingredients	O
are	O
obtained	O
by	O
organic	O
extracting	O
the	O
gynura	O
procumbens	O
whole	O
herb	O
and	O
absorbing	O
by	O
macroporous	O
resin	O
,	O
and	O
the	O
organic	O
acid	O
contains	O
various	O
chemical	O
ingredients	O
such	O
as	O
chlorogenic	B
acid	I
,	O
new	O
chlorogenic	B
acid	I
(	O
chlorogenic	B
acid	I
and	O
its	O
derivatives	O
3~5-dioxygen	B
-	I
caffeoyl	I
quinic	I
acid	I
and	O
4~5-dioxygen	B
-	I
caffeoyl	I
quinic	I
acid	I
)	O
and	O
hydroxyl	O
lactic	O
acid	O
,	O
etc	O
.	O

The	O
organic	O
acid	O
can	O
be	O
used	O
as	O
various	O
diseases	O
medicine	O
material	O
of	O
antibiosis	O
,	O
antiphlogosis	O
,	O
antivirus	O
,	O
anti	O
-	O
influenza	O
or	O
anti	O
-	O
hepatitis	O
B	O
and	O
the	O
like	O
,	O
or	O
as	O
medicine	O
material	O
of	O
herpes	O
caused	O
by	O
filter	O
authenticity	O
pathogen	O
,	O
etc	O
.	O

Gynura	O
procumbens	O
organic	O
acid	O
preparing	O
method	O
and	O
the	O
application	O

The	O
invention	O
discloses	O
a	O
natural	O
polyamine	B
derivant	O
,	O
which	O
is	O
described	O
by	O
the	O
general	O
formula	O
:	O
wherein	O
,	O
m=0	O
or	O
1	O
,	O
n=1	O
or	O
2	O
,	O
o=1	O
or	O
2	O
.	O

The	O
invention	O
synthesizes	O
a	O
polyamine	B
framework	O
and	O
polyamine	B
derivant	O
with	O
a	O
new	O
structure	O
so	O
as	O
to	O
broaden	O
the	O
research	O
and	O
application	O
field	O
of	O
the	O
polyamine	B
.	O

The	O
structure	O
of	O
the	O
inventive	O
natural	O
polyamine	B
derivant	O
is	O
similar	O
to	O
the	O
natural	O
polyamine	B
compound	O
,	O
which	O
is	O
used	O
to	O
produce	O
targeting	O
antineoplastic	O
agents	O
,	O
antineoplastic	O
agents	O
precursor	O
that	O
can	O
reduce	O
the	O
toxic	O
and	O
side	O
-	O
effect	O
by	O
selectively	O
effecting	O
to	O
the	O
polyamine	B
passage	O
of	O
the	O
tumor	O
cells	O
.	O

The	O
reacting	O
art	O
is	O
easy	O
to	O
operate	O
with	O
a	O
gentle	O
condition	O
and	O
a	O
high	O
reaction	O
yield	O
.	O

Natural	O
polyamines	B
derivatives	O
,	O
preparation	O
and	O
application	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
the	O
formula	O
[	O
I	O
]	O
:	O
wherein	O
(	O
a	O
)	O
,	O
in	O
which	O
-Y-	O
,	O
R	O
<	O
sup	O
.	O

Aminoalcohol	B
derivatives	O

The	O
invention	O
relates	O
to	O
trifluoromethyl	B
substituted	I
benzamide	I
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
pharmaceuticals	O
comprising	O
these	O
compounds	O
,	O
their	O
use	O
as	O
or	O
for	O
the	O
manufacture	O
of	O
pharmaceuticals	O
,	O
particularly	O
as	O
inhibitors	O
of	O
protein	O
kinases	O
and/or	O
the	O
treatment	O
of	O
a	O
condition	O
,	O
disorder	O
or	O
disease	O
state	O
mediated	O
by	O
a	O
protein	O
kinase	O
activity	O
and/or	O
a	O
proliferative	O
disease	O
,	O
methods	O
of	O
treatment	O
comprising	O
administering	O
the	O
compounds	O
,	O
especially	O
of	O
therapeutic	O
and	O
prophylactic	O
treatment	O
,	O
methods	O
for	O
the	O
manufacture	O
of	O
the	O
compounds	O
and	O
novel	O
intermediates	O
and	O
partial	O
steps	O
for	O
their	O
synthesis	O
.	O

Trifluoromethyl	B
substituted	I
benzamide	I
as	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
discloses	O
a	O
making	O
method	O
of	O
2'-hydroxy-3'-alkylamino	O
propyl-4	O
'	O
,	O
6'-disubstituted	O
chalcone	O
derivant	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
:	O
adopting	O
2'-hydroxy	O
chalcone	O
as	O
leading	O
material	O
;	O
proceeding	O
allyl	O
etherifying	O
reaction	O
on	O
the	O
mother	O
core	O
of	O
2'-hydroxy	O
chalcone	O
;	O
proceeding	O
Claisen	O
rearrangement	O
;	O
epoxidising	O
;	O
additioning	O
;	O
and	O
thus	O
,	O
obtaining	O
2'-hydroxy-3'-alkylamino	O
propyl-4',5',6'-trisubstituted	O
chalcone	O
derivant	O
;	O
The	O
pharmacology	O
experiment	O
appears	O
and	O
proves	O
that	O
the	O
chalcone	O
derivant	O
has	O
the	O
inhibitory	O
effect	O
on	O
proliferation	O
in	O
vitro	O
and	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
tumors	O
medicines	O
.	O

The	O
making	O
method	O
of	O
2'-hydroxy-3'-alkylamino	O
propyl-4	O
'	O
,	O
6'-disubstituted	O
chalcone	O
derivant	O
provided	O
by	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
materials	O
have	O
extensive	O
sources	O
;	O
the	O
derivant	O
is	O
easy	O
to	O
prepare	O
;	O
the	O
reaction	O
condition	O
is	O
mild	O
;	O
the	O
yield	O
coefficient	O
for	O
each	O
step	O
is	O
high	O
;	O
the	O
production	O
cost	O
is	O
lower	O
and	O
is	O
fit	O
for	O
industrial	O
manufacturing	O
.	O

The	O
general	O
structure	O
formula	O
is	O
...	O
Preparation	O
method	O
and	O
usage	O
for	O
nitrogen	O
-	O
containing	O
chalcone	O
derivatives	O

A	O
paster	O
for	O
antipyresis	O
containing	O
ibuprofen	B
is	O
composed	O
of	O
a	O
substrate	O
layer	O
,	O
a	O
gel	O
layer	O
and	O
a	O
protective	O
film	O
.	O

Its	O
preparing	O
process	O
includes	O
such	O
steps	O
as	O
uniformly	O
dispersing	O
the	O
hydrophilic	O
gel	O
,	O
adhesive	O
,	O
ibuprofen	B
,	O
surfactant	O
,	O
percutaneous	O
promoter	O
,	O
filler	O
and	O
water	O
-	O
insoluble	O
cross	O
-	O
linking	O
agent	O
in	O
humectant	O
by	O
stirring	O
to	O
obtain	O
phase	O
A	O
,	O
uniformly	O
dispersing	O
water	O
-	O
soluble	O
cross	O
-	O
linking	O
agent	O
and	O
other	O
water	O
-	O
soluble	O
substance	O
in	O
water	O
by	O
stirring	O
to	O
obtain	O
phase	O
B	O
,	O
mixing	O
phase	O
A	O
with	O
phase	O
B	O
by	O
stirring	O
in	O
a	O
certain	O
vacuum	O
degree	O
to	O
obtain	O
gel	O
,	O
coating	O
it	O
on	O
a	O
non	O
-	O
woven	O
cloth	O
,	O
covering	O
it	O
with	O
a	O
protective	O
film	O
,	O
and	O
cutting	O
by	O
needed	O
sizes	O
.	O

Cataplasma	O
containing	O
ibuprofen	B
its	O
preparing	O
method	O
and	O
application	O

An	O
exterior	O
-	O
applied	O
composite	O
medicine	O
for	O
preventing	O
and	O
treating	O
dermatopathy	O
with	O
obviously	O
decreased	O
by	O
-	O
effect	O
contains	O
ligustrazine	B
and	O
glucocorticoid	B
.	O

External	O
use	O
medicine	O
containing	O
tetramethylpyrazine	B
GC	O
glucocorticoid	B
with	O
its	O
skin	O
side	O
-	O
effects	O
reducing	O
obviously	O

This	O
inventio	O
relates	O
to	O
preparation	O
method	O
of	O
helicid	B
-huperzine	I
methylal	I
imine	I
.	O

Structural	O
formula	O
as	O
(	O
1	O
)	O
described	O
.	O

It	O
also	O
relates	O
to	O
it	O
'	O
s	O
as	O
drug	O
compound	O
of	O
effective	O
ingredient	O
,	O
as	O
well	O
as	O
application	O
in	O
preparing	O
restraining	O
acetyl	B
lipase	O
activity	O
medicine	O
.	O

Helicid	B
hydrastine	I
acetali	I
mine	I
its	O
preparation	O
method	O
and	O
its	O
application	O

An	O
external	O
-	O
applied	O
medicine	O
for	O
treating	O
onychomycosis	O
is	O
proportionally	O
prepared	O
from	O
fluorescent	O
sophora	O
root	O
powder	O
,	O
boric	B
acid	I
,	O
benzoic	B
acid	I
,	O
salicylic	B
acid	I
,	O
the	O
liquid	O
extract	O
of	O
Chinese	O
prickly	O
ash	O
and	O
glycerin	B
.	O

External	O
remedy	O
for	O
treating	O
onychomycosis	O

This	O
invention	O
relates	O
to	O
2	B
,	I
3	I
,	I
4	I
,	I
5-tetrasubstituted	I
phenyl	I
propylene	I
derivatives	O
with	O
cytotoxicity	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
derivatives	O
,	O
their	O
drug	O
compositions	O
,	O
and	O
their	O
pharmaceutical	O
application	O
.	O

The	O
derivatives	O
can	O
inhibit	O
the	O
bioactivity	O
of	O
prostate	O
cancer	O
cell	O
(	O
PC-3	O
)	O
,	O
nasopharyngeal	O
cancer	O
cell	O
(	O
CNE	O
)	O
,	O
oral	O
epithelial	O
cancer	O
cell	O
(	O
KB	O
)	O
,	O
lung	O
cancer	O
cell	O
(	O
A549	O
)	O
,	O
liver	O
cancer	O
cell	O
(	O
BEL-7404	O
)	O
,	O
and	O
cervical	O
cancer	O
cell	O
(	O
Hela	O
)	O
,	O
thus	O
can	O
be	O
used	O
as	O
anti	O
-	O
tumor	O
drugs	O
.	O

2,3,4,5-tetrasubstituted	O
derivatives	O
of	O
benzyl	B
ethylene	I
class	O
,	O
preparation	O
method	O
and	O
application	O

This	O
invention	O
discloses	O
a	O
method	O
for	O
synthesizing	O
entecavir	B
as	O
an	O
anti	O
-	O
hepatitis	O
B	O
drug	O
.	O

The	O
method	O
is	O
characterized	O
by	O
:	O
diphenyl	B
methylchlorosilane	I
is	O
utilized	O
as	O
a	O
protective	O
agent	O
is	O
step	O
1	O
,	O
and	O
cyclohexyl	B
methanol	I
is	O
utilized	O
as	O
an	O
esterifying	O
agent	O
in	O
step	O
4	O
.	O

The	O
method	O
has	O
such	O
advantages	O
as	O
low	O
cost	O
,	O
high	O
drug	O
purity	O
and	O
high	O
yield	O
,	O
and	O
is	O
suitable	O
for	O
industrialization	O
.	O

Method	O
for	O
synthesizing	O
medication	O
Entecavir	B
of	O
anti	O
hepatitis	O
B	O

The	O
present	O
invention	O
relates	O
to	O
a	O
group	O
of	O
novel	O
compound	O
Chemomicin	B
B	I
,	I
C	I
,	I
D	I
and	O
its	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
containing	O
Chemomicin	B
B	I
,	I
C	I
,	I
D	I
as	O
active	O
ingredients	O
and	O
its	O
uses	O
of	O
Chemomicin	B
B	I
,	I
C	I
,	I
D	I
in	O
preparing	O
antineoplastic	O
drug	O
.	O

Chemomicin	B
B	I
,	I
C	I
,	I
D	I
is	O
Angucyclinone	B
antibiotic	O
separated	O
from	O
Nocardia	O
Mediterranei	O
Var	O
.	O

Kanglensis	O
1747	O
-	O
64	O
culture	O
.	O

In	O
vitro	O
activity	O
test	O
prove	O
Chemomicin	B
B	I
,	I
C	I
,	I
D	I
has	O
strong	O
suppressing	O
activity	O
for	O
human	O
oesophagus	O
cancer	O
cell	O
KYSE150	O
and	O
has	O
good	O
development	O
prospect	O
as	O
a	O
novel	O
antineoplastic	O
drug	O
.	O

Novel	O
antibiotic	O
Chemomycin	B
A	I
,	I
B	I
,	I
C	I
,	I
D	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
frequent	O
cough	O
through	O
dietary	O
treatment	O
by	O
employing	O
the	O
approach	O
of	O
supplementing	O
needed	O
nutrition	O
with	O
right	O
amount	O
for	O
activating	O
the	O
cells	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
invention	O
is	O
characterized	O
in	O
that	O
no	O
injection	O
and	O
drug	O
administration	O
are	O
required	O
,	O
and	O
no	O
injury	O
to	O
internal	O
organs	O
is	O
caused	O
.	O

Effective	O
prescription	O
for	O
food	O
therapeutic	O
and	O
cough	O
relieving	O

The	O
invention	O
discloses	O
a	O
polysaccharide	O
sulfate	B
and	O
application	O
of	O
Codonopsis	O
bulleyana	O
with	O
biological	O
activity	O
,	O
which	O
is	O
composed	O
of	O
xylose	B
,	O
fructose	B
and	O
glucose	B
connected	O
through	O
1	O
-	O
6	O
(	O
or	O
non	O
-	O
reducing	O
end	O
)	O
,	O
1	O
-	O
4	O
and	O
1	O
-	O
3	O
glycosidic	O
bond	O
,	O
wherein	O
the	O
product	O
is	O
based	O
on	O
Codonopsis	O
bulleyana	O
polysaccharide	O
as	O
raw	O
material	O
disposed	O
by	O
sulphonating	O
agent	O
with	O
sulfation	O
degree	O
at	O
0	O
.	O

5	O
-	O
2	O
.	O
5	O
;	O
the	O
sulphonating	O
agent	O
consists	O
of	O
chlorosulfonic	B
acid	I
and	O
pyridine	B
with	O
bulk	O
rate	O
at	O
1:2	O
-	O
8	O
;	O
the	O
invention	O
possesses	O
stronger	O
HIV	O
and	O
single	O
herpetoviridae	O
virus	O
resistant	O
activity	O
,	O
which	O
is	O
low	O
harmful	O
for	O
human	O
cell	O
,	O
therefore	O
fitting	O
for	O
preparing	O
,	O
preventing	O
or	O
treating	O
the	O
agent	O
of	O
HIV	O
and	O
single	O
herpetoviridae	O
virus	O
.	O

Codonopsisbulleyana	O
polysaccharide	O
sulfate	B
and	O
use	O
thereof	O

To	O
obtain	O
a	O
noise	O
filter	O
having	O
a	O
more	O
improved	O
noise	O
elimination	O
effect	O
.	O

First	O
ends	O
of	O
inner	O
conductors	O
22	O
,	O
24	O
having	O
meandering	O
parts	O
22C	O
,	O
24C	O
are	O
led	O
out	O
to	O
the	O
end	O
of	O
a	O
lower	O
ceramic	O
layer	O
12A	O
,	O
and	O
second	O
ends	O
of	O
the	O
conductors	O
22	O
,	O
24	O
are	O
led	O
out	O
to	O
the	O
end	O
of	O
an	O
upper	O
center	O
ceramic	O
layer	O
12A.Planar	O
inner	O
conductors	O
21	O
,	O
23	O
,	O
25	O
are	O
led	O
out	O
to	O
the	O
end	O
of	O
a	O
lower	O
center	O
ceramic	O
layer	O
12A	O
.	O

A	O
signal	O
terminal	O
electrode	O
connected	O
to	O
a	O
leading	O
part	O
22A	O
of	O
the	O
inner	O
conductor	O
22	O
is	O
disposed	O
rightwards	O
on	O
the	O
lower	O
side	O
,	O
and	O
a	O
signal	O
terminal	O
electrode	O
connected	O
to	O
the	O
leading	O
part	O
24A	O
of	O
the	O
inner	O
conductor	O
24	O
is	O
disposed	O
leftwards	O
on	O
the	O
lower	O
side	O
.	O

Grounding	O
terminal	O
electrodes	O
connected	O
to	O
leading	O
parts	O
26	O
of	O
the	O
inner	O
conductors	O
21	O
,	O
23	O
,	O
25	O
are	O
disposed	O
on	O
the	O
central	O
area	O
of	O
the	O
lower	O
side	O
.	O

Connecting	O
electrodes	O
connected	O
to	O
leading	O
parts	O
22B	O
,	O
24B	O
of	O
the	O
inner	O
conductors	O
22	O
,	O
24	O
are	O
disposed	O
on	O
the	O
upper	O
side	O
,	O
respectively	O
.	O

Combination	O
of	O
a	O
NMDA	O
receptor	O
antagonist	O
and	O
an	O
anti	O
-	O
depressive	O
drug	O
mao	O
-	O
inhibitor	O
or	O
a	O
gadph	O
-	O
inhibitor	O
for	O
the	O
treatment	O
of	O
psychiatric	O
conditions	O

The	O
invention	O
relates	O
to	O
a	O
chewing	O
gum	O
for	O
preventing	O
caries	O
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
chewing	O
gum	O
is	O
prepared	O
from	O
green	O
tea	O
polyphenols	B
,	O
powder	O
of	O
honeysuckle	O
flower	O
,	O
giant	O
knotweed	O
rhizome	O
powder	O
,	O
vitamin	B
C	I
,	O
phosphatide	B
,	O
xylitol	B
,	O
glue	O
base	O
and	O
flavoring	O
essence	O
through	O
mixing	O
homogeneously	O
.	O

Chewing	O
gum	O
having	O
functions	O
of	O
preventing	O
and	O
treating	O
decayed	O
tooth	O
and	O
the	O
preparing	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
betulic	B
acid	I
type	O
triterpenoid	B
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
making	O
the	O
chemical	O
structural	O
formula	O
as	O
picture	O
;	O
possessing	O
strong	O
against	O
HIV	O
active	O
with	O
EC50	O
less	O
than	O
0	O
.	O

064mug	O
/	O
ml	O
,	O
CC50	O
as	O
98	O
.	O
43	O
mug	O
/	O
ml	O
and	O
Ti	O
as	O
1538	O
;	O
overcoming	O
the	O
problem	O
of	O
easy	O
to	O
generate	O
drug	O
tolerance	O
.	O

This	O
invention	O
is	O
preparing	O
clinical	O
test	O
,	O
which	O
will	O
possess	O
important	O
meaning	O
for	O
against	O
HIV	O
new	O
medicine	O
exploitation	O
.	O

Novel	O
betulic	B
acid	I
type	O
triterpenoid	B

The	O
invention	O
relates	O
to	O
a	O
preparing	O
method	O
of	O
glycyrrhizic	B
acid	I
derivant	O
and	O
usage	O
.	O

18alpha-	B
liquorice	I
acid	I
derivatives	O
and	O
preparation	O
thereof	O

Compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
wherein	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
and	O
R<4	O
>	O
are	O
as	O
defined	O
in	O
the	O
specification	O
as	O
well	O
as	O
salts	O
and	O
pharmaceutical	O
compositions	O
including	O
the	O
compounds	O
are	O
prepared	O
.	O

They	O
are	O
useful	O
in	O
therapy	O
,	O
in	O
particular	O
in	O
the	O
management	O
of	O
pain	O
.	O

Compounds	O
,	O
compositions	O
containing	O
them	O
,	O
preparations	O
thereof	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
siRNA	O
of	O
one	O
kind	O
of	O
gene	O
inhibiting	O
specifically	O
human	O
core	O
binding	O
factor	O
1	O
(	O
Cbfa1	O
)	O
and	O
its	O
expression	O
vector	O
and	O
application	O
in	O
preparing	O
medicine	O
for	O
treating	O
Cbfa1	O
relevant	O
diseases	O
.	O

Based	O
on	O
RNA	O
interfering	O
technology	O
,	O
the	O
present	O
invention	O
designs	O
one	O
group	O
of	O
siRNA	O
capable	O
of	O
inducing	O
RNA	O
interference	O
,	O
and	O
synthesizes	O
siRNA	O
through	O
chemically	O
or	O
expresses	O
certain	O
amount	O
of	O
siRNA	O
by	O
means	O
of	O
plasmid	O
and	O
virus	O
vector	O
,	O
so	O
as	O
to	O
inhibit	O
specifically	O
the	O
expression	O
of	O
human	O
Cbfa1	O
gene	O
and	O
to	O
reach	O
the	O
aim	O
of	O
inhibiting	O
the	O
differentiation	O
of	O
osteoblast	O
and	O
the	O
hypertrophy	O
and	O
differentiation	O
of	O
chondrocyte	O
.	O

The	O
siRNA	O
and	O
its	O
expression	O
vector	O
may	O
be	O
used	O
in	O
preparing	O
medicine	O
for	O
treating	O
osteoarthritis	O
and	O
diseases	O
relevant	O
to	O
the	O
differentiation	O
of	O
osteoblast	O
and	O
the	O
hypertrophy	O
and	O
differentiation	O
of	O
chondrocyte	O
,	O
and	O
the	O
medicine	O
has	O
high	O
efficiency	O
,	O
fast	O
acting	O
,	O
high	O
specificity	O
and	O
less	O
side	O
effects	O
.	O

Human	O
Cbfal	O
gene	O
siRNA	O
and	O
its	O
expression	O
vector	O
and	O
application	O
in	O
preparing	O
medicine	O

The	O
present	O
invention	O
discloses	O
2-hydroxy-4-methylbenzenesulfonic	B
acid	I
preparation	O
,	O
its	O
preparation	O
method	O
and	O
application	O
.	O

It	O
has	O
the	O
actions	O
of	O
coagulating	O
protein	O
,	O
hemostasis	O
and	O
astringing	O
wound	O
,	O
at	O
the	O
same	O
time	O
has	O
the	O
stronger	O
action	O
for	O
killing	O
pathogens	O
(	O
including	O
Gram	O
-	O
negative	O
bacterium	O
,	O
Gram	O
-	O
positive	O
bacterium	O
,	O
fungi	O
,	O
mycoplasma	O
,	O
chlamydozoan	O
and	O
virus	O
,	O
etc	O
.	O
)	O
.	O

It	O
can	O
be	O
made	O
into	O
various	O
different	O
preparations	O
for	O
curing	O
various	O
diseases	O
.	O

Use	O
of	O
2-hydroxyl	B
-	I
methyl	I
benzenesulfonic	I
acid	I
in	O
preparing	O
medicine	O

The	O
present	O
invention	O
provides	O
a	O
kind	O
of	O
colon	O
target	O
orientation	O
preparation	O
for	O
curing	O
colitis	O
and	O
its	O
preparation	O
method	O
.	O

Said	O
preparation	O
is	O
formed	O
from	O
250	O
-	O
500	O
g	O
of	O
montmorillonite	O
,	O
3	O
-	O
15	O
g	O
of	O
binding	O
agent	O
and	O
0.20	O
-	O
3.0	O
g	O
of	O
lubricating	O
agent	O
.	O

Said	O
colon	O
target	O
orientation	O
preparation	O
can	O
be	O
made	O
into	O
oral	O
enteric	O
soluble	O
tablet	O
or	O
oral	O
enteric	O
soluble	O
capsule	O
.	O

Besides	O
,	O
said	O
invention	O
also	O
provides	O
the	O
concrete	O
steps	O
of	O
its	O
preparation	O
method	O
.	O

Colon	O
target	O
-	O
positioning	O
preparation	O
for	O
treating	O
colonitis	O
and	O
preparing	O
method	O

The	O
invention	O
is	O
concerned	O
with	O
the	O
damp	O
-	O
heat	O
eczema	O
theraphy	O
,	O
and	O
the	O
protion	O
contents	O
:	O
gentiana	O
scabra	O
bge	O
10	O
g	O
,	O
Baikal	O
skullcap	O
root	O
10	O
g	O
,	O
cortex	O
moutan	O
15	O
g	O
,	O
Yinhua	O
30	O
g	O
,	O
Forsythia	O
15	O
g	O
,	O
radix	O
sophorae	O
flavescentis	O
10	O
g	O
,	O
Atractylis	O
<	O
ATRACTYLODES	O
>	O
10	O
g	O
,	O
corktree	O
10	O
g	O
,	O
capillary	O
Artemisia	O
10	O
g	O
,	O
fresh	O
liquorice	O
6	O
g	O
,	O
plaster	O
stone	O
30	O
g	O
,	O
cogongrass	O
rhizome	O
30	O
g	O
as	O
the	O
raw	O
materials	O
.	O

All	O
of	O
the	O
raw	O
materials	O
can	O
be	O
dipped	O
in	O
clear	O
water	O
for	O
30	O
minutes	O
,	O
concentrate	O
two	O
portions	O
to	O
only	O
one	O
by	O
decocting	O
twice	O
.	O

It	O
can	O
be	O
taken	O
twice	O
a	O
day	O
with	O
no	O
sediment	O
.	O

Method	O
for	O
damp	O
-	O
heat	O
eczema	O

An	O
enhancer	O
,	O
for	O
treatment	O
of	O
lymphocytic	O
tumors	O
,	O
of	O
an	O
antibody	O
that	O
specifically	O
binds	O
to	O
protein	O
having	O
the	O
amino	B
acid	I
sequence	O
as	O
set	O
forth	O
in	O
SEQ	O
ID	O
NO	O
:	O
1	O
and	O
that	O
has	O
a	O
cytotoxic	O
activity	O
,	O
said	O
enhancer	O
comprising	O
a	O
biological	O
response	O
modifier	O
as	O
an	O
active	O
ingredient	O
.	O

Enhancer	O
for	O
antibody	O
to	O
lymphocytic	O
tumors	O

The	O
present	O
invention	O
relates	O
to	O
particular	O
quinazoline	B
derivatives	O
useful	O
as	O
intermediates	O
in	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
A	O
is	O
5-membered	B
heteroaryl	I
containing	O
a	O
nitrogen	B
atom	O
and	O
one	O
or	O
two	O
further	O
nitrogen	B
atoms	O
.	O

Phosphine	B
acyloxy	I
quinazoline	I
derivatives	O
and	O
their	O
medicine	O
uses	O

A	O
saponin	B
compound	O
,	O
its	O
production	O
and	O
use	O
are	O
disclosed	O
.	O

The	O
process	O
is	O
carried	O
out	O
by	O
extracting	O
while	O
separating	O
from	O
gray	O
coactus	O
honeysuckle	O
bud	O
and	O
purifying	O
to	O
obtain	O
gray	O
coactus	O
lonicerin	B
.	O

It	O
is	O
made	O
in	O
vitro	O
-	O
inhibiting	O
experiment	O
and	O
experiment	O
for	O
mouse	O
dimethyl	B
benzene	I
inflammation	O
.	O

It	O
can	O
be	O
used	O
as	O
PlA2	O
inhibitor	O
and	O
anti	O
-	O
inflammatory	O
medicine	O
.	O

Saponin	B
compound	O
,	O
its	O
production	O
and	O
use	O

The	O
present	O
invention	O
relates	O
to	O
1,2,4-tri	B
-	I
substituted	I
imidazoline	I
derivatives	O
,	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
compounds	O
,	O
to	O
novel	O
intermediates	O
useful	O
for	O
the	O
synthesis	O
of	O
said	O
imidazoline	B
derivatives	O
,	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
these	O
intermediates	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
these	O
imidazoline	B
derivatives	O
as	O
active	O
ingredient	O
,	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
these	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
psychiatric	O
and	O
neurological	O
disorders	O
.	O

The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O

Imidazoline	B
derivatives	O
having	O
cb1-antagonistic	O
activity	O

The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
compound	O
I	O
in	O
the	O
structure	O
as	O
shown	O
in	O
preparing	O
medicine	O
for	O
treating	O
hyperlipemia	O
,	O
and	O
the	O
medicine	O
composition	O
containing	O
the	O
compound	O
I.	O
The	O
present	O
invention	O
also	O
provides	O
one	O
other	O
compound	O
II	O
,	O
and	O
test	O
shows	O
that	O
the	O
compound	O
II	O
can	O
increase	O
the	O
intracellular	O
RLU	O
obviously	O
.	O

Therefore	O
,	O
the	O
compound	O
II	O
has	O
obvious	O
blood	O
fat	O
reducing	O
activity	O
,	O
and	O
the	O
present	O
invention	O
provides	O
new	O
candidate	O
for	O
clinical	O
blood	O
fat	O
reducing	O
medicine	O
.	O

Application	O
of	O
aurantio	O
-	O
obtusifolin	O
or	O
its	O
derivates	O
in	O
preparing	O
hypolipidemic	O
drug	O

The	O
present	O
invention	O
is	O
non	O
-	O
medicine	O
additive	O
for	O
preventing	O
and	O
treating	O
animal	O
'	O
s	O
nutritional	O
diarrhea	O
.	O

The	O
non	O
-	O
medicine	O
additive	O
consists	O
of	O
lactein	O
60	O
-	O
80	O
wt%	O
,	O
glucose	B
20	O
-	O
40	O
wt%	O
,	O
and	O
vitamins	O
0.01	O
-	O
0.2	O
wt%	O
.	O

The	O
non	O
-	O
medicine	O
additive	O
is	O
superior	O
to	O
antibiotic	O
,	O
which	O
has	O
medicine	O
resistance	O
,	O
medicine	O
residue	O
and	O
lower	O
treating	O
effect	O
,	O
and	O
can	O
ensure	O
the	O
health	O
of	O
animal	O
and	O
the	O
safety	O
of	O
animal	O
product	O
.	O

Technology	O
for	O
preventing	O
and	O
treating	O
animal	O
nutritional	O
diarrhea	O

The	O
present	O
invention	O
relates	O
to	O
preparation	O
process	O
of	O
cross	O
-	O
linked	O
sodium	B
hyaluronate	I
gel	O
as	O
eye	O
implant	O
.	O

The	O
process	O
of	O
preparing	O
the	O
cross	O
-	O
linked	O
sodium	B
hyaluronate	I
gel	O
includes	O
the	O
following	O
steps	O
:	O
pouring	O
the	O
reactant	O
liquid	O
comprising	O
sodium	B
hyaluronate	I
,	O
hydrazide	O
compound	O
,	O
carbodiimide	B
as	O
carboxyl	B
group	O
activator	O
and	O
proper	O
buffer	O
into	O
the	O
gap	O
between	O
two	O
plates	O
to	O
form	O
gel	O
in	O
certain	O
thickness	O
;	O
purifying	O
;	O
cutting	O
;	O
packing	O
and	O
sterilizing	O
.	O

The	O
cross	O
-	O
linked	O
sodium	B
hyaluronate	I
gel	O
is	O
used	O
as	O
eye	O
implant	O
,	O
especially	O
for	O
the	O
non	O
-	O
penetrating	O
glaucoma	O
treating	O
operation	O
,	O
to	O
prevent	O
adhesion	O
of	O
the	O
aqueous	O
humor	O
filtering	O
passage	O
,	O
raise	O
the	O
filtering	O
effect	O
and	O
control	O
the	O
post	O
-	O
operational	O
intraocular	O
pressure	O
.	O

Method	O
for	O
preparation	O
of	O
cross	O
-	O
linking	O
hyaluronic	B
acid	I
sodium	I
jelly	O
glue	O
implanted	O
in	O
eyes	O

The	O
slow	O
released	O
anticancer	O
injection	O
containing	O
tyrosine	B
kinase	O
inhibitor	O
and/or	O
platinum	B
compound	O
consists	O
of	O
slow	O
released	O
microsphere	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microsphere	O
includes	O
effective	O
anticancer	O
components	O
of	O
tyrosine	O
kinase	O
inhibitor	O
and/or	O
platinum	B
compound	O
and	O
slow	O
releasing	O
supplementary	O
material	O
,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O

The	O
suspending	O
agent	O
is	O
carboxymethyl	O
cellulose	O
,	O
etc	O
.	O
and	O
has	O
viscosity	O
of	O
100	O
-	O
3000	O
cp	O
at	O
20	O
-	O
30	O
deg.c	O
.	O

The	O
slow	O
releasing	O
supplementary	O
material	O
is	O
selected	O
from	O
p	O
(	O
LAEG	O
-	O
EOP	O
)	O
,	O
p	O
(	O
DAPG	O
-	O
EOP	O
)	O
,	O
p	O
(	O
BHET	O
-	O
EOP	O
/	O
TC	O
)	O
,	O
etc	O
.	O

The	O
anticancer	O
composition	O
may	O
be	O
also	O
prepared	O
into	O
slow	O
released	O
implant	O
,	O
and	O
the	O
released	O
injection	O
and	O
slow	O
released	O
implant	O
may	O
be	O
injected	O
or	O
set	O
in	O
tumor	O
for	O
slow	O
releasing	O
to	O
maintain	O
effective	O
medicine	O
concentration	O
for	O
over	O
50	O
days	O
,	O
and	O
has	O
obviously	O
lowered	O
systemic	O
reaction	O
on	O
the	O
medicine	O
and	O
capacity	O
of	O
enhancing	O
the	O
chemotherapeutic	O
and	O
radiotherapeutic	O
effect	O
.	O

Slow	O
-	O
release	O
injection	O
containing	O
tyrosine	B
kinase	O
restraining	O
agent	O
and	O
platinum	B
compound	O

The	O
present	O
invention	O
relates	O
to	O
injection	O
of	O
water	O
insoluble	O
quinolone	B
compound	O
,	O
such	O
as	O
Tosufloxacin	B
besilate	I
and	O
prulifloxicin	B
.	O

Water	O
indissoluble	O
carbostyrile	B
compound	O
injection	O
and	O
method	O
for	O
preparing	O
the	O
same	O

The	O
invention	O
discloses	O
a	O
chemical	O
compound	O
in	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
HO-	B
is	O
hydroxy	B
,	O
Br-	B
is	O
bromine	B
,	O
CH3-	B
is	O
methyl	B
,	O
CH2N	B
(	I
CH3	I
)	I
2-	I
is	O
dimethylaminomethyl	B
,	O
and	O
COOC2H5-	B
is	O
acetoacetate	B
.	O

Medicinal	O
composition	O
with	O
the	O
chemical	O
compound	O
as	O
active	O
ingredient	O
has	O
evident	O
antivirus	O
action	O
against	O
Coxsackie	O
b3	O
virus	O
,	O
adenovirus	O
Ad	O
7	O
,	O
parainfluenza	O
virus	O
and	O
rhinovirus	O
.	O

The	O
drug	O
has	O
good	O
antiviral	O
activity	O
against	O
Coxsackie	O
virus	O
,	O
adenovirus	O
Ad	O
7	O
,	O
parainfluenza	O
virus	O
,	O
and	O
rhinovirus	O
.	O

Anti	O
-	O
respiratory	O
virus	O
medicine	O
and	O
use	O

The	O
invention	O
discloses	O
a	O
new	O
use	O
of	O
phenanthridine	B
biologic	O
alcali	O
of	O
general	O
formula	O
I	O
containing	O
coumarone	O
and	O
its	O
derivant	O
in	O
preparing	O
anti	O
-	O
hepatitis	O
b	O
virus	O
medicament	O
.	O

The	O
biologic	O
alcali	O
has	O
tumor	O
cell	O
apoptosis	O
inducing	O
effect	O
,	O
has	O
strong	O
inhibiting	O
activity	O
against	O
to	O
such	O
pathogen	O
,	O
has	O
antiviral	O
effect	O
,	O
and	O
is	O
expected	O
for	O
treating	O
liver	O
cancer	O
,	O
wherein	O
R1	O
to	O
R10	O
,	O
R12	O
and	O
R13	O
is	O
hydrogen	B
,	O
hydroxy	B
,	O
carbon	B
chain	O
or	O
naphthenic	O
base	O
with	O
1	O
-	O
12	O
carbon	B
atoms	O
,	O
alkoxyl	B
or	O
acyloxy	B
group	O
,	O
benzyloxy	B
,	O
chlorine	B
and	O
other	O
halogen	B
atoms	O
,	O
amino	B
group	O
,	O
methylol	B
,	O
aldehyde	B
group	O
,	O
carbonyl	B
,	O
acetonyl	B
,	O
carboxy	B
,	O
sulacyloxy	B
,	O
4-methyl	B
-	I
benzenesulfonyloxyl	I
,	O
arylsulfonyloxy	B
,	O
diphenylphosphonoxyl	B
,	O
'	O
-OCONH2	B
;	O
R11	O
is	O
hydrogen	B
,	O
methyl	B
or	O
oxygen	B
atom	O
;	O
R14	O
and	O
R15	O
are	O
respectively	O
hydrogen	B
or	O
methyl	B
.	O

New	O
use	O
of	O
medicine	O
containing	O
benzophen	B
[	I
C	I
]	I
anthridine	I
alkaloid	B
and	O
its	O
derivatives	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
nicotine	B
aqueous	O
solution	O
in	O
preparing	O
medicaments	O
for	O
abstaining	O
from	O
tobacco	O
,	O
furthermore	O
,	O
the	O
nicotine	B
aqueous	O
solution	O
is	O
tobacco	O
extract	O
which	O
has	O
the	O
advantages	O
of	O
quick	O
effect	O
and	O
stabilized	O
action	O
.	O

Application	O
of	O
aqueous	O
solution	O
containing	O
nicotine	B
in	O
preparing	O
stop	O
smoking	O
medicine	O

Disclosed	O
is	O
a	O
composition	O
containing	O
biological	O
polysaccharides	O
and	O
biological	O
polysaccharide	O
wine	O
prepared	O
therefrom	O
,	O
wherein	O
the	O
composition	O
comprises	O
the	O
following	O
raw	O
materials	O
(	O
by	O
weight	O
portion	O
)	O
:	O
water	O
-	O
soluble	O
chitosan	O
0.5	O
-	O
5	O
parts	O
,	O
tortoise	O
shell	O
extract	O
5	O
-	O
30	O
,	O
matrimony	O
vine	O
extract	O
1	O
-	O
25	O
parts	O
,	O
Siberian	O
solomonseal	O
rhizome	O
extract	O
1	O
-	O
25	O
parts	O
,	O
astragalus	O
root	O
extract	O
5	O
-	O
30	O
parts	O
,	O
rehmannia	O
root	O
extract	O
1	O
-	O
25	O
parts	O
,	O
acanthopanax	O
root	O
extract	O
1	O
-	O
20	O
parts	O
,	O
epimedium	O
extract	O
1	O
-	O
20	O
parts	O
and	O
root	O
of	O
kudzu	O
vine	O
extract	O
1	O
-	O
20	O
parts	O
.	O

the	O
weight	O
ratio	O
of	O
high	O
degree	O
white	O
spirit	O
and	O
composition	O
containing	O
the	O
biological	O
polysaccharides	O
in	O
the	O
biological	O
polysaccharide	O
wine	O
is	O
100:5	O
-	O
20	O
.	O

Composition	O
containing	O
biological	O
polysaccharide	O
and	O
biological	O
polysaccharide	O
wine	O
made	O
from	O
the	O
same	O

An	O
anti	O
-	O
cancer	O
composition	O
comprises	O
anti	O
-	O
cancer	O
effective	O
ingredient	O
selected	O
from	O
tyrosine	B
kinase	O
inhibitor	O
and/or	O
uramustine	B
and	O
sustained	O
release	O
adjuvant	O
,	O
and	O
can	O
be	O
made	O
into	O
sustained	O
release	O
injection	O
and	O
sustained	O
release	O
implant	O
agent	O
.	O

Sustained	O
release	O
injection	O
also	O
comprises	O
special	O
dissolvant	O
containing	O
suspending	O
agent	O
.	O

The	O
Suspending	O
agent	O
has	O
a	O
viscocity	O
of	O
100cp-3000cp	O
(	O
at	O
20deg	O
.	O

C-30deg	O
.	O

C	O
)	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose	O
,	O
and	O
so	O
on	O
.	O

the	O
sustained	O
release	O
adjuvant	O
is	O
selected	O
from	O
p	O
(	O
LAEG	O
-	O
EOP	O
)	O
,	O
p	O
(	O
DAPG	O
-	O
EOP	O
)	O
,	O
p	O
(	O
BHET	O
-	O
EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
BHET	O
-	O
EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
BHDPT	O
-	O
EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
BHDPT	O
-	O
EOP	O
/	O
TC	O
)	O
,	O
p	O
(	O
CHDM	O
-	O
HOP	O
)	O
or	O
p	O
(	O
CHDM	O
-	O
EOP	O
)	O
.Slow	O
releasing	O
injection	O
and	O
implantable	O
agent	O
can	O
keep	O
high	O
medicinal	O
concentration	O
in	O
tumour	O
part	O
through	O
slow	O
releasing	O
for	O
over	O
60	O
days	O
after	O
being	O
injected	O
or	O
implanted	O
in	O
or	O
around	O
tumour	O
.	O

The	O
anticancer	O
composition	O
may	O
also	O
be	O
prepared	O
into	O
sustained	O
-	O
release	O
implant	O
.	O

It	O
can	O
reduce	O
systemic	O
toxic	O
reaction	O
of	O
anticancer	O
drugs	O
,	O
and	O
also	O
selectively	O
improve	O
the	O
therapeutic	O
effect	O
of	O
non	O
-	O
operative	O
therapy	O
such	O
as	O
chemotherapy	O
.	O

Anticancer	O
composition	O
containing	O
semustine	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
antibiotic	O
deodorization	O
powder	O
with	O
rare	O
earth	O
activated	O
inorganic	O
antibiotic	O
powder	O
(	O
silver	B
ion	I
antibiotic	O
powder	O
)	O
and	O
talcum	O
powder	O
as	O
raw	O
material	O
and	O
its	O
preparation	O
method	O
.	O

Silver	B
ion	I
does	O
not	O
generate	O
any	O
toxic	O
and	O
hazardous	O
material	O
during	O
antibiotic	O
and	O
sterilizing	O
process	O
,	O
bring	O
no	O
hazard	O
to	O
body	O
or	O
environment	O
,	O
is	O
the	O
safest	O
technology	O
with	O
high	O
degerming	O
rate	O
and	O
broad	O
noxious	O
strain	O
resisting	O
scope	O
,	O
has	O
antibiotic	O
and	O
foreign	O
flavor	O
removing	O
effects	O
free	O
from	O
environment	O
and	O
pH	O
,	O
and	O
has	O
high	O
safety	O
,	O
no	O
environmental	O
pollution	O
and	O
irritation	O
.	O

Talcum	O
powder	O
has	O
effects	O
in	O
astringing	O
dampness	O
,	O
promoting	O
wound	O
healing	O
,	O
and	O
protecting	O
wound	O
surface	O
,	O
absorbing	O
secretion	O
,	O
and	O
promoting	O
incrustation	O
;	O
and	O
can	O
be	O
used	O
for	O
treating	O
synclonus	O
beriberica	O
,	O
eczema	O
,	O
sore	O
,	O
and	O
body	O
foreign	O
flavor	O
for	O
external	O
use	O
.	O

Compared	O
with	O
traditional	O
foot	O
powder	O
,	O
the	O
inventive	O
antibiotic	O
deodorization	O
powder	O
has	O
improved	O
therapeutic	O
effect	O
in	O
deodorizating	O
,	O
relieving	O
pruritus	O
,	O
and	O
healing	O
wound	O
,	O
has	O
good	O
elimination	O
of	O
rancidity	O
,	O
underarm	O
odor	O
and	O
shoes	O
odor	O
caused	O
by	O
feet	O
odor	O
,	O
and	O
convenient	O
application	O
.	O

Antibacterial	O
and	O
deodorizing	O
powder	O

The	O
present	O
invention	O
discloses	O
a	O
quithiopine	B
fumarate	I
slow	O
(	O
controlled	O
)	O
release	O
preparation	O
and	O
its	O
application	O
.	O

Its	O
preparation	O
composition	O
includes	O
(	O
by	O
wt%	O
)	O
27	O
-	O
50	O
%	O
of	O
quithiopine	B
fumarate	I
,	O
2	O
-	O
7	O
%	O
of	O
organic	O
acid	O
,	O
40	O
-	O
50	O
%	O
of	O
water	O
-	O
soluble	O
macromolecule	O
,	O
2	O
-	O
7	O
%	O
of	O
enteric	O
solubility	O
material	O
,	O
0.1	O
-	O
2	O
%	O
of	O
wax	O
and	O
2	O
-	O
7	O
%	O
of	O
water	O
-	O
insoluble	O
macromolecule	O
.	O

Said	O
preparation	O
can	O
be	O
effectively	O
used	O
for	O
curing	O
schizophrenia	O
.	O

Composition	O
of	O
slow	O
(	O
controlled	O
)	O
releasing	O
preparation	O
of	O
Quetiadine	B
Hemifumarate	I
,	O
and	O
application	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
capable	O
of	O
using	O
natural	O
and	O
artificial	O
synthetic	O
isosulfocyanate	B
compound	O
or	O
its	O
derivative	O
to	O
prevent	O
and	O
cure	O
prostatic	O
diseases	O
and	O
skin	O
carcinoma	O
.	O

The	O
internal	O
tests	O
show	O
that	O
various	O
isosulfocyanate	B
compounds	O
or	O
their	O
derivatives	O
can	O
induce	O
prostatic	O
cell	O
II	O
phase	O
drug	O
metabolic	O
detoxication	O
enzyme	O
-	O
glutathione	O
transferase	O
so	O
as	O
to	O
can	O
inhibit	O
the	O
hyperplasia	O
of	O
prostate	O
and	O
inflammation	O
,	O
and	O
can	O
prevent	O
and	O
cure	O
prostatic	O
carcinoma	O
and	O
skin	O
carcinoma	O
.	O

Application	O
of	O
compounds	O
in	O
isorhodanic	O
ester	O
classes	O
for	O
treating	O
diseases	O
of	O
prostate	O
and	O
skin	O
cancer	O

The	O
invention	O
relates	O
to	O
a	O
policresulen	B
gel	O
product	O
,	O
which	O
comprises	O
policresulen	B
solution	O
with	O
its	O
concentration	O
being	O
45	O
-	O
55	O
%	O
and	O
proportion	O
being	O
2.0	O
-	O
6.0	O
%	O
,	O
sodium	O
carboxymethyl	O
cellulose	O
(	O
CMC	O
-	O
Na	O
)	O
with	O
proportion	O
being	O
2.0	O
-	O
6.0	O
%	O
and	O
glycerin	B
with	O
proportion	O
being	O
10	O
-	O
15	O
%	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
said	O
gel	O
product	O
,	O
which	O
comprises	O
steps	O
of	O
adding	O
CMC	O
-	O
Na	O
into	O
hot	O
purified	O
water	O
for	O
swelling	O
for	O
12	O
hours	O
,	O
adding	O
glycerin	B
and	O
stirring	O
evenly	O
,	O
adding	O
policresulen	B
into	O
CMC	O
-	O
Na	O
solution	O
,	O
or	O
adding	O
some	O
preservative	O
agent	O
,	O
stirring	O
and	O
adding	O
more	O
purified	O
water	O
,	O
and	O
getting	O
policresulen	B
gel	O
product	O
.	O

The	O
gel	O
product	O
is	O
characterized	O
by	O
stable	O
property	O
,	O
strong	O
adhesive	O
ability	O
to	O
mucosa	O
and	O
good	O
skin	O
accidental	O
union	O
effect	O
,	O
prolonged	O
retention	O
time	O
for	O
policresulen	B
in	O
vaginal	O
and	O
improved	O
medicine	O
absorption	O
,	O
increased	O
biological	O
utilization	O
rate	O
and	O
curative	O
effect	O
,	O
favor	O
for	O
water	O
soluble	O
medicine	O
release	O
,	O
and	O
clinical	O
practicability	O
.	O

Policresulen	B
gelling	O
agent	O
,	O
method	O
for	O
preparation	O
the	O
same	O
and	O
the	O
pharmaceutical	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
colitis	O
and	O
its	O
preparing	O
process	O
,	O
wherein	O
the	O
medicinal	O
composition	O
is	O
prepared	O
from	O
pseudostellaria	O
root	O
25	O
-	O
35	O
g	O
,	O
white	O
atractylodes	O
rhizome	O
10	O
-	O
15	O
g	O
,	O
dried	O
orange	O
peel	O
5	O
-	O
9	O
g	O
,	O
poria	O
cocos	O
wolf	O
12	O
-	O
15	O
g	O
,	O
licorice	O
root	O
3	O
-	O
8	O
g	O
,	O
coix	O
seed	O
25	O
-	O
35	O
g	O
,	O
slices	O
of	O
aconite	O
8	O
-	O
12	O
g	O
,	O
root	O
of	O
herbaceous	O
peony	O
10	O
-	O
20	O
g	O
,	O
coptis	O
root	O
1	O
-	O
5	O
g	O
,	O
prepared	O
dark	O
Japanese	O
plum	O
8	O
-	O
12	O
g	O
,	O
ledebouriella	O
root	O
8	O
-	O
12	O
g	O
,	O
kudzuvine	O
root	O
8	O
-	O
12	O
g	O
,	O
rifampicin	B
1	O
-	O
5	O
g	O
,	O
pipemidic	B
acid	I
4	O
-	O
8	O
g	O
and	O
metronidazole	B
7	O
-	O
11	O
g	O
through	O
steps	O
of	O
disintegrating	O
,	O
mixing	O
,	O
sieving	O
,	O
and	O
making	O
into	O
various	O
preparation	O
,	O
in	O
particular	O
capsules	O
by	O
the	O
conventional	O
preparing	O
method	O
.	O

Medicine	O
composition	O
for	O
treating	O
colitis	O
and	O
method	O
of	O
making	O
the	O
same	O

The	O
present	O
invention	O
discloses	O
an	O
optical	O
pure	O
compound	O
in	O
Formula	O
I	O
,	O
the	O
salt	O
and	O
the	O
solvate	O
which	O
are	O
acceptable	O
for	O
the	O
medicine	O
of	O
the	O
compound	O
,	O
and	O
the	O
usage	O
of	O
the	O
salt	O
and	O
the	O
solvate	O
in	O
preparing	O
medicine	O
and	O
medicine	O
compound	O
.	O

The	O
present	O
invention	O
also	O
provides	O
the	O
preparation	O
method	O
for	O
the	O
compound	O
defined	O
in	O
the	O
invention	O
.	O

Substituted	O
sulfoxide	B
compound	O
and	O
its	O
preparing	O
method	O
and	O
application	O

Preparation	O
of	O
tartaric	B
acid	I
ifenprodil	I
is	O
carried	O
out	O
by	O
4-hydroxy	B
-	I
phenpropionate	I
as	O
initial	O
raw	O
material	O
,	O
reacting	O
with	O
copper	B
bromide	I
to	O
remove	O
copper	B
ion	I
,	O
preparing	O
into	O
intermediate	O
1-	B
(	I
4-oxyphenyl	I
)	I
-2-bromopropane-1-ketone	I
,	O
condensation	O
reacting	O
with	O
4-benzyl	B
pyridine	I
to	O
obtain	O
intermediate	O
,	O
hydrogenation	O
reducing	O
intermediate	O
1-	B
(	I
4-hydroxy	I
-	I
phenyl	I
)	I
-2-	I
(	I
4-benzyl	I
pyridine	I
)	I
propane-1-keto	I
-	I
hydro	I
-	I
bromic	I
acid	I
salt	O
to	O
obtain	O
ifenprodil	B
,	O
and	O
salting	O
with	O
tartaric	B
acid	I
to	O
obtain	O
final	O
product	O
.	O

Method	O
for	O
synthesizing	O
ifenprodil	B
tartrate	I

The	O
method	O
is	O
used	O
for	O
preventing	O
or	O
treating	O
an	O
amyloid	O
-	O
beta	O
related	O
disease	O
in	O
a	O
subject	O
.	O

The	O
method	O
comprises	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
first	O
agent	O
that	O
prevents	O
or	O
treats	O
amyloid	O
-	O
beta	O
related	O
disease	O
,	O
and	O
a	O
second	O
agent	O
that	O
is	O
(	O
i	O
)	O
a	O
peptide	O
or	O
peptidomimetic	O
that	O
modulates	O
amyloid	O
-	O
beta	O
fibril	O
formulation	O
or	O
induces	O
a	O
prophylactic	O
or	O
therapeutic	O
immune	O
response	O
against	O
amyloid	O
-	O
beta	O
fibril	O
formulation	O
,	O
or	O
(	O
ii	O
)	O
an	O
immune	O
system	O
modulator	O
that	O
prevents	O
or	O
inhibits	O
amyloid	O
-	O
beta	O
fibril	O
formulation	O
.	O

Therapeutic	O
formulations	O
for	O
the	O
treatment	O
of	O
beta	O
-	O
amyloid	O
related	O
diseases	O

The	O
invention	O
discloses	O
azithromycin	B
eye	O
drops	O
and	O
the	O
preparation	O
.	O

The	O
eye	O
drops	O
is	O
a	O
stable	O
ophthalmic	O
preparation	O
made	O
by	O
azithromycin	B
or	O
axithromycin	B
salt	O
as	O
the	O
active	O
ingredient	O
which	O
is	O
assisted	O
by	O
a	O
stabilizer	O
,	O
a	O
pH	O
regulator	O
,	O
an	O
antiseptic	O
,	O
an	O
isotonic	O
agent	O
and	O
a	O
pasting	O
agent	O
;	O
wherein	O
the	O
optimized	O
stabilizer	O
is	O
propanetriol	B
,	O
the	O
pH	O
regulator	O
is	O
sodium	B
phosphate	I
buffer	O
,	O
the	O
antiseptic	O
is	O
Ethyl	B
p	I
-	I
hydroxybenzoate	I
,	O
the	O
isotonic	O
agent	O
is	O
sodium	B
chloride	I
and	O
the	O
pasting	O
agent	O
is	O
sodium	B
hyaluronate	I
.	O

Compared	O
with	O
oral	O
delivery	O
,	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
less	O
dose	O
,	O
small	O
side	O
effect	O
on	O
a	O
whole	O
body	O
,	O
direct	O
absorption	O
at	O
the	O
ocular	O
region	O
,	O
quick	O
achieving	O
effective	O
antibacterial	O
concentration	O
and	O
quick	O
developing	O
treating	O
function	O
;	O
and	O
compared	O
with	O
ophthalmic	O
gel	O
or	O
ophthalmic	O
ointment	O
,	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
convenient	O
application	O
and	O
good	O
tolerance	O
for	O
a	O
patient	O
;	O
thus	O
the	O
reasonable	O
preparation	O
process	O
and	O
stable	O
performance	O
of	O
the	O
invention	O
guarantees	O
the	O
clarity	O
and	O
stability	O
of	O
eye	O
drops	O
.	O

Azithromycin	B
eye	O
drops	O
and	O
preparing	O
process	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medical	O
technology	O
,	O
in	O
particular	O
to	O
a	O
penciclovir	B
lyophilized	O
royal	O
jelly	O
powder	O
injection	O
and	O
its	O
preparation	O
method	O
,	O
which	O
comprises	O
penciclovir	B
and	O
excipient	O
.	O

The	O
powder	O
injection	O
is	O
made	O
by	O
making	O
penciclovir	B
into	O
penciclovir	B
sodium	I
salt	O
,	O
add	O
the	O
excipient	O
and	O
then	O
freeze	O
out	O
.	O

The	O
weight	O
ratio	O
of	O
the	O
penciclovir	B
and	O
the	O
excipient	O
is	O
:	O
1:0.2	O
to	O
3	O
;	O
the	O
excipient	O
comprises	O
low	O
molecular	O
dextran	O
.	O

The	O
invention	O
resolves	O
the	O
problem	O
of	O
defective	O
water	O
-	O
solubility	O
in	O
the	O
prior	O
art	O
.	O

Besides	O
,	O
with	O
the	O
freezing	O
out	O
technology	O
and	O
by	O
adding	O
low	O
molecular	O
dextran	O
as	O
the	O
excipient	O
,	O
the	O
invention	O
enhances	O
the	O
solubility	O
and	O
stability	O
of	O
penciclovir	B
,	O
resolves	O
the	O
problem	O
of	O
low	O
biologic	O
utilization	O
rate	O
of	O
penciclovir	B
and	O
ensures	O
the	O
safety	O
and	O
convenience	O
of	O
medication	O
.	O

What	O
is	O
more	O
,	O
the	O
invention	O
also	O
provides	O
the	O
preparation	O
method	O
for	O
the	O
penciclovir	B
lyophilized	O
royal	O
jelly	O
powder	O
injection	O
.	O

Penciclovir	B
freeze	O
dried	O
and	O
method	O
of	O
manufacturing	O
the	O
same	O

The	O
invention	O
pertains	O
to	O
the	O
field	O
of	O
pharmaceutical	O
preparation	O
.	O

The	O
invention	O
relates	O
to	O
a	O
cross	O
-	O
linked	O
covered	O
tablet	O
which	O
is	O
used	O
for	O
colon	O
-	O
specific	O
drug	O
delivery	O
.	O

The	O
invention	O
takes	O
a	O
drug	O
-	O
containing	O
tablet	O
as	O
the	O
core	O
,	O
the	O
periphery	O
of	O
which	O
is	O
wrapped	O
with	O
a	O
coating	O
material	O
,	O
and	O
the	O
outer	O
layer	O
coating	O
retarding	O
material	O
adopts	O
the	O
mixture	O
of	O
pectin	O
of	O
the	O
calcium	O
salts	O
/	O
calcium	O
salts	O
with	O
the	O
special	O
amount	O
and	O
high	O
parts	O
by	O
weight	O
;	O
the	O
retarding	O
release	O
effect	O
of	O
the	O
pectin	O
is	O
strengthened	O
through	O
the	O
cross	O
-	O
linked	O
process	O
,	O
so	O
the	O
invention	O
is	O
applicable	O
to	O
the	O
colon	O
-	O
specific	O
drug	O
delivery	O
,	O
in	O
particular	O
to	O
the	O
insoluble	O
drugs	O
.	O

The	O
experimental	O
results	O
show	O
that	O
the	O
invention	O
can	O
retard	O
the	O
release	O
of	O
the	O
drug	O
,	O
so	O
as	O
to	O
achieve	O
the	O
ideal	O
colon	O
-	O
specific	O
drug	O
delivery	O
,	O
at	O
the	O
same	O
time	O
,	O
the	O
invention	O
does	O
not	O
need	O
to	O
use	O
more	O
coating	O
materials	O
,	O
which	O
can	O
significantly	O
save	O
the	O
using	O
amount	O
of	O
the	O
pectin	O
materials	O
.	O

The	O
invention	O
is	O
applicable	O
to	O
the	O
treatments	O
of	O
the	O
diseases	O
with	O
the	O
need	O
of	O
colon	O
-	O
specific	O
drug	O
delivery	O
,	O
such	O
as	O
colitis	O
,	O
colon	O
cancer	O
and	O
other	O
colon	O
diseases	O
.	O

Crosslinking	O
wrapped	O
core	O
slice	O
in	O
vivo	O
for	O

The	O
present	O
invention	O
discloses	O
a	O
silymarin	O
preparation	O
,	O
in	O
particular	O
to	O
a	O
silymarin	O
self	O
-	O
emulsifying	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
includes	O
the	O
silymarin	O
,	O
phospholipids	B
,	O
oil	O
phase	O
,	O
emulsifier	O
and	O
other	O
components	O
.	O

The	O
preparation	O
method	O
is	O
that	O
:	O
the	O
silymarin	O
and	O
phospholipids	B
are	O
weighted	O
in	O
accordance	O
with	O
the	O
prescription	O
dose	O
,	O
and	O
then	O
added	O
into	O
the	O
organic	O
solvents	O
to	O
carry	O
out	O
the	O
heating	O
reflux	O
reaction	O
for	O
certain	O
time	O
till	O
the	O
solution	O
is	O
clarified	O
,	O
so	O
as	O
to	O
get	O
the	O
silymarin	O
precursor	O
;	O
then	O
the	O
oil	O
phase	O
and	O
the	O
emulsifier	O
are	O
weighted	O
and	O
added	O
in	O
the	O
silymarin	O
precursor	O
,	O
afterwards	O
,	O
the	O
organic	O
solvents	O
are	O
volatilized	O
and	O
removed	O
by	O
the	O
rolling	O
thin	O
film	O
organic	O
solvents	O
volatilizing	O
method	O
under	O
certain	O
temperature	O
,	O
then	O
the	O
capsule	O
is	O
prepared	O
.	O

The	O
preparation	O
of	O
the	O
invention	O
can	O
improve	O
the	O
solubility	O
of	O
the	O
silymarin	O
in	O
the	O
oil	O
of	O
the	O
invention	O
and	O
greatly	O
reduce	O
the	O
dose	O
of	O
the	O
preparation	O
;	O
the	O
pharmacological	O
effects	O
and	O
efficacy	O
are	O
increased	O
trough	O
the	O
preparation	O
of	O
the	O
silymarin	O
precursor	O
;	O
the	O
performance	O
after	O
oral	O
administration	O
is	O
the	O
self	O
-	O
emulsifying	O
preparation	O
,	O
and	O
the	O
drug	O
can	O
be	O
absorbed	O
via	O
the	O
two	O
parts	O
of	O
submucosal	O
capillaries	O
and	O
submucosal	O
lymphatic	O
vessels	O
,	O
thus	O
improving	O
the	O
bioavailability	O
again	O
.	O

Hepadestal	O
preparations	O
and	O
method	O
for	O
preparing	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
skin	O
protection	O
wipe	O
,	O
which	O
is	O
composed	O
of	O
base	O
material	O
and	O
skin	O
protection	O
agent	O
;	O
the	O
present	O
invention	O
is	O
characterized	O
in	O
that	O
:	O
the	O
components	O
and	O
parts	O
by	O
weight	O
of	O
the	O
skin	O
protection	O
agent	O
are	O
:	O
isopropanol	B
:	O
20	O
to	O
75	O
parts	O
;	O
acetyl	B
tributyl	I
citrate	I
:	O
8	O
to	O
30	O
parts	O
;	O
butyl	B
PVM	I
/	O
MA	O
copolymer	O
:	O
15	O
to	O
55	O
parts	O
.	O

As	O
the	O
present	O
invention	O
uses	O
the	O
isopropanol	B
,	O
acetyl	B
tributyl	I
citrate	I
and	O
butyl	B
PVM	I
/	O
MA	O
copolymer	O
as	O
the	O
raw	O
materials	O
,	O
the	O
present	O
invention	O
not	O
only	O
has	O
strong	O
sterilization	O
,	O
disinfection	O
and	O
skin	O
cleaning	O
capability	O
,	O
but	O
can	O
also	O
produce	O
a	O
layer	O
of	O
protection	O
membrane	O
on	O
the	O
skin	O
surface	O
to	O
isolate	O
the	O
skin	O
,	O
thus	O
ensuring	O
the	O
chemical	O
components	O
which	O
have	O
the	O
stimulating	O
effect	O
not	O
to	O
contact	O
with	O
the	O
skin	O
directly	O
and	O
avoiding	O
the	O
allergic	O
reactions	O
.	O

The	O
present	O
invention	O
adopts	O
the	O
form	O
of	O
the	O
wipe	O
,	O
which	O
is	O
very	O
convenient	O
to	O
carry	O
and	O
particularly	O
applicable	O
to	O
the	O
medical	O
staff	O
for	O
visiting	O
at	O
the	O
site	O
of	O
the	O
sudden	O
accidents	O
.	O

Skin	O
-	O
protecting	O
wiping	O
slice	O

The	O
invention	O
relates	O
to	O
a	O
ciclopirox	B
olamine	I
gel	O
preparation	O
used	O
to	O
cure	O
vagina	O
candida	O
albicans	O
and	O
mycotic	O
infection	O
,	O
wherein	O
the	O
gel	O
preparation	O
takes	O
ciclopirox	B
olamine	I
as	O
active	O
material	O
and	O
macromolecule	O
polymer	O
carbomer	O
as	O
hydrophilic	O
gel	O
ground	O
substance	O
;	O
meanwhile	O
,	O
the	O
gel	O
preparation	O
is	O
made	O
through	O
adding	O
appropriate	O
amount	O
of	O
cosolvent	O
,	O
pH	O
regulator	O
,	O
percutaneous	O
absorption	O
enhancer	O
,	O
stabilizer	O
and	O
purified	O
water	O
according	O
to	O
the	O
physiologic	O
characteristics	O
of	O
vaginal	O
administration	O
and	O
physical	O
and	O
chemical	O
characters	O
of	O
ciclopirox	B
olamine	I
.	O

The	O
gel	O
preparation	O
is	O
characterized	O
by	O
exquisite	O
and	O
smooth	O
texture	O
,	O
no	O
greasy	O
feeling	O
and	O
easy	O
cleaning	O
and	O
also	O
has	O
the	O
advantages	O
of	O
no	O
stimulus	O
,	O
strong	O
adhesion	O
and	O
good	O
adhering	O
effect	O
on	O
skin	O
;	O
meanwhile	O
,	O
the	O
gel	O
preparation	O
can	O
prolong	O
stay	O
time	O
of	O
ciclopirox	B
olamine	I
in	O
vagina	O
and	O
promote	O
percutaneous	O
absorption	O
of	O
medicine	O
to	O
improve	O
antibacterial	O
efficacy	O
,	O
thereby	O
possessing	O
high	O
safety	O
and	O
clinic	O
practicability	O
.	O

Ciclopirox	B
olamine	I
gelling	O
agent	O
,	O
method	O
for	O
preparing	O
the	O
same	O
and	O
pharmaceutical	O
use	O
thereof	O

The	O
invention	O
pertains	O
to	O
photodynamic	O
treatment	O
field	O
,	O
in	O
particular	O
to	O
photosencitizer	O
of	O
photodynamic	O
treatment	O
.	O

The	O
invention	O
provides	O
a	O
reversed	O
-	O
phase	O
purification	O
method	O
for	O
separating	O
a	O
3	B
(	I
or	I
8	I
)	I
-	I
(	I
1-methoxyethyl	I
)	I
-8	I
(	I
or	I
3	I
)	I
-	I
(	I
1-ethoxyl	I
)	I
deuteroporphyrin	I
IX	I
positional	O
isomer	O
.	O

The	O
method	O
can	O
be	O
used	O
for	O
preparing	O
an	O
8-	B
(	I
1-	I
methoxyethyl	I
)	I
-3-	I
(	I
1-ethoxyl	I
)	I
deuteroporphyrin	I
IX	I
or	O
3-	B
(	I
1-methoxyethyl	I
)	I
-8-	I
(	I
1-ethoxyl	I
)	I
deuteroporphyrin	I
IX	I
single	O
isomer	O
.	O

The	O
two	O
isomers	O
,	O
through	O
an	O
animal	O
experiment	O
,	O
are	O
proved	O
to	O
be	O
applicable	O
to	O
blocking	O
new	O
-	O
born	O
veins	O
effectively	O
as	O
the	O
photosencitizer	O
.	O

The	O
single	O
isomer	O
of	O
the	O
invention	O
can	O
be	O
used	O
for	O
preparing	O
medicine	O
with	O
single	O
molecule	O
structure	O
and	O
steadier	O
properties	O
.	O

Method	O
for	O
separating	O
hemporfin	B
isomer	O
and	O
separated	O
isomer	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
an	O
imiquine	O
chitose	O
nanometer	O
particle	O
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
regarding	O
the	O
microemulsion	O
as	O
the	O
mold	O
;	O
selecting	O
isopropyl	B
myristate	I
-	I
span	I
20	I
,	O
tween	B
80	I
,	O
1	B
,	I
2-octglycol	I
-	I
sodium	I
tripolyphosphate	I
aqueous	O
solution	O
as	O
microemulsion	O
system	O
I	O
;	O
selecting	O
isopropyl	B
myristate	I
-	I
span	I
20	I
,	O
tween	B
80	I
,	O
1	B
,	I
2-octglycol-	I
chitose	I
imiquine	I
acetic	I
acid	I
aqueous	O
solution	O
as	O
microemulsion	O
system	O
II	O
,	O
wherein	O
span	B
20	I
:	O
tween	B
80	I
:	O
1	B
,	I
2	I
octglycol	I
is	O
28:42:30	O
,	O
isopropyl	B
myristate	I
:	O
span	B
20-tween	I
80	I
-	I
1	I
,	I
2	I
octglycol	I
is	O
6	O
.	O

5	O
:	O
3	O
.	O
5	O
,	O
the	O
water	O
content	O
of	O
microemulsion	O
system	O
I	O
and	O
microemulsion	O
system	O
II	O
is	O
30%-60	O
%	O
;	O
adding	O
microemulsion	O
system	O
I	O
and	O
dropping	O
microemulsion	O
system	O
II	O
in	O
the	O
condition	O
of	O
mixing	O
;	O
preparing	O
the	O
imiquine	O
chitose	O
nanometer	O
particle	O
by	O
ionic	O
gel	O
reaction	O
of	O
two	O
microemulsion	O
systems	O
;	O
reacting	O
4	O
hours	O
;	O
acquiring	O
the	O
nanometer	O
particle	O
with	O
the	O
small	O
grain	O
diameter	O
,	O
the	O
high	O
carrying	O
ratio	O
and	O
the	O
high	O
sealing	O
ratio	O
.	O

Method	O
for	O
preparing	O
Imiquimod	B
chitosannano	O
granule	O

The	O
invention	O
relates	O
to	O
an	O
Azithromycin	B
dispersible	O
tablet	O
and	O
its	O
preparing	O
process	O
,	O
wherein	O
the	O
constituents	O
include	O
(	O
by	O
weight	O
percent	O
)	O
Azithromycin	B
45	O
-	O
50	O
%	O
,	O
medicinal	O
starch	O
24	O
-	O
25	O
%	O
,	O
pre	O
-	O
gelatinized	O
starch	O
18	O
-	O
20	O
%	O
,	O
micro	O
-	O
powdered	O
silica	B
gel	I
4	O
-	O
5	O
%	O
and	O
methylcellulose	O
propylene	O
glycol	O
ether	O
.	O

The	O
preparing	O
process	O
consists	O
of	O
disintegrating	O
,	O
sieving	O
,	O
mixing	O
homogeneously	O
,	O
granulating	O
,	O
drying	O
and	O
tabletting	O
.	O
.	O

Azithromycin	B
dispersible	O
tablet	O
and	O
method	O
of	O
preparing	O
the	O
same	O

The	O
invention	O
discloses	O
a	O
medicinal	O
plaster	O
for	O
treating	O
neck	O
and	O
lumbar	O
spine	O
diseases	O
,	O
wherein	O
each	O
120	O
plasters	O
contain	O
medicinal	O
constituents	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
(	O
by	O
weight	O
ratio	O
)	O
:	O
safflower	O
18	O
-	O
23	O
parts	O
,	O
rhizome	O
of	O
Sichuan	O
lovage	O
18	O
-	O
23	O
parts	O
,	O
frank	O
incense	O
8	O
-	O
12	O
parts	O
,	O
myrrh	O
8	O
-	O
12	O
parts	O
,	O
radix	O
aconiti	O
18	O
-	O
23	O
parts	O
,	O
Kusnezoff	O
monkshood	O
root	O
18	O
-	O
23	O
parts	O
,	O
Hippocampus	O
japonicus	O
2	O
-	O
4	O
parts	O
,	O
cinnamon	O
8	O
-	O
15	O
parts	O
,	O
peach	O
kernel	O
8	O
-	O
15	O
parts	O
,	O
campeachy	O
wood	O
18	O
-	O
23	O
parts	O
,	O
asarum	O
herb	O
4	O
-	O
8	O
parts	O
,	O
buthus	O
martensi	O
kirsch	O
8	O
-	O
13	O
parts	O
,	O
centipede	O
20	O
-	O
60	O
pieces	O
,	O
black	O
-	O
tail	O
snake	O
15	O
-	O
22	O
parts	O
,	O
Eupolyphaga	O
Sinensis	O
Walker	O
7	O
-	O
15	O
parts	O
,	O
dipsacus	O
root	O
15	O
-	O
25	O
parts	O
,	O
dragon	O
's	O
blood	O
resin	O
9	O
-	O
15	O
parts	O
,	O
achyranthes	O
and	O
cyathula	O
root	O
7	O
-	O
15	O
parts	O
,	O
black	O
catechu	O
10	O
-	O
15	O
parts	O
,	O
borneol	O
7	O
-	O
15	O
parts	O
,	O
Clematis	O
chinensis	O
17	O
-	O
22	O
parts	O
,	O
spatholobus	O
stem	O

15	O
-	O
25	O
parts	O
,	O
sesame	O
seed	O
oil	O
200	O
-	O
300	O
parts	O
,	O
yellow	O
lead	B
80	O
-	O
130	O
parts	O
.	O

Plaster	O
for	O
treating	O
cervical	O
vertebra	O
/	O
lumbar	O
disease	O

The	O
present	O
invention	O
is	O
the	O
use	O
of	O
one	O
kind	O
of	O
salvianolate	B
B	I
salt	O
or	O
its	O
isomer	O
,	O
precursor	O
,	O
derivative	O
,	O
pharmaceutically	O
acceptable	O
salt	O
and	O
composition	O
as	O
Na+	B
/	O
K+-ATP	B
enzyme	O
inhibitor	O
.	O

The	O
Na+	B
/	O
K+-ATP	B
enzyme	O
activity	O
test	O
on	O
magnesium	B
salvianolate	I
B	I
as	O
one	O
common	O
salvianolate	B
B	I
salt	O
proves	O
that	O
magnesium	B
salvianolate	I
B	I
has	O
suck	O
structure	O
as	O
to	O
be	O
capable	O
of	O
substituting	O
cyclopentahydrophenanathrene	B
,	O
as	O
one	O
kind	O
of	O
cardio	O
-	O
glucoside	O
steroid	O
medicine	O
.	O

The	O
brain	O
ischemia	O
experiment	O
proves	O
the	O
effect	O
of	O
magnesium	B
salvianolate	I
B	I
in	O
reducing	O
injury	O
on	O
brain	O
cell	O
.	O

All	O
the	O
said	O
functions	O
come	O
from	O
that	O
salvianolate	B
B	I
salt	O
can	O
inhibit	O
the	O
hydrolysis	O
of	O
Na+	B
/	O
K+-ATP	B
enzyme	O
actively	O
transported	O
phosphate	B
radical	I
to	O
reduce	O
the	O
Na+	B
/	O
K+	B
exchange	O
of	O
cell	O
and	O
increase	O
calcium	B
ions	I
inside	O
cell	O
.	O

The	O
present	O
invention	O
has	O
the	O
uses	O
of	O
tonifying	O
heart	O
,	O
promoting	O
urination	O
,	O
protecting	O
nerve	O
cell	O
,	O
treating	O
heart	O
failure	O
,	O
etc	O
.	O

Use	O
of	O
alvianolic	B
acid	I
B	I
salt	O
as	O
Na+	B
/	O
K+-ATP	B
enzyme	O
inhibitor	O

The	O
present	O
invention	O
is	O
enteric	O
preparation	O
of	O
rimonabant	O
or	O
its	O
medicinal	O
salt	O
and	O
its	O
preparation	O
process	O
and	O
application	O
.	O

The	O
enteric	O
preparation	O
of	O
rimonabant	O
or	O
its	O
medicinal	O
salt	O
may	O
be	O
micropill	O
,	O
tablet	O
,	O
hard	O
capsule	O
,	O
soft	O
capsule	O
,	O
granule	O
,	O
microcapsule	O
,	O
etc	O
.	O

The	O
enteric	O
preparation	O
of	O
rimonabant	O
or	O
its	O
medicinal	O
salt	O
has	O
no	O
influence	O
of	O
gastric	O
acid	O
on	O
its	O
active	O
component	O
,	O
no	O
side	O
effects	O
of	O
causing	O
nausea	O
,	O
vomiting	O
,	O
etc	O
.	O
,	O
controlled	O
enteric	O
release	O
,	O
concentrated	O
absorption	O
and	O
raised	O
bioavailability	O
.	O

Rimonabant	O
or	O
the	O
enteric	O
-	O
coated	O
preparations	O
of	O
the	O
rimonabant	O
medical	O
salts	O
and	O
method	O
for	O
preparing	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
one	O
kind	O
of	O
new	O
compound	O
,	O
entecavir	B
amido	I
ursodesoxycholate	I
,	O
its	O
preparation	O
process	O
,	O
medicine	O
composition	O
with	O
the	O
compound	O
as	O
active	O
component	O
and	O
the	O
application	O
of	O
the	O
compound	O
in	O
preventing	O
and	O
treating	O
hepatitis	O
B.	O
Ursodeoxycholic	B
acid	I
entecavir	I
acidamide	I
and	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
combination	O
of	O
cefoperazone	B
sodium	I
and	O
sulbactam	B
sodium	I
.	O

The	O
combination	O
consists	O
of	O
the	O
cefoperazone	B
sodium	I
and	O
the	O
sulbactam	B
sodium	I
,	O
and	O
the	O
weight	O
ratio	O
of	O
which	O
is	O
3	O
to	O
1	O
.	O

The	O
combination	O
of	O
cefoperazone	B
sodium	I
and	O
sulbactam	B
sodium	I
of	O
the	O
invention	O
has	O
the	O
comparative	O
curative	O
effect	O
at	O
the	O
aspect	O
of	O
antibacterial	O
effect	O
with	O
a	O
compound	O
preparation	O
of	O
1	O
to	O
1	O
or	O
2	O
to	O
1	O
of	O
the	O
cefoperazone	B
sodium	I
/	O
the	O
sulbactam	B
sodium	I
in	O
markets	O
.	O

The	O
invention	O
reduces	O
the	O
corresponding	O
content	O
of	O
the	O
sulbactam	B
sodium	I
in	O
the	O
combination	O
,	O
so	O
the	O
invention	O
has	O
wider	O
clinical	O
application	O
range	O
and	O
can	O
reduce	O
the	O
production	O
cost	O
of	O
the	O
drug	O
.	O

Compared	O
with	O
the	O
prior	O
compound	O
preparation	O
of	O
the	O
cefoperazone	B
sodium	I
/	O
the	O
sulbactam	B
sodium	I
,	O
the	O
invention	O
is	O
characterized	O
by	O
being	O
fit	O
for	O
the	O
anti	O
-	O
infection	O
remedy	O
of	O
the	O
patient	O
with	O
the	O
renal	O
dysfunction	O
and	O
the	O
remedy	O
of	O
the	O
seriously	O
infected	O
patient	O
.	O

Cefoperazone	B
sodium	I
and	O
sulbactam	B
sodium	I
composition	O

The	O
invention	O
discloses	O
a	O
water	O
soluble	O
phenolic	B
acid	I
extract	O
which	O
is	O
obtained	O
by	O
extracting	O
from	O
a	O
medical	O
plant	O
of	O
a	O
clerodendranthus	O
spicatus	O
by	O
the	O
chemical	O
method	O
.	O

The	O
pharmacological	O
experiment	O
testifies	O
that	O
the	O
extract	O
has	O
strong	O
physiological	O
activity	O
and	O
especially	O
has	O
strong	O
physiological	O
activity	O
of	O
resisting	O
the	O
generation	O
of	O
uric	B
acid	I
,	O
and	O
the	O
extract	O
is	O
used	O
for	O
remedying	O
the	O
pain	O
-	O
louse	O
and	O
has	O
good	O
effect	O
of	O
the	O
treatment	O
towards	O
the	O
urinary	O
tract	O
infection	O
or	O
the	O
urinary	O
tract	O
concretion	O
and	O
has	O
little	O
toxic	O
and	O
side	O
effect	O
.	O

Kidney	O
tea	O
extract	O
and	O
its	O
preparing	O
process	O
and	O
application	O

A	O
drug	O
combination	O
for	O
preventing	O
and	O
remedying	O
the	O
osteoporosis	O
contains	O
one	O
of	O
or	O
a	O
mixture	O
of	O
an	O
extract	O
of	O
coarse	O
cistanche	O
tubulosa	O
water	O
and/or	O
alcohol	O
,	O
the	O
extract	O
of	O
fine	O
cistanche	O
tubulosa	O
water	O
and/or	O
alcohol	O
,	O
the	O
mixture	O
of	O
the	O
cistanche	O
tubulosa	O
with	O
an	O
aurantiamarin	O
part	O
,	O
the	O
cistanche	O
tubulosa	O
powder	O
or	O
coneflower	O
glycoside	O
,	O
and	O
the	O
experiment	O
indicates	O
that	O
all	O
of	O
the	O
components	O
has	O
the	O
effects	O
of	O
prompting	O
the	O
osteoblast	O
proliferation	O
and	O
obviously	O
increasing	O
the	O
bone	O
weight	O
coefficient	O
,	O
the	O
bone	O
ash	O
content	O
,	O
the	O
width	O
of	O
bone	O
trabecula	O
and	O
the	O
content	O
of	O
bone	O
phosphorus	O
,	O
wherein	O
the	O
effect	O
of	O
the	O
mixture	O
of	O
the	O
cistanche	O
tubulosa	O
with	O
the	O
aurantiamarin	O
part	O
is	O
strongest	O
.	O

Composition	O
containing	O
cistanche	O
tubulosa	O
and	O
its	O
extract	O
for	O
treating	O
osteoporosis	O

The	O
present	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

Glucocorticoids	B
as	O
medicines	O
of	O
immunosuppression	O
,	O
anti	O
-	O
inflammation	O
,	O
anti	O
-	O
allergy	O
and	O
anti	O
-	O
shock	O
are	O
widely	O
applied	O
to	O
clinic	O
,	O
but	O
the	O
long	O
-	O
term	O
or	O
over	O
-	O
dose	O
usage	O
easily	O
causes	O
manifold	O
toxic	O
side	O
effects	O
or	O
severe	O
complications	O
.	O

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
new	O
class	O
of	O
glucocorticoid	B
derivative	O
,	O
which	O
not	O
only	O
maintains	O
the	O
curative	O
effect	O
of	O
the	O
original	O
glucocorticoid	B
but	O
also	O
greatly	O
decreases	O
the	O
toxic	O
side	O
effects	O
caused	O
by	O
the	O
long	O
-	O
term	O
or	O
over	O
-	O
dose	O
usage	O
of	O
the	O
glucocorticoid	B
.	O

Hydrophilic	B
amino	I
acid	I
,	O
glycosyl	B
or	O
short	O
peptide	O
as	O
carrier	O
group	O
is	O
coupled	O
with	O
the	O
oxygen	B
or	O
hydroxyl	B
of	O
glucocorticoid	B
molecules	O
to	O
form	O
the	O
new	O
glucocorticoid	B
derivative	O
by	O
the	O
method	O
of	O
ester	O
bond	O
,	O
ether	O
bond	O
or	O
nucleophilic	O
addition	O
reaction	O
,	O
and	O
the	O
present	O
invention	O
also	O
provides	O
the	O
preparation	O
method	O
and	O
applications	O
of	O
the	O
glucocorticoid	B
derivative	O
.	O

Because	O
the	O
water	O
solubility	O
of	O
the	O
glucocorticoid	B
derivative	O
of	O
the	O
present	O
invention	O
is	O
increased	O
,	O
the	O
glucocorticoid	B
derivative	O
can	O
hardly	O
enter	O
into	O
the	O
cellular	O
lipid	O
membrane	O
to	O
be	O
combined	O
with	O
the	O
classical	O
intracellular	O
receptors	O
,	O
but	O
exerts	O
a	O
fast	O
effect	O
mainly	O
via	O
non	O
-	O
genome	O
,	O
and	O
as	O
a	O
result	O
,	O
not	O
only	O
the	O
efficacy	O
is	O
sufficiently	O
excerted	O
but	O
also	O
the	O
toxic	O
side	O
effects	O
are	O
little	O
.	O

Glucocorticoids	B
derivative	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
present	O
invention	O
discloses	O
a	O
calcium	B
-	I
phosphorus	I
mixture	O
and	O
its	O
application	O
.	O

Its	O
composition	O
is	O
formed	O
from	O
(	O
by	O
wt%	O
)	O
1.2%-2.2	O
%	O
of	O
calcium	B
and	O
0.4%-0.67	O
%	O
of	O
phosphorus	B
.	O

Said	O
calcium	B
-	I
phosphorus	I
mixture	O
can	O
be	O
used	O
for	O
preparing	O
food	O
,	O
health	O
-	O
care	O
product	O
or	O
medicine	O
for	O
inhibiting	O
bone	O
absorption	O
,	O
promoting	O
bone	O
formation	O
and	O
curing	O
bone	O
metabolic	O
abnormality	O
due	O
to	O
PTH	O
deficiency	O
.	O

Calcium	B
-	I
phosphorus	I
mixture	O
and	O
its	O
use	O

The	O
present	O
invention	O
relates	O
to	O
an	O
application	O
of	O
chlorogenic	B
acid	I
in	O
preparation	O
of	O
medicine	O
for	O
preventing	O
and	O
curing	O
nasopharyngeal	O
carcinoma	O
.	O

It	O
is	O
made	O
up	O
by	O
using	O
chlorogenic	O
acid	O
as	O
effective	O
medicine	O
component	O
and	O
pharmaceutically	O
-	O
acceptable	O
auxiliary	O
component	O
through	O
a	O
certain	O
preparation	O
process	O
.	O

Application	O
of	O
chlorogenic	B
acid	I
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
nasopharyngeal	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
a	O
medicine	O
composition	O
capable	O
of	O
effectively	O
reducing	O
lipid	O
content	O
and	O
cholesterol	B
content	O
.	O

Said	O
medicine	O
composition	O
contains	O
(	O
by	O
weight	O
portion	O
)	O
200	O
-	O
1000	O
portions	O
of	O
Omega-3	O
ocean	O
oil	O
and	O
2	O
-	O
10	O
portions	O
of	O
priol	O
.	O

Besides	O
,	O
said	O
medicine	O
composition	O
also	O
has	O
the	O
action	O
for	O
resisting	O
blood	O
-	O
platelet	O
agglutination	O
.	O

Composition	O
capable	O
of	O
reducing	O
blood	O
lipoid	O
and	O
lowering	O
cholesterol	B

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
application	O
of	O
asiaticoside	B
in	O
preparation	O
of	O
medicine	O
for	O
resisting	O
radiation	O
pulmonary	O
fibrosis	O
.	O

Application	O
of	O
asiaticoside	B
in	O
preventing	O
pulmonary	O
fibrosis	O

The	O
invention	O
discloses	O
a	O
composite	O
medicament	O
for	O
curing	O
traumatic	O
sprain	O
injury	O
.	O

The	O
components	O
(	O
proportioned	O
by	O
weight	O
)	O
comprise	O
large	O
moxa	O
,	O
artemisia	O
argyi	O
lerl.et	O
vant	O
,	O
whole	O
worm	O
,	O
musk	O
,	O
safflower	O
,	O
camphorand	B
,	O
and	O
camphoric	B
acid	I
and	O
the	O
like	O
,	O
which	O
are	O
combined	O
with	O
75	O
%	O
ethanol	B
according	O
to	O
a	O
certain	O
proportion	O
,	O
sealed	O
and	O
immersed	O
,	O
and	O
stored	O
in	O
cool	O
place	O
for	O
half	O
a	O
month	O
,	O
and	O
the	O
compositemedicament	O
can	O
be	O
obtained	O
after	O
residue	O
is	O
filtered	O
.	O

The	O
invention	O
has	O
the	O
effects	O
of	O
diminishing	O
inflammation	O
and	O
reducing	O
pain	O
,	O
activating	O
blood	O
circulation	O
and	O
removing	O
stasis	O
,	O
and	O
relaxing	O
muscles	O
and	O
tendons	O
and	O
promoting	O
blood	O
circulation	O
.	O

Furthermore	O
,	O
the	O
invention	O
is	O
convenient	O
to	O
prepare	O
and	O
use	O
and	O
has	O
fast	O
activating	O
effect	O
and	O
good	O
curative	O
effect	O
,	O
which	O
is	O
a	O
specific	O
medicament	O
forcuring	O
traumatic	O
sprain	O
injury	O
.	O

Composite	O
medicine	O
for	O
treating	O
traumatic	O
injury	O
and	O
its	O
preparing	O
process	O

The	O
invention	O
discloses	O
a	O
compound	O
pearl	O
buccal	O
tablet	O
and	O
process	O
for	O
preparation	O
and	O
the	O
application	O
of	O
the	O
invention	O
.	O

The	O
invention	O
comprises	O
active	O
components	O
and	O
/	O
or	O
additiver	O
which	O
is	O
acceptable	O
in	O
pharmacy	O
,	O
and	O
the	O
active	O
components	O
comprise	O
pearl	O
powder	O
150	O
to	O
400	O
grams	O
,	O
natrii	O
sulfas	O
exsiccatus	O
50	O
to	O
100	O
grams	O
,	O
borneol	B
10	O
to	O
30	O
grams	O
,	O
borax	B
50	O
to	O
200	O
grams	O
,	O
radix	O
rehmanniae	O
50	O
to	O
200	O
grams	O
,	O
glycyrrhiza	O
50	O
to	O
100	O
grams	O
,	O
menthol	B
1	O
to	O
4	O
grams	O
,	O
lactose	B
100	O
to	O
200	O
grams	O
,	O
citric	B
acid	I
15	O
to	O
35	O
grams	O
,	O
aspartame	B
20	O
to	O
40	O
grams	O
,	O
and	O
fragrant	O
citrus	O
essence	O
80	O
to	O
200	O
grams	O
,	O
which	O
are	O
made	O
into1000	O
tablets	O
.	O

The	O
invention	O
has	O
distinct	O
functions	O
of	O
bacteriostasis	O
and	O
anti	O
-	O
inflammatory	O
,	O
expelling	O
phlegm	O
,	O
analgesia	O
,	O
and	O
accelerating	O
the	O
removal	O
of	O
the	O
rot	O
-	O
ten	O
tissueaction	O
,	O
which	O
has	O
distinct	O
inhibitory	O
effects	O
to	O
oral	O
inflammation	O
and	O
concomitant	O
symptoms	O
of	O
the	O
oral	O
inflammation	O
.	O

The	O
invention	O
is	O
suitable	O
for	O
preventing	O
and	O
curing	O
acute	O
and	O
chronic	O
pharyngolaryngitis	O
,	O
acute	O
and	O
chronic	O
tonsillitis	O
,	O
vocal	O
fold	O
submucous	O
bleeding	O
,	O
vocal	O
nodules	O
,	O
periodontal	O
diseases	O
,	O
and	O
ulcerative	O
stomatitis	O
and	O
the	O
like	O
.	O

Compound	O
pearl	O
lozenge	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
has	O
rapid	O
efficacy	O
and	O
can	O
cure	O
rheumatism	O
thoroughly	O
by	O
clinical	O
application	O
.	O

The	O
invention	O
makes	O
full	O
use	O
of	O
the	O
effects	O
of	O
dredging	O
collaterals	O
,	O
activating	O
blood	O
circulation	O
,	O
relieving	O
pain	O
,	O
eliminating	O
carbuncles	O
,	O
dispelling	O
pathogenic	O
wind	O
and	O
removing	O
dampness	O
of	O
pangolin	O
scales	O
and	O
sea	O
swallows	O
;	O
the	O
effects	O
of	O
relieving	O
rigidity	O
of	O
muscles	O
,	O
dredging	O
collaterals	O
,	O
activating	O
blood	O
circulation	O
,	O
relieving	O
depression	O
,	O
relieving	O
pain	O
and	O
eliminating	O
swelling	O
of	O
musk	O
,	O
radix	O
notoginseng	O
,	O
garden	O
balsam	O
stem	O
and	O
tall	O
gastrodia	O
tuber	O
;	O
the	O
effects	O
of	O
promoting	O
blood	O
circulation	O
,	O
removing	O
blood	O
stasis	O
,	O
dispersing	O
stasis	O
and	O
resolving	O
hard	O
mass	O
of	O
Tibet	O
safflower	O
;	O
the	O
effects	O
of	O
clearing	O
heat	O
,	O
removing	O
toxicity	O
,	O
anti	O
-	O
erosion	O
and	O
generating	O
muscle	O
of	O
the	O
borneol	B
;	O
and	O
the	O
effects	O
of	O
relieving	O
superficial	O
syndrome	O
,	O
dispelling	O
pathogenic	O
wind	O
,	O
overcoming	O
dampness	O
and	O
stopping	O
pain	O
of	O
the	O
divaricate	O
saposhnikovia	O
root	O
.	O

The	O
rheumatism	O
agent	O
is	O
sprayed	O
on	O
medical	O
cotton	O
and	O
is	O
affixed	O
on	O
the	O
affected	O
site	O
,	O
and	O
is	O
removed	O
after	O
1	O
hour	O
,	O
the	O
dosage	O
is	O
once	O
per	O
day	O
and	O
three	O
days	O
per	O
treatment	O
course	O
and	O
the	O
common	O
rheumatism	O
can	O
be	O
cured	O
in	O
two	O
treatment	O
courses	O
.	O

Rheumatism	O
preparation	O
preparing	O
method	O

The	O
invention	O
particularly	O
relates	O
to	O
a	O
drug	O
for	O
rapid	O
-	O
acting	O
treatment	O
of	O
toothache	O
.	O

The	O
drug	O
integrates	O
various	O
causes	O
of	O
toothache	O
disease	O
and	O
carries	O
out	O
the	O
compounding	O
of	O
antibiotic	O
anti	O
-	O
inflammatory	O
drug	O
,	O
anti	O
-	O
spirit	O
sensitivity	O
drug	O
,	O
anti	O
-	O
anaerobic	O
infection	O
drug	O
,	O
anti	O
-	O
inflammatory	O
analgesic	O
drug	O
and	O
other	O
various	O
western	O
patent	O
drugs	O
,	O
and	O
the	O
compound	O
drug	O
mainly	O
consists	O
of	O
drug	O
cefalexin	B
or	O
other	O
antibiotic	O
anti	O
-	O
inflammatory	O
drug	O
,	O
tiapride	B
hydrochloride	I
,	O
metronidazole	B
or	O
other	O
anti	O
-	O
anaerobic	O
infection	O
drug	O
,	O
indometacin	B
enteric	O
-	O
coated	O
tablet	O
,	O
phenylbutazone	B
and	O
prednisone	B
hydrochloride	I
sequentially	O
according	O
to	O
the	O
mixing	O
ratio	O
by	O
weight	O
parts	O
.	O

The	O
drug	O
of	O
the	O
invention	O
is	O
rapid	O
in	O
acting	O
for	O
the	O
toothache	O
disease	O
which	O
is	O
formed	O
by	O
various	O
causes	O
,	O
and	O
generally	O
the	O
drug	O
can	O
act	O
in	O
1	O
to	O
1.5	O
hours	O
after	O
the	O
drug	O
administration	O
,	O
the	O
pain	O
can	O
be	O
stopped	O
after	O
one	O
week	O
of	O
the	O
drug	O
administration	O
,	O
and	O
the	O
effect	O
is	O
significant	O
;	O
the	O
effective	O
rate	O
of	O
the	O
rapid	O
pain	O
stopping	O
is	O
98	O
percent	O
and	O
the	O
cure	O
rate	O
is	O
96.5	O
percent	O
according	O
to	O
the	O
statistics	O
;	O
the	O
used	O
drugs	O
of	O
the	O
invention	O
are	O
the	O
patent	O
drugs	O
which	O
are	O
proved	O
by	O
the	O
state	O
and	O
the	O
efficacies	O
of	O
the	O
drugs	O
are	O
safe	O
and	O
reliable	O
;	O
the	O
administration	O
is	O
convenient	O
,	O
which	O
is	O
easy	O
to	O
be	O
accepted	O
by	O
patients	O
.	O

Composite	O
medicine	O
for	O
treating	O
toothache	O
quickly	O
and	O
effectively	O

The	O
invention	O
discloses	O
the	O
total	O
length	O
cloning	O
of	O
the	O
cDNA	O
of	O
the	O
new	O
gene	O
Xsynuclein	O
of	O
the	O
GRK	O
family	O
of	O
African	O
laevis	O
.	O

The	O
total	O
length	O
of	O
the	O
cDNA	O
is	O
1040bp	O
,	O
which	O
includes	O
a	O
complete	O
and	O
opening	O
reading	O
frame	O
and	O
can	O
code	O
the	O
protein	O
containing	O
129	O
amino	O
acids	O
.	O

The	O
invention	O
also	O
discloses	O
two	O
TR	O
-	O
PCR	O
primers	O
of	O
the	O
gene	O
,	O
TR	O
-	O
PCR	O
method	O
and	O
technique	O
of	O
whole	O
-	O
mount	O
in	O
situ	O
hybridization	O
.	O

The	O
new	O
gene	O
Xsynuclein	O
of	O
the	O
GRK	O
family	O
of	O
African	O
laevis	O
has	O
high	O
level	O
expression	O
in	O
the	O
central	O
nervous	O
system	O
in	O
the	O
period	O
of	O
embryo	O
and	O
adult	O
.	O

The	O
new	O
gene	O
Xsynuclein	O
can	O
take	O
part	O
in	O
the	O
process	O
of	O
forming	O
the	O
forebrain	O
of	O
the	O
embryo	O
and	O
has	O
close	O
relations	O
to	O
neurodegenerative	O
diseases	O
,	O
breast	O
cancer	O
,	O
ovarian	O
cancer	O
and	O
the	O
like	O
.	O

The	O
new	O
gene	O
Xsynuclein	O
of	O
the	O
GRK	O
family	O
of	O
African	O
laevis	O
and	O
the	O
coding	O
protein	O
thereof	O
will	O
hopefully	O
make	O
breakthrough	O
in	O
curing	O
neurodegenerative	O
diseases	O
,	O
breast	O
cancer	O
,	O
ovarian	O
cancer	O
and	O
the	O
like	O
.	O

Novel	O
gene	O
Xsynuclein	O
for	O
xenopus	O
laevis	O
GRK	O
family	O

The	O
invention	O
discloses	O
a	O
diazepam	B
chewable	O
tablet	O
used	O
for	O
dogs	O
and	O
cats	O
.	O

The	O
invention	O
overcomes	O
the	O
poor	O
palatability	O
defect	O
of	O
the	O
existing	O
tablet	O
to	O
promote	O
a	O
thorough	O
chewing	O
absorption	O
by	O
dogs	O
and	O
cats	O
,	O
so	O
as	O
to	O
effectively	O
guarantee	O
the	O
medicine	O
-	O
supply	O
dose	O
,	O
to	O
enhance	O
the	O
cure	O
rate	O
of	O
diseases	O
of	O
dogs	O
and	O
cats	O
and	O
to	O
reduce	O
the	O
medicine	O
waste	O
.	O

The	O
tablet	O
of	O
the	O
invention	O
comprises	O
the	O
following	O
components	O
represented	O
by	O
weight	O
-	O
percentage	O
:	O
1	O
to	O
5	O
percent	O
of	O
aspartame	B
;	O
20	O
to	O
30	O
percent	O
of	O
a	O
mixture	O
of	O
oral	O
dextrose	B
and	O
degreased	O
milk	O
powder	O
;	O
the	O
ratio	O
of	O
1:1	O
to	O
1:4	O
between	O
the	O
oral	O
dextrose	B
and	O
degreased	O
milk	O
powder	O
in	O
the	O
mixture	O
;	O
40	O
to	O
60	O
percent	O
of	O
excipient	O
;	O
0.5	O
to	O
1	O
percent	O
of	O
glidant	O
and	O
5	O
to	O
20	O
percent	O
of	O
diazepam	B
.	O

Diazepam	B
chewable	O
tablets	O
for	O
dog	O
or	O
cat	O

The	O
invention	O
relates	O
to	O
a	O
huperzine	B
B	I
derivative	O
with	O
16	O
substituted	O
dual	O
function	O
groups	O
and	O
the	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
derivative	O
adopts	O
the	O
huperzine	B
B	I
as	O
a	O
lead	O
compound	O
and	O
is	O
obtained	O
by	O
the	O
steps	O
that	O
16-methyl	O
is	O
first	O
oxidated	O
to	O
aldehyde	B
group	O
and	O
then	O
treated	O
with	O
reductive	O
amination	O
with	O
substitution	O
amine	B
compounds	O
.	O

The	O
derivative	O
provided	O
in	O
the	O
invention	O
also	O
expresses	O
higher	O
inhibitory	O
activity	O
of	O
acetylcholinesterase	O
than	O
that	O
of	O
the	O
lead	O
compound	O
of	O
the	O
huperzine	B
B	I
in	O
a	O
test	O
of	O
vitro	O
bioactivity	O
.	O

The	O
huperzine	B
B	I
derivative	O
with	O
16	O
substituted	O
dual	O
function	O
groups	O
has	O
relatively	O
strong	O
inhibiting	O
effect	O
on	O
butyrylcholine	B
esterase	O
and	O
is	O
expected	O
to	O
become	O
a	O
candidate	O
drug	O
with	O
high	O
therapeutic	O
index	O
and	O
little	O
side	O
effect	O
to	O
treat	O
degenerative	O
brain	O
disorder	O
after	O
further	O
optimization	O
and	O
screening	O
.	O

16-site	O
substituted	O
double	O
functional	O
group	O
huperzine	B
B	I
derivative	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

Processes	O
are	O
provided	O
for	O
selectively	O
preparing	O
novel	O
stable	O
crystalline	O
salt	O
forms	O
,	O
selectively	O
and	O
consistently	O
,	O
namely	O
,	O
preparing	O
Form	O
N-1	B
of	O
the	O
methanesulfonic	B
acid	I
salt	O
,	O
and	O
Form	O
N-1	B
and	O
Form	O
N-4	B
of	O
the	O
hydrochloric	B
acid	I
salt	O
of	O
the	O
p38	O
kinase	O
inhibitor	O
4-	B
[	I
[	I
5-	I
[	I
(	I
cyclopropylamino	I
)	I
carbonyl	I
]	I
-2-methylphenyl	I
]	I
amino	I
]	I
-5-methyl	I
-	I
N	I
-	I
propylpyrrolo	I
[	I
2,1-f	I
]	I
[	I
1,2,4	I
]	I
triazine-6-carboxamide	I
.	O

The	O
processes	O
preferably	O
employ	O
solvent	O
systems	O
including	O
formic	B
acid	I
/	O
acetone	B
and	O
formic	B
acid	I
/	O
methylethyl	B
ketone	I
which	O
produce	O
crystals	O
having	O
suitable	O
flow	O
properties	O
and	O
desired	O
particle	O
size	O
,	O
and	O
solvents	O
such	O
as	O
N	B
,	I
N	I
-	I
dimethylformamide	I
and	O
N	B
,	I
N	I
-	I
dimethylacetamide	I
may	O
be	O
employed	O
as	O
well	O
.	O

Novel	O
Form	O
N-1	B
crystals	O
of	O
the	O
Form	O
N-1	B
and	O
Form	O
N-4	B
crystals	O
of	O
the	O
hydrochloride	B
salt	O
and	O
Form	O
N-1	B
crystals	O
of	O
the	O
methanesulfonic	B
acid	I
salt	O
of	O
the	O
above	O
free	O
base	O
,	O
pharmaceutical	O
compositions	O
containing	O
such	O
novel	O
forms	O
and	O
a	O
method	O
of	O
treating	O
p38	O
kinase	O
associated	O
conditions	O
,	O
including	O
rheumatoid	O
arthritis	O
are	O
also	O
provided	O
.	O

Process	O
for	O
preparing	O
salts	O
of	O
4-	B
[	I
[	I
5-	I
[	I
(	I
cyclopropylamino	I
)	I
carbonyl	I
]	I
-2-methylphenyl	I
]	I
amino	I
]	I
-5-methyl	I
-	I
n	I
-	I
propylpyrrolo	I
[	I
2,1-f	I
]	I
[	I
1,2,4	I
]	I
triazine-6-carboxamide	I
and	O
novel	O
stable	O
forms	O
produced	O
therein	O

Disclosed	O
is	O
a	O
preparation	O
drug	O
of	O
precursor	O
multiphase	O
liposome	O
of	O
water	O
grind	O
processing	O
thistle	O
bingham	O
,	O
which	O
contains	O
the	O
precursor	O
multiphase	O
liposome	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
.	O

The	O
preparation	O
drug	O
is	O
mainly	O
composed	O
of	O
the	O
following	O
mass	O
abundance	O
components	O
:	O
1	O
portion	O
of	O
water	O
grind	O
processing	O
thistle	O
bingham	O
,	O
2	O
to	O
10	O
portions	O
of	O
phospholipid	B
,	O
0.1	O
to	O
0.6	O
portion	O
of	O
cholesterol	B
,	O
1	O
to	O
5	O
portions	O
of	O
isopropyl	B
myristate	I
,	O
1	O
to	O
5	O
portions	O
of	O
sodium	B
cholate	I
,	O
and	O
2	O
to	O
10	O
portions	O
of	O
cane	B
sugar	I
powder	O
.	O

Observed	O
by	O
the	O
sem	O
,	O
the	O
appearance	O
of	O
the	O
prepared	O
precursor	O
multiphase	O
liposome	O
powder	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
is	O
ball	O
-	O
shaped	O
or	O
similar	O
to	O
the	O
shape	O
of	O
the	O
ball	O
;	O
the	O
surface	O
of	O
the	O
prepared	O
precursor	O
multiphase	O
liposome	O
powder	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
is	O
smooth	O
;	O
the	O
particle	O
size	O
and	O
the	O
distribution	O
of	O
the	O
prepared	O
precursor	O
multiphase	O
liposome	O
powder	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
are	O
measured	O
byphoton	O
correlation	O
spectroscopy	O
,	O
and	O
the	O
average	O
particle	O
size	O
is	O
106	O
nm	O
;	O
the	O
redispersion	O
in	O
the	O
water	O
is	O
good	O
;	O
no	O
burst	O
effect	O
occurs	O
;	O
and	O
the	O
storage	O
stability	O
is	O
good	O
.	O

The	O
total	O
entrapment	O
efficiency	O
of	O
the	O
precursor	O
multiphase	O
liposome	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
is	O
96	O
percent	O
,	O
wherein	O
,	O
85	O
percent	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
is	O
entrapped	O
inside	O
the	O
liposome	O
,	O
and	O
a	O
small	O
part	O
is	O
entrapped	O
inside	O
emulsion	O
and	O
micelle	O
.	O

With	O
high	O
entrapment	O
efficiency	O
,	O
good	O
stability	O
,	O
simple	O
operation	O
and	O
low	O
cost	O
,	O
the	O
precursor	O
multiphase	O
liposome	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
is	O
easy	O
to	O
be	O
filled	O
,	O
does	O
not	O
need	O
special	O
equipment	O
and	O
is	O
convenient	O
for	O
industrial	O
production	O
.	O

The	O
invention	O
discloses	O
the	O
preparation	O
method	O
of	O
the	O
precursor	O
multiphase	O
liposome	O
of	O
the	O
water	O
grind	O
processing	O
thistle	O
bingham	O
.	O

Silybin	B
precursor	O
multiphase	O
lipidosome	O
formulation	O
and	O
preparing	O
method	O
thereof	O

Disclosed	O
is	O
ketorolac	B
tromethamine	I
,	O
which	O
is	O
a	O
pyrrole	B
acid	I
derivative	O
developed	O
by	O
the	O
Syntex	O
company	O
in	O
the	O
U.S.	O
The	O
invention	O
can	O
effectively	O
inhibit	O
prostaglandin	B
(	O
PG	O
)	O
from	O
synthesizing	O
with	O
functions	O
of	O
analgesia	O
,	O
anti	O
-	O
inflammation	O
,	O
antipyresis	O
and	O
inhibiting	O
the	O
platelets	O
from	O
aggregating	O
.	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
ketorolac	B
tromethamine	I
injection	O
,	O
which	O
well	O
improves	O
the	O
stability	O
and	O
the	O
clarity	O
of	O
the	O
preparation	O
with	O
stable	O
process	O
.	O

Ketoralac	B
ammonia	I
butanetriol	I
injection	O
and	O
preparing	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
hydrochloride	B
benzydamine	I
lotion	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
lotion	O
is	O
mainly	O
composed	O
of	O
effective	O
dose	O
of	O
hydrochloride	B
benzydamine	I
,	O
excipient	O
and	O
distilled	O
water	O
.	O

Wherein	O
,	O
the	O
excipient	O
contains	O
proper	O
buffer	O
pair	O
substance	O
.	O

As	O
the	O
proper	O
buffer	O
pair	O
substance	O
is	O
chosen	O
in	O
the	O
excipient	O
,	O
the	O
disadvantage	O
is	O
overcome	O
that	O
the	O
quality	O
of	O
the	O
product	O
is	O
unstable	O
and	O
the	O
medication	O
is	O
unsafe	O
due	O
to	O
the	O
fact	O
that	O
the	O
pH	O
value	O
is	O
unstable	O
to	O
fluctuate	O
easily	O
when	O
the	O
hydrochloride	B
benzydamine	I
lotion	O
is	O
placed	O
.	O

Thus	O
,	O
the	O
quality	O
of	O
the	O
invention	O
is	O
stable	O
and	O
safe	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
simple	O
,	O
the	O
operation	O
is	O
easy	O
,	O
and	O
the	O
quality	O
is	O
easy	O
to	O
be	O
controlled	O
.	O

Hydrochloric	B
acid	I
benzydamine	I
and	O
preparing	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
oral	O
solid	O
rapidly	O
disintegrating	O
dosage	O
form	O
,	O
comprising	O
4	O
to	O
32	O
weight	O
parts	O
of	O
atorvastatin	B
and	O
acceptable	O
salt	O
in	O
pharmacy	O
,	O
0.1	O
to	O
10	O
weight	O
parts	O
of	O
l	B
-	I
amlodipine	I
and	O
acceptable	O
salt	O
in	O
pharmacy	O
,	O
20	O
to	O
93	O
weight	O
parts	O
of	O
filler	O
and	O
/	O
or	O
adsorbent	O
,	O
0.1	O
to	O
10	O
weight	O
parts	O
of	O
disintegrant	O
,	O
0.5	O
to	O
3	O
weight	O
parts	O
of	O
wetting	O
agent	O
and	O
/	O
or	O
adhesive	O
,	O
0.5	O
to	O
2	O
weight	O
parts	O
of	O
lubricant	O
and	O
/	O
or	O
flow	O
agent	O
and	O
0.1	O
to	O
1	O
weight	O
parts	O
of	O
corrective	O
.	O

The	O
oral	O
solid	O
rapidly	O
disintegrating	O
dosage	O
form	O
has	O
the	O
advantages	O
of	O
rapid	O
disintegration	O
,	O
instant	O
dissolution	O
,	O
taking	O
effect	O
fast	O
,	O
full	O
absorption	O
and	O
high	O
bioavailability	O
.	O

Medicament	O
composition	O
containing	O
levorotatory	O
ammonia	B
chlorine	I
horizon	O
and	O
atorvastatin	B
and	O
preparing	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
health	O
care	O
preparation	O
for	O
improving	O
eyesight	O
and	O
protecting	O
eyesight	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
raw	O
materials	O
of	O
the	O
preparation	O
comprise	O
12	O
to	O
22	O
portions	O
of	O
extract	O
of	O
blueberry	O
,	O
4	O
to	O
14	O
portions	O
of	O
lutein	B
,	O
1	O
to	O
10	O
portions	O
of	O
zinc	B
gluconate	I
,	O
0.1	O
to	O
0.5	O
portion	O
of	O
vitamin	B
A	I
,	O
0.01	O
to	O
0.1	O
portion	O
of	O
vitamin	B
B1	I
,	O
0.01	O
to	O
0.1	O
portion	O
of	O
vitamin	B
B2	I
;	O
the	O
content	O
of	O
anthocyanin	B
in	O
the	O
extract	O
of	O
blueberry	O
is	O
more	O
than	O
or	O
equal	O
to	O
25	O
percent	O
;	O
and	O
the	O
content	O
of	O
the	O
lutein	B
is	O
more	O
than	O
or	O
equal	O
to	O
5	O
percent	O
.	O

The	O
preparation	O
comprises	O
sweetener	O
sucrose	B
powder	O
,	O
crystalline	O
fructose	B
,	O
isomalt	B
,	O
mannitol	B
or	O
aspartame	B
whose	O
dosage	O
is	O
10	O
to	O
15	O
portions	O
.	O

The	O
preparation	O
comprises	O
diluent	O
sodium	B
carboxymethyl	I
starch	O
and	O
microcrystalline	O
cellulose	O
,	O
each	O
of	O
which	O
accounts	O
for	O
5	O
to	O
15	O
portions	O
,	O
and	O
filler	O
starch	O
which	O
accounts	O
for	O
10	O
to	O
23	O
portions	O
.	O

The	O
preparation	O
comprises	O
flow	O
agent	O
magnesium	B
stearate	O
and	O
silica	B
gel	I
,	O
each	O
of	O
which	O
accounts	O
for	O
1	O
to	O
5	O
portions	O
.	O

The	O
preparation	O
procedures	O
are	O
as	O
following	O
:	O
according	O
to	O
the	O
weight	O
portions	O
,	O
qualified	O
raw	O
materials	O
are	O
respectively	O
weighed	O
,	O
and	O
then	O
the	O
raw	O
materials	O
are	O
screened	O
,	O
mixed	O
,	O
granulated	O
,	O
dried	O
,	O
finished	O
and	O
mixed	O
totally	O
,	O
thereby	O
making	O
qualified	O
semi	O
-	O
finished	O
product	O
;	O
and	O
then	O
the	O
semi	O
-	O
finished	O
product	O
is	O
tableted	O
and	O
coated	O
,	O
or	O
is	O
filled	O
by	O
the	O
capsule	O
filling	O
engine	O
and	O
filled	O
by	O
the	O
granule	O
filling	O
machine	O
;	O
and	O
then	O
the	O
preparation	O
can	O
be	O
obtained	O
after	O
the	O
test	O
qualification	O
.	O

With	O
reasonable	O
ratio	O
of	O
composing	O
prescriptions	O
and	O
simple	O
preparation	O
process	O
,	O
the	O
invention	O
effectively	O
relieves	O
asthenopia	O
,	O
protects	O
eyes	O
and	O
improves	O
eyesight	O
.	O

Improving	O
eyesight	O
guard	O
inspect	O
health	O
care	O
preparation	O
and	O
preparing	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
aminophylline	B
soluble	O
tablet	O
with	O
special	O
specification	O
for	O
children	O
,	O
comprising	O
effective	O
amount	O
of	O
aminophylline	B
and	O
water	O
-	O
soluble	O
medicinal	O
excipient	O
which	O
disintegrates	O
fast	O
in	O
the	O
water	O
to	O
release	O
the	O
efficacy	O
.	O

When	O
the	O
patient	O
takes	O
the	O
tablets	O
,	O
the	O
patient	O
can	O
determine	O
the	O
number	O
of	O
the	O
tablets	O
according	O
to	O
the	O
weight	O
of	O
the	O
patient	O
,	O
so	O
the	O
personalized	O
administration	O
can	O
be	O
realized	O
,	O
the	O
drug	O
intake	O
is	O
more	O
accurate	O
,	O
and	O
the	O
safety	O
is	O
higher	O
.	O

After	O
the	O
drug	O
is	O
dissolved	O
in	O
the	O
water	O
,	O
the	O
water	O
becomes	O
a	O
sweet	O
and	O
sour	O
beverage	O
,	O
so	O
the	O
taken	O
method	O
is	O
more	O
acceptable	O
by	O
the	O
children	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
drug	O
solution	O
is	O
easy	O
to	O
be	O
fully	O
absorbed	O
with	O
high	O
bioavailability	O
.	O

Paediatrics	O
aminophylline	B
insant	O
sheet	O

The	O
invention	O
relates	O
to	O
compound	O
sulfamonomethoxine	B
injection	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
sulfamonomethoxine	B
injection	O
.	O

The	O
injection	O
comprises	O
main	O
drug	O
,	O
antioxidant	O
,	O
solvent	O
for	O
injection	O
and	O
water	O
for	O
injection	O
.	O

The	O
preparation	O
method	O
is	O
that	O
the	O
sulfamonomethoxine	B
and	O
trimethoprim	B
(	O
TMP	B
)	O
are	O
used	O
together	O
,	O
which	O
can	O
doubly	O
block	O
folate	O
metabolism	O
of	O
bacteria	O
;	O
under	O
the	O
bidirectional	O
cooperative	O
effect	O
between	O
cyclooxygenase	O
and	O
ethyl	O
inhibitor	O
,	O
the	O
sulfamonomethoxine	B
and	O
doxycycline	B
cooperate	O
,	O
so	O
the	O
drug	O
absorption	O
is	O
fast	O
and	O
the	O
toxicity	O
is	O
reduced	O
with	O
better	O
efficacy	O
and	O
more	O
safety	O
.	O

With	O
scientific	O
compatibility	O
,	O
lower	O
cost	O
and	O
simple	O
and	O
easy	O
preparation	O
method	O
,	O
the	O
invention	O
is	O
suitable	O
for	O
industrialized	O
mass	O
production	O
.	O

Compound	O
sulfamonomethoxine	B
daimeton	B
injection	O
and	O
preparing	O
method	O
thereof	O

Disclosed	O
are	O
a	O
policresulen	O
foam	O
agent	O
and	O
a	O
preparation	O
method	O
,	O
which	O
is	O
characterized	O
in	O
that	O
raw	O
material	O
and	O
excipient	O
such	O
as	O
policresulen	O
,	O
etc	O
.	O
are	O
filled	O
into	O
a	O
container	O
;	O
a	O
foam	O
emulsion	O
pump	O
(	O
or	O
called	O
foam	O
pump	O
or	O
manual	O
foam	O
generating	O
device	O
)	O
is	O
screwed	O
on	O
the	O
container	O
;	O
and	O
when	O
the	O
emulsion	O
pump	O
is	O
pressed	O
by	O
hand	O
,	O
the	O
foams	O
are	O
produced	O
.	O

The	O
preparation	O
method	O
is	O
as	O
following	O
:	O
the	O
policresulen	O
is	O
added	O
into	O
water	O
to	O
be	O
dissolved	O
,	O
and	O
then	O
polysorbate-80	O
,	O
sodium	O
dodecyl	O
sulfate	O
and	O
glycerol	O
,	O
etc	O
.	O
are	O
added	O
into	O
the	O
water	O
;	O
the	O
mixture	O
is	O
well	O
mixed	O
;	O
and	O
then	O
distilled	O
water	O
is	O
added	O
into	O
the	O
mixture	O
to	O
the	O
total	O
amount	O
;	O
all	O
the	O
components	O
are	O
well	O
mixed	O
;	O
the	O
pH	O
value	O
is	O
adjusted	O
;	O
the	O
mixture	O
is	O
filled	O
into	O
the	O
container	O
;	O
the	O
foam	O
emulsion	O
pump	O
(	O
or	O
called	O
foam	O
pump	O
or	O
manual	O
foam	O
generating	O
device	O
)	O
is	O
screwed	O
on	O
the	O
container	O
;	O
and	O
when	O
the	O
emulsion	O
pump	O
is	O
pressed	O
by	O
hand	O
,	O
the	O
foams	O
are	O
produced	O
.	O

The	O
invention	O
adopts	O
drugs	O
,	O
emulsifier	O
and	O
the	O
foam	O
emulsion	O
pump	O
,	O
and	O
the	O
foams	O
are	O
produced	O
when	O
the	O
emulsion	O
pump	O
is	O
pressed	O
by	O
hand	O
,	O
so	O
the	O
cost	O
can	O
be	O
saved	O
;	O
environmental	O
pollution	O
caused	O
by	O
propellent	O
can	O
be	O
eliminated	O
;	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
possibilities	O
of	O
explosiveness	O
of	O
the	O
pressure	O
container	O
are	O
reduced	O
,	O
thereby	O
making	O
the	O
pressure	O
container	O
safer	O
.	O

Therefore	O
,	O
the	O
invention	O
is	O
a	O
novel	O
foam	O
agent	O
with	O
simple	O
preparation	O
method	O
,	O
low	O
price	O
,	O
safety	O
and	O
environmental	O
protection	O
.	O

The	O
policresulen	O
foam	O
agent	O
can	O
make	O
the	O
drugs	O
be	O
distributed	O
evenly	O
inside	O
the	O
vaginal	O
canal	O
and	O
on	O
the	O
surface	O
of	O
skin	O
with	O
wide	O
coating	O
area	O
,	O
and	O
can	O
infiltrate	O
into	O
the	O
mucosa	O
wrinkled	O
wall	O
of	O
the	O
vaginal	O
fast	O
and	O
effectively	O
with	O
characteristics	O
of	O
exerting	O
therapeutic	O
effects	O
fully	O
and	O
fast	O
,	O
good	O
therapeutic	O
effects	O
,	O
safety	O
,	O
sanitation	O
and	O
convenience	O
.	O

Thus	O
,	O
the	O
policresulen	O
foam	O
agent	O
is	O
a	O
good	O
drug	O
for	O
treating	O
gynecologic	O
diseases	O
.	O

Policresulen	O
foam	O
preparation	O

The	O
invention	O
relates	O
to	O
a	O
Chinese	O
drugs	O
preparation	O
,	O
namely	O
a	O
paste	O
medicament	O
for	O
treating	O
acute	O
appendicitis	O
.	O

The	O
medicament	O
is	O
made	O
by	O
following	O
materials	O
by	O
weight	O
:	O
50	O
g	O
of	O
achyranthes	O
,	O
50	O
g	O
of	O
acontum	O
fischeri	O
,	O
50	O
g	O
of	O
dahurian	O
angelica	O
,	O
50	O
g	O
of	O
hemlock	O
parsley	O
,	O
50	O
g	O
of	O
angelica	O
,	O
50	O
g	O
of	O
frankincense	O
,	O
50	O
g	O
of	O
myrrh	O
,	O
80ml	O
of	O
75	O
percent	O
alcohol	B
and	O
80ml	O
of	O
table	O
vinegar	B
.	O

The	O
invention	O
has	O
advantages	O
of	O
novel	O
formula	O
,	O
low	O
cost	O
,	O
easy	O
preparation	O
and	O
remarkable	O
effect	O
.	O

Paste	O
medicament	O
for	O
treating	O
acute	O
appendicitis	O

The	O
invention	O
relates	O
to	O
a	O
Chinese	O
drugs	O
preparation	O
,	O
namely	O
a	O
tincture	O
medicament	O
for	O
treating	O
psoriasis	O
.	O

The	O
medicament	O
is	O
made	O
by	O
following	O
materials	O
by	O
dosage	O
:	O
100	O
g	O
of	O
arsenic	B
sulphide	I
,	O
100	O
g	O
of	O
prickly	O
ash	O
,	O
100	O
g	O
of	O
folia	O
mori	O
,	O
100	O
g	O
of	O
smoked	O
plum	O
,	O
30	O
g	O
of	O
camphor	B
and	O
800ml	O
of	O
70	O
percent	O
alcohol	B
.	O

The	O
invention	O
has	O
advantages	O
of	O
novel	O
formula	O
,	O
low	O
cost	O
,	O
easy	O
preparation	O
and	O
remarkable	O
effect	O
.	O

Tincture	O
medicament	O
for	O
treating	O
psoriasis	O

The	O
invention	O
relates	O
to	O
a	O
derivative	O
of	O
3-pyrryl	B
cyclohexylidene	I
-2-dihydro	I
oxindole	I
and	O
the	O
acceptable	O
salt	O
in	O
the	O
pharmacy	O
with	O
formula	O
(	O
I	O
)	O
and	O
the	O
use	O
thereof	O
.	O

Moreover	O
,	O
the	O
invention	O
also	O
relates	O
to	O
the	O
intermediate	O
with	O
formula	O
(	O
II	O
)	O
for	O
synthesizing	O
the	O
compound	O
.	O

The	O
pharmacological	O
experiment	O
shows	O
that	O
the	O
compound	O
and	O
the	O
acceptable	O
salt	O
in	O
the	O
pharmacy	O
can	O
play	O
the	O
role	O
of	O
inhibition	O
effect	O
for	O
the	O
proliferation	O
of	O
various	O
tumor	O
cells	O
.	O

3-pyrrole	B
ring	O
caproic	O
subunit-2-dihydroindolone	O
derivatives	O
and	O
uses	O
thereof	O

The	O
invention	O
discloses	O
a	O
total	O
bufogenin	B
extract	O
with	O
antitumor	O
function	O
and	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
extract	O
and	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
antitumor	O
medicines	O
.	O

The	O
total	O
bufogenin	B
extract	O
of	O
the	O
invention	O
is	O
prepared	O
by	O
organic	O
solvent	O
extraction	O
,	O
column	O
chromatography	O
separation	O
and	O
purification	O
of	O
dried	O
toadskin	O
;	O
the	O
content	O
of	O
total	O
bufogenin	B
is	O
over	O
80	O
percent	O
,	O
wherein	O
the	O
content	O
of	O
resibufogenin	B
is	O
over	O
12	O
percent	O
,	O
the	O
content	O
of	O
cinobufagin	B
is	O
over	O
4	O
percent	O
,	O
and	O
the	O
content	O
of	O
bufotalin	B
is	O
over	O
10	O
percent	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
invention	O
eliminates	O
bufotenine	B
alkaloid	B
which	O
has	O
irritation	O
,	O
is	O
easy	O
to	O
cause	O
hypersensitivity	O
but	O
has	O
no	O
antitumor	O
activity	O
,	O
efficiently	O
collects	O
the	O
effective	O
part	O
of	O
total	O
bufogenin	B
which	O
has	O
significant	O
antitumor	O
activity	O
,	O
therefore	O
pharmacological	O
action	O
is	O
stronger	O
,	O
the	O
clinical	O
curative	O
effect	O
is	O
higher	O
and	O
the	O
toxic	O
and	O
side	O
effect	O
is	O
lower	O
.	O

The	O
total	O
bufogenin	B
extract	O
can	O
be	O
prepared	O
into	O
variouspharmaceutical	O
preparations	O
for	O
clinical	O
application	O
,	O
therefore	O
the	O
invention	O
has	O
the	O
functions	O
of	O
killing	O
tumor	O
cells	O
,	O
inducing	O
differentiation	O
and	O
apoptosis	O
of	O
tumor	O
cells	O
,	O
inhibiting	O
the	O
neovascularization	O
of	O
tumor	O
cells	O
and	O
lowering	O
the	O
neoplasm	O
metastasis	O
rate	O
,	O
etc	O
.	O

Total	O
toadpoison	O
lactones	B
extraction	O
with	O
anti	O
-	O
tumor	O
function	O
,	O
preparation	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
deguelin	B
.	O

The	O
pure	O
deguelin	B
is	O
obtained	O
through	O
employing	O
powder	O
of	O
plant	O
roots	O
as	O
raw	O
material	O
,	O
choosing	O
suitable	O
entrainer	O
,	O
adopting	O
super	O
-	O
critical	O
CO2	B
fluid	O
for	O
extraction	O
,	O
controlling	O
extracting	O
temperature	O
,	O
extracting	O
pressure	O
,	O
extracting	O
separation	O
time	O
and	O
flow	O
rate	O
of	O
CO2	B
and	O
reducing	O
pressure	O
and	O
separating	O
finally	O
.	O

The	O
method	O
for	O
preparing	O
the	O
deguelin	B
provided	O
by	O
the	O
invention	O
can	O
obviously	O
reduce	O
cost	O
,	O
shorten	O
extraction	O
period	O
and	O
improve	O
quality	O
of	O
products	O
.	O

Method	O
for	O
preparing	O
deguelin	B

The	O
present	O
invention	O
provides	O
a	O
benzydamine	B
hydrochloride	I
gel	O
preparation	O
which	O
is	O
characterized	O
by	O
essentially	O
consisting	O
of	O
the	O
benzydamine	B
hydrochloride	I
with	O
effective	O
quantity	O
,	O
excipient	O
and	O
distilled	O
water	O
,	O
wherein	O
,	O
the	O
excipient	O
contains	O
buffer	O
pair	O
substance	O
with	O
proper	O
quantity	O
.	O

Because	O
the	O
buffer	O
pair	O
substance	O
with	O
the	O
proper	O
quantity	O
is	O
selected	O
to	O
be	O
the	O
excipient	O
of	O
the	O
present	O
invention	O
,	O
the	O
product	O
of	O
the	O
present	O
invention	O
has	O
stable	O
pH	O
value	O
which	O
does	O
not	O
fluctuate	O
easily	O
during	O
the	O
process	O
of	O
placement	O
and	O
stable	O
and	O
safe	O
product	O
quality	O
and	O
is	O
applied	O
to	O
remedy	O
the	O
bacterial	O
vaginitis	O
with	O
good	O
curative	O
effect	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
has	O
simple	O
and	O
convenient	O
product	O
production	O
technics	O
,	O
conveniently	O
implemented	O
operation	O
and	O
easily	O
controllable	O
quality	O
.	O

Benzydamine	B
hydrochloride	I
gel	O
preparation	O
and	O
preparation	O
thereof	O

An	O
anticancer	O
drug	O
sustained	O
-	O
release	O
preparation	O
containing	O
methotrexate	B
is	O
a	O
sustained	O
-	O
release	O
injection	O
.	O

An	O
anticancer	O
sustained	O
-	O
release	O
injection	O
consists	O
of	O
slow	O
-	O
release	O
microsphere	O
and	O
a	O
menstruum	O
,	O
wherein	O
,	O
the	O
sustained	O
-	O
release	O
microsphere	O
comprises	O
an	O
effective	O
anticancer	O
component	O
and	O
sustained	O
-	O
release	O
auxiliary	O
material	O
;	O
the	O
menstruum	O
is	O
an	O
ordinary	O
menstruum	O
or	O
a	O
special	O
menstruum	O
containing	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
component	O
is	O
the	O
combination	O
of	O
the	O
methotrexate	B
and	O
methotrexate	B
synergistic	O
agent	O
which	O
is	O
selected	O
from	O
guanine	B
analogue	O
,	O
alkylating	O
agent	O
and/or	O
botanical	O
alkaloid	B
.	O

The	O
sustained	O
-	O
release	O
auxiliary	O
material	O
is	O
selected	O
from	O
one	O
substance	O
or	O
the	O
combination	O
of	O
copolymer	O
of	O
polylactic	B
acid	I
,	O
polyglycolic	B
acid	I
and	O
glycolic	B
acid	I
,	O
the	O
copolymer	O
of	O
ethylene	B
acetate	I
vinyl	I
ester	I
and	O
the	O
copolymer	O
of	O
polifeprosan	O
and	O
FAD	O
:	O
sebacic	B
acid	I
.	O

The	O
suspending	O
agent	O
is	O
selected	O
from	O
carboxymethyl	O
sodium	O
cellulose	O
,	O
etc	O
.	O

The	O
sustained	O
-	O
release	O
microsphere	O
can	O
also	O
be	O
made	O
into	O
a	O
sustained	O
-	O
release	O
implantable	O
preparation	O
.	O

The	O
sustained	O
-	O
release	O
preparation	O
is	O
injected	O
or	O
arranged	O
inside	O
a	O
tumour	O
or	O
around	O
the	O
tumour	O
,	O
which	O
not	O
only	O
can	O
reduce	O
the	O
whole	O
body	O
toxic	O
reaction	O
of	O
drug	O
but	O
also	O
can	O
selectively	O
improve	O
the	O
partial	O
drug	O
concentration	O
at	O
the	O
tumour	O
,	O
so	O
as	O
to	O
increase	O
the	O
curative	O
effect	O
of	O
non	O
operative	O
treatments	O
,	O
such	O
as	O
chemotherapeutic	O
drug	O
,	O
an	O
irradiation	O
treatment	O
,	O
etc	O
.	O

Sustained	O
-	O
release	O
injection	O
containing	O
amethopterin	B
synergist	O

An	O
application	O
of	O
sodium	B
iodoacetate	I
used	O
for	O
preparing	O
a	O
drug	O
for	O
remedying	O
malignancy	O
belongs	O
to	O
the	O
medicine	O
technical	O
field	O
and	O
is	O
applied	O
to	O
the	O
novel	O
purpose	O
for	O
developing	O
the	O
sodium	B
iodoacetate	I
.	O

A	O
test	O
proves	O
that	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
good	O
inhibiting	O
effect	O
and	O
little	O
side	O
effect	O
towards	O
the	O
malignancy	O
.	O

Application	O
of	O
sodium	B
iodoacetate	I
in	O
preparing	O
medicament	O
for	O
treating	O
malignant	O
tumor	O

The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
tetramethylpyrazine	B
and	O
tetramethylpyrazine	B
salt	O
for	O
preparing	O
for	O
a	O
drug	O
for	O
remedying	O
or	O
preventing	O
intrauterine	O
fetal	O
ischemia	O
and	O
hypoxia	O
,	O
which	O
provides	O
a	O
novel	O
approach	O
for	O
protecting	O
fetus	O
,	O
calming	O
fetus	O
,	O
remedying	O
or	O
preventing	O
the	O
intrauterine	O
fetal	O
ischemia	O
and	O
hypoxia	O
.	O

Use	O
of	O
tetramethylpyrazine	B
and	O
its	O
salt	O

The	O
invention	O
relates	O
to	O
a	O
pilocarpine	B
nitrate	I
emulsion	O
for	O
eye	O
use	O
,	O
constituents	O
and	O
respective	O
weight	O
proportion	O
of	O
which	O
are	O
as	O
follows	O
:	O
pilocarpine	B
nitrate	I
:	O
sodium	B
hyaluronate	I
:	O
edetate	B
disodium	I
:	O
sodium	B
chloride	I
:	O
ethylparaben	B
is	O
equal	O
to	O
1	O
-	O
8	O
:	O
8.0	O
:	O
0.1	O
:	O
1.3	O
:	O
0.1	O
;	O
the	O
preparation	O
method	O
of	O
the	O
emulsion	O
is	O
that	O
:	O
1.pilocarpine	O
nitrate	B
is	O
mixed	O
with	O
a	O
proper	O
amount	O
of	O
water	O
for	O
injection	O
under	O
acidic	O
condition	O
(	O
pH	O
value	O
is	O
equal	O
to	O
5.5	O
-	O
6.5	O
)	O
,	O
sodium	B
chloride	I
,	O
ethylparaben	B
and	O
edetate	B
disodium	I
,	O
heated	O
and	O
dissolved	O
at	O
the	O
temperature	O
of	O
60	O
-	O
90	O
DEG	O
C	O
;	O
2	O
.	O
acquired	O
material	O
is	O
cooled	O
to	O
room	O
temperature	O
,	O
added	O
with	O
sodium	B
hyaluronate	I
and	O
stirred	O
fully	O
till	O
the	O
material	O
turns	O
transparent	O
;	O
3	O
.	O
acquired	O
material	O
is	O
sterilized	O
with	O
100	O
percent	O
flow	O
-	O
steam	O
,	O
scored	O
,	O
mesh	O
divided	O
and	O
put	O
into	O
a	O
refrigerator	O
to	O
be	O
frozen	O
and	O
dried	O
;	O
after	O
membrane	O
is	O
formed	O
,	O
the	O
material	O
is	O
stripped	O
and	O
the	O
emulsion	O
is	O
acquired	O
.	O

The	O
emulsion	O
of	O
the	O
invention	O
is	O
planted	O
into	O
conjunctival	O
sac	O
in	O
external	O
lower	O
border	O
of	O
eyes	O
,	O
and	O
medicine	O
is	O
released	O
in	O
the	O
pilocarpine	B
nitrate	I
and	O
retention	O
time	O
of	O
pilocarpine	B
nitrate	I
is	O
prolonged	O
.	O

Medicine	O
film	O
for	O
eyes	O
and	O
production	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
anticancer	O
drug	O
sustained	O
release	O
agent	O
containing	O
amethopterin	B
,	O
which	O
is	O
a	O
sustained	O
release	O
injection	O
consisting	O
of	O
sustained	O
release	O
microspheres	O
and	O
solvent	O
,	O
wherein	O
,	O
the	O
sustained	O
release	O
microspheres	O
comprise	O
effective	O
anticancer	O
components	O
and	O
sustained	O
-	O
release	O
excipient	O
,	O
and	O
the	O
solvent	O
is	O
normal	O
solvent	O
or	O
special	O
solvent	O
containing	O
a	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
components	O
are	O
amethopterin	B
and	O
the	O
combination	O
of	O
amethopterin	B
synergist	O
chosen	O
from	O
antitumor	O
antibiotics	O
and/or	O
taxane	B
.	O

The	O
sustained	O
-	O
release	O
excipient	O
is	O
one	O
of	O
or	O
the	O
combination	O
of	O
copolymer	O
of	O
polylactic	B
acid	I
,	O
polyglycolic	B
acid	I
and	O
glycolic	B
acid	I
,	O
ethylene	B
vinyl	I
acetate	I
copolymer	O
,	O
Polifeprosan	B
and	O
FAD	B
and	O
sebacie	B
acid	I
copolymer	O
.	O

The	O
suspending	O
agent	O
is	O
chosen	O
from	O
one	O
of	O
or	O
the	O
combination	O
of	O
sodium	O
carboxymethylcellulose	O
,	O
mannitol	B
,	O
sorbitol	B
,	O
Tween	B
80	I
or	O
the	O
combination	O
thereof	O
.	O

The	O
sustained	O
release	O
microspheres	O
can	O
also	O
be	O
produced	O
into	O
a	O
sustained	O
-	O
release	O
implant	O
.	O

The	O
sustained	O
-	O
release	O
agent	O
is	O
arranged	O
around	O
the	O
tumor	O
or	O
injected	O
in	O
the	O
tumor	O
,	O
which	O
not	O
only	O
reduces	O
toxic	O
reaction	O
of	O
the	O
whole	O
body	O
,	O
but	O
also	O
increases	O
the	O
drug	O
concentration	O
at	O
the	O
local	O
tumor	O
selectively	O
,	O
thereby	O
improving	O
treatment	O
effect	O
of	O
chemotherapeutics	O
,	O
radiotherapeutics	O
and	O
other	O
non	O
-	O
operative	O
treatment	O
.	O

Sustained	O
-	O
release	O
injection	O
containing	O
methotrexate	B
potentiating	O
agent	O

The	O
invention	O
provides	O
a	O
compound	O
anticancer	O
drug	O
sustained	O
release	O
agent	O
containing	O
bendamustine	B
,	O
which	O
is	O
a	O
sustained	O
release	O
injection	O
consisting	O
of	O
sustained	O
release	O
microspheres	O
and	O
solvent	O
,	O
wherein	O
,	O
the	O
sustained	O
release	O
microspheres	O
comprise	O
effective	O
anticancer	O
components	O
and	O
sustained	O
-	O
release	O
excipient	O
,	O
and	O
the	O
solvent	O
is	O
a	O
special	O
solvent	O
containing	O
a	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
components	O
are	O
bendamustine	B
and	O
the	O
combination	O
of	O
bendamustine	B
synergist	O
chosen	O
from	O
alkylating	O
agent	O
and/or	O
hormone	O
anticarcinogen	O
.	O

The	O
sustained	O
-	O
release	O
excipient	O
is	O
chosen	O
from	O
one	O
of	O
or	O
the	O
combination	O
of	O
polylactic	B
acid	I
,	O
copolymer	O
thereof	O
,	O
monomethyl	B
polyethylene	I
glycol	I
,	O
polyethylene	B
glycol	I
,	O
carboxyl	B
end	O
polylactide	O
copolymer	O
,	O
dual	O
fatty	B
acid	I
,	O
sebacie	B
acid	I
copolymer	O
,	O
poly	B
(	I
erucic	I
dimer-	I
sebacie	I
acid	I
)	I
,	O
poly	B
(	I
fumarate-	I
sebacie	I
acid	I
)	I
,	O
Polifeprosan	B
,	O
polylactide	O
copolymer	O
or	O
mixture	O
and	O
EVAc	O
.	O

The	O
suspending	O
agent	O
is	O
chosen	O
from	O
carboxymethyl	O
cellulose	O
,	O
etc	O
.	O
,	O
and	O
the	O
viscosity	O
of	O
the	O
suspending	O
agent	O
is	O
80cp-3000cp	O
(	O
in	O
the	O
temperature	O
of	O
20	O
DEG	O
C-30	O
DEG	O
C	O
)	O
.	O

The	O
sustained	O
release	O
microspheres	O
can	O
also	O
be	O
produced	O
into	O
a	O
sustained	O
-	O
release	O
implant	O
.	O

The	O
sustained	O
-	O
release	O
implant	O
and	O
the	O
sustained	O
release	O
injection	O
is	O
arranged	O
around	O
the	O
tumor	O
or	O
injected	O
in	O
the	O
tumor	O
,	O
which	O
can	O
obviously	O
improve	O
the	O
curative	O
effect	O
if	O
being	O
applied	O
independently	O
or	O
combined	O
with	O
chemotherapeutics	O
and/or	O
radiotherapeutics	O
and	O
other	O
non	O
-	O
operative	O
treatment	O
.	O

Compound	O
anticancer	O
sustained	O
-	O
release	O
injection	O
containing	O
bendamustine	B

The	O
invention	O
discloses	O
novel	O
long	O
-	O
circulating	O
nanoparticles	O
of	O
hydroxycamptothecine	B
,	O
which	O
comprises	O
raw	O
material	O
components	O
of	O
hydroxycamptothecine	B
,	O
polymer	O
of	O
glycolide	O
and	O
gactide	O
(	O
PLGA	O
)	O
,	O
a	O
surfactant	O
and	O
a	O
film	O
modified	O
material	O
,	O
and	O
the	O
structure	O
is	O
that	O
the	O
hydroxycamptothecine	B
is	O
sealed	O
in	O
the	O
polymer	O
of	O
glycolide	B
and	O
gactide	B
(	O
PLGA	B
)	O
and	O
is	O
further	O
covered	O
the	O
surfactant	O
and	O
the	O
film	O
modified	O
material	O
on	O
the	O
surface	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
long	O
-	O
circulating	O
nanoparticles	O
of	O
hydroxycamptothecine	B
of	O
the	O
invention	O
have	O
low	O
toxicity	O
,	O
high	O
stability	O
in	O
solutions	O
,	O
long	O
detention	O
time	O
in	O
vivo	O
,	O
small	O
particle	O
diameter	O
,	O
and	O
no	O
obvious	O
change	O
after	O
being	O
lyophilized	O
.	O

The	O
preparation	O
method	O
of	O
the	O
invention	O
can	O
be	O
processed	O
under	O
the	O
condition	O
of	O
stable	O
hydroxycamptothecine	B
to	O
avoid	O
the	O
reduction	O
of	O
the	O
drug	O
effect	O
,	O
which	O
has	O
the	O
advantages	O
of	O
simple	O
steps	O
,	O
good	O
repeatability	O
and	O
easy	O
application	O
in	O
industrialized	O
manufacture	O
.	O

Long	O
-	O
circulation	O
nano	O
-	O
grain	O
of	O
hydroxycamptothecin	B
and	O
method	O
for	O
preparing	O
the	O
same	O

A	O
method	O
for	O
treating	O
drug	O
-	O
resistant	O
cancer	O
,	O
includes	O
:	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
a	O
compound	O
of	O
formula	O
I	O
,	O
a	O
tautomer	O
of	O
the	O
compound	O
,	O
a	O
salt	O
of	O
the	O
compound	O
,	O
a	O
salt	O
of	O
the	O
tautomer	O
,	O
a	O
mixture	O
thereof	O
,	O
or	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
,	O
the	O
tautomer	O
,	O
the	O
salt	O
of	O
the	O
compound	O
,	O
the	O
salt	O
of	O
the	O
tautomer	O
,	O
or	O
the	O
mixture	O
,	O
wherein	O
the	O
patient	O
is	O
a	O
cancer	O
patient	O
with	O
drug	O
-	O
resistant	O
cancer	O
,	O
wherein	O
the	O
compound	O
of	O
Formula	O
I	O
is	O
as	O
defined	O
in	O
the	O
application	O
.	O

Methods	O
for	O
treating	O
drug	O
resistant	O
cancer	O

The	O
invention	O
provides	O
a	O
medical	O
liquor	O
for	O
promoting	O
blood	O
circulation	O
for	O
removing	O
blood	O
stasis	O
and	O
reducing	O
swelling	O
and	O
relieving	O
pain	O
;	O
the	O
composite	O
prescription	O
of	O
the	O
invention	O
has	O
following	O
raw	O
medicines	O
by	O
weight	O
:	O
radix	O
aconiti	O
feri	O
of	O
10	O
to	O
20	O
g	O
,	O
monkshood	O
root	O
of	O
10	O
to	O
15	O
g	O
,	O
rhizoma	O
arisaematis	O
of	O
10	O
to	O
20	O
g	O
,	O
camphor	B
of	O
2	O
to	O
5	O
g	O
,	O
safflower	O
of	O
4	O
to	O
6	O
g	O
,	O
borneol	B
of	O
5	O
to	O
10	O
g	O
,	O
and	O
white	O
spirit	O
with	O
50	O
degrees	O
of	O
500	O
g	O
.	O

the	O
invention	O
has	O
the	O
medicine	O
effects	O
of	O
activating	O
blood	O
to	O
absorb	O
clots	O
,	O
releasing	O
swelling	O
analgesia	O
and	O
detoxifying	O
to	O
relieve	O
itching	O
(	O
with	O
mosquito	O
bites	O
or	O
nonallergic	O
dermatitis	O
)	O
and	O
has	O
the	O
advantages	O
of	O
using	O
safely	O
,	O
healthy	O
and	O
conveniently	O
.	O

Medicated	O
wine	O
capable	O
of	O
promoting	O
blood	O
circulation	O
by	O
removing	O
blood	O
stasis	O
,	O
detumescence	O
and	O
relieving	O
pain	O

The	O
invention	O
discloses	O
a	O
production	O
method	O
for	O
a	O
12	O
hours	O
oral	O
ulcer	O
eliminating	O
powder	O
,	O
with	O
which	O
the	O
oral	O
ulcer	O
can	O
be	O
healed	O
within	O
12	O
hours	O
.	O

The	O
method	O
of	O
the	O
invention	O
is	O
realized	O
through	O
the	O
following	O
technical	O
scheme	O
:	O
peeling	O
off	O
a	O
sorghum	O
straw	O
to	O
acquire	O
an	O
inner	O
white	O
and	O
then	O
drying	O
in	O
a	O
dry	O
box	O
for	O
60	O
-	O
90min	O
at	O
a	O
temperature	O
of	O
50	O
-	O
70	O
DEG	O
C	O
,	O
then	O
spot	O
burning	O
the	O
inner	O
white	O
to	O
be	O
straw	O
carbon	B
and	O
processing	O
to	O
be	O
fine	O
powders	O
of	O
200	O
mesh	O
,	O
grinding	O
bitter	O
alum	O
and	O
borneol	B
into	O
fine	O
powders	O
of	O
200	O
mesh	O
for	O
mixing	O
with	O
the	O
straw	O
carbon	B
fine	O
powders	O
for	O
5	O
-	O
10min	O
,	O
thus	O
acquiring	O
the	O
finished	O
product	O
of	O
the	O
powder	O
medicine	O
after	O
mixing	O
well	O
the	O
fine	O
powders	O
.	O

Production	O
method	O
of	O
powder	O
for	O
eliminating	O
mouth	O
ulcer	O
in	O
12	O
hours	O

The	O
invention	O
relates	O
to	O
a	O
1-substituted-5-trifluoromethyl-2-	B
(	I
1H	I
)	I
pyridine	I
compound	O
,	O
a	O
relative	O
preparation	O
method	O
and	O
a	O
pharmaceutical	O
application	O
of	O
the	O
compound	O
,	O
wherein	O
the	O
compound	O
is	O
represented	O
as	O
formula	O
(	O
X	O
)	O
,	O
with	O
anti	O
-	O
fibrosis	O
function	O
.	O

1-substituted-5-trifluoromethyl-2-	B
(	I
1H	I
)	I
pyridone	I
compound	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
particularly	O
disclosing	O
a	O
dextrosamine	B
injecta	O
and	O
the	O
preparation	O
method	O
.	O

The	O
chemical	O
stability	O
and	O
rate	O
of	O
the	O
finished	O
product	O
of	O
the	O
dextrosamine	B
injecta	O
has	O
more	O
remarkable	O
improvement	O
than	O
the	O
prior	O
art	O
.	O

Aminoglucose	B
injection	O
and	O
preparation	O
thereof	O

The	O
invention	O
discloses	O
1-	B
(	I
substituted	I
benzoyl	I
)	I
-indazole-3-carboxylate	I
or	I
amide	I
compounds	O
A	O
thereof	O
.	O

The	O
compounds	O
have	O
strong	O
antifertility	O
activity	O
so	O
as	O
to	O
be	O
used	O
in	O
preparing	O
antifertility	O
medicine	O
and	O
antivirus	O
medicine	O
.	O

The	O
invention	O
provides	O
novel	O
clinic	O
male	O
prophylactic	O
and	O
antivirus	O
medicine	O
with	O
large	O
application	O
value	O
,	O
the	O
invention	O
also	O
provides	O
preparing	O
methods	O
thereof	O
.	O

1-	B
(	I
substituted	I
benzoyl	I
)	I
-indazole-3-carboxylate	I
or	I
amides	I
compounds	O
thereof	O
,	O
synthesis	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
preventing	O
and	O
treating	O
swine	O
edema	O
disease	O
and	O
a	O
method	O
for	O
further	O
preparing	O
injection	O
,	O
oral	O
dosage	O
and	O
fodder	O
additive	O
.	O

The	O
drug	O
is	O
mainly	O
made	O
by	O
the	O
following	O
components	O
in	O
weight	O
proportion	O
:	O
plantain	O
150	O
g	O
,	O
Grassleaf	O
Sweelflag	O
Rhizome	O
100	O
g	O
,	O
poria	O
coco	O
80	O
g	O
and	O
norfloxacin	B
150	O
mg	O
.	O

The	O
drug	O
and	O
the	O
various	O
preparation	O
has	O
the	O
advantages	O
of	O
good	O
treating	O
and	O
preventing	O
effect	O
on	O
swine	O
edema	O
disease	O
and	O
no	O
poison	O
and	O
side	O
effect	O
.	O

Medicament	O
for	O
preventing	O
and	O
treating	O
hydropsy	O
of	O
pigling	O

The	O
invention	O
relates	O
to	O
a	O
turbidity	O
eliminating	O
and	O
numbness	O
removing	O
powder	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
.	O

The	O
turbidity	O
eliminating	O
and	O
numbness	O
removing	O
powder	O
in	O
the	O
invention	O
comprises	O
the	O
following	O
components	O
:	O
30	O
g	O
dried	O
human	O
placenta	O
,	O
12	O
g	O
rhubarb	O
,	O
30	O
g	O
chicken	O
's	O
gizzardskin	O
,	O
12	O
g	O
dragon	O
's	O
blood	O
,	O
12	O
g	O
Angelica	O
,	O
7	O
full	O
cicadas	O
,	O
12	O
g	O
Nutgrass	O
Galingale	O
Rhizome	O
,	O
12	O
g	O
rhizoma	O
drynariae	O
,	O
15	O
g	O
Chinese	O
polyphaga	O
,	O
18	O
g	O
dried	O
ginger	O
,	O
30	O
g	O
adsuki	O
bean	O
,	O
3	O
g	O
cinnabar	O
,	O
0.05	O
g	O
musk	O
,	O
and	O
12	O
g	O
frankincense	O
.	O

By	O
eliminating	O
the	O
TS	O
and	O
YX	O
substances	O
in	O
human	O
bodies	O
,	O
the	O
composition	O
medicine	O
in	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
preventing	O
and	O
curing	O
the	O
numbness	O
symptoms	O
caused	O
by	O
CFY	O
diseases	O
.	O

Turbidity	O
discharging	O
paralysis	O
relaxing	O
powder	O

The	O
invention	O
provides	O
an	O
injection	O
formulation	O
of	O
diclofenac	B
sodium	I
for	O
intravenous	O
injection	O
and	O
the	O
preparation	O
method	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
diclofenac	B
sodium	I
is	O
included	O
successfully	O
with	O
the	O
inclusion	O
material	O
of	O
propyl	O
-	O
Beta	O
-	O
cyclodextrin	O
.	O

The	O
injection	O
formulation	O
has	O
the	O
advantages	O
of	O
improving	O
the	O
solubility	O
of	O
diclofenac	B
sodium	I
in	O
the	O
solution	O
and	O
reducing	O
the	O
adverse	O
reaction	O
in	O
intravenous	O
injection	O
.	O

The	O
injection	O
formulation	O
exists	O
in	O
the	O
form	O
of	O
injection	O
,	O
frozen	O
powder	O
,	O
sterile	O
powder	O
and	O
large	O
-	O
capacity	O
infusion	O
.	O

The	O
invention	O
also	O
describes	O
the	O
main	O
technical	O
parameters	O
of	O
adopting	O
propyl-	O
Beta	O
-cyclodextrin	O
to	O
include	O
the	O
diclofenac	B
sodium	I
,	O
such	O
as	O
inclusion	O
method	O
,	O
the	O
concentration	O
of	O
propyl	O
-	O
Beta	O
-	O
cyclodextrin	O
,	O
solution	O
temperature	O
in	O
inclusion	O
and	O
inclusion	O
time	O
.	O

Preparation	O
for	O
injection	O
of	O
diclofenac	B
sodium	I
capable	O
of	O
being	O
used	O
for	O
intravenous	O
injection	O
and	O
preparation	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medical	O
technology	O
,	O
in	O
particular	O
to	O
an	O
anti	O
-	O
cancer	O
compound	O
Ananaside	B
C	I
which	O
is	O
separated	O
from	O
thelenota	O
ananas	O
,	O
and	O
the	O
molecular	O
formula	O
is	O
C41H63O17SNa	B
.	O

The	O
chemical	O
structure	O
and	O
the	O
spatial	O
configuration	O
of	O
the	O
compound	O
are	O
determined	O
by	O
various	O
modern	O
spectral	O
analysises	O
,	O
in	O
particular	O
to	O
the	O
comprehensive	O
analysis	O
by	O
applying	O
the	O
advanced	O
two	O
-	O
dimensional	O
nuclear	O
magnetic	O
resonance	O
spectra	O
and	O
high	O
resolution	O
mass	O
spectra	O
.	O

In	O
vitro	O
anti	O
-	O
tumor	O
trials	O
show	O
that	O
the	O
compound	O
has	O
significant	O
inhibition	O
function	O
on	O
A-549	O
lung	O
cancer	O
and	O
IA-9	O
ovarian	O
cancer	O
and	O
other	O
8	O
kinds	O
of	O
tumor	O
cell	O
strains	O
.	O

The	O
compound	O
can	O
provide	O
a	O
lead	O
compound	O
for	O
the	O
development	O
of	O
new	O
anti	O
-	O
tumor	O
drugs	O
,	O
which	O
has	O
important	O
values	O
for	O
the	O
development	O
and	O
the	O
utilization	O
of	O
the	O
marine	O
medicinal	O
and	O
biological	O
resources	O
of	O
China	O
.	O

Novel	O
antineoplastic	O
compound	O
Ananaside	B
C	I
in	O
thelenota	O
ananas	O

A	O
fibrauretine	O
gel	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
are	O
provided	O
.	O

The	O
preparation	O
contains	O
0.25	O
-	O
5wt%	O
of	O
fibrauretine	B
,	O
0.5	O
-	O
5wt%	O
of	O
gel	O
matrix	O
,	O
0.01	O
-	O
1wt%	O
of	O
pH	O
regulator	O
,	O
0.05	O
-	O
0.15wt%	O
of	O
antiseptics	O
and	O
distilled	O
water	O
in	O
balance	O
.	O

The	O
preparation	O
method	O
does	O
n't	O
use	O
any	O
stabilizer	O
and	O
employs	O
heating	O
process	O
to	O
completely	O
swell	O
the	O
gel	O
substrate	O
during	O
a	O
short	O
period	O
of	O
time	O
.	O

The	O
production	O
cycle	O
is	O
short	O
and	O
suitable	O
for	O
industrialized	O
production	O
.	O

The	O
fibrauretine	B
gel	O
has	O
uniform	O
and	O
fine	O
texture	O
and	O
good	O
effect	O
of	O
coupling	O
and	O
hydration	O
to	O
mucosa	O
,	O
and	O
also	O
has	O
the	O
advantages	O
of	O
remarkable	O
curative	O
effect	O
,	O
convenient	O
adminstraiton	O
,	O
long	O
retention	O
time	O
in	O
vagina	O
,	O
long	O
-	O
lasting	O
action	O
,	O
complete	O
release	O
of	O
active	O
components	O
,	O
no	O
foreign	O
body	O
sensation	O
of	O
vagina	O
,	O
no	O
damage	O
to	O
vagina	O
,	O
no	O
deformation	O
,	O
storage	O
stability	O
and	O
no	O
contamination	O
to	O
clothing	O
.	O

Fibraurea	O
stem	O
element	O
jelly	O
glue	O
preparations	O
and	O
preparation	O
technique	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
calcium	O
heparin	O
/	O
sodium	O
salt	O
nano	O
-	O
sized	O
oral	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
a	O
calcium	O
heparin	O
/	O
sodium	O
salt	O
nano	O
-	O
sized	O
liposome	O
with	O
high	O
encapsulation	O
rate	O
for	O
preparing	O
the	O
calcium	O
heparin	O
/	O
sodium	O
salt	O
nano	O
-	O
sized	O
oral	O
preparation	O
.	O

The	O
calcium	O
heparin	O
/	O
sodium	O
salt	O
nano	O
-	O
sized	O
liposome	O
is	O
obtained	O
by	O
the	O
following	O
steps	O
:	O
dissolving	O
chitosan	O
in	O
1	O
-	O
10	O
%	O
diluted	O
solution	O
of	O
acetic	B
acid	I
(	O
the	O
usage	O
amount	O
of	O
chitosan	O
is	O
0.5	O
-	O
5	O
g	O
per	O
100ml	O
acetic	O
acid	O
solution	O
)	O
to	O
obtain	O
an	O
acidified	O
chitosan	O
solution	O
,	O
filtering	O
,	O
collecting	O
filtrate	O
,	O
adding	O
dropwise	O
1	O
-	O
99	O
%	O
aqueous	O
solution	O
of	O
calcium	O
heparin	O
/	O
sodium	O
salt	O
into	O
the	O
filtrate	O
under	O
magnetic	O
stirring	O
until	O
milk	O
white	O
precipitate	O
occurs	O
,	O
centrifugating	O
the	O
resulating	O
suspension	O
,	O
collecting	O
precipitates	O
,	O
and	O
freezes	O
-	O
drying	O
to	O
obtain	O
calcium	O
heparin	O
/	O
sodium	O
salt	O
nano	O
-	O
sized	O
liposome	O
.	O

The	O
calcium	O
heparin	O
/	O
sodium	O
salt	O
nano	O
-	O
sized	O
oral	O
preparation	O
is	O
characterized	O
in	O
that	O
the	O
preparation	O
has	O
good	O
stability	O
,	O
high	O
encapsulation	O
rate	O
(	O
up	O
to	O
98	O
%	O
)	O
,	O
and	O
high	O
in	O
vitro	O
release	O
rate	O
(	O
up	O
to	O
25	O
%	O
at	O
hour	O
4	O
)	O
;	O
the	O
preparation	O
is	O
absorbed	O
in	O
the	O
intestinal	O
tract	O
with	O
high	O
absorption	O
rate	O
and	O
high	O
concentration	O
;	O
the	O
half	O
life	O
is	O
prolonged	O
upon	O
the	O
increase	O
of	O
oral	O
dosage	O
,	O
showing	O
zero	O
-	O
order	O
kinetics	O
;	O
the	O
tissue	O
concentration	O
is	O
larger	O
than	O
blood	O
concentration	O
;	O
the	O
preparation	O
is	O
released	O
sustainedly	O
;	O
and	O
study	O
in	O
rabbits	O
(	O
20	O
mg	O
oral	O
intake	O
)	O
shows	O
that	O
the	O
blood	O
concentration	O
in	O
vivo	O
is	O
kept	O
high	O
for	O
over	O
50	O
hours	O
,	O
thereby	O
proving	O
sustained	O
release	O
.	O

Calciparine	O
/	O
sodium	O
salt	O
nano	O
oral	O
preparation	O
and	O
preparation	O
technique	O
thereof	O

The	O
invention	O
discloses	O
an	O
ointment	O
for	O
improving	O
chapped	O
hands	O
and	O
feet	O
,	O
which	O
is	O
made	O
from	O
pearl	O
powder	O
4	O
parts	O
,	O
Pheretima	O
powder	O
20	O
parts	O
,	O
borax	B
6	O
parts	O
,	O
5	O
%	O
salicylic	B
acid	I
3	O
parts	O
and	O
vaseline	O
67	O
parts	O
.	O

The	O
ointment	O
has	O
heat	O
and	O
toxicity	O
removing	O
,	O
antibacterial	O
,	O
anti	O
-	O
inflammatory	O
,	O
wound	O
healing	O
and	O
keratolytic	O
effects	O
,	O
and	O
has	O
good	O
therapeutic	O
effect	O
on	O
chapped	O
hands	O
and	O
feet	O
.	O

Extremity	O
chap	O
chrisma	O

The	O
invention	O
relates	O
to	O
a	O
paediatric	O
antibechic	O
-	O
antiasthmatic	O
granule	O
is	O
a	O
clinical	O
common	O
pediatric	O
drug	O
.	O

Aiming	O
at	O
ensuring	O
the	O
safe	O
clinical	O
application	O
of	O
the	O
pediatric	O
drug	O
,	O
the	O
invention	O
provides	O
an	O
improved	O
quality	O
control	O
method	O
.	O

The	O
invention	O
has	O
the	O
concrete	O
contents	O
that	O
:	O
2	O
g	O
paediatric	O
antibechic	O
-	O
antiasthmatic	O
granule	O
is	O
obtained	O
,	O
added	O
with	O
20ml	O
ethanol	B
of	O
75	O
percent	O
,	O
and	O
dissolved	O
under	O
the	O
ultra	O
audible	O
sound	O
for	O
10	O
minutes	O
;	O
the	O
solution	O
is	O
filtered	O
,	O
filter	O
liquor	O
is	O
evaporated	O
to	O
dryness	O
,	O
residue	O
is	O
dissolved	O
by	O
adding	O
with	O
10ml	O
methanol	B
to	O
be	O
used	O
as	O
sample	O
solution	O
;	O
proper	O
chlorogenic	B
acid	I
which	O
is	O
used	O
as	O
the	O
reference	O
substance	O
is	O
obtained	O
and	O
added	O
with	O
the	O
methanol	B
to	O
make	O
the	O
solution	O
which	O
contains	O
0.5	O
milligrams	O
chlorogenic	B
acid	I
in	O
1ml	O
solution	O
to	O
be	O
used	O
as	O
the	O
reference	O
substance	O
solution	O
;	O
according	O
to	O
a	O
thin	O
-	O
layer	O
chromatography	O
experiment	O
,	O
1	O
microlitre	O
sample	O
solution	O
and	O
1	O
microlitre	O
reference	O
substance	O
solution	O
are	O
respectively	O
spotted	O
on	O
the	O
same	O
polyamide	B
thin	O
layer	O
,	O
acetic	B
acid	I
of	O
36	O
percent	O
is	O
used	O
as	O
developing	O
agent	O
,	O
the	O
polyamide	B
thin	O
layer	O
spotted	O
by	O
the	O
sample	O
solution	O
and	O
the	O
reference	O
substance	O
solution	O
is	O
developed	O
,	O
taken	O
out	O
from	O
the	O
developing	O
agent	O
,	O
air	O
-	O
dried	O
,	O
sprayed	O
by	O
alchlor	O
solution	O
,	O
and	O
detected	O
by	O
being	O
put	O
under	O
a	O
365	O
nm	O
UV	O
light	O
;	O
in	O
the	O
sample	O
chromatogram	O
,	O
a	O
fluorescence	O
spot	O
with	O
the	O
same	O
color	O
is	O
showed	O
at	O
the	O
position	O
corresponding	O
to	O
the	O
reference	O
substance	O
chromatogram	O
.	O

Quality	O
control	O
method	O
of	O
infusion	O
grain	O
for	O
cough	O
and	O
asthma	O
of	O
children	O

The	O
invention	O
relates	O
to	O
a	O
non	O
-	O
steroidal	O
androgen	O
receptor	O
modulator	O
containing	O
N	B
-	I
aryl	I
-	I
beta	I
-	I
aromatic	I
amine	I
-	I
propionamide	I
compound	O
(	O
I	O
)	O
and	O
a	O
relative	O
preparation	O
method	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
drug	O
compound	O
containing	O
the	O
N	B
-	I
aryl	I
-	I
beta	I
-	I
aromatic	I
amine	I
-	I
propionamide	I
compound	O
(	O
I	O
)	O
.	O

The	O
N	B
-	I
aryl	I
-	I
beta	I
-	I
aromatic	I
amine	I
-	I
propionamide	I
compound	O
(	O
I	O
)	O
has	O
androgen	O
receptor	O
antagonistic	O
activity	O
,	O
therefore	O
,	O
thecompound	O
can	O
be	O
used	O
to	O
prepare	O
the	O
non	O
-	O
steroidal	O
drug	O
for	O
preventing	O
or	O
/	O
treating	O
prostatic	O
hyperplasia	O
,	O
prostate	O
cancer	O
,	O
hirsutism	O
,	O
serious	O
androgen	O
dependence	O
alopecia	O
and	O
acne	O
or	O
the	O
like	O
.	O

N	B
-	I
aryl	I
-	I
beta	I
-	I
aryl	I
amidine	I
-	I
propionamide	I
compounds	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

Disclosed	O
is	O
an	O
adhesive	O
skin	O
patch	O
which	O
has	O
an	O
adhesive	O
layer	O
comprising	O
a	O
readily	O
-	O
soluble	O
agar	O
and	O
at	O
least	O
one	O
additive	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
polyacrylamide	B
,	O
polyvinyl	B
alcohol	I
,	O
polyvinyl	B
pyrrolidone	I
,	O
sodium	B
alginate	I
,	O
ammonium	B
alginate	I
,	O
carboxymethylcellulose	O
,	O
sodium	O
carboxymethylcellulose	O
,	O
methylcellulose	O
,	O
gum	O
arabic	O
,	O
tragacanth	O
gum	O
and	O
xanthan	O
gum	O
.	O

Adhesive	O
skin	O
patch	O

The	O
invention	O
relates	O
to	O
a	O
guacetisal	O
dry	O
suspension	O
,	O
the	O
formula	O
of	O
which	O
for	O
preparing	O
1,000	O
bags	O
comprises	O
the	O
following	O
raw	O
materials	O
(	O
by	O
weight	O
parts	O
)	O
guacetisal	O
160	O
-	O
170	O
,	O
hydroxypropyl	O
methyl	O
cellulose	O
5	O
-	O
10	O
,	O
sodium	B
lauryl	I
sulfate	I
5	I
-	I
10	I
,	O
sucrose	B
815	O
-	O
820	O
,	O
and	O
a	O
proper	O
amount	O
of	O
fresh	O
milk	O
essence	O
,	O
wherein	O
the	O
sodium	B
lauryl	I
sulfate	I
is	O
used	O
as	O
a	O
wetting	O
agent	O
for	O
facilitating	O
suspension	O
.	O

The	O
guacetisal	O
dry	O
suspension	O
has	O
the	O
advantages	O
of	O
good	O
settling	O
volume	O
ratio	O
,	O
long	O
suspension	O
state	O
keeping	O
time	O
,	O
good	O
stability	O
,	O
and	O
good	O
mouthfeel	O
;	O
and	O
is	O
more	O
suitable	O
for	O
administration	O
by	O
children	O
and	O
patients	O
suffering	O
from	O
dysphagia	O
.	O

Guacetisal	O
dry	O
-	O
mixing	O
suspending	O
agents	O
and	O
method	O
of	O
preparing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
a	O
new	O
application	O
of	O
Rhodiola	O
sacra	O
effective	O
ingredients	O
in	O
delay	O
aging	O
,	O
particularly	O
to	O
an	O
application	O
of	O
salidroside	B
in	O
preparing	O
antiaging	O
drugs	O
.	O

Experimental	O
study	O
proves	O
that	O
salidroside	B
has	O
distinct	O
antiaging	O
effect	O
in	O
both	O
cell	O
models	O
and	O
animals	O
.	O

The	O
salidroside	B
is	O
expected	O
to	O
be	O
developed	O
to	O
health	O
products	O
and	O
drugs	O
for	O
delaying	O
aging	O
and	O
preventing	O
diseases	O
.	O

Novel	O
use	O
of	O
salidroside	B
delaying	O
consenescence	O

The	O
invention	O
provides	O
a	O
method	O
for	O
extracting	O
Rhizoma	O
Polygonatum	O
polysaccharide	O
from	O
Rhizoma	O
Polygonatum	O
,	O
comprising	O
dissolving	O
the	O
coarse	O
powder	O
of	O
the	O
Rhizoma	O
Polygonatum	O
in	O
water	O
,	O
heating	O
,	O
boiling	O
and	O
filtering	O
to	O
obtain	O
water	O
extracting	O
solution	O
of	O
Rhizoma	O
Polygonatum	O
;	O
concentrating	O
the	O
water	O
extracting	O
solution	O
to	O
density	O
of	O
1.05	O
-	O
1.18	O
,	O
adding	O
95	O
%	O
of	O
alcohol	O
until	O
the	O
alcohol	O
concentration	O
is	O
75	O
-	O
85	O
%	O
;	O
depositing	O
for	O
12	O
-	O
36	O
hours	O
and	O
filtering	O
to	O
obtain	O
paleyellow	O
deposition	O
;	O
drying	O
,	O
finally	O
the	O
Rhizoma	O
Polygonatum	O
polysaccharide	O
extract	O
product	O
is	O
obtained	O
.	O

The	O
invention	O
has	O
features	O
of	O
simple	O
method	O
,	O
high	O
extracting	O
efficiency	O
.	O

The	O
effective	O
component	O
for	O
enhancing	O
the	O
immunologic	O
function	O
of	O
rat	O
is	O
extracted	O
from	O
the	O
Rhizoma	O
Polygonatum	O
.	O

Method	O
for	O
extracting	O
Siberian	O
solomonseal	O
rhizome	O
polysaccharide	O
from	O
siberian	O
solomonseal	O
rhizome	O

The	O
invention	O
provides	O
an	O
amorphous	O
form	O
of	O
Dorzolamide	B
hydrochloride	I
,	O
processes	O
for	O
the	O
preparation	O
of	O
amorphous	O
Dorzolamide	B
hydrochloride	I
,	O
processes	O
for	O
making	O
Form	O
II	O
from	O
amorphous	O
Dorzolamide	B
HCl5	I
a	O
crystalline	O
form	O
of	O
Dorzolamide	B
hydrochloride	I
,	O
Form	O
IV	O
,	O
process	O
for	O
making	O
Form	O
IV	O
,	O
and	O
pharmaceutical	O
compositions	O
of	O
amorphous	O
Dorzolamide	B
hydrochloride	I
,	O
Dorzolamide	B
hydrochloride	I
Form	O
II	O
and	O
Dorzolamide	B
hydrochloride	I
Form	O
IV	O
.	O

Amorphous	O
and	O
crystalline	O
forms	O
of	O
dorzolamide	B
hydrochloride	I
and	O
processes	O
of	O
making	O
same	O

A	O
root	O
canal	O
anti	O
-	O
inflammatory	O
developer	O
and	O
a	O
preparation	O
thereof	O
of	O
the	O
invention	O
relates	O
to	O
a	O
developer	O
,	O
a	O
root	O
canal	O
anti	O
-	O
inflammatory	O
developer	O
provided	O
with	O
antibacterial	O
and	O
anti	O
-	O
inflammatory	O
and	O
root	O
canal	O
developing	O
functions	O
,	O
and	O
a	O
preparation	O
method	O
.	O

The	O
root	O
canal	O
anti	O
-	O
inflammatory	O
developer	O
comprises	O
two	O
parts	O
of	O
a	O
carrier	O
and	O
medicine	O
,	O
the	O
mass	O
ratio	O
of	O
which	O
is	O
(	O
0.1	O
-	O
0.4	O
)	O
:1	O
;	O
the	O
medicine	O
can	O
be	O
metronidazole	B
,	O
tinidazole	B
or	O
amoxicillin	B
,	O
etc	O
.	O
;	O
the	O
carrier	O
can	O
be	O
titanium	B
stable	O
mesoporous	O
zirconium	B
oxide	I
.	O

The	O
preparation	O
of	O
the	O
carrier	O
comprises	O
following	O
steps	O
:	O
zirconium	B
sulfate	I
is	O
dissolved	O
into	O
water	O
,	O
and	O
zirconium	B
sulfate	I
aqueous	O
solution	O
is	O
prepared	O
;	O
titanium	B
sulfate	I
is	O
dissolved	O
into	O
the	O
zirconium	B
sulfate	I
aqueous	O
solution	O
to	O
obtain	O
the	O
mixed	O
aqueous	O
solution	O
of	O
titanium	B
sulfate	I
and	O
zirconium	B
sulfate	I
;	O
surfactant	O
is	O
dissolved	O
into	O
water	O
and	O
surfactant	O
aqueous	O
solution	O
is	O
obtained	O
;	O
the	O
mixed	O
aqueous	O
solution	O
of	O
titanium	B
sulfate	I
and	O
zirconium	B
sulfate	I
and	O
the	O
surfactant	O
aqueous	O
solution	O
are	O
mixed	O
,	O
heated	O
by	O
water	O
,	O
filtered	O
,	O
dried	O
and	O
treated	O
with	O
phosphate	B
solution	O
,	O
dried	O
,	O
calcined	O
to	O
obtain	O
the	O
carrier	O
of	O
titanium	O
stable	O
mesoporous	O
zirconium	B
oxide	I
.	O

The	O
medicine	O
is	O
provided	O
with	O
carriers	O
:	O
the	O
antibacterial	O
and	O
anti	O
-	O
inflammatory	O
medicine	O
is	O
dissolved	O
into	O
hydrochloric	B
acid	I
to	O
have	O
the	O
aqueous	O
solution	O
of	O
medicine	O
and	O
hydrochloric	B
acid	I
prepared	O
;	O
the	O
carrier	O
of	O
titanium	B
stable	O
mesoporous	O
zirconium	B
oxide	I
is	O
added	O
into	O
the	O
aqueous	O
solution	O
of	O
medicine	O
and	O
hydrochloric	B
acid	I
and	O
stirred	O
.	O

Root	O
canal	O
anti	O
-	O
inflammation	O
developing	O
agent	O
and	O
preparation	O
thereof	O

The	O
invention	O
discloses	O
applications	O
of	O
zoledronic	B
acid	I
in	O
preventing	O
osteoporosis	O
;	O
the	O
zoopery	O
is	O
providence	O
that	O
zoledronic	B
acid	I
has	O
good	O
preventing	O
effect	O
and	O
therapeutical	O
action	O
to	O
osteoporosis	O
;	O
zoledronic	B
acid	I
can	O
be	O
prepared	O
into	O
any	O
clinically	O
acceptable	O
oral	O
preparations	O
such	O
as	O
tablets	O
,	O
capsules	O
,	O
granules	O
,	O
suspensions	O
,	O
dry	O
suspensions	O
and	O
oral	O
liquid	O
,	O
etc	O
.	O

so	O
as	O
to	O
clinically	O
prevent	O
and	O
treat	O
osteoporosis	O
.	O

Zoledronic	B
acid	I
for	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
osteoporosis	O

The	O
present	O
invention	O
provides	O
a	O
medicine	O
for	O
curing	O
cyclomastopathy	O
,	O
which	O
takes	O
dandelion	O
,	O
degelatined	O
deer	O
-	O
horn	O
,	O
edible	O
tulip	O
,	O
orange	O
kernel	O
,	O
green	O
tangerine	O
peel	O
,	O
dried	O
orange	O
peel	O
,	O
citron	O
fruit	O
,	O
chuanxiong	O
rhizome	O
and	O
rhizoma	O
pleionis	O
,	O
tangerine	O
seed	O
,	O
green	O
tangerine	O
orange	O
peel	O
,	O
dried	O
orange	O
peel	O
,	O
bitter	O
orange	O
,	O
hemlock	O
parsley	O
,	O
rhizoma	O
corydalis	O
as	O
raw	O
materials	O
.	O

These	O
raw	O
materials	O
are	O
added	O
with	O
water	O
and	O
decocted	O
,	O
and	O
then	O
is	O
condensed	O
to	O
thick	O
paste	O
,	O
then	O
dried	O
and	O
ground	O
to	O
powder	O
,	O
finally	O
encapsulated	O
and	O
sterilized	O
to	O
obtain	O
the	O
capsule	O
.	O

The	O
medicine	O
provided	O
by	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
addressing	O
both	O
symptoms	O
and	O
root	O
causes	O
,	O
good	O
curing	O
effect	O
and	O
quick	O
effect	O
.	O

The	O
present	O
invention	O
plays	O
an	O
active	O
role	O
in	O
reducing	O
the	O
operation	O
treatment	O
and	O
decreasingcyclomastopathy	O
canceration	O
rate	O
.	O

Being	O
proved	O
by	O
clinical	O
experiment	O
of	O
120	O
cyclomastopathy	O
patients	O
,	O
the	O
effective	O
rate	O
of	O
the	O
present	O
invention	O
is	O
98	O
percent	O
.	O

Medicine	O
for	O
treating	O
hyperplasia	O
of	O
mammary	O
glands	O

The	O
present	O
invention	O
provides	O
a	O
medicine	O
for	O
curing	O
fracture	O
,	O
which	O
overcomes	O
the	O
defects	O
of	O
other	O
technologies	O
.	O

The	O
present	O
invention	O
is	O
made	O
from	O
the	O
following	O
raw	O
materials	O
:	O
5	O
to	O
15	O
g	O
of	O
poplar	O
leaf	O
flour	O
,	O
5	O
to	O
15	O
g	O
of	O
broomcorn	O
millet	O
flour	O
,	O
5	O
to	O
10	O
g	O
of	O
paleaceous	O
knotweed	O
,	O
5	O
to	O
10	O
g	O
of	O
wadalee	O
grm	O
tree	O
,	O
0.1	O
to	O
0.4	O
g	O
of	O
muskiness	O
,	O
4	O
to	O
7	O
g	O
of	O
Scalper	O
horn	O
and	O
500	O
g	O
of	O
mature	O
vinegar	O
.	O

The	O
preparation	O
method	O
includes	O
the	O
following	O
steps	O
:	O
step	O
1	O
is	O
that	O
paleaceous	O
knotweed	O
,	O
wadalee	O
grm	O
tree	O
,	O
muskiness	O
and	O
Scalper	O
horn	O
are	O
ground	O
into	O
flour	O
;	O
step	O
2	O
is	O
that	O
mix	O
poplar	O
leaf	O
flour	O
,	O
broomcorn	O
millet	O
flour	O
,	O
paleaceous	O
knotweed	O
,	O
wadalee	O
grm	O
tree	O
,	O
muskiness	O
and	O
Scalper	O
horn	O
are	O
mixed	O
and	O
then	O
stirred	O
into	O
ointment	O
by	O
mature	O
vinegar	O
;	O
step	O
3	O
is	O
that	O
the	O
mixed	O
ointment	O
is	O
spread	O
on	O
gauze	O
for	O
use	O
.	O

Medicaments	O
for	O
treating	O
bone	O
fracture	O
bone	O
fracture	O
disease	O

The	O
invention	O
relates	O
to	O
aralkyl	B
piperidine	I
derivatives	O
,	O
a	O
compound	O
thereof	O
and	O
an	O
application	O
in	O
the	O
preparation	O
of	O
a	O
novel	O
analgesic	O
and	O
sedative	O
drug	O
.	O

The	O
derivatives	O
of	O
the	O
invention	O
are	O
free	O
alkali	O
or	O
salt	O
of	O
the	O
general	O
formula	O
compound	O
.	O

The	O
pharmacological	O
test	O
shows	O
that	O
the	O
compound	O
of	O
the	O
invention	O
has	O
good	O
analgesic	O
and	O
sedative	O
activity	O
and	O
extremely	O
small	O
side	O
effect	O
.	O

Aralkylpiperidine	B
derivative	O
and	O
application	O
thereof	O
in	O
preparing	O
analgesic	O
and	O
sedative	O
medicament	O

The	O
invention	O
relates	O
to	O
tetrodotoxin	B
and	O
the	O
derivative	O
medicine	O
production	O
in	O
particular	O
to	O
the	O
stable	O
composition	O
of	O
the	O
tetrodotoxin	B
preparation	O
.	O

The	O
invention	O
provides	O
a	O
prepation	O
method	O
to	O
stabilize	O
the	O
tetrodotoxin	B
components	O
in	O
the	O
preparation	O
product	O
.	O

The	O
preparation	O
method	O
is	O
characterized	O
in	O
that	O
the	O
tetrodotoxin	B
preparation	O
for	O
injection	O
is	O
made	O
from	O
adjunct	O
,	O
cosolvent	O
and	O
stabilizer	O
allowed	O
by	O
the	O
pharmacopoeia	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
tetrodotoxin	B
preparation	O
for	O
injection	O
produced	O
by	O
the	O
method	O
of	O
composition	O
production	O
can	O
be	O
stored	O
for	O
long	O
time	O
is	O
the	O
ambient	O
temperature	O
which	O
has	O
solved	O
the	O
problem	O
that	O
tetrodotoxin	B
preparation	O
is	O
not	O
stable	O
in	O
ambient	O
temperature	O
.	O

Stable	O
tetrodotoxin	B
preparations	O
under	O
room	O
temperature	O
for	O
injection	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
and	O
application	O
of	O
a	O
series	O
of	O
diaryl	B
triazine	I
derivatives	O
shown	O
in	O
formula	O
I	O
,	O
which	O
belongs	O
to	O
the	O
field	O
of	O
medical	O
technology	O
.	O

The	O
pharmacological	O
experiment	O
results	O
indicate	O
that	O
the	O
diaryl	B
triazine	I
derivatives	O
have	O
shown	O
not	O
only	O
remarkable	O
anti	O
-	O
HIV-1	O
virus	O
activity	O
,	O
but	O
also	O
good	O
inhibiting	O
effect	O
on	O
HIV-2ROD	O
viral	O
strain	O
.	O

Therefore	O
,	O
the	O
diaryl	B
triazine	I
derivatives	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
related	O
drug	O
for	O
treating	O
AIDS	O
.	O

Diaryltriazine	B
derivatives	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
application	O
describes	O
compounds	O
,	O
including	O
all	O
pharmaceutically	O
acceptable	O
salts	O
,	O
prodrugs	O
,	O
solvates	O
and	O
stereoisomers	O
thereof	O
,	O
according	O
to	O
Formula	O
I	O
,	O
pharmaceutical	O
compositions	O
,	O
comprising	O
at	O
least	O
one	O
compound	O
according	O
to	O
Formula	O
I	O
and	O
optionally	O
at	O
least	O
one	O
additional	O
therapeutic	O
agent	O
and	O
methods	O
of	O
treating	O
various	O
diseases	O
,	O
conditions	O
and	O
disorders	O
associated	O
with	O
modulation	O
of	O
serotonin	B
receptors	O
such	O
as	O
,	O
for	O
example	O
:	O
metabolic	O
diseases	O
,	O
which	O
includes	O
but	O
is	O
not	O
limited	O
to	O
obesity	O
,	O
diabetes	O
,	O
diabetic	O
complications	O
,	O
atherosclerosis	O
,	O
impared	O
glucose	B
tolerance	O
and	O
dyslipidemia	O
;	O
central	O
nervous	O
system	O
diseases	O
which	O
includes	O
but	O
is	O
not	O
limited	O
to	O
,	O
anxiety	O
,	O
depression	O
,	O
obsessive	O
compulsive	O
disorder	O
,	O
panic	O
disorder	O
,	O
psychosis	O
,	O
schizophrenia	O
,	O
sleep	O
disorder	O
,	O
sexual	O
disorder	O
and	O
social	O
phobias	O
;	O
cephalic	O
pain	O
;	O
migraine	O
;	O
and	O
gastrointestinal	O
disorders	O
using	O
compounds	O
according	O
to	O
Formula	O
I.	O
Substituted	O
tetrahydro-1H	B
-	I
pyrido	I
[	I
4,3-B	I
]	I
indoles	I
as	O
serotonin	B
receptors	O
agonists	O
and	O
antagonists	O

The	O
invention	O
relates	O
to	O
a	O
buccal	O
preparation	O
containing	O
ampicillin	B
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
usage	O
thereof	O
.	O

The	O
invention	O
aims	O
at	O
providing	O
a	O
buccal	O
preparation	O
taking	O
ampicillin	B
as	O
ingredient	O
,	O
which	O
is	O
dissolved	O
in	O
saliva	O
of	O
oral	O
cavity	O
by	O
sucking	O
to	O
enter	O
the	O
periphery	O
of	O
the	O
oral	O
cavity	O
,	O
the	O
pharyngeal	O
portion	O
and	O
the	O
pharyngeal	O
tonsils	O
part	O
,	O
so	O
as	O
to	O
play	O
the	O
role	O
of	O
antibacterium	O
.	O

The	O
buccal	O
preparation	O
takes	O
the	O
ampicillin	B
and	O
salt	O
ramification	O
thereof	O
as	O
the	O
raw	O
material	O
,	O
and	O
can	O
be	O
made	O
into	O
preparations	O
such	O
as	O
buccal	O
tablet	O
,	O
candy	O
and	O
pill	O
,	O
etc	O
.	O

The	O
buccal	O
preparation	O
has	O
the	O
characteristics	O
of	O
rapid	O
effect	O
,	O
good	O
healing	O
efficacy	O
and	O
convenient	O
administration	O
,	O
etc	O
.	O
,	O
and	O
can	O
directly	O
increase	O
the	O
concentration	O
of	O
bacteriophage	O
drug	O
at	O
the	O
parts	O
of	O
pathological	O
changes	O
,	O
enhances	O
the	O
antibacterial	O
capacity	O
and	O
is	O
more	O
suitable	O
for	O
the	O
patients	O
.	O

Oral	O
preparation	O
containing	O
ampicillin	B
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
drug	O
compound	O
of	O
medicinal	O
salt	O
containing	O
one	O
or	O
the	O
both	O
of	O
ambroxol	B
and	O
benproperine	B
,	O
the	O
application	O
and	O
the	O
application	O
of	O
the	O
drug	O
compound	O
to	O
the	O
preparation	O
of	O
drugs	O
of	O
phlegm	O
eliminating	O
or	O
cough	O
preventing	O
and	O
of	O
phlegm	O
eliminating	O
and	O
cough	O
preventing	O
.	O

The	O
pharmaceutical	O
preparation	O
of	O
the	O
invention	O
containing	O
the	O
active	O
ingredients	O
of	O
ambroxol	B
and	O
benproperine	B
has	O
the	O
characteristics	O
of	O
stable	O
property	O
,	O
convenient	O
use	O
and	O
large	O
-	O
scale	O
production	O
.	O

The	O
pharmaceutical	O
preparation	O
of	O
the	O
invention	O
has	O
obvious	O
synergic	O
effect	O
-	O
enhancing	O
effect	O
particularly	O
on	O
cough	O
preventing	O
and	O
phlegm	O
eliminating	O
in	O
the	O
application	O
of	O
preparing	O
drugs	O
of	O
preventing	O
and	O
curing	O
diseases	O
related	O
to	O
the	O
respiratory	O
tract	O
.	O

Medicament	O
composition	O
containing	O
ambroxol	B
and	O
benproperine	B
,	O
and	O
uses	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
an	O
immunity	O
regulatory	O
agent	O
for	O
cattle	O
,	O
poultry	O
and	O
aquatic	O
livestock	O
,	O
which	O
belongs	O
to	O
the	O
biological	O
agent	O
field	O
.	O

The	O
method	O
for	O
preparing	O
aloe	O
vaccine	O
pulvis	O
and	O
oral	O
liquid	O
is	O
characterized	O
in	O
that	O
the	O
aloe	O
and	O
the	O
sheep	O
gall	O
are	O
taken	O
as	O
raw	O
materials	O
and	O
are	O
mixed	O
according	O
to	O
the	O
mass	O
ratio	O
of	O
10	O
to	O
15	O
:	O
1	O
to	O
2	O
;	O
the	O
aloe	O
vaccine	O
pulvis	O
and	O
the	O
oral	O
liquid	O
can	O
clear	O
away	O
heat	O
and	O
toxic	O
material	O
,	O
cooperate	O
with	O
counteracting	O
toxic	O
substance	O
,	O
reduce	O
fire	O
,	O
clear	O
up	O
endotoxin	O
,	O
antisepsis	O
and	O
anti	O
-	O
inflammation	O
,	O
remove	O
blood	O
stasis	O
and	O
detumescence	O
,	O
expel	O
bile	O
,	O
be	O
beneficial	O
to	O
larynx	O
,	O
inhibit	O
and	O
killing	O
virus	O
,	O
control	O
the	O
state	O
of	O
an	O
illness	O
,	O
avoid	O
accompanying	O
infection	O
,	O
and	O
improve	O
the	O
immunity	O
of	O
the	O
organism	O
on	O
cattle	O
,	O
poultry	O
and	O
aquatic	O
livestock	O
;	O
moreover	O
,	O
the	O
water	O
and	O
drug	O
administration	O
is	O
convenient	O
,	O
the	O
absorption	O
rate	O
is	O
high	O
,	O
the	O
range	O
of	O
distribution	O
is	O
wide	O
,	O
no	O
medicine	O
is	O
left	O
,	O
no	O
side	O
effect	O
exists	O
,	O
and	O
the	O
safe	O
range	O
is	O
wide	O
.	O

The	O
preparation	O
method	O
has	O
simple	O
process	O
and	O
convenient	O
operation	O
,	O
can	O
obtain	O
a	O
product	O
with	O
high	O
concentration	O
and	O
high	O
productive	O
rate	O
and	O
does	O
not	O
pollute	O
the	O
environment	O
.	O

Method	O
of	O
preparing	O
virus	O
bacterium	O
blood	O
serum	O
Chinese	O
aloe	O
vaccine	O
powder	O
preparation	O
and	O
oral	O
liquid	O
for	O
livestock	O
,	O
poultry	O
biology	O
and	O
aquatic	O
animal	O

The	O
present	O
invention	O
provides	O
a	O
single	O
chain	O
fragment	O
antibody	O
-	O
polypeptide	O
fusion	O
protein	O
and	O
applications	O
thereof	O
,	O
the	O
protein	O
is	O
a	O
fusion	O
protein	O
which	O
can	O
be	O
combined	O
with	O
Her2	O
receptors	O
and	O
can	O
carry	O
anti	O
-	O
cancer	O
siRNA	O
drug	O
,	O
and	O
the	O
fusion	O
protein	O
can	O
serve	O
as	O
the	O
vector	O
of	O
the	O
anti	O
-	O
cancer	O
siRNA	O
drug	O
.	O

The	O
single	O
chain	O
fragment	O
antibody	O
is	O
Her2-ScFv	O
,	O
and	O
the	O
polypeptide	O
is	O
nucleoprotamine	O
fragment	O
polypeptide	O
.	O

The	O
sequence	O
of	O
the	O
single	O
chain	O
fragment	O
antibody	O
-	O
polypeptide	O
fusion	O
protein	O
is	O
shown	O
as	O
SEQ	O
ID	O
NO.1	O
.	O

The	O
Her2	O
single	O
chain	O
fragment	O
antibody	O
and	O
the	O
nucleoprotamine	O
polypeptide	O
fusion	O
protein	O
,	O
which	O
are	O
constructed	O
by	O
the	O
present	O
invention	O
,	O
can	O
be	O
combined	O
with	O
Her2	O
receptors	O
and	O
can	O
carry	O
the	O
anti	O
-	O
cancer	O
siRNA	O
drug	O
.	O

The	O
fusion	O
protein	O
of	O
the	O
present	O
invention	O
can	O
directionallyintroduce	O
the	O
anti	O
-	O
cancer	O
siRNA	O
drug	O
into	O
target	O
cancer	O
cells	O
,	O
and	O
a	O
non	O
-	O
viral	O
vector	O
tool	O
is	O
developed	O
to	O
speed	O
up	O
the	O
application	O
of	O
the	O
RNAi	O
technology	O
in	O
clinic	O
.	O

Single	O
-	O
chain	O
fragment	O
antibody	O
-	O
polypeptide	O
amalgamation	O
protein	O
and	O
uses	O
thereof	O

The	O
invention	O
provides	O
a	O
sulfonamide	B
derivative	O
having	O
DP	O
receptor	O
antagonistic	O
activity	O
;	O
and	O
a	O
medicinal	O
composition	O
and	O
a	O
therapeutic	O
agent	O
for	O
allergic	O
diseases	O
which	O
each	O
contains	O
the	O
compound	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
derivative	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
II	O
)	O
:	O
(	O
II	O
)	O
(	O
wherein	O
ring	O
A	O
is	O
an	O
aromatic	O
carbocycle	B
,	O
etc	O
.	O
;	O
ring	O
B	O
is	O
a	O
nitrogenous	O
nonaromatic	O
heterocycle	B
,	O
etc	O
.	O
;	O
ring	O
C	O
is	O
an	O
aromaticcarbocycle	B
,	O
etc	O
.	O
;	O
R<1	O
>	O
is	O
carboxy	B
,	O
etc	O
.	O
;	O
R<2	O
>	O
's	O
each	O
independently	O
is	O
halogeno	B
,	O
etc	O
.	O
;	O
R<3	O
>	O
is	O
optionally	O
substituted	O
alkyloxy	B
,	O
etc	O
.	O
;	O
R<4	O
>	O
's	O
each	O
independently	O
is	O
halogeno	B
,	O
etc	O
.	O
;	O
R<5	O
>	O
's	O
each	O
independently	O
is	O
optionally	O
substituted	O
alkyl	B
,	O
etc	O
.	O
;	O
M	O
is	O
sulfonyl	B
,	O
etc	O
.	O

;	O
Y	O
is	O
a	O
single	O
bond	O
,	O
etc	O
.	O

;	O
L<1	O
>	O
is	O
a	O
single	O
bond	O
,	O
etc	O
.	O
;	O
L<2	O
>	O
is	O
a	O
single	O
bond	O
,	O
etc	O
.	O

;	O
k	O
is	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
or	O
4	O
;	O
n	O
is	O
0	O
,	O
1	O
,	O
or	O
2	O
;	O
and	O
q	O
is	O
0,1	O
,	O
2	O
,	O
or	O
3	O
,	O
provided	O
that	O
,	O
for	O
example	O
,	O
a	O
)	O
when	O
ring	O
B	O
is	O
a	O
6-membered	O
nitrogenous	O
heterocycle	B
containing	O
one	O
or	O
two	O
nitrogen	B
atoms	O
and	O
ring	O
C	O
is	O
a	O
benzene	B
ring	O
,	O
then	O
k	O
is	O
not	O
0	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
or	O
a	O
hydrate	B
of	O
either	O
.	O

Sulfonamide	B
derivative	O
having	O
PGD2	B
receptor	O
antagonistic	O
activity	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
50	O
to	O
99	O
parts	O
by	O
weight	O
of	O
arctiin	B
with	O
the	O
purity	O
of	O
more	O
than	O
90	O
percent	O
or	O
1	O
to	O
50	O
parts	O
by	O
weight	O
of	O
arctigenin	B
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
the	O
functions	O
of	O
the	O
composition	O
are	O
the	O
treatment	O
and	O
the	O
prevention	O
of	O
diabetic	O
retinopathy	O
.	O

In	O
the	O
invention	O
,	O
by	O
extracting	O
the	O
arctiin	B
and	O
the	O
arctigenin	B
,	O
the	O
pharmacological	O
,	O
toxicological	O
and	O
clinical	O
trial	O
results	O
show	O
that	O
the	O
composition	O
of	O
arctiin	B
or	O
arctigenin	B
of	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
strong	O
treatment	O
effect	O
and	O
small	O
toxicity	O
and	O
side	O
effects	O
in	O
the	O
treatment	O
of	O
the	O
diabetic	O
retinopathy	O
.	O

Pharmaceutical	O
composition	O
for	O
curing	O
diabetic	O
retina	O
pathological	O
changes	O
and	O
method	O
of	O
preparing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
released	O
injection	O
comprising	O
astromicin	B
,	O
which	O
comprises	O
a	O
slow	O
-	O
released	O
microsphere	O
and	O
a	O
dissolvent	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
comprises	O
a	O
slow	O
-	O
release	O
adjuvant	O
and	O
the	O
aminoglycoside	B
antibiotic	O
;	O
the	O
dissolvent	O
is	O
the	O
special	O
dissolvent	O
which	O
comprises	O
a	O
suspending	O
agent	O
such	O
as	O
sodium	O
carboxymethylcellulose	O
,	O
etc	O
.	O
,	O
and	O
the	O
viscosity	O
of	O
which	O
is	O
100cp-3000cp	O
(	O
at	O
20	O
DEG	O
C-30	O
DEC	O
C	O
)	O
;	O
the	O
slow	O
-	O
release	O
adjuvant	O
can	O
be	O
selected	O
from	O
EVAc	O
,	O
polifeprosan	O
,	O
PLA	B
,	O
PLGA	B
,	O
sebacic	B
acid	I
copolymer	O
,	O
albumen	O
glue	O
and	O
gelatin	O
,	O
etc	O
.	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
also	O
can	O
be	O
made	O
into	O
a	O
slow	O
-	O
released	O
implant	O
and	O
an	O
ointment	O
.	O

The	O
slow	O
-	O
released	O
implant	O
and	O
the	O
slow	O
-	O
released	O
injection	O
can	O
be	O
partially	O
placed	O
or	O
injected	O
in	O
a	O
bacterial	O
focus	O
to	O
release	O
locally	O
and	O
slowly	O
for	O
more	O
than	O
5	O
-	O
30	O
days	O
,	O
thereby	O
obviously	O
reducing	O
the	O
toxicity	O
of	O
the	O
entire	O
body	O
while	O
getting	O
and	O
maintaining	O
a	O
valid	O
medicine	O
density	O
in	O
the	O
local	O
focus	O
effectively	O
.	O

The	O
slow	O
-	O
released	O
injection	O
comprising	O
the	O
astromicin	B
of	O
the	O
invention	O
has	O
obvious	O
special	O
treatment	O
effect	O
for	O
focus	O
of	O
local	O
infection	O
such	O
as	O
chronic	O
osteomyelitis	O
,	O
severe	O
bedsore	O
,	O
refractory	O
skin	O
ulcer	O
,	O
diabetic	O
foot	O
,	O
osteonecrosis	O
of	O
femoral	O
head	O
and	O
various	O
abscesses	O
,	O
etc	O
.	O
,	O
caused	O
by	O
staphylococcus	O
,	O
streptococcus	O
,	O
peptostreptococcus	O
,	O
propionibacterium	O
acnes	O
,	O
enterobacter	O
,	O
tubercle	O
bacillus	O
,	O
gonococcus	O
and	O
meningococcus	O
,	O
etc	O
.	O

Sustained	O
-	O
release	O
injection	O
containing	O
astromicin	B

The	O
invention	O
discloses	O
a	O
hanfangchin	B
a	I
nanoemulsion	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
containing	O
the	O
hanfangchin	B
a	I
,	O
surfactant	O
,	O
cosurfactant	O
,	O
oil	O
phase	O
and	O
water	O
phase	O
.	O

The	O
nanoemulsion	O
of	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
,	O
transparent	O
appearance	O
,	O
10	O
-	O
100	O
nm	O
of	O
particle	O
diameter	O
and	O
good	O
stability	O
,	O
thereby	O
remarkably	O
improving	O
solubility	O
of	O
the	O
hanfangchin	B
a	I
,	O
so	O
as	O
to	O
improve	O
bioavailability	O
of	O
drugs	O
,	O
and	O
changing	O
intracorporal	O
process	O
of	O
drugs	O
,	O
so	O
as	O
to	O
increase	O
targeting	O
to	O
liver	O
,	O
reduce	O
toxic	O
and	O
side	O
effect	O
and	O
improve	O
treatment	O
effect	O
.	O

Tetrandrine	B
nanoemulsion	O
injection	O
and	O
method	O
of	O
preparing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
a	O
medicine	O
composition	O
containing	O
dimemorfan	B
and	O
a	O
preparation	O
method	O
.	O

The	O
invention	O
is	O
formed	O
by	O
mixing	O
active	O
component	O
and	O
a	O
medicine	O
carrier	O
;	O
wherein	O
,	O
the	O
active	O
component	O
consists	O
of	O
the	O
dimemorfan	B
,	O
Pseudoephedrine	B
Hydrochloride	I
,	O
a	O
non	O
-	O
sterides	O
anti	O
-	O
inflammatory	O
drug	O
and	O
an	O
antihistamine	O
.	O

In	O
the	O
composition	O
,	O
the	O
unit	O
preparation	O
content	O
of	O
the	O
dimemorfan	B
is	O
2	O
to	O
100	O
mg	O
,	O
10	O
to	O
20	O
mg	O
of	O
which	O
is	O
preferentially	O
selected	O
.	O

The	O
composition	O
can	O
be	O
made	O
into	O
various	O
oral	O
preparations	O
,	O
preferentially	O
-	O
selected	O
tablet	O
,	O
capsule	O
,	O
granule	O
,	O
dispersant	O
,	O
chewable	O
tablet	O
,	O
effervescent	O
tablet	O
and	O
the	O
oral	O
liquid	O
preparation	O
.	O

The	O
medicine	O
composition	O
can	O
be	O
used	O
for	O
treating	O
various	O
colds	O
and	O
relieving	O
the	O
symptoms	O
of	O
the	O
colds	O
.	O

Medicament	O
composition	O
containing	O
dimemorfan	B
and	O
method	O
of	O
preparing	O
the	O
same	O

Disclosed	O
is	O
a	O
method	O
to	O
separate	O
and	O
purify	O
cefamandole	B
nafate	I
,	O
which	O
is	O
characterized	O
in	O
that	O
cefamandole	B
nafate	I
is	O
separated	O
and	O
purified	O
for	O
three	O
times	O
through	O
a	O
high	O
-	O
speed	O
countercurrent	O
chromatograph	O
which	O
adopts	O
a	O
solvent	O
system	O
composed	O
of	O
trichloromethane	B
,	O
ethyl	B
acetate	I
,	O
carbinol	B
and	O
water	O
,	O
with	O
the	O
upper	O
phase	O
being	O
stationary	O
and	O
the	O
lower	O
phase	O
being	O
mobile	O
.	O

The	O
cefamandole	B
nafate	I
can	O
be	O
further	O
froze	O
and	O
dried	O
to	O
prepare	O
freeze	O
-	O
dried	O
powder	O
injection	O
.	O

The	O
method	O
greatly	O
increases	O
the	O
purity	O
of	O
the	O
material	O
up	O
to	O
99	O
%	O
,	O
and	O
the	O
purification	O
process	O
causes	O
no	O
pollution	O
;	O
therefore	O
the	O
method	O
is	O
good	O
for	O
industrial	O
continuous	O
production	O
.	O

Separation	O
and	O
purification	O
method	O
of	O
cefamandole	B
nafate	I
and	O
preparation	O
of	O
cefathiamidine	B
freeze	O
-	O
dried	O
injectable	O
powder	O

The	O
invention	O
discloses	O
a	O
method	O
to	O
separate	O
and	O
purify	O
cefminox	B
sodium	I
.	O

Solvent	O
is	O
prepared	O
from	O
trichloromethane	B
,	O
ethyl	B
acetate	I
,	O
carbinol	B
and	O
water	O
,	O
with	O
the	O
upper	O
phase	O
being	O
stationary	O
and	O
the	O
lower	O
phase	O
being	O
mobile	O
.	O

The	O
whole	O
column	O
of	O
a	O
high	O
-	O
speed	O
countercurrent	O
chromatograph	O
is	O
filled	O
with	O
stationary	O
phase	O
solvent	O
and	O
then	O
the	O
mobile	O
phase	O
solvent	O
is	O
pumped	O
into	O
the	O
column	O
;	O
the	O
raw	O
material	O
of	O
cefminox	B
sodium	I
is	O
dissolved	O
in	O
the	O
solvent	O
at	O
the	O
lower	O
phase	O
and	O
the	O
material	O
is	O
fed	O
by	O
an	O
injection	O
valve	O
;	O
above	O
98	O
%	O
of	O
the	O
product	O
is	O
collected	O
according	O
to	O
the	O
map	O
of	O
the	O
detector	O
and	O
thenthe	O
solvent	O
is	O
removed	O
to	O
obtain	O
refined	O
cefminox	B
sodium	I
.	O

The	O
method	O
is	O
good	O
in	O
effect	O
and	O
the	O
product	O
is	O
of	O
high	O
purity	O
.	O

The	O
cefminox	B
sodium	I
can	O
be	O
further	O
froze	O
and	O
dried	O
to	O
prepare	O
freeze	O
-	O
dried	O
powder	O
injection	O
.	O

The	O
method	O
is	O
good	O
in	O
separation	O
effect	O
and	O
the	O
product	O
is	O
of	O
high	O
purity	O
.	O

Separation	O
and	O
purification	O
method	O
of	O
cefminox	B
sodium	I
and	O
preparation	O
of	O
cefminox	B
sodium	I
freeze	O
-	O
dried	O
powder	O
injection	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
D	B
-	I
methionine	I
in	O
preparing	O
drugs	O
for	O
preventing	O
or	O
treating	O
bone	O
marrow	O
suppression	O
induced	O
by	O
radiation	O
and	O
chemical	O
toxicants	O
.	O

The	O
modern	O
pharmacological	O
experiment	O
shows	O
that	O
after	O
being	O
injected	O
with	O
300	O
-	O
1,000	O
mg	O
/	O
Kg	O
D	B
-	I
methionine	I
,	O
a	O
mouse	O
obtains	O
obvious	O
protective	O
effect	O
on	O
bone	O
marrow	O
suppression	O
induced	O
by	O
radiation	O
and	O
chemical	O
toxicants	O
,	O
indicatingthat	O
preventive	O
administration	O
can	O
prevent	O
and	O
treat	O
bone	O
marrow	O
damage	O
induced	O
by	O
the	O
radiation	O
and	O
the	O
chemical	O
toxicants	O
and	O
has	O
inhibitory	O
effect	O
on	O
tumor	O
cell	O
growth	O
.	O

The	O
D	B
-	I
methionine	I
can	O
be	O
mixed	O
with	O
conventional	O
pharmaceutically	O
-	O
acceptable	O
adjuvant	O
and	O
made	O
into	O
various	O
dosage	O
forms	O
.	O

For	O
radiotherapy	O
patients	O
,	O
the	O
addition	O
of	O
a	O
certain	O
amount	O
of	O
D	B
-	I
methionine	I
into	O
nutrient	O
solution	O
brings	O
effects	O
of	O
inhibiting	O
tumor	O
cell	O
growth	O
and	O
protecting	O
hematopoietic	O
cells	O
.	O

Application	O
of	O
clock	O
wise	O
D	B
-	I
methionine	I
in	O
preparing	O
the	O
medicine	O
for	O
preventing	O
and	O
curing	O
the	O
myelosuppression	O
induced	O
by	O
radiation	O

The	O
invention	O
provides	O
a	O
medicine	O
for	O
protecting	O
liver	O
and	O
reducing	O
aminotransferase	O
.	O

The	O
medicine	O
is	O
composed	O
of	O
danshen	O
root	O
and	O
picrorhiza	O
rhizome	O
by	O
extracting	O
with	O
water	O
or	O
alcohol	B
,	O
purifying	O
with	O
macroporous	O
resin	O
column	O
to	O
obtain	O
composition	O
active	O
component	O
,	O
adding	O
pharmaceutically	O
acceptable	O
medicinal	O
adjuvants	O
and	O
making	O
into	O
various	O
preparations	O
in	O
the	O
conventional	O
method	O
.	O

The	O
composition	O
has	O
the	O
effects	O
of	O
protecting	O
liver	O
,	O
reducing	O
aminotransferase	O
,	O
and	O
preventing	O
hepatic	O
fibrosis	O
.	O

Active	O
ingredient	O
composition	O
for	O
protecting	O
liver	O
and	O
its	O
preparation	O
method	O
and	O
application	O

The	O
invention	O
belongs	O
to	O
the	O
medical	O
technology	O
field	O
,	O
particularly	O
relates	O
to	O
cephalosporin	B
derivatives	O
with	O
nitrogen	B
iodonium	I
ion	I
nitrogen	I
heterocyclic	B
ring	O
indicated	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
the	O
ester	O
thereof	O
which	O
is	O
easy	O
to	O
hydrolyze	O
,	O
the	O
salt	O
thereof	O
which	O
is	O
acceptalbe	O
in	O
pharmacy	O
,	O
the	O
isomer	O
thereof	O
,	O
the	O
hydrate	O
thereof	O
and	O
the	O
eater	O
or	O
salt	O
hydrate	O
thereof	O
;	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
and	O
X	O
are	O
defined	O
as	O
the	O
definitions	O
in	O
the	O
description	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
the	O
drug	O
combination	O
containing	O
the	O
compounds	O
,	O
and	O
the	O
application	O
of	O
the	O
compounds	O
in	O
preparing	O
the	O
drugs	O
of	O
curing	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

Cephalosporin	B
derivatives	O
with	O
nitrogen	B
-	I
onium	I
ion	I
azazocyclo	I

The	O
invention	O
provides	O
a	O
method	O
for	O
preparing	O
dendritic	O
cells	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
firstly	O
,	O
immature	O
dendritic	O
cells	O
are	O
cultured	O
under	O
the	O
condition	O
that	O
1x10<-9	O
>	O
to	O
1x10<-3	O
>	O
mol	O
/	O
liter	O
nicotine	B
or	O
nicotine	B
salt	O
exists	O
;	O
secondly	O
,	O
processed	O
dendritic	O
cells	O
are	O
collected	O
.	O

The	O
method	O
also	O
can	O
comprise	O
the	O
following	O
step	O
:	O
between	O
the	O
first	O
step	O
and	O
the	O
second	O
step	O
,	O
the	O
cells	O
processed	O
by	O
the	O
nicotine	B
obtained	O
in	O
the	O
first	O
step	O
are	O
driven	O
to	O
contact	O
tumor	O
antigens	O
.	O

The	O
invention	O
also	O
provides	O
the	O
dendritic	O
cells	O
prepared	O
by	O
the	O
method	O
and	O
a	O
compound	O
thereof	O
,	O
a	O
reagent	O
kit	O
and	O
the	O
use	O
of	O
the	O
dendritic	O
cells	O
.	O

The	O
dendritic	O
cells	O
have	O
reinforced	O
induced	O
immune	O
response	O
ability	O
and	O
can	O
be	O
used	O
for	O
preventing	O
and	O
curing	O
various	O
tumors	O
.	O

Nicotine	B
-	O
processed	O
dendritic	O
cells	O
for	O
preventing	O
and	O
treating	O
tumors	O

The	O
invention	O
relates	O
to	O
glycyrrhizic	B
acid	I
,	O
glycyrrhetinic	B
acid	I
or	O
glycyrrhetate	B
,	O
or	O
derivative	O
thermosensitive	O
gel	O
thereof	O
,	O
including	O
10	O
-	O
40	O
percent	O
of	O
poloxamer	B
,	O
0.1	O
-	O
10	O
percent	O
of	O
carboxymethyl	O
chitosan	O
,	O
0.0001	O
-	O
10	O
percent	O
of	O
the	O
glycyrrhizic	B
acid	I
,	O
the	O
glycyrrhetinic	B
acid	I
,	O
the	O
glycyrrhetate	B
,	O
the	O
glycyrrhetinic	B
acid	I
salt	O
or	O
the	O
derivative	O
of	O
the	O
glycyrrhetinic	B
acid	I
,	O
and	O
40	O
-	O
90.9	O
percent	O
of	O
water	O
.	O

The	O
preparation	O
method	O
is	O
as	O
follows	O
:	O
the	O
poloxamer	B
is	O
stirred	O
evenly	O
by	O
adding	O
water	O
,	O
the	O
carboxymethyl	O
chitosan	O
is	O
added	O
to	O
be	O
stirred	O
evenly	O
as	O
well	O
,	O
after	O
the	O
defoaming	O
,	O
the	O
gel	O
is	O
added	O
into	O
the	O
mixture	O
until	O
scattered	O
and	O
dissolved	O
by	O
stirring	O
,	O
and	O
then	O
the	O
thermosensitive	O
gel	O
can	O
be	O
obtained	O
by	O
high	O
-	O
pressure	O
sterilizing	O
,	O
filling	O
and	O
sealing	O
;	O
the	O
medicine	O
is	O
the	O
glycyrrhizic	B
acid	I
,	O
the	O
glycyrrhetinic	B
acid	I
,	O
the	O
glycyrrhetate	B
and	O
the	O
glycyrrhetinic	B
acid	I
salt	O
or	O
the	O
derivative	O
of	O
the	O
glycyrrhetinic	B
acid	I
thereof	O
.	O

The	O
invention	O
can	O
be	O
used	O
as	O
a	O
mucosa	O
dosage	O
preparation	O
and	O
an	O
injection	O
dosage	O
preparation	O
and	O
can	O
treat	O
inflammatory	O
bowel	O
disease	O
,	O
stomatitis	O
,	O
oral	O
ulcer	O
,	O
ocular	O
inflammation	O
and	O
intracoelomic	O
inflammations	O
.	O

The	O
invention	O
is	O
convenient	O
for	O
clinical	O
application	O
,	O
which	O
can	O
reduce	O
the	O
frequency	O
of	O
drug	O
administration	O
,	O
improve	O
the	O
patient	O
compliance	O
,	O
enhance	O
the	O
effectiveness	O
of	O
treatment	O
and	O
reduce	O
toxicity	O
and	O
side	O
effects	O
.	O

Glycyrrhizic	B
acid	I
,	O
biogastrone	B
acid	I
or	O
its	O
salt	O
,	O
derivative	O
temperature	O
sensing	O
gel	O
rubber	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

A	O
preparation	O
method	O
of	O
ultra	O
-	O
fine	O
danazol	B
powder	O
belongs	O
to	O
the	O
method	O
of	O
drug	O
micronization	O
.	O

The	O
method	O
is	O
that	O
danazol	B
solution	O
and	O
desolvation	O
are	O
first	O
put	O
into	O
a	O
supergravity	O
rotating	O
bed	O
through	O
a	O
solution	O
entrance	O
4	O
and	O
a	O
desolvation	O
entrance	O
5	O
respectively	O
at	O
the	O
same	O
time	O
,	O
and	O
the	O
recrystallized	O
danazol	B
paste	O
by	O
the	O
desolvation	O
flows	O
out	O
from	O
a	O
discharge	O
hole	O
1	O
;	O
the	O
danazol	B
paste	O
is	O
collected	O
,	O
filtered	O
and	O
dried	O
to	O
obtain	O
the	O
ultra	O
-	O
fine	O
danazol	B
powder	O
.	O

The	O
method	O
can	O
obtain	O
the	O
ultra	O
-	O
fine	O
danazol	B
powder	O
of	O
controlled	O
average	O
grain	O
size	O
,	O
controlled	O
shape	O
and	O
narrow	O
grain	O
size	O
distribution	O
.	O

Method	O
of	O
preparing	O
ultra	O
-	O
fine	O
danazol	B
powder	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
ferulic	B
acid	I
polylactic	B
acid	I
-	O
glycolic	B
acid	I
copolymer	O
microspheres	O
,	O
including	O
the	O
following	O
steps	O
:	O
1	O
)	O
the	O
polylactic	B
acid	I
-	I
glycolic	I
acid	I
copolymer	O
PLGA	B
is	O
dissolved	O
in	O
organic	O
solvent	O
,	O
and	O
then	O
the	O
ferulic	B
acid	I
is	O
added	O
for	O
ultrasound	O
dissolution	O
as	O
an	O
organic	O
phase	O
;	O
2	O
)	O
under	O
the	O
condition	O
of	O
stirring	O
,	O
the	O
organic	O
phase	O
is	O
gradually	O
added	O
into	O
polyvinyl	B
alcohol	I
PVA	O
water	O
solution	O
as	O
the	O
aqueous	O
phase	O
,	O
and	O
then	O
electrolyte	O
is	O
added	O
for	O
continuous	O
stirring	O
under	O
room	O
temperature	O
until	O
the	O
organic	O
solvent	O
fully	O
volatilizes	O
,	O
and	O
after	O
centrifugation	O
,	O
washing	O
and	O
freeze	O
-	O
drying	O
,	O
the	O
ferulic	B
acid	I
polylactic	B
acid	I
-	I
glycolic	I
acid	I
copolymer	O
PLGA	B
microspheres	O
can	O
be	O
obtained	O
.	O

The	O
microspheres	O
have	O
round	O
shape	O
and	O
even	O
grain	O
size	O
distribution	O
.	O

The	O
average	O
grain	O
diameter	O
is	O
below	O
10	O
micron	O
,	O
the	O
drug	O
loading	O
is	O
up	O
to	O
12.6	O
percent	O
and	O
the	O
entrapment	O
rate	O
is	O
about	O
75	O
percent	O
.	O

As	O
a	O
drug	O
carrier	O
,	O
the	O
microsphere	O
of	O
the	O
invention	O
has	O
a	O
good	O
biocompatibility	O
.	O

Method	O
for	O
preparing	O
ferulic	B
acid	I
polylactic	B
acid	I
-	O
hydroxide	B
acetic	I
acid	I
copolymer	O
microsphere	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
use	O
of	O
diacetyl	B
-	I
diphenyl	I
-	I
heptane	I
to	O
prevent	O
and	O
cure	O
chronic	O
Bone	O
marrow	O
-	O
derived	O
leukemia	O
.	O

Specifically	O
,	O
the	O
invention	O
relates	O
to	O
the	O
drug	O
use	O
of	O
3	B
,	I
5-diacetyl	I
group-1-	I
(	I
3-	I
methoxyl	I
group-4	I
,	I
5-dihydroxy	I
phenyl	I
)	I
-7-	I
(	I
4-hydroxy-3-	I
methoxyl	I
group	I
phenyl	I
)	I
heptane	I
and	O
the	O
medicinal	O
salt	O
thereof	O
in	O
the	O
preparation	O
of	O
prevention	O
and	O
treatment	O
of	O
chronic	O
Bone	O
marrow	O
-	O
derived	O
leukemia	O
.	O

The	O
compound	O
is	O
extracted	O
mainly	O
from	O
ginger	O
,	O
curcuma	O
wenyujin	O
,	O
zedoary	O
and	O
other	O
zingiberaceae	O
plants	O
.	O

Pharmacological	O
experiments	O
are	O
proved	O
that	O
the	O
compound	O
has	O
potent	O
inhibitory	O
effect	O
on	O
chronic	O
Bone	O
marrow	O
-	O
derived	O
leukemia	O
cell	O
strain	O
(	O
K562	O
)	O
of	O
human	O
and	O
the	O
adriamycin	B
-	O
resistant	O
strain	O
(	O
K562	O
/	O
ADR	O
)	O
proliferatione	O
in	O
vitro	O
thereof	O
,	O
wherein	O
,	O
the	O
value	O
of	O
IC50	O
is	O
34.9	O
plus	O
or	O
minus	O
0.6	O
and	O
50.6	O
plus	O
or	O
minus	O
23.5	O
Mum	O
respectively	O
.	O

Pharmaceutical	O
use	O
of	O
diacetyl	B
diphenyl	I
sulphone	I
heptane	I
in	O
preventing	O
and	O
controlling	O
chronic	O
marrow	O
-	O
derived	O
leukocythemia	O

The	O
invention	O
relates	O
to	O
an	O
externally	O
applied	O
Mongolian	O
drug	O
powder	O
for	O
treating	O
leukoplakia	O
vulvae	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
which	O
pertains	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
the	O
powder	O
is	O
composed	O
of	O
8	O
pure	O
natural	O
high	O
-	O
quality	O
Mongolian	O
medicines	O
,	O
the	O
names	O
and	O
the	O
percentages	O
thereof	O
are	O
as	O
follows	O
:	O
10	O
to	O
20	O
percent	O
Guguri	O
,	O
10	O
to	O
20	O
percent	O
Hulidoushunqiqige	O
,	O
10	O
to	O
20	O
percent	O
Marushe	O
,	O
10	O
to	O
20	O
percent	O
Temuriaoliyanggu	O
,	O
10	O
to	O
20	O
percent	O
Barula	O
,	O
5	O
to	O
10	O
percent	O
Errialatanjiguri	O
,	O
5	O
to	O
10	O
percent	O
Harimaogai	O
and	O
5	O
to	O
10	O
percent	O
Wurileheqiqige	O
.	O

The	O
medicines	O
are	O
respectively	O
selected	O
and	O
weighed	O
according	O
to	O
the	O
percentages	O
,	O
part	O
of	O
the	O
medicines	O
are	O
firstly	O
carried	O
out	O
the	O
concoction	O
and	O
other	O
treatments	O
according	O
to	O
the	O
specific	O
process	O
requirements	O
and	O
then	O
are	O
evenly	O
mixed	O
,	O
smashed	O
or	O
ground	O
,	O
etc	O
.	O

for	O
preparation	O
,	O
thus	O
having	O
various	O
effects	O
of	O
activating	O
blood	O
circulation	O
,	O
removing	O
blood	O
stasis	O
,	O
promoting	O
fluid	O
production	O
,	O
reliving	O
itch	O
,	O
anti	O
-	O
bacterial	O
,	O
anti	O
-	O
inflammatory	O
,	O
reducing	O
pain	O
,	O
detumescence	O
,	O
enhancing	O
skin	O
blood	O
circulation	O
,	O
effectively	O
promoting	O
skin	O
elasticity	O
,	O
etc	O
.	O
,	O
the	O
efficacy	O
is	O
significant	O
,	O
the	O
total	O
effective	O
rate	O
is	O
as	O
high	O
as	O
98.95	O
percent	O
;	O
and	O
the	O
powder	O
is	O
characterized	O
by	O
rapid	O
efficacy	O
,	O
simple	O
and	O
easy	O
production	O
,	O
low	O
cost	O
,	O
convenient	O
carrying	O
and	O
usage	O
,	O
lasting	O
efficacy	O
and	O
no	O
toxicity	O
or	O
side	O
effects	O
,	O
etc	O
.	O

Externally	O
used	O
Mongolian	O
medicine	O
powder	O
preparation	O
for	O
treating	O
leukoplakia	O
vulvae	O
and	O
preparing	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
essential	O
oil	O
for	O
refreshing	O
,	O
awakening	O
brain	O
and	O
eliminating	O
fatigue	O
;	O
lemon	O
oil	O
,	O
resuscitation	O
aroma	O
oil	O
,	O
peppermint	O
oil	O
,	O
musk	B
ketone	I
,	O
jasmine	O
oil	O
and	O
bergamot	O
oil	O
are	O
evenly	O
mixed	O
according	O
to	O
a	O
certain	O
proportion	O
,	O
then	O
borneol	O
is	O
added	O
for	O
intensive	O
mixing	O
,	O
thus	O
preparing	O
the	O
compound	O
essential	O
oil	O
.	O

The	O
compound	O
essential	O
oil	O
of	O
the	O
invention	O
for	O
refreshing	O
,	O
awakening	O
brain	O
and	O
eliminating	O
fatigue	O
can	O
be	O
widely	O
used	O
for	O
the	O
people	O
with	O
excessive	O
anxiety	O
,	O
fatigue	O
,	O
malaise	O
,	O
dizziness	O
,	O
headache	O
,	O
poor	O
spirit	O
and	O
so	O
on	O
.	O

The	O
essential	O
oil	O
can	O
be	O
applied	O
at	O
forehead	O
,	O
eyebrow	O
center	O
,	O
two	O
temporal	O
parts	O
(	O
Taiyang	O
points	O
)	O
and	O
peripheral	O
parts	O
of	O
nostrils	O
and	O
can	O
be	O
used	O
as	O
electric	O
heating	O
incense	O
tablet	O
by	O
paper	O
absorption	O
and	O
packaging	O
;	O
at	O
the	O
same	O
time	O
,	O
the	O
essential	O
oil	O
can	O
also	O
be	O
heated	O
and	O
emitted	O
by	O
an	O
electric	O
heating	O
incense	O
device	O
.	O

Compound	O
essential	O
oil	O
for	O
refreshing	O
oneself	O
,	O
and	O
eliminating	O
fatigue	O

The	O
invention	O
discloses	O
a	O
dispersible	O
gastralgia	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
the	O
invention	O
carries	O
out	O
the	O
technological	O
reform	O
of	O
the	O
formulation	O
based	O
on	O
the	O
existing	O
ordinary	O
tablets	O
,	O
thus	O
overcoming	O
the	O
shortcomings	O
of	O
heavier	O
fishy	O
smell	O
,	O
difficult	O
administration	O
,	O
slow	O
speed	O
of	O
disintegration	O
and	O
slow	O
onset	O
of	O
action	O
of	O
the	O
original	O
formulation	O
,	O
enriching	O
the	O
types	O
of	O
the	O
drugs	O
,	O
improving	O
the	O
quality	O
standards	O
and	O
further	O
meeting	O
and	O
ensuring	O
the	O
demands	O
on	O
the	O
drugs	O
by	O
the	O
people	O
.	O

The	O
drug	O
has	O
the	O
effects	O
of	O
activating	O
qi	O
-	O
flowing	O
,	O
activating	O
blood	O
circulation	O
,	O
inhibiting	O
acid	O
and	O
stopping	O
pain	O
,	O
which	O
is	O
used	O
for	O
gastralgia	O
,	O
acid	O
regurgitation	O
,	O
belching	O
eructation	O
and	O
epigastric	O
distension	O
caused	O
by	O
qi	O
-	O
stagnancy	O
and	O
blood	O
stasis	O
,	O
as	O
well	O
as	O
gastric	O
and	O
duodenal	O
ulcers	O
and	O
chronic	O
gastritis	O
with	O
the	O
symptoms	O
.	O

The	O
efficacy	O
is	O
significant	O
.	O

The	O
usage	O
and	O
carrying	O
are	O
convenient	O
,	O
which	O
is	O
a	O
clinically	O
popular	O
,	O
safe	O
,	O
stable	O
and	O
effective	O
drug	O
and	O
an	O
ideal	O
product	O
for	O
the	O
modern	O
pharmaceutical	O
enterprises	O
.	O

Gastralgia	O
dispersed	O
tablet	O
and	O
preparation	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
having	O
a	O
superior	O
acid	O
secretion	O
inhibitory	O
effect	O
and	O
showing	O
an	O
antiulcer	O
activity	O
and	O
the	O
like	O
.	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R<1	O
>	O
is	O
a	O
nitrogen	B
-	O
containing	O
monocyclic	B
heterocyclic	I
group	O
optionally	O
condensed	O
with	O
a	O
benzene	B
ring	O
or	O
a	O
heterocycle	B
,	O
the	O
nitrogen	B
-	O
containing	O
monocyclic	B
heterocyclic	I
group	O
optionally	O
condensed	O
with	O
a	O
benzene	B
ring	O
or	O
a	O
heterocycle	B
optionally	O
has	O
substituent	O
(	O
s	O
)	O
,	O
R<2	O
>	O
is	O
an	O
optionally	O
substituted	O
C6	B
-	I
14	I
aryl	I
group	O
,	O
an	O
optionally	O
substituted	O
thienyl	B
group	O
or	O
an	O
optionally	O
substituted	O
pyridyl	B
group	O
,	O
R<3	O
>	O
and	O
R<4	O
>	O
are	O
each	O
a	O
hydrogen	B
atom	O
,	O
or	O
one	O
of	O
R<3	O
>	O
and	O
R<4	O
>	O
is	O
a	O
hydrogen	B
atom	O
and	O
the	O
other	O
is	O
an	O
optionally	O
substituted	O
lower	O
alkyl	B
group	O
,	O
an	O
acyl	B
group	O
,	O
a	O
halogen	B
atom	O
,	O
a	O
cyano	B
group	O
or	O
a	O
nitro	B
group	O
,	O
and	O
R<5	O
>	O
is	O
an	O
alkyl	B
group	O
or	O
a	O
salt	O
thereof	O
.	O

1-heterocyclylsulfonyl	B
,	I
2-aminomethyl	I
,	I
5-	I
(	I
hetero-	I
)	I
aryl	I
substituted	I
1-h	I
-	I
pyrrole	I
derivatives	O
as	O
acid	O
secretion	O
inhibitors	O

The	O
invention	O
discloses	O
a	O
compound	O
mequindox	B
soluble	O
powder	O
for	O
animals	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
which	O
aims	O
to	O
provide	O
the	O
compound	O
mequindox	B
soluble	O
powder	O
for	O
the	O
animals	O
and	O
the	O
preparation	O
method	O
,	O
wherein	O
,	O
the	O
compound	O
mequindox	B
soluble	O
powder	O
for	O
the	O
animals	O
can	O
treat	O
the	O
complex	O
infection	O
of	O
shigella	O
shigae	O
and	O
colon	O
bacillus	O
of	O
pigs	O
,	O
is	O
quick	O
to	O
take	O
effect	O
,	O
can	O
solve	O
the	O
treatment	O
failure	O
phenomenon	O
caused	O
by	O
feeding	O
and	O
drinking	O
conditions	O
of	O
the	O
pigs	O
during	O
the	O
illness	O
,	O
and	O
improve	O
the	O
rate	O
of	O
liveweight	O
growth	O
;	O
and	O
the	O
preparation	O
method	O
has	O
a	O
simple	O
process	O
and	O
is	O
easy	O
torealize	O
.	O

The	O
powder	O
comprises	O
the	O
compositions	O
in	O
percentage	O
by	O
weight	O
:	O
2	O
to	O
10	O
percent	O
of	O
mequindox	B
,	O
0.5	O
to	O
5	O
percent	O
of	O
colistin	B
sulfate	I
,	O
6	O
to	O
30	O
percent	O
of	O
sodium	B
salicylate	I
,	O
and	O
the	O
balance	O
beingoral	O
glucose	B
.	O

The	O
soluble	O
powder	O
is	O
a	O
compound	O
preparation	O
formed	O
by	O
a	O
double	O
antimicrobial	O
drug	O
combined	O
with	O
a	O
suspending	O
agent	O
,	O
has	O
quick	O
effect	O
on	O
the	O
complex	O
infection	O
of	O
the	O
shigella	O
shigae	O
andthe	O
colon	O
bacillus	O
of	O
the	O
pigs	O
due	O
to	O
the	O
fact	O
that	O
the	O
mequindox	B
and	O
the	O
colistin	B
sulfate	I
are	O
jointly	O
used	O
,	O
is	O
effective	O
and	O
highly	O
efficient	O
,	O
can	O
solve	O
the	O
treatment	O
failure	O
phenomenon	O
caused	O
by	O
feeding	O
and	O
drinking	O
problems	O
during	O
the	O
illness	O
,	O
accelerate	O
the	O
recovery	O
of	O
the	O
pigs	O
,	O
and	O
increase	O
the	O
weight	O
of	O
the	O
pigs	O
.	O

Compound	O
mequindox	B
soluble	O
powder	O
for	O
animals	O
and	O
preparation	O
thereof	O

The	O
invention	O
provides	O
a	O
clindamycin	B
phosphate	I
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
which	O
is	O
prepared	O
by	O
the	O
steps	O
that	O
:	O
clindamycin	B
phosphate	I
solution	O
is	O
added	O
with	O
NaOH	B
and	O
is	O
freeze	O
-	O
dried	O
,	O
wherein	O
,	O
the	O
weight	O
ratio	O
of	O
clindamycin	B
phosphate	I
to	O
the	O
NaOH	B
is	O
between	O
12	O
and	O
18	O
to	O
1	O
,	O
and	O
the	O
preferred	O
weight	O
ratio	O
is	O
16.5	O
to	O
1	O
.	O

The	O
clindamycin	B
phosphate	I
freeze	O
-	O
dried	O
powder	O
injection	O
has	O
simple	O
formula	O
and	O
less	O
auxiliary	O
materials	O
,	O
overcomes	O
side	O
effects	O
due	O
to	O
the	O
fact	O
that	O
the	O
auxiliary	O
materials	O
are	O
excessively	O
added	O
,	O
and	O
ensures	O
that	O
patients	O
are	O
safer	O
for	O
use	O
.	O

Clindamycin	B
phosphate	I
freeze	O
-	O
dried	O
powder	O
needle	O
and	O
preparation	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
preparation	O
,	O
which	O
is	O
used	O
to	O
treat	O
beriberi	O
infected	O
by	O
mycotic	O
,	O
tinea	O
corporis	O
,	O
tinea	O
cruris	O
and	O
so	O
on	O
.	O

The	O
compound	O
preparation	O
is	O
an	O
achievement	O
of	O
constant	O
trials	O
and	O
summarization	O
of	O
the	O
inventor	O
during	O
a	O
plurality	O
of	O
years	O
of	O
treatment	O
practice	O
.	O

The	O
main	O
compositions	O
of	O
the	O
product	O
are	O
high	O
-	O
concentration	O
vinegar	O
and	O
western	O
medicine	O
ABC	O
tablets	O
.	O

The	O
high	O
-	O
concentration	O
vinegar	O
has	O
the	O
effects	O
of	O
powerful	O
sterilization	O
and	O
disinfection	O
,	O
the	O
ABC	O
tablets	O
have	O
the	O
effects	O
of	O
reducing	O
fever	O
,	O
analgesia	O
and	O
antiphlogosis	O
,	O
and	O
the	O
combined	O
use	O
of	O
the	O
two	O
compositions	O
can	O
effectively	O
and	O
quickly	O
treat	O
various	O
mycotic	O
infection	O
diseases	O
.	O

The	O
product	O
is	O
mainly	O
characterized	O
in	O
that	O
:	O
the	O
product	O
has	O
unique	O
prescription	O
composition	O
,	O
quick	O
treatment	O
,	O
exact	O
healing	O
effect	O
,	O
uneasy	O
recurrence	O
,	O
short	O
treatment	O
course	O
,	O
low	O
treatment	O
cost	O
,	O
and	O
no	O
side	O
effects	O
.	O

Practice	O
proves	O
that	O
the	O
effective	O
rate	O
of	O
the	O
compound	O
preparation	O
on	O
the	O
treatment	O
of	O
the	O
beriberi	O
can	O
reach	O
100	O
percent	O
,	O
and	O
the	O
recurrence	O
rate	O
is	O
not	O
higher	O
than	O
10	O
percent	O
.	O

Compound	O
preparation	O
for	O
treating	O
beriberi	O
and	O
production	O
method	O

The	O
invention	O
provides	O
a	O
sustained	O
-	O
release	O
injection	O
which	O
is	O
an	O
anti	O
-	O
tumor	O
composite	O
containing	O
anti	O
-	O
metabolite	O
drug	O
and	O
bortezomib	B
.	O

The	O
sustained	O
-	O
release	O
injection	O
comprises	O
a	O
sustained	O
-	O
release	O
microsphere	O
and	O
a	O
solution	O
medium	O
,	O
wherein	O
the	O
sustained	O
-	O
release	O
microsphere	O
comprises	O
effective	O
anti	O
-	O
tumor	O
ingredient	O
and	O
sustained	O
-	O
release	O
excipient	O
,	O
the	O
solution	O
medium	O
is	O
a	O
common	O
solution	O
medium	O
or	O
a	O
special	O
solution	O
medium	O
containing	O
a	O
suspending	O
drug	O
.	O

The	O
suspending	O
drug	O
has	O
the	O
viscosity	O
between	O
100cp	O
and	O
3000cp	O
(	O
under	O
twenty	O
centi	O
degrees	O
to	O
thirty	O
centi	O
degrees	O
)	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose	O
and	O
others	O
;	O
the	O
effective	O
anti	O
-	O
tumor	O
ingredient	O
comprises	O
the	O
anti	O
-	O
metabolite	O
drug	O
and/or	O
the	O
combination	O
thereof	O
;	O
the	O
sustained	O
-	O
release	O
excipient	O
is	O
selected	O
from	O
polyphosphonate	B
copolymer	O
like	O
p	B
(	I
LAEG	I
-	I
EOP	I
)	I
or	O
p	B
(	I
DAPG	I
-	I
EOP	I
)	I
,	O
PLA	B
,	O
polyphosphonate	B
with	I
PLA	I
,	O
polifeprosan	B
,	O
copolymer	O
of	O
dual	O
fatty	B
acid	I
and	O
sebacic	B
acid	I
,	O
the	O
polymer	O
or	O
blending	O
polymer	O
of	O
(	O
erucic	B
acid	I
dipolymer	I
-	I
sebacic	I
acid	I
)	O
or	O
poly	B
(	I
boletic	I
acid	I
-	I
sebacic	I
acid	I
)	I
;	O
the	O
anti	O
-	O
tumor	O
composite	O
can	O
also	O
be	O
prepared	O
to	O
be	O
a	O
sustained	O
-	O
release	O
implant	O
which	O
can	O
maintain	O
the	O
effective	O
concentration	O
of	O
drug	O
over	O
forty	O
days	O
for	O
intratumor	O
or	O
tumor	O
circumference	O
injection	O
or	O
placement	O
,	O
can	O
also	O
reduce	O
general	O
reaction	O
obviously	O
and	O
enhance	O
the	O
treatment	O
effect	O
of	O
non	O
-	O
operative	O
therapeutics	O
such	O
as	O
chemotherapy	O
and	O
radiotherapy	O
.	O

Anticancer	O
composition	O
containing	O
antimetabolism	O
medicament	O
and	O
bortezomib	B

The	O
invention	O
adopts	O
a	O
virtual	O
medicine	O
screening	O
technology	O
and	O
a	O
high	O
-	O
throughput	O
screening	O
technology	O
,	O
assesses	O
the	O
AChE	O
inhibitory	O
activity	O
of	O
more	O
than	O
ten	O
thousand	O
samples	O
in	O
a	O
compound	O
sample	O
library	O
and	O
finds	O
a	O
batch	O
of	O
compounds	O
with	O
higher	O
inhibitory	O
activity	O
by	O
establishing	O
a	O
virtual	O
acetylcholinesterase	O
inhibitor	O
screening	O
method	O
and	O
an	O
AChE	O
activity	O
detection	O
method	O
.	O

Then	O
according	O
to	O
the	O
pathological	O
features	O
of	O
senile	O
dementia	O
,	O
the	O
compounds	O
with	O
higher	O
AChE	O
inhibitory	O
activity	O
are	O
subject	O
to	O
butyryl	B
choline	I
esterase	O
inhibitory	O
activity	O
detection	O
.	O

Research	O
results	O
show	O
that	O
bimolecular	O
3-piperidyl	B
-	I
ethyl	I
phenyl	I
ketone	I
not	O
only	O
has	O
comparatively	O
high	O
AChE	O
inhibitory	O
activity	O
,	O
but	O
also	O
has	O
very	O
strong	O
BuChE	O
inhibitory	O
activity	O
;	O
the	O
results	O
of	O
animal	O
experiments	O
prove	O
that	O
the	O
bimolecular	O
3-piperidyl	B
-	I
ethyl	I
phenyl	I
ketone	I
can	O
remarkably	O
improve	O
aphronesia	O
caused	O
by	O
scopolamine	B
and	O
sodium	B
nitrite	I
and	O
can	O
enhance	O
the	O
ability	O
of	O
learning	O
and	O
memory	O
.	O

Compound	O
with	O
dual	O
restraining	O
activities	O
to	O
acetyl	O
cholinesterase	O
and	O
butyryl	O
cholinesterase	O
and	O
use	O
thereof	O

The	O
invention	O
provides	O
an	O
application	O
of	O
microbial	O
source	O
phaffia	O
rhodozyma	O
astaxanthin	B
in	O
preparation	O
of	O
medicines	O
for	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
.	O

Experiments	O
show	O
that	O
the	O
phaffia	O
rhodozyma	O
astaxanthin	B
has	O
good	O
functions	O
of	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
and	O
can	O
be	O
used	O
to	O
prepare	O
the	O
medicines	O
for	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
.	O

In	O
particular	O
,	O
the	O
phaffia	O
rhodozyma	O
astaxanthin	B
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
reducing	O
individual	O
blood	O
sugar	B
of	O
type	O
II	O
diabetes	O
mellitus	O
,	O
or	O
medicines	O
for	O
preventing	O
individual	O
insulin	O
resistance	O
to	O
type	O
II	O
diabetes	O
mellitus	O
.	O

The	O
application	O
has	O
the	O
advantages	O
that	O
:	O
the	O
invention	O
provides	O
an	O
application	O
of	O
microbial	O
source	O
astaxanthin	B
,	O
namely	O
phaffia	O
rhodozyma	O
astaxanthin	B
in	O
the	O
preparation	O
of	O
medicines	O
for	O
preventing	O
and	O
curing	O
type	O
II	O
diabetes	O
mellitus	O
and	O
provides	O
a	O
foundation	O
for	O
development	O
of	O
new	O
drugs	O
.	O

Application	O
of	O
phaffia	O
rhodozyma	O
astaxanthin	B
in	O
preparing	O
medicament	O
for	O
preventing	O
and	O
controlling	O
type	O
II	O
diabetes	O

The	O
invention	O
discloses	O
an	O
ocular	O
medicine	O
composition	O
containing	O
bromfenac	B
sodium	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medicine	O
composition	O
takes	O
hydroxyethyl	O
cellulose	O
as	O
a	O
latent	O
solvent	O
,	O
has	O
a	O
simple	O
preparation	O
technique	O
,	O
is	O
suitable	O
for	O
industrialized	O
production	O
,	O
and	O
is	O
mainly	O
used	O
for	O
treating	O
ocular	O
inflammation	O
caused	O
by	O
prostaglandin	B
and	O
cataracta	O
postoperative	O
ocular	O
inflammation	O
.	O

Medicament	O
composition	O
for	O
eyes	O
containing	O
sodium	B
bromfenac	I

Disclosed	O
is	O
an	O
excellent	O
pharmaceutical	O
product	O
for	O
treatment	O
or	O
prevention	O
of	O
hypertension	O
and	O
the	O
like	O
.	O

Specifically	O
disclosed	O
is	O
a	O
specific	O
acid	O
addition	O
salt	O
of	O
2-amino-1,4-dihydro-6-methyl-4-	B
(	I
3-nitrophenyl	I
)	I
-3,5-pyridinedicarboxylic	I
acid	I
3-	I
(	I
1-diphenylmethylazetidine-3-yl	I
)	I
ester	I
5-isopropyl	I
ester	I
,	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
product	O
for	O
treatment	O
or	O
prevention	O
of	O
hypertension	O
and	O
the	O
like	O
.	O

Acid	O
addition	O
salt	O
of	O
dihydropyridine	B
derivative	O

The	O
invention	O
discloses	O
a	O
candy	O
tobacco	O
which	O
can	O
release	O
the	O
tobacco	O
addiction	O
and	O
refresh	O
,	O
in	O
particular	O
to	O
a	O
medical	O
candy	O
which	O
is	O
prepared	O
by	O
adding	O
nicotine	B
,	O
caffeine	B
and	O
coca	O
extracts	O
with	O
safe	O
content	O
into	O
the	O
sugar	O
sirup	O
solution	O
during	O
the	O
preparation	O
process	O
of	O
the	O
traditional	O
candy	O
.	O

The	O
candy	O
tobacco	O
has	O
the	O
efficacies	O
of	O
releasing	O
the	O
tobacco	O
addiction	O
,	O
refreshing	O
and	O
promoting	O
the	O
excitation	O
as	O
the	O
candy	O
tobacco	O
contains	O
the	O
nicotine	B
,	O
caffeine	B
and	O
coca	O
extracts	O
.	O

When	O
the	O
tobacco	O
addiction	O
comes	O
,	O
the	O
candy	O
tobacco	O
product	O
can	O
be	O
held	O
in	O
the	O
mouth	O
so	O
as	O
to	O
replace	O
the	O
traditional	O
sucking	O
tobaccos	O
,	O
thus	O
releasing	O
the	O
tobacco	O
addiction	O
,	O
refreshing	O
and	O
promoting	O
the	O
excitation	O
and	O
eliminating	O
the	O
harm	O
of	O
the	O
tobacco	O
smoke	O
on	O
the	O
environment	O
air	O
quality	O
and	O
the	O
human	O
body	O
;	O
therefore	O
,	O
the	O
candy	O
tobacco	O
of	O
the	O
invention	O
is	O
a	O
harmless	O
substitute	O
for	O
traditional	O
tobaccos	O
,	O
which	O
is	O
worthy	O
of	O
generalizing	O
,	O
thereby	O
having	O
wide	O
market	O
prospect	O
.	O

Candy	O
cigarette	O
capable	O
of	O
relieving	O
a	O
craving	O
for	O
tobacco	O
and	O
refreshing	O
oneself	O

The	O
present	O
invention	O
relates	O
to	O
compound	O
glycyrrhizin	B
type	O
powder	O
injection	O
and	O
the	O
preparation	O
method	O
thereof	O
,	O
in	O
particular	O
to	O
compound	O
glycyrrhizin	B
for	O
injection	O
,	O
compound	O
glycyrrhizic	B
acid	I
mono	I
-	I
ammonium	I
S	O
powder	O
injection	O
and	O
the	O
preparation	O
method	O
thereof	O
,	O
which	O
are	O
characterized	O
in	O
that	O
the	O
powder	O
injection	O
consisting	O
of	O
glycyrrhizin	B
(	O
or	O
mono	B
-	I
ammonium	I
glycyrrhizinate	I
)	O
,	O
glycine	B
and	O
cysteine	B
hydrochloride	I
that	O
are	O
taken	O
as	O
the	O
active	O
ingredient	O
and	O
the	O
bearer	O
acceptable	O
in	O
medicine	O
and	O
the	O
preparation	O
method	O
are	O
included	O
in	O
the	O
prescription	O
;	O
wherein	O
,	O
the	O
bearer	O
acceptable	O
in	O
medicine	O
contains	O
dextran	O
.	O

The	O
compound	O
glycyrrhizin	B
type	O
powder	O
injection	O
of	O
the	O
present	O
invention	O
can	O
be	O
preserved	O
at	O
room	O
temperature	O
,	O
thus	O
remarkably	O
improving	O
the	O
stability	O
of	O
the	O
medicine	O
,	O
better	O
guaranteeing	O
safety	O
and	O
significance	O
of	O
the	O
medicine	O
and	O
effectively	O
decreasing	O
the	O
storage	O
and	O
transportation	O
cost	O
in	O
production	O
and	O
transportation	O
processes	O
of	O
the	O
medicine	O
.	O

Powder	O
injection	O
of	O
compound	O
glycyrrhizic	B
acid	I
glycosides	I
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
an	O
external	O
sticking	O
medicine	O
for	O
the	O
constipation	O
,	O
which	O
is	O
characterized	O
in	O
that	O
angelica	O
,	O
rhubarb	O
,	O
mulberry	O
,	O
coptis	O
root	O
and	O
morning	O
glory	O
seed	O
are	O
used	O
for	O
extracting	O
concentrated	O
solution	O
;	O
the	O
concentrated	O
solution	O
is	O
made	O
into	O
extract	O
which	O
is	O
mixed	O
with	O
camphor	B
,	O
borneol	B
and	O
menthol	B
uniformly	O
and	O
then	O
is	O
mixed	O
with	O
matrix	O
glue	O
to	O
be	O
coated	O
.	O

Externally	O
used	O
plaster	O
medicine	O
for	O
constipation	O

The	O
present	O
invention	O
relates	O
to	O
a	O
kidney	O
reinforcing	O
plaster	O
.	O

The	O
present	O
invention	O
is	O
characterized	O
by	O
extracting	O
concentrated	O
solution	O
from	O
cistanche	O
,	O
truestar	O
anisetree	O
,	O
prepared	O
rehmannia	O
rhizome	O
,	O
malaytea	O
scurfpea	O
fruit	O
,	O
common	O
cnidum	O
fruit	O
,	O
bidentate	O
achyranthes	O
,	O
himalayan	O
teasel	O
root	O
,	O
common	O
fenugreek	O
seed	O
,	O
liquorice	O
,	O
cortex	O
eucommiae	O
,	O
dodder	O
seed	O
,	O
plantain	O
seed	O
,	O
aconite	O
root	O
,	O
Chinese	O
magnoliavine	O
fruit	O
,	O
tokay	O
and	O
clove	O
;	O
preparing	O
extract	O
powder	O
to	O
be	O
mixed	O
with	O
camphor	B
,	O
borneol	B
and	O
menthol	B
;	O
then	O
mixing	O
with	O
matrigel	O
and	O
coating	O
,	O
thus	O
obtaining	O
the	O
kidney	O
reinforcing	O
plaster	O
.	O

Kidney	O
tonifying	O
plaster	O
medicine	O

The	O
invention	O
belongs	O
to	O
the	O
medicine	O
technical	O
field	O
,	O
in	O
particular	O
to	O
a	O
compound	O
Ainsliaidimer	B
A	I
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
compound	O
Ainsliaidimer	B
A	I
is	O
obtained	O
through	O
extracting	O
and	O
separating	O
Ainsliaiea	O
macrocephala	O
,	O
and	O
is	O
a	O
colorless	O
prismatic	O
crystal	O
with	O
a	O
molecular	O
formula	O
C30H34O7	B
.	O

Experiments	O
show	O
that	O
the	O
compound	O
has	O
obvious	O
functions	O
in	O
inhibiting	O
tumor	O
and	O
inflammations	O
,	O
so	O
the	O
compound	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
tumor	O
drugs	O
and	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

Dimeric	O
ainsliaea	O
terpene	B
A	O
,	O
preparation	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
compound	O
emodin	B
medicine	O
for	O
treating	O
mastitis	O
.	O

The	O
medicine	O
comprises	O
the	O
pharmaceutical	O
components	O
with	O
the	O
following	O
parts	O
by	O
weight	O
such	O
as	O
emodin	B
,	O
alkannin	B
and	O
eucalyptus	O
oil	O
.	O

The	O
compound	O
emodin	O
can	O
be	O
soluble	O
in	O
oleaginous	O
matrix	O
(	O
such	O
as	O
bean	O
oil	O
)	O
to	O
be	O
made	O
into	O
an	O
oil	O
suspension	O
.	O

The	O
compound	O
emodin	B
of	O
the	O
invention	O
contains	O
no	O
antibiotic	O
component	O
,	O
better	O
solves	O
the	O
problems	O
of	O
antibiotic	O
residue	O
in	O
dairy	O
food	O
and	O
milk	O
discard	O
in	O
the	O
withdrawal	O
period	O
,	O
and	O
greatly	O
reduces	O
the	O
loss	O
in	O
the	O
treatment	O
process	O
of	O
clinical	O
mastitis	O
and	O
improves	O
the	O
economic	O
benefit	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
compound	O
emodin	B
reduces	O
the	O
use	O
of	O
the	O
antibiotic	O
in	O
dairy	O
cow	O
,	O
improves	O
the	O
quality	O
of	O
the	O
dairy	O
food	O
,	O
is	O
favorable	O
for	O
the	O
production	O
of	O
milk	O
without	O
antibiotic	O
and	O
the	O
health	O
of	O
customers	O
and	O
is	O
beneficial	O
to	O
improving	O
the	O
competitive	O
power	O
of	O
the	O
dairy	O
food	O
of	O
our	O
country	O
.	O

Medicament	O
for	O
treating	O
mammitis	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
synthesizing	O
a	O
novel	O
triazolone	B
and	O
a	O
triadimenol	B
compound	O
,	O
namely	O
,	O
benzene	B
or	O
substituted	O
benzene	B
is	O
used	O
as	O
a	O
raw	O
material	O
and	O
subjected	O
to	O
Friedel	O
-	O
Crafts	O
acylation	O
,	O
Tolyltriazole	B
alkylation	O
and	O
halogenous	O
-	O
benzylation	O
to	O
obtain	O
the	O
novel	O
triazolone	B
compound	O
;	O
then	O
carbonyl	B
reduction	O
is	O
carried	O
out	O
to	O
obtain	O
the	O
novel	O
triadimenol	B
compound	O
.	O

The	O
invention	O
also	O
relates	O
to	O
medical	O
and	O
pesticide	O
applications	O
of	O
the	O
novel	O
triazolone	B
and	O
triadimenol	B
compounds	O
.	O

Triadimefon	B
and	O
triadimenol	B
compounds	O
having	O
antimicrobial	O
activity	O
,	O
salts	O
,	O
synthetic	O
methods	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
a	O
novel	O
phosphine	B
transition	B
metal	I
complex	O
exhibiting	O
excellent	O
antitumor	O
activity	O
while	O
having	O
few	O
side	O
effects	O
.	O

Specifically	O
disclosed	O
is	O
a	O
novel	O
phosphine	B
transition	B
metal	I
complex	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
.	O

In	O
the	O
formula	O
,	O
A	O
represents	O
an	O
alkylene	B
group	O
,	O
a	O
phenylene	B
group	O
or	O
a	O
cis	B
-	I
vinylene	I
group	O
;	O
M	O
represents	O
a	O
gold	B
,	O
silver	B
,	O
copper	B
or	O
platinum	B
atom	O
;	O
B1	O
and	O
B2	O
respectively	O
represent	O
a	O
heterocyclic	B
group	O
which	O
may	O
have	O
a	O
substituent	O
containing	O
a	O
trivalent	B
phosphorus	I
atom	O
which	O
can	O
be	O
covalently	O
bonded	O
to	O
A	O
and	O
coordinately	O
bonded	O
to	O
M	O
;	O
and	O
C	O
represents	O
an	O
anion	O
atom	O
.	O

Phosphine	B
transition	B
metal	I
complex	O
,	O
method	O
for	O
producing	O
same	O
and	O
antitumor	O
agent	O
containing	O
same	O

The	O
invention	O
discloses	O
an	O
instant	O
bendazac	B
lysine	I
eye	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
the	O
invention	O
,	O
1000ml	O
of	O
the	O
instant	O
bendazac	B
lysine	I
eye	O
gel	O
contains	O
1	O
g	O
to	O
2	O
g	O
of	O
bendazac	B
lysine	I
,	O
0.05	O
g	O
to	O
1	O
g	O
of	O
preservative	O
,	O
1.0	O
g	O
to	O
7.5	O
g	O
of	O
osmotic	O
pressure	O
adjusting	O
agent	O
,	O
and	O
30	O
g	O
to	O
150	O
g	O
of	O
gel	O
stroma	O
,	O
and	O
the	O
rest	O
includes	O
acid	O
-	O
alkali	O
buffer	O
and	O
water	O
for	O
injection	O
.	O

The	O
invention	O
,	O
through	O
the	O
optimization	O
of	O
accessories	O
and	O
the	O
improvement	O
of	O
the	O
technique	O
,	O
enriches	O
the	O
pharmaceutical	O
dosage	O
form	O
of	O
the	O
bendazac	B
lysine	I
,	O
greatly	O
prolongs	O
the	O
time	O
for	O
which	O
the	O
medicine	O
stays	O
in	O
the	O
eyes	O
,	O
and	O
not	O
only	O
improves	O
the	O
curative	O
effect	O
but	O
also	O
can	O
reduce	O
the	O
times	O
for	O
which	O
the	O
medicine	O
is	O
dropped	O
into	O
the	O
eyes	O
.	O

Bendazac	B
lysine	I
in	O
situ	O
forming	O
eye	O
gel	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
Liaoyuan	O
Qili	O
ultrafine	O
powder	O
,	O
comprising	O
the	O
main	O
steps	O
of	O
coarse	O
crushing	O
,	O
ultrafine	O
crushing	O
,	O
mixing	O
,	O
surface	O
modifying	O
,	O
sub	O
-	O
packaging	O
,	O
bactericidal	O
finishing	O
and	O
so	O
on	O
.	O

The	O
Liaoyuan	O
Qili	O
ultrafine	O
power	O
with	O
the	O
power	O
grain	O
size	O
that	O
D90	O
is	O
less	O
than	O
or	O
equal	O
to	O
12	O
Mu	O
m	O
is	O
made	O
.	O

The	O
Liaoyuan	O
Qili	O
ultrafine	O
power	O
made	O
by	O
the	O
method	O
is	O
evenly	O
dispersed	O
with	O
small	O
power	O
grain	O
size	O
.	O

The	O
in	O
vitro	O
dissolution	O
of	O
the	O
power	O
can	O
be	O
obviously	O
increased	O
,	O
which	O
is	O
in	O
favorable	O
for	O
the	O
realization	O
of	O
the	O
purpose	O
of	O
rapid	O
efficacy	O
in	O
the	O
body	O
and	O
can	O
enhance	O
the	O
curative	O
effect	O
of	O
the	O
medicine	O
.	O

Method	O
for	O
preparing	O
Liaoyuanqili	O
ultramicro	O
powder	O

The	O
invention	O
relates	O
to	O
a	O
low	O
molecular	O
rhamnose	B
sulfuric	I
ester	I
,	O
which	O
is	O
characterized	O
in	O
that	O
:	O
the	O
low	O
molecular	O
rhamnose	B
sulfuric	I
ester	I
is	O
a	O
linear	O
molecule	O
which	O
is	O
connected	O
by	O
alpha-1	O
,	O
3	O
glycosidic	O
bonds	O
of	O
an	O
L	B
-	I
rhamnose	I
group	O
,	O
wherein	O
,	O
a	O
sulfuric	B
ester	I
group	O
is	O
positioned	O
on	O
a	O
C-2	O
position	O
and/or	O
a	O
C-4	O
position	O
of	O
the	O
L	B
-	I
rhamnose	I
group	O
;	O
the	O
substitution	O
value	O
of	O
the	O
sulfuric	B
ester	I
group	O
in	O
the	O
low	O
molecular	O
rhamnose	B
sulfuric	I
ester	I
is	O
between	O
0.4	O
and	O
2	O
;	O
and	O
the	O
molecular	O
weight	O
is	O
between	O
3,000	O
and	O
100,000	O
daltons	O
.	O

Under	O
the	O
condition	O
of	O
preparation	O
,	O
the	O
rhamnose	B
sulfuric	I
ester	I
is	O
prepared	O
into	O
hydrosol	O
;	O
the	O
hydrosol	O
is	O
added	O
with	O
acid	O
or	O
an	O
oxidant	O
,	O
undergoes	O
heating	O
reaction	O
and	O
cooling	O
reaction	O
,	O
and	O
is	O
added	O
with	O
alkali	O
for	O
neutralization	O
or	O
added	O
with	O
an	O
enzyme	O
for	O
reaction	O
termination	O
,	O
and	O
a	O
clear	O
solution	O
is	O
separated	O
,	O
concentrated	O
and	O
desalinated	O
;	O
the	O
desalinated	O
clear	O
solution	O
is	O
concentrated	O
and	O
separated	O
by	O
an	O
ultrafiltration	O
membrane	O
or	O
a	O
gel	O
chromatographic	O
column	O
;	O
and	O
the	O
collected	O
solution	O
is	O
desalinated	O
,	O
concentrated	O
,	O
dried	O
and	O
crushed	O
.	O

The	O
product	O
of	O
the	O
low	O
molecular	O
rhamnose	B
sulfuric	I
ester	I
has	O
good	O
ticoagulant	O
activity	O
and	O
antithrombotic	O
activity	O
,	O
and	O
is	O
hopeful	O
to	O
become	O
a	O
novel	O
anticoagulant	O
or	O
antithrombotic	O
reagent	O
.	O

Low	O
molecular	O
rhamnosan	B
sulfate	I
,	O
preparation	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
discloses	O
a	O
medicine	O
for	O
preventing	O
and	O
treating	O
diarrhea	O
of	O
pigs	O
,	O
which	O
contains	O
vitriol	O
neomycin	B
,	O
sodium	B
bicarbonate	I
/	O
zein	O
powder	O
,	O
lactic	B
ethyl	I
ester	I
and	O
acetic	B
acid	I
.	O

The	O
medicine	O
can	O
promote	O
piglet	O
feeding	O
and	O
improve	O
self	O
immunity	O
,	O
which	O
is	O
convenient	O
for	O
use	O
.	O

Medicine	O
for	O
preventing	O
and	O
curing	O
porcine	O
diarrhea	O

The	O
present	O
invention	O
discloses	O
a	O
sodium	O
hyaluronate	O
in	O
situ	O
forming	O
eye	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

1000ml	O
sodium	O
hyaluronate	O
forming	O
eye	O
gel	O
provided	O
by	O
the	O
present	O
invention	O
contains	O
1	O
to	O
5	O
g	O
of	O
sodium	O
hyaluronate	O
,	O
0.05	O
to	O
1	O
g	O
of	O
antiseptic	O
,	O
1.0	O
to	O
7.5	O
g	O
of	O
osmotic	O
pressure	O
regulating	O
agent	O
and	O
30	O
to	O
150	O
g	O
of	O
gel	O
matrix	O
and	O
the	O
rest	O
is	O
acid	O
-	O
base	O
buffering	O
agent	O
and	O
injection	O
water	O
.	O

By	O
the	O
optimization	O
of	O
auxiliary	O
materials	O
and	O
the	O
process	O
improvement	O
,	O
the	O
eye	O
gel	O
of	O
the	O
present	O
invention	O
enriches	O
the	O
medicinal	O
dosage	O
of	O
sodium	O
hyaluronate	O
,	O
greatly	O
prolongs	O
the	O
staying	O
time	O
of	O
medicine	O
in	O
the	O
eye	O
and	O
improves	O
the	O
curing	O
effect	O
without	O
any	O
adverse	O
stimulation	O
.	O

Sodium	O
hyaluronate	O
in	O
-	O
situ	O
-	O
forming	O
eye	O
gel	O

The	O
present	O
invention	O
concerns	O
combination	O
of	O
an	O
amount	O
of	O
a	O
GPRl	O
19	O
agonist	O
with	O
an	O
amount	O
of	O
a	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPP	O
-	O
IV	O
)	O
inhibitor	O
such	O
that	O
the	O
combination	O
provides	O
an	O
effect	O
in	O
lowering	O
a	O
blood	O
glucose	O
level	O
or	O
in	O
increasing	O
a	O
blood	O
GLP	O
-	O
I	O
level	O
in	O
a	O
subject	O
over	O
that	O
provided	O
by	O
the	O
amount	O
of	O
the	O
GPRl	O
19	O
agonist	O
or	O
the	O
amount	O
of	O
the	O
DPP	O
-	O
FV	O
inhibitor	O
alone	O
and	O
the	O
use	O
of	O
such	O
a	O
combination	O
for	O
treating	O
or	O
preventing	O
diabetes	O
and	O
conditions	O
related	O
thereto	O
or	O
conditions	O
ameliorated	O
by	O
increasing	O
a	O
blood	O
GLP	O
-	O
I	O
level	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
G	O
protein	O
-	O
coupledreceptor	O
to	O
screen	O
for	O
GLP	O
-	O
I	O
secretagogues	O
.	O

Combination	O
therapy	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
conditions	O
related	O
thereto	O
and	O
for	O
the	O
treatment	O
of	O
conditions	O
ameliorated	O
by	O
increasing	O
blood	O
glp-1	O
level	O

The	O
invention	O
relates	O
to	O
a	O
stable	O
p	B
-	I
toluhydroquinone	I
liquid	O
composition	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
an	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
gastrointestinal	O
diseases	O
in	O
animals	O
,	O
and	O
a	O
study	O
concerning	O
growth	O
promotion	O
effect	O
thereof	O
on	O
animals	O
.	O

The	O
long	O
-	O
term	O
stability	O
of	O
p	B
-	I
toluhydroquinone	I
during	O
storage	O
process	O
can	O
be	O
conducted	O
by	O
introducing	O
a	O
new	O
group	O
in	O
the	O
methyl	O
group	O
position	O
of	O
p	B
-	I
toluhydroquinone	I
to	O
inhibit	O
the	O
interchange	O
reaction	O
of	O
hydroxyl	B
group	O
of	O
phenolic	B
hydroxyl	I
group	O
and	O
ketone	B
group	O
.	O

Preparation	O
method	O
and	O
use	O
of	O
stable	O
o	B
-	I
methylhydroquione	I

An	O
anticancer	O
sustained	O
-	O
released	O
injection	O
containing	O
taxane	B
comprises	O
sustained	O
-	O
released	O
microspheres	O
and	O
a	O
solvent	O
.	O

The	O
sustained	O
-	O
released	O
microspheres	O
comprise	O
an	O
anticancer	O
effective	O
ingredient	O
and	O
a	O
sustained	O
-	O
released	O
adjuvant	O
,	O
and	O
the	O
solvent	O
is	O
a	O
common	O
solvent	O
or	O
a	O
special	O
solvent	O
containing	O
a	O
suspending	O
agent	O
.	O

The	O
anticancer	O
effective	O
ingredient	O
is	O
taxane	B
and/or	O
taxane	B
synergist	O
;	O
the	O
taxane	B
synergist	O
is	O
selected	O
from	O
an	O
antitumor	O
antibiotic	O
,	O
an	O
anti	O
-	O
metabolism	O
drug	O
and/or	O
a	O
plant	O
alkaloid	O
;	O
the	O
sustained	O
-	O
released	O
adjuvant	O
is	O
selected	O
from	O
poly	B
(	I
lactic	I
acid	I
)	I
,	O
polyactic	B
acid	I
-	I
polyglycolic	I
acid	I
copolymer	O
,	O
ethylene	B
-	I
vinyl	I
acetate	I
copolymer	O
,	O
polifeprosan	O
,	O
difatty	B
acid	I
and	O
sebacic	B
acid	I
copolymer	O
,	O
etc	O
.	O
;	O
and	O
the	O
suspending	O
agent	O
has	O
a	O
viscosity	O
of	O
100	O
-	O
3,000cp	O
(	O
20	O
-	O
30	O
DEG	O
C	O
)	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
Tween	O
80	O
,	O
etc	O
.	O

The	O
sustained	O
-	O
released	O
microspheres	O
can	O
also	O
be	O
made	O
into	O
a	O
sustained	O
-	O
released	O
implant	O
,	O
which	O
can	O
sustain	O
effective	O
drug	O
concentration	O
by	O
intratumoral	O
or	O
peritumoral	O
injection	O
or	O
placement	O
,	O
and	O
can	O
distinctly	O
reduce	O
the	O
systemic	O
toxic	O
reaction	O
of	O
drug	O
and	O
selectively	O
enhance	O
the	O
curative	O
effect	O
of	O
non	O
-	O
operative	O
treatments	O
such	O
as	O
chemotherapy	O
and	O
radiotherapy	O
.	O

Anticancer	O
sustained	O
-	O
released	O
injection	O
containing	O
taxane	B

A	O
compound	O
sustained	O
-	O
released	O
injection	O
containing	O
an	O
angiogenesis	O
inhibitor	O
marimastat	O
comprises	O
sustained	O
-	O
released	O
microspheres	O
and	O
a	O
solvent	O
.	O

The	O
sustained	O
-	O
released	O
microspheres	O
comprise	O
a	O
sustained	O
-	O
released	O
adjuvant	O
,	O
an	O
angiogenesis	O
inhibitor	O
selected	O
from	O
marimastat	B
and	O
fumagillin	B
,	O
and	O
a	O
cell	O
toxicant	O
selected	O
from	O
hydroxycamptothecin	B
,	O
mitozolomide	B
,	O
4-carboxy	B
temozolomide	I
,	O
docetaxel	B
,	O
oxaliplatin	B
,	O
sunplatinum	B
,	O
iphosphamide	B
,	O
lomustine	B
,	O
estramustine	B
,	O
fotemustine	B
,	O
semustine	B
,	O
etoposide	B
,	O
teniposide	B
,	O
vinblastine	B
,	O
anastrozole	B
,	O
fluorouracil	B
and	O
mitomycin	B
c	I
;	O
and	O
the	O
solvent	O
is	O
a	O
common	O
solvent	O
or	O
a	O
special	O
solvent	O
containing	O
a	O
suspending	O
agent	O
.	O

The	O
sustained	O
-	O
released	O
adjuvant	O
is	O
selected	O
from	O
polifeprosan	B
,	O
poly	B
(	I
lactic	I
acid	I
)	I
,	O
sebacic	B
acid	I
polymer	O
such	O
as	O
poly	B
(	I
erucic	I
acid	I
dimmer	I
-	I
sebacic	I
acid	I
)	I
and	O
poly	B
(	I
fumaric	I
acid	I
-	I
sebacic	I
acid	I
)	I
,	O
EVAc	O
,	O
etc	O
.	O
;	O
and	O
the	O
suspending	O
agent	O
has	O
a	O
viscosity	O
of	O
100	O
-	O
3,000cp	O
(	O
20	O
-	O
30	O
DEG	O
C	O
)	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
etc	O
.	O

The	O
sustained	O
-	O
released	O
microspheres	O
can	O
also	O
be	O
made	O
into	O
a	O
sustained	O
-	O
released	O
implant	O
,	O
which	O
can	O
enhance	O
the	O
curative	O
effect	O
of	O
non	O
-	O
operative	O
treatments	O
such	O
as	O
chemotherapy	O
and	O
radiotherapy	O
by	O
intratumoral	O
or	O
peritumoral	O
injection	O
or	O
placement	O
.	O

Compound	O
sustained	O
-	O
released	O
injection	O
containing	O
marimastat	B
as	O
neovascularization	O
inhibitor	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
tea	O
polyphenols	B
or	O
a	O
solvate	O
thereof	O
in	O
preparing	O
medicaments	O
for	O
treating	O
human	O
colon	O
tumor	O
and	O
rectal	O
tumor	O
,	O
particularly	O
MSH2	O
gene	O
-	O
deleted	O
human	O
colon	O
tumor	O
and	O
rectal	O
tumor	O
.	O

The	O
tea	O
polyphenols	B
can	O
be	O
mixed	O
with	O
an	O
excipient	O
,	O
a	O
diluent	O
or	O
a	O
carrier	O
and	O
made	O
into	O
tablets	O
;	O
or	O
made	O
into	O
medicaments	O
or	O
solutions	O
with	O
oral	O
,	O
intramuscular	O
or	O
intravenous	O
administration	O
.	O

Use	O
of	O
tea	O
polyphenol	B

The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
chemistry	O
filed	O
,	O
and	O
particularly	O
relates	O
to	O
novel	O
nitric	B
oxide	I
donor	O
butyl	B
phthalide	I
derivatives	O
(	O
I	O
)	O
,	O
the	O
preparation	O
method	O
thereof	O
,	O
a	O
drug	O
preparation	O
containing	O
the	O
derivatives	O
(	O
I	O
)	O
and	O
the	O
application	O
as	O
a	O
drug	O
for	O
resisting	O
thrombosis	O
and	O
cerebral	O
ischemia	O
.	O

Wherein	O
,	O
the	O
definitions	O
of	O
R	O
and	O
A	O
are	O
shown	O
in	O
the	O
instruction	O
.	O

Nitric	B
oxide	I
donor	O
type	O
3-butylphthalide	B
derivates	O
,	O
method	O
for	O
preparing	O
same	O
and	O
pharmaceutical	O
use	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
particularly	O
relates	O
to	O
a	O
composition	O
containing	O
loxoprofen	B
sodium	I
,	O
and	O
more	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
a	O
loxoprofen	B
sodium	I
matrix	O
tablet	O
.	O

The	O
loxoprofen	B
sodium	I
matrix	O
tablet	O
is	O
composed	O
of	O
loxoprofen	B
sodium	I
of	O
an	O
active	O
component	O
,	O
hydroxypropyl	O
methylcellulose	O
(	O
HPMC	O
)	O
,	O
ethyl	O
cellulose	O
(	O
EC	O
)	O
and	O
acrylics	O
of	O
polymer	O
materials	O
and	O
filling	O
agents	O
.	O

The	O
loxoprofen	B
sodium	I
matrix	O
tablet	O
of	O
the	O
invention	O
has	O
longer	O
action	O
time	O
than	O
a	O
common	O
tablet	O
and	O
reduces	O
the	O
side	O
effects	O
.	O

The	O
invention	O
has	O
simple	O
operation	O
process	O
,	O
low	O
cost	O
and	O
easy	O
control	O
and	O
is	O
suitable	O
for	O
industry	O
large	O
scale	O
production	O
.	O

Loxoprofen	B
sodium	I
framework	O
tablet	O

The	O
invention	O
discloses	O
a	O
compound	O
topical	O
preparation	O
of	O
fitbamzone	B
dyclonine	I
used	O
for	O
curing	O
viral	O
skin	O
diseases	O
,	O
such	O
as	O
herpes	O
zoster	O
,	O
etc	O
.	O

The	O
topical	O
preparation	O
of	O
fitbamzone	B
dyclonine	I
complex	O
prescription	O
consists	O
of	O
following	O
components	O
by	O
percentage	O
composition	O
:	O
(	O
1	O
)	O
0.1	O
to	O
10	O
weight	O
percent	O
of	O
the	O
fitbamzone	B
,	O
(	O
2	O
)	O
0.1	O
to	O
10	O
weight	O
percent	O
of	O
the	O
dyclonine	B
,	O
and	O
(	O
3	O
)	O
excipient	O
acceptable	O
to	O
pharmacy	O
.	O

The	O
compound	O
topical	O
preparation	O
used	O
for	O
curing	O
the	O
herpes	O
zoster	O
can	O
stop	O
pain	O
,	O
immediately	O
relieve	O
the	O
suffering	O
of	O
a	O
patient	O
to	O
the	O
maximum	O
,	O
improve	O
the	O
life	O
quality	O
of	O
the	O
patient	O
and	O
contribute	O
to	O
improve	O
the	O
clinical	O
compliance	O
of	O
the	O
patient	O
based	O
on	O
ensuring	O
the	O
curative	O
effect	O
of	O
anti	O
-	O
virus	O
and	O
achieving	O
the	O
purpose	O
of	O
treatment	O
.	O

The	O
compound	O
topical	O
preparation	O
has	O
the	O
advantages	O
of	O
having	O
an	O
evident	O
curative	O
effect	O
on	O
the	O
herpes	O
zoster	O
,	O
a	O
good	O
analgesic	O
effect	O
,	O
stable	O
preparation	O
performance	O
,	O
controllable	O
quality	O
,	O
a	O
good	O
curative	O
effect	O
,	O
and	O
nonirritant	O
to	O
skin	O
without	O
causing	O
allergic	O
reaction	O
.	O

Phthiobuzonum	B
/	O
diclothane	B
compound	O
topical	O
formulation	O

The	O
present	O
invention	O
discloses	O
a	O
medicinal	O
compound	O
for	O
curing	O
dysentery	O
,	O
which	O
contains	O
the	O
components	O
with	O
the	O
following	O
weight	O
portions	O
:	O
1.2	O
to	O
2.4	O
portions	O
of	O
lincomycin	B
and	O
0.12	O
to	O
0.24	O
portions	O
of	O
micronomicin	B
.	O

In	O
use	O
,	O
lincomycin	B
and	O
micronomicin	B
are	O
mixed	O
with	O
glucose	B
water	O
or	O
salt	O
water	O
and	O
0.005	O
to	O
0.01	O
weight	O
portions	O
of	O
dexamethasone	B
is	O
added	O
into	O
the	O
compound	O
.	O

When	O
the	O
patient	O
has	O
serious	O
abdominal	O
pain	O
,	O
0.005	O
to	O
0.01	O
weight	O
portions	O
of	O
muriatic	O
racemic	O
antisodamine	O
alkali	O
is	O
added	O
into	O
the	O
compound	O
.	O

The	O
present	O
invention	O
with	O
the	O
matched	O
use	O
of	O
lincomycin	B
and	O
micronomicin	B
has	O
treated	O
nearly	O
100	O
cases	O
of	O
patients	O
and	O
obtains	O
excellent	O
curing	O
effect	O
.	O

Even	O
for	O
severe	O
cases	O
,	O
the	O
recovery	O
is	O
made	O
by	O
only	O
twice	O
transfusion	O
,	O
thus	O
greatly	O
reducing	O
the	O
pain	O
of	O
the	O
patient	O
and	O
saving	O
the	O
medical	O
expense	O
of	O
the	O
patient	O
.	O

Medicament	O
composition	O
for	O
treating	O
dysentery	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
cefquinome	B
sulfate	I
injection	O
and	O
a	O
preparation	O
process	O
thereof	O
.	O

The	O
cefquinome	B
sulfate	I
injection	O
consists	O
of	O
cefquinome	B
sulfate	I
micro	O
-	O
powder	O
which	O
contains	O
not	O
less	O
than	O
50	O
-	O
300	O
g	O
of	O
cefquinome	B
,	O
0.4	O
-	O
40	O
g	O
of	O
antioxidant	O
and	O
a	O
fat	O
or	O
ester	O
organic	O
solvent	O
which	O
is	O
added	O
to	O
be	O
10,000ml	O
.	O

The	O
preparation	O
process	O
is	O
as	O
follows	O
:	O
the	O
antioxidant	O
is	O
dissolved	O
into	O
the	O
fat	O
or	O
ester	O
organic	O
solvent	O
,	O
the	O
mixture	O
is	O
filtrated	O
into	O
a	O
mixing	O
tank	O
,	O
added	O
with	O
the	O
cefquinome	B
sulfate	I
micro	O
-	O
powder	O
,	O
stirred	O
evenly	O
and	O
milled	O
through	O
a	O
colloid	O
mill	O
,	O
thus	O
even	O
suspension	O
is	O
made	O
,	O
and	O
then	O
the	O
suspension	O
is	O
stirred	O
,	O
separately	O
filled	O
and	O
sterilized	O
.	O

The	O
cefquinome	B
sulfate	I
injection	O
and	O
the	O
preparation	O
process	O
solve	O
the	O
problem	O
of	O
no	O
domestic	O
fourth	O
generation	O
cefamandole	B
antibiotic	O
which	O
is	O
special	O
for	O
animals	O
existing	O
in	O
the	O
prior	O
art	O
.	O

The	O
product	O
prepared	O
has	O
wider	O
antimicrobial	O
spectrum	O
,	O
stronger	O
antibacterial	O
activity	O
and	O
more	O
stable	O
Beta	O
-	O
lactamase	O
for	O
bacteria	O
compared	O
with	O
the	O
third	O
generation	O
cephalosporin	B
,	O
fills	O
up	O
the	O
gap	O
of	O
no	O
domestic	O
fourth	O
generation	O
cefamandole	B
antibiotic	O
preparation	O
which	O
is	O
special	O
for	O
animals	O
,	O
and	O
the	O
whole	O
preparation	O
process	O
is	O
simple	O
and	O
practicable	O
.	O

Cefquinome	B
sulfate	I
injection	O
and	O
process	O
for	O
producing	O
the	O
same	O

The	O
invention	O
provides	O
a	O
medicine	O
composition	O
including	O
astragalus	O
polysaccharides	O
and	O
ginseng	O
rhizome	O
saponin	B
and	O
the	O
usage	O
thereof	O
.	O

The	O
medicine	O
composition	O
is	O
characterized	O
in	O
that	O
the	O
weight	O
proportion	O
of	O
astragalus	O
polysaccharides	O
and	O
ginseng	O
rhizome	O
saponin	B
is	O
0.01	O
to	O
200:1	O
.	O

The	O
invention	O
also	O
provides	O
the	O
application	O
of	O
the	O
medicine	O
composition	O
in	O
preparing	O
antineoplastic	O
drugs	O
,	O
strengthening	O
the	O
curing	O
effect	O
of	O
radiotherapy	O
and	O
chemotherapy	O
,	O
decreasing	O
the	O
toxicity	O
and	O
side	O
effect	O
of	O
radiotherapy	O
and	O
chemotherapy	O
and	O
improving	O
the	O
immunity	O
.	O

Medicament	O
composition	O
containing	O
astragalus	O
polysaccharide	O
and	O
ginseng	O
bud	O
saponin	B
and	O
uses	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
medicine	O
for	O
curing	O
chronic	O
renal	O
failure	O
and	O
a	O
production	O
method	O
thereof	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
medicine	O
is	O
calcium	B
-	O
base	O
samoite	O
excluding	O
K+	B
,	O
Na+	B
,	O
Mg2	B
+	I
and	O
other	O
exchangeable	O
cations	O
.	O

The	O
preparation	O
method	O
includes	O
immersing	O
the	O
samoite	O
in	O
calcium	B
chloride	I
solution	O
and	O
then	O
exchanging	O
ions	O
.	O

After	O
oral	O
administration	O
,	O
toxins	O
in	O
the	O
alimentary	O
tract	O
of	O
patients	O
with	O
chronic	O
renal	O
failure	O
is	O
absorbed	O
by	O
samoite	O
of	O
the	O
medicine	O
and	O
then	O
discharged	O
out	O
of	O
the	O
body	O
along	O
with	O
intestinal	O
peristalsis	O
,	O
thus	O
achieving	O
intestinal	O
hemodialysis	O
.	O

While	O
absorbing	O
and	O
fixing	O
the	O
toxins	O
in	O
the	O
alimentary	O
tract	O
,	O
the	O
calcium	B
-	O
base	O
samoite	O
has	O
no	O
side	O
effect	O
on	O
patients	O
of	O
Na	B
and	O
K	B
restriction	O
without	O
releasing	O
K+	B
,	O
Na+	B
,	O
Mg2	B
+	I
and	O
other	O
exchangeable	O
cations	O
.	O

Medicament	O
for	O
treating	O
chronic	O
renal	O
failure	O
and	O
production	O
method	O

The	O
invention	O
discloses	O
a	O
compound	O
of	O
2-aryl-6-aryl'-glucoside	B
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
compound	O
having	O
the	O
following	O
structural	O
formula	O
is	O
used	O
for	O
preparation	O
of	O
a	O
small	O
-	O
molecular	O
inhibitor	O
/	O
anti	O
-	O
neoplasm	O
drug	O
belonging	O
to	O
the	O
bcl-2	O
protein	O
family	O
.	O

The	O
preparation	O
method	O
of	O
the	O
compound	O
comprises	O
the	O
following	O
steps	O
that	O
:	O
1	O
)	O
an	O
epoxidation	O
of	O
2-	B
iodoglucose-1,6-inner	I
ether	I
is	O
carried	O
out	O
;	O
2	O
)	O
a	O
ring	O
opening	O
reaction	O
of	O
a	O
compound	O
obtained	O
from	O
the	O
epoxidation	O
and	O
a	O
phenol	B
is	O
carried	O
out	O
under	O
alkali	O
condition	O
;	O
3	O
)	O
the	O
product	O
of	O
the	O
ring	O
opening	O
reaction	O
undergoes	O
benzyl	B
protection	O
,	O
and	O
then	O
a	O
ring	O
opening	O
reaction	O
of	O
1,6-inner	O
ether	O
is	O
carried	O
out	O
;	O
4	O
)	O
the	O
product	O
obtained	O
from	O
the	O
ring	O
opening	O
reaction	O
of	O
step	O
3	O
)	O
undergoes	O
benzyl	B
protection	O
and	O
then	O
undergoes	O
a	O
substitution	O
reaction	O
with	O
a	O
phenol	B
or	O
an	O
alcohol	B
under	O
alkali	O
condition	O
;	O
and	O
5	O
)	O
the	O
product	O
obtained	O
from	O
the	O
substitution	O
undergoes	O
Pd	B
/	O
C	B
deoxidization	O
to	O
eliminate	O
the	O
benzyl	B
protecting	O
group	O
to	O
obtain	O
the	O
compound	O
of	O
2-aryl-6-aryl'-glucoside	B
.	O

2-aryl-6-arylí»-glucoside	B
compound	O
,	O
and	O
preparation	O
and	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
compound	O
of	O
starfish	O
saponin	B
having	O
a	O
molecular	O
formula	O
of	O
C57H93O28SNa	B
,	O
and	O
a	O
chemical	O
name	O
of	O
sodium	B
(	I
20R,22R23S,24S	I
)	I
-6Alpha	I
-	I
O-	I
{	I
Beta	I
-	I
D	I
-	I
fucopyranosyl-	I
(	I
1,2	I
)	I
-Alpha	I
-	I
L	I
-	I
arabinopyranosyl-	I
(	I
1,4	I
)	I
-	I
[	I
Beta	I
-	I
D	I
-	I
quinovopyranosyl-	I
(	I
1,2	I
)	I
]	I
-Beta	I
-	I
D	I
-	I
qinovopyranosyl-	I
(	I
1	I
,	I
3	I
)	I
-Beta	I
-	I
D	I
-	I
glucopyranosyl	I
}	I
-22,23-epoxy-20-hydroxy-24-methyl-5Alpha	I
-	I
cholest-9	I
(	I
11	I
)	I
-en-3Beta	I
-	I
yl	I
-	I
sulfate	I
,	O
hereafter	O
referred	O
to	O
as	O
EHMC	O
.	O

The	O
compound	O
is	O
an	O
anti	O
-	O
tumor	O
monomer	O
extracted	O
from	O
starfish	O
,	O
as	O
the	O
biological	O
bread	O
in	O
the	O
sea	O
,	O
and	O
is	O
characterized	O
in	O
the	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
drugs	O
against	O
colloid	O
tumors	O
.	O

Anti	O
-	O
tumor	O
researches	O
in	O
vitro	O
imply	O
that	O
the	O
compound	O
has	O
significant	O
inhibiting	O
effects	O
on	O
glioma	O
of	O
C6	O
rat	O
as	O
well	O
as	O
four	O
human	O
gliomas	O
including	O
U87MG	O
,	O
U251MG	O
,	O
BT325	O
and	O
SHG44	O
,	O
without	O
any	O
influence	O
on	O
growth	O
of	O
cultured	O
primitive	O
human	O
neuroglial	O
cells	O
.	O

The	O
compound	O
is	O
expected	O
to	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
drugs	O
against	O
gliomas	O
.	O

Use	O
of	O
starfish	O
saponin	B
compound	O
extracted	O
from	O
Culcita	O
novaeguineae	O

The	O
invention	O
discloses	O
a	O
bedsore	O
plaster	O
which	O
is	O
prepared	O
from	O
the	O
following	O
bulk	O
drugs	O
in	O
part	O
by	O
weight	O
:	O
5	O
to	O
15	O
parts	O
of	O
dried	O
rehmannia	O
root	O
,	O
5	O
to	O
15	O
parts	O
of	O
achyranthes	O
root	O
,	O
10	O
to	O
20	O
parts	O
of	O
angelica	O
,	O
5	O
to	O
20	O
parts	O
of	O
corydalis	O
tuber	O
,	O
5	O
to	O
15	O
parts	O
of	O
frankincense	O
,	O
2	O
to	O
10	O
parts	O
of	O
safflower	O
,	O
5	O
to	O
20	O
parts	O
of	O
scutellaria	O
root	O
,	O
5	O
to	O
20	O
parts	O
of	O
corktree	O
bark	O
,	O
5	O
to	O
20	O
parts	O
of	O
atractylodes	O
rhizome	O
,	O
1	O
to	O
5	O
parts	O
of	O
dragons	O
blood	O
,	O
0.5	O
to	O
5	O
parts	O
of	O
borneol	O
,	O
1	O
to	O
15	O
parts	O
of	O
notoginseng	O
,	O
0.1	O
to	O
2	O
parts	O
of	O
Qingfen	O
,	O
100	O
to	O
150	O
parts	O
of	O
beeswax	O
,	O
and	O
800	O
to	O
1500	O
parts	O
of	O
sesame	O
oil	O
.	O

The	O
production	O
method	O
of	O
the	O
bedsore	O
plaster	O
comprises	O
the	O
steps	O
:	O
materials	O
are	O
selected	O
,	O
purified	O
and	O
processed	O
,	O
and	O
the	O
sesame	O
oil	O
is	O
heated	O
for	O
20	O
to	O
30	O
minutes	O
;	O
the	O
dried	O
rehmannia	O
root	O
,	O
the	O
achyranthes	O
root	O
,	O
the	O
angelica	O
,	O
the	O
corydalis	O
tuber	O
,	O
the	O
frankincense	O
,	O
the	O
safflower	O
,	O
the	O
scutellaria	O
root	O
,	O
the	O
corktree	O
bark	O
and	O
the	O
atractylodes	O
rhizome	O
are	O
put	O
into	O
a	O
container	O
and	O
heated	O
for	O
20	O
to	O
30	O
minutes	O
,	O
purified	O
and	O
filtered	O
to	O
obtain	O
filtrate	O
;	O
the	O
beeswax	O
and	O
the	O
notoginseng	O
powder	O
are	O
added	O
into	O
the	O
filtrate	O
when	O
the	O
filtrate	O
is	O
cooled	O
down	O
to	O
a	O
temperature	O
ranging	O
from	O
120	O
to	O
180	O
DEG	O
C	O
;	O
the	O
borneol	B
,	O
the	O
dragons	O
blood	O
and	O
Qingfen	O
are	O
added	O
to	O
the	O
filtrate	O
when	O
the	O
temperature	O
of	O
the	O
filtrate	O
drops	O
to	O
70	O
to	O
90	O
DEG	O
C	O
;	O
after	O
materials	O
are	O
dissolved	O
,	O
the	O
solution	O
is	O
hermetically	O
sealed	O
,	O
cooled	O
and	O
caned	O
to	O
obtain	O
the	O
bedsore	O
plaster	O
of	O
the	O
invention	O
.	O

The	O
bedsore	O
paste	O
has	O
the	O
advantage	O
of	O
good	O
curative	O
effect	O
,	O
the	O
effective	O
rate	O
is	O
up	O
to	O
96	O
percent	O
and	O
the	O
curative	O
ratio	O
is	O
up	O
to	O
98	O
percent	O
.	O

Bedsore	O
plaster	O
and	O
method	O
for	O
producing	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
following	O
formula	O
useful	O
as	O
inhibitors	O
of	O
voltage	O
-	O
gate	O
sodium	B
channels	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
.	O

Quinazolines	B
useful	O
as	O
modulators	O
of	O
voltage	O
gated	O
ion	O
channels	O

The	O
invention	O
provides	O
an	O
external	O
medicine	O
used	O
for	O
treating	O
parotitis	O
,	O
which	O
is	O
made	O
of	O
the	O
following	O
bulk	O
drugs	O
by	O
weight	O
portions	O
:	O
20	O
-	O
40	O
portions	O
of	O
Chinese	O
rhubarb	O
,	O
60	O
-	O
80	O
portions	O
of	O
mirabilite	O
and	O
20	O
-	O
40	O
portions	O
of	O
climbing	O
groundsel	O
.	O

The	O
bulk	O
drugs	O
are	O
taken	O
out	O
in	O
proportion	O
and	O
crushed	O
into	O
40	O
-	O
500	O
mesh	O
fine	O
powder	O
,	O
and	O
the	O
powder	O
is	O
evenly	O
mixed	O
and	O
then	O
filled	O
in	O
cloth	O
bags	O
.	O

The	O
medicine	O
has	O
efficacies	O
of	O
clearing	O
away	O
pathogenic	O
heat	O
and	O
removing	O
the	O
toxin	O
,	O
dispelling	O
wind	O
and	O
reducing	O
the	O
stagnation	O
,	O
softening	O
hard	O
masses	O
,	O
subduing	O
swelling	O
and	O
relieving	O
pain	O
.	O

The	O
medicine	O
is	O
mainly	O
used	O
for	O
treating	O
the	O
parotitis	O
and	O
can	O
effectively	O
relieve	O
symptoms	O
of	O
chill	O
,	O
fever	O
,	O
sore	O
swellings	O
on	O
cheek	O
,	O
high	O
fever	O
,	O
shortness	O
of	O
breath	O
and	O
eating	O
difficulty	O
caused	O
by	O
the	O
parotitis	O
.	O

External	O
medicine	O
for	O
treating	O
parotiditis	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
for	O
rosemary	B
acid	I
ferrous	I
and	O
rosemary	B
acid	I
magnesium	I
and	O
the	O
antibacterial	O
activity	O
application	O
thereof	O
.	O

Rosemary	O
acid	O
and	O
FeCl2.4H2O	B
or	O
MgCl2	B
solution	O
are	O
mixed	O
fully	O
according	O
to	O
equimolar	O
proportion	O
,	O
and	O
are	O
combined	O
to	O
form	O
rosemary	B
acid	I
ferrous	I
solution	O
or	O
rosemary	B
acid	I
magnesium	I
solution	O
under	O
the	O
acidic	O
condition	O
that	O
the	O
pH	O
value	O
is	O
4.5	O
to	O
5.8	O
;	O
rosemary	B
acid	I
ferrous	I
or	O
rosemary	B
acid	I
magnesium	I
are	O
obtained	O
after	O
decompressed	O
concentration	O
,	O
crystallization	O
,	O
filter	O
and	O
drying	O
in	O
vacuum	O
.	O

Rosemary	B
acid	I
ferrous	I
or	O
rosemary	B
acid	I
magnesium	I
has	O
stronger	O
antibacterial	O
activity	O
than	O
single	O
rosemary	O
acid	O
,	O
and	O
has	O
wide	O
application	O
in	O
the	O
fields	O
of	O
medicine	O
,	O
food	O
,	O
cosmetic	O
,	O
etc	O
.	O

Method	O
for	O
preparing	O
ferrous	B
rosmarinci	I
acid	I
and	O
magnesian	B
rosmarinci	I
acid	I
and	O
antibacterial	O
activity	O
application	O
thereof	O

An	O
application	O
of	O
a	O
polystyrene	B
-	O
poly	B
(	I
styrene	I
-	I
alternative	I
-	I
sodium	I
maleate	I
)	I
relates	O
to	O
a	O
polymer	O
,	O
in	O
particular	O
to	O
a	O
diblock	O
polymer	O
polystyrene	B
-	O
poly	B
(	I
styrene	I
-	I
alternative	I
-	I
sodium	I
maleate	I
)	I
which	O
is	O
used	O
as	O
a	O
microbicide	O
for	O
inhibiting	O
infection	O
of	O
AIDS	O
virus	O
(	O
HIV-1	O
)	O
in	O
reproductive	O
systems	O
,	O
or	O
used	O
as	O
a	O
contraceptive	O
medicine	O
for	O
external	O
use	O
.	O

The	O
application	O
of	O
the	O
polystyrene	B
-	O
poly	B
(	I
styrene	I
-	I
alternative	I
-	I
sodium	I
maleate	I
)	I
is	O
provided	O
.	O

The	O
polystyrene	B
-	O
poly	B
(	I
styrene	I
-	I
alternative	I
-	I
sodium	I
maleate	I
)	I
is	O
used	O
as	O
a	O
microbicide	O
for	O
anti	O
-	O
AIDS	O
virus	O
infection	O
.	O

The	O
polystyrene	B
-	O
poly	B
(	I
styrene	I
-	I
alternative	I
-	I
sodium	I
maleate	I
)	I
can	O
also	O
be	O
used	O
as	O
a	O
contraceptive	O
medicine	O
for	O
external	O
use	O
for	O
inhibiting	O
sperms	O
from	O
impregnation	O
.	O

Use	O
of	O
polystyrol	B
-	O
poly	B
(	I
styrene	I
-	I
alternate	I
-	I
sodium	I
maleate	I
)	I

The	O
invention	O
relates	O
to	O
a	O
skin	O
preparation	O
for	O
external	O
application	O
,	O
which	O
has	O
remarkable	O
efficacies	O
of	O
being	O
anti	O
-	O
inflammatory	O
,	O
relieving	O
itching	O
and	O
sterilizing	O
,	O
and	O
can	O
serve	O
as	O
a	O
treating	O
medicine	O
and	O
/or	O
be	O
used	O
in	O
different	O
forms	O
or	O
different	O
purposes	O
of	O
serving	O
as	O
a	O
disinfector	O
,	O
health	O
article	O
,	O
and	O
the	O
like	O
,	O
for	O
assisting	O
in	O
treatment	O
.	O

The	O
skin	O
preparation	O
aims	O
at	O
solving	O
the	O
technical	O
problem	O
of	O
causing	O
active	O
ingredients	O
to	O
be	O
evenly	O
spread	O
in	O
accessorial	O
added	O
ingredients	O
.	O

The	O
main	O
improvement	O
of	O
the	O
skin	O
preparation	O
for	O
external	O
application	O
is	O
that	O
at	O
least	O
one	O
of	O
borneol	B
and	O
menthol	B
is	O
added	O
in	O
an	O
accessory	O
system	O
in	O
a	O
liquid	O
form	O
and	O
other	O
active	O
ingredients	O
are	O
added	O
in	O
the	O
accessory	O
system	O
in	O
a	O
powder	O
form	O
for	O
preparing	O
.	O

After	O
improvement	O
,	O
the	O
skin	O
preparation	O
for	O
externalapplication	O
is	O
easier	O
to	O
be	O
spread	O
evenly	O
,	O
also	O
reduces	O
material	O
loss	O
caused	O
by	O
grinding	O
and	O
simultaneously	O
improves	O
the	O
percutaneous	O
performance	O
of	O
drugs	O
.	O

Skin	O
external	O
preparation	O
with	O
anti	O
-	O
inflammation	O
,	O
itching	O
-	O
relieving	O
and	O
disinfection	O
and	O
sterilization	O
function	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
treating	O
dysmenorrheal	O
,	O
which	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
according	O
to	O
weight	O
part	O
:	O
7	O
parts	O
to	O
9	O
parts	O
of	O
dry	O
products	O
of	O
China	O
rose	O
,	O
45	O
parts	O
to	O
55	O
parts	O
of	O
brown	O
sugar	O
and	O
10	O
parts	O
to	O
20	O
parts	O
of	O
ginger	O
.	O

The	O
drug	O
has	O
the	O
advantages	O
of	O
good	O
curative	O
effects	O
,	O
quick	O
operating	O
,	O
simple	O
preparation	O
,	O
convenient	O
taking	O
,	O
no	O
toxicity	O
or	O
side	O
effects	O
,	O
convenience	O
for	O
drawing	O
materials	O
and	O
low	O
cost	O
,	O
and	O
is	O
mainly	O
used	O
for	O
treating	O
functional	O
dysmenorrheal	O
.	O

Medicine	O
for	O
curing	O
the	O
dysmenorrhea	O

The	O
invention	O
relates	O
to	O
a	O
derivative	O
of	O
4-	B
(	I
4-benzoyl	I
amino	I
-	I
phenoxy	I
)	I
-2-	I
(	I
methyl	I
ammonia	I
formyl	I
)	I
pyridine	I
and	O
a	O
preparation	O
method	O
and	O
purposes	O
thereof	O
,	O
belonging	O
to	O
the	O
chemical	O
medicine	O
field	O
.	O

The	O
structure	O
of	O
the	O
derivative	O
is	O
shown	O
as	O
Formula	O
I	O
:	O
R1	O
is	O
hydrogen	B
,	O
halogenated	B
base	I
,	O
trifluoromethyl	B
,	O
nitro	B
,	O
alkoxy	B
,	O
dimethoxy	B
or	O
amino	B
;	O
R2	O
is	O
hydrogen	B
,	O
halogenated	B
base	I
,	O
trifluoromethyl	B
,	O
nitro	B
,	O
alkoxy	B
,	O
dimethoxy	B
or	O
amino	B
;	O
R3	O
is	O
hydrogen	B
,	O
halogenated	B
base	I
,	O
trifluoromethyl	B
,	O
nitro	B
,	O
alkoxy	B
,	O
dimethoxy	B
or	O
amino	B
.	O

The	O
derivative	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
tumor	O
medicines	O
.	O

4-	B
(	I
4-benzamido	I
phenoxy	I
)	I
-2-	I
(	I
methylcarbamoyl	I
)	I
pyridine	I
derivatives	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
hydrotalcite	B
doxifluridine	I
sustained	O
release	O
agent	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
which	O
belong	O
to	O
the	O
technical	O
field	O
of	O
hydrotalcite	O
materials	O
.	O

The	O
formula	O
of	O
the	O
hydrotalcite	O
doxifluridine	O
sustained	O
release	O
agent	O
is	O
(	O
M<2+>	O
)	O
1-x	O
(	O
N<3+>	O
)	O
x	O
(	O
OH	O
)	O
2	O
(	O
5dFUR<->	O
)	O
a	O
(	O
B	O
<	O
n->	O
)	O
bN	O
(	O
OH	O
)	O
3.mH2O	O
.	O

The	O
hydrotalcite	O
doxifluridine	B
sustained	O
release	O
agent	O
is	O
a	O
medicine	O
-	O
hydrotalcite	O
composite	O
material	O
;	O
the	O
mass	O
percent	O
of	O
doxifluridine	B
in	O
the	O
sustained	O
release	O
agent	O
is	O
between	O
29.72	O
and	O
38.85	O
percent	O
and	O
the	O
mass	O
percent	O
of	O
water	O
in	O
the	O
sustained	O
release	O
agent	O
is	O
between	O
4	O
and	O
11	O
percent	O
;	O
and	O
the	O
lasting	O
period	O
of	O
sustained	O
release	O
is	O
between	O
0.1	O
and	O
15	O
hours	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
carbonate	B
hydrotalcite	I
is	O
prepared	O
by	O
the	O
coprecipitation	O
method	O
at	O
first	O
and	O
then	O
is	O
sintered	O
into	O
composite	O
oxide	O
LDO	O
;	O
and	O
the	O
composite	O
oxide	O
LDO	O
is	O
mixed	O
with	O
a	O
doxifluridine	B
solution	O
and	O
doxifluridine	B
intercalative	O
hydrotalcite	O
with	O
the	O
sustained	O
release	O
performance	O
is	O
obtained	O
by	O
the	O
restoring	O
method	O
to	O
assemble	O
the	O
doxifluridine	B
between	O
hydrotalcite	O
layers	O
.	O

The	O
hydrotalcite	O
doxifluridine	B
sustained	O
release	O
agent	O
and	O
the	O
preparation	O
method	O
have	O
the	O
advantages	O
of	O
reinforcing	O
the	O
stability	O
,	O
improving	O
the	O
bioavailability	O
,	O
avoiding	O
direct	O
contact	O
of	O
the	O
doxifluridine	B
and	O
a	O
gastrointestinal	O
tract	O
and	O
reducing	O
the	O
stimulary	O
function	O
of	O
the	O
doxifluridine	B
on	O
the	O
gastrointestinal	O
tract	O
.	O

Hydrotalcite	B
doxifluridine	I
slow	O
release	O
formulation	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
formanilide	B
substituted	I
sulfhydryl	I
pyrrolidine	I
carbapenems	I
compound	O
as	O
shown	O
in	O
Formula	O
(	O
I	O
)	O
,	O
easily	O
hydrolyzed	O
ester	O
thereof	O
,	O
acceptable	O
non	O
-	O
toxicity	O
salt	O
thereof	O
in	O
pharmacy	O
,	O
isomer	O
thereof	O
,	O
hydrate	O
thereof	O
,	O
and	O
hydrate	O
of	O
ester	O
or	O
salt	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
as	O
shown	O
in	O
Formula	O
(	O
I	O
)	O
,	O
application	O
of	O
the	O
compounds	O
as	O
active	O
substances	O
for	O
medicine	O
,	O
in	O
particular	O
to	O
the	O
application	O
for	O
preparing	O
the	O
medicine	O
used	O
for	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

The	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
,	O
R<6	O
>	O
,	O
R<7	O
>	O
,	O
R<8	O
>	O
and	O
X	O
are	O
defined	O
in	O
details	O
in	O
the	O
specification	O
.	O

Formyl	B
aniline	I
substituted	I
sulfhydryl	I
pyrrolidine	I
carbpenem	I
compounds	O

The	O
present	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
carbapenem	B
compound	O
containing	O
cyclohexenone	B
formamido	I
group	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
an	O
easily	O
hydrolyzed	O
ester	O
,	O
an	O
isomer	O
,	O
a	O
hydrate	B
and	O
a	O
hydrate	B
of	O
the	O
ester	B
or	O
the	O
salt	O
thereof	O
:	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
and	O
R<5	O
>	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
preparation	O
methods	O
of	O
the	O
compounds	O
,	O
drug	O
combinations	O
and	O
applications	O
of	O
the	O
compounds	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
treating	O
and/or	O
preventing	O
infective	O
diseases	O
.	O

Carbpenem	B
compound	O
containing	O
cyclohexenone	B
formamido	I
group	O

The	O
present	O
invention	O
discloses	O
an	O
11-chlorinated	B
dihydroartemisinin	I
(	O
I	O
)	O
and	O
an	O
ester	B
(	O
II	O
)	O
thereof	O
.	O

The	O
modification	O
of	O
the	O
position	O
11	O
of	O
the	O
dihydroartemisinin	B
enhances	O
the	O
activity	O
of	O
the	O
active	O
center	O
of	O
arteannuin	B
,	O
so	O
the	O
11-chlorinated	B
dihydroartemisinin	I
is	O
a	O
class	O
of	O
compounds	O
with	O
unique	O
physiological	O
activity	O
.	O

Moreover	O
,	O
the	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
11-chlorinated	B
dihydroartemisinin	I
and	O
the	O
ester	B
,	O
and	O
applications	O
in	O
pharmacology	O
thereof	O
.	O

Novel	O
dihydro	B
arteannuin	I
derivant	O
,	O
preparation	O
method	O
and	O
uses	O
as	O
medicament	O

The	O
invention	O
discloses	O
an	O
oral	O
sticking	O
tablet	O
used	O
for	O
treating	O
canker	O
sore	O
of	O
humans	O
or	O
mammals	O
.	O

The	O
oral	O
sticking	O
tablet	O
comprises	O
a	O
sticking	O
layer	O
containing	O
an	O
active	O
ingredient	O
and	O
a	O
water	O
insoluble	O
protective	O
layer	O
,	O
wherein	O
,	O
a	O
non	O
-	O
active	O
ingredient	O
contained	O
in	O
the	O
sticking	O
layer	O
consists	O
of	O
a	O
filling	O
agent	O
,	O
an	O
adhesive	O
sustained	O
-	O
release	O
agent	O
and	O
a	O
lubricant	O
which	O
are	O
applicable	O
to	O
tablets	O
;	O
the	O
water	O
insoluble	O
protective	O
layer	O
is	O
composed	O
of	O
polyacrylic	B
acid	I
resin	O
and/or	O
ethyl	O
cellulose	O
which	O
can	O
be	O
used	O
as	O
protective	O
coating	O
,	O
and	O
a	O
plasticizer	O
;	O
in	O
addition	O
,	O
the	O
active	O
ingredient	O
is	O
fluticasone	B
propionate	I
.	O

Oral	O
sticking	O
tablets	O
using	O
fluticasone	B
propionate	I
as	O
active	O
component	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preventing	O
prawn	O
leukoderma	O
,	O
which	O
is	O
characterized	O
by	O
adding	O
0.1	O
-	O
0.2	O
wt%	O
of	O
gulfweed	O
polysaccharide	O
extract	O
to	O
the	O
foodstuff	O
of	O
prawns	O
.	O

By	O
adopting	O
the	O
method	O
to	O
cultivate	O
prawns	O
,	O
non	O
-	O
specific	O
immune	O
system	O
is	O
stimulated	O
,	O
thus	O
strengthening	O
the	O
immunity	O
and	O
resistance	O
of	O
prawns	O
,	O
obviously	O
enhancing	O
the	O
immune	O
function	O
of	O
prawns	O
,	O
and	O
does	O
not	O
generate	O
adverse	O
influence	O
on	O
the	O
palatability	O
of	O
foodstuff	O
and	O
has	O
significant	O
effect	O
on	O
the	O
prevention	O
of	O
prawn	O
leukoderma	O
.	O

The	O
method	O
has	O
stable	O
source	O
of	O
gulfweed	O
,	O
simplified	O
production	O
technology	O
and	O
significant	O
effect	O
.	O

Method	O
for	O
preventing	O
and	O
treating	O
leukoderma	O
of	O
prawn	O

The	O
invention	O
discloses	O
a	O
compound	O
medicine	O
for	O
inhibiting	O
tumor	O
;	O
the	O
medicine	O
consists	O
of	O
coenzyme	O
Q10	O
,	O
polysaccharide	O
and	O
triterpene	B
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
enhancing	O
immunity	O
,	O
resisting	O
the	O
proliferation	O
of	O
tumor	O
cells	O
,	O
inducing	O
the	O
apoptosis	O
of	O
cells	O
and	O
interfering	O
with	O
the	O
synthesis	O
of	O
tubulin	O
of	O
tumor	O
cells	O
,	O
so	O
as	O
to	O
play	O
the	O
inhibition	O
role	O
.	O

Furthermore	O
,	O
the	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
medicine	O
for	O
inhibiting	O
tumor	O
by	O
processing	O
materials	O
through	O
semi	O
-	O
synthesis	O
method	O
or	O
supercritical	O
CQ2	O
method	O
.	O

Composite	O
medicament	O
for	O
inhibiting	O
tumor	O
and	O
preparation	O
method	O
thereof	O
as	O
well	O
as	O
technique	O
field	O

This	O
invention	O
provides	O
specifically	O
substituted	O
1,2,4-thiadiazole	B
derivatives	O
for	O
use	O
in	O
the	O
treatment	O
of	O
an	O
a	O
-	O
synucleopathy	O
such	O
as	O
Parkinson	O
's	O
disease	O
,	O
diffuse	O
Lewy	O
body	O
disease	O
,	O
traumatic	O
brain	O
injury	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
Niemann	O
-	O
Pick	O
disease	O
,	O
Hallervorden	O
-	O
Spatz	O
syndrome	O
,	O
Down	O
syndrome	O
,	O
neuroaxonal	O
dystrophy	O
,	O
multiple	O
system	O
atrophy	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Thiadiazole	B
derivatives	O
for	O
the	O
treatment	O
of	O
neuro	O
degenerative	O
diseases	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
preparation	O
and	O
discloses	O
a	O
high	O
-	O
density	O
gastric	O
stasis	O
osmotic	O
pump	O
controlled	O
release	O
famotidine	B
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
osmotic	O
pump	O
controlled	O
release	O
preparation	O
is	O
made	O
from	O
a	O
tablet	O
core	O
containing	O
famotidine	B
and	O
a	O
semi	O
-	O
permeable	O
coating	O
membrane	O
with	O
drug	O
release	O
pores	O
which	O
is	O
coated	O
outside	O
the	O
tablet	O
core	O
;	O
the	O
tablet	O
core	O
is	O
made	O
from	O
400	O
mg	O
of	O
the	O
famotidine	B
,	O
100	O
-	O
150	O
mg	O
of	O
medicinal	O
ferrous	O
powder	O
,	O
30	O
-	O
90	O
mg	O
of	O
a	O
suspension	O
,	O
20	O
-	O
80	O
mg	O
of	O
an	O
osmotic	O
pressure	O
active	O
material	O
and	O
0.5	O
-	O
2	O
mg	O
of	O
a	O
lubricant	O
;	O
the	O
semi	O
-	O
permeable	O
coating	O
membrane	O
is	O
made	O
from	O
10	O
-	O
20	O
g	O
of	O
a	O
semi	O
-	O
permeable	O
polymer	O
material	O
and	O
2	O
-	O
5	O
g	O
of	O
a	O
water	O
-	O
soluble	O
pore	O
making	O
agent	O
,	O
and	O
accounts	O
for	O
5	O
-	O
9	O
%	O
of	O
the	O
weight	O
of	O
the	O
tablet	O
core	O
;	O
and	O
the	O
drug	O
release	O
pores	O
are	O
drilled	O
at	O
one	O
side	O
or	O
two	O
sides	O
of	O
a	O
coating	O
tablet	O
by	O
laser	O
and	O
by	O
mechanical	O
means	O
.	O

The	O
medicinal	O
ferrous	O
powder	O
is	O
added	O
to	O
the	O
tablet	O
core	O
to	O
cause	O
the	O
drug	O
to	O
be	O
more	O
completely	O
released	O
from	O
the	O
drug	O
release	O
pores	O
;	O
meanwhile	O
,	O
the	O
medicinal	O
ferrous	O
powder	O
increases	O
the	O
density	O
of	O
the	O
preparation	O
;	O
therefore	O
,	O
the	O
preparation	O
is	O
stagnated	O
in	O
the	O
folds	O
of	O
the	O
lower	O
part	O
of	O
the	O
stomach	O
,	O
which	O
greatly	O
prolongs	O
the	O
release	O
time	O
of	O
the	O
pharmaceutical	O
preparation	O
in	O
the	O
stomach	O
and	O
improves	O
the	O
absorption	O
capacity	O
of	O
the	O
pharmaceutical	O
preparation	O
.	O

Famotidine	B
high	O
density	O
type	O
gastric	O
retention	O
osmotic	O
pump	O
controlled	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
use	O
of	O
cholinesterase	O
inhibitor	O
in	O
the	O
treatment	O
of	O
xerostomia	O
,	O
in	O
particular	O
a	O
use	O
of	O
cholinesterase	O
inhibitor	O
together	O
with	O
topical	O
delivery	O
in	O
the	O
treatment	O
of	O
xerostomia	O
.	O

The	O
invention	O
also	O
provides	O
a	O
use	O
of	O
cholinesterase	O
inhibitor	O
in	O
the	O
treatment	O
of	O
xerostomia	O
for	O
topical	O
delivery	O
to	O
the	O
oral	O
mucosa	O
.	O

The	O
use	O
of	O
cholinesterase	O
inhibitors	O
in	O
pharmacy	O

The	O
invention	O
relates	O
to	O
a	O
composite	O
of	O
an	O
artemisinin	B
derivative	O
and	O
vinorelbine	B
in	O
the	O
technical	O
field	O
of	O
pharmaceuticals	O
and	O
the	O
application	O
thereof	O
;	O
wherein	O
,	O
the	O
ratio	O
of	O
the	O
artemisinin	B
derivative	O
(	O
including	O
dihydroartemisinin	B
or	O
artesunate	B
)	O
and	O
the	O
vinorelbine	B
is	O
1:500	O
to	O
500:1	O
.	O

The	O
composite	O
can	O
be	O
applied	O
to	O
preparing	O
antineoplastics	O
and	O
made	O
into	O
the	O
dosage	O
forms	O
of	O
injection	O
administration	O
and	O
oral	O
administration	O
by	O
adding	O
pharmaceutically	O
acceptable	O
adjuvant	O
carriers	O
.	O

The	O
two	O
effective	O
components	O
(	O
the	O
artemisinin	B
derivative	O
and	O
the	O
vinorelbine	B
)	O
of	O
the	O
composite	O
not	O
only	O
have	O
obvious	O
synergistic	O
effect	O
and	O
but	O
also	O
can	O
be	O
cooperatively	O
applied	O
so	O
as	O
to	O
reduce	O
the	O
amount	O
of	O
the	O
vinorelbine	B
and	O
lower	O
the	O
production	O
cost	O
.	O

By	O
adding	O
the	O
pharmaceutically	O
acceptable	O
adjuvant	O
carriers	O
to	O
prepare	O
the	O
dosage	O
forms	O
of	O
injection	O
administration	O
and	O
oral	O
administration	O
,	O
the	O
composite	O
can	O
be	O
applied	O
to	O
the	O
anti	O
-	O
tumor	O
field	O
.	O

Composition	O
of	O
artemisinin	B
derivative	O
and	O
vinorelbine	B
,	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
propolis	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
relates	O
to	O
the	O
technical	O
field	O
of	O
biochemistry	O
.	O

The	O
compound	O
propolis	O
preparation	O
is	O
a	O
capsule	O
which	O
is	O
prepared	O
by	O
raw	O
materials	O
of	O
propolis	O
,	O
sporoderm	O
-	O
broken	O
ganoderma	O
lucidum	O
spore	O
powder	O
and	O
octacosanol	O
with	O
the	O
weight	O
percentage	O
of	O
50	O
-	O
70	O
to	O
20	O
-	O
40	O
to	O
1	O
-	O
10	O
.	O

The	O
propolis	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
:	O
extracting	O
raw	O
propolis	O
by	O
a	O
complex	O
solvent	O
of	O
70	O
-	O
75	O
%	O
of	O
alcohol	O
and	O
20	O
%	O
of	O
1	O
,	O
2-propanediol	O
,	O
and	O
furthermore	O
extracting	O
by	O
the	O
supercritical	O
CO2	O
and	O
obtaining	O
the	O
high	O
-	O
quality	O
propolis	O
taken	O
as	O
the	O
raw	O
material	O
,	O
taking	O
the	O
cane	O
wax	O
as	O
the	O
raw	O
material	O
of	O
the	O
octacosanol	O
,	O
and	O
using	O
the	O
supercritical	O
CO2	O
extraction	O
method	O
.	O

The	O
compound	O
propolis	O
preparation	O
provided	O
by	O
the	O
invention	O
has	O
great	O
health	O
care	O
function	O
.	O

Preparation	O
method	O
of	O
compound	O
propolis	O
preparation	O

An	O
anticancer	O
composition	O
carrying	O
melphalan	B
and	O
carmustine	B
is	O
a	O
sustained	O
release	O
injection	O
which	O
consists	O
of	O
sustained	O
release	O
microspheres	O
and	O
a	O
dissolvent	O
,	O
wherein	O
,	O
the	O
sustained	O
release	O
microspheres	O
comprise	O
an	O
anticancer	O
active	O
component	O
and	O
a	O
sustained	O
release	O
adjuvant	O
,	O
and	O
the	O
dissolvent	O
is	O
a	O
common	O
dissolvent	O
or	O
a	O
special	O
dissolvent	O
containing	O
a	O
suspending	O
agent	O
.	O

The	O
suspending	O
agent	O
has	O
the	O
viscosity	O
of	O
100cp-3000cp	O
(	O
at	O
the	O
temperature	O
of	O
20	O
-	O
30	O
DEG	O
C	O
)	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethyl	O
cellulose	O
and	O
the	O
like	O
;	O
the	O
anticancer	O
active	O
component	O
is	O
a	O
combination	O
of	O
a	O
nitrosourea	B
drug	O
and	O
an	O
alkylating	O
agent	O
selected	O
from	O
the	O
melphalan	B
,	O
ifosfamide	B
,	O
4H	B
-	I
peroxycyclophosphamide	I
or	O
norcantharidin	B
;	O
the	O
sustained	O
release	O
adjuvant	O
is	O
selected	O
from	O
copolymer	O
of	O
polyphosphate	B
esters	I
such	O
as	O
p	B
(	I
LAEG	I
-	I
EOP	I
)	I
,	O
p	B
(	I
DAPG	I
-	I
EOP	I
)	I
and	O
the	O
like	O
,	O
copolymer	O
of	O
the	O
polyphosphate	B
ester	I
and	O
polylactic	B
acid	I
,	O
polifeprosan	B
,	O
dienoic	B
fatty	I
acid	I
and	O
sebacic	B
acid	I
,	O
or	O
copolymer	O
or	O
polyblend	O
of	O
poly	B
(	I
erucic	I
acid	I
dimmer	I
-	I
sebacic	I
acid	I
)	I
or	O
poly	B
(	I
fumaric	I
acid	I
-	I
sebacic	I
acid	I
)	I
;	O
the	O
anticancer	O
composition	O
is	O
also	O
made	O
into	O
a	O
sustained	O
release	O
implant	O
,	O
and	O
injected	O
into	O
or	O
placed	O
inside	O
or	O
at	O
the	O
periphery	O
of	O
tumor	O
to	O
keep	O
the	O
effective	O
drug	O
concentration	O
more	O
than	O
60	O
days	O
.	O

The	O
anticancer	O
composition	O
can	O
also	O
obviously	O
reduce	O
the	O
general	O
reaction	O
of	O
the	O
drug	O
,	O
and	O
selectively	O
enhance	O
the	O
curative	O
effects	O
of	O
non	O
-	O
operative	O
therapies	O
such	O
as	O
radiotherapy	O
,	O
chemotherapy	O
and	O
the	O
like	O
.	O

Anticancer	O
composition	O
loaded	O
with	O
melphalan	B
and	O
carmustine	B

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
alpha	B
-	I
D-	I
(	I
1	I
-	I
6	I
)	I
-dextran	I
sulfate	I
with	O
the	O
average	O
molecular	O
weight	O
range	O
of	O
1000	O
-	O
100000	O
and	O
the	O
degree	O
of	O
substitution	O
of	O
monosaccharide	B
sulfate	I
of	O
0.2	O
-	O
3.0	O
as	O
the	O
preparation	O
of	O
anti	O
-	O
influenza	O
virus	O
drugs	O
.	O

The	O
invention	O
prepares	O
a	O
practical	O
drug	O
formulation	O
of	O
the	O
alpha	O
-	O
D-	O
(	O
1	O
-	O
6	O
)	O
-dextran	O
sulfate	O
with	O
the	O
average	O
molecular	O
weight	O
range	O
of	O
1000	O
-	O
100000	O
and	O
the	O
degree	O
of	O
substitution	O
of	O
monosaccharide	B
sulfate	I
of	O
0.2	O
-	O
3.0	O
and	O
determines	O
that	O
the	O
polysaccharide	O
sulfate	O
has	O
the	O
use	O
of	O
synergistic	O
anti	O
-	O
A	O
and	O
B	O
-	O
type	O
influenza	O
virus	O
independently	O
or	O
after	O
composing	O
a	O
compound	O
with	O
amantadine	B
,	O
ribavirin	B
and	O
other	O
prior	O
anti	O
-	O
influenza	O
virus	O
drugs	O
.	O

Use	O
of	O
polysaccharide	O
sulfate	O
as	O
anti	O
influenza	O
virus	O
medicine	O

The	O
invention	O
discloses	O
a	O
novel	O
nano	O
preparation	O
with	O
stable	O
protein	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
purpose	O
thereof	O
.	O

The	O
invention	O
is	O
characterized	O
in	O
that	O
:	O
a	O
protein	O
coating	O
is	O
formed	O
from	O
albumin	O
and	O
other	O
materials	O
containing	O
sulphydryl	B
or	O
disulfide	B
bond	O
through	O
the	O
cross	O
linking	O
of	O
the	O
disulfide	B
bond	O
;	O
the	O
protein	O
coating	O
contains	O
free	O
protein	O
or	O
protein	O
derivatives	O
which	O
associate	O
(	O
s	O
)	O
with	O
the	O
protein	O
coating	O
,	O
wherein	O
,	O
part	O
of	O
insoluble	O
drugs	O
are	O
contained	O
in	O
the	O
protein	O
coating	O
and	O
part	O
of	O
such	O
drugs	O
are	O
associated	O
with	O
the	O
free	O
protein	O
or	O
the	O
protein	O
derivatives	O
,	O
and	O
the	O
average	O
diameter	O
of	O
protein	O
coating	O
particles	O
is	O
not	O
more	O
than	O
1	O
micron	O
.	O

The	O
purpose	O
of	O
the	O
preparation	O
is	O
to	O
send	O
water	O
insoluble	O
drugs	O
into	O
the	O
bodies	O
of	O
living	O
things	O
.	O

Novel	O
nano	O
preparation	O
with	O
stable	O
protein	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
5H	B
-	I
dibenz	I
/	I
b	I
,	I
f	I
/	I
azepine-5-carboxamide	I
derivatives	O
in	O
the	O
manufacture	O
of	O
various	O
medicaments	O
for	O
treating	O
neuropathic	O
pain	O
and	O
for	O
treating	O
neurological	O
disorders	O
which	O
involve	O
both	O
motor	O
impairment	O
and	O
neuropathic	O
pain	O
.	O

Use	O
of	O
5H	B
-	I
dibenz	I
/	I
b	I
,	I
f	I
/	I
azepine-5-carboxamide	I
derivatives	O
in	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
and	O
neurological	O
disorders	O

The	O
invention	O
relates	O
to	O
a	O
nelarabine	B
injection	O
,	O
which	O
is	O
characterized	O
by	O
consisting	O
of	O
nelarabine	B
,	O
EDTA	B
or	O
EDTA	B
salt	O
,	O
sodium	B
chloride	I
,	O
and	O
water	O
for	O
injection	O
,	O
wherein	O
the	O
nelarabine	B
accounts	O
for	O
0.25	O
to	O
0.625	O
percent	O
of	O
the	O
total	O
weight	O
of	O
the	O
injection	O
,	O
the	O
EDTA	B
or	O
the	O
EDTA	B
salt	O
accounts	O
for	O
0.001	O
to	O
0.01	O
percent	O
of	O
the	O
total	O
weight	O
of	O
the	O
injection	O
,	O
the	O
content	O
of	O
the	O
sodium	B
chloride	I
is	O
0	O
orthe	O
dose	O
is	O
used	O
for	O
regulating	O
the	O
osmotic	O
pressure	O
,	O
and	O
the	O
balance	O
is	O
the	O
water	O
for	O
injection	O
.	O

The	O
preparing	O
process	O
comprises	O
the	O
following	O
steps	O
:	O
taking	O
80	O
percent	O
of	O
the	O
water	O
for	O
injection	O
,	O
adding	O
raw	O
supplementary	O
materials	O
into	O
the	O
water	O
for	O
injection	O
,	O
stirring	O
the	O
mixture	O
to	O
fully	O
dissolve	O
the	O
raw	O
supplementary	O
materials	O
and	O
mixing	O
the	O
mixture	O
evenly	O
,	O
adjusting	O
the	O
pH	O
value	O
,	O
adding	O
0.02percent	O
of	O
needle	O
activated	O
carbon	O
into	O
the	O
mixture	O
,	O
keeping	O
the	O
water	O
temperature	O
at	O
70	O
DEG	O
C	O
,	O
stirring	O
the	O
mixture	O
for	O
30	O
minutes	O
,	O
filtering	O
the	O
mixture	O
to	O
remove	O
the	O
activated	O
carbon	B
when	O
the	O
mixture	O
is	O
hot	O
,	O
cooling	O
the	O
mixture	O
to	O
room	O
temperature	O
,	O
measuring	O
the	O
contents	O
and	O
the	O
pH	O
value	O
of	O
the	O
solution	O
,	O
adding	O
the	O
water	O
for	O
injection	O
with	O
full	O
dose	O
into	O
the	O
solution	O
,	O
mixing	O
the	O
mixture	O
evenly	O
,	O
filtering	O
the	O
mixture	O
through	O
0.22	O
mu	O
m	O
of	O
microfiltration	O
membrane	O
until	O
the	O
mixture	O
is	O
clear	O
,	O
packaging	O
the	O
filtrate	O
into	O
infusion	O
bottles	O
after	O
intermediates	O
are	O
measured	O
to	O
be	O
qualified	O
,	O
plugging	O
the	O
bottles	O
,	O
and	O
rolling	O
the	O
mouths	O
of	O
the	O
bottoms	O
to	O
obtain	O
the	O
nelarabine	B
injection	O
after	O
hot	O
pressing	O
sterilization	O
.	O

Nelarabine	B
injection	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
preparation	O
,	O
and	O
particularly	O
discloses	O
a	O
timolol	B
liposome	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
timolol	B
liposome	O
comprises	O
timolol	B
,	O
phospholipid	B
,	O
cholesterol	B
,	O
antioxidant	O
and	O
the	O
like	O
,	O
wherein	O

the	O
weight	O
percentages	O
of	O
various	O
composition	O
are	O
as	O
follows	O
:	O
0.01	O
to	O
60.00	O
percent	O
of	O
the	O
timolol	B
,	O
10.00	O
to	O
99.99	O
percent	O
of	O
the	O
phospholipid	B
,	O
0.00	O
to	O
68.00	O
percent	O
of	O
the	O
cholesterol	B
,	O
0.00	O
to	O
50.00	O
percent	O
of	O
the	O
antioxidant	O
,	O
and	O
0.00	O
to	O
89.99	O
percent	O
of	O
osmotic	O
pressure	O
regulator	O
.	O

A	O
gel	O
matrix	O
can	O
be	O
further	O
added	O
into	O
the	O
timolol	B
liposome	O
to	O
prepare	O
a	O
gel	O
.	O

The	O
timolol	B
liposome	O
has	O
the	O
advantages	O
of	O
high	O
envelop	O
rate	O
,	O
good	O
stability	O
,	O
and	O
excellent	O
biocompatibility	O
,	O
bio	O
-	O
adhesion	O
property	O
and	O
biodegradability	O
,	O
can	O
form	O
very	O
good	O
storage	O
effect	O
in	O
a	O
cornea	O
,	O
and	O
can	O
realize	O
the	O
aims	O
of	O
improving	O
bioavailability	O
,	O
reduce	O
toxicity	O
,	O
and	O
reduce	O
pungency	O
,	O
thus	O
the	O
timolol	B
liposome	O
is	O
particularly	O
suitable	O
for	O
eye	O
instillation	O
to	O
better	O
play	O
the	O
effect	O
of	O
the	O
timolol	B
to	O
reduce	O
the	O
intraocular	O
pressure	O
and	O
resist	O
glaucoma	O
.	O

Timolol	B
liposome	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
preparation	O
,	O
in	O
particular	O
to	O
a	O
chewable	O
tablet	O
containing	O
imatinib	B
mesylate	I
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
chewable	O
tablet	O
containing	O
the	O
imatinib	B
mesylate	I
consists	O
of	O
the	O
principal	O
imatinib	B
mesylate	I
,	O
a	O
filling	O
agent	O
,	O
a	O
flavour	O
modifying	O
agent	O
,	O
a	O
glidant	O
,	O
an	O
odor	O
modifying	O
agent	O
,	O
and	O
an	O
adhesive	O
.	O

The	O
chewable	O
tablet	O
containing	O
the	O
imatinib	B
mesylate	I
can	O
be	O
applied	O
to	O
patients	O
having	O
difficulty	O
in	O
orally	O
taking	O
the	O
common	O
tablets	O
,	O
has	O
good	O
drug	O
compliance	O
,	O
can	O
be	O
dissolved	O
in	O
saliva	O
after	O
chewing	O
and	O
being	O
absorbed	O
by	O
oral	O
or	O
esophageal	O
mucosa	O
,	O
and	O
has	O
high	O
bioavailability	O
.	O

The	O
chewable	O
tablet	O
not	O
only	O
has	O
sweet	O
taste	O
and	O
good	O
mouthfeel	O
,	O
but	O
also	O
modifies	O
penetrating	O
odors	O
and	O
has	O
flavor	O
;	O
the	O
chewable	O
tablet	O
is	O
convenient	O
to	O
take	O
and	O
carry	O
around	O
;	O
and	O
the	O
chewable	O
tablet	O
is	O
prepared	O
by	O
a	O
direct	O
tabletting	O
method	O
,	O
and	O
has	O
good	O
drug	O
stability	O
,	O
simple	O
production	O
process	O
,	O
and	O
low	O
cost	O
.	O

Imatinib	B
mesylate	I
chewable	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
mind	O
-	O
refreshing	O
buccal	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
mind	O
-	O
refreshing	O
buccal	O
tablet	O
consists	O
of	O
a	O
tablet	O
core	O
,	O
a	O
middle	O
layer	O
and	O
an	O
outer	O
layer	O
,	O
wherein	O
beta	O
-	O
cyclodextrin	O
,	O
xylitol	B
,	O
microcrystalline	O
cellulose	O
and	O
citric	B
acid	I
are	O
taken	O
as	O
raw	O
materials	O
,	O
mixed	O
with	O
an	O
ethanol	B
aqueous	O
solution	O
as	O
a	O
wetting	O
agent	O
,	O
granulated	O
,	O
sieved	O
,	O
dried	O
,	O
mixed	O
with	O
magnesium	B
stearate	I
and	O
menthol	B
and	O
pressed	O
,	O
so	O
as	O
to	O
obtain	O
the	O
tablet	O
core	O
;	O
the	O
tablet	O
core	O
is	O
placed	O
in	O
a	O
sugar	O
coating	O
machine	O
,	O
sprayed	O
with	O
the	O
ethanol	B
aqueous	O
solution	O
of	O
chili	O
extract	O
and	O
dried	O
,	O
so	O
as	O
to	O
obtain	O
the	O
middle	O
layer	O
;	O
and	O
the	O
middle	O
layer	O
containing	O
the	O
tablet	O
core	O
is	O
placed	O
in	O
the	O
sugar	B
coating	O
machine	O
,	O
sprayed	O
with	O
a	O
maltose	B
syrup	O
aqueous	O
solution	O
and	O
dried	O
,	O
so	O
as	O
to	O
obtain	O
the	O
outer	O
layer	O
.	O

The	O
mind	O
-	O
refreshing	O
buccal	O
tablet	O
has	O
the	O
advantages	O
of	O
stimulating	O
human	O
emotion	O
,	O
eliminating	O
body	O
fatigue	O
,	O
keeping	O
a	O
cool	O
head	O
,	O
eliminating	O
tiredness	O
,	O
overcoming	O
the	O
symptom	O
that	O
sub	O
-	O
health	O
population	O
are	O
easy	O
to	O
fatigue	O
and	O
droop	O
,	O
reducing	O
fat	O
and	O
losing	O
weight	O
.	O

Lozenge	O
for	O
refreshing	O
oneself	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
novel	O
N	B
-	I
tert	I
-	I
butyl	I
-	I
N	I
-	I
substituted	I
aroyl	I
group	I
-	I
N'-	I
(	I
5-substituted	I
aryl-2-furanylcarbonyl	I
)	I
hydrazine	I
compounds	O
,	O
which	O
have	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Ar1	O
and	O
Ar2	O
are	O
as	O
defined	O
in	O
an	O
instruction	O
;	O
and	O
the	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
of	O
the	O
compounds	O
used	O
as	O
an	O
antitumor	O
depressor	O
.	O

Aryl	B
hydrazide	I
compounds	O
with	O
antineoplastic	O
activity	O

A	O
process	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
homogeneous	O
or	O
substantially	O
homogeneous	O
mixture	O
of	O
citric	B
acid	I
,	O
magnesium	B
oxide	I
,	O
potassium	B
bicarbonate	I
and	O
sodium	B
picosulphate	I
and	O
,	O
optionally	O
,	O
saccharin	B
sodium	I
and/or	O
orange	O
flavour	O
;	O
products	O
,	O
intermediate	O
products	O
,	O
and	O
uses	O
thereof	O
.	O

Process	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
product	O

This	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibition	O
of	O
skin	O
atrophy	O
,	O
or	O
epithelial	O
or	O
mucosal	O
atrophy	O
in	O
women	O
,	O
or	O
to	O
a	O
method	O
for	O
treatment	O
or	O
prevention	O
of	O
symptoms	O
related	O
to	O
atrophy	O
,	O
said	O
method	O
comprising	O
administering	O
to	O
the	O
woman	O
an	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
geometric	O
isomer	O
,	O
a	O
stereoisomer	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
an	O
ester	B
thereof	O
or	O
a	O
metabolite	O
thereof	O
.	O

Treatment	O
or	O
prevention	O
of	O
urogenital	O
atrophy	O
and	O
its	O
symptoms	O
in	O
women	O

The	O
invention	O
discloses	O
a	O
health	O
care	O
product	O
with	O
efficacies	O
of	O
expelling	O
toxin	O
and	O
preserving	O
health	O
,	O
which	O
is	O
produced	O
from	O
the	O
following	O
raw	O
materials	O
in	O
weight	O
portion	O
:	O
3	O
portions	O
of	O
honeysuckle	O
,	O
2	O
portions	O
of	O
liquorice	O
,	O
2	O
portions	O
of	O
propolis	O
,	O
1.5	O
portions	O
of	O
wild	O
chrysanthemum	O
flower	O
,	O
1.5	O
portions	O
of	O
dandelion	O
,	O
1.2	O
portions	O
of	O
Chinese	O
violet	O
,	O
and	O
1.2	O
portions	O
of	O
radix	O
semiaquilegiae	O
.	O

When	O
the	O
health	O
care	O
product	O
is	O
produced	O
,	O
the	O
raw	O
materials	O
are	O
ground	O
into	O
fine	O
powder	O
and	O
then	O
are	O
mixed	O
according	O
to	O
the	O
proportion	O
.	O

The	O
health	O
care	O
product	O
with	O
the	O
efficacies	O
of	O
expelling	O
toxin	O
and	O
preserving	O
health	O
has	O
cheap	O
and	O
easily	O
-	O
obtained	O
raw	O
materials	O
,	O
can	O
be	O
produced	O
into	O
a	O
plurality	O
of	O
health	O
care	O
products	O
such	O
as	O
health	O
care	O
wine	O
,	O
health	O
care	O
tea	O
,	O
health	O
care	O
pillows	O
and	O
health	O
care	O
perplex	O
incense	O
,	O
can	O
ensure	O
that	O
people	O
can	O
use	O
anywhere	O
at	O
any	O
time	O
in	O
daily	O
life	O
,	O
can	O
be	O
taken	O
orally	O
for	O
conditioning	O
,	O
and	O
make	O
the	O
drug	O
effect	O
act	O
on	O
human	O
bodies	O
for	O
a	O
long	O
time	O
by	O
methods	O
such	O
as	O
external	O
application	O
,	O
medical	O
lavender	O
or	O
moxibustion	O
,	O
thus	O
the	O
long	O
-	O
term	O
use	O
of	O
the	O
product	O
by	O
people	O
can	O
be	O
assured	O
;	O
and	O
the	O
selected	O
raw	O
materials	O
focus	O
on	O
the	O
toxin	O
expelling	O
and	O
also	O
emphasize	O
the	O
nourishing	O
at	O
the	O
same	O
time	O
,	O
so	O
no	O
side	O
effect	O
can	O
be	O
produced	O
.	O

Health	O
-	O
care	O
product	O
with	O
toxin	O
-	O
expelling	O
and	O
health	O
-	O
preserving	O
efficacy	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
infectious	O
bursal	O
disease	O
of	O
chicken	O
.	O

Gypsum	O
,	O
fructus	O
forsythiae	O
,	O
scutellaria	O
,	O
goose	O
grass	O
,	O
radix	O
isatidis	O
,	O
common	O
andrographis	O
,	O
swamp	O
mahogany	O
,	O
rhizoma	O
anemarrhenae	O
,	O
radix	O
rehmanniae	O
,	O
grifola	O
,	O
climbing	O
fern	O
spore	O
,	O
radix	O
astragali	O
,	O
codonopsis	O
pilosula	O
and	O
rhizoma	O
atractylodis	O
alba	O
are	O
mixed	O
to	O
prepare	O
the	O
medicine	O
according	O
to	O
certain	O
mixture	O
ratio	O
;	O
the	O
effective	O
rate	O
of	O
treating	O
the	O
infectious	O
bursal	O
disease	O
of	O
chicken	O
is	O
96.8	O
percent	O
;	O
and	O
the	O
healing	O
rate	O
is	O
89	O
percent	O
.	O

The	O
medicine	O
for	O
treating	O
infectious	O
bursal	O
disease	O
of	O
chicken	O
has	O
rapid	O
curative	O
effect	O
,	O
high	O
healing	O
effect	O
,	O
raw	O
material	O
saving	O
,	O
environmental	O
protection	O
and	O
money	O
saving	O
.	O

Medicament	O
for	O
treating	O
infectious	O
bursal	O
disease	O
of	O
chicken	O

The	O
invention	O
relates	O
to	O
camptothecin	B
derivatives	O
with	O
anticancer	O
activity	O
and	O
the	O
preparation	O
and	O
application	O
thereof	O
,	O
and	O
the	O
chemical	O
structure	O
is	O
as	O
shown	O
in	O
the	O
right	O
formula	O
.	O

Camptothecine	B
derivative	O
having	O
anticancer	O
activity	O

The	O
invention	O
provides	O
a	O
pyrimidine	B
substituted	I
phenylpropionic	I
acid	I
compound	O
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
and	O
application	O
of	O
enantiomer	O
,	O
racemic	O
modification	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
or	O
a	O
mixture	O
of	O
the	O
enantiomer	O
,	O
the	O
racemic	O
modification	O
and	O
the	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
to	O
preparation	O
of	O
medicine	O
for	O
preventing	O
and/or	O
treating	O
diabetes	O
mellitus	O
.	O

The	O
compound	O
as	O
PPAR	O
-	O
gamma	O
excitant	O
can	O
participate	O
in	O
the	O
regulation	O
of	O
genetic	O
transcription	O
through	O
activating	O
PXR	O
/	O
PPAR	O
heterodimer	O
,	O
thereby	O
effectively	O
treating	O
and/or	O
preventing	O
the	O
diabetes	O
mellitus	O
.	O

The	O
invention	O
also	O
provides	O
a	O
medicine	O
composition	O
which	O
contains	O
the	O
compound	O
and	O
has	O
the	O
effect	O
of	O
preventing	O
and/or	O
treating	O
the	O
diabetes	O
mellitus	O
.	O

Use	O
of	O
pyrimidine	B
-	I
substituted	I
phenylpropionic	I
acid	I
compound	O
in	O
preparing	O
medicament	O
for	O
preventing	O
and/or	O
treating	O
diabetes	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
lincomycin	B
hydrochloride	I
injection	O
for	O
livestock	O
.	O

The	O
compound	O
lincomycin	B
hydrochloride	I
injection	O
is	O
characterized	O
in	O
that	O
the	O
compound	O
lincomycin	B
hydrochloride	I
injection	O
is	O
prepared	O
through	O
evenly	O
mixing	O
the	O
following	O
compositions	O
in	O
weight	O
portion	O
:	O
8	O
to	O
20	O
portions	O
of	O
lincomycin	B
hydrochloride	I
,	O
5	O
to	O
20	O
portions	O
of	O
berberine	B
bisulfate	I
,	O
5	O
to	O
15	O
portions	O
of	O
gentamicin	B
sulfate	I
-	O
micronomicin	B
sulfate	I
and	O
45	O
to	O
100	O
portions	O
of	O
water	O
for	O
injection	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
according	O
to	O
weight	O
portion	O
,	O
8	O
to	O
20	O
portions	O
of	O
the	O
lincomycin	B
hydrochloride	I
,	O
5	O
to	O
20	O
portions	O
of	O
the	O
berberine	B
bisulfate	I
and	O
5	O
to	O
15	O
portions	O
of	O
the	O
gentamicin	B
sulfate	I
-	O
micronomicin	B
sulfate	I
are	O
weighed	O
;	O
(	O
2	O
)	O
the	O
lincomycin	B
hydrochloride	I
is	O
put	O
into	O
30	O
to	O
40	O
portions	O
of	O
the	O
water	O
for	O
injection	O
at	O
a	O
temperature	O
of	O
between	O
45	O
and	O
55	O
DEG	O
C	O
and	O
is	O
stirred	O
for	O
10	O
to	O
25	O
minutes	O
to	O
clarification	O
;	O
(	O
3	O
)	O
10	O
to	O
20	O
portions	O
of	O
the	O
water	O
for	O
injection	O
is	O
taken	O
out	O
,	O
is	O
sequentially	O
added	O
with	O
5	O
to	O
15	O
portions	O
of	O
the	O
gentamicin	B
sulfate	I
-	O
micronomicin	B
sulfate	I
and	O
5	O
to	O
20	O
portions	O
of	O
the	O
berberine	B
bisulfate	I
and	O
is	O
stirred	O
and	O
dissolved	O
;	O
and	O
(	O
4	O
)	O
a	O
solution	O
prepared	O
in	O
the	O
step	O
2	O
and	O
a	O
solution	O
prepared	O
in	O
the	O
step	O
3	O
are	O
mixed	O
,	O
are	O
evenly	O
stirred	O
and	O
are	O
kept	O
for	O
15	O
to	O
20	O
minutes	O
;	O
and	O
after	O
a	O
medicine	O
solution	O
is	O
clarified	O
,	O
the	O
residual	O
part	O
of	O
the	O
water	O
for	O
injection	O
is	O
added	O
into	O
the	O
medicine	O
solution	O
and	O
is	O
evenly	O
stirred	O
and	O
filtered	O
.	O

The	O
compound	O
lincomycin	B
hydrochloride	I
injection	O
has	O
a	O
reasonable	O
formula	O
,	O
simple	O
preparation	O
and	O
remarkable	O
curative	O
effect	O
.	O

Compound	O
lincomycin	B
hydrochloride	I
injection	O
for	O
livestock	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
drug	O
for	O
suppressing	O
tumor	O
and	O
relieving	O
pain	O
,	O
which	O
is	O
prepared	O
from	O
raw	O
materials	O
in	O
the	O
follow	O
weight	O
portion	O
:	O
2	O
to	O
5	O
portions	O
of	O
toad	O
,	O
20	O
to	O
30	O
portions	O
of	O
raw	O
angelica	O
dahurica	O
,	O
20	O
to	O
30	O
portions	O
of	O
curcuma	O
,	O
10	O
to	O
20	O
portions	O
of	O
raw	O
southern	O
star	O
,	O
10	O
to	O
20	O
portions	O
of	O
unprocessed	O
radix	O
aconiti	O
,	O
10	O
to	O
20	O
portions	O
of	O
processed	O
strychnos	O
,	O
3	O
to	O
10	O
portions	O
of	O
camphor	O
,	O
and	O
3	O
to	O
10	O
portions	O
of	O
borneol	O
.	O

The	O
drug	O
uses	O
the	O
toad	O
and	O
the	O
curcuma	O
to	O
promote	O
blood	O
circulation	O
and	O
remove	O
blood	O
stasis	O
,	O
search	O
wind	O
and	O
dispel	O
filth	O
,	O
as	O
well	O
as	O
remove	O
obstruction	O
meridian	O
and	O
relieve	O
pain	O
,	O
uses	O
the	O
processed	O
strychnos	O
and	O
the	O
raw	O
southern	O
star	O
to	O
disperse	O
abscess	O
and	O
nodule	O
,	O
and	O
relieve	O
pain	O
and	O
resist	O
tumor	O
,	O
uses	O
the	O
unprocessed	O
radix	O
aconite	O
and	O
the	O
raw	O
angelica	O
dahurica	O
to	O
expel	O
wind	O
and	O
remove	O
dampness	O
,	O
as	O
well	O
as	O
disperse	O
abscess	O
and	O
relieve	O
pain	O
,	O
and	O
uses	O
the	O
borneol	O
and	O
the	O
camphor	O
as	O
medicinal	O
guides	O
for	O
dispelling	O
filth	O
with	O
aroma	O
,	O
and	O
opening	O
orifices	O
and	O
inducing	O
resuscitation	O
.	O

All	O
the	O
medicines	O
are	O
used	O
together	O
to	O
achieve	O
the	O
effects	O
of	O
softening	O
hardness	O
to	O
dissipate	O
stagnation	O
,	O
dispersing	O
abscess	O
and	O
relieving	O
pain	O
,	O
combating	O
poison	O
with	O
poison	O
,	O
and	O
suppressing	O
cancer	O
and	O
stopping	O
pain	O
.	O

Through	O
clinical	O
applications	O
,	O
the	O
pain	O
relieving	O
rate	O
reaches	O
75	O
percent	O
,	O
the	O
cancer	O
suppressing	O
rate	O
reaches	O
66	O
percent	O
,	O
while	O
the	O
proportion	O
of	O
the	O
side	O
effect	O
is	O
only	O
13	O
percent	O
,	O
so	O
the	O
drug	O
has	O
dual	O
functions	O
of	O
relieving	O
pain	O
and	O
suppressing	O
cancer	O
with	O
smaller	O
side	O
effects	O
.	O

Cancer	O
-	O
suppressing	O
analgesic	O
medicament	O

The	O
invention	O
discloses	O
the	O
application	O
of	O
sophocarpine	B
and	O
medical	O
salts	O
thereof	O
in	O
medicines	O
treating	O
viral	O
dilated	O
cardiomyopath	O
,	O
viral	O
hypertrophic	O
cardiomyopathy	O
,	O
viral	O
coronaritis	O
,	O
viral	O
pericarditis	O
,	O
viral	O
endocarditis	O
,	O
viral	O
valvulitism	O
,	O
pneumonia	O
,	O
bronchitis	O
,	O
hepatitis	O
,	O
encephalitis	O
,	O
meningitis	O
,	O
pancreatitis	O
,	O
epidemic	O
myalgia	O
and	O
epidemic	O
pleurodynia	O
which	O
are	O
caused	O
by	O
Coxsackie	O
B	O
virus	O
.	O

The	O
sophocarpine	B
and	O
the	O
medical	O
salts	O
thereof	O
which	O
are	O
taken	O
as	O
medicines	O
for	O
treating	O
all	O
related	O
internal	O
organ	O
diseases	O
caused	O
by	O
Coxsackie	O
B	O
virus	O
can	O
increase	O
the	O
cure	O
rate	O
,	O
reduce	O
the	O
death	O
rate	O
and	O
cause	O
no	O
obvious	O
cytotoxic	O
effect	O
.	O

Meanwhile	O
,	O
the	O
sophocarpine	B
is	O
applicable	O
to	O
the	O
industrialized	O
production	O
due	O
to	O
the	O
rich	O
medical	O
herb	O
resources	O
,	O
simple	O
and	O
convenient	O
preparation	O
and	O
lowcost	O
.	O

Use	O
of	O
sophocarpine	B
in	O
preparing	O
medicine	O
for	O
treating	O
diseases	O
induced	O
by	O
coxsackie	O
B	O
virus	O

The	O
invention	O
discloses	O
a	O
calcium	B
tablet	O
for	O
nourishing	O
bones	O
,	O
which	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
the	O
following	O
parts	O
of	O
components	O
by	O
weight	O
:	O
10	O
portions	O
to	O
18	O
portions	O
of	O
enzymatic	O
hydrolysate	O
bone	O
powder	O
,	O
7	O
portions	O
to	O
17	O
portions	O
of	O
xylitol	B
,	O
1	O
portion	O
to	O
3	O
portions	O
of	O
vitamin	B
C	I
,	O
18	O
portions	O
to	O
28	O
portions	O
of	O
biological	O
calcium	B
carbonate	I
,	O
0.8	O
portion	O
to	O
1.5	O
portions	O
of	O
magnesium	B
stearate	I
,	O
18	O
portions	O
to	O
25	O
portions	O
of	O
raw	O
milk	O
powder	O
,	O
2	O
portions	O
to	O
5	O
portions	O
of	O
bovine	O
colostrum	O
powder	O
,	O
20	O
portions	O
to	O
30	O
portions	O
of	O
sorbitol	B
,	O
traces	O
of	O
vitamin	B
D3	I
and	O
vitamin	B
K3	I
.	O

In	O
the	O
formula	O
of	O
the	O
invention	O
,	O
complex	O
calcium	B
is	O
easiest	O
to	O
be	O
absorbed	O
and	O
effectively	O
utilized	O
by	O
human	O
body	O
,	O
and	O
calcium	B
in	O
molecular	O
state	O
is	O
absorbed	O
and	O
utilized	O
by	O
human	O
body	O
subsequently	O
;	O
meanwhile	O
,	O
xylitol	B
,	O
which	O
is	O
a	O
noncaloric	O
sweetener	O
and	O
very	O
conducive	O
to	O
the	O
calcium	B
supplementation	O
of	O
diabetic	O
patients	O
is	O
added	O
.	O

Bone	O
-	O
nourishing	O
calcium	B
tablet	O

The	O
invention	O
provides	O
a	O
novel	O
antitumor	O
compound	O
Cu	B
(	I
C10H12NO2	I
)	I
2	I
,	O
wherein	O
the	O
compound	O
has	O
a	O
formula	O
I	O
structure	O
,	O
and	O
is	O
synthesized	O
by	O
two	O
molecular	O
fusaric	B
acid	I
(	O
Fusaric	B
acid	I
,	O
FA	B
,	O
C10H13NO2	B
)	O
and	O
one	O
molecular	O
Cu<2+>.	B
The	O
in	O
vitro	O
antitumor	O
experiment	O
shows	O
that	O
the	O
compound	O
has	O
better	O
inhibition	O
effect	O
on	O
human	O
liver	O
cancer	O
BEL-7402	O
cells	O
.	O

The	O
compound	O
has	O
the	O
advantages	O
of	O
simple	O
steps	O
,	O
high	O
selectivity	O
,	O
good	O
antitumor	O
effect	O
,	O
and	O
low	O
toxic	O
side	O
effect	O
,	O
is	O
a	O
better	O
tumor	O
inhibitor	O
,	O
and	O
has	O
great	O
medicinal	O
value	O
.	O

Antitumor	O
compound	O
Cu	B
(	I
C10H12NO2	I
)	I
2	I

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
DPP	O
-	O
IV	O
inhibitor	O
derivative	O
which	O
is	O
as	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
and	O
contains	O
benzofuran	B
sulfonylurea	I
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
an	O
isomer	O
thereof	O
,	O
wherein	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
A	O
,	O
X	O
,	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
instruction	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds	O
,	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
and/or	O
preventing	O
diabetes	O
,	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
,	O
high	O
blood	O
sugar	B
,	O
and	O
insulin	O
resistance	O
.	O

DPP	O
-	O
IV	O
inhibitor	O
derivates	O
containing	O
benzofuran	B
sulfonyl	I
ureas	I

The	O
invention	O
discloses	O
azithromycin	B
auristillae	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
experiments	O
and	O
researches	O
of	O
researchers	O
,	O
azithromycin	B
,	O
ethanol	B
,	O
propylene	B
glycol	I
and	O
glycerin	B
are	O
produced	O
into	O
auristillae	O
.	O

The	O
auristillae	O
preparation	O
has	O
remarkable	O
pharmacological	O
action	O
and	O
obvious	O
effect	O
on	O
treating	O
tympanitis	O
.	O

Azithromycin	B
auristillae	O
and	O
method	O
of	O
producing	O
the	O
same	O

The	O
invention	O
discloses	O
pantoprazole	B
and	O
the	O
sodium	B
salt	I
enteric	O
sustained	O
-	O
release	O
micropill	O
preparation	O
thereof	O
.	O

The	O
preparation	O
comprises	O
pantoprazole	B
-	O
containing	O
micropills	O
,	O
an	O
isolation	O
layer	O
,	O
a	O
sustained	O
-	O
release	O
layer	O
,	O
another	O
isolation	O
layer	O
and	O
an	O
enteric	O
layer	O
from	O
inside	O
to	O
outside	O
in	O
sequence	O
;	O
the	O
weight	O
of	O
the	O
first	O
isolation	O
layer	O
is	O
0.5	O
%	O
to	O
40	O
%	O
of	O
that	O
of	O
the	O
pantoprazole	B
-	O
containing	O
micropills	O
,	O
the	O
weight	O
of	O
the	O
sustained	O
-	O
release	O
layer	O
is	O
5	O
%	O
to	O
100	O
%	O
of	O
that	O
of	O
the	O
pantoprazole	B
-	O
containing	O
micropills	O
,	O
the	O
weight	O
of	O
the	O
second	O
isolation	O
layer	O
is	O
0.5	O
%	O
to	O
40	O
%	O
of	O
that	O
of	O
the	O
pantoprazole	B
-	O
containing	O
micropills	O
,	O
and	O
the	O
weight	O
of	O
the	O
enteric	O
layer	O
is	O
20	O
%	O
to	O
200	O
%	O
of	O
that	O
of	O
the	O
pantoprazole	B
-	O
containing	O
micropills	O
.	O

The	O
pantoprazole	B
enteric	O
sustained	O
-	O
release	O
micropills	O
can	O
stably	O
release	O
the	O
drug	O
.	O

Pantoprazole	B
and	O
its	O
sodium	B
salt	I
enteric	O
sustained	O
-	O
release	O
pellet	O
preparation	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
fine	O
powder	O
of	O
salbutamol	B
sulfate	I
.	O

The	O
method	O
is	O
carried	O
out	O
by	O
using	O
a	O
supercritical	O
recrystallization	O
device	O
,	O
and	O
comprises	O
the	O
following	O
steps	O
:	O
inputting	O
CO2	B
into	O
a	O
heater	O
through	O
a	O
pump	O
,	O
and	O
after	O
heating	O
,	O
transforming	O
the	O
CO2	B
into	O
supercritical	O
CO2	B
which	O
then	O
entering	O
a	O
crystallization	O
kettle	O
;	O
pumping	O
salbutamol	B
sulfate	I
solution	O
into	O
the	O
crystallization	O
kettle	O
;	O
blending	O
the	O
supercritical	O
CO2	B
with	O
the	O
salbutamol	B
sulfate	I
solution	O
in	O
a	O
nozzle	O
and	O
spraying	O
out	O
via	O
the	O
nozzle	O
,	O
and	O
separating	O
out	O
salbutamol	B
sulfate	I
crystal	O
;	O
after	O
stopping	O
adding	O
the	O
solution	O
,	O
continuing	O
washing	O
and	O
drying	O
the	O
crystal	O
through	O
the	O
supercritical	O
CO2	B
,	O
and	O
finally	O
obtaining	O
the	O
fine	O
powder	O
of	O
salbutamol	B
sulfate	I
.	O

The	O
method	O
has	O
the	O
advantages	O
that	O
the	O
prepared	O
fine	O
powder	O
crystal	O
has	O
uniform	O
grain	O
size	O
and	O
good	O
smoothness	O
,	O
the	O
grain	O
size	O
is	O
in	O
narrow	O
distribution	O
,	O
the	O
obtained	O
granules	O
have	O
smooth	O
surface	O
and	O
are	O
basically	O
spherical	O
;	O
the	O
technique	O
is	O
simple	O
and	O
easy	O
to	O
control	O
,	O
the	O
practicability	O
is	O
strong	O
,	O
the	O
preparation	O
cost	O
is	O
low	O
,	O
the	O
used	O
organic	O
reagent	O
is	O
recoverable	O
,	O
and	O
CO2	B
can	O
not	O
cause	O
pollution	O
after	O
being	O
discharged	O
to	O
the	O
air	O
;	O
the	O
fine	O
powder	O
of	O
salbutamol	B
sulfate	I
can	O
be	O
used	O
as	O
the	O
main	O
component	O
of	O
dry	O
powder	O
inhalation	O
or	O
aerosol	O
,	O
and	O
pharmaceutical	O
preparation	O
can	O
be	O
prepared	O
by	O
blending	O
the	O
fine	O
powder	O
of	O
salbutamol	B
sulfate	I
with	O
other	O
auxiliary	O
materials	O
.	O

Process	O
for	O
producing	O
salbutamol	B
sulfate	I
fine	O
powder	O

The	O
invention	O
relates	O
to	O
an	O
external	O
pharmaceutical	O
composition	O
preparation	O
with	O
functions	O
of	O
resisting	O
inflammation	O
,	O
reducing	O
swelling	O
and	O
relieving	O
pain	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
preparation	O
is	O
prepared	O
by	O
the	O
following	O
effective	O
component	O
raw	O
materials	O
in	O
weight	O
percent	O
of	O
the	O
whole	O
preparation	O
:	O
0.01	O
to	O
20	O
percent	O
of	O
escin	O
and/or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
0.01	O
to	O
10	O
percent	O
of	O
diclofenac	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
the	O
balance	O
being	O
accessories	O
.	O

The	O
external	O
pharmaceutical	O
composition	O
can	O
be	O
made	O
into	O
any	O
pharmaceutically	O
acceptable	O
external	O
dosage	O
form	O
.	O

The	O
preparation	O
can	O
be	O
used	O
for	O
treating	O
symptoms	O
,	O
such	O
as	O
arthralgia	O
,	O
hyperosteogeny	O
,	O
gout	O
,	O
neuropathic	O
pain	O
,	O
injuries	O
from	O
falls	O
,	O
chronic	O
strain	O
diseases	O
and	O
various	O
closed	O
injuries	O
,	O
andthe	O
like	O
,	O
and	O
has	O
strong	O
practicability	O
.	O

External	O
-	O
use	O
pharmaceutical	O
composition	O
formulation	O
with	O
antiphlogistic	O
,	O
swelling	O
-	O
dispersing	O
and	O
analgesic	O
functions	O
,	O
and	O
use	O

The	O
invention	O
discloses	O
a	O
structural	O
analogue	O
of	O
curcumin	B
piperidone	I
,	O
and	O
the	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
antitumor	O
medicaments	O
,	O
more	O
particularly	O
relates	O
to	O
synthesized	O
3	B
,	I
5-bis-	I
(	I
3	I
,	I
4-methylenedioxybenxene	I
-	I
benzylidene	I
)	I
-4-piperidone	I
and	O
3	B
,	I
5-bis-	I
(	I
3-pyridine	I
methylene	I
)	I
-4-piperidone	I
and	O
the	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
antitumor	O
medicaments	O
.	O

The	O
compound	O
3	B
,	I
5-bis-	I
(	I
3	I
,	I
4-methylenedioxybenxene	I
-	I
benzylidene	I
)	I
-4-piperidone	I
and	O
3	B
,	I
5-bis-	I
(	I
3-pyridine	I
methylene	I
)	I
-4-piperidone	I
can	O
be	O
obtained	O
by	O
the	O
Claisen	O
-	O
Schimidt	O
reaction	O
of	O
piperonal	O
or	O
3-pyridylaldehyde	B
and	O
4-piperidone	B
hydrochloride	I
.	O

The	O
compound	O
is	O
used	O
for	O
preparing	O
medicaments	O
for	O
curing	O
leucocythemia	O
,	O
skin	O
cancer	O
,	O
stomach	O
cancer	O
,	O
colon	O
cancer	O
,	O
liver	O
cancer	O
,	O
breast	O
cancer	O
,	O
prostate	O
cancer	O
or	O
other	O
malignant	O
tumors	O
.	O

Curcumin	B
piperidone	I
analog	O
and	O
use	O
thereof	O
in	O
anti	O
-	O
tumor	O
medicament	O

The	O
invention	O
provides	O
a	O
controlled	O
release	O
preparation	O
for	O
doxazosin	B
or	O
salts	O
thereof	O
,	O
wherein	O
,	O
the	O
controlled	O
release	O
preparation	O
comprises	O
a	O
drug	O
containing	O
layer	O
and	O
a	O
boosting	O
layer	O
which	O
have	O
the	O
weight	O
ratio	O
of	O
1	O
:	O
0.5	O
to	O
3	O
.	O

The	O
drug	O
containing	O
layer	O
comprises	O
the	O
doxazosin	B
or	O
salts	O
thereof	O
and	O
a	O
carrier	O
,	O
and	O
the	O
carrier	O
is	O
vinylpyrrolidone	B
polymers	O
which	O
occupy	O
40	O
percent	O
and	O
99	O
percent	O
of	O
the	O
weight	O
of	O
the	O
drug	O
containing	O
layer	O
;	O
the	O
boosting	O
layer	O
at	O
least	O
comprises	O
permeability	O
promoting	O
polymers	O
occupying	O
10	O
percent	O
to	O
80	O
percent	O
of	O
the	O
weight	O
of	O
the	O
boosting	O
layer	O
,	O
10	O
percent	O
to	O
80	O
percent	O
water	O
insoluble	O
polymers	O
and	O
3	O
percent	O
to	O
60	O
percent	O
osmotic	O
pressure	O
accelerators	O
;	O
a	O
controllable	O
speed	O
release	O
drug	O
of	O
the	O
doxazosin	B
or	O
the	O
salts	O
which	O
can	O
be	O
accepted	O
by	O
the	O
doxazosin	B
in	O
pharmacy	O
causes	O
the	O
preparation	O
to	O
achieve	O
the	O
purpose	O
that	O
the	O
doxazosin	B
or	O
the	O
salts	O
which	O
can	O
be	O
accepted	O
by	O
the	O
doxazosin	B
in	O
pharmacy	O
can	O
be	O
released	O
within	O
about	O
24	O
h	O
through	O
once	O
drug	O
feeding	O
daily	O
.	O

Controlled	O
release	O
preparation	O
containing	O
doxazosin	B
or	O
salt	O
thereof	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
paclitaxel	B
lipid	O
compound	O
and	O
a	O
micellar	O
compound	O
used	O
in	O
the	O
injection	O
of	O
the	O
paclitaxel	B
lipid	O
compound	O
.	O

The	O
paclitaxel	B
liposome	O
compound	O
is	O
composed	O
of	O
paclitaxel	B
with	O
a	O
therapeutic	O
dose	O
,	O
phospholipid	O
,	O
cholesterol	B
sulfate	I
or	O
/	O
and	O
similar	O
cholesterol	B
derivative	O
,	O
additive	O
and	O
injection	O
water	O
.	O

By	O
means	O
of	O
the	O
lipidization	O
of	O
the	O
paclitaxel	B
,	O
the	O
problem	O
about	O
organic	O
menstruum	O
of	O
an	O
injection	O
and	O
the	O
problem	O
of	O
hypersusceptibility	O
of	O
a	O
surface	O
active	O
agent	O
are	O
solved	O
.	O

A	O
paclitaxel	B
lipid	O
compound	O
injection	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
small	O
side	O
effect	O
,	O
low	O
blood	O
vessel	O
simulation	O
,	O
high	O
drug	O
-	O
loading	O
rate	O
,	O
narrow	O
particle	O
size	O
distribution	O
,	O
capability	O
of	O
filtering	O
and	O
degerming	O
,	O
good	O
pharmaceutical	O
stability	O
,	O
etc	O
.	O

Paclitaxel	B
lipid	O
complexes	O
and	O
micelle	O
composition	O
thereof	O
for	O
injection	O

The	O
invention	O
relates	O
to	O
the	O
medicine	O
technical	O
field	O
,	O
in	O
particular	O
to	O
an	O
anti	O
-	O
cancer	O
compound	O
Nobiliside	B
B	I
separated	O
from	O
Holothuria	O
nobilis	O
Selenka	O
.	O

The	O
molecular	O
formula	O
of	O
the	O
anti	O
-	O
cancer	O
compound	O
is	O
C41H63O17Sna	B
.	O

By	O
various	O
modern	O
spectral	O
analysis	O
,	O
particularly	O
the	O
application	O
of	O
advanced	O
two	O
-	O
dimensional	O
nuclear	O
magnetic	O
resonance	O
spectrum	O
and	O
high	O
resolution	O
mass	O
spectrum	O
to	O
comprehensive	O
analysis	O
,	O
the	O
chemical	O
structure	O
and	O
the	O
spatial	O
configuration	O
of	O
the	O
composition	O
are	O
determined	O
.	O

Vitro	O
anti	O
-	O
tumor	O
tests	O
show	O
that	O
the	O
compound	O
can	O
obviously	O
inhibit	O
A-549	O
lung	O
tumor	O
cell	O
strains	O
.	O

The	O
invention	O
can	O
provide	O
a	O
lead	O
compound	O
for	O
research	O
on	O
a	O
new	O
anti	O
-	O
tumor	O
medicine	O
,	O
and	O
has	O
essential	O
values	O
on	O
developing	O
and	O
utilizing	O
medical	O
living	O
marine	O
resources	O
in	O
China	O
.	O

Novel	O
antineoplastic	O
compound	O
Holothuria	O
nobilis	O
Selenka	O
saponin	B
B	I
in	O
Holothuria	O
nobilis	O
Selenka	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
diabetes	O
related	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
depressor	O
for	O
a	O
Na	B
-	I
glucose	I
transporter	O
II	O
containing	O
a	O
structure	O
of	O
sulpho	B
-	I
glucose	I
(	O
SGLT2	O
)	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
SGLT2	O
and	O
an	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
diabetes	O
drugs	O
,	O
wherein	O
,	O
a	O
radical	O
group	O
is	O
defined	O
in	O
the	O
specification	O
.	O

Sulpho	B
-	I
glucosan	I
derivative	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
an	O
N-	B
(	I
methylthio	I
-	I
sulfur	I
carbonyl	I
)	I
-17-steroidal	I
hydrazone	I
compound	O
(	O
III	O
)	O
with	O
a	O
brand	O
-	O
new	O
structure	O
,	O
further	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
finds	O
that	O
the	O
compound	O
has	O
more	O
obvious	O
anti	O
-	O
cancer	O
activity	O
.	O

The	O
invention	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
invention	O
uses	O
the	O
condensation	O
of	O
sterone	O
with	O
the	O
protein	O
assimilation	O
and	O
dithio	B
methyl	I
hydrazinocarboxylate	I
for	O
preparing	O
the	O
novel	O
N-	B
(	I
methylthio	I
-	I
sulfur	I
carbonyl	I
)	I
-17-steroidal	I
hydrazone	I
compound	O
,	O
and	O
the	O
compound	O
has	O
a	O
certain	O
anti	O
-	O
cancer	O
activity	O
and	O
the	O
potential	O
for	O
further	O
development	O
,	O
thereby	O
providing	O
a	O
basis	O
for	O
screening	O
of	O
new	O
drugs	O
.	O

N-	B
(	I
methylthio	I
-	I
sulfur	I
carbonyl	I
)	I
-17-steroidal	I
hydrazone	I
compound	O
,	O
preparation	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
nano	O
-	O
scale	O
lycorine	B
hydrochloride	I
microcapsule	O
emulsion	O
and	O
preparing	O
method	O
thereof	O
.	O

The	O
nano	O
-	O
scale	O
lycorine	B
hydrochloride	I
microcapsule	O
emulsion	O
comprises	O
a	O
water	O
phase	O
II	O
and	O
a	O
lycorine	B
hydrochloride	I
nano	O
microcapsule	O
dispersed	O
in	O
the	O
water	O
phase	O
II	O
,	O
the	O
particle	O
diameter	O
range	O
of	O
the	O
lycorine	B
hydrochloride	I
nano	O
microcapsule	O
is	O
5	O
-	O
100	O
nm	O
;	O
the	O
lycorine	B
hydrochloride	I
nanomicrocapsule	O
is	O
composed	O
of	O
a	O
water	O
phase	O
I	O
and	O
an	O
oil	O
phase	O
,	O
the	O
water	O
phase	O
is	O
packaged	O
in	O
the	O
oil	O
phase	O
.	O

The	O
preparing	O
method	O
comprises	O
(	O
1	O
)	O
adding	O
the	O
water	O
phase	O
I	O
into	O
the	O
oil	O
phase	O
to	O
form	O
pre	O
-	O
emulsifiable	O
solution	O
under	O
50000rmp-20000rmp	O
high	O
speed	O
shearing	O
condition	O
;	O
(	O
2	O
)	O
mixing	O
the	O
pre	O
-	O
emulsifiable	O
solution	O
and	O
the	O
water	O
phase	O
II	O
to	O
obtain	O
a	O
premixing	O
liquid	O
under	O
the	O
stirring	O
condition	O
;	O
(	O
3	O
)	O
performing	O
high	O
-	O
pressure	O
homogeneity	O
for	O
the	O
premixing	O
liquid	O
one	O
-	O
four	O
times	O
to	O
obtain	O
the	O
nano	O
-	O
scale	O
lycorine	B
hydrochloride	I
microcapsule	O
emulsion	O
under	O
100	O
-	O
200	O
MPa	O
.	O

Nano	O
lycorine	B
chloride	I
microcapsule	O
latex	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
summer	O
sleeping	O
mat	O
using	O
vitamin	B
C	I
and	O
vitamin	B
E	I
to	O
enhance	O
the	O
resistance	O
,	O
including	O
:	O
(	O
1	O
)	O
preparation	O
of	O
vitamin	O
treatment	O
agent	O
,	O
mixing	O
the	O
following	O
components	O
based	O
on	O
the	O
weight	O
percentage	O
:	O
3	O
-	O
8	O
%	O
of	O
vitamin	B
C	I
,	O
0.5	O
-	O
2	O
%	O
of	O
Vitamin	B
E	I
,	O
5	O
-	O
10	O
%	O
of	O
binder	O
,	O
water	O
allowance	O
,	O
mixing	O
uniformly	O
,	O
to	O
obtain	O
a	O
treatment	O
agent	O
with	O
enhanced	O
resistance	O
;	O
(	O
2	O
)	O
spraying	O
or	O
brushing	O
the	O
treatment	O
agent	O
with	O
enhanced	O
resistance	O
on	O
summer	O
sleeping	O
mat	O
products	O
;	O
(	O
3	O
)	O
drying	O
the	O
summer	O
sleeping	O
mat	O
at	O
100	O
-	O
150	O
DEG	O
C	O
for	O
15	O
-	O
30min	O
after	O
treating	O
to	O
become	O
the	O
summer	O
sleeping	O
mat	O
with	O
enhanced	O
resistance	O
.	O

The	O
summer	O
sleeping	O
mat	O
produced	O
by	O
the	O
invention	O
can	O
maintain	O
immune	O
function	O
of	O
human	O
cells	O
to	O
be	O
younger	O
,	O
and	O
long	O
-	O
term	O
use	O
of	O
the	O
summer	O
sleeping	O
mat	O
caneffectively	O
improve	O
the	O
immune	O
function	O
of	O
human	O
cells	O
;	O
also	O
can	O
make	O
the	O
skin	O
beauty	O
,	O
protect	O
the	O
health	O
of	O
the	O
skin	O
to	O
reduce	O
the	O
occurrence	O
of	O
skin	O
infections	O
;	O
and	O
can	O
maintain	O
the	O
failure	O
-	O
free	O
operation	O
of	O
the	O
immune	O
,	O
nervous	O
,	O
and	O
cardiovascular	O
functioning	O
,	O
to	O
improve	O
physical	O
health	O
of	O
humans	O
.	O

Method	O
for	O
producing	O
summer	O
sleeping	O
mat	O
using	O
vitamin	B
C	I
and	O
vitamin	B
E	I
to	O
build	O
up	O
resistance	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
,	O
in	O
particular	O
to	O
application	O
of	O
a	O
compound	O
,	O
namely	O
butyl	B
-	I
isobutyl	I
-	I
dimethyl	I
phthalate	I
.	O

Particularly	O
,	O
the	O
compound	O
,	O
namely	O
the	O
butyl	B
-	I
isobutyl	I
-	I
dimethyl	I
phthalate	I
shown	O
in	O
a	O
formula	O
I	O
or	O
derivatives	O
of	O
the	O
compound	O
,	O
namely	O
the	O
butyl	B
-	I
isobutyl	I
-	I
dimethyl	I
phthalate	I
shown	O
in	O
the	O
formula	O
I	O
are	O
used	O
for	O
preparing	O
a	O
medicine	O
for	O
diabetes	O
which	O
takes	O
alpha	O
-	O
glucosidase	O
in	O
a	O
body	O
as	O
the	O
target	O
.	O

The	O
compound	O
,	O
namely	O
the	O
butyl	B
-	I
isobutyl	I
-	I
dimethyl	I
phthalate	I
can	O
be	O
obtained	O
through	O
the	O
extraction	O
and	O
separation	O
from	O
kelp	O
roots	O
,	O
Laminaria	O
,	O
Phaeophyta	O
.	O

The	O
compound	O
hasstronger	O
inhibitory	O
activity	O
to	O
alpha	O
-	O
glucosidase	O
under	O
low	O
concentration	O
conditions	O
,	O
the	O
IC50	O
of	O
in	O
vitro	O
inhibition	O
of	O
the	O
alpha	O
-	O
glucosidase	O
is	O
13.6ug	O
/	O
mL	O
,	O
the	O
inhibition	O
type	O
is	O
non	O
-	O
competitive	O
inhibition	O
,	O
and	O
the	O
compound	O
can	O
effectively	O
inhibit	O
the	O
activity	O
of	O
the	O
alpha	O
-	O
glucosidase	O
.	O

Application	O
of	O
compound	O
butyl	B
-	I
isobutyl	I
-	I
dimethyl	I
phthalate	I

The	O
invention	O
discloses	O
an	O
oxalic	B
acid	I
esmolol	I
citalopram	I
oral	O
solid	O
preparation	O
and	O
a	O
preparation	O
method	O
.	O

The	O
oral	O
solid	O
preparation	O
comprises	O
raw	O
materials	O
of	O
:	O
2	O
-	O
40	O
parts	O
by	O
weight	O
of	O
oxalic	B
acid	I
esmolol	I
citalopram	I
,	O
5	O
-	O
60	O
parts	O
by	O
weight	O
of	O
starch	O
,	O
5	O
-	O
200	O
parts	O
by	O
weight	O
of	O
microcrystalline	O
cellulose	O
,	O
5	O
-	O
60	O
parts	O
by	O
weight	O
of	O
lactose	B
,	O
0.05	O
-	O
5	O
parts	O
by	O
weight	O
of	O
binding	O
agent	O
and	O
0.05	O
-	O
3	O
parts	O
by	O
weight	O
of	O
lubricant	O
;	O
the	O
binding	O
agent	O
is	O
one	O
or	O
a	O
plurality	O
of	O
mixed	O
aqueous	O
solutions	O
or	O
alcoholic	O
solutions	O
from	O
the	O
group	O
consisting	O
of	O
polyvinyl	B
pyrrolidone	I
,	O
hydroxyethyl	O
methylcellulose	O
,	O
methylcellulose	O
,	O
hydroxypropyl	O
cellulose	O
and	O
ethyl	O
cellulose	O
,	O
the	O
concentration	O
of	O
the	O
binding	O
agent	O
is	O
0.1	O
-	O
10.0	O
%	O
;	O
and	O
the	O
lubricant	O
is	O
stearic	B
acid	I
,	O
magnesium	B
stearate	I
,	O
calcium	B
stearate	I
,	O
talcum	O
or	O
superfine	O
silica	O
gel	O
powder	O
.	O

Oral	O
solid	O
preparation	O
of	O
escitalopram	B
oxalate	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
cordyceps	O
militaris	O
preparation	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

According	O
to	O
weight	O
parts	O
,	O
the	O
preparation	O
comprises	O
four	O
raw	O
materials	O
of	O
,	O
as	O
active	O
ingredients	O
,	O
cordyceps	O
militaris	O
(	O
also	O
called	O
as	O
North	O
Cordyceps	O
)	O
,	O
yam	O
,	O
adlay	O
core	O
and	O
fructo	O
oligosaccharide	B
,	O
the	O
preparation	O
method	O
thereof	O
comprises	O
the	O
steps	O
as	O
follows	O
:	O
ultrafining	O
thecordyceps	O
militaris	O
(	O
also	O
called	O
as	O
North	O
Cordyceps	O
)	O
to	O
be	O
mixed	O
uniformly	O
with	O
dried	O
concentrations	O
subsequent	O
to	O
the	O
extraction	O
of	O
the	O
yam	O
and	O
the	O
adlay	O
core	O
with	O
water	O
or	O
olefinic	B
alcohol	I
,	O
adding	O
an	O
appropriate	O
amount	O
of	O
auxiliary	O
materials	O
to	O
prepare	O
granular	O
formulation	O
,	O
bag	O
formulation	O
,	O
capsule	O
,	O
tablet	O
and	O
the	O
like	O
.	O

The	O
pharmacodynamical	O
test	O
results	O
demonstrate	O
that	O
the	O
inventive	O
preparation	O
has	O
the	O
functions	O
of	O
enhancing	O
immunity	O
and	O
improving	O
functions	O
of	O
alimentary	O
canal	O
,	O
and	O
is	O
much	O
safer	O
than	O
single	O
-	O
item	O
cordyceps	O
militaris	O
.	O

Compound	O
Cordyceps	O
militaris	O
L.	O
Link	O
preparation	O
and	O
production	O
method	O
and	O
application	O

The	O
invention	O
provides	O
a	O
method	O
for	O
preparing	O
a	O
forsythoside	O
-	O
beta	O
-	O
cyclodextrin	O
inclusion	O
compound	O
.	O

Forsythoside	B
extract	O
with	O
the	O
purity	O
of	O
50%-60	O
%	O
is	O
used	O
as	O
raw	O
material	O
,	O
and	O
the	O
forsythoside	O
-	O
beta	O
-	O
cyclodextrin	O
inclusion	O
compound	O
is	O
prepared	O
by	O
a	O
colloid	O
mill	O
inclusion	O
method	O
.	O

The	O
content	O
of	O
the	O
forsythoside	B
in	O
the	O
forsythoside	O
-	O
beta	O
-	O
cyclodextrin	O
inclusion	O
compound	O
is	O
10%-20	O
%	O
,	O
the	O
inclusion	O
ratio	O
of	O
the	O
forsythoside	B
is	O
more	O
than	O
85	O
percent	O
,	O
and	O
the	O
inclusion	O
compound	O
yield	O
is	O
more	O
than	O
70	O
percent	O
.	O

Preparation	O
method	O
of	O
forsythoside	O
-	O
beta	O
-	O
cyclodextrin	O
inclusion	O
compound	O

This	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
R<1	O
>	O
is	O
optionally	O
substituted	O
lower	O
alkyl	B
,	O
Y	O
is	O
-S	B
(	I
O	I
)	I
n-	I
wherein	O
n	O
is	O
1	O
or	O
2	O
,	O
or	O
-CO-	B
,	O
R<2	O
>	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
,	O
R<7	O
>	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
,	O
X	O
is	O
lower	O
alkylene	B
,	O
lower	O
alkenylene	B
,	O
arylene	B
,	O
cycloalkylene	B
or	O
the	O
like	O
,	O
and	O
Z	O
is	O
lower	O
alkyl	B
,	O
optionally	O
substituted	O
carbocyclyl	B
,	O
optionally	O
substituted	O
heterocyclyl	B
or	O
the	O
like	O
.	O

Amine	B
derivative	O
having	O
npyy5	O
receptor	O
antagonist	O
activity	O

Hepatinica	O
used	O
for	O
golden	O
pompano	O
is	O
prepared	O
from	O
the	O
following	O
components	O
by	O
weight	O
:	O
20	O
to	O
30	O
percent	O
of	O
vitamin	B
E	I
,	O
20	O
to	O
30	O
percent	O
of	O
vitamin	B
C-	I
polyphosphonate	I
,	O
10	O
to	O
15	O
percent	O
of	O
sinkaline	O
,	O
5	O
to	O
10	O
percent	O
of	O
L	B
-	I
Carnitine	I
,	O
5	O
to	O
10	O
percent	O
of	O
lecithin	B
,	O
5	O
to	O
10	O
percent	O
of	O
Rhizoma	O
Atractylodis	O
Macrocephalae	O
,	O
5	O
to	O
10	O
percent	O
of	O
medlar	O
,	O
and	O
5	O
to	O
10	O
percent	O
of	O
Alisma	O
orientale	O
.	O

The	O
hepatinica	O
can	O
be	O
used	O
as	O
additive	O
of	O
golden	O
pompano	O
feed	O
and	O
is	O
added	O
in	O
the	O
golden	O
pompano	O
feed	O
only	O
by	O
0.1	O
to	O
0.2	O
percent	O
,	O
can	O
prevent	O
fatty	O
infiltration	O
of	O
the	O
golden	O
pompano	O
,	O
strengthen	O
the	O
liver	O
function	O
,	O
improve	O
the	O
feed	O
efficiency	O
and	O
promote	O
the	O
growth	O
of	O
the	O
golden	O
pompano	O
,	O
improves	O
the	O
survival	O
rate	O
of	O
golden	O
pompano	O
,	O
has	O
no	O
poor	O
influence	O
to	O
the	O
palatability	O
of	O
feed	O
,	O
and	O
has	O
stable	O
raw	O
material	O
resources	O
,	O
low	O
price	O
and	O
simple	O
production	O
technology	O
.	O

Hepatinica	O
for	O
egg	O
-	O
shaped	O
pompano	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
piroxicam	B
beta	O
-	O
cyclodextrin	O
inclusion	O
compound	O
micropill	O
capsule	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
that	O
:	O
(	O
1	O
)	O
in	O
ammonia	O
water	O
with	O
a	O
mass	O
percent	O
concentration	O
of	O
between	O
23	O
and	O
25	O
percent	O
,	O
piroxicam	B
and	O
beta	O
-	O
cyclodextrin	O
are	O
dissolved	O
into	O
water	O
with	O
a	O
temperature	O
of	O
between	O
65	O
and	O
85	O
DEG	O
C	O
according	O
to	O
a	O
mol	O
ratio	O
of	O
1	O
:	O
2.7	O
-	O
3.8	O
;	O
and	O
(	O
2	O
)	O
underthe	O
atomizing	O
pressure	O
of	O
between	O
0.05	O
and	O
0.5MPa	O
,	O
the	O
airflow	O
temperature	O
is	O
controlled	O
to	O
be	O
between	O
75	O
and	O
85	O
DEG	O
C	O
,	O
the	O
flow	O
rate	O
is	O
between	O
10	O
and	O
150ml	O
/	O
min	O
,	O
a	O
piroxicam	B
beta	O
-	O
cyclodextrin	O
solution	O
is	O
sprayed	O
on	O
a	O
pill	O
core	O
for	O
spraying	O
and	O
coating	O
,	O
and	O
a	O
piroxicam	B
beta	O
-	O
cyclodextrin	O
inclusion	O
compound	O
micropill	O
is	O
prepared	O
after	O
immediate	O
drying	O
.	O

The	O
method	O
does	O
not	O
need	O
to	O
add	O
any	O
auxiliary	O
materials	O
or	O
excipients	O
so	O
as	O
to	O
reduce	O
the	O
relative	O
process	O
difficulty	O
when	O
including	O
a	O
piroxicam	B
beta	O
-	O
cyclodextrin	O
powder	O
preparation	O
,	O
simplifies	O
process	O
flow	O
,	O
and	O
reduces	O
production	O
cost	O
.	O

Preparation	O
method	O
of	O
piroxicam	B
belta	O
-	O
cyclodextrin	O
inclusion	O
compound	O
micro	O
-	O
pill	O
capsules	O

The	O
invention	O
discloses	O
thiazole	B
Schiff	I
base	I
(	O
I	O
,	O
II	O
)	O
containing	O
nitryl	B
with	O
a	O
chemical	O
structural	O
formula	O
as	O
follows	O
.	O

A	O
method	O
for	O
preparing	O
the	O
thiazole	B
Schiff	I
base	I
containing	O
the	O
nitryl	B
comprises	O
the	O
steps	O
as	O
follows	O
:	O
nitrobenzene	B
formaldehyde	I
takes	O
reflux	O
reaction	O
with	O
5-	B
(	I
4-chlorobenzyl	I
)	I
-4-tert	I
-	I
butyl-2-amido	I
thiazole	I
in	O
ethanol	O
to	O
prepare	O
and	O
obtain	O
the	O
thiazole	B
Schiff	I
base	I

[	O
I	O
with	O
chemical	O
name	O
of	O
5-	B
(	I
4-chlorobenzyl	I
)	I
-4-tert	I
-	I
butyl-2-	I
(	I
nitrobenzyl	I
imino	I
)	I
thiazole	I
]	O
containing	O
the	O
nitryl	B
;	O
or	O
salicylaldehyde	B
takes	O
reflux	O
reaction	O
with	O
4-	B
(	I
nitrophenyl	I
)	I
-2-amido	I
thiazole	I
in	O
the	O
ethanol	B
to	O
prepare	O
and	O
obtain	O
the	O
thiazole	B
Schiff	I
base	I
[	O
II	O
with	O
chemical	O
name	O
of	O
4-	B
(	I
nitrophenyl	I
)	I
-2-	I
(	I
2-hydroxy	I
benzyl	I
imino	I
)	I
thiazole	I
]	O
containing	O
the	O
nitryl	B
.	O

The	O
thiazole	B
Schiff	I
base	I
containing	O
the	O
nitryl	B
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
inflammatory	O
analgesics	O
.	O

Thiazole	B
schiff	I
base	I
containing	O
nitryl	B
,	O
preparation	O
and	O
uses	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
pharmaceutical	O
technical	O
field	O
and	O
specifically	O
relates	O
to	O
sulfhydryl	B
imidazopyridine	I
derivatives	O
which	O
are	O
shown	O
in	O
general	O
formula	O
(	O
I	O
)	O
and	O
contain	O
diosulberane	B
pyridine	I
,	O
isomers	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
and	O
R<3	O
>	O
are	O
defined	O
as	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
preparation	O
methods	O
of	O
the	O
compounds	O
,	O
drug	O
compositions	O
containing	O
the	O
compounds	O
and	O
the	O
application	O
of	O
the	O
compounds	O
in	O
preparing	O
drugs	O
for	O
preventing	O
and/or	O
treating	O
digestive	O
ulcer	O
.	O

Sulfhydryl	B
imidazopyridine	I
derivative	O
containing	O
dioxepane	B
-	I
pyridine	I

There	O
are	O
provided	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R<1>,R<2	O
>	O
,	O
R<3	O
>	O
,	O
X	O
,	O
Y	O
,	O
Q	O
,	O
Ring	O
A	O
and	O
Ring	O
B	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O

Thieno	B
[	I
3,2-C	I
]	I
pyridine-7-carboxylic	I
acid	I
derivatives	O

The	O
invention	O
discloses	O
a	O
matching	O
method	O
of	O
lotion	O
for	O
treating	O
barbiers	O
and	O
psoriasis	O
.	O

The	O
lotion	O
consists	O
of	O
eight	O
types	O
of	O
drugs	O
with	O
weight	O
percentage	O
such	O
as	O
10	O
to	O
20	O
percent	O
of	O
Chinese	O
honeylocust	O
spine	O
,	O
10	O
to	O
15	O
percent	O
of	O
tribulus	O
terrestris	O
,	O
10	O
to	O
15	O
percent	O
of	O
safflower	O
,	O
10	O
to	O
15	O
percent	O
of	O
cortex	O
periplocae	O
,	O
10	O
to	O
15	O
percent	O
of	O
cortex	O
lycii	O
radicis	O
,	O
10	O
to	O
20	O
percent	O
of	O
lightyellow	O
sophora	O
root	O
,	O
0.1	O
to	O
0.5	O
percent	O
of	O
alum	O
and	O
acetic	B
acid	I
;	O
after	O
being	O
mixed	O
according	O
to	O
the	O
proportion	O
,	O
the	O
drugs	O
can	O
treat	O
various	O
skin	O
diseases	O
including	O
barbiers	O
and	O
psoriasis	O
and	O
the	O
like	O
,	O
and	O
have	O
obvious	O
effect	O
.	O

Compound	O
formulation	O
of	O
washing	O
lotion	O
for	O
treating	O
beriberi	O
and	O
dermatophytosis	O

The	O
invention	O
provides	O
a	O
method	O
for	O
preparing	O
polyphenol	B
-	O
protein	O
complex	O
,	O
comprising	O
the	O
following	O
steps	O
:	O
according	O
to	O
parts	O
by	O
weight	O
,	O
mixing	O
100	O
parts	O
of	O
denatured	O
protein	O
and	O
30	O
-	O
150	O
parts	O
of	O
polyphenol	B
in	O
aqueous	O
solution	O
and	O
depositing	O
the	O
polyphenol	B
-	O
protein	O
complex	O
,	O
separating	O
the	O
deposited	O
polyphenol	B
-	O
protein	O
complex	O
from	O
the	O
aqueous	O
solution	O
.	O

The	O
invention	O
also	O
provides	O
an	O
antibiotic	O
patch	O
containing	O
the	O
polyphenol	B
-	O
protein	O
complex	O
.	O

Polyphenol	B
-	O
protein	O
complexes	O
and	O
method	O
for	O
producing	O
the	O
same	O
,	O
patch	O
containing	O
the	O
polyphenol	O
-	O
protein	O
complexes	O
and	O
method	O
for	O
producing	O
the	O
same	O

The	O
invention	O
belongs	O
to	O
the	O
biological	O
medicine	O
field	O
,	O
relating	O
to	O
nucleotide	O
molecules	O
and	O
the	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
antitumor	O
medicines	O
.	O

The	O
invention	O
provides	O
the	O
nucleotide	O
molecules	O
for	O
preparing	O
the	O
antitumor	O
medicines	O
.	O

The	O
nucleotide	O
molecules	O
have	O
the	O
activity	O
for	O
inhibiting	O
the	O
tumor	O
growth	O
and	O
the	O
sequence	O
thereof	O
comprises	O
5'-CAACGGCUSUGCUAGACGA-3	O
'	O
or	O
5'-CAACGGCTGTGCTAGACAG-3	O
'	O
which	O
is	O
known	O
as	O
SI	O
-	O
CYPJ-4	O
in	O
the	O
invention	O
.	O

The	O
nucleotide	O
molecules	O
SI	O
-	O
CYPJ-4	O
can	O
obviously	O
inhibit	O
the	O
tumor	O
cell	O
proliferation	O
;	O
when	O
the	O
nucleotide	O
molecules	O
are	O
applied	O
to	O
a	O
naked	O
mouse	O
,	O
the	O
tumor	O
body	O
growth	O
of	O
the	O
naked	O
mouse	O
is	O
obviously	O
inhibited	O
compared	O
with	O
the	O
control	O
naked	O
mouse	O
in	O
the	O
same	O
condition	O
of	O
culture	O
,	O
and	O
the	O
phenomenon	O
becomes	O
obvious	O
day	O
by	O
day	O
as	O
time	O
goeson	O
.	O

The	O
invention	O
provides	O
a	O
new	O
approach	O
and	O
means	O
for	O
the	O
tumor	O
treatment	O
and	O
mitigation	O
.	O

Nucleic	O
acid	O
molecule	O
SI	O
-	O
CYPJ-4	O
and	O
use	O
thereof	O
in	O
anti	O
-	O
cancer	O
medicine	O
preparation	O

The	O
present	O
invention	O
relates	O
to	O
a	O
Triazine	B
derivative	O
compound	O
,	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
.	O

Compound	O
or	O
composition	O
of	O
the	O
present	O
invention	O
is	O
useful	O
for	O
cancer	O
treatment	O
,	O
and	O
especially	O
has	O
superior	O
effect	O
in	O
breast	O
cancer	O
treatment	O
.	O

Triazine	B
derivative	O
compound	O
and	O
composition	O
for	O
treating	O
cancer	O
containing	O
them	O

The	O
invention	O
discloses	O
a	O
continuous	O
preparation	O
method	O
for	O
nanometer	O
dispersed	O
vitamin	B
A	I
microcapsule	O
,	O
comprising	O
the	O
following	O
steps	O
:	O
the	O
vitamin	B
A	I
crystal	O
,	O
the	O
antioxidant	O
and	O
the	O
solvent	O
are	O
ground	O
until	O
the	O
particle	O
size	O
of	O
the	O
vitamin	B
A	I
is	O
2	O
to	O
5	O
mu	O
m	O
,	O
the	O
vitamin	B
A	I
dispersion	O
liquid	O
is	O
prepared	O
;	O
the	O
vitamin	B
A	I
dispersion	O
liquid	O
is	O
heated	O
by	O
a	O
preheater	O
and	O
dissolved	O
and	O
cooled	O
,	O
then	O
the	O
solution	O
is	O
sent	O
into	O
a	O
crystallizer	O
of	O
the	O
supergravity	O
rotating	O
packed	O
bed	O
with	O
the	O
liquid	O
distributor	O
,	O
at	O
the	O
same	O
time	O
the	O
water	O
solution	O
with	O
protection	O
colloid	O
is	O
sent	O
into	O
the	O
above	O
crystallizer	O
of	O
the	O
supergravity	O
rotating	O
packed	O
bed	O
,	O
the	O
nanometer	O
dispersed	O
vitamin	B
A	I
dispersion	O
liquid	O
is	O
obtained	O
at	O
the	O
outlet	O
,	O
the	O
dispersion	O
liquid	O
is	O
in	O
spray	O
drying	O
in	O
the	O
spray	O
drying	O
device	O
with	O
fluidization	O
cooling	O
device	O
to	O
obtain	O
the	O
nanometer	O
dispersed	O
vitamin	B
A	I
microcapsule	O
.	O

The	O
invention	O
has	O
the	O
advantage	O
of	O
continuous	O
production	O
,	O
because	O
the	O
vitamin	B
A	I
crystal	O
grain	O
in	O
the	O
product	O
is	O
small	O
,	O
the	O
product	O
has	O
wide	O
application	O
and	O
high	O
bioavailability	O
.	O

Continuous	O
preparation	O
method	O
for	O
nanometer	O
dispersed	O
vitamin	B
A	I
microcapsule	O

The	O
invention	O
discloses	O
a	O
new	O
use	O
of	O
T-2	B
toxin	I
,	O
that	O
is	O
,	O
application	O
of	O
T-2	B
toxin	I
in	O
the	O
preparation	O
of	O
drugs	O
for	O
treating	O
bone	O
cancers	O
and	O
myeloproliferative	O
disorder	O
,	O
wherein	O
the	O
curative	O
dose	O
thereof	O
is	O
0.1	O
-	O
20	O
mg	O
/	O
Kg	O
(	O
weight	O
)	O
,	O
preferably	O
0.5	O
-	O
8	O
mg	O
/	O
Kg	O
(	O
weight	O
)	O
,	O
during	O
drug	O
administration	O
,	O
the	O
method	O
comprises	O
oral	O
administration	O
,	O
intravenous	O
injection	O
,	O
hypodermic	O
injection	O
and	O
intramuscular	O
injection	O
.	O

The	O
invention	O
establishes	O
animal	O
or	O
cell	O
models	O
of	O
multiple	O
myeloma	O
,	O
osteosarcoma	O
and	O
myelodysplastic	O
syndrome	O
,	O
and	O
inspects	O
the	O
inhibition	O
of	O
the	O
T-2	B
toxin	I
on	O
the	O
tumors	O
or	O
tumor	O
cells	O
by	O
injection	O
or	O
cell	O
co	O
-	O
culture	O
.	O

The	O
experiment	O
shows	O
that	O
the	O
T-2	B
toxin	I
is	O
capable	O
of	O
inhibiting	O
the	O
growth	O
of	O
tumor	O
cells	O
and	O
has	O
good	O
killing	O
effect	O
on	O
the	O
bone	O
cancers	O
and	O
myeloproliferative	O
disorder	O
.	O

Application	O
of	O
T-2	B
toxin	I
in	O
the	O
preparation	O
of	O
drugs	O
for	O
treating	O
bone	O
cancers	O
and	O
myeloproliferative	O
disorder	O

The	O
invention	O
discloses	O
an	O
oral	O
medicament	O
for	O
treating	O
herpes	O
zoster	O
.	O

The	O
oral	O
medicament	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
following	O
raw	O
materials	O
in	O
proportion	O
by	O
weight	O
:	O
12	O
to	O
18	O
grams	O
of	O
snake	O
slough	O
,	O
13	O
to	O
16	O
grams	O
of	O
cicada	O
slough	O
,	O
3	O
centipedes	O
,	O
2	O
long	O
-	O
noded	O
pit	O
vipers	O
of	O
3	O
to	O
7	O
inches	O
,	O
13	O
to	O
16	O
grams	O
of	O
cortex	O
fraxini	O
,	O
12	O
to	O
18	O
grams	O
of	O
lithospermum	O
,	O
11	O
to	O
17	O
grams	O
of	O
Yiyuansan	O
,	O
22	O
to	O
28	O
grams	O
of	O
dried	O
rehamnnia	O
root	O
,	O
15	O
to	O
25	O
grams	O
of	O
fructus	O
gardeniae	O
,	O
13	O
to	O
17	O
grams	O
of	O
scutellaria	O
laterifolia	O
,	O
12	O
to	O
16	O
grams	O
of	O
rhubarb	O
,	O
12	O
to	O
16	O
grams	O
of	O
rhizoma	O
coptidis	O
in	O
Sichuan	O
,	O
14	O
to	O
16	O
grams	O
of	O
white	O
ginseng	O
,	O
45	O
to	O
55	O
grams	O
of	O
taraxacum	O
,	O
60	O
to	O
80	O
grams	O
of	O
radix	O
astragali	O
,	O
35	O
to	O
45	O
grams	O
of	O
gypsum	O
,	O
25	O
to	O
35	O
grams	O
of	O
talcum	O
,	O
10	O
to	O
20	O
grams	O
of	O
gamene	O
,	O
14	O
to	O
17	O
grams	O
of	O
costus	O
root	O
,	O
12	O
to	O
16	O
grams	O
of	O
immature	O
bitter	O
orange	O
,	O
25	O
to	O
28	O
grams	O
of	O
weathered	O
saltpeter	O
,	O
12	O
to	O
16	O
grams	O
of	O
paeonia	O
veitchii	O
,	O
14	O
to	O
16	O
grams	O
of	O
cortex	O
moutan	O
radicis	O
,	O
and	O
10	O
to	O
20	O
grams	O
of	O
radix	O
glycyrrhizae	O
.	O

The	O
medicaments	O
are	O
grinded	O
into	O
fine	O
power	O
,	O
mixed	O
and	O
filled	O
into	O
No.	O
0	O
capsules	O
or	O
compressed	O
into	O
tablets	O
2	O
grams	O
per	O
tablet	O
.	O

The	O
oral	O
medicament	O
has	O
the	O
advantages	O
of	O
short	O
period	O
of	O
treatment	O
,	O
low	O
cost	O
,	O
and	O
over	O
95	O
percent	O
of	O
cure	O
rate	O
.	O

Oral	O
medicament	O
for	O
treating	O
herpes	O
zoster	O

The	O
invention	O
provides	O
an	O
effective	O
food	O
prescription	O
for	O
treating	O
bacillary	O
dysentery	O
.	O

The	O
method	O
for	O
preparing	O
the	O
effective	O
food	O
prescription	O
mainly	O
comprises	O
:	O
7	O
g	O
of	O
green	O
tea	O
is	O
added	O
with	O
200	O
ml	O
of	O
boiled	O
water	O
,	O
and	O
the	O
mixture	O
is	O
added	O
with	O
25	O
g	O
of	O
vinegar	O
.	O

The	O
effective	O
food	O
prescription	O
has	O
special	O
effects	O
of	O
treating	O
abdominal	O
pain	O
,	O
diarrhea	O
and	O
even	O
vomiting	O
caused	O
by	O
improper	O
diet	O
,	O
and	O
the	O
total	O
effective	O
rate	O
is	O
95	O
percent	O
;	O
moreover	O
,	O
the	O
effective	O
food	O
prescription	O
has	O
the	O
advantages	O
of	O
convenient	O
use	O
,	O
no	O
toxic	O
and	O
side	O
effects	O
and	O
good	O
application	O
prospect	O
.	O

Food	O
prescription	O
for	O
treating	O
bacillary	O
dysentery	O

The	O
invention	O
discloses	O
an	O
antifungal	O
pyrazoline	B
-	O
substituting	O
compound	O
with	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
all	O
substitutional	O
groups	O
have	O
the	O
following	O
definitions	O
:	O
R1	O
is	O
(	O
II	O
)	O
;	O
R2	O
and	O
R4	O
are	O
mutually	O
independent	O
as	O
hydrogen	B
,	O
halogen	B
,	O
nitryl	B
,	O
methyl	B
or	O
methoxyl	B
group	O
;	O
and	O
R3	O
is	O
phenyl	B
,	O
acetyl	B
or	O
benzoyl	B
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
pyrazoline	B
-	O
substituting	O
compound	O
and	O
the	O
application	O
in	O
the	O
preparation	O
of	O
antifungal	O
drugs	O
.	O

Antifungal	O
pyrazoline	B
-	O
substituting	O
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
plaster	O
for	O
treating	O
cervical	O
vertebra	O
and	O
lumbar	O
intervertebral	O
disc	O
protrusion	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
plaster	O
is	O
made	O
from	O
highly	O
enriched	O
concentrate	O
of	O
drugs	O
with	O
functions	O
of	O
activating	O
blood	O
circulation	O
to	O
dissipate	O
blood	O
stasis	O
,	O
reducing	O
swelling	O
and	O
easing	O
pain	O
such	O
as	O
frankincense	O
,	O
myrrh	O
,	O
notoginseng	O
,	O
angelica	O
,	O
honeylocust	O
,	O
madder	O
root	O
,	O
burreed	O
rhizome	O
,	O
zedoary	O
and	O
the	O
like	O
by	O
the	O
unique	O
preparation	O
method	O
.	O

The	O
plaster	O
can	O
quickly	O
permeate	O
bones	O
and	O
muscles	O
to	O
cause	O
a	O
fissure	O
and	O
a	O
rupture	O
on	O
lumbar	O
vertebral	O
anulus	O
fibrosus	O
and	O
cartilage	O
with	O
serious	O
injury	O
to	O
heal	O
up	O
quickly	O
,	O
thus	O
achieving	O
a	O
purpose	O
of	O
curing	O
cervical	O
vertebra	O
hyperplasia	O
,	O
lumbar	O
vertebrae	O
hyperplasia	O
and	O
lumbar	O
intervertebral	O
disc	O
protrusion	O
,	O
overcoming	O
a	O
problem	O
which	O
is	O
not	O
solved	O
in	O
the	O
medical	O
field	O
worldwide	O
for	O
ages	O
,	O
that	O
is	O
,	O
a	O
nucleus	O
pulposus	O
issue	O
flows	O
from	O
the	O
rupture	O
to	O
produce	O
qualitative	O
change	O
,	O
sclerosis	O
and	O
hyperplasia	O
,	O
stimulates	O
and	O
presses	O
a	O
sinus	O
nerve	O
and	O
a	O
nerve	O
root	O
to	O
cause	O
stubborn	O
illnesses	O
such	O
as	O
ache	O
on	O
a	O
waist	O
and	O
a	O
neck	O
,	O
dizziness	O
and	O
numbness	O
of	O
limbs	O
.	O

Plaster	O
for	O
treating	O
cervical	O
vertebra	O
and	O
lumbar	O
intervertebral	O
disc	O
protrusion	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
surface	O
self	O
-	O
assembly	O
gold	B
nanoprobe	O
with	O
the	O
free	O
radical	O
capture	O
performance	O
and	O
a	O
preparing	O
method	O
and	O
the	O
application	O
thereof	O
.	O

The	O
surface	O
self	O
-	O
assembly	O
gold	B
nanoprobe	O
with	O
the	O
high	O
free	O
radical	O
capture	O
performance	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
:	O
the	O
surface	O
of	O
a	O
gold	B
nano	O
-	O
particle	O
is	O
connected	O
with	O
nitrone	B
free	I
radical	I
probe	O
ligand	O
with	O
the	O
structure	O
of	O
formula	O
II	O
by	O
a	O
connexon	O
of	O
the	O
structure	O
of	O
formula	O
I.	O
The	O
nitrone	B
free	I
radical	I
probe	O
ligand	O
is	O
connected	O
with	O
R3	O
radical	O
group	O
end	O
.	O

The	O
gold	B
nano	O
-	O
particle	O
is	O
connected	O
with	O
sulfhydryl	B
end	O
of	O
the	O
connexon	O
.	O

In	O
formula	O
Ia	O
and	O
formula	O
Ib	O
,	O
R3	O
is	O
-OH	B
,	O
-NH2	B
or	O
-COOH	B
,	O
n	O
is	O
equal	O
to	O
2	O
-	O
11	O
,	O
and	O
n1	O
is	O
equal	O
to	O
1	O
-	O
4	O
.	O

In	O
formula	O
IIc	O
,	O
R1	O
is	O
-P	B
(	I
O	I
)	I
(	I
OC2H5	I
)	I
2	I
,	O
and	O
R2	O
is	O
OH	B
,	O
COOH	B
or	O
CH2OH	B
.	O

The	O
surface	O
self	O
-	O
assembly	O
gold	B
nanoprobe	O
with	O
the	O
high	O
free	O
radical	O
capture	O
performance	O
can	O
capture	O
free	O
radicals	O
under	O
low	O
concentration	O
and	O
can	O
be	O
applied	O
as	O
an	O
antioxidant	O
.	O

Surface	O
self	O
-	O
assembly	O
gold	B
nanoprobe	O
with	O
free	O
radical	O
capture	O
performance	O
and	O
preparing	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
rebamipide	B
-	O
containing	O
aqueous	O
pharmaceutical	O
suspension	O
which	O
can	O
be	O
prepared	O
by	O
a	O
simple	O
process	O
and	O
keep	O
the	O
dispersed	O
fine	O
-	O
particle	O
state	O
of	O
rebamipide	B
stable	O
without	O
having	O
the	O
fine	O
particle	O
agglutinated	O
.	O

The	O
rebamipide	B
-	O
containing	O
aqueous	O
pharmaceutical	O
suspension	O
of	O
the	O
invention	O
is	O
prepared	O
by	O
mixing	O
polyvinyl	B
alcohol	I
and	O
additionally	O
a	O
sodium	B
salt	O
compound	O
with	O
rebamipide	B
.	O

Aqueous	O
pharmaceutical	O
suspensions	O
containing	O
rebamipide	B
and	O
manufacturing	O
process	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
silibinin	B
solid	O
self	O
-	O
emusifying	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
silibinin	B
solid	O
self	O
-	O
emusifying	O
tablet	O
comprises	O
silibinin	B
,	O
poloxamer	O
F68	O
,	O
glycerin	B
monostearate	I
,	O
microcrystalline	O
cellulose	O
,	O
mannite	B
,	O
polyvinylpolypyrrolidone	B
,	O
superfine	O
silica	B
gel	I
powder	O
and	O
magnesium	B
stearate	I
;	O
the	O
mass	O
ratio	O
of	O
the	O
silibinin	B
to	O
the	O
poloxamer	O
F68+the	O
glycerin	B
monostearate	I
to	O
the	O
microcrystalline	O
cellulose+the	O
mannite+the	O
polyvinylpolypyrrolidone+the	B
superfine	O
silica	B
gel	I
powder+the	O
magnesium	B
stearate=	I
from	O
1:1:3	O
to	O
1:6:20	O
;	O
the	O
silibinin	B
solid	O
self	O
-	O
emusifying	O
tablet	O
exists	O
in	O
an	O
amorphous	O
state	O
,	O
and	O
medical	O
granules	O
are	O
enclosed	O
by	O
soluble	O
carriers	O
;	O
and	O
the	O
mass	O
ratio	O
of	O
the	O
poloxamer	O
F68	O
to	O
the	O
glycerin	B
monostearate=	I
from	O
1:11	O
to	O
1:1	O
.	O

The	O
silibinin	B
solid	O
self	O
-	O
emusifying	O
tablet	O
has	O
good	O
absorption	O
,	O
increases	O
the	O
effectiveness	O
and	O
safety	O
of	O
medications	O
,	O
and	O
obviously	O
reduces	O
the	O
treatment	O
cost	O
of	O
the	O
patient	O
.	O

Silibinin	B
solid	O
self	O
-	O
emusifying	O
tablet	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
adefovir	B
dipivoxil	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
composition	O
comprises	O
100	O
weight	O
portions	O
of	O
adefovir	B
dipivoxil	I
and	O
20	O
to	O
500	O
weight	O
portions	O
of	O
pharmaceutically	O
acceptable	O
solid	O
lipid	O
,	O
wherein	O
the	O
solid	O
lipid	O
is	O
selected	O
from	O
glyceryl	B
behenate	I
,	O
stearic	B
acid	I
or	O
a	O
combination	O
thereof	O
.	O

The	O
invention	O
also	O
provides	O
the	O
method	O
for	O
preparing	O
the	O
composition	O
.	O

The	O
composition	O
has	O
the	O
advantages	O
of	O
remarkably	O
improving	O
the	O
stability	O
of	O
adefovir	B
dipivoxil	I
solid	O
preparations	O
and	O
simultaneously	O
maintaining	O
good	O
dissolution	O
rate	O
.	O

Composition	O
containing	O
adefovir	B
dipivoxil	I
,	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
kazakstan	O
skeleton	O
softening	O
medicine	O
,	O
which	O
is	O
prepared	O
by	O
horse	O
flesh	O
oil	O
and	O
panela	O
according	O
to	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
can	O
be	O
prepared	O
into	O
paste	O
for	O
external	O
use	O
,	O
which	O
has	O
the	O
function	O
of	O
softening	O
skeleton	O
,	O
relieving	O
the	O
pain	O
of	O
users	O
,	O
having	O
no	O
toxic	O
side	O
effect	O
and	O
being	O
effective	O
in	O
treatment	O
.	O

Kazakstan	O
skeleton	O
softening	O
medicine	O

The	O
invention	O
discloses	O
a	O
colchicines	B
gastric	O
floating	O
sustained	O
-	O
release	O
tablet	O
,	O
which	O
comprises	O
active	O
components	O
of	O
colchicines	B
and	O
pharmaceutic	O
adjuvant	O
according	O
to	O
the	O
weight	O
ratio	O
of	O
1:24	O
-	O
1,999	O
,	O
wherein	O
the	O
pharmaceutic	O
adjuvant	O
comprises	O
a	O
hydrophilic	O
gel	O
framework	O
material	O
,	O
a	O
effervescing	O
agent	O
,	O
a	O
floating	O
assistant	O
material	O
,	O
a	O
filler	O
,	O
a	O
pH	O
value	O
regulator	O
and	O
a	O
lubricant	O
.	O

The	O
colchicines	B
gastric	O
floating	O
sustained	O
-	O
release	O
tablet	O
can	O
swell	O
quickly	O
in	O
gastric	O
juice	O
or	O
a	O
similar	O
gastric	O
juice	O
medium	O
and	O
can	O
float	O
on	O
the	O
gastric	O
juice	O
for	O
at	O
least	O
4	O
hours	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
colchicines	B
gastric	O
floating	O
sustained	O
-	O
release	O
tablet	O
.	O

The	O
colchicines	B
gastric	O
floating	O
sustained	O
-	O
release	O
tablet	O
can	O
reach	O
the	O
effective	O
blood	O
-	O
drug	O
concentration	O
quickly	O
after	O
being	O
taken	O
and	O
then	O
release	O
drugs	O
slowly	O
,	O
and	O
can	O
maintain	O
the	O
balanced	O
blood	O
-	O
drug	O
concentration	O
so	O
as	O
to	O
reduce	O
the	O
dose	O
times	O
,	O
relieve	O
the	O
toxic	O
side	O
effect	O
and	O
improve	O
the	O
bioavailability	O
.	O

Colchicines	B
gastric	O
floating	O
sustained	O
-	O
release	O
tablet	O
and	O
method	O
for	O
preparing	O
same	O

The	O
invention	O
relates	O
to	O
a	O
microcapsule	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
aiming	O
at	O
providing	O
a	O
vitamin	B
D3	I
microcapsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
vitamin	B
D3	I
microcapsule	O
comprises	O
core	O
material	O
vitamin	B
D3	I
,	O
oil	O
fat	O
,	O
an	O
oil	O
-	O
soluble	O
emulsifier	O
and	O
a	O
wall	O
material	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
adopting	O
the	O
core	O
material	O
vitamin	B
D3	I
,	O
the	O
oil	O
fat	O
,	O
the	O
oil	O
-	O
soluble	O
emulsifier	O
as	O
oil	O
phase	O
for	O
dissolving	O
and	O
mixing	O
evenly	O
;	O
(	O
2	O
)	O
adding	O
deionized	O
water	O
in	O
the	O
wall	O
material	O
,	O
stirring	O
and	O
dissolving	O
as	O
water	O
phase	O
;	O
(	O
3	O
)	O
adding	O
the	O
oil	O
phase	O
into	O
the	O
water	O
phase	O
,	O
mixing	O
,	O
stirring	O
evenly	O
,	O
then	O
carrying	O
out	O
homogenization	O
and	O
emulsifying	O
the	O
obtained	O
mixture	O
into	O
microcapsule	O
;	O
(	O
4	O
)	O
carrying	O
out	O
spray	O
drying	O
to	O
the	O
microcapsule	O
to	O
form	O
the	O
vitamin	B
D3	I
microcapsule	O
;	O
and	O
(	O
5	O
)	O
screening	O
,	O
mixing	O
,	O
inspecting	O
and	O
packing	O
to	O
obtain	O
the	O
finished	O
product	O
.	O

The	O
microcapsule	O
and	O
the	O
preparation	O
method	O
thereof	O
have	O
the	O
advantages	O
of	O
high	O
embedding	O
rate	O
,	O
good	O
flowability	O
,	O
hard	O
photolysis	O
,	O
oxidation	O
,	O
high	O
heat	O
stability	O
,	O
even	O
dispersion	O
in	O
water	O
and	O
the	O
like	O
.	O

The	O
microcapsule	O
can	O
be	O
widely	O
added	O
into	O
food	O
or	O
feedstuff	O
,	O
is	O
easy	O
to	O
be	O
absorbed	O
by	O
the	O
human	O
body	O
or	O
animals	O
,	O
also	O
can	O
be	O
used	O
as	O
original	O
drug	O
of	O
rat	O
poison	O
to	O
strengthen	O
the	O
stability	O
thereof	O
greatly	O
.	O

Vitamin	B
D3	I
microcapsule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
ginseng	O
alkynol	B
for	O
preparing	O
medicine	O
treating	O
delayed	O
hypersensitivity	O
diseases	O
,	O
in	O
particular	O
to	O
the	O
application	O
of	O
the	O
ginseng	O
alkynol	B
for	O
preparing	O
the	O
medicine	O
treating	O
contact	O
dermatitis	O
,	O
the	O
application	O
of	O
the	O
ginseng	O
alkynol	B
for	O
preparing	O
the	O
medicine	O
treating	O
hypersensitivity	O
pneumonia	O
,	O
the	O
application	O
of	O
the	O
ginseng	O
alkynol	B
for	O
preparing	O
the	O
medicine	O
treating	O
homograft	O
rejection	O
,	O
and	O
the	O
application	O
of	O
the	O
ginseng	O
alkynol	B
for	O
preparing	O
the	O
medicine	O
treating	O
granulomatosis	O
caused	O
by	O
pathogene	O
in	O
cells	O
.	O

The	O
ginseng	O
alkynol	B
is	O
used	O
as	O
main	O
active	O
ingredient	O
used	O
for	O
treating	O
the	O
delayed	O
hypersensitivity	O
diseases	O
,	O
can	O
obviously	O
inhibit	O
the	O
diseases	O
mediated	O
by	O
delayed	O
hypersensitivity	O
,	O
has	O
no	O
obvious	O
inhibition	O
to	O
immune	O
organs	O
and	O
other	O
cells	O
,	O
and	O
is	O
hopeful	O
to	O
be	O
higher	O
effective	O
and	O
lower	O
toxic	O
medicine	O
used	O
for	O
treating	O
the	O
delayed	O
hypersensitivity	O
diseases	O
.	O

Application	O
of	O
ginseng	O
alkynol	B
in	O
pharmacy	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
for	O
preventing	O
osteoporosis	O
and	O
osteoarthrosis	O
.	O

The	O
compound	O
relates	O
to	O
a	O
compound	O
for	O
preventing	O
osteonosuses	O
.	O

The	O
compound	O
for	O
preventing	O
osteoporosis	O
and	O
osteoarthrosis	O
solves	O
the	O
problem	O
that	O
:	O
the	O
prior	O
calcium	B
replenishing	O
agent	O
can	O
purely	O
replenish	O
calcium	B
,	O
while	O
the	O
replenished	O
calcium	B
can	O
not	O
be	O
fully	O
absorbed	O
and	O
utilized	O
by	O
the	O
human	O
body	O
.	O

The	O
compound	O
for	O
preventing	O
osteoporosis	O
and	O
osteoarthrosis	O
comprises	O
the	O
following	O
components	O
by	O
weight	O
portion	O
:	O
10	O
to	O
90	O
portions	O
of	O
glucosamine	B
,	O
10	O
to	O
90	O
portions	O
of	O
calcium	B
agent	O
,	O
0.1	O
to	O
40	O
portions	O
of	O
casein	B
phosphopeptide	I
,	O
0.1	O
to	O
40	O
portions	O
of	O
drynaria	O
rhizome	O
extract	O
,	O
0.0001	O
to	O
0.09	O
portion	O
of	O
vitamin	B
K	I
and	O
0.81	O
to	O
208	O
portions	O
of	O
supplementary	O
materials	O
.	O

The	O
compound	O
for	O
preventing	O
osteoporosis	O
and	O
osteoarthrosis	O
can	O
obviously	O
improve	O
the	O
bone	O
calcium	B
content	O
and	O
bone	O
density	O
;	O
and	O
the	O
replenished	O
calcium	B
agent	O
can	O
be	O
fully	O
absorbed	O
and	O
utilized	O
.	O

Compound	O
for	O
preventing	O
osteoporosis	O
and	O
osteoarthrosis	O

The	O
invention	O
discloses	O
a	O
composition	O
containing	O
a	O
water	O
-	O
insoluble	O
high	O
-	O
activity	O
drug	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
water	O
-	O
insoluble	O
high	O
-	O
activity	O
drug	O
is	O
dissolved	O
in	O
an	O
organic	O
solvent	O
containing	O
a	O
solid	O
dispersion	O
carrier	O
,	O
evenly	O
sprayed	O
on	O
the	O
surface	O
of	O
filler	O
or	O
blank	O
pellets	O
by	O
adopting	O
a	O
fluidized	O
bed	O
and	O
dried	O
.	O

The	O
invention	O
realizes	O
the	O
one	O
-	O
step	O
completion	O
of	O
preparing	O
the	O
solid	O
dispersion	O
of	O
the	O
water	O
-	O
insoluble	O
high	O
-	O
activity	O
drug	O
,	O
pelleting	O
and	O
drying	O
,	O
has	O
simple	O
and	O
convenient	O
process	O
,	O
and	O
no	O
dust	O
pollution	O
,	O
and	O
effectively	O
avoids	O
the	O
adverse	O
influence	O
of	O
the	O
high	O
-	O
activity	O
drug	O
on	O
the	O
health	O
of	O
production	O
staff	O
.	O

The	O
granules	O
prepared	O
by	O
the	O
method	O
has	O
even	O
granularity	O
,	O
and	O
good	O
liquidity	O
and	O
compression	O
formability	O
,	O
and	O
can	O
be	O
further	O
prepared	O
into	O
oral	O
solid	O
preparation	O
.	O

The	O
composition	O
prepared	O
by	O
the	O
method	O
has	O
good	O
drug	O
dissolvability	O
,	O
and	O
high	O
oral	O
absorption	O
and	O
bioavailability	O
.	O

Composition	O
containing	O
water	O
-	O
insoluble	O
high	O
-	O
activity	O
drug	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
synthetic	O
method	O
of	O
high	O
-	O
purity	O
propofol	B
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
as	O
the	O
right	O
formulae	O
,	O
wherein	O
a	O
catalytic	O
agent	O
adopts	O
aluminium	B
trialkyl	I
,	O
the	O
aluminium	B
trialkyl	I
is	O
selected	O
from	O
aluminium	B
triethyl	I
,	O
aluminium	B
methyl	I
and	O
aluminium	O
isopropyl	O
,	O
and	O
the	O
purity	O
of	O
2-isopropyl	B
phenol	I
is	O
higher	O
than	O
99	O
percent	O
.	O

Synthetic	O
method	O
of	O
high	O
-	O
purity	O
propofol	B

The	O
invention	O
relates	O
to	O
a	O
micro	O
-	O
emulsion	O
composition	O
of	O
an	O
etoposide	B
oral	O
medicament	O
,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
composition	O
contains	O
etoposide	B
,	O
a	O
surfactant	O
,	O
an	O
assistant	O
surfactant	O
,	O
oil	O
,	O
and	O
water	O
,	O
and	O
has	O
the	O
characteristics	O
of	O
high	O
bioavailability	O
,	O
small	O
individual	O
difference	O
,	O
and	O
safer	O
and	O
more	O
effective	O
oral	O
administration	O
.	O

Micro	O
-	O
emulsion	O
composition	O
of	O
etoposide	B
oral	O
medicament	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
lung	O
-	O
targeting	O
microsphere	O
for	O
curing	O
lung	O
infection	O
for	O
veterinary	O
use	O
.	O

The	O
preparation	O
takes	O
tiamulin	B
fumarate	I
or	O
tiamulin	B
fumarate	I
salt	O
as	O
the	O
main	O
component	O
and	O
gelatin	O
as	O
the	O
carrier	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
tiamulin	B
fumarate	I
or	O
the	O
tiamulin	B
fumarate	I
salt	O
to	O
the	O
gelatin	O
is	O
5:1	O
to	O
1:5	O
,	O
and	O
the	O
preferable	O
range	O
of	O
the	O
weight	O
ratio	O
is	O
3:1	O
to	O
1:3	O
.	O

The	O
medical	O
clinical	O
experiments	O
show	O
that	O
the	O
tiamulin	B
fumarate	I
and	O
the	O
lung	O
-	O
targeting	O
microsphere	O
of	O
the	O
tiamulin	B
fumarate	I
salt	O
have	O
better	O
tissue	O
selectivity	O
than	O
the	O
common	O
preparation	O
,	O
and	O
have	O
the	O
advantages	O
of	O
higher	O
medicine	O
concentration	O
at	O
the	O
lung	O
tissue	O
,	O
longer	O
duration	O
time	O
,	O
more	O
remarkable	O
and	O
lasting	O
drug	O
action	O
and	O
low	O
toxic	O
side	O
effect	O
.	O

In	O
addition	O
,	O
the	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
preparation	O
.	O

Tiamulin	B
fumarate	I
for	O
veterinary	O
use	O
,	O
lung	O
-	O
targeting	O
microsphere	O
of	O
tiamulin	B
fumarate	I
salt	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
balsatazide	B
sodium	I
enema	O
liquid	O
comprising	O
the	O
balsatazide	B
sodium	I
as	O
basis	O
,	O
xanthan	O
gum	O
as	O
gel	O
substrate	O
,	O
aethylum	B
hydroxybenzoicum	I
as	O
antiseptic	O
agent	O
,	O
EDTA-2Na	B
as	O
antisettle	O
agent	O
and	O
oxidation	O
preventive	O
.	O

In	O
addition	O
,	O
the	O
invention	O
also	O
disclose	O
a	O
preparation	O
method	O
for	O
the	O
balsatazide	B
sodium	I
enema	O
liquid	O
to	O
utilize	O
a	O
unidirectional	O
compression	O
type	O
medical	O
grade	O
rubber	O
enema	O
device	O
to	O
produce	O
the	O
balsatazide	B
sodium	I
enema	O
liquid	O
for	O
treating	O
the	O
ulcerative	O
colitis	O
.	O

The	O
balsatazide	B
sodium	I
enema	O
liquid	O
has	O
the	O
advantages	O
of	O
fast	O
action	O
,	O
good	O
curative	O
effect	O
,	O
low	O
dose	O
and	O
little	O
side	O
-	O
effect	O
,	O
simple	O
production	O
,	O
low	O
cost	O
and	O
convenient	O
administration	O
.	O

Balsatazide	B
sodium	I
enema	O
liquid	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicaments	O
,	O
in	O
particular	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
resisting	O
osteoporosis	O
,	O
which	O
consists	O
of	O
any	O
two	O
,	O
three	O
or	O
four	O
components	O
of	O
icariin	B
,	O
timosaponin	B
-	I
B	I
II	I
,	O
curculigoside	B
B	I
and	O
berberine	B
respectively	O
and	O
is	O
characterized	O
in	O
that	O
the	O
composition	O
consists	O
of	O
the	O
following	O
components	O
by	O
weight	O
portion	O
:	O
0	O
to	O
135	O
portions	O
of	O
the	O
icariin	B
,	O
0	O
to	O
450	O
portions	O
of	O
the	O
timosaponin	B
-	I
B	I
II	I
,	O
0	O
to	O
63	O
portions	O
of	O
the	O
curculigoside	B
B	I
,	O
and	O
0	O
to	O
1,350	O
portions	O
of	O
the	O
berberine	B
.	O

The	O
composition	O
can	O
promote	O
the	O
formation	O
of	O
osteoblasts	O
synergistically	O
and	O
inhibit	O
the	O
bone	O
resorption	O
of	O
osteoclasts	O
,	O
and	O
can	O
reinforce	O
the	O
function	O
of	O
resisting	O
the	O
osteoporosis	O
through	O
synergistic	O
adjustment	O
of	O
a	O
plurality	O
of	O
correlative	O
indexes	O
of	O
bone	O
metabolism	O
to	O
achieve	O
the	O
aim	O
of	O
preventing	O
and	O
treating	O
the	O
osteoporosis	O
,	O
thus	O
the	O
composition	O
can	O
be	O
applied	O
to	O
preparing	O
medicaments	O
for	O
preventing	O
the	O
osteoporosis	O
.	O

Pharmaceutical	O
composition	O
for	O
resisting	O
osteoporosis	O

The	O
invention	O
provides	O
a	O
pressed	O
pharmaceutical	O
composition	O
containing	O
medicinal	O
charcoal	O
and	O
polyethyleneglycol	B
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
medicinal	O
charcoal	O
accounts	O
for	O
65	O
to	O
75	O
percent	O
of	O
the	O
composition	O
,	O
and	O
the	O
polyethyleneglycol	B
of	O
which	O
the	O
molecular	O
weight	O
is	O
between	O
1,500	O
and	O
6,000	O
accounts	O
for	O
15	O
to	O
25	O
percent	O
of	O
the	O
composition	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
applied	O
to	O
correcting	O
a	O
digestive	O
symptom	O
of	O
intestinal	O
constipation	O
caused	O
by	O
the	O
medicinal	O
charcoal	O
while	O
being	O
applied	O
to	O
a	O
clinical	O
nonspecific	O
antidote	O
.	O

People	O
are	O
surprised	O
to	O
find	O
that	O
the	O
composition	O
,	O
such	O
as	O
solid	O
colored	O
film	O
coat	O
tablet	O
,	O
has	O
more	O
acceptable	O
perceptive	O
and	O
clinical	O
curative	O
effects	O
compared	O
with	O
the	O
prior	O
medicinal	O
charcoal	O
tablet	O
.	O

Pressed	O
pharmaceutical	O
composition	O
containing	O
medicinal	O
charcoal	O
and	O
polyethyleneglycol	B

The	O
invention	O
relates	O
to	O
an	O
acarid	O
killing	O
and	O
itching	O
relieving	O
gel	O
preparation	O
which	O
comprises	O
the	O
components	O
of	O
chaulmoogra	O
,	O
stemona	O
root	O
,	O
frutus	O
cnidii	O
,	O
agrimony	O
,	O
angelica	O
dahurica	O
,	O
metronidazole	B
,	O
gel	O
,	O
emulsifier	O
,	O
preservative	O
,	O
organic	O
solvent	O
and	O
water	O
.	O

The	O
gel	O
is	O
convenient	O
to	O
use	O
and	O
easy	O
to	O
adhere	O
to	O
the	O
surface	O
of	O
skin	O
,	O
ensures	O
good	O
skin	O
feeling	O
after	O
use	O
and	O
is	O
easily	O
cleaned	O
.	O

Meanwhile	O
,	O
the	O
preparation	O
is	O
stable	O
;	O
the	O
preparation	O
method	O
of	O
the	O
gel	O
is	O
very	O
convenient	O
without	O
special	O
equipment	O
;	O
the	O
components	O
can	O
be	O
extracted	O
without	O
concentration	O
and	O
can	O
be	O
directly	O
used	O
for	O
preparing	O
the	O
gel	O
after	O
filtration	O
,	O
thereby	O
the	O
cost	O
is	O
reduced	O
,	O
and	O
the	O
industrial	O
production	O
is	O
convenient	O
.	O

Acarid	O
killing	O
gel	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
powder	O
pharmaceutical	O
formulations	O
for	O
treating	O
infantile	O
diarrhea	O
which	O
overcomes	O
weak	O
pocket	O
of	O
other	O
medicament	O
for	O
treating	O
the	O
disease	O
.	O

The	O
powder	O
pharmaceutical	O
formulation	O
is	O
prepared	O
by	O
raw	O
materials	O
as	O
follows	O
:	O
biofermin	B
0.1	O
-	O
1	O
g	O
,	O
compound	O
diphenoxylate	B
0.25	O
-	O
2.5	O
mg	O
,	O
acetylsalicylic	B
acid	I
0.3	O
-	O
0.15	O
g	O
,	O
chlorphenamine	B
0.04	O
-	O
0.2	O
mg	O
and	O
hydrochlorothiazidum	B
tablet1	O
-	O
5	O
mg	O
,	O
the	O
above	O
medicine	O
are	O
grinded	O
to	O
dead	O
small	O
,	O
then	O
are	O
measured	O
and	O
packed	O
for	O
obtaining	O
the	O
powder	O
pharmaceutical	O
formulation	O
.	O

The	O
powder	O
pharmaceutical	O
formulation	O
for	O
treating	O
infantile	O
diarrhea	O
is	O
used	O
about	O
twenty	O
years	O
and	O
is	O
consulted	O
by	O
patients	O
10000	O
times	O
,	O
wherein	O
,	O
males	O
5500	O
times	O
,	O
females	O
4500	O
times	O
,	O
curative	O
rate	O
98	O
%	O
and	O
efficiency	O
rate	O
100	O
%	O
.	O

Powder	O
pharmaceutical	O
formulations	O
for	O
treating	O
infantile	O
diarrhea	O

The	O
invention	O
relates	O
to	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
general	O
formula	O
(	O
II	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
medical	O
acid	O
addition	O
salt	O
thereof	O
or	O
pharmaceutically	O
acceptable	O
hydrate	B
of	O
themedical	O
acid	O
addition	O
salt	O
,	O
wherein	O
the	O
definitions	O
of	O
R	O
,	O
X1	O
,	O
X2	O
,	O
m	O
,	O
n	O
and	O
r	O
are	O
shown	O
in	O
specification	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds	O
and	O
the	O
applications	O
for	O
treating	O
thromboembolism	O
diseases	O
.	O

Novel	O
substituted	O
piperazinyl	B
alkoxy	I
bibenzyl	I
compound	O
,	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
in	O
particular	O
relates	O
to	O
a	O
dipeptidase	O
-	O
IV	O
inhibitor	O
containing	O
v	B
-	I
triazolo	I
[	I
b	I
]	I
pyrazine	I
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
an	O
isomer	O
and	O
a	O
hydrate	B
of	O
the	O
dipeptidase	O
-	O
IV	O
inhibitor	O
,	O
as	O
well	O
as	O
a	O
hydrate	B
of	O
the	O
salt	O
,	O
wherein	O
Ar	B
,	O
R1	O
,	O
R3	O
and	O
n	O
are	O
defined	O
as	O
description	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds	O
and	O
application	O
of	O
the	O
compounds	O
in	O
preparing	O
medicaments	O
for	O
treating	O
and/or	O
preventing	O
diabetes	O
,	O
noninsulin	O
-	O
dependent	O
diabetes	O
,	O
hyperglycemia	O
and	O
insulin	O
resistance	O
.	O

Dipeptidase	O
-	O
IV	O
inhibitor	O
containing	O
v	B
-	I
triazolo	I
[	I
b	I
]	I
pyrazine	I

A	O
method	O
for	O
preparing	O
pregabalin	B
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
synthesis	O
,	O
aiming	O
at	O
overcoming	O
defects	O
of	O
high	O
cost	O
,	O
environment	O
pollution	O
,	O
complicate	O
steps	O
and	O
the	O
like	O
in	O
the	O
prior	O
art	O
for	O
synthesizing	O
the	O
pregabalin	B
.	O

The	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
adopting	O
heterogeneous	O
hydrogenation	O
catalyst	O
for	O
carrying	O
out	O
catalytic	O
hydrogenation	O
on	O
3-cyano	B
-	I
group-5-methyl	I
-	I
hexy-3-ethyl	I
gadoleic	I
acid	I
so	O
as	O
to	O
prepare	O
3-amino	B
methyl-5-methylacetic	I
acid	I
;	O
and	O
splitting	O
(	O
S	O
)	O
-mandel	O
to	O
obtain	O
(	B
S	I
)	I
-pregabalin	I
.	O

The	O
method	O
has	O
the	O
advantages	O
of	O
low	O
cost	O
,	O
environment	O
-	O
friendly	O
process	O
,	O
easy	O
operation	O
,	O
non	O
-	O
byproduct	O
and	O
the	O
like	O
.	O

Method	O
for	O
preparing	O
pregabalin	B

The	O
invention	O
discloses	O
a	O
new	O
preparation	O
method	O
of	O
Tibifuding	B
which	O
comprises	O
the	O
steps	O
as	O
follows	O
:	O
2'-deoxidated-2'-halo-3',5'-bi	B
-	I
O-	I
alkanoyl-5-methyl	I
-	I
beta	I
-	I
L	I
-	I
uridine	I
is	O
used	O
as	O
raw	O
material	O
to	O
react	O
with	O
ortho	B
phosphorous	I
acid	I
or	O
hypophosphite	B
and	O
alkali	O
under	O
effect	O
of	O
radical	O
initiator	O
in	O
latent	O
solvent	O
,	O
thereby	O
preparing	O
Tibifuding	B
.	O

The	O
preparation	O
method	O
of	O
Tibifuding	B
is	O
free	O
of	O
metal	O
catalyst	O
in	O
reaction	O
;	O
therefore	O
,	O
the	O
preparation	O
method	O
of	O
Tibifuding	B
has	O
mild	O
reaction	O
condition	O
,	O
higher	O
yield	O
,	O
economical	O
and	O
effective	O
application	O
which	O
is	O
applicable	O
to	O
mass	O
industrial	O
production	O
.	O

Preparation	O
method	O
of	O
Tibifuding	B

The	O
invention	O
discloses	O
use	O
of	O
butin	B
and	O
derivatives	O
thereof	O
for	O
preparing	O
drugs	O
having	O
inhibitive	O
effect	O
on	O
an	O
immune	O
system	O
.	O

The	O
use	O
is	O
characterized	O
by	O
preparing	O
drugs	O
having	O
inhibitive	O
effect	O
on	O
an	O
immune	O
system	O
with	O
the	O
butin	B
and	O
the	O
derivatives	O
thereof	O
as	O
active	O
ingredients	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Use	O
of	O
butin	B
and	O
derivatives	O
thereof	O
for	O
preparing	O
drugs	O
having	O
inhibitive	O
effect	O
on	O
immune	O
system	O

The	O
invention	O
discloses	O
an	O
oral	O
pharmaceutical	O
composition	O
containing	O
lansoprazole	B
and	O
domperidone	B
.	O

The	O
lansoprazole	B
and	O
the	O
domperidone	B
are	O
dispersed	O
to	O
respective	O
pharmaceutically	O
acceptable	O
carriers	O
in	O
the	O
pharmaceutical	O
composition	O
.	O

The	O
composition	O
has	O
good	O
stability	O
and	O
is	O
used	O
for	O
treatment	O
of	O
digestive	O
systems	O
including	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
reflux	O
esophagitis	O
,	O
functional	O
dyspepsia	O
.	O

Oral	O
pharmaceutical	O
composition	O
containing	O
lansoprazole	B
and	O
domperidone	B

The	O
invention	O
relates	O
to	O
a	O
drug	O
compound	O
for	O
curing	O
hyperlipoidemia	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
contains	O
atorvastatin	B
and	O
nicotinic	B
acid	I
,	O
can	O
be	O
a	O
slow	O
releasing	O
agent	O
and	O
a	O
quick	O
releasing	O
agent	O
and	O
is	O
used	O
for	O
curing	O
essential	O
hyperlipidemia	O
(	O
familial	O
heterozygote	O
and	O
nonfamilial	O
)	O
and	O
hybrid	O
dyslipidemia	O
(	O
Frederickson	O
IIa	O
and	O
IIb	O
type	O
)	O
.	O

Drug	O
compound	O
for	O
curing	O
hyperlipoidemia	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
curing	O
herpes	O
zoster	O
,	O
which	O
is	O
mainly	O
prepared	O
from	O
moroxydine	B
,	O
vitamins	O
,	O
dexamethasone	O
and	O
vaseline	O
as	O
auxiliary	O
material	O
according	O
to	O
certain	O
proportion	O
by	O
parts	O
.	O

The	O
medicament	O
has	O
the	O
advantages	O
of	O
acesodyne	O
,	O
anti	O
-	O
inflammatory	O
,	O
toxin	O
expulsion	O
,	O
sarcogenic	O
convergence	O
,	O
ulceration	O
healing	O
promotion	O
,	O
and	O
the	O
like	O
and	O
also	O
has	O
quick	O
effect	O
,	O
high	O
cure	O
rate	O
and	O
no	O
toxic	O
side	O
effect	O
and	O
pain	O
on	O
curing	O
the	O
toxic	O
side	O
effect	O
for	O
curing	O
herpes	O
zoster	O
.	O

In	O
addition	O
,	O
the	O
medicament	O
is	O
mainly	O
prepared	O
from	O
6	O
-	O
12	O
portions	O
of	O
the	O
moroxydine	B
,	O
3	O
-	O
6	O
portions	O
of	O
vitamin	B
C	I
,	O
3	O
-	O
6	O
portions	O
of	O
the	O
dexamethasone	B
and	O
the	O
Vaseline	O
as	O
theauxiliary	O
material	O
.	O

External	O
medicament	O
for	O
curing	O
herpes	O
zoster	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
oxidation	O
-	O
resistant	O
and	O
anti	O
-	O
ageing	O
health	O
care	O
product	O
,	O
which	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
functional	O
health	O
care	O
foods	O
.	O

The	O
health	O
care	O
product	O
comprises	O
a	O
health	O
-	O
care	O
formulation	O
which	O
is	O
prepared	O
by	O
evenly	O
mixing	O
a	O
rosemary	O
extract	O
,	O
an	O
echinacea	O
purpurea	O
extract	O
and	O
an	O
ascorbic	B
acid	I
,	O
tocopherol	B
,	O
and	O
sodium	B
selenite	I
and	O
has	O
no	O
toxic	O
side	O
effects	O
.	O

The	O
formulation	O
has	O
special	O
effects	O
of	O
resisting	O
oxidation	O
,	O
resisting	O
ageing	O
,	O
eliminating	O
free	O
radicals	O
,	O
controlling	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
and	O
the	O
like	O
,	O
and	O
provides	O
a	O
new	O
formulation	O
choice	O
for	O
the	O
field	O
of	O
the	O
health	O
care	O
foods	O
.	O

Oxidation	O
-	O
resistant	O
and	O
anti	O
-	O
ageing	O
health	O
care	O
product	O

The	O
invention	O
provides	O
a	O
medicament	O
composite	O
using	O
Danshensu	B
and	O
danshinolic	B
acid	I
B	I
as	O
active	O
ingredient	O
.	O

Purification	O
of	O
Danshensu	B
and	O
danshinolic	B
acid	I
B	I
or	O
purification	O
of	O
Danshensu	B
salt	O
and	O
danshinolic	B
acid	I
B	I
salt	O
is	O
larger	O
than	O
or	O
equal	O
to	O
80	O
%	O
.	O

The	O
medicament	O
composition	O
can	O
be	O
used	O
for	O
treating	O
coronary	O
disease	O
,	O
angina	O
,	O
ischemic	O
cerebral	O
,	O
atherosclerosis	O
,	O
myocardial	O
ischemia	O
or	O
myocardial	O
infarction	O
,	O
chronic	O
heptic	O
B	O
fibrosis	O
,	O
fatty	O
liver	O
,	O
senile	O
dementia	O
,	O
cancer	O
,	O
or	O
the	O
like	O
.	O

Composition	O
for	O
Danshensu	B
and	O
danshinolic	B
acid	I
B	I
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
two	O
-	O
chamber	O
type	O
nose	O
spraying	O
agent	O
for	O
treating	O
allergic	O
rhinitis	O
,	O
provided	O
with	O
two	O
linked	O
spraying	O
chambers	O
and	O
containing	O
two	O
medicaments	O
respectively	O
.	O

The	O
medicaments	O
are	O
respectively	O
0.2	O
-	O
1.0	O
mg	O
/	O
ml	O
of	O
aqueous	O
solvent	O
or	O
suspension	O
of	O
oxymetazoline	B
hydrochloride	I
and	O
0.01	O
-	O
0.1	O
mg	O
/	O
ml	O
of	O
suspension	O
or	O
aqueous	O
solvent	O
of	O
beclomethasone	B
dipropionate	I
.	O

The	O
oxymetazoline	B
hydrochloride	I
and	O
the	O
beclomethasone	B
dipropionate	I
are	O
respectively	O
poured	O
in	O
two	O
independent	O
chambers	O
with	O
stable	O
property	O
and	O
controllable	O
quality	O
and	O
have	O
the	O
synergistic	O
effect	O
.	O

The	O
spraying	O
agent	O
has	O
proper	O
graininess	O
,	O
stable	O
quality	O
,	O
convenient	O
carrying	O
,	O
simple	O
operation	O
,	O
easy	O
operation	O
and	O
easy	O
acceptance	O
for	O
patients	O
.	O

Two	O
chamber	O
type	O
nose	O
spraying	O
agent	O
for	O
treating	O
allergic	O
rhinitis	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
restraining	O
the	O
activity	O
of	O
aromatizing	O
enzyme	O
,	O
containing	O
a	O
flavone	B
compound	O
and	O
a	O
fatty	B
acid	I
compound	O
.	O

The	O
flavone	B
compound	O
refers	O
to	O
a	O
compound	O
of	O
formula	O
I	O
,	O
wherein	O
a	O
substituent	O
R1	O
is	O
selected	O
from	O
H	B
or	O
OH	B
,	O
and	O
a	O
substituent	O
R2	O
is	O
selected	O
from	O
H	B
,	O
OH	B
or	O
OCH3	B
;	O
the	O
fatty	B
acid	I
compound	O
refers	O
to	O
a	O
compound	O
with	O
a	O
molecular	O
formula	O
of	O
CH3-CnHm	O
-	O
COB	O
,	O
wherein	O
n	O
is	O
greater	O
than	O
8	O
and	O
less	O
than	O
24	O
,	O
m	O
is	O
greater	O
than	O
or	O
equal	O
to	O
2n-8	O
and	O
less	O
than	O
or	O
equal	O
to	O
2n	O
,	O
and	O
B	O
is	O
a	O
hydroxyl	B
,	O
an	O
N	B
-	I
hydroxyethyl	I
,	O
a	O
fructosyl	B
or	O
a	O
glyceryl	B
.	O

The	O
pharmaceutical	O
composition	O
can	O
effectively	O
restrain	O
the	O
activity	O
of	O
the	O
aromatizing	O
enzyme	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicaments	O
for	O
treating	O
or	O
preventing	O
estrogen	B
dependent	O
diseases	O
.	O

Pharmaceutical	O
composition	O
for	O
restraining	O
activity	O
of	O
aromatizing	O
enzyme	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
new	O
cefmetazole	B
preparation	O
used	O
for	O
injection	O
.	O

The	O
preparation	O
mixes	O
evenly	O
active	O
ingredient	O
cefmetazole	B
acid	O
asepsis	O
powder	O
and	O
complex	O
solubilizer	O
anhydrous	O
sodium	B
carbonate	I
asepsis	O
powder	O
which	O
are	O
respectively	O
bottled	O
in	O
sterilized	O
amoxicillin	B
bottles	O
according	O
to	O
labeled	O
amount	O
and	O
are	O
packaged	O
to	O
obtain	O
the	O
product	O
of	O
cefmetazole	B
used	O
for	O
injection	O
after	O
tamponage	O
,	O
rolling	O
of	O
cover	O
and	O
full	O
inspection	O
;	O
wherein	O
the	O
weight	O
ratio	O
between	O
cefmetazole	B
acid	O
(	O
pure	O
)	O
and	O
anhydrous	O
sodium	B
carbonate	I
is	O
1:0.1	O
to	O
1:0.2	O
with	O
1:0.15	O
being	O
the	O
better	O
ratio	O
,	O
namely	O
,	O
1	O
g	O
of	O
cefmetazole	B
acid	I
(	O
pure	O
)	O
asepsis	O
powder	O
is	O
added	O
into	O
0.1	O
-	O
0.2	O
g	O
of	O
anhydrous	O
sodium	B
carbonate	I
asepsis	O
powder	O
.	O

The	O
preparation	O
is	O
good	O
in	O
stability	O
and	O
safe	O
in	O
usage	O
.	O

Cefmetazole	B
preparation	O
used	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
preparation	O
process	O
for	O
clindamycin	B
phosphate	I
injection	O
.	O

A	O
method	O
for	O
controlling	O
the	O
pH	O
value	O
is	O
adopted	O
for	O
increasing	O
the	O
solubility	O
.	O

The	O
production	O
process	O
adopts	O
a	O
sterilization	O
production	O
process	O
.	O

A	O
mode	O
of	O
combining	O
ultrafiltration	O
and	O
sterilization	O
filtration	O
is	O
adopted	O
for	O
eliminating	O
pyrogen	O
and	O
sterilizing	O
during	O
production	O
.	O

Simultaneously	O
the	O
filling	O
environment	O
is	O
a	O
partial	O
hundred	O
grade	O
in	O
ten	O
-	O
thousand	O
sterilization	O
background	O
,	O
and	O
the	O
total	O
sterilization	O
operation	O
is	O
adopted	O
in	O
the	O
production	O
process	O
,	O
so	O
that	O
the	O
pollution	O
of	O
environment	O
and	O
personnel	O
is	O
effectively	O
prevented	O
,	O
and	O
the	O
sterility	O
assurance	O
level	O
the	O
same	O
as	O
that	O
of	O
the	O
traditional	O
sterilization	O
process	O
is	O
obtained	O
.	O

In	O
addition	O
,	O
the	O
preparation	O
process	O
has	O
the	O
advantages	O
of	O
overcoming	O
the	O
defect	O
of	O
easy	O
decomposition	O
in	O
high	O
temperature	O
and	O
effectively	O
ensuring	O
the	O
quality	O
.	O

Preparation	O
process	O
for	O
clindamycin	B
phosphate	I
injection	O

The	O
invention	O
discloses	O
a	O
medicament	O
,	O
in	O
particular	O
a	O
medicament	O
for	O
treating	O
soft	O
tissue	O
injury	O
and	O
arthritis	O
and	O
a	O
gel	O
preparation	O
method	O
.	O

The	O
medicament	O
for	O
treating	O
the	O
soft	O
tissue	O
injury	O
and	O
the	O
arthritis	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
portion	O
:	O
0.5	O
to	O
4	O
portions	O
of	O
sodium	B
dichlorophenolate	I
,	O
20	O
to	O
80	O
portions	O
of	O
propylene	B
glycol	I
,	O
20	O
to	O
70	O
portions	O
of	O
medicinal	O
ethanol	B
,	O
2	O
to	O
10	O
portions	O
of	O
urea	B
,	O
0.4	O
to	O
3	O
portions	O
of	O
menthol	B
,	O
0.05	O
to	O
0.2	O
portion	O
of	O
sodium	B
citrate	I
,	O
0.5	O
to	O
4	O
portions	O
of	O
carbomer	O
,	O
and	O
50	O
to	O
150	O
portions	O
of	O
water	O
.	O

Proved	O
by	O
large	O
amount	O
of	O
tests	O
of	O
pharmacodynamics	O
,	O
toxicology	O
and	O
the	O
like	O
,	O
the	O
medicament	O
has	O
good	O
effects	O
of	O
relieving	O
pain	O
and	O
diminishing	O
inflammation	O
,	O
is	O
convenient	O
to	O
use	O
,	O
and	O
is	O
safe	O
and	O
reliable	O
.	O

Medicament	O
for	O
treating	O
soft	O
tissue	O
injury	O
and	O
arthritis	O
and	O
gel	O
preparation	O
method	O

The	O
invention	O
discloses	O
application	O
of	O
antagonist	O
of	O
ATP	B
citric	B
acid	I
lyase	O
(	O
ACL	O
)	O
,	O
which	O
is	O
used	O
for	O
preparing	O
a	O
composition	O
preventing	O
or	O
treating	O
glycolipid	O
metabolic	O
disturbance	O
diseases	O
.	O

The	O
invention	O
also	O
discloses	O
very	O
effective	O
antagonist	O
of	O
ATP	B
citric	B
acid	I
lyase	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
sieving	O
potential	O
materials	O
preventing	O
or	O
treating	O
the	O
glycolipid	O
metabolic	O
disturbance	O
diseases	O
.	O

Application	O
of	O
ACL	O
on	O
sieving	O
drugs	O
for	O
preventing	O
obesity	O
-	O
related	O
metabolic	O
disturbance	O
diseases	O

The	O
invention	O
provides	O
an	O
etoposide	B
lipidosome	O
used	O
for	O
injection	O
or	O
oral	O
administration	O
.	O

The	O
etoposide	B
lipidosome	O
is	O
characterized	O
in	O
that	O
etoposide	B
is	O
enveloped	O
with	O
phospholipid	B
type	O
substance	O
,	O
and	O
the	O
etoposide	B
lipidosome	O
with	O
small	O
grain	O
size	O
,	O
high	O
entrapment	O
efficiency	O
,	O
good	O
stability	O
and	O
low	O
toxic	O
side	O
effect	O
is	O
prepared	O
.	O

The	O
prepared	O
etoposide	B
lipidosome	O
enhances	O
the	O
solubility	O
and	O
the	O
stability	O
of	O
the	O
etoposide	B
,	O
reduces	O
the	O
toxicity	O
of	O
the	O
etoposide	B
and	O
prolongs	O
the	O
cycling	O
time	O
of	O
the	O
medicine	O
in	O
the	O
blood	O
,	O
thereby	O
improving	O
the	O
therapeutic	O
effect	O
of	O
the	O
medicine	O
;	O
and	O
the	O
preparation	O
prepared	O
by	O
the	O
etoposide	B
lipidosome	O
has	O
the	O
characteristics	O
of	O
low	O
toxicity	O
,	O
low	O
sensitivity	O
and	O
high	O
efficiency	O
on	O
the	O
clinical	O
application	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
etoposide	B
lipidosome	O
,	O
which	O
has	O
simple	O
preparation	O
process	O
and	O
low	O
cost	O
and	O
is	O
suitable	O
for	O
the	O
industrial	O
production	O
.	O

Etoposide	B
lipidosome	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
discloses	O
a	O
biodegradation	O
type	O
long	O
-	O
acting	O
contraception	O
microsphere	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
,	O
belonging	O
to	O
a	O
pharmacy	O
technology	O
field	O
.	O

The	O
biodegradation	O
type	O
long	O
-	O
acting	O
contraception	O
microsphere	O
is	O
taken	O
a	O
biodegradable	O
manpower	O
synthetic	O
polymer	O
as	O
a	O
carrier	O
and	O
a	O
Nestorone	O
as	O
a	O
basic	O
remedy	O
,	O
wherein	O
a	O
weight	O
shares	O
of	O
the	O
carrier	O
is	O
from	O
100	O
to	O
140	O
shares	O
,	O
the	O
weight	O
share	O
of	O
the	O
basic	O
remedy	O
is	O
from	O
2	O
to	O
10	O
shares	O
.	O

The	O
preparation	O
method	O
includes	O
dissolving	O
the	O
basic	O
remedy	O
and	O
the	O
carrier	O
in	O
an	O
organic	O
solvent	O
to	O
obtain	O
a	O
solution	O
containing	O
the	O
basic	O
remedy	O
and	O
the	O
carrier	O
,	O
adding	O
the	O
solution	O
containing	O
the	O
basic	O
remedy	O
and	O
the	O
carrier	O
into	O
a	O
stabiliser	O
water	O
solution	O
of	O
10	O
-	O
20	O
shares	O
by	O
weight	O
as	O
well	O
as	O
agitating	O
,	O
agitating	O
to	O
emulsify	O
thoroughly	O
,	O
remixing	O
to	O
volatilize	O
the	O
organic	O
solvent	O
,	O
solidifying	O
to	O
obtain	O
a	O
microsphere	O
.	O

The	O
invention	O
also	O
provides	O
an	O
application	O
of	O
the	O
microsphere	O
,	O
that	O
is	O
the	O
microsphere	O
is	O
prepared	O
into	O
an	O
injecting	O
heeling	O
-	O
in	O
agent	O
by	O
a	O
preparation	O
method	O
of	O
a	O
conventional	O
medicinal	O
preparation	O
.	O

The	O
long	O
-	O
acting	O
Nestorone	B
microsphere	O
of	O
the	O
invention	O
has	O
an	O
integral	O
modality	O
,	O
the	O
microsphere	O
dimension	O
is	O
from	O
10	O
to	O
50	O
[	O
Mu	O
]	O
m	O
,	O
the	O
diameter	O
is	O
distributed	O
well	O
,	O
and	O
a	O
vitro	O
release	O
time	O
is	O
from	O
1	O
to	O
12	O
weeks	O
.	O

Biodegradation	O
type	O
long	O
-	O
acting	O
contraception	O
microsphere	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
clofarabine	B
pharmaceutical	O
composition	O
freeze	O
-	O
dried	O
powder	O
injection	O
which	O
is	O
prepared	O
by	O
freeze	O
-	O
drying	O
10	O
-	O
30	O
parts	O
by	O
weight	O
of	O
clofarabine	B
,	O
100	O
-	O
300	O
parts	O
by	O
weight	O
of	O
mannitol	B
,	O
20	O
-	O
60	O
parts	O
by	O
weight	O
of	O
sodium	B
bicarbonate	I
,	O
pH	O
regulator	O
and	O
water	O
for	O
injection	O
.	O

The	O
clofarabine	B
pharmaceutical	O
composition	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
a	O
white	O
or	O
almost	O
white	O
loose	O
mass	O
or	O
powder	O
with	O
good	O
stability	O
and	O
good	O
product	O
redissolution	O
property	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
clofarabine	O
pharmaceutical	O
composition	O
freeze	O
-	O
dried	O
powder	O
injection	O
with	O
simple	O
method	O
and	O
strong	O
operability	O
.	O

Clofarabine	B
pharmaceutical	O
composition	O
freeze	O
-	O
dried	O
powder	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
radix	O
sophorae	O
tonkinensis	O
total	O
flavonoids	B
,	O
flavone	B
salt	O
and	O
extraction	O
method	O
thereof	O
.	O

The	O
extraction	O
method	O
is	O
as	O
follows	O
:	O
extracting	O
the	O
radix	O
sophorae	O
tonkinensi	O
with	O
inorganic	O
acid	O
solution	O
or	O
organic	O
acid	O
solution	O
,	O
further	O
extracting	O
the	O
extracted	O
residue	O
with	O
organic	O
solvent	O
or	O
organic	O
alkaline	O
solution	O
,	O
and	O
then	O
obtaining	O
radix	O
sophorae	O
tonkinensis	O
total	O
flavonoids	B
and	O
flavone	B
salt	O
containing	O
80	O
%	O
of	O
total	O
flavonoids	B
based	O
on	O
total	O
weight	O
of	O
the	O
radix	O
sophorae	O
tonkinensis	O
total	O
flavonoids	B
.	O

The	O
method	O
of	O
the	O
invention	O
utilizes	O
radix	O
sophorae	O
tonkinensis	O
residuefrom	O
which	O
dauricine	B
is	O
extracted	O
as	O
raw	O
material	O
to	O
produce	O
radix	O
sophorae	O
tonkinensis	O
total	O
flavonoids	B
and	O
flavone	B
salt	O
.	O

The	O
method	O
has	O
advantages	O
of	O
low	O
material	O
cost	O
,	O
simple	O
process	O
,	O
and	O
being	O
suitable	O
for	O
industrial	O
production	O
.	O

Radix	O
sophorae	O
tonkinensis	O
total	O
flavonoids	B
,	O
flavone	B
salt	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicament	O
formulations	O
,	O
in	O
particular	O
to	O
clove	O
-	O
pubescent	O
angelica	O
root	O
compound	O
soup	O
used	O
for	O
treating	O
adhesive	O
ileus	O
.	O

Clove	O
,	O
fructus	O
evodiae	O
,	O
sauted	O
radish	O
seed	O
,	O
raw	O
rhubarb	O
,	O
mirabilite	O
,	O
red	O
peony	O
root	O
,	O
immature	O
bitter	O
orange	O
,	O
officinal	O
magnolia	O
bark	O
,	O
pubescent	O
angelica	O
root	O
,	O
costus	O
root	O
and	O
dahurian	O
angelica	O
are	O
used	O
as	O
raw	O
materials	O
;	O
firstly	O
,	O
the	O
raw	O
rhubarb	O
and	O
the	O
mirabilite	O
are	O
separately	O
packed	O
;	O
the	O
clove	O
,	O
the	O
fructus	O
evodiae	O
,	O
the	O
sauted	O
radish	O
seed	O
,	O
the	O
red	O
peony	O
root	O
,	O
the	O
immature	O
bitter	O
orange	O
,	O
the	O
officinal	O
magnolia	O
bark	O
,	O
the	O
pubescent	O
angelicaroot	O
,	O
the	O
costus	O
root	O
and	O
the	O
dahurian	O
angelica	O
are	O
mixed	O
and	O
soaked	O
by	O
water	O
;	O
after	O
the	O
mixture	O
is	O
decocted	O
,	O
the	O
dregs	O
are	O
removed	O
to	O
obtain	O
filtrate	O
;	O
and	O
then	O
the	O
raw	O
rhubarb	O
is	O
added	O
into	O
the	O
filtrate	O
,	O
the	O
mixture	O
is	O
boiled	O
for	O
3	O
to	O
5	O
minutes	O
,	O
the	O
dregs	O
are	O
removed	O
again	O
,	O
then	O
the	O
mirabilite	O
is	O
added	O
into	O
the	O
decoction	O
,	O
the	O
mixture	O
is	O
boiled	O
by	O
low	O
fire	O
,	O
and	O
the	O
decoction	O
is	O
filled	O
into	O
a	O
sterile	O
glass	O
bottle	O
to	O
obtain	O
the	O
clove	O
-	O
pubescent	O
angelica	O
root	O
compound	O
soup	O
.	O

The	O
clove	O
-	O
pubescent	O
angelica	O
root	O
compound	O
soup	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
percentage	O
:	O
11	O
to	O
14	O
percent	O
of	O
the	O
clove	O
,	O
10	O
to	O
12	O
percent	O
of	O
the	O
fructus	O
evodiae	O
,	O
10	O
to	O
12	O
percent	O
of	O
the	O
sauted	O
radish	O
seed	O
,	O
8	O
to	O
10	O
percent	O
of	O
the	O
raw	O
rhubarb	O
,	O
6	O
to	O
8	O
percent	O
of	O
the	O
mirabilite	O
,	O
7	O
to	O
9	O
percent	O
of	O
the	O
red	O
peony	O
root	O
,	O
8	O
to	O
10	O
percent	O
of	O
the	O
immature	O
bitter	O
orange	O
,	O
6	O
to	O
8	O
percent	O
of	O
the	O
officinal	O
magnolia	O
bark	O
,	O
12	O
to	O
14	O
percent	O
of	O
the	O
pubescent	O
angelica	O
root	O
,	O
5	O
to	O
7	O
percent	O
of	O
the	O
costusroot	O
and	O
6	O
to	O
8	O
percent	O
of	O
the	O
dahurian	O
angelica	O
.	O

Clove	O
-	O
pubescent	O
angelica	O
root	O
compound	O
soup	O
used	O
for	O
treating	O
adhesive	O
ileus	O

The	O
invention	O
provides	O
an	O
etoposide	B
solid	O
lipid	O
nanoparticle	O
for	O
injection	O
and	O
oral	O
administration	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
etoposide	B
is	O
encapsulated	O
by	O
using	O
a	O
lipid	O
material	O
and	O
an	O
emulsifying	O
agent	O
to	O
obtain	O
the	O
etoposide	B
solid	O
lipid	O
nanoparticle	O
with	O
small	O
particle	O
diameter	O
,	O
high	O
encapsulation	O
ratio	O
,	O
good	O
stability	O
and	O
low	O
toxicity	O
.	O

The	O
prepared	O
etoposide	B
solid	O
lipid	O
nanoparticle	O
improves	O
the	O
solubility	O
and	O
the	O
stability	O
of	O
the	O
etoposide	B
,	O
reduces	O
vascular	O
stimulation	O
of	O
the	O
etoposide	B
and	O
prolongs	O
circulation	O
time	O
of	O
medicament	O
in	O
blood	O
so	O
as	O
to	O
improve	O
curative	O
effect	O
of	O
the	O
medicament	O
,	O
therefore	O
,	O
the	O
formulation	O
made	O
from	O
the	O
solid	O
lipid	O
nanoparticle	O
clinically	O
has	O
the	O
characteristics	O
of	O
low	O
toxicity	O
,	O
low	O
stimulation	O
and	O
high	O
efficiency	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
etoposide	B
solid	O
lipid	O
nanoparticle	O
with	O
simple	O
preparation	O
process	O
and	O
low	O
cost	O
,	O
and	O
is	O
suitable	O
for	O
industrialization	O
production	O
.	O

Etoposide	B
solid	O
lipid	O
nanoparticle	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
simvastatin	B
slow	O
-	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
simvastatin	B
slow	O
-	O
release	O
tablet	O
comprises	O
a	O
medicine	O
-	O
carrying	O
tablet	O
core	O
and	O
a	O
coating	O
layer	O
coated	O
outside	O
the	O
medicine	O
-	O
carrying	O
tablet	O
core	O
,	O
wherein	O
the	O
medicine	O
-	O
carrying	O
tablet	O
core	O
comprises	O
the	O
following	O
raw	O
materials	O
according	O
to	O
parts	O
by	O
weight	O
:	O
7	O
-	O
13	O
parts	O
of	O
simvastatin	B
,	O
120	O
-	O
140	O
parts	O
of	O
filler	O
and	O
40	O
-	O
60	O
parts	O
of	O
adhesive	O
;	O
the	O
existing	O
short	O
-	O
acting	O
simvastatin	B
tablet	O
is	O
prepared	O
into	O
a	O
coating	O
type	O
slow	O
-	O
release	O
preparation	O
form	O
which	O
controls	O
the	O
diffusion	O
and	O
dissolution	O
of	O
a	O
medicine	O
so	O
as	O
to	O
delay	O
the	O
release	O
of	O
the	O
medicine	O
;	O
after	O
the	O
medicine	O
enters	O
a	O
human	O
body	O
,	O
the	O
coating	O
layer	O
slowly	O
dissolves	O
,	O
so	O
that	O
the	O
medicine	O
is	O
stably	O
and	O
durably	O
released	O
,	O
the	O
blood	O
concentration	O
is	O
kept	O
in	O
a	O
more	O
stable	O
effective	O
state	O
for	O
a	O
long	O
time	O
,	O
the	O
defect	O
of	O
large	O
fluctuation	O
of	O
the	O
effective	O
blood	O
concentration	O
caused	O
by	O
the	O
overlarge	O
fluctuation	O
of	O
the	O
blood	O
concentration	O
existing	O
in	O
the	O
frequent	O
administration	O
of	O
a	O
conventional	O
preparation	O
form	O
is	O
avoided	O
,	O
and	O
the	O
toxic	O
or	O
side	O
effect	O
is	O
reduced	O
;	O
and	O
the	O
simvastatin	B
slow	O
-	O
release	O
tablet	O
is	O
prepared	O
in	O
a	O
closed	O
one	O
-	O
step	O
boiling	O
granulator	O
,	O
thereby	O
being	O
hardly	O
polluted	O
,	O
the	O
quality	O
of	O
a	O
finished	O
product	O
can	O
be	O
better	O
guaranteed	O
,	O
and	O
automatic	O
control	O
is	O
convenient	O
.	O

Simvastatin	B
slow	O
-	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
relieving	O
cough	O
,	O
which	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
prepared	O
from	O
the	O
following	O
compounds	O
according	O
to	O
the	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
hydantoin	B
and	O
0.5	O
-	O
2	O
part	O
of	O
5,5-dimethyl	B
hydantoin	I
.	O

A	O
medicament	O
prepared	O
from	O
the	O
pharmaceutical	O
composition	O
has	O
obvious	O
cough	O
relieving	O
effect	O
,	O
and	O
the	O
cough	O
relieving	O
effect	O
achieved	O
after	O
matching	O
the	O
hydantoin	O
and	O
the	O
5,5-dimethyl	B
hydantoin	I
is	O
obviously	O
better	O
than	O
the	O
cough	O
relieving	O
effect	O
achieved	O
by	O
singly	O
using	O
the	O
hydantoin	B
,	O
the	O
5,5-dimethyl	B
hydantoin	I
or	O
1-methyl	B
hydantoin	I
and	O
the	O
cough	O
relieving	O
effect	O
achieved	O
by	O
codeine	B
phosphate	I
which	O
is	O
a	O
positive	O
medicament	O
.	O

Pharmaceutical	O
composition	O
for	O
relieving	O
cough	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
combination	O
containing	O
nicotinic	B
acid	I
,	O
HMG	O
-	O
CoA	O
reductase	O
inhibitor	O
and	O
TZD	O
medicines	O
and	O
carrier	O
which	O
can	O
be	O
accepted	O
by	O
pharmaceutics	O
and	O
an	O
application	O
of	O
the	O
combination	O
for	O
preparing	O
medicines	O
for	O
preventing	O
or	O
treating	O
diabetes	O
and	O
diabetes	O
-	O
related	O
complications	O
.	O

The	O
effect	O
of	O
the	O
medicines	O
prepared	O
with	O
the	O
combination	O
provided	O
by	O
the	O
invention	O
is	O
better	O
than	O
single	O
-	O
agent	O
in	O
preventing	O
or	O
curing	O
diabetes	O
and	O
diabetes	O
-	O
related	O
complications	O
and	O
the	O
medicines	O
are	O
easier	O
for	O
patients	O
to	O
take	O
.	O

Drug	O
combination	O
containing	O
nicotinic	B
acid	I
,	O
statins	O
compound	O
and	O
TZD	O
compound	O

The	O
invention	O
discloses	O
anticancer	O
healthcare	O
medicinal	O
granules	O
and	O
a	O
production	O
method	O
thereof	O
,	O
and	O
relates	O
to	O
the	O
technical	O
field	O
of	O
biotechnological	O
health	O
care	O
product	O
production	O
process	O
.	O

The	O
anticancer	O
healthcare	O
medicinal	O
granules	O
mainly	O
comprise	O
yolk	O
lecithin	B
,	O
yolk	O
protein	O
,	O
egg	O
white	O
powder	O
,	O
egg	O
membrane	O
element	O
powder	O
and	O
yolk	O
dry	O
powder	O
which	O
are	O
respectively	O
extracted	O
from	O
fresh	O
eggs	O
.	O

The	O
anticancer	O
healthcare	O
medicinal	O
granules	O
are	O
convenient	O
to	O
eat	O
,	O
are	O
easy	O
to	O
be	O
absorbed	O
by	O
human	O
bodies	O
,	O
can	O
relieve	O
pain	O
brought	O
by	O
cancer	O
radiotherapy	O
and	O
chemotherapy	O
,	O
achieve	O
the	O
aims	O
of	O
attenuating	O
toxicity	O
and	O
potentiating	O
efficacy	O
,	O
inhibiting	O
propagation	O
of	O
cancer	O
cells	O
and	O
growth	O
of	O
tumors	O
,	O
softening	O
lumps	O
,	O
reducing	O
tumor	O
bodies	O
,	O
clearing	O
residual	O
cancer	O
cells	O
of	O
tissues	O
removed	O
,	O
and	O
promoting	O
and	O
helping	O
a	O
patient	O
to	O
recuperate	O
quickly	O
,	O
and	O
reduce	O
relapse	O
rate	O
and	O
death	O
rate	O
and	O
improve	O
survival	O
rate	O
of	O
the	O
patient	O
after	O
cancer	O
operation	O
radiotherapy	O
and	O
chemotherapy	O
.	O

Anticancer	O
healthcare	O
medicinal	O
granules	O
and	O
production	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
antioxidant	O
health	O
care	O
soft	O
capsule	O
.	O

The	O
invention	O
solves	O
the	O
problem	O
that	O
soft	O
capsules	O
of	O
the	O
prior	O
art	O
can	O
not	O
realize	O
the	O
effective	O
and	O
full	O
absorption	O
of	O
resveratrol	B
and	O
polyphenol	B
substances	O
by	O
human	O
bodies	O
,	O
and	O
further	O
provides	O
the	O
health	O
care	O
soft	O
capsule	O
which	O
can	O
realize	O
the	O
full	O
absorption	O
of	O
the	O
resveratrol	B
and	O
the	O
polyphenol	B
substances	O
by	O
the	O
human	O
bodies	O
further	O
to	O
realize	O
the	O
complete	O
removal	O
of	O
free	O
radicals	O
produced	O
in	O
the	O
human	O
bodies	O
and	O
can	O
also	O
perform	O
antioxidation	O
effect	O
on	O
human	O
beneficial	O
ingredients	O
susceptible	O
to	O
oxidation	O
at	O
the	O
same	O
time	O
.	O

Antioxidant	O
health	O
care	O
soft	O
capsule	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
an	O
N	B
-	I
glycosylation-3-aryl	I
acrylamide	I
derivative	O
(	O
I	O
)	O
,	O
wherein	O
,	O
the	O
definitions	O
of	O
G	O
and	O
Ar	B
are	O
disclosed	O
in	O
the	O
specification	O
.	O

A	O
pharmacological	O
experiment	O
proves	O
that	O
the	O
compound	O
has	O
a	O
restraining	O
function	O
to	O
the	O
propagation	O
of	O
vascular	O
endothelial	O
cells	O
and	O
can	O
be	O
applied	O
to	O
the	O
clinical	O
therapy	O
of	O
tumours	O
or	O
chronic	O
inflammation	O
.	O

Amino	B
sugar	I
derivative	O
,	O
preparation	O
method	O
thereof	O
and	O
medicinal	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
paste	O
for	O
treating	O
toothache	O
.	O

The	O
paste	O
for	O
treating	O
toothache	O
is	O
characterized	O
in	O
that	O
25	O
grams	O
of	O
white	O
alum	O
and	O
25	O
grams	O
of	O
white	O
pepper	O
powder	O
are	O
put	O
into	O
a	O
container	O
after	O
being	O
mixed	O
and	O
are	O
stirred	O
into	O
a	O
paste	O
shape	O
after	O
being	O
heated	O
at	O
a	O
high	O
temperature	O
;	O
and	O
then	O
,	O
a	O
right	O
amount	O
of	O
paste	O
is	O
taken	O
and	O
put	O
on	O
a	O
trouble	O
tooth	O
,	O
the	O
tooth	O
is	O
gnashed	O
,	O
the	O
mouth	O
is	O
closed	O
,	O
the	O
spitting	O
of	O
saliva	O
is	O
prohibited	O
,	O
and	O
the	O
saliva	O
is	O
spitted	O
after	O
half	O
an	O
hour	O
.	O

The	O
method	O
is	O
commonly	O
successful	O
once	O
,	O
and	O
can	O
be	O
repeatedly	O
applied	O
at	O
the	O
next	O
day	O
if	O
remaining	O
pain	O
still	O
exists	O
.	O

The	O
invention	O
has	O
the	O
beneficial	O
effect	O
that	O
the	O
method	O
has	O
the	O
advantages	O
of	O
convenient	O
acquirement	O
of	O
materials	O
,	O
simple	O
operation	O
,	O
definite	O
curative	O
effect	O
,	O
and	O
never	O
relapse	O
.	O

Paste	O
for	O
treating	O
toothache	O

The	O
invention	O
belongs	O
to	O
the	O
organic	O
chemistry	O
and	O
drug	O
synthesis	O
field	O
and	O
relates	O
to	O
3-	B
(	I
3-methoxyl-4-hydroxybenzyl	I
)	I
-4-aromatic	I
-	I
hexene	I
(	I
hexane	I
)	I
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
comprising	O
3-	B
(	I
3-methoxyl-4-hydroxybenzyl	I
)	I
-4-aromatic	I
-	I
hexane	I
,	O
3-	B
(	I
3-methoxyl-4-hydroxybenzyl	I
)	I
-4-aromatic-2-hexene	I
,	O
3-	B
(	I
3-methoxyl-4-hydroxybenzyl	I
)	I
-4-aromatic-3-hexene	I
,	O
3-	B
(	I
3-methoxyl-4-hydroxybenzyl	I
)	I
-4-aromatic-2,4-hexadiene	I
and	O
other	O
compounds	O
.	O

Human	O
umbilical	O
vein	O
endothelial	O
cells	O
model	O
drug	O
screening	O
experiments	O
and	O
biological	O
activities	O
tests	O
results	O
show	O
that	O
the	O
compound	O
of	O
the	O
invention	O
can	O
inhibit	O
the	O
growth	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
and	O
has	O
the	O
neovascularization	O
suppressive	O
activity	O
,	O
thus	O
be	O
applicable	O
to	O
being	O
prepared	O
into	O
medicines	O
for	O
curing	O
tumour	O
.	O

3-	B
(	I
3-methoxyl-4-hydroxybenzyl	I
)	I
-4-aromatic	I
-	I
hexene	I
(	I
hexane	I
)	I
and	O
medicinal	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
heracleum	O
hemsleyanum	O
michaux	O
and	O
herba	O
artemisiae	O
capillaris	O
oral	O
wine	O
.	O

The	O
phlegm	O
accumulation	O
,	O
headache	O
,	O
dyspnea	O
and	O
back	O
pain	O
can	O
be	O
eliminated	O
within	O
a	O
certain	O
period	O
of	O
time	O
and	O
the	O
effects	O
of	O
reducing	O
phlegm	O
,	O
relaxing	O
tendons	O
and	O
activating	O
meridians	O
can	O
be	O
achieved	O
by	O
using	O
the	O
method	O
.	O

The	O
method	O
is	O
realized	O
by	O
adopting	O
the	O
following	O
technical	O
scheme	O
:	O
grinding	O
Tianxiong	O
(	O
processed	O
)	O
,	O
branch	O
monkshood	O
daughter	O
(	O
processed	O
)	O
and	O
magnetite	O
into	O
fine	O
powder	O
,	O
putting	O
fresh	O
ginger	O
is	O
cut	O
into	O
slices	O
,	O
the	O
fine	O
powder	O
and	O
the	O
slices	O
in	O
a	O
70-degree	O
white	O
wine	O
vessel	O
to	O
be	O
soaked	O
for	O
24	O
hours	O
for	O
later	O
use	O
,	O
then	O
mixing	O
and	O
crushing	O
heracleum	O
hemsleyanum	O
michaux	O
,	O
Hibiscus	O
taiwanensis	O
,	O
lucid	O
asparagus	O
root	O
,	O
milkvetch	O
root	O
,	O
chamomile	O
,	O
ledebouriella	O
root	O
,	O
tetrandra	O
root	O
,	O
white	O
atractylodes	O
rhizome	O
,	O
light	O
red	O
Indian	O
Bread	O
,	O
achyranthes	O
root	O
,	O
wolfberry	O
fruit	O
,	O
basket	O
fern	O
,	O
dried	O
rehamnnia	O
root	O
and	O
herba	O
artemisiae	O
capillaris	O
into	O
10	O
meshes	O
of	O
fragments	O
,	O
mixing	O
the	O
fragments	O
together	O
with	O
the	O
four	O
-	O
flavor	O
medicinal	O
liquor	O
together	O
and	O
putting	O
in	O
the	O
white	O
wine	O
vessel	O
,	O
stirring	O
for	O
10	O
minutes	O
and	O
then	O
heating	O
for	O
10	O
minutes	O
at	O
40	O
DEG	O
C	O
,	O
stopping	O
fire	O
and	O
then	O
sealing	O
and	O
burying	O
the	O
white	O
wine	O
vessel	O
underground	O
for	O
10	O
days	O
,	O
taking	O
out	O
and	O
then	O
filtering	O
to	O
obtain	O
the	O
finished	O
medicinal	O
liquor	O
.	O

Preparation	O
method	O
of	O
heracleum	O
hemsleyanum	O
michaux	O
and	O
herba	O
artemisiae	O
capillaris	O
oral	O
wine	O

The	O
invention	O
relates	O
to	O
a	O
naphthaline	B
lactam	I
derivative	O
and	O
application	O
thereof	O
in	O
the	O
propagation	O
suppression	O
of	O
tumor	O
cells	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
chemistry	O
.	O

N	B
aphthaline	I
lactam	I
is	O
taken	O
as	O
a	O
parent	O
for	O
the	O
naphthaline	B
lactam	I
derivative	O
takes	O
,	O
and	O
a	O
derivative	O
with	O
high	O
biological	O
activity	O
base	O
groups	O
,	O
such	O
as	O
acetylene	B
bonds	O
,	O
nitrile	B
groups	O
,	O
amine	B
groups	O
or	O
acylamide	B
structures	O
,	O
and	O
the	O
like	O
is	O
obtained	O
respectively	O
by	O
synthetic	O
methods	O
of	O
firstly	O
using	O
different	O
alkylogen	B
hydrocarbon	I
to	O
carry	O
out	O
dehydrogenating	O
condensation	O
to	O
two	O
-	O
position	O
carbonyl	B
and	O
a	O
compound	O
with	O
active	O
methylene	B
,	O
introducing	O
different	O
electrophilic	O
substitution	O
base	O
groups	O
by	O
six	O
positions	O
and	O
then	O
carrying	O
out	O
substitution	O
to	O
the	O
active	O
hydrogen	B
of	O
one	O
-	O
position	O
imine	B
.	O

An	O
experiment	O
of	O
the	O
naphthaline	B
lactam	I
derivative	O
for	O
the	O
propagation	O
suppression	O
of	O
tumor	O
cells	O
selects	O
a	O
tetrazolium	B
reduction	O
method	O
and	O
is	O
carried	O
out	O
aiming	O
at	O
7721	O
human	O
body	O
liver	O
cancer	O
cells	O
,	O
MCF-7	O
human	O
body	O
mammarycancer	O
cells	O
,	O
Hela	O
human	O
body	O
cervical	O
carcinoma	O
cells	O
or	O
BGC-823	O
human	O
body	O
stomach	O
cancer	O
cells	O
;	O
and	O
a	O
result	O
indicates	O
that	O
the	O
naphthaline	B
lactam	I
derivative	O
has	O
favorable	O
activity	O
and	O
selectivity	O
in	O
the	O
propagation	O
suppression	O
of	O
the	O
tumor	O
cells	O
.	O

Naphthaline	B
lactam	I
derivative	O
and	O
application	O
thereof	O
in	O
propagation	O
suppression	O
of	O
tumor	O
cells	O

The	O
invention	O
discloses	O
a	O
compound	O
sodium	B
sulfadimidine	I
injection	O
liquid	O
for	O
a	O
pig	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
aiming	O
at	O
providing	O
a	O
compound	O
kanamycin	B
sulfate	I
injection	O
liquid	O
which	O
has	O
fast	O
effect	O
for	O
treating	O
toxoplasmosis	O
of	O
the	O
pig	O
,	O
addresses	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
,	O
reduces	O
the	O
time	O
and	O
dosage	O
of	O
used	O
drug	O
and	O
has	O
convenient	O
drug	O
usage	O
,	O
and	O
a	O
preparation	O
method	O
with	O
simple	O
technique	O
and	O
easy	O
implementation	O
.	O

Each	O
100L	O
injection	O
liquid	O
comprises	O
:	O
5	O
to	O
20	O
sodium	B
sulfadimidine	I
,	O
1	O
to	O
10	O
kg	O
of	O
lincomycin	B
hydrochloride	I
,	O
5	O
to	O
20	O
kg	O
of	O
doxofylline	B
,	O
1	O
to	O
4	O
kg	O
of	O
trimethoprim	B
,	O
0.2	O
kg	O
of	O
sodium	B
bisulfite	I
,	O
0.01	O
kg	O
of	O
EDTA-2Na	B
,	O
40	O
kg	O
of	O
propylene	B
glycol	I
,	O
10	O
kg	O
of	O
95	O
%	O
alcohol	B
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
injection	O
liquid	O
has	O
fast	O
effect	O
for	O
toxoplasmosis	O
of	O
the	O
pig	O
,	O
addresses	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
,	O
can	O
effectively	O
treat	O
and	O
prevent	O
secondary	O
infection	O
of	O
bacterium	O
,	O
reduces	O
drug	O
resistance	O
of	O
pathogenic	O
microorganism	O
and	O
leads	O
the	O
pig	O
to	O
accelerate	O
restoring	O
.	O

Simultaneously	O
,	O
the	O
compound	O
sodium	B
sulfadimidine	I
injection	O
liquid	O
is	O
an	O
injection	O
liquid	O
and	O
has	O
convenient	O
use	O
.	O

Compound	O
sodium	B
sulfadimidine	I
injection	O
liquid	O
for	O
pig	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
tamariskoid	O
spikemoss	O
herb	O
effective	O
part	O
for	O
reducing	O
blood	O
lipid	O
,	O
and	O
an	O
extraction	O
method	O
and	O
application	O
thereof	O
.	O

The	O
effective	O
part	O
is	O
an	O
ethyl	B
acetate	I
part	O
obtained	O
by	O
extracting	O
tamariskoid	O
spikemoss	O
herb	O
by	O
acetone	B
water	O
,	O
concentrating	O
and	O
extracting	O
by	O
ethyl	B
acetate	I
.	O

The	O
tamariskoid	O
spikemoss	O
herb	O
effective	O
part	O
for	O
reducing	O
blood	O
lipid	O
is	O
obtained	O
by	O
extracting	O
from	O
lipid	O
solubility	O
part	O
of	O
tamariskoid	O
spikemoss	O
herb	O
and	O
the	O
tamariskoid	O
spikemoss	O
herb	O
is	O
distributed	O
widely	O
in	O
nature	O
,	O
so	O
that	O
the	O
raw	O
material	O
is	O
easy	O
to	O
obtain	O
and	O
low	O
in	O
cost	O
.	O

In	O
addition	O
,	O
the	O
extraction	O
method	O
has	O
simple	O
technological	O
process	O
and	O
easy	O
operation	O
.	O

Experiment	O
shows	O
that	O
the	O
amentoflavone	B
obtained	O
by	O
further	O
extracting	O
the	O
tamariskoid	O
spikemoss	O
herb	O
effective	O
part	O
for	O
reducing	O
blood	O
lipid	O
has	O
good	O
function	O
of	O
reducing	O
blood	O
lipid	O
.	O

Experiment	O
in	O
vivo	O
shows	O
that	O
the	O
blood	O
lipid	O
level	O
can	O
be	O
reduced	O
by	O
reducing	O
serum	O
total	O
cholesterol	B
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	B
of	O
hyperlipidemic	O
mouse	O
.	O

The	O
amentoflavone	B
has	O
higher	O
extraction	O
rate	O
,	O
and	O
the	O
once	O
extraction	O
rate	O
can	O
reach	O
as	O
high	O
as	O
30	O
to	O
40	O
percent	O
.	O

Tamariskoid	O
spikemoss	O
herb	O
effective	O
part	O
for	O
reducing	O
blood	O
lipid	O
,	O
extraction	O
method	O
and	O
application	O
thereof	O
,	O
and	O
extraction	O
method	O
of	O
amentoflavone	B

A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
,	O
m	O
,	O
n	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
specification	O
;	O
a	O
process	O
for	O
preparing	O
such	O
compounds	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
such	O
compounds	O
;	O
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
medicine	O
.	O

Benzamide	B
derivatives	O
as	O
EP4	O
receptor	O
agonists	O

The	O
invention	O
relates	O
to	O
a	O
new	O
geranium	O
extract	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
in	O
particular	O
to	O
the	O
geranium	O
extract	O
containing	O
corilagin	O
,	O
and	O
application	O
of	O
the	O
geranium	O
extract	O
in	O
medicaments	O
for	O
treating	O
or	O
preventing	O
gastroxia	O
and	O
related	O
diseases	O
.	O

New	O
geranium	O
extract	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
leukemia	O
or	O
aplastic	O
anemia	O
,	O
and	O
the	O
pharmaceutical	O
composition	O
comprises	O
American	O
ginseng	O
,	O
Chinese	O
caterpillar	O
fungus	O
,	O
dragon	O
's	O
blood	O
,	O
pangolin	O
scales	O
,	O
musk	O
,	O
bezoar	O
,	O
pearl	O
,	O
Hawksbill	O
Carapace	O
,	O
palourde	O
powder	O
,	O
prepared	O
nux	O
vomica	O
,	O
toad	O
venom	O
,	O
toad	O
skin	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
mainly	O
used	O
for	O
treating	O
various	O
types	O
of	O
acute	O
and	O
chronic	O
leukemia	O
,	O
aplastic	O
anemia	O
and	O
thrombocytopenia	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
the	O
effects	O
of	O
clearing	O
heat	O
-	O
toxin	O
,	O
promoting	O
blood	O
circulation	O
,	O
removing	O
blood	O
stasis	O
,	O
stopping	O
bleeding	O
,	O
promoting	O
production	O
of	O
blood	O
and	O
activating	O
hematopoietic	O
function	O
.	O

Furthermore	O
,	O
the	O
pharmaceutical	O
composition	O
has	O
the	O
advantages	O
of	O
convenient	O
administration	O
,	O
easy	O
absorption	O
,	O
rapid	O
onset	O
of	O
action	O
,	O
good	O
effect	O
,	O
low	O
cost	O
,	O
no	O
toxicity	O
or	O
side	O
effects	O
and	O
the	O
like	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
leukemia	O
or	O
aplastic	O
anemia	O

The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
cancer	O
drug	O
slow	O
release	O
injection	O
containing	O
gemcitabine	B
,	O
which	O
comprises	O
slow	O
release	O
microspheres	O
and	O
a	O
menstruum	O
,	O
wherein	O
the	O
microsphere	O
comprises	O
anti	O
-	O
cancer	O
active	O
ingredients	O
and	O
slow	O
release	O
auxiliary	O
materials	O
,	O
and	O
the	O
menstruum	O
is	O
a	O
special	O
menstruum	O
containing	O
a	O
suspending	O
agent	O
;	O
the	O
anti	O
-	O
cancer	O
active	O
ingredients	O
are	O
gemcitabine	B
,	O
or	O
antimetabolites	O
selected	O
from	O
zalcitabine	B
,	O
emtricitabine	B
,	O
galocitabine	B
,	O
ibacitabine	B
,	O
ancitabine	B
,	O
decitabine	B
,	O
flurocitabine	B
,	O
enocitabine	B
,	O
imidazole	B
gemcitabine	I
,	O
capecitabine	B
,	O
gemcitabine	B
,	O
fludarabine	B
or	O
cladribine	B
,	O
and/or	O
antimetabolite	O
potentiating	O
agents	O
selected	O
from	O
phosphoinositide	O
3-kinase	O
inhibitor	O
,	O
pyrimidine	B
analogue	O
and/or	O
DNA	O
repair	O
enzyme	O
inhibitor	O
;	O
the	O
slow	O
release	O
auxiliary	O
materials	O
are	O
polifeprosan	B
,	O
dienoic	B
fatty	I
acid	I
,	O
decanedioic	B
acid	I
copolymer	O
,	O
polylactic	B
acid	I
copolymer	O
,	O
EVAc	O
and	O
the	O
like	O
;	O
the	O
suspending	O
agent	O
has	O
a	O
viscosity	O
of	O
100cp-3000cp	O
(	O
20	O
-	O
30	O
DEG	O
C	O
)	O
,	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose	O
and	O
the	O
like	O
.	O

The	O
slow	O
release	O
microspheres	O
can	O
be	O
prepared	O
into	O
slow	O
release	O
implants	O
.	O

When	O
injected	O
or	O
placed	O
into	O
tumors	O
or	O
at	O
peripheries	O
of	O
tumors	O
,	O
the	O
slow	O
release	O
microspheres	O
can	O
enhance	O
the	O
treatment	O
effect	O
of	O
non	O
-	O
operative	O
treatment	O
methods	O
,	O
such	O
as	O
radiotherapy	O
,	O
chemotherapy	O
,	O
etc	O
.	O

Anti	O
-	O
cancer	O
drug	O
slow	O
release	O
injection	O
containing	O
gemcitabine	B

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
ligustrazine	B
phosphate	I
powder	O
injection	O
,	O
comprising	O
the	O
following	O
steps	O
:	O
dissolving	O
ligustrazine	B
phosphate	I
into	O
ethanol	B
;	O
adding	O
medicinal	O
carbon	B
for	O
adsorption	O
;	O
obtaining	O
filter	O
liquor	O
through	O
filtration	O
and	O
decarburization	O
;	O
degerming	O
and	O
filtering	O
the	O
filter	O
liquor	O
by	O
a	O
millipore	O
filter	O
membrane	O
,	O
and	O
then	O
crystallizing	O
under	O
the	O
temperature	O
of	O
0	O
-	O
35DEG	O
C	O
while	O
stirring	O
at	O
the	O
same	O
time	O
;	O
drying	O
crystallized	O
crystals	O
under	O
the	O
temperature	O
of	O
0	O
-	O
80	O
DEG	O
C	O
,	O
and	O
then	O
preparing	O
the	O
ligustrazine	B
phosphate	I
for	O
the	O
injection	O
through	O
subpackage	O
,	O
stopper	O
addition	O
and	O
capping	O
.	O

The	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
easy	O
operation	O
,	O
short	O
production	O
period	O
without	O
special	O
equipment	O
,	O
low	O
cost	O
and	O
high	O
yield	O
coefficient	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Preparation	O
method	O
of	O
ligustrazine	B
phosphate	I
powder	O
injection	O

The	O
invention	O
discloses	O
externally	O
applied	O
toxicity	O
removing	O
and	O
granulation	O
promoting	O
ointment	O
,	O
which	O
mainly	O
comprises	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
parts	O
:	O
3	O
to	O
30	O
parts	O
of	O
calomel	O
,	O
3	O
to	O
40	O
parts	O
of	O
malachite	O
,	O
3	O
to	O
30	O
parts	O
of	O
dragon	O
's	O
blood	O
,	O
3	O
to	O
60	O
parts	O
of	O
catechu	O
,	O
3	O
to	O
40	O
parts	O
of	O
vermillion	O
,	O
100	O
to	O
300	O
parts	O
of	O
beeswax	O
,	O
10	O
to	O
30	O
parts	O
of	O
rhizoma	O
paridis	O
,	O
3	O
to	O
20	O
parts	O
of	O
lithospermum	O
,	O
3	O
to	O
25	O
parts	O
of	O
dahurian	O
patrinia	O
herb	O
,	O
3	O
to	O
25	O
parts	O
of	O
dahurian	O
angelica	O
root	O
,	O
1	O
to	O
5	O
parts	O
of	O
blister	O
beetle	O
,	O
120	O
to	O
300	O
parts	O
of	O
colophony	O
and	O
500	O
parts	O
of	O
sesame	O
oil	O
.	O

When	O
the	O
ointment	O
is	O
prepared	O
,	O
firstly	O
,	O
the	O
lithospermum	O
,	O
the	O
dahurian	O
patrinia	O
herb	O
,	O
the	O
blister	O
beetle	O
,	O
the	O
dahurian	O
angelica	O
root	O
,	O
and	O
the	O
rhizoma	O
paridis	O
are	O
added	O
into	O
the	O
sesame	O
oil	O
,	O
heated	O
and	O
decocted	O
,	O
and	O
dregs	O
are	O
removed	O
;	O
then	O
the	O
beeswax	O
and	O
the	O
colophony	O
are	O
added	O
and	O
dissolved	O
;	O
and	O
finally	O
powder	O
prepared	O
by	O
grinding	O
the	O
calomel	O
,	O
the	O
malachite	O
,	O
the	O
dragon	O
's	O
blood	O
,	O
the	O
catechu	O
,	O
the	O
vermillion	O
is	O
added	O
,	O
and	O
the	O
raw	O
materials	O
are	O
evenly	O
stirred	O
.	O

The	O
externally	O
applied	O
toxicity	O
removing	O
and	O
granulation	O
promoting	O
ointment	O
has	O
the	O
effects	O
of	O
removing	O
blood	O
stasis	O
and	O
softening	O
hard	O
mass	O
,	O
relieving	O
swelling	O
and	O
pain	O
,	O
and	O
removing	O
pus	O
and	O
promoting	O
granulation	O
,	O
and	O
has	O
good	O
treatment	O
effect	O
on	O
ulcer	O
,	O
charbuncle	O
on	O
the	O
back	O
,	O
ulcerated	O
and	O
non	O
-	O
ulcerated	O
furuncle	O
and	O
pyogenic	O
infections	O
,	O
no	O
heal	O
after	O
poisonous	O
insect	O
bite	O
,	O
lymphadenitis	O
caused	O
by	O
erysipelas	O
and	O
the	O
like	O
.	O

Externally	O
applied	O
toxicity	O
removing	O
and	O
muscle	O
promoting	O
ointment	O

Ascorbic	B
acid	I
compositions	O
in	O
the	O
form	O
of	O
a	O
powder	O
and/or	O
granules	O
contain	O
as	O
principal	O
components	O
L	B
-	I
ascorbic	I
acid	I
and/or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
high	O
molecular	O
(	O
300	O
kDaltonor	O
higher	O
)	O
pectin	O
.	O

The	O
compositions	O
are	O
compressible	O
into	O
tablets	O
with	O
improved	O
mechanical	O
strength	O
and	O
hardness	O
.	O

Compositions	O
comprising	O
pectin	O
and	O
ascorbic	B
acid	I

The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
C60-benzoic	O
nitrogen	O
mustard	O
medicament	O
in	O
preparing	O
an	O
antitumor	O
medicament	O
based	O
on	O
nitrogen	O
mustard	O
by	O
using	O
C60	O
as	O
a	O
carrier	O
.	O

The	O
structure	O
is	O
shown	O
in	O
formula	O
I.	O
The	O
C60-benzoic	O
nitrogen	O
mustard	O
has	O
high	O
ingestion	O
rate	O
and	O
longer	O
detention	O
time	O
in	O
stomach	O
by	O
a	O
radial	O
marking	O
technique	O
;	O
the	O
C60-benzoic	O
nitrogen	O
mustard	O
can	O
enhance	O
a	O
kissing	O
functionto	O
tumor	O
tissues	O
of	O
an	O
organism	O
and	O
especially	O
to	O
lymph	O
transfer	O
focus	O
and	O
a	O
tumor	O
inhibiting	O
rate	O
is	O
higher	O
than	O
that	O
of	O
nitrogen	O
mustard	O
.	O

Application	O
of	O
C60-benzoic	O
nitrogen	O
mustard	O
in	O
preparing	O
antitumor	O
medicament	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
biological	O
medicine	O
,	O
discloses	O
an	O
application	O
of	O
ADDA	B
and/or	O
DMTA	B
in	O
preparing	O
medicine	O
for	O
improving	O
expression	O
level	O
of	O
gamma	O
-	O
globin	O
,	O
and	O
provides	O
a	O
candidate	O
drug	O
for	O
curing	O
anemia	O
caused	O
by	O
beta	O
-	O
thalassemia	O
,	O
sickle	O
-	O
cell	O
anemia	O
,	O
hematopoietic	O
system	O
tumor	O
and	O
hematopoietic	O
dysfunction	O
.	O

Application	O
of	O
ADDA	B
and/or	O
DMTA	B
in	O
preparing	O
medicine	O
for	O
improving	O
expression	O
level	O
of	O
gamma	O
-	O
globin	O

The	O
invention	O
relates	O
to	O
vermiculite	O
extracting	O
solution	O
and	O
application	O
thereof	O
.	O

The	O
invention	O
adopts	O
the	O
technical	O
scheme	O
that	O
:	O
the	O
vermiculite	O
extracting	O
solution	O
is	O
prepared	O
by	O
the	O
following	O
method	O
:	O
1	O
)	O
cleaning	O
vermiculite	O
in	O
a	O
cleaning	O
tank	O
;	O
2	O
)	O
grinding	O
the	O
vermiculite	O
into	O
vermiculite	O
powder	O
of	O
which	O
the	O
granularity	O
is	O
smaller	O
than	O
200	O
meshes	O
with	O
a	O
grinder	O
,	O
adding	O
15	O
weight	O
percent	O
sulphuric	B
acid	I
and	O
the	O
vermiculite	O
powder	O
in	O
a	O
weight	O
ratio	O
of	O
1:0.5	O
-	O
1	O
into	O
a	O
reaction	O
kettle	O
,	O
stirring	O
at	O
a	O
temperature	O
of	O
between	O
80	O
and	O
90	O
DEG	O
C	O
for	O
30	O
to	O
50	O
minutes	O
,	O
and	O
naturally	O
cooling	O
;	O
3	O
)	O
adjusting	O
pH	O
to	O
between	O
6	O
and	O
7	O
with	O
sodium	B
hydroxide	I
;	O
and	O
4	O
)	O
performing	O
pressure	O
filtration	O
and	O
collecting	O
filter	O
liquor	O
.	O

The	O
vermiculite	O
extracting	O
solution	O
is	O
extracted	O
from	O
natural	O
vermiculite	O
,	O
and	O
is	O
rich	O
in	O
about	O
80	O
trace	O
elements	O
;	O
and	O
in	O
daily	O
drinking	O
,	O
people	O
mix	O
the	O
vermiculite	O
extracting	O
solution	O
and	O
water	O
in	O
a	O
weight	O
ratio	O
of	O
1:50	O
-	O
100	O
,	O
so	O
that	O
the	O
drinking	O
water	O
is	O
rich	O
in	O
mineral	O
trace	O
elements	O
,	O
and	O
can	O
meet	O
the	O
requirement	O
of	O
a	O
human	O
body	O
on	O
the	O
mineral	O
trace	O
elements	O
and	O
improve	O
the	O
immunity	O
of	O
the	O
human	O
body	O
if	O
the	O
drinking	O
water	O
is	O
drunk	O
by	O
the	O
people	O
frequently	O
.	O

Vermiculite	O
extracting	O
solution	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicine	O
combination	O
for	O
treating	O
stomach	O
and	O
duodenum	O
diseases	O
,	O
which	O
comprises	O
75	O
to	O
85	O
%	O
of	O
aluminium	B
magnesium	I
carbonate	I
powder	O
and	O
15	O
to	O
25	O
%	O
of	O
procaine	O
powder	O
.	O

The	O
combination	O
is	O
prepared	O
by	O
combining	O
the	O
aluminium	B
magnesium	I
carbonate	I
powder	O
and	O
the	O
procaine	O
powder	O
to	O
form	O
a	O
new	O
medicine	O
which	O
can	O
rapidly	O
inhibit	O
the	O
activities	O
of	O
acid	O
and	O
pepsin	O
and	O
also	O
can	O
quickly	O
release	O
the	O
pain	O
in	O
patients	O
suffering	O
from	O
stomach	O
diseases	O
;	O
and	O
the	O
combination	O
of	O
the	O
two	O
raw	O
materials	O
of	O
the	O
medicine	O
can	O
produce	O
certain	O
synergistic	O
effect	O
and	O
is	O
favorable	O
for	O
playing	O
the	O
curative	O
effect	O
of	O
the	O
medicine	O
.	O

Medicine	O
combination	O
for	O
treating	O
stomach	O
and	O
duodenum	O
diseases	O

The	O
invention	O
provides	O
a	O
hypoglycemic	O
ferment	O
compound	O
comprising	O
the	O
following	O
components	O
:	O
40	O
-	O
60	O
percent	O
of	O
protein	O
,	O
zinc	B
(	O
50	O
-	O
5000mg	O
/	O
kg	O
)	O
,	O
selenium	B
(	O
0.5	O
-	O
1000mg	O
/	O
kg	O
)	O
and	O
chromium	B
(	O
0.5	O
-	O
1000mg	O
/	O
kg	O
)	O
,	O
wherein	O
ferment	O
is	O
active	O
ferment	O
or	O
inactive	O
ferment	O
.	O

As	O
a	O
preference	O
,	O
the	O
ferment	O
compound	O
further	O
comprises	O
one	O
or	O
more	O
components	O
selected	O
from	O
the	O
following	O
components	O
:	O
balsam	O
pear	O
or	O
balsam	O
pear	O
extract	O
,	O
kudzu	O
roots	O
or	O
kudzu	O
root	O
extract	O
,	O
gingko	O
extract	O
,	O
green	O
tea	O
extract	O
,	O
ginseng	O
or	O
ginseng	O
extract	O
,	O
glossy	O
ganoderma	O
or	O
glossy	O
ganoderma	O
extract	O
,	O
glossy	O
ganoderma	O
leavening	O
,	O
glossy	O
ganoderma	O
spore	O
powder	O
,	O
sealwort	O
or	O
sealwort	O
extract	O
,	O
yam	O
or	O
yam	O
extract	O
,	O
coix	O
seed	O
or	O
coix	O
seed	O
extract	O
,	O
oats	O
,	O
tartary	O
buckwheat	O
,	O
vitamin	B
C	I
,	O
vitamin	B
E	I
,	O
pearl	O
powder	O
,	O
calcium	B
and	O
iron	B
.	O

The	O
invention	O
also	O
relates	O
to	O
apreparation	O
method	O
of	O
the	O
ferment	O
compound	O
.	O

Hypoglycemic	O
ferment	O
compound	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
for	O
treating	O
fractures	O
of	O
bones	O
and	O
reduction	O
of	O
fracture	O
.	O

The	O
invention	O
comprises	O
the	O
following	O
raw	O
materials	O
of	O
effective	O
components	O
in	O
portions	O
by	O
weight	O
:	O
3	O
-	O
9	O
portions	O
of	O
burnt	O
rhizoma	O
drynariae	O
,	O
0.2	O
-	O
9	O
portions	O
of	O
woodlouse	O
,	O
0.1	O
-	O
9	O
portions	O
of	O
saffron	O
,	O
0.1	O
-	O
2	O
portions	O
of	O
dragon	O
's	O
blood	O
,	O
3	O
-	O
30	O
portions	O
of	O
elderberry	O
,	O
0.1	O
-	O
6	O
portions	O
of	O
scorpion	O
,	O
0.1	O
-	O
9	O
portionsof	O
calcined	O
natural	O
copper	B
,	O
0.1	O
-	O
7.5	O
portions	O
of	O
frankincense	O
,	O
1	O
-	O
30	O
portions	O
of	O
teasel	O
root	O
,	O
0.1	O
-	O
20	O
portions	O
of	O
pseudo	O
-	O
ginseng	O
,	O
1	O
-	O
9	O
portions	O
of	O
silky	O
fowl	O
,	O
and	O
1	O
-	O
30	O
portions	O
of	O
rhubarb	O
.	O

The	O
invention	O
has	O
good	O
treatment	O
function	O
for	O
the	O
fractures	O
of	O
bones	O
,	O
dislocation	O
,	O
contusion	O
,	O
fracture	O
swelling	O
and	O
pain	O
and	O
blood	O
stasis	O
swelling	O
and	O
pain	O
,	O
can	O
effectively	O
relieve	O
pain	O
and	O
fast	O
promote	O
the	O
healingof	O
broken	O
bones	O
,	O
and	O
has	O
fast	O
onset	O
of	O
action	O
(	O
can	O
effectively	O
relieve	O
pain	O
within	O
30	O
minutes	O
,	O
and	O
can	O
achieve	O
clinical	O
healing	O
standard	O
for	O
continuous	O
taking	O
for	O
60	O
days	O
)	O
and	O
long	O
acesodyne	B
time	O
.	O

Preparation	O
for	O
treating	O
fractures	O
of	O
bones	O
and	O
join	O
of	O
fracture	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
purpose	O
of	O
a	O
compound	O
comprising	O
ferulic	B
acid	I
and	O
matrine	O
alkaloid	B
on	O
the	O
prevention	O
and	O
the	O
treatment	O
of	O
osteoarthropathy	O
.	O

The	O
compound	O
comprising	O
the	O
ferulic	B
acid	I
and	O
the	O
matrine	O
alkaloid	B
can	O
exist	O
in	O
a	O
compound	O
mode	O
of	O
sophora	O
and	O
angelica	O
and/or	O
hemlock	O
parsley	O
and	O
asafetida	O
extractive	O
or	O
can	O
be	O
a	O
compound	O
comprising	O
the	O
ferulic	B
acid	I
and	O
the	O
matrine	O
alkaloid	B
in	O
a	O
certain	O
proportion	O
.	O

The	O
osteoarthropathy	O
comprises	O
the	O
acute	O
inflammation	O
and	O
the	O
chronic	O
inflammation	O
of	O
articulationes	O
interphalangeae	O
manus	O
as	O
well	O
as	O
osteoarticular	O
inflammation	O
and	O
ache	O
caused	O
by	O
hyperosteogeny	O
,	O
such	O
as	O
osteoarticular	O
sprain	O
,	O
contusion	O
,	O
rheumatoid	O
arthritis	O
,	O
rheumatoid	O
arthritis	O
and	O
osteoarticular	O
ache	O
and	O
inflammation	O
caused	O
by	O
the	O
hyperosteogeny	O
,	O
and	O
the	O
like	O
.	O

Pharmaceutical	O
purpose	O
of	O
compound	O
comprising	O
ferulic	B
acid	I
and	O
matrine	O
alkaloid	B
on	O
prevention	O
and	O
treatment	O
of	O
osteoarthropathy	O

The	O
invention	O
discloses	O
a	O
medical	O
composite	O
for	O
treating	O
livestock	O
and	O
poultry	O
intestinal	O
canal	O
diseases	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
,	O
aiming	O
at	O
providing	O
a	O
medical	O
composite	O
and	O
the	O
preparation	O
method	O
and	O
the	O
application	O
thereof	O
,	O
which	O
can	O
fast	O
and	O
effectively	O
prevent	O
and	O
cure	O
intestinal	O
canal	O
diseases	O
.	O

The	O
composite	O
comprises	O
the	O
following	O
components	O
in	O
weight	O
percent	O
,	O
2%to	O
5	O
%	O
of	O
pirquinozol	B
antibiotics	O
,	O
3	O
%	O
to	O
10	O
%	O
of	O
beta	O
-	O
lactam	O
antibiotics	O
,	O
0.6	O
%	O
to	O
2	O
%	O
of	O
beta	O
-	O
lactam	O
inhibitor	O
,	O
3	O
%	O
to	O
10	O
%	O
of	O
aminoglycoside	O
antibiotics	O
and	O
the	O
balance	O
auxiliary	O
material	O
acceptable	O
in	O
pharmacy	O
.	O

The	O
pirquinozol	B
antibiotics	O
,	O
such	O
as	O
norfloxacin	B
lactate	I
,	O
is	O
broad	O
-	O
spectrum	O
antibiotics	O
;	O
the	O
beta	O
-	O
lactam	O
inhibitor	O
has	O
the	O
functions	O
of	O
inhibiting	O
enzyme	O
and	O
strengthening	O
the	O
effect	O
;	O
and	O
thebeta	O
-	O
lactam	O
antibiotics	O
can	O
destroy	O
bacterial	O
cell	O
walls	O
,	O
which	O
is	O
favorable	O
for	O
aminoglycoside	B
antibiotics	O
to	O
enter	O
cells	O
to	O
take	O
effect	O
,	O
increases	O
the	O
antibacterial	O
effect	O
and	O
simultaneously	O
enlarges	O
the	O
antibacterial	O
spectrum	O
.	O

The	O
composite	O
of	O
the	O
invention	O
can	O
effectively	O
cure	O
canal	O
diseases	O
caused	O
by	O
Gram	O
negative	O
bacteria	O
or	O
anaerobe	O
and	O
the	O
mixed	O
infection	O
of	O
the	O
Gram	O
negative	O
bacteria	O
andthe	O
anaerobe	O
.	O

Medical	O
composite	O
for	O
treating	O
livestock	O
and	O
poultry	O
intestinal	O
canal	O
diseases	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
a	O
composite	O
glycyrrhizic	B
acid	I
amino	B
acid	I
injection	O
,	O
and	O
simultaneously	O
,	O
the	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparingthe	O
injection	O
and	O
applications	O
thereof	O
in	O
medicines	O
.	O

The	O
invention	O
aims	O
at	O
providing	O
the	O
composite	O
glycyrrhizic	B
acid	I
amino	B
acid	I
injection	O
which	O
has	O
obvious	O
functions	O
of	O
anti	O
-	O
inflammation	O
,	O
antianaphylaxis	O
,	O
oxidation	O
resistance	O
,	O
antiatheroscloresis	O
,	O
immune	O
regulation	O
and	O
detoxication	O
,	O
and	O
also	O
has	O
the	O
characteristics	O
of	O
good	O
product	O
quality	O
,	O
safe	O
and	O
reliable	O
taking	O
and	O
the	O
like	O
;	O
and	O
the	O
method	O
hasthe	O
characteristics	O
of	O
simple	O
technological	O
process	O
and	O
high	O
product	O
yield	O
.	O

The	O
technical	O
scheme	O
provides	O
the	O
composite	O
glycyrrhizic	B
acid	I
amino	B
acid	I
injection	O
which	O
is	O
characterized	O
by	O
being	O
preparedby	O
following	O
crude	O
drug	O
by	O
weight	O
percent	O
:	O
0.05	O
-	O
0.4	O
%	O
of	O
composite	O
glycyrrhizic	B
acid	I
,	O
1.05	O
-	O
3.2	O
%	O
of	O
acid	B
amino	I
,	O
3	O
-	O
8	O
%	O
of	O
xylitol	B
,	O
0.01	O
-	O
0.05	O
%	O
of	O
pH	O
modifier	O
,	O
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

Composite	O
glycyrrhizic	B
acid	I
amino	B
acid	I
injection	O
,	O
and	O
preparation	O
method	O
as	O
well	O
as	O
applications	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
levofloxacin	B
salt	O
,	O
especially	O
relates	O
to	O
a	O
levofloxacin	B
acetylcysteine	I
salt	O
,	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
for	O
the	O
salts	O
and	O
a	O
medicament	O
composition	O
using	O
them	O
as	O
active	O
components	O
.	O

The	O
preparation	O
method	O
for	O
the	O
salts	O
is	O
characterized	O
by	O
mixing	O
the	O
levofloxacin	B
and	O
the	O
acetylcysteine	B
with	O
equal	O
molar	O
ratio	O
in	O
solution	O
.	O

The	O
levofloxacin	B
acetylcysteine	I
salt	O
of	O
thepresent	O
invention	O
can	O
overcome	O
optical	O
instability	O
of	O
the	O
levofloxacin	B
,	O
thereby	O
reducing	O
the	O
medicament	O
degradation	O
.	O

Levofloxacin	B
salt	O
,	O
and	O
preparation	O
method	O
thereof	O
and	O
medicament	O
composition	O

The	O
invention	O
provides	O
a	O
5-lipoxygenase	O
inhibitor	O
and	O
a	O
preparation	O
method	O
,	O
a	O
medical	O
composite	O
and	O
an	O
application	O
thereof	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
provides	O
a	O
compound	O
shown	O
in	O
general	O
formula	O
(	O
I	O
)	O
or	O
acceptable	O
salt	O
,	O
solvate	O
or	O
hydrate	B
thereof	O
in	O
pharmacy	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
,	O
medical	O
composite	O
and	O
application	O
of	O
the	O
compound	O
.	O

The	O
biological	O
activity	O
experiment	O
shows	O
that	O
the	O
compound	O
of	O
the	O
invention	O
is	O
effective	O
5-LOX	O
small	O
molecule	O
inhibitor	O
with	O
novel	O
structure	O
.	O

Therefore	O
the	O
compound	O
is	O
expected	O
to	O
be	O
developed	O
to	O
be	O
new	O
powerful	O
chemical	O
entity	O
forcuring	O
diseases	O
related	O
to	O
leukotriene	B
.	O

5-lipoxygenase	O
inhibitor	O
and	O
preparation	O
method	O
,	O
medical	O
composite	O
and	O
application	O
thereof	O

Disclosed	O
is	O
a	O
substance	O
which	O
has	O
a	O
low	O
molecular	O
weight	O
,	O
can	O
be	O
applied	O
in	O
a	O
simpler	O
manner	O
,	O
and	O
has	O
an	O
immunopotentiating	O
activity	O
against	O
cancer	O
and/or	O
a	O
microorganism	O
-	O
mediated	O
infectious	O
disease	O
.	O

An	O
EP4	O
agonist	O
exhibits	O
an	O
immunopotentiating	O
activity	O
through	O
the	O
activation	O
of	O
a	O
cytotoxic	O
T	O
cell	O
,	O
and	O
is	O
therefore	O
useful	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
cancer	O
or	O
a	O
microorganism	O
-	O
mediatedinfectious	O
disease	O
.	O

Cytotoxic	O
t	O
cell	O
activator	O
comprising	O
ep4	O
agonist	O

A	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
A	O
and	O
B	O
together	O
represent	O
an	O
optionally	O
substituted	O
,	O
fused	B
aromatic	I
ring	O
;	O
X	O
is	O
selected	O
from	O
H	B
and	O
F	B
;	O
R<1	O
>	O
and	O
R<2	O
>	O
are	O
independently	O
selected	O
from	O
H	B
and	O
methyl	B
;	O
R	O
<	O
N1	O
>	O
is	O
selected	O
from	O
H	B
and	O
optionally	O
substituted	O
C1	B
-	I
7	I
alkyl	I
;	O
R	O
<	O
N2	O
>	O
is	O
selected	O
from	O
H	B
,	O
optionally	O
substituted	O
C1	B
-	I
7	I
alkyl	I
,	O
C3	B
-	I
7	I
heterocyclyl	I
and	O
C5	B
-	I
6	I
aryl	I
;	O
or	O
R	O
<	O
N1	O
>	O
and	O
R	O
<	O
N2	O
>	O
and	O
the	O
nitrogen	B
atom	O
to	O
which	O
they	O
are	O
bound	O
form	O
an	O
optionally	O
substituted	O
nitrogen	B
containing	O
C5	B
-	I
7	I
heterocyclic	I
group	O
.	O

Phthalazinone	B
derivatives	O
and	O
their	O
use	O
as	O
medicament	O
to	O
treat	O
cancer	O

The	O
invention	O
relates	O
to	O
a	O
new	O
compound	O
of	O
mangiferin	B
,	O
which	O
has	O
a	O
structural	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
new	O
compound	O
is	O
mangiferin	B
A	I
when	O
R	O
is	O
H	B
;	O
and	O
the	O
new	O
compound	O
is	O
mangiferin	B
B	I
when	O
R	O
is	O
-OCH3	B
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
,	O
as	O
well	O
as	O
the	O
application	O
of	O
the	O
compound	O
and	O
a	O
medicine	O
composition	O
in	O
activity	O
inhibition	O
of	O
alaph	O
-	O
glucosaccharase	O
,	O
wherein	O
the	O
medicine	O
composition	O
takes	O
the	O
compound	O
as	O
an	O
active	O
component	O
,	O
which	O
can	O
further	O
show	O
the	O
application	O
value	O
in	O
the	O
preparation	O
of	O
medicine	O
for	O
treating	O
diabetes	O
.	O

Mangiferin	B
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
medicament	O
for	O
injection	O
,	O
in	O
particular	O
to	O
an	O
injection	O
medicament	O
for	O
treating	O
chronic	O
lymphoid	O
thyreoitis	O
.	O

The	O
medicament	O
is	O
prepared	O
by	O
mixing	O
methylprednisolone	B
sodium	I
succinate	I
for	O
injection	O
,	O
cyclophosphamide	B
for	O
injection	O
and	O
2	O
percent	O
lignocaine	B
injection	O
in	O
certain	O
mixing	O
ratio	O
.	O

The	O
medicament	O
is	O
injected	O
locally	O
,	O
and	O
medicinal	O
strength	O
can	O
not	O
involve	O
the	O
whole	O
body	O
,	O
which	O
is	O
favorable	O
for	O
deferring	O
and	O
protecting	O
other	O
parts	O
of	O
the	O
body	O
against	O
medicament	O
erosion	O
and	O
has	O
small	O
hormone	O
irritability	O
.	O

Injection	O
medicament	O
for	O
treating	O
chronic	O
lymphoid	O
thyreoitis	O

The	O
invention	O
relates	O
to	O
lanthanum	B
fullerenol	I
and	O
application	O
in	O
preparing	O
medicaments	O
for	O
inhibiting	O
tumor	O
growth	O
,	O
in	O
particular	O
to	O
lanthanum	B
fullerenol	I
nanoparticles	O
with	O
the	O
general	O
formula	O
of	O
M@C2m	O
(	O
OH	O
)	O
x	O
and	O
the	O
application	O
thereof	O
in	O
preparing	O
medicaments	O
for	O
inhibiting	O
tumor	O
growth	O
,	O
wherein	O
M	O
is	O
La	O
rare	O
earth	O
metal	O
,	O
m	O
is	O
equal	O
to	O
41	O
or	O
30	O
,	O
and	O
X	O
is	O
equal	O
to	O
or	O
larger	O
than	O
10	O
and	O
is	O
less	O
than	O
50	O
;	O
and	O
because	O
of	O
the	O
reorganization	O
of	O
adjacent	O
hydroxyl	B
groups	O
,	O
the	O
quantity	O
of	O
O	B
on	O
C82	O
carbon	B
cage	O
is	O
actually	O
different	O
from	O
the	O
quantity	O
of	O
H	B
,	O
and	O
therefore	O
,	O
the	O
general	O
formula	O
can	O
be	O
written	O
in	O
the	O
form	O
of	O
M@C2mOXHY	O
.	O

Compared	O
with	O
cyclophosphamide	B
,	O
cis	B
-	I
platinum	I
,	O
taxol	B
,	O
and	O
the	O
like	O
which	O
are	O
clinically	O
and	O
widely	O
used	O
,	O
the	O
lanthanum	B
fullerenol	I
M@C2m	O
(	O
OH	O
)	O
x	O
or	O
M@C2mOXHY	O
has	O
the	O
advantages	O
of	O
low	O
consumption	O
and	O
toxicity	O
and	O
high	O
rate	O
of	O
tumor	O
inhibition	O
.	O

Lanthanum	B
fullerenol	I
and	O
application	O
in	O
preparing	O
medicaments	O
for	O
inhibiting	O
tumor	O
growth	O

The	O
invention	O
discloses	O
a	O
new	O
phenylpropanoid	B
compound	O
contained	O
in	O
rhodiola	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
.	O

The	O
compound	O
has	O
a	O
novel	O
structure	O
of	O
general	O
formula	O
(	O
I	O
)	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
airing	O
and	O
crushing	O
the	O
whole	O
strain	O
of	O
rhodiola	O
,	O
ultrasonically	O
extracting	O
the	O
rhodiola	O
by	O
using	O
70	O
percent	O
acetone	B
gradually	O
after	O
crushing	O
,	O
combining	O
and	O
filtering	O
the	O
extracting	O
solutions	O
,	O
concentrating	O
the	O
extracting	O
solution	O
to	O
form	O
an	O
extract	O
,	O
then	O
primarily	O
separating	O
the	O
extract	O
by	O
using	O
silica	O
gel	O
column	O
chromatography	O
,	O
and	O
further	O
separatingthe	O
extract	O
by	O
adopting	O
efficient	O
liquid	O
semi	O
-	O
preparation	O
chromatograph	O
to	O
obtain	O
the	O
required	O
compound	O
.	O

By	O
performing	O
HIV-1	O
resistant	O
activity	O
screening	O
on	O
the	O
compound	O
,	O
the	O
experimental	O
result	O
shows	O
good	O
HIV-1	O
resistant	O
and	O
anti	O
-	O
oxidation	O
activities	O
,	O
the	O
treatment	O
index	O
of	O
the	O
HIV-1	O
is	O
55.2	O
,	O
and	O
the	O
anti	O
-	O
oxidation	O
median	O
clearance	O
concentration	O
IC50	O
is	O
9.68	O
mug	O
/	O
L.	O
Phenylpropanoid	B
compound	O
contained	O
in	O
rhodiola	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
composite	O
for	O
treating	O
cattle	O
omasum	O
obstruction	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
which	O
relate	O
to	O
a	O
medicine	O
for	O
treating	O
the	O
cattle	O
omasum	O
obstruction	O
;	O
the	O
composite	O
is	O
prepared	O
by	O
mixing	O
rhubarb	O
,	O
immature	O
bitter	O
orange	O
,	O
senna	O
leaf	O
,	O
astragalus	O
root	O
,	O
angelica	O
,	O
coptis	O
root	O
,	O
dried	O
-	O
tangerine	O
peel	O
,	O
licorice	O
,	O
hawthorn	O
,	O
edestan	O
,	O
water	O
,	O
honey	O
and	O
rape	O
oil	O
;	O
the	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
mixing	O
part	O
of	O
the	O
raw	O
materials	O
to	O
prepare	O
superfine	O
micro	O
-	O
powder	O
,	O
keeping	O
the	O
temperature	O
after	O
adding	O
hot	O
water	O
,	O
soaking	O
for	O
a	O
certain	O
time	O
and	O
then	O
stirring	O
evenlyto	O
prepare	O
the	O
composite	O
after	O
adding	O
sodium	O
sulfate	O
,	O
the	O
honey	O
and	O
the	O
rape	O
oil	O
;	O
and	O
the	O
composite	O
has	O
extensive	O
material	O
acquirement	O
,	O
low	O
cost	O
,	O
safety	O
,	O
high	O
efficiency	O
and	O
convenient	O
use	O
and	O
has	O
the	O
effects	O
of	O
removing	O
the	O
stasis	O
,	O
dissipating	O
heat	O
,	O
moisturizing	O
the	O
intestine	O
,	O
relaxing	O
bowels	O
,	O
recovering	O
and	O
enhancing	O
the	O
digestion	O
function	O
of	O
the	O
stomach	O
and	O
reinforcing	O
the	O
resistibility	O
of	O
an	O
organism	O
.	O

Composition	O
for	O
treating	O
cattle	O
omasum	O
obstruction	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
application	O
method	O
of	O
isofraxidin	B
in	O
preparing	O
a	O
medicament	O
for	O
treating	O
osteoporosis	O
.	O

The	O
medicament	O
prepared	O
from	O
the	O
isofraxidin	B
and	O
used	O
for	O
treating	O
the	O
osteoporosis	O
can	O
obviously	O
increase	O
the	O
bone	O
mineral	O
density	O
and	O
improve	O
indexes	O
of	O
osseous	O
biomechanics	O
,	O
and	O
improve	O
the	O
concentration	O
of	O
blood	O
-	O
serum	O
estradiol	B
(	O
E2	B
)	O
,	O
and	O
has	O
an	O
obvious	O
effect	O
.	O

Application	O
of	O
isofraxidin	B
in	O
preparing	O
medicament	O
for	O
treating	O
osteoporosis	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
discloses	O
a	O
medicinal	O
-	O
composition	O
suspension	O
powder	O
injection	O
taking	O
mezlocillin	B
sodium	I
and	O
sulbactam	B
sodium	I
as	O
active	O
components	O
.	O

The	O
injection	O
comprises	O
4	O
parts	O
of	O
mezlocillin	B
sodium	I
,	O
1	O
part	O
of	O
sulbactam	B
sodium	I
,	O
5	O
to	O
20	O
parts	O
of	O
Tween	O
80	O
,	O
1	O
to	O
10	O
parts	O
of	O
cholesterol	B
,	O
0.5	O
to	O
15	O
parts	O
of	O
deoxysodium	B
cholate	I
,	O
and	O
2	O
to	O
30	O
parts	O
of	O
frozen	O
-	O
dried	O
supporting	O
agent	O
.	O

The	O
invention	O
further	O
discloses	O
novel	O
application	O
of	O
the	O
injection	O
in	O
the	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
postoperative	O
infection	O
of	O
appendicitis	O
.	O

Medicinal	O
-	O
composition	O
suspension	O
powder	O
injection	O
with	O
mezlocillin	B
sodium	I
and	O
sulbactam	B
sodium	I
,	O
and	O
novel	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drug	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
walnut	O
shell	O
alcohol	B
preparation	O
and	O
applications	O
thereof	O
for	O
preparing	O
medicine	O
treating	O
wart	O
.	O

The	O
preparation	O
method	O
of	O
the	O
walnut	O
shell	O
alcohol	B
preparation	O
comprises	O
the	O
following	O
steps	O
:	O
juicing	O
walnut	O
shell	O
,	O
and	O
mixing	O
with	O
alcohol	B
,	O
or	O
mixing	O
the	O
walnut	O
shell	O
and	O
the	O
alcohol	B
directly	O
,	O
placing	O
the	O
mixture	O
for	O
15	O
-	O
60	O
days	O
at	O
dark	O
drying	O
position	O
at	O
the	O
temperature	O
of	O
10	O
-	O
35	O
DEG	O
C	O
,	O
and	O
then	O
removing	O
residues	O
to	O
form	O
the	O
preparation	O
;	O
and	O
the	O
applications	O
thereof	O
are	O
as	O
follows	O
:	O
the	O
preparation	O
can	O
be	O
taken	O
as	O
the	O
external	O
medicine	O
for	O
treating	O
wart	O
directly	O
,	O
or	O
is	O
added	O
with	O
inertia	O
molding	O
matters	O
to	O
prepare	O
external	O
paste	O
or	O
cream	O
for	O
use	O
.	O

In	O
the	O
invention	O
,	O
the	O
defects	O
that	O
the	O
existing	O
medicine	O
treating	O
wart	O
has	O
complex	O
components	O
,	O
complicated	O
preparation	O
process	O
,	O
high	O
cost	O
and	O
the	O
like	O
are	O
avoided	O
,	O
the	O
burden	O
of	O
patients	O
is	O
relieved	O
,	O
and	O
the	O
economic	O
value	O
and	O
social	O
benefits	O
are	O
obvious	O
.	O

The	O
invention	O
can	O
be	O
used	O
for	O
treating	O
common	O
wart	O
,	O
and	O
the	O
recovery	O
rate	O
is	O
more	O
than	O
90	O
%	O
;	O
and	O
the	O
verruca	O
plana	O
can	O
be	O
treated	O
,	O
the	O
recovery	O
rate	O
is	O
more	O
than	O
80	O
%	O
,	O
and	O
the	O
effective	O
rate	O
is	O
more	O
than	O
90	O
%	O
.	O

Walnut	O
shell	O
alcohol	B
preparation	O
and	O
applications	O
thereof	O
for	O
preparing	O
medicine	O
treating	O
wart	O

The	O
invention	O
discloses	O
oral	O
liquid	O
capable	O
of	O
clearing	O
heat	O
,	O
resolving	O
toxin	O
,	O
and	O
preventing	O
and	O
treating	O
cold	O
and	O
a	O
production	O
method	O
thereof	O
.	O

The	O
oral	O
liquid	O
consists	O
of	O
the	O
following	O
raw	O
materials	O
:	O
garlic	O
,	O
vitamin	B
C	I
,	O
Mongolian	O
dandelion	O
herb	O
,	O
perilla	O
leaf	O
,	O
raw	O
licorice	O
root	O
and	O
honey	O
.	O

In	O
the	O
production	O
method	O
,	O
the	O
oral	O
liquid	O
is	O
prepared	O
according	O
to	O
the	O
components	O
and	O
processes	O
.	O

Oral	O
liquid	O
capable	O
of	O
clearing	O
heat	O
,	O
resolving	O
toxin	O
,	O
and	O
preventing	O
and	O
treating	O
cold	O
and	O
production	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
pamidronate	B
disodium	I
suspension	O
injection	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
injection	O
is	O
prepared	O
by	O
the	O
following	O
components	O
in	O
part	O
by	O
weight	O
:	O
1	O
part	O
of	O
pamidronate	B
disodium	I
,	O
2	O
to	O
18	O
parts	O
of	O
surfactant	O
,	O
1	O
to	O
10	O
parts	O
of	O
deoxysodium	B
cholate	I
,	O
and	O
4	O
to	O
30	O
parts	O
of	O
freeze	O
-	O
drying	O
support	O
agent	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
pamidronate	B
disodium	I
suspension	O
injection	O
provided	O
by	O
the	O
invention	O
has	O
the	O
unexpected	O
effect	O
,	O
has	O
the	O
main	O
advantages	O
of	O
good	O
stability	O
,	O
high	O
bioavailability	O
,	O
little	O
toxic	O
and	O
side	O
effect	O
and	O
the	O
like	O
,	O
and	O
can	O
be	O
used	O
for	O
hypodermic	O
injection	O
,	O
intramuscular	O
injection	O
and	O
intravenous	O
injection	O
.	O

Pamidronate	B
disodium	I
suspension	O
injection	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
arsenical	B
sulphide	I
taking	O
realgar	B
as	O
a	O
representative	O
in	O
preparing	O
a	O
medicine	O
resisting	O
malignant	O
tumours	O
.	O

The	O
invention	O
also	O
discloses	O
an	O
application	O
of	O
the	O
arsenical	B
sulphide	I
in	O
preparing	O
a	O
medicine	O
resisting	O
bacteria	O
.	O

The	O
problems	O
of	O
long	O
treatment	O
process	O
,	O
easy	O
transfer	O
of	O
the	O
malignant	O
tumours	O
,	O
high	O
mortality	O
rate	O
and	O
the	O
like	O
exist	O
in	O
the	O
process	O
of	O
treating	O
the	O
malignant	O
tumours	O
.	O

The	O
invention	O
is	O
invented	O
for	O
solving	O
these	O
problems	O
.	O

Because	O
the	O
arsenical	B
sulphide	I
has	O
the	O
characteristic	O
of	O
enabling	O
the	O
activities	O
of	O
all	O
proteins	O
to	O
be	O
lost	O
,	O
the	O
arsenical	B
sulphide	I
has	O
a	O
fatal	O
destruction	O
function	O
to	O
DNA	O
in	O
various	O
malignant	O
tumours	O
and	O
DNA	O
in	O
various	O
bacteria	O
.	O

Thereby	O
,	O
the	O
aim	O
of	O
resisting	O
various	O
malignant	O
tumours	O
and	O
various	O
bacteria	O
is	O
achieved	O
.	O

Application	O
of	O
arsenical	B
sulphide	I
,	O
such	O
as	O
realgar	B
and	O
the	O
like	O
,	O
in	O
preparing	O
medicine	O
resisting	O
malignant	O
tumours	O
and	O
application	O
of	O
arsenical	B
sulphide	I
in	O
preparing	O
medicine	O
resisting	O
bacteria	O

The	O
invention	O
relates	O
to	O
a	O
nano	O
floxuridine	B
/	O
LDHs	O
hybrid	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
aiming	O
at	O
providing	O
a	O
method	O
,	O
wherein	O
LDHs	O
is	O
used	O
as	O
a	O
carrier	O
to	O
prepare	O
a	O
nano	O
floxuridine	B
/	O
LDHs	O
hybrid	O
used	O
for	O
the	O
slow	O
release	O
of	O
floxuridine	B
so	O
as	O
to	O
improve	O
the	O
drug	O
effect	O
and	O
reduce	O
the	O
toxic	O
and	O
side	O
effect	O
of	O
medicaments	O
.	O

The	O
invention	O
is	O
characterized	O
in	O
that	O
the	O
LDHs	O
is	O
used	O
as	O
a	O
main	O
body	O
,	O
the	O
floxuridine	B
is	O
used	O
as	O
an	O
intercalation	O
auxiliary	O
body	O
,	O
and	O
the	O
floxuridine	B
is	O
assembled	O
into	O
layers	O
of	O
the	O
LDHs	O
so	O
as	O
to	O
prepare	O
the	O
nano	O
floxuridine	B
/	O
LDHs	O
hybrid	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
hybrid	O
has	O
good	O
slow	O
release	O
effect	O
on	O
the	O
floxuridine	B
;	O
the	O
used	O
preparation	O
method	O
has	O
simple	O
process	O
and	O
moderate	O
reaction	O
;	O
and	O
the	O
control	O
to	O
the	O
structure	O
,	O
the	O
composition	O
and	O
the	O
release	O
speed	O
of	O
floxuridine	B
/	O
LDHs	O
can	O
be	O
achieved	O
through	O
adjusting	O
the	O
synthesis	O
condition	O
of	O
the	O
nano	O
floxuridine	B
/	O
LDHs	O
hybrid	O
,	O
such	O
as	O
changing	O
factors	O
of	O
concentration	O
,	O
synthesis	O
temperature	O
,	O
aging	O
time	O
,	O
and	O
the	O
like	O
of	O
the	O
medicaments	O
.	O

Nano	O
floxuridine	B
/	O
stratiform	O
thermometal	O
hydroxide	O
hybrid	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
application	O
of	O
3'8''-bis	B
-	I
apigenin	I
type	O
bis	B
-	I
flavonoid	I
.	O

The	O
preparation	O
method	O
of	O
the	O
compound	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
hot	O
refluxing	O
and	O
extracting	O
coarse	O
powders	O
of	O
Taxus	O
cuspidatea	O
twigs	O
and	O
leaves	O
by	O
using	O
ethanol	B
to	O
obtain	O
total	O
extract	O
;	O
and	O
performing	O
reversed	O
phase	O
and	O
normal	O
phase	O
column	O
chromatography	O
,	O
gel	O
and	O
recrystallization	O
and	O
separation	O
on	O
the	O
total	O
extract	O
to	O
obtain	O
the	O
3'8''-bis	B
-	I
apigenin	I
type	O
bis	B
-	I
flavonoid	I
.	O

The	O
3'8''-bis	B
-	I
apigenin	I
type	O
bis	B
-	I
flavonoid	I
is	O
used	O
for	O
preparing	O
medicaments	O
for	O
inhibiting	O
formation	O
of	O
senile	O
plaques	O
or	O
treating	O
an	O
Alzheimer	O
disease	O
,	O
can	O
effectively	O
reduce	O
the	O
generation	O
of	O
Beta	O
amyloid	O
,	O
also	O
depolymerizes	O
the	O
aggregated	O
Beta	O
amyloid	O
,	O
has	O
no	O
toxic	O
effect	O
on	O
cells	O
,	O
and	O
also	O
can	O
stimulate	O
growth	O
of	O
cells	O
at	O
a	O
high	O
concentration	O
;	O
and	O
the	O
preparation	O
method	O
has	O
simple	O
process	O
and	O
high	O
yield	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
3'8''-bis	B
-	I
apigenin	I
type	O
bis	B
-	I
flavonoid	I

The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
dandelion	O
extract	O
in	O
preparing	O
a	O
medical	O
composition	O
for	O
preventing	O
and	O
treating	O
asthenopia	O
syndrome	O
,	O
the	O
medical	O
composition	O
containing	O
dandelion	O
extract	O
and	O
a	O
method	O
for	O
preparing	O
the	O
containing	O
dandelion	O
extract	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
variety	O
of	O
ophthalmic	O
medical	O
preparations	O
containing	O
dandelion	O
extract	O
for	O
preventing	O
and	O
treating	O
asthenopia	O
syndrome	O
.	O

Medical	O
composition	O
containing	O
dandelion	O
extract	O
as	O
well	O
as	O
novel	O
application	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
Granisetron	B
and/or	O
a	O
hydrochloride	B
patch	O
thereof	O
,	O
which	O
comprises	O
a	O
lining	O
layer	O
,	O
a	O
medicine	O
carrying	O
pressure	O
sensitive	O
adhesive	O
layer	O
containing	O
the	O
Granisetron	B
or	O
/	O
and	O
the	O
hydrochloride	B
thereof	O
,	O
and	O
an	O
anti	O
-	O
sticking	O
layer	O
,	O
wherein	O
the	O
medicine	O
carrying	O
pressure	O
sensitive	O
adhesive	O
layer	O
is	O
characterized	O
in	O
that	O
pressure	O
sensitive	O
adhesive	O
contains	O
carboxylic	B
groups	O
;	O
the	O
content	O
of	O
the	O
Granisetron	B
or	O
/	O
and	O
the	O
hydrochloride	B
thereof	O
in	O
percentage	O
by	O
weight	O
is	O
1%-12	O
%	O
;	O
the	O
medicine	O
carrying	O
pressure	O
sensitive	O
adhesive	O
layer	O
contains	O
metal	O
ions	O
capable	O
of	O
enabling	O
the	O
pressure	O
sensitive	O
adhesive	O
to	O
generate	O
cross	O
linking	O
,	O
and	O
the	O
content	O
of	O
the	O
metal	O
ions	O
in	O
the	O
medicine	O
carrying	O
pressure	O
sensitive	O
adhesive	O
layer	O
in	O
percentage	O
by	O
weight	O
is	O
0.05%-2	O
%	O
;	O
and	O
the	O
medicine	O
carrying	O
pressure	O
sensitive	O
adhesive	O
layer	O
contains	O
organic	O
acids	O
with	O
2	O
-	O
18	O
carbon	B
atoms	O
,	O
and	O
the	O
molar	O
ratio	O
of	O
the	O
adding	O
amount	O
of	O
the	O
organic	O
acids	O
to	O
the	O
adding	O
amount	O
of	O
the	O
Granisetron	B
or	O
/	O
and	O
the	O
hydrochloride	B
thereof	O
is	O
(	O
1	O
-	O
5	O
)	O
:1	O
.	O

The	O
patch	O
of	O
the	O
invention	O
can	O
obviously	O
increase	O
the	O
percutaneous	O
infiltration	O
capacity	O
of	O
the	O
Granisetron	B
and	O
improve	O
the	O
solvent	O
resistant	O
and	O
ageing	O
resistant	O
action	O
of	O
the	O
substrate	O
,	O
can	O
be	O
applied	O
to	O
preventing	O
and	O
treating	O
the	O
symptoms	O
of	O
nausea	O
,	O
emesis	O
and	O
the	O
like	O
caused	O
by	O
radiotherapy	O
,	O
chemotherapy	O
and	O
operations	O
,	O
and	O
has	O
great	O
foreseeable	O
economic	O
value	O
and	O
social	O
value	O
.	O

Granisetron	B
and/or	O
hydrochloride	B
patch	O
thereof	O

The	O
invention	O
provides	O
a	O
composition	O
for	O
losing	O
weight	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
composition	O
comprises	O
fucoxanthin	B
as	O
an	O
active	O
ingredient	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
losing	O
weight	O
,	O
which	O
comprises	O
the	O
step	O
that	O
:	O
a	O
person	O
needing	O
to	O
lose	O
weight	O
takes	O
the	O
fucoxanthin	B
.	O

The	O
person	O
does	O
not	O
need	O
to	O
change	O
lifestyle	O
,	O
or	O
be	O
on	O
a	O
diet	O
or	O
do	O
additional	O
sports	O
by	O
taking	O
the	O
fucoxanthin	B
so	O
as	O
to	O
achieve	O
the	O
effect	O
of	O
losing	O
weight	O
.	O

Application	O
of	O
fucoxanthin	B
in	O
aspect	O
of	O
losing	O
weight	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
diacetylbaicalein	B
in	O
the	O
preparation	O
of	O
drugs	O
used	O
for	O
curing	O
or	O
preventing	O
liver	O
diseases	O
,	O
which	O
provides	O
more	O
drug	O
selections	O
for	O
curing	O
liver	O
diseases	O
in	O
clinic	O
.	O

The	O
invention	O
realizes	O
the	O
application	O
of	O
diacetylbaicalein	B
in	O
the	O
preparation	O
of	O
drugs	O
used	O
for	O
curing	O
or	O
preventing	O
liver	O
diseases	O
,	O
has	O
better	O
curative	O
and	O
protective	O
functions	O
for	O
various	O
acute	O
and	O
chronic	O
liver	O
injuries	O
and	O
can	O
inhibit	O
and	O
improve	O
liver	O
fibrosis	O
;	O
and	O
diacetylbaicalein	B
has	O
more	O
significant	O
effect	O
for	O
curing	O
and	O
preventing	O
liver	O
diseases	O
than	O
baicalin	B
.	O

Application	O
of	O
diacetylbaicalein	B
in	O
preparation	O
of	O
drugs	O
used	O
for	O
curing	O
or	O
preventing	O
liver	O
diseases	O

The	O
invention	O
discloses	O
a	O
bicarbonate	O
physiological	O
balanced	O
solution	O
which	O
belongs	O
to	O
the	O
field	O
of	O
infusion	O
preparations	O
and	O
is	O
prepared	O
form	O
the	O
following	O
raw	O
materials	O
:	O
sodium	O
chloride	O
,	O
potassium	O
chloride	O
,	O
calcium	O
chloride	O
,	O
magnesium	O
sulfate	O
,	O
sodium	O
bicarbonate	O
,	O
glucose	O
,	O
citric	O
acid	O
and	O
trisodium	O
citrate	O
.	O

All	O
the	O
raw	O
materials	O
are	O
accurately	O
weighed	O
according	O
to	O
corresponding	O
portions	O
,	O
and	O
dissolved	O
in	O
water	O
for	O
injection	O
;	O
the	O
volume	O
is	O
determined	O
;	O
medical	O
standard	O
CO2	O
gas	O
is	O
introduced	O
;	O
the	O
pH	O
value	O
is	O
adjusted	O
;	O
and	O
the	O
solution	O
is	O
filtered	O
,	O
filled	O
,	O
packed	O
,	O
sterilized	O
,	O
labeled	O
and	O
then	O
stored	O
at	O
room	O
temperature	O
.	O

The	O
solution	O
has	O
the	O
advantages	O
that	O
ion	O
components	O
and	O
a	O
penetration	O
concentration	O
are	O
similar	O
to	O
those	O
of	O
extracellular	O
fluid	O
and	O
have	O
physiological	O
performance	O
.	O

The	O
balanced	O
solution	O
is	O
suitable	O
for	O
supplementing	O
the	O
extracellular	O
fluid	O
by	O
injection	O
,	O
intravenous	O
drip	O
or	O
oral	O
administration	O
,	O
has	O
an	O
adjustment	O
function	O
for	O
acid	O
-	O
base	O
balance	O
,	O
and	O
is	O
also	O
used	O
as	O
a	O
surgical	O
washing	O
fluid	O
or	O
buffering	O
solution	O
.	O

Bicarbonate	O
physiological	O
balanced	O
solution	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
ganoderma	O
lucidum	O
spore	O
and	O
nano	O
selenium	B
compound	O
which	O
is	O
prepared	O
by	O
mixing	O
,	O
reducing	O
and	O
vacuum	O
drying	O
sporoderm	O
-	O
broken	O
ganoderma	O
lucidum	O
spore	O
and	O
a	O
selenium	B
dioxide	I
aqueous	O
solution	O
under	O
the	O
action	O
of	O
reductant	O
ascorbic	B
acid	I
and	O
additive	O
biogel	O
or	O
biological	O
oligosaccharide	B
.	O

In	O
the	O
compound	O
,	O
the	O
content	O
of	O
the	O
sporoderm	O
-	O
broken	O
ganoderma	O
lucidum	O
spore	O
is	O
0.8	O
-	O
95g	O
/	O
g	O
,	O
and	O
the	O
content	O
of	O
nano	O
selenium	B
is	O
10	O
-	O
100	O
micrograms	O
/	O
g	O
.	O

The	O
compound	O
combines	O
the	O
effects	O
of	O
preventing	O
and	O
resisting	O
cancer	O
,	O
preventing	O
and	O
treating	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
improving	O
the	O
immunological	O
competence	O
of	O
the	O
human	O
body	O
,	O
and	O
the	O
like	O
of	O
the	O
ganoderma	O
lucidum	O
spore	O
and	O
the	O
nano	O
selenium	B
and	O
enhances	O
the	O
biological	O
effect	O
of	O
the	O
two	O
components	O
through	O
a	O
function	O
synergistic	O
effect	O
.	O

The	O
compound	O
is	O
particularly	O
suitable	O
for	O
the	O
fields	O
of	O
health	O
care	O
,	O
food	O
,	O
medicine	O
,	O
and	O
the	O
like	O
.	O

Ganoderma	O
lucidum	O
spore	O
and	O
nano	O
selenium	B
compound	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
4-carbonayl	B
diaryl	I
pyridine	I
derivatives	O
(	O
CO	O
-	O
DAPYs	O
)	O
shown	O
as	O
a	O
general	O
formula	O
I	O
as	O
well	O
as	O
preparation	O
methods	O
and	O
applications	O
thereof	O
.	O

The	O
compounds	O
of	O
the	O
4-carbonyl	B
diaryl	I
pyridine	I
derivatives	O
also	O
comprise	O
medicinal	O
salts	O
,	O
stereochemical	O
isomers	O
,	O
hydrates	B
,	O
solvates	O
,	O
polycrystals	O
and	O
eutectics	O
,	O
precursors	O
with	O
same	O
biological	O
functions	O
and	O
derivatives	O
thereof	O
.	O

A	O
pharmacological	O
test	O
result	O
shows	O
that	O
the	O
compounds	O
have	O
remarkable	O
anti	O
-	O
HIV-1	O
virus	O
activity	O
and	O
show	O
better	O
inhibiting	O
effect	O
to	O
common	O
mutated	O
virus	O
strains	O
in	O
clinic	O
,	O
therefore	O
,	O
the	O
compositions	O
containing	O
one	O
or	O
a	O
plurality	O
of	O
compounds	O
can	O
be	O
used	O
for	O
preparing	O
related	O
medicines	O
for	O
treating	O
Aids	O
,	O
and	O
the	O
like	O
.	O

4-carbonyl	B
diaryl	I
pyridine	I
derivatives	O
as	O
well	O
as	O
preparation	O
methods	O
and	O
applications	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
biotechnology	O
and	O
medicine	O
,	O
and	O
discloses	O
a	O
new	O
human	O
epididymis	O
specific	O
expression	O
sperm	O
binding	O
protein	O
HEL-6	O
as	O
well	O
as	O
preparation	O
and	O
application	O
thereof	O
.	O

The	O
invention	O
discloses	O
an	O
amino	B
acid	I
sequence	O
of	O
the	O
HEL-6	O
protein	O
and	O
provides	O
a	O
recombination	O
expression	O
carrier	O
carrying	O
the	O
DNA	O
sequence	O
for	O
encoding	O
the	O
protein	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
protein	O
and	O
a	O
method	O
for	O
detecting	O
the	O
biological	O
function	O
of	O
the	O
HEL-6	O
protein	O
.	O

The	O
protein	O
is	O
highly	O
expressed	O
in	O
the	O
head	O
and	O
tail	O
parts	O
of	O
the	O
epididymis	O
,	O
is	O
combined	O
at	O
the	O
head	O
and	O
tail	O
parts	O
of	O
the	O
sperm	O
head	O
and	O
has	O
important	O
function	O
for	O
sperm	O
-	O
egg	O
identification	O
,	O
fertilization	O
and	O
movement	O
.	O

The	O
HEL-6	O
protein	O
can	O
be	O
used	O
as	O
a	O
target	O
protein	O
for	O
researching	O
and	O
developing	O
immunity	O
contraceptive	O
as	O
well	O
as	O
clinical	O
diagnosis	O
and	O
treatment	O
for	O
male	O
sterility	O
.	O

A	O
method	O
for	O
detecting	O
a	O
corresponding	O
gene	O
or	O
protein	O
based	O
on	O
development	O
of	O
the	O
HEL-6	O
protein	O
can	O
be	O
widely	O
used	O
for	O
the	O
research	O
field	O
of	O
reproductive	O
medicine	O
.	O

Human	O
epididymis	O
expression	O
sperm	O
binding	O
protein	O
HEL-6	O
,	O
encoding	O
gene	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
biotechnology	O
and	O
the	O
medical	O
field	O
and	O
discloses	O
a	O
new	O
human	O
epididymal	O
specific	O
expression	O
sperm	O
binding	O
protein	O
HEL-200	O
as	O
well	O
as	O
preparation	O
and	O
application	O
thereof	O
.	O

The	O
invention	O
discloses	O
an	O
amino	B
acid	I
sequence	O
of	O
the	O
HEL-200	O
protein	O
and	O
provides	O
a	O
recombinant	O
expression	O
vector	O
which	O
carries	O
a	O
DNA	O
sequence	O
used	O
for	O
encoding	O
the	O
protein	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
protein	O
and	O
a	O
method	O
for	O
detecting	O
the	O
biological	O
functions	O
of	O
the	O
HEL-200	O
protein	O
.	O

The	O
protein	O
is	O
located	O
at	O
the	O
back	O
part	O
of	O
the	O
head	O
of	O
a	O
sperm	O
and	O
the	O
tail	O
middle	O
section	O
of	O
the	O
sperm	O
and	O
has	O
low	O
abundance	O
expression	O
in	O
an	O
epididymis	O
,	O
a	O
testis	O
and	O
a	O
liver	O
,	O
and	O
a	O
band	O
of	O
about	O
35	O
KD	O
is	O
detected	O
in	O
the	O
epididymis	O
by	O
using	O
western	O
blot	O
.	O

The	O
HEL-200	O
protein	O
can	O
be	O
used	O
as	O
a	O
target	O
protein	O
or	O
developing	O
an	O
immunological	O
contraceptive	O
and	O
clinically	O
diagnosing	O
and	O
treating	O
male	O
infertility	O
.	O

A	O
method	O
for	O
detecting	O
a	O
corresponding	O
gene	O
or	O
protein	O
based	O
on	O
development	O
of	O
the	O
HEL-200	O
protein	O
can	O
be	O
widely	O
used	O
for	O
the	O
research	O
field	O
of	O
reproductive	O
medicine	O
.	O

Human	O
epididymal	O
expression	O
sperm	O
binding	O
protein	O
HEL-200	O
as	O
well	O
as	O
encoding	O
gene	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
application	O
of	O
chlorogenic	B
acid	I
in	O
preparing	O
medicines	O
for	O
preventing	O
and	O
curing	O
senile	O
dementia	O
.	O

The	O
chlorogenic	B
acid	I
in	O
the	O
invention	O
can	O
be	O
prepared	O
into	O
various	O
forms	O
of	O
composites	O
,	O
such	O
as	O
oral	O
preparations	O
,	O
injection	O
preparations	O
,	O
lung	O
inhalation	O
preparations	O
and	O
transdermal	O
preparations	O
,	O
specifically	O
injections	O
,	O
oral	O
solutions	O
,	O
tablets	O
,	O
capsules	O
,	O
granules	O
,	O
aerosols	O
,	O
powders	O
,	O
sprays	O
and	O
patches	O
.	O

Application	O
of	O
chlorogenic	B
acid	I
in	O
preparing	O
medicines	O
for	O
preventing	O
and	O
curing	O
senile	O
dementia	O

The	O
invention	O
discloses	O
application	O
of	O
iridoid	B
compounds	O
in	O
preparing	O
a	O
medicament	O
for	O
treating	O
benign	O
prostatic	O
hyperplasia	O
.	O

The	O
compounds	O
are	O
from	O
valerianaceae	O
plants	O
.	O

The	O
valerianaceae	O
plants	O
have	O
long	O
medicinal	O
history	O
and	O
good	O
safety	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
show	O
more	O
definite	O
medicinal	O
effect	O
substances	O
compared	O
with	O
the	O
conventional	O
valeriana	O
root	O
plant	O
extract	O
,	O
and	O
provide	O
possibility	O
for	O
preparing	O
a	O
new	O
medicament	O
which	O
resists	O
benign	O
prostatic	O
hyperplasia	O
and	O
has	O
good	O
market	O
prospect	O
.	O

Application	O
of	O
iridoid	B
compounds	O
in	O
preparing	O
medicament	O
for	O
treating	O
benign	O
prostatic	O
hyperplasia	O

The	O
invention	O
discloses	O
slush	O
ice	O
prepared	O
from	O
various	O
plants	O
and	O
used	O
for	O
blackening	O
and	O
nourishing	O
hair	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
slush	O
ice	O
is	O
prepared	O
by	O
mixing	O
and	O
processing	O
fleece	O
-	O
flower	O
root	O
,	O
nutgall	O
,	O
mulberry	O
fruit	O
,	O
radix	O
rehmanniae	O
,	O
herba	O
ecliptae	O
and	O
ebony	O
.	O

In	O
the	O
medicine	O
,	O
the	O
fleece	O
-	O
flower	O
root	O
,	O
the	O
nutgall	O
,	O
the	O
mulberry	O
fruit	O
,	O
the	O
radix	O
rehmanniae	O
,	O
the	O
herba	O
ecliptae	O
and	O
the	O
ebony	O
are	O
selected	O
and	O
combined	O
,	O
because	O
of	O
the	O
combination	O
of	O
above	O
medicines	O
,	O
the	O
effect	O
of	O
each	O
medicine	O
generates	O
a	O
synergistic	O
action	O
,	O
thereby	O
tonifying	O
the	O
liver	O
and	O
the	O
kidney	O
,	O
benefiting	O
the	O
essence	O
and	O
the	O
blood	O
,	O
darkening	O
the	O
beard	O
and	O
the	O
hair	O
and	O
strengthening	O
the	O
bones	O
and	O
the	O
muscles	O
effectively	O
;	O
the	O
substances	O
are	O
mixed	O
to	O
generate	O
the	O
synergistic	O
action	O
,	O
thereby	O
tonifying	O
the	O
liver	O
and	O
the	O
kidney	O
,	O
benefiting	O
the	O
essence	O
and	O
the	O
blood	O
,	O
darkening	O
the	O
beard	O
and	O
the	O
hair	O
and	O
strengthening	O
the	O
bones	O
and	O
the	O
muscles	O
effectively	O
;	O
and	O
radix	O
polygoni	O
multiflori	O
preparata	O
in	O
the	O
invention	O
is	O
used	O
for	O
tonifying	O
the	O
liver	O
and	O
the	O
kidney	O
,	O
benefiting	O
the	O
essence	O
and	O
the	O
blood	O
,	O
darkening	O
the	O
beard	O
and	O
the	O
hair	O
and	O
strengthening	O
the	O
bones	O
and	O
the	O
muscles	O
.	O

The	O
product	O
is	O
applied	O
to	O
the	O
hair	O
in	O
a	O
way	O
similar	O
to	O
hair	O
putty	O
,	O
can	O
dye	O
the	O
hair	O
by	O
plants	O
and	O
can	O
also	O
regenerate	O
black	O
hair	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
invention	O
has	O
convenient	O
use	O
and	O
little	O
side	O
effect	O
,	O
treats	O
both	O
the	O
principal	O
and	O
secondary	O
aspects	O
of	O
a	O
disease	O
,	O
is	O
easily	O
accepted	O
by	O
a	O
patient	O
,	O
can	O
dye	O
hair	O
by	O
plants	O
and	O
can	O
also	O
regenerate	O
black	O
hair	O
.	O

Slush	O
ice	O
prepared	O
from	O
various	O
plants	O
and	O
used	O
for	O
blackening	O
and	O
nourishing	O
hair	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
health	O
-	O
care	O
weight	O
losing	O
wine	O
which	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
pine	O
leaf	O
,	O
0.5	O
-	O
3	O
parts	O
of	O
bamboo	O
leaf	O
,	O
0.5	O
-	O
3	O
parts	O
of	O
mugwort	O
,	O
0.2	O
-	O
1	O
part	O
of	O
kuh	O
-	O
seng	O
,	O
0.2	O
-	O
1	O
part	O
of	O
gypsum	O
,	O
0.2	O
-	O
0.6	O
part	O
of	O
radix	O
euphorbiae	O
lantu	O
and	O
5	O
-	O
20	O
parts	O
of	O
white	O
spirit	O
.	O

The	O
health	O
-	O
care	O
weight	O
losing	O
wine	O
can	O
accelerate	O
the	O
mobilization	O
and	O
the	O
decomposition	O
of	O
fat	O
and	O
slow	O
down	O
the	O
synthesis	O
rate	O
of	O
the	O
fat	O
,	O
has	O
good	O
weight	O
losing	O
effect	O
,	O
no	O
rebounce	O
,	O
no	O
side	O
effect	O
and	O
no	O
influence	O
on	O
body	O
health	O
and	O
can	O
prolong	O
the	O
life	O
.	O

Health	O
-	O
care	O
weight	O
losing	O
wine	O

The	O
invention	O
discloses	O
a	O
whelk	O
applying	O
liquid	O
which	O
is	O
prepared	O
by	O
uniformly	O
mixing	O
the	O
following	O
raw	O
materials	O
by	O
volume	O
percent	O
:	O
45	O
-	O
65	O
%	O
of	O
vinegar	O
made	O
of	O
rice	O
,	O
25	O
-	O
55	O
%	O
of	O
alcohol	B
and	O
5	O
-	O
15	O
%	O
of	O
skin	O
wetting	O
agent	O
,	O
wherein	O
0.1	O
-	O
2	O
%	O
of	O
vitamin	B
C	I
is	O
added	O
into	O
the	O
total	O
weight	O
of	O
the	O
physical	O
liquor	O
.	O

The	O
skin	O
wetting	O
agent	O
is	O
one	O
or	O
two	O
types	O
selected	O
from	O
propylene	B
glycol	I
,	O
glycerol	B
,	O
and	O
liquid	O
paraffin	O
,	O
or	O
a	O
mixture	O
of	O
more	O
than	O
two	O
types	O
.	O

In	O
the	O
invention	O
,	O
the	O
vinegar	O
made	O
of	O
rice	O
and	O
the	O
alcohol	B
are	O
utilized	O
to	O
quicken	O
the	O
blood	O
and	O
move	O
qi	O
,	O
disperse	O
blood	O
stasis	O
and	O
dredge	O
collateral	O
,	O
disinfect	O
and	O
sterilize	O
,	O
vitamin	B
C	I
is	O
utilized	O
to	O
sustain	O
metabolism	O
of	O
human	O
body	O
,	O
and	O
the	O
skin	O
wetting	O
agent	O
is	O
added	O
to	O
moisten	O
the	O
skin	O
.	O

Through	O
the	O
experiment	O
of	O
treating	O
500	O
patients	O
,	O
the	O
curing	O
rate	O
reaches	O
100	O
%	O
.	O

The	O
invention	O
has	O
no	O
toxic	O
or	O
side	O
function	O
,	O
can	O
be	O
applied	O
once	O
every	O
day	O
for	O
a	O
long	O
time	O
,	O
and	O
has	O
good	O
protection	O
and	O
nourishing	O
effect	O
on	O
skins	O
.	O

Whelk	O
applying	O
liquid	O

The	O
invention	O
provides	O
compound	O
of	O
brain	O
protein	O
hydrolyzate	O
and	O
maleic	B
acid	I
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
and	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
dispersible	O
tablets	O
of	O
the	O
medicinal	O
compound	O
of	O
brain	O
protein	O
hydrolyzate	O
and	O
maleic	B
acid	I
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
the	O
medicament	O
.	O

The	O
medicinal	O
compound	O
of	O
brain	O
protein	O
hydrolyzate	O
and	O
maleic	B
acid	I
is	O
the	O
peptidergic	O
neural	O
nutritional	O
medicament	O
specially	O
used	O
for	O
the	O
brain	O
and	O
can	O
act	O
on	O
the	O
central	O
nervous	O
system	O
in	O
various	O
ways	O
to	O
adjust	O
and	O
improve	O
the	O
neuronal	O
differentiation	O
.	O

The	O
medicinal	O
compound	O
of	O
brain	O
protein	O
hydrolyzate	O
and	O
maleic	B
acid	I
can	O
promote	O
the	O
synthesis	O
of	O
the	O
brain	O
protein	O
through	O
a	O
blood	O
-	O
brain	O
barrier	O
,	O
has	O
the	O
efficacy	O
of	O
preventing	O
hypoxia	O
,	O
improving	O
the	O
brain	O
energy	O
metabolism	O
and	O
providing	O
neurotransmitter	O
,	O
peptide	O
hormones	O
and	O
coenzyme	O
precursors	O
and	O
can	O
be	O
used	O
for	O
preparing	O
the	O
medicament	O
for	O
improving	O
insomnia	O
,	O
headache	O
,	O
memory	O
loss	O
,	O
irritability	O
and	O
other	O
symptoms	O
,	O
promoting	O
the	O
rehabilitation	O
of	O
acute	O
cerebral	O
infarction	O
and	O
acute	O
brain	O
injury	O
and	O
treating	O
brain	O
dysfunction	O
.	O

Compound	O
of	O
brain	O
protein	O
hydrolyzate	O
and	O
maleic	B
acid	I
and	O
method	O
for	O
preparing	O
same	O

The	O
invention	O
relates	O
to	O
two	O
methods	O
for	O
preparing	O
sterile	O
powder	O
of	O
cefoselis	O
sulfate	O
.	O

The	O
method	O
in	O
one	O
embodiment	O
comprises	O
the	O
following	O
steps	O
:	O
dissolving	O
the	O
raw	O
material	O
of	O
cefoselis	O
sulfate	O
with	O
an	O
appropriate	O
amount	O
of	O
dimethyl	O
sulfoxide	O
in	O
a	O
sterile	O
room	O
,	O
eliminating	O
the	O
heat	O
source	O
,	O
adding	O
an	O
appropriate	O
amount	O
of	O
poor	O
solvent	O
,	O
performing	O
recrystallization	O
and	O
obtaining	O
sterile	O
powder	O
of	O
cefoselis	O
sulfate	O
.	O

The	O
method	O
in	O
another	O
embodiment	O
comprises	O
the	O
following	O
steps	O
:	O
adding	O
the	O
raw	O
material	O
of	O
cefoselis	O
sulfate	O
into	O
an	O
appropriate	O
amount	O
of	O
water	O
in	O
a	O
sterile	O
room	O
,	O
adding	O
alkalinereagent	O
,	O
eliminating	O
the	O
heat	O
source	O
after	O
the	O
solid	O
is	O
dissolved	O
,	O
adding	O
sulfuric	O
acid	O
,	O
performing	O
recrystallization	O
and	O
obtaining	O
sterile	O
powder	O
of	O
cefoselis	O
sulfate	O
.	O

The	O
methods	O
for	O
preparing	O
sterile	O
powder	O
of	O
cefoselis	O
sulfate	O
have	O
the	O
advantages	O
that	O
the	O
recrystallization	O
is	O
easy	O
,	O
the	O
time	O
for	O
recrystallization	O
is	O
short	O
,	O
and	O
purification	O
can	O
be	O
performed	O
to	O
unqualified	O
sterile	O
powder	O
of	O
cefoselis	O
sulfate	O
again	O
,	O
so	O
as	O
to	O
reduce	O
the	O
loss	O
.	O

Methods	O
for	O
preparing	O
sterile	O
powder	O
of	O
cefoselis	O
sulfate	O

The	O
invention	O
takes	O
hypericum	O
perforatum	O
P.E	O
recently	O
sold	O
on	O
the	O
market	O
as	O
raw	O
material	O
,	O
and	O
uses	O
a	O
self	O
-	O
created	O
molecular	O
trapping	O
technology	O
to	O
extract	O
high	O
-	O
content	O
hypericin	B
with	O
30	O
percent	O
to	O
100	O
percent	O
of	O
activity	O
detectable	O
component	O
.	O

The	O
new	O
natural	O
hypericin	B
drug	O
with	O
the	O
30	O
percent	O
to	O
100	O
percent	O
of	O
hypericum	O
has	O
antiviral	O
effect	O
,	O
the	O
hypericin	B
has	O
a	O
killing	O
function	O
on	O
the	O
broad	O
-	O
spectrum	O
virus	O
,	O
and	O
the	O
photosensitive	O
side	O
effect	O
of	O
the	O
hypericum	O
is	O
removed	O
.	O

The	O
content	O
of	O
the	O
hypericum	O
is	O
detected	O
by	O
HPLC	O
to	O
reach	O
30	O
percent	O
to	O
100	O
percent	O
.	O

The	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
simple	O
and	O
quick	O
,	O
the	O
product	O
quality	O
is	O
even	O
and	O
stable	O
,	O
the	O
large	O
-	O
scaled	O
production	O
is	O
easy	O
to	O
realize	O
,	O
and	O
the	O
industrial	O
production	O
is	O
met	O
.	O

New	O
natural	O
hypericin	B
antiviral	O
drug	O

The	O
invention	O
provides	O
an	O
application	O
of	O
notoginseng	O
saponins	B
Rg	O
1	O
in	O
preparing	O
medicine	O
for	O
treating	O
pulmonary	O
interstitial	O
fibrosis	O
.	O

Pharmacological	O
experiments	O
show	O
that	O
if	O
in	O
vitro	O
,	O
the	O
notoginseng	O
saponins	B
Rg	O
1	O
can	O
inhibit	O
the	O
activity	O
of	O
human	O
embryonic	O
lung	O
fibroblast	O
and	O
has	O
good	O
dose	O
-	O
dependent	O
;	O
if	O
in	O
vivo	O
,	O
the	O
notoginseng	O
saponins	B
Rg	O
1	O
can	O
decrease	O
the	O
lung	O
coefficientand	O
the	O
lung	O
hydroxyproline	B
content	O
of	O
a	O
mouse	O
with	O
pulmonary	O
interstitial	O
fibrosis	O
;	O
the	O
notoginseng	O
saponins	B
Rg	O
1	O
can	O
also	O
reduce	O
the	O
pulmonary	O
alveolitis	O
and	O
the	O
degree	O
of	O
pulmonary	O
interstitial	O
fibrosis	O
of	O
the	O
mouse	O
with	O
pulmonary	O
interstitial	O
fibrosis	O
;	O
the	O
raw	O
materials	O
of	O
the	O
notoginseng	O
saponins	B
Rg	O
1	O
are	O
easy	O
to	O
obtain	O
,	O
and	O
can	O
be	O
prepared	O
into	O
various	O
common	O
dosage	O
forms	O
such	O
as	O
tablets	O
,	O
capsules	O
,	O
and	O
injections	O
;	O
and	O
the	O
preparation	O
method	O
is	O
simple	O
.	O

Application	O
of	O
notoginseng	O
saponins	B
Rg	O
1	O
in	O
preparing	O
medicine	O
for	O
treating	O
pulmonary	O
interstitial	O
fibrosis	O

The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
osteoproliferation	O
,	O
in	O
particular	O
to	O
a	O
plaster	O
for	O
treating	O
diseases	O
of	O
osteoproliferation	O
,	O
cervical	O
spondylosis	O
,	O
lumbar	O
disc	O
herniation	O
and	O
the	O
like	O
.	O

The	O
plaster	O
is	O
developed	O
for	O
solving	O
the	O
problems	O
of	O
poor	O
treatment	O
effect	O
and	O
long	O
treatment	O
course	O
of	O
the	O
traditional	O
plaster	O
for	O
treating	O
the	O
osteoproliferation	O
.	O

The	O
plaster	O
is	O
prepared	O
from	O
red	O
flower	O
,	O
scoprio	O
,	O
frankincense	O
,	O
myrrh	O
,	O
vermilion	O
,	O
kukan	O
and	O
red	O
lead	B
.	O

The	O
invention	O
has	O
good	O
treatment	O
effect	O
on	O
the	O
osteoproliferation	O
,	O
the	O
cervical	O
spondylosis	O
,	O
the	O
lumbar	O
disc	O
herniation	O
,	O
scapulohumeral	O
periarthritis	O
,	O
strain	O
of	O
lumbar	O
muscles	O
,	O
joint	O
pain	O
/	O
swelling	O
and	O
the	O
like	O
,	O
has	O
short	O
treatment	O
course	O
,	O
can	O
cure	O
acute	O
disease	O
healing	O
by	O
one	O
plaster	O
and	O
cure	O
chronic	O
disease	O
healing	O
by	O
3	O
-	O
4	O
plasters	O
.	O

Plaster	O
for	O
treating	O
osteoproliferation	O

The	O
invention	O
discloses	O
a	O
medicine	O
composition	O
for	O
treating	O
idiopathic	O
thrombocytopenic	O
purpura	O
,	O
which	O
is	O
prepared	O
from	O
the	O
raw	O
materials	O
of	O
10	O
-	O
50	O
parts	O
of	O
dehydrated	O
dulcitol	O
,	O
30	O
-	O
50	O
parts	O
of	O
pantotrichum	O
,	O
30	O
-	O
50	O
parts	O
of	O
raidx	O
astragali	O
,	O
15	O
-	O
50	O
parts	O
of	O
atractylis	O
ovata	O
,	O
15	O
-	O
50	O
parts	O
of	O
radix	O
salviae	O
miltiorrhizae	O
,	O
15	O
-	O
50	O
parts	O
of	O
salvia	O
przewalskii	O
and	O
10	O
-	O
30	O
parts	O
of	O
lucid	O
ganoderma	O
.	O

The	O
invention	O
has	O
obvious	O
effect	O
on	O
treating	O
leukemia	O
,	O
has	O
a	O
certain	O
curative	O
effect	O
on	O
lung	O
cancer	O
,	O
multiple	O
myeloma	O
,	O
nasopharyngeal	O
darcinoma	O
and	O
the	O
like	O
,	O
particularly	O
has	O
better	O
short	O
-	O
term	O
efficacy	O
on	O
the	O
idiopathic	O
thrombocytopenic	O
purpura	O
,	O
and	O
has	O
the	O
remission	O
rate	O
of	O
86	O
percent	O
and	O
lower	O
toxic	O
or	O
side	O
effect	O
.	O

Medicine	O
composition	O
for	O
treating	O
idiopathic	O
thrombocytopenic	O
purpura	O

The	O
invention	O
relates	O
to	O
an	O
immune	O
polysaccharide	O
intensifier	O
,	O
and	O
the	O
components	O
of	O
the	O
intensifier	O
and	O
the	O
mass	O
percentages	O
are	O
as	O
follows	O
:	O
1	O
-	O
40	O
percent	O
of	O
beta	O
-	O
glucan	O
,	O
1	O
-	O
40	O
percent	O
of	O
mannan	B
-	I
oligosaccharide	I
,	O
1	O
-	O
40	O
percent	O
of	O
immune	O
regulate	O
factor	O
,	O
and	O
1	O
-	O
40	O
percent	O
of	O
poly	B
-	I
isomaltose	I
.	O

The	O
intensifier	O
can	O
increase	O
the	O
resistance	O
to	O
pathogenic	O
microbes	O
and	O
nonspecific	O
defense	O
mechanism	O
of	O
aquaculture	O
animals	O
,	O
has	O
high	O
safety	O
,	O
small	O
effect	O
on	O
environmental	O
pollution	O
,	O
no	O
residue	O
,	O
growth	O
-	O
promoting	O
capacity	O
,	O
convenient	O
use	O
and	O
low	O
cost	O
and	O
is	O
the	O
immune	O
polysaccharide	O
intensifier	O
which	O
can	O
improve	O
physique	O
of	O
the	O
aquaculture	O
animals	O
effectively	O
.	O

Immune	O
polysaccharide	O
intensifier	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
composite	O
for	O
preventing	O
and	O
curing	O
senile	O
dementia	O
,	O
particularly	O
,	O
the	O
invention	O
provides	O
a	O
composite	O
for	O
improving	O
the	O
ability	O
of	O
memory	O
and	O
cognition	O
,	O
which	O
comprises	O
:	O
(	O
a	O
)	O
PQQ	B
(	O
pyrro	B
-	I
quinoline	I
quinone	I
)	O
,	O
salt	O
and/or	O
ester	B
which	O
are	O
(	O
is	O
)	O
pharmaceutically	O
or	O
physiologically	O
acceptable	O
;	O
(	O
b	O
)	O
acetylcholinesterase	O
inhibitor	O
;	O
and	O
(	O
c	O
)	O
carrier	O
which	O
can	O
be	O
pharmaceutically	O
or	O
physiologically	O
acceptable	O
,	O
wherein	O
the	O
molar	O
ratio	O
of	O
the	O
group	O
(	O
a	O
)	O
and	O
the	O
group	O
(	O
b	O
)	O
is	O
1:100	O
-	O
100:1	O
.	O

The	O
invention	O
also	O
provides	O
the	O
method	O
for	O
preparing	O
the	O
composite	O
of	O
the	O
invention	O
,	O
the	O
use	O
of	O
the	O
composite	O
,	O
a	O
kit	O
containing	O
the	O
composite	O
or	O
a	O
medicine	O
box	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
composite	O
.	O

The	O
composite	O
of	O
the	O
invention	O
can	O
effectively	O
and	O
safely	O
improve	O
the	O
ability	O
of	O
memory	O
and	O
cognition	O
,	O
can	O
be	O
optimally	O
used	O
to	O
prevent	O
and	O
cure	O
the	O
senile	O
degenerative	O
neurologic	O
disease	O
.	O

Composite	O
for	O
preventing	O
and	O
curing	O
senile	O
dementia	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
pharmaceutical	O
uses	O
of	O
a	O
curcumin	B
and	O
pidotimod	B
composition	O
.	O

The	O
curcumin	B
and	O
pidotimod	B
composition	O
is	O
used	O
for	O
treating	O
:	O
(	O
1	O
)	O
recurrent	O
upper	O
and	O
lower	O
respiratory	O
tract	O
infections	O
(	O
pharyngitis	O
,	O
tracheitis	O
,	O
bronchitis	O
and	O
tonsillitis	O
)	O
;	O
(	O
2	O
)	O
ENT	O
recurrent	O
infections	O
(	O
rhinitis	O
,	O
sinusitis	O
and	O
otitis	O
)	O
;	O
(	O
3	O
)	O
urinary	O
system	O
infection	O
;	O
(	O
4	O
)	O
gynecological	O
infection	O
;	O
(	O
5	O
)	O
clinical	O
patients	O
with	O
low	O
cellular	O
immune	O
function	O
after	O
chemotherapy	O
;	O
and	O
(	O
6	O
)	O
specific	O
and	O
non	O
-	O
specific	O
immune	O
deficiency	O
diseases	O
such	O
as	O
cancer	O
and	O
the	O
like	O
.	O

The	O
curcumin	B
and	O
pidotimod	B
composition	O
can	O
be	O
used	O
for	O
reducing	O
the	O
number	O
of	O
acute	O
attack	O
,	O
shortening	O
the	O
course	O
of	O
medication	O
and	O
reducing	O
the	O
degree	O
of	O
attack	O
,	O
and	O
also	O
can	O
be	O
used	O
for	O
the	O
adjuvant	O
treatment	O
of	O
antibiotics	O
during	O
acute	O
infection	O
.	O

The	O
pidotimod	B
and	O
curcumin	B
composition	O
together	O
with	O
various	O
pharmaceutically	O
acceptable	O
excipients	O
are	O
comprised	O
,	O
and	O
various	O
pharmaceutically	O
acceptable	O
dosage	O
forms	O
can	O
be	O
prepared	O
,	O
including	O
but	O
not	O
limited	O
to	O
tablets	O
,	O
capsules	O
,	O
injection	O
agents	O
and	O
the	O
like	O
.	O

Preparation	O
method	O
and	O
pharmaceutical	O
uses	O
of	O
curcumin	B
and	O
pidotimod	B
composition	O

The	O
invention	O
relates	O
to	O
a	O
pramipexole	B
-	O
contained	O
pharmaceutical	O
composition	O
capable	O
of	O
being	O
dispersed	O
in	O
a	O
mouth	O
,	O
which	O
is	O
characterized	O
by	O
containing	O
pramipexole	B
or	O
medicinal	O
salt	O
thereof	O
or	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
.	O

The	O
invention	O
is	O
used	O
for	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

Pramipexole	B
-	O
contained	O
pharmaceutical	O
composition	O
capable	O
of	O
being	O
dispersed	O
in	O
mouth	O

The	O
invention	O
discloses	O
a	O
medical	O
composition	O
containing	O
amoxicillin	B
and	O
dicloxacillin	B
sodium	I
,	O
wherein	O
,	O
the	O
amoxicillin	B
and	O
the	O
dicloxacillin	B
sodium	I
in	O
the	O
medical	O
composition	O
are	O
dispersed	O
on	O
respective	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
composition	O
has	O
good	O
stability	O
and	O
broad	O
spectrum	O
antibacterial	O
function	O
.	O

Medical	O
composition	O
containing	O
amoxicillin	B
and	O
dicloxacillin	B
sodium	I

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
Morphine	B
in	O
preparing	O
medicaments	O
for	O
treating	O
the	O
Parkinson	O
disease	O
,	O
in	O
particular	O
to	O
a	O
new	O
medical	O
application	O
of	O
Morphine	B
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

Through	O
a	O
thiazolyl	B
blue	I
(	O
MTT	O
)	O
method	O
,	O
the	O
Morphine	B
is	O
found	O
to	O
be	O
capable	O
of	O
promoting	O
the	O
growth	O
of	O
adrenal	O
gland	O
chromaffin	O
tumor	O
cells	O
(	O
PC12	O
cells	O
)	O
of	O
rats	O
.	O

The	O
Morphine	B
has	O
the	O
activity	O
of	O
promoting	O
the	O
proliferation	O
of	O
nerve	O
cells	O
and	O
can	O
inhibit	O
nerve	O
cell	O
injuries	O
caused	O
by	O
a	O
Parkinson	O
toxic	O
substance	O
MPP+	O
(	O
1-Methyl-4-Phenylpyridiniumion	B
)	O
.	O

Proved	O
by	O
a	O
protein	O
immunoblotting	O
method	O
,	O
the	O
Morphine	B
can	O
induce	O
the	O
expression	O
level	O
of	O
thioredoxin	B
in	O
the	O
PC12	O
cells	O
,	O
thus	O
the	O
Morphine	B
for	O
protecting	O
the	O
nerve	O
cells	O
from	O
injuries	O
of	O
MPP+	O
toxicity	O
is	O
related	O
to	O
the	O
induction	O
of	O
the	O
expression	O
of	O
the	O
thioredoxin	B
.	O

Application	O
of	O
Morphine	B
in	O
preparing	O
medicaments	O
for	O
treating	O
Parkinson	O
disease	O

The	O
invention	O
relates	O
to	O
a	O
soft	O
capsule	O
for	O
preventing	O
and	O
treating	O
climacteric	O
syndrome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
soft	O
capsule	O
for	O
preventing	O
and	O
treating	O
climacteric	O
syndrome	O
comprises	O
the	O
raw	O
materials	O
by	O
weight	O
portion	O
:	O
10	O
-	O
100	O
portions	O
of	O
soybean	O
isoflavone	B
,	O
50	O
-	O
200	O
portions	O
of	O
acanthopanacis	O
senticosi	O
extractum	O
,	O
20	O
-	O
100	O
portions	O
of	O
fructus	O
schizandrae	O
extractum	O
,	O
20	O
-	O
200	O
portions	O
of	O
vitamin	B
E	I
,	O
20	O
-	O
100	O
portions	O
of	O
sodium	B
glycerophosphate	I
,	O
food	O
oil	O
and	O
dried	O
extract	O
mixed	O
powder	O
,	O
wherein	O
the	O
dried	O
extract	O
mixed	O
powder	O
is	O
20	O
-	O
50	O
%	O
of	O
the	O
oil	O
-	O
based	O
quality	O
of	O
the	O
food	O
oil	O
in	O
the	O
soft	O
capsule	O
.	O

The	O
soft	O
capsule	O
is	O
used	O
for	O
preventing	O
and	O
treating	O
climacteric	O
syndrome	O
of	O
women	O
.	O

Soft	O
capsule	O
for	O
preventing	O
and	O
treating	O
climacteric	O
syndrome	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
the	O
application	O
of	O
a	O
polymer	O
system	O
based	O
on	O
beta	O
-	O
cyclodextrin	O
in	O
P	O
-	O
glycoprotein	O
of	O
suppressive	O
tumour	O
cells	O
.	O

The	O
polymer	O
consists	O
of	O
the	O
beta	O
-	O
cyclodextrin	O
and	O
grafted	O
amphipathy	O
polymer	O
.	O

The	O
star	O
-	O
shaped	O
amphipathy	O
polymer	O
based	O
on	O
beta	O
-	O
CD	O
and	O
provided	O
by	O
the	O
invention	O
has	O
remarkable	O
effect	O
of	O
restraining	O
P	O
-	O
gp	O
protein	O
,	O
and	O
the	O
restraining	O
effect	O
thereof	O
is	O
obviously	O
superior	O
to	O
the	O
inhibitor	O
CsA	O
of	O
the	O
P	O
-	O
gp	O
protein	O
.	O

The	O
polymer	O
of	O
the	O
invention	O
has	O
the	O
characteristics	O
of	O
low	O
cytotoxicity	O
,	O
good	O
biocompatibility	O
,	O
biodegradability	O
,	O
long	O
intracorporeal	O
circulation	O
time	O
and	O
the	O
like	O
,	O
and	O
provides	O
an	O
ideal	O
dose	O
carrier	O
material	O
for	O
hydrophobic	O
antineoplastic	O
agents	O
.	O

Application	O
of	O
polymer	O
based	O
on	O
beta	O
-	O
cyclodextrin	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
drugs	O
related	O
to	O
tumors	O
and	O
thrombi	O
,	O
in	O
particular	O
to	O
derivatives	O
containing	O
aminomethyl-5-membered	B
aromatic	I
heterocycle-4-carboxylic	I
acid	I
,	O
and	O
a	O
preparation	O
method	O
,	O
a	O
drug	O
combination	O
and	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
thrombotic	O
drugs	O
,	O
wherein	O
each	O
group	O
of	O
the	O
derivatives	O
is	O
defined	O
in	O
the	O
specification	O
.	O

Derivatives	O
containing	O
aminomethyl-5-membered	B
aromatic	I
heterocycle-4-carboxylic	I
acid	I
,	O
preparation	O
method	O
,	O
drug	O
combination	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicaments	O
for	O
treating	O
tumors	O
and	O
thrombus	O
and	O
particularly	O
relates	O
to	O
derivatives	O
containing	O
(	B
aminomethyl	I
-	I
five	I
-	I
membered	I
heterocyclo-4-carbonyl	I
)	I
-pyrrolidine-2-carboxylic	I
acid	I
,	O
preparation	O
method	O
thereof	O
,	O
medicinal	O
composition	O
thereof	O
and	O
use	O
thereof	O
in	O
the	O
preparation	O
of	O
anti	O
-	O
tumor	O
and	O
antithrombotic	O
medicaments	O
,	O
wherein	O
the	O
groups	O
are	O
defined	O
in	O
the	O
description	O
.	O

Derivatives	O
containing	O
(	B
aminomethyl	I
-	I
five	I
-	I
membered	I
heterocyclo-4-carbonyl	I
)	I
-pyrrolidine-2-carboxylic	I
acid	I
,	O
preparation	O
method	O
thereof	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
pharmaceutical	O
grade	O
citric	B
acid	I
diethyl	I
ester	I
used	O
as	O
an	O
anticoagulant	O
in	O
medicament	O
,	O
in	O
particular	O
to	O
an	O
application	O
in	O
blood	O
purification	O
anticoagulation	O
,	O
belonging	O
to	O
the	O
field	O
of	O
anticoagulation	O
of	O
the	O
medicament	O
.	O

In	O
research	O
findings	O
,	O
the	O
citric	B
acid	I
diethyl	I
ester	I
has	O
obvious	O
blood	O
calcium	B
reducing	O
capacity	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
obvious	O
anticoagulation	O
effect	O
and	O
high	O
dissociation	O
speed	O
in	O
vivo	O
,	O
can	O
fast	O
dissociate	O
from	O
calcium	B
ions	I
,	O
is	O
definite	O
in	O
extracorporeal	O
circulation	O
effect	O
,	O
that	O
is	O
to	O
say	O
,	O
the	O
citric	B
acid	I
diethyl	I
ester	I
can	O
achieve	O
the	O
effect	O
without	O
blood	O
coagulation	O
in	O
vitro	O
and	O
hemorrhage	O
in	O
vivo	O
,	O
and	O
also	O
prevents	O
the	O
side	O
effect	O
possible	O
to	O
generate	O
by	O
citric	B
acid	I
anticoagulation	O
after	O
entering	O
in	O
vivo	O
without	O
metabolic	O
alkalosis	O
,	O
hypernatremia	O
,	O
volume	O
load	O
increase	O
,	O
hypocalcemia	O
or	O
hypercalcemia	O
caused	O
by	O
overabundant	O
calcium	B
supplement	O
due	O
to	O
indefinite	O
calcium	B
supplement	O
,	O
thereby	O
overcoming	O
the	O
defects	O
of	O
sodium	O
citrate	O
anticoagulation	O
,	O
solving	O
the	O
problem	O
of	O
the	O
blood	O
purification	O
anticoagulation	O
of	O
high	O
risk	O
hemorrhage	O
patients	O
and	O
being	O
simple	O
,	O
convenient	O
and	O
safe	O
to	O
use	O
.	O

Application	O
of	O
citric	B
acid	I
diethyl	I
ester	I
in	O
preparation	O
of	O
anticoagulant	O
medicament	O

The	O
invention	O
discloses	O
a	O
compound	O
aloe	O
pill	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
aloe	O
pill	O
is	O
a	O
medicament	O
prepared	O
by	O
mixing	O
active	O
components	O
of	O
aloe	O
,	O
indigo	O
naturalis	O
,	O
cinnabar	B
and	O
amber	O
and	O
a	O
substrate	O
polyethylene	B
glycol	I
in	O
certain	O
weight	O
parts	O
and	O
has	O
the	O
functions	O
of	O
clearing	O
the	O
liver	O
,	O
purging	O
heat	O
,	O
smoothing	O
the	O
bowel	O
,	O
treating	O
constipation	O
,	O
calming	O
the	O
heart	O
and	O
tranquilizing	O
the	O
mind	O
and	O
obvious	O
treating	O
effects	O
for	O
heart	O
and	O
liver	O
heat	O
,	O
constipation	O
,	O
abdominal	O
distension	O
and	O
pain	O
,	O
dysphoria	O
,	O
insomnia	O
,	O
and	O
the	O
like	O
.	O

Compound	O
aloe	O
pill	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
application	O
of	O
inula	O
flower	O
,	O
riddle	O
,	O
bamboo	O
leaf	O
and	O
fermented	O
soybean	O
in	O
the	O
preparation	O
of	O
medicaments	O
or	O
products	O
for	O
preventing	O
and/or	O
treating	O
post	O
-	O
traumatic	O
stress	O
disorder	O
and/or	O
anxiety	O
disorder	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
composition	O
consisting	O
of	O
active	O
components	O
of	O
the	O
inula	O
flower	O
,	O
the	O
riddle	O
,	O
the	O
bamboo	O
leaf	O
and	O
the	O
fermented	O
soybean	O
as	O
well	O
as	O
extracts	O
thereof	O
.	O

The	O
composition	O
and	O
application	O
thereof	O
can	O
be	O
effectively	O
used	O
for	O
clinically	O
preventing	O
and/or	O
treating	O
the	O
post	O
-	O
traumatic	O
stress	O
disorder	O
and/or	O
anxiety	O
disorder	O
.	O

New	O
application	O
of	O
composition	O
containing	O
inula	O
flower	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
5'-acylated	O
cytidine	B
and	O
application	O
in	O
preparing	O
medicaments	O
for	O
treating	O
heart	O
and	O
liver	O
diseases	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
and	O
enzymolyzing	O
ribonucleic	O
acid	O
powder	O
,	O
ultrafiltering	O
and	O
purifying	O
an	O
enzymolysis	O
solution	O
,	O
and	O
then	O
exchanging	O
and	O
separating	O
by	O
using	O
an	O
anion	O
resin	O
column	O
,	O
nanofiltering	O
and	O
centrifuging	O
to	O
obtain	O
5'-cytidine	B
;	O
reacting	O
the	O
5'-cytidine	B
with	O
20	O
%	O
hydrochloric	B
acid	I
to	O
prepare	O
cytidine	B
hydrochloride	I
,	O
dissolving	O
the	O
cytidine	B
hydrochloride	I
in	O
an	O
N	B
,	I
N	I
dimethylformamide	I
solution	O
,	O
then	O
adding	O
equal	O
gram	O
of	O
acid	O
chloride	O
with	O
equivalent	O
modules	O
,	O
and	O
stirring	O
at	O
room	O
temperature	O
and	O
placing	O
the	O
mixture	O
to	O
next	O
day	O
;	O
concentrating	O
the	O
mixture	O
to	O
an	O
oily	O
object	O
in	O
vacuum	O
and	O
grinding	O
with	O
diacetyl	B
ethyl	I
ester	I
in	O
volume	O
ratio	O
of	O
1:1	O
to	O
generate	O
diethyl	B
ester	I
;	O
and	O
then	O
grinding	O
with	O
sodium	B
bicarbonate	I
equivalent	O
to	O
the	O
diethyl	B
ester	I
,	O
collecting	O
solid	O
crystallization	O
,	O
washing	O
in	O
water	O
,	O
and	O
drying	O
for	O
recrystallization	O
so	O
that	O
the	O
5'-acylated	O
cytidine	B
is	O
obtained	O
.	O

Preparation	O
method	O
of	O
5'-acylated	O
cytidine	B
and	O
application	O
in	O
preparing	O
medicaments	O
for	O
treating	O
heart	O
and	O
liver	O
diseases	O

The	O
invention	O
describes	O
the	O
use	O
of	O
a	O
compound	O
which	O
depletes	O
serum	O
amyloid	O
P	O
component	O
from	O
the	O
circulation	O
,	O
in	O
combination	O
with	O
an	O
antibody	O
specific	O
for	O
serum	O
amyloid	O
P	O
component	O
,	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
amyloidosis	O
.	O

Combinations	O
of	O
SAP	O
depleting	O
agents	O
and	O
anti	O
-	O
SAP	O
antibodies	O

The	O
invention	O
relates	O
to	O
a	O
combination	O
containing	O
ceftriaxone	B
sodium	I
.	O

In	O
the	O
combination	O
,	O
the	O
weight	O
ratio	O
of	O
the	O
ceftriaxone	B
sodium	I
to	O
mezlocillin	B
sodium	I
is	O
(	O
1	O
-	O
10	O
)	O
:1	O
;	O
the	O
optimum	O
weight	O
ratio	O
of	O
the	O
ceftriaxone	B
sodium	I
to	O
the	O
mezlocillin	B
sodium	I
is	O
5:1	O
;	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
mixture	O
of	O
the	O
ceftriaxone	B
sodium	I
and	O
the	O
mezlocillin	B
sodium	I
to	O
poloxamer	O
is	O
50:1	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
of	O
good	O
antibacterial	O
activity	O
,	O
wide	O
antimicrobial	O
spectrum	O
and	O
better	O
drug	O
curative	O
effect	O
.	O

Combination	O
containing	O
ceftriaxone	B
sodium	I

The	O
invention	O
discloses	O
quick	O
response	O
powder	O
for	O
beriberi	O
,	O
which	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
material	O
medicaments	O
in	O
part	O
by	O
weight	O
:	O
26	O
to	O
28	O
parts	O
of	O
alum	O
,	O
33	O
to	O
35	O
parts	O
of	O
caffeine	B
,	O
0.26	O
to	O
0.27	O
part	O
of	O
aspirin	B
and	O
0.13	O
to	O
0.14	O
part	O
of	O
paracetamol	B
.	O

The	O
quick	O
response	O
powder	O
for	O
the	O
beriberi	O
is	O
externally	O
used	O
for	O
releasing	O
toxicity	O
,	O
killing	O
insects	O
,	O
eliminating	O
dampness	O
and	O
relieving	O
itching	O
,	O
and	O
has	O
the	O
functions	O
of	O
clearing	O
heat	O
,	O
clearing	O
dampness	O
and	O
diminishing	O
inflammation	O
.	O

When	O
the	O
medicinal	O
powder	O
and	O
own	O
saliva	O
are	O
coated	O
on	O
the	O
sick	O
part	O
,	O
the	O
healing	O
rate	O
is	O
high	O
,	O
and	O
the	O
beriberi	O
is	O
not	O
easy	O
to	O
relapse	O
.	O

Quick	O
response	O
powder	O
for	O
beriberi	O

The	O
invention	O
relates	O
to	O
a	O
heat	O
clearing	O
detoxifying	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
heat	O
clearing	O
antidote	O
.	O

The	O
heat	O
clearing	O
antidote	O
is	O
mixed	O
from	O
peppermint	O
and	O
alum	O
by	O
the	O
weight	O
ratio	O
of	O
25:1	O
;	O
when	O
a	O
patient	O
suffers	O
from	O
a	O
headache	O
and	O
dizziness	O
,	O
a	O
small	O
amount	O
of	O
antidote	O
is	O
applied	O
on	O
the	O
temples	O
to	O
play	O
the	O
roles	O
of	O
calming	O
,	O
refreshing	O
and	O
dispersing	O
pathogenic	O
wind	O
,	O
the	O
cool	O
effect	O
is	O
very	O
effective	O
,	O
symptoms	O
are	O
immediately	O
released	O
,	O
and	O
rhinitis	O
,	O
skin	O
itching	O
,	O
internal	O
and	O
external	O
hemorrhoids	O
and	O
other	O
inflammation	O
are	O
relieved	O
;	O
and	O
a	O
small	O
amount	O
of	O
the	O
antidote	O
is	O
applied	O
on	O
the	O
injured	O
parts	O
and	O
very	O
quickly	O
releases	O
the	O
discomfort	O
of	O
the	O
injured	O
parts	O
,	O
and	O
the	O
symptoms	O
can	O
be	O
cured	O
after	O
a	O
treatment	O
course	O
.	O

The	O
heat	O
clearing	O
antidote	O
is	O
simple	O
and	O
convenient	O
in	O
curing	O
heat	O
disease	O
without	O
side	O
effect	O
,	O
and	O
the	O
symptoms	O
are	O
quickly	O
released	O
,	O
not	O
easy	O
to	O
recover	O
and	O
can	O
be	O
essentially	O
cured	O
fundamentally	O
.	O

Heat	O
clearing	O
antidote	O

The	O
invention	O
provides	O
a	O
lipid	O
nano	O
particle	O
preparation	O
containing	O
a	O
composite	O
formed	O
fatty	B
acid	I
and	O
anthracyclines	B
antitumor	O
antibiotics	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
lipid	O
nano	O
particle	O
preparation	O
comprises	O
a	O
composite	O
formed	O
by	O
the	O
anthracyclines	B
antitumor	O
antibiotics	O
and	O
fatty	B
acid	I
,	O
and	O
phospholipid	O
and	O
lipoid	O
of	O
lipid	O
nano	O
particle	O
carrier	O
ingredients	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
composite	O
,	O
the	O
phospholipid	O
and	O
the	O
lipoid	O
is	O
1:1	O
-	O
10:1	O
-	O
10:1	O
-	O
1000	O
.	O

Lipid	O
nano	O
particle	O
preparation	O
containing	O
composite	O
formed	O
fatty	B
acid	I
and	O
anthracyclines	B
antitumor	O
antibiotics	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
ibuprofen	B
slow	O
-	O
release	O
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relating	O
to	O
medicines	O
,	O
in	O
particular	O
to	O
the	O
technical	O
field	O
of	O
the	O
pharmacy	O
of	O
chemical	O
medicines	O
.	O

The	O
preparation	O
method	O
of	O
the	O
ibuprofen	B
slow	O
-	O
release	O
suspension	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
firstly	O
mixing	O
a	O
flavoring	O
agent	O
,	O
an	O
antiseptic	O
and	O
pure	O
water	O
,	O
and	O
heating	O
to	O
be	O
prepared	O
into	O
simple	O
syrup	O
;	O
preparing	O
ibuprofen	B
and	O
glutin	O
into	O
an	O
ibuprofen	B
microcapsule	O
;	O
then	O
mixing	O
the	O
simple	O
syrup	O
,	O
the	O
ibuprofen	B
microcapsule	O
and	O
a	O
suspending	O
agent	O
,	O
adding	O
edible	O
pigments	O
and	O
the	O
flavoring	O
agent	O
,	O
and	O
uniformly	O
stirring	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
process	O
,	O
easy	O
production	O
and	O
operation	O
,	O
good	O
curative	O
effect	O
of	O
the	O
medicines	O
and	O
convenient	O
carrying	O
and	O
preservation	O
.	O

Ibuprofen	B
slow	O
-	O
release	O
suspension	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
discloses	O
a	O
gossypol	B
intravenous	O
injection	O
fatty	O
emulsion	O
for	O
curing	O
tumors	O
.	O

Every	O
1,000ml	O
of	O
the	O
gossypol	B
intravenous	O
injection	O
fatty	O
emulsion	O
consists	O
of	O
the	O
following	O
components	O
:	O
40	O
to	O
80	O
grams	O
of	O
pharmaceutical	O
salt	O
of	O
gossypol	B
,	O
200	O
to	O
300	O
grams	O
of	O
ethyl	B
oleate	I
or	O
medium	O
-	O
chain	O
fatty	B
acid	I
triglycerides	I
(	O
serving	O
as	O
an	O
oil	O
phase	O
)	O
,	O
30	O
to	O
50	O
grams	O
of	O
soya	O
bean	O
lecithin	B
(	O
serving	O
as	O
a	O
surfactant	O
)	O
,	O
10	O
to	O
40	O
grams	O
of	O
absolute	O
ethanol	B
or	O
PEG400	B
(	O
serving	O
as	O
a	O
cosurfactant	O
)	O
and	O
the	O
balance	O
of	O
water	O
.	O

Research	O
shows	O
that	O
when	O
the	O
drug	O
carrier	O
of	O
the	O
gossypol	B
intravenous	O
injection	O
fatty	O
emulsion	O
is	O
used	O
according	O
to	O
the	O
dosage	O
,	O
the	O
drug	O
-	O
loading	O
rate	O
for	O
the	O
gossypol	B
of	O
the	O
gossypol	B
intravenous	O
injection	O
fatty	O
emulsion	O
is	O
obviously	O
higher	O
than	O
that	O
of	O
the	O
oral	O
preparation	O
and	O
the	O
common	O
injection	O
preparation	O
;	O
and	O
the	O
gossypol	B
intravenous	O
injection	O
fatty	O
emulsion	O
is	O
stable	O
and	O
uniform	O
and	O
is	O
difficult	O
to	O
generate	O
drug	O
separation	O
by	O
crystallization	O
or	O
delamination	O
.	O

Compared	O
with	O
the	O
oral	O
preparation	O
,	O
the	O
gossypol	B
intravenous	O
injection	O
fatty	O
emulsion	O
has	O
obviously	O
improved	O
bioavailability	O
,	O
has	O
the	O
best	O
stability	O
when	O
the	O
average	O
grain	O
diameter	O
of	O
the	O
emulsion	O
droplet	O
is	O
between	O
70	O
and	O
150	O
nm	O
,	O
has	O
slow	O
release	O
effect	O
,	O
has	O
obvious	O
targeting	O
property	O
on	O
the	O
tumor	O
tissues	O
and	O
can	O
avoid	O
incitement	O
of	O
the	O
medicament	O
to	O
the	O
gastrointestinal	O
tract	O
.	O

Gossypol	B
intravenous	O
injection	O
fatty	O
emulsion	O
for	O
curing	O
tumors	O

The	O
invention	O
relates	O
to	O
a	O
pantoprazole	B
sodium	I
freeze	O
-	O
drying	O
medicinal	O
composition	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pantoprazole	B
sodium	I
freeze	O
-	O
drying	O
medicinal	O
composition	O
for	O
injection	O
comprises	O
the	O
following	O
components	O
in	O
part	O
by	O
weight	O
:	O
1	O
part	O
of	O
pantoprazole	B
sodium	I
,	O
0.01	O
to	O
0.1	O
part	O
of	O
mannitol	B
,	O
0.02	O
to	O
0.03	O
part	O
of	O
natrium	B
adetate	I
,	O
0.07	O
to	O
0.10	O
part	O
of	O
sodium	B
sulfite	I
and	O
0	O
to	O
0.1	O
part	O
of	O
sodium	B
citrate	I
.	O

In	O
the	O
method	O
,	O
the	O
stability	O
of	O
the	O
solution	O
of	O
the	O
pantoprazole	B
sodium	I
is	O
improved	O
,	O
related	O
matters	O
of	O
the	O
solution	O
of	O
the	O
pantoprazole	B
sodium	I
in	O
the	O
process	O
of	O
preparation	O
,	O
packaging	O
or	O
freeze	O
-	O
drying	O
during	O
preparation	O
are	O
not	O
increased	O
obviously	O
,	O
the	O
content	O
of	O
the	O
related	O
matters	O
is	O
not	O
reduced	O
obviously	O
;	O
the	O
prepared	O
pantoprazole	B
sodium	I
freeze	O
-	O
drying	O
powder	O
injection	O
is	O
good	O
in	O
stability	O
in	O
the	O
process	O
of	O
transportation	O
and	O
storage	O
;	O
solution	O
mixed	O
with	O
the	O
injection	O
during	O
clinical	O
use	O
can	O
be	O
placed	O
for	O
a	O
long	O
time	O
,	O
so	O
that	O
the	O
clinical	O
use	O
is	O
more	O
convenient	O
;	O
and	O
simultaneously	O
,	O
hidden	O
troubles	O
of	O
the	O
medication	O
safety	O
of	O
patients	O
due	O
to	O
the	O
increase	O
of	O
impurities	O
(	O
related	O
matters	O
)	O
and	O
the	O
problem	O
of	O
the	O
curative	O
effect	O
on	O
the	O
patients	O
due	O
to	O
content	O
reduction	O
are	O
reduced	O
greatly	O
.	O

Pantoprazole	B
sodium	I
freeze	O
-	O
drying	O
medicinal	O
composition	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
application	O
of	O
resveratrol	B
in	O
preparing	O
medicines	O
for	O
preventing	O
and	O
curing	O
vessel	O
endothelial	O
injuries	O
caused	O
by	O
organophosphorus	B
pesticides	O
and	O
also	O
provides	O
an	O
application	O
of	O
the	O
resveratrol	B
in	O
preparing	O
medicines	O
for	O
preventing	O
and	O
curing	O
diseases	O
induced	O
by	O
the	O
vessel	O
endothelial	O
injuries	O
caused	O
by	O
the	O
organophosphorus	B
pesticides	O
.	O

Proved	O
by	O
pharmacological	O
tests	O
,	O
the	O
resveratrol	B
can	O
suppress	O
vessel	O
endothelial	O
dependency	O
diastole	O
reaction	O
reduction	O
caused	O
by	O
the	O
organophosphorus	B
pesticides	O
and	O
has	O
better	O
dose	O
dependency	O
.	O

The	O
resveratrol	B
also	O
has	O
the	O
effects	O
of	O
protecting	O
the	O
vessel	O
endothelial	O
cell	O
activity	O
and	O
preventing	O
vessel	O
endothelial	O
permeability	O
increase	O
caused	O
by	O
oxygen	B
and	O
phosphorus	B
and	O
morphologic	O
changes	O
and	O
can	O
also	O
protect	O
the	O
function	O
of	O
endothelial	O
cells	O
for	O
releasing	O
NO	B
and	O
the	O
activity	O
of	O
superoxide	B
dismutase	O
and	O
reduce	O
the	O
content	O
of	O
malondialdehyde	B
which	O
is	O
a	O
lipid	O
peroxided	O
metabolic	O
product	O
.	O

Application	O
of	O
resveratrol	B
in	O
preparing	O
medicines	O
for	O
preventing	O
and	O
curing	O
vessel	O
endothelial	O
injuries	O
caused	O
by	O
organophosphorus	O
pesticides	O

The	O
invention	O
describes	O
the	O
use	O
of	O
an	O
injectable	O
form	O
of	O
Idebenone	B
to	O
protect	O
against	O
hepatic	O
damage	O
,	O
improve	O
recovery	O
from	O
liver	O
trauma	O
,	O
poisoning	O
,	O
vapor	O
intoxication	O
,	O
degenerative	O
diseases	O
,	O
hepatocyte	O
function	O
loss	O
and	O
pathology	O
associated	O
with	O
inflammation	O
or	O
infection	O
.	O

The	O
use	O
of	O
injectable	O
Idebenone	B
restores	O
liver	O
function	O
,	O
suppresses	O
elevated	O
enzyme	O
levels	O
,	O
decreases	O
alcoholic	O
and	O
drug	O
abuse	O
associated	O
syndromes	O
,	O
symptoms	O
of	O
acute	O
hepatitis	O
of	O
various	O
origins	O
,	O
the	O
consequences	O
of	O
liver	O
reperfusion	O
and	O
other	O
signs	O
of	O
liver	O
damage	O
.	O

Pharmaceutical	O
composition	O
containing	O
idebenone	B
for	O
the	O
treatment	O
of	O
liver	O
disorders	O

The	O
invention	O
relates	O
to	O
a	O
medicament	O
for	O
treating	O
pedopathy	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medicament	O
comprises	O
the	O
following	O
components	O
in	O
part	O
by	O
weight	O
:	O
15	O
g	O
of	O
pricklyash	O
peel	O
,	O
15	O
g	O
of	O
calcined	O
alum	O
,	O
15	O
g	O
of	O
fineleaf	O
schizonepeta	O
herb	O
,	O
15	O
g	O
of	O
divaricate	O
saposhnikovia	O
root	O
,	O
15	O
g	O
of	O
amur	O
corktree	O
bark	O
,	O
15	O
g	O
of	O
safflower	O
,	O
15	O
g	O
of	O
cortex	O
lycii	O
radicis	O
,	O
15	O
g	O
of	O
small	O
gleditsia	O
fruit	O
,	O
60	O
g	O
of	O
hydnocarpus	O
seed	O
(	O
peeled	O
and	O
crushed	O
)	O
,	O
30	O
g	O
of	O
Chinese	O
mugwort	O
leaf	O
,	O
15	O
g	O
of	O
acanthopanax	O
bark	O
and	O
1,500ml	O
of	O
mature	O
vinegar	B
.	O

The	O
method	O
for	O
preparing	O
the	O
medicament	O
and	O
a	O
using	O
method	O
thereof	O
comprises	O
the	O
following	O
steps	O
:	O
soaking	O
mixed	O
medicaments	O
into	O
a	O
porcelain	O
basin	O
in	O
which	O
the	O
mature	O
vinegar	O
is	O
accommodated	O
for	O
3	O
to	O
5	O
days	O
;	O
slightly	O
heating	O
the	O
soaked	O
medicaments	O
during	O
use	O
;	O
soaking	O
feet	O
into	O
the	O
medicinal	O
vinegar	B
for	O
30	O
minutes	O
,	O
and	O
drying	O
the	O
feet	O
;	O
and	O
continuously	O
using	O
the	O
medicament	O
for	O
three	O
days	O
as	O
a	O
course	O
of	O
treatment	O
,	O
and	O
curing	O
the	O
pedopathy	O
after	O
one	O
to	O
three	O
courses	O
of	O
treatment	O
.	O

In	O
addition	O
,	O
the	O
medicament	O
can	O
cure	O
tinea	O
manuum	O
,	O
and	O
chapped	O
or	O
renyam	O
hand	O
(	O
foot	O
)	O
skin	O
.	O

The	O
medicament	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
,	O
high	O
practicality	O
,	O
and	O
capability	O
of	O
effectively	O
treating	O
beriberi	O
.	O

Medicament	O
for	O
treating	O
pedopathy	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
mouth	O
spraying	O
agent	O
consisting	O
of	O
ginseng	O
,	O
epimedium	O
herb	O
,	O
medlar	O
,	O
dogwood	O
,	O
a	O
cell	O
growth	O
factor	O
,	O
vitamin	B
E	I
and	O
other	O
components	O
,	O
which	O
has	O
the	O
efficacies	O
of	O
immunoregulation	O
,	O
fatigue	O
resistance	O
and	O
aging	O
resistance	O
and	O
is	O
particularly	O
applicable	O
for	O
middle	O
-	O
aged	O
and	O
old	O
people	O
.	O

Mouth	O
spraying	O
agent	O
containing	O
cell	O
growth	O
factor	O
and	O
production	O
method	O
thereof	O

The	O
invention	O
is	O
directed	O
to	O
improved	O
methods	O
for	O
modulating	O
the	O
human	O
sexual	O
response	O
by	O
orally	O
administering	O
a	O
vasodilator	O
to	O
the	O
blood	O
circulation	O
,	O
thereby	O
modulating	O
the	O
sexual	O
response	O
on	O
demand	O
.	O

Methods	O
and	O
formulations	O
for	O
modulating	O
the	O
human	O
sexual	O
response	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicaments	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
composition	O
of	O
taxol	B
and	O
phenylalanine	B
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
weight	O
ratio	O
of	O
the	O
taxol	B
to	O
the	O
phenylalanine	B
in	O
the	O
composition	O
is	O
1	O
to	O
0.01	O
-	O
0.8	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
a	O
composition	O
injection	O
and	O
application	O
of	O
the	O
composition	O
in	O
preparing	O
an	O
anti	O
-	O
cancer	O
medicament	O
.	O

Composition	O
of	O
taxol	B
and	O
phenylalanine	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicaments	O
,	O
and	O
discloses	O
an	O
anti	O
-	O
infective	O
medicinal	O
composition	O
of	O
cefmenoxime	B
hydrochloride	I
,	O
Na2HPO4	B
/	O
NaH2PO4	B
buffer	O
salt	O
and	O
PVPK-30	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
weight	O
ratio	O
of	O
the	O
cefmenoxime	B
hydrochloride	I
to	O
the	O
Na2HPO4	B
/	O
NaH2PO4	B
buffer	O
salt	O
to	O
the	O
PVPK-30	O
in	O
the	O
medicinal	O
composition	O
are	O
100	O
to	O
0.1	O
-	O
10	O
to	O
0.1	O
-	O
10	O
;	O
and	O
the	O
optimal	O
weight	O
ratio	O
of	O
the	O
cefmenoxime	B
hydrochloride	I
to	O
the	O
Na2HPO4	B
/	O
NaH2PO4	B
buffer	O
salt	O
to	O
the	O
PVPK-30	O
is	O
100	O
to	O
1	O
to	O
1	O
.	O

The	O
medicinal	O
composition	O
solves	O
the	O
problems	O
of	O
poor	O
dissolubility	O
and	O
stability	O
of	O
the	O
cefmenoxime	B
hydrochloride	I
in	O
the	O
prior	O
art	O
,	O
has	O
stable	O
characteristic	O
,	O
convenient	O
storage	O
and	O
high	O
dissolution	O
velocity	O
,	O
and	O
enhances	O
the	O
clinical	O
medication	O
safety	O
.	O

Anti	O
-	O
infective	O
medicinal	O
composition	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
broad	O
-	O
spectrum	O
contact	O
type	O
hemostatic	O
medical	O
fungicide	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
fungicide	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
5	O
to	O
15	O
percent	O
of	O
povidone	B
iodine	I
,	O
3	O
to	O
10	O
percent	O
of	O
chitosan	O
,	O
3	O
to	O
10	O
percent	O
of	O
petroleum	B
jelly	I
for	O
medical	O
purposes	O
,	O
1	O
to	O
5	O
percent	O
of	O
nonoxinol	B
,	O
and	O
the	O
balance	O
of	O
purified	O
water	O
.	O

After	O
the	O
fungicide	O
is	O
contacted	O
with	O
a	O
wound	O
surface	O
or	O
an	O
affected	O
part	O
,	O
the	O
fungicide	O
can	O
depolymerize	O
and	O
release	O
the	O
contained	O
iodine	O
to	O
achieve	O
the	O
function	O
of	O
sterilization	O
.	O

The	O
product	O
is	O
the	O
broad	O
-	O
spectrum	O
powerful	O
disinfectant	O
,	O
has	O
strong	O
killing	O
effect	O
on	O
viruses	O
,	O
bacteria	O
,	O
fungi	O
and	O
mycoticspore	O
,	O
not	O
only	O
has	O
long	O
constant	O
acting	O
time	O
,	O
but	O
also	O
has	O
small	O
irritation	O
to	O
human	O
skin	O
,	O
greatly	O
reduces	O
pains	O
unbearable	O
for	O
ordinary	O
people	O
,	O
and	O
simultaneously	O
has	O
the	O
function	O
of	O
hemostasis	O
.	O

The	O
fungicide	O
is	O
applicable	O
to	O
skin	O
and	O
mucousmembrane	O
infection	O
,	O
can	O
be	O
directly	O
used	O
for	O
disinfecting	O
graze	O
,	O
and	O
is	O
safe	O
and	O
convenient	O
to	O
use	O
.	O

Broad	O
-	O
spectrum	O
contact	O
type	O
hemostatic	O
medical	O
fungicide	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
crystal	O
form	O
X	O
of	O
sofalcone	B
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
further	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
prepared	O
from	O
the	O
crystal	O
form	O
X	O
of	O
sofalcone	B
and	O
a	O
use	O
thereof	O
.	O

The	O
crystal	O
form	O
X	O
of	O
sofalcone	B
is	O
characterized	O
by	O
comprising	O
a	O
powder	O
X	O
-	O
ray	O
diffraction	O
pattern	O
and	O
an	O
infrared	O
spectrogram	O
.	O

Crystal	O
form	O
X	O
of	O
sofalcone	B
,	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
hybrid	O
pyrimido	B
ketone	I
DPP	O
-	O
IV	O
inhibitor	O
shown	O
as	O
a	O
formula	O
I	O
as	O
well	O
as	O
salts	O
,	O
a	O
preparation	O
method	O
,	O
compounds	O
and	O
application	O
thereof	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
benefit	O
from	O
the	O
DPP	O
-	O
IV	O
inhibitor	O
.	O

A	O
preparation	O
process	O
of	O
the	O
DPP	O
-	O
IV	O
inhibitor	O
is	O
simple	O
,	O
easily	O
-	O
obtained	O
in	O
raw	O
materials	O
and	O
suitable	O
for	O
industrial	O
large	O
-	O
scale	O
production	O
;	O
and	O
in	O
-	O
vitro	O
and	O
in	O
-	O
vivo	O
experiments	O
verify	O
that	O
the	O
DPP	O
-	O
IV	O
inhibitor	O
has	O
very	O
good	O
selective	O
inhibition	O
effect	O
to	O
DPP	O
-	O
IV	O
,	O
nearly	O
has	O
no	O
influence	O
on	O
activities	O
of	O
DPP	O
-	O
VIII	O
and	O
DPP	O
-	O
IX	O
at	O
the	O
same	O
time	O
of	O
effectively	O
inhibiting	O
the	O
DPP	O
-	O
IV	O
activity	O
,	O
lower	O
toxicity	O
after	O
prepared	O
medicine	O
development	O
,	O
stronger	O
effect	O
and	O
longer	O
acting	O
time	O
compared	O
with	O
the	O
effect	O
of	O
a	O
medicine	O
Alogliptin	B
with	O
the	O
same	O
mechanism	O
and	O
shows	O
excellent	O
effects	O
of	O
reducing	O
the	O
blood	O
sugar	B
and	O
increasing	O
the	O
insulin	O
sensitivity	O
.	O

The	O
formula	O
I	O
is	O
shown	O
as	O
follows	O
.	O

DPP	O
-	O
IV	O
inhibitor	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
antifungal	O
action	O
medicine	O
and	O
provides	O
pyrazole	B
derivatives	O
of	O
the	O
structure	O
in	O
the	O
general	O
formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
definition	O
of	O
R	O
is	O
stated	O
as	O
in	O
a	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
discloses	O
a	O
pharmaceutical	O
composition	O
which	O
takes	O
the	O
compounds	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
as	O
effective	O
active	O
components	O
and	O
the	O
application	O
in	O
antifungal	O
medicine	O
.	O

Pyrazole	B
derivatives	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
chewable	O
capsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
chewable	O
capsule	O
comprises	O
a	O
capsule	O
skin	O
and	O
content	O
,	O
wherein	O
the	O
content	O
contains	O
omega-3	B
polyunsaturated	I
fatty	I
acid	I
or	O
derivative	O
thereof	O
,	O
and	O
is	O
taken	O
as	O
active	O
ingredient	O
with	O
medical	O
health	O
protection	O
function	O
.	O

The	O
chewable	O
capsule	O
also	O
can	O
contain	O
peppermint	O
oil	O
and/or	O
xylitol	O
.	O

Chewable	O
capsule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
application	O
of	O
3-carbethoxyphenyl	B
-	I
beta	I
-	I
D	I
-	I
acetylated	I
glucoside	I
in	O
treating	O
depression	O
.	O

The	O
3-carbethoxyphenyl	B
-	I
beta	I
-	I
D	I
-	I
acetylated	I
glucoside	I
comprises	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
or	O
a	O
solvate	O
thereof	O
,	O
and	O
the	O
application	O
relates	O
to	O
the	O
application	O
of	O
the	O
salt	O
,	O
the	O
ester	B
and	O
the	O
solvate	O
in	O
preparing	O
medicaments	O
for	O
treating	O
the	O
depression	O
,	O
wherein	O
a	O
glycosyl	O
part	O
is	O
arbitrary	O
pyranose	B
or	O
furanose	B
,	O
the	O
hydroxy	B
of	O
which	O
is	O
totally	O
acetylated	O
;	O
a	O
representative	O
compound	O
is	O
3-carbethoxyphenyl	B
-	I
beta	I
-	I
D	I
-	I
acetylated	I
glucoside	I
;	O
and	O
the	O
structural	O
formula	O
is	O
disclosed	O
in	O
the	O
specification	O
.	O

The	O
compound	O
is	O
used	O
for	O
treating	O
the	O
depression	O
,	O
on	O
two	O
depression	O
behavior	O
models	O
,	O
through	O
45mg	O
/	O
Kg	O
of	O
single	O
intragastric	O
administration	O
to	O
a	O
mouse	O
of	O
a	O
KM	O
species	O
,	O
the	O
representative	O
compound	O
3-carbethoxyphenyl	B
-	I
beta	I
-	I
D	I
-	I
acetylated	I
glucoside	I
shows	O
definite	O
depression	O
resistant	O
effect	O
,	O
and	O
the	O
depression	O
resistant	O
effect	O
of	O
the	O
compound	O
is	O
higher	O
than	O
that	O
of	O
Hilieidum	O
with	O
equivalent	O
quantity	O
.	O

A	O
test	O
on	O
the	O
spontaneous	O
activity	O
of	O
the	O
mouse	O
also	O
indicates	O
that	O
an	O
effective	O
dose	O
point	O
does	O
not	O
show	O
the	O
effect	O
of	O
interfering	O
in	O
the	O
spontaneous	O
activity	O
of	O
the	O
tested	O
animal	O
.	O

Application	O
of	O
3-carbethoxyphenyl	B
-	I
beta	I
-	I
D	I
-	I
acetylated	I
glucoside	I
in	O
treating	O
depression	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicaments	O
,	O
discloses	O
the	O
function	O
of	O
ginsenoside	B
Rg1	I
of	O
inducing	O
thioredoxin	O
in	O
cells	O
to	O
increase	O
expression	O
,	O
and	O
provides	O
application	O
of	O
the	O
ginsenoside	B
Rg1	I
in	O
preventing	O
and	O
treating	O
the	O
harm	O
of	O
formaldehyde	B
to	O
organisms	O
.	O

The	O
invention	O
provides	O
application	O
of	O
the	O
ginsenoside	O
Rg1	O
in	O
preparing	O
products	O
for	O
preventing	O
and	O
treating	O
the	O
harm	O
of	O
the	O
formaldehyde	B
to	O
the	O
organisms	O
,	O
particularly	O
healthcare	O
products	O
,	O
and	O
application	O
of	O
the	O
ginsenoside	B
Rg1	I
in	O
preparing	O
healthcare	O
products	O
related	O
to	O
oxidative	O
stress	O
.	O

Application	O
of	O
ginsenoside	B
Rg1	I
in	O
healthcare	O
products	O

The	O
invention	O
relates	O
to	O
the	O
preparation	O
process	O
and	O
the	O
application	O
of	O
cinobufagin	B
and	O
angelica	O
sinensis	O
total	O
polysaccharide	O
sustained	O
-	O
release	O
tablet	O
which	O
takes	O
the	O
cinobufagin	B
and	O
the	O
angelica	O
sinensis	O
total	O
polysaccharide	O
as	O
the	O
main	O
components	O
and	O
are	O
used	O
for	O
treating	O
the	O
malignant	O
tumor	O
in	O
the	O
digestive	O
system	O
,	O
belonging	O
to	O
the	O
field	O
of	O
the	O
pharmaceutical	O
preparation	O
and	O
the	O
clinical	O
application	O
.	O

The	O
sustained	O
-	O
release	O
tablet	O
is	O
characterized	O
by	O
comprising	O
3	O
-	O
15	O
percent	O
of	O
cinobufagin	B
,	O
5	O
-	O
30	O
percent	O
of	O
angelica	O
sinensis	O
total	O
polysaccharide	O
,	O
5	O
-	O
30	O
percent	O
of	O
lactose	B
,	O
20	O
-	O
40	O
percent	O
of	O
hydroxypropyl	O
methyl	O
cellulose	O
,	O
0.5	O
-	O
8	O
percent	O
of	O
ethyl	O
cellulose	O
,	O
2	O
-	O
10	O
percent	O
of	O
polyvinylpyrrolidone	B
,	O
and	O
0.5	O
-	O
5	O
percent	O
of	O
magnesium	B
stearate	I
.	O

The	O
method	O
for	O
preparing	O
the	O
sustained	O
-	O
release	O
tablet	O
comprises	O
the	O
following	O
steps	O
:	O
dissolving	O
the	O
angelica	O
sinensis	O
total	O
polysaccharide	O
and	O
the	O
ethyl	O
cellulose	O
with	O
water	O
,	O
stirring	O
evenly	O
the	O
angelica	O
sinensis	O
total	O
polysaccharide	O
and	O
the	O
ethyl	O
cellulose	O
in	O
the	O
cinobufagin	B
,	O
the	O
polyvinylpyrrolidone	B
and	O
the	O
lactose	B
,	O
drying	O
the	O
mixture	O
in	O
vacuum	O
,	O
grinding	O
the	O
mixture	O
,	O
mixing	O
evenly	O
the	O
ground	O
mixture	O
with	O
the	O
hydroxypropyl	O
methyl	O
cellulose	O
,	O
adding	O
the	O
magnesium	B
stearate	I
to	O
the	O
new	O
mixture	O
,	O
and	O
tabletting	O
the	O
new	O
mixture	O
.	O

The	O
sustained	O
-	O
release	O
tablet	O
is	O
used	O
for	O
treating	O
esophageal	O
cancer	O
,	O
gastric	O
cancer	O
,	O
liver	O
cancer	O
,	O
colorectal	O
cancer	O
and	O
other	O
cancers	O
,	O
is	O
effective	O
,	O
has	O
low	O
toxicity	O
and	O
clear	O
active	O
components	O
,	O
and	O
is	O
easy	O
to	O
take	O
.	O

Preparation	O
process	O
and	O
application	O
of	O
cinobufagin	B
and	O
angelica	O
sinensis	O
total	O
polysaccharide	O
sustained	O
-	O
release	O
tablet	O

The	O
invention	O
provides	O
a	O
formula	O
of	O
a	O
medicinal	O
stone	O
for	O
treating	O
intractable	O
pruritus	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
.	O

The	O
medicinal	O
stone	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
500	O
parts	O
of	O
mountain	O
wood	O
,	O
0	O
-	O
50	O
parts	O
of	O
lightyellow	O
Sophora	O
roots	O
,	O
0	O
-	O
50	O
parts	O
of	O
Chinese	O
mugwort	O
leaves	O
,	O
0	O
-	O
50	O
parts	O
of	O
root	O
barks	O
of	O
peony	O
trees	O
,	O
0	O
-	O
50	O
parts	O
of	O
common	O
cnidium	O
fruit	O
,	O
0	O
-	O
50	O
parts	O
of	O
broom	O
cypress	O
fruit	O
,	O
0	O
-	O
50	O
parts	O
of	O
borneol	B
,	O
0	O
-	O
50	O
parts	O
of	O
menthol	B
and	O
0	O
-	O
50	O
parts	O
of	O
caryophyllus	O
oil	O
.	O

The	O
preparation	O
method	O
of	O
the	O
medicinal	O
stone	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preprocessing	O
the	O
mountain	O
wood	O
for	O
standby	O
and	O
then	O
preprocessing	O
the	O
other	O
components	O
;	O
separating	O
the	O
sequentially	O
added	O
and	O
uniformly	O
mixed	O
other	O
components	O
at	O
equal	O
parts	O
from	O
the	O
mountain	O
wood	O
,	O
sealing	O
and	O
roasting	O
,	O
and	O
then	O
preserving	O
for	O
standby	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

The	O
medicinal	O
stone	O
can	O
ensure	O
the	O
safe	O
and	O
effective	O
treatment	O
of	O
a	O
medicinal	O
stone	O
therapy	O
on	O
the	O
intractable	O
pruritus	O
and	O
has	O
the	O
effects	O
of	O
adsorbing	O
toxins	O
out	O
of	O
bodies	O
,	O
clearing	O
dampness	O
and	O
removing	O
heat	O
,	O
detoxicating	O
and	O
relieving	O
itching	O
,	O
eliminating	O
swellings	O
and	O
stopping	O
pains	O
.	O

Formula	O
of	O
medicinal	O
stone	O
for	O
treating	O
intractable	O
pruritus	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicinal	O
compounds	O
and	O
relates	O
to	O
an	O
arteannuin	B
derivative	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
use	O
thereof	O
.	O

The	O
molecular	O
formula	O
of	O
the	O
arteannuin	B
derivative	O
is	O
C24H41O9N	B
;	O
and	O
the	O
arteannuin	B
derivative	O
is	O
in	O
strict	O
accordance	O
with	O
the	O
two	O
major	O
basic	O
characteristics	O
of	O
radiosensitizers	O
,	O
so	O
when	O
used	O
alone	O
(	O
in	O
normal	O
dose	O
of	O
a	O
tumor	O
radiosensitizer	O
)	O
,	O
the	O
arteannuin	B
derivative	O
does	O
not	O
kill	O
cells	O
,	O
but	O
only	O
sensitizes	O
the	O
tumor	O
cells	O
.	O

The	O
arteannuin	B
derivative	O
has	O
the	O
tumor	O
radiosensitization	O
effect	O
of	O
a	O
broad	O
spectrum	O
.	O

Arteannuin	B
derivative	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
5'-acylate	B
uridine	I
and	O
application	O
in	O
preparing	O
medicaments	O
for	O
treating	O
heart	O
diseases	O
and	O
liver	O
diseases	O
.	O

The	O
preparation	O
method	O
specifically	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
carrying	O
out	O
dissolution	O
and	O
enzymolysis	O
on	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
,	O
ultrafiltering	O
and	O
purifying	O
enzymolysis	O
liquid	O
and	O
then	O
carrying	O
out	O
anion	O
resin	O
column	O
exchange	O
separation	O
,	O
nanofiltration	O
and	O
centrifugation	O
to	O
obtain	O
5'-uridine	B
;	O
suspending	O
the	O
5'-uridine	B
in	O
a	O
mixed	O
solution	O
of	O
pyridine	B
and	O
N	B
,	I
N	I
-	I
dimethylformamide	I
,	O
gradually	O
adding	O
an	O
equivalent	O
quantity	O
of	O
anhydride	O
and	O
evaporating	O
the	O
solvent	O
;	O
dissolving	O
residues	O
by	O
using	O
90	O
percent	O
methanol	B
,	O
adsorbing	O
the	O
residues	O
into	O
silicagel	B
granules	O
and	O
then	O
evaporating	O
the	O
excessive	O
solvent	O
;	O
carrying	O
out	O
gradient	O
linear	O
elution	O
by	O
using	O
an	O
eluent	O
of	O
chloroform	B
-	O
methanol	B
and	O
chloroform	B
with	O
a	O
ratio	O
of	O
20:80	O
in	O
a	O
silicagel	B
slurry	O
column	O
containing	O
chloroform	B
liquid	O
on	O
a	O
residual	O
mixed	O
liquid	O
sample	O
and	O
determining	O
a	O
stepwise	O
eluent	O
by	O
using	O
thin	O
layer	O
chromatography	O
;	O
collecting	O
the	O
determined	O
stepwise	O
eluent	O
to	O
obtain	O
a	O
required	O
5'-acylate	B
uridine	I
solution	O
;	O
and	O
carrying	O
out	O
recrystallization	O
and	O
vacuum	O
drying	O
to	O
obtain	O
the	O
5'-acylate	B
uridine	I
.	O

Preparation	O
method	O
of	O
5'-acylate	B
uridine	I
and	O
application	O
in	O
preparing	O
medicaments	O
for	O
treating	O
heart	O
diseases	O
and	O
liver	O
diseases	O

The	O
invention	O
discloses	O
cefamandole	B
nafate	I
/	O
anhydrous	O
sodium	B
carbonate	I
medicinal	O
composition	O
microsphere	O
injection	O
,	O
which	O
is	O
characterized	O
by	O
consisting	O
of	O
cefamandole	B
nafate	I
,	O
anhydrous	O
sodium	B
carbonate	I
,	O
PGLA	B
,	O
Tween-80	O
,	O
propylene	B
glycol	I
and	O
glucose	B
.	O

The	O
invention	O
adopts	O
the	O
preferable	O
scheme	O
that	O
the	O
cefamandole	B
nafate	I
/	O
anhydrous	O
sodium	B
carbonate	I
medicinal	O
composition	O
microsphere	O
injection	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
components	O
in	O
part	O
by	O
weight	O
:	O
1	O
part	O
of	O
cefamandole	B
nafate	I
,	O
0.08	O
to	O
0.12	O
part	O
of	O
anhydrous	O
sodium	B
carbonate	I
,	O
1.5	O
to	O
6	O
parts	O
of	O
PGLA	B
,	O
0.2	O
to	O
2	O
parts	O
of	O
Tween-80	O
,	O
0.3	O
to	O
3	O
parts	O
of	O
propylene	B
glycol	I
and	O
2	O
to	O
8	O
parts	O
of	O
glucose	B
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
prepared	O
cefamandole	B
nafate	I
microspheres	O
have	O
stability	O
,	O
a	O
preparation	O
process	O
is	O
simple	O
and	O
suitable	O
for	O
industrialized	O
production	O
,	O
the	O
entrapment	O
rate	O
is	O
high	O
,	O
and	O
the	O
anhydrous	O
sodium	B
carbonate	I
used	O
as	O
a	O
co	O
-	O
solvent	O
has	O
good	O
resolution	O
and	O
proper	O
slow	O
-	O
release	O
effect	O
.	O

Cefamandole	B
nafate	I
/	O
anhydrous	O
sodium	B
carbonate	I
medicinal	O
composition	O
microsphere	O
injection	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
bendamustine	B
hydrochloride	I
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
which	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
adding	O
the	O
bendamustine	B
hydrochloride	I
and	O
a	O
freeze	O
-	O
dried	O
excipient	O
into	O
water	O
for	O
injection	O
with	O
the	O
temperature	O
of	O
between	O
30	O
and	O
50	O
DEG	O
C	O
,	O
dissolving	O
,	O
and	O
rapidly	O
adding	O
the	O
water	O
for	O
injection	O
with	O
the	O
temperature	O
of	O
between	O
0	O
and10	O
DEG	O
C	O
;	O
mixing	O
uniformly	O
,	O
starting	O
a	O
cooling	O
system	O
,	O
and	O
rapidly	O
cooling	O
the	O
liquid	O
medicament	O
to	O
the	O
temperature	O
of	O
between	O
0	O
and	O
10	O
DEG	O
C	O
;	O
adjusting	O
the	O
pH	O
value	O
to	O
between	O
2.0	O
and	O
3.0	O
,	O
adding	O
active	O
carbon	B
,	O
stirring	O
,	O
filtering	O
the	O
active	O
carbon	B
,	O
filtering	O
,	O
filling	O
,	O
and	O
freeze	O
-	O
drying	O
to	O
obtain	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
.	O

In	O
the	O
technical	O
method	O
,	O
organic	O
solvents	O
are	O
not	O
added	O
and	O
only	O
water	O
is	O
used	O
as	O
the	O
solvent	O
;	O
the	O
pH	O
value	O
and	O
temperature	O
are	O
controlled	O
;	O
and	O
the	O
preparation	O
-	O
related	O
substance	O
has	O
low	O
content	O
.	O

Method	O
for	O
preparing	O
bendamustine	B
hydrochloride	I
freeze	O
-	O
dried	O
powder	O
injection	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
dioscin	B
in	O
preparation	O
of	O
a	O
liver	O
-	O
protecting	O
pharmaceutical	O
preparation	O
.	O

The	O
pharmaceutical	O
preparation	O
can	O
obviously	O
inhibit	O
increase	O
of	O
activity	O
of	O
aminotransferase	O
and	O
lactate	O
dehydrogenase	O
due	O
to	O
medicines	O
(	O
carbon	B
tetrachloride	I
or	O
paracetamol	B
)	O
and	O
alcohol	B
,	O
and	O
reduce	O
the	O
liver	O
indices	O
,	O
thereby	O
performing	O
the	O
liver	O
-	O
protecting	O
function	O
;	O
the	O
pharmaceutical	O
preparation	O
can	O
enhance	O
the	O
activity	O
of	O
SOD	O
,	O
reduce	O
the	O
content	O
of	O
MDA	O
,	O
increase	O
the	O
content	O
of	O
GSH	B
and	O
inhibit	O
liver	O
lipide	O
overoxidation	O
induced	O
by	O
medicines	O
(	O
carbon	B
tetrachloride	I
or	O
paracetamol	B
)	O
;	O
and	O
the	O
pharmaceutical	O
preparation	O
can	O
also	O
reduce	O
the	O
content	O
of	O
TG	O
and	O
TC	O
and	O
inhibit	O
the	O
liver	O
steatosis	O
caused	O
by	O
alcohol	B
.	O

The	O
dioscin	B
can	O
be	O
used	O
as	O
the	O
raw	O
material	O
to	O
prepare	O
various	O
preparation	O
formulations	O
for	O
clinic	O
applications	O
according	O
to	O
pharmaceutic	O
related	O
requirements	O
and	O
clinic	O
requirements	O
,	O
such	O
as	O
tablets	O
,	O
capsules	O
,	O
injections	O
,	O
oral	O
liquids	O
,	O
granules	O
and	O
the	O
like	O
.	O

The	O
invention	O
is	O
safe	O
(	O
no	O
toxicity	O
or	O
side	O
effect	O
)	O
,	O
convenient	O
,	O
economical	O
and	O
the	O
like	O
.	O

Application	O
of	O
dioscin	B
in	O
preparation	O
of	O
liver	O
-	O
protecting	O
pharmaceutical	O
preparation	O

The	O
invention	O
provides	O
a	O
preparation	O
process	O
of	O
a	O
non	O
-	O
PVC	O
soft	O
-	O
bag	O
packing	O
peritoneal	O
dialysis	O
solution	O
and	O
a	O
product	O
thereof	O
.	O

The	O
process	O
is	O
characterized	O
in	O
that	O
at	O
least	O
80	O
%	O
prescription	O
amount	O
of	O
fresh	O
water	O
for	O
injection	O
at	O
the	O
temperature	O
of	O
40	O
-	O
70	O
DEG	O
C	O
is	O
added	O
into	O
a	O
preparation	O
container	O
,	O
glucose	B
,	O
sodium	B
chloride	I
and	O
sodium	B
lactate	I
are	O
sequentially	O
added	O
according	O
to	O
the	O
prescription	O
amount	O
,	O
at	O
least	O
101	O
%	O
prescription	O
amount	O
of	O
calcium	B
chloride	I
and	O
magnesium	B
chloride	I
are	O
fully	O
stirred	O
and	O
dissolved	O
for	O
10	O
-	O
20	O
minutes	O
,	O
the	O
water	O
for	O
injection	O
at	O
the	O
temperature	O
of	O
40	O
-	O
70	O
DEG	O
C	O
is	O
added	O
to	O
full	O
dose	O
and	O
stirred	O
for	O
about	O
20	O
-	O
25	O
minutes	O
,	O
and	O
diluted	O
hydrochloric	B
acid	I
is	O
added	O
for	O
regulating	O
the	O
pH	O
value	O
of	O
the	O
solution	O
to	O
be	O
4.5	O
to	O
5.5	O
;	O
and	O
after	O
pre	O
-	O
filtration	O
and	O
ultimate	O
filtration	O
,	O
the	O
solution	O
is	O
filled	O
into	O
the	O
non	O
-	O
PVC	O
plastic	O
transfusion	O
bag	O
,	O
plugged	O
,	O
sealed	O
and	O
sterilized	O
for	O
5	O
-	O
30	O
minutes	O
in	O
a	O
water	O
bath	O
of	O
110	O
-	O
125	O
DEG	O
C	O
to	O
obtain	O
the	O
product	O
.	O

By	O
improving	O
the	O
process	O
conditions	O
,	O
the	O
pH	O
value	O
of	O
the	O
prepared	O
peritoneal	O
dialysis	O
solution	O
product	O
after	O
being	O
sterilized	O
is	O
stable	O
,	O
and	O
the	O
number	O
of	O
hazardous	O
decomposition	O
products	O
is	O
small	O
;	O
and	O
additionally	O
,	O
by	O
changing	O
the	O
soft	O
-	O
bag	O
packing	O
material	O
,	O
the	O
products	O
can	O
be	O
directly	O
sterilized	O
without	O
package	O
,	O
and	O
the	O
time	O
for	O
sending	O
the	O
produced	O
medicine	O
to	O
be	O
sterilized	O
is	O
shortened	O
.	O

Preparation	O
process	O
of	O
non	O
-	O
PVC	O
soft	O
-	O
bag	O
packing	O
peritoneal	O
dialysis	O
solution	O
and	O
product	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
patch	O
comprising	O
a	O
drug	O
-	O
containing	O
layer	O
with	O
low	O
content	O
of	O
hormones	O
,	O
such	O
as	O
gestodene	O
,	O
and	O
optionally	O
an	O
estrogen	B
(	O
e.g.	O
ethinyl	B
estradiol	I
)	O
.	O

Upon	O
administering	O
the	O
patch	O
to	O
a	O
woman	O
,	O
plasma	O
levels	O
of	O
at	O
least	O
1.0	O
ng	O
/	O
ml	O
of	O
Gestodene	B
is	O
achieved	O
at	O
steady	O
state	O
conditions	O
without	O
the	O
need	O
of	O
incorporating	O
penetration	O
enhancers	O
or	O
permeation	O
enhancers	O
in	O
the	O
drug	O
-	O
containing	O
layer	O
.	O

Satisfactorily	O
plasma	O
levels	O
of	O
the	O
hormones	O
is	O
also	O
achieved	O
throughout	O
a	O
period	O
of	O
at	O
least	O
1	O
week	O
,	O
making	O
the	O
patch	O
applicable	O
for	O
being	O
used	O
in	O
female	O
contraception	O
with	O
the	O
concept	O
of	O
administering	O
the	O
patch	O
ones	O
weekly	O
.	O

Transdermal	O
delivery	O
of	O
hormones	O
without	O
the	O
need	O
of	O
penetration	O
enhancers	O

The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
flu	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
anti	O
-	O
flu	O
injection	O
is	O
prepared	O
from	O
main	O
raw	O
materials	O
of	O
30	O
-	O
50	O
g	O
of	O
garlic	O
,	O
15	O
-	O
25	O
g	O
of	O
fistular	O
onion	O
stalk	O
,	O
30	O
-	O
50	O
g	O
of	O
Chinese	O
cinquefoil	O
herb	O
and	O
1	O
-	O
3ml	O
of	O
pig	O
's	O
bile	O
,	O
and	O
auxiliary	O
materials	O
of	O
95	O
%	O
of	O
alcohol	B
,	O
0.5	O
%	O
of	O
procaine	B
aqueous	O
solution	O
,	O
4	O
%	O
of	O
sodium	B
hydroxide	I
solution	O
and	O
distilled	O
water	O
.	O

The	O
anti	O
-	O
flu	O
injection	O
has	O
good	O
disinfection	O
,	O
antivirus	O
and	O
immunity	O
-	O
improving	O
effects	O
,	O
small	O
toxic	O
or	O
side	O
effects	O
,	O
fast	O
action	O
and	O
low	O
cost	O
.	O

The	O
anti	O
-	O
flu	O
injection	O
is	O
favorable	O
medicament	O
against	O
flu	O
and	O
pestilence	O
.	O

Anti	O
-	O
flu	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
inhalation	O
preparation	O
which	O
takes	O
levalbuterol	B
as	O
active	O
ingredients	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
inhalation	O
preparation	O
is	O
a	O
medicinal	O
composition	O
prepared	O
by	O
mixing	O
levalbuterol	B
serving	O
as	O
medicinal	O
active	O
ingredients	O
with	O
auxiliary	O
materials	O
accepted	O
in	O
pharmaceutical	O
science	O
,	O
and	O
can	O
be	O
used	O
for	O
treating	O
various	O
types	O
of	O
asthma	O
.	O

Orally	O
administrated	O
inhalation	O
preparation	O
formulations	O
such	O
as	O
dry	O
powder	O
inhalation	O
preparations	O
,	O
aerosol	O
and	O
the	O
like	O
are	O
developed	O
by	O
technical	O
means	O
of	O
the	O
invention	O
,	O
and	O
the	O
inhalation	O
preparation	O
has	O
the	O
advantages	O
of	O
quick	O
response	O
,	O
rapid	O
effect	O
,	O
convenient	O
use	O
and	O
the	O
like	O
.	O

Inhalation	O
preparation	O
for	O
treating	O
asthma	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
new	O
application	O
of	O
a	O
2-	B
(	I
4-fluorophenyl	I
)	I
-3-nitro-8-O	I
-	I
ethyl-2-hydro	I
-	I
benzopyran	I
compound	O
,	O
in	O
particular	O
application	O
of	O
the	O
compound	O
serving	O
as	O
phosphatidylinositol-3-kinase	O
(	O
PI3	O
K	O
)	O
inhibitor	O
.	O

The	O
PI3	O
K	O
inhibitor	O
can	O
inhibit	O
PI3	O
K	O
and	O
disturb	O
a	O
PI3K	O
/	O
AKT	O
signal	O
channel	O
,	O
has	O
good	O
treatment	O
effect	O
on	O
multiple	O
tumors	O
,	O
particularly	O
malignant	O
hematological	O
diseases	O
,	O
can	O
effectively	O
control	O
the	O
propagation	O
of	O
tumor	O
cells	O
and	O
induce	O
the	O
apoptosis	O
thereof	O
,	O
and	O
has	O
the	O
effect	O
of	O
inhibiting	O
and	O
treating	O
the	O
tumors	O
;	O
and	O
meanwhile	O
,	O
the	O
PI3	O
K	O
has	O
low	O
toxicity	O
.	O

Phosphatidylinositol-3-kinase	O
inhibitor	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
pueraria	O
isoflavone	B
capsule	O
(	O
or	O
a	O
Hu	O
's	O
Besser	O
capsule	O
)	O
.	O

The	O
capsule	O
is	O
prepared	O
by	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
Panax	O
Notoginsenosides	O
,	O
1	O
part	O
of	O
radix	O
salviae	O
miltiorrhizae	O
extract	O
,	O
1	O
part	O
of	O
ligustrazine	O
,	O
1	O
part	O
of	O
kudzu	O
root	O
extract	O
,	O
0.5	O
part	O
of	O
tea	O
polyphenol	B
and	O
1	O
part	O
of	O
Grifola	O
frondosa	O
extract	O
.	O

The	O
components	O
are	O
combined	O
together	O
to	O
make	O
the	O
effect	O
of	O
each	O
component	O
to	O
generate	O
a	O
synergistic	O
effect	O
to	O
achieve	O
the	O
effect	O
of	O
lowering	O
blood	O
viscosity	O
,	O
reducing	O
blood	O
fat	O
and	O
preventing	O
cardio	O
-	O
cerebral	O
blood	O
vessels	O
from	O
being	O
stiffened	O
and	O
infarcted	O
.	O

The	O
pueraria	O
isoflavone	B
capsule	O
can	O
be	O
used	O
for	O
treating	O
serious	O
diseases	O
influencing	O
the	O
health	O
of	O
the	O
old	O
and	O
lowering	O
the	O
quality	O
of	O
life	O
of	O
the	O
old	O
,	O
such	O
as	O
Alzheimer	O
diseases	O
,	O
hypophrenia	O
caused	O
by	O
cerebral	O
thrombosis	O
,	O
diabetes	O
mellitus	O
,	O
senile	O
benign	O
hypophrenia	O
and	O
the	O
like	O
.	O

Proved	O
by	O
a	O
large	O
number	O
of	O
clinical	O
effect	O
observation	O
tests	O
,	O
through	O
taking	O
effective	O
dose	O
of	O
pueraria	O
isoflavone	B
capsule	O
,	O
patients	O
with	O
mild	O
-	O
moderate	O
dementia	O
can	O
be	O
recovered	O
with	O
self	O
-	O
care	O
ability	O
after	O
taking	O
the	O
capsule	O
for	O
3	O
months	O
,	O
and	O
the	O
serious	O
disease	O
of	O
Parkinson	O
's	O
disease	O
and	O
the	O
like	O
can	O
be	O
cured	O
in	O
3	O
-	O
4	O
months	O
.	O

Pueraria	O
isoflavone	B
capsule	O

The	O
invention	O
discloses	O
an	O
organotin	B
hydroximic	I
acid	I
compound	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
.	O

The	O
compound	O
has	O
a	O
structural	O
formula	O
below	O
.	O

The	O
compound	O
has	O
the	O
characteristics	O
of	O
high	O
anti	O
-	O
tumor	O
activity	O
,	O
high	O
lipid	O
solubility	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
and	O
the	O
like	O
and	O
provides	O
a	O
new	O
way	O
for	O
the	O
development	O
of	O
anti	O
-	O
tumor	O
medicaments	O
.	O

Organotin	B
hydroximic	I
acid	I
compound	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
aspoxicillin	B
freeze	O
-	O
dried	O
powder	O
injection	O
for	O
injection	O
,	O
which	O
is	O
characterized	O
in	O
that	O
:	O
adding	O
aspoxicillin	B
and	O
pharmaceutical	O
excipients	O
into	O
0	O
to	O
10DEG	O
C	O
water	O
,	O
adding	O
in	O
alkali	O
solution	O
so	O
that	O
the	O
aspoxicillin	B
is	O
dissolved	O
,	O
maintaining	O
the	O
temperature	O
of	O
the	O
liquid	O
medicine	O
to	O
be	O
0	O
to	O
10DEG	O
C	O
,	O
using	O
acid	O
solution	O
to	O
adjust	O
the	O
pH	O
value	O
to	O
be	O
6.5	O
to	O
8.0	O
,	O
filtering	O
,	O
filling	O
,	O
freeze	O
-	O
drying	O
to	O
obtain	O
the	O
aspoxicillin	B
freeze	O
-	O
dried	O
powder	O
injection	O
.	O

The	O
process	O
method	O
takes	O
water	O
as	O
the	O
solvent	O
,	O
controls	O
the	O
pH	O
value	O
and	O
the	O
temperature	O
,	O
and	O
the	O
content	O
of	O
relevant	O
substances	O
and	O
polymer	O
of	O
a	O
preparation	O
is	O
low	O
.	O

The	O
process	O
method	O
can	O
prepare	O
and	O
obtain	O
products	O
with	O
more	O
excellent	O
quality	O
.	O

Preparation	O
method	O
of	O
aspoxicillin	B
freeze	O
-	O
dried	O
powder	O
injection	O

The	O
invention	O
provides	O
a	O
glipizide	B
sustained	O
-	O
release	O
capsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
glipizide	B
sustained	O
-	O
release	O
capsule	O
contains	O
glipizide	B
,	O
blank	O
oil	O
cores	O
,	O
a	O
sustained	O
-	O
release	O
agent	O
,	O
a	O
plasticizer	O
and	O
an	O
auxiliary	O
component	O
of	O
an	O
antisticking	O
agent	O
.	O

The	O
preparation	O
process	O
comprises	O
the	O
steps	O
of	O
mixing	O
,	O
granulating	O
,	O
drying	O
,	O
adding	O
talcum	O
powder	O
and	O
filling	O
capsules	O
.	O

The	O
glipizide	B
sustained	O
-	O
release	O
capsule	O
is	O
a	O
safe	O
and	O
effective	O
hypoglycemic	O
medicament	O
,	O
slowly	O
releases	O
to	O
maintain	O
the	O
relatively	O
-	O
stable	O
blood	O
concentration	O
and	O
longer	O
action	O
time	O
and	O
has	O
the	O
advantages	O
of	O
reduction	O
on	O
toxic	O
or	O
side	O
effects	O
and	O
more	O
convenient	O
taking	O
.	O

Glipizide	B
sustained	O
-	O
release	O
capsule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
biodegradable	O
microencapsulated	O
capsaicine	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
adding	O
a	O
surfactant	O
into	O
aqueous	O
solution	O
of	O
polyvinylalcohol	B
,	O
and	O
stirring	O
and	O
mixing	O
;	O
(	O
2	O
)	O
adding	O
dichloromethane	B
initial	O
emulsion	O
of	O
polylactic	B
acid	I
into	O
aqueous	O
solution	O
of	O
capsaicine	O
for	O
emulsification	O
to	O
obtain	O
emulsion	O
;	O
and	O
(	O
3	O
)	O
mixing	O
the	O
emulsion	O
obtained	O
by	O
the	O
step	O
(	O
2	O
)	O
,	O
the	O
product	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
isopropanol	B
solution	O
,	O
stirring	O
,	O
volatilizing	O
isopropanol	B
,	O
and	O
collecting	O
polylactic	B
acid	I
capsules	O
in	O
the	O
system	O
.	O

The	O
polylactic	B
acid	I
is	O
taken	O
as	O
a	O
raw	O
material	O
to	O
prepare	O
the	O
microencapsulated	O
capsaicine	O
by	O
a	O
diphase	O
emulsion	O
method	O
.	O

The	O
raw	O
material	O
is	O
biodegradable	O
,	O
and	O
is	O
environment	O
-	O
friendly	O
;	O
the	O
size	O
distribution	O
of	O
the	O
microcapsules	O
is	O
20	O
to	O
50	O
mu	O
m	O
and	O
can	O
be	O
adjusted	O
;	O
and	O
the	O
preparation	O
process	O
is	O
simple	O
,	O
the	O
production	O
cost	O
is	O
low	O
and	O
the	O
preparation	O
method	O
is	O
easy	O
to	O
implement	O
.	O

The	O
polylactic	B
acid	I
microencapsulated	O
capsaicine	O
prepared	O
by	O
the	O
method	O
can	O
be	O
widely	O
applied	O
to	O
the	O
aspects	O
such	O
as	O
coatings	O
,	O
adhesives	O
,	O
electric	O
wires	O
,	O
cables	O
,	O
communication	O
facilities	O
,	O
medicaments	O
and	O
the	O
like	O
.	O

Biodegradable	O
microencapsulated	O
capsaicine	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
matrine	B
derivative	O
used	O
for	O
preparing	O
drugs	O
for	O
curing	O
cancers	O
.	O

The	O
invention	O
is	O
characterized	O
by	O
improving	O
the	O
structure	O
of	O
a	O
matrine	O
drug	O
so	O
as	O
to	O
provide	O
an	O
antitumor	O
drug	O
which	O
is	O
hopeful	O
to	O
have	O
long	O
acting	O
and	O
strong	O
efficiency	O
,	O
thereby	O
providing	O
one	O
more	O
selection	O
for	O
cancerous	O
patients	O
.	O

Matrine	B
derivative	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
Liriope	O
graminifolia	O
saponin	B
A	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
carrying	O
out	O
ethanol	O
reflux	O
extraction	O
by	O
adopting	O
a	O
pulverized	O
Liriope	O
graminifolia	O
block	O
-	O
shaped	O
root	O
as	O
raw	O
materials	O
;	O
(	O
2	O
)	O
extracting	O
the	O
obtained	O
extract	O
by	O
n	B
-	I
butyl	I
alcohol	I
and	O
then	O
carrying	O
out	O
vacuum	O
concentration	O
;	O
(	O
3	O
)	O
separating	O
the	O
obtained	O
n	B
-	I
butyl	I
alcohol	I
phase	O
extract	O
by	O
adopting	O
macroporous	O
resin	O
D101	O
and	O
eluting	O
components	O
with	O
different	O
polarity	O
respectively	O
by	O
using	O
water	O
and	O
ethanol	B
solutions	O
with	O
different	O
mass	O
concentration	O
;	O
(	O
4	O
)	O
carrying	O
out	O
vacuum	O
concentration	O
,	O
freezing	O
and	O
drying	O
on	O
a	O
saponin	B
eluent	O
obtained	O
by	O
75	O
percent	O
of	O
ethanol	B
solution	O
;	O
(	O
5	O
)	O
separating	O
and	O
purifying	O
a	O
saponin	B
crude	O
extract	O
by	O
adopting	O
a	O
countercurrent	O
chromatography	O
;	O
and	O
(	O
6	O
)	O
carrying	O
out	O
vacuum	O
concentration	O
,	O
freezing	O
and	O
drying	O
the	O
saponin	B
component	O
to	O
obtain	O
the	O
Liriope	O
graminifolia	O
saponin	B
A.	O

The	O
Liriope	O
graminifolia	O
saponin	B
A	O
has	O
favorable	O
in	O
-	O
vitro	O
proliferation	O
inhibiting	O
function	O
on	O
human	O
cervical	O
cancer	O
Hela	O
cells	O
and	O
human	O
liver	O
cancer	O
SMMC-7721	O
cells	O
.	O

Method	O
for	O
separating	O
and	O
preparing	O
Liriope	O
graminifolia	O
saponin	B
A	O
from	O
Liriope	O
graminifolia	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
tenuipesine	B
and	O
a	O
special	O
bacterial	O
strain	O
thereof	O
.	O

The	O
bacterial	O
strain	O
is	O
paecilomyces	O
farinosus	O
6.48	O
with	O
a	O
preservation	O
number	O
of	O
CGMCC	O
No.3627	O
.	O

The	O
paecilomyces	O
farinosus	O
6.48	O
with	O
the	O
preservation	O
number	O
of	O
CGMCC	O
No.3627	O
of	O
the	O
invention	O
has	O
a	O
function	O
of	O
producing	O
tenuipesine	B
.	O

The	O
method	O
for	O
preparing	O
the	O
tenuipesine	B
achieves	O
a	O
thallus	O
yield	O
as	O
high	O
as	O
10mg	O
/	O
g	O
,	O
wherein	O
the	O
extraction	O
rate	O
of	O
a	O
purification	O
method	O
is	O
as	O
high	O
as	O
up	O
to	O
1	O
percent	O
.	O

The	O
tenuipesine	B
prepared	O
by	O
the	O
invention	O
has	O
the	O
purity	O
up	O
to	O
99	O
percent	O
,	O
and	O
the	O
method	O
of	O
the	O
invention	O
is	O
simple	O
in	O
operation	O
,	O
low	O
in	O
cost	O
,	O
time	O
-	O
saving	O
and	O
labor	O
-	O
saving	O
.	O

The	O
invention	O
also	O
provides	O
the	O
use	O
of	O
the	O
tenuipesine	B
in	O
the	O
preparation	O
of	O
antibacterial	O
and	O
anti	O
-	O
fungal	O
activity	O
medicaments	O
.	O

Method	O
for	O
preparing	O
tenuipesine	B
and	O
special	O
bacterial	O
strain	O
thereof	O

It	O
has	O
been	O
required	O
to	O
develop	O
a	O
drink	O
which	O
contains	O
citrulline	B
,	O
generates	O
little	O
offensive	O
odor	O
when	O
stored	O
or	O
heated	O
and	O
is	O
easy	O
to	O
drink	O
.	O

Thus	O
,	O
a	O
drink	O
containing	O
citrulline	B
together	O
with	O
citric	B
acid	I
,	O
sodium	B
citrate	I
or	O
disodium	B
hydrogen	I
phosphate	I
is	O
provided	O
.	O

Citrulline	B
-	O
containing	O
drink	O

The	O
invention	O
relates	O
to	O
doxycycline	B
hydrochloride	I
and	O
rifampicin	B
effervescent	O
granules	O
for	O
livestock	O
and	O
poultry	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
effervescent	O
granules	O
comprise	O
the	O
following	O
raw	O
and	O
auxiliary	O
materials	O
in	O
part	O
by	O
weight	O
:	O
80	O
to	O
120	O
parts	O
of	O
doxycycline	B
hydrochloride	I
,	O
30	O
to	O
70	O
parts	O
of	O
rifampicin	B
,	O
100	O
to	O
140	O
parts	O
of	O
citric	B
acid	I
,	O
150	O
to	O
170	O
parts	O
of	O
sodium	B
bicarbonate	I
,	O
20	O
to	O
40	O
parts	O
of	O
polyethylene	B
glycol	I
6000	I
,	O
170	O
to	O
210	O
parts	O
of	O
dextrin	O
,	O
and	O
330	O
to	O
370	O
parts	O
of	O
cane	B
sugar	I
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
crushing	O
the	O
raw	O
and	O
auxiliary	O
materials	O
,	O
respectively	O
mixing	O
,	O
drying	O
and	O
pelletizing	O
,	O
and	O
fully	O
mixing	O
.	O

The	O
effervescent	O
granules	O
with	O
good	O
curative	O
effect	O
,	O
safety	O
and	O
reliability	O
are	O
prepared	O
by	O
using	O
a	O
modernized	O
detection	O
means	O
and	O
modernized	O
pharmaceutical	O
equipment	O
according	O
to	O
the	O
GMP	O
standard	O
of	O
veterinary	O
medicaments	O
.	O

The	O
effervescent	O
granules	O
are	O
prepared	O
by	O
adding	O
the	O
auxiliary	O
materials	O
and	O
an	O
effervescent	O
disintegrant	O
into	O
the	O
raw	O
materials	O
and	O
have	O
good	O
mouthfeel	O
and	O
stable	O
quality	O
for	O
ill	O
livestock	O
and	O
poultry	O
by	O
oral	O
administration	O
so	O
as	O
to	O
improve	O
the	O
bioavailability	O
of	O
the	O
medicament	O
.	O

Doxycycline	B
hydrochloride	I
and	O
rifampicin	B
effervescent	O
granules	O
for	O
livestock	O
and	O
poultry	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
external	O
liniment	O
for	O
drawing	O
pus	O
out	O
and	O
diminishing	O
inflammation	O
.	O

The	O
external	O
liniment	O
is	O
prepared	O
by	O
processing	O
lead	B
monoxide	I
,	O
vermilion	O
,	O
lead	B
powder	O
,	O
borneol	B
,	O
pearl	O
and	O
sesame	O
oil	O
as	O
raw	O
materials	O
according	O
to	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
external	O
liniment	O
has	O
the	O
efficacy	O
of	O
drawing	O
pus	O
out	O
and	O
prompting	O
tissue	O
regeneration	O
,	O
clearing	O
heat	O
and	O
diminishing	O
inflammation	O
,	O
sterilizing	O
,	O
healing	O
wound	O
abscess	O
and	O
expelling	O
pus	O
,	O
also	O
has	O
extremely	O
strong	O
permeability	O
,	O
can	O
smooth	O
veins	O
and	O
expel	O
toxin	O
,	O
promote	O
local	O
tissue	O
metabolism	O
,	O
dilate	O
blood	O
vessels	O
,	O
eliminate	O
dampness	O
and	O
heal	O
wound	O
abscess	O
and	O
has	O
no	O
any	O
adverse	O
reaction	O
and	O
toxic	O
and	O
side	O
effects	O
when	O
being	O
wiped	O
on	O
lesions	O
.	O

The	O
invention	O
has	O
good	O
healing	O
effect	O
on	O
lower	O
extremity	O
foot	O
ulcers	O
caused	O
by	O
phlebitis	O
,	O
onychomycosis	O
and	O
diabetes	O
,	O
has	O
the	O
healing	O
rate	O
up	O
to	O
more	O
than	O
95	O
percent	O
without	O
recrudescence	O
after	O
treatment	O
and	O
can	O
ensure	O
that	O
the	O
patients	O
are	O
cured	O
fundamentally	O
.	O

External	O
liniment	O
for	O
drawing	O
pus	O
out	O
and	O
diminishing	O
inflammation	O

The	O
invention	O
discloses	O
a	O
preparation	O
process	O
of	O
a	O
bone	O
peptide	O
soft	O
capsule	O
,	O
which	O
is	O
prepared	O
by	O
pressing	O
and	O
forming	O
capsule	O
contents	O
on	O
a	O
soft	O
capsule	O
machine	O
,	O
wherein	O
the	O
capsule	O
contents	O
comprise	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
30	O
parts	O
of	O
extract	O
powder	O
,	O
5	O
-	O
30	O
parts	O
of	O
chondroitin	B
sulfate	I
,	O
5	O
-	O
10	O
parts	O
of	O
protein	O
calcium	B
peptide	O
,	O
1	O
-	O
8	O
parts	O
of	O
beewax	O
and	O
20	O
-	O
50	O
parts	O
of	O
vegetable	O
oil	O
.	O

The	O
preparation	O
process	O
comprises	O
the	O
following	O
steps	O
:	O
by	O
using	O
a	O
principle	O
that	O
the	O
beewax	O
is	O
subject	O
to	O
gradual	O
temperature	O
reduction	O
below	O
a	O
melting	O
point	O
and	O
is	O
cured	O
,	O
slowly	O
dispersing	O
micro	O
powder	O
into	O
mixed	O
solution	O
of	O
the	O
beewax	O
and	O
the	O
vegetable	O
oil	O
to	O
form	O
powder	O
-	O
to	O
-	O
oil	O
cream	O
-	O
shaped	O
contents	O
under	O
highly	O
stirring	O
;	O
and	O
properly	O
diluting	O
the	O
contents	O
with	O
the	O
vegetable	O
oil	O
to	O
form	O
a	O
cream	O
with	O
better	O
flowability	O
,	O
wherein	O
the	O
cream	O
is	O
easily	O
pressed	O
into	O
capsules	O
.	O

The	O
invention	O
has	O
favorable	O
stability	O
and	O
high	O
dissolving	O
speed	O
,	O
solves	O
the	O
problem	O
of	O
low	O
content	O
of	O
high	O
solid	O
contents	O
of	O
the	O
soft	O
capsule	O
contents	O
prepared	O
from	O
water	O
-	O
soluble	O
solid	O
materials	O
,	O
ensures	O
that	O
the	O
content	O
of	O
the	O
water	O
-	O
soluble	O
solid	O
contents	O
in	O
the	O
soft	O
capsule	O
contents	O
is	O
improved	O
to	O
over	O
50	O
percent	O
by	O
weight	O
,	O
improves	O
the	O
efficacy	O
and	O
reduces	O
the	O
administration	O
dose	O
.	O

Meanwhile	O
,	O
no	O
emulsifying	O
agent	O
is	O
added	O
,	O
so	O
that	O
the	O
natural	O
attribute	O
of	O
products	O
can	O
be	O
ensured	O
.	O

Preparation	O
process	O
of	O
bone	O
peptide	O
soft	O
capsule	O

The	O
invention	O
provides	O
a	O
lansoprazole	B
-	O
contained	O
freeze	O
-	O
dried	O
powder	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
comprises	O
1	O
part	O
of	O
lansoprazole	B
,	O
0.05	O
-	O
50	O
parts	O
of	O
excipient	O
and	O
0.1	O
-	O
10	O
parts	O
of	O
polyethylene	B
glycol	I
;	O
the	O
preparation	O
method	O
of	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
weighing	O
the	O
lansoprazole	B
,	O
adding	O
into	O
water	O
for	O
injection	O
,	O
adding	O
a	O
pH	O
regulator	O
for	O
regulating	O
the	O
pH	O
value	O
of	O
a	O
solution	O
to	O
be	O
10	O
-	O
12.5	O
,	O
stirring	O
until	O
the	O
lansoprazole	B
in	O
the	O
solution	O
is	O
completely	O
dissolved	O
,	O
adding	O
the	O
polyethylene	B
glycol	I
and	O
the	O
excipient	O
,	O
adding	O
the	O
water	O
for	O
injection	O
until	O
reaching	O
the	O
whole	O
volume	O
,	O
quantitatively	O
filling	O
into	O
a	O
cillin	O
bottle	O
,	O
and	O
carrying	O
out	O
freeze	O
-	O
drying	O
;	O
and	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
can	O
simultaneously	O
solve	O
the	O
problem	O
of	O
stability	O
and	O
solubility	O
puzzling	O
the	O
preparation	O
and	O
has	O
good	O
redissolution	O
property	O
.	O

Lansoprazole	B
-	O
contained	O
freeze	O
-	O
dried	O
powder	O
injection	O

The	O
invention	O
discloses	O
application	O
of	O
perillene	B
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
medicaments	O
.	O

The	O
application	O
is	O
characterized	O
in	O
that	O
the	O
perillene	B
serving	O
as	O
an	O
anti	O
-	O
inflammatory	O
active	O
ingredient	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
are	O
prepared	O
into	O
various	O
medicinal	O
formulations	O
by	O
using	O
a	O
conventional	O
method	O
.	O

Application	O
of	O
perillene	B
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
medicaments	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
microsphere	O
composition	O
containing	O
an	O
antiparkinsonism	O
drug	O
to	O
preparation	O
of	O
a	O
medicine	O
for	O
preventing	O
and	O
treating	O
parkinson	O
diseases	O
and	O
complicating	O
diseases	O
of	O
parkinson	O
diseases	O
.	O

The	O
microsphere	O
composition	O
containing	O
the	O
antiparkinsonism	O
drug	O
is	O
selected	O
from	O
benserazide	O
microspheres	O
,	O
L	B
-	I
dopa	I
methyl	I
ester	I
microspheres	O
,	O
the	O
L	B
-	I
dopa	I
methyl	I
ester	I
microspheres	O
and	O
the	O
benserazide	B
microspheres	O
,	O
or	O
L	B
-	I
dopa	I
methyl	I
ester	I
and	O
benserazide	B
mixing	O
drug	O
microspheres	O
.	O

The	O
invention	O
also	O
provides	O
a	O
microsphere	O
combination	O
medicament	O
containing	O
the	O
antiparkinsonism	O
drug	O
.	O

The	O
invention	O
explores	O
novel	O
medical	O
application	O
for	O
the	O
microsphere	O
combination	O
medicament	O
containing	O
the	O
antiparkinsonism	O
drug	O
and	O
develops	O
a	O
novel	O
application	O
field	O
.	O

The	O
microsphere	O
combination	O
medicament	O
containing	O
the	O
antiparkinsonism	O
drug	O
of	O
the	O
invention	O
is	O
safe	O
and	O
nontoxic	O
,	O
has	O
strong	O
pharmacological	O
action	O
and	O
indicates	O
good	O
medicinal	O
prospect	O
.	O

Microsphere	O
combination	O
medicament	O
containing	O
antiparkinsonism	O
drug	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
weight	O
-	O
losing	O
medicament	O
formed	O
by	O
matching	O
alpha	B
-	I
ricinoleic	I
acid	I
ethyl	I
ester	I
with	O
berberine	B
,	O
which	O
can	O
be	O
used	O
as	O
a	O
medicament	O
or	O
food	O
for	O
treating	O
and	O
preventing	O
obesity	O
as	O
well	O
as	O
a	O
medicament	O
or	O
food	O
for	O
treating	O
and	O
preventing	O
diseases	O
relevant	O
with	O
the	O
obesity	O
.	O

The	O
weight	O
-	O
losing	O
medicament	O
is	O
formed	O
by	O
matching	O
the	O
alpha	B
-	I
ricinoleic	I
acid	I
ethyl	I
ester	I
with	O
the	O
berberine	B
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
alpha	B
-	I
ricinoleic	I
acid	I
ethyl	I
ester	I
to	O
the	O
berberine	B
is	O
9	O
-	O
1:1	O
;	O
the	O
content	O
of	O
alpha	B
-	I
ricinoleic	I
acid	I
in	O
the	O
alpha	B
-	I
ricinoleic	I
acid	I
ethyl	I
ester	I
is	O
more	O
than	O
or	O
equal	O
to	O
70	O
percent	O
;	O
and	O
the	O
consumption	O
of	O
the	O
berberine	B
is	O
0.3	O
-	O
2.0g	O
/	O
person	O
/	O
day	O
.	O

By	O
using	O
the	O
invention	O
,	O
the	O
deliberate	O
diet	O
can	O
be	O
avoided	O
and	O
the	O
weight	O
can	O
be	O
greatly	O
reduced	O
by	O
only	O
keeping	O
normal	O
living	O
habit	O
and	O
dietary	O
structure	O
;	O
and	O
meanwhile	O
,	O
the	O
invention	O
can	O
be	O
used	O
for	O
remarkably	O
reducing	O
various	O
indexes	O
of	O
serum	O
cholesterol	B
,	O
serum	O
tiglycerides	B
,	O
low	O
density	O
lipoprotein	O
cholesterin	B
,	O
apolipoprotein	O
B	O
and	O
the	O
like	O
accompanied	O
by	O
obese	O
people	O
.	O

In	O
front	O
of	O
the	O
trend	O
that	O
the	O
obese	O
people	O
accompanied	O
with	O
hyperlipidemia	O
derived	O
by	O
the	O
dietary	O
structure	O
gradually	O
increase	O
,	O
the	O
practical	O
significance	O
of	O
the	O
invention	O
is	O
predominant	O
.	O

Weight	O
-	O
losing	O
medicament	O
formed	O
by	O
matching	O
alpha	B
-	I
ricinoleic	I
acid	I
ethyl	I
ester	I
with	O
berberine	B

The	O
invention	O
relates	O
to	O
a	O
Corilagin	B
compound	O
,	O
in	O
particular	O
to	O
the	O
application	O
of	O
Corilagin	B
in	O
preparing	O
anti	O
-	O
tumor	O
drugs	O
.	O

The	O
chemical	O
name	O
of	O
Corilagin	B
is	O
1-O	B
-	I
trigalloyl-3,6-O	I
-	I
hexahydroxydiphenoyl	I
-	I
beta	I
-	I
D	I
-	I
glucose	I
,	O
and	O
the	O
molecular	O
formula	O
thereof	O
is	O
C27H22O18	B
.	O

The	O
anti	O
-	O
tumor	O
drug	O
for	O
oral	O
administration	O
or	O
injection	O
comprises	O
a	O
drug	O
resisting	O
the	O
tumor	O
growth	O
or	O
a	O
drug	O
resisting	O
tumor	O
invasionand	O
metastasis	O
,	O
wherein	O
the	O
injection	O
can	O
be	O
intravenous	O
injection	O
,	O
intramuscular	O
injection	O
,	O
intraperitoneal	O
injection	O
or	O
subcutaneous	O
injection	O
.	O

According	O
to	O
the	O
tests	O
,	O
the	O
Corilagin	B
achieves	O
good	O
anti	O
-	O
tumor	O
effect	O
,	O
more	O
particularly	O
,	O
the	O
Corilagin	B
achieves	O
good	O
curative	O
effect	O
in	O
both	O
in	O
-	O
vitro	O
tumor	O
cell	O
tests	O
and	O
in	O
-	O
vivo	O
tumor	O
animal	O
models	O
.	O

Therefore	O
,	O
the	O
Corilagin	B
as	O
a	O
novel	O
compound	O
achieving	O
the	O
anti	O
-	O
tumor	O
effect	O
is	O
applicable	O
in	O
preparing	O
anti	O
-	O
tumor	O
drugs	O
.	O

Application	O
of	O
Corilagin	B
in	O
preparing	O
anti	O
-	O
tumor	O
drugs	O

The	O
invention	O
discloses	O
a	O
cefuroxime	B
axetil	I
oral	O
liquid	O
,	O
comprising	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
280	O
-	O
350	O
parts	O
of	O
cefuroxime	B
axetil	I
,	O
50	O
-	O
100	O
parts	O
of	O
talcum	O
powders	O
,	O
10	O
-	O
50	O
parts	O
of	O
cross	O
-	O
linked	O
polyvinylpyrrolidone	B
and	O
3	O
-	O
4	O
parts	O
of	O
hydroxypropyl	O
methyl	O
cellulose	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
oral	O
liquid	O
.	O

The	O
cefuroxime	B
axetil	I
oral	O
liquid	O
of	O
the	O
inventionhas	O
good	O
stability	O
;	O
and	O
in	O
addition	O
,	O
the	O
dissolution	O
within	O
15	O
minutes	O
is	O
higher	O
than	O
80	O
%	O
of	O
that	O
of	O
labeled	O
amount	O
and	O
the	O
dissolution	O
within	O
45	O
minutes	O
is	O
higher	O
than	O
90	O
%	O
of	O
that	O
of	O
the	O
labeled	O
amount	O
.	O

Cefuroxime	B
axetil	I
oral	O
liquid	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
composite	O
capable	O
of	O
preventing	O
bacteria	O
,	O
viruses	O
,	O
oxidation	O
and	O
pigment	O
deposition	O
,	O
which	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
proportion	O
by	O
weight	O
:	O
0.1	O
-	O
10	O
of	O
epigallocatechin	B
gallate	I
(	O
EGCG	B
)	O
,	O
0	O
-	O
10	O
of	O
chlorogenic	B
acid	I
,	O
0	O
-	O
10	O
of	O
asiaticoside	B
and	O
0	O
-	O
10	O
of	O
ginkgolide	B
.	O

The	O
invention	O
also	O
discloses	O
application	O
of	O
the	O
composite	O
in	O
preparing	O
drugs	O
,	O
health	O
-	O
care	O
food	O
and	O
cosmetics	O
,	O
which	O
are	O
capable	O
of	O
preventing	O
bacteria	O
,	O
viruses	O
,	O
oxidation	O
and	O
pigment	O
deposition	O
.	O

The	O
composite	O
of	O
the	O
invention	O
has	O
favorable	O
safety	O
,	O
is	O
suitable	O
for	O
curing	O
respiratory	O
tract	O
infection	O
,	O
condyloma	O
acuminatum	O
,	O
herpes	O
progenitalis	O
,	O
chromatosis	O
and	O
other	O
diseases	O
,	O
simultaneously	O
has	O
anti	O
-	O
oxidation	O
and	O
skin	O
whitening	O
functions	O
,	O
protects	O
cells	O
and	O
DNA	O
from	O
being	O
damaged	O
,	O
can	O
prevent	O
and	O
cure	O
dementia	O
and	O
chloasma	O
,	O
and	O
also	O
can	O
be	O
used	O
for	O
cancer	O
adjuvant	O
therapy	O
.	O

Composite	O
capable	O
of	O
preventing	O
bacteria	O
,	O
viruses	O
,	O
oxidation	O
and	O
pigment	O
deposition	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
trifolin	B
in	O
preparing	O
drugs	O
for	O
treating	O
hyperlipidemia	O
,	O
particularly	O
the	O
drugs	O
for	O
treating	O
hyperlipidemia	O
by	O
lowering	O
serum	O
cholesterol	B
and	O
increasing	O
serum	O
high	O
-	O
density	O
lipoprotein	O
.	O

The	O
trifolin	B
has	O
obvious	O
curative	O
effect	O
.	O

In	O
addition	O
,	O
the	O
invention	O
further	O
discloses	O
an	O
application	O
of	O
the	O
trifolin	B
in	O
preparing	O
drugs	O
for	O
treating	O
acute	O
hyperlipidemia	O
,	O
and	O
further	O
provides	O
the	O
drugs	O
for	O
treating	O
the	O
disease	O
.	O

Application	O
of	O
trifolin	B

The	O
invention	O
discloses	O
a	O
composite	O
medicament	O
used	O
for	O
treating	O
herpes	O
zoster	O
.	O

The	O
composite	O
medicament	O
used	O
for	O
treating	O
the	O
herpes	O
zoster	O
is	O
composed	O
of	O
5	O
to	O
10	O
mL	O
of	O
2	O
percent	O
lidocaine	B
injection	O
,	O
0.5	O
to	O
1.0	O
mg	O
of	O
VitB12	B
injection	O
,	O
5	O
to	O
10	O
mg	O
of	O
dexamethasone	B
injection	O
and	O
1	O
to	O
2	O
mL	O
of	O
bacillus	O
calmette	O
guerin	O
polysaccharide	O
nucleic	O
acid	O
injection	O
.	O

The	O
medicament	O
is	O
used	O
for	O
point	O
injection	O
for	O
treating	O
the	O
herpes	O
zoster	O
.	O

The	O
medicament	O
has	O
the	O
characteristics	O
of	O
quick	O
response	O
,	O
small	O
dosage	O
,	O
safety	O
,	O
high	O
cure	O
rate	O
,	O
good	O
stability	O
and	O
small	O
harm	O
to	O
a	O
human	O
body	O
.	O

The	O
medicament	O
is	O
suitable	O
for	O
treating	O
the	O
herpes	O
zoster	O
.	O

Composite	O
medicament	O
used	O
for	O
treating	O
herpes	O
zoster	O

The	O
invention	O
discloses	O
new	O
polynucleotide	O
coding	O
the	O
human	O
protein	O
with	O
the	O
function	O
of	O
causing	O
mitochondrial	O
membrane	O
potential	O
decrease	O
and	O
polypeptide	O
coded	O
by	O
the	O
polynucleotide	O
and	O
an	O
antibody	O
of	O
the	O
polypeptide	O
.	O

The	O
invention	O
also	O
discloses	O
application	O
of	O
the	O
new	O
polynucleotide	O
in	O
causing	O
mitochondrial	O
membrane	O
potential	O
decrease	O
through	O
exogenous	O
expression	O
in	O
host	O
cells	O
.	O

Polynucleotide	O
related	O
to	O
mitochondrial	O
membrane	O
potential	O
decrease	O
and	O
coded	O
polypeptide	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
new	O
application	O
of	O
a	O
compound	O
,	O
in	O
particular	O
to	O
application	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
preventing	O
and	O
controlling	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
acute	O
liver	O
damage	O
.	O

A	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
inhibitor	O
has	O
the	O
advantages	O
of	O
preventing	O
LPS	O
-	O
induced	O
mice	O
acute	O
liver	O
damage	O
,	O
remarkably	O
reducing	O
the	O
phosphorylation	O
level	O
of	O
LPS	O
-	O
induced	O
PKD	O
,	O
lowering	O
death	O
rate	O
and	O
levels	O
of	O
alanine	B
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	B
transaminase	O
(	O
AST	O
)	O
,	O
improving	O
inflammatory	O
reaction	O
,	O
restraining	O
the	O
signal	O
channel	O
of	O
LPS	O
activated	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
p38MAPK	O
)	O
,	O
lowering	O
the	O
level	O
of	O
LPS	O
-	O
induced	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNK	O
-	O
alpha	O
)	O
,	O
reducing	O
the	O
apoptosis	O
number	O
of	O
hepatic	O
cells	O
,	O
the	O
activation	O
of	O
caspases	O
and	O
the	O
expression	O
level	O
of	O
hepatic	O
tissue	O
adhesion	O
molecules	O
and	O
lowering	O
the	O
activation	O
level	O
of	O
myeloperoxidase	O
(	O
MPO	O
)	O
.	O

Application	O
in	O
preparation	O
of	O
medicament	O
for	O
preventing	O
and	O
controlling	O
lipopolysaccharide	O
-	O
induced	O
acute	O
liver	O
damage	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
an	O
edema	O
disease	O
treatment	O
medicament	O
,	O
which	O
is	O
implemented	O
by	O
a	O
technical	O
scheme	O
that	O
:	O
the	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
impregnating	O
rhubarb	O
in	O
wine	O
for	O
4	O
hours	O
,	O
and	O
frying	O
-	O
drying	O
the	O
impregnated	O
rhubarb	O
without	O
burning	O
;	O
impregnating	O
gansui	O
root	O
in	O
the	O
wine	O
for	O
2	O
hour	O
,	O
and	O
frying	O
the	O
impregnated	O
gansui	O
root	O
to	O
yellowish	O
with	O
low	O
fire	O
;	O
and	O
placing	O
the	O
treated	O
rhubarb	O
,	O
the	O
treated	O
gansui	O
root	O
,	O
pharbitis	O
seeds	O
,	O
green	O
tangerine	O
peel	O
,	O
costustoot	O
and	O
calomel	O
into	O
a	O
crusher	O
for	O
crushing	O
,	O
and	O
grinding	O
the	O
crushing	O
product	O
into	O
fine	O
powder	O
of	O
200	O
meshes	O
.	O

The	O
edema	O
disease	O
treatment	O
medicament	O
is	O
taken	O
by	O
several	O
times	O
and	O
is	O
swallowed	O
with	O
plain	O
boiled	O
water	O
.	O

The	O
method	O
has	O
the	O
advantage	O
of	O
remarkably	O
improving	O
curative	O
effect	O
.	O

Edema	O
disease	O
treatment	O
medicament	O

The	O
invention	O
relates	O
to	O
N	B
-	I
substituted	I
benzenesulfonyl	I
-	I
substituted	I
benzamides	I
small	O
molecular	O
inhibitor	O
of	O
Bcl-2	O
protein	O
family	O
anti	O
-	O
apoptosis	O
members	O
and	O
application	O
thereof	O
.	O

The	O
invention	O
relates	O
to	O
N	B
-	I
substituted	I
benzenesulfonyl	I
-	I
substituted	I
benzamides	I
compounds	O
of	O
a	O
formula	O
I	O
for	O
inhibiting	O
Bcl-2	O
protein	O
family	O
anti	O
-	O
apoptosis	O
members	O
(	O
such	O
as	O
Bcl-2	O
,	O
Bcl	O
-	O
xL	O
,	O
Mcl-1	O
,	O
and	O
the	O
like	O
)	O
,	O
wherein	O
the	O
definition	O
of	O
each	O
group	O
is	O
disclosed	O
as	O
a	O
specification	O
for	O
details	O
.	O

The	O
compounds	O
(	O
and	O
stereoisomerides	O
thereof	O
if	O
exist	O
)	O
,	O
medicine	O
salts	O
,	O
hydrates	O
,	O
solvates	O
and	O
medicine	O
compositions	O
thereof	O
can	O
be	O
used	O
for	O
treating	O
diseases	O
or	O
symptoms	O
which	O
are	O
related	O
to	O
the	O
high	O
expression	O
of	O
the	O
Bcl-2	O
protein	O
family	O
anti	O
-	O
apoptosis	O
members	O
or	O
can	O
be	O
used	O
for	O
treating	O
tumors	O
or	O
can	O
be	O
used	O
as	O
a	O
synergistic	O
agent	O
which	O
is	O
combined	O
with	O
other	O
antineoplastics	O
for	O
treating	O
tumors	O
.	O

The	O
invention	O
also	O
relates	O
to	O
preparation	O
methods	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
I	O
and	O
the	O
medicine	O
salts	O
thereof	O
.	O

N	B
-	I
substituted	I
benzenesulfonyl	I
-	I
substituted	I
benzamides	I
small	O
molecular	O
inhibitor	O
of	O
Bcl-2	O
protein	O
and	O
application	O
thereof	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
,	O
R1	O
is	O
optionally	O
substituted	O
pyrazolyl	B
,	O
and	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
herein	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
the	O
compounds	O
for	O
treating	O
diseases	O
associated	O
with	O
P2X3	O
and/or	O
a	O
P2X2	O
/	O
3	O
receptor	O
antagonists	O
and	O
methods	O
of	O
making	O
the	O
compounds	O
.	O

Novel	O
pyrazole	B
-	I
substituted	I
arylamides	I

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
medicinal	O
particles	O
by	O
using	O
a	O
wet	O
-	O
method	O
mixer	O
granulator	O
,	O
in	O
particular	O
to	O
a	O
method	O
for	O
preparing	O
taurine	B
particles	O
by	O
using	O
the	O
wet	O
-	O
method	O
mixer	O
granulator	O
.	O

The	O
method	O
comprises	O
:	O
adding	O
taurine	B
in	O
an	O
amount	O
which	O
is	O
20	O
to	O
30	O
percent	O
(	O
w	O
/	O
w	O
)	O
based	O
on	O
the	O
total	O
weight	O
of	O
pure	O
water	O
and	O
pulping	O
quickly	O
to	O
obtain	O
paste	O
,	O
and	O
using	O
the	O
pulp	O
with	O
a	O
viscosity	O
of	O
300	O
to	O
400Pa.s	O
as	O
a	O
binding	O
agent	O
in	O
the	O
preparation	O
of	O
the	O
taurine	B
particles	O
by	O
using	O
the	O
wet	O
-	O
method	O
mixer	O
granulator	O
.	O

The	O
taurine	B
particles	O
are	O
uniform	O
in	O
size	O
,	O
compact	O
and	O
smooth	O
and	O
are	O
mainly	O
40	O
to	O
80	O
mesh	O
spherical	O
particles	O
which	O
account	O
for	O
85	O
percent	O
of	O
the	O
total	O
particles	O
.	O

Compared	O
with	O
a	O
method	O
for	O
preparing	O
the	O
taurine	B
particles	O
by	O
spray	O
drying	O
,	O
the	O
method	O
has	O
the	O
advantages	O
that	O
:	O
the	O
production	O
process	O
is	O
simple	O
;	O
the	O
energy	O
consumption	O
is	O
low	O
;	O
and	O
the	O
obtained	O
taurine	O
particles	O
are	O
mainly	O
40	O
to	O
80	O
mesh	O
spherical	O
particles	O
with	O
high	O
flowability	O
.	O

Method	O
for	O
preparing	O
taurine	B
particles	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
dermatophytosis	O
,	O
which	O
is	O
prepared	O
from	O
rice	O
vinegar	O
,	O
medicinal	O
alcohol	B
,	O
iodophor	B
,	O
manchurian	O
wildginger	O
,	O
borneol	B
,	O
alum	O
,	O
ketoconazole	B
and	O
distilled	O
water	O
serving	O
as	O
raw	O
materials	O
.	O

The	O
medicament	O
has	O
the	O
characteristics	O
of	O
addressing	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
along	O
with	O
simple	O
preparation	O
,	O
convenient	O
use	O
,	O
high	O
curative	O
effect	O
,	O
no	O
side	O
effect	O
,	O
low	O
cost	O
,	O
short	O
treatment	O
course	O
,	O
definite	O
curative	O
effect	O
on	O
dermatophytosis	O
and	O
tinea	O
manuum	O
which	O
are	O
caused	O
by	O
fungi	O
and	O
total	O
effective	O
rate	O
of	O
98	O
percent	O
.	O

Medicament	O
for	O
treating	O
dermatophytosis	O
and	O
preparation	O
method	O
thereof	O

Compounds	O
of	O
the	O
following	O
formula	O
are	O
provided	O
for	O
use	O
with	O
kinases	O
:	O
(	O
I	O
)	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
kits	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
compounds	O
;	O
methods	O
and	O
intermediates	O
useful	O
for	O
making	O
the	O
compounds	O
;	O
and	O
methods	O
of	O
using	O
said	O
compounds	O
.	O

POLO	O
-	O
like	O
kinase	O
inhibitors	O

Compounds	O
of	O
general	O
structure	O
in	O
which	O
X	O
and	O
Y	O
are	O
each	O
N	B
or	O
C	B
with	O
at	O
least	O
one	O
of	O
X	O
and	O
Y	O
being	O
N	B
;	O
Z	O
is	O
a	O
single	O
bond	O
or	O
an	O
optionally	O
substituted	O
linking	O
group	O
R1	O
is	O
hydrogen	B
or	O
a	O
substituent	O
group	O
;	O
R2	O
is	O
amino	B
or	O
a	O
substituent	O
group	O
;	O
N	O
*	O
is	O
amino	B
when	O
RI	O
is	O
hydrogen	B
or	O
=	B
NH	I
when	O
R1	O
is	O
a	O
substituent	O
group	O
;	O
or	O
N	O
*	O
is	O
a	O
group	O
NRaRb	B
where	O
Ra	O
and	O
Rb	O
are	O
independently	O
H	B
or	O
an	O
alkyl	B
group	O
;	O
or	O
N	O
*	O
is	O
an	O
optionally	O
substituted	O
piperazinyl	B
ring	O
;	O
and	O
A	O
is	O
an	O
optionally	O
substituted	O
heterocyclic	B
or	O
carbocyclic	B
ring	O
system	O
which	O
may	O
be	O
linked	O
to	O
the	O
triazo	B
/	O
diazo	B
ring	O
through	O
R2	O
to	O
form	O
a	O
fused	O
multicyclic	O
ring	O
;	O
are	O
indicated	O
as	O
suitable	O
for	O
treatment	O
of	O
disorders	O
in	O
mammals	O
that	O
are	O
susceptible	O
to	O
sodium	B
channel	O
blockers	O
and	O
antifolates	O
,	O
and	O
particularly	O
disorders	O
such	O
epilepsy	O
,	O
multiple	O
sclerosis	O
,	O
glaucoma	O
and	O
uevitis	O
,	O
cerebral	O
traumas	O
and	O
cerebral	O
ischaemias	O
,	O
stroke	O
,	O
head	O
injury	O
,	O
spinal	O
cord	O
injury	O
,	O
surgical	O
trauma	O
,	O
neurodegenerative	O
disorders	O
,	O
motorneurone	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
chronic	O
inflammatory	O
pain	O
,	O
neuropathic	O
pain	O
,	O
migraine	O
,	O
bipolar	O
disorder	O
,	O
mood	O
,	O
anxiety	O
and	O
cognitive	O
disorders	O
,	O
schizophrenia	O
and	O
trigeminal	O
autonomic	O
cephalalgias	O
;	O
for	O
treatment	O
of	O
mammalian	O
cancers	O
;	O
and	O
for	O
treatment	O
of	O
malaria	O
.	O

Cyclic	O
triazo	B
and	O
diazo	B
sodium	I
channel	O
blockers	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
of	O
compound	O
liposoluble	O
vitamins	O
,	O
comprising	O
vitamin	B
A	I
,	O
vitamin	B
D2	I
,	O
vitamin	B
E	I
,	O
vitamin	B
K1	I
and	O
a	O
metal	O
ion	O
chelant	O
(	O
such	O
as	O
edetate	B
)	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
made	O
into	O
an	O
injection	O
emulsion	O
,	O
preferably	O
solve	O
the	O
problem	O
that	O
degradation	O
products	O
are	O
generated	O
because	O
the	O
active	O
constituents	O
(	O
such	O
as	O
the	O
vitamin	B
D2	I
and	O
the	O
vitaminK1	B
)	O
are	O
oxidized	O
in	O
the	O
preparation	O
and	O
sterilization	O
processes	O
,	O
and	O
ensure	O
the	O
safety	O
of	O
clinical	O
administration	O
.	O

Method	O
for	O
inhibiting	O
content	O
decrease	O
of	O
Vit	B
K1	I
after	O
sterilization	O

The	O
invention	O
discloses	O
an	O
immunosuppressive	O
agent	O
of	O
an	O
advanced	O
higher	O
fatty	B
acid	I
derivative	O
,	O
comprising	O
a	O
compound	O
I	O
,	O
i.e.	O
CH3	B
(	I
CH2	I
)	I
m1CH	I
=	I
CH	I
(	I
CH2	I
)	I
n1COR	I
,	O
a	O
compound	O
II	O
,	O
i.e.	O
CH3	B
(	I
CH2	I
)	I
m2CH	I
=	I
CH	I
(	I
CH2	I
)	I
n2CH	I
=	I
CH	I
(	I
CH2	I
)	I
X1COR	I
,	O
a	O
compound	O
III	O
,	O
i.e.	O
CH3	B
(	I
CH2	I
)	I
m3CH	I
=	I
CH	I
(	I
CH2	I
)	I
n3CH	I
=	I
CH	I
(	I
CH2	I
)	I
x2CH	I
=	I
CH	I
(	I
CH2	I
)	I
yCOR	I
,	O
a	O
compound	O
IV	O
,	O
i.e.	O
CH3	B
(	I
CH2	I
)	I
zCOR	I
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
one	O
or	O
combination	O
of	O
a	O
solvate	O
or	O
a	O
hydrate	O
.	O

The	O
immunosuppressive	O
agent	O
is	O
suitable	O
for	O
treating	O
or	O
preventing	O
mammal	O
patient	O
diseases	O
,	O
treating	O
mammal	O
inflammation	O
diseases	O
,	O
mammal	O
anaphylactic	O
reaction	O
diseases	O
,	O
mammal	O
T	O
-	O
cell	O
,	O
leukemia	O
and	O
T	O
-	O
cell	O
lymphoma	O
,	O
and	O
mammal	O
diseases	O
,	O
and	O
inhibiting	O
immune	O
response	O
of	O
animals	O
suffering	O
from	O
autoimmunity	O
diseases	O
,	O
inflammatory	O
disorders	O
or	O
graft	O
versus	O
host	O
diseases	O
,	O
and	O
has	O
low	O
toxicity	O
and	O
controllable	O
side	O
effects	O
.	O

Immunosuppressive	O
agent	O
of	O
advanced	O
higher	O
fatty	B
acid	I
derivative	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
new	O
use	O
of	O
total	O
aglycone	O
of	O
gleditsia	O
sinensis	O
in	O
the	O
preparation	O
of	O
alpha	O
-	O
glucosidase	O
inhibitor	O
drugs	O
.	O

The	O
total	O
aglycone	O
of	O
the	O
gleditsia	O
sinensis	O
is	O
prepared	O
by	O
alkalization	O
extraction	O
,	O
acid	O
hydrolysis	O
and	O
purification	O
by	O
addition	O
of	O
active	O
carbon	B
and	O
so	O
on	O
.	O

The	O
obtained	O
total	O
aglycone	O
of	O
the	O
gleditsia	O
sinensis	O
is	O
used	O
for	O
activity	O
research	O
of	O
the	O
alpha	O
-	O
glucosidase	O
inhibitor	O
,	O
and	O
the	O
effect	O
is	O
good	O
.	O

Application	O
of	O
total	O
aglycone	O
of	O
Gleditsia	O
sinensis	O
Lam	O
in	O
preparation	O
of	O
alpha	O
-	O
glucosidase	O
inhibitor	O
drugs	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medical	O
technology	O
,	O
in	O
particular	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
cancer	O
treatment	O
,	O
which	O
consists	O
of	O
anti	O
-	O
angiogenesis	O
drug	O
Avastin	B
and	O
autophagy	O
inhibitor	O
chloroquine	B
.	O

When	O
in	O
use	O
,	O
Avastin	B
and	O
chloroquine	B
are	O
mixed	O
according	O
to	O
respective	O
dose	O
,	O
wherein	O
the	O
doses	O
of	O
Avastin	B
and	O
chloroquine	B
are	O
respectively	O
7.6mg	O
/	O
kg	O
and	O
60mg	O
/	O
kg	O
calculated	O
according	O
to	O
weight	O
.	O

Animal	O
experimental	O
results	O
show	O
that	O
the	O
pharmaceutical	O
composition	O
can	O
obviously	O
inhibit	O
the	O
growth	O
of	O
skin	O
cancer	O
and	O
liver	O
cancer	O
cells	O
in	O
mice	O
,	O
and	O
the	O
effect	O
of	O
inhabiting	O
tumors	O
is	O
obviously	O
higher	O
than	O
that	O
of	O
solely	O
using	O
Avastin	B
or	O
chloroquine	B
,	O
thus	O
illustrating	O
that	O
the	O
Avastin	B
and	O
the	O
chloroquine	B
have	O
the	O
function	O
of	O
synergistic	O
inhibition	O
on	O
tumor	O
growth	O
,	O
therefore	O
,	O
the	O
pharmaceutical	O
composition	O
can	O
be	O
used	O
for	O
treating	O
tumors	O
.	O

Pharmaceutical	O
composition	O
for	O
cancer	O
treatment	O

The	O
invention	O
discloses	O
a	O
compound	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
which	O
has	O
the	O
structural	O
general	O
formula	O
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
selected	O
from	O
any	O
one	O
of	O
the	O
following	O
radicals	O
:	O
alkyl	B
or	O
substituted	O
alkyl	B
containing	O
1	O
-	O
3	O
carbon	B
atoms	O
or	O
phenyl	B
;	O
the	O
phenyl	B
can	O
be	O
substituted	O
by	O
any	O
one	O
or	O
more	O
same	O
or	O
different	O
following	O
radicals	O
:	O
H	B
,	O
halogen	B
,	O
C1-C6	O
linear	O
chain	O
or	O
branched	O
chain	O
alkyl	B
,	O
hydroxyl	B
,	O
C1-C4	B
alkoxy	I
,	O
C1-C4	O
unsaturated	O
oxyl	O
,	O
carboxyl	B
,	O
carboxyl	B
substituted	O
C1-C6	O
saturated	O
or	O
unsaturated	O
alkyl	B
,	O
cyan	B
,	O
nitryl	B
,	O
amino	B
,	O
trifluoromethyl	B
,	O
trifluoromethoxy	B
,	O
sulfydryl	B
and	O
C1-C4	B
acyl	I
;	O
R2	O
is	O
selected	O
from	O
H	B
or	O
-ZR1	O
substituent	O
;	O
R3	O
is	O
selected	O
from	O
H	B
,	O
nitryl	B
,	O
trifluoromethyl	B
,	O
amino	B
or	O
methoxyl	B
;	O
X	O
and	O
Y	O
are	O
respectively	O
selected	O
from	O
N	B
or	O
CH	B
independently	O
;	O
Z	O
is	O
selected	O
from	O
N	B
or	O
O	B
;	O
and	O
n	O
is	O
equal	O
to	O
0	O
or	O
1	O
.	O

Preparation	O
of	O
substituted	O
nitrogen	B
-	O
containing	O
benzoheterocycle	B
derivatives	O
and	O
pharmacological	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
in	O
-	O
situ	O
gel	O
preparation	O
of	O
potassium	B
dehydroandrographolide	I
succinate	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
is	O
prepared	O
from	O
potassium	B
dehydroandrographolide	I
succinate	I
(	O
dehydration	O
andrographolide	B
butanedioic	I
acid	I
ester	I
single	O
sylvite	O
half	O
)	O
,	O
in	O
-	O
site	O
gel	O
substrates	O
recognized	O
in	O
the	O
field	O
,	O
and	O
other	O
pharmaceutic	O
adjuvants	O
necessary	O
for	O
other	O
pharmacy	O
by	O
using	O
water	O
as	O
a	O
solvent	O
.	O

In	O
-	O
situ	O
gel	O
of	O
potassium	B
dehydroandrographolide	I
succinate	I
is	O
liquid	O
freely	O
moving	O
outside	O
a	O
body	O
,	O
and	O
forms	O
semisolid	O
gel	O
after	O
patients	O
take	O
the	O
gel	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
of	O
definite	O
effect	O
,	O
stable	O
performance	O
,	O
simple	O
preparation	O
,	O
convenient	O
administration	O
,	O
strong	O
compliance	O
for	O
patients	O
,	O
no	O
toxic	O
and	O
side	O
effect	O
,	O
no	O
untoward	O
effect	O
,	O
high	O
bioavailability	O
,	O
and	O
on	O
the	O
like	O
.	O

The	O
in	O
-	O
situ	O
gel	O
preparation	O
has	O
good	O
antipyretic	O
and	O
antiinflammatory	O
action	O
,	O
can	O
be	O
used	O
for	O
clinically	O
treating	O
viral	O
respiratory	O
tract	O
infection	O
and	O
viral	O
pneumonia	O
,	O
can	O
be	O
used	O
as	O
alternative	O
medicine	O
for	O
potassium	B
dehydroandrographolide	I
succinate	I
injection	O
,	O
and	O
is	O
particularly	O
suitable	O
for	O
infants	O
and	O
patients	O
who	O
have	O
trouble	O
in	O
taking	O
medicine	O
.	O

In	O
-	O
situ	O
gel	O
preparation	O
of	O
potassium	B
dehydroandrographolide	I
succinate	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
quality	O
control	O
method	O
of	O
Xinnaoqing	O
soft	O
capsules	O
,	O
comprising	O
the	O
steps	O
of	O
qualitative	O
testing	O
and	O
quantitative	O
testing	O
.	O

The	O
method	O
is	O
characterized	O
in	O
that	O
the	O
quantitative	O
testing	O
is	O
carried	O
out	O
on	O
the	O
content	O
of	O
linoleic	B
acid	I
in	O
the	O
drugs	O
by	O
utilizing	O
gas	O
chromatography	O
.	O

The	O
content	O
of	O
the	O
linoleic	B
acid	I
in	O
each	O
granule	O
is	O
not	O
less	O
than	O
0.249	O
g	O
.	O

The	O
method	O
is	O
high	O
in	O
precision	O
,	O
good	O
in	O
repeatability	O
and	O
strong	O
in	O
stability	O
and	O
controls	O
the	O
stability	O
of	O
the	O
quality	O
of	O
the	O
Xinnaoqing	O
soft	O
capsules	O
by	O
determining	O
the	O
content	O
of	O
the	O
linoleic	B
acid	I
in	O
the	O
soft	O
capsules	O
.	O

Quality	O
control	O
method	O
of	O
Xinnaoqing	O
soft	O
capsules	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
medicament	O
for	O
treating	O
impotence	O
and	O
premature	O
ejaculation	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
soaking	O
fructus	O
psoraleae	O
,	O
poria	O
,	O
semen	O
allii	O
tuberosi	O
tuber	O
onion	O
seeds	O
,	O
paenoiae	O
alba	O
,	O
whole	O
Chinese	O
angelica	O
and	O
radix	O
glycyrrhizae	O
preparata	O
into	O
table	O
vinegar	O
;	O
putting	O
the	O
mixture	O
into	O
a	O
boiler	O
to	O
boil	O
dry	O
the	O
vinegar	O
;	O
and	O
drying	O
and	O
grinding	O
the	O
medicament	O
to	O
make	O
pills	O
.	O

The	O
medicament	O
has	O
a	O
good	O
curative	O
effect	O
on	O
kidney	O
deficiency	O
,	O
impotence	O
,	O
premature	O
ejaculation	O
and	O
spermatorrhea	O
,	O
and	O
the	O
effect	O
is	O
very	O
significant	O
.	O

Preparation	O
method	O
of	O
medicament	O
for	O
treating	O
impotence	O
and	O
premature	O
ejaculation	O

The	O
invention	O
discloses	O
a	O
specific	O
dermatophytosis	O
cream	O
medicament	O
,	O
which	O
is	O
paste	O
for	O
external	O
application	O
.	O

The	O
paste	O
comprises	O
main	O
elements	O
including	O
chloromycetin	B
,	O
prednisone	B
and	O
hexadecadrol	B
(	O
in	O
a	O
ratio	O
of	O
5	O
:	O
1	O
:	O
1	O
)	O
and	O
auxiliary	O
materials	O
(	O
which	O
are	O
incredible	O
in	O
formula	O
theory	O
,	O
but	O
hasve	O
a	O
very	O
good	O
treatment	O
effect	O
)	O
including	O
glycerin	B
and	O
a	O
proper	O
amount	O
of	O
transdermal	O
agent	O
.	O

According	O
to	O
an	O
action	O
principle	O
-	O
based	O
formula	O
,	O
sterilizing	O
anti	O
-	O
infectious	O
elements	O
in	O
the	O
formula	O
together	O
with	O
the	O
glycerin	B
and	O
the	O
transdermal	O
agent	O
in	O
the	O
auxiliary	O
materials	O
quickly	O
seep	O
into	O
skin	O
tissues	O
to	O
sterilize	O
germs	O
,	O
moisturize	O
skin	O
,	O
promote	O
the	O
union	O
and	O
recovery	O
of	O
ulcer	O
skin	O
and	O
restore	O
immunity	O
.	O

The	O
specific	O
dermatophytosis	O
cream	O
medicament	O
is	O
applied	O
to	O
the	O
following	O
symptoms	O
of	O
:	O
dermatophytosis	O
(	O
athlete	O
's	O
foot	O
)	O
peeling	O
and	O
pus	O
,	O
blisters	O
,	O
foot	O
tickle	O
and	O
foot	O
odor	O
.	O

The	O
using	O
method	O
of	O
the	O
specific	O
dermatophytosis	O
cream	O
medicament	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
washing	O
feet	O
with	O
hot	O
water	O
,	O
drying	O
feet	O
,	O
and	O
coating	O
the	O
paste	O
on	O
infected	O
parts	O
for	O
3	O
to	O
5	O
times	O
a	O
day	O
.	O

Serious	O
patients	O
can	O
restore	O
health	O
in	O
2	O
to	O
3	O
days	O
.	O

The	O
specific	O
dermatophytosis	O
cream	O
medicament	O
has	O
the	O
advantages	O
that	O
:	O
the	O
ulcer	O
face	O
can	O
restore	O
to	O
health	O
completely	O
in	O
a	O
week	O
and	O
is	O
thoroughly	O
cured	O
without	O
recrudescence	O
;	O
and	O
the	O
specific	O
dermatophytosis	O
cream	O
medicament	O
has	O
the	O
same	O
curing	O
effect	O
on	O
re	O
-	O
infection	O
.	O

Specific	O
dermatophytosis	O
cream	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
fat	O
-	O
soluble	O
vitamin	O
freeze	O
-	O
dried	O
powder	O
injection	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
a	O
)	O
adopting	O
a	O
process	O
formula	O
;	O
(	O
b	O
)	O
adding	O
main	O
medicaments	O
according	O
to	O
a	O
certain	O
order	O
and	O
mixing	O
the	O
medicaments	O
;	O
(	O
c	O
)	O
uniformly	O
mixing	O
vitamin	B
D	I
and	O
a	O
left	O
amount	O
of	O
tween-80	B
and	O
combining	O
the	O
mixture	O
with	O
mixed	O
solution	O
in	O
step	O
(	O
6	O
)	O
;	O
(	O
d	O
)	O
controlling	O
the	O
water	O
temperature	O
at	O
2	O
to	O
8	O
DEG	O
C	O
,	O
adding	O
propylene	B
glycol	I
,	O
stirring	O
the	O
solution	O
for	O
dissolving	O
the	O
propylene	B
glycol	I
for	O
further	O
use	O
;	O
(	O
e	O
)	O
mixing	O
two	O
kinds	O
of	O
standby	O
solution	O
,	O
regulating	O
the	O
pH	O
to	O
6.7	O
to	O
7.2	O
,	O
adding	O
activated	O
carbon	B
,	O
adsorbing	O
,	O
decarbonizing	O
,	O
finely	O
filtering	O
and	O
charging	O
separately	O
;	O
(	O
f	O
)	O
,	O
performing	O
freeze	O
-	O
drying	O
,	O
wherein	O
according	O
to	O
a	O
freeze	O
-	O
drying	O
curve	O
,	O
in	O
a	O
pre	O
-	O
freezing	O
period	O
,	O
the	O
temperature	O
is	O
kept	O
for	O
3	O
hours	O
at	O
the	O
temperature	O
of	O
-40	O
DEG	O
C	O
;	O
in	O
a	O
sublimation	O
period	O
,	O
the	O
temperature	O
is	O
raised	O
to	O
-15	O
DEG	O
C	O
,	O
the	O
temperature	O
is	O
kept	O
for	O
10	O
hours	O
and	O
indoor	O
pressure	O
is	O
kept	O
between	O
10	O
and	O
20	O
Pa	O
;	O
and	O
after	O
the	O
sublimation	O
,	O
the	O
temperature	O
of	O
the	O
product	O
is	O
raised	O
to	O
5	O
to	O
8	O
DEG	O
C	O
and	O
the	O
temperature	O
is	O
kept	O
for	O
10	O
hours	O
;	O
and	O
(	O
g	O
)	O
performing	O
vacuum	O
pressure	O
plugging	O
after	O
the	O
freeze	O
-	O
drying	O
.	O

The	O
method	O
ensures	O
the	O
stability	O
of	O
main	O
medicament	O
component	O
and	O
improves	O
product	O
quality	O
;	O
moreover	O
,	O
unpredictable	O
side	O
effects	O
caused	O
by	O
various	O
auxiliary	O
materials	O
can	O
be	O
avoided	O
due	O
to	O
the	O
reduction	O
of	O
the	O
variety	O
and	O
using	O
amount	O
of	O
the	O
used	O
auxiliary	O
materials	O
.	O

Method	O
for	O
preparing	O
fat	O
-	O
soluble	O
vitamin	O
freeze	O
-	O
dried	O
powder	O
injection	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmacy	O
and	O
particularly	O
relates	O
to	O
minocycline	O
hydrochloride	B
sustained	O
-	O
release	O
tablets	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
with	O
different	O
specifications	O
.	O

The	O
sustained	O
release	O
tablets	O
consist	O
of	O
minocycline	O
hydrochloride	B
,	O
a	O
diluting	O
agent	O
,	O
a	O
disintegrating	O
agent	O
,	O
an	O
adhesive	O
,	O
a	O
retarding	O
agent	O
,	O
a	O
lubricant	O
and	O
a	O
coating	O
material	O
.	O

An	O
actual	O
test	O
indicates	O
that	O
the	O
prescription	O
has	O
high	O
process	O
adaptability	O
and	O
is	O
not	O
affected	O
by	O
ambient	O
temperature	O
,	O
humidity	O
and	O
hardness	O
,	O
sustained	O
-	O
release	O
performance	O
is	O
difficultly	O
affected	O
by	O
tableting	O
pressure	O
,	O
formulations	O
with	O
different	O
specifications	O
can	O
be	O
prepared	O
through	O
the	O
same	O
intermediate	O
,	O
the	O
problem	O
that	O
the	O
formulations	O
of	O
the	O
ordinary	O
sustained	O
-	O
release	O
tablets	O
are	O
difficultly	O
divided	O
is	O
solved	O
and	O
the	O
sustained	O
-	O
release	O
tablets	O
of	O
45	O
and	O
115	O
mg	O
can	O
be	O
prepared	O
so	O
as	O
to	O
adapt	O
to	O
patients	O
with	O
different	O
weights	O
.	O

Minocycline	O
hydrochloride	B
sustained	O
-	O
release	O
tablets	O
and	O
method	O
for	O
preparing	O
same	O
with	O
different	O
specifications	O

The	O
invention	O
discloses	O
a	O
preparation	O
of	O
gene	O
immunization	O
treating	O
tumor	O
used	O
for	O
veins	O
,	O
which	O
is	O
composed	O
of	O
replication	O
deficient	O
adenovirus	O
loading	O
human	O
telomerase	O
reverse	O
transcriptase	O
C	O
-	O
terminal	O
polypeptide	O
hTERTC27	O
and	O
an	O
acceptable	O
pharmaceutic	O
adjuvant	O
.	O

The	O
anti	O
-	O
tumor	O
gene	O
preparation	O
rAdv	O
-	O
hTERTC27	O
of	O
the	O
invention	O
has	O
high	O
transfection	O
efficiency	O
,	O
and	O
is	O
more	O
effective	O
on	O
the	O
increment	O
and	O
the	O
apoptosis	O
regulation	O
of	O
the	O
tumor	O
cell	O
.	O

The	O
anti	O
-	O
tumor	O
gene	O
preparation	O
of	O
the	O
invention	O
can	O
effectively	O
lead	O
the	O
peptides	O
transfection	O
to	O
enter	O
into	O
the	O
dendritic	O
cell	O
DCs	O
,	O
so	O
as	O
to	O
activate	O
the	O
DCs	O
,	O
secrete	O
IFN	O
-	O
gamma	O
,	O
IL-2	O
,	O
increase	O
and	O
further	O
stimulate	O
T	O
lymphopoiesis	O
,	O
promote	O
the	O
T	O
lymphocyte	O
to	O
generate	O
the	O
special	O
killing	O
effect	O
CTL	O
corresponding	O
to	O
the	O
tumor	O
cell	O
,	O
and	O
immunoregulation	O
is	O
carried	O
out	O
on	O
the	O
tumor	O
.	O

Preparation	O
of	O
gene	O
immunization	O
treating	O
tumor	O
used	O
for	O
vein	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
tylosin	B
tartrate	I
microspheres	O
.	O

The	O
method	O
uses	O
gelatin	O
as	O
the	O
carrier	O
,	O
liquid	O
paraffin	O
and	O
Span-80	B
as	O
the	O
oil	O
phase	O
,	O
and	O
glutaraldehyde	B
as	O
the	O
crosslinking	O
agent	O
to	O
prepare	O
tylosin	B
tartrate	I
microspheres	O
.	O

The	O
tylosin	B
tartrate	I
microspheres	O
prepared	O
by	O
the	O
invention	O
use	O
gelatin	O
as	O
the	O
carrier	O
material	O
,	O
have	O
no	O
adverse	O
reactions	O
and	O
no	O
immunogenicity	O
,	O
have	O
biodegradability	O
and	O
wide	O
application	O
range	O
and	O
can	O
be	O
taken	O
by	O
mouth	O
or	O
through	O
injection	O
.	O

liquid	O
paraffin	O
and	O
Span-80	B
are	O
used	O
as	O
the	O
oil	O
phase	O
,	O
thus	O
increasing	O
the	O
drug	O
-	O
loading	O
rate	O
and	O
the	O
encapsulation	O
rate	O
,	O
facilitating	O
the	O
crosslinking	O
and	O
curing	O
of	O
glutaraldehyde	B
,	O
prolonging	O
the	O
elimination	O
half	O
life	O
of	O
the	O
microsphere	O
medicine	O
and	O
performing	O
drug	O
controlled	O
release	O
in	O
animals	O
.	O

In	O
addition	O
,	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
has	O
simple	O
operation	O
,	O
the	O
adopted	O
reagent	O
is	O
common	O
,	O
the	O
preparation	O
cost	O
is	O
lower	O
and	O
the	O
method	O
is	O
easy	O
to	O
popularize	O
and	O
apply	O
.	O

Preparation	O
method	O
of	O
tylosin	B
tartrate	I
microspheres	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
vitamin	B
A	I
microcapsule	O
encapsulation	O
system	O
by	O
secondary	O
emulsification	O
and	O
a	O
spray	O
drying	O
method	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
microencapsulation	O
of	O
protection	O
and	O
controlled	O
release	O
of	O
a	O
biologically	O
active	O
functional	O
substance	O
.	O

Vitamin	B
A	I
is	O
taken	O
as	O
a	O
core	O
material	O
and	O
amphoteric	O
lecithin	B
is	O
used	O
as	O
a	O
direct	O
emulsification	O
and	O
encapsulation	O
core	O
;	O
fish	O
skin	O
gelatin	O
with	O
antioxidation	O
,	O
arabic	O
gum	O
and	O
corn	O
protein	O
are	O
used	O
for	O
secondary	O
emulsification	O
and	O
encapsulation	O
;	O
and	O
vitamin	B
A	I
microcapsules	O
with	O
encapsulation	O
rate	O
of	O
90	O
to	O
93	O
percent	O
are	O
prepared	O
by	O
using	O
hot	O
-	O
blast	O
spray	O
drying	O
.	O

In	O
the	O
process	O
,	O
the	O
secondary	O
emulsification	O
process	O
and	O
an	O
antioxidant	O
wall	O
material	O
are	O
adopted	O
,	O
so	O
that	O
a	O
good	O
encapsulation	O
effect	O
is	O
achieved	O
,	O
and	O
oxidation	O
and	O
deterioration	O
of	O
the	O
vitamin	B
A	I
are	O
suppressed	O
.	O

Method	O
for	O
preparing	O
vitamin	B
A	I
microcapsules	O
by	O
secondary	O
emulsification	O
and	O
spray	O
drying	O
method	O

The	O
invention	O
relates	O
to	O
an	O
injection	O
medicament	O
,	O
in	O
particular	O
to	O
a	O
medicament	O
for	O
emasculating	O
sows	O
.	O

The	O
medicament	O
for	O
emasculating	O
the	O
sows	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
:	O
medroxyprogesterone	B
acetate	I
,	O
vitamin	B
C	I
injection	O
,	O
vitamin	B
B12	I
injection	O
and	O
cleaning	O
agent	O
.	O

Thus	O
,	O
the	O
medicament	O
has	O
the	O
advantages	O
of	O
high	O
emasculation	O
applicability	O
,	O
stress	O
reduction	O
,	O
no	O
infection	O
,	O
no	O
mortality	O
rate	O
,	O
obvious	O
emasculation	O
effect	O
,	O
low	O
dosage	O
and	O
low	O
cost	O
,	O
and	O
can	O
increase	O
the	O
economic	O
benefits	O
of	O
sow	O
raisers	O
.	O

Compared	O
with	O
the	O
traditional	O
surgical	O
emasculation	O
method	O
,	O
the	O
medicament	O
can	O
save	O
more	O
time	O
and	O
labor	O
and	O
increase	O
the	O
rate	O
of	O
liveweight	O
growth	O
.	O

Besides	O
,	O
the	O
pork	O
from	O
the	O
slaughtered	O
sow	O
has	O
fresh	O
color	O
and	O
good	O
taste	O
,	O
and	O
the	O
mouth	O
feel	O
of	O
the	O
pork	O
is	O
not	O
reduced	O
.	O

Medicament	O
for	O
emasculating	O
sows	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
for	O
preparation	O
containing	O
glucosamine	B
and	O
an	O
application	O
thereof	O
.	O

The	O
preparation	O
is	O
characterized	O
in	O
that	O
the	O
major	O
component	O
is	O
one	O
or	O
the	O
combination	O
of	O
more	O
of	O
the	O
glucosamine	B
,	O
glucosamine	B
hydrochloride	I
,	O
glucosamine	B
sulfate	I
sodium	I
chloride	I
double	O
salt	O
or	O
potassium	B
chloride	I
double	O
salt	O
,	O
and	O
chondroitin	B
sulfate	I
.	O

The	O
preparation	O
method	O
is	O
simple	O
,	O
convenient	O
and	O
time	O
-	O
saving	O
to	O
operate	O
and	O
is	O
easy	O
for	O
large	O
industrialized	O
production	O
.	O

Preparation	O
method	O
for	O
preparation	O
containing	O
glucosamine	B
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
solid	O
fragrant	O
anti	O
-	O
dizziness	O
agent	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
solid	O
fragrant	O
anti	O
-	O
dizziness	O
agent	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
mass	O
:	O
0.75	O
to	O
1.50	O
percent	O
of	O
anti	O
-	O
dizziness	O
essence	O
,	O
0.50	O
to	O
1.50	O
percent	O
of	O
solid	O
air	O
freshening	O
glue	O
,	O
8.00	O
to	O
10.00	O
percent	O
of	O
high	O
-	O
efficiency	O
solubilizing	O
agent	O
,	O
0.40	O
to	O
0.60	O
percent	O
of	O
preservative	O
and	O
the	O
balance	O
of	O
distilled	O
water	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
four	O
steps	O
of	O
:	O
blending	O
the	O
anti	O
-	O
dizziness	O
essence	O
,	O
solubilizing	O
the	O
anti	O
-	O
dizziness	O
essence	O
,	O
preparing	O
a	O
gel	O
and	O
mixing	O
the	O
anti	O
-	O
dizziness	O
essence	O
and	O
the	O
gel	O
.	O

Because	O
natural	O
essential	O
oil	O
is	O
taken	O
as	O
the	O
main	O
raw	O
material	O
of	O
the	O
anti	O
-	O
dizziness	O
essence	O
component	O
,	O
the	O
solid	O
fragrant	O
anti	O
-	O
dizziness	O
agent	O
is	O
a	O
purely	O
natural	O
,	O
nontoxic	O
,	O
harmless	O
and	O
safe	O
product	O
;	O
in	O
addition	O
,	O
because	O
the	O
solid	O
fragrant	O
anti	O
-	O
dizziness	O
agent	O
also	O
comprises	O
components	O
such	O
as	O
lavender	O
oil	O
and	O
the	O
like	O
,	O
the	O
solid	O
fragrant	O
anti	O
-	O
dizziness	O
agent	O
can	O
emit	O
fresh	O
and	O
soft	O
flower	O
and	O
grass	O
fragrance	O
and	O
bring	O
fresh	O
and	O
fragrant	O
aroma	O
to	O
the	O
air	O
,	O
can	O
continuously	O
give	O
off	O
pleasant	O
aroma	O
for	O
5	O
to	O
8	O
days	O
even	O
in	O
a	O
normal	O
environment	O
and	O
is	O
environmental	O
-	O
friendly	O
.	O

Solid	O
fragrant	O
anti	O
-	O
dizziness	O
agent	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
antineoplastic	O
compound	O
,	O
antineoplastic	O
application	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
has	O
a	O
structure	O
as	O
shown	O
in	O
general	O
formula	O
1	O
,	O
and	O
an	O
in	O
-	O
vitro	O
antineoplastic	O
experiment	O
on	O
the	O
compound	O
indicates	O
that	O
the	O
compounds	O
have	O
obvious	O
inhibiting	O
effect	O
on	O
tested	O
tumor	O
cell	O
strains	O
,	O
can	O
induce	O
the	O
apoptosis	O
of	O
tumor	O
cells	O
and	O
have	O
fewer	O
side	O
effects	O
on	O
the	O
gastrointestinal	O
tract	O
compared	O
with	O
the	O
traditional	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
salt	O
containing	O
at	O
least	O
one	O
of	O
the	O
compounds	O
or	O
formed	O
by	O
the	O
compounds	O
and	O
physiologically	O
acceptable	O
inorganic	B
acid	I
or	O
organic	B
acid	I
of	O
the	O
compounds	O
or	O
,	O
if	O
appropriate	O
,	O
a	O
pharmaceutical	O
excipient	O
and/or	O
diluter	O
or	O
an	O
excipient	O
.	O

The	O
invention	O
also	O
relates	O
to	O
an	O
administration	O
dosage	O
form	O
of	O
the	O
compound	O
containing	O
at	O
least	O
one	O
of	O
the	O
compounds	O
of	O
the	O
structural	O
formula	O
and	O
salts	O
thereof	O
,	O
which	O
includes	O
tablet	O
,	O
capsule	O
,	O
solution	O
or	O
ampoule	O
for	O
infusion	O
,	O
suppository	O
,	O
patch	O
,	O
respirable	O
powder	O
preparation	O
,	O
suspensions	O
,	O
emulsifiable	O
paste	O
or	O
ointment	O
.	O

Thus	O
,	O
the	O
compound	O
1	O
can	O
have	O
favorable	O
application	O
prospects	O
.	O

Novel	O
antineoplastic	O
compound	O

The	O
invention	O
discloses	O
a	O
sinomenine	B
derivative	O
and	O
a	O
synthesis	O
method	O
and	O
aapplications	O
thereof	O
,	O
wherein	O
halogen	B
,	O
carbon	B
-	O
carbon	B
double	O
bond	O
substituent	O
and	O
isoxazoline	B
heterocyclic	B
ring	O
substituent	O
are	O
introduced	O
to	O
the	O
1-site	O
of	O
the	O
sinomenine	B
ring	O
A.	O
When	O
the	O
sinomenine	B
derivative	O
is	O
prepared	O
,	O
sinomenine	B
is	O
used	O
as	O
the	O
matrix	O
and	O
the	O
synthesis	O
technology	O
containing	O
microfluidic	O
synthesis	O
is	O
adopted	O
to	O
perform	O
Heck	O
reaction	O
and	O
1,3-dipolar	O
cycloaddition	O
reaction	O
on	O
the	O
1-site	O
of	O
sinomenine	O
and	O
generate	O
the	O
sinomenine	O
derivative	O
.	O

The	O
obtained	O
compound	O
has	O
better	O
anti	O
-	O
inflammatory	O
activity	O
and	O
is	O
potential	O
to	O
be	O
used	O
for	O
curing	O
arthritis	O
and	O
rheumatoid	O
arthritis	O
and	O
used	O
in	O
the	O
anti	O
-	O
inflammatory	O
medicines	O
thereof	O
.	O

Sinomenine	B
derivative	O
and	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
invention	O
discloses	O
a	O
formula	O
composition	O
of	O
Beiai	O
lecithin	O
soft	O
capsule	O
and	O
a	O
preparation	O
method	O
of	O
the	O
lecithin	O
soft	O
capsule	O
.	O

Total	O
1000	O
g	O
of	O
the	O
lecithin	O
soft	O
capsule	O
comprises	O
the	O
following	O
components	O
:	O
400	O
g	O
of	O
soya	O
bean	O
lecithin	O
,	O
200	O
g	O
of	O
red	O
yeast	O
rice	O
,	O
and	O
400	O
g	O
of	O
soybean	O
oil	O
.	O

After	O
raw	O
materials	O
and	O
auxiliary	O
materials	O
are	O
tested	O
to	O
be	O
qualified	O
,	O
the	O
soya	O
bean	O
lecithin	O
,	O
the	O
red	O
yeast	O
rice	O
and	O
the	O
soybean	O
oil	O
are	O
evenly	O
mixed	O
according	O
to	O
the	O
formula	O
,	O
and	O
are	O
ground	O
three	O
times	O
by	O
a	O
colloid	O
mill	O
to	O
obtain	O
contents	O
for	O
later	O
use	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
dissolving	O
glue	O
,	O
producing	O
pellets	O
,	O
airing	O
the	O
pellets	O
,	O
washing	O
the	O
pellets	O
,	O
airing	O
the	O
pellets	O
again	O
,	O
picking	O
up	O
the	O
pellets	O
,	O
and	O
warehousing	O
finished	O
products	O
.	O

The	O
lecithin	O
soft	O
capsule	O
is	O
suitable	O
for	O
the	O
fields	O
of	O
food	O
,	O
medicine	O
and	O
health	O
care	O
products	O
,	O
and	O
is	O
used	O
for	O
auxiliary	O
antiatheroscloresis	O
.	O

Lecithin	O
soft	O
capsule	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
for	O
treating	O
type	O
2	O
diabetes	O
of	O
mammals	O
including	O
human	O
beings	O
,	O
particularly	O
a	O
medicinal	O
composition	O
prepared	O
by	O
mixing	O
(	B
R	I
)	I
-7-	I
[	I
3-amino-4-	I
(	I
2,4,5-trifluoro	I
-	I
phenyl	I
)	I
-butyryl	I
]	I
-3-trifluoromethyl-5,6,7,8,-tetrahydro	I
-	I
imidazo	I
[	I
1,5-a	I
]	I
-carboxylic	I
methyl	I
ether	I
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
rosiglitazone	B
or	O
pioglitazone	B
or	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
rosiglitazone	B
or	O
pioglitazone	B
in	O
fixed	O
dose	O
ratio	O
,	O
a	O
method	O
for	O
preparing	O
the	O
medicinal	O
composition	O
,	O
and	O
application	O
of	O
the	O
medicinal	O
composition	O
to	O
treating	O
type	O
2	O
diabetes	O
in	O
mammals	O
including	O
human	O
beings	O
.	O

Medicainal	O
composition	O
for	O
treating	O
type	O
2	O
diabetes	O
of	O
mammals	O
including	O
human	O
beings	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
composite	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
drug	O
composite	O
comprises	O
the	O
following	O
components	O
:	O
a	O
)	O
one	O
of	O
isoquinoline	B
composites	O
and	O
b	O
)	O
one	O
or	O
the	O
mixture	O
of	O
two	O
of	O
hyaluronate	B
or	O
hyaluronic	B
acid	I
derivative	O
.	O

The	O
composite	O
of	O
the	O
invention	O
can	O
be	O
used	O
for	O
preparing	O
drug	O
preparations	O
which	O
are	O
taken	O
in	O
a	O
non	O
-	O
oral	O
may	O
,	O
is	O
especially	O
used	O
for	O
preparing	O
the	O
drug	O
preparations	O
for	O
treating	O
relevant	O
diseases	O
in	O
the	O
partial	O
administration	O
of	O
articular	O
cavity	O
and	O
posterior	O
segment	O
eye	O
and	O
has	O
the	O
characteristics	O
of	O
good	O
treatment	O
effect	O
and	O
less	O
toxic	O
and	O
side	O
effects	O
.	O

Drug	O
composite	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
vitamin	B
B	I
complex	O
injection	O
for	O
treating	O
porcine	O
indigestion	O
and	O
a	O
preparation	O
method	O
and	O
aims	O
to	O
provide	O
a	O
vitamin	B
B	I
complex	O
injection	O
which	O
is	O
used	O
for	O
treating	O
porcine	O
indigestion	O
,	O
has	O
quick	O
response	O
to	O
clinic	O
symptom	O
,	O
addresses	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
and	O
is	O
convenient	O
to	O
take	O
and	O
a	O
preparation	O
method	O
thereof	O
which	O
has	O
a	O
simple	O
process	O
and	O
is	O
easy	O
to	O
implement	O
.	O

Every	O
100	O
L	O
of	O
injection	O
comprises	O
the	O
following	O
components	O
by	O
weight	O
:	O
0.5	O
to	O
2	O
kilograms	O
of	O
vitamin	B
B1	I
,	O
250	O
to	O
300	O
grams	O
of	O
vitamin	B
B	I
,	O
50	O
to	O
500	O
grams	O
of	O
vitamin	B
B6	I
,	O
0.5	O
to	O
3	O
kilograms	O
of	O
niacinamide	B
,	O
5	O
to	O
100	O
grams	O
of	O
sodium	B
dextropantothenate	I
,	O
5	O
to	O
100	O
grams	O
of	O
methacholine	B
chloride	I
formyl	I
,	O
2	O
kilograms	O
of	O
Twain-80	O
,	O
20	O
grams	O
of	O
sodium	B
hydroxide	I
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
injection	O
of	O
the	O
invention	O
takes	O
effect	O
from	O
multiple	O
aspects	O
through	O
reasonable	O
mixing	O
of	O
a	O
plurality	O
of	O
medicaments	O
,	O
has	O
the	O
advantages	O
of	O
addressing	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
,	O
rapidly	O
solving	O
clinical	O
symptoms	O
caused	O
by	O
the	O
porcine	O
indigestion	O
,	O
along	O
with	O
quick	O
response	O
to	O
the	O
treatment	O
of	O
the	O
porcine	O
indigestion	O
,	O
speediness	O
and	O
effectiveness	O
,	O
and	O
can	O
make	O
up	O
adverse	O
effects	O
caused	O
by	O
long	O
-	O
term	O
treatment	O
.	O

The	O
injection	O
of	O
the	O
invention	O
is	O
convenient	O
to	O
use	O
.	O

Vitamin	B
B	I
complex	O
injection	O
for	O
treating	O
porcine	O
indigestion	O
and	O
preparation	O
method	O

The	O
invention	O
belongs	O
to	O
the	O
fields	O
of	O
drugs	O
and	O
chemical	O
industry	O
,	O
and	O
discloses	O
a	O
quinazoline	B
derivative	O
and	O
a	O
preparation	O
method	O
thereof	O
and	O
an	O
application	O
of	O
the	O
quinazoline	B
derivative	O
used	O
as	O
an	O
anticancer	O
drug	O
.	O

The	O
structural	O
formula	O
of	O
the	O
quinazoline	B
derivative	O
is	O
shown	O
in	O
the	O
specifications	O
,	O
wherein	O
R1	O
is	O
NH	B
(	I
CH2	I
)	I
mNR5	I
or	O
NH	B
(	I
CH2	I
)	I
m	I
-	I
Ar	I
;	O
R2	O
is	O
NHCO	B
(	I
CH2	I
)	I
n	I
NR5	I
,	O
NHCO	B
(	I
CH2	I
)	I
n	I
-	I
Ar	I
,	O
NHCO	B
(	I
CH2	I
)	I
nNH	I
(	I
CH2	I
)	I
nNR5	I
or	O
NHCO	B
(	I
CH2	I
)	I
nNH	I
(	I
CH2	I
)	I
n	I
-	I
Ar	I
;	O
R3	O
is	O
F	B
,	O
Cl	B
,	O
Br	B
,	O
I	B
,	O
H	B
,	O
CH3	B
,	O
SO2CH3	B
or	O
OCH3	B
;	O
R4	O
is	O
H	B
,	O
NHCO	B
(	I
CH2	I
)	I
nNR5	I
,	O
NHCO	B
(	I
CH2	I
)	I
n	I
-	I
Ar	I
,	O
NHCO	B
(	I
CH2	I
)	I
nNH	I
(	I
CH2	I
)	I
nNR5	I
or	O
NHCO	B
(	I
CH2	I
)	I
nNH	I
(	I
CH2	I
)	I
n	I
-	I
Ar	I
;	O
-Ar	B
represents	O
various	O
aromatic	B
rings	O
comprising	O
various	O
aromatic	B
heterocyclic	I
rings	O
;	O
m	O
is	O
equal	O
to	O
2	O
,	O
3	O
or	O
4	O
;	O
n	O
is	O
equal	O
to	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
or	O
5	O
;	O
and	O
R5	O
represents	O
alkyl	B
of	O
C1	O
-	O
6	O
,	O
cycloalkyl	B
of	O
C3	O
-	O
6	O
,	O
piperidyl	B
,	O
morpholinyl	B
,	O
piperazinyl	B
or	O
quinoxalinyl	B
.	O

The	O
invention	O
simultaneously	O
discloses	O
the	O
preparation	O
method	O
of	O
the	O
quinazoline	B
derivative	O
and	O
the	O
application	O
of	O
the	O
quinazoline	B
derivative	O
used	O
as	O
the	O
anticancer	O
drug	O
.	O

The	O
experiment	O
proves	O
that	O
the	O
quinazoline	B
derivative	O
of	O
the	O
invention	O
has	O
strong	O
inhibiting	O
effect	O
on	O
telomere	O
DNA	O
expression	O
,	O
has	O
obvious	O
inhibiting	O
effect	O
on	O
various	O
kinds	O
of	O
cancer	O
cell	O
strains	O
,	O
has	O
low	O
toxicity	O
to	O
normal	O
cells	O
,	O
and	O
has	O
wide	O
application	O
prospects	O
in	O
preparation	O
of	O
anticancer	O
drugs	O
.	O

Quinazoline	B
derivative	O
and	O
preparation	O
method	O
thereof	O
and	O
application	O
of	O
quinazoline	B
derivative	O
for	O
preparing	O
anticancer	O
drugs	O

The	O
invention	O
discloses	O
a	O
9-	B
(	I
4-beta	I
-	I
D-	I
allopyranosyloxy	I
-	I
phenyl	I
)	I
-decahydroacridine-1,8-diketone	I
as	O
helicidum	B
derivatives	O
,	O
shown	O
in	O
a	O
structural	O
formula	O
.	O

In	O
the	O
structural	O
formula	O
,	O
R1	O
is	O
methyl	B
,	O
ethyl	B
,	O
n	B
-	I
propyl	I
,	O
phenyl	B
or	O
p	B
-	I
methylphenyl	I
,	O
and	O
R2	O
is	O
hydrogen	B
or	O
methyl	B
.	O

The	O
compounds	O
have	O
enhanced	O
sedative	O
hypnotic	O
activity	O
and	O
longer	O
duration	O
of	O
efficacy	O
compared	O
with	O
helicid	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
9-	B
(	I
4-beta	I
-	I
D	I
-	I
allopyranosyloxy	I
-	I
phenyl	I
)	I
-decahydroacridine-1,8-diketone	I
.	O

9-	B
(	I
4-beta	I
-	I
D-	I
allopyranosyloxy	I
-	I
phenyl	I
)	I
-decahydroacridine-1,8-diketone	I
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
veterinary	B
doxycycline	I
hydrochloride	I
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

100	O
ml	O
of	O
injection	O
mainly	O
comprises	O
the	O
following	O
components	O
by	O
weight	O
:	O
10	O
to	O
30	O
g	O
of	O
doxycycline	B
hydrochloride	I
,	O
1	O
to	O
3	O
g	O
of	O
complexant	O
,	O
1	O
to	O
5	O
g	O
of	O
cosolvent	O
,	O
0.5	O
to	O
1	O
g	O
of	O
antioxidant	O
,	O
10	O
to	O
30	O
g	O
of	O
antibacterial	O
synergist	O
,	O
30	O
to	O
60	O
g	O
of	O
organic	O
solvent	O
,	O
5	O
to	O
10	O
g	O
of	O
triethanolamine	B
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

In	O
the	O
veterinary	O
doxycycline	B
hydrochloride	I
injection	O
of	O
the	O
invention	O
,	O
methoxybenzylaminopyrimidine	B
compounds	O
and	O
sodium	B
sulfate	I
or	O
sodium	B
sulfite	I
serving	O
as	O
synergists	O
are	O
adopted	O
to	O
be	O
combined	O
with	O
the	O
doxycycline	O
hydrochloride	O
so	O
as	O
to	O
improve	O
the	O
complexation	O
degree	O
of	O
the	O
doxycycline	O
hydrochloride	O
and	O
the	O
complexant	O
,	O
reduce	O
the	O
temperature	O
of	O
complex	O
reaction	O
,	O
and	O
improve	O
the	O
stability	O
of	O
the	O
doxycycline	B
hydrochloride	I
;	O
and	O
the	O
methoxybenzylaminopyrimidine	B
adopted	O
by	O
the	O
invention	O
is	O
a	O
synergist	O
,	O
can	O
extend	O
the	O
maintenance	O
time	O
of	O
effective	O
blood	O
concentration	O
,	O
improve	O
pharmacodynamic	O
action	O
time	O
,	O
and	O
avoid	O
stress	O
and	O
inconvenience	O
due	O
to	O
repeated	O
medicament	O
administration	O
by	O
a	O
veterinarian	O
.	O

Veterinary	O
doxycycline	B
hydrochloride	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
the	O
antitumor	O
medicine	O
and	O
provides	O
an	O
amide	O
compound	O
with	O
the	O
structure	O
shown	O
in	O
the	O
general	O
formula	O
I	O
and	O
salts	O
thereof	O
which	O
are	O
acceptable	O
in	O
pharmacy	O
,	O
wherein	O
the	O
detailed	O
definitions	O
of	O
R1	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
determined	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
discloses	O
medical	O
composites	O
using	O
the	O
compound	O
or	O
the	O
salts	O
thereof	O
which	O
are	O
acceptable	O
in	O
pharmacy	O
,	O
as	O
the	O
active	O
ingredient	O
and	O
the	O
applications	O
thereof	O
in	O
the	O
aspect	O
of	O
the	O
antitumor	O
medicine	O
.	O

Amide	O
compound	O
and	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
bacterial	O
infections	O
.	O

Because	O
their	O
mechanism	O
of	O
action	O
does	O
not	O
involve	O
killing	O
of	O
bacteria	O
or	O
inhibiting	O
their	O
growth	O
,	O
the	O
potential	O
for	O
these	O
compounds	O
to	O
induce	O
drug	O
resistance	O
in	O
bacteria	O
is	O
minimized	O
.	O

Through	O
inhibiting	O
bacterial	O
virulence	O
,	O
the	O
present	O
invention	O
provides	O
a	O
novel	O
means	O
of	O
treating	O
bacterial	O
infections	O
.	O

Methods	O
of	O
inhibiting	O
bacterial	O
virulence	O
and	O
compounds	O
relating	O
thereto	O

The	O
invention	O
relates	O
to	O
the	O
prescription	O
of	O
a	O
blood	O
circulation	O
invigorating	O
and	O
pain	O
stopping	O
plaster	O
and	O
a	O
preparation	O
method	O
.	O

The	O
plaster	O
mainly	O
comprises	O
1	O
to	O
100	O
parts	O
of	O
sailong	O
bone	O
,	O
1	O
to	O
100	O
parts	O
of	O
saffron	O
,	O
1	O
to	O
100	O
parts	O
of	O
snow	O
lotus	O
herb	O
,	O
1	O
to	O
500	O
parts	O
of	O
magnetite	B
,	O
1	O
to	O
5	O
bags	O
of	O
spontaneous	O
heating	O
elements	O
,	O
a	O
piece	O
of	O
medical	O
proof	O
fabric	O
,	O
an	O
isolation	O
layer	O
and	O
proper	O
amounts	O
of	O
medicinal	O
auxiliary	O
materials	O
.	O

The	O
plaster	O
integrates	O
hot	O
compress	O
,	O
magnet	O
therapy	O
and	O
medication	O
,	O
is	O
used	O
for	O
alleviating	O
and	O
treating	O
the	O
symptoms	O
of	O
pains	O
,	O
swelling	O
and	O
the	O
like	O
caused	O
by	O
the	O
diseases	O
of	O
gout	O
,	O
rheumatoid	O
arthritis	O
,	O
painful	O
swelling	O
from	O
knocks	O
and	O
falls	O
,	O
lumbar	O
muscle	O
strain	O
,	O
acute	O
or	O
chronic	O
sprain	O
and	O
bruise	O
,	O
scapulohumeral	O
periarthritis	O
,	O
stiffneck	O
,	O
irregular	O
menstruation	O
,	O
hyperplasia	O
of	O
mammary	O
glands	O
and	O
the	O
like	O
,	O
and	O
is	O
suitable	O
for	O
clinical	O
popularization	O
and	O
application	O
.	O

Prescription	O
of	O
blood	O
circulation	O
invigorating	O
and	O
pain	O
stopping	O
plaster	O
and	O
preparation	O
method	O

The	O
invention	O
discloses	O
a	O
composition	O
for	O
treating	O
infection	O
of	O
pseudomonas	O
aeruginosa	O
in	O
chicken	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
aiming	O
to	O
provide	O
a	O
composition	O
for	O
treating	O
the	O
infection	O
of	O
pseudomonas	O
aeruginosa	O
in	O
chicken	O
,	O
which	O
is	O
capable	O
of	O
reducing	O
the	O
drug	O
resistance	O
rate	O
of	O
bacteria	O
and	O
addressing	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
composition	O
consists	O
of	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
4	O
to	O
12	O
percent	O
of	O
gentamycin	B
sulfate	I
,	O
4	O
to	O
8	O
percent	O
of	O
amoxicillin	B
,	O
4	O
to	O
8	O
percent	O
of	O
sodium	B
carbonate	I
,	O
10	O
to	O
30	O
percent	O
of	O
analginum	B
,	O
and	O
the	O
balance	O
of	O
anhydrous	O
dextrose	O
.	O

In	O
the	O
composition	O
,	O
the	O
gentamycin	B
sulfate	I
and	O
the	O
amoxicillin	B
are	O
synergized	O
to	O
kill	O
pseudomonas	O
aeruginosa	O
,	O
can	O
reduce	O
the	O
occurrence	O
probability	O
of	O
pathogeny	O
drug	O
resistance	O
,	O
and	O
increase	O
the	O
sensitivity	O
of	O
pathogeny	O
to	O
the	O
composition	O
;	O
the	O
sodium	B
carbonate	I
has	O
the	O
effect	O
of	O
solubilizing	O
the	O
amoxicillin	B
,	O
and	O
can	O
improve	O
the	O
antibacterial	O
effect	O
of	O
the	O
gentamycin	B
sulfate	I
;	O
and	O
the	O
analginum	O
has	O
the	O
effect	O
of	O
defervescence	O
and	O
anti	O
-	O
inflammatory	O
.	O

The	O
composition	O
has	O
the	O
functions	O
of	O
killing	O
the	O
pathogency	O
,	O
effectively	O
resisting	O
pathogenic	O
bacteria	O
and	O
clinical	O
symptoms	O
caused	O
by	O
the	O
pathogenic	O
bacteria	O
,	O
addressing	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
,	O
effectively	O
treating	O
the	O
infection	O
of	O
pseudomonas	O
aeruginosa	O
in	O
chicken	O
,	O
and	O
reducing	O
the	O
pathogeny	O
drug	O
resistance	O
by	O
reasonable	O
compatibility	O
of	O
the	O
components	O
.	O

The	O
composition	O
can	O
be	O
dissolved	O
in	O
water	O
,	O
and	O
is	O
convenient	O
to	O
use	O
.	O

Composition	O
for	O
treating	O
infection	O
of	O
pseudomonas	O
aeruginosa	O
in	O
chicken	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
for	O
resisting	O
thrombus	O
.	O

Clopidogrel	B
,	O
nicotinic	B
acid	I
and	O
statin	O
are	O
used	O
as	O
medicinal	O
active	O
ingredients	O
;	O
and	O
certain	O
auxiliary	O
materials	O
of	O
specific	O
categories	O
and	O
proportions	O
are	O
added	O
into	O
the	O
medicinal	O
active	O
ingredients	O
to	O
prepare	O
and	O
develop	O
an	O
oral	O
preparation	O
according	O
to	O
the	O
technical	O
means	O
stated	O
by	O
the	O
invention	O
.	O

The	O
composition	O
is	O
used	O
for	O
treating	O
and/or	O
preventing	O
heart	O
cerebrovascular	O
diseases	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicaments	O
.	O

Medicinal	O
composition	O
for	O
resisting	O
thrombus	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
stye	O
,	O
which	O
is	O
characterized	O
by	O
mainly	O
being	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
20	O
parts	O
of	O
rose	O
,	O
1	O
-	O
20	O
parts	O
of	O
seville	O
orange	O
flower	O
,	O
1	O
-	O
20	O
parts	O
of	O
angelica	O
longicaudata	O
,	O
1	O
-	O
20	O
parts	O
of	O
thunberg	O
fritillary	O
bulb	O
,	O
1	O
-	O
20	O
parts	O
of	O
radix	O
sophorae	O
flavescentis	O
,	O
1	O
-	O
20	O
parts	O
of	O
honeysuckle	O
,	O
1	O
-	O
20	O
parts	O
of	O
dried	O
orange	O
peel	O
,	O
1	O
-	O
20	O
parts	O
of	O
liquorice	O
and	O
1	O
-	O
20	O
parts	O
of	O
more	O
than	O
95	O
percent	O
of	O
edible	O
ethanol	B
.	O

The	O
medicament	O
can	O
be	O
absorbed	O
by	O
spleen	O
and	O
stomach	O
through	O
oral	O
administration	O
,	O
absorbed	O
by	O
skin	O
by	O
external	O
application	O
and	O
compositely	O
absorbed	O
in	O
two	O
ways	O
of	O
oral	O
administration	O
and	O
external	O
application	O
.	O

The	O
medicament	O
has	O
the	O
advantages	O
of	O
reasonable	O
prescription	O
,	O
precise	O
and	O
simple	O
matching	O
,	O
obvious	O
curative	O
effectand	O
treatment	O
focusing	O
on	O
relieving	O
both	O
the	O
secondary	O
and	O
primary	O
symptoms	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
medicament	O
.	O

Medicament	O
for	O
treating	O
stye	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
externally	O
used	O
medicament	O
for	O
treating	O
warts	O
,	O
corns	O
and	O
naevi	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
with	O
salycilic	B
acid	I
,	O
wheat	O
flour	O
of	O
last	O
year	O
,	O
glacial	B
acetic	I
acid	I
,	O
lithospermum	O
and	O
clove	O
oil	O
as	O
raw	O
materials	O
,	O
crushing	O
the	O
salycilic	B
acid	I
and	O
the	O
wheat	O
flour	O
of	O
last	O
year	O
into	O
120-mesh	O
ultrafine	O
medicinal	O
powder	O
,	O
and	O
blending	O
uniformly	O
;	O
taking	O
the	O
clove	O
oil	O
and	O
the	O
lithospermum	O
,	O
boiling	O
the	O
clove	O
oil	O
in	O
a	O
copper	B
pan	O
,	O
adding	O
the	O
lithospermum	O
,	O
frying	O
for	O
10	O
-	O
15	O
min	O
,	O
and	O
removing	O
the	O
lithospermum	O
to	O
obtain	O
lithospermum	O
oil	O
for	O
later	O
use	O
;	O
and	O
uniformly	O
blending	O
the	O
salycilic	B
acid	I
,	O
the	O
wheat	O
flour	O
of	O
last	O
year	O
,	O
the	O
lithospermum	O
oil	O
and	O
the	O
glacial	B
acetic	I
acid	I
to	O
obtain	O
the	O
externally	O
used	O
medicament	O
.	O

The	O
externally	O
used	O
medicament	O
has	O
the	O
advantages	O
that	O
the	O
salycilic	B
acid	I
and	O
the	O
glacial	B
acetic	I
acid	I
with	O
good	O
effects	O
of	O
dispelling	O
tubercules	O
and	O
dissolving	O
cuticle	O
act	O
on	O
patients	O
,	O
and	O
the	O
strong	O
acidity	O
of	O
the	O
salycilic	B
acid	I
and	O
the	O
glacial	B
acetic	I
acid	I
is	O
buffered	O
through	O
the	O
channel	O
regulating	O
and	O
blood	O
circulation	O
activating	O
effects	O
of	O
the	O
wheat	O
flour	O
of	O
last	O
year	O
so	O
as	O
to	O
alleviate	O
the	O
side	O
effect	O
of	O
the	O
externally	O
used	O
medicament	O
.	O

The	O
clove	O
oil	O
and	O
the	O
lithospermum	O
have	O
the	O
functions	O
of	O
stopping	O
pain	O
,	O
cooling	O
blood	O
,	O
activating	O
blood	O
circulation	O
and	O
moisturizing	O
the	O
skin	O
,	O
and	O
the	O
lithospermum	O
can	O
enhance	O
the	O
pain	O
stopping	O
effect	O
when	O
being	O
used	O
together	O
with	O
the	O
clove	O
oil	O
.	O

The	O
combination	O
of	O
multiple	O
medicinal	O
materials	O
can	O
achieve	O
the	O
effects	O
of	O
dispelling	O
pathogens	O
,	O
activating	O
blood	O
circulation	O
,	O
removing	O
blood	O
stasis	O
,	O
stopping	O
pain	O
,	O
accelerating	O
skin	O
healing	O
and	O
promoting	O
skin	O
regeneration	O
and	O
has	O
good	O
actions	O
on	O
body	O
building	O
and	O
face	O
beautification	O
.	O

Externally	O
used	O
medicament	O
for	O
treating	O
warts	O
,	O
corns	O
and	O
naevi	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
docosahexaenoic	B
acid	I
(	I
DHA	I
)	I
ester	I
fat	O
emulsion	O
intravenous	O
injection	O
and	O
a	O
manufacturing	O
method	O
thereof	O
.	O

The	O
DHA	B
ester	O
fat	O
emulsion	O
intravenous	O
injection	O
comprises	O
the	O
raw	O
materials	O
of	O
DHA	B
(	I
docosahexaenoic	I
acid	I
)	I
ester	I
,	O
lecithin	B
,	O
glycerol	B
,	O
aseptic	O
pure	O
water	O
,	O
antioxidant	O
,	O
stabilizer	O
,	O
pH	O
regulator	O
and	O
the	O
like	O
,	O
and	O
the	O
manufacturing	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
under	O
the	O
protection	O
of	O
nitrogen	B
,	O
mixing	O
the	O
raw	O
materials	O
,	O
violently	O
stirring	O
,	O
shearing	O
at	O
high	O
speed	O
into	O
an	O
initial	O
emulsion	O
,	O
then	O
emulsifying	O
by	O
a	O
high	O
-	O
pressure	O
homogenizer	O
,	O
filtering	O
by	O
a	O
microporous	O
membrane	O
filter	O
,	O
filling	O
,	O
sealing	O
and	O
sterilizing	O
to	O
obtain	O
the	O
DHA	B
ester	I
fat	O
emulsion	O
intravenous	O
injection	O
.	O

The	O
used	O
DHA	B
ester	I
is	O
DHA	B
methyl	I
ester	I
,	O
DHA	B
ethyl	I
ester	I
,	O
DHA	B
ehtylene	I
,	O
DHA	B
propylene	I
and	O
DHA	B
triglyceride	I
,	O
and	O
the	O
content	O
of	O
DHA	B
is	O
greater	O
than	O
90	O
%	O
.	O

The	O
DHA	B
ester	I
fat	O
emulsion	O
intravenous	O
injection	O
is	O
used	O
in	O
the	O
fields	O
of	O
medical	O
treatment	O
and	O
health	O
,	O
and	O
can	O
be	O
supplied	O
for	O
parenteral	O
intravenous	O
injection	O
administration	O
,	O
or	O
enteral	O
tube	O
feeding	O
or	O
oral	O
administration	O
as	O
a	O
trophic	O
and	O
therapeutic	O
medicine	O
.	O

Docosahexaenoic	B
acid	I
(	I
DHA	I
)	I
ester	I
fat	O
emulsion	O
intravenous	O
injection	O
and	O
manufacturing	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
manganoporphyrin	B
-	I
lonidamine	I
combined	O
drug	O
for	O
treating	O
tumor	O
,	O
comprising	O
manganoporphyrin	B
,	O
lonidamine	B
and	O
one	O
or	O
more	O
optional	O
pharmacy	O
-	O
acceptable	O
vectors	O
.	O

The	O
inventor	O
of	O
the	O
application	O
carries	O
out	O
a	O
series	O
of	O
experimental	O
researches	O
.	O

Proved	O
by	O
the	O
experiment	O
,	O
after	O
manganoporphyrin	B
without	O
a	O
tumor	O
-	O
resistant	O
function	O
is	O
combined	O
with	O
the	O
lonidamine	B
for	O
pharmacy	O
,	O
the	O
treatment	O
effect	O
for	O
the	O
tumor	O
can	O
be	O
remarkably	O
improved	O
,	O
the	O
toxicity	O
of	O
the	O
medicine	O
can	O
be	O
reduced	O
,	O
the	O
survival	O
time	O
of	O
animals	O
can	O
be	O
prolonged	O
and	O
the	O
unexpected	O
effects	O
can	O
be	O
obtained	O
.	O

Manganoporphyrin	B
-	I
lonidamine	I
combined	O
drug	O
for	O
treating	O
tumor	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
nicotinamide	B
mononucleotide	I
ribose	I
phosphate	I
transferase	O
inhibitor	O
.	O

The	O
nicotinamide	B
mononucleotide	I
ribose	I
phosphate	I
transferase	O
inhibitor	O
can	O
effectively	O
prevent	O
or	O
treat	O
thrombocyte	O
hyperfunction	O
,	O
and	O
blood	O
hypercoagulative	O
state	O
or	O
thrombi	O
,	O
has	O
the	O
advantages	O
of	O
favorable	O
curative	O
effect	O
,	O
small	O
side	O
effect	O
and	O
high	O
safety	O
,	O
and	O
has	O
an	O
important	O
meaning	O
for	O
treating	O
coagulation	O
hyperfunction	O
diseases	O
.	O

Application	O
of	O
nicotinamide	B
mononucleotide	I
ribose	I
phosphate	I
transferase	O
inhibitor	O

The	O
invention	O
discloses	O
a	O
solid	O
preparation	O
of	O
atorvastatin	B
calcium	I
liposome	O
.	O

The	O
preparation	O
is	O
prepared	O
from	O
the	O
atorvastatin	B
calcium	I
liposome	O
and	O
other	O
pharmaceutically	O
common	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
atorvastatin	B
liposome	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
atorvastatin	B
calcium	I
,	O
2	O
-	O
5	O
parts	O
of	O
phospholipid	O
and	O
0.8	O
-	O
3	O
parts	O
of	O
additive	O
.	O

The	O
atorvastatin	B
solid	O
preparation	O
prepared	O
from	O
the	O
liposome	O
has	O
the	O
advantages	O
that	O
the	O
dissolution	O
rate	O
is	O
increased	O
,	O
the	O
stability	O
and	O
bioavailability	O
are	O
greatly	O
improved	O
,	O
the	O
product	O
quality	O
of	O
the	O
preparation	O
is	O
improved	O
and	O
the	O
toxic	O
and	O
side	O
effect	O
is	O
reduced	O
.	O

Solid	O
preparation	O
of	O
atorvastatin	B
calcium	I
liposome	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
ketoprofen	B
slow	O
release	O
preparation	O
.	O

The	O
slow	O
release	O
preparation	O
can	O
be	O
used	O
for	O
solving	O
the	O
technical	O
problems	O
that	O
blood	O
concentration	O
is	O
stable	O
after	O
the	O
preparation	O
administration	O
,	O
and	O
ketoprofen	B
can	O
be	O
released	O
stably	O
within	O
24	O
hours	O
.	O

The	O
slow	O
release	O
preparation	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
main	O
drugs	O
:	O
200	O
parts	O
of	O
ketoprofen	B
,	O
110	O
-	O
120	O
parts	O
of	O
slow	O
release	O
skeleton	O
matrix	O
,	O
hydroxyl	O
methyl	O
propyl	O
cellulose	O
(	O
HPMC	O
)	O
K4	O
M	O
,	O
and	O
HPMC	O
K100	O
M	O
,	O
wherein	O
ratio	O
of	O
the	O
HPMC	O
K4	O
M	O
to	O
the	O
HPMC	O
K100	O
M	O
is	O
equal	O
to	O
5:1	O
.	O

Pharmaceutically	O
-	O
acceptable	O
accessories	O
are	O
added	O
to	O
the	O
main	O
drugs	O
to	O
prepare	O
the	O
slow	O
release	O
preparation	O
provided	O
by	O
the	O
invention	O
.	O

The	O
slow	O
release	O
preparation	O
is	O
mainly	O
used	O
for	O
treating	O
rheumatoid	O
arthritis	O
or	O
rheumatoid	O
arthritis	O
,	O
osteoarthritis	O
,	O
ankylosing	O
spondylitis	O
,	O
gout	O
,	O
dysmenorrheal	O
and	O
the	O
like	O
,	O
and	O
also	O
used	O
for	O
treating	O
joint	O
strain	O
,	O
soft	O
tissue	O
injury	O
,	O
fracture	O
pain	O
,	O
postoperation	O
pain	O
and	O
the	O
like	O
.	O

By	O
utilizing	O
the	O
slow	O
release	O
preparation	O
,	O
long	O
-	O
acting	O
slow	O
release	O
can	O
be	O
realized	O
,	O
the	O
peak	O
value	O
and	O
valley	O
value	O
of	O
the	O
blood	O
concentration	O
can	O
be	O
reduced	O
,	O
the	O
blood	O
concentration	O
is	O
more	O
stable	O
,	O
the	O
eliminated	O
half	O
-	O
life	O
period	O
is	O
as	O
long	O
as	O
11	O
hours	O
,	O
especially	O
stable	O
release	O
within	O
24	O
hours	O
can	O
be	O
realized	O
and	O
the	O
ketoprofen	B
slow	O
release	O
preparation	O
is	O
taken	O
only	O
oncein	O
a	O
day	O
.	O

Ketoprofen	B
slow	O
release	O
preparation	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
empyrosis	O
,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
part	O
by	O
weight	O
:	O
10	O
to15	O
parts	O
of	O
white	O
chrysanthemum	O
flower	O
,	O
10	O
to	O
12	O
parts	O
of	O
pinellia	O
tuber	O
,	O
500	O
parts	O
of	O
calcined	O
lime	O
,	O
10	O
to	O
15	O
parts	O
of	O
borneol	O
,	O
5	O
to	O
10	O
parts	O
of	O
rhubarb	O
,	O
5	O
to	O
10	O
parts	O
of	O
lightyellow	O
sophora	O
root	O
,	O
5	O
to	O
10	O
parts	O
of	O
amur	O
corktree	O
bark	O
,	O
5	O
to	O
10	O
parts	O
of	O
catechu	O
,	O
11	O
to	O
14	O
parts	O
of	O
golden	O
thread	O
,	O
10	O
to	O
15	O
parts	O
of	O
swordlike	O
atractylodes	O
rhizome	O
,	O
60	O
to	O
100	O
parts	O
of	O
calcined	O
calamine	O
and	O
15	O
to	O
30	O
parts	O
of	O
garden	O
burnet	O
root	O
.	O

The	O
components	O
are	O
crushed	O
,	O
mixed	O
,	O
sealed	O
and	O
buried	O
underground	O
for	O
preserving	O
for	O
three	O
years	O
.	O

In	O
the	O
medicament	O
,	O
the	O
components	O
are	O
subjected	O
to	O
organic	O
compatibility	O
,	O
and	O
have	O
the	O
complementary	O
effect	O
to	O
bring	O
the	O
optimal	O
synergistic	O
effect	O
into	O
play	O
,	O
so	O
that	O
the	O
medicament	O
has	O
powerful	O
medicinal	O
effects	O
of	O
diminishing	O
inflammation	O
and	O
reliving	O
pain	O
quickly	O
,	O
removing	O
nidus	O
of	O
organisms	O
effectively	O
,	O
and	O
achieving	O
an	O
unexpected	O
treatment	O
effect	O
.	O

Medicament	O
for	O
treating	O
empyrosis	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
navel	O
-	O
warming	O
plaster	O
for	O
treating	O
a	O
poor	O
alimentary	O
system	O
caused	O
by	O
catching	O
cold	O
,	O
which	O
can	O
effectively	O
solves	O
the	O
treatment	O
problem	O
of	O
the	O
poor	O
alimentary	O
system	O
caused	O
by	O
catching	O
cold	O
.	O

The	O
plaster	O
is	O
prepared	O
from	O
the	O
following	O
components	O
by	O
weight	O
:	O
70	O
-	O
80	O
g	O
of	O
monkshood	O
,	O
80	O
-	O
120	O
g	O
of	O
white	O
paeony	O
root	O
,	O
80	O
-	O
100	O
g	O
of	O
dried	O
ginger	O
,	O
80	O
-	O
100	O
g	O
of	O
hawthorn	O
,	O
250	O
g	O
of	O
minium	O
and	O
500	O
g	O
of	O
sesame	O
oil	O
,	O
wherein	O
the	O
monkshood	O
,	O
the	O
white	O
paeony	O
root	O
,	O
the	O
dried	O
ginger	O
and	O
the	O
hawthorn	O
are	O
ground	O
into	O
fine	O
powder	O
,	O
and	O
the	O
ground	O
fine	O
powder	O
is	O
screened	O
into	O
fine	O
powder	O
flour	O
for	O
later	O
use	O
;	O
the	O
sesame	O
oil	O
is	O
put	O
in	O
a	O
pan	O
for	O
heating	O
,	O
and	O
then	O
the	O
fine	O
powder	O
flour	O
is	O
poured	O
into	O
hot	O
oil	O
,	O
continuously	O
stirred	O
and	O
boiled	O
with	O
slow	O
fire	O
until	O
black	O
smoke	O
emits	O
;	O
the	O
minium	O
is	O
added	O
for	O
evenly	O
stirring	O
until	O
mixture	O
is	O
decocted	O
to	O
be	O
viscous	O
;	O
the	O
mixture	O
is	O
poured	O
in	O
cold	O
water	O
to	O
soak	O
for	O
7	O
days	O
during	O
which	O
the	O
cold	O
water	O
is	O
changed	O
for	O
three	O
times	O
;	O
and	O
the	O
soaked	O
plaster	O
is	O
heated	O
and	O
evenly	O
coated	O
on	O
a	O
cotton	O
cloth	O
,	O
or	O
a	O
piece	O
of	O
paper	O
,	O
or	O
a	O
plastic	O
cloth	O
.	O

The	O
navel	O
-	O
warming	O
plaster	O
has	O
rich	O
raw	O
materials	O
and	O
low	O
cost	O
,	O
and	O
is	O
easy	O
to	O
produce	O
;	O
when	O
in	O
use	O
,	O
the	O
navel	O
-	O
warming	O
plaster	O
is	O
plastered	O
to	O
a	O
navel	O
,	O
thereby	O
being	O
convenient	O
;	O
the	O
navel	O
-	O
warming	O
plaster	O
has	O
low	O
cost	O
and	O
good	O
effect	O
and	O
is	O
safe	O
to	O
stick	O
;	O
and	O
the	O
plaster	O
does	O
not	O
flow	O
outwardly	O
and	O
has	O
fast	O
response	O
and	O
short	O
treatment	O
time	O
,	O
and	O
can	O
not	O
cause	O
allergy	O
.	O

Navel	O
-	O
warming	O
plaster	O
for	O
treating	O
poor	O
alimentary	O
system	O
caused	O
by	O
catching	O
cold	O

The	O
invention	O
provides	O
roxatidine	B
acetate	I
hydrochloride	I
used	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
roxatidine	B
acetate	I
hydrochloride	I
is	O
prepared	O
by	O
taking	O
the	O
roxatidine	B
acetate	I
hydrochloride	I
as	O
a	O
raw	O
material	O
;	O
adding	O
glycine	B
or	O
mannitol	B
as	O
an	O
excipient	O
;	O
and	O
freezing	O
and	O
drying	O
after	O
preparing	O
the	O
raw	O
material	O
and	O
the	O
excipient	O
into	O
a	O
liquid	O
medicament	O
.	O

The	O
prepared	O
roxatidine	B
acetate	I
hydrochloride	I
used	O
for	O
the	O
injection	O
is	O
used	O
for	O
upper	O
gastrointestinal	O
hemorrhage	O
caused	O
by	O
gastric	O
ulcer	O
,	O
stress	O
ulcer	O
and	O
hemorrhagic	O
gastritis	O
and	O
preanesthetic	O
medication	O
.	O

The	O
product	O
obtained	O
by	O
the	O
method	O
has	O
good	O
quality	O
,	O
exact	O
curative	O
effect	O
and	O
stable	O
quality	O
.	O

Roxatidine	B
acetate	I
hydrochloride	I
used	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicine	O
composition	O
for	O
treating	O
gynaecologic	O
trichomonas	O
vaginitis	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
which	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
.	O

The	O
medicine	O
composition	O
comprises	O
raw	O
materials	O
such	O
as	O
golden	O
thread	O
,	O
lightyellow	O
sophora	O
root	O
,	O
common	O
cnidium	O
fruit	O
,	O
pricklyash	O
peel	O
,	O
alum	O
,	O
Chinese	O
gentian	O
and	O
borneal	O
,	O
has	O
functions	O
of	O
clearing	O
heat	O
,	O
removing	O
toxin	O
,	O
drying	O
dampness	O
and	O
killing	O
worms	O
,	O
and	O
is	O
used	O
for	O
treating	O
trichomonas	O
vaginitis	O
.	O

The	O
curative	O
effect	O
is	O
obvious	O
through	O
many	O
years	O
of	O
clinical	O
application	O
.	O

Medicine	O
composition	O
for	O
treating	O
gynaecologic	O
trichomonas	O
vaginitis	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
new	O
tolvapta	O
crystal	O
form	O
or	O
an	O
amorphous	O
substance	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
infrared	O
spectrum	O
of	O
the	O
tolvapta	O
form	O
is	O
measured	O
by	O
an	O
X	O
-	O
ray	O
powder	O
pattern	O
method	O
or	O
a	O
KBr	O
pellet	O
-	O
transmission	O
method	O
.	O

A	O
preparation	O
prepared	O
from	O
the	O
new	O
-	O
form	O
tolvapta	O
has	O
better	O
dissolution	O
rate	O
and	O
stability	O
and	O
is	O
more	O
suitable	O
for	O
patients	O
in	O
the	O
stage	O
of	O
attack	O
.	O

Tolvapta	O
crystal	O
or	O
amorphous	O
substance	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
a	O
butterbur	O
extract	O
,	O
a	O
butterbur	O
lactone	B
VIa	O
which	O
is	O
a	O
new	O
sesquiterpene	B
lactone	I
compound	O
separated	O
from	O
the	O
butterbur	O
extract	O
,	O
and	O
the	O
application	O
of	O
the	O
butterbur	O
extract	O
and	O
the	O
butterbur	O
lactone	B
VIa	O
.	O

The	O
chemical	O
structural	O
formula	O
of	O
the	O
butterbur	O
lactone	B
VIa	O
is	O
shown	O
as	O
in	O
the	O
specification	O
.	O

The	O
butterbur	O
extract	O
and	O
the	O
butterbur	O
lactone	B
VIa	O
in	O
the	O
invention	O
have	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
and	O
low	O
cost	O
;	O
proved	O
by	O
animal	O
experiments	O
and	O
in	O
vitro	O
experiments	O
,	O
the	O
butterbur	O
extract	O
or	O
the	O
butterbur	O
lactone	B
VIa	O
has	O
the	O
activity	O
of	O
preventing	O
and	O
treating	O
cerebral	O
ischemia	O
,	O
myocardial	O
ischemia	O
,	O
allergic	O
rhinitis	O
,	O
tumors	O
,	O
memory	O
impairment	O
and	O
the	O
like	O
,	O
and	O
therefore	O
,	O
the	O
butterbur	O
extract	O
or	O
the	O
butterbur	O
lactone	B
VIa	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
allergic	O
rhinitis	O
,	O
tumors	O
,	O
senile	O
dementia	O
,	O
depression	O
,	O
diseases	O
related	O
to	O
histamine	B
and/or	O
leukotriene	B
compositions	O
.	O

Butterbur	O
extract	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
long	O
-	O
acting	O
tylosin	B
injection	O
.	O

Every	O
10000ml	O
of	O
propylene	B
glycol	I
contains	O
the	O
following	O
components	O
by	O
weight	O
portion	O
:	O
1000	O
-	O
2000	O
g	O
of	O
tylosin	B
antibiotic	O
,	O
85	O
-	O
100	O
g	O
of	O
benzyl	B
alcohol	I
,	O
450g-500	O
g	O
of	O
polyvinyl	B
pyrrolidone	I
and	O
10	O
-	O
20	O
g	O
of	O
2,6-bi	B
-	I
tert	I
-	I
butyl-4-methylphenol	I
.	O

The	O
injection	O
has	O
long	O
drug	O
-	O
effect	O
duration	O
and	O
low	O
cost	O
,	O
is	O
particularly	O
suitable	O
for	O
curing	O
respiratory	O
diseases	O
for	O
livestock	O
and	O
poultry	O
,	O
and	O
has	O
small	O
dosage	O
.	O

The	O
injection	O
is	O
administrated	O
onto	O
animals	O
in	O
a	O
hypodermic	O
injection	O
mode	O
,	O
and	O
the	O
drug	O
-	O
effect	O
duration	O
can	O
reach	O
more	O
than	O
3days	O
after	O
the	O
injection	O
is	O
administrated	O
once	O
.	O

The	O
injection	O
has	O
obvious	O
prevention	O
and	O
cure	O
effect	O
for	O
mycoplasma	O
infectious	O
diseases	O
of	O
animals	O
such	O
as	O
chickens	O
,	O
piglets	O
,	O
lambs	O
,	O
calves	O
and	O
the	O
like	O
,	O
and	O
has	O
the	O
advantages	O
of	O
fewer	O
injection	O
times	O
,	O
good	O
curative	O
effect	O
,	O
and	O
wide	O
market	O
prospect	O
.	O

Long	O
-	O
acting	O
tylosin	B
injection	O

The	O
invention	O
relates	O
to	O
application	O
of	O
a	O
compound	O
as	O
a	O
medicament	O
,	O
particularly	O
an	O
inflammatory	O
agent	O
,	O
wherein	O
the	O
compound	O
is	O
prepared	O
from	O
cation	O
liposome	O
and	O
polydeoxyribonucleotide	O
with	O
the	O
molecular	O
weight	O
of	O
7000	O
-	O
60000	O
;	O
the	O
polydeoxyribonucleotide	O
is	O
obtained	O
by	O
depolymerizing	O
nucleic	O
acid	O
;	O
and	O
the	O
polydeoxyribonucleotide	O
in	O
the	O
compound	O
is	O
located	O
on	O
the	O
outer	O
surface	O
of	O
the	O
liposome	O
.	O

Application	O
of	O
compound	O
of	O
cation	O
liposome	O
and	O
polydeoxyribonucleotide	O
as	O
medicament	O

The	O
invention	O
discloses	O
a	O
theasapogenol	B
derivative	O
with	O
an	O
antibacterial	O
effect	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
theasapogenol	B
derivative	O
with	O
an	O
antibacterial	O
effect	O
is	O
28-	B
(	I
4-dioxolane-1-ethoxybutoxy	I
)	I
-tea	I
sapogenol	I
and	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
of	O
:	O
making	O
triphenylchloromethane	B
react	O
with	O
theasapogenol	O
for	O
protecting	O
a	O
primary	O
hydroxyl	B
on	O
theasapogenol	B
C28	O
;	O
making	O
acetic	B
anhydride	I
react	O
with	O
theasapogenol	B
for	O
protecting	O
a	O
secondary	O
hydroxyl	B
on	O
the	O
theasapogenol	B
;	O
adding	O
a	O
triphenylmethyl	B
removing	O
protective	O
agent	O
,	O
removing	O
triphenylmethyl	B
and	O
leading	O
the	O
primary	O
hydroxyl	B
on	O
the	O
theasapogenol	B
C28	O
to	O
protect	O
;	O
adding	O
4-dioxolame-1,1-diethyloxy	B
butane	I
for	O
reacting	O
and	O
connecting	O
with	O
the	O
theasapogenol	B
;	O
and	O
finally	O
,	O
adding	O
an	O
acetyl	B
removing	O
protective	O
agent	O
,	O
removing	O
the	O
acetyl	B
on	O
the	O
theasapogenol	B
and	O
crystallizing	O
to	O
obtain	O
the	O
theasapogenol	B
derivative	O
shown	O
as	O
the	O
formula	O
I.	O
The	O
antibacterial	O
activity	O
of	O
the	O
theasapogenol	B
derivative	O
of	O
the	O
invention	O
is	O
obviously	O
improved	O
,	O
and	O
the	O
defect	O
of	O
low	O
bacteriostatic	O
capabiity	O
of	O
the	O
traditional	O
theasapogenol	B
is	O
overcome	O
.	O

Theasapogenol	B
derivative	O
with	O
antibacterial	O
effect	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
gel	O
composition	O
for	O
treating	O
acne	O
,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
0.01	O
to	O
20	O
percent	O
of	O
at	O
least	O
of	O
a	O
retinoic	B
acid	I
active	O
component	O
,	O
0.01	O
to	O
20	O
percent	O
of	O
diphenylperoxyanhydride	B
,	O
0.1	O
to	O
10	O
percent	O
of	O
at	O
least	O
one	O
high	O
polymer	O
gel	O
and	O
0.1	O
to	O
4	O
percent	O
of	O
antioxygen	O
,	O
wherein	O
the	O
antioxygen	O
may	O
be	O
one	O
or	O
more	O
of	O
butylated	B
hydroxytoluene	I
(	O
BHT	B
)	O
,	O
ethylenediaminetetraacetic	B
acid-2	I
(	I
EDTA-2	I
)	I
,	I
Na	I
,	O
butylated	B
hydroxyanisole	I
(	O
BHA	B
)	O
,	O
vitamin	B
E	I
,	O
vitamin	B
E	I
acetate	I
and	O
vitamin	B
E	I
nicotinate	I
.	O

The	O
composite	O
antioxygen	O
used	O
in	O
the	O
invention	O
can	O
effectively	O
solve	O
the	O
chemical	O
and	O
physical	O
stability	O
problems	O
of	O
retinoic	B
acid	I
and	O
diphenylperoxyanhydride	B
composite	O
preparation	O
,	O
and	O
it	O
is	O
found	O
that	O
the	O
antioxygen	O
has	O
good	O
chemical	O
and	O
physical	O
stabilizing	O
effect	O
on	O
common	O
gel	O
systems	O
,	O
greatly	O
improves	O
the	O
gel	O
selection	O
range	O
,	O
recues	O
cost	O
,	O
simplifies	O
operation	O
steps	O
and	O
effectively	O
controls	O
product	O
quality	O
.	O

Medicinal	O
composition	O
for	O
treating	O
acne	O

The	O
invention	O
relates	O
to	O
a	O
medical	O
composition	O
with	O
antiplatelet	O
condensation	O
activity	O
.	O

The	O
medical	O
composition	O
with	O
antiplatelet	O
condensation	O
activity	O
comprises	O
clopidogrel	O
and	O
triflusal	O
,	O
wherein	O
the	O
ratio	O
of	O
the	O
clopidogrel	O
to	O
the	O
triflusal	O
is	O
1:4	O
,	O
1:6	O
or	O
1:12	O
.	O

The	O
medical	O
composition	O
,	O
i.e.	O
a	O
composition	O
of	O
the	O
clopidogrel	O
and	O
the	O
triflusal	O
in	O
specific	O
ratio	O
has	O
an	O
antithrombogenic	O
effect	O
,	O
can	O
inhibit	O
the	O
release	O
reaction	O
of	O
blood	O
platelets	O
,	O
inhibit	O
the	O
aggregation	O
of	O
the	O
blood	O
platelets	O
and	O
prevent	O
thrombosis	O
,	O
is	O
expected	O
to	O
replace	O
aspirin	O
,	O
the	O
clopidogrel	O
or	O
the	O
medicament	O
composition	O
of	O
the	O
aspirin	O
and	O
the	O
clopidogrel	O
and	O
is	O
used	O
for	O
preventing	O
outbreak	O
of	O
heart	O
cerebrovascular	O
diseases	O
.	O

Medical	O
composition	O
with	O
antiplatelet	O
condensation	O
activity	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
whooping	O
cough	O
,	O
comprising	O
the	O
following	O
medicines	O
by	O
fixed	O
weight	O
ratio	O
:	O
radix	O
bupleuri	O
,	O
radix	O
scutellariae	O
,	O
ruddle	O
,	O
indigo	O
and	O
the	O
like	O
.	O

The	O
raw	O
materials	O
of	O
the	O
medicine	O
are	O
easy	O
to	O
obtain	O
and	O
low	O
in	O
cost	O
;	O
and	O
the	O
medicine	O
has	O
the	O
advantages	O
of	O
short	O
period	O
of	O
treatment	O
,	O
excellent	O
curative	O
effect	O
and	O
no	O
side	O
effect	O
,	O
has	O
the	O
efficacies	O
on	O
clearing	O
away	O
heat	O
and	O
toxic	O
materials	O
,	O
expelling	O
phlegm	O
and	O
arresting	O
coughing	O
and	O
has	O
obvious	O
curative	O
effect	O
on	O
treating	O
whooping	O
cough	O
.	O

Medicine	O
for	O
treating	O
whooping	O
cough	O

The	O
invention	O
relates	O
to	O
an	O
efficient	O
cell	O
nucleus	O
targeted	O
medicine	O
vector	O
protein	O
capable	O
of	O
quickly	O
transporting	O
an	O
antineoplastic	O
medicine	O
into	O
the	O
cell	O
nucleus	O
and	O
effectively	O
killing	O
tumor	O
cells	O
and	O
a	O
gene	O
coding	O
the	O
efficient	O
cell	O
nucleus	O
targeted	O
medicine	O
vector	O
protein	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
biopharmacy	O
.	O

The	O
efficient	O
cell	O
nucleus	O
targeted	O
medicine	O
vector	O
comprises	O
at	O
leastone	O
cell	O
nucleus	O
positioning	O
sequence	O
,	O
at	O
lest	O
one	O
transmembrane	O
sequence	O
and	O
at	O
least	O
one	O
polyhistidine	B
sequence	O
.	O

The	O
efficient	O
cell	O
nucleus	O
targeted	O
medicine	O
vector	O
is	O
not	O
only	O
capable	O
of	O
enhancingthe	O
sensitivity	O
of	O
the	O
tumor	O
cells	O
to	O
the	O
antineoplastic	O
medicine	O
coupled	O
with	O
the	O
vector	O
,	O
but	O
also	O
transporting	O
the	O
antineoplastic	O
medicine	O
into	O
the	O
cell	O
nucleus	O
of	O
the	O
tumor	O
cells	O
in	O
a	O
targeted	O
way	O
,	O
thereby	O
suppressing	O
synthesis	O
of	O
nucleic	O
acids	O
of	O
the	O
tumor	O
cells	O
.	O

Besides	O
,	O
the	O
efficient	O
cell	O
nucleus	O
targeted	O
medicine	O
vector	O
has	O
double	O
actions	O
of	O
fastness	O
and	O
targeting	O
,	O
and	O
greatly	O
reduces	O
the	O
dosage	O
of	O
the	O
antineoplastic	O
medicine	O
;	O
and	O
thus	O
,	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
antineoplastic	O
medicine	O
are	O
reduced	O
.	O

Efficient	O
cell	O
nucleus	O
targeted	O
medicine	O
vector	O
and	O
application	O
thereof	O
to	O
preparing	O
antineoplastic	O
medicines	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
new	O
medicament	O
technologies	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
darifenacin	B
hydrobromide	I
sustained	O
-	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
.	O

The	O
darifenacin	B
hydrobromide	I
sustained	O
-	O
release	O
tablet	O
adopts	O
carbomer	O
as	O
a	O
new	O
retardant	O
,	O
and	O
the	O
dosage	O
of	O
the	O
carbomer	O
is	O
1	O
-	O
5	O
%	O
by	O
weight	O
of	O
the	O
preparation	O
and	O
can	O
reach	O
considerable	O
vitro	O
release	O
and	O
bioavailability	O
compared	O
with	O
the	O
dosage	O
of	O
the	O
retardant	O
in	O
the	O
prior	O
art	O
,	O
which	O
is	O
more	O
than	O
half	O
of	O
the	O
dosage	O
of	O
a	O
prescription	O
.	O

The	O
dosage	O
of	O
the	O
retardant	O
in	O
the	O
new	O
method	O
is	O
greatly	O
reduced	O
so	O
that	O
the	O
consumption	O
of	O
materials	O
can	O
be	O
greatly	O
reduced	O
,	O
the	O
process	O
is	O
simpler	O
,	O
the	O
controllability	O
is	O
better	O
,	O
the	O
efficiency	O
is	O
improved	O
,	O
and	O
the	O
production	O
cost	O
is	O
greatly	O
reduced	O
.	O

Darifenacin	B
hydrobromide	I
sustained	O
-	O
release	O
tablet	O
and	O
preparation	O
method	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
for	O
stabilizing	O
pholcodine	B
granules	O
,	O
which	O
consists	O
of	O
pholcodine	B
serving	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
stabilizing	O
agent	O
and	O
a	O
pharmaceutically	O
-	O
acceptable	O
soluble	O
auxiliary	O
material	O
in	O
a	O
weight	O
ratio	O
of	O
1:0.01	O
-	O
1:15	O
-	O
50	O
,	O
preferably	O
1:0.05	O
-	O
0.2:15	O
-	O
30	O
.	O

The	O
medicinal	O
composition	O
solves	O
the	O
problem	O
of	O
unstable	O
phenomenon	O
of	O
brown	O
agglomeration	O
formed	O
by	O
a	O
chemical	O
pickup	O
reaction	O
of	O
the	O
pholcodine	B
and	O
monosaccharide	B
or	O
polysaccharide	O
and	O
even	O
lactose	B
which	O
is	O
mixed	O
with	O
the	O
pholcodine	B
.	O

In	O
addition	O
the	O
operation	O
is	O
simple	O
and	O
convenient	O
,	O
and	O
the	O
cost	O
is	O
saved	O
,	O
so	O
the	O
medicinal	O
composition	O
is	O
suitable	O
for	O
large	O
-	O
scale	O
industrial	O
production	O
.	O

Medicinal	O
composition	O
for	O
stabilizing	O
pholcodine	B
granules	O

The	O
invention	O
discloses	O
a	O
solid	O
dispersion	O
of	O
a	O
24-methylene	B
cycloartanol	I
ferulic	I
acid	I
ester	I
and	O
cycloartenol	B
ferulic	I
acid	I
ester	I
compound	O
refined	O
with	O
oryzanol	B
,	O
comprising	O
the	O
compound	O
and	O
povidone	B
serving	O
as	O
a	O
carrier	O
material	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
pharmaceutical	O
preparation	O
and	O
a	O
preparation	O
method	O
of	O
the	O
solid	O
dispersion	O
.	O

Proved	O
by	O
experiments	O
,	O
the	O
solid	O
dispersion	O
has	O
marked	O
technical	O
progress	O
on	O
the	O
technical	O
indexes	O
such	O
as	O
dissolution	O
rate	O
,	O
stability	O
,	O
water	O
solubility	O
,	O
bioavailability	O
and	O
the	O
like	O
.	O

Solid	O
dispersion	O
and	O
preparation	O
thereof	O

The	O
invention	O
discloses	O
a	O
procaine	B
injection	O
which	O
is	O
prepared	O
from	O
the	O
following	O
bulk	O
pharmaceutical	O
chemicals	O
:	O
procaine	B
,	O
xylitol	B
,	O
30	O
-	O
70	O
%	O
ethanol	B
and	O
polyethylene	B
glycol	I
400	I
.	O

The	O
preparation	O
method	O
of	O
the	O
procaine	B
injection	O
comprises	O
:	O
taking	O
procaine	B
of	O
a	O
prescription	O
amount	O
;	O
dissolving	O
the	O
procaine	B
with	O
ethanol	B
;	O
adjusting	O
pH	O
value	O
;	O
adding	O
the	O
xylitol	B
;	O
then	O
,	O
adding	O
the	O
polyethylene	B
glycol	I
400	I
and	O
propylene	B
glycol	I
;	O
diluting	O
to	O
reach	O
the	O
whole	O
amount	O
;	O
stirring	O
;	O
adjusting	O
the	O
pH	O
value	O
;	O
filtering	O
;	O
splitting	O
;	O
and	O
sterilizing	O
by	O
circulated	O
steam	O
.	O

The	O
injection	O
has	O
stable	O
quality	O
and	O
high	O
bioavailability	O
and	O
is	O
especially	O
suitable	O
for	O
patients	O
with	O
diabetes	O
.	O

Procaine	B
injection	O

The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
canker	O
sore	O
medicinal	O
ranitidine	B
oral	O
adhesive	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
adhesive	O
tablet	O
comprises	O
two	O
layers	O
;	O
one	O
side	O
is	O
a	O
medicament	O
-	O
containing	O
adhesion	O
layer	O
and	O
the	O
other	O
layer	O
is	O
a	O
water	O
-	O
fast	O
protection	O
layer	O
,	O
so	O
that	O
the	O
dissolution	O
of	O
a	O
medicament	O
to	O
the	O
opposite	O
side	O
of	O
oral	O
mucosa	O
and	O
the	O
two	O
-	O
directional	O
adhesion	O
of	O
the	O
tablet	O
between	O
gingival	O
and	O
the	O
oral	O
mucosa	O
are	O
reduced	O
;	O
therefore	O
,	O
the	O
medicament	O
is	O
permeated	O
into	O
a	O
canker	O
surface	O
and	O
the	O
discomfort	O
in	O
an	O
oral	O
cavity	O
as	O
much	O
as	O
possible	O
.	O

Ranitidine	B
canker	O
sore	O
dual	O
-	O
layer	O
patch	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
new	O
application	O
of	O
glucosamine	B
in	O
treating	O
dental	O
ulcer	O
,	O
wherein	O
the	O
chemical	O
name	O
of	O
the	O
glucosamine	B
is	O
2amino-2-deoxidation	B
-	I
D	I
-	I
glucose	I
,	O
and	O
the	O
glucosamine	B
is	O
an	O
in	O
vivo	O
synthesized	O
substance	O
.	O

The	O
glucosamine	B
comprises	O
pharmaceutically	O
acceptable	O
salts	O
such	O
as	O
hydrochloride	B
,	O
nitrate	B
,	O
sulfate	B
,	O
phosphate	B
,	O
hydrobromide	B
,	O
mesylate	B
,	O
citrate	B
,	O
and	O
the	O
like	O
.	O

The	O
effective	O
dosage	O
of	O
the	O
glucosamine	B
for	O
treating	O
dental	O
ulcer	O
is	O
0.01	O
-	O
5	O
g	O
,	O
which	O
is	O
preferable	O
for	O
0.1	O
-	O
1	O
g	O
,	O
and	O
more	O
preferable	O
for	O
0.1	O
-	O
0.5	O
g	O
.	O

New	O
application	O
of	O
glucosamine	B
in	O
treating	O
dental	O
ulcer	O

The	O
invention	O
is	O
concerned	O
with	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	B
thereof	O
,	O
wherein	O
R1-R4	O
are	O
defined	O
in	O
the	O
detailed	O
description	O
and	O
claims	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
manufacturing	O
and	O
using	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
antagonists	O
at	O
the	O
CRTH2	O
receptor	O
and	O
may	O
be	O
useful	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
that	O
receptor	O
such	O
as	O
asthma	O
.	O

Substituted	O
aminotetralines	B

The	O
invention	O
provides	O
a	O
prescription	O
for	O
preventing	O
white	O
-	O
spot	O
disease	O
of	O
turtles	O
,	O
which	O
is	O
prepared	O
from	O
streptomycin	B
sulfate	I
,	O
tetracycline	B
hydrochloride	I
,	O
lignin	B
and	O
chitosan	O
.	O

The	O
prescription	O
for	O
preventing	O
white	O
-	O
spot	O
disease	O
of	O
turtles	O
has	O
the	O
characteristics	O
of	O
excellent	O
performance	O
,	O
lasting	O
and	O
obvious	O
curative	O
effect	O
,	O
low	O
cost	O
,	O
no	O
harm	O
or	O
stimulation	O
to	O
aquatic	O
animals	O
and	O
environmental	O
safety	O
and	O
the	O
like	O
,	O
and	O
improves	O
the	O
cultivation	O
environment	O
.	O

Prescription	O
for	O
preventing	O
white	O
-	O
spot	O
disease	O
of	O
turtles	O

The	O
invention	O
discloses	O
a	O
compound	O
shown	O
as	O
a	O
chemical	O
structural	O
formula	O
I	O
or	O
II	O
and	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
compound	O
shown	O
as	O
the	O
chemical	O
structural	O
formula	O
I	O
or	O
II	O
has	O
a	O
following	O
preparation	O
method	O
that	O
2-toluenyl-1-alkyl-1	B
,	I
3-butanedione	I
and	O
thiourea	B
take	O
reaction	O
under	O
stirring	O
in	O
organic	O
solvents	O
at	O
55	O
DEG	O
C	O
to	O
80	O
DEG	O
C	O
under	O
the	O
catalysis	O
of	O
HY	O
acid	O
to	O
obtain	O
4-alkyl-6-aryl-5-acetyl-2-amino-1	B
,	I
3-thiazine	I
salt	O
(	O
I.HY	O
)	O
,	O
the	O
4-alkyl-6-aryl-5-acetyl-2-amino-1	B
,	I
3-thiazine	I
salt	O
is	O
neutralized	O
by	O
alkali	O
to	O
obtain	O
the	O
compound	O
as	O
shown	O
as	O
the	O
formula	O
I	O
,	O
and	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
is	O
subject	O
to	O
acidylation	O
to	O
obtain	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
II	O
.	O

The	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
or	O
the	O
formula	O
II	O
has	O
good	O
inhibitory	O
activity	O
on	O
human	O
cervical	O
carcinoma	O
cells	O
(	O
Hela	O
cells	O
)	O
,	O
human	O
hepatocarcinoma	O
cells	O
(	O
Bel	O
7402	O
cells	O
)	O
and	O
human	O
lung	O
adenocarcinoma	O
cells	O
(	O
A549	O
cells	O
)	O
and	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
tumor	O
medicine	O
.	O

4-alkyl-6-aryl-5-acetyl-1	B
,	I
3-thiazine	I
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
citicoline	B
sodium	I
liposome	O
solid	O
preparation	O
which	O
is	O
mainly	O
prepared	O
from	O
citicoline	B
sodium	I
,	O
phospholipid	B
,	O
an	O
additive	O
and	O
other	O
pharmaceutic	O
adjuvants	O
,	O
wherein	O
the	O
citicoline	B
sodium	I
accounts	O
for	O
1	O
part	O
by	O
weight	O
,	O
the	O
phospholipids	B
accounts	O
for	O
2	O
-	O
12	O
parts	O
by	O
weight	O
,	O
and	O
the	O
additive	O
accounts	O
for	O
0.5	O
-	O
8	O
parts	O
by	O
weight	O
.	O

The	O
liposome	O
solid	O
preparation	O
prepared	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
stability	O
of	O
the	O
active	O
ingredient	O
citicoline	B
sodium	I
is	O
greatly	O
improved	O
,	O
the	O
valid	O
period	O
of	O
product	O
is	O
prolonged	O
,	O
and	O
phospholipid	O
absorption	O
is	O
cooperated	O
with	O
thecurative	O
activity	O
of	O
the	O
citicoline	B
sodium	I
,	O
thus	O
the	O
bioavailability	O
is	O
improved	O
,	O
the	O
product	O
quality	O
of	O
the	O
preparation	O
is	O
improved	O
,	O
and	O
toxic	O
and	O
side	O
effects	O
are	O
reduced	O
.	O

Citicoline	B
sodium	I
liposome	O
solid	O
preparation	O

The	O
invention	O
discloses	O
application	O
of	O
dehydrocorydaline	B
and	O
scoulerine	B
to	O
medicament	O
production	O
.	O

In	O
the	O
invention	O
,	O
a	O
diagnostic	O
kit	O
for	O
hepatitis	O
B	O
virus	O
surface	O
antigen	O
and	O
a	O
diagnostic	O
kit	O
for	O
hepatitis	O
B	O
virus	O
e	O
antigen	O
are	O
adopted	O
to	O
perform	O
tests	O
of	O
resisting	O
hepatitis	O
B	O
surface	O
antigen	O
and	O
hepatitis	O
B	O
e	O
antigen	O
on	O
protoberberine	B
alkaloids	I
scoulerine	B
and	O
dehydrocorydaline	B
respectively	O
.	O

Results	O
prove	O
that	O
the	O
dehydrocorydaline	B
and	O
the	O
scoulerine	B
have	O
remarkable	O
hepatitis	O
B	O
virus	O
resisting	O
activity	O
,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
hepatitis	O
B	O
virus	O
resistant	O
medicament	O
.	O

Application	O
of	O
dehydrocorydaline	B
and	O
scoulerine	B
to	O
medicament	O
production	O

A	O
nasal	O
composition	O
containing	O
povidone	B
iodine	I
and	O
cyclodextrin	O
inclusion	O
of	O
glucocorticoid	B
comprises	O
povidone	B
iodine	I
and	O
glucocorticoid	B
as	O
active	O
components	O
,	O
and	O
one	O
or	O
several	O
accessories	O
which	O
are	O
suitable	O
for	O
nasal	O
drug	O
administration	O
.	O

The	O
nasal	O
composition	O
is	O
characterized	O
in	O
that	O
the	O
glucocorticoid	B
is	O
included	O
by	O
beta	O
-	O
cyclodextrin	O
or	O
its	O
derivatives	O
,	O
and	O
the	O
povidone	B
iodine	I
content	O
in	O
the	O
nasal	O
composition	O
is	O
0.5%-5	O
%	O
.	O

Nasal	O
composition	O
containing	O
povidone	B
iodine	I
and	O
cyclodextrin	O
inclusion	O
of	O
glucocorticoid	B

The	O
invention	O
discloses	O
a	O
cyclopropyl	B
pregnene	I
compound	O
and	O
application	O
thereof	O
,	O
and	O
discloses	O
a	O
novel	O
adrenocortical	O
hormone	O
compound	O
shown	O
in	O
a	O
formula	O
(	O
I	O
)	O
,	O
a	O
medicine	O
composition	O
containing	O
the	O
compound	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
as	O
an	O
active	O
component	O
and	O
one	O
or	O
more	O
pharmaceutic	O
adjuvants	O
,	O
and	O
application	O
of	O
the	O
compound	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
or	O
physiologically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
as	O
a	O
medicine	O
for	O
treating	O
of	O
the	O
diseases	O
of	O
mammal	O
especially	O
human	O
,	O
especially	O
local	O
inflammation	O
.	O

Cyclopropyl	B
pregnene	I
compound	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
montelukast	B
sodium	I
liposome	O
solid	O
preparation	O
which	O
is	O
prepared	O
from	O
raw	O
and	O
auxiliary	O
materials	O
comprising	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
5	O
parts	O
of	O
montelukast	B
sodium	I
,	O
15	O
-	O
30	O
parts	O
of	O
hydrogenated	O
soybean	O
phosphatidylcholine	O
(	O
HSPC	O
)	O
,	O
8	O
-	O
20	O
parts	O
of	O
cholesterol	B
,	O
4	O
-	O
12	O
parts	O
of	O
Tween	B
80	I
,	O
20	O
-	O
50	O
parts	O
of	O
mannitol	B
and	O
1	O
-	O
3	O
parts	O
of	O
soyasterol	O
.	O

The	O
montelukast	B
sodiumliposome	I
solid	O
preparation	O
has	O
high	O
stability	O
,	O
is	O
stable	O
in	O
light	O
and	O
heat	O
environments	O
,	O
is	O
convenient	O
to	O
store	O
,	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
,	O
high	O
encapsulation	O
rate	O
and	O
uniform	O
particle	O
size	O
and	O
can	O
be	O
preserved	O
in	O
a	O
body	O
for	O
a	O
long	O
time	O
,	O
thereby	O
improving	O
the	O
product	O
quality	O
of	O
the	O
preparation	O
and	O
reducing	O
the	O
toxic	O
side	O
effects	O
.	O

Montelukast	B
sodium	I
liposome	O
solid	O
preparation	O

The	O
invention	O
relates	O
to	O
an	O
oral	O
spray	O
for	O
inflammatory	O
diseases	O
of	O
the	O
oral	O
cavity	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
oral	O
spray	O
comprises	O
the	O
following	O
components	O
:	O
0.1	O
-	O
5	O
%	O
of	O
water	O
-	O
soluble	O
chitosan	O
,	O
0.5	O
-	O
5	O
%	O
of	O
propolis	O
extract	O
,	O
0.1	O
-	O
1	O
%	O
of	O
lactoferrin	O
,	O
0.01	O
-	O
0.5	O
%	O
of	O
lactoperoxidase	O
,	O
0.1	O
-	O
0.5	O
%	O
of	O
lysozyme	O
,	O
0.01	O
-	O
0.1	O
%	O
of	O
immunoglobulin	O
,	O
1	O
-	O
10	O
%	O
of	O
bovine	O
colostrum	O
extract	O
,	O
1	O
-	O
10	O
%	O
of	O
anti	O
-	O
caries	O
sweetener	O
,	O
0.8	O
-	O
1.2	O
%	O
of	O
cold	O
aromatic	B
,	O
0.1	O
-	O
1	O
%	O
of	O
preservative	O
and	O
the	O
balance	O
of	O
water	O
for	O
injections	O
.	O

The	O
preparation	O
method	O
is	O
characterized	O
by	O
mixing	O
the	O
components	O
,	O
stirring	O
uniformly	O
,	O
filling	O
into	O
an	O
oral	O
sprayer	O
,	O
and	O
sterilizing	O
at	O
85	O
DEG	O
C	O
for	O
15	O
minutes	O
to	O
obtain	O
the	O
finished	O
product	O
.	O

The	O
oral	O
spray	O
has	O
the	O
effect	O
of	O
immediately	O
and	O
rapidly	O
treating	O
inflammatory	O
diseases	O
of	O
the	O
oral	O
cavity	O
and	O
the	O
functions	O
of	O
resisting	O
bacteria	O
and	O
viruses	O
,	O
relieving	O
pains	O
,	O
reducing	O
gum	O
inflammation	O
and	O
blooding	O
,	O
promoting	O
the	O
healing	O
of	O
oral	O
ulcer	O
wounds	O
,	O
treating	O
acute	O
and	O
chronic	O
pharyngitis	O
,	O
moistening	O
and	O
freshening	O
the	O
oral	O
cavity	O
and	O
removing	O
halitosis	O
.	O

The	O
oral	O
spray	O
has	O
the	O
advantages	O
of	O
simple	O
and	O
convenient	O
large	O
-	O
scale	O
production	O
process	O
and	O
no	O
environmental	O
pollution	O
in	O
the	O
production	O
process	O
.	O

Oral	O
spray	O
for	O
inflammatory	O
diseases	O
of	O
oral	O
cavity	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
treating	O
lung	O
cancer	O
by	O
sucking	O
and	O
administrating	O
taxol	B
.	O

The	O
method	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
1	O
)	O
preparing	O
composite	O
particles	O
which	O
can	O
be	O
sucked	O
and	O
the	O
main	O
medical	O
component	O
of	O
which	O
is	O
the	O
taxol	B
;	O
and	O
2	O
)	O
depositing	O
the	O
composition	O
on	O
a	O
lung	O
part	O
through	O
an	O
administration	O
way	O
of	O
suction	O
to	O
directly	O
treat	O
the	O
cancer	O
on	O
the	O
lung	O
part	O
.	O

The	O
method	O
has	O
the	O
advantage	O
that	O
:	O
suction	O
administration	O
of	O
the	O
taxol	B
particles	O
which	O
can	O
be	O
sucked	O
has	O
a	O
certain	O
treatment	O
effect	O
on	O
a	O
tumor	O
on	O
the	O
lung	O
part	O
while	O
an	O
administration	O
dosage	O
is	O
reduced	O
;	O
the	O
survival	O
time	O
of	O
a	O
mouse	O
with	O
lung	O
cancer	O
can	O
be	O
obviously	O
prolonged	O
;	O
and	O
an	O
inhabitation	O
effect	O
on	O
white	O
blood	O
cells	O
in	O
which	O
the	O
taxol	B
is	O
injected	O
is	O
not	O
caused	O
.	O

Method	O
for	O
treating	O
lung	O
cancer	O
by	O
sucking	O
and	O
administrating	O
taxol	O

The	O
invention	O
relates	O
to	O
new	O
application	O
of	O
a	O
furocoumarin	B
compound	O
in	O
preparing	O
a	O
drug	O
,	O
in	O
particular	O
to	O
application	O
of	O
the	O
furocoumarin	B
compound	O
as	O
an	O
effective	O
component	O
in	O
preparing	O
the	O
drug	O
for	O
treating	O
or	O
preventing	O
diseases	O
caused	O
or	O
mediated	O
by	O
helicobacter	O
pylori	O
.	O

New	O
application	O
of	O
furocoumarin	B
compound	O
in	O
preparing	O
drug	O

The	O
invention	O
provides	O
a	O
rabeprazole	B
sodium	I
combined	O
medicament	O
and	O
a	O
preparation	O
process	O
thereof	O
.	O

The	O
rabeprazole	B
sodium	I
combined	O
medicament	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
as	O
components	O
in	O
proportion	O
by	O
weight	O
:	O
5	O
-	O
10	O
of	O
ilaprazole	B
sodium	I
,	O
20	O
-	O
30	O
of	O
composition	O
of	O
reduced	O
glutathione	B
and	O
hepatocyte	O
growth	O
-	O
promoting	O
factors	O
in	O
proportion	O
by	O
weight	O
of	O
1:10	O
,	O
and	O
50	O
-	O
60	O
of	O
diammonium	B
glycyrrhizinate	I
.	O

According	O
to	O
a	O
pharmaceutically	O
allowable	O
dose	O
of	O
rabeprazole	B
sodium	I
,	O
pharmaceutical	O
preparations	O
in	O
dosage	O
forms	O
of	O
injection	O
,	O
lyophilized	O
powder	O
injection	O
,	O
enteric	O
coated	O
tablets	O
,	O
enteric	O
coated	O
capsules	O
,	O
spray	O
and	O
the	O
like	O
of	O
the	O
rabeprazole	B
sodium	I
combined	O
medicament	O
are	O
respectively	O
prepared	O
for	O
treating	O
gastric	O
ulcer	O
.	O

Rabeprazole	B
sodium	I
combined	O
medicament	O
and	O
preparation	O
process	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
capsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
capsule	O
comprises	O
lansoprazole	B
enteric	O
coated	O
pellets	O
,	O
clarithromycin	B
stomach	O
-	O
soluble	O
pellets	O
and	O
amoxicillin	B
stomach	O
-	O
soluble	O
pellets	O
.	O

The	O
compound	O
capsule	O
is	O
administered	O
twice	O
one	O
day	O
based	O
on	O
the	O
following	O
dose	O
each	O
time	O
:	O
lansoprazole	B
20	O
-	O
40	O
mg	O
,	O
clarithromycin	B
400	O
-	O
600	O
mg	O
,	O
and	O
amoxicillin	B
900	O
-	O
1100	O
mg	O
.	O

The	O
capsule	O
provided	O
by	O
the	O
invention	O
has	O
a	O
distinct	O
effect	O
on	O
peptic	O
ulcer	O
,	O
is	O
used	O
for	O
thoroughly	O
killing	O
helicobacter	O
pylori	O
,	O
and	O
has	O
the	O
advantages	O
of	O
quick	O
action	O
,	O
strong	O
effect	O
,	O
improved	O
bioavailability	O
,	O
convenience	O
in	O
administration	O
and	O
low	O
cost	O
.	O

Compound	O
capsule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
gynecological	O
lotion	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Each	O
1,000	O
ml	O
of	O
gynecological	O
lotion	O
comprises	O
the	O
following	O
components	O
by	O
weight	O
(	O
volume	O
)	O
:	O
30	O
to	O
50	O
g	O
of	O
hibiscus	O
,	O
50	O
to	O
70	O
g	O
of	O
sessile	O
stemona	O
root	O
,	O
10	O
to	O
30	O
g	O
of	O
giant	O
knotweed	O
rhizome	O
,	O
10	O
to	O
30	O
g	O
of	O
lightyellow	O
sophora	O
root	O
,	O
5	O
to	O
15	O
g	O
of	O
Chinese	O
mugwort	O
leaf	O
,	O
20	O
to	O
40	O
g	O
of	O
Dajieling	O
,	O
5	O
to	O
15	O
g	O
of	O
citric	B
acid	I
,	O
5	O
to	O
15	O
g	O
of	O
glycerin	B
,	O
1	O
to	O
3	O
g	O
of	O
salicylic	B
acid	I
,	O
1	O
to	O
3	O
g	O
of	O
benzoic	B
acid	I
,	O
0.1	O
to	O
0.3	O
g	O
of	O
menthol	B
,	O
4	O
to	O
6	O
g	O
of	O
azone	B
,	O
1	O
to	O
3	O
g	O
of	O
gardenia	O
essence	O
,	O
0.5	O
to	O
1.5	O
g	O
of	O
magnolia	O
denudata	O
desr	O
essence	O
,	O
0.2	O
to	O
0.8	O
g	O
of	O
sweet	O
osmanthus	O
flower	O
essence	O
,	O
300	O
to	O
500	O
ml	O
of	O
absolute	O
ethanol	B
,	O
and	O
pure	O
water	O
serving	O
as	O
a	O
solvent	O
.	O

The	O
gynecological	O
lotion	O
has	O
a	O
novel	O
gynecological	O
lotion	O
formula	O
and	O
can	O
be	O
used	O
for	O
effectively	O
treating	O
various	O
gynecological	O
inflammations	O
caused	O
by	O
pathogenic	O
bacteria	O
,	O
and	O
the	O
sterilization	O
rate	O
of	O
the	O
gynecological	O
lotion	O
within	O
2	O
minutes	O
is	O
100	O
percent	O
.	O

Gynecological	O
lotion	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
muscle	O
and	O
bone	O
paste	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

On	O
the	O
one	O
hand	O
,	O
the	O
muscle	O
and	O
bone	O
paste	O
comprises	O
56	O
medicaments	O
such	O
as	O
vine	O
root	O
,	O
East	O
Asian	O
tree	O
fern	O
rhizome	O
,	O
heracleum	O
,	O
divaricate	O
saposhnikovia	O
root	O
,	O
prepared	O
common	O
monkshood	O
daughter	O
root	O
,	O
ephedra	O
herb	O
,	O
dragon	O
's	O
blood	O
and	O
the	O
like	O
;	O
and	O
on	O
the	O
other	O
hand	O
,	O
the	O
preparation	O
method	O
of	O
the	O
muscle	O
and	O
bone	O
paste	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
crushing	O
the	O
dragon	O
's	O
blood	O
in	O
the	O
muscle	O
and	O
bone	O
paste	O
into	O
fine	O
powder	O
;	O
fragmenting	O
other	O
55	O
medicaments	O
except	O
the	O
dragon	O
's	O
blood	O
in	O
the	O
muscle	O
and	O
bone	O
paste	O
;	O
mixing	O
the	O
medicaments	O
with	O
4,000	O
to	O
6,000	O
g	O
of	O
edible	O
oil	O
,	O
and	O
frying	O
until	O
the	O
medicaments	O
are	O
dry	O
;	O
refining	O
until	O
drips	O
are	O
formed	O
into	O
beads	O
;	O
filtering	O
and	O
deslagging	O
to	O
obtain	O
mixed	O
liquor	O
A	O
;	O
adding	O
2,000	O
to	O
2,500	O
g	O
of	O
red	O
lead	O
into	O
the	O
mixed	O
liquor	O
A	O
;	O
stirring	O
to	O
obtain	O
paste	O
,	O
and	O
collecting	O
the	O
paste	O
;	O
and	O
melting	O
with	O
soft	O
fire	O
,	O
adding	O
the	O
dragon	O
's	O
blood	O
powder	O
,	O
stirring	O
uniformly	O
,	O
and	O
spreading	O
on	O
cloth	O
.	O

The	O
muscle	O
and	O
bone	O
paste	O
has	O
effects	O
of	O
activating	O
blood	O
and	O
dissolving	O
stasis	O
,	O
clearing	O
away	O
heat	O
and	O
toxic	O
materials	O
,	O
diminishing	O
swelling	O
and	O
relieving	O
pain	O
,	O
activating	O
collateral	O
flows	O
and	O
has	O
good	O
effects	O
of	O
treating	O
cervical	O
spondylosis	O
,	O
protrusion	O
of	O
lumbar	O
vertebral	O
discs	O
,	O
rheumatoid	O
arthritis	O
and	O
the	O
like	O
caused	O
by	O
accumulated	O
heat	O
skin	O
and	O
joints	O
,	O
traumatic	O
injuries	O
,	O
sacrodynia	O
and	O
hyperosteogeny	O
.	O

Muscle	O
and	O
bone	O
paste	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
oral	O
solid	O
preparation	O
containing	O
venlafaxine	B
hydrochloride	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
the	O
oral	O
solid	O
preparation	O
containing	O
the	O
venlafaxine	B
hydrochloride	I
,	O
the	O
weight	O
percent	O
of	O
the	O
venlafaxine	B
hydrochloride	I
in	O
the	O
preparation	O
can	O
reach	O
over	O
45	O
percent	O
;	O
and	O
medicinal	O
excipients	O
comprise	O
thinner	O
,	O
disintegrating	O
agent	O
,	O
flow	O
aid	O
,	O
lubricating	O
agent	O
and	O
the	O
like	O
.	O

Oral	O
solid	O
preparation	O
containing	O
venlafaxine	B
hydrochloride	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
eye	O
drops	O
containing	O
vitamin	B
E	I
derivatives	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
eye	O
drops	O
comprise	O
main	O
components	O
of	O
water	O
soluble	O
vitamin	B
E	I
derivatives	O
,	O
a	O
thickening	O
agent	O
,	O
a	O
pH	O
regulator	O
,	O
an	O
isotonic	O
agent	O
and	O
water	O
for	O
injection	O
.	O

The	O
eye	O
drops	O
are	O
mainly	O
used	O
for	O
treating	O
dry	O
eye	O
syndrome	O
,	O
and	O
active	O
pharmacological	O
components	O
can	O
be	O
added	O
according	O
to	O
the	O
need	O
and	O
are	O
used	O
for	O
adjuvant	O
treatment	O
of	O
cataract	O
,	O
retinopathy	O
,	O
macular	O
degeneration	O
,	O
keratitis	O
,	O
conjunctivitis	O
and	O
other	O
various	O
ocular	O
diseases	O
.	O

The	O
eye	O
drops	O
have	O
good	O
effects	O
of	O
moisturizing	O
and	O
lubricating	O
,	O
have	O
antioxidation	O
function	O
,	O
can	O
inhibit	O
lipid	O
peroxide	B
reactions	O
in	O
eyes	O
,	O
have	O
effects	O
of	O
expanding	O
peripheral	O
blood	O
vessels	O
,	O
improving	O
blood	O
circulation	O
,	O
protecting	O
,	O
and	O
accelerating	O
injuries	O
toheal	O
,	O
and	O
have	O
good	O
curative	O
effects	O
on	O
various	O
ocular	O
diseases	O
.	O

Eye	O
drops	O
containing	O
vitamin	B
E	I
derivatives	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
thiazinogeldanamycin	B
(	O
TGDM	O
)	O
,	O
which	O
is	O
a	O
biologically	O
synthesized	O
analogue	O
of	O
geldanamycin	B
.	O

The	O
analogue	O
is	O
a	O
new	O
product	O
obtained	O
by	O
direct	O
fermentation	O
of	O
streptomyces	O
hygroscopicus	O
17997	O
,	O
extraction	O
and	O
separation	O
.	O

Experiment	O
research	O
result	O
shows	O
that	O
the	O
biological	O
activity	O
of	O
the	O
analogue	O
is	O
similar	O
to	O
that	O
of	O
geldanamycin	B
,	O
but	O
the	O
water	O
solubility	O
and	O
photostability	O
of	O
the	O
analogue	O
are	O
both	O
much	O
higher	O
than	O
those	O
of	O
geldanamycin	B
.	O

Thus	O
,	O
the	O
thiazinogeldanamycin	B
is	O
expected	O
to	O
be	O
developed	O
into	O
an	O
antiviral	O
medicine	O
for	O
clinical	O
use	O
.	O

Thiazinogeldanamycin	B
and	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
florfenicol	B
solution	O
and	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
florfenicol	B
solution	O
comprises	O
the	O
following	O
components	O
of	O
:	O
florfenicol	B
,	O
N	B
,	I
N	I
-	I
dimethylformamide	I
(	O
DMF	O
)	O
,	O
glycerol	B
triacetate	I
,	O
tween-80	O
and	O
water	O
;	O
the	O
mass	O
ratio	O
of	O
each	O
component	O
is	O
florfenicol	B
:	O
DMF	B
:	O
glycerol	B
triacetate	I
:	O
tween-80	O
:	O
water	O
=	O
(	O
5	O
-	O
15	O
)	O
:	O
(	O
40	O
-	O
60	O
)	O
:	O
(	O
10	O
-	O
15	O
)	O
:	O
(	O
1	O
-	O
20	O
)	O
:	O
100	O
.	O

The	O
preparation	O
method	O
of	O
the	O
solvent	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
taking	O
45ml	O
of	O
DMF	B
,	O
adding	O
the	O
DMF	B
into	O
the	O
florfenicol	B
,	O
stirring	O
to	O
be	O
dissolved	O
;	O
then	O
adding	O
glycerol	B
triacetate	I
,	O
stirring	O
to	O
be	O
dissolved	O
,	O
and	O
then	O
adding	O
tween-80	O
,	O
stirring	O
to	O
be	O
dissolved	O
;	O
finally	O
adding	O
water	O
to	O
100	O
ml	O
,	O
and	O
stirring	O
until	O
the	O
solution	O
is	O
clear	O
.	O

The	O
florfenicol	B
solution	O
prepared	O
by	O
the	O
method	O
can	O
be	O
dissolved	O
in	O
the	O
water	O
at	O
any	O
proportion	O
;	O
the	O
florfenicol	B
solution	O
greatly	O
improves	O
the	O
bioavailability	O
of	O
the	O
products	O
,	O
and	O
is	O
featured	O
with	O
rapid	O
effect	O
,	O
long	O
effect	O
and	O
high	O
efficiency	O
;	O
and	O
the	O
florfenicol	B
solution	O
can	O
maintain	O
long	O
effective	O
blood	O
concentration	O
in	O
the	O
live	O
stock	O
.	O

Florfenicol	B
solution	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
burn	O
,	O
scald	O
,	O
frostbite	O
,	O
wound	O
and	O
symptoms	O
of	O
red	O
,	O
swell	O
,	O
pain	O
,	O
itch	O
,	O
pus	O
and	O
ulcer	O
on	O
various	O
parts	O
of	O
the	O
body	O
surface	O
.	O

The	O
medicament	O
is	O
mainly	O
prepared	O
from	O
scorpio	O
,	O
scorpion	O
,	O
periostracum	O
serpentis	O
,	O
eupolyphaga	O
,	O
rabiagar	O
,	O
saffron	O
and	O
hydrargyri	O
oxydum	O
rubrum	O
according	O
to	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicament	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
efficacies	O
of	O
relieving	O
pain	O
and	O
itching	O
(	O
5	O
-	O
10	O
seconds	O
)	O
,	O
diminishing	O
inflammation	O
,	O
sterilizing	O
,	O
healing	O
wound	O
and	O
sore	O
,	O
removing	O
the	O
swelling	O
and	O
stasis	O
(	O
3	O
-	O
40	O
minutes	O
)	O
and	O
resisting	O
infection	O
and	O
tetanus	O
,	O
can	O
be	O
used	O
for	O
treating	O
trauma	O
and	O
foreign	O
invasion	O
with	O
symptom	O
wound	O
surfaces	O
and	O
has	O
quick	O
response	O
and	O
treatment	O
rate	O
and	O
no	O
scar	O
left	O
after	O
the	O
wound	O
is	O
cured	O
.	O

The	O
medicament	O
has	O
the	O
functions	O
of	O
inhibiting	O
and	O
killing	O
staphylococcus	O
aureus	O
,	O
streptococcus	O
,	O
anaerobic	O
bacteria	O
,	O
fugus	O
and	O
gram	O
-	O
negative	O
bacilli	O
as	O
well	O
as	O
eczema	O
,	O
urticaria	O
,	O
impetigo	O
,	O
decubitus	O
,	O
herpes	O
zoster	O
,	O
lupus	O
erythematosus	O
,	O
acne	O
and	O
pimple	O
,	O
various	O
bite	O
wound	O
and	O
stings	O
by	O
varipus	O
animals	O
and	O
plants	O
,	O
and	O
the	O
like	O
.	O

The	O
invention	O
emphasizes	O
on	O
making	O
up	O
the	O
defects	O
of	O
singleness	O
,	O
low	O
effect	O
,	O
long	O
period	O
,	O
and	O
the	O
like	O
of	O
the	O
present	O
relative	O
medicaments	O
and	O
solves	O
the	O
problems	O
of	O
inadequate	O
and	O
unaffordable	O
medical	O
services	O
for	O
a	O
part	O
of	O
patients	O
in	O
true	O
sense	O
.	O

Red	O
liquid	O
containing	O
scorpion	O
and	O
centipede	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
tracleer	O
capsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
main	O
medicaments	O
of	O
the	O
capsule	O
is	O
characterized	O
in	O
that	O
per	O
1000	O
capsules	O
comprise	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
31.25	O
to	O
125	O
parts	O
of	O
tracleer	O
,	O
6	O
to	O
15	O
parts	O
of	O
solid	O
dispersion	O
,	O
55	O
to	O
80	O
parts	O
of	O
filler	O
,	O
6	O
to	O
13	O
parts	O
of	O
disintegrant	O
,	O
a	O
proper	O
amount	O
of	O
adhesive	O
,	O
and	O
0.4	O
to	O
1.0	O
part	O
of	O
lubricant	O
,	O
wherein	O
the	O
solid	O
dispersion	O
is	O
polyethylene	B
glycol	I
6000	I
,	O
polyvinylpyrrolidone	B
,	O
or	O
combination	O
of	O
the	O
polyethylene	B
glycol	I
6000	I
and	O
the	O
polyvinylpyrrolidone	B
in	O
an	O
arbitrary	O
proportion	O
;	O
the	O
filler	O
is	O
one	O
or	O
combination	O
of	O
a	O
plurality	O
of	O
lactose	B
,	O
pregelatinized	O
starch	O
and	O
microcrystalline	O
cellulose	O
;	O
the	O
disintegrant	O
is	O
sodium	O
carboxymethyl	O
starch	O
;	O
and	O
the	O
adhesive	O
is	O
hydroxypropyl	O
methylcellulose	O
and	O
povidone	O
;	O
and	O
the	O
lubricant	O
is	O
magnesium	B
stearate	I
.	O

The	O
preparation	O
method	O
is	O
simple	O
,	O
has	O
the	O
advantages	O
of	O
few	O
process	O
links	O
and	O
process	O
parameters	O
,	O
short	O
production	O
cycle	O
,	O
low	O
production	O
cost	O
and	O
suitability	O
for	O
industrial	O
production	O
.	O

Tracleer	O
capsule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
inhibiting	O
angiogenesis	O
which	O
is	O
obtained	O
by	O
extraction	O
and	O
separation	O
from	O
a	O
fermentation	O
culture	O
of	O
symbiotic	O
microbe	O
of	O
sea	O
cucumber	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
firstly	O
,	O
by	O
utilizing	O
a	O
PDA	O
(	O
potato	O
dextrose	O
agar	O
)	O
culture	O
medium	O
,	O
the	O
sea	O
cucumber	O
is	O
cultured	O
to	O
get	O
Alternaria	O
sp.	O
HS-3,2	O
,	O
a	O
colony	O
is	O
white	O
initially	O
and	O
gradually	O
changed	O
to	O
be	O
dark	O
green	O
,	O
single	O
black	O
conidiophores	O
on	O
a	O
matrix	O
are	O
in	O
different	O
length	O
and	O
has	O
no	O
branches	O
on	O
the	O
top	O
,	O
and	O
the	O
conidiophores	O
have	O
vertical	O
and	O
horizontal	O
diagrams	O
and	O
are	O
obclavate	O
and	O
ovate	O
;	O
and	O
secondly	O
,	O
a	O
seed	O
culture	O
medium	O
is	O
produced	O
so	O
as	O
to	O
get	O
a	O
seed	O
culture	O
solution	O
;	O
and	O
thirdly	O
,	O
the	O
fermentation	O
production	O
is	O
performed	O
on	O
the	O
culture	O
medium	O
according	O
to	O
the	O
proportion	O
as	O
follows	O
:	O
0.5	O
-	O
1.5	O
parts	O
of	O
glucose	O
,	O
0.05	O
-	O
0.2	O
part	O
of	O
yeast	O
extract	O
,	O
0.1	O
-	O
0.4	O
part	O
of	O
peptone	O
,	O
1	O
-	O
1.5	O
parts	O
of	O
agar	O
,	O
3	O
-	O
6	O
parts	O
of	O
sodium	B
chloride	I
and	O
100	O
parts	O
of	O
water	O
;	O
bacterial	O
strains	O
after	O
well	O
slant	O
seed	O
culture	O
are	O
selected	O
into	O
the	O
fermentation	O
culture	O
medium	O
and	O
are	O
standed	O
for	O
1	O
-	O
2	O
months	O
at	O
the	O
room	O
temperature	O
of	O
25	O
-	O
30	O
DEG	O
C	O
;	O
and	O
thalli	O
of	O
fermentation	O
broth	O
is	O
removed	O
by	O
being	O
filtered	O
with	O
gauze	O
centrifugally	O
,	O
and	O
supernatant	O
fluid	O
is	O
concentrated	O
at	O
about	O
50	O
-	O
60	O
DEG	O
C	O
till	O
5L	O
,	O
extracted	O
with	O
ethyl	B
acetate	I
for	O
3	O
-	O
5	O
times	O
,	O
is	O
separated	O
by	O
utilizing	O
column	O
chromatography	O
,	O
and	O
eluted	O
with	O
a	O
petroleum	B
ether	I
and	O
an	O
ethyl	B
acetate	I
or	O
chloroform	B
and	O
methanol	B
flow	O
system	O
.	O

Compound	O
inhibiting	O
angiogenesis	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
organic	O
synthesis	O
and	O
pharmaceutical	O
chemistry	O
and	O
relates	O
to	O
synthetic	O
derivatives	O
of	O
a	O
natural	O
product	O
,	O
namely	O
physostigmine	B
,	O
as	O
shown	O
in	O
a	O
chemical	O
structural	O
formula	O
2	O
,	O
which	O
have	O
the	O
activity	O
of	O
inhibiting	O
acetylcholinesterase	O
.	O

In	O
addition	O
,	O
the	O
invention	O
further	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
physostigmine	B
derivatives	O
2	O
,	O
and	O
the	O
structure	O
of	O
the	O
derivatives	O
is	O
basically	O
characterized	O
by	O
enabling	O
indole	B
5-bit	O
to	O
have	O
1,2,3-triazole	B
substituent	O
.	O

The	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
being	O
short	O
in	O
synthetic	O
routes	O
,	O
and	O
being	O
economic	O
and	O
efficient	O
.	O

The	O
in	O
vitro	O
activity	O
screening	O
study	O
shows	O
that	O
part	O
of	O
the	O
newly	O
synthesized	O
physostigmine	B
derivatives	O
have	O
strong	O
activity	O
of	O
inhibiting	O
the	O
acetylcholinesterase	O
,	O
and	O
are	O
candidate	O
medicaments	O
with	O
potential	O
clinical	O
application	O
prospect	O
for	O
preventing	O
senile	O
dementia	O
disease	O
.	O

Preparation	O
method	O
of	O
physostigmine	B
derivatives	O
with	O
resistance	O
to	O
activity	O
of	O
senile	O
dementia	O
disease	O

The	O
invention	O
relates	O
to	O
externally	O
-	O
applied	O
medicinal	O
liquor	O
,	O
which	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
components	O
:	O
morinda	O
umbellata	O
,	O
fortune	O
's	O
drynaria	O
rhizome	O
,	O
Indian	O
buead	O
,	O
acanthopanax	O
root	O
bark	O
,	O
notoginseng	O
root	O
,	O
veronicastrum	O
sibiricum	O
,	O
illigera	O
rhodantha	O
hance	O
,	O
safflower	O
,	O
Himalayan	O
teasel	O
root	O
and	O
ground	O
beetle	O
(	O
gold	O
edge	O
)	O
;	O
and	O
the	O
components	O
are	O
soaked	O
in	O
75	O
percent	O
medical	O
alcohol	B
for	O
30	O
to	O
40	O
days	O
,	O
and	O
the	O
mixed	O
solution	O
is	O
subjected	O
to	O
filtration	O
and	O
residue	O
removal	O
so	O
as	O
to	O
obtain	O
the	O
finished	O
product	O
.	O

After	O
over	O
40	O
years	O
of	O
practice	O
,	O
improvement	O
,	O
perfection	O
and	O
clinicaltest	O
,	O
the	O
externally	O
-	O
applied	O
medicinal	O
liquor	O
has	O
the	O
advantages	O
of	O
quick	O
response	O
,	O
no	O
side	O
effects	O
and	O
lower	O
medical	O
cost	O
of	O
patients	O
,	O
and	O
the	O
total	O
effective	O
rate	O
is	O
nearly	O
98	O
percent	O
.	O

Externally	O
-	O
applied	O
medicinal	O
liquor	O

The	O
invention	O
belongs	O
to	O
medical	O
preparations	O
and	O
relates	O
to	O
a	O
new	O
phenytoin	B
targeting	O
nanopreparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
nanopreparation	O
for	O
targeting	O
therapy	O
of	O
drug	O
-	O
resistant	O
epilepsy	O
is	O
prepared	O
by	O
taking	O
phenytoin	B
as	O
an	O
active	O
ingredient	O
,	O
a	O
P	O
-	O
glycoprotein	O
monoclonal	O
antibody	O
as	O
a	O
targeting	O
head	O
group	O
and	O
a	O
macromolecular	O
polymer	O
as	O
a	O
carrier	O
.	O

The	O
loading	O
rate	O
and	O
the	O
releasing	O
speed	O
of	O
the	O
phenytoin	O
are	O
controlled	O
by	O
changing	O
the	O
proportion	O
of	O
polyethylene	B
glycol	I
to	O
polycaprolactone	B
in	O
the	O
macromolecular	O
polymer	O
;	O
the	O
problems	O
of	O
poor	O
blood	O
brain	O
barrier	O
permeability	O
,	O
low	O
drug	O
concentration	O
at	O
an	O
epilepsy	O
lesion	O
area	O
,	O
poor	O
treatment	O
effect	O
and	O
serious	O
adverse	O
reaction	O
in	O
the	O
conventional	O
treatment	O
of	O
the	O
drug	O
-	O
resistant	O
epilepsy	O
by	O
the	O
phenytoin	B
are	O
solved	O
by	O
using	O
slow	O
release	O
and	O
active	O
targeting	O
technologies	O
;	O
and	O
the	O
safety	O
of	O
the	O
phenytoin	B
is	O
obviously	O
improved	O
.	O

The	O
preparation	O
can	O
be	O
targeted	O
to	O
the	O
lesion	O
area	O
of	O
the	O
drug	O
-	O
resistant	O
epilepsy	O
,	O
so	O
that	O
the	O
phenytoin	B
content	O
of	O
the	O
lesion	O
area	O
is	O
greatly	O
improved	O
and	O
the	O
seizure	O
of	O
the	O
epilepsy	O
is	O
suppressed	O
.	O

P	O
-	O
glycoprotein	O
monoclonal	O
antibody	O
modified	O
phenytoin	B
targeting	O
nanopreparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
dammarane	B
aglycon	I
compound	O
and	O
application	O
thereof	O
,	O
in	O
particular	O
to	O
application	O
of	O
oral	O
administration	O
and	O
injection	O
preparations	O
which	O
are	O
prepared	O
by	O
a	O
single	O
dammarane	B
aglycon	I
compound	O
prepared	O
by	O
basic	O
hydrolysis	O
by	O
utilizing	O
the	O
particular	O
patent	O
technology	O
of	O
the	O
Pegasus	O
Pharmaceuticals	O
Group	O
of	O
Canada	O
by	O
adopting	O
Asian	O
ginseng	O
stem	O
and	O
leave	O
saponin	O
or	O
prepared	O
in	O
the	O
way	O
that	O
the	O
dammarane	B
aglycon	I
compound	O
is	O
matched	O
with	O
other	O
medically	O
permissive	O
auxiliary	O
materials	O
in	O
prevention	O
and	O
treatment	O
on	O
bone	O
marrow	O
suppression	O
caused	O
by	O
different	O
chemotherapy	O
and	O
radiotherapy	O
.	O

Dammarane	B
aglycon	I
compound	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
an	O
externally	O
-	O
applied	O
medicament	O
for	O
treating	O
scald	O
.	O

The	O
medicament	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
2	O
parts	O
of	O
borneol	B
,	O
1	O
-	O
2	O
parts	O
of	O
compound	O
sulfamethoxazole	B
,	O
10	O
-	O
20	O
parts	O
of	O
sesame	O
oil	O
,	O
3	O
-	O
6	O
parts	O
of	O
white	O
paraffin	B
.	O

The	O
externally	O
-	O
applied	O
medicament	O
is	O
prepared	O
by	O
a	O
method	O
comprising	O
the	O
following	O
steps	O
:	O
placing	O
sesame	O
oil	O
into	O
a	O
container	O
,	O
heating	O
,	O
adding	O
white	O
paraffin	B
when	O
sesame	O
oil	O
temperature	O
to	O
75	O
-	O
85	O
DEG	O
C	O
,	O
stirring	O
,	O
adding	O
borneol	B
when	O
white	O
paraffin	B
melts	O
and	O
sesame	O
oil	O
temperature	O
reaches	O
90	O
-	O
100	O
DEG	O
C	O
,	O
and	O
adding	O
powdered	O
compound	O
sulfamethoxazole	B
when	O
borneol	O
melts	O
until	O
paste	O
is	O
obtained	O
.	O

The	O
efficacy	O
of	O
borneol	B
,	O
compound	O
sulfamethoxazole	B
,	O
sesame	O
oil	O
and	O
white	O
paraffin	B
supplements	O
each	O
other	O
,	O
and	O
borneol	B
,	O
compound	O
sulfamethoxazole	B
,	O
sesame	O
oil	O
and	O
white	O
paraffin	B
are	O
scientifically	O
compounded	O
to	O
make	O
into	O
pasty	O
externally	O
-	O
applied	O
medicament	O
.	O

The	O
externally	O
-	O
applied	O
medicament	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
short	O
treatment	O
course	O
,	O
no	O
pain	O
during	O
dressing	O
change	O
,	O
and	O
ideal	O
treatment	O
effect	O
.	O

Externally	O
-	O
applied	O
medicament	O
for	O
treating	O
scald	O

The	O
invention	O
discloses	O
an	O
isoandrographolide	B
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
structure	O
of	O
the	O
isoandrographolide	B
derivative	O
is	O
shown	O
as	O
a	O
formula	O
I	O
in	O
the	O
specifications	O
,	O
wherein	O
R	O
is	O
hydrogen	B
or	O
is	O
substituted	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
substituents	O
:	O
substituted	O
or	O
unsubstituted	O
alkyl	B
with	O
1	O
-	O
8	O
carbon	B
atoms	O
,	O
substituted	O
or	O
unsubstituted	O
alkoxy	B
with	O
1	O
-	O
8	O
carbon	B
atoms	O
,	O
substituted	O
or	O
unsubstituted	O
phenyl	B
,	O
substituted	O
or	O
unsubstituted	O
amino	B
,	O
a	O
nitrile	B
group	O
,	O
nitryl	B
and	O
halogen	B
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
isoandrographolide	B
derivative	O
and	O
application	O
of	O
the	O
isoandrographolide	B
derivative	O
to	O
preparation	O
of	O
a	O
lipid	O
-	O
regulating	O
medicament	O
.	O

Substituted	O
isoandrographolide	B
derivative	O
,	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
application	O
of	O
resveratrol	B
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
and	O
treating	O
respiratory	O
syncytial	O
virus	O
infections	O
,	O
wherein	O
the	O
resveratrol	B
can	O
obviously	O
reduce	O
the	O
infection	O
titer	O
of	O
a	O
respiratory	O
syncytial	O
virus	O
and	O
IL-6	O
secretion	O
induced	O
by	O
the	O
respiratory	O
syncytial	O
virus	O
in	O
vitro	O
;	O
and	O
the	O
resveratrol	B
can	O
obviously	O
reduce	O
the	O
titer	O
of	O
the	O
respiratory	O
syncytial	O
virus	O
in	O
lung	O
tissues	O
of	O
a	O
mouse	O
with	O
the	O
respiratory	O
syncytial	O
virus	O
infection	O
in	O
vivo	O
and	O
has	O
a	O
better	O
therapeutic	O
action	O
on	O
airway	O
inflammations	O
and	O
airway	O
high	O
reaction	O
induced	O
by	O
the	O
respiratory	O
syncytial	O
virus	O
.	O

Application	O
of	O
resveratrol	B
in	O
preparing	O
medicament	O
for	O
preventing	O
and	O
treating	O
respiratory	O
syncytial	O
virus	O
infections	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
a	O
composition	O
containing	O
choline	B
alfoscerate	I
.	O

The	O
composition	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
the	O
following	O
components	O
:	O
5	O
-	O
20	O
percent	O
of	O
choline	B
alfoscerate	I
,	O
0	O
-	O
5	O
percent	O
of	O
glycerin	B
,	O
a	O
suitable	O
amount	O
of	O
other	O
accessories	O
and	O
the	O
balance	O
of	O
injection	O
water	O
;	O
the	O
content	O
and	O
the	O
impurities	O
of	O
the	O
injection	O
are	O
detected	O
by	O
adopting	O
a	O
high	O
-	O
pressure	O
liquid	O
-	O
phase	O
chromatogram	O
;	O
and	O
the	O
total	O
amount	O
of	O
the	O
impurities	O
is	O
controlled	O
to	O
be	O
not	O
more	O
than	O
2	O
percent	O
.	O

The	O
choline	B
alfoscerate	I
is	O
clinically	O
used	O
for	O
treating	O
patients	O
with	O
senile	O
dementia	O
and	O
cerebral	O
apoplexy	O
.	O

Choline	B
alfoscerate	I
injection	O
preparation	O
as	O
well	O
as	O
preparation	O
method	O
and	O
detection	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
solid	O
preparation	O
of	O
a	O
compound	O
sodium	B
rabeprazole	I
medicinal	O
composition	O
.	O

In	O
the	O
compound	O
sodium	B
rabeprazole	I
medicinal	O
composition	O
,	O
sodium	B
rabeprazole	I
,	O
sodium	B
bicarbonate	I
and	O
optional	O
magnesium	B
hydroxide	I
are	O
used	O
as	O
main	O
ingredients	O
in	O
a	O
compound	O
medicament	O
,	O
and	O
the	O
solid	O
preparation	O
is	O
chewable	O
tablets	O
,	O
capsules	O
or	O
dry	O
mixed	O
suspensions	O
.	O

Compared	O
with	O
the	O
conventional	O
sodium	B
rabeprazole	I
preparation	O
,	O
the	O
solid	O
preparation	O
has	O
the	O
advantages	O
that	O
:	O
enteric	O
coatings	O
are	O
replaced	O
by	O
the	O
sodium	B
bicarbonate	I
and/or	O
the	O
magnesium	B
hydroxide	I
,	O
so	O
the	O
solid	O
preparation	O
has	O
the	O
effect	O
of	O
inhibiting	O
and	O
buffering	O
gastric	O
acid	O
,	O
ensures	O
that	O
the	O
sodium	B
rabeprazole	I
can	O
be	O
absorbed	O
quickly	O
,	O
and	O
has	O
the	O
unique	O
pharmacological	O
action	O
.	O

Solid	O
preparation	O
of	O
compound	O
sodium	B
rabeprazole	I
medicinal	O
composition	O

Disclosed	O
is	O
a	O
substance	O
delivery	O
carrier	O
for	O
an	O
extracellular	O
-	O
matrix	O
-	O
producing	O
cell	O
in	O
the	O
bone	O
marrow	O
,	O
which	O
comprises	O
a	O
retinoid	O
.	O

Also	O
disclosed	O
is	O
an	O
agent	O
for	O
treating	O
myelofibrosis	O
by	O
utilizing	O
a	O
substance	O
capable	O
of	O
regulating	O
the	O
activity	O
or	O
proliferation	O
of	O
an	O
extracellular	O
-	O
matrix	O
-	O
producing	O
cell	O
in	O
the	O
bone	O
marrow	O
.	O

Agent	O
for	O
treating	O
myelofibrosis	O

The	O
invention	O
relates	O
to	O
a	O
veterinary	O
long	O
-	O
acting	O
compound	O
doxycycline	B
injection	O
,	O
which	O
consists	O
of	O
doxycycline	B
or	O
doxycycline	B
hydrochloride	I
which	O
serves	O
as	O
a	O
main	O
medicament	O
,	O
a	O
synergist	O
,	O
a	O
solvent	O
,	O
a	O
complexing	O
agent	O
,	O
an	O
antioxidant	O
and	O
a	O
pH	O
regulator	O
,	O
wherein	O
the	O
weight	O
of	O
the	O
doxycycline	B
or	O
the	O
doxycycline	B
hydrochloride	I
which	O
serves	O
as	O
the	O
main	O
medicament	O
is	O
between	O
10.0	O
and	O
20.0	O
grams	O
based	O
on	O
the	O
weight	O
of	O
the	O
doxycycline	B
;	O
the	O
synergist	O
is	O
0.2	O
to	O
5	O
grams	O
of	O
trimethoprim	B
or	O
0.2	O
to	O
5	O
grams	O
of	O
astragalus	O
polysaccharide	O
or	O
a	O
combination	O
of	O
the	O
trimethoprim	B
and	O
the	O
astragalus	O
polysaccharide;a	O
molar	O
ratio	O
of	O
the	O
complexing	O
agent	O
to	O
the	O
doxycycline	B
is	O
(	O
1.00	O
-	O
1.10	O
)	O
:1.00	O
;	O
the	O
using	O
amount	O
of	O
the	O
antioxidant	O
is	O
between	O
0.10	O
and	O
1.00	O
;	O
and	O
the	O
solvent	O
for	O
the	O
used	O
injection	O
is	O
100	O
milliliters	O
after	O
being	O
added	O
,	O
and	O
is	O
water	O
for	O
the	O
injection	O
,	O
propylene	B
glycol	I
,	O
alpha	B
-	I
pyrrolidone	I
,	O
N	B
methyl	I
-	I
pyrrolidone	I
,	O
dimethylformamide	B
,	O
dimethylacetylamide	B
and	O
a	O
combination	O
thereof	O
.	O

In	O
the	O
veterinary	O
long	O
-	O
acting	O
compound	O
doxycycline	B
injection	O
,	O
the	O
curative	O
effect	O
of	O
the	O
injection	O
is	O
improved	O
by	O
the	O
trimethoprim	B
serving	O
as	O
the	O
medicinal	O
intensifier	O
,	O
and	O
the	O
astragalus	O
polysaccharide	O
has	O
the	O
effects	O
of	O
resisting	O
virus	O
and	O
enhancing	O
immunity	O
.	O

Veterinary	O
long	O
-	O
acting	O
compound	O
doxycycline	B
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
chitosan	O
cervix	O
uteri	O
anti	O
-	O
microbial	O
membrane	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
chitosan	O
cervix	O
uteri	O
anti	O
-	O
microbial	O
membrane	O
has	O
a	O
structure	O
of	O
a	O
circular	O
plate	O
,	O
bulged	O
flangings	O
are	O
formed	O
at	O
the	O
periphery	O
of	O
the	O
circular	O
plate	O
,	O
and	O
a	O
convex	O
body	O
is	O
arranged	O
in	O
the	O
center	O
of	O
the	O
reverse	O
side	O
of	O
the	O
circular	O
plate	O
.	O

The	O
chitosan	O
cervix	O
uteri	O
anti	O
-	O
microbial	O
membrane	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
percentage	O
by	O
mass	O
:	O
0.5	O
to	O
5.0	O
percent	O
of	O
chitosan	O
iodine	O
,	O
2.0	O
to	O
10.0	O
percent	O
of	O
polysorbate-20	B
,	O
0.1	O
to	O
2.0	O
percent	O
of	O
acetic	B
acid	I
,	O
0.1	O
to	O
5.0	O
percent	O
of	O
hydroxypropyl	O
methyl	O
cellulose	O
,	O
1.0	O
to	O
10.0	O
percent	O
of	O
gelatin	B
,	O
1.0	O
to	O
10.0	O
percent	O
of	O
glycerol	B
and	O
the	O
balance	O
of	O
purified	O
water	O
.	O

The	O
chitosan	O
cervix	O
uteri	O
anti	O
-	O
microbial	O
membrane	O
is	O
prepared	O
from	O
novel	O
biological	O
materials	O
synthesized	O
by	O
the	O
chitosan	B
and	O
derivatives	O
thereof	O
by	O
processes	O
of	O
freezing	O
,	O
vacuum	O
drying	O
and	O
the	O
like	O
according	O
to	O
characteristics	O
of	O
human	O
anatomy	O
,	O
pathology	O
,	O
physiology	O
and	O
the	O
like	O
,	O
has	O
a	O
shape	O
of	O
a	O
thin	O
curved	O
surface	O
,	O
and	O
can	O
be	O
in	O
full	O
fit	O
with	O
pathological	O
tissue	O
,	O
absorb	O
wound	O
exudate	O
and	O
eliminate	O
necrotic	O
tissue	O
by	O
being	O
attached	O
to	O
cervix	O
uteri	O
surfaces	O
outside	O
uterine	O
cavities	O
,	O
so	O
that	O
wounds	O
are	O
drained	O
fully	O
;	O
and	O
sterilizing	O
inflammation	O
-	O
diminishing	O
active	O
factors	O
are	O
released	O
in	O
a	O
sustained	O
way	O
at	O
the	O
targeting	O
position	O
to	O
promote	O
wound	O
union	O
effectively	O
.	O

The	O
chitosan	O
cervix	O
uteri	O
anti	O
-	O
microbial	O
membrane	O
is	O
suitable	O
for	O
patients	O
who	O
suffer	O
from	O
gynecological	O
cervical	O
diseases	O
.	O

Chitosan	O
cervix	O
uteri	O
anti	O
-	O
microbial	O
membrane	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
selegiline	B
,	O
an	O
adhesive	O
and	O
polyvinylpyrrolidone	B
and	O
the	O
application	O
of	O
the	O
composition	O
to	O
preparing	O
a	O
selegiline	B
transdermal	O
patch	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
selegiline	B
transdermal	O
patch	O
containing	O
the	O
composition	O
.	O

The	O
adhesive	O
of	O
the	O
composition	O
and	O
the	O
selegiline	B
transdermal	O
patch	O
is	O
a	O
mixing	O
system	O
of	O
acrylic	O
polymers	O
,	O
particularly	O
a	O
mixture	O
of	O
two	O
acrylates	O
with	O
different	O
characteristics	O
.	O

The	O
existence	O
of	O
suitable	O
polyvinylpyrrolidone	B
in	O
the	O
system	O
can	O
keep	O
the	O
stabilization	O
of	O
the	O
selegiline	B
in	O
the	O
composition	O
and	O
the	O
transdermal	O
patch	O
and	O
reduce	O
volatilization	O
,	O
and	O
the	O
prepared	O
transdermal	O
patch	O
has	O
favorable	O
physical	O
and	O
chemical	O
characteristics	O
and	O
excellent	O
diadermic	O
performance	O
.	O

Composition	O
containing	O
selegiline	B
and	O
transdermal	O
patch	O
containing	O
composition	O

The	O
invention	O
discloses	O
an	O
oral	O
Chinese	O
medical	O
preparation	O
for	O
treating	O
acute	O
periodontitis	O
.	O

The	O
preparation	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
material	O
herbs	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
20	O
parts	O
of	O
white	O
peony	O
,	O
10	O
-	O
20	O
parts	O
of	O
indigo	O
,	O
10	O
-	O
20	O
parts	O
of	O
root	O
of	O
red	O
-	O
rooted	O
salvia	O
,	O
10	O
-	O
20	O
parts	O
of	O
drynaria	O
rhizome	O
,	O
10	O
-	O
20	O
parts	O
of	O
pseudo	O
-	O
ginseng	O
,	O
10	O
-	O
20	O
parts	O
of	O
radix	O
angelicae	O
formosanae	O
,	O
10	O
-	O
20	O
parts	O
of	O
evodia	O
rutaecarpa	O
,	O
10	O
-	O
20	O
parts	O
of	O
dried	O
rehamnnia	O
root	O
,	O
10	O
-	O
20	O
parts	O
of	O
honeysuckle	O
,	O
10	O
-	O
20	O
parts	O
of	O
dandelion	O
,	O
10	O
-	O
20	O
parts	O
of	O
scutellaria	O
baicalensis	O
,	O
10	O
-	O
20	O
parts	O
of	O
rheum	O
officinale	O
,	O
10	O
-	O
20	O
parts	O
of	O
borneol	B
,	O
10	O
-	O
20	O
parts	O
of	O
fructus	O
forsythiae	O
,	O
10	O
-	O
20	O
parts	O
of	O
cordate	O
houttuynia	O
and	O
10	O
-	O
20	O
parts	O
of	O
catechu	O
.	O

By	O
utilizing	O
different	O
Chinese	O
medical	O
characteristics	O
,	O
the	O
invention	O
researches	O
the	O
Chinese	O
medical	O
preparation	O
which	O
can	O
clear	O
away	O
heat	O
,	O
detoxify	O
,	O
reduce	O
swelling	O
,	O
alleviate	O
pain	O
,	O
remove	O
necrotic	O
tissue	O
,	O
promote	O
granulation	O
and	O
stop	O
bleeding	O
with	O
astringents	O
and	O
has	O
a	O
favorable	O
curative	O
effect	O
on	O
acute	O
periodontitis	O
.	O

The	O
oral	O
Chinese	O
medical	O
preparation	O
for	O
treating	O
acute	O
periodontitis	O
has	O
the	O
maximum	O
advantage	O
of	O
rapidly	O
alleviating	O
pain	O
,	O
can	O
take	O
an	O
auxiliary	O
curative	O
effect	O
on	O
patients	O
subjected	O
to	O
dental	O
operations	O
,	O
and	O
can	O
clear	O
away	O
heat	O
,	O
detoxify	O
,	O
reduce	O
swelling	O
and	O
alleviate	O
pain	O
.	O

Oral	O
Chinese	O
medical	O
preparation	O
for	O
treating	O
acute	O
periodontitis	O

The	O
invention	O
provides	O
a	O
composition	O
for	O
improving	O
the	O
absorbance	O
of	O
aminoglycoside	B
drug	O
,	O
which	O
has	O
greatly	O
-	O
improved	O
absorbance	O
in	O
organisms	O
and	O
exhibits	O
effective	O
pharmacological	O
action	O
.	O

The	O
composition	O
contains	O
0.1	O
to	O
5	O
%	O
absorption	O
enhancer	O
,	O
which	O
is	O
one	O
or	O
more	O
of	O
medium	O
chain	O
sodium	B
aliphatate	I
salt	O
and	O
cholic	B
acid	I
salts	O
;	O
5	O
to	O
20	O
%	O
of	O
aminoglycoside	B
drug	O
,	O
and	O
the	O
balance	O
of	O
pharmaceutically	O
acceptable	O
auxiliaries	O
.	O

Oral	O
administration	O
of	O
the	O
aminoglycoside	B
drug	O
results	O
in	O
quite	O
little	O
absorption	O
of	O
the	O
aminoglycoside	B
drug	O
,	O
and	O
clinical	O
oral	O
drug	O
is	O
used	O
only	O
as	O
the	O
drug	O
for	O
enteric	O
infection	O
.	O

According	O
to	O
the	O
invention	O
,	O
as	O
the	O
absorption	O
enhancer	O
is	O
added	O
,	O
the	O
applicable	O
scope	O
of	O
the	O
aminoglycoside	B
drug	O
is	O
widened	O
,	O
and	O
oral	O
administration	O
can	O
reach	O
the	O
purpose	O
of	O
treating	O
general	O
infection	O
.	O

Composition	O
for	O
improving	O
absorbance	O
of	O
aminoglycoside	B
drug	O

The	O
invention	O
discloses	O
castor	O
oil	O
micro	O
-	O
emulsion	O
composition	O
for	O
coating	O
a	O
Nifeviroc	B
anti	O
-	O
cancer	O
medicine	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
composition	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
mass	O
:	O
0.1	O
to	O
0.3	O
percent	O
of	O
Nifeviroc	B
,	O
1	O
to	O
3	O
percent	O
of	O
lipid	O
material	O
,	O
3	O
to	O
9	O
percent	O
of	O
emulsifier	O
,	O
1.5	O
to	O
4.5	O
percent	O
of	O
auxiliary	O
emulsifier	O
,	O
0.1	O
to	O
0.5	O
percent	O
of	O
bacteriostat	O
and	O
the	O
balance	O
of	O
super	O
-	O
pure	O
water	O
.	O

The	O
micro	O
-	O
emulsion	O
has	O
high	O
stability	O
,	O
high	O
physiological	O
compatibility	O
and	O
high	O
safety	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
and	O
controllable	O
and	O
has	O
high	O
repeatability	O
.	O

The	O
castor	O
oil	O
micro	O
-	O
emulsion	O
composition	O
coated	O
Nifeviroc	B
anti	O
-	O
cancer	O
medicine	O
can	O
prevent	O
and	O
treat	O
acquired	O
immune	O
deficiency	O
syndrome	O
as	O
a	O
microbicide	O
to	O
be	O
applied	O
through	O
vagina	O
.	O

Castor	O
oil	O
micro	O
-	O
emulsion	O
for	O
Nifeviroc	B
anti	O
-	O
cancer	O
medicine	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
externally	O
applied	O
preparation	O
for	O
relieving	O
pain	O
and	O
diminishing	O
inflammation	O
,	O
and	O
a	O
preparation	O
method	O
and	O
a	O
detection	O
method	O
thereof	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmacy	O
.	O

The	O
product	O
is	O
prepared	O
by	O
using	O
camphor	B
,	O
menthol	B
crystal	O
and	O
other	O
raw	O
materials	O
and	O
has	O
a	O
good	O
effect	O
.	O

The	O
preparation	O
is	O
very	O
stable	O
and	O
convenient	O
for	O
use	O
and	O
can	O
be	O
accepted	O
by	O
patients	O
easily	O
.	O

The	O
provided	O
preparation	O
method	O
can	O
effectively	O
prepare	O
the	O
required	O
preparation	O
and	O
ensure	O
the	O
production	O
process	O
of	O
the	O
prepared	O
preparation	O
is	O
scientific	O
and	O
reasonable	O
.	O

The	O
provided	O
detection	O
method	O
effectively	O
ensures	O
the	O
quality	O
of	O
the	O
product	O
.	O

Externally	O
applied	O
preparation	O
for	O
relieving	O
pain	O
and	O
diminishing	O
inflammation	O
,	O
preparation	O
method	O
and	O
detection	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
tremellan	O
with	O
low	O
molecular	O
weight	O
from	O
Tremella	O
fueiformis	O
Berk	O
and	O
application	O
of	O
the	O
tremellan	O
with	O
low	O
molecular	O
weight	O
in	O
treatment	O
for	O
chronic	O
atrophic	O
gastritis	O
and	O
serving	O
as	O
an	O
adjuvant	O
medicament	O
in	O
tumor	O
therapy	O
.	O

The	O
method	O
for	O
preparing	O
the	O
tremellan	O
with	O
low	O
molecular	O
weight	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
cleaning	O
the	O
Tremella	O
fueiformis	O
Berk	O
,	O
homogenating	O
,	O
adding	O
solution	O
of	O
acid	O
water	O
,	O
extracting	O
for	O
1	O
to	O
3	O
hours	O
by	O
using	O
the	O
acid	O
water	O
at	O
certain	O
temperature	O
and	O
under	O
certain	O
pressure	O
,	O
neutralizing	O
extracting	O
solution	O
of	O
the	O
acid	O
water	O
until	O
the	O
extracting	O
solution	O
is	O
neutral	O
by	O
using	O
alkaline	O
water	O
,	O
centrifuging	O
,	O
concentrating	O
supernatant	O
to	O
an	O
appropriate	O
volume	O
,	O
and	O
preparing	O
the	O
tremellan	O
through	O
ultrafiltration	O
membranes	O
with	O
different	O
molecular	O
weight	O
cutoffs	O
or	O
an	O
ethanol	B
fractional	O
precipitation	O
method	O
.	O

The	O
tremellan	O
with	O
low	O
molecular	O
weight	O
prepared	O
by	O
the	O
method	O
is	O
used	O
for	O
treating	O
chronic	O
atrophic	O
gastritis	O
and	O
carrying	O
out	O
pharmacodynamics	O
research	O
of	O
adjuvant	O
medicaments	O
in	O
tumor	O
therapy	O
,	O
and	O
the	O
medicinal	O
effect	O
is	O
high	O
.	O

Method	O
for	O
preparing	O
tremellan	O
with	O
low	O
molecular	O
weight	O
and	O
novel	O
medicinal	O
application	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
halogenated	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
with	O
the	O
substituents	O
as	O
described	O
within	O
the	O
specification	O
.	O

The	O
compounds	O
may	O
be	O
useful	O
as	O
anti	O
-	O
fibrqtic	O
agents	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
their	O
preparation	O
.	O

Halogenated	O
analogues	O
of	O
anti	O
-	O
fibrotic	O
agents	O

The	O
invention	O
relates	O
to	O
a	O
pranlukast	B
injection	O
preparation	O
.	O

In	O
the	O
invention	O
,	O
an	O
alcohols	B
solvent	O
which	O
can	O
be	O
accepted	O
in	O
drugs	O
contains	O
effective	O
doses	O
of	O
pranlukast	B
and	O
alkaline	O
constituents	O
allowed	O
to	O
be	O
used	O
in	O
the	O
needed	O
drugs	O
which	O
can	O
fully	O
convert	O
the	O
pranlukast	B
into	O
water	O
soluble	O
salt	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
pranlukast	B
to	O
the	O
alcohols	B
solvent	O
is	O
1	O
:	O
(	O
7	O
-	O
70	O
)	O
and	O
the	O
pH	O
(	O
potential	O
of	O
Hydrogen	B
)	O
value	O
of	O
the	O
injection	O
preparation	O
is	O
3	O
-	O
10	O
.	O

By	O
utilizing	O
the	O
injection	O
preparation	O
,	O
the	O
problems	O
that	O
the	O
pranlukast	B
has	O
low	O
solubility	O
and	O
the	O
bioavailability	O
of	O
a	O
traditional	O
oral	O
preparation	O
is	O
low	O
are	O
effectively	O
and	O
thoroughly	O
solved	O
;	O
the	O
concentration	O
of	O
the	O
pranlukast	B
in	O
the	O
injection	O
preparation	O
can	O
reach	O
1	O
%	O
;	O
and	O
therefore	O
,	O
the	O
drug	O
dosage	O
can	O
be	O
greatly	O
decreased	O
,	O
the	O
preparation	O
is	O
convenient	O
to	O
prepare	O
and	O
the	O
drug	O
cost	O
is	O
reduced	O
.	O

Pranlukast	B
injection	O
preparation	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composite	O
for	O
treating	O
brain	O
glioma	O
.	O

The	O
medicinal	O
composite	O
comprises	O
the	O
following	O
active	O
pharmaceutical	O
ingredients	O
:	O
temozolomide	B
and	O
ectoine	B
(	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic	B
acid	I
)	O
or	O
a	O
derivative	O
of	O
ectoine	B
,	O
wherein	O
the	O
derivative	O
of	O
the	O
ectoine	B
is	O
1,4,5,6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic	B
acid	I
,	O
and	O
the	O
mass	O
ratio	O
of	O
temozolomide	B
to	O
ectoine	B
or	O
a	O
derivative	O
of	O
ectoine	B
is	O
(	O
2	O
-	O
4	O
)	O
:	O
1	O
.	O

Research	O
shows	O
that	O
,	O
in	O
the	O
case	O
of	O
combined	O
administration	O
of	O
the	O
ectoine	B
,	O
the	O
derivative	O
of	O
the	O
ectoine	B
and	O
the	O
temozolomide	B
in	O
a	O
certain	O
proportion	O
,	O
the1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic	O
acid	B
and	O
the	O
derivative	O
thereof	O
can	O
obviously	O
improve	O
treatment	O
effect	O
of	O
the	O
temozolomide	B
and	O
reduce	O
adverse	O
effect	O
of	O
the	O
temozolomide	B
.	O

Medicinal	O
composite	O
for	O
treating	O
brain	O
glioma	O

The	O
invention	O
discloses	O
a	O
plaster	O
and	O
a	O
preparation	O
method	O
of	O
the	O
plaster	O
.	O

The	O
crude	O
drugs	O
of	O
the	O
plaster	O
include	O
:	O
55	O
-	O
65	O
g	O
of	O
Strychnos	O
,	O
85	O
-	O
95	O
g	O
of	O
radi	O
of	O
x	O
clematidis	O
,	O
40	O
-	O
50	O
g	O
of	O
frankincense	O
,	O
40	O
-	O
50	O
g	O
of	O
myrrh	O
,	O
25	O
-	O
35	O
g	O
of	O
dragon	O
's	O
blood	O
,	O
40	O
-50	O
g	O
of	O
angelica	O
,	O
25	O
-	O
35	O
g	O
of	O
pseudo	O
-	O
ginseng	O
,	O
45	O
-	O
55	O
g	O
of	O
Ligusticum	O
wallichii	O
,	O
45	O
-	O
55	O
g	O
of	O
Rhizoma	O
Wenyujin	O
Concisum	O
,	O
40	O
-	O
50	O
g	O
of	O
safflower	O
,	O
45	O
-	O
55	O
g	O
of	O
Processed	O
Radix	O
Aconiti	O
,	O
45	O
-	O
55	O
g	O
of	O
Processed	O
Radix	O
Aconiti	O
Kusnezoffii	O
,	O
55	O
-	O
65	O
g	O
of	O
ephedra	O
,	O
85	O
-	O
95	O
g	O
of	O
cassia	O
twig	O
,	O
35	O
-	O
45	O
g	O
of	O
notopterygium	O
root	O
,	O
35	O
-	O
45	O
g	O
of	O
radix	O
angelicae	O
pubescentis	O
,	O
55	O
-	O
65	O
g	O
of	O
garden	O
balsam	O
stem	O
,	O
45	O
-	O
55	O
g	O
of	O
lycopodium	O
clavatum	O
,	O
35	O
-	O
45	O
g	O
of	O
Rhizoma	O
Drynariae	O
,	O
45	O
-	O
55	O
g	O
of	O
radix	O
dipsaci	O
,	O
45	O
-	O
55	O
g	O
of	O
Eupolyphaga	O
,	O
25	O
-	O
35	O
g	O
of	O
scorpio	O
,	O
40	O
-	O
50	O
g	O
of	O
lumbricus	O
,	O
40	O
-	O
50	O
g	O
of	O
pangolin	O
,	O
40	O
-	O
50	O
g	O
of	O
Asarum	O
and	O
15	O
-	O
25	O
g	O
of	O
borneol	B
.	O

The	O
formula	O
is	O
unique	O
,	O
the	O
production	O
method	O
is	O
simple	O
and	O
the	O
curative	O
effect	O
is	O
notable	O
.	O

Plaster	O
and	O
preparation	O
method	O
of	O
plaster	O

The	O
invention	O
discloses	O
a	O
new	O
crystal	O
form	O
of	O
lansoprazole	B
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
new	O
crystal	O
form	O
of	O
the	O
lansoprazole	B
is	O
easy	O
to	O
prepare	O
.	O

The	O
crystal	O
form	O
of	O
the	O
lansoprazole	B
prepared	O
by	O
the	O
method	O
has	O
high	O
purity	O
and	O
low	O
impurity	O
content	O
;	O
the	O
required	O
amount	O
of	O
a	O
solvent	O
is	O
small	O
,	O
and	O
production	O
cost	O
is	O
low	O
;	O
the	O
preparation	O
method	O
is	O
easy	O
to	O
operate	O
and	O
high	O
in	O
repeatability	O
;	O
reaction	O
conditions	O
are	O
mild	O
,	O
and	O
easy	O
to	O
control	O
;	O
and	O
the	O
target	O
product	O
crystal	O
form	O
can	O
be	O
stably	O
obtained	O
.	O

New	O
crystal	O
form	O
of	O
lansoprazole	B
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
A	O
,	O
B	O
,	O
W	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
and	O
to	O
pharmaceutically	O
acceptable	O
salts	O
of	O
such	O
compounds	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
calcium	B
channel	O
blockers	O
.	O

Bridged	O
tetrahydronaphthalene	B
derivatives	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
preparation	O
,	O
and	O
relates	O
to	O
a	O
supersaturated	O
self	O
-	O
microemulsified	O
administration	O
system	O
for	O
insoluble	O
anticancer	O
drugs	O
,	O
prepared	O
from	O
insoluble	O
anti	O
-	O
tumor	O
drugs	O
,	O
an	O
emulsifier	O
,	O
a	O
co	O
-	O
emulsifier	O
,	O
an	O
oil	O
phase	O
and	O
a	O
crystallization	O
inhibitor	O
in	O
different	O
mass	O
percents	O
;	O
and	O
the	O
administration	O
system	O
can	O
be	O
filled	O
into	O
soft	O
capsules	O
or	O
hard	O
capsules	O
.	O

The	O
supersaturated	O
self	O
-	O
microemulsified	O
administration	O
system	O
is	O
dispersible	O
after	O
oral	O
administration	O
to	O
form	O
microemulsion	O
with	O
the	O
particle	O
size	O
of	O
10	O
-	O
100	O
nm	O
,	O
thus	O
inhibiting	O
crystallization	O
and	O
separation	O
of	O
drugs	O
,	O
promoting	O
absorption	O
of	O
drugs	O
and	O
improving	O
the	O
bioavailability	O
of	O
drugs	O
.	O

The	O
administration	O
system	O
has	O
the	O
advantages	O
of	O
improving	O
the	O
solubility	O
of	O
the	O
insoluble	O
anticancer	O
drugs	O
in	O
water	O
,	O
inhibiting	O
the	O
exocytosis	O
of	O
the	O
intestinal	O
epithelial	O
cell	O
p	O
-	O
glycoprotein	O
on	O
drugs	O
,	O
improving	O
the	O
bioavailability	O
of	O
drugs	O
,	O
eliminating	O
the	O
influence	O
of	O
foods	O
on	O
the	O
absorption	O
and	O
bioavailability	O
of	O
drugs	O
,	O
and	O
the	O
like	O
.	O

Supersaturated	O
self	O
-	O
microemulsified	O
administration	O
system	O
for	O
insoluble	O
anti	O
-	O
tumor	O
drugs	O
,	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
DSPE	O
-	O
PEG2000-FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
.	O

A	O
molar	O
ratio	O
of	O
the	O
DSPE	O
-	O
PEG2000-FA	O
to	O
egg	O
yolk	O
lecithin	B
is	O
0.05	O
%	O
to	O
0.15	O
%	O
,	O
and	O
a	O
particle	O
size	O
of	O
the	O
liposome	O
is	O
less	O
than	O
150	O
nm	O
.	O

A	O
preparation	O
method	O
of	O
the	O
DSPE	O
-	O
PEG2000-FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
comprises	O
the	O
following	O
steps	O
:	O
first	O
,	O
preparing	O
a	O
DSPE	O
-	O
PEG2000-FA	O
into	O
a	O
DSPE	O
-	O
PEG2000-FA	O
micelle	O
;	O
second	O
,	O
performing	O
incubation	O
on	O
the	O
phosphatidyl	O
ethanolamine	B
-	O
polyethylene	B
glycol2000-folic	I
acid	B
micelle	O
and	O
a	O
paclitaxel	B
liposome	O
together	O
to	O
obtain	O
a	O
DSPE	O
-	O
PEG2000-FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
.	O

Materials	O
,	O
which	O
are	O
forbidden	O
to	O
be	O
used	O
in	O
clinical	O
practice	O
,	O
are	O
not	O
used	O
as	O
crude	O
materials	O
in	O
the	O
present	O
invention	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
DSPE	O
-	O
PEG2000-FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
has	O
a	O
small	O
particle	O
size	O
,	O
and	O
the	O
content	O
of	O
the	O
DSPE	O
-	O
PEG2000-FA	O
is	O
low	O
;	O
besides	O
,	O
the	O
DSPE	O
-	O
PEG2000-FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
has	O
good	O
drug	O
entrapment	O
efficiency	O
and	O
good	O
colloid	O
stability	O
.	O

Moreover	O
,	O
the	O
DSPE	O
-	O
PEG2000-FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
can	O
be	O
absorbed	O
effectively	O
by	O
an	O
ovarian	O
cancer	O
cell	O
having	O
properties	O
of	O
sensitiveness	O
to	O
folic	B
acid	I
(	O
+	O
)	O
and	O
drug	O
resistance	O
,	O
and	O
the	O
cytotoxicity	O
of	O
folic	B
acid	I
dependence	O
is	O
displayed	O
;	O
therefore	O
,	O
the	O
efficacy	O
of	O
the	O
DSPE	O
-	O
PEG2000-FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
is	O
stronger	O
than	O
that	O
of	O
a	O
paclitaxel	B
injection	O
.	O

DSPE	O
-	O
PEG	O
-	O
FA	O
-	O
modified	O
nanometer	O
paclitaxel	B
liposome	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
medicine	O
for	O
preventing	O
and	O
controlling	O
epilepsia	O
.	O

The	O
medicine	O
is	O
prepared	O
into	O
a	O
normal	O
medicine	O
formulation	O
by	O
taking	O
lamotrigine	B
(	O
LTG	B
)	O
,	O
valproate	B
sodium	I
(	O
VPA	B
)	O
,	O
promethazine	B
and	O
caffeine	B
sodium	I
benzoate	I
as	O
active	O
ingredients	O
and	O
using	O
a	O
medicinal	O
excipient	O
as	O
an	O
assistant	O
.	O

In	O
the	O
invention	O
,	O
when	O
the	O
LTG	B
,	O
VPA	B
,	O
promethazine	B
and	O
caffeine	B
sodium	I
benzoate	I
chemical	O
composition	O
is	O
used	O
for	O
treating	O
epilepsia	O
,	O
the	O
synergetic	O
effect	O
of	O
medicine	O
effects	O
is	O
obvious	O
,	O
the	O
treatment	O
effect	O
is	O
remarkable	O
,	O
and	O
the	O
rate	O
of	O
adverse	O
reactions	O
aroused	O
by	O
side	O
effects	O
such	O
as	O
giddiness	O
,	O
ataxia	O
,	O
diplopia	O
and	O
erythra	O
is	O
lowered	O
obviously	O
.	O

Medicines	O
for	O
preventing	O
and	O
treating	O
epilepsia	O

The	O
invention	O
relates	O
to	O
a	O
bone	O
peptide	O
composition	O
,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
part	O
by	O
weight	O
:	O
8	O
to	O
10	O
parts	O
of	O
bond	O
polypeptide	O
compound	O
A	O
,	O
5	O
to	O
8	O
parts	O
of	O
bone	O
polypeptide	O
compound	O
B	O
,	O
5	O
to	O
8	O
parts	O
of	O
bone	O
polypeptide	O
compound	O
C	O
,	O
4.5	O
to	O
7.5	O
parts	O
of	O
bone	O
polypeptide	O
compound	O
D	O
,	O
3	O
to	O
6	O
parts	O
of	O
bone	O
polypeptide	O
compound	O
E	O
,	O
16	O
to	O
22	O
parts	O
of	O
free	O
amino	B
acid	I
,	O
0.3	O
to	O
5.4	O
parts	O
of	O
ribose	B
,	O
0.04	O
to	O
0.12	O
parts	O
of	O
trace	O
element	O
and	O
0	O
to	O
0.01	O
parts	O
of	O
free	O
fatty	B
acid	I
,	O
wherein	O
amino	B
acid	I
sequences	O
of	O
the	O
bone	O
polypeptide	O
compounds	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
and	O
E	O
are	O
measured	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
bone	O
peptide	O
composition	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
,	O
convenient	O
,	O
easy	O
to	O
operate	O
and	O
high	O
in	O
yield	O
,	O
and	O
the	O
prepared	O
bone	O
peptide	O
composition	O
is	O
high	O
in	O
bioactivity	O
.	O

Bone	O
peptide	O
composition	O
,	O
preparation	O
thereof	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
preparation	O
which	O
contains	O
lidocaine	B
and	O
prilocaine	B
and	O
takes	O
a	O
condom	O
as	O
the	O
administration	O
carrier	O
.	O

According	O
to	O
the	O
invention	O
,	O
appropriate	O
medication	O
concentration	O
,	O
accurate	O
medication	O
dosage	O
and	O
medication	O
mode	O
are	O
defined	O
as	O
well	O
as	O
optimum	O
appropriate	O
crowd	O
,	O
the	O
waiting	O
time	O
between	O
the	O
medicine	O
application	O
to	O
a	O
penis	O
and	O
the	O
insertion	O
of	O
the	O
penis	O
into	O
a	O
vagina	O
is	O
greatly	O
shortened	O
,	O
the	O
sexual	O
intercourse	O
time	O
of	O
patients	O
with	O
mild	O
premature	O
ejaculation	O
is	O
obviously	O
prolonged	O
,	O
erection	O
failures	O
are	O
minimized	O
,	O
and	O
the	O
satisfaction	O
of	O
patients	O
and	O
their	O
sex	O
partners	O
is	O
greatly	O
improved	O
.	O

Medicinal	O
preparation	O
for	O
prolonging	O
sexual	O
intercourse	O
time	O

The	O
invention	O
which	O
belongs	O
to	O
the	O
field	O
of	O
drugs	O
for	O
radiotherapy	O
sensitization	O
relates	O
to	O
a	O
new	O
use	O
of	O
sodium	B
oxamate	I
,	O
that	O
is	O
,	O
an	O
application	O
of	O
sodium	B
oxamate	I
in	O
preparing	O
the	O
drugs	O
for	O
radiotherapy	O
sensitization	O
.	O

The	O
structural	O
formula	O
of	O
sodium	B
oxamate	I
is	O
shown	O
as	O
follows	O
:	O
NH2	B
(	I
CO	I
)	I
2ONa	I
.	O

The	O
sodium	B
oxamate	I
can	O
be	O
used	O
to	O
prepare	O
the	O
drugs	O
for	O
radiotherapy	O
sensitization	O
,	O
and	O
low	O
concentration	O
sodium	B
oxamate	I
with	O
no	O
toxic	O
and	O
side	O
effects	O
allows	O
the	O
radiation	O
sensitivity	O
of	O
tumor	O
cells	O
to	O
be	O
improved	O
.	O

Application	O
of	O
sodium	B
oxamate	I
in	O
preparing	O
drugs	O
for	O
radiotherapy	O
sensitization	O

The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
cefotiam	B
hydrochloride	I
compound	O
,	O
which	O
is	O
a	O
powder	O
injection	O
and	O
is	O
composed	O
of	O
,	O
by	O
weight	O
,	O
3	O
-	O
10	O
parts	O
of	O
cefotiam	B
hydrochloride	I
,	O
0.1	O
-	O
0.5	O
parts	O
of	O
sodium	B
carbonate	I
and	O
20	O
-	O
150	O
parts	O
of	O
mannitol	B
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
pharmaceutical	O
composition	O
,	O
comprising	O
steps	O
of	O
:	O
mixing	O
the	O
cefotiam	B
hydrochloride	I
and	O
the	O
mannitol	B
to	O
produce	O
freeze	O
-	O
drying	O
powders	O
,	O
making	O
soda	B
ash	I
into	O
a	O
freeze	O
-	O
drying	O
powder	O
,	O
and	O
mixing	O
the	O
freeze	O
-	O
drying	O
powders	O
,	O
followed	O
by	O
drying	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
stability	O
of	O
thepharmaceutical	O
composition	O
powder	O
injection	O
is	O
raised	O
,	O
the	O
storage	O
time	O
of	O
the	O
pharmaceutical	O
composition	O
is	O
prolonged	O
,	O
and	O
simultaneously	O
medication	O
waste	O
and	O
medication	O
hidden	O
troubles	O
caused	O
by	O
the	O
medicine	O
instability	O
are	O
avoided	O
.	O

The	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
,	O
wherein	O
cefotiam	B
hydrochloride	I
and	O
sodium	B
carbonate	I
are	O
respectively	O
prepared	O
into	O
freeze	O
-	O
drying	O
powders	O
and	O
then	O
the	O
freeze	O
-	O
drying	O
powders	O
are	O
mixed	O
,	O
avoids	O
the	O
influence	O
of	O
CO2	B
released	O
from	O
the	O
dissolved	O
sodium	B
carbonate	I
on	O
the	O
decomposition	O
of	O
the	O
cefotiam	B
hydrochloride	I
,	O
reduces	O
the	O
content	O
of	O
impurities	O
in	O
the	O
freeze	O
-	O
drying	O
powder	O
injection	O
,	O
makes	O
the	O
best	O
use	O
of	O
active	O
ingredients	O
,	O
and	O
is	O
suitable	O
for	O
large	O
scale	O
production	O
.	O

Pharmaceutical	O
composition	O
containing	O
cefotiam	B
hydrochloride	I
compound	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
sensitizing	O
drugs	O
for	O
radiotherapy	O
,	O
and	O
relates	O
to	O
a	O
new	O
application	O
of	O
a	O
tetracycline	B
derivative	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
the	O
tetracycline	B
derivative	O
in	O
preparing	O
a	O
sensitizing	O
drug	O
for	O
radiotherapy	O
.	O

The	O
structural	O
formula	O
of	O
the	O
tetracycline	B
derivative	O
is	O
as	O
shown	O
in	O
the	O
specification	O
.	O

The	O
tetracycline	B
derivative	O
disclosed	O
by	O
the	O
invention	O
can	O
beused	O
for	O
preparing	O
a	O
sensitizing	O
drug	O
for	O
radiotherapy	O
,	O
and	O
can	O
improve	O
the	O
radiosensitivity	O
of	O
tumor	O
cells	O
under	O
low	O
concentration	O
of	O
the	O
tetracycline	B
derivative	O
without	O
toxic	O
side	O
effects	O
.	O

Application	O
of	O
tetracycline	B
derivative	O
in	O
preparing	O
sensitizing	O
drug	O
for	O
radiotherapy	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
as	O
PARP	O
inhibitors	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
n	O
,	O
s	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
Q	O
,	O
X	O
and	O
Y	O
have	O
defined	O
meanings	O
.	O

Substituted	O
6-cyclohexylalkyl	B
substituted	I
2-quinolinones	I
and	O
2-quinoxalinones	B
as	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
salvia	O
extract	O
in	O
treating	O
septicemia	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
the	O
salvia	O
extract	O
,	O
namely	O
dihydroxyl	B
phenyl	I
lactic	I
acid	I
or	O
salvianolic	B
acid	I
B	I
in	O
treating	O
and/or	O
preventing	O
septicemia	O
.	O

Application	O
of	O
salvia	O
extract	O
in	O
treating	O
septicemia	O

The	O
invention	O
provides	O
a	O
medicinal	O
composition	O
,	O
which	O
contains	O
an	O
effective	O
dose	O
of	O
3-aminopyridine-2-formaldehyde	B
thiosemicarbazone	I
for	O
treating	O
cancers	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
invention	O
also	O
provides	O
a	O
composition	O
for	O
oral	O
taking	O
,	O
which	O
contains	O
an	O
effective	O
dose	O
of	O
3-aminopyridine-2-formaldehyde	B
thiosemicarbazone	I
and	O
the	O
acceptable	O
carrier	O
.	O

The	O
invention	O
also	O
provides	O
the	O
medicinal	O
composition	O
for	O
intravenous	O
administration	O
,	O
which	O
contains	O
3-aminopyridine-2-formaldehyde	B
thiosemicarbazone	I
in	O
an	O
amount	O
which	O
is	O
enough	O
for	O
supplying	O
about	O
100	O
to	O
200mg	O
/	O
m<2	O
>	O
to	O
an	O
acceptor	O
every	O
day	O
.	O

Finally	O
,	O
the	O
invention	O
provides	O
a	O
container	O
which	O
can	O
prevent	O
3-aminopyridine-2-formaldehyde	B
thiosemicarbazone	I
from	O
decomposing	O
and	O
being	O
damaged	O
in	O
light	O
and	O
contains	O
at	O
least	O
an	O
effective	O
dose	O
of	O
3-aminopyridine-2-formaldehyde	B
thiosemicarbazone	I
.	O

Use	O
of	O
composition	O
containing	O
3-aminopyridine-2-formaldehyde	B
thiosemicarbazone	I
in	O
treatment	O
of	O
cancers	O

The	O
invention	O
discloses	O
a	O
1,4-pentadiene-3-ketone	B
compound	O
including	O
a	O
sulfonic	B
acid	I
ester	I
group	O
,	O
a	O
structural	O
general	O
formula	O
(	O
I	O
)	O
of	O
which	O
is	O
as	O
follows	O
:	O
FORMULA	O
,	O
wherein	O
a	O
substitutional	O
sulfonic	B
acid	I
ester	I
base	O
on	O
a	O
benzene	B
ring	O
is	O
in	O
an	O
ortho	O
-	O
position	O
,	O
a	O
meta	O
-	O
position	O
or	O
a	O
para	O
-	O
position	O
;	O
R1	O
is	O
C1	B
-	I
6	I
alkyl	I
,	O
phenyl	B
,	O
ortho	O
,	O
meta	O
and	O
para	O
mono	O
-	O
substitutional	O
or	O
multi	O
-	O
substitutional	O
phenyl	B
or	O
heterocyclic	B
ring	O
;	O
and	O
R2	O
is	O
C1	B
-	I
6	I
alkyl	I
,	O
phenyl	B
,	O
ortho	O
,	O
meta	O
and	O
para	O
mono	O
-	O
substitutional	O
or	O
multi	O
-	O
substitutional	O
phenyl	B
or	O
heterocyclic	B
ring	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
method	O
for	O
preparing	O
the	O
1,4-pentadiene-3-ketone	B
compound	O
including	O
the	O
sulfonic	B
acid	I
ester	I
group	O
and	O
use	O
in	O
antitumor	O
inhibitors	O
.	O

1,4-pentadiene-3-ketone	B
compound	O
including	O
sulfonic	B
acid	I
ester	I
group	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
new	O
silodosin	B
crystal	O
form	O
delta	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
.	O

The	O
crystal	O
form	O
is	O
characterized	O
by	O
an	O
X	O
-	O
ray	O
diffraction	O
pattern	O
of	O
the	O
silodosin	B
crystal	O
form	O
delta	O
powder	O
.	O

New	O
silodosin	B
crystal	O
form	O
delta	O
,	O
preparation	O
method	O
thereof	O
and	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O

The	O
invention	O
discloses	O
a	O
pleuromutilin	B
derivate	O
,	O
a	O
preparation	O
method	O
and	O
medical	O
use	O
thereof	O
.	O

The	O
pleuromutilin	B
derivate	O
is	O
a	O
compound	O
,	O
which	O
is	O
obtained	O
by	O
coupling	O
pleuromutilin	B
to	O
alkyl	B
acylamino	I
-	I
thiazole-4-methyl	I
merecaptan	I
with	O
2-different	O
substitutional	O
amino	B
.	O

Pharmacological	O
experimental	O
results	O
show	O
that	O
:	O
compared	O
with	O
the	O
pleuromutilin	B
,	O
the	O
pleuromutilin	B
derivate	O
disclosed	O
by	O
the	O
invention	O
has	O
better	O
antimicrobial	O
and	O
antibiotic	O
resistant	O
bacteria	O
activities	O
;	O
and	O
therefore	O
,	O
the	O
compound	O
is	O
possibly	O
applicable	O
for	O
curing	O
a	O
plurality	O
of	O
infection	O
and	O
inflammatory	O
diseases	O
on	O
clinic	O
.	O

Novel	O
pleuromutilin	B
derivate	O
,	O
preparation	O
method	O
and	O
medical	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
breviscapine	B
ethosome	O
gel	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
.	O

The	O
breviscapine	B
ethosome	O
gel	O
preparation	O
disclosed	O
by	O
the	O
invention	O
is	O
composed	O
of	O
breviscapine	B
ethosome	O
(	O
A	O
)	O
,	O
a	O
penetration	O
enhancer	O
(	O
B	O
)	O
and	O
a	O
gel	O
substrate	O
,	O
and	O
can	O
be	O
used	O
for	O
transdermal	O
administration	O
.	O

The	O
breviscapine	B
ethosome	O
gel	O
preparation	O
uses	O
a	O
novel	O
ethosome	O
administration	O
carrier	O
,	O
obviously	O
improves	O
the	O
transdermal	O
penetrating	O
quality	O
of	O
the	O
breviscapine	B
,	O
controls	O
the	O
drug	O
release	O
,	O
improves	O
the	O
compliance	O
of	O
patients	O
and	O
also	O
reduces	O
the	O
administration	O
frequency	O
and	O
administration	O
dosage	O
.	O

Breviscapine	B
ethosome	O
gel	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
specifically	O
to	O
an	O
alkaloid	B
compound	O
in	O
Agelas	O
clathrodes	O
,	O
wherein	O
the	O
chemical	O
structural	O
formula	O
of	O
the	O
compound	O
is	O
as	O
shown	O
in	O
the	O
figure	O
.	O

The	O
chemical	O
constitution	O
and	O
stereo	O
configuration	O
of	O
the	O
compound	O
is	O
determined	O
by	O
a	O
plurality	O
of	O
modern	O
spectrum	O
analysis	O
and	O
especially	O
by	O
applying	O
a	O
plurality	O
of	O
advanced	O
integrated	O
parsing	O
of	O
two	O
-	O
dimension	O
nuclear	O
magnetic	O
resonance	O
.	O

In	O
vitro	O
antitumor	O
test	O
shows	O
that	O
the	O
alkaloid	B
compound	O
provided	O
by	O
the	O
invention	O
has	O
an	O
obvious	O
effect	O
of	O
inhibiting	O
tumor	O
cells	O
such	O
as	O
HepG2	O
human	O
liver	O
cancer	O
cells	O
and	O
Caco-2	O
human	O
intestinal	O
cancer	O
cells	O
and	O
thus	O
can	O
be	O
used	O
for	O
preparing	O
antitumor	O
drugs	O
.	O

The	O
invention	O
provides	O
a	O
lead	O
compound	O
for	O
developing	O
new	O
antitumor	O
drugs	O
and	O
has	O
an	O
important	O
value	O
to	O
develop	O
and	O
utilize	O
Chinese	O
ocean	O
medicinal	O
resources	O
.	O

Antitumor	O
bioactive	O
alkaloid	B
compound	O
in	O
Agelas	O
clathrodes	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmacology	O
,	O
and	O
provides	O
novel	O
triazole	B
antifungal	O
compounds	O
shown	O
as	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
various	O
optical	O
isomer	O
and	O
medicinal	O
inorganic	O
salts	O
or	O
organic	O
salts	O
thereof	O
,	O
and	O
a	O
preparation	O
method	O
for	O
the	O
novel	O
triazole	B
antifungal	O
compounds	O
.	O

The	O
invention	O
provides	O
a	O
medicinal	O
composition	O
comprising	O
the	O
compounds	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
various	O
optical	O
isomer	O
and	O
medicinal	O
inorganic	O
salts	O
or	O
organic	O
salts	O
thereof	O
,	O
which	O
serve	O
as	O
active	O
ingredients	O
,	O
and	O
also	O
provides	O
application	O
of	O
the	O
compounds	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
various	O
optical	O
isomer	O
and	O
medicinal	O
inorganic	O
salts	O
or	O
organic	O
salts	O
thereof	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
fungal	O
infective	O
diseases	O
(	O
particularly	O
deep	O
infective	O
diseases	O
caused	O
by	O
fungi	O
)	O
.	O

The	O
novel	O
triazole	B
antifungal	O
compounds	O
have	O
higher	O
antifungal	O
activity	O
and	O
better	O
physiochemical	O
properties	O
and	O
medicine	O
metabolism	O
property	O
compared	O
with	O
the	O
conventional	O
medicines	O
.	O

Novel	O
triazole	B
antifungal	O
compounds	O
,	O
and	O
medicinal	O
composition	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
fluorine	B
-	O
containing	O
ticlopidine	B
analogues	O
with	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

In	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
R1	O
is	O
C1-C4	O
straight	O
-	O
chain	O
or	O
branched	O
-	O
chain	O
alkyl	B
,	O
R2	O
is	O
halogen	B
or	O
trifluoromethyl	B
,	O
R3	O
is	O
hydrogen	B
or	O
fluorine	B
,	O
and	O
n	O
is	O
an	O
integer	O
ranging	O
from	O
0	O
to	O
4	O
.	O

The	O
general	O
formula	O
(	O
I	O
)	O
is	O
shown	O
in	O
the	O
specification	O
.	O

Fluorine	B
-	O
containing	O
ticlopidine	B
analogues	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
arctigenin	B
to	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
the	O
allergic	O
asthma	O
.	O

This	O
invention	O
discovers	O
a	O
novel	O
medical	O
application	O
for	O
the	O
known	O
compound	O
of	O
arctigenin	B
and	O
opens	O
up	O
a	O
novel	O
application	O
field	O
.	O

The	O
medicine	O
prepared	O
by	O
the	O
arctigenin	B
in	O
the	O
invention	O
is	O
in	O
an	O
oral	O
dosage	O
form	O
,	O
which	O
can	O
be	O
used	O
as	O
an	O
independent	O
effective	O
medicinal	O
ingredient	O
,	O
and	O
also	O
can	O
be	O
compatible	O
with	O
other	O
non	O
-	O
repulsive	O
components	O
.	O

Application	O
of	O
arctigenin	B
to	O
preparation	O
of	O
medicine	O
for	O
treating	O
allergic	O
asthma	O

The	O
invention	O
provides	O
an	O
apogossypolone	B
self	O
-	O
emulsifying	O
drug	O
delivery	O
system	O
,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
mass	O
:	O
0.2	O
to	O
20	O
percent	O
of	O
apogossypolone	B
,	O
10	O
to	O
89.8	O
percent	O
of	O
oil	O
phase	O
,	O
5	O
to	O
50	O
percent	O
of	O
emulsifier	O
,	O
5	O
to	O
50	O
percent	O
of	O
auxiliary	O
emulsifier	O
and	O
0	O
to	O
20	O
percent	O
of	O
organic	O
acid	O
,	O
wherein	O
the	O
components	O
form	O
a	O
uniform	O
semisolid	O
or	O
liquid	O
or	O
solid	O
formulation	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
apogossypolone	B
self	O
-	O
emulsifying	O
drug	O
delivery	O
system	O
.	O

Compared	O
with	O
the	O
ordinary	O
apogossypolone	B
oral	O
preparation	O
,	O
the	O
apogossypolone	B
self	O
-	O
emulsifying	O
drug	O
delivery	O
system	O
can	O
increase	O
the	O
biomembrane	O
permeability	O
of	O
apogossypolone	B
,	O
improve	O
bioavailability	O
obviously	O
,	O
increase	O
the	O
solubility	O
of	O
the	O
apogossypolone	B
and	O
improve	O
a	O
drug	O
-	O
loading	O
rate	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
and	O
high	O
in	O
operability	O
and	O
industrial	O
degree	O
;	O
and	O
the	O
apogossypolone	B
self	O
-	O
emulsifying	O
drug	O
delivery	O
system	O
is	O
conveniently	O
and	O
stably	O
taken	O
in	O
clinic	O
.	O

Apogossypolone	B
self	O
-	O
emulsifying	O
drug	O
delivery	O
system	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
novel	O
blood	O
lipid	O
lowering	O
composition	O
,	O
which	O
is	O
a	O
medicinal	O
composition	O
comprising	O
aliskiren	B
and	O
a	O
medicinal	O
salt	O
thereof	O
,	O
a	O
hydrate	B
and	O
1	O
-	O
2	O
of	O
statin	B
,	O
fibrate	B
and	O
nicotinic	B
acid	I
lipid	O
lowering	O
medicaments	O
,	O
serving	O
as	O
active	O
ingredients	O
.	O

The	O
composition	O
can	O
be	O
prepared	O
into	O
oral	O
tablets	O
or	O
capsules	O
for	O
treating	O
hyperlipidemia	O
;	O
and	O
the	O
curative	O
effect	O
of	O
the	O
composition	O
is	O
superior	O
to	O
that	O
of	O
the	O
conventional	O
common	O
lipid	O
lowering	O
medicament	O
.	O

Novel	O
blood	O
lipid	O
lowering	O
composition	O

The	O
invention	O
provides	O
an	O
application	O
of	O
taurine	B
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
nerve	O
cell	O
damage	O
caused	O
by	O
dependence	O
producing	O
medicaments	O
.	O

The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
which	O
is	O
a	O
medicament	O
prepared	O
from	O
taurine	B
as	O
an	O
active	O
component	O
by	O
adding	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
.	O

The	O
taurine	B
provided	O
by	O
the	O
invention	O
can	O
obviously	O
reduce	O
the	O
damage	O
of	O
nerve	O
cells	O
caused	O
by	O
methyl	B
amphetamine	I
,	O
morphine	B
and	O
other	O
dependence	O
producing	O
medicaments	O
,	O
enhance	O
the	O
activity	O
of	O
oxides	B
in	O
cells	O
,	O
reduce	O
cell	O
apoptosis	O
,	O
and	O
be	O
used	O
for	O
preparing	O
a	O
protective	O
medicament	O
for	O
nerve	O
cell	O
damage	O
caused	O
by	O
the	O
dependence	O
producing	O
medicaments	O
.	O

Application	O
of	O
taurine	B
in	O
preparing	O
medicament	O
for	O
preventing	O
nerve	O
cell	O
damage	O
caused	O
by	O
dependence	O
producing	O
medicaments	O

The	O
invention	O
provides	O
a	O
dihydro	B
-	I
pyrazolo	I
hexahydropyridine	I
derivative	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
performing	O
Michael	O
addition	O
reaction	O
of	O
substituted	O
amine	B
(	O
a	O
)	O
and	O
methyl	B
acrylate	I
to	O
prepare	O
N	B
,	I
N	I
-	I
bis	I
(	I
beta	I
-	I
methyl	I
propionate	I
)	I
substituted	O
amine	B
(	O
b	O
)	O
;	O
performing	O
Dieckmann	O
condensation	O
of	O
(	O
b	O
)	O
under	O
the	O
action	O
of	O
sodium	B
alcoholate	I
and	O
hydrolyzing	O
and	O
decarboxylating	O
under	O
the	O
action	O
of	O
acid	O
to	O
obtain	O
yellow	O
oily	O
matter	O
N	B
-	I
substituted	I
piperidine-4-ketone	I
(	O
d	O
)	O
;	O
reacting	O
(	O
d	O
)	O
and	O
aromatic	B
aldehyde	I
to	O
remove	O
bimolecular	O
water	O
to	O
obtain	O
N	B
-	I
substitution-3,5-dibenzal	I
piperidine-4-ketone	I
(	O
e	O
)	O
;	O
and	O
performing	O
reaction	O
of	O
(	O
e	O
)	O
to	O
form	O
the	O
dihydro	B
-	I
pyrazolo	I
hexahydropyridine	I
derivative	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
,	O
and	O
the	O
dihydro	B
-	I
pyrazolo	I
hexahydropyridine	I
derivative	O
is	O
convenient	O
to	O
produce	O
in	O
large	O
scale	O
;	O
and	O
a	O
lead	O
compound	O
of	O
the	O
prepared	O
dihydro	B
-	I
pyrazolo	I
hexahydropyridine	I
new	O
medicine	O
has	O
the	O
obvious	O
inhibitory	O
activity	O
on	O
leukemia	O
K562	O
cancer	O
cellproliferation	O
,	O
and	O
has	O
the	O
obvious	O
practicality	O
in	O
the	O
production	O
of	O
modern	O
medicines	O
.	O

Dihydro	B
-	I
pyrazolo	I
hexahydropyridine	I
derivative	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
pitavastatin	B
calcium	I
lipid	O
solid	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
preparing	O
pitavastatin	B
calcium	I
lipid	O
with	O
excellent	O
quality	O
from	O
pitavastatin	B
calcium	I
,	O
DPPC	B
(	O
dipalmitoyl	B
phosphatidylcholine	I
)	O
,	O
stearamide	B
,	O
octadecylamine	B
and	O
Tween	O
80	O
in	O
a	O
specific	O
weight	O
proportion	O
;	O
and	O
preparing	O
the	O
pitavastatin	B
calcium	I
lipid	O
into	O
a	O
solid	O
preparation	O
by	O
a	O
conventional	O
preparation	O
method	O
.	O

Compared	O
with	O
the	O
existing	O
preparation	O
,	O
the	O
preparation	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
greatly	O
improved	O
stability	O
and	O
bioavailability	O
,	O
enhanced	O
quality	O
,	O
reduced	O
toxic	O
and	O
side	O
effects	O
,	O
smooth	O
and	O
stable	O
drug	O
release	O
,	O
and	O
remarkable	O
curative	O
effect	O
.	O

Pitavastatin	B
calcium	I
lipid	O
solid	O
preparation	O

The	O
invention	O
discloses	O
a	O
perospirone	B
hydrochloride	I
rapid	O
-	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
tablet	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
2	O
to	O
12	O
percent	O
of	O
perospirone	B
hydrochloride	I
,	O
25	O
to	O
35	O
percent	O
of	O
anhydrous	O
lactose	O
,	O
40	O
to	O
60	O
percent	O
of	O
microcrystalline	O
cellulose	O
,	O
3	O
to	O
10	O
percent	O
of	O
disintegrant	O
,	O
0.5	O
to	O
3	O
percent	O
of	O
lubricant	O
,	O
and	O
1	O
to	O
4	O
percent	O
of	O
a	O
coating	O
material	O
,	O
wherein	O
the	O
lubricant	O
is	O
at	O
least	O
one	O
of	O
superfine	O
silica	B
gel	I
powder	O
,	O
magnesium	B
stearate	I
or	O
stearic	B
acid	I
;	O
and	O
the	O
auxiliary	O
material	O
is	O
at	O
least	O
one	O
of	O
carboxymethyl	O
cellulose	O
,	O
hydroxypropylcellulose	O
,	O
carboxymethyl	B
starch	I
sodium	I
or	O
polyvinylpolypyrrolidone	B
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
uniformly	O
mixing	O
perospirone	B
hydrochloride	I
,	O
anhydrous	O
lactose	B
,	O
microcrystalline	O
cellulose	O
,	O
the	O
lubricant	O
and	O
the	O
auxiliary	O
material	O
in	O
a	O
proportion	O
;	O
screening	O
with	O
a	O
100-mesh	O
screen	O
;	O
and	O
tabletting	O
after	O
the	O
mixing	O
uniformity	O
is	O
detected	O
to	O
be	O
qualified	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
:	O
labor	O
and	O
time	O
are	O
saved	O
,	O
energy	O
consumption	O
is	O
reduced	O
,	O
and	O
the	O
production	O
efficiency	O
is	O
improved	O
;	O
and	O
the	O
medicament	O
has	O
high	O
disintegrating	O
rate	O
and	O
short	O
dissolution	O
time	O
,	O
and	O
the	O
dissolution	O
rate	O
of	O
the	O
medicament	O
is	O
15	O
percent	O
higher	O
than	O
that	O
of	O
a	O
medicament	O
which	O
is	O
prepared	O
by	O
adopting	O
a	O
conventional	O
wet	O
or	O
dry	O
granulation	O
method	O
.	O

Perospirone	B
hydrochloride	I
rapid	O
-	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
application	O
of	O
lycopene	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
cerebral	O
ischemia	O
injury	O
.	O

In	O
the	O
application	O
,	O
the	O
medicament	O
for	O
treating	O
cerebral	O
ischemia	O
injury	O
is	O
at	O
least	O
one	O
of	O
the	O
following	O
components	O
as	O
shown	O
in	O
1	O
)	O
to	O
3	O
)	O
:	O
1	O
)	O
a	O
medicament	O
for	O
treating	O
encephaledema	O
;	O
2	O
)	O
a	O
medicament	O
for	O
treating	O
cerebral	O
infarction	O
;	O
and	O
3	O
)	O
a	O
medicament	O
for	O
treating	O
nerve	O
injury	O
.	O

The	O
invention	O
provides	O
a	O
possible	O
acute	O
-	O
phase	O
treatment	O
medicament	O
urgently	O
needed	O
in	O
clinic	O
,	O
and	O
the	O
medicament	O
has	O
treatment	O
and	O
protection	O
effects	O
in	O
acute	O
cerebral	O
ischemia	O
-	O
reperfusion	O
injury	O
phase	O
,	O
and	O
has	O
strong	O
clinical	O
pertinence	O
.	O

Researches	O
of	O
the	O
invention	O
indicate	O
that	O
lycopene	O
still	O
can	O
play	O
a	O
good	O
effect	O
of	O
resisting	O
cerebral	O
infarction	O
and	O
protecting	O
nerves	O
in	O
reperfusion	O
phase	O
administration	O
of	O
acute	O
cerebral	O
ischemia	O
,	O
thus	O
the	O
invention	O
has	O
real	O
clinical	O
therapeutics	O
meaning	O
and	O
great	O
clinical	O
advantage	O
.	O

Application	O
of	O
lycopene	O
in	O
preparation	O
of	O
medicament	O
for	O
treating	O
cerebral	O
ischemia	O
injury	O

The	O
invention	O
discloses	O
a	O
medicine	O
composition	O
for	O
treating	O
fungal	O
keratitis	O
,	O
which	O
comprises	O
thiomersalate	B
and	O
benzalkonium	B
chloride	I
or	O
benzalkonium	B
bromide	I
.	O

The	O
weight	O
ratio	O
of	O
the	O
thiomersalate	B
to	O
the	O
benzalkonium	B
chloride	I
or	O
the	O
benzalkonium	B
bromide	I
is	O
1	O
:	O
(	O
1	O
-	O
50	O
)	O
.	O

Action	O
mechanisms	O
of	O
the	O
thiomersalate	B
and	O
the	O
benzalkonium	B
chloride	I
or	O
the	O
benzalkonium	B
bromide	I
for	O
inhibiting	O
fungal	O
growth	O
are	O
different	O
,	O
so	O
that	O
during	O
combine	O
medication	O
,	O
different	O
links	O
of	O
fungal	O
growth	O
are	O
inhibited	O
,	O
and	O
thus	O
a	O
synergy	O
effect	O
is	O
achieved	O
;	O
compared	O
with	O
a	O
single	O
medicine	O
,	O
the	O
medicine	O
composition	O
disclosed	O
by	O
the	O
invention	O
has	O
remarkably	O
-	O
enhanced	O
antibacterial	O
effect	O
,	O
remarkably	O
-	O
reduced	O
dosage	O
,	O
better	O
effect	O
on	O
treating	O
the	O
fungal	O
keratitis	O
and	O
no	O
obvious	O
side	O
effect	O
,	O
thereby	O
providing	O
a	O
novel	O
efficient	O
,	O
broad	O
-	O
spectrum	O
and	O
harmfulless	O
antifungal	O
eye	O
medicine	O
for	O
clinically	O
treating	O
the	O
fungal	O
keratitis	O
in	O
the	O
ophthalmology	O
department	O
.	O

Compared	O
with	O
a	O
single	O
medicine	O
,	O
the	O
medicine	O
composition	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
enhancing	O
the	O
antibacterial	O
effect	O
in	O
vitro	O
by	O
eight	O
times	O
,	O
remarkably	O
decreasing	O
the	O
dosage	O
in	O
vivo	O
,	O
remarkably	O
reducing	O
the	O
toxic	O
and	O
side	O
effects	O
and	O
preventing	O
the	O
occurrence	O
of	O
drug	O
resistance	O
.	O

Medicine	O
composition	O
for	O
treating	O
fungal	O
keratitis	O

The	O
invention	O
relates	O
to	O
morin-7-sodium	B
sulfate	I
for	O
inhibiting	O
enzymatic	O
activity	O
of	O
PRL-3	O
(	O
phosphatase	O
of	O
regenerating	O
liver-3	O
)	O
and	O
application	O
of	O
the	O
morin-7-	B
sodium	I
sulfate	I
in	O
medicines	O
for	O
resisting	O
tumor	O
metastasis	O
.	O

Human	O
PRL-3	O
protein	O
with	O
enzymatic	O
activity	O
is	O
obtained	O
through	O
a	O
gene	O
engineering	O
technology	O
,	O
the	O
water	O
-	O
soluble	O
morin-7-sodium	B
sulfate	I
obtained	O
through	O
screening	O
has	O
an	O
obvious	O
inhibiting	O
effect	O
for	O
the	O
enzymatic	O
activity	O
of	O
the	O
PRL-3	O
,	O
the	O
inhibiting	O
effect	O
of	O
the	O
morin-7-sodium	B
sulfate	I
is	O
stronger	O
than	O
that	O
of	O
parent	O
morin	B
of	O
the	O
morin-7-sodium	B
sulfate	I
and	O
is	O
also	O
superior	O
to	O
the	O
inhibiting	O
effects	O
of	O
other	O
compounds	O
or	O
natural	O
products	O
,	O
a	O
Transwell	O
measurement	O
result	O
shows	O
that	O
the	O
compound	O
can	O
obviously	O
inhibit	O
the	O
invitro	O
invasive	O
capability	O
and	O
the	O
motility	O
of	O
a	O
tumour	O
cell	O
,	O
and	O
a	O
Western	O
blot	O
and	O
fluorescence	O
quantitative	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
result	O
shows	O
that	O
the	O
compound	O
can	O
specifically	O
inhibit	O
the	O
PRL-3	O
protein	O
and	O
mRNA	O
(	O
Messenger	O
RNA	O
)	O
expression	O
rather	O
than	O
PRL-1	O
protein	O
and	O
PRL-2	O
protein	O
(	O
same	O
species	O
as	O
the	O
PRL-3	O
protein	O
)	O
and	O
mRNA	O
expression	O
.	O

The	O
compound	O
provided	O
by	O
the	O
invention	O
has	O
higher	O
application	O
value	O
in	O
researching	O
the	O
effect	O
of	O
the	O
PRL-3	O
in	O
the	O
tumor	O
metastasis	O
and	O
designing	O
,	O
researching	O
and	O
developing	O
the	O
medicines	O
for	O
resisting	O
the	O
tumor	O
metastasis	O
,	O
can	O
be	O
applied	O
to	O
preparing	O
a	O
positive	O
control	O
reagent	O
or	O
compound	O
of	O
a	O
PRL-3	O
enzyme	O
inhibitor	O
,	O
and	O
is	O
used	O
as	O
one	O
component	O
or	O
precursor	O
for	O
preparing	O
the	O
medicines	O
for	O
resisting	O
the	O
tumor	O
metastasis	O
in	O
medicine	O
development	O
.	O

Morin-7-sodium	B
sulfate	I
for	O
inhibiting	O
enzymatic	O
activity	O
of	O
PRL-3	O
(	O
phosphatase	O
of	O
regenerating	O
liver-3	O
)	O
and	O
application	O
of	O
morin-7-	B
sodium	I
sulfate	I
in	O
medicines	O
for	O
resisting	O
tumor	O
metastasis	O

The	O
invention	O
provides	O
applications	O
of	O
an	O
isoflavone	B
compound	O
in	O
preparing	O
antiviral	O
medicaments	O
.	O

The	O
isoflavone	O
compound	O
provided	O
by	O
the	O
invention	O
is	O
calycosin	B
,	O
and	O
has	O
obvious	O
AIDS	O
(	O
Acquired	O
Immune	O
Deficiency	O
Syndrome	O
)	O
virus	O
and	O
coxsakie	O
virus	O
resistant	O
activities	O
.	O

The	O
isoflavone	B
compound	O
provided	O
by	O
the	O
invention	O
as	O
an	O
active	O
component	O
is	O
used	O
for	O
preparing	O
medicaments	O
for	O
preventing	O
or	O
treating	O
viral	O
diseases	O
.	O

Applications	O
of	O
isoflavone	B
compound	O

The	O
invention	O
discloses	O
fenofibrate	O
acid	O
salt	O
,	O
a	O
preparation	O
method	O
,	O
a	O
pharmaceutical	O
composition	O
and	O
application	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
fenofibrate	B
acid	I
salt	O
is	O
shown	O
as	O
an	O
equation	O
or	O
an	O
equation	O
in	O
the	O
specification	O
,	O
wherein	O
X	O
represents	O
methylene	O
,	O
O	B
,	O
CH3-N	B
or	O
CH3-CH	B
;	O
R1	O
represents	O
methyl	B
;	O
m	O
represents	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
R2	O
represents	O
H	B
or	O
methyl	B
;	O
and	O
R3	O
represents	O
HOCH2CH2OCH2CH2-	B
,	O
HOCH2CH2CH2-	B
,	O
HOCH2CH	B
(	I
OH	I
)	I
CH2-	I
,	O
HOCH2CH2-	B
,	O
HOCH2C	B
(	I
CH3	I
)	I
2-	I
,	O
(	B
HOCH2	I
)	I
2CCH3-	I
or	O
HOCH2CH	B
(	I
CH3CH2	I
)	I
-	I
.	O

Compared	O
with	O
the	O
current	O
fenofibrate	B
,	O
the	O
solubility	O
of	O
the	O
fenofibrate	B
acid	I
salt	O
provided	O
by	O
the	O
invention	O
in	O
water	O
is	O
obviously	O
increased	O
;	O
the	O
solubility	O
in	O
1	O
ml	O
of	O
pure	O
water	O
is	O
more	O
than	O
1	O
mg	O
;	O
the	O
highest	O
solubility	O
is	O
above	O
100	O
mg	O
,	O
therefore	O
,	O
the	O
fenofibrate	B
acid	I
salt	O
is	O
easily	O
absorbed	O
by	O
human	O
bodies	O
;	O
and	O
the	O
bioavailability	O
is	O
also	O
relatively	O
and	O
obviously	O
increased	O
.	O

Fenofibrate	B
acid	I
salt	O
,	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O

The	O
invention	O
relates	O
to	O
compounds	O
shown	O
as	O
a	O
general	O
formula	O
(	O
1	O
)	O
and	O
salts	O
of	O
the	O
compounds	O
.	O

The	O
compounds	O
are	O
TRPV1	O
(	O
transient	O
receptor	O
potential	O
cation	O
channel	O
,	O
subfamily	O
V	O
,	O
member	O
1	O
)	O
antagonists	O
,	O
and	O
have	O
better	O
analgesic	O
action	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
for	O
the	O
compounds	O
,	O
medicinal	O
preparations	O
containing	O
the	O
compounds	O
,	O
and	O
application	O
of	O
the	O
compounds	O
and	O
medicinal	O
compositions	O
thereof	O
in	O
treatment	O
of	O
pain	O
.	O

TRPV1	O
(	O
transient	O
receptor	O
potential	O
cation	O
channel	O
,	O
subfamily	O
V	O
,	O
member	O
1	O
)	O
antagonists	O
,	O
and	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
high	O
-	O
efficiency	O
high	O
-	O
stereoselectivity	O
semisynthesis	O
method	O
of	O
harringtonine	B
and	O
allied	O
alkaloids	B
,	O
which	O
uses	O
optical	O
pure	O
cephalotaxin	B
serving	O
as	O
a	O
raw	O
material	O
to	O
perform	O
reactive	O
synthesis	O
with	O
substituted	O
silicon	B
ketene	I
in	O
Lewis	B
acid	I
catalysis	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
compound	O
is	O
shown	O
as	O
(	O
A	O
)	O
,	O
wherein	O
the	O
meaning	O
of	O
each	O
group	O
is	O
shown	O
as	O
the	O
specification	O
.	O

The	O
method	O
has	O
the	O
advantages	O
of	O
high	O
chemical	O
yield	O
and	O
diastereoselectivity	O
of	O
key	O
reactions	O
,	O
convenient	O
operation	O
,	O
short	O
synthesis	O
steps	O
and	O
the	O
like	O
.	O

The	O
method	O
is	O
a	O
universal	O
method	O
for	O
synthesizing	O
the	O
optical	O
pure	O
compound	O
with	O
the	O
structural	O
general	O
formula	O
shown	O
as	O
(	O
A	O
)	O
,	O
and	O
is	O
suitable	O
for	O
massive	O
preparation	O
.	O

The	O
compound	O
is	O
widely	O
applied	O
to	O
anti	O
-	O
tumor	O
(	O
malignant	O
and	O
non	O
-	O
malignant	O
tumors	O
)	O
,	O
anti	O
-	O
parasitic	O
,	O
antifungal	O
and	O
antimicrobial	O
chemotherapy	O
medicaments	O
.	O

High	O
-	O
efficiency	O
high	O
-	O
stereoselectivity	O
semisynthesis	O
method	O
of	O
harringtonine	B
and	O
allied	O
alkaloids	B

The	O
invention	O
discloses	O
a	O
novel	O
crystalline	O
state	O
of	O
roflumilast	B
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
crystalline	O
state	O
is	O
a	O
stable	O
high	O
-	O
purity	O
roflumilast	O
crystalline	O
state	O
form	O
,	O
and	O
has	O
the	O
characteristics	O
of	O
easiness	O
,	O
convenience	O
and	O
practicability	O
in	O
operation	O
and	O
high	O
adaptability	O
to	O
industrial	O
mass	O
production	O
;	O
particularly	O
,	O
the	O
solubility	O
of	O
the	O
product	O
in	O
a	O
water	O
-	O
containing	O
system	O
is	O
properly	O
increased	O
;	O
and	O
further	O
,	O
a	O
medicinal	O
preparation	O
applying	O
the	O
crystalline	O
state	O
roflumilast	O
prepared	O
by	O
the	O
invention	O
can	O
still	O
reach	O
an	O
effective	O
dissolution	O
rate	O
under	O
the	O
condition	O
of	O
not	O
adding	O
PVP	B
(	O
Polyvinyl	B
Pyrrolidone	I
)	O
.	O

Novel	O
crystalline	O
state	O
of	O
roflumilast	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
cefsulodin	B
sodium	I
lyophilized	O
powder	O
.	O

The	O
cefsulodin	B
sodium	I
lyophilized	O
powder	O
is	O
placed	O
under	O
the	O
conditions	O
of	O
a	O
temperature	O
of	O
40	O
DEG	O
C	O
and	O
a	O
relative	O
humidity	O
of	O
75	O
%	O
for	O
6	O
months	O
,	O
and	O
based	O
on	O
anhydrous	O
substances	O
,	O
the	O
content	O
of	O
cefsulodin	B
sodium	I
in	O
the	O
cefsulodin	B
sodium	I
lyophilized	O
powder	O
is	O
more	O
than	O
99.0	O
wt%	O
and	O
the	O
content	O
of	O
related	O
substances	O
is	O
less	O
than	O
1.0	O
wt%	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
cefsulodin	B
sodium	I
lyophilized	O
powder	O
,	O
and	O
especially	O
relates	O
to	O
a	O
method	O
for	O
freeze	O
drying	O
of	O
cefsulodin	B
sodium	I
at	O
a	O
temperature	O
of	O
-60	O
DEG	O
C	O
to	O
60	O
DEG	O
C	O
by	O
using	O
water	O
as	O
a	O
solvent	O
.	O

The	O
cefsulodin	B
sodium	I
lyophilized	O
powder	O
has	O
the	O
advantages	O
of	O
simple	O
process	O
,	O
less	O
organic	O
solvent	O
residual	O
,	O
stable	O
drug	O
quality	O
,	O
and	O
convenient	O
transportation	O
or	O
storage	O
.	O

Cefsulodin	B
sodium	I
lyophilized	O
powder	O
,	O
cefsulodin	B
sodium	I
lyophilized	O
powder	O
preparation	O
and	O
their	O
preparation	O
method	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
curcumin	B
in	O
the	O
preparation	O
of	O
a	O
thyroid	O
carcinoma	O
therapeutic	O
agent	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
curcumin	B
pharmaceutical	O
application	O
.	O

Curcumin	B
can	O
kill	O
thyroid	O
carcinoma	O
cells	O
specifically	O
and	O
has	O
little	O
influence	O
on	O
normal	O
thyroid	O
cells	O
.	O

Curcumin	B
can	O
promote	O
the	O
apoptosis	O
of	O
thyroid	O
carcinoma	O
cells	O
,	O
initiate	O
the	O
digestion	O
of	O
poly	O
adenosine	O
diphosphate	O
-	O
ribose	O
polymerase	O
(	O
PARP	O
)	O
,	O
and	O
significantly	O
inhibit	O
the	O
expression	O
of	O
anti	O
-	O
apoptotic	O
protein	O
Bcl-2	O
;	O
meanwhile	O
,	O
curcumin	B
can	O
also	O
inhibit	O
the	O
secretion	O
of	O
thyroid	O
carcinoma	O
cell	O
matrix	O
metalloproteinase-9	O
and	O
the	O
adhesion	O
to	O
extracellular	O
matrix	O
.	O

Above	O
results	O
show	O
that	O
curcumin	B
has	O
good	O
intervention	O
effect	O
on	O
various	O
links	O
of	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
of	O
thyroid	O
carcinoma	O
cells	O
,	O
and	O
is	O
applicable	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
treating	O
thyroid	O
carcinoma	O
.	O

Application	O
of	O
curcumin	B
in	O
preparation	O
of	O
thyroid	O
carcinoma	O
therapeutic	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
of	O
preparing	O
indazolyl	B
ureas	I
that	O
are	O
useful	O
as	O
antagonists	O
of	O
the	O
vanilloid	B
receptor	O
subtype	O
1	O
(	O
VR1	O
)	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
indazolyl	B
ureas	I
that	O
inhibit	O
vanilloid	O
subtype	O
1	O
(	O
VR1	O
)	O
receptors	O

The	O
invention	O
discloses	O
a	O
solid	O
cefixime	B
lipid	O
nanoparticle	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Cefixime	B
,	O
stearic	B
acid	I
and	O
lauric	B
acid	I
are	O
dissolved	O
in	O
an	O
organic	O
solvent	O
to	O
form	O
an	O
oil	O
phase	O
;	O
and	O
with	O
a	O
water	O
solution	O
of	O
tween	B
80	I
and	O
hydrogenated	O
castor	O
oil	O
polyethenoxy	B
ether	I
40	I
as	O
water	O
phase	O
,	O
the	O
cefixime	B
is	O
entrapped	O
in	O
a	O
solid	O
lipid	O
nanoparticle	O
to	O
obtain	O
the	O
solid	O
cefixime	B
lipid	O
nanoparticle	O
preparation	O
by	O
adopting	O
a	O
mixed	O
emulsifying	O
and	O
high	O
-	O
pressure	O
uniformly	O
-	O
emulsifying	O
combined	O
method	O
.	O

The	O
solid	O
lipid	O
nanoparticle	O
preparation	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
drug	O
loading	O
amount	O
,	O
uniformity	O
in	O
grain	O
size	O
,	O
long	O
reservation	O
time	O
of	O
a	O
medicament	O
in	O
blood	O
circulation	O
and	O
better	O
slowly	O
-	O
releasing	O
and	O
controlled	O
-	O
release	O
effects	O
;	O
and	O
the	O
quality	O
of	O
a	O
preparation	O
product	O
is	O
improved	O
and	O
toxic	O
or	O
side	O
effects	O
are	O
reduced	O
.	O

In	O
addition	O
,	O
equipment	O
used	O
by	O
a	O
preparation	O
method	O
is	O
simple	O
,	O
easy	O
for	O
operation	O
and	O
suitable	O
for	O
industrial	O
large	O
-	O
scale	O
production	O
.	O

Solid	O
cefixime	B
lipid	O
nanoparticle	O
preparation	O

The	O
invention	O
discloses	O
application	O
of	O
four	O
kinds	O
of	O
known	O
flavonoids	B
compounds	O
to	O
treatment	O
of	O
breast	O
cancers	O
.	O

The	O
four	O
kinds	O
of	O
known	O
flavonoids	B
are	O
known	O
compoundes	O
obtained	O
by	O
separating	O
fruit	O
of	O
sinopodophyllum	O
emodi	O
and	O
have	O
structures	O
shown	O
as	O
structural	O
formulas	O
1	O
-	O
4	O
in	O
the	O
specification	O
.	O

Experiments	O
on	O
the	O
effect	O
of	O
the	O
kinds	O
of	O
compounds	O
on	O
inhibiting	O
human	O
breast	O
cancer	O
cells	O
show	O
that	O
the	O
series	O
of	O
compounds	O
have	O
a	O
favorable	O
effect	O
on	O
inhibiting	O
the	O
proliferation	O
of	O
the	O
breast	O
cancer	O
cells	O
.	O

Application	O
of	O
flavonoids	B
compounds	O
to	O
breast	O
cancer	O
resistance	O

A	O
ketorolac	B
tromethamine	I
medicament	O
absorbed	O
through	O
oral	O
mucosa	O
is	O
prepared	O
by	O
the	O
combination	O
of	O
an	O
effective	O
medicinal	O
component	O
ketorolac	B
tromethamine	I
and	O
auxiliary	O
components	O
acceptable	O
in	O
oral	O
mucosa	O
medicaments	O
,	O
wherein	O
the	O
auxiliary	O
components	O
contain	O
a	O
disintegrating	O
agent	O
,	O
a	O
filler	O
,	O
a	O
flavouring	O
agent	O
,	O
an	O
adhesive	O
and	O
a	O
lubricant	O
.	O

Preparation	O
forms	O
of	O
the	O
concrete	O
medicament	O
comprise	O
sublingual	O
tablet	O
,	O
lozenge	O
,	O
buccal	O
tablet	O
,	O
buccal	O
adhesive	O
tablet	O
and	O
buccal	O
patch	O
and	O
the	O
like	O
currently	O
available	O
.	O

The	O
medicament	O
provided	O
by	O
the	O
invention	O
can	O
be	O
fully	O
or	O
mainly	O
absorbed	O
through	O
oral	O
mucosa	O
such	O
as	O
sublingual	O
mucous	O
membrane	O
and/or	O
buccal	O
mucosa	O
and	O
the	O
like	O
,	O
is	O
not	O
irritating	O
to	O
oral	O
cavity	O
,	O
can	O
remarkably	O
raise	O
the	O
bioavailability	O
and	O
curative	O
effect	O
of	O
medicaments	O
and	O
endow	O
patients	O
with	O
good	O
compliance	O
.	O

Ketorolac	B
tromethamine	I
medicament	O
absorbed	O
through	O
oral	O
mucosa	O

The	O
invention	O
relates	O
to	O
an	O
alprostadil	B
composite	O
medicine	O
comprising	O
high	O
-	O
purity	O
alprostadil	B
and	O
a	O
mixture	O
of	O
aspirin	B
-	I
DL	I
-	I
lysine	I
and	O
sodium	B
salicylate	I
,	O
wherein	O
a	O
weight	O
ratio	O
of	O
aspirin	B
-	I
DL	I
-	I
lysine	I
to	O
sodium	B
salicylate	I
is	O
90	O
-	O
95:5	O
-	O
10	O
.	O

The	O
invention	O
also	O
provides	O
a	O
weight	O
ratio	O
of	O
the	O
raw	O
materials	O
of	O
the	O
composite	O
medicine	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
alprostadil	B
composite	O
medicine	O
,	O
and	O
a	O
quality	O
controlling	O
method	O
of	O
the	O
alprostadil	B
composite	O
medicine	O
.	O

With	O
a	O
pharmaceutically	O
acceptable	O
alprostadil	B
composite	O
medicine	O
dosage	O
,	O
the	O
medicine	O
can	O
be	O
prepared	O
into	O
lyophilized	O
injections	O
,	O
oral	O
preparations	O
,	O
aerosols	O
,	O
suppositories	O
,	O
or	O
enemas	O
of	O
the	O
acceptable	O
alprostadil	B
composite	O
medicine	O
.	O

The	O
invention	O
discloses	O
chromatographic	O
conditions	O
for	O
determining	O
the	O
contents	O
of	O
alprostadil	B
,	O
prostaglandin	B
A1	I
and	O
prostaglandin	B
B1	I
.	O

Three	O
peaks	O
before	O
an	O
alprostadil	B
peak	O
are	O
characteristic	O
peaks	O
of	O
alprostadil	B
composite	O
medicine	O
auxiliary	O
materials	O
.	O

The	O
alprostadil	B
composite	O
medicine	O
is	O
used	O
for	O
treating	O
and	O
preventing	O
diseases	O
such	O
as	O
coronary	O
heart	O
disease	O
,	O
myocardial	O
infarction	O
,	O
brain	O
infarction	O
,	O
hypertension	O
,	O
hyperlipemia	O
,	O
atherosclerosis	O
,	O
angiitis	O
,	O
tumour	O
,	O
hepatitis	O
,	O
diabetic	O
angiopathies	O
,	O
kidney	O
insufficiency	O
,	O
bronchial	O
asthma	O
,	O
pancreatitis	O
,	O
gastric	O
ulcer	O
,	O
and	O
vertebrobasilar	O
insufficiency	O
.	O

Alprostadil	B
composite	O
medicine	O
,	O
preparation	O
method	O
thereof	O
,	O
quality	O
controlling	O
method	O
thereof	O
,	O
and	O
purpose	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
health	O
product	O
and	O
specifically	O
discloses	O
a	O
Mythic	O
Fungus	O
wall	O
-	O
broken	O
spore	O
powder	O
capsule	O
which	O
comprises	O
40	O
-	O
60	O
wt%	O
of	O
a	O
Mythic	O
Fungus	O
wall	O
-	O
broken	O
spore	O
powder	O
and	O
the	O
balance	O
being	O
Mythic	O
Fungus	O
polysaccharide	O
.	O

The	O
capsule	O
provided	O
by	O
the	O
invention	O
is	O
more	O
easily	O
absorbed	O
by	O
human	O
body	O
;	O
in	O
addition	O
,	O
various	O
components	O
are	O
combined	O
according	O
to	O
the	O
above	O
proportion	O
and	O
various	O
effects	O
complement	O
each	O
other	O
,	O
thus	O
effectively	O
raising	O
human	O
body	O
's	O
immunity	O
and	O
anti	O
-	O
fatigue	O
ability	O
.	O

Mythic	O
Fungus	O
wall	O
-	O
broken	O
spore	O
powder	O
capsule	O

The	O
invention	O
discloses	O
a	O
health	O
-	O
care	O
product	O
for	O
otitis	O
media	O
.	O

The	O
health	O
-	O
care	O
product	O
is	O
prepared	O
from	O
panax	O
pseudo	O
-	O
ginseng	O
,	O
tea	O
polyphenol	B
,	O
berberine	B
and	O
other	O
raw	O
materials	O
according	O
to	O
a	O
certain	O
ratio	O
,	O
and	O
has	O
good	O
treatment	O
effect	O
and	O
high	O
curing	O
rate	O
when	O
used	O
for	O
treating	O
suppurative	O
otitis	O
media	O
.	O

Health	O
-	O
care	O
product	O
for	O
otitis	O
media	O

The	O
invention	O
discloses	O
a	O
nano	O
iodine	B
-	O
chitosan	O
cervical	O
disease	O
treating	O
membrane	O
agent	O
and	O
a	O
preparation	O
method	O
of	O
the	O
membrane	O
.	O

The	O
treating	O
membrane	O
is	O
prepared	O
by	O
adding	O
plasticizer	O
and	O
adsorbent	O
to	O
chitosan	O
,	O
povidone	B
iodine	I
,	O
dialkyl	B
quaternary	I
ammonium	I
salt	O
and	O
chlorhexidine	O
acetate	O
used	O
as	O
main	O
effective	O
ingredients	O
.	O

The	O
treating	O
membrane	O
disclosed	O
by	O
the	O
invention	O
has	O
killing	O
activity	O
to	O
multiple	O
pathogenic	O
microorganisms	O
,	O
has	O
no	O
irrigation	O
to	O
mucosa	O
,	O
can	O
relieve	O
itching	O
,	O
arrest	O
bleeding	O
and	O
promote	O
the	O
growth	O
of	O
epidermic	O
tissues	O
,	O
can	O
be	O
used	O
for	O
treating	O
colpitis	O
,	O
trichomonas	O
vaginalis	O
,	O
cervicitis	O
,	O
cervical	O
erosion	O
and	O
other	O
gynecological	O
diseases	O
,	O
has	O
better	O
repair	O
action	O
on	O
vaginal	O
and	O
cervical	O
injury	O
,	O
and	O
can	O
effectively	O
prevent	O
the	O
propagation	O
of	O
venereal	O
diseases	O
such	O
as	O
gonorrhoea	O
,	O
syphilis	O
,	O
AIDS	O
(	O
acquired	O
immunodeficiency	O
syndrome	O
)	O
and	O
the	O
like	O
.	O

Nano	O
iodine	B
-	O
chitosan	O
cervical	O
disease	O
treating	O
membrane	O
agent	O
and	O
preparation	O
method	O
of	O
membrane	O

The	O
invention	O
discloses	O
N'-arylmethylene-2-	B
(	I
4-oxothiophene	I
[	I
2,3-d	I
]	I
pyrimidin-3-yl	I
)	I
acetyl	I
hydrazone	I
compounds	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
compounds	O
is	O
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
.	O

Experimental	O
results	O
indicate	O
that	O
the	O
compounds	O
can	O
induce	O
cells	O
to	O
which	O
Caspase-3	O
in	O
human	O
cervical	O
carcinoma	O
cells	O
,	O
human	O
lung	O
carcinoma	O
cells	O
and	O
human	O
breast	O
carcinoma	O
cells	O
is	O
dependent	O
to	O
die	O
so	O
as	O
to	O
inhibit	O
the	O
propagation	O
of	O
the	O
carcinoma	O
cells	O
,	O
also	O
have	O
low	O
toxicity	O
on	O
normal	O
cells	O
,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
antitumor	O
medicines	O
for	O
treating	O
cervical	O
carcinoma	O
,	O
lung	O
cancer	O
or	O
breast	O
cancer	O
.	O

N'-arylmethylene-2-	B
(	I
4-oxothiophene	I
[	I
2,3-d	I
]	I
pyrimidin-3-yl	I
)	I
acetyl	I
hydrazone	I
compounds	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
an	O
application	O
of	O
cyclophosphamide	B
in	O
preparation	O
of	O
a	O
drug	O
for	O
treating	O
hepatitis	O
B	O
and	O
an	O
application	O
of	O
cyclophosphamide	B
in	O
preparation	O
of	O
an	O
auxiliary	O
drug	O
for	O
treating	O
hepatitis	O
B.	O
Studies	O
of	O
the	O
invention	O
prove	O
that	O
cyclophosphamide	B
,	O
which	O
is	O
used	O
as	O
the	O
drug	O
or	O
the	O
auxiliary	O
drug	O
for	O
treating	O
the	O
hepatitis	O
B	O
,	O
can	O
effectively	O
mobilize	O
an	O
organism	O
to	O
produce	O
immune	O
response	O
to	O
human	O
anti	O
-	O
hepatitis	O
B	O
virus	O
and	O
eliminate	O
the	O
hepatitis	O
B	O
virus	O
in	O
a	O
hepatitis	O
B	O
patient	O
,	O
and	O
the	O
inflammatory	O
response	O
generated	O
is	O
acceptable	O
to	O
the	O
organism	O
.	O

The	O
invention	O
has	O
good	O
curative	O
effect	O
to	O
the	O
hepatitis	O
B	O
,	O
can	O
prevent	O
rebound	O
of	O
the	O
virus	O
and	O
has	O
no	O
apparent	O
side	O
effects	O
.	O

Application	O
of	O
cyclophosphamide	B
in	O
preparation	O
of	O
drug	O
for	O
treating	O
hepatitis	O
B	O

The	O
invention	O
relates	O
to	O
steroidal	O
alkaloid	B
compounds	O
(	O
shown	O
in	O
the	O
formula	O
I	O
)	O
capable	O
of	O
inhibiting	O
the	O
activity	O
of	O
cholinesterase	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds	O
,	O
as	O
well	O
as	O
applications	O
of	O
the	O
compounds	O
and	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
compounds	O
in	O
preparation	O
of	O
the	O
drugs	O
for	O
inhibiting	O
the	O
cholinesterase	O
.	O

Steroidal	O
alkaloid	B
compounds	O
and	O
pharmaceutical	O
composition	O
thereof	O
,	O
as	O
well	O
as	O
preparation	O
methods	O
and	O
applications	O
of	O
steroidal	O
alkaloid	B
compounds	O
and	O
pharmaceutical	O
composition	O
of	O
compounds	O

The	O
invention	O
relates	O
to	O
an	O
antioxidant	O
health	O
food	O
composition	O
,	O
and	O
its	O
preparation	O
method	O
and	O
application	O
.	O

The	O
antioxidant	O
health	O
food	O
composition	O
provided	O
in	O
the	O
invention	O
mainly	O
comprises	O
1	O
part	O
to	O
10	O
parts	O
of	O
haematococcus	O
pluvialis	O
and	O
5	O
to	O
50	O
parts	O
of	O
coenzyme	O
Q10	O
.	O

The	O
composition	O
in	O
the	O
invention	O
can	O
substantially	O
improve	O
antioxidant	O
capacity	O
of	O
an	O
organism	O
and	O
reduce	O
oxidative	O
damage	O
caused	O
by	O
sports	O
.	O

Antioxidant	O
health	O
food	O
composition	O
,	O
and	O
its	O
preparation	O
method	O
and	O
application	O

The	O
invention	O
relates	O
to	O
externally	O
-	O
used	O
Chinese	O
patent	O
medicine	O
paste	O
for	O
treating	O
scabies	O
.	O

The	O
externally	O
-	O
used	O
Chinese	O
patent	O
medicine	O
paste	O
is	O
prepared	O
from	O
evodia	O
fruit	O
,	O
sulfur	B
,	O
mercury	B
,	O
borax	B
,	O
alcohol	B
and	O
Vaseline	O
.	O

The	O
externally	O
-	O
used	O
Chinese	O
patent	O
medicine	O
paste	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
effects	O
of	O
killing	O
parasites	O
and	O
relieving	O
itching	O
,	O
clearing	O
heat	O
and	O
detoxicating	O
,	O
removing	O
toxicity	O
and	O
diminishing	O
swelling	O
,	O
and	O
the	O
like	O
,	O
is	O
used	O
for	O
treating	O
the	O
scabies	O
infected	O
in	O
various	O
spreading	O
ways	O
to	O
achieve	O
the	O
effects	O
of	O
killing	O
sarcoptic	O
mites	O
,	O
preventing	O
infection	O
,	O
treating	O
both	O
symptoms	O
and	O
root	O
causes	O
of	O
the	O
disease	O
,	O
and	O
can	O
achieve	O
the	O
purpose	O
that	O
the	O
disease	O
hardly	O
undergoes	O
recurrence	O
after	O
being	O
cured	O
.	O

Externally	O
-	O
used	O
Chinese	O
patent	O
medicine	O
paste	O
for	O
treating	O
scabies	O

The	O
invention	O
relates	O
to	O
a	O
doxycycline	B
hydrochloride	I
injection	O
,	O
its	O
preparation	O
method	O
and	O
an	O
application	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
taking	O
500ml	O
of	O
propylene	B
glycol	I
,	O
adding	O
400ml	O
of	O
injection	O
water	O
,	O
adding	O
45	O
g	O
of	O
magnesium	B
chloride	I
hexahydrate	I
,	O
fully	O
stirring	O
and	O
dissolving	O
,	O
rationing	O
injection	O
water	O
,	O
filtering	O
,	O
filling	O
and	O
sterilizing	O
to	O
obtain	O
the	O
doxycycline	B
hydrochloride	I
injection	O
.	O

The	O
prepared	O
doxycycline	B
hydrochloride	I
injection	O
is	O
stable	O
,	O
is	O
valid	O
for	O
two	O
years	O
,	O
conforms	O
to	O
the	O
quality	O
standard	O
prescribed	O
in	O
Chinese	O
pharmacopeia	O
,	O
and	O
has	O
a	O
good	O
clinic	O
effect	O
.	O

Doxycycline	B
hydrochloride	I
injection	O
,	O
its	O
preparation	O
method	O
and	O
application	O
method	O

The	O
invention	O
discloses	O
an	O
injection	O
for	O
treating	O
iron	B
deficiency	O
anemia	O
,	O
which	O
is	O
characterized	O
in	O
that	O
each	O
1,000	O
milliliters	O
of	O
injection	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
:	O
7	O
to	O
12	O
grams	O
of	O
ferric	B
trichloride	I
,	O
15	O
to	O
20	O
grams	O
of	O
anhydrous	O
sodium	B
carbonate	I
,	O
0.5	O
to	O
1.5	O
grams	O
of	O
sodium	B
hydroxide	I
,	O
10	O
to	O
20	O
grams	O
of	O
cane	B
sugar	I
,	O
0.2	O
to	O
0.8	O
grams	O
of	O
glucose	B
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
preparation	O
method	O
of	O
the	O
injection	O
,	O
which	O
comprises	O
:	O
adding	O
solution	O
of	O
sodium	B
carbonate	I
into	O
solution	O
of	O
ferric	B
trichloride	I
for	O
reaction	O
;	O
washing	O
a	O
precipitate	O
obtained	O
by	O
the	O
reaction	O
with	O
water	O
for	O
injection	O
repeatedly	O
till	O
the	O
solution	O
does	O
not	O
contain	O
chlorine	B
;	O
draining	O
the	O
precipitate	O
till	O
dryness	O
,	O
and	O
crushing	O
;	O
adding	O
the	O
cane	B
sugar	I
and	O
glucose	B
into	O
the	O
crushed	O
precipitate	O
;	O
and	O
adding	O
solution	O
of	O
sodium	B
hydroxide	I
,	O
stirring	O
till	O
the	O
reaction	O
solution	O
is	O
clear	O
without	O
any	O
precipitate	O
,	O
adding	O
water	O
for	O
injection	O
,	O
filtering	O
,	O
filling	O
separately	O
,	O
and	O
sterilizing	O
.	O

The	O
injection	O
disclosed	O
by	O
the	O
invention	O
can	O
quickly	O
remedy	O
anemia	O
and	O
is	O
mainly	O
used	O
for	O
treating	O
people	O
who	O
have	O
difficulty	O
in	O
taking	O
iron	O
preparations	O
orally	O
or	O
people	O
who	O
need	O
to	O
be	O
remedied	O
from	O
anemia	O
quickly	O
.	O

Injection	O
for	O
treating	O
iron	B
deficiency	O
anemia	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
macaranga	O
tanarius	O
extract	O
,	O
which	O
contains	O
20	O
to	O
25	O
percent	O
of	O
deoxypodophyllotoxin	B
.	O

The	O
macaranga	O
tanarius	O
extract	O
is	O
prepared	O
by	O
a	O
method	O
which	O
comprises	O
:	O
crushing	O
hernandia	O
sonora	O
seeds	O
,	O
adding	O
the	O
crushed	O
material	O
into	O
a	O
CO2	B
supercritical	O
extractor	O
,	O
extracting	O
for	O
150	O
minutes	O
by	O
using	O
ethanol	B
as	O
an	O
entrainer	O
which	O
accounts	O
for	O
1	O
percent	O
of	O
the	O
volume	O
of	O
the	O
total	O
extract	O
solution	O
and	O
under	O
conditions	O
of	O
an	O
extraction	O
pressure	O
of	O
20MPa	O
,	O
a	O
temperature	O
of	O
45	O
DEG	O
C	O
and	O
a	O
CO2	B
flow	O
rate	O
per	O
gram	O
of	O
raw	O
medicine	O
per	O
minute	O
of	O
2ml	O
,	O
obtaining	O
the	O
extract	O
,	O
adding	O
the	O
extract	O
onto	O
a	O
D101	O
macroporous	O
adsorption	O
resin	O
column	O
for	O
absorption	O
,	O
eluting	O
with	O
35-percent	O
ethanol	B
,	O
collecting	O
eluent	O
in	O
an	O
amount	O
which	O
is	O
5	O
times	O
of	O
column	O
volume	O
,	O
recovering	O
ethanol	B
under	O
reduced	O
pressure	O
,	O
concentrating	O
the	O
eluent	O
,	O
spray	O
-	O
drying	O
and	O
thus	O
,	O
obtaining	O
the	O
macaranga	O
tanarius	O
extract	O
.	O

The	O
extract	O
provided	O
by	O
the	O
invention	O
has	O
high	O
active	O
ingredient	O
content	O
and	O
high	O
pharmacological	O
activity	O
.	O

Macaranga	O
tanarius	O
extract	O

The	O
invention	O
discloses	O
a	O
spray	O
for	O
beriberi	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
spray	O
comprises	O
the	O
following	O
raw	O
materials	O
:	O
8	O
-	O
12	O
weight	O
portions	O
of	O
radix	O
sophorae	O
flavescentis	O
,	O
10	O
-	O
20	O
weight	O
portions	O
of	O
common	O
cnidium	O
fruit	O
,	O
12	O
-	O
16	O
weight	O
portions	O
of	O
broom	O
cypress	O
fruit	O
,	O
10	O
-	O
20	O
weight	O
portions	O
of	O
safflower	O
,	O
18	O
-	O
20	O
weight	O
portions	O
of	O
dried	O
alum	O
,	O
10	O
-	O
12	O
weight	O
portions	O
of	O
calamine	O
,	O
6	O
-	O
8	O
weight	O
portions	O
of	O
chalcanthite	O
,	O
6	O
-	O
8	O
weight	O
portions	O
of	O
cortex	O
acanthopanacis	O
,	O
3	O
-	O
5	O
weight	O
portions	O
of	O
eucommia	O
,	O
8	O
-	O
12	O
weight	O
portions	O
of	O
pipewort	O
,	O
3	O
-	O
5	O
weight	O
portions	O
of	O
light	O
wheat	O
,	O
and	O
8	O
-	O
12	O
weight	O
portions	O
of	O
realgar	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
putting	O
the	O
raw	O
materials	O
in	O
an	O
extracting	O
tank	O
,	O
adding	O
8	O
times	O
water	O
,	O
and	O
carrying	O
out	O
heating	O
circulating	O
extraction	O
for	O
4	O
hour	O
;	O
(	O
2	O
)	O
filtering	O
and	O
condensing	O
the	O
extract	O
,	O
then	O
transferring	O
the	O
filtered	O
and	O
condensed	O
extract	O
in	O
a	O
reaction	O
pot	O
;	O
controlling	O
the	O
pH	O
value	O
to	O
4	O
,	O
and	O
stirring	O
for	O
30	O
min	O
at	O
the	O
temperature	O
of	O
60	O
DEG	O
C	O
;	O
and	O
(	O
3	O
)	O
cooling	O
,	O
then	O
injecting	O
in	O
an	O
aluminium	O
pressure	O
spray	O
pot	O
,	O
and	O
then	O
introducing	O
Freon	O
or	O
compressed	O
air	O
.	O

Spray	O
for	O
beriberi	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
lidocaine	B
hydrochloride	I
transdermal	O
ointment	O
,	O
comprising	O
a	O
lidocaine	B
hydrochloride	I
paste	O
agent	O
and	O
a	O
transdermal	O
enhancer	O
,	O
wherein	O
the	O
transdermal	O
enhancer	O
consists	O
of	O
mango	O
butter	O
and	O
menthol	B
.	O

Because	O
of	O
the	O
synergism	O
of	O
the	O
mango	O
butter	O
and	O
menthol	O
,	O
the	O
lidocaine	B
hydrochloride	I
has	O
high	O
transdermal	O
efficiency	O
reaching	O
17.09	O
%	O
,	O
good	O
skin	O
softening	O
property	O
and	O
high	O
oxidation	O
resistance	O
,	O
functions	O
of	O
softening	O
skin	O
,	O
smoothing	O
,	O
moisturizing	O
and	O
protecting	O
skin	O
and	O
low	O
price	O
.	O

Lidocaine	B
hydrochloride	I
transdermal	O
ointment	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
itraconazole	B
isomer	O
injection	O
,	O
which	O
comprises	O
itraconazole	B
,	O
cyclodextrin	O
or	O
a	O
derivative	O
thereof	O
and	O
other	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
itraconazole	B
is	O
2S4R	B
itraconazole	I
;	O
the	O
solubility	O
of	O
the	O
2S4R	B
itraconazole	I
in	O
an	O
aqueous	O
medium	O
containing	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
is	O
far	O
higher	O
than	O
racemization	O
mixtures	O
of	O
four	O
isomers	O
of	O
the	O
itraconazole	B
,	O
namely	O
only	O
a	O
smaller	O
amount	O
of	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
is	O
used	O
as	O
a	O
solubilizer	O
under	O
the	O
condition	O
of	O
medicines	O
with	O
the	O
same	O
concentration	O
,	O
so	O
the	O
using	O
amount	O
of	O
the	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
is	O
reduced	O
,	O
the	O
clinical	O
using	O
dose	O
of	O
the	O
medicines	O
are	O
improved	O
,	O
the	O
administration	O
period	O
of	O
the	O
medicines	O
is	O
prolonged	O
,	O
a	O
clinical	O
treatment	O
effect	O
is	O
increased	O
,	O
and	O
adverse	O
effects	O
are	O
reduced	O
;	O
and	O
the	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
is	O
expensive	O
,	O
so	O
the	O
production	O
cost	O
of	O
the	O
injection	O
can	O
be	O
reduced	O
by	O
reducing	O
the	O
using	O
amount	O
of	O
the	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
.	O

Therefore	O
,	O
compared	O
with	O
the	O
conventional	O
itraconazole	B
vein	O
injection	O
,	O
the	O
invention	O
has	O
the	O
advantage	O
that	O
:	O
the	O
using	O
amount	O
of	O
the	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
required	O
to	O
be	O
used	O
in	O
the	O
injection	O
prepared	O
from	O
the	O
2S4R	B
itraconazole	I
serving	O
as	O
active	O
ingredients	O
is	O
reduced	O
by	O
over	O
5	O
times	O
,	O
and	O
the	O
itraconazole	B
isomer	O
injection	O
is	O
suitable	O
to	O
be	O
used	O
as	O
an	O
angiogenesis	O
inhibitor	O
for	O
treating	O
various	O
tumor	O
diseases	O
clinically	O
.	O

Itraconazole	B
isomer	O
injection	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
dermatitis	O
and	O
eczema	O
,	O
which	O
comprises	O
fluocinolone	B
acetonide	I
,	O
borneol	B
,	O
and	O
a	O
emulsion	O
base	O
.	O

The	O
advantage	O
of	O
the	O
invention	O
is	O
that	O
borneol	B
is	O
used	O
in	O
the	O
medicament	O
,	O
which	O
has	O
antibiotic	O
and	O
pain	O
-	O
relieving	O
effect	O
,	O
and	O
has	O
cool	O
and	O
refreshing	O
feeling	O
that	O
makes	O
patient	O
feel	O
comfortable	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
invention	O
has	O
a	O
simple	O
process	O
,	O
is	O
convenient	O
for	O
preparation	O
and	O
application	O
,	O
has	O
significant	O
curative	O
effect	O
,	O
is	O
not	O
easy	O
to	O
cause	O
recurrence	O
,	O
can	O
moisten	O
skin	O
,	O
and	O
is	O
applicable	O
to	O
dermatitis	O
,	O
eczema	O
,	O
psoriasis	O
,	O
non	O
-	O
specific	O
pruritus	O
ani	O
and	O
reproductive	O
organ	O
pruritus	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
dermatitis	O
and	O
eczema	O
and	O
preparation	O
method	O
thereof	O

An	O
external	O
plaster	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
and	O
lactation	O
mastitis	O
relates	O
to	O
an	O
external	O
plaster	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
and	O
lactation	O
mastitis	O
,	O
which	O
is	O
to	O
solve	O
the	O
problems	O
of	O
long	O
treatment	O
course	O
and	O
great	O
medicament	O
side	O
effect	O
for	O
current	O
clinical	O
routine	O
treatment	O
of	O
mammary	O
gland	O
hyperplasia	O
and	O
lactation	O
mastitis	O
.	O

The	O
external	O
plaster	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
and	O
lactation	O
mastitis	O
of	O
the	O
invention	O
comprises	O
pangolin	O
tablets	O
,	O
green	O
tangerine	O
peel	O
,	O
radix	O
bupleuri	O
,	O
licorice	O
,	O
curcuma	O
rhizome	O
,	O
white	O
peony	O
root	O
,	O
radix	O
ophiopogonis	O
,	O
safflower	O
,	O
rhizoma	O
sparganii	O
,	O
poria	O
cocos	O
,	O
angelica	O
,	O
rhizoma	O
cyperi	O
,	O
oyster	O
,	O
corydalis	O
tuber	O
,	O
dandelion	O
,	O
tangerine	O
peel	O
,	O
vaccaria	O
segetalis	O
,	O
minium	O
,	O
musk	O
,	O
frankincense	O
and	O
myrrh	O
.	O

The	O
plaster	O
of	O
the	O
invention	O
has	O
good	O
treatment	O
effect	O
,	O
short	O
treatment	O
course	O
,	O
quick	O
effect	O
,	O
and	O
less	O
side	O
effect	O
.	O

The	O
plaster	O
of	O
the	O
invention	O
is	O
applicable	O
to	O
the	O
treatment	O
of	O
mammary	O
gland	O
hyperplasia	O
and	O
lactation	O
mastitis	O
.	O

External	O
plaster	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
and	O
lactation	O
mastitis	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drugs	O
,	O
and	O
particularly	O
relates	O
to	O
aminopeptidase	O
N	O
inhibitor	O
,	O
a	O
preparation	O
method	O
and	O
application	O
to	O
tumor	O
resistance	O
.	O

The	O
technical	O
scheme	O
includes	O
that	O
the	O
aminopeptidase	O
N	O
inhibitor	O
is	O
chemically	O
named	O
as	O
(	B
S	I
)	I
-4-methyl-2-	I
(	I
3-naphthyl-1-ylmethyl	I
-	I
ureido	I
)	I
-valeryl	I
group	O
hydroxylamine	B
.	O

The	O
constitutional	O
formula	O
(	O
I	O
)	O
of	O
the	O
aminopeptidase	O
N	O
inhibitor	O
is	O
shown	O
here	O
.	O

The	O
pharmacodynamic	O
effect	O
of	O
the	O
aminopeptidase	O
N	O
inhibitor	O
is	O
evaluated	O
by	O
in	O
-	O
vitro	O
APN	O
(	O
adiponectin	O
)	O
inhibitory	O
experiments	O
,	O
in	O
-	O
vitro	O
resistance	O
to	O
tumor	O
cell	O
invasion	O
,	O
antiangiogenesis	O
and	O
mouse	O
in	O
-	O
vivo	O
resistance	O
to	O
melanoma	O
manual	O
transfer	O
and	O
antiangiogenesis	O
experiments	O
.	O

Aminopeptidase	O
N	O
inhibitor	O
,	O
preparation	O
method	O
and	O
application	O

The	O
invention	O
discloses	O
novel	O
phenoxyacetic	B
acid	I
compound	O
as	O
shown	O
in	O
compound	O
of	O
a	O
formula	O
1	O
.	O

The	O
phenoxyacetic	B
acid	I
compound	O
comprises	O
optical	O
isomer	O
,	O
racemic	O
mixture	O
,	O
physiological	O
acceptable	O
salt	O
,	O
solvate	O
and	O
a	O
crystalline	O
form	O
,	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
includes	O
pharmaceutical	O
preparation	O
containing	O
the	O
compound	O
and	O
treatment	O
application	O
and	O
relevant	O
insulin	O
resistance	O
clinical	O
application	O
of	O
the	O
compound	O
.	O

Phenoxyacetic	B
acid	I
compound	O
,	O
preparation	O
method	O
thereof	O
and	O
drug	O
application	O

The	O
invention	O
discloses	O
a	O
novel	O
platinum	B
(	I
II	I
)	I
anticancer	O
coordination	O
complex	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
chloridion	B
(	O
Cl	B
minus	O
)	O
is	O
taken	O
as	O
a	O
leaving	O
group	O
,	O
and	O
CH3CH	B
(	I
NH2	I
)	I
CH3	I
(	O
isopropamide	B
)	O
and	O
NH3	B
(	O
ammonia	B
)	O
are	O
taken	O
as	O
carriers	O
.	O

The	O
platinum	B
(	I
II	I
)	I
coordination	O
complex	O
with	O
the	O
antitumor	O
activity	O
takes	O
trichlorine	B
ammonia	I
potassiumplatinate	I
as	O
a	O
starting	O
material	O
to	O
react	O
at	O
a	O
certain	O
condition	O
,	O
after	O
substitution	O
,	O
hydrolyzation	O
,	O
pressure	O
reduction	O
concentration	O
and	O
recrystallization	O
,	O
maleinoid	O
form	O
-dichloro	B
-	I
amino	I
group	O
is	O
obtained	O
.	O

The	O
isopropamide	B
platinum	I
(	I
II	I
)	I
coordination	O
complex	O
has	O
the	O
structure	O
as	O
showed	O
in	O
the	O
specification	O
,	O
and	O
the	O
thiazolyl	B
blue	O
(	O
MTT	O
)	O
experimental	O
test	O
shows	O
that	O
:	O
the	O
coordination	O
complex	O
has	O
obvious	O
effect	O
on	O
inhibiting	O
the	O
cell	O
proliferation	O
of	O
leukemia	O
HL-60	O
,	O
liver	O
cancer	O
SMMC-7721	O
,	O
lung	O
cancer	O
A-549	O
,	O
breast	O
cancer	O
MCF-7	O
and	O
colon	O
cancer	O
SW480	O
.	O

Platinum	B
(	I
II	I
)	I
coordination	O
complex	O
with	O
antitumor	O
activity	O

The	O
invention	O
relates	O
to	O
a	O
water	O
-	O
soluble	O
amino	B
acid	I
ester	I
derivative	O
of	O
propofol	B
and	O
application	O
thereof	O
.	O

Amino	B
acid	I
ester	I
of	O
the	O
propofol	B
has	O
a	O
structure	O
with	O
a	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
shown	O
in	O
the	O
description	O
.	O

The	O
invention	O
also	O
relates	O
a	O
preparation	O
method	O
for	O
a	O
compound	O
with	O
the	O
formula	O
(	O
I	O
)	O
,	O
a	O
medicinal	O
salt	O
thereof	O
,	O
a	O
compound	O
-	O
containing	O
medicinal	O
composition	O
and	O
application	O
of	O
the	O
compound	O
serving	O
as	O
narcotic	O
medicines	O
.	O

Water	O
-	O
soluble	O
amino	B
acid	I
ester	I
derivative	O
of	O
propofol	B
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
deuteroacetyl	B
-	O
containing	O
kinase	O
inhibitor	O
capable	O
of	O
inhibiting	O
kinase	O
,	O
particularly	O
inhibiting	O
activity	O
of	O
breakpoint	O
cluster	O
region	O
-	O
abelson	O
(	O
BCR	O
-	O
ABL	O
)	O
.	O

The	O
inhibitor	O
has	O
the	O
structure	O
of	O
a	O
formula	O
(	O
I	O
)	O
.	O

The	O
inhibitor	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicinal	O
composition	O
,	O
namely	O
used	O
for	O
inhibiting	O
the	O
kinase	O
of	O
human	O
beings	O
or	O
animals	O
,	O
for	O
example	O
,	O
used	O
for	O
treating	O
tumors	O
and/or	O
other	O
diseases	O
.	O

Deuteroacetyl	B
-	O
containing	O
kinase	O
inhibitor	O

The	O
invention	O
provides	O
application	O
of	O
forsythin	B
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
chronic	O
myeloid	O
leukemia	O
.	O

Cell	O
tests	O
prove	O
that	O
forsythin	B
can	O
inhibit	O
proliferation	O
of	O
K562	O
leukemia	O
cell	O
and	O
inducing	O
the	O
erythroid	O
differentiation	O
of	O
K562	O
leukemia	O
cell	O
.	O

Application	O
of	O
forsythin	B
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
chronic	O
myeloid	O
leukemia	O

The	O
invention	O
provides	O
a	O
pain	O
relief	O
tincture	O
which	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
15	O
parts	O
of	O
borneol	B
,	O
6	O
-	O
10	O
parts	O
of	O
rhizoma	O
corydalis	O
,	O
6	O
-	O
10	O
parts	O
of	O
trogopterus	O
dung	O
,	O
2	O
-	O
6	O
parts	O
of	O
safflower	O
,	O
10	O
-	O
15	O
parts	O
of	O
dried	O
alum	O
,	O
5	O
-	O
9	O
parts	O
of	O
frankincense	O
and	O
6	O
-	O
10	O
parts	O
of	O
radix	O
curcumae	O
.	O

The	O
preparation	O
method	O
of	O
the	O
pain	O
relief	O
tincture	O
comprises	O
the	O
following	O
steps	O
:	O
pulverizing	O
the	O
raw	O
materials	O
,	O
evenly	O
mixing	O
,	O
soaking	O
in	O
200	O
-	O
230	O
parts	O
of	O
30	O
-	O
95	O
%	O
vol	O
alcohol	B
for	O
15	O
-	O
20	O
days	O
,	O
standing	O
at	O
18	O
-	O
25	O
DEG	O
C	O
for	O
3	O
-	O
5	O
days	O
,	O
standing	O
at	O
5	O
-	O
10	O
DEG	O
C	O
for	O
3	O
-	O
5	O
days	O
,	O
standing	O
at	O
roomtemperature	O
for	O
3	O
-	O
5	O
days	O
,	O
filtering	O
and	O
filling	O
.	O

When	O
in	O
use	O
,	O
the	O
pain	O
relief	O
tincture	O
is	O
applied	O
to	O
the	O
center	O
point	O
of	O
pain	O
,	O
and	O
gradually	O
and	O
slowly	O
spread	O
to	O
the	O
periphery	O
for	O
about	O
1	O
minute	O
.	O

Thepain	O
relief	O
tincture	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
low	O
cost	O
and	O
obvious	O
curative	O
effect	O
,	O
and	O
is	O
applicable	O
to	O
patients	O
with	O
late	O
cancer	O
pains	O
and	O
common	O
pain	O
diseases	O
.	O

Pain	O
relief	O
tincture	O

The	O
invention	O
discloses	O
application	O
of	O
2-	B
(	I
2-difluoromethyl	I
benzimidazole-1-yl	I
)	I
-4,6-dimorpholinyl-1,3,5-triazine	I
(	O
ZSTK474	O
for	O
short	O
)	O
to	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
autoimmune	O
and	O
inflammatory	O
diseases	O
.	O

Experimental	O
results	O
prove	O
that	O
the	O
ZSTK474	O
can	O
inhibit	O
the	O
differentiation	O
of	O
human	O
immune	O
dendritic	O
cells	O
,	O
the	O
maturity	O
of	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activated	O
human	O
immune	O
dendritic	O
cells	O
,	O
the	O
antigen	O
uptake	O
capacity	O
of	O
immature	O
dendritic	O
cells	O
,	O
the	O
antigen	O
presenting	O
capacity	O
of	O
mature	O
dendritic	O
cells	O
and	O
T	O
cell	O
proliferation	O
reaction	O
stimulated	O
by	O
the	O
dendritic	O
cells	O
,	O
and	O
particularly	O
can	O
reduce	O
the	O
morbidity	O
degree	O
of	O
mouse	O
experimental	O
autoimmune	O
encephalomyelitis	O
,	O
so	O
the	O
ZSTK474	O
is	O
expected	O
to	O
become	O
a	O
medicine	O
for	O
treating	O
autoimmune	O
and	O
inflammatory	O
diseases	O
such	O
as	O
multiple	O
sclerosis	O
,	O
acute	O
disseminated	O
encephalomyelitis	O
and	O
the	O
like	O
clinically	O
.	O

Application	O
of	O
ZSTK474	O
to	O
preparation	O
of	O
medicine	O
for	O
treating	O
autoimmune	O
diseases	O

The	O
invention	O
provides	O
a	O
compound	O
preparation	O
having	O
an	O
anti	O
-	O
tumor	O
action	O
.	O

The	O
compound	O
preparation	O
comprises	O
therapeutically	O
effective	O
amounts	O
of	O
ingredient	O
A	O
,	O
ingredient	O
B	O
,	O
ingredient	O
C	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
;	O
or	O
mixture	O
of	O
the	O
ingredient	O
A	O
,	O
the	O
ingredient	O
B	O
and	O
the	O
ingredient	O
C	O
;	O
or	O
a	O
capsule	O
taking	O
the	O
mixture	O
of	O
the	O
ingredient	O
B	O
and	O
the	O
ingredient	O
C	O
as	O
restricted	O
substances	O
;	O
the	O
ingredient	O
A	O
is	O
enteric	O
coating	O
particles	O
of	O
dipyridamole	O
and	O
is	O
formed	O
by	O
dipyridamole	B
enteric	O
particles	O
and	O
coating	O
layers	O
for	O
packing	O
the	O
dipyridamole	B
enteric	O
particles	O
;	O
the	O
ingredient	O
B	O
is	O
ubenimex	O
adhesion	O
particles	O
taking	O
insoluble	O
cellulose	O
and	O
biological	O
adhesive	O
materials	O
as	O
carriers	O
;	O
and	O
the	O
ingredient	O
C	O
is	O
dexamethasone	B
with	O
a	O
particle	O
size	O
of	O
100	O
-	O
200	O
nm	O
.	O

The	O
compound	O
preparation	O
having	O
the	O
anti	O
-	O
tumor	O
action	O
formed	O
by	O
the	O
three	O
compositions	O
can	O
reach	O
the	O
peak	O
value	O
in	O
blood	O
at	O
a	O
higher	O
speed	O
,	O
and	O
can	O
remain	O
longer	O
effective	O
concentration	O
time	O
respectively	O
,	O
so	O
that	O
the	O
requirement	O
of	O
clinical	O
application	O
can	O
be	O
met	O
.	O

Compound	O
preparation	O
having	O
anti	O
-	O
tumor	O
action	O

The	O
invention	O
relates	O
to	O
a	O
paeonol	B
micro	O
depot	O
carrier	O
and	O
a	O
method	O
for	O
enhancing	O
oxidation	O
resistance	O
of	O
paeonol	B
.	O

Paeonol	B
is	O
insoluble	O
in	O
cold	O
water	O
,	O
has	O
a	O
special	O
smell	O
and	O
can	O
be	O
easily	O
oxidized	O
,	O
thereby	O
greatly	O
restricting	O
the	O
application	O
range	O
of	O
the	O
paeonol	B
as	O
a	O
medicine	O
.	O

An	O
in	O
-	O
situ	O
coagulation	O
method	O
is	O
utilized	O
to	O
coat	O
the	O
paeonol	B
in	O
a	O
micro	O
depot	O
carrier	O
.	O

The	O
in	O
-	O
situ	O
coagulation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
dissolving	O
0.5	O
-	O
4.0	O
parts	O
of	O
gelatin	O
and	O
0.5	O
-	O
4.0	O
parts	O
of	O
sodium	B
alginate	I
in	O
water	O
to	O
obtain	O
a	O
solution	O
;	O
adding	O
1	O
-	O
6	O
parts	O
of	O
paeonol	O
into	O
the	O
solution	O
obtained	O
in	O
the	O
first	O
step	O
,	O
heating	O
to	O
55	O
-	O
60	O
DEG	O
C	O
,	O
and	O
carrying	O
out	O
high	O
-	O
shear	O
emulsification	O
to	O
obtain	O
a	O
stable	O
O	O
/	O
W	O
emulsion	O
;	O
dropwisely	O
adding	O
a	O
5	O
-	O
10	O
%	O
acetate	B
solution	O
to	O
obtain	O
a	O
suspension	O
;	O
and	O
adding	O
0.01	O
-	O
0.2	O
part	O
by	O
weight	O
of	O
1	O
-	O
5	O
%	O
calcium	B
chloride	I
solution	O
to	O
cure	O
a	O
coagulum	O
,	O
cooling	O
in	O
an	O
ice	O
bath	O
to	O
below	O
5	O
DEG	O
C	O
,	O
filtering	O
,	O
adding	O
0.15	O
-	O
0.5	O
part	O
by	O
weight	O
of	O
anticoagulant	O
magnesium	B
aluminum	I
silicate	I
into	O
the	O
filter	O
cake	O
to	O
disperse	O
the	O
filter	O
cake	O
,	O
and	O
drying	O
under	O
reduced	O
pressure	O
to	O
obtain	O
the	O
paeonol	B
-	O
containing	O
micro	O
depot	O
carrier	O
powder	O
.	O

The	O
invention	O
is	O
applicable	O
to	O
the	O
field	O
of	O
medicine	O
.	O

Paeonol	B
micro	O
depot	O
carrier	O
and	O
method	O
for	O
enhancing	O
oxidation	O
resistance	O
of	O
paeonol	B

The	O
invention	O
relates	O
to	O
a	O
ganoderic	B
acid	I
monomer	I
T	O
tablet	O
and	O
its	O
preparation	O
method	O
.	O

The	O
tablet	O
is	O
composed	O
of	O
:	O
by	O
weight	O
,	O
10	O
-	O
15	O
%	O
of	O
an	O
active	O
substance	O
ganoderic	B
acid	I
monomer	I
T	O
,	O
85	O
-	O
90	O
%	O
of	O
a	O
filler	O
,	O
a	O
flow	O
aid	O
which	O
accounts	O
for	O
0.5	O
-	O
1	O
%	O
of	O
the	O
total	O
feeding	O
amount	O
,	O
and	O
0.25	O
-	O
0.5	O
%	O
of	O
a	O
lubricant	O
.	O

The	O
appropriate	O
weight	O
of	O
the	O
tablet	O
is	O
100	O
-	O
200	O
mg	O
.	O

The	O
preparation	O
method	O
comprises	O
steps	O
of	O
:	O
respectively	O
sieving	O
the	O
ganoderic	B
acid	I
monomer	I
T	O
and	O
the	O
filler	O
through	O
a	O
sieve	O
of	O
80	O
meshes	O
,	O
mixing	O
by	O
an	O
equivalent	O
increment	O
method	O
,	O
adding	O
a	O
proper	O
amount	O
of	O
the	O
lubricant	O
,	O
uniformly	O
mixing	O
,	O
and	O
directly	O
tabletting	O
.	O

The	O
tablet	O
has	O
smooth	O
and	O
round	O
appearance	O
,	O
is	O
fast	O
to	O
disintegrate	O
and	O
can	O
be	O
completely	O
dissolved	O
.	O

Each	O
index	O
of	O
the	O
tablet	O
accords	O
with	O
the	O
tablet	O
quality	O
requirements	O
.	O

The	O
preparation	O
technology	O
provided	O
by	O
the	O
invention	O
is	O
simple	O
,	O
convenient	O
to	O
operate	O
and	O
economical	O
,	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Ganoderic	B
acid	I
monomer	I
T	O
tablet	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
discloses	O
metformin	B
hydrochloride	I
sustained	O
-	O
release	O
tablets	O
which	O
are	O
characterized	O
in	O
that	O
:	O
every	O
10000	O
tablets	O
are	O
prepared	O
from	O
medicine	O
materials	O
and	O
auxiliary	O
materials	O
of	O
,	O
by	O
weight	O
:	O
5000	O
g	O
of	O
metformin	B
hydrochloride	I
,	O
1750	O
g	O
of	O
hypromellose	O
,	O
1750	O
g	O
of	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
180	O
g	O
of	O
stearic	B
acid	I
,	O
200	O
g	O
of	O
magnesium	B
stearate	I
,	O
and	O
an	O
appropriate	O
amount	O
of	O
75	O
%	O
ethanol	B
.	O

The	O
metformin	B
hydrochloride	I
sustained	O
-	O
release	O
tablets	O
can	O
be	O
slowly	O
released	O
in	O
vivo	O
.	O

With	O
the	O
tablets	O
,	O
stability	O
of	O
blood	O
drug	O
level	O
can	O
be	O
maintained	O
,	O
and	O
a	O
half	O
-	O
life	O
period	O
is	O
prolonged	O
.	O

The	O
tablets	O
are	O
safe	O
,	O
can	O
be	O
used	O
for	O
treating	O
type	O
II	O
diabetes	O
,	O
and	O
are	O
advantaged	O
in	O
high	O
efficiency	O
,	O
low	O
toxicity	O
,	O
and	O
convenient	O
administration	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
metformin	B
hydrochloride	I
sustained	O
-	O
release	O
tablets	O
.	O

Metformin	B
hydrochloride	I
sustained	O
-	O
release	O
tablets	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
epalrestat	B
slow	O
-	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
40	O
parts	O
of	O
epalrestat	B
,	O
5	O
-	O
60	O
parts	O
of	O
slow	O
-	O
release	O
material	O
,	O
0	O
-	O
90	O
parts	O
of	O
filler	O
,	O
0.1	O
-	O
2	O
parts	O
of	O
lubricant	O
and	O
right	O
amount	O
of	O
adhesive	O
.	O

The	O
slow	O
-	O
release	O
material	O
comprises	O
hydroxypropyl	O
methylcellulose	O
or	O
a	O
mixture	O
of	O
hydroxypropyl	O
methylcellulose	O
and	O
ethyl	O
cellulose	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
evenly	O
mixing	O
the	O
epalrestat	O
,	O
slow	O
-	O
release	O
material	O
and	O
filler	O
according	O
to	O
the	O
prescription	O
amounts	O
,	O
adding	O
the	O
adhesive	O
to	O
obtain	O
a	O
soft	O
material	O
,	O
granulating	O
the	O
soft	O
material	O
,	O
drying	O
,	O
finishing	O
,	O
adding	O
the	O
lubricant	O
,	O
and	O
tabletting	O
.	O

Compared	O
with	O
the	O
conventional	O
oral	O
epalrestat	B
common	O
preparation	O
,	O
the	O
epalrestat	B
slow	O
-	O
release	O
tablet	O
provided	O
by	O
the	O
invention	O
can	O
smoothly	O
and	O
slowly	O
release	O
the	O
medicines	O
after	O
being	O
orally	O
dosed	O
,	O
and	O
can	O
maintain	O
therapeutic	O
action	O
for	O
a	O
longer	O
time	O
.	O

Epalrestat	B
slow	O
-	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
chlorhexidine	O
acetate	O
-	O
copper	O
/	O
imvite	O
nano	O
antibacterial	O
composite	O
material	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
nano	O
antibacterial	O
composite	O
material	O
comprises	O
sodium	B
-	O
based	O
imvite	O
and	O
chlorhexidine	B
acetate	I
-	I
copper	I
coordination	O
complex	O
bewteetn	O
sodium	O
-	O
based	O
imvite	O
sheet	O
layers	O
.	O

The	O
method	O
disclosed	O
by	O
the	O
invention	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
carrying	O
out	O
metal	O
organic	O
coordination	O
of	O
a	O
broad	O
-	O
spectrum	O
antibacterial	O
agent	O
,	O
namely	O
the	O
chlorhexidine	B
acetate	I
,	O
and	O
copper	B
ions	I
to	O
form	O
a	O
novel	O
antibacterial	O
agent	O
,	O
namely	O
chlorhexidine	B
acetate	I
-	I
copper	I
,	O
wherein	O
the	O
antibacterial	O
property	O
of	O
the	O
chlorhexidine	B
acetate	I
can	O
be	O
effectively	O
increased	O
;	O
and	O
intercalating	O
the	O
chlorhexidine	B
acetate	I
-	I
copper	I
between	O
the	O
imvite	O
layers	O
by	O
adopting	O
a	O
solution	O
intercalated	O
method	O
,	O
wherein	O
the	O
prepared	O
chlorhexidine	B
acetate	I
-	I
copper	I
/	O
imvite	O
nano	O
antibacterial	O
composite	O
material	O
is	O
a	O
novel	O
functional	O
nano	O
antibacterial	O
composite	O
material	O
with	O
controlled	O
release	O
and	O
slow	O
release	O
;	O
the	O
stability	O
of	O
heat	O
resistance	O
and	O
medium	O
resistance	O
can	O
be	O
increased	O
;	O
furthermore	O
,	O
the	O
slow	O
release	O
property	O
of	O
the	O
antibacterial	O
agent	O
,	O
namely	O
the	O
chlorhexidine	B
acetate	I
-	I
copper	I
,	O
can	O
also	O
be	O
improved	O
.	O

Chlorhexidine	B
acetate	I
-	I
copper	I
/	O
imvite	O
nano	O
antibacterial	O
composite	O
material	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
ointment	O
for	O
scalds	O
and	O
burns	O
.	O

The	O
method	O
comprises	O
:	O
first	O
putting	O
a	O
washed	O
rotten	O
orange	O
in	O
a	O
capped	O
bottle	O
,	O
when	O
juice	O
exudes	O
,	O
adding	O
ultrafine	O
powder	O
ground	O
from	O
sophora	O
flavescens	O
,	O
forsythia	O
,	O
stir	O
-	O
fried	O
sanguisorba	O
officinalis	O
,	O
rheum	O
officinale	O
,	O
and	O
phellodendron	O
,	O
etc	O
.	O
into	O
the	O
rotten	O
orange	O
juice	O
so	O
as	O
to	O
prepare	O
a	O
paste	O
,	O
which	O
is	O
then	O
filled	O
into	O
a	O
bottle	O
and	O
can	O
be	O
applied	O
to	O
burns	O
and	O
scalds	O
during	O
usage	O
.	O

The	O
ointment	O
of	O
the	O
invention	O
can	O
be	O
used	O
for	O
treating	O
various	O
burns	O
and	O
scalds	O
by	O
water	O
and	O
fire	O
,	O
has	O
good	O
anti	O
-	O
inflammation	O
and	O
pain	O
relieving	O
effect	O
,	O
and	O
can	O
promote	O
scabbing	O
and	O
recovery	O
wounds	O
without	O
scar	O
,	O
thus	O
being	O
a	O
good	O
medicine	O
for	O
treating	O
burns	O
and	O
scalds	O
.	O

Preparation	O
method	O
of	O
ointment	O
for	O
scalds	O
and	O
burns	O

The	O
invention	O
relates	O
to	O
a	O
recipe	O
of	O
a	O
foot	O
immersing	O
liquid	O
for	O
relieving	O
fatigue	O
.	O

The	O
technical	O
scheme	O
of	O
the	O
invention	O
is	O
as	O
follows	O
:	O
the	O
recipe	O
comprises	O
the	O
following	O
raw	O
materials	O
:	O
1	O
jin	O
of	O
old	O
ginger	O
,	O
2500ml	O
of	O
pure	O
rice	O
wine	O
,	O
100	O
g	O
of	O
salt	O
and	O
100	O
g	O
of	O
vinegar	O
,	O
wherein	O
the	O
old	O
ginger	O
is	O
cleaned	O
and	O
is	O
not	O
subjected	O
to	O
skin	O
removal	O
,	O
the	O
pure	O
rice	O
wine	O
is	O
colorless	O
and	O
transparent	O
rice	O
wine	O
with	O
ethyl	B
alcohol	I
number	O
of	O
degree	O
of	O
30	O
and	O
is	O
not	O
selected	O
from	O
yellow	O
rice	O
wine	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
feet	O
are	O
immersed	O
with	O
the	O
rice	O
wine	O
and	O
the	O
ginger	O
juice	O
,	O
thus	O
blood	O
of	O
the	O
whole	O
body	O
can	O
be	O
enabled	O
to	O
be	O
circulated	O
,	O
body	O
metabolism	O
is	O
accelerated	O
,	O
flatulence	O
can	O
be	O
remarkably	O
reduced	O
,	O
body	O
fatigue	O
is	O
relieved	O
,	O
insomnia	O
is	O
improved	O
,	O
and	O
symptoms	O
of	O
cold	O
,	O
dampness	O
and	O
heat	O
can	O
be	O
dispelled	O
.	O

Recipe	O
of	O
foot	O
immersing	O
liquid	O
for	O
relieving	O
fatigue	O

An	O
aptamer	O
which	O
can	O
bind	O
to	O
chymase	O
to	O
inhibit	O
the	O
activity	O
of	O
chymase	O
and	O
comprises	O
the	O
nucleotide	O
sequence	O
represented	O
by	O
the	O
formula	O
:	O
X1GAUAGAN1N2UAAX2	O
(	O
wherein	O
X1	O
and	O
X2	O
independently	O
represent	O
A	O
or	O
G	O
;	O
and	O
N1	O
and	O
N2	O
independently	O
represent	O
A	O
,	O
G	O
,	O
C	O
,	O
U	O
or	O
T	O
)	O
;	O
a	O
complex	O
comprising	O
the	O
aptamer	O
and	O
a	O
functional	O
substance	O
(	O
e.g.	O
,	O
an	O
affinity	O
substance	O
,	O
a	O
labeling	O
substance	O
,	O
an	O
enzyme	O
,	O
a	O
drug	O
delivery	O
medium	O
,	O
or	O
a	O
medicinal	O
agent	O
)	O
;	O
a	O
medicinal	O
agent	O
or	O
a	O
reagent	O
comprising	O
the	O
aptamer	O
or	O
the	O
complex	O
;	O
a	O
chymase	O
detection	O
method	O
or	O
a	O
chymase	O
purification	O
method	O
characterized	O
by	O
utilizing	O
the	O
aptamer	O
or	O
the	O
complex	O
;	O
and	O
others	O
.	O

Aptamer	O
for	O
chymase	O
,	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
an	O
alpha	B
-	I
pyrone	I
compound	O
,	O
wherein	O
the	O
compound	O
is	O
5-ethyl-4-methoxy-6-methyl-2H	B
-	I
pyrone-9-ethyl	I
ester	I
,	O
the	O
structure	O
of	O
the	O
compound	O
is	O
as	O
follow	O
,	O
and	O
the	O
compound	O
is	O
used	O
for	O
preparation	O
of	O
anti	O
-	O
tumor	O
drugs	O
.	O

Application	O
of	O
pyrone	B
compound	O

The	O
invention	O
provides	O
a	O
method	O
for	O
stabilizing	O
ibuprofen	B
injections	O
,	O
as	O
well	O
as	O
an	O
ibuprofen	B
injection	O
prepared	O
by	O
the	O
method	O
.	O

The	O
main	O
points	O
of	O
the	O
method	O
lie	O
in	O
that	O
nitrogen	B
gas	O
is	O
introduced	O
one	O
or	O
repeatedly	O
during	O
preparation	O
for	O
expelling	O
the	O
oxygen	B
in	O
an	O
enclosed	O
packing	O
container	O
,	O
and	O
finally	O
the	O
oxygen	B
content	O
inside	O
the	O
enclosed	O
container	O
is	O
controlled	O
at	O
0	O
-	O
3	O
%	O
,	O
thus	O
reaching	O
the	O
purpose	O
of	O
avoiding	O
oxidizing	O
ibuprofen	O
.	O

Ibuprofen	B
injection	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
a	O
folacin	O
-	O
carboxymethyl	O
chitosan	O
modified	O
pH	O
sensitive	O
taxol	O
nanoliposome	O
and	O
its	O
preparation	O
method	O
.	O

The	O
liposome	O
is	O
composed	O
of	O
taxol	B
,	O
phosphatide	B
,	O
cholesterol	B
,	O
vitamin	B
E	I
,	O
folacin	O
-	O
carboxymethyl	O
chitosan	O
and	O
the	O
like	O
.	O

The	O
prepared	O
liposome	O
possesses	O
pH	O
sensitivity	O
,	O
tumor	O
targeting	O
and	O
long	O
-	O
circulating	O
active	O
targetable	O
drug	O
delivery	O
function	O
.	O

Folacin	O
-	O
carboxymethyl	O
chitosan	O
modified	O
pH	O
sensitive	O
taxol	B
nanoliposome	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
containing	O
12	O
vitamins	O
,	O
which	O
is	O
characterized	O
that	O
the	O
pharmaceutical	O
composition	O
is	O
an	O
injection	O
preparation	O
prepared	O
from	O
vitamin	B
A	I
palmitate	I
,	O
cocarboxylase	O
tetrahydrate	B
,	O
riboflavin	B
sodium	I
phosphate	I
,	O
vitamin	B
B12	I
,	O
vitamin	B
D3	I
,	O
vitamin	B
B6	I
,	O
vitamin	B
C	I
,	O
nicotinamide	B
,	O
folic	B
acid	I
,	O
racemic	B
alpha	I
-	I
tocopherol	I
,	O
biotin	B
,	O
dexpanthenol	B
,	O
soybean	O
lecithin	O
,	O
glycocholic	B
acid	I
,	O
citric	B
acid	I
,	O
cysteine	B
hydrochloride	I
and	O
an	O
excipient	O
.	O

The	O
pharmaceutical	O
composition	O
overcomes	O
the	O
insufficiency	O
of	O
the	O
prior	O
art	O
,	O
the	O
test	O
result	O
shows	O
that	O
the	O
prepared	O
injection	O
preparation	O
possesses	O
stable	O
quality	O
for	O
long	O
term	O
and	O
safer	O
clinical	O
usage	O
.	O

Pharmaceutical	O
composition	O
containing	O
12	O
vitamins	O

The	O
invention	O
provides	O
a	O
liver	O
aid	O
troche	O
,	O
which	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
components	O
in	O
weight	O
ratio	O
:	O
in	O
each	O
1000	O
troches	O
:	O
60	O
g	O
of	O
silymarin	B
,	O
55	O
-	O
65	O
g	O
of	O
calcium	B
hydrophosphate	I
,	O
70	O
-	O
80	O
g	O
of	O
calcium	B
sulphate	I
,	O
35	O
-	O
45	O
g	O
of	O
cane	O
sugar	O
,	O
6.0	O
-	O
6.2	O
g	O
of	O
starch	O
added	O
with	O
2.0	O
-	O
2.5	O
g	O
of	O
starch	O
slurry	O
which	O
is	O
15	O
%	O
,	O
10	O
-	O
14	O
g	O
of	O
sodium	O
starch	O
glycolate	O
,	O
1	O
-	O
2.0	O
g	O
of	O
magnesium	B
stearate	I
,	O
and	O
7.5	O
-	O
8.5	O
g	O
of	O
Opadry	O
.	O

The	O
liver	O
aid	O
troche	O
disclosed	O
by	O
the	O
invention	O
is	O
formed	O
by	O
adopting	O
a	O
novel	O
preparation	O
method	O
and	O
screening	O
a	O
more	O
appropriate	O
formula	O
;	O
therefore	O
,	O
the	O
weight	O
difference	O
in	O
the	O
tabletting	O
process	O
meets	O
the	O
requirement	O
,	O
and	O
mass	O
production	O
is	O
smooth	O
to	O
carry	O
out	O
;	O
simultaneously	O
,	O
the	O
phenomena	O
of	O
being	O
uneven	O
in	O
troche	O
surface	O
,	O
pocked	O
and	O
broken	O
after	O
troches	O
are	O
coated	O
can	O
be	O
solved	O
;	O
the	O
rejection	O
rate	O
is	O
reduced	O
;	O
the	O
production	O
efficiency	O
is	O
increased	O
;	O
and	O
the	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
simple	O
,	O
free	O
from	O
addition	O
of	O
new	O
cost	O
,	O
easy	O
for	O
scale	O
production	O
and	O
higher	O
in	O
application	O
value	O
.	O

Liver	O
aid	O
troche	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
embelin	B
to	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
an	O
autoimmune	O
disease	O
.	O

As	O
proved	O
by	O
an	O
experimental	O
result	O
,	O
the	O
embelin	B
can	O
be	O
used	O
for	O
suppressing	O
the	O
differentiation	O
of	O
human	O
immune	O
dendritic	O
cells	O
,	O
the	O
maturity	O
of	O
human	O
immune	O
dendritic	O
cells	O
activated	O
by	O
LPS	O
(	O
Lipopolysaccharide	O
)	O
,	O
the	O
antigen	O
uptaking	O
capabilities	O
of	O
immature	O
dendritic	O
cells	O
,	O
the	O
antigen	O
presenting	O
capabilities	O
of	O
mature	O
dendritic	O
cells	O
,	O
cell	O
-	O
T	O
breeder	O
reactions	O
excited	O
by	O
dendritic	O
cells	O
,	O
and	O
the	O
expression	O
of	O
cell	O
factors	O
which	O
are	O
secreted	O
by	O
dendritic	O
cells	O
and	O
are	O
usedfor	O
promoting	O
type	O
1	O
and	O
type	O
17	O
cell	O
differentiation	O
of	O
auxiliary	O
cells	O
T.	O
Particularly	O
,	O
the	O
embelin	B
can	O
be	O
used	O
for	O
lowering	O
the	O
pathogenic	O
degree	O
of	O
mouse	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

The	O
invention	O
relates	O
to	O
preparation	O
of	O
a	O
medicament	O
for	O
suppressing	O
an	O
immune	O
system	O
,	O
which	O
can	O
become	O
a	O
medicament	O
for	O
clinically	O
treating	O
autoimmune	O
inflammatory	O
lesions	O
such	O
as	O
multiple	O
sclerosis	O
,	O
acute	O
disseminated	O
encephalomyelitis	O
and	O
the	O
like	O
.	O

Application	O
of	O
embelin	B
to	O
preparation	O
of	O
medicament	O
for	O
treating	O
autoimmune	O
disease	O

The	O
invention	O
discloses	O
a	O
type	O
of	O
flavanol	B
(	O
isobutene	B
flavanol	I
)	O
compounds	O
.	O

The	O
structural	O
formulae	O
of	O
the	O
compounds	O
are	O
shown	O
in	O
the	O
specifications	O
.	O

The	O
compounds	O
have	O
good	O
inhibiting	O
actions	O
on	O
urease	O
,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicaments	O
for	O
resisting	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
lithangiuria	O
and	O
the	O
like	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
.	O

Flavanol	B
(	O
isobutene	B
flavanol	I
)	O
urease	O
inhibitor	O
and	O
synthesis	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
honokiol	B
in	O
pharmacy	O
,	O
and	O
a	O
medicine	O
used	O
for	O
treating	O
type	O
II	O
diabetes	O
mellitus	O
.	O

The	O
invention	O
provides	O
an	O
application	O
of	O
honokiol	B
in	O
preparing	O
medicines	O
used	O
for	O
treating	O
type	O
II	O
diabetes	O
mellitus	O
,	O
obesity	O
caused	O
by	O
lipid	O
metabolism	O
disorder	O
,	O
or	O
diseases	O
related	O
to	O
insulin	O
resistance	O
.	O

Honokiol	B
is	O
a	O
PPAR	O
alpha	O
/	O
gamma	O
dual	O
agonist	O
.	O

Therefore	O
,	O
honokiol	B
can	O
be	O
used	O
for	O
ameliorating	O
insulin	O
resistance	O
and	O
reducing	O
blood	O
sugar	B
,	O
and	O
honokiol	O
can	O
also	O
be	O
used	O
for	O
ameliorating	O
lipid	O
metabolism	O
disorder	O
and	O
reducing	O
weight	O
.	O

Application	O
of	O
honokiol	B
in	O
pharmacy	O
,	O
and	O
medicine	O
used	O
for	O
treating	O
type	O
II	O
diabetes	O
mellitus	O

The	O
invention	O
provides	O
a	O
medicine	O
controlled	O
release	O
formulation	O
for	O
relieving	O
livestock	O
fluorosis	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
medicine	O
controlled	O
release	O
formulation	O
comprises	O
the	O
following	O
components	O
of	O
:	O
10	O
-	O
35	O
%	O
of	O
acetamide	B
,	O
10	O
-	O
45	O
%	O
of	O
coarse	O
whiting	O
,	O
5	O
-	O
30	O
%	O
of	O
adhesive	O
,	O
2	O
-	O
30	O
%	O
of	O
filling	O
agent	O
,	O
0.01	O
-	O
1	O
%	O
of	O
lubricating	O
agent	O
and	O
7	O
-	O
10	O
%	O
of	O
wetting	O
agent	O
.	O

Through	O
improving	O
the	O
formulation	O
,	O
the	O
livestock	O
drug	O
delivery	O
mode	O
is	O
increased	O
,	O
the	O
stimulation	O
of	O
a	O
medicine	O
to	O
the	O
livestock	O
is	O
reduced	O
,	O
all	O
the	O
medicines	O
can	O
be	O
instantaneously	O
released	O
and	O
also	O
can	O
be	O
delivered	O
in	O
a	O
long	O
-	O
acting	O
way	O
,	O
accordingly	O
,	O
different	O
diseases	O
are	O
treated	O
,	O
the	O
invention	O
also	O
can	O
provide	O
tablets	O
with	O
different	O
concentrations	O
,	O
and	O
so	O
different	O
market	O
requirements	O
can	O
be	O
satisfied	O
.	O

Medicine	O
controlled	O
release	O
formulation	O
for	O
relieving	O
livestock	O
fluorosis	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
discloses	O
an	O
ointment	O
for	O
treating	O
rhinitis	O
.	O

The	O
ointment	O
comprises	O
the	O
following	O
components	O
:	O
0.02	O
to	O
0.05	O
g	O
artificial	O
bezoar	O
,	O
0.25	O
to	O
0.75	O
g	O
concha	O
arcae	O
,	O
0.1	O
to	O
0.3	O
g	O
borneol	B
,	O
0.1	O
to	O
0.5	O
g	O
dried	O
portulaca	O
oleracea	O
L	O
,	O
0.1	O
to	O
0.3	O
g	O
cooling	O
oil	O
and	O
0.25	O
to	O
0.75	O
g	O
vaseline	O
;	O
a	O
production	O
process	O
comprises	O
the	O
following	O
steps	O
:	O
cleaning	O
artificial	O
bezoar	O
,	O
drying	O
and	O
crushing	O
into	O
fine	O
powder	O
capable	O
of	O
passing	O
through	O
a	O
sieve	O
with	O
270	O
meshes	O
,	O
drying	O
dried	O
portulaca	O
oleracea	O
L	O
and	O
crushing	O
into	O
fine	O
powder	O
capable	O
of	O
passing	O
through	O
a	O
sieve	O
with	O
270	O
meshes	O
,	O
then	O
taking	O
artificial	O
bezoar	O
,	O
concha	O
arcae	O
,	O
borneol	B
powder	O
and	O
dried	O
portulaca	O
oleracea	O
L	O
with	O
the	O
above	O
ratio	O
,	O
and	O
finally	O
adding	O
cooling	O
oil	O
and	O
vaseline	O
with	O
the	O
proportion	O
,	O
uniformly	O
mixing	O
and	O
packaging	O
.	O

The	O
ointment	O
for	O
treating	O
rhinitis	O
has	O
the	O
advantages	O
of	O
easy	O
usage	O
,	O
and	O
no	O
toxic	O
and	O
side	O
effect	O
,	O
and	O
the	O
clinical	O
tests	O
of	O
500	O
patients	O
show	O
that	O
the	O
cure	O
rate	O
is	O
100	O
%	O
.	O

Ointment	O
for	O
treating	O
rhinitis	O

The	O
invention	O
relates	O
to	O
a	O
medical	O
ultrasonic	O
couplant	O
,	O
which	O
comprises	O
one	O
viscosity	O
regulator	O
of	O
hydroxyethyl	O
cellulose	O
,	O
Carbomer	O
and	O
hydroxy	O
propyl	O
cellulose	O
or	O
a	O
composition	O
of	O
the	O
hydroxyethyl	O
cellulose	O
,	O
the	O
Carbomer	O
and	O
the	O
hydroxy	O
propyl	O
cellulose	O
,	O
propylene	B
glycol	I
and	O
sterile	O
deionized	O
water	O
.	O

The	O
medical	O
ultrasonic	O
couplant	O
contains	O
an	O
antimicrobial	O
agent	O
and	O
also	O
comprises	O
any	O
one	O
of	O
vitamin	B
B5	I
and	O
vitamin	B
E	I
or	O
a	O
composition	O
prepared	O
from	O
the	O
vitamin	B
B5	I
and	O
the	O
vitamin	B
E	I
in	O
any	O
proportion	O
.	O

The	O
medical	O
ultrasonic	O
couplant	O
is	O
characterized	O
in	O
that	O
the	O
antimicrobial	O
agent	O
is	O
Triclosan	B
,	O
and	O
the	O
medical	O
ultrasonic	O
couplant	O
also	O
comprises	O
chitosan	O
.	O

According	O
to	O
the	O
medical	O
ultrasonic	O
couplant	O
,	O
the	O
Triclosan	O
has	O
a	O
broad	O
-	O
spectrum	O
antimicrobial	O
action	O
;	O
the	O
vitamin	O
B5	O
and	O
the	O
vitamin	B
E	I
have	O
effects	O
of	O
moistening	O
skins	O
and	O
relieving	O
skin	O
irritations	O
;	O
and	O
the	O
chitosan	O
has	O
effects	O
of	O
blood	O
coagulation	O
and	O
blood	O
stop	O
,	O
and	O
for	O
skin	O
damages	O
,	O
the	O
chitosan	O
has	O
a	O
positive	O
effect	O
on	O
promoting	O
wound	O
healing	O
after	O
postoperative	O
type	O
-	O
B	O
ultrasonic	O
detection	O
is	O
performed	O
on	O
patients	O
.	O

The	O
medical	O
ultrasonic	O
couplant	O
is	O
more	O
suitable	O
for	O
contacting	O
with	O
the	O
skins	O
and	O
has	O
lower	O
cost	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
medical	O
ultrasonic	O
couplant	O
.	O

Medical	O
ultrasonic	O
couplant	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
sesquiterpene	B
compound	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
molecular	O
formula	O
of	O
the	O
sesquiterpene	B
compound	O
is	O
C15H18O4	B
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
sesquiterpene	B
compound	O
comprises	O
the	O
steps	O
:	O
adding	O
a	O
whole	O
chloranthus	O
henryi	O
(	O
Chlotanthushenryi	O
Hemsl	O
.	O
)	O
or	O
tissue	O
of	O
the	O
chloranthus	O
henryi	O
into	O
an	O
organic	O
solvent	O
to	O
be	O
leached	O
to	O
obtain	O
a	O
leaching	O
solution	O
,	O
extracting	O
the	O
leaching	O
solution	O
by	O
using	O
ethyl	B
acetate	I
or	O
chloroform	B
,	O
and	O
concentrating	O
,	O
separating	O
and	O
purifying	O
extraction	O
liquid	O
to	O
obtain	O
the	O
sesquiterpene	B
compound	O
,	O
wherein	O
the	O
organic	O
solvent	O
is	O
one	O
of	O
or	O
two	O
of	O
carbinol	B
,	O
ethanol	B
,	O
ethyl	B
acetate	I
and	O
acetone	B
.	O

The	O
sesquiterpene	B
compound	O
extracted	O
and	O
separated	O
from	O
the	O
chloranthus	O
henryi	O
is	O
provided	O
with	O
a	O
novel	O
structure	O
,	O
has	O
good	O
antioxidative	O
activity	O
,	O
can	O
be	O
used	O
for	O
preparing	O
antioxidant	O
pharmaceuticals	O
,	O
antioxidant	O
cosmetics	O
and	O
antioxidant	O
health	O
-	O
care	O
foods	O
and	O
has	O
good	O
developing	O
prospect	O
.	O

Sesquiterpene	B
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
spirotricyclic	B
compound	O
as	O
shown	O
in	O
formula	O
(	O
I	O
)	O
,	O
and	O
simultaneously	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
application	O
thereof	O
,	O
as	O
well	O
as	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
spirotricyclic	B
compound	O
.	O

Being	O
an	O
inhibitor	O
of	O
protein	O
kinase	O
,	O
the	O
compound	O
in	O
the	O
invention	O
can	O
be	O
used	O
to	O
treat	O
diseases	O
caused	O
by	O
abnormal	O
protein	O
kinase	O
activity	O
,	O
such	O
as	O
tumors	O
and	O
the	O
like	O
.	O

Spirotricyclic	B
compound	O
,	O
its	O
preparation	O
method	O
,	O
and	O
pharmaceutical	O
composition	O
containing	O
it	O
as	O
well	O
as	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
contraceptive	O
,	O
in	O
particular	O
to	O
an	O
intelligent	O
compound	O
gestodene	B
vaginal	O
ring	O
preparation	O
with	O
a	O
memory	O
effect	O
.	O

A	O
vaginal	O
ring	O
consists	O
of	O
a	O
controlled	O
release	O
membrane	O
,	O
a	O
gestodene	B
/	O
ethinyloestradiol	B
-	O
containing	O
carrier	O
and	O
a	O
shape	O
memory	O
material	O
,	O
and	O
can	O
slowly	O
release	O
a	O
contraceptive	O
at	O
constant	O
speed	O
within	O
21	O
days	O
.	O

By	O
implementing	O
the	O
preparation	O
,	O
the	O
remarkable	O
contraception	O
effect	O
can	O
be	O
achieved	O
,	O
the	O
inconvenience	O
caused	O
by	O
the	O
oral	O
administration	O
of	O
the	O
contraceptive	O
is	O
avoided	O
,	O
and	O
the	O
appliance	O
of	O
the	O
administration	O
is	O
improved	O
.	O

Intelligent	O
compound	O
gestodene	B
vaginal	O
ring	O
preparation	O
with	O
memory	O
effect	O
and	O
application	O
of	O
intelligent	O
compound	O
gestodene	B
vaginal	O
ring	O
preparation	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
Oxaliplatin	B
for	O
injection	O
.	O

The	O
preparation	O
method	O
of	O
the	O
invention	O
comprises	O
the	O
steps	O
of	O
cleaning	O
rubber	O
plugs	O
and	O
sterilizing	O
;	O
cleaning	O
vials	O
and	O
sterilizing	O
;	O
disinfecting	O
aluminum	O
-	O
plastic	O
covers	O
;	O
preparing	O
a	O
solution	O
;	O
filling	O
the	O
inspection	O
qualified	O
solution	O
into	O
vials	O
and	O
partially	O
inserting	O
the	O
plugs	O
;	O
lyophilizing	O
;	O
pressing	O
the	O
rubber	O
slugs	O
,	O
unboxing	O
,	O
capping	O
and	O
visually	O
inspecting	O
;	O
and	O
packaging	O
.	O

The	O
final	O
products	O
are	O
stored	O
after	O
product	O
quality	O
inspection	O
.	O

Preparation	O
method	O
of	O
Oxaliplatin	B
for	O
injection	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
.	O

The	O
composition	O
has	O
high	O
stability	O
,	O
is	O
resistant	O
to	O
strict	O
high	O
-	O
temperature	O
sterilization	O
,	O
and	O
has	O
high	O
light	O
stability	O
.	O

An	O
additive	O
is	O
reduced	O
greatly	O
in	O
comparison	O
to	O
the	O
conventional	O
product	O
of	O
the	O
same	O
type	O
,	O
production	O
is	O
convenient	O
to	O
realize	O
,	O
and	O
cost	O
is	O
reduced	O
.	O

Stable	O
liquid	O
medicinal	O
composition	O

The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
field	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
new	O
application	O
of	O
a	O
compound	O
sodium	B
chloride	I
potassium	B
chloride	I
injection	O
.	O

The	O
technical	O
problem	O
solved	O
by	O
the	O
invention	O
is	O
that	O
a	O
new	O
application	O
of	O
the	O
compound	O
sodium	B
chloride	I
potassium	B
chloride	I
injection	O
is	O
provided	O
,	O
which	O
is	O
an	O
application	O
in	O
infusion	O
solution	O
preparation	O
,	O
wherein	O
the	O
injection	O
is	O
used	O
for	O
supplementing	O
electrolytes	O
.	O

The	O
injection	O
prescription	O
amount	O
is	O
that	O
100	O
ml	O
of	O
the	O
injection	O
comprises	O
0.05	O
-	O
0.33	O
g	O
of	O
potassium	B
chloride	I
and	O
0.7	O
-	O
1.1	O
g	O
of	O
sodium	B
chloride	I
.	O

The	O
injection	O
is	O
administrated	O
through	O
intravenous	O
drip	O
,	O
and	O
is	O
used	O
for	O
patients	O
with	O
severe	O
hypokalemia	O
or	O
patients	O
which	O
can	O
not	O
take	O
drugs	O
orally	O
.	O

The	O
potassium	B
supplementing	O
dosage	O
,	O
concentration	O
,	O
and	O
speed	O
are	O
determined	O
according	O
to	O
the	O
improvement	O
of	O
clinical	O
conditions	O
,	O
blood	O
potassium	B
concentrations	O
,	O
and	O
electrocardiogram	O
potassium	B
-	O
deficient	O
figures	O
.	O

New	O
application	O
of	O
compound	O
sodium	B
chloride	I
potassium	B
chloride	I
injection	O

The	O
invention	O
discloses	O
medicinal	O
composition	O
,	O
synthesis	O
process	O
and	O
medical	O
application	O
of	O
hydantoin	B
derivatives	O
.	O

The	O
compounds	O
have	O
an	O
effect	O
of	O
inhibiting	O
an	O
androgen	B
receptor	O
,	O
and	O
can	O
be	O
used	O
for	O
treating	O
prostatic	O
cancer	O
and	O
other	O
diseases	O
and	O
physiologic	O
derangement	O
related	O
with	O
androgen	B
receptor	O
activity	O
.	O

Composition	O
,	O
synthesis	O
and	O
application	O
of	O
hydantoin	B
derivatives	O

The	O
invention	O
relates	O
to	O
a	O
fat	O
emulsion	O
of	O
triptolide	B
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
fat	O
emulsion	O
injection	O
comprises	O
an	O
antitumor	O
effective	O
dose	O
of	O
triptolide	B
and	O
pharmaceutically	O
-	O
acceptable	O
auxiliary	O
materials	O
,	O
wherein	O
an	O
oil	O
phase	O
is	O
a	O
mixture	O
prepared	O
from	O
long	O
-	O
chain	O
fat	B
acid	I
triglyceride	I
and	O
middle	O
-	O
chain	O
fat	B
acid	I
triglyceride	I
in	O
the	O
mass	O
ratio	O
of	O
4:1	O
-	O
1:1	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
mixing	O
triptolide	B
,	O
an	O
emulsifier	O
,	O
fat	O
oil	O
,	O
an	O
isotonic	O
regulator	O
,	O
an	O
anti	O
-	O
oxidizing	O
agent	O
and	O
a	O
stabilizer	O
,	O
and	O
heating	O
to	O
obtain	O
an	O
oil	O
phase	O
;	O
weighing	O
water	O
for	O
injection	O
,	O
adding	O
the	O
isotonic	O
regulator	O
,	O
and	O
heating	O
to	O
obtain	O
a	O
water	O
phase	O
;	O
heating	O
and	O
mixing	O
the	O
oil	O
phase	O
and	O
the	O
water	O
phase	O
under	O
the	O
protection	O
of	O
nitrogen	B
gas	O
,	O
and	O
stirring	O
to	O
obtain	O
a	O
primary	O
emulsion	O
;	O
homogenizing	O
the	O
primary	O
emulsion	O
under	O
a	O
high	O
pressure	O
to	O
form	O
a	O
uniform	O
emulsion	O
;	O
and	O
adjusting	O
the	O
pH	O
value	O
to	O
6	O
-	O
7	O
,	O
sterilizing	O
rotationally	O
to	O
obtain	O
a	O
product	O
,	O
i.e.	O
,	O
the	O
triptolide	B
fat	O
emulsion	O
injection	O
,	O
and	O
sterilizing	O
.	O

The	O
average	O
particle	O
diameter	O
of	O
the	O
fat	O
emulsion	O
is	O
250.9+	O
/	O
-60.0	O
nanometers	O
,	O
the	O
polydispersion	O
coefficient	O
is	O
0.143	O
,	O
dispersion	O
is	O
uniform	O
,	O
a	O
system	O
is	O
stable	O
,	O
the	O
targeting	O
property	O
is	O
high	O
,	O
and	O
vessel	O
irritation	O
is	O
low	O
.	O

Triptolide	B
fat	O
emulsion	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
curcumin	B
derivative	O
C2	B
in	O
anti	O
-	O
colon	O
cancer	O
medicaments	O
.	O

The	O
curcumin	B
derivative	O
C2	B
is	O
superior	O
in	O
killing	O
colon	O
cancer	O
cells	O
to	O
curcumin	B
and	O
can	O
cause	O
the	O
decline	O
of	O
mitochondrial	O
membrane	O
potentials	O
of	O
colon	O
cancer	O
cells	O
,	O
induce	O
apoptosis	O
of	O
colon	O
cancer	O
cells	O
and	O
induce	O
apoptosis	O
by	O
accumulation	O
of	O
active	O
oxygen	B
free	O
radicals	O
in	O
colon	O
cancer	O
cells	O
.	O

Under	O
certain	O
circumstances	O
,	O
curcumin	B
derivative	O
C2	B
is	O
more	O
stable	O
and	O
lipophilic	O
than	O
parent	O
compound	O
curcumin	O
.	O

Besides	O
,	O
compared	O
with	O
parent	O
compound	O
curcumin	B
,	O
curcumin	B
derivative	O
C2	B
is	O
advantageous	O
in	O
killing	O
colon	O
cancer	O
cells	O
without	O
damaging	O
healthy	O
colon	O
cells	O
.	O

The	O
invention	O
provides	O
a	O
theoretical	O
basis	O
for	O
developing	O
new	O
anti	O
-	O
colon	O
cancer	O
medicaments	O
of	O
curcumin	O
derivatives	O
.	O

Application	O
of	O
curcumin	B
derivative	O
C2	B
in	O
anti	O
-	O
colon	O
cancer	O
medicaments	O

The	O
invention	O
provides	O
application	O
of	O
two	O
naphthoquinone	O
compounds	O
in	O
preparing	O
antitumor	O
medicaments	O
,	O
wherein	O
the	O
two	O
naphthoquinone	O
compounds	O
are	O
2-methoxyl	O
juglone	O
and	O
3-methoxyl	O
juglone	O
which	O
are	O
obtained	O
by	O
extraction	O
,	O
separation	O
and	O
purification	O
from	O
wild	O
walnuts	O
or	O
other	O
plants	O
or	O
by	O
chemical	O
synthesis	O
.	O

Experiments	O
indicate	O
that	O
the	O
two	O
naphthoquinone	O
compounds	O
have	O
favorable	O
inhibition	O
activities	O
on	O
various	O
tumor	O
cells	O
of	O
human	O
,	O
such	O
as	O
HepG2	O
,	O
Hela	O
,	O
MCF-7	O
,	O
Caco-2	O
,	O
A549	O
,	O
PANC-1	O
and	O
the	O
like	O
,	O
also	O
have	O
obvious	O
inhibition	O
effect	O
on	O
transplanted	O
H22	O
liver	O
cancer	O
tumors	O
of	O
mice	O
and	O
presents	O
a	O
good	O
concentration	O
dependence	O
.	O

Quantitative	O
detection	O
of	O
a	O
flow	O
cytometer	O
indicates	O
that	O
the	O
2-methoxyl	O
juglone	O
and	O
the	O
3-methoxyl	O
juglone	O
have	O
an	O
obvious	O
cell	O
apoptosis	O
induction	O
effect	O
on	O
Hela	O
cells	O
.	O

Therefore	O
,	O
2-methoxyl	O
juglone	O
and	O
3-methoxyl	O
juglone	O
can	O
be	O
used	O
for	O
preparing	O
the	O
antitumor	O
medicaments	O
.	O

Application	O
of	O
two	O
naphthoquinone	O
compounds	O
in	O
preparing	O
antitumor	O
medicaments	O

The	O
invention	O
provides	O
application	O
of	O
a	O
monomer	O
component	O
cajanus	O
cajan	O
stilbene	B
acid	I
in	O
cajanus	O
cajan	O
leaves	O
in	O
preparing	O
a	O
medicinal	O
preparation	O
for	O
preventing	O
and	O
treating	O
bacterial	O
infectious	O
diseases	O
and	O
a	O
preparation	O
method	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicinal	O
preparations	O
.	O

Medicinal	O
auxiliary	O
materials	O
are	O
added	O
into	O
the	O
monomer	O
component	O
cajanus	O
cajan	O
stilbene	B
acid	I
in	O
cajanus	O
cajan	O
leaves	O
serving	O
as	O
a	O
main	O
effective	O
component	O
according	O
to	O
a	O
known	O
method	O
in	O
the	O
field	O
of	O
pharmacy	O
to	O
prepare	O
an	O
oral	O
preparation	O
,	O
suppository	O
,	O
soft	O
capsule	O
preparations	O
,	O
tablets	O
,	O
lyophilized	O
powder	O
injection	O
,	O
injection	O
preparations	O
and	O
other	O
pharmaceutically	O
useable	O
preparations	O
.	O

The	O
prepared	O
medicament	O
has	O
a	O
remarkable	O
curative	O
effect	O
to	O
a	O
series	O
of	O
diseases	O
caused	O
by	O
gram	O
-	O
positive	O
bacteria	O
,	O
in	O
particular	O
staphylococcus	O
aureus	O
,	O
and	O
has	O
the	O
characteristics	O
of	O
low	O
toxic	O
and	O
side	O
effect	O
,	O
exact	O
curative	O
effect	O
,	O
safety	O
and	O
reliability	O
and	O
the	O
like	O
.	O

The	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
prepares	O
a	O
plurality	O
of	O
preparations	O
,	O
and	O
can	O
fulfill	O
the	O
administration	O
requirements	O
in	O
different	O
degrees	O
.	O

Application	O
of	O
cajanus	O
cajan	O
stilbene	B
acid	I
in	O
preparing	O
medicinal	O
preparation	O
for	O
preventing	O
and	O
treating	O
bacterial	O
infectious	O
diseases	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
novel	O
application	O
of	O
sodium	B
oxamate	I
,	O
in	O
particular	O
to	O
the	O
application	O
of	O
sodium	B
oxamate	I
in	O
preparation	O
of	O
a	O
(	O
fat	O
mass	O
and	O
obesity	O
)	O
FTO	O
enzyme	O
inhibitor	O
and	O
a	O
weight	O
-	O
losing	O
medicine	O
.	O

An	O
inventor	O
finds	O
that	O
the	O
sodium	B
oxamate	I
can	O
remarkably	O
suppress	O
the	O
expression	O
of	O
FTO	O
gene	O
through	O
vitro	O
cell	O
experiments	O
for	O
the	O
first	O
time	O
.	O

After	O
the	O
expression	O
of	O
the	O
FTO	O
gene	O
is	O
suppressed	O
,	O
weight	O
and	O
fat	O
tissue	O
of	O
an	O
animal	O
can	O
be	O
remarkably	O
reduced	O
,	O
and	O
the	O
function	O
mechanism	O
of	O
the	O
sodium	B
oxamate	I
is	O
relevant	O
to	O
adjusting	O
organism	O
food	O
intake	O
and	O
controlling	O
energy	O
metabolism	O
balance	O
.	O

The	O
application	O
of	O
sodium	B
oxamate	I
in	O
the	O
preparation	O
of	O
the	O
FTO	O
enzyme	O
inhibitor	O
and	O
the	O
weight	O
-	O
losing	O
medicine	O
adopts	O
sodium	B
oxamate	I
to	O
serve	O
as	O
the	O
novel	O
weight	O
-	O
loosing	O
medicine	O
,	O
can	O
effectively	O
reduce	O
the	O
weight	O
and	O
the	O
fat	O
tissue	O
,	O
and	O
can	O
prevent	O
obesity	O
relevant	O
diseases	O
including	O
diabetes	O
mellitus	O
,	O
cardiovascular	O
diseases	O
and	O
relevant	O
neoplasms	O
from	O
happening	O
.	O

Application	O
of	O
sodium	B
oxamate	I
in	O
preparation	O
of	O
(	O
fat	O
mass	O
and	O
obesity	O
)	O
FTO	O
enzyme	O
inhibitor	O
and	O
weight	O
-	O
losing	O
medicine	O

The	O
invention	O
discloses	O
a	O
compound	O
amino	B
acid	I
injection	O
for	O
livestock	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O

The	O
main	O
components	O
of	O
the	O
injection	O
are	O
18	O
amino	B
acids	I
and	O
gamma	B
-	I
aminobutyric	I
acid	I
needed	O
by	O
an	O
animal	O
organism	O
.	O

In	O
the	O
preparation	O
process	O
,	O
metal	O
ions	O
in	O
disodium	B
ethylene	I
diamine	I
tetraacetic	I
acid	I
complexing	O
water	O
are	O
used	O
,	O
and	O
carbon	B
dioxide	I
airflow	O
is	O
introduced	O
in	O
the	O
whole	O
production	O
process	O
,	O
thereby	O
solving	O
the	O
problem	O
that	O
the	O
injection	O
is	O
easy	O
to	O
oxidize	O
and	O
change	O
color	O
and	O
stabilizing	O
the	O
pH	O
value	O
of	O
the	O
reaction	O
system	O
.	O

The	O
invention	O
can	O
timely	O
supplement	O
essential	O
amino	B
acid	I
and	O
non	O
-	O
essential	O
amino	B
acid	I
required	O
during	O
the	O
disease	O
of	O
the	O
animal	O
organism	O
,	O
so	O
as	O
to	O
strengthen	O
the	O
physical	O
ability	O
of	O
animals	O
and	O
shorten	O
the	O
disease	O
treatment	O
time	O
;	O
and	O
the	O
added	O
gamma	B
-	I
aminobutyric	I
acid	I
can	O
reduce	O
the	O
unconscious	O
movement	O
of	O
the	O
animal	O
so	O
as	O
to	O
reduce	O
energy	O
consumption	O
,	O
promote	O
the	O
secretion	O
of	O
the	O
gastric	O
juice	O
of	O
the	O
animal	O
and	O
increase	O
the	O
feed	O
intake	O
.	O

The	O
compound	O
amino	B
acid	I
injection	O
is	O
used	O
for	O
recovery	O
of	O
the	O
animal	O
organism	O
in	O
the	O
disease	O
treatment	O
period	O
and	O
the	O
after	O
-	O
disease	O
recovery	O
period	O
.	O

Compound	O
amino	B
acid	I
injection	O
for	O
livestock	O
as	O
well	O
as	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
facial	O
neuroparalysis	O
and	O
rheumatic	O
arthritis	O
,	O
and	O
can	O
effectively	O
solve	O
the	O
problem	O
of	O
medication	O
in	O
treating	O
facial	O
neuroparalysis	O
and	O
rheumatic	O
arthritis	O
.	O

The	O
plaster	O
is	O
prepared	O
by	O
the	O
steps	O
of	O
:	O
soaking	O
25	O
-	O
35	O
g	O
of	O
semen	O
strychni	O
,	O
scorpion	O
,	O
stiff	O
silkworm	O
,	O
centipede	O
,	O
pangolin	O
scales	O
,	O
herba	O
schizonepetae	O
,	O
radix	O
saposhnikoviae	O
,	O
impatiens	O
balsamina	O
,	O
rhizoma	O
coptidis	O
,	O
garden	O
balsam	O
stem	O
,	O
diverse	O
wormwood	O
herb	O
,	O
radix	O
clematidis	O
,	O
radix	O
angelicae	O
pubescentis	O
,	O
rhizoma	O
et	O
radix	O
notopterygii	O
,	O
herba	O
asari	O
,	O
ground	O
beeltle	O
,	O
semen	O
momordicae	O
,	O
radix	O
paeoniaerubra	O
,	O
caulis	O
spatholobi	O
,	O
edible	O
fungus	O
,	O
flos	O
carthami	O
,	O
fructus	O
crotonis	O
,	O
rhizoma	O
homalomenae	O
,	O
herba	O
lycopodii	O
,	O
rhizoma	O
gastrodiae	O
,	O
uncaria	O
rhynchophylla	O
respectively	O
in	O
2,500	O
g	O
of	O
sesame	O
oil	O
for	O
7	O
-	O
15days	O
;	O
decocting	O
until	O
the	O
medicines	O
are	O
dried	O
;	O
filtering	O
to	O
obtain	O
the	O
filtrate	O
,	O
adding	O
1,000	O
g	O
of	O
minium	O
,	O
and	O
decocting	O
until	O
the	O
minium	O
turns	O
black	O
;	O
adding	O
25	O
-	O
35	O
g	O
of	O
frankincense	O
,	O
myrrh	O
,	O
sanguis	O
draconis	O
,	O
catechu	O
,	O
rhizoma	O
corydalis	O
and	O
borneol	B
respectively	O
,	O
and	O
mixing	O
to	O
obtain	O
powder	O
;	O
stirring	O
uniformly	O
,	O
and	O
decocting	O
until	O
reaching	O
the	O
effect	O
that	O
the	O
mixture	O
drops	O
into	O
beads	O
and	O
does	O
not	O
scatter	O
;	O
pouring	O
the	O
mixture	O
into	O
clean	O
water	O
and	O
soaking	O
for	O
3	O
-	O
4	O
days	O
to	O
remove	O
fire	O
toxin	O
;	O
and	O
uniformly	O
spreading	O
the	O
product	O
on	O
cotton	O
cloth	O
.	O

The	O
plaster	O
provided	O
by	O
the	O
invention	O
has	O
rich	O
raw	O
materials	O
,	O
is	O
easy	O
to	O
produce	O
and	O
paste	O
,	O
realizes	O
a	O
good	O
effect	O
,	O
and	O
is	O
effective	O
in	O
treating	O
facial	O
neuroparalysis	O
and	O
rheumatic	O
arthritis	O
.	O

Plaster	O
for	O
treating	O
facial	O
neuroparalysis	O
and	O
rheumatic	O
arthritis	O

The	O
invention	O
discloses	O
citicoline	B
sodium	I
brain	O
-	O
targeting	O
thermosensitive	O
gel	O
.	O

The	O
citicoline	B
sodium	I
brain	O
-	O
targeting	O
thermosensitive	O
gel	O
is	O
a	O
preparation	O
which	O
can	O
be	O
absorbed	O
fast	O
and	O
has	O
high	O
bioavailability	O
.	O

The	O
citicoline	B
sodium	I
brain	O
-	O
targeting	O
thermosensitive	O
gel	O
utilizes	O
water	O
as	O
a	O
solvent	O
and	O
comprises	O
solute	O
components	O
of	O
10	O
to	O
400mg	O
/	O
ml	O
of	O
citicoline	B
sodium	I
,	O
0.1	O
to	O
3.0mg	O
/	O
ml	O
of	O
Tween-80	B
,	O
0.5	O
to	O
5.0mg	O
/	O
ml	O
of	O
phosphatide	B
E80	I
,	O
0.5	O
to	O
3.0mg	O
/	O
ml	O
of	O
poloxamer	B
P188	I
,	O
and	O
5.0	O
to	O
10.0mg	O
/	O
ml	O
of	O
poloxamer	O
P407	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
citicoline	B
sodium	I
brain	O
-	O
targetingthermosensitive	O
gel	O
.	O

The	O
citicoline	B
sodium	I
brain	O
-	O
targeting	O
thermosensitive	O
gel	O
has	O
a	O
high	O
drug	O
loading	O
amount	O
,	O
is	O
uniform	O
and	O
stable	O
,	O
has	O
good	O
fluidity	O
,	O
is	O
in	O
a	O
state	O
of	O
gel	O
at	O
a	O
temperature	O
of	O
33	O
DEG	O
C	O
,	O
has	O
good	O
biological	O
adhesion	O
strength	O
,	O
is	O
suitable	O
for	O
being	O
applied	O
through	O
a	O
nasal	O
cavity	O
,	O
has	O
a	O
good	O
appearance	O
,	O
and	O
does	O
not	O
produce	O
floating	O
oil	O
and	O
layering	O
.	O

Citicoline	B
sodium	I
brain	O
-	O
targeting	O
thermosensitive	O
gel	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
formula	O
and	O
a	O
preparation	O
method	O
of	O
an	O
ethaselen	B
intravenous	O
injection	O
.	O

The	O
formula	O
comprises	O
an	O
active	O
component	O
and	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
active	O
component	O
is	O
ethaselen	B
or	O
analogue	O
thereof	O
,	O
and	O
the	O
auxiliary	O
materials	O
include	O
stabilizing	O
agents	O
and	O
an	O
organic	O
solvent	O
.	O

The	O
active	O
component	O
and	O
the	O
auxiliary	O
materials	O
are	O
prepared	O
into	O
an	O
injection	O
which	O
is	O
used	O
for	O
intravenous	O
injection	O
after	O
being	O
diluted	O
appropriately	O
during	O
clinical	O
use	O
.	O

Ethaselen	B
intravenous	O
injection	O

The	O
invention	O
provides	O
nasal	O
drops	O
containing	O
sodium	B
hyaluronate	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
nasal	O
drops	O
in	O
a	O
formula	O
comprise	O
the	O
sodium	B
hyaluronate	I
,	O
glycerol	B
,	O
a	O
Ph	O
value	O
buffer	O
agent	O
,	O
an	O
osmotic	O
pressure	O
regulator	O
,	O
a	O
preservative	O
and	O
water	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
dissolving	O
the	O
sodium	B
hyaluronate	I
in	O
water	O
according	O
to	O
the	O
basic	O
composition	O
and	O
amount	O
of	O
the	O
formula	O
,	O
adding	O
the	O
glycerol	B
,	O
sodium	B
chloride	I
,	O
the	O
Ph	B
value	O
buffer	O
agent	O
,	O
the	O
preservative	O
and	O
a	O
pharmacological	O
active	O
substance	O
,	O
replenishing	O
water	O
to	O
a	O
set	O
volume	O
,	O
filtering	O
through	O
a	O
millipore	O
filter	O
for	O
sterilization	O
,	O
and	O
performing	O
split	O
packaging	O
to	O
obtain	O
the	O
nasal	O
drops	O
containing	O
the	O
sodium	B
hyaluronate	I
.	O

The	O
nasal	O
drops	O
are	O
mainly	O
used	O
for	O
treating	O
seasonal	O
allergic	O
rhinitis	O
and	O
is	O
free	O
from	O
toxicity	O
and	O
side	O
effect	O
and	O
obvious	O
in	O
curative	O
effect	O
.	O

Nasal	O
drops	O
containing	O
sodium	B
hyaluronate	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
sustained	O
-	O
release	O
duloxetine	B
hydrochloride	I
drug	O
composition	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
drug	O
composition	O
is	O
a	O
duloxetine	B
hydrochloride	I
sustained	O
-	O
release	O
capsule	O
,	O
and	O
consists	O
of	O
duloxetine	B
hydrochloride	I
sustained	O
-	O
release	O
pellets	O
and	O
duloxetine	B
hydrochloride	I
sustained	O
-	O
release	O
pellets	O
which	O
are	O
released	O
by	O
a	O
time	O
delay	O
of	O
4h	O
according	O
to	O
a	O
ratio	O
of	O
1:1	O
.	O

The	O
duloxetine	B
hydrochloride	I
drug	O
composition	O
has	O
good	O
stability	O
,	O
and	O
also	O
has	O
the	O
more	O
obvious	O
advantages	O
of	O
improving	O
the	O
product	O
yield	O
,	O
lowering	O
the	O
cost	O
,	O
realizing	O
the	O
industrialization	O
and	O
being	O
better	O
applied	O
clinically	O
.	O

Duloxetine	B
hydrochloride	I
drug	O
composition	O

The	O
invention	O
discloses	O
the	O
application	O
of	O
glycyrrhetinic	B
acid	I
derivatives	O
in	O
the	O
preparation	O
process	O
of	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
in	O
particular	O
to	O
the	O
glycyrrhetinic	B
acid	I
derivatives	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
drug	O
compositions	O
containing	O
the	O
derivatives	O
and	O
anti	O
-	O
inflammatory	O
action	O
of	O
the	O
drug	O
compositions	O
,	O
wherein	O
,	O
the	O
glycyrrhetinic	B
acid	I
derivatives	O
can	O
release	O
gaseous	O
signal	O
molecule	O
hydrogen	B
sulfide	I
.	O

The	O
invention	O
discloses	O
and	O
provides	O
the	O
glycyrrhetinic	B
acid	I
derivatives	O
that	O
can	O
release	O
gaseous	O
signal	O
molecule	O
H2S	O
,	O
wherein	O
,	O
glycyrrhetinic	B
acid	I
and	O
gaseous	O
signal	O
molecule	O
hydrogen	B
sulfide	I
release	O
groups	O
are	O
coupled	O
through	O
ester	B
bonds	O
or	O
amido	B
bonds	O
so	O
as	O
to	O
obtain	O
the	O
glycyrrhetinic	B
acid	I
derivatives	O
.	O

Pharmacology	O
experimental	O
results	O
show	O
that	O
the	O
glycyrrhetinic	B
acid	I
derivatives	O
achieve	O
remarkable	O
anti	O
-	O
inflammatory	O
action	O
and	O
have	O
no	O
significant	O
gastrointestinal	O
tract	O
injury	O
,	O
and	O
show	O
that	O
the	O
glycyrrhetinic	B
acid	I
derivatives	O
can	O
be	O
used	O
for	O
preparing	O
the	O
drugs	O
for	O
treating	O
various	O
inflammations	O
and	O
related	O
diseases	O
thereof	O
.	O

Application	O
of	O
glycyrrhetinic	B
acid	I
derivatives	O
in	O
preparation	O
process	O
of	O
anti	O
-	O
inflammatory	O
drugs	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
capable	O
of	O
expanding	O
tracheal	O
smooth	O
muscles	O
and	O
an	O
application	O
thereof	O
.	O

The	O
medicinal	O
composition	O
consists	O
of	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
5	O
parts	O
of	O
glycyrrhizin	B
,	O
1	O
-	O
5	O
parts	O
of	O
baicalin	B
and	O
1	O
-	O
5	O
parts	O
of	O
sophocarpidine	B
.	O

In	O
the	O
composition	O
,	O
an	O
extract	O
is	O
refined	O
into	O
an	O
effective	O
part	O
,	O
so	O
that	O
the	O
dosage	O
is	O
reduced	O
,	O
tracheal	O
smooth	O
muscles	O
can	O
be	O
expanded	O
,	O
a	O
more	O
superior	O
medicinal	O
effect	O
is	O
achieved	O
,	O
and	O
adverse	O
reactions	O
existing	O
in	O
a	O
prescription	O
of	O
the	O
prior	O
art	O
are	O
reduced	O
;	O
and	O
all	O
used	O
raw	O
materials	O
are	O
nontoxic	O
,	O
and	O
have	O
low	O
prices	O
and	O
low	O
costs	O
.	O

Medicinal	O
composition	O
capable	O
of	O
expanding	O
tracheal	O
smooth	O
muscles	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
Chinese	O
gall	O
sulfur	B
powder	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
soaking	O
China	O
dodder	O
,	O
scurfpea	O
fruit	O
,	O
fructus	O
alpiniae	O
oxyphyllae	O
,	O
dried	O
artemisia	O
leaf	O
and	O
the	O
like	O
with	O
water	O
;	O
placing	O
the	O
mixture	O
into	O
a	O
pot	O
,	O
decocting	O
and	O
obtaining	O
juice	O
;	O
condensing	O
the	O
juice	O
with	O
slow	O
fire	O
to	O
form	O
a	O
thick	O
paste	O
shape	O
;	O
grinding	O
clove	O
and	O
Chinese	O
gall	O
into	O
ultrafine	O
powder	O
;	O
mixing	O
the	O
ultrafine	O
powder	O
with	O
sulfur	B
powder	O
;	O
and	O
pouring	O
the	O
mixed	O
powder	O
into	O
the	O
thick	O
paste	O
,	O
stirring	O
,	O
drying	O
and	O
grinding	O
into	O
powder	O
.	O

The	O
powder	O
is	O
scattered	O
into	O
a	O
navel	O
which	O
is	O
covered	O
with	O
absorbent	O
cotton	O
or	O
fixed	O
by	O
using	O
gauze	O
.	O

The	O
Chinese	O
gall	O
sulfur	B
powder	O
is	O
simple	O
and	O
convenient	O
in	O
use	O
method	O
,	O
favorable	O
in	O
curative	O
effect	O
and	O
quick	O
in	O
response	O
and	O
can	O
play	O
a	O
favorable	O
effect	O
for	O
radically	O
treating	O
enuresis	O
.	O

Chinese	O
gall	O
sulfur	B
powder	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
shown	O
in	O
a	O
structural	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
C1-C5	B
alkyl	I
,	O
alkylene	B
or	O
alkyloxy	B
,	O
x	O
is	O
a	O
reasonable	O
integer	O
more	O
than	O
or	O
equal	O
to	O
1	O
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
series	O
of	O
novel	O
bifunctional	O
free	O
radical	O
scavenger	O
is	O
designed	O
and	O
synthesized	O
,	O
a	O
pharmacodynamic	O
experiment	O
proves	O
that	O
the	O
compound	O
possesses	O
obvious	O
the	O
radiation	O
protection	O
effect	O
,	O
by	O
taking	O
WR2721	O
in	O
the	O
market	O
as	O
a	O
positive	O
control	O
,	O
the	O
drug	O
effect	O
of	O
the	O
compound	O
is	O
equal	O
with	O
that	O
of	O
the	O
WR2721	O
,	O
and	O
the	O
toxicity	O
is	O
substantially	O
reduced	O
.	O

Synthesis	O
of	O
Tempol	B
derivative	O
and	O
radiation	O
protection	O
effect	O

The	O
invention	O
discloses	O
a	O
novel	O
glucosamine	B
cataplasm	O
.	O

D	B
-	I
glucosamine	I
hydrochloride	I
and/or	O
D	B
-	I
glucosamine	I
sulfate	I
are	O
mixed	O
with	O
novel	O
cataplasm	O
matrix	O
to	O
form	O
the	O
novel	O
cataplasm	O
,	O
and	O
the	O
novel	O
cataplasm	O
is	O
used	O
for	O
treating	O
osteoarthritis	O
in	O
an	O
external	O
use	O
manner	O
.	O

Generally	O
,	O
from	O
1	O
to	O
10	O
parts	O
of	O
the	O
D	B
-	I
glucosamine	I
hydrochloride	I
and/or	O
the	O
D	B
-	I
glucosamine	I
sulfate	I
are	O
mixed	O
with	O
from	O
10	O
to	O
100	O
parts	O
of	O
the	O
novel	O
cataplasm	O
matrix	O
to	O
form	O
the	O
novel	O
cataplasm	O
,	O
and	O
the	O
novel	O
cataplasm	O
is	O
externally	O
used	O
and	O
attached	O
on	O
a	O
wounded	O
part	O
and	O
is	O
used	O
for	O
treating	O
osteoarthritis	O
.	O

Compared	O
with	O
a	O
traditional	O
externally	O
used	O
preparation	O
,	O
particularly	O
a	O
traditional	O
cataplasm	O
,	O
the	O
glucosamine	B
cataplasm	O
is	O
simpler	O
in	O
manufacturing	O
process	O
and	O
brings	O
more	O
convenience	O
for	O
industrialization	O
.	O

As	O
the	O
novel	O
cataplasm	O
matrix	O
is	O
adopted	O
,	O
a	O
transdermal	O
agent	O
necessarily	O
added	O
in	O
a	O
traditional	O
externally	O
used	O
preparation	O
is	O
omitted	O
,	O
and	O
the	O
glucosamine	O
cataplasm	O
is	O
simpler	O
in	O
composition	O
and	O
lower	O
in	O
cost	O
.	O

Glucosamine	B
cataplasm	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O

The	O
invention	O
relates	O
to	O
a	O
gallbladder	O
wood	O
leaf	O
composition	O
containing	O
strictosamide	B
and	O
a	O
preparation	O
thereof	O
.	O

The	O
gallbladder	O
wood	O
leaf	O
composition	O
containing	O
the	O
strictosamide	B
is	O
characterized	O
in	O
that	O
the	O
composition	O
is	O
applied	O
in	O
the	O
preparation	O
of	O
medicament	O
for	O
clearing	O
heat	O
and	O
eliminating	O
phlegm	O
and	O
relieving	O
cough	O
and	O
asthma	O
,	O
and	O
or	O
is	O
applied	O
in	O
the	O
preparation	O
of	O
medicines	O
used	O
for	O
treating	O
expectoration	O
,	O
cough	O
with	O
dyspnea	O
and	O
irritability	O
asthma	O
;	O
the	O
composition	O
is	O
composed	O
of	O
alkaloid	B
and	O
flavonoid	B
extracted	O
from	O
gallbladder	O
wood	O
leaf	O
through	O
combination	O
,	O
and	O
the	O
alkaloid	B
contains	O
strictosamide	B
,	O
10-hydroxy	B
-	I
strictosamide	I
and	O
short	O
snakeroot	O
glucoside	B
;	O
and	O
the	O
flavonoid	B
contains	O
kaempferol-3-O	B
-	I
rutinoside	I
and	O
rutin	B
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
of	O
the	O
composition	O
.	O

The	O
gallbladder	O
wood	O
leaf	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
active	O
ingredient	O
is	O
definite	O
,	O
and	O
the	O
gallbladder	O
wood	O
leaf	O
composition	O
has	O
notable	O
curative	O
effects	O
.	O

Gallbladder	O
wood	O
leaf	O
composition	O
containing	O
strictosamide	B
and	O
preparation	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
yellow	O
pine	O
gel	O
medicament	O
for	O
treating	O
vaginitis	O
,	O
which	O
comprises	O
the	O
following	O
active	O
components	O
,	O
auxiliary	O
components	O
and	O
a	O
gel	O
matrix	O
in	O
parts	O
by	O
weight	O
:	O
5	O
to	O
15	O
parts	O
of	O
baeckea	O
oil	O
,	O
2	O
to	O
20	O
parts	O
of	O
encalyptus	O
robusta	O
oil	O
,	O
1	O
to	O
6	O
parts	O
of	O
schisandraceane	O
oil	O
,	O
0.5	O
to	O
3	O
parts	O
of	O
common	O
cnidium	O
fruit	O
oil	O
,	O
40	O
to	O
100	O
parts	O
of	O
groundsel	O
,	O
20	O
to	O
80	O
parts	O
of	O
belvedere	O
fruit	O
,	O
10	O
to	O
20	O
parts	O
of	O
phellodendron	O
,	O
0.5	O
to	O
3	O
parts	O
of	O
chlorhexidine	B
acetate	I
,	O
10	O
to	O
30	O
parts	O
of	O
polysorbate-80	B
,	O
1	O
to	O
6	O
parts	O
of	O
sodium	B
benzoate	I
,	O
0.5	O
to	O
4	O
parts	O
of	O
sodium	B
sulfite	I
,	O
10	O
to	O
20	O
parts	O
of	O
carbomer,5	O
to	O
10	O
parts	O
of	O
sodium	O
carboxymethylcellulose	O
,	O
5	O
to	O
20	O
parts	O
of	O
laurocapram	B
,	O
100	O
to	O
150	O
parts	O
of	O
glycerol	B
,	O
40	O
to	O
140	O
parts	O
of	O
propylene	B
glycol	I
,	O
0.5	O
to	O
3	O
parts	O
of	O
triethanolamine	B
,	O
and	O
200	O
to	O
400	O
parts	O
of	O
purified	O
water	O
.	O

The	O
compound	O
yellow	O
pine	O
gel	O
medicament	O
can	O
be	O
used	O
for	O
treating	O
the	O
vaginitis	O
by	O
directly	O
placing	O
gel	O
into	O
vagina	O
,	O
so	O
that	O
clinical	O
administration	O
to	O
a	O
patient	O
is	O
facilitated	O
.	O

Compound	O
yellow	O
pine	O
gel	O
medicament	O
for	O
treating	O
vaginitis	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
compound	O
tincture	O
for	O
preventing	O
and	O
controlling	O
insect	O
bites	O
and	O
stings	O
of	O
livestock	O
.	O

The	O
compound	O
tincture	O
is	O
mainly	O
prepared	O
by	O
mixing	O
24	O
raw	O
materials	O
,	O
such	O
as	O
40	O
-	O
50	O
parts	O
of	O
cortex	O
meliae	O
,	O
40	O
-	O
50	O
parts	O
of	O
mint	O
leaf	O
,	O
40	O
-	O
50	O
parts	O
of	O
rangooncreeper	O
fruit	O
,	O
40	O
-	O
50	O
parts	O
of	O
Chinese	O
torreya	O
seed	O
,	O
40	O
-	O
50	O
parts	O
of	O
cushaw	O
seed	O
,	O
40	O
-	O
50	O
parts	O
of	O
betel	O
nut	O
,	O
30	O
-	O
40	O
parts	O
of	O
shrubalthea	O
bark	O
,	O
30	O
-	O
40	O
parts	O
of	O
camphor	O
,	O
30	O
-	O
40	O
parts	O
of	O
Chinese	O
hibiscus	O
leaf	O
,	O
30	O
-	O
40	O
parts	O
of	O
rosin	O
,	O
30	O
-	O
40	O
parts	O
of	O
denseflower	O
indigo	O
leaf	O
,	O
30	O
-	O
40	O
parts	O
of	O
Japanese	O
peristrophe	O
herb	O
,	O
20	O
-	O
30	O
parts	O
of	O
philippine	O
violet	O
herb	O
,	O
20	O
-	O
30	O
parts	O
of	O
common	O
carpesium	O
fruit	O
,	O
20	O
-	O
30	O
parts	O
of	O
adder	O
tongue	O
herb	O
,	O
10	O
-	O
20	O
parts	O
of	O
erythromycin	B
and	O
10	O
-	O
20	O
parts	O
of	O
vitamin	B
B.	I
Various	O
effective	O
components	O
are	O
percolated	O
,	O
homogenized	O
and	O
sterilized	O
to	O
obtain	O
an	O
external	O
tincture	O
.	O

The	O
external	O
tincture	O
has	O
remarkable	O
curative	O
effects	O
for	O
body	O
surface	O
diseases	O
caused	O
by	O
pathogenic	O
microorganisms	O
and	O
other	O
reasons	O
as	O
well	O
as	O
quick	O
response	O
and	O
high	O
cure	O
rate	O
.	O

Compound	O
tincture	O
for	O
preventing	O
and	O
controlling	O
insect	O
bites	O
and	O
stings	O
of	O
livestock	O

The	O
invention	O
discloses	O
a	O
furan	B
compound	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
furan	B
compound	O
.	O

The	O
furan	O
compound	O
includes	O
a	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
general	O
formula	O
(	O
II	O
)	O
or	O
a	O
pharmaceutical	O
salt	O
of	O
the	O
compound	O
,	O
wherein	O
Ar1	O
refers	O
to	O
any	O
one	O
of	O
various	O
substituted	O
aromatic	B
rings	O
,	O
preferably	O
refers	O
to	O
2,4-dichlorphenyl	B
,	I
4-chlorphenyl	I
or	I
4-bromophenyl	I
;	O
Ar2	O
refers	O
to	O
any	O
one	O
of	O
substituents	O
of	O
various	O
substituted	O
aromatic	B
ring	O
,	O
preferably	O
refers	O
to	O
phenyl	B
,	O
4-fluorophenyl	B
,	O
2-chlorphenyl	B
,	O
4-chlorphenyl	B
or	O
3-methoxyphenyl	B
;	O
and	O
Ar3	O
refers	O
to	O
any	O
one	O
of	O
various	O
substituted	O
aromatic	O
rings	O
,	O
preferably	O
refers	O
to	O
pyridine	O
,	O
4-chlorphenyl	B
and	O
furan	B
.	O

The	O
furan	B
compound	O
can	O
be	O
applied	O
to	O
drugs	O
resisting	O
to	O
AI-2	O
quorum	O
sensing	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
furan	B
compound	O
is	O
mild	O
in	O
reaction	O
conditions	O
,	O
cheap	O
and	O
easily	O
accessible	O
in	O
raw	O
materials	O
,	O
and	O
simple	O
in	O
operation	O
and	O
post	O
-	O
processing	O
.	O

Furan	B
compound	O
and	O
preparation	O
method	O
and	O
application	O
of	O
furan	B
compound	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
photodynamic	O
therapy	O
and	O
particularly	O
relates	O
to	O
photosensitizers	O
for	O
the	O
photodynamic	O
therapy	O
.	O

The	O
invention	O
provides	O
two	O
IX	O
-	O
site	O
single	O
isomers	O
of	O
hemoporfin	B
,	O
namely	O
,	O
8-	B
(	I
1-methoxy	I
ethyl	I
)	I
-3-	I
(	I
1-hydroxyethyl	I
)	I
deuteroporphyrin	I
IX	I
and	O
3-	B
(	I
1-methoxy	I
ethyl	I
)	I
-8-	I
(	I
1-hydroxyethyl	I
)	I
deuteroporphyrin	I
IX	I
,	O
wherein	O
the	O
isomers	O
are	O
obtained	O
by	O
adopting	O
a	O
reversed	O
-	O
phase	O
purification	O
and	O
separation	O
method	O
.	O

Proved	O
by	O
animal	O
experiments	O
,	O
the	O
two	O
isomers	O
are	O
equally	O
effective	O
in	O
sealing	O
off	O
new	O
vessels	O
when	O
serving	O
as	O
the	O
photosensitizers	O
.	O

The	O
single	O
isomers	O
provided	O
by	O
the	O
invention	O
can	O
be	O
used	O
for	O
preparing	O
a	O
drug	O
with	O
single	O
molecular	O
structure	O
and	O
more	O
stable	O
property	O
.	O

Isomers	O
of	O
hemoporfin	B

The	O
invention	O
discloses	O
application	O
of	O
canosic	B
acid	I
in	O
preparing	O
medicines	O
used	O
for	O
preventing	O
or	O
treating	O
diseases	O
relating	O
to	O
liver	O
injury	O
.	O

Canosic	B
acid	I
can	O
substantially	O
reduce	O
increase	O
of	O
transaminase	O
caused	O
by	O
ischemia	O
reperfusion	O
liver	O
injury	O
or	O
chemical	O
liver	O
injury	O
,	O
obviously	O
improve	O
pathological	O
lesion	O
of	O
liver	O
,	O
inhibit	O
increase	O
of	O
immune	O
factors	O
and	O
the	O
like	O
,	O
has	O
a	O
substantial	O
effect	O
on	O
protecting	O
liver	O
,	O
is	O
applied	O
in	O
preparation	O
of	O
medicines	O
used	O
for	O
preventing	O
or	O
treating	O
diseases	O
relating	O
to	O
liver	O
injury	O
and	O
has	O
the	O
advantages	O
of	O
cheapness	O
and	O
safety	O
.	O

Application	O
of	O
canosic	B
acid	I
in	O
preparing	O
medicines	O
used	O
for	O
preventing	O
or	O
treating	O
diseases	O
relating	O
to	O
liver	O
injury	O

The	O
invention	O
discloses	O
a	O
solid	O
preparation	O
of	O
a	O
compound	O
ammonia	B
phenol	I
renin	O
medicine	O
composition	O
liposome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
method	O
comprises	O
that	O
the	O
compound	O
ammonia	B
phenol	I
renin	O
medicine	O
composition	O
liposome	O
is	O
prepared	O
by	O
acetaminophen	B
,	O
anhydrous	O
caffein	B
,	O
phenylephrine	B
hydrochloride	I
,	O
chlorpheniramine	B
maleate	I
,	O
vitamin	B
B1	I
,	O
egg	O
yolk	O
lecithin	B
acyl	I
serine	I
,	O
phosphatidyl	B
ethanolamine	I
and	O
octadecylamine	B
which	O
are	O
selected	O
according	O
to	O
specified	O
weight	O
ratio	O
,	O
and	O
then	O
the	O
solid	O
preparation	O
is	O
prepared	O
by	O
the	O
compound	O
ammonia	B
phenol	I
renin	O
medicine	O
composition	O
liposome	O
through	O
an	O
ordinary	O
preparation	O
method	O
.	O

The	O
solid	O
preparation	O
of	O
the	O
liposome	O
is	O
high	O
in	O
encapsulation	O
and	O
even	O
in	O
particle	O
size	O
,	O
improves	O
quality	O
of	O
a	O
preparation	O
product	O
,	O
reduces	O
toxic	O
and	O
side	O
effects	O
,	O
andis	O
suitable	O
for	O
industrialized	O
production	O
.	O

In	O
addition	O
,	O
the	O
preparation	O
method	O
is	O
simple	O
,	O
and	O
the	O
medicine	O
is	O
reserved	O
in	O
blood	O
circulation	O
for	O
a	O
long	O
time	O
.	O

Solid	O
preparation	O
of	O
compound	O
ammonia	B
phenol	I
renin	O
medicine	O
composition	O
liposome	O

The	O
invention	O
relates	O
to	O
novel	O
crystal	O
formations	O
of	O
levogyration	B
oxiracetam	I
,	O
including	O
a	O
crystal	O
formation	O
A	O
,	O
a	O
crystal	O
formation	O
B	O
and	O
a	O
crystal	O
formation	O
C	O
,	O
which	O
have	O
excellent	O
stability	O
and	O
are	O
very	O
suitable	O
for	O
the	O
preparation	O
of	O
common	O
formulations	O
of	O
levogyration	B
oxiracetam	I
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
and	O
characterization	O
of	O
the	O
crystal	O
formations	O
,	O
as	O
well	O
as	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
crystal	O
formations	O
.	O

Novel	O
crystal	O
formations	O
of	O
levogyration	B
oxiracetam	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
high	O
-	O
efficiency	O
antibacterial	O
copper	B
ternary	O
complex	O
containing	O
heterocyclic	B
ligand	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
chemical	O
composition	O
of	O
the	O
high	O
-	O
efficiency	O
antibacterial	O
copper	B
ternary	O
complex	O
is	O
Cu	B
(	I
Assb	I
)	I
(	I
Hq	I
)	I
.4H2O	I
,	O
wherein	O
Cu	B
is	O
copper	B
,	O
Assb	B
is	O
2-aminothiazole	B
salicylaldehyde	I
Schiff	I
alkali	I
,	O
and	O
Hq	B
is	O
8-hydroxyquinoline	B
.	O

The	O
high	O
-	O
efficiency	O
antibacterial	O
copper	B
ternary	O
complex	O
containing	O
the	O
heterocyclic	B
ligand	O
has	O
high	O
antibacterial	O
activity	O
,	O
chemical	O
stability	O
,	O
heat	O
stability	O
and	O
lipid	O
solubility	O
,	O
and	O
can	O
be	O
used	O
as	O
an	O
antibacterial	O
agent	O
to	O
be	O
applied	O
in	O
the	O
antibacterial	O
field	O
,	O
and	O
the	O
diameter	O
of	O
inhibition	O
zone	O
of	O
the	O
high	O
-	O
efficiency	O
antibacterial	O
copper	B
ternary	O
complex	O
on	O
escherichia	O
coli	O
and	O
staphylococcus	O
aureus	O
are	O
18	O
millimeters	O
and	O
32	O
millimeters	O
.	O

High	O
-	O
efficiency	O
antibacterial	O
copper	B
ternary	O
complex	O
containing	O
heterocyclic	B
ligand	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
plumbagin-5-O	B
-	I
glucose	I
and	O
a	O
synthetic	O
method	O
and	O
an	O
application	O
thereof	O
.	O

A	O
plumbagin	B
is	O
used	O
to	O
serve	O
as	O
an	O
active	O
mother	O
nucleus	O
to	O
synthesize	O
the	O
plumbagin-5-O	B
-	I
glucose	I
by	O
an	O
glucosidation	O
reaction	O
,	O
compared	O
with	O
a	O
water	O
solubility	O
of	O
the	O
plumbagin	B
,	O
the	O
water	O
solubility	O
of	O
the	O
plumbagin-5-O	B
-	I
glucose	I
is	O
remarkably	O
improved	O
,	O
and	O
the	O
problem	O
that	O
the	O
plumbagin	B
serving	O
as	O
a	O
potential	O
antitumor	O
drug	O
is	O
not	O
good	O
in	O
water	O
solubility	O
is	O
effectively	O
solved	O
;	O
and	O
an	O
inhibitory	O
activity	O
of	O
the	O
plumbagin-5-O	B
-	I
glucose	I
for	O
proliferations	O
of	O
a	O
plurality	O
of	O
human	O
tumor	O
cell	O
lines	O
is	O
investigated	O
,	O
a	O
result	O
shows	O
that	O
an	O
antitumor	O
activity	O
of	O
the	O
plumbagin-5-O	B
-	I
glucose	I
is	O
still	O
maintained	O
on	O
the	O
condition	O
that	O
the	O
water	O
solubility	O
is	O
remarkably	O
improved	O
,	O
and	O
the	O
plumbagin-5-O	B
-	I
glucose	I
has	O
a	O
good	O
potential	O
medical	O
value	O
and	O
is	O
expected	O
to	O
be	O
used	O
for	O
preparing	O
various	O
antitumor	O
drugs	O
.	O

According	O
to	O
the	O
plumbagin-5-O	B
-	I
glucose	I
and	O
the	O
synthetic	O
method	O
and	O
the	O
application	O
thereof	O
,	O
the	O
structural	O
formula	O
of	O
the	O
plumbagin-5-O	B
-	I
glucose	I
is	O
shown	O
as	O
follows	O
.	O

Plumbagin-5-O	B
-	I
glucose	I
and	O
synthetic	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
anticancer	O
compound	O
camellia	O
nitidissima	O
flavonoid	B
glycoside	I
A	I
separated	O
from	O
camellia	O
nitidissima	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

By	O
qualitative	O
and	O
quantitative	O
determination	O
,	O
a	O
monomeric	O
compound	O
and	O
fraction	O
which	O
are	O
obtained	O
by	O
separation	O
from	O
an	O
ethyl	B
acetate	I
extract	O
of	O
a	O
95	O
%	O
ethanol	B
extract	O
of	O
the	O
camellia	O
nitidissima	O
are	O
mainly	O
flavonoid	B
components	O
.	O

The	O
chemical	O
structure	O
of	O
the	O
compound	O
is	O
determined	O
by	O
analysis	O
of	O
a	O
modern	O
spectrum	O
technology	O
,	O
and	O
the	O
chemical	O
name	O
is	O
quercetin-7-O-	B
(	I
6''-O	I
-	I
E-	I
dicaffeoyl	I
group	I
)	I
-beta	I
-	I
D	I
-	I
glucoside	I
.	O

An	O
in	O
vitro	O
anti	O
-	O
tumor	O
experiment	O
proves	O
that	O
the	O
compound	O
can	O
remarkably	O
restrain	O
proliferation	O
of	O
tumor	O
cells	O
and	O
has	O
activity	O
of	O
inducing	O
apoptosis	O
of	O
the	O
tumor	O
cells	O
.	O

An	O
anticancer	O
compound	O
camellia	O
nitidissima	O
flavonoid	B
glycoside	I
A	I
product	O
has	O
the	O
developing	O
potential	O
of	O
antitumor	O
medicines	O
.	O

Camellia	O
nitidissima	O
flavonoid	B
glycoside	I
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
sinomenine	B
hydrochloride	I
infusion	O
solution	O
and	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
which	O
has	O
the	O
advantages	O
that	O
a	O
percolation	O
method	O
is	O
adopted	O
for	O
preparing	O
sinomenine	B
hydrochloride	I
,	O
the	O
operation	O
is	O
simple	O
,	O
and	O
the	O
cold	O
treatment	O
rather	O
than	O
the	O
drying	O
is	O
adopted	O
in	O
the	O
extraction	O
process	O
;	O
the	O
yield	O
is	O
high	O
,	O
the	O
mother	O
liquor	O
treatment	O
is	O
simple	O
;	O
the	O
preparation	O
method	O
is	O
safe	O
and	O
reliable	O
,	O
is	O
low	O
in	O
pollution	O
and	O
plays	O
an	O
active	O
role	O
in	O
protecting	O
the	O
environment	O
.	O

Method	O
for	O
preparing	O
sinomenine	B
hydrochloride	I
infusion	O
solution	O
and	O
freeze	O
-	O
dried	O
powder	O
injection	O

The	O
invention	O
discloses	O
a	O
hydrophilic	O
gel	O
type	O
palmatine	B
sustained	O
-	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
which	O
belong	O
to	O
the	O
technical	O
field	O
of	O
drugs	O
.	O

The	O
raw	O
materials	O
of	O
the	O
hydrophilic	O
gel	O
type	O
palmatine	B
sustained	O
-	O
release	O
tablet	O
are	O
as	O
follows	O
:	O
300	O
-	O
350	O
g	O
of	O
palmatine	B
,	O
30	O
-	O
35	O
g	O
of	O
hydroxypropyl	O
methyl	O
cellulose	O
(	O
HPMC	O
)	O
K15	O
M	O
,	O
70	O
-	O
80	O
g	O
of	O
pregelatinized	O
starch	O
,	O
5	O
-	O
10	O
g	O
of	O
magnesium	B
stearate	I
and	O
10	O
-	O
15	O
g	O
of	O
polyvinyl	B
pyrrolidone	I
(	O
PVP	O
)	O
K30	O
.	O

The	O
hydrophilic	O
gel	O
type	O
palmatine	B
sustained	O
-	O
release	O
tablet	O
is	O
prepared	O
by	O
the	O
method	O
comprising	O
respectively	O
sieving	O
the	O
raw	O
materials	O
through	O
an	O
80-mesh	O
sieve	O
,	O
weighing	O
the	O
palmatine	B
,	O
the	O
HPMC	O
K15	O
M	O
and	O
the	O
pregelatinized	O
starch	O
according	O
to	O
the	O
dosage	O
,	O
evenly	O
mixing	O
,	O
adding	O
8	O
%	O
of	O
PVP	O
K30	O
ethanol	B
water	O
for	O
making	O
soft	O
materials	O
into	O
the	O
mixture	O
,	O
evenly	O
mixing	O
,	O
pelleting	O
the	O
mixture	O
through	O
a	O
30-mesh	O
sieve	O
,	O
drying	O
pellets	O
at	O
the	O
temperature	O
of	O
40	O
DEG	O
C	O
,	O
reshaping	O
the	O
pellets	O
through	O
the	O
30-mesh	O
sieve	O
,	O
adding	O
the	O
magnesium	B
stearate	I
for	O
even	O
mixing	O
,	O
tabletting	O
and	O
coating	O
to	O
obtain	O
the	O
hydrophilic	O
gel	O
type	O
palmatine	B
sustained	O
-	O
release	O
tablet	O
.	O

The	O
hydrophilic	O
gel	O
type	O
palmatine	B
sustained	O
-	O
release	O
tablet	O
avoids	O
clinical	O
daily	O
frequent	O
use	O
and	O
blood	O
concentration	O
fluctuations	O
caused	O
by	O
the	O
clinical	O
daily	O
frequent	O
use	O
,	O
and	O
improves	O
effectiveness	O
and	O
safety	O
of	O
drug	O
usage	O
and	O
compliance	O
of	O
patients	O
.	O

Hydrophilic	O
gel	O
type	O
palmatine	O
sustained	O
-	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
calcium	O
alginate	O
microcapsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
calcium	O
alginate	O
microcapsule	O
is	O
prepared	O
according	O
to	O
the	O
method	O
which	O
comprises	O
the	O
following	O
steps	O
:	O
1	O
)	O
uniformly	O
mixing	O
a	O
sodium	O
alginate	O
solution	O
with	O
a	O
soluble	O
carbonate	B
solution	O
,	O
thereby	O
obtaining	O
a	O
mixed	O
solution	O
;	O
2	O
)	O
adding	O
a	O
soluble	O
calcium	B
salt	I
solution	O
into	O
the	O
mixed	O
solution	O
,	O
and	O
mixing	O
uniformly	O
,	O
thereby	O
obtaining	O
an	O
emulsion	O
;	O
and	O
3	O
)	O
adding	O
an	O
acid	O
solution	O
into	O
the	O
emulsion	O
,	O
enabling	O
calcium	B
ions	I
generated	O
by	O
dissolving	O
calcium	B
carbonate	I
microspheres	O
to	O
crosslink	O
with	O
sodium	O
alginate	O
,	O
thereby	O
forming	O
the	O
calcium	O
alginate	O
microcapsule	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
and	O
is	O
easily	O
performed	O
;	O
the	O
yield	O
of	O
product	O
is	O
high	O
;	O
the	O
size	O
distribution	O
is	O
uniform	O
;	O
and	O
the	O
size	O
is	O
controllable	O
.	O

The	O
microcapsule	O
is	O
a	O
single	O
-	O
component	O
system	O
;	O
the	O
introduction	O
of	O
irrelevant	O
matters	O
is	O
largely	O
reduced	O
,	O
the	O
application	O
range	O
of	O
a	O
carrier	O
is	O
increased	O
and	O
the	O
toxic	O
side	O
effect	O
is	O
reduced	O
.	O

Besides	O
,	O
phospholipid	O
is	O
used	O
for	O
functionalizing	O
the	O
calcium	O
alginate	O
microcapsule	O
,	O
a	O
novel	O
drug	O
carrier	O
is	O
created	O
,	O
and	O
a	O
new	O
more	O
effective	O
way	O
is	O
supplied	O
for	O
combined	O
treatment	O
.	O

Calcium	O
alginate	O
microcapsule	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
salicylic	B
acid	I
and	O
clotrimazole	B
aerosol	O
.	O

Formula	O
raw	O
materials	O
of	O
the	O
aerosol	O
comprise	O
salicylic	B
acid	I
,	O
clotrimazole	B
,	O
phenol	B
,	O
camphor	B
,	O
methyl	B
salicylate	I
,	O
glycerin	B
,	O
and	O
ethanol	B
,	O
and	O
a	O
propellent	O
adopts	O
a	O
hydrofluoroalkane	B
of	O
tetrafluoroethane	B
or	O
heptafluoropropane	B
(	O
HFA227	O
)	O
,	O
dimethyl	B
ether	I
(	O
DME	B
)	O
,	O
a	O
hydrocarbon	B
or	O
a	O
compressed	O
gas	O
.	O

The	O
volume	O
or	O
weight	O
ratio	O
of	O
the	O
propellent	O
to	O
the	O
formula	O
raw	O
materials	O
is	O
1:1	O
.	O

The	O
aerosol	O
which	O
uses	O
HFA134a	O
to	O
substitute	O
F-12	O
as	O
the	O
propellent	O
can	O
avoid	O
the	O
destroy	O
to	O
the	O
atmospheric	O
ozone	B
layer	O
,	O
can	O
realize	O
energy	O
saving	O
and	O
consumption	O
reduction	O
in	O
the	O
medicinal	O
preparation	O
process	O
,	O
and	O
has	O
substantial	O
economic	O
benefits	O
.	O

Compound	O
salicylic	B
acid	I
and	O
clotrimazole	B
aerosol	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
products	O
and	O
provides	O
a	O
method	O
for	O
preparing	O
broad	O
-	O
spectrum	O
antibiotic	O
clindamycin	B
hydrochloride	I
injection	O
.	O

The	O
method	O
is	O
mainly	O
characterized	O
by	O
adopting	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighing	O
sodium	B
dihydrogen	I
phosphate	I
and	O
disodium	B
hydrogen	I
phosphate	I
,	O
putting	O
sodium	B
dihydrogen	I
phosphate	I
and	O
disodium	B
hydrogen	I
phosphate	I
into	O
water	O
for	O
injection	O
accounting	O
for	O
50	O
%	O
of	O
the	O
total	O
prepared	O
solution	O
and	O
stirring	O
and	O
dissolving	O
sodium	B
dihydrogen	I
phosphate	I
and	O
disodium	B
hydrogen	I
phosphate	I
to	O
prepare	O
phosphate	B
buffered	O
solution	O
;	O
(	O
2	O
)	O
adding	O
clindamycin	B
hydrochloride	I
to	O
the	O
phosphate	B
buffered	O
solution	O
and	O
stirring	O
and	O
dissolving	O
clindamycin	B
hydrochloride	I
;	O
(	O
3	O
)	O
using	O
the	O
water	O
for	O
injection	O
to	O
ensure	O
the	O
constant	O
volume	O
to	O
reach	O
the	O
concentration	O
of	O
the	O
injected	O
liquid	O
medicine	O
and	O
maintaining	O
the	O
pH	O
value	O
between	O
5.1	O
and	O
5.4	O
;	O
(	O
4	O
)	O
adding	O
activated	O
carbon	B
for	O
injection	O
,	O
accounting	O
for	O
0.1	O
%	O
of	O
the	O
total	O
liquid	O
medicine	O
,	O
to	O
the	O
liquid	O
medicine	O
for	O
adsorption	O
and	O
then	O
using	O
a	O
0.45mu	O
m	O
microporous	O
membrane	O
or	O
a	O
cartridge	O
filter	O
with	O
a	O
0.45mu	O
m	O
filter	O
element	O
for	O
rough	O
filtration	O
;	O
(	O
5	O
)	O
then	O
using	O
a	O
0.22mu	O
m	O
microporous	O
membrane	O
or	O
a	O
cartridge	O
filter	O
with	O
a	O
0.22mu	O
m	O
filter	O
element	O
for	O
fine	O
filtration	O
until	O
the	O
clarity	O
conforms	O
to	O
the	O
specification	O
;	O
and	O
(	O
6	O
)	O
carrying	O
out	O
nitrogen	O
filling	O
,	O
filling	O
,	O
sealing	O
and	O
sterilizing	O
,	O
thus	O
obtaining	O
the	O
clindamycin	B
hydrochloride	I
injection	O
.	O

Lots	O
of	O
tests	O
show	O
that	O
the	O
single	O
impurity	O
content	O
is	O
lower	O
than	O
0.5	O
%	O
,	O
the	O
total	O
impurity	O
content	O
is	O
lower	O
than	O
4.5	O
%	O
,	O
and	O
the	O
single	O
and	O
total	O
impurity	O
contents	O
are	O
higher	O
than	O
the	O
international	O
and	O
national	O
standards	O
,	O
so	O
the	O
injection	O
has	O
the	O
advantages	O
of	O
safety	O
and	O
stability	O
.	O

Method	O
for	O
preparing	O
clindamycin	B
hydrochloride	I
injection	O

The	O
invention	O
provides	O
an	O
antineoplastic	O
drug	O
containing	O
isothiocyanate	B
and	O
an	O
application	O
of	O
the	O
antineoplastic	O
drug	O
.	O

The	O
antineoplastic	O
drug	O
is	O
isothiocyanate	B
,	O
and	O
the	O
isothiocyanate	B
is	O
beta	B
-	I
phenethyl	I
isothiocyanate	I
.	O

The	O
antineoplastic	O
drug	O
provided	O
by	O
the	O
invention	O
resists	O
drug	O
by	O
the	O
high	O
-	O
efficiency	O
reversal	O
platinum	O
chemotherapeutics	O
drug	O
to	O
achieve	O
the	O
action	O
on	O
killing	O
tumor	O
cells	O
.	O

Antineoplastic	O
drug	O
containing	O
isothiocyanate	B
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
new	O
application	O
of	O
ampelopsin	B
sodium	I
in	O
treating	O
bladder	O
cancer	O
.	O

Particularly	O
,	O
the	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
containing	O
ampelopsin	B
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
.	O

The	O
medicine	O
is	O
administrated	O
intravenously	O
,	O
can	O
effectively	O
treat	O
cancers	O
of	O
the	O
urinary	O
system	O
,	O
especially	O
bladder	O
cancer	O
.	O

New	O
application	O
of	O
ampelopsin	B
sodium	I
in	O
treating	O
bladder	O
cancer	O

The	O
invention	O
provides	O
a	O
selenized	O
microbial	O
exopolysaccharide	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
adding	O
micromolecular	O
Rhizobium	O
sp.	O
exopolysaccharide	O
to	O
nitric	B
acid	I
solution	O
,	O
stirring	O
,	O
adding	O
selenous	B
acid	I
and	O
barium	B
chloride	I
,	O
adding	O
sulfuric	B
acid	I
dropwise	O
,	O
removing	O
precipitates	O
by	O
centrifugation	O
,	O
regulating	O
the	O
pH	O
of	O
supernatant	O
to	O
7	O
by	O
sodium	B
hydroxide	I
,	O
putting	O
the	O
supernatant	O
in	O
a	O
dialysis	O
bag	O
for	O
dialysis	O
,	O
concentrating	O
the	O
dialysate	O
under	O
reduced	O
pressure	O
and	O
then	O
adding	O
edible	O
alcohol	B
,	O
separating	O
out	O
selenized	O
microbial	O
exopolysaccharide	O
,	O
and	O
collecting	O
and	O
freeze	O
-	O
drying	O
the	O
selenized	O
microbial	O
exopolysaccharide	O
to	O
obtain	O
selenized	O
micromolecular	O
microbial	O
exopolysaccharide	O
.	O

The	O
content	O
of	O
selenium	B
in	O
the	O
exopolysaccharide	O
can	O
reach	O
586	O
to	O
790	O
mu	O
g	O
/	O
g	O
according	O
to	O
measurement	O
;	O
mice	O
tests	O
show	O
that	O
the	O
exopolysaccharide	O
has	O
excellent	O
antitumor	O
activity	O
;	O
and	O
the	O
exopolysaccharide	O
can	O
be	O
used	O
in	O
preparing	O
antitumor	O
medicines	O
and	O
healthcare	O
products	O
.	O

Selenized	O
microbial	O
exopolysaccharide	O
,	O
and	O
preparation	O
method	O
and	O
uses	O
thereof	O

The	O
invention	O
provides	O
a	O
pioglitazone	B
hydrochloride	I
and	O
glimepiride	O
combination	O
medicine	O
.	O

Chromium	B
picolinate	I
is	O
added	O
into	O
the	O
pioglitazone	B
hydrochloride	I
and	O
glimepiride	B
combination	O
medicine	O
.	O

The	O
weight	O
ratio	O
of	O
pioglitazone	B
hydrochloride	I
to	O
glimepiride	B
is	O
30:2	O
-	O
4	O
.	O

The	O
pioglitazone	B
hydrochloride	I
and	O
glimepiride	B
combination	O
medicine	O
not	O
only	O
has	O
a	O
good	O
curative	O
effect	O
for	O
diabetes	O
mellitus	O
,	O
but	O
also	O
has	O
a	O
certain	O
therapy	O
effect	O
for	O
early	O
diabetic	O
nephropathy	O
.	O

Pioglitazone	B
hydrochloride	I
and	O
glimepiride	B
combination	O
medicine	O
,	O
tablet	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
for	O
methotrexate	B
/	O
layered	O
double	O
hydroxide	O
(	O
MTX	B
/	O
LDHs	O
)	O
nanocomposite	O
,	O
which	O
belongs	O
to	O
the	O
technical	O
fields	O
of	O
the	O
material	O
and	O
the	O
pharmaceutical	O
preparation	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
1	O
)	O
respectively	O
pre	O
-	O
grinding	O
bivalent	O
metal	O
salt	O
and	O
trivalent	O
metal	O
salt	O
;	O
2	O
)	O
preparing	O
aqueous	O
alkali	O
of	O
which	O
the	O
concentration	O
is	O
8	O
-	O
12mol	O
/	O
L	O
;	O
3	O
)	O
respectively	O
weighing	O
the	O
bivalent	O
metal	O
salt	O
and	O
the	O
trivalent	O
metal	O
salt	O
obtained	O
in	O
step	O
1	O
)	O
,	O
putting	O
the	O
bivalent	O
metal	O
salt	O
and	O
the	O
trivalent	O
metal	O
salt	O
into	O
a	O
mortar	O
,	O
and	O
adding	O
the	O
methotrexate	B
(	O
MTX	B
)	O
;	O
dripping	O
aqueous	O
alkali	O
obtained	O
in	O
step	O
2	O
)	O
,	O
evenly	O
mixing	O
the	O
above	O
substances	O
,	O
grinding	O
for	O
a	O
certain	O
time	O
at	O
constant	O
speed	O
,	O
and	O
carrying	O
out	O
centrifugal	O
washing	O
to	O
mixture	O
by	O
distilled	O
water	O
to	O
obtain	O
an	O
MTX	B
/	O
LDH	O
precursor	O
;	O
and	O
4	O
)	O
dispersing	O
the	O
MTX	B
/	O
LDH	O
precursor	O
into	O
water	O
,	O
putting	O
into	O
a	O
reaction	O
kettle	O
for	O
peptization	O
,	O
and	O
drying	O
an	O
obtained	O
peptized	O
product	O
.	O

By	O
adopting	O
the	O
mechanochemistry	O
method	O
,	O
a	O
product	O
with	O
regular	O
particle	O
morphology	O
and	O
good	O
monodispersity	O
is	O
prepared	O
,	O
and	O
the	O
preparation	O
method	O
is	O
environmentally	O
friendly	O
.	O

Preparation	O
method	O
for	O
methotrexate	B
/	O
layered	O
double	O
hydroxide	O
nanocomposite	O

The	O
invention	O
relates	O
to	O
anthraquinone	B
dimer	I
derivatives	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
firstly	O
conducting	O
strain	O
culture	O
of	O
an	O
endophytic	O
fungus	O
Alternaria	O
sp.	O
(	O
ZJ-2008003	O
)	O
coming	O
from	O
South	O
China	O
Sea	O
soft	O
coral	O
Sarcophyton	O
Sp	O
.	O

in	O
a	O
strain	O
culture	O
medium	O
,	O
conducting	O
fermentation	O
culture	O
in	O
a	O
fermentation	O
culture	O
medium	O
,	O
filtering	O
the	O
obtained	O
fermentation	O
liquid	O
,	O
removing	O
filtrate	O
to	O
obtain	O
thalli	O
,	O
extracting	O
the	O
thalli	O
by	O
using	O
methanol	B
,	O
concentrating	O
the	O
extract	O
,	O
conducting	O
silica	O
gel	O
column	O
chromatography	O
,	O
Sephadex	O
LH-20	O
gel	O
column	O
chromatography	O
and	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
preparation	O
,	O
concentrating	O
the	O
eluent	O
to	O
obtain	O
red	O
powder	O
,	O
which	O
is	O
the	O
anthraquinone	B
dimer	I
derivatives	O
alterporriol	B
Q	I
and	O
alterporriol	B
R.	I
The	O
anthraquinone	B
dimmer	I
derivatives	O
coming	O
from	O
marine	O
fungi	O
have	O
a	O
strong	O
antiviral	O
effect	O
,	O
can	O
effectively	O
inhibit	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
viruses	O
(	O
PRRSV	O
)	O
and	O
can	O
be	O
used	O
as	O
antiviral	O
drugs	O
,	O
raw	O
materials	O
can	O
be	O
produced	O
in	O
a	O
large	O
scale	O
and	O
the	O
application	O
prospect	O
is	O
wide	O
.	O

Anthraquinone	B
dimer	I
derivative	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

A	O
cancer	O
therapy	O
sensitizer	O
is	O
disclosed	O
.	O

The	O
cancer	O
therapy	O
sensitizer	O
includes	O
rapamycin	B
and	O
substituted	O
quinoline	B
.	O

The	O
present	O
invention	O
discloses	O
a	O
cancer	O
therapy	O
sensitization	O
kit	O
containing	O
the	O
two	O
aforementioned	O
compounds	O
and	O
a	O
use	O
of	O
a	O
combination	O
of	O
the	O
two	O
aforementioned	O
compounds	O
as	O
a	O
cancer	O
therapy	O
sensitizer	O
as	O
well	O
.	O

The	O
application	O
of	O
the	O
cancer	O
therapy	O
sensitizer	O
,	O
the	O
kit	O
and	O
the	O
use	O
of	O
the	O
present	O
invention	O
is	O
advantageous	O
for	O
improving	O
the	O
treatment	O
effect	O
of	O
cancer	O
therapies	O
.	O

Sensitizer	O
,	O
kit	O
and	O
use	O
for	O
cancer	O
therapy	O

The	O
invention	O
provides	O
a	O
Gamuzhuer	O
medicinal	O
latex	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
Gamuzhuer	O
medicinal	O
latex	O
preparation	O
comprises	O
the	O
following	O
components	O
by	O
weight	O
percentage	O
:	O
10	O
-	O
40	O
%	O
of	O
Gamuzhuer	O
,	O
0.1	O
-	O
8	O
%	O
of	O
bioadhesive	O
agent	O
,	O
0.1	O
-	O
5	O
%	O
of	O
non	O
-	O
ionic	O
emulsifier	O
,	O
1	O
-	O
30	O
%	O
of	O
glycerol	B
,	O
0	O
-	O
30	O
%	O
of	O
grease	O
and	O
the	O
balance	O
of	O
water	O
.	O

The	O
bioadhesive	O
material	O
is	O
bond	O
with	O
the	O
Gamuzhuer	O
,	O
so	O
thatmedicines	O
are	O
dispersed	O
and	O
adhered	O
to	O
a	O
focus	O
part	O
so	O
as	O
to	O
achieve	O
a	O
therapeutic	O
aim	O
;	O
the	O
Gamuzhuer	O
latex	O
preparation	O
has	O
a	O
higher	O
content	O
,	O
is	O
more	O
convenient	O
to	O
administer	O
and	O
is	O
not	O
added	O
with	O
any	O
irritant	O
solvent	O
;	O
the	O
acting	O
time	O
is	O
prolonged	O
;	O
during	O
preparation	O
,	O
a	O
proper	O
amount	O
of	O
emulsifier	O
is	O
added	O
,	O
so	O
that	O
dissolution	O
of	O
musk	O
and	O
borneol	B
can	O
be	O
promoted	O
;	O
compared	O
with	O
the	O
conventional	O
powdery	O
preparation	O
,	O
the	O
latex	O
preparation	O
takes	O
effect	O
more	O
quickly	O
;	O
a	O
proper	O
amount	O
of	O
grease	O
and	O
a	O
proper	O
amount	O
of	O
emulsifier	O
are	O
added	O
to	O
achieve	O
a	O
good	O
lubricating	O
effect	O
;	O
the	O
grain	O
diameter	O
of	O
the	O
medicinal	O
powder	O
is	O
optimized	O
,	O
so	O
that	O
99	O
percent	O
of	O
the	O
powder	O
is	O
smaller	O
than	O
100	O
um	O
and	O
thus	O
the	O
stability	O
of	O
the	O
medicinal	O
powder	O
is	O
improved	O
;	O
and	O
the	O
medicines	O
have	O
antibacterial	O
and	O
antisepticfunctions	O
,	O
so	O
that	O
a	O
preservative	O
is	O
not	O
required	O
.	O

Gamuzhuer	O
medicinal	O
latex	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
curcumin	B
salicylic	B
acid	I
monoester	I
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
.	O

A	O
synthesis	O
method	O
of	O
the	O
curcumin	B
salicylic	B
acid	I
monoester	I
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
curcumin	B
in	O
absolute	O
methylene	B
dichloride	I
;	O
adding	O
salicylic	B
acid	I
and	O
a	O
catalytic	O
amount	O
of	O
DMAP	B
(	O
N	B
,	I
N-4-dimethyl	I
aminopyridine	I
)	O
;	O
slowly	O
dropwise	O
adding	O
methylene	B
dichloride	I
in	O
which	O
a	O
dehydrant	O
DCC	B
(	O
dicyclohexylcarbodiimide	B
)	O
or	O
EDC.HCl	B
[	O
1-ethyl-	B
(	I
3-dimethyl	I
amino	I
propyl	I
)	I
carbonyl	I
diimine	I
hydrochloride	I
]	O
to	O
perform	O
esterification	O
reaction	O
;	O
and	O
performing	O
separation	O
and	O
purification	O
on	O
a	O
product	O
through	O
column	O
chromatography	O
.	O

The	O
curcumin	B
salicylic	B
acid	I
monoester	I
has	O
an	O
inhibition	O
effect	O
on	O
leukemia	O
,	O
lymphoma	O
,	O
gastric	O
cancer	O
,	O
cancer	O
of	O
colon	O
,	O
liver	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
breast	O
carcinoma	O
,	O
nasopharyngeal	O
carcinoma	O
,	O
cervical	O
cancer	O
,	O
melanoma	O
and	O
multiple	O
myeloma	O
cells	O
;	O
the	O
anti	O
-	O
tumor	O
effect	O
is	O
superior	O
to	O
that	O
of	O
curcumin	B
;	O
and	O
the	O
toxicity	O
of	O
a	O
medicament	O
is	O
not	O
increased	O
while	O
the	O
anti	O
-	O
tumor	O
effect	O
is	O
improved	O
.	O

The	O
curcumin	B
salicylic	B
acid	I
monoester	I
has	O
an	O
obvious	O
inhibition	O
effect	O
on	O
acute	O
and	O
chronic	O
inflammation	O
models	O
.	O

Curcumin	B
salicylic	B
acid	I
monoester	I
and	O
synthesis	O
method	O
thereof	O
and	O
application	O
curcumin	B
salicylic	B
acid	I
monoester	I
to	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
inflammatory	O
aspects	O

The	O
invention	O
relates	O
to	O
an	O
amino	B
aromatic	I
hydrocarbon	I
compound	O
capable	O
of	O
serving	O
as	O
an	O
active	O
-	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
/	O
extracellular	O
signal	O
regulated	O
kinase	O
(	O
ERK	O
)	O
1	O
/	O
2	O
inhibitor	O
and	O
application	O
of	O
the	O
amino	B
aromatic	I
hydrocarbon	I
compound	O
to	O
preparation	O
of	O
a	O
medicine	O
for	O
resisting	O
malignant	O
tumor	O
.	O

The	O
amino	B
aromatic	I
hydrocarbon	I
compound	O
is	O
a	O
selective	O
active	O
-	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
/	O
ERK	O
1	O
/	O
2	O
inhibitor	O
and	O
can	O
be	O
used	O
for	O
preventing	O
or	O
treating	O
malignant	O
tumor	O
,	O
in	O
particular	O
for	O
treating	O
melanoma	O
,	O
colorectal	O
cancer	O
,	O
breast	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
epidermoid	O
tumor	O
,	O
brain	O
tumor	O
and	O
liver	O
cancer	O
.	O

Amino	B
aromatic	I
hydrocarbon	I
compound	O
and	O
application	O
thereof	O
to	O
preparation	O
of	O
medicine	O
for	O
resisting	O
malignant	O
tumor	O

The	O
invention	O
provides	O
a	O
composition	O
consists	O
based	O
on	O
garlic	O
oil	O
,	O
garlic	O
total	O
polysaccharide	O
and	O
garlic	O
total	O
saponin	B
as	O
raw	O
materials	O
.	O

The	O
composition	O
is	O
integrated	O
with	O
water	O
-	O
soluble	O
and	O
fat	O
-	O
soluble	O
effective	O
components	O
of	O
garlic	O
,	O
so	O
that	O
the	O
anti	O
-	O
cancer	O
activity	O
of	O
the	O
garlic	O
is	O
sufficiently	O
played	O
.	O

The	O
composition	O
has	O
excellent	O
anti	O
-	O
tumor	O
activity	O
and	O
has	O
the	O
effects	O
of	O
strengthening	O
body	O
resistance	O
to	O
eliminate	O
pathogenic	O
factors	O
and	O
reducing	O
toxicity	O
,	O
has	O
wide	O
application	O
prospect	O
,	O
and	O
can	O
be	O
prepared	O
into	O
a	O
tumor	O
prevention	O
medicament	O
or	O
health	O
-	O
care	O
product	O
with	O
remarkable	O
curative	O
effect	O
and	O
small	O
toxic	O
or	O
side	O
effect	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
composition	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
preparing	O
the	O
garlic	O
oil	O
from	O
the	O
garlic	O
through	O
double	O
extraction	O
;	O
preparing	O
garlic	O
total	O
polysaccharide	O
from	O
decoction	O
dreg	O
through	O
water	O
extraction	O
and	O
alcohol	O
precipitation	O
;	O
and	O
carrying	O
out	O
alcohol	B
extraction	O
and	O
macroporous	O
resin	O
purification	O
on	O
the	O
decoction	O
dreg	O
to	O
obtain	O
the	O
garlic	O
total	O
saponin	B
.	O

The	O
preparation	O
method	O
is	O
simple	O
to	O
operate	O
,	O
low	O
in	O
cost	O
and	O
controllable	O
in	O
quality	O
,	O
realizes	O
sufficient	O
utilization	O
of	O
each	O
part	O
of	O
garlic	O
raw	O
materials	O
,	O
and	O
can	O
be	O
industrialized	O
.	O

Anti	O
-	O
cancer	O
application	O
of	O
composition	O
containing	O
garlic	O
oil	O
,	O
garlic	O
total	O
polysaccharide	O
and	O
garlic	O
total	O
saponin	B

The	O
invention	O
relates	O
to	O
omega	B
-	I
carboxy	I
-	I
substituted	I
diphenylthiourea	I
derivatives	O
disclosed	O
as	O
Formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
a	O
solvate	O
of	O
the	O
derivatives	O
or	O
salts	O
.	O

The	O
omega	B
-	I
carboxy	I
-	I
substituted	I
diphenylthiourea	I
compounds	O
are	O
an	O
effective	O
tyrosine	B
kinase	O
inhibitor	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
omega	B
-	I
carboxy	I
-	I
substituted	I
diphenylthiourea	I
derivatives	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
omega	B
-	I
carboxy	I
-	I
substituted	I
diphenylthiourea	I
derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
the	O
solvate	O
of	O
the	O
derivatives	O
or	O
salts	O
,	O
and	O
application	O
of	O
the	O
omega	B
-	I
carboxy	I
-	I
substituted	I
diphenylthiourea	I
derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
the	O
solvate	O
of	O
the	O
derivatives	O
or	O
salts	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
or	O
adjuvantly	O
treating	O
tyrosine	B
kinase	O
mediated	O
tumors	O
in	O
mammals	O
(	O
including	O
human	O
)	O
or	O
proliferation	O
and	O
migration	O
of	O
tyrosine	B
kinase	O
driven	O
tumor	O
cells	O
.	O

Omega	B
-	I
carboxy	I
-	I
substituted	I
diphenylthiourea	I
compounds	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

Chemical	O
entities	O
that	O
are	O
bufalin	B
derivatives	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
of	O
cancer	O
are	O
described	O
.	O

Bufalin	B
derivatives	O
,	O
pharmaceutical	O
compositions	O
and	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
an	O
azithromycin	B
pellet	O
,	O
and	O
relates	O
to	O
a	O
manufacture	O
technology	O
of	O
a	O
novel	O
azithromycin	B
preparation	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
uniformly	O
mixing	O
1	O
part	O
by	O
weight	O
of	O
azithromycin	B
and	O
0.5	O
to	O
30	O
parts	O
by	O
weight	O
of	O
auxiliary	O
material	O
;	O
adding	O
0.2	O
to	O
3	O
parts	O
by	O
weight	O
of	O
wetting	O
agent	O
to	O
prepare	O
a	O
pellet	O
core	O
;	O
and	O
drying	O
,	O
and	O
coating	O
the	O
pellet	O
core	O
to	O
realize	O
the	O
weight	O
of	O
the	O
pellet	O
core	O
to	O
be	O
gained	O
by	O
5	O
to	O
30	O
percent	O
.	O

The	O
azithromcin	B
pellet	O
prepared	O
by	O
the	O
preparation	O
method	O
is	O
easily	O
swallowed	O
and	O
not	O
bitter	O
,	O
can	O
be	O
used	O
as	O
an	O
intermediate	O
product	O
for	O
producing	O
granules	O
and	O
suspensions	O
,	O
or	O
directly	O
subpackged	O
into	O
finished	O
products	O
,	O
is	O
suitable	O
for	O
patients	O
with	O
difficulty	O
in	O
swallowing	O
,	O
and	O
is	O
especially	O
suitable	O
for	O
infants	O
if	O
being	O
added	O
with	O
proper	O
flavoring	O
agents	O
and	O
suspending	O
agents	O
.	O

Preparation	O
method	O
of	O
azithromycin	B
pellet	O

The	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
selectively	O
killing	O
tumor	O
stem	O
cells	O
and	O
a	O
use	O
thereof	O
.	O

Specifically	O
,	O
the	O
invention	O
discloses	O
a	O
use	O
of	O
a	O
monomer	O
component	O
isocorydin	B
(	O
ICD	B
)	O
of	O
a	O
dicranostigma	O
leptopodum	O
(	O
Maxmi	O
.	O
)	O

Fedde	O
(	O
DLF	O
)	O
alkaloid	B
,	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
.	O

The	O
monomer	O
component	O
ICD	B
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
be	O
used	O
for	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
tumors	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
inhibit	O
tumor	O
cell	O
proliferation	O
or	O
selectively	O
kill	O
tumor	O
stem	O
cells	O
.	O

Agent	O
for	O
selectively	O
killing	O
tumor	O
stem	O
cells	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
norfloxacin	B
and	O
borneol	B
composition	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicament	O
preparation	O
.	O

The	O
norfloxacin	B
and	O
borneol	B
composition	O
consists	O
of	O
norfloxacin	B
and	O
borneol	O
in	O
a	O
mass	O
ratio	O
of	O
1:0.1	O
-	O
1:10	O
,	O
preferably	O
1:1	O
.	O

The	O
composition	O
can	O
be	O
prepared	O
into	O
various	O
formulations	O
such	O
as	O
tablets	O
,	O
capsules	O
,	O
granules	O
,	O
sustained	O
-	O
release	O
agents	O
and	O
injection	O
with	O
medicinally	O
general	O
auxiliary	O
materials	O
by	O
adopting	O
a	O
conventional	O
medicament	O
preparation	O
method	O
.	O

The	O
composition	O
has	O
a	O
good	O
inhibiting	O
effect	O
on	O
multiple	O
medicament	O
-	O
resistant	O
bacteria	O
;	O
the	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
value	O
declines	O
in	O
order	O
of	O
magnitude	O
,	O
so	O
that	O
a	O
phenomenon	O
of	O
medicament	O
resistance	O
of	O
common	O
antibiotics	O
is	O
greatly	O
eliminated	O
;	O
and	O
the	O
composition	O
has	O
a	O
broad	O
application	O
prospect	O
.	O

Norfloxacin	B
and	O
borneol	B
composition	O

The	O
invention	O
relates	O
to	O
a	O
ketoprofen	B
osmotic	O
pump	O
type	O
controlled	O
release	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
ketoprofen	B
osmotic	O
pump	O
type	O
controlled	O
release	O
preparation	O
comprises	O
an	O
osmotic	O
pump	O
tablet	O
core	O
and	O
a	O
semipermeable	O
controlled	O
release	O
coat	O
film	O
coated	O
outside	O
the	O
tablet	O
core	O
,	O
wherein	O
the	O
osmotic	O
pump	O
tablet	O
core	O
comprises	O
a	O
remedium	O
cardinale	O
,	O
an	O
osmotic	O
active	O
substance	O
,	O
a	O
latent	O
solvent	O
,	O
a	O
retarding	O
agent	O
,	O
a	O
filling	O
agent	O
and	O
a	O
lubricating	O
agent	O
;	O
and	O
the	O
semipermeable	O
controlled	O
release	O
coat	O
film	O
comprises	O
a	O
coating	O
material	O
,	O
a	O
pore	O
-	O
foaming	O
agent	O
and	O
a	O
plasticizing	O
agent	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
osmotic	O
pump	O
type	O
controlled	O
release	O
preparation	O
.	O

The	O
ketoprofen	B
osmotic	O
pump	O
type	O
controlled	O
release	O
preparation	O
disclosed	O
by	O
the	O
invention	O
is	O
prepared	O
by	O
a	O
simple	O
conventional	O
preparation	O
method	O
of	O
general	O
tablets	O
and	O
is	O
mainly	O
characterized	O
in	O
that	O
a	O
single	O
-	O
layer	O
osmotic	O
pump	O
tablet	O
technology	O
is	O
applied	O
to	O
preparation	O
of	O
insoluble	O
drug	O
osmotic	O
pump	O
tablet	O
;	O
the	O
tablet	O
core	O
is	O
tabletted	O
by	O
adopting	O
a	O
conventional	O
method	O
without	O
determining	O
a	O
punching	O
surface	O
;	O
the	O
drug	O
release	O
is	O
safer	O
,	O
so	O
that	O
the	O
toxic	O
or	O
side	O
effects	O
and	O
the	O
administration	O
frequencies	O
of	O
the	O
drug	O
can	O
be	O
reduced	O
;	O
and	O
the	O
influence	O
on	O
the	O
drug	O
adsorption	O
due	O
to	O
food	O
intake	O
and	O
in	O
vivo	O
environment	O
can	O
be	O
avoided	O
,	O
and	O
thus	O
the	O
compliance	O
of	O
patients	O
is	O
improved	O
.	O

Ketoprofen	B
osmotic	O
pump	O
type	O
controlled	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
and	O
a	O
preparation	O
process	O
,	O
a	O
testing	O
process	O
and	O
an	O
application	O
thereof	O
.	O

The	O
composition	O
comprises	O
a	O
therapeutically	O
effective	O
amount	O
of	O
candesartan	B
or	O
pharmaceutically	O
acceptable	O
ester	B
or	O
salt	O
,	O
a	O
therapeutically	O
effective	O
amount	O
of	O
amlodipine	B
or	O
other	O
pharmaceutically	O
acceptable	O
salt	O
,	O
70	O
-	O
150	O
parts	O
of	O
mannitol	B
or	O
lactose	B
,	O
2	O
-	O
5	O
parts	O
of	O
croscarmellose	O
sodium	O
or	O
cross	O
-	O
calcium	O
carboxymethyl	O
cellulose	O
and	O
5	O
-	O
40	O
parts	O
of	O
microcrystalline	O
cellulose	O
or	O
corn	O
starch	O
.	O

The	O
composition	O
is	O
easy	O
to	O
prepare	O
,	O
low	O
in	O
production	O
cost	O
,	O
utilizes	O
accessories	O
of	O
unique	O
prescription	O
,	O
and	O
the	O
like	O
,	O
can	O
be	O
prepared	O
into	O
oral	O
preparation	O
in	O
forms	O
of	O
tablets	O
,	O
capsules	O
,	O
granules	O
and	O
the	O
like	O
by	O
means	O
of	O
pharmaceutics	O
,	O
can	O
be	O
checked	O
by	O
different	O
checking	O
processes	O
,	O
has	O
high	O
quality	O
,	O
has	O
functions	O
of	O
treating	O
hypertension	O
,	O
angina	O
pectoris	O
and	O
kidney	O
diseases	O
and	O
has	O
effect	O
of	O
myocardial	O
protection	O
.	O

Composition	O
containing	O
candesartan	B
and	O
amlodipine	B
,	O
preparation	O
process	O
,	O
testing	O
process	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
urea	B
compound	O
(	O
shown	O
in	O
figure	O
1	O
)	O
in	O
preparation	O
of	O
a	O
nicotinamide	B
phosphoribosyltransferase	O
inhibitor	O
.	O

The	O
invention	O
also	O
discloses	O
an	O
application	O
of	O
a	O
compound	O
I	O
in	O
preparation	O
of	O
medicines	O
for	O
prevention	O
and/or	O
treatment	O
of	O
cancer	O
.	O

The	O
invention	O
finds	O
a	O
fully	O
new	O
application	O
of	O
the	O
compound	O
I.	O
The	O
compound	O
I	O
shows	O
good	O
inhibiting	O
activity	O
on	O
nicotinamide	B
phosphoribosyltransferase	O
,	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
prevention	O
and/or	O
treatment	O
of	O
diseases	O
by	O
inhibiting	O
nicotinamide	B
phosphoribosyltransferase	O
,	O
and	O
also	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
cancer	O
.	O

Application	O
of	O
urea	B
compound	O

The	O
invention	O
discloses	O
novel	O
Cembrane	O
type	O
diterpenoids	B
with	O
anti	O
-	O
tumor	O
activities	O
.	O

In	O
vitro	O
anti	O
-	O
tumor	O
activity	O
study	O
shows	O
that	O
the	O
Cembrane	O
type	O
diterpenoids	B
have	O
strong	O
anti	O
-	O
tumor	O
activities	O
on	O
a	O
plurality	O
of	O
kinds	O
of	O
tumor	O
cells	O
including	O
gastric	O
cancer	O
,	O
colon	O
cancer	O
,	O
liver	O
cancer	O
or	O
renal	O
carcinoma	O
and	O
the	O
like	O
,	O
and	O
toxicity	O
test	O
study	O
shows	O
that	O
the	O
Cembrane	O
type	O
diterpenoids	B
with	O
anti	O
-	O
tumor	O
activities	O
have	O
low	O
toxicity	O
and	O
can	O
be	O
expected	O
to	O
be	O
developed	O
into	O
novel	O
antitumor	O
drugs	O
.	O

Cembrane	O
type	O
diterpenoids	B
with	O
anti	O
-	O
tumor	O
activities	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
tilmicosin	B
micro	O
-	O
capsule	O
preparation	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
tilmicosin	B
micro	O
-	O
capsule	O
preparation	O
and	O
a	O
preparation	O
method	O
of	O
the	O
tilmicosin	B
micro	O
-	O
capsule	O
preparation	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
veterinary	O
medicine	O
.	O

The	O
tilmicosin	B
micro	O
-	O
capsule	O
preparation	O
comprises	O
an	O
inner	O
core	O
layer	O
and	O
a	O
coating	O
layer	O
,	O
wherein	O
the	O
inner	O
core	O
layer	O
comprises	O
a	O
tilmicosin	B
raw	O
material	O
and	O
macromolecule	O
auxiliary	O
materials	O
,	O
the	O
macromolecule	O
auxiliary	O
materials	O
are	O
selected	O
from	O
one	O
or	O
more	O
than	O
one	O
of	O
12-carbon	B
fatty	I
acid-18-carbon	I
fatty	B
acid	I
,	O
paraffins	O
and	O
vegetable	O
wax	O
;	O
and	O
the	O
coating	O
layer	O
comprises	O
an	O
inner	O
coating	O
layer	O
and	O
an	O
outer	O
coating	O
layer	O
,	O
wherein	O
the	O
material	O
of	O
the	O
inner	O
coating	O
layer	O
is	O
one	O
or	O
more	O
than	O
one	O
of	O
starch	O
,	O
calcium	B
carbonate	I
and	O
calcium	B
hydrophosphate	I
,	O
and	O
the	O
material	O
of	O
the	O
outer	O
coating	O
layer	O
is	O
acrylic	O
resin	O
.	O

The	O
tilmicosin	B
micro	O
-	O
capsule	O
preparation	O
disclosed	O
by	O
the	O
invention	O
is	O
tasteless	O
,	O
enteric	O
,	O
and	O
good	O
in	O
palatability	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
tilmicosin	B
is	O
packed	O
by	O
the	O
macromolecule	O
auxiliary	O
materials	O
,	O
a	O
layer	O
of	O
enteric	O
coating	O
layer	O
is	O
sprayed	O
on	O
the	O
surfaces	O
of	O
the	O
tilmicosin	B
grains	O
in	O
the	O
process	O
of	O
rolling	O
circle	O
when	O
the	O
materials	O
are	O
prepared	O
,	O
and	O
the	O
strong	O
bitter	O
taste	O
and	O
odor	O
of	O
the	O
tilmicosin	B
can	O
be	O
completely	O
covered	O
due	O
to	O
the	O
double	O
-	O
layer	O
package	O
,	O
and	O
the	O
preparation	O
method	O
is	O
simple	O
in	O
technology	O
,	O
and	O
low	O
in	O
cost	O
.	O

Tilmicosin	B
micro	O
-	O
capsule	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
discloses	O
a	O
fullerene	O
lysine	B
derivative	O
C60-lys	O
and	O
its	O
preparation	O
method	O
and	O
use	O
in	O
radiation	O
damage	O
protection	O
.	O

The	O
fullerene	O
lysine	B
derivative	O
C60-lys	O
has	O
a	O
molecular	O
formula	O
of	O
C60	B
(	I
HNCH2CH2CH2CH2CH	I
(	I
NH2	I
)	I
COONa	I
)	I
6	I
(	I
H	I
)	I
6	I
.	O

Cytotoxicity	O
and	O
radiation	O
protection	O
experiments	O
of	O
C60-lys	O
to	O
AHH-1	O
prove	O
that	O
in	O
the	O
concentration	O
below	O
1200mg	O
/	O
L	O
,	O
C60-lys	O
has	O
basically	O
no	O
toxicity	O
to	O
a	O
human	O
lymphoma	O
parent	O
cell	O
AHH-1	O
;	O
and	O
in	O
a	O
safe	O
concentration	O
range	O
,	O
C60-lys	O
has	O
radiation	O
protection	O
effects	O
on	O
cells	O
,	O
wherein	O
the	O
optimal	O
concentration	O
of	O
C60-lys	O
for	O
radiation	O
protection	O
is	O
800mg	O
/	O
L.	O
Therefore	O
,	O
C60-lys	O
can	O
be	O
used	O
for	O
preparation	O
a	O
drug	O
for	O
radiation	O
damage	O
protection	O
.	O

The	O
preparation	O
method	O
of	O
C60-lys	O
is	O
simple	O
.	O

C60-lys	O
can	O
be	O
used	O
for	O
preparation	O
of	O
a	O
drug	O
for	O
radiation	O
damage	O
protection	O
by	O
large	O
-	O
scale	O
industrial	O
production	O
.	O

Fullerene	O
lysine	B
derivative	O
and	O
its	O
preparation	O
method	O
and	O
use	O
in	O
radiation	O
protection	O

Provided	O
herein	O
are	O
methods	O
of	O
treating	O
a	O
proliferative	O
disorder	O
in	O
a	O
subject	O
comprising	O
decreasing	O
interstitial	O
pressure	O
and/or	O
increasing	O
vascular	O
permeability	O
in	O
the	O
subject	O
and	O
administering	O
to	O
the	O
subject	O
an	O
oncolytic	O
virus	O
.	O

Such	O
methods	O
improve	O
oncolytic	O
viral	O
delivery	O
and	O
distribution	O
.	O

Modulating	O
interstitial	O
pressure	O
and	O
oncolytic	O
viral	O
delivery	O
and	O
distribution	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicines	O
,	O
and	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
shenxiong	O
glucose	B
injection	O
to	O
preparing	O
a	O
medicine	O
for	O
treating	O
pulmonary	O
hypertension	O
.	O

Clinically	O
,	O
the	O
used	O
amount	O
of	O
shenxiong	O
glucose	B
injection	O
is	O
200ml	O
for	O
general	O
intravenous	O
injection	O
,	O
once	O
for	O
one	O
day	O
and	O
14	O
days	O
for	O
one	O
treatment	O
course	O
.	O

The	O
application	O
is	O
characterized	O
in	O
that	O
the	O
systemic	O
blood	O
pressure	O
(	O
SBP	O
)	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
,	O
systolic	O
pulmonary	O
artery	O
pressure	O
(	O
sPAP	O
)	O
,	O
partial	O
pressure	O
of	O
oxygen	B
(	O
PO2	O
)	O
,	O
partial	O
pressure	O
of	O
carbon	B
dioxide	I
(	O
PCO2	O
)	O
and	O
the	O
condition	O
of	O
6min	O
walking	O
-	O
distance	O
test	O
of	O
a	O
patient	O
with	O
the	O
pulmonary	O
hypertension	O
are	O
monitored	O
,	O
and	O
by	O
contrast	O
observation	O
on	O
all	O
indexes	O
before	O
and	O
after	O
the	O
patient	O
with	O
the	O
pulmonary	O
hypertension	O
accepts	O
the	O
treatment	O
with	O
the	O
shenxiong	O
glucose	B
injection	O
,	O
the	O
shenxiong	O
glucose	B
injection	O
has	O
obvious	O
inhibitory	O
action	O
on	O
the	O
pulmonary	O
hypertension	O
by	O
injection	O
.	O

The	O
shenxiong	O
glucose	B
injection	O
can	O
be	O
used	O
as	O
an	O
ideal	O
medicine	O
for	O
treating	O
the	O
pulmonary	O
hypertension	O
disease	O
.	O

Application	O
of	O
shenxiong	O
glucose	B
injection	O
to	O
preparing	O
medicine	O
for	O
treating	O
pulmonary	O
hypertension	O

The	O
invention	O
discloses	O
applications	O
of	O
pharmorubicin	B
and	O
quercetin	B
to	O
preparation	O
of	O
an	O
anti	O
-	O
tumor	O
combined	O
medicament	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
combined	O
medicament	O
.	O

The	O
pharmorubicin	B
is	O
taken	O
as	O
an	O
anti	O
-	O
tumor	O
medicament	O
;	O
the	O
quercetin	B
is	O
taken	O
as	O
an	O
MDR	O
(	O
Multiple	O
Drug	O
Resistance	O
)	O
reversal	O
agent	O
of	O
the	O
pharmorubicin	B
;	O
PLGA	B
(	O
Poly	B
(	I
Lactic	I
-	I
Co	I
-	I
Glycolic	I
Acid	I
)	I
)	O
is	O
taken	O
as	O
nanoparticle	O
copolymer	O
material	O
;	O
compound	O
nanoparticles	O
of	O
pharmorubicin	B
and	O
quercetin	B
are	O
entrapped	O
during	O
preparation	O
,	O
so	O
that	O
a	O
certain	O
entrapment	O
efficiency	O
and	O
medicament	O
loading	O
amount	O
are	O
achieved	O
;	O
various	O
indexes	O
of	O
the	O
nanoparticles	O
are	O
used	O
for	O
evaluating	O
the	O
property	O
of	O
the	O
medicament	O
;	O
and	O
an	O
in	O
-	O
vitro	O
cell	O
test	O
is	O
used	O
for	O
evaluating	O
the	O
reversed	O
multi	O
-	O
medicament	O
resistance	O
effect	O
of	O
the	O
medicament	O
.	O

EPI	B
-	I
QC	I
(	O
Epichlorohydrin	B
-	I
QC	I
)	O
compound	O
nanoparticles	O
are	O
prepared	O
by	O
adopting	O
an	O
emulsified	O
solvent	O
evaporation	O
method	O
;	O
and	O
according	O
to	O
research	O
on	O
a	O
comparison	O
system	O
,	O
the	O
EPI	B
-	I
QC	I
compound	O
nanoparticles	O
can	O
be	O
used	O
for	O
reverting	O
the	O
medicament	O
tolerance	O
of	O
tumor	O
cells	O
in	O
a	O
certain	O
degree	O
,	O
and	O
the	O
toxicity	O
on	O
normal	O
cells	O
is	O
lowered	O
.	O

Anti	O
-	O
tumor	O
combined	O
medicament	O

The	O
invention	O
discloses	O
an	O
oligo	O
(	O
ethylene	B
glycol	I
)	O
modified	O
chlorambucil	B
medicine	O
.	O

The	O
structural	O
formula	O
of	O
the	O
short	O
-	O
chain	O
polyethylene	B
glycol	I
modified	O
chlorambucil	B
medicine	O
is	O
shown	O
as	O
a	O
formula	O
I	O
;	O
and	O
in	O
the	O
formula	O
I	O
,	O
the	O
number	O
-	O
average	O
molar	O
mass	O
of	O
oligo	O
(	O
ethylene	B
glycol	I
)	O
(	O
OEG	O
)	O
segments	O
is	O
198	O
-	O
1,998	O
.	O

The	O
medicine	O
is	O
an	O
amphiphilic	O
anti	O
-	O
cancer	O
medicine	O
,	O
can	O
be	O
self	O
-	O
assembled	O
to	O
form	O
nanoparticles	O
in	O
water	O
or	O
a	O
buffer	O
solution	O
,	O
has	O
long	O
blood	O
circulation	O
time	O
,	O
can	O
target	O
tumors	O
through	O
ultra	O
permeability	O
and	O
enhanced	O
permeation	O
and	O
retention	O
(	O
EPR	O
)	O
effect	O
and	O
can	O
effectively	O
target	O
cancer	O
tissues	O
through	O
the	O
EPR	O
effect	O
of	O
the	O
tumors	O
;	O
and	O
compared	O
with	O
other	O
chlorambucil	B
medicine	O
systems	O
,	O
the	O
chlorambucil	B
medicine	O
has	O
the	O
advantages	O
of	O
high	O
medicine	O
loading	O
rate	O
,	O
high	O
druggability	O
and	O
the	O
like	O
and	O
is	O
expected	O
to	O
be	O
used	O
for	O
clinical	O
treatment	O
of	O
various	O
tumors	O
.	O

Oligo	O
(	O
ethylene	B
glycol	I
)	O
modified	O
chlorambucil	B
nanomedicine	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
chitosan	O
-	O
supported	O
hydroxycamptothecine	B
-	O
quantum	O
dot	O
FRET	O
(	O
Fluorescence	O
Resonance	O
Energy	O
Transfer	O
)	O
composite	O
probe	O
.	O

In	O
the	O
probe	O
,	O
a	O
quantum	O
dot	O
with	O
a	O
certain	O
wavelength	O
is	O
coupled	O
with	O
hydroxycamptothecine	B
serving	O
as	O
an	O
anticancer	O
medicament	O
,	O
so	O
that	O
a	O
composite	O
structure	O
with	O
a	O
fluorescence	O
resonance	O
energy	O
transfer	O
characteristic	O
is	O
formed	O
;	O
and	O
the	O
composite	O
probe	O
with	O
an	O
FRET	O
characteristic	O
is	O
expressed	O
under	O
the	O
excitation	O
of	O
ultraviolet	O
light	O
or	O
visible	O
light	O
.	O

The	O
composite	O
probe	O
has	O
the	O
beneficial	O
effects	O
:	O
energy	O
is	O
transferred	O
onto	O
hydroxycamptothecine	B
by	O
establishing	O
a	O
hydroxycamptothecine	B
-	O
quantum	O
dot	O
FRET	O
composite	O
structure	O
,	O
so	O
that	O
the	O
fluorescence	O
intensity	O
of	O
hydroxycamptothecine	B
is	O
increased	O
,	O
and	O
a	O
fluorescence	O
in	O
-	O
situ	O
expression	O
characteristic	O
for	O
reacting	O
with	O
cancer	O
cells	O
is	O
realized	O
;	O
the	O
acting	O
process	O
and	O
distribution	O
rule	O
of	O
the	O
composite	O
probe	O
in	O
each	O
region	O
of	O
a	O
tumor	O
cancer	O
cell	O
are	O
observed	O
through	O
the	O
fluorescence	O
action	O
of	O
the	O
composite	O
probe	O
in	O
a	O
targeted	O
delivery	O
process	O
;	O
and	O
the	O
FRET	O
system	O
of	O
the	O
composite	O
probe	O
is	O
damaged	O
in	O
the	O
releasing	O
and	O
tumor	O
cancer	O
cell	O
acting	O
processes	O
of	O
hydroxycamptothecine	B
,	O
the	O
fluorescence	O
of	O
a	O
quantum	O
dot	O
is	O
recovered	O
gradually	O
,	O
and	O
in	O
-	O
situ	O
real	O
-	O
time	O
dynamic	O
monitoring	O
of	O
the	O
acting	O
process	O
of	O
hydroxycamptothecine	B
and	O
tumor	O
cancer	O
cells	O
can	O
be	O
realized	O
indirectly	O
by	O
monitoring	O
information	O
such	O
as	O
the	O
fluorescence	O
intensity	O
change	O
magnitude	O
,	O
change	O
rate	O
and	O
the	O
like	O
of	O
the	O
quantum	O
dot	O
.	O

Chitosan	O
-	O
supported	O
hydroxycamptothecine	B
-	O
quantum	O
dot	O
FRET	O
(	O
Fluorescence	O
Resonance	O
Energy	O
Transfer	O
)	O
composite	O
probe	O

The	O
invention	O
discloses	O
an	O
amorphous	O
peramivir	B
crystal	O
form	O
.	O

The	O
chemical	O
purity	O
and	O
the	O
crystal	O
form	O
purity	O
of	O
the	O
amorphous	O
peramivir	B
are	O
both	O
more	O
than	O
95	O
percent	O
,	O
and	O
the	O
amorphous	O
peramivir	B
does	O
not	O
contain	O
crystal	O
water	O
or	O
other	O
crystal	O
solvents	O
;	O
and	O
meanwhile	O
,	O
the	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
for	O
the	O
amorphous	O
peramivir	B
,	O
and	O
further	O
discloses	O
a	O
medicinal	O
composition	O
containing	O
the	O
amorphous	O
peramivir	B
,	O
and	O
application	O
of	O
the	O
composition	O
to	O
preparation	O
of	O
medicines	O
for	O
treating	O
influenza	O
virus	O
and	O
influenza	O
virus	O
.	O

Amorphous	O
peramivir	B
,	O
preparation	O
method	O
thereof	O
and	O
medicinal	O
composition	O

The	O
invention	O
discloses	O
a	O
solid	O
form	O
containing	O
(	B
+	I
)	I
-2-	I
[	I
1-	I
(	I
3-oxethyl-4-methoxyphenyl	I
)	I
-2-methylsulfonylethyl	I
]	I
-4-acetylaminoisoindoline-1,3-dione	I
,	O
a	O
composition	O
containing	O
the	O
solid	O
form	O
,	O
a	O
method	O
for	O
preparing	O
the	O
solid	O
form	O
and	O
an	O
application	O
method	O
thereof	O
.	O

The	O
method	O
comprises	O
a	O
treatment	O
and/or	O
prevention	O
method	O
capable	O
of	O
improving	O
disease	O
symptoms	O
by	O
lowering	O
TNF	O
-	O
alpha	O
level	O
or	O
inhibiting	O
PDE4	O
.	O

Solid	O
form	O
containing	O
(	B
+	I
)	I
-2-	I
[	I
1-	I
(	I
3-oxethyl-4-methoxyphenyl	I
)	I
-2-methylsulfonylethyl	I
]	I
-4-acetylaminoisoindoline-1,3-dione	I
,	O
composition	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
organic	O
medicament	O
eutectics	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
eutectic	O
of	O
two	O
curcumin	B
organic	O
medicaments	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Curcumin	B
is	O
used	O
a	O
medicinal	O
active	O
ingredient	O
,	O
and	O
4	B
,	I
4'-bipyridine	I
-	I
N	I
,	I
N'-dioxide	I
is	O
used	O
as	O
a	O
eutectic	O
precursor	O
.	O

The	O
curcumin	B
and	O
the	O
4	B
,	I
4'-bipyridine	I
-	I
N	I
,	I
N'-dioxide	I
,	O
ethanol	B
and	O
acetone	B
or	O
carbinol	B
and	O
the	O
acetone	B
are	O
put	O
in	O
a	O
small	O
transparent	O
glass	O
bottle	O
together	O
,	O
and	O
solid	O
content	O
of	O
a	O
reaction	O
system	O
is	O
5	O
-	O
15mg	O
/	O
mL	O
;	O
the	O
small	O
transparent	O
glass	O
bottle	O
is	O
positioned	O
on	O
a	O
stirrer	O
,	O
and	O
the	O
stirrer	O
works	O
for1	O
-	O
5	O
hours	O
at	O
the	O
room	O
temperature	O
;	O
and	O
after	O
the	O
stirring	O
is	O
ended	O
,	O
the	O
small	O
transparent	O
glass	O
bottle	O
is	O
positioned	O
in	O
a	O
drying	O
oven	O
at	O
50	O
-	O
70	O
DEC	O
for	O
12	O
-	O
48	O
hours	O
and	O
then	O
taken	O
out	O
,	O
and	O
bulk	O
crystals	O
are	O
precipitated	O
after	O
the	O
small	O
transparent	O
glass	O
bottle	O
is	O
laid	O
aside	O
for	O
20	O
-	O
40	O
hours	O
at	O
the	O
room	O
temperature	O
.	O

The	O
pharmacological	O
activity	O
of	O
the	O
curcumin	O
is	O
inherited	O
by	O
the	O
eutectic	O
disclosed	O
by	O
the	O
invention	O
,	O
and	O
the	O
dissolubility	O
,	O
the	O
stability	O
and	O
the	O
bioavailability	O
of	O
the	O
eutectic	O
are	O
obviously	O
improved	O
.	O

Eutectic	O
of	O
two	O
curcumin	B
organic	O
medicaments	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
zeamays	O
L.	O
polysaccharide	O
,	O
a	O
preparation	O
method	O
,	O
and	O
an	O
application	O
of	O
the	O
zeamays	O
L.	O
polysaccharide	O
in	O
the	O
preparation	O
of	O
medicaments	O
for	O
reducing	O
blood	O
sugar	B
.	O

The	O
zeamays	O
L.	O
polysaccharide	O
of	O
the	O
invention	O
can	O
be	O
separated	O
,	O
extracted	O
,	O
and	O
purified	O
from	O
zeamays	O
L.	O
by	O
a	O
simple	O
and	O
effective	O
polysaccharide	O
extraction	O
technology	O
and	O
method	O
.	O

Pharmacological	O
experiments	O
show	O
that	O
the	O
zeamays	O
L.	O
polysaccharide	O
has	O
significant	O
in	O
-	O
vivo	O
blood	O
sugar	B
reducing	O
activity	O
.	O

Zeamays	O
L.	O
polysaccharide	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
Cladosporium	O
Sp	O
.	O

XJ	O
-	O
AC03	O
which	O
is	O
preserved	O
in	O
China	O
center	O
for	O
type	O
culture	O
collection	O
under	O
the	O
number	O
of	O
CCTCC	O
NO.M2011483	O
on	O
December	O
26	O
2011	O
.	O

A	O
bacterial	O
colony	O
of	O
the	O
Cladosporium	O
Sp	O
.	O

XJ	O
-	O
AC03	O
is	O
circular	O
with	O
white	O
regular	O
edge	O
.	O

The	O
bacterial	O
colony	O
is	O
in	O
milk	O
white	O
early	O
in	O
culture	O
,	O
and	O
gradually	O
turns	O
gray	O
to	O
deep	O
grayish	O
green	O
over	O
time	O
,	O
and	O
the	O
center	O
of	O
the	O
bacterial	O
colony	O
project	O
slightly	O
.	O

Mycelia	O
of	O
the	O
Cladosporium	O
Sp	O
.	O

XJ	O
-	O
AC03	O
have	O
transverse	O
septa	O
without	O
longitudinal	O
septa	O
and	O
are	O
dense	O
.	O

Certain	O
mycelia	O
have	O
conidiophore	O
which	O
is	O
branched	O
.	O

The	O
conidiophore	O
is	O
olivary	O
with	O
brown	O
to	O
dark	O
brown	O
color	O
and	O
is	O
concentrated	O
with	O
0	O
-	O
3	O
septa	O
.	O

The	O
Cladosporium	O
Sp	O
.	O

XJ	O
-	O
AC03	O
is	O
obtained	O
from	O
root	O
of	O
Xinjiang	O
Aconitum	O
leucostomum	O
by	O
artificial	O
separating	O
and	O
screening	O
.	O

The	O
Cladosporium	O
Sp	O
.	O

XJ	O
-	O
AC03	O
of	O
aconitine	O
can	O
be	O
synthesized	O
effectively	O
,	O
and	O
can	O
be	O
used	O
as	O
material	O
for	O
preparing	O
antineoplastic	O
drugs	O
,	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
and	O
anti	O
-	O
rheumatic	O
drugs	O
.	O

Cladosporium	O
Sp	O
.	O

XJ	O
-	O
AC03	O
and	O
application	O
thereof	O

This	O
invention	O
relates	O
to	O
modulation	O
of	O
the	O
alpha	O
7	O
nicotinic	O
acetylcholine	B
receptor	O
(	O
nAChR	O
)	O
by	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
:	O
wherein	O
R1	O
is	O
imidazolyl	B
,	O
pyridinyl	B
or	O
pyrimidinyl	B
,	O
any	O
of	O
which	O
is	O
optionally	O
substituted	O
by	O
one	O
group	O
independently	O
selected	O
from	O
C1	B
-	I
3alkyl	I
and	O
C1	B
-	I
3alkoxy	I
.	O

Indole	B
derivative	O
modulators	O
of	O
the	O
alpha	O
7	O
nAChR	O

The	O
invention	O
discloses	O
a	O
cefditoren	B
pivoxil	I
liposome	O
solid	O
preparation	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
active	O
ingredient	O
namely	O
cefditoren	B
pivoxil	I
and	O
a	O
specific	O
combination	O
of	O
soybean	O
phosphatidylserine	O
,	O
cholesterol	B
,	O
and	O
polyoxyethylene	B
alkylamine	I
are	O
prepared	O
into	O
liposome	O
,	O
so	O
the	O
stability	O
,	O
dissolution	O
property	O
and	O
bioavailability	O
of	O
the	O
preparation	O
are	O
greatly	O
improved	O
,	O
and	O
moreover	O
,	O
the	O
preparation	O
has	O
a	O
stable	O
and	O
lasting	O
effect	O
,	O
small	O
side	O
effects	O
and	O
obvious	O
efficacy	O
.	O

Cefditoren	B
pivoxil	I
liposome	O
solid	O
preparation	O

The	O
invention	O
discloses	O
an	O
extract	O
of	O
eclipta	O
alba	O
,	O
a	O
method	O
for	O
extracting	O
and	O
separating	O
the	O
extract	O
from	O
the	O
eclipta	O
alba	O
and	O
an	O
application	O
of	O
the	O
extract	O
of	O
the	O
eclipta	O
alba	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
soaking	O
the	O
dry	O
powder	O
of	O
the	O
eclipta	O
alba	O
in	O
methanol	O
for	O
5	O
-	O
10	O
days	O
,	O
extracting	O
and	O
filtering	O
for	O
0	O
-	O
10	O
times	O
and	O
preferentially	O
1	O
-	O
3	O
times	O
,	O
and	O
mixing	O
filtrate	O
,	O
wherein	O
the	O
proportion	O
of	O
the	O
dry	O
powder	O
of	O
the	O
eclipta	O
alba	O
to	O
the	O
methanol	B
is	O
1	O
:	O
(	O
6	O
-	O
10	O
)	O
;	O
and	O
(	O
2	O
)	O
concentrating	O
the	O
filtrate	O
under	O
reduced	O
pressure	O
to	O
obtain	O
the	O
methanol	O
extract	O
of	O
the	O
eclipta	O
alba	O
.	O

The	O
extract	O
of	O
the	O
eclipta	O
alba	O
can	O
be	O
used	O
for	O
inhibiting	O
the	O
appearance	O
of	O
TGF	O
-	O
beta	O
(	O
transforming	O
growth	O
factor	O
beta	O
)	O
effectively	O
so	O
as	O
to	O
prevent	O
the	O
alopecia	O
and	O
promote	O
the	O
hair	O
growth	O
and	O
can	O
be	O
applied	O
to	O
the	O
pharmaceutical	O
compositions	O
and	O
the	O
cosmetics	O
.	O

Extract	O
of	O
eclipta	O
alba	O
,	O
method	O
for	O
extracting	O
and	O
separating	O
extract	O
from	O
eclipta	O
alba	O
and	O
application	O
of	O
extract	O
of	O
eclipta	O
alba	O

The	O
invention	O
relates	O
to	O
a	O
slowly	O
-	O
releasing	O
anticancer	O
drug	O
composition	O
and	O
application	O
thereof	O
.	O

The	O
slowly	O
-	O
releasing	O
anticancer	O
drug	O
composition	O
comprises	O
,	O
by	O
weight	O
,	O
70	O
%	O
to	O
99.9	O
%	O
of	O
effective	O
anticancer	O
components	O
and	O
0.1	O
%	O
to	O
30	O
%	O
of	O
slowly	O
-	O
releasing	O
excipients	O
,	O
wherein	O
the	O
molecular	O
structures	O
of	O
the	O
effective	O
anticancer	O
components	O
simultaneously	O
comprise	O
functional	O
groups	O
which	O
can	O
release	O
nitric	B
oxide	I
and	O
hydrogen	B
sulfide	I
.	O

The	O
slowly	O
-	O
releasing	O
excipients	O
comprise	O
any	O
one	O
or	O
more	O
compound	O
of	O
a	O
poly	B
lactic	I
acid	I
,	O
a	O
polyglycolic	B
acid	I
and	O
glycolic	B
acid	I
copolymer	O
,	O
an	O
ethene	B
acetate	I
ethyl	I
copolymer	O
and	O
a	O
polifeprosan	B
.	O

The	O
ability	O
of	O
the	O
slowly	O
-	O
releasing	O
anticancer	O
drug	O
composition	O
provided	O
by	O
the	O
invention	O
to	O
inhibit	O
proliferation	O
of	O
10	O
kinds	O
of	O
cancer	O
cells	O
is	O
about	O
90000	O
times	O
of	O
aspirin	B
.	O

The	O
toxicity	O
is	O
quite	O
small	O
,	O
and	O
the	O
effect	O
time	O
of	O
the	O
drug	O
can	O
reach	O
13	O
hours	O
.	O

Slowly	O
-	O
releasing	O
anticancer	O
drug	O
composition	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
carbazochrome	B
sodium	I
sulfonate	I
compound	O
and	O
a	O
composition	O
thereof	O
.	O

The	O
carbazochrome	B
sodium	I
sulfonate	I
compound	O
is	O
measured	O
by	O
a	O
powder	O
X	O
-	O
ray	O
diffraction	O
measurement	O
method	O
;	O
and	O
the	O
diffraction	O
angle	O
of	O
2	O
theta	O
+	O
/-	O

0.2	O
degrees	O
can	O
be	O
used	O
for	O
showing	O
that	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
pattern	O
has	O
characteristic	O
diffraction	O
peaks	O
at	O
the	O
parts	O
including	O
10.23	O
degrees	O
,	O
12.12	O
degrees	O
,	O
18.39	O
degrees	O
,	O
22.32	O
degrees	O
,	O
24.79	O
degrees	O
,	O
26.23	O
degrees	O
,	O
28.60	O
degrees	O
,	O
30.25	O
degrees	O
,	O
31.98	O
degrees	O
,	O
33.32	O
degrees	O
,	O
34.32	O
degrees	O
and	O
36.02	O
degrees	O
.	O

The	O
carbazochrome	B
sodium	I
sulfonate	I
compound	O
provided	O
by	O
the	O
invention	O
has	O
the	O
remarkably	O
improved	O
stability	O
and	O
does	O
not	O
change	O
after	O
being	O
placed	O
for	O
a	O
long	O
time	O
,	O
so	O
that	O
the	O
drug	O
safety	O
of	O
patients	O
can	O
be	O
greatly	O
improved	O
.	O

Carbazochrome	B
sodium	I
sulfonate	I
compound	O
and	O
composition	O
thereof	O

The	O
invention	O
provides	O
a	O
nano	O
-	O
silver	B
emulsifiable	O
paste	O
and	O
its	O
preparation	O
method	O
and	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
.	O

The	O
nano	O
-	O
silver	B
emulsifiable	O
paste	O
is	O
an	O
O	O
/	O
W	O
type	O
emulsifiable	O
paste	O
or	O
W	O
/	O
O	O
type	O
emulsifiable	O
paste	O
which	O
is	O
prepared	O
by	O
a	O
certain	O
preparation	O
technology	O
with	O
nano	O
-	O
silver	B
being	O
used	O
as	O
a	O
main	O
drug	O
.	O

The	O
nano	O
-	O
silver	B
emulsifiable	O
paste	O
can	O
be	O
used	O
for	O
treating	O
infection	O
of	O
infected	O
wounds	O
and	O
body	O
surface	O
chronic	O
ulcer	O
(	O
venous	O
ulcer	O
,	O
pressure	O
ulcer	O
and	O
the	O
like	O
)	O
caused	O
by	O
burn	O
and	O
scald	O
and	O
physical	O
and	O
mechanical	O
damage	O
and	O
for	O
promoting	O
healing	O
of	O
the	O
wounds	O
.	O

The	O
O	O
/	O
W	O
type	O
emulsifiable	O
paste	O
is	O
similar	O
to	O
a	O
moistening	O
burn	O
cream	O
and	O
can	O
provide	O
burn	O
and	O
scald	O
wounds	O
with	O
a	O
moistening	O
environment	O
which	O
is	O
beneficial	O
to	O
tissue	O
regeneration	O
.	O

Simultaneously	O
,	O
due	O
to	O
specific	O
high	O
antibacterial	O
activity	O
and	O
good	O
wound	O
heating	O
promotion	O
effect	O
of	O
the	O
nano	O
-	O
silver	B
,	O
the	O
nano	O
-	O
silver	B
emulsifiable	O
paste	O
is	O
better	O
than	O
the	O
moistening	O
burn	O
cream	O
;	O
and	O
in	O
comparison	O
with	O
sulfadiazine	B
silver	I
and	O
other	O
external	O
-	O
use	O
anti	O
-	O
infection	O
drugs	O
,	O
the	O
nano	O
-	O
silver	O
emulsifiable	O
paste	O
is	O
beneficial	O
to	O
wound	O
healing	O
,	O
has	O
no	O
bacterial	O
drug	O
resistance	O
and	O
has	O
high	O
antibacterial	O
activity	O
.	O

Nano	O
-	O
silver	B
emulsifiable	O
paste	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmaceuticals	O
,	O
and	O
in	O
particular	O
relates	O
to	O
an	O
emulsifiable	O
paste	O
for	O
treating	O
non	O
-	O
infectious	O
inflammatory	O
dermatosis	O
.	O

Every	O
100	O
parts	O
by	O
weight	O
of	O
emulsifiable	O
paste	O
contains	O
0.025	O
-	O
0.2	O
part	O
by	O
weight	O
of	O
halometasone	B
monohydrate	I
or	O
hydrate	B
thereof	O
and	O
2.5	O
-	O
25	O
parts	O
by	O
weight	O
of	O
polyethylene	B
glycol-7	I
stearates	I
.	O

The	O
emulsifiable	O
paste	O
further	O
comprises	O
one	O
or	O
a	O
plurality	O
of	O
pharmaceutically	O
acceptable	O
consistence	O
regulator	O
,	O
pharmaceutically	O
acceptable	O
acidoid	O
,	O
pharmaceutically	O
acceptable	O
preservative	O
and	O
pharmaceutically	O
acceptable	O
alkaline	O
pH	O
regulator	O
.	O

According	O
to	O
the	O
emulsifiable	O
paste	O
,	O
related	O
substances	O
in	O
the	O
emulsifiable	O
paste	O
can	O
be	O
obviously	O
inhibited	O
from	O
being	O
increased	O
,	O
so	O
the	O
emulsifiable	O
paste	O
has	O
better	O
thermal	O
stability	O
compared	O
with	O
products	O
on	O
the	O
market	O
.	O

Emulsifiable	O
paste	O
for	O
treating	O
non	O
-	O
infectious	O
inflammatory	O
dermatosis	O
and	O
method	O
for	O
preparing	O
emulsifiable	O
paste	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
with	O
a	O
first	O
active	O
medicament	O
and	O
a	O
second	O
active	O
medicament	O
,	O
and	O
an	O
application	O
thereof	O
for	O
preparing	O
a	O
medicament	O
for	O
treating	O
type	O
II	O
diabetes	O
.	O

Preparation	O
with	O
first	O
active	O
medicament	O
and	O
second	O
active	O
medicament	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
preparation	O
containing	O
levocarnitine	B
and	O
hydroxyphenyl	B
sulfonate	I
.	O

The	O
medicinal	O
preparation	O
can	O
be	O
an	O
injection	O
or	O
of	O
preparation	O
types	O
which	O
can	O
be	O
taken	O
orally	O
,	O
such	O
as	O
granules	O
,	O
capsules	O
,	O
tablets	O
or	O
oral	O
liquid	O
;	O
and	O
in	O
the	O
medicinal	O
preparation	O
,	O
the	O
mass	O
ratio	O
of	O
levocarnitine	B
to	O
hydroxyphenyl	B
sulfonate	I
is	O
about	O
1:10	O
-	O
10:1	O
,	O
preferably	O
about	O
1:3	O
-	O
3:1	O
,	O
more	O
preferably	O
about	O
1:2	O
-	O
2:1	O
,	O
and	O
most	O
preferably	O
1:1	O
.	O

Medicinal	O
composition	O
containing	O
levocarnitine	B
and	O
hydroxyphenyl	B
sulfonate	I

The	O
present	O
invention	O
discloses	O
a	O
use	O
of	O
silymarin	B
in	O
preparations	O
of	O
drugs	O
for	O
prevention	O
or	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
.	O

When	O
silymarin	B
is	O
used	O
for	O
treatment	O
or	O
prevention	O
of	O
human	O
or	O
mammalian	O
Alzheimer	O
's	O
diseases	O
,	O
the	O
silymarin	B
can	O
be	O
adopted	O
as	O
the	O
drug	O
separately	O
,	O
and	O
can	O
further	O
be	O
combined	O
with	O
other	O
drugs	O
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
,	O
wherein	O
action	O
mechanisms	O
of	O
other	O
drugs	O
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
are	O
different	O
to	O
the	O
action	O
mechanism	O
of	O
the	O
silymarin	B
,	O
and	O
the	O
drug	O
combination	O
can	O
provide	O
effects	O
of	O
reducing	O
of	O
toxic	O
and	O
side	O
effects	O
of	O
drugs	O
and	O
synergistic	O
therapeutic	O
effect	O
.	O

The	O
silymarin	B
can	O
significantly	O
inhibit	O
beta	O
amyloid	O
deposition	O
,	O
and	O
provides	O
definite	O
therapeutic	O
effect	O
and	O
low	O
side	O
effects	O
for	O
prevention	O
or	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
so	O
as	O
to	O
provide	O
broad	O
medicine	O
application	O
prospects	O
.	O

Use	O
of	O
silymarin	B
in	O
preparations	O
of	O
drugs	O
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
rheumatoid	O
arthritis	O
,	O
which	O
is	O
composed	O
of	O
Radix	O
Astragali	O
,	O
Chinese	O
angelica	O
,	O
white	O
peony	O
root	O
,	O
Ligusticum	O
wallichii	O
,	O
caulis	O
piperis	O
kadsurae	O
,	O
orienavine	O
,	O
homalomena	O
occulta	O
,	O
processed	O
Semen	O
Strychni	O
,	O
speranskia	O
herb	O
,	O
processed	O
monkshood	O
,	O
processed	O
radix	O
aconiti	O
agrestis	O
,	O
Asarum	O
Herb	O
,	O
Villous	O
Amomum	O
Fruit	O
,	O
sangusis	O
draconis	O
,	O
musk	O
and	O
borneol	B
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
conventional	O
auxiliary	O
material	O
is	O
added	O
in	O
the	O
pharmaceutical	O
composition	O
according	O
to	O
a	O
conventional	O
technology	O
to	O
prepare	O
the	O
clinically	O
acceptable	O
tablets	O
,	O
capsules	O
,	O
particulate	O
agents	O
,	O
pills	O
,	O
powders	O
or	O
oral	O
liquids	O
.	O

The	O
pharmaceutical	O
composition	O
for	O
treating	O
rheumatoid	O
arthritis	O
possesses	O
substantial	O
effect	O
,	O
and	O
no	O
toxic	O
and	O
side	O
-	O
effect	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
rheumatoid	O
arthritis	O

The	O
present	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
tumor	O
drug	O
composition	O
and	O
an	O
application	O
thereof	O
,	O
a	O
kit	O
and	O
a	O
package	O
.	O

The	O
drug	O
composition	O
,	O
the	O
kit	O
and	O
the	O
package	O
comprise	O
a	O
therapeutically	O
effective	O
amount	O
of	O
mannatide	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
cantharidinate	B
sodium	I
,	O
wherein	O
the	O
mannatide	O
and	O
the	O
cantharidinate	B
sodium	I
are	O
adopted	O
as	O
combined	O
preparations	O
,	O
and	O
provided	O
for	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
use	O
.	O

When	O
the	O
drug	O
composition	O
,	O
the	O
kit	O
and	O
the	O
package	O
in	O
the	O
present	O
invention	O
are	O
used	O
for	O
treating	O
tumors	O
,	O
excellent	O
treatment	O
effects	O
can	O
be	O
provided	O
,	O
and	O
various	O
toxic	O
and	O
side	O
-	O
effects	O
are	O
low	O
.	O

Anti	O
-	O
tumor	O
drug	O
composition	O
and	O
application	O
thereof	O
,	O
kit	O
and	O
package	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
specifically	O
to	O
thymol	B
ester	I
compounds	O
(	O
I	O
)	O
,	O
its	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

It	O
is	O
proved	O
through	O
a	O
pharmacology	O
experiment	O
that	O
the	O
thymol	B
ester	I
compounds	O
(	O
I	O
)	O
provided	O
by	O
the	O
invention	O
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
treating	O
or	O
preventing	O
diseases	O
caused	O
by	O
bacteria	O
or	O
diseases	O
caused	O
by	O
fungi	O
and	O
can	O
be	O
also	O
used	O
to	O
prepare	O
animal	O
feed	O
additives	O
or	O
drinking	O
water	O
tonifying	O
formula	O
for	O
treating	O
,	O
mitigating	O
or	O
preventing	O
necrotic	O
enteritis	O
caused	O
by	O
Shigella	O
species	O
,	O
clostridium	O
and	O
Clostridium	O
perfringens	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
derivatives	O
and	O
their	O
pharmaceutical	O
composition	O
.	O

Thymol	B
ester	I
derivatives	O
,	O
its	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
hericium	O
erinaceum	O
biological	O
micro	O
-	O
molecules	O
for	O
inhibiting	O
helicobacter	O
pylori	O
and	O
a	O
use	O
thereof	O
,	O
and	O
especially	O
relates	O
to	O
compounds	O
shown	O
in	O
the	O
formulas	O
I	O
and	O
II	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compounds	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
alcohol	B
extract	O
of	O
a	O
hericium	O
erinaceum	O
culture	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
ethyl	B
acetate	I
extract	O
of	O
the	O
alcohol	B
extract	O
,	O
a	O
food	O
additive	O
,	O
and	O
a	O
food	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
use	O
of	O
the	O
compounds	O
or	O
the	O
extract	O
in	O
treatment	O
or	O
prevention	O
of	O
helicobacter	O
pylori	O
-	O
mediated	O
diseases	O
.	O

Hericium	O
erinaceum	O
biological	O
micro	O
-	O
molecules	O
for	O
inhibiting	O
helicobacter	O
pylori	O
and	O
use	O
of	O
the	O
hericium	O
erinaceum	O
biological	O
micro	O
-	O
molecules	O
in	O
treatment	O
of	O
digestive	O
tract	O
diseases	O

The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
tumor	O
compound	O
containing	O
a	O
benzothiazole	B
heterocyclic	I
structure	O
and	O
application	O
of	O
the	O
anti	O
-	O
tumor	O
compound	O
,	O
which	O
belong	O
to	O
the	O
technical	O
field	O
of	O
biological	O
organic	O
synthesis	O
.	O

The	O
compound	O
provided	O
by	O
the	O
invention	O
is	O
characterized	O
in	O
that	O
a	O
benzothiazole	B
ring	O
is	O
connected	O
on	O
a	O
naphthalimide	B
matrix	O
structure	O
by	O
means	O
of	O
a	O
side	O
chain	O
through	O
Vilsmeier	O
reaction	O
,	O
ring	O
formation	O
,	O
oxidation	O
and	O
nucleophilic	O
reaction	O
.	O

This	O
type	O
of	O
compound	O
has	O
wide	O
anti	O
-	O
tumor	O
activity	O
,	O
and	O
has	O
stronger	O
effect	O
in	O
inhibiting	O
normal	O
growth	O
of	O
various	O
tumor	O
cells	O
.	O

Anti	O
-	O
tumor	O
compound	O
containing	O
benzothiazole	B
heterocyclic	I
structure	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
dibutyltin	B
coordination	O
compound	O
,	O
a	O
preparation	O
method	O
of	O
the	O
dibutyltin	B
coordination	O
compound	O
and	O
application	O
of	O
the	O
dibutyltin	B
coordination	O
compound	O
.	O

The	O
structural	O
formula	O
of	O
the	O
dibutyltin	B
coordination	O
compound	O
is	O
shown	O
in	O
the	O
specification	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
adding	O
1mmol	O
of	O
2-phenoxypropionic	B
acid	I
,	O
0.1	O
-	O
1.5mmol	O
of	O
potassium	B
hydroxide	I
,	O
0.5	O
-	O
1.5mmol	O
of	O
dibutyltin	B
dichloride	I
and	O
20	O
-	O
30ml	O
of	O
methanol	B
into	O
a	O
container	O
,	O
stirring	O
and	O
refluxing	O
for	O
6	O
-	O
7	O
hours	O
at	O
the	O
room	O
temperature	O
,	O
and	O
then	O
carrying	O
out	O
rotary	O
evaporation	O
to	O
obtain	O
a	O
faint	O
yellow	O
solid	O
;	O
and	O
recrystallizing	O
by	O
using	O
dichloromethane	B
-	O
petroleum	B
ether	I
to	O
obtain	O
faint	O
yellow	O
transparent	O
crystal	O
,	O
i.e.	O
the	O
dibutyltin	B
coordination	O
compound	O
,	O
wherein	O
the	O
volume	O
ratio	O
of	O
the	O
dichloromethane	B
to	O
the	O
petroleum	B
ether	I
is	O
1:1	O
-	O
2:1	O
.	O

The	O
application	O
of	O
the	O
dibutyltin	B
coordination	O
compound	O
lies	O
in	O
preparing	O
medicaments	O
for	O
treating	O
human	O
ileocecum	O
adenocarcinoma	O
,	O
human	O
lung	O
adenocarcinoma	O
and	O
human	O
colon	O
cancer	O
.	O

The	O
organic	O
dibutyltin	B
coordination	O
compound	O
has	O
the	O
characteristics	O
of	O
high	O
anti	O
-	O
cancer	O
activity	O
,	O
good	O
fat	O
solubility	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
,	O
and	O
the	O
like	O
and	O
provides	O
a	O
new	O
approach	O
for	O
developing	O
anti	O
-	O
cancer	O
medicaments	O
.	O

Dibutyltin	O
coordination	O
compound	O
,	O
preparation	O
method	O
of	O
dibutyltin	B
coordination	O
compound	O
and	O
application	O
of	O
ibutyltin	B
coordination	O
compound	O

The	O
invention	O
provides	O
timolol	B
hydrogenmaleate	I
eye	O
drops	O
,	O
comprising	O
timolol	B
hydrogenmaleate	I
,	O
an	O
isotonizing	O
agent	O
,	O
a	O
thickener	O
,	O
and	O
a	O
stabilizing	O
agent	O
,	O
wherein	O
glycerol	B
is	O
used	O
as	O
the	O
isotonizing	O
agent	O
,	O
the	O
thickener	O
and	O
the	O
stabilizing	O
agent	O
and	O
plays	O
a	O
stabilizing	O
role	O
in	O
the	O
timolol	B
hydrogenmaleate	I
eye	O
drops	O
since	O
glycerol	O
has	O
osmosis	O
and	O
thickening	O
functions	O
.	O

According	O
to	O
the	O
invention	O
,	O
glycerol	B
is	O
used	O
as	O
the	O
isotonizing	O
agent	O
,	O
the	O
thickener	O
and	O
the	O
stabilizing	O
agent	O
,	O
and	O
the	O
effect	O
that	O
one	O
raw	O
material	O
has	O
multiple	O
functions	O
is	O
achieved	O
,	O
so	O
that	O
the	O
timolol	B
hydrogenmaleate	I
eye	O
drops	O
can	O
be	O
produced	O
conveniently	O
and	O
can	O
be	O
applied	O
comfortably	O
without	O
irritation	O
;	O
moreover	O
,	O
since	O
glycerol	O
which	O
is	O
used	O
as	O
the	O
isotonizing	O
agent	O
,	O
the	O
thickener	O
and	O
the	O
stabilizing	O
agent	O
in	O
the	O
timolol	B
hydrogenmaleate	I
eye	O
drops	O
,	O
the	O
stability	O
of	O
the	O
medicine	O
is	O
increased	O
and	O
the	O
clinical	O
functions	O
of	O
the	O
timolol	B
hydrogenmaleate	I
eye	O
drops	O
are	O
ensured	O
.	O

In	O
addition	O
,	O
the	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
timolol	B
hydrogenmaleate	I
eye	O
drops	O
.	O

Timolol	B
hydrogenmaleate	I
eye	O
drops	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
application	O
of	O
a	O
curcumin	B
chitosan	O
-	O
stearic	B
acid	I
graft	O
micelle	O
.	O

According	O
to	O
the	O
invention	O
,	O
curcumin	B
is	O
used	O
as	O
a	O
bulk	O
drug	O
,	O
and	O
a	O
graft	O
formed	O
by	O
chitosan	O
oligosaccharide	B
and	O
stearic	B
acid	I
is	O
used	O
as	O
a	O
drug	O
carrier	O
;	O
the	O
preparation	O
method	O
comprises	O
a	O
first	O
step	O
of	O
carrying	O
out	O
covalent	O
binding	O
on	O
chitosan	O
oligosaccharide	B
and	O
stearic	B
acid	I
under	O
the	O
action	O
of	O
the	O
cross	O
-	O
linking	O
agent	O
of	O
carbodiimide	B
so	O
as	O
to	O
form	O
a	O
chitosan	O
oligosaccharide	B
-	O
stearic	B
acid	I
graft	O
(	O
CSO	O
-	O
SA	O
)	O
carrier	O
and	O
a	O
second	O
step	O
of	O
adding	O
a	O
certain	O
amount	O
of	O
a	O
curcumin	B
DMSO	O
solution	O
into	O
a	O
solution	O
of	O
the	O
CSO	O
-	O
SA	O
carrier	O
and	O
carrying	O
out	O
complexation	O
to	O
form	O
a	O
CSO	O
-	O
SA	O
/	O
curcumin	B
drug	O
-	O
loaded	O
nanometer	O
micelle	O
.	O

The	O
micelle	O
prepared	O
in	O
the	O
invention	O
has	O
an	O
average	O
particle	O
size	O
of	O
114.7	O
nm	O
and	O
a	O
Zeta	O
potential	O
of	O
18.5	O
mV.	O
In	O
-	O
vivo	O
and	O
in-	O
In	O
-	O
vivo	O
tests	O
show	O
that	O
CSO	O
-	O
SA	O
/	O
curcumin	B
has	O
strong	O
cellular	O
internalization	O
capacity	O
,	O
can	O
improve	O
accumulation	O
of	O
curcumin	B
in	O
tumor	O
cells	O
and	O
has	O
a	O
strong	O
killing	O
effect	O
on	O
MCF-7	O
,	O
MCF-7	O
/	O
Adr	O
and	O
colorectal	O
cancer	O
cells	O
.	O

In	O
-	O
vivo	O
administration	O
enables	O
selective	O
inhibition	O
of	O
growth	O
of	O
tumor	O
cells	O
to	O
be	O
realized	O
while	O
no	O
obvious	O
toxic	O
effect	O
is	O
exerted	O
on	O
mice	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
curcumin	B
chitosan	O
-	O
stearic	B
acid	I
graft	O
micelle	O

The	O
invention	O
relates	O
to	O
a	O
parasite	O
expelling	O
tablet	O
for	O
domestic	O
animals	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
parasite	O
expelling	O
tablet	O
for	O
domestic	O
animals	O
comprises	O
3	O
to	O
8	O
parts	O
by	O
weight	O
of	O
abamectin	B
,	O
2	O
to	O
6	O
parts	O
by	O
weight	O
of	O
ivermectin	B
,	O
0.2	O
to	O
0.8	O
parts	O
by	O
weight	O
of	O
garlicin	B
and	O
45	O
to	O
100.3	O
parts	O
by	O
weight	O
of	O
auxiliary	O
materials	O
.	O

Through	O
the	O
combination	O
of	O
garlicin	B
,	O
abamectin	B
and	O
ivermectin	B
,	O
the	O
parasite	O
expelling	O
tablet	O
for	O
domestic	O
animals	O
can	O
effectively	O
kill	O
parasites	O
in	O
bodies	O
of	O
domestic	O
animals	O
,	O
and	O
has	O
effects	O
of	O
diminishing	O
inflammation	O
,	O
killing	O
germs	O
,	O
improving	O
body	O
immunity	O
,	O
conditioning	O
intestines	O
and	O
stomach	O
,	O
and	O
preventing	O
gastroenteritis	O
.	O

Parasite	O
expelling	O
tablet	O
for	O
domestic	O
animals	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
oral	O
administration	O
preparation	O
comprising	O
the	O
dry	O
granules	O
of	O
Limaprost	B
or	O
Limaprost	O
alpha	O
cyclodextrin	O
with	O
improved	O
stability	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
the	O
dry	O
granules	O
comprising	O
Limaprost	B
or	O
Limaprost	O
alpha	O
cyclodextrin	O
as	O
well	O
as	O
the	O
microcellac	O
or	O
cellactose	O
as	O
the	O
carrier	O
.	O

The	O
invention	O
further	O
comprises	O
the	O
medicine	O
composition	O
containing	O
the	O
dry	O
granules	O
and	O
the	O
oral	O
administration	O
preparation	O
containing	O
the	O
composition	O
with	O
improved	O
stability	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
the	O
oral	O
administration	O
.	O

Medicine	O
composition	O
containing	O
limaprost	O
with	O
improved	O
stability	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
escin	O
B	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
which	O
is	O
prepared	O
from	O
a	O
therapeutic	O
dose	O
of	O
main	O
medicament	O
and	O
pharmaceutically	O
-	O
acceptable	O
latent	O
solvent	O
and	O
freeze	O
-	O
dried	O
excipient	O
.	O

The	O
escin	O
B	O
freeze	O
-	O
dried	O
powder	O
injection	O
prepared	O
according	O
to	O
a	O
prescription	O
mixture	O
ratio	O
and	O
a	O
preparation	O
process	O
provided	O
by	O
the	O
invention	O
has	O
the	O
characteristics	O
of	O
high	O
re	O
-	O
dissolving	O
property	O
,	O
stable	O
quality	O
and	O
high	O
compatibility	O
computability	O
with	O
conventional	O
transfusion	O
.	O

The	O
escin	B
B	I
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
used	O
for	O
treating	O
various	O
inflammatory	O
and	O
traumatic	O
edemas	O
.	O

Escin	B
B	I
freeze	O
-	O
dried	O
powder	O
injection	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
dihydroartemisinin	B
sesquioxide	B
germanium	I
compound	O
and	O
a	O
preparation	O
method	O
as	O
well	O
as	O
an	O
application	O
thereof	O
.	O

The	O
structural	O
formula	O
of	O
the	O
dihydroartemisinin	B
sesquioxide	B
germanium	I
compound	O
is	O
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
;	O
and	O
the	O
dihydroartemisinin	B
sesquioxide	B
germanium	I
compound	O
includes	O
a	O
Ge-132	O
backbone	O
with	O
antineoplastic	O
activity	O
and	O
a	O
dihydroartemisinin	B
backbone	O
with	O
antineoplastic	O
activity	O
,	O
and	O
plays	O
dual	O
antineoplastic	O
activity	O
of	O
Ge-132	O
and	O
dihydroartemisinin	B
.	O

Experiments	O
proves	O
that	O
the	O
dihydroartemisinin	B
sesquioxide	B
germanium	I
compound	O
has	O
higher	O
activity	O
than	O
dihydroartemisinin	B
and	O
Ge-132	O
,	O
and	O
has	O
a	O
good	O
application	O
prospect	O
in	O
the	O
preparation	O
of	O
anti	O
-	O
tumor	O
,	O
antimalarial	O
,	O
antibacterial	O
,	O
or	O
immunomodulatory	O
drugs	O
.	O

Dihydroartemisinin	B
sesquioxide	B
germanium	I
compound	O
and	O
preparation	O
method	O
as	O
well	O
as	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
,	O
and	O
relates	O
to	O
2,3-diaryl	B
thiazolidine-4-one	I
/	O
-thioketone	B
compounds	O
and	O
oxides	B
thereof	O
.	O

The	O
structures	O
of	O
the	O
compounds	O
are	O
shown	O
below	O
:	O
wherein	O
,	O
X	O
is	O
O	B
,	O
or	O
S	B
;	O
n	O
is	O
0	O
,	O
1	O
,	O
or	O
2	O
;	O
when	O
A	O
ring	O
is	O
any	O
ring	O
selected	O
from	O
I	O
to	O
IV	O
,	O
B	O
ring	O
is	O
any	O
ring	O
selected	O
from	O
V	O
to	O
VII	O
;	O
when	O
B	O
ring	O
is	O
any	O
ring	O
selected	O
from	O
I	O
to	O
IV	O
,	O
A	O
ring	O
is	O
any	O
ring	O
selected	O
from	O
V	O
to	O
VII	O
;	O
Y	O
among	O
I	O
to	O
IV	O
represents	O
atoms	O
or	O
functional	O
groups	O
selected	O
from	O
methoxy	B
,	O
ethoxy	B
,	O
hydroxy	B
,	O
halogens	B
,	O
nitryl	B
,	O
amino	B
,	O
benzyloxy	B
,	O
etc	O
.	O
;	O
and	O
R1	O
-	O
R13	O
are	O
respectively	O
selected	O
from	O
hydrogen	B
,	O
methoxy	B
,	O
hydroxy	B
,	O
halogen	B
atoms	O
,	O
nitryl	B
,	O
amino	B
or	O
benzyloxy	B
,	O
or	O
the	O
adjacent	O
two	O
substituents	O
can	O
be	O
-OCH2O-	B
or	O
-CH	B
=	I
CH	I
-	I
NH-	I
,	O
thereby	O
forming	O
a	O
five	O
-	O
membered	O
ring	O
.	O

Pharmacological	O
activity	O
test	O
results	O
show	O
that	O
the	O
derivatives	O
have	O
good	O
anti	O
-	O
tumor	O
activities	O
and	O
can	O
be	O
used	O
as	O
tumor	O
cell	O
proliferation	O
inhibitors	O
in	O
the	O
application	O
of	O
anti	O
-	O
tumor	O
medicine	O
preparation	O
.	O

2,3-diaryl	B
thiazolidine-4-one	I
/	O
-thioketone	B
compounds	O
,	O
oxides	B
thereof	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
ribavirin	B
granules	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
A	O
,	O
after	O
respectively	O
screening	O
a	O
prescription	O
dose	O
of	O
ribavirin	B
,	O
saccharose	B
and	O
vanillin	B
by	O
a	O
screen	O
of	O
100	O
meshes	O
,	O
and	O
uniformly	O
mixing	O
;	O
B	O
,	O
carrying	O
out	O
dry	O
granulating	O
for	O
a	O
mixture	O
obtained	O
in	O
the	O
step	O
A	O
;	O
and	O
C	O
,	O
screening	O
the	O
granules	O
with	O
a	O
particle	O
size	O
of	O
16	O
-	O
40	O
meshes	O
in	O
the	O
step	O
B	O
,	O
detecting	O
the	O
content	O
of	O
a	O
midbody	O
,	O
and	O
split	O
charging	O
to	O
obtain	O
the	O
necessary	O
ribavirin	B
granules	O
.	O

The	O
method	O
provided	O
by	O
the	O
invention	O
is	O
ingenious	O
in	O
concept	O
and	O
simple	O
in	O
process	O
,	O
and	O
the	O
dry	O
granulating	O
is	O
utilized	O
,	O
therefore	O
,	O
a	O
production	O
period	O
of	O
the	O
ribavirin	B
granules	O
can	O
be	O
reduced	O
,	O
production	O
efficiency	O
can	O
be	O
improved	O
,	O
a	O
problem	O
of	O
low	O
finished	O
product	O
yield	O
can	O
be	O
solved	O
,	O
and	O
production	O
cost	O
can	O
be	O
greatly	O
reduced	O
.	O

Method	O
for	O
preparing	O
ribavirin	B
granules	O

Belonging	O
to	O
the	O
technical	O
field	O
of	O
drug	O
processing	O
,	O
the	O
invention	O
relates	O
to	O
application	O
of	O
dihydromyricetin	B
in	O
preparation	O
of	O
a	O
drug	O
preventing	O
and	O
treating	O
influenza	O
,	O
and	O
solves	O
the	O
problem	O
of	O
preventing	O
and	O
treating	O
influenza	O
with	O
dihydromyricetin	B
.	O

Application	O
of	O
dihydromyricetin	B
in	O
preparation	O
of	O
the	O
drug	O
preventing	O
and	O
treating	O
influenza	O
has	O
the	O
advantages	O
of	O
good	O
anti	O
-	O
influenza	O
virus	O
effect	O
,	O
remarkable	O
curative	O
effect	O
,	O
and	O
no	O
toxic	O
or	O
side	O
effect	O
.	O

The	O
preparation	O
method	O
of	O
the	O
influenza	O
drug	O
consists	O
of	O
:	O
mixing	O
dihydromyricetin	B
with	O
starch	O
uniformly	O
,	O
adding	O
a	O
starch	O
slurry	O
and	O
conducting	O
stirring	O
to	O
prepare	O
a	O
soft	O
material	O
,	O
carrying	O
out	O
granulation	O
,	O
and	O
performing	O
drying	O
,	O
then	O
adding	O
aerosol	O
,	O
implementing	O
grain	O
finishing	O
and	O
tabletting	O
so	O
as	O
to	O
obtain	O
1000	O
tablets	O
,	O
each	O
of	O
which	O
weighs	O
about	O
0.5	O
g	O
.	O

Application	O
of	O
dihydromyricetin	B
in	O
preparation	O
of	O
drug	O
preventing	O
and	O
treating	O
influenza	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
alopecia	O
areata	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medicament	O
is	O
mainly	O
prepared	O
from	O
black	O
sesame	O
,	O
prepared	O
rehmannia	O
,	O
mulberry	O
,	O
medlar	O
,	O
polygonum	O
multiflorum	O
,	O
manyflower	O
solomonseal	O
rhizome	O
,	O
red	O
ocher	O
,	O
safflower	O
,	O
glossy	O
privet	O
fruit	O
,	O
angelica	O
root	O
,	O
suberect	O
spatholobus	O
stem	O
and	O
black	O
soybean	O
in	O
a	O
certain	O
weight	O
proportion	O
.	O

The	O
medicament	O
has	O
the	O
functions	O
of	O
nourishing	O
blood	O
and	O
promoting	O
blood	O
circulation	O
,	O
removing	O
stasis	O
and	O
dredging	O
collaterals	O
,	O
tonifying	O
kidney	O
and	O
promoting	O
hair	O
growth	O
,	O
and	O
blackening	O
hair	O
and	O
beard	O
,	O
and	O
has	O
the	O
advantages	O
of	O
short	O
treatment	O
course	O
,	O
quick	O
response	O
,	O
no	O
toxic	O
or	O
side	O
effect	O
in	O
treating	O
alopecia	O
areata	O
.	O

Medicament	O
for	O
treating	O
alopecia	O
areata	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
bio	O
-	O
medicines	O
,	O
and	O
discloses	O
application	O
of	O
a	O
medicament	O
of	O
target	O
adenosine	B
receptor	O
A2BAR	O
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
or	O
treating	O
autoimmune	O
diseases	O
.	O

Studies	O
discover	O
that	O
:	O
compared	O
with	O
a	O
healthy	O
wild	O
mouse	O
,	O
the	O
expression	O
of	O
adenosine	B
receptor	O
A2BAR	O
in	O
the	O
immune	O
tissue	O
in	O
an	O
EAE	O
(	O
Experimental	O
Autoimmune	O
Encephalomyelitis	O
)	O
mouse	O
is	O
up	O
-	O
regulated	O
.	O

After	O
two	O
antagonists	O
of	O
the	O
adenosine	B
receptor	O
A2BAR	O
,	O
CVT-6883	O
and	O
MRS-1754	O
are	O
administrated	O
to	O
the	O
EAE	O
mouse	O
,	O
the	O
onset	O
time	O
of	O
the	O
EAE	O
mouse	O
is	O
delayed	O
,	O
the	O
attack	O
symptom	O
is	O
relieved	O
,	O
the	O
attack	O
rate	O
is	O
reduced	O
,	O
and	O
infiltration	O
of	O
CNS	O
(	O
central	O
nervous	O
system	O
)	O
inflammatory	O
cells	O
is	O
reduced	O
.	O

The	O
application	O
has	O
the	O
advantages	O
that	O
the	O
expression	O
of	O
the	O
adenosine	O
receptor	O
A2BAR	O
in	O
an	O
MS	O
(	O
metabolic	O
syndrome	O
)	O
patient	O
and	O
an	O
animal	O
model	O
EAE	O
thereof	O
is	O
up	O
-	O
regulated	O
,	O
the	O
antagonist	O
CVT-6883	O
of	O
the	O
adenosine	B
receptor	O
A2BAR	O
can	O
be	O
used	O
for	O
effectively	O
relieving	O
the	O
EAE	O
attach	O
symptom	O
.	O

At	O
present	O
,	O
the	O
antagonist	O
CVT-6883	O
of	O
the	O
adenosine	B
receptor	O
A2BAR	O
is	O
used	O
in	O
clinical	O
experimental	O
medicament	O
for	O
treating	O
asthma	O
,	O
has	O
great	O
possibility	O
in	O
serving	O
as	O
a	O
medicament	O
for	O
treating	O
MS	O
diseases	O
,	O
and	O
provides	O
a	O
new	O
action	O
target	O
and	O
medicinal	O
source	O
for	O
treating	O
MS	O
diseases	O
.	O

Application	O
of	O
medicament	O
of	O
target	O
adenosine	B
receptor	O
A2BAR	O
in	O
preparing	O
medicament	O
for	O
preventing	O
or	O
treating	O
autoimmune	O
diseases	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
treating	O
epilepsia	O
and	O
especially	O
relates	O
to	O
a	O
magnesium	B
valproate	I
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
magnesium	B
valproate	I
injection	O
comprises	O
:	O
by	O
weight	O
,	O
0.5	O
to	O
10	O
%	O
of	O
magnesium	B
valproate	I
,	O
0	O
to	O
5.0	O
%	O
of	O
ammonium	B
chloride	I
,	O
0	O
to	O
5.0	O
%	O
of	O
citric	B
acid	I
,	O
89	O
to	O
99.9	O
%	O
of	O
injection	O
water	O
,	O
0	O
to	O
95	O
%	O
of	O
ethanol	B
and	O
0	O
to	O
95	O
%	O
of	O
propylene	B
glycol	I
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
dissolving	O
magnesium	B
valproate	I
in	O
injection	O
water	O
or	O
ethanol	B
,	O
dissolving	O
ammonium	B
chloride	I
and	O
citric	B
acid	I
in	O
the	O
mixed	O
solution	O
,	O
adding	O
an	O
appropriate	O
amount	O
of	O
activated	O
carbon	B
into	O
the	O
mixture	O
,	O
carrying	O
out	O
heat	O
preservation	O
at	O
a	O
temperature	O
of	O
60	O
to	O
90	O
DEG	O
C	O
for	O
about	O
30	O
minutes	O
,	O
carrying	O
out	O
pumping	O
filtration	O
,	O
adding	O
injection	O
water	O
or	O
ethanol	B
or	O
propylene	B
glycol	I
into	O
the	O
filtrate	O
according	O
to	O
content	O
requirements	O
,	O
filtering	O
by	O
a	O
microporous	O
filter	O
membrane	O
,	O
carrying	O
out	O
loading	O
and	O
packaging	O
in	O
nitrogen	B
flows	O
so	O
that	O
each	O
2	O
to	O
100ml	O
of	O
the	O
magnesium	B
valproate	I
injection	O
is	O
put	O
into	O
a	O
bottle	O
,	O
and	O
carrying	O
out	O
sterilization	O
by	O
steam	O
flows	O
having	O
a	O
temperature	O
of	O
100	O
DEG	O
C	O
for	O
30	O
minutes	O
.	O

Clarity	O
,	O
a	O
pH	O
value	O
,	O
osmotic	O
pressure	O
,	O
undue	O
toxicity	O
,	O
hemolysis	O
and	O
stability	O
tests	O
of	O
a	O
medicinal	O
injection	O
for	O
people	O
prove	O
that	O
the	O
magnesium	B
valproate	I
injection	O
satisfies	O
human	O
use	O
requirements	O
.	O

An	O
animal	O
pharmacokinetic	O
test	O
proves	O
that	O
the	O
magnesium	B
valproate	I
injection	O
can	O
be	O
absorbed	O
fast	O
and	O
can	O
enter	O
into	O
brain	O
tissue	O
fast	O
.	O

Magnesium	B
valproate	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
ulifloxacin	B
water	O
-	O
soluble	O
salt	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pH	O
value	O
of	O
the	O
injection	O
is	O
4.5	O
-	O
7.5	O
;	O
1000ml	O
of	O
the	O
injection	O
contains	O
1	O
-	O
30	O
g	O
of	O
a	O
ulifloxacin	B
water	O
-	O
soluble	O
salt	O
,	O
0.1	O
-	O
1.0mol	O
of	O
a	O
cosolvent	O
,	O
and	O
0.1	O
-	O
10mmol	O
of	O
a	O
pH	O
adjustment	O
agent	O
,	O
and	O
the	O
preferable	O
content	O
of	O
the	O
ulifloxacin	B
water	O
-	O
soluble	O
salt	O
is	O
1	O
-	O
5	O
g	O
;	O
and	O
the	O
ulifloxacin	B
water	O
-	O
soluble	O
salt	O
is	O
a	O
compound	O
generated	O
by	O
reacting	O
ulifloxacin	B
with	O
a	O
mixture	O
containing	O
one	O
or	O
more	O
than	O
two	O
of	O
inorganic	O
acids	O
,	O
a	O
compound	O
generated	O
by	O
reacting	O
ulifloxacin	B
with	O
a	O
mixture	O
containing	O
one	O
or	O
more	O
than	O
two	O
of	O
organic	O
acids	O
,	O
or	O
a	O
compound	O
generated	O
by	O
reacting	O
ulifloxacin	B
with	O
a	O
mixture	O
containing	O
one	O
or	O
more	O
than	O
two	O
of	O
alkaline	B
metal	I
and	O
alkaline	B
earth	I
metal	I
compounds	O
.	O

The	O
ulifloxacin	B
water	O
-	O
soluble	O
salt	O
injection	O
prepared	O
in	O
the	O
invention	O
has	O
a	O
better	O
water	O
solubility	O
than	O
ulifloxacin	B
,	O
overcomes	O
the	O
disadvantages	O
of	O
no	O
solubility	O
in	O
water	O
and	O
low	O
biological	O
availability	O
of	O
ulifloxacin	B
,	O
and	O
has	O
a	O
stable	O
and	O
controllable	O
quality	O
.	O

Ulifloxacin	B
water	O
-	O
soluble	O
salt	O
injection	O

The	O
invention	O
provides	O
an	O
isoniazid	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
medicine	O
preparation	O
methods	O
,	O
and	O
mainly	O
solves	O
the	O
problem	O
that	O
a	O
common	O
isoniazid	B
preparation	O
in	O
the	O
prior	O
art	O
is	O
poor	O
in	O
curative	O
effect	O
and	O
inapplicable	O
to	O
children	O
and	O
patients	O
having	O
difficulty	O
in	O
swallowing	O
.	O

The	O
isoniazid	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
is	O
prepared	O
from	O
components	O
including	O
,	O
by	O
weight	O
,	O
25%-60	O
%	O
of	O
isoniazid	B
,	O
40%-75	O
%	O
of	O
mannitol	B
,	O
2%-4	O
%	O
of	O
gelatin	B
,	O
0.1%-0.15	O
%	O
of	O
sucralose	B
and	O
45%-70	O
%	O
of	O
water	O
for	O
injection	O
.	O

The	O
isoniazid	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
prepared	O
from	O
the	O
components	O
according	O
to	O
the	O
weight	O
percent	O
is	O
simple	O
in	O
preparation	O
process	O
and	O
composition	O
,	O
is	O
applicable	O
to	O
the	O
children	O
and	O
the	O
patients	O
having	O
difficulty	O
in	O
swallowing	O
,	O
and	O
has	O
the	O
advantages	O
of	O
rapidness	O
in	O
disintegration	O
and	O
effectiveness	O
,	O
sufficiency	O
in	O
medicine	O
absorption	O
,	O
convenience	O
in	O
taking	O
,	O
fine	O
taste	O
and	O
avoidance	O
of	O
the	O
first	O
-	O
pass	O
effect	O
of	O
livers	O
.	O

Isoniazid	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
rifampicin	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
medicine	O
preparation	O
methods	O
,	O
and	O
mainly	O
solves	O
the	O
problem	O
that	O
a	O
common	O
rifampicin	B
preparation	O
is	O
excessive	O
in	O
first	O
-	O
pass	O
effect	O
and	O
strong	O
in	O
side	O
effect	O
after	O
repeated	O
administration	O
,	O
and	O
is	O
difficultly	O
swallowed	O
by	O
old	O
people	O
and	O
children	O
.	O

The	O
rifampicin	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
is	O
prepared	O
from	O
components	O
including	O
,	O
by	O
weight	O
,	O
30%-60	O
%	O
of	O
rifampicin	B
,	O
25%-70	O
%	O
of	O
mannitol	B
,	O
2%-4	O
%	O
of	O
gelatin	O
,	O
0.1%-0.15	O
%	O
of	O
sucralose	B
and	O
50%-70	O
%	O
of	O
tert	B
-	I
butanol	I
-	O
water	O
.	O

The	O
rifampicin	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
prepared	O
from	O
the	O
components	O
according	O
to	O
the	O
weight	O
percent	O
is	O
simple	O
in	O
preparation	O
process	O
and	O
composition	O
,	O
mainly	O
aims	O
to	O
meet	O
the	O
administration	O
requirements	O
of	O
the	O
children	O
,	O
and	O
has	O
the	O
advantages	O
of	O
rapidness	O
in	O
disintegration	O
and	O
effectiveness	O
,	O
sufficiency	O
in	O
medicine	O
absorption	O
,	O
convenience	O
in	O
taking	O
,	O
fine	O
taste	O
and	O
avoidance	O
of	O
the	O
first	O
-	O
pass	O
effect	O
of	O
livers	O
.	O

Rifampicin	B
composition	O
freeze	O
-	O
dried	O
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicines	O
and	O
discloses	O
a	O
triptolide	B
and	O
chinese	O
brake	O
herb	O
general	O
flavone	B
combined	O
medicinal	O
composition	O
and	O
preparation	O
and	O
application	O
thereof	O
.	O

The	O
medicinal	O
composition	O
is	O
prepared	O
by	O
uniformly	O
mixing	O
1	O
weight	O
part	O
of	O
triptolide	B
and	O
10<-3	O
>	O
to	O
10<5	O
>	O
weight	O
part	O
of	O
chinese	O
brake	O
herb	O
general	O
flavone	B
.	O

The	O
chinese	O
brake	O
herb	O
general	O
flavone	B
is	O
prepared	O
from	O
chinese	O
brake	O
herb	O
through	O
ethanol	B
solution	O
extraction	O
,	O
organic	O
solvent	O
distribution	O
,	O
and	O
macroporous	O
resin	O
and	O
polyamide	B
column	O
refining	O
.	O

The	O
medicinal	O
composition	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
medicines	O
for	O
treating	O
rheumatoid	O
arthritis	O
,	O
anti	O
-	O
tumor	O
medicines	O
,	O
immunosuppression	O
medicines	O
,	O
and	O
anti	O
-	O
inflammatory	O
medicines	O
.	O

Triptolide	B
and	O
chinese	O
brake	O
herb	O
general	O
flavone	B
combined	O
medicinal	O
composition	O
and	O
preparation	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
antiplatelet	O
drugs	O
and	O
provides	O
1,4-disubstituted	B
piperazine	I
derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
1,4-disubstituted	B
piperazine	I
derivatives	O
have	O
a	O
general	O
structural	O
formula	O
I.	O
In	O
the	O
general	O
structural	O
formula	O
I	O
,	O
x	O
,	O
y	O
,	O
m	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
defined	O
in	O
the	O
patent	O
specification	O
.	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
1,4-disubstituted	B
piperazine	I
derivatives	O
,	O
discloses	O
a	O
drug	O
composition	O
containing	O
the	O
1,4-disubstituted	B
piperazine	I
derivatives	O
or	O
their	O
pharmaceutically	O
acceptable	O
salts	O
as	O
active	O
ingredients	O
,	O
and	O
also	O
discloses	O
a	O
use	O
of	O
the	O
1,4-disubstituted	B
piperazine	I
derivatives	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
in	O
antiplatelet	O
drugs	O
.	O

1,4-disubstituted	B
piperazine	I
derivatives	O
and	O
their	O
preparation	O
method	O
and	O
use	O

The	O
invention	O
provides	O
a	O
novel	O
azole	B
antifungal	O
compound	O
.	O

According	O
to	O
the	O
azole	B
antifungal	O
compound	O
,	O
a	O
structural	O
general	O
formula	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
X	O
is	O
hydroxyl	B
,	O
Ar	B
is	O
2,4-difluoro	B
phenyl	I
,	O
and	O
R	O
is	O
selected	O
from	O
hydrogen	B
,	O
alkyl	B
,	O
halogen	B
,	O
cyano	B
-	O
group	O
,	O
nitryl	B
,	O
amino	B
or	O
alkoxy	B
and	O
can	O
be	O
positioned	O
at	O
the	O
ortho	O
-	O
position	O
,	O
meta	O
-	O
position	O
or	O
para	O
-	O
position	O
of	O
a	O
benzene	B
ring	O
and	O
can	O
be	O
mono	O
-	O
substituted	O
or	O
multi	O
-	O
substituted	O
;	O
the	O
alkyl	B
has	O
1	O
to	O
4	O
carbon	B
atoms	O
;	O
the	O
halogen	B
is	O
selected	O
from	O
F	B
,	O
Cl	B
,	O
Br	B
and	O
I	B
;	O
the	O
amino	O
is	O
selected	O
from	O
-NH2	B
,	O
one	O
or	O
two	O
aminos	B
substituted	O
by	O
the	O
alkyl	B
and	O
cyclic	B
amino	I
;	O
and	O
the	O
alkoxy	B
is	O
selected	O
from	O
methoxyl	B
,	O
ethyoxyl	B
and	O
tert	B
-	I
butyl	I
oxygroup	I
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
and	O
application	O
of	O
the	O
compound	O
to	O
preparation	O
of	O
antifungal	O
medicines	O
.	O

Compared	O
with	O
the	O
conventional	O
antifungal	O
medicines	O
which	O
are	O
applied	O
clinically	O
,	O
the	O
azole	B
antifungal	O
compound	O
has	O
the	O
advantages	O
of	O
high	O
antifungal	O
activity	O
on	O
invasive	O
fungi	O
,	O
high	O
efficiency	O
,	O
low	O
toxicity	O
,	O
broad	O
spectrum	O
and	O
the	O
like	O
;	O
and	O
the	O
method	O
is	O
simple	O
and	O
high	O
in	O
yield	O
,	O
and	O
the	O
prepared	O
compound	O
has	O
a	O
good	O
antifungal	O
effect	O
.	O

Novel	O
azole	B
antifungal	O
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemicals	O
,	O
and	O
relates	O
to	O
a	O
substituted	B
phenyl-	I
(	I
diazaspiro	I
-	I
N	I
)	I
-ketone	I
derivative	O
.	O

The	O
compound	O
or	O
pharmaceutical	O
salt	O
thereof	O
are	O
shown	O
as	O
a	O
formula	O
I	O
in	O
the	O
specifications	O
,	O
wherein	O
R1	O
is	O
C1	B
to	I
C6	I
straight	O
-	O
chain	O
or	O
branched	O
-	O
chain	O
alkyl	B
substituted	O
by	O
one	O
or	O
more	O
halogens	B
;	O
R2	O
is	O
selected	O
from	O
hydrogen	B
,	O
C1	B
to	I
C6	I
straight	O
-	O
chain	O
or	O
branched	O
-	O
chain	O
alkyl	B
,	O
halogen	B
,	O
amino	B
,	O
nitro	B
,	O
hydroxyl	B
and	O
C1	B
to	I
C6	I
straight	O
-	O
chain	O
or	O
branched	O
-	O
chain	O
alkoxy	B
;	O
R3	O
is	O
selected	O
from	O
hydrogen	B
,	O
C1	B
to	I
C6	I
straight	O
-	O
chain	O
or	O
branched	O
-	O
chain	O
alkyl	B
and	O
C1	B
to	I
C6	I
straight	O
-	O
chain	O
or	O
branched	O
-	O
chain	O
alkylacyl	B
;	O
m	O
is	O
1	O
or	O
2	O
;	O
and	O
n	O
is	O
1	O
or	O
2	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
medicinal	O
composition	O
,	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
derivative	O
.	O

The	O
compound	O
or	O
the	O
pharmaceutical	O
salt	O
thereof	O
can	O
regulate	O
apolipoprotein	O
A	O
-	O
I	O
(	O
Apo	O
A	O
-	O
I	O
)	O
and	O
high	O
density	O
lipoprotein	O
cholesterol	B
(	O
HDL	B
-	I
C	I
)	O
level	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
medicine	O
for	O
regulating	O
blood	O
fat	O
or	O
preventing	O
and	O
treating	O
atherosclerosis	O
.	O

Substituted	B
phenyl-	I
(	I
diazaspiro	I
-	I
N	I
)	I
-ketone	I
derivative	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
synthesis	O
of	O
medicaments	O
,	O
and	O
relates	O
to	O
a	O
4-aminoquinazoline	B
compound	O
of	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
particular	O
to	O
a	O
4-	B
(	I
3-acetenyl	I
phenyl	I
amino	I
)	I
-7-methoxy	I
-	I
quinazoline	I
compound	O
of	O
which	O
the	O
6th	O
site	O
is	O
substituted	O
by	O
a	O
quaternary	O
heterocyclic	B
ring	O
,	O
a	O
preparation	O
method	O
for	O
the	O
compound	O
and	O
application	O
in	O
medicine	O
.	O

In	O
vitro	O
anti	O
-	O
tumor	O
activity	O
test	O
results	O
show	O
that	O
the	O
compound	O
has	O
high	O
anti	O
-	O
tumor	O
activity	O
and	O
can	O
be	O
used	O
for	O
preparing	O
new	O
anti	O
-	O
tumor	O
medicaments	O
.	O

4-aminoquinazoline	B
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
copolymer	O
based	O
on	O
environmental	O
response	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
copolymer	O
has	O
specific	O
three	O
blocks	O
which	O
are	O
sequentially	O
a	O
hydrophobic	O
block	O
,	O
a	O
hydrophilic	O
environmental	O
response	O
block	O
and	O
a	O
ploy	B
-	I
N	I
-	I
methylacryloyl	I
succinimide	I
(	O
PNAS	B
)	O
chain	O
with	O
reactivity	O
.	O

The	O
preparation	O
method	O
of	O
the	O
copolymer	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
connecting	O
the	O
hydrophobic	O
block	O
with	O
a	O
micromolecular	O
chain	O
transfer	O
agent	O
to	O
prepare	O
a	O
macroinitiator	O
;	O
performing	O
primary	O
polymerization	O
on	O
the	O
hydrophilic	O
environmental	O
response	O
block	O
and	O
the	O
macroinitiator	O
;	O
and	O
performing	O
secondary	O
polymerization	O
on	O
an	O
N	B
-	I
methylacryloyl	I
succinimide	I
(	O
NAS	B
)	O
monomer	O
and	O
a	O
product	O
of	O
the	O
first	O
step	O
,	O
so	O
as	O
to	O
obtain	O
the	O
copolymer	O
based	O
on	O
environmental	O
response	O
.	O

The	O
copolymer	O
has	O
the	O
advantages	O
that	O
the	O
copolymer	O
based	O
on	O
environmental	O
response	O
has	O
a	O
controllable	O
structure	O
,	O
and	O
the	O
hydrophobic	O
block	O
,	O
the	O
hydrophilic	O
environmental	O
response	O
block	O
and	O
the	O
PNAS	B
chain	O
are	O
independent	O
from	O
one	O
another	O
;	O
and	O
the	O
copolymer	O
based	O
on	O
environmental	O
response	O
has	O
a	O
clear	O
specific	O
structure	O
,	O
and	O
can	O
fully	O
play	O
the	O
performances	O
of	O
all	O
the	O
chain	O
segments	O
.	O

Copolymer	O
based	O
on	O
environmental	O
response	O
and	O
preparation	O
method	O
thereof	O

A	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
pain	O
.	O

Purine	B
compounds	O
used	O
as	O
cb2	O
agonists	O

The	O
present	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
treating	O
trauma	O
,	O
surgery	O
,	O
burn	O
and	O
scald	O
.	O

The	O
drug	O
comprises	O
8	O
-	O
10	O
g	O
of	O
lavender	O
,	O
5	O
-	O
8	O
g	O
of	O
argy	O
wormwood	O
leaf	O
,	O
8	O
-	O
10	O
g	O
of	O
cape	O
jasmine	O
,	O
8	O
-	O
10	O
g	O
of	O
borneol	B
,	O
8	O
-	O
10	O
g	O
of	O
pearl	O
plant	O
,	O
10	O
-	O
15	O
g	O
of	O
safflower	O
,	O
10	O
-	O
15	O
g	O
of	O
Chinese	O
nut	O
-	O
gall	O
,	O
10	O
-	O
15	O
g	O
of	O
frankincense	O
,	O
and	O
20	O
-	O
30	O
g	O
of	O
vitamin	B
E.	I
The	O
drug	O
of	O
the	O
present	O
invention	O
has	O
advantages	O
of	O
convenient	O
use	O
,	O
significant	O
effect	O
,	O
and	O
no	O
toxic	O
side	O
effect	O
.	O

With	O
the	O
drug	O
of	O
the	O
present	O
invention	O
,	O
distress	O
of	O
people	O
can	O
be	O
removed	O
.	O

Drug	O
for	O
treating	O
trauma	O
,	O
surgery	O
,	O
burn	O
and	O
scald	O

The	O
invention	O
discloses	O
a	O
1,7-diaryl-1,6-trans	B
-	I
diene-3,5-diketone	I
compound	O
,	O
namely	O
a	O
compound	O
6	O
(	O
a	O
-	O
i	O
)	O
represented	O
by	O
a	O
general	O
formula	O
I	O
as	O
well	O
as	O
a	O
preparation	O
method	O
of	O
the	O
1,7-diaryl-1,6-trans	B
-	I
diene-3,5-diketone	I
compound	O
and	O
an	O
application	O
of	O
the	O
1,7-diaryl-1,6-trans	B
-	I
diene-3,5-diketone	I
compound	O
to	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
tumor	O
.	O

The	O
tumor	O
resistant	O
activity	O
of	O
the	O
1,7-diaryl-1,6-trans	B
-	I
diene-3,5-diketone	I
compound	O
is	O
evaluated	O
on	O
a	O
mouse	O
S180	O
model	O
;	O
and	O
the	O
experiment	O
result	O
shows	O
that	O
the	O
compound	O
6	O
(	O
a	O
-	O
i	O
)	O
has	O
an	O
excellent	O
tumor	O
resisting	O
action	O
and	O
can	O
be	O
applied	O
to	O
production	O
of	O
preparing	O
a	O
tumor	O
-	O
resistant	O
medicament	O
.	O

1,7-diaryl-1,6-trans	B
-	I
diene-3,5-diketone	I
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
chlorhexidine	O
acetate	O
gel	O
for	O
treating	O
livestock	O
endometritis	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
gel	O
is	O
prepared	O
from	O
the	O
following	O
materials	O
by	O
weight	O
:	O
0.3	O
-	O
0.8	O
%	O
of	O
chlorhexidine	O
acetate	O
,	O
0.5	O
-	O
1	O
%	O
of	O
metronidazole	O
,	O
0.6	O
-	O
1.2	O
%	O
of	O
carbomer	O
,	O
0.4	O
-	O
0.7	O
%	O
of	O
pH	O
regulator	O
,	O
30	O
-	O
50	O
%	O
of	O
organic	O
solvent	O
,	O
0.05	O
-	O
0.3	O
%	O
of	O
solubilizer	O
,	O
0.5	O
-	O
0.15	O
%	O
of	O
preservative	O
,	O
and	O
water	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
spreading	O
carbomer	O
to	O
water	O
surface	O
in	O
batches	O
to	O
avoid	O
agglomeration	O
,	O
stirring	O
,	O
standing	O
for	O
24	O
-	O
48	O
h	O
,	O
and	O
adding	O
the	O
pH	O
regulator	O
to	O
obtain	O
matrix	O
;	O
mixing	O
chlorhexidine	O
acetate	O
,	O
metronidazole	O
,	O
organic	O
solvent	O
,	O
solubilizer	O
and	O
preservative	O
,	O
and	O
adding	O
into	O
the	O
matrix	O
;	O
and	O
supplementing	O
water	O
.	O

The	O
gel	O
is	O
adhered	O
to	O
mucous	O
membrane	O
through	O
vaginal	O
administration	O
,	O
and	O
releases	O
drugs	O
in	O
the	O
gel	O
slowly	O
to	O
prolong	O
drug	O
acting	O
time	O
,	O
achieve	O
high	O
curative	O
rate	O
and	O
significant	O
curative	O
effect	O
,	O
and	O
finally	O
realize	O
treatment	O
objective	O
.	O

Compound	O
chlorhexidine	O
acetate	O
gel	O
for	O
treating	O
livestock	O
endometritis	O
,	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Chinese	O
aralis	O
bark	O
total	O
saponins	B
in	O
antitumor	O
,	O
wherein	O
the	O
Chinese	O
aralis	O
bark	O
total	O
saponins	B
have	O
small	O
toxic	O
side	O
effects	O
and	O
a	O
substantial	O
tumor	O
curing	O
effect	O
.	O

The	O
Chinese	O
aralis	O
bark	O
total	O
saponins	B
have	O
a	O
certain	O
inhibition	O
effect	O
on	O
mouse	O
S180	O
sarcomas	O
,	O
the	O
H22	O
liver	O
cancer	O
and	O
the	O
mouse	O
leukemia	O
,	O
wherein	O
the	O
IC50	O
of	O
B16	O
and	O
the	O
IC50	O
of	O
FBL3	O
are	O
0.0774g	O
/	O
L	O
and	O
0.199g	O
/	O
L	O
respectively	O
,	O
and	O
the	O
H22	O
cell	O
inhibition	O
rate	O
of	O
the	O
Chinese	O
aralis	O
bark	O
total	O
saponins	B
in	O
a	O
concentration	O
range	O
of	O
0.025	O
-	O
3.2g	O
/	O
mL	O
is	O
above	O
80	O
%	O
.	O

The	O
mouse	O
S18	O
sarcoma	O
inhibition	O
rates	O
of	O
the	O
Chinese	O
aralis	O
bark	O
total	O
saponins	B
of	O
100mg.kg<-1	O
>	O
,	O
200mg.kg<-1	O
>	O
and	O
300mg.kg<-1	O
>	O
through	O
the	O
gavage	O
to	O
mice	O
are	O
16.9	O
%	O
,	O
37.1	O
%	O
and	O
27.0	O
%	O
respectively	O
;	O
and	O
the	O
H22	O
liver	O
cancer	O
inhibition	O
rates	O
of	O
the	O
Chinese	O
aralis	O
bark	O
total	O
saponins	B
of	O
same	O
dosages	O
are	O
23.7	O
%	O
,	O
10	O
%	O
and	O
13.4	O
%	O
respectively	O
.	O

Application	O
of	O
Chinese	O
aralis	O
bark	O
total	O
saponins	B
in	O
antitumor	O

The	O
invention	O
relates	O
to	O
five	O
-	O
high	O
controlling	O
tablets	O
which	O
are	O
a	O
novel	O
product	O
currently	O
invented	O
for	O
controlling	O
various	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
.	O

Before	O
the	O
invention	O
is	O
provided	O
,	O
Luoyishu	O
Naoxinqing	O
capsules	O
produced	O
by	O
Xi'an	O
QinBa	O
Pharmaceuticals	O
Co.	O
,	O
Ltd.	O
are	O
provided	O
for	O
the	O
market	O
.	O

The	O
product	O
provided	O
by	O
the	O
invention	O
is	O
different	O
from	O
the	O
capsules	O
.	O

A	O
main	O
component	O
of	O
the	O
capsules	O
is	O
organic	O
chromium	B
which	O
is	O
a	O
substance	O
extracted	O
from	O
persimmon	O
leaves	O
.	O

The	O
main	O
component	O
of	O
the	O
tablets	O
provided	O
by	O
the	O
invention	O
is	O
inorganic	O
chromium	B
which	O
is	O
a	O
natural	O
mineral	O
.	O

The	O
former	O
product	O
is	O
a	O
capsule	O
preparation	O
,	O
and	O
the	O
latter	O
is	O
a	O
tablet	O
preparation	O
.	O

The	O
action	O
of	O
the	O
product	O
provided	O
by	O
the	O
invention	O
is	O
similar	O
to	O
that	O
of	O
the	O
capsules	O
.	O

The	O
tablets	O
have	O
substantial	O
treatment	O
effects	O
against	O
various	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
.	O

Five	O
-	O
high	O
controlling	O
tablets	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
chicken	O
proventriculitis	O
and	O
a	O
preparation	O
method	O
of	O
the	O
pharmaceutical	O
composition	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
pharmacodynamic	O
raw	O
materials	O
in	O
weight	O
ratio	O
:	O
5	O
-	O
20	O
of	O
pepsase	O
,	O
20	O
-	O
50	O
of	O
vitamin	B
B1	I
,	O
60	O
-	O
200	O
of	O
astragalus	O
mongholicus	O
,	O
10	O
-	O
50	O
of	O
umbellate	O
pore	O
fungus	O
,	O
100	O
-	O
200	O
of	O
processed	O
bighead	O
atractylodes	O
rhizome	O
and	O
40	O
-	O
100	O
of	O
dried	O
tangerine	O
or	O
orange	O
peel	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
A	O
,	O
weighing	O
each	O
pharmacodynamic	O
raw	O
material	O
;	O
B	O
,	O
flatly	O
paving	O
the	O
pepsase	O
in	O
water	O
,	O
adjusting	O
the	O
pH	O
value	O
to	O
1	O
-	O
5	O
by	O
hydrochloric	B
acid	I
,	O
adding	O
vitamin	B
B1	I
,	O
stirring	O
and	O
dissolving	O
for	O
later	O
use	O
;	O
C	O
,	O
smashing	O
and	O
mixing	O
the	O
other	O
medicaments	O
in	O
the	O
prescription	O
except	O
the	O
pepsase	O
and	O
the	O
vitamin	B
B1	I
,	O
decocting	O
in	O
a	O
heating	O
way	O
,	O
concentrating	O
,	O
putting	O
,	O
and	O
taking	O
liquid	O
supernatant	O
;	O
D	O
,	O
concentrating	O
the	O
liquid	O
supernatant	O
to	O
be	O
free	O
from	O
alcohol	O
smell	O
,	O
adjusting	O
the	O
pH	O
value	O
to	O
1	O
-	O
5	O
by	O
hydrochloric	B
acid	I
,	O
and	O
filtering	O
;	O
and	O
E	O
,	O
evenly	O
mixing	O
the	O
filter	O
liquor	O
obtained	O
by	O
the	O
step	O
D	O
with	O
the	O
solution	O
prepared	O
by	O
the	O
step	O
B	O
,	O
sterilizing	O
,	O
and	O
subpackaging	O
,	O
so	O
that	O
the	O
pharmaceutical	O
composite	O
can	O
be	O
prepared	O
.	O

In	O
combination	O
with	O
the	O
dietary	O
characteristics	O
of	O
poultry	O
,	O
the	O
pharmaceutical	O
composition	O
is	O
optimally	O
designed	O
,	O
not	O
only	O
can	O
make	O
up	O
the	O
defects	O
of	O
the	O
antibiotic	O
therapy	O
,	O
but	O
also	O
has	O
the	O
characteristics	O
of	O
simple	O
prescription	O
and	O
low	O
price	O
,	O
is	O
suitable	O
for	O
the	O
large	O
-	O
scale	O
production	O
,	O
and	O
is	O
good	O
in	O
curative	O
effect	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
chicken	O
proventriculitis	O
and	O
preparation	O
method	O
of	O
pharmaceutical	O
composition	O

Solid	O
-	O
forming	O
local	O
anesthetic	O
formulations	O
for	O
pain	O
control	O
can	O
include	O
a	O
lidocaine	B
base	O
and	O
tetracaine	B
base	O
,	O
polyvinyl	B
alcohol	I
,	O
water	O
,	O
and	O
an	O
emulsifier	O
.	O

The	O
formulation	O
can	O
be	O
prepared	O
to	O
be	O
in	O
a	O
semi	O
-	O
solid	O
state	O
prior	O
to	O
application	O
to	O
a	O
skin	O
surface	O
,	O
can	O
form	O
a	O
soft	O
solidified	O
layer	O
after	O
application	O
,	O
and	O
can	O
provide	O
pain	O
relief	O
when	O
applied	O
to	O
a	O
skin	O
surface	O
proximate	O
a	O
pain	O
site	O
.	O

Solid	O
-	O
forming	O
local	O
anesthetic	O
formulations	O
for	O
pain	O
control	O

The	O
present	O
invention	O
relates	O
to	O
nasal	O
administration	O
preparations	O
of	O
valproic	B
acid	I
and	O
salts	O
thereof	O
,	O
wherein	O
the	O
preparations	O
are	O
suitable	O
for	O
hypovolemic	O
shocks	O
caused	O
by	O
war	O
wound	O
(	O
wound	O
)	O
,	O
burn	O
,	O
and	O
the	O
like	O
.	O

The	O
preparation	O
of	O
the	O
present	O
invention	O
contains	O
a	O
prototype	O
drug	O
of	O
valproic	B
acid	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
an	O
ester	O
,	O
an	O
amide	B
or	O
di	B
-	I
sodium	I
valproate	I
of	O
the	O
valproic	B
acid	I
,	O
and	O
a	O
pharmaceutically	O
effective	O
auxiliary	O
material	O
,	O
wherein	O
the	O
prototype	O
drug	O
of	O
valproic	B
acid	I
,	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
,	O
the	O
ester	B
,	O
the	O
amide	B
or	O
the	O
di	B
-	I
sodium	I
valproate	I
of	O
the	O
valproic	B
acid	I
is	O
adopted	O
as	O
a	O
main	O
component	O
.	O

Hypovolemic	O
shock	O
treatment	O
nasal	O
administration	O
preparations	O
of	O
valproic	B
acid	I
and	O
salts	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicines	O
,	O
and	O
specifically	O
relates	O
to	O
an	O
arctigenin	B
micro	O
-	O
emulsion	O
enteric	O
soft	O
capsule	O
preparation	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
enteric	O
soft	O
capsules	O
are	O
composed	O
of	O
contents	O
containing	O
arctigenin	B
micro	O
-	O
emulsion	O
concentrated	O
liquid	O
and	O
enteric	O
capsule	O
shells	O
.	O

The	O
capsules	O
can	O
be	O
dissolved	O
in	O
intestines	O
.	O

With	O
the	O
capsules	O
,	O
bioavailability	O
of	O
arctigenin	B
is	O
improved	O
,	O
and	O
irritation	O
to	O
the	O
stomach	O
is	O
reduced	O
.	O

The	O
capsules	O
can	O
be	O
directionally	O
released	O
in	O
intestines	O
,	O
and	O
has	O
the	O
advantages	O
of	O
high	O
stability	O
and	O
good	O
sustained	O
-	O
release	O
effect	O
.	O

The	O
capsule	O
preparation	O
has	O
a	O
good	O
medical	O
application	O
prospect	O
.	O

Arctigenin	B
micro	O
-	O
emulsion	O
enteric	O
soft	O
capsule	O
preparation	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
biological	O
medicines	O
and	O
relates	O
to	O
a	O
paclitaxel	B
-	O
entrapped	O
biodegradable	O
nanocomposite	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

A	O
paclitaxel	B
polyethylene	B
glycol	I
-	O
poly	B
trimethylene	I
carbonate	I
(	O
PEG	B
-	O
PTMC	B
)	O
nanocomposite	O
is	O
prepared	O
by	O
adopting	O
an	O
emulsification	O
/	O
solvent	O
evaporation	O
method	O
,	O
and	O
by	O
taking	O
a	O
PEG	B
-	O
PTMC	B
copolymer	O
as	O
a	O
carrier	O
,	O
paclitaxel	B
is	O
entrapped	O
in	O
a	O
hydrophobic	O
core	O
of	O
PTMC	B
.	O

The	O
solubility	O
of	O
the	O
paclitaxel	B
can	O
be	O
effectively	O
increased	O
by	O
the	O
prepared	O
paclitaxel	B
PEG	B
-	O
PTMC	B
nanocomposite	O
,	O
and	O
a	O
PEG	B
long	O
chain	O
of	O
a	O
carrier	O
material	O
can	O
take	O
effect	O
of	O
invisibility	O
,	O
and	O
thereby	O
,	O
the	O
phagocytosis	O
of	O
an	O
in	O
-	O
vivo	O
reticulo	O
-	O
endothelial	O
system	O
is	O
avoided	O
.	O

The	O
nanocomposite	O
has	O
a	O
long	O
circulation	O
effect	O
,	O
and	O
the	O
half	O
-	O
life	O
period	O
of	O
the	O
nanocomposite	O
in	O
blood	O
can	O
be	O
prolonged	O
.	O

Moreover	O
,	O
through	O
controlling	O
the	O
grain	O
size	O
of	O
the	O
nanocomposite	O
,	O
a	O
passive	O
targeting	O
effect	O
on	O
a	O
tumor	O
tissue	O
is	O
realized	O
,	O
and	O
thereby	O
,	O
a	O
treatment	O
effect	O
is	O
improved	O
.	O

As	O
the	O
nanocomposite	O
does	O
not	O
contain	O
Cremophor	O
El	O
or	O
ethanol	B
,	O
compared	O
with	O
commercially	O
available	O
paclitaxel	B
injections	O
,	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
nanocomposite	O
can	O
be	O
reduced	O
,	O
and	O
the	O
safety	O
of	O
the	O
nanocomposite	O
in	O
clinical	O
application	O
is	O
enhanced	O
.	O

Paclitaxel	B
-	O
entrapped	O
biodegradable	O
nanocomposite	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
a	O
sedative	O
hypnotic	O
pharmaceutical	O
preparation	O
.	O

The	O
preparation	O
method	O
includes	O
the	O
steps	O
of	O
dissolving	O
active	O
ingredient	O
dexzopiclone	B
or	O
zopiclone	B
in	O
acidifier	O
-	O
containing	O
acidic	O
solution	O
to	O
give	O
drug	O
-	O
containing	O
acidic	O
solution	O
,	O
and	O
then	O
performing	O
wet	O
granulation	O
with	O
the	O
obtained	O
drug	O
-	O
containing	O
acidic	O
solution	O
,	O
basifier	O
and	O
adjuvant	O
.	O

The	O
acidifier	O
is	O
hydrochloric	B
acid	I
,	O
and	O
the	O
basifier	O
is	O
sodium	B
hydroxide	I
.	O

One	O
or	O
more	O
of	O
organic	O
weak	O
acid	O
,	O
acid	O
salt	O
and	O
conjugate	O
base	O
of	O
organic	O
weak	O
acid	O
are	O
added	O
before	O
or	O
during	O
the	O
addition	O
of	O
the	O
basifier	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
sedative	O
hypnotic	O
pharmaceutical	O
preparation	O
prepared	O
by	O
the	O
method	O
.	O

The	O
inventive	O
preparation	O
method	O
has	O
no	O
potential	O
safety	O
hazard	O
,	O
simple	O
and	O
convenient	O
operation	O
,	O
low	O
pollution	O
and	O
loss	O
,	O
low	O
cost	O
,	O
and	O
good	O
process	O
controllability	O
.	O

The	O
obtained	O
pharmaceutical	O
preparation	O
has	O
excellent	O
dissolution	O
and	O
stability	O
,	O
and	O
lower	O
related	O
substance	O
content	O
.	O

Sedative	O
hypnotic	O
pharmaceutical	O
preparation	O
and	O
its	O
preparation	O
method	O

An	O
S	B
-	I
ornidazole	I
and	O
sodium	B
chloride	I
injection	O
is	O
mainly	O
characterized	O
in	O
that	O
S	B
-	I
ornidazole	I
belongs	O
to	O
a	O
third	O
-	O
generation	O
nitroimidazole	B
,	O
and	O
the	O
microbial	O
resistance	O
of	O
the	O
injection	O
is	O
performed	O
through	O
the	O
reduction	O
of	O
a	O
nitro	B
group	O
in	O
a	O
molecule	O
into	O
an	O
amino	B
group	O
in	O
an	O
anoxic	O
environment	O
or	O
through	O
the	O
formation	O
of	O
a	O
free	O
radical	O
and	O
the	O
interaction	O
of	O
the	O
free	O
radical	O
with	O
a	O
cell	O
,	O
so	O
the	O
injection	O
can	O
kill	O
microbes	O
;	O
the	O
injection	O
has	O
strong	O
killing	O
effects	O
on	O
almost	O
all	O
pathogenic	O
anaerobes	O
and	O
protoza	O
comprising	O
trichomonads	O
,	O
amoebae	O
,	O
Giardia	O
lamblia	O
and	O
the	O
like	O
,	O
so	O
the	O
injection	O
has	O
a	O
wide	O
antimicrobial	O
spectrum	O
;	O
the	O
ED90	O
of	O
the	O
injection	O
to	O
various	O
sensitive	O
pathogens	O
is	O
lower	O
than	O
the	O
ED80	O
of	O
the	O
injection	O
to	O
metronidazole	O
,	O
so	O
the	O
injection	O
has	O
a	O
strong	O
bactericidal	O
activity	O
;	O
the	O
effective	O
rate	O
and	O
the	O
cure	O
rate	O
to	O
the	O
anaerobes	O
and	O
the	O
trichomonads	O
are	O
higher	O
than	O
that	O
of	O
like	O
products	O
,	O
so	O
the	O
injection	O
has	O
a	O
good	O
clinical	O
cure	O
effect	O
;	O
there	O
are	O
no	O
teratogenic	O
,	O
carcinogenic	O
or	O
mutagenic	O
effects	O
,	O
so	O
the	O
injection	O
has	O
a	O
high	O
safety	O
;	O
and	O
the	O
total	O
adverse	O
reaction	O
incidence	O
rate	O
of	O
the	O
injection	O
is	O
lower	O
than	O
that	O
of	O
like	O
products	O
,	O
so	O
the	O
injection	O
has	O
a	O
good	O
tolerance	O
.	O

S	B
-	I
ornidazole	I
and	O
sodium	B
chloride	I
injection	O

The	O
invention	O
provides	O
a	O
medicinal	O
composition	O
containing	O
doxofylline	B
compound	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicinal	O
composition	O
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
freeze	O
-	O
dried	O
powder	O
injection	O
comprises	O
the	O
following	O
components	O
:	O
a	O
doxofylline	B
compound	O
,	O
an	O
excipient	O
and	O
a	O
pH	O
regulator	O
,	O
wherein	O
the	O
excipient	O
is	O
dextran	O
;	O
and	O
the	O
pH	O
regulator	O
is	O
sodium	B
bicarbonate	I
,	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
doxofylline	B
compound	O
to	O
the	O
excipient	O
is	O
1	O
to	O
(	O
1.0	O
-	O
1.2	O
)	O
.	O

The	O
medicinal	O
composition	O
containing	O
the	O
doxofylline	B
compound	O
provided	O
by	O
the	O
invention	O
is	O
good	O
in	O
stability	O
,	O
simple	O
in	O
formula	O
and	O
low	O
in	O
adjuvants	O
dosage	O
.	O

Medicinal	O
composition	O
containing	O
doxofylline	B
compound	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
for	O
treating	O
bone	O
diseases	O
,	O
and	O
preparation	O
thereof	O
.	O

The	O
composition	O
comprises	O
radix	O
notoginseng	O
,	O
rhizoma	O
ligustici	O
chuanxiong	O
,	O
radix	O
angelicae	O
sinensis	O
,	O
fructus	O
foeniculi	O
,	O
olibanum	O
,	O
myrrha	O
,	O
cortex	O
cinnamomi	O
,	O
cortex	O
eucommiae	O
,	O
radix	O
dipsaci	O
,	O
herba	O
taxilli	O
,	O
semen	O
trigonellae	O
,	O
fructus	O
chaenomelis	O
,	O
radix	O
cyathulae	O
,	O
radix	O
gentianae	O
marcrophyllae	O
,	O
lignum	O
pini	O
nodi	O
,	O
radix	O
angelicae	O
pubescentis	O
and	O
borneolum	O
.	O

Pharmacological	O
and	O
clinical	O
tests	O
show	O
that	O
the	O
composition	O
has	O
effects	O
in	O
treating	O
bone	O
diseases	O
.	O

Medicinal	O
composition	O
for	O
treating	O
bone	O
diseases	O
,	O
and	O
preparation	O
thereof	O

The	O
invention	O
falls	O
into	O
the	O
field	O
of	O
biotechnology	O
and	O
relates	O
to	O
an	O
inhibitor	O
for	O
inhibiting	O
histidine	B
kinase	O
activity	O
of	O
PhoQ	O
in	O
bacterial	O
signal	O
transduction	O
system	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
a	O
histidine	B
kinase	O
inhibitor	O
of	O
bacterial	O
PhoQ	O
,	O
especially	O
the	O
PhoQ	O
protein	O
inhibitor	O
of	O
the	O
signal	O
transduction	O
system	O
of	O
gram	O
negative	O
bacteria	O
,	O
containing	O
a	O
small	O
molecular	O
compound	O
.	O

The	O
preparation	O
comprises	O
a	O
small	O
molecular	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
DMSO	B
.	O

The	O
inventive	O
preparation	O
for	O
inhibiting	O
histidine	B
kinase	O
activity	O
of	O
PhoQ	O
in	O
bacterial	O
signal	O
transduction	O
system	O
has	O
inhibitory	O
activity	O
against	O
PhoQ	O
protein	O
of	O
Shigella	O
signal	O
transduction	O
system	O
;	O
and	O
can	O
inhibit	O
the	O
virulence	O
of	O
Shigella	O
,	O
be	O
used	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
inhibiting	O
the	O
virulence	O
of	O
Shigella	O
or	O
drugs	O
for	O
the	O
treatment	O
of	O
gram	O
negative	O
bacteria	O
induced	O
diseases	O
,	O
and	O
be	O
prepared	O
into	O
disinfection	O
solution	O
for	O
use	O
in	O
medical	O
equipments	O
and	O
medical	O
appliances	O
.	O

An	O
inhibitor	O
for	O
inhibiting	O
histidine	B
kinase	O
activity	O
of	O
PhoQ	O
in	O
bacterial	O
signal	O
transduction	O
system	O

The	O
invention	O
relates	O
to	O
a	O
Toll	O
-	O
like	O
receptor	O
regulatory	O
oligonucleotide	B
and	O
a	O
functional	O
analog	O
thereof	O
,	O
and	O
application	O
of	O
the	O
oligonucleotide	B
and	O
the	O
functional	O
analog	O
thereof	O
in	O
prevention	O
and	O
treatment	O
of	O
immune	O
-	O
mediated	O
diseases	O
.	O

The	O
oligonucleotide	B
provided	O
by	O
the	O
invention	O
contains	O
a	O
CT	O
repeated	O
sequence	O
[	O
(	O
CT	O
)	O
n	O
]	O
or	O
a	O
CCT	O
repeated	O
sequence	O
[	O
(	O
CCT	O
)	O
n	O
]	O
or	O
a	O
TC	O
repeated	O
sequence	O
[	O
(	O
TC	O
)	O
n	O
]	O
,	O
or	O
is	O
an	O
oligonucleotide	O
which	O
is	O
rich	O
in	O
CT	O
or	O
CCT	O
or	O
TC	O
.	O

The	O
immune	O
-	O
mediated	O
diseases	O
include	O
autoimmune	O
diseases	O
,	O
graft	O
rejection	O
,	O
hypersensitivity	O
,	O
diseases	O
caused	O
by	O
microbial	O
over	O
-	O
strong	O
stimulation	O
on	O
the	O
immune	O
system	O
of	O
a	O
host	O
and	O
TOLL	O
-	O
like	O
receptor	O
activation	O
-	O
related	O
diseases	O
.	O

Toll	O
-	O
like	O
receptor	O
regulatory	O
oligonucleotide	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
application	O
of	O
Houttuynoid	B
C	I
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
nasopharynx	O
cancer	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
medicine	O
.	O

The	O
invention	O
discovers	O
that	O
Houttuynoid	B
C	I
has	O
the	O
remarkable	O
inhibitory	O
effects	O
on	O
the	O
growth	O
of	O
human	O
nasopharynx	O
cancer	O
cell	O
strains	O
,	O
including	O
HNE1	O
,	O
HNE2	O
,	O
HONE1	O
and	O
CNE1	O
through	O
the	O
evaluation	O
of	O
in	O
vitro	O
MTT	O
antineoplastic	O
activity	O
.	O

Therefore	O
,	O
Houttuynoid	B
C	I
can	O
be	O
used	O
for	O
preparing	O
the	O
anti	O
-	O
nasopharynx	O
cancer	O
medicine	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

The	O
application	O
of	O
Houttuynoid	B
C	I
in	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
nasopharynx	O
cancer	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
firstly	O
.	O

The	O
skeleton	O
type	O
belongs	O
to	O
new	O
skeleton	O
type	O
,	O
and	O
the	O
inhibitory	O
activity	O
of	O
Houttuynoid	B
C	I
on	O
nasopharynx	O
cancer	O
cells	O
is	O
unexpectedly	O
strong	O
.	O

Application	O
of	O
Houttuynoid	B
C	I
in	O
medicine	O
for	O
treating	O
nasopharynx	O
cancer	O

The	O
invention	O
discloses	O
application	O
of	O
Houttuynoid	B
E	I
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
human	O
cervical	O
cancer	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
medicine	O
.	O

The	O
invention	O
discovers	O
that	O
Houttuynoid	B
E	I
has	O
the	O
remarkable	O
inhibitory	O
effects	O
on	O
the	O
growth	O
of	O
human	O
cervical	O
cancer	O
cell	O
strains	O
,	O
including	O
HeLa	O
,	O
HeLa229	O
,	O
HCE1	O
and	O
CaSKi	O
through	O
the	O
evaluation	O
of	O
in	O
vitro	O
MTT	B
antineoplastic	O
activity	O
.	O

Therefore	O
,	O
Houttuynoid	B
E	I
can	O
be	O
used	O
for	O
preparing	O
the	O
anti	O
-	O
cervical	O
cancer	O
medicine	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

The	O
application	O
of	O
Houttuynoid	B
E	I
in	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
human	O
cervical	O
cancer	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
firstly	O
.	O

The	O
skeleton	O
type	O
belongs	O
to	O
new	O
skeleton	O
type	O
,	O
and	O
the	O
inhibitory	O
activity	O
of	O
Houttuynoid	B
E	I
on	O
human	O
cervical	O
cancer	O
cells	O
is	O
unexpectedly	O
strong	O
.	O

Application	O
of	O
Houttuynoid	B
E	I
in	O
medicine	O
for	O
treating	O
cervical	O
cancer	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicines	O
,	O
discloses	O
an	O
application	O
of	O
naringin	B
in	O
preparing	O
drugs	O
for	O
improving	O
brain	O
tissue	O
glucose	O
hypometabolism	O
and	O
long	O
-	O
term	O
hypomnesis	O
.	O

What	O
firstly	O
found	O
is	O
that	O
the	O
naringin	B
can	O
increase	O
glucose	B
uptake	O
and	O
transport	O
of	O
the	O
brain	O
tissues	O
,	O
improve	O
energy	O
metabolism	O
disturbance	O
,	O
simultaneously	O
activate	O
calcium	B
/	O
calmodulin	O
dependence	O
protein	O
kinase	O
and	O
downstream	O
AMPA	O
glutamate	B
receptors	O
,	O
promote	O
excitability	O
transmission	O
of	O
glutamatergic	O
neurons	O
and	O
improve	O
long	O
-	O
term	O
memory	O
,	O
thereby	O
improving	O
symptoms	O
of	O
neurodegenerative	O
diseases	O
and	O
delaying	O
disease	O
's	O
progression	O
.	O

The	O
naringin	B
has	O
the	O
potentiality	O
for	O
developing	O
into	O
drugs	O
or	O
health	O
preparations	O
for	O
treating	O
brain	O
tissue	O
diseases	O
which	O
are	O
characterized	O
by	O
brain	O
glycometabolism	O
disturbance	O
and/or	O
long	O
-	O
term	O
memory	O
impairment	O
.	O

Novel	O
application	O
of	O
naringin	B

The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
hepatitis	O
medicinal	O
preparation	O
.	O

The	O
invention	O
is	O
characterized	O
in	O
that	O
the	O
medicinal	O
preparation	O
is	O
prepared	O
by	O
taking	O
aucubin	B
(	O
aucuboside	B
)	O
or	O
aglycone	O
(	O
aglucone	O
)	O
as	O
a	O
raw	O
material	O
.	O

The	O
invention	O
aims	O
to	O
provide	O
the	O
anti	O
-	O
hepatitis	O
medicinal	O
preparation	O
.	O

A	O
preparation	O
method	O
for	O
the	O
anti	O
-	O
hepatitis	O
medicinal	O
preparation	O
is	O
characterized	O
in	O
that	O
by	O
taking	O
the	O
aucubin	B
(	O
aucuboside	B
)	O
or	O
the	O
aglycone	O
(	O
aglucone	O
)	O
as	O
the	O
raw	O
material	O
,	O
pharmaceutically	O
conventional	O
auxiliary	O
materials	O
are	O
added	O
to	O
prepare	O
any	O
dosage	O
forms	O
,	O
such	O
as	O
injections	O
,	O
granules	O
,	O
tablets	O
,	O
capsules	O
,	O
pills	O
,	O
medicinal	O
tea	O
,	O
powder	O
,	O
dripping	O
pills	O
,	O
soft	O
extracts	O
,	O
mixtures	O
and	O
syrups	O
recorded	O
in	O
Chinese	O
pharmacopoeia	O
.	O

The	O
defect	O
that	O
toxic	O
and	O
side	O
effects	O
with	O
different	O
degrees	O
are	O
caused	O
by	O
pharmaceutically	O
treating	O
hepatitis	O
at	O
present	O
is	O
overcome	O
by	O
the	O
anti	O
-	O
hepatitis	O
medicinal	O
preparation	O
.	O

The	O
anti	O
-	O
hepatitis	O
medicinal	O
preparation	O
has	O
the	O
following	O
advantages	O
:	O
1	O
,	O
the	O
curative	O
effect	O
is	O
exact	O
,	O
and	O
the	O
treatment	O
effect	O
is	O
remarkable	O
;	O
2	O
,	O
the	O
raw	O
material	O
of	O
the	O
anti	O
-	O
hepatitis	O
medicinal	O
preparation	O
can	O
be	O
extracted	O
from	O
plants	O
,	O
such	O
as	O
Eucommia	O
ulmoides	O
,	O
thus	O
,	O
resources	O
are	O
rich	O
and	O
can	O
be	O
easily	O
obtained	O
;	O
3	O
,	O
the	O
anti	O
-	O
hepatitis	O
medicinal	O
preparation	O
has	O
an	O
effect	O
of	O
resisting	O
the	O
hepatitis	O
,	O
and	O
is	O
used	O
for	O
treating	O
acute	O
and	O
chronic	O
hepatitis	O
B	O
,	O
viral	O
hepatitis	O
,	O
chemical	O
liver	O
injury	O
,	O
fatty	O
liver	O
and	O
cirrhosis	O
.	O

Anti	O
-	O
hepatitis	O
medicinal	O
preparation	O

According	O
to	O
the	O
pharmacological	O
study	O
on	O
Houttuynoid	B
B	I
,	O
the	O
inventor	O
discovers	O
that	O
Houttuynoid	B
B	I
has	O
a	O
protective	O
effect	O
on	O
the	O
D	B
-	I
galactosamine	I
(	O
D	O
-	O
GalN	O
)	O
induced	O
mice	O
acute	O
liver	O
injury	O
and	O
the	O
CCl4	B
induced	O
mice	O
acute	O
liver	O
injury	O
.	O

Thus	O
,	O
the	O
Houttuynoid	B
B	I
can	O
be	O
used	O
for	O
preparing	O
a	O
medicine	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
or	O
hepatitis	O
.	O

The	O
application	O
of	O
Houttuynoid	B
B	I
in	O
preparing	O
a	O
medicine	O
for	O
treating	O
liver	O
injury	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
and	O
since	O
the	O
skeleton	O
type	O
is	O
a	O
brand	O
new	O
one	O
and	O
the	O
activity	O
in	O
treating	O
liver	O
injury	O
is	O
unexpectedly	O
strong	O
,	O
the	O
possibility	O
of	O
any	O
other	O
compound	O
offering	O
any	O
inspiration	O
does	O
not	O
exist	O
,	O
outstanding	O
substantial	O
characteristics	O
are	O
obtained	O
,	O
and	O
an	O
obvious	O
progress	O
is	O
made	O
in	O
resisting	O
liver	O
injury	O
.	O

Application	O
of	O
Houttuynoid	B
B	I
in	O
medicine	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O

The	O
invention	O
discloses	O
application	O
of	O
Houttuynoid	B
D	I
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
lung	O
cancer	O
metastasis	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
use	O
of	O
medicaments	O
.	O

Houttuynoid	B
D	I
is	O
capable	O
of	O
suppressing	O
the	O
tumour	O
cell	O
movement	O
and	O
migration	O
abilities	O
.	O

The	O
use	O
of	O
Houttuynoid	B
D	I
in	O
preparing	O
the	O
medicament	O
for	O
preventing	O
the	O
lung	O
cancer	O
metastasis	O
involved	O
in	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
skeleton	O
type	O
of	O
Houttuynoid	B
D	I
is	O
a	O
brand	O
new	O
framework	O
type	O
;	O
and	O
Houttuynoid	B
D	I
has	O
an	O
unexpectedly	O
high	O
inhibition	O
activity	O
for	O
the	O
lung	O
cancer	O
metastasis	O
.	O

Application	O
of	O
Houttuynoid	B
D	I
in	O
medicament	O
for	O
preventing	O
lung	O
cancer	O
metastasis	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	B
D	I
in	O
a	O
medicament	O
for	O
treating	O
human	O
colorectal	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
use	O
of	O
medicaments	O
.	O

Houttuynoid	B
D	I
is	O
found	O
to	O
have	O
an	O
obvious	O
inbibitional	O
effect	O
on	O
the	O
growth	O
of	O
human	O
colorectal	O
cancer	O
cell	O
lines	O
LOVE1	O
,	O
LoVo	O
,	O
SW620	O
and	O
SW480	O
through	O
MTT	B
(	O
Methyl	B
Thiazolyl	I
Ternzolinm	I
)	O
anticancer	O
activity	O
evaluation	O
in	O
vitro	O
.	O

Therefore	O
,	O
Houttuynoid	B
D	I
can	O
be	O
used	O
for	O
preparing	O
the	O
anti	O
-	O
colorectal	O
cancer	O
medicament	O
and	O
has	O
excellent	O
prospects	O
in	O
development	O
and	O
application	O
.	O

The	O
use	O
of	O
Houttuynoid	B
D	I
in	O
preparing	O
the	O
medicament	O
for	O
treating	O
the	O
human	O
colorectal	O
cancer	O
involved	O
in	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
framework	O
type	O
of	O
Houttuynoid	B
D	I
is	O
a	O
brand	O
new	O
framework	O
type	O
;	O
and	O
Houttuynoid	B
D	I
has	O
an	O
unexpectedly	O
high	O
inhibition	O
activity	O
for	O
human	O
colorectal	O
cancer	O
cells	O
.	O

Application	O
of	O
Houttuynoid	B
D	I
in	O
medicament	O
for	O
treating	O
colorectal	O
cancer	O

The	O
invention	O
discloses	O
nitrogen	B
substitution	O
podophyllum	B
type	O
derivatives	O
with	O
antitumor	O
activity	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
nitrogen	B
substitution	O
podophyllum	B
type	O
derivatives	O
(	O
as	O
formula	O
V	O
)	O
with	O
fine	O
antitumor	O
activity	O
are	O
prepared	O
by	O
introducing	O
1-	B
(	I
3-amino	I
propyl	I
)	I
imidazole	I
,	O
benzimidazole	B
,	O
2-thienylmethylamine	B
or	O
trihydroxymethyl	B
aminomethane	I
to	O
C	O
ring	O
4-position	O
activated	O
by	O
4-demethylation	O
surface	O
podophyllotoxin	B
.	O

The	O
nitrogen	B
substitution	O
podophyllum	B
type	O
derivatives	O
can	O
act	O
on	O
tumor	O
cells	O
with	O
multiple	O
paths	O
and	O
multiple	O
target	O
points	O
,	O
and	O
accordingly	O
better	O
antitumor	O
curative	O
effect	O
is	O
achieved	O
.	O

Antitumor	O
activity	O
of	O
the	O
derivatives	O
is	O
evidently	O
increased	O
compared	O
with	O
that	O
of	O
the	O
4-demethylation	O
surface	O
podophyllotoxin	B
.	O

The	O
derivatives	O
can	O
be	O
prepared	O
into	O
antitumor	O
drugs	O
to	O
apply	O
to	O
antitumor	O
therapies	O
.	O

Nitrogen	B
substitution	O
podophyllum	B
type	O
derivatives	O
with	O
antitumor	O
activity	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
mupirocin	B
ointment	O
pharmaceutical	O
composition	O
,	O
particularly	O
to	O
an	O
ointment	O
pharmaceutical	O
composition	O
.	O

The	O
ointment	O
pharmaceutical	O
composition	O
comprises	O
mupirocin	B
shown	O
in	O
the	O
following	O
formula	O
in	O
the	O
specification	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
polyethylene	B
glycol	I
and	O
amino	B
acid	I
,	O
wherein	O
polyethylene	B
glycol	I
comprises	O
polyethylene	B
glycol	I
with	O
a	O
molecular	O
weight	O
of	O
200	O
-	O
600	O
and	O
polyethylene	B
glycol	I
with	O
a	O
molecular	O
weight	O
of	O
2000	O
-	O
6000	O
.	O

The	O
ointment	O
pharmaceutical	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
excellent	O
pharmaceutical	O
characteristics	O
.	O

Novel	O
mupirocin	B
ointment	O
pharmaceutical	O
composition	O

The	O
invention	O
relates	O
to	O
a	O
solid	O
dispersion	O
of	O
arctigenin	B
and	O
an	O
oral	O
solid	O
preparation	O
.	O

The	O
solid	O
dispersion	O
consists	O
of	O
the	O
arctigenin	B
and	O
a	O
carrier	O
material	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
arctigenin	B
to	O
the	O
carrier	O
material	O
is	O
1:1	O
-	O
1:50	O
.	O

The	O
defects	O
of	O
poor	O
oral	O
administration	O
absorption	O
and	O
low	O
bioavailability	O
of	O
the	O
arctigenin	B
are	O
overcome	O
,	O
stability	O
of	O
the	O
arctigenin	B
is	O
improved	O
,	O
objectionable	O
odor	O
and	O
irritation	O
of	O
medicaments	O
are	O
concealed	O
,	O
and	O
a	O
preparation	O
technology	O
is	O
simple	O
and	O
suitable	O
for	O
industrialized	O
production	O
.	O

Solid	O
dispersion	O
of	O
arctigenin	B
and	O
oral	O
solid	O
preparation	O

The	O
invention	O
relates	O
to	O
a	O
2,3-dioxyethyl-5-methyl-8,9-dimethoxy	B
benzophenanthridine	I
derivative	O
disclosed	O
as	O
Formula	O
I	O
,	O
a	O
synthesis	O
method	O
and	O
application	O
thereof	O
in	O
preparing	O
medicines	O
for	O
inhibiting	O
tumor	O
cell	O
activity	O
.	O

The	O
50	O
%	O
inhibition	O
concentrations	O
IC50	O
of	O
the	O
2,3-dioxyethyl-5-methyl-8,9-dimethoxy	B
benzophenanthridine	I
-	I
hydrochloride	I
and	I
hydrobromide	I
for	O
four	O
cancer	O
cell	O
strains	O
of	O
stomach	O
cancer	O
(	O
MGC-803	O
)	O
,	O
liver	O
cancer	O
(	O
BEL7402	O
)	O
,	O
human	O
nasopharyngeal	O
carcinoma	O
(	O
CNE	O
)	O
and	O
human	O
lung	O
adenocarcinoma	O
(	O
A549	O
)	O
are	O
respectively	O
lower	O
than	O
those	O
of	O
nitidine	B
chloride	I
,	O
and	O
are	O
much	O
lower	O
than	O
those	O
of	O
5-FU	B
(	O
control	O
drug	O
)	O
.	O

2,3-dioxyethyl-5-methyl-8,9-dimethoxy	B
benzophenanthridine	I
derivative	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
particularly	O
provides	O
a	O
long	O
-	O
acting	O
donepezil	B
percutaneous	O
absorption	O
sticking	O
agent	O
.	O

The	O
long	O
-	O
acting	O
donepezil	B
percutaneous	O
absorption	O
patch	O
agent	O
consists	O
of	O
a	O
back	O
lining	O
layer	O
,	O
a	O
drug	O
-	O
containing	O
pressure	O
-	O
sensitive	O
glue	O
layer	O
and	O
an	O
anti	O
-	O
sticking	O
layer	O
,	O
wherein	O
the	O
long	O
-	O
acting	O
donepezil	B
percutaneous	O
absorption	O
sticking	O
agent	O
comprises	O
5	O
-	O
15	O
parts	O
of	O
main	O
drug	O
donepezil	B
,	O
70	O
-	O
95	O
parts	O
of	O
pressure	O
-	O
sensitive	O
glue	O
and	O
0.5	O
-	O
15	O
parts	O
of	O
percutaneous	O
absorption	O
accelerant	O
.	O

The	O
long	O
-	O
acting	O
donepezil	B
percutaneous	O
absorption	O
sticking	O
agent	O
is	O
characterized	O
in	O
that	O
the	O
ingredients	O
of	O
a	O
film	O
selected	O
by	O
the	O
back	O
lining	O
layer	O
comprises	O
polyethylene	B
,	O
polyester	B
and	O
ethylvinylacetate	B
.	O

The	O
donepezil	B
percutaneous	O
absorption	O
sticking	O
agent	O
provided	O
by	O
the	O
invention	O
is	O
stable	O
and	O
durable	O
in	O
curative	O
effect	O
,	O
and	O
each	O
sticking	O
agent	O
has	O
5	O
days	O
of	O
effective	O
function	O
.	O

The	O
long	O
-	O
acting	O
donepezil	B
percutaneous	O
absorption	O
sticking	O
agent	O
is	O
characterized	O
in	O
that	O
the	O
back	O
lining	O
layer	O
capable	O
of	O
providing	O
maximum	O
drug	O
-	O
permeable	O
quantity	O
is	O
adopted	O
.	O

The	O
long	O
-	O
acting	O
donepezil	B
percutaneous	O
absorption	O
sticking	O
agent	O
provided	O
by	O
the	O
invention	O
is	O
good	O
in	O
percutaneous	O
permeability	O
,	O
durable	O
and	O
stable	O
in	O
curative	O
effect	O
,	O
and	O
good	O
in	O
skin	O
feeling	O
.	O

Long	O
-	O
acting	O
donepezil	B
percutaneous	O
absorption	O
sticking	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
a	O
preparation	O
technology	O
and	O
a	O
production	O
method	O
for	O
an	O
integrated	O
new	O
formulation	O
of	O
an	O
aluminite	B
decoction	O
,	O
wherein	O
the	O
raw	O
materials	O
of	O
active	O
ingredients	O
comprise	O
:	O
3	O
parts	O
by	O
weight	O
of	O
aluminite	B
,	O
9	O
parts	O
by	O
weight	O
of	O
raw	O
rehmannia	O
root	O
,	O
and	O
3	O
parts	O
by	O
weight	O
of	O
sophora	O
flavescens	O
.	O

The	O
production	O
process	O
of	O
the	O
integrated	O
new	O
formulation	O
aluminite	B
decoction	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
supersonic	O
air	O
-	O
jet	O
crushing	O
,	O
alcohol	O
-	O
water	O
extraction	O
,	O
ultrasonic	O
crushing	O
extraction	O
,	O
water	O
decocting	O
concentration	O
,	O
supersonic	O
spray	O
drying	O
,	O
nanometer	O
grinding	O
,	O
high	O
pressure	O
homogenization	O
,	O
nano	O
particle	O
preparation	O
and	O
the	O
like	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
advantages	O
,	O
such	O
as	O
multi	O
-	O
synergism	O
,	O
multi	O
-	O
target	O
,	O
embodied	O
by	O
a	O
nano	O
-	O
carrier	O
coupling	O
technique	O
,	O
are	O
focused	O
to	O
be	O
taken	O
of	O
.	O

After	O
the	O
integrated	O
new	O
formulation	O
of	O
aluminite	B
decoction	O
is	O
subjected	O
to	O
scale	O
production	O
,	O
the	O
production	O
cost	O
can	O
be	O
greatly	O
reduced	O
,	O
the	O
quality	O
of	O
products	O
is	O
greatly	O
improved	O
and	O
the	O
targeting	O
property	O
and	O
the	O
sustained	O
and	O
controlled	O
release	O
performance	O
of	O
the	O
medicament	O
are	O
enhanced	O
.	O

The	O
internal	O
and	O
external	O
administration	O
of	O
the	O
integrated	O
new	O
formulation	O
of	O
aluminite	B
decoction	O
can	O
be	O
realized	O
simultaneously	O
,	O
and	O
can	O
be	O
respectively	O
taken	O
in	O
four	O
time	O
slices	O
according	O
to	O
midnight	O
-	O
noon	O
ebb	O
-	O
flow	O
and	O
qi	O
and	O
blood	O
flowing	O
rule	O
of	O
a	O
human	O
body	O
.	O

The	O
integrated	O
new	O
formulation	O
of	O
aluminite	B
decoction	O
can	O
be	O
further	O
prepared	O
into	O
films	O
and	O
transdermal	O
agents	O
which	O
are	O
respectively	O
stuck	O
to	O
different	O
parts	O
of	O
a	O
human	O
body	O
according	O
to	O
the	O
midnight	O
-	O
noon	O
ebb	O
-	O
flow	O
and	O
qi	O
and	O
blood	O
flowing	O
rule	O
of	O
the	O
human	O
body	O
and	O
can	O
be	O
directly	O
absorbed	O
through	O
skin	O
.	O

Preparation	O
technology	O
and	O
production	O
method	O
for	O
integrated	O
new	O
formulation	O
of	O
aluminite	B
decoction	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
blended	O
medicine	O
for	O
respiratory	O
diseases	O
of	O
chicken	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
radix	O
bupleuri	O
,	O
herba	O
schizonepetae	O
,	O
pinellia	O
tuber	O
,	O
Indian	O
buead	O
,	O
liquorice	O
,	O
the	O
bulb	O
of	O
fritillary	O
,	O
radix	O
platycodi	O
,	O
almonds	O
,	O
figwort	O
root	O
,	O
red	O
paeony	O
root	O
,	O
mangnolia	O
officinalis	O
,	O
tangerine	O
peel	O
,	O
wild	O
ginger	O
,	O
gypsum	O
,	O
pinellia	O
tuber	O
,	O
radix	O
platycodi	O
,	O
fructus	O
forsythiae	O
and	O
chrysanthemum	O
into	O
coarse	O
powder	O
,	O
sieving	O
the	O
coarse	O
powder	O
with	O
a	O
100	O
-	O
120-mesh	O
sieve	O
and	O
mixing	O
the	O
powder	O
uniformly	O
;	O
adding	O
boiling	O
water	O
to	O
the	O
powder	O
and	O
braising	O
the	O
powder	O
for	O
half	O
an	O
hour	O
and	O
taking	O
the	O
supernatant	O
and	O
adding	O
water	O
for	O
use	O
;	O
or	O
directly	O
stirring	O
the	O
powder	O
obtained	O
after	O
sieving	O
.	O

The	O
preparation	O
method	O
has	O
the	O
following	O
beneficial	O
effects	O
that	O
the	O
blended	O
medicine	O
is	O
simple	O
in	O
proportioning	O
,	O
is	O
convenient	O
to	O
use	O
,	O
has	O
a	O
wide	O
raw	O
material	O
source	O
,	O
lower	O
cost	O
and	O
low	O
side	O
effect	O
and	O
can	O
be	O
blended	O
with	O
feeds	O
;	O
the	O
effective	O
rate	O
is	O
82.6	O
%	O
;	O
and	O
the	O
good	O
rate	O
is	O
90.7	O
%	O
.	O

Preparation	O
method	O
of	O
blended	O
medicine	O
for	O
respiratory	O
diseases	O
of	O
chicken	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
technology	O
of	O
an	O
integrated	O
novel	O
preparation	O
of	O
xiaoqinglong	O
gypsum	O
decoction	O
,	O
comprising	O
the	O
following	O
herbs	O
as	O
effective	O
ingredients	O
:	O
10	O
weight	O
parts	O
of	O
ephedra	O
,	O
10	O
weight	O
parts	O
of	O
white	O
peony	O
root	O
,	O
10	O
weight	O
parts	O
of	O
cassia	O
twig	O
,	O
10	O
weight	O
parts	O
of	O
as	O
arum	O
,	O
10	O
weight	O
parts	O
of	O
prepared	O
radix	O
licorice	O
,	O
10	O
parts	O
of	O
dried	O
ginger	O
,	O
12	O
weight	O
parts	O
of	O
fructus	O
schizandrae	O
,	O
12	O
weight	O
parts	O
of	O
pinellia	O
ternate	O
,	O
and	O
12	O
weight	O
parts	O
of	O
gypsum	O
.	O

The	O
preparation	O
process	O
comprises	O
the	O
following	O
steps	O
:	O
conducting	O
supersonic	O
airflow	O
grinding	O
,	O
alcohol	B
and	O
aqua	O
abstraction	O
,	O
supersonic	O
shattering	O
extraction	O
,	O
decocting	O
for	O
concentration	O
,	O
supersonic	O
spray	O
drying	O
,	O
nanogrinding	O
,	O
high	O
-	O
pressure	O
homogenization	O
,	O
nanoparticle	O
preparation	O
,	O
etc	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
advantages	O
of	O
multi	O
-	O
synergy	O
and	O
multi	O
-	O
targets	O
reflected	O
in	O
nanocarrier	O
combined	O
technology	O
are	O
utilized	O
herein	O
;	O
after	O
large	O
-	O
scale	O
production	O
,	O
the	O
production	O
cost	O
can	O
be	O
greatly	O
reduced	O
,	O
the	O
product	O
quality	O
can	O
be	O
greatly	O
raised	O
,	O
and	O
the	O
drug	O
targeting	O
and	O
slow	O
releasing	O
action	O
are	O
improved	O
;	O
the	O
decoction	O
preparation	O
disclosed	O
herein	O
can	O
be	O
taken	O
internally	O
and	O
externally	O
and	O
can	O
be	O
respectively	O
taken	O
for	O
4	O
periods	O
of	O
time	O
according	O
to	O
midnight	O
-	O
midday	O
ebb	O
flow	O
and	O
qi	O
and	O
blood	O
flow	O
rules	O
of	O
body	O
body	O
;	O
the	O
decoction	O
preparation	O
disclosed	O
herein	O
can	O
be	O
prepared	O
into	O
a	O
film	O
-	O
forming	O
agent	O
and	O
a	O
transdermal	O
agent	O
,	O
can	O
be	O
respectively	O
applied	O
on	O
different	O
parts	O
of	O
human	O
body	O
according	O
to	O
the	O
midnight	O
-	O
midday	O
ebb	O
flow	O
and	O
qi	O
and	O
blood	O
flow	O
rules	O
of	O
human	O
body	O
,	O
and	O
can	O
be	O
adsorbed	O
directly	O
through	O
skins	O
.	O

Preparation	O
technology	O
of	O
integrated	O
novel	O
preparation	O
of	O
xiaoqinglong	O
gypsum	O
decoction	O

The	O
present	O
invention	O
discloses	O
a	O
granule	O
for	O
treatment	O
of	O
heat	O
toxin	O
symptom	O
caused	O
by	O
chicken	O
escherichia	O
coli	O
infection	O
.	O

The	O
raw	O
material	O
ratio	O
by	O
crude	O
medicines	O
includes	O
:	O
30	O
-	O
90	O
g	O
of	O
gypsum	O
,	O
3	O
-	O
20	O
g	O
of	O
honeysuckle	O
,	O
2	O
-	O
30	O
g	O
of	O
figwort	O
root	O
,	O
2	O
-	O
15	O
g	O
of	O
baical	O
skullcap	O
root	O
,	O
2	O
-	O
15	O
g	O
of	O
dried	O
radix	O
rehmannia	O
,	O
2	O
-	O
15	O
g	O
of	O
fructus	O
forsythiae	O
,	O
2	O
-	O
15	O
g	O
of	O
fruit	O
of	O
cape	O
jasmine	O
,	O
2	O
-	O
15	O
g	O
of	O
gentiana	O
scabra	O
bunge	O
,	O
2	O
-	O
30	O
g	O
of	O
bunge	O
corydalis	O
herb	O
,	O
2	O
-	O
40	O
g	O
of	O
isatis	O
root	O
,	O
2	O
-	O
15	O
g	O
of	O
rhizoma	O
anemarrhena	O
,	O
and	O
2	O
-	O
15	O
g	O
of	O
radix	O
ophiopogonis	O
.	O

The	O
granule	O
also	O
includes	O
an	O
excipient	O
.	O

The	O
preparation	O
method	O
of	O
the	O
granule	O
includes	O
:	O
(	O
1	O
)	O
extracting	O
the	O
prescription	O
medicine	O
to	O
make	O
extract	O
powder	O
;	O
(	O
2	O
)	O
adding	O
the	O
excipient	O
and	O
mixing	O
;	O
and	O
(	O
3	O
)	O
granulating	O
,	O
drying	O
and	O
packaging	O
to	O
get	O
finished	O
products	O
.	O

The	O
granule	O
of	O
the	O
present	O
invention	O
has	O
a	O
trade	O
name	O
of	O
clearing	O
and	O
releasing	O
granule	O
,	O
has	O
the	O
effect	O
of	O
clearing	O
heat	O
and	O
detoxifying	O
,	O
is	O
significant	O
in	O
effects	O
and	O
easy	O
to	O
take	O
,	O
and	O
has	O
no	O
toxic	O
side	O
effects	O
.	O

Granule	O
for	O
treatment	O
of	O
heat	O
toxin	O
symptom	O
caused	O
by	O
chicken	O
escherichia	O
coli	O
infection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
medicine	O
composition	O
for	O
treating	O
rash	O
diseases	O
.	O

The	O
medicine	O
composition	O
is	O
a	O
preparation	O
prepared	O
from	O
the	O
following	O
active	O
pharmaceutical	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
4	O
-	O
8	O
parts	O
of	O
donkey	O
-	O
hide	O
glue	O
,	O
8	O
-	O
16	O
parts	O
of	O
angelica	O
sinensis	O
,	O
8	O
-	O
16	O
parts	O
of	O
white	O
paeony	O
root	O
,	O
4	O
-	O
8	O
parts	O
of	O
flaxseed	O
,	O
12	O
-	O
24	O
parts	O
of	O
radix	O
rehmanniae	O
,	O
12	O
-	O
24	O
parts	O
of	O
dwarf	O
lilyturf	O
tuber	O
,	O
16	O
-	O
32	O
parts	O
of	O
gypsum	O
,	O
8	O
-	O
16	O
parts	O
of	O
rhizoma	O
anemarrhenae	O
,	O
7	O
-	O
13	O
parts	O
of	O
cortex	O
moutan	O
,	O
10	O
-	O
20	O
parts	O
of	O
Sinkiang	O
arnebia	O
root	O
,	O
16	O
-	O
32	O
parts	O
of	O
lemna	O
minor	O
,	O
7	O
-	O
13	O
parts	O
of	O
belvedere	O
fruit	O
,	O
7	O
-	O
13	O
parts	O
of	O
radix	O
sophorae	O
flavescentis	O
,	O
5	O
-	O
11	O
parts	O
of	O
periostracum	O
cicadae	O
,	O
2	O
-	O
5	O
parts	O
of	O
Chinese	O
tamarisk	O
twig	O
,	O
5	O
-	O
11	O
parts	O
of	O
great	O
burdock	O
achene	O
and	O
2	O
-	O
5	O
parts	O
of	O
liquorice	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
the	O
medicine	O
composition	O
.	O

The	O
medicine	O
composition	O
can	O
effectively	O
eliminate	O
or	O
greatly	O
relieve	O
such	O
rash	O
diseases	O
as	O
eczema	O
and	O
prurigo	O
,	O
can	O
cure	O
the	O
primary	O
diseases	O
to	O
some	O
extent	O
and	O
provides	O
a	O
new	O
choice	O
for	O
clinical	O
medication	O
.	O

Medicine	O
composition	O
for	O
treating	O
rash	O
diseases	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
for	O
a	O
drug	O
,	O
ginger	O
-	O
garlic	O
ointment	O
,	O
for	O
treating	O
chilblain	O
.	O

The	O
method	O
comprises	O
the	O
steps	O
of	O
smashing	O
ginger	O
,	O
garlic	O
and	O
fistular	O
onion	O
stalk	O
into	O
mud	O
;	O
squeezing	O
the	O
mud	O
;	O
taking	O
juice	O
;	O
putting	O
cassia	O
twig	O
,	O
angelica	O
sinensis	O
,	O
safflower	O
carthamus	O
and	O
the	O
like	O
into	O
a	O
pot	O
;	O
adding	O
water	O
to	O
the	O
pot	O
;	O
boiling	O
the	O
water	O
;	O
filtering	O
juice	O
,	O
concentrating	O
to	O
a	O
dilute	O
paste	O
state	O
;	O
pouring	O
the	O
onion	O
,	O
ginger	O
and	O
garlic	O
juice	O
,	O
edible	O
vinegar	B
and	O
sesame	O
oil	O
into	O
the	O
dilute	O
paste	O
;	O
heating	O
to	O
boil	O
;	O
loading	O
in	O
bottles	O
;	O
storing	O
;	O
and	O
wiping	O
the	O
affected	O
part	O
when	O
the	O
ointment	O
is	O
in	O
use	O
.	O

The	O
ginger	O
-	O
garlic	O
ointment	O
has	O
the	O
functions	O
of	O
warming	O
channel	O
to	O
dissipate	O
cold	O
and	O
nourishing	O
blood	O
to	O
pass	O
veins	O
,	O
and	O
has	O
very	O
ideal	O
curative	O
effects	O
for	O
itches	O
and	O
pains	O
of	O
the	O
chilblain	O
,	O
ulcer	O
ichor	O
flow	O
,	O
etc	O
.	O

Preparation	O
method	O
for	O
drug	O
,	O
ginger	O
-	O
garlic	O
ointment	O
,	O
for	O
treating	O
chilblain	O

The	O
invention	O
discloses	O
a	O
2-hydroxy	B
-	I
N-	I
(	I
2-hydroxybenzoyl	I
)	I
benzo	I
-	I
hydrazide	I
dibutyl	I
tin	I
complex	O
which	O
has	O
higher	O
antitumor	O
activity	O
so	O
as	O
to	O
be	O
taken	O
as	O
raw	O
material	O
to	O
prepare	O
medicines	O
for	O
treating	O
mice	O
chronic	O
myeloid	O
leukemia	O
and	O
cervical	O
cancer	O
;	O
and	O
compared	O
with	O
the	O
existing	O
commonly	O
used	O
platinum	B
anticancer	O
medicines	O
,	O
the	O
organic	O
tin	B
complex	O
has	O
the	O
characteristics	O
of	O
higher	O
antitumor	O
activity	O
,	O
good	O
lipid	O
solubility	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
and	O
the	O
like	O
.	O

2-hydroxy	B
-	I
N-	I
(	I
2-hydroxybenzoyl	I
)	I
benzo	I
-	I
hydrazide	I
dibutyl	I
tin	I
complex	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
application	O
of	O
pectin	O
enzymatic	O
hydrolysis	O
product	O
having	O
functions	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	B
and	O
resisting	O
drunk	O
.	O

Constant	O
-	O
temperature	O
enzymatic	O
hydrolysis	O
and	O
de	O
-	O
fatting	O
are	O
performed	O
to	O
polymer	O
high	O
-	O
fat	O
pectin	O
by	O
pectin	O
esterase	O
and	O
pectinase	O
,	O
filtrate	O
is	O
subjected	O
to	O
alcohol	B
precipitation	O
and	O
alcohol	B
leaching	O
after	O
product	O
is	O
filtered	O
to	O
obtain	O
high	O
-	O
purity	O
product	O
,	O
and	O
the	O
high	O
-	O
purity	O
product	O
is	O
subjected	O
to	O
vacuum	O
drying	O
and	O
crushing	O
and	O
screening	O
to	O
obtain	O
pectin	O
enzymatic	O
hydrolysis	O
product	O
having	O
excellent	O
effects	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	B
and	O
resisting	O
drunk	O
.	O

Esterification	O
degree	O
and	O
molecular	O
weight	O
of	O
the	O
pectin	O
are	O
reduced	O
by	O
enzymatic	O
hydrolysis	O
and	O
de	O
-	O
fatting	O
of	O
the	O
pectin	O
,	O
the	O
effects	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	B
and	O
resisting	O
drunk	O
of	O
product	O
are	O
enhanced	O
by	O
the	O
pectin	O
compared	O
with	O
by	O
the	O
raw	O
materials	O
.	O

Pectin	O
is	O
deeply	O
developed	O
and	O
utilized	O
,	O
additional	O
value	O
of	O
the	O
pectin	O
is	O
convenient	O
to	O
increase	O
,	O
and	O
application	O
range	O
of	O
pectin	O
is	O
broadened	O
.	O

The	O
enzymatic	O
hydrolysis	O
product	O
has	O
high	O
effects	O
of	O
dispelling	O
the	O
effects	O
of	O
alcohol	B
and	O
resisting	O
drunk	O
and	O
can	O
be	O
used	O
as	O
alcohol	B
-	O
effect	O
-	O
dispelling	O
and	O
drunk	O
-	O
resisting	O
components	O
to	O
be	O
applied	O
to	O
the	O
field	O
of	O
medicine	O
and	O
food	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
pectin	O
enzymatic	O
hydrolysis	O
product	O
having	O
functions	O
of	O
dispelling	O
effects	O
of	O
alcohol	B
and	O
resisting	O
drunk	O

The	O
invention	O
relates	O
to	O
composite	O
calcium	B
carbonate	I
/	O
vitamin	B
D3	I
granules	O
for	O
children	O
prepared	O
from	O
the	O
raw	O
materials	O
,	O
such	O
as	O
calcium	B
carbonate	I
/	O
vitamin	B
D3	I
and	O
an	O
adjuvant	O
.	O

The	O
preparation	O
is	O
granules	O
,	O
each	O
bag	O
contains	O
1,250	O
mg	O
of	O
calcium	B
carbonate	I
and	O
vitamin	B
D3	I
with	O
an	O
international	O
unit	O
of	O
200	O
,	O
and	O
the	O
adjuvant	O
is	O
selected	O
from	O
a	O
diluent	O
,	O
a	O
bonding	O
agent	O
,	O
a	O
wetting	O
agent	O
and	O
a	O
flavoring	O
agent	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
composite	O
calcium	B
carbonate	I
/	O
vitamin	B
D3	I
granules	O
for	O
children	O
,	O
a	O
prescription	O
and	O
a	O
preparation	O
technology	O
are	O
feasible	O
,	O
so	O
that	O
the	O
grannles	O
are	O
suitable	O
for	O
mass	O
production	O
;	O
and	O
the	O
prepared	O
composite	O
calcium	B
carbonate	I
/	O
vitamin	B
D3	I
granules	O
are	O
good	O
in	O
granulation	O
property	O
,	O
and	O
have	O
better	O
degree	O
of	O
homogeneity	O
and	O
higher	O
dissolution	O
rate	O
.	O

The	O
composite	O
calcium	B
carbonate	I
/	O
vitamin	B
D3	I
granules	O
for	O
children	O
disclosed	O
by	O
the	O
invention	O
are	O
suitable	O
for	O
children	O
,	O
old	O
people	O
and	O
the	O
persons	O
who	O
have	O
swallowing	O
difficulties	O
,	O
especially	O
suitable	O
for	O
children	O
.	O

Composite	O
calcium	B
carbonate	I
/	O
vitamin	B
D3	I
granules	O
for	O
children	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
crystal	O
form	O
of	O
esomeprazole	O
magnesium	O
.	O

Particularly	O
,	O
the	O
invention	O
relates	O
to	O
I	O
type	O
crystalline	O
and	O
II	O
type	O
crystalline	O
of	O
esomeprazole	O
magnesium	O
salt	O
or	O
hydrate	O
thereof	O
,	O
a	O
method	O
for	O
preparing	O
the	O
crystalline	O
,	O
a	O
crystallization	O
composition	O
and	O
a	O
drug	O
composition	O
with	O
the	O
crystalline	O
and	O
applications	O
of	O
the	O
crystalline	O
in	O
the	O
field	O
of	O
medicine	O
.	O

The	O
crystalline	O
has	O
good	O
stability	O
and	O
is	O
easy	O
to	O
store	O
,	O
the	O
preparation	O
method	O
is	O
simple	O
,	O
and	O
a	O
high	O
-	O
purity	O
product	O
can	O
be	O
prepared	O
.	O

The	O
crystal	O
plane	O
spacing	O
d	O
value	O
for	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
spectrum	O
of	O
the	O
I	O
type	O
crystalline	O
of	O
the	O
esomeprazole	O
magnesium	O
salt	O
shows	O
that	O
a	O
diffraction	O
peak	O
exists	O
.	O

The	O
crystal	O
plane	O
spacing	O
d	O
value	O
for	O
the	O
X	O
-	O
ray	O
powder	O
diffraction	O
spectrum	O
of	O
the	O
II	O
type	O
crystalline	O
of	O
the	O
esomeprazole	O
magnesium	O
salt	O
shows	O
that	O
the	O
diffraction	O
peak	O
exists	O
.	O

Crystal	O
form	O
of	O
esomeprazole	O
magnesium	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
chemical	O
medicaments	O
,	O
and	O
in	O
particular	O
relates	O
to	O
8H	B
-	I
benzopyran	I
[	I
2,3-f	I
]	I
-4-ketone	I
derivatives	O
and	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
derivatives	O
.	O

The	O
first	O
technical	O
problem	O
to	O
be	O
solved	O
by	O
the	O
invention	O
is	O
to	O
provide	O
8,8-dimethyl-3-	B
(	I
2,4,5-trimethoxy	I
phenyl	I
)	I
-8H	I
-	I
benzopyran	I
[	I
2,3-f	I
]	I
-4-ketone	I
and	O
analogs	O
thereof	O
,	O
the	O
structure	O
of	O
which	O
is	O
shown	O
in	O
formula	O
I	O
in	O
the	O
specification	O
.	O

8H	B
-	I
benzopyran	I
[	I
2,3-f	I
]	I
-4-ketone	I
derivatives	O
obtained	O
on	O
the	O
basis	O
of	O
a	O
great	O
deal	O
of	O
screening	O
have	O
antitumor	O
activity	O
,	O
so	O
that	O
a	O
new	O
choice	O
is	O
provided	O
for	O
development	O
and	O
application	O
of	O
antitumor	O
medicaments	O
.	O

8H	B
-	I
benzopyran	I
[	I
2,3-f	I
]	I
-4-ketone	I
derivatives	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
bromophenol	B
compound	O
applied	O
to	O
a	O
receptor	O
inhibitor	O
or	O
a	O
malignant	O
tumor	O
drug	O
of	O
a	O
receptor	O
tyrosine	B
kinasec	O
-	O
kit	O
which	O
is	O
also	O
called	O
KIT	O
,	O
CD117	O
,	O
stem	O
cell	O
factor	O
receptor	O
and	O
mast	O
cell	O
growth	O
factor	O
receptor	O
.	O

The	O
bromophenol	B
compound	O
is	O
a	O
new	O
compound	O
with	O
a	O
novel	O
structure	O
.	O

The	O
molecular	O
biology	O
experiment	O
and	O
pharmacological	O
experiment	O
verify	O
that	O
the	O
compound	O
has	O
a	O
good	O
inhibiting	O
effect	O
on	O
the	O
receptor	O
tyrosine	B
kinasec	O
-	O
kit	O
and	O
an	O
important	O
value	O
for	O
treatment	O
of	O
the	O
malignant	O
tumor	O
.	O

Bromophenol	B
compound	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
an	O
antibacterial	O
health	O
-	O
care	O
pillow	O
which	O
is	O
characterized	O
by	O
comprising	O
a	O
core	O
layer	O
,	O
a	O
health	O
-	O
care	O
cover	O
layer	O
and	O
a	O
health	O
-	O
care	O
material	O
layer	O
arranged	O
between	O
the	O
core	O
layer	O
and	O
the	O
health	O
-	O
care	O
cover	O
layer	O
.	O

An	O
antibacterial	O
layer	O
is	O
further	O
arranged	O
between	O
the	O
health	O
-	O
care	O
material	O
layer	O
and	O
the	O
health	O
-	O
care	O
cover	O
layer	O
,	O
the	O
core	O
layer	O
is	O
made	O
of	O
latex	O
,	O
the	O
health	O
-	O
care	O
material	O
layer	O
is	O
formed	O
by	O
mixing	O
borneol	B
,	O
asarum	O
and	O
musk	O
,	O
and	O
the	O
antibacterial	O
layer	O
is	O
made	O
of	O
chitosan	O
fiber	O
non	O
-	O
woven	O
fabrics	O
.	O

The	O
antibacterial	O
health	O
-	O
care	O
pillow	O
has	O
good	O
effects	O
on	O
heart	O
-	O
fire	O
clearing	O
,	O
eyesight	O
improving	O
,	O
fungi	O
prevention	O
and	O
mite	O
removal	O
,	O
has	O
good	O
comfort	O
,	O
and	O
has	O
good	O
market	O
prospect	O
in	O
the	O
field	O
of	O
high	O
-	O
end	O
pillows	O
.	O

Antibacterial	O
health	O
-	O
care	O
pillow	O

The	O
invention	O
discloses	O
a	O
flurbiprofen	B
axetil	I
micro	O
-	O
emulsion	O
gel	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
flurbiprofen	B
axetil	I
micro	O
-	O
emulsion	O
gel	O
preparation	O
is	O
characterized	O
in	O
that	O
the	O
preparation	O
is	O
composed	O
of	O
a	O
gel	O
substrate	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
medicine	O
-	O
containing	O
micro	O
-	O
emulsion	O
loaded	O
on	O
the	O
substrate	O
.	O

The	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
process	O
and	O
easy	O
operation	O
.	O

The	O
prepared	O
micro	O
-	O
emulsion	O
gel	O
preparation	O
can	O
be	O
prepared	O
into	O
patches	O
,	O
such	O
that	O
a	O
novel	O
administration	O
mode	O
of	O
flurbiprofen	B
axetil	I
is	O
provided	O
,	O
and	O
flurbiprofen	B
axetil	I
efficacy	O
and	O
application	O
efficiency	O
are	O
improved	O
.	O

Flurbiprofen	B
axetil	I
micro	O
-	O
emulsion	O
gel	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
for	O
preventing	O
and	O
treating	O
neuropathic	O
pain	O
.	O

The	O
medicine	O
is	O
prepared	O
from	O
magnoflorine	B
and	O
ranunculin	B
which	O
are	O
used	O
as	O
bulk	O
pharmaceuticals	O
in	O
a	O
certain	O
proportion	O
;	O
the	O
medicine	O
can	O
be	O
prepared	O
into	O
various	O
preparations	O
by	O
the	O
conventional	O
preparation	O
process	O
;	O
the	O
defects	O
in	O
the	O
prior	O
art	O
are	O
overcome	O
;	O
the	O
medicinal	O
composition	O
which	O
is	O
used	O
for	O
treating	O
neuropathic	O
pain	O
and	O
is	O
obvious	O
in	O
curative	O
effect	O
and	O
safe	O
is	O
provided	O
;	O
the	O
provided	O
medicine	O
is	O
easy	O
to	O
prepare	O
and	O
low	O
in	O
cost	O
;	O
and	O
the	O
clinical	O
test	O
proves	O
that	O
the	O
medicine	O
has	O
an	O
obvious	O
clinical	O
effect	O
on	O
neuropathic	O
pain	O
comprising	O
prosopalgia	O
,	O
ischialgia	O
,	O
sciatica	O
of	O
nerve	O
roots	O
,	O
postherpetic	O
neuralgia	O
and	O
diabetic	O
peripheral	O
polyneuritis	O
and	O
the	O
like	O
.	O

Medicinal	O
composition	O
for	O
preventing	O
and	O
treating	O
neuropathic	O
pain	O

The	O
invention	O
discloses	O
an	O
acupuncture	O
point	O
soft	O
body	O
wax	O
moxibustion	O
medicine	O
for	O
external	O
application	O
.	O

The	O
medicine	O
is	O
manufactured	O
by	O
components	O
according	O
to	O
the	O
following	O
weight	O
ratios	O
:	O
50	O
parts	O
of	O
milkvetch	O
root	O
,	O
20	O
parts	O
of	O
cortex	O
moutan	O
,	O
19	O
parts	O
of	O
mirabilite	O
,	O
8	O
parts	O
of	O
pinellia	O
ternate	O
,	O
30	O
parts	O
of	O
frankincense	O
,	O
40	O
parts	O
of	O
myrrh	O
,	O
10	O
parts	O
of	O
liquorice	O
,	O
10	O
parts	O
of	O
ephedra	O
,	O
30	O
parts	O
of	O
cortex	O
acanthopanacis	O
,	O
10	O
parts	O
of	O
safflower	O
carthamus	O
,	O
3	O
parts	O
of	O
radix	O
angelicae	O
,	O
80	O
parts	O
of	O
cassia	O
twig	O
,	O
40	O
parts	O
of	O
cinnamon	O
,	O
60	O
parts	O
of	O
rhizoma	O
zingiberis	O
,	O
30	O
parts	O
of	O
pseudo	O
-	O
ginseng	O
,	O
40	O
parts	O
of	O
radix	O
stephaniae	O
tetrandrae	O
,	O
20	O
parts	O
of	O
lycopodium	O
clavatum	O
,	O
5	O
parts	O
of	O
mentha	O
haplocalyx	O
,	O
2	O
part	O
of	O
indigo	O
naturalis	O
,	O
1	O
part	O
of	O
borneol	B
,	O
150	O
parts	O
of	O
glycerol	B
,	O
60	O
parts	O
of	O
Vaseline	O
,	O
70	O
parts	O
of	O
distilled	O
water	O
,	O
50	O
parts	O
of	O
liquid	O
paraffin	O
,	O
and	O
60	O
parts	O
of	O
alcohol	B
with	O
75	O
%	O
concentration	O
.	O

The	O
production	O
steps	O
are	O
:	O
smashing	O
the	O
components	O
,	O
mixing	O
and	O
stirring	O
,	O
adding	O
the	O
alcohol	B
,	O
and	O
packaging	O
.	O

The	O
method	O
for	O
external	O
application	O
is	O
that	O
using	O
an	O
ashi	O
acupuncture	O
point	O
as	O
a	O
center	O
,	O
medicines	O
are	O
externally	O
applied	O
to	O
the	O
extending	O
area	O
around	O
the	O
ashi	O
acupuncture	O
point	O
through	O
acupuncture	O
point	O
soft	O
body	O
wax	O
moxibustion	O
,	O
medication	O
time	O
is	O
30	O
-	O
40	O
minutes	O
,	O
and	O
10-minute	O
kneading	O
is	O
needed	O
after	O
the	O
application	O
of	O
the	O
medicines	O
.	O

The	O
acupuncture	O
point	O
soft	O
body	O
wax	O
moxibustion	O
medicine	O
for	O
external	O
application	O
and	O
the	O
manufacture	O
and	O
external	O
application	O
methods	O
thereof	O
is	O
good	O
in	O
treatment	O
effects	O
,	O
safe	O
in	O
use	O
,	O
and	O
does	O
not	O
produce	O
allergic	O
reaction	O
.	O

Acupuncture	O
point	O
soft	O
body	O
wax	O
moxibustion	O
medicine	O
for	O
external	O
application	O
and	O
manufacture	O
and	O
external	O
application	O
methods	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
novel	O
crystal	O
form	O
of	O
tigecycline	B
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
novel	O
crystal	O
form	O
of	O
tigecycline	B
has	O
the	O
following	O
diffraction	O
peaks	O
on	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
pattern	O
:	O
4.6	O
,	O
6.2	O
,	O
6.6	O
,	O
8.8	O
,	O
9.3	O
,	O
9.6	O
,	O
12.0	O
,	O
12.4	O
,	O
13.6	O
,	O
17.6	O
,	O
18.0	O
,	O
20.0	O
,	O
21.4	O
,	O
23.2	O
and	O
26.6	O
.	O

Deviation	O
values	O
of	O
the	O
diffraction	O
peaks	O
are	O
+	O
/-0.2	O
degrees	O
.	O

Novel	O
crystal	O
form	O
of	O
tigecycline	B
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
use	O
of	O
a	O
compound	O
Eryngiolide	B
A	I
in	O
a	O
pharmaceutical	O
field	O
.	O

The	O
present	O
invention	O
relates	O
to	O
applications	O
of	O
the	O
Eryngiolide	B
A	I
in	O
platelet	O
increase	O
drug	O
preparation	O
.	O

According	O
to	O
the	O
present	O
invention	O
,	O
the	O
uses	O
of	O
the	O
Eryngiolide	B
A	I
in	O
thrombocytopenia	O
treatment	O
drug	O
preparation	O
are	O
firstly	O
disclosed	O
;	O
and	O
a	O
skeleton	O
type	O
of	O
the	O
Eryngiolide	B
A	I
belongs	O
to	O
a	O
completely	O
new	O
skeleton	O
type	O
,	O
thrombocytopenia	O
treatment	O
activity	O
of	O
the	O
Eryngiolide	B
A	I
is	O
strong	O
,	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelations	O
for	O
the	O
Eryngiolide	B
A	I
can	O
not	O
exist	O
,	O
prominent	O
substantive	O
characteristics	O
are	O
provided	O
,	O
and	O
significant	O
progress	O
for	O
thrombocytopenia	O
prevention	O
and	O
treatment	O
is	O
provided	O
.	O

Applications	O
of	O
Eryngiolide	B
A	I
in	O
platelet	O
increase	O
drugs	O

The	O
invention	O
discloses	O
a	O
medicine	O
composition	O
for	O
treating	O
asthma	O
.	O

The	O
medicine	O
composition	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
15	O
parts	O
of	O
white	O
mulberry	O
root	O
-	O
bark	O
,	O
10	O
-	O
20	O
parts	O
of	O
South	O
China	O
sea	O
cucumbers	O
,	O
1	O
-	O
5	O
parts	O
of	O
white	O
gourd	O
seeds	O
,	O
5	O
-	O
8	O
parts	O
of	O
ginkgoes	O
,	O
5	O
-	O
7	O
parts	O
of	O
lily	O
,	O
5	O
-	O
10	O
parts	O
of	O
raw	O
white	O
atractylodes	O
rhizome	O
,	O
5	O
-	O
15	O
parts	O
of	O
almonds	O
,	O
5	O
-	O
15	O
parts	O
of	O
coptis	O
root	O
,	O
0.1	O
-	O
1	O
part	O
of	O
inactivated	O
-	O
mycobacterium	O
phlei	O
,	O
10	O
-	O
15	O
parts	O
of	O
albuterol	O
sulfate	O
,	O
2	O
-	O
8	O
parts	O
of	O
common	O
andrographis	O
herb	O
and	O
5	O
-	O
10	O
parts	O
of	O
lotus	O
seeds	O
.	O

The	O
medicine	O
composition	O
has	O
a	O
good	O
curative	O
effect	O
,	O
nourishes	O
the	O
heart	O
and	O
lung	O
,	O
and	O
has	O
extensive	O
clinical	O
values	O
.	O

Medicine	O
composition	O
for	O
treating	O
asthma	O

The	O
invention	O
provides	O
flavanol	B
containing	I
3-nitro	I
propionyl	I
,	O
namely	O
a	O
compound	O
HQM-3	O
(	O
compound	O
1	O
)	O
,	O
which	O
is	O
shown	O
in	O
a	O
structural	O
formula	O
(	O
1	O
)	O
and	O
has	O
a	O
hepatic	O
cell	O
damage	O
resistance	O
effect	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
a	O
medical	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
application	O
of	O
the	O
compound	O
and	O
the	O
medical	O
composition	O
thereof	O
in	O
the	O
preparation	O
of	O
medicaments	O
having	O
a	O
hepatic	O
cell	O
damage	O
resistance	O
effect	O
and	O
the	O
preparation	O
of	O
medicaments	O
for	O
liver	O
protection	O
.	O

Flavanol	B
containing	I
3-nitro	I
propionyl	I
,	O
medical	O
composition	O
contain	O
same	O
and	O
application	O
thereof	O
in	O
pharmacy	O

Isolated	O
compounds	O
from	O
adelostemma	O
gracillimum	O
refined	O
fractions	O
and	O
compositions	O
containing	O
the	O
compounds	O
are	O
provided	O
by	O
the	O
present	O
invention	O
.	O

Adelostemma	O
gracillimum	O
refined	O
fractions	O
and	O
the	O
extraction	O
process	O
thereof	O
are	O
also	O
provided	O
by	O
the	O
present	O
invention	O
.	O

The	O
uses	O
of	O
the	O
compounds	O
and	O
the	O
adelostemma	O
gracillimum	O
refined	O
fractions	O
for	O
inhibiting	O
the	O
activities	O
of	O
NMDA	O
receptor	O
or	O
amyloid	O
-	O
beta	O
peptide	O
,	O
for	O
improving	O
memory	O
,	O
and	O
for	O
treating	O
neurodegenerative	O
diseases	O
,	O
neuropathological	O
conditions	O
or	O
epilepsy	O
are	O
further	O
provided	O
by	O
the	O
present	O
invention	O
.	O

Neuro	O
-	O
protective	O
effects	O
of	O
adelostemma	O
gracillimum	O
and	O
its	O
isolated	O
compounds	O

The	O
present	O
invention	O
relates	O
to	O
pyridine	B
compounds	O
useful	O
as	O
inhibitors	O
of	O
ATR	O
protein	O
kinase	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
methods	O
of	O
treating	O
various	O
diseases	O
,	O
disorders	O
,	O
and	O
conditions	O
using	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
processes	O
for	O
preparing	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
intermediates	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
this	O
invention	O
;	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
in	O
vitro	O
applications	O
,	O
such	O
as	O
the	O
study	O
of	O
kinases	O
in	O
biological	O
and	O
pathological	O
phenomena	O
;	O
the	O
study	O
of	O
intracellular	O
signal	O
transduction	O
pathways	O
mediated	O
by	O
such	O
kinases	O
;	O
and	O
the	O
comparative	O
evaluation	O
of	O
new	O
kinase	O
inhibitors	O
.	O

The	O
compounds	O
of	O
this	O
invention	O
have	O
formula	O
(	O
III	O
)	O
:	O
(	O
Formula	O
(	O
III	O
)	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O

2	B
-aminopyridine	I
derivatives	O
useful	O
as	O
inhibitors	O
of	O
atr	O
kinase	O

The	O
invention	O
relates	O
to	O
a	O
nicotinic	B
acid	I
slow	O
-	O
release	O
tablet	O
composition	O
,	O
which	O
comprises	O
nicotinic	B
acid	I
,	O
a	O
slow	O
-	O
release	O
material	O
quaternary	B
ammonium	I
acrylate	I
copolymer	O
and	O
other	O
pharmaceutical	O
auxiliary	O
materials	O
.	O

The	O
composition	O
is	O
a	O
new	O
nicotinic	B
acid	I
slow	O
-	O
release	O
tablet	O
composition	O
adopting	O
a	O
quaternary	B
ammonium	I
acrylate	I
copolymer	O
as	O
a	O
slow	O
release	O
auxiliary	O
material	O
,	O
wherein	O
defects	O
in	O
the	O
existing	O
products	O
and	O
the	O
existing	O
patents	O
are	O
solved	O
with	O
the	O
composition	O
of	O
the	O
present	O
invention	O
,	O
and	O
slow	O
release	O
of	O
the	O
nicotinic	B
acid	I
in	O
human	O
body	O
can	O
be	O
ensured	O
.	O

Nicotinic	B
acid	I
slow	O
-	O
release	O
tablet	O
composition	O

The	O
invention	O
provides	O
amoxicillin	B
sodium	I
and	O
potassium	B
clavulanate	I
for	O
injection	O
,	O
which	O
comprises	O
amoxicillin	B
,	O
potassium	B
clavulanate	I
and	O
a	O
pH	O
(	O
Potential	O
of	O
Hydrogen	B
)	O
value	O
regulating	O
reagent	O
,	O
wherein	O
the	O
quantity	O
of	O
the	O
pH	O
value	O
regulating	O
reagent	O
enables	O
the	O
pH	O
value	O
of	O
a	O
solution	O
to	O
be	O
between	O
6.5	O
and	O
7.0	O
when	O
water	O
is	O
added	O
for	O
preparing	O
the	O
100mg	O
/	O
ml	O
solution	O
;	O
the	O
weight	O
ratio	O
of	O
the	O
amoxicillin	B
to	O
the	O
potassium	B
clavulanate	I
is	O
(	O
16	O
-	O
5	O
)	O
:1	O
;	O
and	O
the	O
grain	O
size	O
of	O
each	O
component	O
is	O
between	O
25	O
and	O
100	O
microns	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
amoxicillin	B
sodium	I
and	O
potassium	B
clavulanate	I
for	O
injection	O
.	O

Amoxicillin	B
sodium	I
and	O
potassium	B
clavulanate	I
for	O
injection	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
blumea	O
balsamifera	O
.	O

According	O
to	O
the	O
research	O
,	O
the	O
blumea	O
balsamifera	O
has	O
an	O
obvious	O
suppression	O
effect	O
on	O
mastocyte	O
activated	O
degranulation	O
reaction	O
and	O
can	O
be	O
used	O
for	O
treating	O
or	O
/	O
and	O
preventing	O
type	O
I	O
hypersensitivity	O
diseases	O
.	O

Therefore	O
,	O
the	O
invention	O
provides	O
the	O
application	O
of	O
blumea	O
balsamifera	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
or	O
/	O
and	O
preventing	O
type	O
I	O
hypersensitivity	O
diseases	O
.	O

Application	O
of	O
blumea	O
balsamifera	O

The	O
invention	O
discloses	O
a	O
cervical	O
cancer	O
cell	O
inhibitor	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
weighing	O
Cd	B
(	I
NO3	I
)	I
24H20	I
to	O
2-pyridine	B
benzimidazole	I
(	O
2-Pbim	B
)	O
to	O
5-hydroxyisoph	B
(	O
OH	B
-	I
H2Bdc	I
)	O
in	O
a	O
molar	O
ratio	O
of	O
(	O
1	O
-	O
3	O
)	O
:	O
(	O
1	O
-	O
2	O
)	O
:1	O
;	O
adding	O
water	O
and	O
putting	O
into	O
a	O
container	O
,	O
adding	O
triethylamine	B
,	O
and	O
uniformly	O
stirring	O
;	O
putting	O
the	O
stirred	O
raw	O
materials	O
in	O
a	O
reaction	O
kettle	O
,	O
sealing	O
the	O
cover	O
,	O
and	O
heating	O
to	O
a	O
temperature	O
between	O
140	O
and	O
145	O
DEG	O
C	O
to	O
react	O
for	O
115	O
to	O
120	O
hours	O
in	O
an	O
insulating	O
state	O
;	O
and	O
cooling	O
to	O
room	O
temperature	O
by	O
adopting	O
gradient	O
cooling	O
method	O
to	O
obtain	O
a	O
colorless	O
block	O
crystal	O
complex	O
[	B
Cd	I
(	I
OH	I
-	I
H2Bdc	I
)	I
(	I
2-Pbim	I
)	I
]	I
n	I
,	O
namely	O
the	O
cervical	O
cancer	O
cell	O
inhibitor	O
.	O

The	O
cervical	O
cancer	O
cell	O
inhibitor	O
has	O
the	O
characteristics	O
of	O
high	O
stability	O
and	O
strong	O
inhibition	O
capability	O
,	O
and	O
provides	O
guidance	O
to	O
research	O
and	O
development	O
of	O
anti	O
-	O
cervical	O
cancer	O
medicaments	O
.	O

Cervical	O
cancer	O
cell	O
inhibitor	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
medicine	O
powder	O
for	O
treating	O
dermatosis	O
,	O
which	O
is	O
suitable	O
for	O
treating	O
dermatophytosis	O
and	O
bromhidrosis	O
.	O

The	O
medicine	O
powder	O
is	O
prepared	O
by	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
part	O
:	O
8	O
-	O
10	O
parts	O
of	O
urotropin	B
,	O
2	O
-	O
5	O
parts	O
of	O
aspirin	B
and	O
48	O
-	O
54	O
parts	O
of	O
talcum	O
powder	O
.	O

The	O
medicine	O
powder	O
is	O
prepared	O
by	O
grinding	O
urotropin	B
and	O
aspirin	B
with	O
specific	O
amount	O
to	O
be	O
powdery	O
,	O
then	O
mixing	O
the	O
powdery	O
urotropin	B
and	O
aspirin	B
and	O
talcum	O
powder	O
with	O
specific	O
amount	O
uniformly	O
to	O
prepare	O
powdery	O
medicine	O
,	O
and	O
then	O
packaging	O
for	O
delivery	O
.	O

When	O
being	O
used	O
,	O
the	O
medicine	O
powder	O
is	O
applied	O
on	O
a	O
wounded	O
part	O
.	O

The	O
medicine	O
powder	O
is	O
reasonable	O
in	O
compatibility	O
and	O
exclusive	O
in	O
prescription	O
,	O
has	O
a	O
good	O
treatment	O
effect	O
in	O
the	O
practical	O
clinical	O
application	O
due	O
to	O
the	O
drug	O
synergism	O
,	O
and	O
has	O
the	O
total	O
treatment	O
effective	O
rate	O
more	O
than	O
95	O
%	O
.	O

The	O
medicine	O
powder	O
is	O
particularly	O
obvious	O
in	O
dermatophytosis	O
and	O
bromhidrosis	O
treatment	O
effect	O
,	O
short	O
in	O
course	O
of	O
treatment	O
,	O
quick	O
in	O
effect	O
taking	O
,	O
low	O
in	O
cost	O
,	O
convenient	O
to	O
apply	O
and	O
high	O
in	O
cure	O
rate	O
,	O
can	O
relieve	O
pain	O
,	O
itching	O
and	O
bromhidrosis	O
instantly	O
,	O
does	O
not	O
have	O
any	O
side	O
or	O
toxic	O
effect	O
,	O
and	O
can	O
not	O
cause	O
pain	O
.	O

Medicine	O
powder	O
for	O
treating	O
dermatosis	O

The	O
invention	O
provides	O
a	O
fishery	O
chitosan	O
immunoenhancer	O
.	O

The	O
fishery	O
chitosan	O
immunoenhancer	O
is	O
prepared	O
by	O
taking	O
dilute	O
acetic	B
acid	I
,	O
purified	O
water	O
and	O
chitosan	O
as	O
raw	O
materials	O
,	O
wherein	O
the	O
concentration	O
of	O
the	O
dilute	O
acetic	B
acid	I
is	O
0.1mol	O
/	O
L	O
,	O
the	O
volume	O
ratio	O
of	O
the	O
dilute	O
acetic	B
acid	I
and	O
the	O
purified	O
water	O
is	O
1:1	O
,	O
the	O
concentration	O
of	O
the	O
chitosan	O
is	O
0.02	O
-	O
0.08g	O
/	O
ml	O
,	O
and	O
the	O
chitosan	O
is	O
of	O
chitosan	O
oligosaccharide	B
with	O
molecular	O
weight	O
of	O
lower	O
than	O
60	O
thousand	O
.	O

The	O
fishery	O
chitosan	O
immunoenhancer	O
has	O
the	O
following	O
technical	O
effects	O
of	O
being	O
capable	O
of	O
improving	O
the	O
non	O
-	O
specific	O
immunity	O
protective	O
capability	O
of	O
aquatic	O
animals	O
,	O
enhancing	O
the	O
antiviral	O
infection	O
and	O
anti	O
-	O
bacteria	O
infection	O
capabilities	O
of	O
the	O
aquatic	O
animals	O
,	O
thereby	O
controlling	O
the	O
occurrence	O
and	O
prevalence	O
of	O
diseases	O
.	O

Fishery	O
chitosan	O
immunoenhancer	O

The	O
present	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemical	O
,	O
and	O
relates	O
to	O
a	O
doripenem	B
monohydrate	I
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
uses	O
thereof	O
.	O

Specifically	O
,	O
X	O
-	O
ray	O
powder	O
diffraction	O
characteristic	O
diffraction	O
angle	O
(	O
2	O
Theta	O
)	O
peaks	O
of	O
the	O
doripenem	B
monohydrate	I
of	O
the	O
present	O
invention	O
are	O
6.40	O
,	O
10.84	O
,	O
11.20	O
,	O
12.98	O
,	O
14.92	O
,	O
15.22	O
,	O
15.82	O
,	O
16.58	O
,	O
17.42	O
,	O
18.00	O
,	O
19.60	O
,	O
20.60	O
,	O
21.00	O
,	O
22.12	O
,	O
23.06	O
,	O
23.36	O
,	O
23.82	O
,	O
24.42	O
,	O
25.32	O
,	O
26.00	O
,	O
27.90	O
,	O
28.16	O
,	O
28.90	O
,	O
31.62	O
,	O
34.10	O
,	O
and	O
34.84	O
.	O

The	O
doripenem	B
monohydrate	I
of	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
good	O
stability	O
,	O
long	O
storage	O
time	O
at	O
room	O
temperature	O
,	O
being	O
easy	O
to	O
dissolve	O
in	O
water	O
,	O
etc	O
.	O

Doripenem	B
monohydrate	I
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
preparation	O
method	O
thereof	O
and	O
uses	O
thereof	O

The	O
invention	O
provides	O
a	O
supermolecular	O
inclusion	O
complex	O
formed	O
by	O
pinocembrin	B
and	O
beta	O
-	O
cyclodextrin	O
or	O
derivatives	O
thereof	O
.	O

The	O
molecular	O
molar	O
ratio	O
of	O
the	O
pinocembrin	B
to	O
the	O
beta	O
-	O
cyclodextrin	O
or	O
derivatives	O
thereof	O
is	O
1:2	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
supermolecular	O
inclusion	O
complex	O
formed	O
by	O
pinocembrin	B
and	O
beta	O
-	O
cyclodextrin	O
or	O
derivatives	O
thereof	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
weighing	O
beta	O
-	O
cyclodextrin	O
or	O
derivatives	O
thereof	O
,	O
adding	O
water	O
for	O
injection	O
,	O
stirring	O
and	O
dissolving	O
;	O
(	O
2	O
)	O
weighing	O
pinocembrin	B
,	O
crushing	O
,	O
and	O
adding	O
the	O
pinocembrin	B
into	O
an	O
aqueous	O
solution	O
of	O
the	O
beta	O
-	O
cyclodextrin	O
or	O
derivatives	O
thereof	O
;	O
and	O
(	O
3	O
)	O
slowly	O
dripping	O
an	O
aqueous	O
solution	O
of	O
sodium	B
hydroxide	I
in	O
a	O
stirring	O
state	O
,	O
regulating	O
and	O
keeping	O
a	O
pH	O
value	O
of	O
the	O
solution	O
to	O
be	O
6.5	O
-	O
9.0	O
,	O
and	O
stirring	O
until	O
the	O
pinocembrin	B
is	O
totally	O
dissolved	O
.	O

Compared	O
with	O
an	O
inclusion	O
complex	O
of	O
other	O
ratios	O
,	O
the	O
supermolecular	O
inclusion	O
complex	O
provided	O
by	O
the	O
invention	O
is	O
more	O
stable	O
and	O
excellent	O
in	O
pesticide	O
effect	O
.	O

Pinocembrin	B
and	O
cyclodextrin	O
supermolecular	O
inclusion	O
complex	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
process	O
(	O
method	O
)	O
for	O
preparing	O
racanisodamine	B
hydrochloride	I
used	O
for	O
injection	O
.	O

The	O
invention	O
overcomes	O
the	O
defects	O
that	O
the	O
traditional	O
racanisodamine	B
hydrochloride	I
preparation	O
process	O
can	O
not	O
effectively	O
guarantee	O
clarity	O
and	O
complete	O
filtering	O
of	O
impurities	O
such	O
as	O
fibers	O
by	O
utilizing	O
high	O
pressure	O
ultrafiltration	O
equipment	O
and	O
provides	O
a	O
preparation	O
process	O
with	O
low	O
cost	O
,	O
high	O
yield	O
and	O
more	O
stable	O
quality	O
of	O
the	O
finished	O
product	O
.	O

The	O
preparation	O
process	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
placing	O
water	O
used	O
for	O
injection	O
in	O
a	O
preparation	O
tank	O
,	O
lowering	O
water	O
temperature	O
to	O
39	O
-	O
41	O
DEG	O
C	O
;	O
(	O
2	O
)	O
dissolving	O
sodium	B
chloride	I
with	O
the	O
water	O
used	O
for	O
injection	O
in	O
the	O
preparation	O
tank	O
for	O
spare	O
use	O
,	O
adding	O
the	O
racanisodamine	B
hydrochloride	I
into	O
the	O
preparation	O
tank	O
,	O
opening	O
a	O
stirrer	O
,	O
adding	O
0.2mol	O
/	O
L	O
of	O
hydrochloric	B
acid	I
into	O
the	O
preparation	O
tank	O
,	O
adding	O
sodium	B
chloride	I
solution	O
into	O
the	O
preparation	O
tank	O
,	O
circulating	O
and	O
stirring	O
until	O
racanisodamine	B
is	O
completely	O
dissolved	O
;	O
and	O
(	O
3	O
)	O
regulating	O
pH	O
value	O
of	O
liquid	O
medicine	O
obtained	O
in	O
step	O
(	O
2	O
)	O
to	O
be	O
5.5	O
-	O
6.0	O
with	O
0.2mol	O
/	O
L	O
of	O
hydrochloric	B
acid	I
.	O

The	O
liquid	O
medicine	O
is	O
filtered	O
by	O
a	O
high	O
pressure	O
ultrafilter	O
,	O
then	O
whether	O
an	O
intermediate	O
product	O
is	O
qualified	O
is	O
inspected	O
,	O
a	O
filling	O
process	O
is	O
carried	O
out	O
,	O
and	O
the	O
preparation	O
process	O
disclosed	O
by	O
the	O
invention	O
enhances	O
market	O
competitiveness	O
of	O
the	O
racanisodamine	B
hydrochloride	I
product	O
,	O
is	O
convenient	O
to	O
the	O
marketing	O
of	O
the	O
racanisodamine	B
hydrochloride	I
product	O
and	O
is	O
worthy	O
of	O
popularization	O
.	O

Process	O
for	O
preparing	O
racanisodamine	B
hydrochloride	I
used	O
for	O
injection	O

The	O
invention	O
discloses	O
an	O
oxaliplatin	B
folic	B
acid	I
targeted	O
lipidosome	O
and	O
an	O
application	O
thereof	O
.	O

The	O
raw	O
materials	O
of	O
the	O
oxaliplatin	B
folic	B
acid	I
targeted	O
lipidosome	O
comprise	O
oxaliplatin	B
,	O
phospholipids	O
,	O
cholesterol	B
acid	I
,	O
folic	B
acid-	I
polyethylene	B
glycol	I
monostearate	I
and	O
poloxamer	O
F68	O
.	O

The	O
structure	O
of	O
the	O
folic	B
acid-	I
polyethylene	B
glycol	I
monostearate	I
is	O
demonstrated	O
as	O
follows	O
,	O
wherein	O
n	O
is	O
equal	O
to	O
45	O
to	O
136	O
.	O

The	O
oxaliplatin	B
folic	B
acid	I
targeted	O
lipidosome	O
which	O
is	O
prepared	O
by	O
the	O
invention	O
can	O
be	O
applied	O
to	O
preparing	O
medicine	O
for	O
treating	O
gastrointestinal	O
tumors	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
obtained	O
oxaliplatin	B
folic	B
acid	I
targeted	O
lipidosome	O
has	O
the	O
advantages	O
of	O
small	O
grain	O
size	O
,	O
high	O
entrapment	O
efficiency	O
,	O
improving	O
pharmacokinetic	O
behavior	O
,	O
good	O
targeting	O
and	O
enhancing	O
antineoplastic	O
efficacy	O
.	O

In	O
addition	O
,	O
the	O
cost	O
of	O
raw	O
materials	O
is	O
low	O
and	O
the	O
process	O
is	O
simple	O
.	O

Oxaliplatin	B
folic	B
acid	I
targeted	O
lipidosome	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
blood	O
circulation	O
promoting	O
and	O
meridian	O
obstruction	O
removing	O
pill	O
for	O
preventing	O
and	O
treating	O
osteoporosis	O
.	O

The	O
pill	O
is	O
prepared	O
by	O
uniformly	O
mixing	O
,	O
crushing	O
and	O
pelleting	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
4	O
to	O
6	O
parts	O
of	O
hemlock	O
parsley	O
,	O
8	O
to	O
12	O
parts	O
of	O
safflower	O
,	O
2	O
to	O
4	O
parts	O
of	O
notopterygium	O
root	O
,	O
8	O
to	O
12	O
parts	O
of	O
Chinese	O
angelica	O
,	O
and	O
10	O
to	O
30	O
parts	O
of	O
chondroitin	B
sulfate	I
.	O

The	O
product	O
has	O
good	O
effect	O
of	O
preventing	O
and	O
treating	O
osteoporosis	O
.	O

Preparation	O
method	O
of	O
blood	O
circulation	O
promoting	O
and	O
meridian	O
obstruction	O
removing	O
pill	O
for	O
preventing	O
and	O
treating	O
osteoporosis	O

The	O
invention	O
discloses	O
new	O
medical	O
salt	O
of	O
dexibuprofen	B
.	O

According	O
to	O
the	O
salt	O
,	O
x	O
can	O
be	O
0	O
,	O
0.5	O
,	O
1	O
,	O
1.5	O
,	O
2	O
,	O
2.5	O
and	O
3	O
,	O
n	O
can	O
be	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
and	O
M	O
can	O
be	O
sodium	B
,	O
potassium	B
,	O
magnesium	B
,	O
zinc	B
,	O
arginine	B
and	O
lysine	B
.	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
salt	O
,	O
and	O
also	O
a	O
medicine	O
composite	O
containing	O
the	O
salt	O
.	O

The	O
composite	O
contains	O
a	O
carrier	O
which	O
can	O
be	O
accepted	O
by	O
medicines	O
;	O
and	O
the	O
medicine	O
composite	O
can	O
be	O
produced	O
in	O
an	O
appropriate	O
and	O
medical	O
dosage	O
form	O
during	O
the	O
producing	O
of	O
medicaments	O
.	O

New	O
medical	O
salt	O
of	O
dexibuprofen	B

The	O
invention	O
discloses	O
seven	O
-	O
element	O
-	O
ring	O
polyhydroxy	B
nitrone	I
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
seven	O
-	O
element	O
-	O
ring	O
polyhydroxy	B
nitrone	I
is	O
shown	O
as	O
the	O
formula	O
I	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
respectively	O
selected	O
from	O
the	O
following	O
groups	O
:	O
C1-C12	O
linear	O
or	O
branched	O
saturated	O
alkyl	B
groups	O
,	O
allyl	B
,	O
propylidene	B
,	O
acetyl	B
,	O
benzoyl	B
,	O
benzyl	B
,	O
or	O
benzyl	B
of	O
which	O
partial	O
or	O
all	O
the	O
positions	O
of	O
the	O
benzene	B
ring	O
are	O
replaced	O
by	O
alkoxy	B
or	O
halogen	B
;	O
and	O
the	O
spatial	O
configurations	O
of	O
the	O
Cs	O
at	O
the	O
positions	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
are	O
in	O
R	O
or	O
S.	B
According	O
to	O
the	O
seven	O
-	O
element	O
-	O
ring	O
polyhydroxy	B
nitrone	I
,	O
various	O
kinds	O
of	O
aldohexose	B
are	O
taken	O
as	O
raw	O
materials	O
,	O
and	O
the	O
condensation	O
reaction	O
of	O
intramolecular	O
hydroxylamine	B
and	O
aldehyde	B
is	O
taken	O
as	O
a	O
key	O
step	O
,	O
so	O
as	O
to	O
finish	O
the	O
preparation	O
of	O
seven	O
-	O
element	O
-	O
ring	O
polyhydroxy	B
nitrone	I
,	O
so	O
that	O
a	O
method	O
for	O
simply	O
and	O
effectively	O
synthesizing	O
seven	O
-	O
element	O
-	O
ring	O
polyhydroxy	B
nitrone	I
is	O
provided	O
;	O
and	O
seven	O
-	O
element	O
-	O
ring	O
polyhydroxy	B
nitrone	I
prepared	O
by	O
using	O
the	O
method	O
can	O
be	O
used	O
for	O
preparing	O
imino	B
sugar	B
with	O
glycosidase	O
inhibitory	O
activity	O
.	O

Seven	O
-	O
element	O
-	O
ring	O
polyhydroxy	B
nitrone	I
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
anticoagulant	O
tablet	O
containing	O
a	O
sodium	B
chloride	I
medicine	O
carrier	O
and	O
a	O
preparation	O
method	O
for	O
the	O
tablet	O
,	O
which	O
are	O
suitable	O
for	O
a	O
pharmaceutical	O
enterprise	O
.	O

The	O
disclosed	O
tablet	O
comprises	O
the	O
sodium	B
chloride	I
,	O
clopidogre	B
salt	O
and	O
pharmaceutically	O
acceptable	O
adjuvants	O
.	O

The	O
sodium	B
chloride	I
is	O
stable	O
in	O
property	O
and	O
good	O
in	O
water	O
solubility	O
and	O
compressibility	O
,	O
and	O
is	O
well	O
compatible	O
with	O
the	O
clopidogre	B
salt	O
.	O

The	O
sodium	B
chloride	I
is	O
taken	O
as	O
the	O
carrier	O
for	O
the	O
clopidogre	B
salt	O
;	O
by	O
injecting	O
polyethylene	B
glycol	I
6000	I
solution	O
or	O
polyethylene	B
glycol	I
8000	I
solution	O
,	O
a	O
medicine	O
is	O
loaded	O
on	O
the	O
sodium	B
chloride	I
and	O
the	O
mixed	O
carrier	O
containing	O
other	O
pharmaceutically	O
acceptable	O
adjuvants	O
of	O
the	O
medicine	O
;	O
the	O
adjuvants	O
,	O
such	O
as	O
a	O
lubricant	O
,	O
are	O
added	O
to	O
mix	O
uniformly	O
,	O
and	O
the	O
mixture	O
is	O
subjected	O
to	O
tabletting	O
and	O
can	O
be	O
molded	O
by	O
compression	O
under	O
a	O
pretty	O
low	O
pressure	O
;	O
by	O
reducing	O
the	O
pressure	O
in	O
the	O
tabletting	O
process	O
,	O
the	O
crystal	O
transformation	O
of	O
the	O
clopidogre	B
,	O
the	O
reduction	O
of	O
the	O
clopidogre	B
content	O
,	O
and	O
the	O
increase	O
of	O
the	O
impurity	O
content	O
can	O
be	O
prevented	O
;	O
and	O
simultaneously	O
,	O
the	O
sticking	O
problem	O
in	O
the	O
tabletting	O
process	O
can	O
be	O
better	O
solved	O
.	O

The	O
tablet	O
prepared	O
by	O
the	O
invention	O
has	O
good	O
stability	O
and	O
is	O
released	O
quickly	O
.	O

Anticoagulant	O
tablet	O
containing	O
sodium	B
chloride	I
medicine	O
carrier	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pH	O
buffering	O
bioactive	O
glass	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
pH	O
buffering	O
bioactive	O
glass	O
comprises	O
SiO2	B
,	O
CaO	B
,	O
Na2O	B
,	O
and	O
P2O5	B
.	O

The	O
glass	O
also	O
comprises	O
acidic	O
solid	O
particles	O
or	O
a	O
Tris	O
buffering	O
solution	O
.	O

With	O
the	O
pH	O
buffering	O
bioactive	O
glass	O
,	O
pH	O
of	O
preparation	O
composed	O
of	O
the	O
bioactive	O
glass	O
can	O
be	O
regulated	O
.	O

The	O
treatment	O
effect	O
is	O
good	O
,	O
and	O
a	O
dosage	O
is	O
small	O
.	O

PH	O
buffering	O
bioactive	O
glass	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
composition	O
of	O
coriolus	O
versicolor	O
polysaccharide	O
and	O
ginkgo	O
flavone	B
and	O
a	O
blood	O
lipid	O
degrading	O
method	O
thereof	O
.	O

In	O
the	O
blood	O
lipid	O
degrading	O
method	O
,	O
the	O
coriolus	O
versicolor	O
polysaccharide	O
and	O
the	O
ginkgo	O
flavone	B
are	O
combined	O
and	O
orally	O
administered	O
to	O
reduce	O
the	O
blood	O
lipid	O
level	O
of	O
a	O
hyperlipidemia	O
rat	O
model	O
.	O

Medicinal	O
fungus	O
coriolus	O
versicolor	O
polysaccharide	O
and	O
a	O
flavonoid	B
compound	O
in	O
natural	O
medicinal	O
plant	O
ginkgo	O
leaves	O
are	O
respectively	O
extracted	O
.	O

When	O
the	O
coriolus	O
versicolor	O
polysaccharide	O
and	O
the	O
ginkgo	O
flavone	B
are	O
combined	O
for	O
administration	O
,	O
liver	O
index	O
of	O
a	O
rat	O
,	O
and	O
TC	O
value	O
,	O
TG	B
value	O
,	O
LDL	B
-	I
C	I
value	O
and	O
NEFA	B
content	O
of	O
serum	O
can	O
be	O
significantly	O
reduced	O
,	O
and	O
the	O
HDL	B
-	I
C	I
value	O
of	O
the	O
serum	O
can	O
be	O
significantly	O
increased	O
;	O
and	O
through	O
combined	O
oral	O
administration	O
of	O
the	O
coriolus	O
versicolor	O
polysaccharide	O
and	O
the	O
ginkgo	O
flavone	B
,	O
a	O
hyperlipidemia	O
liver	O
-	O
injury	O
rat	O
model	O
can	O
be	O
improved	O
to	O
a	O
certain	O
extent	O
.	O

Composition	O
capable	O
of	O
effectively	O
degrading	O
blood	O
lipid	O

The	O
invention	O
discloses	O
a	O
throat	O
-	O
clearing	O
aerosol	O
and	O
a	O
preparation	O
method	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
preparing	O
indigo	O
naturalis	O
,	O
liquorice	O
,	O
myrobalan	O
,	O
menthol	B
,	O
borneol	B
and	O
calculus	O
bovis	O
factitious	O
;	O
(	O
2	O
)	O
carrying	O
out	O
aqueous	O
extraction	O
on	O
the	O
myrobalan	O
,	O
filtering	O
the	O
myrobalan	O
,	O
concentrating	O
the	O
myrobalan	O
to	O
obtain	O
a	O
paste	O
I	O
,	O
carrying	O
out	O
ethanol	B
precipitation	O
,	O
recycling	O
ethanol	B
to	O
obtain	O
a	O
myrobalan	O
paste	O
,	O
soaking	O
the	O
indigo	O
naturalis	O
by	O
a	O
hydrochloric	B
acid	I
water	O
solution	O
,	O
carrying	O
out	O
washing	O
until	O
the	O
indigo	O
naturalis	O
becomes	O
neutral	O
,	O
carrying	O
out	O
oven	O
drying	O
to	O
obtain	O
the	O
refined	O
indigo	O
naturalis	O
,	O
carrying	O
out	O
water	O
adding	O
and	O
extraction	O
on	O
the	O
liquorice	O
,	O
filtering	O
the	O
liquorice	O
,	O
concentrating	O
the	O
liquorice	O
to	O
obtain	O
a	O
paste	O
II	O
,	O
adding	O
the	O
ethanol	O
into	O
the	O
paste	O
II	O
,	O
stewing	O
,	O
obtaining	O
supernatant	O
,	O
carrying	O
out	O
pH	O
regulation	O
and	O
filtering	O
,	O
recycling	O
the	O
ethanol	B
from	O
filter	O
liquor	O
,	O
adding	O
water	O
,	O
carrying	O
out	O
the	O
pH	O
regulation	O
and	O
the	O
filtering	O
,	O
washing	O
sediment	O
by	O
the	O
water	O
,	O
and	O
drying	O
to	O
obtain	O
liquorice	O
extract	O
;	O
(	O
3	O
)	O
drying	O
and	O
grinding	O
the	O
myrobalan	O
paste	O
,	O
uniformly	O
mixing	O
the	O
myrobalan	O
paste	O
with	O
the	O
grinded	O
refined	O
indigo	O
naturalis	O
,	O
calculus	O
bovis	O
factitious	O
,	O
borneol	O
,	O
menthol	B
and	O
liquorice	O
extract	O
to	O
obtain	O
a	O
mixture	O
,	O
dissolving	O
the	O
mixture	O
by	O
the	O
ethanol	B
,	O
packaging	O
the	O
mixture	O
into	O
a	O
packaging	O
bottle	O
,	O
carrying	O
out	O
pressurizing	O
,	O
and	O
adding	O
a	O
streaming	O
agent	O
,	O
thus	O
obtaining	O
the	O
throat	O
-	O
clearing	O
aerosol	O
.	O

The	O
throat	O
-	O
clearing	O
aerosol	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
sugar	O
free	O
,	O
low	O
cost	O
,	O
safety	O
,	O
quickness	O
in	O
effect	O
taking	O
,	O
good	O
curative	O
effect	O
,	O
convenience	O
in	O
carrying	O
,	O
little	O
task	O
time	O
and	O
high	O
transfer	O
rates	O
of	O
effective	O
constituents	O
.	O

Throat	O
-	O
clearing	O
aerosol	O
and	O
preparation	O
method	O

The	O
invention	O
provides	O
an	O
injection	O
injected	O
into	O
an	O
acupoint	O
Houhai	O
to	O
treat	O
piglet	O
diarrhea	O
.	O

Every	O
100ml	O
of	O
the	O
injection	O
contains	O
the	O
following	O
raw	O
medicines	O
:	O
2	O
%	O
procaine*	B
(	O
18	O
-	O
22	O
)	O
mL	O
,	O
ceftiofur	B
sodium	I
(	O
0.5g	O
/	O
bottle	O
)	O
*	O
(	O
22	O
-	O
28	O
)	O
bottles	O
,	O
Newcastle	O
disease	O
IV	O
(	O
1000	O
feathers	O
)	O
,	O
dexamethasone	B
(	O
2mg	O
/	O
mL	O
)	O
*	O
(	O
18	O
-	O
22	O
)	O
mL	O
and	O
the	O
balance	O
of	O
physiological	O
saline	O
.	O

Compared	O
with	O
the	O
existing	O
treatment	O
medicines	O
,	O
the	O
injection	O
injected	O
into	O
the	O
acupoint	O
Houhai	O
of	O
piglets	O
to	O
treatment	O
diarrhea	O
has	O
higher	O
cure	O
rate	O
and	O
reduces	O
the	O
treatment	O
cost	O
by	O
20	O
%	O
.	O

Injection	O
injected	O
into	O
acupoint	O
Houhai	O
to	O
treat	O
piglet	O
diarrhea	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
corresponding	O
to	O
a	O
formula	O
(	O
I	O
)	O
.	O

In	O
the	O
formula	O
(	O
I	O
)	O
,	O
R1	O
,	O
R2	O
and	O
R2	O
are	O
defined	O
in	O
the	O
claim	O
1	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
and	O
a	O
therapeutic	O
application	O
of	O
the	O
compound	O
.	O

Pyrazolo	B
quinolinone	I
derivative	O
and	O
preparation	O
method	O
thereof	O
as	O
well	O
as	O
therapeutic	O
application	O
of	O
derivative	O

The	O
invention	O
relates	O
to	O
an	O
imidazoquinoline	B
derivative	O
and	O
a	O
medicinal	O
salt	O
thereof	O
and	O
a	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O
.	O

Specifically	O
,	O
the	O
invention	O
relates	O
to	O
an	O
imidazoquinoline	B
derivative	O
shown	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
a	O
medicinal	O
salt	O
thereof	O
and	O
application	O
thereof	O
serving	O
as	O
a	O
cancer	O
treatment	O
agent	O
and	O
particularly	O
as	O
an	O
mTOR	O
and/or	O
PI3K	O
-	O
kinase	O
inhibitor	O
,	O
wherein	O
the	O
definition	O
of	O
each	O
substituent	O
group	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
is	O
the	O
same	O
as	O
that	O
in	O
the	O
specification	O
.	O

Imidazoquinoline	B
derivative	O
and	O
medicinal	O
salt	O
thereof	O
and	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
application	O
of	O
Houttuynoid	B
E	I
in	O
preparation	O
of	O
a	O
drug	O
for	O
promoting	O
small	O
bowel	O
peristalsis	O
.	O

The	O
invention	O
discloses	O
the	O
application	O
of	O
Houttuynoid	B
E	I
in	O
preparation	O
of	O
the	O
drug	O
for	O
promoting	O
small	O
bowel	O
peristalsis	O
.	O

According	O
to	O
the	O
pharmacological	O
experiment	O
,	O
the	O
Houttuynoid	B
E	I
has	O
good	O
effect	O
of	O
promoting	O
small	O
bowel	O
peristalsis	O
.	O

The	O
use	O
of	O
the	O
Houttuynoid	B
E	I
disclosed	O
by	O
the	O
invention	O
in	O
the	O
preparation	O
of	O
the	O
drug	O
for	O
promoting	O
small	O
bowel	O
peristalsis	O
is	O
firstly	O
disclosed	O
.	O

The	O
framework	O
type	O
is	O
a	O
brand	O
-	O
new	O
framework	O
type	O
and	O
has	O
an	O
unexpected	O
strong	O
effect	O
of	O
restraining	O
the	O
bacterial	O
activity	O
,	O
and	O
so	O
the	O
Houttuynoid	B
E	I
is	O
impossibly	O
reveled	O
by	O
other	O
compounds	O
,	O
and	O
has	O
outstanding	O
substantial	O
characteristics	O
.	O

Meanwhile	O
,	O
the	O
Houttuynoid	B
E	I
has	O
significant	O
progress	O
in	O
preparing	O
the	O
drug	O
for	O
promoting	O
small	O
bowel	O
peristalsis	O
.	O

Application	O
of	O
Houttuynoid	B
E	I
in	O
preparation	O
of	O
drug	O
for	O
promoting	O
small	O
bowel	O
peristalsis	O

The	O
invention	O
discloses	O
a	O
solid	O
preparation	O
of	O
a	O
telbivudine	B
liposome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

An	O
active	O
component	O
telbivudine	B
,	O
specific	O
combined	O
egg	O
yolk	O
lecithin	B
,	O
dipalmitoyl	B
phosphatidylglycerol	I
,	O
cholesterol	B
acetyl	I
ester	I
and	O
Tween	O
80	O
are	O
prepared	O
into	O
the	O
liposome	O
,	O
so	O
that	O
the	O
stability	O
,	O
the	O
dissolvability	O
and	O
the	O
bioavailability	O
of	O
the	O
solid	O
preparation	O
of	O
the	O
telbivudine	B
liposome	O
are	O
greatly	O
improved	O
and	O
the	O
solid	O
preparation	O
of	O
the	O
telbivudine	B
liposome	O
is	O
steady	O
and	O
lasting	O
in	O
effect	O
and	O
significant	O
in	O
therapeutic	O
effect	O
;	O
and	O
the	O
product	O
quality	O
of	O
the	O
solid	O
preparation	O
of	O
the	O
telbivudine	B
liposome	O
is	O
improved	O
and	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
solid	O
preparation	O
of	O
the	O
telbivudine	B
liposome	O
are	O
reduced	O
.	O

Solid	O
preparation	O
of	O
telbivudine	B
liposome	O

The	O
present	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
azithromycin	B
dispersible	O
tablet	O
granule	O
coating	O
.	O

The	O
granule	O
coating	O
process	O
is	O
added	O
after	O
mixing	O
the	O
materials	O
and	O
granulating	O
.	O

The	O
coating	O
materials	O
are	O
three	O
or	O
more	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydroxypropyl	O
methyl	O
cellulose	O
,	O
ethyl	O
cellulose	O
,	O
methyl	O
cellulose	O
,	O
polyvinylpyrrolidone	B
,	O
and	O
polyethylene	B
glycol	I
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
(	O
1	O
)	O
preparing	O
the	O
coating	O
solution	O
,	O
(	O
2	O
)	O
granulating	O
,	O
(	O
3	O
)	O
coating	O
the	O
granules	O
,	O
and	O
(	O
4	O
)	O
preparing	O
the	O
dispersible	O
tablets	O
.	O

The	O
present	O
invention	O
overcomes	O
the	O
problems	O
that	O
the	O
finished	O
dispersible	O
tablets	O
are	O
ugly	O
in	O
appearance	O
caused	O
by	O
serious	O
moisture	O
absorption	O
in	O
the	O
conventional	O
preparation	O
process	O
of	O
azithromycin	B
dispersible	O
tablets	O
,	O
the	O
production	O
cost	O
is	O
high	O
,	O
and	O
the	O
storage	O
conditions	O
are	O
high	O
.	O

Thus	O
the	O
drug	O
production	O
costs	O
are	O
reduced	O
.	O

The	O
finished	O
products	O
can	O
reach	O
moistureproof	O
requirements	O
by	O
just	O
ordinary	O
plastic	O
packaging	O
.	O

The	O
composite	O
membrane	O
moistureproof	O
protection	O
for	O
the	O
finished	O
product	O
can	O
be	O
abolished	O
.	O

Preparation	O
method	O
of	O
azithromycin	B
dispersible	O
tablet	O
granule	O
coating	O

The	O
invention	O
provides	O
an	O
azithromycin	B
dispersible	O
tablet	O
which	O
is	O
a	O
preparation	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
:	O
10	O
-	O
16	O
parts	O
of	O
micro	O
-	O
powder	O
silicon	B
gel	O
,	O
60	O
-	O
120	O
parts	O
of	O
microcrystalline	O
cellulose	O
,	O
20	O
-	O
40	O
parts	O
of	O
low	O
substituted	O
hydroxy	O
propyl	O
cellulose	O
,	O
8	O
-	O
15	O
parts	O
of	O
tablet	O
lubricant	O
and	O
0	O
-	O
50	O
parts	O
of	O
filler	O
,	O
wherein	O
the	O
filler	O
is	O
one	O
or	O
combination	O
of	O
more	O
than	O
two	O
of	O
lactose	O
,	O
pregelatinized	O
starch	O
,	O
starch	O
,	O
dextrin	O
,	O
mannitol	B
,	O
powdered	O
sugar	B
and	O
calcium	B
carbonate	I
.	O

The	O
invention	O
further	O
provides	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
the	O
dispersible	O
tablet	O
.	O

Through	O
a	O
great	O
deal	O
of	O
experimental	O
research	O
on	O
dispersible	O
tablet	O
recipes	O
,	O
an	O
azithromycin	B
dispersible	O
tablet	O
recipe	O
applicable	O
to	O
the	O
mode	O
that	O
powder	O
is	O
directly	O
pressed	O
into	O
tablets	O
is	O
ultimately	O
found	O
,	O
so	O
that	O
not	O
only	O
are	O
phenomena	O
of	O
sticking	O
,	O
crack	O
,	O
uncovering	O
and	O
the	O
like	O
in	O
the	O
process	O
that	O
the	O
azithromycin	B
powder	O
is	O
directly	O
pressed	O
into	O
tablets	O
solved	O
,	O
but	O
also	O
dispersible	O
tablets	O
with	O
good	O
properties	O
of	O
uniform	O
dispersion	O
,	O
dissolution	O
rate	O
and	O
the	O
like	O
are	O
obtained	O
;	O
and	O
meanwhile	O
the	O
dispersible	O
table	O
ensures	O
the	O
stability	O
of	O
a	O
main	O
medicine	O
,	O
avoids	O
degradation	O
of	O
the	O
main	O
medicine	O
and	O
provides	O
safer	O
choice	O
for	O
clinical	O
medication	O
.	O

Azithromycin	B
dispersible	O
tablet	O
,	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
oral	O
solid	O
medicine	O
composition	O
for	O
nervous	O
system	O
diseases	O
.	O

The	O
composition	O
is	O
a	O
tablet	O
and	O
comprises	O
an	O
active	O
component	O
,	O
lactose	B
anhydrous	O
,	O
a	O
disintegrating	O
agent	O
and	O
an	O
adhesive	O
.	O

The	O
medicine	O
composition	O
can	O
be	O
used	O
for	O
a	O
cerebrovascular	O
disease	O
,	O
used	O
for	O
improving	O
brain	O
metabolism	O
and	O
mental	O
symptoms	O
,	O
activating	O
respiratory	O
activity	O
of	O
brain	O
mitochondria	O
,	O
improving	O
brain	O
energy	O
metabolism	O
of	O
brain	O
ischemia	O
,	O
increasing	O
a	O
utilization	O
ratio	O
of	O
glucose	B
in	O
a	O
brain	O
,	O
allowing	O
adenosine	B
triphosphate	I
produced	O
in	O
the	O
brain	O
to	O
be	O
increased	O
,	O
preventing	O
brain	O
mitochondrion	O
from	O
generating	O
peroxidized	O
lipin	O
,	O
and	O
inhibiting	O
a	O
membrane	O
obstruction	O
due	O
to	O
lipid	O
peroxidation	O
of	O
a	O
brain	O
mitochondrial	O
membrane	O
,	O
used	O
for	O
brain	O
function	O
injures	O
caused	O
by	O
the	O
chronic	O
cerebrovascular	O
disease	O
,	O
brain	O
trauma	O
and	O
the	O
like	O
,	O
and	O
used	O
for	O
improving	O
mental	O
and	O
behavioral	O
disorders	O
such	O
as	O
a	O
subjective	O
symptom	O
,	O
a	O
language	O
disorder	O
,	O
anxiety	O
,	O
depression	O
,	O
hypomnesia	O
and	O
brain	O
power	O
declining	O
,	O
promoting	O
brain	O
power	O
,	O
activating	O
a	O
brain	O
mitochondrion	O
function	O
,	O
improving	O
the	O
brain	O
energy	O
metabolism	O
and	O
a	O
brain	O
function	O
,	O
improving	O
emotion	O
depression	O
,	O
low	O
consciousness	O
,	O
an	O
affective	O
disorder	O
,	O
a	O
language	O
disorder	O
and	O
the	O
like	O
that	O
are	O
caused	O
by	O
a	O
cerebral	O
infarction	O
sequela	O
,	O
a	O
cerebral	O
hemorrhage	O
sequela	O
and	O
cerebral	O
arteriosclerosis	O
,	O
improving	O
brain	O
metabolism	O
,	O
and	O
protecting	O
cranial	O
neural	O
cells	O
.	O

Oral	O
solid	O
medicine	O
composition	O
for	O
nervous	O
system	O
diseases	O

The	O
invention	O
relates	O
to	O
preparation	O
and	O
medical	O
application	O
of	O
aromatic	B
ring	O
substituted	O
ethyl	B
valerate	I
and	O
particularly	O
discloses	O
a	O
compound	O
2-methyl-3-oxo-5-hydroxy-5-	B
(	I
3,4-dimethoxyphenyl	I
)	I
-ethyl	I
valerate	I
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
a	O
preparation	O
method	O
and	O
medicinal	O
application	O
thereof	O
.	O

The	O
compound	O
has	O
the	O
advantages	O
that	O
the	O
compounding	O
steps	O
are	O
simple	O
and	O
convenient	O
,	O
the	O
preparation	O
method	O
is	O
simple	O
and	O
feasible	O
,	O
the	O
raw	O
materials	O
are	O
conveniently	O
and	O
easily	O
acquired	O
,	O
the	O
cost	O
is	O
low	O
,	O
and	O
the	O
pollution	O
is	O
little	O
.	O

The	O
compound	O
has	O
remarkable	O
fungal	O
growth	O
inhibition	O
activity	O
,	O
and	O
the	O
80	O
%	O
inhibition	O
concentration	O
of	O
the	O
compound	O
is	O
125	O
micrograms	O
/	O
milliliter	O
.	O

Shown	O
by	O
pharmacodynamic	O
results	O
,	O
the	O
substituted	O
ethyl	B
valerate	I
compound	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
can	O
be	O
expected	O
to	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
drugs	O
for	O
prevention	O
and	O
treatment	O
of	O
diseases	O
caused	O
by	O
fungal	O
infection	O
.	O

Preparation	O
and	O
medical	O
application	O
of	O
aromatic	B
ring	O
substituted	O
ethyl	B
valerate	I

The	O
invention	O
discloses	O
a	O
composition	O
for	O
treating	O
miliaria	O
.	O

The	O
composition	O
is	O
composed	O
of	O
components	O
in	O
parts	O
by	O
weight	O
as	O
follows	O
:	O
2	O
-	O
6	O
parts	O
of	O
zinc	B
stearate	I
,	O
1	O
-	O
3	O
parts	O
of	O
calcium	B
chloride	I
,	O
1	O
-	O
3	O
parts	O
of	O
sodium	B
bisulfate	I
,	O
10	O
-	O
20	O
parts	O
of	O
borax	B
,	O
10	O
-	O
20	O
parts	O
of	O
honeysuckles	O
,	O
1	O
-	O
3	O
parts	O
of	O
CMC	O
(	O
carboxy	O
methyl	O
cellulose	O
)	O
,	O
4	O
-	O
8	O
parts	O
of	O
pearl	O
powder	O
,	O
4	O
-	O
8	O
parts	O
of	O
borneol	B
,	O
1	O
-	O
3	O
parts	O
of	O
salicylic	B
acid	I
,	O
0.3	O
-	O
0.5	O
part	O
of	O
essence	O
,	O
100	O
-	O
200	O
parts	O
of	O
talcum	O
powder	O
and	O
50	O
-	O
80	O
parts	O
of	O
kaolin	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
composition	O
has	O
the	O
benefits	O
of	O
being	O
capable	O
of	O
treating	O
miliaria	O
effectively	O
and	O
provided	O
with	O
functions	O
such	O
as	O
itching	O
relieving	O
,	O
inflammation	O
diminishing	O
,	O
sterilization	O
and	O
the	O
like	O
,	O
and	O
capable	O
of	O
performing	O
a	O
treating	O
effect	O
on	O
the	O
skin	O
;	O
and	O
being	O
simple	O
in	O
preparation	O
process	O
,	O
low	O
in	O
cost	O
and	O
convenient	O
to	O
use	O
.	O

Composition	O
for	O
treating	O
miliaria	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
total	O
saponins	B
and	O
polysaccharides	O
from	O
Apios	O
americana	O
flowers	O
simultaneously	O
and	O
relates	O
to	O
the	O
technical	O
field	O
of	O
plant	O
extraction	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
harvesting	O
raw	O
materials	O
,	O
cleaning	O
and	O
drying	O
;	O
(	O
2	O
)	O
reflux	O
-	O
extracting	O
with	O
ethanol	B
,	O
and	O
filtering	O
to	O
obtain	O
a	O
supernatant	O
and	O
filter	O
residues	O
;	O
(	O
3	O
)	O
defatting	O
the	O
supernatant	O
with	O
petroleum	B
ether	I
,	O
extracting	O
with	O
n	B
-	I
butanol	I
,	O
performing	O
adsorption	O
and	O
elution	O
,	O
concentrating	O
,	O
and	O
drying	O
to	O
obtain	O
powdery	O
Apios	O
americana	O
flower	O
saponins	B
;	O
(	O
4	O
)	O
removing	O
the	O
solvent	O
from	O
the	O
filter	O
residues	O
,	O
reflux	O
-	O
extracting	O
with	O
water	O
,	O
filtering	O
,	O
collecting	O
and	O
mixing	O
the	O
filtrates	O
;	O
and	O
(	O
5	O
)	O
decolorizing	O
the	O
filtrate	O
,	O
performing	O
deproteinization	O
,	O
concentrating	O
,	O
precipitating	O
with	O
alcohols	B
,	O
dialyzing	O
and	O
concentrating	O
,	O
and	O
drying	O
to	O
obtain	O
Apios	O
americana	O
flower	O
polysaccharides	O
.	O

The	O
method	O
has	O
the	O
advantages	O
of	O
simple	O
process	O
,	O
high	O
yield	O
and	O
low	O
cost	O
.	O

Besides	O
,	O
the	O
total	O
saponins	B
and	O
polysaccharides	O
of	O
Apios	O
americana	O
flowers	O
are	O
prepared	O
simultaneously	O
,	O
have	O
high	O
purity	O
and	O
strong	O
activity	O
,	O
and	O
can	O
be	O
widely	O
used	O
in	O
pharmaceuticals	O
or	O
functional	O
foods	O
with	O
antioxidant	O
and	O
blood	O
sugar	B
regulating	O
effects	O
.	O

Method	O
for	O
preparing	O
total	O
saponins	O
and	O
polysaccharides	O
from	O
Apios	O
americana	O
flowers	O
simultaneously	O
,	O
and	O
application	O
of	O
total	O
saponins	B
and	O
polysaccharides	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
cabazitaxel	B
crystal	O
forms	O
and	O
preparation	O
methods	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
cabazitaxel	B
amorphous	O
crystal	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

A	O
DSC	O
(	O
differential	O
scanning	O
calorimetry	O
)	O
map	O
of	O
the	O
cabazitaxel	B
amorphous	O
crystal	O
has	O
an	O
exothermic	O
peak	O
at	O
210	O
-	O
260	O
DEG	O
C.	O

The	O
cabazitaxel	B
amorphous	O
crystal	O
is	O
a	O
novel	O
crystal	O
form	O
of	O
cabazitaxel	B
,	O
and	O
has	O
good	O
stability	O
.	O

The	O
preparation	O
method	O
simplifies	O
operation	O
steps	O
,	O
does	O
not	O
require	O
special	O
equipment	O
,	O
is	O
low	O
in	O
production	O
cost	O
,	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Cabazitaxel	B
amorphous	O
crystal	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
high	O
-	O
efficient	O
DPP	O
(	O
dipeptidyl	O
peptidase	O
)	O
-IV	O
inhibitor	O
,	O
and	O
specifically	O
relates	O
to	O
a	O
compound	O
taking	O
uracil	O
as	O
a	O
mother	O
nucleus	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
preparation	O
method	O
,	O
a	O
composition	O
and	O
an	O
application	O
of	O
the	O
compound	O
as	O
the	O
DPP	O
-	O
IV	O
inhibitor	O
in	O
prevention	O
or	O
treatment	O
of	O
diseases	O
which	O
benefit	O
from	O
DPP	O
-	O
IV	O
inhibition	O
.	O

The	O
compound	O
disclosed	O
by	O
the	O
invention	O
has	O
a	O
very	O
good	O
selective	O
inhibition	O
effect	O
against	O
DPP	O
-	O
IV	O
and	O
has	O
very	O
low	O
cardiotoxicity	O
,	O
thereby	O
being	O
a	O
DPP	O
-	O
IV	O
inhibitor	O
type	O
medicament	O
with	O
great	O
prospects	O
.	O

Preparation	O
method	O
of	O
high	O
-	O
efficient	O
DPP	O
(	O
dipeptidyl	O
peptidase	O
)	O
-IV	O
inhibitor	O

The	O
invention	O
discloses	O
a	O
de	B
-	I
malonate	I
monoacyl	I
azalomycin	I
F	I
,	O
a	O
preparation	O
method	O
thereof	O
and	O
the	O
application	O
thereof	O
to	O
preparation	O
of	O
an	O
MRSA	O
(	O
Methicillin	B
-	O
resistant	O
Staphylococcus	O
aureus	O
)	O
infection	O
therapeutic	O
drug	O
.	O

Azalomycin	B
F	I
reacts	O
in	O
an	O
alkaline	B
methanol	I
solution	O
to	O
produce	O
de	B
-	I
malonate	I
azalomycin	I
F	I
,	O
the	O
de	B
-	I
malonate	I
azalomycin	I
F	I
is	O
separated	O
to	O
obtain	O
the	O
de	B
-	I
malonate	I
monoacyl	I
azalomycin	I
F.	I

The	O
MRSA	O
activity	O
test	O
shows	O
that	O
the	O
MIC	O
(	O
Minimal	O
Inhibitory	O
Concentration	O
)	O
of	O
the	O
obtained	O
de	O
-	O
malonate	O
monoacyl	O
azalomycin	B
F	I
to	O
MRSA	O
tester	O
strain	O
is	O
0.25	O
-	O
0.50	O
Mug	O
/	O
mL	O
,	O
which	O
is	O
8	O
-	O
16	O
times	O
of	O
that	O
of	O
azalomycin	B
F	I
,	O
and	O
the	O
de	B
-	I
malonate	I
monoacyl	I
azalomycin	I
F	I
has	O
enhanced	O
stability	O
and	O
water	O
solubility	O
.	O

The	O
de	B
-	I
malonate	I
monoacyl	I
azalomycin	I
F	I
has	O
remarkable	O
MRSA	O
activity	O
and	O
a	O
favorable	O
development	O
prospect	O
and	O
can	O
be	O
used	O
for	O
preparing	O
an	O
MRSA	O
infection	O
therapeutic	O
drug	O
.	O

De	B
-	I
malonate	I
monoacyl	I
azalomycin	I
F	I
,	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
to	O
preparation	O
of	O
MRSA	O
infection	O
therapeutic	O
drug	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
flavone	B
-	I
C	I
-	I
glycoside	I
6	I
'	I
'	I
hydroxyl	I
-	I
ester	I
derivative	O
.	O

By	O
taking	O
a	O
flavone	B
-	I
C	I
-	I
glycoside	I
6	I
'	I
'	I
hydroxyl	I
extract	O
having	O
wide	O
source	O
and	O
low	O
activity	O
as	O
a	O
substrate	O
,	O
the	O
method	O
enables	O
esterification	O
reaction	O
between	O
the	O
substrate	O
and	O
carboxylic	B
acid	I
in	O
the	O
presence	O
of	O
microorganism	O
lipase	O
and	O
organic	O
solvent	O
so	O
as	O
to	O
obtain	O
a	O
flavone	B
-	I
C	I
-	I
glycoside	I
6	I
'	I
'	I
hydroxyl	I
-	I
ester	I
derivative	O
rarely	O
seen	O
in	O
nature	O
and	O
having	O
high	O
activity	O
through	O
local	O
specific	O
synthesis	O
.	O

In	O
the	O
reaction	O
process	O
,	O
monitoring	O
is	O
performed	O
by	O
a	O
detection	O
method	O
of	O
thin	O
-	O
layer	O
chromatography	O
or	O
efficient	O
liquid	O
chromatography	O
until	O
all	O
start	O
raw	O
materials	O
are	O
consumed	O
;	O
and	O
after	O
the	O
reaction	O
,	O
lipase	O
is	O
filtered	O
,	O
and	O
the	O
esterified	O
product	O
is	O
washed	O
and	O
purified	O
by	O
the	O
organic	O
solvent	O
.	O

The	O
method	O
has	O
the	O
advantages	O
of	O
easily	O
available	O
substrate	O
,	O
simple	O
preparation	O
technology	O
,	O
high	O
specificity	O
and	O
mild	O
reaction	O
conditions	O
;	O
the	O
obtained	O
product	O
is	O
easy	O
to	O
purify	O
;	O
and	O
sufficient	O
raw	O
material	O
guarantee	O
is	O
provided	O
to	O
the	O
application	O
of	O
flavone	B
-	I
C	I
-	I
glycoside	I
6	I
'	I
'	I
hydroxyl	I
-	I
ester	I
derivative	O
in	O
the	O
fields	O
of	O
functional	O
food	O
,	O
beverage	O
,	O
cosmetics	O
,	O
medicine	O
and	O
the	O
like	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
flavone	B
-	I
C	I
-	I
glycoside	I
6	I
'	I
'	I
hydroxyl	I
-	I
ester	I
derivative	O

The	O
invention	O
discloses	O
a	O
tebipenem	B
pivoxil	I
oral	O
solid	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
oral	O
solid	O
preparation	O
disclosed	O
by	O
the	O
invention	O
comprises	O
particles	O
,	O
an	O
isolation	O
coating	O
layer	O
,	O
a	O
taste	O
masking	O
coating	O
layer	O
and	O
a	O
coloring	O
tender	O
taste	O
coating	O
layer	O
,	O
wherein	O
the	O
particles	O
are	O
prepared	O
from	O
tebipenem	B
pivoxil	I
,	O
microcrystalline	O
cellulose	O
and	O
binders	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
preparation	O
can	O
be	O
used	O
for	O
overcoming	O
the	O
problem	O
that	O
a	O
part	O
of	O
water	O
in	O
main	O
medicines	O
and	O
excipients	O
has	O
an	O
interaction	O
to	O
affect	O
the	O
quality	O
of	O
a	O
finished	O
product	O
,	O
and	O
is	O
suitably	O
prepared	O
into	O
a	O
medicine	O
.	O

Tebipenem	B
pivoxil	I
oral	O
solid	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
vidarabine	B
monophosphate	I
pharmaceutical	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pharmaceutical	O
composition	O
consists	O
of	O
vidarabine	B
monophosphate	I
,	O
vidarabine	B
,	O
sodium	B
chloride	I
and	O
water	O
-	O
soluble	O
cyclodextrin	O
or	O
a	O
water	O
-	O
soluble	O
cyclodextrin	O
derivative	O
,	O
wherein	O
the	O
mass	O
ratio	O
of	O
vidarabine	B
monophosphate	I
,	O
vidarabine	B
,	O
sodium	B
chloride	I
and	O
water	O
-	O
soluble	O
cyclodextrin	O
or	O
the	O
water	O
-	O
soluble	O
cyclodextrin	O
derivative	O
is	O
25	O
-	O
35:1	O
-	O
3:1:10	O
-	O
20	O
,	O
preferably	O
30:2:1:15	O
.	O

The	O
vidarabine	B
monophosphate	I
pharmaceutical	O
composition	O
provided	O
by	O
the	O
present	O
invention	O
has	O
significantly	O
reduced	O
irritation	O
to	O
muscle	O
and	O
blood	O
vessels	O
,	O
and	O
better	O
long	O
-	O
term	O
storage	O
stability	O
.	O

Meanwhile	O
,	O
the	O
vidarabine	B
monophosphate	I
pharmaceutical	O
composition	O
provided	O
by	O
the	O
present	O
invention	O
contains	O
both	O
vidarabine	B
monophosphate	I
and	O
vidarabine	B
,	O
thereby	O
having	O
more	O
significant	O
efficacy	O
.	O

The	O
preparation	O
method	O
for	O
the	O
vidarabine	B
monophosphate	I
pharmaceutical	O
composition	O
is	O
simple	O
and	O
feasible	O
,	O
suitable	O
for	O
industrial	O
production	O
.	O

Vidarabine	B
monophosphate	I
pharmaceutical	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
ranitidine	B
bismuth	I
citrate	I
intra	O
-	O
gastric	O
floating	O
sustained	O
-	O
release	O
tablet	O
which	O
is	O
composed	O
of	O
a	O
tablet	O
core	O
containing	O
ranitidine	B
bismuth	I
citrate	I
and	O
a	O
coating	O
film	O
wrapped	O
over	O
the	O
tablet	O
core	O
.	O

The	O
tablet	O
core	O
is	O
prepared	O
from	O
raw	O
materials	O
at	O
least	O
containing	O
,	O
by	O
weight	O
,	O
110	O
to	O
120	O
parts	O
of	O
ranitidine	B
bismuth	I
citrate	I
,	O
30	O
to	O
60	O
parts	O
of	O
a	O
skeletal	O
material	O
,	O
5	O
to	O
20	O
parts	O
of	O
a	O
foaming	O
agent	O
and	O
45	O
to	O
130	O
parts	O
of	O
a	O
bleaching	O
assistant	O
.	O

The	O
coating	O
film	O
accounts	O
for	O
1	O
to	O
5	O
%	O
of	O
the	O
weight	O
of	O
the	O
tablet	O
.	O

The	O
tablet	O
provided	O
by	O
the	O
invention	O
can	O
effectively	O
adjust	O
the	O
rate	O
of	O
constant	O
speed	O
release	O
of	O
the	O
drug	O
ranitidine	B
bismuth	I
citrate	I
and	O
enables	O
a	O
steady	O
and	O
lasting	O
effective	O
plasma	O
concentration	O
to	O
be	O
obtained	O
,	O
so	O
side	O
effects	O
of	O
the	O
drug	O
,	O
frequency	O
of	O
administration	O
and	O
influence	O
of	O
the	O
drug	O
on	O
an	O
in	O
-	O
vivo	O
environment	O
are	O
reduced	O
,	O
and	O
compliance	O
of	O
a	O
patient	O
is	O
improved	O
.	O

Ranitidine	B
bismuth	I
citrate	I
intra	O
-	O
gastric	O
floating	O
sustained	O
-	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
minocycline	O
hydrochloride	B
sustained	O
-	O
release	O
capsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

A	O
substance	O
in	O
the	O
capsule	O
is	O
a	O
sustained	O
-	O
release	O
pellet	O
which	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
and	O
accessory	O
material	O
by	O
weight	O
:	O
minocycline	O
hydrochloride	B
,	O
a	O
filler	O
,	O
an	O
adhesive	O
,	O
an	O
isolating	O
layer	O
film	O
forming	O
material	O
,	O
a	O
plasticizer	O
A	O
,	O
an	O
opacifying	O
agent	O
,	O
a	O
sustained	O
-	O
release	O
material	O
,	O
a	O
plasticizer	O
B	O
,	O
an	O
antiadherent	O
and	O
a	O
pore	O
forming	O
agent	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
preparing	O
a	O
drug	O
-	O
loaded	O
pellet	O
core	O
according	O
to	O
a	O
formula	O
;	O
preparing	O
an	O
isolating	O
layer	O
pellet	O
from	O
the	O
pellet	O
core	O
;	O
preparing	O
the	O
sustained	O
-	O
release	O
pellet	O
from	O
the	O
isolating	O
layer	O
pellet	O
;	O
and	O
filling	O
the	O
sustained	O
-	O
release	O
pellet	O
into	O
a	O
capsule	O
so	O
as	O
to	O
obtain	O
the	O
minocycline	O
hydrochloride	B
sustained	O
-	O
release	O
capsule	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
opacifying	O
agent	O
is	O
added	O
into	O
an	O
isolating	O
layer	O
,	O
so	O
stability	O
of	O
the	O
photosensitive	O
drug	O
minocycline	O
is	O
improved	O
;	O
a	O
sustained	O
-	O
release	O
layer	O
is	O
prepared	O
by	O
using	O
an	O
optimized	O
prescription	O
,	O
so	O
usage	O
amount	O
of	O
a	O
coating	O
material	O
is	O
substantially	O
reduced	O
;	O
and	O
the	O
method	O
provided	O
by	O
the	O
invention	O
has	O
good	O
reproducibility	O
and	O
is	O
applicable	O
to	O
industrial	O
production	O
.	O

Minocycline	O
hydrochloride	B
sustained	O
-	O
release	O
capsule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
application	O
of	O
T0901317	O
(	O
N-	B
(	I
2	I
,	I
2	I
,	I
2-trifluoroethyl	I
)	I
-N-	I
[	I
4-	I
[	I
2	I
,	I
2	I
,	I
2-trifluoro-1-hydroxy-1-	I
(	I
trifluoromethyl	I
)	I
ethyl	I
]	I
phenyl	I
]	I
-benzenesulfonamide	I
)	O
in	O
preparation	O
of	O
drugs	O
treating	O
or	O
preventing	O
hepatitis	O
C	O
virus	O
drugs	O
.	O

A	O
drug	O
without	O
toxic	O
concentration	O
is	O
chosen	O
for	O
an	O
antiviral	O
experiment	O
,	O
the	O
influence	O
of	O
T0901317	O
on	O
virus	O
gene	O
duplication	O
is	O
detected	O
,	O
and	O
results	O
show	O
that	O
the	O
small	O
molecule	O
compound	O
has	O
significant	O
antiviral	O
activity	O
and	O
is	O
dose	O
dependent	O
.	O

Then	O
,	O
the	O
T0901317	O
is	O
employed	O
to	O
treat	O
the	O
hepatitis	O
C	O
pseudovirus	O
system	O
of	O
different	O
gene	O
subtypes	O
,	O
and	O
results	O
show	O
that	O
the	O
compound	O
inhibits	O
the	O
virus	O
entrance	O
link	O
at	O
the	O
early	O
stage	O
of	O
a	O
virus	O
lifecycle	O
.	O

Also	O
,	O
the	O
anti	O
-	O
virus	O
capability	O
of	O
drug	O
combination	O
of	O
T0901317	O
and	O
other	O
anti	O
-	O
HCV	O
drugs	O
is	O
detected	O
.	O

T0901317	O
can	O
inhibit	O
1a	O
,	O
1b	O
,	O
and	O
2a	O
genotype	O
virus	O
entrance	O
,	O
and	O
has	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
and	O
a	O
novel	O
target	O
,	O
while	O
there	O
is	O
no	O
anti	O
-	O
hepatitis	O
C	O
virus	O
drug	O
with	O
entrance	O
as	O
the	O
target	O
yet	O
clinically	O
.	O

And	O
drug	O
combination	O
of	O
T0901317	O
with	O
other	O
anti	O
-	O
hepatitis	O
C	O
virus	O
drugs	O
can	O
achieve	O
a	O
good	O
effect	O
.	O

Application	O
of	O
T0901317	O
in	O
preparation	O
of	O
drugs	O
treating	O
or	O
preventing	O
hepatitis	O
C	O

The	O
invention	O
discloses	O
a	O
combination	O
drug	O
of	O
curing	O
rash	O
and	O
burn	O
and	O
preparation	O
method	O
thereof	O
.	O

The	O
combination	O
drug	O
is	O
composed	O
of	O
carbonized	O
hair	O
,	O
astragalus	O
membranaceus	O
,	O
rehmannia	O
glutinosa	O
libosch	O
,	O
Chinese	O
angelica	O
,	O
plaster	O
stone	O
,	O
raw	O
calamine	O
,	O
beewax	O
,	O
elephant	O
hide	O
,	O
sesame	O
oil	O
and	O
cuttle	O
bone	O
.	O

A	O
production	O
method	O
includes	O
that	O
the	O
carbonized	O
hair	O
is	O
purified	O
by	O
water	O
containing	O
soda	O
and	O
dried	O
,	O
impurities	O
of	O
the	O
carbonized	O
hair	O
are	O
removed	O
,	O
the	O
elephant	O
hide	O
is	O
cut	O
into	O
blocks	O
and	O
porphyrized	O
,	O
the	O
astragalus	O
membranaceus	O
,	O
the	O
rehmannia	O
glutinosa	O
libosch	O
and	O
the	O
Chinese	O
angelica	O
are	O
cut	O
into	O
slices	O
,	O
the	O
raw	O
calamine	O
and	O
the	O
plaster	O
stone	O
are	O
porphyrized	O
,	O
then	O
the	O
sesame	O
oil	O
is	O
put	O
in	O
an	O
iron	B
pan	O
and	O
heated	O
to	O
250	O
DEG	O
C	O
,	O
the	O
carbonized	O
hair	O
is	O
added	O
into	O
the	O
iron	B
pan	O
for	O
10	O
-	O
15min	O
,	O
then	O
the	O
carbonized	O
hair	O
is	O
fished	O
out	O
,	O
the	O
astragalus	O
membranaceus	O
,	O
the	O
rehmannia	O
glutinosa	O
libosch	O
and	O
the	O
Chinese	O
angelica	O
are	O
added	O
into	O
the	O
iron	B
pan	O
,	O
after	O
5	O
minutes	O
,	O
the	O
astragalus	O
membranaceus	O
,	O
the	O
rehmannia	O
glutinosa	O
libosch	O
and	O
the	O
Chinese	O
angelica	O
are	O
together	O
fished	O
out	O
,	O
the	O
sesame	O
oil	O
in	O
the	O
iron	B
pan	O
is	O
filtered	O
and	O
conducts	O
deslag	O
,	O
then	O
the	O
sesame	O
oil	O
is	O
heated	O
to	O
220	O
DEG	O
C	O
,	O
the	O
plaster	O
stone	O
,	O
the	O
raw	O
calamine	O
,	O
cuttle	O
bone	O
powder	O
and	O
melting	O
beewax	O
are	O
added	O
into	O
the	O
sesame	O
oil	O
,	O
and	O
after	O
filtered	O
,	O
elephant	O
hide	O
powder	O
is	O
added	O
to	O
be	O
blended	O
to	O
be	O
pasty	O
to	O
form	O
paste	O
.	O

The	O
combination	O
drug	O
is	O
reasonable	O
in	O
combination	O
,	O
and	O
clear	O
in	O
curative	O
effect	O
,	O
and	O
has	O
the	O
efficacy	O
of	O
promoting	O
granulation	O
and	O
removing	O
necrotic	O
tissue	O
,	O
stopping	O
pain	O
and	O
removing	O
stasis	O
,	O
activating	O
blood	O
and	O
dispersing	O
blood	O
stasis	O
,	O
and	O
promoting	O
granulation	O
growth	O
.	O

Combination	O
drug	O
of	O
curing	O
rash	O
and	O
burn	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
novel	O
pantoprazole	B
sodium	I
compound	O
.	O

The	O
purity	O
of	O
the	O
novel	O
pantoprazole	B
sodium	I
compound	O
reaches	O
more	O
than	O
99.8	O
%	O
.	O

Meanwhile	O
,	O
the	O
invention	O
also	O
discloses	O
a	O
pharmaceutical	O
composition	O
of	O
the	O
novel	O
pantoprazole	B
sodium	I
compound	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
45	O
-	O
80	O
parts	O
of	O
pantoprazole	B
sodium	I
,	O
3	O
-	O
20	O
parts	O
of	O
ethylene	B
diamine	I
tetraacetic	I
acid	I
,	O
0.5	O
-	O
3	O
parts	O
of	O
sodium	B
tartrate	I
and	O
4	O
-	O
52	O
parts	O
of	O
mannitol	B
.	O

According	O
to	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
novel	O
pantoprazole	B
sodium	I
compound	O
,	O
a	O
synergistic	O
effect	O
is	O
generated	O
between	O
ethylene	B
diamine	I
tetraacetic	I
acid	I
and	O
sodium	B
tartrate	I
,	O
so	O
that	O
the	O
stability	O
of	O
pantoprazole	B
sodium	I
is	O
remarkably	O
improved	O
,	O
and	O
the	O
pharmaceutical	O
composition	O
has	O
important	O
significance	O
for	O
pantoprazole	B
sodium	I
in	O
clinical	O
popularization	O
and	O
application	O
.	O

Novel	O
pantoprazole	B
sodium	I
compound	O
and	O
pharmaceutical	O
composition	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
body	O
moistening	O
oil	O
for	O
removing	O
HPV	O
virus	O
and	O
a	O
preparation	O
method	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
:	O
1	O
)	O
cleaning	O
and	O
disinfecting	O
the	O
appliances	O
required	O
by	O
production	O
;	O
2	O
)	O
respectively	O
weighting	O
30	O
-	O
90	O
%	O
of	O
olive	O
oil	O
,	O
5	O
-	O
50	O
%	O
of	O
pearl	O
powder	O
,	O
1	O
-	O
40	O
%	O
of	O
mint	O
powder	O
and	O
1	O
-	O
20	O
%	O
of	O
arbutin	B
for	O
standby	O
;	O
3	O
)	O
pumping	O
the	O
olive	O
oil	O
in	O
a	O
main	O
tank	O
of	O
a	O
vacuum	O
homogeneous	O
emulsifying	O
machine	O
,	O
starting	O
a	O
stirrer	O
,	O
adding	O
the	O
pearl	O
powder	O
,	O
the	O
mint	O
powder	O
and	O
the	O
arbutin	B
,	O
and	O
uniformly	O
stirring	O
to	O
obtain	O
the	O
body	O
moistening	O
oil	O
for	O
removing	O
HPV	O
virus	O
.	O

According	O
to	O
the	O
invention	O
,	O
olive	O
oil	O
is	O
taken	O
as	O
a	O
solvent	O
,	O
the	O
pearl	O
powder	O
and	O
the	O
mint	O
powder	O
are	O
taken	O
as	O
a	O
skin	O
conditioning	O
agent	O
,	O
the	O
arbutin	B
is	O
taken	O
as	O
a	O
pigment	O
inhibitor	O
,	O
and	O
the	O
body	O
moistening	O
oil	O
for	O
removing	O
HPV	O
virus	O
is	O
prepared	O
,	O
the	O
targeting	O
coating	O
seepage	O
force	O
is	O
strong	O
,	O
the	O
seepage	O
force	O
of	O
the	O
body	O
moistening	O
oil	O
for	O
removing	O
HPV	O
virus	O
exceeds	O
2000	O
kinds	O
of	O
essential	O
oil	O
,	O
and	O
the	O
external	O
application	O
can	O
reach	O
the	O
effect	O
of	O
rapid	O
treatment	O
.	O

The	O
body	O
moistening	O
oil	O
for	O
removing	O
HPV	O
virus	O
can	O
resist	O
HPV	O
virus	O
and	O
various	O
types	O
of	O
virus	O
,	O
fungi	O
,	O
mould	O
and	O
spiral	O
bacillus	O
.	O

Body	O
moistening	O
oil	O
for	O
removing	O
HPV	O
virus	O
and	O
preparation	O
method	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
a	O
tropisetron	B
citrate	I
crystal	O
form	O
II	O
.	O

The	O
tropisetron	B
citrate	I
crystal	O
form	O
II	O
is	O
obtained	O
through	O
selecting	O
from	O
different	O
crystal	O
solvents	O
and	O
temperatures	O
.	O

The	O
tropisetron	B
citrate	I
crystal	O
form	O
is	O
simple	O
in	O
preparation	O
technology	O
,	O
and	O
has	O
good	O
stability	O
;	O
a	O
sample	O
prepared	O
with	O
the	O
method	O
can	O
effectively	O
reduce	O
residual	O
quantity	O
of	O
introduced	O
solvents	O
,	O
such	O
as	O
methylbenzene	B
,	O
trichloromethane	B
and	O
pyridine	B
in	O
a	O
synthesis	O
process	O
;	O
product	O
purity	O
is	O
better	O
;	O
and	O
industrial	O
production	O
is	O
facilitated	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
tropisetron	B
citrate	I
crystal	O
form	O
II	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
sulfamethoxypyridazine	B
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
synergistic	O
sulfamethoxypyridazine	B
injection	O
has	O
enduring	O
drug	O
effect	O
and	O
obvious	O
curative	O
effect	O
.	O

The	O
injection	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
20	O
parts	O
of	O
sulfamethoxypyridazine	B
,	O
2	O
-	O
4	O
parts	O
of	O
indometacin	B
,	O
2	O
-	O
4	O
parts	O
of	O
trimethoprim	B
,	O
5	O
-	O
10	O
parts	O
of	O
polyethyleneglycol	B
8000	I
,	O
30	O
-	O
40	O
parts	O
of	O
propanediol	B
,	O
0.1	O
-	O
0.2	O
part	O
of	O
antioxidant	O
,	O
30	O
-	O
55	O
parts	O
of	O
water	O
for	O
injection	O
,	O
and	O
sufficient	O
amount	O
of	O
pH	O
regulator	O
for	O
regulating	O
the	O
pH	O
value	O
of	O
the	O
system	O
to	O
9.5	O
-	O
10.5	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
adding	O
the	O
antioxidant	O
into	O
the	O
water	O
for	O
injection	O
to	O
prepare	O
a	O
solution	O
A	O
,	O
adding	O
the	O
polyethyleneglycol	B
8000	I
,	O
sulfamethoxypyridazine	B
,	O
indometacin	B
and	O
trimethoprim	B
into	O
the	O
propanediol	B
,	O
and	O
completely	O
dissolving	O
by	O
stirring	O
to	O
prepare	O
a	O
solution	O
B	O
;	O
and	O
merging	O
,	O
filtering	O
,	O
packaging	O
and	O
sterilizing	O
to	O
obtain	O
the	O
finished	O
product	O
.	O

The	O
injection	O
provided	O
by	O
the	O
invention	O
is	O
a	O
new	O
drug	O
preparation	O
with	O
triple	O
effects	O
,	O
and	O
has	O
the	O
advantages	O
of	O
long	O
drug	O
effect	O
,	O
low	O
consumption	O
,	O
low	O
application	O
frequency	O
,	O
small	O
irritation	O
,	O
quick	O
drug	O
effect	O
taking	O
and	O
wide	O
curative	O
range	O
.	O

Preparation	O
method	O
of	O
synergistic	O
sulfamethoxypyridazine	B
injection	O
for	O
livestock	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
healthcare	O
medicines	O
/	O
foods	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
nutritional	O
healthcare	O
product	O
for	O
dispelling	O
alcohol	B
and	O
protecting	O
liver	O
.	O

The	O
nutritional	O
healthcare	O
product	O
for	O
dispelling	O
the	O
alcohol	B
and	O
protecting	O
the	O
liver	O
is	O
prepared	O
from	O
amino	B
nicotinicum	I
acidum	I
,	O
a	O
circium	O
japonicum	O
extract	O
,	O
a	O
feverfew	O
extract	O
and	O
a	O
kudzu	O
vine	O
root	O
extract	O
by	O
certain	O
proportions	O
,	O
and	O
contains	O
a	O
plurality	O
of	O
rare	O
and	O
famous	O
herb	O
medicine	O
extracts	O
.	O

The	O
nutritional	O
healthcare	O
product	O
is	O
scientific	O
in	O
formula	O
,	O
safe	O
and	O
free	O
from	O
toxic	O
and	O
side	O
effects	O
,	O
and	O
is	O
capable	O
of	O
effectively	O
dissolving	O
alcohol	O
toxin	O
and	O
decomposing	O
alcohol	O
,	O
so	O
as	O
to	O
achieve	O
a	O
purpose	O
of	O
preventing	O
and	O
treating	O
drunkenness	O
;	O
the	O
product	O
can	O
protect	O
the	O
liver	O
and	O
eliminate	O
free	O
radicals	O
,	O
so	O
as	O
to	O
reduce	O
the	O
liver	O
injury	O
to	O
the	O
greatest	O
extent	O
and	O
to	O
accelerate	O
repair	O
of	O
the	O
liver	O
,	O
so	O
that	O
the	O
regeneration	O
function	O
of	O
the	O
liver	O
is	O
improved	O
;	O
and	O
the	O
nutritional	O
healthcare	O
product	O
disclosed	O
by	O
the	O
invention	O
can	O
actually	O
and	O
effectively	O
dispel	O
the	O
alcohol	B
and	O
protect	O
the	O
liver	O
in	O
real	O
time	O
,	O
to	O
avoid	O
serious	O
irreversible	O
damage	O
on	O
the	O
liver	O
.	O

Nutritional	O
healthcare	O
product	O
for	O
dispelling	O
alcohol	B
and	O
protecting	O
liver	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
in	O
particular	O
relates	O
to	O
indoles	B
derivatives	O
shown	O
in	O
general	O
formula	O
(	O
I	O
)	O
and	O
functioning	O
as	O
a	O
CRTH2	O
receptor	O
antagonist	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
stereoisomerides	O
of	O
the	O
indoles	B
derivatives	O
,	O
wherein	O
X1	O
,	O
X2	O
,	O
X3	O
,	O
X4	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
Z	O
,	O
Y	O
,	O
A	O
,	O
and	O
B	O
are	O
defined	O
in	O
specifications	O
,	O
and	O
the	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
medicine	O
preparations	O
and	O
medicine	O
compositions	O
containing	O
the	O
compounds	O
,	O
and	O
an	O
application	O
of	O
the	O
compounds	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
and/or	O
preventing	O
CRTH2	O
activity	O
relevant	O
diseases	O
.	O

Indoles	B
derivative	O
functioning	O
as	O
CRTH2	O
receptor	O
antagonist	O

The	O
invention	O
relates	O
to	O
a	O
(	B
1,2,3-triazolyl	I
)	I
sulfonyl	I
derivative	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
substituent	O
groups	O
and	O
pharmaceutical	O
salts	O
of	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
are	O
defined	O
in	O
the	O
invention	O
.	O

Due	O
to	O
the	O
characteristics	O
of	O
inhibiting	O
inflammation	O
,	O
the	O
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
and	O
salts	O
thereof	O
can	O
be	O
used	O
for	O
treating	O
and	O
preventing	O
adaptation	O
diseases	O
related	O
to	O
inflammation	O
,	O
such	O
as	O
arthritic	O
disease	O
and	O
other	O
diseases	O
caused	O
by	O
chronic	O
inflammation	O
.	O

The	O
invention	O
relates	O
to	O
the	O
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
,	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
,	O
and	O
an	O
application	O
thereof	O
for	O
preparing	O
medicines	O
for	O
treating	O
human	O
and	O
animals	O
.	O

The	O
target	O
compound	O
in	O
the	O
invention	O
is	O
unique	O
and	O
novel	O
;	O
chemical	O
characteristics	O
of	O
sulfonyl	B
or	O
1,2,3-triazolyl	B
are	O
combined	O
into	O
one	O
molecule	O
for	O
the	O
first	O
time	O
;	O
biological	O
functions	O
thereof	O
are	O
displayed	O
through	O
a	O
nearly	O
brand	O
-	O
new	O
action	O
mechanism	O
;	O
and	O
the	O
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
and	O
the	O
pharmaceutical	O
salts	O
thereof	O
have	O
the	O
effects	O
of	O
resisting	O
inflammation	O
,	O
easing	O
pain	O
,	O
and	O
resisting	O
platelet	O
activity	O
and	O
proliferation	O
of	O
tumour	O
cells	O
,	O
in	O
particular	O
colon	O
cancer	O
.	O

(	B
1,2,3-triazolyl	I
)	I
sulfonyl	I
derivative	O

The	O
invention	O
provides	O
sesquiterpenes	B
ester	I
compound	O
with	O
a	O
novel	O
structure	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
use	O
thereof	O
.	O

The	O
compound	O
is	O
prepared	O
from	O
aspergilluspseudodeflectus	O
(	O
Aspergilluspseudodeflectus	O
)	O
by	O
fermentation	O
;	O
the	O
preservation	O
department	O
of	O
the	O
aspergilluspseudodeflectus	O
is	O
the	O
China	O
general	O
microbiology	O
preservation	O
management	O
center	O
;	O
and	O
the	O
preservation	O
number	O
is	O
CGMCC	O
No.3550	O
.	O

The	O
sesquiterpenes	O
ester	O
compound	O
prepared	O
by	O
the	O
preparation	O
method	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicament	O
for	O
preventing	O
or	O
treating	O
photoacoustic	O
therapy	O
pulse	O
(	O
PTP	O
)	O
mediated	O
disease	O
.	O

Sesquiterpenes	B
ester	I
compound	O
,	O
as	O
well	O
as	O
preparation	O
method	O
and	O
use	O
thereof	O

Antimicrobial	O
molecular	O
conjugates	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
infectious	O
diseases	O
caused	O
by	O
pathogenic	O
microorganisms	O
in	O
human	O
and	O
animals	O
are	O
provided	O
.	O

The	O
key	O
to	O
these	O
conjugates	O
is	O
connecting	O
dihydroxychlorins	B
or	O
beta-	B
functionalized	I
chlorins	I
to	O
carbohydrate	B
moieties	O
.	O

These	O
conjugates	O
are	O
found	O
to	O
be	O
very	O
effective	O
in	O
combating	O
bacterial	O
infections	O
caused	O
by	O
Gram	O
-	O
positive	O
and	O
Gram-	O
negative	O
bacteria	O
,	O
including	O
their	O
resistant	O
strains	O
.	O

Significantly	O
,	O
they	O
are	O
also	O
effective	O
in	O
complex	O
environments	O
,	O
including	O
blood	O
,	O
serum	O
,	O
and	O
other	O
body	O
fluids	O
which	O
are	O
present	O
in	O
patient	O
's	O
body	O
.	O

A	O
method	O
of	O
use	O
to	O
control	O
pathogenic	O
microorganisms	O
in	O
human	O
and	O
animals	O
is	O
also	O
provided	O
.	O

Glyco	B
-	I
substituted	I
dihydroxy	I
-	I
chlorins	I
and	O
b	B
-	I
functionalized	I
chlorins	I
for	O
anti	O
-	O
microbial	O
photodynamic	O
therapy	O

The	O
invention	O
discloses	O
application	O
of	O
13-methyitetradecanoic	B
acid	I
(	O
MTD	B
)	O
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
focal	O
cerebral	O
ischemia	O
.	O

The	O
13-MTD	B
in	O
different	O
dosages	O
shows	O
different	O
obvious	O
effects	O
in	O
different	O
cerebral	O
ischemia	O
time	O
intervals	O
,	O
including	O
the	O
effects	O
of	O
relieving	O
neurofunction	O
deficit	O
symptom	O
,	O
reducing	O
cerebral	O
infarction	O
,	O
relieving	O
encephaledema	O
by	O
down	O
regulating	O
protein	O
expression	O
of	O
brain	O
tissue	O
AQP4	O
(	O
Aquaporins	O
)	O
,	O
and	O
up	O
regulating	O
protein	O
expression	O
of	O
brain	O
tissue	O
ZO-1	O
in	O
order	O
to	O
protect	O
blood	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

The	O
13-MTD	B
possibly	O
becomes	O
a	O
promising	O
lead	O
component	O
for	O
treatment	O
of	O
ischemic	O
cerebrovascular	O
disease	O
.	O

The	O
13-MTD	O
has	O
the	O
following	O
advantages	O
of	O
treating	O
cerebral	O
ischemia	O
:	O
13-MTD	B
can	O
be	O
chemically	O
synthesized	O
,	O
has	O
molecular	O
weight	O
,	O
high	O
lipid	O
solubility	O
,	O
high	O
penetration	O
rate	O
with	O
respect	O
to	O
BBB	O
and	O
good	O
affinity	O
to	O
lipid	O
conformation	O
of	O
brain	O
tissue	O
,	O
and	O
can	O
quickly	O
and	O
efficiently	O
act	O
on	O
the	O
target	O
tissue	O
.	O

The	O
13-MTD	B
serving	O
as	O
a	O
cell	O
membrane	O
component	O
can	O
be	O
embedded	O
into	O
a	O
membrane	O
lipid	O
,	O
so	O
that	O
the	O
effect	O
of	O
stabilizing	O
the	O
membrane	O
can	O
be	O
realized	O
;	O
the	O
brain	O
is	O
rich	O
in	O
lipid	O
,	O
the	O
cerebral	O
ischemia	O
degrade	O
the	O
membrane	O
phospholipids	O
to	O
result	O
in	O
serious	O
injury	O
to	O
the	O
brain	O
cells	O
;	O
the	O
13-MTD	B
can	O
take	O
a	O
good	O
membrane	O
protection	O
effect	O
;	O
and	O
the	O
13-MTD	B
is	O
less	O
in	O
adverse	O
reaction	O
and	O
larger	O
in	O
safe	O
scope	O
,	O
can	O
be	O
taken	O
intravenously	O
;	O
and	O
the	O
13-MTD	B
specifically	O
has	O
greater	O
clinical	O
applicability	O
for	O
the	O
treatment	O
of	O
cerebral	O
ischemia	O
at	O
critical	O
disease	O
level	O
.	O

Application	O
of	O
13-methyitetradecanoic	B
acid	I
in	O
preparation	O
of	O
medicine	O
for	O
treating	O
focal	O
cerebral	O
ischemia	O

The	O
invention	O
belongs	O
to	O
a	O
chick	O
bacterial	O
disease	O
preventing	O
and	O
treating	O
composition	O
in	O
veterinary	O
drugs	O
.	O

The	O
chick	O
bacterial	O
disease	O
preventing	O
and	O
treating	O
composition	O
is	O
mainly	O
composed	O
of	O
the	O
effective	O
component	O
by	O
weight	O
:	O
1	O
%	O
of	O
norfloxacin	B
,	O
2	O
%	O
of	O
vitamin	B
C	I
,	O
17	O
%	O
of	O
sodium	B
chloride	I
and	O
80	O
%	O
of	O
glucose	B
.	O

The	O
composition	O
is	O
used	O
for	O
prevention	O
and	O
treatment	O
of	O
the	O
bacterial	O
diseases	O
of	O
1	O
-	O
15-day	O
-	O
old	O
chicks	O
,	O
and	O
the	O
prevention	O
and	O
treatment	O
rate	O
and	O
the	O
cure	O
rate	O
both	O
are	O
higher	O
than	O
96	O
%	O
.	O

The	O
process	O
for	O
processing	O
the	O
composition	O
comprises	O
accurately	O
weighing	O
all	O
of	O
the	O
effective	O
components	O
dried	O
previously	O
,	O
mixing	O
,	O
weighing	O
and	O
packaging	O
,	O
testing	O
quality	O
and	O
warehousing	O
.	O

The	O
method	O
of	O
using	O
the	O
composition	O
comprises	O
mixing	O
the	O
composition	O
with	O
other	O
materials	O
by	O
the	O
proportion	O
of	O
1.6	O
%	O
,	O
or	O
mixing	O
the	O
composition	O
with	O
drinking	O
water	O
by	O
the	O
proportion	O
of	O
0.8	O
%	O
.	O

Chick	O
bacterial	O
disease	O
preventing	O
and	O
treating	O
composition	O

The	O
invention	O
relates	O
to	O
a	O
stilbene	B
glucoside	I
compound	O
2,3,5,4'-tetrahydroxy	B
stilbene-2-O	I
-	I
beta	I
-	I
D	I
-	I
glucoside	I
and	O
new	O
application	O
of	O
an	O
extract	O
or	O
preparation	O
containing	O
the	O
stilbene	B
glucoside	I
compound	O
as	O
a	O
tyrosinase	O
inhibitor	O
.	O

The	O
new	O
application	O
includes	O
application	O
of	O
the	O
compound	O
and	O
the	O
extract	O
containing	O
the	O
compound	O
in	O
skin	O
whitening	O
cosmetic	O
,	O
stain	O
prevention	O
medicine	O
,	O
food	O
browning	O
inhibitor	O
and	O
biological	O
insecticide	O
.	O

Stilbene	B
glucoside	I
compound	O
and	O
new	O
application	O
of	O
extract	O
or	O
preparation	O
containing	O
stilbene	B
glucoside	I
compound	O
as	O
tyrosinase	O
inhibitor	O

The	O
invention	O
relates	O
to	O
a	O
metformin	B
hydrochloride	I
gastric	O
floating	O
tablet	O
.	O

The	O
metformin	B
hydrochloride	I
gastric	O
floating	O
tablet	O
contains	O
metformin	B
hydrochloride	I
,	O
a	O
polymer	O
gel	O
material	O
,	O
a	O
wax	O
material	O
and	O
a	O
foaming	O
material	O
,	O
wherein	O
the	O
polymer	O
gel	O
material	O
is	O
a	O
mixture	O
of	O
water	O
-	O
soluble	O
resin	O
and	O
lactose	O
;	O
the	O
wax	O
material	O
is	O
at	O
least	O
one	O
of	O
octodecyl	B
alcohol	I
and	O
stearic	B
acid	I
;	O
and	O
the	O
foaming	O
material	O
is	O
a	O
mixture	O
of	O
sodium	B
bicarbonate	I
and	O
magnesium	B
stearate	I
.	O

A	O
preparation	O
method	O
comprises	O
wet	O
process	O
pelletization	O
and	O
powder	O
direct	O
tabletting	O
,	O
wherein	O
the	O
wet	O
process	O
pelletization	O
comprises	O
the	O
following	O
steps	O
:	O
A1	O
)	O
preparing	O
the	O
materials	O
;	O
A2	O
)	O
mixing	O
the	O
materials	O
;	O
A3	O
)	O
pelletizing	O
;	O
and	O
A4	O
)	O
tabletting	O
;	O
and	O
the	O
powder	O
direct	O
tabletting	O
comprises	O
the	O
following	O
steps	O
:	O
B1	O
)	O
preparing	O
the	O
materials	O
;	O
B2	O
)	O
mixing	O
the	O
materials	O
;	O
and	O
B3	O
)	O
tabletting	O
.	O

Each	O
metformin	B
hydrochloride	I
gastric	O
floating	O
tablet	O
contains	O
0.25	O
-	O
0.75	O
g	O
of	O
metformin	B
hydrochloride	I
.	O

The	O
metformin	B
hydrochloride	I
gastric	O
floating	O
tablet	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
after	O
the	O
tablets	O
are	O
taken	O
by	O
a	O
patient	O
,	O
hydrophilic	O
gel	O
is	O
hydrated	O
and	O
expanded	O
,	O
a	O
medicament	O
is	O
simultaneously	O
controlled	O
to	O
be	O
released	O
slowly	O
,	O
the	O
onset	O
of	O
action	O
of	O
the	O
medicament	O
is	O
fast	O
,	O
the	O
medicament	O
effect	O
is	O
lasting	O
and	O
the	O
bioavailability	O
of	O
the	O
medicament	O
is	O
high	O
;	O
and	O
the	O
frequency	O
of	O
taking	O
the	O
tablets	O
of	O
the	O
patient	O
can	O
be	O
reduced	O
,	O
the	O
side	O
effects	O
are	O
reduced	O
,	O
and	O
the	O
incidence	O
rate	O
of	O
poor	O
reactions	O
is	O
also	O
reduced	O
.	O

Metformin	B
hydrochloride	I
gastric	O
floating	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
cefaclor	B
dispersible	O
tablet	O
,	O
which	O
is	O
prepared	O
from	O
a	O
drug	O
pellet	O
containing	O
cefaclor	B
,	O
a	O
filler	O
and	O
a	O
lubricating	O
agent	O
in	O
a	O
direct	O
tabletting	O
manner	O
;	O
the	O
drug	O
pellet	O
is	O
prepared	O
by	O
the	O
following	O
method	O
comprising	O
steps	O
of	O
:	O
weighing	O
cefaclor	B
and	O
a	O
disintegrating	O
agent	O
to	O
disperse	O
in	O
ethanol	B
;	O
and	O
atomizing	O
formed	O
suspension	O
in	O
a	O
fluidized	O
bed	O
on	O
a	O
lactose	B
pellet	O
to	O
envelop	O
,	O
so	O
as	O
to	O
prepare	O
the	O
drug	O
pellet	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
cefaclor	B
material	O
is	O
enveloped	O
at	O
the	O
outer	O
layer	O
of	O
the	O
lactose	B
pellet	O
;	O
and	O
the	O
drug	O
is	O
evenly	O
distributed	O
at	O
the	O
surface	O
of	O
the	O
pellet	O
.	O

Therefore	O
,	O
the	O
specific	O
surface	O
area	O
of	O
the	O
drug	O
is	O
greatly	O
improved	O
;	O
and	O
the	O
material	O
can	O
be	O
rapidly	O
released	O
,	O
so	O
as	O
to	O
improve	O
the	O
drug	O
dissolution	O
and	O
the	O
bioavailability	O
of	O
the	O
drug	O
.	O

Cefaclor	B
dispersible	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
soft	O
polyprenol	B
capsule	O
.	O

The	O
soft	O
polyprenol	B
capsule	O
is	O
characterized	O
in	O
that	O
the	O
primary	O
effective	O
component	O
of	O
the	O
soft	O
polyprenol	B
capsule	O
is	O
polyprenol	B
,	O
and	O
the	O
auxiliary	O
materials	O
of	O
the	O
soft	O
polyprenol	B
capsule	O
comprise	O
edible	O
plant	O
oil	O
,	O
gelatin	O
and	O
glycerin	B
,	O
wherein	O
polyprenol	B
is	O
a	O
natural	O
product	O
extracted	O
from	O
one	O
or	O
more	O
of	O
ginkgo	O
leaf	O
,	O
and	O
coniferous	O
trees	O
,	O
such	O
as	O
masson	O
pine	O
,	O
Pinus	O
thunbergii	O
Parl	O
,	O
slash	O
pine	O
,	O
Sabina	O
chinensis	O
,	O
cedar	O
and	O
the	O
like	O
,	O
and	O
the	O
content	O
of	O
polyprenol	B
in	O
each	O
soft	O
polyprenol	B
capsule	O
is	O
1	O
-	O
50	O
mg	O
The	O
making	O
method	O
of	O
the	O
soft	O
polyprenol	B
capsule	O
comprises	O
a	O
step	O
of	O
preparation	O
of	O
a	O
polyprenol	B
-	O
containing	O
extract	O
(	O
the	O
content	O
of	O
polyprenol	B
in	O
the	O
polyprenol	B
-	O
containing	O
extract	O
can	O
reach	O
30	O
%	O
or	O
more	O
,	O
preferably	O
50	O
%	O
or	O
more	O
,	O
and	O
most	O
preferably	O
90	O
%	O
or	O
more	O
)	O
,	O
a	O
step	O
of	O
material	O
burdening	O
and	O
gelatin	O
dissolving	O
,	O
a	O
step	O
of	O
pelleting	O
,	O
a	O
step	O
of	O
drying	O
,	O
a	O
step	O
of	O
capsule	O
washing	O
,	O
and	O
a	O
step	O
of	O
capsule	O
choosing	O
.	O

The	O
content	O
of	O
polyprenol	B
in	O
the	O
soft	O
polyprenol	B
capsule	O
prepared	O
through	O
the	O
method	O
can	O
be	O
detected	O
through	O
high	O
-	O
performance	O
liquid	O
chromatography	O
internal	O
and	O
external	O
standard	O
methods	O
,	O
and	O
the	O
soft	O
polyprenol	B
capsule	O
can	O
be	O
used	O
for	O
liver	O
protection	O
,	O
virus	O
resistance	O
,	O
immunity	O
adjustment	O
,	O
tumor	O
resistance	O
and	O
the	O
like	O
.	O

Soft	O
polyprenol	B
capsule	O
and	O
its	O
making	O
method	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
suloctidil	B
to	O
prepare	O
an	O
anti	O
-	O
angiogenesis	O
medicine	O
.	O

Suloctidil	B
has	O
the	O
characteristics	O
of	O
low	O
price	O
,	O
high	O
safety	O
and	O
wide	O
raw	O
material	O
source	O
;	O
and	O
the	O
suloctidil	B
can	O
be	O
used	O
for	O
preparing	O
various	O
oral	O
,	O
injection	O
and	O
external	O
preparations	O
through	O
adopting	O
a	O
conventional	O
preparation	O
technology	O
under	O
the	O
combination	O
of	O
pharmaceutically	O
acceptable	O
adjuvants	O
,	O
therefore	O
the	O
invention	O
has	O
a	O
good	O
development	O
prospect	O
.	O

Application	O
of	O
suloctidil	B
to	O
prepare	O
anti	O
-	O
angiogenesis	O
medicine	O

The	O
invention	O
discloses	O
a	O
use	O
of	O
tryptophan	B
nanometer	O
microspheres	O
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
tumor	O
diseases	O
.	O

According	O
to	O
the	O
invention	O
,	O
tryptophan	B
is	O
embedded	O
by	O
using	O
an	O
emulsification	O
method	O
nanometer	O
microsphere	O
technology	O
to	O
enter	O
tumor	O
cells	O
,	O
so	O
that	O
a	O
large	O
number	O
of	O
exogenous	O
tryptophans	B
are	O
released	O
in	O
the	O
cells	O
to	O
cytoplasm	O
of	O
tumor	O
cells	O
,	O
so	O
as	O
to	O
resist	O
tumors	O
.	O

Researches	O
show	O
that	O
the	O
tryptophan	B
nanometer	O
microspheres	O
have	O
a	O
strong	O
killing	O
effect	O
for	O
human	O
lymphoma	O
cell	O
lines	O
,	O
breast	O
cancer	O
cell	O
lines	O
,	O
lung	O
cancer	O
cell	O
lines	O
,	O
colorectal	O
carcinoma	O
cell	O
lines	O
,	O
cervical	O
cancer	O
cell	O
lines	O
,	O
brain	O
tumor	O
cell	O
lines	O
and	O
human	O
leukemia	O
cell	O
lines	O
.	O

By	O
a	O
manner	O
of	O
local	O
administration	O
,	O
the	O
medicine	O
has	O
an	O
obvious	O
inhibition	O
on	O
the	O
growth	O
of	O
the	O
colorectal	O
cancer	O
cell	O
line	O
nude	O
mice	O
metastatic	O
tumor	O
.	O

Use	O
of	O
tryptophan	B
nanometer	O
microspheres	O
in	O
preparation	O
of	O
medicine	O
for	O
treating	O
tumor	O
diseases	O

The	O
invention	O
provides	O
powder	O
injection	O
of	O
a	O
drug	O
composition	O
of	O
ceftazidime	B
for	O
injection	O
,	O
relating	O
to	O
the	O
fields	O
of	O
pharmaceutical	O
preparations	O
and	O
preparation	O
methods	O
and	O
mainly	O
solving	O
the	O
problems	O
that	O
single	O
preparations	O
of	O
ceftazidime	B
and	O
metronidazole	B
in	O
the	O
prior	O
art	O
have	O
great	O
dosages	O
,	O
poor	O
treatment	O
effects	O
after	O
being	O
combined	O
and	O
big	O
side	O
effects	O
.	O

The	O
drug	O
composition	O
comprises	O
main	O
drugs	O
such	O
as	O
ceftazidime	B
and	O
metronidazole	B
lipid	O
microspheres	O
and	O
an	O
auxiliary	O
material	O
arginine	B
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
ceftazidime	B
to	O
metronidazole	B
lipid	O
microspheres	O
is	O
(	O
100:3	O
)	O
-	O
(	O
100:10	O
)	O
;	O
the	O
weight	O
ratio	O
of	O
ceftazidime	B
to	O
arginine	B
is	O
100:27	O
;	O
and	O
the	O
weight	O
of	O
the	O
metronidazole	B
lipid	O
microspheres	O
is	O
based	O
on	O
metronidazole	B
.	O

The	O
drug	O
composition	O
is	O
prepared	O
into	O
powder	O
injection	O
.	O

The	O
pH	O
value	O
of	O
water	O
solution	O
of	O
the	O
drug	O
composition	O
is	O
5.0	O
-	O
7.0	O
.	O

The	O
powder	O
injection	O
of	O
the	O
drug	O
composition	O
provided	O
by	O
the	O
invention	O
not	O
only	O
has	O
high	O
curative	O
effect	O
but	O
also	O
can	O
reduce	O
the	O
dosage	O
of	O
metronidazole	B
by	O
over	O
80	O
%	O
,	O
thus	O
greatly	O
reducing	O
or	O
avoiding	O
the	O
toxic	O
and	O
side	O
effects	O
,	O
especially	O
gastrointestinal	O
reactions	O
including	O
nausea	O
,	O
emesis	O
,	O
anorexia	O
,	O
abdominal	O
cramp	O
and	O
neurotoxicity	O
,	O
of	O
metronidazole	B
and	O
further	O
reducing	O
the	O
occurrence	O
rate	O
of	O
adverse	O
reactions	O
.	O

Powder	O
injection	O
of	O
drug	O
composition	O
of	O
ceftazidime	B
for	O
injection	O

The	O
invention	O
provides	O
a	O
cefminox	B
sodium	I
drug	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relating	O
to	O
the	O
fields	O
of	O
pharmaceutical	O
preparations	O
and	O
preparation	O
methods	O
and	O
mainly	O
solving	O
the	O
problems	O
that	O
single	O
preparations	O
of	O
cefminox	B
sodium	I
and	O
metronidazole	B
in	O
the	O
prior	O
art	O
have	O
great	O
dosages	O
,	O
poor	O
treatment	O
effects	O
after	O
being	O
combined	O
and	O
big	O
side	O
effects	O
.	O

The	O
drug	O
composition	O
comprises	O
cefminox	B
sodium	I
and	O
metronidazole	B
lipid	O
microspheres	O
in	O
a	O
weight	O
ratio	O
of	O
(	O
100:3	O
)	O
-	O
(	O
100:10	O
)	O
,	O
wherein	O
the	O
weight	O
of	O
the	O
metronidazole	B
lipid	O
microspheres	O
is	O
based	O
on	O
metronidazole	B
.	O

The	O
drug	O
composition	O
is	O
prepared	O
into	O
powder	O
injection	O
.	O

The	O
pH	O
value	O
of	O
water	O
solution	O
of	O
the	O
drug	O
composition	O
is	O
6.5	O
-	O
7.0	O
.	O

The	O
powder	O
injection	O
of	O
the	O
drug	O
composition	O
provided	O
by	O
the	O
invention	O
not	O
only	O
has	O
high	O
curative	O
effect	O
but	O
also	O
can	O
reduce	O
the	O
dosage	O
of	O
metronidazole	B
by	O
over	O
80	O
%	O
,	O
thus	O
greatly	O
reducing	O
or	O
avoiding	O
the	O
toxic	O
and	O
side	O
effects	O
,	O
especially	O
gastrointestinal	O
reactions	O
including	O
nausea	O
,	O
emesis	O
,	O
anorexia	O
,	O
abdominal	O
cramp	O
and	O
neurotoxicity	O
,	O
of	O
metronidazole	B
and	O
further	O
reducing	O
the	O
occurrence	O
rate	O
of	O
adverse	O
reactions	O
.	O

Cefminox	B
sodium	I
drug	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
alkyl	B
-	I
substituted	I
quinolinone	I
compound	O
with	O
side	O
chains	O
.	O

The	O
alkyl	B
-	I
substituted	I
quinolinone	I
compound	O
has	O
a	O
chemical	O
structure	O
represented	O
by	O
formula	O
I	O
,	O
the	O
name	O
of	O
the	O
alkyl	B
-	I
substituted	I
quinolinone	I
compound	O
is	O
2-	B
(	I
4'-methyl-	I
)	I
heptane-3-methyl-4	I
(	I
1H	I
)	I
-quinolinone	I
,	O
the	O
chemical	O
formula	O
of	O
the	O
alkyl	B
-	I
substituted	I
quinolinone	I
compound	O
is	O
C18H22NO	B
,	O
and	O
the	O
alkyl	B
-	I
substituted	I
quinolinone	I
compound	O
is	O
named	O
as	O
heptanone	B
.	O

The	O
invention	O
further	O
provides	O
an	O
application	O
of	O
pharmaceutical	O
composition	O
of	O
the	O
compound	O
provided	O
by	O
the	O
invention	O
in	O
preparation	O
of	O
drugs	O
for	O
prevention	O
and/or	O
treatment	O
of	O
gastritis	O
caused	O
by	O
Helicobacter	O
pylori	O
.	O

According	O
to	O
the	O
alkyl	B
-	I
substituted	I
quinolinone	I
compound	O
,	O
a	O
first	O
-	O
site	O
N	B
of	O
the	O
quinolinone	B
is	O
not	O
hydroxylated	O
,	O
and	O
a	O
second	O
-	O
site	O
of	O
the	O
quinolinone	B
is	O
substituted	O
by	O
4-methyl	B
-	I
heptane	I
;	O
the	O
quinolinone	B
is	O
prepared	O
by	O
utilizing	O
total	O
synthesis	O
;	O
and	O
the	O
compound	O
,	O
represented	O
by	O
the	O
formula	O
I	O
and	O
provided	O
by	O
the	O
invention	O
,	O
has	O
a	O
relatively	O
high	O
selective	O
inhibition	O
effect	O
on	O
the	O
Helicobacter	O
pylori	O
and	O
is	O
an	O
efficient	O
proton	O
pump	O
inhibitor	O
,	O
so	O
that	O
a	O
possibility	O
for	O
developing	O
a	O
novel	O
drug	O
for	O
treating	O
the	O
gastritis	O
caused	O
by	O
the	O
Helicobacter	O
pylori	O
is	O
provided	O
.	O

Alkyl	B
-	I
substituted	I
quinolinone	I
compound	O
with	O
side	O
chains	O
as	O
well	O
as	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
new	O
application	O
of	O
6'-O	B
-	I
caffeoyl	I
-	I
arbutin	I
in	O
the	O
technical	O
field	O
of	O
medicines	O
for	O
inhibiting	O
melanin	O
,	O
particularly	O
application	O
of	O
6'-O	B
-	I
caffeoyl	I
-	I
arbutin	I
or	O
derivatives	O
thereof	O
,	O
or	O
a	O
natural	O
,	O
synthetic	O
or	O
semisynthetic	O
mixture	O
containing	O
the	O
6'-O	B
-	I
caffeoyl	I
-	I
arbutin	I
,	O
or	O
a	O
composition	O
containing	O
the	O
6'-O	B
-	I
caffeoyl	I
-	I
arbutin	I
in	O
preparing	O
cosmetics	O
for	O
whitening	O
skin	O
and	O
removing	O
freckles	O
or	O
medicines	O
for	O
whitening	O
skin	O
and	O
treating	O
chromatodermatosis	O
.	O

The	O
6'-O	B
-	I
caffeoyl	I
-	I
arbutin	I
can	O
effectively	O
inhibit	O
and	O
decompose	O
melanin	O
,	O
thoroughly	O
remove	O
the	O
melanin	O
freckles	O
,	O
and	O
have	O
the	O
effect	O
of	O
whitening	O
skin	O
and	O
removing	O
freckles	O
;	O
and	O
the	O
zebra	O
fish	O
acute	O
toxicity	O
test	O
indicates	O
that	O
compared	O
with	O
arbutin	B
,	O
the	O
6'-O	B
-	I
caffeoyl	I
-	I
arbutin	I
has	O
the	O
characteristics	O
of	O
lower	O
toxicity	O
,	O
higher	O
activity	O
,	O
higher	O
efficiency	O
and	O
higher	O
safety	O
.	O

6'-O	B
-	I
caffeoyl	I
-	I
arbutin	I
and	O
derivatives	O
thereof	O
,	O
and	O
application	O
of	O
compound	O
prescription	O
in	O
preparing	O
cosmetics	O
or	O
medicines	O

The	O
invention	O
discloses	O
a	O
gastrodin	B
injection	O
preparation	O
,	O
which	O
comprises	O
the	O
following	O
components	O
by	O
weight	O
:	O
5	O
-	O
10	O
%	O
of	O
gastrodin	B
,	O
0.01	O
-	O
0.1	O
%	O
of	O
metal	O
ion	O
complexing	O
agent	O
,	O
0.6	O
-	O
1.2	O
%	O
of	O
stabilizing	O
agent	O
,	O
1	O
-	O
2.5	O
%	O
of	O
buffer	O
and	O
the	O
balance	O
of	O
injection	O
water	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
gastrodin	B
injection	O
preparation	O
.	O

The	O
gastrodin	B
injection	O
of	O
the	O
present	O
invention	O
can	O
effectively	O
stop	O
the	O
addition	O
of	O
visible	O
foreign	O
matter	O
during	O
a	O
placing	O
process	O
of	O
the	O
gastrodin	B
injection	O
,	O
the	O
defective	O
index	O
of	O
the	O
visible	O
foreign	O
matter	O
in	O
a	O
solution	O
is	O
reduced	O
,	O
the	O
white	O
point	O
and	O
white	O
block	O
precipitation	O
are	O
not	O
generated	O
,	O
the	O
expectation	O
effect	O
can	O
be	O
reached	O
,	O
thereby	O
the	O
treatment	O
effect	O
of	O
gastrodin	B
can	O
be	O
fully	O
performed	O
.	O

The	O
gastrodin	B
injection	O
preparation	O
has	O
the	O
advantages	O
of	O
simple	O
prescription	O
,	O
good	O
stability	O
,	O
high	O
clear	O
degree	O
,	O
safe	O
clinical	O
usage	O
,	O
small	O
adverse	O
reaction	O
and	O
convenient	O
industrial	O
large	O
batch	O
production	O
.	O

Gastrodin	B
injection	O
preparation	O
and	O
preparation	O
method	O

A	O
difluprednate	B
emulsion	O
comprises	O
difluprednate	B
used	O
as	O
active	O
ingredients	O
,	O
one	O
type	O
or	O
multiple	O
types	O
of	O
oil	O
,	O
one	O
type	O
or	O
multiple	O
types	O
of	O
emulgator	O
and	O
water	O
.	O

The	O
emulsion	O
comprises	O
,	O
by	O
weight	O
,	O
0.01	O
%	O
to	O
0.1	O
%	O
of	O
difluprednate	B
,	O
1	O
%	O
to	O
20	O
%	O
of	O
oil	O
,	O
and	O
1	O
%	O
to	O
10	O
%	O
of	O
emulgator	O
.	O

The	O
difluprednate	B
dissolves	O
in	O
the	O
oil	O
and	O
the	O
emulgator	O
.	O

Difluprednate	B
emulsion	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
with	O
lanthanum	B
acetate	I
,	O
and	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
medicinal	O
composition	O
with	O
the	O
lanthanum	B
acetate	I
and	O
application	O
of	O
the	O
medicinal	O
composition	O
with	O
the	O
lanthanum	B
acetate	I
.	O

The	O
medicinal	O
composition	O
with	O
the	O
lanthanum	B
acetate	I
can	O
be	O
used	O
for	O
curing	O
a	O
hyperphosphatemia	O
disease	O
.	O

Medicinal	O
composition	O
with	O
lanthanum	B
acetate	I
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
medicine	O
technical	O
field	O
,	O
and	O
relates	O
to	O
6-	B
[	I
2-	I
(	I
dimethylamino	I
)	I
ethoxy	I
]	I
flavone	I
(	O
a	O
flavone	B
compound	O
WX-02	O
)	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
or	O
its	O
stereoisomers	O
and	O
prodrugs	O
,	O
and	O
applications	O
of	O
its	O
pharmaceutically	O
compatibility	O
-	O
acceptable	O
carriers	O
or	O
diluents	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
vascular	O
smooth	O
muscle	O
spasm	O
diseases	O
,	O
and	O
applications	O
as	O
a	O
calcium	B
channel	O
antagonist	O
in	O
treating	O
cardiovascular	O
diseases	O
.	O

In	O
animal	O
in	O
-	O
vitro	O
experiments	O
,	O
WX-02	O
can	O
dilatate	O
vascular	O
smooth	O
muscles	O
which	O
are	O
constricted	O
by	O
norepinephrine	B
and	O
potassium	B
chloride	I
.	O

Additionally	O
,	O
preliminary	O
research	O
of	O
WX-02	O
dilatation	O
mechanism	O
finds	O
that	O
WX-02	O
can	O
inhibit	O
intracellular	O
calcium	O
release	O
and	O
calcium	B
influx	O
caused	O
by	O
norepinephrine	B
.	O

Therefore	O
,	O
WX-02	O
can	O
be	O
used	O
for	O
preparation	O
of	O
drugs	O
for	O
treating	O
vascular	O
smooth	O
muscle	O
spasm	O
diseases	O
,	O
and	O
used	O
as	O
a	O
calcium	B
channel	O
blocker	O
.	O

Medical	O
application	O
of	O
6-	B
[	I
2-	I
(	I
dimethylamino	I
)	I
ethoxy	I
]	I
flavone	I

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
chemical	O
industry	O
and	O
medicines	O
,	O
and	O
relates	O
to	O
application	O
of	O
13'-acetyl	O
silver	O
grass	O
alcohol	O
C	O
in	O
manufacturing	O
of	O
antineoplastic	O
drugs	O
.	O

According	O
to	O
the	O
application	O
of	O
the	O
13'-acetyl	O
silver	O
grass	O
alcohol	O
C	O
in	O
the	O
manufacturing	O
of	O
the	O
antineoplastic	O
drugs	O
,	O
cancer	O
cells	O
comprise	O
hepatoma	O
carcinoma	O
cells	O
,	O
leukemia	O
cells	O
,	O
gastric	O
carcinoma	O
cells	O
and	O
pancreatic	O
cancer	O
cells	O
.	O

The	O
13'-acetyl	O
silver	O
grass	O
alcohol	O
C	O
belongs	O
to	O
natural	O
products	O
,	O
is	O
small	O
in	O
toxic	O
and	O
side	O
effects	O
,	O
high	O
in	O
biological	O
utilization	O
rate	O
and	O
stable	O
in	O
properties	O
,	O
and	O
has	O
clinical	O
application	O
value	O
.	O

Small	O
molecule	O
compounds	O
of	O
the	O
13'-acetyl	O
silver	O
alcohol	O
C	O
are	O
used	O
as	O
new	O
antineoplastic	O
drugs	O
or	O
used	O
as	O
auxiliary	O
components	O
for	O
developing	O
,	O
are	O
significant	O
in	O
tumor	O
suppression	O
effect	O
,	O
environmental	O
-	O
protecting	O
,	O
and	O
capable	O
of	O
providing	O
a	O
new	O
approach	O
and	O
means	O
for	O
curing	O
and	O
treatment	O
of	O
tumors	O
.	O

Application	O
of	O
13'-acetyl	O
silver	O
grass	O
alcohol	O
C	O
in	O
manufacturing	O
of	O
antineoplastic	O
drugs	O

The	O
invention	O
relates	O
to	O
a	O
rasagiline	B
/	O
folic	B
acid	I
compound	O
medicine	O
combination	O
and	O
a	O
purpose	O
thereof	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmacy	O
.	O

The	O
medicine	O
combination	O
comprises	O
the	O
rasagiline	B
with	O
an	O
officinal	O
dose	O
,	O
the	O
folic	B
acid	I
compounds	O
with	O
an	O
officinal	O
dose	O
,	O
and	O
a	O
carrier	O
which	O
can	O
be	O
accepted	O
in	O
pharmacy	O
.	O

The	O
dose	O
of	O
the	O
rasagiline	B
is	O
0.5	O
-	O
2	O
mg	O
,	O
and	O
the	O
dose	O
of	O
the	O
folic	B
acid	I
compounds	O
is	O
0.2	O
-	O
1.6	O
mg	O
.	O

The	O
medicine	O
combination	O
has	O
the	O
advantages	O
that	O
through	O
synergistic	O
effect	O
of	O
multiple	O
target	O
points	O
,	O
curative	O
effect	O
on	O
the	O
Parkinson	O
's	O
disease	O
is	O
improved	O
,	O
life	O
quality	O
of	O
a	O
patient	O
is	O
improved	O
,	O
through	O
a	O
homocysteine	B
(	O
Hcy	O
)	O
target	O
point	O
,	O
cerebral	O
apoplexy	O
of	O
the	O
patient	O
with	O
the	O
Parkinson	O
's	O
disease	O
can	O
be	O
effectively	O
prevented	O
,	O
occurring	O
risk	O
of	O
the	O
cerebral	O
apoplexy	O
can	O
be	O
effectively	O
lowered	O
,	O
and	O
in	O
addition	O
,	O
the	O
patient	O
can	O
conveniently	O
take	O
medicine	O
.	O

Rasagiline	B
/	O
folic	B
acid	I
compound	O
medicine	O
combination	O
and	O
purpose	O
thereof	O

The	O
invention	O
provides	O
a	O
cefoperazone	B
sodium	I
pharmaceutical	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relating	O
to	O
the	O
field	O
of	O
a	O
pharmaceutical	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
mainly	O
solves	O
the	O
problems	O
of	O
high	O
dosage	O
of	O
single	O
cefoperazone	B
sodium	I
and	O
metronidazole	B
preparation	O
,	O
poor	O
treatment	O
effect	O
after	O
combination	O
,	O
and	O
great	O
side	O
effect	O
in	O
the	O
prior	O
art	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
cefoperazone	B
sodium	I
and	O
metronidazole	B
lipid	O
microspheres	O
in	O
a	O
weight	O
ratio	O
of	O
100:3	O
-	O
100:10	O
,	O
wherein	O
the	O
weight	O
of	O
the	O
metronidazole	B
lipid	O
microspheres	O
is	O
metered	O
on	O
the	O
basis	O
of	O
on	O
metronidazole	B
;	O
and	O
when	O
the	O
pharmaceutical	O
composition	O
is	O
prepared	O
into	O
a	O
powder	O
injection	O
,	O
the	O
pH	O
value	O
of	O
the	O
water	O
solution	O
of	O
the	O
pharmaceutical	O
composition	O
is	O
6.5	O
-	O
7.0	O
.	O

The	O
pharmaceutical	O
composition	O
powder	O
injection	O
provided	O
by	O
the	O
invention	O
has	O
high	O
curative	O
effect	O
,	O
and	O
can	O
reduce	O
the	O
consumption	O
of	O
the	O
metronidazole	B
by	O
more	O
than	O
80	O
%	O
,	O
thereby	O
greatly	O
relieving	O
or	O
avoiding	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
metronidazole	B
,	O
especially	O
digestive	O
tract	O
reactions	O
,	O
including	O
nausea	O
,	O
vomit	O
,	O
inappetence	O
,	O
abdominal	O
colic	O
and	O
neurotoxicity	O
,	O
and	O
lowering	O
the	O
incidence	O
rate	O
of	O
adverse	O
reactions	O
.	O

Cefoperazone	B
sodium	I
pharmaceutical	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
application	O
of	O
Gypensapogenin	B
B	I
in	O
preparing	O
medicines	O
treating	O
liver	O
fibrosis	O
.	O

Pharmacological	O
experiments	O
prove	O
that	O
:	O
the	O
Gypensapogenin	B
B	I
can	O
obviously	O
inhibit	O
occurring	O
and	O
developing	O
of	O
the	O
liver	O
fibrosis	O
,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
anti	O
-	O
liver	O
fibrosis	O
and	O
preventing	O
and	O
treating	O
cirrhosis	O
.	O

The	O
application	O
of	O
the	O
Gypensapogenin	B
B	I
in	O
preparing	O
medicines	O
inhibiting	O
liver	O
fibroblast	O
proliferation	O
is	O
made	O
public	O
for	O
the	O
first	O
time	O
,	O
due	O
to	O
the	O
fact	O
that	O
matrix	O
type	O
is	O
brand	O
novel	O
,	O
besides	O
,	O
the	O
Eryngiolide	B
B	I
has	O
an	O
unexpectedly	O
high	O
liver	O
fibroblast	O
proliferation	O
inhibitory	O
activity	O
,	O
the	O
probability	O
that	O
inspiration	O
is	O
obtained	O
from	O
other	O
compounds	O
does	O
not	O
exist	O
,	O
and	O
the	O
Gypensapogenin	B
B	I
possesses	O
outstanding	O
substantial	O
characteristics	O
,	O
meanwhile	O
,	O
significant	O
progress	O
is	O
obviously	O
achieved	O
by	O
the	O
application	O
of	O
the	O
Gypensapogenin	B
B	I
in	O
anti	O
-	O
liver	O
fibroblast	O
proliferation	O
.	O

Application	O
of	O
Gypensapogenin	B
B	I
in	O
medicines	O
inhibiting	O
liver	O
fibroblast	O
proliferation	O

The	O
invention	O
relates	O
to	O
cyclocarya	O
paliurus	O
extract	O
and	O
the	O
application	O
of	O
the	O
cyclocarya	O
paliurus	O
extract	O
.	O

The	O
cyclocarya	O
paliurus	O
extract	O
at	O
least	O
comprises	O
the	O
following	O
effective	O
ingredients	O
:	O
10-methoxy	B
-	I
nb	I
-	I
alpha	I
-	I
methyl	I
corynantheol	I
,	O
n	B
-	I
nonyl	I
nitrate	I
,	O
iso	B
-	I
butoxyamine	I
,	O
pentadecanoic	B
acid	I
,	O
4	B
,	I
6	I
,	I
10	I
,	I
14-tetramethyl	I
-	I
methyl	I
-	I
ester	I
,	O
adipic	B
acid	I
,	O
bis--	B
(	I
2-ethylhexyl	I
)	I
ester	I
,	O
2-butyl	B
,	O
1-octanol	B
,	O
octadecyl	B
vinyl	I
ether	I
and	O
erythro	B
cis-4	I
,	I
5-dimethyl-2-undecene	I
.	O

The	O
weight	O
percentage	O
of	O
the	O
effective	O
ingredients	O
in	O
the	O
cyclocarya	O
paliurus	O
extract	O
is	O
50	O
%	O
to	O
98	O
%	O
.	O

The	O
cyclocarya	O
paliurus	O
extract	O
can	O
significantly	O
promote	O
the	O
secretion	O
of	O
insulin	O
by	O
islet	O
beta	O
cells	O
so	O
as	O
to	O
enhance	O
glucose	B
tolerance	O
of	O
mice	O
and	O
regulate	O
blood	O
sugar	B
,	O
and	O
therefore	O
the	O
cyclocarya	O
paliurus	O
extract	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
diabetes	O
,	O
and	O
the	O
direction	O
is	O
pointed	O
out	O
for	O
further	O
developing	O
and	O
utilizing	O
the	O
medical	O
value	O
of	O
cyclocarya	O
paliurus	O
.	O

Cyclocarya	O
paliurus	O
extract	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
oyster	O
larval	O
bacterial	O
canker	O
,	O
which	O
comprises	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
:	O
10	O
-	O
20	O
parts	O
of	O
Agastache	O
rugosus	O
,	O
10	O
-	O
20	O
parts	O
of	O
Fortune	O
Eupatorium	O
Herb	O
,	O
20	O
-	O
30	O
parts	O
of	O
dandelion	O
,	O
10	O
-	O
20	O
parts	O
of	O
Ligusticum	O
wallichii	O
,	O
20	O
-	O
30	O
parts	O
of	O
herba	O
lycopi	O
,	O
20	O
-	O
30	O
parts	O
of	O
Long	O
Xingcao	O
,	O
20	O
-	O
30	O
parts	O
of	O
radix	O
bupleuri	O
,	O
5	O
-	O
15	O
parts	O
of	O
capillary	O
artemisia	O
,	O
25	O
-	O
35	O
parts	O
of	O
Coptis	O
chinensis	O
,	O
10	O
-	O
20	O
parts	O
of	O
radix	O
polygonati	O
officinalis	O
,	O
15	O
-	O
25	O
parts	O
of	O
dendrobe	O
,	O
100	O
-	O
200	O
parts	O
of	O
chloromycetin	B
and	O
50	O
-	O
60	O
parts	O
of	O
gentamicin	B
.	O

The	O
medicine	O
provided	O
by	O
the	O
invention	O
has	O
good	O
treatment	O
effect	O
on	O
oyster	O
larva	O
at	O
early	O
stage	O
of	O
bacterial	O
diseases	O
,	O
the	O
larva	O
death	O
probability	O
is	O
reduce	O
,	O
and	O
the	O
medicine	O
for	O
treating	O
oyster	O
larval	O
bacterial	O
canker	O
has	O
the	O
advantages	O
of	O
simple	O
raw	O
material	O
,	O
low	O
cost	O
and	O
convenient	O
usage	O
.	O

Medicine	O
for	O
treating	O
oyster	O
larval	O
bacterial	O
canker	O

The	O
invention	O
relates	O
to	O
a	O
tree	O
-	O
like	O
polymer	O
nanometer	O
drug	O
delivery	O
carrier	O
targeting	O
doxorubicin	B
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
targeting	O
doxorubicin	B
is	O
PEG	O
-	O
b	O
-	O
PAMAM	O
-	O
hydrozone-	O
(	O
DOX	O
)	O
n	O
.	O

A	O
tree	O
-	O
like	O
polymer	O
nanometer	O
drug	O
delivery	O
carrier	O
targeting	O
doxorubicin	B
of	O
liquid	O
tumors	O
representative	O
to	O
myeloma	O
is	O
provided	O
in	O
the	O
invention	O
.	O

The	O
acidic	O
environment	O
(	O
pH	O
of	O
5.5	O
)	O
of	O
myeloma	O
makes	O
a	O
hydrogen	B
bond	O
connecting	O
a	O
carrier	O
with	O
doxorubicin	B
be	O
broken	O
,	O
so	O
complete	O
doxorubicin	B
molecules	O
are	O
released	O
.	O

The	O
release	O
is	O
only	O
carried	O
out	O
under	O
the	O
acidic	O
condition	O
of	O
the	O
myeloma	O
,	O
so	O
the	O
treatment	O
pertinence	O
of	O
the	O
drug	O
is	O
greatly	O
improved	O
.	O

P	O
-	O
glycoprotein	O
will	O
diffuse	O
to	O
doxorubicin	B
monomer	O
elimination	O
cells	O
in	O
cells	O
,	O
so	O
tumor	O
cells	O
generate	O
multiple	O
drug	O
resistances	O
.	O

The	O
carrier	O
drug	O
can	O
avoid	O
the	O
medicine	O
efflux	O
phenomenon	O
caused	O
by	O
the	O
p	O
-	O
glycoprotein	O
and	O
can	O
also	O
avoid	O
the	O
multiple	O
drug	O
resistances	O
.	O

Tree	O
-	O
like	O
polymer	O
nanometer	O
drug	O
delivery	O
carrier	O
targeting	O
doxorubicin	B
and	O
its	O
preparation	O
method	O

The	O
invention	O
discloses	O
silicone	B
dressing	O
,	O
and	O
a	O
preparation	O
method	O
and	O
the	O
use	O
thereof	O
.	O

The	O
silicone	B
dressing	O
is	O
prepared	O
from	O
silicone	B
,	O
an	O
organosilicon	B
antibacterial	O
agent	O
,	O
and	O
matrix	O
.	O

The	O
silicone	B
dressing	O
is	O
reasonable	O
in	O
formula	O
and	O
convenient	O
to	O
prepare	O
,	O
can	O
effectively	O
restrain	O
various	O
hyperplastic	O
scars	O
caused	O
by	O
the	O
reasons	O
of	O
burn	O
,	O
trauma	O
,	O
surgery	O
,	O
infection	O
and	O
the	O
like	O
,	O
protects	O
various	O
wound	O
surfaces	O
caused	O
by	O
the	O
reasons	O
of	O
burn	O
,	O
trauma	O
,	O
surgery	O
,	O
infection	O
and	O
the	O
like	O
,	O
controls	O
wound	O
surface	O
infection	O
,	O
keeps	O
the	O
wound	O
surface	O
wet	O
,	O
and	O
promotes	O
the	O
wound	O
surface	O
to	O
heal	O
.	O

The	O
effective	O
rate	O
achieves	O
over	O
95	O
%	O
by	O
validation	O
of	O
more	O
than	O
100	O
clinical	O
cases	O
;	O
and	O
the	O
bacteriostatic	O
ability	O
of	O
the	O
product	O
on	O
staphylococcus	O
aureus	O
and	O
escherichia	O
coli	O
can	O
be	O
over	O
99	O
%	O
.	O

Silicone	B
dressing	O
,	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pyrimidine	B
amide	I
alkaloid	I
compound	O
I	O
,	O
and	O
a	O
preparation	O
method	O
,	O
anti	O
-	O
HIV	O
activity	O
and	O
anti	O
-	O
TMV	O
activity	O
thereof	O
.	O

A	O
general	O
formula	O
I	O
has	O
very	O
good	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
activity	O
,	O
can	O
well	O
inhibit	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
and	O
at	O
the	O
same	O
time	O
,	O
has	O
anti	O
-	O
tobacco	O
mosaic	O
virus	O
(	O
TMV	O
)	O
.	O

In	O
the	O
formula	O
,	O
specific	O
representation	O
contents	O
of	O
substituents	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
defined	O
in	O
the	O
specification	O
.	O

Pyrimidine	B
amide	I
compound	O
,	O
and	O
preparation	O
method	O
,	O
anti	O
-	O
HIV	O
activity	O
and	O
anti	O
-	O
TMV	O
activity	O
thereof	O

The	O
invention	O
discloses	O
a	O
lurasidone	B
HCl	I
crystal	O
A	O
which	O
is	O
an	O
orthorhombic	O
system	O
.	O

A	O
space	O
group	O
is	O
P212121	O
,	O
cell	O
parameters	O
meet	O
the	O
equation	O
of	O
alpha	O
=	O
gamma	O
=	O
beta	O
=	O
90.00	O
degrees	O
.	O

The	O
unsymmetrical	O
unit	O
number	O
Z	O
in	O
a	O
cell	O
is	O
four	O
.	O

The	O
crystal	O
A	O
can	O
be	O
a	O
single	O
crystal	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
purpose	O
when	O
the	O
crystal	O
A	O
is	O
used	O
for	O
preparing	O
medicine	O
for	O
curing	O
schizophrenia	O
.	O

Compared	O
with	O
existing	O
lurasidone	B
HCl	I
,	O
the	O
lurasidone	B
HCl	I
crystal	O
A	O
has	O
good	O
solubility	O
.	O

Total	O
related	O
substances	O
in	O
the	O
lurasidone	B
HCl	I
crystal	O
A	O
(	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
detection	O
)	O
can	O
be	O
below	O
0.2	O
%	O
,	O
single	O
impurity	O
is	O
smaller	O
than	O
0.1	O
%	O
,	O
and	O
high	O
purity	O
is	O
achieved	O
.	O

Solvent	O
with	O
little	O
toxicity	O
is	O
used	O
during	O
preparing	O
,	O
a	O
production	O
preparing	O
process	O
is	O
safe	O
,	O
toxic	O
substances	O
with	O
large	O
toxicity	O
can	O
not	O
be	O
left	O
in	O
obtained	O
products	O
,	O
and	O
the	O
lurasidone	B
HCl	I
crystal	O
A	O
is	O
suitable	O
for	O
officinal	O
.	O

Lurasidone	B
HCl	I
crystal	O
A	O
and	O
purpose	O
thereof	O

The	O
invention	O
relates	O
to	O
methocarbamol	B
diammonium	I
phosphate	I
,	O
and	O
a	O
polymorphism	O
,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
structural	O
formula	O
of	O
the	O
methocarbamol	B
diammonium	I
phosphate	I
is	O
shown	O
in	O
the	O
specification	O
.	O

The	O
polymorphism	O
of	O
the	O
methocarbamol	B
diammonium	I
phosphate	I
is	O
a	O
crystal	O
form	O
A	O
,	O
and	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
pattern	O
of	O
the	O
crystal	O
form	O
A	O
is	O
shown	O
as	O
Figure	O
1	O
.	O

An	O
H	O
nuclear	O
magnetic	O
resonance	O
spectrum	O
of	O
the	O
crystal	O
form	O
A	O
is	O
shown	O
as	O
Figure	O
2	O
;	O
a	O
C	O
nuclear	O
magnetic	O
resonance	O
spectrum	O
is	O
shown	O
as	O
Figure	O
3	O
;	O
a	O
thermogravimetry	O
-	O
differential	O
thermal	O
analysis	O
chart	O
is	O
shown	O
as	O
Figure	O
4	O
;	O
mass	O
spectrograms	O
are	O
shown	O
as	O
Figure	O
5	O
and	O
Figure	O
6	O
;	O
and	O
a	O
KBr	O
middle	O
infrared	O
absorption	O
spectrogram	O
of	O
the	O
crystal	O
form	O
A	O
of	O
the	O
methocarbamol	B
diammonium	I
phosphate	I
is	O
shown	O
as	O
Figure	O
7	O
.	O

The	O
invention	O
provides	O
a	O
method	O
for	O
synthesizing	O
the	O
methocarbamol	B
diammonium	I
phosphate	I
by	O
using	O
intermediate	O
methocarbamol	B
dihydric	I
phosphate	I
and	O
studies	O
the	O
polymorphism	O
of	O
the	O
methocarbamol	B
diammonium	I
phosphate	I
.	O

Ammonia	B
water	O
is	O
a	O
salification	O
reagent	O
which	O
is	O
cheap	O
,	O
accessible	O
,	O
and	O
safe	O
,	O
and	O
ammonia	B
is	O
low	O
in	O
boiling	O
point	O
,	O
so	O
that	O
ammonia	B
can	O
not	O
remain	O
in	O
the	O
product	O
due	O
to	O
excess	O
,	O
the	O
feeding	O
of	O
the	O
material	O
can	O
be	O
easily	O
controlled	O
,	O
the	O
production	O
cost	O
is	O
saved	O
,	O
and	O
the	O
purity	O
of	O
the	O
product	O
is	O
improved	O
.	O

Methocarbamol	B
diammonium	I
phosphate	I
,	O
and	O
polymorphism	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
alfacalcidol	B
sustained	O
-	O
release	O
granule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
alfacalcidol	B
sustained	O
-	O
release	O
granule	O
disclosed	O
by	O
the	O
invention	O
consists	O
of	O
a	O
quick	O
-	O
release	O
granule	O
core	O
and	O
a	O
sustained	O
-	O
release	O
coating	O
layer	O
,	O
wherein	O
the	O
quick	O
-	O
release	O
granule	O
core	O
consists	O
of	O
alfacalcidol	B
and	O
filler	O
,	O
and	O
the	O
sustained	O
-	O
release	O
coating	O
layer	O
consists	O
of	O
a	O
sustained	O
-	O
release	O
material	O
,	O
a	O
plasticizer	O
,	O
a	O
pore	O
-	O
forming	O
agent	O
and	O
an	O
antisticking	O
agent	O
;	O
and	O
during	O
preparation	O
,	O
the	O
alfacalcidol	B
sustained	O
-	O
release	O
granule	O
is	O
obtained	O
through	O
coating	O
the	O
sustained	O
-	O
release	O
coating	O
layer	O
outside	O
the	O
quick	O
-	O
release	O
granule	O
core	O
.	O

According	O
to	O
the	O
alfacalcidol	B
sustained	O
-	O
release	O
granule	O
and	O
the	O
preparation	O
method	O
of	O
the	O
alfacalcidol	B
sustained	O
-	O
release	O
granule	O
,	O
the	O
drug	O
is	O
convenient	O
in	O
taking	O
and	O
slow	O
in	O
release	O
,	O
the	O
aims	O
of	O
long	O
acting	O
and	O
curative	O
effect	O
improving	O
can	O
be	O
reached	O
,	O
and	O
the	O
dosage	O
can	O
be	O
reduced	O
while	O
the	O
same	O
drug	O
action	O
is	O
maintained	O
,	O
so	O
that	O
side	O
effects	O
to	O
patients	O
caused	O
by	O
drug	O
taking	O
are	O
reduced	O
;	O
and	O
the	O
preparation	O
method	O
is	O
simple	O
,	O
the	O
quality	O
of	O
obtained	O
products	O
is	O
stable	O
,	O
and	O
thus	O
,	O
the	O
method	O
is	O
applicable	O
to	O
large	O
-	O
scale	O
production	O
application	O
.	O

Alfacalcidol	B
sustained	O
-	O
release	O
granule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
high	O
-	O
quality	O
composition	O
containing	O
oxaliplatin	B
.	O

The	O
bacterial	O
endotoxin	O
of	O
the	O
composition	O
is	O
detected	O
by	O
the	O
method	O
specified	O
by	O
standards	O
on	O
registration	O
of	O
imported	O
drug	O
of	O
oxaliplatin	B
for	O
injection	O
;	O
and	O
the	O
composition	O
contains	O
the	O
bacterial	O
endotoxin	O
less	O
than	O
0.5EU	O
per	O
1	O
mg	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
high	O
-	O
quality	O
oxaliplatin	B
freeze	O
-	O
dried	O
powder	O
.	O

The	O
oxaliplatin	B
composition	O
disclosed	O
by	O
the	O
invention	O
is	O
high	O
in	O
quality	O
and	O
high	O
in	O
safety	O
.	O

The	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
easy	O
for	O
industrialization	O
.	O

High	O
-	O
quality	O
composition	O
containing	O
oxaliplatin	B
and	O
preparation	O
method	O
of	O
composition	O

The	O
invention	O
relates	O
to	O
a	O
calcitriol	B
controlled	O
-	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
controlled	O
-	O
release	O
tablet	O
consists	O
of	O
a	O
tablet	O
core	O
and	O
a	O
controlled	O
-	O
release	O
coating	O
layer	O
,	O
wherein	O
the	O
controlled	O
-	O
release	O
coating	O
layer	O
contains	O
an	O
controlled	O
-	O
release	O
material	O
accounting	O
for	O
10	O
-	O
20	O
%	O
by	O
weight	O
,	O
and	O
the	O
tablet	O
core	O
is	O
prepared	O
from	O
the	O
following	O
ingredients	O
in	O
percentage	O
by	O
weight	O
:	O
0.002	O
%	O
of	O
calcitriol	B
,	O
2.0	O
-	O
4.0	O
%	O
of	O
meglumine	B
,	O
1.2	O
-	O
1.8	O
%	O
of	O
polyethylene	B
glycol	I
400	I
,	O
15	O
-	O
25	O
%	O
of	O
polyethylene	B
glycol	I
6000	I
,	O
50.0	O
-	O
70.0	O
%	O
of	O
filler	O
,	O
5.0	O
-	O
10.0	O
%	O
of	O
disintegrant	O
,	O
an	O
appropriate	O
amount	O
of	O
binder	O
and	O
an	O
appropriate	O
amount	O
of	O
lubricant	O
.	O

According	O
to	O
the	O
controlled	O
-	O
release	O
tablet	O
,	O
the	O
content	O
of	O
calcitriol	B
is	O
remarkably	O
increased	O
,	O
so	O
that	O
the	O
drug	O
dosage	O
is	O
reduced	O
;	O
and	O
the	O
stability	O
of	O
calcitriol	B
to	O
light	O
and	O
air	O
is	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
calcitriol	B
is	O
also	O
remarkably	O
improved	O
.	O

Calcitriol	B
controlled	O
-	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
enteric	O
capsule	O
of	O
etoposide	B
.	O

The	O
etoposide	B
is	O
prepared	O
into	O
an	O
inclusion	O
compound	O
,	O
and	O
then	O
the	O
inclusion	O
compound	O
is	O
prepared	O
into	O
the	O
enteric	O
capsule	O
.	O

Enteric	O
capsule	O
of	O
etoposide	B

The	O
invention	O
relates	O
to	O
a	O
calcitriol	O
enteric	O
capsule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
enteric	O
capsule	O
consists	O
of	O
a	O
core	O
and	O
an	O
enteric	O
coating	O
layer	O
,	O
wherein	O
the	O
enteric	O
coating	O
layer	O
contains	O
an	O
enteric	O
material	O
accounting	O
for	O
10	O
-	O
20	O
%	O
by	O
weight	O
,	O
and	O
the	O
core	O
is	O
prepared	O
from	O
the	O
following	O
ingredients	O
in	O
percentage	O
by	O
weight	O
:	O
0.0005	O
%	O
of	O
calcitriol	O
,	O
2.0	O
-	O
4.0	O
%	O
of	O
meglumine	O
,	O
1.2	O
-	O
1.8	O
%	O
of	O
polyethylene	O
glycol	O
400	O
,	O
15	O
-	O
25	O
%	O
of	O
polyethylene	O
glycol	O
6000	O
,	O
50.0	O
-	O
70.0	O
%	O
of	O
filler	O
,	O
5.0	O
-	O
10.0	O
%	O
of	O
disintegrant	O
and	O
an	O
appropriate	O
amount	O
of	O
binder	O
.	O

According	O
to	O
the	O
enteric	O
capsule	O
,	O
the	O
content	O
of	O
calcitriol	O
is	O
remarkably	O
increased	O
,	O
so	O
that	O
the	O
drug	O
dosage	O
is	O
reduced	O
;	O
and	O
the	O
stability	O
of	O
calcitriol	O
to	O
light	O
and	O
air	O
is	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
calcitriol	O
is	O
also	O
remarkably	O
improved	O
.	O

Calcitriol	O
enteric	O
capsule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
softening	O
and	O
dissolving	O
method	O
of	O
an	O
ossific	O
mass	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
:	O
A.	O
adding	O
pure	O
water	O
into	O
100	O
%	O
glacial	B
acetic	I
acid	I
to	O
prepare	O
an	O
18	O
-	O
20	O
%	O
solution	O
,	O
and	O
adding	O
1	O
/	O
1000	O
deodorant	O
to	O
obtain	O
a	O
mixed	O
liquid	O
;	O
B.	O
taking	O
a	O
common	O
towel	O
,	O
folding	O
into	O
4	O
-	O
6	O
layers	O
,	O
pouring	O
20	O
ml	O
of	O
the	O
mixed	O
liquid	O
obtained	O
in	O
the	O
step	O
A	O
to	O
the	O
middle	O
part	O
of	O
the	O
towel	O
,	O
and	O
applying	O
the	O
towel	O
on	O
the	O
ossific	O
mass	O
part	O
;	O
and	O
C.	O
putting	O
a	O
heating	O
unit	O
on	O
the	O
towel	O
until	O
the	O
temperature	O
reaches	O
50	O
DEG	O
C	O
,	O
and	O
carrying	O
out	O
hot	O
compress	O
for	O
30	O
minutes	O
so	O
that	O
the	O
mixed	O
liquid	O
obtained	O
in	O
the	O
step	O
A	O
becomes	O
gas	O
and	O
permeates	O
into	O
the	O
ossific	O
mass	O
part	O
via	O
the	O
skin	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
method	O
disclosed	O
by	O
the	O
invention	O
can	O
effectively	O
soften	O
and	O
dissolve	O
the	O
ossific	O
mass	O
,	O
relieve	O
the	O
pain	O
of	O
the	O
patient	O
,	O
avoid	O
the	O
danger	O
of	O
operative	O
treatment	O
,	O
and	O
perform	O
the	O
function	O
of	O
radical	O
cure	O
;	O
and	O
the	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
low	O
in	O
cost	O
and	O
simple	O
to	O
operate	O
.	O

Softening	O
and	O
dissolving	O
method	O
of	O
ossific	O
mass	O

The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
gastric	O
ulcer	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
colloidal	O
bismuth	O
pectin	O
and	O
omeprazole	B
,	O
wherein	O
colloidal	O
bismuth	O
pectin	O
and	O
omeprazole	B
have	O
synergistic	O
treatment	O
effects	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
gastric	O
ulcer	O

The	O
invention	O
relates	O
to	O
a	O
calcium	B
carbonate	I
-	I
vitamin	I
K	I
pharmaceutical	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
.	O

The	O
calcium	B
carbonate	I
-	I
vitamin	I
K	I
pharmaceutical	O
preparation	O
is	O
prepared	O
from	O
800	O
-	O
2800	O
parts	O
by	O
weight	O
of	O
calcium	B
carbonate	I
,	O
2	O
-	O
30	O
parts	O
by	O
weight	O
of	O
vitamin	B
K	I
and	O
a	O
right	O
amount	O
of	O
auxiliary	O
material	O
,	O
wherein	O
the	O
auxiliary	O
material	O
is	O
selected	O
from	O
one	O
or	O
more	O
of	O
sucrose	B
,	O
microcrystalline	O
cellulose	O
,	O
sodium	O
carboxymethyl	O
starch	O
,	O
micropowder	O
silica	B
gel	I
,	O
magnesium	B
stearate	I
,	O
hydroxypropyl	O
methylcellulose	O
,	O
talcum	O
powder	O
,	O
lactose	B
and	O
mannitol	B
.	O

By	O
using	O
the	O
scientific	O
formula	O
,	O
the	O
calcium	B
carbonate	I
-	I
vitamin	I
K	I
pharmaceutical	O
preparation	O
can	O
effectively	O
supplement	O
calcium	O
,	O
and	O
is	O
safe	O
and	O
convenient	O
to	O
take	O
.	O

Calcium	B
carbonate	I
-	I
vitamin	I
K	I
pharmaceutical	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
high	O
stability	O
composite	O
guaiacol	B
phenolsulfonic	I
acid	I
oral	O
liquid	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutics	O
.	O

The	O
oral	O
liquid	O
is	O
prepared	O
by	O
adopting	O
promethazine	B
hydrochloride	I
,	O
guaiacol	B
phenolsulfonic	I
acid	I
,	O
ammonium	B
chloride	I
,	O
sodium	B
citrate	I
,	O
benzoic	B
acid	I
,	O
ethylparaben	B
,	O
cane	O
sugar	O
,	O
caramel	O
,	O
Litchi	O
chinensis	O
essence	O
and	O
banana	O
essence	O
as	O
raw	O
and	O
auxiliary	O
materials	O
,	O
adding	O
an	O
antioxidant	O
cysteine	B
hydrochloride	I
or	O
vitamin	B
C	I
and	O
adopting	O
ethanol	B
and	O
water	O
as	O
a	O
solvent	O
.	O

According	O
to	O
the	O
invention	O
,	O
deficiencies	O
of	O
conventional	O
formula	O
are	O
improved	O
,	O
and	O
the	O
antioxidant	O
is	O
added	O
to	O
effectively	O
prevent	O
promethazine	B
hydrochloride	I
form	O
being	O
oxidized	O
.	O

The	O
guaiacol	B
phenolsulfonic	I
acid	I
oral	O
liquid	O
prepared	O
by	O
the	O
formula	O
and	O
process	O
is	O
high	O
in	O
stability	O
in	O
the	O
placing	O
process	O
,	O
so	O
that	O
the	O
medicine	O
quality	O
and	O
medication	O
safety	O
of	O
patients	O
can	O
be	O
effectively	O
ensured	O
.	O

High	O
stability	O
composite	O
guaiacol	B
phenolsulfonic	I
acid	I
oral	O
liquid	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
rhinitis	O
treatment	O
medicine	O
.	O

The	O
medicine	O
is	O
a	O
medicinal	O
composition	O
prepared	O
by	O
carrying	O
out	O
certain	O
technologies	O
of	O
raw	O
materials	O
comprising	O
pure	O
natural	O
plants	O
,	O
animals	O
and	O
other	O
materials	O
.	O

The	O
medicine	O
has	O
the	O
characteristics	O
of	O
carrying	O
convenience	O
,	O
realization	O
of	O
use	O
at	O
all	O
times	O
and	O
places	O
,	O
suitableness	O
for	O
inpatient	O
adults	O
and	O
inpatient	O
children	O
,	O
self	O
operation	O
for	O
above	O
six	O
-	O
year	O
-	O
old	O
children	O
,	O
fast	O
absorption	O
,	O
high	O
bioavailability	O
,	O
high	O
curative	O
effects	O
and	O
no	O
toxic	O
side	O
effects	O
on	O
acute	O
and	O
chronic	O
rhinitis	O
,	O
nasosinusitis	O
and	O
allergic	O
rhinitis	O
through	O
a	O
large	O
amount	O
of	O
clinical	O
applications	O
,	O
and	O
no	O
recurrence	O
after	O
curing	O
.	O

The	O
rhinitis	O
treatment	O
medicine	O
has	O
the	O
advantages	O
of	O
wide	O
sources	O
of	O
the	O
used	O
raw	O
materials	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
,	O
and	O
no	O
discharge	O
of	O
three	O
wastes	O
in	O
the	O
production	O
process	O
.	O

Rhinitis	O
treatment	O
medicine	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
preparation	O
for	O
treating	O
porcine	O
contagious	O
pleuropneumonia	O
and	O
respiratory	O
tract	O
mixed	O
infection	O
;	O
the	O
preparation	O
comprises	O
the	O
following	O
components	O
in	O
dose	O
:	O
each	O
100ml	O
compound	O
preparation	O
contains	O
5	O
-	O
20	O
g	O
of	O
florfenicol	B
,	O
3	O
-	O
10	O
g	O
of	O
azithromycin	B
,	O
2	O
-	O
6	O
g	O
of	O
antisepsis	O
synergist	O
,	O
2	O
-	O
8	O
g	O
of	O
antipyretic	O
analgesic	O
anti	O
-	O
inflammatory	O
agent	O
,	O
0.03	O
-	O
0.08	O
g	O
of	O
glucocorticoid	B
,	O
8	O
-	O
18	O
g	O
of	O
stabilizer	O
and	O
the	O
balance	O
of	O
organic	O
solvent	O
.	O

The	O
invention	O
further	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
preparation	O
.	O

In	O
the	O
compound	O
preparation	O
,	O
the	O
antibacterial	O
medicines	O
and	O
the	O
symptomatic	O
treatment	O
medicines	O
,	O
which	O
are	O
highly	O
sensitive	O
to	O
bacteria	O
,	O
are	O
used	O
and	O
are	O
compounded	O
on	O
the	O
basis	O
of	O
treating	O
both	O
symptoms	O
and	O
root	O
causes	O
,	O
therefore	O
the	O
compound	O
preparation	O
has	O
excellent	O
curative	O
effect	O
on	O
porcine	O
contagious	O
pleuropneumonia	O
and	O
respiratory	O
tract	O
mixed	O
infection	O
diseases	O
,	O
is	O
wide	O
in	O
antibacterial	O
spectrum	O
and	O
high	O
in	O
cure	O
rate	O
,	O
and	O
is	O
long	O
-	O
acting	O
,	O
efficient	O
and	O
stable	O
.	O

Compound	O
preparation	O
for	O
treating	O
porcine	O
contagious	O
pleuropneumonia	O
and	O
respiratory	O
tract	O
mixed	O
infection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
antibacterial	O
derivative	O
of	O
quinoxaline-1,4-dioxide	B
and	O
an	O
application	O
in	O
animal	O
production	O
thereof	O
.	O

The	O
derivatives	O
of	O
quinoxaline-1,4-dioxide	B
shown	O
in	O
formulas	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
or	O
6	O
and	O
salts	O
thereof	O
have	O
high	O
antibacterial	O
activities	O
,	O
are	O
low	O
in	O
toxicity	O
or	O
non	O
-	O
toxic	O
to	O
beasts	O
and	O
birds	O
and	O
have	O
higher	O
antibacterial	O
activities	O
and	O
higher	O
safety	O
compared	O
with	O
the	O
quinoxaline	B
derivatives	O
of	O
the	O
varieties	O
in	O
the	O
market	O
at	O
present	O
;	O
and	O
therefore	O
,	O
the	O
derivatives	O
can	O
serve	O
as	O
a	O
growth	O
promoter	O
for	O
feed	O
,	O
the	O
animal	O
growth	O
is	O
promoted	O
,	O
and	O
the	O
derivatives	O
have	O
good	O
application	O
prospects	O
in	O
the	O
breeding	O
industry	O
.	O

Antibacterial	O
derivative	O
of	O
quinoxaline-1,4-dioxide	B
and	O
application	O
in	O
animal	O
production	O
thereof	O

The	O
invention	O
discloses	O
a	O
crystal	O
R	O
of	O
sodium	B
esomeprazole	I
,	O
a	O
preparation	O
method	O
and	O
a	O
purpose	O
thereof	O
.	O

The	O
crystal	O
R	O
provided	O
by	O
the	O
invention	O
is	O
a	O
novel	O
crystal	O
form	O
of	O
the	O
sodium	B
esomeprazole	I
,	O
has	O
a	O
good	O
chemical	O
purity	O
(	O
without	O
isomer	O
,	O
and	O
an	O
ee	O
value	O
being	O
100	O
%	O
)	O
and	O
physical	O
stability	O
,	O
and	O
is	O
easy	O
to	O
filter	O
,	O
separate	O
and	O
wash	O
.	O

The	O
crystal	O
is	O
low	O
in	O
moisture	O
content	O
(	O
1.31	O
%	O
)	O
after	O
being	O
vacuum	O
-	O
dried	O
for	O
5	O
minutes	O
at	O
35	O
DEG	O
C	O
,	O
and	O
good	O
in	O
stability	O
.	O

Crystal	O
samples	O
of	O
the	O
sodium	B
esomeprazole	I
provided	O
by	O
the	O
invention	O
in	O
different	O
batches	O
are	O
subjected	O
to	O
an	O
HPLC	O
detection	O
,	O
and	O
has	O
a	O
purity	O
of	O
more	O
than	O
99.8	O
%	O
,	O
with	O
no	O
isomers	O
being	O
detected	O
.	O

The	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
can	O
prepare	O
the	O
crystal	O
R	O
with	O
stable	O
and	O
consistent	O
performances	O
in	O
each	O
batch	O
,	O
and	O
is	O
simple	O
in	O
preparation	O
technology	O
and	O
good	O
in	O
repeatability	O
.	O

Crystal	O
R	O
of	O
sodium	B
esomeprazole	I
,	O
preparation	O
method	O
and	O
purpose	O
thereof	O

Disclosed	O
is	O
a	O
rizatriptan	B
drug	O
absorbed	O
through	O
mouth	O
mucosa	O
.	O

Malic	B
acid	I
rizatriptan	I
is	O
an	O
effective	O
drug	O
ingredient	O
,	O
and	O
the	O
rizatriptan	B
drug	O
absorbed	O
through	O
mouth	O
mucosa	O
is	O
jointly	O
composed	O
of	O
malic	B
acid	I
rizatriptan	I
and	O
auxiliary	O
ingredients	O
which	O
are	O
acceptable	O
in	O
a	O
mouth	O
mucosa	O
drug	O
,	O
wherein	O
the	O
auxiliary	O
ingredients	O
comprise	O
a	O
disintegrating	O
agent	O
,	O
a	O
filling	O
agent	O
,	O
a	O
flavoring	O
agent	O
,	O
a	O
bonding	O
agent	O
,	O
a	O
mucosa	O
sorbefacient	O
and	O
a	O
lubricating	O
agent	O
.	O

Preparation	O
forms	O
of	O
specific	O
drugs	O
comprise	O
sublingual	O
tablets	O
,	O
lozenges	O
,	O
mouth	O
and	O
check	O
lozenges	O
,	O
mouth	O
adhering	O
tablets	O
and	O
mouth	O
pasting	O
tablets	O
and	O
the	O
like	O
.	O

The	O
drug	O
can	O
be	O
completely	O
or	O
mainly	O
absorbed	O
through	O
mouth	O
mucosa	O
such	O
as	O
hypogloeeis	O
mucosa	O
and/or	O
mouth	O
and	O
cheek	O
mucosa	O
and	O
is	O
non	O
-	O
irritant	O
to	O
a	O
mouth	O
.	O

Bioavailability	O
and	O
the	O
curative	O
effect	O
of	O
the	O
drug	O
can	O
be	O
obviously	O
improved	O
,	O
and	O
the	O
rizatriptan	B
drug	O
absorbed	O
through	O
mouth	O
mucosa	O
can	O
be	O
taken	O
conveniently	O
,	O
so	O
that	O
a	O
patient	O
is	O
enabled	O
to	O
take	O
the	O
drug	O
obediently	O
.	O

Rizatriptan	B
drug	O
absorbed	O
through	O
mouth	O
mucosa	O

The	O
invention	O
relates	O
to	O
a	O
diclofenac	B
sodium	I
osmotic	O
-	O
pump	O
controlled	O
-	O
release	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
is	O
composed	O
of	O
an	O
osmotic	O
pump	O
tablet	O
core	O
and	O
a	O
semipermeable	O
controlled	O
-	O
release	O
coating	O
coated	O
outside	O
the	O
tablet	O
core	O
,	O
wherein	O
the	O
osmotic	O
pump	O
tablet	O
core	O
comprises	O
a	O
main	O
drug	O
,	O
permeable	O
active	O
substances	O
,	O
a	O
binding	O
agent	O
,	O
a	O
cosolvent	O
,	O
a	O
filler	O
and	O
a	O
lubricant	O
;	O
and	O
the	O
semipermeable	O
controlled	O
-	O
release	O
coating	O
comprises	O
a	O
coating	O
material	O
,	O
a	O
pore	O
-	O
forming	O
agent	O
and	O
a	O
plasticizer	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
osmotic	O
-	O
pump	O
preparation	O
.	O

The	O
preparation	O
technique	O
is	O
simple	O
,	O
and	O
adopts	O
a	O
conventional	O
tablet	O
preparation	O
method	O
;	O
the	O
tablet	O
core	O
is	O
pressed	O
by	O
a	O
conventional	O
method	O
without	O
determining	O
the	O
punching	O
surface	O
;	O
and	O
by	O
using	O
the	O
osmotic	O
pressure	O
between	O
the	O
inner	O
and	O
outer	O
sides	O
of	O
the	O
semipermeable	O
membrane	O
as	O
driving	O
force	O
,	O
the	O
preparation	O
releases	O
the	O
drug	O
at	O
zero	O
-	O
level	O
release	O
rate	O
to	O
maintain	O
the	O
stable	O
blood	O
concentration	O
in	O
vivo	O
,	O
has	O
the	O
characteristics	O
of	O
moderate	O
drug	O
in	O
-	O
vivo	O
action	O
time	O
and	O
low	O
side	O
effect	O
,	O
and	O
can	O
not	O
easily	O
generate	O
drug	O
resistance	O
after	O
repeated	O
administration	O
.	O

The	O
invention	O
can	O
reduce	O
the	O
drug	O
taking	O
frequency	O
,	O
and	O
enables	O
the	O
drug	O
absorption	O
to	O
be	O
free	O
from	O
the	O
influence	O
of	O
food	O
intake	O
and	O
in	O
-	O
vivo	O
environment	O
,	O
thereby	O
enhancing	O
the	O
compliance	O
of	O
the	O
patient	O
.	O

Diclofenac	B
sodium	I
osmotic	O
-	O
pump	O
controlled	O
-	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
schizonepeta	O
active	O
component	O
composition	O
with	O
clear	O
pharmacological	O
action	O
.	O

The	O
schizonepeta	O
active	O
component	O
composition	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
more	O
than	O
90	O
percent	O
of	O
menthone	B
and	O
more	O
than	O
90	O
percent	O
of	O
pulegone	B
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
menthone	B
to	O
the	O
pulegone	B
is	O
1:	O
(	O
0.5	O
-	O
5	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
an	O
application	O
of	O
the	O
schizonepeta	O
active	O
extractive	O
composition	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
allergic	O
rhinitis	O
.	O

Schizonepeta	O
active	O
component	O
composition	O
and	O
medical	O
application	O
thereof	O

According	O
to	O
a	O
technical	O
scheme	O
on	O
the	O
first	O
aspect	O
,	O
the	O
invention	O
provides	O
a	O
drug	O
for	O
treatment	O
of	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
and	O
abnormal	O
glucose	B
metabolism	O
coexisting	O
diseases	O
.	O

The	O
drug	O
is	O
characterized	O
by	O
including	O
the	O
following	O
four	O
fatty	B
acid	I
components	O
by	O
mass	O
:	O
17	O
-	O
22	O
%	O
of	O
palmitic	B
acid	I
,	O
11	O
-	O
23	O
%	O
of	O
hexadecenoic	B
acid	I
,	O
22	O
-	O
28	O
%	O
of	O
9-octadecenoic	B
acid	I
,	O
13	O
-	O
35	O
%	O
of	O
9	B
,	I
12	I
,	I
15-octatecatrienoic	I
acid	I
,	O
and	O
the	O
balance	O
pharmaceutically	O
acceptable	O
additives	O
or	O
excipients	O
.	O

The	O
components	O
are	O
mixed	O
according	O
to	O
compatibility	O
to	O
be	O
prepared	O
into	O
soft	O
capsules	O
and	O
other	O
oral	O
preparations	O
,	O
so	O
that	O
the	O
insulin	O
receptor	O
substrate	O
(	O
IRS	O
)	O
protein	O
level	O
can	O
be	O
effectively	O
reduced	O
so	O
as	O
to	O
inhibit	O
the	O
glucose	B
way	O
,	O
the	O
insulin	O
receptor	O
active	O
time	O
can	O
be	O
increased	O
and	O
the	O
insulin	O
level	O
can	O
be	O
enhanced	O
,	O
and	O
the	O
insulin	O
sensitivity	O
is	O
increased	O
so	O
as	O
to	O
facilitate	O
the	O
reduction	O
of	O
insulin	O
resistance	O
degree	O
.	O

Thus	O
,	O
the	O
drug	O
can	O
have	O
the	O
functions	O
of	O
improving	O
and	O
recuperating	O
ovary	O
ovulatory	O
dysfunction	O
,	O
i.e.	O
PCOS	O
and	O
abnormal	O
glucose	B
metabolism	O
diseases	O
.	O

Compared	O
with	O
other	O
drugs	O
,	O
the	O
drug	O
has	O
simple	O
components	O
,	O
and	O
belongs	O
to	O
highly	O
effective	O
,	O
safety	O
,	O
and	O
simplified	O
drugs	O
.	O

Drug	O
for	O
treatment	O
of	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
and	O
abnormal	O
glucose	B
metabolism	O
coexisting	O
diseases	O

The	O
invention	O
provides	O
an	O
isatin-5-amide	B
compound	O
represented	O
by	O
a	O
formula	O
(	O
1	O
)	O
.	O

The	O
compound	O
has	O
an	O
inhibition	O
activity	O
against	O
SARS	O
coronavirus	O
main	O
protease	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
SARS	O
coronavirus	O
main	O
protease	O
inhibiting	O
agent	O
,	O
and	O
can	O
be	O
applied	O
in	O
SARS	O
treatment	O
.	O

The	O
structural	O
formula	O
of	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
is	O
as	O
the	O
following	O
.	O

Isatin-5-amide	B
inhibiting	O
agent	O
with	O
inhibition	O
effect	O
against	O
SARS	O
coronavirus	O
main	O
protease	O

The	O
invention	O
provides	O
an	O
isatin	B
derivative	O
with	O
a	O
structural	O
formula	O
represented	O
below	O
,	O
wherein	O
R	O
is	O
selected	O
from	O
H	B
,	O
C1-C8	B
alkyl	I
,	O
C1-C8	B
alkoxy	I
,	O
nitro	B
,	O
hydroxyl	B
,	O
or	O
halogen	B
.	O

R	O
is	O
positioned	O
at	O
ortho	O
-	O
position	O
,	O
meta	O
-	O
position	O
or	O
para	O
-	O
position	O
of	O
nitrogen	B
atom	O
.	O

The	O
invention	O
also	O
provides	O
an	O
application	O
of	O
the	O
isatin	B
derivative	O
in	O
preparing	O
anti	O
-	O
SARS	O
medicines	O
,	O
a	O
medicine	O
composition	O
comprising	O
the	O
isatin	B
derivative	O
,	O
and	O
preparation	O
methods	O
thereof	O
.	O

Isatin	B
derivative	O
and	O
purpose	O
thereof	O

The	O
invention	O
discloses	O
prepared	O
ginkgetin	B
lipidosome	O
oral	O
emulsion	O
with	O
high	O
encapsulation	O
efficiency	O
.	O

The	O
ratio	O
of	O
the	O
ginkgetin	B
to	O
the	O
phospholipid	O
in	O
the	O
prepared	O
oral	O
emulsion	O
is	O
(	O
0.5:1	O
)	O
-	O
(	O
5:1	O
)	O
;	O
and	O
the	O
prepared	O
ginkgetin	B
lipidosome	O
oral	O
emulsion	O
further	O
comprises	O
vitamin	B
E	I
,	O
cholesterol	B
,	O
sorbitol	B
,	O
beta	O
-	O
cyclodextrin	O
,	O
polyethylene	B
glycol	I
(	O
PEG2000-PEG5000	B
)	O
,	O
lactose	B
and	O
polyvinyl	B
alcohol	I
(	O
PVA	B
)	O
.	O

The	O
prepared	O
ginkgetin	B
lipidosome	O
oral	O
emulsion	O
is	O
high	O
in	O
encapsulation	O
efficiency	O
and	O
capable	O
of	O
satisfying	O
pharmacopoeia	O
requirements	O
.	O

Moreover	O
,	O
the	O
prepared	O
ginkgetin	B
lipidosome	O
oral	O
emulsion	O
is	O
capable	O
of	O
tolerating	O
thermal	O
sterilization	O
treatment	O
for	O
30	O
minutes	O
at	O
121	O
DEG	O
C	O
,	O
high	O
in	O
tolerance	O
to	O
a	O
pH	O
environment	O
and	O
low	O
in	O
leakage	O
rate	O
,	O
so	O
that	O
the	O
preparation	O
requirements	O
of	O
large	O
pH	O
changes	O
of	O
the	O
gastrointestinal	O
tract	O
after	O
orally	O
taking	O
the	O
emulsion	O
are	O
satisfied	O
,	O
the	O
oral	O
emulsion	O
is	O
digested	O
,	O
absorbed	O
and	O
transferred	O
by	O
the	O
human	O
body	O
in	O
the	O
form	O
of	O
lipidosome	O
,	O
and	O
the	O
pharmacological	O
effect	O
of	O
the	O
ginkgetin	B
can	O
be	O
ensured	O
.	O

Prepared	O
ginkgetin	B
lipidosome	O
oral	O
emulsion	O
with	O
high	O
encapsulation	O
efficiency	O

The	O
invention	O
relates	O
to	O
a	O
benzisothiazole-3-ketone-2-amide	B
compound	O
with	O
Caspase-3	O
inhibiting	O
activity	O
.	O

The	O
benzisothiazole-3-ketone-2-amide	B
compound	O
has	O
the	O
Caspase-3	O
inhibiting	O
activity	O
,	O
can	O
be	O
used	O
for	O
treating	O
diseases	O
mediated	O
by	O
Caspase-3	O
,	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
and	O
has	O
a	O
structural	O
formula	O
(	O
I	O
)	O
as	O
shown	O
in	O
the	O
specification	O
.	O

Benzisothiazole-3-ketone-2-amide	B
compound	O
with	O
Caspase-3	O
inhibiting	O
activity	O

The	O
invention	O
provides	O
biodegradable	O
polyurethane	B
with	O
an	O
amino	B
on	O
the	O
side	O
chain	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
,	O
belonging	O
to	O
the	O
field	O
of	O
biomedical	O
materials	O
.	O

Polyurethane	B
is	O
formed	O
by	O
a	O
soft	O
segment	O
and	O
a	O
hard	O
segment	O
,	O
wherein	O
the	O
soft	O
segment	O
is	O
biodegradable	O
polyester	O
diol	O
or	O
biodegradable	O
polyether	B
diol	I
;	O
the	O
hard	O
segment	O
is	O
formed	O
by	O
aliphatic	B
diisocyanate	I
and	O
a	O
chain	O
extender	O
;	O
and	O
the	O
hard	O
segment	O
is	O
provided	O
with	O
the	O
free	O
or	O
protected	O
amino	B
.	O

The	O
biodegradable	O
polyurethane	B
serves	O
as	O
a	O
drug	O
carrier	O
,	O
can	O
wrap	O
drug	O
molecules	O
to	O
form	O
drug	O
carrying	O
microspheres	O
in	O
the	O
nanometer	O
or	O
micrometer	O
scale	O
and	O
can	O
be	O
used	O
for	O
bonding	O
drug	O
molecules	O
,	O
fluorescent	O
molecules	O
and	O
targeted	O
molecules	O
to	O
prepare	O
polyurethane	B
bonded	O
drugs	O
,	O
polyurethane	B
fluorescent	O
probes	O
or	O
polyurethane	O
targeting	O
carriers	O
.	O

Biodegradable	O
polyurethane	B
with	O
amino	B
on	O
side	O
chain	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R1a	O
,	O
R1b	O
have	O
the	O
meaning	O
as	O
cited	O
in	O
the	O
description	O
and	O
the	O
claims	O
.	O

Said	O
compounds	O
are	O
useful	O
as	O
JAK	O
inhibitors	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
immunological	O
,	O
inflammatory	O
,	O
autoimmune	O
,	O
allergic	O
disorders	O
,	O
and	O
immunologically	O
-	O
mediated	O
diseases	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
including	O
said	O
compounds	O
,	O
the	O
preparation	O
of	O
such	O
compounds	O
as	O
well	O
as	O
the	O
use	O
as	O
medicaments	O
.	O

Pyrazole	B
compounds	O
as	O
jak	O
inhibitors	O

The	O
invention	O
discloses	O
a	O
dihydroartemisinin	B
controlled	O
-	O
release	O
preparation	O
used	O
for	O
treating	O
lupus	O
erythematosus	O
.	O

The	O
controlled	O
-	O
release	O
preparation	O
shows	O
at	O
least	O
one	O
property	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
according	O
to	O
an	O
in	O
-	O
vitro	O
release	O
curve	O
,	O
when	O
the	O
preparation	O
is	O
placed	O
for	O
0.5h	O
according	O
to	O
a	O
standard	O
dissolution	O
test	O
,	O
an	O
accumulative	O
release	O
rate	O
of	O
dihydroartemisinin	B
is	O
10	O
-	O
25	O
%	O
;	O
and	O
(	O
2	O
)	O
according	O
to	O
a	O
healthy	O
adult	O
single	O
-	O
dose	O
oral	O
administration	O
dihydroartemisinin	B
in	O
-	O
vivo	O
absorption	O
curve	O
,	O
an	O
average	O
time	O
for	O
40	O
%	O
absorption	O
is	O
longer	O
than	O
approximately	O
2h	O
,	O
and/or	O
an	O
average	O
time	O
for	O
70	O
%	O
absorption	O
is	O
longer	O
than	O
approximately	O
6h	O
.	O

With	O
the	O
preparation	O
,	O
dihydroartemisinin	B
in	O
-	O
vivo	O
release	O
speed	O
can	O
be	O
controlled	O
.	O

The	O
preparation	O
can	O
be	O
taken	O
only	O
once	O
every	O
day	O
,	O
and	O
long	O
-	O
time	O
effective	O
blood	O
concentration	O
can	O
be	O
maintained	O
,	O
such	O
that	O
medication	O
is	O
more	O
convenient	O
.	O

The	O
preparation	O
has	O
stable	O
performance	O
,	O
and	O
low	O
toxic	O
and	O
side	O
effect	O
.	O

Because	O
the	O
preparation	O
only	O
needs	O
to	O
be	O
taken	O
once	O
a	O
day	O
,	O
treatment	O
cost	O
is	O
reduced	O
.	O

Dihydroartemisinin	B
controlled	O
-	O
release	O
preparation	O
used	O
for	O
treating	O
lupus	O
erythematosus	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
a	O
specific	O
piperidone	B
-	O
containing	O
single	O
-	O
carbonyl	B
curcumin	I
compound	O
in	O
preparation	O
of	O
an	O
anti	O
-	O
inflammatory	O
drug	O
and	O
medicines	O
used	O
for	O
treating	O
related	O
inflammation	O
diseases	O
.	O

The	O
curcumin	B
compound	O
can	O
inhibit	O
expression	O
and	O
release	O
of	O
an	O
inflammation	O
-	O
suppressing	O
factor	O
IL-6	O
,	O
obviously	O
reverse	O
degradation	O
of	O
I	O
kappa	O
B	O
related	O
to	O
regulation	O
of	O
inflammation	O
and	O
inhibit	O
phosphorylation	O
of	O
inflammation	O
signal	O
channels	O
such	O
as	O
ERK	O
and	O
JNK	O
;	O
and	O
in	O
vivo	O
experiments	O
show	O
the	O
curcumin	B
compound	O
can	O
obviously	O
improve	O
survival	O
rate	O
of	O
mice	O
which	O
are	O
about	O
to	O
die	O
owning	O
to	O
induction	O
by	O
virtue	O
of	O
LPS	O
(	O
lean	O
process	O
solution	O
)	O
.	O

Application	O
of	O
piperidone	B
-	O
containing	O
single	O
-	O
carbonyl	B
curcumin	I
compound	O
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
drug	O

The	O
invention	O
discloses	O
honeysuckle	O
flower	O
oil	O
enteric	O
-	O
coated	O
capsules	O
comprising	O
honeysuckle	O
flower	O
oil	O
and	O
40	O
-	O
60wt%	O
of	O
microencapsulated	O
ester	O
-	O
type	O
catechin	B
-	O
tea	O
flavonoid	B
crystals	O
.	O

The	O
microencapsulated	O
ester	O
-	O
type	O
catechin	B
-	O
tea	O
flavonoid	B
crystals	O
are	O
composed	O
of	O
ester	O
-	O
type	O
catechin	B
-	O
tea	O
flavonoid	B
crystals	O
as	O
a	O
core	O
material	O
and	O
liposome	O
as	O
a	O
wall	O
material	O
.	O

The	O
capsules	O
provided	O
by	O
the	O
invention	O
have	O
the	O
advantages	O
that	O
:	O
with	O
the	O
ester	O
-	O
type	O
catechin	B
-	O
tea	O
flavonoid	B
crystals	O
,	O
honeysuckle	O
flower	O
oil	O
enteric	O
-	O
coated	O
capsule	O
antibacterial	O
and	O
antiviral	O
capacities	O
are	O
substantially	O
improved	O
;	O
the	O
honeysuckle	O
flower	O
oil	O
is	O
obtained	O
by	O
ultrafine	O
crushing	O
and	O
high	O
-	O
speed	O
centrifugal	O
separation	O
,	O
such	O
that	O
original	O
physiochemical	O
properties	O
are	O
maintained	O
,	O
and	O
bioactivity	O
and	O
bioavailability	O
are	O
ensured	O
;	O
and	O
with	O
silver	O
ions	O
,	O
better	O
adhesion	O
effect	O
is	O
provided	O
,	O
and	O
catechin	B
-	O
tea	O
flavonoid	B
antibacterial	O
and	O
antiviral	O
functions	O
can	O
be	O
developed	O
better	O
.	O

Honeysuckle	O
flower	O
oil	O
enteric	O
-	O
coated	O
capsules	O

The	O
invention	O
discloses	O
a	O
multi	O
-	O
functional	O
spot	O
-	O
removing	O
medicinal	O
liquid	O
.	O

The	O
multi	O
-	O
functional	O
spot	O
-	O
removing	O
medicinal	O
liquid	O
mainly	O
comprises	O
fig	O
leaf	O
juice	O
,	O
chitosan	O
and	O
acetic	O
acid	O
.	O

The	O
medicinal	O
liquid	O
gas	O
the	O
effects	O
for	O
removing	O
black	O
spots	O
,	O
brown	O
spots	O
and	O
white	O
spots	O
,	O
compounds	O
the	O
wart	O
-	O
removing	O
and	O
spot	O
-	O
removing	O
effects	O
of	O
the	O
fig	O
leaf	O
juice	O
,	O
fungus	O
-	O
sterilizing	O
and	O
fresh	O
-	O
keeping	O
effects	O
of	O
the	O
acetic	O
acid	O
and	O
the	O
bacterium	O
-	O
sterilizing	O
and	O
skin	O
-	O
protecting	O
effects	O
of	O
the	O
chitosan	O
.	O

The	O
prepared	O
multi	O
-	O
functional	O
spot	O
-	O
removing	O
medicinal	O
liquid	O
has	O
relatively	O
good	O
curative	O
effects	O
for	O
a	O
plurality	O
of	O
spots	O
and	O
warts	O
,	O
particularly	O
for	O
leucoderma	O
that	O
is	O
difficult	O
to	O
treat	O
,	O
can	O
also	O
be	O
used	O
for	O
treating	O
tinea	O
and	O
beriberi	O
,	O
and	O
is	O
a	O
good	O
and	O
easily	O
prepared	O
multi	O
-	O
functional	O
medicinal	O
liquid	O
for	O
external	O
use	O
.	O

Multi	O
-	O
functional	O
spot	O
-	O
removing	O
medicinal	O
liquid	O

The	O
invention	O
discloses	O
enteric	O
-	O
coated	O
capsules	O
comprising	O
a	O
blue	O
turmeric	O
rhizome	O
extract	O
.	O

The	O
capsules	O
comprise	O
microencapsulated	O
liposome	O
and	O
ultrafine	O
blue	O
turmeric	O
rhizome	O
oil	O
.	O

Compared	O
with	O
prior	O
arts	O
,	O
the	O
capsules	O
provided	O
by	O
the	O
invention	O
have	O
the	O
advantages	O
that	O
:	O
with	O
an	O
ultrafine	O
crushing	O
process	O
and	O
a	O
high	O
-	O
speed	O
centrifugal	O
separation	O
method	O
,	O
blue	O
turmeric	O
rhizome	O
raw	O
material	O
original	O
physiochemical	O
properties	O
are	O
maintained	O
,	O
bioavailability	O
is	O
high	O
,	O
and	O
blue	O
turmeric	O
herb	O
active	O
components	O
are	O
preserved	O
;	O
ultrafine	O
blue	O
turmeric	O
rhizome	O
oil	O
is	O
subjected	O
to	O
microencapsulated	O
liposome	O
coating	O
,	O
such	O
that	O
blue	O
turmeric	O
rhizome	O
oil	O
volatility	O
is	O
controlled	O
,	O
blue	O
turmeric	O
rhizome	O
oil	O
content	O
stability	O
is	O
maintained	O
,	O
and	O
blue	O
turmeric	O
rhizome	O
oil	O
oxidation	O
and	O
deterioration	O
are	O
prevented	O
;	O
the	O
liposome	O
has	O
high	O
targeting	O
property	O
,	O
such	O
that	O
blue	O
turmeric	O
rhizome	O
oil	O
anti	O
-	O
inflammatory	O
and	O
antibacterial	O
functions	O
are	O
utilized	O
and	O
developed	O
;	O
microencapsulated	O
catechin	B
-	O
tea	O
flavonoid	O
crystals	O
are	O
added	O
,	O
such	O
that	O
anti	O
-	O
inflammatory	O
and	O
antibacterial	O
capacities	O
of	O
the	O
product	O
provided	O
by	O
the	O
invention	O
can	O
be	O
developed	O
,	O
and	O
an	O
antiviral	O
effect	O
can	O
be	O
provided	O
;	O
silver	B
ions	O
are	O
added	O
as	O
an	O
absorbent	O
and	O
disinfectant	O
,	O
such	O
that	O
catechin	B
is	O
prevented	O
from	O
being	O
corroded	O
,	O
and	O
catechin	B
antibacterial	O
and	O
antiviral	O
functions	O
can	O
be	O
developed	O
.	O

Enteric	O
-	O
coated	O
capsules	O
comprising	O
blue	O
turmeric	O
rhizome	O
extract	O

The	O
invention	O
provides	O
a	O
minodronic	B
acid	I
new	O
crystal	O
form	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
,	O
the	O
new	O
crystal	O
form	O
uses	O
Cu	B
-	O
Ka	B
radiation	O
,	O
a	O
X	O
ray	O
powder	O
diffraction	O
spectrum	O
shown	O
with	O
angle	O
of	O
2	O
theta	O
degree	O
is	O
shown	O
as	O
a	O
graph	O
1	O
,	O
a	O
thermogravimetry	O
analysis	O
graph	O
of	O
the	O
new	O
crystal	O
form	O
is	O
shown	O
as	O
a	O
graph	O
2	O
,	O
the	O
crystallization	O
dehydrated	O
temperature	O
of	O
the	O
new	O
crystal	O
form	O
is	O
147	O
-	O
162	O
DEG	O
C	O
,	O
the	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
dissolving	O
the	O
minodronic	B
acid	I
raw	O
material	O
in	O
a	O
solvent	O
,	O
heating	O
and	O
preparing	O
the	O
minodronic	B
acid	I
-	O
containing	O
solution	O
,	O
wherein	O
the	O
solvent	O
is	O
dilute	O
hydrochloric	B
acid	I
,	O
dilute	O
glacial	B
acetic	I
acid	I
or	O
dilute	O
sulfuric	B
acid	I
;	O
slowly	O
cooling	O
to	O
the	O
temperature	O
to	O
20	O
-	O
40	O
DEG	O
C	O
under	O
stirring	O
,	O
standing	O
for	O
8	O
-	O
36	O
hours	O
,	O
precipitating	O
the	O
crystals	O
;	O
filtering	O
,	O
collecting	O
the	O
crystals	O
and	O
drying	O
,	O
and	O
the	O
application	O
is	O
the	O
application	O
of	O
the	O
minodronic	B
acid	I
-	I
hydrate	I
crystal	O
form	O
used	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
osteoporosis	O
.	O

The	O
crystal	O
form	O
of	O
the	O
minodronic	B
acid	I
-	I
hydrate	I
new	O
crystal	O
form	O
is	O
stable	O
,	O
and	O
is	O
the	O
optimal	O
crystal	O
form	O
for	O
preparing	O
the	O
minodronic	B
acid	I
pharmaceutical	O
composition	O
.	O

Minodronic	B
acid	I
new	O
crystal	O
form	O
,	O
preparation	O
method	O
and	O
application	O

The	O
invention	O
discloses	O
a	O
saponin	B
derivative	O
which	O
has	O
a	O
structure	O
presented	O
in	O
a	O
formula	O
as	O
follows	O
.	O

An	O
animal	O
experiment	O
proves	O
that	O
the	O
saponin	B
derivative	O
has	O
a	O
remarkable	O
anti	O
-	O
depression	O
pharmacological	O
activity	O
,	O
so	O
that	O
the	O
saponin	B
derivative	O
can	O
be	O
used	O
as	O
an	O
active	O
ingredient	O
to	O
prepare	O
medicines	O
,	O
food	O
and	O
health	O
care	O
products	O
,	O
and	O
can	O
be	O
used	O
independently	O
or	O
be	O
combined	O
with	O
other	O
substances	O
for	O
prevention	O
and	O
treatment	O
of	O
tristimania	O
.	O

Saponin	B
derivative	O
and	O
application	O
thereof	O

Triphenylene	B
derivative	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
X1	O
and	O
X2	O
are	O
CH	B
,	O
CR3	B
or	O
N	B
;	O
Z	O
is	O
-OH	B
or	O
a	O
O	B
-	I
C1	I
-	I
6	I
alkyl	I
;	O
R2	O
is	O
C1	B
-	I
4	I
alkyl	I
,	O
C1	B
-	I
4	I
fluoroalkyl	I
,	O
C1	B
-	I
4	I
deuteroalkyl	I
,	O
C3	B
-	I
6	I
cycloalkyl	I
or	O
C1	B
-	I
4	I
alkylene	I
-	I
W	I
,	O
where	O
W	O
is	O
hydroxyl	B
,	O
halogen	B
,	O
CN	B
,	O
C1	B
-	I
4	I
alkyl	I
,	O
C1	B
-	I
4	I
haloalkyl	I
,	O
C1	B
-	I
4	I
alkoxy	I
,	O
C1	B
-	I
4	I
haloalkoxy	I
or	O
C3	B
-	I
6	I
cycloalkyl	I
;	O
R3-R5	O
are	O
halogen	B
,	O
C1	B
-	I
4	I
alkyl	I
or	O
other	O
substituents	O
;	O
R6	O
and	O
R7	O
are	O
H	B
,	O
C1	B
-	I
4	I
alkyl	I
or	O
halogen	B
;	O
m	O
is	O
0	O
-	O
2	O
;	O
n	O
is	O
0	O
-	O
4	O
;	O
and	O
p	O
is	O
0	O
-	O
2	O
;	O
may	O
be	O
useful	O
as	O
estrogen	O
receptor	O
modulators	O
.	O

Also	O
described	O
are	O
pharmaceutical	O
compositions	O
and	O
medicaments	O
that	O
include	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

These	O
compounds	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
conditions	O
that	O
are	O
mediated	O
by	O
or	O
dependent	O
upon	O
estrogen	O
receptors	O
.	O
;	O
Such	O
diseases	O
include	O
cancer	O
,	O
for	O
example	O
breast	O
,	O
ovarian	O
,	O
endometrial	O
,	O
prostate	O
and	O
uterine	O
cancers	O
,	O
and	O
also	O
cardiovascular	O
disease	O
and	O
conditions	O
such	O
as	O
Parkinsona	O
s	O
disease	O
and	O
dementia	O
.	O

Estrogen	B
receptor	O
modulators	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
tegafur	B
/	O
layered	O
double	O
hydroxide	B
(	O
TF	O
/	O
LDHs	O
)	O
nanohybrid	O
-	O
magnetic	O
matrix	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
utilizes	O
LDHs	O
as	O
carriers	O
to	O
prepare	O
the	O
TF	O
/	O
LDHs	O
nanohybrid	O
-	O
magnetic	O
matrix	O
compound	O
.	O

The	O
TF	O
/	O
LDHs	O
nanohybrid	O
-	O
magnetic	O
matrix	O
compound	O
is	O
used	O
for	O
targeted	O
delivery	O
and	O
controlled	O
release	O
of	O
tegafur	B
,	O
improves	O
drug	O
effects	O
and	O
reduces	O
drug	O
toxic	O
and	O
side	O
effects	O
.	O

By	O
a	O
coprecipitation	O
method	O
,	O
Fe3O4	B
or	O
MgFe2O4	B
as	O
a	O
magnetic	O
matrix	O
is	O
synthesized	O
into	O
the	O
TF	O
/	O
LDHs	O
nanohybrid	O
-	O
magnetic	O
matrix	O
compound	O
which	O
is	O
a	O
nano	O
-	O
complex	O
composed	O
of	O
the	O
magnetic	O
matrix	O
and	O
TF	O
intercalated	O
LDHs	O
coated	O
on	O
the	O
magnetic	O
matrix	O
and	O
is	O
recorded	O
as	O
magnetic	O
matrix	O
@	O
(	O
TF	O
/	O
LDHs	O
)	O
.	O

The	O
TF	O
/	O
LDHs	O
nanohybrid	O
-	O
magnetic	O
matrix	O
compound	O
has	O
strong	O
magnetism	O
and	O
has	O
good	O
TF	O
slow	O
release	O
effects	O
.	O

The	O
preparation	O
method	O
has	O
simple	O
processes	O
and	O
allows	O
mild	O
reaction	O
conditions	O
.	O

Through	O
adjustment	O
of	O
magnetic	O
matrix	O
@	O
(	O
TF	O
/	O
LDHs	O
)	O
nano	O
-	O
compound	O
synthesis	O
conditions	O
and	O
change	O
of	O
a	O
drug	O
concentration	O
,	O
a	O
synthesis	O
temperature	O
,	O
magnetic	O
matrix	O
content	O
and	O
applied	O
magnetic	O
field	O
intensity	O
,	O
the	O
structure	O
,	O
the	O
composition	O
and	O
a	O
release	O
rate	O
of	O
the	O
magnetic	O
matrix	O
@	O
(	O
TF	O
/	O
LDHs	O
)	O
can	O
be	O
controlled	O
.	O

Tegafur	B
/	O
layered	O
double	O
hydroxide	B
(	O
TF	O
/	O
LDHs	O
)	O
nanohybrid	O
-	O
magnetic	O
matrix	O
compound	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
aqueous	O
suspension	O
injection	O
of	O
cephalosporin	B
medicines	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
aqueous	O
suspension	O
injection	O
comprises	O
the	O
components	O
of	O
5	O
-	O
20	O
%	O
W	O
/	O
V	O
of	O
a	O
7-aminocephalosporanic	B
acid	I
derivative	O
,	O
10	O
-	O
40	O
%	O
W	O
/	O
V	O
of	O
an	O
excipient	O
,	O
5	O
-	O
25	O
%	O
W	O
/	O
V	O
of	O
a	O
suspending	O
agent	O
,	O
0.1	O
-	O
0.6	O
%	O
W	O
/	O
V	O
of	O
a	O
suspending	O
aid	O
,	O
0.1	O
-	O
0.5	O
%	O
W	O
/	O
V	O
of	O
a	O
pH	O
buffer	O
,	O
0.1	O
-	O
1.0	O
%	O
of	O
an	O
addition	O
amount	O
of	O
a	O
surfactant	O
,	O
and	O
balance	O
of	O
injection	O
water	O
.	O

The	O
7-aminocephalosporanic	B
acid	I
derivative	O
is	O
micronized	O
,	O
wherein	O
7-aminocephalosporanic	B
acid	I
derivative	O
particles	O
with	O
size	O
smaller	O
than	O
100mum	O
account	O
for	O
no	O
lower	O
than	O
95	O
%	O
by	O
volume	O
of	O
the	O
total	O
volume	O
of	O
the	O
raw	O
materials	O
,	O
and	O
7-aminocephalosporanic	B
acid	I
derivative	O
particles	O
with	O
size	O
smaller	O
than	O
20mum	O
and	O
larger	O
than	O
2mum	O
account	O
for	O
no	O
lower	O
than	O
90	O
%	O
of	O
the	O
total	O
volume	O
of	O
the	O
raw	O
materials	O
.	O

Compared	O
with	O
oily	O
preparations	O
or	O
powdery	O
preparations	O
of	O
cephalosporin	B
medicines	O
,	O
the	O
aqueous	O
suspension	O
injection	O
of	O
cephalosporin	B
medicines	O
provided	O
by	O
the	O
invention	O
has	O
lower	O
viscosity	O
and	O
better	O
injection	O
performance	O
,	O
such	O
that	O
cephalosporin	B
medicine	O
stability	O
is	O
improved	O
.	O

The	O
viscosity	O
of	O
cephalosporin	B
medicines	O
is	O
reduced	O
,	O
such	O
that	O
injection	O
irritation	O
is	O
reduced	O
.	O

Aqueous	O
suspension	O
injection	O
of	O
cephalosporin	B
medicines	O
,	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
scabies	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medicine	O
is	O
prepared	O
from	O
hydnocarpus	O
anthelmintica	O
,	O
rheum	O
officinale	O
,	O
babysbreath	O
,	O
radix	O
euphorbiae	O
lantu	O
,	O
borneol	O
,	O
indigo	O
naturalis	O
,	O
calomel	O
,	O
common	O
cnidium	O
fruit	O
,	O
radix	O
sophorae	O
flavescentis	O
,	O
realgar	O
and	O
the	O
like	O
according	O
to	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
functions	O
of	O
clearing	O
away	O
heat	O
and	O
toxic	O
materials	O
,	O
sterilizing	O
,	O
relieving	O
pitching	O
,	O
diminishing	O
inflammation	O
,	O
activating	O
blood	O
and	O
dispersing	O
blood	O
stasis	O
,	O
is	O
good	O
in	O
curative	O
effect	O
and	O
high	O
in	O
recovery	O
rate	O
for	O
treatment	O
of	O
the	O
scabies	O
,	O
and	O
fast	O
becomes	O
effective	O
.	O

Medicine	O
for	O
treating	O
scabies	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
dragon	O
blood	O
spraying	O
film	O
agent	O
applied	O
to	O
a	O
superficial	O
wound	O
and	O
a	O
preparation	O
technology	O
thereof	O
.	O

The	O
dragon	O
blood	O
spraying	O
film	O
agent	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
components	O
by	O
weight	O
percent	O
of	O
1	O
-	O
3	O
%	O
of	O
dragon	O
blood	O
,	O
2	O
-	O
4	O
%	O
of	O
borneol	B
,	O
2	O
-	O
6	O
%	O
of	O
polyvinylpyrrolidone	B
,	O
1	O
-	O
3	O
%	O
of	O
polyethylene	B
glycol	I
2000	O
,	O
0.5	O
-	O
2	O
%	O
of	O
methylcellulose	O
,	O
0.5	O
-	O
2	O
%	O
of	O
ethyecellulose	O
,	O
0.5	O
-	O
3	O
%	O
of	O
polyving	B
alcohol	I
,	O
0.01	O
-	O
0.5	O
%	O
of	O
glycerol	B
,	O
40	O
-	O
70	O
%	O
of	O
ethanol	B
and	O
the	O
balance	O
of	O
distilled	O
water	O
.	O

The	O
preparation	O
technology	O
comprises	O
the	O
steps	O
of	O
dissolving	O
the	O
dragon	O
blood	O
and	O
the	O
borneol	B
drug	O
into	O
solution	O
A	O
by	O
the	O
ethanol	B
with	O
the	O
weight	O
percent	O
;	O
evenly	O
agitating	O
the	O
polyvinylpyrrolidone	B
,	O
the	O
polyethylene	B
glycol	I
2000	O
,	O
the	O
methylcellulose	O
,	O
the	O
ethyecellulose	O
and	O
the	O
polyving	B
alcohol	I
into	O
the	O
distilled	O
water	O
to	O
swell	O
for	O
24	O
hours	O
to	O
prepare	O
solution	O
B	O
,	O
mixing	O
the	O
solution	O
A	O
with	O
the	O
solution	O
B	O
,	O
blending	O
the	O
glycerol	B
,	O
and	O
charging	O
into	O
a	O
pressure	O
spray	O
bottle	O
,	O
and	O
finally	O
obtaining	O
the	O
dragon	O
blood	O
spraying	O
film	O
agent	O
.	O

The	O
spraying	O
film	O
agent	O
sprays	O
the	O
solution	O
containing	O
a	O
drug	O
into	O
fog	O
to	O
be	O
attached	O
to	O
the	O
skin	O
surface	O
to	O
quickly	O
form	O
a	O
film	O
under	O
the	O
effects	O
of	O
bottle	O
pressure	O
and	O
the	O
nozzle	O
pressure	O
.	O

The	O
spray	O
film	O
agent	O
has	O
the	O
effects	O
of	O
stopping	O
bleeding	O
,	O
inhibiting	O
bacterium	O
,	O
healing	O
sore	O
and	O
relieving	O
pain	O
,	O
and	O
is	O
especially	O
suitable	O
for	O
the	O
symptoms	O
such	O
as	O
small	O
-	O
area	O
burns	O
and	O
scalds	O
,	O
scratch	O
,	O
bruise	O
and	O
unhealing	O
score	O
.	O

Dragon	O
blood	O
spraying	O
film	O
agent	O
applied	O
to	O
superficial	O
wound	O
and	O
preparation	O
technology	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
polymer	O
synthesis	O
and	O
in	O
particular	O
relates	O
to	O
a	O
specific	O
inhibition	O
compound	O
of	O
an	O
SAHN	O
enzyme	O
protein	O
and	O
a	O
synthetic	O
method	O
of	O
the	O
specific	O
inhibition	O
compound	O
.	O

The	O
specific	O
inhibition	O
compound	O
of	O
escherichia	O
coli	O
SAHN	O
enzyme	O
protein	O
is	O
obtained	O
in	O
a	O
targeted	O
manner	O
by	O
virtue	O
of	O
an	O
organic	O
synthetic	O
method	O
,	O
so	O
that	O
a	O
novel	O
anti	O
-	O
infective	O
drug	O
pilot	O
compound	O
is	O
developed	O
.	O

Specific	O
inhibition	O
compound	O
of	O
SAHN	O
enzyme	O
protein	O
and	O
synthetic	O
method	O
of	O
specific	O
inhibition	O
compound	O

The	O
invention	O
relates	O
to	O
application	O
of	O
ginsenoside	B
F4	I
in	O
preparation	O
of	O
a	O
drug	O
for	O
treating	O
lymphoma	O
.	O

The	O
drug	O
for	O
preparing	O
the	O
lymphoma	O
,	O
which	O
is	O
prepared	O
from	O
ginsenoside	B
F4	I
,	O
can	O
restrain	O
oncocyte	O
,	O
and	O
is	O
significant	O
in	O
effect	O
.	O

Application	O
of	O
ginsenoside	B
F4	I
in	O
preparation	O
of	O
drug	O
for	O
treating	O
lymphoma	O

The	O
invention	O
discloses	O
a	O
pig	O
bone	O
nutrient	O
and	O
a	O
bone	O
-	O
strengthening	O
and	O
blood	O
-	O
generating	O
oral	O
liquid	O
prepared	O
by	O
the	O
same	O
.	O

The	O
oral	O
liquid	O
is	O
made	O
and	O
refined	O
by	O
a	O
scientific	O
method	O
by	O
using	O
the	O
pig	O
bone	O
nutrient	O
prepared	O
by	O
pig	O
bones	O
supported	O
by	O
medical	O
extraction	O
liquids	O
capable	O
of	O
reinforcing	O
qi	O
and	O
nourishing	O
blood	O
and	O
replenishing	O
the	O
blood	O
and	O
pharmaceutical	O
adjuvants	O
such	O
as	O
sucrose	B
,	O
malic	B
acid	I
,	O
aspartame	B
and	O
the	O
like	O
.	O

The	O
oral	O
liquid	O
has	O
the	O
functions	O
of	O
reinforcing	O
qi	O
and	O
nourishing	O
the	O
blood	O
,	O
nourishing	O
liver	O
and	O
kidney	O
and	O
filling	O
marrow	O
and	O
strengthening	O
bone	O
,	O
and	O
is	O
suitable	O
for	O
diseases	O
such	O
as	O
deficiency	O
of	O
qi	O
and	O
the	O
blood	O
,	O
deficiency	O
of	O
the	O
liver	O
and	O
the	O
kidney	O
,	O
sallow	O
complexion	O
,	O
muscle	O
and	O
bone	O
weekness	O
,	O
iron	O
-	O
deficiency	O
anemia	O
,	O
rickets	O
,	O
woman	O
pregnancy	O
calciprivia	O
,	O
osteoporosis	O
,	O
etc	O
.	O

Pig	O
bone	O
nutrient	O
and	O
bone	O
-	O
strengthening	O
and	O
blood	O
-	O
generating	O
oral	O
liquid	O
prepared	O
by	O
same	O

The	O
invention	O
discloses	O
application	O
of	O
Shen	O
-	O
Gui	O
pills	O
in	O
preparation	O
of	O
drugs	O
for	O
tumor	O
inhibition	O
and	O
combined	O
chemotherapy	O
drugs	O
.	O

The	O
application	O
has	O
the	O
advantages	O
that	O
effective	O
tumor	O
inhibition	O
rate	O
of	O
the	O
Shen	O
-	O
Gui	O
pills	O
is	O
30	O
%	O
,	O
effective	O
body	O
weight	O
of	O
cis	B
-	I
platinum	I
chemotherapy	O
tumor	O
-	O
bearing	O
mouse	O
is	O
increased	O
,	O
living	O
states	O
of	O
the	O
tumor	O
-	O
bearing	O
mouse	O
are	O
improved	O
,	O
reduction	O
of	O
neutrophile	O
granulocyte	O
and	O
monocytes	O
caused	O
by	O
cis	B
-	I
platinum	I
chemotherapy	O
is	O
reduced	O
,	O
reduction	O
of	O
spleen	O
and	O
thymus	O
indexes	O
caused	O
by	O
cis	B
-	I
platinum	I
chemotherapy	O
can	O
be	O
resisted	O
by	O
the	O
Shen	O
-	O
Gui	O
pills	O
,	O
the	O
spleen	O
and	O
thymus	O
indexes	O
can	O
be	O
increased	O
,	O
important	O
immune	O
organs	O
of	O
the	O
mouse	O
are	O
protected	O
to	O
some	O
extent	O
,	O
concentration	O
of	O
HIF-1alpha	O
(	O
hypoxia	O
inducible	O
factor-1	O
alpha	O
)	O
can	O
be	O
reduced	O
,	O
hypoxia	O
resistance	O
of	O
tumor	O
cells	O
is	O
weakened	O
,	O
death	O
of	O
the	O
tumor	O
cells	O
is	O
accelerated	O
,	O
activity	O
of	O
LDH	O
(	O
lactate	O
dehydrogenase	O
)	O
is	O
lowered	O
,	O
damages	O
of	O
LDH	O
on	O
normal	O
cells	O
are	O
reduced	O
,	O
and	O
toxic	O
action	O
of	O
the	O
cis	B
-	I
platinum	I
chemotherapy	O
can	O
be	O
alleviated	O
.	O

Application	O
of	O
Shen	O
-	O
Gui	O
pills	O
in	O
preparation	O
of	O
drugs	O
for	O
tumor	O
inhibition	O
and	O
combined	O
chemotherapy	O
drugs	O

The	O
invention	O
provides	O
an	O
externally	O
applied	O
medicine	O
used	O
for	O
treating	O
a	O
wound	O
difficult	O
to	O
heal	O
,	O
relates	O
to	O
externally	O
applied	O
medicine	O
powder	O
or	O
ointment	O
used	O
for	O
treating	O
the	O
wound	O
difficult	O
to	O
heal	O
and	O
is	O
especially	O
applicable	O
to	O
healing	O
of	O
chronic	O
ulcer	O
,	O
bedsore	O
,	O
scald	O
and	O
a	O
deep	O
wound	O
.	O

According	O
to	O
the	O
externally	O
applied	O
medicine	O
,	O
rheum	O
officinale	O
,	O
giant	O
knot	O
weed	O
,	O
sanguisorba	O
officinalis	O
and	O
calomel	O
are	O
taken	O
as	O
main	O
raw	O
materials	O
to	O
prepare	O
the	O
powder	O
or	O
ointment	O
.	O

The	O
externally	O
applied	O
medicine	O
used	O
for	O
treating	O
the	O
wound	O
difficult	O
to	O
heal	O
has	O
good	O
effects	O
of	O
eliminating	O
inflammation	O
,	O
promoting	O
tissue	O
regeneration	O
,	O
protecting	O
granulation	O
and	O
epithelial	O
tissue	O
and	O
promoting	O
wound	O
healing	O
and	O
is	O
easy	O
to	O
prepare	O
and	O
use	O
,	O
raw	O
materials	O
are	O
available	O
,	O
price	O
is	O
low	O
,	O
and	O
a	O
good	O
medical	O
treatment	O
effect	O
and	O
good	O
social	O
benefit	O
can	O
be	O
achieved	O
.	O

Externally	O
applied	O
medicine	O
used	O
for	O
treating	O
wound	O
difficult	O
to	O
heal	O

The	O
invention	O
discloses	O
a	O
kidney	O
-	O
tonifying	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
kidney	O
-	O
tonifying	O
composition	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
15	O
parts	O
of	O
polygonatum	O
kingianum	O
,	O
3	O
-	O
20	O
parts	O
of	O
astragalus	O
mongholicus	O
and	O
1	O
-	O
15	O
parts	O
of	O
seeds	O
of	O
Chinese	O
dodder	O
.	O

The	O
preparation	O
method	O
of	O
the	O
kidney	O
-	O
tonifying	O
composition	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
,	O
crushing	O
the	O
medicinal	O
raw	O
materials	O
and	O
sieving	O
the	O
crushed	O
medicinal	O
raw	O
materials	O
through	O
a	O
10	O
-	O
40	O
meshes	O
sieve	O
;	O
(	O
2	O
)	O
,	O
adding	O
3	O
-	O
5-times	O
water	O
to	O
the	O
medicinal	O
raw	O
materials	O
,	O
and	O
extracting	O
for	O
35	O
-	O
50	O
minutes	O
under	O
the	O
microwave	O
frequency	O
of	O
1000MHz-2500MHz	O
and	O
the	O
stirring	O
frequency	O
of	O
4r	O
/	O
min-7r	O
/	O
min	O
;	O
(	O
3	O
)	O
,	O
filtering	O
the	O
extracting	O
solution	O
,	O
compressing	O
the	O
filtrate	O
under	O
reduced	O
pressure	O
until	O
clear	O
paste	O
with	O
relative	O
density	O
of	O
1.05	O
-	O
1.15	O
at	O
80	O
DEG	O
C	O
is	O
obtained	O
;	O
(	O
4	O
)	O
,	O
cooling	O
to	O
the	O
room	O
temperature	O
,	O
slowly	O
adding	O
an	O
alcohol	B
aqueous	O
solution	O
with	O
volume	O
percentage	O
concentration	O
of	O
95	O
%	O
while	O
stirring	O
,	O
so	O
that	O
the	O
alcohol	B
-	O
containing	O
content	O
is	O
45%-55	O
%	O
;	O
standing	O
for	O
18	O
-	O
24	O
hours	O
,	O
filtering	O
out	O
liquid	O
supernatant	O
and	O
recycling	O
alcohol	B
;	O
(	O
5	O
)	O
,	O
drying	O
in	O
vacuum	O
until	O
the	O
moisture	O
content	O
is	O
3%-5	O
%	O
to	O
obtain	O
the	O
kidney	O
-	O
tonifying	O
composition	O
.	O

According	O
to	O
the	O
experiments	O
,	O
the	O
kidney	O
-	O
tonifying	O
composition	O
has	O
the	O
effects	O
of	O
increasing	O
bone	O
density	O
,	O
slowing	O
down	O
osteoporosis	O
and	O
delaying	O
caducity	O
.	O

Kidney	O
-	O
tonifying	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
cardiovascular	O
and	O
cerebtovascular	O
diseases	O
.	O

The	O
medicine	O
is	O
a	O
medicine	O
composition	O
which	O
is	O
prepared	O
from	O
pure	O
natural	O
plants	O
,	O
animals	O
and	O
minerals	O
according	O
to	O
a	O
certain	O
process	O
,	O
the	O
raw	O
materials	O
are	O
elaborately	O
prepared	O
.	O

The	O
medicine	O
has	O
an	O
obvious	O
curative	O
effect	O
on	O
hemiplegia	O
and	O
insufficient	O
blood	O
supply	O
to	O
heart	O
and	O
brain	O
caused	O
by	O
cerebral	O
thrombosis	O
,	O
cerebral	O
infarction	O
and	O
cerebral	O
atrophy	O
and	O
can	O
be	O
used	O
for	O
thoroughly	O
healing	O
diseases	O
such	O
as	O
palpitation	O
,	O
oppression	O
in	O
chest	O
,	O
dizziness	O
and	O
coma	O
caused	O
by	O
myocardial	O
infarction	O
and	O
coronary	O
heart	O
disease	O
without	O
any	O
toxic	O
or	O
side	O
effects	O
,	O
and	O
after	O
being	O
healed	O
,	O
the	O
diseases	O
do	O
not	O
relapse	O
.	O

The	O
raw	O
materials	O
used	O
by	O
the	O
medicine	O
are	O
wide	O
in	O
source	O
and	O
low	O
in	O
cost	O
;	O
and	O
the	O
preparation	O
method	O
of	O
the	O
medicine	O
is	O
simple	O
.	O

Medicine	O
for	O
treating	O
cardiovascular	O
and	O
cerebtovascular	O
diseases	O

The	O
invention	O
discloses	O
a	O
5-	B
[	I
[	I
4-	I
[	I
(	I
2	I
,	I
3-dimethyl-2H	I
-	I
indazole-6-yl	I
)	I
methylamino	I
]	I
-2-pyrimidyl	I
]	I
amino	I
]	I
-2-methyl	I
-	I
benzsulfamide	I
derivative	O
and	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O

The	O
compound	O
disclosed	O
by	O
the	O
invention	O
is	O
shown	O
in	O
the	O
structural	O
formula	O
I	O
,	O
wherein	O
R	O
is	O
selected	O
from	O
any	O
one	O
of	O
the	O
following	O
groups	O
:	O
an	O
alkyl	B
or	O
benzyl	B
substituted	O
six	O
-	O
membered	O
nitrogen	B
-	O
containing	O
heterocyclic	B
group	O
,	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	B
containing	O
5	O
-	O
8	O
carbon	B
atoms	O
,	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	B
containing	O
one	O
oxygen	B
atom	O
and	O
6	O
-	O
11	O
carbon	B
atoms	O
,	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	B
containing	O
one	O
carboxyl	B
and	O
at	O
least	O
4	O
carbon	B
atoms	O
,	O
and	O
a	O
linear	O
or	O
branched	O
chain	O
alkylamino	B
containing	O
one	O
carboxyl	B
and	O
at	O
least	O
5	O
carbon	B
atoms	O
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
new	O
compound	O
is	O
obtained	O
through	O
modifying	O
the	O
structure	O
of	O
an	O
amino	B
-	O
side	O
chain	O
part	O
on	O
the	O
basis	O
of	O
a	O
drug	O
Pazopanib	B
applied	O
to	O
the	O
clinic	O
.	O

Pharmacodynamic	O
tests	O
prove	O
that	O
the	O
compound	O
has	O
a	O
better	O
anti	O
-	O
blood	O
-	O
vessel	O
-	O
endothelium	O
-	O
growth	O
factor	O
receptor	O
inhibition	O
effect	O
.	O

5-	B
[	I
[	I
4-	I
[	I
(	I
2	I
,	I
3-dimethyl-2H	I
-	I
indazole-6-yl	I
)	I
methylamino	I
]	I
-2-pyrimidyl	I
]	I
amino	I
]	I
-2-methyl	I
-	I
benzsulfamide	I
derivative	O
and	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
relates	O
to	O
a	O
type	O
of	O
compounds	O
with	O
antitumor	O
activities	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
compounds	O
have	O
a	O
structural	O
general	O
formula	O
represented	O
below	O
.	O

R1	O
is	O
alkyl	B
group	O
,	O
heterocyclic	B
group	O
,	O
substituted	O
phenyl	B
group	O
,	O
substituted	O
alicyclic	B
group	O
,	O
or	O
aliphatic	B
heterocyclic	I
group	O
,	O
wherein	O
the	O
substituent	O
is	O
2,3-ethylenedioxy	B
,	O
3,4-ethylenedioxy	B
,	O
2,3-methylenedioxy	B
,	O
or	O
3,4-methylenedioxy	B
;	O
or	O
all	O
-	O
site	O
-	O
substituted	O
hydrogen	B
,	O
alkyl	B
,	O
alkoxy	B
,	O
halogen	B
,	O
amino	B
,	O
hydroxyl	B
,	O
trifluoromethyl	B
,	O
formate	B
,	O
and	O
the	O
like	O
.	O

R2	O
is	O
heterocyclic	B
group	O
or	O
substituted	O
phenyl	B
group	O
,	O
wherein	O
the	O
phenyl	B
substituent	O
is	O
2,3-ethylenedioxy	B
,	O
3,4-ethylenedioxy	B
,	O
2,3-methylenedioxy	B
,	O
or	O
3,4-methylenedioxy	B
;	O
or	O
all	O
-	O
site	O
-	O
substituted	O
hydrogen	B
,	O
alkyl	B
,	O
alkoxy	B
,	O
halogen	B
,	O
amino	B
,	O
hydroxyl	B
,	O
trifluoromethyl	B
,	O
formate	B
,	O
and	O
the	O
like	O
.	O

The	O
compounds	O
provided	O
by	O
the	O
invention	O
have	O
substantial	O
tumor	O
cytotoxic	O
effect	O
and	O
broad	O
-	O
spectrum	O
kinase	O
inhibitory	O
activity	O
,	O
and	O
can	O
be	O
used	O
in	O
preparing	O
antitumor	O
medicines	O
.	O

Multi	O
-	O
target	O
kinase	O
inhibitors	O
with	O
antitumor	O
activities	O
,	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
relates	O
to	O
a	O
physalin	B
A	I
extracting	O
process	O
and	O
medical	O
application	O
thereof	O
,	O
in	O
particular	O
relates	O
to	O
a	O
novel	O
application	O
of	O
physalin	B
A	I
in	O
preparation	O
of	O
an	O
anti	O
-	O
tumor	O
dug	O
and	O
in	O
particular	O
relates	O
to	O
the	O
use	O
of	O
physalin	B
A	I
in	O
treatment	O
of	O
human	O
fibrosarcoma	O
and	O
human	O
malignant	O
melanoma	O
.	O

After	O
process	O
optimization	O
,	O
the	O
extracting	O
rate	O
of	O
physalin	B
A	I
is	O
0.2133	O
%	O
.	O

Physalin	B
A	I
can	O
be	O
used	O
for	O
inhibiting	O
the	O
growth	O
of	O
various	O
tumor	O
cells	O
,	O
particularly	O
has	O
obvious	O
inhibiting	O
action	O
on	O
the	O
growth	O
of	O
the	O
human	O
fibrosarcoma	O
and	O
human	O
malignant	O
melanoma	O
,	O
but	O
does	O
not	O
inhibit	O
the	O
activities	O
of	O
the	O
human	O
normal	O
cells	O
obviously	O
.	O

The	O
mechanism	O
is	O
that	O
the	O
downstream	O
caspase	O
family	O
-	O
associated	O
protein	O
is	O
activated	O
by	O
activating	O
Fas	O
death	O
receptors	O
,	O
so	O
that	O
the	O
tumor	O
cells	O
are	O
induced	O
to	O
generate	O
apoptosis	O
.	O

Meanwhile	O
,	O
the	O
physalin	B
A	I
can	O
be	O
used	O
for	O
inducing	O
the	O
tumor	O
cells	O
to	O
generate	O
autophagy	O
for	O
achieving	O
autophagy	O
antagonism	O
apoptosis	O
in	O
the	O
HT1080	O
and	O
the	O
A375-S2	O
cells	O
;	O
and	O
the	O
p53	O
protein	O
and	O
the	O
MAPK	O
(	O
Mitogen	O
-	O
Activated	O
Protein	O
Kinase	O
)	O
-familty	O
p38	O
protein	O
have	O
a	O
key	O
regulation	O
effect	O
.	O

The	O
physalin	B
A	I
can	O
be	O
used	O
for	O
preparing	O
a	O
digestive	O
tract	O
dosage	O
form	O
or	O
a	O
non	O
-	O
digestive	O
tract	O
dosage	O
form	O
,	O
which	O
can	O
be	O
used	O
for	O
treating	O
tumors	O
including	O
the	O
human	O
fibrosarcoma	O
and	O
human	O
malignant	O
melanoma	O
.	O

Physalin	B
A	I
extracting	O
process	O
and	O
medical	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
stable	O
liquid	O
medicine	O
composition	O
containing	O
epinastine	B
or	O
hydrochloride	B
of	O
epinastine	B
.	O

1000ml	O
of	O
the	O
liquid	O
medicine	O
composition	O
mainly	O
comprises	O
0.1	O
-	O
10.0	O
g	O
of	O
epinastine	B
or	O
hydrochloride	B
of	O
epinastine	B
,	O
10	O
-	O
50	O
g	O
of	O
polyethylene	B
pyrrolidone	I
and	O
5	O
-	O
100ml	O
of	O
polyethylene	B
glycol	I
400	I
.	O

Meanwhile	O
,	O
the	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
liquid	O
medicine	O
composition	O
,	O
wherein	O
pH	O
of	O
liquid	O
is	O
controlled	O
to	O
be	O
4.5	O
-	O
6.5	O
.	O

The	O
liquid	O
medicine	O
composition	O
can	O
also	O
be	O
taken	O
as	O
a	O
medicine	O
which	O
urgently	O
needs	O
to	O
be	O
developed	O
in	O
clinic	O
and	O
has	O
an	O
excellent	O
effect	O
on	O
allergic	O
reaction	O
diseases	O
of	O
children	O
.	O

Stable	O
solution	O
containing	O
epinastine	B
or	O
hydrochloride	B
of	O
epinastine	B

The	O
invention	O
relates	O
to	O
a	O
preparation	O
prepared	O
by	O
micro	O
-	O
powder	O
cellulose	O
,	O
which	O
is	O
suitable	O
for	O
drug	O
administration	O
for	O
oral	O
cavity	O
and	O
nasal	O
cavity	O
,	O
and	O
is	O
specially	O
used	O
for	O
preventing	O
and	O
controlling	O
respiratory	O
infectious	O
disease	O
.	O

Because	O
that	O
micro	O
-	O
powder	O
cellulose	O
is	O
a	O
strong	O
polar	O
adsorbent	O
,	O
and	O
is	O
easily	O
absorbing	O
virus	O
and	O
bacteria	O
with	O
strong	O
polarity	O
,	O
the	O
viability	O
and	O
pathogenecity	O
of	O
pathogen	O
can	O
be	O
rapidly	O
deprived	O
.	O

The	O
tests	O
show	O
that	O
the	O
micro	O
-	O
powder	O
cellulose	O
has	O
efficacy	O
for	O
preventing	O
and	O
controlling	O
respiratory	O
infectious	O
disease	O
.	O

After	O
drug	O
administration	O
is	O
carried	O
out	O
,	O
the	O
symptoms	O
which	O
are	O
lassitude	O
,	O
intolerance	O
of	O
cold	O
and	O
chills	O
at	O
early	O
stage	O
of	O
disease	O
can	O
be	O
rapidly	O
disappeared	O
.	O

No	O
symptom	O
like	O
high	O
fever	O
and	O
bacterial	O
inflammation	O
of	O
respiratory	O
system	O
can	O
be	O
generated	O
.	O

The	O
micro	O
-	O
powder	O
cellulose	O
can	O
avoid	O
virus	O
denaturation	O
and	O
bacteria	O
mutation	O
,	O
is	O
nontoxic	O
,	O
has	O
no	O
adverse	O
reaction	O
,	O
and	O
is	O
absolutely	O
safe	O
.	O

The	O
micro	O
-	O
powder	O
cellulose	O
has	O
the	O
advantages	O
of	O
odourlessness	O
,	O
no	O
flavor	O
,	O
no	O
stimulation	O
and	O
good	O
mouthfeel	O
,	O
the	O
users	O
are	O
likely	O
to	O
use	O
the	O
micro	O
-	O
powder	O
cellulose	O
,	O
the	O
usage	O
method	O
is	O
easy	O
,	O
the	O
product	O
is	O
easy	O
to	O
be	O
prepared	O
,	O
the	O
cost	O
is	O
cheap	O
,	O
and	O
the	O
micro	O
-	O
powder	O
cellulose	O
can	O
meet	O
supply	O
.	O

Micro	O
-	O
powder	O
cellulose	O
capable	O
of	O
preventing	O
and	O
controlling	O
respiratory	O
infectious	O
disease	O

The	O
invention	O
discloses	O
a	O
group	O
of	O
tenofovir	B
disoproxil	I
compounds	O
with	O
activity	O
for	O
inhibiting	O
HIV-1	O
/	O
HBV	O
virus	O
replication	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
a	O
preparation	O
method	O
and	O
pharmaceutical	O
applications	O
thereof	O
.	O

The	O
group	O
of	O
the	O
compounds	O
have	O
a	O
general	O
formula	O
I	O
,	O
wherein	O
X	O
=	O
H	B
,	O
Y	O
=	O
H	B
,	O
R1=-CH2	O
(	B
CH2	I
)	I
mCH2O	I
(	I
CH2	I
)	I
nCH3	I
,	O
m=0	O
-	O
4	O
,	O
n=10	O
-	O
20	O
,	O
and	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
respectively	O
described	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
group	O
of	O
the	O
compounds	O
.	O

Experiments	O
show	O
that	O
one	O
of	O
the	O
compounds	O
has	O
the	O
advantages	O
that	O
an	O
activity	O
for	O
inhibiting	O
HIV-1	O
virus	O
replication	O
is	O
20	O
times	O
that	O
of	O
a	O
positive	O
control	O
medicine	O
zidovudine	B
(	O
AZT	B
)	O
,	O
1,000	O
times	O
that	O
of	O
TDF	O
that	O
is	O
the	O
best	O
medicine	O
for	O
treating	O
Aids	O
and	O
about	O
9	O
times	O
that	O
of	O
CMX157	O
in	O
a	O
clinical	O
stage	O
,	O
and	O
lipid	O
solubility	O
is	O
about	O
2	O
times	O
that	O
of	O
CMX157	O
.	O

Experiments	O
also	O
show	O
that	O
the	O
compounds	O
provided	O
by	O
the	O
invention	O
have	O
the	O
activity	O
for	O
inhibiting	O
HBV	O
virus	O
replication	O
,	O
and	O
can	O
be	O
used	O
for	O
development	O
of	O
drugs	O
for	O
treating	O
the	O
Aids	O
and	O
hepatitis	O
B.	O
Tenofovir	B
disoproxil	I
compounds	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
in	O
anti	O
-	O
virus	O
aspects	O

Provided	O
herein	O
are	O
methods	O
,	O
compositions	O
,	O
and	O
kits	O
for	O
preventing	O
,	O
inhibiting	O
,	O
reducing	O
the	O
severity	O
of	O
,	O
or	O
treating	O
a	O
disease	O
or	O
condition	O
.	O

A	O
pharmaceutical	O
composition	O
provided	O
herein	O
can	O
comprise	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
an	O
antigen	O
fused	O
to	O
an	O
immune	O
cell	O
product	O
,	O
e.g.	O
,	O
MIP-3a	O
,	O
and	O
an	O
adjuvant	O
.	O

The	O
antigen	O
can	O
be	O
from	O
a	O
bacteria	O
,	O
virus	O
,	O
fungus	O
,	O
parasite	O
,	O
or	O
cancer	O
.	O

The	O
antigen	O
can	O
be	O
an	O
Alzheimer	O
's	O
disease	O
antigen	O
.	O

Methods	O
and	O
compositions	O
for	O
preventing	O
a	O
condition	O

The	O
invention	O
provides	O
a	O
novel	O
slow	O
-	O
release	O
breast	O
perfusion	O
agent	O
for	O
preventing	O
cow	O
subclinical	O
mastitis	O
in	O
a	O
milk	O
shortage	O
stage	O
.	O

100	O
g	O
of	O
the	O
novel	O
slow	O
-	O
release	O
breast	O
perfusion	O
agent	O
comprises	O
7	O
-	O
11	O
g	O
of	O
cefalonium	B
,	O
0.5	O
to	O
8	O
g	O
of	O
polyethylene	B
glycol-400	I
,	O
Tween	B
materials	O
or	O
propylene	B
glycol	I
,	O
0.5	O
to	O
8	O
g	O
of	O
fatty	B
alcohol	I
polyoxyethylene	I
ether	I
,	O
cyclomethylene	B
glyceryl	I
ether	I
,	O
triacetin	B
or	O
poloxamer	B
,	O
0.5	O
to	O
8	O
g	O
of	O
aluminum	B
stearate	I
or	O
silica	B
,	O
0.02	O
to	O
0.05	O
g	O
of	O
vitamin	B
E	I
,	O
0.05	O
to	O
0.1	O
g	O
of	O
benzyl	B
alcohol	I
,	O
and	O
the	O
balance	O
liquid	O
paraffin	B
,	O
soybean	O
oil	O
for	O
injection	O
or	O
median	O
chain	O
triglyceride	B
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
novel	O
slow	O
-	O
release	O
breast	O
perfusion	O
agent	O
.	O

The	O
novel	O
slow	O
-	O
release	O
breast	O
perfusion	O
agent	O
is	O
suspension	O
colloid	O
,	O
can	O
be	O
slowly	O
released	O
,	O
can	O
effectively	O
reduce	O
administration	O
frequency	O
,	O
can	O
effectively	O
prevent	O
and	O
treat	O
cow	O
subclinical	O
mastitis	O
by	O
being	O
used	O
in	O
a	O
milk	O
shortage	O
stage	O
,	O
and	O
does	O
not	O
produce	O
residues	O
.	O

Compared	O
with	O
the	O
like	O
foreign	O
products	O
,	O
the	O
suspension	O
colloid	O
has	O
better	O
stability	O
.	O

Novel	O
slow	O
-	O
release	O
breast	O
perfusion	O
agent	O
for	O
preventing	O
cow	O
subclinical	O
mastitis	O
in	O
milk	O
shortage	O
stage	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
treating	O
mental	O
diseases	O
and	O
in	O
particular	O
relates	O
to	O
a	O
solid	O
drug	O
composition	O
.	O

The	O
composition	O
comprises	O
(	O
a	O
)	O
a	O
compound	O
shown	O
in	O
the	O
formula	O
I	O
in	O
the	O
specification	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
(	O
b	O
)	O
a	O
fatty	B
acid	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
c	O
)	O
optional	O
pharmaceutic	O
adjuvants	O
,	O
wherein	O
in	O
the	O
formula	O
I	O
,	O
R1	O
is	O
bromine	B
,	O
and	O
R2	O
and	O
R3	O
are	O
methyl	B
.	O

The	O
composition	O
has	O
good	O
pharmaceutical	O
properties	O
.	O

Composition	O
for	O
treating	O
mental	O
diseases	O

The	O
invention	O
relates	O
to	O
a	O
vitamin	B
C	I
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medical	O
technology	O
.	O

The	O
vitamin	B
C	I
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
is	O
composed	O
of	O
vitamin	B
C	I
,	O
sodium	B
carbonate	I
,	O
an	O
excipient	O
,	O
an	O
anti	O
-	O
oxidant	O
,	O
an	O
antioxidant	O
synergist	O
and	O
injection	O
water	O
.	O

The	O
preparation	O
method	O
comprises	O
seven	O
steps	O
:	O
filling	O
the	O
injection	O
water	O
with	O
carbon	B
dioxide	I
until	O
the	O
mixture	O
is	O
saturated	O
,	O
preparing	O
a	O
liquid	O
medicine	O
,	O
removing	O
pyrogen	O
,	O
degerming	O
,	O
filtering	O
,	O
loading	O
,	O
freeze	O
-	O
drying	O
and	O
capping	O
.	O

The	O
product	O
provided	O
by	O
the	O
invention	O
has	O
advantages	O
of	O
good	O
external	O
properties	O
,	O
good	O
stability	O
,	O
definite	O
therapeutic	O
effect	O
,	O
simple	O
operation	O
and	O
low	O
cost	O
,	O
and	O
can	O
be	O
widely	O
used	O
in	O
the	O
field	O
of	O
preparations	O
of	O
medicines	O
which	O
are	O
not	O
stable	O
at	O
normal	O
temperature	O
.	O

Vitamin	B
C	I
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
an	O
arthritis	O
bone	O
disease	O
.	O

The	O
medicament	O
mainly	O
comprises	O
primary	O
medicinal	O
materials	O
such	O
as	O
gastrodia	O
elata	O
,	O
lucid	O
ganoderma	O
,	O
hericium	O
erinaceus	O
,	O
pollen	O
pini	O
,	O
cordyceps	O
mycelia	O
,	O
ganoderma	O
lucidum	O
spore	O
,	O
artemisia	O
rupestris	O
,	O
radix	O
angelicae	O
,	O
radices	O
sileris	O
,	O
myrrh	O
,	O
testiset	O
penis	O
phocae	O
,	O
musk	O
,	O
long	O
-	O
noded	O
pit	O
viper	O
,	O
and	O
leech	O
,	O
and	O
auxiliary	O
medicinal	O
materials	O
such	O
as	O
golden	O
camellia	O
,	O
semen	O
strychni	O
,	O
notopterygium	O
root	O
,	O
ginseng	O
,	O
frankincense	O
,	O
borneol	B
,	O
gecko	O
,	O
tortoise	O
plastron	O
,	O
lucid	O
ganoderma	O
,	O
blood	O
scorpion	O
and	O
ophisaurus	O
harti	O
.	O

Thus	O
,	O
the	O
medicament	O
prepared	O
according	O
to	O
the	O
formula	O
disclosed	O
by	O
the	O
invention	O
has	O
an	O
obvious	O
curative	O
effect	O
on	O
the	O
arthritis	O
bone	O
disease	O
,	O
especially	O
has	O
a	O
particularly	O
obvious	O
treatment	O
effect	O
on	O
rheumatoid	O
arthritis	O
,	O
cervical	O
spondylosis	O
and	O
lumbar	O
disc	O
herniation	O
,	O
and	O
does	O
not	O
easily	O
reappear	O
after	O
treatment	O
,	O
and	O
is	O
consolidated	O
in	O
curative	O
effect	O
,	O
convenient	O
and	O
practical	O
,	O
and	O
suitable	O
for	O
generalization	O
and	O
use	O
.	O

Medicament	O
for	O
treating	O
arthritis	O
bone	O
disease	O

The	O
invention	O
discloses	O
an	O
indole	B
derivative	O
,	O
which	O
is	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
derivative	O
is	O
a	O
selective	O
antagonist	O
of	O
a	O
muscarinic	B
acetylcholine	I
receptor	O
;	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
linear	O
or	O
branched	O
alkyl	B
containing	O
1	O
-	O
3	O
carbon	B
atoms	O
;	O
R2	O
and	O
R3	O
independently	O
represent	O
hydrogen	B
atoms	O
or	O
linear	O
or	O
branched	O
alkyl	B
containing	O
1	O
-	O
3	O
carbon	B
atoms	O
;	O
and	O
R4	O
represents	O
hydrogen	B
atom	O
or	O
halogen	B
.	O

In	O
addition	O
,	O
the	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
,	O
and	O
use	O
as	O
a	O
muscarinic	O
acetylcholine	B
receptor	O
antagonist	O
.	O

Indole	B
derivative	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
(	O
E	O
)	O
-1,3-dihydro	O
-5,6-dimethoxy-3-	O
[	O
(	O
4-hydroxyphenyl	O
)	O
methylene	O
]	O
-2H	O
-	O
indol-2-one	O
and	O
a	O
derivative	O
fumarate	O
or	O
a	O
pharmaceutically	O
acceptable	O
solvate	O
thereof	O
,	O
and	O
an	O
application	O
thereof	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
cancers	O
.	O

Salt	O
of	O
dimethoxy	O
indolone	O
derivative	O

The	O
invention	O
provides	O
a	O
new	O
capecitabine	B
tablet	O
composition	O
and	O
a	O
preparation	O
method	O
of	O
a	O
capecitabine	B
table	O
which	O
realizes	O
controllable	O
quality	O
and	O
guarantees	O
product	O
stability	O
.	O

By	O
adopting	O
a	O
wet	O
granulation	O
tabletting	O
technology	O
,	O
the	O
particle	O
has	O
good	O
compression	O
formability	O
,	O
the	O
particle	O
size	O
is	O
uniform	O
,	O
the	O
fluidity	O
is	O
good	O
,	O
and	O
the	O
wear	O
resistance	O
is	O
stronger	O
;	O
the	O
preparation	O
technology	O
has	O
better	O
feasibility	O
,	O
does	O
not	O
need	O
to	O
perform	O
superfine	O
grinding	O
treatment	O
on	O
raw	O
materials	O
,	O
improves	O
the	O
yield	O
of	O
the	O
raw	O
materials	O
and	O
reduces	O
the	O
production	O
processes	O
;	O
and	O
moreover	O
,	O
a	O
small	O
quantity	O
of	O
accessories	O
are	O
used	O
in	O
a	O
prescription	O
,	O
thus	O
the	O
production	O
cost	O
is	O
effectively	O
reduced	O
.	O

Capecitabine	B
tablet	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
phenazopyridine	B
in	O
preparing	O
an	O
anti	O
-	O
angiogenesis	O
medicine	O
.	O

Reports	O
related	O
to	O
the	O
anti	O
-	O
angiogenesis	O
activity	O
of	O
phenazopyridine	B
are	O
unavailable	O
so	O
far	O
.	O

The	O
invention	O
provides	O
an	O
application	O
of	O
phenazopyridine	B
in	O
preparing	O
an	O
anti	O
-	O
angiogenesis	O
medicine	O
,	O
an	O
anti	O
-	O
tumor	O
medicine	O
and	O
an	O
anti	O
-	O
wet	O
senile	O
vision	O
macular	O
degeneration	O
medicine	O
.	O

An	O
in	O
-	O
vivo	O
pharmacodynamic	O
experiment	O
adopting	O
a	O
zebra	O
fish	O
angiogenesis	O
model	O
proves	O
that	O
the	O
phenazopyridine	B
can	O
obviously	O
inhibit	O
the	O
zebra	O
fish	O
angiogenesis	O
and	O
the	O
growth	O
of	O
transplanted	O
human	O
cancer	O
cells	O
,	O
and	O
has	O
a	O
therapeutic	O
effect	O
on	O
wet	O
senile	O
vision	O
macular	O
degeneration	O
.	O

Therefore	O
,	O
the	O
phenazopyridine	B
can	O
be	O
used	O
for	O
preparing	O
a	O
medicine	O
for	O
resisting	O
angiogenesis	O
,	O
tumor	O
or	O
wet	O
senile	O
vision	O
macular	O
degeneration	O
.	O

Application	O
of	O
phenazopyridine	B
in	O
preparing	O
anti	O
-	O
angiogenesis	O
medicine	O

The	O
invention	O
relates	O
to	O
a	O
small	O
molecule	O
medicament	O
based	O
on	O
PI3	O
K	O
(	O
Phosphatidyl	O
Inositol	O
3-kinase	O
)	O
/	O
mTOR	O
(	O
Mammalian	O
Target	O
of	O
Rapamycin	B
)	O
double	O
targets	O
,	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
chemical	O
medicines	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
five	O
-	O
membered	O
urea	O
ring	O
-	O
coumarin	B
derivative	O
or	O
a	O
pharmaceutical	O
salt	O
and	O
an	O
application	O
thereof	O
.	O

A	O
compound	O
claimed	O
by	O
the	O
invention	O
has	O
a	O
structure	O
shown	O
as	O
formula	O
I	O
described	O
in	O
the	O
specification	O
,	O
and	O
pharmacological	O
experiments	O
show	O
that	O
the	O
compound	O
has	O
excellent	O
inhibitory	O
activity	O
in	O
a	O
plurality	O
of	O
tumor	O
cell	O
strains	O
.	O

Five	O
-	O
membered	O
urea	B
ring	O
-	O
coumarin	B
derivative	O
or	O
pharmaceutical	O
salt	O
and	O
application	O
thereof	O

Disclosed	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
treating	O
various	O
diseases	O
,	O
syndromes	O
,	O
conditions	O
and	O
disorders	O
,	O
including	O
pain	O
.	O

Such	O
compounds	O
,	O
and	O
enantiomers	O
,	O
diastereomers	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
are	O
represented	O
by	O
Formula	O
(	O
I	O
)	O
as	O
follows	O
:	O
(	O
I	O
)	O
wherein	O
Y	O
,	O
Z	O
,	O
and	O
R1	O
and	O
R2	O
are	O
defined	O
herein	O
.	O

Amino	B
-	I
pyrrolidine	I
-	I
zetidine	I
diamides	I
as	O
monoacylglycerol	B
lipase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
pyrazole	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
having	O
pharmacological	O
activity	O
and	O
to	O
processes	O
of	O
preparation	O
of	O
such	O
compounds	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
,	O
and	O
to	O
their	O
use	O
in	O
therapy	O
and/or	O
prophylaxis	O
of	O
pain	O
.	O

5-methyl-1-	B
(	I
naphthalen	I
--	I
yl	I
)	I
-1h	I
-	I
pyrazole	I
derivatives	O
and	O
their	O
use	O
in	O
potentiating	O
the	O
effect	O
of	O
opioid	O
analgesics	O

The	O
invention	O
discloses	O
a	O
gynecological	O
cleaning	O
fluid	O
prepared	O
by	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
parts	O
:	O
8	O
-	O
15	O
parts	O
of	O
sophora	O
flavescens	O
,	O
8	O
-	O
15	O
parts	O
of	O
common	O
cnidium	O
fruit	O
,	O
3	O
-	O
5	O
parts	O
of	O
Herba	O
Commelinae	O
,	O
3	O
-	O
5	O
parts	O
of	O
tarragon	O
,	O
1	O
-	O
3	O
parts	O
of	O
Senecio	O
scandens	O
,	O
5	O
-	O
10	O
parts	O
of	O
Fructus	O
Rosae	O
Laevigatae	O
,	O
3	O
-	O
7	O
parts	O
of	O
savatier	O
monochasma	O
,	O
3	O
-	O
6	O
parts	O
of	O
mulberry	O
bark	O
,	O
2	O
-	O
5	O
parts	O
of	O
cordate	O
houttuynia	O
,	O
6	O
-	O
9	O
parts	O
of	O
aerial	O
parts	O
of	O
epimedium	O
,	O
0.5	O
-	O
1	O
part	O
of	O
borneol	B
,	O
0.2	O
-	O
0.3	O
parts	O
of	O
menthol	B
,	O
0.1	O
-	O
0.3	O
parts	O
of	O
Chlorhexidine	B
Acetate	I
,	O
0.1	O
-	O
0.3	O
parts	O
of	O
vitamin	O
E	O
,	O
3	O
-	O
5	O
parts	O
of	O
chitosan	O
and	O
0.3	O
-	O
0.5	O
parts	O
of	O
tea	O
polyphenol	B
.	O

The	O
gynecological	O
cleaning	O
fluid	O
provided	O
by	O
the	O
invention	O
has	O
efficacies	O
of	O
inhibiting	O
bacteria	O
and	O
killing	O
peats	O
,	O
dispelling	O
pathogenic	O
wind	O
and	O
removing	O
dampness	O
,	O
clearing	O
away	O
heat	O
and	O
toxic	O
materials	O
,	O
relieve	O
itching	O
and	O
diminishing	O
inflammation	O
,	O
and	O
cooling	O
the	O
blood	O
and	O
dissipating	O
blood	O
stasis	O
;	O
also	O
has	O
nursing	O
effect	O
;	O
treats	O
both	O
symptoms	O
and	O
root	O
causes	O
;	O
can	O
substantially	O
reduce	O
dryness	O
and	O
burning	O
sensation	O
generated	O
after	O
treatment	O
and	O
improve	O
using	O
comfortableness	O
;	O
and	O
enables	O
effective	O
components	O
of	O
the	O
medicine	O
to	O
stay	O
at	O
affected	O
areas	O
for	O
a	O
relatively	O
long	O
time	O
,	O
thereby	O
greatly	O
prolonging	O
an	O
effect	O
time	O
of	O
the	O
medicine	O
,	O
shortening	O
a	O
treatment	O
course	O
and	O
being	O
substantial	O
in	O
curative	O
effect	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
gynecological	O
cleaning	O
fluid	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
in	O
technology	O
steps	O
and	O
suitable	O
for	O
industrial	O
production	O
.	O

The	O
prepared	O
gynecological	O
cleaning	O
fluid	O
is	O
good	O
in	O
drug	O
effect	O
and	O
using	O
effect	O
.	O

Gynecological	O
cleaning	O
fluid	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
triazole	B
alcohol	I
compound	O
.	O

The	O
triazole	B
alcohol	I
compound	O
has	O
a	O
following	O
chemical	O
structural	O
formula	O
as	O
shown	O
in	O
a	O
chemical	O
structure	O
in	O
the	O
specification	O
,	O
wherein	O
X	O
is	O
CH	B
=	I
CH	I
or	O
O	B
;	O
R	O
is	O
selected	O
from	O
alkyl	B
,	O
halogen	B
,	O
alkoxy	B
or	O
nitryl	B
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
:	O
the	O
compound	O
has	O
good	O
antifungal	O
activity	O
for	O
various	O
superficial	O
and	O
deep	O
fungi	O
,	O
has	O
the	O
advantages	O
of	O
high	O
efficiency	O
,	O
low	O
toxicity	O
and	O
wide	O
antifungal	O
spectrum	O
compared	O
with	O
conventional	O
clinical	O
applied	O
antifungal	O
drugs	O
,	O
and	O
can	O
be	O
used	O
in	O
the	O
preparation	O
of	O
antifungal	O
drugs	O
.	O

The	O
compound	O
is	O
simple	O
in	O
the	O
preparation	O
method	O
,	O
high	O
in	O
yield	O
,	O
and	O
good	O
in	O
antifungal	O
effect	O
,	O
and	O
a	O
novel	O
compound	O
is	O
provided	O
for	O
the	O
preparation	O
of	O
antifungal	O
drugs	O
.	O

Azole	B
antifungal	O
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
discloses	O
a	O
veterinary	O
tiamulin	B
suspension	O
injection	O
and	O
preparation	O
method	O
thereof	O
.	O

The	O
veterinary	O
tiamulin	B
suspension	O
injection	O
comprises	O
the	O
following	O
compositions	O
in	O
percents	O
by	O
weight	O
:	O
20	O
%	O
of	O
tiamulin	B
,	O
6	O
-	O
10	O
%	O
of	O
a	O
suspending	O
agent	O
Arabic	O
gum	O
,	O
0.2	O
-	O
1	O
%	O
of	O
a	O
suspending	O
agent	O
polyvinyl	B
pyrrolidone	I
,	O
0.1	O
-	O
0.3	O
%	O
of	O
a	O
surfactant	O
,	O
0.3	O
-	O
0.9	O
%	O
of	O
a	O
flocculating	O
agent	O
,	O
other	O
auxiliary	O
agent	O
and	O
the	O
balance	O
water	O
.	O

The	O
veterinary	O
tiamulin	B
suspension	O
injection	O
of	O
the	O
invention	O
is	O
good	O
in	O
stability	O
,	O
rapid	O
in	O
absorption	O
,	O
high	O
in	O
bioavailability	O
and	O
substantial	O
in	O
effect	O
,	O
and	O
helps	O
to	O
provide	O
a	O
new	O
efficient	O
dosage	O
form	O
for	O
veterinary	O
tiamulin	B
.	O

Veterinary	O
tiamulin	B
suspension	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
belongs	O
to	O
the	O
field	O
of	O
medicament	O
synthesis	O
and	O
preparation	O
thereof	O
,	O
and	O
relates	O
to	O
the	O
stable	O
fructose	B
composition	O
preparation	O
and	O
preparation	O
method	O
thereof	O
.	O

Aseptic	O
beta	B
-	I
fructose	I
is	O
suspended	O
in	O
water	O
,	O
and	O
aseptic	O
fructose	B
is	O
added	O
for	O
adjusting	O
pH	O
for	O
dissolving	O
the	O
aseptic	O
beta	B
-	I
fructose	I
totally	O
,	O
and	O
the	O
aqueous	O
solution	O
of	O
fructose	B
/	O
glycerin	B
is	O
obtained	O
,	O
and	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
(	O
HP	O
-	O
beta	O
-	O
CD	O
)	O
is	O
added	O
into	O
the	O
aqueous	O
solution	O
for	O
clathration	B
,	O
and	O
after	O
package	O
and	O
freeze	O
drying	O
,	O
the	O
fructose	B
powder	O
injection	O
for	O
injection	O
is	O
obtained	O
.	O

The	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
is	O
simple	O
,	O
and	O
the	O
fructose	B
glycerin	B
compound	O
is	O
clathrated	O
by	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
,	O
thereby	O
the	O
water	O
-	O
solubility	O
and	O
stability	O
of	O
fructose	B
medicament	O
are	O
increased	O
,	O
and	O
the	O
biological	O
availability	O
of	O
the	O
medicament	O
is	O
improved	O
;	O
the	O
preparation	O
technology	O
is	O
simple	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Stable	O
fructose	B
composition	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
medical	O
application	O
of	O
a	O
benzothiazine	B
derivative	O
,	O
namely	O
an	O
application	O
of	O
a	O
2-methyl-4-hydroxy	B
-	I
N-	I
(	I
aryl	I
)	I
-2H-1,2	I
benzothiazine-3-formamide-1,1-dioxide	I
compound	O
in	O
an	O
antitumor	O
drug	O
.	O

A	O
pharmacodynamic	O
test	O
proves	O
that	O
the	O
compound	O
with	O
a	O
general	O
formula	O
(	O
I	O
)	O
has	O
a	O
certain	O
anti	O
-	O
tumor	O
curative	O
effect	O
.	O

Medical	O
application	O
of	O
benzothiazine	B
derivative	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
polyflavanostilbene	B
A	I
in	O
preparing	O
anti	O
-	O
hypoxic	O
medication	O
.	O

According	O
to	O
the	O
invention	O
,	O
with	O
hypoxia	O
models	O
at	O
overall	O
level	O
or	O
cellular	O
level	O
,	O
the	O
anti	O
-	O
hypoxic	O
function	O
of	O
the	O
polyflavanostilbene	B
A	I
can	O
be	O
observed	O
,	O
which	O
shows	O
that	O
the	O
polyflavanostilbene	B
A	I
can	O
obviously	O
improve	O
survival	O
rate	O
and	O
survival	O
time	O
of	O
a	O
mouse	O
subjected	O
to	O
asphyxia	O
anoxia	O
and	O
acute	O
decompression	O
hypoxia	O
,	O
reduce	O
myocardium	O
impairment	O
of	O
the	O
mouse	O
subjected	O
to	O
hypoxia	O
due	O
to	O
drug	O
specificity	O
,	O
and	O
has	O
remarkable	O
protective	O
effect	O
for	O
anoxic	O
impairment	O
of	O
myocardial	O
cells	O
and	O
nerve	O
cells	O
of	O
a	O
suckling	O
mouse	O
in	O
vitro	O
culture	O
.	O

Therefore	O
,	O
the	O
invention	O
provides	O
the	O
application	O
of	O
the	O
polyflavanostilbene	B
A	I
in	O
preparing	O
the	O
anti	O
-	O
hypoxic	O
medication	O
.	O

Application	O
of	O
polyflavanostilbene	B
A	I
in	O
preparing	O
anti	O
-	O
hypoxic	O
medication	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
chronic	O
rhinitis	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
medicines	O
such	O
as	O
alum	O
and	O
borneol	O
by	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
provided	O
by	O
the	O
invention	O
has	O
the	O
functions	O
of	O
detoxifying	O
and	O
diminishing	O
inflammation	O
,	O
promoting	O
qi	O
to	O
activate	O
blood	O
,	O
inducing	O
resuscitation	O
and	O
purging	O
intense	O
heat	O
.	O

The	O
medicine	O
for	O
treating	O
chronic	O
rhinitis	O
is	O
quick	O
in	O
effect	O
,	O
good	O
in	O
curative	O
effect	O
and	O
high	O
in	O
cure	O
rate	O
.	O

Medicine	O
for	O
treating	O
chronic	O
rhinitis	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
fuming	O
and	O
washing	O
drug	O
for	O
treating	O
an	O
anorectal	O
disease	O
,	O
and	O
particularly	O
relates	O
to	O
smoked	O
lotion	O
for	O
treating	O
hemorrhoids	O
and	O
fistula	O
.	O

The	O
smoked	O
lotion	O
is	O
prepared	O
from	O
compound	O
of	O
salt	O
and	O
liquorice	O
,	O
gypsum	O
rubrum	O
,	O
realgar	O
,	O
white	O
alum	O
,	O
borax	O
,	O
ossa	O
draconis	O
,	O
borneol	B
and	O
fructus	O
zanthoxyli	O
in	O
a	O
processing	O
manner	O
according	O
to	O
certain	O
parts	O
by	O
weight	O
.	O

Each	O
component	O
drug	O
of	O
the	O
smoked	O
lotion	O
is	O
reasonable	O
in	O
compatibility	O
,	O
so	O
that	O
the	O
effects	O
of	O
clearing	O
away	O
heat	O
and	O
drying	O
dampness	O
,	O
detoxifying	O
and	O
diminishing	O
inflammation	O
,	O
removing	O
dampness	O
to	O
relieve	O
itching	O
,	O
activating	O
meridians	O
to	O
stop	O
pain	O
,	O
removing	O
swelling	O
and	O
lump	O
,	O
promoting	O
blood	O
circulation	O
to	O
remove	O
blood	O
stasis	O
,	O
stopping	O
bleeding	O
and	O
astringing	O
intestine	O
to	O
stop	O
diarrhea	O
,	O
regenerating	O
tissue	O
to	O
heal	O
wound	O
and	O
the	O
like	O
are	O
achieved	O
;	O
and	O
the	O
smoked	O
lotion	O
has	O
good	O
restraining	O
and	O
killing	O
roles	O
on	O
failing	O
to	O
close	O
of	O
ulcer	O
and	O
pathogenic	O
bacteria	O
after	O
the	O
hemorrhoids	O
and	O
fistula	O
operation	O
,	O
can	O
be	O
used	O
for	O
rapidly	O
relieving	O
the	O
symptoms	O
of	O
inflammatory	O
external	O
hemorrhoids	O
,	O
earlier	O
anal	O
fissure	O
,	O
incarceration	O
of	O
internal	O
hemorrhoid	O
,	O
acute	O
infection	O
of	O
anal	O
fistula	O
,	O
perianal	O
abscess	O
and	O
the	O
like	O
,	O
preventing	O
and	O
treating	O
wound	O
infection	O
after	O
the	O
hemorrhoids	O
and	O
fistula	O
operation	O
and	O
accelerating	O
wound	O
healing	O
,	O
has	O
important	O
clinical	O
significance	O
,	O
and	O
is	O
good	O
in	O
curative	O
effect	O
,	O
fast	O
to	O
become	O
effective	O
,	O
small	O
in	O
toxic	O
and	O
side	O
effects	O
,	O
and	O
convenient	O
to	O
store	O
,	O
carry	O
and	O
use	O
.	O

Smoked	O
lotion	O
for	O
treating	O
hemorrhoids	O
and	O
fistula	O

The	O
invention	O
discloses	O
dibutyltin	O
pepper	O
acid	O
ester	O
with	O
a	O
trapezoidal	B
structure	O
,	O
which	O
is	O
a	O
compound	O
with	O
the	O
following	O
structural	O
formula	O
(	O
1	O
)	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R	O
represents	O
normal	B
-	I
butyl	I
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
dibutyltin	B
pepper	O
acid	O
ester	O
with	O
the	O
trapezoidal	B
structure	O
.	O

The	O
dibutyltin	B
pepper	O
acid	O
ester	O
with	O
the	O
trapezoidal	B
structure	O
,	O
which	O
is	O
disclosed	O
by	O
the	O
invention	O
,	O
has	O
good	O
antitumor	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
raw	O
material	O
for	O
preparing	O
medicaments	O
for	O
resisting	O
to	O
liver	O
cancer	O
,	O
nasopharynx	O
cancer	O
,	O
breast	O
cancer	O
,	O
lung	O
cancer	O
and	O
colon	O
cancer	O
.	O

Compared	O
with	O
a	O
currently	O
and	O
generally	O
used	O
platinum	B
anti	O
-	O
cancer	O
drug	O
,	O
the	O
dibutyltin	B
pepper	O
acid	O
ester	O
with	O
the	O
trapezoidal	O
structure	O
,	O
which	O
is	O
disclosed	O
by	O
the	O
invention	O
,	O
has	O
the	O
characteristics	O
of	O
high	O
antitumor	O
activity	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
and	O
the	O
like	O
and	O
provides	O
a	O
novel	O
approach	O
for	O
developing	O
anti	O
-	O
cancer	O
drugs	O
.	O

Dibutyltin	O
pepper	O
acid	O
ester	O
with	O
trapezoidal	B
structure	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
natural	O
medicines	O
,	O
and	O
particularly	O
relates	O
to	O
use	O
of	O
gamma	B
-	I
elemene	I
and	O
derivatives	O
thereof	O
in	O
preventing	O
atherosclerosis	O
,	O
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
atherosclerosis	O
.	O

According	O
to	O
the	O
invention	O
,	O
respectively	O
aiming	O
at	O
main	O
pathogenesis	O
of	O
atherosclerosis	O
,	O
the	O
treatment	O
effect	O
of	O
gamma	B
-	I
elemene	I
and	O
derivatives	O
(	O
I	O
)	O
thereof	O
to	O
atherosclerosis	O
are	O
verified	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
test	O
results	O
show	O
that	O
gamma	B
-	I
elemene	I
and	O
the	O
derivatives	O
thereof	O
can	O
remarkably	O
reduce	O
the	O
atherosclerotic	O
plaque	O
area	O
in	O
the	O
coronary	O
artery	O
of	O
an	O
animal	O
model	O
,	O
and	O
meanwhile	O
has	O
remarkable	O
improving	O
effect	O
to	O
two	O
key	O
links	O
in	O
development	O
process	O
of	O
atherosclerosis	O
:	O
adhesion	O
of	O
leukocyte	O
and	O
endothelial	O
cells	O
and	O
peroxidation	O
of	O
lipids	O
.	O

Expression	O
of	O
adherence	O
factors	O
closely	O
related	O
to	O
atherosclerosis	O
can	O
be	O
reduced	O
,	O
so	O
that	O
peroxidation	O
damage	O
of	O
endothelial	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
caused	O
by	O
high	O
fat	O
and	O
H2O2	B
is	O
avoided	O
.	O

Use	O
of	O
gamma	B
-	I
elemene	I
and	O
derivatives	O
thereof	O
in	O
preventing	O
atherosclerosis	O

The	O
invention	O
provides	O
an	O
application	O
of	O
alkannin	O
and/or	O
derivatives	O
thereof	O
in	O
preparing	O
a	O
medicine	O
for	O
prohibiting	O
cancer	O
cell	O
metastasis	O
.	O

The	O
cancer	O
cell	O
refers	O
to	O
one	O
or	O
more	O
of	O
brain	O
tumor	O
,	O
hematologic	O
tumer	O
,	O
esophagus	O
cancer	O
,	O
liver	O
cancer	O
,	O
skin	O
cancer	O
,	O
prostate	O
cancer	O
,	O
bone	O
cancer	O
,	O
breast	O
cancer	O
and	O
lung	O
carcinoma	O
cells	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
application	O
of	O
the	O
alkannin	O
and	O
derivatives	O
thereof	O
;	O
the	O
alkannin	O
can	O
effectively	O
prohibit	O
adhesion	O
,	O
migration	O
and	O
invasion	O
of	O
cells	O
,	O
expression	O
of	O
alkannin	O
beta1	O
and	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
,	O
so	O
that	O
cancer	O
cell	O
metastasis	O
is	O
effectively	O
prohibited	O
;	O
moreover	O
the	O
alkannin	O
and	O
derivatives	O
thereof	O
are	O
low	O
in	O
toxicity	O
,	O
are	O
nonhazardous	O
for	O
ordinary	O
cells	O
of	O
human	O
bodies	O
,	O
and	O
have	O
good	O
clinical	O
antineoplastic	O
application	O
prospects	O
.	O

Application	O
of	O
alkannin	O
and/or	O
derivative	O
thereof	O
in	O
preparing	O
medicine	O
for	O
prohibiting	O
cancer	O
cell	O
metastasis	O

The	O
invention	O
relates	O
to	O
wogonin	B
and	O
derivatives	O
thereof	O
,	O
a	O
prodrug	O
of	O
wogonin	B
as	O
well	O
as	O
medical	O
use	O
of	O
wogonin	B
and	O
biologically	O
-	O
physiologically	O
acceptable	O
salts	O
of	O
wogonin	B
and	O
derivatives	O
thereof	O
for	O
treating	O
a	O
chronic	O
kidney	O
disease	O
,	O
particularly	O
for	O
treating	O
renal	O
fibrosis	O
and	O
renal	O
fibrosis	O
-	O
induced	O
diseases	O
.	O

Use	O
of	O
wogonin	B
in	O
preparation	O
of	O
drug	O
for	O
treating	O
chronic	O
kidney	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
a	O
Xiaomi	O
vagina	O
expansion	O
suppository	O
,	O
which	O
comprises	O
an	O
active	O
component	O
,	O
a	O
matrix	O
and	O
an	O
expansible	O
expansion	O
carrier	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
preparation	O
method	O
and	O
a	O
detection	O
method	O
of	O
the	O
expansion	O
suppository	O
.	O

According	O
to	O
the	O
expansion	O
suppository	O
,	O
seven	O
original	O
leading	O
technologies	O
are	O
adopted	O
;	O
the	O
expansion	O
suppository	O
is	O
made	O
into	O
a	O
hollow	O
expansion	O
suppository	O
,	O
and	O
the	O
matrix	O
and	O
the	O
active	O
component	O
are	O
completely	O
separated	O
,	O
such	O
that	O
stability	O
of	O
the	O
expansion	O
suppository	O
is	O
increased	O
compared	O
with	O
stability	O
of	O
the	O
ordinary	O
suppository	O
;	O
the	O
active	O
component	O
,	O
the	O
dispersion	O
carrier	O
and	O
the	O
absorption	O
blocking	O
agent	O
are	O
combined	O
so	O
as	O
to	O
increase	O
an	O
active	O
component	O
dissolution	O
rate	O
,	O
well	O
release	O
the	O
active	O
component	O
,	O
and	O
prolong	O
a	O
drug	O
action	O
time	O
;	O
and	O
the	O
Xiaomi	O
vagina	O
expansion	O
suppository	O
has	O
effects	O
of	O
rapid	O
effect	O
,	O
prolonged	O
action	O
time	O
,	O
drug	O
liquid	O
outflow	O
prevention	O
,	O
vagina	O
cleaning	O
,	O
secondary	O
infection	O
prevention	O
,	O
and	O
the	O
like	O
.	O

Xiaomi	O
vagina	O
expansion	O
suppository	O
,	O
preparation	O
method	O
and	O
detection	O
method	O
thereof	O

The	O
invention	O
discloses	O
Dabigatran	B
etexilate	I
benzene	I
sulfonate	I
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
Dabigatran	B
etexilate	I
benzene	I
sulfonate	I
has	O
a	O
structure	O
shown	O
in	O
a	O
formula	O
I	O
in	O
the	O
specification	O
.	O

According	O
to	O
the	O
Dabigatran	B
etexilate	I
benzene	I
sulfonate	I
,	O
the	O
active	O
substance	O
Dabigatran	B
etexilate	I
is	O
salified	O
to	O
change	O
the	O
physical	O
and	O
chemical	O
properties	O
of	O
the	O
active	O
substance	O
,	O
and	O
then	O
effect	O
of	O
a	O
medicament	O
is	O
significantly	O
improved	O
under	O
the	O
condition	O
without	O
pharmacokinetic	O
differences	O
,	O
so	O
that	O
the	O
Dabigatran	B
etexilate	I
benzene	I
sulfonate	I
has	O
a	O
wide	O
prospect	O
in	O
the	O
aspect	O
of	O
preparing	O
an	O
anticoagulant	O
medicament	O
.	O

Dabigatran	B
etexilate	I
benzene	I
sulfonate	I
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
veterinary	O
drug	O
,	O
in	O
particular	O
to	O
a	O
stable	O
,	O
efficient	O
and	O
broad	O
-	O
spectrum	O
veterinary	O
amoxicillin	B
-	O
sulbactam	B
suspension	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
veterinary	O
amoxicillin	B
-	O
sulbactam	B
suspension	O
injection	O
comprises	O
the	O
following	O
ingredients	O
by	O
volume	O
weight	O
:	O
5%-30	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
amoxicillin	B
,	O
0.15%-5	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
sulbactam	B
,	O
5%-20	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
suspending	O
agent	O
,	O
0.3%-8	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
antimicrobial	O
preservative	O
,	O
and	O
the	O
balance	O
of	O
injection	O
oil	O
,	O
wherein	O
the	O
suspending	O
agent	O
is	O
aluminum	B
stearate	I
,	O
and	O
the	O
antimicrobial	O
preservative	O
is	O
benzyl	B
alcohol	I
or	O
acetone	B
chloroform	B
.	O

Specific	O
raw	O
materials	O
and	O
proportions	O
are	O
selected	O
to	O
greatly	O
prolong	O
the	O
stability	O
of	O
the	O
amoxicillin	B
-	O
sulbactam	B
suspension	O
injection	O
,	O
and	O
meanwhile	O
,	O
the	O
raw	O
materials	O
are	O
simple	O
and	O
available	O
,	O
the	O
processing	O
technique	O
is	O
simple	O
,	O
the	O
operation	O
is	O
convenient	O
and	O
the	O
production	O
cost	O
is	O
low	O
.	O

Veterinary	O
amoxicillin	B
-	O
sulbactam	B
suspension	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
nasal	O
spray	O
of	O
seaweed	O
extract	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
content	O
of	O
active	O
ingredient	O
seaweed	O
polysaccharide	O
of	O
the	O
nasal	O
spray	O
in	O
every	O
millimeter	O
of	O
solution	O
is	O
1mg-2.5	O
mg	O
;	O
the	O
content	O
of	O
glycerin	B
in	O
every	O
millimeter	O
of	O
solution	O
is	O
0.1mg-0.3	O
mg	O
;	O
the	O
content	O
of	O
sodium	B
chloride	I
in	O
every	O
millimeter	O
of	O
solution	O
is	O
4.0mg-5.0	O
mg	O
.	O

The	O
preparation	O
method	O
of	O
the	O
nasal	O
spray	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
sterilizing	O
seaweed	O
polysaccharide	O
;	O
adding	O
injection	O
water	O
and	O
humectants	O
;	O
uniformly	O
stirring	O
;	O
adding	O
the	O
rest	O
of	O
injection	O
water	O
to	O
adjust	O
osmotic	O
pressure	O
;	O
filtering	O
,	O
sterilizing	O
,	O
cooling	O
and	O
filling	O
.	O

The	O
nasal	O
spray	O
disclosed	O
by	O
the	O
invention	O
is	O
convenient	O
to	O
use	O
;	O
the	O
preparation	O
method	O
is	O
simple	O
and	O
easy	O
to	O
operate	O
;	O
the	O
preparation	O
is	O
free	O
of	O
preservative	O
,	O
sterile	O
,	O
stable	O
,	O
capable	O
of	O
keeping	O
nasal	O
mucosa	O
moist	O
and	O
capable	O
of	O
effectively	O
preventing	O
viral	O
flu	O
.	O

Nasal	O
spray	O
of	O
seaweed	O
extract	O
and	O
preparation	O
method	O
of	O
nasal	O
spray	O

The	O
invention	O
relates	O
to	O
a	O
levofloxacin	B
granule	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
levofloxacin	B
granule	O
at	O
least	O
comprises	O
a	O
levofloxacin	B
medicated	O
pellet	O
and	O
a	O
taste	O
masking	O
controlled	O
-	O
release	O
coating	O
layer	O
,	O
wherein	O
the	O
levofloxacin	B
medicated	O
pellet	O
comprises	O
a	O
blank	O
pellet	O
core	O
and	O
a	O
levofloxacin	B
medicine	O
layer	O
which	O
are	O
in	O
the	O
weight	O
ratio	O
of	O
1:	O
(	O
1.5	O
-	O
3	O
)	O
;	O
the	O
weight	O
of	O
the	O
taste	O
masking	O
controlled	O
-	O
release	O
coating	O
layer	O
is	O
increased	O
by	O
20	O
-	O
25	O
%	O
;	O
and	O
the	O
taste	O
masking	O
controlled	O
-	O
release	O
coating	O
layer	O
is	O
coated	O
by	O
using	O
an	O
acrylic	O
resin	O
and	O
ethylene	B
glycol	I
solution	O
.	O

The	O
levofloxacin	B
granule	O
provided	O
by	O
the	O
invention	O
is	O
good	O
in	O
taste	O
masking	O
effect	O
and	O
capable	O
of	O
completely	O
masking	O
the	O
bad	O
taste	O
of	O
the	O
levofloxacin	B
;	O
in	O
addition	O
,	O
the	O
levofloxacin	B
granule	O
also	O
has	O
a	O
controlled	O
-	O
release	O
function	O
and	O
can	O
be	O
used	O
for	O
solving	O
the	O
problem	O
that	O
the	O
effective	O
blood	O
concentration	O
can	O
be	O
maintained	O
by	O
taking	O
medicines	O
many	O
times	O
because	O
the	O
levofloxacin	B
is	O
shorter	O
in	O
half	O
-	O
life	O
period	O
;	O
and	O
the	O
effective	O
blood	O
concentration	O
can	O
be	O
maintained	O
for	O
a	O
longer	O
term	O
by	O
only	O
taking	O
the	O
levofloxacin	B
granule	O
once	O
every	O
day	O
.	O

Levofloxacin	B
granule	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
hyperlipidemia	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
applications	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
the	O
following	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
10	O
parts	O
of	O
evodiamine	B
,	O
and	O
5	O
-	O
15	O
parts	O
of	O
berberine	B
.	O

The	O
pharmaceutical	O
composition	O
is	O
prepared	O
by	O
combining	O
active	O
ingredients	O
of	O
natural	O
pharmaceutical	O
raw	O
materials	O
or	O
the	O
extract	O
of	O
active	O
ingredients	O
of	O
pharmaceutical	O
raw	O
materials	O
,	O
is	O
simple	O
in	O
constituents	O
,	O
is	O
affirmed	O
for	O
curative	O
effect	O
,	O
is	O
not	O
required	O
for	O
being	O
decocted	O
for	O
administration	O
,	O
is	O
convenient	O
to	O
carry	O
and	O
take	O
after	O
being	O
prepared	O
into	O
tablets	O
,	O
capsules	O
,	O
pills	O
,	O
granules	O
and	O
oral	O
liquid	O
.	O

Compared	O
with	O
the	O
traditional	O
natural	O
pharmaceutical	O
formulation	O
,	O
the	O
composition	O
has	O
the	O
advantages	O
of	O
less	O
impurity	O
content	O
,	O
high	O
purity	O
,	O
clear	O
action	O
mechanism	O
and	O
stable	O
character	O
,	O
is	O
capable	O
of	O
better	O
controlling	O
the	O
product	O
quality	O
in	O
industrialization	O
,	O
and	O
the	O
like	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
hyperlipidemia	O
as	O
well	O
as	O
preparation	O
method	O
and	O
applications	O

The	O
invention	O
provides	O
an	O
azasetron	B
composition	O
for	O
injection	O
,	O
relating	O
to	O
the	O
field	O
of	O
drugs	O
and	O
drug	O
production	O
technology	O
.	O

The	O
main	O
drug	O
of	O
the	O
composition	O
includes	O
azasetron	B
and	O
melatonin	B
(	O
MT	B
)	O
,	O
wherein	O
the	O
melatonin	B
comprises	O
a	O
quick	O
release	O
part	O
and	O
a	O
cyclodextrin	O
-	O
inclusion	O
slow	O
release	O
part	O
.	O

With	O
the	O
azasetron	B
composition	O
for	O
injection	O
,	O
the	O
treatment	O
effect	O
of	O
the	O
azasetron	B
can	O
be	O
improved	O
;	O
the	O
instability	O
,	O
fast	O
distribution	O
and	O
removal	O
and	O
the	O
like	O
of	O
the	O
MT	B
due	O
to	O
absorption	O
through	O
oral	O
administration	O
can	O
be	O
avoided	O
,	O
and	O
the	O
first	O
pass	O
effect	O
of	O
the	O
MT	B
can	O
be	O
reduced	O
;	O
the	O
administration	O
dosage	O
of	O
the	O
azasetron	B
can	O
be	O
reduced	O
;	O
the	O
drug	O
administration	O
design	O
of	O
combining	O
quick	O
release	O
and	O
slow	O
release	O
meets	O
the	O
physiological	O
secretion	O
characteristic	O
of	O
the	O
MT	B
,	O
solves	O
the	O
defect	O
of	O
short	O
half	O
life	O
period	O
of	O
the	O
MT	B
,	O
and	O
improves	O
the	O
bioavailability	O
of	O
the	O
product	O
;	O
the	O
synergism	O
of	O
the	O
azasetron	B
on	O
treating	O
CINV	O
(	O
Chemotherapy	O
Induced	O
Nausea	O
And	O
Vomiting	O
)	O
can	O
be	O
achieved	O
,	O
the	O
azasetron	B
and	O
MT	B
are	O
combined	O
to	O
be	O
capable	O
of	O
not	O
only	O
treating	O
CINV	O
to	O
improve	O
the	O
curative	O
effect	O
of	O
CINV	O
and	O
shorten	O
the	O
curative	O
period	O
,	O
but	O
also	O
reducing	O
the	O
usage	O
amount	O
of	O
the	O
azasetron	B
to	O
reduce	O
the	O
side	O
effect	O
of	O
the	O
azasetron	B
and	O
improve	O
the	O
human	O
immunity	O
;	O
a	O
certain	O
concentration	O
of	O
MT	B
kept	O
in	O
the	O
human	O
blood	O
can	O
effectively	O
reduce	O
the	O
stress	O
response	O
of	O
an	O
organism	O
,	O
thus	O
being	O
beneficial	O
to	O
the	O
treatment	O
of	O
CINV	O
.	O

Azasetron	B
composition	O
for	O
injection	O

The	O
invention	O
discloses	O
houttuynoids	B
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
houttuynoids	B
have	O
a	O
structural	O
formula	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
which	O
is	O
described	O
in	O
the	O
invention	O
;	O
in	O
the	O
formula	O
(	O
I	O
)	O
,	O
R1	O
is	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
formula	O
(	O
II	O
)	O
,	O
formula	O
(	O
IV	O
)	O
,	O
formula	O
(	O
V	O
)	O
,	O
formula	O
(	O
VI	O
)	O
,	O
formula	O
(	O
VII	O
)	O
,	O
formula	O
(	O
VIII	O
)	O
,	O
formula	O
(	O
IX	O
)	O
or	O
formula	O
(	O
X	O
)	O
as	O
described	O
in	O
the	O
invention	O
,	O
and	O
R2	O
is	O
hydrogen	B
or	O
is	O
represented	O
by	O
formula	O
(	O
XI	O
)	O
,	O
formula	O
(	O
XII	O
)	O
,	O
formula	O
(	O
XIII	O
)	O
or	O
formula	O
(	O
XIV	O
)	O
as	O
described	O
in	O
the	O
invention	O
.	O

12	O
houttuynoids	B
are	O
separated	O
from	O
Saururaceae	O
Houttuynia	O
cordata	O
Thunb	O
.	O

and	O
are	O
all	O
furan	B
-	O
flavones	B
with	O
novel	O
structures	O
.	O

An	O
in	O
-	O
vitro	O
anti	O
-	O
herpes	O
simplex	O
virus	O
activity	O
screening	O
system	O
is	O
used	O
for	O
evaluating	O
activity	O
of	O
the	O
houttuynoids	B
,	O
and	O
it	O
is	O
found	O
that	O
the	O
houttuynoids	B
can	O
effectively	O
inhibit	O
a	O
herpes	O
simplex	O
virus	O
;	O
thus	O
,	O
the	O
houttuynoids	B
have	O
effects	O
on	O
preventing	O
and	O
treating	O
herpes	O
simplex	O
virus	O
infection	O
,	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
drugs	O
used	O
for	O
resisting	O
the	O
herpes	O
simplex	O
virus	O
and	O
have	O
good	O
research	O
and	O
development	O
prospects	O
.	O

Houttuynoid	B
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
preparation	O
,	O
and	O
discloses	O
a	O
nimodipine	B
polymer	O
blending	O
micelle	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
nimodipine	O
polymer	O
blending	O
micelle	O
preparation	O
is	O
formed	O
by	O
embedding	O
nimodipine	B
in	O
polyethylene	B
glycol	I
-	O
polylactic	B
acid	I
(	O
PEG	B
-	O
PLA	B
)	O
and	O
D	B
-	I
alpha	I
-	I
Tocopheryl	I
polyethylene	I
glycol	I
1000	I
succinate	I
(	O
TPGS	B
)	O
,	O
wherein	O
the	O
mass	O
ratio	O
of	O
nimodipine	B
,	O
PEG	B
-	O
PLA	B
and	O
TPGS	B
is	O
2	O
-	O
10:20:5	O
-	O
30	O
.	O

The	O
weight	O
average	O
molecular	O
weight	O
of	O
PEG	B
-	O
PLA	B
is	O
7000	O
-	O
45000	O
,	O
wherein	O
the	O
molecular	O
weight	O
of	O
PEG	B
is	O
2000	O
-	O
15000	O
,	O
and	O
the	O
molecular	O
weight	O
of	O
PLA	B
is	O
5000	O
-	O
30000	O
.	O

The	O
nimodipine	B
polymer	O
blending	O
micelle	O
preparation	O
is	O
prepared	O
by	O
employing	O
solvent	O
evaporation	O
method	O
with	O
optimized	O
technology	O
conditions	O
,	O
wherein	O
the	O
ratios	O
of	O
an	O
organic	O
phase	O
to	O
a	O
water	O
phase	O
and	O
PEG	B
-	O
PLA	B
to	O
TPGS	B
,	O
dosage	O
and	O
the	O
like	O
are	O
all	O
best	O
defined	O
,	O
and	O
the	O
obtained	O
preparation	O
can	O
help	O
to	O
prolong	O
drug	O
release	O
time	O
by	O
experiments	O
in	O
vitro	O
.	O

Nimodipine	B
polymer	O
blending	O
micelle	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
2-	B
(	I
1-methylethyl	I
)	I
-5-	I
[	I
(	I
E	I
)	I
-2-phenylethenyl	I
]	I
benzene-1,3-diol	I
nanoemulsion	O
and	O
its	O
preparation	O
method	O
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
compound	O
surfactant	O
is	O
adopted	O
to	O
adjust	O
HLB	O
value	O
to	O
13	O
-	O
14	O
and	O
stipulate	O
to	O
a	O
specific	O
HLB	O
point	O
value	O
.	O

The	O
particle	O
size	O
range	O
of	O
the	O
prepared	O
nanoemulsion	O
is	O
10	O
-	O
50	O
nm	O
,	O
the	O
particles	O
are	O
uniform	O
,	O
and	O
the	O
nanoemulsion	O
has	O
characteristics	O
of	O
increased	O
drug	O
loading	O
capacity	O
and	O
stronger	O
stability	O
.	O

0.5	O
-	O
4h	O
transmitance	O
of	O
the	O
nanoemulsion	O
is	O
9	O
times	O
greater	O
than	O
a	O
single	O
surfactant	O
and	O
45	O
times	O
greater	O
than	O
an	O
original	O
medicine	O
.	O

The	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
is	O
suitable	O
for	O
preparation	O
of	O
the	O
2-	B
(	I
1-methylethyl	I
)	I
-5-	I
[	I
(	I
E	I
)	I
-2-phenylethenyl	I
]	I
benzene-1,3-diol	I
nanoemulsion	O
,	O
and	O
further	O
can	O
be	O
adopted	O
to	O
treat	O
diseases	O
such	O
as	O
intractable	O
psoriasis	O
and	O
the	O
like	O
.	O

2-	B
(	I
1-methylethyl	I
)	I
-5-	I
[	I
(	I
E	I
)	I
-2-phenylethenyl	I
]	I
benzene-1,3-diol	I
nanoemulsion	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
belongs	O
to	O
a	O
medical	O
field	O
,	O
more	O
specifically	O
a	O
sarafloxacin	B
hydrochloride	I
clathrate	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
sarafloxacin	B
hydrochloride	I
clathrate	O
is	O
prepared	O
by	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
:	O
1	O
part	O
of	O
sarafloxacin	B
hydrochloride	I
,	O
2	O
-	O
5	O
parts	O
of	O
CH	O
-	O
beta	O
-	O
CD	O
or	O
HP	O
-	O
beta	O
-	O
CD	O
and	O
1	O
-	O
5	O
parts	O
of	O
polymer	O
drug	O
accessory	O
;	O
wherein	O
the	O
polymer	O
drug	O
accessory	O
is	O
one	O
selected	O
from	O
polyvinylpyrrolidone	B
,	O
polyethylene	B
glycol	I
6000	I
or	O
hydroxypropyl	O
methyl	O
cellulose	O
.	O

The	O
sarafloxacin	B
hydrochloride	I
clathrate	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
of	O
:	O
weighting	O
sarafloxacin	B
hydrochloride	I
,	O
adding	O
it	O
into	O
a	O
sodium	B
hydroxide	I
solution	O
,	O
adding	O
CH	O
-	O
beta	O
-	O
CD	O
or	O
HP	O
-	O
beta	O
-	O
CD	O
into	O
a	O
sarafloxacin	B
hydrochloride	I
solution	O
,	O
heating	O
,	O
stirring	O
,	O
adding	O
the	O
polymer	O
drug	O
accessory	O
,	O
mechanically	O
grinding	O
,	O
vacuum	O
-	O
filtrating	O
,	O
and	O
then	O
freezing	O
and	O
drying	O
to	O
obtain	O
the	O
product	O
.	O

The	O
sarafloxacin	B
hydrochloride	I
clathrate	O
increases	O
solubility	O
of	O
sarafloxacin	B
hydrochloride	I
,	O
raises	O
drug	O
loading	O
and	O
yield	O
of	O
sarafloxacin	B
hydrochloride	I
,	O
and	O
enhances	O
chemical	O
stability	O
.	O

Sarafloxacin	B
hydrochloride	I
clathrate	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Myriberine	B
A	I
in	O
preparation	O
of	O
an	O
anti	O
-	O
hypoxic	O
drug	O
.	O

The	O
anti	O
-	O
hypoxic	O
effect	O
of	O
the	O
Myriberine	B
A	I
is	O
observed	O
through	O
an	O
entire	O
body	O
and	O
a	O
cellular	O
hypoxia	O
model	O
;	O
the	O
result	O
shows	O
that	O
the	O
survival	O
rate	O
and	O
the	O
survival	O
time	O
of	O
asphyxia	O
anoxia	O
and	O
acute	O
hypobaric	O
hypoxia	O
mice	O
can	O
be	O
significantly	O
improved	O
by	O
the	O
Myriberine	B
A	I
;	O
a	O
myocardial	O
damage	O
of	O
the	O
drug	O
specificity	O
to	O
the	O
hypoxia	O
mice	O
is	O
reduced	O
;	O
and	O
the	O
Myriberine	B
A	I
plays	O
a	O
significant	O
protecting	O
role	O
on	O
hypoxia	O
damage	O
to	O
in	O
-	O
vitro	O
cultured	O
neonatal	O
cardiomyocytes	O
and	O
nerve	O
corpuscles	O
.	O

Therefore	O
,	O
use	O
of	O
the	O
Myriberine	B
A	I
in	O
preparation	O
of	O
the	O
anti	O
-	O
hypoxic	O
drug	O
is	O
provided	O
.	O

Application	O
of	O
Myriberine	B
A	I
in	O
preparation	O
of	O
anti	O
-	O
hypoxic	O
drug	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Aspeverin	B
in	O
the	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
skin	O
cancer	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
medicines	O
.	O

It	O
is	O
found	O
through	O
in	O
vitro	O
MTT	B
antineoplastic	O
activity	O
rating	O
that	O
Aspeverin	B
also	O
has	O
a	O
remarkable	O
effect	O
of	O
inhibiting	O
the	O
growth	O
of	O
human	O
skin	O
cancer	O
cell	O
strains	O
A431	O
,	O
HME1	O
,	O
A375	O
and	O
SK23	O
.	O

Thus	O
,	O
Aspeverin	B
can	O
be	O
used	O
in	O
the	O
preparation	O
of	O
an	O
anti	O
-	O
skin	O
cancer	O
medicine	O
and	O
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
Aspeverin	B
in	O
the	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
skin	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

Aspeverin	B
has	O
an	O
unexpected	O
inhibitory	O
activity	O
of	O
skin	O
cancer	O
cell	O
.	O

Application	O
of	O
Aspeverin	B
in	O
preparation	O
of	O
medicine	O
for	O
treating	O
skin	O
cancer	O

The	O
invention	O
discloses	O
applications	O
of	O
latanoprost	B
in	O
preparation	O
of	O
medications	O
for	O
treating	O
diabetes	O
and/or	O
hypertriglyceridemia	O
and	O
complications	O
thereof	O
;	O
and	O
to	O
be	O
specific	O
,	O
the	O
diabetes	O
is	O
type	O
2	O
diabetes	O
induced	O
by	O
insulin	O
resistance	O
.	O

In	O
the	O
applications	O
,	O
latanoprost	B
is	O
used	O
as	O
an	O
antagonist	O
to	O
retinoid	O
X	O
receptor	O
alpha	O
(	O
RXR	O
alpha	O
)	O
which	O
is	O
a	O
type	O
of	O
nuclear	O
receptors	O
,	O
and/or	O
an	O
agonist	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

Latanoprost	B
has	O
an	O
antagonistic	O
effect	O
on	O
retinoid	O
X	O
receptor	O
alpha	O
(	O
RXR	O
alpha	O
)	O
and	O
can	O
antagonize	O
the	O
transcriptional	O
activity	O
of	O
PPAR	O
gamma	O
:	O
RXR	O
alpha	O
heterodimers	O
,	O
so	O
that	O
latanoprost	O
has	O
the	O
activity	O
to	O
inhibit	O
synthesis	O
and	O
storage	O
of	O
triglycerides	O
in	O
fat	O
cells	O
.	O

At	O
the	O
same	O
time	O
,	O
latanoprost	B
has	O
the	O
activity	O
to	O
activate	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
and	O
facilitates	O
the	O
translocation	O
of	O
glucose	B
transporter	O
4	O
(	O
GLUT4	O
)	O
to	O
plasma	O
membranes	O
and	O
further	O
glucose	B
absorption	O
.	O

Besides	O
,	O
latanoprost	B
acid	I
also	O
has	O
significant	O
activity	O
to	O
activate	O
AMPK	O
.	O

Applications	O
of	O
latanoprost	B
in	O
preparation	O
of	O
medications	O
for	O
treating	O
diabetes	O
and/or	O
hypertriglyceridemia	O
and	O
complications	O
thereof	O

The	O
present	O
invention	O
provides	O
application	O
of	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
to	O
medicine	O
for	O
autoimmunity	O
disease	O
and	O
transplant	O
rejection	O
disease	O
.	O

Through	O
experiments	O
,	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
is	O
found	O
to	O
be	O
capable	O
of	O
restraining	O
multiplication	O
of	O
human	O
dendritic	O
cells	O
in	O
vitro	O
,	O
restraining	O
human	O
denderitic	O
cells	O
to	O
promote	O
breeder	O
reaction	O
of	O
allogeneic	O
T	O
cells	O
,	O
and	O
enhancing	O
the	O
ability	O
of	O
human	O
denderitic	O
cells	O
to	O
secrete	O
interleukin	O
10	O
.	O

In	O
a	O
model	O
of	O
experimental	O
autoimmunity	O
disease	O
cerebrospinal	O
meningitis	O
,	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
is	O
capable	O
of	O
reducing	O
an	O
average	O
mouse	O
clinical	O
score	O
and	O
restraining	O
spinal	O
cord	O
invasion	O
degree	O
of	O
the	O
mononuclear	O
cells	O
.	O

In	O
an	O
experiment	O
of	O
heart	O
transplantation	O
,	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
is	O
capable	O
of	O
prolonging	O
the	O
survival	O
time	O
of	O
the	O
transplanted	O
heart	O
.	O

In	O
a	O
model	O
of	O
delayed	O
type	O
hypersensitivity	O
,	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
is	O
capable	O
of	O
reducing	O
mouse	O
ear	O
swelling	O
degree	O
.	O

According	O
to	O
the	O
results	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
possesses	O
a	O
certain	O
effect	O
on	O
autoimmunity	O
disease	O
and	O
transplant	O
rejection	O
disease	O
.	O

The	O
medicine	O
provided	O
by	O
the	O
invention	O
comprises	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
as	O
an	O
active	O
component	O
and	O
a	O
medicinal	O
carrier	O
,	O
and	O
the	O
medicine	O
includes	O
oral	O
dosage	O
form	O
,	O
injection	O
,	O
suppository	O
,	O
and	O
topical	O
dosage	O
form	O
,	O
etc	O
.	O

Application	O
of	O
p	B
-	I
hydroxyl	I
acetophenone	I
glycosidase	O
to	O
medicine	O
for	O
autoimmunity	O
disease	O
and	O
transplant	O
rejection	O
disease	O

The	O
invention	O
relates	O
to	O
a	O
medicament	O
for	O
treating	O
nasal	O
obstruction	O
when	O
catching	O
a	O
cold	O
,	O
and	O
relates	O
to	O
a	O
new	O
medical	O
application	O
of	O
chloramphenicol	B
.	O

In	O
the	O
prior	O
art	O
,	O
chloramphenicol	B
can	O
be	O
prepared	O
to	O
be	O
nasal	O
drops	O
,	O
which	O
can	O
be	O
dropped	O
into	O
nasal	O
cavities	O
for	O
1	O
-	O
2	O
droplets	O
each	O
time	O
when	O
nasal	O
obstruction	O
,	O
and	O
makes	O
an	O
immediate	O
effect	O
.	O

Medicament	O
for	O
treating	O
nasal	O
obstruction	O
when	O
catching	O
a	O
cold	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
biguanide	B
based	O
medicament	O
in	O
medicaments	O
for	O
delaying	O
or	O
reversing	O
acquired	O
drug	O
-	O
resistance	O
of	O
NSELC	O
treated	O
by	O
EGFR	O
-	O
TKI	O
,	O
wherein	O
the	O
biguanide	B
based	O
medicament	O
and	O
EGFR	O
-	O
TKI	O
are	O
taken	O
simultaneously	O
or	O
intervally	O
.	O

A	O
new	O
application	O
of	O
the	O
biguanide	B
based	O
medicament	O
is	O
discovered	O
.	O

The	O
biguanide	B
based	O
medicament	O
is	O
used	O
to	O
delay	O
or	O
reverse	O
generation	O
of	O
EGFR	O
-	O
TKI	O
acquired	O
drug	O
-	O
resistance	O
,	O
and	O
performs	O
varying	O
-	O
degree	O
inhibition	O
effects	O
on	O
main	O
mechanisms	O
of	O
EGFR	O
-	O
TKI	O
acquired	O
drug	O
-	O
resistance	O
of	O
NSCLC	O
patients	O
,	O
and	O
thus	O
the	O
sensibility	O
of	O
the	O
lung	O
-	O
cancer	O
patients	O
to	O
EGFR	O
-	O
TKI	O
is	O
increased	O
,	O
the	O
disadvantage	O
that	O
EGFR	O
-	O
TKI	O
is	O
easy	O
to	O
resist	O
drugs	O
is	O
overcome	O
,	O
and	O
the	O
curative	O
effect	O
of	O
EGFR	O
-	O
TKI	O
is	O
improved	O
.	O

Application	O
of	O
biguanide	B
based	O
medicament	O
in	O
medicaments	O
for	O
delaying	O
or	O
reversing	O
acquired	O
drug	O
-	O
resistance	O
of	O
NSELC	O
treated	O
by	O
EGFR	O
-	O
TKI	O

The	O
invention	O
discloses	O
a	O
new	O
use	O
of	O
a	O
5-HT2A	O
receptor	O
stimulant	O
,	O
and	O
provides	O
an	O
application	O
of	O
the	O
5-HT2A	O
receptor	O
stimulant	O
in	O
the	O
preparation	O
of	O
products	O
.	O

The	O
products	O
can	O
alleviate	O
the	O
inhibition	O
of	O
gestational	O
sootiness	O
to	O
the	O
filial	O
generation	O
medulla	O
respiratory	O
center	O
.	O

The	O
invention	O
also	O
provides	O
an	O
application	O
of	O
the	O
5-HT2A	O
receptor	O
stimulant	O
in	O
the	O
preparation	O
of	O
other	O
products	O
.	O

The	O
other	O
products	O
are	O
medicines	O
for	O
preventing	O
and/or	O
treating	O
sootiness	O
damages	O
;	O
and	O
the	O
sootiness	O
damages	O
comprise	O
(	O
I	O
)	O
the	O
damages	O
of	O
gestational	O
sootiness	O
to	O
the	O
filial	O
generation	O
medulla	O
respiratory	O
center	O
and/or	O
(	O
II	O
)	O
the	O
reduction	O
of	O
the	O
oxygen	B
consumption	O
of	O
the	O
filial	O
generation	O
in	O
the	O
low	O
-	O
oxygen	B
environment	O
,	O
caused	O
by	O
gestational	O
sootiness	O
.	O

The	O
use	O
provides	O
a	O
new	O
idea	O
and	O
experimental	O
basis	O
for	O
the	O
clinic	O
treatment	O
or	O
prevention	O
of	O
central	O
respiratory	O
diseases	O
caused	O
by	O
gestational	O
sootiness	O
in	O
the	O
invention	O
,	O
and	O
has	O
great	O
practical	O
values	O
.	O

New	O
use	O
of	O
5-HT2A	O
receptor	O
stimulant	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
application	O
of	O
an	O
N	B
-	I
substituted	I
hydroxamic	I
acid	I
compound	O
.	O

The	O
histone	O
compound	O
with	O
a	O
4-benzamido	B
-	I
N	I
-	I
hydroxy	I
-	I
N	I
-	I
benzoylphenyl	I
ammonia	I
structure	O
,	O
i.e.	O
,	O
the	O
N	B
-	I
substituted	I
hydroxamic	I
acid	I
compound	O
,	O
is	O
represented	O
by	O
formula	O
1	O
as	O
described	O
in	O
the	O
specification	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
with	O
methyl	B
p	I
-	I
aminobenzoate	I
,	O
benzoyl	B
chloride	I
and	O
nitrobenzene	B
as	O
raw	O
materials	O
,	O
allowing	O
methyl	B
p	I
-	I
aminobenzoate	I
and	O
benzoyl	B
chloride	I
to	O
undergo	O
aminoacylation	O
and	O
subjecting	O
a	O
reaction	O
product	O
to	O
hydrolysis	O
and	O
acylation	O
so	O
as	O
to	O
prepare	O
4-benzamido	B
-	I
benzoyl	I
chloride	I
or	O
4-	B
(	I
4-chlorphenyl	I
-	I
formamido	I
)	I
benzoyl	I
chloride	I
or	O
4-phenylacetamido	B
-	I
benzoyl	I
chloride	I
;	O
and	O
reducing	O
nitrobenzene	B
into	O
N	B
-	I
hydroxy	I
aniline	I
under	O
the	O
catalysis	O
of	O
Raney	B
nickel	I
and	O
reacting	O
N	B
-	I
hydroxy	I
aniline	I
with	O
4-benzamido	B
-	I
benzoyl	I
chloride	I
so	O
as	O
to	O
obtain	O
the	O
target	O
compound	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
N	B
-	I
substituted	I
hydroxamic	I
acid	I
compound	O

The	O
invention	O
discloses	O
polycyclic	O
polyketone	O
compounds	O
from	O
marine	O
verrucosispora	O
sp.	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
structure	O
of	O
the	O
compounds	O
is	O
represented	O
as	O
formula	O
I	O
,	O
wherein	O
,	O
R	O
is	O
represented	O
as	O
formula	O
II	O
or	O
OH	B
or	O
OCH3	B
.	O

The	O
compounds	O
are	O
obtained	O
by	O
separating	O
and	O
purifying	O
a	O
fermentation	O
broth	O
of	O
verrucosispora	O
sp.	O

MS100128	O
CGMCC	O
No.5847	O
.	O

Activity	O
test	O
results	O
show	O
that	O
the	O
compounds	O
represented	O
by	O
the	O
formula	O
I	O
have	O
an	O
anti	O
-	O
tb	O
activity	O
.	O

Polycyclic	O
polyketone	O
compounds	O
from	O
marine	O
verrucosispora	O
sp.	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
5	B
alpha-	I
androstane-3	I
beta	I
,	I
5	I
,	I
6	I
beta	I
-	I
triol	I
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
injection	O
comprises	O
5	B
alpha-	I
androstane-3	I
beta	I
,	I
5	I
,	I
6	I
beta	I
-	I
triol	I
,	O
solvent	O
for	O
injection	O
,	O
and	O
soluble	O
excipient	O
,	O
which	O
contains	O
sulfobutyl	O
-	O
beta	O
-	O
cyclodextrin	O
.	O

In	O
the	O
5	B
alpha-	I
androstane-3	I
beta	I
,	I
5	I
,	I
6	I
beta	I
-	I
triol	I
injection	O
,	O
sulfobutyl	O
-	O
beta	O
-	O
cyclodextrin	O
is	O
taken	O
as	O
a	O
solubilizer	O
,	O
not	O
only	O
solubility	O
of	O
androstane	B
triol	I
is	O
improved	O
,	O
and	O
problems	O
of	O
instable	O
clarity	O
and	O
irritation	O
of	O
androstane	B
triol	I
are	O
solved	O
,	O
but	O
also	O
isoosmotic	O
adjusting	O
agent	O
does	O
not	O
need	O
to	O
be	O
added	O
in	O
to	O
the	O
injection	O
or	O
in	O
application	O
,	O
and	O
hemolysis	O
phenomenon	O
does	O
not	O
appear	O
.	O

Furthermore	O
,	O
the	O
applicant	O
discovers	O
that	O
solubilization	O
effect	O
of	O
sulfobutyl	O
-	O
beta	O
-	O
cyclodextrin	O
to	O
androstane	O
triol	O
is	O
better	O
than	O
that	O
of	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
,	O
is	O
larger	O
than	O
30	O
mg	O
/	O
ml	O
,	O
and	O
no	O
crystal	O
precipitates	O
after	O
being	O
diluted	O
with	O
water	O
.	O

5	B
alpha-	I
androstane-3	I
beta	I
,	I
5,6	I
beta	I
-	I
triol	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
novel	O
compound	O
3,3'-	B
(	I
3,4-dichlorobenzylidene	I
)	I
-bis-4-hydroxycoumarin	I
with	O
a	O
strong	O
antibacterial	O
effect	O
which	O
is	O
optimized	O
by	O
transforming	O
the	O
structure	O
of	O
bishydroxycoumarin	B
compounds	O
,	O
and	O
provides	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
chemical	O
structure	O
and	O
crystal	O
structure	O
are	O
obtained	O
.	O

The	O
novel	O
compound	O
3,3'-	B
(	I
3,4-dichlorobenzylidene	I
)	I
-bis-4-hydroxycoumarin	I
has	O
an	O
antibacterial	O
application	O
value	O
in	O
preparation	O
of	O
a	O
medicine	O
resisting	O
staphylococcus	O
aureus	O
(	O
ATCC29213	O
)	O
,	O
methicillin	O
-	O
resistant	O
staphylococcus	O
aureus	O
(	O
MRSA	O
,	O
XJ7502	O
)	O
,	O
USA300	O
(	O
LAC	O
)	O
and	O
vancomycin	B
-	O
resistant	O
staphylococcus	O
aureus	O
(	O
Mu20ATCC700699	O
)	O
.	O

3,3'-	B
(	I
3,4-dichlorobenzylidene	I
)	I
-bis-4-hydroxycoumarin	I
and	O
application	O
thereof	O
in	O
preparation	O
of	O
medicine	O
for	O
resisting	O
multi	O
-	O
drug	O
resistant	O
bacteria	O

The	O
invention	O
discloses	O
a	O
coumarone	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
.	O

The	O
coumarone	O
derivative	O
is	O
prepared	O
by	O
reacting	O
4-amino-1-benzylpiperidine	B
with	O
a	O
carboxylic	B
acid	I
derivative	O
prepared	O
by	O
oxidation	O
of	O
oleanolic	B
alcohol	I
with	O
chromium	B
trioxide	I
.	O

The	O
coumarone	B
derivative	O
can	O
be	O
used	O
for	O
preparation	O
of	O
an	O
inhibitor	O
for	O
aggregation	O
of	O
acetylcholinesterase	O
and	O
amyloid	O
protein	O
.	O

Coumarone	B
derivative	O
,	O
and	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
purinylpyridinylamino-2,4-difluorophenyl	B
sulfonamide	I
derivative	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
with	O
an	O
inhibitory	O
activity	O
against	O
Raf	O
kinase	O
,	O
containing	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
purinylpyridinylamino-2,4-difluorophenyl	B
sulfonamide	I
derivative	O
of	O
the	O
present	O
invention	O
effectively	O
regulates	O
the	O
activity	O
of	O
B	O
-	O
raf	O
kinase	O
,	O
and	O
thus	O
may	O
be	O
useful	O
for	O
preventing	O
or	O
treating	O
cancer	O
induced	O
by	O
the	O
over	O
-	O
activation	O
of	O
Raf	O
kinase	O
,	O
especially	O
various	O
melanoma	O
,	O
colorectal	O
cancer	O
,	O
prostate	O
cancer	O
,	O
thyroid	O
cancer	O
,	O
ovarian	O
cancer	O
and	O
the	O
like	O
.	O

Novel	O
purinylpyridinylamino-2,4-difluorophenyl	B
sulfonamide	I
derivative	O
,	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
preparation	O
method	O
thereof	O
,	O
and	O
pharmaceutical	O
composition	O
with	O
inhibitory	O
activity	O
against	O
raf	O
kinase	O
,	O
containing	O
same	O
as	O
active	O
ingredi	O

The	O
invention	O
discloses	O
a	O
mongolian	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
nephropathy	O
.	O

The	O
mongolian	O
medicine	O
composition	O
is	O
prepared	O
from	O
the	O
following	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
15	O
-	O
25	O
parts	O
of	O
gypsum	O
,	O
15	O
-	O
25	O
parts	O
of	O
flowers	O
carthami	O
,	O
15	O
-	O
25	O
parts	O
of	O
clove	O
,	O
15	O
-	O
25	O
parts	O
of	O
myristica	O
fragrans	O
,	O
15	O
-	O
25	O
parts	O
of	O
amomum	O
cardamomum	O
,	O
15	O
-	O
25	O
parts	O
of	O
amomum	O
tsao	O
-	O
ko	O
,	O
15	O
-	O
25	O
parts	O
of	O
rhizoma	O
polygonati	O
,	O
15	O
-	O
25	O
parts	O
of	O
radix	O
polygonati	O
officinalis	O
,	O
15	O
-	O
25	O
parts	O
of	O
bletilla	O
striata	O
,	O
15	O
-	O
25	O
parts	O
of	O
radix	O
asparagi	O
,	O
15	O
-	O
25	O
parts	O
of	O
fructus	O
choerospondiatis	O
,	O
90	O
-	O
150	O
parts	O
of	O
ginseng	O
,	O
and	O
82.5	O
-	O
138	O
parts	O
of	O
polygonum	O
bistorta	O
.	O

Meanwhile	O
,	O
the	O
invention	O
also	O
discloses	O
a	O
corresponding	O
preparation	O
method	O
.	O

The	O
product	O
disclosed	O
by	O
the	O
invention	O
has	O
good	O
effects	O
of	O
improving	O
symptoms	O
and	O
protecting	O
the	O
kidney	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
and	O
easy	O
to	O
popularize	O
.	O

Mongolian	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
nephropathy	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
diethylstilbestrol	B
compound	O
and	O
application	O
thereof	O
in	O
preparation	O
of	O
a	O
drug	O
for	O
treating	O
osteoporosis	O
and/or	O
hyperlipemia	O
.	O

The	O
structural	O
formula	O
of	O
the	O
diethylstilbestrol	B
compound	O
is	O
shown	O
in	O
the	O
specification	O
.	O

The	O
data	O
of	O
a	O
cellular	O
level	O
pharmacodynamic	O
test	O
show	O
that	O
cajanstilbene	B
H	I
(	O
R	O
is	O
H	B
,	O
and	O
X	O
is	O
Cl	O
)	O
can	O
promote	O
multiplication	O
and	O
osteogenic	O
differentiation	O
of	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMSCs	O
)	O
of	O
an	O
SD	O
rat	O
.	O

After	O
an	O
ob	O
/	O
ob	O
obese	O
mice	O
orally	O
takes	O
the	O
cajanstilbene	B
H	I
(	O
20	O
mg	O
/	O
kg	O
/	O
d	O
)	O
continuously	O
for	O
21	O
days	O
,	O
the	O
results	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
no	O
obvious	O
effect	O
on	O
weight	O
is	O
generated	O
;	O
(	O
2	O
)	O
the	O
bone	O
density	O
of	O
the	O
mice	O
is	O
obviously	O
increased	O
;	O
serum	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
and	O
tartrate	O
resistant	O
acid	O
phosphatase	O
(	O
TRACP	O
)	O
level	O
are	O
obviously	O
reduced	O
;	O
and	O
the	O
serum	O
calcium	B
concentration	O
is	O
improved	O
;	O
and	O
(	O
3	O
)	O
levels	O
of	O
total	O
cholesterol	B
(	O
TC	O
)	O
,	O
triglyceride	B
(	O
TG	O
)	O
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	B
(	O
LDL	O
-	O
C	O
)	O
in	O
the	O
serum	O
of	O
the	O
mice	O
are	O
obviously	O
reduced	O
.	O

The	O
results	O
show	O
that	O
the	O
cajanstilbene	B
H	I
has	O
positive	O
significance	O
in	O
treatment	O
of	O
the	O
osteoporosis	O
caused	O
by	O
obesity	O
and	O
high	O
blood	O
sugar	B
,	O
and	O
has	O
a	O
clear	O
curative	O
effect	O
on	O
the	O
aspect	O
of	O
improvement	O
of	O
lipid	O
metabolism	O
of	O
the	O
obese	O
mice	O
.	O

The	O
cajanstilbene	O
H	O
has	O
a	O
clear	O
treatment	O
effect	O
on	O
the	O
osteoporosis	O
caused	O
by	O
obesity	O
and	O
high	O
blood	O
sugar	B
and	O
simultaneously	O
can	O
improve	O
lipid	O
metabolism	O
;	O
and	O
metabasis	O
of	O
hyperlipemia	O
to	O
diabetes	O
mellitus	O
to	O
chronic	O
complication	O
of	O
diabetes	O
mellitus	O
to	O
osteoporosis	O
can	O
be	O
avoided	O
to	O
a	O
certain	O
extent	O
.	O

Diethylstilbestrol	B
compound	O
and	O
application	O
thereof	O
in	O
preparation	O
of	O
drug	O
for	O
treating	O
osteoporosis	O
and	O
hyperlipemia	O

The	O
invention	O
relates	O
to	O
a	O
moxifloxacin	B
hydrochloride	I
injection	O
aqua	O
.	O

The	O
moxifloxacin	B
hydrochloride	I
injection	O
aqua	O
is	O
characterized	O
in	O
that	O
the	O
moxifloxacin	B
hydrochloride	I
injection	O
aqua	O
is	O
formed	O
by	O
using	O
a	O
sodium	B
carbonate	I
solution	O
as	O
a	O
pH	O
adjusting	O
agent	O
,	O
and	O
the	O
pH	O
value	O
of	O
the	O
above	O
preparation	O
is	O
7.1	O
-	O
8.0	O
.	O

The	O
preparation	O
method	O
of	O
the	O
preparation	O
is	O
characterized	O
in	O
that	O
water	O
accounting	O
for	O
50	O
-	O
80	O
%	O
of	O
the	O
total	O
water	O
consumption	O
is	O
preferably	O
used	O
for	O
dissolving	O
moxifloxacin	B
hydrochloride	I
,	O
and	O
water	O
accounting	O
for	O
15	O
-	O
35	O
%	O
the	O
total	O
water	O
consumption	O
is	O
introduced	O
in	O
a	O
sodium	B
carbonate	I
solution	O
manner	O
,	O
and	O
standing	O
or	O
weak	O
stirring	O
for	O
a	O
period	O
of	O
time	O
is	O
carried	O
out	O
at	O
room	O
temperature	O
after	O
the	O
adjustment	O
of	O
the	O
pH	O
value	O
to	O
make	O
the	O
pH	O
value	O
constant	O
.	O

The	O
preparation	O
obtained	O
in	O
the	O
invention	O
has	O
a	O
high	O
effective	O
concentration	O
and	O
a	O
good	O
storage	O
stability	O
.	O

Moxifloxacin	B
hydrochloride	I
injection	O
aqua	O

The	O
invention	O
relates	O
to	O
a	O
new	O
medicinal	O
application	O
of	O
Sarcaboside	B
A	I
,	O
i.e.	O
,	O
application	O
of	O
Sarcaboside	B
A	I
in	O
preparation	O
of	O
a	O
drug	O
for	O
treating	O
acute	O
renal	O
failure	O
.	O

The	O
application	O
of	O
Sarcaboside	B
A	I
in	O
preparation	O
of	O
the	O
drug	O
for	O
preventing	O
the	O
acute	O
rental	O
failure	O
is	O
disclosed	O
by	O
the	O
invention	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
is	O
brand	O
new	O
and	O
Sarcaboside	B
A	I
has	O
unexpectedly	O
strong	O
acute	O
renal	O
failure	O
inhibiting	O
activity	O
,	O
the	O
possibility	O
that	O
any	O
enlightenments	O
are	O
given	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

Sarcaboside	B
A	I
has	O
prominent	O
substantive	O
features	O
and	O
has	O
remarkable	O
progress	O
when	O
being	O
used	O
for	O
preventing	O
the	O
acute	O
renal	O
failure	O
.	O

Application	O
of	O
Sarcaboside	B
A	I
in	O
preparation	O
of	O
drug	O
for	O
treating	O
acute	O
renal	O
failure	O

The	O
invention	O
discloses	O
application	O
of	O
Sarcaboside	B
A	I
in	O
preparation	O
of	O
a	O
drug	O
for	O
treating	O
skin	O
cancer	O
,	O
which	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
drug	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
in	O
-	O
vitro	O
MTT	B
(	O
Methyl	B
Thiazolyl	I
Tetrazolium	I
)	O
antitumor	O
activity	O
evaluation	O
discovers	O
that	O
Sarcaboside	B
A	I
also	O
has	O
an	O
obvious	O
inhibiting	O
effect	O
on	O
the	O
growth	O
of	O
human	O
skin	O
cancer	O
cell	O
strains	O
A431	O
,	O
HME1	O
,	O
A375	O
and	O
SK23	O
.	O

Thus	O
,	O
Sarcaboside	B
A	I
can	O
be	O
used	O
for	O
preparing	O
an	O
anti	O
-	O
skin	O
cancer	O
drug	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

The	O
application	O
of	O
Sarcaboside	B
A	I
in	O
preparation	O
of	O
the	O
drug	O
for	O
treating	O
skin	O
cancer	O
is	O
disclosed	O
by	O
the	O
invention	O
for	O
the	O
first	O
time	O
.	O

The	O
skeleton	O
type	O
is	O
brand	O
new	O
and	O
Sarcaboside	B
A	I
has	O
unexpectedly	O
strong	O
inhibitory	O
activity	O
to	O
the	O
human	O
skin	O
cancer	O
cell	O
.	O

Application	O
of	O
Sarcaboside	B
A	I
in	O
preparation	O
of	O
drug	O
for	O
treating	O
skin	O
cancer	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Sarcaboside	B
A	I
in	O
preparing	O
a	O
medicine	O
for	O
preventing	O
and/or	O
treating	O
renal	O
insufficiency	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
a	O
new	O
application	O
of	O
a	O
medicine	O
.	O

The	O
application	O
of	O
the	O
Sarcaboside	B
A	I
in	O
preparing	O
a	O
medicine	O
for	O
preventing	O
and	O
treating	O
renal	O
insufficiency	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
since	O
a	O
brand	O
new	O
skeleton	O
type	O
is	O
adopted	O
and	O
the	O
inhibitory	O
activity	O
on	O
renal	O
insufficiency	O
is	O
unexpectedly	O
high	O
,	O
the	O
possibility	O
of	O
other	O
compounds	O
giving	O
any	O
prompt	O
is	O
avoided	O
,	O
and	O
the	O
Sarcaboside	B
A	I
has	O
outstanding	O
substantive	O
features	O
;	O
and	O
a	O
remarkable	O
progress	O
is	O
made	O
in	O
applying	O
the	O
Sarcaboside	B
A	I
to	O
the	O
prevention	O
of	O
renal	O
insufficiency	O
.	O

Application	O
of	O
Sarcaboside	B
A	I
in	O
preparing	O
medicine	O
for	O
preventing	O
or	O
treating	O
renal	O
insufficiency	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
disease	O
,	O
wherein	O
the	O
Chukrasone	B
B	I
has	O
an	O
acetylcholin	B
esterase	O
inhibiting	O
activity	O
and	O
a	O
nerve	O
cell	O
protective	O
effect	O
.	O

The	O
Chukrasone	B
B	I
,	O
serving	O
as	O
a	O
multiple	O
effect	O
target	O
compound	O
,	O
can	O
be	O
used	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
alzheimer	O
disease	O
.	O

The	O
application	O
of	O
the	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
disease	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
framework	O
type	O
is	O
a	O
brand	O
new	O
framework	O
type	O
and	O
the	O
acetylcholin	B
esterase	O
inhibiting	O
activity	O
of	O
the	O
Chukrasone	B
B	I
is	O
unimaginably	O
strong	O
,	O
the	O
probability	O
of	O
giving	O
any	O
enlightenment	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

The	O
Chukrasone	B
B	I
has	O
remarkable	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkable	O
progress	O
in	O
treatment	O
of	O
Alzheimer	O
disease	O
.	O

Application	O
of	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
disease	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
anti	O
-	O
diabetic	O
medicines	O
.	O

The	O
invention	O
provides	O
a	O
brand	O
new	O
selection	O
and	O
concept	O
to	O
existing	O
anti	O
-	O
diabetic	O
medicines	O
,	O
expands	O
the	O
selective	O
field	O
of	O
anti	O
-	O
diabetic	O
medicines	O
and	O
further	O
makes	O
contribution	O
to	O
development	O
of	O
the	O
technical	O
field	O
.	O

The	O
application	O
of	O
Chukrasone	B
B	I
disclosed	O
by	O
the	O
invention	O
is	O
proved	O
to	O
have	O
a	O
remarkable	O
anti	O
-	O
diabetic	O
effect	O
.	O

A	O
compound	O
with	O
a	O
definite	O
chemical	O
structure	O
is	O
used	O
by	O
the	O
invention	O
.	O

The	O
application	O
of	O
the	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
anti	O
-	O
diabetic	O
medicines	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
framework	O
type	O
is	O
a	O
brand	O
new	O
framework	O
type	O
and	O
the	O
activity	O
of	O
the	O
Chukrasone	B
B	I
in	O
prevention	O
and	O
treatment	O
of	O
diabetes	O
is	O
unimaginably	O
strong	O
,	O
the	O
probability	O
of	O
giving	O
any	O
enlightenment	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

The	O
Chukrasone	B
B	I
has	O
remarkable	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkable	O
progress	O
in	O
treatment	O
of	O
diabetes	O
.	O

Application	O
of	O
Chukrasone	B
B	I
in	O
preparation	O
medicines	O
for	O
reducing	O
blood	O
glucose	B

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
Houttuynoid	B
C	I
in	O
preparation	O
of	O
anti	O
-	O
platelet	O
aggregation	O
medicines	O
.	O

The	O
application	O
of	O
the	O
Houttuynoid	B
C	I
in	O
preparation	O
of	O
anti	O
-	O
platelet	O
aggregation	O
medicines	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
framework	O
type	O
is	O
a	O
brand	O
new	O
framework	O
type	O
and	O
the	O
anti	O
-	O
platelet	O
aggregation	O
activity	O
of	O
Houttuynoid	B
C	I
is	O
unimaginably	O
strong	O
,	O
the	O
probability	O
of	O
giving	O
any	O
enlightenment	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

The	O
Houttuynoid	B
C	I
has	O
remarkable	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkable	O
progress	O
in	O
resistance	O
against	O
platelet	O
aggregation	O
.	O

Application	O
of	O
Houttuynoid	B
C	I
in	O
anti	O
-	O
platelet	O
aggregation	O
medicines	O

The	O
invention	O
discloses	O
composition	O
used	O
for	O
preventing	O
and	O
treating	O
tumor	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
composition	O
is	O
prepared	O
with	O
the	O
raw	O
materials	O
of	O
,	O
by	O
mass	O
:	O
70	O
-	O
90	O
parts	O
of	O
aceraceae	O
acer	O
plant	O
seed	O
oil	O
,	O
10	O
-	O
30	O
parts	O
of	O
an	O
apricot	O
kernel	O
extract	O
,	O
0.001	O
-	O
1	O
part	O
of	O
selenium	B
,	O
and	O
0.5	O
-	O
5	O
parts	O
of	O
organic	O
germanium	B
.	O

The	O
preparation	O
method	O
comprises	O
material	O
blending	O
,	O
grinding	O
,	O
degassing	O
,	O
capsule	O
material	O
preparing	O
,	O
pill	O
pressing	O
,	O
forming	O
and	O
drying	O
,	O
pill	O
washing	O
,	O
sorting	O
,	O
and	O
packaging	O
.	O

The	O
composition	O
is	O
used	O
for	O
preparing	O
medicines	O
used	O
for	O
preventing	O
and	O
treating	O
tumors	O
.	O

The	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
selective	O
killing	O
effect	O
against	O
cancer	O
cells	O
,	O
and	O
assists	O
in	O
enhancing	O
immunity	O
and	O
cancer	O
resistance	O
.	O

Compared	O
with	O
existing	O
tumor	O
preventing	O
and	O
treating	O
products	O
,	O
the	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
substantial	O
progress	O
and	O
creativity	O
.	O

Composition	O
used	O
for	O
preventing	O
and	O
treating	O
tumor	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
biological	O
medicine	O
and	O
relates	O
to	O
a	O
compound	O
with	O
antituberculous	O
activity	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
thiourea	O
type	O
compound	O
for	O
inhibiting	O
growth	O
of	O
mycobacterium	O
tuberculosis	O
in	O
a	O
formula	O
(	O
I	O
)	O
structure	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
compound	O
.	O

An	O
extracorporal	O
mycobacterium	O
tuberculosis	O
inhibition	O
test	O
proves	O
that	O
the	O
compound	O
prepared	O
by	O
the	O
method	O
disclosed	O
by	O
the	O
invention	O
not	O
only	O
has	O
remarkably	O
good	O
anti	O
-	O
sensitive	O
mycobacterium	O
tuberculosis	O
activity	O
(	O
MIC	O
0.09	O
-	O
1.5	O
mug	O
/	O
ml	O
)	O
,	O
but	O
also	O
has	O
quite	O
remarkable	O
inhibition	O
effect	O
on	O
drug	O
resisting	O
mycobacterium	O
tuberculosis	O
(	O
MIC	O
0.37	O
-	O
1.5	O
mug	O
/	O
ml	O
)	O
.	O

The	O
compound	O
shows	O
extremely	O
high	O
medicine	O
preparation	O
value	O
and	O
can	O
be	O
further	O
used	O
for	O
preparing	O
medicaments	O
for	O
inhibiting	O
mycobacterium	O
tuberculosis	O
and	O
treating	O
tuberculosis	O
caused	O
by	O
the	O
mycobacterium	O
tuberculosis	O
.	O

Compound	O
with	O
antituberculous	O
activity	O
,	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
skimmianine	B
,	O
fumarate	B
of	O
derivates	O
of	O
skimmianine	B
or	O
pharmaceutically	O
acceptable	O
solvates	O
of	O
the	O
fumarate	O
as	O
well	O
as	O
applications	O
of	O
solvates	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
hepatitis	O
B.	O
Salt	O
for	O
skimmianine	B
derivates	O

The	O
invention	O
discloses	O
a	O
benzyltin	B
aromatic	I
aldehyde	I
condensed	I
arylamine	I
Schiff	I
base	I
complex	O
which	O
is	O
as	O
shown	O
in	O
the	O
structural	O
formula	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
is	O
-OCH3	B
or	O
Cl	B
,	O
R2	O
is	O
-H	B
or	O
-Cl	B
,	O
and	O
R3	O
is	O
-NO2	B
or	O
-H.	B
The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
benzyltin	B
aromatic	I
aldehyde	I
condensed	I
arylamine	I
Schiff	I
base	I
complex	O
and	O
its	O
application	O
in	O
drugs	O
for	O
treating	O
tumour	O
.	O

Benzyltin	B
aromatic	I
aldehyde	I
condensed	I
arylamine	I
Schiff	I
base	I
complex	O
and	O
its	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
new	O
application	O
of	O
a	O
Chukrasone	B
B	I
compound	O
in	O
the	O
pharmaceutical	O
field	O
,	O
and	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
the	O
Chukrasone	B
B	I
in	O
the	O
preparation	O
of	O
medicines	O
for	O
increasing	O
red	O
blood	O
cells	O
.	O

The	O
application	O
of	O
the	O
Chukrasone	B
B	I
in	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
treating	O
the	O
reduction	O
of	O
red	O
blood	O
cells	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Chukrasone	B
B	I
belongs	O
to	O
a	O
bran	O
-	O
new	O
skeleton	O
type	O
and	O
the	O
Chukrasone	B
B	I
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
the	O
reduction	O
of	O
the	O
red	O
blood	O
cells	O
,	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O

The	O
Chukrasone	B
B	I
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
reduction	O
of	O
the	O
red	O
blood	O
cells	O
.	O

Application	O
of	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
medicines	O
for	O
increasing	O
red	O
blood	O
cells	O

The	O
invention	O
discloses	O
a	O
chelate	O
and	O
a	O
preparation	O
method	O
.	O

According	O
to	O
impact	O
tests	O
on	O
focal	O
ischemia	O
-	O
reperfusion	O
model	O
rats	O
,	O
the	O
chelate	O
has	O
good	O
functions	O
of	O
protecting	O
nerve	O
cells	O
both	O
in	O
behavioral	O
scoring	O
and	O
cerebral	O
infarction	O
size	O
,	O
and	O
can	O
be	O
used	O
for	O
preparation	O
of	O
neuroprotective	O
agents	O
.	O

Chelate	O
with	O
functions	O
of	O
protecting	O
nerve	O
cells	O

The	O
invention	O
relates	O
to	O
serial	O
methylated	B
fucus	I
evanescens	O
oligose	B
or	O
methylated	B
sulfated	I
fucus	I
evanescens	O
oligose	B
or	O
a	O
salt	O
thereof	O
as	O
well	O
as	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
in	O
preparing	O
an	O
anti	O
-	O
parkison	O
medicament	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
oligose	B
by	O
carrying	O
out	O
desulphidation	O
esterification	O
onto	O
fucoidan	O
polysaccharide	O
sulfate	O
;	O
purifying	O
and	O
separating	O
by	O
column	O
chromatography	O
to	O
obtain	O
serial	O
high	O
-	O
purity	O
methylated	O
fucus	O
evanescens	O
oligose	B
and	O
methylated	B
sulfated	I
fucus	I
evanescens	O
oligose	B
.	O

The	O
methylated	B
fucus	I
evanescens	O
oligose	B
and	O
methylated	B
sulfated	I
fucus	I
evanescens	O
oligose	B
have	O
a	O
nerve	O
protection	O
effect	O
for	O
nerve	O
cell	O
injuries	O
induced	O
by	O
neurotoxin	O
,	O
and	O
can	O
be	O
used	O
for	O
medicaments	O
and	O
health	O
-	O
care	O
products	O
for	O
preventing	O
and	O
treating	O
neurodegenerative	O
diseases	O
.	O

Methylated	B
fucus	I
evanescens	O
oligose	B
or	O
methylated	B
sulfated	I
fucus	I
evanescens	O
oligose	B
or	O
salt	O
thereof	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
relates	O
to	O
a	O
polymer	O
-	O
coated	O
oleanolic	B
acid	I
liposome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
preparing	O
an	O
oleanolic	B
acid	I
liposome	O
suspension	O
,	O
adding	O
a	O
polymer	O
into	O
the	O
oleanolic	B
acid	I
liposome	O
suspension	O
,	O
carrying	O
out	O
coating	O
to	O
obtain	O
a	O
polymer	O
-	O
coated	O
oleanolic	B
acid	I
liposome	O
suspension	O
,	O
and	O
carrying	O
out	O
spray	O
drying	O
or	O
freeze	O
drying	O
to	O
obtain	O
polymer	O
-	O
coated	O
oleanolic	B
acid	I
liposome	O
powder	O
,	O
wherein	O
before	O
use	O
,	O
hydration	O
reconstruction	O
is	O
carried	O
out	O
according	O
to	O
requirements	O
.	O

The	O
polymer	O
-	O
coated	O
oleanolic	B
acid	I
liposome	O
utilizes	O
long	O
-	O
circulating	O
characteristics	O
,	O
biological	O
adhesion	O
and	O
penetration	O
promotion	O
of	O
the	O
coating	O
material	O
,	O
improves	O
drug	O
encapsulation	O
efficiency	O
and	O
liposome	O
stability	O
,	O
prolongs	O
in	O
-	O
vivo	O
residence	O
and	O
cycle	O
time	O
of	O
particulates	O
,	O
promotes	O
intercellular	O
transmembrane	O
transport	O
of	O
the	O
particulates	O
,	O
improves	O
oral	O
bioavailability	O
of	O
oleanolic	B
acid	I
,	O
is	O
processed	O
into	O
solid	O
powder	O
,	O
and	O
is	O
convenient	O
for	O
package	O
,	O
storage	O
,	O
transport	O
and	O
use	O
.	O

Polymer	O
-	O
coated	O
oleanolic	B
acid	I
liposome	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
solid	O
preparation	O
including	O
finasteride	B
.	O

The	O
solid	O
preparation	O
contains	O
finasteride	B
and	O
polyvinylpyrrolidone	B
K30	I
,	O
and	O
a	O
weight	O
ratio	O
of	O
finasteride	B
to	O
polyvinylpyrrolidone	B
K30	I
is	O
in	O
a	O
range	O
of	O
0.5	O
:	O
3	O
to	O
10	O
:	O
3	O
.	O

The	O
invention	O
further	O
provides	O
a	O
composite	O
preparation	O
including	O
the	O
solid	O
preparation	O
and	O
a	O
preparation	O
method	O
for	O
the	O
solid	O
preparation	O
.	O

Solid	O
preparation	O
including	O
finasteride	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
applications	O
of	O
Chukrasone	B
A	I
in	O
medicines	O
used	O
for	O
treating	O
dengue	O
virus	O
infection	O
.	O

Chukrasone	B
A	I
is	O
capable	O
of	O
inhibiting	O
dengue	O
virus	O
multiplication	O
effectively	O
,	O
and	O
possesses	O
little	O
toxicity	O
on	O
cells	O
,	O
so	O
that	O
Chukrasone	B
A	I
can	O
be	O
further	O
used	O
for	O
preparation	O
of	O
medicines	O
used	O
for	O
treating	O
diseases	O
caused	O
by	O
dengue	O
virus	O
infection	O
,	O
and	O
the	O
application	O
prospect	O
is	O
promising	O
.	O

The	O
applications	O
of	O
Chukrasone	B
A	I
in	O
preparation	O
of	O
medicines	O
used	O
for	O
treating	O
or	O
preventing	O
dengue	O
virus	O
infection	O
are	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

The	O
molecular	O
skeleton	O
is	O
novel	O
,	O
so	O
that	O
inhibitory	O
activity	O
on	O
dengue	O
virus	O
is	O
surprisingly	O
strong	O
,	O
and	O
it	O
is	O
impossible	O
to	O
estimate	O
the	O
inhibitory	O
activity	O
according	O
to	O
the	O
activities	O
of	O
other	O
compounds	O
.	O

Chukrasone	B
A	I
possesses	O
outstanding	O
substantiality	O
,	O
and	O
the	O
applications	O
of	O
Chukrasone	B
A	I
in	O
treatment	O
and	O
prevention	O
of	O
dengue	O
virus	O
infection	O
possess	O
significant	O
advantages	O
.	O

Applications	O
of	O
Chukrasone	B
A	I
in	O
medicines	O
used	O
for	O
treating	O
dengue	O
virus	O
infection	O

The	O
invention	O
discloses	O
applications	O
of	O
Chukrasone	B
A	I
in	O
preparation	O
of	O
medicines	O
used	O
for	O
preventing	O
or	O
treating	O
pancreatic	O
fibrosis	O
.	O

The	O
applications	O
of	O
Chukrasone	B
A	I
in	O
preparation	O
of	O
medicines	O
used	O
for	O
preventing	O
or	O
treating	O
pancreatic	O
fibrosis	O
are	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

Due	O
to	O
the	O
fact	O
that	O
skeleton	O
type	O
belongs	O
to	O
completely	O
novel	O
skeleton	O
type	O
,	O
and	O
Chukrasone	B
A	I
has	O
an	O
unexpectedly	O
high	O
inhibitory	O
activity	O
on	O
pancreatic	O
fibrosis	O
,	O
probability	O
of	O
other	O
compounds	O
giving	O
any	O
revelation	O
for	O
Chukrasone	B
A	I
does	O
not	O
exist	O
,	O
outstanding	O
substantive	O
features	O
are	O
provided	O
,	O
meanwhile	O
,	O
prominent	O
improvement	O
is	O
evidently	O
possessed	O
in	O
preventing	O
pancreatic	O
fibrosis	O
.	O

Applications	O
of	O
Chukrasone	B
A	I
in	O
medicines	O
used	O
for	O
preventing	O
pancreatic	O
fibrosis	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	B
B	I
in	O
preparing	O
an	O
anti	O
-	O
hypoxia	O
drug	O
.	O

An	O
anti	O
-	O
hypoxia	O
action	O
of	O
Houttuynoid	B
B	I
is	O
observed	O
through	O
an	O
integral	O
and	O
cellular	O
level	O
hypoxia	O
model	O
,	O
and	O
a	O
result	O
indicates	O
that	O
:	O
Houttuynoid	B
B	I
can	O
significantly	O
increase	O
the	O
survival	O
rate	O
and	O
the	O
survival	O
time	O
of	O
asphyxia	O
hypoxia	O
and	O
acute	O
decompression	O
hypoxia	O
mice	O
,	O
relieves	O
myocardial	O
damage	O
of	O
drug	O
specific	O
hypoxia	O
mice	O
,	O
and	O
also	O
has	O
a	O
significant	O
protective	O
effect	O
on	O
hypoxia	O
damage	O
to	O
myocardial	O
cells	O
and	O
nerve	O
cells	O
of	O
suckling	O
mice	O
cultured	O
in	O
vitro	O
.	O

The	O
invention	O
also	O
provides	O
the	O
application	O
of	O
the	O
Houttuynoid	B
B	I
in	O
preparing	O
the	O
anti	O
-	O
hypoxia	O
drug	O
.	O

Application	O
of	O
Houttuynoid	B
B	I
in	O
anti	O
-	O
hypoxia	O
drug	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	O
C	O
in	O
preparing	O
an	O
anti	O
-	O
hypoxia	O
drug	O
.	O

An	O
anti	O
-	O
hypoxia	O
action	O
of	O
Houttuynoid	B
C	I
is	O
observed	O
through	O
an	O
integral	O
and	O
cellular	O
level	O
hypoxia	O
model	O
,	O
and	O
a	O
result	O
indicates	O
that	O
:	O
Houttuynoid	B
C	I
can	O
significantly	O
increase	O
the	O
survival	O
rate	O
and	O
the	O
survival	O
time	O
of	O
asphyxia	O
hypoxia	O
and	O
acute	O
decompression	O
hypoxia	O
mice	O
,	O
relieves	O
myocardial	O
damage	O
of	O
drug	O
specific	O
hypoxia	O
mice	O
,	O
and	O
also	O
has	O
a	O
significant	O
protective	O
effect	O
on	O
hypoxia	O
damage	O
to	O
myocardial	O
cells	O
and	O
nerve	O
cells	O
of	O
suckling	O
mice	O
cultured	O
in	O
vitro	O
.	O

The	O
invention	O
also	O
provides	O
the	O
application	O
of	O
Houttuynoid	B
C	I
in	O
preparing	O
the	O
anti	O
-	O
hypoxia	O
drug	O
.	O

Application	O
of	O
Houttuynoid	B
C	I
in	O
anti	O
-	O
hypoxia	O
drug	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
treating	O
a	O
cough	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
drug	O
has	O
a	O
low	O
cost	O
and	O
good	O
cough	O
treatment	O
effects	O
.	O

The	O
drug	O
is	O
obtained	O
by	O
mixing	O
a	O
towel	O
gourd	O
stem	O
juice	O
,	O
rock	O
sugar	B
and	O
water	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
1	O
,	O
in	O
spring	O
,	O
planting	O
towel	O
gourd	O
and	O
removing	O
buds	O
after	O
the	O
towel	O
gourd	O
grows	O
,	O
and	O
on	O
July	O
to	O
August	O
,	O
cutting	O
off	O
the	O
towel	O
gourd	O
at	O
a	O
position	O
6	O
-	O
8	O
cm	O
away	O
from	O
the	O
towel	O
gourd	O
root	O
,	O
and	O
collecting	O
a	O
towel	O
gourd	O
juice	O
flowing	O
from	O
the	O
cut	O
position	O
by	O
a	O
water	O
cup	O
,	O
and	O
2	O
,	O
adding	O
rock	O
sugar	O
and	O
water	O
into	O
the	O
towel	O
gourd	O
juice	O
,	O
carrying	O
full	O
mixing	O
,	O
carrying	O
out	O
standing	O
for	O
1	O
-	O
5h	O
,	O
and	O
carrying	O
out	O
refrigeration	O
in	O
a	O
refrigerator	O
at	O
a	O
temperature	O
of	O
2	O
-	O
5	O
DEG	O
C.	O
Drug	O
for	O
treating	O
cough	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
especially	O
relates	O
to	O
a	O
composition	O
used	O
for	O
treating	O
cervical	O
erosion	O
,	O
which	O
belongs	O
to	O
the	O
field	O
of	O
gynaecological	O
medical	O
treatment	O
.	O

The	O
composition	O
comprises	O
,	O
by	O
mass	O
,	O
0.3	O
to	O
0.6	O
part	O
of	O
nano	O
-	O
silver	B
,	O
3	O
to	O
7	O
parts	O
of	O
oxymatrine	B
,	O
3	O
to	O
7	O
parts	O
of	O
locust	O
essential	O
oil	O
and	O
0.5	O
to	O
1.5	O
parts	O
of	O
placentin	O
.	O

A	O
gel	O
,	O
a	O
spraying	O
agent	O
,	O
a	O
paraffin	O
suppository	O
or	O
the	O
like	O
can	O
be	O
prepared	O
from	O
the	O
composition	O
used	O
for	O
treating	O
cervical	O
erosion	O
as	O
needed	O
;	O
and	O
the	O
composition	O
can	O
effectively	O
treat	O
cervical	O
erosion	O
and	O
exerts	O
a	O
good	O
therapeutic	O
effect	O
on	O
severe	O
cervical	O
erosion	O
.	O

Composition	O
used	O
for	O
treating	O
cervical	O
erosion	O
and	O
application	O
thereof	O

Provided	O
is	O
the	O
thioamide	B
compound	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
.	O

In	O
general	O
formula	O
(	O
1	O
)	O
:	O
R1	O
represents	O
-OR11	B
or	O
-NR12R13	B
;	O
R2	O
and	O
R3	O
each	O
independently	O
represent	O
a	O
protecting	O
group	O
of	O
an	O
amide	B
group	O
or	O
a	O
hydrogen	B
atom	O
;	O
R11	O
represents	O
a	O
protecting	O
group	O
of	O
a	O
hydroxide	B
group	O
or	O
a	O
hydrogen	B
atom	O
;	O
and	O
R12	O
and	O
R13	O
each	O
independently	O
represent	O
a	O
protecting	O
group	O
of	O
an	O
amino	B
group	O
or	O
a	O
hydrogen	B
atom	O
(	O
moreover	O
,	O
R12	O
and	O
R13	O
may	O
together	O
form	O
a	O
ring	O
-	O
structured	O
protecting	O
group	O
)	O
.	O

Thioamide	B
compound	O
,	O
method	O
for	O
producing	O
thioamide	B
compound	O
,	O
method	O
for	O
producing	O
[	B
(	I
4r,6r	I
)	I
-6-aminoethyl-1,3-dioxane-4-yl	I
]	I
acetate	I
derivative	O
,	O
and	O
method	O
for	O
producing	O
atorvastatin	B

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
special	O
pharmaceutical	O
preparations	O
for	O
animals	O
,	O
and	O
relates	O
to	O
an	O
in	O
-	O
situ	O
gel	O
preparation	O
for	O
enrofloxacin	B
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
5.0	O
-	O
20.0	O
parts	O
of	O
enrofloxacin	B
,	O
14.5	O
-	O
32.5	O
parts	O
of	O
P407	O
,	O
0.5	O
-	O
10.5	O
parts	O
of	O
P188	O
,	O
25.0	O
-	O
90.0	O
parts	O
of	O
water	O
,	O
0.01	O
-	O
10.0	O
parts	O
of	O
a	O
high	O
molecular	O
retardant	O
,	O
0.01	O
-	O
3.0	O
parts	O
of	O
a	O
preservative	O
and	O
appropriate	O
amount	O
of	O
a	O
pH	O
adjustor	O
.	O

The	O
preparation	O
provided	O
by	O
the	O
invention	O
is	O
a	O
freely	O
flowing	O
liquid	O
at	O
room	O
temperature	O
,	O
and	O
forms	O
a	O
semi	O
-	O
solid	O
gel	O
through	O
dosage	O
by	O
intramuscular	O
injection	O
or	O
subcutaneous	O
injection	O
,	O
so	O
that	O
the	O
preparation	O
is	O
just	O
delivered	O
once	O
in	O
a	O
course	O
of	O
treatment	O
.	O

The	O
preparation	O
has	O
the	O
advantages	O
of	O
stable	O
property	O
,	O
long	O
lasting	O
time	O
for	O
delivery	O
,	O
exact	O
curative	O
effect	O
,	O
strong	O
animal	O
adaptability	O
,	O
no	O
toxic	O
and	O
side	O
effects	O
and	O
adverse	O
reaction	O
and	O
the	O
like	O
,	O
and	O
is	O
simple	O
to	O
prepare	O
and	O
convenient	O
to	O
delivery	O
.	O

The	O
preparation	O
provided	O
by	O
the	O
invention	O
has	O
broad	O
-	O
spectrum	O
antibacterial	O
effect	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
medicine	O
for	O
preventing	O
and	O
treating	O
diseases	O
of	O
animals	O
such	O
as	O
pigs	O
,	O
sheep	O
,	O
dogs	O
,	O
cats	O
and	O
cattle	O
.	O

In	O
-	O
situ	O
gel	O
for	O
enrofloxacin	B
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
sodium	B
azulene	I
sulfonate	I
sustained	O
-	O
release	O
preparation	O
.	O

The	O
sodium	B
azulene	I
sulfonate	I
sustained	O
-	O
release	O
preparation	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
and	O
auxiliary	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
0.1	O
-	O
20	O
parts	O
of	O
sodium	B
azulene	I
sulfonate	I
,	O
35	O
-	O
235	O
parts	O
of	O
starch	O
,	O
10	O
-	O
40	O
parts	O
of	O
dextrin	O
,	O
80	O
-	O
200	O
parts	O
of	O
sodium	B
bicarbonate	I
,	O
0	O
-	O
1	O
part	O
of	O
magnesium	B
stearate	I
,	O
0.2	O
-	O
0.8	O
part	O
of	O
menthol	B
,	O
2	O
-	O
50	O
parts	O
of	O
framework	O
material	O
or	O
/	O
and	O
6	O
-	O
90	O
parts	O
of	O
coating	O
agent	O
.	O

According	O
to	O
the	O
sodium	B
azulene	I
sulfonate	I
sustained	O
-	O
release	O
preparation	O
,	O
through	O
selecting	O
and	O
using	O
sustained	O
-	O
release	O
auxiliary	O
materials	O
,	O
the	O
sodium	B
azulene	I
sulfonate	I
sustained	O
-	O
release	O
preparation	O
which	O
is	O
uniformly	O
released	O
is	O
finally	O
prepared	O
,	O
the	O
release	O
degree	O
of	O
sodium	B
azulene	I
sulfonate	I
is	O
increased	O
,	O
the	O
stability	O
of	O
a	O
drug	O
is	O
improved	O
,	O
and	O
the	O
disadvantage	O
that	O
the	O
curative	O
effect	O
of	O
the	O
drug	O
is	O
lowered	O
due	O
to	O
the	O
fluctuation	O
of	O
plasma	O
drug	O
concentration	O
is	O
overcome	O
,	O
the	O
plasma	O
drug	O
concentration	O
keeps	O
stable	O
for	O
a	O
long	O
time	O
,	O
the	O
compliance	O
of	O
a	O
patient	O
is	O
improved	O
,	O
and	O
the	O
clinical	O
treatment	O
effect	O
is	O
guaranteed	O
.	O

Sodium	B
azulene	I
sulfonate	I
sustained	O
-	O
release	O
preparation	O

The	O
invention	O
provides	O
an	O
application	O
of	O
10-arylmethylideneanthrone	B
compounds	O
to	O
preparing	O
antitumor	O
drugs	O
.	O

The	O
10-arylmethylideneanthrone	B
compounds	O
are	O
preferably	O
selected	O
from	O
compounds	O
represented	O
by	O
formula	O
(	O
I-3	O
)	O
,	O
formula	O
(	O
I-4	O
)	O
,	O
formula	O
(	O
I-5	O
)	O
,	O
formula	O
(	O
I-7	O
)	O
or	O
formula	O
(	O
I-8	O
)	O
,	O
and	O
most	O
preferably	O
selected	O
from	O
compounds	O
represented	O
by	O
formula	O
(	O
I-3	O
)	O
or	O
formula	O
(	O
I-7	O
)	O
.	O

The	O
invention	O
provides	O
the	O
application	O
of	O
the	O
10-arylmethylideneanthrone	B
compounds	O
to	O
preparing	O
the	O
antitumor	O
drugs	O
,	O
especially	O
the	O
compounds	O
represented	O
by	O
formula	O
(	O
I-3	O
)	O
or	O
formula	O
(	O
I-7	O
)	O
have	O
substantial	O
effect	O
on	O
various	O
different	O
tumors	O
,	O
and	O
a	O
foundation	O
is	O
provided	O
for	O
screening	O
of	O
new	O
drugs	O
.	O

Application	O
of	O
10-arylmethylideneanthrone	B
compounds	O
to	O
preparing	O
antitumor	O
drugs	O

The	O
invention	O
discloses	O
a	O
drug	O
for	O
curing	O
red	O
and	O
white	O
dysentery	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
drug	O
is	O
prepared	O
from	O
purslane	O
and	O
euphorbia	O
humifusae	O
according	O
to	O
a	O
certain	O
weight	O
proportion	O
.	O

The	O
drug	O
has	O
the	O
functions	O
of	O
clearing	O
away	O
heat	O
and	O
toxic	O
materials	O
,	O
promoting	O
blood	O
circulation	O
to	O
arrest	O
pain	O
,	O
diminishing	O
inflammation	O
and	O
sterilizing	O
,	O
and	O
has	O
the	O
advantages	O
of	O
rapid	O
and	O
good	O
curative	O
effect	O
on	O
curing	O
red	O
and	O
white	O
dysentery	O
and	O
high	O
cure	O
rate	O
.	O

Drug	O
for	O
curing	O
red	O
and	O
white	O
dysentery	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
tamoxifen	B
citrate	I
enteric	O
coated	O
particles	O
which	O
are	O
prepared	O
by	O
the	O
following	O
steps	O
:	O
firstly	O
,	O
preparing	O
tamoxifen	B
citrate	I
into	O
inclusion	O
compounds	O
;	O
and	O
then	O
,	O
preparing	O
the	O
enteric	O
coated	O
particles	O
.	O

Tamoxifen	B
citrate	I
enteric	O
coated	O
particles	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
of	O
paclitaxel	B
and	O
ranitidine	B
hydrochloride	I
,	O
and	O
especially	O
relates	O
to	O
an	O
application	O
product	O
of	O
the	O
pharmaceutical	O
composition	O
,	O
wherein	O
the	O
application	O
product	O
comprises	O
paclitaxel	B
injection	O
and	O
an	O
injection	O
containing	O
ranitidine	B
hydrochloride	I
.	O

Administration	O
comprises	O
following	O
steps	O
,	O
the	O
injection	O
containing	O
ranitidine	B
hydrochloride	I
is	O
applied	O
firstly	O
by	O
intravenous	O
injection	O
,	O
the	O
paclitaxel	B
injection	O
is	O
dissolved	O
and	O
diluted	O
by	O
normal	O
saline	O
or	O
5	O
%	O
glucose	B
and	O
sodium	B
chloride	I
solution	O
,	O
and	O
then	O
the	O
diluted	O
paclitaxel	B
injection	O
is	O
applied	O
by	O
intravenous	O
drop	O
infusion	O
.	O

Pharmaceutical	O
composition	O
of	O
paclitaxel	B
and	O
ranitidine	B
hydrochloride	I

The	O
invention	O
discloses	O
application	O
of	O
Sarcaboside	B
A	I
to	O
preparation	O
of	O
medicaments	O
for	O
treatment	O
of	O
bladder	O
cancer	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
novel	O
application	O
of	O
medicaments	O
.	O

Through	O
in	O
vitro	O
MTT	O
antineoplastic	O
activity	O
evaluation	O
,	O
it	O
is	O
discovered	O
that	O
Sarcaboside	B
A	I
has	O
substantial	O
inhibition	O
effect	O
on	O
growth	O
of	O
a	O
human	O
bladder	O
cancer	O
cell	O
strain	O
T-24	O
.	O

Accordingly	O
,	O
the	O
Sarcaboside	B
A	I
can	O
be	O
applied	O
to	O
preparation	O
of	O
medicaments	O
for	O
resisting	O
bladder	O
cancer	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

The	O
application	O
of	O
Sarcaboside	B
A	I
to	O
preparation	O
of	O
medicaments	O
for	O
treatment	O
of	O
bladder	O
cancer	O
involved	O
in	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

The	O
Sarcaboside	B
A	I
has	O
a	O
novel	O
skeleton	O
type	O
and	O
unimaginably	O
strong	O
activity	O
in	O
inhibition	O
of	O
bladder	O
cancer	O
cells	O
.	O

Application	O
of	O
Sarcaboside	B
A	I
to	O
medicament	O
for	O
treatment	O
of	O
bladder	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
an	O
application	O
of	O
Neonectrolide	B
A	I
in	O
anti	O
-	O
inflammation	O
drug	O
preparation	O
,	O
wherein	O
the	O
inflammation	O
is	O
aseptic	O
inflammation	O
,	O
and	O
the	O
Neonectrolide	B
A	I
has	O
a	O
good	O
anti	O
-	O
inflammation	O
and	O
inflammation	O
elimination	O
effect	O
.	O

According	O
to	O
the	O
present	O
invention	O
,	O
the	O
use	O
of	O
the	O
Neonectrolide	B
A	I
in	O
anti	O
-	O
inflammation	O
drug	O
preparation	O
is	O
firstly	O
disclosed	O
;	O
and	O
a	O
skeleton	O
type	O
of	O
the	O
Neonectrolide	B
A	I
belongs	O
to	O
a	O
completely	O
new	O
skeleton	O
type	O
,	O
inflammation	O
inhibition	O
activity	O
of	O
the	O
Neonectrolide	B
A	I
is	O
strong	O
,	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelations	O
for	O
the	O
Neonectrolide	B
A	I
can	O
not	O
exist	O
,	O
prominent	O
substantive	O
characteristics	O
are	O
provided	O
,	O
and	O
significant	O
progress	O
for	O
anti	O
-	O
inflammation	O
is	O
provided	O
.	O

Application	O
of	O
compound	O
in	O
anti	O
-	O
aseptic	O
inflammation	O
drug	O
preparation	O

The	O
invention	O
discloses	O
a	O
mercury	B
expelling	O
agent	O
.	O

The	O
mercury	O
expelling	O
agent	O
comprises	O
effective	O
components	O
of	O
pearl	O
powder	O
and	O
sea	O
-	O
buckthorn	O
juice	O
,	O
wherein	O
the	O
pearl	O
powder	O
is	O
prepared	O
by	O
physical	O
methods	O
such	O
as	O
ball	O
milling	O
or	O
air	O
jet	O
pulverization	O
,	O
and	O
the	O
mercury	B
expelling	O
agent	O
also	O
comprises	O
pectin	O
,	O
carotene	B
,	O
reduced	O
glutathione	B
and	O
glucan	B
.	O

The	O
mercury	B
expelling	O
agent	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
20%-40	O
%	O
of	O
pearl	O
powder	O
,	O
1%-5	O
%	O
of	O
sea	O
-	O
buckthorn	O
juice	O
,	O
2%-7	O
%	O
of	O
milk	O
powder	O
,	O
1%-2	O
%	O
of	O
pectin	O
,	O
3%-7	O
%	O
of	O
reduced	O
glutathione	B
,	O
0.1%-1	O
%	O
of	O
carotene	B
,	O
0.2%-0.8	O
%	O
of	O
glucan	B
,	O
and	O
the	O
balance	O
of	O
brown	O
sugar	B
.	O

If	O
taken	O
by	O
people	O
getting	O
mercury	O
poisoning	O
,	O
the	O
mercury	O
expelling	O
agent	O
can	O
relieve	O
toxicity	O
of	O
the	O
mercury	O
or	O
even	O
realize	O
detoxification	O
.	O

Mercury	B
expelling	O
agent	O

The	O
invention	O
discloses	O
a	O
paste	O
for	O
relieving	O
cough	O
.	O

The	O
paste	O
comprises	O
the	O
following	O
components	O
:	O
128mg-384	O
mg	O
of	O
liquorice	O
tablets	O
,	O
62.5mg-250	O
mg	O
of	O
promethazine	B
hydrochloride	I
tablets	O
,	O
0.05ml-0.1ml	O
of	O
Huoxiang	O
Zhengqi	O
liquid	O
,	O
0.5g-1.5	O
g	O
of	O
bombyx	O
batryticatus	O
and	O
0.3g-0.8	O
g	O
of	O
white	O
alum	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
mixing	O
and	O
grinding	O
the	O
above	O
components	O
to	O
obtain	O
powder	O
;	O
(	O
2	O
)	O
dissolving	O
the	O
white	O
alum	O
into	O
warm	O
water	O
of	O
20	O
-	O
40	O
DEG	O
C	O
,	O
then	O
mixing	O
components	O
which	O
are	O
well	O
processed	O
in	O
step	O
(	O
1	O
)	O
,	O
adding	O
Huoxiang	O
Zhengqi	O
liquid	O
,	O
vaseline	O
and	O
white	O
alum	O
water	O
to	O
mix	O
,	O
wherein	O
the	O
vaseline	O
and	O
white	O
alum	O
water	O
can	O
be	O
added	O
in	O
an	O
amount	O
which	O
can	O
ensure	O
that	O
the	O
raw	O
materials	O
are	O
clustered	O
;	O
and	O
(	O
3	O
)	O
putting	O
the	O
cream	O
well	O
processed	O
in	O
step	O
(	O
2	O
)	O
into	O
a	O
medical	O
paste	O
,	O
and	O
placing	O
in	O
a	O
medicine	O
bag	O
to	O
seal	O
and	O
store	O
.	O

The	O
paste	O
for	O
relieving	O
cough	O
has	O
the	O
advantages	O
of	O
good	O
curative	O
effect	O
on	O
pharyngitis	O
,	O
pneumonia	O
,	O
and	O
bronchitis	O
complications	O
while	O
treating	O
cough	O
,	O
wide	O
applicable	O
persons	O
,	O
simple	O
preparation	O
method	O
,	O
low	O
cost	O
and	O
good	O
application	O
prospect	O
,	O
and	O
patients	O
can	O
be	O
more	O
easily	O
coordinated	O
in	O
treatment	O
.	O

The	O
paste	O
for	O
relieving	O
cough	O
is	O
a	O
Chinese	O
and	O
western	O
medicine	O
cough	O
-	O
reliving	O
paste	O
having	O
good	O
application	O
prospect	O
.	O

Paste	O
for	O
relieving	O
cough	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
burns	O
.	O

The	O
medicine	O
is	O
made	O
of	O
the	O
following	O
materials	O
by	O
weight	O
:	O
3	O
-	O
10	O
parts	O
of	O
dandelion	O
,	O
5	O
-	O
15	O
parts	O
of	O
Polygonum	O
cuspidatum	O
,	O
3	O
-	O
5	O
parts	O
of	O
calomel	O
,	O
5	O
-	O
15	O
parts	O
of	O
dried	O
alum	O
,	O
5	O
-	O
10	O
parts	O
of	O
Bletilla	O
striata	O
,	O
1	O
-	O
5	O
parts	O
of	O
myrrh	O
,	O
20	O
-	O
30	O
parts	O
of	O
Coptis	O
chinensis	O
,	O
5	O
-	O
10	O
parts	O
of	O
elephant	O
leather	O
,	O
0.5	O
-	O
1	O
part	O
of	O
dragon	O
's	O
blood	O
,	O
5	O
-	O
10	O
parts	O
of	O
borneol	B
,	O
15	O
-	O
30	O
parts	O
of	O
dog	O
bones	O
,	O
20	O
-	O
30	O
parts	O
of	O
garden	O
burnet	O
,	O
2	O
-	O
5	O
parts	O
of	O
Siberian	O
elm	O
bark	O
and	O
3	O
-	O
8	O
parts	O
of	O
aloe	O
.	O

Medicine	O
for	O
treating	O
burns	O

The	O
invention	O
discloses	O
a	O
monobutyltin	B
trichloride	I
substituted	I
salicylidenedimine	I
Schiff	I
base	I
complex	O
which	O
is	O
a	O
complex	O
with	O
the	O
following	O
structural	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Bu	B
represents	O
n	B
-	I
butyl	I
,	O
R1	O
is	O
-H	B
,	O
-Cl	B
or	O
-Br	B
,	O
R2	O
is	O
-H	B
or	O
-N	B
(	I
CH2CH3	I
)	I
2	I
,	O
R3	O
is	O
-H	B
,	O
-Cl	B
or	O
-Br	B
,	O
and	O
R4	O
is	O
-H	B
,	O
-Cl	B
,	O
-NO2	B
or	O
-Me	B
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
monobutyltin	B
trichloride	I
substituted	I
salicylidenedimine	I
Schiff	I
base	I
complex	O
,	O
and	O
applications	O
of	O
the	O
monobutyltin	B
trichloride	I
substituted	I
salicylidenedimine	I
Schiff	I
base	I
complex	O
in	O
drugs	O
for	O
treating	O
tumor	O
.	O

Monobutyltin	B
trichloride	I
substituted	I
salicylidenedimine	I
Schiff	I
base	I
complex	O
as	O
well	O
as	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
multifunctional	O
cationic	O
polymer	O
gene	O
vector	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

A	O
multifunctional	O
cationic	O
polymer	O
is	O
synthesized	O
by	O
oxidizing	O
low	O
molecular	O
weight	O
chitosan	O
used	O
as	O
a	O
framework	O
material	O
with	O
potassium	B
periodate	I
and	O
subjecting	O
the	O
oxidized	O
low	O
molecular	O
weight	O
chitosan	O
and	O
polyethyleneimine	B
coupled	O
with	O
a	O
sartan	O
-	O
class	O
drug	O
to	O
reduction	O
and	O
ammonification	O
.	O

To	O
overcome	O
technical	O
problems	O
,	O
the	O
invention	O
provides	O
the	O
novel	O
cationic	O
polymer	O
with	O
targeting	O
performance	O
of	O
the	O
acceptor	O
of	O
the	O
tumor	O
cell	O
AT1	O
,	O
multiple	O
proton	O
buffering	O
capability	O
and	O
adjuvant	O
therapy	O
effects	O
on	O
tumors	O
and	O
provides	O
a	O
preparation	O
method	O
with	O
the	O
advantages	O
of	O
mild	O
conditions	O
,	O
low	O
cost	O
,	O
applicability	O
and	O
reliability	O
for	O
the	O
cationic	O
polymer	O
.	O

A	O
compound	O
formed	O
by	O
the	O
cationic	O
polymer	O
provided	O
by	O
the	O
invention	O
and	O
plasmid	O
DNA	O
has	O
the	O
advantages	O
of	O
low	O
cytotoxicity	O
,	O
good	O
targeting	O
performance	O
,	O
high	O
transfection	O
efficiency	O
,	O
substantial	O
in	O
-	O
vitro	O
antineoplastic	O
effects	O
,	O
etc	O
.	O
;	O
the	O
polymer	O
can	O
be	O
used	O
for	O
preparation	O
of	O
a	O
non	O
-	O
virus	O
gene	O
transfer	O
system	O
capable	O
of	O
simultaneously	O
transferring	O
a	O
gene	O
drug	O
and	O
a	O
chemical	O
drug	O
for	O
cooperated	O
treatment	O
of	O
a	O
tumor	O
.	O

Multifunctional	O
cationic	O
polymer	O
gene	O
vector	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

This	O
application	O
discloses	O
novel	O
phosphoramidate	B
and	O
phosphonoamidate	B
prodrugs	O
of	O
nucleosides	O
,	O
nucleotides	O
,	O
C	O
-	O
nucleosides	O
,	O
C	O
-	O
nucleotides	O
,	O
phosphonates	B
,	O
and	O
other	O
alcohol	B
-	O
containing	O
drugs	O
;	O
use	O
of	O
these	O
prodrugs	O
for	O
treatment	O
of	O
infectious	O
diseases	O
and	O
cancers	O
,	O
in	O
particular	O
,	O
liver	O
infections	O
and	O
cancers	O
;	O
and	O
methods	O
of	O
preparing	O
these	O
novel	O
phosphoramidate	O
and	O
phosphonoamidate	O
prodrugs	O
.	O

O-	B
(	I
replaced	I
benzyl	I
)	I
phosphoramidate	I
and	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
2alpha	B
,	I
3beta	I
-	I
dihydroxyl	I
oleanane-13	I
(	I
18	I
)	I
-ene-28-acid	I
and	O
an	O
application	O
of	O
2alpha	B
,	I
3beta	I
-	I
dihydroxyl	I
oleanane-13	I
(	I
18	I
)	I
-ene-28-acid	I
in	O
preparing	O
an	O
antibacterial	O
agent	O
.	O

A	O
potent	O
antibacterial	O
agent	O
(	O
medicine	O
)	O
is	O
extracted	O
and	O
separated	O
from	O
Rosaceae	O
Rose	O
fructus	O
rosae	O
laevigatae	O
widely	O
distributed	O
in	O
China	O
.	O

The	O
acid	O
is	O
abundant	O
in	O
plant	O
source	O
and	O
convenient	O
to	O
extract	O
.	O

The	O
plant	O
is	O
not	O
damaged	O
but	O
utilized	O
for	O
a	O
long	O
time	O
when	O
plant	O
fruits	O
are	O
extracted	O
.	O

The	O
acid	O
provided	O
by	O
the	O
invention	O
is	O
environmentally	O
-	O
friendly	O
and	O
has	O
better	O
economic	O
benefit	O
.	O

The	O
monomer	O
compound	O
product	O
is	O
stable	O
and	O
easy	O
to	O
store	O
.	O

The	O
acid	O
is	O
wide	O
in	O
bacteriostatic	O
activity	O
spectrum	O
and	O
high	O
in	O
bacteriostatic	O
activity	O
,	O
can	O
be	O
further	O
developed	O
as	O
an	O
effective	O
and	O
safe	O
antibacterial	O
agent	O
of	O
foods	O
such	O
as	O
fruits	O
and	O
vegetables	O
and	O
novel	O
anti	O
-	O
infection	O
medicines	O
,	O
and	O
has	O
good	O
market	O
prospect	O
.	O

Preparation	O
method	O
of	O
2alpha	B
,	I
3beta	I
-	I
dihydroxyl	I
oleanane-13	I
(	I
18	I
)	I
-ene-28-acid	I
and	O
application	O
of	O
2alpha	B
,	I
3beta	I
-	I
dihydroxyl	I
oleanane-13	I
(	I
18	I
)	I
-ene-28-acid	I
in	O
preparing	O
antibacterial	O
agent	O

The	O
invention	O
discloses	O
application	O
of	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
breast	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
medicines	O
.	O

The	O
in	O
-	O
vitro	O
MTT	B
(	O
3	B
-	I
4	I
,	I
5-Dimethylthiazol-2-yl	I
)	I
-2	I
,	I
5-diphenyltetrazolium	I
bromide	I
)	O
antitumor	O
evaluation	O
shows	O
that	O
Chukrasone	B
B	I
has	O
remarkable	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
breast	O
cancer	O
cell	O
lines	O
4T1	O
,	O
MCF-7	O
,	O
MDA	O
-	O
MB-231	O
and	O
MCF-7B	O
,	O
so	O
that	O
Chukrasone	B
B	I
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
breast	O
cancer	O
.	O

The	O
application	O
of	O
Chukrasone	B
B	I
in	O
the	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
breast	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
framework	O
type	O
of	O
Chukrasone	B
B	I
is	O
brand	O
new	O
;	O
Chukrasone	B
B	I
brings	O
unexpected	O
inhibition	O
activity	O
for	O
breast	O
cancer	O
cells	O
.	O

Application	O
of	O
Chukrasone	B
B	I
in	O
medicine	O
for	O
treating	O
breast	O
cancer	O

The	O
invention	O
discloses	O
application	O
of	O
Chukrasone	B
B	I
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
human	O
colorectal	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
medicines	O
.	O

The	O
in	O
-	O
vitro	O
MTT	O
(	O
3	B
-	I
4	I
,	I
5-Dimethylthiazol-2-yl	I
)	I
-2	I
,	I
5-diphenyltetrazolium	I
bromide	I
)	O
antitumor	O
activity	O
evaluation	O
shows	O
that	O
Chukrasone	B
B	I
has	O
remarkable	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
colorectal	O
cancer	O
cell	O
lines	O
LOVE	O
1	O
,	O
LoVo	O
,	O
SW620	O
and	O
SW480	O
,	O
so	O
that	O
Chukrasone	B
B	I
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
colorectal	O
cancer	O
.	O

The	O
application	O
of	O
Chukrasone	B
B	I
in	O
the	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
colorectal	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
framework	O
type	O
of	O
Chukrasone	B
B	I
is	O
brand	O
new	O
;	O
Chukrasone	B
B	I
brings	O
unexpected	O
inhibition	O
activity	O
for	O
human	O
colorectal	O
cancer	O
cells	O
.	O

Application	O
of	O
Chukrasone	B
B	I
in	O
medicine	O
for	O
treating	O
colorectal	O
cancer	O

The	O
invention	O
provides	O
a	O
novel	O
use	O
of	O
Aphanamgrandiol	B
A	I
in	O
medical	O
science	O
,	O
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
Aphanamgrandiol	B
A	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
acute	O
gout	O
.	O

Experimental	O
research	O
results	O
show	O
that	O
the	O
Aphanamgrandiol	B
A	I
has	O
the	O
protective	O
effect	O
on	O
an	O
acute	O
gout	O
model	O
of	O
urate	O
-	O
caused	O
injury	O
of	O
human	O
vascular	O
endothelial	O
cells	O
and	O
inhibits	O
expression	O
of	O
ICAM-1	O
(	O
Intercellular	O
Adhesion	O
Molecule	O
1	O
)	O
,	O
so	O
that	O
the	O
Aphanamgrandiol	B
A	I
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
treating	O
acute	O
gouty	O
inflammation	O
.	O

The	O
application	O
of	O
the	O
Aphanamgrandiol	B
A	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
acute	O
gout	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
framework	O
type	O
of	O
the	O
Aphanamgrandiol	B
A	I
is	O
a	O
novel	O
framework	O
type	O
,	O
and	O
the	O
activity	O
of	O
the	O
Aphanamgrandiol	B
A	I
to	O
prevent	O
and	O
treat	O
acute	O
gout	O
is	O
unexpectedly	O
strong	O
,	O
the	O
probability	O
of	O
giving	O
any	O
indication	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

The	O
Aphanamgrandiol	B
A	I
has	O
remarkable	O
substantive	O
characteristics	O
and	O
meanwhile	O
has	O
a	O
remarkable	O
progress	O
for	O
preventing	O
and	O
treating	O
acute	O
gout	O
.	O

Application	O
of	O
compound	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
acute	O
gout	O

The	O
invention	O
provides	O
an	O
externally	O
applied	O
medicament	O
for	O
treating	O
herpes	O
zoster	O
.	O

The	O
medicament	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
60	O
-	O
80	O
parts	O
of	O
fresh	O
artemisia	O
annual	O
leaf	O
,	O
15	O
-	O
20	O
parts	O
of	O
herba	O
orostachyos	O
,	O
10	O
-	O
20	O
parts	O
of	O
castor	O
bean	O
,	O
20	O
-	O
40	O
parts	O
of	O
fresh	O
purslane	O
,	O
20	O
-	O
40	O
parts	O
of	O
fresh	O
luffa	O
leaf	O
,	O
20	O
-	O
30	O
parts	O
of	O
calamine	O
and	O
40	O
-	O
60	O
parts	O
of	O
chimney	O
water	O
.	O

The	O
invention	O
further	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
externally	O
applied	O
medicament	O
for	O
treating	O
herpes	O
zoster	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
juicing	O
,	O
burning	O
into	O
ash	O
,	O
smashing	O
,	O
grinding	O
into	O
powder	O
,	O
stirring	O
and	O
the	O
like	O
.	O

The	O
externally	O
applied	O
medicament	O
for	O
treating	O
herpes	O
zoster	O
has	O
the	O
functions	O
of	O
rapidly	O
eliminating	O
dampness	O
and	O
heat	O
,	O
drawing	O
out	O
poison	O
,	O
detoxifying	O
,	O
resisting	O
inflammations	O
,	O
diminishing	O
swelling	O
,	O
astringing	O
for	O
promoting	O
tissue	O
regeneration	O
,	O
removing	O
scars	O
and	O
relieving	O
pain	O
,	O
can	O
take	O
effect	O
quickly	O
,	O
has	O
remarkable	O
effects	O
,	O
is	O
convenient	O
to	O
apply	O
and	O
hardly	O
causes	O
toxic	O
and	O
side	O
effects	O
.	O

Externally	O
applied	O
medicament	O
for	O
treating	O
herpes	O
zoster	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
inclusion	O
compound	O
containing	O
celecoxib	B
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
inclusion	O
compound	O
containing	O
celecoxib	B
comprises	O
celecoxib	B
and	O
an	O
inclusion	O
material	O
,	O
wherein	O
the	O
inclusion	O
material	O
is	O
preferable	O
one	O
or	O
two	O
of	O
beta	O
-	O
cyclodextrin	O
and	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
;	O
the	O
weight	O
ratio	O
of	O
the	O
inclusion	O
material	O
to	O
the	O
celecoxib	B
is	O
(	O
0.5	O
-	O
10	O
)	O
:1	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
respectively	O
dissolving	O
the	O
inclusion	O
material	O
and	O
the	O
celecoxib	B
in	O
water	O
and	O
an	O
organic	O
solvent	O
;	O
slowly	O
dropwise	O
adding	O
the	O
saturated	O
aqueous	O
solution	O
of	O
the	O
inclusion	O
material	O
into	O
the	O
organic	O
solution	O
containing	O
the	O
celecoxib	B
;	O
continuously	O
stirring	O
to	O
form	O
a	O
white	O
suspension	O
;	O
preparing	O
the	O
inclusion	O
compound	O
containing	O
the	O
celecoxib	B
by	O
adopting	O
a	O
vacuum	O
drying	O
or	O
freeze	O
-	O
drying	O
mode	O
.	O

The	O
inclusion	O
compound	O
can	O
be	O
crushed	O
to	O
be	O
prepared	O
into	O
various	O
solid	O
preparations	O
.	O

According	O
to	O
the	O
inclusion	O
compound	O
containing	O
celecoxib	B
,	O
the	O
problem	O
of	O
extremely	O
poor	O
dissolubility	O
of	O
celecoxib	B
in	O
water	O
can	O
be	O
solved	O
,	O
a	O
high	O
-	O
bioavailability	O
solid	O
preparation	O
with	O
stable	O
property	O
can	O
be	O
prepared	O
by	O
adopting	O
a	O
simple	O
and	O
practical	O
process	O
,	O
and	O
the	O
problem	O
that	O
a	O
celecoxib	B
raw	O
material	O
medicine	O
is	O
difficult	O
to	O
crush	O
can	O
be	O
solved	O
.	O

Inclusion	O
compound	O
containing	O
celecoxib	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
inositol	B
crystal	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
use	O
thereof	O
.	O

In	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
(	O
XRPD	O
)	O
drawing	O
of	O
crystal	O
form	O
C	O
,	O
characteristic	O
peaks	O
of	O
angles	O
of	O
2	O
theta	O
plus	O
/	O
minus	O
0.2	O
degrees	O
are	O
14.86	O
degrees	O
,	O
17.82	O
degrees	O
,	O
20.38	O
degrees	O
,	O
25.32	O
degrees	O
,	O
26.42	O
degrees	O
,	O
28.39	O
degrees	O
,	O
31.28	O
degrees	O
and	O
34.33	O
degrees	O
.	O

Inositol	B
crystal	O
as	O
well	O
as	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
quickly	O
preparing	O
a	O
furacilin	B
ear	O
drop	O
by	O
adopting	O
ultrasonic	O
wave	O
-	O
microwave	O
.	O

Furacilin	B
ear	O
drop	O
is	O
an	O
externally	O
applied	O
partial	O
antibacterial	O
agent	O
commonly	O
used	O
in	O
clinic	O
of	O
an	O
otolaryngological	O
department	O
in	O
domestic	O
hospitals	O
.	O

The	O
furacilin	B
ear	O
drop	O
prepared	O
through	O
the	O
conventional	O
preparation	O
method	O
has	O
the	O
following	O
defects	O
:	O
the	O
stability	O
is	O
poor	O
,	O
the	O
color	O
is	O
easy	O
to	O
deepen	O
during	O
the	O
process	O
of	O
storing	O
and	O
clinical	O
use	O
,	O
the	O
furacilin	B
ear	O
drop	O
is	O
easy	O
to	O
separate	O
out	O
claybank	O
crystals	O
under	O
low	O
temperature	O
in	O
winter	O
,	O
the	O
heating	O
and	O
long	O
-	O
time	O
stirring	O
are	O
required	O
to	O
be	O
performed	O
during	O
preparation	O
;	O
the	O
content	O
of	O
furacilin	B
is	O
declined	O
with	O
the	O
quantity	O
of	O
the	O
crystals	O
to	O
varying	O
degrees	O
,	O
so	O
that	O
the	O
clinical	O
effects	O
of	O
the	O
furacilin	B
ear	O
drop	O
is	O
reduced	O
,	O
and	O
the	O
furacilin	B
ear	O
drop	O
can	O
not	O
be	O
used	O
.	O

The	O
furacilin	B
ear	O
drop	O
prepared	O
through	O
the	O
method	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
process	O
is	O
optimized	O
greatly	O
,	O
the	O
phenomena	O
of	O
crystal	O
,	O
muddiness	O
and	O
the	O
like	O
are	O
not	O
seen	O
after	O
the	O
reserved	O
sample	O
of	O
products	O
is	O
observed	O
for	O
24	O
months	O
,	O
the	O
strong	O
stability	O
is	O
achieved	O
,	O
the	O
content	O
of	O
the	O
furacilin	B
can	O
be	O
measured	O
through	O
ultraviolet	O
-	O
visible	O
spectrophotometry	O
and	O
is	O
not	O
changed	O
during	O
the	O
storage	O
period	O
,	O
and	O
the	O
percentage	O
loss	O
of	O
the	O
furacilin	B
content	O
is	O
less	O
than	O
1	O
%	O
.	O

Method	O
for	O
quickly	O
preparing	O
furacilin	B
ear	O
drop	O
preparation	O
by	O
adopting	O
ultrasonic	O
wave	O
-	O
microwave	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutic	O
preparation	O
,	O
in	O
particular	O
to	O
a	O
novel	O
method	O
for	O
preparing	O
an	O
omeprazole	B
sodium	B
bicarbonate	I
magnesium	B
hydrate	I
pill	O
.	O

According	O
to	O
the	O
method	O
,	O
particles	O
can	O
be	O
formed	O
without	O
being	O
dried	O
,	O
the	O
fluidity	O
of	O
the	O
particles	O
is	O
good	O
,	O
stability	O
in	O
pressing	O
the	O
pill	O
is	O
ensured	O
and	O
the	O
method	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

The	O
omeprazole	B
sodium	B
bicarbonate	I
magnesium	B
hydrate	I
pill	O
prepared	O
and	O
obtained	O
with	O
the	O
method	O
is	O
good	O
in	O
content	O
uniformity	O
of	O
omeprazole	B
and	O
dissolution	O
,	O
little	O
in	O
relevant	O
substance	O
and	O
stable	O
in	O
quality	O
.	O

Novel	O
method	O
for	O
preparing	O
omeprazole	B
sodium	B
bicarbonate	I
magnesium	B
hydrate	I
pill	O

The	O
invention	O
discloses	O
dedicated	O
liquid	O
medicine	O
,	O
a	O
dedicated	O
tool	O
and	O
a	O
method	O
for	O
building	O
an	O
animal	O
model	O
of	O
parkinson	O
's	O
disease	O
through	O
intracerebral	O
administration	O
and	O
belongs	O
to	O
a	O
biomedical	O
technology	O
.	O

The	O
dedicated	O
liquid	O
medicine	O
is	O
solution	O
which	O
is	O
prepared	O
in	O
such	O
a	O
manner	O
that	O
MPP<+	B
>	I
is	O
dissolved	O
into	O
normal	O
saline	O
,	O
wherein	O
the	O
concentration	O
of	O
the	O
MMP<+	B
>	O
is	O
0.08	O
-	O
0.12	O
g	O
/	O
ml	O
.	O

The	O
dedicated	O
tool	O
is	O
a	O
multi	O
-	O
point	O
dosing	O
needle	O
tube	O
which	O
adopts	O
the	O
structure	O
that	O
one	O
end	O
of	O
a	O
hollow	O
metal	O
tube	O
is	O
closed	O
and	O
the	O
other	O
end	O
of	O
the	O
metal	O
tube	O
is	O
opened	O
;	O
substantia	O
nigra	O
dosing	O
side	O
holes	O
and	O
corpus	O
striatum	O
dosing	O
side	O
holes	O
are	O
formed	O
in	O
the	O
side	O
wall	O
of	O
the	O
hollow	O
metal	O
tube	O
.	O

A	O
path	O
passing	O
through	O
both	O
the	O
substantia	O
nigra	O
and	O
the	O
corpus	O
striatum	O
in	O
the	O
cerebrum	O
of	O
a	O
primate	O
which	O
is	O
not	O
a	O
human	O
is	O
selected	O
as	O
a	O
needle	O
insertion	O
path	O
.	O

Injection	O
dosing	O
is	O
preformed	O
on	O
the	O
substantia	O
nigra	O
and	O
the	O
corpus	O
striatum	O
through	O
the	O
multi	O
-	O
point	O
dosing	O
needle	O
tube	O
.	O

The	O
total	O
dosage	O
is	O
9	O
-	O
11	O
microlitres	O
,	O
and	O
12	O
hours	O
after	O
once	O
dosing	O
by	O
needle	O
insertion	O
,	O
the	O
animal	O
model	O
of	O
parkinson	O
's	O
disease	O
is	O
prepared	O
successfully	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
anatomical	O
characteristics	O
of	O
the	O
substantia	O
nigra	O
in	O
the	O
mesencephalon	O
and	O
corpus	O
striatum	O
nuclei	O
,	O
the	O
own	O
attributes	O
of	O
the	O
chemical	O
medicine	O
(	O
i.e.	O
the	O
liquid	O
medicine	O
)	O
and	O
the	O
specific	O
damage	O
effects	O
,	O
to	O
a	O
dopaminergic	O
neuron	O
,	O
of	O
the	O
chemical	O
medicine	O
are	O
well	O
utilized	O
,	O
so	O
that	O
an	O
obvious	O
hemi	O
-	O
parkinson	O
's	O
disease	O
symptom	O
occurs	O
to	O
the	O
animal	O
model	O
immediately	O
and	O
can	O
keep	O
stable	O
for	O
a	O
long	O
time	O
.	O

Moreover	O
,	O
the	O
basic	O
physiological	O
status	O
of	O
the	O
animal	O
model	O
is	O
good	O
,	O
and	O
the	O
individual	O
difference	O
is	O
smaller	O
.	O

Dedicated	O
liquid	O
medicine	O
,	O
dedicated	O
tool	O
and	O
method	O
for	O
building	O
animal	O
model	O
of	O
parkinson	O
's	O
disease	O
through	O
intracerebral	O
administration	O

The	O
invention	O
discloses	O
a	O
health	O
care	O
product	O
having	O
an	O
effect	O
of	O
losing	O
weight	O
.	O

The	O
health	O
care	O
product	O
adopts	O
L	B
-	I
carnitine	I
,	O
konjaku	O
flour	O
and	O
tea	O
polyphenols	O
as	O
raw	O
materials	O
.	O

The	O
raw	O
materials	O
are	O
prepared	O
into	O
capsules	O
and	O
other	O
preparation	O
forms	O
according	O
to	O
a	O
ratio	O
.	O

The	O
health	O
care	O
product	O
has	O
a	O
reasonable	O
formula	O
and	O
a	O
unique	O
preparation	O
method	O
,	O
and	O
has	O
the	O
effect	O
of	O
losing	O
weight	O
.	O

Health	O
care	O
product	O
containing	O
L	B
-	I
carnitine	I

The	O
invention	O
relates	O
to	O
the	O
new	O
application	O
of	O
a	O
stahlianthus	O
involucratus	O
,	O
an	O
extractive	O
of	O
the	O
stahlianthus	O
involucratus	O
,	O
a	O
fat	O
-	O
soluble	O
extractive	O
of	O
the	O
stahlianthus	O
involucratus	O
and	O
an	O
essential	O
oil	O
composition	O
of	O
the	O
stahlianthus	O
involucratus	O
,	O
namely	O
the	O
new	O
application	O
of	O
the	O
stahlianthus	O
involucratus	O
,	O
the	O
extractive	O
of	O
the	O
stahlianthus	O
involucratus	O
,	O
the	O
fat	O
-	O
soluble	O
extractive	O
of	O
the	O
stahlianthus	O
involucratus	O
and	O
the	O
essential	O
oil	O
composition	O
of	O
the	O
stahlianthus	O
involucratus	O
in	O
preparing	O
drugs	O
for	O
treating	O
and/or	O
preventing	O
liver	O
cancer	O
.	O

Application	O
of	O
stahlianthus	O
involucratus	O
and	O
extractive	O
of	O
stahlianthus	O
involucratus	O
in	O
preparing	O
drugs	O
for	O
treating	O
and/or	O
preventing	O
liver	O
cancer	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
as	O
further	O
described	O
herein	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
enantiomers	O
,	O
rotamers	O
,	O
tautomers	O
,	O
or	O
racemates	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
PIM	O
kinase	O
using	O
the	O
compounds	O
of	O
Formula	O
I	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O

Tetrasubstituted	B
cyclohexyl	I
compounds	O
as	O
kinase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
process	O
for	O
glycyrrhizic	B
acid	I
-	O
mediated	O
hydroxycamptothecine	B
albumin	O
liver	O
cancer	O
targeting	O
nanoparticle	O
lyophilized	O
powder	O
.	O

The	O
glycyrrhizic	B
acid	I
-	O
mediated	O
hydroxycamptothecine	B
albumin	O
liver	O
cancer	O
targeting	O
nanoparticle	O
lyophilized	O
powder	O
is	O
obtained	O
by	O
the	O
steps	O
of	O
reacting	O
glycyrrhizic	B
acid	I
and	O
albumin	O
under	O
a	O
certain	O
conditions	O
to	O
successfully	O
couple	O
glycyrrhizic	B
acid	I
and	O
albumin	O
;	O
removing	O
glycyrrhizic	B
acid	I
uncoupled	O
with	O
albumin	O
by	O
a	O
dialysis	O
method	O
;	O
then	O
lyophilizing	O
albumin	O
coupled	O
with	O
glycyrrhizic	B
acid	I
to	O
obtain	O
lyophilized	O
powder	O
of	O
albumin	O
coupled	O
with	O
glycyrrhizic	B
acid	I
;	O
dissolving	O
albumin	O
coupled	O
with	O
glycyrrhizic	B
acid	I
in	O
water	O
at	O
a	O
certain	O
concentration	O
and	O
hydroxycamptothecine	B
in	O
a	O
mixed	O
solution	O
of	O
chloroform	O
and	O
ethanol	B
;	O
dropwise	O
adding	O
the	O
hydroxycamptothecine	B
solution	O
to	O
the	O
albumin	O
solution	O
slowly	O
;	O
homogenizing	O
at	O
a	O
certain	O
rotation	O
speed	O
and	O
time	O
;	O
homogenizing	O
the	O
homogenized	O
mixed	O
suspension	O
for	O
a	O
certain	O
times	O
under	O
a	O
certain	O
pressure	O
to	O
obtain	O
an	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
;	O
removing	O
organic	O
solvents	O
-	O
ethanol	B
and	O
chloroform	B
from	O
the	O
mixed	O
suspension	O
by	O
a	O
rotary	O
evaporation	O
method	O
;	O
and	O
then	O
removing	O
water	O
from	O
the	O
mixed	O
suspension	O
in	O
a	O
lyophilization	O
manner	O
.	O

Preparation	O
process	O
for	O
glycyrrhizic	B
acid	I
-	O
mediated	O
hydroxycamptothecine	B
albumin	O
liver	O
cancer	O
targeting	O
nanoparticle	O
lyophilized	O
powder	O

The	O
invention	O
provides	O
a	O
production	O
technology	O
of	O
a	O
particle	O
comprising	O
ten	O
vitamins	O
for	O
children	O
.	O

The	O
production	O
technology	O
comprises	O
the	O
steps	O
of	O
firstly	O
reasonably	O
grouping	O
the	O
vitamins	O
,	O
choosing	O
a	O
centrifugal	O
pelletizer	O
for	O
pelletizing	O
while	O
controlling	O
the	O
temperature	O
and	O
humidity	O
of	O
the	O
environment	O
and	O
operating	O
in	O
a	O
dark	O
place	O
,	O
drying	O
by	O
decompression	O
drying	O
equipment	O
,	O
introducing	O
nitrogen	B
,	O
filtering	O
out	O
ultraviolet	O
lights	O
and	O
packing	O
.	O

According	O
to	O
the	O
production	O
technology	O
,	O
mutual	O
interference	O
and	O
interaction	O
of	O
the	O
vitamins	O
in	O
the	O
particle	O
are	O
reduced	O
,	O
and	O
the	O
problem	O
that	O
the	O
vitamins	O
are	O
easy	O
to	O
degrade	O
and	O
are	O
sensitive	O
to	O
light	O
,	O
heat	O
,	O
acid	O
and	O
alkali	O
,	O
humidity	O
and	O
temperature	O
is	O
solved	O
.	O

Therefore	O
,	O
the	O
particle	O
comprising	O
ten	O
vitamins	O
for	O
children	O
prepared	O
by	O
the	O
production	O
technology	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
effective	O
ingredient	O
content	O
is	O
high	O
and	O
the	O
effective	O
ingredients	O
are	O
stable	O
.	O

Production	O
technology	O
of	O
particle	O
comprising	O
ten	O
vitamins	O
for	O
children	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
composition	O
for	O
preventing	O
and	O
treating	O
fatty	O
liver	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
field	O
of	O
a	O
chemical	O
technology	O
.	O

The	O
composition	O
comprises	O
ginkgo	O
biloba	O
extractive	O
,	O
allicin	B
,	O
vitamin	B
C	I
,	O
vitamin	B
B12	I
and	O
vinegar	O
,	O
thus	O
being	O
capable	O
of	O
relieving	O
lipid	O
oxidation	O
damage	O
of	O
the	O
liver	O
,	O
enhancing	O
the	O
oxidation	O
resistance	O
of	O
the	O
liver	O
,	O
inhibiting	O
the	O
activity	O
of	O
Kupffer	O
cells	O
,	O
lowering	O
the	O
inflammatory	O
reaction	O
,	O
protecting	O
the	O
liver	O
,	O
reducing	O
serum	O
free	O
fatty	B
acid	I
(	O
FFA	O
)	O
,	O
reducing	O
accumulation	O
of	O
liver	O
fat	O
,	O
and	O
preventing	O
the	O
fatty	O
liver	O
.	O

Composition	O
for	O
preventing	O
and	O
treating	O
fatty	O
liver	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
new	O
use	O
of	O
a	O
common	O
pternopetalum	O
root	O
extract	O
,	O
and	O
particularly	O
relates	O
to	O
the	O
use	O
of	O
the	O
common	O
pternopetalum	O
root	O
extract	O
in	O
the	O
field	O
of	O
pharmacy	O
.	O

The	O
use	O
concretely	O
comprises	O
the	O
functions	O
of	O
treating	O
and	O
preventing	O
dysmenorrheal	O
,	O
treating	O
and	O
preventing	O
hypertension	O
,	O
treating	O
and	O
preventing	O
atherosclerosis	O
,	O
treating	O
and	O
preventing	O
cerebral	O
thrombosis	O
and	O
the	O
like	O
caused	O
by	O
cerebral	O
apoplexy	O
.	O

The	O
common	O
pternopetalum	O
root	O
extract	O
is	O
safe	O
and	O
non	O
-	O
toxic	O
,	O
and	O
strong	O
in	O
pharmacologic	O
action	O
,	O
and	O
heralds	O
a	O
good	O
medicinal	O
prospect	O
;	O
meanwhile	O
,	O
the	O
common	O
pternopetalum	O
root	O
extract	O
is	O
simple	O
in	O
preparation	O
process	O
,	O
and	O
can	O
be	O
prepared	O
into	O
capsules	O
,	O
tablets	O
,	O
cream	O
and	O
oiling	O
agents	O
to	O
be	O
taken	O
orally	O
or	O
used	O
externally	O
.	O

Common	O
pternopetalum	O
root	O
extract	O
and	O
new	O
use	O
thereof	O
in	O
pharmacy	O

The	O
invention	O
discloses	O
an	O
esomeprazole	B
sodium	I
freeze	O
-	O
dried	O
powder	O
injection	O
for	O
injection	O
,	O
wherein	O
the	O
additive	O
contained	O
in	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
includes	O
tromethamine	O
,	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
formed	O
by	O
freeze	O
-	O
drying	O
a	O
confected	O
liquid	O
medicine	O
.	O

The	O
freeze	O
-	O
dried	O
powder	O
disclosed	O
by	O
the	O
invention	O
is	O
high	O
in	O
stability	O
and	O
a	O
little	O
in	O
variety	O
of	O
auxiliary	O
material	O
,	O
therefore	O
the	O
preparation	O
is	O
safer	O
;	O
furthermore	O
,	O
the	O
process	O
is	O
simple	O
,	O
and	O
the	O
requirement	O
of	O
mass	O
production	O
is	O
met	O
.	O

Esomeprazole	B
sodium	I
freeze	O
-	O
dried	O
powder	O
injection	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
oral	O
tablet	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
tablet	O
contains	O
N-	B
[	I
4-	I
[	I
4-	I
(	I
1	I
,	I
2-benzisothiazole-3-group	I
)	I
-1-piperazine	I
]	I
-	I
(	I
2R	I
,	I
3R	I
)	I
-2	I
,	I
3-tetramethylene	I
-	I
butyl	I
]	I
-	I
(	I
1'R	I
,	I
2	I
'S	I
,	I
3'R	I
,	I
4'R	I
)	I
-2	I
,	I
3-bicyclo	I
[	I
2	I
,	I
2	I
,	I
1	I
]	I
heptane	I
diimide	I
hydrochloride	I
,	O
as	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
.	O

The	O
oral	O
tablet	O
enables	O
the	O
medicine	O
to	O
release	O
within	O
a	O
short	O
time	O
,	O
so	O
that	O
the	O
medicine	O
can	O
be	O
quickly	O
dissolved	O
out	O
;	O
in	O
addition	O
,	O
the	O
medicine	O
formability	O
is	O
high	O
.	O

Oral	O
tablet	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
,	O
relates	O
to	O
a	O
new	O
application	O
of	O
Bostrycin	B
and	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
Bostrycin	B
to	O
preparation	O
of	O
protein	O
tyrodine	O
phosphatase	O
(	O
PTP	O
)	O
bonding	O
agents	O
or	O
inhibitors	O
.	O

By	O
adopting	O
the	O
method	O
,	O
the	O
PTP	O
dephosphorylation	O
inhibiting	O
activity	O
of	O
Bostrycin	B
is	O
found	O
for	O
the	O
first	O
time	O
.	O

The	O
human	O
PTP1B	O
enzyme	O
activity	O
inhibiting	O
activity	O
IC50	O
of	O
Bostrycin	B
is	O
150mu	O
M.	O
Application	O
of	O
Bostrycin	B
to	O
preparation	O
of	O
protein	O
tyrodine	O
phosphatase	O
(	O
PTP	O
)	O
bonding	O
agents	O
or	O
inhibitors	O

The	O
invention	O
discloses	O
application	O
of	O
Scopariusins	B
in	O
preparation	O
of	O
an	O
anti	O
-	O
hypoxic	O
drug	O
.	O

The	O
anti	O
-	O
hypoxic	O
effect	O
of	O
the	O
Scopariusins	B
is	O
observed	O
through	O
a	O
whole	O
ad	O
a	O
cellular	O
level	O
hypoxia	O
model	O
,	O
and	O
a	O
result	O
shows	O
that	O
the	O
Scopariusins	B
can	O
remarkably	O
improve	O
the	O
survival	O
rate	O
and	O
survival	O
time	O
of	O
asphyxiant	O
hypoxa	O
and	O
acute	O
decompression	O
hypoxia	O
rats	O
,	O
reduce	O
myocardial	O
damage	O
caused	O
by	O
drug	O
specificity	O
to	O
the	O
rats	O
,	O
also	O
has	O
remarkable	O
protecting	O
effect	O
on	O
cardiac	O
myocytes	O
and	O
nerve	O
cell	O
hypoxia	O
damage	O
of	O
in	O
-	O
vitro	O
cultured	O
neonatal	O
rats	O
and	O
is	O
applied	O
to	O
the	O
preparation	O
of	O
the	O
anti	O
-	O
hypoxic	O
drug	O
.	O

Application	O
of	O
Scopariusins	B
in	O
preparation	O
of	O
anti	O
-	O
hypoxic	O
drug	O

The	O
invention	O
discloses	O
application	O
of	O
aplysin	B
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
glioma	O
,	O
aiming	O
at	O
researching	O
the	O
anti	O
-	O
tumor	O
activity	O
of	O
aplysin	B
to	O
glioma	O
.	O

The	O
MTT	B
(	O
Methyl	B
Thiazolyl	I
Tetrazolium	I
)	O
experiment	O
shows	O
that	O
the	O
inhibition	O
ratio	O
of	O
aplysin	B
to	O
C6	O
cell	O
is	O
increased	O
along	O
with	O
the	O
raise	O
of	O
the	O
concentration	O
of	O
aplysin	B
;	O
after	O
the	O
concentration	O
is	O
raised	O
beyond	O
80mcg	O
/	O
m	O
,	O
the	O
inhibition	O
ratio	O
of	O
C6	O
cell	O
does	O
not	O
raise	O
obviously	O
,	O
namely	O
,	O
the	O
most	O
effective	O
anti	O
-	O
tumor	O
concentration	O
of	O
aplysin	B
is	O
80mc	O
/	O
ml	O
;	O
the	O
best	O
effect	O
appears	O
in	O
48	O
hours	O
in	O
light	O
of	O
the	O
action	O
time	O
;	O
with	O
the	O
prolonging	O
of	O
the	O
time	O
,	O
the	O
cell	O
inhibition	O
ratio	O
does	O
not	O
raise	O
obviously	O
.	O

The	O
animal	O
experiment	O
result	O
shows	O
that	O
after	O
the	O
dose	O
of	O
aplysin	B
is	O
increased	O
,	O
the	O
life	O
time	O
of	O
a	O
rat	O
is	O
prolonged	O
,	O
the	O
weight	O
of	O
glioma	O
is	O
reduced	O
,	O
and	O
the	O
infiltration	O
of	O
lymphocyte	O
is	O
improved	O
;	O
40mg	O
/	O
kg.bw	O
is	O
the	O
best	O
dose	O
for	O
reaching	O
the	O
best	O
effect	O
.	O

The	O
experiment	O
shows	O
that	O
aplysin	B
belongs	O
to	O
natural	O
marine	O
drugs	O
and	O
has	O
small	O
toxic	O
and	O
side	O
effects	O
,	O
so	O
that	O
aplysin	B
can	O
be	O
used	O
as	O
the	O
medicine	O
for	O
treating	O
glioma	O
;	O
aplysin	B
is	O
good	O
in	O
market	O
application	O
prospect	O
.	O

Application	O
of	O
aplysin	B
in	O
preparation	O
of	O
medicine	O
for	O
treating	O
glioma	O

The	O
invention	O
discloses	O
application	O
of	O
Incarviatone	B
A	I
in	O
preparation	O
of	O
an	O
anti	O
-	O
respiratory	O
syncytial	O
virus	O
drug	O
.	O

An	O
experiment	O
proves	O
that	O
the	O
Incarviatone	B
A	I
has	O
remarkable	O
inhibiting	O
effect	O
on	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
.	O

An	O
experimental	O
basis	O
is	O
provided	O
for	O
clinic	O
application	O
of	O
the	O
Incarviatone	O
A	O
for	O
treating	O
the	O
RSV	O
infectious	O
diseases	O
,	O
a	O
certain	O
guiding	O
significance	O
is	O
provided	O
for	O
development	O
of	O
the	O
anti	O
-	O
RSV	O
drug	O
,	O
and	O
the	O
application	O
of	O
the	O
Incarviatone	B
A	I
has	O
important	O
reference	O
value	O
.	O

Application	O
of	O
Incarviatone	B
A	I
in	O
anti	O
-	O
respiratory	O
syncytial	O
virus	O
drug	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Chukrasone	B
B	I
in	O
a	O
medicament	O
for	O
treating	O
liver	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
novel	O
medicament	O
applications	O
.	O

In	O
-	O
vitro	O
MTT	B
(	O
Methyl	B
Thiazolyl	I
Tetrazolium	I
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
shows	O
that	O
Chukrasone	B
B	I
has	O
a	O
remarkable	O
inhibiting	O
effect	O
on	O
growth	O
of	O
human	O
liver	O
cancer	O
cell	O
strains	O
HepG2	O
,	O
MHCC	O
-	O
LM3	O
,	O
Bel-7402	O
and	O
HuH-7	O
.	O

Therefore	O
,	O
Chukrasone	B
B	I
can	O
be	O
applied	O
to	O
preparation	O
of	O
anti	O
-	O
hepatoma	O
medicament	O
,	O
and	O
has	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
Chukrasone	B
B	I
in	O
the	O
medicament	O
for	O
treating	O
liver	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
as	O
the	O
skeleton	O
is	O
of	O
a	O
completely	O
novel	O
type	O
,	O
the	O
inhibitory	O
activity	O
of	O
Chukrasone	B
B	I
on	O
hepatoma	O
cells	O
is	O
beyond	O
the	O
imagination	O
.	O

Application	O
of	O
Chukrasone	B
B	I
in	O
medicament	O
for	O
treating	O
liver	O
cancer	O

The	O
invention	O
relates	O
to	O
application	O
of	O
amphiphilic	O
poly	O
-	O
fullerene	O
tree	O
-	O
based	O
cross	O
-	O
linked	O
poly	O
-	O
cation	O
gel	O
as	O
a	O
chelating	O
agent	O
for	O
binding	O
phosphate	B
,	O
fatty	B
acid	I
and	O
bile	B
acid	I
.	O

According	O
to	O
the	O
application	O
,	O
the	O
gel	O
has	O
effects	O
of	O
resisting	O
obesity	O
and	O
reducing	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
the	O
fields	O
of	O
prevention	O
and	O
healthcare	O
.	O

The	O
composition	O
in	O
the	O
application	O
is	O
provided	O
with	O
components	O
comprising	O
different	O
chemical	O
formulae	O
.	O

In	O
the	O
chemical	O
formulae	O
,	O
F	B
represents	O
a	O
fullerene	O
core	O
;	O
P1	O
and	O
P2	O
represent	O
poly	O
-	O
cation	O
halides	O
of	O
low	O
polymers	O
or	O
high	O
polymers	O
containing	O
polyamine	B
;	O
E	O
represents	O
an	O
affine	O
substituent	O
group	O
;	O
n	O
is	O
2	O
to	O
50	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
the	O
poly	O
-	O
cation	O
polymer	O
gel	O
substance	O
by	O
taking	O
nitryl	O
poly	O
-	O
fullerene	O
or	O
cyclically	O
sulfated	O
poly	O
-	O
fullerene	O
as	O
an	O
intermediate	O
reactant	O
.	O

Application	O
of	O
amphiphilic	O
poly	O
-	O
fullerene	O
tree	O
-	O
based	O
cross	O
-	O
linked	O
poly	O
-	O
cation	O
gel	O
as	O
chelating	O
agent	O
for	O
binding	O
phosphate	B
,	O
fatty	B
acid	I
and	O
bile	B
acid	I

The	O
invention	O
provides	O
a	O
zeolite	O
medicine	O
composition	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
zeolite	O
in	O
the	O
composition	O
includes	O
clinoptilolite	O
and	O
further	O
contains	O
one	O
or	O
more	O
of	O
gramineous	O
plants	O
,	O
leguminous	O
plants	O
or	O
cephalopoda	O
organisms	O
.	O

The	O
method	O
for	O
preparing	O
the	O
medicine	O
composition	O
is	O
environmentally	O
-	O
friendly	O
.	O

The	O
experimental	O
verification	O
result	O
shows	O
that	O
the	O
medicine	O
composition	O
has	O
a	O
good	O
effect	O
on	O
treating	O
alzheimer	O
disease	O
and	O
parkinsonism	O
and	O
has	O
no	O
side	O
effect	O
.	O

Zeolite	O
medicine	O
composition	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
double	O
-	O
target	O
point	O
medicine	O
compound	O
for	O
treating	O
tumors	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
double	O
-	O
target	O
point	O
medicine	O
compound	O
has	O
a	O
structure	O
shown	O
in	O
a	O
general	O
formula	O
II	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
treating	O
chronic	O
inflammations	O
and	O
tumors	O
of	O
liver	O
cancers	O
,	O
pancreatic	O
cancers	O
,	O
lung	O
cancers	O
,	O
breast	O
cancers	O
,	O
brain	O
cancers	O
,	O
colon	O
cancers	O
and	O
gastric	O
cancers	O
.	O

Double	O
-	O
target	O
point	O
medicine	O
compound	O
for	O
treating	O
tumors	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
triazole	B
alcohol	I
compound	O
containing	O
a	O
benzamide	B
structure	O
,	O
and	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
triazole	B
alcohol	I
compound	O
.	O

The	O
structure	O
of	O
the	O
triazole	B
alcohol	I
compound	O
containing	O
the	O
benzamide	B
structure	O
is	O
shown	O
as	O
the	O
formulain	O
the	O
specification	O
,	O
wherein	O
R	O
is	O
selected	O
from	O
hydrogen	B
,	O
alkyl	B
,	O
alkoxy	B
,	O
halogen	B
,	O
nitryl	B
or	O
trifluoromethyl	B
,	O
located	O
in	O
ortho	O
-	O
position	O
,	O
meta	O
-	O
position	O
and	O
para	O
-	O
position	O
of	O
an	O
aromatic	B
ring	O
,	O
and	O
is	O
mono	O
-	O
substituted	O
or	O
poly	O
-	O
substituted	O
;	O
the	O
alkyl	B
is	O
the	O
alkyl	B
containing	O
1	O
to	O
5	O
carbon	B
atoms	O
;	O
the	O
alkoxy	B
is	O
selected	O
from	O
methoxy	B
or	O
ethyoxyl	B
;	O
and	O
the	O
halogen	B
is	O
selected	O
from	O
F	B
,	O
CI	B
,	O
Br	B
or	O
I.	B
The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
compound	O
.	O

The	O
compound	O
shows	O
high	O
inhibition	O
activity	O
for	O
deep	O
fungus	O
,	O
and	O
has	O
the	O
advantages	O
of	O
high	O
efficiency	O
and	O
low	O
toxicity	O
,	O
therefore	O
,	O
the	O
compound	O
can	O
be	O
used	O
for	O
preparing	O
an	O
efficient	O
antifungal	O
drug	O
;	O
in	O
addition	O
,	O
the	O
preparation	O
method	O
is	O
simple	O
,	O
and	O
the	O
yield	O
is	O
high	O
.	O

Triazole	B
alcohol	I
compound	O
containing	O
benzamide	B
structure	O
and	O
preparation	O
method	O
and	O
application	O
of	O
triazole	B
alcohol	I
compound	O

The	O
invention	O
discloses	O
aryl	B
-	I
linked	I
pyrrolone	I
-	I
phenyl	I
-	I
oxazolidinone	I
compounds	O
with	O
the	O
structural	O
general	O
formulas	O
as	O
shown	O
in	O
the	O
specification	O
.	O

The	O
compounds	O
have	O
better	O
inhibiting	O
and	O
killing	O
effects	O
on	O
various	O
germs	O
,	O
and	O
some	O
of	O
the	O
pyrrolone	B
-	I
phenyl	I
-	I
oxazolidinone	I
compounds	O
have	O
higher	O
bacteriostatic	O
activity	O
than	O
positive	O
control	O
penicillihe	B
G	I
,	O
kalamycin	B
and	O
ketoconazole	B
,	O
so	O
that	O
the	O
pyrrolone	B
-	I
phenyl	I
-	I
oxazolidinone	I
compounds	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
infective	O
drugs	O
.	O

The	O
invention	O
also	O
discloses	O
preparation	O
methods	O
of	O
the	O
pyrrolone	B
-	I
phenyl	I
-	I
oxazolidinone	I
compounds	O
.	O

Pyrrolone	B
-	I
phenyl	I
-	I
oxazolidinone	I
compounds	O
as	O
well	O
as	O
preparation	O
methods	O
and	O
applications	O
thereof	O

The	O
invention	O
discloses	O
a	O
ganciclovir	B
capsule	O
preparation	O
which	O
comprises	O
a	O
capsule	O
casing	O
and	O
materials	O
contained	O
in	O
the	O
capsule	O
casing	O
,	O
wherein	O
the	O
materials	O
contained	O
in	O
the	O
capsule	O
casing	O
are	O
ganciclovir	B
slow	O
-	O
release	O
pellets	O
.	O

The	O
ganciclovir	B
slow	O
-	O
release	O
pellets	O
are	O
prepared	O
by	O
a	O
method	O
as	O
follows	O
:	O
dissolving	O
ganciclovir	B
,	O
ethyecellulose	O
and	O
high	O
-	O
substituted	O
hydroxyproxyl	O
celluloses	O
in	O
ethyl	B
alcohol	I
;	O
adding	O
the	O
mixture	O
into	O
liquid	O
paraffin	O
containing	O
a	O
surfactant	O
under	O
a	O
stirring	O
condition	O
;	O
gradually	O
heating	O
to	O
38	O
DEG	O
C	O
to	O
42	O
DEG	O
C	O
and	O
stirring	O
for	O
4	O
to	O
8	O
hours	O
in	O
a	O
heat	O
preservation	O
manner	O
;	O
then	O
heating	O
to	O
68	O
DEG	O
C	O
to	O
72	O
DEG	O
C	O
and	O
stirring	O
for	O
0.5	O
to	O
2	O
hours	O
;	O
and	O
performing	O
filtration	O
under	O
reduced	O
pressure	O
,	O
thereby	O
obtaining	O
the	O
ganciclovir	B
slow	O
-	O
release	O
pellets	O
.	O

According	O
to	O
the	O
ganciclovir	B
capsule	O
preparation	O
,	O
the	O
consumption	O
of	O
the	O
slow	O
-	O
release	O
materials	O
is	O
greatly	O
reduced	O
;	O
and	O
the	O
sudden	O
-	O
release	O
phenomenon	O
of	O
the	O
preparation	O
is	O
avoided	O
.	O

Ganciclovir	B
capsule	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
new	O
medical	O
application	O
of	O
racemosins	B
A	I
,	O
in	O
particular	O
to	O
the	O
application	O
of	O
the	O
racemosins	B
A	I
in	O
preparation	O
of	O
the	O
medicine	O
treating	O
the	O
acute	O
renal	O
failure	O
.	O

The	O
application	O
of	O
the	O
racemosins	B
A	I
in	O
preparation	O
of	O
the	O
medicine	O
treating	O
the	O
acute	O
renal	O
failure	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

The	O
matrix	O
type	O
of	O
the	O
racemosins	B
A	I
belongs	O
to	O
a	O
brand	O
new	O
matrix	O
type	O
.	O

The	O
racemosins	B
A	I
has	O
the	O
advantages	O
of	O
being	O
high	O
in	O
inhibitory	O
activity	O
for	O
the	O
acute	O
renal	O
failure	O
and	O
prominent	O
in	O
substantive	O
features	O
,	O
and	O
makes	O
remarkable	O
progress	O
in	O
preventing	O
the	O
acute	O
renal	O
failure	O
.	O

Application	O
of	O
racemosins	B
A	I
in	O
preparation	O
of	O
medicine	O
treating	O
acute	O
renal	O
failure	O

The	O
invention	O
discloses	O
the	O
application	O
of	O
fluevirosines	B
A	I
in	O
preparation	O
of	O
the	O
medicine	O
inhibiting	O
the	O
tubercle	O
bacillus	O
.	O

The	O
fluevirosines	B
A	I
has	O
remarkable	O
activity	O
for	O
inhibiting	O
the	O
tubercle	O
bacillus	O
and	O
good	O
application	O
prospect	O
.	O

The	O
fluevirosines	B
A	I
belongs	O
to	O
a	O
brand	O
new	O
matrix	O
type	O
,	O
has	O
the	O
advantages	O
of	O
being	O
high	O
in	O
inhibitory	O
activity	O
to	O
the	O
tubercle	O
bacillus	O
and	O
prominent	O
in	O
substantive	O
features	O
,	O
and	O
makes	O
remarkable	O
progress	O
in	O
prevention	O
and	O
treatment	O
of	O
infection	O
of	O
the	O
tubercle	O
bacillus	O
.	O

Application	O
of	O
fluevirosines	B
A	I
in	O
preparation	O
of	O
medicine	O
inhibiting	O
tubercle	O
bacillus	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Lycojaponicumin	B
B	I
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
ileocecum	O
cancer	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

According	O
to	O
the	O
application	O
disclosed	O
by	O
the	O
invention	O
,	O
the	O
in	O
-	O
vitro	O
MTT	B
(	O
methyl	B
thiazolyl	I
tetrazolium	I
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
discovers	O
that	O
the	O
Lycojaponicumin	B
B	I
also	O
has	O
an	O
obvious	O
inhibitory	O
effect	O
on	O
the	O
growth	O
of	O
a	O
human	O
ileocecum	O
cancer	O
cell	O
strain	O
HCT-8	O
.	O

Thus	O
,	O
the	O
Lycojaponicumin	B
B	I
can	O
be	O
used	O
for	O
preparing	O
an	O
ileocecum	O
cancer	O
resisting	O
medicine	O
and	O
has	O
good	O
prospects	O
in	O
development	O
and	O
application	O
.	O

The	O
application	O
of	O
the	O
Lycojaponicumin	B
B	I
in	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
ileocecum	O
cancer	O
,	O
disclosed	O
by	O
the	O
invention	O
,	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

The	O
skeleton	O
type	O
of	O
the	O
Lycojaponicumin	B
B	I
belongs	O
to	O
a	O
brand	O
new	O
skeleton	O
type	O
,	O
and	O
the	O
inhibitory	O
activity	O
of	O
the	O
Lycojaponicumin	B
B	I
on	O
human	O
ileocecum	O
cancer	O
cells	O
is	O
unexpectedly	O
strong	O
.	O

Application	O
of	O
Lycojaponicumin	B
B	I
in	O
medicine	O
for	O
treating	O
ileocecum	O
cancer	O

The	O
invention	O
provides	O
Phyllanthoid	B
A	I
for	O
treating	O
immune	O
inflammation	O
,	O
which	O
is	O
a	O
medicament	O
for	O
treating	O
rheumatoid	O
arthritis	O
.	O

By	O
adopting	O
terfenatine	B
and	O
diclofenac	B
sodium	I
as	O
controls	O
,	O
Phyllanthoid	B
A	I
has	O
an	O
exact	O
curative	O
effect	O
,	O
and	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

The	O
frame	O
model	O
is	O
a	O
brand	O
-	O
new	O
frame	O
model	O
,	O
and	O
Phyllanthoid	B
A	I
has	O
a	O
strong	O
activity	O
in	O
treating	O
rheumatoid	O
arthritis	O
,	O
has	O
a	O
highlighted	O
substantial	O
characteristic	O
,	O
and	O
is	O
remarkably	O
progressed	O
when	O
being	O
used	O
for	O
preventing	O
and	O
treating	O
rheumatoid	O
arthritis	O
.	O

Application	O
of	O
Phyllanthoid	B
A	I
in	O
preparing	O
medicament	O
for	O
treating	O
rheumatoid	O
arthritis	O

The	O
invention	O
relates	O
to	O
application	O
of	O
Phyllanthoid	B
A	I
in	O
preparing	O
a	O
medicament	O
for	O
treating	O
and	O
promoting	O
small	O
intestine	O
peristalsis	O
.	O

Pharmacological	O
experiments	O
discover	O
that	O
Phyllanthoid	B
A	I
has	O
a	O
good	O
effect	O
in	O
promoting	O
small	O
intestine	O
peristalsis	O
.	O

The	O
application	O
of	O
Phyllanthoid	B
A	I
in	O
preparing	O
the	O
medicament	O
for	O
promoting	O
small	O
intestine	O
peristalsis	O
related	O
in	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
frame	O
model	O
.	O

Phyllanthoid	B
A	I
has	O
a	O
strong	O
activity	O
in	O
promoting	O
small	O
intestine	O
peristalsis	O
,	O
has	O
a	O
highlighted	O
substantial	O
characteristic	O
,	O
and	O
is	O
remarkably	O
progressed	O
in	O
preparing	O
the	O
medicament	O
for	O
promoting	O
small	O
intestine	O
peristalsis	O
.	O

Application	O
of	O
Phyllanthoid	B
A	I
in	O
preparing	O
medicament	O
for	O
treating	O
and	O
promoting	O
small	O
intestine	O
peristalsis	O

The	O
invention	O
provides	O
a	O
compound	O
fluorouracil	B
injection	O
as	O
well	O
as	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
encapsulation	O
efficiency	O
of	O
the	O
compound	O
fluorouracil	B
injection	O
is	O
within	O
65	O
-	O
75	O
%	O
,	O
and	O
the	O
average	O
grain	O
diameter	O
of	O
the	O
injection	O
is	O
less	O
than	O
or	O
equal	O
to	O
0.30	O
micron	O
.	O

The	O
encapsulation	O
efficiency	O
of	O
the	O
compound	O
fluorouracil	B
injection	O
provided	O
by	O
the	O
invention	O
is	O
relatively	O
high	O
and	O
the	O
injection	O
is	O
good	O
in	O
stability	O
.	O

According	O
to	O
the	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
,	O
the	O
mixing	O
mode	O
of	O
liposoluble	O
components	O
and	O
water	O
soluble	O
components	O
in	O
a	O
compound	O
fluorouracil	B
injection	O
prescription	O
is	O
changed	O
,	O
so	O
that	O
the	O
higher	O
encapsulation	O
efficiency	O
of	O
the	O
product	O
prepared	O
is	O
obtained	O
compared	O
with	O
that	O
in	O
the	O
prior	O
art	O
.	O

Compound	O
fluorouracil	B
injection	O
as	O
well	O
as	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
biomedical	O
field	O
,	O
and	O
relates	O
to	O
a	O
compound	O
preparation	O
containing	O
pseudo	O
-	O
ginseng	O
.	O

The	O
preparation	O
is	O
prepared	O
from	O
main	O
raw	O
materials	O
of	O
a	O
pseudo	O
-	O
ginseng	O
powder	O
and	O
L	B
-	I
carnitine	I
according	O
to	O
a	O
conventional	O
preparation	O
process	O
,	O
and	O
has	O
function	O
of	O
regulating	O
blood	O
fat	O
.	O

Compound	O
preparation	O
containing	O
pseudo	O
-	O
ginseng	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
,	O
and	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
a	O
ginseng	O
total	O
sub	O
-	O
glycoside	B
combination	O
,	O
ginseng	O
prosapogenin	B
or	O
ginseng	O
protosaponin	B
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
tinnitus	O
,	O
dizziness	O
and	O
Meniere	O
's	O
syndrome	O
.	O

Plants	O
for	O
preparing	O
the	O
ginseng	O
total	O
sub	O
-	O
glycoside	B
medicine	O
combination	O
are	O
panax	O
plants	O
,	O
and	O
are	O
preferably	O
selected	O
from	O
at	O
least	O
one	O
of	O
ginseng	O
,	O
pseudo	O
-	O
ginseng	O
,	O
panax	O
japonicus	O
,	O
American	O
gingseng	O
and	O
Korean	O
ginseng	O
.	O

The	O
ginseng	O
total	O
sub	O
-	O
glycoside	B
combination	O
is	O
a	O
mixture	O
of	O
ginsenoside	B
partially	O
hydrolyzed	O
and	O
a	O
degradation	O
product	O
,	O
namely	O
secondary	O
saponin	B
,	O
part	O
of	O
glycosyl	B
of	O
which	O
is	O
removed	O
.	O

The	O
physiological	O
activity	O
of	O
the	O
ginseng	O
total	O
sub	O
-	O
glycoside	B
combination	O
is	O
greatly	O
enhanced	O
,	O
and	O
the	O
ginseng	O
total	O
sub	O
-	O
glycoside	B
combination	O
has	O
the	O
physiological	O
activities	O
such	O
as	O
blood	O
vessel	O
expansion	O
,	O
heart	O
dynamic	O
enhancement	O
and	O
platelet	O
aggregation	O
inhibition	O
.	O

The	O
ginseng	O
total	O
sub	O
-	O
glycoside	O
combination	O
,	O
the	O
ginseng	O
prosapogenin	B
or	O
the	O
ginseng	O
protosaponin	B
is	O
used	O
for	O
treating	O
the	O
Meniere	O
's	O
syndrome	O
,	O
is	O
definite	O
in	O
curative	O
effect	O
and	O
has	O
high	O
effective	O
rate	O
,	O
small	O
individual	O
difference	O
and	O
high	O
safety	O
without	O
side	O
effects	O
.	O

Application	O
of	O
ginseng	O
total	O
sub	O
-	O
glycoside	O
combination	O
,	O
ginseng	O
prosapogenin	B
or	O
ginseng	O
protosaponin	B
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
Meniere	O
's	O
syndrome	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
an	O
ointment	O
for	O
treating	O
oral	O
ulcer	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
extracting	O
essential	O
oils	O
from	O
citronella	O
and	O
herba	O
erigerontis	O
;	O
decocting	O
spiranthes	O
sinensis	O
mes	O
,	O
buchnera	O
and	O
purslane	O
by	O
using	O
water	O
,	O
concentrating	O
the	O
filtrating	O
solution	O
,	O
drying	O
and	O
crushing	O
;	O
adding	O
camellia	O
oil	O
with	O
the	O
temperature	O
of	O
200	O
-	O
220	O
DEG	O
C	O
;	O
filtering	O
the	O
oil	O
material	O
,	O
then	O
adding	O
colophony	O
powder	O
and	O
phicalcite	O
powder	O
,	O
decocting	O
till	O
the	O
obtained	O
decoction	O
becomes	O
beads	O
when	O
dropping	O
off	O
;	O
spraying	O
cold	O
water	O
to	O
remove	O
water	O
toxin	O
,	O
cooling	O
to	O
normal	O
temperature	O
,	O
and	O
adding	O
the	O
essential	O
oils	O
,	O
uniformly	O
mixing	O
to	O
obtain	O
the	O
ointment	O
.	O

Clinical	O
experiments	O
prove	O
that	O
the	O
healing	O
time	O
can	O
be	O
shortened	O
,	O
the	O
postoperative	O
pain	O
can	O
be	O
relieved	O
,	O
the	O
curative	O
effect	O
is	O
reliable	O
and	O
the	O
use	O
is	O
safe	O
when	O
the	O
ointment	O
disclosed	O
by	O
the	O
invention	O
is	O
used	O
for	O
treating	O
the	O
oral	O
ulcer	O
.	O

Preparation	O
method	O
of	O
ointment	O
for	O
treating	O
oral	O
ulcer	O

The	O
invention	O
discloses	O
5-cyclohexyl	B
uracil	I
arabinoside	I
,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
in	O
leukemia	O
treatment	O
.	O

The	O
synthetic	O
method	O
avoids	O
a	O
heavy	O
metal	O
catalyst	O
in	O
the	O
conventional	O
synthetic	O
method	O
,	O
avoids	O
heavy	O
metal	O
residue	O
in	O
a	O
product	O
,	O
simplifies	O
the	O
synthesis	O
operation	O
,	O
and	O
is	O
suitable	O
for	O
research	O
and	O
further	O
large	O
-	O
scale	O
preparation	O
of	O
medicaments	O
.	O

5-cyclohexyl	B
uracil	I
arabinoside	I
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
hydrochloric	B
acid	I
topotecan	I
intratumor	O
injection	O
preparation	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
field	O
of	O
medicament	O
preparations	O
.	O

According	O
to	O
the	O
composition	O
,	O
a	O
lipidosome	O
technique	O
and	O
an	O
in	O
-	O
situ	O
gel	O
technique	O
are	O
combined	O
and	O
used	O
,	O
the	O
main	O
medicine	O
component	O
,	O
namely	O
,	O
hydrochloric	B
acid	I
topotecan	I
,	O
is	O
carried	O
into	O
a	O
lipid	O
bilayer	O
film	O
through	O
an	O
active	O
medicine	O
carrying	O
method	O
;	O
and	O
the	O
temperature	O
sensitive	O
gel	O
of	O
chitosan	O
/	O
sodium	B
beta	I
-	I
glycerophosphate	I
is	O
used	O
as	O
a	O
gel	O
material	O
which	O
can	O
be	O
kept	O
be	O
liquid	O
at	O
a	O
low	O
temperature	O
,	O
and	O
is	O
converted	O
into	O
solid	O
when	O
the	O
temperature	O
is	O
risen	O
to	O
the	O
body	O
temperature	O
.	O

The	O
invention	O
discloses	O
the	O
preparation	O
method	O
of	O
the	O
composition	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
preparing	O
the	O
hydrochloric	B
acid	I
topotecan	I
lipidosome	O
by	O
using	O
an	O
ammonium	B
sulfate	I
gradient	O
method	O
,	O
selecting	O
a	O
freeze	O
-	O
drying	O
protecting	O
agent	O
,	O
determining	O
the	O
concentration	O
of	O
the	O
chitosan	O
and	O
the	O
sodium	O
beta	O
-	O
glycerophosphate	O
,	O
and	O
preparing	O
the	O
composition	O
.	O

Due	O
to	O
the	O
composition	O
and	O
the	O
preparation	O
method	O
,	O
on	O
the	O
basis	O
that	O
active	O
components	O
are	O
protected	O
and	O
the	O
stability	O
of	O
the	O
preparation	O
is	O
improved	O
,	O
the	O
release	O
of	O
the	O
medicine	O
is	O
controlled	O
,	O
and	O
the	O
biological	O
utilization	O
degree	O
of	O
the	O
main	O
medicine	O
is	O
improved	O
;	O
due	O
to	O
adoption	O
of	O
an	O
intratumor	O
injection	O
mode	O
,	O
the	O
side	O
effect	O
of	O
the	O
main	O
medicine	O
component	O
is	O
reduced	O
,	O
and	O
the	O
compliance	O
of	O
a	O
patient	O
is	O
improved	O
;	O
and	O
the	O
composition	O
is	O
easy	O
to	O
fill	O
,	O
and	O
the	O
industrial	O
production	O
is	O
facilitated	O
.	O

Novel	O
hydrochloric	B
acid	I
topotecan	I
intratumor	O
injection	O
preparation	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
fields	O
of	O
medicine	O
and	O
food	O
technology	O
,	O
and	O
provides	O
an	O
application	O
of	O
a	O
natural	O
compound	O
petasiphenol	O
in	O
preparation	O
of	O
a	O
tyrosinase	O
inhibitor	O
,	O
wherein	O
the	O
natural	O
compound	O
petasiphenol	B
represented	O
by	O
a	O
formula	O
(	O
1	O
)	O
is	O
extracted	O
from	O
petasites	O
tricholobus	O
franch	O
.	O

The	O
tyrosinase	O
inhibitor	O
shows	O
remarkable	O
effects	O
of	O
inhibiting	O
tyrosinase	O
activity	O
and	O
inhibiting	O
melanophores	O
to	O
generate	O
melanin	O
,	O
and	O
is	O
used	O
for	O
prevention	O
of	O
browning	O
of	O
fruits	O
and	O
vegetables	O
,	O
for	O
prevention	O
and	O
treatment	O
of	O
primary	O
and	O
secondary	O
skin	O
pigmentation	O
skin	O
diseases	O
,	O
and	O
for	O
whitening	O
skin	O
.	O

Application	O
of	O
petasiphenol	B
compound	O
in	O
preparation	O
of	O
tyrosinase	O
inhibitor	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
and	O
antioxidation	O
and	O
bacteriostatic	O
actions	O
of	O
an	O
ethanol	B
extract	O
from	O
ginger	O
.	O

The	O
preparation	O
method	O
is	O
characterized	O
in	O
that	O
the	O
ginger	O
and	O
a	O
ginger	O
product	O
are	O
taken	O
as	O
raw	O
materials	O
and	O
extracted	O
by	O
60	O
-	O
99	O
%	O
of	O
ethanol	B
,	O
ethanol	B
is	O
recycled	O
,	O
and	O
the	O
extract	O
or	O
dry	O
powder	O
is	O
prepared	O
.	O

The	O
ethanol	B
extract	O
from	O
the	O
ginger	O
contains	O
more	O
gingerol	B
.	O

The	O
experiment	O
proves	O
that	O
the	O
ethanol	B
extract	O
from	O
the	O
ginger	O
has	O
obvious	O
antioxidation	O
and	O
peroxy	B
radical	I
clearing	O
actions	O
and	O
also	O
has	O
obvious	O
bacteriostatic	O
action	O
on	O
staphylococcus	O
aureus	O
,	O
colibacillus	O
,	O
pseudomonas	O
aeruginosa	O
and	O
bacillus	O
subtilis	O
.	O

The	O
ethanol	B
extract	O
from	O
the	O
ginger	O
is	O
a	O
natural	O
antioxidative	O
and	O
antibacterial	O
substance	O
and	O
has	O
a	O
certain	O
application	O
prospect	O
in	O
safe	O
,	O
effective	O
and	O
harmfulless	O
natural	O
food	O
additives	O
.	O

Preparation	O
method	O
and	O
antioxidation	O
and	O
bacteriostatic	O
actions	O
of	O
ethanol	B
extract	O
from	O
ginger	O

The	O
invention	O
discloses	O
4-oxethyl-2-hydroxyl-6-methyl	B
benzoic	I
acid	I
with	O
a	O
structure	O
shown	O
in	O
a	O
formula	O
(	O
1	O
)	O
as	O
well	O
as	O
a	O
medicinal	O
composition	O
and	O
an	O
application	O
thereof	O
.	O

The	O
compound	O
is	O
capable	O
of	O
significantly	O
killing	O
and/or	O
inhibiting	O
the	O
various	O
tumour	O
cells	O
of	O
human	O
and	O
animals	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
the	O
compound	O
has	O
a	O
significant	O
combined	O
antitumour	O
effect	O
with	O
clinic	O
antitumour	O
medicines	O
,	O
and	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
antitumour	O
medicines	O
,	O
antitumour	O
medicine	O
compositions	O
,	O
combined	O
antitumour	O
medicine	O
compositions	O
or	O
auxiliary	O
antitumour	O
healthcare	O
products	O
.	O

The	O
compound	O
is	O
capable	O
of	O
significantly	O
promoting	O
the	O
apoptosis	O
and	O
necrosis	O
of	O
cancer	O
cells	O
,	O
adjusting	O
the	O
growth	O
cycle	O
of	O
cancer	O
cells	O
,	O
and	O
inhibiting	O
the	O
proliferation	O
of	O
cancer	O
cells	O
.	O

The	O
compound	O
has	O
no	O
significant	O
toxicity	O
on	O
the	O
ponderal	O
growth	O
and	O
organ	O
development	O
of	O
mice	O
under	O
an	O
effective	O
anticancer	O
dosage	O
,	O
or	O
the	O
toxic	O
effect	O
significance	O
of	O
the	O
compound	O
is	O
lower	O
than	O
clinic	O
anticancer	O
medicines	O
such	O
as	O
cyclophosphamide	B
and	O
5-fluorouracil	B
.	O

4-oxethyl-2-hydroxyl-6-methyl	B
benzoic	I
acid	I
as	O
well	O
as	O
medicinal	O
composition	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
quinolone	B
carboxylic	I
acid	I
compounds	O
with	O
the	O
antibacterial	O
activity	O
and	O
a	O
preparation	O
method	O
thereof	O
as	O
well	O
as	O
an	O
antibacterial	O
drug	O
combination	O
containing	O
the	O
quinolone	B
carboxylic	I
acid	I
compounds	O
.	O

More	O
specifically	O
,	O
according	O
to	O
the	O
quinolone	B
carboxylic	I
acid	I
compounds	O
,	O
the	O
substituent	O
of	O
7-bit	O
is	O
3-aminomethyl-4-alkoxyimino-1-piperidyl	B
,	O
and	O
the	O
substituent	O
of	O
1-bit	O
is	O
(	B
1R,2S	I
)	I
-2-fluorocyclopropyl	I
.	O

Compared	O
with	O
the	O
conventional	O
new	O
fluoroquinolone	B
antibacterial	O
drugs	O
(	O
e.g.	O
moxifloxacin	B
,	O
gemifloxacin	B
)	O
in	O
the	O
market	O
,	O
the	O
7-	B
(	I
3-aminomethyl-4-alkoxyimino-1-piperidyl	I
)	I
-1-	I
[	I
(	I
1R,2S	I
)	I
-2-fluorocyclopropyl	I
]	I
quinolone	I
carboxylic	I
acid	I
compounds	O
have	O
higher	O
advantageous	O
activity	O
of	O
preventing	O
clinical	O
important	O
pathogenic	O
germs	O
(	O
e.g.	O
MRSA	O
and	O
MRSE	O
)	O
.	O

7-	B
(	I
3-aminomethyl-4-alkoxyimino-1-piperidyl	I
)	I
-1-	I
[	I
(	I
1R,2S	I
)	I
-2-fluorocyclopropyl	I
]	I
quinolone	I
carboxylic	I
acid	I
compounds	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
the	O
application	O
of	O
cyclocarya	O
paliurus	O
extract	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
preventing	O
and	O
treating	O
leukemia	O
.	O

High	O
-	O
content	O
cyclocarya	O
paliurus	O
extract	O
is	O
obtained	O
by	O
performing	O
the	O
purification	O
treatment	O
combined	O
of	O
water	O
extraction	O
,	O
ethanol	B
extraction	O
,	O
membrane	O
dialysis	O
,	O
and	O
gel	O
chromatographic	O
column	O
on	O
cyclocarya	O
paliurus	O
leaves	O
.	O

The	O
cyclocarya	O
paliurus	O
extract	O
contains	O
90	O
to	O
98	O
percent	O
of	O
polysaccharide	O
;	O
killing	O
activity	O
detection	O
experiments	O
show	O
that	O
the	O
cyclocarya	O
paliurus	O
extract	O
can	O
be	O
used	O
for	O
improving	O
the	O
activity	O
of	O
the	O
splenocytes	O
for	O
killing	O
human	O
leukemia	O
cells	O
K652	O
in	O
vitro	O
;	O
the	O
killing	O
multiples	O
can	O
reach	O
2.47	O
to	O
the	O
maximum	O
.	O

After	O
granules	O
,	O
tablets	O
,	O
buccal	O
tablets	O
,	O
capsules	O
,	O
pills	O
,	O
powder	O
injection	O
or	O
oral	O
liquid	O
prepared	O
by	O
adding	O
certain	O
additives	O
into	O
the	O
cyclocarya	O
paliurus	O
extract	O
disclosed	O
by	O
the	O
invention	O
are	O
orally	O
taken	O
,	O
the	O
effects	O
of	O
preventing	O
and	O
treating	O
the	O
leukemia	O
can	O
be	O
achieved	O
.	O

Application	O
of	O
cyclocarya	O
paliurus	O
extract	O
in	O
preparation	O
of	O
medicament	O
for	O
preventing	O
and	O
treating	O
leukemia	O

The	O
invention	O
provides	O
a	O
multi	O
-	O
effect	O
external	O
preparation	O
used	O
for	O
treating	O
superficial	O
skin	O
injury	O
and	O
an	O
application	O
thereof	O
.	O

The	O
multi	O
-	O
effect	O
external	O
preparation	O
used	O
for	O
treating	O
the	O
superficial	O
skin	O
injury	O
comprises	O
the	O
following	O
components	O
in	O
mass	O
fraction	O
:	O
1	O
-	O
20	O
%	O
of	O
coagulant	O
,	O
0.2	O
-	O
10	O
%	O
of	O
pain	O
-	O
easing	O
medicine	O
,	O
0.2	O
-	O
20	O
%	O
of	O
healing	O
accelerant	O
,	O
0.005	O
-	O
10	O
%	O
of	O
antibacterial	O
material	O
and	O
40	O
-	O
90	O
%	O
of	O
pharmaceutical	O
adjuvant	O
.	O

The	O
multi	O
-	O
effect	O
external	O
preparation	O
has	O
multiple	O
effects	O
of	O
stopping	O
bleeding	O
,	O
easing	O
pain	O
,	O
accelerating	O
healing	O
and	O
fighting	O
infection	O
and	O
can	O
enhance	O
treatment	O
effect	O
on	O
superficial	O
skin	O
injury	O
.	O

Multi	O
-	O
effect	O
external	O
preparation	O
used	O
for	O
treating	O
superficial	O
skin	O
injury	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
and	O
in	O
particular	O
relates	O
to	O
cefdinir	B
dispersible	O
tablets	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
cefdinir	B
is	O
crystal	O
;	O
the	O
X	O
-	O
ray	O
powder	O
diffraction	O
pattern	O
obtained	O
by	O
measuring	O
the	O
cefdinir	B
by	O
Cu	O
-	O
K	O
alpha	O
rays	O
is	O
as	O
shown	O
in	O
the	O
figure	O
1	O
.	O

The	O
cefdinir	B
dispersible	O
tablets	O
contain	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
50	O
to	O
100	O
parts	O
of	O
cefdinir	B
compound	O
,	O
80	O
to	O
180	O
parts	O
of	O
lactose	B
,	O
2	O
to	O
8	O
parts	O
of	O
silicon	B
dioxide	I
,	O
6	O
to	O
14	O
parts	O
of	O
carboxymethyl	O
starch	O
sodium	O
,	O
12	O
to	O
28	O
parts	O
of	O
crosslinked	O
povidone	B
,	O
and	O
0.5	O
to	O
2	O
parts	O
of	O
magnesium	B
stearate	I
.	O

Through	O
experimental	O
tests	O
,	O
the	O
cefdinir	B
dispersible	O
tablets	O
disclosed	O
by	O
the	O
invention	O
have	O
high	O
stability	O
,	O
and	O
are	O
especially	O
suitable	O
for	O
clinical	O
application	O
.	O

Cefdinir	B
compound	O
,	O
as	O
well	O
as	O
dispersible	O
tablets	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
novel	O
bromhexine	B
hydrochloride	I
freeze	O
-	O
dried	O
powder	O
injection	O
.	O

The	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
made	O
from	O
1	O
-	O
4	O
parts	O
of	O
bromhexine	B
hydrochloride	I
and	O
10	O
-	O
40	O
parts	O
of	O
polyethylene	B
glycol	I
200	O
by	O
weight	O
.	O

The	O
invention	O
further	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
novel	O
bromhexine	B
hydrochloride	I
freeze	O
-	O
dried	O
powder	O
injection	O
.	O

By	O
improving	O
the	O
freeze	O
-	O
drying	O
technology	O
and	O
shortening	O
the	O
freeze	O
-	O
drying	O
time	O
,	O
the	O
product	O
quality	O
can	O
be	O
improved	O
,	O
the	O
energy	O
can	O
be	O
saved	O
,	O
and	O
the	O
consumption	O
can	O
be	O
reduced	O
.	O

Bromhexine	B
hydrochloride	I
freeze	O
-	O
dried	O
powder	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
cefixime	B
tablets	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
cefixime	B
tablets	O
are	O
characterized	O
in	O
that	O
the	O
composition	O
of	O
unit	O
dose	O
contains	O
50	O
-	O
100	O
mg	O
of	O
cefixime	B
,	O
30	O
-	O
90	O
mg	O
of	O
lactose	B
,	O
50	O
-	O
100	O
mg	O
of	O
microcrystalline	O
cellulose	O
,	O
15	O
-	O
20	O
mg	O
of	O
crosslinked	O
sodium	O
carboxymethylcellulose	O
,	O
and	O
1	O
-	O
2	O
mg	O
of	O
magnesium	B
stearate	I
.	O

Cefixime	B
tablets	O

The	O
invention	O
discloses	O
application	O
of	O
a	O
nucleotide	O
sequence	O
as	O
shown	O
in	O
SEQ	O
ID	O
NO.1	O
or	O
SEQ	O
ID	O
NO.2	O
in	O
the	O
preparation	O
of	O
medicine	O
for	O
treating	O
a	O
malignant	O
breast	O
cancer	O
.	O

The	O
invention	O
further	O
discloses	O
the	O
medicine	O
for	O
treating	O
the	O
malignant	O
breast	O
cancer	O
.	O

The	O
nucleotide	O
sequence	O
disclosed	O
by	O
the	O
invention	O
is	O
a	O
target	O
locus	O
for	O
the	O
diagnosis	O
of	O
the	O
malignant	O
breast	O
cancer	O
and	O
can	O
be	O
used	O
for	O
quickly	O
screening	O
the	O
medicine	O
for	O
treating	O
the	O
breast	O
cancer	O
.	O

The	O
medicine	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
used	O
for	O
treating	O
the	O
malignant	O
breast	O
cancer	O
and	O
has	O
practical	O
application	O
value	O
.	O

Application	O
of	O
nucleotide	O
sequence	O

The	O
invention	O
discloses	O
application	O
of	O
tetrahydropalmatine	B
and	O
naringin	B
in	O
preparing	O
oral	O
care	O
products	O
,	O
i.e.	O
,	O
tetrahydropalmatine	B
and	O
naringin	B
are	O
added	O
into	O
an	O
oral	O
care	O
health	O
-	O
care	O
product	O
as	O
active	O
ingredients	O
with	O
analgesic	O
effect	O
in	O
form	O
of	O
a	O
compound	O
in	O
a	O
process	O
of	O
preparing	O
oral	O
care	O
products	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
oral	O
care	O
products	O
provided	O
by	O
the	O
invention	O
not	O
only	O
are	O
safe	O
to	O
use	O
,	O
but	O
also	O
have	O
remarkable	O
analgesic	O
effects	O
.	O

Application	O
of	O
tetrahydropalmatine	B
and	O
naringin	B
in	O
preparing	O
oral	O
care	O
products	O

The	O
invention	O
relates	O
to	O
a	O
miconazole	B
nitrate	I
expandable	O
vaginal	O
suppository	O
,	O
and	O
a	O
preparation	O
method	O
and	O
a	O
detection	O
method	O
thereof	O
.	O

The	O
expandable	O
vaginal	O
suppository	O
comprises	O
a	O
drug	O
-	O
containing	O
matrix	O
formed	O
by	O
miconazole	B
nitrate	I
and	O
a	O
matrix	O
,	O
and	O
an	O
expansion	O
carrier	O
.	O

Miconazole	B
nitrate	I
and	O
a	O
specific	O
solid	O
dispersion	O
carrier	O
are	O
prepared	O
into	O
a	O
solid	O
dispersion	O
to	O
improve	O
the	O
stability	O
of	O
the	O
suppository	O
and	O
solubility	O
of	O
active	O
ingredients	O
,	O
and	O
increase	O
bioavailability	O
of	O
the	O
suppository	O
.	O

The	O
outer	O
layer	O
of	O
the	O
expandable	O
vaginal	O
suppository	O
is	O
coated	O
with	O
a	O
film	O
coating	O
to	O
prolong	O
the	O
action	O
time	O
of	O
the	O
suppository	O
on	O
the	O
vagina	O
and	O
improve	O
the	O
stability	O
of	O
the	O
suppository	O
.	O

The	O
miconazole	B
nitrate	I
expandable	O
vaginal	O
suppository	O
provided	O
by	O
the	O
invention	O
employs	O
seven	O
originally	O
created	O
leading	O
technologies	O
,	O
and	O
has	O
the	O
beneficial	O
effects	O
of	O
prevention	O
of	O
outflow	O
liquid	O
,	O
high	O
stability	O
,	O
lasting	O
effect	O
and	O
prevention	O
of	O
secondary	O
infection	O
.	O

Miconazole	B
nitrate	I
expandable	O
vaginal	O
suppository	O
,	O
and	O
preparation	O
method	O
and	O
detection	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technology	O
that	O
sucrose	B
acetate	I
isobutyrate	I
is	O
applied	O
to	O
preparation	O
of	O
an	O
oily	O
injection	O
agent	O
for	O
animals	O
,	O
in	O
particular	O
to	O
the	O
technology	O
which	O
combines	O
the	O
sucrose	B
acetate	I
isobutyrate	I
with	O
hydrogenated	O
castor	O
oil	O
or	O
aluminium	B
stearate	I
and	O
is	O
used	O
for	O
preparing	O
a	O
long	O
-	O
acting	O
injection	O
agent	O
containing	O
valnemulin	B
.	O

A	O
dispersion	O
medium	O
of	O
the	O
long	O
-	O
acting	O
injection	O
agent	O
is	O
isopropyl	B
myristate	I
or	O
benzyl	B
benzoate	I
or	O
ethyl	B
oleate	I
or	O
a	O
mixture	O
mixing	O
more	O
than	O
one	O
of	O
isopropyl	B
myristate	I
,	O
benzyl	B
benzoate	I
and	O
ethyl	B
oleate	I
.	O

The	O
injection	O
agent	O
is	O
good	O
in	O
sustained	O
release	O
effect	O
,	O
stable	O
in	O
character	O
,	O
good	O
in	O
histocompatibility	O
and	O
easy	O
to	O
prepare	O
.	O

Long	O
-	O
acting	O
injection	O
agent	O
containing	O
valnemulin	B
serving	O
as	O
effective	O
component	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
phyllanthoid	B
A	I
in	O
preparing	O
an	O
antidiabetic	O
medicament	O
.	O

The	O
application	O
of	O
the	O
phyllanthoid	B
A	I
is	O
proved	O
to	O
have	O
remarkable	O
antidiabetic	O
effects	O
.	O

The	O
Phyllanthoid	B
A	I
is	O
a	O
compound	O
with	O
a	O
definite	O
chemical	O
structure	O
,	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
has	O
strong	O
activities	O
for	O
preventing	O
and	O
treating	O
diabetes	O
and	O
remarkable	O
substantial	O
characteristics	O
and	O
has	O
significant	O
progresses	O
apparently	O
when	O
being	O
used	O
for	O
treating	O
diabetes	O
at	O
the	O
same	O
time	O
.	O

Application	O
of	O
phyllanthoid	B
A	I
in	O
preparing	O
medicament	O
for	O
reducing	O
blood	O
sugar	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicine	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
cefprozil	B
compound	O
,	O
and	O
dispersible	O
tablets	O
,	O
a	O
dry	O
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
cefprozil	B
compound	O
is	O
a	O
crystal	O
,	O
and	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
diagram	O
obtained	O
by	O
Cu	B
-	I
K	I
alpha	O
ray	O
measurement	O
is	O
shown	O
in	O
figure	O
1	O
.	O

Through	O
experimental	O
detection	O
,	O
the	O
cefprozil	B
dispersible	O
tablets	O
and	O
the	O
dry	O
suspension	O
have	O
the	O
advantages	O
of	O
superior	O
stability	O
and	O
quite	O
good	O
smell	O
and	O
taste	O
,	O
and	O
are	O
quite	O
suitable	O
for	O
clinical	O
application	O
.	O

Cefprozil	B
compound	O
,	O
and	O
dispersible	O
tablets	O
,	O
dry	O
suspension	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
preparation	O
of	O
aripiprazole	B
crystal	O
form	O
II	O
by	O
recrystallizing	O
aripiprazole	B
in	O
a	O
mixture	O
of	O
acetone	B
and	O
1-methoxy-2-propanol	B
or	O
a	O
single	O
solvent	O
of	O
1-methoxy-2-propanol	B
.	O

The	O
simple	O
process	O
according	O
to	O
the	O
present	O
invention	O
can	O
produce	O
aripiprazole	B
crystal	O
form	O
II	O
with	O
high	O
purity	O
and	O
high	O
yield	O
in	O
a	O
mass	O
scale	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
anhydrous	O
aripiprazole	B
crystal	O
form	O
ii	O

The	O
invention	O
discloses	O
a	O
drug	O
for	O
hair	O
loss	O
prevention	O
and	O
hair	O
growth	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
drug	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
30	O
parts	O
of	O
fructus	O
psoraleae	O
,	O
10	O
-	O
30	O
parts	O
of	O
rhizoma	O
drynariae	O
,	O
10	O
-	O
30	O
parts	O
of	O
angelica	O
sinensis	O
,	O
15	O
-	O
35	O
parts	O
of	O
rhizoma	O
zingiberis	O
,	O
15	O
-	O
35	O
parts	O
of	O
root	O
of	O
common	O
peony	O
,	O
15	O
-	O
35	O
parts	O
of	O
radix	O
angelicae	O
,	O
20	O
-	O
40	O
parts	O
of	O
cortex	O
dictamni	O
,	O
20	O
-	O
40	O
parts	O
of	O
eclipta	O
alba	O
,	O
15	O
-	O
35	O
parts	O
of	O
flowers	O
carthami	O
,	O
25	O
-	O
45	O
parts	O
of	O
ligusticum	O
wallichii	O
,	O
20	O
-	O
40	O
parts	O
of	O
rehmannia	O
glutinosa	O
,	O
20	O
-	O
40	O
parts	O
of	O
radix	O
aconite	O
,	O
20	O
-	O
40	O
parts	O
of	O
radix	O
stemonae	O
,	O
30	O
-	O
60	O
parts	O
of	O
cacumen	O
biotae	O
,	O
20	O
-	O
40	O
parts	O
of	O
fructus	O
cnidii	O
,	O
15	O
-	O
35	O
parts	O
of	O
spina	O
gleditsiae	O
,	O
15	O
-	O
35	O
parts	O
of	O
iron	O
vitriol	O
,	O
and	O
5490	O
-	O
13420	O
parts	O
of	O
alcohol	B
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
drug	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
required	O
nutrient	O
substances	O
for	O
invigorating	O
the	O
circulation	O
of	O
blood	O
,	O
cooling	O
blood	O
,	O
nourishing	O
yin	O
and	O
supplementing	O
blood	O
,	O
and	O
compensating	O
hair	O
can	O
be	O
obtained	O
;	O
blood	O
circulation	O
of	O
scalp	O
is	O
facilitated	O
;	O
the	O
blood	O
supply	O
situation	O
is	O
improved	O
;	O
the	O
effects	O
of	O
preventing	O
hair	O
loss	O
,	O
breeding	O
hair	O
,	O
nourishing	O
hair	O
and	O
preserving	O
hair	O
are	O
achieved	O
.	O

Drug	O
for	O
hair	O
loss	O
prevention	O
and	O
hair	O
growth	O
,	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
cardiac	O
glycoside	B
compound	O
in	O
treatment	O
of	O
a	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
and	O
particularly	O
relates	O
to	O
use	O
of	O
the	O
cardiac	O
glycoside	B
compound	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
the	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

The	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
is	O
the	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
which	O
has	O
tolerance	O
on	O
a	O
tyrosine	B
kinase	O
inhibitor	O
.	O

Application	O
of	O
cardiac	O
glycoside	B
compound	O
in	O
treatment	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
targeted	O
ferroferric	B
oxide	I
-	O
porphyrin	B
containing	O
composite	O
nanoparticles	O
,	O
and	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
composite	O
nanoparticles	O
.	O

The	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
aims	O
at	O
solving	O
the	O
problems	O
that	O
a	O
photosensitizer	O
is	O
high	O
in	O
accumulation	O
effect	O
within	O
normal	O
tissues	O
and	O
even	O
performs	O
a	O
photochemical	O
reaction	O
under	O
a	O
dark	O
light	O
because	O
a	O
photosensitizer	O
fluorescence	O
signal	O
is	O
low	O
in	O
intensity	O
and	O
low	O
in	O
selective	O
uptake	O
for	O
tumour	O
tissues	O
,	O
existing	O
in	O
photodynamic	O
diagnosis	O
and	O
therapy	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
1	O
,	O
preparing	O
magnetic	O
ferroferric	B
oxide	I
nanoparticles	O
coated	O
by	O
silicon	B
dioxide	I
;	O
2	O
,	O
preparing	O
a	O
porphyrin	B
compound	O
;	O
3	O
,	O
preparing	O
a	O
porphyrin	B
compound	O
bound	O
by	O
a	O
silane	O
reagent	O
;	O
4	O
,	O
preparing	O
a	O
porphyrin	B
-	O
folic	B
acid	I
compound	O
;	O
and	O
5	O
,	O
preparing	O
the	O
targeted	O
ferroferric	B
oxide	I
-	O
porphyrin	B
containing	O
composite	O
nanoparticles	O
.	O

The	O
preparation	O
method	O
based	O
on	O
the	O
magnetic	O
ferroferric	B
oxide	I
-	O
porphyrin	B
composite	O
nanoparticles	O
and	O
disclosed	O
by	O
the	O
invention	O
integrates	O
magnetofluid	O
thermal	O
therapy	O
,	O
magnetic	O
targeting	O
and	O
photodynamic	O
therapy	O
as	O
a	O
therapy	O
means	O
for	O
tumours	O
.	O

The	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
used	O
for	O
preparing	O
the	O
targeted	O
ferroferric	B
oxide	I
-	O
porphyrin	B
containing	O
composite	O
nanoparticles	O
.	O

Preparation	O
method	O
of	O
targeted	O
ferroferric	B
oxide	I
-	O
porphyrin	B
containing	O
composite	O
nanoparticles	O

The	O
invention	O
provides	O
a	O
rivaroxaban	B
oral	O
microsphere	O
preparation	O
.	O

The	O
rivaroxaban	B
oral	O
microsphere	O
preparation	O
comprises	O
rivaroxaban	B
and	O
a	O
water	O
-	O
soluble	O
polymer	O
carrier	O
,	O
wherein	O
the	O
water	O
-	O
soluble	O
polymer	O
carrier	O
comprises	O
one	O
or	O
a	O
few	O
of	O
hydroxypropyl	O
methyl	O
cellulose	O
,	O
polyethylene	B
glycol	I
,	O
polyvinylpyrrolidone	B
and	O
cellulose	O
polymer	O
,	O
the	O
weight	O
ratio	O
of	O
the	O
rivaroxaban	B
and	O
water	O
-	O
soluble	O
polymer	O
carrier	O
is	O
1:	O
(	O
1	O
-	O
10	O
)	O
,	O
and	O
the	O
average	O
grain	O
diameter	O
of	O
the	O
microsphere	O
is	O
38	O
-	O
79	O
m	O
um	O
.	O

According	O
to	O
the	O
microsphere	O
preparation	O
,	O
the	O
solubility	O
and	O
bioavailability	O
of	O
indissolvable	O
medicines	O
are	O
improved	O
,	O
and	O
the	O
preparation	O
of	O
rivaroxaban	B
medicinal	O
preparation	O
is	O
no	O
longer	O
restricted	O
by	O
crystal	O
form	O
.	O

Rivaroxaban	B
oral	O
microsphere	O
preparation	O

The	O
invention	O
discloses	O
an	O
enteric	O
-	O
coated	O
sustained	O
release	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
is	O
in	O
form	O
of	O
a	O
double	O
-	O
layer	O
enteric	O
-	O
coated	O
sustained	O
release	O
tablet	O
containing	O
paroxetine	B
or	O
pharmaceutically	O
applicative	O
salt	O
thereof	O
.	O

According	O
to	O
the	O
preparation	O
,	O
Acryl	O
-	O
EZE	O
is	O
used	O
as	O
the	O
material	O
of	O
an	O
enteric	O
coating	O
,	O
so	O
that	O
the	O
stability	O
of	O
the	O
sustained	O
release	O
tablet	O
in	O
releasing	O
can	O
be	O
improved	O
.	O

Enteric	O
-	O
coated	O
sustained	O
release	O
composition	O

The	O
invention	O
discloses	O
an	O
ibuprofen	B
and	O
its	O
salt	O
painless	O
microneedle	O
transdermal	O
patch	O
and	O
its	O
preparation	O
method	O
.	O

the	O
painless	O
microneedle	O
transdermal	O
patch	O
is	O
composed	O
of	O
an	O
array	O
microneedle	O
,	O
an	O
antistick	O
layer	O
and	O
a	O
fixed	O
bonding	O
layer	O
,	O
wherein	O
the	O
array	O
microneedle	O
contains	O
ibuprofen	B
and	O
its	O
isomers	O
or	O
salt	O
and	O
is	O
prepared	O
from	O
an	O
organic	O
material	O
of	O
a	O
substrate	O
such	O
as	O
a	O
cellulose	O
polymer	O
(	O
such	O
as	O
PEG	O
and	O
HPMC	O
,	O
etc	O
.	O
)	O
or	O
chitosan	O
or	O
carbomer	O
and	O
the	O
like	O
or	O
silicon	B
or	O
a	O
metal	O
material	O
.	O

The	O
medicine	O
-	O
containing	O
array	O
microneedle	O
comprises	O
the	O
following	O
components	O
:	O
by	O
weight	O
,	O
2	O
-	O
40	O
%	O
of	O
ibuprofen	B
,	O
8	O
-	O
55.9	O
%	O
of	O
a	O
cellulose	O
polymer	O
(	O
such	O
as	O
PEG	B
and	O
HPMC	O
,	O
etc	O
.	O
)	O
or	O
chitosan	O
or	O
carbomer	O
,	O
2	O
-	O
40	O
%	O
of	O
other	O
auxiliary	O
material	O
such	O
as	O
a	O
solvent	O
aid	O
arginine	B
or	O
sodium	B
bicarbonate	I
or	O
sodium	B
carbonate	I
,	O
0.1	O
-	O
2	O
%	O
of	O
a	O
preservative	O
sodium	B
benzoate	I
and	O
10	O
-	O
40	O
%	O
of	O
water	O
for	O
injection	O
.	O

Ibuprofen	B
and	O
its	O
salt	O
painless	O
microneedle	O
transdermal	O
patch	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
an	O
external	O
veterinary	O
drug	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
veterinary	O
drugs	O
.	O

The	O
external	O
veterinary	O
drug	O
is	O
prepared	O
by	O
mixing	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
500	O
-	O
600	O
parts	O
of	O
65V%-75V%	O
ethyl	B
alcohol	I
and	O
12	O
-	O
16	O
parts	O
of	O
camphor	B
.	O

The	O
external	O
veterinary	O
drug	O
can	O
further	O
comprise	O
0.2	O
-	O
0.5	O
part	O
of	O
VB2	B
(	O
Vitamin	B
B2	I
)	O
and	O
10	O
-	O
15	O
parts	O
of	O
dandelion	O
.	O

The	O
external	O
veterinary	O
drug	O
provided	O
by	O
the	O
invention	O
is	O
directly	O
sprayed	O
on	O
a	O
wounded	O
part	O
,	O
and	O
can	O
be	O
used	O
for	O
treating	O
symptoms	O
such	O
as	O
stomatitis	O
of	O
pigs	O
,	O
cattle	O
and	O
sheep	O
,	O
mammary	O
swelling	O
of	O
cows	O
,	O
hoof	O
and	O
joint	O
swelling	O
,	O
and	O
parotitis	O
,	O
and	O
has	O
remarkable	O
treatment	O
effects	O
especially	O
of	O
swine	O
foot	O
and	O
mouth	O
disease	O
,	O
swine	O
vesicular	O
disease	O
and	O
dairy	O
cow	O
breast	O
herpes	O
.	O

In	O
addition	O
,	O
the	O
external	O
veterinary	O
drug	O
is	O
simple	O
in	O
preparation	O
process	O
,	O
convenient	O
to	O
apply	O
and	O
low	O
in	O
cost	O
,	O
and	O
has	O
the	O
advantages	O
of	O
short	O
treatment	O
course	O
,	O
fast	O
result	O
,	O
convenience	O
,	O
practicability	O
,	O
and	O
low	O
cost	O
.	O

External	O
veterinary	O
drug	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
reducing	O
cardiotoxicity	O
and/or	O
improving	O
survival	O
from	O
treatment	O
with	O
anthracycline	B
agents	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
a	O
vasopressin	B
antagonist	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
,	O
administered	O
simultaneously	O
or	O
prior	O
to	O
the	O
anthracycline	B
administration	O
.	O

Methods	O
for	O
using	O
vasopressin	B
antagonists	O
with	O
anthracycline	B
chemotherapy	O
agents	O
to	O
reduce	O
cardiotoxicity	O
and/or	O
improve	O
survival	O

The	O
invention	O
relates	O
to	O
a	O
Chinese	O
patent	O
medicine	O
for	O
treating	O
cutaneous	O
pruritus	O
.	O

The	O
Chinese	O
patent	O
medicine	O
is	O
prepared	O
from	O
the	O
bulk	O
drugs	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
15	O
parts	O
of	O
cortex	O
dictamni	O
,	O
10	O
-	O
15	O
parts	O
of	O
blackend	O
swallowwort	O
roots	O
,	O
10	O
-	O
15	O
parts	O
of	O
rhizoma	O
typhonii	O
,	O
10	O
-	O
15	O
parts	O
of	O
radix	O
ampelopsis	O
,	O
20	O
-	O
30	O
parts	O
of	O
angelica	O
roots	O
,	O
10	O
-	O
15	O
parts	O
of	O
borneol	B
.	O

The	O
Chinese	O
patent	O
medicine	O
has	O
the	O
functions	O
of	O
invigorating	O
the	O
circulation	O
of	O
blood	O
,	O
dispelling	O
wind	O
and	O
arresting	O
itching	O
,	O
clearing	O
away	O
heat	O
and	O
drying	O
dampness	O
,	O
promoting	O
diuresis	O
and	O
dehumidifying	O
;	O
the	O
medicine	O
can	O
solve	O
the	O
current	O
problems	O
and	O
eliminate	O
the	O
root	O
causes	O
of	O
the	O
common	O
cutaneous	O
pruritus	O
so	O
that	O
the	O
disease	O
can	O
not	O
recur	O
after	O
curing	O
,	O
and	O
the	O
curative	O
effect	O
is	O
strengthened	O
and	O
the	O
total	O
effective	O
rate	O
is	O
up	O
to	O
95	O
percent	O
.	O

The	O
medicine	O
is	O
scientific	O
in	O
formula	O
,	O
and	O
the	O
functions	O
of	O
all	O
components	O
are	O
complementary	O
to	O
generate	O
a	O
good	O
synergistic	O
effect	O
;	O
the	O
good	O
effect	O
in	O
healing	O
and	O
recovery	O
of	O
cutaneous	O
pruritus	O
is	O
achieved	O
,	O
the	O
toxic	O
and	O
side	O
effects	O
are	O
avoided	O
,	O
and	O
the	O
Chinese	O
patent	O
medicine	O
is	O
convenient	O
to	O
use	O
.	O

Chinese	O
patent	O
medicine	O
for	O
treating	O
cutaneous	O
pruritus	O

The	O
invention	O
discloses	O
tetravalent	O
platinum	B
complexes	O
containing	O
an	O
imidazole	B
group	O
,	O
protein	O
complexes	O
formed	O
by	O
binding	O
the	O
tetravalent	O
platinum	B
complexes	O
and	O
azurin	O
mutant	O
,	O
and	O
a	O
preparation	O
method	O
of	O
the	O
protein	O
complexes	O
.	O

Specifically	O
,	O
the	O
invention	O
relates	O
to	O
azurin	O
and	O
tetravalent	O
platinum	B
complexes	O
,	O
wherein	O
the	O
azurin	O
has	O
a	O
mutant	O
histidine	B
at	O
a	O
copper	B
binding	O
site	O
,	O
and	O
each	O
platinum	B
complex	O
contains	O
an	O
imidazole	B
group	O
,	O
and	O
a	O
protein	O
complex	O
is	O
constructed	O
by	O
coordination	O
of	O
the	O
azurin	O
and	O
the	O
platinum	B
complex	O
.	O

The	O
coordination	O
manner	O
of	O
each	O
tetravalent	O
platinum	B
complex	O
and	O
the	O
azurin	O
mutant	O
is	O
that	O
:	O
the	O
imidazole	B
group	O
of	O
the	O
tetravalent	O
platinum	B
complex	O
is	O
coordinated	O
with	O
the	O
copper	B
atom	O
by	O
replacing	O
the	O
imidazole	B
group	O
of	O
the	O
mutant	O
histidine	B
of	O
the	O
azurin	O
protein	O
,	O
so	O
that	O
the	O
tetravalent	O
platinum	B
complex	O
is	O
coordinated	O
to	O
the	O
copper	B
atom	O
center	O
of	O
the	O
azurin	O
protein	O
mutant	O
.	O

Results	O
of	O
tumor	O
cell	O
growth	O
inhibition	O
experiments	O
show	O
that	O
:	O
the	O
azurin	O
protein	O
contains	O
the	O
tetravalent	O
platinum	B
complex	O
has	O
relatively	O
good	O
tumor	O
-	O
cell	O
growth	O
inhibition	O
effect	O
,	O
and	O
has	O
antitumor	O
drug	O
application	O
prospect	O
.	O

Platinum	B
complexes	O
,	O
protein	O
complexes	O
prepared	O
from	O
same	O
,	O
and	O
preparation	O
method	O
of	O
protein	O
complexes	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
preparations	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
racecadotril	B
particle	O
for	O
treating	O
infantile	O
diarrhea	O
as	O
well	O
as	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pharmaceutical	O
particle	O
is	O
a	O
solid	O
preparation	O
which	O
is	O
prepared	O
in	O
the	O
following	O
steps	O
:	O
firstly	O
,	O
carrying	O
out	O
clathration	O
on	O
racecadotril	B
by	O
cyclodextrin	O
or	O
a	O
cyclodextrin	O
derivative	O
;	O
and	O
then	O
,	O
matching	O
with	O
a	O
diluent	O
,	O
an	O
adhesive	O
,	O
a	O
disintegrating	O
agent	O
,	O
a	O
flow	O
aid	O
and	O
a	O
corrigent	O
or	O
other	O
pharmaceutically	O
accepted	O
auxiliary	O
materials	O
.	O

The	O
particle	O
provided	O
by	O
the	O
invention	O
effectively	O
solves	O
the	O
problem	O
of	O
difficult	O
administration	O
and	O
bad	O
taste	O
for	O
children	O
and	O
better	O
satisfies	O
the	O
clinical	O
demands	O
.	O

Racecadotril	B
particle	O
as	O
well	O
as	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
bromhexine	B
hydrochloride	I
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
,	O
which	O
relates	O
to	O
the	O
field	O
of	O
medicines	O
and	O
medicine	O
manufacturing	O
technology	O
.	O

The	O
bromhexine	B
hydrochloride	I
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
comprises	O
the	O
following	O
raw	O
material	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
bromhexine	B
hydrochloride	I
,	O
0.5	O
-	O
1.3	O
parts	O
of	O
chitosan	O
nanoparticles	O
and	O
5	O
-	O
10	O
parts	O
of	O
injection	O
water	O
.	O

The	O
bromhexine	B
hydrochloride	I
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
:	O
1	O
)	O
the	O
chitosan	O
nanoparticles	O
replace	O
mannitol	B
to	O
serve	O
as	O
a	O
skeleton	O
agent	O
of	O
the	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
,	O
the	O
obtained	O
product	O
is	O
good	O
in	O
shape	O
,	O
high	O
in	O
stability	O
and	O
capable	O
of	O
avoiding	O
a	O
kidney	O
failure	O
risk	O
caused	O
by	O
clinic	O
use	O
of	O
the	O
mannitol	B
;	O
2	O
)	O
the	O
bromhexine	B
hydrochloride	I
is	O
slightly	O
soluble	O
in	O
water	O
,	O
the	O
chitosan	O
nanoparticles	O
can	O
also	O
be	O
used	O
as	O
a	O
cosolvent	O
of	O
the	O
hydrochloride	B
bromhexine	I
to	O
improve	O
the	O
solubleness	O
of	O
the	O
hydrochloride	B
bromhexine	I
and	O
facilitate	O
industrial	O
production	O
and	O
clinic	O
use	O
;	O
and	O
3	O
)	O
the	O
chitosan	O
nanoparticles	O
have	O
certain	O
antibacterial	O
activity	O
,	O
when	O
being	O
clinically	O
used	O
with	O
the	O
hydrochloride	B
bromhexine	I
,	O
the	O
chitosan	O
nanoparticles	O
can	O
cooperatively	O
treat	O
respiratory	O
tract	O
infection	O
accompanied	O
with	O
a	O
symptom	O
that	O
viscous	O
sputum	O
is	O
unlikely	O
to	O
expectorate	O
caused	O
by	O
sensitive	O
bacteria	O
.	O

Bromhexine	B
hydrochloride	I
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O

The	O
invention	O
provides	O
ceftibuten	B
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
,	O
which	O
relates	O
to	O
the	O
field	O
of	O
medicine	O
and	O
medicine	O
manufacturing	O
technology	O
.	O

The	O
ceftibuten	B
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
comprises	O
the	O
following	O
raw	O
material	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
ceftibuten	B
,	O
0.1	O
-	O
1.0	O
part	O
of	O
chitosan	O
nanoparticles	O
and	O
5	O
-	O
10	O
parts	O
of	O
injection	O
water	O
.	O

The	O
ceftibuten	B
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
1	O
)	O
the	O
composition	O
can	O
significantly	O
enhance	O
the	O
antibacterial	O
effect	O
of	O
the	O
ceftibuten	B
,	O
clinically	O
reduce	O
the	O
ceftibuten	B
dosage	O
and	O
reduce	O
the	O
adverse	O
reactions	O
of	O
the	O
ceftibuten	B
,	O
and	O
as	O
shown	O
in	O
experiments	O
in	O
vitro	O
,	O
0.2	O
g	O
of	O
ceftibuten	B
composition	O
freeze	O
-	O
dried	O
powder	O
containing	O
the	O
chitosan	O
nanoparticles	O
has	O
the	O
same	O
curative	O
effect	O
as	O
0.4	O
g	O
of	O
ceftibuten	B
containing	O
no	O
chitosan	O
nanoparticles	O
;	O
and	O
2	O
)	O
the	O
chitosan	O
nanoparticles	O
can	O
replace	O
mannitol	B
to	O
serve	O
as	O
a	O
freeze	O
drying	O
skeleton	O
agent	O
of	O
the	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O
so	O
as	O
to	O
eliminate	O
the	O
activity	O
of	O
the	O
mannitol	B
on	O
human	O
body	O
.	O

Ceftibuten	B
composition	O
freeze	O
-	O
dried	O
powder	O
for	O
injection	O

The	O
invention	O
provides	O
an	O
oral	O
administration	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
containing	O
curcuma	O
phaeocaulis	O
valeton	O
cyclic	B
diolefine	I
.	O

The	O
preparation	O
is	O
an	O
oral	O
administration	O
solid	O
troche	O
or	O
a	O
capsule	O
.	O

According	O
to	O
the	O
oral	O
administration	O
solid	O
troche	O
or	O
the	O
capsule	O
,	O
phaeocaulis	O
valeton	O
cyclic	B
diolefine	I
is	O
micronized	O
by	O
a	O
low	O
temperature	O
crushing	O
technology	O
,	O
so	O
that	O
the	O
grain	O
size	O
reaches	O
200	O
meshes	O
,	O
thereby	O
improving	O
the	O
mobility	O
of	O
the	O
medicine	O
,	O
increasing	O
the	O
bioavailability	O
of	O
the	O
oral	O
administration	O
preparation	O
,	O
reducing	O
the	O
content	O
of	O
the	O
medicine	O
in	O
the	O
oral	O
administration	O
solid	O
preparation	O
and	O
indirectly	O
lowering	O
the	O
cost	O
at	O
the	O
same	O
time	O
.	O

Pharmaceutical	O
composition	O
containing	O
curcuma	O
phaeocaulis	O
valeton	O
cyclic	B
diolefine	I
and	O
pharmaceutical	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
blood	O
matching	O
injection	O
of	O
Aiaikang	O
capsules	O
and	O
activated	O
carbon	B
nanoparticles	O
.	O

The	O
Aiaikang	O
capsules	O
are	O
prepared	O
from	O
green	O
activated	O
carbon	B
nanoparticles	O
,	O
nucleic	O
acid	O
,	O
calcium	B
,	O
corn	O
stigma	O
,	O
honeysuckle	O
,	O
herba	O
violae	O
,	O
hedge	O
glorybind	O
flower	O
,	O
fructus	O
forsythiae	O
,	O
pulsatilla	O
root	O
,	O
perilla	O
leaf	O
,	O
astragalus	O
membranaceus	O
,	O
herba	O
cistanche	O
,	O
fructus	O
psoraleae	O
,	O
acorus	O
calamus	O
,	O
frankincense	O
,	O
myrrh	O
,	O
mimatsu	O
bark	O
,	O
ailanthus	O
altissima	O
,	O
folium	O
ginkgo	O
bilobae	O
,	O
euphorbia	O
lunulata	O
seeds	O
,	O
Chinese	O
-	O
date	O
,	O
camphor	O
,	O
borneol	O
,	O
snake	O
grape	O
root	O
,	O
oldenlandia	O
diffusa	O
,	O
sculellaria	O
barbata	O
,	O
rhizoma	O
phragmitis	O
,	O
stir	O
-	O
baked	O
squama	O
manitis	O
,	O
folium	O
artemisiae	O
argyi	O
,	O
propolis	O
,	O
semen	O
cuscutae	O
,	O
radix	O
sophorae	O
flavescentis	O
,	O
scorpio	O
,	O
herba	O
geranii	O
,	O
ginger	O
powder	O
,	O
square	O
-	O
stem	O
,	O
bighead	O
atractylodes	O
rhizome	O
,	O
horseleech	O
and	O
the	O
like	O
in	O
a	O
manner	O
of	O
crushing	O
by	O
2	O
-	O
10fold	O
airflow	O
at	O
a	O
supersonic	O
speed	O
,	O
wherein	O
the	O
activated	O
carbon	O
nanoparticles	O
for	O
the	O
capsule	O
achieve	O
over	O
3000	O
meshes	O
;	O
the	O
other	O
medicines	O
are	O
over	O
2000	O
meshes	O
;	O
the	O
green	O
activated	O
carbon	O
nanoparticles	O
for	O
injection	O
are	O
over	O
30000	O
meshes	O
.	O

The	O
blood	O
matching	O
injection	O
is	O
ultra	O
-	O
micro	O
in	O
particle	O
size	O
,	O
and	O
over	O
-	O
large	O
in	O
activity	O
,	O
and	O
can	O
enter	O
inside	O
cell	O
nucleus	O
to	O
kill	O
viruses	O
;	O
an	O
infected	O
cell	O
repair	O
function	O
can	O
be	O
rescued	O
;	O
the	O
nutrients	O
in	O
the	O
medicine	O
or	O
blood	O
can	O
be	O
obtained	O
;	O
the	O
vigor	O
and	O
vitality	O
of	O
the	O
cells	O
are	O
enhanced	O
;	O
an	O
antibody	O
can	O
be	O
generated	O
after	O
recovery	O
.	O

Thus	O
,	O
the	O
blood	O
matching	O
injection	O
is	O
applicable	O
to	O
curing	O
uremia	O
avian	O
influenza	O
of	O
aids	O
cancer	O
septicemia	O
and	O
an	O
intractable	O
skin	O
disease	O
once	O
and	O
for	O
all	O
.	O

Blood	O
matching	O
injection	O
of	O
Aiaikang	O
capsules	O
and	O
activated	O
carbon	B
nanoparticles	O

The	O
present	O
invention	O
provides	O
pyrazolopyridine	B
compounds	O
represented	O
by	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
preparation	O
method	O
,	O
uses	O
and	O
a	O
drug	O
composition	O
thereof	O
.	O

The	O
compounds	O
can	O
inhibit	O
PI3	O
K	O
activity	O
so	O
as	O
to	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
treatments	O
of	O
diseases	O
or	O
disorders	O
caused	O
by	O
PI3K	O
-	O
AKT	O
-	O
mTOR	O
signaling	O
pathway	O
dysfunction	O
,	O
wherein	O
the	O
diseases	O
or	O
disorders	O
are	O
malignant	O
tumors	O
,	O
immunologic	O
diseases	O
,	O
cardiovascular	O
diseases	O
,	O
inflammations	O
,	O
metabolism	O
/	O
endocrine	O
dysfunction	O
,	O
neurological	O
diseases	O
and	O
the	O
like	O
.	O

The	O
general	O
formula	O
(	O
I	O
)	O
.	O

Pyrazolopyridine	B
compounds	O
,	O
preparation	O
method	O
,	O
uses	O
and	O
drug	O
composition	O
thereof	O

The	O
invention	O
discloses	O
a	O
meropenem	B
raw	O
medicine	O
which	O
is	O
characterized	O
in	O
that	O
the	O
content	O
of	O
meropenem	B
in	O
the	O
raw	O
medicine	O
is	O
98.0	O
-	O
101.0	O
%	O
by	O
weight	O
based	O
on	O
anhydride	B
;	O
the	O
content	O
of	O
the	O
impurity	O
A	O
and	O
impurity	O
B	O
in	O
the	O
related	O
substances	O
of	O
the	O
raw	O
medicine	O
is	O
not	O
greater	O
than	O
0.25	O
%	O
respectively	O
;	O
the	O
content	O
of	O
any	O
unknown	O
single	O
impurity	O
is	O
not	O
greater	O
than	O
0.05	O
%	O
;	O
the	O
total	O
content	O
of	O
other	O
impurities	O
except	O
the	O
A	O
and	O
B	O
is	O
not	O
greater	O
than	O
0.25	O
%	O
;	O
the	O
acetone	B
residue	O
is	O
not	O
greater	O
than	O
300ppm	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
meropenem	B
pharmaceutical	O
composition	O
for	O
injection	O
,	O
and	O
the	O
pharmaceutical	O
composition	O
takes	O
the	O
meropenem	B
raw	O
medicine	O
provided	O
by	O
the	O
invention	O
as	O
an	O
active	O
ingredient	O
and	O
has	O
excellent	O
stability	O
.	O

The	O
meropenem	B
raw	O
medicine	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
purity	O
,	O
clear	O
impurity	O
condition	O
,	O
low	O
solvent	O
residue	O
,	O
good	O
solubility	O
and	O
good	O
long	O
-	O
term	O
storage	O
stability	O
,	O
and	O
can	O
guarantee	O
the	O
effectiveness	O
and	O
safety	O
of	O
the	O
medicine	O
.	O

Meropenem	B
raw	O
medicine	O
,	O
preparation	O
method	O
thereof	O
and	O
pharmaceutical	O
composition	O
containing	O
same	O

The	O
invention	O
discloses	O
pharmaceutical	O
composition	O
for	O
treating	O
acute	O
urticaria	O
and	O
an	O
application	O
of	O
the	O
pharmaceutical	O
composition	O
to	O
preparation	O
of	O
drugs	O
for	O
preventing	O
or	O
treating	O
the	O
acute	O
urticaria	O
,	O
and	O
aims	O
at	O
overcoming	O
the	O
defect	O
that	O
drugs	O
for	O
treating	O
the	O
acute	O
urticaria	O
are	O
poor	O
in	O
effect	O
and	O
non	O
-	O
sustainable	O
in	O
action	O
at	O
present	O
,	O
the	O
pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
the	O
acute	O
urticaria	O
is	O
low	O
in	O
treatment	O
cost	O
,	O
convenient	O
to	O
take	O
by	O
a	O
patient	O
,	O
quick	O
in	O
curative	O
effect	O
and	O
free	O
of	O
side	O
effects	O
and	O
comprises	O
levocetirizine	B
and	O
triptolide	B
.	O

The	O
pharmaceutical	O
composition	O
has	O
a	O
good	O
treatment	O
effect	O
in	O
treating	O
the	O
acute	O
urticaria	O
and	O
obvious	O
clinical	O
promotional	O
values	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
acute	O
urticaria	O

The	O
invention	O
relates	O
to	O
a	O
psychotherapeutic	O
drug	O
for	O
OA	O
(	O
Oarthritis	O
)	O
and	O
RA	O
(	O
Rheumatoid	O
Arthritis	O
)	O
,	O
in	O
particular	O
to	O
a	O
celecoxib	B
solid	O
composition	O
with	O
an	O
increased	O
dissolution	O
rate	O
,	O
and	O
the	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
celecoxib	B
solid	O
composition	O
comprises	O
celecoxib	B
,	O
a	O
dispersion	O
promoter	O
and	O
an	O
alkali	O
compound	O
,	O
wherein	O
the	O
mass	O
ratio	O
of	O
the	O
celecoxib	B
,	O
the	O
dispersion	O
promoter	O
and	O
the	O
alkali	O
compound	O
is	O
100	O
:	O
(	O
5-	O
95	O
)	O
:	O
(	O
0.1-	O
1.5	O
)	O
;	O
the	O
D90	O
of	O
the	O
celecoxib	B
solid	O
composition	O
ranges	O
from	O
5	O
to	O
20	O
micron	O
.	O

The	O
celecoxib	B
solid	O
composition	O
provided	O
by	O
the	O
invention	O
solves	O
the	O
technological	O
difficulties	O
of	O
strong	O
material	O
static	O
and	O
low	O
probability	O
of	O
powder	O
mixing	O
no	O
matter	O
under	O
a	O
condition	O
that	O
the	O
celecoxib	B
bulk	O
drug	O
is	O
monocrystal	O
or	O
mixed	O
polycrystal	O
,	O
so	O
that	O
the	O
problem	O
that	O
the	O
celecoxib	B
is	O
hydrophilic	O
is	O
solved	O
,	O
the	O
physical	O
property	O
that	O
the	O
drug	O
is	O
difficult	O
to	O
dissolve	O
is	O
improved	O
,	O
and	O
the	O
dissolution	O
rate	O
of	O
the	O
drug	O
is	O
increased	O
,	O
thereby	O
being	O
beneficial	O
to	O
drug	O
absorbing	O
.	O

Celecoxib	B
solid	O
composition	O
with	O
increased	O
dissolution	O
rate	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
new	O
use	O
of	O
a	O
sivery	O
aleuritopteris	O
herb	O
extract	O
,	O
and	O
the	O
new	O
use	O
is	O
the	O
application	O
of	O
the	O
silvery	O
aleuritopteris	O
herb	O
extract	O
in	O
preparation	O
of	O
anticancer	O
drugs	O
.	O

The	O
silvery	O
aleuritopteris	O
herb	O
extract	O
is	O
prepared	O
by	O
the	O
following	O
method	O
:	O
extracting	O
silvery	O
aleuritopteris	O
herb	O
as	O
a	O
raw	O
material	O
with	O
50%-90	O
%	O
ethanol	B
,	O
and	O
then	O
using	O
high	O
-	O
speed	O
counter	O
current	O
chromatography	O
,	O
macroporous	O
adsorption	O
resin	O
and	O
the	O
like	O
for	O
chromatography	O
purification	O
to	O
obtain	O
the	O
silvery	O
aleuritopteris	O
herb	O
extract	O
.	O

The	O
silvery	O
aleuritopteris	O
herb	O
extract	O
has	O
important	O
significance	O
in	O
preparation	O
of	O
the	O
anticancer	O
drugs	O
,	O
especially	O
anti	O
liver	O
cancer	O
,	O
anti	O
lung	O
cancer	O
,	O
and	O
anti	O
-	O
gastric	O
cancer	O
drugs	O
.	O

Application	O
of	O
silvery	O
aleuritopteris	O
herb	O
extract	O
in	O
preparation	O
of	O
anticancer	O
drugs	O

The	O
invention	O
provides	O
foot	O
bath	O
powder	O
.	O

The	O
foot	O
bath	O
powder	O
consists	O
of	O
the	O
following	O
materials	O
by	O
weight	O
percent	O
:	O
98	O
%	O
of	O
red	O
bean	O
cedar	O
dry	O
powder	O
,	O
0.4	O
%	O
of	O
Chinese	O
yew	O
bark	O
powder	O
,	O
0.5	O
%	O
of	O
Chinese	O
yew	O
root	O
powder	O
,	O
0.2	O
%	O
of	O
Chinese	O
yew	O
leaf	O
powder	O
,	O
0.7	O
%	O
of	O
Chinese	O
yew	O
kernel	O
powder	O
and	O
0.2	O
%	O
of	O
taxol	O
.	O

The	O
foot	O
bath	O
powder	O
has	O
the	O
advantages	O
that	O
the	O
cancer	O
cell	O
growth	O
can	O
be	O
controlled	O
,	O
the	O
circulation	O
and	O
metabolism	O
of	O
human	O
bodies	O
can	O
be	O
promoted	O
,	O
the	O
physique	O
of	O
human	O
bodies	O
can	O
be	O
enhanced	O
,	O
and	O
the	O
functions	O
of	O
bacteriostasis	O
and	O
antiphlogosis	O
are	O
achieved	O
.	O

Foot	O
bath	O
powder	O

The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
used	O
for	O
treating	O
neurasthenia	O
,	O
which	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medical	O
preparations	O
.	O

According	O
to	O
a	O
technical	O
scheme	O
in	O
the	O
invention	O
,	O
each	O
part	O
of	O
the	O
pharmaceutical	O
composition	O
comprises	O
9	O
to	O
50	O
g	O
of	O
lily	O
bulb	O
,	O
6	O
to	O
15	O
g	O
of	O
spine	O
date	O
seed	O
,	O
6	O
to	O
15	O
g	O
of	O
common	O
selfheal	O
fruit	O
-	O
spike	O
,	O
1.5	O
to	O
3	O
g	O
of	O
coptis	O
,	O
9	O
to	O
13	O
g	O
of	O
prepared	O
rehmannia	O
root	O
,	O
9	O
to	O
15	O
g	O
of	O
red	O
sage	O
root	O
,	O
3	O
to	O
6	O
g	O
of	O
licorice	O
,	O
with	O
the	O
balance	O
being	O
a	O
proper	O
amount	O
of	O
oryzanol	B
and	O
vitamin	B
B12	I
.	O

The	O
pharmaceutical	O
composition	O
is	O
capable	O
of	O
nourishing	O
yin	O
and	O
blood	O
,	O
clearing	O
liver	O
,	O
purging	O
fire	O
,	O
tranquilizing	O
the	O
mind	O
,	O
warming	O
qi	O
and	O
blood	O
and	O
tonifying	O
the	O
nerves	O
,	O
realizes	O
omnibearing	O
comprehensive	O
treatment	O
and	O
has	O
a	O
substantial	O
treatment	O
effect	O
.	O

Pharmaceutical	O
composition	O
used	O
for	O
treating	O
neurasthenia	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
cancer	O
pain	O
medicament	O
with	O
the	O
following	O
structural	O
formula	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
composition	O
containing	O
the	O
medicament	O
.	O

Cancer	O
pain	O
medicament	O

The	O
invention	O
relates	O
to	O
an	O
officinal	O
composition	O
of	O
vidarabine	B
monophosphate	I
for	O
injection	O
,	O
wherein	O
the	O
main	O
active	O
components	O
of	O
the	O
composition	O
comprise	O
vidarabine	B
monophosphate	I
and	O
lysine	B
.	O

Officinal	O
composition	O
of	O
vidarabine	B
monophosphate	I
for	O
injection	O

The	O
invention	O
discloses	O
a	O
2	B
,	I
2'-bipyridine-6	I
,	I
6'-diformyl	I
-	I
quinolyl-2-amine	I
derivative	O
,	O
and	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O

The	O
2	B
,	I
2'-bipyridine-6	I
,	I
6'-diformyl	I
-	I
quinolyl-2-amine	I
derivative	O
is	O
represented	O
by	O
formula	O
I.	O
The	O
2	B
,	I
2'-bipyridine-6	I
,	I
6'-diformyl	I
-	I
quinolyl-2-amine	I
derivative	O
can	O
be	O
prepared	O
by	O
a	O
multi	O
-	O
step	O
organic	O
synthetic	O
reaction	O
including	O
Mitsunobu	O
Reaction	O
,	O
acid	B
amine	I
condensation	O
,	O
and	O
the	O
like	O
.	O

The	O
2	B
,	I
2'-bipyridine-6	I
,	I
6'-diformyl	I
-	I
quinolyl-2-amine	I
derivative	O
possesses	O
pervasive	O
high	O
-	O
efficient	O
inhibition	O
effect	O
on	O
a	O
plurality	O
of	O
cell	O
strains	O
,	O
and	O
is	O
of	O
significant	O
importance	O
in	O
preparation	O
of	O
antitumor	O
drugs	O
.	O

2	B
,	I
2'-bipyridine-6	I
,	I
6'-diformyl	I
-	I
quinolyl-2-amine	I
derivative	O
,	O
and	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
triamcinolone	B
acetonide	I
acetate	I
solution	O
preparation	O
method	O
.	O

According	O
to	O
the	O
method	O
,	O
a	O
solution	O
product	O
with	O
excellent	O
stability	O
is	O
obtained	O
by	O
adding	O
appropriate	O
amount	O
of	O
a	O
sodium	B
chloride	I
aqueous	O
solution	O
;	O
in	O
addition	O
,	O
with	O
adoption	O
of	O
the	O
method	O
,	O
the	O
production	O
cost	O
is	O
low	O
,	O
the	O
safety	O
and	O
effectiveness	O
of	O
the	O
product	O
are	O
not	O
affected	O
,	O
the	O
environmental	O
pollution	O
pressure	O
is	O
not	O
worsened	O
,	O
and	O
industrial	O
production	O
and	O
application	O
are	O
suitable	O
.	O

Compound	O
triamcinolone	B
acetonide	I
acetate	I
solution	O
preparation	O
method	O

The	O
invention	O
provides	O
a	O
high	O
-	O
content	O
jujube	O
cyclic	B
adenosine	I
monophosphate	I
extract	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
concentration	O
of	O
cyclic	B
adenosine	I
monophosphate	I
in	O
the	O
extract	O
is	O
more	O
than	O
15mg	O
/	O
100	O
g	O
,	O
solid	O
or	O
semi	O
-	O
solid	O
jujubes	O
are	O
taken	O
as	O
raw	O
materials	O
,	O
and	O
the	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
extracting	O
by	O
a	O
continuous	O
low	O
-	O
temperature	O
extractor	O
with	O
high	O
pressure	O
difference	O
,	O
concentrating	O
an	O
extraction	O
solution	O
,	O
performing	O
vacuum	O
drying	O
and	O
crushing	O
to	O
obtain	O
a	O
jujube	O
crude	O
extract	O
;	O
extracting	O
the	O
crude	O
extract	O
by	O
adopting	O
a	O
supercritical	O
extraction	O
technology	O
to	O
obtain	O
the	O
jujube	O
cyclic	B
adenosine	I
monophosphate	I
extract	O
.	O

The	O
jujube	O
cyclic	B
adenosine	I
monophosphate	I
extract	O
has	O
prominent	O
effects	O
in	O
the	O
aspects	O
of	O
hypoxia	O
resistance	O
,	O
fatigue	O
resistance	O
and	O
improvement	O
of	O
life	O
quality	O
.	O

The	O
preparation	O
method	O
has	O
the	O
following	O
obvious	O
advantages	O
:	O
(	O
1	O
)	O
the	O
extraction	O
transfer	O
rate	O
is	O
high	O
;	O
(	O
2	O
)	O
the	O
production	O
efficiency	O
is	O
high	O
;	O
(	O
3	O
)	O
the	O
quality	O
controllability	O
is	O
high	O
;	O
(	O
4	O
)	O
the	O
operation	O
controllable	O
degree	O
is	O
high	O
;	O
(	O
5	O
)	O
the	O
comprehensive	O
utilization	O
rate	O
of	O
resources	O
is	O
high	O
;	O
(	O
6	O
)	O
the	O
comprehensive	O
operation	O
cost	O
is	O
low	O
;	O
(	O
7	O
)	O
the	O
degree	O
of	O
automation	O
is	O
high	O
;	O
(	O
8)	O
the	O
environmental	O
pollution	O
is	O
little	O
.	O

High	O
-	O
content	O
jujube	O
cyclic	B
adenosine	I
monophosphate	I
extract	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
habitual	O
abortion	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
medicines	O
,	O
namely	O
,	O
hawthorn	O
,	O
radix	O
paeoniae	O
alba	O
,	O
eucommia	O
ulmoides	O
,	O
rhizoma	O
cibotii	O
,	O
ligusticum	O
wallichii	O
,	O
cornu	O
cervi	O
degelatinatum	O
,	O
rhizoma	O
cyperi	O
,	O
hairyvein	O
agrimony	O
,	O
black	O
fungus	O
,	O
madder	O
and	O
the	O
like	O
according	O
to	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
tonifying	O
deficiency	O
and	O
supporting	O
Yang	O
,	O
promoting	O
the	O
circulation	O
of	O
qi	O
and	O
regulating	O
middle	O
energizer	O
,	O
and	O
tonifying	O
liver	O
for	O
miscarriage	O
prevention	O
,	O
and	O
is	O
rapid	O
to	O
take	O
effect	O
,	O
good	O
in	O
curative	O
effect	O
and	O
free	O
of	O
toxic	O
and	O
side	O
effect	O
when	O
being	O
used	O
for	O
treating	O
habitual	O
abortion	O
.	O

Medicine	O
for	O
treating	O
habitual	O
abortion	O
and	O
preparation	O
method	O
of	O
medicine	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
biological	O
medicine	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
protamine	O
-	O
deoxycholic	B
acid	I
conjugate	O
with	O
a	O
heparin	O
transfer	O
function	O
.	O

The	O
amidogen	B
of	O
protamine	O
and	O
the	O
carboxyl	B
of	O
deoxycholic	B
acid	I
form	O
an	O
amide	B
bond	O
through	O
teh	O
effect	O
of	O
a	O
cross	O
-	O
linking	O
agent	O
to	O
prepare	O
an	O
amphipathic	O
conjugate	O
,	O
and	O
then	O
the	O
amphipathic	O
conjugate	O
and	O
heparin	O
form	O
a	O
self	O
-	O
assembled	O
aggregation	O
in	O
order	O
to	O
conveniently	O
release	O
the	O
heparin	O
in	O
cells	O
.	O

The	O
hydrophobic	O
modification	O
of	O
the	O
conjugate	O
can	O
enhance	O
the	O
self	O
-	O
aggregation	O
stability	O
of	O
nano	O
-	O
composites	O
;	O
the	O
cationic	O
performance	O
of	O
the	O
conjugate	O
entraps	O
the	O
heparin	O
,	O
so	O
that	O
the	O
distribution	O
capability	O
of	O
the	O
heparin	O
in	O
the	O
cells	O
is	O
increased	O
,	O
and	O
the	O
heparin	O
is	O
prevented	O
from	O
,	O
degradation	O
caused	O
by	O
the	O
effect	O
of	O
heparinase	O
and	O
further	O
the	O
transfer	O
of	O
the	O
heparin	O
into	O
cancer	O
cells	O
and	O
the	O
release	O
and	O
biological	O
effect	O
of	O
the	O
heparin	O
in	O
the	O
cells	O
are	O
realized	O
.	O

Method	O
for	O
preparing	O
protamine	O
-	O
deoxycholic	B
acid	I
conjugate	O
with	O
heparin	O
transfer	O
function	O

The	O
invention	O
discloses	O
an	O
adsorbing	O
and	O
sterilizing	O
material	O
,	O
and	O
particularly	O
discloses	O
an	O
adsorbing	O
material	O
for	O
air	O
purification	O
.	O

The	O
adsorbing	O
and	O
sterilizing	O
material	O
contains	O
the	O
following	O
ingredients	O
:	O
zinc	B
oxide	I
,	O
montmorillonite	O
and	O
activated	O
carbon	B
.	O

According	O
to	O
the	O
material	O
for	O
air	O
purification	O
,	O
a	O
composition	O
formed	O
by	O
mixing	O
the	O
montmorillonite	O
,	O
the	O
zinc	B
oxide	I
and	O
the	O
activated	O
carbon	B
has	O
a	O
large	O
porosity	O
,	O
moreover	O
,	O
the	O
three	O
ingredients	O
respectively	O
have	O
pertinence	O
adsorption	O
performance	O
for	O
toxic	O
and	O
harmful	O
substances	O
,	O
and	O
the	O
respective	O
selective	O
adsorption	O
characteristics	O
of	O
the	O
three	O
ingredients	O
are	O
utilized	O
to	O
mutually	O
enhance	O
the	O
adsorption	O
effect	O
so	O
that	O
the	O
toxic	O
and	O
harmful	O
substances	O
can	O
be	O
hidden	O
nowhere	O
.	O

More	O
importantly	O
,	O
after	O
the	O
montmorillonite	O
,	O
the	O
zinc	B
oxide	I
and	O
the	O
activated	O
carbon	O
are	O
mixed	O
,	O
the	O
bulk	O
density	O
is	O
decreased	O
,	O
the	O
weight	O
of	O
adsorption	O
material	O
with	O
the	O
monomer	O
size	O
is	O
relatively	O
light	O
,	O
the	O
weight	O
of	O
the	O
air	O
purifier	O
is	O
greatly	O
reduced	O
,	O
and	O
the	O
air	O
purifier	O
is	O
more	O
conveniently	O
used	O
.	O

The	O
specific	O
surface	O
area	O
of	O
the	O
activated	O
carbon	B
,	O
the	O
montmorillonite	O
and	O
the	O
zinc	B
oxide	I
is	O
large	O
,	O
the	O
absorbability	O
to	O
harmful	O
gas	O
,	O
bacteria	O
and	O
mould	O
is	O
good	O
,	O
and	O
the	O
sterilization	O
,	O
mould	O
removal	O
and	O
detoxification	O
effect	O
is	O
good	O
.	O

Purifying	O
,	O
adsorbing	O
and	O
sterilizing	O
material	O
and	O
application	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
particularly	O
to	O
a	O
series	O
of	O
unsaturated	O
cyclic	B
amine	I
derivatives	O
.	O

The	O
present	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
and	O
medical	O
uses	O
of	O
the	O
compounds	O
.	O

Unsaturated	O
cyclic	B
amine	I
derivatives	O
,	O
preparation	O
method	O
and	O
medical	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
fumarate	B
of	O
a	O
harmol	B
derivative	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
solvate	O
thereof	O
,	O
and	O
applications	O
of	O
the	O
fumarate	B
and	O
the	O
solvate	O
thereof	O
in	O
preparation	O
of	O
acetylcholine	B
esterase	O
inhibitor	O
drugs	O
.	O

Salt	O
of	O
harmol	B
derivative	O

The	O
invention	O
relates	O
to	O
a	O
long	O
-	O
acting	O
lomefloxacin	B
hydrochloride	I
injection	O
for	O
livestock	O
and	O
a	O
preparation	O
method	O
of	O
the	O
injection	O
.	O

Each	O
1000ml	O
of	O
injection	O
comprises	O
the	O
components	O
of	O
20	O
-	O
25	O
g	O
of	O
lomefloxacin	B
hydrochloride	I
(	O
LMF.HCL	B
)	O
,	O
10	O
-	O
15	O
g	O
of	O
water	O
soluble	O
chitosan	O
,	O
8	O
-	O
10ml	O
of	O
glacial	B
acetic	I
acid	I
(	O
HAC	B
)	O
,	O
0.2	O
-	O
0.3	O
g	O
of	O
ethylenediamine	B
tetraacetic	I
acid	I
disodium	I
(	O
EDTA-2Na	B
)	O
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
(	O
1	O
)	O
,	O
preparing	O
a	O
water	O
soluble	O
chitosan	O
solution	O
;	O
(	O
2	O
)	O
,	O
preparing	O
a	O
lomefloxacin	B
hydrochloride	I
and	O
glacial	B
acetic	I
acid	I
mixed	O
solution	O
;	O
(	O
3	O
)	O
,	O
mixing	O
the	O
solutions	O
prepared	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
the	O
step	O
(	O
2	O
)	O
,	O
fully	O
stirring	O
to	O
produce	O
a	O
water	O
soluble	O
lomefloxacin	B
hydrochloride	I
chitosan	O
microballoon	O
sphere	O
under	O
the	O
condition	O
of	O
acidic	O
catalysis	O
;	O
and	O
(	O
4	O
)	O
,	O
dissolving	O
the	O
ethylenediamine	B
tetraacetic	I
acid	I
disodium	I
by	O
using	O
the	O
water	O
for	O
injection	O
,	O
mixing	O
the	O
solution	O
prepared	O
in	O
the	O
step	O
(	O
3	O
)	O
,	O
adding	O
the	O
water	O
for	O
injection	O
until	O
reaching	O
the	O
full	O
amount	O
,	O
uniformly	O
stirring	O
,	O
filtering	O
,	O
charging	O
nitrogen	B
and	O
encapsulating	O
,	O
and	O
sterilizing	O
by	O
circulating	O
steam	O
at	O
a	O
temperature	O
of	O
120	O
DEG	O
C	O
for	O
20	O
-	O
30min	O
to	O
obtain	O
the	O
long	O
-	O
acting	O
lomefloxacin	B
hydrochloride	I
injection	O
.	O

The	O
long	O
-	O
acting	O
lomefloxacin	B
hydrochloride	I
injection	O
provided	O
by	O
the	O
invention	O
is	O
good	O
in	O
stability	O
;	O
the	O
targeting	O
of	O
the	O
medicine	O
is	O
enhanced	O
,	O
the	O
irritation	O
is	O
reduced	O
,	O
the	O
toxic	O
and	O
side	O
effects	O
are	O
reduced	O
,	O
and	O
the	O
treatment	O
effect	O
of	O
the	O
medicine	O
is	O
improved	O
.	O

Long	O
-	O
acting	O
lomefloxacin	B
hydrochloride	I
injection	O
for	O
livestock	O
and	O
preparation	O
method	O
of	O
injection	O

The	O
invention	O
provides	O
an	O
omeprazole	B
nano	O
emulsion	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
emulsion	O
is	O
respectively	O
prepared	O
from	O
the	O
following	O
components	O
by	O
weight	O
percent	O
:	O
0.1	O
-	O
1	O
%	O
of	O
omeprazole	B
,	O
16	O
-	O
30	O
%	O
of	O
surfactant	O
,	O
0.15	O
-	O
20	O
%	O
of	O
cosurfactant	O
,	O
2	O
-	O
25	O
%	O
of	O
oil	O
and	O
34	O
-	O
50	O
%	O
of	O
water	O
for	O
injection	O
.	O

The	O
omeprazole	B
nano	O
emulsion	O
is	O
good	O
in	O
thermodynamic	O
stability	O
,	O
good	O
in	O
storage	O
stability	O
,	O
and	O
free	O
of	O
layering	O
after	O
being	O
placed	O
for	O
a	O
long	O
period	O
of	O
time	O
,	O
and	O
can	O
be	O
subjected	O
to	O
oral	O
medication	O
and	O
intramuscular	O
injection	O
;	O
a	O
stable	O
emulsion	O
state	O
can	O
be	O
completely	O
recovered	O
by	O
placement	O
and	O
sufficient	O
oscillation	O
after	O
heating	O
to	O
80	O
DEG	O
C	O
;	O
especially	O
,	O
the	O
omeprazole	B
can	O
be	O
well	O
prevented	O
from	O
being	O
destroyed	O
by	O
gastric	O
acid	O
after	O
a	O
nano	O
emulsion	O
matrix	O
is	O
orally	O
taken	O
,	O
and	O
the	O
first	O
-	O
pass	O
effect	O
of	O
the	O
liver	O
can	O
be	O
overcome	O
.	O

Therefore	O
,	O
the	O
omeprazole	B
nano	O
emulsion	O
is	O
simple	O
in	O
preparation	O
method	O
,	O
and	O
applicable	O
to	O
the	O
requirements	O
of	O
large	O
-	O
scale	O
industrial	O
production	O
.	O

Omeprazole	B
nano	O
emulsion	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
liquid	O
drug	O
composition	O
of	O
oxycodone	B
.	O

The	O
liquid	O
drug	O
composition	O
disclosed	O
by	O
the	O
invention	O
comprises	O
effective	O
dose	O
of	O
oxycodone	B
for	O
treatment	O
and/or	O
prevention	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
preservative	O
and	O
water	O
.	O

The	O
liquid	O
drug	O
composition	O
of	O
oxycodone	B
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
as	O
mentioned	O
in	O
the	O
specification	O
.	O

Particularly	O
,	O
according	O
to	O
the	O
composition	O
disclosed	O
by	O
the	O
invention	O
,	O
oxycodone	B
is	O
prepared	O
into	O
a	O
preparation	O
for	O
intranasal	O
administration	O
,	O
such	O
as	O
a	O
spray	O
or	O
a	O
drop	O
by	O
adopting	O
a	O
unique	O
formula	O
.	O

The	O
liquid	O
drug	O
composition	O
not	O
only	O
is	O
convenient	O
to	O
use	O
by	O
a	O
sufferer	O
,	O
but	O
also	O
can	O
obtain	O
anticipated	O
high	O
bioavailability	O
.	O

Liquid	O
drug	O
composition	O
of	O
oxycodone	B

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
Artoxanthochromane	B
in	O
preparation	O
of	O
antibacterial	O
drugs	O
.	O

The	O
Artoxanthochromane	B
has	O
strong	O
effect	O
in	O
inhibiting	O
escherichia	O
coli	O
,	O
pseudomonas	O
fluorescens	O
,	O
staphylococcus	O
aureus	O
,	O
proteusbacillus	O
vulgaris	O
and	O
cryptococcus	O
neoformans	O
,	O
and	O
can	O
be	O
used	O
as	O
an	O
antibacterial	O
compound	O
;	O
the	O
application	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
bacteriostasis	O
activity	O
of	O
the	O
Artoxanthochromane	B
is	O
strong	O
,	O
and	O
the	O
Artoxanthochromane	B
has	O
outstanding	O
substantive	O
features	O
;	O
meanwhile	O
,	O
a	O
remarkable	O
progress	O
is	O
obviously	O
realize	O
by	O
applying	O
the	O
Artoxanthochromane	B
to	O
the	O
prevention	O
of	O
bacterial	O
infection	O
.	O

Application	O
of	O
Artoxanthochromane	B
in	O
antibacterial	O
drugs	O

The	O
invention	O
provides	O
an	O
ointment	O
capable	O
of	O
eliminating	O
inflammation	O
and	O
releasing	O
itching	O
and	O
a	O
preparation	O
method	O
of	O
the	O
oniment	O
.	O

The	O
ointment	O
comprises	O
the	O
following	O
raw	O
materials	O
:	O
metronidazole	B
tablets	O
,	O
moroxydine	B
hydrochloride	I
tablets	O
,	O
erythromycin	B
ointment	O
,	O
lincomycin	B
hydrochloride	I
gel	O
,	O
and	O
ketoconazole	B
ointment	O
.	O

The	O
ointment	O
has	O
the	O
advantages	O
of	O
good	O
inflammation	O
eliminating	O
effect	O
,	O
high	O
absorption	O
capability	O
and	O
the	O
like	O
,	O
and	O
is	O
convenient	O
to	O
duab	O
.	O

Ointment	O
capable	O
of	O
eliminating	O
inflammation	O
and	O
releasing	O
itching	O
and	O
preparation	O
method	O
of	O
onitment	O

The	O
invention	O
relates	O
to	O
bicarbonate	B
concentrate	O
powder	O
for	O
direct	O
-	O
on	O
-	O
line	O
use	O
and	O
a	O
preparation	O
process	O
thereof	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medical	O
instruments	O
.	O

The	O
bicarbonate	B
concentrate	O
powder	O
for	O
direct	O
-	O
on	O
-	O
line	O
use	O
contains	O
granular	O
sodium	B
bicarbonate	I
with	O
the	O
particle	O
size	O
of	O
3	O
to	O
6	O
MM	O
and	O
the	O
hardness	O
of	O
4	O
to	O
5KG	O
/	O
CM<3>.	O
By	O
the	O
adoption	O
of	O
the	O
bicarbonate	B
concentrate	O
powder	O
for	O
direct	O
-	O
on	O
-	O
line	O
use	O
,	O
the	O
defect	O
that	O
the	O
widespread	O
use	O
is	O
limited	O
because	O
the	O
raw	O
materials	O
can	O
not	O
meet	O
the	O
requirements	O
of	O
the	O
product	O
at	O
present	O
is	O
overcome	O
;	O
the	O
bicarbonate	B
concentrate	O
powder	O
has	O
a	O
great	O
medicinal	O
value	O
.	O

Bicarbonate	B
concentrate	O
powder	O
for	O
direct	O
-	O
on	O
-	O
line	O
use	O
and	O
preparation	O
process	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
medicine	O
for	O
treating	O
solar	O
dermatitis	O
.	O

Every	O
dose	O
is	O
composed	O
of	O
20	O
g	O
of	O
gypsum	O
,	O
15	O
g	O
of	O
radix	O
rehmanniae	O
,	O
10	O
g	O
of	O
cortex	O
moutan	O
,	O
8	O
g	O
of	O
radix	O
geutianae	O
,	O
15	O
g	O
of	O
silver	O
flower	O
,	O
15	O
g	O
of	O
Fructus	O
Forsythiae	O
,	O
15	O
g	O
of	O
isatis	O
leaf	O
,	O
30	O
g	O
of	O
coix	O
seed	O
,	O
15	O
g	O
of	O
Plantain	O
seed	O
(	O
decoction	O
of	O
a	O
wrapped	O
drug	O
)	O
,	O
15	O
g	O
of	O
liuyipowd	O
(	O
decoction	O
of	O
a	O
wrapped	O
drug	O
)	O
,	O
10	O
g	O
of	O
radix	O
trichosanthis	O
and	O
10	O
g	O
of	O
licorice	O
.	O

The	O
preparation	O
and	O
application	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
decocting	O
in	O
water	O
,	O
and	O
orally	O
taking	O
1	O
dose	O
a	O
day	O
respectively	O
in	O
the	O
morning	O
and	O
at	O
night	O
.	O

In	O
the	O
medicine	O
taking	O
period	O
,	O
hot	O
and	O
spicy	O
food	O
is	O
forbidden	O
.	O

The	O
medicine	O
solves	O
the	O
problem	O
of	O
great	O
side	O
effect	O
in	O
the	O
existing	O
medicine	O
for	O
treating	O
solar	O
dermatitis	O
,	O
and	O
is	O
suitable	O
for	O
treating	O
solar	O
dermatitis	O
.	O

Medicine	O
for	O
treating	O
solar	O
dermatitis	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
urinary	O
retention	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
polygonatum	O
odoratum	O
,	O
pangolin	O
,	O
cinnamon	O
,	O
cowherb	O
seed	O
,	O
motherwort	O
,	O
chingma	O
abutilon	O
seed	O
,	O
pyrrosia	O
lingua	O
,	O
semen	O
cuscutae	O
,	O
Chinese	O
magnoliavine	O
fruit	O
,	O
alpinia	O
oxyphylla	O
and	O
other	O
medicines	O
in	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
clearing	O
heat	O
and	O
removing	O
toxicity	O
,	O
inducing	O
diuresis	O
to	O
reduce	O
edema	O
,	O
decreasing	O
internal	O
heat	O
and	O
treating	O
stranguria	O
,	O
is	O
quick	O
in	O
response	O
and	O
good	O
in	O
curative	O
effect	O
when	O
used	O
for	O
treating	O
urinary	O
retention	O
,	O
and	O
prevents	O
relapse	O
after	O
healing	O
.	O

Medicine	O
for	O
treating	O
urinary	O
retention	O
and	O
preparation	O
method	O
of	O
medicine	O

The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
technical	O
field	O
.	O

The	O
extraction	O
method	O
of	O
apigenin	B
comprises	O
the	O
steps	O
of	O
1	O
)	O
enzymatically	O
hydrolyzing	O
celery	O
which	O
is	O
taken	O
as	O
a	O
substrate	O
for	O
10	O
hours	O
at	O
30	O
-	O
35	O
DEG	O
C	O
through	O
a	O
mixing	O
solution	O
of	O
apigenin	B
which	O
is	O
33	O
-	O
37	O
%	O
and	O
glucosidase	O
which	O
is	O
43	O
-	O
47	O
%	O
in	O
mass	O
percentage	O
concentration	O
;	O
and	O
2	O
)	O
ultrasonically	O
extracting	O
enzymatic	O
hydrolysate	O
obtained	O
from	O
the	O
step	O
1	O
)	O
through	O
an	O
ethanol	B
solution	O
of	O
70	O
%	O
,	O
condensing	O
an	O
extracting	O
solution	O
,	O
extracting	O
respectively	O
through	O
petroleum	B
ether	I
and	O
ethyl	B
acetate	I
,	O
evaporating	O
the	O
extracting	O
solution	O
,	O
dissolving	O
through	O
ethanol	B
of	O
70	O
%	O
,	O
and	O
separating	O
and	O
extracting	O
through	O
a	O
high	O
performance	O
liquid	O
chromatograph	O
.	O

The	O
pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
consists	O
of	O
apigenin	B
and	O
glucobay	O
at	O
mass	O
ratio	O
of	O
1	O
:	O
(	O
2	O
-	O
5	O
)	O
.	O

The	O
extraction	O
method	O
,	O
which	O
extracts	O
apigenin	B
through	O
a	O
multi	O
-	O
enzymatic	O
process	O
,	O
greatly	O
improves	O
extraction	O
yield	O
.	O

The	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
not	O
only	O
can	O
effectively	O
control	O
blood	O
sugar	B
but	O
also	O
can	O
avoid	O
circumstances	O
of	O
low	O
blood	O
sugar	B
and	O
rapid	O
weight	O
loss	O
of	O
a	O
patient	O
due	O
to	O
simple	O
use	O
of	O
a	O
diabetes	O
medicine	O
.	O

Extraction	O
method	O
of	O
apigenin	B
,	O
pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
JNK	O
inhibitors	O
and	O
corresponding	O
methods	O
,	O
formulations	O
,	O
and	O
compositions	O
for	O
inhibiting	O
JNK	O
and	O
treating	O
JNK	O
-	O
mediated	O
disorders	O
.	O

The	O
application	O
discloses	O
the	O
JNK	O
inhibitors	O
,	O
as	O
described	O
below	O
in	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
variables	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
are	O
useful	O
to	O
modulate	O
the	O
activity	O
of	O
the	O
JNK	O
and	O
treat	O
diseases	O
associated	O
with	O
the	O
JNK	O
activity	O
.	O

Disclosed	O
are	O
the	O
methods	O
and	O
the	O
formulations	O
for	O
inhibiting	O
the	O
JNK	O
and	O
treating	O
the	O
JNK	O
-	O
mediated	O
disorders	O
,	O
and	O
the	O
like	O
,	O
with	O
the	O
compounds	O
,	O
and	O
processes	O
for	O
making	O
said	O
compounds	O
,	O
and	O
corresponding	O
compositions	O
,	O
disclosed	O
herein	O
.	O

Aminomethyl	B
quinolone	I
compounds	O

Provided	O
are	O
a	O
novel	O
derivative	O
of	O
5-carbamoyl	B
adamantan-2-yl	I
amide	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
use	O
thereof	O
for	O
inhibiting	O
the	O
activity	O
of	O
11hydroxystreroid	B
dehydrogenase	O
type1	O
(	O
11b	O
-	O
HSD1	O
)	O
or	O
for	O
preventing	O
and/or	O
treating	O
various	O
diseases	O
mediated	O
by	O
11hydroxystreroid	B
dehydrogenase	O
type1	O
.	O

5-carbamoyl	B
-	I
adamantan-2-yl	I
amide	I
derivatives	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
preparation	O
process	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
fermented	O
food	O
,	O
and	O
particularly	O
relates	O
to	O
nutritional	O
supplement	O
enzyme	O
food	O
for	O
diabetic	O
patients	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
nutritional	O
supplement	O
enzyme	O
food	O
comprises	O
the	O
following	O
raw	O
material	O
by	O
weight	O
percent	O
:	O
47	O
percent	O
of	O
passion	O
flower	O
pulp	O
,	O
47	O
percent	O
of	O
kiwi	O
fruit	O
pulp	O
,	O
3	O
percent	O
of	O
miracle	O
fruit	O
pulp	O
with	O
peel	O
,	O
0.8	O
percent	O
of	O
probiotics	O
leavening	O
agent	O
,	O
0.2	O
percent	O
of	O
curdlan	O
,	O
and	O
2	O
percent	O
of	O
sterile	O
water	O
,	O
and	O
is	O
prepared	O
through	O
the	O
steps	O
of	O
pulping	O
,	O
mixing	O
,	O
defibrination	O
,	O
irradiation	O
sterilization	O
,	O
feeding	O
leavening	O
agent	O
to	O
perform	O
fermentation	O
and	O
fermenting	O
in	O
different	O
time	O
periods	O
and	O
at	O
different	O
temperature	O
.	O

The	O
nutritional	O
supplement	O
enzyme	O
food	O
contains	O
abundant	O
and	O
comprehensive	O
amino	B
acid	I
,	O
peptide	O
,	O
peptone	O
,	O
vitamins	O
,	O
mineral	O
substance	O
,	O
cellulose	O
and	O
bioactive	O
substance	O
,	O
is	O
low	O
in	O
heat	O
content	O
,	O
and	O
is	O
particularly	O
suitable	O
for	O
being	O
served	O
as	O
daily	O
nutritional	O
supplement	O
food	O
for	O
diabetic	O
patients	O
under	O
the	O
condition	O
that	O
the	O
diabetic	O
patients	O
adopt	O
dieting	O
measures	O
,	O
and	O
has	O
practical	O
significance	O
and	O
positive	O
significance	O
for	O
improving	O
and	O
maintaining	O
the	O
health	O
condition	O
of	O
the	O
diabetic	O
patients	O
.	O

Nutritional	O
supplement	O
enzyme	O
food	O
for	O
diabetic	O
patients	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
-	O
loaded	O
mesoporous	O
-	O
silica	B
-	O
reinforced	O
dental	O
binder	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
binder	O
comprises	O
following	O
components	O
by	O
weight	O
:	O
40	O
-	O
60	O
%	O
of	O
a	O
resin	O
component	O
,	O
35	O
-	O
50	O
%	O
of	O
a	O
dilution	O
component	O
,	O
2	O
-	O
10	O
%	O
of	O
an	O
acid	O
monomer	O
,	O
0.2	O
-	O
0.5	O
%	O
of	O
a	O
photoinitiator	O
,	O
0.1	O
-	O
0.3	O
%	O
of	O
a	O
promoter	O
,	O
a	O
trace	O
amount	O
of	O
a	O
polymerization	O
inhibitor	O
and	O
1	O
-	O
10	O
%	O
of	O
mesoporous	O
silica	B
.	O

The	O
binder	O
has	O
high	O
strength	O
and	O
drug	O
releasing	O
property	O
,	O
and	O
therefore	O
the	O
binder	O
is	O
advantaged	O
by	O
loading	O
and	O
performing	O
controlled	O
releasing	O
of	O
antibacterial	O
agents	O
,	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
hemostatics	O
,	O
etc	O
..	O

The	O
binder	O
not	O
only	O
has	O
a	O
binding	O
function	O
,	O
but	O
also	O
has	O
certain	O
functions	O
of	O
treating	O
and	O
preventing	O
bacterial	O
infection	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
dentine	O
binder	O
in	O
clinic	O
.	O

Drug	O
-	O
loaded	O
mesoporous	O
-	O
silica	B
-	O
reinforced	O
dental	O
binder	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
lansoprazole	B
drug	O
composition	O
which	O
comprises	O
15	O
-	O
30	O
parts	O
by	O
weight	O
of	O
lansoprazole	B
,	O
300	O
-	O
1000	O
parts	O
by	O
weight	O
of	O
antacid	O
,	O
0.5	O
-	O
5	O
parts	O
by	O
weight	O
of	O
solubilizer	O
and	O
medicinal	O
auxiliary	O
materials	O
.	O

The	O
antacid	B
is	O
one	O
or	O
more	O
out	O
of	O
sodium	B
bicarbonate	I
,	O
sodium	B
carbonate	I
,	O
potassium	B
carbonate	I
,	O
potassium	B
bicarbonate	I
,	O
calcium	B
carbonate	I
,	O
aluminum	B
carbonate	I
,	O
magnesium	B
carbonate	I
,	O
magnesium	B
hydrate	I
,	O
aluminum	B
hydroxide	I
,	O
magnesium	B
aluminum	I
carbonate	I
,	O
and	O
the	O
preferable	O
antacid	O
is	O
sodium	B
bicarbonate	I
or	O
/	O
and	O
magnesium	B
hydrate	I
,	O
potassium	B
bicarbonate	I
or	O
/	O
and	O
magnesium	B
oxide	I
,	O
sodium	B
bicarbonate	I
or	O
/	O
and	O
magnesium	B
aluminum	I
carbonate	I
.	O

The	O
lansoprazole	B
drug	O
composition	O
further	O
comprises	O
the	O
solubilizer	O
which	O
can	O
effectively	O
improve	O
the	O
dissolubility	O
and	O
dissolution	O
rate	O
of	O
the	O
lansoprazole	B
;	O
compared	O
with	O
a	O
micronization	O
treatment	O
mode	O
,	O
a	O
technique	O
is	O
simplified	O
;	O
and	O
the	O
cost	O
is	O
lowered	O
.	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
lansoprazole	B
drug	O
composition	O
.	O

Inner	O
addition	O
and	O
outer	O
addition	O
are	O
adopted	O
to	O
mix	O
the	O
antacid	O
,	O
the	O
dosage	O
of	O
the	O
antacid	B
is	O
reduced	O
,	O
and	O
an	O
anti	O
-	O
acid	O
effect	O
is	O
better	O
simultaneously	O
.	O

Lansoprazole	B
drug	O
composition	O

The	O
invention	O
discloses	O
a	O
mesna	B
pharmaceutical	O
composition	O
for	O
injection	O
.	O

The	O
mesna	B
injection	O
consists	O
of	O
mesna	B
,	O
sodium	B
calcium	I
edetate	I
and	O
water	O
for	O
injection	O
;	O
each	O
dose	O
of	O
mesna	B
injection	O
contains	O
200	O
-	O
400	O
mg	O
of	O
mesna	O
and	O
5	O
-	O
10	O
mg	O
of	O
sodium	B
calcium	I
edetate	I
.	O

The	O
mesna	B
pharmaceutical	O
composition	O
has	O
good	O
stability	O
;	O
the	O
product	O
yield	O
is	O
increased	O
,	O
the	O
cost	O
is	O
lowered	O
,	O
and	O
industrialization	O
is	O
realized	O
;	O
the	O
mesna	B
pharmaceutical	O
composition	O
is	O
well	O
applied	O
to	O
clinical	O
application	O
and	O
has	O
more	O
obvious	O
advantages	O
.	O

Mesna	B
pharmaceutical	O
composition	O
for	O
injection	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
for	O
improving	O
stability	O
of	O
a	O
doxofylline	B
injection	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
taking	O
prescription	O
amount	O
of	O
doxofylline	B
,	O
adding	O
injection	O
water	O
to	O
set	O
specification	O
,	O
boiling	O
and	O
stirring	O
to	O
dissolve	O
;	O
adding	O
0.05	O
-	O
0.1	O
%	O
of	O
(	O
W	O
/	O
V	O
)	O
active	O
carbon	B
for	O
a	O
needle	O
,	O
stirring	O
for	O
10	O
-	O
15	O
minutes	O
;	O
decarburizing	O
and	O
filtering	O
;	O
adding	O
the	O
injection	O
water	O
to	O
gross	O
,	O
wherein	O
the	O
pH	O
is	O
about	O
6.5	O
at	O
the	O
moment	O
;	O
adjusting	O
the	O
pH	O
to	O
5.0	O
-	O
6.0	O
by	O
3	O
-	O
5	O
%	O
hydrochloric	B
acid	I
solution	O
;	O
finely	O
filtering	O
the	O
soup	O
until	O
the	O
soup	O
is	O
clear	O
by	O
using	O
a	O
0.45-micron	O
millipore	O
filter	O
;	O
checking	O
the	O
pH	O
,	O
the	O
clarity	O
and	O
the	O
content	O
;	O
filtering	O
by	O
a	O
0.22-micron	O
millipore	O
filter	O
terminal	O
after	O
passing	O
;	O
and	O
subpackaging	O
in	O
a	O
specified	O
ampoule	O
,	O
hermetically	O
sealing	O
,	O
sterilizing	O
,	O
and	O
detecting	O
leakage	O
.	O

By	O
adopting	O
the	O
preparation	O
method	O
,	O
the	O
yield	O
and	O
the	O
aseptic	O
security	O
level	O
of	O
the	O
product	O
are	O
improved	O
,	O
the	O
stability	O
of	O
the	O
product	O
is	O
greatly	O
improved	O
,	O
and	O
the	O
period	O
of	O
validity	O
can	O
be	O
greatly	O
prolonged	O
.	O

Preparation	O
method	O
for	O
improving	O
stability	O
of	O
doxofylline	B
injection	O

A	O
formula	O
of	O
a	O
liver	O
targeting	O
demehylcanthardin	B
esterified	O
derivative	O
submicron	O
emulsion	O
injection	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
is	O
characterized	O
by	O
comprising	O
demehylcanthardin	B
esterified	O
derivatives	O
3	O
-	O
5	O
g	O
,	O
soybean	O
oil	O
50	O
g	O
,	O
medium	O
-	O
chain	O
triglyceride	B
50	O
g	O
,	O
lecithin	B
10	O
-	O
14	O
g	O
,	O
glycerine	B
20	O
-	O
24	O
g	O
,	O
oleic	B
acid	I
1	O
g	O
and	O
poloxamer	O
F68	O
1	O
g.	O
The	O
formula	O
adopts	O
a	O
submicron	O
emulsion	O
as	O
an	O
insoluble	O
medicine	O
carrier	O
,	O
as	O
a	O
result	O
,	O
the	O
injection	O
has	O
liver	O
targeting	O
performance	O
,	O
mainly	O
concentrates	O
in	O
liver	O
,	O
spleen	O
,	O
lung	O
and	O
marrow	O
tissues	O
,	O
avoids	O
damage	O
to	O
other	O
tissues	O
,	O
and	O
has	O
active	O
effect	O
on	O
improvement	O
of	O
medicine	O
therapeutic	O
effect	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
preparation	O
technology	O
is	O
reasonable	O
,	O
the	O
optimized	O
process	O
route	O
is	O
simple	O
,	O
the	O
practicability	O
and	O
operability	O
are	O
both	O
high	O
,	O
quality	O
safety	O
is	O
controllable	O
,	O
the	O
reproducibility	O
is	O
good	O
,	O
and	O
industrial	O
production	O
is	O
applicative	O
.	O

Formula	O
of	O
liver	O
targeting	O
demehylcantharidin	B
esterified	O
derivative	O
submicron	O
emulsion	O
injection	O
and	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
a	O
medicament	O
of	O
the	O
medicine	O
field	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
rapidly	O
dispersed	O
candesartan	B
cilexetil	I
medicament	O
composition	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicament	O
composition	O
.	O

Rapidly	O
dispersed	O
candesartan	B
cilexetil	I
medicament	O
composition	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
synthesizing	O
branched	O
chain	O
amino	B
acid	I
nitrate	I
,	O
and	O
belongs	O
to	O
a	O
method	O
for	O
synthesizing	O
amino	B
acid	I
mixed	O
nitrate	B
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
adding	O
65	O
percent	O
by	O
mass	O
of	O
nitric	B
acid	I
into	O
a	O
reactor	O
;	O
slowly	O
heating	O
to	O
a	O
certain	O
temperature	O
under	O
stirring	O
;	O
sequentially	O
adding	O
leucine	B
,	O
valine	B
and	O
isoleucine	B
,	O
insulating	O
and	O
reacting	O
for	O
a	O
while	O
;	O
filtering	O
the	O
solution	O
in	O
the	O
reaction	O
,	O
cooling	O
the	O
filtrate	O
to	O
crystalize	O
;	O
drying	O
the	O
separated	O
crystal	O
product	O
to	O
obtain	O
a	O
solid	O
product	O
of	O
the	O
branched	O
chain	O
amino	B
acid	I
nitrate	I
.	O

By	O
adopting	O
the	O
method	O
for	O
synthesizing	O
the	O
mixed	O
branched	O
chain	O
amino	B
acid	I
nitrate	I
,	O
a	O
pure	O
product	O
can	O
be	O
directly	O
obtained	O
by	O
reactions	O
in	O
the	O
method	O
.	O

The	O
method	O
is	O
simple	O
and	O
practical	O
in	O
steps	O
,	O
short	O
in	O
time	O
,	O
high	O
in	O
production	O
efficiency	O
,	O
can	O
produce	O
products	O
with	O
qualified	O
quality	O
and	O
high	O
yield	O
,	O
does	O
not	O
produce	O
wastewater	O
,	O
waste	O
gas	O
or	O
waste	O
residues	O
,	O
and	O
is	O
applicable	O
to	O
industrial	O
large	O
-	O
scale	O
production	O
.	O

Method	O
for	O
synthesizing	O
branched	O
chain	O
amino	B
acid	I
nitrate	I

The	O
invention	O
relates	O
to	O
an	O
oral	O
solid	O
medicine	O
composition	O
of	O
canagliflozin	B
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
composition	O
comprises	O
canagliflozin	B
and	O
pharmaceutic	O
adjuvants	O
,	O
wherein	O
the	O
canagliflozin	B
is	O
in	O
an	O
amorphous	O
form	O
,	O
and	O
the	O
average	O
grain	O
size	O
of	O
particles	O
is	O
2.5	O
-	O
30	O
microns	O
.	O

The	O
composition	O
can	O
be	O
used	O
for	O
effectively	O
solving	O
the	O
technical	O
problems	O
that	O
the	O
crystal	O
transformation	O
and	O
the	O
compressibility	O
of	O
the	O
canagliflozin	B
in	O
the	O
amorphous	O
form	O
are	O
poor	O
in	O
the	O
preparation	O
process	O
of	O
the	O
solid	O
preparation	O
.	O

Oral	O
solid	O
preparation	O
of	O
canagliflozin	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
a	O
myricetin	B
crystal	O
compound	O
to	O
a	O
medicament	O
of	O
a	O
nerve	O
inhibitor	O
,	O
and	O
in	O
particular	O
relates	O
to	O
the	O
application	O
of	O
the	O
myricetin	B
crystal	O
compound	O
in	O
the	O
field	O
of	O
narcotics	O
.	O

Application	O
of	O
myricetin	B
crystal	O
compound	O
to	O
medicament	O
of	O
nerve	O
inhibitor	O

The	O
invention	O
discloses	O
a	O
small	O
molecule	O
compound	O
for	O
promoting	O
bone	O
formation	O
.	O

The	O
compound	O
shown	O
as	O
a	O
formula	O
I	O
can	O
be	O
used	O
in	O
preparation	O
of	O
medicines	O
for	O
promoting	O
bone	O
formation	O
and	O
preparation	O
of	O
a	O
BMP	O
sensitizing	O
agent	O
.	O

The	O
invention	O
also	O
provides	O
one	O
of	O
the	O
applications	O
of	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
:	O
(	O
1	O
)	O
preparation	O
of	O
products	O
for	O
improving	O
osteogenic	O
potential	O
of	O
cells	O
,	O
wherein	O
the	O
cells	O
are	O
specifically	O
myogenic	O
precursor	O
cells	O
or	O
osteogenic	O
precursor	O
cells	O
;	O
(	O
2	O
)	O
preparation	O
of	O
products	O
for	O
improving	O
alkaline	O
phosphatase	O
,	O
osteocalcin	O
and	O
/	O
or	O
type	O
I	O
collagen	O
mRNA	O
levels	O
in	O
cells	O
,	O
wherein	O
the	O
cells	O
are	O
specifically	O
myogenic	O
precursor	O
cells	O
or	O
osteogenic	O
precursor	O
cells	O
;	O
(	O
3	O
)	O
preparation	O
of	O
products	O
for	O
improving	O
activity	O
of	O
alkaline	O
phosphatase	O
in	O
myogenic	O
precursor	O
cells	O
or	O
osteogenic	O
precursor	O
cells	O
or	O
osteoblasts	O
;	O
(	O
4	O
)	O
preparation	O
of	O
products	O
for	O
inhibiting	O
degradation	O
of	O
an	O
Smad1	O
/	O
5	O
protein	O
under	O
the	O
condition	O
of	O
BMP	O
pathway	O
activation	O
;	O
and	O
(	O
5	O
)	O
preparation	O
of	O
products	O
for	O
reducing	O
ubiquitination	O
level	O
of	O
the	O
Smad1	O
/	O
5	O
protein	O
under	O
the	O
condition	O
of	O
BMP	O
pathway	O
activation	O
.	O

Small	O
molecule	O
compound	O
for	O
promoting	O
bone	O
formation	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
sitagliptin	B
and	O
melbine	B
compound	O
sustained	O
-	O
release	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
sustained	O
-	O
release	O
preparation	O
comprises	O
a	O
sustained	O
-	O
release	O
part	O
,	O
a	O
quick	O
-	O
release	O
part	O
and	O
a	O
blank	O
auxiliary	O
,	O
wherein	O
the	O
sustained	O
-	O
release	O
part	O
comprises	O
metformin	B
hydrochloride	I
,	O
pellets	O
,	O
a	O
binder	O
,	O
a	O
sustained	O
-	O
release	O
coating	O
layer	O
and	O
a	O
plasticizer	O
;	O
the	O
quick	O
-	O
release	O
part	O
comprises	O
sitagliptin	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
filler	O
and	O
a	O
binder	O
;	O
the	O
blank	O
auxiliary	O
comprises	O
a	O
disintegrating	O
agent	O
,	O
a	O
lubricant	O
and	O
a	O
gastric	O
-	O
soluble	O
coating	O
layer	O
.	O

In	O
the	O
compound	O
sustained	O
-	O
release	O
preparation	O
,	O
a	O
plurality	O
of	O
unit	O
sustained	O
-	O
release	O
pellets	O
are	O
prepared	O
from	O
metformin	B
hydrochloride	I
in	O
the	O
sustained	O
release	O
part	O
,	O
each	O
pellet	O
can	O
release	O
drugs	O
independently	O
and	O
is	O
stable	O
in	O
drug	O
release	O
speed	O
,	O
and	O
the	O
plurality	O
of	O
pellets	O
are	O
widely	O
distributed	O
in	O
the	O
gastrointestinal	O
tract	O
to	O
release	O
drugs	O
,	O
so	O
that	O
over	O
-	O
high	O
concentration	O
of	O
the	O
drugs	O
at	O
local	O
parts	O
can	O
be	O
effectively	O
avoided	O
,	O
and	O
the	O
irritation	O
of	O
metformin	B
hydrochloride	I
to	O
the	O
stomach	O
can	O
be	O
reduced	O
.	O

The	O
problem	O
of	O
metformin	B
hydrochloride	I
dosage	O
pouring	O
of	O
each	O
sustained	O
-	O
release	O
tablet	O
caused	O
by	O
broken	O
coating	O
film	O
or	O
dose	O
fractionation	O
can	O
be	O
solved	O
,	O
so	O
that	O
the	O
possibility	O
of	O
adverse	O
response	O
occurrence	O
can	O
be	O
reduced	O
.	O

Sitagliptin	B
and	O
melbine	B
compound	O
sustained	O
-	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
gastrodin	B
controlled	O
release	O
preparation	O
.	O

The	O
gastrodin	B
controlled	O
release	O
preparation	O
comprises	O
a	O
quick	O
release	O
part	O
with	O
high	O
bioavailability	O
and	O
a	O
controlled	O
release	O
part	O
,	O
wherein	O
the	O
gastrodin	B
(	O
gastrodin	B
I	O
)	O
of	O
the	O
quick	O
release	O
part	O
accounts	O
for	O
30%-60	O
%	O
of	O
the	O
total	O
weight	O
of	O
the	O
gastrodin	B
in	O
the	O
controlled	O
release	O
preparation	O
,	O
and	O
the	O
gastrodin	B
(	O
gastrodin	B
II	O
)	O
of	O
the	O
controlled	O
release	O
part	O
accounts	O
for	O
40%-70	O
%	O
of	O
the	O
total	O
weight	O
of	O
the	O
gastrodin	B
in	O
the	O
controlled	O
release	O
preparation	O
.	O

Single	O
dose	O
of	O
the	O
gastrodin	B
controlled	O
release	O
preparation	O
comprises	O
100	O
-	O
800	O
mg	O
of	O
gastrodin	B
,	O
preferably	O
,	O
300	O
-	O
600	O
mg	O
.	O

In	O
initial	O
releasing	O
stage	O
,	O
the	O
gastrodin	O
controlled	O
release	O
preparation	O
is	O
released	O
through	O
special	O
quick	O
release	O
technology	O
,	O
thus	O
accelerating	O
the	O
onset	O
time	O
,	O
improving	O
the	O
bioavailability	O
,	O
and	O
achieving	O
the	O
purpose	O
of	O
rapidly	O
working	O
;	O
in	O
middle	O
and	O
last	O
releasing	O
phases	O
,	O
the	O
gastrodin	B
controlled	O
release	O
preparation	O
is	O
released	O
by	O
controlled	O
release	O
technology	O
,	O
thus	O
maintaining	O
stable	O
drug	O
release	O
amount	O
,	O
keeping	O
stable	O
blood	O
concentration	O
,	O
improving	O
the	O
treatment	O
effect	O
of	O
the	O
drug	O
,	O
and	O
lowering	O
the	O
toxic	O
and	O
side	O
effects	O
.	O

The	O
preparation	O
is	O
not	O
affected	O
to	O
be	O
released	O
and	O
absorbed	O
in	O
body	O
by	O
pH	O
value	O
and	O
food	O
in	O
the	O
body	O
,	O
guarantees	O
to	O
have	O
slightly	O
different	O
treatment	O
effect	O
in	O
different	O
individuals	O
under	O
different	O
conditions	O
,	O
and	O
has	O
important	O
clinical	O
application	O
value	O
.	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
gastrodin	B
controlled	O
release	O
preparation	O
,	O
and	O
is	O
applicable	O
to	O
industrial	O
application	O
.	O

Gastrodin	B
controlled	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
dendrimer	O
drug	O
delivery	O
system	O
with	O
high	O
tumor	O
recognition	O
ability	O
and	O
environmental	O
response	O
drug	O
release	O
ability	O
.	O

The	O
dendrimer	O
drug	O
delivery	O
system	O
comprises	O
a	O
dendrimer	O
(	O
Dendrimers	O
)	O
,	O
an	O
antitumor	O
drug	O
(	O
Drug	O
)	O
,	O
hydrophilic	O
block	O
polyethylene	B
glycol	I
(	O
PEG	B
)	O
of	O
undecorated	O
ligand	O
,	O
and	O
a	O
targeting	O
ligand	O
chain	O
with	O
specific	O
tumor	O
recognition	O
ability	O
,	O
wherein	O
the	O
dendrimer	O
is	O
the	O
dendrimer	O
with	O
amino	B
;	O
the	O
hydrophilic	O
block	O
PEG	O
of	O
the	O
undecorated	O
ligand	O
and	O
the	O
targeting	O
ligand	O
chain	O
are	O
connected	O
to	O
the	O
surface	O
by	O
taking	O
the	O
dendrimer	O
as	O
a	O
center	O
;	O
the	O
targeting	O
ligand	O
chain	O
is	O
a	O
polyethylene	B
glycol	I
-	O
targeting	O
ligand	O
intercalated	O
compound	O
PEG	O
-	O
X	O
;	O
and	O
Drug	O
is	O
linked	O
to	O
the	O
surface	O
of	O
the	O
dendrimer	O
through	O
an	O
acid	O
sensitive	O
chemical	O
bond	O
-	O
hydrazone	B
bond	O
.	O

By	O
adopting	O
the	O
dendrimer	O
drug	O
delivery	O
system	O
,	O
a	O
plurality	O
of	O
functions	O
of	O
combining	O
active	O
targeting	O
with	O
passive	O
targeting	O
of	O
the	O
drug	O
,	O
response	O
drug	O
release	O
inside	O
a	O
tumor	O
microenvironment	O
and	O
an	O
organelle	O
and	O
the	O
like	O
can	O
be	O
achieved	O
,	O
improvement	O
of	O
the	O
targeting	O
efficiency	O
and	O
accumulation	O
of	O
the	O
drug	O
in	O
the	O
tumor	O
part	O
are	O
facilitated	O
,	O
and	O
the	O
pharmaceutical	O
effect	O
is	O
enhanced	O
.	O

Thus	O
,	O
the	O
dendrimer	O
drug	O
delivery	O
system	O
is	O
a	O
multifunctional	O
tumor	O
-	O
targeted	O
drug	O
delivery	O
system	O
with	O
potential	O
.	O

Dendrimer	O
drug	O
delivery	O
system	O
with	O
high	O
tumor	O
recognition	O
ability	O
and	O
environmental	O
response	O
drug	O
release	O
ability	O
and	O
building	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
novel	O
application	O
of	O
astragaloside	B
IV	I
,	O
in	O
particular	O
relates	O
to	O
an	O
application	O
of	O
the	O
astragaloside	B
IV	I
in	O
preparing	O
a	O
medicine	O
for	O
treating	O
HAAF	O
(	O
hypoglycemia	O
associated	O
autonomic	O
failure	O
)	O
diabetic	O
complications	O
,	O
namely	O
hormone	O
retroregulation	O
disorder	O
when	O
diabetic	O
hypoglycemia	O
occurs	O
.	O

Animal	O
experiments	O
indicate	O
that	O
the	O
astragaloside	B
IV	I
can	O
be	O
used	O
for	O
improving	O
destruction	O
of	O
neuroendocrine	O
retroregulation	O
caused	O
by	O
hypoglycemia	O
,	O
stopping	O
occurrence	O
of	O
further	O
hypoglycemia	O
of	O
a	O
reverse	O
damaged	O
rat	O
model	O
and	O
reconstructing	O
partial	O
hormone	O
retroregulation	O
,	O
and	O
can	O
activate	O
cerebral	O
nuclei	O
of	O
VMH	O
(	O
ventromedial	O
nucleus	O
of	O
the	O
hypothalamus	O
)	O
,	O
BLV	O
(	O
bovine	O
leukemia	O
virus	O
)	O
and	O
other	O
glucose	B
sensitive	O
parts	O
in	O
a	O
brain	O
through	O
a	O
blood	O
brain	O
barrier	O
,	O
so	O
that	O
the	O
prewarning	O
mechanism	O
of	O
a	O
body	O
to	O
hypoglycemia	O
can	O
be	O
improved	O
.	O

The	O
application	O
has	O
a	O
good	O
treatment	O
prospect	O
to	O
occurrence	O
of	O
diabetic	O
hypoglycemia	O
.	O

Application	O
of	O
astragaloside	B
IV	I
in	O
preparing	O
medicine	O
for	O
treating	O
HAAF	O
(	O
hypoglycemia	O
associated	O
autonomic	O
failure	O
)	O
diabetic	O
complications	O

The	O
invention	O
provides	O
a	O
water	O
-	O
soluble	O
vitamin	O
combination	O
medicament	O
which	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
the	O
medical	O
components	O
in	O
parts	O
by	O
weight	O
:	O
2.0	O
-	O
4.0	O
parts	O
of	O
thiamine	B
hydrochloride	I
,	O
3.0	O
-	O
5.0	O
parts	O
of	O
riboflavin	B
sodium	I
phosphate	I
,	O
3.5	O
-	O
7.0	O
parts	O
of	O
pyridoxine	B
hydrochloride	I
,	O
0.002	O
-	O
0.008	O
part	O
of	O
cobamamide	B
,	O
100	O
-	O
150	O
parts	O
of	O
vitamin	B
C	I
sodium	I
,	O
30	O
-	O
50	O
parts	O
of	O
nicotinamide	B
,	O
0.3	O
-	O
0.7	O
part	O
of	O
folic	B
acid	I
,	O
0.04	O
-	O
0.08	O
part	O
of	O
biotin	O
,	O
10	O
-	O
20	O
parts	O
of	O
sodium	B
pantothenate	I
,	O
30	O
-	O
80	O
parts	O
of	O
sodium	B
glutamate	I
,	O
0.02	O
-	O
0.04	O
part	O
of	O
reduced	O
glutathione	B
and	O
0.2	O
-	O
0.8	O
part	O
ethylenediamine	B
tetraacetic	I
acid	I
disodium	I
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
combination	O
medicament	O
.	O

All	O
the	O
aspects	O
of	O
safety	O
,	O
stability	O
and	O
treating	O
effect	O
of	O
the	O
water	O
-	O
soluble	O
vitamin	O
combination	O
medicament	O
disclosed	O
by	O
the	O
invention	O
are	O
higher	O
than	O
those	O
of	O
the	O
conventional	O
water	O
-	O
soluble	O
vitamin	O
medicament	O
prepared	O
in	O
the	O
prior	O
art	O
.	O

Water	O
-	O
soluble	O
vitamin	O
combination	O
medicament	O

The	O
invention	O
provides	O
a	O
glucan	O
-	O
adriamycin	B
conjugate	O
drug	O
,	O
which	O
adopts	O
the	O
structure	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
or	O
the	O
formula	O
(	O
II	O
)	O
of	O
the	O
Specification	O
,	O
and	O
n	O
is	O
the	O
degree	O
of	O
polymerization	O
of	O
the	O
glucan	O
and	O
is	O
equal	O
to	O
or	O
greater	O
than	O
10	O
and	O
equal	O
to	O
or	O
smaller	O
than	O
3125	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
glucan	O
,	O
sodium	B
cyanoborohydride	I
and	O
adriamycin	B
are	O
used	O
as	O
raw	O
materials	O
to	O
prepare	O
the	O
glucan	O
-	O
adriamycin	B
conjugate	O
drug	O
;	O
as	O
the	O
glucan	O
as	O
a	O
raw	O
material	O
has	O
good	O
biological	O
activity	O
and	O
biocompatibility	O
,	O
the	O
prepared	O
glucan	O
-	O
adriamycin	B
has	O
good	O
biological	O
activity	O
and	O
biocompatibility	O
;	O
besides	O
,	O
the	O
glucan	O
is	O
connected	O
with	O
the	O
adriamycin	B
through	O
an	O
oxime	B
bond	O
,	O
so	O
that	O
the	O
glucan	O
-	O
adriamycin	B
conjugate	O
drug	O
can	O
be	O
released	O
quickly	O
in	O
tumor	O
tissue	O
or	O
a	O
cell	O
under	O
the	O
condition	O
of	O
relatively	O
low	O
pH	O
value	O
,	O
so	O
that	O
the	O
drug	O
effect	O
is	O
improved	O
;	O
reduced	O
glucan	O
-	O
adriamycin	B
conjugate	O
drug	O
adopting	O
the	O
structure	O
of	O
the	O
formula	O
(	O
II	O
)	O
of	O
the	O
Specification	O
has	O
relatively	O
stable	O
performance	O
,	O
and	O
the	O
adriamycin	B
can	O
be	O
released	O
relatively	O
slowly	O
,	O
so	O
that	O
ideal	O
long	O
-	O
acting	O
therapy	O
can	O
be	O
realized	O
.	O

Glucan	O
-	O
adriamycin	B
conjugate	O
drug	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
Modhephane	B
type	O
sesquiterpene	O
derivatives	O
which	O
have	O
significant	O
cytotoxic	O
activity	O
and	O
are	O
expressed	O
by	O
the	O
following	O
general	O
formula	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
usage	O
of	O
the	O
Modhephane	B
type	O
sesquiterpene	O
derivatives	O
.	O

Whole	O
dichrocephala	O
benthamii	O
clarke	O
is	O
extracted	O
by	O
ethanol	B
,	O
and	O
the	O
extract	O
is	O
repeatedly	O
purified	O
by	O
a	O
plurality	O
of	O
methods	O
to	O
obtain	O
the	O
Modhephane	B
type	O
sesquiterpene	O
derivatives	O
disclosed	O
by	O
the	O
invention	O
,	O
and	O
the	O
structures	O
of	O
the	O
Modhephane	B
type	O
sesquiterpene	O
derivatives	O
are	O
verified	O
by	O
a	O
modern	O
spectroscopic	O
technique	O
.	O

As	O
shown	O
in	O
pharmacological	O
experiments	O
,	O
the	O
Modhephane	B
type	O
sesquiterpene	B
derivatives	O
have	O
significant	O
cytotoxic	O
activity	O
on	O
a	O
variety	O
of	O
tumor	O
cells	O
,	O
and	O
are	O
applied	O
in	O
the	O
pharmaceutical	O
field	O
to	O
serve	O
as	O
potential	O
anticancer	O
drugs	O
.	O

Modhephane	B
type	O
sesquiterpene	B
derivatives	O
with	O
significant	O
cytotoxic	O
activity	O
as	O
well	O
as	O
preparation	O
method	O
and	O
usage	O
thereof	O

The	O
invention	O
provides	O
a	O
2-undecyl-3-methyl	B
-	I
hydroxyl	I
-	I
quinoline	I
compound	O
,	O
a	O
preparation	O
method	O
of	O
the	O
2-undecyl-3-methyl	B
-	I
hydroxyl	I
-	I
quinoline	I
compound	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
2-undecyl-3-methyl	B
-	I
hydroxyl	I
-	I
quinoline	I
compound	O
and	O
use	O
of	O
the	O
2-undecyl-3-methyl	B
-	I
hydroxyl	I
-	I
quinoline	I
compound	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
.	O

Particularly	O
,	O
the	O
invention	O
provides	O
a	O
compound	O
shown	O
in	O
a	O
formula	O
I	O
and	O
a	O
use	O
of	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
compound	O
in	O
the	O
preparation	O
of	O
medicine	O
for	O
preventing	O
and/or	O
treating	O
gastritis	O
and	O
tumor	O
caused	O
by	O
Helicobacter	O
Pylori	O
.	O

The	O
I	O
compound	O
provided	O
by	O
the	O
invention	O
not	O
only	O
has	O
relatively	O
high	O
selective	O
inhibition	O
effect	O
on	O
the	O
Helicobacter	O
Pylori	O
,	O
but	O
also	O
has	O
obvious	O
inhibition	O
effect	O
on	O
tumor	O
angiogenesis	O
,	O
so	O
that	O
a	O
possibility	O
is	O
provided	O
for	O
developing	O
new	O
anti	O
-	O
tumor	O
medicine	O
and	O
medicine	O
for	O
treating	O
the	O
gastritis	O
caused	O
by	O
the	O
Helicobacter	O
Pylori	O
.	O

2-undecyl-3-methyl	B
-	I
hydroxyl	I
-	I
quinoline	I
compound	O
as	O
well	O
as	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
compounds	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
and	O
new	O
application	O
thereof	O
in	O
preparing	O
medicines	O
for	O
treating	O
narrow	O
chamber	O
angle	O
.	O

The	O
compounds	O
for	O
treating	O
narrow	O
chamber	O
angle	O
can	O
have	O
very	O
obvious	O
effect	O
.	O

Compounds	O
for	O
treating	O
narrow	O
chamber	O
angle	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
aminoglycoside	B
compound	O
and	O
an	O
extraction	O
separation	O
method	O
thereof	O
.	O

The	O
compound	O
is	O
separated	O
and	O
obtained	O
from	O
a	O
crude	O
etimicin	B
sulfate	I
product	O
and	O
has	O
a	O
chemical	O
structure	O
as	O
follows	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
separation	O
method	O
of	O
the	O
aminoglycoside	B
compound	O
.	O

Aminoglycoside	B
compound	O
and	O
extraction	O
separation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medical	O
preparations	O
prepared	O
from	O
animal	O
and	O
plant	O
materials	O
,	O
in	O
particular	O
to	O
a	O
drug	O
helpful	O
for	O
postpartum	O
recovery	O
of	O
lying	O
-	O
in	O
women	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
drug	O
comprises	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
100	O
-	O
140	O
parts	O
of	O
astragalus	O
membranaceus	O
,	O
60	O
-	O
70	O
parts	O
of	O
red	O
ginseng	O
,	O
55	O
-	O
70	O
parts	O
of	O
jujubes	O
,	O
60	O
-	O
68	O
parts	O
of	O
angelica	O
,	O
80	O
-	O
86	O
parts	O
of	O
leonurus	O
artemisia	O
,	O
58	O
-	O
72	O
parts	O
of	O
poria	O
cocos	O
,	O
84	O
-	O
90	O
parts	O
of	O
radix	O
ophiopogonis	O
,	O
42	O
-	O
54	O
parts	O
of	O
mangnolia	O
officinalis	O
,	O
120	O
-	O
140	O
parts	O
of	O
brown	O
sugar	B
,	O
62	O
-	O
78	O
parts	O
of	O
rhizoma	O
cyperi	O
and	O
50	O
-	O
56	O
parts	O
of	O
tetrapanax	O
papyriferus	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
soaking	O
,	O
decocting	O
,	O
heating	O
and	O
concentrating	O
the	O
raw	O
materials	O
into	O
paste	O
;	O
adding	O
honey	O
and	O
water	O
to	O
prepare	O
the	O
oral	O
liquid	O
.	O

Oral	O
liquid	O
for	O
postpartum	O
uterus	O
recovery	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
biological	O
medicines	O
,	O
in	O
particular	O
to	O
a	O
preparation	O
method	O
of	O
hemostatic	O
powder	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
uniformly	O
mixing	O
chitosan	O
extracted	O
from	O
an	O
antarctic	O
krill	O
shell	O
with	O
an	O
antimicrobial	O
medicine	O
in	O
a	O
mass	O
ratio	O
of	O
(	O
2	O
-	O
4	O
)	O
:	O
1	O
,	O
sterilizing	O
at	O
120	O
DEG	O
C	O
,	O
and	O
packaging	O
.	O

The	O
invention	O
further	O
provides	O
components	O
and	O
contents	O
of	O
the	O
hemostatic	O
powder	O
.	O

The	O
chitosan	O
extracted	O
from	O
the	O
antarctic	O
krill	O
shell	O
as	O
a	O
raw	O
material	O
is	O
used	O
as	O
a	O
main	O
component	O
of	O
the	O
hemostatic	O
powder	O
;	O
and	O
compared	O
with	O
ordinary	O
chitosan	O
,	O
the	O
chitosan	O
extracted	O
from	O
the	O
antarctic	O
krill	O
shell	O
has	O
a	O
better	O
hemostatic	O
effect	O
because	O
a	O
chitosan	O
source	O
is	O
small	O
in	O
pollution	O
,	O
chitosan	O
quality	O
is	O
greatly	O
optimized	O
and	O
a	O
raw	O
material	O
with	O
high	O
degree	O
of	O
deacetylation	O
can	O
be	O
extracted	O
.	O

Hemostatic	O
powder	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
incense	O
formula	O
capable	O
of	O
preventing	O
cold	O
.	O

The	O
incense	O
formula	O
consists	O
of	O
the	O
following	O
raw	O
material	O
in	O
percentage	O
by	O
weight	O
:	O
20	O
%	O
of	O
pericarpium	O
citri	O
reticulatae	O
,	O
5	O
%	O
of	O
raw	O
rhizoma	O
atractylodis	O
,	O
10	O
%	O
of	O
calamus	O
,	O
1	O
%	O
of	O
borneol	B
,	O
1	O
%	O
of	O
realgar	O
,	O
3	O
%	O
of	O
astragalus	O
membranaceus	O
,	O
10	O
%	O
of	O
rhizoma	O
nardostachyos	O
and	O
50	O
%	O
of	O
folium	O
artemisiae	O
argyi	O
.	O

Moxa	O
obtained	O
by	O
mixing	O
the	O
raw	O
materials	O
is	O
favorable	O
for	O
burning	O
,	O
and	O
smoke	O
generated	O
from	O
burning	O
is	O
capable	O
of	O
effectively	O
killing	O
cold	O
virus	O
and	O
is	O
fragrant	O
;	O
and	O
meanwhile	O
,	O
the	O
incense	O
formula	O
is	O
free	O
from	O
any	O
organic	O
compounds	O
,	O
free	O
from	O
any	O
hurt	O
to	O
human	O
body	O
,	O
and	O
is	O
good	O
in	O
effect	O
of	O
preventing	O
cold	O
.	O

Incense	O
formula	O
capable	O
of	O
preventing	O
cold	O

The	O
invention	O
discloses	O
a	O
synthesis	O
method	O
of	O
laminine	O
schiff	B
base	I
with	O
anticancer	O
activity	O
and	O
a	O
pharmaceutical	O
composition	O
thereof	O
.	O

The	O
synthesis	O
method	O
comprises	O
the	O
following	O
specific	O
steps	O
:	O
(	O
1	O
)	O
,	O
synthesizing	O
a	O
laminine	O
aldolactal	B
schiff	I
base	I
;	O
(	O
2	O
)	O
,	O
synthesizing	O
a	O
double	O
-	O
laminine	O
diethyl	B
acetal	I
schiff	I
base	I
;	O
(	O
3	O
)	O
,	O
synthesizing	O
a	O
laminine	O
3,5-dibromosalicylaldehyde	B
acetal	I
schiff	I
base	I
;	O
(	O
4	O
)	O
,	O
synthesizing	O
a	O
laminine	O
2-hydrol-1-naphthaldehyde	B
acetal	I
schiff	I
base	I
;	O
(	O
5	O
)	O
,	O
synthesizing	O
the	O
laminine	O
2-pyridylaldehyde	B
acetal	I
schiff	I
base	I
.	O

A	O
pharmacological	O
analytical	O
research	O
for	O
the	O
compound	O
comprises	O
the	O
following	O
specific	O
steps	O
:	O
(	O
1	O
)	O
,	O
researching	O
interaction	O
of	O
the	O
compound	O
and	O
DNA	O
(	O
Deoxyribonucleic	O
Acid	O
)	O
,	O
including	O
ultraviolet	O
-	O
absorption	O
spectroscopic	O
titration	O
and	O
fluorescence	O
-	O
quenching	O
spectroscopic	O
titration	O
;	O
(	O
2	O
)	O
,	O
researching	O
interaction	O
of	O
the	O
compound	O
and	O
BSA	O
(	O
Bull	O
Serum	O
Albumin	O
)	O
,	O
including	O
tryptophan	B
fluorescence	O
-	O
quenching	O
spectroscopic	O
titration	O
;	O
(	O
3	O
)	O
,	O
applying	O
SBR	O
(	O
Sulfate	O
Reducing	O
Bacteria	O
)	O
to	O
detect	O
for	O
an	O
in	O
-	O
vitro	O
cell	O
toxicity	O
test	O
.	O

The	O
technology	O
disclosed	O
by	O
the	O
invention	O
is	O
suitable	O
for	O
popularization	O
and	O
application	O
in	O
the	O
anticancer	O
filed	O
,	O
has	O
certain	O
medical	O
value	O
,	O
and	O
provides	O
a	O
certain	O
basis	O
for	O
popularizing	O
an	O
anticancer	O
medicament	O
.	O

Synthesis	O
of	O
laminine	O
schiff	B
base	I
with	O
anticancer	O
activity	O
and	O
pharmaceutical	O
composition	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
a	O
hydrophobically	O
modified	O
poly	O
-	O
cation	O
chelating	O
agent	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
(	O
1	O
)	O
dissolving	O
allylamine	B
and	O
sodium	B
carbonate	I
in	O
an	O
organic	O
solvent	O
,	O
dripping	O
bromo	B
-	I
hydrocarbon	I
,	O
and	O
filtering	O
,	O
washing	O
and	O
concentrating	O
to	O
obtain	O
N	B
-	I
alkyl	I
allylamine	I
after	O
reaction	O
;	O
(	O
2	O
)	O
dripping	O
hydrochloric	B
acid	I
into	O
N	B
-	I
alkyl	I
allylamine	I
to	O
be	O
neutral	O
,	O
and	O
collecting	O
and	O
drying	O
precipitate	O
to	O
obtain	O
N	B
-	I
alkyl	I
allylamine	I
hydrochloride	I
;	O
(	O
3	O
)	O
dissolving	O
N	B
-	I
alkyl	I
allylamine	I
hydrochloride	I
and	O
dimethyl	B
diallyl	I
ammonium	I
chloride	I
in	O
water	O
,	O
adding	O
an	O
initiator	O
into	O
the	O
mixture	O
,	O
performing	O
polymerization	O
reaction	O
,	O
dripping	O
absolute	O
ethyl	B
alcohol	I
to	O
the	O
reaction	O
product	O
,	O
and	O
collecting	O
precipitate	O
to	O
produce	O
the	O
hydrophobically	O
modified	O
poly	O
-	O
cation	O
chelating	O
agent	O
.	O

The	O
fatty	B
alkyl	I
chain	O
is	O
introduced	O
into	O
the	O
side	O
chain	O
of	O
macromolecule	O
,	O
so	O
that	O
compared	O
with	O
the	O
commercially	O
available	O
hydrophobically	O
modified	O
poly	O
-	O
cation	O
chelating	O
agent	O
as	O
a	O
cholic	B
acid	I
chelating	O
agent	O
,	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
hydrophobically	O
modified	O
poly	O
-	O
cation	O
chelating	O
agent	O
are	O
obviously	O
reduced	O
due	O
to	O
hydrophobic	O
association	O
action	O
;	O
the	O
hydrophobically	O
modified	O
poly	O
-	O
cation	O
chelating	O
agent	O
has	O
wide	O
application	O
prospect	O
in	O
the	O
development	O
field	O
of	O
new	O
hypolipidemic	O
drugs	O
.	O

Preparation	O
method	O
of	O
hydrophobically	O
modified	O
poly	O
-	O
cation	O
chelating	O
agent	O

A	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
.	O

R1	O
represents	O
a	O
halogen	B
atom	O
or	O
the	O
like	O
;	O
R2	O
and	O
R3	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
R4	O
and	O
R5	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
or	O
R4	O
and	O
R5	O
may	O
form	O
an	O
oxo	B
group	O
;	O
Ra	O
and	O
Rb	O
represent	O
an	O
optionally	O
substituted	O
lower	O
alkyl	B
group	O
or	O
the	O
like	O
or	O
may	O
bond	O
and	O
form	O
a	O
nitrogen	B
-	O
containing	O
heterocycle	B
optionally	O
substituted	O
by	O
one	O
or	O
multiple	O
Rc	O
;	O
Rc	O
represents	O
an	O
optionally	O
substituted	O
aryl	B
group	O
or	O
the	O
like	O
;	O
ring	O
A	O
represents	O
a	O
benzene	B
ring	O
or	O
the	O
like	O
;	O
m	O
represents	O
0	O
,	O
1	O
,	O
or	O
2	O
.	O

Novel	O
compound	O
having	O
parp	O
inhibitory	O
activity	O

The	O
invention	O
discloses	O
an	O
oily	O
long	O
-	O
acting	O
injection	O
containing	O
valnemulin	B
hydrochloride	I
/	O
poloxamer	O
407	O
drug	O
-	O
loading	O
particles	O
,	O
which	O
is	O
prepared	O
by	O
combining	O
the	O
valnemulin	B
hydrochloride	I
with	O
poloxamer	O
407	O
into	O
drug	O
-	O
loading	O
particles	O
and	O
further	O
dispersing	O
the	O
drug	O
-	O
loading	O
particles	O
into	O
an	O
oily	O
medium	O
and	O
grinding	O
.	O

Hydroxypropyl	O
methyl	O
cellulose	O
or	O
high	O
-	O
substituted	O
hydroxypropyl	O
cellulose	O
also	O
can	O
be	O
added	O
into	O
the	O
drug	O
-	O
loading	O
particles	O
,	O
and	O
the	O
sustained	O
-	O
release	O
effect	O
of	O
the	O
preparation	O
is	O
obviously	O
enhanced	O
.	O

The	O
preparation	O
process	O
of	O
the	O
injection	O
is	O
simple	O
,	O
the	O
drug	O
release	O
is	O
uniform	O
,	O
the	O
biocompatibility	O
is	O
good	O
,	O
irreversible	O
damage	O
to	O
the	O
tissue	O
of	O
the	O
injection	O
part	O
is	O
avoided	O
,	O
and	O
the	O
adopted	O
sustained	O
-	O
release	O
carrier	O
can	O
be	O
degraded	O
and	O
excreted	O
.	O

Oily	O
injection	O
containing	O
valnemulin	B
hydrochloride	I
/	O
poloxamer	O
407	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
chloroxine	B
in	O
preparing	O
a	O
drug	O
for	O
treating	O
or	O
preventing	O
influenza	O
virus	O
infections	O
.	O

Firstly	O
,	O
toxicity	O
of	O
chloroxine	B
to	O
MDCK	O
cells	O
is	O
detected	O
.	O

The	O
result	O
shows	O
that	O
the	O
maximum	O
non	O
-	O
toxic	O
concentration	O
of	O
chloroxine	B
is	O
25.0	O
[	O
mu	O
]	O
M.	O
Secondly	O
,	O
antiviral	O
activity	O
of	O
chloroxine	B
is	O
measured	O
within	O
a	O
completely	O
non	O
-	O
toxic	O
concentration	O
range	O
.	O

The	O
result	O
shows	O
that	O
the	O
small	O
molecular	O
compound	O
has	O
significant	O
antiviral	O
activity	O
and	O
the	O
antiviral	O
activity	O
presents	O
a	O
dosage	O
-	O
dependent	O
effect	O
.	O

Finally	O
,	O
the	O
antiviral	O
activities	O
of	O
chloroxine	B
to	O
influenza	O
viruses	O
in	O
different	O
types	O
and	O
subtypes	O
are	O
detected	O
.	O

The	O
results	O
show	O
that	O
chloroxine	B
can	O
suppress	O
replication	O
of	O
all	O
the	O
detected	O
influenza	O
virus	O
strains	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
so	O
that	O
the	O
anti	O
-	O
influenza	O
virus	O
activity	O
of	O
chloroxine	B
has	O
a	O
broad	O
spectrum	O
.	O

Therefore	O
,	O
chloroxine	B
disclosed	O
by	O
the	O
invention	O
is	O
a	O
novel	O
broad	O
-	O
spectrum	O
anti	O
-	O
influenza	O
virus	O
drug	O
and	O
can	O
be	O
used	O
for	O
preparing	O
the	O
drug	O
for	O
treating	O
or	O
preventing	O
the	O
influenza	O
virus	O
infections	O
.	O

Application	O
of	O
chloroxine	B
in	O
preparing	O
drug	O
for	O
treating	O
or	O
preventing	O
influenza	O
virus	O
infections	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
promethazine	B
hydrochlorine	I
in	O
preparation	O
of	O
a	O
drug	O
for	O
prevention	O
or	O
treatment	O
of	O
influenza	O
virus	O
infection	O
.	O

Firstly	O
,	O
the	O
toxicity	O
of	O
promethazine	B
hydrochlorine	I
on	O
MDCK	O
cells	O
is	O
detected	O
,	O
and	O
a	O
result	O
shows	O
that	O
the	O
maximum	O
non	O
-	O
toxic	O
concentration	O
of	O
promethazine	B
hydrochlorine	I
is	O
25.0	O
[	O
mu	O
]	O
M	O
;	O
secondly	O
,	O
the	O
antiviral	O
activity	O
of	O
promethazine	B
hydrochlorine	I
is	O
determined	O
in	O
a	O
completely	O
non	O
-	O
toxic	O
concentration	O
range	O
,	O
and	O
a	O
result	O
shows	O
that	O
the	O
small	O
molecular	O
compound	O
has	O
significant	O
antiviral	O
activity	O
,	O
and	O
the	O
antiviral	O
function	O
has	O
a	O
dose	O
-	O
dependent	O
effect	O
;	O
and	O
finally	O
,	O
the	O
antiviral	O
activity	O
of	O
promethazine	B
hydrochlorine	I
to	O
different	O
types	O
and	O
subtypes	O
of	O
influenza	O
viruses	O
is	O
detected	O
,	O
and	O
a	O
result	O
shows	O
that	O
promethazine	B
hydrochlorine	I
can	O
inhibit	O
replication	O
of	O
all	O
detected	O
influenza	O
viral	O
strains	O
in	O
a	O
dose	O
-	O
dependent	O
mode	O
,	O
thereby	O
representing	O
that	O
the	O
anti	O
-	O
influenza	O
virus	O
activity	O
of	O
promethazine	B
hydrochlorine	I
has	O
a	O
broad	O
-	O
spectrum	O
property	O
.	O

Therefore	O
,	O
promethazine	B
hydrochlorine	I
disclosed	O
by	O
the	O
invention	O
can	O
be	O
used	O
as	O
a	O
novel	O
broad	O
-	O
spectrum	O
anti	O
-	O
influenza	O
virus	O
drug	O
,	O
and	O
can	O
be	O
used	O
for	O
preparation	O
of	O
the	O
drug	O
for	O
prevention	O
or	O
treatment	O
of	O
influenza	O
virus	O
infection	O
.	O

Application	O
of	O
promethazine	B
hydrochlorine	I
in	O
preparation	O
of	O
drug	O
for	O
treatment	O
or	O
prevention	O
of	O
influenza	O
virus	O
infection	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
prostacyclin	B
and	O
analogues	O
in	O
in	O
-	O
vitro	O
inhibition	O
of	O
proliferation	O
of	O
cardiac	O
fibroblasts	O
.	O

The	O
invention	O
explores	O
novel	O
medical	O
uses	O
of	O
prostacyclin	B
and	O
analogues	O
thereof	O
and	O
exploits	O
a	O
novel	O
application	O
field	O
,	O
and	O
provides	O
significative	O
reference	O
for	O
inhibiting	O
proliferation	O
of	O
cardiac	O
muscle	O
fibers	O
and	O
improving	O
myocardial	O
remodeling	O
.	O

Application	O
of	O
prostacyclin	B
and	O
analogues	O
in	O
in	O
-	O
vitro	O
inhibition	O
of	O
proliferation	O
of	O
cardiac	O
fibroblasts	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
poultry	O
infectious	O
diseases	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
applications	O
thereof	O
.	O

Concretely	O
,	O
the	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
chicken	O
infective	O
diseases	O
,	O
the	O
preparation	O
method	O
thereof	O
and	O
the	O
applications	O
thereof	O
,	O
wherein	O
the	O
pharmaceutical	O
composition	O
,	O
according	O
to	O
100	O
mass	O
portions	O
,	O
comprises	O
1	O
-	O
50	O
parts	O
of	O
chitosan	O
and	O
derivatives	O
thereof	O
,	O
0	O
-	O
10	O
parts	O
of	O
solid	O
acid	O
,	O
and	O
the	O
balance	O
being	O
a	O
carrier	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
advantages	O
of	O
wide	O
raw	O
material	O
source	O
,	O
good	O
treatment	O
effect	O
,	O
non	O
-	O
repeated	O
attack	O
,	O
and	O
improvement	O
of	O
growth	O
state	O
of	O
the	O
poultry	O
body	O
.	O

Pharmaceutical	O
composition	O
for	O
preventing	O
poultry	O
infectious	O
diseases	O
,	O
preparation	O
method	O
thereof	O
,	O
and	O
applications	O
thereof	O

The	O
invention	O
provides	O
manure	O
-	O
borne	O
compound	O
probiotics	O
soluble	O
powder	O
for	O
animals	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
10	O
-	O
45	O
percent	O
of	O
bacterial	O
strain	O
,	O
3	O
-	O
10	O
percent	O
of	O
allicin	B
,	O
3	O
-	O
7	O
percent	O
of	O
whey	O
protein	O
,	O
0.5	O
-	O
3	O
percent	O
of	O
available	O
energy	O
,	O
0.2	O
-	O
3	O
percent	O
of	O
bovine	O
coloctrum	O
,	O
0.3	O
-	O
1	O
percent	O
of	O
vitamins	O
,	O
1	O
-	O
5	O
percent	O
of	O
cryoprotectant	O
and	O
26	O
-	O
82	O
percent	O
of	O
excipient	O
.	O

The	O
preparation	O
method	O
has	O
the	O
characteristics	O
of	O
simplicity	O
,	O
feasibility	O
and	O
suitableness	O
for	O
large	O
-	O
scale	O
industrial	O
production	O
.	O

The	O
multi	O
-	O
bacterial	O
strain	O
soluble	O
powder	O
is	O
simple	O
and	O
feasible	O
in	O
preparation	O
method	O
and	O
convenient	O
to	O
use	O
,	O
has	O
an	O
effect	O
of	O
regulating	O
multiple	O
colonies	O
in	O
animal	O
intestines	O
,	O
can	O
be	O
transported	O
,	O
preserved	O
and	O
used	O
under	O
normal	O
temperature	O
conditions	O
and	O
has	O
wide	O
application	O
and	O
popularization	O
prospects	O
.	O

Manure	O
-	O
borne	O
compound	O
probiotics	O
soluble	O
powder	O
for	O
animals	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
terra	O
flava	O
usta	O
,	O
felwort	O
,	O
blackberry	O
lily	O
and	O
pearl	O
vomiting	O
-	O
relieving	O
powder	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
mixing	O
terra	O
flava	O
usta	O
,	O
felwort	O
,	O
pearl	O
,	O
red	O
ochre	O
,	O
blackberry	O
lily	O
,	O
rhizoma	O
pinelliae	O
preparata	O
,	O
codonopsis	O
affinis	O
,	O
indigo	O
naturalis	O
,	O
raw	O
ginger	O
,	O
hawthorn	O
,	O
malt	O
and	O
fructus	O
evodiae	O
;	O
respectively	O
decocting	O
and	O
extracting	O
with	O
water	O
which	O
is	O
8	O
times	O
and	O
6	O
times	O
that	O
of	O
the	O
medicinal	O
materials	O
twice	O
,	O
and	O
2	O
hours	O
each	O
time	O
;	O
combining	O
the	O
extracts	O
,	O
concentrating	O
and	O
drying	O
to	O
prepare	O
dry	O
extracts	O
;	O
combining	O
the	O
two	O
dry	O
extracts	O
,	O
and	O
crushing	O
into	O
fine	O
powder	O
;	O
mixing	O
with	O
soda	O
ash	O
,	O
milk	O
powder	O
,	O
cane	O
sugar	O
,	O
dextrin	O
,	O
edible	O
essence	O
and	O
protein	O
honey	O
,	O
adding	O
auxiliary	O
starch	O
to	O
prepare	O
grains	O
or	O
powder	O
,	O
and	O
packaging	O
into	O
bags	O
.	O

The	O
powder	O
has	O
the	O
advantages	O
of	O
remarkable	O
effect	O
,	O
simple	O
administration	O
,	O
delicious	O
taste	O
and	O
no	O
toxic	O
or	O
side	O
effect	O
.	O

Terra	O
flava	O
usta	O
,	O
felwort	O
,	O
blackberry	O
lily	O
and	O
pearl	O
grains	O
and	O
powder	O
for	O
relieving	O
vomiting	O

The	O
invention	O
relates	O
to	O
application	O
of	O
ginkgol	O
C17:1	O
in	O
treatment	O
of	O
liver	O
cancer	O
,	O
belonging	O
to	O
the	O
field	O
of	O
biological	O
drugs	O
.	O

The	O
ginkgol	O
C17:1	O
is	O
prepared	O
through	O
a	O
method	O
comprising	O
the	O
following	O
steps	O
:	O
preparing	O
ginkgolic	B
acid	I
from	O
gingko	O
(	O
leaves	O
,	O
fruits	O
and	O
episperm	O
)	O
;	O
performing	O
heat	O
treatment	O
to	O
decarboxylate	O
the	O
ginkgolic	B
acid	I
;	O
and	O
separating	O
,	O
and	O
purifying	O
to	O
obtain	O
the	O
ginkgol	O
C17:1	O
,	O
wherein	O
structural	O
identification	O
shows	O
that	O
the	O
ginkgol	O
C17:1	O
has	O
cis	O
/	O
trans	O
isomeric	O
structures	O
.	O

The	O
prepared	O
ginkgol	O
C17:1	O
can	O
effectively	O
inhibit	O
proliferation	O
of	O
human	O
liver	O
cancer	O
cells	O
SMMC-7721	O
and	O
inhibit	O
migration	O
of	O
the	O
SMMC-7721	O
cells	O
in	O
vitro	O
,	O
and	O
drug	O
resistance	O
can	O
not	O
be	O
easily	O
produced	O
;	O
and	O
the	O
prepared	O
ginkgol	O
C17:1	O
can	O
inhibit	O
growth	O
of	O
nude	O
mouse	O
loaded	O
HepG	O
solid	O
tumors	O
in	O
vivo	O
.	O

The	O
new	O
application	O
of	O
the	O
ginkgol	O
C17:1	O
provided	O
by	O
the	O
invention	O
is	O
of	O
great	O
importance	O
in	O
preparation	O
of	O
antitumor	O
drugs	O
and	O
especially	O
in	O
preparation	O
of	O
anti	O
-	O
liver	O
cancer	O
drugs	O
.	O

Application	O
of	O
ginkgol	O
C17:1	O
in	O
treatment	O
of	O
liver	O
cancer	O

The	O
invention	O
provides	O
quinoline-4-amine	B
derivatives	O
containing	O
a	O
benzimidazole	B
structure	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
medical	O
use	O
thereof	O
.	O

The	O
quinoline-4-amine	B
derivatives	O
containing	O
the	O
benzimidazole	B
structure	O
have	O
a	O
general	O
formula	O
as	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
in	O
the	O
formula	O
represents	O
hydrogen	B
,	O
methyl	B
,	O
methoxyl	B
,	O
hydroxy	B
,	O
chlorine	B
,	O
fluorine	B
or	O
trifluoromethyl	B
;	O
R2	O
represents	O
hydrogen	B
,	O
methyl	B
,	O
fluorine	B
,	O
chlorine	B
,	O
bromine	B
or	O
trifluoromethyl	B
;	O
R3	O
represents	O
hydrogen	B
,	O
methyl	B
,	O
ethyl	B
,	O
fluorine	B
,	O
chlorine	B
,	O
bromine	B
or	O
trifluoromethyl	B
;	O
R4	O
represents	O
hydrogen	B
,	O
fluorine	B
or	O
chlorine	B
;	O
R5	O
represents	O
hydrogen	B
or	O
chlorine	B
.	O

Study	O
results	O
indicate	O
that	O
the	O
quinoline-4-amine	B
derivatives	O
containing	O
the	O
benzimidazole	B
structure	O
provided	O
by	O
the	O
invention	O
have	O
a	O
remarkable	O
inhibition	O
effect	O
on	O
mouse	O
melanoma	O
cells	O
(	O
F10	O
)	O
,	O
human	O
cervical	O
cancer	O
cells	O
(	O
Hela	O
)	O
,	O
human	O
hepatoma	O
carcinoma	O
cells	O
(	O
Hepg2	O
)	O
and	O
human	O
breast	O
cancer	O
cells	O
(	O
MCF7	O
)	O
,	O
so	O
that	O
the	O
quinoline-4-amine	B
derivatives	O
containing	O
the	O
benzimidazole	B
structure	O
provided	O
by	O
the	O
invention	O
can	O
be	O
applied	O
to	O
preparing	O
antitumor	O
drugs	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
quinoline-4-amine	B
derivatives	O
containing	O
the	O
benzimidazole	B
structure	O
.	O

Quinoline-4-amine	B
derivatives	O
containing	O
benzimidazole	B
structure	O
,	O
as	O
well	O
as	O
preparation	O
method	O
and	O
medical	O
use	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
the	O
pharmaceutical	O
chemistry	O
,	O
and	O
concretely	O
discloses	O
benzimidazole	B
derivatives	O
,	O
and	O
a	O
preparation	O
method	O
and	O
a	O
medicinal	O
use	O
thereof	O
.	O

The	O
benzimidazole	B
derivatives	O
comprise	O
ligustrazine	B
and	O
NO	B
donor	O
derivatives	O
,	O
and	O
the	O
benzimidazole	B
derivatives	O
can	O
rapidly	O
release	O
ligustrazine	B
or	O
NO	B
in	O
vivo	O
,	O
so	O
there	O
is	O
an	O
effective	O
synergistic	O
effect	O
between	O
the	O
benzimidazole	B
derivatives	O
and	O
azilsartan	B
,	O
thereby	O
the	O
benzimidazole	B
derivatives	O
enhances	O
the	O
antihypertension	O
effect	O
,	O
reduces	O
untoward	O
effects	O
,	O
has	O
an	O
ideal	O
protection	O
effect	O
on	O
the	O
liver	O
and	O
kidney	O
of	O
a	O
patient	O
,	O
and	O
fills	O
a	O
gap	O
in	O
the	O
prior	O
art	O
.	O

Benzimidazole	B
derivatives	O
,	O
preparation	O
method	O
and	O
medicinal	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
dammarane	B
triterpene	I
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
;	O
a	O
pharmaceutical	O
salt	O
thereof	O
;	O
a	O
preparation	O
method	O
of	O
the	O
dammarane	B
triterpene	I
derivative	O
;	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
dammarane	B
triterpene	I
derivative	O
as	O
an	O
active	O
ingredient	O
;	O
applications	O
of	O
the	O
dammarane	B
triterpene	I
derivative	O
,	O
the	O
pharmaceutical	O
salt	O
,	O
and	O
the	O
pharmaceutical	O
composition	O
in	O
preparation	O
of	O
medicines	O
used	O
for	O
treating	O
or	O
preventing	O
obesity	O
,	O
diabetes	O
,	O
hypertension	O
,	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
and	O
related	O
metabolic	O
diseases	O
;	O
and	O
applications	O
of	O
the	O
dammarane	B
triterpene	I
derivative	O
,	O
the	O
pharmaceutical	O
salt	O
,	O
and	O
the	O
pharmaceutical	O
composition	O
in	O
preparation	O
of	O
11	O
<	O
beta>-HSD1	O
inhibitor	O
.	O

Dammarane	B
triterpene	I
derivative	O
,	O
pharmaceutical	O
composition	O
thereof	O
,	O
and	O
applications	O
of	O
dammarane	B
triterpene	I
derivative	O
in	O
pharmacy	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicinal	O
preparations	O
,	O
and	O
provides	O
an	O
aripiprazole	B
micro	O
-	O
emulsion	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
comprises	O
aripiprazole	B
,	O
an	O
emulsifying	O
agent	O
,	O
a	O
co	O
-	O
emulsifier	O
,	O
an	O
oil	O
phase	O
and	O
an	O
aqueous	O
phase	O
.	O

Compared	O
with	O
other	O
preparations	O
,	O
the	O
micro	O
-	O
emulsion	O
is	O
stable	O
in	O
drug	O
-	O
loading	O
system	O
,	O
has	O
the	O
advantages	O
of	O
targeting	O
,	O
improved	O
solubility	O
and	O
high	O
bioavailability	O
,	O
can	O
cover	O
the	O
unpleasant	O
taste	O
of	O
the	O
medicine	O
,	O
and	O
is	O
excellent	O
in	O
oral	O
compliance	O
.	O

Aripiprazole	B
micro	O
-	O
emulsion	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
chemical	O
and	O
pharmaceutical	O
technology	O
,	O
and	O
particularly	O
relates	O
to	O
Montelukast	O
sodium	B
chewable	O
tablets	O
and	O
a	O
preparation	O
method	O
thereof	O
by	O
direct	O
powder	O
compression	O
.	O

The	O
Montelukast	O
sodium	B
chewable	O
tablets	O
comprise	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
1.5	O
-	O
2	O
parts	O
of	O
Montelukast	O
sodium	B
,	O
30	O
-	O
35	O
parts	O
of	O
mannitol	B
,	O
15	O
-	O
20	O
parts	O
of	O
xylitol	B
,	O
30	O
-	O
40	O
parts	O
of	O
microcrystalline	O
cellulose	O
,	O
6	O
-	O
12	O
parts	O
of	O
sodium	O
carboxymethyl	O
starch	O
,	O
0.5	O
-	O
1.5	O
parts	O
of	O
magnesium	B
stearate	I
,	O
1.5	O
-	O
3	O
parts	O
of	O
aerosol	O
and	O
0.5	O
-	O
2	O
parts	O
of	O
red	O
iron	B
oxide	I
.	O

In	O
the	O
invention	O
,	O
by	O
adopting	O
the	O
direct	O
powder	O
compression	O
process	O
for	O
tablet	O
compression	O
,	O
the	O
preparation	O
instability	O
caused	O
by	O
the	O
Montelukast	O
sodium	B
sensitive	O
to	O
dampness	O
is	O
avoided	O
,	O
so	O
that	O
the	O
Montelukast	O
sodium	B
chewable	O
tablets	O
provided	O
by	O
the	O
invention	O
have	O
relatively	O
good	O
stability	O
;	O
moreover	O
,	O
since	O
the	O
granulation	O
process	O
is	O
saved	O
,	O
the	O
preparation	O
process	O
is	O
simplified	O
and	O
convenient	O
to	O
implement	O
,	O
the	O
production	O
cycle	O
is	O
greatly	O
shortened	O
,	O
and	O
the	O
production	O
efficiency	O
is	O
improved	O
.	O

Montelukast	O
sodium	B
chewable	O
tablets	O
and	O
preparation	O
method	O
thereof	O
by	O
direct	O
powder	O
compression	O

The	O
invention	O
discloses	O
application	O
of	O
dicyclomine	B
hydrochloride	I
in	O
the	O
preparation	O
of	O
a	O
drug	O
for	O
treating	O
or	O
preventing	O
influenza	O
virus	O
infection	O
.	O

Firstly	O
,	O
the	O
toxicity	O
effect	O
of	O
dicyclomine	B
hydrochloride	I
on	O
an	O
MDCK	O
(	O
Madin	O
Darby	O
Canine	O
Kidney	O
)	O
cell	O
is	O
detected	O
,	O
and	O
the	O
result	O
shows	O
that	O
the	O
maximum	O
non	O
-	O
toxic	O
concentration	O
of	O
the	O
dicyclomine	B
hydrochloride	I
is	O
50.0	O
MuM	O
;	O
secondly	O
,	O
the	O
antivirus	O
activity	O
of	O
the	O
dicyclomine	B
hydrochloride	I
is	O
measured	O
within	O
a	O
completely	O
non	O
-	O
toxic	O
concentration	O
range	O
,	O
and	O
the	O
result	O
shows	O
that	O
the	O
small	O
molecular	O
compound	O
has	O
remarkable	O
antivirus	O
activity	O
,	O
and	O
the	O
antiviral	O
effect	O
has	O
a	O
dosage	O
dependence	O
effect	O
;	O
finally	O
,	O
the	O
activity	O
of	O
the	O
dicyclomine	B
hydrochloride	I
for	O
resisting	O
different	O
types	O
and	O
subtypes	O
of	O
influenza	O
viruses	O
is	O
detected	O
,	O
and	O
the	O
result	O
shows	O
that	O
the	O
dicyclomine	B
hydrochloride	I
can	O
resist	O
the	O
copy	O
of	O
all	O
detected	O
influenza	O
virus	O
strains	O
in	O
a	O
dosage	O
dependence	O
manner	O
and	O
the	O
influenza	O
virus	O
resistance	O
activity	O
of	O
the	O
dicyclomine	B
hydrochloride	I
is	O
broad	O
-	O
spectrum	O
.	O

Therefore	O
,	O
the	O
dicyclomine	B
hydrochloride	I
disclosed	O
by	O
the	O
invention	O
is	O
a	O
novel	O
broad	O
-	O
spectrum	O
influenza	O
virus	O
resistant	O
drug	O
,	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
drugs	O
for	O
preventing	O
or	O
treating	O
the	O
influenza	O
virus	O
infection	O
.	O

Application	O
of	O
dicyclomine	B
hydrochloride	I
in	O
preparation	O
of	O
drug	O
for	O
treating	O
or	O
preventing	O
influenza	O
virus	O
infection	O

The	O
invention	O
discloses	O
use	O
of	O
a	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-beta1	O
inhibitor	O
in	O
lung	O
cancer	O
treatment	O
.	O

The	O
TGF	O
-	O
beta1	O
inhibitor	O
inhibits	O
a	O
TGF	O
-	O
beta1	O
channel	O
to	O
increase	O
the	O
radiosensitivity	O
of	O
lung	O
cancer	O
cells	O
.	O

Through	O
the	O
manner	O
,	O
according	O
to	O
the	O
use	O
of	O
the	O
TGF	O
-	O
beta1	O
inhibitor	O
in	O
lung	O
cancer	O
treatment	O
,	O
the	O
sensitivity	O
enhancement	O
effect	O
of	O
the	O
TGF	O
-	O
beta1	O
inhibitor	O
on	O
the	O
lung	O
cancer	O
cells	O
is	O
caused	O
by	O
inhibition	O
on	O
non	O
-	O
homologous	O
end	O
joining	O
repair	O
of	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
double	O
-	O
strand	O
break	O
,	O
change	O
of	O
cycle	O
distribution	O
of	O
the	O
lung	O
cancer	O
cells	O
after	O
irradiation	O
,	O
and	O
obvious	O
reduction	O
of	O
tumor	O
growth	O
by	O
the	O
TGF	O
-	O
beta1	O
inhibitor	O
combined	O
with	O
X	O
-	O
ray	O
treatment	O
of	O
5Gy	O
.	O

The	O
DNA	O
repair	O
capacity	O
can	O
be	O
reduced	O
by	O
inhibition	O
on	O
the	O
TGF	O
-	O
beta1	O
channel	O
of	O
tumor	O
cells	O
before	O
irradiation	O
,	O
the	O
cell	O
cycle	O
distribution	O
is	O
changed	O
,	O
the	O
cell	O
cloning	O
ability	O
is	O
reduced	O
,	O
the	O
tumor	O
growth	O
is	O
delayed	O
,	O
and	O
effective	O
auxiliary	O
means	O
are	O
provided	O
by	O
inhibiting	O
the	O
TGF	O
-	O
beta1	O
channel	O
as	O
radiotherapy	O
of	O
a	O
patient	O
with	O
a	O
lung	O
cancer	O
.	O

Use	O
of	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-beta1	O
inhibitor	O
in	O
lung	O
cancer	O
treatment	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
swine	O
erysipelas	O
.	O

The	O
medicine	O
is	O
prepared	O
from	O
the	O
following	O
bulk	O
drugs	O
:	O
honeysuckle	O
,	O
sesame	O
curd	O
,	O
choerospondias	O
axillaris	O
,	O
radices	O
trichosanthis	O
,	O
garlic	O
,	O
potato	O
,	O
ant	O
,	O
stylocoryna	O
attenuata	O
voigt	O
,	O
rheum	O
officinale	O
,	O
sticky	O
rice	O
,	O
talc	O
,	O
rhizoma	O
belamcandae	O
,	O
radix	O
sophorae	O
tonkinensis	O
,	O
folium	O
isatidis	O
,	O
semen	O
lepidii	O
,	O
moutan	O
bark	O
,	O
raw	O
rehmannia	O
,	O
radix	O
scrophulariae	O
,	O
liquorice	O
,	O
apricot	O
kernal	O
,	O
bunge	O
corydalis	O
herb	O
,	O
catkin	O
,	O
duckweed	O
,	O
alum	O
and	O
dandelion	O
.	O

The	O
medicine	O
for	O
treating	O
swine	O
erysipelas	O
has	O
the	O
beneficial	O
effects	O
of	O
remarkable	O
curative	O
effect	O
,	O
low	O
side	O
effect	O
,	O
high	O
cure	O
rate	O
,	O
short	O
course	O
of	O
treatment	O
,	O
no	O
relapse	O
and	O
the	O
like	O
.	O

Medicine	O
for	O
treating	O
swine	O
erysipelas	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
an	O
angiotensin	B
II	I
receptor	O
blocker	O
(	O
ARB	O
)	O
/	O
thiazide	B
diuretics	O
/	O
5-methyltetrahydrofolate	B
and	O
an	O
application	O
of	O
the	O
pharmaceutical	O
composition	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
the	O
ARB	O
with	O
pharmaceutical	O
dosage	O
,	O
the	O
thiazide	O
diuretics	O
with	O
pharmaceutical	O
dosage	O
,	O
the	O
5-methyltetrahydrofolate	B
with	O
pharmaceutical	O
dosage	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
invention	O
provides	O
the	O
application	O
of	O
the	O
pharmaceutical	O
composition	O
in	O
the	O
preparation	O
of	O
medicines	O
used	O
for	O
treating	O
hypertension	O
as	O
well	O
as	O
preventing	O
,	O
treating	O
or	O
delaying	O
target	O
-	O
organ	O
damage	O
caused	O
by	O
the	O
hypertension	O
.	O

The	O
invention	O
also	O
provides	O
the	O
application	O
of	O
the	O
pharmaceutical	O
composition	O
in	O
the	O
preparation	O
of	O
medicines	O
used	O
for	O
reducing	O
the	O
risk	O
of	O
cardiovascular	O
and	O
cerebrovascular	O
events	O
caused	O
by	O
the	O
hypertension	O
.	O

Through	O
the	O
implementation	O
of	O
the	O
invention	O
,	O
the	O
pharmaceutical	O
composition	O
with	O
the	O
specific	O
purposes	O
is	O
provided	O
for	O
patients	O
,	O
the	O
medication	O
compliance	O
of	O
the	O
patients	O
also	O
can	O
be	O
increased	O
,	O
and	O
the	O
curative	O
effect	O
is	O
improved	O
.	O

Angiotensin	B
II	I
receptor	O
blocker	O
/	O
thiazide	B
diuretics	O
/	O
5-methyltetrahydrofolate	B
pharmaceutical	O
composition	O

The	O
invention	O
provides	O
novel	O
allergic	O
reaction	O
-	O
resistant	O
benzocyclothiophthene	B
compounds	O
,	O
particularly	O
benzocyclothiophthene	B
compounds	O
shown	O
as	O
a	O
chemical	O
formula	O
I.	O
The	O
benzocyclothiophthene	B
compounds	O
have	O
the	O
advantages	O
of	O
resisting	O
histamine	B
and	O
asthma	O
and	O
reducing	O
the	O
side	O
effects	O
of	O
sedation	O
.	O

The	O
invention	O
further	O
provided	O
pharmaceutically	O
acceptable	O
salts	O
and	O
configurational	O
isomers	O
.	O

The	O
compounds	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
and	O
configurational	O
isomers	O
can	O
be	O
prepared	O
into	O
clinical	O
compositions	O
and	O
corresponding	O
dosage	O
forms	O
in	O
combination	O
with	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
.	O

Novel	O
allergic	O
reaction	O
-	O
resistant	O
benzocyclothiophthene	B
compounds	O

The	O
invention	O
discloses	O
a	O
Grifola	O
frondosa	O
polysaccharide	O
F2	O
with	O
blood	O
sugar	B
lowering	O
function	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
taking	O
Grifola	O
frondosa	O
sporophores	O
,	O
pulverizing	O
,	O
extracting	O
with	O
hot	O
water	O
,	O
filtering	O
,	O
adding	O
ethanol	B
into	O
the	O
filtrate	O
to	O
precipitate	O
,	O
and	O
separating	O
the	O
precipitate	O
;	O
passing	O
the	O
precipitate	O
through	O
a	O
DEAE	B
(	O
diethylaminoethanol	B
)	O

Sepharose	O
Fast	O
Flow	O
chromatographic	O
column	O
,	O
balancing	O
with	O
Tris	B
-	I
HCl	I
(	O
10mM	O
,	O
pH=8.0	O
)	O
,	O
and	O
collecting	O
to	O
obtain	O
a	O
fraction	O
F1	O
;	O
and	O
eluting	O
with	O
Tris	B
-	I
HCl	I
(	O
10mM	O
,	O
pH=8.0	O
)	O
containing	O
0.1	O
M	O
NaCl	B
to	O
obtain	O
a	O
fraction	O
F2	O
,	O
concentrating	O
the	O
F2	O
under	O
reduced	O
pressure	O
,	O
dialyzing	O
,	O
and	O
drying	O
to	O
obtain	O
the	O
Grifola	O
frondosa	O
polysaccharide	O
F2	O
.	O

The	O
new	O
Grifola	O
frondosa	O
polysaccharide	O
F2	O
separated	O
from	O
the	O
Grifola	O
frondosa	O
sporophores	O
has	O
blood	O
sugar	B
lowering	O
activity	O
,	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
treating	O
diabetes	O
,	O
and	O
lays	O
foundation	O
for	O
developing	O
new	O
medicines	O
for	O
treating	O
diabetes	O
.	O

Preparation	O
method	O
and	O
blood	O
sugar	B
lowering	O
function	O
of	O
Grifola	O
frondosa	O
polysaccharide	O
F2	O

The	O
invention	O
discloses	O
a	O
compound	O
donkey	O
-	O
hide	O
gelatin	O
lyceum	O
-	O
barbarum	O
beverage	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
food	O
processing	O
.	O

The	O
compound	O
donkey	O
-	O
hide	O
gelatin	O
lyceum	O
-	O
barbarum	O
beverage	O
is	O
prepared	O
by	O
employing	O
donkey	O
-	O
hide	O
gelatin	O
as	O
a	O
main	O
raw	O
material	O
and	O
supplementing	O
with	O
lyceum	O
barbarum	O
,	O
raw	O
ginger	O
,	O
red	O
date	O
and	O
the	O
like	O
.	O

Multiple	O
medicinal	O
materials	O
are	O
compounded	O
and	O
promote	O
each	O
other	O
for	O
improving	O
medicinal	O
effects	O
,	O
and	O
the	O
insufficient	O
of	O
a	O
single	O
medicinal	O
material	O
is	O
supplemented	O
.	O

The	O
product	O
is	O
good	O
in	O
mouthfeel	O
,	O
obvious	O
in	O
effect	O
and	O
long	O
in	O
shelf	O
life	O
.	O

The	O
production	O
technology	O
is	O
scientific	O
and	O
effect	O
,	O
and	O
is	O
simple	O
and	O
convenient	O
to	O
operate	O
.	O

Purification	O
is	O
performed	O
by	O
aiming	O
at	O
the	O
characteristics	O
of	O
different	O
medicine	O
raw	O
materials	O
,	O
and	O
the	O
effective	O
components	O
are	O
furthest	O
kept	O
,	O
so	O
that	O
the	O
health	O
demands	O
of	O
different	O
consumers	O
are	O
satisfied	O
.	O

Compound	O
donkey	O
-	O
hide	O
gelatin	O
lyceum	O
-	O
barbarum	O
beverage	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
fructose	B
diphosphate	I
injection	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
cooling	O
injection	O
water	O
to	O
below	O
40	O
DEG	O
C	O
for	O
later	O
use	O
;	O
(	O
2	O
)	O
weighing	O
a	O
pH	O
regulating	O
agent	O
,	O
and	O
stirring	O
with	O
injection	O
water	O
to	O
dissolve	O
;	O
(	O
3	O
)	O
weighing	O
20	O
-	O
80	O
percent	O
by	O
weight	O
of	O
injection	O
water	O
,	O
introducing	O
nitrogen	O
into	O
water	O
,	O
weighing	O
the	O
prescribed	O
fructose	B
diphosphate	I
,	O
adding	O
,	O
stirring	O
and	O
dissolving	O
the	O
fructose	B
diphosphate	I
,	O
regulating	O
the	O
pH	O
value	O
to	O
be	O
3	O
-	O
4	O
by	O
using	O
the	O
pH	O
regulating	O
agent	O
solution	O
,	O
and	O
adding	O
an	O
auxiliary	O
material	O
to	O
prepare	O
q	O
liquid	O
medicine	O
;	O
(	O
4	O
)	O
adding	O
activated	O
carbon	B
into	O
the	O
liquid	O
medicine	O
,	O
stirring	O
and	O
adsorbing	O
for	O
10	O
-	O
40	O
minutes	O
,	O
filtering	O
and	O
decarburizing	O
,	O
adding	O
the	O
injection	O
water	O
to	O
a	O
prescribed	O
amount	O
,	O
and	O
simultaneously	O
regulating	O
the	O
pH	O
value	O
the	O
same	O
as	O
that	O
in	O
the	O
step	O
(	O
3	O
)	O
by	O
using	O
the	O
pH	O
regulating	O
agent	O
solution	O
;	O
(	O
5	O
)	O
sampling	O
to	O
inspect	O
,	O
filtering	O
with	O
a	O
microfiltration	O
membrane	O
of	O
0.22	O
micron	O
after	O
the	O
sample	O
is	O
qualified	O
,	O
filling	O
into	O
a	O
glass	O
bottle	O
which	O
is	O
baked	O
and	O
sterilized	O
at	O
high	O
temperature	O
,	O
plugging	O
,	O
sterilizing	O
,	O
capping	O
and	O
packaging	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
fructose	B
diphosphate	I
injection	O
prepared	O
by	O
the	O
method	O
is	O
simple	O
in	O
process	O
,	O
safe	O
and	O
reliable	O
,	O
good	O
in	O
stability	O
and	O
convenient	O
in	O
clinical	O
application	O
.	O

Method	O
for	O
preparing	O
fructose	B
diphosphate	I
injection	O

The	O
invention	O
provides	O
a	O
new	O
tapentadol	B
hydrochloride	I
injection	O
,	O
particularly	O
a	O
small	O
-	O
capacity	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
injection	O
is	O
composed	O
of	O
tapentadol	B
hydrochloride	I
or	O
tapentadol	B
alkali	O
with	O
active	O
ingredients	O
,	O
and	O
medicinal	O
carriers	O
.	O

The	O
tapentadol	B
hydrochloride	I
injection	O
can	O
be	O
suitable	O
for	O
small	O
-	O
capacity	O
injections	O
with	O
various	O
sizes	O
.	O

Compared	O
with	O
the	O
conventional	O
oral	O
preparations	O
,	O
the	O
tapentadol	B
hydrochloride	I
injection	O
has	O
the	O
advantages	O
of	O
high	O
bioavailability	O
,	O
good	O
absorption	O
effect	O
of	O
medicine	O
,	O
fast	O
distribution	O
,	O
good	O
treatment	O
effect	O
and	O
the	O
like	O
.	O

The	O
medicinal	O
occasion	O
of	O
the	O
tapentadol	B
hydrochloride	I
is	O
enlarged	O
,	O
and	O
the	O
clinical	O
medication	O
level	O
of	O
the	O
tapentadol	B
hydrochloride	I
is	O
improved	O
.	O

Tapentadol	B
hydrochloride	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
an	O
erythromycin	B
thiocyanate	I
emulsion	O
,	O
wherein	O
erythromycin	B
thiocyanate	I
is	O
weighed	O
,	O
is	O
mixed	O
with	O
a	O
dispersing	O
agent	O
in	O
water	O
,	O
is	O
blended	O
with	O
an	O
auxiliary	O
solvent	O
,	O
is	O
subjected	O
to	O
thickening	O
through	O
a	O
carrageenan	O
,	O
and	O
then	O
is	O
subjected	O
to	O
volume	O
metering	O
to	O
prepare	O
the	O
finished	O
product	O
.	O

According	O
to	O
the	O
present	O
invention	O
,	O
with	O
detection	O
,	O
the	O
emulsions	O
with	O
different	O
contents	O
can	O
be	O
completely	O
and	O
uniformly	O
mixed	O
with	O
water	O
,	O
the	O
solubility	O
of	O
the	O
emulsion	O
is	O
far	O
higher	O
than	O
the	O
monomer	O
erythromycin	B
thiocyanate	I
,	O
the	O
character	O
is	O
stable	O
and	O
no	O
precipitation	O
is	O
generated	O
after	O
long	O
-	O
term	O
storage	O
,	O
and	O
the	O
agents	O
with	O
a	O
plurality	O
of	O
concentrations	O
can	O
be	O
prepared	O
according	O
to	O
requirements	O
of	O
different	O
diseases	O
,	O
such	O
that	O
the	O
use	O
is	O
convenient	O
.	O

Erythromycin	B
thiocyanate	I
emulsion	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
oxcarbazepine	B
tablets	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
oxcarbazepine	B
tablets	O
comprise	O
tablet	O
cores	O
and	O
coating	O
,	O
wherein	O
the	O
tablet	O
cores	O
are	O
obtained	O
by	O
directly	O
pressing	O
,	O
and	O
comprise	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
in	O
the	O
oxcarbazepine	B
tablets	O
:	O
45	O
to	O
60	O
percent	O
of	O
oxcarbazepine	B
,	O
5	O
to	O
10	O
percent	O
of	O
partially	O
pregelatinized	O
starch	O
,	O
25	O
to	O
35	O
percent	O
of	O
starch	O
and	O
lactose	B
compound	O
,	O
3	O
to	O
7	O
percent	O
of	O
S-630	O
copovidone	B
,	O
2	O
to	O
6	O
percent	O
of	O
cross	O
-	O
linked	O
sodium	O
carboxymethyl	O
cellulose	O
and	O
0.5	O
to	O
2.5	O
percent	O
of	O
sodium	B
stearyl	I
fumarate	I
.	O

By	O
combining	O
the	O
characteristics	O
that	O
the	O
oxcarbazepine	B
is	O
unstable	O
in	O
light	O
and	O
water	O
,	O
and	O
is	O
easy	O
to	O
deteriorate	O
,	O
the	O
processes	O
of	O
adding	O
water	O
and	O
drying	O
are	O
omitted	O
in	O
the	O
preparation	O
process	O
of	O
the	O
oxcarbazepine	B
,	O
so	O
that	O
the	O
production	O
time	O
is	O
shortened	O
,	O
the	O
production	O
energy	O
consumption	O
is	O
reduced	O
,	O
and	O
manpower	O
rand	O
material	O
resources	O
are	O
saved	O
.	O

The	O
oxcarbazepine	B
tablets	O
disclosed	O
by	O
the	O
invention	O
have	O
reasonable	O
compositions	O
,	O
few	O
impurities	O
in	O
a	O
finished	O
product	O
,	O
and	O
obvious	O
advantages	O
of	O
high	O
dissolution	O
rate	O
and	O
high	O
tablet	O
uniformity	O
.	O

Oxcarbazepine	B
tablets	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
application	O
of	O
xanthohumol	B
in	O
preparation	O
of	O
a	O
drug	O
or	O
a	O
health	O
-	O
care	O
product	O
for	O
inhibiting	O
alpha	O
-	O
glucosaccharase	O
activity	O
.	O

An	O
experiment	O
proves	O
that	O
the	O
xanthohumol	B
has	O
strong	O
inhibitory	O
activity	O
on	O
the	O
alpha	O
-	O
glucosaccharase	O
under	O
a	O
low	O
-	O
concentration	O
condition	O
,	O
IC50	O
for	O
in	O
vitro	O
inhibition	O
of	O
the	O
alpha	O
-	O
glucosaccharase	O
is	O
8.8mu	O
M	O
,	O
the	O
inhibition	O
type	O
is	O
noncompetitive	O
inhibition	O
,	O
the	O
alpha	O
-	O
glucosaccharase	O
activity	O
can	O
be	O
effectively	O
inhibited	O
,	O
the	O
xanthohumol	B
has	O
reversibility	O
on	O
the	O
activity	O
of	O
the	O
alpha	O
-	O
glucosaccharase	O
,	O
and	O
a	O
potential	O
side	O
effect	O
of	O
an	O
irreversible	O
inhibitor	O
can	O
be	O
effectively	O
avoided	O
.	O

Furthermore	O
,	O
the	O
xanthohumol	B
is	O
from	O
a	O
main	O
raw	O
material	O
lupulus	O
for	O
brewing	O
beer	O
,	O
belongs	O
to	O
a	O
natural	O
product	O
of	O
a	O
food	O
source	O
,	O
is	O
abundant	O
in	O
source	O
,	O
and	O
mature	O
in	O
preparation	O
technology	O
,	O
and	O
can	O
be	O
greatly	O
extracted	O
and	O
prepared	O
.	O

Meanwhile	O
,	O
the	O
xanthohumol	B
is	O
safe	O
and	O
nontoxic	O
,	O
and	O
free	O
of	O
toxic	O
and	O
side	O
effects	O
,	O
and	O
appearance	O
of	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
drug	O
is	O
avoided	O
.	O

The	O
xanthohumol	B
can	O
be	O
applied	O
to	O
preparation	O
of	O
drugs	O
for	O
treating	O
diabetes	O
mellitus	O
,	O
acquired	O
immune	O
deficiency	O
syndrome	O
,	O
malignant	O
tumors	O
,	O
and	O
a	O
lysosomal	O
storage	O
disease	O
,	O
and	O
has	O
a	O
good	O
market	O
application	O
prospect	O
.	O

Application	O
of	O
xanthohumol	B
in	O
preparation	O
of	O
drug	O
or	O
health	O
-	O
care	O
product	O
for	O
inhibiting	O
alpha	O
-	O
glucosaccharase	O
activity	O

The	O
invention	O
relates	O
to	O
a	O
new	O
substance	O
citric	B
acid	I
dehydrogenated	O
calcium	B
ascorbate	I
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
preparation	O
method	O
of	O
the	O
citric	B
acid	I
dehydrogenated	O
calcium	B
ascorbate	I
is	O
characterized	O
by	O
comprising	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighing	O
raw	O
materials	O
,	O
including	O
citric	B
acid	I
monohydrate	I
,	O
ascorbic	B
acid	I
,	O
calcium	B
hydroxide	I
and	O
water	O
,	O
and	O
putting	O
into	O
a	O
reaction	O
kettle	O
,	O
wherein	O
the	O
molar	O
ratio	O
of	O
citric	B
acid	I
monohydrate	I
to	O
ascorbic	B
acid	I
to	O
calcium	B
hydroxide	I
is	O
2:1:3	O
;	O
(	O
2	O
)	O
starting	O
the	O
machine	O
for	O
chemical	O
reaction	O
for	O
half	O
a	O
hour	O
;	O
(	O
3	O
)	O
shutting	O
down	O
for	O
half	O
an	O
hour	O
and	O
adding	O
ethanol	B
so	O
that	O
the	O
chemical	O
reaction	O
gets	O
mature	O
;	O
(	O
4	O
)	O
starting	O
the	O
machine	O
for	O
half	O
a	O
hour	O
,	O
and	O
releasing	O
citric	B
acid	I
dehydrogenated	O
calcium	B
ascorbate	I
.	O

The	O
citric	B
acid	I
dehydrogenated	O
calcium	B
ascorbate	I
prepared	O
by	O
the	O
invention	O
can	O
easily	O
dissolve	O
in	O
water	O
and	O
is	O
beneficial	O
to	O
the	O
assimilation	O
of	O
human	O
and	O
animals	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
calcium	B
supplementing	O
Vc	O
bone	O
strengthening	O
antioxidation	O
fresh	O
-	O
keeping	O
agent	O
,	O
a	O
calcium	B
supplementing	O
Vc	O
bone	O
strengthening	O
food	O
additive	O
,	O
and	O
a	O
medicine	O
for	O
treating	O
osteoporosis	O
,	O
leg	O
cramps	O
,	O
stomach	O
illness	O
,	O
bronchitis	O
,	O
pneumonia	O
,	O
liver	O
cancer	O
and	O
hypertension	O
.	O

Citric	B
acid	I
dehydrogenated	O
calcium	B
ascorbate	I
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
kind	O
of	O
7-	B
(	I
3-acylamino-4-oxyiminomethyl-1-piperidyl	I
)	I
fluoroquinolone	I
carboxylic	I
acid	I
compounds	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
an	O
antibacterial	O
agent	O
composition	O
containing	O
the	O
7-	B
(	I
3-acylamino-4-oxyiminomethyl-1-piperidyl	I
)	I
fluoroquinolone	I
carboxylic	I
acid	I
compounds	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
a	O
series	O
of	O
amino	B
acid	I
prodrugs	O
of	O
carbostyril	B
antibacterial	O
candidates	O
IMB-070593	O
,	O
and	O
a	O
7-substituted	O
group	O
is	O
3-	B
(	I
substituted	I
)	I
acylamino-4-oxyiminomethyl-1-piperidyl	I
.	O

The	O
water	O
solubility	O
of	O
these	O
prodrugs	O
is	O
remarkably	O
more	O
than	O
that	O
of	O
the	O
IMB-070593	O
;	O
compared	O
with	O
the	O
IMB-070593	O
and	O
novel	O
fluoroquinolones	B
antibacterial	O
agents	O
(	O
such	O
as	O
moxifloxacin	B
)	O
,	O
the	O
7-	B
(	I
3-acylamino-4-oxyiminomethyl-1-piperidyl	I
)	I
fluoroquinolone	I
carboxylic	I
acid	I
compounds	O
have	O
a	O
more	O
excellent	O
activity	O
of	O
resisting	O
clinical	O
important	O
pathogenic	O
bacteria	O
(	O
such	O
as	O
MRSA	O
(	O
Methicillin	B
-	O
resistant	O
Staphylococcus	O
Aureus	O
)	O
and	O
MRSE	O
(	O
Methicillin	B
Resistant	O
Staphylococcus	O
Epidermidis	O
)	O
)	O
.	O

7-	B
(	I
3-acylamino-4-oxyiminomethyl-1-piperidyl	I
)	I
fluoroquinolone	I
carboxylic	I
acid	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
epidemic	O
disease	O
wind	O
expelling	O
,	O
preventing	O
and	O
treating	O
perfume	O
satchel	O
which	O
is	O
made	O
by	O
selecting	O
raw	O
materials	O
such	O
as	O
snow	O
lotus	O
herb	O
and	O
wild	O
chrysanthemum	O
growing	O
in	O
an	O
extreme	O
cold	O
environment	O
,	O
wherein	O
the	O
raw	O
materials	O
specifically	O
consist	O
of	O
the	O
following	O
components	O
:	O
0.5	O
g	O
of	O
snow	O
lotus	O
herb	O
,	O
3	O
g	O
of	O
lily	O
magnolia	O
,	O
3	O
g	O
of	O
wild	O
chrysanthemum	O
,	O
3	O
g	O
of	O
fennel	O
,	O
3	O
g	O
of	O
cassia	O
bark	O
,	O
3	O
g	O
of	O
agilawood	O
,	O
3	O
g	O
of	O
rhizoma	O
atractylodis	O
,	O
3	O
g	O
of	O
mentha	O
haplocalyx	O
,	O
0.6	O
g	O
of	O
borneol	B
and	O
1	O
g	O
of	O
schizonepeta	O
.	O

The	O
perfume	O
satchel	O
is	O
prepared	O
by	O
the	O
steps	O
of	O
respectively	O
drying	O
and	O
crushing	O
the	O
components	O
,	O
screening	O
by	O
using	O
a	O
sieve	O
of	O
200	O
-	O
300	O
meshes	O
to	O
obtain	O
the	O
crushed	O
materials	O
,	O
uniformly	O
mixing	O
the	O
materials	O
,	O
subsequently	O
packaging	O
by	O
using	O
a	O
breathable	O
material	O
,	O
putting	O
into	O
a	O
satchel	O
,	O
and	O
storing	O
while	O
keeping	O
damp	O
,	O
preventing	O
freezing	O
and	O
sealing	O
.	O

Living	O
articles	O
can	O
be	O
further	O
carried	O
or	O
filled	O
into	O
the	O
satchel	O
to	O
help	O
people	O
to	O
resist	O
invasion	O
of	O
epidemic	O
diseases	O
,	O
influenza	O
and	O
rhinitis	O
diseases	O
caused	O
by	O
cold	O
can	O
be	O
rapidly	O
,	O
simply	O
and	O
conveniently	O
healed	O
,	O
a	O
pleasant	O
living	O
environment	O
can	O
be	O
constructed	O
,	O
and	O
the	O
living	O
quality	O
is	O
improved	O
.	O

The	O
medicines	O
are	O
harmony	O
in	O
odor	O
,	O
are	O
capable	O
of	O
calming	O
the	O
nerve	O
,	O
inducing	O
resuscitation	O
and	O
enlightening	O
the	O
brain	O
,	O
expelling	O
dampness	O
and	O
relieving	O
exterior	O
syndrome	O
,	O
and	O
bringing	O
fragrance	O
and	O
expelling	O
smell	O
,	O
and	O
are	O
beneficial	O
for	O
bodies	O
and	O
minds	O
.	O

The	O
satchel	O
is	O
simple	O
,	O
convenient	O
and	O
safe	O
to	O
use	O
,	O
stable	O
and	O
long	O
-	O
lasting	O
in	O
effect	O
,	O
convenient	O
to	O
carry	O
over	O
and	O
prepare	O
and	O
wide	O
in	O
applicability	O
.	O

Epidemic	O
disease	O
wind	O
expelling	O
,	O
preventing	O
and	O
treating	O
perfume	O
satchel	O

The	O
invention	O
relates	O
to	O
a	O
long	O
-	O
acting	O
cefquinome	O
sulfate	O
injection	O
.	O

The	O
injection	O
is	O
prepared	O
by	O
a	O
method	O
in	O
the	O
following	O
steps	O
:	O
adding	O
cefquinome	O
sulfate	O
into	O
an	O
ethanol	O
solution	O
containing	O
ethyecellulose	O
and	O
hydroxy	O
propyl	O
cellulose	O
;	O
filtering	O
,	O
sterilizing	O
and	O
performing	O
spray	O
-	O
drying	O
to	O
obtain	O
a	O
cefquinome	O
sulfate	O
carrier	O
;	O
adding	O
a	O
suspending	O
agent	O
,	O
a	O
dispersing	O
agent	O
and	O
a	O
stabilizing	O
agent	O
into	O
partial	O
injection	O
solvent	O
,	O
dissolving	O
at	O
100	O
DEG	O
C	O
,	O
and	O
adding	O
an	O
injection	O
solvent	O
to	O
the	O
whole	O
amount	O
,	O
and	O
performing	O
dry	O
heat	O
sterilization	O
at	O
150	O
DEG	O
C	O
for	O
1	O
hour	O
;	O
cooling	O
the	O
dispersion	O
liquid	O
to	O
room	O
temperature	O
,	O
adding	O
the	O
cefquinome	O
sulfate	O
carrier	O
into	O
the	O
dispersion	O
liquid	O
,	O
and	O
uniformly	O
stirring	O
;	O
passing	O
through	O
a	O
high	O
-	O
speed	O
cutting	O
dispersion	O
machine	O
to	O
prepare	O
the	O
long	O
-	O
acting	O
cefquinome	O
sulfate	O
injection	O
.	O

The	O
prepared	O
suspension	O
injection	O
is	O
uniform	O
in	O
granularity	O
,	O
good	O
in	O
fluidity	O
,	O
slow	O
in	O
settlement	O
,	O
good	O
in	O
redispersion	O
property	O
,	O
wall	O
adhesion	O
prevention	O
of	O
liquid	O
medicine	O
,	O
good	O
needle	O
cleaning	O
performance	O
,	O
no	O
discoloration	O
after	O
long	O
-	O
term	O
storage	O
and	O
stable	O
chemical	O
property	O
.	O

After	O
the	O
preparation	O
is	O
injected	O
in	O
a	O
pig	O
in	O
an	O
intramuscular	O
manner	O
,	O
the	O
preparation	O
is	O
slowly	O
released	O
,	O
long	O
in	O
elimination	O
half	O
life	O
and	O
smooth	O
in	O
plasma	O
concentration	O
,	O
can	O
be	O
used	O
for	O
prolonging	O
the	O
effective	O
action	O
duration	O
of	O
the	O
medicine	O
in	O
the	O
body	O
and	O
reducing	O
the	O
number	O
of	O
administration	O
times	O
,	O
and	O
is	O
convenient	O
to	O
use	O
.	O

Long	O
-	O
acting	O
cefquinome	O
sulfate	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
tetrahydropalmatine	B
intra	O
-	O
gastric	O
floating	O
oral	O
microsphere	O
.	O

The	O
microsphere	O
is	O
prepared	O
by	O
the	O
method	O
comprising	O
the	O
following	O
steps	O
:	O
uniformly	O
mixing	O
the	O
tetrahydropalmatine	B
and	O
pharmaceutically	O
acceptable	O
carrier	O
materials	O
,	O
dissolving	O
in	O
a	O
pharmaceutically	O
acceptable	O
organic	O
solvent	O
to	O
form	O
an	O
organic	O
phase	O
;	O
preparing	O
a	O
pharmaceutically	O
acceptable	O
hydrophilic	O
emulsifier	O
aqueous	O
solution	O
as	O
an	O
aqueous	O
solution	O
;	O
slowly	O
dripping	O
the	O
organic	O
phase	O
into	O
the	O
aqueous	O
phase	O
under	O
a	O
stirring	O
state	O
,	O
constantly	O
stirring	O
until	O
the	O
organic	O
solvent	O
is	O
volatized	O
,	O
standing	O
,	O
filtering	O
,	O
removing	O
the	O
filtrate	O
,	O
washing	O
the	O
filter	O
cake	O
with	O
distilled	O
water	O
,	O
and	O
drying	O
in	O
vacuum	O
to	O
obtain	O
the	O
tetrahydropalmatine	B
intra	O
-	O
gastric	O
floating	O
oral	O
microsphere	O
.	O

The	O
tetrahydropalmatine	B
intra	O
-	O
gastric	O
floating	O
oral	O
microsphere	O
is	O
simple	O
in	O
preparation	O
process	O
,	O
good	O
in	O
reproducibility	O
,	O
high	O
in	O
drug	O
-	O
loading	O
capacity	O
and	O
encapsulation	O
efficiency	O
,	O
good	O
in	O
intra	O
-	O
gastric	O
floating	O
and	O
sustained	O
-	O
releasing	O
performance	O
and	O
can	O
constantly	O
float	O
and	O
slowly	O
release	O
drugs	O
at	O
constant	O
speed	O
in	O
12	O
hours	O
,	O
and	O
the	O
drug	O
can	O
be	O
released	O
over	O
90	O
percent	O
in	O
accumulation	O
of	O
12	O
hours	O
,	O
so	O
that	O
the	O
drug	O
can	O
be	O
released	O
stably	O
,	O
slowly	O
and	O
directionally	O
.	O

Tetrahydropalmatine	B
intra	O
-	O
gastric	O
floating	O
oral	O
microsphere	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
gentamicin	B
sulphate	I
-	O
loading	O
porous	O
hydroxyapatite	B
/	O
PLGA	B
(	O
poly	B
(	I
DL	I
-	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	O
microspheres	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
adding	O
PLGA	B
microspheres	O
in	O
an	O
acetone	B
/	O
alcohol	B
solution	O
,	O
adding	O
a	O
diammonium	B
hydrogen	I
phosphate	I
solution	O
,	O
pouring	O
in	O
a	O
calcium	B
nitrate	I
solution	O
,	O
adjusting	O
pH	O
,	O
ageing	O
,	O
washing	O
,	O
drying	O
,	O
calcining	O
,	O
and	O
grinding	O
to	O
obtain	O
porous	O
hydroxyapatite	O
;	O
placing	O
the	O
porous	O
hydroxyapatite	B
powder	O
in	O
a	O
water	O
solution	O
containing	O
gentamicin	B
sulphate	I
/	O
PEG	B
(	O
polyethylene	B
glycol	I
)	O
,	O
and	O
carrying	O
out	O
freeze	O
drying	O
to	O
obtain	O
gentamicin	B
sulphate	I
-	O
loading	O
porous	O
hydroxyapatite	B
;	O
and	O
uniformly	O
mixing	O
the	O
PLGA	O
solution	O
and	O
the	O
gentamicin	B
sulphate	I
-	O
loading	O
porous	O
hydroxyapatite	B
,	O
pouring	O
in	O
a	O
polyvinyl	B
alcohol	I
solution	O
,	O
stirring	O
,	O
washing	O
,	O
and	O
carrying	O
out	O
freeze	O
drying	O
to	O
obtain	O
the	O
gentamicin	B
sulphate	I
-	O
loading	O
porous	O
hydroxyapatite	B
/	O
PLGA	B
(	O
poly	B
(	I
DL	I
-	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	O
microspheres	O
.	O

The	O
gentamicin	B
sulphate	I
-	O
loading	O
porous	O
hydroxyapatite	B
/	O
PLGA	B
(	O
poly	B
(	I
DL	I
-	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	O
microspheres	O
prepared	O
by	O
adopting	O
the	O
preparation	O
method	O
are	O
high	O
in	O
medicine	O
loading	O
rate	O
,	O
small	O
in	O
burst	O
release	O
,	O
good	O
in	O
biocompatibility	O
,	O
simple	O
in	O
preparation	O
process	O
,	O
easily	O
available	O
in	O
raw	O
materials	O
,	O
and	O
low	O
in	O
cost	O
;	O
and	O
industrialization	O
is	O
easily	O
realized	O
.	O

Preparation	O
method	O
of	O
gentamicin	B
sulphate	I
-	O
loading	O
porous	O
hydroxyapatite	B
/	O
PLGA	B
(	O
poly	B
(	I
DL	I
-	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	O
microspheres	O

The	O
invention	O
provides	O
a	O
composite	O
medicine	O
comprising	O
cefazolin	B
,	O
which	O
is	O
prepared	O
from	O
the	O
following	O
active	O
ingredients	O
:	O
cefazolin	B
,	O
vitamin	B
C	I
,	O
propylene	B
glycol	I
and	O
lidocaine	B
at	O
a	O
fraction	O
ratio	O
of	O
(	O
63	O
-	O
130	O
)	O
:	O
(	O
6	O
-	O
12	O
)	O
:	O
(	O
12	O
-	O
40	O
)	O
:	O
(	O
15	O
-	O
36	O
)	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
composite	O
medicine	O
.	O

The	O
composite	O
medicine	O
provided	O
by	O
the	O
invention	O
is	O
superior	O
to	O
the	O
prior	O
art	O
in	O
safety	O
,	O
stability	O
and	O
therapeutic	O
effect	O
,	O
and	O
the	O
preparation	O
method	O
is	O
energy	O
-	O
saving	O
and	O
environment	O
-	O
friendly	O
.	O

Composite	O
medicine	O
comprising	O
cefazolin	B

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
medicinal	O
composition	O
for	O
preventing	O
vascular	O
dementia	O
and	O
an	O
application	O
thereof	O
.	O

The	O
medicinal	O
composition	O
comprises	O
the	O
following	O
raw	O
materials	O
:	O
Lycium	O
barbarum	O
polysaccharide	O
component	O
II	O
,	O
Lycium	O
barbarum	O
polysaccharide	O
component	O
VI	O
,	O
Astragalus	O
polysaccharides	O
component	O
A2	O
,	O
ajugol	O
A	O
and	O
friedelin-3beta	B
-	I
ol	I
.	O

The	O
medicinal	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
a	O
remarkably	O
curative	O
effect	O
on	O
preventing	O
vascular	O
dementia	O
,	O
and	O
has	O
stable	O
quality	O
control	O
and	O
is	O
suitable	O
for	O
long	O
-	O
term	O
administration	O
of	O
patients	O
.	O

Medicinal	O
composition	O
for	O
preventing	O
vascular	O
dementia	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
medicament	O
of	O
dsRNA	O
and	O
saikosaponin	B
and	O
application	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
medicament	O
applied	O
to	O
prevention	O
and	O
treatment	O
of	O
viral	O
infection	O
of	O
cultured	O
animals	O
,	O
a	O
preparation	O
method	O
and	O
stability	O
control	O
method	O
of	O
the	O
medicament	O
.	O

The	O
medicament	O
comprises	O
the	O
following	O
ingredients	O
:	O
20	O
-	O
50	O
mug	O
/	O
ml	O
of	O
saikosaponin	B
,	O
bupleurum	O
oil	O
with	O
the	O
content	O
range	O
of	O
ultraviolet	O
absorption	O
value	O
of	O
above	O
0.45	O
;	O
and	O
1	O
-	O
3	O
mg	O
/	O
ml	O
of	O
polyinosinic	B
polycytidylic	I
acid	I
with	O
the	O
molecular	O
weight	O
range	O
of	O
200	O
-	O
500	O
bp	O
(	O
agarose	O
gel	O
electrophoresis	O
method	O
)	O
.	O

The	O
preparation	O
method	O
of	O
the	O
medicament	O
comprises	O
is	O
in	O
accordance	O
with	O
a	O
water	O
injection	O
production	O
technology	O
:	O
adding	O
proper	O
pharmaceutic	O
adjuvant	O
into	O
the	O
ingredients	O
,	O
preparing	O
liquid	O
,	O
filtering	O
,	O
filling	O
,	O
encapsulating	O
,	O
sterilizing	O
and	O
examining	O
for	O
qualification	O
.	O

The	O
medicament	O
can	O
induce	O
generation	O
of	O
endogenous	O
interferon	O
in	O
animal	O
bodies	O
,	O
thus	O
avoiding	O
virus	O
breeding	O
in	O
the	O
animal	O
bodies	O
.	O

Medicament	O
of	O
dsRNA	O
and	O
saikosaponin	B

The	O
invention	O
discloses	O
medicine	O
for	O
treating	O
simple	O
obesity	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
herbal	O
medicines	O
including	O
astragalus	O
,	O
rose	O
,	O
alisma	O
,	O
fetid	O
cassia	O
,	O
prunella	O
,	O
erythrinae	O
cortex	O
,	O
talcum	O
,	O
poria	O
,	O
pinellia	O
,	O
bamboo	O
shavings	O
and	O
the	O
like	O
according	O
to	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
for	O
treating	O
the	O
simple	O
obesity	O
has	O
functions	O
of	O
disinhibiting	O
water	O
,	O
dispersing	O
swelling	O
,	O
rectifying	O
qi	O
and	O
freeing	O
stool	O
,	O
has	O
a	O
good	O
curative	O
effect	O
on	O
treatment	O
of	O
the	O
simple	O
obesity	O
,	O
is	O
high	O
in	O
taking	O
effect	O
and	O
has	O
no	O
side	O
effects	O
.	O

Medicine	O
for	O
treating	O
simple	O
obesity	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pyridine	B
primary	I
amine	I
ruthenium	I
complex	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
pyridine	B
primary	I
amine	I
ruthenium	I
complex	O
is	O
excellent	O
in	O
anti	O
-	O
cancer	O
activity	O
in	O
anti	O
-	O
cancer	O
screening	O
in	O
vitro	O
and	O
especially	O
has	O
a	O
good	O
inhibition	O
effect	O
on	O
the	O
lung	O
cancer	O
and	O
the	O
human	O
breast	O
cancer	O
,	O
so	O
that	O
the	O
pyridine	B
primary	I
amine	I
ruthenium	I
complex	O
has	O
huge	O
development	O
potential	O
and	O
application	O
value	O
in	O
clinical	O
treatment	O
of	O
tumor	O
diseases	O
.	O

Pyridine	B
primary	I
amine	I
ruthenium	I
complex	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
pharmacochemistry	O
and	O
discloses	O
a	O
camellia	O
saponin	B
compound	O
,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
and	O
an	O
anti	O
-	O
tumour	O
drug	O
prepared	O
from	O
the	O
same	O
.	O

The	O
oil	O
-	O
tea	O
camellia	O
saponin	B
chemical	O
compound	O
adopts	O
the	O
structure	O
shown	O
in	O
the	O
formula	O
I	O
,	O
has	O
remarkable	O
effects	O
on	O
inhibiting	O
liver	O
cancer	O
cell	O
,	O
breast	O
cancer	O
cell	O
,	O
melanoma	O
cell	O
and	O
lung	O
cancer	O
cell	O
,	O
and	O
can	O
effectively	O
inhibit	O
the	O
growth	O
of	O
liver	O
tumour	O
,	O
so	O
that	O
the	O
oil	O
-	O
tea	O
camellia	O
saponin	O
chemical	O
compound	O
has	O
remarkable	O
tumour	O
resisting	O
activity	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
anti	O
-	O
tumour	O
drugs	O
.	O

(	O
The	O
formula	O
I	O
is	O
shown	O
in	O
the	O
specification	O
)	O
.	O

Camellia	O
saponin	B
compound	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
and	O
anti	O
-	O
tumour	O
drug	O
prepared	O
from	O
same	O

A	O
pharmaceutical	O
composition	O
containing	O
nicorandil	B
,	O
mannitol	B
,	O
and	O
the	O
alkali	B
metal	I
salt	O
of	O
an	O
organic	O
carboxylic	B
acid	I
,	O
wherein	O
(	O
1	O
)	O
""""	O
the	O
peak	O
value	O
of	O
the	O
delta	O
crystals	O
of	O
mannitol	B
at	O
9.8	O
DEG	O
+	O
-0.3	O
DEG	O
(	O
2	O
[	O
theta	O
]	O
)	O
in	O
X	O
-	O
ray	O
diffraction	O
""""	O
"/""the"	O
peak	O
value	O
of	O
nicorandil	B
crystals	O
at	O
10.6	O
DEG	O
+	O
-0.3	O
DEG	O
(	O
2	O
[	O
theta	O
]	O
)	O
in	O
X	O
-	O
ray	O
diffraction	O
""""	O
is	O
2.0	O
or	O
less	O
or	O
(	O
2	O
)	O
""""	O
the	O
peak	O
intensity	O
at	O
1.01	O
THz	O
+	O
-0.2	O
THz	O
of	O
the	O
secondary	O
derivative	O
spectrum	O
in	O
the	O
absorption	O
spectrum	O
of	O
the	O
delta	O
crystals	O
of	O
mannitol	B
measured	O
by	O
means	O
of	O
terahertz	O
transmission	O
"spectroscopy"""	O
/	O
""""	O
the	O
peak	O
intensity	O
at	O
0.95	O
THz	O
+	O
-0.2	O
THz	O
of	O
the	O
secondary	O
derivative	O
spectrum	O
in	O
the	O
absorption	O
spectrum	O
of	O
nicorandil	B
crystals	O
measured	O
by	O
means	O
of	O
terahertz	O
transmission	O
spectroscopy	O
""""	O
is	O
1.5	O
or	O
less	O
.	O

This	O
pharmaceutical	O
composition	O
exhibits	O
excellent	O
storage	O
stability	O
.	O

Nicorandil	B
-	O
containing	O
pharmaceutical	O
composition	O

Pharmaceutical	O
and/or	O
cosmetic	O
compositions	O
for	O
the	O
treatment	O
and	O
the	O
prevention	O
of	O
scalp	O
disorders	O
,	O
containing	O
as	O
active	O
components	O
extracts	O
of	O
Serenoa	O
repens	O
and	O
of	O
Vitis	O
vinifera	O
.	O

Oral	O
compositions	O
for	O
the	O
treatment	O
of	O
scalp	O
disorders	O

A	O
composite	O
medicine	O
of	O
ibuprofen	B
,	O
arginine	B
and	O
codeine	B
is	O
proportionally	O
prepared	O
from	O
ibuprofen	B
,	O
arginine	B
and	O
codeine	B
or	O
its	O
pharmacologically	O
acceptable	O
salt	O
.	O

It	O
has	O
high	O
water	O
solubility	O
and	O
less	O
stimulation	O
to	O
stomach	O
and	O
intestine	O
.	O

Compound	O
prepn	O
.	O

contg	O
.	O

Brufen	B
arginine	B
codeine	B

An	O
intravenous	O
injection	O
of	O
gastrodine	B
is	O
prepared	O
from	O
gastrodine	B
,	O
isotonic	O
regulator	O
,	O
cosolvent	O
,	O
antioxidizing	O
agent	O
,	O
stabilizer	O
,	O
metallic	O
ion	O
complexing	O
agent	O
and	O
water	O
for	O
injection	O
.	O

Gastrodin	O
venous	O
injection	O
liquid	O
,	O
and	O
its	O
prepn	O
.	O

method	O

A	O
powder	O
injection	O
of	O
sodium	B
neohouttuyfonate	I
for	O
treating	O
pelvic	O
inflammation	O
,	O
adnexitis	O
,	O
chronic	O
cervicitis	O
,	O
upper	O
respiratory	O
tract	O
infection	O
,	O
etc	O
contains	O
sodium	B
neohouttuyfonate	I
,	O
solubilizer	O
,	O
and	O
excipient	O
.	O

Novel	O
sodium	B
houttuyfonate	I
powder	O
injection	O

A	O
medicine	O
-	O
class	O
raw	O
VE	B
oil	O
is	O
prepared	O
through	O
proportional	O
acetate	B
reaction	O
of	O
d	B
-	I
alpha	I
-	I
VE	I
,	O
solvent	O
,	O
catalyst	O
and	O
dewatering	O
agent	O
,	O
cooling	O
,	O
washing	O
with	O
clean	O
water	O
,	O
laying	O
aside	O
,	O
distilling	O
to	O
remove	O
solvnet	O
and	O
obtain	O
d	B
-	I
alpha	I
-	I
VE	I
acetate	I
,	O
and	O
purifying	O
by	O
molecular	O
distilling	O
.	O

Process	O
for	O
producing	O
medicine	O
grade	O
natural	O
vitamin	B
E	I
raw	O
oil	O

An	O
injection	O
of	O
fluarizine	B
hydrochloride	I
as	O
a	O
Ca	O
channel	O
blocker	O
for	O
preventing	O
cell	O
injury	O
caused	O
by	O
ischemia	O
,	O
relaxing	O
vascular	O
spasm	O
,	O
suppressing	O
vestibule	O
,	O
preventing	O
and	O
treating	O
epilepsy	O
,	O
protecting	O
heart	O
and	O
kidney	O
,	O
etc	O
and	O
its	O
preparing	O
process	O
are	O
disclosed	O
.	O

Flunarizine	B
hydrochoride	I
injection	O
and	O
preparing	O
method	O

A	O
medicine	O
for	O
treating	O
otopathy	O
,	O
such	O
as	O
tympanitis	O
,	O
otitis	O
externa	O
,	O
otitis	O
,	O
etc	O
,	O
is	O
prepared	O
form	O
baked	O
alum	O
,	O
borneol	B
and	O
terramycin	B
.	O

Chinese	O
-	O
western	O
compound	O
preparation	O
for	O
treating	O
ear	O
diseases	O

The	O
invention	O
provides	O
a	O
base	O
sequence	O
of	O
new	O
neurotrophin	O
-	O
humanized	O
neurotrophin-6-	O
(	O
NT-6	O
)	O
and	O
proves	O
application	O
of	O
said	O
hummnized	O
NT-6	O
gene	O
.	O

the	O
humanized	O
NT-6	O
gene	O
described	O
by	O
said	O
invention	O
can	O
be	O
obtained	O
from	O
RNA	O
of	O
brain	O
tissue	O
of	O
abortus	O
by	O
adopting	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
method	O
.	O

the	O
experiments	O
show	O
that	O
the	O
prokaryotic	O
expression	O
product	O
of	O
coded	O
mature	O
peptide	O
fragment	O
in	O
the	O
above	O
-	O
mentioned	O
humanized	O
NT-6	O
cDNA	O
has	O
trophic	O
action	O
on	O
neuron	O
,	O
and	O
can	O
resist	O
the	O
neuronal	O
degeneration	O
due	O
to	O
axonal	O
injury	O
,	O
so	O
that	O
the	O
medicine	O
containing	O
the	O
above	O
-	O
mentioned	O
humanized	O
NT-6	O
gene	O
can	O
be	O
prepared	O
,	O
and	O
used	O
for	O
curing	O
the	O
diseaxes	O
of	O
traumatic	O
pathologic	O
changes	O
of	O
nervous	O
system	O
.	O

6	O
gene	O
of	O
neurenergen	O
sourced	O
from	O
human	O
,	O
and	O
application	O

The	O
invention	O
discloses	O
an	O
AIDS	O
drug	O
didanosine	B
granula	O
compostion	O
and	O
its	O
preparation	O
method	O
,	O
the	O
particle	O
composition	O
comprises	O
therapeutic	O
effective	O
dosage	O
of	O
inosine	B
,	O
acid	O
preparation	O
,	O
filler	O
and	O
binder	O
.	O

AIDS	O
drug	O
didanosine	B
granula	O
composition	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
a	O
tomatine	B
preparation	O
for	O
prevention	O
and	O
cure	O
of	O
tissue	O
and	O
organ	O
fibrosis	O
,	O
and	O
conserving	O
dosage	O
type	O
,	O
wherein	O
the	O
preparation	O
comprises	O
proportioning	O
the	O
tomatine	B
,	O
physiological	O
acceptable	O
oiliness	O
substance	O
and	O
alcohols	B
for	O
applying	O
to	O
pharmaceutical	O
product	O
,	O
health	O
product	O
and	O
foodstuff	O
.	O

Tomatine	B
preparation	O
for	O
prevention	O
and	O
cure	O
of	O
tissue	O
and	O
organ	O
fibrosis	O

The	O
present	O
invention	O
provides	O
locally	O
applied	O
medicine	O
preparation	O
with	O
honeysuckle	O
and	O
astragaloside	B
as	O
material	O
,	O
and	O
is	O
especially	O
eye	O
drop	O
and	O
eye	O
filming	O
preparation	O
for	O
treating	O
acute	O
catarrhal	O
conjunctivitis	O
and	O
herpes	O
simplex	O
viral	O
keratitis	O
.	O

The	O
present	O
invention	O
also	O
provides	O
the	O
preparation	O
process	O
and	O
optimal	O
material	O
ratio	O
of	O
the	O
eye	O
preparation	O
.	O

Pharmaceutical	O
test	O
shows	O
that	O
the	O
medicine	O
preparation	O
has	O
the	O
synergistic	O
effect	O
of	O
both	O
honeysuckle	O
and	O
astragaloside	B
,	O
obvious	O
treating	O
effect	O
,	O
no	O
irritation	O
,	O
no	O
toxicity	O
and	O
high	O
safety	O
.	O

Preparation	O
for	O
eyes	O
and	O
preparing	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
mulberry	O
leaf	O
effective	O
ingredient	O
extract	O
and	O
its	O
manufacturing	O
method	O
.	O

The	O
extract	O
is	O
deposited	O
out	O
from	O
the	O
water	O
extracting	O
liquid	O
of	O
the	O
mulberry	O
leaf	O
,	O
and	O
then	O
carries	O
on	O
alcohol	B
sediment	O
;	O
the	O
nojirimycin	B
in	O
it	O
is	O
1.0	O
-	O
3.0	O
%	O
,	O
gamma	B
-	I
aminobutyric	I
acid	I
0.8	O
-	O
1.5	O
%	O
.	O

The	O
purity	O
of	O
the	O
extract	O
can	O
be	O
upgraded	O
greatly	O
,	O
the	O
effective	O
ingredient	O
will	O
be	O
upgraded	O
prominently	O
,	O
and	O
it	O
can	O
be	O
applied	O
to	O
product	O
food	O
,	O
healthy	O
keeping	O
product	O
and	O
medicine	O
for	O
reducing	O
blood	O
sugar	B
,	O
controlling	O
blood	O
pressure	O
,	O
and	O
improving	O
the	O
intestinal	O
canal	O
.	O

Effective	O
-	O
component	O
extract	O
of	O
Foliun	O
-	O
Mori	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
discloses	O
a	O
new	O
type	O
of	O
large	O
ring	O
lactone	O
antibiotics	O
,	O
carat	B
teichomycin	I
amino	I
acid	I
salt	O
whose	O
chemical	O
formula	O
is	O
C38H69NO13R	B
,	O
and	O
its	O
preparation	O
method	O
and	O
application	O
.	O

The	O
R	O
is	O
amino	B
acid	I
and	O
,	O
to	O
be	O
specific	O
,	O
is	O
aspartic	B
acid	I
and	O
L	B
-	I
glutamic	I
acid	I
.	O

The	O
preparation	O
method	O
of	O
the	O
carat	B
teichomycin	I
amino	I
acid	I
salt	O
is	O
as	O
follows	O
:	O
mix	O
the	O
carat	B
teichomycin	I
with	O
the	O
amino	B
acid	I
in	O
solution	O
and	O
whisk	O
it	O
for	O
1hour	O
at	O
the	O
temperature	O
between	O
20deg	O
.	O

C	O
and	O
40deg	O
.	O

C	O
;	O
condense	O
the	O
solution	O
with	O
lower	O
pressure	O
at	O
room	O
temperature	O
,	O
freeze	O
and	O
dry	O
the	O
concentrated	O
solution	O
and	O
get	O
the	O
white	O
crystal	O
powder	O
,	O
carat	B
teichomycin	I
amino	I
acid	I
salt	O
.	O

The	O
invention	O
is	O
featured	O
by	O
simple	O
operation	O
,	O
high	O
purity	O
,	O
stable	O
quality	O
and	O
good	O
water	O
-	O
solubility	O
and	O
is	O
adaptable	O
to	O
pharmaceutical	O
preparation	O
.	O

The	O
carat	B
teichomycin	I
amino	I
acid	I
salt	O
can	O
be	O
the	O
pharmaceutical	O
product	O
and	O
can	O
be	O
made	O
into	O
the	O
injection	O
and	O
oral	O
preparation	O
.	O

Clarithromycin	B
amino	I
acid	I
salt	O
,	O
and	O
its	O
preparing	O
method	O
and	O
use	O

A	O
dripping	O
pill	O
of	O
phenylhydroxyformamine	B
hydrochloride	I
is	O
prepared	O
by	O
superfine	O
pulverizing	O
and	O
conventional	O
process	O
for	O
preparing	O
dripping	O
pills	O
.	O

Drops	O
of	O
benzohydroxymethylamine	B
and	O
their	O
preparation	O

A	O
slow	O
-	O
releasing	O
VC	B
in	O
the	O
form	O
of	O
micropills	O
is	O
composed	O
of	O
pill	O
and	O
coated	O
layer	O
.	O

Said	O
pill	O
is	O
prepared	O
from	O
core	O
,	O
VC	B
,	O
antioxidizing	O
agent	O
,	O
synergistic	O
,	O
adhesive	O
and	O
other	O
auxiliary	O
.	O

Said	O
coated	O
layer	O
is	O
prepared	O
from	O
slow	O
-	O
releasing	O
material	O
,	O
plasticizer	O
,	O
pore	O
forming	O
agent	O
and	O
defoaming	O
agent	O
.	O

Sustained	O
releasing	O
preparation	O
of	O
vilamin	B
C	I
and	O
its	O
preparing	O
method	O

The	O
azasaccharide	B
compounds	O
,	O
their	O
three	O
formulas	O
,	O
their	O
preparing	O
process	O
and	O
their	O
medical	O
application	O
are	O
disclosed	O
.	O

Said	O
compounds	O
have	O
high	O
immunosuppression	O
activity	O
and	O
glycosidase	O
(	O
galactosidase	O
or	O
alpha	O
-	O
glucosidase	O
A	O
)	O
suppressing	O
activity	O
.	O

New	O
type	O
azesaccharide	B
compound	O
,	O
their	O
synthesis	O
method	O
and	O
use	O
as	O
immune	O
inhibitor	O
and	O
glycocidase	O
inhibitor	O

A	O
method	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
cardiac	O
insulin	O
resistance	O
or	O
conditions	O
associated	O
with	O
cardiac	O
insulin	O
resistance	O
,	O
in	O
humans	O
or	O
non	O
-	O
human	O
mammals	O
,	O
which	O
method	O
comprises	O
the	O
administration	O
of	O
an	O
effective	O
,	O
non	O
-	O
toxic	O
and	O
pharmaceutically	O
acceptable	O
amount	O
of	O
PPARy	O
agonist	O
,	O
such	O
as	O
Compound	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
.	O

Conditions	O
associated	O
with	O
cardiac	O
insulin	O
resistance	O
are	O
:	O
microvascular	O
angina	O
,	O
atherosclerosis	O
and	O
congestive	O
heart	O
failure	O
.	O

Compounds	O
include	O
rosiglitazone	B
,	O
troglitazone	B
,	O
englitazone	B
and	O
pioglitazone	B
.	O

Treating	O
and	O
preventing	O
method	O
of	O
disease	O
relative	O
to	O
cardiac	O
insulin	O
resistance	O

The	O
invention	O
discloses	O
a	O
cool	O
plaster	O
and	O
its	O
processing	O
method	O
and	O
usage	O
,	O
wherein	O
the	O
preparation	O
comprises	O
,	O
(	O
1	O
)	O
grinding	O
mint	O
10	O
-	O
500	O
parts	O
,	O
borneol	B
10	O
-	O
1000	O
parts	O
,	O
charging	O
in	O
10	O
-	O
1100	O
parts	O
and/or	O
castor	O
oil	O
10	O
-	O
1200	O
parts	O
,	O
dissolving	O
,	O
charging	O
sodium	B
polyacrylate	I
10	O
-	O
800	O
parts	O
and	O
stirring	O
,	O
(	O
2	O
)	O
mixing	O
gelatin	O
10	O
-	O
1100	O
parts	O
and	O
sodium	O
carboxymethyl	O
cellulose	O
50	O
-	O
1000	O
parts	O
in	O
water	O
-	O
bath	O
,	O
(	O
3	O
)	O
mixing	O
the	O
components	O
obtained	O
in	O
step	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
applying	O
to	O
obtain	O
the	O
cool	O
plaster	O
.	O

Cool	O
plaster	O
and	O
its	O
processing	O
method	O
and	O
usage	O

The	O
invention	O
discloses	O
an	O
oral	O
health	O
liquor	O
of	O
ass	O
hide	O
glue	O
flavone	B
which	O
is	O
prepared	O
from	O
high	O
grade	O
donkey	O
-	O
hide	O
gelatin	O
,	O
soybean	O
isoflavones	B
,	O
vitamin	B
E	I
,	O
and	O
other	O
ingredients	O
through	O
the	O
steps	O
ofdissolving	O
into	O
water	O
,	O
mixing	O
homogeneously	O
,	O
loading	O
the	O
material	O
liquid	O
,	O
packing	O
and	O
sterilizing	O
.	O

Manufacture	O
method	O
of	O
nutrient	O
oral	O
liquor	O
of	O
ass	O
hide	O
glue	O
flavone	B

The	O
invention	O
relates	O
to	O
a	O
kind	O
of	O
3-aryl	B
group	O
-	O
beta	B
-	I
carboline-1-ketone	I
compound	O
and	O
its	O
manufacturing	O
method	O
and	O
usage	O
.	O

3-aryl	B
group	O
-	O
beta	B
-	I
carboline-1-ketone	I
compound	O
in	O
this	O
invention	O
is	O
the	O
compound	O
in	O
expression	O
IV	O
(	O
in	O
the	O
expression	O
,	O
R	O
is	O
H	B
or	O
CH3O	B
,	O
OCH2O	B
;	O
Ar	B
is	O
C6H5	B
OR	O
4-CH3OC6H4	B
,	O
4-ClC6H4	B
)	I
.	O

The	O
manufacturing	O
method	O
has	O
the	O
steps	O
as	O
follows	O
:	O
1	O
)	O
make	O
2-cyanogen	O
group-2-acetyl	O
amino	B
ethyl	I
acetate	I
and	O
Charles	O
ketone	B
have	O
Michael	O
additione	O
reaction	O
;	O
2	O
)	O
make	O
the	O
compound	O
generated	O
in	O
the	O
addition	O
reaction	O
have	O
nitrile	B
-	I
ketone	I
ring	O
-	O
form	O
reaction	O
in	O
acid	O
catalysis	O
condition	O
,	O
in	O
order	O
to	O
manufacture	O
pyridone	B
;	O
3	O
)	O
in	O
the	O
pyridone	B
compound	O
,	O
acyl	B
amino	I
has	O
intramolecular	O
aryl	B
amination	O
reaction	O
with	O
mental	O
catalysis	O
,	O
so	O
that	O
produce	O
nitric	O
five	O
-	O
membered	O
ring	O
,	O
and	O
get	O
3-aryl	B
group	O
-	O
beta	B
-	I
carboline-1-ketone	I
compound	O
.	O

The	O
3-aryl	B
group	O
-	O
beta	B
-	I
carboline-1-ketone	I
compound	O
in	O
this	O
invention	O
can	O
be	O
used	O
as	O
antitumor	O
lead	O
compound	O
in	O
order	O
to	O
have	O
extensive	O
utilization	O
in	O
antineoplastic	O
.	O

3-aryl	B
-	I
Beta	I
-	I
carboline-1-ketone	I
compound	O
,	O
and	O
its	O
preparing	O
method	O
and	O
use	O

A	O
powder	O
injection	O
of	O
levo	B
-	I
ofloxacin	I
lactate	O
is	O
prepared	O
from	O
the	O
aqueous	O
solution	O
of	O
levo	B
-	I
ofloxacin	I
lactate	O
through	O
decoloring	O
,	O
filtering	O
for	O
removing	O
bacteria	O
,	O
and	O
crystallizing	O
in	O
alcohol	B
or	O
acetone	B
.	O

Its	O
advantages	O
are	O
high	O
purity	O
and	O
stabiliuty	O
and	O
low	O
by	O
-	O
effect	O
.	O

Powder	O
injection	O
of	O
lactatelevo	B
-	I
ofloxacin	I
and	O
its	O
preparation	O

The	O
flunarizine	B
hydrochloride	I
injection	O
consists	O
of	O
flunarizine	B
hydrochloride	I
1	O
-	O
5	O
g	O
,	O
0.1	O
mol	O
/	O
L	O
sodium	B
hydroxide	I
solution	O
0	O
-	O
250	O
ml	O
and	O
water	O
for	O
injection	O
or	O
5	O
%	O
or	O
10	O
%	O
glucose	B
solution	O
50,000	O
ml	O
;	O
or	O
flunarizine	B
hydrochloride	I
1	O
-	O
5	O
g	O
,	O
and	O
0.1	O
mol	O
/	O
L	O
hydrochloric	B
acid	I
solution	O
0	O
-	O
600	O
ml	O
or	O
10	O
%	O
glucose	B
solution	O
1,000,000	O
ml	O
.	O

The	O
preparation	O
process	O
makes	O
flunarizine	B
hydrochloride	I
dissolved	O
fully	O
through	O
adding	O
flunarizine	B
hydrochloride	I
into	O
solution	O
at	O
low	O
temperature	O
to	O
disperse	O
flunarizine	B
hydrochloride	I
through	O
stirring	O
,	O
and	O
heating	O
to	O
relatively	O
high	O
temperature	O
to	O
dissolve	O
flunarizine	B
hydrochloride	I
fully	O
.	O

The	O
injection	O
contains	O
no	O
solabilizer	O
and	O
analgetic	O
,	O
thus	O
has	O
no	O
bad	O
irritation	O
to	O
blood	O
vessel	O
and	O
muscle	O
,	O
and	O
is	O
convenient	O
in	O
use	O
,	O
safe	O
and	O
obvious	O
in	O
curative	O
effect	O
.	O

Flunarizine	B
hydrochloride	I
injection	O
and	O
its	O
preparing	O
method	O

The	O
invention	O
relates	O
to	O
a	O
Tenatoprazole	B
pharmaceutical	O
composition	O
for	O
treating	O
hepatitis	O
and	O
process	O
for	O
preparation	O
comprising	O
Tenatoprazole	B
core	O
material	O
,	O
the	O
core	O
material	O
comprises	O
alkaline	O
compound	O
and	O
active	O
substance	O
of	O
Tenatoprazole	B
or	O
Tenatoprazole	B
alkaline	I
salt	I
,	O
the	O
core	O
material	O
can	O
be	O
coated	O
by	O
one	O
or	O
several	O
insulating	O
layers	O
,	O
the	O
insulating	O
layer	O
can	O
also	O
be	O
coated	O
by	O
intestine	O
-	O
dissolvable	O
layer	O
,	O
the	O
preparation	O
can	O
be	O
prepared	O
into	O
capsule	O
or	O
tablet	O
.	O

Pharmaceutical	O
preparation	O
of	O
Tenatoprazole	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
dispersive	O
tablet	O
of	O
montelukast	B
sodium	I
,	O
which	O
comprises	O
montelukast	B
sodium	I
as	O
main	O
constituent	O
as	O
well	O
as	O
disintegrating	O
agent	O
,	O
and	O
auxiliary	O
additive	O
,	O
the	O
disintegrating	O
agent	O
is	O
of	O
dispersion	O
tablet	O
type	O
commonly	O
used	O
,	O
the	O
auxiliary	O
agent	O
is	O
of	O
dispersion	O
tablet	O
type	O
commonly	O
used	O
,	O
the	O
advantages	O
of	O
the	O
preparation	O
include	O
easy	O
administering	O
for	O
the	O
elderly	O
and	O
children	O
,	O
stabilized	O
preparation	O
,	O
quick	O
absorption	O
,	O
high	O
biological	O
availability	O
,	O
and	O
less	O
adverse	O
effect	O
.	O

Dispersive	O
tablet	O
of	O
montelukast	B
sodium	I

The	O
invention	O
relates	O
to	O
a	O
compound	O
dried	O
suspension	O
of	O
dextromethorphan	B
and	O
gualfenesin	B
and	O
preparation	O
method	O
,	O
wherein	O
each	O
bag	O
of	O
suspension	O
comprises	O
dextromethorphan	B
2.5	O
-	O
32.5	O
mg	O
,	O
preferably	O
5	O
-	O
30	O
mg	O
,	O
guaifenesin	B
20	O
-	O
400	O
mg	O
,	O
preferably	O
50	O
-	O
300	O
mg	O
,	O
thickening	O
agent	O
and	O
suspending	O
agent	O
whose	O
total	O
amount	O
is	O
0.5	O
-	O
7	O
%	O
of	O
prescription	O
amount	O
,	O
preferably	O
1	O
-	O
5	O
%	O
,	O
0.5	O
-	O
2	O
%	O
,	O
preferably	O
1	O
-	O
1.5	O
%	O
of	O
stabilizing	O
agent	O
,	O
0.1	O
-	O
2	O
%	O
,	O
preferably	O
0.5	O
-	O
1.5	O
%	O
of	O
surface	O
-	O
active	O
agent	O
,	O
75	O
-	O
97	O
%	O
,	O
preferably	O
80	O
-	O
95	O
%	O
of	O
fragrant	O
taste	O
correction	O
agent	O
,	O
the	O
preparation	O
has	O
the	O
advantages	O
of	O
good	O
taste	O
,	O
high	O
medicament	O
dissolving	O
degree	O
,	O
and	O
fitting	O
for	O
children	O
.	O

Compound	O
dried	O
suspension	O
of	O
dextromethorphan	B
and	O
gualfenesin	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
ophthalmic	O
preparation	O
containing	O
roxithromycin	B
and	O
its	O
preparation	O
process	O
,	O
wherein	O
the	O
preparation	O
comprises	O
roxithromycin	B
or	O
its	O
salts	O
as	O
active	O
constituents	O
,	O
gel	O
base	O
material	O
and/or	O
other	O
pharmaceutically	O
acceptable	O
carrying	O
agent	O
,	O
whose	O
content	O
is	O
sufficient	O
to	O
adjust	O
the	O
viscosity	O
of	O
the	O
gelling	O
agent	O
.	O

The	O
invention	O
employs	O
suitable	O
methods	O
to	O
prepare	O
stabilized	O
preparation	O
.	O

Ophthalmic	O
preparation	O
containing	O
roxithromycin	B

The	O
invention	O
provides	O
a	O
citron	B
acid	I
azithromycin	B
frozen	O
-	O
dried	O
preparation	O
for	O
injection	O
and	O
preparation	O
method	O
,	O
wherein	O
the	O
preparation	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
,	O
azithromycin	B
1	O
weight	O
part	O
,	O
acidum	O
citricum	O
0.64	O
-	O
0.80	O
weight	O
part	O
,	O
sodium	B
hydroxide	I
0.32	O
weight	O
part	O
,	O
mannitol	B
0.57	O
-	O
0.87	O
weight	O
part	O
,	O
and	O
water	O
for	O
injection	O
14	O
-	O
18	O
weight	O
parts	O
.	O

Citron	B
acid	I
Azithromycin	B
frozen	O
-	O
dried	O
preparation	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
eEnteric	O
coated	O
orally	O
disintegrating	O
tablet	O
of	O
aspirin	B
wherein	O
the	O
orally	O
disintegrating	O
tablet	O
comprises	O
physiological	O
effective	O
dose	O
of	O
enteric	O
-	O
coated	O
aspirin	B
and	O
pharmaceutically	O
acceptable	O
carrying	O
agents	O
suitable	O
for	O
preparing	O
orally	O
disintegrating	O
tablet	O
,	O
which	O
comprises	O
macromolecular	O
material	O
,	O
bulking	O
agent	O
,	O
crumbling	O
agent	O
,	O
effervescent	O
agent	O
,	O
lubricating	O
agent	O
,	O
flavoring	O
agent	O
,	O
and	O
other	O
pharmaceutically	O
acceptable	O
carrying	O
agents	O
suitable	O
for	O
preparing	O
orally	O
disintegrating	O
tablet	O
.	O

Enteric	O
coated	O
orally	O
disintegrating	O
tablet	O
of	O
aspirin	B

A	O
composite	O
medicine	O
for	O
improving	O
the	O
metabolism	O
of	O
brain	O
tissue	O
and	O
increasing	O
the	O
anti	O
-	O
injury	O
power	O
of	O
brain	O
cells	O
and	O
nerve	O
tissue	O
,	O
or	O
for	O
the	O
first	O
aid	O
and	O
recovery	O
of	O
cerebral	O
injury	O
is	O
proportionally	O
prepared	O
from	O
cytidine	B
disodium	I
triphosphate	I
and	O
ebselen	B
.	O

Medication	O
of	O
combination	O
of	O
sodium	B
cytidine	I
triphosphate	I
and	O
ebselen	B

A	O
uric	B
acid	I
absorbent	O
is	O
prepared	O
through	O
dissolving	O
cellulose	O
in	O
NaOH	B
solution	O
,	O
adding	O
cross	O
-	O
linking	O
agent	O
,	O
polymerizing	O
reaction	O
,	O
proportionally	O
adding	O
cyclodextrin	O
,	O
reaction	O
,	O
drying	O
,	O
and	O
pulverizing	O
.	O

It	O
has	O
high	O
adsorptive	O
speed	O
and	O
power	O
to	O
uric	B
acid	I
.	O

Method	O
for	O
preparing	O
agent	O
of	O
cyclodextrin	O
-	O
cellulose	O
for	O
adsorbing	O
uric	B
acid	I

Disclosed	O
is	O
a	O
novel	O
tribiofosfor	O
oral	O
administration	O
preparation	O
which	O
is	O
prepared	O
into	O
the	O
form	O
of	O
enteric	O
-	O
coated	O
capsule	O
,	O
the	O
preparation	O
can	O
protect	O
enzymatic	O
activity	O
and	O
improve	O
enzyme	O
absorption	O
simultaneously	O
.	O

The	O
preparation	O
can	O
be	O
used	O
for	O
treating	O
progressive	O
muscular	O
atrophy	O
,	O
cerebral	O
hemorrhage	O
sequelae	O
,	O
cardiac	O
functional	O
insufficiency	O
,	O
hepatitis	O
and	O
nourishment	O
replenishing	O
for	O
aged	O
or	O
weak	O
people	O
.	O

Oral	O
formulation	O
of	O
adetphos	B

An	O
application	O
of	O
substituted	O
nitrobenzene	B
derivatives	O
in	O
preparing	O
the	O
medical	O
and	O
functional	O
health	O
-	O
care	O
food	O
for	O
preventing	O
and	O
treating	O
diseases	O
is	O
disclosed	O
.	O

Use	O
of	O
substituting	O
nitrobenzene	B
derivative	O
in	O
products	O
preparation	O

An	O
extract	O
of	O
red	O
sage	O
root	O
and	O
its	O
sodium	B
salt	O
for	O
preventing	O
and	O
treating	O
the	O
nerve	O
retrograde	O
diseases	O
,	O
especially	O
the	O
senile	O
dementia	O
are	O
disclosed	O
.	O

Its	O
molecular	O
formula	O
is	O
C5H10O5	B
.	O

It	O
can	O
increase	O
the	O
blood	O
flow	O
in	O
arteria	O
coronaria	O
,	O
suppress	O
the	O
thrombocyte	O
coagulation	O
,	O
stabilize	O
the	O
membrane	O
of	O
red	O
cell	O
,	O
and	O
sedate	O
central	O
nerve	O
.	O

Danshensu	B
and	O
its	O
sodium	B
salt	O
for	O
preventing	O
from	O
and	O
treating	O
various	O
regressive	O
nervous	O
diseases	O

An	O
application	O
of	O
FK506	O
nanoparticles	O
as	O
immunodepressant	O
prepared	O
from	O
FK506	O
and	O
biodegradable	O
material	O
in	O
prepare	O
the	O
medicine	O
for	O
treating	O
the	O
immune	O
associated	O
diseases	O
caused	O
by	O
corneal	O
transplantation	O
is	O
disclosed	O
.	O

Said	O
medicine	O
is	O
prepared	O
from	O
said	O
FK506	O
nanoparticles	O
and	O
pharmacological	O
acceptable	O
excipient	O
or	O
additive	O
.	O

Use	O
of	O
FK506	O
nano	O
powder	O
in	O
preparation	O
of	O
medicine	O
for	O
immuno	O
-	O
concerned	O
diseases	O
caused	O
by	O
corneal	O
transplantation	O

An	O
injection	O
for	O
treating	O
primary	O
facial	O
spasm	O
is	O
proportionally	O
prepared	O
from	O
lidocaine	B
,	O
anisodamine	B
and	O
diazepam	B
.	O

Its	O
advantages	O
are	O
high	O
curative	O
effect	O
and	O
low	O
by	O
-	O
effect	O
.	O

Medicinal	O
injection	O
for	O
treating	O
primary	O
mimic	O
tic	O

A	O
stable	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
of	O
vinorelbine	B
for	O
intravenous	O
injection	O
is	O
prepared	O
from	O
vinorelbine	B
,	O
the	O
oil	O
for	O
injection	O
,	O
emulsifier	O
,	O
and	O
the	O
water	O
for	O
injection	O
.	O

Its	O
advantages	O
are	O
high	O
tageting	O
function	O
,	O
low	O
poison	O
,	O
and	O
high	O
safety	O
.	O

Stabilized	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
of	O
vinca	O
alkaloids	B
for	O
vein	O
and	O
production	O
thereof	O

A	O
health	O
-	O
care	O
product	O
in	O
the	O
form	O
of	O
softgel	O
for	O
supplementing	O
omega-3	B
fatty	I
acid	I
,	O
lecithin	B
and	O
VE	B
to	O
human	O
body	O
,	O
regulating	O
blood	O
fat	O
,	O
relaxing	O
fatty	O
liver	O
,	O
delaying	O
senility	O
,	O
preventing	O
sanile	O
dementia	O
,	O
etc	O
features	O
that	O
it	O
contains	O
proportionally	O
alpha	B
-	I
linolenic	I
acid	I
,	O
lecithin	B
and	O
VE	B
.	O

Composite	O
preparation	O
containing	O
alpha	B
-	I
linolenic	I
acid	I
free	O
acid	O
,	O
soybean	O
phospholipid	O
and	O
vitamin	B
E	I

An	O
anticancer	O
composite	O
medicine	O
is	O
proportionally	O
prepared	O
from	O
sendoxan	B
,	O
kuraminol	B
or	O
its	O
derivative	O
and	O
additive	O
.	O

Its	O
advantages	O
are	O
low	O
poison	O
to	O
white	O
cells	O
,	O
low	O
dosage	O
and	O
high	O
curative	O
effect	O
.	O

Anticarcinogenic	O
compound	O
medicinal	O
preparation	O

Production	O
of	O
active	O
saponin	B
and	O
its	O
use	O
are	O
disclosed	O
.	O

R	O
is	O
H	B
,	O
Me	B
SO3-	I
or	O
other	O
saccharic	O
unit	O
in	O
general	O
formula	O
,	O
R1	O
can	O
be	O
H	B
,	O
CH3	B
,	O
CH2OH	B
,	O
CH2OSO3-	B
,	O
COOH	B
or	O
other	O
saccharic	O
unit	O
,	O
R2	O
and	O
R3	O
can	O
be	O
H	B
,	O
OH	B
,	O
OSO3-	B
or	O
other	O
saccharic	O
unit	O
.	O

It	O
can	O
be	O
used	O
for	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
cancer	O
and	O
composition	O
.	O

Preparation	O
and	O
use	O
for	O
active	O
saponin	B

The	O
present	O
invention	O
relates	O
to	O
a	O
kind	O
of	O
anti	O
-	O
anoxia	O
medicinal	O
composition	O
and	O
features	O
that	O
the	O
anti	O
-	O
anoxia	O
medicinal	O
composition	O
consists	O
of	O
taurine	B
0	O
-	O
5	O
weight	O
portions	O
,	O
vitamin	B
C	I
0	O
-	O
6	O
weight	O
portions	O
and	O
arginine	B
0	O
-	O
5	O
weight	O
portions	O
.	O

Said	O
components	O
are	O
prepared	O
into	O
pharmaceutically	O
acceptable	O
orally	O
taken	O
preparation	O
and	O
health	O
food	O
via	O
conventional	O
technological	O
process	O
.	O

The	O
anti	O
-	O
anoxia	O
medicinal	O
composition	O
has	O
the	O
effects	O
of	O
resisting	O
anoxia	O
damage	O
,	O
inhibiting	O
lipoid	O
overoxidation	O
,	O
increasing	O
NO	B
yield	O
,	O
and	O
reducing	O
the	O
influence	O
of	O
anoxia	O
pulmonary	O
hypertension	O
and	O
right	O
ventricle	O
hypertrophy	O
.	O

In	O
addition	O
,	O
it	O
can	O
promote	O
the	O
adaptation	O
to	O
oxygen	B
lack	O
,	O
and	O
is	O
a	O
ideal	O
medicine	O
for	O
preventing	O
high	O
mountain	O
anoxia	O
and	O
preventing	O
and	O
treating	O
pulmonary	O
hypertension	O
.	O

Anti	O
-	O
anoxia	O
medicinal	O
composition	O

The	O
;	O
present	O
invention	O
discloses	O
S	B
-	I
omeprazole	I
zinc	I
and	O
its	O
preparation	O
process	O
and	O
application	O
in	O
preparing	O
medicine	O
for	O
treating	O
gastric	O
acid	O
relevant	O
diseases	O
.	O

The	O
S	B
-	I
omeprazole	I
zinc	I
of	O
the	O
present	O
invention	O
is	O
used	O
in	O
treating	O
gastric	O
acid	O
relevant	O
diseases	O
and	O
has	O
the	O
advantages	O
of	O
fast	O
curative	O
effect	O
and	O
less	O
side	O
effect	O
.	O

The	O
preparation	O
process	O
is	O
simple	O
,	O
easy	O
to	O
operate	O
and	O
suitable	O
for	O
industrial	O
production	O
.	O

S	B
-	I
omeprazole	I
zinc	I
salt	O
and	O
its	O
preparing	O
method	O
and	O
use	O

Production	O
of	O
paclitaxel	B
and	O
muramic	O
acid	O
dipeptide	O
conjugale	O
as	O
immunopotentiator	O
and	O
its	O
use	O
are	O
disclosed	O
.	O

The	O
process	O
is	O
carried	O
out	O
by	O
combination	O
of	O
solid	O
-	O
phase	O
chemistry	O
and	O
liquid	O
-	O
phase	O
chemistry	O
.	O

It	O
improves	O
water	O
solubility	O
of	O
paclitaxel	B
.	O

Production	O
and	O
use	O
for	O
taxol	B
and	O
muramic	O
acyl	B
dipeptide	O
conjugate	O
substance	O
of	O
immune	O
reinforcer	O

The	O
invention	O
relates	O
to	O
a	O
transdermal	O
plaster	O
containing	O
beta	B
-	I
asaricin	I
,	O
which	O
comprises	O
a	O
medicament	O
storage	O
layer	O
,	O
a	O
back	O
lining	O
layer	O
,	O
an	O
adhesive	O
layer	O
and	O
a	O
protection	O
layer	O
,	O
wherein	O
the	O
medicament	O
storage	O
layer	O
comprises	O
0.1	O
-	O
40	O
wt%	O
of	O
beta	B
-	I
asaricin	I
and	O
pharmaceutically	O
acceptable	O
matrix	O
material	O
.	O

The	O
transdermal	O
plaster	O
has	O
antiepileptic	O
action	O
and	O
the	O
advantages	O
of	O
appreciable	O
curative	O
effect	O
,	O
stabilized	O
quality	O
,	O
higher	O
safety	O
,	O
ease	O
in	O
application	O
,	O
and	O
less	O
side	O
effects	O
.	O

Beta	B
-	I
Asarone	I
transdermal	O
plaster	O

An	O
application	O
of	O
white	O
fleece	O
flower	O
's	O
general	O
hypnone	B
and	O
hypnone	B
compound	O
in	O
preparing	O
the	O
medicine	O
for	O
treating	O
gastrointestinal	O
diseases	O
including	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
etc	O
is	O
disclosed	O
.	O

The	O
9	B
hypnone	I
and	O
their	O
compound	O
are	O
extracted	O
from	O
white	O
fleece	O
flower	O
root	O
.	O

Application	O
of	O
total	O
hypone	O
of	O
radix	O
cynanchi	O
bungei	O
and	O
hypnone	B
for	O
preparing	O
medicine	O
for	O
treating	O
gastrointestinal	O
tract	O
diseases	O

An	O
orally	O
disintegrating	O
tablet	O
of	O
cefixime	B
features	O
that	O
its	O
excipient	O
includes	O
bitter	O
-	O
shielding	O
agent	O
chosen	O
from	O
hexadecanol	B
,	O
stearic	B
acid	I
and	O
semi	O
-	O
synthetic	O
ester	O
of	O
fatty	B
acid	I
,	O
diluent	O
chosen	O
from	O
mannitol	B
,	O
cane	O
sugar	B
and	O
lactose	B
,	O
flavouring	O
,	O
disintegrant	O
,	O
wetting	O
agent	O
and	O
lubricant	O
.	O

Its	O
advantage	O
is	O
short	O
disintegrating	O
time	O
(	O
tens	O
seconds	O
)	O
.	O

Oral	O
disintegration	O
tablet	O
of	O
cefixime	B

A	O
temozolomide-8-carboxylate	B
with	O
the	O
activity	O
of	O
suppressing	O
cancer	O
cells	O
and	O
cancer	O
mass	O
,	O
its	O
application	O
in	O
preparing	O
anticancer	O
medicines	O
,	O
its	O
composition	O
and	O
its	O
preparing	O
process	O
are	O
disclosed	O
.	O

Temozolomide	B
8-carboxylic	I
ester	I
,	O
and	O
combination	O

The	O
invention	O
discloses	O
a	O
soft	O
capsule	O
composition	O
of	O
Fibrauretin	B
,	O
which	O
comprises	O
soft	O
capsule	O
shells	O
and	O
medicinal	O
composition	O
coated	O
therein	O
,	O
the	O
medicinal	O
composition	O
mainly	O
comprises	O
Fibrauretin	B
,	O
plant	O
oil	O
and	O
/	O
or	O
polyethylene	B
glycol	I
,	O
suspension	O
auxiliary	O
agent	O
.	O

Soft	O
capsule	O
of	O
fibrauretine	B
composition	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
for	O
treating	O
various	O
diseases	O
,	O
especially	O
a	O
dripping	O
pill	O
of	O
diosgenin	B
and	O
its	O
preparation	O
process	O
,	O
wherein	O
the	O
pill	O
is	O
prepared	O
from	O
polyethylene	B
glycol	I
,	O
polyoxyl	B
(	O
40	O
)	O
stearate	B
as	O
the	O
base	O
material	O
,	O
and	O
diosgenin	B
as	O
the	O
raw	O
material	O
.	O

Dripping	O
pills	O
of	O
diosgenin	B
and	O
its	O
preparation	O
process	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composition	O
for	O
treating	O
rheumatoid	O
arthritis	O
,	O
kidney	O
disease	O
and	O
autoimmune	O
hepatitis	O
,	O
especially	O
a	O
dripping	O
pill	O
of	O
tripterigium	O
wilfordi	O
glycosides	O
and	O
its	O
preparation	O
process	O
,	O
wherein	O
the	O
composition	O
is	O
prepared	O
from	O
tripterigium	O
wilfordi	O
glycosides	O
as	O
raw	O
material	O
,	O
and	O
medicinal	O
carrying	O
agent	O
as	O
the	O
base	O
material	O
.	O

Dripping	O
pills	O
of	O
tripterigium	O
wilfordi	O
glycosides	O
and	O
its	O
preparation	O
process	O

The	O
invention	O
relates	O
to	O
chemical	O
synthesis	O
for	O
salicylic	O
betaine	O
salt	O
.	O

The	O
product	O
can	O
match	O
with	O
other	O
drugs	O
to	O
external	O
use	O
or	O
take	O
orally	O
as	O
aqua	O
,	O
soft	O
plaster	O
,	O
capsule	O
or	O
injection	O
,	O
which	O
has	O
wide	O
application	O
in	O
reducing	O
fever	O
,	O
easing	O
pain	O
,	O
anti	O
platelet	O
aggregation	O
,	O
anti	O
senile	O
cataract	O
,	O
protecting	O
normal	O
cell	O
,	O
anti	O
atherosclerosis	O
and	O
other	O
functions	O
.	O

Synthesis	O
and	O
biological	O
and	O
pharmacological	O
action	O
of	O
betaine	O
salicylate	O

Compounds	O
having	O
formula	O
I	O
are	O
provided	O
where	O
the	O
variables	O
have	O
the	O
values	O
described	O
herein	O
.	O

(	O
I	O
)	O
.	O

Pharmaceutical	O
formulations	O
include	O
the	O
compounds	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
apharmaceutically	O
acceptable	O
carrier	O
and	O
combinations	O
with	O
other	O
agents	O
.	O

A	O
method	O
of	O
treating	O
a	O
patient	O
comprises	O
administering	O
a	O
pharmaceutical	O
formulation	O
according	O
to	O
the	O
invention	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

2,4,6-trisubstituted	B
pyrimidines	I
as	O
phosphotidylinositol	B
(	O
PI	O
)	O
3-kinase	O
inhibitors	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O

The	O
dietotherapeutic	O
nutrient	O
for	O
preventing	O
and	O
treating	O
non	O
-	O
insulin	O
dependent	O
diabetes	O
consists	O
of	O
purine	B
nucleotide	O
,	O
compound	O
vitamin	O
,	O
compound	O
trace	O
elements	O
,	O
compound	O
mineral	O
matter	O
,	O
essential	O
fatty	O
acid	O
oil	O
and	O
proper	O
amount	O
of	O
edible	O
cellulose	O
as	O
stuffing	O
and	O
hypoglycemic	O
.	O

The	O
dietotherapeutic	O
nutrient	O
is	O
used	O
as	O
main	O
material	O
or	O
additive	O
for	O
food	O
products	O
and	O
medicines	O
for	O
preventing	O
and	O
treating	O
diabetes	O
through	O
balancing	O
insulin	O
and	O
hyperglycemic	O
hormone	O
,	O
repairing	O
the	O
functions	O
of	O
pancreatic	O
island	O
and	O
kidney	O
,	O
preventing	O
and	O
treating	O
complication	O
and	O
restoring	O
normal	O
synthesis	O
and	O
metabolism	O
.	O

The	O
present	O
invention	O
has	O
c	O
-	O
GMP	O
,	O
trace	O
elements	O
,	O
etc	O
.	O
to	O
regulate	O
second	O
messenger	O
c	O
-	O
AMP	O
amount	O
,	O
lift	O
,	O
activity	O
and	O
release	O
time	O
of	O
hyperglycemic	O
hormone	O
,	O
calcium	B
carbonate	I
to	O
buffer	O
and	O
neutralize	O
flavone	B
and	O
other	O
acid	O
matter	O
and	O
acid	O
poisoning	O
,	O
potassium	B
citrate	I
to	O
replenish	O
potassium	B
and	O
to	O
maintain	O
acid	O
-	O
alkali	O
and	O
electrolyte	O
balance	O
.	O

The	O
dietotherapeutic	O
nutrient	O
has	O
no	O
toxic	O
side	O
effect	O
and	O
dependence	O
.	O

Dietotherapeutic	O
nutrient	O
for	O
preventing	O
and	O
treating	O
non	O
-	O
insulin	O
dependent	O
diabetes	O
and	O
its	O
prepn	O
process	O

The	O
dietotherapeutic	O
nutrient	O
for	O
preventing	O
and	O
treating	O
primary	O
gout	O
consists	O
of	O
alkaline	O
potassium	B
-	I
sodium	I
matter	O
,	O
nucleotide	O
,	O
vitamin	O
and	O
trace	O
elements	O
.	O

The	O
dietotherapeutic	O
nutrient	O
operates	O
on	O
that	O
the	O
alkaline	O
potassium	B
-	I
sodium	I
matter	O
makes	O
alcoholic	O
urate	B
formed	O
in	O
body	O
to	O
create	O
salt	O
capable	O
of	O
dissolving	O
in	O
water	O
and	O
being	O
removed	O
in	O
alkaline	O
condition	O
,	O
the	O
nucleotide	O
avoids	O
purine	O
to	O
synthesize	O
urate	B
,	O
and	O
the	O
vitamin	O
and	O
the	O
trace	O
elements	O
reinforce	O
the	O
activity	O
of	O
enzyme	O
,	O
protect	O
the	O
functions	O
of	O
cell	O
and	O
organ	O
,	O
recover	O
nucleotide	O
and	O
make	O
purine	B
to	O
synthesize	O
nucleic	O
acid	O
to	O
reduce	O
purine	B
and	O
urate	B
and	O
avoid	O
gout	O
.	O

The	O
dietotherapeutic	O
nutrient	O
has	O
obvious	O
curative	O
effect	O
,	O
no	O
toxic	O
side	O
effect	O
,	O
simple	O
preparation	O
process	O
,	O
and	O
low	O
cost	O
.	O

Dietotherapeutic	O
nutrient	O
for	O
preventing	O
and	O
treating	O
primary	O
gout	O
and	O
its	O
prepn	O
process	O

The	O
dietotherapeutic	O
nutrient	O
for	O
preventing	O
and	O
treating	O
gout	O
consists	O
of	O
alkaline	O
potassium	B
-	I
sodium	I
matter	O
,	O
nucleotide	B
,	O
vitamin	O
and	O
trace	O
elements	O
.	O

The	O
dietotherapeutic	O
nutrient	O
operates	O
on	O
that	O
the	O
alkaline	O
potassium	B
-	I
sodium	I
matter	O
makes	O
alcoholic	O
urate	B
formed	O
in	O
body	O
to	O
create	O
salt	O
capable	O
of	O
dissolving	O
in	O
water	O
and	O
being	O
removed	O
in	O
alkaline	O
condition	O
,	O
the	O
nucleotide	B
avoids	O
purine	B
to	O
synthesize	O
urate	B
,	O
and	O
the	O
vitamin	B
and	O
the	O
trace	O
elements	O
reinforce	O
the	O
activity	O
of	O
enzyme	O
,	O
protect	O
the	O
functions	O
of	O
cell	O
and	O
organ	O
,	O
recover	O
nucleotide	B
and	O
make	O
purine	B
to	O
synthesize	O
nucleic	O
acid	O
to	O
reduce	O
purine	B
and	O
urate	B
and	O
avoid	O
gout	O
.	O

The	O
dietotherapeutic	O
nutrient	O
has	O
obvious	O
curative	O
effect	O
,	O
no	O
toxic	O
side	O
effect	O
,	O
simple	O
preparation	O
process	O
,	O
and	O
low	O
cost	O
.	O

Dietotherapeutic	O
nutrient	O
for	O
preventing	O
and	O
treating	O
gout	O
and	O
its	O
prepn	O
process	O

The	O
present	O
invention	O
discloses	O
a	O
kind	O
of	O
cereshi	O
dripping	O
pills	O
.	O

It	O
is	O
formed	O
from	O
cereshi	O
raw	O
material	O
and	O
dripping	O
pills	O
matrix	O
.	O

Said	O
invention	O
can	O
be	O
used	O
for	O
curing	O
male	O
erectile	O
disorder	O
.	O

Cialis	O
drop	O
pilles	O
and	O
preparing	O
method	O
therefor	O

The	O
present	O
invention	O
relates	O
to	O
a	O
medicine	O
for	O
curing	O
diseases	O
of	O
respiratory	O
tract	O
,	O
specially	O
for	O
curing	O
asthma	O
.	O

In	O
particular	O
,	O
it	O
relates	O
to	O
a	O
glucocorticoid	B
hormone	O
capsule	O
type	O
inhalation	O
powder	O
aerosol	O
preparation	O
and	O
its	O
preparation	O
method	O
.	O

It	O
is	O
made	O
up	O
by	O
mixing	O
glucocorticoid	B
hormone	O
and	O
carrier	O
,	O
the	O
described	O
carrier	O
is	O
lactose	B
,	O
glycine	B
and	O
mannitol	B
or	O
their	O
mixture	O
,	O
and	O
the	O
average	O
grain	O
size	O
of	O
powder	O
is	O
0.1	O
-	O
10	O
micrometers	O
.	O

Glucocorticoid	B
capsule	O
type	O
inhaling	O
atomized	O
powder	O
and	O
preparation	O
method	O

An	O
inclusion	O
compound	O
of	O
sodium	O
allenphosphonate	O
in	O
the	O
form	O
of	O
oral	O
liquid	O
,	O
dispersing	O
tablet	O
,	O
effervescent	O
tablet	O
,	O
buccal	O
lozenge	O
,	O
oral	O
disintegrating	O
tablet	O
,	O
enteric	O
tablet	O
,	O
capsule	O
,	O
or	O
particles	O
is	O
prepared	O
from	O
sodium	O
allenphosphonate	O
and	O
cyclodextrin	O
.	O

Its	O
advantages	O
are	O
high	O
water	O
solubility	O
and	O
high	O
biologic	O
utilization	O
rate	O
.	O

Airphosphosodium	O
clathrate	O
compound	O
and	O
its	O
preparation	O

An	O
Aibomycine	B
analog	O
,	O
its	O
preparing	O
process	O
,	O
its	O
composite	O
medicines	O
,	O
and	O
its	O
application	O
for	O
treating	O
cancers	O
and	O
hyperplastic	O
diseases	O
and	O
inducing	O
apoptosis	O
are	O
disclosed	O
.	O

Aibomycin	B
analogue	O
,	O
its	O
preparation	O
method	O
,	O
medicinal	O
composition	O
and	O
use	O

An	O
entenic	O
clamycin	B
and	O
its	O
preparing	O
process	O
are	O
disclosed	O
.	O

Said	O
enteric	O
clamycin	B
contains	O
one	O
or	O
more	O
units	O
and	O
each	O
unit	O
is	O
composed	O
of	O
a	O
core	O
prepared	O
from	O
clamycin	B
and	O
one	O
or	O
more	O
medicinal	O
excipients	O
and	O
an	O
enteric	O
polymer	O
film	O
coated	O
on	O
the	O
surface	O
of	O
said	O
core	O
.	O

Enteric	O
coated	O
preparation	O
of	O
Clarithromycin	B

The	O
invention	O
discloses	O
a	O
vertical	O
transmitted	O
antidysenteric	O
medicament	O
,	O
wherein	O
the	O
medicament	O
comprises	O
the	O
following	O
raw	O
materials	O
(	O
by	O
weight	O
proportion	O
)	O
:	O
sulfadimidine	B
3	O
-	O
8	O
parts	O
,	O
trimethoprim	B
1	O
-	O
5	O
parts	O
,	O
the	O
medicament	O
can	O
be	O
transferred	O
through	O
mother	O
's	O
milk	O
.	O

Vertical	O
transmitted	O
antidysenteric	O

The	O
invention	O
discloses	O
a	O
polyene	B
phosphatidyl	I
choline	I
freeze	O
dried	O
injection	O
for	O
the	O
treatment	O
of	O
hepatic	O
diseases	O
,	O
which	O
comprises	O
polyene	B
phosphatidyl	I
choline	I
as	O
the	O
main	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
carrying	O
agents	O
,	O
wherein	O
the	O
carrying	O
agent	O
can	O
be	O
auxiliary	O
solvent	O
selected	O
from	O
sodium	B
cholate	I
,	O
sodium	B
deoxycholate	I
,	O
sodium	B
deoxycholate	I
,	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
,	O
hydroxyethyl	O
-	O
beta	O
-	O
cyclodextrin	O
and/or	O
methyl	O
cyclodextrin	O
.	O

The	O
injection	O
has	O
higher	O
stability	O
.	O

Polyene	B
phosphatidyl	I
choline	I
lyophilized	O
powdered	O
injection	O

The	O
invention	O
relates	O
to	O
a	O
Gynostemma	O
pentaphylla	O
saponin	B
drop	O
pill	O
preparation	O
for	O
enlivening	O
the	O
spleen	O
,	O
eliminating	O
phlegm	O
and	O
lowering	O
blood	O
fat	O
,	O
and	O
its	O
preparing	O
process	O
.	O

The	O
drop	O
pill	O
is	O
prepared	O
from	O
Ursodeoxycholic	B
acid	I
as	O
the	O
main	O
constituent	O
,	O
and	O
right	O
amount	O
of	O
base	O
by	O
a	O
predetermined	O
proportion	O
through	O
combined	O
processes	O
.	O

Gypenosides	B
pills	O
formula	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
provides	O
a	O
pachyman	O
preparation	O
,	O
wherein	O
the	O
dosage	O
forms	O
include	O
oral	O
liquid	O
,	O
capsule	O
,	O
pill	O
,	O
tablet	O
,	O
pelletized	O
granule	O
,	O
dispersible	O
tablet	O
,	O
effervescent	O
tablet	O
,	O
and	O
injection	O
,	O
the	O
main	O
composition	O
is	O
pachyman	O
(	O
C6H1206	O
)	O
n	O
no	O
less	O
than	O
90	O
%	O
calculated	O
by	O
glucose	B
.	O

The	O
preparing	O
process	O
for	O
the	O
pachyman	O
is	O
also	O
disclosed	O
.	O

Indian	O
bread	O
polysaccharide	O
formulation	O
and	O
its	O
preparation	O
method	O

The	O
present	O
invention	O
relates	O
to	O
kind	O
one	O
ginsenoside	O
Rg2	O
preparing	O
process	O
suitable	O
for	O
industrial	O
production	O
,	O
and	O
gradient	O
salt	O
separation	O
process	O
with	O
simple	O
operation	O
is	O
used	O
in	O
substituting	O
traditional	O
silicon	B
gel	I
chromatography	O
process	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
medicine	O
composition	O
with	O
ginsenoside	B
Rg2	I
as	O
active	O
component	O
and	O
its	O
application	O
in	O
medicine	O
for	O
preventing	O
and	O
treating	O
dementia	O
,	O
depression	O
,	O
peripheral	O
circulation	O
disturbance	O
and	O
related	O
diseases	O
.	O

Gen	O
-	O
seng	O
saponin	B
Rg2	O
preparation	O
method	O
,	O
its	O
pharmaceutical	O
composition	O
and	O
uses	O
in	O
pharmacy	O

The	O
dermatosis	O
treating	O
medicine	O
liquid	O
features	O
that	O
it	O
consists	O
of	O
alcohol	B
in	O
75	O
%	O
concentration	O
,	O
metrifonate	B
and	O
cinnabar	O
in	O
certain	O
weight	O
proportion	O
.	O

It	O
has	O
the	O
advantages	O
of	O
high	O
treating	O
effect	O
and	O
short	O
treating	O
period	O
,	O
and	O
may	O
be	O
used	O
in	O
treating	O
virus	O
caused	O
herpes	O
,	O
bacteria	O
caused	O
pyogenic	O
infection	O
,	O
and	O
fungi	O
caused	O
beriberi	O
,	O
psoriasis	O
and	O
tinea	O
unguium	O
.	O

Dermatosis	O
treating	O
medicine	O
liquid	O

The	O
present	O
invention	O
discloses	O
a	O
kind	O
of	O
new	O
camptothecine	B
derivatives	O
and	O
their	O
preparation	O
process	O
and	O
use	O
.	O

The	O
camptothecine	B
derivatives	O
include	O
9	B
,	I
10-dihydro	I
furan	I
ring	O
camptothecine	B
derivative	O
obtained	O
with	O
10-hydroxy-9-allyl	B
/	O
substituted	O
allyl	B
camptothecine	I
through	O
oxidation	O
to	O
break	O
double	O
bond	O
,	O
acid	O
catalyzed	O
addition	O
other	O
reaction	O
;	O
corresponding	O
furan	B
ring	I
camptothecine	I
derivative	O
obtained	O
through	O
dewatering	O
;	O
and	O
dihydro	B
furan	I
ring	I
camptothecine	I
derivative	O
with	O
NBS	B
treated	O
9-allyl	B
radical	O
or	O
10-hydroxy	B
clip	O
ring	O
.	O

Pharmacological	O
screening	O
shows	O
that	O
all	O
the	O
compounds	O
have	O
excellent	O
antitumor	O
activity	O
.	O

Camptothecine	B
derivative	O
,	O
preparing	O
method	O
and	O
use	O

A	O
process	O
for	O
refining	O
the	O
raw	O
fibranine	B
(	O
anhydrous	O
palmatine	B
hydrochloride	I
C12H21O4N	B
HCl	I
)	O
,	O
its	O
quality	O
control	O
method	O
,	O
its	O
fibranine	B
injection	O
for	O
intravenous	O
application	O
,	O
and	O
its	O
preparing	O
process	O
are	O
disclosed	O
.	O

The	O
content	O
of	O
fibranine	B
can	O
reach	O
98	O
%	O
or	O
more	O
,	O
resulting	O
in	O
high	O
curative	O
rate	O
.	O

Method	O
for	O
refining	O
raw	O
material	O
of	O
venous	O
administration	O
fibranine	B
,	O
its	O
quality	O
control	O
tech	O
.	O

,	O
its	O
prepns	O
.	O

and	O
its	O
prepn	O
.	O

method	O

The	O
present	O
invention	O
discloses	O
slow	O
released	O
Leucogen	B
composition	O
and	O
its	O
preparation	O
process	O
.	O

The	O
slow	O
released	O
Leucogen	B
composition	O
consists	O
of	O
Leucogen	B
10	O
-	O
80	O
wt%	O
,	O
slow	O
releasing	O
retardant	O
5	O
-	O
60	O
wt%	O
and	O
other	O
medicinal	O
supplementary	O
material	O
15	O
-	O
80	O
wt%	O
.	O

The	O
slow	O
releasing	O
retardant	O
is	O
selected	O
from	O
filming	O
material	O
,	O
dissolving	O
skeleton	O
material	O
,	O
insoluble	O
skeleton	O
material	O
and	O
hydrophilic	O
skeleton	O
material	O
;	O
and	O
the	O
other	O
medicinal	O
supplementary	O
material	O
includes	O
diluent	O
,	O
adhesive	O
and	O
lubricant	O
.	O

The	O
slow	O
released	O
composition	O
is	O
tablet	O
or	O
capsule	O
preferably	O
.	O

The	O
present	O
invention	O
aims	O
at	O
providing	O
the	O
preparation	O
superior	O
to	O
available	O
tablet	O
,	O
and	O
the	O
slow	O
released	O
composition	O
has	O
the	O
advantages	O
of	O
slow	O
release	O
of	O
main	O
medicinal	O
components	O
,	O
less	O
blood	O
medicine	O
concentration	O
fluctuation	O
,	O
prolonged	O
effective	O
blood	O
medicine	O
concentration	O
maintaining	O
period	O
,	O
reduced	O
toxic	O
side	O
effect	O
,	O
etc	O
.	O

Leucogen	B
slow	O
release	O
composition	O
and	O
preparation	O
process	O
thereof	O

The	O
present	O
invention	O
discloses	O
one	O
kind	O
of	O
compound	O
dispersive	O
cold	O
-	O
resisting	O
tablet	O
containing	O
Brufen	B
and	O
possessing	O
the	O
features	O
of	O
high	O
medicine	O
stability	O
,	O
fast	O
absorption	O
and	O
high	O
bioavailability	O
.	O

The	O
compound	O
dispersive	O
cold	O
-	O
resisting	O
tablet	O
is	O
prepared	O
with	O
the	O
medicine	O
components	O
including	O
Brufen	B
in	O
31	O
-	O
62	O
wt%	O
,	O
zinc	B
gluconate	I
in	O
37	O
-	O
68	O
wt%	O
and	O
chlorphenamine	B
maleate	I
in	O
0.5	O
-	O
1.5	O
wt%	O
,	O
as	O
well	O
as	O
one	O
or	O
several	O
disintegrating	O
agent	O
of	O
stevioside	O
,	O
microcrystal	O
cellulose	O
,	O
low	O
substituted	O
hydroxypropyl	O
cellulose	O
,	O
PVPP	O
,	O
etc	O
.	O
and	O
adhesive	O
,	O
and	O
through	O
mixing	O
,	O
making	O
soft	O
material	O
with	O
distilled	O
water	O
or	O
PVP	B
,	O
pelletizing	O
and	O
stoving	O
,	O
adding	O
sodium	O
carboxymethyl	O
starch	O
,	O
fine	O
silica	O
gel	O
powder	O
and	O
magnesium	B
stearate	I
,	O
and	O
pressing	O
into	O
tablet	O
.	O

Compound	O
dispersion	O
tablet	O
containing	O
brufen	B
for	O
treating	O
cold	O

A	O
scaffold	O
of	O
the	O
granular	O
anticancer	O
medicine	O
for	O
treating	O
the	O
benign	O
or	O
malignant	O
stenosis	O
of	O
esophagus	O
and	O
digestive	O
tract	O
is	O
disclosed	O
,	O
which	O
has	O
4	O
structures	O
consisting	O
of	O
scaffold	O
,	O
granular	O
anticancer	O
medicine	O
,	O
selective	O
coated	O
film	O
on	O
the	O
surface	O
of	O
scaffold	O
,	O
and	O
selective	O
external	O
protective	O
layer	O
.	O

Digestive	O
tract	O
stent	O
with	O
anti	O
-	O
cancer	O
medicinal	O
particles	O

A	O
softgel	O
containing	O
the	O
liver	O
-	O
protecting	O
pentacyclic	B
triterpene	I
composition	O
is	O
prepared	O
from	O
the	O
pentacyclic	B
triterpene	I
as	O
active	O
component	O
and	O
phosphatide	B
in	O
the	O
weight	O
ratio	O
of	O
(	O
1	O
-	O
10	O
)	O
:	O
(	O
1	O
-	O
20	O
)	O
through	O
mixing	O
and	O
conventional	O
process	O
.	O

It	O
has	O
low	O
irritation	O
.	O

Soft	O
capsule	O
of	O
pentacycle	B
triterpene	I
composition	O
possessing	O
activity	O
for	O
nourish	O
the	O
liver	O

A	O
belamcanda	O
flavone	B
-	O
phosphatide	O
composition	O
for	O
resisting	O
against	O
virus	O
,	O
inflammation	O
and	O
anaphylaxis	O
and	O
benefiting	O
gallbladder	O
and	O
urination	O
is	O
prepared	O
from	O
the	O
belamcanda	O
flavone	B
and	O
phosphatide	O
in	O
mole	O
ratio	O
of	O
1	O
:	O
(	O
0.5	O
-	O
2	O
)	O
through	O
mixing	O
,	O
dissolving	O
in	O
the	O
organic	O
solvent	O
with	O
low	O
dielectric	O
constant	O
while	O
stirring	O
,	O
filtering	O
,	O
and	O
vacuum	O
(	O
or	O
freeze	O
)	O
drying	O
.	O

Complex	O
of	O
total	O
flavone	B
phospholipid	O
of	O
blackberry	O
lily	O
and	O
preparation	O
method	O

A	O
medicine	O
with	O
sanility	O
-	O
delaying	O
activity	O
for	O
treating	O
PADAM	O
of	O
man	O
and	O
early	O
climacteric	O
syndrome	O
of	O
woman	O
is	O
prepared	O
from	O
one	O
or	O
more	O
low	O
-	O
polarity	O
ginsenosides	B
without	O
glycosyl	O
on	O
the	O
20th	O
C	O
site	O
.	O

Medication	O
possessing	O
activity	O
of	O
fighting	O
against	O
senium	O

A	O
blastocyst	O
nidation	O
associated	O
factor	O
EMO-2	O
able	O
to	O
promote	O
the	O
nidation	O
of	O
blastocyst	O
is	O
disclosed	O
.	O

Its	O
antisense	O
nucleic	O
acid	O
and	O
its	O
polypeptide	O
antibody	O
can	O
suppress	O
the	O
nidation	O
of	O
blastocyst	O
.	O

A	O
process	O
for	O
screening	O
the	O
compounds	O
to	O
suppress	O
or	O
promote	O
the	O
nidation	O
of	O
blastocyst	O
by	O
use	O
of	O
said	O
EMO-2	O
factor	O
is	O
also	O
disclosed	O
.	O

Correlation	O
factor	O
of	O
blastocyst	O
nidation	O
and	O
application	O

The	O
invention	O
relates	O
to	O
a	O
tablet	O
for	O
treating	O
thrombus	O
,	O
and	O
its	O
preparing	O
process	O
,	O
wherein	O
the	O
tablet	O
comprises	O
Notoginsen	B
triterpenes	I
100	O
g	O
,	O
calcium	B
sulfate	I
150	O
g	O
,	O
crystalline	O
cellulose	O
50	O
g	O
,	O
miropowdered	O
silica	B
gel	I
3	O
g	O
,	O
and	O
magnesium	B
stearate	I
1.5	O
g	O
.	O

Thrombus	O
dissolving	O
tablet	O
and	O
preparation	O

The	O
present	O
invention	O
relates	O
to	O
medicine	O
technology	O
,	O
and	O
is	O
especially	O
the	O
preparation	O
process	O
and	O
use	O
of	O
total	O
andrographolide	B
emulsion	O
.	O

The	O
total	O
andrographolide	B
includes	O
Andrographolide	B
,	O
deoxyandrographolide	B
,	O
Neoandrographolide	B
or	O
deoxydidehydroandrographolide	B
or	O
their	O
composition	O
.	O

The	O
total	O
andrographolide	B
emulsion	O
contains	O
total	O
andrographolide	B
,	O
oil	O
,	O
water	O
,	O
emulsifier	O
and	O
surfactant	O
in	O
the	O
weight	O
ratio	O
of	O
1:1	O
-	O
200:1	O
-	O
100:0	O
-	O
30	O
.	O

The	O
total	O
andrographolide	B
emulsion	O
may	O
be	O
used	O
in	O
preparing	O
antiphlogistic	O
and	O
anticontagious	O
medicines	O
.	O

Prepn	O
process	O
and	O
use	O
of	O
total	O
andrographolide	B
emulsion	O

The	O
present	O
invention	O
relates	O
to	O
antimer	O
selective	O
catalytic	O
oxidation	O
process	O
for	O
preparing	O
optical	O
active	O
antimer	O
or	O
optically	O
pure	O
antimer	O
(	B
S	I
)	I
-omeprazole	I
.	O

In	O
the	O
presence	O
of	O
the	O
titanium	O
containing	O
catalyst	O
in	O
-	O
situ	O
created	O
with	O
metal	O
titanium	O
reagent	O
and	O
chiral	O
glycol	O
ligand	O
and	O
the	O
oxidant	O
,	O
omeprazole	B
sulfide	I
is	O
catalytically	O
oxidized	O
with	O
antimer	O
.	O

Compared	O
with	O
the	O
process	O
utilizing	O
tetraisopropanol	B
titanium	I
-	O
diethyl	B
tartrate	I
system	O
,	O
the	O
process	O
of	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
cheap	O
material	O
,	O
high	O
antimer	O
selectivity	O
and	O
high	O
yield	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
thepreparation	O
of	O
(	B
S	I
)	I
-omeprazole	I
in	O
neutralized	O
state	O
,	O
partial	O
crystallized	O
state	O
or	O
completely	O
crystallized	O
state	O
.	O

Method	O
for	O
high	O
enantiomer	O
selection	O
preparation	O
of	O
(	B
S	I
)	I
-Omeprazole	I

The	O
present	O
invention	O
relates	O
to	O
an	O
Yanhuning	O
injection	O
and	O
its	O
preparation	O
method	O
.	O

Said	O
invention	O
provides	O
a	O
solution	O
type	O
Yanhuning	O
injection	O
,	O
at	O
the	O
same	O
time	O
provides	O
an	O
Yanhuning	O
infusion	O
preparation	O
which	O
has	O
no	O
need	O
of	O
dilution	O
and	O
can	O
be	O
directly	O
used	O
for	O
intravenous	O
injection	O
Besides	O
,	O
said	O
invention	O
also	O
provides	O
their	O
preparation	O
method	O
.	O

Solution	O
type	O
potassium	B
sodium	I
dehydroandroan	I
drographolide	I
succinate	I
injection	O
and	O
its	O
preparing	O
method	O

The	O
present	O
invention	O
discloses	O
a	O
bilobalide	B
(	O
mixture	O
or	O
ginkgo	O
extract	O
)	O
emulsion	O
for	O
injection	O
,	O
in	O
particular	O
,	O
it	O
relates	O
to	O
a	O
bilobalide	B
(	O
including	O
single	O
bilobalide	B
A	I
,	I
B	I
and	I
C	I
,	O
etc	O
.	O
)	O

injection	O
emulsion	O
for	O
curing	O
angiocardiopathy	O
and	O
cerebrovascular	O
disease	O
.	O

It	O
is	O
made	O
up	O
by	O
using	O
bilobalide	B
and	O
medicinal	O
auxiliary	O
material	O
according	O
to	O
a	O
certain	O
ratio	O
through	O
the	O
processes	O
of	O
dissolving	O
,	O
heating	O
,	O
uniformly	O
mixing	O
,	O
emulsifying	O
,	O
cooling	O
and	O
filling	O
to	O
obtain	O
the	O
invented	O
product	O
.	O

Ginkgolide	B
emulsion	O
for	O
injection	O

The	O
present	O
invention	O
relates	O
to	O
a	O
quality	O
control	O
method	O
of	O
Keke	O
oral	O
preparation	O
for	O
relieving	O
cough	O
and	O
asthma	O
.	O

It	O
includes	O
trait	O
,	O
examination	O
,	O
identification	O
and	O
content	O
determination	O
.	O

The	O
described	O
trait	O
identification	O
includes	O
:	O
soft	O
extract	O
identification	O
,	O
said	O
product	O
is	O
a	O
dark	O
brown	O
thick	O
semifluid	O
,	O
its	O
taste	O
is	O
sweet	O
and	O
slight	O
bitter	O
;	O
syrup	O
identification	O
,	O
said	O
product	O
is	O
a	O
brownish	O
yellow	O
thick	O
liquid	O
,	O
its	O
taste	O
is	O
sweet	O
and	O
slight	O
bitter	O
;	O
and	O
oral	O
liquor	O
identification	O
,	O
said	O
product	O
is	O
a	O
brownish	O
yellow	O
liquid	O
,	O
its	O
taste	O
is	O
sweet	O
and	O
light	O
bitter	O
.	O

The	O
described	O
identification	O
includes	O
thin	O
-	O
layer	O
identification	O
of	O
ephedra	O
root	O
,	O
poppy	O
husk	O
and	O
licorice	O
,	O
the	O
described	O
content	O
determination	O
includes	O
the	O
content	O
determination	O
of	O
ephedrine	B
hydrochloride	I
and	O
codeine	B
phosphate	I
.	O

Said	O
invention	O
can	O
effectively	O
control	O
the	O
quality	O
of	O
Keke	O
soft	O
extract	O
,	O
Keke	O
syrup	O
and	O
Keke	O
oral	O
liquor	O
preparation	O
.	O

Quality	O
control	O
method	O
of	O
keke	O
oral	O
preparation	O
for	O
relieving	O
cough	O

The	O
invention	O
is	O
a	O
medicine	O
for	O
curing	O
blebs	O
and	O
sores	O
,	O
uniformly	O
mixing	O
and	O
pounding	O
garlic	O
,	O
alum	O
,	O
borneol	O
,	O
and	O
salt	O
in	O
a	O
certain	O
proportion	O
and	O
soaking	O
the	O
mixture	O
in	O
a	O
ceramatic	O
jar	O
with	O
tea	O
oil	O
by	O
20	O
times	O
and	O
sealing	O
for	O
above	O
three	O
months	O
so	O
as	O
to	O
make	O
it	O
.	O

The	O
invention	O
can	O
radically	O
cure	O
various	O
blebs	O
and	O
sores	O
within	O
two	O
days	O
,	O
where	O
the	O
cure	O
rate	O
is	O
up	O
to	O
100	O
%	O
,	O
and	O
also	O
has	O
peculiar	O
effect	O
on	O
nameless	O
galls	O
,	O
piles	O
;	O
various	O
skin	O
diseases	O
,	O
dermatophytosis	O
,	O
scalds	O
by	O
water	O
and	O
fire	O
,	O
burn	O
,	O
wound	O
,	O
and	O
knife	O
wound	O
.	O

Medicine	O
for	O
treating	O
Lump	O
sore	O

An	O
application	O
of	O
resveratrol	B
in	O
preparing	O
food	O
(	O
dairy	O
products	O
,	O
milk	O
powder	O
,	O
sweets	O
,	O
beverage	O
,	O
etc	O
)	O
for	O
taking	O
care	O
of	O
human	O
health	O
and	O
improving	O
immunity	O
includes	O
such	O
steps	O
as	O
dissolving	O
it	O
in	O
edible	O
alcohol	B
or	O
organic	O
solvent	O
,	O
diluting	O
and	O
mixing	O
it	O
with	O
other	O
raw	O
materials	O
of	O
said	O
food	O
.	O

Use	O
of	O
resveratrol	B
for	O
food	O

The	O
present	O
invention	O
relates	O
to	O
the	O
application	O
of	O
compound	O
PS-341	O
in	O
preparing	O
medicine	O
for	O
treating	O
chronic	O
granulocytic	O
leukemia	O
,	O
and	O
the	O
effective	O
concentration	O
is	O
1E	O
(	O
-8	O
)	O
to	O
1E	O
(	O
-6	O
)	O
M.	O
The	O
compound	O
PS-341	O
as	O
the	O
new	O
medicine	O
for	O
treating	O
chronic	O
granulocytic	O
leukemia	O
has	O
the	O
advantages	O
of	O
small	O
dosage	O
,	O
medium	O
cost	O
,	O
convenient	O
taking	O
,	O
obvious	O
curative	O
effect	O
,	O
etc	O
.	O
and	O
may	O
be	O
used	O
in	O
treating	O
chronic	O
granulocytic	O
leukemia	O
in	O
the	O
chronic	O
period	O
,	O
the	O
acceleration	O
period	O
and	O
acute	O
period	O
.	O

Use	O
of	O
compound	O
PS-341	O
in	O
preparing	O
medicine	O
for	O
treating	O
chronic	O
granulocytic	O
leukemia	O

An	O
application	O
of	O
the	O
ganoderic	B
acid	I
T	O
and	O
ganoderic	B
acid	I
Me	O
in	O
preparing	O
the	O
depressant	O
,	O
sensitizer	O
and	O
synergist	O
for	O
suppressing	O
the	O
growth	O
and	O
reproduction	O
of	O
the	O
cancer	O
cells	O
resistant	O
to	O
multiple	O
medicines	O
and	O
improving	O
the	O
sensitivity	O
of	O
said	O
cancer	O
cells	O
to	O
anticancer	O
medicines	O
is	O
disclosed	O
.	O

Application	O
of	O
lucid	O
ganoderma	O
acid	O
in	O
treating	O
cancer	O
as	O
synergistic	O
agent	O
and	O
inhibitor	O

An	O
enteric	O
micropill	O
is	O
prepared	O
from	O
adefovirdipivoxil	B
dipivalyloxy	I
methylester	I
as	O
active	O
component	O
,	O
hydroxypropylmethyl	O
cellulose	O
phthalate	O
as	O
enteric	O
material	O
,	O
and	O
detackifier	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Atfuweibi	O
terveleryl	O
oxo	O
methyl	O
ester	O
enteric	O
micropill	O
and	O
its	O
preparation	O
method	O

A	O
deproteinized	O
oral	O
cream	O
of	O
calf	O
serum	O
is	O
prepared	O
proportionally	O
from	O
the	O
deproteinized	O
extract	O
powder	O
of	O
calf	O
serum	O
,	O
anesthone	B
,	O
carboxymethyl	O
cellulose	O
sodium	O
,	O
pectin	B
,	O
hydroxyphenyl	B
ethylester	I
,	O
menthol	B
,	O
atoleine	B
and	O
white	O
vaseline	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Calf	O
serum	O
deprotein	O
oral	O
cavity	O
ointment	O
and	O
its	O
preparation	O
method	O

An	O
injection	O
of	O
troxerutin	B
for	O
treating	O
obliterative	O
syndrome	O
,	O
thrombophlebitis	O
,	O
capillary	O
hemorrhage	O
is	O
prepared	O
through	O
ion	O
exchange	O
of	O
troxerutin	B
,	O
mixing	O
with	O
the	O
water	O
for	O
injection	O
,	O
pouring	O
in	O
containers	O
,	O
sterilizing	O
,	O
and	O
lamp	O
examining	O
.	O

Preparation	O
method	O
of	O
troxerutin	B
injection	O

The	O
present	O
invention	O
discloses	O
tobramycin	B
eye	O
drop	O
and	O
its	O
preparation	O
process	O
.	O

The	O
preparation	O
process	O
of	O
tobramycin	B
eye	O
drop	O
includes	O
dissolving	O
tobramycin	B
and	O
relevant	O
supplementary	O
material	O
in	O
water	O
,	O
adding	O
water	O
with	O
swelled	O
sodium	O
hyaluronate	O
through	O
stirring	O
,	O
adding	O
water	O
in	O
the	O
enough	O
amount	O
,	O
filtering	O
and	O
packing	O
.	O

The	O
improved	O
tobramycin	B
eye	O
drop	O
is	O
superior	O
to	O
available	O
one	O
and	O
has	O
the	O
physically	O
thickening	O
,	O
wet	O
storing	O
and	O
lubricating	O
effects	O
of	O
sodium	O
hyaluronate	O
,	O
prolonged	O
remaining	O
time	O
of	O
medicine	O
inside	O
eye	O
,	O
less	O
medicine	O
flow	O
into	O
oral	O
cavity	O
and	O
nose	O
,	O
less	O
medicine	O
loss	O
,	O
raised	O
patientí»s	O
dependence	O
and	O
ensured	O
clinical	O
effect	O
.	O

Tobramycin	B
eye	O
drops	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
discloses	O
a	O
process	O
for	O
preparing	O
Nicorandil	B
freeze	O
-	O
dried	O
powder	O
,	O
which	O
consists	O
of	O
charging	O
0.1	O
-	O
50.0	O
wt%	O
of	O
Nicorandil	B
into	O
water	O
for	O
injection	O
,	O
dissolving	O
excipient	O
simultaneously	O
,	O
degerming	O
and	O
filtering	O
,	O
loading	O
,	O
and	O
finally	O
freeze	O
drying	O
.	O

Nicorandil	B
freeze	O
-	O
drying	O
powder	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
notoginseng	O
-	O
containing	O
tablet	O
for	O
treating	O
traumatic	O
injury	O
,	O
which	O
comprises	O
comminuting	O
cinnabar	O
,	O
musk	O
,	O
dragon	O
's	O
blood	O
resin	O
,	O
baras	O
camphor	B
,	O
notoginseng	O
,	O
myrrh	O
,	O
safflower	O
,	O
frankincense	O
,	O
Chinese	O
angelica	O
root	O
and	O
black	O
catechu	O
,	O
mixing	O
and	O
sieving	O
to	O
obtain	O
granules	O
,	O
drying	O
and	O
charging	O
musk	O
,	O
baras	O
camphor	B
fines	O
,	O
mixing	O
homogenously	O
and	O
tabletting	O
.	O

Preparation	O
method	O
of	O
notoginseng	O
-	O
containing	O
tablet	O
for	O
treating	O
traumatic	O
injury	O

The	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
certain	O
neurologic	O
and	O
psychiatric	O
disorders	O
in	O
mammals	O
,	O
including	O
humans	O
,	O
comprising	O
administration	O
of	O
a	O
selective	O
PDE10	O
inhbitor	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
treatment	O
of	O
mood	O
,	O
movement	O
,	O
and	O
anxiety	O
disorders	O
;	O
psychosis	O
;	O
drug	O
,	O
for	O
example	O
alcohol	O
,	O
addiction	O
;	O
and	O
disorders	O
having	O
as	O
a	O
symptom	O
deficient	O
cognition	O
.	O

The	O
invention	O
furthermore	O
provides	O
the	O
use	O
of	O
papaverine	O
as	O
a	O
selective	O
inhibitor	O
of	O
PDE10	O
.	O

Therapeutic	O
use	O
of	O
selective	O
PDE10	O
inhibitors	O

The	O
slow	O
released	O
anticancer	O
injection	O
containing	O
fluoroplex	B
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material	O
,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
component	O
is	O
5-FU	B
and/or	O
5-FU	B
synergist	O
selected	O
from	O
platinum	B
compound	O
,	O
topoisomerase	O
inhibitor	O
,	O
guanine	B
analogue	O
and	O
tetrazine	B
compound	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA	B
,	O
PLGA	B
,	O
EVAc	B
,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
Tween-40	B
and/or	O
Tween-80	B
.	O

Injecting	O
the	O
slow	O
released	O
injection	O
to	O
tumor	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
medicine	O
concentration	O
of	O
local	O
tumor	O
part	O
selectively	O
to	O
raise	O
the	O
treating	O
effect	O
.	O

Slow	O
-	O
released	O
injection	O
containing	O
fluoroplex	B
synergist	O

The	O
slow	O
released	O
anticancer	O
injection	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material	O
,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
component	O
is	O
5-FU	B
synergist	O
or	O
the	O
combination	O
of	O
5-FU	B
and	O
5-FU	B
synergist	O
selected	O
from	O
antitumor	O
antibiotic	O
,	O
antimetabolite	O
,	O
taxane	B
and	O
plant	O
alkaloid	B
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA	B
,	O
PLGA	B
,	O
EVAc	B
,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
mannitol	B
,	O
sorbitol	B
,	O
Tween-80	B
or	O
their	O
composition	O
.	O

The	O
slow	O
released	O
microballoon	O
may	O
be	O
also	O
prepared	O
into	O
slow	O
released	O
implantation	O
preparation	O
.	O

Implanting	O
or	O
injecting	O
the	O
slow	O
released	O
preparation	O
to	O
local	O
tumor	O
part	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
medicine	O
concentration	O
of	O
local	O
tumor	O
part	O
selectively	O
to	O
raise	O
the	O
treating	O
effect	O
.	O

Slow	O
-	O
released	O
anticancer	O
injection	O

The	O
slow	O
released	O
anticancer	O
preparation	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material	O
,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
component	O
is	O
bendamustine	B
and/or	O
bendamustine	B
synergist	O
of	O
topoisomerase	O
inhibitor	O
,	O
guanine	B
analogue	O
,	O
tetrazine	B
compound	O
and/or	O
platinum	B
compound	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA	B
,	O
PLGA	B
,	O
EVAc	B
,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
etc	O
of	O
viscosity	O
of	O
100	O
-	O
3000	O
cp	O
(	O
at	O
20	O
-	O
30	O
deg.c	O
)	O
.	O

The	O
slow	O
released	O
microballoon	O
may	O
be	O
also	O
prepared	O
into	O
slow	O
released	O
implantation	O
preparation	O
.	O

Implanting	O
or	O
injecting	O
the	O
slow	O
released	O
preparation	O
to	O
local	O
tumor	O
part	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
medicine	O
concentration	O
of	O
local	O
tumor	O
part	O
selectively	O
to	O
raise	O
the	O
treating	O
effect	O
.	O

Slow	O
-	O
released	O
injection	O
containing	O
bendamustine	B
and	O
its	O
synergist	O

The	O
slow	O
released	O
injection	O
containing	O
taxane	B
and	O
its	O
synergist	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material	O
,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
component	O
is	O
taxane	B
and/or	O
taxane	B
synergist	O
of	O
topoisomerase	O
inhibitor	O
,	O
guanine	B
analogue	O
,	O
tetrazine	B
compound	O
and/or	O
platinum	B
compound	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA	O
,	O
PLGA	O
,	O
EVAc	O
,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
Tween-40	O
,	O
Tween-80	O
or	O
their	O
composition	O
.	O

The	O
slow	O
released	O
microballoon	O
may	O
be	O
also	O
prepared	O
into	O
implantation	O
preparation	O
.	O

Implanting	O
or	O
injecting	O
the	O
slow	O
released	O
preparation	O
to	O
local	O
tumor	O
part	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
treating	O
effect	O
.	O

Slow	O
-	O
released	O
injection	O
containing	O
taxol	B
and	O
its	O
synergist	O

The	O
slow	O
released	O
injection	O
containing	O
taxane	B
and	O
its	O
synergist	O
consists	O
of	O
slow	O
released	O
microballoon	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microballoon	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material	O
,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
component	O
is	O
taxane	B
and/or	O
taxane	B
synergist	O
of	O
phosphorinositide	O
3-kinase	O
inhibitor	O
,	O
pyrimidine	B
analogue	O
and/or	O
DNA	O
repair	O
enzyme	O
inhibitor	O
;	O
the	O
slow	O
releasing	O
supplementary	O
material	O
is	O
PLA	O
,	O
PLGA	O
,	O
EVAc	O
,	O
etc	O
or	O
their	O
composition	O
;	O
and	O
the	O
suspending	O
agent	O
is	O
sodium	O
carboxymethyl	O
cellulose	O
,	O
etc	O
.	O

The	O
slow	O
released	O
microballoon	O
may	O
be	O
also	O
prepared	O
into	O
implantation	O
preparation	O
.	O

Implanting	O
or	O
injecting	O
the	O
slow	O
released	O
preparation	O
to	O
local	O
tumor	O
part	O
can	O
lower	O
the	O
systematic	O
toxic	O
reaction	O
of	O
the	O
medicine	O
and	O
raise	O
the	O
medicine	O
concentration	O
of	O
local	O
tumor	O
part	O
selectively	O
to	O
raise	O
the	O
treating	O
effect	O
.	O

Slow	O
-	O
released	O
prepn	O
containing	O
taxane	B
and	O
its	O
synergist	O

The	O
compound	O
piracetam	B
-	O
cerebral	O
protolysate	O
capsule	O
is	O
prepared	O
with	O
piracetam	O
,	O
cerebral	O
protolysate	O
,	O
glutamic	B
acid	I
,	O
chondrotin	B
sulfate	I
,	O
vitamin	B
B1	I
,	O
vitamin	B
B2	I
,	O
vitamin	B
B6	I
and	O
vitamin	B
E	I
in	O
certain	O
weight	O
proportion	O
as	O
main	O
components	O
,	O
and	O
PVP	O
as	O
supplementary	O
material	O
.	O

Its	O
preparation	O
process	O
includes	O
the	O
steps	O
of	O
preparing	O
soft	O
material	O
,	O
preparing	O
wet	O
pellet	O
,	O
stoving	O
at	O
20	O
-	O
50	O
deg.c	O
,	O
finishing	O
,	O
and	O
encapsulating	O
.	O

The	O
present	O
invention	O
has	O
high	O
bioavailability	O
,	O
simple	O
preparation	O
process	O
and	O
other	O
advantages	O
.	O

Compound	O
piracetam	B
-	O
cerebral	O
protein	O
hydrolysate	O
capsule	O
and	O
its	O
prepn	O

The	O
present	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
released	O
injection	O
containing	O
aminoglycoside	B
antibiotics	O
.	O

It	O
composed	O
of	O
slow	O
-	O
released	O
microsphere	O
and	O
solvent	O
.	O

Said	O
slow	O
-	O
released	O
microsphere	O
contains	O
slow	O
-	O
released	O
auxiliary	O
material	O
and	O
aminoglycoside	B
antibiotics	O
,	O
and	O
the	O
solvent	O
is	O
special	O
solvent	O
containing	O
suspension	O
adjuvant	O
of	O
carboxymethyl	O
cellulose	O
sodium	O
,	O
its	O
viscosity	O
is	O
100	O
cp-3000	O
cp	O
(	O
20	O
deg	O
.	O

C-30	O
deg	O
.	O

C	O
)	O
,	O
the	O
slow	O
-	O
released	O
auxiliary	O
material	O
is	O
selected	O
from	O
EVAc	B
,	O
PLA	B
,	O
PLGA	B
,	O
sebacic	B
acid	I
copolymer	O
,	O
albumin	O
glue	O
and	O
gelatin	O
,	O
etc	O
.	O

The	O
slow	O
-	O
released	O
microsphere	O
also	O
can	O
be	O
made	O
into	O
slow	O
-	O
released	O
implant	O
preparation	O
and	O
ointment	O
preparation	O
.	O

Said	O
invention	O
also	O
provides	O
its	O
application	O
range	O
and	O
can	O
obtain	O
obvious	O
therapeutic	O
effect	O
for	O
curing	O
various	O
infective	O
diseases	O
.	O

Slow	O
-	O
release	O
injecta	O
containing	O
amino	B
glucosides	I
antibiotics	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
medicinal	O
compound	O
for	O
improving	O
blood	O
lipid	O
and	O
body	O
insulin	O
resistance	O
state	O
.	O

Said	O
medicinal	O
compound	O
contains	O
phenoxyaromatic	B
acid	I
medicine	O
(	O
including	O
fenofibrate	B
,	O
bezafibrate	B
and	O
gemfibrozil	B
,	O
etc	O
.	O
)	O
or	O
its	O
medicinal	O
salt	O
,	O
taurine	B
and	O
medicinal	O
carrier	O
or	O
excipient	O
.	O

Said	O
medicinal	O
compound	O
also	O
can	O
be	O
used	O
for	O
reducing	O
total	O
cholesterol	B
(	O
TC	O
)	O
,	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
and	O
triglyceride	B
(	O
TG	O
)	O
and	O
raising	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
,	O
and	O
can	O
be	O
used	O
for	O
curing	O
abnormal	O
blood	O
-	O
lipid	O
and	O
metabolic	O
syndrome	O
,	O
etc	O
.	O

Composition	O
containing	O
fibrate	B
drug	O
and	O
taurine	B

A	O
weight	O
-	O
losing	O
prescription	O
used	O
individually	O
or	O
as	O
the	O
additive	O
of	O
beverage	O
and	O
food	O
without	O
by	O
-	O
effect	O
contains	O
levo	B
-	I
carnitine	I
,	O
nicotinic	B
acid	I
,	O
folic	B
acid	I
,	O
inositol	B
,	O
VC	B
,	O
VB6	B
,	O
VB12	B
,	O
powder	O
of	O
chrysanthemum	O
flower	O
,	O
refined	O
konjak	O
starch	O
,	O
sweetening	O
agent	O
,	O
edible	O
perfume	O
and	O
citric	B
acid	I
.	O

Non	O
-	O
effect	O
components	O
for	O
beverage	O
or	O
solid	O
oral	O
agent	O
or	O
food	O
additive	O
with	O
weight	O
-	O
losing	O
function	O

An	O
application	O
of	O
the	O
veratrum	O
alkaloid	B
used	O
as	O
hedgehog	O
signal	O
channel	O
inhibitor	O
in	O
treating	O
tumor	O
without	O
damage	O
to	O
DNA	O
of	O
human	O
body	O
is	O
disclosed	O
.	O

A	O
process	O
for	O
preparing	O
the	O
composition	O
of	O
veratrum	O
alkaloid	B
is	O
also	O
disclosed	O
.	O

Use	O
of	O
hellebore	O
alkaloid	B
in	O
tumor	O
treatment	O

A	O
freeze	O
-	O
dried	O
powder	O
injection	O
of	O
thioctic	B
acid	I
contains	O
proprotionally	O
the	O
thioctic	B
acid	I
,	O
antioxidizing	O
agent	O
and	O
pH	O
regulator	O
.	O

Its	O
advantages	O
are	O
high	O
curative	O
effect	O
and	O
high	O
stability	O
.	O

Zinc	B
sulfate	I
freeze	O
-	O
dried	O
preparation	O
for	O
injection	O

An	O
application	O
of	O
the	O
polygonati	O
polyose	O
in	O
preparing	O
three	O
medicines	O
respectively	O
used	O
for	O
treating	O
the	O
endarterial	O
thrombosis	O
and	O
atherosclerosis	O
,	O
treating	O
the	O
fatty	O
liver	O
,	O
and	O
preventing	O
and	O
treating	O
Alzheimer	O
disease	O
.	O

Use	O
III	O
of	O
sealwort	O
polysaccharide	O

The	O
invention	O
relates	O
to	O
a	O
group	O
of	O
novel	O
benzimidazolone	B
and	O
quinazolinone	B
derivatives	O
which	O
are	O
agonists	O
on	O
human	O
ORL1	O
(	O
nociceptin	O
)	O
receptors	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
of	O
these	O
compounds	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
a	O
pharmacologically	O
active	O
amount	O
of	O
at	O
least	O
one	O
of	O
these	O
imidazolone	B
and	O
quinazolinone	B
derivatives	O
as	O
an	O
active	O
ingredient	O
,	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
these	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
disorders	O
in	O
which	O
ORL1	O
receptors	O
are	O
involved	O
.	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
.	O

Benzimidazolone	B
and	O
quinazolinone	B
derivatives	O
as	O
agonists	O
on	O
human	O
ORL1	O
receptors	O

It	O
is	O
intended	O
to	O
provide	O
a	O
skin	O
examination	O
method	O
for	O
predicting	O
spot	O
formation	O
on	O
the	O
skin	O
.	O

This	O
method	O
is	O
characterized	O
by	O
comprising	O
judging	O
the	O
skin	O
as	O
having	O
a	O
high	O
risk	O
of	O
spot	O
formation	O
in	O
the	O
case	O
where	O
the	O
expression	O
of	O
MCP-2	O
gene	O
,	O
a	O
polynucleotide	O
hybridizable	O
with	O
mouse	O
AK012157	O
gene	O
,	O
human	O
FLJ21763	O
gene	O
or	O
rat	O
S74257	O
gene	O
under	O
highly	O
stringent	O
conditions	O
,	O
or	O
Mcp9	O
,	O
Mcp10	O
,	O
Isg15	O
,	O
Usp18	O
,	O
Oas	O
12	O
,	O
Gbp2	O
,	O
Gtpi	O
,	O
Ifi47	O
,	O
Igtp	O
,	O
Tgtp	O
,	O
Sprr2A	O
,	O
Krt2	O
-	O
6b	O
,	O
Cdk5rap2	O
,	O
Mef2C	O
,	O
Gsta4	O
,	O
Osf2	O
,	O
Tnc	O
,	O
Igfbp6	O
,	O
Ppicap	O
,	O
MCP-6	O
or	O
Mm.74656	O
gene	O
is	O
accelerated	O
in	O
the	O
epidermis	O
compared	O
with	O
the	O
expression	O
thereof	O
in	O
normal	O
epidermis	O
.	O

Method	O
of	O
predicting	O
spot	O
formation	O
on	O
the	O
skin	O
with	O
the	O
use	O
of	O
spot	O
site	O
-	O
accelerating	O
genes	O
as	O
indication	O
and	O
method	O
of	O
screening	O
inhibitor	O
for	O
spot	O
formation	O
on	O
the	O
skin	O

The	O
slow	O
released	O
anticancer	O
injection	O
containing	O
blood	O
vessel	O
inhibitor	O
consists	O
of	O
slow	O
released	O
microsphere	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microsphere	O
includes	O
effective	O
anticancer	O
component	O
and	O
slow	O
releasing	O
supplementary	O
material	O
,	O
and	O
the	O
solvent	O
is	O
common	O
solvent	O
or	O
special	O
solvent	O
containing	O
suspending	O
agent	O
.	O

The	O
effective	O
anticancer	O
component	O
is	O
blood	O
vessel	O
inhibitor	O
and/or	O
blood	O
vessel	O
inhibitor	O
synergist	O
selected	O
from	O
taxane	B
,	O
alkylating	O
agent	O
and/or	O
plant	O
alkaloid	B
.	O

The	O
slow	O
releasing	O
supplementary	O
material	O
is	O
selected	O
from	O
difatty	B
acid	I
-	O
sebacic	B
acid	I
copolymer	O
,	O
poly	B
(	I
erucic	I
acid	I
dipolymer	I
-	I
sebacic	I
acid	I
)	I
,	O
poly	B
(	I
fumaric	I
acid	I
-	I
sebacic	I
acid	I
)	I
,	O
etc	O
.	O

The	O
suspending	O
agent	O
is	O
carboxymethyl	O
cellulose	O
sodium	O
,	O
etc	O
.	O
and	O
has	O
viscosity	O
of	O
100	O
-	O
3000	O
cp	O
at	O
20	O
-	O
30	O
deg.c	O
.	O

The	O
slow	O
released	O
microsphere	O
may	O
be	O
also	O
prepared	O
into	O
slow	O
released	O
implanting	O
agent	O
for	O
lowering	O
systemic	O
toxic	O
reaction	O
,	O
raising	O
local	O
concentration	O
optionally	O
and	O
raising	O
the	O
effect	O
of	O
chemotherapeutic	O
and/or	O
radiotherapeutic	O
medicine	O
.	O

Slow	O
released	O
anticancer	O
injection	O
containing	O
blood	O
vessel	O
inhibitor	O

The	O
slow	O
released	O
antituberculotic	O
preparation	O
is	O
implanting	O
agent	O
or	O
injection	O
with	O
slow	O
releasing	O
of	O
medicine	O
in	O
the	O
local	O
tuberculosis	O
focus	O
to	O
maintain	O
the	O
local	O
effective	O
medicine	O
concentration	O
while	O
lowing	O
the	O
systemic	O
toxicity	O
.	O

The	O
slow	O
released	O
injection	O
consists	O
of	O
slow	O
released	O
microsphere	O
and	O
solvent	O
.	O

The	O
slow	O
released	O
microsphere	O
consists	O
of	O
slow	O
releasing	O
supplementary	O
material	O
and	O
antituberculotic	O
selected	O
from	O
rifampicin	O
,	O
rifamycin	O
,	O
rifapentine	B
and/or	O
rifabutine	B
.	O

The	O
solvent	O
is	O
special	O
solvent	O
containing	O
suspending	O
agent	O
of	O
carboxymethyl	O
cellulose	O
sodium	O
,	O
etc	O
.	O
and	O
has	O
viscosityof	O
100	O
-	O
3000	O
cp	O
at	O
20	O
-	O
30	O
deg.c	O
.	O

The	O
slow	O
releasing	O
supplementary	O
material	O
is	O
selected	O
from	O
EVAc	O
,	O
PLA	O
,	O
PLGA	O
,	O
etc	O
.	O

The	O
slow	O
released	O
preparation	O
may	O
be	O
prepared	O
with	O
slow	O
released	O
microsphere	O
.	O

The	O
present	O
invention	O
has	O
obvious	O
and	O
unique	O
treating	O
effect	O
on	O
various	O
kinds	O
of	O
intractable	O
tuberculosis	O
.	O

Slow	O
released	O
antituberculotic	O
preparation	O

The	O
present	O
invention	O
provides	O
submicron	O
docetaxel	B
emulsion	O
for	O
intravenous	O
injection	O
and	O
its	O
preparation	O
process	O
,	O
and	O
docetaxel	B
is	O
prepared	O
into	O
submicron	O
docetaxel	B
emulsion	O
for	O
intravenous	O
injectionwith	O
proper	O
emulsifier	O
and	O
other	O
pharmaceutical	O
supplementary	O
material	O
.	O

Docetaxel	B
,	O
injection	O
oil	O
,	O
emulsifier	O
,	O
stabilizer	O
,	O
injection	O
water	O
and	O
isoosmotic	O
regulator	O
are	O
stirred	O
separately	O
to	O
obtain	O
both	O
oil	O
phase	O
and	O
water	O
phase	O
,	O
the	O
oil	O
phase	O
and	O
the	O
water	O
phase	O
are	O
mixed	O
and	O
emulsified	O
to	O
obtain	O
initial	O
emulsion	O
,	O
and	O
the	O
initial	O
emulsion	O
is	O
further	O
emulsified	O
and	O
high	O
pressure	O
homogenized	O
to	O
prepare	O
the	O
required	O
docetaxel	B
emulsion	O
for	O
intravenous	O
injection	O
.	O

The	O
submicron	O
docetaxel	B
emulsion	O
has	O
stable	O
property	O
,	O
long	O
preservation	O
period	O
,	O
convenient	O
use	O
and	O
simple	O
preparation	O
process	O
,	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Submicron	O
docetaxel	B
emulsion	O
for	O
intravenous	O
injection	O
and	O
its	O
preparing	O
process	O

The	O
slow	O
released	O
aminoglycoside	B
containing	O
antituberculotic	O
preparation	O
is	O
slow	O
released	O
implanting	O
agent	O
and	O
slow	O
released	O
injection	O
..	O

The	O
slow	O
released	O
injection	O
consists	O
of	O
slow	O
released	O
microsphere	O
and	O
solvent	O
,	O
the	O
slow	O
released	O
microsphere	O
contains	O
slow	O
releasing	O
supplementary	O
material	O
and	O
antituberculotic	O
,	O
and	O
the	O
solvent	O
is	O
special	O
solvent	O
containing	O
suspending	O
agent	O
carboxymethyl	O
cellulose	O
sodium	O
and	O
of	O
viscosity	O
of	O
100	O
-	O
3000	O
cp	O
at	O
20	O
-	O
30	O
deg.c	O
.	O

The	O
antituberculotic	O
is	O
selected	O
from	O
streptomycin	B
,	O
kanamycin	B
,	O
amidacin	B
and	O
amikacin	B
.	O

The	O
slow	O
releasing	O
supplementary	O
material	O
is	O
EVAc	B
,	O
PLA	B
,	O
PLGA	B
,	O
sebacic	B
acid	I
copolymer	O
,	O
etc	O
.	O

The	O
slow	O
released	O
compound	O
antituberculotic	O
preparation	O
is	O
set	O
or	O
injected	O
into	O
local	O
tuberulosis	O
focus	O
to	O
treat	O
various	O
kinds	O
of	O
intractable	O
tuberulosis	O
,	O
and	O
has	O
less	O
systemic	O
toxicity	O
and	O
unique	O
curative	O
effect	O
.	O

Slow	O
released	O
aminoglycoside	B
antituberculotic	O
preparation	O

The	O
nanometer	O
silver	B
spray	O
for	O
women	O
consists	O
of	O
distilled	O
water	O
,	O
nanometer	O
silver	B
powder	O
,	O
foaming	O
agent	O
,	O
foaming	O
assistant	O
and	O
propellant	O
,	O
and	O
is	O
prepared	O
through	O
dispersing	O
nanometer	O
silver	B
powder	O
into	O
distilled	O
water	O
,	O
adding	O
foaming	O
agent	O
and	O
foaming	O
assistant	O
,	O
filling	O
,	O
and	O
adding	O
propellant	O
.	O

The	O
present	O
invention	O
applies	O
the	O
medicine	O
deeply	O
and	O
makes	O
the	O
medicine	O
foam	O
without	O
flow	O
to	O
maintain	O
long	O
time	O
,	O
and	O
this	O
can	O
prolong	O
the	O
medicine	O
retaining	O
time	O
in	O
the	O
disease	O
focus	O
part	O
to	O
reach	O
high	O
curative	O
effect	O
.	O

The	O
present	O
invention	O
is	O
suitable	O
for	O
use	O
in	O
preventing	O
and	O
treating	O
bacterial	O
,	O
fungal	O
and	O
trichomonad	O
diseases	O
.	O

Nano	O
silver	B
spray	O
for	O
women	O
and	O
its	O
preparing	O
method	O

An	O
antiviral	O
agent	O
is	O
provided	O
which	O
is	O
effective	O
in	O
treating	O
coronaviruses	O
and	O
can	O
be	O
formed	O
into	O
various	O
products	O
whose	O
efficacy	O
sustainability	O
is	O
promising	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
an	O
antiviral	O
agent	O
which	O
is	O
effective	O
in	O
treating	O
a	O
coronavirus	O
,	O
comprising	O
a	O
silver	O
ion	O
carrier	O
;	O
a	O
product	O
capable	O
of	O
inactivating	O
a	O
coronavirus	O
,	O
comprising	O
the	O
same	O
;	O
and	O
a	O
method	O
of	O
inactivating	O
a	O
coronavirus	O
.	O

The	O
silver	O
ion	O
carrier	O
is	O
at	O
least	O
one	O
selected	O
from	O
a	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
1	O
)	O
,	O
potassium	B
titanate	I
,	O
potassium	B
uranate	I
,	O
potassium	B
vanadate	I
,	O
potassium	B
niobate	I
,	O
sodium	B
tangustate	I
,	O
magnesium	B
molybdate	I
,	O
calcium	B
pentaborate	I
,	O
aluminosilicate	B
,	O
aluminum	B
phosphate	I
,	O
nickel	B
hexacyanoferrate	I
,	O
sepiolite	B
,	O
montmorillonite	B
,	O
silica	B
gel	I
,	O
zeolite	B
,	O
-alumina	B
,	O
titanium	B
oxide	I
hydrate	I
,	O
hydroxyapatite	B
and	O
a	O
glassy	O
carrier	O
.	O

AgaAbM2c	O
(	O
PO4	O
)	O
dnH2O	O
(	O
1	O
)	O
.	O

Anti	O
-	O
coronavirus	O
agent	O

A	O
slow	O
-	O
release	O
anticancer	O
injection	O
contains	O
the	O
slow	O
-	O
release	O
microspheres	O
and	O
solvent	O
.	O

Said	O
slow	O
-	O
release	O
microsphere	O
contains	O
the	O
active	O
anticancer	O
component	O
chosen	O
from	O
6	O
Pt	O
compounds	O
including	O
bicycloplatinum	B
,	O
etc	O
and	O
3	O
cytotoxins	O
including	O
antimitotic	O
medicine	O
,	O
anticancer	O
antibiotic	O
,	O
or	O
antimetabolic	O
medicine	O
,	O
and	O
the	O
slow	O
-	O
release	O
auxiliary	O
.	O

Slow	O
-	O
releasing	O
injection	O
contg	O
.	O

platinum	B
compounds	O
and	O
cytotoxin	O
type	O
anticarcinogen	O

A	O
compound	O
desogestrel	B
in	O
the	O
form	O
of	O
dripping	O
pill	O
,	O
capsule	O
or	O
soft	O
capsule	O
is	O
prepared	O
from	O
desogestrel	B
and	O
ethinyl	B
estradiol	I
through	O
proportional	O
mixing	O
or	O
dissolving	O
(	O
or	O
dispersing	O
)	O
in	O
the	O
hydrophilic	O
high	O
-	O
molecular	O
carrier	O
containing	O
non	O
-	O
ionic	O
surfactant	O
,	O
and	O
shaping	O
.	O

Medicine	O
prepn	O
.	O

of	O
compounding	O
deoxypregnene	B
contg	O
.	O

non	O
-	O
ionic	O
surfactant	O

The	O
present	O
invention	O
relates	O
to	O
the	O
polymorphic	O
crystalline	O
hydrochloride	B
salts	O
of	O
a	O
nucleoside	B
valinate	O
ester	O
according	O
to	O
formula	O
Ib	O
,	O
methods	O
of	O
treating	O
diseases	O
mediated	O
by	O
Hepatitis	O
C	O
Virus	O
and	O
pharmaceutical	O
composition	O
containing	O
Ib	O
.	O

Polymorphic	O
antiviral	O
nucleoside	O
compounds	O

The	O
freeze	O
dried	O
levofloxacin	B
mesilate	I
powder	O
for	O
injection	O
consists	O
of	O
levofloxacin	B
mesilate	I
as	O
active	O
component	O
and	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

The	O
preparation	O
process	O
of	O
the	O
freeze	O
dried	O
levofloxacin	B
mesilate	I
powder	O
for	O
injection	O
includes	O
the	O
following	O
steps	O
:	O
dissolving	O
excipient	O
in	O
water	O
for	O
injection	O
,	O
regulating	O
pH	O
value	O
to	O
3.8	O
-	O
4.0	O
,	O
adding	O
injection	O
purpose	O
active	O
carbon	O
and	O
boiling	O
through	O
steam	O
heating	O
,	O
cooling	O
and	O
filtering	O
to	O
eliminating	O
active	O
carbon	O
,	O
adding	O
levofloxacin	B
mesilate	I
,	O
regulating	O
pH	O
value	O
to	O
3.0	O
-	O
4.5	O
,	O
adding	O
water	O
for	O
injection	O
,	O
eliminating	O
pyrogen	O
,	O
filtering	O
,	O
washing	O
,	O
drying	O
,	O
and	O
freeze	O
drying	O
to	O
obtain	O
the	O
freeze	O
dried	O
levofloxacin	B
mesilate	I
powder	O
for	O
injection	O
.	O

Or	O
,	O
The	O
preparation	O
process	O
includes	O
the	O
following	O
steps	O
:	O
dissolving	O
excipient	O
and	O
levofloxacin	B
mesilate	I
in	O
water	O
for	O
injection	O
,	O
regulating	O
pH	O
value	O
to	O
3.0	O
-	O
4.5	O
,	O
eliminating	O
pyrogen	O
,	O
filtering	O
,	O
washing	O
,	O
drying	O
,	O
and	O
freeze	O
drying	O
to	O
obtain	O
the	O
freeze	O
dried	O
levofloxacin	B
mesilate	I
powder	O
for	O
injection	O
.	O

The	O
present	O
invention	O
has	O
high	O
stability	O
and	O
use	O
convenience	O
.	O

Lyophilized	O
powder	O
injection	O
of	O
levofloxacin	B
mesylate	I
and	O
preparation	O
method	O
thereof	O

A	O
slow	O
-	O
release	O
anticancer	O
injection	O
is	O
composed	O
of	O
the	O
slow	O
-	O
release	O
microballs	O
containing	O
active	O
component	O
and	O
slow	O
-	O
releasing	O
auxiliary	O
and	O
the	O
special	O
solvent	O
containing	O
the	O
suspending	O
aid	O
.	O

Said	O
active	O
component	O
is	O
the	O
combination	O
of	O
Pt	O
compound	O
chosen	O
from	O
dicycloplatinum	O
,	O
etc	O
and	O
the	O
anticancer	O
hormone	O
and/or	O
vascular	O
inhibitor	O
.	O

Said	O
slow	O
-	O
releasing	O
auxiliary	O
is	O
chosen	O
from	O
polylactic	O
acid	O
or	O
its	O
copolymer	O
,	O
monoethyl	O
polyethanediol	O
or	O
its	O
copolymer	O
,	O
EVAc	O
,	O
etc	O
.	O

Anticancer	O
slow	O
-	O
release	O
injection	O
contg	O
.	O

platinum	O
compounds	O

A	O
nano	O
-	O
class	O
suspension	O
injection	O
of	O
oxaliplatin	B
-	I
phoshpatide	I
composition	O
for	O
intravenous	O
injection	O
is	O
proportionally	O
prepared	O
from	O
oxaliplatin	B
,	O
surfactant	O
,	O
pH	O
regulator	O
,	O
isotonic	O
agent	O
,	O
antioxidant	O
,	O
water	O
for	O
injection	O
,	O
and	O
optional	O
excipient	O
(	O
for	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
)	O
.	O

Intravenous	O
nanometer	O
suspension	O
injection	O
contg	O
.	O

oxaliplatin	B
platinum	I
phospholipid	I
compound	O

The	O
instant	O
invention	O
provides	O
novel	O
cholesterol	B
absorption	O
inhibitors	O
of	O
Formula	O
I	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	B
thereof	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
lowering	O
plasma	O
cholesterol	B
levels	O
,	O
particularly	O
LDL	O
cholesterol	B
,	O
and	O
for	O
treating	O
and	O
preventing	O
atherosclerosis	O
and	O
atherosclerotic	O
disease	O
events	O
.	O

2-azetidinones	B
as	O
anti	O
-	O
hypercholesterolemic	O
agents	O

A	O
nano	O
-	O
emulsion	O
injection	O
of	O
prostaglandin	B
E1	I
contains	O
the	O
nano	O
-	O
emulsion	O
particles	O
of	O
rostaglandin	B
E1	I
,	O
the	O
oil	O
for	O
injection	O
,	O
hydrophilic	O
emulsifier	O
,	O
lipophilic	O
emulsifier	O
,	O
isotonic	O
agent	O
,	O
and	O
stabilizer	O
.	O

Its	O
preparing	O
process	O
and	O
its	O
quality	O
control	O
method	O
are	O
also	O
disclosed	O
.	O

Nano	O
emulsion	O
injection	O
of	O
alprostadil	B
and	O
preparation	O
method	O

A	O
Chinese	O
-	O
medicinal	O
erosion	O
-	O
eliminating	O
lotion	O
is	O
prepared	O
from	O
7	O
Chinese	O
-	O
medicinal	O
materials	O
including	O
ginseng	O
,	O
arnebia	O
root	O
,	O
baked	O
alum	O
,	O
borneol	B
,	O
etc	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Solution	O
agent	O
for	O
eliminating	O
erosion	O
,	O
and	O
preparation	O
method	O

This	O
invention	O
relates	O
to	O
a	O
purine	B
derivative	O
whose	O
chemical	O
formula	O
is	O
shown	O
in	O
Formula	O
II	O
,	O
wherein	O
M	O
is	O
medically	O
acceptable	O
anion	O
of	O
acid	O
groups	O
.	O

This	O
invention	O
also	O
relates	O
to	O
the	O
method	O
for	O
preparing	O
the	O
compound	O
,	O
drug	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
its	O
application	O
in	O
treating	O
hepatitis	O
B	O
infection	O
and/or	O
its	O
complicated	O
infections	O
.	O

Derivative	O
of	O
purine	B

Disclosed	O
is	O
a	O
process	O
for	O
preparing	O
tannic	B
acid	I
sophocarpidine	I
dispersion	O
tablet	O
,	O
wherein	O
the	O
auxiliary	O
materials	O
include	O
polyvidon	O
K3O	O
,	O
crosslinked	O
povidone	O
,	O
polyvinyl	B
alcohol	I
,	O
NaHCO3	B
,	O
NaCO3	B
,	O
ethanolamine	B
,	O
sodium	B
dodecylsulfate	I
,	O
crystalline	O
cellulose	O
,	O
and	O
sodium	O
carboxymethylstarch	O
.	O

The	O
obtained	O
tablet	O
has	O
good	O
dispersity	O
.	O

Method	O
for	O
preparing	O
dispersible	O
tablet	O
of	O
sophora	O
alkaloids	B
tannate	I

The	O
invention	O
discloses	O
an	O
adhesive	O
plaster	O
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
plaster	O
comprises	O
the	O
following	O
raw	O
materials	O
(	O
by	O
weight	O
portion	O
)	O
:	O
45	O
-	O
55	O
parts	O
of	O
tortoise	O
shells	O
,	O
35	O
-	O
45	O
parts	O
of	O
Sichuan	O
aconite	O
root	O
and	O
dragon	O
's	O
blood	O
resin	O
,	O
26	O
-	O
34	O
parts	O
of	O
Kusnezoff	O
monkshood	O
root	O
,	O
achyranthes	O
and	O
cyathula	O
root	O
,	O
frankincense	O
,	O
black	O
catechu	O
,	O
eucommia	O
bark	O
and	O
ledebouriella	O
root	O
,	O
21	O
-	O
29	O
parts	O
of	O
levisticum	O
,	O
momordica	O
seed	O
and	O
carbonized	O
hair	O
,	O
16	O
-	O
24	O
parts	O
of	O
prepared	O
aconite	O
root	O
,	O
tangerine	O
peel	O
and	O
red	O
lead	O
,	O
11	O
-	O
19	O
parts	O
of	O
centipede	O
,	O
1800	O
-	O
1950	O
parts	O
of	O
sesame	O
oil	O
.	O

The	O
plaster	O
can	O
also	O
comprise	O
lead	O
powder	O
,	O
zedoary	O
,	O
safflower	O
,	O
Chinese	O
flowering	O
quince	O
,	O
notopterygium	O
root	O
,	O
Chinese	O
angelica	O
root	O
,	O
pangolin	O
scales	O
,	O
buthus	O
martensi	O
kirsch	O
,	O
burred	O
tuber	O
,	O
myrrh	O
,	O
turtle	O
shell	O
,	O
speranskia	O
herb	O
,	O
pagodatree	O
branch	O
,	O
licorice	O
root	O
,	O
calomel	O
,	O
Cinnamomum	O
cassia	O
,	O
Schizonepeta	O
tenuifolia	O
,	O
asafetida	O
,	O
bee	O
wax	O
and	O
wood	O
louse	O
.	O

A	O
medicinal	O
plaster	O
and	O
method	O
for	O
making	O
same	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
arctiin	O
in	O
preparing	O
anti	O
-	O
inflammatory	O
medicament	O
,	O
more	O
specifically	O
to	O
the	O
use	O
in	O
preparing	O
medicament	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
infectious	O
or	O
non	O
-	O
infectious	O
inflammations	O
caused	O
by	O
various	O
reasons	O
.	O

The	O
preferred	O
administration	O
mode	O
is	O
oral	O
administration	O
.	O

Use	O
of	O
actiin	O
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
drug	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
fowl	O
infectious	O
laryngotracheitis	O
prepared	O
from	O
the	O
following	O
constituents	O
(	O
by	O
weight	O
proportions	O
)	O
:	O
natural	O
indigo	O
1	O
-	O
6	O
parts	O
,	O
coptis	O
root	O
1	O
-	O
4	O
parts	O
,	O
yellow	O
corktree	O
bark	O
1	O
-	O
2	O
part	O
,	O
allume	O
1	O
-	O
3	O
parts	O
,	O
peppermint	O
1	O
-	O
3	O
parts	O
,	O
root	O
of	O
balloonflower	O
1	O
-	O
5	O
parts	O
,	O
black	O
catechu	O
1	O
-	O
4	O
parts	O
.	O

Medicament	O
for	O
treating	O
poultry	O
infectious	O
laryngotracheitis	O

Disclosed	O
is	O
a	O
medicinal	O
liquid	O
for	O
treating	O
body	O
odor	O
,	O
which	O
is	O
prepared	O
from	O
raw	O
materials	O
including	O
sweet	O
basil	O
,	O
orpiment	O
,	O
goldthread	O
root	O
,	O
fresh	O
ginger	O
,	O
perfume	O
compound	O
and	O
ethanol	B
.	O

The	O
medicament	O
has	O
non	O
-	O
irritating	O
property	O
,	O
and	O
no	O
side	O
effects	O
are	O
found	O
.	O

Dew	O
for	O
treating	O
tragomaschalia	O

The	O
invention	O
discloses	O
a	O
Minocycline	B
hydrochloride	I
chitosan	O
microsphere	O
and	O
the	O
process	O
for	O
preparing	O
the	O
microsphere	O
.	O

The	O
prepared	O
microsphere	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
oral	O
diseases	O
such	O
as	O
periodontitis	O
.	O

Preparation	O
method	O
of	O
minocycline	B
hydrochloride	I
chitosan	O
microsphere	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
granules	O
for	O
benefiting	O
liver	O
,	O
promoting	O
blood	O
circulation	O
and	O
improving	O
acuity	O
of	O
vision	O
,	O
which	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
:	O
gypsum	B
rubrum	O
90	O
-	O
130	O
g	O
,	O
iron	B
powder	O
60	O
-	O
90	O
g	O
,	O
aragonite	B
60	O
-	O
90	O
g	O
,	O
cane	O
sugar	B
300	O
-	O
500	O
g	O
,	O
tabasheer	O
,	O
safflower	O
,	O
clove	O
,	O
chebula	O
fruit	O
,	O
belleric	O
terminalia	O
fruit	O
,	O
emblic	O
leafflower	O
fruit	O
,	O
licorice	O
root	O
,	O
multibanded	O
krait	O
,	O
Epuisetum	O
hiemale	O
,	O
caraway	O
seeds	O
,	O
Meconopsis	O
integrifolia	O
,	O
and	O
Mumiyah	O
-	O
asil	O
each	O
20	O
-	O
40	O
g	O
.	O

Liver	O
-	O
benefiting	O
blood	O
circulation	O
-	O
activating	O
eyesight	O
-	O
improving	O
granule	O

The	O
invention	O
provides	O
a	O
modified	O
diet	O
fiber	O
,	O
which	O
is	O
characterized	O
in	O
that	O
it	O
comprises	O
reactant	O
of	O
monosaccharide	B
and	O
/	O
or	O
diose	B
with	O
modifier	O
,	O
and	O
said	O
modifier	O
possesses	O
function	O
group	O
that	O
can	O
react	O
with	O
hydroxyl	B
group	O
.	O

The	O
invention	O
also	O
relates	O
to	O
application	O
of	O
modified	O
diet	O
fiber	O
in	O
preparing	O
fat	O
-	O
reducing	O
drug	O
or	O
health	O
care	O
drug	O
,	O
and	O
the	O
method	O
for	O
preparing	O
modified	O
fiber	O
.	O

The	O
diet	O
fiber	O
in	O
this	O
invention	O
can	O
be	O
prepared	O
with	O
current	O
normal	O
process	O
and	O
realizes	O
industrialization	O
.	O

The	O
invention	O
enlarges	O
application	O
range	O
for	O
monosaccharide	B
and	O
diose	B
.	O

Modified	O
glycose	B
/	O
biose	B
as	O
meal	O
fiber	O
and	O
fat	O
-	O
reducing	O
product	O

The	O
present	O
invention	O
discloses	O
preparation	O
process	O
of	O
influenza	O
treating	O
Julan	O
granule	O
.	O

The	O
recipe	O
of	O
the	O
influenza	O
treating	O
Julan	O
granule	O
includes	O
wild	O
chrysanthemum	O
flower	O
,	O
isatis	O
root	O
,	O
artificial	O
bezoar	O
,	O
aspirin	B
and	O
concentrated	O
buffalo	O
horn	O
powder	O
.	O

The	O
preparation	O
process	O
of	O
influenza	O
treating	O
Julan	O
granule	O
includes	O
the	O
following	O
steps	O
:	O
grinding	O
artificial	O
bezoar	O
,	O
aspirin	B
and	O
concentrated	O
buffalo	O
horn	O
powder	O
separately	O
;	O
ethanol	B
refluxing	O
wild	O
chrysanthemum	O
flower	O
and	O
concentrating	O
to	O
obtain	O
concentrated	O
liquid	O
;	O
ethanol	B
refluxing	O
isatis	O
root	O
and	O
concentrating	O
to	O
obtain	O
concentrated	O
liquid	O
;	O
mixing	O
the	O
concentrated	O
liquid	O
and	O
powder	O
as	O
well	O
as	O
stevioside	O
in	O
certain	O
weight	O
proportion	O
;	O
pelletizing	O
and	O
drying	O
.	O

The	O
present	O
invention	O
also	O
provides	O
the	O
quality	O
control	O
technology	O
.	O

The	O
medicine	O
has	O
effect	O
of	O
clearing	O
away	O
heat	O
and	O
toxic	O
material	O
.	O

Prepn	O
process	O
of	O
influenza	O
treating	O
Julan	O
granule	O
and	O
its	O
quality	O
control	O
technology	O

The	O
present	O
invention	O
relates	O
to	O
one	O
kind	O
of	O
Tiopronin	B
amidate	I
for	O
treating	O
acute	O
and	O
chronic	O
hepatosis	O
and	O
its	O
preparation	O
process	O
.	O

The	O
general	O
expression	O
of	O
Tiopronin	B
amidate	I
is	O
shown	O
.	O

The	O
present	O
invention	O
changes	O
Tiopronin	B
with	O
easy	O
oxidation	O
,	O
degradation	O
,	O
volatilation	O
and	O
decomposition	O
into	O
stable	O
Tiopronin	B
amidate	I
with	O
raised	O
smelting	O
point	O
and	O
raised	O
medicinal	O
effect	O
.	O

The	O
Tiopronin	B
amidate	I
may	O
be	O
further	O
used	O
to	O
prepare	O
other	O
medicine	O
preparation	O
.	O

Tiopronin	B
amidate	I
and	O
its	O
prepn	O

The	O
present	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
injection	O
curcumin	O
freeze	O
-	O
dried	O
liposome	O
.	O

Its	O
prescription	O
is	O
composed	O
of	O
curcumin	B
,	O
phospholipids	B
,	O
emulsifier	O
,	O
proppant	O
,	O
antioxidant	O
,	O
pH	O
regulating	O
agent	O
and	O
injection	O
water	O
.	O

Its	O
preparation	O
method	O
includes	O
the	O
following	O
steps	O
:	O
using	O
organic	O
solvent	O
to	O
dissolve	O
the	O
above	O
-	O
mentioned	O
medicinal	O
material	O
,	O
evaporation	O
,	O
emulsification	O
,	O
pH	O
regulation	O
,	O
filtration	O
,	O
filling	O
,	O
freeze	O
-	O
drying	O
and	O
packaging	O
so	O
as	O
to	O
obtain	O
the	O
invented	O
product	O
.	O

Method	O
for	O
preparing	O
curcumin	B
lyophilized	O
liposome	O

An	O
activator	O
capsule	O
as	O
a	O
health	O
-	O
care	O
product	O
is	O
proportionally	O
prepared	O
from	O
high	O
-	O
purity	O
(	O
more	O
than	O
99	O
%	O
)	O
docosanol	B
,	O
VE	B
,	O
beta	B
-	I
carotene	I
,	O
lycopene	B
and	O
starch	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Archaeus	O
-	O
agent	O
capsules	O
and	O
production	O
thereof	O

A	O
Chinese	O
veterinary	O
medicine	O
in	O
the	O
form	O
of	O
oral	O
liquid	O
for	O
treating	O
the	O
diseases	O
in	O
respiratory	O
tract	O
of	O
fowls	O
is	O
prepared	O
from	O
alcohol	B
and	O
8	O
Chinese	O
-	O
medicinal	O
materials	O
including	O
isatis	O
root	O
,	O
bezoar	O
,	O
toad	O
venom	O
,	O
natural	O
indigo	O
,	O
etc	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Oral	O
liquid	O
for	O
treating	O
fowl	O
upper	O
disease	O
and	O
its	O
preparation	O

A	O
fowl	O
Chinese	O
-	O
medicinal	O
powder	O
for	O
nourishing	O
kidney	O
and	O
protecting	O
liver	O
relates	O
to	O
a	O
fowl	O
Chinese	O
-	O
medicinal	O
powder	O
,	O
and	O
is	O
especially	O
suitable	O
for	O
preventing	O
and	O
treating	O
the	O
renal	O
swelling	O
and	O
hepatitis	O
of	O
domestic	O
fowls	O
is	O
prepared	O
from	O
7	O
Chinese	O
-	O
medicinal	O
materials	O
including	O
,	O
by	O
weight	O
,	O
5	O
-	O
20	O
parts	O
of	O
rhubarb	O
,	O
5	O
-	O
20	O
parts	O
of	O
burreed	O
tuber	O
,	O
10	O
-	O
30	O
parts	O
of	O
long	O
tube	O
ground	O
ivy	O
herb	O
,	O
5	O
-	O
15	O
parts	O
of	O
hiraute	O
shiny	O
bugleweek	O
herb	O
,	O
5	O
-	O
15	O
parts	O
of	O
danshen	O
root	O
,	O
5	O
-	O
15	O
parts	O
of	O
borax	B
and	O
10	O
-	O
30	O
parts	O
of	O
tiger	O
stick	O
through	O
checking	O
,	O
washing	O
,	O
drying	O
,	O
pulverizing	O
by	O
grinder	O
,	O
sieving	O
to	O
reach	O
the	O
demand	O
of	O
particle	O
size	O
20	O
-	O
300	O
of	O
the	O
end	O
product	O
,	O
and	O
proportionally	O
and	O
uniformly	O
mixing	O
according	O
to	O
above	O
proportion	O
to	O
obtain	O
the	O
particle	O
size	O
20	O
-	O
300	O
khaki	O
powder	O
end	O
product	O
which	O
is	O
nice	O
on	O
smell	O
and	O
bitter	O
on	O
taste	O
.	O

The	O
invention	O
can	O
get	O
an	O
effect	O
of	O
preventing	O
and	O
treating	O
the	O
renal	O
swelling	O
and	O
hepatitis	O
of	O
domestic	O
fowls	O
.	O

The	O
invention	O
can	O
improve	O
the	O
resistance	O
ability	O
of	O
fowls	O
and	O
has	O
better	O
treatment	O
and	O
remission	O
effect	O
for	O
renal	O
swelling	O
and	O
kidney	O
disease	O
evocated	O
by	O
a	O
plurality	O
of	O
diseases	O
to	O
achieve	O
an	O
aim	O
of	O
nourishing	O
kidney	O
and	O
protecting	O
liver	O
.	O

Chinese	O
-	O
medicinal	O
powder	O
for	O
nourishing	O
kidney	O
of	O
fowl	O

The	O
present	O
invention	O
discloses	O
a	O
kind	O
of	O
medicinal	O
superfine	O
capsaicine	B
microcapsule	O
and	O
its	O
preparation	O
process	O
.	O

The	O
preparation	O
process	O
includes	O
the	O
following	O
steps	O
:	O
1	O
.	O
compounding	O
gelatin	O
aqua	O
,	O
swelling	O
and	O
heating	O
to	O
40	O
-	O
50deg.c	O
;	O
2	O
.	O
adding	O
capsaicine	B
and	O
water	O
solution	O
of	O
polyoxyethylene	B
and	O
sorbitol	B
oleate	I
through	O
stirring	O
;	O
3	O
.	O
adding	O
coagulant	O
to	O
react	O
and	O
cooling	O
;	O
4	O
.	O
adding	O
water	O
solution	O
of	O
glutaraldehyde	B
for	O
crosslinking	O
solidification	O
;	O
and	O
5	O
.	O
water	O
washing	O
the	O
product	O
of	O
the	O
step	O
4	O
,	O
dropping	O
water	O
solution	O
of	O
tannic	B
acid	I
and	O
collecting	O
the	O
medicinal	O
superfine	O
capsaicine	B
microcapsule	O
.	O

The	O
microcapsule	O
has	O
homogeneous	O
and	O
controllable	O
particle	O
size	O
of	O
100	O
-	O
300	O
nm	O
,	O
and	O
may	O
be	O
used	O
widely	O
in	O
medicine	O
,	O
health	O
product	O
,	O
food	O
,	O
etc	O
.	O

Medical	O
super	O
fire	O
micro	O
capsule	O
capsaicine	B
and	O
its	O
preparing	O
method	O

The	O
present	O
invention	O
is	O
a	O
kind	O
of	O
norcantharidimde	B
complex	O
of	O
organic	O
plantinum	B
,	O
and	O
the	O
norcantharidimde	O
complex	O
includes	O
four	O
kinds	O
of	O
compounds	O
.	O

The	O
norcantharidimde	B
complex	O
possesses	O
anticancer	O
effect	O
,	O
and	O
the	O
medicinal	O
composition	O
containing	O
the	O
norcantharidimde	B
complex	O
may	O
be	O
used	O
in	O
treating	O
lung	O
cancer	O
,	O
liver	O
cancer	O
,	O
mammary	O
cancer	O
,	O
colon	O
cancer	O
,	O
leukemia	O
,	O
etc	O
and	O
may	O
be	O
prepared	O
into	O
different	O
preparation	O
forms	O
,	O
such	O
as	O
tablet	O
,	O
granule	O
,	O
injection	O
,	O
etc	O
.	O

Organic	O
platinum	B
new	O
complex	O

A	O
fast	O
-	O
release	O
enteric	O
tablet	O
containing	O
aconitine	B
is	O
proportionally	O
prepared	O
from	O
aconitine	B
-	O
type	O
medicine	O
,	O
fast	O
-	O
releasing	O
additive	O
,	O
enteric	O
polymer	O
,	O
plasticizer	O
and	O
solvent	O
through	O
superfine	O
pulverizing	O
,	O
mixing	O
,	O
tabletting	O
and	O
coating	O
.	O

Enteric	O
quick	O
-	O
dissolving	O
tablets	O
contg	O
.	O

aconitine	B
,	O
and	O
its	O
prepn	O
.	O

method	O

An	O
application	O
of	O
artesunate	B
in	O
preparing	O
the	O
medicines	O
for	O
preventing	O
and	O
treating	O
the	O
hepatic	O
fibrosis	O
and	O
preventing	O
heptocirrhosis	O
and	O
liver	O
cancer	O
is	O
disclosed	O
.	O

Application	O
of	O
artesunate	B
for	O
preparing	O
medicine	O
to	O
treat	O
fibrosis	O
of	O
liver	O

An	O
oral	O
liquid	O
of	O
citalopram	B
hydrobromate	I
is	O
proportionally	O
prepared	O
from	O
citalopram	B
hydrobromate	I
,	O
sweetening	O
agent	O
,	O
plasticizer	O
,	O
antiseptic	O
,	O
aromatic	B
and	O
solvent	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Oral	O
liquor	O
contg	O
.	O

citalopram	B
hydrobromide	I
and	O
its	O
prepn	O
.	O

method	O

An	O
oral	O
disintegrating	O
tablet	O
of	O
propagermanium	O
for	O
treating	O
chronic	O
hepatitis	O
is	O
proportionally	O
prepared	O
from	O
propagermanium	O
,	O
filler	O
,	O
disintegrant	O
,	O
flavouring	O
and	O
lubricant	O
through	O
sieving	O
,	O
mixing	O
,	O
stirring	O
,	O
and	O
tabletting	O
.	O

Oral	O
disintegration	O
tablets	O
of	O
Bingpazhe	O
germanium	O
for	O
treating	O
chronic	O
hepatitis	O
and	O
its	O
making	O
method	O

A	O
compound	O
injection	O
contains	O
ticarcillin	B
sodium	I
and	O
sulbactam	B
sodium	I
in	O
weight	O
ratio	O
of	O
(	O
1	O
-	O
8	O
)	O
:	O
1	O
.	O

Compounding	O
injection	O
contg	O
.	O

Ticarcillin	B
Disodium	I
and	O
Sulbactam	B

An	O
application	O
of	O
doxycycline	O
in	O
promoting	O
the	O
reproduction	O
of	O
cells	O
,	O
such	O
as	O
the	O
cells	O
MTEC1	O
,	O
TEC1C8	O
,	O
TNC	O
-	O
R3.1	O
,	O
HEK293	O
,	O
CTX-3	O
,	O
etc	O
,	O
is	O
disclosed	O
.	O

Application	O
of	O
doxycycline	O
ad	O
medicine	O
for	O
promoting	O
cell	O
proliferation	O

The	O
present	O
invention	O
discloses	O
one	O
new	O
kind	O
of	O
podophyllic	O
compound	O
and	O
its	O
use	O
and	O
preparation	O
process	O
.	O

Podophyllum	O
kind	O
compound	O
and	O
its	O
use	O

A	O
composite	O
medicine	O
for	O
treating	O
gout	O
with	O
high	O
safety	O
is	O
proportionally	O
prepared	O
from	O
olsapozine	B
or	O
ketoprofen	B
and	O
phellodendron	O
bark	O
.	O

Composition	O
for	O
treating	O
gout	O

A	O
general	O
flavone	B
of	O
lilac	O
daphne	O
root	O
is	O
prepared	O
from	O
lilac	O
daphne	O
root	O
through	O
breaking	O
,	O
proportionally	O
mixing	O
it	O
with	O
alcohol	B
,	O
extracting	O
at	O
40	O
-	O
70	O
deg	O
.	O

C	O
for	O
12	O
-	O
48	O
hr	O
,	O
removing	O
deposit	O
,	O
adsorbing	O
by	O
macroreticular	O
resin	O
,	O
water	O
washing	O
,	O
eluting	O
with	O
alcohol	B
,	O
vacuum	O
distilling	O
,	O
passing	O
through	O
silicon	B
gel	I
column	O
,	O
eluting	O
with	O
the	O
mixture	O
of	O
chloroform	B
and	O
methanol	B
,	O
and	O
concentrating	O
.	O

It	O
can	O
be	O
used	O
to	O
prepare	O
the	O
medicines	O
for	O
preventing	O
and	O
treating	O
the	O
sexual	O
tumor	O
.	O

General	O
flavone	B
of	O
root	O
of	O
lilac	O
daphne	O
,	O
method	O
of	O
extraction	O
,	O
and	O
application	O

The	O
invention	O
relates	O
to	O
a	O
pilocarpine	B
nitrate	I
dispersible	O
tablet	O
and	O
method	O
for	O
preparation	O
,	O
wherein	O
the	O
dispersible	O
tablet	O
comprises	O
the	O
following	O
constituents	O
(	O
by	O
weight	O
ratio	O
)	O
:	O
pilocarpine	B
nitrate	I
0.5	O
-	O
5	O
parts	O
,	O
filling	O
agent	O
50	O
-	O
185	O
parts	O
,	O
crumbling	O
agent	O
20	O
-	O
140	O
parts	O
,	O
lubricant	O
0.2	O
-	O
5	O
parts	O
.	O

Pilocarpine	B
nitrate	I
dispersible	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
20	B
(	I
S	I
)	I
-protopanaxadiol	I
glycosylated	O
derivative	O
and	O
preparing	O
method	O
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
adopting	O
20	B
(	I
S	I
)	I
-protopanaxadiol	I
as	O
3-positional	O
and	O
12-positional	O
mother	O
core	O
to	O
be	O
glycosylated	O
;	O
possessing	O
excellent	O
antineoplastic	O
effect	O
.	O

20	B
(	I
s	I
)	I
-protopanaxadiol	I
glycosylated	O
derivative	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
eye	O
drops	O
,	O
which	O
comprises	O
phthiobuzonum	O
at	O
1	O
-	O
1200	O
deals	O
,	O
soda	O
glass	O
at	O
1	O
-	O
1200	O
deals	O
,	O
osmoregulation	O
adjuster	O
at	O
100	O
-	O
3000	O
deals	O
,	O
and	O
carrier	O
.	O

Wherein	O
,	O
the	O
pH	O
value	O
of	O
it	O
is	O
4.0	O
-	O
7.5	O
.	O

The	O
invention	O
can	O
avoid	O
overflow	O
,	O
keep	O
drug	O
on	O
needed	O
part	O
,	O
and	O
humidify	O
cornea	O
.	O

Phthiobuzonum	O
eye	O
drops	O
containing	O
sodium	B
hyaluronate	I
and	O
its	O
preparing	O
process	O

Disclosed	O
is	O
an	O
anticancer	O
slow	O
release	O
injection	O
containing	O
tetrazole	B
Ionone	I
and	O
cytotoxic	O
drugs	O
,	O
which	O
comprises	O
slow	O
release	O
micro	O
-	O
balloons	O
and	O
dissolvent	O
,	O
wherein	O
the	O
slow	O
release	O
microballoons	O
comprise	O
anti	O
-	O
cancer	O
active	O
constituents	O
and	O
slow	O
release	O
auxiliary	O
materials	O
,	O
the	O
dissolvent	O
being	O
specific	O
dissolvent	O
containing	O
suspension	O
adjuvant	O
.	O

The	O
anticancer	O
active	O
constituents	O
include	O
tetrazole	B
lonone	I
and	O
cytotoxic	O
drugs	O
selected	O
from	O
docetaxel	B
,	O
Fotemustine	B
,	O
alkylating	O
agent	O
,	O
Topo	O
enzyme	O
inhibitor	O
and/or	O
plant	O
alkaloid	B
,	O
the	O
slow	O
release	O
auxiliary	O
materials	O
include	O
polylactic	B
acid	I
and	O
glycollic	B
acid	I
copolymer	O
,	O
polyethylene	B
glycol	I
and	O
polylactic	B
acid	I
copolymer	O
,	O
PLA	B
-	I
COOH	I
copolymer	O
,	O
EVAc	B
,	O
aliphatic	B
acid	I
and	O
sebacylic	B
acid	I
copolymer	O
,	O
the	O
viscosity	O
of	O
the	O
suspension	O
adjuvant	O
is	O
100	O
-	O
3000cp	O
(	O
at	O
25	O
-	O
30	O
deg	O
C	O
)	O
,	O
and	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose	O
.	O

The	O
slow	O
release	O
microspheres	O
can	O
also	O
be	O
prepared	O
into	O
slow	O
release	O
implanting	O
agent	O
for	O
injection	O
or	O
placement	O
in	O
or	O
around	O
tumor	O
with	O
the	O
effects	O
of	O
lowering	O
general	O
reaction	O
of	O
drugs	O
,	O
selectively	O
increasing	O
and	O
maintaining	O
local	O
concentration	O
to	O
around	O
30	O
-	O
50	O
days	O
,	O
as	O
a	O
result	O
,	O
the	O
injection	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
tumor	O
independently	O
,	O
and	O
has	O
the	O
functions	O
of	O
improving	O
the	O
treatment	O
effect	O
of	O
the	O
non	O
-	O
operative	O
methods	O
such	O
as	O
chemotherapy	O
and/or	O
radiotheraphy	O
.	O

Anticancer	O
slow	O
release	O
comprising	O
tetrazole	B
violet	I
and	O
cytotoxic	O
drug	O

The	O
invention	O
discloses	O
an	O
externally	O
-	O
used	O
medicament	O
for	O
the	O
treatment	O
of	O
burns	O
,	O
bedsore	O
and	O
chronic	O
ulcer	O
,	O
as	O
well	O
as	O
the	O
process	O
for	O
preparation	O
,	O
the	O
medicament	O
is	O
prepared	O
from	O
the	O
following	O
medicinal	O
herbs	O
:	O
Chinese	O
angelica	O
root	O
30	O
-	O
80	O
parts	O
,	O
coptis	O
root	O
30	O
-	O
180	O
parts	O
,	O
garden	O
burnet	O
root	O
30	O
-	O
120	O
parts	O
,	O
giant	O
knotweed	O
rhizome	O
30	O
-	O
90	O
parts	O
,	O
rheum	O
officinale	O
30	O
-	O
90	O
parts	O
,	O
borneol	B
30	O
-	O
90	O
parts	O
,	O
emollient	O
30	O
-	O
90	O
parts	O
and	O
water	O
3000	O
-	O
5000	O
parts	O
.	O

External	O
use	O
drug	O
for	O
treating	O
burn	O
,	O
bedsore	O
,	O
chronic	O
ulcer	O
and	O
etc	O
.	O
and	O
preparation	O
method	O
thereof	O

The	O
nanometer	O
emulsion	O
oral	O
liquid	O
of	O
andrographolide	B
consists	O
of	O
surfactant	O
,	O
oil	O
,	O
andrographolide	B
and	O
distilled	O
water	O
.	O

Its	O
preparation	O
process	O
includes	O
the	O
following	O
steps	O
:	O
weighing	O
surfactant	O
with	O
or	O
without	O
co	O
-	O
surfactant	O
;	O
calculating	O
HLB	O
value	O
and	O
selecting	O
oil	O
for	O
reaching	O
emulsifying	O
HLB	O
value	O
near	O
that	O
of	O
the	O
surfactant	O
phase	O
;	O
changing	O
the	O
ratio	O
between	O
the	O
surfactant	O
phase	O
and	O
the	O
oil	O
phase	O
regularly	O
to	O
dissolve	O
andrographolide	B
in	O
the	O
surfactant	O
;	O
adding	O
distilled	O
water	O
slowly	O
at	O
20	O
-	O
25	O
deg.c	O
to	O
form	O
clear	O
and	O
flowing	O
O	O
/	O
W	O
type	O
stable	O
nanometer	O
emulsion	O
oral	O
liquid	O
.	O

The	O
nanometer	O
emulsion	O
oral	O
liquid	O
has	O
high	O
dissolubility	O
of	O
andrographolide	B
,	O
raised	O
bioavailability	O
of	O
andrographolide	O
,	O
less	O
stimulation	O
to	O
gastrointestinal	O
tract	O
and	O
raised	O
patient	O
's	O
compliance	O
,	O
and	O
may	O
be	O
also	O
taken	O
easily	O
by	O
children	O
and	O
persons	O
with	O
dysphagia	O
.	O

Nanometer	O
emulsion	O
oral	O
liquid	O
of	O
andrographolide	B
and	O
its	O
prepn	O
process	O

The	O
slow	O
released	O
tolterodine	B
tartate	I
microcapsule	O
preparation	O
with	O
homogeneous	O
medicine	O
release	O
is	O
one	O
kind	O
of	O
slow	O
release	O
capsule	O
with	O
slow	O
released	O
microcapsule	O
as	O
main	O
component	O
,	O
and	O
the	O
slow	O
released	O
microcapsule	O
contains	O
tolterodine	B
tartate	I
as	O
the	O
active	O
component	O
,	O
slow	O
releasing	O
material	O
and	O
medicinal	O
supplementary	O
material	O
in	O
the	O
weight	O
ratio	O
of	O
1	O
-	O
5	O
to	O
1	O
-	O
30	O
to	O
100	O
-	O
380	O
.	O

The	O
preparation	O
process	O
of	O
the	O
slow	O
released	O
microcapsule	O
includes	O
the	O
steps	O
of	O
mixing	O
the	O
main	O
medicine	O
component	O
and	O
the	O
supplementary	O
material	O
,	O
preparing	O
the	O
mixture	O
into	O
soft	O
material	O
,	O
extruding	O
and	O
rounding	O
.	O

The	O
slow	O
released	O
preparation	O
can	O
prolong	O
the	O
in	O
vivo	O
residence	O
time	O
of	O
medicine	O
,	O
control	O
the	O
release	O
of	O
medicine	O
,	O
reduce	O
medicine	O
-taking	O
times	O
,	O
lower	O
the	O
toxic	O
side	O
effect	O
and	O
raise	O
curative	O
effect	O
.	O

Slow	O
released	O
tolterodine	B
tartrate	I
microcapsule	O
and	O
its	O
prepn	O
process	O

The	O
present	O
invention	O
relates	O
to	O
active	O
dextran	O
tetrasaccharide	O
alkyl	O
glycoside	O
compound	O
with	O
the	O
structure	O
as	O
shown	O
in	O
the	O
generation	O
expression	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
process	O
and	O
application	O
in	O
preparing	O
antitumor	O
medicine	O
of	O
the	O
compound	O
.	O

Active	O
dextran	O
tetra	O
saccharide	O
alkyl	O
glycoside	O
and	O
its	O
prepn	O
process	O
and	O
application	O

A	O
composite	O
collagen	O
liquid	O
for	O
treating	O
skin	O
anaphylactin	O
contains	O
proportionally	O
the	O
collagen	O
extracted	O
from	O
the	O
tendon	O
of	O
ox	O
or	O
pig	O
,	O
the	O
vitamin	O
which	O
is	O
the	O
VC	B
including	O
VC	B
magnesium	I
phosphate	I
,	O
levo	B
-	I
VC	I
and	O
VC	B
glycoside	I
,	O
and	O
purified	O
water	O
.	O

Composite	O
collagen	O
protein	O
liquid	O

A	O
medicinal	O
composition	O
used	O
for	O
preparing	O
the	O
medicines	O
to	O
prevent	O
and	O
treat	O
hyperglycemia	O
,	O
diabetes	O
,	O
and	O
their	O
complications	O
contains	O
insulin	O
sensitizer	O
and	O
B	O
-	O
family	O
vitamins	O
.	O

Medicine	O
composition	O
containing	O
insulin	O
sensibilizer	O
and	O
B	O
-	O
family	O
vatamines	O

Compound	O
for	O
treating	O
AIDS	O
,	O
its	O
accepted	O
salt	O
and	O
its	O
use	O
for	O
inhibiting	O
HIV	O
virus	O
are	O
disclosed	O
.	O

It	O
can	O
inhibit	O
HIV	O
virus	O
infect	O
human	O
-	O
body	O
cell	O
and	O
has	O
less	O
by	O
-	O
effects	O
.	O

Compound	O
for	O
treating	O
AIDS	O

2-monocarboxyl	B
substituted	I
zinc	I
phthalocyanine	I
-	I
oligopoly	I
lysine	I
coupler	O
,	O
its	O
production	O
and	O
use	O
are	O
disclosed	O
.	O

The	O
process	O
is	O
carried	O
out	O
by	O
taking	O
zinc	B
acetate	I
,	O
phthalic	B
anhydride	I
and	O
metaben	O
anhydride	B
triformate	I
as	O
initial	O
raw	O
materials	O
,	O
solid	O
-	O
phase	O
synthesizing	O
,	O
chromatograph	O
column	O
separating	O
to	O
obtain	O
pure	O
2-monocarboxy	B
substituted	I
zinc	I
phthalocyanine	I
,	O
coupling	O
it	O
with	O
oligopoly	B
lysine	I
to	O
obtain	O
the	O
final	O
product	O
.	O

It	O
's	O
multi	O
-	O
functional	O
,	O
non	O
-	O
toxic	O
and	O
has	O
excellent	O
broad	O
-	O
spectrum	O
performance	O
.	O

It	O
can	O
be	O
used	O
to	O
treat	O
periodontal	O
diseases	O
.	O

Low	O
-	O
toxic	O
and	O
broad	O
-	O
spectrum	O
phthalocyanine	B
bactericide	O
,	O
its	O
production	O
and	O
use	O

The	O
invention	O
relates	O
to	O
uses	O
of	O
composition	O
of	O
vitamin	B
C	I
and	O
arginine	B
in	O
antianoxia	O
medicine	O
and	O
health	O
care	O
product	O
.	O

Said	O
composition	O
is	O
prepared	O
into	O
oral	O
taking	O
medicine	O
and	O
health	O
care	O
food	O
acceptable	O
by	O
patent	O
medicine	O
according	O
to	O
common	O
practice	O
.	O

Said	O
invention	O
is	O
characterized	O
by	O
said	O
composition	O
has	O
the	O
effect	O
of	O
antianixia	O
damage	O
,	O
curbing	O
lipid	O
peroxidation	O
,	O
increasing	O
NO	B
output	O
,	O
and	O
decreasing	O
pulmonary	O
artery	O
pressure	O
caused	O
by	O
oxygen	B
shortage	O
and	O
the	O
degree	O
of	O
hypertrophy	O
of	O
right	O
ventricle	O
.	O

Use	O
of	O
vitamin	B
C	I
and	O
arginine	B
composition	O
in	O
anti	O
-	O
anoxic	O
medicine	O
and	O
health	O
product	O

This	O
invention	O
provides	O
a	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
and	O
its	O
preparation	O
method	O
.	O

Weight	O
ratio	O
of	O
the	O
effective	O
ingredients	O
in	O
the	O
said	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
is	O
:	O
spiny	O
grape	O
seed	O
oiling	O
capsule	O
powder	O
(	O
60	O
-	O
70wt%	O
)	O
,	O
extracts	O
of	O
spiny	O
grape	O
seed	O
(	O
10	O
-	O
20wt%	O
)	O
,	O
lecithin	B
(	O
10	O
-	O
15wt%	O
)	O
,E	O
vitamin	B
E	I
(	O
1	O
-	O
5wt%	O
)	O
.The	O
preparing	O
method	O
is	O
as	O
the	O
following	O
steps:	O
(	O
1	O
)	O
.	O

Extracting	O
spiny	O
grape	O
seed	O
oil	O
and	O
spiny	O
grape	O
seed	O
extracts	O
from	O
the	O
spiny	O
grape	O
seeds	O
by	O
using	O
the	O
super	O
critical	O
line	O
CO2	B
extracting	O
technology.	O
(	O
2	O
)	O
.	O

Implement	O
capsule	O
processing	O
to	O
the	O
extracted	O
spiny	O
grape	O
seed	O
oil	O
.	O

(	O
3	O
)	O
.Weighing	O
the	O
extracted	O
ingredients	O
according	O
to	O
the	O
given	O
ratio	O
,	O
and	O
evenly	O
mix	O
the	O
extracted	O
ingredients	O
,	O
the	O
mixed	O
ingredients	O
is	O
the	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
.	O

The	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
of	O
this	O
invention	O
of	O
this	O
invention	O
can	O
effectively	O
decrease	O
the	O
contents	O
of	O
tracyglycerol	O
of	O
the	O
total	O
cholesterol	B
in	O
blood	O
serum	O
,	O
increase	O
the	O
contents	O
of	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B
and	O
upgrade	O
the	O
energy	O
and	O
total	O
anti	O
-	O
oxidation	O
ability	O
of	O
blood	O
serum	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
,	O
glutathione	B
cholesterol	B
enzyme	O
.	O

The	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
is	O
easy	O
for	O
storage	O
.	O

A	O
spiny	O
grape	O
seed	O
extract	O
preparation	O
and	O
its	O
preparation	O
method	O

An	O
antineoplastic	O
self	O
-	O
microemulsifying	O
solid	O
of	O
resveratrol	B
with	O
high	O
stability	O
and	O
solubility	O
in	O
gastonintesinal	O
tract	O
is	O
prepared	O
through	O
preparing	O
the	O
concentrated	O
liquid	O
of	O
self	O
-	O
microemulsifying	O
composition	O
proportionally	O
from	O
resveratrol	B
,	O
emulsifier	O
,	O
emulsifying	O
aid	O
,	O
and	O
oil	O
,	O
adding	O
the	O
mixture	O
of	O
mannitol	B
and	O
calcium	B
lactate	I
,	O
stirring	O
or	O
ultrasonic	O
dissolving	O
,	O
and	O
freeze	O
-	O
drying	O
.	O

Solid	O
self	O
-	O
micro	O
emulsion	O
contg	O
.	O

jervic	O
alcohol	B
for	O
antineoplastic	O
medicine	O
and	O
its	O
prepn	O
.	O

method	O

The	O
invention	O
relates	O
to	O
a	O
composite	O
salt	O
crystal	O
used	O
in	O
human	O
physiotherapy	O
.	O

Wherein	O
,	O
it	O
at	O
least	O
comprisescommon	O
salt	O
(	O
NaCl	B
)	O
,	O
mirabilite	B
(	O
Na2SO4*yH2O	B
)	O
,	O
potassium	B
chloride	I
(	O
KCl	B
)	O
and/or	O
cobalt	B
chloride	I
(	O
CoCl2*aH2O	B
)	O
.	O

The	O
invention	O
also	O
provides	O
a	O
relative	O
production	O
.	O

The	O
invention	O
can	O
dissolve	O
the	O
cutin	O
;	O
activate	O
the	O
blood	O
circulation	O
,	O
etc	O
.	O

Complex	O
salt	O
crystal	O
used	O
for	O
body	O
surface	O
physical	O
therapy	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
new	O
medicinal	O
use	O
of	O
protocatechuic	B
aldehyde	I
in	O
the	O
prevention	O
or	O
treatment	O
of	O
infectious	O
,	O
hemorrhage	O
,	O
trauma	O
,	O
heart	O
source	O
or	O
anaphylactic	O
shocks	O
.	O

Novel	O
medical	O
usage	O
of	O
protocatechualdehyde	B

The	O
invention	O
discloses	O
a	O
benzo	B
dinaphthaquinone	I
derivant	O
with	O
general	O
formula	O
(	O
I	O
)	O
and	O
preparing	O
method	O
and	O
application	O
on	O
the	O
tumour	O
proof	O
aspect	O
as	O
well	O
as	O
lead	O
compound	O
to	O
study	O
new	O
cancer	O
-	O
proof	O
drug	O
,	O
wherein	O
the	O
R1,R2,R3,R4	O
is	O
hydrogen	B
,	O
R5	O
,	O
COR5	B
or	O
C3-C8	O
monosaccharide	B
;	O
R5	O
is	O
(	B
CH2	I
)	I
n	I
-	I
R6	I
;	O
R6	O
is	O
H	B
,	O
R7,-OR7,NHR7,N	O
(	B
R7	I
)	I
2,N	I
(	B
R7	I
)	I
3+X-	I
,	O
-S	B
-	I
R7,OH	I
,	O
NH2,Cl	B
,	O
Br	B
,	O
I	B
,	O
CN	B
,	O
NO2,SO3	B
M	B
;	O
R7	O
is	O
C1-C12	B
alkyl	I
,	O
COR5,R5	B
;	O
X	O
is	O
Cl-	B
,	O
Br-,I-,ClO4-,SO3CH3-,SO3C2H4PCH3-,	B
(	O
n=1	O
-	O
12,M	O
=	O
Na	B
,	O
H	B
,	O
K	B
,	O
Ca	B
,	O
Mg	B
,	O
Zn	B
,	O
Li	B
,	O
Cu	B
)	O
.	O

Benzobinaphthoquinone	B
derivative	O
with	O
anticancer	O
activity	O

The	O
invention	O
discloses	O
a	O
quinoxaline	B
dioxide	I
with	O
sulphur	B
,	O
which	O
possesses	O
structural	O
formula	O
as	O
follows	O
:	O
R1	O
=	O
CH3,OCH3,Cl	B
,	O
H	B
;	O
R2	O
=	O
CH3,F	B
,	O
Cl	B
,	O
Br	B
,	O
OCH3,H	B
;	O
R3	O
=	O
CH2CH3,C6H6	B
.	O

The	O
preparing	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
adopting	O
quinoxaline	B
dioxide	I
ZM-81853	O
as	O
lead	O
;	O
modifying	O
benzene	B
ring	O
and	O
3-amino	B
;	O
synthesizing	O
2-substituted	O
benzene-3-thioalkylation	O
or	O
thioaryl	B
-	I
quinoxaline-1	I
,	I
4-dioxide	I
;	O
possessing	O
tumour	O
-	O
resistance	O
activity	O
and	O
low	O
-	O
oxygen	B
selectivity	O
corresponding	O
to	O
ZM-81853	O
.	O

Sulfur	B
-	O
containing	O
quinoxaline	B
dioxide	I
,	O
method	O
for	O
producing	O
same	O
and	O
their	O
application	O

The	O
invention	O
discloses	O
a	O
compound	O
(	O
I	O
)	O
or	O
stereomer	O
or	O
drug	O
salt	O
,	O
wherein	O
each	O
group	O
is	O
defined	O
in	O
the	O
introduction	O
,	O
which	O
can	O
be	O
applied	O
in	O
the	O
hepatitis	O
drug	O
.	O

[	B
N-	I
(	I
3',4'methylenedioxy	I
)	I
phenylethyl	I
]	I
formamidobenzoic	I
acid	I
derivative	O
,	O
its	O
preparation	O
method	O
and	O
uses	O

The	O
present	O
invention	O
provides	O
an	O
ocular	O
medicine	O
of	O
digitalis	O
leaf	O
and	O
esculin	B
,	O
comprising	O
0.04	O
to	O
0.06	O
parts	O
by	O
weight	O
of	O
digitalis	O
leaf	O
,	O
0.05	O
to	O
0.2	O
parts	O
by	O
weight	O
of	O
esculin	B
,	O
0.05	O
to	O
15	O
parts	O
by	O
weight	O
of	O
sodium	O
hyaluronate	O
,	O
and	O
pharmacologically	O
acceptable	O
carrier	O
.	O

The	O
ocular	O
medicine	O
of	O
digitalis	O
leaf	O
and	O
esculin	O
provided	O
by	O
the	O
invention	O
has	O
advantages	O
of	O
lasting	O
effect	O
,	O
and	O
excellent	O
efficacy	O
,	O
as	O
well	O
as	O
can	O
make	O
the	O
eyes	O
moisten	O
.	O

Eye	O
preparation	O
containing	O
sodium	O
hyaluronate	O
for	O
treating	O
fundus	O
macular	O
degeneration	O
and	O
its	O
preparation	O
method	O

A	O
medicine	O
for	O
treating	O
the	O
elermatopathy	O
caused	O
by	O
fungus	O
,	O
such	O
as	O
mycosis	O
,	O
tinea	O
pedis	O
and	O
tinea	O
manuum	O
,	O
is	O
prepared	O
from	O
surfactant	O
,	O
synthetic	O
ester	O
,	O
zinc	B
oxide	I
,	O
palmic	B
acid	I
,	O
phosphate	B
and	O
additive	O
.	O

Method	O
of	O
medicament	O
for	O
curing	O
skin	O
disease	O

The	O
invention	O
relates	O
to	O
a	O
vein	O
injection	O
/	O
oral	O
general	O
anesthetic	O
,	O
and	O
relative	O
production	O
,	O
wherein	O
it	O
comprises	O
fluorocarbon	B
and	O
volatile	O
general	O
anesthetic	O
,	O
while	O
the	O
general	O
anesthetic	O
is	O
alorbatalotane	B
,	O
enflurane	B
,	O
furane	B
,	O
sevoflurane	B
,	O
etc	O
.	O

And	O
the	O
invention	O
can	O
be	O
injected	O
in	O
vein	O
or	O
orally	O
taken	O
,	O
with	O
low	O
cost	O
.	O

It	O
has	O
simple	O
control	O
without	O
side	O
effect	O
.	O

Intravenous	O
injection	O
/	O
inhalation	O
dual	O
-	O
purpose	O
general	O
anesthetic	O
and	O
preparation	O
process	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
used	O
to	O
restrain	O
the	O
combination	O
between	O
corticosteroid	B
and	O
its	O
acceptor	O
,	O
and	O
used	O
to	O
prevent	O
the	O
weight	O
increase	O
caused	O
by	O
antipsychotics	O
.	O

It	O
uses	O
glucocorticoids	B
acceptor	O
antagonist	O
Mifepristone	B
.	O

The	O
invention	O
also	O
provides	O
a	O
drug	O
box	O
for	O
preventing	O
weight	O
increase	O
caused	O
by	O
AP	O
,	O
while	O
it	O
comprises	O
glucocorticoids	B
acceptor	O
antagonist	O
,	O
and	O
the	O
instructor	O
for	O
instructing	O
feeding	O
agent	O
and	O
feeding	O
time	O
.	O

Method	O
for	O
preventing	O
weight	O
increase	O
caused	O
by	O
antipsychotic	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
composite	O
that	O
feeds	O
drug	O
into	O
nasal	O
to	O
treat	O
cold	O
and	O
influenza	O
,	O
wherein	O
the	O
invention	O
is	O
characterized	O
in	O
that	O
:	O
it	O
comprises	O
0.1	O
-	O
10	O
%	O
glycyrrhizin	B
and	O
non	O
-	O
toxic	O
salt	O
as	O
active	O
components	O
.	O

Said	O
salt	O
can	O
be	O
glycyrrhizin	B
and	O
other	O
cation	O
as	O
sodium	B
ion	O
,	O
k	O
ion	O
,	O
etc	O
.	O

And	O
the	O
inventive	O
drug	O
can	O
be	O
made	O
into	O
injection	O
,	O
atomization	O
,	O
gel	O
,	O
etc	O
.	O

Nasal	O
administered	O
pharmaceutical	O
composition	O
containing	O
glycyrrhetic	B
acid	I
and	O
medical	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
nasal	O
administration	O
preparation	O
comprising	O
melatonin	B
and	O
at	O
least	O
one	O
kind	O
of	O
polyethylene	B
glycol	I
selected	O
from	O
polyethylene	B
glycol	I
200	I
,	O
polyethylene	B
glycol	I
300	I
,	O
polyethylene	B
glycol	I
400	I
,	O
or	O
polyethylene	B
glycol	I
600	I
.	O

Nasal	O
administered	O
preparation	O
of	O
melatonin	B

Disclosed	O
is	O
an	O
anticancer	O
slow	O
release	O
injection	O
containing	O
fluorouracil	B
and	O
synergistic	O
agents	O
,	O
which	O
comprises	O
slow	O
release	O
micro	O
-	O
balloons	O
and	O
dissolvent	O
,	O
wherein	O
the	O
slow	O
release	O
microballoons	O
comprise	O
anti	O
-	O
cancer	O
active	O
constituents	O
and	O
slow	O
release	O
auxiliary	O
materials	O
,	O
the	O
dissolvent	O
being	O
specific	O
dissolvent	O
containing	O
suspension	O
adjuvant	O
.	O

The	O
suspending	O
agent	O
is	O
selected	O
from	O
sodium	O
carboxymethylcellulose	O
,	O
mannitol	B
,	O
sorbitol	B
,	O
Tween-80	O
or	O
their	O
combination	O
.	O

The	O
anticancer	O
active	O
constituents	O
are	O
the	O
combination	O
of	O
5-FU	B
and	O
Mitozolomide	B
,	O
Tegafur	B
,	O
temozolomide	B
as	O
5-FU	B
synergistic	O
agent	O
.	O

The	O
slow	O
release	O
auxiliary	O
materials	O
are	O
selected	O
from	O
polylactic	B
acid	I
,	O
ethylene	B
-	I
vinylacetate	I
copolymer	O
,	O
Polifeprosan	B
,	O
FAD	B
,	O
sebacic	B
acid	I
copolymer	O
,	O
polyglycolic	B
acid	I
and	O
glycolic	B
acid	I
copolymer	O
or	O
their	O
combination	O
.	O

The	O
viscosity	O
of	O
the	O
injection	O
is	O
50	O
-	O
1000cp	O
(	O
at	O
20	O
-	O
30	O
deg	O
C	O
)	O
,	O
The	O
slow	O
release	O
microspheres	O
can	O
also	O
be	O
prepared	O
into	O
slow	O
release	O
implanting	O
agent	O
,	O
when	O
in	O
-	O
tumor	O
or	O
around	O
-	O
tumor	O
injected	O
or	O
placed	O
,	O
the	O
slow	O
release	O
agent	O
can	O
not	O
only	O
lower	O
down	O
the	O
whole	O
body	O
toxicity	O
reaction	O
of	O
the	O
anti	O
-	O
cancer	O
medicament	O
,	O
but	O
also	O
can	O
selectively	O
increase	O
the	O
tumor	O
local	O
medicinal	O
concentration	O
,	O
and	O
improve	O
the	O
treatment	O
effect	O
of	O
the	O
non	O
-	O
operative	O
treatment	O
methods	O
such	O
as	O
chemotherapy	O
,	O
medicament	O
and	O
radiation	O
.	O

Fluorouracil	B
and	O
its	O
synergist	O
carried	O
sustained	O
release	O
agent	O

The	O
invention	O
discloses	O
a	O
ferulic	B
acid	I
and	O
sodium	B
salt	O
agent	O
and	O
drug	O
application	O
to	O
induce	O
embryo	O
stem	O
cell	O
into	O
nerve	O
stem	O
cell	O
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
the	O
molecular	O
formula	O
of	O
ferulic	B
acid	I
(	O
3-	B
(	I
4-hydroxyl-3-methoxyphenyl	I
)	I
-2-propenoic	I
acid	I
)	O
is	O
C10H10O4	B
with	O
relative	O
molecular	O
weight	O
at	O
194.18	O
,	O
whose	O
sodium	B
salt	O
is	O
more	O
stable	O
;	O
the	O
ferulic	B
acid	I
and	O
its	O
sodium	B
salt	O
can	O
be	O
applied	O
to	O
treat	O
cerebral	O
thrombus	O
,	O
coronary	O
disease	O
,	O
angiitis	O
,	O
which	O
prevents	O
ischemic	O
heart	O
,	O
brain	O
and	O
vessel	O
disease	O
,	O
acute	O
renal	O
failure	O
and	O
other	O
diseases	O
;	O
the	O
invention	O
can	O
accelerate	O
harmed	O
embryo	O
brain	O
to	O
repair	O
due	O
to	O
monosodium	B
glutamate	I
into	O
stomach	O
in	O
the	O
terminal	O
phase	O
of	O
pregnant	O
mouse	O
,	O
which	O
can	O
restore	O
the	O
injury	O
of	O
spinal	O
marrow	O
and	O
brain	O
.	O

Ferulic	B
acid	I
and	O
sodium	B
ferulate	I
preparation	O
for	O
inducing	O
stem	O
cell	O
differentiating	O
into	O
nerve	O
stem	O
cell	O
and	O
pharmaceutical	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
chronic	O
trachitis	O
with	O
cough	O
-	O
relieving	O
and	O
phlegm	O
reducing	O
functions	O
,	O
the	O
purpose	O
of	O
the	O
invention	O
is	O
to	O
overcome	O
the	O
drawbacks	O
of	O
the	O
conventional	O
preparations	O
and	O
provide	O
a	O
composition	O
with	O
the	O
advantages	O
of	O
high	O
biological	O
availability	O
,	O
quick	O
-	O
speed	O
medicine	O
release	O
,	O
quick	O
-	O
speed	O
effect	O
,	O
less	O
toxic	O
and	O
side	O
effects	O
,	O
higher	O
medicinal	O
content	O
,	O
smaller	O
amount	O
of	O
administration	O
,	O
accurate	O
administration	O
dosage	O
,	O
easy	O
administering	O
,	O
and	O
low	O
cost	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
made	O
into	O
dose	O
form	O
of	O
dripping	O
pills	O
.	O

The	O
dripping	O
pills	O
comprise	O
extract	O
oil	O
of	O
Ledum	O
palustre	O
Linn	O
.	O

as	O
the	O
effective	O
constituent	O
and	O
medicinal	O
carrying	O
agent	O
as	O
the	O
base	O
material	O
.	O

Ledum	O
palustre	O
Linn	O
.	O

oil	O
drop	O
pills	O
for	O
treating	O
chronic	O
bronchitis	O
and	O
preparation	O
process	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
specific	O
ointment	O
for	O
curing	O
wart	O
.	O

It	O
is	O
made	O
up	O
by	O
using	O
Vaseline	O
,	O
cupric	B
nitrate	I
,	O
sulfur	B
and	O
salicylic	B
acid	I
through	O
a	O
special	O
preparation	O
process	O
.	O

At	O
the	O
same	O
time	O
,	O
it	O
also	O
can	O
be	O
used	O
for	O
curing	O
horny	O
layer	O
,	O
heloma	O
and	O
dermatasclerosis	O
,	O
etc	O
.	O

Special	O
ointment	O
for	O
treating	O
verruca	O

The	O
present	O
invention	O
relates	O
to	O
an	O
inclusion	O
state	O
puerarin	O
/	O
cyclodextrin	O
composition	O
in	O
which	O
the	O
mole	O
ratio	O
of	O
cyclodextrin	O
and	O
puerarin	O
is	O
1	O
-	O
5:1	O
.	O

the	O
described	O
cyclodextrin	O
can	O
be	O
beta	O
-	O
cyclodextrin	O
or	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
or	O
sulfo	O
-	O
bulyl	O
-	O
beta	O
-	O
cyclodextrin	O
or	O
their	O
mixture	O
.	O

Besides	O
,	O
said	O
invention	O
also	O
provides	O
its	O
preparation	O
method	O
and	O
concrete	O
steps	O
.	O

Inclusion	O
puerarin	O
/	O
cyclodextrin	O
composition	O
and	O
its	O
preparing	O
method	O

A	O
medicinal	O
composition	O
for	O
preparing	O
the	O
medicines	O
to	O
treat	O
hepatism	O
and	O
protect	O
liver	O
is	O
prepared	O
proportionally	O
from	O
silibinin	B
or	O
its	O
derivative	O
or	O
silybin	B
,	O
oriental	O
wormwood	O
or	O
its	O
extract	O
,	O
and	O
capejasmine	O
or	O
its	O
extract	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Medicinal	O
composition	O
of	O
elutriate	O
,	O
virgate	O
wormwood	O
herb	O
and	O
and	O
cape	O
-	O
jasmine	O

Laevo	O
isomer	O
and	O
dextroisomer	O
of	O
alpha	B
-	I
substituted	I
2-methyl-5-nitrodazole-1-ethanol	I
derivative	O
,	O
its	O
production	O
,	O
medicinal	O
composition	O
containing	O
the	O
derivative	O
or	O
its	O
solvent	O
or	O
accepted	O
salt	O
and	O
use	O
for	O
preparing	O
anti	O
-	O
anaerobe	O
medicine	O
are	O
disclosed	O
.	O

Alpha	B
-	I
substituted-2-methyl-5-nitro	I
-	I
diazole-1-alcohol	I
derivative	O
with	O
optical	O
activity	O

Disclosed	O
are	O
4-arylamino	B
-	I
quinazolines	I
and	O
analogs	O
thereof	O
effective	O
as	O
activators	O
of	O
caspases	O
and	O
inducers	O
of	O
apoptosis	O
.	O

The	O
compounds	O
of	O
this	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
clinical	O
conditions	O
in	O
which	O
uncontrolled	O
growth	O
and	O
spread	O
of	O
abnormal	O
cells	O
occurs	O
.	O

4-arylamino	B
-	I
quinazolines	I
as	O
activators	O
of	O
aspartic	B
acid	I
specificity	O
cysteine	B
protease	O
and	O
inducers	O
of	O
apoptosis	O

The	O
present	O
invention	O
relates	O
to	O
new	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
pharmaceutical	O
formulations	O
containing	O
the	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
mGluR5	O
receptor	O
-	O
mediated	O
disorders	O
.	O

Novel	O
heteropolycyclic	O
compounds	O
and	O
their	O
use	O
as	O
metabotropic	O
glutamate	B
receptor	O
antagonists	O

The	O
process	O
of	O
extracting	O
and	O
purifying	O
Holathuria	O
nobilis	O
polyose	O
includes	O
the	O
following	O
steps	O
:	O
crushing	O
Holathuria	O
nobilis	O
,	O
mixing	O
with	O
solvent	O
and	O
pulping	O
,	O
extracting	O
at	O
certain	O
temperature	O
and	O
through	O
stirring	O
,	O
double	O
enzyme	O
hydrolyzing	O
the	O
extracted	O
liquid	O
,	O
centrifuging	O
,	O
filtering	O
,	O
concentrating	O
filtrate	O
,	O
and	O
freeze	O
drying	O
to	O
obtain	O
white	O
Holathuria	O
nobilis	O
polyose	O
.	O

Research	O
proves	O
that	O
Holathuria	O
nobilis	O
polyose	O
possesses	O
inhibition	O
on	O
the	O
growth	O
of	O
the	O
tumor	O
cell	O
strain	O
of	O
K-562	O
,	O
SHG-44	O
,	O
HCT-8	O
,	O
PC-3	O
M	O
,	O
A-549	O
,	O
especially	O
on	O
the	O
growth	O
of	O
S180	O
tumor	O
tissue	O
of	O
mouse	O
.	O

The	O
Holathuria	O
nobilis	O
polyose	O
is	O
immunity	O
promoter	O
with	O
relatively	O
high	O
effect	O
,	O
and	O
may	O
be	O
prepared	O
into	O
antitumor	O
medicine	O
.	O

Holathuria	O
nobilis	O
polyose	O
extracting	O
process	O
and	O
its	O
medicinal	O
use	O

The	O
invention	O
relates	O
to	O
a	O
lotion	O
for	O
dispelling	O
acne	O
,	O
wherein	O
the	O
lotion	O
is	O
prepared	O
mainly	O
from	O
dimethyl	B
carbinol	I
,	O
distilled	O
water	O
,	O
glycerin	B
,	O
triethanolamine	B
and	O
ethanol	B
through	O
specific	O
processes	O
.	O

The	O
medicament	O
provided	O
by	O
the	O
invention	O
has	O
good	O
treatment	O
action	O
for	O
acne	O
with	O
simple	O
process	O
of	O
production	O
and	O
method	O
of	O
use	O
.	O

Acne	O
lotion	O

There	O
are	O
described	O
novel	O
active	O
substance	O
combinations	O
of	O
valinamide	B
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
in	O
which	O
R<1	O
>	O
and	O
R<2	O
>	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
with	O
known	O
fungicidal	O
active	O
substances	O
,	O
and	O
their	O
use	O
for	O
controlling	O
phytopathogenic	O
fungi	O
.	O

Fungicidal	O
active	O
compound	O
combinations	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
azone	B
in	O
preparing	O
external	O
use	O
medicament	O
or	O
cosmetic	O
products	O
for	O
the	O
treatment	O
of	O
constipation	O
,	O
wherein	O
substantial	O
curative	O
effects	O
can	O
be	O
achieved	O
without	O
any	O
toxic	O
effects	O
or	O
side	O
effects	O
,	O
the	O
invention	O
also	O
realizes	O
ease	O
in	O
use	O
.	O

Use	O
of	O
laurocapram	B
in	O
preparation	O
of	O
externally	O
used	O
drug	O
for	O
treating	O
constipation	O
and	O
cosmetic	O
product	O

The	O
invention	O
concerns	O
quinazoline	B
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
each	O
of	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
,	O
R<6	O
>	O
,	O
R<7	O
>	O
,	O
X<1	O
>	O
,	O
Q<1	O
>	O
,	O
m	O
and	O
n	O
have	O
any	O
of	O
the	O
meanings	O
defined	O
in	O
the	O
description	O
;	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
as	O
an	O
antiproliferative	O
agent	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
tumours	O
which	O
are	O
sensitive	O
to	O
inhibition	O
of	O
erbB	O
receptor	O
tyrosine	O
kinases	O
.	O

Quinazoline	B
derivatives	O
as	O
ERBB	O
receptor	O
tyrosine	O
kinases	O

The	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
R<1	O
>	O
,	O
R	O
<	O
A	O
>	O
,	O
R<8	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
and	O
R<4	O
>	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
C	B
-	O
C	B
chemokine	O
mediated	O
conditions	O
.	O

Novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
described	O
and	O
claimed	O
.	O

Thiazole	B
derivatives	O
as	O
chemokine	O
receptor	O
antagonists	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
of	O
mycophenolic	B
salt	I
with	O
enteric	O
dressing	O
,	O
the	O
composition	O
contains	O
mycophenolic	O
salt	O
and	O
enteric	O
dressing	O
,	O
and	O
can	O
be	O
used	O
for	O
releasing	O
mycophenolic	B
salts	I
to	O
the	O
upper	O
portion	O
of	O
intestinal	O
tract	O
,	O
thereby	O
preventing	O
mycophenolic	O
salts	O
from	O
releasing	O
in	O
stomach	O
.	O

Enteric	O
-	O
coated	O
pharmaceutical	O
composition	O
of	O
mycophenolic	B
acid	I
salt	O

The	O
utility	O
model	O
discloses	O
an	O
intrauterine	O
device	O
,	O
which	O
is	O
a	O
Y	O
-	O
typed	O
object	O
covered	O
in	O
helix	O
tube	O
.	O

The	O
device	O
comprises	O
a	O
trailing	O
arm	O
with	O
a	O
U	O
-	O
shaped	O
tail	O
,	O
a	O
neck	O
,	O
and	O
two	O
transverse	O
arms	O
with	O
a	O
ring	O
-	O
shaped	O
end	O
.	O

The	O
two	O
transverse	O
arms	O
are	O
formed	O
with	O
the	O
two	O
frames	O
of	O
the	O
trailing	O
arm	O
crossing	O
at	O
the	O
neck	O
and	O
then	O
extending	O
outward	O
at	O
the	O
same	O
angle	O
.	O

The	O
utility	O
model	O
is	O
of	O
improved	O
persistence	O
and	O
contraceptive	O
effectiveness	O
,	O
lowered	O
adverse	O
effects	O
and	O
prolonged	O
effective	O
time	O
.	O

Intrauterine	O
device	O

The	O
utility	O
model	O
relates	O
to	O
a	O
lovastatin	B
-	O
nicotinic	B
acid	I
double	O
-	O
release	O
capsule	O
preparation	O
,	O
which	O
comprises	O
a	O
capsule	O
casing	O
and	O
a	O
pharmaceutical	O
preparation	O
filled	O
inside	O
the	O
capsule	O
casing	O
.	O

The	O
pharmaceutical	O
preparation	O
includes	O
a	O
lovastatin	B
rapid	O
-	O
release	O
tablet	O
and	O
a	O
nicotinic	B
acid	I
sustained	O
-	O
release	O
tablet	O
.	O

The	O
lovastatin	B
-	O
nicotinic	B
acid	I
double	O
-	O
release	O
capsule	O
has	O
simple	O
preparation	O
technique	O
,	O
requires	O
no	O
double	O
incompression	O
of	O
the	O
tablets	O
,	O
and	O
has	O
proper	O
hardness	O
,	O
high	O
yield	O
,	O
low	O
requirements	O
on	O
a	O
compression	O
machine	O
,	O
better	O
accuracy	O
than	O
capsules	O
with	O
double	O
-	O
layer	O
tablets	O
or	O
containing	O
small	O
pills	O
as	O
shown	O
in	O
finished	O
product	O
quality	O
inspection	O
,	O
and	O
no	O
mutual	O
interference	O
between	O
two	O
compositions	O
,	O
thereby	O
being	O
capable	O
of	O
providing	O
more	O
accurate	O
relevant	O
materials	O
,	O
content	O
,	O
and	O
release	O
and	O
dissolution	O
rates	O
.	O

Lovastatin	B
-	O
nicotinic	B
acid	I
double	O
-	O
release	O
capsule	O

The	O
utility	O
model	O
relates	O
to	O
an	O
oral	O
administration	O
hard	O
capsule	O
,	O
in	O
particular	O
to	O
a	O
tablet	O
capsule	O
filled	O
with	O
the	O
Dihydroergocryptine	B
mesylate	I
A	I
tablet	O
and	O
the	O
caffeine	B
tablet	O
.	O

The	O
tablet	O
capsule	O
of	O
the	O
utility	O
model	O
is	O
composed	O
of	O
a	O
capsule	O
and	O
tablets	O
in	O
the	O
capsule	O
,	O
wherein	O
the	O
capsule	O
comprises	O
an	O
upper	O
capsule	O
body	O
and	O
a	O
lower	O
capsule	O
body	O
,	O
the	O
capsule	O
is	O
at	O
least	O
filled	O
with	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
Dihydroergocryptine	B
mesylate	I
A	I
and	O
filled	O
with	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
caffeine	B
.	O

Because	O
active	O
ingredients	O
in	O
the	O
capsule	O
do	O
not	O
mutually	O
contact	O
,	O
each	O
ingredient	O
does	O
not	O
generate	O
chemical	O
compatibility	O
and	O
byproduct	O
so	O
as	O
to	O
protect	O
a	O
caffeine	B
ester	O
bond	O
and	O
an	O
N	B
substituted	I
amido	I
bond	O
and	O
improve	O
product	O
stability	O
,	O
and	O
especially	O
a	O
degradation	O
product	O
generated	O
after	O
the	O
Dihydroergocryptine	B
mesylate	I
A	I
tablet	O
contacts	O
with	O
caffeine	B
tablet	O
is	O
reduced	O
;	O
in	O
addition	O
,	O
because	O
of	O
adopting	O
the	O
design	O
of	O
cylindrical	O
slice	O
and	O
different	O
colors	O
and	O
applying	O
a	O
transparent	O
capsule	O
shell	O
,	O
the	O
product	O
of	O
the	O
utility	O
model	O
is	O
very	O
suitable	O
for	O
industrial	O
production	O
and	O
enhances	O
the	O
obedience	O
of	O
patients	O
.	O

Meanwhile	O
,	O
the	O
utility	O
model	O
adopts	O
active	O
ingredients	O
to	O
respectively	O
prepare	O
the	O
tablet	O
,	O
so	O
that	O
the	O
utility	O
model	O
is	O
easy	O
to	O
test	O
drug	O
and	O
control	O
quality	O
.	O

Tablet	O
capsule	O
filled	O
with	O
Dihydroergocryptine	B
mesylate	I
A	I
tablet	O
and	O
caffeine	B
tablet	O

The	O
utility	O
model	O
discloses	O
a	O
complex	O
gastrointestinal	O
capsule	O
containing	O
the	O
combination	O
of	O
diclofenac	B
sodium	I
and	O
acetaminophen	B
.	O

The	O
complex	O
gastrointestinal	O
capsule	O
comprises	O
a	O
capsule	O
casing	O
1	O
,	O
a	O
capsule	O
casing	O
2	O
and	O
drugs	O
,	O
wherein	O
,	O
the	O
drugs	O
are	O
arranged	O
inside	O
the	O
capsule	O
;	O
gastric	O
soluble	O
preparations	O
a	O
and	O
the	O
capsule	O
casing	O
2	O
are	O
arranged	O
in	O
the	O
capsule	O
casing	O
1	O
;	O
the	O
drug	O
that	O
is	O
arranged	O
in	O
the	O
capsule	O
casing	O
2	O
is	O
enteric	O
preparations	O
b	O
;	O
the	O
gastric	O
soluble	O
preparations	O
a	O
are	O
gastric	O
soluble	O
granules	O
containing	O
acetaminophen	O
and	O
supplementary	O
materials	O
;	O
the	O
enteric	O
preparations	O
b	O
are	O
pellets	O
containing	O
diclofenac	B
sodium	I
and	O
the	O
supplementary	O
materials	O
;	O
the	O
capsule	O
casing	O
1	O
is	O
a	O
gastric	O
soluble	O
capsule	O
;	O
and	O
the	O
capsule	O
casing	O
2	O
is	O
an	O
enteric	O
capsule	O
.	O

Complex	O
gastrointestinal	O
capsule	O
containing	O
combination	O
of	O
diclofenac	B
sodium	I
and	O
acetaminophen	B

An	O
aspirin	B
dipyridamole	B
slow	O
-	O
release	O
tablet	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
a	O
medicine	O
dosage	O
structure	O
.	O

The	O
utility	O
model	O
aims	O
to	O
solve	O
the	O
technical	O
problem	O
of	O
providing	O
an	O
aspirin	B
dipyridamole	B
slow	O
-	O
release	O
tablet	O
which	O
has	O
the	O
advantages	O
of	O
novel	O
dosage	O
structure	O
,	O
easy	O
quality	O
control	O
,	O
easy	O
fabrication	O
and	O
no	O
requirement	O
of	O
special	O
equipment	O
.	O

The	O
utility	O
model	O
is	O
characterized	O
in	O
that	O
a	O
tablet	O
core	O
of	O
a	O
tablet	O
is	O
sequentially	O
composed	O
of	O
a	O
dipyridamole	B
layer	O
(	O
1	O
)	O
,	O
an	O
isolating	O
layer	O
(	O
2	O
)	O
and	O
an	O
aspirin	B
layer	O
(	O
3	O
)	O
.	O

The	O
utility	O
model	O
has	O
the	O
technical	O
effects	O
that	O
the	O
isolating	O
layer	O
which	O
uses	O
medicinal	O
auxiliary	O
material	O
which	O
does	O
not	O
contain	O
the	O
two	O
main	O
drugs	O
of	O
the	O
aspirin	B
layer	O
and	O
the	O
dipyridamole	B
layer	O
is	O
arranged	O
between	O
the	O
aspirin	B
layer	O
and	O
the	O
dipyridamole	B
layer	O
,	O
so	O
the	O
influence	O
between	O
the	O
two	O
main	O
drugs	O
of	O
the	O
aspirin	B
layer	O
and	O
the	O
dipyridamole	B
layer	O
is	O
effectively	O
isolated	O
,	O
and	O
products	O
achieve	O
quality	O
standards	O
;	O
besides	O
,	O
the	O
utility	O
model	O
is	O
simple	O
in	O
technology	O
operation	O
and	O
the	O
existing	O
markets	O
in	O
market	O
can	O
be	O
utilized	O
to	O
achieve	O
the	O
purpose	O
of	O
scale	O
production	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
suitable	O
for	O
patients	O
who	O
suffer	O
from	O
transient	O
local	O
cerebral	O
ischemia	O
and	O
full	O
ischemia	O
,	O
and	O
can	O
reduce	O
apoplexy	O
risk	O
.	O

Aspirin	B
dipyridamole	B
slow	O
-	O
release	O
tablet	O

Use	O
of	O
an	O
ascorbate	B
compound	O
(	O
I	O
)	O
and	O
sympathomimetic	O
(	O
II	O
)	O
for	O
topical	O
treatment	O
of	O
inflammation	O
of	O
the	O
respiratory	O
mucosa	O
.	O

-	O
Independent	O
claims	O
are	O
also	O
included	O
for	O
:	O
-	O
(	O
1	O
)	O
Pharmaceutical	O
composition	O
containing	O
the	O
specified	O
concentrations	O
of	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
in	O
solution	O
;	O
-	O
(	O
2	O
)	O
Kit	O
comprising	O
two	O
containers	O
,	O
one	O
for	O
solid	O
(	O
I	O
)	O
and	O
the	O
other	O
for	O
a	O
solution	O
of	O
(	O
II	O
)	O
,	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
by	O
mixing	O
;	O
and	O
-	O
(	O
3	O
)	O
Kit	O
similar	O
to	O
(	O
2	O
)	O
but	O
comprising	O
a	O
single	O
container	O
with	O
a	O
separating	O
barrier	O
,	O
which	O
is	O
removed	O
or	O
mechanically	O
damaged	O
to	O
allow	O
mixing	O
of	O
components	O
.	O

-	O
ACTIVITY	O
-	O
Antiinflammatory	O
;	O
Antiallergic	O
;	O
Respiratory	O
-	O
Gen	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
-	O
None	O
given	O
.	O

Use	O
of	O
synergistic	O
combination	O
of	O
ascorbate	B
and	O
a	O
sympathomimetic	O
for	O
topical	O
treatment	O
of	O
inflammation	O
of	O
respiratory	O
mucosa	O
,	O
particularly	O
where	O
caused	O
by	O
viral	O
infection	O

Method	O
and	O
composition	O
(	O
A	O
)	O
for	O
topical	O
treatment	O
to	O
improve	O
the	O
symptoms	O
of	O
hypersensitive	O
teeth	O
or	O
toothache	O
comprises	O
applying	O
(	O
A	O
)	O
(	O
comprising	O
a	O
dosage	O
of	O
sodium	B
channel	O
blockers	O
(	O
local	O
anesthetic	O
of	O
ester	B
or	O
amide	B
type	O
)	O
(	O
B	O
)	O
,	O
which	O
influences	O
the	O
hypersensitive	O
irritated	O
terminal	O
nerves	O
for	O
tooth	O
normalizing	O
)	O
on	O
one	O
or	O
more	O
tooth	O
surface	O
in	O
a	O
mechanical	O
order	O
.	O

-	O
ACTIVITY	O
:	O
Analgesic	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Sodium	B
channel	O
blocker	O
.	O

Method	O
and	O
composition	O
useful	O
e.g.	O
to	O
improve	O
the	O
symptoms	O
of	O
hypersensitive	O
teeth	O
or	O
toothache	O
comprises	O
applying	O
topical	O
formulation	O
comprising	O
sodium	B
-	O
channel	O
blockers	O
(	O
e.g.	O
tetracaine	B
or	O
bupivacaine	B
)	O
and	O
additives	O
on	O
the	O
tooth	O
surface	O

Acids	O
are	O
used	O
to	O
stabilize	O
chloral	B
hydrate	I
.	O

Independent	O
claims	O
are	O
also	O
included	O
for	O
:	O
(	O
1	O
)	O
pharmaceutical	O
composition	O
comprising	O
chloral	B
hydrate	I
and	O
an	O
acid	O
;	O
(	O
2	O
)	O
gelatin	O
capsule	O
containing	O
the	O
above	O
composition	O
.	O

-	O
ACTIVITY	O
:	O
Hypnotic	O
;	O
Sedative	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Use	O
of	O
acids	O
to	O
stabilize	O
chloral	B
hydrate	I
,	O
especially	O
in	O
pharmaceutical	O
compositions	O
for	O
filling	O
gelatin	O
capsules	O

Cosmetic	O
or	O
dermatological	O
preparation	O
comprises	O
a	O
diaminobenzimidazol	B
(	O
A	O
)	O
.	O

-	O
ACTIVITY	O
:	O
Antiinflammatory	O
;	O
Dermatological	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Cosmetic	O
/	O
dermatological	O
preparation	O
,	O
useful	O
to	O
prevent	O
and/or	O
treat	O
e.g.	O
inflammatory	O
skin	O
conditions	O
and/or	O
skin	O
protection	O
by	O
sensitive	O
determination	O
,	O
symptoms	O
of	O
UV	O
radiation	O
damage	O
on	O
the	O
skin	O
,	O
comprises	O
a	O
diaminobenzimidazol	B

Active	O
substance	O
combination	O
comprises	O
glucosylglycerides	B
,	O
boundary	O
surface	O
-	O
active	O
glucose	B
derivatives	O
(	O
A	O
)	O
and	O
boundary	O
surface	O
-	O
active	O
oligoglycerine	B
derivatives	O
.	O

Active	O
substance	O
combination	O
comprises	O
glucosylglycerides	B
,	O
a	O
boundary	O
surface	O
-	O
active	O
glucose	B
derivative	O
of	O
formula	O
(	O
A	O
)	O
,	O
and	O
a	O
boundary	O
surface	O
-	O
active	O
oligoglycerine	B
derivative	O
of	O
formula	O
(	O
R3-O-	B
(	I
CH2-CH	I
(	I
O	I
-	I
R4	I
)	I
-CH2-O	I
)	I
n	I
-	I
R5	I
)	O
.	O

R	O
:	O
1	B
-	I
24C	I
alkyl	I
group	O
;	O
R1	O
>	O
H	B
or	O
1	B
-	I
24C	I
alkyl	I
group	O
;	O
R2	O
>	O
H	B
or	O
1	B
-	I
24C	I
acyl	I
group	O
;	O
R3>-R5	O
>	O
H	B
or	O
8	B
-	I
24C	I
fatty	I
acid	I
group	O
,	O
in	O
which	O
up	O
to	O
three	O
aliphatic	O
H	B
-	O
atoms	O
are	O
substituted	O
by	O
OH	B
groups	O
;	O
and	O
n	O
:	O
2	O
-	O
8	O
.	O

An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
a	O
cosmetic	O
preparation	O
comprising	O
the	O
active	O
substance	O
combination	O
.	O

[	O
Image	O
]	O
Active	O
substance	O
combination	O
,	O
useful	O
for	O
skin	O
moisturizing	O
and	O
for	O
stabilizing	O
skin	O
barrier	O
,	O
comprises	O
glucosylglycerides	B
,	O
boundary	O
surface	O
-	O
active	O
glucose	B
derivatives	O
and	O
boundary	O
surface	O
-	O
active	O
oligoglycerine	B
derivatives	O

Use	O
of	O
isocitrate	B
,	O
isocitronic	B
acid	I
and/or	O
their	O
derivatives	O
,	O
in	O
the	O
preparation	O
of	O
medicament	O
to	O
reduce	O
sequences	O
of	O
aging	O
-	O
conditions	O
mutations	O
in	O
cells	O
of	O
an	O
organism	O
.	O

Use	O
of	O
isocitrate	B
,	O
isocitric	B
acid	I
(	O
I	O
)	O
of	O
formula	O
(	O
C	B
(	I
=O	I
)	I
(	I
R1	I
)	I
-C	I
(	I
H	I
)	I
(	I
O	I
)	I
(	I
R2	I
)	I
-C	I
(	I
=O	I
)	I
(	I
C	I
)	I
(	I
R3	I
)	I
(	I
H	I
)	I
-C	I
(	I
H	I
)	I
(	I
H	I
)	I
(	I
C	I
)	I
(	I
R4	I
)	I
(	I
=O	I
)	I
)	O
or	O
their	O
derivatives	O
,	O
in	O
the	O
preparation	O
of	O
medicament	O
to	O
reduce	O
sequences	O
of	O
aging	O
-	O
conditions	O
mutations	O
in	O
cells	O
in	O
an	O
organism	O
.	O

R1	O
,	O
R3	O
,	O
R4-OH	B
,	O
-O-	B
>	O
or	O
-O	B
-	I
R5	I
;	O
R2hydrocarbon	B
,	O
organic	O
compound	O
,	O
fatty	B
acid	I
(	O
preferably	O
food	O
fatty	B
acid	I
)	O
,	O
alcohol	B
,	O
alcohol	B
ester	I
,	O
polyol	B
,	O
polyol	B
ester	I
(	O
preferably	O
glycerin	B
ester	I
)	O
,	O
H	B
or	O
-C	B
(	I
R6	I
)	I
=O	I
;	O
and	O
R5	O
,	O
R6R2	O
excluding	O
-C	B
(	I
R6	I
)	I
=O.	I
-	O
ACTIVITY	O
:	O
Nootropic	O
;	O
Dermatological	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Aconitase	O
Inhibitor	O
.	O

Use	O
of	O
isocitrate-	B
/	O
isocitric	B
acid	I
derivatives	O
,	O
in	O
the	O
preparation	O
of	O
medicament	O
to	O
reduce	O
sequences	O
of	O
aging	O
-	O
conditions	O
mutations	O
in	O
cells	O
of	O
an	O
organism	O

Medium	O
comprises	O
benzalkonium	B
chloride	I
,	O
which	O
is	O
basically	O
an	O
exclusive	O
pharmaceutically	O
active	O
component	O
or	O
the	O
main	O
active	O
component	O
.	O

A	O
mixture	O
of	O
pharmaceutical	O
or	O
deodorant	O
or	O
disinfecting	O
active	O
substances	O
is	O
also	O
provided	O
in	O
which	O
,	O
benzalkonium	B
chloride	I
is	O
greater	O
or	O
equal	O
to	O
50	O
wt.%	O
.	O

-	O
ACTIVITY	O
:	O

Antibacterial	O
;	O
Vulnerary	O
;	O
Antiseborrheic	O
;	O
Dermatological	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Medium	O
for	O
use	O
during	O
care	O
and	O
antimicrobial	O
treatment	O
of	O
skin	O
,	O
for	O
topical	O
dermatological	O
application	O
,	O
and	O
for	O
therapeutic	O
skin	O
and	O
sore	O
treatment	O
,	O
comprises	O
benzalkonium	B
chloride	I
,	O
which	O
is	O
basically	O
exclusive	O
pharmaceutically	O
active	O

Oil	O
-	O
in	O
-	O
water	O
-	O
emulsion	O
(	O
I	O
)	O
comprises	O
at	O
least	O
a	O
retinoid	O
;	O
0.1	O
-	O
40	O
wt.%	O
of	O
at	O
least	O
a	O
wax	O
component	O
with	O
a	O
melting	O
point	O
of	O
at	O
least	O
30	O
[	O
deg	O
]	O
C	O
,	O
preferably	O
pentaerythritol	B
ester	I
,	O
dipentaerythritol	B
ester	I
and/or	O
tripentaerythritol	B
ester	I
;	O
1	O
-	O
30	O
wt.%	O
of	O
at	O
least	O
an	O
oil	O
component	O
,	O
which	O
is	O
liquid	O
at	O
25	O
[	O
deg	O
]	O
C	O
;	O
and	O
40	O
-	O
95	O
wt.%	O
of	O
water	O
.	O

Oil	O
-	O
in	O
-	O
water	O
-	O
emulsion	O
,	O
useful	O
e.g.	O
in	O
the	O
non	O
-	O
therapeutic	O
treatment	O
of	O
wrinkle	O
,	O
acne	O
and	O
impure	O
skin	O
,	O
comprises	O
a	O
retinoid	O
,	O
a	O
wax	O
component	O
,	O
preferably	O
pentaerythritol	B
ester	I
and/or	O
dipentaerythritol	B
ester	I
,	O
an	O
oil	O
component	O
and	O
water	O

Adherent	O
,	O
sperm	O
blocking	O
drug	O
combination	O
with	O
contraceptive	O
effect	O
,	O
comprises	O
:	O
pure	O
deionized	O
water	O
;	O
0.3	O
-	O
10	O
wt.%	O
of	O
a	O
polysaccharide	O
-	O
gum	O
from	O
cellulose	O
and	O
its	O
derivatives	O
,	O
hemicellulose	O
,	O
fibers	O
,	O
starch	O
and	O
its	O
derivatives	O
,	O
polydextran	O
and	O
its	O
derivatives	O
,	O
pectin	O
and	O
its	O
derivatives	O
,	O
seaweed	O
-	O
saccharide	O
and	O
its	O
derivatives	O
and	O
salts	O
or	O
natural	O
gums	O
;	O
and	O
0.5	O
-	O
10	O
wt.%	O
of	O
alcohol	B
as	O
a	O
lubricant	O
.	O

Adherent	O
,	O
sperm	O
blocking	O
drug	O
combination	O
with	O
contraceptive	O
effect	O
,	O
comprises	O
:	O
pure	O
deionized	O
water	O
;	O
0.3	O
-	O
10	O
wt.%	O
of	O
a	O
polysaccharide	O
-	O
gum	O
from	O
cellulose	O
and	O
its	O
derivatives	O
,	O
hemicellulose	O
,	O
fibers	O
,	O
starch	O
and	O
its	O
derivatives	O
,	O
polydextran	O
and	O
its	O
derivatives	O
,	O
pectin	O
and	O
its	O
derivatives	O
,	O
seaweed	O
-	O
saccharide	O
and	O
its	O
derivatives	O
and	O
salts	O
or	O
natural	O
gums	O
;	O
and	O
0.5	O
-	O
10	O
wt.%	O
of	O
alcohol	B
as	O
a	O
lubricant	O
,	O
where	O
the	O
alcohol	B
is	O
at	O
least	O
a	O
polyethylene	B
glycol	I
with	O
a	O
molecular	O
weight	O
of	O
greater	O
than	O
200	O
,	O
polypropylene	B
glycol	I
with	O
a	O
molecular	O
weight	O
,	O
poly	B
(	I
ethylene	I
oxide	I
)	I
-polymer	O
and	O
glycerin	B
,	O
and	O
the	O
total	O
viscosity	O
of	O
the	O
composition	O
is	O
9000	O
cst	O
.	O

-	O
ACTIVITY	O
:	O
Contraceptive	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Adherent	O
,	O
sperm	O
blocking	O
drug	O
combination	O
with	O
contraceptive	O
effect	O
,	O
useful	O
as	O
contraceptive	O
,	O
comprises	O
deionized	O
water	O
,	O
polysaccharide	O
-	O
gum	O
,	O
and	O
alcohol	B
as	O
lubricant	O
,	O
where	O
composition	O
has	O
specific	O
total	O
viscosity	O

Substance	O
comprises	O
a	O
mixture	O
of	O
Chenopodium	O
,	O
quinine	B
,	O
acetylsalicylic	B
acid	I
and	O
Conium	O
maculatumin	O
homeopathic	O
dilution	O
.	O

-	O
ACTIVITY	O
:	O
Auditory	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Substance	O
,	O
useful	O
to	O
produce	O
composition	O
or	O
medicament	O
to	O
treat	O
otological	O
disorders	O
,	O
preferably	O
tinnitus	O
and	O
hearing	O
disorders	O
,	O
comprises	O
mixture	O
of	O
Chenopodium	O
,	O
quinine	B
,	O
acetylsalicylic	B
acid	I
and	O
Conium	B
maculatum	I
in	O
homeopathic	O
dilution	O

Preparation	O
comprises	O
allopurinol	B
.	O

-	O
ACTIVITY	O
:	O
Endocrine	O
-	O
Gen	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Preparation	O
,	O
useful	O
for	O
the	O
treatment	O
of	O
equine	O
Cushing	O
's	O
syndrome	O
,	O
comprises	O
allopurinol	B

Transdermal	O
system	O
comprises	O
:	O
at	O
least	O
an	O
immunomodulator	O
,	O
as	O
active	O
agent	O
,	O
comprising	O
quinoline	B
,	O
isoxazoles	B
,	O
fumaric	B
acid	I
derivatives	O
or	O
sphingosine-1-phosphatase	O
receptor	O
modulators	O
or	O
their	O
salts	O
and	O
metabolites	O
;	O
an	O
active	O
agent	O
impermeable	O
protective	O
layer	O
;	O
an	O
active	O
agent	O
reservoir	O
;	O
and	O
a	O
carrier	O
for	O
the	O
active	O
agent	O
reservoir	O
.	O

-	O
ACTIVITY	O
:	O
Neuroprotective	O
;	O
Antiinflammatory	O
;	O
Gastrointestinal	O
-	O
Gen	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Transdermal	O
system	O
,	O
useful	O
for	O
treating	O
multiple	O
sclerosis	O
and	O
Crohn	O
's	O
disease	O
,	O
comprises	O
an	O
immunomodulator	O
comprising	O
e.g.	O
quinoline	B
,	O
active	O
agent	O
impermeable	O
protective	O
layer	O
,	O
active	O
agent	O
reservoir	O
and	O
a	O
carrier	O

Bacterial	O
nanocellulose	O
comprises	O
a	O
structure	O
consisting	O
of	O
a	O
wide	O
-	O
meshed	O
phase	O
(	O
1	O
)	O
of	O
the	O
bacterial	O
nanocellulose	O
and	O
at	O
least	O
one	O
close	O
-	O
meshed	O
phase	O
(	O
2	O
)	O
of	O
the	O
bacterial	O
nanocellulose	O
firmly	O
connected	O
with	O
wide	O
-	O
meshed	O
phase	O
.	O

Independent	O
claims	O
are	O
included	O
for	O
:	O
(	O
1	O
)	O
use	O
of	O
bacterial	O
nanocellulose	O
,	O
where	O
the	O
bacterial	O
nanocellulose	O
is	O
used	O
without	O
drying	O
after	O
the	O
cultivation-	O
and	O
purification	O
-	O
process	O
as	O
initial	O
-	O
wet	O
implant	O
for	O
cartilage	O
formation	O
;	O
and	O
(	O
2	O
)	O
producing	O
the	O
bacterial	O
nanocellulose	O
,	O
comprising	O
generating	O
the	O
structure	O
in	O
a	O
cultivation	O
step	O
of	O
the	O
cultivation	O
process	O
as	O
a	O
two	O
-	O
phase	O
implant	O
.	O

Bacterial	O
nanocellulose	O
,	O
useful	O
e.g.	O
for	O
cartilage	O
regeneration	O
,	O
comprises	O
a	O
structure	O
consisting	O
of	O
a	O
wide	O
-	O
meshed	O
phase	O
of	O
bacterial	O
nanocellulose	O
and	O
a	O
close	O
-	O
meshed	O
phase	O
of	O
bacterial	O
nanocellulose	O
firmly	O
connected	O
with	O
wide	O
-	O
meshed	O
phase	O

Use	O
of	O
the	O
active	O
substance	O
propyphenazone	B
for	O
the	O
therapeutic	O
treatment	O
of	O
tumor	O
,	O
is	O
claimed	O
.	O

The	O
active	O
substance	O
inhibits	O
the	O
growth	O
of	O
tumor	O
cells	O
and/or	O
degenerates	O
the	O
tumor	O
cells	O
.	O

-	O
ACTIVITY	O
:	O
Cytostatic	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Use	O
of	O
the	O
active	O
substance	O
propyphenazone	B
for	O
the	O
therapeutic	O
treatment	O
of	O
tumor	O
,	O
where	O
the	O
active	O
substance	O
inhibits	O
the	O
growth	O
of	O
tumor	O
cells	O
and/or	O
degenerates	O
the	O
tumor	O
cells	O

Gastric	O
juice	O
-	O
resistant	O
composition	O
for	O
oral	O
ingestion	O
of	O
plant	O
-	O
based	O
components	O
for	O
preventing	O
colorectal	O
cancer	O
comprises	O
:	O
a	O
glucosinolate	O
or	O
a	O
mixture	O
of	O
glucosinolates	O
,	O
which	O
are	O
coated	O
with	O
a	O
gastric	O
juice	O
-	O
resistant	O
layer	O
;	O
and	O
at	O
least	O
one	O
three	O
-	O
dimensional	O
construct	O
of	O
a	O
glucan	O
-	O
melanin	O
-	O
chitin	O
complex	O
,	O
which	O
is	O
coated	O
with	O
at	O
least	O
one	O
plant	O
-	O
based	O
component	O
,	O
where	O
the	O
respective	O
component	O
layer	O
applied	O
on	O
the	O
glucan	O
-	O
melanin	O
-	O
chitin	O
complex	O
is	O
respectively	O
coated	O
with	O
a	O
separating	O
layer	O
soluble	O
in	O
the	O
intestine	O
for	O
isolating	O
an	O
additional	O
plant	O
-	O
based	O
component	O
present	O
in	O
the	O
composition	O
.	O
-	O
ACTIVITY	O
:	O
Cytostatic	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Gastric	O
juice	O
-	O
resistant	O
composition	O
for	O
oral	O
ingestion	O
of	O
plant	O
-	O
based	O
components	O
,	O
useful	O
for	O
preventing	O
colorectal	O
cancer	O
,	O
comprises	O
glucosinolate	B
,	O
and	O
a	O
construct	O
of	O
glucan	O
-	O
melanin	O
-	O
chitin	O
complex	O
coated	O
with	O
plant	O
-	O
based	O
component	O

Lisuride	B
(	O
I	O
)	O
,	O
terguride	B
(	O
II	O
)	O
or	O
a	O
1,1-diethyl-3-	B
(	I
R	I
)	I
-4,6,6a,7,8,9,10,1	I
0a	I
-	I
octahydro	I
-	I
indolo	I
[	I
4,3-fg	I
]	I
quinolin-9-yl	I
-	I
urea	I
derivative	O
(	O
III	O
)	O
is	O
new	O
,	O
where	O
(	O
I	O
)	O
-	O
(	O
III	O
)	O
is	O
useful	O
for	O
treating	O
and/or	O
preventing	O
of	O
fibrotic	O
changes	O
of	O
organ	O
and	O
other	O
vascular	O
structure	O
in	O
human	O
or	O
animal	O
for	O
arresting	O
and/or	O
for	O
remodeling	O
of	O
fibrotic	O
changes	O
of	O
organs	O
and	O
their	O
vascular	O
structure	O
.	O

Lisuride	B
(	O
I	O
)	O
,	O
terguride	B
(	O
II	O
)	O
or	O
a	O
1,1-diethyl-3-	B
(	I
R	I
)	I
-4,6,6a,7,8,9,10,1	I
0a	I
-	I
octahydro	I
-	I
indolo	I
[	I
4,3-fg	I
]	I
quinolin-9-yl	I
-	I
urea	I
derivative	O
of	O
formula	O
(	O
III	O
)	O
is	O
new	O
,	O
where	O
(	O
I	O
)	O
-	O
(	O
III	O
)	O
is	O
useful	O
for	O
treating	O
and/or	O
preventing	O
of	O
fibrotic	O
changes	O
of	O
organ	O
and	O
other	O
vascular	O
structure	O
in	O
human	O
or	O
animal	O
for	O
arresting	O
and/or	O
for	O
remodeling	O
of	O
fibrotic	O
changes	O
of	O
organs	O
and	O
their	O
vascular	O
structure	O
.	O

R	O
1	O
>	O
:	O
alkyl	B
or	O
alkynyl	B
;	O
R	O
2	O
>	O
:	O
C	B
2H	I
5	I
,	O
n	B
-	I
propyl	I
,	O
isopropyl	B
or	O
alkyl	B
;	O
R	O
3	O
>	O
:	O
H	B
,	O
CH	B
3	I
,	O
C	B
2H	I
5	I
,	O
isopropyl	B
or	O
CH	B
2OH	I
;	O
and	O
dotted	O
line	O
:	O
single	O
or	O
double	O
bond	O
.	O

[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O

Hypotensive	O
;	O
Respiratory	O
-	O
Gen	O
.	O
;	O
Cardiant	O
;	O
Anti	O
-	O
HIV	O
;	O
Fungicide	O
;	O
Antibacterial	O
;	O
Antiparasitic	O
;	O
Antiinflammatory	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
5-Hydroxytryptamine	B
2A	O
receptor	O
antagonist	O
;	O
5-Hydroxytryptamine	B
2B	O
receptor	O
antagonist	O
.	O

The	O
5-hydroxytryptamine	B
2A	O
receptor	O
antagonistic	O
activity	O
of	O
(	O
I	O
)	O
was	O
tested	O
.	O

The	O
results	O
showed	O
that	O
lisuride	O
exhibited	O
an	O
IC	O
5	O
0value	O
of	O
1	O
mmole	O
/	O
l	O
.	O

New	O
lisuride	B
,	O
terguride	B
or	O
1,1-diethyl-3-	B
(	I
R	I
)	I
-4,6,6a,7,8,9,10,10a	I
-	I
octa	I
hydro	I
-	I
indolo	I
(	I
4,3-fg	I
)	I
quinolin-9-yl	I
-	I
urea	I
derivative	O
,	O
is	O
5-hydroxytryptamine	B
2A	O
receptor	O
antagonist	O
,	O
useful	O
to	O
treat	O
and/or	O
prevent	O
pulmonary	O
arterial	O
hypertension	O

Chlorin	B
derivatives	O
(	O
Ia	O
)	O
and	O
(	O
Ib	O
)	O
,	O
are	O
new	O
.	O

Chlorin	B
derivative	O
of	O
formula	O
(	O
Ia	O
)	O
or	O
(	O
Ib	O
)	O
are	O
new	O
.	O

R10	O
:	O
OH	B
,	O
alkoxy	B
,	O
monoalkylamino	B
and	O
dialkylamino	B
;	O
and	O
M	O
:	O
2H	B
or	O
metal	O
,	O
provided	O
that	O
when	O
M	O
is	O
H	B
,	O
then	O
each	O
hydrogen	B
is	O
linked	O
to	O
nitrogen	B
of	O
the	O
chlorin	B
derivative	O
.	O

N.B.	O
:	O
Structures	O
(	O
Ia	O
)	O
and	O
(	O
Ib	O
)	O
are	O
not	O
present	O
in	O
the	O
patent	O
specification	O
.	O

New	O
chlorin	B
derivative	O
useful	O
as	O
photosensitizer	O
in	O
photodynamic	O
tumor	O
therapy	O

Dosage	O
forms	O
comprise	O
beta	O
blockers	O
.	O

The	O
beta	O
blockers	O
containing	O
pharmaceutical	O
formulations	O
are	O
liquid	O
aerosols	O
,	O
which	O
are	O
suitable	O
for	O
mucous	O
membrane	O
application	O
.	O

The	O
pharmaceutical	O
formulations	O
do	O
not	O
contain	O
components	O
for	O
delayed	O
release	O
and	O
are	O
administered	O
by	O
devices	O
which	O
release	O
in	O
volume	O
controlled	O
dosages	O
as	O
spray	O
.	O

-	O
ACTIVITY	O
:	O

Neuroprotective	O
;	O
Tranquilizer	O
;	O
Antidepressant	O
;	O
Analgesic	O
;	O
Auditory	O
;	O
Hypotensive	O
;	O
Antianginal	O
;	O
Anticonvulsant	O
;	O
Cardiant	O
;	O
Vasotropic	O
;	O
Antiarrhythmic	O
;	O
Hypnotic	O
;	O
Uropathic	O
;	O
Gastrointestinal	O
-	O
Gen	O
;	O
Endocrine	O
-	O
Gen	O
;	O
Antithyroid	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Beta	O
-	O
adrenergic	O
antagonist	O
.	O

Dosage	O
forms	O
,	O
useful	O
e.g.	O
for	O
the	O
acute	O
treatment	O
of	O
stress	O
-	O
induced	O
pathologies	O
in	O
the	O
central	O
nervous	O
system	O
and	O
cardiovascular	O
system	O
,	O
comprise	O
beta	O
blockers	O
,	O
which	O
are	O
in	O
the	O
form	O
of	O
liquid	O
aerosols	O

An	O
adenoviral	O
vector	O
including	O
at	O
least	O
one	O
DNA	O
sequence	O
encoding	O
a	O
clotting	O
factor	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
Factor	O
VIII	O
,	O
or	O
Factor	O
IX	O
.	O

Such	O
vectors	O
may	O
be	O
administered	O
to	O
a	O
host	O
in	O
an	O
amount	O
effective	O
to	O
treat	O
hemophilia	O
in	O
the	O
host	O
.	O

The	O
vectors	O
infect	O
hepatocytes	O
very	O
efficiently	O
,	O
whereby	O
the	O
hepatocytes	O
express	O
the	O
DNA	O
sequence	O
encoding	O
the	O
clotting	O
factor	O
.	O

Adenoviral	O
vectors	O
for	O
treatment	O
of	O
hemophilia	O

The	O
present	O
invention	O
relates	O
,	O
in	O
general	O
,	O
to	O
a	O
method	O
of	O
modulating	O
physiological	O
and	O
pathological	O
processes	O
and	O
,	O
in	O
particular	O
,	O
to	O
a	O
method	O
of	O
modulating	O
intra-	O
and	O
extracellular	O
levels	O
of	O
superoxide	B
radicals	O
and	O
thereby	O
processes	O
in	O
which	O
such	O
radicals	O
are	O
a	O
participant	O
.	O

The	O
invention	O
also	O
relates	O
to	O
compounds	O
and	O
compositions	O
suitable	O
for	O
use	O
in	O
such	O
methods	O
.	O

Superoxide	B
dismutase	O
mimetics	O

A	O
purine	B
compound	O
,	O
which	O
has	O
a	O
desired	O
and	O
an	O
undesired	O
effect	O
when	O
a	O
dosage	O
sufficient	O
to	O
induce	O
the	O
desired	O
effect	O
is	O
administered	O
to	O
a	O
mammal	O
,	O
is	O
combined	O
with	O
a	O
counteracting	O
agent	O
,	O
wherein	O
the	O
counteracting	O
agent	O
can	O
reduce	O
the	O
undesired	O
effect	O
when	O
the	O
combination	O
containing	O
an	O
effective	O
amount	O
of	O
the	O
purine	B
compound	O
is	O
administered	O
to	O
a	O
mammal	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
an	O
adenosine	B
compound	O
is	O
combined	O
in	O
vitro	O
with	O
a	O
catecholamine	B
in	O
a	O
predetermined	O
ratio	O
to	O
form	O
an	O
adenosine	B
composition	O
.	O

Very	O
high	O
dosages	O
of	O
a	O
purine	B
compound	O
,	O
such	O
as	O
adenosine	B
,	O
ATP	B
or	O
their	O
analogs	O
can	O
be	O
administered	O
to	O
a	O
mammal	O
via	O
administration	O
of	O
compositions	O
containing	O
the	O
purine	B
compound	O
and	O
a	O
counteracting	O
agent	O
,	O
while	O
reducing	O
the	O
dangerous	O
,	O
undesired	O
effects	O
associated	O
with	O
administering	O
the	O
same	O
dosage	O
of	O
purine	B
compound	O
without	O
first	O
combining	O
it	O
with	O
the	O
counteracting	O
agent	O
.	O

New	O
catecholamine	B
compositions	O
are	O
also	O
taught	O
.	O

The	O
purine	B
and	O
catecholamine	B
compositions	O
of	O
the	O
present	O
invention	O
pioneer	O
new	O
therapies	O
which	O
take	O
advantage	O
of	O
the	O
diversity	O
of	O
physiological	O
effects	O
of	O
purine	B
and	O
catecholamine	B
compounds	O
.	O

Purine	B
compositions	O

The	O
present	O
invention	O
concerns	O
the	O
discovery	O
that	O
proteins	O
encoded	O
by	O
a	O
family	O
of	O
vertebrate	O
genes	O
,	O
termed	O
here	O
hedgehog	O
-	O
related	O
genes	O
,	O
comprise	O
morphogenic	O
signals	O
produced	O
by	O
embryonic	O
patterning	O
centers	O
,	O
and	O
are	O
involved	O
in	O
the	O
formation	O
of	O
ordered	O
spatial	O
arrangements	O
of	O
differentiated	O
tissues	O
in	O
vertebrates	O
.	O

The	O
present	O
invention	O
makes	O
available	O
compositions	O
and	O
methods	O
that	O
can	O
be	O
utilized	O
,	O
for	O
example	O
to	O
generate	O
and/or	O
maintain	O
an	O
array	O
of	O
different	O
vertebrate	O
tissue	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Vertebrate	O
embryonic	O
pattern	O
-	O
inducing	O
hedgehog	O
-	O
like	O
proteins	O

The	O
human	O
PKD1	O
gene	O
,	O
responsible	O
for	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
(	O
APKD	O
)	O
,	O
or	O
adult	O
onset	O
polycystic	O
kidney	O
disease	O
,	O
has	O
been	O
identified	O
.	O

The	O
genomic	O
and	O
cDNA	O
sequences	O
of	O
the	O
5	O
'	O
end	O
of	O
PKD1	O
are	O
disclosed	O
.	O

Polycystic	O
kidney	O
disease	O
gene	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
bone	O
mass	O
anabolic	O
preservation	O
or	O
augmentation	O
in	O
human	O
or	O
other	O
animal	O
subjects	O
affected	O
by	O
osteoporosis	O
or	O
other	O
metabolic	O
bone	O
disorder	O
characterized	O
by	O
systemic	O
or	O
regional	O
bone	O
loss	O
,	O
using	O
bisphosphonates	B
formulations	O
,	O
wherein	O
the	O
bone	O
mass	O
anabolic	O
composition	O
contains	O
effective	O
non	O
-	O
toxic	O
doses	O
of	O
[	B
3-	I
(	I
N	I
,	I
N	I
-	I
dimethylamine	I
)	I
-1-hydroxypropylidene	I
]	I
-bisphosphonic	I
acid	I
or	O
olpadronate	B
or	O
the	O
monosodium	B
or	O
other	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Bone	O
mass	O
anabolic	O
composition	O
comprising	O
olpadronate	B

A	O
pharmaceutical	O
composition	O
is	O
provided	O
for	O
treating	O
hyperlipidemia	O
or	O
hypercholesterolemia	O
or	O
both	O
in	O
a	O
mammal	O
,	O
which	O
contains	O
an	O
effective	O
amount	O
of	O
each	O
of	O
fenofibrate	B
and	O
an	O
excipient	O
containing	O
one	O
or	O
more	O
polyglycolyzed	O
glycerides	O
.	O

Pharmaceutical	O
composition	O
containing	O
fenofibrate	B
and	O
polyglycolized	O
glycerides	O

A	O
method	O
,	O
using	O
a	O
multi	O
-	O
phasic	O
solvent	O
system	O
,	O
for	O
the	O
simultaneous	O
purification	O
and	O
separation	O
of	O
different	O
classes	O
of	O
compounds	O
,	O
which	O
may	O
be	O
cell	O
-	O
wall	O
components	O
or	O
derivatives	O
or	O
analogues	O
thereof	O
which	O
may	O
be	O
extracted	O
from	O
a	O
culture	O
of	O
the	O
relevant	O
cells	O
or	O
which	O
may	O
be	O
synthesized	O
.	O

The	O
cell	O
-	O
wall	O
components	O
may	O
be	O
lipid	O
cell	O
-	O
wall	O
components	O
of	O
microbial	O
origin	O
which	O
can	O
be	O
separated	O
from	O
contaminating	O
material	O
as	O
a	O
group	O
.	O

A	O
method	O
for	O
the	O
isolation	O
and	O
purification	O
of	O
lipid	O
cell	O
-	O
wall	O
components	O

Novel	O
compounds	O
of	O
Formula	O
(	O
1.0	O
)	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
Ras	O
function	O
and	O
therefore	O
inhibiting	O
the	O
abnormal	O
growth	O
of	O
cells	O
.	O

The	O
method	O
comprises	O
administering	O
a	O
compound	O
of	O
formula	O
(	O
1.0	O
)	O
to	O
a	O
biological	O
system	O
.	O

In	O
particular	O
,	O
the	O
method	O
inhibits	O
the	O
abnormal	O
growth	O
of	O
cells	O
in	O
a	O
mammal	O
such	O
as	O
a	O
human	O
being	O
.	O

Tricyclic	O
compounds	O
useful	O
for	O
inhibition	O
of	O
g	O
-	O
protein	O
function	O
and	O
for	O
treatment	O
of	O
proliferative	O
diseases	O

This	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
their	O
preparation	O
containing	O
conjugated	O
estrogens	B
for	O
the	O
treatment	O
of	O
peri	O
-	O
menopausal	O
,	O
menopausal	O
and	O
post	O
-	O
menopausal	O
disorders	O
in	O
women	O
.	O

The	O
novel	O
pharmaceutical	O
compositions	O
comprise	O
a	O
carrier	O
base	O
material	O
and	O
conjugated	O
estrogens	B
formed	O
into	O
a	O
solid	O
unit	O
dosage	O
form	O
possessing	O
a	O
regular	O
incremental	O
release	O
of	O
the	O
medicament	O
upon	O
oral	O
administration	O
.	O

Further	O
,	O
the	O
invention	O
comprises	O
the	O
combination	O
of	O
conjugated	O
estrogens	B
with	O
progestogens	B
in	O
a	O
solid	O
,	O
shaped	O
dosage	O
unit	O
.	O

Specifically	O
,	O
the	O
invention	O
comprises	O
the	O
use	O
of	O
an	O
organic	O
excipient	O
such	O
as	O
high	O
molecular	O
weight	O
hydroxyalkyl	O
alkylcelluloses	O
.	O

The	O
use	O
of	O
an	O
organic	O
excipient	O
such	O
as	O
hydroxypropylmethylcellulose	O
in	O
a	O
stable	O
,	O
solid	O
dosage	O
formulation	O
containing	O
either	O
conjugated	O
estrogens	O
alone	O
or	O
in	O
combination	O
with	O
a	O
progestogen	B
is	O
described	O
.	O

Pharmaceutical	O
compositions	O
of	O
conjugated	O
estrogens	B
and	O
methods	O
for	O
their	O
use	O

A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
G	O
,	O
T?1	O
,	O
T2	O
and	O
T3	O
¿	O
are	O
selected	O
from	O
CH	B
and	O
N	B
;	O
provided	O
that	O
T?2	O
and	O
T3	O
¿	O
are	O
not	O
both	O
CH	B
;	O
A	O
is	O
selected	O
from	O
a	O
direct	O
bond	O
and	O
(	B
1	I
-	I
4C	I
)	I
alkylene	I
;	O
X	O
is	O
selected	O
from	O
oxy	B
,	O
thio	B
,	O
sulphinyl	B
,	O
sulphonyl	B
,	O
carbonyl	B
,	O
carbonylamino	B
,	O
N	B
-	I
di-	I
(	I
1	I
-	I
6C	I
)	I
alkylcarbonylamino	I
,	O
sulphonamido	B
,	O
methylene	B
,	O
(	B
1	I
-	I
4C	I
)	I
alkylmethylene	I
and	O
di-	B
(	I
1	I
-	I
6C	I
)	I
alkylmethylene	I
,	O
and	O
when	O
T2	O
is	O
CH	B
,	O
X	O
may	O
also	O
be	O
selected	O
from	O
aminosulphonyl	B
and	O
oxycarbonyl	B
;	O
and	O
Q	O
is	O
selected	O
from	O
(	B
5	I
-	I
7C	I
)	I
cycloalkyl	I
,	O
a	O
heterocyclic	B
moiety	O
containing	O
up	O
to	O
4	O
heteroatoms	B
selected	O
from	O
nitrogen	B
,	O
oxygen	B
and	O
sulphur	B
;	O
phenyl	B
,	O
naphthyl	B
,	O
phenyl	B
(	I
1	I
-	I
4C	I
)	I
alkyl	I
and	O
phenyl	B
(	I
2	I
-	I
6C	I
)	I
alkenyl	I
;	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
diseases	O
or	O
medical	O
conditions	O
in	O
which	O
an	O
inhibition	O
of	O
oxido	B
-	I
squalene	I
cyclase	O
is	O
desirable	O
.	O

Use	O
of	O
oxido	B
-	I
squalene	I
cyclase	O
inhibitors	O
to	O
lower	O
blood	O
cholesterol	B

The	O
object	O
is	O
to	O
provide	O
a	O
promoting	O
agent	O
for	O
bone	O
formation	O
,	O
a	O
therapeutic	O
method	O
for	O
bone	O
formation	O
and	O
a	O
process	O
for	O
preparing	O
a	O
promoting	O
agent	O
for	O
bone	O
formation	O
.	O

A	O
promoting	O
agent	O
for	O
bone	O
formation	O
which	O
comprises	O
at	O
least	O
one	O
of	O
kistrin	O
,	O
echstatin	O
,	O
a	O
peptide	O
or	O
polypeptide	O
containing	O
the	O
amino	B
acid	I
sequence	O
ArgGlyAsp	B
in	O
the	O
molecule	O
such	O
as	O
a	O
peptide	O
represented	O
by	O
Gly	B
-	I
Arg	I
-	I
Gly	I
-	I
Asp	I
-	I
Ser	I
or	O
a	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
IX	O
)	O
and	O
so	O
on	O
,	O
as	O
well	O
as	O
a	O
biologically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R16	O
represents	O
-N	B
(	I
R20	I
)	I
2	I
(	O
R20	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
C1-C4	B
alkyl	I
group	O
)	O
,	O
R17	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
C1-C4	B
alkyl	I
group	O
,	O
R18	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1-C4	B
alkyl	I
group	O
and	O
so	O
on	O
,	O
R19	O
represents	O
OH	B
,	O
NH2	B
and	O
so	O
on	O
,	O
Y	O
represents	O
-NH-	B
,	O
-O-	B
or	O
a	O
direct	O
bond	O
,	O
a	O
represents	O
1	O
-	O
3	O
,	O
b	O
represents	O
1	O
or	O
2	O
,	O
c	O
represents	O
0	O
or	O
1	O
and	O
d	O
represents	O
0	O
or	O
1	O
.	O

Agents	O
for	O
promoting	O
bone	O
formation	O

The	O
invention	O
features	O
methods	O
for	O
treating	O
hepatitis	O
B	O
infection	O
by	O
administering	O
an	O
asialo	O
-	O
interferon	O
.	O

The	O
invention	O
also	O
features	O
an	O
animal	O
model	O
of	O
hepatitis	O
and	O
methods	O
for	O
measuring	O
hepatitis	O
B	O
virus	O
in	O
a	O
biological	O
sample	O
.	O

Method	O
for	O
treating	O
hepatitis	O
virus	O
infection	O

Methods	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
colorectal	O
cancer	O
are	O
provided	O
.	O

Specifically	O
,	O
the	O
method	O
relates	O
to	O
the	O
administration	O
of	O
an	O
effective	O
adenoma	O
or	O
microadenoma	O
preventing	O
amount	O
of	O
6-fluoroursodeoxycholic	B
acid	I
(	O
6-FUDCA	B
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
pharmaceutically	O
acceptable	O
conjugate	O
thereof	O
to	O
a	O
mammal	O
in	O
need	O
of	O
such	O
treatment	O
.	O

The	O
methods	O
find	O
general	O
use	O
in	O
the	O
prevention	O
of	O
the	O
formation	O
of	O
secondary	O
bile	O
acids	O
,	O
the	O
reduction	O
of	O
deoxycholic	B
acid	I
,	O
and	O
the	O
protection	O
against	O
cytotoxic	O
effects	O
of	O
other	O
bioacids	O
and	O
carcinogens	O
.	O

Prevention	O
and	O
treatment	O
of	O
colonic	O
adenoma	O
or	O
colonic	O
microadenoma	O
by	O
6-fluoroursodeoxycholic	B
acid	I
(	O
6-fudca	B
)	O

The	O
active	O
substances	O
identified	O
as	O
inhibitors	O
of	O
the	O
cellular	O
Na+	B
/	O
H+	B
exchanger	O
(	O
NHE	O
)	O
are	O
used	O
to	O
prepare	O
a	O
medicament	O
for	O
normalizing	O
serum	O
lipids	O
.	O

They	O
are	O
used	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
which	O
reduces	O
lipid	O
levels	O
in	O
the	O
blood	O
and	O
can	O
be	O
administered	O
for	O
treating	O
diseases	O
caused	O
by	O
lipid	O
levels	O
which	O
are	O
too	O
high	O
,	O
and	O
for	O
alleviating	O
the	O
endothelial	O
dysfunctional	O
syndrome	O
and	O
for	O
treating	O
diseases	O
caused	O
thereby	O
.	O

USE	O
OF	O
INHIBITORS	O
OF	O
THE	O
CELLULAR	O
Na+	B
/H+	O
EXCHANGER	O
(	O
NHE	O
)	O
FOR	O
PREPARING	O
A	O
MEDICAMENT	O
FOR	O
NORMALIZING	O
SERUM	O
LIPIDS	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
implanting	O
producer	O
cells	O
into	O
the	O
mammalian	O
brain	O
.	O

The	O
producer	O
cells	O
are	O
engineered	O
with	O
a	O
retroviral	O
based	O
recombinant	O
vector	O
encoding	O
a	O
tumorcidal	O
factor	O
or	O
susceptibility	O
factor	O
that	O
confers	O
on	O
tumor	O
cells	O
sensitivity	O
to	O
chemotherapeutic	O
or	O
radiotherapeutic	O
agents	O
.	O

Prior	O
to	O
transplantation	O
into	O
the	O
mammalian	O
brain	O
,	O
the	O
producer	O
cells	O
are	O
first	O
cultured	O
in	O
vitro	O
on	O
a	O
support	O
matrix	O
to	O
increase	O
the	O
long	O
-	O
term	O
viability	O
of	O
the	O
transplanted	O
cells	O
and	O
to	O
provide	O
long	O
-	O
term	O
functional	O
benefit	O
.	O

Compositions	O
for	O
gene	O
transfer	O
to	O
the	O
central	O
nervous	O
system	O

This	O
invention	O
is	O
directed	O
to	O
monocyclic	B
N	I
-	I
heterocyclics	I
which	O
are	O
substituted	O
by	O
acyclic	O
or	O
cyclic	O
thio	O
derivatives	O
which	O
are	O
useful	O
as	O
anti	O
-	O
coagulants	O
.	O

This	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
the	O
invention	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
to	O
treat	O
disease	O
-	O
states	O
characterized	O
by	O
thrombotic	O
activity	O
.	O

Thio	B
acid	I
derived	O
monocyclic	O
n	O
-	O
heterocyclics	O
as	O
anticoagulants	O

The	O
present	O
inventors	O
have	O
now	O
discovered	O
that	O
humans	O
have	O
a	O
gene	O
that	O
encodes	O
a	O
novel	O
protein	O
of	O
the	O
thymosin	O
beta	O
family	O
.	O

This	O
novel	O
protein	O
,	O
herein	O
referred	O
to	O
as	O
thymosin	O
beta	O
15	O
,	O
has	O
the	O
ability	O
to	O
bind	O
and	O
sequester	O
G	O
-	O
actin	O
,	O
like	O
other	O
members	O
of	O
the	O
thymosin	O
beta	O
family	O
,	O
but	O
unlike	O
what	O
is	O
known	O
about	O
other	O
members	O
it	O
also	O
directly	O
regulates	O
cell	O
motility	O
in	O
prostatic	O
carcinoma	O
cells	O
.	O

The	O
present	O
invention	O
is	O
directed	O
to	O
an	O
isolated	O
cDNA	O
encoding	O
the	O
human	O
thymosin	O
beta	O
15	O
gene	O
(	O
SEQ	O
ID	O
NO	O
:	O
1	O
)	O
and	O
have	O
deduced	O
the	O
amino	B
acid	I
sequence	O
(	O
SEQ	O
ID	O
NO	O
:	O
2	O
)	O
.	O

HUMAN	O
THYMOSIN	O
beta	O
15	O
GENE	O
,	O
PROTEIN	O
AND	O
USES	O
THEREOF	O

A	O
method	O
of	O
treating	O
infections	O
of	O
mononuclear	O
blood	O
cells	O
,	O
other	O
than	O
retroviral	O
infections	O
,	O
is	O
disclosed	O
.	O

A	O
method	O
of	O
modulating	O
the	O
function	O
of	O
monocytes	O
is	O
also	O
disclosed	O
.	O

The	O
method	O
involves	O
the	O
treatment	O
of	O
a	O
patient	O
's	O
blood	O
with	O
a	O
photoactivatable	O
compound	O
followed	O
by	O
ultraviolet	O
light	O
activation	O
of	O
the	O
photoactivatable	O
compound	O
.	O

The	O
blood	O
treated	O
as	O
such	O
is	O
returned	O
to	O
the	O
patient	O
in	O
a	O
process	O
known	O
as	O
extracorporeal	O
photopheresis	O
.	O

Monocyte	O
function	O
is	O
modulated	O
by	O
this	O
treatment	O
.	O

Photopheresis	O
treatment	O
of	O
leukocytes	O

A	O
method	O
for	O
stimulating	O
host	O
defense	O
mechanisms	O
in	O
a	O
mammal	O
via	O
administering	O
to	O
the	O
mammal	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
interferon	O
via	O
oromucosal	O
contact	O
.	O

The	O
amount	O
of	O
interferon	O
administered	O
is	O
less	O
than	O
an	O
amount	O
which	O
induces	O
a	O
pathological	O
response	O
when	O
administered	O
parenterally	O
.	O

Stimulation	O
of	O
host	O
defense	O
mechanisms	O
against	O
viral	O
challenges	O

In	O
accordance	O
with	O
the	O
present	O
invention	O
,	O
there	O
are	O
provided	O
compositions	O
and	O
methods	O
useful	O
for	O
the	O
in	O
vivo	O
delivery	O
of	O
substantially	O
water	O
-	O
insoluble	O
pharmacologically	O
active	O
agents	O
(	O
such	O
as	O
the	O
anticancer	O
drug	O
paclitaxel	B
)	O
in	O
which	O
the	O
pharmacologically	O
active	O
agent	O
is	O
delivered	O
in	O
the	O
form	O
of	O
suspended	O
particles	O
coated	O
with	O
protein	O
(	O
which	O
acts	O
as	O
a	O
stabilizing	O
agent	O
)	O
.	O

In	O
particular	O
,	O
protein	O
and	O
pharmacologically	O
active	O
agent	O
in	O
a	O
biocompatible	O
dispersing	O
medium	O
are	O
subjected	O
to	O
high	O
shear	O
,	O
in	O
the	O
absence	O
of	O
any	O
conventional	O
surfactants	O
,	O
and	O
also	O
in	O
the	O
absence	O
of	O
any	O
polymeric	O
core	O
material	O
for	O
the	O
particles	O
.	O

The	O
procedure	O
yields	O
particles	O
with	O
a	O
diameter	O
of	O
less	O
than	O
about	O
1	O
micron	O
.	O

The	O
use	O
of	O
specific	O
composition	O
and	O
preparation	O
conditions	O
(	O
e.g.	O
,	O
addition	O
of	O
a	O
polar	O
solvent	O
to	O
the	O
organic	O
phase	O
)	O
,	O
and	O
careful	O
selection	O
of	O
the	O
proper	O
organic	O
phase	O
and	O
phase	O
fraction	O
,	O
enables	O
the	O
reproducible	O
production	O
of	O
unusually	O
small	O
nanoparticles	O
of	O
less	O
than	O
200	O
nm	O
diameter	O
,	O
which	O
can	O
be	O
sterile	O
-	O
filtered	O
.	O

The	O
particulate	O
system	O
produced	O
according	O
to	O
the	O
invention	O
can	O
be	O
converted	O
into	O
a	O
redispersible	O
dry	O
power	O
comprising	O
nanoparticles	O
of	O
water	O
-	O
insoluble	O
drug	O
coated	O
with	O
a	O
protein	O
,	O
and	O
free	O
protein	O
to	O
which	O
molecules	O
of	O
the	O
pharmacological	O
agent	O
are	O
bound	O
.	O

This	O
results	O
in	O
a	O
unique	O
delivery	O
system	O
,	O
in	O
which	O
part	O
of	O
the	O
pharmacologically	O
active	O
agent	O
is	O
readily	O
bioavailable	O
(	O
in	O
the	O
form	O
of	O
molecules	O
bound	O
to	O
the	O
protein	O
)	O
,	O
and	O
part	O
of	O
the	O
agent	O
is	O
present	O
within	O
particles	O
without	O
any	O
polymeric	O
matrix	O
therein	O
.	O

Protein	O
stabilized	O
pharmacologically	O
active	O
agents	O
and	O
their	O
use	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
antagonists	O
of	O
the	O
actions	O
of	O
leukotrienes	B
.	O

These	O
compounds	O
are	O
useful	O
as	O
anti	O
-	O
asthmatic	O
,	O
anti	O
-	O
allergic	O
,	O
anti	O
-	O
inflammatory	O
,	O
and	O
cytoprotective	O
agents	O
.	O

They	O
are	O
also	O
useful	O
in	O
treating	O
angina	O
,	O
cerebral	O
spasm	O
,	O
glomerular	O
nephritis	O
,	O
hepatitis	O
,	O
endotoxemia	O
,	O
uveitis	O
,	O
and	O
allograft	O
rejection	O
.	O

Quinoline	B
leukotriene	B
antagonists	O

The	O
invention	O
concerns	O
compositions	O
in	O
the	O
form	O
of	O
microcapsules	O
or	O
implants	O
comprising	O
a	O
biodegradable	O
polymer	O
or	O
copolymer	O
vehicle	O
or	O
mixture	O
of	O
vehicles	O
with	O
logarithmic	O
viscosity	O
number	O
between	O
0.5	O
dl	O
/	O
g	O
and	O
1.6	O
dl	O
/	O
g	O
in	O
CHCl3	B
and	O
an	O
active	O
substance	O
or	O
mixture	O
of	O
active	O
substances	O
,	O
said	O
microcapsules	O
or	O
implants	O
being	O
capable	O
of	O
releasing	O
the	O
active	O
substance	O
or	O
mixture	O
of	O
active	O
substances	O
over	O
a	O
prolonged	O
period	O
up	O
to	O
three	O
months	O
or	O
more	O
.	O

These	O
compositions	O
can	O
also	O
comprise	O
an	O
active	O
substance	O
with	O
high	O
specific	O
surface	O
area	O
.	O

Sustained	O
-	O
release	O
compositions	O
and	O
method	O
for	O
preparing	O
same	O

Liquid	O
vitamin	B
C	I
concentrate	O
compositions	O
comprise	O
a	O
mineral	O
ascorbate	B
and	O
a	O
pharmacologically	O
acceptable	O
liquid	O
organic	O
polyol	O
solvent	O
for	O
the	O
mineral	O
ascorbate	B
,	O
the	O
concentrate	O
having	O
a	O
pH	O
between	O
about	O
5	O
and	O
7	O
.	O

The	O
concentrate	O
may	O
also	O
contain	O
an	O
aldonic	O
compound	O
and/or	O
a	O
pharmacologically	O
acceptable	O
zinc	B
compound	O
.	O

The	O
concentrate	O
compositions	O
are	O
prepared	O
by	O
heating	O
the	O
solvent	O
at	O
50	O
-	O
90	O
°	O
C	O
and	O
mixing	O
the	O
ascorbate	O
and/or	O
aldonic	O
compound	O
and/or	O
zinc	B
compound	O
into	O
the	O
heated	O
solvent	O
,	O
preferably	O
in	O
the	O
absence	O
of	O
oxygen	B
.	O

The	O
concentrate	O
compositions	O
are	O
also	O
characterized	O
as	O
a	O
composition	O
which	O
comprises	O
the	O
reaction	O
product	O
of	O
a	O
mineral	O
ascorbate	B
and	O
a	O
pharmacologically	O
acceptable	O
liquid	O
organic	O
polyol	O
solvent	O
and	O
,	O
optionally	O
,	O
an	O
aldonic	O
compound	O
and/or	O
a	O
soluble	O
non	O
-	O
toxic	O
zinc	B
compound	O
,	O
which	O
reaction	O
product	O
includes	O
4-hydroxy-5-methyl-3	B
(	I
2H	I
)	I
-furanone	I
and/or	O
3-hydroxy	B
kojic	I
acid	I
.	O

Finished	O
vitamin	B
C	I
products	O
,	O
characterized	O
by	O
excellent	O
long	O
term	O
vitamin	B
C	I
stability	O
,	O
are	O
conveniently	O
prepared	O
by	O
incorporating	O
the	O
concentrates	O
into	O
finished	O
cosmetic	O
,	O
medical	O
and	O
food	O
products	O
.	O

Stable	O
liquid	O
calcium	B
ascorbate	I
compositions	O
and	O
methods	O
of	O
manufacture	O
and	O
use	O

The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
delivering	O
immunogenic	O
or	O
therapeutic	O
proteins	O
to	O
bone	O
marrow	O
cells	O
using	O
alphavirus	O
vectors	O
.	O

The	O
alphavirus	O
vectors	O
disclosed	O
herein	O
target	O
specifically	O
to	O
bone	O
marrow	O
tissue	O
,	O
and	O
viral	O
genomes	O
persist	O
in	O
bone	O
marrow	O
for	O
at	O
least	O
three	O
months	O
post	O
-	O
infection	O
.	O

No	O
or	O
very	O
low	O
levels	O
of	O
virus	O
were	O
detected	O
in	O
quadricep	O
,	O
brain	O
,	O
and	O
sera	O
of	O
treated	O
animals	O
.	O

The	O
sequence	O
of	O
a	O
consensus	O
Sindbis	O
cDNA	O
clone	O
,	O
pTR339	O
,	O
and	O
infectious	O
RNA	O
transcripts	O
,	O
infectious	O
virus	O
particles	O
,	O
and	O
pharmaceutical	O
formulations	O
derived	O
therefrom	O
are	O
also	O
disclosed	O
.	O

The	O
sequence	O
of	O
the	O
genomic	O
RNA	O
of	O
the	O
Girdwood	O
S.A.	O
virus	O
,	O
and	O
cDNA	O
clones	O
,	O
infectious	O
RNA	O
transcripts	O
,	O
infectious	O
virus	O
particles	O
,	O
and	O
pharmaceutical	O
formulations	O
derived	O
therefrom	O
are	O
also	O
disclosed	O
.	O

System	O
for	O
the	O
in	O
vivo	O
delivery	O
and	O
expression	O
of	O
heterologous	O
genes	O
in	O
the	O
bone	O
marrow	O

The	O
present	O
application	O
describes	O
inhibitors	O
of	O
factor	O
Xa	O
with	O
a	O
neutral	O
P1	O
specificity	O
group	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
wherein	O
R	O
and	O
E	O
may	O
be	O
groups	O
such	O
as	O
methoxy	B
and	O
halo	B
.	O

Inhibitors	O
of	O
factor	O
xa	O
with	O
a	O
neutral	O
p1	O
specificity	O
group	O

In	O
accordance	O
with	O
the	O
present	O
invention	O
,	O
there	O
are	O
provided	O
therapeutically	O
effective	O
compounds	O
comprising	O
an	O
amphipathic	O
carboxylate	B
of	O
the	O
formula	O
R	B
-	I
COOH	I
,	O
or	O
a	O
salt	O
or	O
an	O
ester	B
or	O
amide	B
of	O
such	O
compound	O
,	O
where	O
R	O
designates	O
a	O
saturated	O
or	O
unsaturated	O
alkyl	B
chain	O
of	O
10	O
-	O
24	O
carbon	B
atoms	O
,	O
one	O
or	O
more	O
of	O
which	O
may	O
be	O
replaced	O
by	O
heteroatoms	O
,	O
where	O
one	O
or	O
more	O
of	O
said	O
carbon	B
or	O
heteroatom	O
chain	O
members	O
optionally	O
forms	O
part	O
of	O
a	O
ring	O
,	O
and	O
where	O
said	O
chain	O
is	O
optionally	O
substituted	O
by	O
a	O
hydrocarbyl	B
radical	I
,	O
heterocyclyl	B
radical	I
,	O
lower	O
alkoxy	B
,	O
hydroxyl	B
-	O
substituted	O
lower	O
alkyl	B
,	O
hydroxyl	B
,	O
carboxyl	B
,	O
halogen	B
,	O
phenyl	B
or	O
(	O
hydroxy-	B
,	O
lower	O
alkyl-	B
,	O
lower	O
alkoxy-	B
,	O
lower	O
alkenyl-	B
or	O
lower	O
alkynyl	B
)	O
-substituted	O
phenyl	B
,	O
C3-C7	B
cycloalkyl	I
or	O
(	O
hydroxy-	B
,	O
lower	O
alkyl-	B
,	O
lower	O
alkoxy-	B
,	O
lower	O
alkenyl-	B
or	O
lower	O
alkynyl	B
)	O
-substituted	O
C3-C7	B
cycloalkyl	I
wherein	O
said	O
amphiphatic	O
carboxylate	B
is	O
capable	O
of	O
being	O
endogenously	O
converted	O
to	O
its	O
respective	O
coenzyme	O
A	O
thioester	O
.	O

Carboxylic	B
acids	I
and	O
derivatives	O
thereof	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O

This	O
invention	O
is	O
directed	O
to	O
quinoline	B
/	O
quinoxaline	B
compounds	O
which	O
inhibit	O
platelet	O
-	O
derived	O
growth	O
factor	O
or	O
p56	O
<	O
lck	O
>	O
tyrosine	B
kinase	O
activity	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
these	O
compounds	O
for	O
treating	O
a	O
patient	O
suffering	O
from	O
or	O
subject	O
to	O
disorders	O
/	O
conditions	O
involving	O
cellular	O
differentiation	O
,	O
proliferation	O
,	O
extracellular	O
matrix	O
production	O
or	O
mediator	O
release	O
and/or	O
T	O
cell	O
activation	O
and	O
proliferation	O
.	O

QUINOXALINE	B
COMPOUNDS	O
WHICH	O
INHIBIT	O
PLATELET	O
-	O
DERIVED	O
GROWTH	O
FACTOR	O
AND	O
/	O
OR	O
p56lck	O
TYROSINE	B
KINASES	O

The	O
present	O
invention	O
discloses	O
useful	O
surfactant	O
molecules	O
including	O
polypeptides	O
,	O
proteins	O
,	O
and	O
a	O
variety	O
of	O
other	O
organic	O
molecules	O
,	O
as	O
well	O
as	O
methods	O
of	O
making	O
and	O
using	O
same	O
.	O

Surfactant	O
compositions	O
,	O
including	O
liposomal	O
surfactant	O
compositions	O
,	O
are	O
also	O
disclosed	O
.	O

Use	O
of	O
the	O
surfactant	O
molecules	O
of	O
the	O
present	O
invention	O
in	O
pulmonary	O
lavage	O
procedures	O
for	O
a	O
variety	O
of	O
therapeutic	O
applications	O
is	O
also	O
disclosed	O
,	O
including	O
the	O
treatment	O
of	O
respiratory	O
distress	O
syndrome	O
;	O
the	O
removal	O
of	O
inflammatory	O
exudate	O
from	O
inflamed	O
lung	O
tissues	O
;	O
and	O
the	O
treatment	O
of	O
meconium	O
aspiration	O
syndrome	O
in	O
infants	O
.	O

Therapeutic	O
pulmonary	O
lavage	O
with	O
diluted	O
surfactants	O

It	O
comprises	O
an	O
inert	O
nucleus	O
;	O
and	O
active	O
layer	O
which	O
is	O
soluble	O
or	O
which	O
desintegrates	O
in	O
water	O
and	O
is	O
obtained	O
from	O
a	O
unique	O
aqueous	O
or	O
hydro	O
-	O
alcoholic	O
solution	O
-	O
suspension	O
which	O
comprises	O
:	O
an	O
active	O
principle	O
having	O
an	O
antiulcer	O
activity	O
with	O
formula	O
(	O
I	O
,	O
II	O
or	O
III	O
)	O
and	O
at	O
least	O
one	O
excipient	O
;	O
and	O
a	O
gastroresistant	O
external	O
coating	O
layer	O
obtained	O
from	O
a	O
solution	O
which	O
comprises	O
an	O
enteric	O
covering	O
polymer	O
and	O
at	O
least	O
one	O
excipient	O
.	O

The	O
process	O
is	O
carried	O
out	O
by	O
(	O
1	O
)	O
covering	O
the	O
inert	O
nucleus	O
by	O
nebulisation	O
of	O
the	O
aqueous	O
or	O
hydroalcoholic	O
suspension	O
-	O
solution	O
;	O
(	O
2	O
)	O
drying	O
the	O
active	O
layer	O
formed	O
during	O
the	O
nebulisation	O
of	O
the	O
prior	O
step	O
;	O
and	O
(	O
3	O
)	O
covering	O
the	O
nucleus	O
charged	O
through	O
nebulisation	O
with	O
the	O
solution	O
comprising	O
an	O
enteric	O
coating	O
polymer	O
with	O
at	O
least	O
one	O
excipient	O
to	O
obtain	O
an	O
external	O
gastroresistant	O
coating	O
layer	O
.	O

Oral	O
pharmaceutical	O
preparation	O
comprising	O
an	O
antiulcer	O
benzimidazole	B
derivative	O
,	O
and	O
process	O
for	O
its	O
production	O

The	O
present	O
invention	O
concerns	O
compositions	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
skin	O
disorders	O
,	O
particularly	O
,	O
but	O
not	O
limited	O
to	O
,	O
eczema	O
,	O
psoriasis	O
and	O
dermatitis	O
,	O
and	O
also	O
compositions	O
and	O
their	O
use	O
in	O
treatment	O
of	O
cancer	O
,	O
particularly	O
skin	O
cancer	O
.	O

Use	O
of	O
zinc	B
salts	O
of	O
conjugated	O
linoleic	B
acids	I
to	O
treat	O
skin	O
disorders	O

A	O
dry	O
powder	O
composition	O
comprising	O
budesonide	B
and	O
a	O
carrier	O
substance	O
,	O
both	O
of	O
which	O
are	O
in	O
finely	O
divided	O
form	O
,	O
wherein	O
the	O
formulation	O
has	O
a	O
poured	O
bulk	O
density	O
of	O
from	O
0.28	O
to	O
0.38	O
g	O
/	O
ml	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
respiratory	O
disorders	O
.	O

New	O
formulation	O
for	O
inhalation	O
having	O
a	O
poured	O
bulk	O
density	O
of	O
from	O
0.28	O
to	O
0.38	O
g	O
/	O
ml	O
,	O
comprising	O
budesonide	B

The	O
invention	O
concerns	O
a	O
lactic	B
acid	I
bacteria	O
strain	O
(	O
1	O
)	O
,	O
whereof	O
the	O
RNA	O
ribosome	O
16S	O
is	O
characteristic	O
of	O
the	O
genus	O
Streptococcus	O
(	O
2	O
)	O
,	O
whose	O
profile	O
in	O
crude	O
proteins	O
,	O
obtained	O
after	O
migration	O
of	O
crude	O
proteins	O
on	O
SDS	O
-	O
PAGE	O
gel	O
electrophoresis	O
,	O
is	O
characteristic	O
of	O
that	O
of	O
the	O
CNCM	O
I-1926	O
lactic	B
acid	I
bacteria	O
strain	O
,	O
but	O
distinct	O
from	O
those	O
of	O
species	O
recognised	O
as	O
belonging	O
to	O
the	O
genus	O
Streptococcus	O
,	O
namely	O
S.	O
acidominimus	O
,	O
S.agalactiae	O
,	O
S.	O
alactolyticus	O
,	O
S.	O
anginosus	O
,	O
S.	O
bovis	O
,	O
S.	O
canis	O
,	O
S.	O
caprinus	O
,	O
S.	O
constellatus	O
,	O
S.	O
cricetus	O
,	O
S.	O
cristatus	O
,	O
S.	O
difficile	O
,	O
S.	O
downei	O
,	O
S.	O
dysgalactiae	O
ssp	O
.	O

dysgalactiae	O
,	O
S.	O
dysgalactiae	O
ssp	O
.	O

equisimilis	O
,	O
S.	O
equi	O
,	O
S.	O
equi	O
ssp	O
.	O

equi	O
,	O
S.	O
equi	O
ssp	O
.	O

zooepidemicus	O
,	O
S.	O
equinus	O
,	O
S.ferus	O
,	O
S.	O
gallolyticus	O
,	O
S.	O
gordonii	O
,	O
S.	O
hyointestinalis	O
,	O
S.	O
hyovaginalis	O
,	O
S.	O
iniae	O
,	O
S.	O
intermedius	O
,	O
S.	O
intestinalis	O
,	O
S.	O
macacae	O
,	O
S.	O
mitis	O
,	O
S.	O
mutans	O
,	O
S.	O
oralis	O
,	O
S.	O
parasanguinis	O
,	O
S.	O
parauberis	O
,	O
S.	O
phocae	O
,	O
S.	O
pleomorphus	O
,	O
S.	O
pneumoniae	O
,	O
S.	O
porcinus	O
,	O
S.	O
pyogenes	O
,	O
S.	O
ratti	O
,	O
S.	O
salivarius	O
,	O
S.	O
sanguinis	O
,	O
S.	O
shiloi	O
,	O
S.	O
sobrinus	O
,	O
S.	O
suis	O
,	O
S.	O
thermophilus	O
,	O
S.	O
thoraltensis	O
,	O
S.	O
uberis	O
,	O
S.	O
vestibularis	O
,	O
S.	O
viridans	O
.	O

The	O
invention	O
also	O
concerns	O
the	O
use	O
of	O
said	O
lactic	B
acid	I
bacteria	O
strain	O
,	O
or	O
a	O
polysaccharide	O
secreted	O
by	O
said	O
strain	O
,	O
for	O
preparing	O
a	O
food	O
composition	O
,	O
in	O
particular	O
a	O
lactic	O
milk	O
or	O
fresh	O
cheese	O
.	O

The	O
invention	O
further	O
concerns	O
a	O
food	O
or	O
pharmaceutical	O
composition	O
comprising	O
a	O
lactic	B
acid	I
bacteria	O
or	O
a	O
polysaccharide	O
constituted	O
by	O
a	O
chain	O
of	O
glucose	B
,	O
galactose	B
and	O
N	B
-	I
acetylglucosamine	I
in	O
a	O
ratio	O
of	O
3:2:1	O
respectively	O
.	O

Novel	O
lactic	B
acid	I
bacteria	O
species	O

Methods	O
and	O
compositions	O
are	O
disclosed	O
which	O
comprise	O
red	O
rice	O
fermentation	O
products	O
,	O
that	O
can	O
be	O
used	O
as	O
natural	O
dietary	O
supplements	O
and/or	O
medicaments	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
hyperlipidermia	O
and	O
associated	O
disorders	O
and	O
symptoms	O
,	O
such	O
as	O
cardiovascular	O
diseases	O
,	O
cerebrovascular	O
diseases	O
,	O
diabetes	O
,	O
hypertension	O
,	O
obesity	O
,	O
asthenic	O
breathing	O
,	O
chronic	O
headache	O
,	O
chest	O
pain	O
and	O
tightness	O
,	O
limb	O
swelling	O
and	O
distention	O
,	O
loss	O
of	O
appetite	O
and	O
excess	O
expectoration	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
effective	O
in	O
lowering	O
both	O
the	O
serum	O
cholesterol	B
and	O
serum	O
triglyceride	B
levels	O
in	O
human	O
,	O
and	O
can	O
be	O
used	O
for	O
maintaining	O
cardiovascular	O
health	O
.	O

The	O
invention	O
also	O
encompasses	O
particular	O
Monascus	O
strains	O
that	O
yield	O
fermentation	O
products	O
with	O
the	O
desired	O
biological	O
activities	O
.	O

Methods	O
and	O
compositions	O
employing	O
red	O
rice	O
fermentation	O
products	O

Methods	O
for	O
obtaining	O
beneficial	O
stable	O
levels	O
of	O
circulating	O
histamine	B
are	O
disclosed	O
for	O
use	O
in	O
methods	O
for	O
enhancing	O
natural	O
killer	O
cell	O
cytotoxicity	O
and	O
for	O
elevating	O
histamine	B
levels	O
in	O
individuals	O
in	O
need	O
thereof	O
.	O

In	O
such	O
methods	O
,	O
a	O
beneficial	O
level	O
of	O
circulating	O
histamine	B
is	O
attained	O
and	O
an	O
agent	O
whose	O
ability	O
to	O
enhance	O
natural	O
killer	O
cell	O
cytotoxicity	O
is	O
augmented	O
by	O
histamine	B
is	O
administered	O
.	O

Alternatively	O
,	O
stable	O
beneficial	O
levels	O
of	O
circulating	O
histamine	B
can	O
be	O
attained	O
in	O
subjects	O
receiving	O
chemotherapy	O
or	O
antiviral	O
treatment	O
.	O

The	O
invention	O
may	O
also	O
be	O
employed	O
in	O
treatments	O
combining	O
histamine	B
,	O
agents	O
which	O
enhance	O
natural	O
killer	O
cell	O
cytotoxicity	O
,	O
and	O
chemotherapeutic	O
agents	O
.	O

Optimization	O
of	O
the	O
delivery	O
of	O
histamine	B
and	O
substances	O
which	O
induce	O
the	O
release	O
of	O
endogenous	O
histamine	B
are	O
also	O
disclosed	O
.	O

Use	O
of	O
histamine	B
for	O
elevating	O
blood	O
histamine	B
levels	O

The	O
present	O
invention	O
describes	O
novel	O
treatments	O
for	O
movement	O
disorders	O
,	O
including	O
tardive	O
dyskinesia	O
and	O
tardive	O
dystonia	O
,	O
tic	O
disorders	O
,	O
Tourette	O
's	O
syndrome	O
,	O
and	O
blepharospasm	O
,	O
and	O
other	O
focal	O
dystonias	O
.	O

The	O
treatments	O
of	O
the	O
present	O
invention	O
utilize	O
agents	O
that	O
simultaneously	O
act	O
as	O
NMDA	O
-	O
type	O
glutamate	B
receptor	O
antagonists	O
.	O

Additionally	O
,	O
the	O
treatments	O
of	O
the	O
present	O
invention	O
utilize	O
agents	O
that	O
simultaneously	O
act	O
as	O
NMDA	O
-	O
type	O
glutamate	B
receptor	O
antagonists	O
and	O
GABA	O
-	O
A	O
receptor	O
agonists	O
.	O

Preferably	O
these	O
two	O
activities	O
are	O
characteristic	O
of	O
a	O
single	O
agent	O
,	O
for	O
example	O
acamprosate	B
.	O

Alternatively	O
,	O
separate	O
agents	O
having	O
these	O
activities	O
can	O
be	O
combined	O
and	O
administered	O
together	O
.	O

The	O
invention	O
also	O
provides	O
a	O
third	O
agent	O
that	O
can	O
be	O
used	O
in	O
combination	O
with	O
a	O
treatment	O
for	O
movement	O
disorders	O
,	O
that	O
acts	O
as	O
a	O
non	O
-	O
competitive	O
NMDA	O
-	O
receptor	O
blocking	O
agent	O
or	O
ion	O
channel	O
blocker	O
that	O
augments	O
the	O
effect	O
of	O
the	O
primary	O
treatment	O
.	O

A	O
particularly	O
preferred	O
ion	O
channel	O
blocking	O
agent	O
is	O
magnesium	B
.	O

Alternatively	O
,	O
magnesium	B
can	O
be	O
administered	O
alone	O
for	O
prevention	O
and	O
treatment	O
of	O
movement	O
disorders	O
.	O

N	B
-	I
acetylhomotaurinates	I
for	O
use	O
in	O
treating	O
hyperkinesias	O

The	O
invention	O
relates	O
to	O
new	O
piperazinyl	O
-	B
substituted	I
pyridylalkane	I
alkene	I
and	O
alkine	B
acid	I
amides	I
with	O
a	O
saturated	O
or	O
one	O
or	O
several	O
-	O
fold	O
unsaturated	O
hydrocarbon	B
residue	O
in	O
the	O
carboxylic	B
acid	I
group	O
according	O
to	O
general	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
methods	O
for	O
the	O
production	O
of	O
these	O
compounds	O
,	O
medicaments	O
containing	O
these	O
and	O
their	O
production	O
as	O
well	O
as	O
their	O
therapeutic	O
use	O
,	O
especially	O
as	O
cytostatic	O
agents	O
and	O
immunosuppressive	O
agents	O
,	O
for	O
example	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
various	O
types	O
of	O
tumors	O
and	O
control	O
of	O
immune	O
reactions	O
such	O
as	O
autoimmune	O
diseases	O
.	O

New	O
piperazinyl	B
-	I
substituted	I
pyridylalkane	I
,	O
alkene	B
and	O
alkine	B
carboxamides	I

The	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
pharmacological	O
agents	O
to	O
be	O
used	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
related	O
pathological	O
conditions	O
and	O
compositions	O
for	O
treatment	O
of	O
conditions	O
caused	O
by	O
amyloidosis	O
,	O
Aβ	O
-	O
mediated	O
formation	O
of	O
ROS	O
,	O
or	O
both	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
are	O
disclosed	O
.	O

Metal	O
chelators	O
for	O
use	O
in	O
the	O
treatment	O
of	O
alzheimer	O
's	O
disease	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
active	O
agent	O
from	O
the	O
following	O
group	O
:	O
17α	B
-	I
estradiol	I
,	O
its	O
chemically	O
modified	O
derivatives	O
and	O
chemically	O
modified	O
derivatives	O
of	O
17β	B
-	I
estradiol	I
or	O
estriol	B
;	O
for	O
producing	O
pharmaceutical	O
preparations	O
for	O
treating	O
side	O
effects	O
such	O
as	O
hot	O
flushes	O
during	O
and/or	O
after	O
a	O
treatment	O
with	O
analogs	O
or	O
antagonists	O
of	O
the	O
gonadotropin	O
-	O
releasing	O
hormone	O
(	O
GnRHa	O
-	O
therapy	O
)	O
.	O

Said	O
pharmaceutical	O
preparations	O
can	O
be	O
produced	O
in	O
oral	O
and	O
parenteral	O
,	O
including	O
topical	O
,	O
rectal	O
,	O
sub	O
-	O
cutaneous	O
,	O
intravenous	O
,	O
intramuscular	O
,	O
intraperitoneal	O
,	O
intranasal	O
,	O
intravaginal	O
,	O
intrabuccal	O
or	O
sub	O
-	O
lingual	O
forms	O
of	O
administration	O
.	O

THE	O
USE	O
OF17-ALPHA	O
-	B
ESTRADIOL	I
DERIVATIVES	O
FOR	O
TREATING	O
SIDE	O
-	O
EFFECTS	O
DURING	O
AND	O
/	O
OR	O
AFTER	O
GnRHa	O
THERAPY	O

Pharmaceutical	O
dosage	O
forms	O
for	O
anticancer	O
drugs	O
,	O
and	O
paclitaxel	B
in	O
particular	O
,	O
are	O
described	O
in	O
which	O
the	O
active	O
drug	O
is	O
formulated	O
as	O
storage	O
stable	O
self	O
-	O
emulsifying	O
preconcentrate	O
.	O

Taxane	B
microemulsions	O

The	O
present	O
invention	O
provides	O
topical	O
compositions	O
comprising	O
high	O
surface	O
area	O
zinc	B
oxide	I
,	O
having	O
a	O
surface	O
area	O
between	O
30	O
m2	O
/	O
g	O
and	O
100	O
m2	O
/	O
g	O
and	O
an	O
average	O
particle	O
size	O
between	O
0.1	O
and	O
200	O
νm	O
in	O
diameter	O
,	O
said	O
high	O
surface	O
area	O
zinc	B
oxide	I
being	O
present	O
in	O
an	O
amount	O
sufficient	O
to	O
absorb	O
liquids	O
from	O
parts	O
of	O
the	O
body	O
to	O
which	O
the	O
topical	O
composition	O
is	O
applied	O
.	O

The	O
compositions	O
are	O
particularly	O
good	O
at	O
absorbing	O
sweat	O
,	O
sebum	O
,	O
urine	O
and	O
water	O
,	O
making	O
them	O
suitable	O
for	O
treating	O
acne	O
,	O
athletes	O
foot	O
and	O
nappy	O
rash	O
.	O

Use	O
of	O
a	O
topical	O
composition	O

A	O
new	O
class	O
of	O
cyclin	O
dependent	O
kinase	O
inhibitors	O
that	O
also	O
have	O
antiproliferative	O
activity	O
in	O
human	O
tumor	O
cell	O
line	O
assays	O
are	O
described	O
.	O

Most	O
of	O
these	O
compounds	O
satisfy	O
formula	O
(	O
I	O
)	O
;	O
wherein	O
A	O
is	O
oxygen	B
or	O
sulfur	B
coupled	O
to	O
the	O
right	O
by	O
a	O
single	O
or	O
double	O
bond	O
;	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
aryl	B
,	O
lower	O
aliphatic	O
substituents	O
,	O
particularly	O
alkyl	B
and	O
lower	O
alkyl	B
ester	I
;	O
R4-R7	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alkoxy	B
,	O
amino	B
,	O
acyl	B
,	O
aliphatic	B
substituents	O
,	O
particularly	O
alkyl	B
,	O
alkenyl	B
and	O
alkinyl	B
substituents	O
,	O
aliphatic	O
alcohols	B
,	O
particularly	O
alkyl	B
alcohols	I
,	O
aliphatic	B
nitriles	I
,	O
particularly	O
alkyl	B
nitriles	I
,	O
cyano	B
,	O
nitro	B
,	O
carboxyl	B
,	O
halogen	B
,	O
hydrogen	B
,	O
hydroxyl	B
,	O
imino	B
,	O
and	O
α	O
,	O
β	O
unsaturated	O
ketones	O
;	O
R8-R11	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aliphatic	B
substituents	O
,	O
particularly	O
alkyl	B
,	O
alkenyl	B
and	O
alkinyl	B
substituents	O
,	O
particularly	O
lower	O
aliphatic	B
substituents	O
,	O
aliphatic	B
alcohols	I
,	O
particularly	O
alkyl	B
alcohols	I
,	O
alkoxy	B
,	O
acyl	B
,	O
cyano	B
,	O
nitro	B
,	O
epoxy	B
,	O
haloalkyl	B
groups	O
,	O
halogen	B
,	O
hydrogen	B
and	O
hydroxyl	B
;	O
R12	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aliphatic	B
groups	O
,	O
particularly	O
lower	O
alkyl	B
groups	O
,	O
aliphatic	B
alcohols	I
,	O
particularly	O
alkyl	B
alcohols	I
,	O
carboxylic	B
acids	I
and	O
hydrogen	B
.	O

Compositions	O
comprising	O
effective	O
amounts	O
of	O
such	O
compounds	O
also	O
are	O
described	O
.	O

These	O
compounds	O
and	O
compositions	O
can	O
be	O
used	O
in	O
a	O
method	O
for	O
inhibiting	O
the	O
proliferation	O
of	O
living	O
cells	O
in	O
a	O
subject	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
the	O
compound	O
(	O
s	O
)	O
,	O
or	O
composition	O
(	O
s	O
)	O
comprising	O
the	O
compound	O
(	O
s	O
)	O
,	O
to	O
a	O
subject	O
to	O
inhibit	O
the	O
proliferation	O
of	O
living	O
cells	O
,	O
such	O
as	O
neoplastic	O
cells	O
.	O

Fused	O
azepinone	B
cyclin	O
dependent	O
kinase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
aryl	B
alkanoylpyridazine	I
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
their	O
physiologically	O
compatible	O
salts	O
and	O
solvates	O
,	O
where	O
R1	O
,	O
R2	O
,	O
Q	O
and	O
B	O
have	O
the	O
meanings	O
given	O
in	O
claim	O
1	O
.	O

Said	O
compounds	O
have	O
a	O
phosphodiesterase	O
-	O
IV	O
inhibiting	O
action	O
and	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
allergic	O
disorders	O
,	O
asthma	O
,	O
chronic	O
bronchitis	O
,	O
atopic	O
dermatitis	O
,	O
psoriasis	O
and	O
other	O
skin	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
auto	O
-	O
immune	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
multiple	O
sclerosis	O
,	O
Crohn	O
's	O
disease	O
,	O
diabetes	O
mellitus	O
or	O
ulcerative	O
colitis	O
,	O
osteoporosis	O
,	O
transplant	O
rejection	O
reactions	O
,	O
cachexia	O
,	O
tumour	O
growth	O
or	O
tumour	O
metastases	O
,	O
sepsis	O
,	O
memory	O
disturbances	O
,	O
atherosclerosis	O
and	O
AIDS	O
.	O

Aryl	B
alkanoylpyridazines	I

A	O
method	O
of	O
treating	O
a	O
hyperproliferative	O
disorder	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
,	O
in	O
combination	O
,	O
a	O
treatment	O
effective	O
amount	O
of	O
:	O
(	O
a	O
)	O
a	O
ceramide	O
-	O
generating	O
retinoid	O
such	O
as	O
fenretinide	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
(	O
b	O
)	O
at	O
least	O
one	O
(	O
and	O
in	O
certain	O
embodiments	O
at	O
least	O
two	O
)	O
ceramide	O
degredation	O
inhibitor	O
,	O
such	O
as	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	O
i	O
)	O
glucosylceramide	O
synthesis	O
inhibitors	O
,	O
(	O
ii	O
)	O
sphingosine-1-phosphate	B
synthesis	O
inhibitors	O
,	O
and	O
(	O
iii	O
)	O
protein	O
kinase	O
C	O
inhibitors	O
.	O

A	O
preferred	O
glucosyl	O
ceramide	O
synthesis	O
inhibitor	O
is	O
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol	B
.	O

A	O
preferred	O
sphingosine-1-phosphate	B
synthesis	O
inhibitor	O
is	O
D	B
-	I
erytho	I
-	I
N	I
,	I
N	I
-	I
dimethylsphingosine	I
.	O

A	O
preferred	O
protein	O
kinase	O
C	O
inhibitor	O
is	O
L	B
-	I
threo	I
-	I
dihydrosphingosine	I
.	O

Treatment	O
of	O
hyperproliferative	O
disorders	O

The	O
present	O
invention	O
provides	O
new	O
retinoid	O
compounds	O
and	O
uses	O
of	O
the	O
compounds	O
in	O
humans	O
and	O
animals	O
for	O
chemoprevention	O
of	O
skin	O
and/or	O
breast	O
cancer	O
and	O
for	O
therapy	O
of	O
leukemia	O
.	O

Novel	O
retinoids	O
and	O
use	O
thereof	O

A	O
biocompatible	O
and	O
biodegradable	O
material	O
is	O
applied	O
to	O
a	O
tissue	O
region	O
,	O
e.g.	O
,	O
to	O
seal	O
a	O
vascular	O
puncture	O
site	O
,	O
or	O
to	O
arrest	O
the	O
flow	O
of	O
blood	O
or	O
fluid	O
from	O
body	O
tissue	O
,	O
or	O
to	O
arrest	O
diffuse	O
bleeding	O
.	O

The	O
material	O
preferably	O
includes	O
a	O
protein	O
comprising	O
recombinant	O
or	O
natural	O
serum	O
albumin	O
,	O
which	O
is	O
mixed	O
with	O
a	O
polymer	O
that	O
comprises	O
poly	B
(	I
ethylene	I
)	I
glycol	I
(	O
PEG	B
)	O
,	O
and	O
,	O
most	O
preferably	O
,	O
a	O
multi	O
-	O
armed	O
PEG	B
polymer	O
.	O

Kit	O
for	O
creating	O
in	O
situ	O
,	O
chemically	O
cross	O
-	O
linked	O
,	O
mechanical	O
barriers	O
or	O
covering	O
structures	O
for	O
vascular	O
puncture	O
sites	O

A	O
patient	O
with	O
an	O
inflammatory	O
disease	O
of	O
the	O
head	O
and	O
neck	O
is	O
treated	O
with	O
a	O
therapeutic	O
amount	O
of	O
a	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	O
or	O
a	O
cyclooxygenase-2	O
inhibitor	O
from	O
a	O
natural	O
source	O
.	O

In	O
one	O
embodiment	O
,	O
a	O
patient	O
with	O
a	O
sore	O
throat	O
caused	O
by	O
tonsillitis	O
or	O
pharyngitis	O
is	O
treated	O
with	O
the	O
topical	O
application	O
of	O
a	O
cyclooxygenase-2	O
inhibitor	O
from	O
a	O
natural	O
source	O
.	O

In	O
other	O
embodiments	O
,	O
patients	O
with	O
sore	O
throat	O
caused	O
by	O
tonsillitis	O
or	O
pharyngitis	O
or	O
a	O
patient	O
with	O
sinusitis	O
are	O
treated	O
by	O
systemic	O
administration	O
of	O
a	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	O
.	O

In	O
another	O
embodiment	O
,	O
a	O
patient	O
with	O
periodontitis	O
is	O
treated	O
by	O
administration	O
of	O
a	O
cyclooxygenase-2	O
inhibitor	O
from	O
a	O
natural	O
source	O
.	O

Use	O
of	O
cyclooxygenase-2	O
inhibitors	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
of	O
the	O
head	O
and	O
neck	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
hydroxystilbene	B
compounds	O
of	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
A	O
means	O
a	O
radical	O
of	O
formula	O
(	O
1a	O
)	O
or	O
a	O
radical	O
of	O
formula	O
(	O
1b	O
)	O
and	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
,	O
independently	O
of	O
each	O
other	O
,	O
mean	O
hydrogen	B
,	O
halogen	B
,	O
hydroxy	B
,	O
C1-C16-alkyl	B
,	O
C1-C16-alkoxy	B
,	O
phenyl	B
;	O
C1-C3-phenylalkyl	B
;	O
C6-C10-aryloxy	B
,	O
amino	B
,	O
mono	B
-	I
C1-C5-alkylamino	I
,	O
Di	B
-	I
C1-C5-alkylamino	I
,	O
or	O
-NO2	B
;	O
as	O
microbicidal	O
active	O
substances	O
.	O

These	O
compounds	O
have	O
a	O
marked	O
effect	O
on	O
pathogenic	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
,	O
as	O
well	O
as	O
on	O
yeasts	O
and	O
moulds	O
.	O

For	O
this	O
reason	O
,	O
they	O
are	O
suitable	O
for	O
antimicrobial	O
treatments	O
,	O
especially	O
for	O
preserving	O
and	O
disinfecting	O
surfaces	O
.	O

Hydroxystilbene	B
compounds	O
used	O
as	O
microbicidal	O
active	O
substances	O

Piperidine	B
derivatives	O
and	O
pharmaceutical	O
derivatives	O
thereof	O
useful	O
in	O
methods	O
of	O
treatment	O
of	O
bacterial	O
infections	O
in	O
mammals	O
,	O
particularly	O
in	O
man	O
.	O

Quinoline	B
derivatives	O
and	O
their	O
use	O
as	O
antibacterial	O
agents	O

The	O
invention	O
relates	O
to	O
a	O
nucleotide	O
sequence	O
coding	O
for	O
the	O
PRV-1	O
gene	O
and	O
essentially	O
comprising	O
sequence	O
ID	O
No.	O
1	O
and	O
to	O
a	O
method	O
for	O
detecting	O
said	O
gene	O
as	O
well	O
as	O
to	O
the	O
polypeptide	O
coded	O
by	O
said	O
gene	O
.	O

Prv-1	O
gene	O
and	O
the	O
use	O
thereof	O

The	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
decreasing	O
atheroma	O
formation	O
in	O
a	O
mammal	O
comprising	O
administering	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
PON-1	O
or	O
its	O
functional	O
equivalent	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

Also	O
included	O
herein	O
are	O
pharmaceutical	O
compositions	O
,	O
and	O
a	O
method	O
for	O
diagnosing	O
predisposition	O
to	O
hypercholesterolemia	O
by	O
assessing	O
the	O
level	O
of	O
native	O
circulating	O
PON-1	O
.	O

Use	O
of	O
paraoxanase-1	O
(	O
pon-1	O
)	O
to	O
decrease	O
atheroma	O
formation	O
and	O
hypercholesterolemia	O

The	O
present	O
invention	O
provides	O
a	O
5,6-dihydrodibenzo	B
[	I
a	I
,	I
g	I
]	I
quinolizinium	I
derivative	O
and	O
the	O
salts	O
thereof	O
of	O
formula	O
(	O
I	O
)	O
which	O
specifically	O
inhibits	O
the	O
sterol	B
14-reductase	O
which	O
is	O
involved	O
in	O
the	O
distal	O
pathway	O
of	O
cholesterol	B
biosynthesis	O
,	O
and	O
the	O
use	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
for	O
treating	O
hypercholesterolaemia	O
or	O
hyperlipidaemia	O
,	O
wherein	O
R?1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
¿	O
,	O
X	O
and	O
2	O
are	O
defined	O
in	O
the	O
claims	O
.	O

DIBENZO	B
a	I
,	I
g	I
]	I
QUINOLIZINIUM	I
DERIVATIVES	O
AND	O
THE	O
SALTS	O
THEREOF	O

Chimeric	O
oligonucleotide	B
of	O
the	O
formula	O
5'-W	O
-	O
X1-Y	O
-	O
X2-Z-3	O
'	O
,	O
where	O
W	O
represents	O
a	O
5'-O	B
-	I
alkyl	I
nucleotide	I
,	O
each	O
of	O
X?1	O
and	O
X2	O
¿	O
represented	O
a	O
block	O
of	O
seven	O
to	O
twelve	O
phosphodiester	B
-	I
linked	I
2'-O	I
-	I
alkyl	I
ribonucleotides	I
,	O
Y	O
represents	O
a	O
block	O
of	O
five	O
to	O
twelve	O
phosphorothioate	O
-	O
linked	O
deoxyribonucleotides	O
,	O
and	O
Z	O
represents	O
a	O
blocking	O
group	O
effective	O
to	O
block	O
nuclease	O
activity	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
oligonucleotide	O
,	O
are	O
described	O
.	O

These	O
compounds	O
exhibit	O
high	O
resistance	O
to	O
endo-	O
and	O
exonucleases	O
,	O
high	O
sequence	O
specificity	O
,	O
and	O
the	O
ability	O
to	O
activate	O
RNAse	O
H	O
,	O
as	O
evidenced	O
by	O
efficient	O
and	O
long	O
-	O
lasting	O
suppression	O
of	O
target	O
mRNA	O
.	O

The	O
oligonucleotides	O
are	O
preferably	O
transfected	O
into	O
cells	O
in	O
formulations	O
containing	O
a	O
lipid	O
-	O
peptoid	O
conjugate	O
carrier	O
molecule	O
of	O
the	O
formula	O
L	O
-	O
linker-	O
[	B
N	I
(	I
CH¿2?CH2NH2	I
)	I
CH2	I
(	I
C	I
=	I
O	I
)	I
-N	I
(	I
CH2CH2R	I
)	I
CH2	I
(	I
C	I
=	I
O	I
)	I
-N	I
(	I
CH2CH2R	I
)	I
CH2	I
(	I
C	I
=	I
O	I
)	I
]	I
3-NH2	I
,	O
where	O
L	O
is	O
a	O
lipid	O
moiety	O
,	O
including	O
a	O
steroid	B
,	O
and	O
each	O
group	O
R	O
is	O
independently	O
selected	O
from	O
alkyl	B
,	O
aminoalkyl	B
,	O
and	O
aralkyl	B
.	O

Chimeric	O
antisense	O
oligonucleotides	B
and	O
cell	O
transfecting	O
formulations	O
thereof	O

The	O
present	O
invention	O
is	O
the	O
novel	O
use	O
of	O
NK-3	O
receptor	O
antagonist	O
compounds	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
caused	O
by	O
high	O
or	O
inappropriate	O
levels	O
of	O
gonadotropins	O
and/or	O
androgens	B
,	O
particularly	O
testosterone	B
.	O

Anti	O
-	O
androgens	B
and	O
methods	O
for	O
treating	O
disease	O

A	O
2,6,9-trisubstituted	B
purine	I
composition	O
that	O
is	O
useful	O
for	O
inhibiting	O
cell	O
proliferative	O
disorders	O
and	O
as	O
an	O
antifungal	O
agent	O
.	O

PURINE	B
INHIBITORS	O
OF	O
CYCLIN	O
DEPENDENT	O
KINASE	O
2	O
AND	O
IkB	O
-	O
alpha	O

The	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R?1	O
and	O
R2	O
¿	O
independently	O
represent	O
H	B
or	O
C¿1	B
-	I
6	I
?	I
alkyl	I
;	O
R?3	O
¿	O
represents	O
phenyl	B
substituted	O
by	O
at	O
least	O
one	O
group	O
selected	O
form	O
halo	B
,	O
CF¿3	B
?	I
,	O
OCF3	B
,	O
CN	B
,	O
OH	B
,	O
C1	B
-	I
6	I
alkyl	I
and	O
C1	B
-	I
6	I
alkoxy	I
;	O
and	O
R?4	O
,	O
R5	O
and	O
R11	O
¿	O
independently	O
represent	O
H	B
or	O
-	B
(	I
CH¿2?	I
)	I
n	I
-	I
A	O
,	O
wherein	O
n	O
represents	O
0	O
,	O
1	O
or	O
2	O
,	O
provided	O
that	O
at	O
least	O
one	O
of	O
R?4	O
,	O
R5	O
and	O
R11	O
¿	O
is	O
other	O
than	O
H	B
;	O
A	O
represents	O
CONR6R7	B
or	O
SO¿2NR?6R7	B
,	O
wherein	O
R?6	O
and	O
R7	O
¿	O
independently	O
represent	O
H	B
,	O
C¿3	B
-	I
6	I
?	I
cycloalkyl	I
or	O
C1	B
-	I
6	I
alkyl	I
,	O
the	O
C?1	B
-	I
6	I
¿	I
alkyl	I
group	O
being	O
optionally	O
substituted	O
,	O
in	O
addition	O
,	O
R?6	O
and	O
R7	O
¿	O
may	O
,	O
together	O
with	O
the	O
N	B
atom	O
to	O
which	O
they	O
are	O
attached	O
,	O
represent	O
a	O
ring	O
which	O
is	O
optionally	O
substituted	O
;	O
CO¿2R?8	B
,	O
wherein	O
R8	O
represents	O
H	B
or	O
C¿1	B
-	I
6	I
?	I
alkyl	I
;	O
NR?9R10	B
¿	I
,	O
wherein	O
R?9	O
and	O
R10	O
¿	O
independently	O
represent	O
H	B
,	O
C¿1	B
-	I
6	I
?	I
alkyl	I
(	O
optionally	O
substituted	O
)	O
,	O
(	B
C1	I
-	I
6	I
alkyl	I
)	I
SO2-	I
,	O
(	B
C1	I
-	I
6	I
alkyl	I
)	I
CO-	I
,	O
H2NSO2-	B
or	O
H2NCO-	B
;	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	B
ring	O
containing	O
1	O
,	O
2	O
or	O
3	O
heteroatoms	B
selected	O
from	O
N	B
,	O
S	B
and	O
O	B
,	O
which	O
is	O
optionally	O
substituted	O
;	O
S	B
(	I
O	I
)	I
x	I
(	I
C1	I
-	I
6	I
alkyl	I
)	I
,	O
wherein	O
x	O
represents	O
0	O
,	O
1	O
or	O
2	O
;	O
OH	B
;	O
CN	B
,	O
NO2	B
;	O
or	O
C1	B
-	I
6	I
alkoxy	I
which	O
is	O
optionally	O
substituted	O
;	O
provided	O
that	O
when	O
NR?1R2	B
¿	I
represents	O
N	B
(	I
H	I
)	I
methyl	I
,	O
R4	O
represents	O
H	B
and	O
R3	O
represents	O
4-	B
chlorophenyl	I
,	O
then	O
R5	O
does	O
not	O
represent	O
methoxy	B
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
variety	O
of	O
disorders	O
,	O
including	O
those	O
in	O
which	O
the	O
regulation	O
of	O
monoamine	B
transporter	O
function	O
is	O
implicated	O
.	O

1,2,3,4-tetrahydro-1-naphthalenamine	B
compounds	O
useful	O
in	O
therapy	O

The	O
present	O
invention	O
is	O
drawn	O
to	O
methods	O
of	O
killing	O
bacteria	O
,	O
including	O
antibiotic	O
resistant	O
bacteria	O
,	O
by	O
contacting	O
said	O
bacteria	O
with	O
a	O
membrane	O
permeabilizing	O
compound	O
or	O
combination	O
of	O
compounds	O
and	O
a	O
membrane	O
impermeant	O
toxic	O
agent	O
or	O
combination	O
of	O
agents	O
,	O
resulting	O
in	O
the	O
death	O
of	O
the	O
bacteria	O
without	O
substantial	O
injury	O
to	O
the	O
infected	O
host	O
or	O
patient	O
.	O

The	O
present	O
invention	O
is	O
further	O
drawn	O
to	O
compositions	O
and	O
kits	O
for	O
effecting	O
the	O
method	O
of	O
the	O
present	O
invention	O
.	O

The	O
present	O
invention	O
is	O
further	O
drawn	O
to	O
methods	O
of	O
rendering	O
toxic	O
agents	O
such	O
as	O
toxic	O
organic	O
molecules	O
,	O
membrane	O
impermeant	O
for	O
use	O
in	O
the	O
methods	O
and	O
compositions	O
of	O
the	O
present	O
invention	O
.	O

Combination	O
of	O
antibiotic	O
and	O
nucleic	O
acid	O
binding	O
compound	O
for	O
bacterial	O
antibiotic	O
resistance	O

The	O
present	O
invention	O
provides	O
methods	O
,	O
kits	O
,	O
and	O
pharmaceutical	O
compositions	O
for	O
limiting	O
scar	O
or	O
adhesion	O
formation	O
by	O
administration	O
of	O
angiotensinogen	B
,	O
AI	O
,	O
AI	O
analogues	O
,	O
and/or	O
AI	O
fragments	O
and	O
analogues	O
thereof	O
,	O
AII	O
analogues	O
,	O
AII	O
fragments	O
or	O
analogues	O
thereof	O
,	O
ACE	O
inhibitors	O
,	O
AII	O
AT2	O
type	O
2	O
receptor	O
agonists	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
compounds	O
.	O

Angiotensin	B
ii	I
and	O
analogs	O
thereof	O
for	O
limiting	O
scar	O
and	O
adhesion	O
formation	O

The	O
use	O
of	O
a	O
3-substituted	B
indole	I
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
amide	B
or	O
ester	B
thereof	O
;	O
X	O
is	O
CH2	B
or	O
SO2	B
and	O
R?1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
¿	O
are	O
certain	O
specified	O
organic	O
moieties	O
,	O
for	O
use	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
inhibition	O
of	O
monocyte	O
chemoattractant	O
protein-1	O
and/or	O
RANTES	O
induced	O
chemotaxis	O
.	O

Pharmaceutical	O
compositions	O
containing	O
certain	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
also	O
described	O
and	O
claimed	O
.	O

Indole	B
derivatives	O
as	O
anti	O
-	O
inflammation	O
agents	O

A	O
hydroxamic	B
acid	I
derivative	O
represented	O
by	O
formula	O
(	O
1	O
)	O
or	O
a	O
prodrug	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
which	O
has	O
a	O
matrix	O
metalo	O
-	O
proteinase	O
inhibitor	O
.	O

Hydroxamic	B
acid	I
derivative	O

The	O
therapy	O
with	O
cannabinoids	B
in	O
the	O
treatment	O
of	O
cerebral	O
tumors	O
involves	O
(	O
intracranial	O
or	O
systematic	O
)	O
administration	O
of	O
(	O
natural	O
or	O
synthetic	O
)	O
cannabinoids	B
to	O
(	O
human	O
or	O
non	O
-	O
human	O
)	O
mammals	O
having	O
cerebral	O
tumors	O
.	O

Activation	O
of	O
the	O
specific	O
receptors	O
of	O
the	O
cannabinoids	B
leads	O
to	O
selective	O
death	O
of	O
the	O
transformed	O
cells	O
.	O

Regression	O
or	O
eradication	O
of	O
the	O
cerebral	O
tumors	O
is	O
achieved	O
without	O
any	O
significant	O
side	O
-	O
effects	O
.	O

Therapy	O
with	O
cannabinoids	B
in	O
the	O
treatment	O
of	O
cerebral	O
tumor	O

The	O
present	O
invention	O
relates	O
to	O
ion	O
channel	O
modulating	O
agents	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
particular	O
class	O
of	O
chemical	O
compounds	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
that	O
has	O
proven	O
useful	O
as	O
modulators	O
of	O
SKCa	O
,	O
IKCa	O
and	O
BKCa	O
channels	O
.	O

In	O
further	O
aspects	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
SK	O
/	O
IK	O
/	O
BK	O
channel	O
modulating	O
agents	O
for	O
the	O
manufacture	O
of	O
medicaments	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
SK	O
/	O
IK	O
/	O
BK	O
channel	O
modulating	O
agents	O
.	O

The	O
SK	O
/	O
IK	O
/	O
BK	O
channel	O
modulating	O
agents	O
of	O
the	O
invention	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
alleviation	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
the	O
SK	O
/	O
IK	O
/	O
BK	O
channels	O
.	O

Ion	O
channel	O
modulating	O
agents	O

A	O
process	O
for	O
feeding	O
a	O
companion	O
animal	O
such	O
as	O
dog	O
a	O
diet	O
containing	O
an	O
effective	O
amount	O
of	O
a	O
combination	O
of	O
antioxidants	O
to	O
enhance	O
immune	O
response	O
and	O
improve	O
the	O
overall	O
health	O
of	O
the	O
animal	O
is	O
provided	O
.	O

Preferably	O
,	O
the	O
diet	O
includes	O
from	O
about	O
175	O
to	O
about	O
400	O
IU	O
of	O
vitamin	B
E	I
per	O
kilogram	O
of	O
diet	O
,	O
from	O
about	O
1	O
to	O
about	O
50	O
mg	O
/	O
day	O
of	O
lutein	B
,	O
and	O
from	O
about	O
1	O
to	O
about	O
50	O
mg	O
/	O
day	O
of	O
$	O
g	O
/	O
b	O
)	O
-carotene	O
.	O

Process	O
for	O
manufacturing	O
a	O
product	O
for	O
enhancing	O
immune	O
response	O
in	O
companion	O
animal	O
using	O
a	O
combination	O
of	O
antioxidants	O

The	O
invention	O
provides	O
viral	O
vectors	O
and	O
charged	O
molecules	O
for	O
use	O
in	O
gene	O
therapy	O
.	O

Use	O
of	O
viral	O
vectors	O
and	O
charged	O
molecules	O
for	O
gene	O
therapy	O

Compounds	O
of	O
the	O
formula	O
A	O
-	O
Q	O
-	O
D	O
-	O
E	O
-	O
G	O
-	O
J	O
-	O
X	O
in	O
which	O
D	O
is	O
a	O
direct	O
link	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	B
or	O
naphthyl	B
group	O
or	O
a	O
heterocyclic	B
ring	O
system	O
;	O
X	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	B
or	O
naphthyl	B
group	O
or	O
a	O
heterocyclic	B
system	O
;	O
and	O
the	O
other	O
variables	O
are	O
as	O
defined	O
in	O
the	O
claims	O
,	O
their	O
salts	O
and	O
compositions	O
related	O
thereto	O
having	O
activity	O
against	O
mammalian	O
factor	O
Xa	O
are	O
disclosed	O
.	O

The	O
compounds	O
are	O
useful	O
in	O
vitro	O
or	O
in	O
vivo	O
for	O
preventing	O
or	O
treating	O
coagulation	O
disorders	O
.	O

BENZAMIDES	B
AND	O
RELATED	O
INHIBITORS	O
OF	O
FACTOR	O
Xa	O

This	O
invention	O
encompasses	O
the	O
novel	O
compounds	O
of	O
formula	O
(	O
A	O
)	O
,	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
prostaglandin	B
mediated	O
diseases	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	B
or	O
ester	B
thereof	O
.	O

The	O
invention	O
also	O
encompasses	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treatment	O
of	O
prostaglandin	B
mediated	O
diseases	O
.	O

Carboxylic	B
acids	I
and	O
acylsulfonamides	B
,	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O

Fibrous	O
-	O
liponutritional	O
complexes	O
comprising	O
one	O
or	O
more	O
nutritional	O
substances	O
capable	O
of	O
promoting	O
health	O
and	O
therapeutical	O
beneficial	O
activities	O
together	O
with	O
one	O
or	O
more	O
phospholipid	O
component	O
and	O
one	O
or	O
more	O
fibrous	O
polysaccharide	O
component	O
;	O
pharmaceutical	O
formulations	O
and	O
foodstuffs	O
containing	O
said	O
fibrous	O
-	O
liponutritional	O
complexes	O
;	O
processes	O
for	O
the	O
preparation	O
of	O
said	O
complexes	O
which	O
are	O
capable	O
of	O
inducing	O
a	O
surprisingly	O
higher	O
increase	O
in	O
the	O
health	O
and	O
therapeutical	O
beneficial	O
activities	O
than	O
that	O
expected	O
for	O
the	O
single	O
nutritional	O
substances	O
used	O
.	O

Fibrous	O
-	O
liponutritional	O
complexes	O
and	O
compositions	O
containing	O
them	O

The	O
invention	O
provides	O
isolated	O
anti	O
-	O
prostate	O
stem	O
cell	O
antigen	O
(	O
PSCA	O
)	O
antibodies	O
that	O
internalize	O
upon	O
binding	O
to	O
PSCA	O
on	O
a	O
mammalian	O
in	O
vivo	O
.	O

The	O
invention	O
also	O
encompasses	O
compositions	O
comprising	O
an	O
anti	O
-	O
PSCA	O
antibody	O
and	O
a	O
carrier	O
.	O

These	O
compositions	O
can	O
be	O
provided	O
in	O
an	O
article	O
of	O
manufacture	O
or	O
a	O
kit	O
.	O

Another	O
aspect	O
of	O
the	O
invention	O
is	O
an	O
isolated	O
nucleic	O
acid	O
encoding	O
an	O
anti	O
-	O
PSCA	O
antibody	O
,	O
as	O
well	O
as	O
an	O
expression	O
vector	O
comprising	O
the	O
isolated	O
nucleic	O
acid	O
.	O

Also	O
provided	O
are	O
cells	O
that	O
produce	O
the	O
anti	O
-	O
PSCA	O
antibodies	O
.	O

The	O
invention	O
encompasses	O
a	O
method	O
of	O
producing	O
the	O
anti	O
-	O
PSCA	O
antibodies	O
.	O

Other	O
aspects	O
of	O
the	O
invention	O
are	O
a	O
method	O
of	O
killing	O
a	O
PSCA	O
-	O
expressing	O
cancer	O
cell	O
,	O
comprising	O
contacting	O
the	O
cancer	O
cell	O
with	O
an	O
anti	O
-	O
PSCA	O
antibody	O
and	O
a	O
method	O
of	O
alleviating	O
or	O
treating	O
a	O
PSCA	O
-	O
expressing	O
cancer	O
in	O
a	O
mammal	O
,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
anti	O
-	O
PSCA	O
antibody	O
to	O
the	O
mammal	O
.	O

Anti	O
-	O
prostate	O
stem	O
cell	O
antigen	O
(	O
psca	O
)	O
antibody	O
compositions	O
and	O
methods	O
of	O
use	O

A	O
pharmaceutical	O
composition	O
is	O
disclosed	O
which	O
comprises	O
a	O
soliddispersion	O
of	O
an	O
HIV	O
protease	O
inhibitor	O
in	O
a	O
water	O
soluble	O
carrier	O
,	O
such	O
as	O
PEG	O
,	O
having	O
enhanced	O
bioavailability	O
and	O
improved	O
dissolution	O
properties	O
.	O

The	O
solid	O
dispersion	O
may	O
optionally	O
be	O
encapsulated	O
in	O
hard	O
gelatin	O
capsules	O
,	O
compressed	O
into	O
a	O
tablet	O
,	O
or	O
may	O
be	O
granulated	O
with	O
a	O
pharmaceutically	O
acceptable	O
granulating	O
agent	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
making	O
said	O
solid	O
dispersion	O
and	O
methods	O
of	O
treating	O
an	O
HIV	O
infection	O
employing	O
said	O
solid	O
dispersion	O
.	O

Solid	O
dispersion	O
pharmaceutical	O
formulations	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
metabolic	O
bone	O
disease	O
and	O
the	O
method	O
of	O
preparation	O
thereof	O
,	O
and	O
more	O
particularly	O
,	O
to	O
an	O
improved	O
pharmaceutical	O
composition	O
for	O
the	O
therapeutic	O
treatment	O
of	O
metabolic	O
disease	O
and	O
the	O
method	O
of	O
preparation	O
thereof	O
,	O
wherein	O
said	O
composition	O
is	O
prepared	O
as	O
a	O
composite	O
pharmaceutical	O
agent	O
which	O
comprises	O
calcitriol	B
;	O
which	O
reduces	O
the	O
rate	O
of	O
spine	O
fractures	O
and	O
increases	O
bone	O
density	O
;	O
alendronate	B
,	O
a	O
bone	O
resorption	O
inhibitor	O
,	O
as	O
two	O
main	O
active	O
ingredients	O
in	O
an	O
optimal	O
mixing	O
ratio	O
to	O
exert	O
the	O
greatest	O
synergistic	O
therapeutic	O
effect	O
;	O
and	O
adequate	O
amount	O
of	O
other	O
additives	O
such	O
as	O
a	O
resorption	O
fortifier	O
of	O
alendronate	B
.	O

Therefore	O
,	O
the	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
present	O
invention	O
can	O
inhibit	O
hypercalcemia	O
caused	O
when	O
administered	O
by	O
calcitriol	B
alone	O
,	O
compensate	O
the	O
inhibitory	O
activity	O
of	O
bone	O
remodeling	O
caused	O
by	O
alendronate	B
due	O
to	O
the	O
presence	O
of	O
calcitriol	B
,	O
and	O
improve	O
drug	O
compliance	O
associated	O
with	O
the	O
usual	O
difficulty	O
in	O
administration	O
as	O
well	O
as	O
a	O
side	O
effect	O
in	O
esophagus	O
,	O
thus	O
effectively	O
preventing	O
the	O
occurence	O
of	O
osteoporosis	O
.	O

Pharmaceutical	O
compositions	O
and	O
preparations	O
for	O
treatment	O
of	O
metabolic	O
bone	O
disease	O

There	O
is	O
provided	O
according	O
to	O
the	O
invention	O
a	O
pharmaceutical	O
aerosol	O
formulation	O
which	O
comprises	O
:	O
(	O
i	O
)	O
salmeterol	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
ii	O
)	O
a	O
hydrofluoroalkane	B
(	O
HFA	B
)	O
propellant	O
,	O
characterised	O
in	O
that	O
the	O
salmeterol	B
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
completely	O
dissolved	O
in	O
the	O
formulation	O
.	O

Pharmaceutical	O
formulations	O
of	O
salmeterol	B

The	O
present	O
invention	O
includes	O
the	O
cloning	O
of	O
a	O
novel	O
human	O
Cα	O
isoform	O
,	O
identified	O
as	O
the	O
human	O
Cα	O
-	O
s	O
protein	O
on	O
the	O
basis	O
of	O
its	O
similarity	O
to	O
a	O
recently	O
characterized	O
Cα	O
isoform	O
which	O
was	O
identified	O
by	O
purification	O
and	O
peptide	O
sequencing	O
of	O
Cα	O
from	O
ovine	O
sperm	O
[	O
11	O
]	O
.	O

The	O
human	O
Cα	O
-	O
s	O
protein	O
was	O
present	O
in	O
testis	O
and	O
ejaculated	O
sperm	O
and	O
Cα	O
-	O
s	O
localized	O
to	O
the	O
midpiece	O
of	O
human	O
sperm	O
.	O

The	O
present	O
invention	O
includes	O
in	O
this	O
respect	O
a	O
cDNA	O
sequence	O
encoding	O
a	O
Cα	O
-	O
s	O
protein	O
and	O
comprises	O
the	O
specific	O
nucleotide	O
sequence	O
shown	O
in	O
SEQ	O
ID	O
NO:1	O
,	O
(	O
underlined	O
)	O
wherein	O
the	O
said	O
protein	O
is	O
a	O
new	O
splice	O
variant	O
of	O
Cα	O
catalytic	O
subunit	O
of	O
cAMP	O
dependent	O
protein	O
kinase	O
.	O

The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
a	O
vector	O
comprising	O
the	O
said	O
cDNA	O
sequence	O
.	O

The	O
invention	O
also	O
includes	O
a	O
protein	O
characterised	O
by	O
the	O
Cα	O
-	O
s	O
protein	O
specific	O
amino	B
acid	I
sequence	O
shown	O
in	O
SEQ	O
ID	O
NO:2	O
(	O
underlined	O
)	O
.	O

The	O
invention	O
includes	O
further	O
use	O
of	O
Cα	O
-	O
s	O
protein	O
and	O
cDNA	O
sequence	O
in	O
preparation	O
of	O
pharmaceuticals	O
,	O
medicaments	O
to	O
manipulate	O
the	O
motility	O
in	O
sperm	O
or	O
for	O
use	O
as	O
contraceptive	O
,	O
as	O
well	O
as	O
methods	O
and	O
testsystems	O
for	O
screening	O
molecules	O
interacting	O
with	O
Cα	O
-	O
s	O
.	O

The	O
present	O
invention	O
includes	O
also	O
a	O
kit	O
.	O

A	O
NOVEL	O
ISOFORM	O
OF	O
HUMAN	O
cAMP	O
-	O
DEPENDENT	O
PROTEIN	O
KINASE	O
,	O
C	O
ALPHA	O
-	O
s	O
,	O
LOCALIZES	O
TO	O
SPERM	O
MIDPIECE	O
AND	O
THE	O
USE	O
THEREOF	O

The	O
invention	O
relates	O
to	O
azoles	B
which	O
are	O
suitable	O
for	O
the	O
prevention	O
of	O
irradiation	O
-	O
induced	O
skin	O
cancer	O
.	O

Use	O
of	O
azoles	B
for	O
preventing	O
skin	O
cancer	O
due	O
to	O
radiation	O

Piperidinyloxy	B
,	O
pyrrolidinyloxyl	B
and	O
azetidinyloxy	B
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
a	O
piperidinyl	B
,	O
pyrrolidinyl	B
or	O
azetidinyl	B
moiety	O
as	O
described	O
herein	O
and	O
in	O
which	O
the	O
substituents	O
have	O
the	O
meaning	O
indicated	O
in	O
the	O
description	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
antibacterial	O
agents	O
.	O

Piperidinyloxy	B
and	I
pyrrolidinyloxyphenyl	I
oxazolidinones	I
as	O
antibacterials	O

The	O
invention	O
relates	O
to	O
cosmetic	O
or	O
dermatological	O
formulations	O
which	O
contain	O
one	O
or	O
more	O
active	O
substances	O
selected	O
from	O
phyllochinon	B
,	O
2-hydroxy-5-methyllaurophenonoxime	B
,	O
vitamin	B
A	I
and	O
derivatives	O
thereof	O
,	O
vitamin	B
E	I
and	O
derivatives	O
thereof	O
,	O
vitamin	B
H	I
,	O
allantoin	B
,	O
bisabolol	B
,	O
nicotine	B
acid	I
derivatives	O
,	O
caffeine	B
and	O
,	O
optionally	O
:	O
(	O
a	O
)	O
one	O
or	O
more	O
antioxidants	O
and/or	O
;	O
(	O
b	O
)	O
one	O
or	O
more	O
UV	O
filters	O
.	O

The	O
formulations	O
are	O
particularly	O
characterized	O
in	O
that	O
the	O
active	O
substances	O
containing	O
the	O
inventive	O
formulations	O
are	O
stabilized	O
.	O

Galenic	O
formulation	O

This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
that	O
inhibit	O
farnesylation	O
of	O
gene	O
products	O
through	O
inhibition	O
of	O
the	O
enzyme	O
farnesyl	B
-	O
protein	O
transferase	O
(	O
FPTase	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
manufacturing	O
the	O
compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treating	O
diseases	O
,	O
especially	O
cancer	O
,	O
which	O
are	O
mediated	O
through	O
farnesylation	O
.	O

Farnesyl	B
transferase	O
inhibitors	O

The	O
inventions	O
relates	O
to	O
the	O
use	O
of	O
the	O
carboxamidine	B
of	O
Formula	O
1	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
Hepatitis	O
C	O
Virus	O
(	O
HCV	O
)	O
viral	O
infection	O
or	O
a	O
Hepatitis	O
B	O
Virus	O
(	O
HBV	O
)	O
viral	O
infection	O
,	O
wherein	O
the	O
compound	O
is	O
in	O
L	O
-	O
configuration	O
or	O
D	O
-	O
configuration	O
.	O

Nucleoside	O
analogs	O
with	O
carboxamidine	B
modified	O
monocyclic	O
base	O

This	O
invention	O
relates	O
to	O
methods	O
and	O
pharmaceutical	O
compositions	O
for	O
providing	O
hormone	O
replacement	O
therapy	O
in	O
perimenopausal	O
,	O
menopausal	O
,	O
and	O
postmenopausal	O
women	O
through	O
the	O
continuous	O
administration	O
of	O
combinations	O
of	O
conjugated	O
estrogens	B
and	O
medroxyprogesterone	B
acetate	I
.	O

Hormone	O
replacement	O
therapy	O
using	O
a	O
combination	O
of	O
conjugated	O
estrogens	B
and	O
medroxyprogesterone	B
acetate	I

Compositions	O
comprising	O
ferrous	B
ion	I
and	O
an	O
ascorbate	B
have	O
a	O
synergistic	O
effect	O
on	O
cartilage	O
development	O
.	O

Therapeutic	O
compositions	O
comprising	O
ferrous	B
ion	I
and	O
an	O
ascorbate	B
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
osteoarthritis	O
.	O

The	O
addition	O
of	O
a	O
glucosamine	B
,	O
such	O
as	O
glucosamine	B
hydrochloride	I
,	O
to	O
the	O
composition	O
has	O
a	O
further	O
enhanced	O
effect	O
on	O
cartilage	O
production	O
.	O

Therapeutic	O
compositions	O
comprising	O
ferrous	B
ion	I
,	O
an	O
ascorbate	B
and	O
a	O
glucosamine	B
derivative	O
are	O
even	O
more	O
useful	O
in	O
the	O
treatment	O
of	O
osteoarthritis	O
.	O

Compositions	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
of	O
connective	O
tissues	O
comprising	O
a	O
ferrous	B
ion	I
and	O
an	O
ascorbate	B

The	O
present	O
invention	O
relates	O
to	O
an	O
improved	O
mode	O
of	O
administration	O
for	O
cannabis	O
and	O
its	O
natural	O
and	O
synthetic	O
derivatives	O
.	O

A	O
pharmaceutical	O
composition	O
suitable	O
for	O
sublingual	O
aerosol	O
or	O
spray	O
delivery	O
of	O
cannabis	O
is	O
provided	O
.	O

The	O
formulation	O
may	O
be	O
dispensed	O
using	O
a	O
pump	O
spray	O
or	O
the	O
formulation	O
may	O
include	O
a	O
propellant	O
,	O
such	O
as	O
butane	O
,	O
1,1,1,2-tetrafuorethane	O
(	O
HFC-134a	O
)	O
or	O
1,1,1,2,3,3,3-heptafluropropane	O
(	O
HFC-227	O
)	O
.	O

The	O
term	O
cannabis	O
is	O
used	O
herein	O
to	O
refer	O
to	O
all	O
physiologically	O
active	O
substances	O
derived	O
from	O
the	O
cannabis	O
family	O
of	O
plants	O
and	O
synthetic	O
cannabis	O
analogues	O
and	O
derivatives	O
,	O
precursors	O
,	O
metabolites	O
etc	O
.	O
,	O
or	O
related	O
substances	O
having	O
cannabis	O
-	O
like	O
physiological	O
effects	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
cannabis	O

The	O
present	O
invention	O
provides	O
a	O
thiazine	B
oxazolidinone	I
useful	O
as	O
antimicrobial	O
.	O

A	O
thiazine	B
oxazolidinone	I

A	O
method	O
is	O
provided	O
for	O
inhibiting	O
growth	O
of	O
a	O
fungus	O
comprising	O
contacting	O
the	O
fungus	O
with	O
an	O
effective	O
amount	O
of	O
a	O
non	O
-	O
antibacterial	O
tetracycline	B
compound	O
.	O

Non	O
-	O
antibacterial	O
tetracycline	B
as	O
anti	O
-	O
fungal	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
certain	O
N-	B
(	I
substituted	I
glycyl	I
)	I
-2-cyanopyrrolidines	I
of	O
formula	O
(	O
I	O
)	O
wherein	O
Y	O
is	O
as	O
defined	O
herein	O
,	O
in	O
free	O
form	O
or	O
in	O
acid	O
addition	O
salt	O
form	O
.	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
inhibit	O
DPP	O
-	O
IV	O
(	O
dipeptidyl	O
-	O
peptidase	O
-	O
IV	O
)	O
activity	O
.	O

They	O
are	O
therefore	O
indicated	O
for	O
use	O
as	O
pharmaceuticals	O
in	O
inhibiting	O
DPP	O
-	O
IV	O
and	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
DPP	O
-	O
IV	O
,	O
such	O
as	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
,	O
arthritis	O
,	O
obesity	O
,	O
osteoporosis	O
and	O
further	O
conditions	O
of	O
impaired	O
glucose	B
tolerance	O
.	O

2-cyanopyrrolidine	B
derivatives	O
and	O
their	O
use	O
as	O
medicaments	O

A	O
novel	O
pharmaceutical	O
compound	O
5-	B
[	I
4-	I
[	I
2-	I
(	I
N	I
-	I
methyl	I
-	I
N-	I
(	I
2-pyridyl	I
)	I
amino	I
)	I
ethoxy	I
]	I
benzyl	I
]	I
thiazolidine-2,4-dione	I
DL-	I
Tartrate	I
or	O
a	O
solvate	O
thereof	O
,	O
a	O
process	O
for	O
preparing	O
such	O
a	O
compound	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
such	O
a	O
compound	O
and	O
the	O
use	O
of	O
such	O
a	O
compound	O
in	O
medicine	O
.	O

Tartrate	B
salt	O
of	O
thiazolidinedione	B
derivative	O

A	O
method	O
employing	O
a	O
compositon	O
comprising	O
a	O
2	O
to	O
10	O
base	O
synthetic	O
oligonucleotide	B
sequence	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	O
GG	O
)	O
n	O
,	O
(	O
GT	O
)	O
n	O
,	O
at	O
(	O
GT	O
)	O
nb	O
,	O
a	O
(	O
GA	O
)	O
nb	O
,	O
and	O
a	O
(	O
GC	O
)	O
nb	O
,	O
wherein	O
n	O
is	O
an	O
integer	O
between	O
1	O
and	O
3	O
,	O
and	O
a	O
and	O
b	O
are	O
independently	O
either	O
none	O
or	O
one	O
or	O
more	O
As	O
,	O
Cs	O
,	O
Gs	O
,	O
or	O
Ts	O
,	O
or	O
combinations	O
thereof	O
,	O
for	O
modulation	O
of	O
Fas	O
and	O
FasL	O
expression	O
or	O
for	O
modulation	O
of	O
the	O
efficacy	O
of	O
therapeutic	O
agents	O
.	O

The	O
composition	O
is	O
administered	O
to	O
an	O
animal	O
or	O
human	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
and	O
optionally	O
with	O
a	O
therapeutic	O
agent	O
,	O
in	O
an	O
amount	O
effective	O
to	O
modulate	O
Fas	O
and	O
FasL	O
expression	O
,	O
to	O
treat	O
the	O
disease	O
,	O
or	O
to	O
modulate	O
efficacy	O
of	O
the	O
therapeutic	O
agent	O
.	O

Modulation	O
of	O
fas	O
and	O
fasl	O
expression	O
by	O
a	O
synthetic	O
phosphodiester	O
oligonucleotide	B
and	O
an	O
anti	O
-	O
fas	O
antibody	O

The	O
present	O
invention	O
relates	O
to	O
trimesic	B
acid	I
amides	I
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
,	O
uses	O
of	O
said	O
compounds	O
and	O
compositions	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

Specifically	O
,	O
this	O
invention	O
relates	O
to	O
means	O
to	O
enhance	O
insulin	O
-	O
dependent	O
glucose	O
uptake	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
concerns	O
compounds	O
and	O
pharmaceutical	O
compositions	O
that	O
active	O
the	O
insulin	O
receptor	O
kinase	O
,	O
which	O
leads	O
to	O
an	O
increased	O
sensitivity	O
to	O
insulin	O
and	O
an	O
increase	O
in	O
glucose	B
uptake	O
,	O
as	O
well	O
as	O
processes	O
for	O
preparation	O
of	O
the	O
compounds	O
.	O

As	O
such	O
,	O
the	O
invention	O
also	O
concerns	O
methods	O
or	O
uses	O
of	O
the	O
compounds	O
for	O
the	O
treatment	O
of	O
animals	O
with	O
hyperglycemia	O
,	O
especially	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

Benzene	B
tricarboxylic	I
acid	I
amides	I
as	O
insulin	O
receptor	O
activators	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
gel	O
composition	O
for	O
application	O
on	O
skin	O
,	O
said	O
composition	O
comprising	O
at	O
least	O
one	O
vitamin	B
D	I
or	O
vitamin	B
D	I
analogue	O
and	O
at	O
least	O
one	O
corticosteroid	B
as	O
well	O
as	O
a	O
viscosity	O
-	O
increasing	O
excipient	O
.	O

Topical	O
composition	O
containing	O
at	O
least	O
one	O
vitamin	B
d	I
or	O
one	O
vitamin	B
d	I
analogue	O
and	O
at	O
least	O
one	O
corticosteroid	B

There	O
is	O
provided	O
a	O
topical	O
composition	O
for	O
treating	O
preventing	O
skin	O
irritation	O
induced	O
by	O
a	O
retinoid	B
,	O
which	O
composition	O
has	O
comfrey	O
.	O

There	O
is	O
also	O
provided	O
a	O
method	O
treating	O
and/or	O
preventing	O
skin	O
irritation	O
induced	O
by	O
a	O
retinoid	B
,	O
which	O
method	O
comprises	O
applying	O
to	O
the	O
skin	O
an	O
effective	O
amount	O
of	O
comfrey	O
.	O

Compositions	O
having	O
comfrey	O
and	O
methods	O
for	O
reducing	O
retinoid	B
-	O
induced	O
skin	O
irritation	O

Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
wherein	O
:	O
(	O
i	O
)	O
represents	O
:	O
(	O
ii	O
,	O
iii	O
,	O
iv	O
,	O
v	O
)	O
and	O
A	O
,	O
B	O
,	O
G	O
,	O
D	O
,	O
E	O
,	O
Ra	O
,	O
Rb	O
,	O
W	O
,	O
and	O
Z	O
are	O
defined	O
herein	O
.	O

These	O
compounds	O
are	O
agonists	O
,	O
antagonists	O
or	O
inverse	O
agonists	O
for	O
GABAA	B
brain	O
receptors	O
or	O
prodrugs	O
of	O
agonists	O
,	O
antagonists	O
or	O
inverse	O
agonists	O
for	O
GABAA	B
brain	O
receptors	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
anxiety	O
,	O
depression	O
,	O
down	O
Syndrome	O
,	O
sleep	O
and	O
seizure	O
disorders	O
,	O
overdose	O
with	O
benzodiazepine	B
drugs	O
and	O
for	O
enhancement	O
of	O
memory	O
.	O

Pharmaceutical	O
compositions	O
,	O
including	O
packaged	O
pharmaceutical	O
compositions	O
,	O
are	O
further	O
provided	O
.	O

Compounds	O
of	O
the	O
invention	O
are	O
also	O
useful	O
as	O
probes	O
for	O
the	O
localization	O
of	O
GABAA	B
receptors	O
in	O
tissue	O
samples	O
.	O

2,4-substituted	B
pyridine	I
derivatives	O

The	O
invention	O
relates	O
to	O
the	O
production	O
of	O
a	O
pharmaceutical	O
preparation	O
for	O
blocking	O
the	O
adsorption	O
of	O
germs	O
in	O
bird	O
cells	O
,	O
according	O
to	O
which	O
one	O
or	O
more	O
oligogalacturonides	B
having	O
a	O
degree	O
of	O
polymerization	O
of	O
greater	O
than	O
or	O
equal	O
to	O
2	O
and	O
having	O
a	O
degree	O
of	O
esterification	O
of	O
less	O
than	O
20	O
%	O
serving	O
as	O
an	O
active	O
substance	O
is	O
/	O
are	O
,	O
optionally	O
together	O
with	O
pharmaceutically	O
common	O
excipients	O
,	O
diluents	O
,	O
adjuvants	O
and	O
fillers	O
,	O
are	O
rendered	O
into	O
a	O
form	O
suited	O
for	O
administering	O
.	O

Blocking	O
the	O
adsorption	O
of	O
germs	O
in	O
birds	O

Indole	B
derivatives	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
(	O
particularly	O
d	O
opioid	O
receptor	O
agonist	O
)	O
containing	O
the	O
same	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen	B
,	O
C¿1	B
-	I
5	I
?	I
alkyl	I
,	O
or	O
the	O
like	O
;	O
R?2	O
¿	O
is	O
hydrogen	B
,	O
hydroxyl	B
,	O
or	O
the	O
like	O
;	O
R3	O
is	O
hydrogen	B
,	O
hydroxyl	B
,	O
or	O
the	O
like	O
;	O
-Z-	O
is	O
a	O
bridge	O
having	O
2	O
to	O
5	O
carbon	B
atoms	O
;	O
m	O
is	O
an	O
integer	O
of	O
0	O
to	O
3	O
;	O
n	O
is	O
an	O
integer	O
of	O
0	O
to	O
10	O
;	O
R?4	O
and	O
R5	O
¿	O
are	O
each	O
fluoro	B
,	O
hydroxyl	B
,	O
or	O
the	O
like	O
;	O
R9	O
is	O
hydrogen	B
,	O
C¿1	B
-	I
5	I
?	I
alkyl	I
,	O
or	O
the	O
like	O
;	O
and	O
R?10	O
and	O
R11	O
¿	O
may	O
be	O
united	O
to	O
form	O
O-	O
or	O
the	O
like	O
.	O

Indole	B
derivatives	O
and	O
use	O
thereof	O
in	O
medicines	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
compounds	O
represented	O
by	O
structural	O
Formulas	O
(	O
I	O
)	O
and	O
(	O
I	O
-	O
a	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
,	O
R4a	O
,	O
R4b	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
n	O
,	O
and	O
X	O
are	O
described	O
.	O

The	O
invention	O
is	O
also	O
concerned	O
with	O
pharmaceutical	O
formulations	O
comprising	O
these	O
novel	O
compounds	O
as	O
active	O
ingredients	O
and	O
the	O
use	O
of	O
the	O
novel	O
compounds	O
and	O
their	O
formulations	O
in	O
the	O
treatment	O
of	O
certain	O
disorders	O
.	O

The	O
compounds	O
of	O
this	O
invention	O
are	O
serotonin	B
agonists	O
and	O
antagonists	O
and	O
are	O
useful	O
in	O
the	O
control	O
or	O
prevention	O
of	O
central	O
nervous	O
system	O
disorders	O
including	O
obesity	O
,	O
anxiety	O
,	O
depression	O
,	O
psychosis	O
,	O
schizophrenia	O
,	O
sleep	O
and	O
sexual	O
disorders	O
,	O
migraine	O
and	O
other	O
conditions	O
associated	O
with	O
cephalic	O
pain	O
,	O
social	O
phobias	O
,	O
and	O
gastrointestinal	O
disorders	O
such	O
as	O
dysfunction	O
of	O
the	O
gastrointestinal	O
tract	O
motility	O
.	O

Pyrazinoquinoxaline	B
derivatives	O
as	O
serotonin	B
agonists	O
and	O
antagonists	O

This	O
invention	O
relates	O
to	O
stable	O
pharmaceutical	O
compositions	O
of	O
the	O
NMDA	O
receptor	O
agonist	O
,	O
(	B
1S	I
,	I
2S	I
)	I
-1-	I
(	I
4-hydroxyphenyl	I
)	I
-2-	I
(	I
4-hydroxy-4-phenylpiperidin-1-yl	I
)	I
-1-propanol	I
]	I
,	O
methods	O
of	O
preparing	O
such	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treating	O
stroke	O
,	O
spinal	O
cord	O
trauma	O
,	O
traumatic	O
brain	O
injury	O
,	O
multiinfarct	O
dementia	O
,	O
CNS	O
degenerative	O
diseases	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
's	O
type	O
,	O
Huntington	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
epilepsy	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
pain	O
,	O
AIDS	O
dementia	O
,	O
psychotic	O
conditions	O
,	O
drug	O
addictions	O
,	O
migraine	O
,	O
hypoglycemia	O
,	O
anxiolytic	O
conditions	O
,	O
urinary	O
incontinence	O
and	O
an	O
ischemic	O
event	O
arising	O
from	O
CNS	O
surgery	O
,	O
open	O
heart	O
surgery	O
or	O
any	O
procedure	O
during	O
which	O
the	O
function	O
of	O
the	O
cardiovascular	O
system	O
is	O
compromised	O
using	O
the	O
pharmaceutical	O
compositions	O
.	O

Nmda	O
receptor	O
agonist	O
pharmaceutical	O
compositions	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
glucosamine	B
sulphate	I
metal	I
salts	I
for	O
use	O
in	O
the	O
treatment	O
of	O
acute	O
and	O
chronic	O
forms	O
of	O
rheumatic	O
and	O
arthritic	O
diseases	O
and	O
of	O
all	O
the	O
pathological	O
conditions	O
originating	O
from	O
metabolic	O
disorders	O
of	O
the	O
osteo	O
-	O
articular	O
tissues	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
glucosamine	B
sulphate	I
metal	I
salts	I
having	O
low	O
metal	O
content	O
wherein	O
the	O
metal	O
may	O
be	O
either	O
sodium	B
or	O
potassium	B
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
solution	O
-	O
based	O
and	O
a	O
solvent	O
-	O
free	O
process	O
for	O
the	O
preparation	O
of	O
the	O
novel	O
crystalline	O
glucosamine	B
sulphate	I
metal	I
salts	I
having	O
low	O
metal	O
content	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
novel	O
crystalline	O
glucosamine	B
sulphate	I
metal	I
salts	I
having	O
low	O
metal	O
content	O
.	O

Crystalline	O
glucosamine	B
sulphate	I
metal	I
salts	I
and	O
processes	O
for	O
preparing	O
the	O
same	O

A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
is	O
a	O
linkage	O
independently	O
selected	O
from	O
(	B
CH2	I
)	I
12	I
or	O
(	B
CH2CH2	I
)	I
4O3	I
and	O
wherein	O
R3	O
is	O
independently	O
selected	O
from	O
H	B
,	O
CH2CH3	B
,	O
COCH3	B
or	O
Formula	O
(	O
II	O
)	O
,	O
and	O
acid	O
addition	O
salts	O
,	O
solvates	O
and	O
hydrates	B
thereof	O
.	O

The	O
compounds	O
have	O
unusually	O
high	O
affinity	O
for	O
muscarinic	O
receptors	O
,	O
and	O
exhibit	O
agonist	O
activity	O
useful	O
in	O
the	O
treatment	O
of	O
neurological	O
and	O
other	O
disorders	O
,	O
in	O
which	O
stimulating	O
cholinergic	O
activity	O
is	O
desirable	O
.	O

Muscarinic	O
receptor	O
agonists	O

Biocompatible	O
materials	O
that	O
have	O
the	O
ability	O
to	O
release	O
nitric	B
oxide	I
(	O
NO	B
)	O
in	O
situ	O
at	O
the	O
surface	O
-	O
blood	O
interface	O
when	O
in	O
contact	O
with	O
blood	O
.	O

The	O
materials	O
which	O
may	O
be	O
polymers	O
(	O
e.g.	O
,	O
polyurethane	B
,	O
poly	B
(	I
vinyl	I
chloride	I
)	I
,	O
silicone	B
rubbers	O
)	O
,	O
metals	O
,	O
such	O
as	O
stainless	O
steel	O
,	O
carbon	B
,	O
and	O
the	O
like	O
are	O
provided	O
with	O
biocatalysts	O
or	O
biomimetic	O
catalysts	O
on	O
their	O
surface	O
that	O
have	O
nitrite	B
,	O
nitrate	B
and/or	O
nitrosothiol	B
-	O
reducing	O
capability	O
that	O
.	O

Illustratively	O
,	O
the	O
catalysts	O
are	O
adsorbed	O
or	O
immobilized	O
at	O
the	O
surface	O
of	O
the	O
material	O
.	O

The	O
catalysts	O
can	O
act	O
on	O
endogenous	O
nitrite	O
/	O
nitrate	O
or	O
nitrosothiols	B
within	O
the	O
blood	O
creating	O
a	O
local	O
increase	O
in	O
the	O
NO	B
levels	O
at	O
the	O
surface	O
of	O
the	O
material	O
.	O

An	O
illustrative	O
enzymatic	O
biocatalyst	O
is	O
mammalian	O
xanthine	B
oxidase	O
.	O

In	O
another	O
illustrative	O
embodiment	O
,	O
a	O
biomimetic	O
catalyst	O
is	O
a	O
copper	B
(	O
Cu	B
(	I
II	I
)	I
-ligands	O
complex	O
,	O
e.g.	O
,	O
dibenzo	B
[	I
e	I
,	I
k	I
]	I
-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza	I
-	I
cyclododeca-1,3,7,9-tetraene	I
.	O

In	O
some	O
cases	O
,	O
lipophilic	O
salts	O
of	O
nitrite	B
/	O
nitrate	B
(	O
e.g.	O
,	O
tridodecylmethylammonium	B
nitrite	I
(	O
TDMA<+>NO2<->	B
/	O
NO3<-	B
>	O
)	O
)	O
or	O
certain	O
salts	O
of	O
nitrosothiols	B
can	O
be	O
doped	O
within	O
a	O
polymer	O
material	O
,	O
or	O
an	O
underlying	O
polymeric	O
film	O
,	O
to	O
create	O
a	O
reservoir	O
of	O
nitrite	B
or	O
nitrosothiol	B
that	O
continuously	O
leaks	O
into	O
the	O
immobilized	O
catalytic	O
layer	O
.	O

Adequate	O
levels	O
of	O
endogenous	O
reducing	O
equivalents	O
are	O
present	O
within	O
blood	O
to	O
provide	O
catalytically	O
-	O
generated	O
surface	O
levels	O
of	O
NO	B
that	O
are	O
above	O
the	O
threshold	O
reportedly	O
required	O
to	O
prevent	O
platelet	O
adhesion	O
or	O
activation	O
.	O

Biocatalytic	O
and	O
biomimetic	O
generation	O
of	O
nitric	B
oxide	I
in	O
situ	O
at	O
substrate	O
/	O
blood	O
interfaces	O

Disclosed	O
is	O
a	O
composition	O
for	O
human	O
consumption	O
,	O
comprising	O
creatine	B
and	O
creatinine	B
,	O
the	O
latter	O
being	O
in	O
sufficient	O
quantity	O
to	O
render	O
creatine	B
in	O
an	O
aqueous	O
medium	O
substantially	O
stable	O
,	O
and	O
a	O
method	O
of	O
making	O
the	O
composition	O
.	O

Compositions	O
containing	O
creatine	O
and	O
creatinine	B

Substituted	O
diarylureas	B
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
use	O
for	O
stimulating	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

The	O
compounds	O
,	O
as	O
single	O
stereoisomers	O
or	O
mixtures	O
of	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
are	O
useful	O
in	O
methods	O
of	O
treating	O
autoimmune	O
diseases	O
,	O
infectious	O
diseases	O
,	O
and	O
malignancies	O
.	O

Substituted	O
diarylureas	B
as	O
stimulators	O
for	O
fas	O
-	O
mediated	O
apoptosis	O

Compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
or	O
veterinarily	O
acceptable	O
salts	O
,	O
solvates	O
,	O
polymorphs	O
or	O
pro	O
-	O
drugs	O
thereof	O
wherein	O
:	O
wherein	O
R?1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
¿	O
,	O
X	O
and	O
A	O
have	O
the	O
meanings	O
given	O
herein	O
which	O
are	O
useful	O
in	O
the	O
curative	O
and	O
prophylactic	O
treatment	O
of	O
a	O
medical	O
condition	O
for	O
which	O
inhibition	O
of	O
a	O
cyclic	B
guanosine	I
3',5'-monophosphate	I
phosphodiesterase	O
(	O
e.g.	O
cGMP	B
PDE5	O
)	O
is	O
desired	O
.	O

Pyrazolo	B
[	I
4,3-d	I
]	I
pyrimidinone	I
compounds	O
as	O
cgmp	O
pde	O
inhibitors	O

The	O
invention	O
discloses	O
a	O
process	O
of	O
extracting	O
,	O
fractionating	O
and	O
purifying	O
bioactive	O
molecules	O
from	O
an	O
associated	O
mangrove	O
plant	O
,	O
methods	O
of	O
screening	O
for	O
pharmacological	O
activities	O
of	O
crude	O
extract	O
,	O
its	O
fractions	O
and	O
purified	O
compounds	O
and	O
use	O
of	O
the	O
aqueous	O
fraction	O
of	O
the	O
crude	O
extract	O
as	O
a	O
tocolytic	O
agent	O
.	O

Biologically	O
active	O
aqueous	O
fraction	O
of	O
an	O
extract	O
obtained	O
from	O
a	O
mangrove	O
plant	O
salvadora	O
persica	O
l	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
depression	O
and	O
other	O
diseases	O
such	O
as	O
obsessive	O
compulsive	O
disorder	O
,	O
panic	O
attacks	O
,	O
generalized	O
anxiety	O
disorder	O
,	O
social	O
anxiety	O
disorder	O
,	O
sexual	O
dysfunction	O
,	O
eating	O
disorders	O
,	O
obesity	O
,	O
addictive	O
disorders	O
caused	O
by	O
ethanol	O
or	O
cocaine	O
abuse	O
and	O
related	O
illnesses	O
.	O

ANTIDEPRESSANT	O
AZAHETEROCYCLYLMETHYL	B
DERIVATIVES	O
OF	O
2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE	B

Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
inhibitors	O
of	O
trypsin	B
like	O
serine	B
protease	O
enzymes	O
such	O
as	O
thrombin	O
,	O
factor	O
VIIa	O
,	O
factor	O
Xa	O
,	O
TF	O
/	O
FVIIa	O
,	O
and	O
trypsin	O
.	O

These	O
compounds	O
could	O
be	O
useful	O
to	O
treat	O
and/or	O
prevent	O
clotting	O
disorders	O
,	O
and	O
as	O
anticoagulating	O
agents	O
.	O

Biaryl	B
compounds	O
as	O
serine	B
protease	O
inhibitors	O

The	O
present	O
invention	O
provides	O
for	O
improved	O
therapeutic	O
regimens	O
for	O
treating	O
benign	O
hyperproliferative	O
diseases	O
and	O
cancers	O
.	O

The	O
Egr-1	O
promoter	O
,	O
long	O
known	O
to	O
be	O
radiation	O
-	O
responsive	O
,	O
has	O
now	O
been	O
shown	O
to	O
be	O
inducible	O
for	O
DNA	O
damaging	O
chemical	O
agents	O
,	O
many	O
of	O
which	O
themselves	O
are	O
used	O
in	O
therapies	O
.	O

Thus	O
,	O
the	O
present	O
invention	O
provides	O
for	O
the	O
advantages	O
combination	O
of	O
a	O
DNA	O
damaging	O
chemical	O
and	O
an	O
expression	O
vector	O
containing	O
a	O
therapeutic	O
gene	O
driven	O
by	O
the	O
Egr-1	O
promoter	O
.	O

Chemotherapeutic	O
induction	O
of	O
egr-1	O
promoter	O
activity	O
in	O
gene	O
therapy	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
and	O
system	O
for	O
delivering	O
a	O
drug	O
into	O
the	O
systemic	O
circulation	O
.	O

The	O
method	O
comprises	O
establishing	O
a	O
drug	O
depot	O
in	O
a	O
patient	O
's	O
skin	O
and/or	O
sub	O
-	O
skin	O
tissues	O
by	O
applying	O
a	O
transdermal	O
drug	O
delivery	O
system	O
on	O
the	O
patients	O
skin	O
,	O
for	O
a	O
predetermined	O
time	O
so	O
that	O
a	O
drug	O
depot	O
is	O
formed	O
in	O
said	O
user	O
's	O
skin	O
and/or	O
sub	O
-	O
skin	O
tissues	O
.	O

A	O
heating	O
source	O
is	O
placed	O
proximate	O
to	O
the	O
skin	O
area	O
to	O
rapidly	O
release	O
a	O
bolus	O
of	O
the	O
drug	O
from	O
the	O
depot	O
into	O
the	O
systemic	O
circulation	O
when	O
there	O
is	O
a	O
need	O
to	O
rapidly	O
increase	O
the	O
drug	O
's	O
concentrations	O
in	O
the	O
systemic	O
circulation	O
.	O

Controlled	O
heat	O
induced	O
rapid	O
delivery	O
of	O
pharmaceuticals	O
from	O
skin	O
depot	O

The	O
invention	O
concerns	O
an	O
injectable	O
galenic	O
formulation	O
for	O
use	O
in	O
a	O
diagnosis	O
or	O
a	O
photodynamic	O
therapy	O
and	O
the	O
method	O
for	O
preparing	O
same	O
.	O

The	O
formulation	O
contains	O
:	O
a	O
compound	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
R2	O
represents	O
a	O
H	B
,	O
OH	B
or	O
COOR4	B
group	O
,	O
where	O
R4	O
is	O
a	O
hydrogen	B
or	O
an	O
C1-C12	B
alkyl	I
or	O
a	O
C3-C12	B
cycloalkyl	I
;	O
R3	O
represents	O
H	B
,	O
OH	B
or	O
a	O
C1-C12	B
alkyl	I
or	O
alkoxy	O
;	O
and	O
*	O
represents	O
an	O
asymmetric	O
carbon	B
in	O
the	O
form	O
of	O
an	O
alkali	O
metal	O
salt	O
in	O
an	O
amount	O
not	O
exceeding	O
10	O
mg	O
/	O
ml	O
,	O
as	O
photosensitizing	O
agent	O
,	O
and	O
a	O
carrier	O
in	O
aqueous	O
phase	O
containing	O
at	O
least	O
a	O
benzyl	B
alcohol	I
-	O
ethanol	B
mixture	O
or	O
propylene	B
glycol	I
as	O
solubilizing	O
agent	O
for	O
the	O
photosensitizing	O
agent	O
and	O
a	O
surfactant	O
in	O
an	O
amount	O
not	O
exceeding	O
20	O
wt	O
.	O

%	O
relative	O
to	O
the	O
total	O
weight	O
of	O
the	O
formulation	O
.	O

Injectable	O
galenic	O
formulation	O
for	O
use	O
in	O
a	O
diagnosis	O
or	O
a	O
photodynamic	O
therapy	O
and	O
method	O
for	O
preparing	O
same	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
and	O
pharmaceutical	O
compositions	O
which	O
are	O
proteomimetic	O
and	O
to	O
methods	O
for	O
inhibiting	O
the	O
interaction	O
of	O
an	O
alpha	O
-	O
helical	O
protein	O
with	O
another	O
protein	O
or	O
binding	O
site	O
.	O

Methods	O
for	O
treating	O
diseases	O
or	O
conditions	O
which	O
are	O
modulated	O
through	O
interactions	O
between	O
alpha	O
helical	O
protein	O
and	O
their	O
binding	O
sites	O
are	O
other	O
aspects	O
of	O
the	O
invention	O
.	O

Proteomimetic	O
compounds	O
and	O
methods	O

GnRH	O
receptor	O
antagonists	O
of	O
formula	O
I	O
are	O
disclosed	O
which	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
sex	O
-	O
hormone	O
related	O
conditions	O
in	O
both	O
men	O
and	O
women	O
.	O

Also	O
disclosed	O
are	O
compositions	O
containing	O
a	O
compound	O
of	O
this	O
invention	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
as	O
well	O
as	O
methods	O
relating	O
to	O
the	O
use	O
thereof	O
for	O
antagonizing	O
gonadotropin	O
-	O
releasing	O
hormone	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

1,3,5-triazine-2,4,6-triones	B
,	O
preparation	O
and	O
use	O
as	O
gonadotropin	O
-	O
releasing	O
hormone	O
receptor	O
antagonists	O

There	O
are	O
provided	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

wherein	O
R?1	O
,	O
R2	O
,	O
R3	O
¿	O
,	O
Q	O
,	O
T	O
,	O
U	O
,	O
X	O
,	O
Y	O
,	O
V	O
and	O
W	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
enantiomers	O
and	O
racemates	O
thereof	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O

The	O
compounds	O
are	O
inhibitors	O
of	O
nitric	B
oxide	I
synthase	O
and	O
are	O
thereby	O
particularly	O
useful	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
inflammatory	O
disease	O
and	O
pain	O
.	O

Heteroarylheteroalkylamine	B
derivatives	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
nitric	B
oxide	I
synthase	O

This	O
invention	O
provides	O
non	O
-	O
immunosuppressive	O
rapamycin	B
29-enols	I
,	O
which	O
are	O
useful	O
as	O
neurotrophic	O
agents	O
,	O
in	O
the	O
treatment	O
of	O
solid	O
tumors	O
,	O
and	O
vascular	O
disease	O
.	O

Rapamycin	B
29-enols	I

The	O
present	O
invention	O
describes	O
cell	O
-	O
based	O
screening	O
methods	O
that	O
allows	O
for	O
the	O
elimination	O
of	O
false	O
-	O
positive	O
results	O
due	O
to	O
nonspecific	O
toxicity	O
of	O
test	O
compounds	O
,	O
while	O
detecting	O
those	O
compounds	O
that	O
specifically	O
modulate	O
cellular	O
metabolites	O
in	O
metabolic	O
pathways	O
associated	O
with	O
diseases	O
and	O
disorders	O
.	O

The	O
methods	O
of	O
the	O
invention	O
involved	O
determining	O
within	O
a	O
cell	O
system	O
the	O
levels	O
of	O
both	O
a	O
metabolic	O
precursor	O
and	O
a	O
metabolite	O
of	O
interest	O
that	O
are	O
associated	O
with	O
disease	O
and	O
disease	O
progression	O
with	O
particular	O
regard	O
to	O
Alzheimer	O
's	O
disease	O
.	O

Cell	O
-	O
based	O
high	O
-	O
throughput	O
screening	O
methods	O

The	O
present	O
invention	O
relates	O
to	O
compound	O
which	O
are	O
capable	O
of	O
preventing	O
the	O
extracellular	O
release	O
of	O
inflammatory	O
cytokines	O
,	O
said	O
compounds	O
,	O
including	O
all	O
enantiomeric	O
and	O
diasteriomeric	O
forms	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
have	O
the	O
formula	O
:	O
wherein	O
R	O
comprises	O
ethers	B
or	O
amines;R<1	O
>	O
is	O
:	O
a	O
)	O
substituted	O
or	O
unsubstituted	O
aryl	B
;	O
orb	O
)	O
substituted	O
or	O
unsubstituted	O
heteroaryl;R<2a	B
>	O
and	O
R<2b	O
>	O
units	O
are	O
each	O
independently	O
hydrogen	B
,	O
ethers	B
,	O
amines	B
,	O
amides	B
,	O
carboxylates	B
,	O
or	O
said	O
units	O
can	O
form	O
a	O
double	O
bond	O
,	O
a	O
carbonyl	B
,	O
or	O
R<2a	O
>	O
and	O
R<2b	O
>	O
can	O
be	O
taken	O
together	O
to	O
form	O
a	O
substituted	O
or	O
unsubstituted	O
ring	O
comprising	O
from	O
4	O
to	O
8	O
atoms	O
,	O
said	O
ring	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
i	O
)	O
carbocyclic;ii	O
)	O
heterocyclic;iii	O
)	O
aryl;iv	O
)	O
heteroaryl;v	B
)	O
bicyclic	O
;	O
andvi	O
)	O
heterobicyclic	B
.	O

Spirocyclic-6,7-dihydro-5h	B
-	I
pyrazolo	I
1,2-a|pyrazol-1-ones	I
which	O
control	O
inflammatory	O
cytokines	O

The	O
invention	O
provides	O
the	O
use	O
of	O
an	O
indole	B
or	O
indoline	B
derivative	O
of	O
Formula	O
,	O
II	O
or	O
III	O
:	O
wherein	O
the	O
substituents	O
are	O
as	O
described	O
in	O
the	O
specification	O
;	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
obesity	O
or	O
for	O
the	O
reduction	O
of	O
food	O
intake	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
indole	B
or	O
indoline	B
derivatives	O
of	O
Formula	O
I	O
,	O
II	O
or	O
III	O
for	O
improving	O
the	O
bodily	O
appearance	O
of	O
a	O
mammal	O
by	O
causing	O
loss	O
of	O
weight	O
,	O
as	O
well	O
as	O
cosmetic	O
compositions	O
containing	O
said	O
compounds	O
.	O

Use	O
of	O
indole	B
and	O
indoline	B
derivatives	O
in	O
the	O
treatment	O
of	O
obesity	O
or	O
for	O
the	O
reduction	O
of	O
food	O
intake	O

Therapeutical	O
method	O
comprising	O
administration	O
to	O
a	O
patient	O
of	O
an	O
effective	O
amount	O
of	O
especially	O
soluble	O
laminarin	B
for	O
the	O
treatment	O
of	O
tumors	O
and	O
more	O
generally	O
of	O
cancers	O
of	O
the	O
group	O
comprising	O
breast	O
cancer	O
,	O
lung	O
cancer	O
,	O
oesophagus	O
cancer	O
,	O
stomach	O
cancer	O
,	O
intestine	O
and	O
colon	O
cancers	O
,	O
and	O
for	O
the	O
treatment	O
of	O
viral	O
,	O
bacterial	O
and	O
fungal	O
diseases	O
as	O
well	O
as	O
diseases	O
related	O
to	O
immunostimulant	O
deficiencies	O
of	O
human	O
beings	O
and	O
warm	O
-	O
blood	O
animals	O
.	O

Use	O
of	O
laminarin	B
in	O
the	O
treatment	O
of	O
cancer	O

This	O
invention	O
discloses	O
pyrimidine	B
compounds	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
and	O
prodrugs	O
thereof	O
,	O
useful	O
in	O
therapeutically	O
and/or	O
prophylactically	O
treating	O
patients	O
with	O
cancer	O
by	O
inhibiting	O
receptor	O
tyrosine	B
kinases	O
and/or	O
dihydrofolate	B
reductase	O
and/or	O
thymidylate	B
synthase	O
.	O

The	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
,	O
are	O
disclosed	O
.	O

Multiple	O
acting	O
anti	O
-	O
angiogenic	O
and	O
cytotoxic	O
compounds	O
and	O
methods	O
for	O
using	O
the	O
same	O

The	O
invention	O
relates	O
to	O
starch	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
:	O
X	O
represents	O
a	O
bromine	B
or	O
iodine	B
atom	O
;	O
R	O
""""	O
represents	O
a	O
straight	O
-	O
chain	O
or	O
branched	O
alkyl	B
group	O
,	O
aryl	B
group	O
or	O
aralkyl	B
group	O
,	O
and	O
;	O
R	B
-	I
CO-	I
represents	O
an	O
oxidized	O
substituted	O
or	O
unsubstituted	O
starch	O
radical	O
that	O
is	O
oxidized	O
on	O
the	O
reducing	O
terminal	O
group	O
to	O
form	O
a	O
carboxylic	B
acid	I
.	O

Starch	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
can	O
selectively	O
couple	O
to	O
active	O
substances	O
containing	O
SH	O
groups	O
and	O
have	O
a	O
prolonged	O
half	O
-	O
life	O
period	O
in	O
the	O
human	O
body	O
.	O

The	O
invention	O
also	O
relates	O
to	O
coupling	O
products	O
of	O
compound	O
(	O
I	O
)	O
with	O
active	O
substances	O
,	O
to	O
methods	O
for	O
the	O
production	O
thereof	O
,	O
and	O
to	O
their	O
use	O
as	O
medicaments	O
.	O

Starch	O
derivatives	O
,	O
starch	O
active	O
substance	O
conjugates	O
,	O
method	O
for	O
the	O
production	O
thereof	O
and	O
their	O
use	O
as	O
medicaments	O

The	O
present	O
disclosure	O
is	O
directed	O
to	O
methods	O
for	O
alleviating	O
the	O
symptoms	O
associated	O
with	O
peripheral	O
neuropathy	O
by	O
administering	O
R	B
(	I
-	I
)	I
-desmethylselegiline	I
,	O
S	B
(	I
+	I
)	I
desmethylselegiline	I
,	O
or	O
a	O
combination	O
of	O
the	O
two	O
.	O

The	O
neuropathy	O
may	O
be	O
the	O
result	O
of	O
a	O
genetically	O
inherited	O
condition	O
,	O
a	O
systemic	O
disease	O
,	O
or	O
exposure	O
to	O
a	O
toxic	O
agent	O
.	O

The	O
disclosure	O
is	O
also	O
directed	O
to	O
a	O
method	O
for	O
treating	O
patients	O
with	O
cancer	O
by	O
administering	O
a	O
chemotherapeutic	O
agent	O
known	O
to	O
have	O
a	O
toxic	O
affect	O
on	O
peripheral	O
nerves	O
together	O
with	O
R	B
(	I
-	I
)	I
-desmethylselegiline	I
,	O
S	B
(	I
+	I
)	I
desmethylselegiline	I
,	O
or	O
a	O
mixture	O
of	O
the	O
two	O
.	O

Methods	O
for	O
preventing	O
and	O
treating	O
peripheral	O
neuropathy	O
by	O
administering	O
desmethylselegiline	B

Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
inhibitors	O
,	O
and	O
are	O
useful	O
in	O
therapeutic	O
and	O
prophylactic	O
treatment	O
of	O
persons	O
infected	O
with	O
hepatitis	O
C	O
virus	O
.	O

Pyranon	B
and	O
pyrandion	B
inhibitors	O
of	O
hepatitis	O
c	O
virus	O
rna	O
-	O
dependent	O
rna	O
polymerase	O

The	O
present	O
invention	O
relates	O
to	O
a	O
thiazolidinedione	B
derivative	O
,	O
represented	O
in	O
formula	O
(	O
1	O
)	O
below	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and/or	O
pharmaceutically	O
acceptable	O
solvates	O
thereof	O
.	O

Further	O
,	O
the	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
represented	O
in	O
formula	O
(	O
1	O
)	O
wherein	O
:	O
X	O
represents	O
a	O
carbon	O
or	O
nitrogen	B
atom	O
,	O
Y	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
alkyl	B
group	O
,	O
an	O
alkoxy	B
group	O
,	O
a	O
halogen	B
,	O
or	O
an	O
aryl	B
group	O
,	O
Z	O
represents	O
an	O
oxygen	B
,	O
nitrogen	B
,	O
or	O
sulfur	B
atom	O
,	O
and	O
R1	O
and	O
R2	O
each	O
represent	O
a	O
hydrogen	B
atom	O
;	O
or	O
R1	O
and	O
R2	O
together	O
form	O
a	O
bond	O
.	O

Thiazolidinedione	B
derivatives	O
and	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O

Novel	O
α	B
,	I
ω	I
-	I
dicarboximide	I
derivatives	O
which	O
selectively	O
inhibit	O
binding	O
to	O
the	O
α-1A	O
adrenergic	O
receptor	O
,	O
a	O
receptor	O
which	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O

Alpha	B
,	I
omega	I
-	I
dicarboximide	I
derivatives	O
as	O
useful	O
uro	O
-	O
selective	O
a1a	O
adrenoceptor	O
blockers	O

The	O
invention	O
relates	O
to	O
novel	O
Acyl	B
coenzyme	O
-	O
A	O
mimics	O
,	O
compositions	O
comprising	O
ketone	B
compounds	O
,	O
and	O
methods	O
useful	O
for	O
treating	O
and	O
preventing	O
cardiovascular	O
diseases	O
,	O
dyslipidemias	O
,	O
dysproteinemias	O
,	O
and	O
glucose	B
metabolism	O
disorders	O
comprising	O
administering	O
a	O
composition	O
comprising	O
a	O
ketone	B
compound	O
.	O

The	O
Acyl	B
coenzyme	O
-	O
A	O
mimics	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
the	O
invention	O
are	O
also	O
useful	O
for	O
treating	O
and	O
preventing	O
Alzheimer	O
's	O
Disease	O
,	O
Syndrome	O
X	O
,	O
peroxisome	O
proliferator	O
activated	O
receptor	O
-	O
related	O
disorders	O
,	O
septicemia	O
,	O
thrombotic	O
disorders	O
,	O
obesity	O
,	O
pancreatitis	O
,	O
hypertension	O
,	O
renal	O
disease	O
,	O
cancer	O
,	O
inflammation	O
,	O
bacterial	O
infection	O
and	O
impotence	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
Acyl	B
coenzyme	O
-	O
A	O
mimics	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
the	O
invention	O
are	O
useful	O
in	O
combination	O
therapy	O
with	O
other	O
therapeutics	O
,	O
such	O
as	O
hypocholesterolemic	O
and	O
hypoglycemic	O
agents	O
.	O

Mimics	O
of	O
acyl	B
coenzyme	O
-	O
a	O
,	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
cholesterol	B
management	O
and	O
related	O
uses	O

The	O
invention	O
relates	O
to	O
a	O
physiologically	O
compatible	O
,	O
phospholipid	O
-	O
containing	O
,	O
stable	O
and	O
hard	O
matrix	O
,	O
comprised	O
of	O
a	O
supporting	O
material	O
and	O
of	O
a	O
bioactive	O
constituent	O
,	O
which	O
has	O
an	O
overall	O
diameter	O
ranging	O
from	O
0.1	O
to	O
5000	O
µm	O
and	O
which	O
contains	O
,	O
as	O
bioactive	O
constituents	O
,	O
=	O
5	O
wt	O
.	O

%	O
,	O
with	O
regard	O
to	O
the	O
starting	O
material	O
,	O
of	O
acetone	B
-	O
insoluble	O
phospholipid	O
constituents	O
that	O
,	O
in	O
particular	O
,	O
are	O
phosphatidylserine	O
,	O
phosphatidylcholine	O
and	O
the	O
like	O
,	O
as	O
well	O
as	O
lyso	O
variants	O
and/or	O
derivatives	O
thereof	O
.	O

This	O
matrix	O
together	O
with	O
a	O
preferred	O
supporting	O
material	O
comprised	O
of	O
carbohydrates	O
and/or	O
of	O
proteins	O
and	O
,	O
preferably	O
,	O
of	O
additional	O
bioactive	O
substances	O
provided	O
in	O
the	O
form	O
of	O
ingredients	O
such	O
as	O
amino	B
acids	I
,	O
vitamins	O
,	O
trace	O
elements	O
and	O
the	O
like	O
can	O
have	O
a	O
liquid	O
content	O
and	O
is	O
used	O
,	O
in	O
particular	O
,	O
in	O
functional	O
foods	O
,	O
special	O
foods	O
and	O
food	O
supplements	O
.	O

Physiologically	O
compatible	O
,	O
phospholipid	O
-	O
containing	O
,	O
stable	O
and	O
hard	O
matrix	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
N	B
-	I
retinyl	I
-	I
N	I
-	I
retinylidene	I
ethanolamine	I
(	O
A2E	O
)	O
,	O
isoforms	O
of	O
A2E	O
or	O
derivatives	O
thereof	O
which	O
induce	O
apoptosis	O
by	O
detaching	O
pro	O
-	O
apoptotic	O
proteins	O
from	O
mitochondria	O
.	O

Further	O
,	O
an	O
antidote	O
for	O
said	O
pharmaceutical	O
composition	O
is	O
disclosed	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
use	O
of	O
N	B
-	I
retinyl	I
-	I
N	I
-	I
retinylidene	I
ethanolamine	I
(	O
A2E	O
)	O
,	O
isoforms	O
of	O
A2E	O
or	O
derivatives	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
and	O
the	O
use	O
of	O
phospholipids	O
for	O
the	O
preparation	O
of	O
an	O
antidote	O
for	O
said	O
pharmaceutical	O
composition	O
.	O

Moreover	O
a	O
method	O
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
and	O
a	O
method	O
of	O
screening	O
for	O
isoforms	O
of	O
A2E	O
or	O
derivatives	O
thereof	O
which	O
induce	O
apoptosis	O
by	O
detaching	O
pro	O
-	O
apoptotic	O
proteins	O
from	O
mitochondria	O
are	O
disclosed	O
.	O

Pharmaceutical	O
composition	O
comprising	O
N	B
-	I
retinyl	I
-	I
N	I
-	I
retinylidene	I
Ethanolamine	I
(	O
A2E	O
)	O
,	O
isoforms	O
of	O
A2E	O
or	O
derivatives	O
thereof	O

The	O
invention	O
relates	O
to	O
substituted	O
thiophene	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
R1	O
to	O
R8	O
have	O
the	O
meanings	O
as	O
cited	O
in	O
the	O
claims	O
.	O

Medicaments	O
containing	O
compounds	O
of	O
this	O
type	O
are	O
useful	O
in	O
preventing	O
or	O
treating	O
various	O
diseases	O
.	O

Thus	O
,	O
these	O
compounds	O
can	O
be	O
used	O
,	O
among	O
other	O
things	O
,	O
for	O
treating	O
breathing	O
disturbances	O
and	O
snoring	O
,	O
for	O
improving	O
the	O
breathing	O
drive	O
,	O
for	O
treating	O
acute	O
and	O
chronic	O
diseases	O
,	O
diseases	O
triggered	O
by	O
ischemic	O
and/or	O
reperfusion	O
events	O
as	O
well	O
as	O
by	O
proliferative	O
or	O
fibrotic	O
events	O
,	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
,	O
lipid	O
metabolism	O
and	O
diabetes	O
,	O
blood	O
clotting	O
and	O
parasitic	O
infection	O
.	O

Substituted	O
thiophenes	B
,	O
method	O
for	O
the	O
production	O
thereof	O
,	O
their	O
use	O
as	O
a	O
medicament	O
or	O
diagnostic	O
reagent	O
,	O
and	O
a	O
medicament	O
containing	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
of	O
preparing	O
a	O
water	O
-	O
soluble	O
complex	O
of	O
water	O
-	O
insoluble	O
or	O
sparingly	O
-	O
soluble	O
organic	O
medicines	O
and	O
beta	O
-	O
cyclodextrin	O
derivatives	O
:	O
a.	O
dissolving	O
successively	O
or	O
simultaneously	O
the	O
organic	O
medicines	O
and	O
the	O
beta	O
-	O
cyclodextrin	O
derivatives	O
in	O
organic	O
solvent	O
(	O
s	O
)	O
at	O
certain	O
mole	O
ratio	O
or	O
mass	O
ratio	O
in	O
the	O
presence	O
of	O
suitable	O
amount	O
of	O
water	O
;	O
b.	O
removing	O
the	O
organic	O
solvent	O
from	O
the	O
solution	O
of	O
the	O
step	O
a	O
to	O
obtain	O
aqueous	O
solution	O
of	O
the	O
organic	O
medicine	O
and	O
beta	O
-	O
cyclodextrin	O
derivative	O
;	O
and	O
c.	O
removing	O
water	O
from	O
the	O
aqueous	O
solution	O
to	O
obtain	O
the	O
complex	O
of	O
the	O
organic	O
medicine	O
and	O
beta	O
-	O
cyclodextrin	O
derivative	O
.	O

The	O
invention	O
also	O
provides	O
a	O
sterile	O
water	O
-	O
soluble	O
complex	O
of	O
water	O
-	O
insoluble	O
or	O
sparingly	O
-	O
soluble	O
organic	O
medicines	O
and	O
beta	O
-	O
cyclodextrin	O
derivatives	O
.	O

A	O
fully	O
-	O
water	O
-	O
soluble	O
complex	O
can	O
be	O
prepared	O
from	O
any	O
water	O
-	O
insoluble	O
or	O
sparingly	O
-	O
soluble	O
organic	O
medicines	O
or	O
other	O
organic	O
compounds	O
according	O
to	O
the	O
present	O
invention	O
.	O

Thus	O
,	O
appreciably	O
convenient	O
means	O
are	O
provided	O
for	O
industrial	O
uses	O
of	O
such	O
organic	O
medicine	O
preparations	O
and	O
of	O
other	O
organic	O
compounds	O
.	O

Complex	O
of	O
organic	O
medicines	O
and	O
beta	O
-	O
cyclodextrin	O
derivatives	O
and	O
its	O
preparing	O
process	O

The	O
present	O
invention	O
relates	O
to	O
2-naphthamides	B
,	O
which	O
are	O
useful	O
as	O
an	O
active	O
ingredient	O
of	O
pharmaceutical	O
preparations	O
.	O

The	O
2-naphthamides	B
of	O
the	O
present	O
invention	O
have	O
IP	O
receptor	O
antagonistic	O
activity	O
,	O
and	O
can	O
be	O
used	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
associated	O
with	O
IP	O
receptor	O
activity	O
.	O

Such	O
diseases	O
include	O
urological	O
diseases	O
or	O
disorder	O
as	O
follows	O
:	O
bladder	O
outlet	O
obstruction	O
,	O
overactive	O
bladder	O
,	O
urinary	O
incontinence	O
,	O
detrusor	O
hyper	O
-	O
reflexia	O
,	O
detrusor	O
instability	O
,	O
reduced	O
bladder	O
capacity	O
,	O
frequency	O
of	O
micturition	O
,	O
urge	O
incontinence	O
,	O
stress	O
incontinence	O
,	O
bladder	O
hyperreactivity	O
,	O
benign	O
prostatic	O
hypertrophy	O
(	O
BPH	O
)	O
,	O
prostatitis	O
,	O
urinary	O
frequency	O
,	O
nocturia	O
,	O
urinary	O
urgency	O
,	O
pelvic	O
hypersensitivity	O
,	O
urethritis	O
,	O
pelvic	O
pain	O
syndrome	O
,	O
prostatodynia	O
,	O
cystitis	O
,	O
or	O
idiophatic	O
bladder	O
hypersensitivity	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
also	O
useful	O
for	O
treatment	O
of	O
pain	O
including	O
,	O
but	O
not	O
limited	O
to	O
inflammatory	O
pain	O
,	O
neuropathic	O
pain	O
,	O
acute	O
pain	O
,	O
chronic	O
pain	O
,	O
dental	O
pain	O
,	O
premenstrual	O
pain	O
,	O
visceral	O
pain	O
,	O
headaches	O
,	O
and	O
the	O
like	O
;	O
hypotension	O
;	O
hemophilia	O
and	O
hemorrhage	O
;	O
and	O
inflammation	O
,	O
since	O
the	O
disease	O
is	O
also	O
alleviated	O
by	O
treatment	O
with	O
an	O
IP	O
receptor	O
antagonist	O
.	O

2-naphthamide	B
derivatives	O

The	O
present	O
invention	O
provides	O
carbocyclic	O
nucleoside	O
compounds	O
and	O
certain	O
derivatives	O
thereof	O
which	O
are	O
inhibitors	O
of	O
RNA	O
-	O
dependent	O
RNA	O
viral	O
polymerase	O
.	O

These	O
compounds	O
are	O
inhibitors	O
of	O
RNA	O
-	O
dependent	O
RNA	O
viral	O
replication	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
RNA	O
-	O
dependent	O
RNA	O
viral	O
infection	O
.	O

They	O
are	O
particularly	O
useful	O
as	O
inhibitors	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS5B	O
polymerase	O
,	O
as	O
inhibitors	O
of	O
HCV	O
replication	O
,	O
and/or	O
for	O
the	O
treatment	O
of	O
hepatitis	O
C	O
infection	O
.	O

The	O
invention	O
also	O
describes	O
pharmaceutical	O
compositions	O
containing	O
such	O
carbocyclic	O
nucleoside	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
other	O
agents	O
active	O
against	O
RNA	O
-	O
dependent	O
RNA	O
viral	O
infection	O
,	O
in	O
particular	O
HCV	O
infection	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
inhibiting	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
,	O
inhibiting	O
RNA	O
-	O
dependent	O
RNA	O
viral	O
replication	O
,	O
and/or	O
treating	O
RNA	O
-	O
dependent	O
RNA	O
viral	O
infection	O
with	O
the	O
carbocyclic	O
nucleoside	O
compounds	O
of	O
the	O
present	O
invention	O
Carbocyclic	O
nucleoside	O
derivatives	O
as	O
inhibitors	O
of	O
rna	O
-	O
dependent	O
rna	O
viral	O
polymerase	O

Dosage	O
forms	O
and	O
devices	O
for	O
enhancing	O
controlled	O
delivery	O
of	O
pharmaceutical	O
agents	O
by	O
use	O
of	O
a	O
drug	O
core	O
composition	O
containing	O
a	O
polymer	O
carrier	O
(	O
e.g.	O
polyethylene	B
oxide	I
)	O
and	O
a	O
surfactant	O
(	O
e.g.	O
polyoxyl	B
stearate	I
,	O
poloxamer	O
)	O
that	O
increases	O
the	O
solubility	O
of	O
the	O
pharmaceutical	O
agent	O
are	O
described	O
.	O

The	O
present	O
invention	O
provides	O
a	O
means	O
of	O
delivering	O
high	O
doses	O
of	O
lowly	O
soluble	O
drug	O
in	O
oral	O
drug	O
delivery	O
systems	O
that	O
are	O
convenient	O
to	O
swallow	O
,	O
for	O
once	O
-	O
a	O
-	O
day	O
administration	O
.	O

Osmotic	O
devices	O
are	O
described	O
.	O

Dosage	O
forms	O
for	O
increasing	O
the	O
solubility	O
and	O
extending	O
the	O
release	O
of	O
drugs	O
such	O
as	O
e.g.	O
topiramate	B
and	O
phenyton	B

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
formulation	O
comprising	O
a	O
polypeptide	O
selected	O
from	O
a	O
group	O
containing	O
insulin	O
,	O
an	O
insulin	O
metabolite	O
,	O
an	O
insulin	O
analogue	O
,	O
an	O
insulin	O
derivative	O
or	O
combinations	O
thereof	O
and	O
also	O
comprising	O
a	O
surfactant	O
or	O
combinations	O
of	O
several	O
surfactants	O
,	O
optionally	O
a	O
preservative	O
or	O
combinations	O
of	O
several	O
preservatives	O
and	O
optionally	O
an	O
isotonic	O
agent	O
,	O
buffers	O
or	O
additional	O
auxiliary	O
agents	O
or	O
combinations	O
thereof	O
.	O

According	O
to	O
the	O
invention	O
,	O
said	O
pharmaceutical	O
formulation	O
has	O
an	O
acidic	O
pH	O
value	O
.	O

Acidic	O
insulin	O
preparations	O
with	O
improved	O
stability	O

Drug	O
delivery	O
film	O
compositions	O
containing	O
a	O
combination	O
of	O
a	O
water	O
-	O
soluble	O
,	O
film	O
-	O
forming	O
polymers	O
and	O
a	O
fatty	B
acid	I
glyceride	I
or	I
ester	I
are	O
suitable	O
for	O
delivering	O
ophthalmic	O
drugs	O
.	O

Bioerodible	O
film	O
for	O
ophthalmic	O
drug	O
delivery	O

The	O
invention	O
relates	O
to	O
novel	O
anthracene	B
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
the	O
production	O
and	O
use	O
thereof	O
as	O
a	O
medicament	O
,	O
particularly	O
for	O
treating	O
tumors	O
.	O

Novel	O
anthracene	B
derivatives	O
and	O
the	O
use	O
thereof	O
as	O
a	O
medicament	O

An	O
improved	O
Transdermal	O
Delivery	O
System	O
(	O
TDS	O
)	O
comprising	O
a	O
backing	O
layer	O
inert	O
to	O
the	O
components	O
of	O
the	O
matrix	O
,	O
a	O
self	O
-	O
adhesive	O
matrix	O
containing	O
an	O
amine	O
-	O
functional	O
drug	O
and	O
a	O
protective	O
foil	O
or	O
sheet	O
to	O
be	O
removed	O
priorto	O
use	O
,	O
characterized	O
in	O
that	O
the	O
self	O
-	O
adhesive	O
matrix	O
consists	O
of	O
a	O
solid	O
or	O
semi	O
-	O
solid	O
semi	O
-	O
permeable	O
polymer	O
(	O
1	O
)	O
wherein	O
an	O
amine	B
functional	O
drug	O
in	O
its	O
free	O
base	O
form	O
has	O
been	O
incorporated	O
,	O
(	O
2	O
)	O
which	O
is	O
saturated	O
with	O
the	O
aminefunctional	B
drug	O
and	O
contains	O
said	O
drug	O
as	O
a	O
multitude	O
of	O
microreservoirs	O
within	O
the	O
matrix	O
,	O
(	O
3	O
)	O
which	O
is	O
highly	O
permeable	O
for	O
the	O
free	O
base	O
of	O
the	O
amine	B
functional	O
drug	O
,	O
(	O
4	O
)	O
which	O
is	O
impermeable	O
for	O
the	O
protonated	O
form	O
of	O
the	O
amine	B
functional	O
drug	O
,	O
(	O
5	O
)	O
wherein	O
the	O
maximum	O
diameter	O
of	O
the	O
microreservoirs	O
is	O
less	O
than	O
the	O
thickness	O
of	O
the	O
matrix	O
.	O
is	O
provided	O
.	O

Said	O
TDS	O
provides	O
for	O
enhanced	O
flux	O
of	O
the	O
amine	O
functional	O
drug	O
across	O
the	O
TDS	O
/	O
skin	O
interface	O
.	O

Improved	O
transdermal	O
delivery	O
system	O

The	O
invention	O
relates	O
to	O
cholesterol	B
reducing	O
agents	O
made	O
of	O
dietary	O
fibre	O
and	O
at	O
least	O
one	O
cholesterol	B
-	O
reducing	O
active	O
ingredient	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
the	O
production	O
of	O
said	O
agent	O
and	O
the	O
use	O
thereof	O
.	O

Cholesterol	B
-	O
reducing	O
agent	O
made	O
of	O
dietary	O
fibre	O
and	O
cholesterol	B
-	O
reducing	O
substances	O

A	O
novel	O
ErbB-4	O
ligand	O
,	O
referred	O
to	O
herein	O
as	O
Neuregulin-4	O
(	O
NRG-4	O
)	O
is	O
disclosed	O
as	O
well	O
as	O
polynucleotide	O
sequences	O
encoding	O
NRG-4	O
,	O
oligonucleotides	B
and	O
oligonucleotide	B
analogs	O
derived	O
from	O
polynucleotide	O
sequences	O
,	O
a	O
display	O
library	O
displaying	O
short	O
peptides	O
derived	O
from	O
NRG-4	O
,	O
antibodies	O
recognizing	O
NRG-4	O
,	O
peptides	O
or	O
peptide	O
analogs	O
derived	O
from	O
NRG-4	O
,	O
and	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
employing	O
peptides	O
or	O
peptide	O
analogs	O
,	O
oligonucleotides	B
and	O
oligonucleotide	B
analogs	O
,	O
and/or	O
polynucleotide	O
sequences	O
to	O
up	O
-	O
regulate	O
or	O
down	O
-	O
regulate	O
ErbB-4	O
receptor	O
activity	O
(	O
signaling	O
)	O
.	O

Growth	O
factor	O
which	O
acts	O
through	O
erb	O
b-4	O
rtk	O

The	O
present	O
invention	O
relates	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
in	O
the	O
field	O
of	O
malignant	O
disorders	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
provides	O
methods	O
of	O
determining	O
the	O
invasivity	O
of	O
malignant	O
disorders	O
and	O
methods	O
for	O
reducing	O
the	O
invasivity	O
of	O
malignant	O
disorders	O
including	O
the	O
prevention	O
or	O
treatment	O
of	O
cancer	O
cell	O
invasion	O
.	O

Diagnosis	O
and	O
prevention	O
of	O
cancer	O
cell	O
invasion	O

Disclosed	O
are	O
methods	O
of	O
detecting	O
ovarian	O
endometriosis	O
using	O
differentially	O
expressed	O
genes	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
screening	O
compounds	O
serving	O
as	O
agents	O
for	O
treating	O
ovarian	O
endometriosis	O
,	O
and	O
methods	O
of	O
treating	O
ovarian	O
endometriosis	O
and	O
method	O
or	O
vaccinating	O
a	O
subject	O
against	O
ovarian	O
endometriosis	O
.	O

Method	O
of	O
diagnosing	O
ovarian	O
endometriosis	O

The	O
present	O
invention	O
provides	O
the	O
hybrids	O
wherein	O
itraconazole	B
,	O
cyclosporine	B
or	O
carvedilol	B
are	O
intercalated	O
into	O
the	O
interlayers	O
and/or	O
absorbed	O
onto	O
the	O
surfaces	O
of	O
layered	O
silicates	B
.	O

The	O
hybrids	O
according	O
to	O
the	O
present	O
invention	O
enable	O
the	O
maximization	O
of	O
bioavailability	O
of	O
drugs	O
by	O
dissolving	O
the	O
drugs	O
from	O
the	O
layered	O
silicates	B
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
provides	O
the	O
preparing	O
methods	O
of	O
the	O
hybrids	O
.	O

The	O
process	O
comprises	O
:	O
(	O
1	O
)	O
dispersing	O
a	O
layered	O
silicate	B
in	O
an	O
aqueous	O
solution	O
to	O
form	O
an	O
aqueous	O
solution	O
containing	O
the	O
layered	O
silicate	B
;	O
(	O
2	O
)	O
dissolving	O
a	O
drug	O
in	O
a	O
organic	O
solvent	O
to	O
form	O
an	O
organic	O
solution	O
containing	O
the	O
drug	O
,	O
the	O
organic	O
solvent	O
having	O
a	O
solubility	O
higher	O
than	O
that	O
in	O
the	O
aqueous	O
solution	O
;	O
and	O
(	O
3	O
)	O
mixing	O
and	O
hybridizing	O
in	O
the	O
inerrface	O
of	O
the	O
aqueous	O
solution	O
containing	O
the	O
layered	O
silicate	B
and	O
the	O
organic	O
phase	O
solution	O
containing	O
the	O
drug	O
in	O
order	O
to	O
intercalate	O
the	O
drug	O
into	O
the	O
interlayers	O
of	O
the	O
layered	O
silicate	B
and/or	O
to	O
absorb	O
the	O
drug	O
onto	O
the	O
surface	O
of	O
the	O
layered	O
silicate	B
.	O

Hybrid	O
of	O
itraconazole	B
,	O
cyclosporine	B
or	O
carvedilol	B
with	O
a	O
layered	O
silicate	B
and	O
a	O
process	O
for	O
preparing	O
the	O
same	O

A	O
process	O
for	O
substantially	O
enhancing	O
the	O
regio	O
and	O
stereoselective	O
synthesis	O
of	O
9-β	O
-	O
anomeric	O
nucleoside	O
analogs	O
is	O
described	O
.	O

The	O
introduction	O
of	O
the	O
sugar	B
moiety	O
onto	O
a	O
6-substituted	B
purine	I
base	O
was	O
preformed	O
so	O
that	O
only	O
the	O
9-β	O
-	O
D-	O
or	O
L	O
-	O
purine	O
nucleoside	O
analogs	O
were	O
obtained	O
.	O

This	O
regio	O
and	O
stereoselective	O
introduction	O
of	O
the	O
sugar	O
moiety	O
allows	O
the	O
synthesis	O
of	O
nucleoside	O
analogs	O
and	O
in	O
particular	O
2'-deoxy	O
,	O
3'-deoxy	O
,	O
2'-deoxy-2'-β	O
-	O
fluoro	O
and	O
2	O
'	O
,	O
3'-dideoxy-2'-β	O
-	O
fluoro	O
purine	O
nucleoside	O
analogs	O
in	O
high	O
yield	O
without	O
virtually	O
any	O
formation	O
of	O
the	O
7-positional	O
isomers	O
.	O

The	O
compounds	O
are	O
drugs	O
or	O
intermediates	O
to	O
drugs	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
9-beta	O
-	O
anomeric	O
nucleoside	O
analogs	O

Growth	O
differentiation	O
factor-10	O
(	O
GDF-10	O
)	O
is	O
disclosed	O
along	O
with	O
its	O
polynucleotide	O
sequence	O
and	O
amino	B
acid	I
sequence	O
.	O

Also	O
disclosed	O
are	O
diagnostic	O
and	O
therapeutic	O
methods	O
of	O
using	O
the	O
GDF-10	O
polypeptide	O
and	O
polynucleotide	O
sequences	O
.	O

Growth	O
differentiation	O
factor-10	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
delaying	O
the	O
onset	O
or	O
progression	O
of	O
motor	O
impairment	O
associated	O
with	O
amyotrophic	O
lateral	O
sclerosis	O
in	O
a	O
subject	O
by	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
nimesulide	B
.	O

It	O
further	O
provides	O
for	O
a	O
means	O
of	O
detecting	O
and	O
monitoring	O
the	O
progression	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
via	O
a	O
protein	O
biomarker	O
for	O
the	O
disease	O
.	O

Treatment	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
with	O
nimesulide	B

The	O
present	O
invention	O
relates	O
to	O
orally	O
administered	O
pharmaceutical	O
compositions	O
that	O
include	O
a	O
combination	O
of	O
antidiabetic	O
agents	O
wherein	O
one	O
agent	O
is	O
present	O
in	O
an	O
extended	O
release	O
form	O
and	O
the	O
other	O
agent	O
is	O
present	O
in	O
an	O
immediate	O
release	O
form	O
.	O

For	O
example	O
,	O
in	O
one	O
embodiment	O
the	O
dosage	O
form	O
includes	O
an	O
extended	O
release	O
layer	O
that	O
includes	O
a	O
biguanide	B
;	O
and	O
an	O
immediate	O
release	O
layer	O
that	O
includes	O
a	O
sulfonylurea	B
.	O

Pharmaceutical	O
dosage	O
forms	O
of	O
biguanide	B
-	O
sulfonylurea	B
combinations	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
providing	O
alpha	O
-glucosidase	O
inhibition	O
to	O
a	O
subject	O
by	O
administering	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
alpha	O
-glucosidase	O
inhibitory	O
agent	O
selected	O
from	O
pipataline	B
(	O
formula	O
1a	O
)	O
,	O
sesamin	B
(	O
formula	O
1b	O
)	O
,	O
pellitorine	B
(	O
Formula	O
1c	O
)	O
,	O
guineensine	B
(	O
Formula	O
1d	O
)	O
and	O
brachystamide	B
-	I
B	I
(	O
formula	O
1e	O
)	O
having	O
therapeutic	O
application	O
for	O
diabetes	O
mellitus	O
,	O
cancer	O
,	O
viral	O
diseases	O
such	O
as	O
hepatitis	O
B	O
and	O
C	O
,	O
HIV	O
,	O
AIDS	O
etc	O
;	O
also	O
the	O
invention	O
provides	O
a	O
process	O
for	O
the	O
isolation	O
of	O
said	O
alpha	O
-glucosidase	O
inhibitory	O
agent	O
from	O
the	O
plant	O
source	O
Piper	O
longum	O
in	O
significant	O
yields	O
.	O

New	O
use	O
of	O
pipataline	B

The	O
present	O
invention	O
relates	O
to	O
spirocyclic	B
ureas	I
,	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
The	O
compounds	O
are	O
glucagon	O
receptor	O
antagonists	O
and	O
thus	O
are	O
useful	O
for	O
treating	O
,	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Spirocyclic	B
ureas	I
,	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
use	O

Disclosed	O
are	O
methods	O
of	O
lowering	O
plasma	O
CRP	O
levels	O
,	O
reducing	O
systemic	O
inflammation	O
,	O
and	O
inhibiting	O
proinlammatory	O
cytokine	O
induced	O
CRP	O
production	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
substituted	O
dialkyl	B
ether	I
,	O
substituted	O
alkyl	B
,	O
substituted	O
aryl	B
-	I
alkyl	I
,	O
substituted	O
dialkyl	B
thioether	I
,	O
substituted	O
dialkyl	B
ketone	I
,	O
substituted	O
-	O
alkyl	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
substituted	O
dialkyl	B
ether	I
,	O
substituted	O
alkyl	B
,	O
substituted	O
aryl	B
-	I
alkyl	I
,	O
substituted	O
dialkyl	B
thioether	I
,	O
substituted	O
dialkyl	B
ketone	I
,	O
or	O
substituted	O
-	O
alkyl	B
or	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
substituted	O
dialkyl	B
ether	I
,	O
substituted	O
alkyl	B
,	O
substituted	O
aryl	B
-	I
alkyl	I
,	O
substituted	O
dialkyl	B
thioether	I
,	O
substituted	O
dialkyl	B
ketone	I
,	O
substituted	B
-	I
alkyl	I
.	O

Method	O
of	O
lowering	O
crp	O
and	O
reducing	O
systemic	O
inflammation	O

Pharmaceutical	O
compositions	O
comprise	O
1-	B
(	I
3-hydroxy-4-methoxyphenyl	I
)	I
-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
compositions	O
are	O
used	O
for	O
treating	O
,	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
disorders	O
mediated	O
by	O
LTB4	O
or	O
TXA2	O
.	O

Pharmaceutical	O
composition	O
of	O
1-	B
(	I
3-hydroxy-4-methoxyphenyl	I
)	I
-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine	I
and	O
uses	O
therof	O

This	O
invention	O
provides	O
novel	O
transcriptional	O
regulatory	O
elements	O
from	O
the	O
human	O
TRPM4	O
(	O
Transient	O
Receptor	O
Potential	O
-	O
Melastatin	O
4	O
)	O
gene	O
.	O

These	O
promoter	O
and	O
enhancer	O
elements	O
preferentially	O
activate	O
transcription	O
in	O
prostate	O
tumor	O
cells	O
and	O
tissues	O
as	O
compared	O
to	O
other	O
tissues	O
.	O

Methods	O
and	O
compositions	O
are	O
provided	O
to	O
employ	O
TRPM4	O
promoter	O
elements	O
for	O
prostate	O
tumor	O
-	O
specific	O
expression	O
of	O
therapeutic	O
molecules	O
.	O

Prostate	O
tumor	O
-	O
restricted	O
replicating	O
adenoviral	O
vectors	O
are	O
also	O
provided	O
.	O

Novel	O
prostate	O
tumor	O
-	O
specific	O
promoter	O

The	O
present	O
invention	O
provides	O
agents	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
intrauterine	O
growth	O
retardation	O
or	O
gestational	O
toxicosis	O
comprising	O
as	O
an	O
active	O
ingredient	O
phenylethanolaminotetralin	B
derivatives	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
such	O
as	O
a	O
sulfate	B
salt	O
thereof	O
,	O
which	O
exert	O
a	O
remarkable	O
improving	O
effect	O
on	O
fetal	O
weight	O
loss	O
and	O
static	O
gangrene	O
in	O
the	O
tip	O
of	O
fetal	O
extremities	O
and	O
a	O
remarkable	O
improving	O
effect	O
on	O
elevation	O
of	O
maternal	O
urinary	O
protein	O
and	O
plasma	O
triglyceride	B
level	O
with	O
ease	O
of	O
anxiety	O
on	O
palpitation	O
of	O
dams	O
or	O
the	O
like	O
.	O

Examples	O
of	O
administration	O
forms	O
include	O
,	O
for	O
example	O
,	O
tablets	O
,	O
capsules	O
,	O
injections	O
and	O
so	O
on	O
.	O

As	O
diseases	O
to	O
be	O
treated	O
,	O
for	O
example	O
,	O
asymmetrical	O
intrauterine	O
growth	O
retardation	O
and	O
hyperlipidemia	O
associated	O
with	O
gestational	O
toxicosis	O
are	O
specially	O
preferable	O
.	O

Preventive	O
or	O
remedy	O
for	O
intrauterine	O
late	O
embryonic	O
development	O
or	O
pregnancy	O
toxemia	O

Use	O
of	O
a	O
glycoalkaloid	B
composition	O
containing	O
at	O
least	O
one	O
Z	O
Glycoalkaloid	B
of	O
formula	O
I	O
,	O
wherein	O
:	O
either	O
one	O
or	O
both	O
of	O
the	O
dotted	O
lines	O
represents	O
a	O
double	O
bond	O
,	O
and	O
the	O
other	O
a	O
single	O
bond	O
,	O
or	O
both	O
represent	O
single	O
bonds	O
;	O
A	O
:	O
represents	O
a	O
radical	O
selected	O
from	O
the	O
radicals	O
of	O
general	O
formulae	O
(	O
II	O
)	O
to	O
(	O
V	O
)	O
;	O
each	O
of	O
R<1	O
>	O
is	O
a	O
radical	O
separately	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
amino	B
,	O
oxo	B
and	O
OR<4	B
>	I
;	O
each	O
of	O
R<2	O
>	O
is	O
a	O
radical	O
separately	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
amino	B
and	O
OR<4	B
>	I
;	O
each	O
of	O
R<3	O
>	O
is	O
a	O
radical	O
separately	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
carbohydrate	B
and	O
a	O
carbohydrate	B
;	O
""""	O
X	O
""""	O
is	O
a	O
radical	O
selected	O
from	O
the	O
group	O
comprising	O
-CH2-	B
,	O
-O-	B
and	O
-NH2-	B
;	O
and	O
wherein	O
the	O
compound	O
includes	O
at	O
least	O
one	O
R<4	O
>	O
group	O
that	O
is	O
a	O
carbohydrate	B
or	O
a	O
derivative	O
such	O
as	O
one	O
selected	O
from	O
the	O
group	O
comprising	O
glyceric	B
aldehyde	I
,	O
glycerose	B
,	O
erythrose	B
,	O
threose	B
,	O
ribose	B
,	O
arabinose	B
,	O
xylose	B
,	O
lyxose	B
,	O
altrose	B
,	O
allose	B
,	O
gulose	B
,	O
mannose	B
,	O
glucose	B
,	O
idose	B
,	O
galactose	B
,	O
talose	B
,	O
rhamnose	B
,	O
dihydroxyactone	B
,	O
erythrulose	B
,	O
ribulose	B
,	O
xylulose	B
,	O
psicose	B
,	O
fructose	B
,	O
sorbose	B
,	O
tagatose	B
,	O
and	O
other	O
hexoses	B
,	O
heptoses	B
,	O
octoses	B
,	O
nanoses	B
,	O
decoses	B
,	O
deoxysugars	B
with	O
branched	O
chains	O
,	O
(	O
e.g.	O
apiose	B
,	O
hamamelose	B
,	O
streptose	B
,	O
cordycepose	B
,	O
mycarose	B
and	O
cladinose	B
)	O
,	O
compounds	O
wherein	O
the	O
aldehyde	B
,	O
ketone	B
or	O
hydroxyl	B
groups	O
have	O
been	O
substituted	O
(	O
e.g.	O
N	B
-	I
acetyl	I
,	O
acetyl	B
,	O
methyl	B
,	O
replacement	O
of	O
CH2OH	B
)	O
,	O
sugar	B
alcohols	I
,	O
sugar	B
acids	I
,	O
benzimidazoles	B
,	O
the	O
enol	B
salts	O
of	O
the	O
carbohydrates	B
,	O
saccharinic	B
acids	I
,	O
sugar	B
phosphates	I
;	O
as	O
an	O
IL-6	O
antagonist	O
.	O

Method	O
of	O
modulating	O
il-6	O

The	O
present	O
invention	O
relates	O
to	O
a	O
boron	B
containing	O
therapeutic	O
composition	O
comprising	O
:	O
(	O
i	O
)	O
a	O
boron	B
component	O
formed	O
at	O
least	O
partly	O
from	O
boron-10	B
;	O
and	O
(	O
ii	O
)	O
a	O
silicon	B
component	O
.	O

The	O
composition	O
is	O
of	O
value	O
in	O
the	O
treatment	O
of	O
cancers	O
by	O
boron	B
neutron	O
capture	O
therapy	O
or	O
in	O
the	O
treatment	O
of	O
arthritis	O
by	O
boron	B
neutron	O
capture	O
synovectomy	O
.	O

Devices	O
and	O
compositions	O
containing	O
boron	B
and	O
silicon	B
for	O
use	O
in	O
neutron	O
capture	O
therapy	O

Methods	O
of	O
inhibiting	O
virus	O
replication	O
of	O
in	O
a	O
cell	O
infected	O
with	O
a	O
resistant	O
strain	O
of	O
HIV	O
that	O
includes	O
administering	O
to	O
the	O
infected	O
cell	O
a	O
virus	O
replication	O
inhibiting	O
amount	O
of	O
an	O
aryl	B
phosphate	I
derivative	O
of	O
d4	O
T	O
.	O

ARYL	B
PHOSPHATE	I
DERIVATIVES	O
OF	O
d4	O
T	O
HAVING	O
ACTIVITY	O
AGAINST	O
RESISTANT	O
HIV	O
STRAINS	O

A	O
liquid	O
composition	O
for	O
adherence	O
to	O
a	O
bodily	O
surface	O
,	O
notably	O
to	O
a	O
bodily	O
surface	O
,	O
especially	O
a	O
mucosal	O
surface	O
,	O
comprises	O
water	O
-	O
swellable	O
polymer	O
particles	O
suspended	O
in	O
a	O
water	O
-	O
miscible	O
liquid	O
diluent	O
,	O
wherein	O
the	O
liquid	O
diluent	O
is	O
substantially	O
free	O
of	O
water	O
or	O
includes	O
an	O
amount	O
of	O
water	O
insufficient	O
to	O
fully	O
swell	O
the	O
polymer	O
particles	O
.	O

On	O
admixture	O
with	O
water	O
the	O
composition	O
thickens	O
and	O
becomes	O
more	O
adherent	O
to	O
surfaces	O
.	O

Thus	O
the	O
composition	O
may	O
be	O
easy	O
to	O
administer	O
but	O
may	O
become	O
thick	O
and	O
adherent	O
at	O
the	O
treatment	O
site	O
.	O

Bioadhesive	O
liquid	O
composition	O
which	O
is	O
substantially	O
free	O
of	O
water	O

The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
,	O
kits	O
,	O
combinations	O
,	O
and	O
compositions	O
for	O
treating	O
,	O
preventing	O
or	O
reducing	O
the	O
risk	O
of	O
developing	O
a	O
gastrointestinal	O
disorder	O
or	O
disease	O
,	O
or	O
the	O
symptoms	O
associated	O
with	O
,	O
or	O
related	O
to	O
a	O
gastrointestinal	O
disorder	O
or	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

In	O
one	O
aspect	O
,	O
the	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
proton	O
pump	O
inhibiting	O
agent	O
and	O
a	O
buffering	O
agent	O
for	O
oral	O
administration	O
and	O
ingestion	O
by	O
a	O
subject	O
.	O

Upon	O
administration	O
,	O
the	O
composition	O
contacts	O
the	O
gastric	O
fluid	O
of	O
the	O
stomach	O
and	O
increases	O
the	O
gastric	O
fluid	O
pH	O
of	O
the	O
stomach	O
to	O
a	O
pH	O
that	O
substantially	O
prevents	O
or	O
inhibits	O
acid	O
degradation	O
of	O
the	O
proton	O
pump	O
inhibiting	O
agent	O
in	O
the	O
gastric	O
fluid	O
and	O
allows	O
a	O
measurable	O
serum	O
concentration	O
of	O
the	O
proton	O
pump	O
inhibiting	O
agent	O
to	O
be	O
absorbed	O
into	O
the	O
blood	O
serum	O
of	O
the	O
subject	O
.	O

A	O
novel	O
formulation	O
,	O
omeprazole	B
antacid	O
complex	O
-	O
immediate	O
release	O
for	O
rapid	O
and	O
sustained	O
supression	O
of	O
gastric	O
acid	O

The	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
functional	O
PNA	O
monomer	O
units	O
and	O
a	O
novel	O
synthesis	O
method	O
for	O
functional	O
PNA	O
oligomers	O
for	O
introducing	O
a	O
plurality	O
of	O
functional	O
molecules	O
at	O
arbitrary	O
locations	O
by	O
means	O
of	O
linkers	O
having	O
various	O
lengths	O
either	O
directly	O
or	O
post	O
-	O
synthetically	O
even	O
in	O
the	O
case	O
of	O
compounds	O
that	O
are	O
unstable	O
in	O
liquid	O
under	O
acidic	O
,	O
alkaline	O
or	O
neutral	O
conditions	O
,	O
along	O
with	O
novel	O
functional	O
PNA	O
monomer	O
units	O
and	O
functional	O
PNA	O
oligomers	O
.	O

This	O
object	O
is	O
achieved	O
by	O
means	O
of	O
a	O
compound	O
in	O
the	O
form	O
of	O
a	O
functional	O
PNA	O
monomer	O
unit	O
,	O
and	O
production	O
method	O
thereof	O
,	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
wherein	O
R	O
represents	O
H	O
,	O
a	O
functional	O
molecule	O
or	O
a	O
protecting	O
group	O
,	O
and	O
n	O
represents	O
an	O
integer	O
of	O
1	O
to	O
11	O
)	O
.	O

Novel	O
functional	O
peptide	O
nucleic	O
acid	O
and	O
process	O
for	O
producing	O
the	O
same	O

The	O
present	O
invention	O
provides	O
an	O
oral	O
delivery	O
system	O
for	O
the	O
treatment	O
of	O
periodontal	O
disease	O
,	O
being	O
in	O
a	O
solid	O
unit	O
dosage	O
form	O
for	O
administration	O
to	O
a	O
patient	O
and	O
comprising	O
:	O
(	O
i	O
)	O
a	O
biodegradable	O
or	O
bioerodible	O
pharmaceutically	O
acceptable	O
polymer	O
;	O
(	O
ii	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
antibacterial	O
agent	O
;	O
and	O
(	O
iii	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
anti	O
-	O
inflammatory	O
agent	O
,	O
the	O
relative	O
weight	O
ratio	O
between	O
the	O
antibacterial	O
agent	O
and	O
the	O
anti	O
-	O
inflammatory	O
agent	O
ranking	O
from	O
about	O
7:1	O
to	O
about	O
1:5	O
.	O

The	O
system	O
may	O
further	O
comprise	O
at	O
least	O
one	O
of	O
a	O
cross	O
-	O
linking	O
agent	O
,	O
a	O
plasticizing	O
agent	O
,	O
a	O
wetting	O
agent	O
,	O
a	O
suspending	O
agent	O
,	O
a	O
surfactant	O
and	O
a	O
dispersing	O
agent	O
.	O

Oral	O
delivery	O
system	O
comprising	O
an	O
antibacterial	O
and	O
an	O
anti	O
-	O
inflammatory	O
agent	O

The	O
invention	O
relates	O
to	O
pure	O
7-	B
amino	I
(	I
p	I
-	I
hydroxyphenylglycyl	I
)	I
cephem	I
compounds	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
pure	O
7-	B
amino	I
(	I
p	I
-	I
hydroxyphenylglycyl	I
)	I
cephem	I
compounds	O
and	O
pharmaceutical	O
compositions	O
that	O
include	O
the	O
pure	O
7-	B
amino	I
(	I
p	I
-	I
hydroxyphenylglycyl	I
)	I
cephem	I
compounds	O
.	O

Process	O
for	O
the	O
preparaton	O
of	O
7-	B
(	I
p	I
-	I
hydroxyphenylglycylamido	I
)	I
cephem	I
compounds	O

There	O
are	O
provided	O
novel	O
crystals	O
of	O
(	B
-	I
)	I
-N-	I
{	I
2-	I
[	I
(	I
R	I
)	I
-3-	I
(	I
6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl	I
)	I
piperidino	I
]	I
ethyl	I
}	I
-4-fluorobenzamide	I
monophosphate	I
.	O

Novel	O
crystal	O
of	O
fluorobenzamide	B
derivative	O

A	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
neuropathic	O
pain	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
having	O
histamine	B
H3-receptor	O
antagonism	O
such	O
as	O
a	O
compound	O
represented	O
by	O
Formula	O
(	O
II	O
)	O
:	O
(	O
wherein	O
W	O
represents	O
a	O
residue	O
which	O
imparts	O
antagonistic	O
and/or	O
agonistic	O
activity	O
at	O
histamine	B
H3-receptors	O
when	O
attached	O
to	O
an	O
imidazole	B
ring	O
in	O
4-	O
or	O
5-position	O
,	O
and	O
R3	O
and	O
R4	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
or	O
the	O
like	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
provided	O
.	O

Preventive	O
and/or	O
therapeutic	O
agent	O
for	O
neuropathic	O
pain	O

Provided	O
are	O
polypeptide	O
ligands	O
for	O
the	O
receptor	O
tyrosine	B
kinase	O
,	O
Flt4	O
.	O

Also	O
provided	O
are	O
cDNAs	O
and	O
vectors	O
encoding	O
the	O
ligands	O
,	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
reagents	O
comprising	O
the	O
ligands	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
ligands	O
.	O

Receptor	O
ligand	O
VEGF	O
-	O
C	O

A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
:	O
(	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
each	O
independently	O
represents	O
hydrogen	B
or	O
C1	B
-	I
6	I
alkyl	I
and	O
n	O
is	O
an	O
integer	O
of	O
1	O
or	O
2	O
)	O
;	O
a	O
process	O
for	O
producing	O
the	O
compound	O
;	O
an	O
antioxidizing	O
drug	O
containing	O
the	O
compound	O
as	O
an	O
active	O
ingredient	O
;	O
and	O
a	O
therapeutic	O
drug	O
for	O
renal	O
diseases	O
,	O
therapeutic	O
drug	O
for	O
cerebrovascular	O
disorders	O
,	O
inhibitory	O
drug	O
for	O
retinal	O
oxidation	O
disorders	O
,	O
and	O
lipoxygenase	O
inhibitory	O
drug	O
each	O
containing	O
the	O
antioxidizing	O
drug	O
.	O

Diamine	B
derivative	O
,	O
production	O
process	O
,	O
and	O
antioxidizing	O
drug	O

The	O
use	O
of	O
substituted	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidines	I
for	O
modulating	O
the	O
activity	O
of	O
11β	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
1	O
(	O
11βHSD1	O
)	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
phar	O
-	O
maceutical	O
compositions	O
are	O
described	O
.	O

Also	O
a	O
novel	O
class	O
of	O
substituted	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidines	I
their	O
use	O
in	O
therapy	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
are	O
described	O
The	O
present	O
com	O
-	O
pounds	O
are	O
modulators	O
and	O
more	O
specifically	O
inhibitors	O
of	O
the	O
activity	O
of	O
11βHSD1	O
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and/or	O
prophylaxis	O
of	O
a	O
range	O
of	O
medical	O
disorders	O
where	O
a	O
decreased	O
intracellular	O
concentration	O
of	O
active	O
glucocorticoid	B
is	O
desirable	O
.	O

New	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidine	I
derivatives	O
and	O
pharmaceutical	O
use	O
thereof	O

New	O
medicaments	O
contain	O
a	O
quaternized	O
2,2-diphenylpropionic	B
acid	I
scopine	B
ester	I
anticholinergic	O
agent	O
(	O
I	O
)	O
and	O
a	O
beta	O
-mimetic	O
agent	O
(	O
II	O
)	O
.	O

New	O
medicaments	O
contain	O
:	O
(	O
a	O
)	O
a	O
scopine	B
derivative	O
anticholinergic	O
agent	O
of	O
formula	O
(	O
I	O
)	O
;	O
(	O
b	O
)	O
at	O
least	O
one	O
beta	O
-mimetic	O
agent	O
(	O
II	O
)	O
(	O
optionally	O
in	O
the	O
form	O
of	O
enantiomers	O
,	O
enantiomer	O
mixtures	O
,	O
racemates	O
,	O
solvates	O
or	O
hydrates	B
)	O
;	O
and	O
optionally	O
(	O
c	O
)	O
pharmaceutical	O
auxiliaries	O
.	O

[	O
Image	O
]	O
X->monovalent	O
anion	O
,	O
preferably	O
chloride	B
,	O
bromide	B
,	O
iodide	B
,	O
sulfate	B
,	O
phosphate	B
,	O
methanesulfonate	B
,	O
nitrate	B
,	O
maleate	B
,	O
acetate	B
,	O
citrate	B
,	O
fumarate	B
,	O
tartrate	B
,	O
oxalate	B
,	O
succinate	B
,	O
benzoate	B
or	O
p	B
-	I
toluenesulfonate	I
.	O

-	O
ACTIVITY	O
:	O
Antiinflammatory	O
;	O
Antiasthmatic	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O

Anticholinergic	O
;	O
Synergist	O
.	O

Composition	O
comprising	O
a	O
steroid	B
and	O
an	O
anticholinergic	O
agent	O

This	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
combinations	O
of	O
salmeterol	B
and	O
ciclesonide	B
and	O
the	O
use	O
of	O
such	O
pharmaceutical	O
compositions	O
in	O
medicine	O
,	O
in	O
particular	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
respiratory	O
disease	O
.	O

Salmeterol	B
and	O
ciclesonide	B
combination	O

An	O
antimicrobial	O
composition	O
comprising	O
silver	B
and	O
at	O
least	O
one	O
compound	O
which	O
interacts	O
with	O
a	O
microbial	O
cell	O
wall	O
to	O
inhibit	O
microbial	O
silver	B
resistance	O
.	O

The	O
resistance	O
inhibitors	O
include	O
molecules	O
that	O
can	O
promote	O
the	O
transport	O
of	O
silver	B
across	O
the	O
cell	O
wall	O
,	O
and/or	O
disrupt	O
the	O
cell	O
wall	O
to	O
allow	O
silver	B
into	O
the	O
cell	O
,	O
and/or	O
disrupt	O
ion	O
pump	O
mechanisms	O
in	O
the	O
cell	O
wall	O
for	O
removing	O
silver	O
from	O
the	O
cell	O
.	O

Inhibitor	O
compounds	O
include	O
fusaric	B
acid	I
,	O
tocopherol	B
,	O
resveratrol	B
,	O
and	O
myristic	B
acid	I
.	O

Also	O
provided	O
are	O
wound	O
dressings	O
comprising	O
the	O
inventive	O
compositions	O
.	O

Antimicrobial	O
silver	B
comprising	O
silver	B

The	O
invention	O
relates	O
to	O
substituted	O
pyrimidines	B
of	O
formula	O
(	O
I	O
)	O
wherein	O
V	O
represents	O
a	O
bond	O
or	O
CR6R7	B
,	O
W	O
represents	O
a	O
bond	O
,	O
NR8	B
or	O
oxygen	B
,	O
X	O
represents	O
sulfur	B
,	O
or	O
nitrogen	B
substituted	O
by	O
hydrogen	B
or	O
R5	O
,	O
Y	O
represents	O
-CH2-	B
,	O
-CH2CH2-	B
,	O
-CO-	B
or	O
-CS-	B
,	O
R1	O
represents	O
unsubstituted	O
or	O
substituted	O
aryl	B
or	O
heteroaryl	B
,	O
and	O
the	O
substituents	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
are	O
selectively	O
inducing	O
apoptosis	O
in	O
cancer	O
cells	O
and	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
neoplastic	O
and	O
autoimmune	O
diseases	O
.	O

The	O
invention	O
relates	O
also	O
to	O
methods	O
of	O
synthesis	O
of	O
such	O
compounds	O
,	O
to	O
their	O
use	O
as	O
medicaments	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
same	O
,	O
and	O
to	O
methods	O
of	O
treatment	O
of	O
neoplastic	O
and	O
autoimmune	O
diseases	O
using	O
such	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
of	O
pharmaceutical	O
compositions	O
containing	O
same	O
.	O

2	B
,	I
4	I
,	I
6-trisubstituted	I
pyrimidine	I
derivatives	O
useful	O
for	O
the	O
treatment	O
of	O
neoplastic	O
and	O
autoimmune	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
which	O
are	O
therapeutically	O
active	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
one	O
aspect	O
,	O
the	O
invention	O
relates	O
to	O
certain	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
Another	O
object	O
of	O
the	O
present	O
invention	O
is	O
the	O
use	O
of	O
said	O
compound	O
to	O
manufacture	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
serotonin	B
-	O
related	O
disorder	O
.	O

Piperazinylpyrazines	B
as	O
serotonin	B
5-HT2C	O
receptor	O
modulators	O

The	O
invention	O
refers	O
to	O
a	O
synergistic	O
pharmaceutical	O
combination	O
which	O
comprises	O
(	O
a	O
)	O
a	O
first	O
pharmaceutical	O
composition	O
containing	O
cicletanine	B
or	O
a	O
pharmaceutically	O
suitable	O
acid	O
addition	O
salt	O
thereof	O
and	O
one	O
or	O
more	O
conventional	O
carrier	O
(	O
s	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
second	O
pharmaceutical	O
composition	O
containing	O
an	O
antidiabetic	O
or	O
anti	O
-	O
hyperlipidemic	O
active	O
agent	O
or	O
,	O
if	O
desired	O
and	O
chemically	O
possible	O
,	O
a	O
pharmaceutically	O
suitable	O
acid	O
addition	O
salt	O
or	O
a	O
salt	O
formed	O
with	O
a	O
pharmaceutically	O
suitable	O
base	O
thereof	O
and	O
one	O
or	O
more	O
conventional	O
carrier	O
(	O
s	O
)	O
.	O

The	O
pharmaceutical	O
combination	O
is	O
suitable	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
,	O
among	O
others	O
,	O
diabetes	O
mellitus	O
.	O

A	O
synergistic	O
pharmaceutical	O
combination	O
comprising	O
cicletanine	B
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diabetes	O

A	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
-	O
A	O
)	O
:	O
wherein	O
R1	O
is	O
hydroxy	B
and	O
the	O
like	O
;	O
R2	O
is	O
optionally	O
substituted	O
lower	O
alkyl	B
and	O
the	O
like	O
;	O
R3	O
is	O
hydrogen	B
atom	O
and	O
the	O
like	O
;	O
R4	O
is	O
optionally	O
substituted	O
arylene	B
and	O
the	O
like	O
;	O
R5	O
is	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
or	O
R6	O
is	O
optionally	O
substituted	O
aryl	B
and	O
the	O
like	O
,	O
its	O
optically	O
active	O
substance	O
,	O
their	O
pharmaceutically	O
acceptable	O
salt	O
,	O
or	O
a	O
solvate	O
thereof	O
;	O
and	O
a	O
metalloproteinase	O
inhibitor	O
containing	O
them	O
.	O

Sulfonamide	B
derivative	O
having	O
isoxazole	B
ring	O

Compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
metabolic	O
and	O
cell	O
proliferative	O
diseases	O
or	O
conditions	O
are	O
provided	O
herein	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
compounds	O
which	O
modulate	O
the	O
activity	O
of	O
proteins	O
involved	O
in	O
lipid	O
metabolism	O
and	O
cell	O
proliferation	O
.	O

Pyrrolo	B
1,2-b	I
pyridazine	I
derivatives	O

A	O
combination	O
product	O
for	O
use	O
in	O
treating	O
asthma	O
and	O
other	O
respiratory	O
conditions	O
comprising	O
a	O
medicament	O
comprising	O
a	O
surface	O
active	O
phospholipids	B
composition	O
in	O
the	O
form	O
of	O
a	O
fine	O
powder	O
and	O
an	O
antiasthma	O
drug	O
.	O

The	O
product	O
is	O
arranged	O
to	O
be	O
administered	O
to	O
the	O
lungs	O
by	O
inhalation	O
,	O
for	O
example	O
,	O
by	O
a	O
device	O
1	O
.	O

Anti	O
-	O
asthmatic	O
combinations	O
comprising	O
surface	O
active	O
phospholipids	B

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
treatment	O
of	O
the	O
symptoms	O
associated	O
with	O
disorders	O
related	O
to	O
normal	O
hormonal	O
variations	O
in	O
women	O
and	O
particularly	O
it	O
provides	O
a	O
pulsatile	O
release	O
formulation	O
of	O
magnesium	B
for	O
treating	O
said	O
symptoms	O
.	O

Use	O
of	O
magnesium	B
in	O
the	O
treatment	O
of	O
disorders	O
related	O
to	O
hormonal	O
variations	O
in	O
women	O

A	O
pharmaceutical	O
combination	O
comprising	O
either	O
(	B
S	I
)	I
-2-ethoxy-3-	I
[	I
4-	I
(	I
2-	I
{	I
4-methanesulfonyloxyphenyl	I
}	I
ethoxy	I
)	I
phenyl	I
]	I
propanoic	I
acid	I
or	O
3-	B
{	I
4-	I
[	I
2-	I
(	I
4-tert	I
-	I
butoxycarbonylaminophenyl	I
)	I
ethoxy	I
]	I
phenyl	I
}	I
-	I
(	I
S	I
)	I
-2-ethoxy	I
propanoic	I
acid	I
,	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
and	O
any	O
solvates	O
of	O
either	O
thereof	O
and	O
a	O
biguanide	B
drug	O
.	O

Pharmaceutical	O
combination	O
comprising	O
a	O
biguanide	B

The	O
present	O
invention	O
relates	O
to	O
an	O
animal	O
feed	O
composition	O
that	O
comprises	O
free	O
indole	B
acetic	I
acid	I
(	O
free	O
IAA	B
)	O
or	O
a	O
derivative	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
enhancing	O
animal	O
growth	O
by	O
feeding	O
the	O
animal	O
with	O
a	O
composition	O
according	O
to	O
the	O
invention	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
free	O
IAA	B
or	O
a	O
derivative	O
thereof	O
in	O
a	O
method	O
of	O
therapy	O
of	O
animals	O
in	O
need	O
of	O
a	O
growth	O
-	O
promoting	O
treatment	O
,	O
such	O
as	O
immunocompromised	O
animals	O
,	O
animals	O
with	O
a	O
growth	O
deficit	O
or	O
slow	O
growing	O
animals	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
free	O
IAA	B
or	O
a	O
derivative	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
therapeutical	O
composition	O
for	O
increasing	O
the	O
growth	O
rate	O
and/or	O
the	O
feed	O
conversion	O
rate	O
and/or	O
the	O
immunity	O
of	O
animals	O
in	O
need	O
of	O
such	O
a	O
treatment	O
,	O
in	O
particular	O
immunocompromised	O
or	O
slow	O
growing	O
animals	O
.	O

A	O
composition	O
according	O
to	O
the	O
invention	O
may	O
preferably	O
be	O
in	O
the	O
form	O
of	O
a	O
food	O
or	O
feed	O
supplement	O
.	O

Animal	O
feed	O
composition	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
fatty	O
acid	O
esters	O
of	O
the	O
reversible	O
Iloperidone	B
metabolite	O
P-88	O
-	O
8991	O
,	O
their	O
preparation	O
,	O
their	O
use	O
as	O
pharmaceuticals	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Benzisoxazoles	B

A	O
series	O
of	O
thieno	B
[	I
2,3-b	I
]	I
pyridin-6	I
(	I
7H	I
)	I
-one	I
derivatives	O
,	O
substituted	O
in	O
the	O
3-position	O
by	O
an	O
arylcarbonyl	B
or	O
heteroarylcarbonyl	B
moiety	O
,	O
being	O
inhibitors	O
of	O
p38	O
MAP	O
kinase	O
,	O
are	O
accordingly	O
of	O
use	O
in	O
medicine	O
,	O
for	O
example	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
immune	O
or	O
inflammatory	O
disorders	O
.	O

Thieno	B
-	I
pyridinone	I
derivatives	O
as	O
kinase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
a	O
new	O
combination	O
for	O
treating	O
dysfunction	O
of	O
the	O
bladder	O
,	O
containing	O
alpha	O
agonists	O
and	O
a	O
beta-3	O
adrenoceptor	O
agonist	O
.	O

Pharmaceutical	O
composition	O
consisting	O
of	O
a	O
beta-3	O
adrenoceptor	O
agonist	O
and	O
an	O
alpha	O
agonist	O

A	O
treatment	O
for	O
obesity	O
and	O
overweight	O
comprises	O
administering	O
a	O
vitamin	B
D	I
analog	O
.	O

The	O
analog	O
effectively	O
inhibits	O
an	O
increase	O
in	O
body	O
fat	O
to	O
animals	O
at	O
risk	O
and	O
decreases	O
the	O
basal	O
fat	O
content	O
of	O
animals	O
.	O

The	O
treatment	O
has	O
a	O
positive	O
effect	O
on	O
the	O
lean	O
body	O
component	O
such	O
that	O
while	O
there	O
is	O
an	O
overall	O
decrease	O
in	O
body	O
weight	O
,	O
there	O
is	O
also	O
a	O
decrease	O
in	O
percent	O
body	O
fat	O
.	O

This	O
decrease	O
can	O
be	O
proportionally	O
greater	O
than	O
the	O
overall	O
decrease	O
in	O
body	O
weight	O
.	O

In	O
addition	O
,	O
the	O
treatment	O
has	O
a	O
positive	O
effect	O
on	O
bone	O
turnover	O
and	O
osteogeneses	O
making	O
the	O
vitamin	B
D	I
analog	O
a	O
beneficial	O
treatment	O
for	O
the	O
symptoms	O
of	O
menopause	O
.	O

Various	O
exemplary	O
embodiments	O
of	O
the	O
treatment	O
use	O
the	O
2-alkylidene	B
derivatives	O
of	O
vitamin	B
D3	I
,	O
such	O
as	O
the	O
2-alkyliden-19-nor	B
derivatives	O
in	O
both	O
the	O
R	O
and	O
S	O
configurations	O
at	O
carbon-20	B
.	O

Methods	O
for	O
reducing	O
body	O
fat	O
using	O
vitamin	B
d	I
compounds	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
:	O
wherein	O
X	O
=	O
CH2	B
or	O
S	B
or	O
an	O
pharmaceutical	O
acceptable	O
salt	O
thereof	O
.	O

Such	O
compounds	O
and	O
their	O
corresponding	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
forms	O
,	O
are	O
useful	O
in	O
treating	O
conditions	O
mediated	O
by	O
DPIV	O
or	O
DPIV	O
-	O
like	O
enzymes	O
,	O
such	O
as	O
arthritis	O
,	O
obesity	O
,	O
immune	O
and	O
autoimmune	O
disorders	O
,	O
allograft	O
transplantation	O
,	O
cancer	O
,	O
neuronal	O
disorders	O
and	O
dermal	O
diseases	O
.	O

Peptides	O
useful	O
for	O
competitive	O
modulation	O
of	O
dipeptidyl	O
peptidase	O
IV	O
catalysis	O

Cosmetic	O
use	O
of	O
piperidine	O
derivatives	O
(	O
I	O
)	O
and	O
their	O
salts	O
or	O
isomers	O
to	O
stimulate	O
the	O
growth	O
,	O
to	O
reduce	O
the	O
fall	O
and/or	O
to	O
increase	O
the	O
density	O
of	O
keratinous	O
fibers	O
of	O
humans	O
.	O

Cosmetic	O
use	O
of	O
piperidine	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
salts	O
or	O
isomers	O
to	O
stimulate	O
the	O
growth	O
,	O
to	O
reduce	O
the	O
hair	O
fall	O
and/or	O
to	O
increase	O
the	O
density	O
of	O
keratinous	O
fibers	O
of	O
the	O
human	O
beings	O
.	O

R1halo	O
or	O
1	O
-	O
6C	O
alkyl	O
,	O
OR	O
,	O
NRR	O
-	O
a	O
,	O
CF3	O
,	O
NHCOR	O
or	O
CONRR	O
-	O
a	O
;	O
R21	O
-	O
20C	O
alkyl	O
,	O
1	O
-	O
20C	O
alkenyl	O
(	O
where	O
both	O
hydrocarbon	O
chain	O
is	O
optionally	O
interrupted	O
by	O
CO	O
(	O
optionally	O
substituted	O
by	O
OR	O
,	O
COOR	O
,	O
NRR	O
-	O
a	O
,	O
NHCOR	O
or	O
CONRR	O
-	O
a	O
)	O
)	O
and/or	O
phenyl	O
(	O
optionally	O
substituted	O
by	O
R1	O
)	O
;	O
R	O
,	O
R	O
-	O
a	O
:	O
H	O
or	O
1	O
-	O
6C	O
alkyl	O
;	O
and	O
n	O
,	O
m	O
:	O
0	O
-	O
5	O
.	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Endocrine	O
-	O
Gen	O
;	O
Vasotropic	O
;	O
Antimicrobial	O
;	O
Antiinflammatory	O
;	O
Fungicide	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Use	O
of	O
cyclic	O
amine	O
derivatives	O
in	O
capillary	O
products	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
pharmaceutical	O
composition	O
consisting	O
of	O
a	O
statin	B
(	O
especially	O
fluvastatin	B
or	O
pitavastatin	B
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
metabolic	O
syndrome	O
(	O
or	O
syndrome	O
X	O
)	O
.	O

Use	O
of	O
statins	B
for	O
the	O
treatment	O
of	O
metabolic	O
syndrome	O

This	O
invention	O
relates	O
to	O
prevention	O
and/or	O
treatment	O
of	O
antibiotic	O
associated	O
diarrhea	O
,	O
including	O
Clostridium	O
difficile	O
associated	O
diarrhea	O
(	O
CDAD	O
)	O
,	O
pseudomembranous	O
colitis	O
(	O
PMC	O
)	O
and	O
other	O
conditions	O
associated	O
with	O
C.	O
difficile	O
infection	O
,	O
using	O
oligosaccharide	B
compositions	O
which	O
bind	O
C.	O
difficile	O
toxin	O
B	O
,	O
More	O
specifically	O
,	O
the	O
invention	O
concerns	O
neutralization	O
of	O
C.	O
difficile	O
toxin	O
B	O
associated	O
with	O
such	O
conditions	O
.	O

Treatment	O
of	O
C.	O
difficile	O
toxin	O
B	O
associated	O
conditions	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
pyrimido	B
[	I
5,4-d	I
]	I
pyrimidines	I
in	O
the	O
treatment	O
of	O
inflammatory	O
and	O
obstructive	O
respiratory	O
tract	O
diseases	O
,	O
preferably	O
asthma	O
or	O
COPD	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
said	O
compounds	O
.	O

Use	O
of	O
substituted	O
pyrimido	B
pyrimido	I
5,4-d¨pyrimidines	I
in	O
the	O
treatment	O
of	O
diseases	O
of	O
the	O
respiratory	O
tract	O

Thieno	B
[	I
2,3-c	I
]	I
pyrazole	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
as	O
defined	O
in	O
the	O
specification	O
,	O
process	O
for	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comrising	O
them	O
are	O
disclosed	O
;	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
in	O
therapy	O
,	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
a	O
disregulated	O
protein	O
kinase	O
activity	O
,	O
like	O
cancer	O
.	O

1H	B
-	I
THIENO	I
2,3-c	I
PYRAZOLE	I
DERIVATIVES	O
USEFUL	O
AS	O
KINASE	O
I	O
INHIBITORS	O

This	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
R1	O
wherein	O
R	O
'	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
and	O
X1	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

The	O
2-	B
(	I
pyridin-3-ylamino	I
)	I
-pyrido	I
[	I
2,3-d	I
]	I
pyrimidin-7-one	I
compounds	O
of	O
formula	O
I	O
,	O
which	O
are	O
inhibitors	O
of	O
cyclin	O
-	O
dependent	O
kinases	O
2	O
and	O
4	O
(	O
Cdk2	O
and	O
Cdk4	O
)	O
,	O
are	O
useful	O
in	O
treating	O
cell	O
proliferative	O
disorders	O
.	O

2-	B
(	I
pyridin-3-ylamino	I
)	I
-pyrido	I
2,3-d	I
pyrimidin-7-ones	I

Use	O
of	O
a	O
cannabidiol	B
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
identified	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
diabetes	O
and/or	O
insulitis	O
.	O

Treating	O
or	O
preventing	O
diabetes	O
with	O
cannabidiol	B

The	O
present	O
invention	O
is	O
comprised	O
of	O
culturing	O
a	O
microorganism	O
belonging	O
to	O
fungi	O
and	O
having	O
ability	O
to	O
produce	O
antibiotic	O
FKI-1778A	O
and/or	O
antibiotic	O
FKI-1778B	O
and/or	O
antibiotic	O
FKI-1778C	O
and/or	O
antibiotic	O
FKI-1778D	O
,	O
accumulating	O
the	O
antibiotic	O
FKI-1778A	O
and/or	O
antibiotic	O
FKI-1778B	O
and/or	O
antibiotic	O
FKI-1778C	O
and/or	O
antibiotic	O
FKI-1778D	O
in	O
the	O
cultured	O
mass	O
and	O
isolating	O
the	O
antibiotic	O
FKI-1778A	O
and/or	O
antibiotic	O
FKI-1778B	O
and/or	O
antibiotic	O
FKI-1778C	O
and/or	O
antibiotic	O
FKI-1778D	O
from	O
said	O
cultured	O
mass	O
.	O

The	O
thus	O
obtained	O
substance	O
is	O
expected	O
as	O
pharmaceuticals	O
,	O
animal	O
drugs	O
and	O
agricultural	O
chemicals	O
,	O
or	O
as	O
pharmaceuticals	O
having	O
growth	O
inhibitory	O
activities	O
against	O
cancer	O
cells	O
.	O

Antibiotic	O
fki-1778	B
and	O
process	O
for	O
producing	O
the	O
same	O

Quinolone	B
carboxylic	I
acid	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
Ar	B
is	O
an	O
optionally	O
substituted	O
phenyl	B
,	O
pyridyl	B
,	O
or	O
pyrimidinyl	B
group	O
and	O
the	O
substituent	O
groups	O
R1	O
,	O
R4	O
,	O
R10	O
,	O
R11	O
,	O
R19	O
,	O
and	O
R20	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
methods	O
of	O
using	O
them	O
in	O
treatment	O
of	O
hyperproliferative	O
diseases	O
such	O
as	O
cancer	O
are	O
disclosed	O
and	O
claimed	O
.	O

Quinolone	B
carboxylic	I
acid	I
derivatives	O
for	O
treatment	O
of	O
hyperproliferative	O
conditions	O

A	O
method	O
for	O
treating	O
demyelinating	O
diseases	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
by	O
treatment	O
with	O
an	O
effective	O
amount	O
of	O
a	O
PPAR	O
delta	O
agonist	O
is	O
disclosed	O
.	O

Demyelinating	O
diseases	O
that	O
may	O
be	O
effectively	O
treated	O
by	O
this	O
method	O
include	O
but	O
are	O
not	O
limited	O
to	O
multiple	O
sclerosis	O
,	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
,	O
Pelizaeus	O
-	O
Merzbacher	O
disease	O
,	O
encephalomyelitis	O
,	O
neuromyelitis	O
optica	O
,	O
adrenoleukodystrophy	O
,	O
Guillian	O
-	O
Barre	O
syndrome	O
and	O
disorders	O
in	O
which	O
myelin	O
forming	O
glial	O
cells	O
are	O
damaged	O
including	O
spinal	O
cord	O
injuries	O
,	O
neuropathies	O
and	O
nerve	O
injury	O
.	O

Use	O
of	O
ppar	O
delta	O
agonists	O
for	O
treating	O
demyelinating	O
diseases	O

Aqueous	O
pharmaceutical	O
preparation	O
comprises	O
a	O
vecuronium	B
bromide	I
as	O
a	O
pharmaceutically	O
active	O
component	O
,	O
an	O
amino	B
acid	I
with	O
an	O
isoelectric	O
point	O
greater	O
than	O
7	O
and	O
at	O
least	O
an	O
acid	O
to	O
adjust	O
the	O
pH	O
value	O
to	O
3	O
-	O
5	O
.	O

An	O
independent	O
claim	O
is	O
included	O
for	O
the	O
preparation	O
of	O
the	O
aqueous	O
pharmaceutical	O
preparation	O
comprising	O
providing	O
an	O
amino	B
acid	I
with	O
an	O
isoelectric	O
point	O
greater	O
than	O
7	O
and	O
dissolving	O
under	O
agitation	O
;	O
providing	O
an	O
acid	O
for	O
adjusting	O
the	O
pH	O
value	O
to	O
3	O
-	O
5	O
and	O
agitating	O
for	O
dissolution	O
;	O
providing	O
an	O
vecuronium	B
bromide	I
and	O
agitating	O
for	O
dissolution	O
;	O
and	O
optionally	O
providing	O
an	O
acid	O
for	O
adjusting	O
the	O
pH	O
value	O
to	O
3	O
-	O
5	O
.	O

Aqueous	O
formulation	O
for	O
vecuronium	B
bromide	I

Use	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
R	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
X1	O
and	O
X2	O
have	O
the	O
definitions	O
illustrated	O
in	O
detail	O
in	O
the	O
description	O
,	O
as	O
beta	O
-	O
secretase	O
,	O
cathepsin	O
D	O
,	O
plasmepsin	O
II	O
and/or	O
HIV	O
protease	O
inhibitors	O
.	O

Amido	B
-	I
aminoalcohols	I
as	O
therapeutic	O
compounds	O

The	O
invention	O
relates	O
to	O
a	O
depigmenting	O
composition	O
for	O
the	O
skin	O
,	O
comprising	O
mequinol	B
associated	O
with	O
another	O
depigmenting	O
agent	O
such	O
as	O
alpha	B
hydroxyl	I
acids	I
in	O
a	O
physiologically	O
acceptable	O
medium	O
,	O
and	O
to	O
the	O
pharmaceutical	O
or	O
cosmetic	O
use	O
thereof	O
.	O

Mequinol	B
-	O
based	O
dermatological	O
depigmenting	O
composition	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
benzo	B
[	I
g	I
]	I
quinoline	I
derivatives	O
,	O
their	O
preparation	O
,	O
their	O
use	O
as	O
pharmaceuticals	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Quinoline	B
derivatives	O
and	O
their	O
use	O
in	O
glaucoma	O
and	O
myopia	O

The	O
present	O
invention	O
relates	O
to	O
a	O
Multi	O
-	O
tumor	O
Aberrant	O
Growth	O
(	O
MAG	O
)	O
gene	O
having	O
the	O
nucleotide	O
sequence	O
of	O
any	O
one	O
of	O
the	O
strands	O
of	O
any	O
one	O
of	O
the	O
members	O
of	O
the	O
High	O
Mobility	O
Group	O
protein	O
genes	O
,	O
including	O
modified	O
versions	O
thereof	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
Multi	O
-	O
tumor	O
Aberrant	O
Growth	O
(	O
MAG	O
)	O
gene	O
having	O
essentially	O
the	O
nucleotide	O
sequence	O
of	O
the	O
HMGI	O
-	O
C	O
gene	O
as	O
depicted	O
in	O
Fig.	O
7	O
,	O
or	O
the	O
complementary	O
strand	O
thereof	O
,	O
including	O
modified	O
or	O
elongated	O
versions	O
of	O
both	O
strands	O
.	O

Multiple	O
-	O
tumor	O
aberrant	O
growth	O
genes	O

Use	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
X	O
have	O
the	O
definitions	O
elucidated	O
in	O
more	O
detail	O
in	O
the	O
description	O
,	O
as	O
beta	O
-	O
secretase	O
,	O
cathepsin	O
D	O
,	O
plasmepsin	O
II	O
and/or	O
HIV	O
protease	O
inhibitors	O
.	O

Diaminoalcohol	B
derivatives	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
,	O
malaria	O
,	O
HIV	O

A	O
method	O
of	O
contraception	O
is	O
provided	O
which	O
involves	O
delivery	O
of	O
21	O
to	O
27	O
consecutive	O
days	O
of	O
one	O
or	O
more	O
PR	O
antagonists	O
in	O
the	O
absence	O
of	O
a	O
progestin	B
,	O
estrogen	B
,	O
or	O
other	O
steroidal	O
compound	O
,	O
followed	O
by	O
1	O
to	O
7	O
days	O
without	O
any	O
active	O
agent	O
.	O

Also	O
described	O
is	O
a	O
pharmaceutically	O
useful	O
kit	O
to	O
facilitate	O
delivery	O
of	O
this	O
regimen	O
.	O

Progesterone	B
receptor	O
antagonist	O
contraceptive	O
regimens	O
and	O
kits	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
-X	O
-	O
Y-	O
,	O
Rl	O
to	O
R11	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
which	O
are	O
mediated	O
by	O
CETP	O
inhibitors	O
.	O

Indole	B
,	I
indazole	I
or	I
indoline	I
derivatives	O

A	O
composition	O
for	O
binding	O
FKBP	O
proteins	O
is	O
disclosed	O
,	O
along	O
with	O
a	O
method	O
of	O
treating	O
conditions	O
associated	O
with	O
neuronal	O
degeneration	O
,	O
wherein	O
said	O
composition	O
comprises	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
,	O
R	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
X	O
are	O
as	O
defined	O
herein	O
.	O

FKBP	O
-	O
binding	O
composition	O
and	O
pharmaceutical	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
crystalline	O
1,2-ethanedisulfonic	B
acid	I
salt	I
of	I
biphenyl-2-ylcarbamic	I
acid	I
1-	I
[	I
2-	I
(	I
2-chloro-4-	I
{	I
[	I
(	I
R	I
)	I
-2-hydroxy-2-	I
(	I
8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl	I
)	I
ethylamino	I
]	I
methyl	I
}	I
-5-methoxyphenylcarbamoyl	I
)	I
ethyl	I
]	I
piperidin-4-yl	I
ester	I
or	O
a	O
solvate	O
thereof	O
.	O

This	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
such	O
a	O
salt	O
or	O
prepared	O
using	O
such	O
a	O
salt	O
;	O
processes	O
and	O
intermediates	O
for	O
preparing	O
such	O
a	O
salt	O
;	O
and	O
methods	O
of	O
using	O
such	O
a	O
salt	O
to	O
treat	O
a	O
pulmonary	O
disorder	O
.	O

Crystalline	O
form	O
of	O
a	O
biphenyl	B
compound	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R	O
,	O
R	O
'	O
and	O
R	O
'	O
are	O
as	O
defined	O
in	O
the	O
disclosure	O
and	O
the	O
pharmaceutically	O
acceptable	O
esters	B
thereof	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
reduce	O
the	O
synthesis	O
of	O
kynurenic	B
acid	I
thus	O
inhibiting	O
the	O
enzyme	O
kynurenine	B
aminotransferase	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
those	O
psychiatric	O
and	O
neurological	O
diseases	O
which	O
benefit	O
from	O
an	O
increase	O
in	O
glutamatergic	O
and/or	O
cholinergic	O
neurotransmission	O
,	O
such	O
as	O
depression	O
,	O
bipolar	O
illness	O
,	O
anxiety	O
,	O
Alzheimer	O
's	O
disease	O
.	O

Furthemore	O
,	O
the	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
for	O
stimulating	O
attention	O
,	O
memory	O
and	O
other	O
cognitive	O
processes	O
in	O
normal	O
individuals	O
of	O
any	O
age	O
,	O
including	O
children	O
,	O
adolescents	O
and	O
the	O
elderly	O
.	O

4-sulfonyl	B
-	I
substituted	I
benzoylalanine	I
derivatives	O
useful	O
as	O
kynurenine	B
-	O
aminotransferase	O
inhibitors	O

This	O
invention	O
relates	O
to	O
novel	O
substituted	O
aryloxy	B
alkylamines	I
useful	O
as	O
monoamine	B
neurotransmitter	O
re	O
-	O
uptake	O
inhibitors	O
.	O

In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Novel	O
substituted	O
aryloxy	B
alkylamines	I
and	O
their	O
use	O
as	O
monoamine	B
neurotransmitter	O
re	O
-	O
uptake	O
inhibitors	O

A	O
subject	O
with	O
symptoms	O
of	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
,	O
who	O
does	O
not	O
have	O
end	O
-	O
stage	O
renal	O
disease	O
(	O
ESRO	O
)	O
,	O
can	O
be	O
treated	O
by	O
orally	O
administering	O
a	O
pharmaceutical	O
composition	O
as	O
an	O
active	O
ingredient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
non	O
-	O
toxic	O
lanthanum	B
compound	O
.	O

In	O
a	O
preferred	O
embodiement	O
,	O
the	O
composition	O
contains	O
lanthanum	B
carbonate	I
hydrate	I
or	O
lanthanum	B
hydroxycarbonate	I
.	O

Administration	O
of	O
a	O
lanthanum	B
compound	O
can	O
prevent	O
the	O
progression	O
of	O
CKD	O
,	O
treat	O
soft	O
tissue	O
calcification	O
,	O
and	O
treat	O
secondary	O
hyperparathyroidism	O
.	O

Treatment	O
of	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
subjects	O
using	O
lanthanum	B
compounds	O

The	O
use	O
of	O
fused	O
1,2,4-triazoles	B
for	O
modulating	O
the	O
activity	O
of	O
11	O
β	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
1	O
(	O
11βHSD1	O
)	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
pharmaceutical	O
compositions	O
has	O
been	O
described	O
.	O

Also	O
a	O
novel	O
class	O
of	O
fused	O
1,2,4-triazoles	B
,	O
their	O
use	O
in	O
therapy	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
has	O
been	O
described	O
.	O

The	O
present	O
compounds	O
are	O
modulators	O
and	O
more	O
specifically	O
inhibitors	O
of	O
the	O
activity	O
of	O
11βHSD1	O
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and/or	O
prophylaxis	O
of	O
a	O
range	O
of	O
medical	O
disorders	O
where	O
a	O
decreased	O
intracellular	O
concentration	O
of	O
active	O
glucocorticoid	B
is	O
desirable	O
.	O

Fused	B
1,2,4-triazoles	I
and	O
pharmaceutical	O
uses	O
thereof	O

A	O
ruthenium	B
(	I
II	I
)	I
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
wherein	O
:	O
R1	O
,	O
R1	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
H	B
,	O
C1	B
-	I
7	I
alkyl	I
,	O
C5	B
-	I
20	I
aryl	I
,	O
C3	B
-	I
20	I
heterocyclyl	I
,	O
halo	B
,	O
ester	B
,	O
amido	B
,	O
acyl	B
,	O
sulfo	B
,	O
sulfonamido	B
,	O
ether	B
,	O
thioether	B
,	O
azo	B
,	O
amino	B
,	O
or	O
R1	O
and	O
R2	O
together	O
with	O
the	O
ring	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
saturated	O
or	O
unsaturated	O
carbocyclic	B
or	O
heterocyclic	B
group	O
containing	O
up	O
to	O
three	O
3-	O
to	O
8-	O
membered	O
carbocyclic	B
or	O
heterocyclic	B
rings	O
,	O
wherein	O
each	O
carbocyclic	B
or	O
heterocyclic	B
ring	O
may	O
be	O
fused	O
to	O
one	O
or	O
more	O
other	O
carbocyclic	B
or	O
heterocyclic	B
rings	O
;	O
X	O
is	O
a	O
neutral	O
or	O
negatively	O
charged	O
N-	B
or	O
S-	B
donor	O
ligand	O
;	O
Y	O
is	O
a	O
counterion	O
;	O
m	O
is	O
0	O
or	O
1	O
;	O
q	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
C	O
'	O
is	O
C1	B
-	I
12	I
alkylene	I
bound	O
to	O
two	O
A	O
groups	O
;	O
p	O
is	O
0	O
or	O
1	O
and	O
r	O
is	O
1	O
when	O
p	O
is	O
0	O
and	O
r	O
is	O
2	O
when	O
p	O
is	O
1	O
;	O
and	O
A	O
and	O
B	O
are	O
each	O
independently	O
O	B
-	I
donor	O
,	O
N	B
-	I
donor	O
or	O
S	B
-	I
donor	O
ligands	O
,	O
and	O
may	O
be	O
connected	O
to	O
one	O
another	O
.	O

The	O
compounds	O
are	O
used	O
in	O
cancer	O
therapy	O
.	O

Arene	B
ruthenium	I
(	I
ii	I
)	I
compounds	O
and	O
their	O
use	O
in	O
cancer	O
therapy	O

The	O
present	O
invention	O
relates	O
to	O
heterocyclic	B
substituted	I
bisarylurea	I
derivatives	O
of	O
formula	O
I	O
,	O
the	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
inhibitors	O
of	O
one	O
or	O
more	O
kinases	O
,	O
the	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
and	O
a	O
method	O
of	O
treatment	O
,	O
comprising	O
administering	O
said	O
pharmaceutical	O
composition	O
to	O
a	O
patient	O
.	O

Heterocyclic	B
substituted	I
bisarylurea	I
derivatives	O
as	O
kinase	O
inhibitors	O

A	O
method	O
of	O
screening	O
a	O
novel	O
BAFF	O
suppressor	O
or	O
inhibitor	O
.	O

More	O
specifically	O
speaking	O
,	O
a	O
method	O
which	O
comprises	O
adding	O
a	O
combination	O
of	O
TPA	O
with	O
ionomycin	B
and/or	O
an	O
anti	O
-	O
CD3	O
antibody	O
to	O
a	O
cultured	O
human	O
cell	O
to	O
thereby	O
induce	O
the	O
production	O
of	O
BAFF	O
by	O
the	O
cell	O
;	O
a	O
method	O
of	O
screening	O
a	O
substance	O
capable	O
of	O
suppressing	O
the	O
expression	O
or	O
activity	O
of	O
BAFF	O
which	O
comprises	O
adding	O
a	O
test	O
substance	O
to	O
a	O
BAFF	O
-	O
production	O
system	O
prepared	O
by	O
adding	O
a	O
combination	O
of	O
TPA	O
with	O
ionomycin	O
and/or	O
an	O
anti	O
-	O
CD3	O
antibody	O
to	O
a	O
cultured	O
human	O
cell	O
and	O
measuring	O
the	O
expression	O
amount	O
and/or	O
the	O
activity	O
of	O
BAFF	O
in	O
the	O
BAFF	O
-	O
production	O
system	O
;	O
and	O
a	O
BAFF	O
production	O
inducer	O
for	O
a	O
BAFF	O
-	O
producing	O
cell	O
which	O
contains	O
a	O
combination	O
of	O
TPA	O
with	O
ionomycin	B
and/or	O
an	O
anti	O
-	O
CD3	O
antibody	O
.	O

Method	O
of	O
screening	O
baff	O
suppressor	O
or	O
inhibitor	O

Substituted	O
dipiperidine	B
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
isomer	O
,	O
prodrug	O
,	O
metabolite	O
or	O
polymorph	O
thereof	O
,	O
which	O
are	O
CCR2	O
antagonists	O
and	O
are	O
useful	O
in	O
preventing	O
,	O
treating	O
or	O
ameliorating	O
CCR2	O
mediated	O
inflammatory	O
syndromes	O
,	O
disorders	O
or	O
diseases	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

Substituted	O
dipiperdine	B
ccr2	O
antagonists	O

A	O
polymerizable	O
antimicrobial	O
formulation	O
for	O
forming	O
a	O
wound	O
closure	O
adhesive	O
comprising	O
cyanoacrylate	B
monomer	O
,	O
diiodomethyl	B
-	I
p	I
-	I
tolylsulfone	I
and	O
a	O
halogenated	O
hydroxyl	B
diphenyl	I
ether	I
;	O
and	O
a	O
method	O
for	O
closing	O
the	O
approximated	O
edges	O
of	O
a	O
wound	O
with	O
a	O
polymeric	O
film	O
that	O
substantially	O
inhibits	O
the	O
growth	O
of	O
microorganisms	O
,	O
where	O
the	O
polymeric	O
film	O
is	O
formed	O
by	O
use	O
of	O
the	O
polymerizable	O
antimicrobial	O
formulation	O
.	O

Cyanoacrylate	B
monomer	O
formulation	O
containing	O
diiodomethyl	B
-	I
p	I
-	I
tolylsulfone	I
and	O
hydroxydiphenyl	B
ether	I

Novel	O
chroman	B
derivatives	O
and	O
intermediate	O
compounds	O
,	O
compositions	O
containing	O
same	O
,	O
methods	O
for	O
their	O
preparation	O
and	O
uses	O
thereof	O
as	O
therapeutic	O
agents	O
particularly	O
as	O
anti	O
-	O
cancer	O
and	O
chemotherapeutic	O
selective	O
agents	O
are	O
described	O
.	O

Chroman	B
derivatives	O
,	O
medicaments	O
and	O
use	O
in	O
therapy	O

A	O
present	O
invention	O
provides	O
aromatic	B
amide	I
derivatives	O
which	O
have	O
an	O
agonism	O
of	O
V2	O
receptor	O
,	O
are	O
useful	O
as	O
agents	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
diabetes	O
insipidus	O
,	O
nocturia	O
,	O
nocturnal	O
enuresis	O
,	O
overactive	O
bladder	O
or	O
the	O
like	O
,	O
and	O
are	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
which	O
may	O
have	O
a	O
substituent	O
,	O
R2	O
is	O
a	O
hydrogen	B
atom	O
or	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
,	O
R3	O
is	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
or	O
the	O
like	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
independently	O
a	O
hydrogen	B
atom	O
,	O
a	O
halogen	B
atom	O
or	O
the	O
like	O
,	O
R7	O
is	O
a	O
hydrogen	B
atom	O
,	O
a	O
heteroaryl	B
group	O
which	O
may	O
have	O
a	O
substituent	O
,	O
a	O
C3	B
-	I
8	I
cycloalkyl	I
group	O
'	O
,	O
an	O
amino	B
group	O
which	O
may	O
have	O
a	O
substituent	O
or	O
a	O
C1	B
-	I
6	I
alkoxy	I
group	O
which	O
may	O
have	O
a	O
substituted	O
group	O
;	O
M1	O
is	O
a	O
single	O
bond	O
,	O
a	O
C1	B
-	I
4	I
alkylene	I
group	O
or	O
the	O
like	O
Y	O
is	O
N	O
or	O
CRF	O
(	O
in	O
the	O
formula	O
,	O
RF	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
or	O
the	O
like	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
prodrug	O
thereof	O
,	O
or	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
and	O
pharmaceutical	O
uses	O
thereof	O
.	O

Aromatic	B
amide	I
derivatives	O
,	O
medicinal	O
compositions	O
containing	O
the	O
same	O
,	O
medical	O
uses	O
of	O
both	O

The	O
invention	O
is	O
aimed	O
at	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
,	O
R1	O
is	O
a	O
linear	O
or	O
branched	O
alkyl	B
group	O
,	O
R2	O
is	O
selected	O
from	O
a	O
substituted	O
or	O
non	O
substituted	O
alkyl	B
group	O
,	O
substituted	O
or	O
non	O
substituted	O
aryl	B
group	O
,	O
substituted	O
or	O
non	O
substituted	O
aralkyl	B
group	O
,	O
substituted	O
or	O
non	O
substituted	O
heterocyclyl	B
group	O
,	O
or	O
a	O
substituted	O
or	O
non	O
substituted	O
heterocyclylalkyl	B
group	O
.	O

Another	O
object	O
of	O
the	O
invention	O
is	O
a	O
process	O
for	O
obtaining	O
these	O
compounds	O
from	O
the	O
corresponding	O
compound	O
with	O
a	O
hydroxy	B
group	O
in	O
position	O
4	O
by	O
means	O
of	O
reacting	O
with	O
a	O
sulfonamide	B
in	O
the	O
presence	O
of	O
a	O
phosphine	B
and	O
a	O
dialkyl	B
azadicarboxylate	I
.	O

The	O
deprotection	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
gives	O
rise	O
to	O
the	O
corresponding	O
amine	B
.	O

The	O
intermediate	O
and	O
the	O
processes	O
described	O
are	O
very	O
useful	O
in	O
the	O
synthesis	O
of	O
pharmaceutical	O
products	O
.	O

Method	O
of	O
obtaining	O
derivatives	O
of	O
4-	B
(	I
n	I
-	I
alkylamine	I
)	I
-5,6-dihydro-4h	I
-	I
thieno-	I
[	I
2,3-b	I
]	I
-thiopyran	I

Solid	O
pharmaceutical	O
compositions	O
containing	O
atorvastatin	B
are	O
disclosed	O
.	O

The	O
compositions	O
include	O
a	O
solid	O
dispersion	O
of	O
amorphous	O
atorvastatin	B
and	O
one	O
or	O
more	O
optional	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

The	O
solid	O
dispersion	O
is	O
prepared	O
by	O
mixing	O
crystalline	O
atorvastatin	B
with	O
a	O
melt	O
-	O
processible	O
polymer	O
and	O
an	O
optional	O
stabilizer	O
and	O
an	O
optional	O
plasticizer	O
at	O
a	O
temperature	O
sufficiently	O
high	O
to	O
soften	O
or	O
melt	O
the	O
polymer	O
and	O
to	O
melt	O
or	O
dissolve	O
the	O
crystalline	O
atorvastatin	B
in	O
the	O
polymer	O
,	O
thereby	O
forming	O
a	O
dispersion	O
of	O
amorphous	O
atorvastatin	B
.	O

Pharmaceutical	O
compositions	O
of	O
amorphous	O
atorvastatin	B
and	O
process	O
for	O
preparing	O
same	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
salt	O
or	O
zwitterionic	O
form	O
,	O
wherein	O
J	O
,	O
L	O
,	O
M	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
have	O
the	O
meanings	O
as	O
indicated	O
in	O
the	O
specification	O
,	O
are	O
useful	O
for	O
treating	O
conditions	O
that	O
are	O
mediated	O
by	O
the	O
muscarinic	O
M3	O
receptor	O
.	O

Pharmaceutical	O
compositions	O
that	O
contain	O
the	O
compounds	O
and	O
a	O
process	O
for	O
preparing	O
the	O
compounds	O
are	O
also	O
described	O
.	O

Quaternary	B
ammonium	I
salts	O
as	O
m3	O
antagonists	O

Monoclonal	O
antibodies	O
directed	O
against	O
coagulation	O
factors	O
and	O
their	O
use	O
in	O
inhibiting	O
thrombosis	O
is	O
disclosed	O
.	O

Anticoagulant	O
agents	O
useful	O
in	O
treatment	O
of	O
thrombosis	O

Combinations	O
of	O
avermectins	B
and	O
milbemycins	B
and	O
their	O
derivatives	O
with	O
bis	B
-	I
aryl	I
compounds	O
and	O
their	O
use	O
in	O
combating	O
parasite	O
,	O
especially	O
helminth	O
,	O
infections	O
.	O

Anthelmintic	O
compositions	O
containing	O
combinations	O
of	O
avermectins	B
or	O
milbemycins	B
with	O
bis	B
-	I
aryl	I
compounds	O

There	O
is	O
provided	O
inter	O
alia	O
use	O
of	O
2',3'-dideoxy-3'-hydroxymethylcytosine	B
or	O
a	O
prodrug	O
or	O
salt	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
HIV	O
infection	O
wherein	O
the	O
reverse	O
transcriptase	O
of	O
the	O
HIV	O
bears	O
at	O
least	O
one	O
mutation	O
that	O
allows	O
an	O
obligate	O
chain	O
terminating	O
nucleoside-	O
or	O
nucleotide	O
phosphate	O
to	O
be	O
excised	O
from	O
the	O
nascent	O
DNA	O
strand	O
by	O
ATP-	O
or	O
pyrophosphate	O
-	O
mediated	O
excision	O
.	O

Compounds	O
useful	O
in	O
the	O
treatment	O
of	O
hiv	O

Humanized	O
forms	O
of	O
an	O
anti	O
-	O
CRIPTO	O
antibody	O
and	O
portions	O
thereof	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
variable	O
regions	O
of	O
these	O
antibodies	O
or	O
polypeptides	O
comprising	O
them	O
(	O
e.g.	O
,	O
full	O
-	O
length	O
antibodies	O
or	O
domain	O
deleted	O
antibodies	O
)	O
can	O
be	O
used	O
to	O
treat	O
disorders	O
,	O
such	O
as	O
cancer	O
.	O

Cripto	O
binding	O
molecules	O

Methods	O
of	O
treating	O
metastatic	O
cancer	O
such	O
as	O
metastasized	O
tumors	O
include	O
administering	O
a	O
compound	O
of	O
Structure	O
I	O
,	O
a	O
tautomer	O
of	O
the	O
compound	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
the	O
tautomer	O
,	O
or	O
a	O
mixture	O
thereof	O
to	O
a	O
subject	O
.	O

The	O
compound	O
,	O
tautomer	O
,	O
salt	O
of	O
the	O
compound	O
,	O
salt	O
of	O
the	O
tautomer	O
,	O
or	O
mixture	O
thereof	O
may	O
be	O
used	O
to	O
prepare	O
medicaments	O
for	O
treating	O
metastatic	O
cancer	O
.	O

The	O
variable	O
A	O
has	O
the	O
values	O
defined	O
herein	O
.	O

Treatment	O
of	O
metastasized	O
tumors	O

Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
treating	O
or	O
preventing	O
neurodegenerative	O
disorders	O
or	O
blood	O
coagulation	O
disorders	O
.	O

Methods	O
may	O
comprise	O
modulating	O
the	O
activity	O
or	O
level	O
of	O
a	O
sirtuin	O
,	O
such	O
as	O
SIRTl	O
or	O
Sir2	O
.	O

Exemplary	O
methods	O
comprise	O
contacting	O
a	O
cell	O
with	O
a	O
sirtuin	O
activating	O
compound	O
,	O
such	O
as	O
a	O
flavone	B
,	O
stilbene	B
,	O
flavanone	B
,	O
isoflavone	B
,	O
catechin	B
,	O
chalcone	B
,	O
tannin	B
or	O
anthocyanidin	B
;	O
or	O
an	O
inhibitory	O
compound	O
,	O
such	O
as	O
nicotinamide	B
.	O

Novel	O
compositions	O
for	O
preventing	O
and	O
treating	O
neurodegenerative	O
and	O
blood	O
coagulation	O
disorders	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
,	O
wherein	O
Ra	O
is	O
-C	B
(	I
O	I
)	I
ORI	I
,	O
in	O
which	O
R1	O
is	O
1	B
-	I
7C	I
-	I
alkyl	I
,	O
3	B
-	I
7C	I
-	I
cycloalkyl	I
,	O
or	O
1	B
-	I
7C	I
-	I
alkyl	I
substituted	O
by	O
one	O
to	O
four	O
substituents	O
independently	O
selected	O
from	O
R2	O
,	O
Rb	O
is	O
-T	O
-	O
Q	O
,	O
in	O
which	O
T	O
is	O
1	B
-	I
6C	I
-	I
alkylene	I
or	O
3	B
-	I
7C	I
-	I
cycloalkylene	I
,	O
and	O
either	O
Q	O
is	O
optionally	O
substituted	O
by	O
Rba	O
and/or	O
Rbb	O
and/or	O
Rbc	O
,	O
and	O
is	O
phenyl	B
or	O
naphthyl	B
,	O
or	O
Q	O
is	O
optionally	O
substituted	O
by	O
Rca	O
and/or	O
Rcb	O
,	O
and	O
is	O
Har	O
,	O
or	O
Q	O
is	O
optionally	O
substituted	O
by	O
Rda	O
and/or	O
Rdb	O
,	O
and	O
is	O
Het	B
,	O
or	O
Q	O
is	O
optionally	O
substituted	O
by	O
Rea	O
and/or	O
Reb	O
,	O
and	O
is	O
3	B
-	I
7C	I
-	I
cycloalkyl	I
,	O
which	O
are	O
useful	O
for	O
the	O
therapy	O
of	O
hyperproliferative	O
diseases	O
,	O
in	O
particular	O
human	O
cancer	O
.	O

Tetrahydropyridothiophenes	B
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
such	O
as	O
cancer	O

HIV	O
replication	O
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
;	O
or	O
a	O
stereochemically	O
isomeric	O
form	O
thereof	O
;	O
wherein	O
R1	O
is	O
halo	O
;	O
R2	O
and	O
R3	O
each	O
independently	O
are	O
C1	B
-	I
6alkyl	I
.	O

Pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
as	O
active	O
ingredient	O
and	O
processes	O
for	O
preparing	O
these	O
compounds	O
and	O
compositions	O
.	O

Hiv	O
inhibiting	O
2-	B
(	I
4-cyanophenylamino	I
)	I
pyrimidine	I
oxide	I
derivatives	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
having	O
the	O
structure	O
(	O
I	O
)	O
and	O
processes	O
for	O
the	O
production	O
thereof	O
and	O
the	O
intermediates	O
used	O
in	O
such	O
process	O
.	O

Protease	O
inhibitor	O
precursor	O
synthesis	O

The	O
present	O
invention	O
is	O
concerned	O
with	O
novel	O
pyrazine	B
2-carboxyamide	I
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
useful	O
as	O
metabotropic	O
glutamate	B
receptor	O
antagonists	O
:	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
.	O

PYRAZINE	B
-2-CARBOXAMIDE	I
DERIVATIVES	O
AS	O
mGluR5	O
ANTAGONISTS	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
enantiomers	O
of	O
amino	B
pyrimidine	I
compounds	O
for	O
the	O
modulation	O
of	O
the	O
histamine	B
H4	O
receptor	O
and	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
mediated	O
by	O
the	O
histamine	B
H4	O
receptor	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
of	O
such	O
compounds	O
.	O

Enantiomers	O
of	O
Amino	B
Pyrimidine	I
compounds	O
for	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O

[	O
Object	O
]	O
To	O
provide	O
an	O
oligonucleotide	B
derivative	O
that	O
can	O
be	O
used	O
without	O
a	O
problem	O
of	O
falling	O
of	O
a	O
DNA	O
probe	O
from	O
a	O
support	O
.	O

[	O
Solving	O
Means	O
]	O

The	O
oligonucleotide	B
derivative	O
of	O
the	O
present	O
invention	O
is	O
represented	O
by	O
the	O
following	O
General	O
Formula	O
(	O
1	O
)	O
.	O

The	O
oligonucleotide	B
derivative	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
in	O
a	O
DNA	O
chip	O
,	O
a	O
microarray	O
,	O
and	O
so	O
on	O
and	O
further	O
used	O
in	O
a	O
method	O
of	O
detecting	O
gene	O
and	O
a	O
method	O
of	O
regulating	O
gene	O
expression	O
,	O
for	O
example	O
.	O

Oligonucleotide	B
derivative	O
,	O
probe	O
for	O
detection	O
of	O
gene	O
,	O
and	O
dna	O
chip	O

A	O
method	O
for	O
inhibiting	O
and/or	O
treating	O
infection	O
in	O
a	O
vagina	O
is	O
provided	O
.	O

The	O
method	O
comprises	O
exposing	O
one	O
or	O
more	O
microbes	O
to	O
a	O
treatment	O
composition	O
.	O

The	O
microbes	O
are	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Gardnerella	O
,	O
Candida	O
,	O
and	O
Trichomonas	O
,	O
and	O
the	O
treatment	O
composition	O
comprises	O
an	O
effective	O
amount	O
of	O
a	O
saccharide	O
-	O
based	O
nonionic	O
surfactant	O
.	O

For	O
example	O
,	O
in	O
one	O
embodiment	O
,	O
the	O
saccharide	O
-	O
based	O
nonionic	O
surfactant	O
is	O
an	O
alkyl	B
glycoside	I
.	O

Method	O
for	O
inhibiting	O
and/or	O
treating	O
vaginal	O
infection	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
is	O
methyl	B
;	O
and	O
R1	O
is	O
4-methyl-4-oxy	B
-	I
piperazin	I
-	I
l	I
-	I
yl	I
;	O
or	O
R	O
is	O
CH2OH	B
and	O
R1	O
is	O
4-methyl	B
-	I
piperazin	I
-	I
l	I
-	I
yl	I
or	O
is	O
4-methyl-4-oxy	B
-	I
piperazin	I
-	I
l	I
-	I
yl	I
;	O
and	O
to	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
for	O
the	O
treatment	O
of	O
NK	O
-	O
I	O
receptor	O
related	O
diseases	O
.	O

Metabolites	O
for	O
nk	O
-	O
i	O
antagonists	O
for	O
emesis	O

The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
an	O
HMG	O
-	O
CoA	O
reductase	O
inhibitor	O
which	O
is	O
protected	O
from	O
destabilization	O
in	O
acidic	O
environments	O
by	O
utilizing	O
cyclodextrin	O
as	O
an	O
inclusion	O
complexing	O
agent	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
the	O
preparation	O
of	O
inclusion	O
complexes	O
of	O
HMG	O
-	O
CoA	O
and	O
cyclodextrin	O
and	O
to	O
their	O
use	O
in	O
the	O
treatment	O
of	O
hypercholesterolemia	O
and	O
hyperlipidemia	O
.	O

Stabilized	O
pharmaceutical	O
compositions	O
comprising	O
an	O
hmg	O
-	O
coa	O
reductase	O
inhibitor	O

A	O
water	O
-	O
absorptive	O
resin	O
is	O
coated	O
by	O
geranyl	B
acetate	I
type	O
Eucalyptus	O
oil	O
to	O
form	O
an	O
essential	O
oil	O
coated	O
resin	O
,	O
subsequently	O
a	O
carbon	B
-	O
coated	O
particle	O
is	O
prepared	O
by	O
coating	O
the	O
essential	O
oil	O
coated	O
resin	O
with	O
a	O
carbon	B
fine	O
powder	O
,	O
which	O
is	O
an	O
essential	O
oil	O
adsorption	O
and	O
desorption	O
regulator	O
;	O
and	O
then	O
mixed	O
with	O
an	O
adsorption	O
promoter	O
and	O
a	O
heat	O
transfer	O
inhibitor	O
to	O
form	O
a	O
sleep	O
inducing	O
composition	O
.	O

After	O
that	O
,	O
the	O
percutaneous	O
sleep	O
inducer	O
comprising	O
thereof	O
is	O
prepared	O
.	O

Composition	O
for	O
inducing	O
sleep	O
containing	O
vegetable	O
essential	O
oil	O
component	O
as	O
the	O
active	O
component	O
,	O
transdermal	O
absorption	O
type	O
sleep	O
inducing	O
agent	O
containing	O
the	O
composition	O
and	O
method	O
of	O
producing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
substituted	O
sulphoximines	B
according	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
A	O
,	O
E	O
,	O
G	O
,	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
m	O
,	O
p	O
,	O
q	O
,	O
are	O
given	O
in	O
the	O
claims	O
,	O
and	O
salts	O
thereof	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
substituted	O
sulphoximines	B
,	O
to	O
methods	O
of	O
preparing	O
said	O
substituted	O
sulphoximines	B
as	O
well	O
as	O
the	O
use	O
thereof	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
dysregulated	O
vascular	O
growth	O
or	O
of	O
diseases	O
which	O
are	O
accompanied	O
with	O
dysregulated	O
vascular	O
growth	O
,	O
wherein	O
the	O
compounds	O
effectively	O
interfere	O
with	O
Tie2	O
signalling	O
.	O

Substituted	O
sulphoximines	B
as	O
Tie2	O
inhibitors	O
and	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
,	O
methods	O
of	O
preparing	O
the	O
same	O
and	O
uses	O
of	O
the	O
same	O

In	O
accordance	O
with	O
the	O
present	O
invention	O
,	O
there	O
are	O
provided	O
fully	O
human	O
monoclonal	O
antibodies	O
against	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGF	O
-	O
r	O
)	O
.	O

Nucleotide	O
sequences	O
encoding	O
and	O
amino	B
acid	I
sequences	O
comprising	O
heavy	O
and	O
light	O
chain	O
immunoglobulin	O
molecules	O
,	O
particularly	O
sequences	O
corresponding	O
to	O
contiguous	O
heavy	O
and	O
light	O
chain	O
sequences	O
from	O
CDR1	O
through	O
CDR3	O
,	O
are	O
provided	O
.	O

Hybridomas	O
expressing	O
such	O
immunoglobulin	O
molecules	O
and	O
monoclonal	O
antibodies	O
are	O
also	O
provided	O
.	O

Human	O
monoclonal	O
antibodies	O
to	O
epidermal	O
growth	O
factor	O
receptor	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
antagonists	O
of	O
oxytocin	B
,	O
antagonists	O
of	O
oxytocin	B
and	O
vasopressin	B
or	O
antagonists	O
of	O
vasopressin	B
,	O
or	O
their	O
pharmaceutically	O
accepted	O
salts	O
,	O
or	O
their	O
combinations	O
with	O
other	O
drugs	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
which	O
main	O
profile	O
of	O
action	O
is	O
inhibition	O
of	O
oxytocin	B
and/or	O
vasopressin	B
receptors	O
in	O
non	O
-	O
pregnant	O
uterus	O
of	O
mammals	O
,	O
that	O
results	O
in	O
improvement	O
of	O
uterine	O
receptivity	O
in	O
embryo	O
transfer	O
.	O

It	O
further	O
relates	O
to	O
the	O
application	O
of	O
these	O
substances	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
regulating	O
the	O
uterine	O
contractile	O
activity	O
in	O
cases	O
of	O
artificial	O
insemination	O
.	O

Use	O
of	O
antagonists	O
of	O
oxytocin	B
and/or	O
vasopressin	B
in	O
assisted	O
reproduction	O

[	O
Solving	O
means	O
]	O
A	O
thienotriazolodiazepine	B
compound	O
of	O
the	O
following	O
formula	O
(	O
I	O
)	O
a	O
pharmaceutical	O
agent	O
containing	O
the	O
compound	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
a	O
production	O
intermediate	O
and	O
a	O
production	O
method	O
of	O
the	O
thienotriazolodiazepine	B
compound	O
.	O

[	O
Effect	O
]	O
Since	O
this	O
compound	O
has	O
an	O
inhibitory	O
action	O
on	O
costimulatory	O
signal	O
from	O
CD28	O
on	O
T	O
cell	O
,	O
it	O
is	O
useful	O
for	O
the	O
prophylaxis	O
or	O
suppression	O
of	O
rejection	O
reaction	O
in	O
transplantation	O
of	O
organ	O
or	O
bone	O
marrow	O
and	O
the	O
like	O
,	O
and	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
autoimmune	O
diseases	O
or	O
allergic	O
diseases	O
.	O

Thienotriazolodiazepine	B
compound	O
and	O
a	O
medicinal	O
use	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
foam	O
formulation	O
.	O

Generally	O
,	O
the	O
formulation	O
includes	O
a	O
therapeutically	O
effective	O
amount	O
of	O
imiquimod	B
,	O
sotirimod	B
or	O
resiquimod	B
and	O
a	O
fatty	B
acid	I
.	O

Immune	O
response	O
modifier	O
foam	O
formulations	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
laminarine	B
as	O
food	O
ingredient	O
.	O

Food	O
products	O
containing	O
laminarin	B

Nitrogen	B
heterocycle	I
biaryls	I
having	O
a	O
carboxylate	B
terminus	O
are	O
useful	O
for	O
treating	O
endometriosis	O
,	O
osteoporosis	O
,	O
restenosis	O
following	O
angioplasty	O
,	O
rheumatoid	O
arthritis	O
,	O
cancer	O
,	O
macular	O
degeneration	O
and	O
obesity	O
.	O

Compounds	O
of	O
formula	O
:	O
(	O
I	O
)	O
are	O
disclosed	O
.	O

A	O
representative	O
example	O
is	O
:	O
(	O
II	O
)	O
Nitrogen	B
heterocycle	I
biaryls	I
for	O
osteoporosis	O
and	O
other	O
diseases	O

The	O
present	O
application	O
describes	O
compounds	O
according	O
to	O
Formula	O
I	O
,	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
compound	O
according	O
to	O
Formula	O
I	O
and	O
optionally	O
one	O
or	O
more	O
additional	O
therapeutic	O
agents	O
,	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
according	O
to	O
Formula	O
I	O
both	O
alone	O
and	O
in	O
combination	O
with	O
one	O
or	O
more	O
additional	O
therapeutic	O
agents	O
.	O

The	O
compounds	O
have	O
the	O
following	O
general	O
formula	O
I	O
including	O
all	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
stereoisomers	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
described	O
herein	O
.	O
'	O

Triazolopyridine	B
derivatives	O
as	O
cannabinoid	B
receptor	O
1	O
antagonists	O

The	O
methods	O
and	O
compositions	O
disclosed	O
herein	O
relate	O
to	O
using	O
carbazole	B
,	O
and	O
derivatives	O
thereof	O
to	O
modify	O
a	O
signaling	O
activity	O
such	O
as	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
signalling	O
,	O
and	O
angiogenesis	O
activity	O
,	O
in	O
a	O
cell	O
.	O

Carbazole	B
formulations	O
for	O
the	O
treatment	O
of	O
psoriasis	O
and	O
angiogenesis	O

This	O
invention	O
relates	O
to	O
novel	O
N	B
-	I
phenyl	I
-	I
piperidine	I
derivatives	O
useful	O
as	O
monoamine	B
neurotransmitter	O
re	O
-	O
uptake	O
inhibitors	O
.	O

In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Novel	O
n	B
-	I
phenyl	I
-	I
piperidine	I
derivatives	O
and	O
their	O
use	O
as	O
monoamine	B
neurotransmitter	O
re	O
-	O
uptake	O
inhibitors	O

The	O
present	O
invention	O
provides	O
novel	O
ureas	B
containing	O
N	B
/	I
-aryl	I
or	I
N	I
-	I
heteroaryl	I
substituted	I
heterocycles	I
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
stereoisomer	O
,	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
form	O
thereof	O
,	O
wherein	O
the	O
variables	O
A	O
,	O
B	O
,	O
D	O
and	O
W	O
are	O
defined	O
herein	O
.	O

These	O
compounds	O
are	O
selective	O
inhibitors	O
of	O
the	O
human	O
P2Y	O
,	O
receptor	O
which	O
can	O
be	O
used	O
as	O
medicaments	O
for	O
treating	O
thromboembolic	O
disorders	O
.	O

N	B
-	I
linked	I
heterocyclic	I
antagonists	O
of	O
p2y1	O
receptor	O
useful	O
in	O
the	O
treatment	O
of	O
thrombotic	O
conditions	O

The	O
present	O
invention	O
relates	O
to	O
an	O
adsorbate	O
,	O
comprising	O
an	O
adsorbent	O
and	O
bicalutamide	B
adsorbed	O
on	O
said	O
adsorbent	O
,	O
a	O
process	O
for	O
preparing	O
same	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
thereof	O
.	O

Bicalutamide	B
adsorbates	O
,	O
process	O
for	O
preparing	O
same	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O

A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
which	O
has	O
a	O
therapeutic	O
or	O
prophylactic	O
effect	O
on	O
an	O
SNS	O
-	O
related	O
disease	O
such	O
as	O
neuropathic	O
pain	O
.	O

(	O
1	O
)	O
wherein	O
R1	O
and	O
R2	O
independently	O
represent	O
an	O
alkyl	B
group	O
having	O
1	O
to	O
4	O
carbon	B
atoms	O
or	O
the	O
like	O
,	O
or	O
R1	O
and	O
R2	O
may	O
together	O
form	O
a	O
5-	O
to	O
7-membered	O
ring	O
;	O
n	O
represents	O
a	O
numerical	O
number	O
of	O
1	O
to	O
3	O
;	O
A	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
aryl	B
group	O
or	O
the	O
like	O
or	O
a	O
formula	O
:	O
-N	B
(	I
R5	I
)	I
R6	I
(	O
wherein	O
R5	O
and	O
R6	O
independently	O
represent	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	B
group	O
or	O
the	O
like	O
)	O
;	O
and	O
R3	O
and	O
R4	O
independently	O
represent	O
a	O
sustituted	O
or	O
unsubstituted	O
alkyl	B
group	O
or	O
the	O
like	O
,	O
or	O
R3	O
and	O
R4	O
may	O
together	O
form	O
a	O
substituted	O
or	O
unsubstituted	O
,	O
saturated	O
or	O
unsubstituted	O
nitrogenated	O
heterocyclic	B
ring	O
,	O
provided	O
that	O
both	O
of	O
R1	O
and	O
R2	O
are	O
not	O
a	O
hydrogen	B
atom	O
when	O
R3	O
and	O
R4	O
together	O
form	O
a	O
piperidine	B
ring	O
.	O

Novel	O
2-quinolone	B
derivative	O

The	O
present	O
invention	O
provides	O
compositions	O
comprising	O
a	O
sterol	B
absorption	O
inhibitor	O
,	O
lactose	B
monohydrate	I
,	O
microcrystalline	O
cellulose	O
,	O
povidone	B
,	O
croscarmellose	B
sodium	I
,	O
sodium	B
lauryl	I
sulfate	I
and	O
magnesium	B
stearate	I
.	O

Compositions	O
comprising	O
a	O
sterol	B
absorption	O
inhibitor	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
the	O
field	O
of	O
therapeutics	O
and	O
in	O
particular	O
,	O
chemotherapy	O
.	O

Even	O
more	O
particularly	O
,	O
the	O
present	O
invention	O
provides	O
therapeutic	O
strategies	O
which	O
reduce	O
the	O
toxicity	O
or	O
enhance	O
the	O
efficacy	O
of	O
chemotherapeutic	O
agents	O
.	O

Compositions	O
and	O
methods	O
of	O
treatment	O
and	O
prophylaxis	O
are	O
also	O
contemplated	O
by	O
the	O
present	O
invention	O
.	O

Therapeutic	O
protocols	O
using	O
hyaluronan	B

Novel	O
compounds	O
are	O
provided	O
which	O
are	O
11-beta	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
I	O
inhibitors	O
.	O

11-beta	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
I	O
inhibitors	O
are	O
useful	O
in	O
treating	O
,	O
preventing	O
,	O
or	O
slowing	O
the	O
progression	O
of	O
diseases	O
requiring	O
11-beta	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
I	O
inhibitor	O
therapy	O
.	O

These	O
novel	O
compounds	O
have	O
the	O
structure	O
:	O
W	O
-	O
L	O
-	O
Z	O
(	O
I	O
)	O
or	O
stereoisomers	O
or	O
prodrugs	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
W	O
,	O
L	O
and	O
Z	O
are	O
defined	O
herein	O
.	O

Imidiazo	B
-and	I
triazolopyridines	I
as	O
inhibitors	O
of	O
11-beta	B
hydroxysteroid	I
dehydrogenase	O
type	O
i	O

The	O
present	O
invention	O
provides	O
derivatives	O
of	O
pyrido	B
[	I
2,3-d	I
]	I
pyrimidin-7-one	I
of	O
formula	O
(	O
I	O
)	O
.	O

These	O
compounds	O
are	O
kinase	O
inhibitors	O
,	O
including	O
compounds	O
that	O
show	O
anti	O
-	O
proliferative	O
activity	O
,	O
including	O
against	O
tumor	O
cells	O
,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
including	O
cancer	O
.	O

Pyrido	B
[	I
2,3-d	I
]	I
pyrimidines	I
and	O
their	O
use	O
as	O
kinase	O
inhibitors	O

A	O
method	O
of	O
combating	O
toxicity	O
caused	O
by	O
an	O
antifolate	O
compound	O
of	O
Formula	O
I	O
,	O
in	O
an	O
individual	O
who	O
has	O
been	O
administered	O
the	O
compound	O
.	O

The	O
method	O
comprises	O
administering	O
an	O
enzyme	O
that	O
has	O
carboxypeptidase	O
G	O
activity	O
to	O
the	O
individual	O
.	O

A	O
method	O
of	O
cleaving	O
a	O
compound	O
comprising	O
a	O
structural	O
fragment	O
of	O
Formula	O
IV	O
,	O
the	O
method	O
comprising	O
contacting	O
the	O
compound	O
comprising	O
the	O
structural	O
fragment	O
of	O
Formula	O
IV	O
with	O
an	O
enzyme	O
that	O
has	O
carboxypeptidase	O
G	O
activity	O
.	O

Cleavage	O
of	O
antifolate	O
compounds	O

Improved	O
pharmaceutical	O
compositions	O
are	O
provided	O
comprising	O
one	O
or	O
more	O
solubilized	O
HIV	O
protease	O
inhibiting	O
compounds	O
having	O
improved	O
solubility	O
properties	O
in	O
a	O
medium	O
and/or	O
long	O
chain	O
fatty	B
acid	I
,	O
or	O
mixtures	O
thereof	O
,	O
a	O
pharmaceutically	O
acceptable	O
alcohol	B
,	O
and	O
water	O
.	O

Improved	O
HIV	O
protease	O
inhibitors	O
pharmaceutical	O
formulations	O

The	O
present	O
invention	O
relates	O
to	O
genetically	O
engineered	O
recombinant	O
respiratory	O
syncytial	O
viruses	O
and	O
viral	O
vectors	O
which	O
contain	O
deletions	O
of	O
various	O
viral	O
accessory	O
gene	O
(	O
s	O
)	O
either	O
singly	O
or	O
in	O
combination	O
.	O

In	O
accordance	O
with	O
the	O
present	O
invention	O
,	O
the	O
recombinant	O
respiratory	O
syncytial	O
viral	O
vectors	O
and	O
viruses	O
are	O
engineered	O
to	O
contain	O
complete	O
deletions	O
of	O
the	O
M2	O
-	O
2	O
,	O
NS1	B
,	O
NS2	B
or	O
SH	B
viral	O
accessory	O
genes	O
or	O
various	O
combinations	O
thereof	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
attenuation	O
of	O
respiratory	O
syncytial	O
virus	O
by	O
mutagenisis	O
of	O
the	O
M2	O
-	O
1	O
gene	O
.	O

Recombinant	O
RSV	O
virus	O
expression	O
systems	O
and	O
vaccines	O

Alkoxy	B
indolinone	I
based	O
acid	O
and	O
amide	O
derivatives	O
have	O
enhanced	O
and	O
unexpected	O
drug	O
properties	O
as	O
inhibitors	O
of	O
protein	O
kinases	O
and	O
are	O
useful	O
in	O
treating	O
disorders	O
related	O
to	O
abnormal	O
protein	O
kinase	O
activities	O
such	O
as	O
cancer	O
.	O

Alkoxy	B
indolinone	I
based	O
protein	O
kinase	O
inhibitors	O

The	O
applications	O
discloses	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O
,	O
in	O
particular	O
those	O
associated	O
with	O
rheumatoid	O
,	O
arthritis	O
,	O
gout	O
,	O
gouty	O
arthritis	O
and	O
Behcet	O
's	O
syndrome	O
,	O
with	O
2-methoxyestradiol	B
.	O

2-Methoxyestradiol	B
for	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O

The	O
present	O
invention	O
has	O
an	O
object	O
to	O
provide	O
a	O
means	O
for	O
durably	O
exerting	O
an	O
action	O
of	O
enhancing	O
collagen	O
-	O
production	O
,	O
and	O
the	O
object	O
is	O
attained	O
by	O
providing	O
a	O
collagen	O
-	O
production	O
enhancer	O
which	O
contains	O
,	O
as	O
an	O
effective	O
ingredient	O
,	O
α	B
,	I
α	I
-	I
trehalose	I
and/or	O
a	O
saccharide	O
derivative	O
thereof	O
,	O
and	O
by	O
a	O
composition	O
incorporated	O
with	O
the	O
collagen	O
-	O
production	O
enhancer	O
to	O
be	O
used	O
for	O
such	O
purpose	O
.	O

Agent	O
for	O
enhancing	O
collagen	O
production	O
and	O
utilization	O
of	O
the	O
same	O

Vaccine	O
compositions	O
useful	O
in	O
inducing	O
immune	O
protection	O
in	O
a	O
host	O
against	O
arthritogenic	O
peptides	O
involved	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
are	O
disclosed	O
.	O

Each	O
vaccine	O
composition	O
provides	O
antigenic	O
dnaJp1	O
peptide	O
(	O
by	O
including	O
the	O
peptide	O
or	O
a	O
polynucleotide	O
which	O
encodes	O
the	O
peptide	O
)	O
and	O
,	O
optionally	O
,	O
other	O
peptide	O
fragments	O
of	O
the	O
microbial	O
dnaJ	O
protein	O
and/or	O
human	O
homologs	O
thereof	O
.	O

Methods	O
for	O
identifying	O
persons	O
who	O
are	O
predisposed	O
to	O
develop	O
rheumatoid	O
arthritis	O
and	O
use	O
of	O
the	O
inventive	O
vaccines	O
are	O
also	O
disclosed	O
.	O

Vaccine	O
compostions	O
and	O
methods	O
useful	O
in	O
inducing	O
immune	O
protection	O
against	O
arthritogenic	O
peptides	O
involved	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O

Rivastigmine	B
hydrogentartrate	I
in	O
amorphous	O
form	O
or	O
in	O
a	O
crystalline	O
form	O
characterized	O
by	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
pattern	O
exhibiting	O
peaks	O
at	O
2Θ	O
values	O
of	O
5.1	O
,	O
14.7	O
,	O
16.5	O
,	O
17.6	O
,	O
18.6	O
,	O
20.4	O
,	O
21.1	O
°	O
±	O
0.2	O
°	O
(	O
Form	O
I	O
)	O
,	O
or	O
2Θ	O
values	O
of	O
9.5	O
,	O
11.3	O
,	O
13.2	O
,	O
14.1	O
,	O
15.5	O
,	O
19.1	O
20.0	O
°	O
±	O
0.2	O
°	O
(	O
Form	O
II	O
)	O
,	O
methods	O
for	O
its	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
.	O

Amorphous	O
and	O
crystalline	O
forms	O
of	O
rivastigmine	B
hydrogentartrate	I

The	O
invention	O
relates	O
to	O
an	O
agent	O
or	O
a	O
composition	O
for	O
protecting	O
body	O
cells	O
for	O
the	O
preventive	O
and/or	O
performance	O
-	O
enhancing	O
influencing	O
of	O
body	O
cells	O
.	O

The	O
agent	O
comprises	O
a	O
combination	O
of	O
herbal	O
active	O
substances	O
and	O
vitamins	O
and	O
amino	B
acids	I
,	O
with	O
one	O
active	O
substance	O
consisting	O
of	O
polyphenols	B
from	O
green	O
tea	O
.	O

Agent	O
for	O
protecting	O
body	O
cells	O

Contemplated	O
compositions	O
and	O
methods	O
include	O
a	O
combination	O
of	O
a	O
tea	O
polyphenol	B
composition	O
and	O
lactoferrin	O
and	O
are	O
effective	O
to	O
prevent	O
and/or	O
treat	O
oral	O
cancer	O
at	O
efficiencies	O
significantly	O
higher	O
than	O
treatments	O
with	O
either	O
tea	O
polyphenol	B
compositions	O
or	O
lactoferrin	O
alone	O
.	O

Such	O
improved	O
efficiency	O
is	O
also	O
reflected	O
in	O
various	O
clinical	O
and	O
systemic	O
parameters	O
,	O
including	O
modulated	O
activity	O
of	O
phase	O
I	O
/	O
II	O
enzymes	O
,	O
expression	O
of	O
cytokeratins	O
,	O
NF	O
-	O
kB	O
,	O
Bcl-2	O
,	O
PCNA	O
,	O
and	O
changes	O
in	O
cellular	O
proliferation	O
and	O
induction	O
of	O
apoptosis	O
.	O

Black	O
tea	O
polyphenols	B
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
solid	O
state	O
chemistry	O
of	O
N	B
-	I
piperidino-5-	I
(	I
4-chlorophenyl	I
)	I
-1-	I
(	I
2,4-dichlorophenyl	I
)	I
-4-methyl-3-pyrazolecarboxamide	I
which	O
international	O
nonproprietary	O
name	O
is	O
rimonabant	B
,	O
its	O
preparation	O
and	O
pharmaceutical	O
compositions	O
containing	O
said	O
novel	O
polymorph	O
.	O

Thus	O
,	O
the	O
subject	O
of	O
the	O
present	O
invention	O
is	O
a	O
novel	O
polymorphic	O
form	O
of	O
rimonabant	B
,	O
called	O
form	O
III	O
,	O
it	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
rimonabant	O
in	O
its	O
polymorphic	O
form	O
III	O
,	O
and	O
an	O
amorphous	O
form	O
Solid	O
and	O
crystalline	O
rimonabant	B
and	O
processes	O
for	O
preparation	O
,	O
and	O
pharmaceutical	O
composition	O
thereof	O

It	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
quinazoline	B
derivative	O
with	O
less	O
skin	O
irritation	O
and	O
an	O
excellent	O
action	O
of	O
strongly	O
suppressing	O
scratching	O
behavior	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
quinazoline	B
derivative	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
quinazoline	B
derivative	O
represented	O
by	O
the	O
general	O
formula	O
[	O
1	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

In	O
the	O
general	O
formula	O
[	O
1	O
]	O
,	O
R1	O
represents	O
hydrogen	B
or	O
the	O
like	O
,	O
R2	O
represents	O
hydrogen	B
or	O
the	O
like	O
,	O
R3	O
and	O
R4	O
are	O
the	O
same	O
or	O
different	O
and	O
represent	O
hydrogen	B
,	O
alkyl	B
,	O
alkoxy	B
or	O
halogen	B
,	O
R5	O
is	O
combined	O
with	O
R6	O
to	O
represent	O
alkylene	B
or	O
represents	O
hydrogen	B
,	O
hydroxy	B
,	O
alkyl	B
,	O
phenyl	B
or	O
alkoxy	B
,	O
R6	O
represents	O
(	O
1	O
)	O
alkyl	B
,	O
(	O
2	O
)	O
cycloalkyl	B
,	O
(	O
3	O
)	O
phenyl	B
,	O
(	O
4	O
)	O
a	O
5-	O
to	O
10-membered	O
aromatic	B
heterocyclic	I
group	O
containing	O
one	O
to	O
three	O
heteroatoms	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
nitrogen	B
atom	O
,	O
an	O
oxygen	B
atom	O
and	O
a	O
sulfur	B
atom	O
,	O
or	O
(	O
5	O
)	O
-N	B
(	I
R61	I
)	I
(	I
R62	I
)	I
.	O

Quinazoline	B
derivative	O
and	O
pharmaceutical	O

Mast	O
cell	O
degranulation	O
inhibitors	O
having	O
a	O
carboxyl	B
group	O
have	O
not	O
been	O
developed	O
as	O
external	O
preparations	O
due	O
to	O
the	O
low	O
transdermal	O
permeability	O
thereof	O
.	O

By	O
formulating	O
external	O
preparations	O
thereof	O
,	O
side	O
effects	O
on	O
the	O
internal	O
organs	O
by	O
oral	O
administration	O
can	O
be	O
avoided	O
.	O

Some	O
of	O
the	O
mast	O
cell	O
degranulation	O
inhibitors	O
show	O
drastically	O
inferior	O
photostability	O
,	O
which	O
is	O
also	O
one	O
cause	O
of	O
suppressed	O
development	O
of	O
the	O
drug	O
as	O
an	O
external	O
preparation	O
.	O

The	O
present	O
invention	O
aims	O
at	O
improving	O
the	O
transdermal	O
permeability	O
and	O
photostability	O
of	O
mast	O
cell	O
degranulation	O
inhibitors	O
by	O
forming	O
a	O
salt	O
of	O
the	O
mast	O
cell	O
degranulation	O
inhibitor	O
with	O
an	O
organic	O
amine	B
.	O

Consequently	O
,	O
an	O
external	O
preparation	O
of	O
a	O
mast	O
cell	O
degranulation	O
inhibitor	O
can	O
be	O
provided	O
and	O
the	O
photostability	O
of	O
the	O
mast	O
cell	O
degranulation	O
inhibitor	O
itself	O
,	O
and	O
a	O
preparation	O
containing	O
same	O
can	O
be	O
improved	O
.	O

Preparation	O
for	O
external	O
application	O
comprising	O
salt	O
of	O
mast	O
cell	O
degranulation	O
inhibitor	O
having	O
carboxyl	B
group	O
with	O
organic	O
amine	B

A	O
composition	O
including	O
a	O
CXCR4	O
antagonist	O
and	O
a	O
CCR5	O
antagonist	O
represented	O
by	O
formula	O
I	O
or	O
II	O
:	O
or	O
an	O
acceptable	O
salt	O
,	O
solvate	O
or	O
ester	B
thereof	O
.	O

The	O
GXCR4	O
antagonist	O
includes	O
at	O
least	O
one	O
of	O
AMD-070	O
.	O

CS-3955	O
,	O
KRH-1	O
120	O
,	O
KRH-2731	O
,	O
and	O
KRH-1636	O
.	O

These	O
compositions	O
are	O
used	O
to	O
manufacture	O
medicaments	O
for	O
the	O
treatment	O
of	O
HIV	O
infections	O
.	O

Compositions	O
comprising	O
a	O
combination	O
of	O
ccr5	O
and	O
cxcr4	O
antagonists	O

The	O
present	O
invention	O
relates	O
to	O
new	O
mGluRl	O
and	O
mGluR5	O
receptor	O
subtype	O
preferring	O
ligands	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
represents	O
a	O
group	O
selected	O
from	O
SO	B
,	O
SO2	B
;	O
Y	O
represents	O
a	O
group	O
selected	O
from	O
(	B
CH2	I
)	I
n	I
,	O
NH	B
,	O
NHCH2	B
;	O
n	O
is	O
an	O
integer	O
of	O
0	O
to	O
1	O
;	O
Z	O
is	O
H	B
or	O
monosubstituted	O
by	O
alkyl	B
,	O
nitro	B
,	O
halogen	B
,	O
alkoxy	B
,	O
trifluoromethyl	B
,	O
cyano	B
,	O
amino	B
,	O
alkylamino	B
,	O
dialkylamino	B
,	O
aminomethyl	B
,	O
alkylaminomethyl	B
,	O
dialkylaminomethyl	B
,	O
hydroxyl	B
,	O
alkylsulfonylamino	B
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
alkyl	B
,	O
cycloalkyl	B
,	O
phenyl	B
,	O
biphenyl	B
,	O
heterocyclyl	B
;	O
R2	O
is	O
an	O
optionally	O
substituted	O
phenyl	B
,	O
heterocyclyl	B
,	O
or	O
NR3R4	B
group	O
wherein	O
R3	O
and	O
R4	O
are	O
independently	O
selected	O
from	O
the	O
group	O
of	O
hydrogen	B
and	O
an	O
optionally	O
substituted	O
alkyl	B
,	O
or	O
R3	O
and	O
R4	O
together	O
with	O
the	O
N	B
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
C5	B
-	I
7	I
heterocyclyl	I
group	O
,	O
containing	O
one	O
or	O
more	O
heteroatom	O
(	O
s	O
)	O
,	O
or	O
NH	B
-	I
CO	I
-	I
NR5R6	I
group	O
,	O
wherein	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
the	O
group	O
of	O
hydrogen	B
and	O
an	O
optionally	O
substituted	O
alkyl	B
,	O
or	O
R5	O
and	O
R6	O
together	O
with	O
the	O
N	B
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
C5	B
-	I
7	I
heterocyclyl	I
group	O
,	O
containing	O
one	O
or	O
more	O
heteroatom	O
(	O
s	O
)	O
;	O
and/or	O
hydrates	O
and/or	O
solvates	O
and/or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
formed	O
with	O
acids	O
or	O
bases	O
,	O
to	O
the	O
processes	O
for	O
producing	O
the	O
same	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
and	O
to	O
their	O
use	O
in	O
therapy	O
and/or	O
prevention	O
of	O
pathological	O
conditions	O
which	O
require	O
the	O
modulation	O
of	O
mGluRl	O
and	O
mGluR5	O
receptors	O
such	O
as	O
neurological	O
disorders	O
,	O
psychiatric	O
disorders	O
,	O
acute	O
and	O
chronic	O
pain	O
,	O
neuromuscular	O
dysfunctions	O
of	O
the	O
lower	O
urinary	O
tract	O
and	O
gastrointestinal	O
disorders	O
.	O

THIENO	B
[	I
2,3-b	I
]	I
PYRIDINE	I
DERIVATIVES	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
phosphonic	B
acid	I
compounds	O
having	O
the	O
structural	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
(	O
a	O
)	O
R	O
is	O
a	O
group	O
of	O
1	O
to	O
5	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
fluoro	B
,	O
chloro	B
,	O
bromo	B
,	O
C1	B
-	I
4	I
alkoxy	I
,	O
C1	B
-	I
4	I
alkyl	I
,	O
hydroxy	B
,	O
formyl	B
,	O
trifluoromethoxy	B
,	O
phenyl	B
,	O
heterocyclic	B
,	O
heterocyclic	B
-	I
substituted	I
methyl	I
,	O
aminomethyl	B
,	O
hydroxy	B
methyl	I
,	O
bromomethyl	B
,	O
sulfonyl	B
chloride	I
,	O
acetyl	B
chloride	I
,	O
nitroso	B
and	O
cyano	B
,	O
(	O
b	O
)	O
R1	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
C1	B
-	I
7	I
alkyl	I
,	O
C3	B
-	I
10	I
cycloalkyl	I
,	O
aryl	B
,	O
arylalkyl	B
and	O
heterocyclic	B
,	O
and	O
(	O
c	O
)	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydroxy	B
and	O
hydroxy	B
-	O
protecting	O
groups	O
,	O
and	O
stereoisomer	O
,	O
solvates	O
and	O
salts	O
thereof	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
anti	O
-	O
infectious	O
and	O
anti	O
-	O
parasitic	O
agents	O
,	O
in	O
particular	O
anti	O
-	O
malaria	O
agents	O
.	O

Organophosphoric	B
derivatives	O
useful	O
as	O
anti	O
-	O
parasitic	O
agents	O

Disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
clodronic	B
acid	I
and	O
hyaluronic	O
acid	O
or	O
their	O
salts	O
as	O
active	O
constituents	O
,	O
mixed	O
with	O
suitable	O
vehicles	O
.	O

Pharmaceutical	O
formulation	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
containing	O
clodronic	B
acid	I
and	O
hyaluronic	O
acid	O

The	O
invention	O
provides	O
methods	O
for	O
decreasing	O
or	O
inhibiting	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
or	O
pathogenesis	O
(	O
e.g.	O
,	O
illness	O
)	O
of	O
a	O
cell	O
in	O
vitro	O
,	O
ex	O
vivo	O
or	O
in	O
vivo	O
,	O
a	O
symptom	O
or	O
pathology	O
associated	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
or	O
pathogenesis	O
(	O
e.g.	O
,	O
illness	O
)	O
in	O
vitro	O
,	O
ex	O
vivo	O
or	O
in	O
vivo	O
,	O
or	O
an	O
adverse	O
side	O
effect	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HTV	O
)	O
infection	O
or	O
pathogenesis	O
(	O
e.g	O
,	O
illness	O
)	O
in	O
vitro	O
,	O
ex	O
vivo	O
or	O
in	O
vivo	O
.	O

In	O
one	O
embodiment	O
,	O
a	O
method	O
of	O
the	O
invention	O
includes	O
treating	O
a	O
subject	O
with	O
an	O
invention	O
compound	O
(	O
e.g.	O
,	O
cationic	O
steroid	B
antimicrobial	O
or	O
CSA	O
)	O
.	O

Cationic	O
steroid	B
antimicrobial	O
compositions	O
for	O
treating	O
or	O
preventing	O
hiv	O
infections	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
the	O
modulation	O
of	O
H3	O
receptors	O
.	O

Cyclohexyl	B
sulfonamide	I
derivatives	O
having	O
h3	O
receptor	O
activity	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
as	O
dual	O
modulators	O
of	O
the	O
5-HT2a	O
and	O
D3	O
receptors	O
useful	O
against	O
CNS	O
disorders	O
,	O
wherein	O
A	O
,	O
R1	O
,	O
R2	O
,	O
n	O
,	O
p	O
,	O
q	O
and	O
r	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Benzoyl	B
-	I
piperidine	I
derivatives	O
as	O
5ht2	O
/	O
d3	O
modulators	O

Compound	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
where	O
R	O
,	O
X	O
and	O
n	O
have	O
the	O
meanings	O
mentioned	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
.	O

Thiopyrophosphate	B
organic	O
compounds	O
,	O
method	O
for	O
preparing	O
thereof	O
and	O
compositions	O
containing	O
them	O

An	O
improved	O
pharmaceutical	O
formulation	O
that	O
is	O
effective	O
in	O
adversely	O
affecting	O
the	O
viability	O
of	O
microorganisms	O
or	O
in	O
inhibiting	O
their	O
growth	O
and	O
that	O
provides	O
better	O
safety	O
and/or	O
comfort	O
to	O
the	O
users	O
.	O

The	O
pharmaceutical	O
formulation	O
comprises	O
at	O
least	O
a	O
polyanionic	O
material	O
and	O
at	O
least	O
a	O
zinc	B
-	O
based	O
compound	O
.	O

Pharmaceutical	O
formulations	O
comprising	O
polyanionic	O
materials	O
and	O
zinc	B
-	O
based	O
preservatives	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
have	O
antibacterial	O
activity	O
wherein	O
R	O
represents	O
hydrogen	B
or	O
1	O
,	O
2	O
or	O
3	O
optional	O
substituents	O
;	O
W	O
is	O
=	B
C	I
(	I
R1	I
)	I
-	I
or	O
=	B
N-	I
;	O
R1	O
is	O
hydrogen	B
or	O
an	O
optional	O
substituent	O
and	O
R2	O
is	O
hydrogen	B
,	O
methyl	B
,	O
or	O
fluorine	B
;	O
or	O
R1	O
and	O
R2	O
taken	O
together	O
are	O
-CH2-	B
,	O
-CH2CH2-	B
,	O
-O-	B
,	O
or	O
,	O
in	O
either	O
orientation	O
,	O
-O-	B
CH2-	I
Or	O
-OCH2CH2-	B
;	O
R3	O
is	O
a	O
radical	O
of	O
formula	O
-	B
(	I
Alk1	I
)	I
m-	I
(	I
Z	I
)	I
p-	I
(	I
Alk2	I
)	I
n	I
-	I
Q	I
wherein	O
m	O
,	O
p	O
and	O
n	O
are	O
independently	O
0	O
or	O
1	O
,	O
provided	O
that	O
at	O
least	O
one	O
of	O
m	O
,	O
p	O
and	O
n	O
is	O
1	O
,	O
Z	O
is	O
-O-	B
,	O
-S-	B
,	O
-S	B
(	I
O	I
)	I
-	I
,	O
-S	B
(	I
O2	I
)	I
-	I
,	O
-NH-	B
,	O
-N	B
(	I
CH3	I
)	I
-	I
,	O
-N	B
(	I
CH2CH3	I
)	I
-	I
,	O
-C	B
(	I
=O	I
)	I
-	I
,	O
-O-	B
(	I
C	I
=	I
O	I
)	I
-	I
,	O
-C	B
(	I
=O	I
)	I
-O-	I
,	O
or	O
an	O
optionally	O
substituted	O
divalent	O
monocyclic	B
carbocyclic	I
or	O
heterocyclic	B
radical	O
having	O
3	O
to	O
6	O
ring	O
atoms	O
;	O
or	O
an	O
optionally	O
substituted	O
divalent	O
bicyclic	B
heterocyclic	I
radical	O
having	O
5	O
to	O
10	O
ring	O
atoms	O
;	O
Alk1	O
and	O
Alk2	O
are	O
optionally	O
substituted	O
C1C6	B
alkylene	I
,	O
C2-C6	B
alkenylene	I
,	O
or	O
C2-C6	B
alkynylene	I
radicals	O
,	O
which	O
may	O
optionally	O
terminate	O
with	O
or	O
be	O
interrupted	O
by	O
-O-	B
,	O
-S-	B
,	O
-S	B
(	I
O	I
)	I
-	I
,	O
-S	B
(	I
O2	I
)	I
-	I
,	O
-NH-	B
,	O
-N	O
(	B
CH3	I
)	I
-	I
,	O
or	O
-N	B
(	I
CH2CH3	I
)	I
-	I
;	O
and	O
Q	O
is	O
hydrogen	B
,	O
halogen	B
,	O
nitrile	B
,	O
or	O
hydroxyl	B
or	O
an	O
optionally	O
substituted	O
monocyclic	B
carbocyclic	I
or	O
heterocyclic	B
radical	O
having	O
3	O
to	O
6	O
ring	O
atoms	O
;	O
or	O
an	O
optionally	O
substituted	O
bicyclic	B
heterocyclic	I
radical	O
having	O
5	O
to	O
10	O
ring	O
atoms	O
.	O

Benzamide	B
and	O
pyridylamide	B
derivatives	O
as	O
antibacterial	O
agents	O

Disclosed	O
herein	O
is	O
an	O
immunologically	O
active	O
,	O
chimeric	O
anti	O
-	O
CD20	O
antibody	O
for	O
use	O
as	O
a	O
medicament	O
,	O
which	O
antibody	O
is	O
capable	O
of	O
substantial	O
B	O
-	O
cell	O
depletion	O
when	O
administered	O
to	O
a	O
subject	O
.	O

Chimeric	O
anti	O
-	O
CD20	O
antibody	O

A	O
rapamycin	B
analog	O
with	O
an	O
antioxidant	O
moiety	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
,	O
is	O
an	O
immunomodulatory	O
agent	O
and	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
restenosis	O
and	O
immune	O
and	O
autoimmune	O
diseases	O
.	O

Also	O
disclosed	O
are	O
cancer-	O
,	O
fungal	O
growth-	O
,	O
restenosis-	O
,	O
post-	O
transplant	O
tissue	O
rejection-	O
and	O
immune-	O
and	O
autoimmune	O
disease-	O
inhibiting	O
compositions	O
and	O
a	O
method	O
of	O
inhibiting	O
cancer	O
,	O
fungal	O
growth	O
,	O
restenosois	O
,	O
post	O
-	O
transplant	O
tissue	O
rejection	O
,	O
and	O
immune	O
and	O
autoimmune	O
disease	O
in	O
a	O
mammal	O
.	O

One	O
particular	O
preferred	O
application	O
of	O
such	O
antioxidant	O
moiety	O
containing	O
rapamycin	B
analog	O
is	O
in	O
medicated	O
devices	O
wherein	O
the	O
stability	O
and	O
resistance	O
to	O
oxidative	O
processes	O
are	O
essential	O
to	O
the	O
success	O
of	O
rapamycin	B
containing	O
combination	O
devices	O
.	O

Rapamycin	B
Analogs	O
Containing	O
an	O
Antioxidant	O
Moiety	O

A	O
composition	O
comprising	O
pinolenic	B
acid	I
or	O
a	O
derivative	O
thereof	O
may	O
be	O
used	O
in	O
treating	O
or	O
preventing	O
a	O
condition	O
of	O
the	O
liver	O
.	O

Preferably	O
,	O
the	O
pinolenic	B
acid	I
or	O
derivative	O
represents	O
at	O
least	O
75	O
%	O
by	O
weight	O
of	O
the	O
total	O
Δ5-polyunsaturated	O
C18-C20	B
fatty	I
acids	I
in	O
the	O
composition	O
.	O

Pinolenic	B
acid	I
compositions	O
for	O
treating	O
fatty	O
liver	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
muscular	O
dystrophies	O
or	O
myopathies	O
resulting	O
from	O
mutations	O
in	O
genes	O
encoding	O
for	O
collagen	O
VI	O
.	O

USE	O
OF	O
N-	B
(	I
DIBENZ	I
(	I
b	I
,	I
f	I
)	I
OXEPIN-10-YLMETHYL	I
)	I
N	I
-	I
METHYL	I
-	I
N-	I
PROP-	I
2	I
-YNYLAMINE	I
(	O
OMIGAPIL	B
)	O
FOR	O
THE	O
PROPHYLAXIS	O
AND	O
/	O
OR	O
TREATMENT	O
OF	O
CONGENITAL	O
MUSCULAR	O
DYSTROPHY	O
OR	O
MYOPATHY	O
RESULTING	O
FROM	O
COLLAGEN	O
VI	O
DEFICIENCY	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
antihistamine	O
agent	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
preventive	O
or	O
early	O
treatment	O
of	O
inflammatory	O
syndromes	O
of	O
viral	O
origin	O
,	O
in	O
particular	O
arthritis	O
of	O
the	O
distal	O
joints	O
,	O
more	O
particularly	O
those	O
triggered	O
by	O
togaviruses	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
combination	O
product	O
of	O
at	O
least	O
one	O
antihistamine	O
agent	O
and	O
of	O
at	O
least	O
one	O
antiserotonin	O
agent	O
for	O
its	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
use	O
in	O
preventive	O
or	O
early	O
therapy	O
for	O
inflammatory	O
syndromes	O
of	O
viral	O
origin	O
,	O
in	O
particular	O
arthritis	O
of	O
the	O
distal	O
joints	O
,	O
more	O
particularly	O
those	O
triggered	O
by	O
togaviruses	O
.	O

Novel	O
use	O
of	O
antihistamine	O
agents	O
for	O
the	O
preventive	O
or	O
early	O
treatment	O
of	O
inflammatory	O
syndromes	O
,	O
in	O
particular	O
those	O
triggered	O
by	O
togaviruses	O

The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
prevention	O
,	O
reversal	O
and	O
medical	O
treatment	O
of	O
dystonia	O
and	O
dyskinesia	O
as	O
well	O
as	O
other	O
diseases	O
related	O
to	O
movement	O
disorders	O
,	O
both	O
in	O
human	O
beings	O
and	O
animals	O
by	O
administering	O
a	O
neuronal	O
potassium	B
channel	O
opener	O
such	O
as	O
flupirtine	B
,	O
retigabine	B
or	O
maxipost	B
.	O

Potassium	B
channel	O
activators	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
dystonia	O
and	O
dystonia	O
-	O
like	O
symptoms	O

A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
Y	O
is	O
oxygen	B
or	O
sulfur	B
,	O
and	O
X1	O
,	O
X2	O
and	O
X3	O
are	O
independently	O
hydrogen	B
,	O
halogen	B
,	O
hydroxy	B
or	O
linear	O
or	O
branched	O
(	B
C1	I
-	I
6	I
)	I
alkyl	I
,	O
or	O
hydroxy-	B
(	I
C1	I
-	I
6	I
)	I
alkyl	I
or	O
(	B
C1	I
-	I
6	I
)	I
alkoxy-	I
(	I
C1	I
-	I
6	I
)	I
alkyl	I
,	O
mono-	B
or	I
dihalogenated	I
(	I
C1	I
-	I
6	I
)	I
alkyl	I
,	O
amino-	B
(	I
C1	I
-	I
6	I
)	I
alkyl	I
,	O
hydroxy-	B
(	I
C1	I
-	I
6	I
)	I
alkyl	I
,	I
with	O
the	O
provisos	O
that	O
(	O
1	O
)	O
at	O
least	O
one	O
of	O
X1	O
,	O
X2	O
and	O
X3	O
is	O
not	O
hydrogen	B
,	O
and	O
(	O
2	O
)	O
X2	O
is	O
not	O
hydroxy	B
when	O
X1	O
and	O
X3	O
are	O
hydrogen	B
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
microbes	O
.	O

Pleuromutilin	B
derivatives	O

The	O
present	O
invention	O
provides	O
compounds	O
1	O
and	O
2	O
according	O
to	O
formula	O
I	O
,	O
respectively	O
,	O
wherein	O
R	O
is	O
hydrogen	B
or	O
an	O
ester	B
forming	O
group	O
linked	O
to	O
C-1	B
,	O
respectively	O
.	O

The	O
compounds	O
have	O
antibacterial	O
and	O
anti	O
-	O
viral	O
activity	O
.	O

Etnangien	B
derivatives	O
and	O
their	O
use	O
as	O
antibiotics	O

The	O
present	O
invention	O
discloses	O
novel	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
(	O
in	O
which	O
X1	O
-	O
X5	O
,	O
R5	O
-	O
R8b	O
,	O
Z1	O
-	O
Z2	O
and	O
Ar1	O
are	O
defined	O
herein	O
)	O
,	O
pharmaceutical	O
compositions	O
including	O
those	O
compounds	O
and	O
a	O
process	O
for	O
making	O
those	O
compounds	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
useful	O
for	O
treating	O
pain	O
,	O
bladder	O
overreactivity	O
,	O
urinary	O
incontinence	O
,	O
inflammatory	O
hyperalgesia	O
by	O
inhibiting	O
the	O
VR1	O
receptor	O
in	O
mammals	O
.	O

Fused	O
compounds	O
that	O
inhibit	O
vanilloid	B
receptor	O
subtype	O
1	O
(	O
VR1	O
)	O
receptor	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
composition	O
comprising	O
lycopene	B
and	O
genistein	B
in	O
the	O
prevention	O
and	O
coadjuvant	O
treatment	O
of	O
prostate	O
carcinoma	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
the	O
use	O
of	O
a	O
composition	O
comprising	O
lycopene	B
and	O
epigallocatechin	B
gallate	I
in	O
the	O
prevention	O
and	O
coadjuvant	O
treatment	O
of	O
prostate	O
carcinoma	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
one	O
of	O
these	O
compositions	O
in	O
the	O
primary	O
prevention	O
(	O
i.e.	O
,	O
the	O
prophylactic	O
supplementation	O
of	O
healthy	O
subjects	O
)	O
of	O
the	O
onset	O
of	O
prostate	O
carcinoma	O
,	O
in	O
the	O
coadjuvant	O
treatment	O
(	O
i.e.	O
the	O
supplementation	O
accompanying	O
a	O
running	O
therapy	O
of	O
prostate	O
carcinoma	O
)	O
and	O
in	O
the	O
secondary	O
prevention	O
(	O
i.e.	O
,	O
the	O
supplementation	O
after	O
a	O
successful	O
therapy	O
for	O
the	O
prevention	O
of	O
relapse	O
)	O
of	O
prostate	O
carcinoma	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
is	O
also	O
directed	O
to	O
the	O
reduction	O
/	O
decrease	O
of	O
the	O
PSA	O
plasma	O
level	O
in	O
the	O
blood	O
of	O
subjects	O
to	O
whom	O
either	O
a	O
composition	O
comprising	O
lycopene	B
and	O
genistein	B
or	O
to	O
whom	O
either	O
a	O
composition	O
comprising	O
lycopene	B
and	O
epigallocatechin	B
gallate	I
are	O
administered	O
.	O

Further	O
compounds	O
that	O
may	O
preferably	O
also	O
be	O
present	O
in	O
the	O
composition	O
of	O
the	O
present	O
invention	O
are	O
vitamin	B
E	I
,	O
resveratrol	B
and	O
polyunsaturated	B
fatty	I
acid	I
(	O
derivative	O
)	O
s	O
.	O

Novel	O
actives	O
against	O
prostate	O
carcinoma	O

Provided	O
herein	O
are	O
methods	O
for	O
treatment	O
of	O
ocular	O
diseases	O
.	O

The	O
methods	O
comprise	O
administering	O
a	O
compound	O
of	O
general	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
Ak	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Cyclosporins	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
ocular	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
new	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
as	O
well	O
as	O
salts	O
and	O
enantiomers	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
said	O
compounds	O
in	O
therapy	O
,	O
e.g.	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
.	O

The	O
invention	O
further	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
.	O

The	O
compounds	O
are	O
neurokinin	O
(	O
NK	O
)	O
receptor	O
antagonists	O
.	O

1-	B
[	I
(	I
4-	I
[	I
benzoyl	I
(	I
methyl	I
)	I
amino	I
]	I
-3-	I
(	I
phenyl	I
)	I
butyl	I
]	I
azetidine	I
derivatives	O
for	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
1	O

The	O
present	O
invention	O
relates	O
to	O
2-	B
(	I
substituted	I
-	I
amino	I
)	I
-benzothiazole	I
sulfonamide	I
compounds	O
and	O
derivatives	O
,	O
their	O
use	O
as	O
protease	O
inhibitors	O
,	O
in	O
particular	O
as	O
broadspectrum	O
HIV	O
protease	O
inhibitors	O
,	O
processes	O
for	O
their	O
preparation	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
kits	O
comprising	O
them	O
.	O

The	O
present	O
invention	O
also	O
concerns	O
combinations	O
of	O
the	O
present	O
2-	B
(	I
substituted	I
-	I
amino	I
)	I
-benzothiazole	I
sulfonamide	I
compounds	O
and	O
derivatives	O
with	O
another	O
anti	O
-	O
retroviral	O
agent	O
.	O

It	O
further	O
relates	O
to	O
their	O
use	O
in	O
assays	O
as	O
reference	O
compounds	O
or	O
as	O
reagents	O
.	O

2-	B
(	I
Substituted	I
-	I
amino	I
)	I
-benzothiazole	I
sulfonamide	I
HIV	O
protease	O
inhibitors	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
composition	O
comprising	O
:	O
(	O
a	O
)	O
one	O
or	O
more	O
UV-	O
absorbing	O
agents	O
,	O
wherein	O
all	O
the	O
UV	O
-	O
absorbing	O
agents	O
are	O
in	O
solution	O
;	O
and	O
(	O
b	O
)	O
an	O
excipient	O
;	O
wherein	O
the	O
composition	O
is	O
ophthalmically	O
acceptable	O
,	O
and	O
wherein	O
the	O
composition	O
does	O
not	O
contain	O
an	O
active	O
agent	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
UV	O
-	O
absorbing	O
agent	O
is	O
a	O
vitamin	B
E	I
compound	O
,	O
ascorbic	B
acid	I
,	O
sodium	B
ascorbate	I
,	O
sorbic	B
acid	I
,	O
potassium	B
sorbate	I
,	O
amino	B
acid	I
,	O
or	O
combination	O
thereof	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
kits	O
comprising	O
the	O
composition	O
described	O
herein	O
.	O

Ultraviolet	O
absorbing	O
ophthalmic	O
compositions	O

A	O
compound	O
of	O
the	O
formula	O
(	O
Ib	O
)	O
:	O
wherein	O
X	O
is	O
NCH3	B
,	O
Y	O
is	O
N	B
,	O
Z	O
is	O
N	B
,	O
R3	O
is	O
N	B
(	I
CH3	I
)	I
2	I
,	O
and	O
(	O
a	O
)	O
R1	O
is	O
CH3	B
,	O
R2	O
,	O
R4	O
and	O
R5	O
to	O
R11	O
are	O
hydrogen	B
or	O
(	O
b	O
)	O
R5	O
is	O
CH3	B
and	O
R1	O
,	O
R2	O
,	O
R4	O
and	O
R6	O
to	O
R11	O
are	O
hydrogen	B
,	O
and	O
salts	O
and	O
tautomers	O
thereof	O
.	O

Radioprotectors	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
:	O
X	O
is	O
CH	B
or	O
N	B
;	O
one	O
of	O
R1	O
and	O
R2	O
is	O
H	B
,	O
and	O
the	O
other	O
is	O
selected	O
from	O
from	O
OR6	B
,	O
SR6	B
,	O
NR6R7	B
,	O
N3	B
,	O
Me	B
,	O
Et	B
,	O
CF3	B
,	O
SOR8	B
and	O
SO2R8	B
;	O
R3	O
is	O
selected	O
from	O
tert	B
-	I
butylmethyl	I
,	O
iso	B
-	I
propylmethyl	I
,	O
sec	B
-	I
butyl	I
,	O
tert	B
-	I
butyl	I
,	O
cyclopentyl	B
and	O
cyclohexyl	B
;	O
R4	O
is	O
optionally	O
substituted	O
C1	B
-	I
8	I
alkyl	I
or	O
optionally	O
substituted	O
C3	B
-	I
8	I
cycloalkyl	I
;	O
R6	O
and	O
R7	O
are	O
each	O
independently	O
selected	O
from	O
H	B
,	O
C1	B
-	I
8-alkyl	I
and	O
C3	B
-	I
8-cycloalkyl	I
,	O
or	O
R6	O
and	O
R7	O
are	O
linked	O
to	O
form	O
a	O
cyclic	O
group	O
together	O
with	O
the	O
nitrogen	B
to	O
which	O
they	O
are	O
attached	O
;	O
and	O
R8	O
is	O
C1	B
-	I
8-alkyl	I
or	O
C3	B
-	I
8-cycloalkyl	I
.	O

The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
selected	O
from	O
osteoporosis	O
,	O
Paget	O
's	O
disease	O
,	O
Chagas	O
's	O
disease	O
,	O
malaria	O
,	O
gingival	O
diseases	O
,	O
hypercalaemia	O
,	O
metabolic	O
bone	O
disease	O
,	O
diseases	O
involving	O
matrix	O
or	O
cartilage	O
degradation	O
,	O
and	O
bone	O
cancer	O
disorders	O
such	O
as	O
bone	O
metastases	O
and	O
associated	O
pain	O
.	O

Tetrahydrofuro	B
[	I
3	I
,	I
2	I
-b	I
]	I
pyrr0l-3-ones	I
as	O
cathepsin	O
k	O
inhibitors	O

The	O
present	O
invention	O
relates	O
the	O
use	O
of	O
a	O
beta	O
blocker	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
hemangiomas	O
,	O
for	O
example	O
of	O
infantile	O
hemangiomas	O
.	O

The	O
beta	O
blocker	O
may	O
be	O
a	O
non	O
-	O
selective	O
beta	O
-	O
blocker	O
,	O
for	O
example	O
propranolol	B
.	O

The	O
present	O
invention	O
provides	O
an	O
alternative	O
to	O
the	O
known	O
compounds	O
,	O
e.g.	O
coroticosteroïds	B
,	O
interferon	O
or	O
vincristine	B
,	O
generally	O
used	O
for	O
the	O
treatment	O
of	O
hemangiomas	O
.	O

Use	O
of	O
beta	O
blocker	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
hemangiomas	O

Described	O
is	O
the	O
treatment	O
of	O
immunologically	O
relevant	O
diseases	O
such	O
as	O
infections	O
or	O
a	O
proliferative	O
disease	O
,	O
in	O
particular	O
cancer	O
,	O
by	O
increasing	O
the	O
IL-12	O
/	O
IL-10	O
ratio	O
caused	O
by	O
the	O
sequential	O
administration	O
of	O
lipopeptides	O
(	O
e.g.	O
,	O
FSL-1	O
,	O
FSL-2	O
or	O
OspA	O
-	O
Lp	O
)	O
and	O
lipopolysaccharides	O
(	O
e.g.	O
,	O
LPS	O
R60	O
)	O
alone	O
or	O
in	O
combination	O
with	O
IFN	O
-	O
γ	O
.	O

Compounds	O
leading	O
to	O
an	O
increase	O
of	O
the	O
IL-12	O
/	O
IL-10	O
ratio	O
and	O
their	O
use	O
for	O
therapy	O
of	O
infectious	O
and	O
proliferative	O
diseases	O

The	O
present	O
invention	O
provides	O
a	O
novel	O
compound	O
having	O
an	O
excellent	O
AMPA	O
receptor	O
inhibitory	O
action	O
and/or	O
kainate	O
inhibitory	O
action	O
.	O

A	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
,	O
a	O
salt	O
thereof	O
or	O
hydrates	O
thereof	O
.	O

In	O
the	O
formula	O
,	O
Q	O
indicates	O
NH	B
,	O
O	B
or	O
S	B
;	O
and	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
the	O
same	O
as	O
or	O
different	O
from	O
each	O
other	O
and	O
each	O
indicates	O
hydrogen	B
atom	O
,	O
a	O
halogen	B
atom	O
,	O
a	O
C1	B
-	I
6alkyl	I
group	O
or	O
a	O
group	O
represented	O
by	O
the	O
formula	O
-X	O
-	O
A	O
(	O
wherein	O
X	O
indicates	O
a	O
single	O
bond	O
,	O
an	O
optionally	O
sbutituted	O
C1	B
-	I
6	I
alkylene	I
group	O
etc	O
.	O
;	O
and	O
A	O
indicates	O
an	O
optionally	O
substituted	O
C6	B
-	I
14	I
aromatic	I
hydrocarbocyclic	I
group	O
or	O
5-	O
to	O
14-membered	O
aromatic	B
heterocyclic	I
group	O
etc	O
.	O
)	O
.	O

1,3,5-Trisubstituted	B
2	I
(	I
1H	I
)	I
-pyridones	I
as	O
AMPA	O
receptor	O
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
eg	O
Parkinson	O
's	O
disease	O

The	O
invention	O
relates	O
to	O
novel	O
nutraceutical	O
and	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
and	O
R2	O
are	O
independently	O
from	O
each	O
other	O
C1	B
-	I
8-alk	I
(	I
en	I
)	I
yl	I
and	O
R3	O
and	O
R4	O
are	O
independently	O
from	O
each	O
other	O
hydroxy	B
or	O
C1	B
-	I
8-alkyloxy	I
,	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
these	O
compositions	O
for	O
the	O
treatment	O
,	O
co	O
-	O
treatment	O
or	O
prevention	O
of	O
joint	O
disorders	O
.	O

Novel	O
nutraceutical	O
and	O
pharmaceutical	O
compositions	O
and	O
use	O
thereof	O
for	O
the	O
treatment	O
,	O
co	O
-	O
treatment	O
or	O
prevention	O
of	O
cartilage	O
degradation	O
or	O
cartilage	O
damage	O
in	O
joints	O

A	O
gel	O
type	O
enteral	O
nutrient	O
,	O
which	O
is	O
excellent	O
in	O
the	O
form	O
-	O
maintaining	O
capability	O
of	O
solid	O
matter	O
(	O
gel	O
)	O
in	O
the	O
stomach	O
,	O
is	O
not	O
easily	O
disintegrated	O
or	O
dissolved	O
even	O
depending	O
upon	O
a	O
pH	O
change	O
,	O
shows	O
little	O
change	O
in	O
the	O
physical	O
properties	O
such	O
as	O
water	O
liberation	O
,	O
or	O
the	O
like	O
even	O
during	O
long	O
-	O
term	O
strage	O
,	O
can	O
be	O
thermally	O
sterilized	O
and	O
has	O
a	O
preferable	O
property	O
passing	O
through	O
a	O
feeding	O
tube	O
,	O
can	O
be	O
prepared	O
by	O
blending	O
agar	O
and	O
alginic	O
acid	O
and/or	O
its	O
salt	O
,	O
and	O
further	O
soybean	O
protein	O
as	O
a	O
nitrogen	B
source	O
.	O

It	O
is	O
expected	O
to	O
exert	O
effects	O
that	O
neither	O
gastro	O
-	O
esophageal	O
reflux	O
nor	O
leakage	O
of	O
the	O
nutrient	O
occur	O
when	O
intaking	O
the	O
gel	O
type	O
enteral	O
nutrient	O
of	O
the	O
present	O
invention	O
.	O

Gel	O
type	O
enteric	O
nutrient	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
that	O
has	O
superior	O
gastric	O
acid	O
secretion	O
inhibitory	O
action	O
,	O
ample	O
long	O
-	O
lasting	O
gastric	O
acid	O
secretion	O
inhibitory	O
action	O
,	O
and	O
is	O
able	O
to	O
maintain	O
intragastric	O
pH	O
at	O
a	O
high	O
level	O
for	O
an	O
extended	O
period	O
of	O
time	O
,	O
making	O
it	O
useful	O
as	O
a	O
therapeutic	O
or	O
prophylactic	O
agent	O
for	O
diseases	O
or	O
symptoms	O
caused	O
by	O
gastric	O
acid	O
,	O
as	O
well	O
as	O
an	O
active	O
form	O
of	O
this	O
compound	O
(	O
form	O
to	O
which	O
the	O
compound	O
is	O
converted	O
in	O
the	O
body	O
following	O
administration	O
thereof	O
)	O
in	O
the	O
form	O
of	O
a	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
1	O
a	O
)	O
(	O
wherein	O
R2	O
represents	O
a	O
group	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
the	O
like	O
,	O
and	O
R1	O
,	O
R3	O
,	O
W1	O
and	O
X-	O
are	O
as	O
defined	O
in	O
the	O
description	O
)	O
.	O

Benzimidazole	B
compound	O
having	O
gastric	O
acid	O
secretion	O
inhibitory	O
activity	O

A	O
pharmaceutical	O
composition	O
comprising	O
cyclodextrin	O
/	O
paclitaxel	B
inclusion	O
,	O
which	O
consists	O
of	O
paclitaxel	B
,	O
cyclodextrin	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
,	O
wherein	O
the	O
mass	O
ratio	O
of	O
the	O
paclitaxel	B
to	O
cyclodextrin	O
is	O
1:10	O
-	O
150	O
,	O
the	O
said	O
cyclodextrin	O
is	O
hyoxylpropyl-	O
sulfobutyl-7-β	O
-	O
cyclodextrin	O
,	O
or	O
sulfobutylether-7-β	O
-	O
cyclodextrin	O
,	O
or	O
their	O
mixture	O
;	O
the	O
stability	O
constant	O
of	O
the	O
cyclodextrin	O
/	O
paclitaxel	B
inclusion	O
is	O
Ka	O
=	O
5396M-1	O
-	O
1412M-1	O
.	O

The	O
preparation	O
method	O
of	O
the	O
pharmaceutical	O
composition	O
is	O
as	O
follow	O
:	O
(	O
a	O
)	O
A	O
solution	O
of	O
cyclodextrin	O
is	O
added	O
dropwise	O
to	O
a	O
solution	O
of	O
paclitaxel	B
in	O
ethanol	B
.	O

(	O
b	O
)	O
The	O
resulting	O
mixture	O
is	O
filtered	O
through	O
microporous	O
membrane	O
of	O
0.2	O
-	O
0.4	O
&	O
mgr;m	O
after	O
being	O
dissolved	O
.	O

(	O
c	O
)	O
Ethanol	B
is	O
removed	O
under	O
reduced	O
pressure	O
to	O
give	O
a	O
liquid	O
inclusion	O
which	O
has	O
the	O
ethanol	B
level	O
of	O
less	O
than	O
2	O
%	O
,	O
or	O
alternatively	O
water	O
is	O
also	O
removed	O
under	O
reduced	O
pressure	O
,	O
the	O
resulting	O
product	O
is	O
dried	O
giving	O
a	O
solid	O
inclusion	O
.	O

Pharmaceutical	O
composition	O
comprising	O
cyclodextrin	O
paclitaxel	B
inclusion	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrazoline	B
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
methods	O
for	O
their	O
preparation	O
,	O
medicaments	O
comprising	O
these	O
compounds	O
as	O
well	O
as	O
their	O
use	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
humans	O
and	O
animals	O
.	O

Sulfonamide	B
substituted	O
pyrazoline	B
compounds	O
,	O
their	O
preparation	O
and	O
use	O
as	O
cb1	O
modulators	O

Disclosed	O
herein	O
is	O
a	O
transnasal	O
anticonvulsive	O
pharmaceutical	O
composition	O
comprising	O
diazepam	B
as	O
an	O
active	O
ingredient	O
,	O
water	O
,	O
a	O
fatty	B
acid	I
ester	I
,	O
diethylene	B
glycol	I
monoethyl	I
ether	I
,	O
ethanol	B
and	O
sodium	B
glycocholate	I
,	O
wherein	O
the	O
weight	O
of	O
the	O
fatty	B
acid	I
ester	I
is	O
at	O
least	O
2-fold	O
higher	O
than	O
that	O
of	O
water	O
and	O
is	O
at	O
least	O
2-fold	O
higher	O
than	O
that	O
of	O
ethanol	B
.	O

The	O
anticonvulsive	O
pharmaceutical	O
composition	O
for	O
transmucosal	O
delivery	O
of	O
diazepam	B
according	O
to	O
the	O
present	O
invention	O
includes	O
a	O
minimized	O
content	O
of	O
water	O
and	O
ethanol	B
,	O
a	O
fatty	B
acid	I
ester	I
as	O
a	O
main	O
ingredient	O
and	O
no	O
use	O
of	O
a	O
polar	O
solvent	O
,	O
e.g.	O
glycol	B
,	O
and	O
exhibits	O
improved	O
diazepam	B
solubility	O
and	O
transmucosal	O
permeability	O
due	O
to	O
using	O
a	O
small	O
amount	O
of	O
water	O
and	O
ethanol	B
.	O

The	O
present	O
invention	O
also	O
includes	O
treatment	O
of	O
convulsions	O
by	O
transnasally	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
disclosed	O
compositions	O
.	O

Transnasal	O
anticonvulsive	O
pharmaceutical	O
composition	O

The	O
present	O
invention	O
describes	O
provides	O
the	O
use	O
of	O
anandamide	B
for	O
the	O
manufacture	O
of	O
a	O
nutraceutical	O
for	O
oral	O
intake	O
preferably	O
a	O
medicament	O
for	O
reducing	O
appetite	O
,	O
giving	O
a	O
satiety	O
effect	O
,	O
preventing	O
or	O
reducing	O
inflammatory	O
bowel	O
disease	O
or	O
preventing	O
or	O
reducing	O
irritable	O
bowel	O
syndrome	O
.	O

Anandamide	B

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cholesterylamines	B
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
.	O

These	O
pharmaceutical	O
compositions	O
are	O
to	O
be	O
used	O
in	O
the	O
medical	O
intervention	O
of	O
infectious	O
diseases	O
,	O
in	O
particular	O
diseases	O
caused	O
by	O
a	O
virus	O
or	O
a	O
bacterium	O
.	O

Cholesterylamines	B
for	O
the	O
treatment	O
and	O
prevention	O
of	O
infectious	O
diseases	O

The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
acute	O
lung	O
injuries	O
,	O
such	O
as	O
acute	O
lung	O
injury	O
induced	O
by	O
peritonitis	O
during	O
sepsis	O
,	O
acute	O
lung	O
injury	O
induced	O
by	O
intravenous	O
bacteremia	O
during	O
sepsis	O
,	O
acute	O
lung	O
injury	O
caused	O
by	O
smoke	O
inhalation	O
,	O
acute	O
lung	O
injury	O
occurring	O
in	O
a	O
premature	O
infant	O
with	O
deficiency	O
of	O
surfactant	O
,	O
acute	O
lung	O
injury	O
caused	O
by	O
oxygen	B
toxicity	O
or	O
acute	O
lung	O
injury	O
caused	O
by	O
barotraumas	O
from	O
mechanical	O
ventilation	O
,	O
using	O
an	O
ERβ	O
selective	O
ligand	O
such	O
as	O
2-	B
(	I
3-fluoro-4-hydroxyphenyl	I
)	I
-7-vinyl-1,3-benzoxazol-5-ol	I
or	I
3-	I
(	I
3-fluoro-4-hydroxy	I
-	I
phenyl	I
)	I
-7-hydroxy	I
-	I
naphthalene-1-carbonitrile	I
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
use	O
of	O
ERβ	O
selective	O
ligands	O
or	O
compositions	O
thereof	O
for	O
the	O
prevention	O
of	O
acute	O
lung	O
injuries	O
in	O
those	O
being	O
at	O
risk	O
thereof	O
.	O

Use	O
of	O
estrogen	B
receptor	O
beta	O
selective	O
ligands	O
for	O
treating	O
acute	O
lung	O
injuries	O

Use	O
of	O
the	O
general	O
formula	O
compound	O
(	O
I	O
)	O
,	O
or	O
any	O
salt	O
thereof	O
,	O
for	O
preparation	O
of	O
a	O
pharmaceutical	O
compound	O
for	O
the	O
treatment	O
of	O
infectious	O
illnesses	O
,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
helicobacter	O
.	O

Y	O
equals	O
NO2	B
,	O
COOH	B
or	O
SO3H	B
;	O
Z	O
equals	O
O	B
,	O
N	B
or	O
S	B
;	O
X1	O
and	O
X2	O
are	O
halogens	B
which	O
may	O
be	O
equal	O
or	O
different	O
;	O
and	O
m	O
and	O
y	O
take	O
values	O
from	O
0	O
to	O
3	O
and	O
may	O
be	O
equal	O
or	O
different	O
.	O

Use	O
of	O
compounds	O
as	O
inhibitors	O
for	O
helicobacter	O
flavodoxin	B

The	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
bisbenzamidine	B
compounds	O
of	O
Formula	O
(	O
I	O
)	O
as	O
antioxidant	O
and	O
as	O
neuroprotective	O
agents	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
L	O
have	O
the	O
meaning	O
defined	O
in	O
the	O
claims	O
.	O

Bisbenzamidine	B
derivatives	O
for	O
use	O
as	O
antioxidant	O

The	O
present	O
invention	O
provides	O
novel	O
crystalline	O
forms	O
of	O
5-deazacytidine	B
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
these	O
novel	O
forms	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
preparation	O
of	O
the	O
novel	O
forms	O
and	O
compositions	O
.	O

Solid	O
state	O
forms	O
of	O
5-azacytidine	B
and	O
processes	O
for	O
preparation	O
thereof	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
composition	O
consisting	O
of	O
the	O
active	O
ingredient	O
valsartan	O
and	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
excipient	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
,	O
delay	O
of	O
progression	O
or	O
treatment	O
of	O
diabetes	O
,	O
in	O
particular	O
type	O
2	O
diabetes	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
a	O
composition	O
consisting	O
of	O
the	O
active	O
ingredient	O
valsartan	O
and	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
excipient	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
improvement	O
of	O
microalbuminurea	O
.	O

Formulations	O
comprising	O
valsartan	O
for	O
treating	O
diabetes	O
or	O
microalbuminuria	O

Substituted	O
thiazolidinone	B
compounds	O
(	O
I	O
)	O
are	O
new	O
.	O

Substituted	O
thiazolidinone	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
new	O
.	O

R1	O
:	O
optionally	O
one	O
or	O
more	O
times	O
halo	B
substituted	O
1	B
-	I
3C	I
-	I
alkyl	I
or	O
cyclopropyl	B
;	O
X	O
:	O
1	B
-	I
3C	I
-	I
alkyl	I
optionally	O
one	O
or	O
more	O
times	O
substituted	O
by	O
cyano	B
,	O
methyl	B
,	O
ethyl	B
,	O
isopropyl	B
,	O
ethynyl	B
,	O
hydroxyl	B
,	O
aryl	B
,	O
furanyl	B
or	O
halo	B
;	O
Q	O
:	O
a	O
substituted	O
aromatic	O
group	O
of	O
formula	O
(	O
a	O
)	O
,	O
where	O
a	O
single	O
bone	O
or	O
a	O
double	O
bond	O
is	O
present	O
between	O
V1	O
and	O
W1	O
,	O
W1	O
and	O
U1	O
,	O
U1	O
and	O
Y1	O
,	O
Y1	O
and	O
Z	O
,	O
and	O
Z	O
and	O
V1	O
,	O
where	O
the	O
bonds	O
are	O
=	O
2	O
double	O
bond	O
;	O
V1	O
,	O
W1	O
:	O
C	B
or	O
N	B
;	O
U1	O
:	O
-CH	B
2-	I
,	O
-CH=	B
,	O
-CR2=	B
,	O
-N=	B
or	O
-NR3-	B
;	O
Y1	O
:	O
-CH	B
2-	I
,	O
-CH=	B
,	O
-CR2=	B
,	O
-C	B
=	I
O-	I
,	O
-N=	B
or	O
-NR3-	B
;	O
Z	O
:	O
-CH	B
2-	I
,	O
-CH=	B
,	O
-CR2=	B
,	O
-O-	B
,	O
-N=	B
or	O
-NR3	B
;	O
R2	O
:	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyloxy	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
a	I
lkyl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NH	I
2	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
-R8	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NR4R5	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
2R6	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
3	B
-	I
10C	I
-	I
heterocycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
,	O
-O	B
(	I
CH	I
2	I
)	I
p-6	I
-	I
10C	I
-	I
aryl	I
,	O
-O	B
(	I
CH	I
2	I
)	I
q	I
-	I
heteroaryl	I
,	O
-C	B
(	I
O	I
)	I
2R6	I
,	O
-NR4R5	B
,	O
-C	B
(	I
O	I
)	I
NH	I
2	I
,	O
-C	B
(	I
O	I
)	I
-R8	I
,	O
-S	B
(	I
O	I
)	I
R7	I
,	O
-S	B
(	I
O	I
)	I
2R7	I
,	O
-S	B
(	I
O	I
)	I
2R8	I
,	O
-S	B
(	I
O	I
)	I
2NR4R5	I
,	O
-C	B
(	I
O	I
)	I
H	I
or	O
-C	B
(	I
O	I
)	I
R7	I
(	O
all	O
optionally	O
one	O
or	O
more	O
times	O
substituted	O
by	O
1	B
-	I
6-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
3	B
-	I
10C	I
-	I
heterocycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
,	O
-C	B
(	I
O	I
)	I
R7	I
,	O
-C	B
(	I
O	I
)	I
2R6	I
,	O
-NR4R5	B
,	O
-C	B
(	I
O	I
)	I
NR4R5	I
,	O
-S	B
(	I
O	I
)	I
R7	I
,	O
-S	B
(	I
O	I
)	I
2R7	I
,	O
-S	B
(	I
O	I
)	I
2NR4R5	I
,	O
R8	O
,	O
R9	O
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NR4R5	I
or	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
2R6	I
)	I
,	O
H	B
,	O
halo	B
,	O
CN	B
or	O
nitro	B
;	O
R3	O
:	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NH	I
2	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
R8	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NR4R5	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
2R6	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
3	B
-	I
10C	I
-	I
heterocycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
,	O
-C	B
(	I
O	I
)	I
2R6	I
,	O
-C	B
(	I
O	I
)	I
NH	I
2	I
,	O
-C	B
(	I
O	I
)	I
R8	I
,	O
,	O
-C	B
(	I
O	I
)	I
NR4R5	I
,	O
-S	B
(	I
O	I
)	I
R7	I
,	O
-S	B
(	I
O	I
)	I
2R7	I
,	O
-S	B
(	I
O	I
)	I
2R8	I
or	O
-S	B
(	I
O	I
)	I
2NR4R5	I
(	O
all	O
optionally	O
one	O
or	O
more	O
times	O
substituted	O
by	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
3	B
-	I
10C	I
-	I
heterocycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
,	O
-C	B
(	I
O	I
)	I
R7	I
,	O
-C	B
(	I
O	I
)	I
2R6	I
,	O
-NR4R5	B
,	O
-C	B
(	I
O	I
)	I
NR4R5	I
,	O
-S	B
(	I
O	I
)	I
R7	I
,	O
-S	B
(	I
O	I
)	I
2R7	I
,	O
-S	B
(	I
O	I
)	I
2NR4R5	I
,	O
R8	O
,	O
R9	O
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NR4R5	I
or	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
2R6	I
)	I
,	O
or	O
CN	B
,	O
-C	B
(	I
O	I
)	I
H	I
or	O
-C	B
(	I
O	I
)	I
R7	I
;	O
R4	O
,	O
R5	O
:	O
H	B
,	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
heteroaryl	B
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
or	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
;	O
R6	O
:	O
H	B
,	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
heteroaryl	B
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
or	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
;	O
R7	O
:	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
heteroaryl	B
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
or	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
;	O
R8	O
:	O
3	B
-	I
10C	I
-	I
heterocycloalkyl	I
(	O
optionally	O
one	O
or	O
more	O
times	O
substituted	O
by	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
3	B
-	I
10C	I
-	I
heterocycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
,	I
-C	B
(	I
O	I
)	I
R7	I
,	O
-C	B
(	I
O	I
)	I
2R6	I
,	O
-NR4R5	B
,	O
-C	B
(	I
O	I
)	I
NR4R5	I
,	O
-S	B
(	I
O	I
)	I
R7	I
,	O
-S	B
(	I
O	I
)	I
2R7	I
,	O
-S	O
(	B
O	I
)	I
2NR4R5	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NR4R5	I
or	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
2R6	I
)	I
;	O
R9	O
:	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
(	O
optionally	O
one	O
or	O
more	O
times	O
substituted	O
by	O
1	B
-	I
6C-	I
(	I
halo	I
)	I
alkyl	I
,	O
(	B
halo	I
)	I
-1	I
-	I
6C	I
-	I
alkoxy-1	I
-	I
6C	I
-	I
alkyl	I
,	O
2	B
-	I
6C	I
-	I
alkenyl	I
,	O
2	B
-	I
6C	I
-	I
alkynyl	I
,	O
3	B
-	I
10C	I
-	I
cycloalkyl	I
,	O
3	B
-	I
10C	I
-	I
heterocycloalkyl	I
,	O
6	B
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
m-6	I
-	I
10C	I
-	I
aryl	I
,	O
-	B
(	I
CH	I
2	I
)	I
nheteroaryl	I
,	O
-C	B
(	I
O	I
)	I
R7	I
,	O
-C	B
(	I
O	I
)	I
2R6	I
,	O
-NR4R5	B
,	O
-C	B
(	I
O	I
)	I
NR4R5	I
-S	B
(	I
O	I
)	I
R7	I
,	O
-S	B
(	I
O	I
)	I
2R7	I
,	O
-S	B
(	I
O	I
)	I
2NR4R5	I
,	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
NR4R5	I
or	O
-	B
(	I
CH	I
2	I
)	I
nC	I
(	I
O	I
)	I
2R6	I
)	I
;	O
and	O
n	O
,	O
m	O
,	O
p	O
,	O
q	O
:	O
1	O
-	O
4	O
.	O

Independent	O
claims	O
are	O
included	O
for	O
:	O
(	O
1	O
)	O
the	O
preparations	O
of	O
(	O
I	O
)	O
;	O
and	O
(	O
2	O
)	O
isothiazolidin-3-one	B
compounds	O
of	O
formula	O
(	O
II	O
)	O
and	O
(	O
VII	O
)	O
.	O

P1	O
:	O
1	B
-	I
6C	I
-	I
alkyl	I
.	O

[	O
Image	O
]	O
[	O
Image	O
]	O
[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Cytostatic	O
;	O
Immunosuppressive	O
;	O
Antipsoriatic	O
;	O
Endocrine	O
-	O
Gen	O
.	O
;	O
Neuroprotective	O
;	O
Antiinflammatory	O
;	O
Cardiovascular	O
-	O
Gen	O
.	O
;	O
Vasotropic	O
;	O
Antiarteriosclerotic	O
;	O
Antiparasitic	O
;	O
Protozoacide	O
;	O
Antimalarial	O
;	O
Fungicide	O
;	O
Nephrotropic	O
;	O
Anticonvulsant	O
;	O
Nootropic	O
;	O
Antiparkinsonian	O
;	O
Virucide	O
;	O
Hepatotropic	O
;	O
Anti	O
-	O
HIV	O
.	O
-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Polo	O
-	O
like	O
kinase	O
inhibitor	O
.	O

The	O
ability	O
of	O
(	O
I	O
)	O
to	O
inhibit	O
polo	O
-	O
like	O
kinase	O
was	O
tested	O
in	O
insect	O
cell	O
(	O
Hi5	O
)	O
.	O

The	O
results	O
showed	O
that	O
(	B
Z	I
,	I
E	I
/	I
Z	I
)	I
-2-cyan-2-	I
[	I
3-ethyl-5-	I
[	I
[	I
[	I
1-	I
(	I
1-methyl-4-piperidinyl	I
)	I
-1H	I
-	I
indol-6-	I
yl	I
]	I
amino	I
]	I
methylen	I
]	I
-4-oxo-2-thiazolidinyliden	I
]	I
-N-	I
(	I
2-hydroxy-1,1-dimeth	I
ylethyl	I
)	I
acetamide	I
exhibited	O
an	O
IC	O
5	O
0	O
value	O
of	O
1	O
M.	O
Substituted	O
thiazolidinones	B
,	O
their	O
production	O
and	O
utilisation	O
as	O
medicine	O

This	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
L1	O
are	O
as	O
defined	O
herein	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
,	O
and	O
the	O
use	O
of	O
the	O
compound	O
to	O
treat	O
allergic	O
and/or	O
inflammatory	O
disorders	O
,	O
particularly	O
disorders	O
such	O
as	O
allergic	O
rhinitis	O
,	O
asthma	O
and/or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

Pyrimidine	B
hydrazide	I
compounds	O
as	O
pgds	O
inhibitors	O

The	O
invention	O
relates	O
to	O
pyrrolidine	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen	B
,	O
halogen	B
or	O
lower	O
alkyl	B
;	O
R2	O
is	O
hydrogen	B
,	O
halogen	B
,	O
lower	O
alkoxy	B
or	O
lower	O
alkyl	B
substituted	O
by	O
halogen	B
;	O
R3	O
is	O
-	B
(	I
CH2	I
)	I
p	I
-	I
heterocyclyl	I
optionally	O
substituted	O
by	O
lower	O
alkyl	B
,	O
halogen	B
,	O
-S	B
(	I
O	I
)	I
2-lower	I
alkyl	I
,	O
-C	B
(	I
O	I
)	I
-lower	I
alkyl	I
,	O
-C	B
(	I
O	I
)	I
O	I
-	I
lower	I
alkyl	I
,	O
hydroxy	B
,	O
lower	O
alkyl	B
substituted	O
by	O
hydroxy	B
,	O
-	B
(	I
CH2	I
)	I
p	I
-	I
O	I
-	I
lower	I
alkyl	I
,	O
-NHCO	B
-	I
lower	I
alkyl	I
,	O
or	O
is	O
C3	B
-	I
6-cycloalkyl	I
optionally	O
substituted	O
by	O
=	B
O	I
,	O
-	B
(	I
CH2	I
)	I
p	I
-	I
O	I
-	I
lower	I
alkyl	I
or	I
lower	I
alkinyl	I
,	O
or	O
is	O
unsubstituted	O
or	O
substituted	O
aryl	B
or	O
heteroaryl	B
,	O
wherein	O
the	O
substituents	O
are	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
lower	O
alkyl	B
,	O
CN	B
,	O
-S	B
(	I
O	I
)	I
2-lower	I
alkyl	I
,	O
halogen	B
,	O
-C	B
(	I
O	I
)	I
-lower	I
alkyl	I
,	O
hydroxy	B
,	O
lower	O
alkoxy	B
or	O
lower	O
alkoxy	B
substituted	O
by	O
halogen	B
;	O
or	O
is	O
-	B
(	I
CH2	I
)	I
P	I
-	I
NR4R5	I
;	O
R4	O
/	O
R5	O
are	O
independently	O
from	O
each	O
other	O
hydrogen	B
,	O
lower	O
alkyl	B
,	O
-	B
(	I
CRR'	I
)	I
p	I
-	I
lower	I
alkyl	I
substituted	O
by	O
hydroxy	B
,	O
-	B
(	I
CRR'	I
)	I
p	I
-	I
O	I
-	I
lower	I
alkyl	I
,	O
-	B
(	I
CRR'	I
)	I
p	I
-	I
S	I
-	I
lower	I
alkyl	I
,	O
-	B
(	I
CRR'	I
)	I
p	I
-	I
O	I
-	I
lower	I
alkyl	I
substituted	O
by	O
hydroxy	B
or	O
C3	B
-	I
6-cycloalkyl	I
;	O
R	O
/	O
R	O
'	O
are	O
independently	O
from	O
each	O
other	O
hydrogen	B
,	O
lower	O
alkyl	B
or	O
lower	O
alkyl	B
substituted	O
by	O
hydroxyl	B
;	O
n	O
is	O
1	O
or	O
2	O
;	O
o	O
is	O
1	O
or	O
2	O
;	O
P	O
is	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
or	O
to	O
pharmaceutically	O
active	O
acid	O
-	O
addition	O
salts	O
thereof	O
.	O

Pyrrolidine	B
derivatives	O
as	O
dual	O
nk1	O
/	O
nk3	O
receptor	O
antagonists	O

An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
safe	O
and	O
effective	O
method	O
for	O
enhancing	O
an	O
immune	O
response	O
and	O
a	O
medicament	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
disease	O
comprising	O
amyloid	O
β	O
peptide	O
that	O
induces	O
an	O
enhanced	O
immune	O
response	O
.	O

An	O
amyloid	O
β	O
peptide	O
or	O
a	O
portion	O
thereof	O
with	O
addition	O
or	O
insertion	O
of	O
cysteine	B
and	O
a	O
method	O
for	O
enhancing	O
an	O
immune	O
response	O
using	O
the	O
peptide	O
or	O
a	O
method	O
for	O
enhancing	O
an	O
immune	O
response	O
using	O
the	O
peptide	O
together	O
with	O
an	O
adjuvant	O
.	O

A	O
medicament	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
disease	O
comprising	O
an	O
amyloid	O
β	O
peptide	O
or	O
a	O
portion	O
thereof	O
that	O
induces	O
an	O
enhanced	O
immune	O
response	O
.	O

A	O
DNA	O
vaccine	O
,	O
that	O
may	O
have	O
the	O
same	O
effect	O
,	O
comprising	O
the	O
gene	O
encoding	O
an	O
amyloid	O
β	O
peptide	O
or	O
a	O
portion	O
thereof	O
that	O
induces	O
an	O
enhanced	O
immune	O
response	O
with	O
addition	O
or	O
insertion	O
of	O
cysteine	B
.	O

Method	O
for	O
enhancing	O
immune	O
response	O
with	O
peptide	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
tri	B
-	I
aryl	I
compounds	O
,	O
compositions	O
comprising	O
the	O
same	O
and	O
processes	O
for	O
the	O
preparation	O
thereof	O
.	O

Telomerase	O
activating	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
A	O
,	O
Y	O
,	O
R1	O
,	O
R1a	O
,	O
R2	O
,	O
and	O
R2a	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O

Compounds	O
of	O
Formula	O
I	O
are	O
useful	O
in	O
treating	O
and/or	O
preventing	O
cognitive	O
disorders	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
.	O

The	O
invention	O
also	O
encompasses	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
methods	O
of	O
preparing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
methods	O
of	O
treating	O
cognitive	O
disorders	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
.	O

Pyrazolopyrrolidines	B
as	O
inhibitors	O
of	O
gamma	O
secretase	O

A	O
compound	O
having	O
calcium	O
-	O
receptor	O
activation	O
action	O
can	O
be	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diarrhea	O
.	O

The	O
compound	O
including	O
a	O
peptide	O
such	O
as	O
γ	B
-	I
Glu	I
-	I
X	I
-	I
Gly	I
(	O
X	O
represents	O
an	O
amino	B
acid	I
or	O
an	O
amino	B
acid	I
derivative	O
)	O
,	O
γ	B
-	I
Glu	I
-	I
Val	I
-	I
Y	I
(	O
Y	O
represents	O
an	O
amino	B
acid	I
or	O
an	O
amino	B
acid	I
derivative	O
)	O
,	O
γ	B
-	I
Glu	I
-	I
Ala	I
,	O
γ	B
-	I
Glu	I
-	I
Gly	I
,	O
γ	B
-	I
Glu	I
-	I
Cys	I
,	O
γ	B
-	I
Glu	I
-	I
Met	I
,	O
γ	B
-	I
Glu	I
-	I
Thr	I
,	O
γ	B
-	I
Glu	I
-	I
Val	I
,	O
γ	B
-	I
Glu	I
-	I
Orn	I
,	O
Asp	B
-	I
Gly	I
,	O
Cys	B
-	I
Gly	I
,	O
Cys	B
-	I
Met	I
,	O
Glu	B
-	I
Cys	I
,	O
Gly	B
-	I
Cys	I
,	O
Leu	B
-	I
Asp	I
,	O
γ	B
-	I
Glu	I
-	I
Met	I
(	I
O	I
)	I
,	O
γ	B
-	I
Glu	I
-	I
γ	I
-	I
Glu	I
-	I
Val	I
,	O
γ	B
-	I
Glu	I
-	I
Val	I
-	I
NH2	I
,	O
γ	B
-	I
Glu	I
-	I
Val	I
-	I
ol	I
,	O
γ	B
-	I
Glu	I
-	I
Ser	I
,	O
γ	B
-	I
Glu	I
-	I
Tau	I
,	O
γ	B
-	I
Glu	I
-	I
Cys	I
(	I
S	I
-	I
Me	I
)	I
(	I
O	I
)	I
,	O
γ	B
-	I
Glu	I
-	I
Leu	I
,	O
γ	B
-	I
Glu	I
-	I
Ile	I
,	O
γ	B
-	I
Glu	I
-	I
t	I
-	I
Leu	I
,	O
and	O
γ	B
-	I
Glu	I
-	I
Cys	I
(	I
S	I
-	I
Me	I
)	I
.	O

Prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diarrhea	O

A	O
device	O
for	O
the	O
transdermal	O
administration	O
of	O
nicotine	O
comprises	O
a	O
backing	O
layer	O
,	O
a	O
drug	O
reservoir	O
layer	O
containing	O
nicotine	B
carried	O
by	O
said	O
backing	O
layer	O
,	O
and	O
means	O
for	O
maintaining	O
the	O
device	O
in	O
nicotine	B
transmitting	O
relationship	O
with	O
the	O
skin	O
.	O

The	O
the	O
device	O
absorbs	O
less	O
than	O
48.6	O
%	O
of	O
incidental	O
light	O
passing	O
through	O
the	O
device	O
so	O
as	O
to	O
permit	O
the	O
natural	O
skin	O
colour	O
of	O
the	O
subject	O
to	O
whom	O
the	O
device	O
is	O
applied	O
to	O
be	O
visible	O
through	O
said	O
device	O
,	O
and	O
is	O
effective	O
for	O
nicotine	B
replacement	O
therapy	O
under	O
exposure	O
of	O
the	O
device	O
to	O
light	O
.	O

Transparent	O
Transdermal	O
Nicotine	B
Delivery	O
Devices	O

A	O
hybrid	O
type	O
I	O
polyketide	O
synthase	O
gene	O
typically	O
containing	O
a	O
starter	O
module	O
and	O
a	O
plurality	O
of	O
heterologous	O
extender	O
modules	O
is	O
used	O
to	O
synthesise	O
novel	O
polyketides	O
.	O

It	O
is	O
preferably	O
under	O
the	O
control	O
of	O
a	O
type	O
II	O
polypolyketide	O
synthase	O
promoter	O
e.g.	O
act	O
I	O
of	O
S.	O
coelicolor	O
.	O

Hybrid	O
polyketide	O
synthases	O

Compositions	O
and	O
methods	O
for	O
treating	O
mitochondrial	O
disorders	O
are	O
provided	O
.	O

The	O
compositions	O
include	O
compounds	O
having	O
a	O
mitochondrial	O
targeting	O
moiety	O
,	O
for	O
example	O
a	O
lipophilic	O
cation	O
.	O

Certain	O
compounds	O
are	O
effective	O
for	O
increasing	O
the	O
ratio	O
of	O
phosphocreatine	O
/	O
creatine	O
in	O
a	O
host	O
,	O
for	O
example	O
a	O
mammal	O
.	O

Other	O
compounds	O
decrease	O
the	O
ratio	O
of	O
phophocreatine	O
/	O
creating	O
in	O
a	O
host	O
.	O

An	O
exemplary	O
compound	O
is	O
defined	O
by	O
the	O
following	O
structure	O
(	O
Formula	O
Ia	O
)	O
:	O
wherein	O
R1	O
is	O
H	B
or	O
phosphate	B
and	O
the	O
double	O
bond	O
is	O
between	O
N1	O
and	O
C1	O
or	O
between	O
N2	O
and	O
C1	O
;	O
R2	O
is	O
a	O
mitochondrial	O
targeting	O
moiety	O
;	O
R3	O
an	O
alkyl	B
,	O
alkylaryl	B
,	O
alkylheteroaryl	B
spacer	O
group	O
,	O
a	O
cleavable	O
linker	O
,	O
or	O
absent	O
;	O
R4	O
is	O
H	B
or	O
an	O
alkyl	B
,	O
aryl	B
,	O
or	O
heteroaryl	B
group	O
;	O
and	O
R5	O
is	O
alkyl	B
,	O
aryl	B
,	O
or	O
heteroaryl	B
;	O
or	O
N1	O
C1	O
,	O
and	O
N3	O
together	O
form	O
a	O
heterocyclic	B
ring	O
containing	O
at	O
least	O
5	O
atoms	O
,	O
wherein	O
N1	O
,	O
N3	O
,	O
and	O
R1-R5	O
are	O
as	O
defined	O
above	O
,	O
or	O
N3	O
and	O
R5	O
together	O
form	O
a	O
heterocyclic	B
ring	O
containing	O
at	O
least	O
four	O
atoms	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
.	O

Mitochondrial	O
compositions	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
.	O

These	O
compounds	O
are	O
inhibitors	O
of	O
protein	O
kinases	O
,	O
particularly	O
inhibitors	O
of	O
GSK-3	O
mammalian	O
protein	O
kinases	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compounds	O
and	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
protein	O
kinase	O
mediated	O
disorders	O
,	O
such	O
as	O
diabetes	O
,	O
cancer	O
,	O
stroke	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Pyrimidine	B
-	O
based	O
compounds	O
useful	O
as	O
GSK-3	O
inhibitors	O

The	O
present	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
compound	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
such	O
as	O
an	O
analgesic	O
.	O

The	O
present	O
invention	O
is	O
to	O
provide	O
the	O
novel	O
histidine	B
derivative	O
having	O
an	O
excellent	O
analgesic	O
action	O
and	O
the	O
like	O
.	O

The	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
very	O
high	O
intermigration	O
into	O
the	O
blood	O
upon	O
oral	O
administration	O
and	O
is	O
very	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
,	O
especially	O
an	O
analgesic	O
for	O
the	O
treatment	O
of	O
acute	O
or	O
chronic	O
pain	O
diseases	O
and	O
of	O
neuropathic	O
pain	O
diseases	O
.	O

Novel	O
histidine	B
derivative	O

Provided	O
herein	O
are	O
novel	O
,	O
stilbene	B
like	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
analogs	O
,	O
tautomeric	O
forms	O
,	O
stereoisomers	O
,	O
polymorphs	O
,	O
hydrates	O
,	O
metabolites	O
,	O
prodrugs	O
,	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
compositions	O
thereof	O
.	O

These	O
compounds	O
can	O
inhibit	O
HDACs	O
and	O
are	O
useful	O
as	O
a	O
therpeautic	O
or	O
ameliorating	O
agent	O
for	O
diseases	O
that	O
are	O
involved	O
in	O
cellular	O
growth	O
such	O
as	O
malignant	O
tumors	O
,	O
autoimmune	O
diseases	O
,	O
skin	O
diseases	O
,	O
infections	O
,	O
inflammation	O
,	O
etc	O
.	O

Novel	O
histone	B
deacetylase	O
inhibitors	O

A	O
gel	O
sheet	O
including	O
a	O
hydrogel	O
,	O
the	O
hydrogel	O
including	O
at	O
least	O
50	O
parts	O
by	O
mass	O
of	O
water	O
-	O
soluble	O
divalent	O
metal	O
salt	O
with	O
respect	O
to	O
100	O
parts	O
by	O
mass	O
of	O
anionic	O
polymer	O
compound	O
is	O
provided	O
.	O

Gel	O
sheet	O
and	O
cosmetic	O
preparation	O
in	O
sheet	O
form	O
using	O
the	O
same	O

A	O
method	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
cell	O
or	O
tissue	O
damage	O
in	O
a	O
living	O
subject	O
due	O
to	O
the	O
exposure	O
to	O
ionizing	O
radiation	O
is	O
provided	O
,	O
which	O
comprises	O
administration	O
to	O
said	O
subject	O
of	O
a	O
quaternary	B
pyridinium	I
salt	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
'	O
is	O
H	B
,	O
OH	B
,	O
CONH2	B
or	O
COCH3	B
,	O
R	O
'	O
is	O
H	B
or	O
CH3	B
,	O
R	O
'	O
'	O
is	O
H	B
or	O
CH3	B
,	O
and	O
X-	O
is	O
a	O
pharmaceutically	O
acceptable	O
counterion	O
,	O
in	O
an	O
amount	O
sufficient	O
to	O
inhibit	O
radiation	O
-	O
induced	O
damage	O
.	O

Use	O
of	O
quaternary	B
pyridinium	I
salts	O
for	O
radioprotection	O

The	O
invention	O
discloses	O
water	O
-	O
soluble	O
triterpenephenol	B
compounds	O
having	O
antitumor	O
activity	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
substituents	O
R1∼R4	O
and	O
M	O
are	O
defined	O
as	O
in	O
the	O
description	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
used	O
quinone	B
methide	O
triterpene	B
compounds	O
as	O
starting	O
materials	O
.	O

The	O
water	O
-	O
soluble	O
triterpenephenol	B
compounds	O
disclosed	O
in	O
the	O
invention	O
can	O
be	O
made	O
into	O
various	O
dosage	O
forms	O
including	O
injection	O
,	O
tablet	O
,	O
capsule	O
,	O
granule	O
and	O
liniment	O
,	O
particularly	O
suitable	O
for	O
making	O
into	O
injection	O
.	O

Water	O
-	O
soluble	O
triterpenephenol	B
compounds	O
having	O
antitumor	O
activity	O
and	O
the	O
preparation	O
thereof	O

Described	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
directed	O
to	O
the	O
treatment	O
of	O
ophthalmic	O
conditions	O
characterized	O
by	O
oxidative	O
stress	O
or	O
damage	O
in	O
a	O
subject	O
by	O
reducing	O
the	O
reactive	O
oxygen	B
species	O
in	O
the	O
subject	O
.	O

Also	O
described	O
herein	O
are	O
methods	O
for	O
reducing	O
ophthalmic	O
photooxidative	O
damage	O
in	O
a	O
subject	O
.	O

Modulators	O
of	O
ocular	O
oxidative	O
stress	O

Imidazo	B
[	I
1,2-a	I
]	I
pyridine	I
and	O
imidazo	B
[	I
1,2-b	I
]	I
pyridazine	I
derivatives	O
which	O
inhibit	O
Btk	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
auto	O
-	O
immune	O
and	O
inflammatory	O
diseases	O
caused	O
by	O
aberrant	O
B	O
-	O
cell	O
activation	O
,	O
e.g.	O
arthritis	O
.	O

Novel	O
imidazoý1,2-a¨pyridine	O
and	O
imidazoý1,2-b¨pyridazine	B
derivatives	O

Substituted	O
porphyrin	B
compounds	O
of	O
formulas	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O
are	O
disclosed	O
.	O

Synthesis	O
of	O
new	O
asymmetrically	O
meso	O
-	O
substituted	O
water	O
-	O
soluble	O
porphyrins	B
acting	O
as	O
cytostatic	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
salt	O
forms	O
of	O
the	O
compound	O
4-	B
[	I
(	I
Z	I
)	I
-	I
[	I
[	I
4-	I
[	I
(	I
dimethylaminoJmethyllphenyllaminolCe	I
-	I
fluoro-1,2-dihydro2-oxo-3H	I
-	I
indol-3-ylidene	I
)	I
methyl	I
]	I
-benzenepropanoic	I
acid	I
which	O
are	O
suitable	O
for	O
pharmaceutical	O
development	O
and	O
to	O
a	O
process	O
for	O
their	O
manufacture	O
.	O

Salt	O
forms	O
of	O
a	O
6-fluoro-1,2-dihydro-2-oxo-3h	B
-	I
indol-3-ylidene	I
derivative	O
,	O
process	O
for	O
their	O
manufacture	O
and	O
pharmaceutical	O
compositions	O
containing	O
same	O

Disclosed	O
herein	O
are	O
compounds	O
useful	O
in	O
treating	O
glaucoma	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
the	O
stimulation	O
of	O
hair	O
growth	O
,	O
and	O
the	O
stimulation	O
of	O
the	O
conversion	O
of	O
vellus	O
hair	O
to	O
terminal	O
hair	O
.	O

The	O
compounds	O
themselves	O
are	O
herein	O
.	O

Hydrazines	B
in	O
glaucoma	O
therapy	O

Acid	O
addition	O
salts	O
of	O
2-acetoxy-5-	B
(	I
α	I
-	I
cyclopropylcarbonyl-2-fluorobenzyl	I
)	I
-4,5,6,7-tetrahydrothieno	I
[	I
3,2-c	I
]	I
pyridine	I
with	O
sulfuric	B
acid	I
or	O
sulfonic	B
acids	I
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
and	O
processes	O
for	O
the	O
production	O
thereof	O
.	O

The	O
acid	O
addition	O
salts	O
have	O
a	O
low	O
toxicity	O
.	O

Prasugrel	B
salts	O
with	O
improved	O
properties	O

Uric	B
acid	I
in	O
mammalian	O
subjects	O
is	O
reduced	O
and	O
excretion	O
of	O
uric	B
acid	I
is	O
increased	O
by	O
administering	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

In	O
Formula	O
(	O
I	O
)	O
m	O
is	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
n	O
is	O
0	O
or	O
1	O
;	O
m	O
+	O
n	O
is	O
not	O
more	O
than	O
4	O
;	O
t	O
is	O
0	O
or	O
1	O
;	O
q	O
is	O
0	O
or	O
1	O
;	O
and	O
r	O
is	O
0	O
,	O
1	O
or	O
2	O
.	O

R6	O
is	O
hydrogen	B
,	O
methyl	B
or	O
ethyl	B
and	O
R12	O
is	O
hydrogen	B
or	O
methyl	B
,	O
or	O
R6	O
is	O
hydroxy	B
and	O
R12	O
is	O
hydrogen	B
,	O
or	O
R6	O
is	O
O	O
and	O
R12	O
is	O
absent	O
,	O
or	O
R6	O
and	O
R12	O
together	O
are	O
-CH2CH2-	B
.	O

R7	O
is	O
hydrogen	B
or	O
alkyl	B
having	O
from	O
1	O
to	O
3	O
carbon	B
atoms	O
.	O

One	O
of	O
R8	O
and	O
R9	O
is	O
alkyl	B
having	O
from	O
1	O
to	O
3	O
carbon	B
atoms	O
,	O
and	O
the	O
other	O
is	O
hydrogen	B
or	O
alkyl	B
having	O
from	O
1	O
to	O
3	O
carbon	B
atoms	O
.	O

R10	O
is	O
hydrogen	B
,	O
halo	B
,	O
alkyl	B
having	O
from	O
1	O
to	O
3	O
carbon	B
atoms	O
or	O
alkoxy	B
having	O
from	O
1	O
to	O
3	O
carbon	B
atoms	O
.	O

X	O
is	O
C	B
(	I
O	I
)	I
and	O
r	O
is	O
0	O
and	O
t	O
is	O
0	O
;	O
or	O
X	O
is	O
NH	B
(	I
R11	I
)	I
wherein	O
R11	O
is	O
hydrogen	B
or	O
alkyl	B
having	O
from	O
1	O
to	O
3	O
carbon	B
atoms	O
.	O

A	O
is	O
phenyl	B
,	O
unsubstituted	O
or	O
substituted	O
by	O
1	O
or	O
2	O
groups	O
selected	O
from	O
halo	B
,	O
hydroxy	B
,	O
methyl	B
,	O
ethyl	B
,	O
perfluoromethyl	B
,	O
methoxy	B
,	O
ethoxy	B
,	O
and	O
perfluoromethoxy	B
;	O
or	O
a	O
5	O
or	O
6	O
membered	O
heteroaromatic	B
ring	O
having	O
1	O
or	O
2	O
ring	O
heteroatoms	O
selected	O
from	O
N	B
,	O
S	B
and	O
O	B
and	O
the	O
heteroaromatic	B
ring	O
is	O
covalently	O
bound	O
to	O
the	O
remainder	O
of	O
the	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
by	O
a	O
ring	O
carbon	B
;	O
or	O
cycloalkyl	B
having	O
from	O
3	O
to	O
6	O
ring	O
carbon	B
atoms	O
wherein	O
the	O
cycloalkyl	B
is	O
unsubstituted	O
or	O
one	O
or	O
two	O
ring	O
carbons	B
are	O
independently	O
monosubstituted	O
by	O
methyl	B
or	O
ethyl	B
.	O

The	O
uric	B
acid	I
-	O
lowering	O
effects	O
of	O
the	O
Compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
used	O
to	O
treat	O
or	O
prevent	O
a	O
variety	O
of	O
conditions	O
including	O
gout	O
,	O
hyperuricemia	O
,	O
elevated	O
levels	O
of	O
uric	B
acid	I
that	O
do	O
not	O
meet	O
the	O
levels	O
customarily	O
justifying	O
a	O
diagnosis	O
of	O
hyperuricemia	O
,	O
renal	O
dysfunction	O
,	O
kidney	O
stones	O
,	O
cardiovascular	O
disease	O
,	O
risk	O
for	O
developing	O
cardiovascular	O
disease	O
,	O
tumor	O
-	O
lysis	O
syndrome	O
,	O
and	O
cognitive	O
impairment	O
.	O

Compounds	O
and	O
method	O
for	O
reducing	O
uric	B
acid	I

The	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
patients	O
(	O
either	O
adult	O
or	O
paediatric	O
)	O
with	O
tumours	O
using	O
G	O
rich	O
oligonucleotides	B
.	O

In	O
embodiments	O
of	O
the	O
invention	O
,	O
methods	O
of	O
treating	O
patients	O
with	O
tumours	O
using	O
a	O
combination	O
of	O
G	O
rich	O
oligonucleotides	B
and	O
a	O
chemotherapeutic	O
agent	O
are	O
provided	O
.	O

There	O
are	O
also	O
provided	O
pharmaceutical	O
compositions	O
and	O
kits	O
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
invention	O
.	O

Use	O
of	O
g	O
-	O
rich	O
oligonucleotides	B
for	O
treating	O
neoplastic	O
diseases	O

This	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
single	O
solid	O
oral	O
dosage	O
form	O
containing	O
an	O
effective	O
dose	O
of	O
metformin	B
and	O
an	O
effective	O
dose	O
of	O
glibenclamide	B
wherein	O
,	O
after	O
oral	O
administration	O
thereof	O
to	O
a	O
human	O
,	O
the	O
bioavailibility	O
of	O
glibenclamide	B
is	O
comparable	O
to	O
the	O
bioavailability	O
of	O
glibenclamide	B
achieved	O
by	O
oral	O
administration	O
of	O
separate	O
solid	O
oral	O
dosage	O
forms	O
to	O
a	O
human	O
,	O
one	O
containing	O
glibenclamide	B
and	O
the	O
other	O
metformin	B
,	O
in	O
the	O
same	O
respective	O
effective	O
doses	O
as	O
in	O
said	O
single	O
oral	O
dosage	O
form	O
.	O

Solid	O
orald	O
dosage	O
form	O
comprising	O
a	O
combination	O
of	O
metformin	B
and	O
glibenclamide	B

Disclosed	O
herein	O
are	O
6-oxa-2-azabicyclo	B
[	I
3.2.0	I
]	I
heptane-3,7-dione	I
or	O
heterobicyclic	B
γ	I
-	I
lactam	I
-	I
β	I
-	I
lactone	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
that	O
include	O
a	O
sulfonate	B
ester	I
,	O
ester	O
or	O
ether	O
group	O
in	O
the	O
substituent	O
at	O
the	O
4-position	O
as	O
proteasome	O
inhibitors	O
.	O

These	O
Salinosporamide	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
included	O
in	O
pharmaceutical	O
compositions	O
and	O
can	O
be	O
used	O
for	O
treating	O
or	O
ameliorating	O
a	O
disease	O
or	O
condition	O
such	O
as	O
cancer	O
,	O
a	O
microbial	O
disease	O
or	O
inflammation	O
.	O

Salinosporamide	B
derivatives	O
as	O
proteasome	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
the	O
compound	O
4-	B
(	I
acetylamino	I
)	I
-3-	I
[	I
(	I
4-chlorophenyl	I
)	I
thio	I
]	I
-2-	I
methyl-1H	I
-	I
indole	I
-	I
acetic	I
acid	I
ethyl	I
ester	I
as	O
intermediate	O
for	O
the	O
preparation	O
of	O
4-	B
(	I
acetylamino	I
)	I
-3-	I
[	I
(	I
4-chlorophenyl	I
)	I
thio	I
]	I
-2-methyl-1H	I
-	I
indole	I
-	I
acetic	I
acid	I
which	O
is	O
a	O
modulator	O
of	O
the	O
CRTh2	O
receptor	O
activity	O
useful	O
for	O
the	O
treatment	O
of	O
respiratory	O
disorders	O
.	O

4-	B
(	I
Acetylamino	I
)	I
-3-	I
[	I
(	I
4-chlorophenyl	I
)	I
thio	I
]	I
-2-methyl-1H	I
-	I
indole-1-acetic	I
acid	I
ethyl	I
ester	I
intermediate	O
compound	O

Modification	O
II	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	B
-	I
N-	I
(	I
{	I
(	I
5S	I
)	I
-2-oxo-3-	I
[	I
4-	I
(	I
3-oxo-4-morpholinyl	I
)	I
phenyl	I
]	I
-1,3-oxazolidin-5-yl	I
}	I
methyl	I
)	I
-2-thiophen	I
ecarboxamide	I
(	O
rivaroxaban	B
)	O
(	O
I	O
)	O
,	O
are	O
new	O
.	O

Modification	O
II	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	B
-	I
N-	I
(	I
{	I
(	I
5S	I
)	I
-2-oxo-3-	I
[	I
4-	I
(	I
3-oxo-4-morpholinyl	I
)	I
phenyl	I
]	I
-1,3-oxazolidin-5-yl	I
}	I
methyl	I
)	I
-2-thiophen	I
ecarboxamide	I
(	O
rivaroxaban	B
)	O
of	O
formula	O
(	O
I	O
)	O
,	O
are	O
new	O
.	O

Independent	O
claims	O
are	O
also	O
included	O
for	O
:	O
(	O
1	O
)	O
method	O
for	O
preparing	O
modification	O
II	O
by	O
either	O
:	O
(	O
a	O
)	O
dissolving	O
modification	O
I	O
in	O
inert	O
solvent	O
,	O
then	O
precipitating	O
;	O
(	O
b	O
)	O
dissolving	O
modification	O
I	O
in	O
inert	O
solvent	O
and	O
storing	O
the	O
solution	O
at	O
elevated	O
temperature	O
until	O
all	O
solvent	O
has	O
evaporated	O
;	O
or	O
(	O
c	O
)	O
suspending	O
amorphous	O
(	O
I	O
)	O
in	O
anhydrous	O
,	O
inert	O
solvent	O
and	O
stirring	O
or	O
shaking	O
the	O
suspension	O
until	O
quantitative	O
conversion	O
to	O
modification	O
II	O
has	O
occurred	O
;	O
and	O
(	O
2	O
)	O
method	O
for	O
preparing	O
amorphous	O
(	O
I	O
)	O
by	O
melting	O
crystalline	O
(	O
I	O
)	O
then	O
cooling	O
rapidly	O
.	O

[	O
Image	O
]	O
-	O
ACTIVITY	O
:	O
Thrombolytic	O
;	O
Anticoagulant	O
;	O
Cardiant	O
;	O
Antianginal	O
;	O
Vasotropic	O
;	O
Cerebroprotective	O
;	O
Antiarteriosclerotic	O
;	O
Antiinflammatory	O
;	O
Antirheumatic	O
;	O
Nootropic	O
;	O
Neuroprotective	O
;	O
Cytostatic	O
;	O
Ophthalmological	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Inhibition	O
of	O
blood	O
coagulation	O
factor	O
Xa	O
.	O

No	O
biological	O
data	O
given	O
.	O

Novel	O
polymorphic	O
form	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	B
-	I
N-	I
(	I
{	I
(	I
5S	I
)	I
-2-oxo-3-	I
[	I
4-	I
(	I
3-oxo-4-morpholinyl	I
)	I
-phenyl	I
]	I
-1,3-oxazolidin-5-yl	I
}	I
-methyl	I
)	I
-2-thiophenecarboxamide	I

A	O
process	O
for	O
producing	O
N-6	B
demethylated	I
9,10-dihydrolysergic	I
acid	I
alkyl	I
ester	I
is	O
described	O
,	O
which	O
comprises	O
a	O
step	O
of	O
N-6	O
demethylation	O
of	O
9,10-dihydrolysergic	B
acid	I
alkyl	I
esters	I
with	O
chloroformate	B
and	O
wherein	O
the	O
N-6	O
demethylation	O
step	O
is	O
performed	O
in	O
the	O
presence	O
of	O
an	O
organic	O
catalyst	O
.	O

Further	O
,	O
a	O
process	O
for	O
converting	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
(	O
DHLSAIkyl	O
)	O
into	O
a	O
compound	O
of	O
formula	O
(	O
Il	O
)	O
(	O
DHLSAIkyl	O
-	O
F	O
)	O
comprises	O
the	O
steps	O
of	O
:	O
providing	O
(	O
and	O
maintaining	O
)	O
a	O
reaction	O
medium	O
free	O
of	O
water	O
and/or	O
HCI	B
,	O
and	O
reacting	O
DHLSAIkyl	O
with	O
chloroformate	B
in	O
said	O
reaction	O
medium	O
free	O
of	O
water	O
and/or	O
HCI	B
,	O
to	O
obtain	O
the	O
compound	O
of	O
formula	O
(	O
Il	O
)	O
(	O
DHLSAIkyl	O
-	O
F	O
)	O
.	O

Preparation	O
of	O
n-6	B
demethylated	I
,	I
9	I
-	I
10-dihydrolysergic	I
acid	I
alkyl	I
esters	I

Compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
N	B
-	I
oxides	I
thereof	O
;	O
formula	O
(	O
I	O
)	O
(	O
relative	O
chemistry	O
shown	O
)	O
pharmaceutical	O
compositions	O
comprising	O
them	O
,	O
their	O
use	O
in	O
therapy	O
especially	O
against	O
tuberculosis	O
,	O
and	O
methods	O
of	O
preparing	O
them	O
.	O

Tricyclic	B
nitrogen	I
containing	O
compounds	O
and	O
their	O
use	O
as	O
antibacterials	O

Subject	O
of	O
the	O
present	O
invention	O
are	O
assays	O
and	O
in	O
vitro	O
methods	O
for	O
the	O
in	O
vitro	O
diagnosis	O
,	O
prognosis	O
and	O
risk	O
stratification	O
of	O
a	O
patient	O
having	O
a	O
primary	O
,	O
non	O
-	O
infectious	O
disease	O
,	O
whereby	O
the	O
level	O
of	O
Procalcitonin	O
(	O
PCT	O
)	O
in	O
a	O
sample	O
of	O
a	O
body	O
fluid	O
of	O
the	O
patient	O
is	O
indicative	O
for	O
the	O
risk	O
of	O
the	O
patient	O
to	O
contract	O
a	O
further	O
disease	O
or	O
medical	O
condition	O
.	O

Antibiotic	O
for	O
use	O
in	O
local	O
infection	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
phentermine	O
and	O
a	O
selective	O
5HT-2C	O
receptor	O
agonist	O
.	O

In	O
addition	O
,	O
the	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
phentermine	B
and	O
a	O
selective	O
5HT-2C	O
receptor	O
agonist	O
having	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
hydrate	O
thereof	O
.	O

The	O
compositions	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
whose	O
use	O
includes	O
the	O
treatment	O
of	O
obesity	O
.	O

5HT2C	O
receptor	O
modulator	O
compositions	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
describes	O
compounds	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
use	O
in	O
therapy	O
.	O

Iap	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
class	O
of	O
rosamine	B
derivatives	O
,	O
in	O
one	O
embodiment	O
,	O
the	O
compounds	O
have	O
the	O
structure	O
(	O
I	O
)	O
or	O
any	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
:	O
R1	O
represents	O
aryl	B
,	O
Het1	O
or	O
C1	B
-	I
6	I
alkyl	I
,	O
which	O
latter	O
group	O
is	O
optionally	O
substituted	O
by	O
aryl	B
or	O
Het2	O
;	O
R2a	O
and	O
R2b	O
together	O
form	O
C3.8	B
n	I
-	I
alkylene	I
,	O
which	O
alkylene	B
group	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halo	B
,	O
C1	B
-	I
4	I
alkyl	I
,	O
C	B
(	I
O	I
)	I
OH	I
and	O
C	B
(	I
O	I
)	I
O	I
-	I
C1	I
-	I
4	I
,	I
alkyl.and	I
which	O
alkylene	B
group	O
is	O
optionally	O
interrupted	O
by	O
X1	O
;	O
R3a	O
and	O
R3b	O
together	O
form	O
C3	B
-	I
6	I
/7-alkylene	I
,	O
which	O
alkylene	B
group	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halo	B
,	O
C1	B
-	I
4	I
alkyl	I
,	O
C	B
(	I
O	I
)	I
OH	I
and	O
C	B
(	I
O	I
)	I
O	I
-	I
C1	I
-	I
4	I
alkyl	I
,	O
and	O
which	O
alkylene	B
group	O
is	O
optionally	O
interrupted	O
by	O
X2	O
;	O
X1	O
and	O
X2	O
independently	O
represent	O
O	B
,	O
S	B
,	O
or	O
NR4	B
;	O
R4	O
represents	O
,	O
independently	O
at	O
each	O
occurrence	O
,	O
H	B
,	O
C	B
(	I
O	I
)	I
OR5	I
,	O
C	B
(	I
0	I
)	I
R6a	I
,	O
C	B
(	I
O	I
)	I
N	I
(	I
R6b	I
)	I
R6c	I
or	O
C1	B
-	I
6	I
,	I
alkyl	I
,	O
which	O
latter	O
group	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halo	B
,	O
aryl	B
and	O
Het3	O
or	O
is	O
substituted	O
by	O
a	O
single	O
C	B
(	I
0	I
)	I
0R1a	I
group	O
;	O
R4a	O
represents	O
H	B
or	O
C1	B
-	I
4	I
alkyl	I
;	O
R5	O
represents	O
aryl	B
,	O
Het4	O
or	O
C1	B
-	I
6	I
alkyl	I
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halo	B
,	O
aryl	B
and	O
Het5	O
;	O
R5e	O
to	O
R6d	O
independently	O
represent	O
H	B
or	O
R5	O
;	O
each	O
aryl	B
independently	O
represents	O
a	O
C6	B
-	I
10	I
carbocyclic	I
aromatic	I
group	O
,	O
which	O
group	O
may	O
comprise	O
either	O
one	O
or	O
two	O
rings	O
and	O
may	O
be	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halo	B
,	O
CN	B
,	O
C1	B
-	I
6	I
alkyl	I
(	O
which	O
latter	O
group	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halo	B
,	O
OR7	B
,	O
phenyl	B
,	O
naphthyl	B
and	O
Het6	O
)	O
and	O
OR8	B
;	O
R7	O
and	O
R8	O
independently	O
represent	O
H	B
,	O
C1	B
-	I
4	I
alkyl	I
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
halo	B
groups	O
or	O
by	O
a	O
single	O
phenyl	B
or	O
C	B
(	I
O	I
)	I
OR8a	I
substituent	O
)	O
,	O
Het7	O
,	O
phenyl	B
or	O
naphthyl	B
;	O
R8a	O
represents	O
H	O
or	O
C1	B
-	I
4	I
alkyl	I
;	O
Het1	O
to	O
Het7	O
independently	O
represent	O
5-	O
to	O
10-membered	O
aromatic	O
,	O
fully	O
saturated	O
or	O
partially	O
unsaturated	O
heterocyclic	O
groups	O
containing	O
one	O
or.more	O
heteroatoms	O
selected	O
from	O
oxygen	B
,	O
nitrogen	B
and/or	O
sulfur	B
,	O
which	O
heterocyclic	B
groups	O
may	O
comprise	O
one	O
or	O
two	O
rings	O
and	O
may	O
be	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
Halo	B
,	O
CN	B
,	O
C1	B
-	I
6	I
alkyl	I
(	O
which	O
latter	O
group	O
is	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
halo	B
,	O
OR9	B
and	O
phenyl	B
)	O
and	O
OR10	B
;	O
R9	O
and	O
R10	O
independently	O
represent	O
H	B
,	O
C1	B
-	I
4	I
alkyl	I
or	O
phenyl	B
;	O
unless	O
otherwise	O
specified	O
,	O
alkyl	B
groups	O
are	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
halo	B
atoms	O
;	O
and	O
A	O
'	O
represents	O
a	O
pharmaceutically	O
acceptable	O
anion	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
making	O
and	O
using	O
'	O
compounds	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
.	O

Rosamine	B
derivatives	O
as	O
agents	O
for	O
the	O
treatment	O
of	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
asthma	O
and	O
other	O
airway	O
dysfunctions	O
,	O
diseases	O
and/or	O
symptoms	O
thereof	O
,	O
more	O
particularly	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cytostatic	O
and/or	O
cytotoxic	O
purine	B
analogues	O
for	O
such	O
treatment	O
and	O
prophylaxis	O
.	O

Use	O
of	O
purine	B
analogues	O
for	O
treating	O
airway	O
diseases	O

The	O
present	O
invention	O
relates	O
in	O
general	O
to	O
an	O
inhibitor	O
of	O
a	O
glutaminyl	O
peptide	O
cyclotransferase	O
-	O
like	O
protein	O
(	O
QPCTL	O
)	O
,	O
and	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
an	O
inflammatory	O
disease	O
or	O
disorderselected	O
from	O
the	O
group	O
consisting	O
of	O
a.chronic	O
and	O
acute	O
inflammations	O
,	O
e.g.	O
rheumatoid	O
arthritis	O
,	O
atherosclerosis	O
,	O
restenosis	O
,	O
pancreatitis	O
,	O
b.other	O
inflammatory	O
diseases	O
,	O
e.g.	O
neuropathic	O
pain	O
,	O
graft	O
rejection	O
/	O
graft	O
failure	O
/	O
graft	O
vasculopathy	O
,	O
HIV	O
infections	O
/	O
AIDS	O
,	O
gestosis	O
,	O
tuberous	O
sclerosis	O
,	O
Guillain	O
-	O
Barr	O
syndrome	O
,	O
chronic	O
inflammatory	O
demyelinising	O
polyradiculoneuropathy	O
and	O
multiple	O
sclerosis	O
,	O
c.neuroinflammation	O
,	O
and	O
d.neurodegenerative	O
diseases	O
,	O
e.g.	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
,	O
Alzheimer	O
's	O
disease	O
,	O
neurodegeneration	O
in	O
Down	O
Syndrome	O
,	O
Familial	O
British	O
Dementia	O
,	O
and	O
Familial	O
Danish	O
Dementia	O
,	O
which	O
may	O
result	O
from	O
neuroinflammation	O
.	O

Use	O
of	O
isoQC	O
inhibitors	O

Compounds	O
are	O
provided	O
according	O
to	O
formula	O
(	O
I	O
)	O
,	O
where	O
A	O
,	O
B	O
,	O
W	O
,	O
X	O
'	O
,	O
L	O
,	O
R1	O
,	O
R3	O
,	O
R4b	O
,	O
and	O
m	O
'	O
are	O
as	O
defined	O
herein	O
.	O

Provided	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non	O
-	O
limiting	O
example	O
,	O
pain	O
,	O
inflammation	O
,	O
cognitive	O
disorders	O
,	O
anxiety	O
,	O
depression	O
,	O
and	O
others	O
.	O

Modulators	O
of	O
p2x3	O
receptor	O
activity	O

The	O
preparation	O
of	O
flupirtine	B
carboxylate	I
acid	I
addition	O
salts	O
having	O
the	O
following	O
formula	O
(	O
2	O
)	O
,	O
wherein	O
R	O
represents	O
hydrogen	B
or	O
a	O
C1-C6	B
alkyl	I
group	O
,	O
with	O
the	O
proviso	O
that	O
RCOOH	B
is	O
neither	O
maleic	B
acid	I
nor	O
gluconic	B
acid	I
,	O
is	O
described	O
.	O

Carboxylic	B
acid	I
salts	O
of	O
2-amino-3-carbethoxyamino-6-	B
(	I
4-fluoro	I
-	I
benzylamino	I
)	I
-pyridine	I

The	O
invention	O
relates	O
to	O
an	O
injectable	O
aqueous	O
composition	O
of	O
hyaluronic	O
acid	O
or	O
one	O
of	O
the	O
salts	O
thereof	O
,	O
one	O
or	O
more	O
polyol	O
(	O
s	O
)	O
and	O
lidocaine	B
.	O

Said	O
composition	O
,	O
used	O
for	O
cosmetic	O
purposes	O
or	O
for	O
therapeutic	O
purposes	O
,	O
has	O
improved	O
viscoelastic	O
rheological	O
properties	O
and	O
long	O
in	O
vivo	O
persistence	O
.	O

The	O
polyol	O
is	O
chosen	O
,	O
for	O
example	O
,	O
from	O
glycerol	B
,	O
sorbitol	B
,	O
propylene	B
glycol	I
,	O
mannitol	B
,	O
erythritol	B
,	O
xylitol	B
,	O
maltitol	B
and	O
lactitol	B
.	O

Said	O
particular	O
properties	O
are	O
obtained	O
by	O
heat	O
sterilising	O
the	O
mixture	O
.	O

Heat	O
sterilised	O
injectable	O
composition	O
of	O
hyaluronic	O
acid	O
or	O
one	O
of	O
the	O
salts	O
thereof	O
,	O
polyols	O
and	O
lidocaine	B

The	O
present	O
invention	O
relates	O
to	O
compounds	O
I	O
suitable	O
for	O
use	O
in	O
mediating	O
hypoxia	O
inducible	O
factor	O
and	O
for	O
treating	O
erythropoietin	O
-	O
associated	O
conditions	O
by	O
increasing	O
endogenous	O
erythropoietin	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

isoquinoline	O
derivatives	O
AND	O
THEIR	O
USE	O
IN	O
INCREASING	O
ENDOGENEOUS	O
ERYTHROPOIETIN	O

Provided	O
herein	O
are	O
isoindoline	B
compounds	O
such	O
as	O
those	O
of	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
of	O
such	O
compounds	O
,	O
and	O
methods	O
of	O
their	O
use	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
managing	O
various	O
diseases	O
.	O

Formula	O
(	O
I	O
)	O
Isoindoline	B
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O

There	O
is	O
provided	O
an	O
adhesive	O
preparation	O
containing	O
5-methyl-1-phenyl-2-	B
(	I
1H	I
)	I
-pyridone	I
.	O

The	O
adhesive	O
preparation	O
is	O
a	O
5-methyl-1-phenyl-2-	B
(	I
1H	I
)	I
-pyridone	I
-	O
containing	O
adhesive	O
preparation	O
including	O
an	O
active	O
medicinal	O
ingredient	O
-	O
containing	O
layer	O
,	O
characterized	O
in	O
that	O
the	O
active	O
medicinal	O
ingredient	O
-	O
containing	O
layer	O
contains	O
an	O
lipophilic	O
base	O
,	O
a	O
dissolving	O
agent	O
(	O
except	O
glycerin	B
and	O
a	O
medium	O
-	O
chain	O
aliphatic	B
acid	I
triglyceride	I
)	O
,	O
and	O
5-methyl-1-phenyl-2-	B
(	I
1H	I
)	I
-pyridone	I
or	O
medically	O
acceptable	O
salts	O
thereof	O
.	O

Adhesive	O
material	O
containing	O
5-methyl-1-phenyl-2-	B
(	I
1h	I
)	I
-pyridone	I

The	O
subject	O
of	O
the	O
inventions	O
are	O
a	O
compound	O
,	O
a	O
process	O
for	O
its	O
preparation	O
,	O
a	O
pharmaceutical	O
composition	O
,	O
use	O
of	O
a	O
compound	O
,	O
a	O
method	O
for	O
modulating	O
or	O
regulating	O
serine	B
/	O
threonine	B
kinases	O
and	O
a	O
serine	B
/	O
threonine	B
kinases	O
modulating	O
agent	O
.	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
small	O
-	O
molecule	O
compounds	O
with	O
kinase	O
inhibitory	O
activity	O
,	O
having	O
superior	O
properties	O
as	O
pharmaceutical	O
agents	O
,	O
production	O
method	O
thereof	O
and	O
uses	O
thereof	O
.	O

In	O
particular	O
,	O
this	O
invention	O
relates	O
to	O
new	O
derivatives	O
of	O
tetrabromobenzimidazole	B
with	O
serine	B
/	O
threonine	B
kinases	O
inhibitory	O
properties	O
,	O
preferably	O
selected	O
from	O
the	O
group	O
of	O
Pim	O
,	O
HIPK	O
,	O
DYRK	O
and	O
CLK	O
kinases	O
,	O
which	O
exhibits	O
superior	O
pharmacological	O
actions	O
,	O
and	O
can	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
disease	O
conditions	O
,	O
especially	O
cancers	O
depending	O
on	O
serine	B
/	O
threonine	B
kinases	O
,	O
such	O
as	O
leukemias	O
and	O
prostate	O
cancer	O
.	O

A	O
compound	O
,	O
a	O
process	O
for	O
its	O
preparation	O
,	O
a	O
pharmaceutical	O
composition	O
,	O
use	O
of	O
a	O
compound	O
,	O
a	O
method	O
for	O
modulating	O
or	O
regulating	O
serine	O
/	O
threonine	B
kinases	O
and	O
a	O
serine	B
/	O
threonine	B
kinases	O
modulating	O
agent	O

A	O
method	O
of	O
treating	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
sexual	O
dysfunction	O
or	O
erectile	O
dysfunction	O
in	O
a	O
man	O
by	O
administration	O
of	O
a	O
5alpha	O
reductase	O
inhibitor	O
together	O
with	O
a	O
testosterone	O
supplement	O
is	O
described	O
.	O

The	O
method	O
is	O
also	O
concerned	O
with	O
the	O
use	O
of	O
the	O
5alpha	O
reductase	O
inhibiting	O
compound	O
and	O
the	O
testosterone	O
supplement	O
together	O
with	O
another	O
agent	O
useful	O
for	O
treating	O
erectile	O
dysfunction	O
,	O
including	O
PDE	O
V	O
inhibitors	O
;	O
AGE	O
(	O
advanced	O
glycation	O
end	O
-	O
product	O
)	O
breakers	O
;	O
alpha	O
1	O
blockers	O
;	O
alpha	O
1A	O
antagonists	O
;	O
alpha	O
2	O
antagonists	O
;	O
dopamine	O
agonists	O
;	O
dopamine	O
D4	O
agonists	O
;	O
melanocortin	O
agonists	O
;	O
oxytocin	O
agonists	O
;	O
prostaglandin	O
;	O
radical	O
scavengers	O
;	O
rotamase	O
inhibitors	O
;	O
aviptadil	O
;	O
nitroglycerine	O
;	O
and	O
GPCR	O
agonists	O
for	O
treating	O
male	O
sexual	O
dysfunction	O
or	O
erectile	O
dysfunction	O
.	O

Method	O
of	O
treating	O
men	O
with	O
testosterone	O
supplement	O
and	O
5alpha	O
reductase	O
inhibitor	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
general	O
formulae	O
(	O
8a	O
-	O
i	O
)	O
,	O
(	O
11a	O
-	O
i	O
)	O
,	O
(	O
14a	O
-	O
i	O
)	O
,	O
and	O
(	O
17a	O
-	O
i	O
)	O
,	O
useful	O
as	O
potential	O
antitumour	O
agents	O
against	O
human	O
cancer	O
cell	O
lines	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
process	O
for	O
the	O
preparation	O
of	O
Cinnamido	B
-	I
pyrrolo	I
[	I
2,1-c	I
]	I
[	I
1,4	I
]	I
benzodiazepines	I
of	O
general	O
formulae	O
(	O
8a	O
-	O
i	O
)	O
,	O
(	O
11a	O
-	O
i	O
)	O
,	O
(	O
14a	O
-	O
i	O
)	O
,	O
and	O
(	O
17a	O
-	O
i	O
)	O
.	O

Cinnamido	B
-	I
pvrrolor	I
[	I
2,1-c	I
]	I
[	I
1,4	I
]	I
benzodiazepines	I
as	O
potential	O
anticancer	O
agents	O
and	O
process	O
for	O
the	O
preparation	O
thereof	O

[	O
Problems	O
]	O

The	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
Medical	O
Drugs	O
which	O
reduce	O
damage	O
of	O
gastrointestinal	O
mucosal	O
induced	O
by	O
NSAIDs	O
.	O

[	O
Means	O
for	O
Solving	O
Problems	O
]	O

The	O
Medical	O
Drugs	O
that	O
comprises	O
a	O
mixture	O
of	O
NSAIDs	O
and	O
sugar	B
that	O
reduce	O
damage	O
of	O
gastrointestinal	O
mucosal	O
induced	O
by	O
NSAIDs	O
is	O
already	O
known	O
.	O

However	O
the	O
mixture	O
is	O
not	O
enough	O
to	O
suppress	O
damage	O
of	O
gastrointestinal	O
mucosal	O
.	O

The	O
inventors	O
invented	O
new	O
molecular	O
compounds	O
with	O
NSAIDs	O
and	O
trehalose	B
.	O

The	O
new	O
molecular	O
compounds	O
effectively	O
reduce	O
damage	O
of	O
gastrointestinal	O
mucosal	O
induced	O
by	O
NSAIDs	O
.	O

Nsaids	O
-	O
induced	O
gastrointestinal	O
mucosal	O
disorder	O
alleviator	O
and	O
manufacturing	O
method	O
thereof	O

A	O
dinitrate	O
ester	O
of	O
a	O
valsartanamide	B
is	O
described	O
.	O

It	O
has	O
superior	O
properties	O
in	O
the	O
treatment	O
of	O
vascular	O
and	O
metabolic	O
diseases	O
.	O

A	O
valsartanamide	B
dinitrate	I
derivative	O
for	O
the	O
treatment	O
of	O
vascular	O
and	O
metabolic	O
diseases	O

Provided	O
are	O
compounds	O
having	O
an	O
inhibitory	O
effect	O
on	O
Mixed	O
Lineage	O
Kinases	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
preparing	O
the	O
compounds	O
,	O
synthetic	O
intermediates	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
,	O
independently	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
,	O
for	O
treating	O
diseases	O
and	O
conditions	O
which	O
are	O
affected	O
by	O
Mixed	O
Lineage	O
Kinase	O
inhibition	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
which	O
comprise	O
the	O
inhibition	O
of	O
Mixed	O
Lineage	O
Kinases	O
.	O

Mlk	O
inhibitors	O
and	O
methods	O
of	O
use	O

The	O
invention	O
refers	O
to	O
the	O
use	O
of	O
a	O
sigma	O
ligand	O
,	O
preferably	O
a	O
sigma	O
ligand	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
prevent	O
or	O
treat	O
emesis	O
induced	O
by	O
a	O
chemotherapeutic	O
agent	O
or	O
radioactivity	O
,	O
especially	O
emesis	O
induced	O
by	O
taxanes	O
,	O
vinca	O
alkaloids	B
or	O
platin	O
chemotherapeutic	O
drugs	O
.	O

Sigma	O
ligands	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
emesis	O
induced	O
by	O
chemotherapy	O
or	O
radiotherapy	O

An	O
oral	O
pharmaceutical	O
composition	O
of	O
dutasteride	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
comprising	O
admixture	O
of	O
a	O
)	O
dutasteride	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
;	O
b	O
)	O
one	O
or	O
more	O
surfactant	O
(	O
s	O
)	O
/co	O
-	O
surfactant	O
(	O
s	O
)	O
;	O
c	O
)	O
one	O
or	O
more	O
oil	O
(	O
s	O
)	O
;	O
d	O
)	O
optionally	O
antioxidant	O
(	O
s	O
)	O
;	O
and	O
e	O
)	O
optionally	O
excipient	O
(	O
s	O
)	O
;	O
wherein	O
the	O
composition	O
upon	O
dilution	O
with	O
aqueous	O
medium	O
forms	O
microemulsion	O
with	O
atleast	O
95	O
%	O
particles	O
having	O
mean	O
particle	O
size	O
below	O
200	O
nm	O
.	O

An	O
oral	O
pharmaceutical	O
composition	O
of	O
dutasteride	B

There	O
is	O
provided	O
an	O
inhibitor	O
that	O
inhibits	O
casein	O
kinase	O
1δ	O
and	O
casein	O
kinase	O
1ε	O
,	O
and	O
thus	O
,	O
there	O
is	O
also	O
provided	O
a	O
pharmaceutical	O
agent	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
a	O
disease	O
,	O
with	O
the	O
pathological	O
condition	O
of	O
which	O
the	O
mechanism	O
of	O
activation	O
of	O
casein	O
kinase	O
1δ	O
or	O
casein	O
kinase	O
1ε	O
is	O
associated	O
.	O

Particularly	O
,	O
the	O
above	O
-	O
described	O
inhibitor	O
is	O
used	O
to	O
provide	O
a	O
pharmaceutical	O
agent	O
useful	O
for	O
the	O
treatment	O
of	O
circadian	O
rhythm	O
disorder	O
(	O
including	O
sleep	O
disorder	O
)	O
,	O
central	O
neurodegenerative	O
disease	O
,	O
and	O
cancer	O
.	O

An	O
inhibitor	O
of	O
casein	O
kinase	O
1δ	O
and	O
casein	O
kinase	O
1ε	O
,	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
an	O
oxazolone	B
derivative	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
,	O
a	O
salt	O
thereof	O
,	O
a	O
solvate	O
thereof	O
,	O
or	O
a	O
hydrate	O
thereof	O
:	O
[	O
wherein	O
,	O
in	O
the	O
formula	O
(	O
1	O
)	O
,	O
each	O
of	O
R1	O
and	O
R2	O
independently	O
represents	O
any	O
one	O
of	O
a	O
substituted	O
or	O
unsubstituted	O
6-membered	O
or	O
5-membered	O
heterocyclic	O
group	O
optionally	O
having	O
a	O
condensed	O
ring	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	B
hydrocarbon	I
group	O
optionally	O
having	O
a	O
condensed	O
ring	O
,	O
and	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	B
hydrocarbon	I
lower	O
alkyl	B
group	O
or	O
aromatic	B
hydrocarbon	I
lower	O
alkenyl	B
group	O
optionally	O
having	O
a	O
condensed	O
ring	O
.	O
]	O

Inhibitor	O
of	O
casein	O
kinase	O
1delta	O
and	O
casein	O
kinase	O
1epsilon	O

2',3'-Dideoxy-3'-fluoro-4-thiothymidine	B
(	O
4-SFLT	B
)	O
derivatives	O
according	O
to	O
the	O
invention	O
substituted	O
at	O
5'-O	B
position	O
of	O
4-SFLT	B
with	O
12-tetradodecanoyl	B
,	O
12-bromododecanoyl	B
,	O
12-metoxydodecanoyl	B
,	O
12-ethylothiododecanoyl	B
,	O
11-ethylothioundecanoyl	B
or	O
12-azidodocanoyl	B
group	O
(	O
represented	O
by	O
the	O
symbols	O
WA18	O
,	O
WA19	O
,	O
WA21,WA22,WA23	O
and	O
WA20	O
in	O
the	O
deCIPhR	O
™	O
cell	O
system	O
exert	O
high	O
antiviral	O
activity	O
against	O
wild	O
type	O
HIV-1	O
strain	O
,	O
as	O
well	O
as	O
against	O
its	O
drug	O
and	O
multidrug	O
resistant	O
strains	O
,	O
and	O
moreover	O
very	O
low	O
citotoxicity	O
(	O
CC50	O
>	O
200	O
µM	O
)	O
and	O
very	O
high	O
selectivity	O
.	O

The	O
compounds	O
,	O
because	O
of	O
lack	O
of	O
toxicity	O
may	O
be	O
applied	O
at	O
all	O
AIDS	O
phases	O
i.e.	O
also	O
them	O
the	O
T4	O
lymphocytes	O
level	O
in	O
patients	O
drops	O
down	O
below	O
200	O
/	O
µL	O
of	O
peripheral	O
blood	O
.	O

2',3'-Dideoxy-3'-fluoro-4-thiothymidine	B
derivatives	O
according	O
to	O
the	O
invention	O
are	O
synthesized	O
by	O
the	O
transformation	O
of	O
the	O
known	O
compound	O
2',3'-dideoxy-3'-fluoro-4-thiothymidine	B
(	O
4-SFLT	B
)	O
.	O

Modified	O
2',3'-dideoxynucleosides	B
for	O
treatment	O
infections	O
caused	O
by	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
multidrug	O
resistant	O
strains	O
,	O
method	O
of	O
their	O
synthesis	O
and	O
the	O
pharmaceutical	O
agent	O
containing	O
these	O
nucleosides	O

Methods	O
and	O
compositions	O
containing	O
a	O
berberine	B
related	O
compound	O
are	O
provided	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
and	O
cardiovascular	O
disorders	O
including	O
metabolic	O
syndrome	O
,	O
hyperlipidemia	O
,	O
obesity	O
,	O
diabetes	O
,	O
insulin	O
resistance	O
,	O
hyperglycemia	O
,	O
hypertension	O
and	O
elevated	O
cholesterol	B
in	O
mammalian	O
subjects	O
.	O

The	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
are	O
effective	O
for	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
syndrome	O
,	O
hyperlipidemia	O
,	O
obesity	O
,	O
diabetes	O
,	O
insulin	O
resistance	O
,	O
hyperglycemia	O
,	O
hypertension	O
and	O
elevated	O
cholesterol	B
.	O

Additional	O
compositions	O
and	O
methods	O
are	O
provided	O
which	O
employ	O
a	O
berberine	B
related	O
or	O
derivative	O
compound	O
including	O
demethylated	O
derivatives	O
in	O
combination	O
with	O
a	O
second	O
anti-	O
therapeutic	O
agent	O
to	O
yield	O
more	O
effective	O
treatment	O
tools	O
against	O
metabolic	O
disorders	O
,	O
and/or	O
dual	O
activity	O
therapeutic	O
methods	O
and	O
formulations	O
useful	O
to	O
prevent	O
or	O
reduce	O
hyperlipidemia	O
and/or	O
hyperglycemia	O
and	O
one	O
or	O
more	O
causal	O
or	O
related	O
symptoms	O
or	O
conditions	O
associated	O
with	O
hyperlipidemia	O
and/or	O
hyperglycemia	O
in	O
mammalian	O
subjects	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
metabolic	O
and	O
cardiovascular	O
disorders	O

This	O
invention	O
provides	O
an	O
isolated	O
nucleic	O
acid	O
molecule	O
which	O
encodes	O
immunoglobulin	O
receptor	O
,	O
Immunoglobulin	O
superfamily	O
Receptor	O
Translocation	O
Associated	O
,	O
IRTA	O
,	O
protein	O
.	O

Provided	O
too	O
,	O
are	O
the	O
IRTA	O
proteins	O
encoded	O
by	O
the	O
isolated	O
nucleic	O
acid	O
molecules	O
,	O
IRTA1	O
,	O
IRTA2	O
,	O
IRTA3	O
,	O
IRTA4	O
or	O
IRTA5	O
proteins	O
,	O
having	O
the	O
amino	B
acid	I
sequences	O
set	O
forth	O
in	O
any	O
of	O
Figures	O
18A	O
,	O
18B-1	O
-	O
18B-3	O
,	O
18C-1	O
-	O
18C-2	O
,	O
18D-1	O
-	O
18D-2	O
or	O
18E-1	O
-	O
18E-2	O
.	O

Oligonucleotides	B
of	O
the	O
isolated	O
nucleic	O
acid	O
molecules	O
are	O
provided	O
.	O

Antibodies	O
directed	O
to	O
an	O
epitope	O
of	O
a	O
purified	O
IRTA1	O
,	O
IRTA2	O
,	O
IRTA3	O
,	O
IRTA4	O
or	O
IRTA5	O
proteins	O
are	O
also	O
provided	O
,	O
as	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
antibodies	O
or	O
oligonucleotides	B
.	O

Methods	O
for	O
detecting	O
a	O
B	O
cell	O
malignancy	O
in	O
a	O
sample	O
from	O
a	O
subject	O
;	O
diagnosing	O
B	O
cell	O
malignancy	O
in	O
a	O
sample	O
from	O
a	O
subject	O
;	O
detecting	O
human	O
IRTA	O
protein	O
in	O
a	O
sample	O
;	O
and	O
treating	O
a	O
subject	O
having	O
a	O
B	O
cell	O
cancer	O
are	O
also	O
provided	O
.	O

Isolation	O
of	O
five	O
novel	O
genes	O
coding	O
for	O
new	O
fc	O
receptors	O
-	O
type	O
melanoma	O
involved	O
in	O
the	O
pathogenesis	O
of	O
lymphoma	O
/	O
melanoma	O

The	O
present	O
invention	O
provides	O
a	O
means	O
for	O
prevention	O
and	O
treatment	O
of	O
sarcopenia	O
by	O
administration	O
of	O
a	O
substance	O
that	O
both	O
reduces	O
the	O
sensibility	O
of	O
beta	O
-	O
adrenergic	O
receptors	O
and	O
of	O
5-HT1a	O
receptors	O
.	O

(	B
S	I
)	I
-pindolol	I
,	O
(	B
S	I
)	I
-propanol	I
,	O
tertatolol	B
or	O
bopindolol	B
are	O
preferred	O
for	O
this	O
purpose	O
.	O

Prevention	O
and	O
treatment	O
of	O
sarcopenia	O

The	O
present	O
invention	O
relates	O
to	O
methylene	B
urea	I
derivatives	O
of	O
formula	O
I	O
,	O
the	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
inhibitors	O
of	O
raf	O
-	O
kinase	O
,	O
the	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
and	O
a	O
method	O
of	O
treatment	O
,	O
comprising	O
administering	O
said	O
pharmaceutical	O
composition	O
to	O
a	O
patient	O
.	O

Methylene	B
urea	I
derivative	O
as	O
RAF	O
kinasse	O
inhibitors	O

The	O
present	O
invention	O
discloses	O
compositions	O
of	O
facially	O
amphiphilic	O
polymers	O
and	O
oligomers	B
and	O
their	O
use	O
in	O
methods	O
for	O
treating	O
or	O
reducing	O
cancers	O
in	O
humans	O
or	O
animals	O
.	O

Facially	O
amphiphilic	O
polymers	O
and	O
oligomers	B
,	O
compositions	O
thereof	O
,	O
and	O
use	O
thereof	O
in	O
methods	O
of	O
treating	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
intermediate	O
compounds	O
used	O
in	O
preparing	O
Rosuvastatin	B
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
to	O
a	O
method	O
for	O
preparing	O
same	O
,	O
and	O
to	O
a	O
method	O
for	O
preparing	O
Rosuvastatin	B
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
from	O
the	O
intermediates	O
.	O

The	O
preparation	O
method	O
of	O
the	O
present	O
invention	O
has	O
the	O
effect	O
of	O
providing	O
Rosuvastatin	B
hemi	B
-	I
calcium	I
salts	O
with	O
an	O
excellent	O
yield	O
rate	O
.	O

Novel	O
method	O
for	O
preparing	O
rosuvastatin	B
,	O
intermediate	O
compounds	O
useful	O
for	O
preparing	O
same	O
,	O
and	O
method	O
for	O
preparing	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
an	O
outer	O
eye	O
disorder	O
selected	O
from	O
a	O
cataract	O
,	O
neovascularization	O
,	O
keratitis	O
,	O
epithelium	O
deficiency	O
,	O
or	O
chronic	O
opacity	O
,	O
by	O
administering	O
to	O
the	O
eye	O
a	O
composition	O
comprising	O
acidic	O
electrolytic	O
water	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
stable	O
acidic	O
electrolyzed	O
oxidizing	O
water	O
characterized	O
by	O
low	O
conductivity	O
,	O
the	O
presence	O
of	O
dissolved	O
chlorine	B
gas	O
(	O
Cl2	B
)	O
,	O
hypochlorous	B
acid	I
(	O
HOCl	B
)	O
and	O
chloride	B
ions	I
(	O
Cl-	B
)	O
,	O
and	O
by	O
the	O
presence	O
of	O
negligible	O
quantities	O
of	O
hypochlorite	B
ion	I
(	O
OCl-	B
)	O
.	O

Methods	O
of	O
treating	O
outer	O
eye	O
disorders	O
using	O
high	O
orp	O
acid	O
water	O
and	O
compositions	O
thereof	O

The	O
present	O
invention	O
concerns	O
a	O
substituted	O
pyrrolidinone	B
of	O
the	O
following	O
formula	O
I	O
or	O
a	O
salt	O
,	O
solvate	O
,	O
tautomer	O
,	O
isotope	O
,	O
enantiomer	O
,	O
diastereoisomer	O
or	O
racemic	O
mixture	O
thereof	O
:	O
(	O
I	O
)	O
,	O
for	O
the	O
treatment	O
of	O
hepatitis	O
C.	O
Substituted	O
pyrrolidinone	B
as	O
inhibitors	O
of	O
hepatitis	O
c	O
ns5b	O
polymerase	O
,	O
the	O
pharmaceutical	O
composition	O
thereof	O
and	O
their	O
therapeutic	O
use	O

The	O
invention	O
relates	O
to	O
FGF	O
receptor	O
-	O
activating	O
N	B
-	I
sulfate	I
oligosaccharides	B
having	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R4	O
,	O
R6	O
,	O
and	O
R8	O
are	O
OSO3-	B
or	O
hydroxyl	B
groups	O
,	O
R2	O
is	O
an	O
O	B
-	I
alkyl	I
group	O
or	O
a	O
monosaccharide	B
having	O
Formula	O
(	O
II	O
)	O
,	O
R3	O
is	O
a	O
disaccharide	B
having	O
Formula	O
(	O
III	O
)	O
,	O
R5	O
is	O
a	O
disaccharide	B
having	O
Formula	O
(	O
IV	O
)	O
,	O
R7	O
is	O
a	O
hydroxyl	B
group	O
or	O
a	O
disaccharide	B
having	O
Formula	O
(	O
VI	O
)	O
,	O
and	O
R9	O
is	O
a	O
hydroxyl	B
or	O
O	B
-	I
alkyl	I
group	O
or	O
a	O
disaccharide	B
having	O
Formula	O
(	O
VII	O
)	O
,	O
where	O
R10	O
is	O
an	O
O	B
-	I
alkyl	I
group	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
preparation	O
of	O
said	O
oligosaccharides	B
and	O
to	O
the	O
therapeutic	O
use	O
thereof	O
.	O

N	O
-	O
sulfated	O
oligosaccharides	O
activating	O
fgfs	O
receptors	O
,	O
their	O
synthesis	O
and	O
their	O
therapeutical	O
application	O

Methods	O
of	O
treating	O
or	O
suppressing	O
mitochondrial	O
diseases	O
,	O
such	O
as	O
Friedreich	O
's	O
ataxia	O
(	O
FRDA	O
)	O
,	O
Leber	O
's	O
Hereditary	O
Optic	O
Neuropathy	O
(	O
LHON	O
)	O
,	O
mitochondrial	O
myopathy	O
,	O
encephalopathy	O
,	O
lactacidosis	O
,	O
stroke	O
(	O
MELAS	O
)	O
,	O
or	O
Kearns	O
-	O
Sayre	O
Syndrome	O
(	O
KSS	O
)	O
are	O
disclosed	O
,	O
as	O
well	O
as	O
compounds	O
useful	O
in	O
the	O
methods	O
of	O
the	O
invention	O
,	O
such	O
as	O
alpha	B
-	I
tocopherol	I
quinone	I
.	O

Methods	O
and	O
compounds	O
useful	O
in	O
treating	O
other	O
disorders	O
are	O
also	O
disclosed	O
.	O

Energy	O
biomarkers	O
useful	O
in	O
assessing	O
the	O
metabolic	O
state	O
of	O
a	O
subject	O
and	O
the	O
efficacy	O
of	O
treatment	O
are	O
also	O
disclosed	O
.	O

Methods	O
of	O
modulating	O
,	O
normalizing	O
,	O
or	O
enhancing	O
energy	O
biomarkers	O
,	O
as	O
well	O
as	O
compounds	O
useful	O
for	O
such	O
methods	O
,	O
are	O
also	O
disclosed	O
.	O

Redox	O
-	O
active	O
Therapeutics	O
For	O
Treatment	O
Of	O
Mitochondrial	O
Diseases	O
And	O
Other	O
Conditions	O
And	O
Modulation	O
Of	O
Energy	O
Biomarkers	O

The	O
present	O
invention	O
is	O
related	O
to	O
pharmacology	O
,	O
medicine	O
,	O
veterinary	O
science	O
and	O
pharmaceutical	O
industry	O
,	O
in	O
particular	O
to	O
the	O
process	O
of	O
production	O
original	O
composite	O
antimicrobial	O
and	O
anti	O
-	O
inflammatory	O
preparations	O
for	O
parenteral	O
administration	O
having	O
an	O
increased	O
therapeutic	O
efficiency	O
in	O
the	O
treatment	O
of	O
severe	O
forms	O
of	O
infectious	O
inflammatory	O
diseases	O
.	O

The	O
claimed	O
pharmaceutical	O
composition	O
contains	O
fosfomycin	B
and	O
finely	O
dispersed	O
nanostructured	O
silica	B
dioxide	I
active	O
agents	O
.	O

The	O
claimed	O
process	O
for	O
the	O
production	O
of	O
a	O
pharmaceutical	O
composition	O
includes	O
mixing	O
fosfomycin	B
with	O
finely	O
dispersed	O
nanostructured	O
silica	O
dioxide	O
,	O
characterized	O
in	O
that	O
the	O
mixture	O
of	O
said	O
substances	O
in	O
a	O
weight	O
ratio	O
from	O
10:1	O
to	O
70:1	O
respectively	O
is	O
being	O
exposed	O
to	O
mechanical	O
treatment	O
by	O
impact	O
and	O
abrasive	O
actions	O
to	O
increase	O
the	O
weight	O
percentage	O
of	O
the	O
finely	O
dispersed	O
fraction	O
(	O
≤	O
5	O
micron	O
)	O
to	O
at	O
least	O
25	O
%	O
.	O

The	O
received	O
mixture	O
is	O
used	O
to	O
prepare	O
for	O
injection	O
solutions	O
.	O

Pharmaceutical	O
composition	O
having	O
antimicrobial	O
and	O
anti	O
-	O
inflammatory	O
activity	O
for	O
parenteral	O
administration	O
,	O
process	O
for	O
preparing	O
same	O

Embodiments	O
of	O
the	O
invention	O
relate	O
to	O
compositions	O
and	O
methods	O
of	O
using	O
the	O
same	O
to	O
treat	O
conditions	O
caused	O
by	O
exposure	O
to	O
a	O
pore	O
-	O
forming	O
toxin	O
.	O

Zinc	B
-	O
containing	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
,	O
illnesses	O
and	O
syndromes	O
associated	O
with	O
exposure	O
to	O
pore	O
forming	O
toxins	O

Benzoxepin	B
compounds	O
of	O
Formula	O
I	O
,	O
and	O
including	O
stereoisomers	O
,	O
geometric	O
isomers	O
,	O
tautomers	O
,	O
solvates	O
,	O
metabolites	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
:	O
Z1	O
is	O
CR1	B
or	O
N	B
;	O
Z2	O
is	O
CR2	B
or	O
N	B
;	O
Z3	O
is	O
CR3	B
or	O
N	B
;	O
Z4	O
is	O
CR4	B
or	O
N	B
;	O
and	O
where	O
(	O
i	O
)	O
X1	O
is	O
N	B
and	O
X2	O
is	O
S	B
,	O
(	O
ii	O
)	O
X1	O
is	O
S	B
and	O
X2	O
is	O
N	B
,	O
(	O
iii	O
)	O
X1	O
is	O
CR7	B
and	O
X2	O
is	O
S	B
,	O
(	O
iv	O
)	O
X1	O
is	O
S	B
and	O
X2	O
is	O
CR7	B
;	O
(	O
v	O
)	O
X1	O
is	O
NR8	B
and	O
X2	O
is	O
N	B
,	O
(	O
vi	O
)	O
X1	O
is	O
N	B
and	O
X2	O
is	O
NR8	B
,	O
(	O
vii	O
)	O
X1	O
is	O
CR7	B
and	O
X2	O
is	O
O	B
,	O
(	O
viii	O
)	O
X1	O
is	O
O	B
and	O
X2	O
is	O
CR7	B
,	O
(	O
ix	O
)	O
X1	O
is	O
CR7	B
and	O
X2	O
is	O
C	B
(	I
R7	I
)	I
2	I
,	O
(	O
x	O
)	O
X1	O
is	O
C	B
(	I
R7	I
)	I
2	I
and	O
X2	O
is	O
CR7	B
;	O
(	O
xi	O
)	O
X1	O
is	O
N	B
and	O
X2	O
is	O
O	B
,	O
or	O
(	O
xii	O
)	O
X1	O
is	O
O	B
and	O
X2	O
is	O
N	B
,	O
are	O
useful	O
for	O
inhibiting	O
lipid	O
kinases	O
including	O
p110	O
alpha	O
and	O
other	O
isoforms	O
of	O
P13	O
K	O
,	O
and	O
for	O
treating	O
disorders	O
such	O
as	O
cancer	O
mediated	O
by	O
lipid	O
kinases	O
.	O

Methods	O
of	O
using	O
compounds	O
of	O
Formula	O
I	O
for	O
in	O
vitro	O
,	O
in	O
situ	O
,	O
and	O
in	O
vivo	O
diagnosis	O
,	O
prevention	O
or	O
treatment	O
of	O
such	O
disorders	O
in	O
mammalian	O
cells	O
,	O
or	O
associated	O
pathological	O
conditions	O
,	O
are	O
disclosed	O
.	O

Benzoxepin	O
pi3k	O
inhibitor	O
compounds	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
crystalline	O
folinic	B
acid	I
in	O
essentially	O
pure	O
6S	O
-	O
form	O
,	O
comprising	O
the	O
steps	O
of	O
:	O
-	O
preparing	O
a	O
first	O
aqueous	O
or	O
hydroalcoholic	O
solution	O
,	O
having	O
a	O
pH	O
value	O
higher	O
than	O
4.5	O
,	O
of	O
a	O
soluble	O
levofolinate	B
salt	I
;	O
-	O
forming	O
a	O
second	O
solution	O
,	O
by	O
adding	O
said	O
first	O
solution	O
and	O
a	O
second	O
acid	O
to	O
a	O
batch	O
of	O
water	O
or	O
an	O
hydroalcoholic	O
mixture	O
,	O
containing	O
up	O
to	O
60	O
%	O
V	O
/	O
V	O
of	O
an	O
alcohol	B
,	O
pre	O
-	O
heated	O
at	O
a	O
temperature	O
comprised	O
between	O
30	O
and	O
60	O
°	O
C	O
,	O
operating	O
in	O
such	O
a	O
way	O
that	O
the	O
levofolinate	B
salt	I
concentration	O
in	O
the	O
second	O
solution	O
never	O
exceeds	O
4	O
%	O
m	O
/	O
V	O
,	O
the	O
pH	O
value	O
of	O
the	O
second	O
solution	O
always	O
remains	O
in	O
the	O
range	O
between	O
3.0	O
and	O
4.5	O
,	O
and	O
the	O
temperature	O
of	O
the	O
second	O
solution	O
always	O
remains	O
in	O
the	O
range	O
between	O
30	O
and	O
60	O
°	O
C	O
;	O
-	O
upon	O
completion	O
of	O
the	O
addition	O
of	O
said	O
first	O
solution	O
to	O
said	O
batch	O
of	O
water	O
or	O
hydroalcoholic	O
mixture	O
,	O
stirring	O
the	O
thus	O
formed	O
second	O
solution	O
while	O
the	O
precipitation	O
of	O
levofoliriic	B
acid	I
occurs	O
,	O
maintaining	O
the	O
solution	O
at	O
a	O
temperature	O
between	O
30	O
and	O
60	O
°	O
C	O
,	O
monitoring	O
the	O
pH	O
and	O
continuously	O
adding	O
said	O
second	O
acid	O
to	O
keep	O
the	O
pH	O
stable	O
,	O
until	O
it	O
is	O
observed	O
that	O
the	O
pH	O
value	O
becomes	O
stable	O
with	O
no	O
need	O
of	O
further	O
addition	O
of	O
said	O
second	O
acid	O
,	O
indicating	O
the	O
end	O
of	O
the	O
precipitation	O
of	O
levofolinic	B
acid	I
;	O
-	O
recovering	O
crystalline	O
levofolinic	B
thus	O
formed	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
crystalline	O
levofolinic	B
acid	I

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
Ra	O
,	O
Rb	O
,	O
Rc	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
X1	O
,	O
Y1	O
,	O
Z1	O
,	O
A	O
,	O
n	O
and	O
m	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
as	O
well	O
as	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O

Imidazoquinolines	B
which	O
act	O
via	O
toll	O
-	O
like	O
receptors	O
(	O
tlr	O
)	O

Oxadiazole	B
substituted	I
indazole	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
salts	O
thereof	O
having	O
pharmacological	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
mediated	O
by	O
S1P1	O
receptor	O
are	O
disclosed	O
.	O

Oxadiazole	B
substituted	I
indazole	I
derivatives	O
for	O
use	O
as	O
sphingosine	B
1-phosphate	I
1	I
(	O
s1p1	B
)	O
receptor	O
agonists	O

The	O
present	O
invention	O
concerns	O
compounds	O
and	O
their	O
use	O
to	O
treat	O
cell	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
.	O

Compounds	O
of	O
the	O
present	O
invention	O
display	O
significant	O
potency	O
as	O
inhibitors	O
of	O
Jak2	O
/	O
STAT3	O
pathways	O
and	O
downstream	O
targets	O
and	O
inhibit	O
the	O
growth	O
and	O
survival	O
of	O
cancerous	O
cell	O
lines	O
.	O

Orally	O
bioavailable	O
cafeic	O
acid	O
related	O
anticancer	O
drugs	O

The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
prevention	O
,	O
treatment	O
,	O
or	O
management	O
of	O
pulmonary	O
hypertension	O
using	O
piperidine	B
,	O
pyrrolidine	B
,	O
or	O
azepane	B
derivatives	O
comprising	O
one	O
to	O
four	O
nitric	B
oxide	I
(	O
NO	B
)	O
donor	O
groups	O
and	O
a	O
reactive	B
oxygen	I
species	I
(	O
ROS	B
)	O
degradation	O
catalyst	O
.	O

The	O
invention	O
further	O
provides	O
a	O
water	O
dispersible	O
powder	O
comprising	O
nanoparticles	O
comprising	O
said	O
derivatives	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
of	O
use	O
.	O

Compositions	O
and	O
methods	O
for	O
prevention	O
and	O
treatment	O
of	O
pulmonary	O
hypertension	O

The	O
present	O
invention	O
relates	O
to	O
antiandrogenic	O
compounds	O
which	O
may	O
be	O
administered	O
for	O
the	O
treatment	O
of	O
androgen	B
excess	O
in	O
the	O
skin	O
and	O
by	O
way	O
of	O
consequence	O
,	O
the	O
treatment	O
of	O
acne	O
,	O
baldness	O
or	O
hirsuitism	O
in	O
subject	O
or	O
patient	O
.	O

These	O
compounds	O
have	O
the	O
general	O
chemical	O
structure	O
I	O
,	O
II	O
,	O
III	O
or	O
IV	O
:	O
or	O
Locally	O
active	O
""""	O
soft	O
""""	O
antiandrogens	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
isorhamnetin	B
triglycosides	I
and	O
of	O
extracts	O
containing	O
same	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
neurological	O
and	O
mental	O
illnesses	O
which	O
are	O
associated	O
with	O
a	O
reduction	O
in	O
everyday	O
activity	O
and/or	O
with	O
a	O
disorder	O
of	O
mental	O
functions	O
which	O
affect	O
everyday	O
activities	O
,	O
and/or	O
of	O
inattentiveness	O
and	O
states	O
of	O
restlessness	O
and	O
for	O
improving	O
memory	O
functions	O
.	O

The	O
invention	O
further	O
relates	O
to	O
isorhamnetin	B
triglycoside	I
2	O
and	O
plant	O
extracts	O
containing	O
said	O
glycoside	B
.	O

Use	O
of	O
isorhamnetin	B
triglycosides	I

A	O
method	O
of	O
synthesizing	O
and	O
isolating	O
N-	B
(	I
bromoacetyl	I
)	I
-3,3-dinitroazetidine	I
(	O
ABDNAZ	B
)	O
by	O
reacting	O
DNAZ	B
with	O
bromoacetyl	B
bromide	I
and	O
boron	B
trifluoride	I
etherate	I
in	O
a	O
solvent	O
to	O
produce	O
a	O
mixture	O
comprising	O
ABDNAZ	B
and	O
a	O
salt	O
of	O
DNAZ	B
.	O

Water	O
and	O
an	O
additional	O
volume	O
of	O
the	O
solvent	O
are	O
added	O
to	O
the	O
mixture	O
to	O
form	O
an	O
organic	O
phase	O
comprising	O
the	O
ABDNAZ	B
and	O
an	O
aqueous	O
phase	O
comprising	O
the	O
salt	O
of	O
DNAZ	B
.	O

The	O
organic	O
phase	O
and	O
the	O
aqueous	O
phase	O
are	O
separated	O
to	O
produce	O
an	O
ABDNAZ	B
/	O
solvent	O
solution	O
comprising	O
the	O
ABDNAZ	B
and	O
the	O
aqueous	O
phase	O
comprising	O
the	O
salt	O
of	O
DNAZ	B
.	O

A	O
nonsolvent	O
is	O
added	O
to	O
the	O
ABDNAZ	B
/	O
solvent	O
solution	O
to	O
produce	O
an	O
ABDNAZ	B
/	O
solvent	O
/	O
nonsolvent	O
mixture	O
.	O

The	O
ABDNAZ	B
is	O
subsequently	O
recovered	O
.	O

A	O
composition	O
comprising	O
ABDNAZ	B
is	O
also	O
disclosed	O
.	O

Methods	O
of	O
synthesizing	O
and	O
isolating	O
n-	B
(	I
bromoacetyl	I
)	I
-3,3-dinitroazetidine	I
and	O
a	O
composition	O
including	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
Prasugrel	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
compositions	O
containing	O
said	O
active	O
ingredient	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
said	O
active	O
ingredient	O
or	O
a	O
composition	O
containing	O
said	O
active	O
ingredient	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
the	O
novel	O
compositions	O
.	O

Prasugrel	B
in	O
micronized	O
,	O
crystalline	O
form	O
and	O
pharmaceutical	O
composition	O
thereof	O

Anhydrous	O
Polymorphic	O
Forms	O
A	O
,	O
B	O
,	O
D	O
and	O
E	O
and	O
polymorphic	O
form	O
C	O
of	O
1-	B
[	I
(	I
4-methyl	I
-	I
quinazolin-2-yl	I
)	I
methyl	I
]	I
-3-methyl-7-	I
(	I
2-butyn-1-yl	I
)	I
-8-	I
(	I
3-	I
(	I
R	I
)	I
-amino	I
-	I
piperidin-1-yl	I
)	I
-xanthine	I
(	O
I	O
)	O
,	O
are	O
new	O
.	O

Form	O
A	O
has	O
a	O
melting	O
point	O
of	O
206	O
+	O
-	O
[	O
deg	O
]	O
C	O
;	O
Form	O
D	O
melts	O
at	O
150	O
+	O
-3	O
[	O
deg	O
]	O
C	O
;	O
and	O
Form	O
E	O
melts	O
at	O
175	O
+	O
-3	O
[	O
deg	O
]	O
C.	O
Form	O
B	O
transforms	O
reversibly	O
into	O
the	O
polymorph	O
A	O
at	O
10	O
-	O
40	O
[	O
deg	O
]	O
C.	O
Form	O
C	O
loses	O
water	O
at	O
30	O
-	O
100	O
[	O
deg	O
]	O
C.	O
An	O
independent	O
claim	O
is	O
included	O
for	O
a	O
method	O
(	O
M1	O
)	O
of	O
preparing	O
polymorph	O
form	O
C	O
involving	O
refluxing	O
(	O
I	O
)	O
in	O
methanol	B
;	O
cooling	O
the	O
methanolic	O
solution	O
to	O
40	O
-	O
60	O
[	O
deg	O
]	O
C	O
;	O
adding	O
a	O
solvent	O
such	O
as	O
tert	B
-	I
butylmethylether	I
;	O
cooling	O
the	O
resulting	O
suspension	O
to	O
15	O
-	O
25	O
[	O
deg	O
]	O
C	O
and	O
then	O
to	O
0	O
-	O
5	O
[	O
deg	O
]	O
C	O
;	O
filtering	O
the	O
crystals	O
by	O
suction	O
and	O
drying	O
in	O
vacuo	O
at	O
70	O
[	O
deg	O
]	O
C.	O
ACTIVITY	O
:	O
Antidiabetic	O
;	O
Anorectic	O
;	O
Antarthritic	O
;	O
Antirheumatoid	O
;	O
Osteopathic	O
;	O
Immunosuppressive	O
.	O

No	O
biological	O
data	O
is	O
given	O
.	O

MECHANISM	O
OF	O
ACTION	O
:	O
Dipeptidyl	O
peptidase	O
(	O
DPP	O
)	O
-IV	O
inhibitor	O
.	O

Polymorphs	O
of	O
1-	B
(	I
(	I
4-Methyl	I
-	I
chinazolin-2-yl	I
)	I
methyl	I
)	I
-3-methyl-7-	I
(	I
2-butin-1-yl	I
)	I
-8-	I
(	I
3-	I
(	I
R	I
)	I
-amino	I
-	I
piperidin-1-yl	I
)	I
xanthin	I

The	O
invention	O
provides	O
an	O
oral	O
liquid	O
composition	O
of	O
a	O
hypoxic	O
radiation	O
sensitiser	O
comprising	O
the	O
radiation	O
sensitiser	O
in	O
a	O
concentration	O
of	O
greater	O
than	O
5mg	O
/	O
ml	O
,	O
and	O
a	O
method	O
of	O
treating	O
a	O
subject	O
with	O
a	O
hypoxic	O
condition	O
comprising	O
administration	O
to	O
the	O
subject	O
of	O
a	O
combination	O
of	O
a	O
composition	O
of	O
the	O
invention	O
and	O
radiation	O
.	O

Radiation	O
sensitiser	O
compositions	O

The	O
invention	O
relates	O
to	O
drugs	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
acute	O
and	O
chronic	O
pancreatitis	O
.	O

The	O
technical	O
result	O
from	O
the	O
application	O
of	O
the	O
drug	O
proposed	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
acute	O
and	O
chronic	O
pancreatitis	O
consists	O
in	O
the	O
elimination	O
of	O
inflammation	O
and	O
stimulation	O
of	O
the	O
regeneration	O
of	O
pancreas	O
cells	O
.	O

The	O
drug	O
for	O
the	O
treatment	O
of	O
acute	O
and	O
chronic	O
pancreatitis	O
contains	O
at	O
least	O
one	O
polyprenyl	B
phosphate	I
or	O
polyprenyl	B
pyrophosphate	I
with	O
a	O
number	O
of	O
isoprene	B
units	O
from	O
7	O
to	O
30	O
or	O
a	O
mixture	O
of	O
different	O
polyprenyl	B
phosphates	I
and	O
polyprenyl	B
pyrophospates	I
.	O

Means	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
acute	O
and	O
chronic	O
pancreatitis	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
modulating	O
miRNA	O
content	O
in	O
living	O
beings	O
and	O
the	O
use	O
thereof	O
,	O
whereof	O
the	O
miRNAs	O
are	O
delivered	O
initiatively	O
and	O
selectively	O
by	O
microparticles	O
/	O
MVs	O
/	O
exosomes	O
to	O
the	O
circulatory	O
system	O
and	O
target	O
cells	O
/	O
tissues	O
to	O
perform	O
various	O
functions	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
combination	O
of	O
molecules	O
that	O
mediates	O
the	O
inter	O
-	O
cellular	O
communication	O
:	O
the	O
miRNAs	O
secreted	O
by	O
cells	O
through	O
cellular	O
MVs	O
.	O

Meanwhile	O
,	O
the	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
cellular	O
MVs	O
entrapping	O
certain	O
miRNAs	O
,	O
and	O
,	O
according	O
to	O
the	O
regulation	O
and	O
modification	O
of	O
gene	O
expression	O
in	O
cells	O
and	O
tissues	O
with	O
the	O
miRNA	O
-	O
entrapping	O
cellular	O
MVs	O
,	O
provides	O
a	O
novel	O
method	O
for	O
modulating	O
miRNA	O
content	O
in	O
living	O
beings	O
,	O
which	O
is	O
effective	O
and	O
adoptable	O
to	O
all	O
cell	O
types	O
.	O

Method	O
for	O
regulating	O
microrna	O
content	O
in	O
organisms	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
provides	O
compositions	O
of	O
recombinant	O
human	O
lysosomal	O
acid	O
lipase	O
having	O
particular	O
glycosylation	O
patterns	O
for	O
internalization	O
into	O
target	O
cells	O
,	O
a	O
vector	O
containing	O
the	O
nucleic	O
acid	O
encoding	O
human	O
lysosomal	O
acid	O
lipase	O
,	O
a	O
host	O
cell	O
transformed	O
with	O
the	O
vector	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
recombinant	O
human	O
lysosomal	O
acid	O
lipase	O
and	O
method	O
of	O
treating	O
conditions	O
associated	O
with	O
lysosomal	O
acid	O
lipase	O
deficiency	O
.	O

Lysosomal	O
storage	O
disease	O
enzyme	O

The	O
present	O
invention	O
relates	O
to	O
the	O
novel	O
use	O
(	O
anti	O
-	O
inflammatory	O
activity	O
)	O
of	O
Ramalin	B
isolated	O
from	O
the	O
Antarctic	O
lichen	O
Ramalina	O
terebrata	O
,	O
and	O
more	O
specifically	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
Ramalin	B
as	O
an	O
active	O
ingredient	O
.	O

Ramalin	B
of	O
the	O
invention	O
is	O
a	O
compound	O
derived	O
from	O
natural	O
material	O
,	O
has	O
no	O
toxicity	O
or	O
side	O
effects	O
,	O
and	O
inhibits	O
the	O
expression	O
of	O
inducible	O
nitric	B
oxide	I
synthase	O
(	O
iNOS	O
)	O
in	O
the	O
transcription	O
stage	O
to	O
significantly	O
inhibit	O
the	O
production	O
of	O
nitric	B
oxide	I
(	O
NO	O
)	O
that	O
is	O
a	O
key	O
mediator	O
of	O
inflammatory	O
responses	O
.	O

In	O
addition	O
,	O
it	O
inhibits	O
the	O
activation	O
of	O
the	O
inflammatory	O
mediator	O
NF	O
-	O
κB	O
,	O
inhibits	O
p38	O
MAPK	O
,	O
ERK1	O
/	O
2	O
and	O
JNK	O
signaling	O
pathways	O
,	O
and	O
inhibits	O
the	O
expression	O
of	O
the	O
LPS	O
receptor	O
TLR4	O
,	O
suggesting	O
that	O
Ramalin	B
has	O
an	O
excellent	O
anti	O
-	O
inflammatory	O
effect	O
.	O

Thus	O
,	O
the	O
composition	O
containing	O
Ramalin	B
can	O
be	O
effectively	O
used	O
to	O
fundamentally	O
treat	O
or	O
prevent	O
inflammatory	O
diseases	O
or	O
immune	O
diseases	O
and	O
to	O
relieve	O
or	O
alleviate	O
the	O
symptoms	O
of	O
the	O
diseases	O
.	O

Pharmaceutical	O
composition	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
inflammatory	O
diseases	O
or	O
immune	O
diseases	O
containing	O
ramalin	B

GPR120	O
agonists	O
are	O
provided	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
diseases	O
,	O
including	O
Type	O
II	O
diabetes	O
and	O
diseases	O
associated	O
with	O
poor	O
glycemic	O
control	O
.	O

Gpr120	O
receptor	O
agonists	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
a	O
medicament	O
characterized	O
by	O
the	O
combination	O
of	O
:	O
epigallocatechin	B
gallate	I
,	O
methylated	B
epigallocatechin	I
gallate	I
,	O
or	O
a	O
pharmacologically	O
permitted	O
salt	O
thereof	O
;	O
and	O
a	O
phosphodiesterase	O
inhibitor	O
.	O

Combination	O
of	O
egcg	B
or	O
methylated	B
egcg	I
and	O
a	O
pde	O
inhibitor	O

Methods	O
for	O
treating	O
a	O
disease	O
state	O
for	O
which	O
HGF	O
/	O
cMET	O
possesses	O
activity	O
that	O
contributes	O
to	O
the	O
pathology	O
and/or	O
symptomology	O
of	O
the	O
disease	O
state	O
,	O
as	O
well	O
as	O
kits	O
and	O
articles	O
of	O
manufacture	O
for	O
use	O
in	O
practicing	O
these	O
methods	O
.	O

COMBINATION	O
OF	O
A	O
cMET	O
INHIBITOR	O
AND	O
AN	O
ANTIBODY	O
TO	O
HGF	O
AND	O
/	O
OR	O
cMET	O

A	O
pharmaceutical	O
active	O
ingredient	O
for	O
cell	O
differentiation	O
to	O
alleviate	O
cell	O
and	O
cell	O
-	O
related	O
deficiencies	O
in	O
mammals	O
comprising	O
porous	O
silica	O
containing	O
a	O
releasable	O
agent	O
capable	O
of	O
contributing	O
to	O
a	O
cell	O
environment	O
conducive	O
for	O
stem	O
cell	O
differentiation	O
in	O
co	O
-	O
implanted	O
stem	O
cells	O
and/or	O
in	O
endogenous	O
stem	O
cells	O
.	O

Improved	O
method	O
for	O
stem	O
cell	O
differentiation	O
in	O
vivo	O
by	O
delivery	O
of	O
morphogenes	O
with	O
mesoporous	O
silica	O
and	O
corresponding	O
pharmaceutical	O
active	O
ingredients	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
fused	B
heterocyclic	I
derivative	O
of	O
the	O
formula	O
(	O
I	O
)	O
The	O
variables	O
R1-R4	O
,	O
z	O
,	O
A	O
,	O
Q	O
,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O

The	O
following	O
heterocycles	B
are	O
exemplified	O
substructures	O
of	O
formula	O
(	O
I	O
)	O
:	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
modulators	O
of	O
the	O
S1P	B
receptor	O
(	O
Sphingosine-1-phosphate	B
receptor	O
)	O
,	O
More	O
specifically	O
,	O
they	O
are	O
agonists	O
of	O
S1P5	O
.	O

The	O
compounds	O
have	O
therapeutic	O
use	O
in	O
treatment	O
of	O
cognitive	O
disorders	O
,	O
age	O
-	O
relate	O
cognitive	O
decline	O
and	O
dementia	O
.	O

Fused	B
heterocyclic	I
derivatives	O
as	O
s1p	O
modulators	O

The	O
present	O
invention	O
discloses	O
novel	O
compounds	O
useful	O
for	O
the	O
inhibition	O
of	O
IL-6	O
/	O
STAT	O
signaling	O
and/or	O
PI3K	O
/	O
NF	O
-	O
ĸΒ	O
signaling	O
in	O
the	O
treatment	O
of	O
associated	O
diseases	O
or	O
conditions	O
,	O
e.g.	O
cancer	O
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
such	O
novel	O
compounds	O
,	O
its	O
use	O
and	O
a	O
method	O
thereof	O
,	O
is	O
also	O
disclosed	O
.	O

Tricyclic	B
lactones	I
for	O
treatment	O
of	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
complex	O
,	O
obtainable	O
by	O
mixing	O
hyaluronic	B
acid	I
or	O
a	O
salt	O
thereof	O
and	O
chondroitin	B
sulphate	I
or	O
a	O
salt	O
thereof	O
,	O
and	O
forming	O
an	O
aqueous	O
solution	O
of	O
said	O
mixture	O
,	O
which	O
is	O
further	O
subjected	O
to	O
a	O
drying	O
process	O
.	O

The	O
invention	O
also	O
relates	O
to	O
various	O
compositions	O
and	O
formulations	O
comprising	O
the	O
complex	O
of	O
the	O
invention	O
,	O
process	O
for	O
obtaining	O
the	O
complex	O
and	O
uses	O
thereof	O
.	O

Complex	O
obtained	O
from	O
hyaluronic	B
acid	I
or	O
a	O
salt	O
thereof	O
and	O
chondroitin	B
sulphate	I
mixtures	O

Composition	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
herpes	O
simplex	O
labialis	O
comprising	O
,	O
in	O
combination	O
,	O
the	O
following	O
substances	O
:	O
Mimosa	O
tenuiflora	O
bark	O
extract	O
,	O
Aqua	O
,	O
sodium	B
carboxymethyl	I
betaglucan	I
,	O
Echinacea	O
angustifolia	O
root	O
extract	O
and	O
Glycyrrhetinic	B
acid	I
.	O

Composition	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
herpes	O
simplex	O
labialis	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
4-methyl-8-phenoxy-1-	B
(	I
2-phenylethyl	I
)	I
-2,3-dihydro-1H-	I
pyrrolo	I
[	I
3,2-c	I
]	I
quinoline	I
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
in	O
combination	O
with	O
an	O
aminoglycoside	O
antimicrobial	O
agent	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
microbial	O
infections	O
.	O

Combination	O
of	O
a	O
pyrroloquinoline	B
compound	O
and	O
an	O
aminoglycodise	O
antimicrobial	O
agent	O

The	O
present	O
invention	O
relates	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
stereoisomers	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
prodrugs	O
thereof	O
;	O
wherein	O
R	O
'	O
and	O
R1	O
-	O
R5	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O

The	O
invention	O
also	O
relates	O
to	O
said	O
compounds	O
for	O
use	O
as	O
a	O
medicament	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
drug	O
addiction	O
and	O
CNS	O
related	O
diseases	O
.	O

Novel	O
6,7-disubstituted	B
-	I
isoquinoline	I
derivatives	O
and	O
their	O
use	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
which	O
is	O
effective	O
in	O
inhibiting	O
the	O
function	O
of	O
the	O
TRPM4	O
ion	O
channel	O
and	O
the	O
use	O
of	O
such	O
compound	O
in	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
,	O
such	O
as	O
Multiple	O
Sclerosis	O
,	O
Parkinson	O
's	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
or	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
in	O
a	O
subject	O
.	O

The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
TRPM4	O
inhibitory	O
compound	O
.	O

The	O
invention	O
further	O
relates	O
to	O
in	O
vitro	O
methods	O
for	O
identifying	O
pharmaceutically	O
active	O
compounds	O
that	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
.	O

Novel	O
methods	O
for	O
treating	O
or	O
preventing	O
neurodegeneration	O

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
probiotic	O
(	O
s	O
)	O
which	O
can	O
activate	O
an	O
aromatic	B
hydrocarbon	I
receptor	O
(	O
AhR	O
)	O
and	O
can	O
consequently	O
prevent	O
inflammatory	O
damage	O
in	O
the	O
digestive	O
tract	O
.	O

The	O
present	O
invention	O
relates	O
to	O
;	O
a	O
probiotic	O
(	O
s	O
)	O
capable	O
of	O
activating	O
an	O
AhR	O
;	O
an	O
anti	O
-	O
inflammatory	O
agent	O
comprising	O
the	O
probiotic	O
(	O
s	O
)	O
;	O
an	O
orally	O
ingestible	O
composition	O
containing	O
the	O
anti	O
-	O
inflammatory	O
agent	O
;	O
and	O
a	O
method	O
for	O
screening	O
for	O
the	O
probiotic	O
(	O
s	O
)	O
.	O

Composition	O
for	O
preventing	O
inflammations	O

Use	O
of	O
a	O
compound	O
of	O
Formula	O
1	O
for	O
inducing	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
to	O
chondrocytes	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
a	O
cartilage	O
disease	O
,	O
which	O
includes	O
chondrocytes	O
in	O
which	O
differentiation	O
from	O
mesenchymal	O
stem	O
cells	O
is	O
induced	O
by	O
the	O
compound	O
of	O
Formula	O
1	O
,	O
are	O
provided	O
.	O

Differentiation	O
of	O
the	O
mesenchymal	O
stem	O
cells	O
treated	O
with	O
the	O
compound	O
of	O
Formula	O
1	O
to	O
chondrocytes	O
is	O
specifically	O
induced	O
,	O
and	O
thus	O
the	O
compound	O
can	O
be	O
used	O
to	O
effectively	O
treat	O
a	O
cartilage	O
disease	O
such	O
as	O
arthritis	O
,	O
cartilage	O
damage	O
,	O
and	O
a	O
cartilage	O
defect	O
.	O

Use	O
of	O
a	O
compound	O
for	O
inducing	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
into	O
cartilage	O
cells	O

The	O
present	O
invention	O
is	O
intended	O
to	O
provide	O
a	O
pharmaceutical	O
product	O
for	O
inhibiting	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA	O
,	O
SCD-1	O
mRNA	O
,	O
and	O
SREBP1c	O
mRNA	O
,	O
the	O
present	O
invention	O
is	O
also	O
intended	O
to	O
provide	O
a	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
various	O
diseases	O
based	O
on	O
inhibition	O
of	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA	O
,	O
SCD-1	O
mRNA	O
,	O
and	O
SREBP1c	O
mRNA	O
,	O
and	O
the	O
present	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
inhibiting	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA	O
,	O
SCD-1	O
mRNA	O
,	O
and	O
SREBP1c	O
mRNA	O
,	O
and	O
relates	O
also	O
to	O
a	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
various	O
diseases	O
based	O
on	O
the	O
inhibition	O
of	O
the	O
expression	O
of	O
at	O
least	O
one	O
lipid	O
metabolism	O
related	O
mRNA	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Angptl4	O
mRNA	O
,	O
SCD-1	O
mRNA	O
,	O
and	O
SREBP1c	O
mRNA	O
,	O
the	O
agent	O
comprising	O
a	O
compound	O
represented	O
by	O
Formula	O
(	O
I	O
)	O
,	O
its	O
salt	O
,	O
or	O
a	O
solvate	O
of	O
any	O
of	O
them	O
as	O
an	O
active	O
ingredient	O
:	O
wherein	O
the	O
symbols	O
are	O
the	O
same	O
as	O
those	O
given	O
in	O
the	O
description	O
..	O

Agent	O
for	O
inhibiting	O
expression	O
of	O
lipid	O
metabolism	O
related	O
mrna	O

Provided	O
are	O
salts	O
of	O
kukoamine	B
B	I
,	O
their	O
preparation	O
method	O
and	O
their	O
use	O
in	O
preventing	O
and	O
treating	O
sepsis	O
diseases	O
.	O

Salts	O
of	O
kukoamine	B
b	I
,	O
preparation	O
method	O
and	O
use	O
thereof	O

Combinations	O
of	O
the	O
antibody	O
-	O
drug	O
conjugate	O
trastuzumab	O
-	O
MCC	O
-	O
DM	O
and	O
docetaxel	B
.	O

Combinations	O
of	O
an	O
anti	O
-	O
HER2	O
antibody	O
-	O
drug	O
conjugate	O
and	O
docetaxel	B

Disclosed	O
are	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
and	O
the	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
as	O
modulators	O
of	O
histone	O
methyltransferases	O
,	O
and	O
for	O
treating	O
diseases	O
influenced	O
by	O
modulation	O
of	O
histone	O
methyltransferase	O
activity	O
.	O

Modulators	O
of	O
histone	O
methyltransferase	O
,	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
M	O
-	O
L	O
-	O
M	O
'	O
(	O
where	O
M	O
and	O
M	O
'	O
are	O
each	O
independently	O
a	O
monomeric	O
moiety	O
of	O
Formula	O
(	O
I	O
)	O
and	O
L	O
is	O
a	O
linker	O
)	O
.	O

The	O
dimeric	O
compounds	O
have	O
been	O
found	O
to	O
be	O
effective	O
in	O
promoting	O
apoptosis	O
in	O
rapidly	O
dividing	O
cells	O
.	O

(	O
I	O
)	O
Dimeric	O
iap	O
inhibitors	O

A	O
method	O
for	O
treating	O
or	O
preventing	O
obesity	O
or	O
to	O
facilitate	O
weight	O
loss	O
,	O
particularly	O
in	O
overweight	O
individuals	O
with	O
a	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
of	O
about	O
25	O
or	O
greater	O
or	O
in	O
obese	O
individuals	O
with	O
a	O
BMI	O
of	O
about	O
25	O
or	O
greater	O
,	O
as	O
well	O
as	O
nutraceutical	O
or	O
pharmaceutical	O
compositions	O
and	O
supplements	O
therefor	O
.	O

The	O
methods	O
involve	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
cannabis	O
,	O
at	O
least	O
one	O
cannabinoid	B
or	O
derivative	O
thereof	O
,	O
an	O
extract	O
prepared	O
from	O
at	O
least	O
one	O
cannabis	O
plant	O
,	O
or	O
a	O
combination	O
thereof	O
.	O

Use	O
of	O
marihuana	O
and	O
compounds	O
therein	O
for	O
treating	O
obesity	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
I	O
,	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
wherein	O
R	O
is	O
aryl	B
substituted	O
by	O
R3	O
;	O
or	O
R	O
is	O
(	B
C3-Ci3	I
)	I
-cycloalkyl	I
,	O
(	B
C3-Ci3	I
)	I
-cycloalkenyl	I
or	O
(	B
C7-Ci3	I
)	I
-cycloalkynyl	I
optionally	O
substituted	O
by	O
R4	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
,	O
or	O
solvates	O
thereof	O
,	O
for	O
use	O
-	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds	O
-	O
in	O
therapy	O
,	O
for	O
preventing	O
,	O
treating	O
or	O
ameliorating	O
diseases	O
or	O
conditions	O
responsive	O
to	O
stimulation	O
of	O
neutrophil	O
oxidative	O
burst	O
,	O
responsive	O
to	O
stimulation	O
of	O
keratinocyte	O
IL-8	O
release	O
or	O
responsive	O
to	O
induction	O
of	O
necrosis	O
.	O

3-acyl	B
-	I
ingenols	I
ii	I

The	O
present	O
invention	O
describes	O
new	O
compounds	O
(	O
e.g.	O
Haprolid	B
)	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
antiviral	O
agents	O
such	O
as	O
inhibitors	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
:	O
Haprolid	B
and	O
derivatives	O
thereof	O
as	O
inhibitors	O
of	O
hcv	O

Methods	O
employing	O
chemiluminescent	O
agents	O
as	O
therapeutically	O
active	O
agents	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders	O
are	O
disclosed	O
.	O

The	O
chemiluminiscent	O
agents	O
are	O
used	O
in	O
the	O
disclosed	O
method	O
without	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
photosensitizer	O
.	O

Novel	O
chemiluminescent	O
agents	O
having	O
the	O
general	O
formula	O
:	O
are	O
also	O
disclosed	O
,	O
wherein	O
X	O
,	O
Y	O
,	O
Z	O
,	O
R3	O
and	O
R5-R9	O
are	O
as	O
defined	O
herein	O
.	O

Treatment	O
of	O
proliferative	O
disorders	O
with	O
a	O
chemiluminescent	O
agent	O

A	O
process	O
of	O
making	O
a	O
pemetrexed	B
salt	O
comprising	O
:	O
a	O
)	O
reacting	O
a	O
compound	O
of	O
formula	O
II	O
or	O
an	O
acid	O
salt	O
thereof	O
,	O
wherein	O
each	O
of	O
R1	O
and	O
R2	O
is	O
independently	O
a	O
C1-C6	B
alkyl	I
group	O
,	O
with	O
an	O
aqueous	O
basic	O
solution	O
at	O
a	O
temperature	O
of	O
no	O
more	O
than	O
10	O
°	O
C	O
to	O
obtain	O
a	O
first	O
mixture	O
comprising	O
the	O
pemetrexed	B
salt	O
;	O
b	O
)	O
isolating	O
the	O
pemextrexed	B
salt	O
from	O
the	O
first	O
mixture	O
.	O

Process	O
for	O
the	O
production	O
of	O
a	O
pemetrexed	B
salt	O

The	O
invention	O
relates	O
to	O
a	O
double	O
-	O
stranded	O
ribonucleic	O
acid	O
(	O
dsRNA	O
)	O
targeting	O
a	O
mutant	O
Epidermal	O
Growth	O
Factor	O
Receptor	O
(	O
EGFR	O
)	O
,	O
and	O
methods	O
of	O
using	O
the	O
dsRNA	O
to	O
inhibit	O
expression	O
of	O
mutant	O
EGFR	O
.	O

Compositions	O
and	O
methods	O
for	O
combined	O
inhibition	O
of	O
mutant	O
EGFR	O
gene	O
and	O
IL-6	O
expression	O

The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
.	O

The	O
pharmaceutical	O
composition	O
includes	O
a	O
block	O
copolymer	O
includng	O
:	O
a	O
hydrophilic	O
segment	O
;	O
a	O
hydrophobic	O
segment	O
;	O
and	O
a	O
boronic	B
acid	I
compound	O
bonded	O
to	O
a	O
side	O
chain	O
of	O
the	O
hydrophobic	O
segment	O
via	O
a	O
linker	O
moiety	O
including	O
a	O
heterocyclic	O
structure	O
,	O
wherein	O
:	O
a	O
cyclic	O
skeleton	O
of	O
the	O
heterocyclic	B
structure	O
has	O
a	O
boron	B
atom	O
derived	O
from	O
the	O
boronic	B
acid	I
compound	O
,	O
atoms	O
X	O
's	O
bonded	O
to	O
the	O
boron	B
atom	O
and	O
each	O
selected	O
from	O
an	O
oxygen	B
atom	O
and	O
a	O
nitrogen	B
atom	O
,	O
and	O
carbon	B
atoms	O
bonded	O
to	O
the	O
atoms	O
X	O
's	O
;	O
and	O
the	O
block	O
copolymer	O
further	O
comprises	O
an	O
organic	O
group	O
bonded	O
to	O
the	O
carbon	B
atoms	O
,	O
the	O
organic	O
group	O
containing	O
an	O
aromatic	O
group	O
or	O
cyclic	B
alkyl	I
group	O
as	O
a	O
structure	O
for	O
protecting	O
a	O
boronic	B
acid	I
ester	I
bond	O
and/or	O
a	O
boron	B
amide	I
bond	O
resulting	O
from	O
bonding	O
between	O
the	O
boron	B
atom	O
and	O
the	O
atoms	O
X	O
's	O
.	O

Pharmaceutical	O
composition	O
containing	O
block	O
copolymer	O
comprising	O
boric	B
acid	I
compound	O

The	O
invention	O
provides	O
a	O
combination	O
of	O
a	O
)	O
a	O
compound	O
of	O
Formula	O
(	O
Ia	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
b	O
)	O
abiraterone	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
treatment	O
of	O
a	O
hyperproliferative	O
disorder	O
,	O
such	O
as	O
cancer	O
.	O

Combinations	O
of	O
akt	O
inhibitor	O
compounds	O
and	O
abiraterone	B
,	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
cartilage	O
product	O
comprising	O
a	O
protein	O
hydrolysate	O
with	O
a	O
degree	O
of	O
hydrolysis	O
comprised	O
between	O
0.5	O
%	O
and	O
3.0	O
%	O
,	O
at	O
least	O
one	O
glycosaminoglycan	O
and	O
at	O
least	O
one	O
growth	O
factor	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
cartilage	O
product	O
obtainable	O
through	O
said	O
method	O
.	O

Said	O
cartilage	O
product	O
is	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
wounds	O
,	O
ulcers	O
,	O
burns	O
,	O
psoriasis	O
,	O
osteoarthritis	O
,	O
synovitis	O
,	O
osteoporosis	O
,	O
osteopenia	O
,	O
diseases	O
of	O
the	O
tendons	O
and	O
ligaments	O
,	O
periodontal	O
diseases	O
,	O
signs	O
of	O
skin	O
aging	O
,	O
the	O
harmful	O
effects	O
of	O
ultraviolet	O
radiation	O
exposure	O
or	O
stretch	O
marks	O
.	O

Cartilage	O
product	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
producing	O
a	O
complex	O
crystal	O
composed	O
of	O
two	O
or	O
more	O
different	O
compounds	O
,	O
comprising	O
crystallizing	O
the	O
two	O
or	O
more	O
different	O
compounds	O
under	O
a	O
condition	O
at	O
which	O
menthol	B
is	O
heat	O
melted	O
,	O
and	O
a	O
method	O
for	O
screening	O
a	O
complex	O
crystal	O
.	O

Method	O
for	O
producing	O
complex	O
crystal	O
and	O
method	O
for	O
screening	O
complex	O
crystal	O

The	O
present	O
invention	O
relates	O
to	O
bioactive	O
fractions	O
and	O
compounds	O
from	O
Dalbergia	O
sissoo	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
osteo	O
-	O
health	O
related	O
disorders	O
.	O

The	O
present	O
invention	O
relates	O
in	O
the	O
field	O
of	O
pharmaceutical	O
composition	O
that	O
provides	O
new	O
plant	O
extracts	O
,	O
their	O
fractions	O
and	O
pure	O
compound	O
isolated	O
from	O
natural	O
sources	O
that	O
are	O
useful	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
various	O
medical	O
indications^	O
associated	O
with	O
estrogen	B
dependent	O
or	O
independent	O
diseases	O
or	O
syndromes	O
or	O
disorders	O
preferably	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
estrogen	B
dependent	O
or	O
independent	O
diseases	O
or	O
syndromes	O
or	O
disorders	O
caused	O
in	O
humans	O
and	O
animals	O
,	O
and	O
achievement	O
of	O
peak	O
bone	O
mass	O
during	O
skeletal	O
growth	O
and	O
health	O
in	O
humans	O
and	O
animals	O
.	O

Particularly	O
the	O
present	O
invention	O
further	O
relates	O
to	O
the	O
processes	O
for	O
the	O
preparation	O
of	O
biologically	O
active	O
extracts	O
,	O
fractions	O
,	O
and	O
isolation	O
of	O
pure	O
compounds	O
,	O
from	O
Dalbergia	O
sissoo	O
plant	O
from	O
the	O
family	O
Fabaceae	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
compositions	O
of	O
the	O
principal	O
aspect	O
of	O
the	O
present	O
invention	O
.	O

Bioactive	O
fractions	O
and	O
compounds	O
from	O
dalbergia	O
sissoo	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
osteo	O
-	O
health	O
related	O
disorders	O

The	O
present	O
disclosure	O
relates	O
to	O
delivering	O
neutral	O
bioimaging	O
molecules	O
encapsulated	O
within	O
icosahedral	O
DNA	O
capsules	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
present	O
disclosure	O
also	O
discloses	O
the	O
entrapment	O
of	O
neutral	O
bioimaging	O
molecules	O
like	O
FITC	O
dextran	O
within	O
the	O
cavity	O
of	O
a	O
DNA	O
polyhedron	O
without	O
any	O
molecular	O
recognition	O
or	O
chemical	O
conjugation	O
between	O
host	O
(	O
DNA	O
icosahedron	O
)	O
and	O
cargo	O
(	O
like	O
FITC	O
Dextran	O
)	O
.	O

This	O
DNA	O
polyhedron	O
is	O
structurally	O
well	O
defined	O
and	O
shows	O
high	O
encapsulation	O
efficiency	O
.	O

The	O
present	O
disclosure	O
also	O
relates	O
to	O
complex	O
formed	O
due	O
to	O
the	O
encapsulation	O
of	O
neutral	O
bioimaging	O
agents	O
within	O
icosahedral	O
DNA	O
capsules	O
.	O

A	O
process	O
for	O
delivering	O
encapsulated	O
neutral	O
bioimaging	O
molecules	O
,	O
complex	O
,	O
and	O
process	O
thereof	O

Steroid	B
compounds	O
having	O
increased	O
resistance	O
against	O
metabolism	O
and	O
increased	O
water	O
solubility	O
are	O
disclosed	O
,	O
together	O
with	O
methods	O
for	O
their	O
production	O
.	O

These	O
substances	O
are	O
suitable	O
for	O
the	O
manufacture	O
of	O
pharmaceuticals	O
for	O
the	O
treatment	O
of	O
steroid	B
related	O
or	O
steroid	B
induced	O
CNS	O
disorders	O
and	O
for	O
use	O
in	O
methods	O
of	O
prevention	O
,	O
alleviation	O
or	O
treatment	O
of	O
such	O
disorders	O
.	O

The	O
use	O
of	O
pregnane	B
and	O
androstane	B
steroids	B
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
CNS	O
disorders	O

Clenbuterol	B
or	O
its	O
salt	O
for	O
use	O
in	O
the	O
treatment	O
of	O
autism	O
,	O
in	O
particular	O
pediatric	O
autism	O
.	O

Improved	O
contact	O
with	O
surroundings	O
,	O
better	O
concentration	O
,	O
improved	O
ability	O
to	O
plan	O
a	O
specific	O
task	O
,	O
improved	O
understanding	O
,	O
calming	O
,	O
and	O
reduced	O
psychomotor	O
anxiety	O
were	O
observed	O
.	O

Clenbuterol	B
for	O
use	O
in	O
treatment	O
of	O
autism	O

Methods	O
are	O
provided	O
for	O
treating	O
mesothelioma	O
patients	O
with	O
a	O
dual	O
PI3K	O
/	O
m	O
TOR	O
inhibitor	O
,	O
GDC-0980	O
:	O
(	B
S	I
)	I
-1-	I
(	I
4-	I
(	I
(	I
2-	I
(	I
2-aminopyrimidin-5-yl	I
)	I
-7-methyl-4-morpholinothieno	I
[	I
3,2-	I
d	I
]	I
pyrimidin-6-yl	I
)	I
methyl	I
)	I
piperazin-1-yl	I
)	I
-2-hydroxypropan-1-one	I
,	O
and	O
having	O
the	O
structure	O
:	O
Methods	O
of	O
treating	O
mesothelioma	O
with	O
a	O
pi3k	O
inhibitor	O
compound	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
comprising	O
the	O
steps	O
of	O
a	O
)	O
reacting	O
a	O
compound	O
of	O
formula	O
(	O
II	O
)	O
with	O
a	O
silylating	O
or	O
an	O
acylating	O
agent	O
to	O
produce	O
compound	O
of	O
formula	O
(	O
III	O
)	O
,	O
wherein	O
P1	O
is	O
a	O
protecting	O
group	O
selected	O
from	O
R2-Si	B
-	I
R3R4	I
or	O
R1CO-	B
,	O
R1	O
is	O
a	O
group	O
selected	O
from	O
C1	B
-	I
6alkyl	I
or	O
C3	B
-	I
6cycloalkyl	I
,	O
each	O
group	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
independently	O
selected	O
from	O
fluoro	B
or	O
C1	B
-	I
4alkyl	I
;	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
each	O
independently	O
a	O
group	O
selected	O
from	O
C1	B
-	I
6alkyl	I
or	O
phenyl	B
,	O
each	O
group	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
independently	O
selected	O
from	O
fluoro	B
or	O
C1	B
-	I
4alkyl	I
;	O
b	O
)	O
halogenation	O
or	O
sulfinylation	O
of	O
the	O
compound	O
of	O
formula	O
(	O
III	O
)	O
to	O
produce	O
a	O
compound	O
of	O
formula	O
(	O
IV	O
)	O
;	O
wherein	O
X	O
is	O
halo	B
,	O
or	O
-O	B
-	I
SO	I
-	I
R5	I
,	O
and	O
R5	O
is	O
a	O
group	O
selected	O
from	O
C6	B
-	I
10aryl	I
or	O
heteroaryl	B
,	O
each	O
group	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
independently	O
selected	O
from	O
chloro	B
or	O
C1	B
-	I
4alkyl	I
;	O
c	O
)	O
dehalogenation	O
or	O
desulfinylation	O
of	O
the	O
compound	O
of	O
formula	O
(	O
IV	O
)	O
to	O
produce	O
compound	O
of	O
formula	O
(	O
V	O
)	O
;	O
and	O
d	O
)	O
reacting	O
the	O
compound	O
of	O
formula	O
(	O
V	O
)	O
with	O
a	O
reducing	O
agent	O
to	O
produce	O
compound	O
of	O
formula	O
(	O
I	O
)	O
.	O

Process	O
for	O
the	O
production	O
of	O
estetrol	B
intermediates	O

The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
trauma	O
haemorrhage	O
or	O
trauma	O
haemorrhage	O
-	O
induced	O
organ	O
injury	O
and	O
associated	O
disorders	O
(	O
in	O
particular	O
stoke	O
,	O
burns	O
and	O
brain	O
injury	O
)	O
using	O
the	O
anti	O
-	O
malarial	O
compound	O
artemisinin	B
and	O
its	O
derivatives	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
treatment	O
of	O
myocardial	O
infarction	O
and	O
coronary	O
heart	O
disease	O
(	O
and	O
associated	O
disorders	O
)	O
using	O
the	O
anti	O
-	O
malarial	O
compound	O
artemisinin	B
and	O
its	O
derivatives	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
artemisinin	B
and	O
its	O
derivatives	O
in	O
coronary	O
artery	O
bypass	O
surgery	O
,	O
heart	O
transplantation	O
,	O
and	O
diseases	O
associated	O
with	O
ischaemia	O
-	O
reperfusion	O
.	O

Artemisinin	B
and	O
its	O
derivatives	O
for	O
use	O
in	O
the	O
treatment	O
of	O
trauma	O
haemorrhage	O
and	O
associated	O
conditions	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
4,6,4	B
'	I
-trimethylangelicin	I
(	O
TMA	B
)	O
and	O
structural	O
analogues	O
thereof	O
to	O
prepare	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
with	O
the	O
primary	O
objective	O
of	O
correcting	O
the	O
defective	O
CFTR	O
in	O
a	O
sub	O
-	O
group	O
of	O
cystic	O
fibrosis	O
patients	O
consisting	O
of	O
patients	O
carrying	O
the	O
F508del	O
-	O
CFTR	O
mutation	O
.	O

Trimethylangelicin	B
as	O
cftr	O
corrector	O
in	O
bronchial	O
epithelial	O
cells	O

The	O
present	O
invention	O
provides	O
a	O
protein	O
comprising	O
a	O
truncated	O
form	O
of	O
an	O
extracellular	O
region	O
protein	O
of	O
Frizzled	O
2	O
,	O
which	O
has	O
higher	O
secretion	O
activity	O
than	O
that	O
of	O
a	O
known	O
protein	O
comprising	O
an	O
extralellular	O
cysteine	B
-	O
rich	O
domain	O
of	O
Frizzled	O
2	O
in	O
a	O
production	O
cell	O
and	O
bone	O
mass	O
-	O
increasing	O
activity	O
higher	O
than	O
or	O
equal	O
to	O
that	O
of	O
the	O
known	O
protein	O
,	O
or	O
DNA	O
encoding	O
said	O
protein	O
.	O

Protein	O
comprising	O
truncated	O
form	O
of	O
extracellular	O
domain	O
protein	O
of	O
frizzled	O
2	O
,	O
and	O
pharmaceutical	O
composition	O
for	O
treating	O
bone	O
diseases	O
which	O
comprises	O
said	O
protein	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
,	O
devices	O
and	O
methods	O
of	O
delayed	O
and	O
sustained	O
release	O
of	O
energy	O
molecules	O
for	O
brain	O
function	O
to	O
treat	O
nocturnal	O
hypoglycemia	O
.	O

The	O
composition	O
comprises	O
an	O
energy	O
molecule	O
required	O
for	O
human	O
brain	O
function	O
;	O
wherein	O
the	O
release	O
of	O
the	O
energy	O
molecule	O
is	O
delayed	O
and	O
then	O
sustained	O
over	O
a	O
period	O
of	O
time	O
.	O

The	O
device	O
is	O
a	O
transdermal	O
delivery	O
device	O
comprising	O
a	O
reservoir	O
layer	O
containing	O
the	O
composition	O
and	O
a	O
skin	O
permeation	O
enhancer	O
formulation	O
,	O
an	O
adhesive	O
layer	O
,	O
a	O
backing	O
layer	O
and	O
a	O
release	O
liner	O
.	O

The	O
method	O
comprises	O
administering	O
the	O
composition	O
either	O
orally	O
or	O
through	O
the	O
transdermal	O
delivery	O
device	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
immediately	O
prior	O
to	O
going	O
to	O
sleep	O
.	O

A	O
composition	O
,	O
device	O
and	O
method	O
for	O
delayed	O
and	O
sustained	O
release	O
of	O
brain	O
energy	O
molecules	O

This	O
invention	O
generally	O
provides	O
compounds	O
,	O
pharmaceutical	O
compositions	O
,	O
and	O
methods	O
for	O
their	O
use	O
,	O
which	O
include	O
methods	O
that	O
result	O
in	O
increased	O
expression	O
in	O
an	O
Atoh1	O
gene	O
(	O
e.g.	O
,	O
Hath1	O
)	O
in	O
a	O
biological	O
cell	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
diseases	O
and/or	O
disorders	O
that	O
would	O
benefit	O
from	O
increased	O
Atoh1	O
expression	O
,	O
e.g.	O
a	O
hearing	O
impairment	O
or	O
imbalance	O
disorder	O
associated	O
with	O
a	O
loss	O
of	O
auditory	O
hair	O
cells	O
,	O
or	O
a	O
disorder	O
associated	O
with	O
abnormal	O
cellular	O
proliferation	O
.	O

Compounds	O
that	O
enhance	O
Atoh-1	O
expression	O

The	O
present	O
invention	O
relates	O
to	O
9-aminomethyl	B
substituted	I
tetracycline	I
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
,	O
solvate	O
or	O
isomer	O
thereof	O
,	O
as	O
well	O
as	O
a	O
method	O
for	O
preparing	O
these	O
compounds	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
.	O

The	O
present	O
invention	O
relates	O
also	O
to	O
a	O
use	O
of	O
these	O
compounds	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
tetracycline	B
drug	O
-	O
sensitive	O
disease	O
.	O

wherein	O
,	O
R2a	O
,	O
R2b	O
,	O
R3	O
,	O
R4a	O
,	O
R4b	O
,	O
R5	O
,	O
R6a	O
,	O
R6b	O
,	O
R7	O
,	O
R8	O
,	O
R9a	O
,	O
R9b	O
,	O
R10	O
,	O
R11	O
,	O
R12	O
,	O
R13a	O
and	O
R13b	O
are	O
each	O
independently	O
as	O
defined	O
in	O
the	O
description	O
.	O

9-aminomethyl	B
substituted	I
tetracycline	I
compound	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
which	O
are	O
inhibitors	O
of	O
CRAC	O
channel	O
activity	O
.	O

This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
therapy	O
.	O

New	O
bicyclic	O
compounds	O
as	O
crac	O
channel	O
modulators	O

The	O
invention	O
relates	O
to	O
fluorinated	O
fentanyl	B
derivatives	O
that	O
function	O
as	O
opioid	B
receptor	O
agonists	O
,	O
which	O
activate	O
target	O
opioid	B
receptors	O
in	O
a	O
pH	O
-	O
dependent	O
manner	O
,	O
and	O
are	O
thus	O
selective	O
for	O
the	O
receptors	O
in	O
inflamed	O
(	O
acidic	O
)	O
milieu	O
;	O
uses	O
thereof	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

Fentanyl	B
derivatives	O
as	O
ph	O
-	O
dependent	O
opioid	B
receptor	O
agonists	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R4	O
,	O
R8	O
,	O
X	O
and	O
Y	O
as	O
defined	O
herein	O
are	O
provided	O
as	O
useful	O
for	O
the	O
inhibition	O
of	O
certain	O
types	O
of	O
cancer	O
cells	O
,	O
amongst	O
others	O
,	O
breast	O
cancer	O
cells	O
,	O
or	O
for	O
the	O
manufacture	O
of	O
anti	O
-	O
cancer	O
agents	O
.	O

Substituted	O
2-imidazolidinones	B
and	O
2-imidazolones	B
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O

The	O
novel	O
positively	O
charged	O
pro	O
-	O
drugs	O
of	O
acetaminophen	B
,	O
acetaminosalol	B
,	O
and	O
related	O
compounds	O
in	O
the	O
general	O
formula	O
(	O
1	O
)	O
'	O
Structure	O
1	O
'	O
were	O
designed	O
and	O
synthesized	O
.	O

The	O
positively	O
charged	O
amino	B
groups	O
of	O
these	O
pro	O
-	O
drugs	O
not	O
only	O
largely	O
increases	O
the	O
solubility	O
of	O
the	O
drugs	O
,	O
but	O
also	O
bonds	O
to	O
the	O
negative	O
charge	O
on	O
the	O
phosphate	O
head	O
group	O
of	O
membranes	O
and	O
pushes	O
the	O
pro	O
-	O
drug	O
into	O
the	O
cytosol	O
.	O

The	O
results	O
suggest	O
that	O
the	O
pro	O
-	O
drugs	O
diffuses	O
through	O
human	O
skin	O
∼150	O
times	O
faster	O
than	O
does	O
acetaminophen	B
,	O
acetaminosalol	B
,	O
and	O
related	O
compounds	O
.	O

It	O
takes	O
1	O
-	O
2	O
hours	O
for	O
acetaminophen	B
and	O
acetaminosalol	B
,	O
and	O
related	O
compounds	O
to	O
reach	O
the	O
peak	O
plasma	O
level	O
when	O
they	O
are	O
taken	O
orally	O
,	O
but	O
these	O
prodrugs	O
only	O
took	O
about	O
∼50	O
minutes	O
to	O
reach	O
the	O
peak	O
plasma	O
level	O
when	O
they	O
are	O
taken	O
transdermally	O
.	O

In	O
plasma	O
,	O
more	O
than	O
90	O
%	O
of	O
these	O
pro	O
-	O
drugs	O
can	O
be	O
changed	O
back	O
to	O
the	O
parent	O
drugs	O
in	O
a	O
few	O
minutes	O
.	O

The	O
prodrugs	O
can	O
be	O
used	O
medicinally	O
for	O
treating	O
any	O
NSAIAs	O
-	O
treatable	O
conditions	O
in	O
humans	O
or	O
animals	O
.	O

The	O
prodrugs	O
can	O
be	O
administered	O
not	O
only	O
orally	O
,	O
but	O
also	O
transdermally	O
for	O
any	O
kind	O
of	O
medical	O
treatments	O
and	O
avoid	O
most	O
of	O
the	O
side	O
effects	O
of	O
NSAIAs	O
.	O

Controlled	O
transdermal	O
administration	O
systems	O
of	O
the	O
prodrugs	O
enables	O
acetaminophen	B
,	O
acetaminosalol	B
,	O
and	O
related	O
compounds	O
to	O
reach	O
constantly	O
optimal	O
therapeutic	O
blood	O
levels	O
to	O
increase	O
effectiveness	O
and	O
reduce	O
the	O
side	O
effects	O
of	O
acetaminophen	B
,	O
acetaminosalol	B
,	O
and	O
related	O
compounds	O
.	O

Another	O
great	O
benefit	O
of	O
transdermal	O
administration	O
of	O
these	O
pro	O
-	O
drugs	O
is	O
that	O
administering	O
medication	O
,	O
especially	O
to	O
children	O
,	O
will	O
be	O
much	O
easier	O
.	O

Positively	O
charged	O
water	O
-	O
soluble	O
prodrugs	O
of	O
acetaminophen	B
and	O
related	O
compunds	O
with	O
very	O
fast	O
skin	O
penetration	O
rate	O

The	O
present	O
invention	O
provides	O
a	O
novel	O
amino	B
compound	O
that	O
blocks	O
the	O
IKur	O
current	O
or	O
the	O
Kv1.5	O
channel	O
potently	O
and	O
more	O
selectively	O
than	O
other	O
K+	B
channels	O
.	O

The	O
present	O
invention	O
relates	O
to	O
an	O
amino	B
compound	O
represented	O
by	O
General	O
Formula	O
(	O
1	O
)	O
:	O
or	O
a	O
salt	O
thereof	O
,	O
wherein	O
R1	O
and	O
R2	O
are	O
each	O
independently	O
hydrogen	B
or	O
organic	O
group	O
;	O
XA	O
and	O
XB	O
are	O
each	O
independently	O
a	O
bond	O
,	O
alkylene	B
,	O
alkenylene	B
,	O
-CO-	B
,	O
-SO2-	B
,	O
or	O
-CONH-	B
,	O
wherein	O
each	O
of	O
the	O
alkylene	B
and	O
alkenylene	B
chains	O
can	O
optionally	O
contain	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
-S-	B
,	O
-C	B
(	I
=S	I
)	I
-	I
,	O
-SO2-	B
,	O
-CO-	B
,	O
-O-	B
,	O
-NH-	B
,	O
-CONH-	B
and	O
-SO2NH-	B
,	O
and	O
the	O
hydrogen	B
atom	O
(	O
H	O
)	O
bonded	O
to	O
the	O
nitrogen	B
atom	O
(	O
N	B
)	O
in	O
XA	O
and	O
XB	O
is	O
optionnally	O
substituted	O
with	O
a	O
subsituent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
lower	O
alkyl	B
,	O
phenyl	B
lower	O
alkyl	B
and	O
phenyl	B
;	O
A1	O
is	O
lower	O
alkylene	B
optionally	O
substituted	O
with	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydroxyl	B
and	O
oxo	B
;	O
R3	O
is	O
(	O
i	O
)	O
a	O
heterocyclic	B
group	O
which	O
is	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
substituents	O
,	O
or	O
(	O
ii	O
)	O
an	O
aryl	B
group	O
substituted	O
with	O
one	O
or	O
more	O
substituents	O
select	O
from	O
the	O
group	O
consisting	O
of	O
oxo	B
,	O
lower	O
alkyl	B
,	O
carboxyl	B
,	O
halo	B
-	O
lower	O
alkyl	B
,	O
lower	O
alkanoyl	B
lower	O
alkyl	B
,	O
phenyl	B
lower	O
alkyl	B
,	O
cyclo	O
lower	O
alkyl	B
,	O
lower	O
alkoxy	B
,	O
halo	B
lower	O
alkoxy	B
,	O
phenyl	B
lower	O
alkoxy	B
,	O
phenoxy	B
,	O
cyano	B
,	O
hydroxyl	B
,	O
halogen	B
,	O
nitro	B
,	O
lower	O
alkylthio	B
,	O
lower	O
alkanoyl	B
,	O
lower	O
alkoxy	B
carbonyl	I
,	O
lower	O
alkenyl	B
,	O
phenyl	B
,	O
triazolyl	B
,	O
isoxazolyl	B
,	O
imidazolyl	B
,	O
pyrrolyl	B
,	O
benzo	B
[	I
d	I
]	I
oxazolyl	I
,	O
benzo	B
[	I
d	I
]	I
thiazolyl	I
and	O
the	O
group	O
represented	O
by	O
General	O
Formula	O
(	O
2	O
)	O
:	O
wherein	O
Y	O
is	O
a	O
bond	O
,	O
lower	O
alkylene	B
,	O
or	O
-CO-	B
;	O
R4	O
and	O
R5	O
are	O
each	O
independently	O
hydrogen	B
,	O
lower	O
alkyl	B
,	O
cyclo	O
lower	O
alkyl	B
,	O
phenyl	B
,	O
or	O
lower	O
alkanoyl	B
;	O
or	O
R4	O
and	O
R5	O
may	O
be	O
linked	O
to	O
form	O
a	O
ring	O
together	O
with	O
the	O
neighboring	O
nitrogen	B
,	O
and	O
the	O
ring	O
may	O
optionally	O
have	O
one	O
or	O
more	O
substituents	O
.	O

Nitrogen	B
-	O
containing	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
for	O
the	O
treatment	O
of	O
atrial	O
fibrillation	O

The	O
present	O
disclosure	O
relates	O
in	O
part	O
to	O
methods	O
of	O
treating	O
cholangiocarcinoma	O
or	O
tonsillar	O
cancer	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
comprising	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
nanoparticle	O
composition	O
,	O
wherein	O
nanoparticle	O
composition	O
comprises	O
nanoparticles	O
.	O

Methods	O
of	O
treating	O
cancers	O
with	O
therapeutic	O
nanoparticles	O

Inhibitory	O
oligonucleotide	B
having	O
the	O
general	O
formula	O
:	O
X	O
1	O
⁢	O
C	O
C	O
N	O
1	O
N	O
2	O
N	O
3	O
X	O
2	O
N	O
4	O
N	O
5	O
G	O
G	O
G	O
N	O
6	O
X	O
3	O
N	O
7	O
are	O
disclosed	O
which	O
can	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
,	O
whereby	O
in	O
formula	O
(	O
I	O
)	O
C	O
is	O
cytidine	B
or	O
a	O
derivative	O
thereof	O
,	O
whereby	O
the	O
cytidine	B
derivative	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
5-methylcytidine	B
,	O
a	O
cytidine	B
-	O
like	O
nucleotide	O
having	O
a	O
chemical	O
modification	O
involving	O
the	O
cytosine	B
base	O
,	O
cytidine	B
nucleoside	O
sugar	B
,	O
or	O
both	O
the	O
cytosine	B
base	O
and	O
the	O
cytidine	B
nucleoside	O
sugar	B
,	O
2'-O	B
-	I
methylcytidine	I
,	O
5-bromocytidine	B
,	O
5-hydroxycytidine	B
,	O
ribocytidine	B
and	O
cytosine	B
-	I
β	I
-	I
D	I
-	I
arabinofuranoside	I
,	O
G	O
is	O
guanosine	B
or	O
a	O
derivative	O
thereof	O
,	O
whereby	O
the	O
guanosine	B
derivative	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
7-deazaguanosine	B
,	O
a	O
guanosine	B
-	O
like	O
nucleotide	O
having	O
a	O
chemical	O
modification	O
involving	O
the	O
guanine	B
base	O
,	O
the	O
guanosine	B
nucleoside	O
sugar	B
or	O
both	O
the	O
guanine	B
base	O
and	O
the	O
guanosine	B
nucleoside	O
sugar	B
,	O
X1	O
and	O
X3	O
is	O
any	O
nucleotide	O
sequence	O
with	O
0	O
to	O
12	O
bases	O
and	O
each	O
nucleotide	O
is	O
independent	O
of	O
any	O
other	O
,	O
X2	O
is	O
any	O
nucleotide	O
sequence	O
having	O
0	O
to	O
3	O
nucleotides	O
,	O
N1	O
,	O
N2	O
and	O
N3	O
are	O
each	O
independently	O
any	O
nucleotide	O
,	O
N4	O
and	O
N7	O
is	O
a	O
pyrimidine	B
or	O
a	O
modified	O
pyrimidine	B
,	O
N5	O
is	O
a	O
purin	B
or	O
a	O
modified	O
purin	B
,	O
N6	O
is	O
a	O
modified	O
pyrimidine	B
,	O
A	O
or	O
a	O
modified	O
purin	B
,	O
wherein	O
at	O
least	O
two	O
of	O
the	O
nucleotides	O
N4	O
,	O
N5	O
,	O
N6	O
or	O
N7	O
are	O
modified	O
purins	B
or	O
modified	O
pyrimidines	B
.	O

Inhibitory	O
oligonucleotides	B
and	O
their	O
use	O
in	O
therapy	O

Disclosed	O
are	O
a	O
category	O
of	O
platinum	B
compounds	O
having	O
amino-	B
or	O
alkylamino	B
-	O
containing	O
succinato	B
derivatives	O
as	O
leaving	O
group	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
preparation	O
method	O
thereof	O
,	O
and	O
medicinal	O
compositions	O
containing	O
the	O
compounds	O
.	O

Also	O
disclosed	O
is	O
a	O
use	O
of	O
the	O
compounds	O
in	O
treating	O
cell	O
proliferative	O
diseases	O
,	O
especially	O
cancers	O
.	O

The	O
platinum	B
compounds	O
of	O
the	O
present	O
invention	O
have	O
high	O
water	O
solubility	O
and	O
small	O
toxic	O
side	O
effect	O
.	O

Platinum	B
compound	O
having	O
amino-	B
or	O
alkylamino	B
-	O
containing	O
succinic	B
acid	I
derivatives	O
as	O
leaving	O
group	O
,	O
preparation	O
method	O
therefor	O
,	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
defined	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
variables	O
R1-R8	O
are	O
defined	O
as	O
in	O
the	O
description	O
,	O
possessing	O
valuable	O
pharmacological	O
activity	O
.	O

Particularly	O
,	O
the	O
compounds	O
are	O
inhibitors	O
of	O
cholesterol	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
and	O
thus	O
are	O
suitable	O
for	O
treatment	O
and	O
prevention	O
of	O
diseases	O
which	O
can	O
be	O
influenced	O
by	O
inhibition	O
of	O
this	O
protein	O
.	O

Furo	O
[	O
3,4-c	O
]	O
quinoline	O
derivatives	O
,	O
medicaments	O
containing	O
such	O
compounds	O
,	O
their	O
use	O
and	O
process	O
for	O
their	O
preparation	O

Provided	O
are	O
:	O
composition	O
and	O
methods	O
for	O
:	O
treating	O
aging	O
or	O
an	O
age	O
-	O
related	O
condition	O
,	O
symptom	O
or	O
disease	O
;	O
stimulating	O
hair	O
growth	O
,	O
regrowth	O
or	O
pigmentation	O
(	O
or	O
preventing	O
hair	O
loss	O
)	O
;	O
for	O
increasing	O
the	O
expression	O
of	O
an	O
adenosine	B
receptor	O
in	O
dermal	O
cells	O
(	O
in	O
combination	O
with	O
hair	O
growth	O
)	O
;	O
for	O
treating	O
a	O
condition	O
or	O
disease	O
of	O
the	O
skin	O
or	O
at	O
least	O
one	O
symptom	O
thereof	O
,	O
including	O
cosmetic	O
treatment	O
(	O
e.g.	O
,	O
wrinkles	O
,	O
hyperpigmentation	O
,	O
redness	O
,	O
rosacea	O
,	O
dryness	O
,	O
cracking	O
,	O
loss	O
of	O
firmness	O
,	O
loss	O
of	O
elasticity	O
,	O
thinning	O
,	O
and	O
loss	O
of	O
vibrance	O
)	O
.	O

The	O
methods	O
comprise	O
administering	O
a	O
sufficient	O
amount	O
of	O
the	O
disclosed	O
CBP	O
/	O
catenin	O
(	O
e.g.	O
,	O
CBP	O
/	O
B	O
-	O
catenin	O
)	O
antagonist	O
compositions	O
,	O
and	O
particularly	O
wherein	O
administration	O
is	O
in	O
an	O
amount	O
and	O
manner	O
sufficient	O
to	O
provide	O
for	O
increasing	O
the	O
number	O
of	O
asymmetric	O
renewing	O
divisions	O
relative	O
to	O
,	O
or	O
at	O
the	O
expense	O
of	O
symmetric	O
divisions	O
in	O
relevant	O
somatic	O
stem	O
cell	O
population	O
.	O

In	O
particular	O
aspects	O
,	O
the	O
CBP	O
/	O
catenin	O
(	O
e.g.	O
,	O
CBP	O
/	O
B	O
-	O
catenin	O
)	O
antagonist	O
comprises	O
an	O
alkyl	B
and/or	O
fatty	B
acid	I
ester	I
derivative	O
thereof	O
as	O
disclosed	O
herein	O
.	O

Cbp	O
/	O
catenin	O
antagonists	O
for	O
enhancing	O
asymmetric	O
division	O
of	O
somatic	O
stem	O
cells	O

Disclosed	O
are	O
quinazolines	B
of	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
and	O
hydrates	B
thereof	O
.	O

The	O
compounds	O
have	O
protein	O
kinases	O
inhibitory	O
activities	O
and	O
are	O
expected	O
to	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
protein	O
kinases	O
mediated	O
diseases	O
and	O
conditions	O
.	O

Quinazoline	B
derivatives	O
as	O
kinases	O
inhibitors	O
and	O
methods	O
of	O
use	O
thereof	O

(	B
-	I
)	I
-	I
(	I
S	I
)	I
-3-	I
(	I
3'-hydroxy	I
)	I
-butylphthalide	I
(	O
a	O
compound	O
shown	O
by	O
Formula	O
I	O
)	O
and	O
an	O
ester	B
formed	O
of	O
the	O
same	O
and	O
an	O
acid	O
are	O
proved	O
by	O
experiments	O
to	O
be	O
applicable	O
to	O
treatment	O
and	O
prevention	O
of	O
cerebral	O
ischemic	O
diseases	O
and	O
have	O
a	O
sleep	O
-	O
improving	O
function	O
.	O

The	O
acid	O
refers	O
to	O
a	O
pharmaceutically	O
acceptable	O
inorganic	O
or	O
organic	O
acid	O
.	O

The	O
inorganic	O
acid	O
refers	O
to	O
nitric	O
acid	O
,	O
sulfuric	O
acid	O
,	O
or	O
phosphoric	O
acid	O
.	O

In	O
addition	O
to	O
an	O
acid	O
radical	O
,	O
the	O
organic	O
acid	O
at	O
least	O
comprises	O
at	O
least	O
one	O
of	O
an	O
amino	B
group	O
,	O
a	O
hydroxyl	B
group	O
,	O
and	O
a	O
carboxyl	B
group	O
.	O

None	O
of	O
the	O
compound	O
shown	O
by	O
Formula	O
I	O
and	O
the	O
ester	B
thereof	O
is	O
water	O
-	O
soluble	O
.	O

An	O
ester	B
generated	O
from	O
the	O
compound	O
and	O
the	O
acid	O
further	O
react	O
with	O
an	O
acid	O
or	O
a	O
base	O
to	O
generate	O
a	O
salt	O
which	O
is	O
water	O
-	O
soluble	O
and	O
is	O
used	O
to	O
prepare	O
injection	O
preparation	O
.	O

The	O
experiment	O
proves	O
that	O
the	O
salt	O
does	O
not	O
stimulate	O
vessels	O
.	O

Derivative	O
of	O
butylphthalide	B
and	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
pharmaceutical	O
composition	O
or	O
a	O
kit	O
-	O
of	O
-	O
parts	O
and	O
its	O
use	O
in	O
the	O
treatment	O
of	O
burnout	O
syndrome	O
and	O
longevity	O
therapy	O
.	O

Pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
burnout	O
syndrome	O

Agents	O
,	O
methods	O
,	O
and	O
devices	O
for	O
affecting	O
nerve	O
function	O
are	O
described	O
.	O

One	O
embodiment	O
of	O
an	O
agent	O
includes	O
a	O
cardiac	O
glycoside	B
,	O
an	O
ACE	O
inhibitor	O
,	O
and	O
an	O
NSAID	O
.	O

The	O
agent	O
may	O
be	O
delivered	O
locally	O
in	O
a	O
site	O
-	O
specific	O
manner	O
to	O
a	O
targeted	O
nerve	O
or	O
portion	O
of	O
a	O
nerve	O
.	O

For	O
example	O
,	O
the	O
agent	O
may	O
be	O
delivered	O
locally	O
to	O
the	O
renal	O
nerves	O
to	O
impair	O
their	O
function	O
and	O
treat	O
hypertension	O
.	O

One	O
embodiment	O
of	O
a	O
delivery	O
device	O
includes	O
one	O
or	O
more	O
needle	O
housings	O
supported	O
by	O
a	O
balloon	O
.	O

A	O
delivery	O
needle	O
is	O
slidably	O
disposed	O
within	O
a	O
needle	O
lumen	O
of	O
each	O
needle	O
housing	O
.	O

Agents	O
,	O
methods	O
,	O
and	O
devices	O
for	O
affecting	O
nerve	O
function	O

Provided	O
herein	O
are	O
compounds	O
and	O
methods	O
of	O
synthesis	O
thereof	O
.	O

The	O
compounds	O
provided	O
herein	O
are	O
useful	O
for	O
the	O
treatment	O
,	O
prevention	O
,	O
and/or	O
management	O
of	O
various	O
disorders	O
,	O
such	O
as	O
pain	O
,	O
neurological	O
disorders	O
,	O
psychiatric	O
disorders	O
,	O
and	O
neuromuscular	O
disorders	O
.	O

Compounds	O
provided	O
herein	O
modulate	O
the	O
activity	O
of	O
opioid	B
receptor	O
(	O
e.g.	O
,	O
μ	O
-	O
opioid	O
receptor	O
)	O
in	O
the	O
central	O
nervous	O
system	O
or	O
the	O
periphery	O
.	O

Pharmaceutical	O
formulations	O
containing	O
the	O
compounds	O
and	O
their	O
methods	O
of	O
use	O
are	O
also	O
provided	O
herein	O
.	O

Modulators	O
of	O
opioid	B
receptors	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pyrrolopyridine	B
derivative	O
represented	O
by	O
the	O
Chemical	O
Formula	O
I	O
,	O
and	O
a	O
racemate	O
or	O
a	O
stereoisomer	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
relates	O
to	O
an	O
antiviral	O
composition	O
including	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
compound	O
of	O
the	O
Chemical	O
Formula	O
I	O
has	O
excellent	O
antiviral	O
activity	O
and	O
selectivity	O
for	O
wild	O
type	O
and	O
resistant	O
HIV-1	O
,	O
and	O
thereby	O
is	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

Novel	O
antiviral	O
pyrrolopyridine	B
derivative	O
and	O
a	O
production	O
method	O
for	O
same	O

Methods	O
for	O
modulating	O
the	O
activity	O
of	O
the	O
mammalian	O
BAR	O
/	O
FXR	O
receptor	O
.	O

The	O
methods	O
include	O
methods	O
of	O
treating	O
a	O
hypocholesterolemic	O
mammal	O
comprising	O
contacting	O
the	O
mammal	O
with	O
synthetic	O
compounds	O
able	O
to	O
modulate	O
an	O
activity	O
characteristic	O
of	O
the	O
BAR	O
/	O
FXR	O
receptor	O
.	O

Other	O
methods	O
include	O
a	O
method	O
of	O
treating	O
colon	O
cancer	O
in	O
a	O
mammal	O
comprising	O
administering	O
a	O
compound	O
having	O
a	O
BAR	O
/	O
FXR	O
antagonistic	O
activity	O
.	O

Composition	O
and	O
method	O
for	O
modulating	O
BAR	O
/	O
FXR	O
receptor	O
activity	O

This	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
an	O
allosteric	O
inhibitor	O
of	O
matrix	O
metalloproteinase-13	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
ligand	O
to	O
an	O
alpha-2-delta	O
receptor	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
combination	O
,	O
and	O
a	O
method	O
of	O
using	O
the	O
combination	O
to	O
treat	O
a	O
disease	O
or	O
disorder	O
in	O
a	O
mammal	O
suffering	O
therefrom	O
,	O
wherein	O
the	O
disease	O
or	O
disorder	O
is	O
responsive	O
to	O
treatment	O
in	O
one	O
aspect	O
by	O
an	O
allosteric	O
inhibitor	O
of	O
MMP-13	O
and	O
in	O
the	O
same	O
or	O
a	O
different	O
aspect	O
by	O
a	O
ligand	O
to	O
an	O
alpha-2-delta	O
receptor	O
.	O

Joint	O
cartilage	O
damage	O
,	O
inflammation	O
,	O
stiffness	O
,	O
impaired	O
function	O
and/or	O
pain	O
;	O
osteoarthritis	O
,	O
rheumatoid	O
arthritis	O

Disclosed	O
are	O
methods	O
for	O
preventing	O
or	O
treating	O
a	O
gastrointestinal	O
(	O
GI	O
)	O
disorder	O
in	O
a	O
mammal	O
such	O
as	O
a	O
human	O
patient	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
methods	O
include	O
administering	O
to	O
the	O
mammal	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
modulates	O
a	O
nitric	B
oxide	I
(	O
NO	B
)	O
signaling	O
pathway	O
,	O
particularly	O
in	O
GI	O
neurons	O
.	O

Methods	O
of	O
the	O
invention	O
are	O
particularly	O
useful	O
for	O
the	O
treatment	O
(	O
including	O
prophylactic	O
treatment	O
)	O
of	O
diabetic	O
gastropathies	O
and	O
other	O
GI	O
disorders	O
.	O

Methods	O
for	O
prevention	O
and	O
treatment	O
of	O
gastrointestinal	O
disorders	O

The	O
present	O
invention	O
provides	O
cationic	O
dendrimers	O
for	O
delivering	O
bioactive	O
molecules	O
,	O
such	O
as	O
polynucleotide	O
molecules	O
,	O
peptides	O
and	O
polypeptides	O
and/or	O
pharmaceutical	O
agents	O
,	O
to	O
a	O
mammalian	O
body	O
.	O

The	O
dendrimers	O
disclosed	O
herein	O
are	O
suitable	O
for	O
targeting	O
the	O
delivery	O
of	O
the	O
bioactive	O
molecules	O
to	O
,	O
for	O
example	O
,	O
the	O
liver	O
,	O
spleen	O
,	O
lung	O
,	O
kidney	O
or	O
heart	O
.	O

Nucleotide	O
sequences	O
comprising	O
cationic	O
polypropylenimine	B
dendrimer	O
and	O
diaminobutane	B
core	O
for	O
use	O
as	O
tool	O
in	O
delivery	O
of	O
drug	O
agents	O
and	O
tissue	O
targeted	O
therapy	O

The	O
present	O
invention	O
discloses	O
a	O
method	O
for	O
treating	O
a	O
subject	O
affected	O
by	O
an	O
autoimmune	O
disease	O
,	O
in	O
particular	O
multiple	O
sclerosis	O
,	O
lupus	O
erythematosus	O
systemicus	O
and	O
rheumatoid	O
arthritis	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
amount	O
of	O
3-	B
(	I
2-ethylphenyl	I
)	I
-5-methoxy-1H-1,2,4-tirazole	I
.	O

The	O
present	O
invention	O
further	O
discloses	O
a	O
method	O
for	O
inhibiting	O
γδ	O
T	O
cells	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
said	O
method	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
amount	O
of	O
the	O
same	O
compound	O
.	O

Use	O
of	O
(	B
3-	I
(	I
2-ethylphenyl	I
)	I
-5-methoxyphenyl	I
)	I
-1H-	I
[	I
1,2,4	I
]	I
-triazole	I
for	O
the	O
treatment	O
of	O
autoimmune	O
diseases	O

This	O
invention	O
is	O
aimed	O
to	O
provide	O
a	O
stabilized	O
formulation	O
of	O
ramosetron	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
under	O
a	O
temperature	O
/	O
humidity	O
condition	O
,	O
especially	O
at	O
a	O
low	O
content	O
and	O
relates	O
to	O
a	O
stable	O
oral	O
solid	O
drug	O
composition	O
of	O
ramosetron	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
which	O
is	O
characterized	O
by	O
containing	O
one	O
or	O
two	O
or	O
more	O
members	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
aliphatic	B
carboxylic	I
acid	I
or	O
an	O
ester	B
thereof	O
,	O
a	O
hydroxycarboxylic	B
acid	I
or	O
an	O
ester	B
thereof	O
,	O
an	O
acidic	O
amino	B
acid	I
,	O
an	O
enolic	B
acid	I
,	O
an	O
aromatic	B
carboxyl	I
compound	O
or	O
an	O
ester	B
thereof	O
,	O
and	O
a	O
carboxyl	B
group	O
-	O
containing	O
high	O
-	O
molecular	O
substance	O
,	O
and	O
to	O
a	O
stabilization	O
method	O
of	O
the	O
same	O
.	O

Also	O
,	O
this	O
invention	O
relates	O
to	O
a	O
therapeutic	O
agent	O
of	O
diarrhea	O
-	O
predominant	O
irritable	O
bowel	O
syndrome	O
containing	O
from	O
0.002	O
to	O
0.02	O
mg	O
of	O
ramosetron	B
hydrochloride	I
as	O
a	O
daily	O
dose	O
or	O
an	O
equivalent	O
molar	O
amount	O
of	O
ramosetron	B
or	O
its	O
pharmaceutically	O
acceptable	O
other	O
salt	O
as	O
an	O
active	O
ingredient	O
.	O

Stable	O
oral	O
solid	O
drug	O
composition	O

A	O
pharmaceutical	O
dispenser	O
,	O
comprising	O
a	O
liquid	O
formulation	O
comprising	O
nitric	B
oxide	I
,	O
and	O
means	O
for	O
forming	O
a	O
nebulised	O
mist	O
of	O
the	O
liquid	O
formulation	O
.	O

The	O
nebulised	O
mist	O
of	O
the	O
liquid	O
formulation	O
is	O
used	O
primarily	O
in	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O

A	O
pharmaceutical	O
dispenser	O
;	O
a	O
liquid	O
formulation	O
comprising	O
nitric	B
oxide	I
;	O
respiratory	O
system	O
diseases	O
;	O
atomizing	O

The	O
present	O
invention	O
is	O
a	O
method	O
of	O
treating	O
Alzheimer	O
's	O
disease	O
,	O
and	O
other	O
diseases	O
,	O
and/or	O
inhibiting	O
beta	O
-	O
secretase	O
enzyme	O
,	O
and/or	O
inhibiting	O
deposition	O
of	O
A	O
beta	O
peptide	O
in	O
a	O
mammal	O
,	O
by	O
use	O
of	O
known	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
,	O
A	O
,	O
R	O
,	O
J	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O

Hydroxy	B
substituted	I
amides	I
for	O
the	O
treatment	O
of	O
alzheimer	O
's	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
product	O
for	O
administration	O
to	O
a	O
patient	O
,	O
the	O
product	O
comprising	O
4′-cyano	B
-	I
α′,α′,α′-trifluoro-3-	I
(	I
4-fluorophenylsulphonyl	I
)	I
-2-hydroxy-2-methylpropiono	I
-	I
m	I
-	I
toluidide	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
in	O
solid	O
dispersion	O
with	O
an	O
enteric	O
polymer	O
having	O
a	O
pKa	O
from	O
3	O
to	O
6	O
,	O
the	O
product	O
further	O
comprising	O
an	O
anti	O
-	O
oestrogen	O
(	O
eg	O
,	O
tamoxifen	B
citrate	I
)	O
and/or	O
an	O
aromatase	O
inhibitor	O
(	O
eg	O
,	O
anastrozole	B
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
dose	O
of	O
the	O
drug	O
and	O
anti	O
-	O
oestrogen	O
/	O
aromatase	O
inhibitor	O
provided	O
by	O
such	O
a	O
formulation	O
.	O

An	O
advantage	O
is	O
the	O
treating	O
and/or	O
preventing	O
of	O
at	O
least	O
one	O
side	O
effect	O
selected	O
from	O
gynaecomastia	O
,	O
breast	O
tenderness	O
,	O
hot	O
flushes	O
,	O
impotence	O
and	O
reduction	O
in	O
libido	O
,	O
while	O
increasing	O
the	O
bioavailability	O
of	O
the	O
drug	O
;	O
reducing	O
inter	O
-	O
patient	O
variability	O
in	O
plasma	O
concentrations	O
of	O
the	O
4′-cyano	B
-	I
α′,α′,α′-trifluoro-3-	I
(	I
4-fluorophenylsulphonyl	I
)	I
-2-hydroxy-2-methylpropiono	I
-	I
m	I
-	I
toluidide	I
;	O
enhancing	O
the	O
storage	O
stability	O
of	O
the	O
drug	O
;	O
and/or	O
treating	O
and/or	O
reducing	O
the	O
risk	O
of	O
prostate	O
cancer	O
in	O
a	O
patient	O
.	O

4'-cyano-	B
alpha	I
'	I
,	I
alpha	I
'	I
,	I
alpha	I
'	I
-trifluoro-3-	I
(	I
4-fluorophenylsulphonyl	I
)	I
-2-hydroxy-2-methylpropiono	I
-	I
m	I
-	I
toluidide	I
;	O
anti	O
-	O
oestrogen	O
(	O
eg	O
,	O
tamoxifen	B
citrate	I
)	O
and/or	O
an	O
aromatase	O
inhibitor	O
(	O
eg	O
,	O
anastrozole	B
)	O
;	O
preventing	O
side	O
effect	O
;	O
bioavailability	O
;	O
storage	O
stability	O
;	O
prostate	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
a	O
micronized	O
film	O
-	O
forming	O
powder	O
having	O
a	O
particle	O
size	O
of	O
at	O
most	O
100	O
μm	O
and	O
comprising	O
a	O
combination	O
of	O
at	O
least	O
one	O
active	O
substance	O
,	O
at	O
least	O
one	O
bioadhesive	O
agent	O
,	O
and	O
at	O
least	O
a	O
plasticizer	O
.	O

Pharmaceuticals	O
,	O
cosmetics	O
or	O
nutraceuticals	O
with	O
a	O
bioadhesive	O
and	O
plasticizer	O
on	O
a	O
biodegradable	O
support	O
for	O
transdermal	O
or	O
transmucosal	O
application	O

Pharmaceutical	O
composition	O
comprising	O
an	O
anti	O
-	O
IgE	O
antibody	O
and	O
at	O
least	O
one	O
further	O
antiallergic	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
leukotriene	O
modifiers	O
,	O
bronchodilators	O
,	O
antihistamines	O
,	O
interleukin	O
antagonists	O
,	O
mast	O
cell	O
inhibitors	O
,	O
and	O
immunotherapeutical	O
agents	O
,	O
such	O
as	O
33-epichloro,33-desoxyzascomycin	B
(	O
pimecrolimus	B
)	O
,	O
in	O
which	O
the	O
active	O
ingredients	O
are	O
present	O
in	O
each	O
case	O
in	O
free	O
form	O
or	O
in	O
the	O
form	O
of	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and	O
optionally	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
carrier	O
;	O
for	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
use	O
.	O

Combination	O
treatments	O
for	O
allergic	O
disease	O
comprising	O
administering	O
an	O
anti	O
-	O
ige	O
antibody	O
and	O
antiallergic	O
compound	O

The	O
invention	O
relates	O
generally	O
to	O
phosphoinositide	O
3-kinases	O
(	O
PI3Ks	O
)	O
,	O
and	O
more	O
particularly	O
to	O
methods	O
of	O
inhibiting	O
leukocyte	O
accumulation	O
comprising	O
selectively	O
inhibiting	O
phosphoinositide	O
3-kinase	O
delta	O
(	O
PI3Kδ	O
)	O
activity	O
in	O
endothelial	O
cells	O
.	O

Methods	O
of	O
inhibiting	O
leukocyte	O
accumulation	O

Compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
their	O
acid	O
addition	O
salts	O
are	O
provided	O
wherein	O
:	O
R1	O
signifies	O
a	O
piperazino	B
,	O
p	B
-	I
phenylenediamino	I
,	O
a	O
2,5-diazabicyclo-	B
[	I
2.2.1	I
]	I
-heptane	I
,	O
a	O
2,5-diazabicyclo-	B
[	I
2.2.2	I
]	I
-octane	I
radical	O
or	O
a	O
3,8-diazabicyclo-	B
[	I
3.2.1	I
]	I
-octane	I
radical	O
,	O
which	O
in	O
each	O
case	O
can	O
be	O
substituted	O
with	O
at	O
least	O
one	O
substituent	O
,	O
R2	O
,	O
R4	O
,	O
which	O
are	O
in	O
each	O
case	O
the	O
same	O
,	O
signify	O
a	O
pyrrolidino	B
,	O
thiazolidino	B
,	O
oxazolidino	B
or	O
imidazolidino	B
radical	O
,	O
which	O
in	O
each	O
case	O
can	O
be	O
substituted	O
with	O
at	O
least	O
one	O
substituent	O
,	O
and	O
R3	O
signifies	O
an	O
alkyl	B
,	O
alkoxy	B
,	O
alkylmercapto	B
or	O
an	O
alkylamino	B
radical	O
,	O
which	O
in	O
each	O
case	O
can	O
be	O
substituted	O
with	O
at	O
least	O
one	O
substituent	O
.	O

These	O
pteridine	O
derivatives	O
are	O
suitable	O
for	O
the	O
inhibition	O
of	O
phosphodiesterases	O
and	O
therefore	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
thrombo	O
-	O
embolic	O
,	O
neurodegenerative	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
asthmatic	O
diseases	O
as	O
well	O
as	O
hemato	O
-	O
oncological	O
diseases	O
.	O

Pteridine	B
derivatives	O
,	O
method	O
of	O
producing	O
them	O
and	O
their	O
application	O

A	O
process	O
for	O
preparing	O
a	O
compound	O
of	O
the	O
formula	O
I	O
:	O
or	O
pharmaceutical	O
acceptable	O
salts	O
thereof	O
wherein	O
X	O
is	O
—NR1—	B
,	O
—S	B
(	I
O	I
)	I
g—	I
,	O
or	O
—O—	B
;	O
R1	O
is	O
—H	B
,	O
C1	B
-	I
6	I
alkyl	I
optionally	O
substituted	O
with	O
one	O
or	O
more	O
—OH	B
,	O
—CN	B
,	O
or	O
halo	B
,	O
or	O
R1	O
is	O
—	B
(	I
CH2	I
)	I
h	I
-	I
aryl	I
,	O
—COR1	B
-	I
1	I
,	O
—COOR1	B
-	I
2	I
,	O
—CO—	B
(	I
CH2	I
)	I
h	I
—	I
COR1	I
-	I
1	I
,	O
C1	B
-	I
6	I
alkyl	I
sulfonyl	I
,	O
—SO2—	B
(	I
CH2	I
)	I
h	I
-	I
aryl	I
,	O
or	O
—	B
(	I
CO	I
)	I
i	I
-	I
Het	I
;	O
R2	O
is	O
—H	B
,	O
C1	B
-	I
6	I
alkyl	I
,	O
—	B
(	I
CH2	I
)	I
h	I
-	I
aryl	I
,	O
or	O
halo	B
;	O
R3	O
and	O
R4	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
—H	B
or	O
halo	B
;	O
R5	O
is	O
—H	B
,	O
C1	B
-	I
12	I
alkyl	I
optionally	O
substituted	O
with	O
one	O
or	O
more	O
halo	B
,	O
C3	B
-	I
12	I
cycloalkyl	I
,	O
C1	B
-	I
6	I
alkoxy	I
.	O

The	O
compounds	O
are	O
useful	O
antimicrobial	O
agents	O
.	O

Microbiocides	O
;	O
bacteriocides	O
;	O
oxazolidinone	B
compound	O

The	O
present	O
invention	O
discloses	O
novel	O
peptide	O
compounds	O
which	O
have	O
HCV	O
protease	O
inhibitory	O
activity	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
such	O
compounds	O
.	O

In	O
another	O
embodiment	O
,	O
the	O
invention	O
discloses	O
pharmaceutical	O
compositions	O
comprising	O
such	O
peptides	O
as	O
well	O
as	O
methods	O
of	O
using	O
them	O
to	O
treat	O
disorders	O
associated	O
with	O
the	O
HCV	O
protease	O
.	O

hexapeptides	O
including	O
enantiomers	O
,	O
stereoisomers	O
and	O
tautomers	O
,	O
used	O
as	O
enzyme	O
inhibitors	O
for	O
prophylaxis	O
or	O
prevention	O
of	O
viral	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
a	O
controlled	O
dosage	O
release	O
element	O
adapted	O
to	O
be	O
inserted	O
into	O
and	O
retained	O
in	O
the	O
rumen	O
of	O
a	O
ruminant	O
animal	O
.	O

The	O
element	O
comprises	O
:	O
a	O
)	O
one	O
or	O
more	O
discrete	O
and	O
predetermined	O
amounts	O
of	O
at	O
least	O
a	O
first	O
formulation	O
comprising	O
at	O
least	O
a	O
first	O
active	O
agent	O
,	O
the	O
formulation	O
being	O
adapted	O
to	O
dissolve	O
in	O
rumen	O
fluids	O
at	O
a	O
rate	O
such	O
that	O
dissolution	O
of	O
each	O
of	O
the	O
one	O
or	O
more	O
amounts	O
of	O
first	O
formulation	O
provides	O
a	O
short	O
or	O
pulsed	O
episode	O
of	O
release	O
of	O
the	O
first	O
active	O
agent	O
into	O
the	O
rumen	O
;	O
and	O
b	O
)	O
one	O
or	O
more	O
predetermined	O
amounts	O
of	O
at	O
least	O
a	O
second	O
formulation	O
adapted	O
to	O
dissolve	O
at	O
a	O
controlled	O
rate	O
in	O
rumen	O
fluids	O
;	O
wherein	O
the	O
one	O
or	O
more	O
amounts	O
of	O
first	O
formulation	O
are	O
provided	O
at	O
one	O
or	O
more	O
predetermined	O
locations	O
within	O
the	O
element	O
relative	O
to	O
said	O
one	O
or	O
more	O
amounts	O
of	O
second	O
formulation	O
for	O
one	O
or	O
more	O
delayed	O
releases	O
of	O
at	O
least	O
the	O
first	O
active	O
agent	O
into	O
the	O
rumen	O
at	O
predetermined	O
times	O
before	O
,	O
during	O
,	O
after	O
,	O
or	O
any	O
combination	O
thereof	O
,	O
of	O
a	O
predetermined	O
extended	O
time	O
period	O
defined	O
by	O
said	O
second	O
formulation	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
delivering	O
at	O
least	O
a	O
first	O
active	O
agent	O
to	O
the	O
rumen	O
of	O
a	O
ruminant	O
animal	O
in	O
a	O
delayed	O
manner	O
at	O
one	O
or	O
more	O
predetermined	O
times	O
after	O
administration	O
to	O
the	O
animal	O
of	O
a	O
composition	O
containing	O
the	O
active	O
agent	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
animal	O
a	O
controlled	O
dosage	O
release	O
element	O
according	O
to	O
the	O
invention	O
.	O

The	O
first	O
active	O
agent	O
will	O
typically	O
be	O
for	O
the	O
treatment	O
,	O
prophylaxis	O
or	O
both	O
of	O
a	O
diseased	O
or	O
infested	O
state	O
in	O
a	O
ruminant	O
animal	O
,	O
or	O
for	O
altering	O
the	O
physiological	O
status	O
of	O
a	O
ruminant	O
animal	O
.	O

Dosage	O
form	O
,	O
device	O
,	O
and	O
methods	O
of	O
treatment	O

The	O
present	O
invention	O
relates	O
to	O
plasmids	O
suitable	O
for	O
IL-2	O
expression	O
,	O
particularly	O
,	O
human	O
IL-2	O
expression	O
,	O
and	O
related	O
methods	O
.	O

Plasmids	O
suitable	O
for	O
IL-2	O
expression	O

A	O
method	O
for	O
treating	O
increased	O
uninary	O
urgency	O
or	O
urinary	O
incontinence	O
,	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
corresponding	O
to	O
formula	O
I	O
It	O
has	O
been	O
surprisingly	O
discovered	O
that	O
the	O
methods	O
of	O
the	O
present	O
invention	O
are	O
effective	O
for	O
treating	O
increased	O
urinary	O
urgency	O
or	O
urinary	O
incontinence	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treatment	O
using	O
related	O
pharmaceutical	O
compositions	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
urinary	O
incontinence	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R3	O
is	O
the	O
group	O
;	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
,	O
particularly	O
as	O
p38	O
kinase	O
inhibitors	O
.	O

Oxadiazolyl	B
-	I
biphenylcarboxamides	I
and	O
their	O
use	O
as	O
p38	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
a	O
photosensitizing	O
agent	O
and	O
a	O
skin	O
-	O
penetration	O
enhancer	O
.	O

The	O
composition	O
herein	O
show	O
improved	O
delivery	O
of	O
the	O
photosensitizer	O
through	O
the	O
stratum	O
corneum	O
.	O

In	O
addition	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
show	O
improved	O
stability	O
and	O
a	O
reduced	O
incidence	O
of	O
skin	O
photosensitivity	O
.	O

having	O
improved	O
stability	O
and	O
side	O
effect	O
reduction	O
;	O
tissue	O
-	O
targeted	O
therapy	O

The	O
invention	O
relates	O
to	O
a	O
new	O
formulation	O
for	O
oral	O
administration	O
of	O
active	O
substances	O
with	O
pH	O
-	O
dependent	O
solubility	O
characteristics	O
and	O
the	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
improves	O
the	O
bioavailability	O
of	O
the	O
active	O
substance	O
.	O

Bioavailability	O
of	O
drug	O
independent	O
of	O
gastric	O
pH	O
;	O
core	O
comprised	O
of	O
water	O
soluble	O
acid	O
(	O
s	O
)	O
of	O
tartaric	B
acid	I
,	O
fumaric	B
acid	I
,	O
succinic	B
acid	I
,	O
citric	B
acid	I
,	O
malic	B
acid	I
,	O
glutamic	B
acid	I
,	O
and/or	O
aspartic	B
acid	I
or	O
salts	O
;	O
acid	O
resistance	O
;	O
drug	O
delivery	O

NK3	O
receptor	O
antagonists	O
of	O
formula	O
(	O
I	O
)	O
:	O
are	O
useful	O
in	O
treating	O
inter	O
alia	O
pulmonary	O
disorders	O
,	O
CNS	O
disorders	O
and	O
neurodegenerative	O
disorders	O
.	O

Quinoline	B
derivatives	O
(	O
2	O
)	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
creatine	B
pyruvate	I
for	O
increasing	O
stamina	O
during	O
highly	O
intensive	O
intermittent	O
physical	O
exertion	O
.	O

Said	O
use	O
is	O
to	O
be	O
applied	O
in	O
particular	O
during	O
short	O
-	O
term	O
intensive	O
muscular	O
exertion	O
and/or	O
muscular	O
exertion	O
of	O
short	O
-	O
duration	O
and/or	O
that	O
is	O
repeated	O
in	O
short	O
intervals	O
,	O
preferably	O
during	O
sprinting	O
and	O
sporting	O
performances	O
in	O
running	O
disciplines	O
and	O
during	O
exercises	O
using	O
sports	O
equipment	O
provided	O
with	O
rollers	O
,	O
wheels	O
or	O
sliding	O
surfaces	O
,	O
in	O
addition	O
to	O
during	O
raising	O
,	O
pulling	O
and/or	O
lifting	O
movements	O
of	O
the	O
extremities	O
and	O
the	O
neck	O
.	O

The	O
invention	O
relates	O
in	O
particular	O
to	O
variants	O
,	O
in	O
which	O
muscular	O
exertion	O
is	O
maintained	O
for	O
between	O
0.1	O
seconds	O
and	O
5	O
minutes	O
and/or	O
during	O
which	O
the	O
muscular	O
exertion	O
is	O
carried	O
out	O
with	O
a	O
frequency	O
of	O
between	O
0.1	O
and	O
600	O
minutes	O
.	O

In	O
the	O
latter	O
variant	O
,	O
the	O
muscular	O
exertion	O
can	O
increase	O
with	O
each	O
interval	O
.	O

The	O
creatine	B
pyruvate	I
is	O
administered	O
in	O
the	O
required	O
application	O
in	O
daily	O
doses	O
of	O
between	O
500	O
mg	O
and	O
30	O
g	O
and	O
in	O
particular	O
over	O
a	O
period	O
of	O
between	O
1	O
day	O
and	O
12	O
weeks	O
in	O
powder	O
,	O
lozenge	O
,	O
capsule	O
or	O
coated	O
tablet	O
form	O
,	O
in	O
liquids	O
and	O
also	O
as	O
a	O
food	O
supplement	O
or	O
functional	O
food	O
.	O

Use	O
of	O
creatine	B
pyruvate	I
for	O
increasing	O
stamina	O
during	O
highly	O
intensive	O
intermittent	O
physical	O
exertion	O

This	O
invention	O
provides	O
combinatorial	O
chemistry	O
libraries	O
containing	O
thiourea	B
and	O
urea	B
compounds	O
.	O

In	O
addition	O
,	O
the	O
invention	O
relates	O
to	O
methods	O
for	O
constructing	O
combinatorial	O
chemistry	O
libraries	O
containing	O
thiourea	B
and	O
urea	B
compounds	O
.	O

Furthermore	O
,	O
this	O
invention	O
relates	O
to	O
methods	O
for	O
the	O
identification	O
of	O
bioactive	O
thiourea	O
and	O
urea	O
compounds	O
as	O
well	O
as	O
compositions	O
and	O
therapeutic	O
methods	O
for	O
treating	O
cancer	O
.	O

Reacting	O
1,1'-thiocarbonyldiimidazole	B
with	O
an	O
aryl	B
amine	I
,	O
e.g.	O
,	O
benzylamine	B
,	O
to	O
form	O
1830	O
thiourea	B
(	O
or	O
urea	B
)	O
prodoucts	O
;	O
high	O
speed	O
,	O
automatic	O
process	O
;	O
anticarcinogenic	O
agents	O
,	O
leukemia	O
;	O
enzyme	O
inhibitors	O
for	O
HIV	O
reverse	O
transcriptase	O
(	O
polymerase	O
)	O

The	O
phosphoric	B
acid	I
salt	O
of	O
3-	B
(	I
2-methoxy	I
-	I
pyrimidin-5-yl	I
)	I
-5-oxo-9-	I
(	I
6,7,8,9-tetrahydro-5H	I
-	I
pyrido	I
[	I
2,3-b	I
]	I
azepin-2-yl	I
)	I
-nonanoic	I
acid	I
is	O
a	O
potent	O
antagonist	O
of	O
the	O
integrin	O
αvβ3	O
receptor	O
and	O
is	O
useful	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
osteoporosis	O
and	O
vascular	O
restenosis	O
,	O
as	O
well	O
as	O
conditions	O
associated	O
with	O
excessive	O
angiogenesis	O
,	O
such	O
as	O
macular	O
degeneration	O
,	O
diabetic	O
retinopathy	O
,	O
atherosclerosis	O
,	O
inflammatory	O
arthritis	O
,	O
cancer	O
,	O
and	O
metastatic	O
tumor	O
growth	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
novel	O
salt	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
.	O

Phosphoric	B
acid	I
salt	O
of	O
an	O
integrin	O
receptor	O
antagonist	O

A	O
method	O
for	O
treating	O
,	O
eliminating	O
and	O
preventing	O
an	O
inflammation	O
of	O
the	O
skin	O
or	O
mucous	O
membrane	O
of	O
a	O
mammal	O
,	O
including	O
a	O
human	O
,	O
by	O
administering	O
to	O
the	O
skin	O
or	O
mucous	O
membrane	O
a	O
composition	O
containing	O
dimethicone	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
dimethicone	O
composition	O
is	O
applied	O
to	O
the	O
skin	O
or	O
mucous	O
membrane	O
in	O
an	O
amount	O
effective	O
to	O
treat	O
,	O
eliminate	O
or	O
prevent	O
the	O
inflammation	O
.	O

Treating	O
inflammation	O
of	O
the	O
skin	O
or	O
mucous	O
membrane	O
by	O
topical	O
administration	O
of	O
an	O
anti	O
-	O
inflammatory	O
amount	O
of	O
dimethicone	O
in	O
the	O
absence	O
of	O
any	O
other	O
anti	O
-	O
inflammatory	O
agent	O

The	O
present	O
invention	O
provides	O
a	O
heterocyclic	B
compound	O
having	O
potent	O
tyrosine	B
kinase	O
-	O
inhibiting	O
activity	O
represented	O
by	O
formula	O
:	O
(	O
wherein	O
,	O
R1b	O
is	O
a	O
C6	B
-	I
10	I
aryl	I
group	O
which	O
has	O
substituent	O
(	O
s	O
)	O
,	O
and	O
the	O
like	O
;	O
Ta	O
is	O
a	O
single	O
bond	O
,	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
,	O
—CH2O—	B
,	O
and	O
the	O
like	O
;	O
X	O
and	O
Y	O
are	O
the	O
same	O
or	O
different	O
,	O
and	O
each	O
is	O
a	O
nitrogen	B
atom	O
which	O
may	O
have	O
substituent	O
(	O
s	O
)	O
,	O
and	O
the	O
like	O
;	O
the	O
broken	O
line	O
is	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
;	O
Za	O
is	O
a	O
nitrogen	B
atom	O
or	O
CH	B
;	O
W	O
is	O
a	O
single	O
bond	O
,	O
an	O
oxygen	B
atom	O
,	O
and	O
the	O
like	O
;	O
Q	O
is	O
a	O
C6	B
-	I
10	I
aryl	I
group	O
which	O
may	O
have	O
substituent	O
(	O
s	O
)	O
or	O
an	O
aromatic	B
heterocyclic	I
group	O
which	O
may	O
have	O
substituent	O
(	O
s	O
)	O
)	O
;	O
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
thereof	O
.	O

For	O
example	O
,	O
2-	B
(	I
1,3-benzodioxol-5-yl	I
)	I
-6-phenyl-1H	I
-	I
imidazo	I
[	I
4,5-b	I
]	I
pyridinetyrosine	I
;	O
kinase	O
-	O
inhibiting	O
activity	O
;	O
use	O
in	O
treatment	O
of	O
breast	O
cancer	O
,	O
prostate	O
cancer	O
,	O
lung	O
cancer	O
or	O
pancreatic	O
carcinoma	O

The	O
present	O
invention	O
relates	O
to	O
gangliosides	O
derived	O
or	O
isolated	O
from	O
buffalo	O
milk	O
,	O
skimmed	O
buffalo	O
milk	O
,	O
buffalo	O
milk	O
serum	O
or	O
derivatives	O
of	O
either	O
.	O

Buffalo	O
milk	O
is	O
reported	O
to	O
comprise	O
gangliosides	O
that	O
are	O
not	O
contained	O
in	O
bovine	O
milk	O
,	O
such	O
as	O
gangliosides	O
that	O
belong	O
to	O
the	O
GM1-class	O
.	O

Furthermore	O
,	O
bufalo	O
milk	O
is	O
found	O
to	O
comprise	O
unknown	O
gangliosides	O
,	O
denoted	O
herein	O
as	O
ganglioside	O
""""	O
F	O
""""	O
and	O
""""	O
L	O
""""	O
.	O

Furthermore	O
,	O
the	O
invention	O
reports	O
that	O
gangliosides	O
are	O
surprisingly	O
found	O
in	O
fractions	O
of	O
isolation	O
procedures	O
that	O
were	O
so	O
far	O
not	O
considered	O
to	O
comprise	O
gangliosides	O
.	O

Finally	O
,	O
milk	O
or	O
milk	O
serum	O
from	O
buffalo	O
,	O
for	O
example	O
as	O
derived	O
from	O
mozzarella	O
cheese	O
production	O
,	O
contains	O
specific	O
gangliosides	O
in	O
the	O
same	O
amounts	O
as	O
human	O
breast	O
milk	O
,	O
which	O
makes	O
it	O
suitable	O
for	O
humanisation	O
of	O
infant	O
and	O
other	O
formulas	O
.	O

buffalo	O
milk	O
and	O
human	O
milk	O
have	O
comparable	O
GM1	O
and	O
polysialo	O
-	O
ganglioside	O
levels	O
;	O
infant	O
formula	O
;	O
pet	O
foods	O
;	O
instant	O
milk	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
1	O
)	O
in	O
which	O
R1	O
=	O
H	B
,	O
F	B
or	O
OCH3	B
and	O
may	O
occupy	O
the	O
2	O
,	O
3	O
,	O
4	O
or	O
5	O
position	O
on	O
the	O
aromatic	B
carbocycle	I
,	O
R2	O
=	O
H	B
or	O
CH3	B
,	O
R3	O
=	O
H	B
,	O
CH3	B
,	O
OH	B
or	O
OCH3	B
,	O
R4	O
=	O
H	B
and	O
R3	O
and	O
R4	O
together	O
can	O
be	O
a	O
carbonyl	B
group	O
(	O
C=0	B
)	O
,	O
the	O
addition	O
salts	O
and	O
optionally	O
the	O
hydrates	O
of	O
additional	O
salts	O
with	O
pharmaceutically	O
-	O
acceptable	O
mineral	O
or	O
organic	O
acids	O
and	O
the	O
isomers	O
and	O
tautomers	O
thereof	O
.	O

Novel	O
tricycloimidazoline	B
derivatives	O
method	O
for	O
production	O
and	O
use	O
thereof	O
as	O
medicaments	O

The	O
invention	O
relates	O
to	O
the	O
combined	O
administration	O
of	O
PDE4	O
or	O
PDE3	O
/	O
4	O
inhibitors	O
and	O
histamine	B
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O

Pharmaceutical	O
composition	O
of	O
a	O
pde4	O
or	O
pde	O
3	O
/	O
4	O
inhibitor	O
and	O
histamine	B
receptor	O
antagonist	O

It	O
has	O
been	O
unexpectedly	O
found	O
that	O
a	O
drug	O
resistant	O
strain	O
of	O
HIV	O
exhibits	O
the	O
behavior	O
of	O
drug	O
-	O
naïve	O
virus	O
when	O
given	O
the	O
combination	O
of	O
a	O
β	B
-	I
D-1,3-dioxolanyl	I
nucleoside	I
and	O
an	O
IMPDH	O
inhibitor	O
.	O

In	O
one	O
nonlimiting	O
embodiment	O
,	O
the	O
HIV	O
strain	O
is	O
resistant	O
to	O
a	O
β	B
-	I
D-1,3-dioxolanyl	I
nucleoside	I
.	O

DAPD	O
combination	O
therapy	O
with	O
inosine	B
monophosphate	I
dehydrogenase	O
inhibitor	O

Compounds	O
and	O
methods	O
are	O
provided	O
for	O
the	O
treatment	O
of	O
disease	O
conditions	O
in	O
which	O
modification	O
of	O
cholinergic	O
,	O
especially	O
muscarinic	O
m1	O
,	O
m4	O
,	O
or	O
both	O
m1	O
and	O
m4	O
,	O
receptor	O
activity	O
has	O
a	O
beneficial	O
effect	O
.	O

In	O
the	O
method	O
,	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
is	O
administered	O
to	O
a	O
patient	O
in	O
need	O
of	O
such	O
treatment	O
.	O

Cholinergic	O
agents	O
such	O
as	O
3-	B
[	I
3-	I
(	I
4-methoxypiperidine	I
)	I
-1-yl	I
-	I
propyl	I
]	I
-1H	I
-	I
indole	I
;	O
for	O
therapy	O
of	O
cognitive	O
dysfunction	O
,	O
forgetfulness	O
,	O
confusion	O
,	O
memory	O
loss	O
,	O
attention	O
deficits	O
,	O
deficits	O
in	O
visual	O
perception	O
,	O
depression	O
,	O
pain	O
,	O
sleep	O
disorders	O
,	O
and	O
psychosis	O

The	O
invention	O
relates	O
to	O
a	O
substantially	O
non	O
-	O
colloidal	O
solution	O
comprising	O
(	O
a	O
)	O
water	O
;	O
(	O
b	O
)	O
silver	B
ions	I
;	O
and	O
(	O
c	O
)	O
a	O
substantially	O
non	O
-	O
toxic	O
,	O
substantially	O
thiol	O
-	O
free	O
,	O
substantially	O
water	O
-	O
soluble	O
complexing	O
agent	O
.	O

Substantially	O
non	O
-	O
colloidal	O
solution	O
made	O
by	O
combining	O
ingredients	O
comprising	O
(	O
a	O
)	O
water	O
;	O
(	O
b	O
)	O
a	O
source	O
of	O
free	O
silver	B
ions	I
;	O
and	O
(	O
c	O
)	O
a	O
substantially	O
non	O
-	O
toxic	O
,	O
substantially	O
thiol	O
-	O
free	O
,	O
substantially	O
water	O
-	O
soluble	O
complexing	O
agent	O
.	O

There	O
is	O
provided	O
the	O
use	O
of	O
a	O
phosphodiesterase	O
antagonist	O
to	O
reduce	O
insulin	O
resistance	O
,	O
and	O
to	O
amplify	O
the	O
effect	O
of	O
nitric	B
oxide	I
on	O
skeletal	O
muscle	O
insulin	O
-	O
mediated	O
glucose	B
uptake	O
in	O
a	O
mammal	O
.	O

In	O
some	O
instances	O
,	O
the	O
antagonist	O
is	O
targeted	O
to	O
the	O
liver	O
.	O

In	O
some	O
instances	O
,	O
the	O
insulin	O
resistance	O
is	O
hepatic	O
insulin	O
sensitizing	O
substance	O
(	O
""""	O
HISS	O
""""	O
)	O
dependant	O
insulin	O
resistance	O
.	O

amplify	O
the	O
effect	O
of	O
nitric	B
oxide	I
on	O
skeletal	O
muscle	O
insulin	O
-	O
mediated	O
glucose	B
uptake	O
;	O
antidiabetic	O
agents	O

The	O
present	O
invention	O
concerns	O
therapeutic	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
PTH	O
and	O
PTHrP.	O
In	O
accordance	O
with	O
the	O
present	O
invention	O
,	O
modulators	O
of	O
PTH	O
and	O
PTHrP	O
comprise	O
:	O
(	O
a	O
)	O
a	O
PTH	O
/	O
PTHrP	O
modulating	O
domain	O
;	O
and	O
(	O
b	O
)	O
a	O
vehicle	O
,	O
such	O
as	O
a	O
polymer	O
(	O
e.g.	O
,	O
PEG	B
or	O
dextran	O
)	O
or	O
an	O
Fc	O
domain	O
,	O
which	O
is	O
preferred	O
;	O
wherein	O
the	O
vehicle	O
is	O
covalently	O
attached	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
PTH	O
/	O
PTHrP	O
modulating	O
domain	O
or	O
through	O
a	O
sidechain	O
at	O
any	O
residue	O
from	O
residue	O
14	O
through	O
the	O
C	O
-	O
terminal	O
residue	O
.	O

The	O
vehicle	O
and	O
the	O
PTH	O
/	O
PTHrP	O
modulating	O
domain	O
may	O
be	O
linked	O
through	O
the	O
N-	O
or	O
C	O
-	O
terminus	O
of	O
the	O
PTH	O
/	O
PTHrP	O
modulating	O
domain	O
,	O
as	O
described	O
further	O
below	O
.	O

The	O
preferred	O
vehicle	O
is	O
PEG	O
.	O

Preferred	O
PTH	O
/	O
PTHrP	O
modulating	O
domains	O
comprise	O
the	O
PTH	O
and	O
PTHrP	O
-	O
derived	O
amino	B
acid	I
sequences	O
described	O
hereinafter	O
.	O

Other	O
PTH	O
/	O
PTHrP	O
modulating	O
domains	O
can	O
be	O
generated	O
by	O
phage	O
display	O
,	O
RNA	O
-	O
peptide	O
screening	O
and	O
the	O
other	O
techniques	O
mentioned	O
herein	O
.	O

Such	O
peptides	O
typically	O
will	O
be	O
modulators	O
of	O
both	O
PTH	O
activity	O
and	O
PTHrP	O
activity	O
,	O
although	O
such	O
techniques	O
can	O
be	O
used	O
to	O
generate	O
peptide	O
sequences	O
that	O
serve	O
as	O
selective	O
modulators	O
(	O
e.g.	O
,	O
agonists	O
of	O
PTH	O
activity	O
but	O
not	O
PTHrP	O
activity	O
)	O
.	O

Modulators	O
of	O
receptors	O
for	O
parathyroid	O
hormone	O
and	O
parathyroid	O
hormone	O
-	O
related	O
protein	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
α	B
-	I
substituted	I
heteroarylalkylphosphonate	I
derivatives	O
and	O
their	O
uses	O
for	O
lowering	O
plasma	O
levels	O
of	O
apo	O
(	O
a	O
)	O
,	O
Lp	O
(	O
a	O
)	O
,	O
apo	O
B	O
,	O
apo	O
B	O
associated	O
lipoproteins	O
(	O
low	O
density	O
lipoproteins	O
and	O
very	O
low	O
density	O
lipoproteins	O
)	O
and	O
for	O
lowering	O
plasma	O
levels	O
of	O
total	O
cholesterol	B
.	O

Alpha	B
-	I
substituted	I
heteroarylalkyl	I
phosphonate	I
derivatives	O

Derivatives	O
of	O
aryl	B
(	I
or	I
heteroaryl	I
)	I
azolylcarbinoles	I
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
Ar	O
represents	O
a	O
phenyl	B
radical	O
or	O
a	O
thienyl	B
radical	I
,	O
optionally	O
substituted	O
,	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
lower	O
alkyl	B
group	O
,	O
R2	O
represents	O
a	O
dialkylaminoalkyl	B
or	O
azaheterocylclylalkyl	B
and	O
Het	B
represents	O
an	O
azole	B
unsubstituted	O
or	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
substituents	O
,	O
and	O
their	O
physiologically	O
acceptable	O
salts	O
;	O
are	O
useful	O
as	O
drugs	O
in	O
human	O
and/or	O
veterinary	O
therapeutics	O
to	O
treat	O
urinary	O
incontinence	O
in	O
mammals	O
,	O
including	O
man	O
.	O

Derivatives	O
of	O
aryl	B
(	I
or	I
heteroaryl	I
)	I
azolylcarbinoles	I
for	O
the	O
treatment	O
of	O
urinary	O
incontinence	O

The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treating	O
and/or	O
preventing	O
lower	O
gastrointestinal	O
(	O
GI	O
)	O
disorders	O
in	O
mammalian	O
patients	O
,	O
more	O
particularly	O
for	O
alleviating	O
and/or	O
preventing	O
the	O
lower	O
GI	O
symptoms	O
associated	O
with	O
such	O
disorders	O
.	O

Trimebutine	B
and/or	O
fedotozine	B
combined	O
with	O
laxatives	O
,	O
antidiarrheals	O
,	O
antibiotics	O
,	O
antiulceratives	O
,	O
gastric	O
secretion	O
inhibitors	O
,	O
peristalitc	O
stimulants	O
,	O
serotonin	B
(	O
5HT3	O
)	O
receptor	O
antagonists	O
,	O
serotonin	B
(	O
5HT4	O
)	O
receptor	O
agonists	O
and/or	O
selective	O
serotonin	B
reuptake	O
inhibitors	O

A	O
composition	O
and	O
a	O
kit	O
for	O
treating	O
cancer	O
comprising	O
N	B
,	I
N	I
-	I
dimethylphytosphingosine	I
.	O

The	O
composition	O
represses	O
the	O
activity	O
of	O
sphingosine	B
kinase	O
,	O
and	O
therefore	O
,	O
intercepts	O
various	O
mechanisms	O
which	O
sphingosine	B
kinase	O
induces	O
.	O

For	O
example	O
,	O
the	O
composition	O
blocks	O
the	O
phosphorylation	O
of	O
ceramide	B
and	O
sphingosine	B
,	O
thereby	O
maintaining	O
high	O
concentration	O
of	O
ceramide	B
and	O
sphingosine	B
.	O

The	O
ceramide	B
and	O
sphingosine	B
induce	O
apoptosis	O
in	O
cancer	O
cells	O
.	O

Therefore	O
,	O
the	O
composition	O
according	O
to	O
the	O
present	O
invention	O
induces	O
apoptosis	O
in	O
cancer	O
cells	O
and	O
accordingly	O
kills	O
the	O
cancer	O
cells	O
.	O

Blocks	O
the	O
phosphorylation	O
of	O
ceramide	B
and	O
sphingosine	B
,	O
thereby	O
maintaining	O
high	O
concentration	O
of	O
ceramide	B
and	O
sphingosine	B
;	O
has	O
inhibitory	O
activity	O
of	O
sphingosine	B
kinase	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
substituted	O
quinoline	B
derivatives	O
according	O
to	O
the	O
general	O
Formula	O
(	O
Ia	O
)	O
or	O
the	O
general	O
Formula	O
(	O
Ib	O
)	O
the	O
pharmaceutically	O
acceptable	O
acid	O
or	O
base	O
addition	O
salts	O
thereof	O
,	O
the	O
stereochemically	O
isomeric	O
forms	O
thereof	O
,	O
the	O
tautomeric	O
forms	O
thereof	O
and	O
the	O
N	B
-	I
oxide	I
forms	O
thereof	O
.	O

The	O
claimed	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
mycobacterial	O
diseases	O
,	O
particularly	O
those	O
diseases	O
caused	O
by	O
pathogenic	O
mycobacteria	O
such	O
as	O
Mycobacterium	O
tuberculosis	O
,	O
M.	O
bovis	O
,	O
M.	O
avium	O
and	O
M.	O
marinum	O
.	O

In	O
particular	O
,	O
compounds	O
are	O
claimed	O
in	O
which	O
,	O
independently	O
from	O
each	O
other	O
,	O
R1	O
is	O
bromo	B
,	O
p=1	O
,	O
R2	O
is	O
alkyloxy	B
,	O
R3	O
is	O
optionally	O
substituted	O
naphthyl	B
or	O
phenyl	B
,	O
q=1	O
,	O
R4	O
and	O
R5	O
each	O
independently	O
are	O
hydrogen	B
,	O
methyl	B
or	O
ethyl	B
,	O
R6	O
is	O
hydrogen	B
,	O
r	O
is	O
equal	O
to	O
0	O
or	O
1	O
and	O
R7	O
is	O
hydrogen	B
.	O

Also	O
claimed	O
is	O
a	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
,	O
as	O
active	O
ingredient	O
,	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
claimed	O
compounds	O
,	O
the	O
use	O
of	O
the	O
claimed	O
compounds	O
or	O
compositions	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
mycobacterial	O
diseases	O
and	O
a	O
process	O
for	O
preparing	O
the	O
claimed	O
compounds	O
.	O

Quinolines	B
;	O
1-	B
(	I
6-bromo-2-methoxy	I
-	I
quinolin-3-yl	I
)	I
-4-dimethylamino-2-naphthalen-1-yl-1-phenyl	I
-	I
butan-2-ol	I
;	O
Mycobacterium	O
tuberculosis	O
,	O
M.	O
bovis	O
,	O
M.	O
avium	O
and	O
M.	O
marinum	O
;	O
reduces	O
the	O
total	O
length	O
of	O
treatment	O
and	O
the	O
frequency	O
of	O
drug	O
administration	O
;	O
multi	O
-	O
drug	O
and	O
antibiotic	O
resistance	O

A	O
Her2	O
and/or	O
EGFR	O
inhibitor	O
to	O
be	O
administered	O
to	O
a	O
subject	O
determined	O
to	O
show	O
overexpression	O
or	O
activation	O
of	O
Her2	O
and/or	O
EGFR	O
as	O
a	O
result	O
of	O
a	O
diagnosis	O
of	O
the	O
subject	O
for	O
the	O
expression	O
or	O
activity	O
of	O
Her2	O
and/or	O
EGFR	O
based	O
on	O
a	O
test	O
for	O
detecting	O
the	O
expression	O
or	O
activity	O
of	O
Her2	O
and/or	O
EGFR	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
inhibitor	O
.	O

Administering	O
to	O
show	O
overactivation	O
or	O
expression	O
from	O
diagnosis	O
of	O
diseases	O
,	O
immunoassay	O
,	O
anticancer	O
agents	O
or	O
skin	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
formulation	O
for	O
use	O
in	O
the	O
administration	O
of	O
a	O
long	O
-	O
acting	O
β2-agonist	O
by	O
inhalation	O
.	O

In	O
particular	O
this	O
invention	O
relates	O
to	O
a	O
chemically	O
stable	O
highly	O
efficient	O
formoterol	B
HFA	B
solution	O
formulation	O
to	O
be	O
administered	O
by	O
pressurised	O
metered	O
dose	O
inhalers	O
(	O
pMDIs	O
)	O
characterized	O
by	O
a	O
deep	O
lung	O
penetration	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
said	O
formulation	O
and	O
to	O
its	O
use	O
in	O
respiratory	O
diseases	O
such	O
as	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

Hydrofluoroalkane	B
(	O
HFA	B
)	O
propellant	O
and	O
co	O
-	O
solvents	O
;	O
inhalants	O
;	O
storage	O
stability	O
;	O
deep	O
lung	O
penetration	O

Calcium	B
channels	O
which	O
form	O
in	O
neuronal	O
membranes	O
in	O
response	O
to	O
injury	O
are	O
disclosed	O
.	O

Methods	O
and	O
compositions	O
for	O
blocking	O
this	O
injury	O
induced	O
calcium	B
channel	O
and	O
preventing	O
further	O
injury	O
to	O
neuronal	O
cells	O
and/or	O
neuronal	O
cell	O
death	O
are	O
disclosed	O
.	O

The	O
compositions	O
and	O
methods	O
disclosed	O
may	O
be	O
used	O
to	O
alleviate	O
acute	O
or	O
chronic	O
injury	O
to	O
neuronal	O
cells	O
.	O

Via	O
gadolinium	B
compounds	O
as	O
calcium	B
channel	O
blockers	O
;	O
drug	O
screening	O

4-	B
(	I
4-methylpiperazin-1-ylmethyl	I
)	I
-N-	I
[	I
4-methyl-3-	I
(	I
4-pyridin-3-yl	I
)	I
pyrimidin-2-ylamino	I
)	I
phenyl	I
]	I
-benzamide	I
of	O
the	O
formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
seminomas	O
.	O

Y823D	O
,	O
N822	O
K	O
or	O
D816H	O
mutations	O
in	O
the	O
c	O
-	O
Kit	O
tyrosine	O
kinase	O
;	O
antitumour	O
agent	O
;	O
alternative	O
to	O
radiation	O
or	O
chemotherapy	O
;	O
reduce	O
consequent	O
infertility	O
;	O
good	O
tolerability	O
of	O
compound	O
mesylate	B
treatment	O
;	O
no	O
drug	O
-	O
related	O
liver	O
,	O
renal	O
or	O
cardiac	O
toxicity	O

Novel	O
compounds	O
of	O
structural	O
formula	O
(	O
I	O
)	O
are	O
antagonists	O
and/or	O
inverse	O
agonists	O
of	O
the	O
Cannabinoid-1	B
(	O
CB1	B
)	O
receptor	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
CB1	O
receptor	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
psychotropic	O
drugs	O
in	O
the	O
treatment	O
of	O
psychosis	O
,	O
memory	O
deficits	O
,	O
cognitive	O
disorders	O
,	O
migraine	O
,	O
neuropathy	O
,	O
neuro	O
-	O
inflammatory	O
disorders	O
including	O
multiple	O
sclerosis	O
and	O
Guillain	O
-	O
Barre	O
syndrome	O
and	O
the	O
inflammatory	O
sequelae	O
of	O
viral	O
encephalitis	O
,	O
cerebral	O
vascular	O
accidents	O
,	O
and	O
head	O
trauma	O
,	O
anxiety	O
disorders	O
,	O
stress	O
,	O
epilepsy	O
,	O
Parkinson	O
's	O
disease	O
,	O
movement	O
disorders	O
,	O
and	O
schizophrenia	O
.	O

The	O
compounds	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
substance	O
abuse	O
disorders	O
,	O
the	O
treatment	O
of	O
obesity	O
or	O
eating	O
disorders	O
,	O
as	O
well	O
as	O
,	O
the	O
treatment	O
of	O
asthma	O
,	O
constipation	O
,	O
chronic	O
intestinal	O
pseudo	O
-	O
obstruction	O
,	O
and	O
cirrhosis	O
of	O
the	O
liver	O
.	O

Substituted	O
aryl	B
amides	I

The	O
invention	O
relates	O
to	O
a	O
pyridazine	B
derivative	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
,	O
pharmaceutical	O
composition	O
thereof	O
,	O
process	O
for	O
its	O
preparation	O
,	O
and	O
its	O
pharmaceutical	O
use	O
.	O

Such	O
as	O
(	B
3S	I
)	I
-2-	I
[	I
3-	I
[	I
(	I
phenylacetyl	I
)	I
amino	I
]	I
-1-oxopropyl	I
]	I
-N-	I
[	I
cyano	I
(	I
3-phenoxyphenyl	I
)	I
methyl	I
]	I
hexahydro-3-pyridazinecarboxamide	I
;	O
for	O
treatment	O
of	O
osteoporosis	O
,	O
hypercalcaemia	O
,	O
osteoporosis	O
,	O
gingival	O
disease	O
,	O
arthritis	O
,	O
Paget	O
's	O
disease	O
,	O
and	O
bone	O
cancer	O

This	O
invention	O
relates	O
to	O
novel	O
3-substituted	B
quinuclidine	I
derivatives	O
,	O
which	O
are	O
found	O
to	O
be	O
cholinergic	O
ligands	O
at	O
the	O
nicotinic	O
acetylcholine	B
receptors	O
and	O
modulators	O
of	O
the	O
monoamine	B
receptors	O
and	O
transporters	O
.	O

Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction	O
,	O
endocrine	O
diseases	O
or	O
disorders	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
neurodegeneration	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation	O
,	O
pain	O
,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O

Cholinergic	O
ligands	O
at	O
the	O
nicotinic	O
acetylcholine	B
receptors	O
and	O
modulators	O
of	O
the	O
monoamine	B
receptors	O
and	O
transporters	O
;	O
treating	O
pain	O
,	O
neurodegeneration	O
,	O
inflammation	O
,	O
and	O
drug	O
or	O
alcohol	O
withdrawal	O
symptoms	O
;	O
3-benzimidazole	B
,	O
indole	B
or	O
triazole	B
substituted	O

This	O
invention	O
relates	O
to	O
selective	O
m1	O
muscarinic	O
agonist	O
,	O
their	O
use	O
or	O
a	O
formulation	O
thereof	O
in	O
the	O
treatment	O
of	O
glaucoma	O
and/or	O
other	O
conditions	O
which	O
are	O
related	O
to	O
elevated	O
intraocular	O
pressure	O
in	O
the	O
eye	O
of	O
a	O
patient	O
.	O

This	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
compounds	O
to	O
provide	O
a	O
neuroprotective	O
effect	O
to	O
the	O
eye	O
of	O
mammalian	O
species	O
,	O
particularly	O
humans	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
compounds	O
in	O
the	O
treatment	O
of	O
dementia	O
such	O
as	O
Alzheimer	O
's	O
disease	O
and	O
vascular	O
dementia	O
,	O
depression	O
,	O
attention	O
deficit	O
disorder	O
,	O
sleep	O
disorder	O
,	O
schizophrenia	O
,	O
pain	O
,	O
ischemia	O
,	O
atrophic	O
gastritis	O
,	O
and	O
atony	O
of	O
gastrointestinal	O
tract	O
.	O

For	O
therapy	O
of	O
glaucoma	O
,	O
dementia	O
such	O
as	O
Alzheimer	O
's	O
disease	O
and	O
vascular	O
dementia	O
,	O
depression	O
,	O
attention	O
deficit	O
disorder	O
,	O
sleep	O
disorder	O
,	O
schizophrenia	O
,	O
pain	O
,	O
ischemia	O
;	O
-	O
[	O
1-	B
[	I
1-	I
(	I
3-Thienoyl	I
)	I
piperidin-4-yl	I
]	I
piperidin-4-yl	I
]	I
-1,3-dihydro-2H	I
-	I
benzimidazol-2-one	I

The	O
present	O
invention	O
relates	O
to	O
a	O
class	O
of	O
compounds	O
represented	O
by	O
the	O
Formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
the	O
Formula	O
I	O
,	O
and	O
methods	O
of	O
selectively	O
inhibiting	O
or	O
antagonizing	O
the	O
αvβ3	O
integrin	O
.	O

Meta	B
-	I
substituted	I
phenylene	I
sulphonamide	I
derivatives	O

A	O
solid	O
pharmaceutical	O
or	O
food	O
supplement	O
tablet	O
or	O
suppository	O
composition	O
has	O
a	O
melting	O
point	O
of	O
25	O
°	O
C.	O
or	O
higher	O
and	O
comprises	O
a	O
continuous	O
lipid	O
component	O
comprising	O
one	O
or	O
more	O
polar	O
lipids	O
,	O
one	O
or	O
more	O
non	O
-	O
polar	O
lipids	O
,	O
optionally	O
one	O
or	O
several	O
of	O
water	O
and	O
mono-	O
to	O
trivalent	O
alcohol	B
in	O
an	O
amount	O
of	O
up	O
to	O
15	O
%	O
by	O
weight	O
of	O
the	O
composition	O
,	O
and	O
one	O
or	O
more	O
agents	O
selected	O
from	O
pharmacologically	O
active	O
agent	O
and	O
food	O
supplement	O
agent	O
.	O

Also	O
disclosed	O
is	O
a	O
corresponding	O
tablet	O
and	O
a	O
corresponding	O
suppository	O
,	O
processes	O
for	O
production	O
of	O
the	O
composition	O
and	O
the	O
tablet	O
and	O
the	O
suppository	O
,	O
and	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
conditions	O
amenable	O
to	O
preventive	O
or	O
therapeutic	O
treatment	O
by	O
administration	O
of	O
the	O
tablet	O
or	O
suppository	O
.	O

Composition	O
for	O
oral	O
or	O
rectal	O
administration	O

Antisense	O
oligomers	B
directed	O
to	O
bacterial	O
cell	O
division	O
and	O
cell	O
cycle	O
-	O
encoding	O
nucleic	O
acids	O
are	O
capable	O
of	O
selectively	O
modulating	O
the	O
biological	O
activity	O
thereof	O
,	O
and	O
are	O
useful	O
in	O
treatment	O
and	O
prevention	O
of	O
bacterial	O
infection	O
.	O

The	O
antisense	O
oligomers	B
are	O
substantially	O
uncharged	O
,	O
and	O
contain	O
from	O
8	O
to	O
40	O
nucleotide	O
subunits	O
,	O
including	O
a	O
targeting	O
nucleic	O
acid	O
sequence	O
at	O
least	O
10	O
nucleotides	O
in	O
length	O
which	O
is	O
effective	O
to	O
hybridize	O
to	O
(	O
i	O
)	O
a	O
bacterial	O
tRNA	O
or	O
(	O
ii	O
)	O
a	O
target	O
sequence	O
,	O
containing	O
a	O
translational	O
start	O
codon	O
,	O
within	O
a	O
bacterial	O
nucleic	O
acid	O
which	O
encodes	O
a	O
protein	O
associated	O
with	O
cell	O
division	O
or	O
the	O
cell	O
cycle	O
.	O

Such	O
proteins	O
include	O
zipA	O
,	O
sulA	O
,	O
secA	O
,	O
dicA	O
,	O
dicB	O
,	O
diCc	O
,	O
dicF	O
,	O
ftsA	O
,	O
ftsl	O
,	O
ftsN	O
,	O
ftsK	O
,	O
ftsL	O
,	O
ftsQ	O
,	O
ftsw	O
,	O
ftsZ	O
,	O
murC	O
,	O
murD	O
,	O
murE	O
,	O
murF	O
,	O
murg	O
,	O
minC	O
,	O
minD	O
,	O
minE	O
,	O
mraY	O
,	O
mraW	O
,	O
mraZ	O
,	O
seqA	O
,	O
ddlB	O
,	O
carbamate	O
kinase	O
,	O
D	B
-	I
ala	I
D	I
-	I
ala	I
ligase	O
,	O
topoisomerase	O
,	O
alkyl	B
hydroperoxide	I
reductase	O
,	O
thioredoxin	O
reductase	O
,	O
dihydrofolate	B
reductase	O
,	O
and	O
cell	O
wall	O
enzyme	O
.	O

Antisense	O
antibacterial	O
cell	O
division	O
composition	O
and	O
method	O

A	O
compound	O
of	O
the	O
formula	O
and	O
physiologically	O
acceptable	O
salts	O
and	O
or	O
N	B
-	I
oxides	I
thereof	O
wherein	O
,	O
X1	O
is	O
N	B
or	O
CR3	B
;	O
X2	O
is	O
N	B
or	O
CR4	B
;	O
X3	O
is	O
N	B
or	O
CR5	B
;	O
X4	O
is	O
N	B
or	O
CR6	B
.	O

with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
but	O
not	O
more	O
than	O
two	O
of	O
X1	O
,	O
X2	O
,	O
X3	O
and	O
X4	O
represents	O
N.	B
R1	O
is	O
a	O
5-	O
,	O
or	O
6-membered	O
heterocyclic	B
group	O
selected	O
from	O
group	O
a	O
,	O
b	O
,	O
c	O
or	O
d	O
wherein	O
X5	O
is	O
a	O
group	O
selected	O
from	O
N	B
or	O
CR7	B
and	O
X6	O
is	O
a	O
group	O
selected	O
from	O
O	B
,	O
S	B
or	O
NR8	B
;	O
X7	O
and	O
X8	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
is	O
a	O
group	O
selected	O
from	O
N	B
or	O
CR9	B
;	O
X9	O
is	O
a	O
group	O
selected	O
from	O
O	B
,	O
S	B
or	O
NR8	B
and	O
X10	O
is	O
N	B
or	O
CR10	B
;	O
X11	O
,	O
X12	O
and	O
X13	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
selected	O
from	O
a	O
group	O
N	B
or	O
CR11	B
;	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
medicine	O
.	O

2-	B
(	I
4-amino	I
-	I
furazan-3-yl	I
)	I
-1-ethyl	I
-	I
N-	I
[	I
(	I
2R	I
)	I
-2-morpholinylmethyl	I
]	I
-1H	I
-	I
imidazo	I
[	I
4,5-c	I
]	I
pyridine-7-carboxamide	I
;	O
Mitogen-	O
and	O
Stress	O
-	O
Activated	O
Protein	O
(	O
MSK	O
)	O
and	O
Rho	O
(	O
guanosine	O
triphosphate	O
)	O
1	O
or	O
2	O
kinase	O
inhibitor	O
;	O
neurodegenerative	O
diaeases	O
;	O
antiinflammatory	O
,	O
anticarcinogenic	O
,	O
antiviral	O
and	O
antibacterial	O
agent	O

The	O
preferred	O
embodiments	O
are	O
directed	O
to	O
small	O
molecule	O
inhibitors	O
that	O
are	O
cellular	O
proliferation	O
inhibitors	O
and	O
thus	O
are	O
useful	O
as	O
anticancer	O
agents	O
.	O

The	O
small	O
molecules	O
have	O
the	O
general	O
formulas	O
that	O
include	O
a	O
phenylbenzimidazole	B
core	O
ring	O
.	O

Use	O
of	O
benzimidazole	B
analogs	O
in	O
the	O
treatment	O
of	O
cell	O
proliferation	O

The	O
invention	O
provides	O
methods	O
for	O
delivering	O
a	O
therapeutic	O
or	O
diagnostic	O
agent	O
to	O
the	O
eye	O
of	O
a	O
mammal	O
.	O

The	O
method	O
involves	O
contacting	O
sclera	O
with	O
a	O
therapeutic	O
or	O
diagnostic	O
agent	O
so	O
as	O
to	O
permit	O
its	O
passage	O
through	O
the	O
sclera	O
into	O
the	O
choroidal	O
and	O
retinal	O
tissues	O
.	O

The	O
sclera	O
may	O
be	O
contacted	O
with	O
a	O
therapeutic	O
or	O
diagnostic	O
agent	O
together	O
with	O
a	O
device	O
for	O
enhancing	O
transport	O
of	O
the	O
agent	O
through	O
the	O
sclera	O
.	O

Contacting	O
sclera	O
with	O
a	O
therapeutic	O
or	O
diagnostic	O
agent	O
so	O
as	O
to	O
permit	O
its	O
passage	O
into	O
the	O
choroidal	O
and	O
retinal	O
tissues	O
;	O
no	O
significant	O
systemic	O
absorption	O
or	O
tissue	O
damage	O
;	O
eye	O
disorders	O

An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
method	O
of	O
testing	O
for	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
a	O
method	O
of	O
screening	O
for	O
candidate	O
compounds	O
for	O
treating	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
and	O
a	O
pharmaceutical	O
agent	O
for	O
treating	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

The	O
present	O
invention	O
identified	O
genes	O
whose	O
expression	O
levels	O
varied	O
between	O
respiratory	O
epithelial	O
cells	O
that	O
had	O
been	O
stimulated	O
by	O
IL-13	O
to	O
induce	O
the	O
goblet	O
cell	O
differentiation	O
,	O
and	O
unstimulated	O
respiratory	O
epithelial	O
cells	O
.	O

The	O
respiratory	O
epithelial	O
cells	O
were	O
cultured	O
according	O
to	O
the	O
air	O
interface	O
method	O
.	O

The	O
genes	O
were	O
revealed	O
to	O
be	O
useful	O
as	O
markers	O
for	O
testing	O
for	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
screening	O
for	O
therapeutic	O
agents	O
for	O
such	O
diseases	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
provides	O
methods	O
of	O
testing	O
for	O
bronchial	O
asthma	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
methods	O
of	O
screening	O
for	O
compounds	O
to	O
treat	O
the	O
diseases	O
based	O
on	O
the	O
comparison	O
of	O
the	O
expression	O
levels	O
of	O
marker	O
genes	O
identified	O
as	O
described	O
above	O
.	O

Using	O
enhanced	O
interleukin	O
gene	O
expression	O
as	O
diagnostic	O
indicator	O
of	O
respiratory	O
system	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
a	O
diclofenac	B
sodium	I
oral	O
pharmaceutical	O
containing	O
diclofenac	B
sodium	I
,	O
a	O
nonionic	O
surfactant	O
,	O
a	O
cholic	B
acid	I
derivative	O
as	O
an	O
absorption	O
promoting	O
agent	O
,	O
and	O
a	O
glycerin	B
or	O
a	O
glycol	B
.	O

The	O
oral	O
pharmaceutical	O
has	O
a	O
rapid	O
-	O
acting	O
effect	O
and	O
a	O
good	O
internal	O
absorption	O
even	O
under	O
non	O
-	O
fasting	O
condition	O
.	O

Further	O
,	O
the	O
pharmaceutical	O
can	O
be	O
processed	O
in	O
a	O
hard	O
capsule	O
pharmaceutical	O
by	O
filling	O
it	O
in	O
a	O
hard	O
capsule	O
as	O
such	O
,	O
and	O
has	O
an	O
excellent	O
internal	O
absorption	O
under	O
non	O
-	O
fasting	O
condition	O
,	O
similarly	O
to	O
suppositories	O
.	O

Diclofenac	B
sodium	I
oral	O
pharmaceutical	O

The	O
present	O
invention	O
provides	O
novel	O
use	O
of	O
PGD2	B
,	O
a	O
PGD2	B
agonist	O
and	O
a	O
PGD2	B
antagonist	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
provides	O
uses	O
of	O
PGD2	B
and	O
a	O
PGD2	B
agonist	O
as	O
eating	O
promoter	O
and	O
use	O
of	O
a	O
PGD2	B
antagonist	O
as	O
an	O
eating	O
inhibitor	O
.	O

Novel	O
uses	O
of	O
prostaglandin	B
d2	I
,	O
prostaglandin	B
d2	I
agonist	O
and	O
prostaglandin	B
d2	I
antagonist	O

The	O
invention	O
provides	O
methods	O
for	O
treating	O
cognitive	O
decline	O
that	O
is	O
associated	O
with	O
systemic	O
stress	O
.	O

Methods	O
for	O
restoring	O
cognitive	O
function	O
following	O
systemic	O
stress	O

Disclosed	O
is	O
a	O
process	O
for	O
preparing	O
9-	B
[	I
4-acetoxy-3-	I
(	I
acetoxymethyl	I
)	I
but-1-yl	I
]	I
-2-aminopurine	I
(	O
called	O
Famciclovir	B
)	O
,	O
a	O
drug	O
of	O
purine	O
derivatives	O
having	O
antiviral	O
activity	O
.	O

This	O
process	O
comprises	O
reacting	O
2-aminopurine	B
with	O
2-acetoxymethyl-4-bromobut-1-yl	B
-	I
acetate	I
in	O
the	O
presence	O
of	O
thallium	B
(	I
1	I
)	I
ethoxide	I
to	O
give	O
the	O
desired	O
compound	O
.	O

According	O
to	O
this	O
process	O
,	O
the	O
desired	O
compound	O
can	O
be	O
prepared	O
in	O
very	O
high	O
selectivity	O
and	O
purity	O
under	O
mild	O
reaction	O
conditions	O
.	O

(	O
Famciclovir	B
)	O
;	O
reacting	O
the	O
thallium	B
salt	I
of	I
2-aminopurine	I
and	I
2-acetoxymethyl-4-bromobut-1-yl	I
-	I
acetate	I
in	O
a	O
polar	O
organic	O
solvent	O
under	O
mild	O
reaction	O
conditions	O
;	O
selective	O
coupling	O
at	O
the	O
9-position	O
;	O
by	O
-	O
product	O
inhibition	O
;	O
antiviral	O
drug	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
Asialo	O
-	O
Gm1	O
(	O
Agm1	O
)	O
and/or	O
GM	B
gangliosides	I
,	O
and	O
substances	O
which	O
simulate	O
the	O
carbohydrate	O
part	O
of	O
said	O
gangliosides	B
in	O
terms	O
of	O
binding	O
to	O
anti	O
-	O
AGm1	O
antibodies	O
and/or	O
anti	O
-	O
Gm1	O
antibodies	O
,	O
for	O
producing	O
an	O
agent	O
which	O
blocks	O
or	O
binds	O
to	O
anti	O
-	O
AGm1	O
antibodies	O
and/or	O
anti	O
-	O
Gm1	O
antibodies	O
which	O
bind	O
to	O
natural	O
killer	O
cells	O
(	O
NKC	O
)	O
,	O
said	O
agent	O
being	O
administered	O
to	O
patients	O
at	O
high	O
risk	O
of	O
sepsis	O
and	O
to	O
patients	O
with	O
sepsis	O
,	O
in	O
whom	O
such	O
antibodies	O
have	O
been	O
detected	O
,	O
for	O
the	O
prevention	O
,	O
inhibition	O
and	O
treatment	O
of	O
sepsis	O
.	O

Use	O
of	O
Asialo	O
-	O
Gm1	O
(	O
Agm1	O
,	O
)	O
and/or	O
GM	O
gangliosides	B
,	O
and	O
substances	O
which	O
simulate	O
carbohydrate	B
moiety	O
of	O
these	O
gangliosides	B
with	O
regard	O
to	O
binding	O
to	O
anti	O
-	O
AGM1	O
antibodies	O
and/or	O
anti	O
-	O
GM1	O
antibodies	O
,	O
for	O
the	O
preparation	O
of	O
an	O
agent	O
for	O
binding	O
or	O
blocking	O
anti	O
-	O
AGM1	O
antibodies	O
and/or	O
anti	O
-	O
GM1	O
antibodies	O

The	O
use	O
of	O
resveratrol	B
is	O
described	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
influenza	O
.	O

Said	O
medicament	O
exerts	O
its	O
therapeutic	O
activity	O
through	O
inhibition	O
of	O
viral	O
replication	O
.	O

Use	O
of	O
resveratrol	B
for	O
the	O
preparation	O
of	O
a	O
medicament	O
useful	O
for	O
the	O
treatment	O
of	O
influenza	O
virus	O
infections	O

The	O
invention	O
concerns	O
combination	O
products	O
comprising	O
(	O
i	O
)	O
at	O
least	O
a	O
substance	O
capable	O
of	O
inhibiting	O
CSF-1	O
activity	O
and/or	O
at	O
least	O
a	O
nucleic	O
acid	O
,	O
comprising	O
at	O
least	O
a	O
sequence	O
coding	O
for	O
a	O
substance	O
capable	O
of	O
inhibiting	O
CSF-1	O
activity	O
and	O
(	O
ii	O
)	O
at	O
least	O
a	O
substance	O
having	O
a	O
cytotoxic	O
activity	O
and/or	O
at	O
least	O
a	O
nucleic	O
acid	O
,	O
comprising	O
at	O
least	O
a	O
sequence	O
coding	O
for	O
a	O
substance	O
having	O
cytotoxic	O
activity	O
.	O

The	O
invention	O
also	O
concerns	O
oligonucleotides	O
capable	O
of	O
inhibiting	O
CSF-1	O
expression	O
.	O

The	O
invention	O
is	O
particular	O
useful	O
for	O
implementing	O
an	O
antitumoral	O
treatment	O
.	O

Combination	O
products	O
for	O
use	O
in	O
antitumoral	O
treatment	O

Methods	O
for	O
identifying	O
a	O
compound	O
that	O
activates	O
a	O
TLR	O
-	O
mediated	O
cellular	O
signaling	O
pathway	O
is	O
disclosed	O
.	O

The	O
method	O
includes	O
(	O
a	O
)	O
exposing	O
a	O
TLR	O
-	O
positive	O
cell	O
culture	O
to	O
a	O
test	O
compound	O
and	O
measuring	O
a	O
TLR	O
-	O
mediated	O
cellular	O
response	O
;	O
(	O
b	O
)	O
exposing	O
a	O
TLR	O
-	O
negative	O
cell	O
culture	O
to	O
a	O
test	O
compound	O
and	O
measuring	O
a	O
TLR	O
-	O
mediated	O
cellular	O
response	O
;	O
and	O
(	O
c	O
)	O
identifying	O
the	O
test	O
compound	O
as	O
an	O
IRM	O
if	O
the	O
cellular	O
response	O
in	O
the	O
TLR	O
-	O
positive	O
cell	O
culture	O
is	O
greater	O
than	O
the	O
cellular	O
response	O
of	O
the	O
TLR	O
-	O
negative	O
cell	O
culture	O
.	O

Methods	O
of	O
eliciting	O
a	O
TLR	O
-	O
mediated	O
cellular	O
response	O
are	O
also	O
disclosed	O
.	O

Such	O
methods	O
include	O
administration	O
of	O
an	O
IRM	O
compound	O
to	O
an	O
IRM	O
-	O
responsive	O
cell	O
so	O
that	O
the	O
IRM	O
compound	O
affects	O
at	O
least	O
one	O
TLR	O
-	O
mediate	O
cellular	O
signaling	O
pathway	O
.	O

Methods	O
and	O
compositions	O
related	O
to	O
IRM	O
compounds	O
and	O
toll	O
-	O
like	O
receptor	O
pathways	O

This	O
invention	O
is	O
directed	O
to	O
compounds	O
which	O
are	O
selective	O
antagonists	O
for	O
melanin	O
concentrating	O
hormone-1	O
(	O
MCH1	O
)	O
receptors	O
.	O

The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

This	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
made	O
by	O
combining	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
this	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

This	O
invention	O
further	O
provides	O
a	O
process	O
for	O
making	O
a	O
pharmaceutical	O
composition	O
comprising	O
combining	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

This	O
invention	O
also	O
provides	O
a	O
method	O
of	O
reducing	O
the	O
body	O
mass	O
of	O
a	O
subject	O
which	O
comprises	O
administering	O
to	O
the	O
subject	O
an	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
effective	O
to	O
reduce	O
the	O
body	O
mass	O
of	O
the	O
subject	O
.	O

This	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
depression	O
and/or	O
anxiety	O
which	O
comprises	O
administering	O
to	O
the	O
subject	O
an	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
effective	O
to	O
treat	O
the	O
subject	O
=	O
s	O
depression	O
and/or	O
anxiety	O
.	O

This	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
urinary	O
disorder	O
.	O

depression	O
and/or	O
anxiety	O
,	O
obesity	O
,	O
urinary	O
disorder	O
;	O
5-	B
(	I
2-Methoxyphenyl	I
)	I
-N-	I
[	I
3-	I
(	I
4-Piperidinyl	I
)	I
Phenyl	I
]	I
Pentanamide	I

(	O
wherein	O
R1	O
represents	O
hydroxy	B
or	O
substituted	O
or	O
unsubstituted	O
lower	O
alkoxy	B
;	O
R2	O
represents	O
an	O
aromatic	B
heterocyclic	I
group	O
or	O
the	O
like	O
;	O
Y	O
represents	O
lower	O
alkyl	B
or	O
the	O
like	O
;	O
and	O
n	O
represents	O
an	O
integer	O
of	O
from	O
1	O
to	O
6	O
)	O
For	O
example	O
,	O
a	O
process	O
for	O
preparing	O
a	O
1,3-benzodioxole-2-spirocycloalkane	B
derivative	O
represented	O
by	O
the	O
above	O
formula	O
(	O
VII	O
)	O
,	O
which	O
comprises	O
adding	O
a	O
base	O
to	O
a	O
mixture	O
containing	O
a	O
compound	O
represented	O
by	O
the	O
above	O
formula	O
(	O
V	O
)	O
and	O
a	O
compound	O
represented	O
by	O
the	O
above	O
formula	O
(	O
VI	O
)	O
;	O
and	O
allowing	O
the	O
compound	O
represented	O
by	O
the	O
above	O
formula	O
(	O
V	O
)	O
to	O
react	O
with	O
the	O
compound	O
represented	O
by	O
the	O
above	O
formula	O
(	O
VI	O
)	O
,	O
are	O
provided	O
.	O

Process	O
for	O
preparing	O
1,3-benzodioxole-2-spirocycloalkane	B
derivative	O

A	O
combination	O
therapy	O
for	O
the	O
treatment	O
of	O
acute	O
myocardial	O
infarction	O
comprises	O
administering	O
a	O
combination	O
of	O
a	O
thrombolytic	O
agent	O
and	O
levosimendan	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
a	O
patient	O
.	O

The	O
combination	O
synergistically	O
reduces	O
mortality	O
of	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

Combination	O
treatment	O
for	O
acute	O
myocardial	O
infarction	O

Dioxolane	B
analogs	O
of	O
the	O
following	O
formula	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
defined	O
herein	O
,	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

For	O
example	O
,	O
the	O
compounds	O
can	O
be	O
used	O
to	O
treat	O
patients	O
with	O
cancer	O
in	O
which	O
the	O
cancer	O
cells	O
are	O
deficient	O
in	O
nucleoside	O
or	O
nucleoside	O
base	O
transporters	O
.	O

Dioxolane	B
analogs	O
for	O
improved	O
inter	O
-	O
cellular	O
delivery	O

Disclosed	O
are	O
substituted	O
pyridazinones	B
that	O
are	O
useful	O
for	O
treating	O
diseases	O
and	O
conditions	O
caused	O
or	O
exacerbated	O
by	O
unregulated	O
p38	O
MAP	O
Kinase	O
and/or	O
TNF	O
activity	O
.	O

Pharmaceutical	O
composition	O
containing	O
the	O
pyridazinone	B
compounds	O
,	O
methods	O
of	O
preparing	O
the	O
compounds	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
are	O
also	O
disclosed	O
.	O

Substituted	O
pyridazinones	B

The	O
present	O
invention	O
provides	O
a	O
composition	O
containing	O
β	O
-	O
glucan	O
in	O
which	O
the	O
physiologically	O
active	O
effects	O
of	O
β-1,3	O
-	O
1,6-glucan	O
contained	O
in	O
a	O
cultured	O
composition	O
of	O
a	O
bacterium	O
belonging	O
to	O
the	O
genus	O
Aureobasidium	O
sp.	O
are	O
further	O
enhanced	O
,	O
and	O
a	O
constipation	O
-	O
relieving	O
drug	O
,	O
preparation	O
an	O
immunopotentiator	O
,	O
and	O
a	O
skin	O
moistening	O
agent	O
using	O
the	O
composition	O
.	O

A	O
composition	O
containing	O
β	O
-	O
glucan	O
,	O
which	O
contains	O
a	O
cultured	O
composition	O
containing	O
β-1,3	O
-	O
1,6-glucan	O
obtained	O
by	O
culturing	O
a	O
bacterium	O
belonging	O
to	O
the	O
genus	O
Aureobasidium	O
sp.	O
and	O
lactic	O
acid	O
bacterium	O
cells	O
,	O
is	O
obtained	O
.	O

This	O
composition	O
containing	O
β	O
-	O
glucan	O
is	O
employed	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
constipation	O
-	O
relieving	O
drug	O
,	O
an	O
immunopotentiator	O
,	O
or	O
a	O
skin	O
moistening	O
agent	O
.	O

Aureobasidium	O
pullulans	O
M-1	O
(	O
FERM	O
BP-08615	O
)	O
is	O
preferable	O
as	O
the	O
bacterium	O
belonging	O
to	O
the	O
genus	O
Aureobasidium	O
sp.	O

Moreover	O
,	O
Enterococcus	O
faecalis	O
is	O
preferable	O
as	O
the	O
lactic	B
acid	I
bacterium	O
.	O

It	O
is	O
still	O
preferable	O
that	O
the	O
lactic	B
acid	I
bacterium	O
has	O
been	O
killed	O
by	O
heating	O
.	O

Furthermore	O
,	O
the	O
content	O
of	O
the	O
cultured	O
composition	O
in	O
solid	O
matters	O
preferably	O
ranges	O
from	O
1	O
to	O
80	O
%	O
by	O
mass	O
in	O
terms	O
of	O
β-1,3	O
-	O
1,6-glucan	O
,	O
while	O
the	O
content	O
of	O
the	O
lactic	B
acid	I
bacterium	O
cells	O
preferably	O
ranges	O
from	O
4	O
to	O
95	O
%	O
by	O
mass	O
.	O

Composition	O
containing	O
beta	O
-	O
glucan	O
and	O
constipation	O
-	O
relieving	O
drug	O
,	O
immunopotentiatior	O
,	O
and	O
skin	O
moistening	O
agent	O
using	O
the	O
composition	O

Substituted	O
piperidine	O
compounds	O
represented	O
by	O
the	O
structure	O
I	O
are	O
provided	O
,	O
wherein	O
each	O
of	O
R1a	O
,	O
R1b	O
,	O
R1c	O
,	O
R1d	O
,	O
R1e	O
,	O
R1f	O
,	O
R1	O
g	O
,	O
R1h	O
,	O
R2	O
,	O
R2A	O
,	O
R3	O
,	O
R4	O
,	O
A	O
,	O
X	O
,	O
a	O
,	O
x	O
and	O
n	O
is	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Substituted	O
piperidine	B
compounds	O
of	O
structure	O
I	O
may	O
permeate	O
or	O
penetrate	O
across	O
a	O
nerve	O
cell	O
membrane	O
into	O
the	O
interior	O
of	O
a	O
nerve	O
cell	O
,	O
may	O
inhibit	O
intracellular	O
Rho	O
kinase	O
enzyme	O
found	O
in	O
nerve	O
cells	O
in	O
mammals	O
,	O
and	O
may	O
find	O
utility	O
in	O
repair	O
of	O
damaged	O
nerves	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
of	O
such	O
mammals	O
.	O

These	O
compounds	O
may	O
induce	O
the	O
regeneration	O
or	O
growth	O
of	O
neurites	O
in	O
mammalian	O
nerve	O
cells	O
and	O
may	O
thereby	O
induce	O
regeneration	O
of	O
damaged	O
or	O
diseased	O
nerve	O
tissue	O
.	O

These	O
compounds	O
also	O
find	O
additional	O
utility	O
as	O
antagonists	O
of	O
the	O
enzyme	O
Rho	O
kinase	O
in	O
treatment	O
of	O
disease	O
states	O
in	O
which	O
Rho	O
kinase	O
is	O
implicated	O
.	O

Pharmaceutical	O
compositions	O
containing	O
these	O
substituted	O
piperidine	O
compounds	O
may	O
be	O
useful	O
to	O
promote	O
neurite	O
growth	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
Rho	O
kinase	O
inhibition	O
is	O
indicated	O
.	O

Inhibitors	O
of	O
Rho	O
kinase	O
;	O
N	B
-	I
Benzyloxycarbonyl-4-	I
[	I
N''-	I
(	I
tert	I
-	I
butyloxycarbonyl	I
)	I
hydrazino	I
]	I
piperidine	I
;	O
4-	B
{	I
[	I
N''-	I
(	I
tert	I
-	I
butyloxycarbonyl	I
)	I
-N'-	I
(	I
1'-propyl	I
)	I
]	I
hydrazino	I
}	I
piperidine	I

The	O
present	O
invention	O
is	O
for	O
a	O
method	O
for	O
decreasing	O
C	O
-	O
reactive	O
protein	O
levels	O
(	O
CRP	O
)	O
in	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O

The	O
method	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
non	O
-	O
antibacterial	O
tetracycline	B
formulation	O
,	O
to	O
the	O
mammal	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
non	O
-	O
antibacterial	O
tetracycline	B
formulation	O
is	O
a	O
non	O
-	O
antibacterial	O
amount	O
of	O
an	O
antibacterial	O
tetracycline	B
.	O

In	O
another	O
embodiment	O
,	O
the	O
non	O
-	O
antibacterial	O
tetracycline	B
formulation	O
is	O
a	O
non	O
-	O
antibacterial	O
tetracycline	B
.	O

Method	O
for	O
reducing	O
c	O
-	O
rective	O
protein	O
levels	O
with	O
non	O
-	O
antibacterial	O
tetracycline	B
formulations	O

Novel	O
substituted	O
indoloquinoxalines	B
of	O
formula	O
(	O
I	O
wherein	O
R1	O
is	O
hydrogen	B
or	O
represents	O
one	O
or	O
more	O
similar	O
or	O
different	O
substituents	O
in	O
the	O
positions	O
7	O
to	O
10	O
selected	O
from	O
the	O
group	O
halogen	O
,	O
lower	O
alkyl	B
/	O
alkoxy	B
,	O
hydroxy	B
,	O
trifluoromethyl	B
,	O
trichloromethyl	B
,	O
trifluoromethoxy	B
,	O
R2	O
represents	O
similar	O
or	O
different	O
C1-C4	B
alkyl	I
substituents	O
,	O
X	O
is	O
CO	B
or	O
CH2	B
,	O
Y	O
is	O
OH	B
,	O
NH2	B
,	O
NH—	B
(	I
CH2	I
)	I
n	I
—	I
R3	I
wherein	O
R3	O
represents	O
lower	O
alkyl	B
,	O
OH	B
,	O
NH2	B
,	O
NHR4	B
or	O
NR5R6	B
wherein	O
R4	O
,	O
R5	O
and	O
R6	O
independently	O
are	O
lower	O
alkyl	B
or	O
cyclo	B
-	I
alkyl	I
and	O
n	O
is	O
an	O
integer	O
of	O
from	O
2	O
to	O
4	O
,	O
with	O
the	O
provision	O
that	O
when	O
X	O
is	O
CH2	B
,	O
Y	O
is	O
OH	B
or	O
NH—	B
(	I
CH2	I
)	I
n	I
—	I
OH	I
,	O
and	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
are	O
described	O
.	O

The	O
compounds	O
are	O
useful	O
as	O
drugs	O
for	O
preventing	O
and/or	O
treating	O
autoimmune	O
diseases	O
.	O

2,3-Dimethylindolo	B
[	I
2,3-b	I
]	I
quinoxaline-6-yl	I
-	I
acetamide	I
;	O
9-Chloro-2,3-dimethyl-6-	B
(	I
aminoethylamino-2-oxoethyl	I
)	I
-6H	I
-	I
indolo	I
[	I
2,3-b	I
]	I
quinoxaline	I
;	O
autoimmune	O
diseases	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
R	O
is	O
hydrogen	B
,	O
alkyl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
aryl	B
,	O
heteroaryl	B
or	O
heterocyclyl	B
;	O
and	O
R1	O
is	O
bicyclyl	B
or	O
heterobicyclyl	B
,	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
conditions	O
mediated	O
by	O
s	O
-	O
CD23	O
.	O

Bicyclyl	B
or	I
heterobicyclylmethanesulfonylanimo	I
-	I
substituted	I
N	I
-	I
hydroxyformamides	I

Compounds	O
of	O
formula	O
(	O
1	O
)	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
and	O
in	O
vivo	O
hydrolysable	O
esters	O
thereof	O
,	O
have	O
activity	O
as	O
pharmaceuticals	O
,	O
in	O
particular	O
as	O
modulators	O
of	O
chemokine	O
receptor	O
(	O
especially	O
CXCR2	O
)	O
activity	O
,	O
and	O
may	O
be	O
in	O
the	O
treatment	O
(	O
therapeutic	O
or	O
prophylactic	O
)	O
of	O
conditions	O
/	O
diseases	O
in	O
human	O
and	O
non	O
-	O
human	O
animals	O
which	O
are	O
exacerbated	O
or	O
caused	O
by	O
excessive	O
or	O
unregulated	O
production	O
of	O
chemokines	O
.	O

Asthma	O
,	O
antiallergens	O
;	O
rheumatoid	O
arthritis	O
and	O
atherosclerosis	O
;	O
anticarcinogenic	O
agents	O
;	O
2-	B
(	I
Benzylthio	I
)	I
-6-	I
{	I
[	I
(	I
1R	I
)	I
-2-hydroxy-1-methylethyl	I
]	I
amino	I
}	I
-4-pyrimidinol	I

The	O
invention	O
relates	O
to	O
a	O
dermal	O
application	O
system	O
for	O
aminolevulinic	B
acid	I
-	O
derivatives	O
,	O
i.e.	O
a	O
pressure	O
-	O
sensitive	O
matrix	O
system	O
containing	O
a	O
crystalline	O
aminolevulinic	B
acid	I
derivative	O
.	O

Dermal	O
application	O
system	O
for	O
aminolevulinic	B
acid	I
-	O
derivatives	O

A	O
novel	O
method	O
has	O
led	O
to	O
the	O
identification	O
of	O
novel	O
mixed	O
ester	O
-	O
amidates	O
of	O
PMPA	O
for	O
retroviral	O
or	O
hepadnaviral	O
therapy	O
,	O
including	O
compounds	O
of	O
structure	O
(	O
5a	O
)	O
having	O
substituent	O
groups	O
as	O
defined	O
herein	O
.	O

Compositions	O
of	O
these	O
novel	O
compounds	O
in	O
pharmaceutically	O
acceptable	O
excipients	O
and	O
their	O
use	O
in	O
therapy	O
and	O
prophylaxis	O
are	O
provided	O
.	O

Prodrugs	O
of	O
phosphonate	O
nucleotide	O
analogues	O
and	O
methods	O
for	O
selecting	O
and	O
making	O
same	O

The	O
present	O
invention	O
provides	O
:	O
a	O
skin	O
protection	O
composition	O
that	O
can	O
effectively	O
suppress	O
intrusion	O
of	O
contagious	O
bacteria	O
such	O
as	O
Pseudomonas	O
aeruginosa	O
,	O
Bacillus	O
subtilis	O
,	O
Bacillus	O
anthracis	O
,	O
Escherichia	O
coli	O
,	O
Staphylococcus	O
aureus	O
,	O
or	O
MRSA	O
,	O
and	O
viruses	O
such	O
as	O
influenza	O
virus	O
from	O
wounds	O
,	O
skin	O
and	O
mucosa	O
such	O
as	O
those	O
of	O
the	O
eyes	O
,	O
nose	O
,	O
throat	O
,	O
ears	O
,	O
anus	O
and	O
vagina	O
into	O
the	O
body	O
,	O
and	O
can	O
also	O
suppress	O
growth	O
of	O
the	O
bacteria	O
and	O
viruses	O
;	O
a	O
skin	O
protection	O
composition	O
that	O
can	O
effectively	O
prevent	O
hospital	O
infections	O
or	O
the	O
like	O
caused	O
by	O
resistant	O
bacteria	O
;	O
a	O
composition	O
to	O
prevent	O
and/or	O
treat	O
bacterial	O
and	O
viral	O
infections	O
including	O
hospital	O
infections	O
;	O
an	O
antiseptic	O
;	O
and	O
a	O
filter	O
apparatus	O
that	O
can	O
effectively	O
suppress	O
intrusion	O
into	O
the	O
body	O
and	O
growth	O
therein	O
of	O
contagious	O
bacteria	O
and	O
viruses	O
.	O

The	O
skin	O
protection	O
composition	O
;	O
skin	O
protection	O
composition	O
that	O
can	O
effectively	O
prevent	O
hospital	O
infections	O
or	O
the	O
like	O
caused	O
by	O
resistant	O
bacteria	O
;	O
composition	O
to	O
prevent	O
and/or	O
treat	O
bacterial	O
and	O
viral	O
infections	O
including	O
hospital	O
infections	O
;	O
antiseptic	O
;	O
and	O
filter	O
apparatus	O
that	O
can	O
effectively	O
suppress	O
intrusion	O
into	O
the	O
body	O
of	O
contagious	O
bacteria	O
and	O
viruses	O
characterized	O
by	O
comprising	O
Sasa	O
extract	O
,	O
or	O
Sasa	O
extract	O
and	O
an	O
organic	O
acid	O
as	O
the	O
active	O
component	O
.	O

Skin	O
protection	O
composition	O

The	O
present	O
invention	O
is	O
to	O
provide	O
a	O
β-1,4-mannobiose	B
-	O
containing	O
composition	O
which	O
can	O
inhibit	O
colonization	O
of	O
salmonella	O
in	O
animal	O
body	O
and	O
effectively	O
excrete	O
salmonella	O
outside	O
the	O
body	O
and	O
the	O
method	O
for	O
producing	O
thereof	O
,	O
a	O
feed	O
additive	O
containing	O
the	O
β-1,4-mannobiose	B
-	O
containing	O
composition	O
,	O
and	O
a	O
feed	O
blended	O
with	O
the	O
β-1,4-mannobiose	B
-	O
containing	O
composition	O
.	O

The	O
present	O
invention	O
is	O
intended	O
to	O
provide	O
a	O
method	O
for	O
producing	O
the	O
β-1,4-mannobiose	B
-	O
containing	O
composition	O
wherein	O
a	O
mannan	B
degrading	O
enzyme	O
is	O
functioned	O
to	O
a	O
mannan	B
-	O
containing	O
natural	O
material	O
for	O
producing	O
at	O
least	O
10	O
%	O
by	O
weight	O
of	O
β-1,4-mannobiose	B
based	O
on	O
the	O
mannan	B
before	O
the	O
degradation	O
,	O
the	O
β-1,4-mannobiose	B
-	O
containing	O
composition	O
prepared	O
through	O
the	O
function	O
of	O
a	O
mannan	B
degrading	O
enzyme	O
to	O
a	O
mannan	B
-	O
containing	O
natural	O
material	O
,	O
which	O
contains	O
at	O
least	O
10	O
%	O
by	O
weight	O
of	O
β-1,4-mannobiose	B
in	O
terms	O
of	O
dry	O
matter	O
,	O
a	O
feed	O
additive	O
containing	O
the	O
β-1,4-mannobiose	B
-	O
containing	O
composition	O
,	O
and	O
a	O
feed	O
blended	O
with	O
the	O
β-1,4-mannobiose	B
-	O
containing	O
composition	O
.	O

B-1	B
,	I
4-mannobiose	I
-	O
containing	O
composition	O

An	O
improved	O
adjuvant	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
in	O
which	O
patients	O
are	O
administered	O
an	O
anthracycline	B
chemotherapeutic	O
agent	O
and	O
a	O
taxane	B
chemotherapeutic	O
agent	O
is	O
provided	O
in	O
which	O
a	O
diphenyl	B
compound	O
which	O
is	O
a	O
potent	O
antagonist	O
of	O
histamine	B
binding	O
at	O
the	O
intracellular	O
histamine	B
receptor	O
is	O
initially	O
administered	O
prior	O
to	O
administration	O
of	O
the	O
chemotherapeutic	O
agents	O
.	O

Treatment	O
of	O
metastatic	O
breast	O
cancer	O
with	O
anthracyclines	B
,	O
and	O
taxanes	B

The	O
invention	O
concerns	O
the	O
use	O
of	O
low	O
molecular	O
weight	O
heparin	O
for	O
preventing	O
and/or	O
treating	O
motor	O
neuron	O
diseases	O
.	O

Novel	O
therapeutic	O
use	O
of	O
low	O
molecular	O
weight	O
heparins	O

The	O
present	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
pollakiuria	O
comprising	O
a	O
compound	O
having	O
an	O
antagonism	O
to	O
an	O
EP1	O
receptor	O
which	O
is	O
a	O
prostaglandin	B
E2	I
receptor	O
subtype	O
.	O

A	O
compound	O
having	O
an	O
antagonism	O
to	O
an	O
EP1	O
receptor	O
antagonistically	O
acts	O
on	O
an	O
EP1	O
receptor	O
which	O
is	O
a	O
prostaglandin	B
PGE2	I
receptor	O
subtype	O
and	O
significantly	O
shows	O
a	O
suppressive	O
activity	O
for	O
urination	O
frequency	O
in	O
models	O
where	O
pollakiuria	O
is	O
induced	O
.	O

Therefore	O
,	O
it	O
is	O
effective	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
pollakiuria	O
(	O
that	O
which	O
is	O
due	O
to	O
nurogenic	O
bladder	O
,	O
nervous	O
bladder	O
,	O
stimulated	O
bladder	O
,	O
unstable	O
bladder	O
,	O
benign	O
prostatic	O
hypertrophy	O
,	O
etc	O
.	O
)	O
.	O

Remedies	O
for	O
urinary	O
frequency	O

A	O
compound	O
having	O
a	O
xanthine	B
oxidase	O
inhibitory	O
activity	O
,	O
such	O
as	O
1-	B
(	I
3-cyano-4-neopentyloxyphenyl	I
)	I
pyrazole-4-carboxylic	I
acid	I
and	O
the	O
like	O
,	O
can	O
be	O
a	O
drug	O
for	O
preventing	O
cancer	O
including	O
colon	O
cancer	O
and	O
the	O
like	O
,	O
as	O
an	O
agent	O
for	O
suppressing	O
tumorigenesis	O
.	O

Phenylpyrazole	B
compounds	O
such	O
as	O
1-	B
(	I
3-cyano-4-neopentyloxyphenyl	I
)	I
pyrazole-4-carboxylic	I
acid	I
and	O
the	O
like	O
for	O
preventing	O
colon	O
cancer	O
and	O
the	O
like	O
,	O
and	O
as	O
an	O
agent	O
for	O
suppressing	O
tumorigenesis	O

A	O
pharmaceutical	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
amyloidosis	O
such	O
as	O
familial	O
amyloid	O
polyneuropathy	O
is	O
provided	O
.	O

A	O
pharmaceutical	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
amyloidosis	O
that	O
contains	O
a	O
compound	O
containing	O
the	O
trivalent	O
chromium	B
ion	I
,	O
such	O
as	O
a	O
fatty	B
acid	I
chromium	B
salt	I
,	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
that	O
is	O
capable	O
of	O
suppressing	O
the	O
decomposition	O
of	O
mutant	O
transthyretin	O
in	O
amyloidosis	O
.	O

Medicine	O
for	O
prevention	O
of	O
and	O
treatment	O
for	O
amyloidosis	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
a	O
warm	O
-	O
blooded	O
animal	O
,	O
especially	O
a	O
human	O
,	O
having	O
agnogenic	O
myeloid	O
metaplasia	O
(	O
AMM	O
)	O
,	O
especially	O
agnogenic	O
myeloid	O
metaplasia	O
which	O
is	O
resistant	O
to	O
conventional	O
chemotherapy	O
.	O

Treatment	O
of	O
amm	O

The	O
present	O
invention	O
provides	O
a	O
drug	O
product	O
for	O
the	O
prevention	O
,	O
improvement	O
in	O
conditions	O
relating	O
to	O
,	O
and/or	O
treatment	O
of	O
diabetes	O
,	O
comprising	O
β	O
(	O
1→3	O
)	O
glucan	O
derived	O
from	O
vegetable	O
material	O
and	O
having	O
a	O
molecular	O
weight	O
of	O
from	O
about	O
5,000	O
to	O
about	O
20,000	O
.	O

The	O
drug	O
product	O
of	O
the	O
present	O
invention	O
can	O
be	O
widely	O
employed	O
as	O
a	O
diabetes	O
drug	O
for	O
both	O
IDDM	O
and	O
NIDDM	O
,	O
exhibits	O
almost	O
no	O
side	O
effects	O
and	O
does	O
not	O
have	O
an	O
obese	O
effect	O
even	O
when	O
orally	O
administered	O
,	O
can	O
be	O
widely	O
employed	O
as	O
a	O
medical	O
drug	O
for	O
patients	O
in	O
various	O
states	O
of	O
morbidity	O
,	O
and	O
can	O
be	O
employed	O
by	O
patients	O
,	O
generally	O
healthy	O
persons	O
,	O
and	O
other	O
animals	O
in	O
the	O
form	O
of	O
food	O
and	O
drink	O
products	O
such	O
as	O
therapeutic	O
foods	O
and	O
health	O
foods	O
.	O

The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
preventing	O
,	O
improving	O
conditions	O
relating	O
to	O
,	O
and/or	O
treating	O
diabetes	O
comprising	O
administering	O
the	O
above	O
-	O
specified	O
β	O
(	O
1→3	O
)	O
glucan	O
.	O

Drug	O
product	O
for	O
diabetes	O

Medical	O
devices	O
comprising	O
an	O
interventional	O
component	O
for	O
delivering	O
multiple	O
beneficial	O
agents	O
in	O
which	O
a	O
hydration	O
inhibitor	O
controls	O
release	O
of	O
at	O
least	O
one	O
beneficial	O
agent	O
from	O
the	O
device	O
.	O

The	O
hydration	O
inhibitor	O
is	O
relatively	O
less	O
hydrophilic	O
than	O
the	O
beneficial	O
agent	O
and	O
preferably	O
is	O
a	O
drug	O
.	O

Suitable	O
beneficial	O
agents	O
include	O
(	O
I	O
)	O
dexamethasone	B
,	O
estradiol	B
,	O
anti	O
-	O
proliferative	O
agents	O
,	O
anti	O
-	O
platelet	O
agents	O
,	O
anti	O
-	O
inflammatory	O
agents	O
,	O
anti	O
-	O
thrombotic	O
agents	O
,	O
cytotoxic	O
drugs	O
,	O
agents	O
that	O
inhibit	O
cytokine	O
or	O
chemokine	O
binding	O
,	O
cell	O
de	O
-	O
differentiation	O
inhibitors	O
,	O
anti	O
-	O
lipacdemic	O
agents	O
,	O
matrix	O
metalloproteinase	O
inhibitors	O
,	O
cytostatic	O
drugs	O
,	O
or	O
combinations	O
of	O
these	O
drugs	O
,	O
radiopaque	O
markers	O
,	O
beta	B
-	I
carotene	I
,	O
tocopherols	B
,	O
tocotrienols	B
,	O
and	O
antioxidants	O
Device	O
having	O
hydration	O
inhibitor	O

The	O
present	O
invention	O
relates	O
to	O
new	O
compounds	O
,	O
a	O
process	O
for	O
their	O
preparation	O
and	O
new	O
intermediates	O
used	O
therein	O
,	O
pharmaceutical	O
formulations	O
containing	O
said	O
therapeutically	O
active	O
compounds	O
and	O
to	O
the	O
use	O
of	O
said	O
active	O
compounds	O
in	O
therapy	O
,	O
such	O
as	O
provide	O
compounds	O
having	O
a	O
selective	O
inhibiting	O
effect	O
at	O
GSK3	O
.	O

Useful	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
cognitive	O
disorders	O
;	O
3-Amino	B
-	I
N-	I
(	I
3-nitrophenyl	I
)	I
-6-	I
[	I
4-	I
(	I
pyrrolidin-1-ylsulfonyl	I
)	I
phenyl	I
]	I
pyrazine-2-carboxamide	I
,	O
for	O
example	O

A	O
method	O
providing	O
the	O
treating	O
or	O
prophylaxis	O
of	O
one	O
or	O
more	O
symptoms	O
of	O
viral	O
infection	O
.	O

The	O
method	O
involving	O
the	O
administration	O
of	O
citrate	O
and/or	O
succinate	B
salts	O
.	O

The	O
present	O
invention	O
also	O
encompasses	O
the	O
use	O
of	O
citrate	B
and/or	O
succinate	B
salts	O
for	O
the	O
treatment	O
of	O
prevention	O
of	O
lesions	O
or	O
blisters	O
,	O
or	O
other	O
symptoms	O
of	O
infection	O
by	O
members	O
of	O
the	O
herpes	O
virus	O
family	O
.	O

Method	O
of	O
treatment	O
or	O
prophylaxis	O
of	O
symptoms	O
of	O
herpes	O
viral	O
infection	O

A	O
method	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
active	O
ingredient	O
fenofibrate	O
or	O
one	O
of	O
its	O
derivatives	O
,	O
optionally	O
in	O
combination	O
with	O
a	O
second	O
active	O
ingredient	O
,	O
in	O
the	O
form	O
of	O
tablets	O
,	O
characterized	O
in	O
that	O
it	O
comprises	O
a	O
compression	O
step	O
of	O
the	O
active	O
ingredient	O
and	O
excipients	O
by	O
means	O
of	O
a	O
dry	O
method	O
of	O
granulation	O
Method	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
in	O
the	O
form	O
of	O
tablets	O
containing	O
a	O
fibrate	O
and	O
tablets	O
obtained	O
according	O
to	O
the	O
method	O

The	O
invention	O
discloses	O
the	O
use	O
of	O
a	O
number	O
of	O
saponins	B
and	O
sapogenins	B
,	O
notably	O
those	O
of	O
steroidal	O
structure	O
,	O
in	O
the	O
treatment	O
of	O
cognitive	O
disfunction	O
and	O
similar	O
conditions	O
.	O

Methods	O
of	O
treatment	O
,	O
and	O
pharmaceutical	O
compositions	O
are	O
also	O
disclosed	O
.	O

Steroidal	O
sapogenins	B
and	O
their	O
derivatives	O
for	O
treating	O
Alzheimer	O
's	O
disease	O

The	O
subject	O
invention	O
provides	O
therapeutically	O
useful	O
and	O
therapeutically	O
effective	O
compounds	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
disorders	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
exhibit	O
significantly	O
reduced	O
levels	O
of	O
drug	O
-	O
drug	O
interactions	O
(	O
DDI	O
)	O
and	O
are	O
metabolized	O
,	O
primarily	O
,	O
via	O
non	O
-	O
oxidative	O
systems	O
.	O

Non	O
-	O
oxidatively	O
metabolized	O
compounds	O
and	O
compositions	O
,	O
synthetic	O
pathways	O
therefor	O
,	O
and	O
uses	O
thereof	O

There	O
are	O
provided	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
L1	O
,	O
L2	O
,	O
L3	O
and	O
Q	O
are	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O

The	O
compounds	O
are	O
inhibitors	O
of	O
nitric	B
oxide	I
synthase	O
and	O
are	O
thereby	O
particularly	O
useful	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
inflammatory	O
disease	O
and	O
pain	O
.	O

Novel	O
6-substituted	B
2-aminopyridine	I
derivatives	O

A	O
combination	O
of	O
a	O
5HT1B	O
/	O
1D	O
agonist	O
and	O
a	O
COX-2	O
selective	O
inhibitor	O
is	O
useful	O
in	O
the	O
treatment	O
and	O
or	O
prevention	O
of	O
migraine	O
.	O

Method	O
of	O
treating	O
migraines	O
and	O
pharmaceutical	O
compositions	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
suitable	O
for	O
use	O
as	O
topical	O
pharmaceutical	O
compositions	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
superficial	O
microbial	O
species	O
infection	O
,	O
and/or	O
as	O
anti	O
-	O
microbial	O
cleansing	O
compositions	O
for	O
use	O
in	O
the	O
sanitary	O
cleaning	O
of	O
animate	O
or	O
inanimate	O
surfaces	O
.	O

The	O
pharmaceutical	O
compositions	O
comprise	O
a	O
physiologically	O
acceptable	O
metal	O
ion	O
chelating	O
agent	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
therefor	O
,	O
in	O
which	O
composition	O
said	O
metal	O
ion	O
chelating	O
agent	O
has	O
a	O
metal	O
ion	O
chelating	O
capacity	O
for	O
metal	O
ions	O
on	O
which	O
said	O
microbial	O
species	O
is	O
dependent	O
for	O
viability	O
.	O

The	O
cleansing	O
compositions	O
comprise	O
:	O
a	O
cleaning	O
composition	O
wherein	O
is	O
provided	O
a	O
metal	O
ion	O
chelating	O
agent	O
and	O
in	O
which	O
composition	O
said	O
metal	O
ion	O
chelating	O
agent	O
has	O
a	O
metal	O
ion	O
chelating	O
capacity	O
for	O
metal	O
ions	O
on	O
which	O
a	O
microbial	O
species	O
is	O
dependent	O
for	O
viability	O
.	O

Personal	O
hygiene	O
and	O
hard	O
surface	O
cleaning	O
agent	O
;	O
acne	O
,	O
skin	O
complaints	O
;	O
effective	O
against	O
antibiotic	O
resistant	O
bacteria	O

The	O
present	O
invention	O
provides	O
a	O
TGR5	O
receptor	O
agonist	O
comprising	O
a	O
fused	O
ring	O
compound	O
represented	O
by	O
the	O
formula	O
wherein	O
ring	O
A	O
is	O
an	O
optionally	O
substituted	O
aromatic	B
ring	O
;	O
and	O
ring	O
B′	O
is	O
a	O
5-	O
to	O
8-membered	O
ring	O
having	O
one	O
or	O
more	O
substituents	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
,	O
which	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
various	O
diseases	O
.	O

e.g.	O
2-	B
[	I
3,5-trans-5-	I
(	I
3-aminophenyl	I
)	I
-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl	I
]	I
-N-	I
(	I
2-fluorobenzyl	I
)	I
acetamide	I
;	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
(	O
TGR5	O
)	O
agonist	O
;	O
central	O
nervous	O
system	O
diseases	O
;	O
antiinflammatory	O
agent	O
;	O
learning	O
enhancement	O
;	O
angina	O
pectoris	O
,	O
arrhythmia	O
,	O
bronchial	O
asthma	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
preparation	O
containing	O
at	O
least	O
one	O
compound	O
of	O
general	O
formula	O
(	O
1	O
)	O
:	O
Pd	B
(	I
S2COR	I
)	I
2	I
wherein	O
R	O
is	O
a	O
straight	O
-	O
chain	O
or	O
branched	O
alkyl	B
residue	O
having	O
1	O
to	O
30	O
carbon	B
atoms	O
,	O
a	O
straight	O
-	O
chain	O
or	O
branched	O
alkenyl	B
residue	O
having	O
2	O
to	O
30	O
carbon	B
atoms	O
,	O
a	O
monocyclic	O
or	O
polycyclic	O
alkyl	B
residue	O
having	O
3	O
to	O
30	O
carbon	B
atoms	O
,	O
a	O
monocyclic	B
or	I
polycyclic	I
alkenyl	I
residue	O
having	O
4	O
to	O
30	O
carbon	B
atoms	O
,	O
or	O
a	O
monocyclic	B
or	I
polycyclic	I
aromatic	I
residue	O
having	O
6	O
to	O
30	O
carbon	B
atoms	O
,	O
these	O
residues	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
several	O
substituents	O
.	O

Pharmaceutical	O
preparation	O
containing	O
palladium	B
complex	O
compounds	O
and	O
the	O
uses	O
thereof	O
for	O
treating	O
cancer	O
and	O
autoimmune	O
disease	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
dopamine	B
receptor	O
agonists	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
reduction	O
of	O
excessive	O
food	O
intake	O
.	O

Dopamine	B
D1	O
,	O
D2	O
,	O
D3	O
,	O
and	O
D4	O
receptor	O
agonist	O
such	O
as	O
pramipexole	B
in	O
combination	O
with	O
a	O
second	O
active	O
substance	O
selected	O
from	O
D1	O
,	O
D2	O
,	O
D3	O
,	O
and	O
D4	O
receptor	O
agonists	O
,	O
anorectics	O
,	O
lipase	O
inhibitors	O
and	O
sympathomimetics	O
;	O
for	O
treating	O
overweight	O
or	O
obesity	O
or	O
type	O
2	O
diabetes	O

Method	O
for	O
purification	O
and	O
synthesis	O
of	O
RNA	O
molecules	O
and	O
enzymatic	O
RNA	O
molecules	O
in	O
enzymatically	O
active	O
form	O
.	O

Synthesis	O
,	O
deprotection	O
,	O
analysis	O
&	O
purification	O
of	O
RNA	O
&	O
ribozymes	O

A	O
sustained	O
release	O
delivery	O
apparatus	O
including	O
a	O
silicone	O
support	O
material	O
formed	O
from	O
a	O
methyl	B
-	I
vinyl	I
siloxane	I
polymer	O
including	O
a	O
fumed	O
silica	B
as	O
a	O
reinforcing	O
filler	O
;	O
a	O
pharmaceutically	O
active	O
composition	O
carried	O
in	O
or	O
on	O
the	O
silicone	B
support	O
material	O
;	O
the	O
pharmaceutically	O
active	O
composition	O
including	O
at	O
least	O
one	O
growth	O
and/or	O
reproduction	O
-	O
associated	O
pharmaceutical	O
component	O
;	O
analogue	O
thereof	O
or	O
derivative	O
thereof	O
;	O
and	O
a	O
carrier	O
therefor	O
.	O

Sustained	O
release	O
pharmaceutical	O
composition	O

Disclosed	O
is	O
the	O
unexpected	O
finding	O
that	O
enantiomers	O
of	O
phenothiazines	B
,	O
preferably	O
the	O
(	O
+	O
)	O
enantiomer	O
of	O
promethazine	B
,	O
are	O
particularly	O
effective	O
in	O
inhibiting	O
the	O
bone	O
resorbing	O
cells	O
,	O
osteoclasts	O
,	O
thus	O
providing	O
new	O
uses	O
and	O
methods	O
for	O
reducing	O
bone	O
loss	O
and	O
,	O
e.g.	O
,	O
treating	O
periodontitis	O
and	O
osteoporosis	O
.	O

The	O
invention	O
provides	O
a	O
range	O
of	O
such	O
uses	O
,	O
methods	O
,	O
medicaments	O
and	O
associated	O
compositions	O
and	O
kits	O
.	O

Phenothiazine	B
enantiomers	O
as	O
agents	O
for	O
the	O
prevention	O
of	O
bone	O
loss	O

The	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
(	B
4-hydroxy-6-oxo	I
-	I
tetrahydro	I
-	I
pyran-2-yl	I
)	I
-acetonitrile	I
from	O
6-X	B
-	I
substituted	I
-	I
methyl-4-hydroxy	I
-	I
tetrahydro	I
-	I
pyran-2-one	I
,	O
wherein	O
X	O
stands	O
for	O
a	O
leaving	O
group	O
,	O
by	O
reacting	O
6-X	B
-	I
substituted	I
-	I
methyl-4-hydroxy	I
-	I
tetrahydro	I
-	I
pyran-2-one	I
with	O
a	O
cyanide	B
ion	I
in	O
water	O
and	O
by	O
subsequent	O
lowering	O
of	O
the	O
pH	O
to	O
a	O
pH	O
between	O
0	O
and	O
5	O
.	O

(	B
4-hydroxy-6-oxo	I
-	I
tetrahydro	I
-	I
pyran-2-yl	I
)	I
-acetonitrile	I
and	O
other	O
compounds	O
obtainable	O
from	O
(	B
4-hydroxy-6-oxo	I
-	I
tetrahydro	I
-	I
pyran-2-yl	I
)	I
-acetonitrile	I
may	O
suitably	O
be	O
used	O
in	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
preparation	O
,	O
more	O
in	O
particular	O
in	O
the	O
preparation	O
of	O
statins	O
,	O
more	O
in	O
particular	O
in	O
the	O
preparation	O
of	O
Atorvastatine	B
or	O
a	O
salt	O
thereof	O
,	O
for	O
instance	O
its	O
calcium	B
salt	O
.	O

The	O
invention	O
also	O
relates	O
to	O
(	B
4-hydroxy-6-oxo	I
-	I
tetrahydro	I
-	I
pyran-2-yl	I
)	I
-acetonitrile	I
and	O
other	O
compounds	O
obtainable	O
therefrom	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
(	B
4-hydroxy-6-oxo	I
-	I
tetrahydropyran-2-yl	I
)	I
acetonitrile	I
and	O
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
multifunctional	O
compounds	O
comprising	O
an	O
anti	O
-	O
inflammatory	O
or	O
immunomodulatory	O
component	O
,	O
and	O
at	O
least	O
one	O
SOD	O
mimic	O
component	O
capable	O
of	O
reacting	O
with	O
reactive	O
oxygen	B
species	O
,	O
and	O
to	O
their	O
use	O
in	O
treating	O
inflammatory	O
bowel	O
disease	O
comprising	O
ulcerative	O
colitis	O
and	O
Crohn	O
's	O
disease	O
.	O

Preferred	O
anti	O
-	O
inflammatory	O
or	O
immunomodulatory	O
components	O
comprise	O
derivatives	O
of	O
salicylic	B
acid	I
and	O
steroids	B
.	O

Sod	O
minic	O
multifunctional	O
compounds	O
for	O
treating	O
inflammatory	O
bowel	O
disease	O

The	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
:	O
R1	O
is	O
aryl	B
;	O
R2	O
is	O
H	B
,	O
alkyl	B
or	O
aryl	B
;	O
and	O
R3	O
is	O
hydrogen	B
or	O
alkyl	B
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
,	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
mediated	O
by	O
CB1	O
receptors	O
.	O

Use	O
of	O
azetidinecarboxamide	B
derivatives	O
in	O
therapy	O

Methods	O
are	O
described	O
for	O
the	O
isolation	O
of	O
nucleic	O
acid	O
ligands	O
to	O
integrins	O
using	O
the	O
SELEX	O
process	O
.	O

SELEX	O
is	O
an	O
acronym	O
for	O
Systematic	O
Evolution	O
of	O
Ligands	O
by	O
EXponential	O
enrichment	O
.	O

The	O
nucleic	O
acid	O
ligands	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
therapeutic	O
and	O
diagnostic	O
agents	O
.	O

Nucleic	O
acid	O
ligands	O
to	O
integrins	O

An	O
inhibitor	O
for	O
an	O
inflammatory	O
cell	O
infiltration	O
in	O
the	O
respiratory	O
tract	O
,	O
an	O
inhibitor	O
for	O
hyperirritability	O
in	O
the	O
respiratory	O
tract	O
,	O
a	O
muciparous	O
inhibitor	O
,	O
or	O
a	O
bronchodilator	O
which	O
contains	O
as	O
an	O
active	O
ingredient	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
:	O
wherein	O
R1	O
is	O
the	O
group	O
represented	O
by	O
the	O
formula	O
:	O
—C	O
(	B
=Z	I
)	I
-W	I
—	I
R4	I
wherein	O
Z	O
is	O
an	O
oxygen	B
atom	O
or	O
the	O
like	O

;	O
W	O
is	O
an	O
oxygen	B
atom	O
or	O
the	O
like	O
;	O

R4	O
is	O
optionally	O
substituted	O
alkyl	B
or	O
the	O
like	O
;	O
R2	O
and	O
R3	O
are	O
independently	O
optionally	O
substituted	O
alkyl	B
or	O
the	O
like	O
;	O
or	O
R2	O
and	O
R3	O
are	O
taken	O
together	O
to	O
form	O
optionally	O
substituted	O
alkylene	B
which	O
may	O
contain	O
a	O
heteroatom	O
(	O
s	O
)	O
;	O
m	O
is	O
an	O
integer	O
of	O
0	O
to	O
2	O
;	O
A	O
is	O
optionally	O
substituted	O
aryl	B
or	O
optionally	O
substituted	O
heteroaryl	B
;	O
wherein	O
R5	O
is	O
the	O
group	O
represented	O
by	O
the	O
formula	O
:	O
—Y1—Y2—Y3—Ra	O
wherein	O
Y1	O
and	O
Y3	O
are	O
each	O
independently	O
a	O
bond	O
or	O
the	O
like	O
;	O
Y2	O
is	O
—C	B
(	I
═	I
O	I
)	I
—NRb—	I
or	O
the	O
like	O
;	O
Ra	O
is	O
optionally	O
substituted	O
alkyl	B
,	O
or	O
the	O
like	O
;	O
Rb	O
is	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
R6	O
is	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
R7	O
and	O
R8	O
are	O
each	O
independently	O
optionally	O
substituted	O
alkyl	B
or	O
the	O
like	O
;	O
or	O
R7	O
and	O
R8	O
are	O
taken	O
together	O
with	O
the	O
adjacent	O
carbon	B
atoms	O
to	O
form	O
a	O
5	O
to	O
8	O
membered	O
ring	O
which	O
may	O
contain	O
a	O
heteroatom	O
(	O
s	O
)	O
and/or	O
an	O
unsaturated	O
bond	O
(	O
s	O
)	O
;	O
R9	O
is	O
optionally	O
substituted	O
alkyl	B
which	O
may	O
contain	O
a	O
heteroatom	O
(	O
s	O
)	O
and/or	O
an	O
unsaturated	O
bond	O
(	O
s	O
)	O
,	O
or	O
the	O
like	O
;	O
X	O
is	O
a	O
oxygen	B
atom	O
or	O
the	O
like	O
.	O

Novel	O
use	O
of	O
cannabinoid	B
receptor	O
agonist	O

The	O
present	O
invention	O
relates	O
to	O
certain	O
pyrazole	B
carboxylic	I
acid	I
and	O
ester	O
derivatives	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
exhibit	O
useful	O
pharmaceutical	O
properties	O
,	O
for	O
example	O
as	O
agonists	O
for	O
the	O
RUP25	O
receptor	O
.	O

(	O
I	O
)	O
Also	O
provided	O
by	O
the	O
present	O
invention	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
the	O
invention	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
of	O
the	O
invention	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
metabolic	O
-	O
related	O
disorders	O
,	O
including	O
dyslipidemia	O
,	O
atherosclerosis	O
,	O
coronary	O
heart	O
disease	O
,	O
insulin	O
resistance	O
,	O
type	O
2	O
diabetes	O
,	O
Syndrome	O
-	O
X	O
and	O
the	O
like	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
also	O
provides	O
for	O
the	O
use	O
of	O
the	O
compounds	O
of	O
the	O
invention	O
in	O
combination	O
with	O
other	O
active	O
agents	O
such	O
as	O
those	O
belonging	O
to	O
the	O
class	O
of	O
α	O
-	O
glucosidase	O
inhibitors	O
,	O
aldose	B
reductase	O
inhibitors	O
,	O
biguanides	B
,	O
HMG	O
-	O
CoA	O
reductase	O
inhibitors	O
,	O
squalene	O
synthesis	O
inhibitors	O
,	O
fibrates	O
,	O
LDL	O
catabolism	O
enhancers	O
,	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
,	O
insulin	O
secretion	O
enhancers	O
and	O
the	O
like	O
the	O
substituents	O
are	O
defined	O
in	O
claim	O
1	O
.	O

5-Substituted	B
2h	I
-	I
pyrazole-3-carboxylic	I
acid	I
derivatives	O
as	O
agonists	O
for	O
the	O
acid	O
receptor	O
rup25	O
for	O
the	O
treatment	O
of	O
dyslipidemia	O
and	O
related	O
diseases	O

A	O
stable	O
solvent	O
-	O
based	O
composition	O
is	O
described	O
which	O
is	O
particularly	O
useful	O
in	O
warm	O
blooded	O
animals	O
such	O
as	O
dogs	O
.	O

The	O
composition	O
comprises	O
a	O
therapeutically	O
effective	O
amount	O
of	O
carprofen	B
,	O
one	O
or	O
more	O
polyols	B
,	O
one	O
or	O
more	O
stabilising	O
agents	O
and	O
optionally	O
,	O
one	O
or	O
more	O
co	O
-	O
solvents	O
.	O

Stable	O
carprofen	B
composition	O

The	O
present	O
invention	O
provides	O
an	O
anti	O
-	O
stress	O
agent	O
which	O
can	O
effectively	O
prevent	O
or	O
alleviate	O
various	O
symptoms	O
caused	O
by	O
stress	O
and	O
which	O
is	O
safe	O
and	O
easily	O
taken	O
or	O
ingested	O
.	O

The	O
anti	O
-	O
stress	O
agent	O
comprises	O
an	O
aroma	O
component	O
of	O
coffee	O
or	O
teas	O
as	O
an	O
active	O
ingredient	O
.	O

Anti	O
-	O
stress	O
agent	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
which	O
contain	O
a	O
heterocyclic	B
triazine	I
moiety	O
which	O
inhibit	O
the	O
activity	O
of	O
Akt	O
,	O
a	O
serine	B
/	O
threonine	B
protein	O
kinase	O
.	O

The	O
invention	O
is	O
further	O
directed	O
to	O
chemotherapeutic	O
compositions	O
containing	O
the	O
compounds	O
of	O
this	O
invention	O
and	O
methods	O
for	O
treating	O
cancer	O
comprising	O
administration	O
of	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

1-	B
(	I
1-	I
{	I
4-	I
[	I
3-	I
(	I
1,3-oxazol-	I
2-yl	I
)	I
-6-phenyl-1,2,4-	I
triazin-5-	I
yl	I
]	I
benzyl	I
}	I
piperidin-4-	I
yl	I
)	I
-1,3-dihydro-2H-	I
benzimidazol-2-one	I
;	O
inhibit	O
activity	O
of	O
a	O
serine	B
,	O
threonine	B
protein	O
kinase	O
;	O
hyperproliferative	O
disorders	O
,	O
restenosis	O
,	O
inflammation	O
,	O
autoimmune	O
diseases	O
,	O
allergy	O
,	O
asthma	O

The	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
at	O
least	O
two	O
therapeutic	O
combination	O
components	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	O
i	O
)	O
an	O
AT1-receptor	O
antagonist	O
or	O
an	O
AT1	O
receptor	O
antagonist	O
combined	O
with	O
a	O
diuretic	O
or	O
,	O
in	O
each	O
case	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
(	O
ii	O
)	O
a	O
HMG	O
-	O
Co	O
-	O
A	O
reductase	O
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
iii	O
)	O
an	O
ACE	O
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
use	O
in	O
the	O
prevention	O
of	O
,	O
delay	O
of	O
progression	O
of	O
,	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hyperlipidaemia	O
and	O
dyslipidemia	O
,	O
atherosclerosis	O
,	O
insulin	O
resistance	O
and	O
syndrome	O
X	O
,	O
diabetes	O
mellitus	O
type	O
2	O
,	O
obesity	O
,	O
nephropathy	O
,	O
renal	O
failure	O
,	O
e.g.	O
chronic	O
renal	O
failure	O
,	O
hypothyroidism	O
,	O
survival	O
post	O
myocardial	O
infarction	O
(	O
MI	O
)	O
,	O
coronary	O
heart	O
diseases	O
,	O
hypertension	O
in	O
the	O
elderly	O
,	O
familial	O
dyslipidemic	O
hypertension	O
,	O
and	O
remodeling	O
following	O
hypertension	O
(	O
antiproliferative	O
effect	O
of	O
the	O
combination	O
)	O
,	O
all	O
these	O
diseases	O
or	O
conditions	O
associated	O
with	O
or	O
without	O
hypertension	O
,	O
and	O
,	O
furthermore	O
,	O
in	O
the	O
prevention	O
of	O
,	O
delay	O
of	O
progression	O
of	O
,	O
treatment	O
of	O
stroke	O
,	O
erectile	O
dysfunction	O
and	O
vascular	O
disease	O
.	O

Combination	O
of	O
at	O
least	O
two	O
compounds	O
selected	O
from	O
an	O
AT1-receptorantagonist	O
or	O
an	O
ACE	O
inhibitor	O
or	O
a	O
HMG	O
-	O
Co	O
-	O
A	O
reductase	O
inhibitor	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
prophylaxis	O
and	O
therapy	O
of	O
infectious	O
diseases	O
caused	O
by	O
microorganisms	O
present	O
in	O
biofilms	O
adherent	O
to	O
cell	O
surfaces	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
an	O
individual	O
in	O
need	O
thereof	O
a	O
composition	O
comprising	O
a	O
combination	O
of	O
at	O
least	O
one	O
compound	O
chosen	O
from	O
the	O
group	O
of	O
peroxidase	O
,	O
lactoferrin	O
,	O
lactoferrin	O
peptides	O
,	O
lysozyme	O
and	O
immunoglobulins	O
and	O
at	O
least	O
one	O
growth	O
factor	O
.	O

Novel	O
methods	O
and	O
medicament	O
for	O
treating	O
infectious	O
diseases	O
involving	O
microbial	O
biofilms	O

A	O
polymorph	O
(	O
A	O
)	O
of	O
4-	B
(	I
3-chloro-4-	I
(	I
cyclopropylaminocarbonyl	I
)	I
aminophenoxy	I
)	I
-7-methoxy-6-quinolinecarboxamide	I
,	O
having	O
a	O
diffraction	O
peak	O
at	O
a	O
diffraction	O
angle	O
(	O
2θ±0.2	O
°	O
)	O
of	O
15.75	O
°	O
in	O
a	O
powder	O
X	O
-	O
ray	O
diffraction	O
;	O
and	O
a	O
polymorph	O
(	O
B	O
)	O
of	O
4-	B
[	I
3-chloro-4-	I
(	I
cyclopropylaminocarbonyl	I
)	I
aminophenoxy	I
]	I
-7-methoxy-6-quinolinecarboxamide	I
,	O
having	O
a	O
diffraction	O
peak	O
at	O
a	O
diffraction	O
angle	O
(	O
2θ±0.2	O
°	O
)	O
of	O
21.75	O
°	O
in	O
a	O
powder	O
X	O
-	O
ray	O
diffraction	O
.	O

Polymorph	O
of	O
4-	B
[	I
3-chloro-4-	I
(	I
cyclopropylaminocarbonyl	I
)	I
aminophenoxy	I
]	I
-7-methoxy-6-	I
quinolinecarboxamide	I
and	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O

This	O
invention	O
provides	O
a	O
method	O
of	O
determining	O
a	O
chromosomal	O
breakpoint	O
in	O
a	O
subject	O
suffering	O
from	O
multiple	O
myeloma	O
which	O
comprises	O
steps	O
of	O
:	O
(	O
a	O
)	O
obtaining	O
a	O
DNA	O
sample	O
from	O
the	O
subject	O
suffering	O
from	O
multiple	O
myeloma	O
;	O
(	O
b	O
)	O
determining	O
whether	O
there	O
is	O
J	O
and	O
C	O
disjunction	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
in	O
the	O
obtained	O
DNA	O
sample	O
;	O
(	O
c	O
)	O
obtaining	O
a	O
genomic	O
library	O
having	O
clones	O
which	O
contain	O
genomic	O
DNA	O
fragments	O
from	O
the	O
DNA	O
sample	O
which	O
shows	O
positive	O
J	O
and	O
C	O
disjunction	O
;	O
(	O
d	O
)	O
selecting	O
and	O
isolating	O
clones	O
of	O
the	O
obtained	O
library	O
which	O
show	O
positive	O
hybridization	O
with	O
a	O
probe	O
which	O
is	O
capable	O
of	O
specifically	O
hybridizing	O
with	O
the	O
C	O
but	O
not	O
the	O
J	O
region	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
;	O
(	O
e	O
)	O
preparing	O
fluorescent	O
probes	O
from	O
the	O
genomic	O
DNA	O
fragments	O
of	O
the	O
isolated	O
clones	O
from	O
step	O
(	O
d	O
)	O
;	O
(	O
f	O
)	O
hybridizing	O
said	O
fluorescent	O
probes	O
with	O
metaphase	O
chromosomes	O
;	O
and	O
(	O
g	O
)	O
determining	O
the	O
identity	O
of	O
the	O
chromosomes	O
which	O
are	O
capable	O
of	O
hybridizing	O
to	O
said	O
fluorescent	O
probes	O
,	O
wherein	O
the	O
identification	O
of	O
a	O
chromosome	O
other	O
than	O
chromosome	O
14	O
would	O
indicate	O
that	O
the	O
chromosomal	O
breakpoint	O
is	O
between	O
chromosome	O
14	O
and	O
the	O
identified	O
chromosome	O
,	O
thereby	O
determining	O
a	O
chromosomal	O
breakpoint	O
in	O
a	O
subject	O
suffering	O
from	O
multiple	O
myeloma	O
.	O

This	O
invention	O
also	O
provides	O
the	O
identified	O
gene	O
altered	O
by	O
a	O
chromosomal	O
breakpoint	O
and	O
various	O
uses	O
thereof	O
.	O

MUM-1	O
protein	O
expressed	O
by	O
multiple	O
myeloma	O
-	O
related	O
gene	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
enhancing	O
resistance	O
to	O
the	O
onset	O
of	O
skin	O
damage	O
caused	O
by	O
irradiation	O
of	O
the	O
skin	O
with	O
ultraviolet	O
light	O
by	O
inhibiting	O
ultraviolet	O
irradiation	O
-	O
induced	O
apoptosis	O
of	O
epidermal	O
cells	O
as	O
a	O
result	O
of	O
increasing	O
expression	O
of	O
SCCA-1	O
and/or	O
SCCA-2	O
in	O
epidermal	O
cells	O
.	O

Moreover	O
,	O
the	O
present	O
invention	O
provides	O
a	O
skin	O
testing	O
method	O
for	O
evaluating	O
resistance	O
of	O
the	O
skin	O
to	O
skin	O
damage	O
caused	O
by	O
ultraviolet	O
irradiation	O
by	O
measuring	O
the	O
expression	O
of	O
SCCA-1	O
and/or	O
SCCA-2	O
in	O
epidermal	O
cells	O
,	O
and	O
judging	O
UV	O
resistance	O
of	O
the	O
epidermis	O
to	O
be	O
weak	O
in	O
the	O
case	O
expression	O
is	O
decreased	O
as	O
compared	O
with	O
expression	O
in	O
epidermal	O
cells	O
.	O

Moreover	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
screening	O
drugs	O
which	O
enhance	O
resistance	O
of	O
the	O
skin	O
to	O
skin	O
damage	O
by	O
ultraviolet	O
irradiation	O
by	O
selecting	O
a	O
drug	O
that	O
increases	O
expression	O
of	O
SCCA-1	O
and/or	O
SCCA-2	O
as	O
a	O
UV	O
resistance	O
enhancer	O
.	O

Method	O
for	O
reducing	O
ultraviolet	O
light	O
induced	O
apoptosis	O

The	O
present	O
invention	O
relates	O
to	O
a	O
muscular	O
strength	O
enhancing	O
agent	O
produced	O
from	O
fruits	O
,	O
and	O
provides	O
a	O
strength	O
enhancing	O
agent	O
or	O
a	O
body	O
-	O
fat	O
regulating	O
agent	O
,	O
derived	O
from	O
natural	O
products	O
,	O
that	O
may	O
enhance	O
muscle	O
strength	O
,	O
decrease	O
body	O
fat	O
or	O
suppress	O
body	O
-	O
fat	O
accumulation	O
without	O
decreasing	O
the	O
amount	O
of	O
skeletal	O
muscle	O
or	O
the	O
weight	O
of	O
viscus	O
;	O
more	O
specifically	O
,	O
a	O
polyphenol	B
produced	O
from	O
fruits	O
is	O
used	O
to	O
provide	O
muscular	O
strength	O
enhancing	O
agents	O
or	O
body	O
-	O
fat	O
regulating	O
agents	O
,	O
foods	O
/	O
beverages	O
and	O
pharmaceuticals	O
that	O
may	O
enhance	O
muscular	O
strength	O
,	O
decrease	O
body	O
fat	O
or	O
suppress	O
body	O
-	O
fat	O
accumulation	O
.	O

Strength	O
enhancing	O
agents	O
or	O
body	O
-	O
fat	O
regulating	O
agents	O
effective	O
to	O
enhance	O
muscular	O
strength	O
,	O
of	O
which	O
active	O
component	O
being	O
a	O
polyphenol	B
derived	O
from	O
fruits	O
,	O
and	O
foods	O
/	O
beverages	O
and	O
pharmaceuticals	O
containing	O
them	O
.	O

Muscular	O
strength	O
enhancing	O
agent	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
naturally	O
occurring	O
mammalian	O
intermediary	O
metabolites	O
,	O
Tcell	O
ligands	O
or	O
Tcell	O
receptor	O
ligands	O
,	O
preferably	O
glycosylceramides	B
,	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
immune	O
mediated	O
or	O
immune	O
related	O
diseases	O
or	O
disorders	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
pulmonary	O
,	O
respiratory	O
or	O
airway	O
diseases	O
or	O
disorders	O
such	O
as	O
asthma	O
.	O

Glucocerebroside	B
treatment	O
of	O
pulmonary	O
or	O
respiratory	O
diseases	O
or	O
disorders	O

The	O
invention	O
provides	O
compounds	O
of	O
formula	O
wherein	O
m	O
,	O
R1	O
,	O
n	O
,	O
R2	O
,	O
q	O
,	O
X	O
,	O
Y	O
,	O
Z	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
t	O
and	O
R9	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O

Novel	O
Tricyclic	O
Spiroderivatives	O
as	O
Modulators	O
of	O
Chemokine	O
Receptor	O
Activity	O

Remedies	O
or	O
prophylactics	O
for	O
diseases	O
in	O
association	O
with	O
CCR5	O
such	O
as	O
AIDS	O
,	O
rheumatoid	O
arthritis	O
or	O
nephritis	O
comprising	O
a	O
cyclic	O
amine	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
C1-C6	B
alkyl	I
addition	O
salt	O
thereof	O
,	O
as	O
an	O
active	O
ingredient	O
.	O

Cyclic	O
amine	O
CCR5	O
receptor	O
antagonists	O

The	O
invention	O
relates	O
to	O
compounds	O
capable	O
of	O
inhibiting	O
the	O
visual	O
cycle	O
and/or	O
dark	O
adaptation	O
and	O
their	O
use	O
for	O
treatment	O
and	O
prevention	O
of	O
non	O
-	O
degenerative	O
retinal	O
diseases	O
with	O
specific	O
emphasis	O
on	O
the	O
prevention	O
and	O
treatment	O
of	O
diabetic	O
retinopathy	O
,	O
retinopathy	O
of	O
prematurity	O
,	O
branch	O
retinal	O
vein	O
occlusion	O
,	O
central	O
retinal	O
vein	O
occlusion	O
,	O
open	O
-	O
angle	O
glaucoma	O
,	O
veovascular	O
glaucoma	O
,	O
and	O
other	O
diseases	O
of	O
the	O
retinal	O
and/or	O
optic	O
nerve	O
where	O
an	O
imbalance	O
between	O
metabolic	O
demand	O
and	O
blood	O
supply	O
contribute	O
to	O
the	O
development	O
of	O
tissue	O
damage	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O

Prevention	O
of	O
Retinopathy	O
by	O
Inhibition	O
of	O
the	O
Visual	O
Cycle	O

Use	O
of	O
neboglamine	B
,	O
(	B
S	I
)	I
-4-amino	I
-	I
N-	I
(	I
4,4-dimethylcyclohexyl	I
)	I
glutamic	I
acid	I
(	O
CR	O
2249	O
)	O
(	O
CAS	O
Registry	O
Number	O
163000	O
-	O
63	O
-	O
3	O
)	O
,	O
of	O
the	O
racemate	O
thereof	O
or	O
of	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O

treating	O
schizophrenia	O
in	O
a	O
patient	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
4,4-dimethylcyclohexylamine	B

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
wherein	O
A	O
is	O
a	O
benzene	B
ring	O
optionally	O
having	O
substituents	O
,	O
R1	O
,	O
R2a	O
and	O
R3	O
are	O
each	O
a	O
hydrogen	B
atom	O
,	O
a	O
hydrocarbon	B
group	O
optionally	O
having	O
substituents	O
or	O
a	O
heterocyclic	B
group	O
optionally	O
having	O
substituents	O
,	O
R1	O
and	O
R2a	O
may	O
form	O
a	O
ring	O
via	O
X	O
,	O
when	O
R1	O
and	O
R2a	O
form	O
a	O
ring	O
via	O
X	O
,	O
R1	O
and	O
R2a	O
are	O
each	O
a	O
bond	O
or	O
a	O
divalent	O
C1	B
-	I
5	I
acyclic	I
hydrocarbon	I
group	O
optionally	O
having	O
substituents	O
,	O
and	O
X	O
is	O
a	O
bond	O
,	O
an	O
oxygen	B
atom	O
,	O
an	O
optionally	O
oxidized	O
sulfur	B
atom	O
or	O
an	O
imino	B
group	O
optionally	O
having	O
a	O
substituent	O
,	O
provided	O
that	O
R1	O
,	O
R2a	O
and	O
X	O
are	O
not	O
bonds	O
at	O
the	O
same	O
time	O
,	O
or	O
a	O
salt	O
thereof	O
,	O
and	O
an	O
agent	O
for	O
inhibiting	O
kinase	O
(	O
phosphorylation	O
enzyme	O
)	O
,	O
which	O
contains	O
this	O
compound	O
or	O
a	O
prodrug	O
thereof	O
.	O

The	O
compound	O
of	O
the	O
present	O
invention	O
has	O
an	O
inhibitory	O
activity	O
against	O
kinase	O
such	O
as	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
and	O
the	O
like	O
,	O
and	O
is	O
useful	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
cancer	O
and	O
the	O
like	O
.	O

Indole	B
Derivative	O
and	O
Use	O
for	O
Treatment	O
of	O
Cancer	O

Pharmaceutical	O
composition	O
comprising	O
compounds	O
and/or	O
compositions	O
useful	O
to	O
inhibit	O
HIV	O
replication	O
are	O
disclosed	O
.	O

Methods	O
of	O
treating	O
individuals	O
infected	O
with	O
HIV	O
are	O
disclosed	O
.	O

Methods	O
of	O
preventing	O
HIV	O
infection	O
in	O
high	O
risk	O
individuals	O
are	O
disclosed	O
.	O

Compositions	O
for	O
and	O
Methods	O
for	O
Treating	O
Hiv	O

The	O
invention	O
relates	O
to	O
compounds	O
that	O
inhibit	O
thyrotropin	O
-	O
releasing	O
hormone	O
(	O
TRH	O
)	O
degrading	O
ectoenzyme	O
and/or	O
enhance	O
,	O
and/or	O
mimic	O
the	O
biological	O
actions	O
of	O
TRH	O
.	O

The	O
compounds	O
find	O
therapeutic	O
application	O
,	O
particularly	O
in	O
conditions	O
involving	O
neuronal	O
cell	O
injury	O
and	O
disturbances	O
in	O
neurobiological	O
function	O
.	O

Compounds	O
That	O
Modulate	O
Trh	O
Actions	O

1-heterocyclyl-1,5-dihydro	B
-	I
pyrido	I
[	I
3,2-b	I
]	I
indol-2-ones	I
of	O
formula	O
(	O
I	O
)	O
:	O
the	O
N	B
-	I
oxides	I
,	O
salts	O
,	O
stereoisomeric	O
forms	O
,	O
racemic	O
mixtures	O
,	O
prodrugs	O
,	O
esters	O
and	O
metabolites	O
thereof	O
,	O
wherein	O
n	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
R1	O
is	O
hydrogen	B
,	O
cyano	B
,	O
halo	B
,	O
substituted	O
carbonyl	B
,	O
methanimidamidyl	B
,	O
N	B
-	I
hydroxy	I
-	I
methanimidamidyl	I
,	O
mono-	B
or	I
di	I
(	I
C1	I
-	I
4alkyl	I
)	I
methanimidamidyl	I
,	O
Het1	O
or	O
Het2	O
;	O
X	O
is	O
NR2	B
,	O
O	B
,	O
S	B
,	O
SO	B
,	O
SO2	B
;	O
R2	O
is	O
hydrogen	B
,	O
C1	B
-	I
10alkyl	I
,	O
C2	B
-	I
10alkenyl	I
,	O
C3	B
-	I
7cycloalkyl	I
,	O
which	O
are	O
optionally	O
substituted	O
;	O
R2	O
is	O
aryl	B
substituted	O
with	O
—COOR4	B
;	O
or	O
R2	O
is	O
:	O
—CpH2p	B
—	I
CH	I
(	I
OR14	I
)	I
—CqH2q	I
—	I
R15	I
(	O
b-3	O
)	O
;	O
—CH2—CH2—	B
(	I
O	I
—	I
CH2—CH2	I
)	I
m	I
—	I
OR14	I
(	O
b-4	O
)	O
;	O
—CH2—CH2—	B
(	I
O	I
—	I
CH2—CH2	I
)	I
m	I
—	I
NR5aR5b	I
(	O
b-5	O
)	O
;	O
-a1	O
=	O
a2-a3	O
=	O
a4-	O
is	O
—CH	B
═	I
CH	I
—	I
CH	I
═	I
CH—	I
;	O
—N	B
═	I
CH	I
—	I
CH	I
═	I
CH—	I
;	O
—CH	B
═	I
N	I
—	I
CH	I
═	I
CH—	I
;	O
—CH	B
═	I
CH	I
—	I
N	I
═	I
CH—	I
;	O
—CH	B
═	I
CH	I
—	I
CH	I
═	I
N—	I
;	O
wherein	O
hydrogen	B
atoms	O
in	O
(	O
c-1	O
)	O
-	O
(	O
c-5	O
)	O
may	O
be	O
replaced	O
by	O
certain	O
radicals	O
;	O
R3	O
is	O
a	O
monocyclic	B
or	I
bicyclic	I
aromatic	I
heterocyclic	I
ring	O
system	O
that	O
can	O
be	O
substituted	O
.	O

1-Heterocyclyl-1,5-Dihydro	B
-	I
Pyrido	I
[	I
3,2-B	I
]	I
Indol-2-Ones	I

Eye	O
drops	O
for	O
the	O
treatment	O
of	O
dry	O
eye	O
is	O
disclosed	O
.	O

The	O
eye	O
drops	O
is	O
a	O
solution	O
-	O
type	O
,	O
emulsion	O
-	O
type	O
or	O
two	O
separate	O
phase	O
-	O
type	O
eye	O
drops	O
containing	O
squalane	O
and	O
is	O
,	O
among	O
others	O
,	O
an	O
oil	O
-	O
in	O
-	O
water	O
-	O
type	O
emulsion	O
further	O
containing	O
a	O
water	O
-	O
soluble	O
macromolecular	O
compound	O
such	O
as	O
polyvinylpyrrolidone	B
.	O

Also	O
disclosed	O
are	O
use	O
of	O
squalane	O
for	O
the	O
production	O
of	O
eye	O
drops	O
for	O
the	O
treatment	O
of	O
dry	O
eye	O
,	O
and	O
a	O
method	O
for	O
the	O
treatment	O
of	O
dry	O
eye	O
.	O

Eye	O
Drops	O
for	O
the	O
Treatment	O
of	O
Dry	O
Eye	O

An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
eyedrop	O
which	O
has	O
a	O
relatively	O
low	O
viscosity	O
before	O
instillation	O
but	O
is	O
thickened	O
on	O
the	O
eyeball	O
surface	O
at	O
instillation	O
.	O

The	O
eyedrop	O
containing	O
a	O
viscous	O
agent	O
for	O
ophthalmic	O
use	O
,	O
which	O
comprises	O
a	O
combination	O
of	O
hydroxyethylcellulose	O
and	O
dextran	O
,	O
exhibits	O
a	O
specific	O
and	O
synergistic	O
thickening	O
effect	O
in	O
the	O
coexistence	O
of	O
mucin	O
.	O

Therefore	O
,	O
the	O
eyedrop	O
of	O
the	O
present	O
invention	O
is	O
thickened	O
on	O
the	O
eyeball	O
surface	O
upon	O
contact	O
with	O
mucin	O
in	O
the	O
precorneal	O
tear	O
film	O
at	O
instillation	O
,	O
whereby	O
a	O
desired	O
pharmacological	O
efficacy	O
or	O
refreshing	O
feel	O
can	O
be	O
sustained	O
.	O

Viscous	O
Agent	O
for	O
Ophthalmic	O
Use	O

This	O
invention	O
relates	O
to	O
oligonucleotide	B
sequences	O
and	O
their	O
derivatives	O
.	O

These	O
oligonucleotide	B
sequences	O
are	O
capable	O
of	O
hybridising	O
with	O
the	O
genes	O
or	O
with	O
products	O
of	O
the	O
genes	O
coding	O
for	O
the	O
PKC	O
-	O
beta	O
1	O
.	O

This	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
these	O
oligonucleotide	B
sequences	O
as	O
a	O
depigmenting	O
or	O
bleaching	O
agent	O
for	O
the	O
skin	O
in	O
a	O
cosmetic	O
composition	O
or	O
in	O
a	O
topical	O
pharmaceutical	O
composition	O
.	O

Oligonucleotide	B
and	O
the	O
Use	O
Thereof	O
for	O
Modulating	O
an	O
Isoform	O
C	O
Beta-1	O
Protein	O
-	O
Kinase	O
in	O
the	O
Form	O
of	O
a	O
Skin	O
Depigmentation	O
Agent	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
inhibiting	O
secretase	O
activity	O
.	O

A	O
method	O
for	O
promoting	O
the	O
sensitivity	O
of	O
a	O
secretase	O
inhibitor	O
,	O
a	O
method	O
for	O
binding	O
synoviolin	O
to	O
Herp	O
(	O
homocysteine	B
-	O
inducible	O
endoplasmic	O
reticulum	O
stress	O
-	O
inducible	O
ubiquitin	O
-	O
like	O
domain	O
member	O
1	O
)	O
,	O
or	O
the	O
like	O
is	O
employed	O
to	O
inhibit	O
secretase	O
activity	O
.	O

Method	O
of	O
Inhibiting	O
Secretase	O
Activity	O

The	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
(	O
wherein	O
D	O
and	O
G	O
are	O
cyclic	O
group	O
which	O
may	O
have	O
a	O
substituent	O
(	O
s	O
)	O
or	O
alkyl	O
which	O
may	O
have	O
a	O
substituent	O
(	O
s	O
)	O
,	O
W	O
and	O
Y	O
are	O
a	O
bond	O
or	O
a	O
spacer	O
of	O
which	O
main	O
chain	O
has	O
an	O
atom	O
number	O
of	O
1	O
-	O
4	O
,	O
ringA	O
and	O
ringB	O
are	O
heterocyclic	O
ring	O
which	O
may	O
have	O
a	O
substituent	O
(	O
s	O
)	O
,	O
containing	O
at	O
least	O
one	O
carbon	O
atom	O
and	O
one	O
nitrogen	O
atom	O
and	O
the	O
ringA	O
and	O
ringB	O
share	O
one	O
spiro	O
carbon	O
atom	O
)	O
,	O
a	O
salt	O
thereof	O
,	O
an	O
N	O
-	O
oxide	O
thereof	O
or	O
a	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
thereof	O
.	O

Since	O
the	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
a	O
salt	O
thereof	O
,	O
an	O
N	O
-	O
oxide	O
thereof	O
or	O
a	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
thereof	O
have	O
the	O
affinity	O
to	O
MBR	O
,	O
they	O
are	O
useful	O
for	O
the	O
prevention	O
and/or	O
treatment	O
for	O
disease	O
caused	O
by	O
stress	O
.	O

Heterocyclic	O
Spiro	O
Compound	O

The	O
present	O
invention	O
describes	O
a	O
method	O
for	O
treating	O
a	O
disease	O
or	O
condition	O
associated	O
with	O
the	O
activity	O
of	O
a	O
G	O
protein	O
coupled	O
receptor	O
(	O
GPCR	O
)	O
comprising	O
administering	O
an	O
inverse	O
agonist	O
for	O
the	O
GPCR	O
,	O
alone	O
or	O
in	O
combination	O
with	O
an	O
agonist	O
for	O
the	O
GPCR	O
,	O
to	O
an	O
organism	O
with	O
a	O
disease	O
or	O
condition	O
associated	O
with	O
the	O
activity	O
of	O
the	O
GPCR	O
in	O
a	O
quantity	O
and	O
for	O
a	O
period	O
that	O
causes	O
an	O
increase	O
in	O
the	O
population	O
of	O
spontaneously	O
active	O
GPCRs	O
associated	O
with	O
that	O
physiological	O
function	O
,	O
thereby	O
producing	O
a	O
therapeutic	O
effect	O
to	O
ameliorate	O
the	O
disease	O
or	O
condition	O
.	O

This	O
provides	O
a	O
basis	O
for	O
so	O
-	O
called	O
""""	O
paradoxical	O
pharmacology	O
.	O
""""	O

These	O
methods	O
can	O
be	O
used	O
to	O
treat	O
pulmonary	O
airway	O
diseases	O
,	O
including	O
asthma	O
and	O
chronic	O
allergic	O
rhinitis	O
,	O
among	O
other	O
diseases	O
and	O
conditions	O
,	O
including	O
obesity	O
.	O

The	O
present	O
invention	O
further	O
describes	O
a	O
screening	O
method	O
for	O
screening	O
a	O
compound	O
for	O
inverse	O
agonist	O
activity	O
to	O
a	O
GPCR	O
.	O

Methods	O
for	O
Treating	O
Diseases	O
and	O
Conditions	O
with	O
Inverse	O
Agonists	O
and	O
for	O
Screening	O
for	O
Agents	O
Acting	O
as	O
Inverse	O
Agonists	O

The	O
present	O
invention	O
is	O
drawn	O
to	O
adhesive	O
solid	O
gel	O
-	O
forming	O
formulations	O
,	O
methods	O
of	O
drug	O
delivery	O
,	O
and	O
solidified	O
gel	O
layers	O
for	O
dermal	O
delivery	O
of	O
a	O
drug	O
.	O

The	O
formulation	O
can	O
include	O
a	O
drug	O
,	O
a	O
solvent	O
vehicle	O
,	O
and	O
a	O
gelling	O
agent	O
.	O

The	O
solvent	O
vehicle	O
can	O
include	O
a	O
volatile	O
solvent	O
system	O
having	O
one	O
or	O
more	O
volatile	O
solvent	O
,	O
and	O
a	O
non	O
-	O
volatile	O
solvent	O
system	O
having	O
one	O
or	O
more	O
non	O
-	O
volatile	O
solvent	O
,	O
wherein	O
at	O
least	O
one	O
non	O
-	O
volatile	O
solvent	O
is	O
flux	O
-	O
enabling	O
non	O
-	O
volatile	O
solvent	O
(	O
s	O
)	O
capable	O
of	O
facilitating	O
the	O
delivery	O
of	O
the	O
drug	O
at	O
therapeutically	O
effective	O
rates	O
over	O
a	O
sustained	O
period	O
of	O
time	O
.	O

The	O
formulation	O
can	O
have	O
a	O
viscosity	O
suitable	O
for	O
application	O
to	O
a	O
skin	O
surface	O
prior	O
to	O
evaporation	O
of	O
the	O
volatile	O
solvents	O
system	O
.	O

When	O
applied	O
to	O
the	O
skin	O
,	O
the	O
formulation	O
can	O
form	O
a	O
solidified	O
gel	O
layer	O
after	O
at	O
least	O
a	O
portion	O
of	O
the	O
volatile	O
solvent	O
system	O
is	O
evaporated	O
.	O

The	O
solidified	O
gel	O
layer	O
is	O
can	O
be	O
removed	O
by	O
either	O
peeling	O
or	O
washing	O
using	O
a	O
designated	O
solvent	O
or	O
solvents	O
.	O

Adhesive	O
solid	O
gel	O
-	O
forming	O
formulations	O
for	O
dermal	O
drug	O
delivery	O

The	O
present	O
invention	O
relates	O
to	O
therapeutic	O
combinations	O
and	O
methods	O
of	O
inhibiting	O
the	O
proliferation	O
of	O
cancerous	O
cells	O
,	O
the	O
abnormal	O
growth	O
of	O
cells	O
,	O
and	O
tumor	O
cell	O
growth	O
using	O
the	O
combination	O
of	O
a	O
hedgehog	O
inhibitor	O
with	O
chemotherapy	O
and/or	O
radiation	O
therapy	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
enhancing	O
the	O
antiproliferative	O
effect	O
of	O
chemotherapy	O
and/or	O
radiation	O
therapy	O
in	O
a	O
mammalian	O
cancer	O
patient	O
undergoing	O
either	O
chemotherapy	O
or	O
radiation	O
or	O
a	O
combination	O
of	O
radiation	O
and	O
chemotherapy	O
by	O
co	O
-	O
administering	O
a	O
therapeutically	O
amount	O
of	O
a	O
hedgehog	O
inhibitor	O
,	O
concurrently	O
or	O
sequentially	O
,	O
with	O
the	O
chemotherapy	O
and/or	O
radiation	O
therapy	O
.	O

Combination	O
therapy	O
of	O
hedgehog	O
inhibitors	O
,	O
radiation	O
and	O
chemotherapeutic	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
and	O
methods	O
of	O
treating	O
,	O
preventing	O
,	O
or	O
lessening	O
the	O
severity	O
of	O
drug	O
-	O
resistant	O
Gram	O
-	O
positive	O
bacterial	O
infections	O
in	O
mammals	O
.	O

The	O
compounds	O
consist	O
of	O
a	O
combination	O
of	O
a	O
gyrase	O
B	O
inhibitor	O
and	O
a	O
protein	O
synthesis	O
inhibitor	O
.	O

These	O
compounds	O
demonstrate	O
antibacterial	O
activity	O
against	O
drug	O
-	O
resistant	O
strains	O
of	O
Gram	O
-	O
positive	O
bacteria	O
,	O
and	O
in	O
particular	O
,	O
methicillin	B
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
.	O

Methods	O
for	O
inhibiting	O
the	O
activity	O
of	O
strains	O
of	O
Gram	O
-	O
positive	O
bacteria	O
and	O
methods	O
for	O
treating	O
a	O
bacterial	O
infection	O
caused	O
by	O
such	O
organisms	O
are	O
described	O
herein	O
.	O

Combination	O
of	O
gyrase	O
b	O
inhibitors	O
and	O
protein	O
synthesis	O
inhibitors	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
or	O
reducing	O
neurologic	O
disorders	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
and	O
preventing	O
neurologic	O
disorders	O

Geldanamycin	B
derivatives	O
that	O
block	O
the	O
uPA	O
-	O
plasmin	O
network	O
and	O
inhibit	O
growth	O
and	O
invasion	O
by	O
glioblastoma	O
cells	O
and	O
other	O
tumors	O
at	O
femtomolar	O
concentrations	O
are	O
potentially	O
highly	O
active	O
anti	O
-	O
cancer	O
drugs	O
.	O

GA	B
and	O
various	O
17-amino-17-demethoxygelddanamycin	B
derivatives	O
are	O
disclosed	O
that	O
block	O
HGF	O
/	O
SF	O
-	O
mediated	O
Met	O
tyrosine	B
kinase	O
receptor	O
-	O
dependent	O
uPA	O
activation	O
at	O
fM	O
levels	O
.	O

Other	O
ansamycins	B
(	O
macbecins	B
I	I
and	I
II	I
)	O
,	O
GA	B
derivatives	O
,	O
and	O
radicicol	O
required	O
concentrations	O
several	O
logs	O
higher	O
(	O
≧nM	O
)	O
to	O
achieve	O
such	O
inhibition	O
.	O

The	O
inhibitory	O
activity	O
of	O
tested	O
compounds	O
was	O
discordant	O
with	O
the	O
known	O
ability	O
of	O
drugs	O
of	O
this	O
class	O
to	O
bind	O
to	O
hsp90	O
,	O
indicating	O
the	O
existence	O
of	O
a	O
novel	O
target	O
(	O
s	O
)	O
for	O
HGF	O
/	O
SF	O
-	O
mediated	O
events	O
in	O
tumor	O
development	O
.	O

Methods	O
of	O
using	O
such	O
compounds	O
to	O
inhibit	O
cancer	O
cell	O
activities	O
and	O
to	O
treat	O
tumors	O
are	O
disclosed	O
.	O

Such	O
treatment	O
with	O
low	O
doses	O
of	O
these	O
highly	O
active	O
compounds	O
provide	O
an	O
option	O
for	O
treating	O
various	O
Met	O
-	O
expressing	O
tumors	O
,	O
in	O
particular	O
invasive	O
brain	O
cancers	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
conventional	O
surgery	O
,	O
chemotherapy	O
,	O
or	O
radiotherapy	O
.	O

Geldanamycin	B
and	O
Derivatives	O
Inhibit	O
Cancer	O
Invasion	O
and	O
Identify	O
Novel	O
Targets	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
transdermal	O
delivery	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
Naltrexone	B
Hydrochloride	I
,	O
Naltrexol	B
Hydrochloride	I
,	O
and/or	O
Naltrexone	B
Diol	I
Ester	I
using	O
microneedles	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
treatment	O
of	O
narcotic	O
dependence	O
,	O
alcohol	B
abuse	O
,	O
and/or	O
alcoholism	O
.	O

Preferably	O
,	O
the	O
Naltrexone	B
Hydrochloride	I
,	O
Naltrexol	B
Hydrochloride	I
,	O
and/or	O
Naltrexone	B
Diol	I
Ester	I
is	O
administered	O
by	O
creating	O
a	O
microneedle	O
-	O
treated	O
site	O
in	O
the	O
skin	O
of	O
a	O
subject	O
by	O
inserting	O
microneedles	O
,	O
followed	O
by	O
applying	O
the	O
Naltrexone	B
Hydrochloride	I
,	O
Naltrexol	B
Hydrochloride	I
,	O
and/or	O
Naltrexone	B
Diol	I
Ester	I
to	O
the	O
microneedle	O
-	O
treated	O
site	O
.	O

Transdermal	O
delivery	O
of	O
naltrexone	B
hydrochloride	I
,	O
naltrexol	B
hydrochloride	I
,	O
and	O
bis	B
(	I
hydroxy	I
-	I
methyl	I
)	I
propionyl-3	I
-	I
0	I
ester	I
naltrexone	I
using	O
microneedles	O

The	O
present	O
invention	O
relates	O
to	O
a	O
photosensitizer	O
containing	O
indole-3-alkylcarboxyl	B
acid	I
(	O
ICA	O
)	O
,	O
and	O
kit	O
for	O
photodynamic	O
therapy	O
containing	O
the	O
same	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
ICA	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
novel	O
method	O
for	O
photodynamic	O
therapy	O
using	O
ICA	O
as	O
a	O
photosensitizer	O
.	O

Photosensitizer	O
containing	O
indole-3-alkylcarboxylic	B
acid	I
,	O
and	O
kit	O
for	O
photodynamic	O
therapy	O
containing	O
the	O
same	O

Micronutrient	O
combination	O
product	O
,	O
wherein	O
the	O
micronutrient	O
combination	O
product	O
comprises	O
zeaxanthin	B
,	O
lutein	B
,	O
zinc	B
and	O
copper	B
.	O

Micronutrient	O
Combination	O
Product	O

For	O
Use	O

As	O
A	O
Dietetic	O
Food	O
Supplement	O
In	O
Age	O
-	O
Related	O
Macular	O
Degeneration	O

Compounds	O
of	O
the	O
present	O
invention	O
,	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
thereof	O
,	O
are	O
useful	O
as	O
modulators	O
of	O
ATP	O
-	O
Binding	O
Cassette	O
(	O
""""	O
ABC	O
""""	O
)	O
transporters	O
or	O
fragments	O
thereof	O
,	O
including	O
Cystic	O
Fibrosis	O
Transmembrane	O
Conductance	O
Regulator	O
(	O
""""	O
CFTR	O
""""	O
)	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
ABC	O
transporter	O
mediated	O
diseases	O
using	O
compounds	O
of	O
the	O
present	O
invention	O
.	O

including	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
""""	O
CFTR	O
""""	O
)	O
;	O
N	B
[	I
6-	I
(	I
2-hydroxymethylphenyl-1yl	I
)	I
-5-methylpyrimidine	I
]	I
[	I
(	I
4-methoxophenyl-1-yl	I
)	I
cyclopopyl	I
]	I
-amide	I
;	O
genetic	O
disorders	O
;	O
respiratory	O
system	O
disorders	O
,	O
cystic	O
fibrosis	O
,	O
hereditary	O
emphysema	O
and	O
hemochromatosis	O
,	O
coagulation	O
-	O
fibrinolysis	O

The	O
use	O
of	O
7-ter	B
-	I
butoxyiminomethylcamptothecin	I
is	O
described	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
useful	O
for	O
the	O
treatment	O
of	O
uterine	O
neoplasms	O
,	O
particularly	O
cancer	O
of	O
the	O
endometrium	O
and	O
of	O
the	O
neck	O
of	O
the	O
womb	O
.	O

Use	O
Of	O
7-T	B
-	I
Butoxyiminomethylcamptothecin	I
For	O
The	O
Preparation	O
Of	O
A	O
Medicament	O
For	O
The	O
Treatment	O
Of	O
Uterine	O
Neoplasms	O

Methods	O
and	O
compounds	O
for	O
increasing	O
or	O
decreasing	O
mucus	O
secretion	O
in	O
subjects	O
,	O
and	O
particularly	O
mucus	O
secretion	O
in	O
the	O
airways	O
,	O
are	O
described	O
.	O

Methods	O
of	O
screening	O
compounds	O
for	O
the	O
ability	O
to	O
increase	O
or	O
decrease	O
mucus	O
secretion	O
are	O
also	O
described	O
.	O

Methods	O
and	O
compositions	O
for	O
altering	O
mucus	O
secretion	O

The	O
present	O
invention	O
relates	O
to	O
36	O
novel	O
human	O
secreted	O
proteins	O
and	O
isolated	O
nucleic	O
acids	O
containing	O
the	O
coding	O
regions	O
of	O
the	O
genes	O
encoding	O
such	O
proteins	O
.	O

Also	O
provided	O
are	O
vectors	O
,	O
host	O
cells	O
,	O
antibodies	O
,	O
and	O
recombinant	O
methods	O
for	O
producing	O
human	O
secreted	O
proteins	O
.	O

The	O
invention	O
further	O
relates	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
useful	O
for	O
diagnosing	O
and	O
treating	O
disorders	O
related	O
to	O
these	O
novel	O
human	O
secreted	O
proteins	O
.	O

36	O
Human	O
Secreted	O
Proteins	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R	O
,	O
R1	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
dyslipidaemia	O
,	O
atherosclerosis	O
and	O
diabetes	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
,	O
and	O
.	O

processes	O
for	O
the	O
preparation	O
of	O
these	O
compounds	O
.	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
activators	O
of	O
PPARα	O
and	O
PPARα	O
isoforms	O
.	O

2-	B
{	I
2-	I
[	I
3-	I
(	I
4-chlorophenyl	I
)	I
acryloyl	I
]	I
-4-methylphenoxy	I
}	I
-4-phenylbutanoic	I
acid	I
;	O
Peroxisome	O
Proliferator	O
Activated	O
Receptors	O
(	O
PPAR	O
)	O
;	O
diabetes	O
,	O
dyslipidemia	O
and/or	O
atherosclerosis	O

A	O
method	O
for	O
improving	O
liver	O
clearance	O
of	O
xenobiotic	O
substances	O
in	O
an	O
animal	O
by	O
feeding	O
the	O
animal	O
lipoic	B
acid	I
in	O
amounts	O
of	O
from	O
about	O
10	O
mg	O
to	O
about	O
1000	O
mg	O
per	O
day	O
.	O

Methods	O
for	O
Improving	O
Liver	O
Clearance	O
of	O
Xenobiotic	O
Substances	O
in	O
an	O
Animal	O

The	O
invention	O
provides	O
a	O
rapidly	O
disintegrating	O
and	O
dissolving	O
multilayer	O
tablet	O
comprising	O
at	O
least	O
a	O
tetracycline	B
in	O
a	O
first	O
layer	O
,	O
a	O
buffer	O
in	O
a	O
second	O
layer	O
,	O
and	O
optionally	O
,	O
an	O
inert	O
layer	O
separating	O
the	O
first	O
and	O
second	O
layers	O
.	O

The	O
multilayer	O
tablets	O
of	O
the	O
invention	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
mucositis	O
,	O
when	O
administered	O
topically	O
to	O
the	O
oral	O
cavity	O
.	O

Tetracycline	B
Package	O
Formulations	O

Dry	O
powder	O
formulations	O
of	O
drugs	O
such	O
as	O
antihistamine	B
for	O
nasal	O
administration	O
are	O
provided	O
where	O
the	O
drug	O
is	O
retained	O
in	O
the	O
nasal	O
cavity	O
,	O
and	O
systemic	O
side	O
effects	O
minimized	O
or	O
eliminated	O
,	O
through	O
the	O
selection	O
of	O
a	O
narrow	O
particle	O
size	O
range	O
,	O
between	O
approximately	O
10	O
and	O
20	O
microns	O
in	O
diameter	O
.	O

In	O
a	O
preferred	O
embodiment	O
wherein	O
the	O
drug	O
is	O
an	O
antihistamine	B
,	O
retention	O
of	O
the	O
antihistamine	B
at	O
the	O
nasal	O
mucosa	O
is	O
improved	O
and	O
the	O
bitter	O
aftertaste	O
associated	O
with	O
liquid	O
antihistamine	B
formulations	O
significantly	O
reduced	O
.	O

By	O
making	O
a	O
dry	O
powder	O
formulation	O
of	O
an	O
antihistamine	B
(	O
e.g.	O
,	O
azelastine	B
)	O
having	O
an	O
average	O
particle	O
size	O
of	O
between	O
10	O
and	O
20	O
microns	O
,	O
the	O
antihistamine	B
is	O
restricted	O
primarily	O
to	O
the	O
desired	O
target	O
organ	O
,	O
the	O
nasal	O
mucosa	O
.	O

Because	O
the	O
active	O
ingredient	O
stays	O
in	O
the	O
nasal	O
region	O
,	O
a	O
lower	O
dose	O
can	O
be	O
used	O
to	O
achieve	O
the	O
same	O
desired	O
effect	O
.	O

As	O
demonstrated	O
by	O
the	O
examples	O
,	O
this	O
lower	O
dose	O
reduces	O
the	O
incidence	O
of	O
somnolence	O
,	O
and	O
because	O
the	O
active	O
ingredient	O
remains	O
at	O
the	O
target	O
organ	O
and	O
does	O
not	O
accumulate	O
in	O
the	O
back	O
of	O
the	O
throat	O
and	O
mouth	O
,	O
this	O
formulation	O
does	O
not	O
impart	O
a	O
bitter	O
taste	O
.	O

Dry	O
powder	O
formulations	O
of	O
antihistamine	B
for	O
nasal	O
administration	O

A	O
device	O
,	O
method	O
,	O
and	O
system	O
for	O
producing	O
a	O
condensation	O
aerosol	O
are	O
disclosed	O
.	O

The	O
device	O
includes	O
a	O
chamber	O
having	O
an	O
upstream	O
opening	O
and	O
a	O
downstream	O
opening	O
which	O
allow	O
gas	O
to	O
flow	O
through	O
the	O
chamber	O
,	O
and	O
a	O
heat	O
-	O
conductive	O
substrate	O
located	O
at	O
a	O
position	O
between	O
the	O
upstream	O
and	O
downstream	O
openings	O
.	O

Formed	O
on	O
the	O
substrate	O
is	O
a	O
drug	O
composition	O
film	O
containing	O
a	O
therapeutically	O
effective	O
dose	O
of	O
a	O
drug	O
when	O
the	O
drug	O
is	O
administered	O
in	O
aerosol	O
form	O
.	O

A	O
heat	O
source	O
in	O
the	O
device	O
is	O
operable	O
to	O
supply	O
heat	O
to	O
the	O
substrate	O
to	O
produce	O
a	O
substrate	O
temperature	O
greater	O
than	O
300	O
oC	O
,	O
and	O
to	O
substantially	O
volatilize	O
the	O
drug	O
composition	O
film	O
from	O
the	O
substrate	O
in	O
a	O
period	O
of	O
2	O
seconds	O
or	O
less	O
.	O

The	O
device	O
produces	O
an	O
aerosol	O
containing	O
less	O
than	O
about	O
10	O
%	O
by	O
weight	O
drug	O
composition	O
degradation	O
products	O
and	O
at	O
least	O
50	O
%	O
of	O
the	O
drug	O
composition	O
of	O
said	O
film	O
.	O

Aerosol	O
delivery	O
system	O
and	O
uses	O
thereof	O

This	O
invention	O
encompasses	O
an	O
expeditious	O
method	O
and	O
compositions	O
that	O
have	O
been	O
found	O
to	O
show	O
selective	O
cytotoxicity	O
against	O
several	O
different	O
cancer	O
cell	O
lines	O
.	O

for	O
treating	O
a	O
wide	O
variety	O
cancer	O
neoplasms	O
that	O
have	O
tumor	O
microenvironments	O
by	O
administering	O
a	O
stand	O
-	O
alone	O
anti	O
-	O
tumor	O
chemotherapeutic	O
composition	O
or	O
administered	O
as	O
an	O
adjunct	O
with	O
chemotherapy	O
and/or	O
radiotherapy	O
with	O
enhanced	O
tumor	O
site	O
affinity	O
that	O
preferentially	O
elevates	O
the	O
pH	O
at	O
the	O
tumor	O
site	O
to	O
suppress	O
and	O
eliminates	O
the	O
acidic	O
tumor	O
microenvironment	O
,	O
administered	O
as	O
chemosensitizing	O
and/or	O
radiosensitizers	O
enhancing	O
the	O
tumor	O
,	O
suppression	O
,	O
remission	O
and	O
inhibit	O
tumor	O
metastisis	O
.	O

The	O
invention	O
encompasses	O
controlling	O
mechanisms	O
of	O
intracellular	O
and	O
extracellular	O
ionic	O
physiology	O
through	O
the	O
administration	O
of	O
alkali	O
salts	O
for	O
pH	O
modulating	O
and	O
for	O
restoring	O
and	O
enhancing	O
ionic	O
physiology	O
.	O

The	O
compositions	O
are	O
useful	O
in	O
effective	O
treatment	O
of	O
cancers	O
,	O
particularly	O
malignant	O
melanomas	O
and	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
thereby	O
inhibiting	O
angiogenesis	O
,	O
reducing	O
metastatic	O
proliferation	O
,	O
supressing	O
tumor	O
generated	O
induced	O
acidotic	O
pain	O
.	O

Anti	O
-	O
cancer	O
composition	O
and	O
method	O
for	O
using	O
the	O
same	O

An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
cerebral	O
infarction	O
suppressant	O
which	O
is	O
effective	O
for	O
brain	O
tissue	O
necrosis	O
attributed	O
to	O
long	O
-	O
time	O
ischemia	O
as	O
in	O
actual	O
cerebral	O
infarction	O
and	O
has	O
fewer	O
side	O
effects	O
.	O

The	O
suppressant	O
for	O
cerebral	O
infarction	O
attributed	O
to	O
long	O
-	O
time	O
ischemia	O
according	O
to	O
the	O
present	O
invention	O
is	O
characterized	O
in	O
that	O
a	O
histidine	B
and	O
an	O
H3-receptor	O
blocker	O
or	O
a	O
histidine	B
and	O
a	O
histamine	B
N	O
-	O
methyltransferase	O
inhibitor	O
are	O
comprised	O
as	O
active	O
ingredients	O
.	O

Cerebral	O
Infarction	O
Suppressant	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
process	O
for	O
the	O
preparation	O
of	O
crystal	O
modifications	O
for	O
use	O
in	O
the	O
preparation	O
of	O
esomeprazole	B
sodium	I
salt	O
.	O

Further	O
,	O
the	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
the	O
new	O
crystal	O
modifications	O
for	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
as	O
well	O
as	O
the	O
crystal	O
modifications	O
,	O
as	O
such	O
.	O

Process	O
For	O
The	O
Preparation	O
Of	O
Crystalline	O
Modifications	O

For	O
Use	O
In	O
The	O
Preparation	O
Of	O
Esomeperazole	B
Sodium	I
Salt	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
solvate	O
thereof	O
,	O
or	O
a	O
combination	O
thereof	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
and	O
X	O
are	O
as	O
defined	O
herein	O
.	O

Compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
progesterone	B
receptor	O
modulators	O
.	O

2-chloro-4-	B
{	I
[	I
(	I
3S	I
)	I
-1-methyl-5-oxo-3-pyrrolidinyl	I
]	I
[	I
(	I
2-methylphenyl	I
)	I
methyl	I
]	I
amino	I
}	I
benzonitrile	I
;	O
for	O
treatment	O
of	O
endometreosis	O
,	O
uterine	O
fibroids	O
,	O
dysmenorrhea	O
,	O
menorrhagia	O
,	O
pre	O
-	O
term	O
labor	O
,	O
or	O
infertility	O

Piperazinyl	B
-	I
pyridine	I
analogues	O
are	O
provided	O
,	O
of	O
the	O
Formula	O
:	O
wherein	O
variables	O
are	O
as	O
described	O
herein	O
.	O

Such	O
compounds	O
are	O
ligands	O
that	O
may	O
be	O
used	O
to	O
.	O

modulate	O
specific	O
receptor	O
activity	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
and	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
pathological	O
receptor	O
activation	O
in	O
humans	O
,	O
domesticated	O
companion	O
animals	O
and	O
livestock	O
animals	O
.	O

Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat	O
such	O
disorders	O
are	O
provided	O
,	O
as	O
are	O
methods	O
for	O
using	O
such	O
ligands	O
for	O
receptor	O
localization	O
studies	O
.	O

Piperazinyl	B
-	I
Pyridine	I
Analogues	O

Processes	O
for	O
assaying	O
potential	O
antitumor	O
agents	O
based	O
on	O
their	O
modulation	O
of	O
the	O
expression	O
of	O
specified	O
genes	O
,	O
or	O
sets	O
,	O
of	O
suspected	O
cancer	O
cell	O
genes	O
are	O
disclosed	O
,	O
along	O
with	O
methods	O
for	O
diagnosing	O
cancerous	O
,	O
or	O
potentially	O
cancerous	O
,	O
conditions	O
as	O
a	O
result	O
of	O
the	O
expression	O
,	O
or	O
patterns	O
of	O
expression	O
,	O
of	O
such	O
genes	O
,	O
or	O
sets	O
of	O
genes	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
determining	O
functionally	O
related	O
genes	O
,	O
or	O
gene	O
sets	O
,	O
as	O
well	O
as	O
methods	O
for	O
treating	O
cancer	O
based	O
on	O
targeting	O
expression	O
products	O
of	O
such	O
genes	O
,	O
or	O
gene	O
sets	O
,	O
and	O
determining	O
genes	O
involved	O
in	O
the	O
cancerous	O
process	O
.	O

Cancer	O
gene	O
determination	O
and	O
therapeutic	O
screening	O
using	O
signature	O
gene	O
sets	O

The	O
present	O
invention	O
provides	O
stereoisomers	O
and	O
stereoisomeric	O
mixtures	O
of	O
3-aminocarbonyl	B
-	I
bicycloheptene-2,4-pyrimidinediamine	I
compounds	O
having	O
antiproliferative	O
activity	O
,	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
to	O
inhibit	O
cellular	O
proliferation	O
and	O
to	O
treat	O
proliferate	O
diseases	O
such	O
as	O
tumorigenic	O
cancers	O
.	O

Stereoisomerically	O
Enriched	O
3-Aminocarbonyl	B
Bicycloheptene	I
Pyrimidinediamine	I
Compounds	O
and	O
their	O
Uses	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
hexanoic	B
acid	I
derivatives	O
which	O
are	O
inhibitors	O
of	O
the	O
dipeptidyl	O
peptidase	O
-	O
IV	O
enzyme	O
(	O
""""	O
DPP	O
-	O
IV	O
inhibitors	O
""""	O
)	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
dipeptidyl	O
peptidase	O
-	O
IV	O
enzyme	O
is	O
involved	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
and	O
conditions	O
that	O
are	O
associated	O
with	O
the	O
same	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
provides	O
pharmaceutical	O
compositions	O
useful	O
in	O
inhibiting	O
DPP	O
-	O
IV	O
enzyme	O
,	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
hexanoic	B
acid	I
derivatives	O
.	O

Moreover	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
inhibiting	O
DPP	O
-	O
IV	O
comprising	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
of	O
such	O
treatment	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
single	O
or	O
a	O
combination	O
of	O
hexanoic	B
acid	I
derivatives	O
of	O
the	O
invention	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
kits	O
and	O
other	O
articles	O
of	O
manufacture	O
for	O
treating	O
disease	O
states	O
associated	O
with	O
DPP	O
-	O
IV	O
enzyme	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
identifying	O
a	O
compound	O
that	O
has	O
dipeptidyl	O
peptidase	O
-	O
IV	O
enzyme	O
inhibition	O
activity	O
,	O
comprising	O
following	O
steps	O
:	O
1	O
.	O

Define	O
the	O
residues	O
of	O
the	O
active	O
site	O
of	O
DPP	O
-	O
IV	O
2	O
.	O

Define	O
the	O
geometry	O
and	O
force	O
field	O
relationship	O
of	O
the	O
residues	O
identified	O
above	O
in	O
(	O
I	O
)	O
3	O
.	O

Define	O
the	O
physical	O
parameters	O
of	O
the	O
active	O
site	O
identified	O
in	O
(	O
1	O
)	O
4	O
.	O

Validate	O
the	O
model	O
based	O
on	O
mutational	O
analysis	O
and	O
in	O
-	O
vitro	O
inhibitor	O
binding	O
studies	O
5	O
.	O

Screen	O
the	O
library	O
for	O
scaffolds	O
and	O
small	O
molecules	O
that	O
satisfy	O
the	O
model	O
developed	O
in	O
(	O
3	O
)	O
and	O
validated	O
in	O
(	O
4	O
)	O
above	O
.	O

6	O
.	O

Dock	O
each	O
inhibitor	O
identified	O
in	O
(	O
5	O
)	O
above	O
to	O
the	O
active	O
site	O
of	O
DPP	O
-	O
IV	O
defined	O
in	O
(	O
1	O
)	O
.	O

7	O
.	O
Minimize	O
the	O
energy	O
of	O
the	O
inhibitor	O
and	O
DPP	O
-	O
IV	O
complex	O
using	O
force	O
fields	O
used	O
in	O
(	O
2	O
)	O
above	O
.	O

8	O
.	O

Compare	O
the	O
energy	O
of	O
interaction	O
of	O
each	O
inhibitor	O
to	O
that	O
of	O
known	O
inhibitors	O
.	O

9	O
.	O
Synthesize	O
and	O
validate	O
in	O
in	O
-	O
vitro	O
assays	O
Hexanoic	B
acid	I
derivatives	O
as	O
dipeptidyl	O
peptidase	O
inhibitors	O

Compounds	O
and	O
methods	O
for	O
protein	O
kinase	O
modulation	O
for	O
cancer	O
treatment	O
are	O
disclosed	O
.	O

The	O
compounds	O
and	O
methods	O
disclosed	O
are	O
based	O
on	O
isoalpha	B
acids	I
,	O
commonly	O
found	O
in	O
hops	O
.	O

Isoalpha	B
acid	I
based	O
protein	O
kinase	O
modulation	O
cancer	O
treatment	O

Applicants	O
disclose	O
herein	O
novel	O
methods	O
,	O
vectors	O
,	O
and	O
vector	O
compositions	O
for	O
improving	O
the	O
efficiency	O
of	O
adenoviral	O
vectors	O
in	O
the	O
delivery	O
and	O
expression	O
of	O
heterologous	O
nucleic	O
acid	O
encoding	O
a	O
polypeptide	O
(	O
s	O
)	O
(	O
e.g	O
,	O
a	O
protein	O
or	O
antigen	O
)	O
of	O
interest	O
.	O

Adenoviral	O
infection	O
is	O
quite	O
common	O
in	O
the	O
general	O
population	O
,	O
and	O
a	O
large	O
percentage	O
of	O
people	O
have	O
neutralizing	O
antibodies	O
to	O
the	O
more	O
prevalent	O
adenoviral	O
serotypes	O
.	O

Such	O
pre	O
-	O
existing	O
anti	O
-	O
adenoviral	O
immunity	O
can	O
dampen	O
or	O
possibly	O
abrogate	O
the	O
effectiveness	O
of	O
this	O
virus	O
for	O
the	O
delivery	O
and	O
expression	O
of	O
heterologous	O
proteins	O
or	O
antigens	O
.	O

The	O
method	O
taught	O
herein	O
functions	O
to	O
offset	O
pre	O
-	O
existing	O
immunity	O
through	O
the	O
delivery	O
of	O
the	O
protein	O
or	O
antigen	O
by	O
a	O
cocktail	O
of	O
at	O
least	O
two	O
adenoviral	O
serotypes	O
.	O

Utilizing	O
a	O
composition	O
of	O
at	O
least	O
two	O
adenoviral	O
serotypes	O
in	O
this	O
manner	O
has	O
been	O
found	O
to	O
increase	O
the	O
effectiveness	O
of	O
adenoviral	O
administration	O
.	O

Adenoviral	O
vectors	O
of	O
utility	O
in	O
the	O
elicitation	O
of	O
an	O
immune	O
response	O
against	O
Human	O
Immunodeficiency	O
Virus	O
(	O
""""	O
HIV	O
""""	O
)	O
are	O
also	O
disclosed	O
.	O

Adenoviral	O
Vector	O
Compositions	O

Disclosed	O
is	O
a	O
method	O
of	O
treating	O
a	O
wart	O
in	O
a	O
subject	O
by	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
containing	O
(	O
1	O
)	O
a	O
heat	O
shock	O
protein	O
or	O
an	O
immunostimulatory	O
fragment	O
thereof	O
,	O
and	O
(	O
2	O
)	O
a	O
protein	O
of	O
a	O
human	O
papilloma	O
virus	O
or	O
an	O
antigenic	O
fragment	O
thereof	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
of	O
treating	O
a	O
human	O
papilloma	O
virus	O
infection	O
in	O
a	O
subject	O
infected	O
or	O
suspected	O
of	O
being	O
infected	O
with	O
a	O
human	O
papilloma	O
virus	O
of	O
a	O
first	O
type	O
by	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
containing	O
(	O
1	O
)	O
a	O
heat	O
shock	O
protein	O
or	O
an	O
antigenic	O
fragment	O
thereof	O
,	O
and	O
(	O
2	O
)	O
a	O
protein	O
of	O
a	O
human	O
papilloma	O
virus	O
of	O
a	O
second	O
type	O
or	O
an	O
antigenic	O
fragment	O
thereof	O
,	O
where	O
the	O
first	O
type	O
and	O
second	O
type	O
are	O
different	O
.	O

treating	O
a	O
wart	O
with	O
a	O
fusion	O
protein	O
comprising	O
(	O
1	O
)	O
a	O
heat	O
shock	O
protein	O
and	O
(	O
2	O
)	O
a	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
protein	O
;	O
Mycobacterium	O
bovis	O
heat	O
shock	O
protein	O
;	O
HPV	O
is	O
an	O
E7	O
protein	O
;	O
cervical	O
dysplasia	O
,	O
anal	O
cancer	O
,	O
anal	O
dysplasia	O

This	O
invention	O
provides	O
pharmaceutical	O
compositions	O
containing	O
lipoxin	O
compounds	O
and	O
therapeutic	O
uses	O
for	O
the	O
compounds	O
in	O
treating	O
or	O
preventing	O
a	O
disease	O
or	O
condition	O
associated	O
with	O
columnar	O
epithelial	O
inflammation	O
.	O

The	O
invention	O
also	O
discloses	O
methods	O
for	O
screening	O
for	O
compounds	O
useful	O
in	O
preventing	O
columnar	O
epithelial	O
inflammation	O
.	O

Modulation	O
of	O
Inflammation	O
Related	O
to	O
Columnar	O
Epithelia	O

The	O
invention	O
discloses	O
a	O
method	O
of	O
administering	O
an	O
anti	O
-	O
diabetic	O
combination	O
comprising	O
a	O
DPP	O
inhibitor	O
and	O
a	O
slow	O
release	O
biguanide	O
to	O
a	O
mammal	O
in	O
need	O
of	O
thereof	O
.	O

This	O
invention	O
further	O
discloses	O
anti	O
-	O
diabetic	O
combination	O
comprising	O
a	O
DPP	O
inhibitor	O
and	O
a	O
slow	O
release	O
biguanide	O
for	O
treating	O
diabetes	O
.	O

Controlling	O
blood	O
glucose	B
levels	O
in	O
type	O
2	O
diabetic	O
patients	O
with	O
dipeptidyl	O
peptidase-4	O
proteolytic	O
activity	O
inhibitor	O
and	O
biguanide	O
slow	O
release	O
medicant	O

A	O
method	O
of	O
treating	O
cholesterol	B
imbalance	O
,	O
high	O
LDLs	O
,	O
and	O
other	O
metabolic	O
syndrome	O
problems	O
and	O
symptoms	O
of	O
osteoarthritis	O
.	O

The	O
regimen	O
preferred	O
embodiment	O
includes	O
lipids	O
as	O
60	O
%	O
or	O
more	O
of	O
daily	O
caloric	O
content	O
,	O
protein	O
up	O
to	O
10%-15	O
%	O
of	O
daily	O
caloric	O
content	O
;	O
and	O
carbohydrates	B
up	O
to	O
25	O
%	O
or	O
less	O
of	O
daily	O
caloric	O
content	O
,	O
primarily	O
in	O
the	O
form	O
of	O
non	O
-	O
starchy	O
,	O
low	O
-	O
glycemic	O
fresh	O
fruit	O
and	O
vegetables	O
,	O
and	O
nuts	O
,	O
along	O
with	O
a	O
daily	O
intake	O
of	O
35	O
grams	O
of	O
dietary	O
fiber	O
,	O
with	O
a	O
significant	O
percentage	O
of	O
this	O
as	O
soluble	O
fiber	O
;	O
average	O
daily	O
cholesterol	B
intake	O
of	O
less	O
than	O
10	O
mg	O
,	O
and	O
30	O
grams	O
of	O
cocoa	O
solids	O
.	O

Cholesterol	B
-	O
reducing	O
diet	O

Provided	O
herein	O
is	O
a	O
method	O
of	O
treating	O
a	O
patient	O
suffering	O
from	O
,	O
or	O
subject	O
to	O
,	O
acute	O
asthma	O
exacerbations	O
comprising	O
administering	O
to	O
the	O
patient	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
a	O
ketolide	B
.	O

Treating	O
acute	O
exacerbations	O
of	O
asthma	O
using	O
a	O
ketolide	B

This	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
agent	O
for	O
preventing	O
metastasis	O
of	O
cancer	O
,	O
which	O
comprises	O
a	O
substance	O
that	O
inhibits	O
expression	O
of	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
.	O

Such	O
substance	O
includes	O
siRNA	O
of	O
MIF	O
.	O

Comprises	O
a	O
substance	O
that	O
inhibits	O
expression	O
of	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
such	O
as	O
siRNA	O
of	O
MIF	O
;	O
adenocarcinoma	O
or	O
colon	O
cancer	O

The	O
present	O
invention	O
pertains	O
to	O
a	O
method	O
for	O
treatment	O
of	O
allergic	O
diseases	O
by	O
administering	O
a	O
natriuretic	O
hormone	O
peptide	O
(	O
NHP	O
)	O
,	O
or	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	O
,	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

In	O
another	O
aspect	O
,	O
the	O
present	O
invention	O
concerns	O
an	O
expression	O
vector	O
comprising	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	O
.	O

In	O
another	O
aspect	O
,	O
the	O
present	O
invention	O
concerns	O
a	O
host	O
cell	O
genetically	O
modified	O
with	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	O
.	O

In	O
another	O
aspect	O
,	O
the	O
present	O
invention	O
concerns	O
a	O
pharmaceutical	O
composition	O
comprising	O
NHP	O
or	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

In	O
another	O
aspect	O
,	O
the	O
present	O
invention	O
pertains	O
to	O
novel	O
fragments	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
exhibiting	O
bronchodilatory	O
and	O
anti	O
-	O
inflammatory	O
activity	O
,	O
and	O
isolated	O
nucleic	O
acid	O
sequences	O
encoding	O
the	O
fragments	O
.	O

Administering	O
a	O
natriuretic	O
hormone	O
peptide	O
(	O
NHP	O
)	O
,	O
or	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
NHP	O
;	O
respiratory	O
system	O
disorders	O

The	O
present	O
invention	O
provides	O
novel	O
dihydropyrancarboxamide	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
and	O
collections	O
of	O
these	O
compounds	O
,	O
and	O
provides	O
methods	O
for	O
the	O
synthesis	O
of	O
these	O
compounds	O
;	O
wherein	O
R1-R6	O
are	O
as	O
defined	O
herein	O
.	O

Additionally	O
,	O
the	O
present	O
invention	O
provides	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
disorders	O
such	O
as	O
proliferative	O
diseases	O
,	O
and	O
cancer	O
,	O
to	O
name	O
a	O
few	O
.	O

Treating	O
disorders	O
such	O
as	O
proliferative	O
diseases	O
,	O
and	O
cancer	O
;	O
compounds	O
can	O
act	O
as	O
probes	O
of	O
biological	O
function	O
;	O
libraries	O
;	O
for	O
example	O
,	O
2-ethoxy-3-	B
(	I
2-hydroxyethoxyethoxyethyl	I
)	I
-4-	I
(	I
1-acetylindol-3-yl	I
)	I
-6-	I
(	I
morpholinocarbonyl	I
)	I
-2H-3,4-dihydropyran	I

This	O
invention	O
relates	O
to	O
3-aryl-1,2-benzisoxazole	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
derivatives	O
,	O
and	O
to	O
methods	O
of	O
treatment	O
comprising	O
administering	O
of	O
such	O
derivatives	O
.	O

Novel	O
3-Aryl-1,2-Benzisoxazole	B
Derivatives	O
and	O
Use	O
Thereof	O
as	O
Medicinal	O
Products	O
Against	O
Cancer	O

Methods	O
of	O
treating	O
blood	O
disorders	O
are	O
described	O
.	O

prophylaxis	O
of	O
blood	O
disorder	O
such	O
as	O
sickle	O
cell	O
anemia	O
,	O
beta	O
-thalassemia	O
,	O
neutropenia	O
or	O
thrombocytopenia	O
,	O
comprising	O
administering	O
carboxylic	B
acids	I
,	O
that	O
stimulates	O
production	O
of	O
fetal	O
hemoglobin	O
,	O
hematopoiesis	O
,	O
erythropoiesis	O
,	O
myelopoiesis	O
and	O
neutrophil	O
production	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
molecules	O
such	O
as	O
peptides	O
,	O
polypeptides	O
and	O
proteins	O
which	O
interact	O
immunologically	O
with	O
T	O
lymphocytes	O
in	O
subjects	O
having	O
peanut	O
allergy	O
,	O
or	O
allergy	O
to	O
other	O
tree	O
nuts	O
,	O
and	O
genetic	O
sequences	O
encoding	O
same	O
.	O

These	O
molecules	O
are	O
preferentially	O
immunointeractive	O
with	O
T	O
cells	O
in	O
subjects	O
having	O
an	O
allergy	O
to	O
the	O
Ara	O
h	O
2	O
allergen	O
.	O

The	O
molecules	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
development	O
of	O
diagnostic	O
,	O
therapeutic	O
and	O
prophylactic	O
agents	O
for	O
conditions	O
characterised	O
by	O
an	O
aberrant	O
,	O
inappropriate	O
or	O
otherwise	O
unwanted	O
immune	O
response	O
to	O
Ara	O
h	O
2	O
or	O
derivative	O
or	O
homologue	O
thereof	O
.	O

Novel	O
Immunointeractive	O
Molecules	O
and	O
uses	O
Thereof	O

A	O
method	O
for	O
treating	O
genetic	O
disorders	O
or	O
conditions	O
or	O
diseases	O
in	O
patients	O
in	O
need	O
of	O
such	O
treatments	O
.	O

The	O
method	O
includes	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
comprising	O
a	O
cholesterol	B
group	O
or	O
derivative	O
thereof	O
having	O
linked	O
thereto	O
a	O
head	O
group	O
.	O

The	O
head	O
group	O
is	O
more	O
positive	O
than	O
the	O
heat	O
group	O
of	O
DC	O
-	O
Chol	O
.	O

The	O
heat	O
group	O
may	O
be	O
a	O
straight	O
chain	O
polymeric	O
group	O
having	O
two	O
or	O
more	O
amine	B
groups	O
separated	O
by	O
an	O
ethylene	B
group	O
.	O

Polycationic	O
sterol	B
derivatives	O
as	O
transfection	O
agents	O

Novel	O
HIV	O
integrase	O
inhibitor	O
compounds	O
having	O
at	O
least	O
one	O
phosphonate	B
group	O
,	O
protected	O
intermediates	O
thereof	O
,	O
and	O
methods	O
for	O
inhibition	O
of	O
HIV	O
-	O
integrase	O
are	O
disclosed	O
.	O

antiviral	O
:	O
improved	O
pharmacokinetics	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
arthritis	O
comprising	O
administering	O
a	O
Triheterocyclic	B
Compound	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
using	O
Triheterocyclic	B
Compounds	O
for	O
treating	O
or	O
preventing	O
rheumatoid	O
arthritis	O
comprising	O
administering	O
a	O
Triheterocyclic	B
Compound	O
.	O

anticancer	O
,	O
antitumor	O
;	O
Phosphoric	B
acid	I
mono-	I
(	I
2-	I
(	I
3-	I
{	I
2-	I
[	I
5-	I
(	I
3,5-dimethyl-1H	I
-	I
pyrrol-2-ylmethylene	I
)	I
-4-methoxy-5H	I
-	I
pyrrol-2-yl	I
]	I
-indol-1-yl	I
]	I
-1,1-dimethyl-3-oxo	I
-	I
propyl	I
)	I
-3-methylphenyl	I
]	I
ester	I

The	O
acyclic	O
hydrazides	O
of	O
the	O
invention	O
are	O
antagonists	O
and/or	O
inverse	O
agonists	O
of	O
the	O
Cannabinoid-1	O
(	O
CB1	O
)	O
receptor	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
CB1	O
receptor	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
centrally	O
acting	O
drugs	O
in	O
the	O
treatment	O
of	O
psychosis	O
,	O
memory	O
deficits	O
,	O
cognitive	O
disorders	O
,	O
migraine	O
,	O
neuropathy	O
,	O
neuro	O
-	O
inflammatory	O
disorders	O
including	O
multiple	O
sclerosis	O
and	O
Guillain	O
-	O
Barre	O
syndrome	O
and	O
the	O
inflammatory	O
sequelae	O
of	O
viral	O
encephalitis	O
,	O
cerebral	O
vascular	O
accidents	O
,	O
and	O
head	O
trauma	O
,	O
anxiety	O
disorders	O
,	O
stress	O
,	O
epilepsy	O
,	O
Parkinson	O
's	O
disease	O
,	O
movement	O
disorders	O
,	O
and	O
schizophrenia	O
.	O

The	O
compounds	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
substance	O
abuse	O
disorders	O
(	O
including	O
smoking	O
cessation	O
)	O
,	O
the	O
treatment	O
of	O
obesity	O
or	O
eating	O
disorders	O
,	O
as	O
well	O
as	O
the	O
treatment	O
of	O
asthma	O
,	O
constipation	O
,	O
chronic	O
intestinal	O
pseudo	O
-	O
obstruction	O
,	O
and	O
cirrhosis	O
of	O
the	O
liver	O
.	O

Antagonists	O
and/or	O
inverse	O
agonists	O
of	O
CB1	O
;	O
N'-	B
[	I
1-	I
(	I
3-chlorophenyl	I
)	I
-2-	I
(	I
4-chlorophenyl	I
)	I
ethyl	I
]	I
-N'-methyl	I
-	I
N-	I
(	I
2-methyl-2-	I
[	I
5-	I
(	I
trifluoromethylpyridin-2-yl	I
)	I
oxy	I
]	I
propanoyl	I
)	I
hydrazide	I
for	O
example	O
;	O
obesity	O
,	O
psychological	O
disorders	O
,	O
analgesics	O
,	O
drug	O
abuse	O
,	O
constipation	O
,	O
asthma	O
,	O
cirrhosis	O

The	O
present	O
invention	O
comprises	O
a	O
method	O
of	O
improving	O
bone	O
health	O
and	O
muscle	O
health	O
in	O
a	O
companion	O
animal	O
comprising	O
administering	O
a	O
composition	O
comprising	O
a	O
fatty	O
acid	O
component	O
to	O
the	O
companion	O
animal	O
wherein	O
the	O
fatty	O
acid	O
component	O
comprises	O
a	O
ratio	O
of	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
to	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
from	O
about	O
3:1	O
to	O
about	O
25:1	O
.	O

The	O
present	O
invention	O
additionally	O
comprises	O
a	O
composition	O
comprising	O
a	O
fatty	O
acid	O
component	O
comprising	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
and	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
wherein	O
the	O
ratio	O
of	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
to	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
is	O
from	O
about	O
3:1	O
to	O
about	O
25:1	O
.	O

Methods	O
of	O
improving	O
bone	O
health	O
and	O
muscle	O
health	O

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
granular	O
component	O
comprising	O
a	O
plurality	O
of	O
solidified	O
melt	O
granules	O
of	O
a	O
sugar	B
alcohol	I
having	O
a	O
salt	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
salt	O
)	O
and	O
paracetamol	O
contained	O
therein	O
.	O

Granules	O
Comprising	O
Paracetamol	B
,	O
a	O
Nsaid	O
and	O
a	O
Sugar	B
Alchohol	I
Made	O
by	O
Melt	O
Extrusion	O

The	O
invention	O
relates	O
to	O
compounds	O
,	O
compositions	O
and	O
methods	O
comprised	O
of	O
a	O
chemical	O
moiety	O
attached	O
to	O
hydrocodone	B
.	O

The	O
invention	O
provides	O
embodiments	O
that	O
provide	O
a	O
decrease	O
in	O
the	O
potential	O
of	O
hydrocodone	B
to	O
cause	O
overdose	O
or	O
to	O
be	O
abused	O
while	O
still	O
delivering	O
therapeutic	O
activity	O
similar	O
to	O
that	O
of	O
the	O
parent	O
hydrocodone	B
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
delivering	O
hydrocodone	B
as	O
conjugates	O
that	O
release	O
the	O
hydrocodone	B
following	O
oral	O
administration	O
while	O
being	O
resistant	O
to	O
abuse	O
by	O
other	O
routes	O
such	O
as	O
intravenous	O
injection	O
(	O
""""	O
shooting	O
""""	O
)	O
and	O
intranasal	O
administration	O
(	O
""""	O
snorting	O
""""	O
)	O
.	O

Further	O
,	O
hydrocodone	B
compositions	O
of	O
the	O
invention	O
are	O
resistant	O
to	O
oral	O
abuse	O
as	O
well	O
,	O
since	O
release	O
of	O
the	O
hydrocodone	B
at	O
suprapharmacological	O
doses	O
reaches	O
saturation	O
.	O

Modification	O
of	O
pharmacokinetic	O
and	O
pharmacological	O
properties	O
of	O
hydrocodone	B
through	O
covalent	O
modification	O
by	O
conjugating	O
hydrocodone	B
with	O
a	O
carrier	O
selected	O
from	O
an	O
amino	B
acid	I
,	O
a	O
dipeptide	O
,	O
a	O
tripeptide	O
,	O
a	O
tetrapeptide	O
and	O
a	O
pentapeptide	O
;	O
analgesic	O
;	O
bioavailability	O

A	O
new	O
crystalline	O
form	O
of	O
the	O
Zoledronic	B
acid	I
,	O
characterized	O
by	O
its	O
X	O
-	O
rays	O
diffractogram	O
as	O
well	O
as	O
by	O
its	O
spatial	O
atomic	O
distribution	O
in	O
the	O
red	O
crystalline	O
and	O
its	O
curves	O
of	O
thermal	O
analysis	O
.	O

There	O
is	O
also	O
included	O
a	O
method	O
to	O
obtain	O
this	O
crystalline	O
form	O
,	O
which	O
includes	O
the	O
synthesis	O
of	O
the	O
corresponding	O
acid	O
and	O
the	O
pharmaceutical	O
composition	O
this	O
crystalline	O
form	O
comprises	O
.	O

Crystalline	O
form	O
of	O
the	O
zoledronic	B
acid	I
,	O
a	O
process	O
to	O
obtain	O
it	O
and	O
the	O
pharmaceutical	O
composition	O
comprising	O
it	O

Methods	O
for	O
treating	O
MM	O
using	O
anti	O
-	O
CS1	O
antibodies	O
are	O
provided	O
herein	O
.	O

Use	O
of	O
allogeneic	O
effector	O
cells	O
and	O
anti	O
-	O
cs1	O
antibodies	O
for	O
selective	O
killing	O
of	O
multiple	O
myeloma	O
cells	O

Combination	O
therapy	O
comprising	O
PPAR	O
modulators	O
and	O
glucose	B
reabsorption	O
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
Syndrome	O
X	O
are	O
disclosed	O
.	O

administering	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
agonists	O
(	O
PPAR	O
)	O
and	O
sodium	B
glucose	I
co	O
-	O
transporters	O
(	O
SGLTs	O
)	O
inhibitors	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
Syndrome	O
X	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
(	O
I	O
)	O
along	O
with	O
methods	O
of	O
making	O
the	O
same	O
,	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
,	O
particularly	O
methods	O
of	O
use	O
as	O
fungicides	O
.	O

For	O
crops	O
;	O
3-	B
(	I
2,6-Dichlorophenyl	I
)	I
-4-	I
[	I
(	I
3-pyridyl	I
)	I
hydroxymethyl	I
]	I
-5-trimethylsilylisoxazole	I
for	O
example	O

Autoimmune	O
disease	O
therapy	O
in	O
a	O
patient	O
treated	O
with	O
apoptosis	O
-	O
inducing	O
agents	O
is	O
enhanced	O
by	O
co	O
-	O
administration	O
of	O
sphingomyelin	B
.	O

The	O
combination	O
most	O
likely	O
enhances	O
an	O
autoimmune	O
disease	O
cell	O
's	O
ability	O
to	O
undergo	O
ceramide	O
-	O
induced	O
apoptosis	O
by	O
increasing	O
the	O
levels	O
of	O
sphingomyelin	B
in	O
all	O
cellular	O
compartments	O
,	O
thereby	O
providing	O
sufficient	O
substrate	O
for	O
activated	O
sphingomyelinase	O
.	O

In	O
alternative	O
embodiments	O
,	O
sphingomyelin	B
may	O
be	O
administered	O
alone	O
,	O
in	O
combination	O
with	O
corticosteroids	B
,	O
and/or	O
in	O
combination	O
with	O
a	O
apoptosis	O
-	O
inducing	O
agent	O
.	O

Sphingomyelin	B
therapy	O
of	O
autoimmune	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
neuropathological	O
disorders	O
involving	O
impaired	O
locomotor	O
functions	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
and	O
method	O
for	O
inducing	O
and	O
restoring	O
locomotor	O
functions	O
,	O
such	O
as	O
basic	O
walking	O
movements	O
in	O
the	O
lower	O
extremities	O
of	O
chronic	O
spinal	O
cord	O
injured	O
animals	O
,	O
such	O
as	O
paraplegic	O
or	O
tetraplegic	O
individuals	O
.	O

More	O
than	O
one	O
dopamine	B
receptor	O
agonist	O
such	O
as	O
apomorphine	B
,	O
ropinirole	B
,	O
pramipexole	B
,	O
pergoline	B
,	O
cabergoline	B
,	O
SKF-81297	O
;	O
and/or	O
more	O
than	O
one	O
noradrenaline	B
/	O
dopamine	B
precursor	O
and/or	O
more	O
than	O
one	O
serotonin	B
receptor	O
agonist	O
;	O
spinal	O
cord	O
injuries	O
;	O
nervous	O
system	O
disorders	O
;	O
paraplegics	O
or	O
tetraplegics	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
(	O
where	O
variables	O
A1	O
,	O
A2	O
,	O
B	O
,	O
J	O
,	O
K	O
,	O
m	O
,	O
n	O
,	O
R4	O
,	O
R5a	O
,	O
R5b	O
and	O
R5c	O
are	O
as	O
defined	O
herein	O
)	O
useful	O
as	O
antagonists	O
of	O
CGRP	O
receptors	O
and	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
CGRP	O
is	O
involved	O
,	O
such	O
as	O
headache	O
,	O
migraine	O
and	O
cluster	O
headache	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
CGRP	O
is	O
involved	O
.	O

CGRP	O
(	O
Calcitonin	O
Gene	O
-	O
Related	O
Peptide	O
)	O
;	O
migraine	O
and	O
cluster	O
headaches	O
;	O
2-	B
(	I
5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro	I
[	I
indole-3,4'-thiopyran	I
]	I
-1	I
(	I
2H	I
)	I
-yl	I
)	I
-N-	I
(	I
2'-oxo-1,1',2',3-tetrahydrospiro	I
[	I
indene-2,3'-pyrrolo	I
[	I
2,3-b	I
]	I
pyridin	I
]	I
-5-yl	I
)	I
acetamide	I
for	O
example	O
;	O
use	O
with	O
other	O
drugs	O

The	O
present	O
invention	O
relates	O
to	O
specific	O
Nα-	B
(	I
menthanecarbonyl	I
)	I
amino	I
acid	I
amides	I
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
and	O
mixtures	O
thereof	O
and	O
to	O
the	O
use	O
of	O
the	O
specific	O
Nα-	O
(	O
menthanecarbonyl	O
)	O
amino	O
acid	O
amides	O
and	O
mixtures	O
thereof	O
as	O
physiological	O
cooling	O
active	O
ingredients	O
.	O

L	B
-	I
N	I
alpha	I
-	I
(	I
menthanecarboxyl	I
)	I
glycine	I
-	I
N	I
-	I
isobutylamide	I
;	O
mixture	O
additionally	O
cause	O
a	O
flavor	O
-	O
modulating	O
effect	O
and/or	O
a	O
trigeminal	O
and/or	O
a	O
salivatory	O
stimulus	O
;	O
on	O
the	O
skin	O
and/or	O
mucous	O
membranes	O
;	O
for	O
nutrition	O
,	O
pleasure	O
,	O
oral	O
hygiene	O
,	O
a	O
pharmaceutical	O
,	O
or	O
a	O
cosmetic	O
;	O
nonhydrolyzing	O

A	O
topical	O
preparation	O
,	O
which	O
includes	O
sunscreens	O
,	O
UV	O
protective	O
lotions	O
and	O
cosmetics	O
is	O
described	O
which	O
includes	O
,	O
at	O
least	O
one	O
physical	O
agent	O
compound	O
,	O
at	O
least	O
one	O
natural	O
or	O
chemically	O
-	O
derived	O
extract	O
,	O
and	O
at	O
least	O
one	O
additional	O
compound	O
.	O

In	O
addition	O
,	O
methods	O
for	O
preparing	O
these	O
topical	O
preparations	O
are	O
disclosed	O
which	O
include	O
:	O
providing	O
at	O
least	O
one	O
physical	O
agent	O
compound	O
,	O
providing	O
at	O
least	O
one	O
natural	O
or	O
chemically	O
-	O
derived	O
extract	O
,	O
providing	O
at	O
least	O
one	O
additional	O
ingredient	O
,	O
and	O
blending	O
the	O
at	O
least	O
one	O
physical	O
agent	O
compound	O
,	O
the	O
at	O
least	O
one	O
natural	O
or	O
chemically	O
-	O
derived	O
extract	O
and	O
the	O
at	O
least	O
one	O
additional	O
ingredient	O
at	O
one	O
or	O
more	O
appropriate	O
temperatures	O
to	O
form	O
the	O
topical	O
preparation	O
.	O

Sunscreens	O
,	O
ultraviolet	O
radiation	O
protective	O
lotions	O
,	O
cosmetics	O
;	O
includes	O
zinc	B
oxide	I
and/or	O
titanium	B
dioxide	I

Particulate	O
β	O
-	O
glucan	O
is	O
solubilized	O
at	O
elevated	O
pressure	O
and	O
temperature	O
to	O
form	O
soluble	O
β	O
-	O
glucan	O
.	O

The	O
method	O
is	O
safe	O
and	O
economical	O
and	O
produces	O
a	O
product	O
that	O
is	O
an	O
improved	O
pharmaceutical	O
agent	O
.	O

pressurizing	O
deoxygenated	O
suspension	O
of	O
particules	O
and	O
acetic	B
acid	I
and	O
heating	O
to	O
form	O
soluble	O
material	O
;	O
higher	O
dosage	O
,	O
reduced	O
side	O
effects	O
;	O
immunostimulants	O

An	O
alkyl	O
ether	O
derivative	O
represented	O
by	O
the	O
formula	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
salts	O
thereof	O
exhibits	O
synergistically	O
improved	O
anti	O
-	O
hypoxic	O
activity	O
when	O
combined	O
with	O
a	O
compound	O
having	O
an	O
acetylcholine	B
esterase	O
inhibitory	O
activity	O
.	O

Therefore	O
,	O
the	O
combination	O
according	O
to	O
the	O
present	O
invention	O
is	O
useful	O
as	O
a	O
method	O
for	O
improving	O
cerebral	O
function	O
.	O

Further	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
relating	O
to	O
the	O
combination	O
according	O
to	O
the	O
present	O
invention	O
is	O
useful	O
for	O
treatment	O
and	O
prevention	O
of	O
dysfunction	O
of	O
cerebral	O
acetylcholine	B
neurons	O
in	O
the	O
sequelae	O
of	O
cerebrovascular	O
dementia	O
,	O
senile	O
dementia	O
,	O
Alzheimer	O
's	O
disease	O
and	O
ischemic	O
cerebral	O
lesion	O
and	O
in	O
the	O
cerebral	O
apoplexy	O
or	O
the	O
memory	O
impairment	O
caused	O
by	O
selective	O
neuronal	O
death	O
.	O

2-	B
[	I
[	I
3-	I
(	I
2-benzo	I
[	I
b	I
]	I
thiophen-5-yl	I
-	I
ethoxy	I
)	I
propyl	I
]	I
(	I
methyl	I
)	I
amino	I
]	I
-1-ethanol	I
;	O
antihypoxic	O
agent	O
;	O
synergistic	O
mixture	O
with	O
acetylcholine	B
esterase	O
inhibitor	O
(	O
Tacrine	B
,	O
Donepezil	B
,	O
Rivastigmine	B
)	O
;	O
neurodegenerative	O
diseases	O
,	O
ischemic	O
cerebral	O
lesion	O
,	O
cerebral	O
apoplexy	O
,	O
Alzheimer	O
's	O
disease	O
,	O
cognition	O
activator	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
:	O
wherein	O
n	O
,	O
m	O
and	O
p	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
either	O
0	O
or	O
1	O
.	O

Also	O
disclosed	O
are	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
particularly	O
in	O
treating	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Compounds	O
Having	O
Activity	O
At	O
Nk3	O
Receptor	O

And	O
Uses	O
Thereof	O
In	O
Medicine	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
Wherein	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
preparation	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
to	O
their	O
therapeutic	O
application	O
.	O

Alkyl-	B
,	I
alkenyl-	I
and	I
alkynylcarbamate	I
derivatives	O
,	O
their	O
preparation	O
and	O
their	O
application	O
in	O
therapeutics	O

This	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
providing	O
otoprotection	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Formula	O
(	O
I	O
)	O
and	O
Formula	O
(	O
II	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
:	O
wherein	O
phenyl	O
is	O
substituted	O
at	O
X	O
with	O
one	O
to	O
five	O
halogen	B
atoms	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
fluorine	B
,	O
chlorine	B
,	O
bromine	B
and	O
iodine	B
;	O
and	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
and	O
C1-C4	B
alkyl	I
;	O
wherein	O
C1-C4	B
alkyl	I
is	O
optionally	O
substituted	O
with	O
phenyl	B
(	O
wherein	O
phenyl	B
is	O
optionally	O
substituted	O
with	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	B
,	O
C1-C4	B
alkyl	I
,	O
C1-C4	B
alkoxy	I
,	O
amino	B
,	O
nitro	B
and	O
cyano	O
)	O
.	O

2-chlorophenyl-2-hydroethyl	B
-	I
carbamate	I
;	O
neuroprotective	O
agent	O
;	O
otoprotection	O
from	O
damage	O
to	O
neural	O
tissue	O
and	O
cells	O
of	O
the	O
mammalian	O
inner	O
ear	O
from	O
neural	O
injury	O
or	O
insult	O
and	O
from	O
neurotoxic	O
or	O
ototoxic	O
agents	O
;	O
loss	O
of	O
hearing	O
and	O
balance	O
impairments	O

Compositions	O
and	O
methods	O
for	O
treating	O
noninflammatory	O
pain	O
,	O
including	O
but	O
not	O
limited	O
to	O
,	O
neuropathic	O
pain	O
by	O
using	O
peroxisome	O
proliferator	O
activated	O
receptor	O
a	O
(	O
PPARa	O
)	O
agonists	O
to	O
treat	O
a	O
subject	O
having	O
such	O
pain	O
are	O
described	O
.	O

The	O
agonists	O
may	O
be	O
used	O
with	O
additional	O
therapeutic	O
agents	O
such	O
as	O
an	O
inhibitor	O
of	O
fatty	B
acid	I
amide	I
hydrolase	O
or	O
a	O
cannabinoid	B
CB1	I
or	I
CB2	I
cannabinoid	O
receptor	O
agonist	O
.	O

Compounds	O
And	O
Methods	O

For	O
Treating	O
Non	O
-	O
Inflammatory	O
Pain	O
Using	O
Ppar	O
Alpha	O
Agonists	O

Compositions	O
and	O
methods	O
are	O
provided	O
for	O
treating	O
diseases	O
associated	O
with	O
aberrant	O
silencing	O
of	O
gene	O
expression	O
such	O
as	O
cancer	O
and	O
hematological	O
disorders	O
by	O
reestablishing	O
the	O
gene	O
expression	O
through	O
inhibition	O
of	O
DNA	O
hypomethylation	O
and	O
histone	O
deacetylase	O
.	O

The	O
method	O
comprises	O
:	O
administering	O
to	O
a	O
patient	O
suffering	O
from	O
the	O
disease	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
DNA	O
methylation	O
inhibitor	O
such	O
as	O
a	O
cysteine	B
analog	O
such	O
as	O
decitabine	B
,	O
in	O
combination	O
with	O
an	O
effective	O
amount	O
of	O
histone	O
deacetylase	O
inhibitor	O
such	O
as	O
hydroxamic	B
acid	I
,	O
cyclic	O
peptide	O
,	O
benzamide	B
,	O
butyrate	B
,	O
and	O
depudecin	B
.	O

Compositions	O
and	O
methods	O
for	O
treating	O
diseases	O
through	O
inhibition	O
of	O
dna	O
methylation	O
and	O
histone	O
deacetylase	O

An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
excellent	O
cartilage	O
regeneration	O
-	O
promoting	O
agent	O
that	O
can	O
promote	O
regeneration	O
of	O
cartilage	O
efficiently	O
and	O
is	O
highly	O
safe	O
,	O
and	O
a	O
medicine	O
and	O
a	O
food	O
that	O
utilizes	O
the	O
cartilage	O
regeneration	O
-	O
promoting	O
agent	O
.	O

Thus	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
cartilage	O
regeneration	O
-	O
promoting	O
agent	O
that	O
includes	O
at	O
least	O
one	O
of	O
hydroxytyrosol	B
and	O
a	O
precursor	O
of	O
hydroxytyrosol	B
,	O
and	O
to	O
a	O
medicine	O
and	O
a	O
food	O
that	O
includes	O
the	O
cartilage	O
regeneration	O
-	O
promoting	O
agent	O
.	O

Cartilage	O
regeneration	O
promoting	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
comprising	O
quetiapine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
zolmitriptan	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
pharmaceutical	O
compositions	O
,	O
processes	O
for	O
its	O
preparation	O
,	O
the	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
and	O
a	O
method	O
of	O
treatment	O
of	O
disease	O
and	O
more	O
particularly	O
to	O
a	O
method	O
of	O
treatment	O
of	O
diseases	O
typically	O
treated	O
with	O
5-HT1D	O
agonists	O
and/or	O
atypical	O
antipsychotics	O
,	O
in	O
particularly	O
,	O
migraine	O
,	O
related	O
conditions	O
and	O
for	O
reducing	O
or	O
eliminating	O
of	O
migraine	O
recurrence	O
.	O

Antiserotonine	O
agents	O
;	O
psycholgical	O
disorders	O
;	O
headaches	O
;	O
kits	O

The	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
diseases	O
or	O
disorders	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	O
activity	O
,	O
particularly	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
the	O
Abl	O
,	O
BCR	O
-	O
Abl	O
,	O
Bmx	O
,	O
CSK	O
,	O
TrkB	O
,	O
FGFR3	O
,	O
Fes	O
,	O
Lck	O
,	O
B	O
-	O
RAF	O
,	O
C	O
-	O
RAF	O
,	O
MKK6	O
,	O
SAPK2α	O
and	O
SAPK2β	O
kinases	O
.	O

as	O
serine	B
/	O
threonine	B
,	O
fusion	O
,	O
and	O
tyrosine	B
kinase	O
receptors	O
as	O
nerve	O
and	O
fibroblast	O
growth	O
factor	O
;	O
abnormal	O
activation	O
of	O
immune	O
and	O
nervous	O
systems	O
;	O
antiproliferative	O
;	O
lung	O
;	O
4-	B
(	I
3-Trifluoromethyl	I
-	I
phenylamino	I
)	I
-pyrrolo	I
[	I
2,3-d	I
]	I
pyrimidine-7-carboxylic	I
acid	I
[	I
3-	I
(	I
4-morpholin-4-yl	I
-	I
phenylcarbamoyl	I
)	I
-phenyl	I
]	I
-amide	I

The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrazoles	B
,	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
.	O

The	O
compounds	O
are	O
glucagon	O
receptor	O
antagonists	O
and	O
thus	O
are	O
useful	O
for	O
treating	O
,	O
preventing	O
or	O
delaying	O
the	O
onset	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O

N-	B
(	I
4-	I
{	I
(	I
1S	I
)	I
-1-	I
[	I
3-	I
(	I
3,5-DICHLOROPHENYL	I
)	I
-5-QUINOLIN-3-YL-1H	I
-	I
PYRAZOL-1-YL	I
]	I
ETHYL	I
}	I
BENZOYL	I
)	I
-	I
beta	I
-ALANINE	I
;	O
glucagon	O
receptor	O
antagonists	O
;	O
antidiabetic	O
agent	O
;	O
insulin	O
resistance	O
and	O
its	O
complications	O
,	O
including	O
coronary	O
heart	O
disease	O
,	O
stroke	O
,	O
hypertension	O
,	O
nephropathy	O
,	O
neuropathy	O
,	O
retinopathy	O
;	O
atherosclerosis	O

The	O
present	O
invention	O
relates	O
to	O
optically	O
pure	O
S-	B
(	I
−	I
)	I
-benzoquinolizine	I
carboxylic	I
acids	I
,	O
their	O
derivatives	O
,	O
salts	O
,	O
pseudopolymorphs	O
,	O
polymorphs	O
and	O
hydrates	O
thereof	O
,	O
substantially	O
free	O
of	O
their	O
R-	O
(	O
+	O
)	O
-isomers	O
,	O
to	O
processes	O
for	O
preparation	O
of	O
the	O
optically	O
pure	O
S-	B
(	I
−	I
)	I
-benzoquinolizine	I
carboxylic	I
acids	I
,	O
their	O
derivatives	O
,	O
salts	O
,	O
pseudopolymorphs	O
,	O
polymorphs	O
and	O
hydrates	O
thereof	O
substantially	O
free	O
of	O
their	O
R-	O
(	O
+	O
)	O
-isomers	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
S	B
(	I
−	I
)	I
-benzoquinolizine	I
carboxylic	I
acids	I
,	O
their	O
derivatives	O
,	O
salts	O
,	O
pseudopolymorphs	O
,	O
polymorphs	O
and	O
hydrates	O
thereof	O
.	O

9-fluoro-6,7,-dihydro-8-	B
(	I
4-hydroxypiperidin-1-yl	I
)	I
-5-methyl-1-oxo-1H,5H	I
-	I
benzo	I
[	I
i	I
,	I
j	I
]	I
quinolizine-2-carboxylic	I
acid	I
;	O
optically	O
pure	O
isomers	O
of	O
Nadifloxacin	B
;	O
bactericide	B
;	O
systemic	O
or	O
topical	O
Gram	O
-	O
positive	O
,	O
Gram	O
-	O
negative	O
bacterial	O
,	O
mycobacterial	O
and	O
nosocomlal	O
pathogen	O
infections	O

Methods	O
of	O
improving	O
the	O
bioavailability	O
of	O
ethinyl	B
estradiol	I
by	O
orally	O
administering	O
to	O
a	O
patient	O
a	O
solid	O
dosage	O
form	O
containing	O
ethinyl	B
estradiol	I
or	O
prodrug	O
thereof	O
where	O
that	O
dosage	O
form	O
releases	O
at	O
least	O
some	O
of	O
the	O
ethinyl	B
estradiol	I
or	O
prodrug	O
thereof	O
in	O
the	O
oral	O
cavity	O
for	O
absorption	O
through	O
the	O
oral	O
mucosa	O
to	O
treat	O
the	O
patient	O
for	O
a	O
predetermined	O
indication	O
such	O
as	O
,	O
for	O
example	O
,	O
hormone	O
replacement	O
therapy	O
or	O
contraception	O
.	O

The	O
solid	O
dosage	O
forms	O
may	O
be	O
selected	O
from	O
,	O
among	O
others	O
,	O
chewable	O
tablets	O
,	O
fast	O
melt	O
tablets	O
,	O
films	O
,	O
dissolving	O
films	O
,	O
mucoadhesive	O
tablets	O
,	O
lozenges	O
,	O
and	O
chewing	O
gum	O
.	O

Administering	O
ethinyl	B
estradiol	I
or	O
prodrug	O
thereof	O
to	O
patient	O
with	O
improved	O
bioavailability	O
by	O
orally	O
administering	O
solid	O
dosage	O
form	O
that	O
releases	O
effective	O
amount	O
of	O
ethinyl	B
estradiol	I
or	O
prodrug	O
thereof	O
in	O
oral	O
cavity	O
for	O
absorption	O
through	O
oral	O
mucosa	O
;	O
for	O
hormone	O
replacement	O
therapy	O
or	O
contraception	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
having	O
Formula	O
I	O
or	O
II	O
:	O
wherein	O
B	O
,	O
R	O
,	O
X	O
,	O
Ar	B
,	O
and	O
Y	O
are	O
defined	O
herein	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
pharmaceutically	O
acceptable	O
prodrugs	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
making	O
and	O
using	O
the	O
compound	O
.	O

Compounds	O
,	O
compositions	O
,	O
processes	O
of	O
making	O
,	O
and	O
methods	O
of	O
use	O
related	O
to	O
inhibiting	O
macrophage	O
migration	O
inhibitory	O
factor	O

A	O
medicament	O
for	O
suppressing	O
intracellular	O
excess	O
accumulation	O
of	O
sodium	B
ions	I
and	O
a	O
medicament	O
for	O
therapeutic	O
and/or	O
preventive	O
treatment	O
of	O
cardiac	O
disorders	O
resulting	O
from	O
cardiosurgery	O
operations	O
which	O
comprises	O
an	O
aminobenzenesulfonic	B
acid	I
derivative	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
,	O
or	O
a	O
hydrate	B
thereof	O
or	O
a	O
solvate	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

Suppressor	O
of	O
excess	O
accumulation	O
of	O
intracellular	O
sodium	B
ions	I

A	O
method	O
and	O
composition	O
for	O
inhibiting	O
a	O
variety	O
of	O
pain	O
,	O
inflammation	O
,	O
spasm	O
and	O
restenosis	O
processes	O
resulting	O
from	O
cardiovascular	O
or	O
general	O
vascular	O
therapeutic	O
and	O
diagnostic	O
procedures	O
.	O

The	O
composition	O
preferably	O
includes	O
multiple	O
pain	O
and	O
inflammation	O
inhibitory	O
agents	O
and	O
spasm	O
inhibitory	O
agents	O
.	O

Specific	O
preferred	O
embodiments	O
of	O
the	O
solution	O
of	O
the	O
present	O
invention	O
for	O
use	O
in	O
cardiovascular	O
and	O
general	O
vascular	O
procedures	O
also	O
may	O
include	O
anti	O
-	O
restenosis	O
agents	O
.	O

Inhibiting	O
a	O
variety	O
of	O
pain	O
,	O
inflammation	O
,	O
spasm	O
and	O
restenosis	O
processes	O
resulting	O
from	O
cardiovascular	O
or	O
general	O
vascular	O
therapeutic	O
and	O
diagnostic	O
procedures	O
;	O
use	O
of	O
ADP	O
receptor	O
antagonist	O
and	O
a	O
thromboxane	O
A2	O
receptor	O
antagonist	O

A	O
bone	O
implant	O
composite	O
comprising	O
a	O
collagen	O
matrix	O
and	O
a	O
calcium	B
-	O
based	O
mineral	O
,	O
the	O
calcium	B
-	O
based	O
mineral	O
having	O
a	O
particle	O
size	O
of	O
25	O
-	O
2000	O
μm	O
and	O
being	O
interspersed	O
in	O
the	O
collagen	O
matrix	O
;	O
wherein	O
the	O
bone	O
implant	O
composite	O
contains	O
3	O
-	O
60	O
%	O
by	O
weight	O
the	O
collagen	O
matrix	O
and	O
40	O
-	O
97	O
%	O
by	O
weight	O
the	O
calcium	B
-	O
based	O
mineral	O
,	O
and	O
has	O
a	O
pore	O
size	O
of	O
50	O
-	O
500	O
μm	O
,	O
a	O
density	O
range	O
of	O
0.02	O
-	O
0.8	O
g	O
/	O
cm3	O
,	O
a	O
tensile	O
strength	O
range	O
of	O
0.4	O
-	O
100	O
kg	O
/	O
cm2	O
,	O
and	O
a	O
compression	O
modulus	O
range	O
of	O
0.2	O
-	O
10	O
kg	O
/	O
cm2	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
preparing	O
the	O
above	O
-	O
described	O
composite	O
.	O

Bone	O
implant	O
composite	O

Disclosed	O
are	O
compounds	O
which	O
inhibit	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
enzymatic	O
activity	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
as	O
well	O
as	O
methods	O
to	O
treat	O
conditions	O
,	O
particularly	O
proliferative	O
conditions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
HDAC	O
.	O

1-	B
(	I
2-naphthylsulfonyl	I
)	I
-4-	I
(	I
5-hydroxyaminocarbonylthiazol-2-yl	I
)	I
piperazine	I
;	O
antiproliferative	O
agent	O
;	O
cell	O
cycle	O
arrest	O
,	O
cellular	O
differentiation	O
,	O
apoptosis	O
and	O
reversal	O
of	O
the	O
transformed	O
phenotype	O
;	O

Compositions	O
and	O
methods	O
for	O
promoting	O
neural	O
regeneration	O
in	O
a	O
patient	O
determined	O
to	O
have	O
a	O
lesion	O
in	O
a	O
mature	O
CNS	O
neuron	O
are	O
disclosed	O
.	O

The	O
method	O
comprises	O
the	O
step	O
of	O
contacting	O
the	O
neuron	O
with	O
an	O
EGFR	O
inhibitor	O
sufficient	O
to	O
promote	O
regeneration	O
of	O
the	O
neuron	O
.	O

EGFR	O
inhibitors	O
promote	O
axon	O
regeneration	O

It	O
is	O
intended	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
which	O
contains	O
a	O
proton	O
pump	O
inhibitor	O
and	O
is	O
stable	O
even	O
if	O
it	O
is	O
stored	O
for	O
a	O
long	O
time	O
.	O

It	O
is	O
also	O
intended	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
which	O
contains	O
a	O
proton	O
pump	O
inhibitor	O
susceptible	O
to	O
acid	O
,	O
and	O
does	O
not	O
dissolve	O
in	O
the	O
stomach	O
but	O
dissolves	O
in	O
the	O
intestine	O
to	O
release	O
a	O
primary	O
drug	O
product	O
promptly	O
.	O

The	O
object	O
could	O
be	O
achieved	O
by	O
the	O
pharmaceutical	O
composition	O
characterized	O
in	O
that	O
a	O
layer	O
containing	O
a	O
proton	O
pump	O
inhibitor	O
and	O
ethyl	O
cellulose	O
,	O
a	O
layer	O
containing	O
an	O
enteric	O
polymer	O
,	O
and	O
if	O
necessary	O
an	O
intermediate	O
layer	O
composed	O
of	O
one	O
or	O
more	O
layers	O
are	O
formed	O
on	O
a	O
pharmacologically	O
inactive	O
core	O
substance	O
.	O

The	O
intermediate	O
layer	O
is	O
composed	O
of	O
a	O
water	O
-	O
insoluble	O
polymer	O
,	O
a	O
water	O
-	O
soluble	O
polymer	O
,	O
a	O
lubricant	O
and	O
the	O
like	O
.	O

Stabilized	O
composition	O

A	O
new	O
prophylactic	O
mixture	O
is	O
prepared	O
for	O
the	O
effective	O
decorporation	O
of	O
*	O
Cs	B
,	O
*	O
Sr	B
,	O
*	O

I	B
from	O
affected	O
subjects	O
in	O
the	O
event	O
of	O
an	O
accidental	O
release	O
of	O
the	O
radioisotopes	O
in	O
the	O
environment	O
due	O
to	O
any	O
nuclear	O
accident	O
.	O

The	O
prophylactic	O
mixture	O
comprising	O
:	O
1	O
)	O
Calcium	B
Potassium	I
Ferrocyanide	I
[	O
CaK2Fe	B
(	I
CN	I
)	I
6	I
]	O
2	O
)	O
Calcium	B
Iodate	I
,	O
and	O
3	O
)	O
Calcium	B
Carbonate	I
,	O
can	O
be	O
formulated	O
in	O
the	O
form	O
of	O
a	O
single	O
tablet	O
,	O
capsule	O
or	O
suspension	O
for	O
easy	O
administration	O
to	O
the	O
radiation	O
affected	O
subjects	O
in	O
cases	O
of	O
emergency	O
or	O
nuclear	O
fallout	O
.	O

Also	O
claimed	O
are	O
the	O
compound	O
calcium	B
potassium	I
ferrocyanide	I
(	O
CaK2Fe	B
(	I
CN	I
)	I
6	I
)	O
and	O
the	O
use	O
thereof	O
for	O
decorporation	O
of	O
*	O
Cs	B
in	O
subjects	O
affected	O
by	O
nuclear	O
radiation	O
.	O

mixture	O
with	O
Calcium	B
Iodate	I
,	O
and	O
Calcium	B
Carbonate	I
for	O
removal	O
of	O
all	O
three	O
radionuclides	O
Cesium	B
,	O
Strontium	B
,	O
Iodine	B

The	O
present	O
invention	O
relates	O
generally	O
to	O
chemical	O
agents	O
useful	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
disease	O
conditions	O
and	O
in	O
particular	O
chronic	O
disease	O
conditions	O
such	O
as	O
inflammatory	O
including	O
allergic	O
diseases	O
,	O
metastatic	O
cancers	O
and	O
infection	O
by	O
pathogenic	O
agents	O
including	O
bacteria	O
,	O
viruses	O
or	O
parasites	O
.	O

More	O
particularly	O
,	O
the	O
chemical	O
agents	O
contemplated	O
by	O
the	O
present	O
invention	O
are	O
selected	O
from	O
glycosaminoglycan	O
(	O
GAG	O
)	O
molecules	O
derived	O
from	O
a	O
larger	O
GAG	O
,	O
GAG	O
-	O
like	O
molecules	O
which	O
resemble	O
GAGs	O
in	O
some	O
of	O
their	O
characteristics	O
but	O
may	O
be	O
derived	O
from	O
a	O
larger	O
non	O
-	O
GAG	O
polysaccharide	O
and	O
molecules	O
having	O
a	O
GAG	O
-	O
like	O
composite	O
structure	O
as	O
well	O
as	O
agents	O
which	O
bind	O
to	O
the	O
same	O
sites	O
as	O
GAGs	O
,	O
GAG	O
-	O
like	O
molecules	O
or	O
GAG	O
-	O
like	O
composite	O
molecules	O
.	O

The	O
present	O
invention	O
also	O
provides	O
assays	O
to	O
identify	O
GAG	O
and	O
GAG	O
-	O
like	O
therapeutic	O
agents	O
including	O
GAG	O
-	O
like	O
composite	O
structures	O
as	O
well	O
as	O
analogs	O
,	O
homologs	O
and	O
orthologs	O
thereof	O
.	O

Inflammation	O
,	O
allergic	O
diseases	O
,	O
metastatic	O
cancers	O
,	O
pathogen	O
infections	O
;	O
glycosaminoglycan	O
related	O
molecules	O

Novel	O
florfenicol	O
compounds	O
having	O
the	O
chemical	O
structure	O
:	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
or	O
a	O
solvate	O
thereof	O
,	O
or	O
prodrug	O
thereof	O
,	O
wherein	O
R1	O
is	O
CHCl2	B
,	O
CHClF	B
,	O
CHF2	B
,	O
CHBrCl	B
,	O
CH3	B
,	O
CH2N3	B
,	O
CH2CN	B
,	O
CH	B
(	I
R2	I
)	I
NH2	I
or	O
CH	B
X1X2	I
;	O
where	O
R2	O
is	O
H	B
,	O
CH3	B
or	O
CH2OH	B
,	O
and	O
X1	O
and	O
X2	O
are	O
independently	O
selected	O
halogens	B
;	O
and	O
R3	O
is	O
CH2Cl	B
,	O
CH2F	B
,	O
CHF2	B
,	O
CHCl2	B
or	O
CH2OH	B
are	O
disclosed	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
bacterial	O
infections	O
in	O
a	O
broad	O
range	O
of	O
patients	O
such	O
as	O
,	O
without	O
limitation	O
,	O
birds	O
,	O
fish	O
,	O
shellfish	O
and	O
mammals	O
.	O

Antibacterial	O
1-	B
(	I
4-mono-	I
and	I
di	I
-	I
halomethylsulphonylphenyl	I
)	I
-2-acylamino-3-fluoroproponals	I
and	O
preparation	O
thereof	O

The	O
invention	O
relates	O
to	O
methods	O
identify	O
or	O
characterize	O
compounds	O
that	O
can	O
be	O
used	O
to	O
treat	O
specified	O
clinical	O
disorders	O
such	O
as	O
hyperglycemia	O
and	O
type	O
2	O
diabetes	O
.	O

Compounds	O
that	O
can	O
be	O
used	O
in	O
these	O
methods	O
include	O
4α	B
-	I
fluoro-17α	I
-	I
ethynylandrost-5-ene-3β	I
,	I
7β,17β	I
-	I
triol	I
,	O
4α	B
-	I
fluoro-17α	I
-	I
ethynylandrost-5-ene-3β,7α,17β	I
-	I
triol	I
,	O
4α	B
-	I
fluoro-17α	I
-	I
ethynylandrost-5-ene-3α,7β,17β	I
-	I
triol	I
and	O
4α	B
-	I
fluoro-17α	I
-	I
ethynylandrost-5-ene-3β,17β	I
-	I
triol-7-one	I
.	O

Drug	O
Screening	O
and	O
Treatment	O
Methods	O

The	O
present	O
invention	O
provides	O
amino	O
ceramide	O
-	O
like	O
compounds	O
which	O
inhibit	O
glucosyl	O
ceramide	O
(	O
GlyCer	O
)	O
formation	O
by	O
inhibiting	O
the	O
enzyme	O
GlyCer	O
synthase	O
,	O
thereby	O
lowering	O
the	O
level	O
of	O
glycosphingolipids	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
have	O
improved	O
GlcCer	O
synthase	O
inhibition	O
activity	O
and	O
are	O
therefore	O
useful	O
in	O
therapeutic	O
methods	O
for	O
treating	O
various	O
conditions	O
and	O
diseases	O
associated	O
with	O
altered	O
glycosphingolipid	O
levels	O
.	O

Containing	O
tertiary	O
amine	O
linked	O
pyrrolidine	B
,	O
azetidine	B
,	O
morpholine	B
or	O
piperidine	B
group	O
;	O
inhibiting	O
GlyCer	O
synthase	O
,	O
lowering	O
glycosphingolipid	O
levels	O
;	O
collagen	O
vascular	O
diseases	O
,	O
atherosclerosis	O
,	O
diabetic	O
renal	O
hypertrophy	O

The	O
present	O
invention	O
concerns	O
hydrazinocarbonyl	B
-	I
thieno	I
[	I
2,3-c	I
]	I
pyrazoles	I
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
,	O
R3	O
,	O
R4	O
,	O
are	O
R5	O
are	O
as	O
defined	O
in	O
the	O
disclosure	O
;	O
their	O
preparation	O
method	O
,	O
compositions	O
containing	O
the	O
same	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
pathological	O
conditions	O
,	O
in	O
particular	O
as	O
anticancer	O
agents	O
.	O

Hydrazinocarbonyl	B
-	I
thieno	I
[	I
2,3-C	I
]	I
pyrazoles	I
,	O
Process	O
for	O
Preparing	O
Them	O
,	O
Compositions	O
Containing	O
Them	O
and	O
Use	O
Thereof	O

There	O
is	O
provided	O
use	O
of	O
a	O
compound	O
capable	O
of	O
inhibiting	O
a	O
steroid	B
sulphatase	O
enzyme	O
(	O
E.C.3.1.6.2	O
)	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
inhibiting	O
in	O
vivo	O
synthesis	O
of	O
at	O
least	O
one	O
of	O
androstenedione	B
and	O
testosterone	B
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
hirsutism	O
,	O
excess	O
sebum	O
production	O
,	O
benign	O
breast	O
disease	O
,	O
benign	O
ovarian	O
disease	O
,	O
polycystic	O
ovarian	O
disease	O
and	O
female	O
infertility	O
among	O
others	O
.	O

Use	O
of	O
a	O
steroid	B
sulphatase	O
inhibitor	O
for	O
inhibiting	O
the	O
synthesis	O
of	O
androstenedione	B
and/or	O
testosterone	B

Antisense	O
compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
stearoyl	O
-	O
CoA	O
desaturase	O
.	O

The	O
compositions	O
comprise	O
antisense	O
compounds	O
,	O
particularly	O
antisense	O
oligonucleotides	B
,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
stearoyl	O
-	O
CoA	O
desaturase	O
.	O

Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
stearoyl	O
-	O
CoA	O
desaturase	O
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
stearoyl	O
-	O
CoA	O
desaturase	O
are	O
provided	O
.	O

Non	O
-	O
insulin	O
dependent	O
diabetes	O
mellitus	O
;	O
lowers	O
hepatic	O
fatty	O
degeneration	O
;	O
improving	O
liver	O
function	O
by	O
reducing	O
alanine	B
transaminase	O
and	O
aspartate	B
transaminase	O
levels	O

Pyrimidine	B
I	I
and	I
pyrimidinone	I
II	I
phosphonate	I
compounds	O
and	O
methods	O
for	O
viral	O
inhibition	O
are	O
disclosed	O
.	O

The	O
compounds	O
include	O
at	O
least	O
one	O
phosphonate	B
group	O
covalently	O
attached	O
at	O
any	O
site	O
.	O

Pyrimidyl	B
Phosphonate	I
Antiviral	O
Compounds	O
and	O
Methods	O
of	O
Use	O

The	O
present	O
invention	O
provides	O
compositions	O
useful	O
in	O
treating	O
cancer	O
.	O

The	O
compositions	O
include	O
a	O
synergistic	O
combination	O
of	O
an	O
antineoplastic	O
thiol	B
-	O
binding	O
mitochondrial	O
oxidant	O
with	O
an	O
antineoplastic	O
nucleic	O
acid	O
binding	O
agent	O
,	O
an	O
antineoplastic	O
antimetabolite	O
base	O
analog	O
,	O
or	O
docetaxel	B
.	O

Also	O
provided	O
are	O
methods	O
of	O
assaying	O
the	O
synergistic	O
effects	O
of	O
the	O
combinations	O
and	O
methods	O
of	O
treating	O
cancer	O
using	O
the	O
synergistic	O
combinations	O
.	O

Synergistic	O
anti	O
-	O
cancer	O
compositions	O

Pyrazole	B
carboxamides	I
of	O
structural	O
formula	O
I	O
are	O
selective	O
inhibitors	O
of	O
the	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase-1	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
such	O
as	O
noninsulin	O
-	O
dependent	O
diabetes	O
(	O
NIDDM	O
)	O
,	O
hyperglycemia	O
,	O
obesity	O
,	O
insulin	O
resistance	O
,	O
dyslipidemia	O
,	O
hyperlipidemia	O
,	O
hypertension	O
,	O
Metabolic	O
Syndrome	O
,	O
and	O
other	O
symptoms	O
associated	O
with	O
NIDDM	O
.	O

Pyrazole	B
Carboxamides	I
as	O
Inhibitors	O
of	O
11-Beta	B
-	I
Hydroxysteroid	I
Dehydrogenase-1	O

A	O
method	O
is	O
provided	O
for	O
treatment	O
of	O
an	O
infective	O
condition	O
in	O
an	O
udder	O
of	O
a	O
milk	O
producing	O
animal	O
.	O

The	O
method	O
comprises	O
intramammary	O
administration	O
of	O
an	O
antibacterial	O
agent	O
in	O
combination	O
therapy	O
with	O
a	O
selective	O
COX-2	O
inhibitor	O
in	O
therapeutically	O
effective	O
amounts	O
of	O
each	O
.	O

Also	O
provided	O
is	O
a	O
pharmaceutical	O
composition	O
comprising	O
an	O
antibacterial	O
agent	O
and	O
a	O
selective	O
COX-2	O
inhibitor	O
,	O
together	O
with	O
one	O
or	O
more	O
excipients	O
,	O
in	O
a	O
dosage	O
form	O
suitable	O
for	O
intramammary	O
administration	O
to	O
a	O
milk	O
producing	O
animal	O
.	O

Cyclooxygenase-2	O
inhibitor	O
and	O
antibacterial	O
agent	O
combination	O
for	O
intramammary	O
treatment	O
of	O
mastitis	O

A	O
method	O
for	O
the	O
use	O
of	O
creatine	O
pyroglutamic	B
acid	I
salts	O
is	O
provided	O
by	O
the	O
present	O
invention	O
.	O

The	O
salt	O
of	O
the	O
present	O
invention	O
act	O
substantially	O
simultaneously	O
to	O
increase	O
the	O
neural	O
health	O
of	O
a	O
mammal	O
.	O

Administering	O
creatine	O
pyroglutamate	B
to	O
improve	O
neuron	O
health	O
;	O
improving	O
cognitive	O
functions	O
and	O
preventing	O
and	O
fighting	O
the	O
onset	O
of	O
stress	O
and	O
its	O
deleterious	O
effects	O
on	O
mental	O
and	O
physical	O
performances	O
.	O

This	O
invention	O
relates	O
to	O
novel	O
penetrating	O
compositions	O
including	O
one	O
or	O
more	O
effectors	O
included	O
within	O
a	O
water	O
soluble	O
composition	O
,	O
immersed	O
in	O
a	O
hydrophobic	O
medium	O
The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
or	O
preventing	O
diseases	O
by	O
administering	O
such	O
penetrating	O
compositions	O
to	O
affected	O
subjects	O
.	O

Compositions	O
Capable	O
of	O
Facilitating	O
Penetration	O
Across	O
a	O
Biological	O
Barrier	O

The	O
present	O
invention	O
involves	O
diagnostic	O
and	O
treatment	O
methods	O
for	O
prostate	O
cancer	O
.	O

We	O
have	O
shown	O
that	O
prostate	O
cancer	O
cells	O
overexpress	O
variant	O
isoforms	O
of	O
CD44	O
(	O
CD44v7	O
-	O
10	O
)	O
.	O

Overexpression	O
is	O
observed	O
at	O
the	O
messenger	O
RNA	O
and	O
protein	O
levels	O
.	O

The	O
present	O
invention	O
includes	O
using	O
diagnostic	O
procedures	O
such	O
as	O
RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
to	O
distinguish	O
prostate	O
cancer	O
cells	O
from	O
benign	O
prostate	O
tissue	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
involves	O
RNA	O
interference	O
(	O
RNAi	O
)	O
targeted	O
to	O
a	O
region	O
of	O
CD44v7	O
-	O
10	O
and	O
to	O
Muc18	O
as	O
a	O
treatment	O
method	O
for	O
PC	O
.	O

We	O
have	O
shown	O
that	O
RNAi	O
targeted	O
to	O
CD44v7	O
-	O
10	O
and	O
to	O
Muc	O
18	O
decreased	O
invasiveness	O
of	O
two	O
PC	O
cell	O
lines	O
.	O

Therapeutic	O
methods	O
of	O
the	O
present	O
invention	O
include	O
gene	O
therapy	O
with	O
RNAi	O
,	O
antisense	O
,	O
or	O
ribozymes	O
targeted	O
against	O
CD44v7	O
-	O
10	O
or	O
Muc18	O
in	O
cancer	O
cells	O
in	O
vivo	O
.	O

Using	O
antisense	O
agents	O
to	O
prevent	O
/	O
reduce	O
cell	O
surface	O
glycoprotein	O
expression	O
and	O
treat	O
cell	O
proliferative	O
disorders	O
of	O
prostate	O
gland	O

A	O
compound	O
of	O
Formula	O

I	O
and	O
enantiomers	O
,	O
diastereomers	O
and	O
pharmaceutically	O
-	O
acceptable	O
salts	O
thereof	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
I	O
,	O
and	O
methods	O
of	O
treating	O
conditions	O
associated	O
with	O
the	O
activity	O
of	O
p38	O
kinase	O
.	O

e.g.	O
5-	B
(	I
4-Chlorophenyl	I
)	I
-N-	I
(	I
5-	I
(	I
cyclopropylcarbamoyl	I
)	I
-2-methylphenyl	I
)	I
furan-2-carboxamide	I
;	O
p38	O
alpha	O
and	O
beta	O
kinase	O
inhibitor	O
;	O
antiinflammatory	O
agent	O
;	O
asthma	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
osteoporosis	O
,	O
psoriasis	O
,	O
graft	O
vs.	O
host	O
rejection	O
,	O
atherosclerosis	O
,	O
multiple	O
myeloma	O
,	O
pain	O
,	O
myocardial	O
ischemia	O

New	O
aniline	O
or	O
phenol	O
N	O
-	O
mustards	O
linked	O
to	O
DNA	O
-	O
affinity	O
carriers	O
(	O
such	O
as	O
9-anilinoacridines	B
,	O
acridines	B
and	O
quinolines	B
)	O
,	O
aminobenzamides	B
or	O
aminophenol	B
ethers	I
by	O
a	O
urea	B
,	O
carbamic	B
acid	I
,	O
carbanic	B
acid	I
ester	I
,	O
hydrazineurea	B
,	O
hydrazinecarbamic	B
acid	I
ester	I
,	O
phenoxyurea	B
,	O
phenoxycarbamic	B
acid	I
ester	I
linkage	O
with	O
improved	O
chemical	O
stability	O
and	O
anti	O
-	O
tumor	O
therapeutic	O
efficacy	O
are	O
provided	O
.	O

e.g.	O
1-	B
[	I
3-	I
(	I
acridin-9-ylamino	I
)	I
-5-hydroxymethylphenyl	I
]	I
-3-	I
{	I
4-	I
[	I
bis	I
(	I
2-chloroethyl	I
)	I
amino	I
]	I
phenyl	I
}	I
urea	I
;	O
anticarcinogenic	O
agent	O
;	O
improved	O
chemical	O
stability	O
and	O
efficacy	O
;	O
brain	O
tumor	O
,	O
breast	O
cancer	O
,	O
colon	O
cancer	O
,	O
leukemia	O
,	O
and	O
neuroblastoma	O

Oligonucleotides	B
directed	O
against	O
the	O
Ha	O
-	O
ras	O
gene	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
Ha	O
-	O
ras	O
.	O

The	O
compositions	O
comprise	O
oligonucleotides	B
,	O
particularly	O
antisense	O
oligonucleotides	B
,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
the	O
Ha	O
-	O
ras	O
.	O

Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
Ha	O
-	O
ras	O
expression	O
and	O
for	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
either	O
overexpression	O
of	O
Ha	O
-	O
ras	O
,	O
expression	O
of	O
mutated	O
Ha	O
-	O
ras	O
or	O
both	O
are	O
provided	O
.	O

Examples	O
of	O
diseases	O
are	O
cancer	O
such	O
as	O
lung	O
,	O
breast	O
,	O
colon	O
,	O
prostate	O
,	O
pancreas	O
,	O
lung	O
,	O
liver	O
,	O
thyroid	O
,	O
kidney	O
,	O
brain	O
,	O
testes	O
,	O
stomach	O
,	O
intestine	O
,	O
bowel	O
,	O
spinal	O
cord	O
,	O
sinuses	O
,	O
bladder	O
,	O
urinary	O
tract	O
or	O
ovaries	O
cancers	O
.	O

The	O
oligonucleotides	B
may	O
be	O
composed	O
of	O
deoxyribonucleosides	O
or	O
a	O
nucleic	O
acid	O
analogue	O
such	O
as	O
for	O
example	O
locked	O
nucleic	O
acid	O
or	O
a	O
combination	O
thereof	O
.	O

Short	O
nucleotide	B
subsequences	O
located	O
within	O
number	O
15	O
;	O
such	O
as	O
locked	O
nucleic	O
acids	O
antisense	O
oligonucleotides	B
;	O
biostability	O
,	O
cell	O
permeability	O
;	O
anticancer	O
agents	O

The	O
present	O
invention	O
discloses	O
uses	O
for	O
treating	O
various	O
diseases	O
with	O
novel	O
dual	O
prodrug	O
compounds	O
of	O
Formula	O
1	O
,	O
wherein	O
A	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
single	O
bond	O
,	O
—O—	B
,	O
or	O
—CH2—	B
;	O
m	O
and	O
n	O
vary	O
independently	O
and	O
are	O
an	O
integer	O
from	O
1	O
to	O
15	O
;	O
p	O
and	O
q	O
vary	O
independently	O
from	O
0	O
to	O
1	O
;	O
B	O
is	O
—CR3R4	B
;	O
D	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
—CO2R5	B
,	O
—OR6	B
,	O
—OCOR7	B
,	O
—SO3R8	B
,	O
—SO2NH2	B
,	O
—OPO	B
(	I
OR9	I
)	I
(	I
OR10	I
)	I
,	O
—OPO	B
(	I
OR9	I
)	I
(	I
NH2	I
)	I
,	O
—OPO	B
(	I
OR9	I
)	I
—O	I
—	I
PO	I
(	I
OR10	I
)	I
(	I
OR11	I
)	I
,	O
wherein	O
R1	O
to	O
R4	O
are	O
independently	O
selected	O
from	O
C1-C6	B
alkyl	I
;	O
and	O
R5	O
to	O
R11	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
;	O
C1-C6	B
alkyl	I
;	O
C3-C6	B
cycloalkyl	I
;	O
C2-C6	B
alkenyl	I
;	O
C6	B
alkynyl	I
;	O
C5-C10	B
aryl	I
unsubstituted	O
or	O
substituted	O
with	O
C1-C6	B
alkyl	I
,	O
hydroxyl	B
,	O
C1-C6	B
alkoxyl	I
,	O
1,3-dioxolanyl	B
,	O
cyano	B
,	O
halo	B
,	O
nitro	B
,	O
trihaloalkyl	B
,	O
carboxyl	B
,	O
C1-C6	B
acyl	I
,	O
C1-C6	B
hydroxyalkyl	I
,	O
amino	B
,	O
C1-C6	B
alkylamino	I
,	O
C1-C6	B
dialkylamino	I
,	O
C1-C6	B
acylamino	I
,	O
C1-C6	B
alkoxylcarbonyl	I
;	O
C5-C6	B
arylalkyl	I
unsubstituted	O
or	O
substituted	O
with	O
C1-C6	B
alkyl	I
,	O
hydroxyl	B
,	O
C1-C6	B
alkoxyl	I
,	O
1,3-dioxolanyl	B
,	O
cyano	B
,	O
halo	B
,	O
trihaloalkyl	B
,	O
carboxyl	B
,	O
C1-C6	B
acyl	I
,	O
C1-C6	B
hydroxyalkyl	I
,	O
amino	B
,	O
C1-C6	B
alkylamino	I
,	O
C1-C6	B
dialkylamino	I
,	O
C1-C6	B
alkoxylcarbonyl	I
;	O
C1-C6	B
carboxyalkyl	I
;	O
C1-C6	B
acylamino	I
;	O
C1-C6	B
sulfonatoalkyl	I
;	O
C1-C6	B
sulfamylalkyl	I
;	O
and	O
C1-C6	B
phosphonatoalkyl	I
.	O

The	O
various	O
terms	O
in	O
Formula	O
1	O
are	O
selected	O
to	O
optimize	O
the	O
physiochemical	O
and	O
biological	O
properties	O
such	O
as	O
,	O
lipophilicity	O
,	O
bioavailability	O
,	O
and	O
pharmacokinetics	O
of	O
compounds	O
of	O
Formula	O
1	O
.	O

There	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
various	O
metabolic	O
,	O
cardiovascular	O
and	O
neurological	O
disorders	O
.	O

Improved	O
lipophilicity	O
,	O
toxicity	O
,	O
bioavailability	O
,	O
and	O
pharmacokinetics	O
;	O
for	O
treatment	O
of	O
cardiovascular	O
and	O
neurological	O
disorders	O
;	O
alzheimer	O
's	O
disease	O

Multi	O
-	O
part	O
pharmaceutical	O
formulations	O
containing	O
tetracycline	B
for	O
topical	O
administration	O
,	O
as	O
well	O
as	O
methods	O
of	O
making	O
and	O
administering	O
the	O
same	O
,	O
are	O
disclosed	O
.	O

Tetracycline	B
compositions	O
for	O
topical	O
administration	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
wherein	O
one	O
of	O
R1	O
and	O
R2	O
is	O
hydrogen	B
and	O
the	O
other	O
one	O
is	O
and	O
wherein	O
A	O
and	O
R1	O
to	O
R4	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
the	O
modulation	O
of	O
H3	O
receptors	O
.	O

e.g.	O
(	B
1-cyclopentylmethyl-1H	I
-	I
indol-5-yl	I
)	I
-	I
(	I
4-isopropyl	I
-	I
piperazin-1-yl	I
)	I
-methanone	I
;	O
antagonists	O
and/or	O
inverse	O
agonists	O
at	O
the	O
histamine	B
3	O
receptor	O
;	O
antidepressant	O
,	O
anxiolytic	O
agent	O
;	O
obesity	O
,	O
cardiovascular	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
1.0	O
)	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
such	O
compounds	O
.	O

The	O
present	O
invention	O
relates	O
to	O
chemical	O
entities	O
containing	O
a	O
nitrofuran	B
or	O
other	O
antibiotic	O
linked	O
to	O
an	O
activity	O
enhancing	O
distal	O
ring	O
system	O
either	O
directly	O
or	O
via	O
an	O
imine	B
group	O
,	O
the	O
vinyl	B
group	O
,	O
the	O
carbo-	B
or	I
hetero	I
-	I
cyclic	I
chain	I
or	I
ring	I
or	O
a	O
combination	O
of	O
an	O
imine	B
group	O
or	O
a	O
vinyl	B
group	O
and	O
a	O
carbo-	B
or	I
hetero	I
-	I
cyclic	I
chain	I
or	I
ring	I
.	O

Antibiotic	O
activity	O
is	O
obtained	O
,	O
for	O
example	O
,	O
by	O
the	O
nitrofuran	B
moiety	O
,	O
while	O
the	O
remaining	O
structure	O
of	O
the	O
molecule	O
contributes	O
to	O
additional	O
antimicrobial	O
activity	O
and/or	O
extends	O
the	O
antimicrobial	O
spectrum	O
of	O
activity	O
,	O
by	O
facilitating	O
nitroreduction	O
by	O
microorganisms	O
,	O
uptake	O
in	O
target	O
bacterial	O
,	O
and/or	O
intracellular	O
penetration	O
,	O
while	O
also	O
contributing	O
to	O
pharmacological	O
properties	O
(	O
absorption	O
,	O
body	O
distribution	O
,	O
and	O
others	O
)	O
.	O

catecholpyrazine	B
analogs	O
,	O
e.g.	O
2-	B
[	I
2-	I
(	I
5-nitro-2-furyl	I
)	I
vinyl	I
]	I
-4-	I
[	I
2-	I
(	I
3,4-dihydroxyphenyl	I
)	I
ethylamino	I
]	I
quinazoline	I
;	O
inhibitors	O
of	O
bacterial	O
lipid	O
A	O
biosynthesis	O
;	O
antibiotic	O
and	O
bactericide	O
;	O
sterilization	O
agent	O
and	O
antiseptic	O

Pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
formula	O
I	O
are	O
provided	O
:	O
wherein	O
the	O
constituent	O
variables	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compositions	O
are	O
useful	O
as	O
inhibitors	O
of	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
for	O
treating	O
conditions	O
resulting	O
from	O
fibrinolytic	O
disorders	O
,	O
such	O
as	O
deep	O
vein	O
thrombosis	O
and	O
coronary	O
heart	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
and	O
pulmonary	O
fibrosis	O
.	O

Pharmaceutical	O
compositions	O
containing	O
substituted	O
indole	B
acid	I
derivatives	O
as	O
inhibitors	O
of	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
pai-1	O
)	O

The	O
invention	O
is	O
directed	O
to	O
compositions	O
(	O
e.g.	O
,	O
feeds	O
,	O
feed	O
supplements	O
,	O
and	O
therapeutic	O
products	O
)	O
and	O
methods	O
for	O
inhibiting	O
an	O
animal	O
pathogen	O
using	O
RNA	O
-	O
interference	O
technology	O
.	O

Rna	O
-	O
Mediated	O
Interference	O
to	O
Control	O
Disease	O
in	O
Terrestrial	O
and	O
Aquaculture	O
Animals	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
and	O
preventing	O
obesity	O
and	O
obesity	O
-	O
related	O
disorders	O
in	O
a	O
subject	O
comprising	O
administering	O
a	O
neurokinin-1	O
antagonist	O
and	O
an	O
anti	O
-	O
obesity	O
agent	O
,	O
such	O
as	O
a	O
melanocortin	O
4	O
receptor	O
agonist	O
,	O
to	O
said	O
subject	O
.	O

The	O
present	O
invention	O
further	O
related	O
to	O
methods	O
of	O
treating	O
or	O
preventing	O
sexual	O
dysfunction	O
,	O
including	O
male	O
erectile	O
dysfunction	O
,	O
in	O
a	O
subject	O
comprising	O
administering	O
a	O
neurokinin-1	O
antagonist	O
and	O
a	O
sexual	O
dysfunction	O
therapeutic	O
agent	O
,	O
such	O
as	O
a	O
melanocortin	O
4	O
receptor	O
agonist	O
,	O
to	O
said	O
subject	O
.	O

The	O
present	O
invention	O
further	O
provides	O
for	O
pharmaceutical	O
compositions	O
and	O
medicaments	O
useful	O
in	O
carrying	O
out	O
these	O
methods	O
.	O

Compositions	O
and	O
Methods	O
For	O
the	O
Treatment	O
Of	O
Obesity	O
and	O
Sexual	O
Dysfunction	O

The	O
present	O
invention	O
relates	O
to	O
a	O
waterless	O
composition	O
and	O
foam	O
as	O
a	O
vehicle	O
in	O
which	O
an	O
active	O
pharmaceutical	O
or	O
cosmetic	O
agent	O
,	O
when	O
added	O
is	O
stable	O
or	O
stabilized	O
by	O
or	O
its	O
destabilization	O
is	O
impeded	O
by	O
the	O
presence	O
of	O
a	O
modulating	O
agent	O
.	O

The	O
pharmaceutical	O
or	O
cosmetic	O
composition	O
and	O
foam	O
,	O
includes	O
:	O
a	O
waterless	O
solvent	O
,	O
a	O
modulating	O
agent	O
and	O
one	O
or	O
more	O
active	O
pharmaceutical	O
or	O
cosmetic	O
agents	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
administering	O
the	O
waterless	O
composition	O
and	O
foam	O
.	O

Drug	O
mixture	O
contains	O
solvents	O
,	O
nonionic	O
surfactants	O
,	O
gelling	O
agent	O
,	O
therapeutic	O
active	O
agent	O
,	O
liquefied	O
or	O
compressed	O
gas	O
propellant	O
;	O
pressurized	O
dispenser	O
;	O
treating	O
skin	O
diseases	O
,	O
dermal	O
and	O
mucosal	O
delivery	O
;	O
stable	O
and	O
non	O
-	O
irritating	O
emulsions	O

Sustained	O
release	O
oral	O
dosage	O
forms	O
of	O
R	B
-	I
baclofen	I
and	O
methods	O
of	O
treating	O
diseases	O
comprising	O
orally	O
administering	O
such	O
dosage	O
forms	O
are	O
disclosed	O
.	O

Tablet	O
of	O
(	B
3R	I
)	I
-4-	I
{	I
[	I
(	I
1S	I
)	I
-2-methyl-1-	I
(	I
2-methylpropanoyloxy	I
)	I
propoxy	I
]	I
carbonylamino	I
}	I
-3-	I
(	I
4-chlorophenyl	I
)	I
butanoic	I
acid	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
;	O
polyvinyl	B
acetate	I
phthalate	I
release	O
rate	O
modifying	O
polymer	O
;	O
hydroxypropylmethyl	O
cellulose	O
polymer	O
;	O
neuropathies	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
2-propene-1-one	B
series	O
,	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
analogs	O
,	O
tautomeric	O
forms	O
,	O
stereoisomers	O
,	O
polymorphs	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
,	O
wherein	O
R5	O
,	O
R6	O
,	O
Q	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
preparing	O
such	O
compounds	O
,	O
compositions	O
containing	O
such	O
compounds	O
,	O
and	O
use	O
of	O
such	O
compound	O
and	O
composition	O
in	O
medicine	O
.	O

The	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
induce	O
HSP-70	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
accompanying	O
pathological	O
stress	O
in	O
a	O
living	O
mammalian	O
organism	O
,	O
including	O
a	O
human	O
being	O
,	O
such	O
as	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
inflammatory	O
disorder	O
,	O
hepatotoxicity	O
,	O
sepsis	O
,	O
diseases	O
of	O
viral	O
origin	O
,	O
allograft	O
rejection	O
,	O
tumourous	O
diseases	O
,	O
gastric	O
mucosal	O
damage	O
,	O
brain	O
haemorrhage	O
,	O
endothelial	O
dysfunctions	O
,	O
diabetic	O
complications	O
,	O
neuro	O
-	O
degenerative	O
diseases	O
,	O
post	O
-	O
traumatic	O
neuronal	O
damage	O
,	O
acute	O
renal	O
failure	O
,	O
glaucoma	O
and	O
aging	O
related	O
skin	O
degeneration	O
.	O

Stroke	O
;	O
antiinflammatory	O
agents	O
;	O
sepsis	O
;	O
allograft	O
;	O
transplant	O
rejection	O
;	O
antitumor	O
agents	O
;	O
liver	O
disorders	O
;	O
brain	O
hemorrage	O
;	O
neurodegenerative	O
diseases	O
;	O
vision	O
defects	O

Pharmaceutical	O
formulations	O
in	O
an	O
aqueous	O
gel	O
formulation	O
including	O
1-	B
(	I
2-methylpropyl	I
)	I
-1H	I
-	I
imidazo	I
[	I
4,5-c	I
]	I
[	I
1,5	I
]	I
naphthyridin-4-amine	I
are	O
provided	O
.	O

Methods	O
of	O
use	O
and	O
kits	O
are	O
also	O
provided	O
.	O

Aqueous	O
Gel	O
Formulations	O
Containing	O
1-	B
(	I
2-Methylpropyl	I
)	I
-1H	I
-	I
Imidazo	I
[	I
4,5-C	I
]	I
[	I
1,5	I
]	I
Naphthyridin-4-Amine	I

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
cancer	O
diagnosis	O
,	O
research	O
and	O
therapy	O
,	O
including	O
but	O
not	O
limited	O
to	O
,	O
cancer	O
markers	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
AGTR1	O
and	O
LBP	O
markers	O
for	O
breast	O
cancer	O
.	O

Diagnosis	O
And	O
Treatment	O
Of	O
Breast	O
Cancer	O

Exemplary	O
embodiments	O
of	O
the	O
invention	O
provide	O
a	O
dispersing	O
liquid	O
for	O
coating	O
internal	O
body	O
tissues	O
with	O
a	O
bio	O
-	O
absorbable	O
oil	O
,	O
a	O
method	O
of	O
making	O
the	O
dispersing	O
liquid	O
,	O
methods	O
of	O
using	O
the	O
dispersing	O
liquid	O
and	O
a	O
kit	O
for	O
coating	O
internal	O
body	O
tissues	O
using	O
the	O
dispersing	O
liquid	O
.	O

The	O
dispersing	O
liquid	O
includes	O
a	O
suspension	O
of	O
a	O
bio	O
-	O
absorbable	O
oil	O
suspended	O
in	O
a	O
liquid	O
carrier	O
.	O

The	O
invention	O
results	O
in	O
a	O
uniform	O
thin	O
coating	O
of	O
bio	O
-	O
absorbable	O
oil	O
on	O
internal	O
body	O
tissues	O
.	O

Dispensing	O
liquid	O
for	O
coating	O
interior	O
body	O
tissue	O
;	O
prevent	O
tissue	O
dessciation	O
during	O
surgery	O

Described	O
herein	O
are	O
synthetically	O
modified	O
fullerene	O
molecules	O
,	O
wherein	O
the	O
fullerene	O
is	O
preferably	O
ellipsoid	O
in	O
shape	O
with	O
an	O
equatorial	O
band	O
and	O
two	O
opposing	O
poles	O
,	O
comprising	O
an	O
adduct	O
at	O
one	O
or	O
both	O
poles	O
,	O
at	O
least	O
one	O
adduct	O
being	O
a	O
hydrophobic	O
chemical	O
moiety	O
capable	O
of	O
anchoring	O
the	O
fullerene	O
on	O
or	O
in	O
a	O
lipid	O
membrane	O
.	O

Amphiphilic	O
or	O
lipophilic	O
polar	O
functionalized	O
fullerenes	O
and	O
their	O
uses	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutically	O
active	O
composition	O
or	O
pharmaceutical	O
form	O
of	O
administering	O
that	O
contains	O
at	O
least	O
one	O
of	O
the	O
active	O
ingredients	O
indomethacin	B
or	O
acemetacin	B
and	O
optionally	O
other	O
adjuvants	O
,	O
the	O
composition	O
containing	O
the	O
active	O
ingredient	O
,	O
or	O
a	O
mixture	O
of	O
the	O
active	O
ingredients	O
,	O
in	O
micronized	O
form	O
,	O
preferably	O
mixed	O
with	O
at	O
least	O
one	O
flavonoid	B
derivative	O
or	O
a	O
polypeptide	O
or	O
with	O
a	O
mixture	O
of	O
such	O
compounds	O
.	O

Pharmaceutical	O
Composition	O
Containing	O
Indometacin	B
and/or	O
Acemetacin	B

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
two	O
or	O
more	O
anti	O
-	O
irritants	O
,	O
each	O
having	O
at	O
least	O
about	O
7.2	O
%	O
oxygen	B
content	O
.	O

In	O
a	O
separate	O
embodiment	O
,	O
the	O
composition	O
may	O
be	O
defined	O
to	O
include	O
a	O
skin	O
conditioning	O
agent	O
,	O
a	O
skin	O
protectant	O
agent	O
,	O
and	O
an	O
anti	O
-	O
irritant	O
agent	O
,	O
each	O
having	O
an	O
oxygen	B
content	O
of	O
at	O
least	O
about	O
7.2	O
%	O
.	O

The	O
invention	O
further	O
comprises	O
methods	O
of	O
treating	O
and	O
preventing	O
skin	O
conditions	O
by	O
applying	O
the	O
composition	O
to	O
the	O
skin	O
,	O
and	O
then	O
optionally	O
washing	O
the	O
skin	O
.	O

Triple	O
anti	O
-	O
irritant	O
composition	O

This	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
,	O
preventing	O
and/or	O
managing	O
cancer	O
in	O
a	O
subject	O
including	O
enhancing	O
the	O
efficacy	O
of	O
a	O
Vascular	O
Disrupting	O
Agent	O
(	O
e.g.	O
,	O
a	O
combretastatin	O
or	O
derivative	O
thereof	O
)	O
by	O
administering	O
to	O
the	O
subject	O
a	O
Chemokine	O
Receptor	O
Antagonist	O
(	O
e.g.	O
,	O
a	O
CXCR4	O
antagonist	O
)	O
or	O
Chemokine	O
Antagonist	O
(	O
e.g.	O
,	O
a	O
SDF-1	O
antagonist	O
)	O
sequentially	O
or	O
simultaneously	O
in	O
combination	O
with	O
said	O
Vascular	O
Disrupting	O
Agent	O
.	O

Methods	O
for	O
enhancing	O
the	O
efficacy	O
of	O
vascular	O
disrupting	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
betulinic	B
acid	I
derivatives	O
with	O
increased	O
activity	O
for	O
the	O
treatment	O
of	O
carcinomas	O
and	O
HIV	O
diseases	O
,	O
a	O
method	O
for	O
preparing	O
such	O
novel	O
betulinic	B
acid	I
derivatives	O
as	O
well	O
as	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

Methods	O
and	O
compositions	O
for	O
inhibiting	O
tumor	O
growth	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
predicting	O
or	O
designing	O
,	O
detecting	O
,	O
and/or	O
verifying	O
a	O
novel	O
cell	O
-	O
penetrating	O
peptide	O
(	O
CPP	O
)	O
and	O
to	O
a	O
method	O
for	O
using	O
said	O
new	O
CPP	O
and/or	O
a	O
novel	O
usage	O
of	O
a	O
known	O
CPP	O
for	O
an	O
improved	O
cellular	O
uptake	O
of	O
a	O
cellular	O
effector	O
,	O
coupled	O
to	O
said	O
CPP	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
predicting	O
or	O
designing	O
,	O
detecting	O
and/or	O
verifying	O
a	O
novel	O
cell	O
-	O
penetrating	O
peptide	O
(	O
CPP	O
)	O
that	O
mimics	O
cellular	O
effector	O
activity	O
and/or	O
inhibits	O
cellular	O
effector	O
activity	O
.	O

The	O
present	O
invention	O
additionally	O
relates	O
to	O
the	O
use	O
of	O
said	O
CPP	O
for	O
treating	O
and/or	O
preventing	O
a	O
medical	O
condition	O
and	O
to	O
the	O
use	O
of	O
said	O
CPP	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
a	O
medical	O
condition	O
.	O

Predicting	O
or	O
designing	O
,	O
detecting	O
,	O
and/or	O
verifying	O
a	O
novel	O
cell	O
-	O
penetrating	O
peptide	O
that	O
mimics	O
cellular	O
effector	O
activity	O
;	O
vectors	O
;	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
,	O
diabetes	O
type	O
I	O
and	O
II	O
,	O
Alzheimer	O
's	O
Disease	O
,	O
Parkinson	O
's	O
Disease	O
,	O
and	O
cancer	O
.	O

The	O
present	O
invention	O
relates	O
to	O
therapeutic	O
,	O
cosmetic	O
,	O
and	O
nutraceutical	O
applications	O
for	O
eggshell	O
membrane	O
,	O
processed	O
eggshell	O
membrane	O
preparations	O
and	O
eggshell	O
membrane	O
isolates	O
.	O

The	O
invention	O
is	O
directed	O
to	O
treating	O
a	O
mammal	O
that	O
will	O
benefit	O
from	O
the	O
administration	O
of	O
naturally	O
occurring	O
material	O
found	O
in	O
eggshell	O
membrane	O
,	O
processed	O
eggshell	O
membrane	O
,	O
eggshell	O
membrane	O
isolates	O
and	O
combinations	O
thereof	O
by	O
administering	O
to	O
the	O
mammal	O
a	O
composition	O
containing	O
eggshell	O
membrane	O
,	O
processed	O
eggshell	O
membrane	O
,	O
eggshell	O
membrane	O
isolates	O
and	O
combinations	O
thereof	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
active	O
ingredients	O
.	O

Therapeutic	O
,	O
nutraceutical	O
and	O
cosmetic	O
applications	O
for	O
eggshell	O
membrane	O
and	O
processed	O
eggshell	O
membrane	O
preparations	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R	O
,	O
X	O
,	O
X′	O
and	O
R2	O
,	O
R2′	O
,	O
R2″	O
,	O
R3″	O
,	O
R2″″	O
and	O
R7	O
have	O
the	O
meanings	O
indicated	O
in	O
claim	O
1	O
,	O
are	O
inhibitors	O
of	O
CHK1	O
CHK2	O
and	O
SGK	O
kinases	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Squaric	B
Acid	I
Derivatives	O
II	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
delivery	O
device	O
for	O
providing	O
local	O
analgesia	O
,	O
local	O
anesthesia	O
or	O
nerve	O
blockade	O
at	O
a	O
site	O
in	O
a	O
human	O
or	O
animal	O
in	O
need	O
thereof	O
,	O
the	O
device	O
comprising	O
a	O
fibrillar	O
collagen	O
matrix	O
;	O
and	O
at	O
least	O
one	O
drug	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
amino	B
amide	I
anesthetics	O
,	O
amino	O
ester	O
anesthetics	O
and	O
mixtures	O
thereof	O
,	O
the	O
at	O
least	O
one	O
drug	O
substance	O
being	O
substantially	O
homogeneously	O
dispersed	O
in	O
the	O
collagen	O
matrix	O
,	O
and	O
the	O
at	O
least	O
one	O
drug	O
substance	O
being	O
present	O
in	O
an	O
amount	O
sufficient	O
to	O
provide	O
a	O
duration	O
of	O
local	O
analgesia	O
,	O
local	O
anesthesia	O
or	O
nerve	O
blockade	O
which	O
lasts	O
for	O
at	O
least	O
about	O
one	O
day	O
after	O
administration	O
.	O

Biodegradable	O
,	O
disposable	O
fibrillar	O
collagen	O
matrix	O
;	O
such	O
as	O
bupivacaine	B
contained	O
in	O
sponge	O
;	O
extended	O
time	O
postoperative	O
pain	O
management	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
selected	O
from	O
substituted	O
oxazole	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
that	O
selectively	O
modulate	O
,	O
regulate	O
,	O
and/or	O
inhibit	O
signal	O
transduction	O
mediated	O
by	O
certain	O
native	O
and/or	O
mutant	O
tyrosine	B
kinases	O
implicated	O
in	O
a	O
variety	O
of	O
human	O
and	O
animal	O
diseases	O
such	O
as	O
cell	O
proliferative	O
,	O
metabolic	O
,	O
allergic	O
,	O
and	O
degenerative	O
disorders	O
.	O

More	O
particularly	O
,	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
c	O
-	O
kit	O
,	O
bcr	O
-	O
abl	O
and	O
Fit-3	O
inhibitors	O
.	O

selectively	O
modulate	O
,	O
regulate	O
,	O
and/or	O
inhibit	O
signal	O
transduction	O
;	O
potent	O
and	O
selective	O
c	O
-	O
kit	O
,	O
bcr	O
-	O
abl	O
and	O
Fit-3	O
inhibitors	O
;	O
diseases	O
like	O
cell	O
proliferation	O
,	O
metabolic	O
,	O
allergic	O
,	O
cancers	O
,	O
degenerative	O
,	O
autoimmune	O
disorders	O
;	O
4-	B
{	I
2-	I
[	I
5-	I
(	I
Benzothiazol-2-ylammo	I
)	I
-2-methyl	I
-	I
phenylamino	I
]	I
-oxazol-5-yl	I
}	I
-benzonitrile	I

The	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
fluridone	O
—	O
compound	O
known	O
per	O
se	O
and	O
used	O
as	O
an	O
aquatic	O
erbicide	O
—	O
in	O
the	O
medical	O
field	O
,	O
in	O
particular	O
as	O
an	O
active	O
compound	O
for	O
preparing	O
a	O
medicament	O
having	O
anti	O
-	O
inflammatory	O
activity	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
fluridone	O
as	O
an	O
active	O
compound	O
and	O
pharmaceutically	O
acceptable	O
carriers	O
and/or	O
diluents	O
are	O
also	O
disclosed	O
.	O

Finally	O
,	O
there	O
is	O
disclosed	O
the	O
pro	O
-	O
inflammatory	O
activity	O
of	O
abscisic	O
acid	O
(	O
ABA	O
)	O
,	O
a	O
plant	O
hormone	O
which	O
is	O
also	O
found	O
in	O
mammal	O
serum	O
and	O
against	O
which	O
fluridone	O
acts	O
an	O
inhibitor	O
.	O

Fluridone	O
as	O
an	O
Anti	O
-	O
Inflammatory	O
Agent	O

The	O
invention	O
relates	O
to	O
novel	O
heparanases	O
,	O
heparanase	O
splice	O
variants	O
,	O
and	O
to	O
polynucleotides	O
encoding	O
them	O
.	O

Particularly	O
,	O
the	O
invention	O
relates	O
to	O
Spalax	O
heparanases	O
,	O
and	O
to	O
Spalax	O
and	O
human	O
heparanase	O
splice	O
variants	O
.	O

Heparanase	O
splice	O
variants	O
can	O
be	O
used	O
,	O
for	O
example	O
,	O
to	O
modulate	O
the	O
activity	O
of	O
heparanase	O
in	O
diseases	O
disorders	O
or	O
conditions	O
caused	O
by	O
or	O
associated	O
with	O
the	O
enzymatic	O
activity	O
of	O
heparanase	O
.	O

For	O
instance	O
,	O
a	O
splice	O
variant	O
capable	O
of	O
down	O
regulating	O
the	O
activity	O
of	O
heparanase	O
can	O
be	O
used	O
to	O
treat	O
primary	O
tumors	O
and/or	O
to	O
prevent	O
or	O
treat	O
metastasis	O
.	O

Variant	O
lyase	O
for	O
use	O
in	O
treatment	O
and	O
prevention	O
of	O
cell	O
proliferative	O
disorders	O

This	O
invention	O
relates	O
to	O
a	O
combination	O
product	O
or	O
medicament	O
comprising	O
at	O
least	O
one	O
novel	O
substituted	O
pyrrole	B
derivative	O
and	O
one	O
or	O
more	O
dyslipidemic	O
agents	O
,	O
antiobesity	O
agents	O
,	O
antihyperglycaemic	O
agents	O
,	O
anti	O
-	O
inflammatory	O
agents	O
or	O
mixture	O
thereof	O
.	O

Also	O
provided	O
herein	O
are	O
the	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
novel	O
substituted	O
pyrrole	B
derivative	O
and	O
one	O
or	O
more	O
dyslipidemic	O
agents	O
,	O
antiobesity	O
agents	O
,	O
antihyperglycaemic	O
agents	O
,	O
anti	O
-	O
inflammatory	O
agents	O
or	O
mixture	O
thereof	O
and	O
optionally	O
together	O
with	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
and	O
methods	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
cardiovascular	O
diseases	O
,	O
Alzheimer	O
's	O
disease	O
,	O
obesity	O
,	O
diabetes	O
or	O
inflammatory	O
diseases	O
comprising	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
therapeutically	O
effective	O
amounts	O
of	O
combination	O
pharmaceutical	O
composition	O
comprising	O
at	O
least	O
one	O
novel	O
substituted	O
pyrrole	B
derivative	O
and	O
one	O
or	O
more	O
dyslipidemic	O
agents	O
,	O
antiobesity	O
agents	O
,	O
antihyperglycaemic	O
agents	O
,	O
anti	O
-	O
inflammatory	O
agents	O
or	O
mixtures	O
thereof	O
.	O

Pyrrole	B
derivatives	O
,	O
dyslipidemic	O
agents	O
(	O
cholesteryl	O
ester	O
transfer	O
protein	O
inhibitors	O
)	O
,	O
antiobesity	O
agents	O
(	O
serontonin	B
receptor	O
inhibitors	O
)	O
,	O
antihyperglycemic	O
agents	O
(	O
insulin	O
sensitizing	O
agents	O
/	O
PPAR	O
agonists	O
)	O
,	O
anti	O
-	O
inflammatory	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
producing	O
a	O
pharmaceutical	O
composition	O
which	O
can	O
stably	O
contain	O
an	O
active	O
ingredient	O
unstable	O
against	O
water	O
and	O
can	O
sustained	O
-	O
release	O
such	O
the	O
active	O
ingredient	O
for	O
a	O
long	O
period	O
of	O
time	O
by	O
remaining	O
at	O
an	O
administrated	O
portion	O
as	O
well	O
as	O
a	O
pharmaceutical	O
composition	O
produced	O
by	O
the	O
same	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
producing	O
a	O
pharmaceutical	O
composition	O
,	O
comprising	O
steps	O
of	O
:	O
mixing	O
and	O
heating	O
a	O
first	O
phase	O
,	O
prepared	O
by	O
mixing	O
a	O
polyhydric	B
alcohol	I
and	O
a	O
salt	O
,	O
and	O
a	O
second	O
phase	O
containing	O
a	O
water	O
-	O
soluble	O
polymer	O
under	O
a	O
reduced	O
pressure	O
,	O
before	O
evaporating	O
substantially	O
all	O
water	O
in	O
the	O
first	O
phase	O
by	O
mixing	O
and	O
heating	O
a	O
mixture	O
of	O
first	O
and	O
second	O
phases	O
under	O
a	O
reduced	O
pressure	O
or	O
after	O
evaporating	O
substantially	O
all	O
water	O
in	O
the	O
first	O
phase	O
by	O
mixing	O
and	O
heating	O
the	O
first	O
phase	O
under	O
a	O
reduced	O
pressure	O
;	O
and	O
adding	O
a	O
third	O
phase	O
containing	O
an	O
active	O
ingredient	O
unstable	O
against	O
water	O
and	O
mixing	O
them	O
to	O
obtain	O
the	O
pharmaceutical	O
composition	O
,	O
as	O
well	O
as	O
a	O
pharmaceutical	O
composition	O
produced	O
the	O
same	O
.	O

Process	O
for	O
producing	O
pharmaceutical	O
composition	O

A	O
composition	O
for	O
hyperuricemia	O
disease	O
or	O
a	O
related	O
disorder	O
,	O
use	O
thereof	O
and	O
method	O
of	O
using	O
thereof	O
are	O
provided	O
.	O

Pharmaceutical	O
composition	O
for	O
gout	O

The	O
invention	O
is	O
based	O
on	O
the	O
discovery	O
that	O
the	O
human	O
protein	O
referred	O
to	O
herein	O
as	O
INSP181	O
protein	O
is	O
a	O
lipocalin	O
.	O

Expression	O
vector	O
comprising	O
lipocalin	O
gene	O
sequences	O
for	O
use	O
in	O
prevention	O
and	O
treatment	O
of	O
cell	O
proliferative	O
,	O
inflammatory	O
,	O
autoimmune	O
and	O
cardiovascular	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
Pirlindole	B
,	O
if	O
needed	O
with	O
suitable	O
adjuvants	O
and	O
additives	O
for	O
the	O
production	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
hyperproliferation	O
of	O
keratinocytes	O
and/or	O
T	O
cells	O
,	O
in	O
particular	O
psoriasis	O
and	O
neurodermatitis	O
as	O
well	O
as	O
compositions	O
comprising	O
Pirlindole	B
and	O
use	O
thereof	O
.	O

Using	O
antidepressant	O
drug	O
2,3,3a,4,5,6-hexahydro-8-methyl-1H	B
-	I
pyrazino	I
[	I
3,2,1-jk	I
]	I
carbazole	I
(	O
pirlindole	B
)	O
in	O
combination	O
with	O
other	O
active	O
agents	O
;	O
topical	O
delivery	O

The	O
invention	O
relates	O
to	O
the	O
delta	O
and	O
epsilon	O
crystal	O
form	O
of	O
the	O
methanesulfonic	B
acid	I
addition	O
salt	O
of	O
4-	B
(	I
4-methylpiperazin-1-ylmethyl	I
)	I
-N-	I
[	I
4-methyl-3-	I
(	I
4-	I
(	I
pyridin-3-yl	I
)	I
pyrimidin-2-ylamino	I
)	I
phenyl	I
]	I
-benzamide	I
(	O
the	O
compound	O
of	O
formula	O
I	O
,	O
see	O
below	O
)	O
,	O
certain	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
crystal	O
forms	O
,	O
and	O
their	O
use	O
in	O
diagnostic	O
methods	O
or	O
for	O
the	O
therapeutic	O
treatment	O
of	O
warm	O
-	O
blooded	O
animals	O
,	O
and	O
their	O
use	O
as	O
an	O
intermediate	O
or	O
for	O
the	O
preparation	O
of	O
pharmaceutical	O
preparations	O
for	O
use	O
in	O
diagnostic	O
methods	O
or	O
for	O
the	O
therapeutic	O
treatment	O
of	O
warm	O
-	O
blooded	O
animals	O
,	O
especially	O
humans	O
.	O

Delta	O
and	O
Epsilon	O
Crystal	O
Forms	O
of	O
Imatinib	B
Mesylate	I

A	O
method	O
of	O
clotting	O
blood	O
includes	O
the	O
step	O
of	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
zeolite	B
as	O
the	O
active	O
ingredient	O
to	O
a	O
wound	O
from	O
which	O
the	O
blood	O
emanates	O
.	O

A	O
method	O
of	O
arresting	O
blood	O
flowing	O
from	O
a	O
wound	O
includes	O
the	O
steps	O
of	O
providing	O
a	O
patient	O
being	O
inflicted	O
with	O
a	O
bleeding	O
wound	O
and	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
zeolite	B
as	O
the	O
active	O
ingredient	O
to	O
the	O
bleeding	O
wound	O
.	O

A	O
method	O
of	O
facilitating	O
the	O
formation	O
of	O
blood	O
clots	O
includes	O
the	O
step	O
of	O
contacting	O
blood	O
with	O
a	O
negatively	O
charged	O
surface	O
wherein	O
upon	O
contacting	O
the	O
blood	O
with	O
the	O
negatively	O
charged	O
surface	O
a	O
clotting	O
mechanism	O
is	O
initiated	O
.	O

In	O
any	O
of	O
the	O
foregoing	O
methods	O
,	O
the	O
blood	O
has	O
a	O
compromised	O
ability	O
to	O
form	O
clots	O
.	O

The	O
blood	O
may	O
be	O
from	O
a	O
person	O
diagnosed	O
with	O
hemophilia	O
or	O
von	O
Willebrand	O
disease	O
.	O

Method	O
of	O
providing	O
hemostasis	O
in	O
anti	O
-	O
coagulated	O
blood	O

Disclosed	O
herein	O
are	O
substituted	O
pyrimidine	B
-	O
based	O
endothelin	O
modulators	O
of	O
Formula	O
I	O
,	O
processes	O
of	O
preparation	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Substituted	O
thiophenes	B

The	O
present	O
invention	O
relates	O
to	O
the	O
a	O
method	O
of	O
inhibiting	O
bone	O
resorption	O
in	O
a	O
mammal	O
in	O
need	O
thereof	O
with	O
an	O
oral	O
pharmaceutical	O
composition	O
comprising	O
a	O
cathepsin	O
K	O
inhibitor	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
mixture	O
thereof	O
,	O
according	O
to	O
a	O
continuous	O
schedule	O
having	O
a	O
dosage	O
interval	O
of	O
once	O
weekly	O
,	O
biweekly	O
,	O
twice	O
monthly	O
or	O
once	O
monthly	O
.	O

Composition	O
for	O
Inhibition	O
of	O
Cathepsin	O
K	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
dithiocarbamate	B
derivatives	O
for	O
the	O
therapeutic	O
or	O
prophylactic	O
treatment	O
of	O
infectious	O
diseases	O
in	O
mammals	O
(	O
humans	O
and	O
animals	O
)	O
caused	O
by	O
bacteria	O
,	O
especially	O
diseases	O
like	O
tuberculosis	O
(	O
TB	O
)	O
and	O
lepra	O
caused	O
by	O
mycobacteria	O
and	O
infectious	O
diseases	O
caused	O
by	O
staphylococci	O
.	O

The	O
invention	O
further	O
relates	O
to	O
novel	O
dithiocarbamate	B
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
is	O
a	O
bivalent	O
residue	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
formulae	O
having	O
excellent	O
antibacterial	O
activities	O
,	O
and	O
to	O
pharmaceutical	O
preparations	O
containing	O
the	O
same	O
.	O

E.g.	O
,	O
5-dinitro-2-dimethyldithio	B
-	I
carbamoyl	I
-	I
pyridine	I
;	O
strong	O
bacteriacidal	O
activity	O
,	O
especially	O
against	O
mycobacteria	O
;	O
tuberculosis	O
and	O
leprosy	O
caused	O
by	O
mycobacteria	O
and	O
infectious	O
diseases	O
caused	O
by	O
staphylococci	O
;	O
side	O
effect	O
reductions	O
;	O
effective	O
against	O
drug	O
,	O
multidrug	O
-	O
resistant	O
infections	O

Compounds	O
and	O
compositions	O
useful	O
in	O
methods	O
for	O
treating	O
cancer	O
in	O
mammals	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
of	O
the	O
formula	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
entantiomer	O
or	O
disastereomer	O
thereof	O
,	O
wherein	O
the	O
""""	O
A	O
""""	O
ring	O
is	O
a	O
nitrogen	B
-	O
aryl	B
group	O
;	O
each	O
occurrence	O
of	O
Y	O
is	O
independently	O
oxygen	B
or	O
H2	B
;	O
Z	O
is	O
oxygen	B
or	O
—CH2—	B
;	O
X	O
is	O
nitrogen	B
or	O
—CH	B
;	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
and	O
R7	O
are	O
subsitutents	O
;	O
n	O
is	O
an	O
integer	O
from	O
1	O
-	O
7	O
;	O
m	O
is	O
an	O
integer	O
having	O
a	O
value	O
of	O
1	O
-	O
5	O
;	O
and	O
the	O
dotted	O
line	O
represents	O
an	O
optional	O
bond	O
.	O

4-Ethyl-4-	B
(	I
1,4-dioxo-3-azahept-5-enoxy-	I
)	I
,9-desamino	I
-	I
camptothecin	I
where	O
the	O
9-amino	B
may	O
be	O
present	O
as	O
dimethylamino	B
with	O
an	O
alkyl	B
sulfo	I
group	O
on	O
carbon	B
#	O
8	O
;	O
Camptothecin	B
derivatives	O
having	O
greater	O
biological	O
activity	O
/	O
enhanced	O
stability	O
,	O
topoisomerase	O
I	O
inhibitors	O
;	O
side	O
effect	O
reductions	O
;	O
antitumor	O
agents	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
psoriasis	O
and	O
psoriatic	O
-	O
related	O
skin	O
conditions	O
via	O
administration	O
of	O
a	O
cannabinoid	B
agonist	O
,	O
especially	O
nabinone	B
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
agents	O
that	O
possess	O
anti	O
-	O
psoriatic	O
pharmacological	O
activity	O
.	O

Administering	O
a	O
cannabinoid	B
agonist	O

The	O
present	O
invention	O
relates	O
to	O
a	O
disposable	O
article	O
to	O
prevent	O
the	O
misuse	O
of	O
a	O
transdermal	O
dosage	O
form	O
(	O
FIG	O
.	O

1	O
(	O
a	O
)	O
)	O
.	O

The	O
article	O
is	O
comprised	O
of	O
an	O
outer	O
layer	O
(	O
1	O
)	O
having	O
an	O
inner	O
layer	O
-	O
facing	O
side	O
and	O
an	O
opposite	O
side	O
;	O
an	O
inner	O
layer	O
(	O
3	O
)	O
having	O
an	O
outer	O
layer	O
-	O
facing	O
side	O
and	O
an	O
opposite	O
side	O
,	O
the	O
inner	O
layer	O
(	O
3	O
)	O
joined	O
to	O
the	O
outer	O
layer	O
(	O
1	O
)	O
to	O
form	O
one	O
or	O
more	O
closed	O
material	O
reservoir	O
(	O
2	O
)	O
between	O
the	O
outer	O
layer	O
-	O
facing	O
side	O
of	O
the	O
inner	O
layer	O
(	O
2	O
)	O
and	O
the	O
inner	O
layer	O
-	O
facing	O
side	O
of	O
the	O
outer	O
layer	O
(	O
1	O
)	O
;	O
and	O
adhesive	O
(	O
4	O
)	O
covering	O
a	O
first	O
portion	O
of	O
the	O
opposite	O
side	O
of	O
the	O
inner	O
layer	O
(	O
3	O
)	O
,	O
wherein	O
the	O
adhesive	O
(	O
4	O
)	O
is	O
a	O
heat	O
activated	O
adhesive	O
that	O
changes	O
color	O
and/or	O
is	O
activated	O
when	O
the	O
article	O
is	O
subjected	O
to	O
elevated	O
temperatures	O
,	O
thereby	O
sealing	O
the	O
transdermal	O
dosage	O
form	O
within	O
the	O
article	O
.	O

Disposable	O
products	O
;	O
multilayer	O
;	O
interior	O
and	O
exterior	O
layers	O
forming	O
reservoirs	O
;	O
heat	O
activated	O
adhesives	O
;	O
sealing	O
;	O
colorimetric	O
analysis	O

An	O
artificial	O
physiological	O
salt	O
solution	O
,	O
wherein	O
the	O
active	O
hydrogen	B
reaction	O
value	O
is	O
0.01	O
to	O
1	O
,	O
the	O
pH	O
is	O
4.0	O
to	O
7.9	O
and	O
the	O
osmotic	O
pressure	O
is	O
260	O
mOsm	O
/	O
L	O
to	O
2560	O
mOsm	O
/	O
L	O
,	O
as	O
well	O
as	O
a	O
manufacturing	O
method	O
for	O
the	O
same	O
are	O
provided	O
as	O
a	O
novel	O
artificial	O
physiological	O
salt	O
solution	O
,	O
which	O
has	O
active	O
oxygen	B
eliminating	O
activity	O
and	O
anti	O
-	O
inflammation	O
effects	O
,	O
and	O
can	O
be	O
appropriately	O
used	O
in	O
a	O
multitude	O
of	O
applications	O
such	O
as	O
organ	O
cleaning	O
solutions	O
(	O
cleaning	O
solutions	O
for	O
the	O
eyes	O
,	O
cleaning	O
solutions	O
for	O
the	O
nose	O
and	O
the	O
like	O
)	O
,	O
artificial	O
infusions	O
,	O
artificial	O
amniotic	O
fluid	O
,	O
protective	O
solutions	O
,	O
cell	O
/	O
tissue	O
cultures	O
and	O
the	O
like	O
,	O
as	O
well	O
as	O
a	O
manufacturing	O
method	O
for	O
the	O
same	O
.	O

Artificial	O
physiological	O
salt	O
solution	O
and	O
manufacturing	O
method	O
for	O
same	O

A	O
treatment	O
method	O
for	O
restoring	O
of	O
age	O
related	O
tissue	O
loss	O
in	O
the	O
face	O
or	O
selected	O
areas	O
of	O
the	O
body	O
is	O
disclosed	O
which	O
includes	O
injecting	O
an	O
injectable	O
composition	O
containing	O
a	O
growth	O
factor	O
and	O
hyaluronic	B
acid	I
as	O
a	O
carrier	O
into	O
the	O
dermis	O
,	O
the	O
hypodermis	O
,	O
or	O
both	O
,	O
in	O
various	O
areas	O
of	O
the	O
face	O
,	O
or	O
selected	O
areas	O
of	O
the	O
body	O
of	O
a	O
person	O
to	O
stimulate	O
collagen	O
,	O
elastin	O
,	O
or	O
fat	O
cell	O
production	O
,	O
thereby	O
restoring	O
age	O
related	O
tissue	O
loss	O
in	O
the	O
face	O
and	O
selected	O
areas	O
of	O
the	O
body	O
.	O

Further	O
disclosed	O
is	O
an	O
injectable	O
composition	O
for	O
restoring	O
of	O
age	O
related	O
tissue	O
loss	O
in	O
the	O
face	O
and	O
selected	O
areas	O
of	O
the	O
body	O
,	O
which	O
contains	O
a	O
growth	O
factor	O
and	O
hyaluronic	B
acid	I
as	O
a	O
carrier	O
for	O
providing	O
time	O
release	O
of	O
the	O
growth	O
factor	O
into	O
tissues	O
.	O

The	O
growth	O
factor	O
can	O
be	O
insulin	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
,	O
thyroid	O
hormone	O
,	O
fibroblast	O
growth	O
factor	O
,	O
estrogen	B
,	O
retinoic	B
acid	I
,	O
or	O
their	O
combinations	O
.	O

Method	O
and	O
composition	O
for	O
restoration	O
of	O
age	O
related	O
tissue	O
loss	O
in	O
the	O
face	O
or	O
selected	O
areas	O
of	O
the	O
body	O

A	O
method	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
Flaviviridae	O
infections	O
,	O
in	O
particular	O
,	O
hepatitis	O
C	O
virus	O
infection	O
,	O
in	O
a	O
host	O
,	O
and	O
in	O
particular	O
,	O
a	O
human	O
,	O
is	O
provided	O
that	O
includes	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
β	B
-	I
L-	I
or	I
β	I
-	I
D-2′,3′-dideoxynucleoside	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
,	O
optionally	O
in	O
a	O
pharmaceutically	O
acceptable	O
diluent	O
or	O
excipient	O
.	O

2	B
'	I
,	I
3'-dideoxynucleoside	I
analogues	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
flaviviridae	O
infections	O

The	O
present	O
invention	O
is	O
related	O
to	O
the	O
G	O
-	O
protein	O
coupled	O
orphan	O
receptor	O
GPR43	O
and	O
the	O
identification	O
of	O
short	O
chain	O
fatty	O
acids	O
as	O
natural	O
ligands	O
of	O
the	O
receptor	O
.	O

The	O
invention	O
further	O
relates	O
to	O
assays	O
for	O
the	O
identification	O
of	O
agents	O
that	O
modulate	O
GPR43	O
ligand	O
binding	O
and	O
signalling	O
activity	O
,	O
as	O
well	O
as	O
compositions	O
consisting	O
essentially	O
of	O
an	O
isolated	O
GPR43	O
polypeptide	O
and	O
an	O
isolated	O
short	O
chain	O
fatty	B
acid	I
.	O

The	O
invention	O
also	O
relates	O
to	O
diagnostic	O
methods	O
and	O
kits	O
that	O
take	O
advantage	O
of	O
the	O
novel	O
interaction	O
of	O
GPR43	O
with	O
short	O
chain	O
fatty	B
acids	I
.	O

Ligand	O
for	O
G	O
-	O
protein	O
coupled	O
receptor	O
GPR43	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
for	O
reducing	O
the	O
emetogenic	O
effects	O
of	O
PDE	O
inhibitors	O
,	O
and	O
more	O
particularly	O
is	O
directed	O
to	O
compounds	O
having	O
PDE4	O
inhibition	O
activity	O
with	O
little	O
or	O
no	O
emetogenic	O
side	O
-	O
effects	O
,	O
and	O
chemical	O
methods	O
including	O
benzylation	O
for	O
preparing	O
such	O
compounds	O
.	O

A	O
benzyl	B
group	O
may	O
be	O
attached	O
to	O
either	O
a	O
carbon	B
or	O
nitrogen	B
atom	O
of	O
a	O
PDE4	O
inhibitor	O
.	O

Suitable	O
benzylation	O
chemistry	O
is	O
to	O
extract	O
a	O
hydrogen	B
from	O
a	O
PDE4	O
inhibitor	O
,	O
preferably	O
with	O
a	O
base	O
,	O
and	O
then	O
react	O
the	O
resulting	O
nucleophilic	O
PDE4	O
inhibitor	O
with	O
a	O
benzylating	O
agent	O
,	O
e.g.	O
,	O
benzyl	B
bromide	I
or	O
a	O
derivative	O
thereof	O
.	O

reduced	O
or	O
no	O
emetogenic	O
effects	O
;	O
benzylated	O
phosphodiesterase	O
4	O
inhibitors	O
;	O
e.g.	O
Rolipram	B
,	O
Ariflo	B
,	O
Arofylline	B
;	O
preparation	O
by	O
benzylation	O
using	O
benzyl	B
bromide	I
or	O
a	O
derivative	O
;	O
antiinflammatory	O
agents	O
;	O
to	O
treat	O
autoimmune	O
diseases	O
;	O
cystic	O
fibrosis	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compositions	O
comprising	O
clomiphene	B
isomers	O
for	O
controlling	O
rodent	O
populations	O
.	O

The	O
clomiphene	B
isomers	O
lower	O
testosterone	B
and/or	O
suppress	O
appetite	O
in	O
the	O
rodent	O
population	O
.	O

Methods	O
and	O
materials	O
for	O
controlling	O
rodent	O
populations	O

Human	O
parvovirus	O
,	O
genus	O
Bocavirus	O
,	O
associated	O
with	O
respiratory	O
tract	O
infections	O
in	O
children	O
.	O

Nucleic	O
acid	O
and	O
polypeptide	O
sequences	O
of	O
the	O
virus	O
.	O

Methods	O
and	O
products	O
for	O
diagnosing	O
presence	O
of	O
bocavirus	O
in	O
a	O
sample	O
using	O
nucleic	O
acid	O
probes	O
or	O
primers	O
,	O
or	O
specific	O
binding	O
members	O
such	O
as	O
antibodies	O
.	O

Methods	O
and	O
products	O
for	O
diagnosing	O
past	O
or	O
present	O
infection	O
of	O
bocavirus	O
in	O
an	O
individual	O
e.g.	O
by	O
serology	O
testing	O
.	O

Viral	O
nucleic	O
acid	O
,	O
polypeptide	O
and/or	O
viral	O
particles	O
for	O
generating	O
immune	O
response	O
in	O
an	O
individual	O
,	O
including	O
vaccine	O
compositions	O
.	O

Human	O
Bocavirus	O
and	O
Methods	O
of	O
Diagnosis	O
and	O
Treatment	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
inducing	O
ovulation	O
in	O
a	O
female	O
host	O
comprising	O
the	O
administration	O
of	O
a	O
non	O
-	O
polypeptide	O
cyclic	B
adenosine	I
monophosphate	I
(	O
cAMP	O
)	O
level	O
modulator	O
to	O
the	O
female	O
host	O
.	O

In	O
another	O
aspect	O
,	O
the	O
invention	O
provides	O
for	O
specific	O
administration	O
of	O
the	O
phosphodiesterase	O
inhibitor	O
prior	O
to	O
the	O
luteal	O
phase	O
of	O
the	O
host	O
's	O
ovulatory	O
cycle	O
.	O

Preferred	O
non	O
-	O
polypeptide	O
cAMP	O
level	O
modulators	O
include	O
phosphodiesterase	O
inhibitors	O
,	O
particularly	O
inhibitors	O
of	O
phosphodiesterase	O
4	O
isoforms	O
.	O

Methods	O
of	O
inducing	O
ovulation	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
chemical	O
compounds	O
,	O
methods	O
for	O
their	O
discovery	O
,	O
and	O
their	O
therapeutic	O
use	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
benzodiazepine	B
derivatives	O
and	O
methods	O
of	O
using	O
benzodiazepine	B
derivatives	O
as	O
therapeutic	O
agents	O
to	O
treat	O
a	O
number	O
of	O
conditions	O
associated	O
with	O
the	O
faulty	O
regulation	O
of	O
the	O
processes	O
of	O
programmed	O
cell	O
death	O
,	O
autoimmunity	O
,	O
inflammation	O
,	O
and	O
hyperproliferation	O
,	O
and	O
the	O
like	O
.	O

Compositions	O
and	O
Methods	O
Relating	O
to	O
Novel	O
Compounds	O
and	O
Targets	O
Thereof	O

A	O
pharmaceutical	O
formulation	O
,	O
comprising	O
:	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
a	O
tautomer	O
of	O
the	O
compound	O
,	O
a	O
salt	O
of	O
the	O
compound	O
,	O
a	O
salt	O
of	O
the	O
tautomer	O
,	O
or	O
a	O
mixture	O
thereof	O
and	O
at	O
least	O
one	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	O
i	O
)	O
cellulose	O
;	O
(	O
ii	O
)	O
silicon	B
dioxide	I
;	O
(	O
iii	O
)	O
magnesium	B
stearate	I
;	O
and	O
(	O
iv	O
)	O
an	O
ingredient	O
selected	O
from	O
crospovidone	O
,	O
starch	O
,	O
or	O
lactose	O
.	O

Formulation	O
of	O
Quinolinones	B

Pyrrolidine	B
(	I
thi	I
)	I
one	I
compounds	O
substituted	O
by	O
heterocyclic	B
substituents	O
in	O
the	O
3-position	O
,	O
their	O
preparation	O
and	O
use	O
in	O
pharmaceutical	O
compositions	O
,	O
in	O
particular	O
as	O
immunomodulators	O
for	O
treatment	O
and/or	O
inhibition	O
of	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
haematological	O
-	O
oncological	O
diseases	O
.	O

Pyrrolidine	B
(	I
thi	I
)	I
ones	I
Substituted	O
by	O
Heterocyclic	B
Substituents	O
in	O
The	O
3-Position	O

A	O
composition	O
comprises	O
a	O
solid	O
amorphous	O
dispersion	O
comprising	O
(	B
S	I
)	I
—N-	I
{	I
2-	I
[	I
benzyl	I
(	I
methyl	I
)	I
amino	I
]	I
-2-oxo-1-phenylethyl	I
}	I
-methyl-5-	I
[	I
4′-	I
(	I
trifluoromethyl	I
)	I
[	I
1,1′-biphenyl	I
]	I
-2-carboxamido	I
]	I
-1H	I
-	I
indole-2-carboxamide	I
and	O
a	O
polymer	O
.	O

Solid	O
Amorphous	O
Dispersions	O
of	O
An	O
Mtp	O
Inhibitor	O
For	O
Treatment	O
of	O
Obesity	O

The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
an	O
A3	O
adenosine	B
receptor	O
agonist	O
(	O
A3AR	O
agonist	O
)	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
a	O
mammal	O
subject	O
having	O
osteoarthritis	O
(	O
OA	O
)	O
,	O
as	O
well	O
as	O
to	O
a	O
method	O
for	O
the	O
treatment	O
of	O
OA	O
in	O
a	O
mammal	O
subject	O
,	O
the	O
method	O
comprises	O
administering	O
to	O
said	O
subject	O
in	O
need	O
of	O
said	O
treatment	O
an	O
amount	O
of	O
an	O
A3AR	O
agonist	O
,	O
the	O
amount	O
being	O
effective	O
to	O
treat	O
or	O
prevent	O
the	O
development	O
of	O
OA	O
.	O

Preferred	O
but	O
not	O
exclusive	O
A3AR	O
agonists	O
in	O
accordance	O
with	O
the	O
invention	O
are	O
IB	O
-	O
MECA	O
and	O
Cl	O
—	O
IB	O
-	O
MECA	O
.	O

The	O
A3AR	O
agonist	O
may	O
be	O
administered	O
in	O
combination	O
with	O
another	O
drug	O
,	O
such	O
as	O
,	O
Methotrexate	B
(	O
MTX	B
)	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
for	O
treatment	O
of	O
osteoarthritis	O
comprising	O
an	O
amount	O
of	O
an	O
A3AR	O
agonist	O
.	O

Use	O
of	O
A3	O
Adenosine	B
Receptor	O
Agonist	O
in	O
Osteoarthritis	O
Treatment	O

Disclosed	O
herein	O
are	O
compounds	O
of	O
the	O
formula	O
or	O
salts	O
or	O
bioisosteres	O
thereof	O
.	O

Therapeutic	O
methods	O
,	O
medicaments	O
,	O
and	O
compositions	O
related	O
thereto	O
are	O
also	O
disclosed	O
.	O

Glaucoma	O
;	O
prostaglandin	B
receptor	O
modulators	O
;	O
cyclopentyl	O
compounds	O
such	O
as	O
5-	B
{	I
3-	I
[	I
(	I
1S,5S	I
)	I
-5-	I
(	I
3-Chloro-5-hydroxymethyl	I
-	I
phenoxymethyl	I
)	I
-4-oxo	I
-	I
cyclopent-2-enyl	I
]	I
-propyl	I
}	I
-thiophene-2-carboxylic	I
acid	I

A	O
therapeutic	O
method	O
for	O
treating	O
intestinal	O
damage	O
,	O
enteritis	O
,	O
diarrhea	O
,	O
or	O
a	O
combination	O
thereof	O
caused	O
by	O
a	O
C.	O
difficile	O
is	O
provided	O
.	O

The	O
method	O
includes	O
administration	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
an	O
A2A	O
adenosine	B
receptor	O
agonist	O
,	O
optionally	O
in	O
combination	O
with	O
an	O
effective	O
amount	O
of	O
a	O
stable	O
glutamine	B
derivative	O
,	O
e.g.	O
,	O
alanyl	B
-	I
glutamine	I
.	O

Method	O
of	O
treating	O
enteritis	O
,	O
intestinal	O
damage	O
,	O
and	O
diarrhea	O
from	O
c.	O
difficile	O
with	O
an	O
a2a	O
adenosine	B
receptor	O
agonist	O

D	B
-	I
ribose	I
is	O
incorporated	O
into	O
a	O
cosmetic	O
composition	O
and	O
applied	O
to	O
the	O
skin	O
to	O
reduce	O
the	O
length	O
and	O
area	O
of	O
wrinkles	O
and	O
to	O
improve	O
the	O
complexion	O
of	O
the	O
skin	O
.	O

Cosmetic	O
use	O
of	O
D	B
-	I
ribose	I

Compounds	O
of	O
the	O
formula	O
I	O
,	O
in	O
which	O
R	O
,	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
CHK1	O
CHK2	O
and	O
SGK	O
kinases	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Squaric	B
Acid	I
Derivatives	O
as	O
Protein	O
Kinase	O
Inhibitors	O

The	O
invention	O
relates	O
to	O
heteroaryl	B
aryl	I
ureas	I
of	O
the	O
formula	O
IA	O
,	O
wherein	O
the	O
radicals	O
and	O
symbols	O
have	O
the	O
meanings	O
as	O
defined	O
herein	O
,	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
protein	O
kinase	O
dependent	O
diseases	O
;	O
to	O
pharmaceutical	O
preparations	O
comprising	O
said	O
heteroaryl	B
aryl	I
ureas	I
,	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
such	O
novel	O
compounds	O
and	O
to	O
methods	O
of	O
treatment	O
comprising	O
the	O
use	O
of	O
such	O
heteroaryl	B
aryl	I
ureas	I
.	O

Pyrimidinyl	B
Aryl	I
Urea	I
Derivatives	O
Being	O
Fgf	O
Inhibitors	O

A	O
pharmaceutical	O
composition	O
for	O
treating	O
the	O
hypertension	O
is	O
provided	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
a	O
chemical	O
compound	O
of	O
7-	B
[	I
2-	I
[	I
4-	I
(	I
2-Chlorobenzene	I
)	I
piperazinyl	I
]	I
ethyl	I
]	I
-1,3-dimethyl	I
xanthine	I
and	O
one	O
of	O
a	O
pharmaceutical	O
acceptable	O
salt	O
thereof	O
and	O
a	O
solvate	O
thereof	O
,	O
wherein	O
the	O
chemical	O
compound	O
treats	O
the	O
hypertension	O
by	O
cGMP	O
-	O
dependent	O
inhibition	O
on	O
Rho	O
kinase	O
.	O

Kmup-1	O
capable	O
of	O
treating	O
hypertension	O

The	O
present	O
application	O
relates	O
to	O
immunoglobulin	O
polypeptides	O
comprising	O
at	O
least	O
two	O
immunoglobulin	O
complementarity	O
determining	O
regions	O
,	O
one	O
that	O
binds	O
to	O
an	O
immune	O
receptor	O
and	O
the	O
other	O
which	O
comprises	O
an	O
idiotype	O
to	O
which	O
an	O
immune	O
response	O
is	O
desired	O
.	O

Idiotype	O
Vaccination	O
with	O
Bispecific	O
and	O
Multispecific	O
Immunoglobulin	O
Molecules	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
CKα-5	O
protein	O
which	O
is	O
a	O
member	O
of	O
the	O
alpha	O
chemokine	O
family	O
.	O

In	O
particular	O
,	O
isolated	O
nucleic	O
acid	O
molecules	O
are	O
provided	O
encoding	O
the	O
human	O
CKα-5	O
protein	O
.	O

CKα-5	O
polypeptides	O
are	O
also	O
provided	O
,	O
as	O
are	O
vectors	O
,	O
host	O
cells	O
and	O
recombinant	O
methods	O
for	O
producing	O
the	O
same	O
.	O

Antibodies	O
and	O
fragments	O
thereof	O
that	O
specifically	O
bind	O
to	O
CKα-5	O
polypeptides	O
are	O
also	O
disclosed	O
,	O
as	O
are	O
compositions	O
and	O
methods	O
for	O
making	O
such	O
antibodies	O
.	O

The	O
invention	O
further	O
relates	O
to	O
screening	O
methods	O
for	O
identifying	O
agonists	O
and	O
antagonists	O
of	O
CKα-5	O
activity	O
.	O

Also	O
provided	O
are	O
diagnostic	O
methods	O
for	O
detecting	O
immune	O
system	O
-	O
related	O
disorders	O
and	O
therapeutic	O
methods	O
for	O
treating	O
immune	O
system	O
-	O
related	O
disorders	O
.	O

Antibodies	O
to	O
Chemokine	O
Alpha-5	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
disorders	O
related	O
to	O
cellular	O
overproliferation	O
comprising	O
neutralizing	O
the	O
production	O
or	O
activity	O
of	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
therapeutic	O
compositions	O
comprising	O
factors	O
which	O
inhibit	O
or	O
neutralize	O
MIF	O
activity	O
,	O
such	O
as	O
,	O
MIF	O
antisense	O
RNA	O
molecules	O
and	O
MIF	O
monoclonal	O
antibodies	O
and	O
derivatives	O
or	O
analogs	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
uses	O
of	O
such	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
malignancies	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
B	O
and	O
T	O
cell	O
lymphomas	O
.	O

Therapeutic	O
uses	O
of	O
factors	O
which	O
inhibit	O
or	O
neutralize	O
MIF	O
activity	O

The	O
present	O
invention	O
provides	O
a	O
composition	O
for	O
inhibiting	O
thrombus	O
formation	O
,	O
comprising	O
a	O
given	O
plant	O
component	O
derived	O
from	O
amla	O
,	O
tea	O
,	O
hibiscus	O
,	O
cocklebur	O
,	O
gymnema	O
,	O
Hizikia	O
fusiforme	O
or	O
carrageenan	O
,	O
which	O
can	O
be	O
used	O
for	O
foodstuff	O
,	O
quasi	O
-	O
drugs	O
,	O
medicaments	O
and	O
feeds	O
.	O

Composition	O
For	O
Inhibiting	O
Thrombosis	O

Disclosed	O
herein	O
are	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
variety	O
of	O
mood	O
and	O
behavioral	O
disorders	O
,	O
including	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
anxiety	O
,	O
depression	O
,	O
memory	O
loss	O
,	O
as	O
well	O
as	O
other	O
conditions	O
.	O

Also	O
disclosed	O
herein	O
are	O
methods	O
for	O
diagnosing	O
certain	O
conditions	O
,	O
such	O
as	O
ADHD	O
,	O
using	O
these	O
compositions	O
.	O

Method	O
and	O
compositions	O
for	O
treatment	O
of	O
ADD	O
/	O
ADHD	O
,	O
depression	O
,	O
memory	O
problems	O
and	O
other	O
conditions	O

4-Oxadiazolyl	B
-	I
piperidine	I
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
,	O
their	O
compositions	O
and	O
use	O
for	O
the	O
treatment	O
of	O
pain	O
and	O
diarrhoea	O
.	O

4-Oxadiazolyl	B
-	I
Piperidine	I
Compounds	O
and	O
Use	O
Thereof	O

The	O
invention	O
provides	O
a	O
glucitol	B
derivative	O
having	O
the	O
function	O
of	O
reducing	O
a	O
blood	O
sugar	B
level	O
and	O
having	O
preferable	O
properties	O
required	O
of	O
medicines	O
,	O
such	O
as	O
long	O
-	O
lasting	O
drug	O
activity	O
;	O
and	O
a	O
medicinal	O
composition	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
attributable	O
to	O
hyperglycemia	O
,	O
such	O
as	O
diabetes	O
,	O
complications	O
of	O
diabetes	O
,	O
and	O
obesity	O
.	O

The	O
derivative	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
m	O
is	O
an	O
integer	O
selected	O
among	O
1	O
-	O
3	O
;	O
R1	O
to	O
R4	O
each	O
independently	O
is	O
optionally	O
substituted	O
alkyl	B
,	O
etc	O
.	O
;	O
Ar1	O
is	O
optionally	O
substituted	O
naphthyl	B
;	O
and	O
A	O
is	O
optionally	O
substituted	O
heteroaryl	B
,	O
a	O
prodrug	O
of	O
the	O
compound	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
either	O
.	O

Also	O
provided	O
are	O
a	O
medicine	O
,	O
a	O
medicinal	O
composition	O
,	O
and	O
the	O
like	O
each	O
containing	O
the	O
compound	O
.	O

Novel	O
Glucitol	B
Derivative	O
,	O
Prodrug	O
Thereof	O
And	O
Salt	O
Thereof	O
,	O
And	O
Therapeutic	O
Agent	O
Containing	O
The	O
Same	O
For	O
Diabetes	O

This	O
invention	O
relates	O
,	O
in	O
part	O
,	O
to	O
unique	O
and	O
newly	O
identified	O
genetic	O
polynucleotides	O
involved	O
in	O
the	O
process	O
of	O
bone	O
remodeling	O
;	O
variants	O
and	O
derivatives	O
of	O
the	O
polynucleotides	O
and	O
corresponding	O
polypeptides	O
;	O
uses	O
of	O
polynucleotides	O
,	O
polypeptides	O
,	O
variants	O
and	O
derivatives	O
;	O
and	O
methods	O
and	O
compositions	O
for	O
the	O
amelioration	O
of	O
symptoms	O
caused	O
by	O
bone	O
remodeling	O
disorders	O
.	O

Disclosed	O
in	O
particular	O
are	O
,	O
the	O
isolation	O
and	O
identification	O
of	O
polynucleotides	O
,	O
polypeptides	O
,	O
variants	O
and	O
derivatives	O
involved	O
in	O
osteoclast	O
activity	O
,	O
validation	O
of	O
the	O
identified	O
polynucleotides	O
for	O
their	O
potential	O
as	O
therapeutic	O
targets	O
and	O
use	O
of	O
the	O
polynucleotides	O
,	O
polypeptides	O
,	O
variants	O
and	O
derivatives	O
for	O
the	O
amelioration	O
of	O
disease	O
states	O
and	O
research	O
purposes	O
.	O

Polynucleotides	O
and	O
Polypeptide	O
Sequences	O
Involved	O
in	O
the	O
Process	O
of	O
Bone	O
Remodeling	O

The	O
present	O
invention	O
relates	O
to	O
a	O
multiparticulate	O
osmotic	O
delivery	O
system	O
.	O

The	O
system	O
is	O
a	O
modified	O
release	O
composition	O
suitable	O
for	O
oral	O
administration	O
.	O

The	O
composition	O
includes	O
a	O
core	O
that	O
includes	O
at	O
least	O
one	O
drug	O
in	O
combination	O
with	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

The	O
composition	O
further	O
includes	O
an	O
osmotic	O
subcoat	O
surrounding	O
the	O
core	O
,	O
and	O
a	O
modified	O
release	O
overcoat	O
surrounding	O
the	O
osmotic	O
subcoated	O
core	O
.	O

Multiparticulate	O
osmotic	O
delivery	O
system	O

A	O
novel	O
antiseptic	O
composition	O
comprising	O
an	O
antiseptic	O
in	O
a	O
carrier	O
composition	O
comprising	O
nanostructures	O
and	O
a	O
liquid	O
and	O
methods	O
of	O
use	O
thereof	O
are	O
provided	O
.	O

Antiseptic	O
Compositions	O
and	O
Methods	O
of	O
Using	O
Same	O

A	O
method	O
for	O
inhibiting	O
a	O
decline	O
in	O
learning	O
and/or	O
memory	O
in	O
an	O
animal	O
comprising	O
maintaining	O
the	O
animal	O
on	O
an	O
antioxidant	O
-	O
fortified	O
diet	O
for	O
a	O
period	O
of	O
at	O
least	O
about	O
3	O
years	O
.	O

The	O
diet	O
comprises	O
at	O
least	O
one	O
antioxidant	O
in	O
a	O
total	O
antioxidant	O
amount	O
effective	O
to	O
achieve	O
such	O
inhibition	O
.	O

Suitable	O
antioxidants	O
include	O
vitamin	B
E	I
,	O
vitamin	B
C	I
,	O
α	B
-	I
lipoic	I
acid	I
and	O
antioxidant	O
-	O
containing	O
plant	O
meals	O
.	O

The	O
methods	O
are	O
particularly	O
useful	O
for	O
young	O
adult	O
canines	O
such	O
as	O
dogs	O
.	O

Methods	O
for	O
Inhibiting	O
a	O
Decline	O
in	O
Learning	O
and/or	O
Memory	O
in	O
Animals	O

Anthracyclines	B
-	O
treated	O
tumor	O
cells	O
are	O
particularly	O
effective	O
in	O
eliciting	O
an	O
anti	O
-	O
cancer	O
immune	O
response	O
,	O
where	O
the	O
rDNA	O
-	O
damaging	O
agents	O
,	O
such	O
as	O
etoposide	B
and	O
mitomycin	B
C	I
do	O
not	O
induce	O
immunogenic	O
cell	O
death	O
.	O

Anthracyclines	B
induce	O
the	O
rapid	O
,	O
pre	O
-	O
apoptotic	O
translocation	O
of	O
calreticulin	O
(	O
CRT	O
)	O
to	O
the	O
cell	O
surface	O
.	O

Blockade	O
or	O
knock	O
down	O
of	O
CRT	O
suppressed	O
the	O
phagocytosis	O
of	O
anthracyclines	O
-	O
treated	O
tumor	O
cells	O
by	O
dendritic	O
cells	O
and	O
abolished	O
their	O
immunogenicity	O
in	O
mammals	O
,	O
such	O
as	O
mice	O
.	O

The	O
anthracyclines	B
-	O
induced	O
CRT	O
translocation	O
was	O
mimicked	O
by	O
inhibition	O
of	O
the	O
protein	O
phosphatase1	O
/	O
GADD34	O
complex	O
.	O

Administration	O
of	O
recombinant	O
CRT	O
or	O
inhibitors	O
of	O
protein	O
phosphatase1	O
/	O
GADD34	O
restored	O
the	O
immunogenicity	O
of	O
cell	O
death	O
elicited	O
by	O
etoposide	B
and	O
mitomycin	B
C	I
,	O
and	O
enhanced	O
their	O
antitumor	O
effects	O
in	O
vivo	O
.	O

These	O
data	O
identify	O
CRT	O
as	O
a	O
key	O
feature	O
determining	O
anti	O
-	O
cancer	O
immune	O
responses	O
and	O
delineate	O
a	O
possible	O
strategy	O
for	O
immunogenic	O
chemotherapy	O
.	O

Service	O
for	O
effecting	O
localized	O
,	O
non	O
-	O
systemic	O
and	O
systemic	O
,	O
immunogenic	O
treatment	O
of	O
cancer	O
using	O
crt	O
translocation	O

The	O
compounds	O
of	O
formula	O
I	O
in	O
which	O
R1	O
and	O
R2	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
are	O
novel	O
effective	O
PDE2	O
inhibitors	O
.	O

Cyclopropanecarboxylic	B
acid	I
{	I
4-	I
[	I
3-	I
(	I
4-methoxy	I
-	I
phenyl	I
)	I
-	I
[	I
1,2,4	I
]	I
triazolo	I
[	I
3,4-a	I
]	I
phthalazin-6-ylamino	I
]	I
-phenyl	I
}	I
-amide	I
;	O
phosphodiesterase	O
inhibitors	O
;	O
neoangiogenesis	O
or	O
inflammatory	O
disease	O

Substituted	O
imidazo	B
[	I
2,1-b	I
]	I
thiazole	I
compounds	O
corresponding	O
to	O
formula	O
I	O
,	O
a	O
method	O
for	O
producing	O
them	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
the	O
use	O
thereof	O
for	O
regularing	O
mGluR5	O
receptors	O
,	O
or	O
for	O
treating	O
or	O
inhibiting	O
disorders	O
or	O
disease	O
states	O
at	O
least	O
partially	O
mediated	O
by	O
mGluR5	O
receptor	O
such	O
as	O
pain	O
,	O
anxiety	O
attacks	O
,	O
drug	O
or	O
alcohol	B
dependency	O
,	O
and	O
others	O
.	O

Substituted	O
Imidazo	B
[	I
2,1-b	I
]	I
thiazole	I
Compounds	O
and	O
Uses	O
Thereof	O

The	O
present	O
invention	O
relates	O
to	O
dihydroisoxazoles	B
that	O
are	O
useful	O
for	O
treating	O
cellular	O
proliferative	O
diseases	O
,	O
for	O
treating	O
disorders	O
associated	O
with	O
KSP	O
kinesin	O
activity	O
,	O
and	O
for	O
inhibiting	O
KSP	O
kinesin	O
.	O

The	O
invention	O
also	O
relates	O
to	O
compositions	O
which	O
comprise	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
them	O
to	O
treat	O
cancer	O
in	O
mammals	O
.	O

such	O
as	O
2-benzyl-5-	B
(	I
2,5-difluorophenyl	I
)	I
-3-phenyl-2,3-dihydroisoxazole	I
,	O
useful	O
for	O
treating	O
cellular	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
,	O
hyperplasias	O
,	O
restenosis	O
,	O
cardiac	O
hypertrophy	O
,	O
immune	O
disorders	O
and	O
inflammation	O
in	O
mammals	O

The	O
invention	O
relates	O
to	O
novel	O
pyridine	B
derivatives	O
,	O
their	O
preparation	O
and	O
their	O
use	O
as	O
pharmaceutically	O
active	O
compounds	O
.	O

Said	O
compounds	O
particularly	O
act	O
as	O
immunosuppressive	O
agents	O
.	O

Novel	O
Pyridine	B
Derivatives	O

The	O
present	O
invention	O
provides	O
compositions	O
,	O
including	O
pharmaceutical	O
compositions	O
,	O
comprising	O
an	O
amount	O
of	O
an	O
antibody	O
,	O
antibody	O
fragment	O
or	O
antibody	O
conjugate	O
sufficient	O
to	O
treat	O
Group	O
A	O
streptococcus	O
(	O
GAS	O
)	O
infection	O
or	O
complication	O
thereof	O
in	O
a	O
subject	O
or	O
a	O
disease	O
or	O
complication	O
associated	O
with	O
GAS	O
infection	O
in	O
a	O
subject	O
wherein	O
said	O
antibody	O
,	O
antibody	O
fragment	O
or	O
antibody	O
conjugate	O
binds	O
immunospecifically	O
to	O
a	O
B	O
-	O
cell	O
epitope	O
of	O
GAS	O
M	O
-	O
protein	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
treatment	O
of	O
infection	O
by	O
GAS	O
and	O
complications	O
thereof	O
comprising	O
administering	O
the	O
compositions	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

Therapeutic	O
Antibodies	O
,	O
Antibody	O
Fragments	O
and	O
Antibody	O
Conjugates	O

Improved	O
compositions	O
,	O
methods	O
and	O
systems	O
for	O
oral	O
transmucosal	O
administration	O
of	O
small	O
volume	O
bioadhesive	O
drug	O
dosage	O
forms	O
to	O
pediatric	O
subjects	O
are	O
provided	O
.	O

The	O
drug	O
dosage	O
form	O
is	O
easily	O
administered	O
and	O
may	O
be	O
delivered	O
using	O
a	O
single	O
dose	O
applicator	O
or	O
a	O
device	O
.	O

Drug	O
formulations	O
for	O
oral	O
transmucosal	O
delivery	O
to	O
pediatric	O
patients	O

Methods	O
of	O
treatment	O
of	O
sepsis	O
are	O
disclosed	O
.	O

These	O
methods	O
comprise	O
administering	O
to	O
a	O
subject	O
a	O
composition	O
comprising	O
at	O
least	O
one	O
siRNA	O
directed	O
against	O
at	O
least	O
one	O
gene	O
encoding	O
a	O
pro	O
-	O
apoptotic	O
polypeptide	O
.	O

The	O
pro	O
-	O
apoptotic	O
polypeptide	O
,	O
in	O
some	O
aspects	O
,	O
can	O
be	O
other	O
than	O
Fas	O
or	O
caspase-8	O
.	O

In	O
some	O
embodiments	O
,	O
an	O
siRNA	O
can	O
be	O
directed	O
against	O
a	O
pro	O
-	O
apoptotic	O
component	O
of	O
the	O
mitochondrial	O
pathway	O
,	O
such	O
as	O
a	O
pro	O
-	O
apoptotic	O
bcl-2	O
protein	O
.	O

In	O
some	O
aspects	O
,	O
an	O
siRNA	O
can	O
be	O
directed	O
against	O
a	O
BH3-only	B
bcl-2	O
protein	O
,	O
while	O
in	O
other	O
aspects	O
,	O
siRNAs	O
can	O
be	O
directed	O
against	O
multi	O
BH	O
domain	O
Bcl-2	O
family	O
members	O
such	O
as	O
bax	O
and	O
bak	O
.	O

In	O
some	O
embodiments	O
,	O
an	O
siRNA	O
can	O
be	O
directed	O
against	O
a	O
death	O
receptor	O
pathway	O
molecule	O
such	O
as	O
FADD	O
.	O

In	O
various	O
configurations	O
,	O
a	O
composition	O
can	O
also	O
comprise	O
a	O
cationic	O
lipid	O
such	O
as	O
DOTAP	O
,	O
or	O
nanoparticles	O
comprising	O
a	O
cyclodextrin	O
-	O
containing	O
polycation	O
and	O
a	O
polymer	O
such	O
as	O
a	O
poly	B
(	I
ethylene	I
glycol	I
)	I
.	O

Methods	O
and	O
Compositions	O
for	O
Treatment	O
of	O
Sepsis	O

The	O
present	O
invention	O
relates	O
to	O
Mycobacterium	O
avium	O
subspecies	O
paratuberculosis	O
(	O
MAP	O
)	O
as	O
the	O
etiological	O
agent	O
of	O
IBD	O
,	O
including	O
ulcerative	O
colitis	O
and	O
Crohn	O
's	O
disease	O
,	O
as	O
well	O
as	O
Multiple	O
Sclerosis	O
and	O
Alzheimer	O
's	O
Disease	O
.	O

As	O
such	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
diagnosing	O
Multiple	O
Sclerosis	O
and	O
Alzheimer	O
's	O
Disease	O
by	O
detecting	O
the	O
presence	O
of	O
MAP	O
nucleic	O
acid	O
molecules	O
as	O
well	O
as	O
methods	O
for	O
inhibiting	O
the	O
proliferation	O
of	O
MAP	O
and	O
treating	O
a	O
MAP	O
infection	O
using	O
anti	O
-	O
MAP	O
agents	O
.	O

Pharmaceutical	O
compositions	O
containing	O
anti	O
-	O
MAP	O
agents	O
and	O
methods	O
for	O
determining	O
the	O
antibiotic	O
susceptibility	O
of	O
MAP	O
isolated	O
from	O
a	O
subject	O
are	O
also	O
provided	O
.	O

Methods	O
for	O
diagnosing	O
and	O
treating	O
a	O
mycobacterium	O
avium	O
subspecies	O
paratuberculosis	O
infection	O

Described	O
are	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
VI	O
and	O
(	O
VII	O
)	O
.	O

Also	O
described	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
identified	O
.	O

The	O
compounds	O
and	O
pharmaceutical	O
compositions	O
described	O
are	O
inhibitors	O
of	O
5′-methylthioadenosine	B
/	O
S	B
-	I
adenosylhomocystein	I
nucleosidase	O
(	O
MTAN	O
)	O
and/or	O
5′-methylthioadenosine	B
phosphorylase	O
(	O
MTAP	O
)	O
.	O

Methods	O
of	O
treatment	O
using	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
described	O
are	O
also	O
provided	O
for	O
preventing	O
and/or	O
treating	O
disease	O
states	O
and/or	O
conditions	O
by	O
inhibiting	O
MTAN	O
and/or	O
MTAP	O
in	O
patients	O
.	O

Inhibitors	O
of	O
5'-Methylthioadenosine	B
Phosphorylase	O
and	O
5'-Methylthioadenosine	B
/	O
S	B
-	I
Adenosylhomocysteine	I
Nucleosidase	O

The	O
instant	O
invention	O
describes	O
methods	O
of	O
identifying	O
compounds	O
that	O
modulate	O
the	O
activity	O
of	O
Sir2	O
enzymes	O
.	O

Sir2	O
enzymes	O
form	O
a	O
unique	O
class	O
Of	O
NAD+	O
dependent	O
deacetylases	O
required	O
for	O
diverse	O
biological	O
processes	O
including	O
transcriptional	O
silencing	O
,	O
regulation	O
of	O
apoptosis	O
,	O
fat	O
mobilization	O
,	O
and	O
lifespan	O
regulation	O
.	O

Sir2	O
activity	O
is	O
regulated	O
by	O
nicotinamide	O
,	O
a	O
non	O
-	O
competitive	O
inhibitor	O
that	O
promotes	O
a	O
base	O
exchange	O
reaction	O
at	O
the	O
expense	O
of	O
deacetylation	O
.	O

Strategies	O
for	O
Designing	O
Drugs	O
that	O
Target	O
the	O
Sir2	O
Family	O
of	O
Enzymes	O

An	O
oral	O
formulation	O
that	O
is	O
a	O
combination	O
of	O
three	O
mineral	O
ascorbates	O
and	O
metabolites	O
for	O
antioxidant	O
protection	O
against	O
free	O
radical	O
damage	O
,	O
healthy	O
skin	O
maintenance	O
,	O
support	O
for	O
vision	O
health	O
,	O
healthy	O
joint	O
support	O
,	O
cardiovascular	O
support	O
,	O
and	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

Tri	B
ascorbate	I
formulation	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
,	O
non	O
-	O
secosteroidal	O
,	O
diaryl	B
compounds	O
with	O
vitamin	B
D	I
receptor	O
(	O
VDR	O
)	O
modulating	O
and	O
psoriasis	O
.	O

Vitamin	B
D	I
Receptor	O
Modulators	O

The	O
invention	O
provides	O
uses	O
and	O
methods	O
for	O
reducing	O
nephropathy	O
in	O
persons	O
with	O
diabetes	O
mellitus	O
(	O
particularly	O
Type	O
2	O
diabetes	O
)	O
,	O
in	O
persons	O
with	O
metabolic	O
syndrome	O
,	O
in	O
persons	O
with	O
triglyceride	B
levels	O
over	O
215	O
mg	O
/	O
dL	O
,	O
and	O
in	O
persons	O
with	O
a	O
cholesterol	B
level	O
over	O
200	O
mg	O
/	O
dL	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
soluble	O
epoxide	B
hydrolase	O
(	O
""""	O
sEH	O
""""	O
)	O
.	O

Optionally	O
,	O
a	O
cis	B
-	I
epoxyeicosantrienoic	I
acid	I
(	O
""""	O
EET	B
""""	O
)	O
can	O
be	O
administered	O
with	O
the	O
sEH	O
inhibitor	O
.	O

The	O
invention	O
further	O
provides	O
for	O
using	O
EETs	B
in	O
conjunction	O
with	O
one	O
or	O
more	O
sEH	O
inhibitors	O
to	O
reduce	O
hypertension	O
,	O
and	O
for	O
compositions	O
of	O
EETs	B
coated	O
with	O
a	O
material	O
insoluble	O
in	O
an	O
acid	O
of	O
pH	O
3	O
but	O
soluble	O
in	O
a	O
solution	O
with	O
a	O
pH	O
of	O
7.4	O
or	O
higher	O
.	O

Reducing	O
Nephropathy	O
with	O
Inhibitors	O
of	O
Soluble	O
Epoxide	O
Hydrolase	O
and	O
Epoxyeicosanoids	B

Diaminoalkanes	B
of	O
Formula	O
I	O
have	O
now	O
been	O
found	O
which	O
are	O
orally	O
active	O
and	O
bind	O
to	O
aspartic	O
proteases	O
to	O
inhibit	O
their	O
activity	O
.	O

They	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
amelioration	O
of	O
diseases	O
associated	O
with	O
elevated	O
levels	O
of	O
aspartic	O
protease	O
activity	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
the	O
use	O
of	O
the	O
compounds	O
of	O
Formula	O
I	O
in	O
ameliorating	O
or	O
treating	O
aspartic	O
protease	O
related	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I.	O
Diaminoalkane	B
Aspartic	O
Protease	O
Inhibitors	O

A	O
therapeutic	O
agent	O
for	O
a	O
corneal	O
disease	O
comprising	O
irsogladine	B
or	O
a	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
purpose	O
is	O
to	O
find	O
a	O
substance	O
capable	O
of	O
effectively	O
treating	O
/	O
ameliorating	O
a	O
corneal	O
disease	O
which	O
has	O
been	O
increased	O
in	O
the	O
number	O
of	O
cases	O
thereof	O
in	O
recent	O
years	O
and	O
to	O
provide	O
a	O
therapeutic	O
agent	O
for	O
a	O
corneal	O
disease	O
comprising	O
the	O
substance	O
as	O
an	O
active	O
ingredient	O
.	O

Therapeutic	O
agent	O
for	O
corneal	O
disease	O

Compositions	O
,	O
methods	O
and	O
kits	O
to	O
be	O
used	O
as	O
a	O
lubricant	O
and	O
for	O
treatment	O
of	O
a	O
cavity	O
pathology	O
including	O
joint	O
pathology	O
are	O
provided	O
.	O

The	O
composition	O
comprises	O
therapeutically	O
effective	O
amounts	O
of	O
at	O
least	O
one	O
bioactive	O
agent	O
,	O
such	O
as	O
magnesium	B
compound	O
,	O
at	O
least	O
one	O
lubricating	O
agent	O
,	O
such	O
as	O
hyaluronic	B
acid	I
,	O
and	O
at	O
least	O
one	O
cell	O
membrane	O
repairing	O
agent	O
,	O
such	O
as	O
polyethylene	B
glycol	I
.	O

The	O
components	O
of	O
these	O
compositions	O
may	O
be	O
administered	O
by	O
a	O
direct	O
application	O
,	O
an	O
application	O
through	O
a	O
cannula	O
,	O
an	O
intra	O
-	O
articular	O
injection	O
,	O
as	O
a	O
flush	O
fluid	O
during	O
an	O
arthroscopy	O
of	O
the	O
affected	O
area	O
,	O
as	O
a	O
post	O
-	O
arthroscopy	O
injection	O
,	O
or	O
as	O
part	O
of	O
a	O
lavage	O
of	O
the	O
area	O
affected	O
by	O
the	O
intra	O
-	O
articular	O
pathology	O
.	O

In	O
addition	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
may	O
be	O
administered	O
to	O
the	O
patient	O
from	O
a	O
pump	O
or	O
a	O
depot	O
.	O

Compositions	O
and	O
methods	O
for	O
treating	O
cavity	O
conditions	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
esters	O
,	O
or	O
prodrugs	O
thereof	O
,	O
which	O
can	O
inhibit	O
serine	B
protease	O
activity	O
,	O
particularly	O
the	O
activity	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS3-NS4A	O
protease	O
.	O

Consequently	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
interfere	O
with	O
the	O
life	O
cycle	O
of	O
the	O
hepatitis	O
C	O
virus	O
and	O
are	O
also	O
useful	O
as	O
antiviral	O
agents	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
aforementioned	O
compounds	O
for	O
administration	O
to	O
a	O
subject	O
suffering	O
from	O
HCV	O
infection	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
an	O
HCV	O
infection	O
in	O
a	O
subject	O
by	O
administering	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
of	O
the	O
present	O
invention	O
.	O

Acyclic	B
,	I
pyridazinone	I
-	O
derived	O
hepatitis	O
c	O
serine	B
protease	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
and	O
pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
inflammatory	O
diseases	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
lymphocyte	O
adhesion	O
to	O
an	O
endothelial	O
cell	O
,	O
or	O
a	O
method	O
for	O
treating	O
an	O
inflammatory	O
disease	O
,	O
which	O
comprises	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	O
polypeptide	O
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
the	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	O
polypeptide	O
,	O
and	O
the	O
use	O
of	O
the	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	O
polypeptide	O
are	O
also	O
disclosed	O
.	O

Further	O
,	O
a	O
method	O
for	O
screening	O
a	O
medicament	O
for	O
inhibiting	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	O
polypeptide	O
or	O
a	O
medicament	O
for	O
treating	O
an	O
inflammatory	O
disease	O
,	O
which	O
comprises	O
a	O
step	O
of	O
selecting	O
an	O
inhibitor	O
against	O
lymphocyte	O
adhesion	O
to	O
a	O
FEX-2	O
polypeptide	O
,	O
is	O
disclosed	O
.	O

Method	O
and	O
pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
diseases	O
associated	O
with	O
inflammation	O

The	O
invention	O
relates	O
to	O
a	O
carrier	O
for	O
administering	O
biologically	O
active	O
compounds	O
comprising	O
one	O
or	O
more	O
C1-C4	B
alcohols	I
,	O
polyols	O
and	O
polymers	O
thereof	O
,	O
water	O
and	O
one	O
or	O
more	O
di	O
and/or	O
mono-	O
(	O
electron	O
transfer	O
agent	O
)	O
phosphate	B
derivatives	O
or	O
complexes	O
thereof	O
.	O

The	O
carrier	O
may	O
be	O
used	O
in	O
administering	O
biologically	O
active	O
compounds	O
,	O
in	O
particular	O
pharmaceuticals	O
including	O
cosmetic	O
agents	O
.	O

Carrier	O
comprising	O
one	O
or	O
more	O
di	O
and/or	O
mono-	O
(	O
electron	O
transfer	O
agent	O
)	O
phosphate	B
derivatives	O
or	O
complexes	O
thereof	O

A	O
method	O
is	O
provided	O
for	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
raf	O
kinase	O
,	O
which	O
includes	O
administering	O
a	O
guanylhydrazone	B
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

A	O
method	O
is	O
also	O
provided	O
,	O
which	O
includes	O
modulating	O
or	O
inhibiting	O
signal	O
transduction	O
in	O
a	O
c	O
-	O
raf	O
pathway	O
with	O
at	O
least	O
one	O
guanylhydrazone	B
.	O

Another	O
method	O
is	O
provided	O
,	O
which	O
includes	O
contacting	O
one	O
or	O
more	O
human	O
mononuclear	O
cells	O
with	O
at	O
least	O
one	O
guanylhydrazone	B
and	O
at	O
least	O
one	O
lipopolysaccharide	O
to	O
obtain	O
one	O
or	O
more	O
treated	O
cells	O
;	O
contacting	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
including	O
said	O
treated	O
cells	O
,	O
one	O
or	O
more	O
lysates	O
thereof	O
,	O
and	O
combinations	O
thereof	O
,	O
with	O
at	O
least	O
one	O
surface	O
-	O
bound	O
peptide	O
in	O
a	O
surface	O
-	O
bound	O
peptide	O
array	O
;	O
and	O
selectively	O
modulating	O
or	O
inhibiting	O
the	O
phosphorylation	O
of	O
the	O
surface	O
-	O
bound	O
peptide	O
.	O

Guanylhydrazones	B
in	O
Methods	O
of	O
Treatment	O
or	O
Diagnosis	O
as	O
Modulators	O
of	O
Signal	O
Transduction	O

The	O
present	O
invention	O
relates	O
to	O
high	O
affinity	O
compounds	O
,	O
able	O
to	O
bind	O
CB1	O
and	O
CB2	O
endocannabinoid	O
receptors	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
find	O
particular	O
application	O
as	O
agents	O
for	O
pain	O
therapy	O
and/or	O
anti	O
-	O
inflammatory	O
and/or	O
anti	O
-	O
stress	O
and/or	O
anti	O
-	O
oxidising	O
and/or	O
hypotensive	O
and/or	O
immune	O
suppressive	O
therapy	O
and/or	O
anti	O
-	O
spastic	O
activity	O
in	O
multiple	O
sclerosis	O
and/or	O
anti	O
-	O
cancer	O
.	O

Potent	O
and	O
selective	O
ligands	O
of	O
cannabinoid	B
receptors	O

The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
cancer	O
or	O
the	O
like	O
,	O
an	O
agent	O
for	O
promoting	O
apoptosis	O
of	O
cancer	O
cells	O
,	O
an	O
agent	O
for	O
suppressing	O
proliferation	O
of	O
cancer	O
cells	O
,	O
and	O
the	O
like	O
,	O
which	O
comprises	O
a	O
compound	O
or	O
its	O
salt	O
that	O
inhibits	O
an	O
activity	O
of	O
a	O
protein	O
comprising	O
the	O
same	O
or	O
substantially	O
the	O
same	O
amino	B
acid	I
sequence	O
as	O
the	O
amino	B
acid	I
sequence	O
represented	O
by	O
SEQ	O
ID	O
NO	O
:	O
1	O
,	O
a	O
compound	O
or	O
its	O
salt	O
that	O
inhibits	O
the	O
expression	O
of	O
a	O
gene	O
for	O
the	O
protein	O
,	O
an	O
antisense	O
polynucleotide	O
comprising	O
the	O
entirety	O
or	O
part	O
of	O
a	O
nucleotide	O
sequence	O
complementary	O
or	O
substantially	O
complementary	O
to	O
a	O
nucleotide	O
sequence	O
of	O
a	O
polynucleotide	O
encoding	O
the	O
protein	O
or	O
its	O
partial	O
peptide	O
,	O
an	O
antibody	O
against	O
the	O
protein	O
,	O
or	O
the	O
like	O
.	O

Prophylactic	O
/	O
Therapeutic	O
Agent	O
for	O
Cancer	O

This	O
invention	O
relates	O
to	O
methods	O
and	O
kits	O
for	O
enhancing	O
the	O
permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
of	O
abnormal	O
brain	O
tissue	O
or	O
the	O
blood	O
-	O
tumor	O
barrier	O
.	O

Particularly	O
,	O
methods	O
comprising	O
the	O
administration	O
of	O
5-phosphodiesterase	O
inhibitors	O
,	O
such	O
as	O
sildenafil	B
and	O
vardenafil	B
,	O
to	O
selectively	O
enhance	O
the	O
permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
of	O
abnormal	O
brain	O
tissue	O
or	O
the	O
blood	O
-	O
tumor	O
barrier	O
are	O
described	O
.	O

This	O
selective	O
enhancement	O
allows	O
for	O
selective	O
delivery	O
of	O
therapeutic	O
agents	O
or	O
imaging	O
to	O
treat	O
the	O
abnormal	O
brain	O
tissue	O
or	O
a	O
tumor	O
,	O
including	O
brain	O
tumors	O
and	O
non	O
-	O
central	O
nervous	O
system	O
tumors	O
.	O

Use	O
of	O
5-phosphodiesterase	O
inhibitors	O
to	O
enhance	O
the	O
permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
of	O
abnormal	O
brain	O
tissue	O
and	O
the	O
blood	O
-	O
tumor	O
barrier	O

The	O
invention	O
is	O
concerned	O
with	O
novel	O
piperazine	B
amide	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R11	O
,	O
W	O
,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims	O
,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
thereof	O
.	O

These	O
compounds	O
bind	O
to	O
LXR	O
alpha	O
and	O
LXR	O
beta	O
and	O
can	O
be	O
used	O
as	O
medicaments	O
.	O

Piperazine	B
amide	I
derivatives	O

Tropisetron	B
or	O
salt	O
thereof	O
,	O
formulated	O
into	O
diverse	O
pharmaceutical	O
/	O
dermatological	O
compositions	O
,	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
inflammatory	O
skin	O
disorders	O
/	O
diseases	O
,	O
e.g.	O
,	O
eczema	O
,	O
psoriasis	O
,	O
rosacea	O
,	O
acne	O
vulgaris	O
,	O
ulcers	O
,	O
seborrhoeic	O
dermatitis	O
and	O
irritations	O
induced	O
by	O
chemical	O
,	O
physical	O
or	O
mechanical	O
agents	O
,	O
notably	O
rosacea	O
.	O

Administration	O
of	O
tropisetron	B
for	O
treating	O
inflammatory	O
skin	O
diseases	O
/	O
disorders	O

A	O
method	O
and	O
composition	O
for	O
treating	O
allergic	O
diseases	O
and/or	O
airway	O
inflammation	O
including	O
pollinosis	O
,	O
bronchial	O
asthma	O
,	O
allergic	O
rhinitis	O
,	O
atopic	O
dermatitis	O
and	O
anaphylactic	O
shock	O
with	O
the	O
administration	O
to	O
a	O
subject	O
an	O
amount	O
of	O
an	O
anti	O
-	O
infectious	O
agent	O
such	O
as	O
ribavirin	B
and	O
optionally	O
combined	O
with	O
an	O
anti	O
-	O
inflammatory	O
agent	O
selected	O
from	O
inhaled	O
steroids	B
,	O
leukotriene	O
receptor	O
antagonists	O
and	O
beta-2	O
receptor	O
agonist	O
.	O

Method	O
and	O
Composition	O
for	O
Treating	O
Allergic	O
Diseases	O

Novel	O
compositions	O
of	O
silicon	B
-	O
containing	O
anti	O
-	O
metabolite	O
compounds	O
,	O
their	O
preparation	O
and	O
use	O
in	O
methods	O
for	O
treating	O
cancer	O
are	O
described	O
.	O

The	O
silyl	O
group	O
confers	O
lipophilicity	O
that	O
can	O
enhance	O
the	O
penetration	O
of	O
the	O
compounds	O
across	O
the	O
gut	O
wall	O
,	O
cell	O
membranes	O
and	O
blood	O
brain	O
barrier	O
,	O
thus	O
improving	O
therapeutic	O
properties	O
including	O
bioavailability	O
,	O
metabolism	O
,	O
and/or	O
pharmacokinetics	O
.	O

The	O
triorganosilyl	O
group	O
provides	O
compounds	O
having	O
improved	O
pharmacokinetics	O
and	O
anti	O
-	O
tumor	O
activity	O
.	O

The	O
invention	O
encompasses	O
novel	O
compounds	O
,	O
analogs	O
,	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treatment	O
of	O
diseases	O
and	O
other	O
maladies	O
or	O
conditions	O
involving	O
cancer	O
and	O
the	O
like	O
.	O

The	O
subject	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
making	O
such	O
compounds	O
as	O
well	O
as	O
to	O
intermediates	O
useful	O
in	O
such	O
processes	O
.	O

Pharmaceutical	O
compositions	O
of	O
silicon	B
-	O
containing	O
substituted	O
adenosine	B
nucleoside	O
amide	B
analogs	O

Novel	O
thienopyridine	B
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
Y	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
HSP90	O
inhibitors	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
the	O
inhibition	O
,	O
regulation	O
and/or	O
modulation	O
of	O
HSP90	O
plays	O
a	O
role	O
.	O

Thienopyridine	B
Derivatives	O
and	O
the	O
Use	O
Thereof	O
as	O
Hsp90	O
Modulators	O

A	O
method	O
for	O
treating	O
a	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
including	O
providing	O
a	O
fiber	O
/	O
granule	O
complex	O
made	O
of	O
non	O
-	O
absorbable	O
fibers	O
having	O
granules	O
attached	O
thereto	O
,	O
and	O
ingesting	O
the	O
fiber	O
/	O
granule	O
complex	O
orally	O
,	O
wherein	O
the	O
fiber	O
/	O
granule	O
complex	O
treats	O
materials	O
in	O
the	O
GI	O
tract	O
as	O
it	O
passes	O
through	O
the	O
GI	O
tract	O
,	O
the	O
fiber	O
/	O
granule	O
complex	O
not	O
being	O
substantially	O
absorbed	O
by	O
the	O
GI	O
tract	O
.	O

Fiber	O
/	O
granule	O
complex	O
for	O
treatment	O
of	O
the	O
gi	O
tract	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
inhibiting	O
or	O
blocking	O
TGF	O
-	O
β	O
activity	O
in	O
cells	O
and/or	O
tissues	O
expressing	O
TGF	O
-	O
β	O
comprising	O
,	O
contacting	O
cells	O
and/or	O
tissues	O
expressing	O
TGF	O
-	O
β	O
with	O
an	O
amount	O
of	O
cholesterol	O
or	O
cholesterol	O
derivative	O
effective	O
to	O
inhibit	O
the	O
activity	O
of	O
TGF	O
-	O
β	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
for	O
treating	O
a	O
condition	O
associated	O
with	O
overactivity	O
of	O
TGF	O
-	O
β	O
or	O
negative	O
regulation	O
in	O
normal	O
physiology	O
by	O
TGF	O
-	O
β	O
in	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
,	O
comprising	O
contacting	O
cells	O
and/or	O
tissue	O
overexpressing	O
TGF	O
-	O
β	O
in	O
the	O
subject	O
with	O
an	O
amount	O
of	O
cholesterol	O
or	O
cholesterol	O
derivative	O
effective	O
to	O
inhibit	O
activity	O
of	O
TGF	O
-	O
β	O
thereby	O
treating	O
the	O
condition	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
cholesterol	O
derivative	O
is	O
oxidized	O
7-DHC	O
.	O

METHODS	O
FOR	O
INHIBITING	O
TGF	O
-	O
beta	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
inhibit	O
a5b1	O
function	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
as	O
the	O
active	O
ingredient	O
,	O
to	O
their	O
use	O
as	O
medicaments	O
and	O
to	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
use	O
in	O
the	O
treatment	O
in	O
warm	O
-	O
blooded	O
animals	O
such	O
as	O
humans	O
of	O
diseases	O
that	O
have	O
a	O
significant	O
angiogenesis	O
or	O
vascular	O
component	O
such	O
as	O
for	O
treatment	O
of	O
solid	O
tumours	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
compounds	O
that	O
inhibit	O
a5b1	O
,	O
and	O
also	O
that	O
exhibit	O
appropriate	O
selectivity	O
profile	O
(	O
s	O
)	O
against	O
other	O
integrins	O
.	O

L	B
-	I
ALANINE	I
DERIVATIVES	O
AS	O
a5beta1	O
ANTAGONISTS	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
or	O
preventing	O
autoimmune	O
diseases	O
with	O
spiro	B
2,4-pyrimidinediamine	I
compounds	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
,	O
preventing	O
or	O
ameliorating	O
symptoms	O
associated	O
with	O
such	O
diseases	O
.	O

Specific	O
examples	O
of	O
autoimmune	O
diseases	O
that	O
can	O
be	O
treated	O
or	O
prevented	O
with	O
the	O
compounds	O
include	O
rheumatoid	O
arthritis	O
and/or	O
its	O
associated	O
symptoms	O
,	O
systemic	O
lupus	O
erythematosis	O
and/or	O
its	O
associated	O
symptoms	O
and	O
multiple	O
sclerosis	O
and/or	O
its	O
associated	O
symptoms	O
.	O

Spiro	B
2,4	I
pyrimidinediamine	I
compounds	O
and	O
their	O
uses	O

The	O
present	O
application	O
describes	O
deuterium	B
-	I
enriched	I
linezolid	I
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Deuterium	B
-	I
enriched	I
linezolid	I

The	O
present	O
application	O
describes	O
deuterium	B
-	I
enriched	I
maraviroc	I
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Deuterium	B
-	I
enriched	I
maraviroc	I

The	O
present	O
application	O
describes	O
deuterium	B
-	I
enriched	I
fesoterodine	I
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Deuterium	B
-	I
enriched	I
fesoterodine	I

A	O
delivery	O
vehicle	O
for	O
a	O
silver	B
ion	I
source	O
such	O
as	O
silver	B
nitrate	I
and	O
the	O
like	O
,	O
suitable	O
for	O
use	O
in	O
the	O
treatment	O
of	O
menorrhagia	O
,	O
comprises	O
a	O
plurality	O
of	O
physiologically	O
inert	O
beads	O
bearing	O
a	O
tissue	O
cauterizing	O
amount	O
of	O
a	O
silver	B
ion	I
source	O
.	O

Preferably	O
the	O
beads	O
are	O
made	O
of	O
a	O
physiologically	O
inert	O
polymer	O
,	O
ceramic	O
or	O
stainless	O
steel	O
.	O

The	O
silver	B
ion	I
source	O
preferably	O
is	O
silver	B
nitrate	I
and	O
can	O
be	O
substantially	O
pure	O
silver	B
nitrate	I
,	O
or	O
can	O
comprise	O
silver	B
nitrate	I
in	O
combination	O
with	O
a	O
physiologically	O
tolerable	O
binder	O
or	O
a	O
diluent	O
.	O

Suitable	O
binders	O
include	O
physiologically	O
tolerable	O
synthetic	O
polymeric	O
binders	O
,	O
polysaccharide	O
binders	O
,	O
and	O
the	O
like	O
.	O

Diluents	O
can	O
include	O
other	O
salt	O
materials	O
such	O
as	O
potassium	B
nitrate	I
.	O

The	O
beads	O
are	O
useful	O
in	O
treating	O
menorrhagia	O
of	O
a	O
mammalian	O
uterus	O
.	O

The	O
beads	O
can	O
be	O
delivered	O
to	O
the	O
uterus	O
via	O
a	O
catheter	O
,	O
and	O
are	O
distributed	O
throughout	O
the	O
uterine	O
cavity	O
by	O
uterine	O
massage	O
or	O
like	O
expedient	O
.	O

Silver	B
ions	I
are	O
delivered	O
to	O
the	O
endometrium	O
and	O
cause	O
necrosis	O
of	O
the	O
endometrial	O
tissue	O
.	O

The	O
silver	B
ions	I
remaining	O
within	O
the	O
uterine	O
cavity	O
can	O
then	O
be	O
neutralized	O
with	O
a	O
sodium	B
chloride	I
solution	O
delivered	O
to	O
the	O
uterus	O
e.g.	O
,	O
by	O
catheter	O
,	O
and	O
the	O
beads	O
recovered	O
from	O
the	O
uterus	O
.	O

administering	O
to	O
the	O
uterine	O
cavity	O
a	O
plurality	O
of	O
physiologically	O
inert	O
beads	O
bearing	O
a	O
tissue	O
necrosing	O
amount	O
of	O
silver	B
nitrate	I
as	O
a	O
solid	O
silver	B
ion	I
source	O
;	O

The	O
present	O
specification	O
provides	O
,	O
inter	O
alia	O
,	O
methods	O
of	O
using	O
Wnt	O
and	O
FZD	O
proteins	O
,	O
genes	O
,	O
FZD	O
and	O
Wnt	O
-	O
specific	O
antibodies	O
and	O
probes	O
in	O
diagnosis	O
and	O
treatment	O
of	O
cancer	O
and	O
for	O
screening	O
test	O
compounds	O
for	O
an	O
ability	O
to	O
treat	O
cancer	O
.	O

Also	O
disclosed	O
are	O
compounds	O
useful	O
for	O
treating	O
cancer	O
such	O
as	O
liver	O
cancer	O
.	O

Wnt	O
proteins	O
and	O
detection	O
and	O
treatment	O
of	O
cancer	O

Methods	O
and	O
compositions	O
are	O
provided	O
for	O
the	O
persistent	O
modification	O
of	O
cell	O
membranes	O
with	O
exogenous	O
proteins	O
so	O
as	O
to	O
alter	O
the	O
function	O
of	O
the	O
cell	O
to	O
achieve	O
effects	O
similar	O
to	O
those	O
of	O
gene	O
therapy	O
,	O
without	O
the	O
introduction	O
of	O
exogenous	O
DNA	O
.	O

DNA	O
sequences	O
,	O
the	O
proteins	O
and	O
polypeptides	O
embodying	O
these	O
sequences	O
are	O
disclosed	O
for	O
modulating	O
the	O
immune	O
system	O
.	O

The	O
modulations	O
include	O
down	O
-	O
regulation	O
,	O
up	O
-	O
regulation	O
and	O
apoptosis	O
.	O

Alteration	O
of	O
cell	O
membrane	O
for	O
new	O
functions	O

Described	O
are	O
drug	O
formulations	O
that	O
increase	O
regional	O
delivery	O
of	O
the	O
drugs	O
to	O
cells	O
.	O

Methods	O
for	O
reversibly	O
increasing	O
the	O
hydrophobicity	O
of	O
a	O
drug	O
through	O
hydrolytically	O
labile	O
attachment	O
of	O
a	O
hydrophobic	O
moiety	O
and	O
methods	O
for	O
delivering	O
the	O
modified	O
drug	O
to	O
cells	O
are	O
described	O
.	O

Hydrophobic	O
modification	O
increases	O
drug	O
delivery	O
,	O
while	O
lability	O
minimizes	O
entry	O
of	O
the	O
drug	O
into	O
non	O
-	O
target	O
cells	O
.	O

Reversible	O
Hydrophobic	O
Modification	O
of	O
Drugs	O
for	O
Improved	O
Delivery	O
to	O
Cells	O

The	O
present	O
application	O
describes	O
deuterium	B
-	I
enriched	I
fospropofol	I
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Deuterium	B
-	I
enriched	I
fospropofol	I

Orally	O
deliverable	O
pharmaceutical	O
compositions	O
are	O
provided	O
comprising	O
a	O
drug	O
of	O
tow	O
water	O
solubility	O
suspended	O
in	O
an	O
aqueous	O
liquid	O
vehicle	O
comprising	O
a	O
wetting	O
agent	O
,	O
a	O
thixotropic	O
thickening	O
agent	O
,	O
and	O
an	O
inorganic	O
suspending	O
agent	O
.	O

The	O
compositions	O
are	O
thixotropic	O
,	O
substantially	O
deflocculated	O
,	O
and	O
substantially	O
physically	O
stable	O
.	O

Stabilized	O
Oral	O
Suspension	O
Formulation	O

A	O
tissue	O
adhesive	O
antimicrobial	O
material	O
that	O
is	O
placed	O
into	O
a	O
tooth	O
extraction	O
site	O
for	O
the	O
sustained	O
release	O
of	O
silver	B
for	O
the	O
prevention	O
and	O
treatment	O
of	O
alveolar	O
osteitis	O
.	O

The	O
antimicrobial	O
material	O
is	O
placed	O
into	O
a	O
tooth	O
extraction	O
site	O
via	O
syringe	O
,	O
hand	O
instrument	O
or	O
hand	O
delivery	O
device	O
.	O

Prevention	O
and	O
treatment	O
of	O
alveolar	O
osteitis	O

The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
immunologic	O
diseases	O
or	O
pathological	O
conditions	O
involving	O
an	O
immunologic	O
component	O
using	O
certain	O
Lck	O
inhibitors	O
already	O
known	O
as	O
kinase	O
inhibitors	O
for	O
therapy	O
in	O
oncology	O
,	O
optionally	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
drugs	O
selected	O
from	O
NSAIDs	O
,	O
steroids	O
,	O
DMARDs	O
,	O
immunsuppressives	O
,	O
biologic	O
response	O
modifiers	O
and	O
antinfectives	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
Lck	O
inhibitors	O
together	O
with	O
said	O
other	O
drugs	O
,	O
and	O
the	O
use	O
of	O
the	O
Lck	O
inhibitors	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
immunologic	O
diseases	O
or	O
pathological	O
conditions	O
involving	O
an	O
immunologic	O
component	O
.	O

Use	O
of	O
Lck	O
inhibitors	O
for	O
treatment	O
of	O
immunologic	O
diseases	O

A	O
new	O
class	O
of	O
paromomycin	B
-	O
derived	O
aminoglycosides	B
,	O
which	O
exhibit	O
efficient	O
stop	O
-	O
codon	O
mutation	O
suppression	O
activity	O
,	O
low	O
toxicity	O
and	O
high	O
selectivity	O
towards	O
eukaryotic	O
cells	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
chemical	O
and	O
chemo	O
-	O
enzymatic	O
processes	O
of	O
preparing	O
these	O
paromomycin	B
-	O
derived	O
aminoglycosides	B
and	O
intermediates	O
thereof	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
uses	O
thereof	O
in	O
the	O
treatment	O
of	O
genetic	O
disorders	O
.	O

Novel	O
aminoglycosides	B
and	O
uses	O
thereof	O
in	O
the	O
treatment	O
of	O
genetic	O
disorders	O

A	O
method	O
of	O
diagnosing	O
melanoma	O
and/or	O
monitoring	O
melanoma	O
progression	O
,	O
in	O
particular	O
for	O
determining	O
whether	O
the	O
melanoma	O
is	O
likely	O
to	O
have	O
metastatic	O
capabilities	O
,	O
in	O
a	O
subject	O
includes	O
the	O
steps	O
of	O
in	O
a	O
test	O
sample	O
determining	O
the	O
methylation	O
status	O
of	O
FABP5	O
wherein	O
methylation	O
of	O
the	O
gene	O
indicates	O
a	O
positive	O
diagnosis	O
of	O
melanoma	O
and/or	O
increased	O
methylation	O
of	O
the	O
gene	O
indicates	O
the	O
progression	O
of	O
melanoma	O
.	O

Methods	O
of	O
monitoring	O
melanoma	O
progression	O
may	O
also	O
incorporate	O
measuring	O
the	O
expression	O
levels	O
of	O
FABP5	O
,	O
with	O
low	O
levels	O
of	O
expression	O
indicating	O
a	O
positive	O
diagnosis	O
of	O
melanoma	O
and/or	O
lower	O
levels	O
of	O
expression	O
being	O
indicative	O
of	O
progression	O
of	O
melanoma	O
.	O

Methods	O
of	O
treating	O
melanoma	O
in	O
a	O
subject	O
comprise	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
DNA	O
methyltransferase	O
inhibitor	O
or	O
a	O
histone	O
deacetylase	O
inhibitor	O
to	O
the	O
subject	O
such	O
that	O
expression	O
of	O
FABP5	O
is	O
increased	O
.	O

Microarrays	O
for	O
use	O
in	O
these	O
diagnostic	O
methods	O
and	O
compound	O
screening	O
methods	O
based	O
around	O
monitoring	O
methylation	O
and/or	O
expression	O
of	O
FABP5	O
are	O
also	O
envisaged	O
.	O

Markers	O
for	O
melanoma	O

A	O
composition	O
is	O
provided	O
that	O
allows	O
for	O
treatment	O
of	O
cancer	O
,	O
prophylactic	O
treatment	O
,	O
and	O
treatment	O
of	O
infection	O
in	O
the	O
urinary	O
tract	O
.	O

The	O
composition	O
comprises	O
a	O
nitric	B
oxide	I
(	O
NO	B
)	O
eluting	O
polymer	O
that	O
elutes	O
nitric	B
oxide	I
(	O
NO	B
)	O
in	O
a	O
therapeutic	O
dose	O
.	O

The	O
nitric	B
oxide	I
(	O
NO	B
)	O
eluting	O
polymer	O
may	O
be	O
integrated	O
with	O
a	O
carrier	O
material	O
,	O
such	O
that	O
said	O
carrier	O
material	O
,	O
in	O
use	O
,	O
regulates	O
and	O
controls	O
the	O
elution	O
of	O
said	O
therapeutic	O
dosage	O
of	O
nitric	B
oxide	I
(	O
NO	B
)	O
.	O

The	O
nitric	B
oxide	I
(	O
NO	B
)	O
eluting	O
polymer	O
may	O
be	O
provided	O
as	O
a	O
Solution	O
or	O
Suspension	O
.	O

Furthermore	O
,	O
a	O
manufacturing	O
method	O
for	O
said	O
composition	O
is	O
disclosed	O
,	O
as	O
well	O
as	O
uses	O
of	O
said	O
composition	O
in	O
the	O
urinary	O
tract	O
.	O

Composition	O
And	O
Its	O
Use	O
For	O
The	O
Manufacture	O
Of	O
A	O
Medicament	O
For	O
Treating	O
,	O
Prophylactically	O
Treating	O
,	O
Preventing	O
Cancer	O
And	O
/	O
Or	O
Infections	O
In	O
The	O
Urinary	O
Tract	O

Stabilized	O
transdermal	O
acid	O
sensitive	O
drug	O
formulations	O
and	O
their	O
associated	O
methods	O
of	O
production	O
and	O
use	O
are	O
described	O
.	O

The	O
formulations	O
containing	O
acid	O
sensitive	O
drugs	O
can	O
also	O
an	O
acrylic	B
adhesive	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
base	O
.	O

The	O
formulations	O
can	O
further	O
contain	O
other	O
adhesives	O
,	O
permeation	O
enhancers	O
,	O
and	O
other	O
stabilizing	O
compounds	O
such	O
as	O
free	O
radical	O
inhibitors	O
.	O

Use	O
of	O
bases	O
to	O
stabilize	O
transdermal	O
formulations	O

The	O
present	O
invention	O
provides	O
combination	O
therapy	O
methods	O
of	O
treating	O
proliferative	O
diseases	O
(	O
such	O
as	O
cancer	O
)	O
comprising	O
a	O
first	O
therapy	O
comprising	O
administering	O
to	O
an	O
individual	O
an	O
effective	O
amount	O
of	O
a	O
taxane	O
in	O
a	O
nanoparticle	O
composition	O
,	O
and	O
a	O
second	O
therapy	O
which	O
may	O
include	O
,	O
for	O
example	O
,	O
radiation	O
,	O
surgery	O
,	O
administration	O
of	O
chemotherapeutic	O
agents	O
,	O
or	O
combinations	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
administering	O
to	O
an	O
individual	O
a	O
drug	O
taxane	B
in	O
a	O
nanoparticle	O
composition	O
based	O
on	O
a	O
metronomic	O
dosing	O
regime	O
.	O

antiproliferative	O
agents	O
,	O
anticancer	O
agents	O
such	O
as	O
paclitaxel	B
particles	O
coated	O
with	O
albumin	O
,	O
and	O
gemcitabine	B
;	O
pancreas	O
cancer	O

A	O
topical	O
cosmetic	O
or	O
dermatological	O
preparation	O
which	O
is	O
effective	O
for	O
treating	O
a	O
pruritic	O
condition	O
,	O
is	O
present	O
as	O
a	O
non	O
-	O
ionic	O
O	O
/	O
W	O
emulsion	O
,	O
and	O
comprises	O
water	O
,	O
one	O
or	O
more	O
oil	O
phases	O
,	O
PEG	B
12	O
cetearylether	B
and/or	O
PEG	B
40	O
monostearate	B
,	O
polidocanol	B
,	O
menthol	B
,	O
and	O
one	O
or	O
more	O
O	O
/	O
W	O
emulsifiers	O
or	O
co	O
-	O
emulsifiers	O
.	O

Antipruritic	O
cosmetic	O
and	O
dermatological	O
preparations	O

Compounds	O
of	O
formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
Z	O
are	O
as	O
defined	O
in	O
the	O
specification	O
as	O
well	O
as	O
salts	O
and	O
pharmaceutical	O
compositions	O
including	O
the	O
compounds	O
are	O
prepared	O
.	O

They	O
are	O
useful	O
in	O
therapy	O
,	O
in	O
particular	O
in	O
the	O
management	O
of	O
pain	O
.	O

Benzimidazole	B
Derivatives	O
,	O
Compositions	O
Containing	O
Them	O
,	O
Preparation	O
Thereof	O
and	O
Uses	O
Thereof	O

An	O
acetone	B
extract	O
,	O
chloroform	B
extract	O
or	O
hexane	B
extract	O
of	O
Angelicae	O
sinensis	O
and/or	O
the	O
active	O
components	O
purified	O
therefrom	O
,	O
such	O
as	O
n	B
-	I
butylidenephthalide	I
,	O
are	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
chemotherapy	O
drugs	O
and	O
are	O
effective	O
in	O
treating	O
cancers	O
.	O

Angelicae	O
Sinensis	O
Extracts	O
Useful	O
for	O
Treatment	O
of	O
Cancers	O

Methods	O
for	O
enhancing	O
the	O
quality	O
of	O
life	O
of	O
a	O
senior	O
or	O
super	O
senior	O
animal	O
by	O
feeding	O
the	O
animal	O
a	O
composition	O
comprising	O
at	O
least	O
one	O
omega-3	O
polyunsaturated	O
fatty	O
acid	O
and	O
various	O
combinations	O
of	O
amino	B
acids	I
,	O
minerals	O
,	O
and	O
antioxidants	O
in	O
amounts	O
effective	O
to	O
enhance	O
alertness	O
,	O
improve	O
vitality	O
,	O
protect	O
cartilage	O
,	O
maintain	O
muscle	O
mass	O
,	O
enhance	O
digestibility	O
,	O
and	O
improve	O
skin	O
and	O
pelage	O
quality	O
.	O

Changes	O
in	O
expression	O
of	O
genes	O
associated	O
with	O
several	O
biological	O
pathways	O
induced	O
in	O
an	O
animal	O
by	O
feeding	O
it	O
said	O
composition	O
are	O
consistent	O
with	O
an	O
enhanced	O
quality	O
of	O
life	O
.	O

Methods	O
for	O
Enhancing	O
the	O
Quality	O
of	O
Life	O
of	O
a	O
Senior	O
Animal	O

The	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
is	O
administered	O
to	O
a	O
subject	O
suffering	O
from	O
diabetes	O
or	O
obesity	O
.	O

In	O
the	O
formula	O
(	O
I	O
)	O
,	O
R1	O
and	O
R2	O
independently	O
represent	O
an	O
aliphatic	B
hydrocarbon	I
group	O
having	O
1	O
to	O
10	O
carbon	B
atoms	O
or	O
phenyl	B
group	O
,	O
and	O
arbitrary	O
hydrogen	B
atoms	O
on	O
the	O
aliphatic	B
hydrocarbon	I
group	O
and	O
the	O
phenyl	B
group	O
may	O
be	O
replaced	O
by	O
halogen	B
,	O
X1	O
represents	O
halogen	B
,	O
and	O
X2	O
represents	O
hydrogen	B
or	O
halogen	B
.	O

Method	O
of	O
lowering	O
blood	O
glucose	B
and	O
method	O
of	O
preventing	O
or	O
treating	O
blood	O
glucose	B
and	O
method	O
of	O
preventing	O
or	O
treating	O
diabetes	O
and	O
obesity	O

Methods	O
of	O
treating	O
or	O
suppressing	O
mitochondrial	O
diseases	O
,	O
such	O
as	O
Friedreich	O
's	O
ataxia	O
(	O
FRDA	O
)	O
,	O
Leber	O
's	O
Hereditary	O
Optic	O
Neuropathy	O
(	O
LHON	O
)	O
,	O
mitochondrial	O
myopathy	O
,	O
encephalopathy	O
,	O
lactacidosis	O
,	O
and	O
stroke	O
(	O
MELAS	O
)	O
,	O
Kearns	O
-	O
Sayre	O
Syndrome	O
(	O
KSS	O
)	O
,	O
are	O
disclosed	O
,	O
as	O
well	O
as	O
compounds	O
useful	O
in	O
the	O
methods	O
of	O
the	O
invention	O
,	O
such	O
as	O
4-	B
(	I
p	I
-	I
quinolyl	I
)	I
-2-hydroxybutanamide	I
derivatives	O
.	O

Methods	O
and	O
compounds	O
useful	O
in	O
treating	O
other	O
disorders	O
such	O
as	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
Huntington	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
and	O
pervasive	O
developmental	O
disorders	O
such	O
as	O
autism	O
are	O
also	O
disclosed	O
.	O

Energy	O
biomarkers	O
useful	O
in	O
assessing	O
the	O
metabolic	O
state	O
of	O
a	O
subject	O
and	O
the	O
efficacy	O
of	O
treatment	O
are	O
also	O
disclosed	O
.	O

Methods	O
of	O
modulating	O
,	O
normalizing	O
,	O
or	O
enhancing	O
energy	O
biomarkers	O
,	O
as	O
well	O
as	O
compounds	O
useful	O
for	O
such	O
methods	O
,	O
are	O
also	O
disclosed	O
.	O

4-	B
(	I
p	I
-	I
QUINONYL	I
)	I
-2-HYDROXYBUTANAMIDE	I
DERIVATIVES	O
FOR	O
TREATMENT	O
OF	O
MITOCHONDRIAL	O
DISEASES	O

This	O
invention	O
relates	O
to	O
gene	O
polypeptides	O
and	O
polynucleotides	O
that	O
encode	O
proteins	O
of	O
the	O
Nogo-66	O
receptor	O
(	O
NgR	O
)	O
family	O
and	O
are	O
therefore	O
called	O
NgR	O
homologue	O
1	O
(	O
NgRH1	O
)	O
.	O

The	O
invention	O
further	O
relates	O
to	O
their	O
use	O
in	O
identifying	O
compounds	O
that	O
may	O
be	O
agonists	O
or	O
antagonists	O
that	O
are	O
potentially	O
useful	O
in	O
regeneration	O
and	O
protection	O
of	O
the	O
nervous	O
system	O
,	O
and	O
to	O
production	O
of	O
NgRH1	O
polypepfldes	O
,	O
derivatives	O
,	O
and	O
antibodies	O
.	O

Nogo	O
receptor	O
homologues	O
and	O
their	O
use	O

A	O
peptide	O
having	O
any	O
one	O
of	O
the	O
amino	B
acid	I
sequences	O
of	O
SEQ	O
ID	O
NO	O
:	O
1	O
or	O
13	O
,	O
preferably	O
a	O
peptide	O
having	O
any	O
one	O
of	O
the	O
amino	B
acid	I
sequences	O
of	O
SEQ	O
ID	O
NOS	O
:	O
2	O
to	O
9	O
or	O
a	O
peptide	O
having	O
any	O
one	O
of	O
the	O
amino	B
acid	I
sequences	O
of	O
SEQ	O
ID	O
NOS	O
:	O
10	O
and	O
15	O
to	O
17	O
,	O
is	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
an	O
agent	O
for	O
promoting	O
growth	O
or	O
differentiation	O
of	O
cells	O
such	O
as	O
osteoblasts	O
,	O
chondroblasts	O
,	O
cementoblasts	O
,	O
bone	O
marrow	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
and	O
periodontal	O
ligament	O
-	O
derived	O
cells	O
.	O

Biologically	O
active	O
peptide	O
and	O
agent	O
containing	O
the	O
same	O

The	O
present	O
invention	O
provides	O
novel	O
compounds	O
of	O
Formula	O
I	O
:	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
I	O
and	O
to	O
methods	O
of	O
using	O
compounds	O
of	O
Formula	O
I	O
to	O
treat	O
neuropsychiatric	O
disorders	O
(	O
e.g.	O
,	O
psychosis	O
,	O
depression	O
,	O
schizophrenia	O
)	O
.	O

Atypical	O
antipsychotic	O
agents	O
having	O
low	O
affinity	O
for	O
the	O
D2	O
receptor	O

Methods	O
for	O
using	O
death	O
receptor	O
ligands	O
,	O
such	O
as	O
Apo-2	O
ligand	O
/	O
TRAIL	O
polypeptides	O
or	O
death	O
receptor	O
antibodies	O
,	O
and	O
EGFR	O
inhibitors	O
to	O
treat	O
pathological	O
conditions	O
such	O
as	O
cancer	O
are	O
provided	O
.	O

Embodiments	O
of	O
the	O
invention	O
include	O
methods	O
of	O
using	O
Apo2L	O
/	O
TRAIL	O
or	O
death	O
receptor	O
antibodies	O
such	O
as	O
DR5	O
antibodies	O
and	O
DR4	O
antibodies	O
in	O
combination	O
with	O
EGFR	O
inhibitors	O
,	O
such	O
as	O
Tarceva	B
™	I
.	O

Methods	O
of	O
Using	O
Death	O
Receptor	O
Agonists	O
and	O
EGFR	O
Inhibitors	O

The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
the	O
prophylaxis	O
of	O
blood	O
cell	O
disorders	O
such	O
as	O
neutropenia	O
,	O
thrombocytopenia	O
,	O
lymphocytopenia	O
,	O
and	O
anaemia	O
.	O

The	O
invention	O
provides	O
methods	O
wherein	O
compositions	O
comprising	O
at	O
least	O
one	O
cytokinin	O
compound	O
are	O
administered	O
either	O
therapeutically	O
or	O
prophylactically	O
.	O

The	O
invention	O
further	O
has	O
utility	O
in	O
methods	O
of	O
DNA	O
repair	O
.	O

Compositions	O
and	O
methods	O
for	O
modulating	O
the	O
immune	O
system	O

The	O
pharmaceutical	O
compositions	O
having	O
analgesic	O
effect	O
referred	O
to	O
in	O
this	O
invention	O
are	O
composed	O
of	O
the	O
aconitine	B
ingredients	O
as	O
the	O
active	O
medical	O
ingredients	O
and	O
other	O
acceptable	O
auxiliary	O
ingredients	O
.	O

The	O
active	O
medical	O
ingredients	O
shall	O
at	O
least	O
include	O
the	O
fuziline	B
compound	O
of	O
Formula	O
(	O
I	O
)	O
.	O

The	O
drugs	O
exert	O
desirable	O
analgesic	O
effect	O
with	O
low	O
toxicity	O
.	O

They	O
can	O
be	O
made	O
into	O
commonly	O
used	O
oral	O
preparations	O
,	O
injectable	O
preparations	O
and/or	O
external	O
preparations	O
,	O
including	O
ointments	O
,	O
suppositories	O
lotions	O
,	O
medicinal	O
dressings	O
,	O
etc	O
.	O

Pharmaceutical	O
composition	O
having	O
analgesic	O
effects	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
diagnosing	O
epilepsy	O
in	O
a	O
mammal	O
by	O
detecting	O
ST3	O
β	O
-	O
galactoside	O
α-2,3-sialyltransferase	O
3	O
(	O
ST3Gal	O
-	O
III	O
)	O
activity	O
or	O
by	O
detecting	O
for	O
one	O
or	O
more	O
mutations	O
in	O
a	O
ST3Gal	O
-	O
III	O
gene	O
that	O
decrease	O
that	O
activity	O
of	O
a	O
ST3Gal	O
-	O
III	O
polypeptide	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
of	O
treating	O
an	O
epileptic	O
condition	O
associated	O
with	O
decreased	O
ST3Gal	O
-	O
III	O
activity	O
by	O
administering	O
one	O
or	O
more	O
agents	O
that	O
increase	O
the	O
activity	O
of	O
ST3Gal	O
-	O
III	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
identifying	O
one	O
or	O
more	O
agents	O
that	O
increase	O
the	O
activity	O
of	O
ST3Gal	O
-	O
III	O
.	O

Treatment	O
of	O
epilepsy	O
by	O
expressing	O
st3gal	O
-	O
iii	O

The	O
present	O
invention	O
is	O
directed	O
to	O
an	O
improved	O
system	O
for	O
controlled	O
release	O
of	O
a	O
bone	O
growth	O
promoting	O
compound	O
and	O
to	O
a	O
flowable	O
composition	O
for	O
its	O
formation	O
.	O

The	O
flowable	O
composition	O
is	O
composed	O
of	O
a	O
bone	O
growth	O
promoting	O
compound	O
,	O
a	O
thermoplastic	O
polymer	O
and	O
an	O
organic	O
solvent	O
.	O

The	O
flowable	O
composition	O
is	O
capable	O
of	O
forming	O
a	O
biodegradable	O
and/or	O
bioerodible	O
microporous	O
,	O
solid	O
polymer	O
matrix	O
.	O

The	O
matrix	O
is	O
useful	O
as	O
an	O
implant	O
in	O
patients	O
(	O
humans	O
and	O
animals	O
)	O
for	O
delivery	O
of	O
a	O
bone	O
growth	O
promoting	O
compound	O
to	O
certain	O
tissues	O
.	O

Controlled	O
Release	O
Polymeric	O
Compositions	O
of	O
Bone	O
Growth	O
Promoting	O
Compounds	O

The	O
present	O
invention	O
discloses	O
Mnk	O
homologous	O
proteins	O
regulating	O
the	O
energy	O
homeostasis	O
,	O
the	O
metabolism	O
of	O
triglycerides	B
,	O
and/or	O
is	O
contributing	O
to	O
membrane	O
stability	O
and/or	O
function	O
of	O
organelles	O
,	O
and	O
polynucleotides	O
,	O
which	O
identify	O
and	O
encode	O
the	O
proteins	O
disclosed	O
in	O
this	O
invention	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
these	O
sequences	O
in	O
the	O
diagnosis	O
,	O
study	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
diseases	O
and	O
disorders	O
related	O
to	O
body	O
-	O
weight	O
regulation	O
and	O
thermogenesis	O
,	O
for	O
example	O
,	O
but	O
not	O
limited	O
to	O
,	O
metabolic	O
diseases	O
such	O
as	O
obesity	O
,	O
as	O
well	O
as	O
related	O
disorders	O
such	O
as	O
eating	O
disorder	O
,	O
cachexia	O
,	O
diabetes	O
mellitus	O
,	O
hypertension	O
,	O
coronary	O
heart	O
disease	O
,	O
hypercholesterolemia	O
,	O
dyslipidemia	O
,	O
osteoarthritis	O
,	O
gallstones	O
,	O
and	O
sleep	O
apnea	O
,	O
and	O
disorders	O
related	O
to	O
ROS	O
defence	O
,	O
such	O
as	O
diabetes	O
mellitus	O
,	O
neurodegenerative	O
disorders	O
,	O
and	O
cancer	O
,	O
e.g.	O
cancers	O
of	O
the	O
reproductive	O
organs	O
,	O
and	O
others	O
.	O

Mnk	O
KINASE	O
HOMOLOGOUS	O
PROTEINS	O
INVOLVED	O
IN	O
THE	O
REGULATION	O
OF	O
ENERGY	O
HOMEOSTASIS	O
AND	O
ORGANELLE	O
METABOLISM	O

The	O
present	O
invention	O
relates	O
to	O
nucleic	O
acid	O
molecules	O
such	O
as	O
ribozymes	O
,	O
DNAzymes	O
,	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
,	O
and	O
antisense	O
which	O
modulate	O
the	O
synthesis	O
,	O
expression	O
and/or	O
stability	O
of	O
an	O
mRNA	O
encoding	O
one	O
or	O
more	O
receptors	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
such	O
as	O
flt-1	O
(	O
VEGFR1	O
)	O
and/or	O
KDR	O
(	O
VEGFR2	O
)	O
.	O

Nucleic	O
acid	O
molecules	O
and	O
methods	O
for	O
the	O
inhibition	O
of	O
angiogenesis	O
and	O
treatment	O
of	O
cancer	O
and	O
other	O
conditions	O
associated	O
with	O
VEGF	O
-	O
R	O
are	O
provided	O
,	O
optionally	O
in	O
conjunction	O
with	O
other	O
therapeutic	O
agents	O
such	O
as	O
interferons	O
.	O

Nucleic	O
Acid	O
-	O
Mediated	O
Treatment	O
of	O
Diseases	O
or	O
Conditions	O
Related	O
to	O
Levels	O
of	O
Vascular	O
Endothelial	O
Growth	O
Factor	O
Receptor	O
(	O
VEGF	O
-	O
R	O
)	O

Substituted	O
benzoimidazole	B
compounds	O
useful	O
as	O
anti	O
-	O
infectives	O
that	O
decrease	O
resistance	O
,	O
virulence	O
,	O
or	O
growth	O
of	O
microbes	O
are	O
provided	O
.	O

Methods	O
of	O
making	O
and	O
using	O
substituted	O
benzoimidazole	B
compounds	O
,	O
as	O
well	O
as	O
pharmaceutical	O
preparations	O
thereof	O
,	O
in	O
,	O
e.g.	O
,	O
reducing	O
antibiotic	O
resistance	O
and	O
inhibiting	O
biofilms	O
.	O

Transcription	O
factor	O
modulating	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
R1	O
represents	O
:	O
halogen	B
,	O
CN	B
or	O
NO2	B
;	O
R2	O
represents	O
:	O
hydrogen	B
or	O
halogen	B
;	O
n	O
represents	O
:	O
1	O
or	O
2	O
;	O
R3	O
represents	O
:	O
phenyl	B
substituted	O
by	O
one	O
or	O
more	O
halogens	B
or	O
C1-C6	B
alkyls	I
;	O
or	O
a	O
cyclohexyl	B
;	O
as	O
well	O
as	O
the	O
therapeutically	O
-	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
protease	O
-	O
activated	O
receptor-1	O
(	O
PAR-1	O
)	O
antagonists	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
thrombosis	O
.	O

Cinnamoyl	B
-	I
piperazine	I
derivatives	O
and	O
their	O
use	O
as	O
par-1	O
antagonists	O

Nanoparticles	O
,	O
the	O
particle	O
matrix	O
of	O
which	O
is	O
based	O
on	O
at	O
least	O
one	O
protein	O
and	O
has	O
at	O
least	O
one	O
active	O
agent	O
embedded	O
therein	O
and	O
methods	O
of	O
producing	O
the	O
nanoparticles	O
with	O
at	O
least	O
one	O
active	O
agent	O
embedded	O
in	O
the	O
protein	O
matrix	O
are	O
disclosed	O
.	O

The	O
use	O
of	O
the	O
nanoparticles	O
for	O
the	O
treatment	O
of	O
tumours	O
,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
tumours	O
which	O
are	O
resistant	O
to	O
chemical	O
medicaments	O
is	O
also	O
disclosed	O
.	O

Protein	O
-	O
Based	O
Carrier	O
System	O
for	O
Overcoming	O
Resistance	O
in	O
Tumour	O
Cells	O

Aromatase	O
inhibitors	O
(	O
AIs	O
)	O
are	O
disclosed	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
post	O
-	O
menopausal	O
breast	O
cancer	O
.	O

New	O
AIs	O
derived	O
from	O
natural	O
products	O
are	O
disclosed	O
that	O
are	O
evaluated	O
for	O
clinical	O
utility	O
for	O
treating	O
post	O
-	O
menopausal	O
breast	O
cancer	O
and	O
may	O
also	O
act	O
as	O
chemopreventive	O
agents	O
for	O
preventing	O
breast	O
cancer	O
.	O

Several	O
pure	O
compounds	O
demonstrated	O
AI	O
activity	O
using	O
a	O
noncellular	O
,	O
enzyme	O
-	O
based	O
microsomal	O
and	O
a	O
cell	O
-	O
based	O
aromatase	O
assay	O
.	O

Correlations	O
are	O
made	O
between	O
structural	O
classes	O
with	O
levels	O
of	O
aromatase	O
inhibition	O
.	O

The	O
disclosure	O
may	O
be	O
utilized	O
to	O
direct	O
synthetic	O
modification	O
of	O
natural	O
product	O
scaffolds	O
to	O
enhance	O
aromatase	O
inhibition	O
or	O
to	O
standardize	O
botanical	O
dietary	O
supplements	O
for	O
increased	O
aromatase	O
inhibition	O
activity	O
.	O

Compositions	O
from	O
Garcinia	O
as	O
Aromatase	O
Inhibitors	O
for	O
Breast	O
Cancer	O
Chemoprevention	O
and	O
Chemotherapy	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
chalcone	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
X	O
,	O
Y	O
,	O
Z	O
,	O
W	O
,	O
RI	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
as	O
defined	O
,	O
said	O
derivatives	O
having	O
antimitotic	O
activity	O
,	O
as	O
well	O
as	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
to	O
their	O
use	O
for	O
making	O
drugs	O
.	O

Novel	O
Chalcone	B
Derivatives	O
With	O
Antimitotic	O
Activity	O

The	O
present	O
invention	O
regards	O
cancer	O
-	O
specific	O
control	O
sequences	O
that	O
direct	O
expression	O
of	O
a	O
polynucleotide	O
encoding	O
a	O
therapeutic	O
gene	O
product	O
for	O
treatment	O
of	O
the	O
cancer	O
.	O

Specifically	O
,	O
the	O
invention	O
encompasses	O
breast	O
cancer	O
-	O
specific	O
and	O
ovarian	O
cancer	O
-	O
specific	O
control	O
sequences	O
.	O

Two	O
breast	O
cancer	O
-	O
specific	O
sequences	O
utilize	O
specific	O
regions	O
of	O
fatty	B
acid	I
synthase	O
and	O
claudin	O
4	O
promoters	O
,	O
particularly	O
in	O
combination	O
with	O
a	O
two	O
-	O
step	O
transcription	O
amplification	O
sequence	O
and/or	O
a	O
post	O
-	O
transcriptional	O
control	O
sequence	O
.	O

Two	O
ovarian	O
cancer	O
-	O
specific	O
sequences	O
utilize	O
specific	O
regions	O
of	O
hTERT	O
and	O
survivin	O
promoters	O
,	O
particularly	O
in	O
combination	O
with	O
a	O
two	O
-	O
step	O
transcription	O
amplification	O
sequence	O
and/or	O
a	O
post	O
-	O
transcriptional	O
control	O
sequence	O
.	O

In	O
more	O
particular	O
embodiments	O
,	O
these	O
polynucleotides	O
are	O
administered	O
in	O
combination	O
with	O
liposomes	O
.	O

Cancer	O
-	O
specific	O
promoters	O

Disclosed	O
are	O
a	O
protein	O
encoded	O
by	O
a	O
gene	O
having	O
a	O
nucleotide	O
sequence	O
represented	O
by	O
any	O
of	O
SEQ	O
ID	O
NOs	O
:	O
1	O
to	O
65	O
or	O
a	O
fragment	O
thereof	O
,	O
an	O
antibody	O
recognizing	O
the	O
protein	O
or	O
antigen	O
-	O
binding	O
fragment	O
thereof	O
,	O
and	O
a	O
polynucleotide	O
having	O
a	O
sequence	O
comprising	O
at	O
least	O
12	O
consecutive	O
nucleotides	O
of	O
a	O
nucleotide	O
sequence	O
represented	O
by	O
any	O
of	O
SEQ	O
ID	O
NOs	O
:	O
1	O
to	O
65	O
or	O
a	O
nucleotide	O
sequence	O
complementary	O
thereto	O
.	O

The	O
gene	O
and	O
the	O
protein	O
of	O
the	O
invention	O
is	O
useful	O
for	O
diagnosing	O
and	O
treating	O
cancer	O
.	O

Gene	O
overexpressed	O
in	O
cancer	O

The	O
instant	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
which	O
are	O
5-lipoxygenase	O
activating	O
protein	O
inhibitors	O
.	O

Compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
anti	O
-	O
atherosclerotic	O
,	O
anti	O
-	O
asthmatic	O
,	O
anti	O
-	O
allergic	O
,	O
anti	O
-	O
inflammatory	O
and	O
cytoprotective	O
agents	O
.	O

Diphenyl	B
Substituted	I
Cycloalkanes	I
,	O
Compositions	O
Containing	O
Such	O
Compounds	O
and	O
Methods	O
Of	O
Use	O

Provided	O
herein	O
are	O
methods	O
of	O
improving	O
,	O
maintaining	O
and	O
restoring	O
renal	O
function	O
,	O
treating	O
heart	O
failure	O
,	O
treating	O
subjects	O
with	O
acute	O
fluid	O
overload	O
,	O
and	O
slowing	O
or	O
reversing	O
an	O
existing	O
or	O
developing	O
renal	O
impairment	O
in	O
subjects	O
with	O
BNP	O
levels	O
of	O
at	O
least	O
400	O
pg	O
/	O
mL	O
and/or	O
NT	O
-	O
proBNP	O
levels	O
of	O
at	O
least	O
about	O
1500	O
pg	O
/	O
mL	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
AA1RA	O
to	O
the	O
subject	O
.	O

Methods	O
of	O
treating	O
heart	O
failure	O
and	O
renal	O
dysfunction	O
in	O
individuals	O
with	O
an	O
adenosine	B
a1	O
receptor	O
antagonist	O

The	O
patent	O
application	O
relates	O
to	O
new	O
heterocyclic	B
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
R	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
n	O
have	O
the	O
definitions	O
elucidated	O
in	O
more	O
detail	O
in	O
the	O
description	O
,	O
to	O
a	O
process	O
for	O
preparing	O
them	O
and	O
to	O
the	O
use	O
of	O
these	O
C	O
compounds	O
as	O
medicaments	O
,	O
particularly	O
as	O
aldosterone	B
synthase	O
inhibitors	O
.	O

Bis	B
-	I
Heterocyclic	I
Imidazolyl	I
Compounds	O

Methods	O
and	O
formulations	O
are	O
provided	O
for	O
treating	O
migraine	O
and	O
other	O
acute	O
pain	O
episodes	O
using	O
diclofenac	B
,	O
and	O
formulations	O
of	O
diclofenac	B
that	O
provide	O
both	O
rapid	O
and	O
sustained	O
relief	O
from	O
acute	O
pain	O
.	O

Methods	O
and	O
formulations	O
are	O
also	O
provided	O
for	O
treating	O
symptoms	O
that	O
often	O
accompany	O
migraine	O
and	O
acute	O
pain	O
such	O
as	O
photophobia	O
,	O
phonophobia	O
,	O
nausea	O
and	O
vomiting	O
.	O

Diclofenac	B
Formulations	O
and	O
Methods	O
of	O
Use	O

The	O
invention	O
provides	O
a	O
nucleotide	O
sequence	O
that	O
encodes	O
an	O
HIV-1	O
gag	O
protein	O
or	O
fragment	O
thereof	O
containing	O
a	O
gag	O
epitope	O
and	O
a	O
second	O
HIV	O
antigen	O
or	O
a	O
fragment	O
encoding	O
an	O
epitope	O
of	O
said	O
second	O
HIV	O
antigen	O
,	O
operably	O
linked	O
to	O
a	O
heterologous	O
promoter	O
.	O

Preferred	O
polynucleotide	O
sequences	O
further	O
encodes	O
nef	O
or	O
a	O
fragment	O
thereof	O
and	O
RT	O
or	O
a	O
fragment	O
thereof	O
.	O

Hiv	O
-	O
gag	O
codon	O
-	O
optimised	O
dna	O
vaccines	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
that	O
are	O
inhibitors	O
of	O
cysteine	B
proteases	O
,	O
in	O
particular	O
,	O
cathepsins	O
B	O
,	O
K	O
,	O
L	O
,	O
F	O
,	O
and	O
S	O
and	O
are	O
therefore	O
useful	O
in	O
treating	O
diseases	O
mediated	O
by	O
these	O
proteases	O
.	O

The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
processes	O
for	O
preparing	O
them	O
.	O

Wherein	O
R3	O
is	O
-alkylene	B
-	I
SO2NR5R6	I
.	O

Sulfonamide	B
compounds	O
as	O
cysteine	B
protease	O
inhibitors	O

The	O
present	O
invention	O
provides	O
novel	O
T	O
type	O
calcium	B
channel	O
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
,	O
the	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
in	O
a	O
mammal	O
associated	O
with	O
influx	O
of	O
extracellular	O
calcium	B
via	O
T	O
type	O
calcium	B
channels	O
,	O
wherein	O
R1	O
is	O
C1-C4	B
alkyl	I
,	O
hydroxy	B
,	O
or	O
C1-C4	B
alkoxy	I
;	O
Z	O
is	O
NH	B
,	O
NCH3	B
,	O
O	B
,	O
S	B
,	O
or	O
CH2	B
;	O
Y	O
is	O
NH	B
,	O
O	B
,	O
or	O
CH2	B
with	O
the	O
proviso	O
that	O
Y	O
and	O
Z	O
are	O
not	O
the	O
same	O
;	O
R2	O
is	O
H	B
,	O
halo	B
,	O
NH2	B
,	O
C1-C4	B
alkyl	I
,	O
hydroxy	B
,	O
or	O
C1-C4	B
alkoxy	I
;	O
m	O
and	O
n	O
are	O
independently	O
selected	O
from	O
integers	O
ranging	O
from	O
1	O
-	O
5	O
with	O
the	O
proviso	O
that	O
m+n	O
=	O
an	O
integer	O
ranging	O
from	O
2	O
-	O
9	O
;	O
and	O
R3	O
is	O
H	B
,	O
halo	B
,	O
NH2	B
,	O
C1-C4	B
alkyl	I
,	O
hydroxy	B
,	O
or	O
C1-C4	B
alkoxy	I
.	O

T	O
Type	O
Calcium	B
Channel	O
Inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
skin	O
disorders	O
,	O
particularly	O
to	O
the	O
prevention	O
and/or	O
treatment	O
of	O
benignant	O
or	O
malignant	O
changes	O
of	O
the	O
epidermis	O
visible	O
in	O
form	O
of	O
e.g.	O
nevus	O
.	O

A	O
pharmaceutical	O
,	O
dermatological	O
and/or	O
cosmetic	O
composition	O
is	O
disclosed	O
comprising	O
as	O
active	O
constituent	O
the	O
boroxine	B
compound	O
.	O

The	O
present	O
invention	O
further	O
provides	O
the	O
respective	O
uses	O
of	O
the	O
boroxine	B
compound	O
in	O
medicine	O
,	O
particularly	O
in	O
the	O
field	O
of	O
skin	O
disorders	O
,	O
and	O
in	O
dermatological	O
and/or	O
cosmetic	O
applications	O
.	O

Removal	O
of	O
skin	O
changes	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
cancer	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
by	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
first	O
amount	O
of	O
a	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
such	O
as	O
suberoylanilide	B
hydroxamic	I
acid	I
(	O
SAHA	B
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	B
thereof	O
,	O
and	O
a	O
second	O
amount	O
of	O
one	O
or	O
more	O
anti	O
-	O
cancer	O
agents	O
,	O
including	O
Bortezomib	B
.	O

The	O
HDAC	O
inhibitor	O
and	O
the	O
anti	O
-	O
cancer	O
agent	O
may	O
be	O
administered	O
to	O
comprise	O
therapeutically	O
effective	O
amounts	O
.	O

In	O
various	O
aspects	O
,	O
the	O
effect	O
of	O
the	O
HDAC	O
inhibitor	O
and	O
the	O
anti	O
-	O
cancer	O
agent	O
may	O
be	O
additive	O
or	O
synergistic	O
.	O

Methods	O
of	O
using	O
saha	O
and	O
bortezomib	B
for	O
treating	O
cancer	O

Compositions	O
and	O
methods	O
for	O
treating	O
ocular	O
disease	O
are	O
provided	O
.	O

Specifically	O
,	O
siRNA	O
molecules	O
and	O
mixtures	O
of	O
siRNA	O
molecules	O
are	O
provided	O
that	O
inhibit	O
angiogenesis	O
and/or	O
neovascularization	O
.	O

The	O
compositions	O
and	O
methods	O
are	O
suitable	O
for	O
treating	O
ocular	O
diseases	O
associated	O
with	O
angiogenesis	O
and/or	O
neovascularization	O
.	O

RNAi	O
Therapeutics	O
for	O
Treatment	O
of	O
Eye	O
Neovascularization	O
Diseases	O

Disclosed	O
herein	O
is	O
a	O
method	O
for	O
reducing	O
the	O
rate	O
of	O
degradation	O
of	O
proteins	O
in	O
an	O
animal	O
,	O
comprising	O
contacting	O
cells	O
of	O
the	O
animal	O
with	O
certain	O
boronic	B
ester	I
and	I
acid	I
compounds	O
.	O

Also	O
disclosed	O
herein	O
are	O
novel	O
boronic	B
ester	I
and	I
acid	I
compounds	O
,	O
their	O
synthesis	O
and	O
uses	O
.	O

Boronic	B
ester	I
and	I
acid	I
compounds	O
,	O
synthesis	O
and	O
uses	O

The	O
invention	O
relates	O
to	O
modulation	O
of	O
fungal	O
morphology	O
between	O
yeast	O
-	O
to	O
-	O
hyphal	O
growth	O
transition	O
by	O
controlling	O
muramyl	B
-	I
L	I
-	I
alanine	I
concentration	O
and	O
uses	O
thereof	O
.	O

Modulators	O
of	O
Candida	O
Hyphal	O
Morphogenesis	O
and	O
Uses	O
Thereof	O

The	O
disclosure	O
relates	O
to	O
medical	O
devices	O
coated	O
with	O
zein	O
admixed	O
with	O
levulinic	B
acid	I
.	O

The	O
medical	O
device	O
may	O
further	O
include	O
a	O
therapeutic	O
agent	O
in	O
contact	O
with	O
zein	O
admixed	O
with	O
levulinic	B
acid	I
.	O

Zein	O
admixed	O
with	O
levulinic	B
acid	I
allows	O
the	O
therapeutic	O
agent	O
to	O
be	O
retained	O
on	O
the	O
device	O
during	O
delivery	O
and	O
also	O
controls	O
the	O
elution	O
rate	O
of	O
the	O
therapeutic	O
agent	O
following	O
implantation	O
.	O

The	O
disclosure	O
further	O
relates	O
to	O
methods	O
of	O
delivering	O
a	O
therapeutic	O
agent	O
on	O
said	O
medical	O
devices	O
as	O
well	O
as	O
their	O
use	O
especially	O
in	O
the	O
form	O
of	O
stents	O
for	O
prevention	O
of	O
restenosis	O
.	O

Controlled	O
Drug	O
Delivery	O
Using	O
a	O
Zein	O
Layer	O
Modified	O
with	O
Levulinic	B
Acid	I

Anti	O
-	O
viral	O
agents	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
A	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
processes	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
HCV	O
treatment	O
are	O
provided	O
.	O

2-carboxy	B
thiophene	I
derivatives	O
as	O
anti	O
viral	O
agents	O

Novel	O
immune	O
potentiators	O
,	O
novel	O
vaccine	O
adjuvants	O
,	O
novel	O
compounds	O
and	O
pharmaceutical	O
compositions	O
,	O
as	O
well	O
as	O
novel	O
methods	O
for	O
treating	O
viral	O
infections	O
,	O
including	O
HCV	O
,	O
by	O
administering	O
the	O
compounds	O
and	O
compositions	O
,	O
and	O
novel	O
methods	O
for	O
modulating	O
the	O
immune	O
response	O
by	O
administering	O
the	O
compounds	O
and/or	O
compositions	O
.	O

Thiosemicarbazones	B
as	O
anti	O
-	O
virals	O
and	O
immunopotentiators	O

Provided	O
herein	O
are	O
oral	O
skin	O
care	O
supplements	O
and	O
nutraceutical	O
compositions	O
and	O
methods	O
of	O
use	O
for	O
improving	O
the	O
health	O
and	O
appearance	O
of	O
skin	O
.	O

Also	O
provided	O
are	O
nutraceutical	O
compositions	O
that	O
,	O
when	O
orally	O
consumed	O
will	O
provide	O
nourishment	O
and	O
deliver	O
essential	O
skin	O
health	O
nutrition	O
to	O
the	O
skin	O
.	O

These	O
nutraceutical	O
compositions	O
include	O
omega	O
3	O
rich	O
oils	O
,	O
vitamins	O
,	O
lutein	O
,	O
marine	O
collagen	O
and	O
elastin	O
.	O

Also	O
provided	O
is	O
a	O
unique	O
microalgae	O
oral	O
delivery	O
system	O
targeting	O
the	O
health	O
and	O
appearance	O
of	O
skin	O
.	O

Oral	O
Carotenoid	B
Supplementation	O
Methods	O
for	O
Improving	O
the	O
Health	O
and	O
Appearance	O
of	O
Skin	O

A	O
transdermal	O
antidementia	O
active	O
agent	O
formulation	O
is	O
provided	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
formulation	O
includes	O
a	O
backing	O
,	O
an	O
active	O
agent	O
reservoir	O
layer	O
including	O
an	O
antidementia	O
active	O
agent	O
,	O
wherein	O
the	O
antidementia	O
active	O
agent	O
is	O
present	O
as	O
both	O
a	O
freebase	O
and	O
optionally	O
also	O
present	O
as	O
a	O
salt	O
,	O
an	O
adhesive	O
layer	O
including	O
the	O
antidementia	O
active	O
agent	O
,	O
and	O
optionally	O
an	O
adhesive	O
overlay	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
using	O
the	O
formulations	O
,	O
e.g.	O
for	O
administering	O
an	O
antidementia	O
active	O
agent	O
to	O
a	O
subject	O
,	O
and	O
kits	O
containing	O
the	O
formulations	O
.	O

Transdermal	O
anti	O
-	O
dementia	O
active	O
agent	O
formulations	O
and	O
methods	O
for	O
using	O
the	O
same	O

Compounds	O
and	O
methods	O
of	O
treating	O
anti	O
-	O
inflammatory	O
conditions	O
are	O
disclosed	O
.	O

Boron	B
-	O
Containing	O
Small	O
Molecules	O
as	O
Anti	O
-	O
Inflammatory	O
Agents	O

Provided	O
is	O
a	O
composition	O
containing	O
isoleucine	B
,	O
leucine	B
and	O
valine	B
as	O
active	O
ingredients	O
for	O
improving	O
or	O
suppressing	O
side	O
effects	O
associated	O
with	O
a	O
steroid	B
treatment	O
and	O
a	O
composition	O
for	O
suppressing	O
muscular	O
atrophy	O
-	O
related	O
gene	O
.	O

The	O
composition	O
improves	O
or	O
suppresses	O
side	O
effects	O
in	O
a	O
steroid	B
treatment	O
such	O
as	O
muscular	O
atrophy	O
,	O
muscular	O
pain	O
,	O
arthritic	O
pain	O
,	O
impaired	O
glucose	B
tolerance	O
,	O
decreased	O
bone	O
metabolism	O
,	O
impaired	O
immunity	O
,	O
loss	O
of	O
appetite	O
,	O
body	O
weight	O
loss	O
,	O
fatigability	O
and	O
the	O
like	O
,	O
and	O
further	O
suppresses	O
muscular	O
atrophy	O
associated	O
with	O
various	O
diseases	O
.	O

In	O
addition	O
,	O
the	O
composition	O
suppresses	O
muscular	O
atrophy	O
associated	O
with	O
promoted	O
expression	O
of	O
muscular	O
atrophy	O
-	O
related	O
gene	O
associated	O
with	O
glucocorticoid	B
excess	O
or	O
renal	O
failure	O
pathology	O
and	O
the	O
like	O
.	O

Therefore	O
,	O
the	O
composition	O
is	O
effective	O
form	O
improving	O
the	O
QOL	O
of	O
patients	O
.	O

Composition	O
for	O
amelioration	O
/	O
prevention	O
of	O
adverse	O
side	O
effect	O
in	O
steroid	O
therapy	O

Acyl	B
sulfonamide	I
,	I
peri	I
-	I
substituted	I
,	I
fused	I
bicyclic	I
ring	O
compounds	O
useful	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
prostaglandin	O
-	O
mediated	O
disease	O
or	O
condition	O
are	O
disclosed	O
.	O

The	O
compounds	O
are	O
of	O
the	O
general	O
formula	O
A	O
representative	O
example	O
is	O
:	O
Sulfonamide	B
peri	I
-	I
substituted	I
bicyclics	I
for	O
occlusive	O
artery	O
disease	O

Provided	O
are	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
alleviation	O
of	O
pain	O
in	O
a	O
patient	O
with	O
optimal	O
ratios	O
of	O
morphine	O
and	O
oxycodone	O
that	O
provide	O
superior	O
analgesic	O
efficacy	O
and	O
lower	O
incidence	O
of	O
adverse	O
side	O
effects	O
compared	O
to	O
morphine	O
and	O
oxycodone	O
alone	O
.	O

The	O
pharmaceutical	O
compositions	O
comprise	O
morphine	O
and	O
oxycodone	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
in	O
ratios	O
of	O
about	O
3	O
to	O
2	O
to	O
about	O
1	O
to	O
2	O
,	O
morphine	O
to	O
oxycodone	O
by	O
weight	O
.	O

Dual	O
opioid	O
pain	O
therapy	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
compound	O
of	O
formula	O
(	O
I	O
)	O
as	O
follows	O
:	O
or	O
of	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
drug	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
memory	O
disorders	O
.	O

Anti	O
-	O
amnesic	O
compounds	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O

Bicycloheteroaryl	B
compounds	O
are	O
disclosed	O
that	O
have	O
a	O
formula	O
represented	O
by	O
the	O
following	O
:	O
Formula	O
(	O
I	O
)	O
.	O

The	O
compounds	O
may	O
be	O
prepared	O
as	O
pharmaceutical	O
compositions	O
,	O
and	O
may	O
be	O
used	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non	O
-	O
limiting	O
example	O
,	O
pain	O
,	O
inflammation	O
,	O
traumatic	O
injury	O
,	O
and	O
others	O
.	O

Bicycloheteroaryl	B
Compounds	O
as	O
P2x7	O
Modulators	O
and	O
Uses	O
Thereof	O

A	O
strontium	B
salt	I
of	I
esomeprazole	I
is	O
provided	O
.	O

A	O
process	O
for	O
preparing	O
a	O
strontium	B
salt	I
of	I
esomeprazole	I
is	O
also	O
provided	O
comprising	O
reacting	O
esomeprazole	B
free	O
base	O
or	O
a	O
sodium	B
,	O
potassium	B
or	O
lithium	B
salt	O
of	O
esomeprazole	B
with	O
a	O
strontium	B
source	O
in	O
one	O
or	O
more	O
solvents	O
.	O

Esomeprazole	B
Strontium	I
Salt	O
,	O
Process	O
For	O
Its	O
Preparation	O
and	O
Pharmaceutical	O
Compositions	O
Containing	O
Same	O

The	O
present	O
invention	O
relates	O
to	O
phosphodiesterase	O
(	O
PDE	O
)	O
type	O
IV	O
selective	O
inhibitors	O
.	O

Processes	O
for	O
the	O
preparation	O
of	O
disclosed	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
disclosed	O
compounds	O
and	O
their	O
use	O
as	O
PDE	O
type	O
IV	O
selective	O
inhibitors	O
are	O
provided	O
.	O

Prepared	O
compounds	O
correspond	O
to	O
structure	O
XIV	O
Formula	O
(	O
XIV	O
)	O
.	O

Substituted	O
pyrazolo	B
[	I
3,4-b	I
]	I
pyridines	I
as	O
phosphodiesterase	O
inhibitors	O

D	O
-	O
Camosine	O
lipophilic	O
derivatives	O
are	O
disclosed	O
,	O
characterized	O
by	O
higher	O
bioavailability	O
than	O
L	O
-	O
camosine	O
and	O
intended	O
for	O
the	O
pulmonary	O
distribution	O
where	O
they	O
can	O
exert	O
detoxifying	O
activity	O
on	O
the	O
cytotoxic	O
carbonyl	O
compounds	O
induced	O
by	O
cigarette	O
smoke	O
.	O

Dipeptide	O
compounds	O
containing	O
d	O
-	O
histidine	O

The	O
invention	O
includes	O
cysteine	B
-	O
modified	O
PSMA	O
polypeptides	O
and	O
disulfide	O
-	O
bond	O
-	O
stabilized	O
dimers	O
thereof	O
,	O
compositions	O
and	O
kits	O
containing	O
the	O
cysteine	O
-	O
modified	O
PSMA	O
polypeptides	O
,	O
including	O
dimers	O
thereof	O
,	O
as	O
well	O
as	O
methods	O
of	O
producing	O
and	O
using	O
these	O
compositions	O
.	O

Such	O
methods	O
include	O
methods	O
for	O
eliciting	O
or	O
enhancing	O
an	O
immune	O
response	O
to	O
cells	O
expressing	O
PSMA	O
,	O
methods	O
of	O
producing	O
antibodies	O
to	O
PSMA	O
,	O
including	O
dimeric	O
PSMA	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
cancer	O
,	O
such	O
as	O
prostate	O
cancer	O
.	O

Compositions	O
of	O
and	O
Methods	O
of	O
Using	O
Stabilized	O
PSMA	O
Dimers	O

The	O
invention	O
provides	O
a	O
method	O
for	O
modulating	O
the	O
activity	O
of	O
the	O
hedgehog	O
signaling	O
pathway	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
a	O
method	O
for	O
inhibiting	O
aberrant	O
growth	O
states	O
resulting	O
from	O
phenotypes	O
such	O
as	O
Ptc	O
loss	O
-	O
of	O
-	O
function	O
,	O
hedgehog	O
gain	O
-	O
of	O
-	O
function	O
,	O
smoothened	O
gain	O
-	O
of	O
-	O
function	O
or	O
Gli	O
gain	O
-	O
of	O
-	O
function	O
,	O
comprising	O
contacting	O
a	O
cell	O
with	O
a	O
sufficient	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I.	O
Compounds	O
and	O
compositions	O
as	O
hedgehog	O
signaling	O
pathway	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
use	O
of	O
oxindole	B
derivatives	O
of	O
formula	O
I	O
,	O
as	O
a	O
free	O
base	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
[	O
Chemical	O
formula	O
should	O
be	O
inserted	O
here	O
.	O

Please	O
see	O
paper	O
copy	O
.	O

]	O

wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
as	O
in	O
claim	O
1	O
,	O
as	O
well	O
as	O
to	O
new	O
compounds	O
,	O
a	O
process	O
for	O
their	O
preparation	O
and	O
new	O
intermediates	O
used	O
in	O
the	O
preparation	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
said	O
therapeutically	O
active	O
compounds	O
and	O
to	O
the	O
use	O
of	O
said	O
active	O
compounds	O
in	O
therapy	O
,	O
especially	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
dementia	O
related	O
diseases	O
,	O
Alzheimer	O
's	O
Disease	O
and	O
conditions	O
associated	O
with	O
glycogen	O
synthase	O
kinase-3	O
.	O

Use	O
of	O
Oxindole	B
Derivatives	O
in	O
the	O
Treatment	O
of	O
Dementia	O
Related	O
Diseases	O
,	O
Alzheimer	O
's	O
Disease	O
and	O
Conditions	O
Associated	O
with	O
Glycogen	O
Synthase	O
Kinase-3	O

Amorphous	O
rifaximin	B
,	O
methods	O
of	O
making	O
it	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
it	O
.	O

Also	O
described	O
are	O
methods	O
of	O
converting	O
amorphous	O
rifaximin	B
to	O
crystalline	O
rifaximin	B
and	O
vice	O
versa	O
.	O

Rifaximin	O

The	O
present	O
invention	O
relates	O
to	O
aminopyrazine	B
derivatives	O
,	O
compositions	O
and	O
medicaments	O
containing	O
the	O
same	O
,	O
as	O
well	O
as	O
processes	O
for	O
the	O
preparation	O
and	O
use	O
of	O
such	O
compounds	O
,	O
compositions	O
and	O
medicaments	O
.	O

Such	O
aminopyrazine	B
derivatives	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
inappropriate	O
tyrosine	B
and/or	O
serine	B
/	O
threonine	B
kinase	O
activity	O
.	O

Aminopyrazine	B
derivatives	O
and	O
compositions	O

The	O
present	O
invention	O
relates	O
to	O
administering	O
a	O
doxycycline	B
compound	O
into	O
a	O
diseased	O
intervertebral	O
disc	O
.	O

Transdiscal	O
administration	O
of	O
cycline	B
compounds	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
isomaltulose	B
or	O
mixtures	O
of	O
isomaltulose	B
for	O
the	O
production	O
of	O
functional	O
food	O
products	O
for	O
improving	O
the	O
regeneration	O
of	O
individuals	O
exposed	O
to	O
physical	O
exertion	O
.	O

Use	O
of	O
isomaltulose	B
in	O
food	O
products	O
having	O
a	O
regenerative	O
effect	O

The	O
present	O
invention	O
relates	O
to	O
formulations	O
of	O
poorly	O
water	O
soluble	O
pharmaceutical	O
agents	O
of	O
Formula	O
I	O
and	O
II	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
I	O
or	O
II	O
,	O
and	O
glucocorticoids	B
,	O
and	O
methods	O
for	O
reducing	O
side	O
effects	O
from	O
glucocorticoid	B
treatment	O
by	O
co	O
-	O
administration	O
of	O
compounds	O
of	O
Formula	O
I	O
and	O
II	O
.	O

The	O
compositions	O
herein	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
obesity	O
related	O
diseases	O
including	O
metabolic	O
syndrome	O
.	O

Topical	O
steroidal	O
formulations	O

The	O
present	O
invention	O
discloses	O
a	O
novel	O
azelaic	B
acid	I
topical	O
pharmaceutical	O
gel	O
composition	O
that	O
does	O
not	O
contain	O
lecithin	B
and	O
a	O
process	O
for	O
its	O
preparation	O
.	O

Topical	O
gel	O
composition	O
comprising	O
azelaic	B
acid	I

The	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
mycobacterial	O
infections	O
,	O
autoimmune	O
disorders	O
,	O
lymphoproliferative	O
disorders	O
and	O
induction	O
of	O
immunosuppression	O
following	O
transplantation	O
using	O
coronin	O
1	O
and	O
modulators	O
of	O
coronin	O
1	O
.	O

Particular	O
modulators	O
of	O
coronin	O
1	O
are	O
compounds	O
which	O
inhibit	O
the	O
production	O
of	O
coronin	O
1	O
or	O
the	O
formation	O
of	O
active	O
coronin	O
1	O
from	O
a	O
coronin	O
1	O
precursor	O
,	O
partly	O
or	O
entirely	O
inactivate	O
coronin	O
1	O
,	O
inhibit	O
concentration	O
of	O
coronin	O
1	O
at	O
the	O
site	O
of	O
T	O
cell	O
activation	O
,	O
or	O
inhibit	O
the	O
coronin	O
1	O
mediated	O
signaling	O
pathway	O
downstream	O
of	O
the	O
T	O
cell	O
receptor	O
Examples	O
of	O
such	O
modulators	O
are	O
antibody	O
or	O
antibody	O
fragments	O
,	O
coronin	O
1	O
peptide	O
fragments	O
or	O
corresponding	O
phosphopeptides	O
,	O
or	O
anti	O
-	O
sense	O
oligonucleotides	O
,	O
e.g.	O
siRNA	O
or	O
shRNA	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
screening	O
for	O
a	O
compound	O
effective	O
in	O
the	O
treatment	O
of	O
mycobacterial	O
infections	O
,	O
autoimmune	O
disorders	O
,	O
lymphoproliferative	O
disorders	O
and	O
induction	O
of	O
immunosuppression	O
following	O
transplantation	O
comprising	O
contacting	O
a	O
candidate	O
compound	O
with	O
coronin	O
1	O
or	O
coronin	O
1	O
expressing	O
cells	O
,	O
and	O
selecting	O
appropriate	O
compounds	O
.	O

Coronin	O
1	O
Modulators	O
for	O
the	O
Treatment	O
of	O
Autoimmune	O
and	O
Lymphoproliferative	O
Disorders	O
and	O
Mycobacterial	O
Infections	O

This	O
invention	O
provides	O
,	O
among	O
other	O
things	O
,	O
protein	O
,	O
polypeptides	O
,	O
and	O
fragments	O
thereof	O
,	O
derived	O
from	O
bacteria	O
Histophilus	O
somni	O
.	O

Also	O
provided	O
are	O
nucleic	O
acids	O
encoding	O
for	O
such	O
proteins	O
,	O
polypeptides	O
,	O
and/or	O
fragments	O
,	O
as	O
well	O
as	O
nucleic	O
acids	O
complementary	O
thereto	O
.	O

Additionally	O
,	O
this	O
invention	O
provides	O
antibodies	O
which	O
bind	O
to	O
the	O
proteins	O
,	O
polypeptides	O
,	O
and/or	O
fragments	O
.	O

This	O
invention	O
further	O
provides	O
expression	O
vectors	O
useful	O
for	O
making	O
the	O
proteins	O
,	O
polypeptides	O
,	O
fragments	O
,	O
and/or	O
nucleic	O
acids	O
,	O
for	O
use	O
as	O
vaccines	O
,	O
diagnostic	O
reagents	O
,	O
immunogenic	O
compositions	O
,	O
and	O
the	O
like	O
.	O

Methods	O
of	O
making	O
the	O
compositions	O
and	O
methods	O
of	O
treatment	O
with	O
the	O
compositions	O
are	O
also	O
provided	O
.	O

This	O
invention	O
also	O
provides	O
methods	O
of	O
detecting	O
the	O
proteins	O
,	O
polypeptides	O
,	O
fragments	O
,	O
variants	O
and/or	O
nucleic	O
acids	O
as	O
well	O
as	O
detecting	O
antibodies	O
against	O
the	O
proteins	O
,	O
polypeptides	O
,	O
variants	O
and	O
fragments	O
.	O

Histophilus	O
Somni	O
Polynucleotides	B
,	O
Polypeptides	O
and	O
Methods	O
of	O
Use	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
or	O
a	O
salt	O
thereof	O
,	O
which	O
is	O
useful	O
as	O
a	O
CRTH2	O
antagonist	O
,	O
especially	O
as	O
a	O
medicament	O
for	O
disorder	O
that	O
participates	O
eosinophil	O
,	O
for	O
example	O
,	O
allergic	O
disorder	O
such	O
as	O
asthma	O
,	O
allergic	O
rhinitis	O
,	O
allergic	O
dermatitis	O
,	O
conjunctival	O
inflammation	O
,	O
hives	O
,	O
eosinophilic	O
bronchitis	O
,	O
food	O
allergy	O
,	O
inflammation	O
of	O
the	O
nasal	O
sinuses	O
,	O
multiple	O
sclerosis	O
,	O
angiitis	O
,	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
the	O
like	O
.	O

Polycyclic	B
acid	I
compounds	O
useful	O
as	O
crth2	O
antagonists	O
and	O
antiallergic	O
agents	O

A	O
reactive	O
oxygen	O
generating	O
enzyme	O
inhibitor	O
with	O
NO	B
donor	O
bioactivity	O
,	O
e.g.	O
,	O
nitrated	O
allopurinol	B
,	O
is	O
useful	O
to	O
treat	O
heart	O
failure	O
,	O
stable	O
angina	O
,	O
ischemic	O
disorder	O
,	O
ischemic	O
reperfusion	O
injury	O
,	O
atherosclerosis	O
,	O
sickle	O
cell	O
disease	O
,	O
diabetes	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
ALS	O
and	O
asthma	O
and	O
to	O
obtain	O
proper	O
contraction	O
of	O
heart	O
,	O
skeletal	O
and	O
smooth	O
muscle	O
.	O

Reactive	O
Oxygen	B
Generating	O
Enzyme	O
Inhibitor	O
With	O
Nitric	B
Oxide	I
Bioactivity	O
and	O
Uses	O
Thereof	O

A	O
pharmaceutical	O
anti	O
-	O
inflammatory	O
preparation	O
and	O
method	O
for	O
preparation	O
and	O
treatment	O
of	O
arthritis	O
and	O
related	O
inflammatory	O
conditions	O
used	O
for	O
mild	O
to	O
severe	O
pain	O
for	O
relatively	O
long	O
acting	O
results	O
.	O

This	O
anti	O
-	O
inflammatory	O
preparation	O
comprises	O
anti	O
-	O
inflammatory	O
corticord	B
steroid	I
in	O
aqueous	O
-	O
like	O
suspension	O
,	O
a	O
muscle	O
relaxant	O
in	O
oil	O
-	O
like	O
composition	O
,	O
and	O
amide	B
anesthetic	O
compound	O
in	O
aqueous	O
-	O
like	O
composition	O
and	O
Vitamin	B
B-12	I
in	O
aqueous	O
-	O
like	O
composition	O
.	O

It	O
is	O
prepared	O
by	O
mixing	O
the	O
anti	O
-	O
inflammatory	O
preparation	O
at	O
a	O
rate	O
and	O
for	O
a	O
time	O
sufficient	O
to	O
create	O
a	O
suspended	O
emulsion	O
.	O

The	O
anti	O
-	O
inflammatory	O
preparation	O
is	O
administered	O
while	O
in	O
suspended	O
emulsion	O
by	O
intramuscular	O
patient	O
injection	O
.	O

Anti	O
-	O
inflammatory	O
composition	O
and	O
method	O
for	O
preparation	O

This	O
application	O
discloses	O
6-Phenyl	B
-	I
imidazo	I
[	I
1,2-a	I
]	I
pyrazine	I
derivatives	O
according	O
to	O
generic	O
Formulae	O
I	O
-	O
V	O
:	O
wherein	O
,	O
variables	O
Q	O
,	O
R	O
,	O
Y1	O
,	O
Y2	O
,	O
Y3	O
,	O
Y4	O
,	O
n	O
,	O
and	O
m	O
are	O
defined	O
as	O
described	O
herein	O
,	O
which	O
inhibit	O
Btk	O
.	O

The	O
compounds	O
disclosed	O
herein	O
are	O
useful	O
to	O
modulate	O
the	O
activity	O
of	O
Btk	O
and	O
treat	O
diseases	O
associated	O
with	O
excessive	O
Btk	O
activity	O
.	O

The	O
compounds	O
are	O
further	O
useful	O
to	O
treat	O
inflammatory	O
and	O
auto	O
immune	O
diseases	O
associated	O
with	O
aberrant	O
B	O
-	O
cell	O
proliferation	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O

Also	O
disclosed	O
are	O
compositions	O
comprising	O
compounds	O
of	O
Formulae	O
I	O
-	O
V	O
and	O
at	O
least	O
one	O
carrier	O
,	O
diluent	O
or	O
excipient	O
.	O

7-tert	B
-	I
Butyl-3-	I
(	I
3-	I
{	I
8-	I
[	I
4-	I
(	I
morpholine-4-carbonyl	I
)	I
-phenylamino	I
]	I
-imidazo	I
[	I
1,2-a	I
]	I
pyrazin-6-yl	I
}	I
-phenyl	I
)	I
-3H	I
-	I
quinazolin-4-one	I
;	O
arthritis	O
;	O
inhibit	O
Btk	O

Gel	O
strips	O
containing	O
reactants	O
capable	O
of	O
reacting	O
to	O
form	O
nitric	O
oxide	O
are	O
maintained	O
separate	O
until	O
application	O
.	O

Upon	O
application	O
,	O
the	O
gel	O
strips	O
are	O
placed	O
in	O
contact	O
with	O
one	O
another	O
,	O
and	O
may	O
mix	O
,	O
or	O
operate	O
by	O
diffusion	O
,	O
to	O
deliver	O
nitric	O
oxide	O
directly	O
to	O
the	O
stream	O
of	O
breathing	O
air	O
of	O
a	O
user	O
.	O

Adhesive	O
strips	O
bonded	O
to	O
a	O
substrate	O
supporting	O
the	O
gel	O
strips	O
may	O
provide	O
for	O
securing	O
the	O
nitric	O
oxide	O
generator	O
directly	O
to	O
an	O
upper	O
lip	O
of	O
a	O
user	O
for	O
breathing	O
the	O
nitric	O
oxide	O
through	O
the	O
nostrils	O
.	O

Nitric	O
oxide	O
gel	O
apparatus	O
and	O
method	O

I	O
have	O
invented	O
a	O
vitamin	B
formula	O
named	O
as	O
""""	O
OM	O
VITAMIN	B
FORMULA	O
""""	O
that	O
will	O
alleviate	O
the	O
ill	O
-	O
health	O
symptoms	O
induced	O
by	O
Lead	O
intoxication	O
from	O
tap	O
water	O
or	O
by	O
some	O
other	O
means	O
.	O

Ill	O
-	O
health	O
symptoms	O
are	O
:	O
pain	O
,	O
itching	O
,	O
burning	O
,	O
insomnia	O
,	O
depression	O
,	O
panic	O
attacks	O
,	O
infections	O
,	O
elevated	O
blood	O
pressure	O
,	O
elevated	O
cholesterol	B
.	O
.	O
.	O
.	O

Also	O
likely	O
blood	O
sugar	B
level	O
will	O
be	O
elevated	O
.	O

Lack	O
of	O
vitamins	B
in	O
presence	O
of	O
Lead	O
in	O
body	O
will	O
affect	O
body	O
growth	O
and	O
other	O
body	O
functions	O
.	O

As	O
Lead	O
increases	O
the	O
requirements	O
of	O
vitamins	B
in	O
body	O
so	O
body	O
cells	O
start	O
becoming	O
mega	O
(	O
bloated	O
)	O
and	O
will	O
result	O
in	O
obesity	O
.	O

I	O
have	O
BS	O
in	O
Science	O
and	O
MS	O
in	O
Mathematics	O
from	O
India	O
.	O

I	O
have	O
MS	O
in	O
Engineering	O
from	O
UT	O
Austin	O
Tex	O
.	O

Currently	O
,	O
I	O
am	O
working	O
as	O
an	O
Engineer	O
for	O
Dept	O
.	O

of	O
Defense	O
.	O

I	O
sought	O
medical	O
help	O
once	O
I	O
started	O
having	O
multitude	O
of	O
ill	O
-	O
health	O
symptoms	O
.	O

I	O
was	O
prescribed	O
pain	O
killer	O
,	O
sleeping	O
tablets	O
,	O
and	O
depression	O
medicine	O
.	O

My	O
mathematical	O
mind	O
convinced	O
me	O
that	O
something	O
somewhere	O
is	O
wrong	O
and	O
worked	O
overtime	O
for	O
resolution	O
.	O

After	O
15	O
+	O
years	O
of	O
suffering	O
and	O
continual	O
experimenting	O
the	O
vitamins	B
supplement	O
in	O
varying	O
dose	O
,	O
I	O
came	O
up	O
with	O
this	O
vitamin	B
formula	O
.	O

Nowadays	O
when	O
causes	O
for	O
many	O
ill	O
-	O
health	O
symptoms	O
are	O
unknown	O
,	O
this	O
formula	O
will	O
be	O
a	O
blessing	O
to	O
all	O
of	O
us	O
.	O

Om	O
vitamin	B
formula	O

A	O
secondary	O
drying	O
process	O
is	O
disclosed	O
for	O
removing	O
residual	O
solvent	O
from	O
drug	O
-	O
containing	O
particles	O
that	O
have	O
been	O
formed	O
by	O
solvent	O
-	O
based	O
processes	O
.	O

Drying	O
of	O
drug	O
-	O
containing	O
particles	O

A	O
composition	O
for	O
a	O
broad	O
-	O
spectrum	O
antiviral	O
agent	O
with	O
excellent	O
preservation	O
stability	O
,	O
which	O
comprises	O
a	O
pure	O
chlorine	B
dioxide	I
solution	O
comprising	O
a	O
chlorine	B
dioxide	I
gas	O
dissolved	O
therein	O
,	O
a	O
chlorite	B
,	O
and	O
a	O
pH	O
adjuster	O
.	O

Broad	O
-	O
spectrum	O
antiviral	O
composition	O
with	O
excellent	O
preservation	O
stabilty	O

The	O
present	O
invention	O
relates	O
to	O
the	O
constitutive	O
activity	O
of	O
the	O
Hedgehog	O
pathway	O
in	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
.	O

A	O
method	O
for	O
diagnosing	O
NSCLC	O
by	O
detecting	O
the	O
level	O
of	O
a	O
component	O
of	O
the	O
Hedgehog	O
pathway	O
is	O
provided	O
,	O
as	O
is	O
a	O
method	O
for	O
identifying	O
subjects	O
that	O
will	O
respond	O
positively	O
to	O
treatment	O
with	O
a	O
Hedgehog	O
pathway	O
antagonist	O
.	O

Methods	O
for	O
treating	O
subjects	O
with	O
cancer	O
or	O
cancers	O
resistant	O
to	O
Hedgehog	O
pathway	O
antagonists	O
are	O
also	O
provided	O
.	O

Method	O
for	O
Diagnosing	O
Non	O
-	O
Small	O
Cell	O
Lung	O
Carcinoma	O

The	O
present	O
application	O
discloses	O
prodrugs	O
of	O
substituted	O
3,3-diphenyl-1,3-dihydro	B
-	I
indol-2-one	I
compounds	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
.	O

The	O
4-position	O
of	O
the	O
phenyl	B
moieties	O
and	O
the	O
N	O
-	O
position	O
of	O
the	O
indole	B
represent	O
useful	O
handles	O
for	O
the	O
introduction	O
of	O
particular	O
prodrug	O
groups	O
,	O
in	O
particular	O
those	O
comprising	O
an	O
amino	B
acid	I
moiety	O
.	O

The	O
prodrug	O
compounds	O
are	O
believed	O
to	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
mammal	O
,	O
possibly	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
chemotherapeutic	O
agents	O
.	O

The	O
application	O
also	O
discloses	O
the	O
compounds	O
for	O
use	O
in	O
a	O
method	O
of	O
treating	O
a	O
mammal	O
suffering	O
from	O
or	O
being	O
susceptible	O
to	O
cancer	O
Prodrugs	O
of	O
diphenyl	B
ox	I
-	I
indol-2-one	I
compounds	O

Disclosed	O
are	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
I	O
and	O
compositions	O
that	O
comprise	O
said	O
compounds	O
of	O
formula	O
I.	O
Also	O
disclosed	O
are	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
III	O
and	O
compositions	O
that	O
comprise	O
said	O
compounds	O
of	O
formula	O
III	O
.	O

Processes	O
For	O
The	O
Preparation	O
Of	O
Anti	O
-	O
Viral	O
Compounds	O
And	O
Compositions	O
Containing	O
Them	O

There	O
are	O
provided	O
a	O
method	O
for	O
identifying	O
a	O
compound	O
having	O
an	O
anti	O
-	O
anxiety	O
effect	O
,	O
an	O
inhibitor	O
of	O
a	O
function	O
of	O
a	O
protein	O
having	O
a	O
function	O
as	O
a	O
G	O
-	O
protein	O
coupled	O
receptor	O
,	O
characterized	O
by	O
finding	O
the	O
protein	O
and	O
a	O
gene	O
encoding	O
the	O
protein	O
and	O
using	O
at	O
least	O
one	O
of	O
a	O
DNA	O
represented	O
by	O
the	O
nucleotide	O
sequence	O
of	O
this	O
gene	O
or	O
a	O
complementary	O
strand	O
thereof	O
,	O
a	O
homologue	O
of	O
the	O
DNA	O
,	O
a	O
protein	O
encoded	O
by	O
the	O
DNA	O
,	O
and	O
a	O
cell	O
expressing	O
the	O
protein	O
encoded	O
by	O
the	O
DNA	O
,	O
an	O
agent	O
and	O
a	O
method	O
for	O
improving	O
an	O
anxiety	O
condition	O
,	O
a	O
method	O
and	O
an	O
agent	O
for	O
prophylactic	O
and/or	O
therapeutic	O
treatment	O
of	O
an	O
anxiety	O
disorder	O
,	O
and	O
a	O
measurement	O
method	O
for	O
diagnosis	O
and	O
a	O
diagnostic	O
method	O
of	O
an	O
anxiety	O
disorder	O
.	O

Method	O
For	O
Identification	O
of	O
Compound	O
Having	O
Anti	O
-	O
Anxiety	O
Effect	O

Compounds	O
of	O
following	O
formula	O
(	O
I	O
)	O
are	O
provided	O
that	O
have	O
both	O
angiotensin	B
II	I
receptor	O
antagonist	O
activity	O
and	O
PPARy	O
agonist	O
activity	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
treatment	O
of	O
diseases	O
with	O
the	O
compounds	O
including	O
type	O
2	O
diabetes	O
,	O
insulin	O
resistance	O
,	O
hyperinsulinemia	O
,	O
hyperlipidemia	O
,	O
hypertriglyceridemia	O
,	O
metabolic	O
syndrome	O
,	O
congestive	O
heart	O
failure	O
,	O
and	O
hypertension	O
.	O

COMPOUNDS	O
HAVING	O
BOTH	O
ANGIOTENSIN	B
II	I
RECEPTOR	O
ANTAGONISM	O
AND	O
PPARy	O
ACTIVATING	O
ACTIVITIES	O

Topical	O
aqueous	O
compositions	O
for	O
the	O
treatment	O
of	O
a	O
skin	O
disorder	O
particularly	O
acne	O
.	O

Topical	O
aqueous	O
composition	O
comprising	O
tretinoin	B
and	O
a	O
hydrophilic	O
cellulose	O
derivative	O
as	O
a	O
gelling	O
agent	O
,	O
wherein	O
the	O
composition	O
has	O
a	O
pH	O
of	O
about	O
4	O
to	O
about	O
6.5	O
and	O
viscosity	O
of	O
less	O
than	O
about	O
20,000	O
cP	O
or	O
provided	O
.	O

The	O
composition	O
also	O
relates	O
to	O
the	O
topical	O
administration	O
of	O
tretinoin	B
in	O
combination	O
with	O
an	O
antibiotic	O
.	O

Topical	O
aqueous	O
composition	O
comprising	O
tretinoin	B

The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
treatment	O
of	O
addiction	O
,	O
and	O
particularly	O
to	O
addictions	O
with	O
a	O
chemical	O
dependency	O
component	O
,	O
with	O
gamma	B
-	I
hydroxybutyrate	I
(	O
GHB	B
)	O
and	O
at	O
least	O
one	O
gamma	B
-	I
aminobutyric	I
acid	I
(	O
B	O
)	O
receptor	O
agonist	O
(	O
GABAB	O
receptor	O
agonist	O
)	O
,	O
for	O
example	O
,	O
baclofen	B
.	O

Pharmaceutical	O
compositions	O
therefor	O
are	O
also	O
provided	O
.	O

Treatment	O
of	O
addictive	O
disorders	O

Methods	O
and	O
compositions	O
for	O
detecting	O
and	O
treating	O
diseases	O
,	O
especially	O
cancer	O
,	O
and	O
particularly	O
breast	O
,	O
bladder	O
,	O
colon	O
,	O
gastrointestinal	O
,	O
kidney	O
,	O
liver	O
,	O
lung	O
,	O
melanoma	O
,	O
ovary	O
,	O
pancreatic	O
,	O
pharyngeal	O
,	O
prostate	O
cancer	O
and	O
renal	O
,	O
associated	O
with	O
differential	O
expression	O
of	O
prominin-1	O
(	O
CD133	O
)	O
in	O
disease	O
cells	O
compared	O
to	O
healthy	O
cells	O
.	O

Also	O
provided	O
are	O
antagonists	O
or	O
agonists	O
of	O
prominin-1	O
,	O
and	O
methods	O
for	O
screening	O
agents	O
that	O
modulate	O
the	O
prominin-1	O
level	O
or	O
activity	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O

Methods	O
and	O
Composition	O
for	O
Treating	O
Diseases	O
Targeting	O
Prominin-1	O
(	O
CD133	O
)	O

Fixation	O
devices	O
for	O
tissue	O
repair	O
,	O
for	O
example	O
sutures	O
,	O
surgical	O
arrows	O
,	O
staples	O
,	O
darts	O
,	O
bolts	O
,	O
screws	O
,	O
buttons	O
,	O
anchors	O
,	O
nails	O
,	O
rivets	O
,	O
or	O
barbed	O
devices	O
comprise	O
at	O
least	O
one	O
of	O
angiogenic	O
material	O
;	O
angiogenic	O
precursor	O
material	O
which	O
is	O
capable	O
of	O
breaking	O
down	O
in	O
vivo	O
to	O
form	O
angiogenic	O
material	O
;	O
or	O
tissue	O
-	O
engineered	O
material	O
,	O
which	O
tissue	O
-	O
engineered	O
material	O
is	O
capable	O
of	O
producing	O
angiogenic	O
material	O
.	O

In	O
a	O
preferred	O
form	O
,	O
the	O
material	O
is	O
incorporated	O
into	O
a	O
polymer	O
matrix	O
having	O
predetermined	O
hydrophobicity	O
to	O
allow	O
controlled	O
release	O
of	O
angiogenic	O
materials	O
such	O
as	O
butyric	B
or	I
hydroxybutyric	I
acid	I
or	O
salts	O
thereof	O
.	O

Polymer	O
matrix	O
compositions	O
comprising	O
angiogenic	O
materials	O
and	O
methods	O
for	O
tissue	O
repair	O
are	O
also	O
provided	O
.	O

Fixation	O
Devices	O
For	O
Tissue	O
Repair	O

The	O
present	O
invention	O
provides	O
recombinant	O
viral	O
and	O
non	O
-	O
viral	O
vectors	O
comprising	O
a	O
transgene	O
encoding	O
a	O
biologically	O
active	O
human	O
lysosomal	O
enzyme	O
that	O
are	O
able	O
to	O
infect	O
and/or	O
transfect	O
and	O
sustain	O
expression	O
of	O
the	O
biologically	O
active	O
human	O
lysosomal	O
enzyme	O
transgene	O
in	O
mammalian	O
cells	O
deficient	O
therein	O
.	O

In	O
addition	O
,	O
methods	O
are	O
provided	O
for	O
providing	O
a	O
biologically	O
active	O
human	O
lysosomal	O
enzyme	O
to	O
cells	O
deficient	O
therein	O
,	O
which	O
comprises	O
introducing	O
into	O
the	O
cells	O
a	O
vector	O
comprising	O
and	O
expressing	O
a	O
transgene	O
encoding	O
the	O
biologically	O
active	O
human	O
lysosomal	O
enzyme	O
,	O
wherein	O
the	O
vector	O
is	O
taken	O
up	O
by	O
the	O
cells	O
,	O
the	O
transgene	O
is	O
expressed	O
and	O
biologically	O
active	O
enzyme	O
is	O
produced	O
.	O

The	O
cells	O
may	O
be	O
infected	O
and/or	O
transfected	O
by	O
the	O
vector	O
,	O
dependent	O
upon	O
whether	O
the	O
vector	O
is	O
a	O
viral	O
vector	O
and/or	O
plasmid	O
or	O
the	O
like	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
of	O
supplying	O
a	O
biologically	O
active	O
human	O
lysosomal	O
enzyme	O
to	O
other	O
distant	O
cells	O
deficient	O
therein	O
wherein	O
the	O
transfected	O
and/or	O
infected	O
cells	O
harboring	O
the	O
vector	O
secrete	O
the	O
biologically	O
active	O
enzyme	O
which	O
is	O
then	O
taken	O
up	O
by	O
the	O
other	O
deficient	O
cells	O
.	O

In	O
a	O
preferred	O
embodiment	O
the	O
present	O
invention	O
provides	O
for	O
sustained	O
production	O
of	O
biologically	O
human	O
active	O
α	O
-	O
galactosidase	O
A	O
in	O
cells	O
of	O
Fabry	O
individuals	O
that	O
are	O
deficient	O
in	O
said	O
enzyme	O
.	O

Compositions	O
and	O
methods	O
for	O
treating	O
lysosomal	O
storage	O
disease	O

Medical	O
devices	O
having	O
a	O
coating	O
comprising	O
an	O
ionic	O
polymer	O
for	O
electromagnetically	O
-	O
controlled	O
release	O
of	O
a	O
therapeutic	O
agent	O
.	O

Release	O
of	O
the	O
therapeutic	O
agent	O
from	O
the	O
coating	O
is	O
facilitated	O
or	O
modulated	O
by	O
the	O
application	O
of	O
an	O
electromagnetic	O
field	O
to	O
the	O
medical	O
device	O
.	O

Exposure	O
to	O
the	O
electromagnetic	O
field	O
may	O
cause	O
the	O
release	O
of	O
the	O
therapeutic	O
agent	O
in	O
various	O
ways	O
,	O
including	O
electrochemical	O
changes	O
in	O
the	O
ionic	O
polymer	O
,	O
structural	O
changes	O
in	O
the	O
coating	O
and/or	O
ionic	O
polymers	O
,	O
changes	O
in	O
the	O
permeability	O
of	O
the	O
coating	O
,	O
changes	O
in	O
the	O
orientation	O
of	O
the	O
ionic	O
polymers	O
,	O
or	O
motion	O
of	O
the	O
ionic	O
polymers	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
delivering	O
a	O
therapeutic	O
agent	O
using	O
electromagnetic	O
fields	O
.	O

Medical	O
devices	O
having	O
a	O
coating	O
for	O
electromagnetically	O
-	O
controlled	O
release	O
of	O
therapeutic	O
agents	O

A	O
method	O
of	O
enhancing	O
physical	O
performance	O
during	O
exercise	O
by	O
administering	O
an	O
amount	O
of	O
a	O
grape	O
extract	O
effective	O
to	O
treat	O
a	O
subject	O
.	O

A	O
preferred	O
grape	O
extract	O
comprises	O
a	O
concentration	O
of	O
flavanol	B
monomers	O
of	O
greater	O
than	O
about	O
5	O
%	O
by	O
weight	O
,	O
and	O
more	O
preferably	O
within	O
a	O
range	O
from	O
about	O
12	O
%	O
by	O
weight	O
to	O
about	O
50	O
%	O
by	O
weight	O
,	O
and	O
a	O
concentration	O
of	O
flavanol	B
dimers	O
preferably	O
greater	O
than	O
about	O
2	O
%	O
by	O
weight	O
,	O
and	O
more	O
preferably	O
within	O
a	O
range	O
from	O
about	O
6	O
%	O
by	O
weight	O
to	O
about	O
20	O
%	O
by	O
weight	O
.	O

The	O
flavanol	B
monomers	O
preferably	O
include	O
catechin	B
,	O
epicatechin	B
,	O
epicatechin	B
gallate	I
,	O
and	O
gallic	B
acid	I
.	O

The	O
flavanol	B
dimers	O
preferably	O
include	O
procyanidin	B
B1	I
,	O
procyanidin	B
B2	I
,	O
procyanidin	B
B3	I
,	O
procyanidin	B
B4	I
,	O
and	O
procyanidin	B
B2-O	I
-	I
gallate	I
.	O

Antioxidant	O
and	O
physical	O
performance	O
effects	O
of	O
a	O
grape	O
extract	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
and	O
prodrugs	O
thereof	O
,	O
and	O
to	O
their	O
use	O
as	O
cholesterol	B
absorption	O
inhibitors	O
for	O
the	O
treatment	O
of	O
hyperlipidaemia	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
their	O
manufacture	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

New	O
2-Azetidinone	B
Derivatives	O
Useful	O

In	O
The	O
Treatment	O
Of	O
Hyperlipidaemic	O
Conditions	O

The	O
present	O
invention	O
relates	O
to	O
agents	O
and	O
methods	O
for	O
growth	O
-	O
factor	O
receptor	O
activation	O
by	O
modulating	O
the	O
G	O
-	O
protein	O
mediated	O
signal	O
transduction	O
pathway	O
.	O

EGF	O
RECEPTOR	O
TRANSACTIVATION	O
BY	O
G	O
-	O
PROTEIN	O
-	O
COUPLED	O
RECEPTORS	O
REQUIRES	O
METALLOPROTEINASE	O
CLEAVAGE	O
OF	O
proHB	O
-	O
EGF	O

The	O
present	O
invention	O
provides	O
crystalline	O
forms	O
of	O
Rosiglitazone	B
hydrobromide	I
,	O
methods	O
of	O
their	O
preparation	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
these	O
crystalline	O
forms	O
.	O

Polymorphic	O
forms	O
of	O
rosiglitazone	B
hydrobromide	I
and	O
processes	O
for	O
their	O
preparation	O

The	O
present	O
invention	O
relates	O
to	O
an	O
animal	O
model	O
for	O
human	O
perimenopause	O
and	O
menopause	O
.	O

Also	O
provided	O
by	O
the	O
present	O
invention	O
are	O
methods	O
of	O
making	O
the	O
animal	O
model	O
and	O
methods	O
of	O
screening	O
using	O
the	O
model	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
inducing	O
ovarian	O
failure	O
in	O
animals	O
such	O
as	O
pets	O
and	O
wildlife	O
.	O

Animal	O
model	O
for	O
perimenopause	O
and	O
menopause	O
and	O
methods	O
of	O
inducing	O
ovarian	O
failure	O

The	O
invention	O
provides	O
a	O
cancer	O
chemotherapeutic	O
agent	O
which	O
has	O
fewer	O
side	O
effects	O
and	O
excellent	O
efficacy	O
.	O

The	O
cancer	O
chemotherapeutic	O
agent	O
of	O
the	O
invention	O
includes	O
a	O
cholestanol	B
derivative	O
represented	O
by	O
formula	O
(	O
1	O
)	O
:	O
(	O
wherein	O
G	O
represents	O
GlcNAc	B
-	I
Gal-	I
,	O
GlcNAc	B
-	I
Gal	I
-	I
Glc-	I
,	O
Fuc	B
-	I
Gal-	I
,	O
Gal	B
-	I
Glc-	I
,	O
Gal-	B
,	O
or	O
GlcNAc-	B
)	O
or	O
a	O
cyclodextrin	O
inclusion	O
compound	O
thereof	O
,	O
and	O
an	O
anti	O
-	O
cancer	O
agent	O
.	O

Cholestanol	B
derivative	O
for	O
combined	O
use	O

The	O
present	O
invention	O
provides	O
a	O
triazole	B
compound	O
of	O
the	O
following	O
formula	O
:	O
a	O
prodrug	O
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
above	O
-	O
mentioned	O
triazole	B
compound	O
has	O
superior	O
HSD1	O
inhibitory	O
activity	O
,	O
and	O
is	O
useful	O
as	O
an	O
HSD1	O
inhibitor	O
,	O
a	O
therapeutic	O
drug	O
of	O
diabetes	O
or	O
a	O
therapeutic	O
drug	O
of	O
obesity	O
or	O
a	O
therapeutic	O
drug	O
of	O
metabolic	O
syndrome	O
.	O

Triazole	B
compounds	O
and	O
uses	O
related	O
thereto	O

Disclosed	O
is	O
the	O
most	O
optimal	O
biomarker	O
for	O
the	O
BIOLOGICAL	O
POTENCY	O
of	O
Emblica	O
Officinalis	O
Gaertn	O
.	O

(	O
Amla	O
)	O
fruit	O
and	O
products	O
standardized	O
for	O
5	O
%	O
and	O
above	O
w	O
/	O
w	O
of	O
the	O
said	O
biomarker	O
.	O

Further	O
,	O
the	O
products	O
described	O
herein	O
contain	O
from	O
about	O
0.00010	O
%	O
to	O
about	O
4	O
%	O
of	O
free	O
ascorbic	B
acid	I
depending	O
on	O
the	O
raw	O
material	O
used	O
.	O

The	O
optimal	O
biomarker	O
for	O
amla	O
described	O
herein	O
above	O
is	O
represented	O
by	O
STR#1	O
.	O

OPTIMAL	O
BIOLOGICAL	O
MARKER	O
FOR	O
THE	O
BIOLOGICAL	O
POTENCY	O
OF	O
Emblica	O
Officinalis	O
Gaertn	O
.	O

(	O
AMLA	O
)	O
FRUIT	O
-	O
METHODS	O
AND	O
PRODUCTS	O
THEREOF	O

The	O
present	O
invention	O
relates	O
to	O
acyclovir	B
formulations	O
having	O
improved	O
bioavailability	O
resulting	O
in	O
better	O
efficacy	O
and/or	O
requiring	O
less	O
frequent	O
administration	O
.	O

acyclovir	B
formulations	O

Quinazoline	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
A	O
is	O
5-membered	O
heteroaryl	B
containing	O
a	O
nitrogen	B
atom	O
and	O
one	O
or	O
two	O
further	O
nitrogen	B
atoms	O
;	O
compositions	O
containing	O
them	O
,	O
processes	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
therapy	O
.	O

Phosphonoxy	B
quinazoline	I
derivatives	O
and	O
their	O
pharmaceutical	O
use	O

The	O
present	O
invention	O
relates	O
to	O
oxalate	B
salt	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
all	O
its	O
stereochemical	O
configurations	O
,	O
a	O
process	O
for	O
its	O
preparation	O
and	O
its	O
use	O
in	O
treating	O
mood	O
disorders	O
,	O
disorders	O
of	O
anxiety	O
,	O
depression	O
and	O
convulsive	O
conditions	O
,	O
in	O
the	O
improvement	O
of	O
learning	O
ability	O
,	O
in	O
the	O
reversal	O
of	O
amnesia	O
,	O
in	O
resolving	O
the	O
abstinence	O
syndrome	O
from	O
drugs	O
and	O
drugs	O
of	O
abuse	O
.	O

Preferably	O
,	O
the	O
invention	O
concerns	O
oxalate	B
salt	I
of	I
rel-	I
(	I
3R,3aS,7aS	I
)	I
-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a	I
-	I
octahydrobenzo	I
[	I
d	I
]	I
isoxazol-4-one	I
.	O

Salt	O
of	O
3-benzyl-2-methyl-2,3,3a,4,5,6,7	B
,	I
7a-	I
octahydrobenzo	I
[	I
d	I
]	I
isoxazol-4-one	I

A	O
method	O
for	O
producing	O
a	O
bone	O
filler	O
basically	O
comprising	O
:	O
a	O
bone	O
model	O
producing	O
step	O
(	O
step	O
1	O
)	O
for	O
producing	O
a	O
bone	O
model	O
;	O
a	O
figure	O
forming	O
material	O
filling	O
step	O
(	O
step	O
2	O
)	O
for	O
filling	O
a	O
figure	O
forming	O
material	O
into	O
a	O
bone	O
defect	O
site	O
of	O
the	O
bone	O
model	O
obtained	O
in	O
the	O
bone	O
model	O
producing	O
step	O
;	O
and	O
a	O
bone	O
filler	O
producing	O
step	O
(	O
step	O
3	O
)	O
for	O
producing	O
a	O
bone	O
filler	O
which	O
is	O
to	O
be	O
filled	O
in	O
a	O
bone	O
defect	O
site	O
based	O
on	O
the	O
figure	O
forming	O
material	O
filled	O
in	O
the	O
bone	O
defect	O
site	O
of	O
the	O
bone	O
model	O
in	O
the	O
figure	O
forming	O
material	O
filling	O
step	O
.	O

Bone	O
model	O
,	O
bone	O
filler	O
and	O
process	O
for	O
producing	O
bone	O
filler	O

It	O
is	O
described	O
a	O
gel	O
composed	O
of	O
a	O
mixture	O
of	O
a	O
polymer	O
which	O
forms	O
a	O
gel	O
,	O
a	O
buffer	O
;	O
a	O
saccharide	B
and	O
one	O
or	O
more	O
active	O
ingredients	O
useful	O
for	O
treating	O
diseases	O
of	O
the	O
eyes	O
.	O

Gel	O
useful	O
for	O
the	O
delivery	O
of	O
ophthalmic	O
drugs	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
formulations	O
and	O
methods	O
for	O
the	O
improved	O
delivery	O
and	O
administration	O
of	O
hydrophobic	O
therapeutic	O
compounds	O
that	O
are	O
substantially	O
insoluble	O
and/or	O
susceptible	O
to	O
precipitation	O
in	O
aqueous	O
solution	O
at	O
physiological	O
pH	O
,	O
including	O
,	O
e.g.	O
,	O
growth	O
and	O
differentiation	O
factor-5	O
and	O
related	O
proteins	O
.	O

Many	O
therapeutic	O
compounds	O
are	O
hydrophobic	O
at	O
physiological	O
pH	O
levels	O
.	O

Lipid	O
growth	O
factor	O
formulations	O

Disclosed	O
are	O
high	O
-	O
loading	O
,	O
controlled	O
-	O
release	O
dosage	O
forms	O
for	O
oral	O
administration	O
of	O
magnesium	B
salts	O
.	O

For	O
example	O
,	O
an	O
oral	O
dosage	O
form	O
can	O
comprise	O
from	O
about	O
80	O
%	O
to	O
about	O
95	O
%	O
magnesium	B
lactate	I
and	O
one	O
or	O
more	O
components	O
.	O

As	O
another	O
example	O
,	O
an	O
oral	O
dosage	O
form	O
can	O
comprise	O
at	O
least	O
about	O
50	O
%	O
magnesium	B
salt	O
and	O
exhibit	O
a	O
controlled	O
release	O
dissolution	O
profile	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
making	O
controlled	O
release	O
dosage	O
forms	O
for	O
oral	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
magnesium	B
salt	O
to	O
a	O
mammal	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
treating	O
a	O
disorder	O
characterized	O
by	O
magnesium	B
deficiency	O
and	O
methods	O
for	O
preventing	O
or	O
alleviating	O
low	O
magnesium	B
levels	O
.	O

This	O
abstract	O
is	O
intended	O
as	O
a	O
scanning	O
tool	O
for	O
purposes	O
of	O
searching	O
in	O
the	O
particular	O
art	O
and	O
is	O
not	O
intended	O
to	O
be	O
limiting	O
of	O
the	O
present	O
invention	O
.	O

High	O
-	O
loading	O
,	O
controlled	O
-	O
release	O
magnesium	B
oral	O
dosage	O
forms	O
and	O
methods	O
of	O
making	O
and	O
using	O
same	O

Novel	O
polypeptides	O
and	O
polynucleotides	O
encoding	O
same	O
are	O
provided	O
.	O

Also	O
provided	O
methods	O
and	O
pharmaceutical	O
compositions	O
which	O
can	O
be	O
used	O
to	O
treat	O
various	O
disorders	O
such	O
as	O
cancer	O
,	O
immunological	O
-	O
related	O
,	O
blood	O
-	O
related	O
and	O
skin	O
-	O
related	O
disorders	O
using	O
the	O
polypeptides	O
and	O
polynucleotides	O
of	O
the	O
present	O
invention	O
.	O

Also	O
provided	O
are	O
methods	O
and	O
kits	O
for	O
diagnosing	O
,	O
determining	O
predisposition	O
and/or	O
prognosis	O
of	O
various	O
disorders	O
using	O
as	O
diagnostic	O
markers	O
the	O
novel	O
polypeptides	O
and	O
polynucleotides	O
of	O
the	O
present	O
invention	O
.	O

Novel	O
polynucleotides	O
encoding	O
polypeptides	O
and	O
methods	O
using	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
the	O
HIV	O
NC	O
protein	O
,	O
and	O
more	O
particularly	O
,	O
it	O
is	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
AIDS	O
having	O
a	O
polypeptide	O
comprising	O
HIV	O
NC	O
protein	O
as	O
an	O
active	O
component	O
and	O
the	O
method	O
of	O
inhibiting	O
HIV	O
proliferation	O
by	O
using	O
the	O
polypeptide	O
.	O

The	O
polypeptide	O
comprising	O
HIV	O
NC	O
protein	O
of	O
the	O
present	O
invention	O
,	O
when	O
it	O
is	O
overexpressed	O
,	O
has	O
the	O
effect	O
on	O
inhibiting	O
HIV	O
proliferation	O
.	O

Accordingly	O
,	O
the	O
present	O
invention	O
provides	O
not	O
only	O
the	O
novel	O
means	O
of	O
inhibition	O
of	O
HIV	O
proliferation	O
,	O
but	O
also	O
the	O
novel	O
method	O
for	O
preventing	O
and	O
treating	O
AIDS	O
.	O

Novel	O
use	O
of	O
hiv	O
nc	O
protein	O

The	O
invention	O
relates	O
to	O
dihydroimidazoles	B
of	O
formula	O
rac-	O
(	O
I	O
)	O
,	O
wherein	O
the	O
radicals	O
and	O
symbols	O
are	O
as	O
defined	O
herein	O
;	O
their	O
use	O
as	O
inhibitors	O
of	O
the	O
interaction	O
of	O
the	O
MDM2	O
protein	O
with	O
a	O
p53-like	O
peptide	O
,	O
new	O
pharmaceutical	O
formulations	O
comprising	O
said	O
compounds	O
,	O
said	O
compounds	O
for	O
use	O
in	O
the	O
therapeutic	O
treatment	O
of	O
warm	O
-	O
blooded	O
animals	O
,	O
especially	O
humans	O
,	O
their	O
use	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
or	O
for	O
the	O
manufacture	O
of	O
pharmaceutical	O
formulations	O
useful	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
interaction	O
of	O
the	O
MDM2	O
protein	O
with	O
a	O
p53-like	O
peptide	O
,	O
a	O
pharmaceutical	O
formulation	O
e.g.	O
useful	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
interaction	O
of	O
the	O
MDM2	O
protein	O
with	O
a	O
p53-like	O
peptide	O
comprising	O
said	O
compound	O
,	O
methods	O
of	O
treatment	O
comprising	O
administration	O
of	O
said	O
compounds	O
to	O
a	O
warm	O
-	O
blooded	O
animal	O
,	O
and/or	O
processes	O
for	O
the	O
manufacture	O
of	O
said	O
compounds	O
.	O

Substituted	O
Dihydroimidazoles	B
and	O
their	O
Use	O
in	O
the	O
Treatment	O
of	O
Tumors	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
A	O
,	O
B	O
,	O
D	O
,	O
M	O
,	O
Ar	B
,	O
W	O
,	O
X	O
,	O
Y	O
,	O
Z	O
and	O
R1	O
are	O
as	O
defined	O
herein	O
,	O
are	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
hepatitis	O
C	O
infections	O
.	O

The	O
compounds	O
,	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
medicine	O
are	O
disclosed	O
.	O

Antiviral	O
Indoles	B

The	O
subject	O
matters	O
of	O
this	O
invention	O
are	O
a	O
sequence	O
of	O
double	O
-	O
stranded	O
RNA	O
:	O
ATN	O
-	O
RNA	O
,	O
intervention	O
using	O
interference	O
RNA	O
(	O
iRNAi	O
)	O
,	O
use	O
of	O
a	O
sequence	O
of	O
double	O
-	O
stranded	O
RNA	O
:	O
ATN	O
-	O
RNA	O
,	O
a	O
method	O
of	O
treating	O
a	O
brain	O
tumor	O
and	O
a	O
method	O
of	O
inhibiting	O
a	O
brain	O
tumor	O
cells	O
which	O
express	O
tenascin	O
,	O
a	O
kit	O
for	O
inhibiting	O
cancer	O
cell	O
which	O
expresses	O
tenascin	O
and	O
a	O
method	O
for	O
a	O
kit	O
preparation	O
in	O
a	O
brain	O
tumor	O
therapy	O
.	O

Malignant	O
gliomas	O
preferentially	O
express	O
a	O
number	O
of	O
surface	O
markers	O
that	O
may	O
be	O
exploited	O
as	O
therapeutic	O
targets	O
,	O
including	O
tenascin	O
-	O
C	O
,	O
an	O
extracellular	O
matrix	O
glycoprotein	O
that	O
is	O
ubiquitously	O
expressed	O
by	O
malignant	O
gliomas	O
and	O
probably	O
contributes	O
to	O
tumor	O
cell	O
adhesion	O
,	O
invasion	O
,	O
migration	O
and	O
proliferation	O
.	O

For	O
tenascin	O
-	O
C	O
inhibition	O
,	O
RNA	O
interference	O
intervention	O
(	O
iRNAi	O
)	O
approach	O
have	O
been	O
applied	O
.	O

Sequence	O
of	O
dsrna	O
:	O
atn	O
-	O
rna	O
,	O
intervention	O
using	O
irnai	O
,	O
use	O
of	O
a	O
sequence	O
of	O
dsrna	O
:	O
atn	O
-	O
rna	O
,	O
a	O
method	O
of	O
treating	O
and	O
inhibiting	O
a	O
brain	O
tumor	O
,	O
a	O
kit	O
for	O
inhibiting	O
cancer	O
cell	O
which	O
expresses	O
tenascin	O
,	O
a	O
method	O
for	O
a	O
kit	O
preparation	O
in	O
a	O
brain	O
tumor	O
therapy	O

A	O
method	O
of	O
culturing	O
human	O
or	O
mammalian	O
mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
or	O
osteoblastic	O
cells	O
to	O
form	O
corresponding	O
cell	O
aggregates	O
evenly	O
distributed	O
in	O
the	O
culturing	O
medium	O
having	O
a	O
reduced	O
content	O
of	O
cells	O
with	O
fibroblast	O
morphology	O
comprises	O
contacting	O
MSC	O
or	O
OC	O
with	O
a	O
water	O
-	O
soluble	O
cellulose	O
derivative	O
over	O
a	O
period	O
of	O
from	O
1	O
day	O
to	O
one	O
or	O
two	O
weeks	O
.	O

Also	O
disclosed	O
are	O
a	O
corresponding	O
aggregates	O
,	O
a	O
culture	O
medium	O
and	O
a	O
pharmaceutical	O
composition	O
,	O
and	O
uses	O
of	O
the	O
aggregate	O
,	O
the	O
culturing	O
medium	O
and	O
the	O
composition	O
.	O

Method	O
and	O
means	O
for	O
culturing	O
osteoblastic	O
cells	O

The	O
present	O
invention	O
provides	O
a	O
preparing	O
method	O
of	O
microcapsule	O
containing	O
unsaturated	O
fatty	B
acid	I
comprising	O
the	O
steps	O
of	O
(	O
a	O
)	O
preparing	O
a	O
first	O
coating	O
material	O
by	O
mixing	O
and	O
gelatinating	O
one	O
or	O
more	O
gums	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
xanthan	B
gum	O
,	O
guar	O
gum	O
,	O
and	O
locusbean	O
gum	O
,	O
with	O
poly	B
glycerin	I
esters	I
of	O
fatty	B
acid	I
in	O
sterilized	O
water	O
,	O
adding	O
unsaturated	O
fatty	B
acid	I
to	O
the	O
solution	O
,	O
and	O
homogenizing	O
the	O
solution	O
;	O
(	O
b	O
)	O
preparing	O
a	O
second	O
coating	O
material	O
by	O
mixing	O
and	O
gelatinating	O
starch	O
or	O
modified	O
starch	O
,	O
gelatin	O
or	O
casein	O
,	O
and	O
poly	B
glycerin	I
esters	I
of	O
fatty	B
acid	I
in	O
sterilized	O
water	O
,	O
adding	O
the	O
first	O
coating	O
material	O
prepared	O
in	O
(	O
a	O
)	O
to	O
the	O
solution	O
,	O
and	O
homogenizing	O
the	O
solution	O
;	O
and	O
(	O
c	O
)	O
spraying	O
the	O
second	O
coating	O
material	O
prepared	O
in	O
(	O
b	O
)	O
in	O
cold	O
sterilized	O
water	O
;	O
a	O
microcapsule	O
prepared	O
by	O
the	O
method	O
;	O
and	O
articles	O
containing	O
the	O
microcapsule	O
.	O

The	O
present	O
microcapsule	O
has	O
effects	O
of	O
preventing	O
the	O
oxidation	O
of	O
unsaturated	O
fatty	B
acid	I
and	O
inhibiting	O
offensive	O
smell	O
.	O

Method	O
of	O
preparing	O
a	O
microcapsule	O
containing	O
unsaturated	O
fatty	B
acids	I
,	O
the	O
microcapsule	O
prepared	O
by	O
the	O
method	O
,	O
and	O
articles	O
containing	O
the	O
microcapsule	O

A	O
composition	O
and	O
a	O
method	O
for	O
administering	O
the	O
composition	O
to	O
a	O
patient	O
in	O
order	O
to	O
accelerate	O
wound	O
healing	O
,	O
particularly	O
postoperative	O
wound	O
healing	O
.	O

The	O
composition	O
,	O
which	O
essentially	O
comprises	O
ornithine	B
α	I
-	I
ketoglutarate	I
,	O
is	O
water	O
-	O
soluble	O
and	O
formulated	O
for	O
oral	O
administration	O
in	O
single	O
-	O
dose	O
packets	O
.	O

The	O
method	O
for	O
using	O
the	O
composition	O
for	O
promoting	O
wound	O
healing	O
includes	O
the	O
step	O
of	O
administering	O
the	O
composition	O
to	O
a	O
patient	O
preoperatively	O
as	O
well	O
as	O
-	O
postoperatively	O
in	O
accordance	O
with	O
a	O
prescribed	O
protocol	O
.	O

The	O
composition	O
may	O
be	O
customized	O
to	O
include	O
one	O
or	O
more	O
additional	O
agents	O
that	O
are	O
effective	O
for	O
promoting	O
nutritional	O
health	O
and/or	O
treating	O
a	O
particular	O
medical	O
problem	O
.	O

The	O
composition	O
may	O
also	O
be	O
taken	O
daily	O
by	O
athletes	O
to	O
minimize	O
the	O
healing	O
time	O
of	O
closed	O
wounds	O
such	O
as	O
muscle	O
or	O
tendon	O
tears	O
that	O
occur	O
during	O
participation	O
in	O
sports	O
,	O
even	O
when	O
the	O
symptoms	O
of	O
such	O
injury	O
are	O
subclinical	O
.	O

Method	O
and	O
composition	O
for	O
postoperative	O
wound	O
healing	O

The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
treatment	O
of	O
cystic	O
fibrosis	O
.	O

The	O
invention	O
includes	O
a	O
method	O
for	O
treatment	O
of	O
cystic	O
fibrosis	O
in	O
a	O
patient	O
by	O
increasing	O
the	O
activity	O
of	O
sarcoendoplasmic	O
reticulum	O
calcium	B
ATPase	O
(	O
SERCA	O
)	O
in	O
a	O
patient	O
.	O

More	O
specifically	O
,	O
the	O
step	O
of	O
increasing	O
SERCA	O
activity	O
can	O
include	O
but	O
is	O
not	O
limited	O
to	O
,	O
administration	O
of	O
SERCA	O
protein	O
or	O
its	O
homologues	O
,	O
gene	O
therapy	O
to	O
restore	O
or	O
enhance	O
SERCA	O
activity	O
,	O
or	O
the	O
administration	O
of	O
compounds	O
stimulating	O
the	O
activity	O
of	O
endogenous	O
SERCA	O
.	O

Reference	O
herein	O
to	O
SERCA	O
,	O
can	O
include	O
in	O
preferred	O
embodiments	O
,	O
the	O
isoform	O
SERCA2	O
,	O
which	O
is	O
the	O
principal	O
lung	O
isoform	O
of	O
SERCA	O
.	O

The	O
present	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
SERCA2	O
(	O
a	O
calcium	B
pump	O
)	O
is	O
deficient	O
(	O
not	O
100	O
%	O
)	O
in	O
the	O
lung	O
epithelial	O
cells	O
of	O
cystic	O
fibrosis	O
samples	O
.	O

Methods	O
for	O
Treatment	O
and	O
Diagnosis	O
of	O
Pulmonary	O
Diseases	O
Based	O
on	O
the	O
Expression	O
of	O
SERCA2	O
Protein	O

The	O
present	O
invention	O
provides	O
compositions	O
comprising	O
compounds	O
that	O
selectively	O
bind	O
to	O
hexokinases	O
thereby	O
promoting	O
dissociation	O
of	O
these	O
enzymes	O
from	O
mitochondria	O
,	O
and	O
methods	O
of	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
to	O
induce	O
cell	O
death	O
in	O
diseases	O
and	O
disorders	O
characterized	O
by	O
the	O
high	O
levels	O
of	O
mitochondrial	O
bound	O
hexokinase	O
.	O

The	O
present	O
invention	O
further	O
discloses	O
methods	O
and	O
assays	O
for	O
detecting	O
and	O
identifying	O
molecules	O
having	O
these	O
activities	O
.	O

Jasmonate	O
based	O
assays	O
for	O
identifying	O
compounds	O
that	O
selectively	O
inhibit	O
mitochondrial	O
bound	O
hexokinases	O

A	O
method	O
of	O
increasing	O
the	O
bioavailability	O
of	O
balsalazide	O
by	O
administration	O
of	O
an	O
oral	O
dosage	O
form	O
with	O
food	O
is	O
provided	O
,	O
as	O
well	O
as	O
an	O
article	O
of	O
manufacture	O
comprising	O
an	O
oral	O
dosage	O
form	O
of	O
balsalazide	B
in	O
a	O
suitable	O
container	O
and	O
associated	O
with	O
printed	O
labeling	O
which	O
describes	O
the	O
increased	O
bioavailability	O
of	O
the	O
medication	O
in	O
the	O
container	O
when	O
taken	O
with	O
food	O
.	O

Formulations	O
and	O
uses	O
of	O
2-hydroxy-5-phenylazobenzoic	B
acid	I
derivatives	O

This	O
invention	O
relates	O
to	O
compositions	O
(	O
e.g.	O
,	O
otic	O
compositions	O
)	O
comprising	O
an	O
antibiotic	O
(	O
generally	O
a	O
quinolone	B
or	O
naphthyridinone	B
)	O
,	O
corticosteroid	B
,	O
and	O
organic	O
acid	O
(	O
generally	O
a	O
fatty	B
acid	I
)	O
.	O

This	O
invention	O
also	O
relates	O
to	O
treatment	O
methods	O
using	O
such	O
a	O
composition	O
,	O
uses	O
of	O
such	O
a	O
composition	O
to	O
make	O
medicaments	O
,	O
and	O
therapeutic	O
kits	O
comprising	O
such	O
a	O
composition	O
.	O

Composition	O
comprising	O
an	O
antibiotic	O
and	O
a	O
corticosteroid	B

The	O
present	O
invention	O
provides	O
novel	O
crystalline	O
and	O
amorphous	O
lapatinib	B
compounds	O
and	O
processes	O
for	O
preparing	O
them	O
Forms	O
of	O
lapatinib	B
compounds	O
and	O
processes	O
for	O
the	O
preparation	O
thereof	O

It	O
is	O
an	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
a	O
drug	O
solution	O
which	O
has	O
a	O
reduced	O
dissolved	O
oxygen	B
content	O
and	O
is	O
less	O
susceptible	O
to	O
oxidative	O
degradation	O
and	O
highly	O
stable	O
over	O
time	O
,	O
a	O
production	O
method	O
therefor	O
,	O
and	O
a	O
drug	O
solution	O
containing	O
pack	O
which	O
is	O
capable	O
of	O
maintaining	O
the	O
dissolved	O
oxygen	B
content	O
of	O
a	O
drug	O
solution	O
at	O
a	O
reduced	O
level	O
,	O
less	O
susceptible	O
to	O
oxidative	O
degradation	O
of	O
the	O
drug	O
solution	O
and	O
highly	O
stable	O
over	O
time	O
.	O

To	O
achieve	O
the	O
aforementioned	O
object	O
,	O
the	O
reduced	O
-	O
dissolved	O
-	O
oxygen	B
-	O
content	O
drug	O
solution	O
is	O
produced	O
by	O
filling	O
and	O
sealing	O
the	O
drug	O
solution	O
in	O
a	O
drug	O
solution	O
container	O
(	O
15	O
)	O
formed	O
of	O
a	O
plastic	O
material	O
having	O
an	O
oxygen	B
permeability	O
of	O
not	O
lower	O
than	O
200	O
cm3	O
/	O
m2·24	O
h·atm	O
at	O
25	O
°	O
C.	O
at	O
60	O
%	O
RH	O
within	O
12	O
hours	O
after	O
a	O
steam	O
sterilization	O
process	O
or	O
a	O
hot	O
water	O
sterilization	O
process	O
and	O
having	O
a	O
steady	O
-	O
state	O
oxygen	B
permeability	O
of	O
not	O
higher	O
than	O
100	O
cm3	O
/	O
m2·24	O
h·atm	O
at	O
25	O
°	O
C.	O
at	O
60	O
%	O
RH	O
,	O
subjecting	O
the	O
drug	O
solution	O
container	O
to	O
the	O
steam	O
sterilization	O
process	O
or	O
the	O
hot	O
water	O
sterilization	O
process	O
,	O
and	O
storing	O
the	O
drug	O
solution	O
container	O
in	O
an	O
environment	O
having	O
deoxidization	O
means	O
for	O
reducing	O
the	O
dissolved	O
oxygen	B
concentration	O
of	O
the	O
drug	O
solution	O
to	O
not	O
higher	O
than	O
2	O
ppm	O
when	O
the	O
oxygen	B
permeability	O
of	O
the	O
plastic	O
material	O
reaches	O
the	O
steady	O
-	O
state	O
level	O
.	O

Drug	O
solution	O
having	O
reduced	O
dissolved	O
oxygen	B
content	O
,	O
method	O
of	O
producing	O
the	O
same	O
and	O
drug	O
solution	O
containing	O
unit	O
having	O
reduced	O
dissolved	O
oxygen	B
content	O

The	O
present	O
invention	O
relates	O
to	O
solid	O
microparticulate	O
oral	O
pharmaceutical	O
forms	O
whose	O
composition	O
and	O
structure	O
make	O
it	O
possible	O
to	O
avoid	O
misuse	O
of	O
the	O
pharmaceutical	O
active	O
principle	O
(	O
AP	O
)	O
they	O
contain	O
.	O

The	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
prevent	O
solid	O
oral	O
drugs	O
from	O
being	O
misappropriated	O
for	O
any	O
use	O
other	O
than	O
the	O
therapeutic	O
use	O
(	O
s	O
)	O
officially	O
approved	O
by	O
the	O
competent	O
public	O
health	O
authorities	O
.	O

In	O
other	O
words	O
,	O
the	O
object	O
is	O
to	O
avoid	O
the	O
voluntary	O
or	O
involuntary	O
misuse	O
of	O
solid	O
oral	O
drugs	O
.	O

The	O
invention	O
relates	O
to	O
a	O
solid	O
oral	O
pharmaceutical	O
form	O
which	O
is	O
characterized	O
in	O
that	O
it	O
contains	O
anti	O
-	O
misuse	O
means	O
,	O
in	O
that	O
at	O
least	O
part	O
of	O
the	O
AP	O
it	O
comprises	O
is	O
contained	O
in	O
coated	O
microparticles	O
for	O
modified	O
release	O
of	O
the	O
AP	O
,	O
and	O
in	O
that	O
the	O
coated	O
microparticles	O
of	O
AP	O
have	O
a	O
coating	O
layer	O
(	O
Ra	O
)	O
which	O
assures	O
the	O
modified	O
release	O
of	O
the	O
AP	O
and	O
simultaneously	O
imparts	O
crushing	O
resistance	O
to	O
the	O
coated	O
microparticles	O
of	O
AP	O
so	O
as	O
to	O
avoid	O
misuse	O
.	O

anti	O
-	O
misuse	O
microparticulate	O
oral	O
pharmaceutical	O
form	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O

I	O
and	O
their	O
use	O
for	O
controlling	O
phytopathogenic	O
fungi	O
,	O
and	O
also	O
to	O
fungicidal	O
mixtures	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
I	O
,	O
where	O
the	O
variables	O
and	O
substituents	O
have	O
the	O
meanings	O
defined	O
in	O
the	O
claims	O
and	O
in	O
the	O
description	O
.	O

Fungicidal	O
Compounds	O
and	O
Fungicidal	O
Compositions	O

Disclosed	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
treating	O
various	O
diseases	O
,	O
syndromes	O
,	O
conditions	O
and	O
disorders	O
,	O
including	O
pain	O
.	O

Such	O
compounds	O
are	O
represented	O
by	O
Formula	O
I	O
as	O
follows	O
:	O
wherein	O
W1	O
,	O
W2	O
,	O
W3	O
,	O
R1	O
,	O
R1a	O
,	O
R2	O
,	O
R2a	O
,	O
R3	O
,	O
V	O
,	O
Q	O
,	O
and	O
X	O
are	O
defined	O
herein	O
.	O

Heterocyclic	B
benzimidazoles	I
as	O
trpm8	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
and	O
stable	O
crystalline	O
polymorph	O
of	O
lansoprazole	B
,	O
a	O
process	O
for	O
its	O
preparation	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
it	O
.	O

Thus	O
,	O
for	O
example	O
,	O
lansoprazole	B
crude	O
is	O
dissolved	O
in	O
methanol	O
at	O
20	O
-	O
30	O
°	O
C.	O
followed	O
by	O
stirring	O
and	O
the	O
solution	O
is	O
cooled	O
to	O
0	O
-	O
10	O
°	O
C.	O
The	O
resulting	O
solution	O
is	O
stirred	O
for	O
1	O
hour	O
to	O
1	O
hour	O
30	O
minutes	O
at	O
0	O
-	O
10	O
°	O
C.	O
,	O
the	O
solid	O
is	O
filtered	O
and	O
then	O
dried	O
to	O
give	O
lansoprazole	B
crystalline	O
form	O
III	O
.	O

novel	O
crystalline	O
form	O
of	O
lansoprazole	B

A	O
method	O
of	O
treating	O
a	O
tar	O
-	O
responsive	O
dermatological	O
disorder	O
includes	O
topically	O
applying	O
an	O
anhydrous	O
tar	O
composition	O
to	O
skin	O
of	O
a	O
mammal	O
,	O
preferably	O
a	O
human	O
,	O
that	O
is	O
involved	O
with	O
the	O
disorder	O
,	O
the	O
composition	O
including	O
a	O
wax	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
tar	O
for	O
topical	O
treatment	O
of	O
the	O
tar	O
-	O
responsive	O
dermatological	O
disorder	O
,	O
the	O
composition	O
being	O
in	O
liquid	O
form	O
when	O
at	O
a	O
temperature	O
selected	O
from	O
room	O
temperature	O
and	O
a	O
temperature	O
of	O
skin	O
of	O
a	O
mammal	O
upon	O
application	O
of	O
the	O
composition	O
to	O
the	O
skin	O
of	O
the	O
mammal	O
.	O

Method	O
for	O
topical	O
treatment	O
of	O
tar	O
-	O
responsive	O
dermatological	O
disorders	O

The	O
invention	O
relates	O
to	O
soap	O
-	O
based	O
liquid	O
body	O
and	O
facial	O
wash	O
compositions	O
using	O
high	O
solvent	O
,	O
low	O
water	O
compositions	O
and	O
incompletely	O
neutralized	O
fatty	B
acids	I
to	O
help	O
structure	O
the	O
compositions	O
,	O
all	O
in	O
combination	O
with	O
modified	O
benefit	O
agents	O
,	O
enhanced	O
deposition	O
of	O
antimicrobial	O
agents	O
is	O
obtained	O
.	O

Soap	O
-	O
based	O
liquid	O
wash	O
formulations	O
with	O
enhanced	O
deposition	O
of	O
antimicrobial	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
for	O
the	O
protection	O
,	O
treatment	O
and	O
repair	O
of	O
connective	O
tissues	O
in	O
humans	O
and	O
animals	O
comprising	O
any	O
or	O
all	O
of	O
anabolic	O
,	O
anti	O
-	O
catabolic	O
,	O
anti	O
-	O
oxidant	O
and	O
analgesic	O
agents	O
,	O
including	O
aminosugars	O
,	O
S	B
-	I
adenosylmethionine	I
,	O
arachadonic	B
acid	I
,	O
GAGs	O
,	O
including	O
pentosan	O
,	O
collagen	O
type	O
II	O
,	O
tetracyclines	B
or	O
tetracycline	B
-	O
like	O
compounds	O
,	O
diacerin	B
,	O
super	B
oxide	I
dismutase	O
,	O
L	B
-	I
ergothionine	I
,	O
one	O
or	O
more	O
avocado	O
/	O
soybean	O
unsaponifiables	O
,	O
and	O
an	O
analgesic	O
,	O
e.g.	O
,	O
acetaminophen	B
,	O
and	O
to	O
methods	O
of	O
treating	O
humans	O
and	O
animals	O
by	O
administration	O
of	O
these	O
novel	O
compositions	O
to	O
humans	O
and	O
animals	O
in	O
need	O
thereof	O
.	O

Use	O
of	O
anabolic	O
agents	O
,	O
anti	O
-	O
catabolic	O
agents	O
,	O
antioxidant	O
agents	O
,	O
and	O
analgesics	O
for	O
protection	O
,	O
treatment	O
and	O
repair	O
of	O
connective	O
tissues	O
in	O
humans	O
and	O
animals	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
W	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O

Novel	O
compounds	O
409	O

A	O
composition	O
for	O
the	O
treatment	O
of	O
skin	O
comprises	O
a	O
non	O
-	O
emulsified	O
,	O
aqueous	O
suspension	O
of	O
retinol	B
.	O

The	O
composition	O
may	O
further	O
include	O
at	O
least	O
one	O
protein	O
species	O
,	O
and	O
some	O
proteins	O
used	O
in	O
the	O
composition	O
include	O
collagen	O
and	O
elastin	O
.	O

The	O
composition	O
may	O
also	O
include	O
hyaluronic	O
acid	O
.	O

The	O
composition	O
may	O
also	O
include	O
one	O
or	O
more	O
of	O
tocopheryl	B
acetate	I
,	O
propylene	B
glycol	I
,	O
and	O
linseed	O
extract	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
making	O
the	O
composition	O
and	O
use	O
of	O
the	O
composition	O
for	O
the	O
treatment	O
of	O
skin	O
.	O

Retinol	B
formulations	O
and	O
methods	O
for	O
their	O
use	O

A	O
pharmaceutical	O
composition	O
for	O
intranasal	O
administration	O
to	O
a	O
mammal	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
an	O
effective	O
amount	O
of	O
a	O
benzodiazepine	B
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
nasal	O
carrier	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
pharmaceutical	O
composition	O
when	O
administered	O
intranasally	O
produces	O
a	O
rapid	O
physiological	O
response	O
.	O

Pharmaceutical	O
compositions	O
may	O
also	O
include	O
at	O
least	O
one	O
or	O
more	O
sweeteners	O
,	O
flavoring	O
agents	O
,	O
or	O
masking	O
agents	O
or	O
combinations	O
thereof	O
.	O

Intranasal	O
Benzodiazepine	B
Compositions	O

Improved	O
methods	O
for	O
production	O
of	O
stilbenoids	B
including	O
resveratrol	B
,	O
pinosylvin	B
and	O
their	O
respective	O
derivatives	O
are	O
provided	O
,	O
including	O
producing	O
root	O
cultures	O
from	O
plant	O
cells	O
and	O
eliciting	O
production	O
of	O
the	O
stilbenes	O
.	O

The	O
plant	O
cells	O
in	O
an	O
embodiment	O
are	O
contacted	O
with	O
substances	O
which	O
elicit	O
production	O
of	O
the	O
stilbenoid	B
compounds	O
.	O

Production	O
of	O
stilbenes	B
in	O
plant	O
hairy	O
root	O
cultures	O
and	O
other	O
root	O
cultures	O

Certain	O
embodiments	O
disclosed	O
relate	O
to	O
compositions	O
,	O
including	O
therapeutic	O
compositions	O
,	O
methods	O
,	O
devices	O
,	O
and	O
systems	O
that	O
modulate	O
at	O
least	O
one	O
inflammatory	O
response	O
or	O
reaction	O
.	O

According	O
to	O
various	O
embodiments	O
,	O
the	O
compositions	O
,	O
methods	O
,	O
devices	O
,	O
and	O
systems	O
relate	O
to	O
modulating	O
one	O
or	O
more	O
of	O
Toll	O
-	O
like	O
receptors	O
,	O
Src	O
family	O
kinases	O
,	O
NF	O
-	O
kB	O
molecules	O
,	O
proteases	O
,	O
or	O
proteasomes	O
.	O

Anti	O
-	O
inflammatory	O
compositions	O
and	O
methods	O

The	O
invention	O
pertains	O
to	O
the	O
area	O
of	O
pharmaceutical	O
compositions	O
that	O
are	O
useful	O
for	O
treating	O
pathologies	O
resulting	O
from	O
a	O
deregulation	O
of	O
the	O
angiogenesis	O
mechanism	O
.	O

The	O
invention	O
particularly	O
concerns	O
new	O
genes	O
whose	O
function	O
had	O
not	O
been	O
identified	O
before	O
now	O
as	O
well	O
as	O
genes	O
that	O
are	O
known	O
but	O
whose	O
involvement	O
in	O
the	O
angiogenesis	O
mechanism	O
has	O
been	O
shown	O
for	O
the	O
first	O
time	O
.	O

Genes	O
involved	O
in	O
the	O
regulation	O
of	O
angiogenesis	O
,	O
pharmaceutical	O
preparations	O
containing	O
them	O
an	O
uses	O
thereof	O

A	O
composition	O
comprises	O
a	O
material	O
capable	O
of	O
selectively	O
controlling	O
a	O
level	O
or	O
activity	O
of	O
HDAC6	O
in	O
an	O
ocular	O
environment	O
for	O
effecting	O
ocular	O
neuroprotection	O
in	O
subjects	O
in	O
risk	O
of	O
developing	O
or	O
worsening	O
an	O
ocular	O
neurodegenerative	O
condition	O
,	O
or	O
for	O
treating	O
or	O
controlling	O
glaucoma	O
.	O

Such	O
a	O
composition	O
can	O
be	O
administered	O
to	O
a	O
patient	O
in	O
combination	O
with	O
another	O
therapy	O
directed	O
at	O
providing	O
ocular	O
neuroprotection	O
or	O
treating	O
or	O
controlling	O
glaucoma	O
.	O

Selective	O
Inhibition	O
of	O
Histone	B
Deacetylase	O
6	O
for	O
Ocular	O
Neuroprotection	O
or	O
for	O
Treatment	O
or	O
Control	O
of	O
Glaucoma	O

An	O
implant	O
with	O
a	O
metal	O
structure	O
for	O
use	O
in	O
a	O
surgical	O
procedure	O
,	O
in	O
which	O
at	O
least	O
part	O
of	O
the	O
metal	O
structure	O
is	O
coated	O
with	O
a	O
biocompatible	O
metal	O
such	O
as	O
titanium	B
by	O
plasma	O
spraying	O
of	O
the	O
metal	O
powder	O
.	O

Biocidal	O
metal	O
cations	O
are	O
then	O
absorbed	O
by	O
ion	O
exchange	O
into	O
the	O
coating	O
,	O
so	O
that	O
after	O
being	O
implanted	O
the	O
biocidal	O
ions	O
gradually	O
leach	O
out	O
into	O
the	O
surrounding	O
body	O
fluids	O
and	O
suppress	O
infection	O
.	O

The	O
ion	O
exchange	O
properties	O
of	O
the	O
coating	O
may	O
be	O
modified	O
by	O
pretreatment	O
with	O
dilute	O
phosphoric	B
acid	I
.	O

Metal	O
Implants	O

A	O
method	O
for	O
contouring	O
the	O
body	O
by	O
destroying	O
adipose	O
tissue	O
is	O
disclosed	O
.	O

This	O
method	O
can	O
reduce	O
the	O
circumference	O
of	O
the	O
treated	O
area	O
,	O
improve	O
skin	O
contour	O
irregularities	O
and	O
smooth	O
the	O
appearance	O
of	O
the	O
skin	O
surface	O
.	O

The	O
method	O
is	O
also	O
used	O
as	O
a	O
body	O
treatment	O
before	O
and	O
after	O
a	O
liposuction	O
procedure	O
.	O

Device	O
and	O
Method	O
for	O
Treating	O
Human	O
Body	O

The	O
present	O
invention	O
relates	O
to	O
a	O
TRPV3	O
(	O
transient	O
receptor	O
potential	O
vanilloid	O
3	O
)	O
activity	O
inhibitor	O
,	O
more	O
precisely	O
to	O
a	O
method	O
for	O
inhibiting	O
TRPV3	O
activity	O
including	O
the	O
step	O
of	O
treating	O
isopentenyl	B
pyrophosphate	I
and	O
a	O
method	O
for	O
treating	O
skin	O
disease	O
containing	O
the	O
step	O
of	O
administering	O
isopentenyl	B
pyrophosphate	I
to	O
a	O
subject	O
with	O
skin	O
disease	O
or	O
applying	O
the	O
same	O
on	O
the	O
skin	O
of	O
the	O
subject	O
.	O

Isopentenyl	B
pyrophosphate	I
of	O
the	O
present	O
invention	O
controls	O
increase	O
of	O
sensory	O
cell	O
reactivity	O
to	O
current	O
or	O
migration	O
and	O
proliferation	O
of	O
skin	O
cells	O
induced	O
by	O
TRPV3	O
,	O
so	O
that	O
it	O
can	O
be	O
effectively	O
used	O
for	O
the	O
development	O
of	O
a	O
pain	O
reliever	O
or	O
a	O
therapeutic	O
agent	O
for	O
skin	O
disease	O
.	O

compound	O
for	O
inhibiting	O
trpv3	O
function	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
A	O
is	O
C1-C6-alkyl	B
,	O
C1-C6-haloalkyl	B
,	O
C1-C6-hydroxyalkyl	B
,	O
C2-C6-alkenyl	B
,	O
C2-C6-halo	B
-	I
alkenyl	I
,	O
C3-C6-cycloalkyl	B
,	O
aryl	B
-	I
C1-C4-alkyl	I
,	O
aryl	B
-	I
C2-C4-alkenyl	I
,	O
aryl	B
or	O
hetaryl	B
,	O
is	O
a	O
single	O
or	O
double	O
bond	O
;	O
X1	O
and	O
X2	O
are	O
N	B
,	O
CRx1	O
,	O
NRx2	O
,	O
or	O
CRx3Rx4	O
;	O
Rx1	O
,	O
Rx3	O
and	O
Rx4	O
are	O
H	B
,	O
halogen	B
,	O
CN	B
,	O
NO2	B
,	O
C1-C6-alkyl	B
,	O
C1-C6-alkoxy	B
,	O
C1-C6-alkylcarbonyl	B
,	O
etc	O
.	O
or	O
two	O
geminal	O
radicals	O
Rx3	O
and	O
Rx4	O
together	O
with	O
the	O
carbon	B
atom	O
to	O
which	O
they	O
are	O
bound	O
may	O
form	O
a	O
carbonyl	B
group	O
or	O
a	O
3-	O
to	O
6-membered	O
carbocyclic	B
or	O
heterocyclic	B
spiro	O
-	O
annulated	O
ring	O
;	O
Rx2	O
is	O
hydrogen	B
,	O
C1-C6-alkyl	B
,	O
C1-C6-alkylcarbonyl	B
,	O
C1-C6-haloalkyl	B
,	O
etc	O
.	O
;	O
or	O
two	O
vicinal	O
radicals	O
Rx1	O
,	O
Rx2	O
,	O
Rx3	O
or	O
Rx4	O
together	O
with	O
X1	O
and	O
X2	O
form	O
a	O
five-	O
or	O
six	O
-	O
membered	O
carbocyclic	B
or	O
heterocyclic	B
fused	O
ring	O
;	O
Y1	O
,	O
Y2	O
and	O
Y3	O
are	O
N	B
or	O
CRy	B
;	O
Ry	O
is	O
H	B
,	O
halogen	B
,	O
CN	B
,	O
NO2	B
,	O
C1-C6-alkyl	B
,	O
C1-C6-alkoxy	B
,	O
C1-C6-alkylcarbonyl	B
,	O
C1-C6-haloalkyl	B
,	O
etc	O
.	O
;	O
wherein	O
a	O
maximum	O
of	O
3	O
of	O
the	O
radicals	O
X1	O
,	O
X2	O
,	O
Y1	O
,	O
Y2	O
and	O
Y3	O
are	O
selected	O
from	O
NRx1	B
and	O
N	B
;	O
R1	O
is	O
hydrogen	B
,	O
C1-C6-alkyl	B
,	O
C1-C6-hydroxyalkyl	B
,	O
C1-C6-haloalkyl	B
,	O
etc	O
.	O
;	O
R2	O
is	O
C1-C4-alkyl	B
or	O
C1-C4-haloalkyl	B
;	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
physiologically	O
tolerated	O
acid	O
addition	O
salts	O
and	O
the	O
N	B
-	I
oxides	I
thereof	O
,	O
pharmaceutical	O
composition	O
comprising	O
them	O
,	O
a	O
method	O
for	O
treating	O
medical	O
disorders	O
selected	O
from	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
,	O
addiction	O
diseases	O
or	O
obesity	O
,	O
said	O
method	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
such	O
compounds	O
to	O
a	O
subject	O
in	O
need	O
and	O
the	O
use	O
of	O
such	O
a	O
compound	O
for	O
preparing	O
a	O
pharmaceutical	O
compositions	O
.	O

Azetidin	B
compounds	O
suitable	O
for	O
treating	O
disorders	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	B
5-ht6	O
receptor	O

The	O
present	O
disclosure	O
relates	O
,	O
according	O
to	O
some	O
embodiments	O
,	O
to	O
compositions	O
,	O
systems	O
,	O
and	O
methods	O
for	O
ameliorating	O
,	O
preventing	O
,	O
and/or	O
treating	O
(	O
collectively	O
""""	O
treating	O
""""	O
)	O
hyperhidrosis	O
and/or	O
excessive	O
perspiration	O
(	O
collectively	O
""""	O
hyperhidrosis	O
""""	O
)	O
.	O

For	O
example	O
,	O
a	O
method	O
for	O
treating	O
hyperhidrosis	O
may	O
comprise	O
administering	O
(	O
e.g.	O
,	O
topically	O
administering	O
)	O
a	O
composition	O
comprising	O
an	O
anticholinergic	O
compound	O
(	O
e.g.	O
,	O
an	O
ipratropium	B
compound	O
)	O
to	O
a	O
mammal	O
.	O

A	O
composition	O
(	O
e.g.	O
,	O
a	O
topical	O
composition	O
)	O
for	O
treating	O
hyperhidrosis	O
may	O
comprise	O
an	O
anticholinergic	O
compound	O
(	O
e.g.	O
,	O
an	O
ipratropium	B
compound	O
)	O
and	O
a	O
vehicle	O
(	O
e.g.	O
,	O
a	O
physiologically	O
acceptable	O
vehicle	O
)	O
.	O

In	O
some	O
embodiments	O
,	O
administering	O
a	O
composition	O
comprising	O
an	O
anticholinergic	O
compound	O
may	O
comprise	O
contacting	O
the	O
subject	O
with	O
a	O
medicated	O
article	O
comprising	O
the	O
composition	O
.	O

Compositions	O
and	O
methods	O
for	O
hyperhidrosis	O

The	O
present	O
invention	O
discloses	O
a	O
non	O
-	O
hygroscopic	O
crystalline	O
bepotastine	B
metal	O
salt	O
hydrate	B
,	O
a	O
method	O
for	O
preparing	O
same	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
same	O
for	O
treating	O
or	O
preventing	O
a	O
histamine	O
-	O
mediated	O
disease	O
or	O
an	O
allergic	O
disease	O
.	O

Novel	O
crystalline	O
bepotastine	B
metal	O
salt	O
hydrate	B
,	O
method	O
for	O
preparing	O
same	O
,	O
and	O
pharmaceutical	O
composition	O
comprising	O
same	O

Disclosed	O
are	O
compositions	O
and	O
methods	O
for	O
reducing	O
the	O
proliferation	O
of	O
ALL	O
cancer	O
cells	O
through	O
targeted	O
interactions	O
with	O
ALL1	O
fusion	O
proteins	O
.	O

Oncogenic	O
ALL-1	O
Fusion	O
Proteins	O
for	O
Targeting	O
Drosha	O
-	O
Mediated	O
MicroRNA	O
Processing	O

The	O
present	O
invention	O
relates	O
to	O
new	O
trifluoromethylphenyl	B
modulators	O
of	O
calcium	B
-	O
sensing	O
receptor	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Trifluoromethylphenyl	B
modulators	O
of	O
calcium	B
-	O
sensing	O
receptor	O

The	O
subject	O
application	O
provides	O
for	O
a	O
method	O
for	O
enhancing	O
oxygen	B
delivery	O
to	O
a	O
tissue	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
comprising	O
two	O
or	O
more	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
hemoglobin	O
based	O
oxygen	B
carrier	O
,	O
a	O
nonhemoglobin	O
based	O
oxygen	B
carrier	O
,	O
a	O
rheologic	O
modulator	O
,	O
a	O
diffusion	O
changing	O
compound	O
,	O
a	O
volume	O
expander	O
,	O
and	O
a	O
vasomodulator	O
.	O

The	O
subject	O
application	O
also	O
provides	O
for	O
a	O
method	O
for	O
enhancing	O
oxygen	B
delivery	O
to	O
a	O
tissue	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
composition	O
comprising	O
a	O
perfluorocarbon	O
and	O
one	O
or	O
more	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
hemoglobin	O
based	O
oxygen	B
carrier	O
,	O
a	O
nonhemoglobin	O
based	O
oxygen	B
carrier	O
,	O
a	O
rheologic	O
modulator	O
,	O
a	O
diffusion	O
changing	O
compound	O
,	O
a	O
volume	O
expander	O
,	O
and	O
a	O
vasomodulator	O
.	O

Novel	O
combinatorial	O
approaches	O
to	O
enhancing	O
oxygen	B
transport	O
to	O
tissues	O

The	O
present	O
invention	O
relates	O
to	O
new	O
biomaterials	O
in	O
the	O
form	O
of	O
fibres	O
,	O
essentially	O
consisting	O
of	O
a	O
mixture	O
of	O
gellan	O
and	O
hyaluronic	B
acid	I
derivatives	O
,	O
for	O
use	O
in	O
surgery	O
,	O
especially	O
in	O
the	O
treatment	O
of	O
wounds	O
and	O
mild	O
burns	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
process	O
for	O
the	O
preparation	O
of	O
said	O
biomaterials	O
.	O

Biomaterials	O
In	O
the	O
Form	O
of	O
Fibres	O
for	O
Use	O
as	O
Medical	O
Devices	O

In	O
the	O
Treatment	O
of	O
Wounds	O
,	O
and	O
Their	O
Production	O
Process	O

Calcium	B
glycerophosphate	I
is	O
found	O
to	O
be	O
effective	O
in	O
treating	O
and	O
preventing	O
a	O
disease	O
,	O
disorder	O
and/or	O
condition	O
of	O
the	O
respiratory	O
system	O
.	O

The	O
disease	O
,	O
disorder	O
and/or	O
condition	O
is	O
related	O
to	O
an	O
obstructive	O
or	O
a	O
restrictive	O
condition	O
of	O
the	O
respiratory	O
airway	O
.	O

The	O
disease	O
,	O
disorder	O
and/or	O
condition	O
can	O
be	O
a	O
respiratory	O
airway	O
inflammatory	O
disease	O
,	O
a	O
respiratory	O
airway	O
stenosis	O
or	O
a	O
nasal	O
cavity	O
inflammatory	O
disease	O
,	O
such	O
as	O
an	O
asthma	O
,	O
a	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
an	O
emphysema	O
,	O
a	O
reactive	O
airway	O
disease	O
(	O
RADS	O
)	O
,	O
rhinitis	O
,	O
bronchitis	O
,	O
bronchiolitis	O
,	O
congestion	O
,	O
sinusitis	O
,	O
tonsillitis	O
,	O
or	O
laryngitis	O
,	O
post	O
-	O
nasal	O
drip	O
(	O
PND	O
)	O
and	O
a	O
related	O
complication	O
thereof	O
,	O
inflamed	O
degranulating	O
and	O
non	O
-	O
degranulating	O
mast	O
cell	O
activity	O
,	O
any	O
irritation	O
occasioning	O
mucus	O
secretion	O
from	O
goblet	O
cells	O
breathing	O
difficulty	O
,	O
restriction	O
,	O
obstruction	O
;	O
airways	O
constriction	O
or	O
closure	O
or	O
mucus	O
interference	O
with	O
air	O
passage	O
;	O
sleep	O
apnea	O
,	O
snoring	O
,	O
inflammatory	O
or	O
non	O
-	O
inflammatory	O
responses	O
to	O
an	O
airborne	O
or	O
non	O
-	O
airborne	O
allergen	O
or	O
irritant	O
;	O
nasal	O
or	O
non	O
-	O
nasal	O
airway	O
inflammation	O
or	O
irritation	O
caused	O
by	O
a	O
problem	O
in	O
any	O
area	O
of	O
the	O
body	O
;	O
and	O
a	O
physical	O
damage	O
to	O
the	O
respiratory	O
system	O
.	O

Methods	O
,	O
compositions	O
and	O
devices	O
are	O
described	O
for	O
using	O
calcium	O
glycerophosphate	O
to	O
treat	O
and	O
prevent	O
the	O
disease	O
,	O
disorder	O
and/or	O
condition	O
of	O
the	O
respiratory	O
system	O
.	O

Calcium	B
Glycerophosphate	I
for	O
Treating	O
and	O
Preventing	O
Respiratory	O
Diseases	O
or	O
Conditions	O

Provided	O
herein	O
are	O
methods	O
for	O
reducing	O
or	O
preventing	O
neutrophilic	O
inflammation	O
in	O
a	O
subject	O
comprising	O
selecting	O
a	O
subject	O
with	O
or	O
at	O
risk	O
for	O
neutrophilic	O
inflammation	O
and	O
administering	O
to	O
the	O
subject	O
an	O
agent	O
that	O
inhibits	O
the	O
expression	O
or	O
activity	O
of	O
prolyl	O
endopeptidase	O
.	O

Provided	O
herein	O
are	O
also	O
methods	O
for	O
treatment	O
or	O
prevention	O
of	O
diseases	O
associated	O
with	O
neutrophilic	O
inflammation	O
.	O

Prolyl	O
Endopeptidase	O
Inhibitors	O
For	O
Reducing	O
or	O
Preventing	O
Neutrophilic	O
Inflammation	O

The	O
present	O
invention	O
discloses	O
an	O
agent	O
for	O
treating	O
a	O
polyglutamine	O
aggregation	O
-	O
caused	O
disease	O
or	O
suppressing	O
its	O
onset	O
,	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
(	O
1	O
)	O
(	O
i	O
)	O
HGF	O
protein	O
,	O
(	O
ii	O
)	O
a	O
partial	O
peptide	O
of	O
HGF	O
protein	O
that	O
is	O
substantially	O
equivalent	O
in	O
activity	O
to	O
HGF	O
protein	O
,	O
or	O
a	O
salt	O
of	O
either	O
of	O
them	O
,	O
or	O
(	O
2	O
)	O
DNA	O
containing	O
(	O
i	O
)	O
DNA	O
encoding	O
HGF	O
protein	O
,	O
(	O
ii	O
)	O
DNA	O
encoding	O
a	O
partial	O
peptide	O
of	O
HGF	O
protein	O
that	O
is	O
substantially	O
equivalent	O
in	O
activity	O
to	O
HGF	O
protein	O
or	O
(	O
iii	O
)	O
DNA	O
which	O
encodes	O
a	O
protein	O
or	O
a	O
peptide	O
that	O
is	O
substantially	O
equivalent	O
in	O
activity	O
to	O
HGF	O
protein	O
and	O
hybridizes	O
with	O
DNA	O
comprising	O
a	O
complementary	O
base	O
sequence	O
of	O
either	O
of	O
the	O
above	O
-	O
mentioned	O
DNAs	O
under	O
a	O
stringent	O
condition	O
.	O

Agent	O
for	O
Treating	O
Polyglutamine	O
Aggregation	O
-	O
Caused	O
Disease	O
or	O
Suppressing	O
Onset	O
Thereof	O

The	O
present	O
invention	O
relates	O
to	O
new	O
AGC	O
kinase	O
inhibitors	O
,	O
in	O
particular	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
or	O
a	O
stereoisomer	O
tautomer	O
,	O
racemic	O
,	O
metabolite	O
,	O
pro-	O
or	O
predrug	O
,	O
salt	O
,	O
hydrate	B
,	O
or	O
solvate	O
thereof	O
,	O
wherein	O
Ar1	O
,	O
Ar2	O
,	O
R1	O
,	O
R3	O
,	O
p	O
and	O
n	O
have	O
the	O
meaning	O
defined	O
in	O
the	O
claims	O
In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
more	O
specifically	O
AGC	O
kinases	O
inhibitors	O
,	O
compositions	O
,	O
in	O
particular	O
pharmaceuticals	O
,	O
comprising	O
such	O
inhibitors	O
,	O
and	O
to	O
uses	O
of	O
such	O
inhibitors	O
in	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
disease	O
.	O

Amide	B
Derivatives	O
as	O
Kinase	O
Inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
controlling	O
blood	O
glucose	B
level	O
and	O
a	O
method	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
diabetes	O
mellitus	O
and/or	O
its	O
complications	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
an	O
anti	O
-	O
diabetic	O
formulation	O
for	O
controlling	O
blood	O
glucose	B
level	O
and/or	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
diabetes	O
mellitus	O
and/or	O
its	O
complications	O
.	O

Hypoglycemic	O
Activity	O
of	O
Osthole	B

The	O
invention	O
provides	O
anticholinergic	O
agents	O
that	O
are	O
chemically	O
modified	O
by	O
covalent	O
attachment	O
of	O
a	O
water	O
-	O
soluble	O
oligomer	B
.	O

A	O
conjugate	O
of	O
the	O
invention	O
,	O
when	O
administered	O
by	O
any	O
of	O
a	O
number	O
of	O
administration	O
routes	O
,	O
exhibits	O
characteristics	O
that	O
are	O
different	O
as	O
compared	O
to	O
the	O
characteristics	O
of	O
the	O
anticholinergic	O
agent	O
not	O
attached	O
to	O
the	O
water	O
-	O
soluble	O
oligomer	O
.	O

Oligomer	B
-	O
Anticholinergic	O
Agent	O
Conjugates	O

Disclosed	O
are	O
microcapsules	O
and	O
methods	O
for	O
preparing	O
and	O
using	O
them	O
,	O
as	O
well	O
as	O
methods	O
for	O
improving	O
various	O
properties	O
of	O
microcapsules	O
like	O
impermeability	O
.	O

Microcapsules	O
with	O
improved	O
shells	O

Provided	O
is	O
an	O
injectable	O
comprising	O
:	O
an	O
anthracycline	B
antineoplastic	O
antibiotic	O
;	O
and	O
at	O
least	O
one	O
acid	B
amide	I
selected	O
from	O
the	O
group	O
consisting	O
of	O
nicotinic	B
acid	I
amide	I
,	O
isonicotinic	B
acid	I
amide	I
and	O
gentisic	B
acid	I
ethanolamide	I
.	O

Injectable	O
,	O
injection	O
solution	O
,	O
and	O
injection	O
kit	O
preparation	O

The	O
present	O
invention	O
discloses	O
and	O
claims	O
a	O
series	O
of	O
substituted	O
N	B
-	I
phenyl	I
-	I
bipyrrolidine	I
carboxamides	I
of	O
formula	O
(	O
I	O
)	O
.	O

Wherein	O
R	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
described	O
herein	O
.	O

More	O
specifically	O
,	O
the	O
compounds	O
of	O
this	O
invention	O
are	O
modulators	O
of	O
H3	O
receptors	O
and	O
are	O
,	O
therefore	O
,	O
useful	O
as	O
pharmaceutical	O
agents	O
,	O
especially	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
a	O
variety	O
of	O
diseases	O
modulated	O
by	O
H3	O
receptors	O
including	O
diseases	O
associated	O
with	O
the	O
central	O
nervous	O
system	O
.	O

Additionally	O
,	O
this	O
invention	O
also	O
discloses	O
methods	O
of	O
preparation	O
of	O
substituted	O
N	B
-	I
phenyl	I
-	I
bipyrrolidine	I
carboxamides	I
and	O
intermediates	O
therefor	O
.	O

Substituted	O
n	B
-	I
phenyl	I
-	I
bipyrrolidine	I
carboxamides	I
and	O
therapeutic	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
a	O
bisphosphonic	B
acid	I
in	O
combination	O
with	O
a	O
non	O
-	O
activated	O
metabolite	O
of	O
vitamin	B
D	I
for	O
oral	O
administration	O
.	O

The	O
compositions	O
of	O
the	O
invention	O
either	O
do	O
not	O
contain	O
or	O
contain	O
only	O
low	O
concentrations	O
of	O
a	O
glidant	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
preparing	O
such	O
compositions	O
and	O
methods	O
of	O
use	O
thereof	O
,	O
for	O
preventing	O
or	O
treating	O
abnormal	O
bone	O
resorption	O
in	O
mammals	O
.	O

Composition	O
Containing	O
a	O
Bisphosphonic	B
Acid	I
in	O
Combination	O
with	O
Vitamin	B
D	I

This	O
invention	O
relates	O
to	O
a	O
heterogeneously	O
configured	O
multiparticulate	O
drug	O
delivery	O
system	O
for	O
gastrointestinal	O
delivery	O
of	O
at	O
least	O
one	O
or	O
a	O
combination	O
of	O
active	O
pharmaceutical	O
compositions	O
.	O

The	O
system	O
comprises	O
a	O
multiplicity	O
of	O
enterosoluble	O
or	O
gastrosoluble	O
multiparticulates	O
loaded	O
with	O
the	O
active	O
pharmaceutical	O
composition	O
or	O
compositions	O
for	O
the	O
site	O
-	O
specific	O
delivery	O
of	O
said	O
active	O
pharmaceutical	O
composition	O
or	O
compositions	O
to	O
a	O
specific	O
region	O
in	O
the	O
gastrointestinal	O
tract	O
of	O
a	O
human	O
or	O
animal	O
body	O
.	O

The	O
system	O
can	O
be	O
supplied	O
as	O
reconstitutable	O
granules	O
which	O
are	O
reconstituted	O
immediately	O
before	O
oral	O
administration	O
.	O

Heterogeneously	O
configured	O
multiparticulate	O
gastrointestinal	O
drug	O
delivery	O
system	O

An	O
article	O
of	O
manufacture	O
comprising	O
packaging	O
prasugrel	B
tablets	O
,	O
caplets	O
,	O
capsule	O
or	O
other	O
solid	O
form	O
of	O
prasugrel	O
in	O
an	O
air	O
and/or	O
moisture	O
impervious	O
container	O
under	O
a	O
positive	O
liquid	O
gas	O
pressure	O
.	O

Article	O
of	O
manufacture	O
for	O
prasugrel	B

This	O
application	O
provides	O
a	O
method	O
for	O
the	O
use	O
of	O
select	O
quaternary	B
ammonium	I
antagonists	O
to	O
alpha-7	O
nAChR	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
HIV	O
and	O
AIDS	O
.	O

USE	O
OF	O
A	O
NOVEL	O
ALPHA-7	O
nAChR	O
ANTAGONIST	O
TO	O
SUPPRESS	O
PATHOGENIC	O
SIGNAL	O
TRANSDUCTION	O
IN	O
CANCER	O
AND	O
AIDS	O

2-oxothiazolidine-4-carboxylic	B
acid	I
compounds	O
having	O
the	O
structural	O
formula	O
(	O
I	O
)	O
:	O
are	O
suited	O
for	O
promoting	O
desquamation	O
of	O
the	O
skin	O
and/or	O
stimulating	O
epidermal	O
renewal	O
and/or	O
combating	O
aging	O
of	O
the	O
skin	O
.	O

2-oxothiazolidine	B
4-carboxylic	I
acid	I
compounds	O
for	O
promoting	O
desquamation	O
of	O
the	O
skin	O

A	O
composition	O
containing	O
Zolmitriptan	B
in	O
the	O
form	O
of	O
oral	O
disintegrating	O
tablet	O
for	O
the	O
acute	O
treatment	O
of	O
migraines	O
is	O
disclosed	O
.	O

The	O
said	O
composition	O
comprises	O
(	O
a	O
)	O
Zolmitriptan	B
,	O
a	O
salt	O
or	O
solvate	O
or	O
polymorph	O
thereof	O
as	O
active	O
ingredient	O
,	O
(	O
b	O
)	O
mannitol	B
,	O
and	O
(	O
c	O
)	O
calcium	B
silicate	I
,	O
and	O
(	O
d	O
)	O
optionally	O
,	O
one	O
or	O
more	O
polysaccharides	O
along	O
with	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Orally	O
disintegrating	O
composition	O
of	O
zolmitriptan	B

The	O
present	O
invention	O
concerns	O
methods	O
and	O
compositions	O
for	O
treating	O
a	O
patient	O
having	O
,	O
suspected	O
of	O
having	O
,	O
or	O
at	O
risk	O
of	O
developing	O
cancer	O
by	O
targeting	O
cancer	O
stem	O
cells	O
.	O

Methods	O
and	O
Compositions	O
Involving	O
miRNAs	O
In	O
Cancer	O
Stem	O
Cells	O

The	O
present	O
invention	O
provides	O
an	O
isolated	O
RNA	O
molecule	O
comprising	O
:	O
a	O
)	O
an	O
alphavirus	O
5′	O
replication	O
recognition	O
sequence	O
,	O
wherein	O
at	O
least	O
one	O
initiation	O
codon	O
has	O
been	O
removed	O
from	O
the	O
5′	O
replication	O
recognition	O
sequence	O
;	O
b	O
)	O
a	O
nucleotide	O
sequence	O
encoding	O
an	O
alphavirus	O
structural	O
protein	O
;	O
and	O
c	O
)	O
an	O
alphavirus	O
3′	O
replication	O
recognition	O
sequence	O
,	O
with	O
the	O
proviso	O
that	O
the	O
RNA	O
molecule	O
does	O
not	O
contain	O
a	O
promoter	O
that	O
directs	O
transcription	O
of	O
the	O
nucleotide	O
sequence	O
of	O
(	O
b	O
)	O
,	O
and	O
wherein	O
the	O
alphavirus	O
5′	O
and	O
3′	O
replication	O
recognition	O
sequences	O
of	O
(	O
a	O
)	O
and	O
(	O
c	O
)	O
direct	O
replication	O
of	O
the	O
RNA	O
molecule	O
in	O
the	O
presence	O
of	O
alphavirus	O
non	O
-	O
structural	O
proteins	O
.	O

Promoterless	O
cassettes	O
for	O
expression	O
of	O
alpha	O
virus	O
structural	O
proteins	O

A	O
skin	O
dressing	O
comprises	O
a	O
hydrated	O
hydrogel	O
material	O
including	O
a	O
source	O
of	O
lactate	B
ions	I
and	O
a	O
supply	O
of	O
glucose	B
,	O
optionally	O
also	O
including	O
a	O
source	O
of	O
zinc	B
ions	I
and	O
a	O
source	O
of	O
iodide	B
ions	I
.	O

The	O
dressing	O
has	O
beneficial	O
effects	O
on	O
skin	O
.	O

Wound	O
Dressings	O
comprising	O
hydrated	O
hydrogels	O
and	O
enzymes	O

The	O
present	O
invention	O
includes	O
compositions	O
and	O
methods	O
for	O
making	O
and	O
using	O
a	O
rapid	O
dissolving	O
,	O
high	O
potency	O
,	O
substantially	O
amorphous	O
nanostructured	O
aggregate	O
for	O
pulmonary	O
delivery	O
of	O
tacrolimus	B
and	O
a	O
stabilizer	O
matrix	O
comprising	O
,	O
optionally	O
,	O
a	O
polymeric	O
or	O
non	O
-	O
polymeric	O
surfactant	O
,	O
a	O
polymeric	O
or	O
non	O
-	O
polymeric	O
saccharide	O
or	O
both	O
,	O
wherein	O
the	O
aggregate	O
comprises	O
a	O
surface	O
area	O
greater	O
than	O
5	O
m2	O
/	O
g	O
as	O
measured	O
by	O
BET	O
analysis	O
and	O
exhibiting	O
supersaturation	O
for	O
at	O
least	O
0.5	O
hours	O
when	O
11	O
-	O
15-times	O
the	O
aqueous	O
crystalline	O
solubility	O
of	O
tacrolimus	O
is	O
added	O
to	O
simulated	O
lung	O
fluid	O
.	O

Enhanced	O
delivery	O
of	O
immunosuppressive	O
drug	O
compositions	O
for	O
pulmonary	O
delivery	O

The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
cancers	O
associated	O
with	O
overexpression	O
of	O
a	O
BCL2	O
gene	O
and/or	O
gene	O
product	O
in	O
a	O
subject	O
,	O
and	O
methods	O
and	O
compositions	O
for	O
the	O
improvement	O
of	O
anti	O
-	O
cancer	O
therapy	O
,	O
such	O
as	O
chemotherapy	O
and	O
radiation	O
therapy	O
.	O

The	O
invention	O
also	O
encompasses	O
methods	O
for	O
determining	O
the	O
efficacy	O
of	O
a	O
cancer	O
therapy	O
in	O
a	O
subject	O
and	O
methods	O
for	O
inducing	O
apoptosis	O
of	O
a	O
cell	O
.	O

Compositions	O
and	O
Methods	O
for	O
the	O
Diagnosis	O
and	O
Therapy	O
of	O
BCL2-Associated	O
Cancers	O

The	O
present	O
invention	O
refers	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen	B
or	O
hydroxy	B
;	O
R2	O
is	O
butyl	B
or	O
butyryl	B
if	O
R1	O
is	O
hydroxy	B
,	O
but	O
R2	O
is	O
butyl	B
if	O
R1	O
is	O
hydrogen	B
;	O
or	O
R3	O
and	O
R2	O
taken	O
together	O
are	O
1-propylidene	B
or	O
1-butylidene	B
optionally	O
substituted	O
by	O
hydroxy	B
,	O
methyl	B
,	O
or	O
3-	B
(	I
α	I
,	I
β	I
-	I
dimethylacryloyloxy	I
)	I
;	O
the	O
dotted	O
line	O
is	O
an	O
optional	O
bond	O
;	O
X	O
is	O
an	O
optionally	O
substituted	O
aliphatic	O
C4-residue	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
X1	O
,	O
X2	O
,	O
X3	O
,	O
X4	O
,	O
and	O
X5	O
;	O
wherein	O
X	O
is	O
X2	O
,	O
X3	O
or	O
X5	O
if	O
the	O
dotted	O
line	O
in	O
formula	O
(	O
I	O
)	O
is	O
absent	O
;	O
and	O
X	O
is	O
X1	O
,	O
X4	O
or	O
X5	O
if	O
the	O
dotted	O
line	O
signifies	O
a	O
bond	O
in	O
formula	O
(	O
I	O
)	O
above	O
;	O
R3	O
and	O
R4	O
are	O
,	O
independently	O
from	O
each	O
other	O
,	O
hydrogen	B
or	O
hydroxy	B
;	O
and	O
R5	O
is	O
hydroxy	B
or	O
butyryl	B
,	O
for	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
connected	O
to	O
impaired	O
neurotransmission	O
,	O
as	O
well	O
as	O
to	O
dietary	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
,	O
and	O
their	O
uses	O
.	O

Organic	O
compounds	O
for	O
treatment	O
of	O
disorders	O
connected	O
to	O
impaired	O
neurotransmission	O

The	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
Duchenne	O
muscular	O
dystrophy	O
with	O
flavonoids	O
.	O

The	O
methods	O
may	O
include	O
(	O
a	O
)	O
providing	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
flavonoid	B
,	O
and	O
(	O
b	O
)	O
administering	O
the	O
composition	O
to	O
a	O
human	O
patient	O
,	O
wherein	O
the	O
flavonoid	B
comprises	O
an	O
isoflav-4-one	B
with	O
at	O
least	O
one	O
of	O
the	O
carbons	O
located	O
at	O
positions	O
8	O
,	O
7	O
,	O
6	O
,	O
5	O
,	O
2	O
,	O
2′	O
,	O
3′	O
,	O
4′	O
,	O
5′	O
,	O
or	O
6′	O
modified	O
by	O
an	O
alcohol	B
group	O
.	O

Alternatively	O
,	O
the	O
flavonoid	B
may	O
comprise	O
(	O
1	O
)	O
a	O
flavan-3-ol	B
with	O
at	O
least	O
one	O
of	O
the	O
carbons	B
located	O
at	O
positions	O
8	O
,	O
7	O
,	O
6	O
,	O
5	O
,	O
4	O
,	O
2′	O
,	O
3′	O
,	O
4′	O
,	O
5′	O
,	O
or	O
6′	O
modified	O
by	O
an	O
alcohol	B
group	O
,	O
or	O
(	O
2	O
)	O
a	O
Free	O
-	O
B	O
-	O
Ring	O
flavone	B
with	O
at	O
least	O
one	O
of	O
the	O
carbons	B
located	O
at	O
positions	O
8	O
,	O
7	O
,	O
6	O
,	O
5	O
or	O
3	O
modified	O
by	O
an	O
alcohol	B
group	O
and	O
with	O
at	O
least	O
one	O
of	O
the	O
carbons	B
located	O
at	O
positions	O
8	O
,	O
7	O
,	O
6	O
,	O
5	O
or	O
3	O
modified	O
by	O
a	O
glycoside	B
group	O
.	O

Methods	O
of	O
Treating	O
Muscular	O
Dystrophies	O

A	O
system	O
and	O
method	O
to	O
improve	O
sensory	O
functions	O
in	O
the	O
hand	O
or	O
foot	O
by	O
dermal	O
topical	O
application	O
of	O
a	O
local	O
anaesthetic	O
substance	O
to	O
adjacent	O
skin	O
areas	O
,	O
using	O
a	O
tailored	O
application	O
device	O
or	O
kit	O
specially	O
designed	O
to	O
fit	O
the	O
size	O
and	O
anatomical	O
shape	O
of	O
the	O
body	O
part	O
which	O
is	O
to	O
be	O
anaesthetised	O
.	O

The	O
concept	O
is	O
to	O
block	O
sensory	O
input	O
from	O
the	O
anaesthetised	O
skin	O
area	O
hereby	O
inducing	O
a	O
functional	O
reorganisation	O
in	O
sensory	O
brain	O
cortex	O
resulting	O
in	O
enhanced	O
sensory	O
functions	O
in	O
body	O
parts	O
adjacent	O
to	O
the	O
anaesthetised	O
area	O
with	O
focus	O
on	O
the	O
hand	O
and	O
sole	O
of	O
the	O
foot	O
.	O

System	O
and	O
method	O
to	O
improve	O
sensory	O
function	O

The	O
present	O
invention	O
relates	O
to	O
a	O
controlled	O
pharmaceutical	O
dosage	O
forms	O
for	O
oral	O
administration	O
,	O
and	O
in	O
particular	O
to	O
the	O
excipients	O
used	O
to	O
prepare	O
such	O
medicaments	O
.	O

For	O
example	O
,	O
a	O
dosage	O
form	O
for	O
oral	O
administration	O
is	O
provided	O
consisting	O
of	O
a	O
minimum	O
of	O
15	O
%	O
w	O
/	O
w	O
of	O
magnesium	B
aluminometasilicate	I
,	O
one	O
or	O
more	O
pharmaceutically	O
active	O
agents	O
and	O
optionally	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
diluents	O
.	O

Controlled	O
release	O
tablet	O
formulation	O
containing	O
magnesium	B
aluminometasilicate	I

Methods	O
of	O
providing	O
neuroprotection	O
are	O
disclosed	O
comprising	O
administering	O
a	O
non	O
-	O
sedative	O
barbiturate	B
compound	O
in	O
an	O
amount	O
sufficient	O
to	O
achieve	O
neuroprotection	O
in	O
a	O
mammalian	O
subject	O
.	O

Preferred	O
compounds	O
are	O
in	O
the	O
family	O
of	O
diphenylbarbituric	B
acid	I
and	O
analogs	O
.	O

Preferred	O
doses	O
for	O
a	O
neuroprotective	O
effect	O
exceed	O
the	O
dosage	O
of	O
a	O
corresponding	O
sedative	O
barbiturate	B
without	O
sedative	O
side	O
-	O
effects	O
such	O
as	O
anesthesia	O
and	O
death	O
.	O

Non	O
-	O
sedating	O
barbiturate	B
compounds	O
as	O
neuroprotective	O
agents	O

The	O
present	O
invention	O
is	O
related	O
to	O
the	O
use	O
of	O
Cladribine	B
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
formulation	O
for	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
,	O
especially	O
relapsing	O
-	O
remitting	O
multiple	O
sclerosis	O
or	O
early	O
secondary	O
progressive	O
multiple	O
sclerosis	O
,	O
wherein	O
the	O
preparation	O
is	O
to	O
be	O
the	O
orally	O
administered	O
and	O
wherein	O
re	O
-	O
treatments	O
are	O
possible	O
.	O

Cladribine	B
Regimen	O
for	O
Treating	O
Multiple	O
Sclerosis	O

The	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
genetic	O
products	O
expressed	O
in	O
association	O
with	O
tumours	O
and	O
to	O
coding	O
nucleic	O
acids	O
for	O
said	O
products	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
therapy	O
and	O
diagnosis	O
of	O
diseases	O
in	O
which	O
the	O
genetic	O
products	O
are	O
aberrantly	O
expressed	O
in	O
association	O
with	O
tumours	O
,	O
proteins	O
,	O
polypeptides	O
and	O
peptides	O
which	O
are	O
expressed	O
in	O
association	O
with	O
tumours	O
and	O
to	O
the	O
coding	O
nucleic	O
acids	O
for	O
said	O
proteins	O
,	O
polypeptides	O
and	O
peptides	O
.	O

Genetic	O
Products	O
Which	O
are	O
Differentially	O
Expressed	O
in	O
Tumors	O
and	O
Use	O
Thereof	O

An	O
injectable	O
polymer	O
-	O
lipid	O
blend	O
is	O
provided	O
as	O
a	O
localized	O
drug	O
delivery	O
system	O
for	O
a	O
pharmaceutically	O
active	O
agent	O
.	O

The	O
blend	O
may	O
be	O
prepared	O
from	O
a	O
chitosan	O
-	O
based	O
material	O
,	O
fatty	B
acid	I
and	O
phospholipid	O
.	O

The	O
chitosan	O
-	O
based	O
material	O
may	O
be	O
a	O
water	O
soluble	O
chitosan	O
derivative	O
.	O

The	O
fatty	B
acid	I
may	O
be	O
a	O
fatty	B
acid	I
or	O
a	O
fatty	B
aldehyde	I
,	O
such	O
as	O
laurinaldehyde	O
,	O
having	O
an	O
acyl	B
chain	O
length	O
of	O
C8-C16	O
.	O

The	O
rheological	O
properties	O
of	O
the	O
blend	O
relates	O
to	O
the	O
ratio	O
of	O
the	O
components	O
and	O
to	O
the	O
acyl	B
chain	O
length	O
of	O
the	O
fatty	B
acid	I
.	O

The	O
injectable	O
system	O
is	O
well	O
suited	O
for	O
the	O
delayed	O
release	O
of	O
pharmaceutically	O
active	O
agents	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
diseases	O
requiring	O
localized	O
drug	O
delivery	O
Injectable	O
polymer	O
-	O
lipid	O
blend	O
for	O
localized	O
drug	O
delivery	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
non	O
-	O
steroidal	O
17beta	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
inhibitors	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
hormone	O
-	O
dependent	O
,	O
particularly	O
estrogen	B
-	O
dependent	O
,	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
suitable	O
inhibitors	O
and	O
to	O
a	O
method	O
for	O
the	O
production	O
thereof	O
.	O

17Beta	B
-	I
Hydroxysteroid	I
Dehydrogenase	O
Type	O
1	O
Inhibitors	O
for	O
the	O
Treatment	O
of	O
Hormone	O
-	O
Related	O
Diseases	O

This	O
invention	O
relates	O
to	O
novel	O
N	B
-	I
piperidin-4-ylmethyl	I
amide	I
derivatives	O
useful	O
as	O
monoamine	B
neurotransmitter	O
re	O
-	O
uptake	O
inhibitors	O
.	O

In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

N	B
-	I
piperidin-4-ylmethyl	I
-	I
amide	I
derivatives	O
and	O
their	O
use	O
as	O
monoamine	B
neurotransmitter	O
re	O
-	O
uptake	O
inhibitors	O

It	O
is	O
intended	O
to	O
provide	O
a	O
simple	O
normal	O
-	O
tension	O
glaucoma	O
model	O
capable	O
of	O
spontaneously	O
,	O
age	O
-	O
dependently	O
and	O
surly	O
developing	O
conditions	O
similar	O
to	O
symptoms	O
of	O
normal	O
-	O
tension	O
glaucoma	O
which	O
occurs	O
more	O
frequently	O
in	O
elder	O
people	O
,	O
and	O
a	O
method	O
of	O
evaluating	O
therapeutic	O
effect	O
on	O
normal	O
-	O
tension	O
glaucoma	O
whereby	O
a	O
drug	O
useful	O
in	O
treating	O
and	O
diagnosing	O
can	O
be	O
conveniently	O
screened	O
by	O
using	O
the	O
normal	O
-	O
tension	O
glaucoma	O
model	O
.	O

A	O
normal	O
-	O
tension	O
glaucoma	O
model	O
comprising	O
a	O
nonhuman	O
mammal	O
,	O
which	O
is	O
deficient	O
in	O
a	O
transcriptional	O
regulator	O
NF	O
-	O
κBp50	O
and	O
thus	O
spontaneously	O
develops	O
the	O
normal	O
-	O
tension	O
glaucoma	O
symptom	O
age	O
-	O
relatedly	O
,	O
an	O
organ	O
or	O
a	O
tissue	O
thereof	O
or	O
cells	O
collected	O
from	O
any	O
of	O
the	O
same	O
.	O

A	O
method	O
of	O
evaluating	O
therapeutic	O
effect	O
on	O
normal	O
-	O
tension	O
glaucoma	O
of	O
a	O
test	O
substance	O
which	O
comprises	O
administering	O
or	O
adding	O
the	O
test	O
substance	O
to	O
the	O
above	O
-	O
described	O
nonhuman	O
mammal	O
,	O
an	O
organ	O
or	O
a	O
tissue	O
thereof	O
or	O
cells	O
collected	O
from	O
any	O
of	O
the	O
same	O
,	O
and	O
measuring	O
a	O
morphological	O
defect	O
,	O
cell	O
count	O
,	O
pressure	O
,	O
the	O
expression	O
amount	O
or	O
activity	O
strength	O
of	O
a	O
protein	O
,	O
the	O
expression	O
amount	O
of	O
a	O
nucleic	O
acid	O
and/or	O
the	O
activity	O
strength	O
of	O
an	O
antibody	O
in	O
the	O
organ	O
,	O
tissue	O
and/or	O
cells	O
as	O
indication	O
(	O
s	O
)	O
for	O
the	O
evaluation	O
.	O

Normal	O
-	O
tension	O
glaucoma	O
model	O
and	O
method	O
for	O
evaluation	O
of	O
test	O
substances	O
by	O
using	O
same	O

Disclosed	O
is	O
a	O
novel	O
sirtuin	O
modulating	O
composition	O
comprising	O
an	O
orally	O
bioavailable	O
SIRT-1	O
enhancing	O
compound	O
3,5-dimethoxy-3,4′-dihydroxystilbene	B
represented	O
by	O
STR#I.	O
Also	O
disclosed	O
is	O
an	O
anti	O
-	O
acne	O
composition	O
comprising	O
3,5-dimethoxy-	B
3,4′-dihydroxystilbenes	I
represented	O
by	O
STR#I.	O
Further	O
,	O
a	O
novel	O
sirtuin	O
modulating	O
composition	O
comprising	O
an	O
orally	O
bioavailable	O
SIRT-1	O
enhancing	O
compound	O
2,3′,5′	B
,	I
6-tetrahydroxy	I
-	I
trans	I
-	I
stilbene	I
represented	O
by	O
STR#II	O
is	O
also	O
disclosed	O
.	O

Orally	O
Bioavailable	O
Stilbenoids-	B
Compositions	O
and	O
Therapeutic	O
Applications	O
Thereof	O

The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
determining	O
a	O
subject	O
's	O
adipose	O
tissue	O
activity	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
composition	O
comprises	O
a	O
solid	O
support	O
comprising	O
probes	O
for	O
measuring	O
a	O
biomarker	O
panel	O
comprising	O
,	O
for	O
example	O
,	O
adiponectin	O
,	O
resistin	O
,	O
PAI-1	O
,	O
optionally	O
leptin	O
and	O
optionally	O
visfatin	O
.	O

The	O
simultaneous	O
use	O
of	O
multiple	O
biomarkers	O
with	O
independent	O
classification	O
power	O
will	O
increase	O
the	O
performance	O
of	O
the	O
biomarker	O
panel	O
in	O
identifying	O
adipose	O
tissue	O
activity	O
,	O
which	O
is	O
associated	O
with	O
various	O
disease	O
states	O
including	O
chronic	O
or	O
systemic	O
inflammation	O
,	O
atherosclerosis	O
and	O
other	O
cardiovascular	O
risks	O
and	O
complications	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
a	O
subject	O
and	O
determining	O
the	O
efficacy	O
of	O
a	O
therapy	O
through	O
assaying	O
the	O
various	O
biomarkers	O
of	O
a	O
biomarker	O
panel	O
disclosed	O
herein	O
.	O

Biomarkers	O
for	O
Adipose	O
Tissue	O
Activity	O

The	O
present	O
invention	O
provides	O
an	O
amphiphilic	O
molecule	O
having	O
a	O
plurality	O
of	O
zwitterionic	O
functional	O
groups	O
in	O
its	O
hydrophilic	O
moiety	O
and	O
a	O
molecular	O
assembly	O
comprising	O
the	O
amphiphilic	O
molecule	O
as	O
a	O
constituent	O
lipid	O
.	O

According	O
to	O
a	O
preferred	O
embodiment	O
of	O
the	O
present	O
invention	O
,	O
the	O
molecular	O
assembly	O
of	O
the	O
present	O
invention	O
forms	O
a	O
stable	O
vesicular	O
structure	O
under	O
a	O
physiological	O
pH	O
environment	O
to	O
carry	O
a	O
substance	O
of	O
interest	O
in	O
the	O
vesicular	O
structure	O
,	O
and	O
can	O
release	O
the	O
substance	O
of	O
interest	O
to	O
the	O
outside	O
of	O
the	O
vesicular	O
structure	O
when	O
it	O
is	O
deformed	O
under	O
an	O
acidic	O
pH	O
environment	O
.	O

The	O
molecular	O
assembly	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
as	O
a	O
carrier	O
for	O
a	O
drug	O
,	O
a	O
probe	O
,	O
a	O
nucleic	B
acid	I
,	O
a	O
protein	O
or	O
the	O
like	O
.	O

Amphiphilic	O
molecule	O
,	O
molecular	O
assembly	O
comprising	O
the	O
amphiphilic	O
molecule	O
,	O
and	O
use	O
of	O
the	O
molecular	O
assembly	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
,	O
in	O
particular	O
,	O
to	O
composition	O
and	O
methods	O
comprising	O
nanostructures	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
present	O
invention	O
provides	O
a	O
composition	O
comprising	O
a	O
mixture	O
,	O
the	O
mixture	O
comprising	O
at	O
least	O
one	O
nanoparticle	O
and	O
at	O
least	O
one	O
chemotherapeutic	O
.	O

Compositions	O
And	O
Methods	O
For	O
Treating	O
Cancer	O

A	O
process	O
for	O
producing	O
a	O
granule	O
-	O
containing	O
tablet	O
comprising	O
mixing	O
more	O
than	O
25	O
mass	O
%	O
to	O
89	O
mass	O
%	O
or	O
less	O
of	O
crystalline	O
cellulose	O
exhibiting	O
a	O
tensile	O
displacement	O
at	O
break	O
of	O
25	O
to	O
80	O
μm	O
and	O
a	O
relative	O
fluidity	O
index	O
of	O
2.15	O
to	O
2.80	O
at	O
a	O
maximum	O
compaction	O
stress	O
of	O
15	O
kPa	O
,	O
10	O
to	O
70	O
mass	O
%	O
of	O
spherical	O
granules	O
,	O
and	O
20	O
mass	O
%	O
or	O
less	O
of	O
a	O
disintegrant	O
,	O
and	O
then	O
compressing	O
the	O
obtained	O
mixture	O
.	O

Process	O
for	O
production	O
of	O
crystalline	O
cellulose	O
and	O
tablets	O
containing	O
granules	O

A	O
mutual	O
prodrug	O
of	O
a	O
corticosteroid	B
and	O
a	O
substituted	O
phenylphosphate	B
(	O
β	O
-	O
agonist	O
derivative	O
)	O
for	O
formulation	O
for	O
delivery	O
by	O
aerosolization	O
to	O
inhibit	O
pulmonary	O
inflammation	O
and	O
bronchoconstriction	O
is	O
described	O
.	O

The	O
mutual	O
prodrug	O
is	O
preferably	O
formulated	O
in	O
a	O
small	O
volume	O
solution	O
(	O
10	O
-	O
500	O
μL	O
)	O
dissolved	O
in	O
a	O
quarter	O
normal	O
saline	O
having	O
pH	O
between	O
5.0	O
and	O
7.0	O
for	O
the	O
treatment	O
of	O
respiratory	O
tract	O
inflammation	O
and	O
bronchoconstriction	O
by	O
an	O
aerosol	O
having	O
mass	O
median	O
average	O
diameter	O
predominantly	O
between	O
1	O
to	O
5μ	O
,	O
produced	O
by	O
nebulization	O
or	O
by	O
dry	O
powder	O
inhaler	O
.	O

Substituted	O
Phenylphosphates	B
as	O
Mutual	O
Prodrugs	O
of	O
Steroids	O
and	O
ß	O
-	O
Agonists	O
for	O
the	O
Treatment	O
of	O
Title	O
Pulmonary	O
Inflammation	O
and	O
Bronchoconstriction	O

Compositions	O
comprising	O
5-amino-2-hydroxybenzoic	B
acid	I
(	O
5-amino	B
salicylic	I
acid	I
,	O
mesalamine	B
)	O
and	O
a	O
reducing	O
sugar	B
,	O
e.g.	O
,	O
lactose	B
,	O
undergo	O
the	O
Maillard	O
and	O
other	O
chemical	O
reactions	O
and	O
produce	O
,	O
in	O
the	O
case	O
of	O
lactose	B
,	O
a	O
degradant	O
5-	B
[	I
2-formyl-5-	I
(	I
hydroxymethyl	I
)	I
-1H	I
-	I
pyrrol-1-yl	I
]	I
-2-hydroxybenzoic	I
acid	I
.	O

Inventors	O
have	O
developed	O
means	O
to	O
contain	O
and/or	O
reduce	O
the	O
formation	O
of	O
degradants	O
of	O
5-amino-2-hydroxybenzoic	B
acid	I
.	O

Compositions	O
Comprising	O
5-Amino-2-Hydroxybenzoic	B
Acid	I
and	O
a	O
Reducing	O
Sugar	B

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
using	O
GPR119	O
receptor	O
to	O
identify	O
peptide	O
YY	O
(	O
PYY	O
)	O
secretagogues	O
and	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
modulated	O
by	O
PYY	O
,	O
such	O
as	O
conditions	O
modulated	O
by	O
stimulation	O
of	O
NPY	O
Y2	O
receptor	O
(	O
Y2R	O
)	O
.	O

Agonists	O
of	O
GPR119	O
receptor	O
are	O
useful	O
as	O
therapeutic	O
agents	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
modulated	O
by	O
PYY	O
,	O
such	O
as	O
a	O
condition	O
modulated	O
by	O
stimulation	O
of	O
Y2R	O
.	O

Conditions	O
modulated	O
by	O
PYY	O
such	O
as	O
may	O
be	O
a	O
condition	O
modulated	O
by	O
stimulation	O
of	O
Y2R	O
include	O
bone	O
-	O
related	O
conditions	O
,	O
metabolic	O
disorders	O
,	O
angiogenesis	O
-	O
related	O
conditions	O
,	O
ischemia	O
-	O
related	O
conditions	O
,	O
convulsive	O
disorders	O
,	O
malabsorptive	O
disorders	O
,	O
cancers	O
,	O
and	O
inflammatory	O
disorders	O
.	O

Methods	O
of	O
using	O
a	O
g	O
protein	O
-	O
coupled	O
receptor	O
to	O
identify	O
peptide	O
yy	O
(	O
pyy	O
)	O
secretagogues	O
and	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
modulated	O
by	O
pyy	O

The	O
compound	O
of	O
formula	O
(	O
I	O
)	O
is	O
a	O
water	O
-	O
stable	O
,	O
long	O
acting	O
β2-selective	O
adrenoceptor	O
agonist	O
useful	O
as	O
a	O
bronchodilator	O
in	O
the	O
treatment	O
of	O
bronchoconstriction	O
associated	O
with	O
reversible	O
obstructive	O
airways	O
diseases	O
and	O
the	O
like	O
.	O

Carbamate	O
Stereoisomer	O

This	O
inventions	O
relates	O
to	O
compounds	O
having	O

the	O
structure	O
Formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
which	O
are	O
soluble	O
guanylate	B
cyclase	O
activators	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
treatment	O
or	O
prevention	O
of	O
cardiovascular	O
diseases	O
,	O
endothelial	O
dysfunction	O
,	O
diastolic	O
dysfunction	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
pulmonary	O
hypertension	O
,	O
angina	O
pectoris	O
,	O
thromboses	O
,	O
restenosis	O
,	O
myocardial	O
infarction	O
,	O
strokes	O
,	O
cardiac	O
insufficiency	O
,	O
pulmonary	O
hypertonia	O
,	O
erectile	O
dysfunction	O
,	O
asthma	O
bronchiale	O
,	O
chronic	O
kidney	O
insufficiency	O
,	O
diabetes	O
,	O
or	O
cirrhosis	O
of	O
the	O
liver	O
.	O

Soluble	O
Guanylate	O
Cyclase	O
Activators	O

This	O
invention	O
concerns	O
adamantanamines	O
(	O
e.g.	O
memantine	O
,	O
amantadine	B
,	O
and	O
rimantadine	B
)	O
and	O
neramexane	B
salts	O
of	O
thiomolybdic	B
and	I
thiotungstic	I
acids	I
,	O
including	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
,	O
as	O
dual	O
acting	O
drugs	O
.	O

These	O
salts	O
are	O
used	O
to	O
treat	O
or	O
potentially	O
arrest	O
the	O
neurodegenerative	O
pathophysiology	O
,	O
clinical	O
signs	O
and	O
symptoms	O
of	O
dementia	O
of	O
the	O
Alzheimer	O
's	O
type	O
,	O
Parkinson	O
's	O
,	O
Huntington	O
's	O
,	O
AIDS	O
-	O
related	O
dementia	O
and	O
Schizophrenia	O
and	O
its	O
cognitive	O
deficits	O
.	O

Additional	O
uses	O
of	O
these	O
derivatives	O
include	O
antiviral	O
activity	O
.	O

The	O
novel	O
compositions	O
of	O
the	O
present	O
invention	O
appear	O
particularly	O
useful	O
in	O
enhancing	O
the	O
therapeutic	O
benefits	O
of	O
copper	B
-	O
sequestering	O
tetrathiomolybdates	O
in	O
treating	O
elevated	O
copper	B
-	O
induced	O
toxicities	O
in	O
neurologically	O
presenting	O
Wilson	O
's	O
disease	O
,	O
and	O
in	O
treating	O
diseases	O
of	O
the	O
inflammatory	O
etiology	O
and	O
abnormal	O
copper	O
biochemistry	O
,	O
such	O
as	O
tumor	O
angiogenesis	O
,	O
liver	O
cirrhosis	O
,	O
hepatitis	O
,	O
pulmonary	O
fibrosis	O
and	O
other	O
fibrotic	O
diseases	O
,	O
cardiovascular	O
disease	O
,	O
cerebral	O
ischemia	O
,	O
renal	O
anemia	O
,	O
rheumatoid	O
arthritis	O
,	O
diabetes	O
,	O
obesity	O
,	O
gastrointestinal	O
disorders	O
,	O
and	O
eye	O
diseases	O
such	O
as	O
glaucoma	O
,	O
proliferative	O
diabetic	O
retinopathy	O
,	O
and	O
age	O
related	O
macular	O
degeneration	O
.	O

These	O
compounds	O
have	O
excellent	O
stability	O
and	O
aqueous	O
solubility	O
for	O
good	O
oral	O
bioavailability	O
.	O

Adamantanamines	B
and	O
Neramexane	B
Salts	O
of	O
Thiomolybdic	B
and	I
Thiotungstic	I
Acids	I

The	O
invention	O
relates	O
to	O
novel	O
crystalline	O
forms	O
of	O
fexofenadine	B
base	O
,	O
a	O
process	O
for	O
the	O
preparation	O
thereof	O
and	O
the	O
use	O
thereof	O
in	O
therapy	O
.	O

Fexofenadine	B
base	O
polymorphic	O
forms	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
identifying	O
compounds	O
that	O
modulate	O
the	O
activity	O
of	O
p300	O
/	O
CBP	O
.	O

Compounds	O
of	O
the	O
invention	O
are	O
identified	O
by	O
designing	O
or	O
screening	O
for	O
a	O
compound	O
which	O
binds	O
to	O
at	O
least	O
one	O
amino	B
acid	I
residue	O
of	O
the	O
newly	O
identified	O
lysine	B
-	O
CoA	O
inhibitor	O
binding	O
site	O
,	O
L1	O
loop	O
,	O
electronegative	O
pocket	O
,	O
or	O
electronegative	O
groove	O
of	O
the	O
HAT	O
domain	O
of	O
p300	O
/	O
CBP	O
and	O
testing	O
the	O
compound	O
for	O
its	O
ability	O
to	O
modulate	O
the	O
activity	O
of	O
p300	O
/	O
CBP	O
.	O

Compositions	O
and	O
methods	O
for	O
preventing	O
or	O
treating	O
diseases	O
or	O
disorders	O
associated	O
with	O
p300	O
/	O
CBP	O
are	O
also	O
provided	O
as	O
is	O
a	O
method	O
for	O
producing	O
a	O
semi	O
-	O
synthetic	O
HAT	O
domain	O
.	O

Methods	O
and	O
Compositions	O
for	O
Modulating	O
P300	O
/	O
CBP	O
Activity	O

The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
bcl-2	O
antisense	O
oligomers	O
to	O
treat	O
and	O
prevent	O
bcl-2	O
related	O
disorders	O
.	O

These	O
disorders	O
include	O
cancers	O
,	O
tumors	O
,	O
carcinomas	O
and	O
cell	O
-	O
proliferative	O
related	O
disorders	O
.	O

In	O
one	O
embodiment	O
of	O
the	O
invention	O
,	O
a	O
bcl-2	O
antisense	O
oligomer	O
is	O
administered	O
at	O
high	O
doses	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
a	O
bcl-2	O
related	O
disorder	O
,	O
in	O
particular	O
cancer	O
,	O
comprising	O
administering	O
a	O
bcl-2	O
antisense	O
oligomer	O
for	O
short	O
periods	O
of	O
time	O
.	O

The	O
present	O
invention	O
is	O
further	O
drawn	O
to	O
the	O
use	O
of	O
bcl-2	O
antisense	O
oligomers	O
to	O
increase	O
the	O
sensitivity	O
of	O
a	O
subject	O
to	O
cancer	O
therapeutics	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
bcl-2	O
antisense	O
oligomers	O
,	O
which	O
may	O
comprise	O
one	O
or	O
more	O
cancer	O
therapeutic	O
agents	O
.	O

Methods	O
of	O
treatment	O
of	O
a	O
bcl-2	O
disorder	O
using	O
bcl-2	O
antisense	O
oligomers	O

The	O
present	O
specification	O
provides	O
,	O
amongst	O
other	O
things	O
,	O
a	O
method	O
of	O
treating	O
scoliosis	O
comprising	O
delivering	O
a	O
therapeutically	O
acceptable	O
amount	O
of	O
a	O
growth	O
modulator	O
to	O
an	O
epiphyseal	O
growth	O
plate	O
to	O
correct	O
or	O
compensate	O
for	O
disproportionate	O
growth	O
.	O

Modulating	O
bone	O
growth	O
in	O
treating	O
scoliosis	O

An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
osteogenic	O
biomaterial	O
which	O
achieves	O
long	O
-	O
term	O
sustained	O
release	O
and	O
localized	O
functional	O
expression	O
of	O
a	O
substance	O
which	O
promotes	O
the	O
formation	O
of	O
bone	O
tissue	O
.	O

The	O
present	O
inventors	O
have	O
found	O
out	O
that	O
a	O
nanogel	O
efficiently	O
encloses	O
an	O
osteogenesis	O
promoting	O
substance	O
to	O
suppress	O
the	O
substance	O
from	O
diffusion	O
into	O
blood	O
,	O
and	O
that	O
the	O
nanogel	O
functions	O
as	O
a	O
carrier	O
for	O
local	O
administration	O
of	O
the	O
osteogenesis	O
promoting	O
substance	O
.	O

Furthermore	O
,	O
they	O
have	O
found	O
out	O
that	O
the	O
osteogenesis	O
promoting	O
substance	O
-	O
containing	O
nanogel	O
can	O
be	O
cross	O
-	O
linked	O
with	O
a	O
water	O
-	O
soluble	O
polymer	O
to	O
allow	O
sustained	O
release	O
of	O
the	O
osteogenesis	O
promoting	O
substance	O
at	O
a	O
local	O
area	O
over	O
a	O
long	O
period	O
of	O
time	O
.	O

Based	O
on	O
these	O
findings	O
,	O
the	O
present	O
invention	O
was	O
completed	O
.	O

The	O
osteogenic	O
biomaterial	O
of	O
the	O
present	O
invention	O
which	O
contains	O
the	O
osteogenesis	O
promoting	O
substance	O
and	O
the	O
nanogel	O
shows	O
osteogenesis	O
promoting	O
activity	O
over	O
a	O
long	O
period	O
of	O
time	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
preventive	O
and	O
therapeutic	O
agent	O
against	O
bone	O
diseases	O
.	O

Osteogenic	O
biomaterial	O
containing	O
osteogenesis	O
promoting	O
substance	O
and	O
nanogel	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treatment	O
(	O
particularly	O
the	O
prevention	O
or	O
suppression	O
)	O
of	O
formation	O
or	O
reformation	O
of	O
adhesions	O
,	O
particularly	O
in	O
the	O
peritoneal	O
or	O
pelvic	O
cavities	O
resulting	O
from	O
wound	O
,	O
surgery	O
,	O
infection	O
,	O
inflammation	O
or	O
trauma	O
.	O

The	O
invention	O
provides	O
methods	O
useful	O
for	O
inhibiting	O
,	O
suppressing	O
or	O
ameliorating	O
adhesion	O
formation	O
in	O
mammals	O
,	O
including	O
humans	O
wherein	O
an	O
individual	O
is	O
administered	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
sunitinib	B
malate	I
,	O
axitinib	B
,	O
semaxanib	B
,	O
sorafenib	B
,	O
ZD1839	O
,	O
and	O
erlotinib	B
.	O

The	O
invention	O
applies	O
to	O
human	O
and	O
veterinary	O
applications	O
.	O

The	O
inventive	O
method	O
has	O
been	O
shown	O
to	O
be	O
especially	O
effective	O
in	O
preventing	O
adhesion	O
formation	O
in	O
the	O
peritoneum	O
following	O
surgery	O
.	O

Prevention	O
of	O
surgical	O
adhesions	O

The	O
present	O
invention	O
concerns	O
products	O
containing	O
(	O
i	O
)	O
at	O
least	O
one	O
nucleic	O
acid	O
sequence	O
coding	O
for	O
the	O
human	O
somatostatin	O
2	O
receptor	O
protein	O
(	O
sst2	O
)	O
having	O
the	O
sequence	O
SEQ	O
ID	O
NO	O
:	O
1	O
,	O
ortholog	O
or	O
derivative	O
thereof	O
,	O
(	O
ii	O
)	O
at	O
least	O
one	O
nucleic	O
acid	O
sequence	O
coding	O
for	O
the	O
human	O
deoxycytidine	B
kinase	O
protein	O
(	O
dck	O
)	O
having	O
the	O
sequence	O
SEQ	O
ID	O
NO:2	O
,	O
ortholog	O
or	O
derivative	O
thereof	O
,	O
(	O
iii	O
)	O
at	O
least	O
one	O
nucleic	O
acid	O
sequence	O
coding	O
for	O
the	O
human	O
uridine	B
monophosphate	I
kinase	O
protein	O
(	O
umk	O
)	O
having	O
the	O
sequence	O
SEQ	O
ID	O
NO	O
:	O
3	O
ortholog	O
or	O
derivative	O
thereof	O
,	O
and	O
(	O
iv	O
)	O
gemcitabine	O
,	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous	O
,	O
separate	O
,	O
or	O
sequential	O
use	O
for	O
treating	O
cancer	O
in	O
a	O
subject	O
.	O

Combination	O
Products	O
For	O
Treating	O
Cancer	O

It	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
method	O
of	O
screening	O
a	O
drug	O
with	O
the	O
use	O
of	O
a	O
67	O
kDa	O
laminin	O
receptor	O
and	O
a	O
drug	O
obtained	O
thereby	O
.	O

A	O
method	O
of	O
screening	O
a	O
drug	O
having	O
an	O
effect	O
on	O
inhibiting	O
cell	O
proliferation	O
,	O
an	O
angiogenesis	O
inhibitory	O
effect	O
,	O
an	O
effect	O
of	O
inhibiting	O
cancer	O
cell	O
metastasis	O
,	O
a	O
neuroprotective	O
effect	O
,	O
and	O
anti	O
-	O
allergic	O
effect	O
,	O
and	O
anti	O
-	O
arteriosclerotic	O
effect	O
and/or	O
an	O
effect	O
of	O
inhibiting	O
infection	O
with	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
which	O
involves	O
the	O
step	O
,	O
of	O
qualitatively	O
or	O
quantitatively	O
measuring	O
the	O
degree	O
of	O
the	O
binding	O
of	O
a	O
test	O
compound	O
to	O
a	O
67	O
kDa	O
laminin	O
receptor	O
,	O
and	O
judging	O
that	O
the	O
test	O
compound	O
is	O
a	O
drug	O
having	O
an	O
effect	O
of	O
inhibiting	O
cell	O
proliferation	O
,	O
and	O
angiogenesis	O
inhibitory	O
effect	O
,	O
an	O
effect	O
of	O
inhibiting	O
cancer	O
cell	O
metastasis	O
,	O
a	O
neuroprotective	O
effect	O
,	O
and	O
anti	O
-	O
allergic	O
-	O
effect	O
,	O
and	O
anti	O
-	O
arteriosclerotic	O
effect	O
and/or	O
an	O
effect	O
of	O
inhibiting	O
infection	O
with	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
in	O
the	O
case	O
where	O
it	O
is	O
found	O
out	O
by	O
the	O
results	O
of	O
the	O
measurement	O
that	O
the	O
test	O
compound	O
binds	O
to	O
the	O
67	O
kDa	O
laminin	O
receptor	O
,	O
and	O
a	O
drug	O
obtained	O
thereby	O
.	O

Method	O
of	O
Screening	O
Drug	O
with	O
the	O
Use	O
of	O
67	O
kDa	O
Laminin	O
Receptor	O
and	O
Drug	O

Obtained	O
Thereby	O

Methods	O
to	O
prepare	O
synthetic	O
carbon	B
nanotubes	O
having	O
controllable	O
properties	O
and	O
synthetic	O
carbon	B
nanotubes	O
having	O
controllable	O
properties	O
are	O
provided	O
.	O

The	O
properties	O
which	O
are	O
controllable	O
using	O
the	O
methods	O
provided	O
here	O
include	O
independently	O
and	O
in	O
combination	O
:	O
diameter	O
,	O
length	O
,	O
identity	O
and	O
number	O
of	O
functional	O
groups	O
present	O
and	O
identity	O
and	O
number	O
of	O
heteroatoms	O
present	O
.	O

Synthetic	O
Carbon	B
Nanotubes	O

It	O
is	O
an	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
a	O
gel	O
-	O
forming	O
composition	O
which	O
permits	O
on	O
-	O
site	O
administration	O
and	O
can	O
form	O
a	O
gel	O
exhibiting	O
prescribed	O
strength	O
and	O
sustained	O
drug	O
release	O
,	O
devices	O
for	O
the	O
administration	O
thereof	O
,	O
and	O
a	O
kit	O
for	O
medical	O
use	O
.	O

A	O
gel	O
-	O
forming	O
composition	O
which	O
is	O
composed	O
of	O
the	O
first	O
composition	O
comprising	O
a	O
drug	O
,	O
a	O
first	O
gelling	O
agent	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
the	O
like	O
,	O
and	O
the	O
first	O
diluent	O
and	O
the	O
second	O
composition	O
comprising	O
the	O
second	O
gelling	O
agent	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
the	O
like	O
and	O
the	O
second	O
diluent	O
;	O
and	O
application	O
devices	O
and	O
kits	O
for	O
medical	O
use	O
,	O
which	O
can	O
hold	O
the	O
gel	O
-	O
forming	O
composition	O
.	O

X1—	O
(	O
OCH2CH2	O
)	O
n	O
—	O
X2	O
(	O
I	O
)	O
wherein	O
X1	O
and	O
X2	O
are	O
each	O
—R1COONHS	O
(	O
wherein	O
R1	O
is	O
C1	O
-	O
7	O
alkylene	O
)	O
,	O
—COR1COONHS	O
,	O
—NOCOR1—R2	O
(	O
wherein	O
R2	O
is	O
maleimido	O
)	O
,	O
—R1NH2	O
,	O
—R1SH	O
,	O
or	O
—CO2PhNO2	O
,	O
and	O
n	O
is	O
an	O
integer	O
of	O
80	O
to	O
1000	O
.	O

Gel	O
-	O
forming	O
composition	O
for	O
medical	O
use	O
,	O
administration	O
device	O
for	O
the	O
composition	O
,	O
and	O
drug	O
release	O
controlling	O
carrier	O

The	O
present	O
invention	O
relates	O
to	O
development	O
of	O
efficacious	O
pharmaceutical	O
implant	O
compositions	O
comprising	O
an	O
active	O
agent	O
in	O
a	O
therapeutically	O
effective	O
amount	O
and	O
a	O
polyethylene	B
glycol	I
having	O
a	O
molecular	O
weight	O
of	O
at	O
least	O
2000	O
.	O

Pharmaceutical	O
Composition	O
for	O
Delivery	O
of	O
Receptor	O
Tyrosine	B
Kinase	O
Inhibiting	O
(	O
RTKi	O
)	O
Compounds	O
to	O
the	O
Eye	O

The	O
present	O
invention	O
relates	O
to	O
a	O
microparticle	O
comprising	O
a	O
crosslinked	O
polymer	O
,	O
which	O
polymer	O
is	O
composed	O
of	O
a	O
crosslinkable	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
—	O
X	O
is	O
a	O
residue	O
of	O
a	O
multifunctional	O
radically	O
polymerisable	O
compound	O
(	O
having	O
at	O
least	O
a	O
functionality	O
equal	O
to	O
n	O
)	O
;—each	O
Y	O
independently	O
is	O
optionally	O
present	O
,	O
and	O
—	O
if	O
present	O
—	O
each	O
Y	O
independently	O
represents	O
a	O
moiety	O
selected	O
from	O
the	O
group	O
of	O
O	B
,	O
S	B
and	O
NR0;—each	B
R0	O
is	O
independently	O
chosen	O
from	O
the	O
group	O
of	O
hydrogen	B
and	O
substituted	O
and	O
unsubstituted	O
,	O
aliphatic	O
,	O
cycloaliphatic	O
and	O
aromatic	B
hydrocarbon	I
groups	O
which	O
groups	O
optionally	O
contain	O
one	O
or	O
more	O
moieties	O
selected	O
from	O
the	O
group	O
of	O
ester	O
moieties	O
,	O
ether	O
moieties	O
,	O
thioester	O
moieties	O
,	O
thioether	O
moieties	O
,	O
carbamate	B
moieties	O
,	O
thiocarbamate	B
moieties	O
,	O
amide	B
moieties	O
and	O
other	O
moieties	O
comprising	O
one	O
or	O
more	O
heteroatoms	O
,	O
in	O
particular	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
S	B
,	O
O	B
,	O
P	B
and	O
N	B
,	O
each	O
R0	O
in	O
particular	O
independently	O
being	O
chosen	O
from	O
the	O
group	O
of	O
hydrogen	B
and	O
substituted	O
and	O
unsubstituted	O
alkyl	B
groups	O
,	O
which	O
alkyl	B
groups	O
optionally	O
contain	O
one	O
or	O
more	O
heteroatoms	O
,	O
in	O
particular	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
P	B
,	O
S	B
,	O
O	B
and	O
N	B
;—	O
each	O
Z	O
is	O
independently	O
chosen	O
from	O
O	B
and	O
S	B
;—	O
each	O
R1	O
is	O
independently	O
chosen	O
from	O
the	O
group	O
of	O
substituted	O
and	O
unsubstituted	O
,	O
aliphatic	B
,	O
cycloaliphatic	O
and	O
aromatic	B
hydrocarbon	I
groups	O
which	O
groups	O
optionally	O
contain	O
one	O
or	O
more	O
moieties	O
selected	O
from	O
the	O
group	O
of	O
ester	B
moieties	O
,	O
ether	B
moieties	O
,	O
thioester	O
moieties	O
,	O
thioether	O
moieties	O
,	O
carbamate	B
moieties	O
,	O
thiocarbamate	B
moieties	O
,	O
amide	O
moieties	O
and	O
other	O
moieties	O
comprising	O
one	O
or	O
more	O
heteroatoms	O
,	O
in	O
particular	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
S	B
,	O
O	B
,	O
P	B
and	O
N	B
;—	O
each	O
R2	O
is	O
independently	O
chosen	O
from	O
hydrogen	B
and	O
substituted	O
and	O
unsubstituted	O
,	O
aliphatic	B
,	O
cycloaliphatic	O
and	O
aromatic	B
hydrocarbon	I
groups	O
which	O
groups	O
optionally	O
contain	O
one	O
or	O
more	O
moieties	O
selected	O
from	O
the	O
group	O
of	O
ester	B
moieties	O
,	O
ether	B
moieties	O
,	O
thioester	B
moieties	O
,	O
thioether	B
moieties	O
,	O
carbamate	B
moieties	O
,	O
thiocarbamate	B
moieties	O
,	O
amide	O
moieties	O
and	O
other	O
moieties	O
comprising	O
one	O
or	O
more	O
heteroatoms	O
,	O
in	O
particular	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
S	B
,	O
O	B
,	O
P	B
and	O
N	B
,	O
each	O
R0	O
in	O
particular	O
independently	O
being	O
chosen	O
from	O
the	O
group	O
of	O
hydrogen	B
and	O
substituted	O
and	O
unsubstituted	O
alkyl	B
groups	O
,	O
which	O
alkyl	B
groups	O
optionally	O
contain	O
one	O
or	O
more	O
heteroatoms	O
,	O
in	O
particular	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
P	B
,	O
S	B
,	O
O	B
and	O
N	B
;	O
and	O
n	O
is	O
at	O
least	O
2,—each	O
R3	O
is	O
chosen	O
from	O
hydrogen	B
,	O
—COOCH3	B
,	O
—COOC2H5	B
,	O
—COOC3H7	B
,	O
—COOC4H9.R.	B
Microparticles	O
comprising	O
a	O
crosslinked	O
polymer	O

Sustained	O
release	O
pharmaceutical	O
composition	O
comprising	O
at	O
least	O
one	O
poorly	O
soluble	O
active	O
agent	O
(	O
s	O
)	O
,	O
at	O
least	O
one	O
solubilizer	O
,	O
a	O
release	O
rate	O
controlling	O
polymer	O
system	O
consisting	O
of	O
an	O
acid	O
-	O
soluble	O
polymer	O
and	O
a	O
pH	O
-	O
dependent	O
polymer	O
,	O
and	O
optionally	O
other	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

The	O
present	O
invention	O
also	O
describes	O
a	O
process	O
for	O
preparation	O
of	O
such	O
compositions	O
and	O
method	O
of	O
using	O
such	O
compositions	O
.	O

The	O
sustained	O
release	O
compositions	O
are	O
useful	O
in	O
providing	O
therapeutically	O
effective	O
levels	O
of	O
active	O
agent	O
(	O
s	O
)	O
for	O
extended	O
periods	O
of	O
time	O
.	O

SUSTAINED	O
RELEASE	O
PHARMACEUTICAL	O
COMPOSITION	O
ON	O
THE	O
BASIS	O
OF	O
RELEASE	O
SYSTEM	O
COMPRISING	O
AN	O
ACID	O
-	O
SOLUBLE	O
POLYMER	O
AND	O
A	O
pH	O
-	O
DEPENDENT	O
POLYMER	O

A	O
method	O
for	O
predicting	O
the	O
likelihood	O
a	O
mammal	O
will	O
respond	O
therapeutically	O
to	O
a	O
method	O
of	O
treating	O
cancer	O
comprising	O
administering	O
a	O
VEGFR-2	O
modulator	O
or	O
a	O
dual	O
VEGFR-2	O
/	O
FGFR-1	O
modulator	O
wherein	O
the	O
method	O
comprises	O
:	O
(	O
a	O
)	O
measuring	O
in	O
the	O
mammal	O
the	O
level	O
of	O
FGF2	O
;	O
(	O
b	O
)	O
either	O
comparing	O
the	O
level	O
of	O
FGF2	O
in	O
the	O
sample	O
relative	O
to	O
a	O
standard	O
to	O
permit	O
assignment	O
of	O
the	O
sample	O
to	O
either	O
being	O
a	O
member	O
of	O
an	O
FGF2	O
positive	O
class	O
or	O
an	O
FGF2	O
negative	O
class	O
,	O
or	O
comparing	O
the	O
level	O
of	O
FGF2	O
in	O
the	O
sample	O
relative	O
to	O
a	O
standard	O
,	O
wherein	O
assignment	O
of	O
the	O
mammal	O
to	O
the	O
FGF2	O
positive	O
sample	O
class	O
or	O
a	O
determination	O
that	O
the	O
mammal	O
has	O
an	O
elevated	O
level	O
of	O
FGF2	O
,	O
indicates	O
an	O
increased	O
likelihood	O
the	O
patient	O
will	O
respond	O
therapeutically	O
to	O
the	O
cancer	O
treatment	O
.	O

Methods	O
of	O
predicting	O
whether	O
a	O
mammal	O
has	O
received	O
an	O
efficacious	O
dose	O
of	O
a	O
VEGFR-2	O
modulator	O
or	O
a	O
dual	O
VEGFR-2	O
/	O
FGFR-1	O
modulator	O
is	O
also	O
disclosed	O
,	O
in	O
addition	O
to	O
kits	O
comprising	O
these	O
methods	O
.	O

Biomarkers	O
and	O
methods	O
for	O
determining	O
sensitivity	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
receptor-2	O
modulators	O

[	O
Object	O
]	O

In	O
the	O
case	O
of	O
using	O
3-	B
[	I
3-amino-4-	I
(	I
indan-2-yloxy	I
)	I
-5-	I
(	I
1-methyl-1H	I
-	I
indazol-5-yl	I
)	I
phenyl	I
]	I
propionic	I
acid	I
,	O
methyl	B
3-	I
[	I
4-	I
(	I
indan-2-yloxy	I
)	I
-3-	I
(	I
1-methyl-1H	I
-	I
indazol-5-yl	I
)	I
-5-nitrophenyl	I
]	I
propionate	I
,	O
or	O
methyl	B
3-	I
[	I
3-amino-4-	I
(	I
indan-2-yloxy	I
)	I
-5-	I
(	I
1-methyl-1H	I
-	I
indazol-5-yl	I
)	I
phenyl	I
]	I
propionate	I
as	O
a	O
medicine	O
,	O
more	O
preferable	O
aspects	O
or	O
improved	O
methods	O
are	O
provided	O
.	O

[	O
Means	O
]	O
Crystals	O
of	O
any	O
compound	O
among	O
3-	B
[	I
3-amino-4-	I
(	I
indan-2-yloxy	I
)	I
-5-	I
(	I
1-methyl-1H	I
-	I
indazol-5-yl	I
)	I
phenyl	I
]	I
propionic	I
acid	I
,	O
methyl	B
3-	I
[	I
4-	I
(	I
indan-2-yloxy	I
)	I
-3-	I
(	I
1-methyl-1H	I
-	I
indazol-5-yl	I
)	I
-5-nitrophenyl	I
]	I
propionate	I
,	O
and	O
methyl	B
3-	I
[	I
3-amino-4-	I
(	I
indan-2-yloxy	I
)	I
-5-	I
(	I
1-methyl-1H	I
-	I
indazol-5-yl	I
)	I
phenyl	I
]	I
propionate	I
,	O
and	O
methods	O
of	O
producing	O
the	O
same	O
are	O
provided	O
.	O

Novel	O
crystal	O
of	O
substituted	O
phenylalkanoic	B
acid	I
ester	I
and	O
process	O
for	O
producing	O
the	O
same	O

Compositions	O
comprising	O
microaggregates	O
containing	O
hydrophobic	O
drugs	O
,	O
as	O
well	O
as	O
methods	O
for	O
their	O
production	O
,	O
are	O
described	O
.	O

Such	O
microaggregates	O
may	O
include	O
micelle	O
structures	O
or	O
combinations	O
thereof	O
with	O
liposomes	O
,	O
and	O
constitute	O
an	O
effective	O
delivery	O
vehicle	O
for	O
a	O
hydrophobic	O
agent	O
.	O

Methods	O
for	O
microaggregate	O
production	O
include	O
the	O
use	O
of	O
preferred	O
lipid	O
compounds	O
and	O
processing	O
conditions	O
favoring	O
the	O
production	O
of	O
small	O
aggregates	O
for	O
improved	O
filter	O
sterilization	O
.	O

Drug	O
delivery	O
system	O
for	O
hydrophobic	O
drugs	O

Novel	O
N	B
-	I
phenylacetamide	I
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
and	O
cosmetic	O
and	O
pharmaceutical	O
compositions	O
containing	O
same	O
are	O
useful	O
for	O
treating	O
disorders	O
of	O
the	O
sebaceous	O
gland	O
,	O
e.g.	O
,	O
acne	O
,	O
or	O
have	O
cosmetic	O
applications	O
.	O

Novel	O
n	B
-	I
phenylacetamide	I
inhibitors	O
of	O
the	O
enzyme	O
soat-1	O
and	O
pharmaceutical	O
/	O
cosmetic	O
compositions	O
comprised	O
thereof	O

Compositions	O
are	O
provided	O
for	O
preferential	O
distribution	O
of	O
active	O
agents	O
to	O
injury	O
sites	O
.	O

Such	O
compositions	O
may	O
comprise	O
a	O
ligand	O
with	O
hydrophilic	O
properties	O
and	O
one	O
or	O
more	O
active	O
agents	O
,	O
such	O
as	O
compounds	O
comprising	O
hydrophilic	O
metal	O
ions	O
.	O

Because	O
the	O
delivery	O
ligand	O
and	O
the	O
active	O
agent	O
are	O
specifically	O
selected	O
so	O
the	O
interactions	O
between	O
them	O
are	O
mainly	O
of	O
an	O
ionic	O
nature	O
so	O
that	O
binding	O
of	O
the	O
active	O
agent	O
to	O
the	O
delivery	O
ligand	O
and	O
release	O
of	O
the	O
active	O
agent	O
into	O
the	O
target	O
site	O
are	O
not	O
dependent	O
on	O
enzymatic	O
activity	O
.	O

Methods	O
of	O
using	O
such	O
compositions	O
are	O
also	O
disclosed	O
.	O

Compositions	O
and	O
Methods	O
for	O
Preferential	O
Distribution	O
of	O
Active	O
Agents	O
to	O
Injury	O
Sites	O

An	O
NR2B	O
receptor	O
antagonist	O
is	O
useful	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
agents	O
,	O
for	O
promoting	O
wakefulness	O
,	O
treating	O
narcolepsy	O
,	O
excessive	O
daytime	O
sleepiness	O
,	O
enhancing	O
cognition	O
,	O
treating	O
sleepiness	O
associated	O
with	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
fibromyalgia	O
,	O
chronic	O
pain	O
,	O
sleep	O
disorders	O
,	O
autism	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O

Modulation	O
of	O
sleep	O
with	O
nr2b	O
receptor	O
antagonists	O

Compositions	O
,	O
compounds	O
,	O
and	O
methods	O
for	O
modulating	O
the	O
activity	O
of	O
glutamate	B
dehydrogenase	O
are	O
disclosed	O
.	O

In	O
addition	O
,	O
compositions	O
,	O
compounds	O
,	O
and	O
methods	O
for	O
regulating	O
insulin	O
secretion	O
and	O
treating	O
hyperinsulism	O
/	O
hyperammonemia	O
and/or	O
diabetes	O
are	O
disclosed	O
.	O

Methods	O
and	O
compositions	O
for	O
modulating	O
glutamate	B
dehydrogenase	O

Targeted	O
therapeutic	O
delivery	O
systems	O
comprising	O
gas-	O
or	O
gaseous	O
precursor	O
-	O
filled	O
lipid	O
microspheres	O
comprising	O
a	O
therapeutic	O
are	O
described	O
.	O

Methods	O
for	O
employing	O
such	O
microspheres	O
in	O
therapeutic	O
delivery	O
applications	O
are	O
also	O
provided	O
.	O

Targeted	O
therapeutic	O
delivery	O
systems	O
comprising	O
gas-	O
or	O
gaseous	O
precursor	O
-	O
filled	O
liposomes	O
having	O
a	O
drug	O
encapsulated	O
therein	O
are	O
preferred	O
.	O

Methods	O
of	O
and	O
apparatus	O
for	O
preparing	O
such	O
liposomes	O
and	O
methods	O
for	O
employing	O
such	O
liposomes	O
in	O
therapeutic	O
delivery	O
applications	O
are	O
also	O
disclosed	O
.	O

Novel	O
therapeutic	O
delivery	O
systems	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
sterilization	O
of	O
dispersions	O
of	O
one	O
or	O
more	O
nanoparticulate	O
active	O
agents	O
via	O
gamma	O
irradiation	O
.	O

Sterilization	O
of	O
dispersions	O
of	O
nanoparticulate	O
active	O
agents	O
with	O
gamma	O
radiation	O

The	O
present	O
invention	O
provides	O
stabilized	O
antioxidant	O
particles	O
,	O
each	O
of	O
which	O
includes	O
a	O
core	O
consisting	O
of	O
an	O
antioxidant	O
and	O
a	O
first	O
coating	O
layer	O
formed	O
on	O
the	O
surface	O
of	O
the	O
core	O
,	O
wherein	O
the	O
first	O
coating	O
layer	O
is	O
formed	O
by	O
polymerizing	O
at	O
least	O
one	O
α	B
-	I
lipoic	I
acid	I
or	O
its	O
derivative	O
,	O
a	O
composition	O
including	O
the	O
same	O
,	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

Stabilized	O
antioxidant	O
particles	O
,	O
composition	O
comprising	O
the	O
same	O
and	O
method	O
for	O
preparing	O
the	O
same	O

Clusterin	O
possesses	O
an	O
excellent	O
anorexigenic	O
effect	O
and	O
,	O
accordingly	O
,	O
is	O
useful	O
for	O
treating	O
or	O
preventing	O
obesity	O
or	O
an	O
obesity	O
-	O
related	O
disorder	O
.	O

Co	O
-	O
administration	O
of	O
sub	O
-	O
clinical	O
dose	O
of	O
clustrin	O
potentiates	O
the	O
anorexigenic	O
effect	O
of	O
leptin	O
.	O

Method	O
of	O
preventing	O
or	O
treating	O
body	O
weight	O
disorders	O
by	O
employing	O
clusterin	O

Compositions	O
and	O
methods	O
for	O
the	O
inhibition	O
of	O
viral	O
replication	O
are	O
provided	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
compositions	O
include	O
a	O
nucleic	O
acid	O
sequence	O
that	O
is	O
identical	O
to	O
a	O
region	O
of	O
the	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
genome	O
.	O

In	O
other	O
embodiments	O
,	O
the	O
compositions	O
may	O
include	O
a	O
nucleic	O
acid	O
sequence	O
that	O
has	O
at	O
least	O
about	O
45	O
%	O
to	O
about	O
95	O
%	O
sequence	O
identity	O
to	O
the	O
native	O
HCV	O
sequence	O
and	O
that	O
has	O
a	O
similar	O
secondary	O
and	O
tertiary	O
structure	O
to	O
the	O
native	O
HCV	O
sequence	O
.	O

In	O
other	O
embodiments	O
,	O
the	O
compositions	O
may	O
include	O
a	O
nucleic	O
acid	O
sequence	O
that	O
does	O
not	O
have	O
significant	O
sequence	O
identity	O
to	O
the	O
native	O
HCV	O
sequence	O
and	O
that	O
has	O
a	O
similar	O
secondary	O
and	O
tertiary	O
structure	O
to	O
the	O
native	O
HCV	O
sequence	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
the	O
treatment	O
of	O
a	O
patient	O
having	O
an	O
HCV	O
infection	O
by	O
administering	O
one	O
of	O
the	O
compositions	O
described	O
herein	O
,	O
and	O
uses	O
of	O
the	O
compositions	O
described	O
herein	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
inhibition	O
of	O
HCV	O
replication	O
.	O

Compositions	O
and	O
Methods	O
for	O
the	O
Inhibition	O
of	O
Hepatitis	O
C	O
Viral	O
Replication	O
with	O
Structural	O
Analogs	O

The	O
present	O
disclosure	O
is	O
directed	O
to	O
methods	O
and	O
systems	O
for	O
stabilizing	O
an	O
extracellular	O
matrix	O
in	O
a	O
wall	O
of	O
a	O
blood	O
vessel	O
.	O

The	O
method	O
comprises	O
delivering	O
a	O
therapeutic	O
agent	O
into	O
mural	O
thrombus	O
,	O
which	O
covers	O
the	O
wall	O
of	O
the	O
blood	O
vessel	O
.	O

The	O
agent	O
is	O
transported	O
from	O
the	O
mural	O
thrombus	O
into	O
the	O
extracellular	O
matrix	O
of	O
the	O
vessel	O
wall	O
by	O
diffusion	O
.	O

The	O
agent	O
then	O
acts	O
to	O
reduce	O
the	O
enzymatic	O
degradation	O
of	O
protein	O
in	O
the	O
extracellular	O
matrix	O
.	O

Utilization	O
of	O
mural	O
thrombus	O
for	O
local	O
drug	O
delivery	O
into	O
vascular	O
tissue	O

The	O
invention	O
relates	O
to	O
a	O
double	O
-	O
stranded	O
compound	O
,	O
preferably	O
an	O
oligoribonucleotide	B
,	O
which	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
a	O
gene	O
of	O
the	O
TGase	O
family	O
at	O
post	O
-	O
transcriptional	O
level	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
,	O
or	O
a	O
vector	O
capable	O
of	O
expressing	O
the	O
oligoribonucleotide	B
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
also	O
contemplates	O
a	O
method	O
of	O
treating	O
a	O
patient	O
suffering	O
from	O
fibrotic	O
disease	O
such	O
as	O
kidney	O
and	O
liver	O
fibrosis	O
and	O
ocular	O
scarring	O
comprising	O
administering	O
to	O
the	O
patient	O
the	O
pharmaceutical	O
composition	O
in	O
a	O
therapeutically	O
effective	O
amount	O
so	O
as	O
to	O
thereby	O
treat	O
the	O
patient	O
.	O

The	O
invention	O
also	O
relates	O
to	O
treatment	O
of	O
fibrotic	O
and	O
other	O
diseases	O
by	O
use	O
of	O
antibodies	O
to	O
TGase	O
polypeptides	O
.	O

Oligoribonucleotides	B
and	O
Methods	O
of	O
Use	O
Thereof	O
for	O
Treatment	O
of	O
Fibrotic	O
Conditions	O
and	O
Other	O
Diseases	O

The	O
present	O
invention	O
is	O
based	O
on	O
the	O
seminal	O
discovery	O
that	O
an	O
antibody	O
or	O
fragment	O
thereof	O
combined	O
with	O
Antennapedia	O
or	O
a	O
fragment	O
thereof	O
,	O
is	O
an	O
effective	O
therapeutic	O
agent	O
.	O

The	O
invention	O
describes	O
the	O
construction	O
of	O
antibody	O
or	O
antibody	O
fragment	O
fused	O
or	O
chemically	O
conjugated	O
with	O
Antennapedia	O
at	O
its	O
carboxyl	B
or	O
its	O
amino	B
terminus	O
(	O
a	O
""""	O
cargo	O
-	O
carrier	O
""""	O
construct	O
)	O
.	O

Therapeutic	O
antennapedia	O
-	O
antibody	O
molecules	O
and	O
methods	O
of	O
use	O
thereof	O

A	O
drug	O
-	O
eluting	O
device	O
comprising	O
a	O
drug	O
-	O
eluting	O
matrix	O
containing	O
at	O
least	O
one	O
elutable	O
drug	O
,	O
a	O
method	O
of	O
manufacturing	O
a	O
preformed	O
drug	O
-	O
eluting	O
device	O
,	O
and	O
an	O
implant	O
kit	O
comprising	O
the	O
same	O
.	O

Preformed	O
drug	O
-	O
eluting	O
device	O
to	O
be	O
affixed	O
to	O
an	O
anterior	O
spinal	O
plate	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
the	O
fields	O
of	O
genetics	O
and	O
medicine	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
improved	O
methods	O
of	O
treating	O
cancers	O
using	O
a	O
TLR3	O
agonist	O
,	O
by	O
assessing	O
the	O
expression	O
of	O
a	O
TLR3	O
receptor	O
by	O
cancer	O
cells	O
.	O

Treatment	O
of	O
Cancer	O
Using	O
TLR3	O
Agonists	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
burns	O
comprising	O
administering	O
to	O
a	O
burn	O
area	O
of	O
a	O
subject	O
in	O
need	O
thereof	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
an	O
anti	O
-	O
cytokine	O
or	O
anti	O
-	O
inflammatory	O
agent	O
or	O
a	O
functional	O
derivative	O
thereof	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

Compositions	O
and	O
Methods	O
for	O
Treating	O
Burns	O

Compounds	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
Q	O
are	O
as	O
described	O
in	O
the	O
specification	O
,	O
pharmaceutically	O
-	O
acceptable	O
salts	O
,	O
methods	O
of	O
making	O
,	O
pharmaceutical	O
compositions	O
containing	O
and	O
methods	O
for	O
using	O
the	O
same	O
.	O

Oxadiazole	B
Derivatives	O
and	O
Their	O
Use	O
as	O
Metabotropic	O
Glutamate	B
Receptor	O
Potentiators	O
-	O
842	O

The	O
subject	O
application	O
provides	O
for	O
an	O
emulsion	O
comprising	O
an	O
amount	O
of	O
a	O
perfluorocarbon	B
liquid	O
dispersed	O
as	O
particles	O
within	O
,	O
a	O
continuous	O
liquid	O
phase	O
,	O
wherein	O
the	O
dispersed	O
particles	O
have	O
a	O
monomodal	O
particle	O
size	O
distribution	O
and	O
uses	O
thereof	O
.	O

The	O
subject	O
application	O
also	O
provides	O
for	O
a	O
method	O
of	O
manufacturing	O
a	O
perfluorocarbon	B
emulsion	O
,	O
a	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
product	O
containing	O
a	O
PFC	O
emulsion	O
and	O
a	O
process	O
for	O
validating	O
a	O
batch	O
of	O
an	O
emulsion	O
for	O
pharmaceutical	O
use	O
.	O

Emulsions	O
of	O
Perfluorocarbons	B

Provided	O
herein	O
are	O
methods	O
for	O
treating	O
a	O
subject	O
having	O
or	O
at	O
risk	O
for	O
an	O
angiogenesis	O
-	O
related	O
disorder	O
.	O

The	O
methods	O
include	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
that	O
inhibits	O
JNK3	O
expression	O
,	O
or	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
that	O
inhibits	O
JNK3	O
activity	O
.	O

Disorders	O
that	O
can	O
be	O
treated	O
by	O
these	O
methods	O
include	O
cancer	O
,	O
rheumatoid	O
arthritis	O
,	O
vascular	O
diseases	O
,	O
and	O
other	O
disorders	O
resulting	O
from	O
excessive	O
angiogenesis	O
.	O

The	O
therapeutic	O
agent	O
may	O
be	O
a	O
compound	O
,	O
small	O
molecule	O
,	O
peptide	O
,	O
antibody	O
,	O
antisense	O
nucleic	O
acid	O
,	O
ribozyme	O
,	O
or	O
the	O
like	O
.	O

Methods	O
of	O
identifying	O
a	O
candidate	O
agent	O
that	O
modulates	O
JNK3	O
expression	O
are	O
also	O
provided	O
.	O

Jnk3	O
as	O
a	O
target	O
for	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
related	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
immobilized	O
biologically	O
active	O
entities	O
that	O
retain	O
significant	O
biological	O
activity	O
following	O
sterilization	O
of	O
the	O
immobilized	O
biologically	O
active	O
entities	O
.	O

Immobilized	O
biologically	O
active	O
entities	O
having	O
a	O
high	O
degree	O
of	O
biological	O
activity	O
following	O
sterilization	O

This	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
disease	O
or	O
disorder	O
of	O
the	O
nervous	O
system	O
,	O
associated	O
with	O
an	O
inflammatory	O
response	O
.	O

This	O
invention	O
further	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
,	O
inter	O
alia	O
,	O
an	O
agent	O
which	O
increases	O
brain	O
levels	O
of	O
interferon	O
-	O
γ	O
;	O
and	O
an	O
agent	O
which	O
reduces	O
the	O
number	O
of	O
brain	O
T	O
regulatory	O
(	O
Treg	O
)	O
cells	O
,	O
and	O
optionally	O
further	O
comprising	O
an	O
agent	O
which	O
suppresses	O
neurotoxic	O
inflammatory	O
brain	O
responses	O
.	O

Amethod	O
of	O
treating	O
neurodegenerative	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
terpenes	B
which	O
are	O
particularly	O
suitable	O
for	O
treating	O
plant	O
infections	O
,	O
to	O
methods	O
of	O
making	O
such	O
compositions	O
,	O
and	O
to	O
methods	O
of	O
using	O
them	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
compositions	O
comprising	O
terpenes	B
and	O
hollow	O
glucan	O
particles	O
or	O
cell	O
wall	O
particles	O
and	O
methods	O
for	O
preparing	O
such	O
compositions	O
;	O
such	O
compositions	O
increase	O
terpene	O
stability	O
and	O
activity	O
and	O
provide	O
a	O
suitable	O
carrier	O
for	O
the	O
terpenes	B
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
using	O
such	O
compositions	O
in	O
the	O
medical	O
,	O
veterinary	O
and	O
agricultural	O
fields	O
.	O

In	O
particular	O
,	O
the	O
terpenes	B
disclosed	O
are	O
thymol	B
,	O
eugenol	B
,	O
geraniol	B
,	O
citral	B
and	O
L	B
-	I
carvone	I
.	O

Compositions	O
and	O
methods	O
comprising	O
terpenes	B
or	O
terpene	B
mixtures	O
selected	O
from	O
thymol	B
,	O
eugenol	B
,	O
geraniol	B
,	O
citral	B
,	O
and	O
l	B
-	I
carvone	I

The	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
treating	O
an	O
HIV	O
infection	O
comprising	O
administering	O
an	O
aminoalkanol	B
and	O
a	O
glucocorticoid	B
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
aminoalkanol	B
and	O
the	O
glucocorticoid	B
in	O
amounts	O
effective	O
to	O
selectively	O
eliminate	O
HIV	O
-	O
infected	O
cells	O
and/or	O
to	O
inhibit	O
HIV	O
replication	O
.	O

A	O
method	O
of	O
enhancing	O
the	O
anti	O
-	O
HIV	O
effect	O
of	O
the	O
antiretroviral	O
drug	O
AZT	O
by	O
administering	O
with	O
the	O
AZT	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
an	O
aminoalkanol	B
and	O
a	O
glucocorticoid	B
.	O

HIV	O
Treatment	O

The	O
present	O
invention	O
relates	O
to	O
serotonin	B
receptor	O
antagonists	O
for	O
treating	O
inflammatory	O
arthritis	O
and	O
related	O
conditions	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
kit	O
comprising	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
serotonin	B
receptor	O
antagonist	O
and	O
instructions	O
indicating	O
that	O
the	O
composition	O
is	O
for	O
use	O
in	O
treating	O
inflammatory	O
arthritis	O
and	O
related	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
inflammatory	O
arthritis	O
and	O
related	O
conditions	O
comprising	O
administration	O
of	O
a	O
serotonin	B
receptor	O
antagonist	O
.	O

The	O
method	O
is	O
preferably	O
carried	O
out	O
on	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
.	O

The	O
inflammatory	O
arthritis	O
is	O
preferably	O
rheumatoid	O
arthritis	O
.	O

Serotonin	B
receptor	O
antagonists	O
for	O
treating	O
arthritis	O

The	O
invention	O
relates	O
to	O
novel	O
oxindole	B
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
substituents	O
R1	O
,	O
R2	O
,	O
A	O
,	O
B	O
,	O
and	O
Y	O
are	O
defined	O
as	O
in	O
claim	O
1	O
.	O

The	O
invention	O
further	O
relates	O
to	O
medicaments	O
containing	O
said	O
derivatives	O
,	O
and	O
use	O
thereof	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
vasopressin	B
-	O
dependent	O
diseases	O
.	O

Substituted	O
oxindol	B
derivatives	O
,	O
medicaments	O
containing	O
said	O
derivatives	O
and	O
use	O
thereof	O

Compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
treating	O
cancer	O
and	O
inflammatory	O
diseases	O
,	O
and	O
for	O
releasing	O
cells	O
such	O
as	O
stem	O
cells	O
(	O
e.g.	O
,	O
bone	O
marrow	O
progenitor	O
cells	O
)	O
into	O
circulating	O
blood	O
and	O
enhancing	O
retention	O
of	O
the	O
cells	O
in	O
the	O
blood	O
.	O

More	O
specifically	O
,	O
heterobifunctional	O
compounds	O
that	O
inhibit	O
both	O
E	O
-	O
selectins	O
and	O
CXCR4	O
chemokine	O
receptors	O
are	O
described	O
.	O

Heterobifunctional	O
inhibitors	O
of	O
e	O
-	O
selectins	O
and	O
cxcr4	O
chemokine	O
receptors	O

A	O
cellulose	O
derivative	O
which	O
has	O
a	O
suitable	O
elastic	O
modulus	O
and	O
viscosity	O
when	O
it	O
is	O
dissolved	O
in	O
water	O
and	O
is	O
useful	O
as	O
an	O
adhesion	O
barrier	O
.	O

The	O
cellulose	O
derivative	O
has	O
a	O
molecular	O
weight	O
of	O
5	O
×	O
103	O
to	O
5	O
×	O
106	O
and	O
is	O
composed	O
of	O
a	O
repeating	O
unit	O
represented	O
by	O
the	O
following	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
the	O
following	O
formulas	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
,	O
(	O
c	O
)	O
and	O
(	O
d	O
)	O
in	O
predetermined	O
amount	O
:	O
(	O
X	O
in	O
the	O
formula	O
(	O
c	O
)	O
is	O
an	O
alkali	O
metal	O
,	O
and	O
R4	O
and	O
R5	O
in	O
the	O
formula	O
(	O
d	O
)	O
are	O
each	O
independently	O
an	O
alkyl	B
group	O
or	O
alkenyl	B
group	O
having	O
10	O
to	O
28	O
carbon	O
atoms	O
)	O
.	O

Cellulose	O
derivative	O

The	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
fibrosis	O
in	O
a	O
subject	O
by	O
administering	O
a	O
5-HT	B
modulator	O
,	O
e.g.	O
,	O
a	O
5-HT2B	O
modulator	O
.	O

In	O
particular	O
embodiments	O
,	O
the	O
5-HT	B
modulator	O
is	O
a	O
piperidinylamino	B
-	I
thieno	I
[	I
2,3-d	I
]	I
pyrimidine	I
compound	O
.	O

Piperidinylamino	B
-	I
Thieno	I
[	I
2,3-D	I
]	I
Pyrimidine	I
Compounds	O
for	O
Treating	O
Fibrosis	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
delivering	O
local	O
anesthetic	O
after	O
dental	O
extraction	O
surgery	O
.	O

The	O
present	O
invention	O
relates	O
to	O
packing	O
the	O
tooth	O
socket	O
with	O
a	O
tinned	O
release	O
local	O
anesthetic	O
which	O
is	O
coordinated	O
with	O
an	O
initial	O
local	O
anesthetic	O
and	O
which	O
lasts	O
up	O
to	O
5	O
days	O
.	O

The	O
socket	O
can	O
be	O
surgically	O
sealed	O
or	O
the	O
implant	O
can	O
act	O
as	O
the	O
sealing	O
means	O
.	O

Controlled	O
release	O
local	O
anesthetic	O
for	O
post	O
dental	O
surgery	O
and	O
method	O
of	O
use	O

Disclosed	O
is	O
a	O
Menorrhagia	O
Instrument	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
menstrual	O
bleeding	O
disorders	O
.	O

Menorrhagia	O
Instrument	O
and	O
Method	O
for	O
the	O
Treatment	O
of	O
Menstrual	O
Bleeding	O
Disorders	O

The	O
invention	O
provides	O
molecular	O
markers	O
that	O
are	O
associated	O
with	O
responsiveness	O
of	O
a	O
cancer	O
patient	O
to	O
a	O
chemotherapy	O
treatment	O
,	O
and	O
methods	O
and	O
computer	O
systems	O
for	O
determining	O
such	O
responsiveness	O
based	O
on	O
measurements	O
of	O
these	O
molecular	O
markers	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
and	O
compositions	O
for	O
enhancing	O
the	O
efficacy	O
of	O
chemotherapies	O
in	O
patients	O
by	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
genes	O
encoding	O
these	O
molecular	O
markers	O
and/or	O
their	O
encoded	O
proteins	O
.	O

Genes	O
associated	O
with	O
chemotherapy	O
response	O
and	O
uses	O
thereof	O

Treating	O
and/or	O
preventing	O
prostate	O
problems	O
and/or	O
metastases	O
,	O
by	O
selectively	O
occluding	O
various	O
groin	O
vessels	O
and	O
tools	O
for	O
selective	O
occluding	O
of	O
various	O
groin	O
veins	O
,	O
including	O
,	O
for	O
example	O
,	O
the	O
deferential	O
vein	O
.	O

Optionally	O
providing	O
anti	O
-	O
androgen	O
treatment	O
after	O
such	O
occluding	O
.	O

Methods	O
and	O
apparatus	O
for	O
treating	O
the	O
prostate	O

Disclosed	O
are	O
methods	O
and	O
compositions	O
relating	O
to	O
antagonists	O
of	O
HNF4α	O
.	O

HNF4alpha	O
ANTAGONISTS	O
AND	O
METHODS	O
OF	O
USE	O

Methods	O
are	O
provided	O
for	O
diagnosing	O
whether	O
a	O
subject	O
has	O
,	O
or	O
is	O
at	O
risk	O
of	O
developing	O
,	O
pancreatic	O
cancer	O
.	O

The	O
methods	O
include	O
measuring	O
the	O
level	O
of	O
at	O
least	O
one	O
miR	O
gene	O
product	O
in	O
a	O
biological	O
sample	O
derived	O
from	O
the	O
subject	O
's	O
pancreas	O
.	O

An	O
alteration	O
in	O
the	O
level	O
of	O
the	O
miR	O
gene	O
product	O
in	O
the	O
biological	O
sample	O
as	O
compared	O
to	O
the	O
level	O
of	O
a	O
corresponding	O
miR	O
gene	O
product	O
in	O
a	O
control	O
sample	O
,	O
is	O
indicative	O
of	O
the	O
subject	O
either	O
having	O
,	O
or	O
being	O
at	O
risk	O
for	O
developing	O
,	O
pancreatic	O
cancer	O
.	O

Microrna	O
expression	O
profile	O
associated	O
with	O
pancreatic	O
cancer	O

The	O
present	O
invention	O
provides	O
nucleic	O
acid	O
molecules	O
that	O
inhibit	O
K	O
-	O
ras	O
expression	O
.	O

Methods	O
of	O
using	O
the	O
nucleic	O
acid	O
molecules	O
are	O
also	O
provided	O
.	O

Compositions	O
comprising	O
k	O
-	O
ras	O
sirna	O
and	O
methods	O
of	O
use	O

MicroRNAs	O
are	O
shown	O
to	O
be	O
up-	O
and/or	O
down	O
-	O
regulated	O
in	O
inflammation	O
and	O
immune	O
cells	O
using	O
a	O
mouse	O
model	O
of	O
asthma	O
and	O
regulatory	O
T	O
cells	O
as	O
source	O
of	O
RNA	O
,	O
respectively	O
.	O

Modulating	O
the	O
expression	O
of	O
these	O
microRNAs	O
can	O
be	O
effective	O
in	O
redirecting	O
inflammation	O
and	O
immunity	O
and	O
hence	O
,	O
can	O
be	O
beneficial	O
as	O
biomarkers	O
or	O
as	O
therapeutic	O
agents	O
against	O
diverse	O
human	O
immunologic	O
and	O
inflammatory	O
diseases	O
.	O

Micro	O
-	O
RNAS	O
Modulating	O
Immunity	O
and	O
Inflammation	O

Disclosed	O
are	O
:	O
a	O
peptide	O
comprising	O
an	O
amino	B
acid	I
sequence	O
composed	O
of	O
contiguous	O
nine	O
amino	B
acid	I
residues	O
derived	O
from	O
a	O
WT1	O
protein	O
,	O
wherein	O
an	O
amino	B
acid	I
residue	O
at	O
position	O
2	O
in	O
the	O
amino	B
acid	I
sequence	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Ala	B
,	O
Ile	B
,	O
Leu	B
,	O
Val	B
,	O
Phe	B
,	O
Tyr	B
,	O
Ser	B
and	O
Asp	B
and	O
an	O
amino	B
acid	I
residue	O
at	O
position	O
9	O
in	O
the	O
amino	B
acid	I
sequence	O
is	O
Arg	B
;	O
a	O
polynucleotide	O
encoding	O
the	O
peptide	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
peptide	O
;	O
and	O
others	O
.	O

Hla	O
-	O
a	O
*	O
3303-restricted	O
wt1	O
peptide	O
and	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O

A	O
method	O
of	O
inhibiting	O
replication	O
of	O
a	O
flavivirus	O
in	O
animal	O
cells	O
,	O
and	O
an	O
oligonucleotide	B
compound	O
for	O
use	O
in	O
the	O
method	O
are	O
disclosed	O
.	O

The	O
oligonucleotide	B
analog	O
(	O
i	O
)	O
has	O
a	O
nuclease	O
-	O
resistant	O
backbone	O
,	O
(	O
ii	O
)	O
is	O
capable	O
of	O
uptake	O
by	O
the	O
cells	O
,	O
(	O
iii	O
)	O
contains	O
between	O
8	O
-	O
40	O
nucleotide	O
bases	O
,	O
and	O
(	O
iv	O
)	O
has	O
a	O
sequence	O
of	O
at	O
least	O
8	O
bases	O
complementary	O
to	O
a	O
region	O
of	O
the	O
virus	O
'	O
positive	O
strand	O
RNA	O
genome	O
that	O
includes	O
at	O
least	O
a	O
portion	O
of	O
SEQ	O
ID	O
NOS:1	O
-	O
4	O
.	O

Exposure	O
of	O
cells	O
infected	O
with	O
a	O
flavivirus	O
to	O
the	O
analog	O
is	O
effective	O
to	O
form	O
within	O
the	O
cells	O
,	O
a	O
heteroduplex	O
structure	O
composed	O
of	O
the	O
virus	O
ssRNA	O
and	O
the	O
oligonucleotide	B
,	O
characterized	O
by	O
a	O
Tm	O
of	O
dissociation	O
of	O
at	O
least	O
45	O
°	O
C.	O
,	O
and	O
having	O
disrupted	O
base	O
pairing	O
between	O
the	O
virus	O
'	O
5′	O
and	O
3′	O
cyclization	O
sequences	O
.	O

Oligonucleotide	B
analog	O
and	O
method	O
for	O
treating	O
flavivirus	O
infections	O

The	O
compositions	O
of	O
the	O
present	O
invention	O
composition	O
comprise	O
a	O
therapeutically	O
effective	O
amount	O
of	O
particles	O
comprising	O
lamotrigine	B
,	O
in	O
combination	O
with	O
granules	O
comprising	O
a	O
disintegrant	O
,	O
and	O
a	O
sugar	B
alcohol	B
and/or	O
a	O
saccharide	B
.	O

These	O
compositions	O
are	O
useful	O
in	O
treating	O
epilepsy	O
and	O
bipolar	O
disorder	O
,	O
particularly	O
for	O
patients	O
with	O
dysphagia	O
,	O
and	O
to	O
improve	O
compliance	O
with	O
bipolar	O
patients	O
.	O

Orally	O
Disintegrating	O
Tablet	O
Compositions	O
of	O
Lamotrigine	B

The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
the	O
formula	O
I	O
,	O
as	O
well	O
as	O
other	O
invention	O
embodiments	O
related	O
to	O
these	O
compounds	O
.	O

The	O
compounds	O
are	O
e.g.	O
useful	O
in	O
the	O
treatment	O
of	O
the	O
animal	O
or	O
human	O
body	O
in	O
view	O
of	O
their	O
ability	O
to	O
inhibit	O
protein	O
kinases	O
such	O
as	O
especially	O
PI3	O
kinase	O
.	O

Substituted	O
Imidazopyridazines	B
as	O
Lipid	O
Kinase	O
Inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
ACE2	O
for	O
the	O
therapeutic	O
treatment	O
or	O
prevention	O
of	O
a	O
fibrosis	O
or	O
liver	O
disorder	O
.	O

Treatment	O
of	O
fibroses	O
and	O
liver	O
disorders	O

Gene	O
expression	O
profiling	O
in	O
multiple	O
myeloma	O
patients	O
identifies	O
genes	O
that	O
distinguish	O
between	O
patients	O
with	O
subsequent	O
early	O
death	O
or	O
long	O
survival	O
after	O
treatment	O
.	O

Poor	O
survival	O
is	O
linked	O
to	O
over	O
-	O
expression	O
of	O
genes	O
such	O
as	O
ASPM	O
,	O
OPN3	O
and	O
CKS1B	O
which	O
are	O
located	O
in	O
chromosome	O
1q	O
.	O

Given	O
the	O
frequent	O
amplification	O
of	O
1q	O
in	O
many	O
cancers	O
,	O
it	O
is	O
possible	O
that	O
these	O
genes	O
can	O
be	O
used	O
as	O
powerful	O
prognostic	O
markers	O
and	O
therapeutic	O
targets	O
for	O
multiple	O
myeloma	O
and	O
other	O
cancer	O
.	O

Use	O
of	O
gene	O
expression	O
profiling	O
to	O
predict	O
survival	O
in	O
cancer	O
patient	O

Covalent	O
conjugates	O
of	O
an	O
α	B
,	I
α	I
-	I
disubstituted	I
glycine	I
ester	I
and	O
a	O
modulator	O
of	O
the	O
activity	O
of	O
a	O
target	O
intracellular	O
enzyme	O
or	O
receptor	O
,	O
wherein	O
the	O
ester	B
group	O
of	O
the	O
conjugate	O
is	O
hydrolysable	O
by	O
one	O
or	O
more	O
intracellular	O
carboxylesterase	O
enzymes	O
to	O
the	O
corresponding	O
acid	O
and	O
the	O
α	B
,	I
α	I
-	I
disubstituted	I
glycine	I
ester	I
is	O
conjugated	O
to	O
the	O
modulator	O
at	O
a	O
position	O
remote	O
from	O
the	O
binding	O
interface	O
between	O
the	O
inhibitor	O
and	O
the	O
target	O
enzyme	O
or	O
receptor	O
pass	O
into	O
cells	O
and	O
the	O
active	O
acid	O
hydrolysis	O
product	O
accumulates	O
within	O
the	O
cells	O
.	O

Enzyme	O
and	O
receptor	O
modulation	O

The	O
invention	O
relates	O
to	O
an	O
injectable	O
biocompatible	O
composition	O
based	O
on	O
a	O
polymeric	O
support	O
as	O
well	O
as	O
to	O
a	O
method	O
for	O
producing	O
it	O
,	O
which	O
composition	O
which	O
comprises	O
at	O
least	O
one	O
hydrophilic	O
polymer	O
,	O
wherein	O
the	O
polymer	O
is	O
polymerizable	O
in	O
situ	O
to	O
form	O
a	O
gel	O
,	O
and	O
wherein	O
the	O
hydrophilic	O
polymer	O
is	O
crosslinkable	O
serum	O
albumin	O
or	O
crosslinkable	O
serum	O
protein	O
.	O

The	O
composition	O
can	O
be	O
used	O
in	O
the	O
restoration	O
,	O
the	O
reconstruction	O
,	O
and/or	O
the	O
replacement	O
of	O
tissues	O
and/or	O
organs	O
,	O
or	O
as	O
a	O
drug	O
release	O
implant	O
in	O
mammals	O
.	O

The	O
composition	O
is	O
particularly	O
suitable	O
for	O
treating	O
cartilage	O
disorders	O
of	O
a	O
diseased	O
or	O
injured	O
articular	O
site	O
in	O
a	O
mammal	O
.	O

Injectable	O
biocompatible	O
composition	O

The	O
present	O
invention	O
relates	O
to	O
a	O
cancer	O
sensitizer	O
comprising	O
chlorogenic	B
acid	I
or	O
a	O
derivative	O
thereof	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
cancer	O
sensitizer	O
comprising	O
chlorogenic	B
acid	I
or	O
a	O
derivative	O
thereof	O
,	O
which	O
can	O
make	O
cancer	O
cells	O
sensitive	O
to	O
anticancer	O
agents	O
to	O
increase	O
the	O
therapeutic	O
effect	O
of	O
anticancer	O
agents	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
inhibiting	O
the	O
chemo	O
-	O
resistance	O
of	O
cancer	O
cells	O
,	O
comprising	O
chlorogenic	B
acid	I
or	O
a	O
derivative	O
thereof	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
an	O
anticancer	O
composition	O
comprising	O
an	O
anticancer	O
agent	O
in	O
addition	O
to	O
the	O
composition	O
,	O
and	O
a	O
method	O
for	O
disrupting	O
the	O
chemo	O
-	O
resistance	O
of	O
cancer	O
cells	O
,	O
comprising	O
administration	O
of	O
the	O
cancer	O
sensitizer	O
.	O

Cancer	O
sensitizer	O
comprising	O
chlorogenic	B
acid	I

The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
forms	O
of	O
naltrexone	B
methobromide	I
including	O
hydrated	O
and	O
solvated	O
forms	O
.	O

The	O
invention	O
also	O
describes	O
methods	O
of	O
preparing	O
the	O
various	O
crystalline	O
forms	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
crystalline	O
forms	O
of	O
naltrexone	B
methobromide	I
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
or	O
preventing	O
opioid	O
induced	O
side	O
effects	O
by	O
administering	O
the	O
pharmaceutical	O
compositions	O
.	O

Crystalline	O
Forms	O
of	O
Naltrexone	B
Methobromide	I

The	O
present	O
invention	O
is	O
directed	O
to	O
fused	O
pyridone	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
(	O
I	O
)	O
that	O
are	O
M1	O
receptor	O
positive	O
allosteric	O
modulators	O
and	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
the	O
M1	O
receptor	O
is	O
involved	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
schizophrenia	O
,	O
pain	O
or	O
sleep	O
disorders	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
and	O
compositions	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
the	O
M1	O
receptor	O
.	O

Fused	O
Pyridone	B
M1	O
Receptor	O
Positive	O
Allosteric	O
Modulators	O

An	O
enhanced	O
activity	O
aqueous	O
disinfecting	O
solution	O
having	O
a	O
pH	O
of	O
from	O
about	O
0.5	O
to	O
about	O
6	O
and	O
consisting	O
essentially	O
of	O
(	O
i	O
)	O
hydrogen	B
peroxide	I
in	O
a	O
concentration	O
of	O
from	O
about	O
0.05	O
to	O
about	O
8	O
w	O
/	O
w	O
%	O
of	O
the	O
solution	O
;	O
(	O
ii	O
)	O
at	O
least	O
one	O
anionic	O
surfactant	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
C8	B
to	I
C16	I
alkyl	I
aryl	I
sulfonic	I
acids	I
and	O
alkali	B
metal	I
,	O
ammonium	B
,	O
ethanolamine	B
,	O
calcium	B
and	O
magnesium	B
salts	O
thereof	O
,	O
sulfonated	B
C12	I
to	I
C22	I
carboxylic	I
acids	I
and	O
alkali	B
metal	I
,	O
ammonium	B
,	O
calcium	B
and	O
magnesium	B
salts	O
thereof	O
,	O
C6	B
to	I
C22	I
alkyl	I
diphenyl	I
oxide	I
sulfonic	I
acids	I
and	O
alkali	B
metal	I
,	O
ammonium	B
,	O
ethanolamine	B
,	O
calcium	B
and	O
magnesium	B
salts	O
thereof	O
,	O
naphthalene	B
sulfonic	I
acids	I
and	O
alkali	B
metal	I
,	O
ammonium	B
,	O
calcium	B
and	O
magnesium	B
salts	O
thereof	O
,	O
C8	B
to	I
C22	I
alkyl	I
sulfonic	I
acids	I
and	O
alkali	B
metal	I
,	O
ammonium	B
,	O
calcium	B
and	O
magnesium	B
salts	O
thereof	O
,	O
alkali	B
metal	I
,	O
ammonium	B
,	O
calcium	B
and	O
magnesium	B
C8	B
to	I
C18	I
alkyl	I
sulfates	I
,	O
alkyl	B
or	O
alkenyl	B
esters	I
or	O
diesters	B
of	I
sulfosuccinic	I
acid	I
in	O
which	O
the	O
alkyl	B
or	O
alkenyl	B
groups	O
independently	O
contain	O
from	O
six	O
to	O
eighteen	O
carbon	B
atoms	O
and	O
alkali	B
metal	I
,	O
ammonium	B
,	O
calcium	B
and	O
magnesium	B
salts	O
thereof	O
,	O
and	O
mixtures	O
thereof	O
,	O
in	O
a	O
concentration	O
range	O
of	O
from	O
about	O
0.02	O
to	O
about	O
8	O
w	O
/	O
w	O
%	O
of	O
the	O
solution	O
.	O

Optionally	O
,	O
the	O
solution	O
may	O
contain	O
(	O
iii	O
)	O
at	O
least	O
one	O
additional	O
ingredient	O
chosen	O
from	O
a	O
monocarboxylic	B
acid	I
,	O
a	O
polycarboxylic	B
acid	I
,	O
and	O
mixtures	O
thereof	O
,	O
in	O
a	O
concentration	O
of	O
from	O
about	O
0.05	O
to	O
about	O
4	O
w	O
/	O
w	O
%	O
of	O
the	O
solution	O
;	O
and	O
(	O
iv	O
)	O
at	O
least	O
one	O
further	O
additional	O
ingredient	O
chosen	O
from	O
benzyl	B
alcohol	I
,	O
an	O
alcohol	B
comprising	O
one	O
to	O
six	O
carbon	B
atoms	O
,	O
and	O
mixtures	O
thereof	O
,	O
in	O
a	O
concentration	O
of	O
from	O
about	O
0.1	O
to	O
about	O
10	O
w	O
/	O
w	O
%	O
of	O
the	O
solution	O
.	O

Enhanced	O
activity	O
hydrogen	B
peroxide	I
disinfectant	O

The	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
treating	O
addiction	O
to	O
drugs	O
of	O
abuse	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
cabamoyl	B
compound	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
.	O

Methods	O
for	O
treating	O
drug	O
addiction	O
and	O
improving	O
addiction	O
-	O
related	O
behavior	O

The	O
adrenergic	O
receptors	O
or	O
adrenoceptors	O
are	O
a	O
family	O
of	O
G	O
-	O
protein	O
coupled	O
receptors	O
split	O
into	O
α	O
and	O
β	O
subclasses	O
.	O

The	O
adrenoceptors	O
have	O
important	O
roles	O
in	O
regulating	O
a	O
myriad	O
of	O
physiological	O
conditions	O
and	O
their	O
malfunction	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
a	O
number	O
of	O
diseases	O
.	O

Disclosed	O
herein	O
are	O
a	O
series	O
of	O
novel	O
guanidine	B
and	O
2-aminoimidazoline	B
compounds	O
which	O
are	O
ligands	O
of	O
the	O
alpha2-adrenoceptor	O
(	O
α2-ARs	O
)	O
subclass	O
of	O
adrenergic	O
receptors	O
.	O

The	O
invention	O
also	O
provides	O
for	O
pharmaceutical	O
compositions	O
comprising	O
the	O
novel	O
compounds	O
.	O

The	O
compounds	O
are	O
suitable	O
for	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
α2-ARs	O
associated	O
disorders	O
,	O
such	O
as	O
depression	O
,	O
schizophrenia	O
,	O
glaucoma	O
and	O
analgesia	O
.	O

Guanidine	B
based	O
compounds	O

In	O
this	O
application	O
is	O
described	O
a	O
novel	O
,	O
multiparameter	O
analysis	O
of	O
TCR	O
-	O
coupled	O
signaling	O
and	O
function	O
in	O
resting	O
and	O
activated	O
naive	O
and	O
memory	O
CD4	O
T	O
cells	O
,	O
revealing	O
a	O
biochemical	O
basis	O
for	O
immunological	O
recall	O
.	O

Results	O
reveal	O
a	O
novel	O
biochemical	O
signature	O
imparted	O
to	O
memory	O
CD4	O
T	O
cells	O
enabling	O
efficacious	O
responses	O
through	O
increased	O
ZAP-70	O
expression	O
and	O
reduced	O
accumulation	O
of	O
downstream	O
signaling	O
events	O
.	O

Zap-70	O
as	O
predictor	O
and	O
modulator	O
of	O
effector	O
function	O
of	O
t	O
cells	O

Piperazinyl	B
oxoalkyl	I
tetrahydro	I
-	I
beta	I
-	I
carbolines	I
and	O
related	O
analogues	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
are	O
provided	O
,	O
as	O
are	O
methods	O
for	O
their	O
preparation	O
and	O
use	O
.	O

Such	O
compounds	O
may	O
generally	O
be	O
used	O
to	O
modulate	O
ligand	O
binding	O
to	O
histamine	O
H3	O
receptors	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
and	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
disorders	O
in	O
humans	O
,	O
domesticated	O
companion	O
animals	O
and	O
livestock	O
animals	O
.	O

Pharmaceutical	O
compositions	O
and	O
therapeutic	O
methods	O
are	O
provided	O
,	O
as	O
are	O
methods	O
for	O
using	O
such	O
ligands	O
for	O
detecting	O
histamine	B
H3	O
receptors	O
(	O
e.g.	O
,	O
receptor	O
localization	O
studies	O
)	O
.	O

Piperazinyl	B
oxoalkyl	I
tetrahydro	I
-	I
beta	I
-	I
carbolines	I
and	O
related	O
analogues	O

The	O
non	O
-	O
toxic	O
proteolytic	O
C	O
fragment	O
of	O
tetanus	O
toxin	O
(	O
TTC	O
peptide	O
)	O
has	O
the	O
same	O
ability	O
to	O
bind	O
nerve	O
cells	O
and	O
be	O
retrogradely	O
transported	O
through	O
a	O
synapse	O
as	O
the	O
native	O
toxin	O
.	O

A	O
hybrid	O
protein	O
encoded	O
by	O
the	O
LacZ	O
-	O
TTC	O
gene	O
fusion	O
retains	O
the	O
biological	O
functions	O
of	O
both	O
proteins	O
in	O
vivo	O
,	O
i.e.	O
retrograde	O
transynaptic	O
transport	O
of	O
the	O
TTC	O
fragment	O
and	O
βgal	O
enzymatic	O
activity	O
.	O

After	O
intramuscular	O
injection	O
,	O
enzymatic	O
activity	O
can	O
be	O
detected	O
in	O
motoneurons	O
and	O
connected	O
neurons	O
of	O
brainstem	O
areas	O
.	O

This	O
strategy	O
is	O
useful	O
for	O
the	O
delivery	O
of	O
a	O
biological	O
activity	O
to	O
neurons	O
from	O
the	O
periphery	O
to	O
the	O
central	O
nervous	O
system	O
.	O

Such	O
a	O
hybrid	O
protein	O
can	O
also	O
be	O
used	O
to	O
map	O
synaptic	O
connections	O
between	O
neural	O
cells	O
.	O

Hybrid	O
tetnus	O
toxoid	O
proteins	O
that	O
migrate	O
retrogradely	O
and	O
transynaptically	O
into	O
the	O
cns	O

Novel	O
non	O
-	O
steroidal	O
compounds	O
are	O
provided	O
which	O
are	O
useful	O
in	O
treating	O
diseases	O
or	O
disorders	O
associated	O
with	O
modulation	O
of	O
the	O
glucocorticoid	O
receptor	O
,	O
AP-1	O
,	O
and/or	O
NF	O
-	O
κB	O
activity	O
,	O
including	O
metabolic	O
and	O
inflammatory	O
and	O
immune	O
diseases	O
or	O
disorders	O
,	O
having	O
the	O
structure	O
of	O
formula	O
(	O
I	O
)	O
:	O
an	O
enantiomer	O
,	O
diastereomer	O
,	O
or	O
tautomer	O
thereof	O
,	O
or	O
a	O
prodrug	O
ester	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
,	O
in	O
which	O
:	O
Z	O
is	O
heterocyclo	B
or	O
heteroaryl	B
;	O
-A	O
is	O
a	O
5-	O
to	O
8-membered	O
carbocyclic	B
ring	O
or	O
a	O
5-	O
to	O
8-membered	O
heterocyclic	B
ring	O
;	O
B1	O
and	O
B2	O
rings	O
are	O
pyridyl	B
rings	O
,	O
wherein	O
the	O
B1	O
and	O
B2	O
rings	O
are	O
each	O
fused	O
to	O
the	O
A	O
ring	O
and	O
the	O
B1	O
ring	O
is	O
optionally	O
substituted	O
by	O
one	O
to	O
three	O
groups	O
which	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
independently	O
selected	O
from	O
R1	O
,	O
R2	O
,	O
and	O
R4	O
,	O
and	O
the	O
B2	O
ring	O
is	O
optionally	O
substituted	O
by	O
one	O
to	O
three	O
groups	O
which	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
independently	O
selected	O
from	O
R3	O
,	O
R7	O
,	O
and	O
R3	O
71	O
,	O
J2	O
,	O
and	O
J3	O
are	O
at	O
each	O
occurrence	O
the	O
same	O
or	O
different	O
and	O
are	O
independently	O
-AIQA2-	O
;	O
Q	O
is	O
a	O
bond	O
,	O
O	B
,	O
S	B
,	O
S	B
(	I
0	I
)	I
,	O
or	O
S	B
(	I
O	I
)	I
2	I
;	O
A1	O
and	O
A2	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
at	O
each	O
occurrence	O
independently	O
selected	O
from	O
a	O
bond	O
,	O
C1	B
-	I
3	I
alkylene	I
,	O
substituted	O
C1	B
-	I
3	I
alkylene	I
,	O
C24	B
alkenylene	I
,	O
and	O
substituted	O
C24	B
alkenylene	I
,	O
provided	O
that	O
A1	O
and	O
A2	O
are	O
chosen	O
so	O
that	O
ring	O
A	O
is	O
a	O
5-	O
to	O
8-membered	O
carbocyclic	B
or	O
heterocyclic	B
ring	O
;	O
R1	O
to	O
R11	O
are	O
as	O
defined	O
herein	O
.	O

FUSED	O
HETEROARYL	B
MODULATORS	O
OF	O
GLUCOCORTICOID	O
RECEPTOR	O
,	O
AP-1	O
,	O
AND	O
/	O
OR	O
NF	O
-	O
kappaB	O
ACTIVITY	O
AND	O
USE	O
THEREOF	O

The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
mineralocorticoid	O
receptor	O
antagonists	O
for	O
preparing	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
endometriosis	O
.	O

The	O
present	O
invention	O
relates	O
in	O
particular	O
to	O
an	O
improved	O
therapeutic	O
composition	O
for	O
endometriosis	O
which	O
has	O
a	O
more	O
favorable	O
activity	O
and	O
side	O
-	O
effect	O
profile	O
than	O
treatment	O
therapies	O
currently	O
available	O
.	O

Using	O
a	O
mineralocorticoid	O
receptor	O
antagonist	O
,	O
it	O
is	O
possible	O
to	O
threat	O
endometriosis	O
permanently	O
without	O
any	O
loss	O
of	O
bone	O
mass	O
.	O

Mineralcorticoid	O
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
endometriosis	O

Active	O
pharmaceutical	O
ingredients	O
being	O
retinoic	B
acid	I
ester	I
compounds	O
including	O
all-	B
trans	I
-	I
retinoic	I
acid	I
tent	I
-	I
butyl	I
ester	I
,	O
all	B
-	I
trans	I
-	I
retinoic	I
acid	I
iso	I
-	I
butyl	I
ester	I
,	O
all	B
-	I
trans	I
-	I
retinoic	I
acid	I
iso	I
-	I
propyl	I
ester	I
,	O
all	B
-	I
trans	I
-	I
retinoic	I
acid	I
sec	I
-	I
butyl	I
ester	I
,	O
and	O
,	O
all	B
-	I
trans	I
-	I
retinoic	I
acid	I
1-adamantyl	I
ester	I
,	O
oral	O
and	O
topical	O
dosage	O
form	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
various	O
skin	O
conditions	O
thereof	O
.	O

All	B
-	I
trans	I
retinoid	I
esters	I
as	O
active	O
pharmaceutical	O
ingredients	O
,	O
oral	O
and	O
topical	O
dosage	O
form	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
skin	O
conditions	O
thereof	O

The	O
present	O
invention	O
pertains	O
to	O
complexes	O
comprising	O
sterols	B
and	O
saponins	B
.	O

The	O
complexes	O
are	O
capable	O
of	O
binding	O
a	O
genetic	O
determinant	O
including	O
a	O
polynucleotide	O
.	O

The	O
complexes	O
may	O
further	O
comprise	O
a	O
lipophilic	O
moiety	O
,	O
optionally	O
a	O
lipophilic	O
moiety	O
comprising	O
a	O
contacting	O
group	O
and/or	O
a	O
targeting	O
ligand	O
,	O
and/or	O
a	O
saccharide	O
moiety	O
.	O

The	O
complexes	O
may	O
further	O
comprise	O
an	O
immunogenic	O
determinant	O
and/or	O
an	O
antigenic	O
determinant	O
and/or	O
a	O
medicament	O
and/or	O
a	O
diagnostic	O
compound	O
.	O

The	O
complexes	O
may	O
in	O
even	O
further	O
embodiments	O
be	O
encapsulated	O
by	O
an	O
encapsulation	O
agent	O
including	O
a	O
biodegradable	O
microsphere	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
of	O
an	O
individual	O
by	O
therapy	O
and/or	O
surgery	O
,	O
methods	O
of	O
cosmetic	O
treatment	O
,	O
and	O
diagnostic	O
methods	O
practised	O
on	O
the	O
human	O
or	O
animal	O
body	O
.	O

Particle	O
structures	O
comprising	O
sterols	B
and	O
saponins	B

Methods	O
for	O
treating	O
neuroblastoma	O
in	O
a	O
subject	O
are	O
provided	O
.	O

The	O
methods	O
include	O
administering	O
to	O
the	O
subject	O
nucleic	O
acid	O
that	O
is	O
capable	O
of	O
causing	O
a	O
significant	O
reduction	O
of	O
the	O
amount	O
of	O
doublecortin	O
like	O
protein	O
(	O
DCL	O
)	O
in	O
the	O
subject	O
.	O

The	O
nucleic	O
acids	O
include	O
antisense	O
oligonucleotides	B
and	O
small	O
interfering	O
RNA	O
.	O

Novel	O
mRNA	O
splice	O
variant	O
of	O
the	O
doublecortin	O
-	O
like	O
kinase	O
gene	O
and	O
its	O
use	O
in	O
cancer	O
diagnosis	O
and	O
therapy	O

A	O
polymer	O
-	O
surfactant	O
nanoparticle	O
formulation	O
,	O
using	O
the	O
anionic	O
surfactant	O
aerosol	O
OT	O
(	O
AOT	O
)	O
and	O
polysaccharide	O
polymer	O
alginate	O
,	O
is	O
used	O
for	O
sustained	O
release	O
of	O
water	O
-	O
soluble	O
drugs	O
.	O

The	O
AOT	O
-	O
alginate	O
nanoparticles	O
are	O
suitable	O
for	O
encapsulating	O
doxorubicin	B
,	O
verapamil	B
and	O
clonidine	B
,	O
as	O
well	O
as	O
therapeutic	O
agents	O
effective	O
against	O
dermal	O
conditions	O
such	O
as	O
psoriasis	O
.	O

The	O
nanoparticles	O
are	O
also	O
suitable	O
for	O
encapsulating	O
photo	O
-	O
activated	O
compounds	O
such	O
as	O
methylene	B
blue	O
for	O
use	O
in	O
photo	O
-	O
dynamic	O
therapy	O
of	O
cancer	O
and	O
other	O
diseases	O
,	O
and	O
for	O
treating	O
tumor	O
cells	O
that	O
exhibit	O
resistance	O
to	O
at	O
least	O
one	O
chemotherapeutic	O
drug	O
.	O

Polymer	O
-	O
surfactant	O
nanoparticles	O
for	O
sustained	O
release	O
of	O
compounds	O

The	O
present	O
invention	O
provides	O
mTOR	O
inhibitors	O
of	O
the	O
formula	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
kits	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
compounds	O
;	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
intermediates	O
thereof	O
;	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O

Dihyrofuropyrmindine	B
compounds	O

An	O
aqueous	O
parenteral	O
pharmaceutical	O
formulation	O
of	O
the	O
IRM	O
drug	O
compound	O
N-	B
[	I
4-	I
(	I
4-amino-2-ethyl-1H	I
-	I
imidazo	I
[	I
4,5-c	I
]	I
quinolin-1-yl	I
)	I
butyl	I
]	I
methanesulfonamide	I
dissolved	O
in	O
water	O
,	O
buffer	O
selected	O
from	O
citric	B
acid	I
,	O
acetic	B
acid	I
,	O
lactic	B
acid	I
,	O
succinic	B
acid	I
,	O
and	O
tartaric	B
acid	I
,	O
and	O
optionally	O
a	O
tonicity	O
adjuster	O
,	O
preferably	O
selected	O
from	O
sorbitol	B
and	O
mannitol	B
,	O
wherein	O
the	O
pH	O
is	O
no	O
greater	O
than	O
6	O
and	O
the	O
formulation	O
is	O
sterile	O
and	O
preferably	O
substantially	O
free	O
of	O
sodium	B
chloride	I
.	O

Immune	O
response	O
modifier	O
formulations	O
and	O
methods	O

Processes	O
for	O
the	O
preparation	O
of	O
substantially	O
pure	O
lenalidomide	B
.	O

The	O
application	O
also	O
relates	O
to	O
an	O
enriched	O
,	O
substantially	O
pure	O
,	O
and	O
pure	O
amorphous	O
form	O
of	O
lenalidomide	B
and	O
solid	O
dispersions	O
containing	O
amorphous	O
lenalidomide	B
.	O

Preparation	O
of	O
lenalidomide	B

The	O
invention	O
provides	O
a	O
transmucosal	O
pharmaceutical	O
composition	O
comprising	O
an	O
active	O
compound	O
,	O
a	O
bile	O
salt	O
and	O
an	O
osmolality	O
adjusting	O
ingredient	O
,	O
wherein	O
the	O
osmolality	O
adjusting	O
ingredient	O
generates	O
a	O
localized	O
hyperosmotic	O
environment	O
and	O
maintains	O
an	O
osmolality	O
level	O
for	O
a	O
period	O
of	O
time	O
sufficient	O
to	O
produce	O
hypertonicity	O
-	O
facilitated	O
transmucosal	O
transport	O
of	O
said	O
active	O
compound	O
across	O
the	O
mucosal	O
tissue	O
.	O

The	O
invention	O
also	O
provides	O
a	O
solid	O
transmucosal	O
dosage	O
form	O
containing	O
the	O
composition	O
,	O
as	O
well	O
as	O
a	O
method	O
of	O
treatment	O
comprising	O
administering	O
the	O
same	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
active	O
compound	O
is	O
a	O
triptan	B
compound	O
,	O
e.g.	O
,	O
sumatriptan	B
and	O
zolmitriptan	B
.	O

Enhanced	O
transmucosal	O
composition	O
and	O
dosage	O
form	O

The	O
present	O
inventors	O
developed	O
5a	O
/	O
2a	O
intergenotypic	O
recombinants	O
in	O
which	O
the	O
JFH1	O
structural	O
genes	O
(	O
Core	O
,	O
E1	O
and	O
E2	O
)	O
,	O
p7	O
and	O
all	O
of	O
or	O
part	O
of	O
NS2	O
were	O
replaced	O
by	O
the	O
corresponding	O
genes	O
of	O
the	O
genotype	O
5a	O
reference	O
strain	O
SA13	O
.	O

Compared	O
to	O
the	O
J6	O
/	O
JFH	O
control	O
virus	O
,	O
after	O
transfection	O
of	O
in	O
vitro	O
transcripts	O
in	O
Huh7.5	O
cells	O
,	O
production	O
of	O
infectious	O
viruses	O
was	O
delayed	O
.	O

However	O
,	O
in	O
subsequent	O
viral	O
passages	O
efficient	O
spread	O
of	O
infection	O
and	O
HCV	O
RNA	O
titers	O
as	O
high	O
as	O
for	O
J6	O
/	O
JFH	O
were	O
obtained	O
.	O

Infectivity	O
titers	O
were	O
at	O
all	O
time	O
points	O
analyzed	O
comparable	O
to	O
J6	O
/	O
JFH	O
control	O
virus	O
.	O

Sequence	O
analysis	O
of	O
recovered	O
5a	O
/	O
2a	O
recombinants	O
from	O
2	O
serial	O
passages	O
and	O
subsequent	O
reverse	O
genetic	O
studies	O
revealed	O
adaptive	O
mutations	O
in	O
p7	O
,	O
NS2	O
and/or	O
NS3	O
.	O

Infectivity	O
of	O
the	O
5a	O
/	O
2a	O
viruses	O
was	O
CD81	O
and	O
SR	O
-	O
BI	O
dependant	O
,	O
and	O
the	O
recombinant	O
viruses	O
could	O
be	O
neutralized	O
by	O
chronic	O
phase	O
sera	O
from	O
patients	O
infected	O
with	O
genotype	O
5a	O
.	O

Conclusion	O
:	O
The	O
developed	O
5a	O
/	O
2a	O
viruses	O
provide	O
a	O
robust	O
in	O
vitro	O
tool	O
for	O
research	O
in	O
HCV	O
genotype	O
5	O
,	O
including	O
vaccine	O
studies	O
and	O
functional	O
analyses	O
of	O
an	O
increasingly	O
important	O
genotype	O
in	O
South	O
Africa	O
and	O
Europe	O
.	O

Efficient	O
cell	O
culture	O
system	O
for	O
hepatitis	O
c	O
virus	O
genotype	O
5a	O

The	O
present	O
embodiments	O
relate	O
to	O
a	O
novel	O
method	O
of	O
making	O
quaternary	B
ammonium	I
polymers	O
comprising	O
the	O
steps	O
of	O
:	O
a	O
)	O
mixing	O
1,4-bis	B
-	I
dimethylamino-2-butene	I
,	O
triethanolamine	B
,	O
water	O
and	O
an	O
acid	O
;	O
and	O
b	O
)	O
introducing	O
a	O
1,4-dihalo-2-butene	B
to	O
the	O
mixture	O
so	O
as	O
to	O
initiate	O
a	O
reaction	O
resulting	O
in	O
the	O
quaternary	B
ammonium	I
polymer	O
.	O

Polyquaternium-	O
1	O
synthesis	O
methods	O

Oral	O
compositions	O
comprising	O
an	O
association	O
of	O
one	O
or	O
of	O
a	O
mixture	O
of	O
phytoestrogens	O
,	O
selective	O
for	O
the	O
estrogen	B
receptor	O
-	O
β	O
,	O
with	O
dietary	O
fibres	O
are	O
described	O
.	O

The	O
compositions	O
thereof	O
can	O
be	O
profitably	O
used	O
for	O
the	O
prophylactic	O
and	O
therapeutic	O
treatment	O
in	O
mammals	O
,	O
including	O
humans	O
,	O
of	O
health	O
conditions	O
characterised	O
by	O
a	O
high	O
risk	O
of	O
onset	O
and	O
recurrence	O
of	O
intestinal	O
adenomas	O
(	O
adenopolyposis	O
coli	O
)	O
,	O
and	O
of	O
adenoma	O
's	O
progression	O
to	O
colorectal	O
carcinoma	O
.	O

In	O
presence	O
of	O
pre	O
-	O
cancerous	O
lesions	O
in	O
the	O
colon	O
,	O
characterised	O
by	O
mutations	O
of	O
the	O
APC	O
tumor	O
suppressor	O
and	O
defined	O
as	O
polyps	O
or	O
adenomas	O
,	O
the	O
oral	O
compositions	O
disclosed	O
can	O
be	O
in	O
fact	O
profitably	O
used	O
to	O
reduce	O
the	O
number	O
and	O
volume	O
of	O
polyps	O
,	O
and	O
to	O
prevent	O
their	O
progression	O
to	O
neoplastic	O
transformation	O
,	O
reducing	O
their	O
degree	O
of	O
dysplasia	O
.	O

Compositions	O
comprising	O
phytoestrogenes	O
selective	O
for	O
estrogen	B
beta	O
receptor	O
and	O
dietary	O
fibres	O

Compositions	O
comprising	O
Hirsutella	O
sinensis	O
mycelia	O
extracts	O
and	O
chromatographically	O
separated	O
polysaccharide	O
-	O
enriched	O
fractions	O
thereof	O
are	O
provided	O
.	O

Methods	O
for	O
extracting	O
Hirsutella	O
sinensis	O
mycelia	O
are	O
provided	O
.	O

Compositions	O
for	O
methods	O
for	O
their	O
use	O
in	O
amelioration	O
,	O
prevention	O
and	O
treatment	O
of	O
sepsis	O
,	O
acute	O
endotoxemia	O
and	O
inflammatory	O
responses	O
are	O
disclosed	O
.	O

Hirsutella	O
sinensis	O
mycelia	O
compositions	O
and	O
methods	O
for	O
treating	O
sepsis	O
and	O
related	O
inflammatory	O
responses	O

The	O
present	O
invention	O
relates	O
to	O
2-phenyl-4-cyclopropyl	B
-	I
pyrimidine	I
derivatives	O
and	O
their	O
use	O
as	O
P2Y12	O
receptor	O
antagonists	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
peripheral	O
vascular	O
,	O
of	O
visceral-	O
,	O
hepatic-	O
and	O
renal	O
-	O
vascular	O
,	O
of	O
cardiovascular	O
and	O
of	O
cerebrovascular	O
diseases	O
or	O
conditions	O
associated	O
with	O
platelet	O
aggregation	O
,	O
including	O
thrombosis	O
in	O
humans	O
and	O
other	O
mammals	O
.	O

2-phenyl-4-cyclopropyl	B
-	I
pyrimidine	I
derivatives	O

Ophthalmic	O
compositions	O
comprising	O
ketotifen	B
and	O
a	O
source	O
of	O
hydrogen	B
peroxide	I
providing	O
an	O
amount	O
of	O
hydrogen	B
peroxide	I
of	O
from	O
about	O
0.001	O
to	O
about	O
0.1	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
hydrogen	B
peroxide	I
,	O
and	O
methods	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
allergic	O
conjunctivitis	O
using	O
these	O
compositions	O
are	O
provided	O
herein	O
.	O

Stabilized	O
and	O
preserved	O
ketoifen	B
ophthalmic	O
compositions	O

Robust	O
polymeric	O
hydrogels	O
and	O
a	O
method	O
to	O
fabricate	O
antimicrobial	O
non	O
-	O
woven	O
fibrous	O
wound	O
dressing	O
with	O
controlled	O
silver	B
release	O
that	O
may	O
be	O
used	O
for	O
anti	O
-	O
infective	O
medical	O
implants	O
and	O
anti	O
-	O
infective	O
coating	O
for	O
implantable	O
medical	O
device	O
.	O

The	O
hydrogels	O
may	O
be	O
provided	O
in	O
non	O
-	O
woven	O
fibrous	O
wound	O
dressing	O
and	O
anti	O
-	O
infective	O
implantable	O
medical	O
devices	O
,	O
especially	O
for	O
reconstructive	O
oral	O
and	O
bone	O
surgery	O
.	O

Antimicrobial	O
Nanostructured	O
Hydrogel	O
Web	O
Containing	O
Silver	B

Use	O
of	O
dried	O
compositions	O
of	O
silver	B
dihydrogen	I
citrate	I
along	O
with	O
citric	O
acid	O
in	O
antimicrobial	O
amounts	O
directly	O
as	O
disinfectants	O
is	O
described	O
.	O

Formulations	O
and	O
methods	O
employing	O
anhydrous	O
disinfectant	O

Methods	O
and	O
compositions	O
comprising	O
an	O
anti	O
-	O
ostepontin	O
agent	O
and/or	O
a	O
PDGF	O
receptor	O
blocker	O
or	O
antagonist	O
,	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
anti	O
-	O
connexin	O
agents	O
,	O
for	O
example	O
,	O
one	O
or	O
more	O
anti	O
-	O
connexin	O
polynucleotides	O
and/or	O
one	O
or	O
more	O
anti	O
-	O
connexin	O
peptides	O
or	O
peptidomimetics	O
,	O
are	O
provided	O
for	O
the	O
promotion	O
and/or	O
improvement	O
of	O
wound	O
healing	O
and/or	O
tissue	O
repair	O
,	O
and	O
for	O
anti	O
-	O
scarring	O
,	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
fibrosis	O
and	O
anti	O
-	O
adhesion	O
indications	O
.	O

Wound	O
healing	O
compositions	O
and	O
treatments	O

Biodegradable	O
resorbable	O
drug	O
delivery	O
systems	O
characterized	O
by	O
an	O
electrospun	O
biodegradable	O
resorbable	O
polymeric	O
fiber	O
matrix	O
with	O
at	O
least	O
one	O
therapeutic	O
agent	O
incorporated	O
into	O
the	O
fibers	O
of	O
the	O
matrix	O
,	O
wherein	O
the	O
fiber	O
matrix	O
has	O
an	O
interfibrillar	O
space	O
of	O
at	O
least	O
65	O
%	O
by	O
volume	O
.	O

Therapeutic	O
methods	O
for	O
delivering	O
a	O
chemotherapeutic	O
agent	O
to	O
body	O
cavities	O
from	O
which	O
a	O
tumor	O
has	O
been	O
excised	O
and	O
for	O
strengthening	O
weakened	O
blood	O
vessel	O
walls	O
are	O
also	O
disclosed	O
.	O

System	O
and	O
method	O
for	O
electrospun	O
drug	O
loaded	O
biodegradable	O
chemotherapy	O
applications	O

The	O
invention	O
relates	O
to	O
compositions	O
and	O
processes	O
for	O
producing	O
novel	O
hop	O
acid	O
formulations	O
having	O
improved	O
bioavailability	O
,	O
and	O
the	O
use	O
of	O
such	O
compositions	O
as	O
anti	O
-	O
inflammatory	O
agents	O
,	O
dietary	O
supplements	O
,	O
and	O
pharmaceuticals	O
.	O

Compositions	O
comprising	O
and	O
processes	O
for	O
producing	O
inorganic	O
salts	O
of	O
hop	O
acids	O

This	O
invention	O
is	O
directed	O
to	O
β-1	O
-	O
6-glucans	O
,	O
compositions	O
and	O
devices	O
comprising	O
the	O
same	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
modulating	O
immune	O
responses	O
.	O

The	O
β-1	O
-	O
6-glucans	O
of	O
certain	O
embodiments	O
of	O
the	O
invention	O
are	O
enriched	O
for	O
O	O
-	O
acetylated	O
groups	O
and/or	O
conjugated	O
to	O
a	O
solid	O
support	O
or	O
linked	O
to	O
a	O
targeting	O
moiety	O
.	O

Immunomodulating	O
compositions	O
and	O
methods	O
of	O
use	O

Disclosed	O
herein	O
are	O
a	O
kit	O
and	O
a	O
method	O
for	O
forming	O
a	O
tissue	O
coating	O
that	O
prevents	O
undesired	O
tissue	O
-	O
to	O
-	O
tissue	O
adhesions	O
resulting	O
from	O
trauma	O
,	O
surgery	O
,	O
infection	O
,	O
or	O
other	O
stimulus	O
.	O

The	O
tissue	O
coating	O
is	O
a	O
hydrogel	O
formed	O
by	O
reacting	O
an	O
aminocarboxymethyldextran	O
containing	O
primary	O
amine	O
groups	O
with	O
an	O
oxidized	O
carboxymethylcellulose	O
containing	O
aldehyde	O
groups	O
.	O

Tissue	O
coating	O
for	O
preventing	O
undesired	O
tissue	O
-	O
to	O
-	O
tissue	O
adhesions	O

The	O
present	O
invention	O
is	O
related	O
to	O
a	O
nucleic	O
acid	O
,	O
preferably	O
binding	O
to	O
C5a	O
,	O
selected	O
from	O
the	O
group	O
comprising	O
type	O
A	O
nucleic	O
acids	O
,	O
type	O
B	O
nucleic	O
acids	O
,	O
type	O
C	O
nucleic	O
acids	O
,	O
type	O
D	O
nucleic	O
acids	O
and	O
nucleic	O
acids	O
having	O
a	O
nucleic	O
acid	O
sequence	O
according	O
to	O
any	O
of	O
SEQ.ID.No	O
.	O

73	O
to	O
79	O
.	O

C5a	O
binding	O
nucleic	O
acids	O

The	O
HIV	O
regulatory	O
proteins	O
Tat	O
and	O
Rev	O
accumulate	O
in	O
nucleoli	O
of	O
human	O
cells	O
.	O

No	O
functional	O
role	O
has	O
been	O
attributed	O
to	O
this	O
localization	O
.	O

Recently	O
it	O
was	O
demonstrated	O
that	O
expression	O
of	O
Rev	O
induces	O
nucleolar	O
re	O
-	O
localization	O
of	O
some	O
nuclear	O
factors	O
involved	O
in	O
Rev	O
export	O
.	O

Thus	O
,	O
it	O
is	O
likely	O
that	O
the	O
nucleolus	O
plays	O
a	O
critical	O
role	O
in	O
Rev	O
-	O
mediated	O
export	O
of	O
singly	O
spliced	O
and	O
unspliced	O
HIV-1	O
RNAs	O
.	O

As	O
a	O
test	O
for	O
trafficking	O
of	O
HIV-1	O
RNAs	O
into	O
the	O
nucleolus	O
,	O
a	O
hammerhead	O
ribozyme	O
which	O
specifically	O
cleaves	O
HIV-1	O
RNA	O
was	O
joined	O
to	O
the	O
U16	O
snoRNA	O
resulting	O
in	O
accumulation	O
of	O
the	O
ribozyme	O
within	O
nucleoli	O
of	O
human	O
cells	O
.	O

Stably	O
transduced	O
human	O
T	O
-	O
cells	O
expressing	O
this	O
nucleolar	O
localized	O
ribozyme	O
dramatically	O
suppressed	O
HIV-1	O
replication	O
,	O
confirming	O
a	O
possible	O
trafficking	O
of	O
the	O
HIV	O
RNA	O
through	O
the	O
nucleoli	O
of	O
human	O
cells	O
.	O

In	O
addition	O
,	O
a	O
TAR	O
element	O
which	O
binds	O
Tat	O
was	O
joined	O
to	O
the	O
U16	O
snoRNA	O
,	O
also	O
resulting	O
in	O
localization	O
in	O
the	O
nucleoli	O
and	O
inhibiting	O
HIV	O
replication	O
.	O

Nucleolar	O
targeting	O
of	O
therapeutics	O
against	O
hiv	O

Provided	O
are	O
fatty	B
acid	I
amides	I
of	O
amino	B
acids	I
,	O
uses	O
thereof	O
and	O
pharmaceutical	O
compositions	O
including	O
them	O
.	O

Fatty	B
acid	I
amides	I
and	O
uses	O
thereof	O

The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
iron	B
deficiency	O
,	O
and	O
in	O
particular	O
of	O
iron	B
deficiency	O
anemia	O
,	O
by	O
administering	O
a	O
composition	O
containing	O
an	O
effective	O
amount	O
of	O
a	O
pharmaceutically	O
acceptable	O
ferrous	B
iron	I
salt	O
;	O
and	O
an	O
effective	O
amount	O
of	O
polysaccharide	O
iron	O
complex	O
.	O

Toleration	O
Iron	B
Supplement	O
Compositions	O

The	O
present	O
invention	O
refers	O
to	O
the	O
use	O
of	O
compounds	O
binding	O
to	O
the	O
sigma	O
receptor	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
neuropathic	O
pain	O
resulting	O
from	O
chemotherapy	O
.	O

Use	O
of	O
compounds	O
binding	O
to	O
the	O
sigma	O
receptor	O
ligands	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
developing	O
as	O
a	O
consequence	O
of	O
chemotherapy	O

This	O
invention	O
relates	O
to	O
a	O
Bicyclic	B
triterpenoid	I
Iripallidal	B
as	O
a	O
novel	O
anti	O
-	O
glioma	O
and	O
anti	O
neoplastic	O
agent	O
,	O
having	O
the	O
composition	O
[	O
(	B
−	I
)	I
(	I
6R,10S,11S,18R,22S	I
)	I
-26	I
Hydroxy-22-α	I
methylcyloirid-16-enal	I
NSC	O
631939	O
]	O
,	O
wherein	O
it	O
binds	O
to	O
Ras	O
GRP3	O
,	O
a	O
phorbol	B
ester	I
receptor	O
that	O
links	O
DAG	O
/	O
phorbolester	O
signaling	O
with	O
Ras	O
activation	O
and	O
induces	O
phosphorylation	O
of	O
ER	O
K1	O
/	O
2	O
in	O
a	O
Ras	O
dependent	O
manner	O
,	O
reducing	O
proliferation	O
of	O
cancer	O
cell	O
lines	O
to	O
the	O
extent	O
of	O
50	O
-	O
70	O
%	O
.	O

Bicyclic	B
Triterpenoid	I
Iripallidal	B
as	O
a	O
Novel	O
Anti	O
-	O
Glioma	O
and	O
Anti	O
-	O
Neoplastic	O
Therapy	O

The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
predicting	O
patient	O
responses	O
to	O
cancer	O
treatment	O
using	O
a	O
proliferation	O
gene	O
signature	O
.	O

These	O
methods	O
can	O
comprise	O
measuring	O
in	O
a	O
biological	O
sample	O
from	O
a	O
patient	O
the	O
levels	O
of	O
gene	O
expression	O
of	O
a	O
group	O
of	O
the	O
genes	O
designated	O
herein	O
.	O

The	O
present	O
invention	O
also	O
provides	O
for	O
microarrays	O
that	O
can	O
detect	O
expression	O
from	O
a	O
group	O
of	O
genes	O
.	O

Knowledge	O
-	O
Based	O
Proliferation	O
Signatures	O
and	O
Methods	O
of	O
Use	O

A	O
modified	O
sodium	B
silicate	I
composition	O
,	O
and	O
methods	O
of	O
treating	O
cancer	O
and	O
viral	O
infections	O
utilizing	O
the	O
modified	O
sodium	B
silicate	I
composition	O
(	O
Na8.2Si4.4H9.7O17.6	B
)	O
.	O

Na8.2Si4.4H9.7O17.6	B
can	O
be	O
administered	O
to	O
increase	O
the	O
nitric	B
oxide	I
concentration	O
in	O
the	O
body	O
,	O
effect	O
apoptosis	O
,	O
increase	O
NO	B
formation	O
by	O
neutrophils	O
.	O

Inhibit	O
cell	O
mutations	O
,	O
and	O
inhibit	O
oxidative	O
stress	O
.	O

Method	O
and	O
composition	O
for	O
treating	O
cancer	O
,	O
effecting	O
apoptosis	O
and	O
treating	O
retroviral	O
infections	O

4-	B
[	I
4-	I
(	I
2-Adamantylcarbamoyl	I
)	I
-5-tert	I
-	I
butyl	I
-	I
pyrazol-1-yl	I
]	I
benzoic	I
acid	I
and	O
pharmaceutically	O
-	O
acceptable	O
salts	O
thereof	O
and	O
a	O
particular	O
crystalline	O
form	O
of	O
the	O
Agent	O
(	O
Form	O
1	O
)	O
;	O
their	O
use	O
in	O
the	O
inhibition	O
of	O
11βHSD1	O
,	O
processes	O
for	O
making	O
them	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
also	O
described	O
.	O

4-	B
[	I
4-	I
(	I
2-adamantylcarbamoyl	I
)	I
-5-tert	I
-	I
butyl	I
-	I
pyrazol-1-yl	I
]	I
Benzoic	I
Acid	I
-	O
465	O

Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
promoting	O
neuroprotection	O
in	O
a	O
subject	O
and	O
for	O
treating	O
a	O
neural	O
disorder	O
associated	O
with	O
protein	O
aggregation	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
agent	O
that	O
increases	O
expression	O
or	O
activity	O
of	O
cathepsin	O
-	O
D.	O
Also	O
provided	O
are	O
methods	O
of	O
screening	O
for	O
agents	O
that	O
increase	O
expression	O
or	O
activity	O
of	O
cathepsin	O
-	O
D	O
and	O
methods	O
of	O
screening	O
for	O
neuroprotective	O
agents	O
.	O

Cathepsin	O
-	O
d	O
neuroprotection	O

Novel	O
polynucleotide	O
and	O
amino	B
acids	I
of	O
Brachyspira	O
hyodysenteriae	O
are	O
described	O
.	O

These	O
sequences	O
are	O
useful	O
for	O
diagnosis	O
of	O
B.	O
hyodysenteriae	O
disease	O
in	O
animals	O
and	O
as	O
a	O
therapeutic	O
treatment	O
or	O
prophylactic	O
treatment	O
of	O
B.	O
hyodysenteriae	O
disease	O
in	O
animals	O
.	O

These	O
sequences	O
may	O
also	O
be	O
useful	O
for	O
diagnostic	O
and	O
therapeutic	O
and/or	O
prophylactic	O
treatment	O
of	O
diseases	O
in	O
animals	O
caused	O
by	O
other	O
Brachyspira	O
species	O
Novel	O
sequences	O
of	O
brachyspira	O
,	O
immunogenic	O
compounds	O
,	O
methods	O
for	O
preparation	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
comprising	O
a	O
nanoparticulate	O
vitamin	O
K2	O
having	O
improved	O
bioavailability	O
.	O

The	O
nanoparticulate	O
vitamin	O
K2	O
particles	O
of	O
the	O
composition	O
have	O
an	O
effective	O
average	O
particle	O
size	O
of	O
less	O
than	O
about	O
2000	O
nm	O
and	O
are	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
osteoporosis	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
controlled	O
release	O
composition	O
comprising	O
a	O
vitamin	O
K2	O
or	O
a	O
nanoparticulate	O
vitamin	O
K2	O
that	O
in	O
operation	O
delivers	O
the	O
drug	O
in	O
a	O
pulsed	O
or	O
multi	O
-	O
modal	O
manner	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
osteoporosis	O
.	O

Nanoparticulate	O
and	O
controlled	O
release	O
compositions	O
comprising	O
vitamin	O
k2	O

The	O
present	O
invention	O
relates	O
to	O
a	O
veterinary	O
composition	O
in	O
a	O
semisolid	O
form	O
adapted	O
for	O
transmucosal	O
administration	O
for	O
providing	O
sedation	O
and	O
analgesia	O
in	O
large	O
animals	O
such	O
as	O
horses	O
and	O
cattle	O
.	O

The	O
semisolid	O
transmucosal	O
composition	O
of	O
the	O
invention	O
comprises	O
detomidine	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
composition	O
provides	O
a	O
rapid	O
onset	O
of	O
action	O
while	O
having	O
low	O
irritation	O
potential	O
in	O
the	O
oral	O
mucosa	O
.	O

Transmucosal	O
veterinary	O
composition	O
comprising	O
detomidine	B

The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
modulating	O
the	O
expression	O
of	O
the	O
RhoA	O
gene	O
,	O
and	O
more	O
particularly	O
to	O
the	O
downregulation	O
of	O
RhoA	O
by	O
chemically	O
modified	O
oligonucleotides	B
.	O

RNAi	O
Modulation	O
of	O
the	O
RHO	O
-	O
A	O
Gene	O
and	O
Uses	O
Thereof	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
cancer	O
,	O
and	O
is	O
predicated	O
at	O
least	O
in	O
part	O
on	O
the	O
use	O
of	O
gene	O
fusion	O
regions	O
as	O
therapeutic	O
targets	O
.	O

The	O
fusion	O
region	O
target	O
may	O
be	O
physically	O
embodied	O
at	O
the	O
level	O
of	O
DNA	O
,	O
RNA	O
or	O
protein	O
.	O

Typically	O
the	O
fusion	O
region	O
is	O
specific	O
to	O
cancerous	O
or	O
precancerous	O
cells	O
,	O
meaning	O
that	O
any	O
therapy	O
directed	O
to	O
the	O
target	O
may	O
not	O
significantly	O
affect	O
non	O
-	O
cancerous	O
tissue	O
.	O

The	O
fusion	O
region	O
may	O
be	O
targeted	O
by	O
protein	O
or	O
nucleic	O
acid	O
molecules	O
capable	O
of	O
specifically	O
binding	O
to	O
the	O
region	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
cancer	O

Disclosed	O
is	O
a	O
method	O
for	O
treating	O
PPAR	O
(	O
peroxisome	O
proliferator	O
activated	O
receptor	O
)	O
mediated	O
diseases	O
,	O
such	O
as	O
diabetes	O
mellitus	O
and	O
diabetic	O
complications	O
,	O
which	O
includes	O
administering	O
to	O
a	O
subject	O
an	O
effective	O
amount	O
of	O
macelignan	O
represented	O
by	O
the	O
following	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Method	O
for	O
treating	O
conditions	O
mediated	O
by	O
ppar	O
using	O
macelignan	O

A	O
method	O
for	O
obtaining	O
a	O
sequoyitol	O
-	O
containing	O
extract	O
from	O
a	O
plant	O
of	O
genus	O
Nephrolepis	O
,	O
comprising	O
extracting	O
with	O
a	O
solvent	O
,	O
recovering	O
the	O
solvent	O
to	O
give	O
an	O
extractum	O
,	O
subjecting	O
the	O
extractum	O
to	O
two	O
-	O
phase	O
extraction	O
and	O
column	O
chromatography	O
,	O
collecting	O
the	O
fractions	O
containing	O
sequoyitol	B
,	O
concentrating	O
,	O
filtration	O
and	O
drying	O
.	O

The	O
main	O
active	O
ingredient	O
of	O
the	O
extract	O
obtained	O
is	O
sequoyitol	B
,	O
which	O
can	O
be	O
used	O
for	O
treating	O
diabetes	O
and	O
its	O
complications	O
.	O

Method	O
for	O
obtaining	O
a	O
sequoyitol	O
-	O
containing	O
extract	O
from	O
genus	O
nephrolepis	O
and	O
uses	O
thereof	O

Disclosed	O
are	O
immunogenic	O
peptides	O
,	O
related	O
fusion	O
proteins	O
,	O
nucleic	O
acids	O
encoding	O
the	O
peptides	O
or	O
fusion	O
proteins	O
,	O
conjugates	O
,	O
expression	O
vectors	O
,	O
host	O
cells	O
,	O
and	O
antibodies	O
.	O

Also	O
,	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
,	O
vaccines	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
cancer	O
,	O
e.g.	O
,	O
alveolar	O
rhabodomyosarcoma	O
,	O
methods	O
of	O
stimulating	O
a	O
T	O
cell	O
to	O
kill	O
a	O
tumor	O
cell	O
,	O
methods	O
of	O
stimulating	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
,	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
cancer	O
are	O
further	O
provided	O
herein	O
.	O

Immunogenic	O
peptides	O
and	O
methods	O
of	O
use	O
for	O
treating	O
and	O
preventing	O
cancer	O

The	O
present	O
invention	O
is	O
directed	O
to	O
mutants	O
of	O
HCV	O
NS3	O
/	O
4A	O
protease	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
identifies	O
mutant	O
of	O
HCV	O
NS3	O
/	O
4A	O
protease	O
that	O
are	O
resistant	O
to	O
drug	O
treatment	O
.	O

HCV	O
NS3-NS4	O
Protease	O
Resistance	O
Mutants	O

Berberine	B
or	O
its	O
salts	O
or	O
derivatives	O
are	O
identified	O
as	O
the	O
active	O
compound	O
for	O
selectively	O
inhibiting	O
lung	O
cancer	O
,	O
potentially	O
without	O
toxic	O
side	O
effects	O
.	O

Berberine	B
is	O
preferably	O
obtained	O
by	O
synthesis	O
or	O
partial	O
synthesis	O
,	O
or	O
is	O
obtained	O
from	O
natural	O
sources	O
,	O
such	O
as	O
Coptis	O
teeta	O
,	O
or	O
other	O
berberine	B
containing	O
plants	O
.	O

Berberine	B
and	O
its	O
derivatives	O
are	O
also	O
active	O
against	O
HIV	O
,	O
and	O
may	O
be	O
a	O
safe	O
new	O
drug	O
for	O
the	O
prevention	O
of	O
AIDS	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antiviral	O
agents	O
.	O

Composition	O
and	O
method	O
of	O
inhibiting	O
tumor	O
or	O
viral	O
infections	O
and	O
malaria	O
without	O
toxic	O
side	O
effects	O
.	O

A	O
natural	O
composition	O
from	O
the	O
rhizome	O
of	O
Coptis	O
teeta	O
may	O
be	O
used	O
as	O
a	O
safe	O
new	O
drug	O
for	O
the	O
prevention	O
of	O
human	O
breast	O
cancer	O
.	O

Berberine	B
as	O
a	O
selective	O
lung	O
cancer	O
agent	O
and	O
other	O
compositions	O
and	O
methods	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
toxin	O
moiety	O
(	O
e.g.	O
,	O
a	O
chlorotoxin	O
moiety	O
)	O
as	O
a	O
carrier	O
for	O
therapeutic	O
agents	O
,	O
e.g.	O
,	O
therapeutic	O
agents	O
that	O
require	O
intracellular	O
uptake	O
to	O
exert	O
their	O
effects	O
.	O

For	O
example	O
,	O
in	O
some	O
embodiments	O
,	O
the	O
present	O
invention	O
provides	O
conjugates	O
comprising	O
a	O
toxin	O
(	O
e.g.	O
,	O
a	O
chlorotoxin	O
)	O
moiety	O
and	O
an	O
anti	O
-	O
cancer	O
moiety	O
and	O
methods	O
for	O
using	O
such	O
conjugates	O
to	O
increase	O
cellular	O
uptake	O
and/or	O
increase	O
specificity	O
for	O
cancer	O
cells	O
of	O
the	O
anti	O
-	O
cancer	O
drug	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
present	O
invention	O
provides	O
conjugates	O
comprising	O
a	O
toxin	O
moiety	O
(	O
e.g.	O
,	O
a	O
chlorotoxin	O
moiety	O
)	O
and	O
a	O
nucleic	O
acid	O
agent	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treatment	O
involving	O
administration	O
of	O
such	O
conjugates	O
,	O
and	O
pharmaceutical	O
compositions	O
and	O
kits	O
useful	O
for	O
carrying	O
out	O
such	O
methods	O
of	O
treatment	O
.	O

Chlorotoxins	O
as	O
drug	O
carriers	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
benzophenanthridine	B
alkaloids	I
,	O
benzofuran	B
compounds	O
and	O
catechin	B
polyphenols	B
,	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
infections	O
of	O
the	O
oral	O
cavity	O
.	O

Compositions	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
infections	O
of	O
the	O
oral	O
cavity	O

This	O
invention	O
relates	O
to	O
novel	O
calcimimetic	B
compounds	O
,	O
their	O
derivatives	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
and	O
hydrates	B
thereof	O
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
binding	O
to	O
,	O
and	O
modulating	O
the	O
sensitivity	O
of	O
,	O
calcium	B
receptors	O
on	O
the	O
parathyroid	O
gland	O
.	O

Pharmaceutical	O
Calcimimetics	B

Omega-3	B
fatty	I
acid	I
compositions	O
comprising	O
eicosapentaenoic	B
acid	I
(	O
EPA	B
)	O
and	O
docosahexaenoic	B
acid	I
(	O
DHA	B
)	O
are	O
provided	O
,	O
where	O
the	O
compositions	O
are	O
useful	O
for	O
treating	O
,	O
reducing	O
the	O
occurrence	O
of	O
,	O
or	O
preventing	O
major	O
adverse	O
cardiovascular	O
events	O
or	O
major	O
coronary	O
events	O
in	O
patients	O
who	O
have	O
established	O
cardiovascular	O
disease	O
without	O
prior	O
myocardial	O
infarction	O
,	O
preventing	O
their	O
further	O
progression	O
,	O
and	O
treating	O
underlying	O
risk	O
factors	O
for	O
CVD	O
such	O
as	O
hypertension	O
,	O
dyslipidemia	O
,	O
obesity	O
and/or	O
diabetes	O
.	O

Treatment	O
and	O
Prevention	O
of	O
Major	O
Adverse	O
Cardiovascular	O
Events	O
or	O
Major	O
Coronary	O
Events	O
by	O
Administering	O
Omega-3	B
Fatty	I
Acids	I

The	O
present	O
invention	O
provides	O
azole	B
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
,	O
methods	O
of	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
their	O
use	O
in	O
treating	O
human	O
or	O
animal	O
disorders	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
can	O
be	O
useful	O
as	O
inhibitors	O
of	O
protein	O
tyrosine	O
phosphatases	O
and	O
thus	O
can	O
be	O
useful	O
for	O
the	O
management	O
,	O
treatment	O
,	O
control	O
,	O
or	O
the	O
adjunct	O
treatment	O
of	O
diseases	O
mediated	O
by	O
PTPase	O
activity	O
.	O

Such	O
diseases	O
include	O
Type	O
I	O
diabetes	O
and	O
Type	O
II	O
diabetes	O
.	O

Substituted	O
Azole	B
Derivatives	O
,	O
Compositions	O
,	O
and	O
Methods	O
of	O
Use	O

Antisense	O
compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
MyD88	O
.	O

The	O
compositions	O
comprise	O
antisense	O
compounds	O
,	O
particularly	O
antisense	O
oligonucleotides	B
,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
MyD88	O
.	O

Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
MyD88	O
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
MyD88	O
are	O
provided	O
.	O

Modification	O
of	O
myd88	O
splicing	O
using	O
modified	O
oligonucleotides	B

Disclosed	O
is	O
a	O
diagnosis	O
or	O
treatment	O
method	O
which	O
utilizes	O
the	O
content	O
of	O
a	O
specific	O
fatty	B
acid	I
in	O
plasma	O
as	O
a	O
marker	O
that	O
reflects	O
the	O
condition	O
of	O
NASH	O
or	O
NAFLD	O
,	O
or	O
utilizes	O
the	O
above	O
-	O
mentioned	O
content	O
in	O
combination	O
with	O
another	O
test	O
,	O
another	O
marker	O
or	O
the	O
like	O
.	O

Diagnosis	O
and	O
treatment	O
of	O
hepatic	O
disorder	O

The	O
present	O
invention	O
describes	O
novel	O
methods	O
for	O
using	O
9-deoxy-2′,9-α	B
-	I
methano-3-oxa-4,5,6-trinor-3,7-	I
(	I
1′,3′-interphenylene	I
)	I
-13,14-dihydro	I
-	I
prostaglandin	I
F1	I
(	O
also	O
known	O
as	O
Treprostinil	B
)	O
or	O
its	O
derivative	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
foot	O
ulcers	O
in	O
subjects	O
with	O
diabetic	O
neuropathy	O
.	O

The	O
invention	O
also	O
relates	O
to	O
kits	O
for	O
treatment	O
and/or	O
prevention	O
of	O
foot	O
ulcers	O
,	O
comprising	O
an	O
effective	O
amount	O
of	O
Treprostinil	B
or	O
its	O
derivative	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Use	O
of	O
Treprostinil	B
to	O
treat	O
neuropathic	O
diabetic	O
foot	O
ulcers	O

A	O
method	O
,	O
computer	O
-	O
readable	O
medium	O
,	O
and	O
system	O
for	O
identifying	O
compounds	O
from	O
chemical	O
libraries	O
that	O
can	O
be	O
used	O
for	O
the	O
therapeutic	O
treatment	O
of	O
a	O
disease	O
or	O
used	O
as	O
lead	O
compounds	O
in	O
a	O
drug	O
development	O
program	O
.	O

In	O
particular	O
,	O
information	O
from	O
homologous	O
proteins	O
is	O
used	O
to	O
predict	O
,	O
for	O
a	O
target	O
protein	O
,	O
molecular	O
functions	O
that	O
can	O
be	O
used	O
to	O
screen	O
libraries	O
of	O
compounds	O
for	O
individual	O
compounds	O
that	O
are	O
predicted	O
to	O
have	O
high	O
binding	O
affinities	O
for	O
the	O
target	O
protein	O
.	O

Elucidating	O
ligand	O
-	O
binding	O
information	O
based	O
on	O
protein	O
templates	O

A	O
method	O
of	O
administering	O
an	O
antibiotic	O
to	O
an	O
animal	O
in	O
need	O
thereof	O
,	O
including	O
the	O
step	O
of	O
injecting	O
the	O
antibiotic	O
subcutaneously	O
at	O
the	O
junction	O
of	O
a	O
pinna	O
with	O
the	O
cranium	O
of	O
the	O
animal	O
,	O
is	O
disclosed	O
.	O

Method	O
of	O
administering	O
an	O
injectable	O
antibiotic	O
to	O
an	O
animal	O

The	O
invention	O
relates	O
to	O
a	O
topical	O
composition	O
and	O
a	O
method	O
for	O
treating	O
psoriasis	O
.	O

The	O
topical	O
composition	O
comprises	O
one	O
or	O
more	O
compound	O
that	O
inhibits	O
the	O
production	O
of	O
IL-12	O
and	O
IL-23	O
.	O

Topical	O
formulations	O
for	O
the	O
treatment	O
of	O
psoriasis	O

The	O
present	O
invention	O
provides	O
compounds	O
according	O
to	O
Formulas	O
I	O
,	O
II	O
,	O
III	O
,	O
IV	O
,	O
V	O
,	O
VI	O
,	O
VII	O
or	O
VIII	O
:	O
their	O
use	O
as	O
H3	O
antagonists	O
/	O
inverse	O
agonists	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

Substituted	O
Pyridazinone	B
Derivatives	O
as	O
Histamine-3	B
(	O
H3	O
)	O
Receptor	O
Ligands	O

This	O
invention	O
is	O
directed	O
to	O
compounds	O
,	O
which	O
are	O
PDE10A	O
enzyme	O
inhibitors	O
.	O

The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
formula	O
I.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
neurodegenerative	O
disorder	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I.	O
The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
psychiatric	O
disorder	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I.	O
(	O
3-aryl	B
-	I
piperazin-1-yl	I
)	O
,	O
(	O
2-aryl	B
-	I
morpholin-4-yl	I
)	O
and	O
(	O
2-aryl	B
-	I
thiomorpholin-4-yl	I
)	O
derivatives	O
of	O
6,7-dialkoxy	B
-	I
quinazoline	I
,	O
6,7-dialkoxyphtalazine	B
and	O
6,7-dialkoxyisoquinoline	B

The	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
treating	O
organ	O
specific	O
infections	O
in	O
a	O
host	O
organism	O
by	O
administering	O
compounds	O
that	O
target	O
host	O
receptors	O
and/or	O
host	O
cellular	O
signaling	O
molecules	O
to	O
prevent	O
a	O
pathogen	O
from	O
infecting	O
the	O
organ	O
.	O

For	O
example	O
,	O
the	O
administration	O
of	O
a	O
compound	O
to	O
prevent	O
a	O
pathogen	O
from	O
crossing	O
the	O
blood	O
-	O
brain	O
barrier	O
to	O
prevent	O
a	O
brain	O
infection	O
.	O

Methods	O
for	O
treating	O
or	O
preventing	O
brain	O
infections	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
modulating	O
the	O
uptake	O
and/or	O
clearance	O
of	O
cells	O
with	O
a	O
disrupted	O
cell	O
membrane	O
,	O
cells	O
infected	O
with	O
a	O
pathogen	O
,	O
dying	O
cells	O
or	O
dead	O
cells	O
,	O
or	O
a	O
portion	O
thereof	O
,	O
which	O
can	O
be	O
used	O
to	O
treat	O
and/or	O
prevent	O
diseases	O
such	O
as	O
cancer	O
,	O
autoimmunity	O
and	O
infections	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
modulating	O
antigen	O
recognition	O
,	O
processing	O
and/or	O
presentation	O
,	O
as	O
well	O
as	O
immune	O
responses	O
to	O
material	O
derived	O
from	O
cells	O
with	O
a	O
disrupted	O
cell	O
membrane	O
,	O
cells	O
infected	O
with	O
a	O
pathogen	O
,	O
dying	O
cells	O
or	O
dead	O
cells	O
,	O
or	O
a	O
portion	O
thereof	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
detecting	O
cells	O
with	O
a	O
disrupted	O
cell	O
membrane	O
,	O
cells	O
infected	O
with	O
a	O
pathogen	O
,	O
dying	O
cells	O
or	O
dead	O
cells	O
,	O
or	O
a	O
portion	O
thereof	O
.	O

Methods	O
of	O
Detecting	O
Cells	O
with	O
a	O
Disrupted	O
Cell	O
Membrane	O
,	O
Cells	O
Infected	O
with	O
A	O
Pathogen	O
,	O
Dying	O
Cells	O
or	O
Dead	O
Cells	O

Methods	O
for	O
modulating	O
the	O
level	O
of	O
a	O
chemokine	O
in	O
a	O
cell	O
by	O
administering	O
to	O
a	O
cell	O
an	O
effective	O
amount	O
of	O
a	O
depside	O
or	O
an	O
anthocyanin	O
are	O
provided	O
.	O

More	O
particularly	O
,	O
a	O
method	O
for	O
modulating	O
the	O
level	O
of	O
a	O
chemokine	O
in	O
a	O
cell	O
by	O
administering	O
to	O
a	O
cell	O
an	O
effective	O
amount	O
of	O
a	O
depside	O
having	O
the	O
structure	O
of	O
formula	O
(	O
IV	O
)	O
:	O
Formula	O
(	O
IV	O
)	O
wherein	O
R	O
is	O
selected	O
from	O
H	O
or	O
CH3	O
or	O
an	O
anthocyanin	O
selected	O
from	O
cyanidin	O
3-glucoside	O
,	O
delphinidin	O
3-glucoside	O
,	O
or	O
combinations	O
thereof	O
,	O
or	O
an	O
enantiomer	O
,	O
optical	O
isomer	O
,	O
diastereomer	O
,	O
N	O
-	O
oxide	O
,	O
crystalline	O
form	O
,	O
hydrate	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
provided	O
.	O

Also	O
provided	O
are	O
compounds	O
according	O
to	O
Formulas	O
I	O
-	O
IV	O
,	O
pharmaceutical	O
compositions	O
,	O
unit	O
dosage	O
forms	O
,	O
and	O
food	O
or	O
feed	O
supplements	O
containing	O
such	O
compounds	O
.	O

Methods	O
for	O
treating	O
a	O
condition	O
in	O
a	O
mammal	O
and	O
for	O
treating	O
or	O
ameliorating	O
a	O
condition	O
,	O
such	O
as	O
for	O
example	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
composition	O
containing	O
such	O
compounds	O
are	O
also	O
provided	O
.	O

Further	O
provided	O
is	O
an	O
extract	O
obtained	O
from	O
the	O
fruit	O
of	O
Myrciaria	O
cauliflora	O
containing	O
at	O
least	O
one	O
compound	O
of	O
the	O
present	O
invention	O
in	O
substantially	O
pure	O
form	O
.	O

Bioactive	O
Depside	O
and	O
Anthocyanin	O
Compounds	O
,	O
Compositions	O
,	O
and	O
Methods	O
of	O
Use	O

The	O
present	O
invention	O
relates	O
to	O
a	O
biocompatible	O
ceramic	O
material	O
comprising	O
Sr	B
,	O
Mg	B
or	O
Ba	B
doped	O
Hardystonite	B
(	O
Ca2ZnSi2O7	B
)	O
,	O
and	O
a	O
method	O
for	O
its	O
synthetic	O
preparation	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
an	O
implantable	O
medical	O
device	O
comprising	O
biocompatible	O
doped	O
Hardystonite	B
,	O
and	O
a	O
method	O
for	O
its	O
production	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
method	O
for	O
improving	O
the	O
long	O
term	O
stability	O
of	O
an	O
implantable	O
medical	O
device	O
and	O
an	O
implantable	O
drug	O
delivery	O
device	O
comprising	O
doped	O
Hardystonite	B
.	O

Further	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
comprising	O
biocompatible	O
doped	O
Hardystonite	B
in	O
the	O
regeneration	O
or	O
resurfacing	O
of	O
tissue	O
.	O

Biocompatible	O
material	O
and	O
uses	O
thereof	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
headaches	O
,	O
such	O
as	O
migraine	O
and	O
cluster	O
headaches	O
,	O
comprising	O
co	O
-	O
administration	O
of	O
a	O
first	O
therapeutic	O
component	O
comprising	O
topiramate	B
and	O
a	O
second	O
therapeutic	O
component	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
or	O
mixture	O
of	O
one	O
or	O
more	O
therapeutic	O
agents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
riboflavin	B
,	O
magnesium	B
,	O
coenzyme	B
Q10	I
,	O
petasin	B
,	O
isopetasin	B
,	O
and	O
parthenolide	B
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
increasing	O
the	O
efficacy	O
,	O
and	O
reducing	O
or	O
preventing	O
side	O
effects	O
,	O
of	O
topiramate	B
treatment	O
.	O

Compositions	O
and	O
methods	O
for	O
treating	O
headache	O

Compositions	O
and	O
methods	O
for	O
tissue	O
repair	O
are	O
provided	O
including	O
cell	O
binding	O
peptides	O
and	O
growth	O
factor	O
binding	O
peptides	O
.	O

The	O
cell	O
binding	O
peptides	O
bind	O
to	O
one	O
or	O
more	O
of	O
stem	O
cells	O
,	O
fibroblasts	O
,	O
or	O
endothelial	O
cells	O
.	O

The	O
growth	O
factor	O
binding	O
peptides	O
include	O
platelet	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
binding	O
peptides	O
and	O
growth	O
differentiation	O
factor	O
(	O
GDF	O
)	O
binding	O
peptides	O
.	O

The	O
tissue	O
for	O
repair	O
includes	O
tendon	O
,	O
muscle	O
,	O
connective	O
tissue	O
,	O
ligament	O
,	O
cardiac	O
tissue	O
,	O
vascular	O
tissue	O
,	O
or	O
dermis	O
.	O

Implantable	O
devices	O
for	O
tissue	O
repair	O
are	O
provided	O
to	O
which	O
the	O
cell	O
and	O
growth	O
factor	O
binding	O
peptides	O
are	O
attached	O
,	O
such	O
as	O
acellular	O
extracellular	O
matrix	O
having	O
attached	O
binding	O
peptide	O
.	O

Methods	O
and	O
compositions	O
for	O
soft	O
tissue	O
repair	O

A	O
method	O
of	O
delivering	O
a	O
drug	O
composition	O
comprises	O
providing	O
a	O
carrier	O
having	O
a	O
phosphatidylcholine	B
component	O
and	O
a	O
drug	O
entrapped	O
therein	O
,	O
and	O
applying	O
the	O
composition	O
to	O
the	O
skin	O
for	O
transdermal	O
delivery	O
of	O
the	O
drug	O
,	O
wherein	O
the	O
composition	O
is	O
stable	O
at	O
room	O
temperature	O
.	O

Method	O
Of	O
Delivering	O
Stable	O
Topical	O
Drug	O
Compositions	O

Provided	O
herein	O
is	O
an	O
ophthalmic	O
formulation	O
that	O
comprises	O
a	O
fine	O
particle	O
of	O
an	O
A1	O
agonist	O
in	O
an	O
aqueous	O
suspension	O
and	O
a	O
manufacturing	O
process	O
thereof	O
.	O

More	O
specifically	O
,	O
provided	O
herein	O
is	O
a	O
topically	O
applied	O
ophthalmic	O
aqueous	O
suspension	O
which	O
is	O
obtainable	O
by	O
suspending	O
a	O
fine	O
particle	O
of	O
an	O
A1	O
agonist	O
in	O
a	O
surfactant	O
and	O
preservative	O
;	O
a	O
method	O
of	O
reduction	O
of	O
intraocular	O
pressure	O
using	O
the	O
formulation	O
and	O
a	O
manufacturing	O
process	O
of	O
the	O
aqueous	O
suspension	O
thereof	O
.	O

Ophthalmic	O
formulation	O
and	O
method	O
of	O
manufacture	O
thereof	O

According	O
to	O
an	O
aspect	O
of	O
the	O
present	O
invention	O
,	O
a	O
medical	O
article	O
is	O
provided	O
which	O
comprises	O
a	O
latex	O
antimicrobial	O
region	O
.	O

The	O
latex	O
antimicrobial	O
region	O
can	O
constitute	O
the	O
entirety	O
of	O
the	O
medical	O
article	O
,	O
or	O
it	O
can	O
constitute	O
only	O
a	O
portion	O
of	O
the	O
medical	O
article	O
.	O

The	O
latex	O
antimicrobial	O
region	O
comprises	O
release	O
-	O
modulating	O
microparticles	O
,	O
which	O
are	O
dispersed	O
within	O
a	O
latex	O
polymer	O
.	O

The	O
release	O
-	O
modulating	O
microparticles	O
further	O
comprise	O
an	O
antimicrobial	O
agent	O
,	O
and	O
the	O
microparticles	O
are	O
adapted	O
to	O
release	O
the	O
antimicrobial	O
agent	O
.	O

Examples	O
of	O
medical	O
articles	O
that	O
can	O
be	O
produced	O
in	O
accordance	O
with	O
the	O
present	O
invention	O
are	O
gloves	O
,	O
finger	O
cots	O
,	O
supply	O
and	O
drainage	O
tubes	O
,	O
catheters	O
,	O
condoms	O
,	O
and	O
contraceptive	O
diaphragms	O
.	O

Also	O
described	O
are	O
methods	O
for	O
forming	O
such	O
articles	O
.	O

Latex	O
medical	O
articles	O
for	O
release	O
of	O
antimicrobial	O
agents	O

This	O
invention	O
effects	O
a	O
change	O
in	O
the	O
accommodation	O
of	O
the	O
human	O
lens	O
affected	O
by	O
presbyopia	O
through	O
the	O
use	O
of	O
various	O
reducing	O
agents	O
that	O
change	O
accommodative	O
abilities	O
of	O
the	O
human	O
lens	O
,	O
and/or	O
by	O
applying	O
energy	O
to	O
affect	O
a	O
change	O
in	O
the	O
accommodative	O
abilities	O
of	O
the	O
human	O
lens	O
.	O

This	O
invention	O
both	O
prevents	O
the	O
onset	O
of	O
presbyopia	O
as	O
well	O
as	O
treats	O
it	O
.	O

By	O
breaking	O
and/or	O
preventing	O
the	O
formation	O
of	O
bonds	O
that	O
adhere	O
lens	O
fibers	O
together	O
causing	O
hardening	O
of	O
the	O
lens	O
,	O
the	O
present	O
invention	O
increases	O
the	O
elasticity	O
and	O
distensibility	O
of	O
the	O
lens	O
and/or	O
lens	O
capsule	O
.	O

Presbyopia	O
Treatment	O
by	O
Lens	O
Alteration	O

In	O
certain	O
aspects	O
,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
inducing	O
utrophin	O
expression	O
in	O
muscle	O
with	O
an	O
ActRIIB	O
protein	O
as	O
therapy	O
for	O
muscular	O
dystrophy	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
screening	O
compounds	O
that	O
modulate	O
activity	O
of	O
an	O
ActRIIB	O
protein	O
and/or	O
an	O
ActRIIB	O
ligand	O
.	O

Actriib	O
proteins	O
and	O
variants	O
and	O
uses	O
therefore	O
relating	O
to	O
utrophin	O
induction	O
for	O
muscular	O
dystrophy	O
therapy	O

The	O
present	O
invention	O
provides	O
opioid	B
formulations	O
suitable	O
for	O
long	O
-	O
term	O
delivery	O
to	O
a	O
subject	O
.	O

The	O
formulation	O
of	O
the	O
invention	O
comprises	O
an	O
opioid	B
or	O
opioid	B
derivative	O
(	O
e.g.	O
,	O
morphine	B
,	O
hydromorphone	B
,	O
fentanyl	B
or	O
a	O
fentanyl	B
congener	O
)	O
,	O
and	O
an	O
aqueous	O
solvent	O
comprising	O
a	O
low	O
molecular	O
weight	O
carboxylic	B
acid	I
(	O
e.g.	O
,	O
C2	O
-	O
4	O
,	O
C2	O
-	O
7	O
)	O
.	O

The	O
invention	O
thus	O
provides	O
for	O
formulations	O
comprising	O
morphine	B
,	O
hydromorphone	B
,	O
fentanyl	B
or	O
fentanyl	B
congeners	O
in	O
concentrations	O
significantly	O
in	O
excess	O
of	O
conventional	O
aqueous	O
formulations	O
,	O
e.g.	O
,	O
on	O
the	O
order	O
about	O
2-fold	O
to	O
about	O
10,000-fold	O
greater	O
than	O
conventional	O
formulations	O
,	O
e.g.	O
,	O
currently	O
commercially	O
available	O
formulations	O
.	O

High	O
Concentration	O
Formulations	O
of	O
Opioids	B
and	O
Opioid	B
Derivatives	O

The	O
invention	O
provides	O
methods	O
for	O
treating	O
disorders	O
associated	O
with	O
selective	O
subtype	O
modulation	O
of	O
alpha	O
2	O
adrenergic	O
receptors	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
methods	O
employing	O
well	O
-	O
defined	O
N-	B
[	I
1-	I
(	I
2	I
and/or	I
3-substituted	I
-	I
phenyl	I
)	I
-alkyl	I
]	I
-	I
(	I
4,5-dihydro-1H	I
-	I
imidazol-2-yl	I
)	I
-amines	I
and	O
pharmaceutical	O
compositions	O
thereof	O
to	O
treat	O
disorders	O
associated	O
with	O
selective	O
subtype	O
alpha	O
2	O
adrenergic	O
receptor	O
modulation	O
,	O
such	O
as	O
ocular	O
disorders	O
,	O
pain	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
motor	O
disorders	O
.	O

Selective	O
subtype	O
alpha	O
2	O
adrenergic	O
agents	O
and	O
methods	O
for	O
use	O
thereof	O

Provided	O
is	O
a	O
method	O
for	O
characterising	O
a	O
sample	O
comprising	O
nucleic	O
acid	O
derived	O
from	O
a	O
cell	O
.	O

The	O
method	O
comprises	O
determining	O
whether	O
a	O
sample	O
comprises	O
at	O
least	O
a	O
minimal	O
sequence	O
of	O
at	O
least	O
one	O
new	O
microRNA	O
(	O
miRNA	O
)	O
as	O
disclosed	O
herein	O
or	O
a	O
mammalian	O
ortholog	O
thereof	O
and	O
characterizing	O
the	O
sample	O
on	O
the	O
basis	O
of	O
the	O
presence	O
or	O
absence	O
of	O
the	O
miRNA	O
.	O

The	O
invention	O
further	O
provides	O
new	O
nucleic	O
acid	O
molecules	O
and	O
collections	O
thereof	O
and	O
their	O
use	O
in	O
therapeutic	O
and	O
diagnostic	O
applications	O
.	O

The	O
invention	O
furthermore	O
provides	O
a	O
method	O
for	O
identifying	O
a	O
miRNA	O
molecule	O
or	O
a	O
precursor	O
molecule	O
thereof	O
.	O

Nucleic	O
acid	O
molecules	O
and	O
collections	O
thereof	O
,	O
their	O
application	O
and	O
Identification	O

A	O
conjugate	O
or	O
compound	O
comprising	O
polyethyleneglycol	O
and	O
an	O
oligonucleotide	O
,	O
wherein	O
at	O
least	O
one	O
polyethyleneglycol	O
is	O
linked	O
to	O
the	O
5′-end	O
of	O
the	O
oligonucleotide	O
and	O
at	O
least	O
one	O
polyethyleneglycol	O
is	O
linked	O
to	O
the	O
3′-end	O
of	O
the	O
oligonucleotide	O
,	O
wherein	O
the	O
molecular	O
weight	O
of	O
the	O
polyethyleneglycol	O
linked	O
to	O
the	O
5′-	O
and	O
3′-end	O
of	O
the	O
oligonucleotide	O
is	O
identical	O
and	O
is	O
<	O
5000	O
Da	O
,	O
or	O
wherein	O
the	O
molecular	O
weight	O
of	O
the	O
polyethyleneglycol	O
linked	O
to	O
the	O
5′-	O
and	O
3′-end	O
of	O
the	O
oligonucleotide	O
is	O
different	O
.	O

Oligonucleotide-	O
,	O
protein	O
and/or	O
peptide	O
-	O
polymer	O
conjugates	O

The	O
present	O
invention	O
is	O
directed	O
to	O
an	O
ophthalmic	O
emulsion	O
.	O

The	O
emulsion	O
has	O
a	O
unique	O
combination	O
of	O
ingredients	O
that	O
promotes	O
the	O
stability	O
of	O
small	O
oil	O
droplets	O
within	O
the	O
emulsion	O
.	O

The	O
emulsion	O
also	O
includes	O
a	O
mucoadhesive	O
polymer	O
that	O
aid	O
in	O
delivering	O
a	O
lipid	O
to	O
the	O
ocular	O
surface	O
.	O

Ophthalmic	O
emulsion	O

A	O
method	O
for	O
determining	O
a	O
therapeutically	O
effective	O
amount	O
of	O
suramin	B
for	O
administering	O
to	O
a	O
patient	O
,	O
who	O
is	O
to	O
receive	O
a	O
cytotoxic	O
agent	O
,	O
which	O
comprises	O
the	O
steps	O
of	O
determining	O
the	O
circulating	O
suramin	B
concentration	O
in	O
the	O
patient	O
;	O
administering	O
suramin	B
,	O
if	O
required	O
,	O
to	O
establish	O
a	O
low	O
circulating	O
concentration	O
of	O
suramin	B
in	O
the	O
patient	O
of	O
below	O
about	O
200	O
μM	O
;	O
and	O
administering	O
the	O
chemotherapeutic	O
agent	O
to	O
the	O
patient	O
when	O
the	O
low	O
circulating	O
concentration	O
of	O
suramin	B
is	O
present	O
in	O
the	O
patient	O
.	O

Conveniently	O
a	O
nomogram	O
can	O
be	O
constructed	O
for	O
use	O
in	O
clinical	O
settings	O
with	O
the	O
suramin	O
.	O

Methods	O
and	O
Compositions	O
to	O
Determine	O
the	O
Chemosensitizing	O
Dose	O
of	O
Suramin	B
Used	O
in	O
Combination	O
Therapy	O

A	O
controlled	O
release	O
dosage	O
form	O
of	O
tacrolimus	B
,	O
comprising	O
a	O
solid	O
dispersion	O
of	O
tacrolimus	B
,	O
wherein	O
a	O
controlled	O
release	O
base	O
,	O
which	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
water	O
-	O
soluble	O
macromolecule	O
,	O
a	O
gum	O
base	O
,	O
and	O
a	O
membrane	O
forming	O
agent	O
and	O
does	O
not	O
form	O
the	O
solid	O
dispersion	O
of	O
tacrolimus	B
,	O
is	O
further	O
contained	O
,	O
is	O
disclosed	O
.	O

The	O
controlled	O
release	O
dosage	O
form	O
of	O
tacrolimus	B
has	O
an	O
excellent	O
controlled	O
release	O
and	O
shows	O
a	O
stable	O
blood	O
concentration	O
.	O

Controlled	O
Release	O
Dosage	O
Form	O
of	O
Tacrolimus	B

A	O
novel	O
maintenance	O
therapy	O
regime	O
/	O
regimen	O
for	O
the	O
treatment	O
of	O
acne	O
related	O
diseases	O
includes	O
administering	O
an	O
oral	O
antibiotic	O
with	O
a	O
topical	O
fixed	O
-	O
dose	O
combination	O
of	O
a	O
retinoid	B
,	O
such	O
as	O
adapalene	B
,	O
and	O
an	O
anti	O
-	O
bacterial	O
agent	O
,	O
such	O
as	O
benzoyl	B
peroxide	I
.	O

Maintenance	O
therapy	O
regime	O
/	O
regimen	O
for	O
the	O
treatment	O
of	O
acne	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
their	O
synthesis	O
,	O
and	O
their	O
use	O
as	O
CHK-1	O
inhibitors	O
.	O

6	B
substituted	I
2-	I
heterocyclylamino	I
pyrazine	I
compounds	O
as	O
chk-1	O
inhibitors	O

A	O
method	O
of	O
treating	O
at	O
least	O
one	O
symptom	O
or	O
condition	O
associated	O
with	O
but	O
not	O
limited	O
to	O
:	O
1	O
)	O
Schizophrenia	O
and	O
other	O
Psychotic	O
Disorders	O
including	O
but	O
not	O
limited	O
to	O
Psychotic	O
Disorder	O
,	O
Schizophreniform	O
Disorder	O
,	O
Schizoaffective	O
Disorder	O
,	O
Delusional	O
Disorder	O
,	O
Brief	O
Psychotic	O
Disorder	O
,	O
Shared	O
Psychotic	O
Disorder	O
,	O
and	O
Psychotic	O
Disorder	O
Due	O
to	O
a	O
General	O
Medical	O
Condition	O
and	O
2	O
)	O
Dementia	O
and	O
other	O
Cognitive	O
Disorders	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
Formula	O
I	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
.	O

In	O
another	O
aspect	O
of	O
the	O
invention	O
a	O
pharmaceutical	O
composition	O
is	O
provided	O
comprising	O
an	O
effective	O
amount	O
of	O
Formula	O
I	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
and	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
diluent	O
.	O

Method	O
of	O
treating	O
schizophrenia	O
and	O
other	O
disorders	O

The	O
invention	O
features	O
compositions	O
and	O
methods	O
that	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
neoplasia	O
(	O
e.g.	O
,	O
breast	O
cancer	O
)	O
by	O
increasing	O
DNA	O
damage	O
and	O
reducing	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
.	O

Therapeutic	O
combinations	O
for	O
use	O
in	O
neoplasia	O

This	O
invention	O
relates	O
to	O
sustained	O
release	O
formulations	O
comprising	O
silk	O
fibroin	O
biopolymer	O
and	O
adenosine	B
,	O
that	O
provide	O
for	O
sustained	O
,	O
focal	O
release	O
of	O
adenosine	B
at	O
therapeutic	O
levels	O
for	O
the	O
treatment	O
of	O
epilepsy	O
and/or	O
the	O
prevention	O
of	O
epileptogenesis	O
.	O

An	O
embodiment	O
provides	O
for	O
a	O
silk	O
-	O
based	O
,	O
adeno	B
sine	I
-	O
releasing	O
implant	O
that	O
alleviates	O
seizures	O
or	O
prevents	O
epileptogenesis	O
.	O

Another	O
embodiment	O
provides	O
for	O
a	O
method	O
of	O
treating	O
epilepsy	O
or	O
preventing	O
epileptogenesis	O
comprising	O
focally	O
administering	O
adenosine	B
in	O
a	O
sustained	O
-	O
release	O
,	O
silk	O
-	O
based	O
adenosine	B
delivery	O
system	O
.	O

Silk	O
polymer	O
-	O
based	O
adenosine	B
release	O
:	O
therapeutic	O
potential	O
for	O
epilepsy	O

Provided	O
herein	O
are	O
novel	O
ergoline	B
derivatives	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

In	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
treatment	O
,	O
prevention	O
,	O
or	O
amelioration	O
of	O
a	O
variety	O
of	O
medical	O
disorders	O
such	O
as	O
,	O
for	O
example	O
,	O
migraine	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
agonizing	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
5-HT1D	O
and	O
or	O
5-HT1B	O
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
antagonizing	O
or	O
inhibiting	O
activity	O
at	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
5-HT2B	O
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
regulating	O
serotonin	B
transport	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

Novel	O
ergoline	B
analogs	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
osmolytes	O
,	O
for	O
example	O
,	O
ectoine	B
,	O
hydroxyectoine	B
,	O
firoin	B
,	O
firoin	B
-	I
A	I
,	O
diglycerol	B
phosphate	I
,	O
cyclic	B
diphosphoglycerate	I
,	O
1,3-dimannosyl	B
-	I
di	I
-	I
myo	I
-	I
inositol	I
-	I
phosphate	I
(	O
DMIP	B
)	O
and/or	O
diinositol	B
phosphate	I
and	O
their	O
equally	O
effective	O
derivatives	O
and/or	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
,	O
for	O
the	O
combating	O
of	O
pulmonary	O
diseases	O
caused	O
by	O
the	O
effect	O
of	O
airborne	O
particles	O
and/or	O
causally	O
related	O
cardiovascular	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
dosing	O
device	O
suitable	O
for	O
inhalable	O
medicaments	O
and	O
filled	O
with	O
active	O
agent	O
,	O
the	O
atomizable	O
content	O
of	O
which	O
consisting	O
of	O
an	O
active	O
agent	O
composition	O
comprising	O
at	O
least	O
one	O
osmolyte	B
or	O
its	O
derivatives	O
and/or	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
.	O

Use	O
of	O
osmolytes	O
obtained	O
from	O
extremophilic	O
bacteria	O
for	O
the	O
production	O
of	O
inhalable	O
medicaments	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
pulmonary	O
and	O
cardiovascular	O
diseases	O
and	O
an	O
inhalation	O
device	O
comprising	O
osmolyte	B
as	O
active	O
agent	O
component	O

The	O
invention	O
provides	O
the	O
combination	O
use	O
of	O
antisense	O
oligomers	O
targeting	O
androgen	B
receptor	O
mRNA	O
and	O
androgen	B
receptor	O
binding	O
inhibitors	O
that	O
reduce	O
androgen	B
receptor	O
activity	O
for	O
the	O
treatment	O
of	O
androgen	B
receptor	O
related	O
medical	O
disorders	O
,	O
such	O
as	O
cancers	O
,	O
particularly	O
prostate	O
cancers	O
and	O
breast	O
cancers	O
.	O

Methods	O
for	O
treating	O
androgen	B
receptor	O
dependent	O
disorders	O
including	O
cancers	O

The	O
invention	O
relates	O
to	O
a	O
double	O
-	O
stranded	O
ribonucleic	O
acid	O
(	O
dsRNA	O
)	O
targeting	O
X	O
-	O
Box	O
Protein	O
1	O
(	O
XBP-1	O
)	O
,	O
and	O
methods	O
of	O
using	O
the	O
dsRNA	O
to	O
inhibit	O
expression	O
of	O
XBP-1	O
.	O

Compositions	O
and	O
Methods	O
for	O
Inhibiting	O
Expression	O
of	O
XBP-1	O
Gene	O

Methods	O
and	O
algorithms	O
for	O
modeling	O
biological	O
interaction	O
networks	O
using	O
integer	O
linear	O
programming	O
(	O
ILP	O
)	O
are	O
provided	O
.	O

Methods	O
to	O
identify	O
the	O
effect	O
of	O
a	O
drug	O
on	O
such	O
interaction	O
networks	O
are	O
also	O
provided	O
.	O

Methods	O
to	O
use	O
ILP	O
-	O
base	O
modeling	O
of	O
biological	O
interaction	O
networks	O
and	O
drug	O
effects	O
to	O
personalize	O
clinical	O
interventions	O
are	O
also	O
provided	O
.	O

Identification	O
of	O
drug	O
effects	O
on	O
signaling	O
pathways	O
using	O
integer	O
linear	O
programming	O

Methods	O
and	O
pharmaceutical	O
compositions	O
for	O
treating	O
viral	O
infections	O
,	O
by	O
administering	O
certain	O
compounds	O
in	O
therapeutically	O
effective	O
amounts	O
are	O
disclosed	O
.	O

Methods	O
of	O
using	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
also	O
disclosed	O
.	O

In	O
particular	O
,	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
viral	O
infections	O
such	O
as	O
caused	O
by	O
flavivirus	O
is	O
disclosed	O
,	O
i.e.	O
,	O
including	O
but	O
not	O
limited	O
to	O
,	O
Dengue	O
virus	O
,	O
West	O
Nile	O
virus	O
,	O
yellow	O
fever	O
virus	O
,	O
Japanese	O
encephalitis	O
virus	O
,	O
and	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
.	O

Samll	O
molecule	O
inhibitors	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
dengue	O
virus	O
infection	O

Described	O
herein	O
are	O
methods	O
for	O
treating	O
obesity	O
or	O
promoting	O
weight	O
loss	O
using	O
agents	O
that	O
alter	O
pyruvate	B
flux	O
in	O
an	O
adipocyte	O
.	O

Methods	O
are	O
provided	O
for	O
administering	O
an	O
agent	O
or	O
combination	O
of	O
agents	O
to	O
an	O
obese	O
individual	O
to	O
alter	O
the	O
flux	O
of	O
pyruvate	B
in	O
an	O
adipocyte	O
.	O

Also	O
described	O
herein	O
is	O
a	O
method	O
for	O
modifying	O
triglyceride	B
storage	O
in	O
an	O
adipocyte	O
by	O
contacting	O
an	O
adipocyte	O
with	O
an	O
agent	O
or	O
combination	O
of	O
agents	O
that	O
alter	O
pyruvate	B
flux	O
.	O

Methods	O
to	O
treat	O
and	O
screen	O
for	O
agents	O
to	O
treat	O
obesity	O

3-	B
(	I
2-amino	I
-	I
ethyl	I
)	I
-5-	I
(	I
3-cyclohexyl	I
-	I
propylidene	I
)	I
-thiazolidine-2,4-dione	I
and	O
derivatives	O
thereof	O
are	O
provided	O
for	O
use	O
as	O
dual	O
inhibitors	O
of	O
the	O
Raf	O
/	O
MEK	O
/	O
ERK	O
and	O
PI3K	O
/	O
Akt	O
pathways	O
and	O
for	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

3-	B
(	I
2-amino	I
-	I
ethyl	I
)	I
-5-	I
(	I
3-cyclohexyl	I
-	I
propylidene	I
)	I
-thiazolidine-2,4-dione	I
and	O
its	O
derivatives	O
as	O
multiple	O
signaling	O
pathway	O
inhibitors	O
and	O
for	O
the	O
treatment	O
of	O
cancer	O

The	O
present	O
invention	O
embraces	O
Niemann	O
-	O
Pick	O
C1-like	O
1	O
protein	O
antagonists	O
and	O
agents	O
that	O
inhibit	O
hepatic	O
virus	O
infection	O
for	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
hepatic	O
virus	O
infection	O
.	O

Compositions	O
and	O
Methods	O
for	O
Inhibiting	O
Entry	O
of	O
a	O
Hepatic	O
Virus	O

There	O
is	O
presently	O
provided	O
methods	O
for	O
delivering	O
an	O
anti	O
-	O
fibrotic	O
or	O
anti	O
-	O
cancer	O
agent	O
to	O
a	O
cell	O
.	O

The	O
methods	O
comprise	O
contacting	O
a	O
cell	O
with	O
an	O
effective	O
amount	O
of	O
imidazolium	B
and	O
imidazolinium	B
compounds	O
as	O
described	O
herein	O
,	O
including	O
imidazolium	B
and	O
imidazolinium	B
salts	O
.	O

Method	O
for	O
treating	O
fibrosis	O
and	O
cancer	O
with	O
imidazolium	B
and	O
imidazolinium	B
compounds	O

Described	O
are	O
methods	O
for	O
treating	O
cancers	O
,	O
e.g.	O
,	O
glioblastoma	O
,	O
including	O
administering	O
an	O
inhibitor	O
of	O
Notch	O
signalling	O
,	O
e.g.	O
,	O
a	O
gamma	O
secretase	O
inhibitor	O
,	O
in	O
combination	O
with	O
a	O
chemotherapeutic	O
agent	O
.	O

Methods	O
for	O
Treating	O
Glioblastoma	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
which	O
comprises	O
administering	O
a	O
compound	O
of	O
formula	O
wherein	O
the	O
substituents	O
are	O
as	O
described	O
herein	O
or	O
a	O
pharmaceutically	O
active	O
acid	O
-	O
addition	O
salt	O
thereof	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
treating	O
both	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
through	O
dual	O
inhibition	O
of	O
NK1	O
and	O
NK3	O
receptors	O
.	O

The	O
invention	O
also	O
provides	O
novel	O
compounds	O
with	O
formula	O
I	O
and	O
methods	O
for	O
preparing	O
compounds	O
of	O
the	O
invention	O
.	O

Dual	O
nk1	O
/	O
nk3	O
receptor	O
antagonists	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
of	O
a	O
thiazolium	B
compound	O
of	O
formula	O
I	O
or	O
a	O
solvate	O
thereof	O
,	O
wherein	O
the	O
definitions	O
of	O
groups	O
in	O
the	O
formula	O
I	O
are	O
as	O
those	O
given	O
in	O
the	O
claims	O
:	O
Thiazoliums	B
and	O
Their	O
Use	O
for	O
Treating	O
Protein	O
Aging	O
Associated	O
Diseases	O

A	O
gene	O
profiling	O
signature	O
is	O
disclosed	O
herein	O
.	O

The	O
gene	O
signature	O
can	O
predict	O
whether	O
a	O
subject	O
with	O
ovarian	O
cancer	O
will	O
be	O
chemorefractory	O
,	O
chemoresistant	O
or	O
chemosensitive	O
.	O

Thus	O
,	O
methods	O
are	O
disclosed	O
for	O
determining	O
whether	O
a	O
subject	O
with	O
ovarian	O
cancer	O
is	O
sensitive	O
to	O
treatment	O
with	O
a	O
chemotherapeutic	O
agent	O
.	O

Methods	O
are	O
also	O
provided	O
for	O
increasing	O
sensitivity	O
to	O
the	O
chemotherapeutic	O
agent	O
if	O
the	O
presence	O
of	O
differential	O
expression	O
indicates	O
that	O
the	O
ovarian	O
cancer	O
has	O
a	O
decreased	O
sensitivity	O
to	O
chemotherapeutic	O
agent	O
.	O

gene	O
expression	O
profile	O
that	O
predicts	O
ovarian	O
cancer	O
subject	O
response	O
to	O
chemotherapy	O

Provided	O
are	O
compositions	O
and	O
methods	O
for	O
preventing	O
,	O
treating	O
,	O
ameliorating	O
or	O
diagnosing	O
conditions	O
or	O
diseases	O
involving	O
a	O
myeloid	O
cell	O
proliferation	O
disorder	O
.	O

Such	O
compositions	O
and	O
methods	O
target	O
miRNA	O
function	O
myeloproliferative	O
diseases	O
.	O

More	O
particularly	O
,	O
such	O
compositions	O
and	O
methods	O
target	O
miR-29a	O
function	O
in	O
myeloid	O
cell	O
proliferation	O
disorders	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
diagnosing	O
risk	O
or	O
presence	O
of	O
a	O
myeloid	O
cell	O
proliferation	O
disorder	O
in	O
a	O
subject	O
.	O

Inhibitory	O
rnas	O
that	O
regulate	O
hematopoietic	O
cells	O

The	O
present	O
invention	O
relates	O
to	O
uses	O
of	O
compounds	O
having	O
a	O
structure	O
as	O
shown	O
by	O
formula	O
(	O
I	O
)	O
for	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Moreover	O
,	O
the	O
present	O
invention	O
encompasses	O
methods	O
of	O
treatment	O
for	O
said	O
diseases	O
.	O

Griseofulvin	B
analogues	O
for	O
the	O
treatment	O
of	O
cancer	O
by	O
inhibition	O
of	O
centrosomal	O
clustering	O

Topical	O
treatments	O
for	O
neuropathy	O
are	O
described	O
.	O

The	O
treatments	O
include	O
topical	O
formulations	O
of	O
NMDA	O
antagonists	O
and	O
one	O
additional	O
active	O
ingredient	O
.	O

In	O
one	O
example	O
,	O
the	O
formulation	O
includes	O
ketamine	B
and	O
gabapentin	B
for	O
the	O
treatment	O
of	O
a	O
subject	O
's	O
neuropathy	O
.	O

These	O
transdermal	O
or	O
topical	O
compositions	O
provide	O
a	O
surprising	O
degree	O
of	O
effective	O
relief	O
from	O
the	O
symptoms	O
of	O
peripheral	O
neuropathy	O
and	O
can	O
be	O
administered	O
to	O
subjects	O
to	O
treat	O
various	O
neuropathies	O
.	O

Topical	O
formulations	O
for	O
treatment	O
of	O
neuropathy	O

The	O
subject	O
matter	O
of	O
the	O
invention	O
is	O
compounds	O
corresponding	O
to	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
:	O
R1	O
and	O
R2	O
,	O
together	O
with	O
the	O
nitrogen	B
atom	O
to	O
which	O
they	O
are	O
attached	O
,	O
constitute	O
a	O
saturated	O
heterocyclic	B
radical	I
containing	O
from	O
4	O
to	O
7	O
atoms	O
,	O
which	O
is	O
preferably	O
substituted	O
;	O
one	O
of	O
the	O
two	O
substituents	O
R3	O
and	O
R6	O
is	O
a	O
group	O
Y	O
-	O
A	O
-	O
R9	O
;	O
Y	O
is	O
an	O
oxygen	B
atom	O
or	O
an	O
—S	B
(	I
O	I
)	I
n′—	I
,	O
or	O
—OSO2	B
group	O
;	O
A	O
is	O
an	O
unsubstituted	O
(	B
C1-C4	I
)	I
alkylene	I
group	O
;	O
R9	O
is	O
an	O
—OR19	B
,	O
—CH3	B
,	O
—NR19R20	B
,	O
—CONR19R20	O
,	O
—NR15COR19	B
,	O
—S	B
(	I
O	I
)	I
nR21	I
,	O
or	O
—NR13SO2R21	B
group	O
;	O
—R10	O
is	O
a	O
hydrogen	B
atom	O
or	O
a	O
(	B
C1-C4	I
)	I
alkyl	I
group	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
methods	O
of	O
preparation	O
and	O
the	O
therapeutic	O
uses	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

Thiophene-2-carboxamide	B
derivatives	O
,	O
preparation	O
thereof	O
and	O
therapeutic	O
use	O
thereof	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
drug	O
Eltoprazine	O
for	O
combating	O
dyskinesias	O
arising	O
from	O
chronic	O
Levodopa	O
(	O
L	O
-	O
DOPA	O
)	O
therapy	O
in	O
patients	O
suffering	O
from	O
Parkinson	O
's	O
disease	O
.	O

Eltoprazine	O
for	O
suppression	O
of	O
l	O
-	O
dopa	O
induced	O
dyskinesias	O

The	O
invention	O
relates	O
to	O
substituted	O
pyridines	B
and	O
to	O
processes	O
for	O
preparation	O
thereof	O
,	O
and	O
to	O
the	O
use	O
thereof	O
for	O
production	O
of	O
medicaments	O
for	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
especially	O
of	O
haematological	O
disorders	O
,	O
preferably	O
of	O
leukopenia	O
and	O
neutropenia	O
.	O

Substituted	O
pyridines	B
,	O
and	O
use	O
thereof	O
as	O
Gsk3	O
inhibitors	O

Embodiments	O
of	O
the	O
present	O
invention	O
provide	O
compounds	O
(	O
such	O
as	O
Formula	O
(	O
I	O
)	O
compounds	O
,	O
Formula	O
(	O
II	O
)	O
compounds	O
,	O
and	O
various	O
embodiments	O
thereof	O
)	O
.	O

Compositions	O
comprising	O
those	O
compounds	O
are	O
also	O
provided	O
.	O

Methods	O
for	O
their	O
preparation	O
are	O
included	O
.	O

Also	O
,	O
uses	O
of	O
the	O
compounds	O
are	O
included	O
,	O
such	O
as	O
administering	O
and	O
treating	O
diseases	O
(	O
e.g.	O
,	O
cancer	O
and	O
infections	O
)	O
.	O

Compounds	O
,	O
their	O
syntheses	O
,	O
and	O
thier	O
uses	O

The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
the	O
coat	O
of	O
an	O
animal	O
.	O

The	O
method	O
includes	O
the	O
steps	O
of	O
applying	O
a	O
composition	O
to	O
the	O
coat	O
of	O
the	O
animal	O
,	O
diffusing	O
the	O
composition	O
by	O
action	O
of	O
a	O
carrier	O
,	O
storing	O
the	O
active	O
ingredients	O
of	O
the	O
composition	O
by	O
the	O
sebaceous	O
glands	O
of	O
the	O
animal	O
,	O
and	O
gradually	O
releasing	O
the	O
active	O
ingredients	O
from	O
the	O
sebaceous	O
glands	O
.	O

The	O
dermo	O
-	O
cosmetic	O
composition	O
includes	O
a	O
diffusion	O
solvent	O
vehicle	O
that	O
enables	O
,	O
by	O
a	O
simple	O
application	O
to	O
one	O
or	O
more	O
points	O
of	O
the	O
cutaneous	O
surface	O
,	O
a	O
diffusion	O
over	O
the	O
entirety	O
thereof	O
and	O
at	O
the	O
level	O
of	O
the	O
sebaceous	O
glands	O
.	O

The	O
active	O
ingredients	O
,	O
primarily	O
including	O
a	O
complex	O
of	O
essential	O
oils	O
and	O
of	O
polyunsaturated	O
fatty	B
acids	I
,	O
stored	O
in	O
these	O
sebaceous	O
glands	O
can	O
be	O
salted	O
out	O
progressively	O
with	O
the	O
sebum	O
product	O
to	O
the	O
surface	O
of	O
the	O
skin	O
.	O

Dermo	O
-	O
cosmetic	O
composition	O
for	O
pets	O

A	O
method	O
of	O
treating	O
inflammation	O
and	O
joint	O
deterioration	O
in	O
mammals	O
includes	O
administering	O
a	O
therapeutically	O
effective	O
dose	O
of	O
alpha	O
1A	O
receptor	O
antagonists	O
alone	O
or	O
in	O
combination	O
with	O
a	O
beta	O
2	O
adrenergic	O
antagonists	O
or	O
beta	O
2	O
adrenergic	O
antagonists	O
and	O
beta	O
2	O
adrenergic	O
agonists	O
.	O

Methods	O
of	O
treating	O
inflammatory	O
conditions	O
with	O
adrenergic	O
antagonists	O

A	O
method	O
of	O
treating	O
a	O
lysosomal	O
storage	O
disease	O
comprises	O
administering	O
a	O
pyrimethamine	B
derivative	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

Compounds	O
for	O
the	O
treatment	O
of	O
lysosomal	O
storage	O
diseases	O

A	O
thermosensitive	O
liposome	O
for	O
the	O
delivery	O
of	O
active	O
agents	O
and	O
a	O
composition	O
thereof	O
are	O
disclosed	O
,	O
wherein	O
the	O
liposome	O
comprises	O
at	O
least	O
one	O
phosphatidylcholine	B
,	O
at	O
least	O
one	O
phosphatidylglycerol	B
and	O
at	O
least	O
one	O
lysolipid	O
,	O
and	O
the	O
gel	O
to	O
liquid	O
phase	O
transition	O
temperature	O
of	O
said	O
liposome	O
is	O
from	O
39	O
0	O
°	O
C.	O
to	O
45	O
°	O
C.	O
Novel	O
Thermosensitive	O
Liposomes	O
Containing	O
Therapeutic	O
Agents	O

The	O
invention	O
provides	O
a	O
nanoparticle	O
composition	O
that	O
is	O
decorated	O
with	O
a	O
urea	O
-	O
based	O
small	O
-	O
molecule	O
peptidomimetic	O
inhibitor	O
of	O
prostate	O
specific	O
membrane	O
antigen	O
(	O
PSMA	O
)	O
,	O
which	O
is	O
expressed	O
by	O
almost	O
all	O
solid	O
tumors	O
.	O

This	O
strategy	O
takes	O
advantage	O
of	O
both	O
the	O
avidity	O
of	O
the	O
functionalized	O
nanoparticle	O
for	O
binding	O
to	O
PSMA	O
and	O
the	O
ability	O
of	O
the	O
nanoparticle	O
to	O
be	O
retained	O
for	O
longer	O
periods	O
of	O
time	O
in	O
the	O
tumor	O
due	O
to	O
enhanced	O
leakage	O
via	O
EPR	O
into	O
the	O
tumor	O
interstitium	O
and	O
poor	O
clearance	O
due	O
to	O
underdeveloped	O
or	O
non	O
-	O
existent	O
lymphatics	O
within	O
the	O
tumor	O
.	O

Prostate	O
specific	O
membrane	O
antigen	O
(	O
psma	O
)	O
targeted	O
nanoparticles	O
for	O
therapy	O
of	O
prostate	O
cancer	O

A	O
stable	O
freeze	O
-	O
dried	O
powder	O
preparation	O
of	O
tetrodotoxin	B
and	O
the	O
producing	O
method	O
thereof	O
.	O

The	O
freeze	O
-	O
dried	O
powder	O
preparation	O
has	O
tetrodotoxin	B
as	O
the	O
main	O
active	O
ingredient	O
,	O
and	O
comprises	O
solubilizer	O
,	O
excipient	O
and	O
stabilizer	O
.	O

The	O
said	O
solubilizer	O
is	O
citric	B
acid	I
.	O

The	O
excipient	O
is	O
sodium	B
chloride	I
,	O
mannitol	B
or	O
their	O
composite	O
.	O

The	O
stabilizer	O
is	O
dextran	O
,	O
trehalose	B
or	O
their	O
composite	O
.	O

The	O
ratio	O
of	O
tetrodotoxin	B
,	O
excipient	O
and	O
stabilizer	O
is	O
1:150	O
-	O
3000:50	O
-	O
500	O
or	O
50	O
-	O
6000	O
.	O

Preferably	O
,	O
the	O
preparation	O
comprises	O
lidocaine	B
hydrochloride	I
as	O
function	O
modulator	O
.	O

The	O
preparation	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
for	O
avoiding	O
the	O
dependent	O
abstinence	O
syndrome	O
of	O
drugs	O
such	O
as	O
opiates	B
and	O
cannabis	O
.	O

Freeze	O
-	O
dried	O
reparation	O
of	O
tetrodotoxin	B
and	O
the	O
producing	O
method	O
thereof	O

Disclosed	O
herein	O
is	O
a	O
driver	O
gene	O
signature	O
for	O
predicting	O
survival	O
in	O
patients	O
with	O
solid	O
tumors	O
,	O
such	O
as	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
and	O
breast	O
cancer	O
.	O

The	O
gene	O
signature	O
includes	O
ten	O
tumor	O
-	O
associated	O
genes	O
,	O
SH2D4A	O
,	O
CCDC25	O
,	O
ELP3	O
,	O
DLC1	O
,	O
PROSC	O
,	O
SORBS3	O
,	O
HNRPD	O
,	O
PAQR3	O
,	O
PHF17	O
and	O
DCK	O
.	O

A	O
decrease	O
in	O
DNA	O
copy	O
number	O
or	O
mRNA	O
expression	O
of	O
SH2D4A	O
,	O
CCDC25	O
,	O
ELP3	O
,	O
DLC1	O
,	O
PROSC	O
and	O
SORBS3	O
in	O
solid	O
tumors	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
,	O
while	O
a	O
decrease	O
in	O
DNA	O
copy	O
number	O
or	O
mRNA	O
expression	O
of	O
HNRPD	O
,	O
PAQR3	O
,	O
PHF17	O
and	O
DCK	O
in	O
solid	O
tumors	O
is	O
associated	O
with	O
a	O
good	O
prognosis	O
.	O

Thus	O
,	O
provided	O
herein	O
is	O
a	O
method	O
of	O
predicting	O
the	O
prognosis	O
of	O
a	O
patient	O
diagnosed	O
with	O
HCC	O
or	O
breast	O
cancer	O
by	O
detecting	O
expression	O
of	O
one	O
of	O
more	O
tumor	O
-	O
associated	O
genes	O
in	O
a	O
tumor	O
sample	O
and	O
comparing	O
expression	O
of	O
the	O
one	O
or	O
more	O
tumor	O
-	O
associated	O
genes	O
in	O
the	O
tumor	O
sample	O
to	O
a	O
control	O
.	O

Also	O
provided	O
is	O
a	O
method	O
of	O
treating	O
a	O
patient	O
diagnosed	O
with	O
HCC	O
or	O
breast	O
cancer	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
that	O
alters	O
expression	O
or	O
activity	O
of	O
one	O
or	O
more	O
of	O
the	O
disclosed	O
tumor	O
-	O
associated	O
genes	O
.	O

Further	O
provided	O
are	O
arrays	O
comprising	O
probes	O
or	O
antibodies	O
specific	O
for	O
a	O
plurality	O
of	O
tumor	O
-	O
associated	O
genes	O
or	O
proteins	O
.	O

Gene	O
signature	O
for	O
predicting	O
prognosis	O
of	O
patients	O
with	O
solid	O
tumors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
nutritional	O
composition	O
for	O
infants	O
and/or	O
toddlers	O
comprising	O
a	O
lipid	O
component	O
which	O
has	O
a	O
large	O
lipid	O
globule	O
size	O
.	O

The	O
composition	O
can	O
be	O
used	O
to	O
prevent	O
obesity	O
and/or	O
improve	O
body	O
composition	O
later	O
in	O
life	O
.	O

Said	O
lipid	O
component	O
comprises	O
10	O
-	O
50	O
wt	O
%	O
vegetable	O
lipids	O
,	O
and	O
the	O
lipid	O
globules	O
have	O
a	O
volume	O
-	O
weighted	O
diameter	O
above	O
1.0	O
m	O
and/or	O
a	O
diameter	O
of	O
2	O
-	O
12	O
m	O
in	O
an	O
amount	O
of	O
at	O
least	O
45	O
vol	O
%	O
.	O

Nutritional	O
compositions	O
with	O
lipid	O
globules	O
with	O
a	O
core	O
comprising	O
vegetable	O
lipids	O
and	O
a	O
coating	O
comprising	O
phospholipids	O
or	O
polar	O
lipids	O

Certain	B
biphenyl	I
compounds	O
are	O
serotonin	B
modulators	O
useful	O
in	O
the	O
treatment	O
of	O
serotonin	B
-	O
mediated	O
diseases	O
.	O

Modulators	O
of	O
serotonin	B
receptor	O

The	O
present	O
invention	O
is	O
directed	O
to	O
disubstituted	O
azepan	B
and	O
oxazepan	B
amide	I
compounds	O
which	O
are	O
antagonists	O
of	O
orexin	O
receptors	O
,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
neurological	O
and	O
psychiatric	O
disorders	O
and	O
diseases	O
in	O
which	O
orexin	O
receptors	O
are	O
involved	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
orexin	O
receptors	O
are	O
involved	O
.	O

Disubstituted	O
Azepan	B
Orexin	O
Receptor	O
Antagonists	O

A	O
series	O
of	O
novel	O
anthra	B
[	I
1,2-d	I
]	I
imidazole-6,11-dione	I
derivatives	O
,	O
and	O
the	O
preparation	O
method	O
and	O
application	O
of	O
said	O
derivatives	O
,	O
wherein	O
said	O
application	O
includes	O
a	O
pharmaceutical	O
composition	O
containing	O
said	O
derivatives	O
for	O
treating	O
cancer	O
,	O
and	O
said	O
application	O
involves	O
effects	O
of	O
said	O
derivatives	O
for	O
inhibiting	O
telomerase	O
activity	O
,	O
inhibiting	O
the	O
growth	O
of	O
cancer	O
cell	O
,	O
treating	O
cancer	O
and	O
the	O
like	O
.	O

Novel	O
Anthra	B
[	I
1	I
,	I
2-d	I
]	I
imidazole-6,11-dione	I
Derivatives	O
,	O
Preparation	O
Method	O
and	O
application	O
thereof	O

This	O
invention	O
relates	O
to	O
novel	O
4-	B
(	I
indazolyl	I
)	I
-1,4-dihydropyridine	I
og	O
the	O
following	O
formula	O
(	O
I	O
)	O
derivatives	O
having	O
protein	O
tyrosine	B
kinase	O
inhibitory	O
activity	O
,	O
to	O
a	O
process	O
for	O
the	O
manufacture	O
thereof	O
and	O
to	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
c	O
-	O
Met	O
-	O
mediated	O
diseases	O
or	O
c	O
-	O
Met	O
-	O
mediated	O
conditions	O
,	O
particularly	O
cancer	O
and	O
other	O
proliferative	O
disorders	O
.	O

Substituted	O
4-	B
(	I
indazolyl	I
)	I
-1,4-dihydropyridines	I
and	O
methods	O
of	O
use	O
thereof	O

Novel	O
compounds	O
having	O
a	O
fused	B
bicyclic	I
heteroaromatic	I
ring	O
system	O
substituted	O
with	O
a	O
thiazole	B
ring	O
are	O
disclosed	O
.	O

The	O
compounds	O
inhibit	O
growth	O
of	O
a	O
variety	O
of	O
types	O
of	O
cancer	O
cells	O
,	O
and	O
are	O
thus	O
useful	O
for	O
treating	O
cancer	O
.	O

Efficacy	O
of	O
these	O
compounds	O
is	O
demonstrated	O
with	O
a	O
system	O
for	O
monitoring	O
cell	O
growth	O
/	O
migration	O
,	O
which	O
shows	O
they	O
are	O
potent	O
inhibitors	O
of	O
growth	O
and/or	O
migration	O
of	O
cancer	O
cells	O
.	O

In	O
addition	O
,	O
compounds	O
of	O
the	O
invention	O
were	O
shown	O
to	O
stop	O
growth	O
of	O
tumors	O
in	O
vivo	O
,	O
and	O
to	O
reduce	O
the	O
size	O
of	O
tumors	O
in	O
vivo	O
.	O

Compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
methods	O
to	O
use	O
these	O
compounds	O
and	O
compositions	O
for	O
treatment	O
of	O
cancers	O
,	O
are	O
disclosed	O
.	O

Heterocyclic	B
compounds	O
and	O
uses	O
as	O
anticancer	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
,	O
use	O
and	O
a	O
method	O
for	O
reducing	O
inflammation	O
and	O
promoting	O
tissue	O
repair	O
or	O
tissue	O
regeneration	O
through	O
a	O
synergistic	O
effect	O
of	O
T	O
-	O
ChOS	O
and	O
Glucosamine	B
and/or	O
N	B
-	I
acetyl	I
glucosamine	I
systemically	O
or	O
locally	O
administered	O
in	O
humans	O
and	O
other	O
mammals	O
in	O
need	O
thereof	O
.	O

Composition	O
for	O
treating	O
autoimmune	O
disorders	O

The	O
present	O
invention	O
provides	O
a	O
Cinnamomum	O
subavenium	O
extract	O
for	O
inhibiting	O
melanogenesis	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
composition	O
for	O
inhibiting	O
melanogenesis	O
including	O
compounds	O
inhibit	O
tyrosinase	O
activity	O
.	O

Composition	O
for	O
Inhibiting	O
Melanogenesis	O
and	O
Use	O
Thereof	O

The	O
present	O
invention	O
relates	O
to	O
mixtures	O
of	O
polysaccharides	O
derived	O
from	O
heparin	O
having	O
a	O
mean	O
molecular	O
weight	O
of	O
1500	O
to	O
3000	O
Daltons	O
and	O
an	O
anti	O
-	O
Xa	O
/	O
anti	O
-	O
IIa	O
ratio	O
greater	O
than	O
30	O
,	O
their	O
method	O
of	O
preparation	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Mixtures	O
of	O
polysaccharides	O
derived	O
from	O
heparin	O
,	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O

Provided	O
are	O
effective	O
and	O
highly	O
safe	O
agents	O
,	O
medicaments	O
and	O
the	O
like	O
for	O
ameliorating	O
various	O
disorders	O
caused	O
by	O
brain	O
hypofunction	O
.	O

Also	O
provided	O
is	O
a	O
preventing	O
or	O
ameliorating	O
agent	O
for	O
brain	O
hypofunction	O
containing	O
N	B
-	I
acetyl	I
-	I
D	I
-	I
mannosamine	I
,	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
disorders	O
due	O
to	O
brain	O
hypofunction	O
,	O
containing	O
an	O
effective	O
amount	O
of	O
N	B
-	I
acetyl	I
-	I
D	I
-	I
mannosamine	I
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
and	O
a	O
food	O
comprising	O
N	B
-	I
acetyl	I
-	I
D	I
-	I
mannosamine	I
added	O
thereto	O
.	O

Agent	O
for	O
ameliorating	O
brain	O
hypofunction	O

The	O
invention	O
relates	O
to	O
novel	O
phenethylamide	B
derivatives	O
and	O
their	O
wherein	O
A	O
,	O
B	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
described	O
in	O
the	O
application	O
,	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds	O
,	O
or	O
of	O
pharmaceutically	O
acceptable	O
salts	O
of	O
such	O
compounds	O
,	O
as	O
medicaments	O
,	O
especially	O
as	O
orexin	O
receptor	O
antagonists	O
.	O

Phenethylamide	B
derivatives	O
and	O
their	O
heterocyclic	B
analogues	O

Compounds	O
having	O
drug	O
and	O
bio	O
-	O
affecting	O
properties	O
,	O
their	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
set	O
forth	O
.	O

In	O
particular	O
,	O
diketo	B
fused	I
azolopiperidine	I
and	O
azolopiperazine	B
derivatives	O
that	O
possess	O
unique	O
antiviral	O
activity	O
are	O
provided	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV	O
and	O
AIDS	O
.	O

Diketo	B
fused	I
azolopiperidines	I
and	O
azolopiperazines	B
as	O
anti	O
-	O
hiv	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
polymorph	O
of	O
moxifloxacin	B
hydrochloride	I
,	O
processes	O
for	O
its	O
preparation	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
it	O
.	O

Thus	O
,	O
for	O
example	O
moxifloxacin	B
hydrochloride	I
is	O
suspended	O
in	O
methanol	B
and	O
water	O
and	O
the	O
pH	O
is	O
adjusted	O
to	O
1.0	O
-	O
2.0	O
with	O
concentrated	O
hydrochloric	B
acid	I
at	O
25	O
°	O
C.	O
and	O
the	O
separated	O
solid	O
is	O
collected	O
and	O
dried	O
to	O
obtain	O
moxifloxacin	B
hydrochloride	I
monohydrate	I
polymorph	O
IV	O
.	O

Novel	O
polymorph	O
of	O
moxifloxacin	B
hydrochloride	I

The	O
present	O
invention	O
provides	O
novel	O
topically	O
-	O
applied	O
skin	O
and	O
face	O
coating	O
and	O
paint	O
compositions	O
comprising	O
near	O
infrared	O
reflecting	O
pigments	O
and	O
hydrogels	O
swollen	O
with	O
aqueous	O
solution	O
and/or	O
with	O
simulated	O
sweat	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
of	O
making	O
and	O
using	O
the	O
compositions	O
.	O

The	O
novel	O
compositions	O
protect	O
the	O
skin	O
of	O
the	O
wearer	O
from	O
damage	O
due	O
to	O
intense	O
external	O
heat	O
or	O
thermal	O
flux	O
and	O
simultaneously	O
divert	O
thermal	O
energy	O
to	O
a	O
complementary	O
evaporative	O
cooling	O
mechanism	O
.	O

The	O
compositions	O
protect	O
skin	O
from	O
external	O
thermal	O
fluxes	O
,	O
conform	O
to	O
skin	O
chemistry	O
,	O
and	O
are	O
easy	O
to	O
apply	O
and	O
remove	O
.	O

Compositions	O
and	O
methods	O
for	O
protection	O
of	O
skin	O
against	O
thermal	O
insult	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
diagnosis	O
and	O
therapy	O
of	O
hematological	O
malignancies	O
,	O
such	O
as	O
multiple	O
myeloma	O
,	O
as	O
well	O
as	O
solid	O
tumors	O
based	O
on	O
cytokine	O
interleukin-16	B
(	O
IL-16	B
)	O
and	O
agents	O
specifically	O
targeting	O
this	O
antigen	O
or	O
cells	O
expressing	O
the	O
same	O
,	O
e.g.	O
,	O
antibodies	O
.	O

The	O
inventors	O
were	O
able	O
to	O
prove	O
that	O
IL-16	B
is	O
expressed	O
and	O
secreted	O
at	O
high	O
levels	O
by	O
myeloma	O
cells	O
.	O

Most	O
importantly	O
,	O
the	O
inventors	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
IL-16	B
supports	O
the	O
proliferation	O
of	O
the	O
malignant	O
cells	O
.	O

Therefore	O
,	O
this	O
cytokine	O
represents	O
a	O
particularly	O
advantageous	O
target	O
in	O
cancer	O
therapy	O
and	O
diagnosis	O
.	O

IL-16	B
as	O
a	O
target	O
for	O
diagnosis	O
and	O
therapy	O
of	O
hematological	O
malignancies	O
and	O
solid	O
tumors	O

Disclosed	O
is	O
a	O
controlled	O
-	O
release	O
microparticle	O
:	O
including	O
a	O
matrix	O
comprising	O
a	O
pharmacologically	O
active	O
component	O
;	O
and	O
a	O
controlled	O
-	O
release	O
layer	O
comprising	O
a	O
substance	O
which	O
forms	O
a	O
controlled	O
-	O
release	O
stratum	O
on	O
the	O
matrix	O
.	O

The	O
disclosed	O
controlled	O
-	O
release	O
microparticle	O
not	O
only	O
allows	O
effective	O
dual	O
release	O
control	O
of	O
a	O
drug	O
but	O
can	O
also	O
exhibit	O
outstanding	O
dissolution	O
characteristics	O
even	O
when	O
a	O
small	O
amount	O
of	O
coating	O
substance	O
is	O
used	O
.	O

Controlled	O
-	O
release	O
microparticles	O
and	O
method	O
of	O
preparing	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
modulating	O
a	O
selected	O
biological	O
activity	O
of	O
a	O
naturally	O
occurring	O
material	O
having	O
one	O
or	O
more	O
biological	O
activities	O
in	O
an	O
extract	O
of	O
the	O
naturally	O
occurring	O
material	O
,	O
the	O
method	O
comprising	O
incubating	O
the	O
extract	O
in	O
a	O
medium	O
in	O
the	O
presence	O
of	O
an	O
aerobically	O
metabolizing	O
microorganism	O
,	O
under	O
suitable	O
aerobic	O
conditions	O
,	O
for	O
a	O
period	O
of	O
time	O
sufficient	O
to	O
modulate	O
the	O
selected	O
activity	O
with	O
respect	O
to	O
baseline	O
activity	O
of	O
the	O
unincubated	O
extract	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
bioconverted	O
material	O
so	O
prepared	O
,	O
and	O
the	O
use	O
of	O
same	O
in	O
cosmetic	O
or	O
pharmaceutical	O
compositions	O
.	O

Method	O
of	O
Enhancing	O
Biological	O
Activity	O
of	O
Plant	O
Extracts	O

The	O
present	O
invention	O
provides	O
for	O
compounds	O
of	O
Formula	O
I	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
and	O
R7	O
have	O
any	O
of	O
the	O
values	O
defined	O
therefor	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
that	O
are	O
useful	O
as	O
therapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
TGFβ	O
-	O
mediated	O
conditions	O
,	O
including	O
cancer	O
and	O
fibrotic	O
disorders	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
compounds	O
of	O
Formula	O
I.	O
Therapeutic	O
Pyrazolyl	B
Thienopyridines	I

Compositions	O
and	O
methods	O
for	O
treating	O
and	O
preventing	O
cancer	O
,	O
particularly	O
lung	O
cancer	O
,	O
are	O
provided	O
.	O

Compositions	O
and	O
Methods	O
of	O
Treating	O
and	O
Preventing	O
Lung	O
Cancer	O

The	O
invention	O
provides	O
neuregulin	O
antagonists	O
and	O
methods	O
of	O
using	O
the	O
neuregulin	O
antagonists	O
in	O
delaying	O
the	O
time	O
to	O
tumor	O
recurrence	O
or	O
preventing	O
resistance	O
of	O
cancer	O
cells	O
to	O
treatment	O
with	O
a	O
therapeutic	O
agent	O
.	O

Neuregulin	O
antagonists	O
and	O
use	O
thereof	O
in	O
treating	O
cancer	O

There	O
is	O
provided	O
a	O
single	O
unit	O
oral	O
dose	O
pharmaceutical	O
composition	O
comprising	O
a	O
)	O
levodopa	B
or	O
salts	O
thereof	O
from	O
about	O
50	O
mg	O
to	O
about	O
300	O
mg	O
in	O
extended	O
release	O
form	O
,	O
b	O
)	O
carbidopa	B
or	O
salts	O
thereof	O
from	O
about	O
10	O
mg	O
to	O
about	O
100	O
mg	O
in	O
extended	O
release	O
and	O
c	O
)	O
entacapone	B
or	O
salts	O
thereof	O
from	O
about	O
100	O
mg	O
to	O
about	O
1000	O
mg	O
in	O
immediate	O
release	O
form	O
,	O
optionally	O
with	O
other	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

The	O
invention	O
also	O
relates	O
to	O
process	O
of	O
preparation	O
of	O
such	O
compositions	O
.	O

Single	O
Unit	O
Oral	O
Dose	O
Pharmaceutical	O
Composition	O
Comprising	O
Levodopa	B
,	O
Carbidopa	B
And	O
Entacapone	B
Or	O
Salts	O
Thereof	O

Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
for	O
modulation	O
of	O
Hec1	O
/	O
Nek2	O
interaction	O
are	O
provided	O
.	O

Especially	O
preferred	O
compounds	O
disrupt	O
Nek2	O
/	O
Hec1	O
binding	O
and	O
are	O
therefore	O
useful	O
as	O
chemotherapeutic	O
agent	O
for	O
neoplastic	O
diseases	O
.	O

Modulators	O
Of	O
HEC1	O
Activity	O
And	O
Methods	O
Therefor	O

A	O
medical	O
adhesive	O
composition	O
comprising	O
,	O
based	O
upon	O
the	O
total	O
weight	O
of	O
the	O
composition	O
,	O
from	O
about	O
50	O
wt	O
.	O

%	O
to	O
about	O
99.9	O
wt	O
.	O

%	O
of	O
one	O
or	O
more	O
α	B
-	I
cyanoacrylate	I
monomers	I
and	O
from	O
about	O
0.1	O
wt	O
.	O

%	O
to	O
about	O
5	O
wt	O
.	O

%	O
of	O
one	O
or	O
more	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

Suitable	O
NSAIDs	O
include	O
ibuprofen	B
and	O
acetaminophen	B
.	O

The	O
resulting	O
compositions	O
provide	O
enhances	O
fibroblast	O
proliferation	O
and	O
reduced	O
cytotoxicity	O
compared	O
to	O
compositions	O
that	O
do	O
not	O
contain	O
NSAID	O
.	O

Medical	O
adhesive	O
compositions	O

The	O
invention	O
relates	O
to	O
methods	O
for	O
inducing	O
male	O
contraception	O
and	O
to	O
methods	O
of	O
treating	O
cell	O
proliferation	O
related	O
disorders	O
or	O
diseases	O
,	O
such	O
as	O
cancer	O
.	O

The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
for	O
inducing	O
male	O
contraception	O
and	O
for	O
treating	O
cell	O
proliferation	O
related	O
disorders	O
or	O
diseases	O
.	O

Ant4	O
inhibitor	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
new	O
synthetic	O
receptors	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
synthetic	O
receptors	O
for	O
delivering	O
a	O
protein	O
,	O
peptide	O
,	O
drug	O
,	O
prodrug	O
,	O
lipid	O
,	O
nucleic	O
acid	O
,	O
carbohydrate	B
or	O
small	O
molecule	O
into	O
a	O
target	O
cell	O
via	O
receptor	O
-	O
mediated	O
endocytosis	O
.	O

According	O
to	O
the	O
invention	O
,	O
novel	O
synthetic	O
mimics	O
of	O
cell	O
surface	O
receptors	O
have	O
been	O
designed	O
and	O
methods	O
for	O
use	O
of	O
the	O
same	O
are	O
disclosed	O
.	O

Synthetic	O
mimics	O
of	O
mammalian	O
cell	O
surface	O
receptors	O
:	O
method	O
and	O
compositions	O

A	O
method	O
of	O
supplementing	O
a	O
diet	O
and	O
ameliorating	O
oxidative	O
stress	O
in	O
a	O
mammal	O
includes	O
administering	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
lipid	O
soluble	O
,	O
hydrophobic	O
active	O
compounds	O
having	O
a	O
chemical	O
structure	O
:	O
wherein	O
R1	O
is	O
an	O
aromatic	B
backbone	O
and	O
R2	O
is	O
a	O
sulfur	B
containing	O
ligand	O
.	O

Through	O
formation	O
of	O
disulfide	B
linkages	O
other	O
moieties	O
can	O
be	O
attached	O
to	O
R2	O
converting	O
the	O
hydrophobic	O
base	O
into	O
a	O
water	O
soluble	O
entity	O
,	O
for	O
ease	O
of	O
delivery	O
,	O
which	O
can	O
be	O
reconverted	O
back	O
to	O
the	O
original	O
compound	O
by	O
biochemical	O
reduction	O
in	O
the	O
blood	O
stream	O
.	O

Method	O
of	O
ameliorating	O
oxidative	O
stress	O
and	O
supplementing	O
the	O
diet	O

A	O
molecular	O
crystal	O
form	O
of	O
(	B
S	I
)	I
-3-	I
(	I
2,5-dimethyl-6-	I
(	I
4-	I
(	I
5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl	I
)	I
piperidin-1-yl	I
)	I
pyrimidin-4-ylamino	I
)	I
-2-	I
(	I
4-methoxyphenylsulfonamido	I
)	I
propanoic	I
acid	I
is	O
characterized	O
by	O
an	O
X	O
-	O
ray	O
powder	O
diffraction	O
(	O
""""	O
XRPD	O
""""	O
)	O
spectrum	O
that	O
comprises	O
peaks	O
at	O
2θ	O
angles	O
of	O
7.44	O
,	O
14.80	O
,	O
16.64	O
,	O
and	O
23.04±0.2	O
°	O
.	O

The	O
molecular	O
crystal	O
can	O
be	O
formulated	O
into	O
pharmaceutical	O
composition	O
for	O
treating	O
or	O
controlling	O
diseases	O
resulting	O
from	O
pathological	O
angiogenesis	O
.	O

Molecular	O
Crystal	O
of	O
(	B
4-	I
(	I
1,8-Naphthyridin-2-YL	I
)	I
Piperidin-1-YL	I
)	I
Pyrimidine	I
Derivative	O

The	O
present	O
invention	O
provides	O
transient	O
receptor	O
potential	O
vanilloid	O
(	O
TRPV	O
)	O
modulators	O
of	O
formula	O
(	O
I	O
)	O
.	O

In	O
particular	O
,	O
compounds	O
described	O
herein	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
conditions	O
and/or	O
disorders	O
modulated	O
by	O
TRPV3	O
.	O

Also	O
provided	O
herein	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein	O
,	O
intermediates	O
used	O
in	O
their	O
synthesis	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
conditions	O
and/or	O
disorders	O
modulated	O
by	O
TRPV3	O
.	O

Chromenone	B
derivatives	O
as	O
trpv3	O
antagonists	O

Disclosed	O
is	O
a	O
self	O
-	O
adhesive	O
matrix	O
system	O
comprising	O
a	O
styrene	B
-	I
ethylene	I
/	O
butylene	B
-	I
styrene	I
(	O
SEBS	B
)	O
copolymer	O
in	O
an	O
oil	O
/	O
ethyl	B
acetate	I
mixture	O
,	O
a	O
hydrogenated	O
resin	O
and	O
a	O
pharmaceutical	O
or	O
cosmetic	O
active	O
ingredient	O
.	O

Self	O
-	O
adhesive	O
matrix	O
system	O
comprising	O
a	O
styrene	B
block	O
copolymer	O

The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
contraception	O
,	O
which	O
method	O
comprises	O
administering	O
to	O
a	O
woman	O
in	O
need	O
thereof	O
an	O
emergency	O
contraception	O
during	O
one	O
or	O
two	O
days	O
,	O
followed	O
by	O
a	O
prolonged	O
low	O
dosage	O
contraceptive	O
treatment	O
until	O
next	O
menstrual	O
period	O
.	O

Method	O
for	O
contraception	O

A	O
method	O
for	O
treating	O
a	O
pulmonary	O
hypertension	O
condition	O
such	O
as	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
)	O
in	O
a	O
subject	O
comprises	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
ambrisentan	B
,	O
wherein	O
,	O
at	O
baseline	O
,	O
time	O
from	O
first	O
diagnosis	O
of	O
the	O
condition	O
in	O
the	O
subject	O
is	O
not	O
greater	O
than	O
about	O
2	O
years	O
.	O

Method	O
for	O
treating	O
a	O
pulmonary	O
hypertension	O
condition	O

This	O
invention	O
relates	O
to	O
novel	O
hydroxyethylamino	B
sulfonamides	I
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
compound	O
with	O
the	O
ability	O
to	O
act	O
as	O
an	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
protease	O
inhibitor	O
.	O

Hydroxyethlamino	B
Sulfonamide	I
Derivatives	O

The	O
present	O
invention	O
relates	O
to	O
co	O
-	O
crystals	O
of	O
tramadol	B
and	O
co	O
-	O
crystal	O
formers	O
selected	O
from	O
NSAIDs	O
,	O
processes	O
for	O
preparation	O
of	O
the	O
same	O
,	O
their	O
uses	O
in	O
pharmaceutical	O
formulations	O
,	O
and	O
for	O
the	O
treatment	O
of	O
various	O
disorders	O
,	O
including	O
pain	O
.	O

CO	O
-	O
CRYSTALS	O
OF	O
TRAMADOL	B
AND	O
NSAIDs	O

The	O
invention	O
relates	O
to	O
a	O
new	O
crystalline	O
form	O
of	O
tiotropium	B
bromide	I
,	O
processes	O
for	O
preparing	O
it	O
and	O
its	O
use	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
respiratory	O
complaints	O
,	O
particularly	O
for	O
the	O
treatment	O
of	O
COPD	O
(	O
chronic	O
obstructive	O
pulmonary	O
disease	O
)	O
and	O
asthma	O
.	O

Novel	O
co	O
-	O
crystal	O
of	O
tiotropium	B
bromide	I

There	O
is	O
provided	O
a	O
process	O
for	O
preparing	O
a	O
HA	O
cryogel	O
,	O
the	O
process	O
comprising	O
the	O
steps	O
of	O
combining	O
HA	O
,	O
a	O
cross	O
-	O
linking	O
agent	O
and	O
a	O
solvent	O
to	O
form	O
a	O
solution	O
,	O
freezing	O
the	O
solution	O
before	O
the	O
formation	O
of	O
less	O
than	O
10	O
%	O
of	O
the	O
cross	O
-	O
linking	O
bonds	O
of	O
the	O
cross	O
-	O
linked	O
HA	O
cryogel	O
formed	O
and	O
thawing	O
the	O
solution	O
.	O

An	O
HA	O
cryogel	O
is	O
also	O
provided	O
,	O
in	O
particular	O
an	O
HA	O
cryogel	O
obtained	O
from	O
this	O
process	O
.	O

Hyaluronic	O
acid	O
cryogel	O
-	O
compositions	O
,	O
uses	O
,	O
processes	O
for	O
manufacturing	O

Carrier	O
particles	O
in	O
which	O
at	O
least	O
60	O
%	O
of	O
the	O
surface	O
is	O
coated	O
with	O
magnesium	B
stearate	I
are	O
useful	O
for	O
preparing	O
dry	O
powder	O
formulations	O
for	O
inhalation	O
.	O

Process	O
for	O
preparing	O
carrier	O
particles	O
for	O
dry	O
powders	O
for	O
inhalation	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
cell	O
proliferation	O
disorders	O
comprising	O
(	O
1	O
)	O
administering	O
to	O
the	O
subject	O
at	O
least	O
one	O
activatable	O
pharmaceutical	O
agent	O
that	O
is	O
capable	O
of	O
activation	O
by	O
a	O
simultaneous	O
two	O
photon	O
absorption	O
event	O
and	O
of	O
effecting	O
a	O
predetermined	O
cellular	O
change	O
when	O
activated	O
,	O
(	O
2	O
)	O
administering	O
at	O
least	O
one	O
plasmonics	O
-	O
active	O
agent	O
to	O
the	O
subject	O
,	O
and	O
(	O
3	O
)	O
applying	O
an	O
initiation	O
energy	O
from	O
an	O
initiation	O
energy	O
source	O
to	O
the	O
subject	O
,	O
wherein	O
the	O
plasmonics	O
-	O
active	O
agent	O
enhances	O
or	O
modifies	O
the	O
applied	O
initiation	O
energy	O
,	O
such	O
that	O
the	O
enhanced	O
or	O
modified	O
initiation	O
energy	O
activates	O
the	O
activatable	O
pharmaceutical	O
agent	O
by	O
the	O
simultaneous	O
two	O
photon	O
absorption	O
event	O
in	O
situ	O
,	O
thus	O
causing	O
the	O
predetermined	O
cellular	O
change	O
to	O
occur	O
,	O
wherein	O
said	O
predetermined	O
cellular	O
change	O
treats	O
the	O
cell	O
proliferation	O
related	O
disorder	O
,	O
and	O
the	O
use	O
of	O
plasmonics	O
enhanced	O
photospectral	O
therapy	O
(	O
PEPST	O
)	O
and	O
exiton	O
-	O
plasmon	O
enhanced	O
phototherapy	O
(	O
EPEP	O
)	O
in	O
the	O
treatment	O
of	O
various	O
cell	O
proliferation	O
disorders	O
,	O
and	O
the	O
PEPST	O
and	O
EPEP	O
agents	O
and	O
probes	O
Advanced	O
methods	O
and	O
systems	O
for	O
treating	O
cell	O
proliferation	O
disorders	O

The	O
invention	O
provides	O
a	O
composition	O
comprising	O
a	O
plurality	O
of	O
nanoceria	O
particles	O
,	O
a	O
sufficient	O
amount	O
of	O
at	O
least	O
one	O
inhibitor	O
of	O
human	O
carbonic	O
anhydrase	O
II	O
associated	O
with	O
said	O
plurality	O
of	O
nanoceria	O
particles	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
containing	O
said	O
plurality	O
of	O
nanoceria	O
particles	O
with	O
associated	O
inhibitor	O
.	O

One	O
preferred	O
inhibitor	O
of	O
human	O
carbonic	O
anhydrase	O
II	O
comprises	O
4-carboxybenzene	B
sulfonamide	I
.	O

The	O
disclosed	O
composition	O
is	O
useful	O
in	O
treatment	O
of	O
glaucoma	O
.	O

Functionalized	O
nanoceria	O
composition	O
for	O
ophthalmic	O
treatment	O

A	O
novel	O
gastroretentive	O
delivery	O
system	O
comprising	O
a	O
tablet	O
comprising	O
a	O
pharmaceutical	O
ingredient	O
or	O
diagnostic	O
,	O
which	O
tablet	O
comprises	O
a	O
gas	O
releasing	O
ingredient	O
or	O
a	O
tandem	O
of	O
two	O
gas	O
releasing	O
ingredients	O
,	O
an	O
ingredient	O
capable	O
of	O
unrestricted	O
swelling	O
in	O
gastric	O
fluid	O
,	O
an	O
ingredient	O
capable	O
of	O
limiting	O
the	O
unrestricted	O
swelling	O
and	O
a	O
hardening	O
ingredient	O
.	O

The	O
said	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
three	O
different	O
gastroretentive	O
mechanisms	O
:	O
flotation	O
,	O
swelling	O
and	O
mechanical	O
strength	O
,	O
the	O
three	O
mechanisms	O
acting	O
in	O
a	O
complimentary	O
way	O
.	O

Processes	O
for	O
manufacturing	O
same	O
and	O
methods	O
of	O
treatment	O
are	O
also	O
disclosed	O
.	O

Novel	O
gastroretentive	O
delivery	O
system	O

Resorbable	O
polymer	O
barrier	O
membranes	O
and	O
methods	O
of	O
their	O
applications	O
are	O
disclosed	O
.	O

In	O
a	O
broad	O
embodiment	O
,	O
methods	O
of	O
governing	O
tissue	O
growth	O
,	O
or	O
preventing	O
tissue	O
growth	O
into	O
a	O
certain	O
spatial	O
area	O
,	O
includes	O
the	O
step	O
of	O
forming	O
a	O
spatial	O
barrier	O
with	O
the	O
present	O
resorbable	O
barrier	O
membrane	O
.	O

The	O
barrier	O
membrane	O
separates	O
a	O
tissue	O
-	O
growth	O
area	O
and	O
a	O
non	O
-	O
bone	O
-	O
growth	O
area	O
,	O
and	O
prevents	O
tissue	O
from	O
growing	O
into	O
the	O
non	O
-	O
growth	O
area	O
.	O

Methods	O
for	O
governing	O
tissue	O
growth	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
formulation	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
diclofenac	B
,	O
at	O
least	O
one	O
polyoxyalkylene	B
ester	I
of	O
a	O
hydroxy	B
fatty	I
acid	I
,	O
water	O
,	O
and	O
,	O
optionally	O
,	O
a	O
co	O
-	O
solvent	O
.	O

Pharmaceutical	O
formulation	O
comprising	O
diclofenac	B

Embodiments	O
of	O
the	O
invention	O
relate	O
to	O
methods	O
and	O
compositions	O
for	O
the	O
expansion	O
of	O
hematopoietic	O
stem	O
cell	O
(	O
HSC	O
)	O
self	O
renewal	O
.	O

The	O
microRNA-125a	O
is	O
a	O
master	O
control	O
of	O
HSC	O
self	O
-	O
renewal	O
.	O

Increased	O
expression	O
of	O
mir-125a	O
increased	O
HSC	O
self	O
-	O
renewal	O
by	O
6	O
-	O
30	O
folds	O
.	O

Increased	O
expression	O
of	O
mir-125a	O
can	O
be	O
used	O
to	O
expand	O
HSC	O
ex	O
vivo	O
and	O
in	O
vivo	O
.	O

Method	O
for	O
mir-125a	O
in	O
promoting	O
hematopoietic	O
stem	O
cell	O
self	O
renewal	O
and	O
expansion	O

The	O
present	O
application	O
describes	O
deuterium	B
-	I
enriched	I
doripenem	I
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Deuterium	B
-	I
enriched	I
doripenem	I

Pharmaceutical	O
compositions	O
including	O
an	O
HDAC	O
inhibitor	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
the	O
HDAC	O
inhibitor	O
is	O
present	O
in	O
an	O
amount	O
sufficient	O
to	O
achieve	O
a	O
plasma	O
concentration	O
from	O
about	O
100	O
nM	O
to	O
about	O
2	O
uM	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
same	O
.	O

Pharmaceutical	O
compositions	O
including	O
an	O
HDAC	O
inhibitor	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
the	O
HDAC	O
inhibitor	O
is	O
present	O
in	O
an	O
amount	O
from	O
0.1	O
mg	O
to	O
100	O
mg	O
.	O

Pharmaceutical	O
compositions	O
including	O
an	O
HDAC	O
inhibitor	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
wherein	O
the	O
concentration	O
of	O
the	O
HDAC	O
inhibitor	O
is	O
sufficient	O
to	O
decrease	O
the	O
relative	O
viability	O
of	O
lymphoblastoid	O
cells	O
by	O
at	O
least	O
about	O
50	O
percent	O
and/or	O
is	O
sufficient	O
to	O
decrease	O
the	O
proliferation	O
of	O
lymphoblastoid	O
cells	O
by	O
at	O
least	O
about	O
60	O
percent	O
and/or	O
is	O
sufficient	O
to	O
decrease	O
the	O
relative	O
viability	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
less	O
than	O
about	O
50	O
percent	O
and	O
methods	O
of	O
treatment	O
using	O
the	O
same	O
.	O

Compositions	O
and	O
methods	O
for	O
reducing	O
proliferation	O
and	O
viability	O
of	O
lymphoblastoid	O
cells	O

The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
that	O
Tat	O
polypeptides	O
may	O
be	O
used	O
as	O
immunoregulators	O
to	O
enhance	O
the	O
immune	O
response	O
to	O
infectious	O
diseases	O
.	O

More	O
particularly	O
,	O
Tat	O
polypeptides	O
may	O
be	O
used	O
as	O
immunoregulators	O
to	O
enhance	O
immune	O
responses	O
to	O
microbial	O
infections	O
,	O
for	O
example	O
,	O
viral	O
and	O
bacterial	O
infections	O
.	O

In	O
accordance	O
with	O
the	O
present	O
invention	O
,	O
Tat	O
polypeptides	O
interact	O
with	O
CCR3	O
to	O
stimulate	O
platelet	O
activation	O
.	O

The	O
novel	O
finding	O
of	O
the	O
present	O
inventors	O
,	O
therefore	O
,	O
presents	O
new	O
applications	O
for	O
which	O
Tat	O
nucleic	O
and	O
amino	O
acid	O
sequences	O
,	O
and	O
compositions	O
thereof	O
may	O
be	O
used	O
to	O
advantage	O
.	O

Applications	O
for	O
which	O
the	O
Tat	O
nucleic	O
and	O
amino	B
acid	I
sequences	O
and	O
compositions	O
thereof	O
of	O
the	O
invention	O
may	O
be	O
used	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
various	O
research	O
and	O
therapeutic	O
applications	O
as	O
described	O
herein	O
.	O

Also	O
provided	O
is	O
a	O
kit	O
comprising	O
Tat	O
nucleic	O
and/or	O
amino	B
acid	I
sequences	O
,	O
Tat	O
activity	O
compatible	O
buffers	O
,	O
and	O
instruction	O
materials	O
.	O

Enhanced	O
immune	O
response	O
against	O
infections	O

Described	O
herein	O
is	O
the	O
synthesis	O
of	O
reinforced	O
adhesive	O
complex	O
coacervates	O
and	O
their	O
use	O
thereof	O
.	O

The	O
reinforced	O
adhesive	O
complex	O
coacervates	O
are	O
composed	O
of	O
(	O
a	O
)	O
at	O
least	O
one	O
polycation	O
,	O
(	O
b	O
)	O
at	O
least	O
one	O
polyanion	O
,	O
and	O
(	O
c	O
)	O
a	O
reinforcing	O
component	O
.	O

The	O
adhesive	O
complex	O
coacervates	O
described	O
herein	O
can	O
be	O
subsequently	O
cured	O
to	O
produce	O
strong	O
,	O
cohesive	O
adhesives	O
.	O

The	O
reinforced	O
adhesive	O
complex	O
coacervates	O
have	O
several	O
desirable	O
features	O
when	O
compared	O
to	O
conventional	O
adhesives	O
.	O

The	O
reinforced	O
adhesive	O
complex	O
coacervates	O
are	O
effective	O
in	O
wet	O
or	O
underwater	O
applications	O
.	O

The	O
reinforced	O
adhesive	O
complex	O
coacervates	O
described	O
herein	O
,	O
being	O
phase	O
separated	O
from	O
water	O
,	O
can	O
be	O
applied	O
underwater	O
without	O
dissolving	O
or	O
dispersing	O
into	O
the	O
water	O
.	O

The	O
reinforced	O
adhesive	O
complex	O
coacervates	O
have	O
numerous	O
biological	O
applications	O
as	O
bioadhesives	O
and	O
bioactive	O
delivery	O
devices	O
.	O

In	O
particular	O
,	O
the	O
reinforced	O
adhesive	O
complex	O
coacervates	O
described	O
herein	O
are	O
particularly	O
useful	O
in	O
underwater	O
applications	O
and	O
situations	O
where	O
water	O
is	O
present	O
such	O
as	O
,	O
for	O
example	O
,	O
wet	O
tissues	O
in	O
physiological	O
conditions	O
.	O

Reinforced	O
adhesive	O
complex	O
coacervates	O
and	O
methods	O
of	O
making	O
and	O
using	O
thereof	O

Substituted	O
pyrrolo	B
-	I
pyrazole	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
as	O
defined	O
in	O
the	O
specification	O
,	O
process	O
for	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
disclosed	O
;	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
in	O
therapy	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
dysregulated	O
protein	O
kinase	O
activity	O
,	O
like	O
cancer	O
.	O

Substituted	O
pyrrolo	B
-	I
pyrazole	I
derivatives	O
active	O
as	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
a	O
disease	O
in	O
an	O
animal	O
,	O
which	O
disease	O
is	O
responsive	O
to	O
blocking	O
of	O
calcium	B
activated	O
chloride	B
echannel	O
(	O
CaCC	O
)	O
by	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
defined	O
herein	O
(	O
including	O
those	O
compounds	O
set	O
forth	O
in	O
Tables	O
1	O
-	O
2	O
or	O
encompassed	O
by	O
formulas	O
I	O
-	O
IV	O
)	O
or	O
compositions	O
thereof	O
,	O
thereby	O
treating	O
the	O
disease	O
.	O

Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
comprising	O
1,3,4-oxadiazole	B
derivatives	O

A	O
nucleic	O
acid	O
construct	O
and	O
construct	O
system	O
are	O
disclosed	O
.	O

The	O
nucleic	O
acid	O
construct	O
and	O
system	O
comprise	O
a	O
regulatory	O
sequence	O
which	O
regulates	O
inducible	O
expression	O
of	O
a	O
polypeptide	O
of	O
interest	O
,	O
the	O
regulatory	O
sequence	O
comprising	O
a	O
choroid	O
plexus	O
specific	O
promoter	O
,	O
with	O
the	O
proviso	O
that	O
the	O
choroid	B
plexus	O
specific	O
promoter	O
is	O
not	O
a	O
transthyretin	O
promoter	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
same	O
and	O
uses	O
thereof	O
are	O
also	O
disclosed	O
.	O

Methods	O
of	O
expressing	O
a	O
polypeptide	O
in	O
the	O
brain	O
and	O
nucleic	O
acid	O
constructs	O
capable	O
of	O
same	O

A	O
ProNGF	O
inhibitor	O
for	O
preparing	O
a	O
drug	O
,	O
said	O
drug	O
being	O
in	O
particular	O
useful	O
for	O
blocking	O
remote	O
dissemination	O
and	O
cell	O
invasion	O
in	O
patients	O
suffering	O
from	O
cancer	O
,	O
in	O
particular	O
breast	O
,	O
thyroid	O
or	O
lung	O
cancer	O
.	O

Method	O
for	O
prongf	O
assay	O
for	O
in	O
vitro	O
diagnosis	O
of	O
cancer	O
in	O
particular	O
breast	O
,	O
thyroid	O
or	O
lung	O
cancer	O
and	O
therapeutic	O
use	O
of	O
prongf	O

The	O
invention	O
relates	O
to	O
the	O
development	O
of	O
chimeric	O
OspA	O
molecules	O
for	O
use	O
in	O
a	O
new	O
Lyme	O
vaccine	O
.	O

More	O
specifically	O
,	O
the	O
chimeric	O
OspA	O
molecules	O
comprise	O
the	O
proximal	O
portion	O
from	O
one	O
OspA	O
serotype	O
,	O
together	O
with	O
the	O
distal	O
portion	O
from	O
another	O
OspA	O
serotype	O
,	O
while	O
retaining	O
antigenic	O
properties	O
of	O
both	O
of	O
the	O
parent	O
polypeptides	O
.	O

The	O
chimeric	O
OspA	O
molecules	O
are	O
delivered	O
alone	O
or	O
in	O
combination	O
to	O
provide	O
protection	O
against	O
a	O
variety	O
of	O
Borrelia	O
genospecies	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
administering	O
the	O
chimeric	O
OspA	O
molecules	O
to	O
a	O
subject	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
Lyme	O
disease	O
or	O
borreliosis	O
.	O

Chimeric	O
ospa	O
genes	O
,	O
proteins	O
,	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
nucleic	O
acid	O
preparation	O
with	O
a	O
content	O
of	O
below	O
1	O
%	O
protein	O
,	O
preferably	O
below	O
0.1	O
%	O
protein	O
,	O
free	O
of	O
ethidium	B
bromide	I
,	O
phenol	B
,	O
cesium	B
chloride	I
and	O
detergents	O
based	O
on	O
octyl	B
phenol	I
poly	I
(	I
ethylene	I
glycol	I
ether	I
)	I
n	I
and	O
with	O
a	O
content	O
of	O
below	O
1	O
EU	O
/	O
mg	O
DNA	O
of	O
endotoxins	O
.	O

Said	O
preparation	O
is	O
suitable	O
as	O
a	O
drug	O
particularly	O
in	O
gene	O
therapy	O
.	O

Process	O
for	O
preparing	O
purified	O
nucleic	O
acid	O
and	O
the	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
group	O
of	O
Ljungan	O
viruses	O
,	O
proteins	O
expressed	O
by	O
the	O
viruses	O
,	O
antibodies	O
to	O
the	O
viruses	O
and	O
proteins	O
,	O
vaccines	O
against	O
the	O
viruses	O
,	O
diagnostic	O
kits	O
for	O
detecting	O
the	O
viruses	O
,	O
uses	O
of	O
the	O
viruses	O
,	O
proteins	O
,	O
antibodies	O
and	O
vaccines	O
in	O
therapy	O
,	O
uses	O
of	O
the	O
viruses	O
,	O
proteins	O
,	O
antibodies	O
and	O
vaccines	O
in	O
treating	O
diseases	O
caused	O
by	O
the	O
viruses	O
and	O
methods	O
of	O
treatment	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
viruses	O
.	O

Ljungan	O
virus	O

A	O
hydromorphone	B
composition	O
,	O
a	O
hydromorphone	B
dosage	O
form	O
and	O
a	O
method	O
for	O
administering	O
hydromorphone	B
are	O
disclosed	O
,	O
indicated	O
for	O
the	O
management	O
of	O
pain	O
.	O

Hydromorphone	B
therapy	O

A	O
method	O
and	O
composition	O
that	O
allows	O
for	O
the	O
penetration	O
of	O
lipid	O
insoluble	O
medicaments	O
through	O
cell	O
membranes	O
using	O
small	O
S	B
-	I
Allyl	I
-	O
containing	O
molecules	O
with	O
phospholipid	B
permeable	O
molecules	O
as	O
carrier	O
molecules	O
.	O

S	B
-	I
Allyl	I
-	O
containing	O
compounds	O
can	O
include	O
alliin	B
,	O
allicin	B
,	O
Allium	O
sativum	O
extract	O
and	O
DMSO	B
.	O

Lipid	O
insoluble	O
medicaments	O
can	O
include	O
1	O
%	O
xylocaine	B
,	O
curcumin	B
,	O
acyclovir	B
,	O
valacyclovir	B
,	O
famciclovir	B
,	O
terbenafin	B
,	O
griseofulvin	B
,	O
clotrimazole	B
,	O
ketoconazole	B
,	O
clindamycin	B
,	O
neomycin	B
,	O
polysporin	O
,	O
bactricin	B
,	O
among	O
others	O
.	O

The	O
lipid	O
insoluble	O
medicaments	O
are	O
mixed	O
with	O
the	O
phospholipid	B
permeable	O
molecules	O
and	O
painted	O
on	O
the	O
skin	O
using	O
a	O
swab	O
or	O
other	O
suitable	O
tool	O
,	O
thereby	O
allowing	O
for	O
penetration	O
of	O
the	O
medicament	O
and	O
providing	O
relief	O
from	O
pain	O
potentially	O
caused	O
by	O
a	O
subsequent	O
injection	O
.	O

The	O
composition	O
can	O
also	O
be	O
administered	O
through	O
an	O
inhaler	O
or	O
directly	O
into	O
mucous	O
membranes	O
.	O

If	O
appropriately	O
packaged	O
and	O
given	O
intravenously	O
,	O
S	B
-	I
allyl	I
molecules	O
may	O
also	O
be	O
used	O
to	O
enhance	O
the	O
penetration	O
of	O
non	O
-	O
lipid	O
soluble	O
molecules	O
,	O
including	O
curcumin	B
,	O
through	O
cell	O
membranes	O
in	O
solid	O
organs	O
,	O
such	O
as	O
the	O
liver	O
,	O
pancreas	O
,	O
kidneys	O
,	O
uterus	O
,	O
prostrate	O
,	O
bone	O
,	O
joints	O
and	O
brain	O
.	O

Method	O
for	O
enhancing	O
penetration	O
of	O
lipid	O
insoluble	O
medicaments	O
through	O
cell	O
membranes	O
using	O
small	O
S	B
-	I
Allyl	I
-	O
containing	O
molecules	O
with	O
phospholipid	B
permeability	O
as	O
carrier	O
molecules	O

The	O
present	O
invention	O
aims	O
to	O
provide	O
a	O
glucokinase	O
activator	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
such	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
diabetes	O
,	O
obesity	O
and	O
the	O
like	O
,	O
and	O
the	O
like	O
.	O

A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
an	O
optionally	O
substituted	O
4-	O
to	O
7-membered	O
nitrogen	B
-	O
containing	O
heterocyclic	B
group	O
,	O
optionally	O
substituted	O
carbamoyl	B
,	O
or	O
optionally	O
substituted	O
sulfamoyl	B
;	O
R2	O
is	O
optionally	O
substituted	O
alkyl	B
,	O
optionally	O
substituted	O
alkoxy	B
,	O
an	O
optionally	O
substituted	O
3-	O
to	O
7-membered	O
cyclic	O
group	O
,	O
—SR′	B
,	O
—SOR′	B
,	O
or	O
—SO2R′	B
(	O
R′	O
is	O
a	O
substituent	O
)	O
;	O
R3	O
is	O
hydrogen	B
,	O
halogen	B
,	O
optionally	O
substituted	O
alkyl	B
,	O
optionally	O
substituted	O
alkenyl	B
,	O
optionally	O
substituted	O
alkoxy	B
,	O
—O	B
-	I
Cy	I
(	O
Cy	O
is	O
an	O
optionally	O
substituted	O
3-	O
to	O
7-membered	O
cyclic	O
group	O
which	O
may	O
be	O
condensed	O
with	O
benzene	B
)	O
,	O
—SR″	B
,	O
—SOR″	B
,	O
or	O
—SO2R″	B
(	O
R″	O
is	O
a	O
substituent	O
)	O
,	O
or	O
an	O
optionally	O
substituted	O
3-	O
to	O
7-membered	O
cyclic	O
group	O
which	O
may	O
be	O
condensed	O
with	O
benzene	B
;	O
R4	O
is	O
hydrogen	B
,	O
or	O
optionally	O
substituted	O
alkyl	B
;	O
provided	O
that	O
when	O
R3	O
is	O
hydrogen	B
,	O
halogen	B
,	O
or	O
methoxy	B
,	O
then	O
R2	O
is	O
not	O
optionally	O
substituted	O
alkyl	B
,	O
or	O
optionally	O
substituted	O
alkoxy	B
;	O
further	O
provided	O
that	O
5-	B
[	I
5-	I
{	I
[	I
(	I
2S	I
)	I
-2-amino-3-phenylpropyl	I
]	I
oxy	I
}	I
-2-	I
(	I
3-furyl	I
)	I
pyridin-3-yl	I
]	I
-N	I
-	I
pyridin-4-yl-1H	I
-	I
indazol-3-amine	I
and	O
5-	B
[	I
5-	I
{	I
[	I
(	I
2S	I
)	I
-2-amino-3-phenylpropyl	I
]	I
oxy	I
}	I
-2-	I
(	I
3-furyl	I
)	I
pyridin-3-yl	I
]	I
-1-	I
(	I
4-methoxybenzyl	I
)	I
-N	I
-	I
pyridin-4-yl-1H	I
-	I
indazol-3-amine	I
are	O
excluded	O
;	O
or	O
a	O
salt	O
thereof	O
.	O

Indazole	B
compounds	O
for	O
activating	O
glucokinase	O

The	O
present	O
invention	O
relates	O
to	O
isoxazole	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
having	O
fungicidal	O
activity	O
,	O
to	O
agricultural	O
compositions	O
comprising	O
them	O
,	O
and	O
to	O
the	O
use	O
of	O
said	O
compounds	O
and	O
compositions	O
in	O
agriculture	O
for	O
the	O
control	O
of	O
microbial	O
pests	O
,	O
particularly	O
fungal	O
pests	O
,	O
on	O
plants	O
.	O

Isoxazole	B
derivatives	O
for	O
use	O
as	O
fungicides	O

Novel	O
polyisoprenylated	O
benzophenone	B
derivatives	O
isolated	O
from	O
the	O
plant	O
Garcinia	O
paucinervis	O
.	O

Among	O
these	O
new	O
compounds	O
,	O
paucinones	B
A	I
-	I
C	I
(	O
Compounds	O
1	O
-	O
3	O
)	O
contains	O
an	O
unexpected	O
cyclohexane	B
-	I
spiro	I
-	I
tetrahydrofuran	I
moiety	O
.	O

A	O
1-methylene-3,3-dimethylcyclohexane	B
group	O
never	O
reported	O
before	O
was	O
found	O
in	O
the	O
structure	O
of	O
paucinone	B
D	I
(	O
Compound	O
4	O
)	O
.	O

Structures	O
of	O
these	O
compounds	O
were	O
elucidated	O
with	O
spectroscopic	O
evidence	O
.	O

The	O
relative	O
stereochemistry	O
of	O
1	O
-	O
4	O
was	O
determined	O
by	O
NOESY	O
correlations	O
.	O

These	O
compounds	O
a	O
potent	O
ability	O
to	O
activate	O
caspase-3	O
in	O
HeLa	O
-	O
C3	O
cells	O
within	O
72	O
hours	O
at	O
a	O
low	O
concentration	O
and	O
significant	O
cytotoxicity	O
against	O
HeLa	O
-	O
C3	O
cells	O
.	O

Novel	O
Polyisoprenylated	O
Benzophenone	B
Derivatives	O
from	O
Garcinia	O
paucinervis	O

In	O
a	O
dissolving	O
step	O
,	O
in	O
a	O
container	O
13	O
,	O
a	O
poorly	O
soluble	O
drug	O
and	O
a	O
dispersion	O
stabilizer	O
(	O
polyvinylpyrrolidone	B
and	O
sodium	B
lauryl	I
sulfate	I
)	O
are	O
dissolved	O
in	O
a	O
volatile	O
organic	O
solvent	O
.	O

In	O
a	O
solid	O
composition	O
forming	O
step	O
following	O
the	O
dissolving	O
step	O
,	O
the	O
organic	O
solvent	O
contained	O
in	O
the	O
solution	O
is	O
removed	O
by	O
evaporation	O
,	O
and	O
by	O
the	O
organic	O
solvent	O
removal	O
,	O
a	O
solid	O
composition	O
1	O
is	O
obtained	O
as	O
a	O
residue	O
,	O
and	O
the	O
solid	O
composition	O
1	O
becomes	O
fixed	O
on	O
the	O
inner	O
wall	O
of	O
the	O
container	O
13	O
.	O

In	O
a	O
water	O
injecting	O
step	O
following	O
the	O
solid	O
composition	O
forming	O
step	O
,	O
water	O
2	O
is	O
injected	O
into	O
the	O
interior	O
of	O
the	O
container	O
13	O
.	O

In	O
a	O
microparticle	O
dispersion	O
liquid	O
preparing	O
step	O
following	O
the	O
water	O
injecting	O
step	O
,	O
laser	O
light	O
L	O
emitted	O
from	O
a	O
laser	O
light	O
source	O
11	O
is	O
irradiated	O
on	O
the	O
solid	O
composition	O
1	O
fixed	O
on	O
the	O
inner	O
wall	O
of	O
the	O
container	O
13	O
and	O
optical	O
energy	O
is	O
thereby	O
applied	O
to	O
the	O
solid	O
composition	O
1	O
.	O

Solid	O
composition	O
,	O
microparticles	O
,	O
microparticle	O
dispersion	O
liquid	O
,	O
and	O
manufacturing	O
methods	O
for	O
these	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
of	O
treating	O
skin	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
topical	O
application	O
to	O
the	O
skin	O
of	O
compositions	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
damage	O
to	O
skin	O
.	O

Topical	O
skin	O
cream	O
comprising	O
phosphatidylcholine	O
dha	O
and	O
l	B
-	I
tyrosine	I

A	O
crystalline	O
form	O
of	O
a	O
γ	B
-	I
aminobutyric	I
acid	I
analog	O
,	O
and	O
methods	O
of	O
preparing	O
same	O
,	O
are	O
provided	O
.	O

CRYSTALLINE	O
FORM	O
OF	O
y	B
-	I
AMINOBUTYRIC	I
ACID	I
ANALOG	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
compounds	O
such	O
as	O
alkylglycerol	B
and	O
alkoxyglycerol	B
for	O
use	O
in	O
increasing	O
the	O
endogenous	O
level	O
of	O
plasmalogens	O
in	O
a	O
mammal	O
.	O

In	O
particular	O
,	O
these	O
compounds	O
are	O
used	O
for	O
increasing	O
the	O
endogenous	O
plasmalogen	O
level	O
to	O
a	O
level	O
greater	O
than	O
the	O
level	O
in	O
healthy	O
mammals	O
.	O

According	O
to	O
the	O
present	O
invention	O
such	O
compounds	O
are	O
also	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
caused	O
or	O
affected	O
by	O
a	O
decreased	O
endogenous	O
level	O
of	O
plasmalogens	O
.	O

A	O
method	O
for	O
the	O
manufacture	O
of	O
a	O
dietary	O
precursor	O
for	O
the	O
use	O
of	O
the	O
present	O
invention	O
is	O
also	O
part	O
of	O
the	O
present	O
disclosure	O
.	O

Method	O
for	O
increasing	O
endogenous	O
plasmalogen	O
levels	O
in	O
mammals	O

A	O
method	O
of	O
inducing	O
apoptosis	O
or	O
cell	O
death	O
in	O
a	O
leukemia	O
cell	O
includes	O
subjecting	O
the	O
cell	O
to	O
a	O
purine	B
nucleotide	O
analogue	O
,	O
LMP-420	O
(	O
2-amino-6-chloro-9-	B
[	I
5	I
(	I
dihydroxyboryl	I
)	I
-pentyl	I
]	I
purine	I
)	O
.	O

Method	O
of	O
including	O
apoptosis	O
/	O
Cell	O
death	O
in	O
leukemia	O
cell	O
using	O
a	O
purine	B
nucleoside	O
analogue	O

The	O
present	O
invention	O
provides	O
thiazole	B
sulfonamide	I
and	O
oxazole	B
sulfonamide	I
compounds	O
,	O
compositions	O
containing	O
the	O
same	O
,	O
as	O
well	O
as	O
processes	O
for	O
the	O
preparation	O
and	O
methods	O
for	O
their	O
use	O
as	O
pharmaceutical	O
agents	O
.	O

Thiazole	B
Sulfonamide	I
And	O
Oxazole	B
Sulfonamide	I
Kinase	O
Inhibitors	O

Methods	O
are	O
provided	O
for	O
using	O
methotrexate	B
(	O
MTX	B
)	O
active	O
agents	O
in	O
which	O
reduced	O
host	O
toxicity	O
is	O
observed	O
.	O

Aspects	O
of	O
the	O
methods	O
include	O
administering	O
to	O
a	O
subject	O
an	O
effective	O
amount	O
of	O
an	O
MTX	B
active	O
agent	O
in	O
conjunction	O
with	O
a	O
MTX	B
toxicity	O
-	O
reducing	O
adjuvant	O
,	O
such	O
as	O
a	O
2,2′-anhydropyrimidine	B
,	O
a	O
derivative	O
thereof	O
or	O
a	O
uridine	B
phosphorylase	O
inhibitor	O
.	O

Also	O
provided	O
are	O
compositions	O
and	O
kits	O
that	O
find	O
use	O
in	O
practicing	O
embodiments	O
of	O
the	O
invention	O
.	O

The	O
methods	O
and	O
compositions	O
find	O
use	O
in	O
a	O
variety	O
of	O
applications	O
,	O
including	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
different	O
disease	O
conditions	O
.	O

Methotrexate	B
Adjuvants	O
to	O
Reduce	O
Toxicity	O
and	O
Methods	O
for	O
Using	O
the	O
Same	O

Compounds	O
useful	O
as	O
allosteric	O
potentiators	O
/	O
positive	O
allosteric	O
modulators	O
of	O
the	O
metabotropic	O
glutamate	B
receptor	O
subtype	O
4	O
(	O
mGluR4	O
)	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O

Substituted	O
1,1,3,1-tetraoxidobenzo	B
[	I
d	I
]	I
[	I
1,3,2	I
]	I
dithiazoles	I
as	O
mglur4	O
allosteric	O
potentiators	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
treating	O
neurological	O
dysfunction	O

A	O
pharmaceutical	O
formulation	O
comprising	O
:	O
VX-950	O
;	O
and	O
a	O
taste	O
improving	O
composition	O
.	O

Palatable	O
pharmaceutical	O
composition	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formulae	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
the	O
treatment	O
of	O
cancer	O
,	O
inflammation	O
,	O
auto	O
-	O
immune	O
diseases	O
,	O
diabetes	O
and	O
diabetic	O
complications	O
,	O
infection	O
,	O
cardiovascular	O
disease	O
and	O
ischemia	O
-	O
reperfusion	O
injuries	O
.	O

Inhibitors	O
of	O
NF	O
-	O
KB	O

Provided	O
herein	O
are	O
small	O
molecule	O
inhibitors	O
of	O
Taspase1	O
and	O
methods	O
of	O
using	O
the	O
small	O
molecule	O
inhibitors	O
of	O
Taspase1	O
to	O
treat	O
neoplasm	O
in	O
subjects	O
in	O
need	O
thereof	O
.	O

Taspase1	O
inhibitors	O
and	O
their	O
uses	O

A	O
lycogen	O
extract	O
comprising	O
active	O
ingredient	O
of	O
ζ	B
-	I
carotene	I
,	O
neurosporene	B
,	O
spheroidenone	B
and/or	O
methoxyneurosporene	B
is	O
described	O
.	O

A	O
composition	O
comprising	O
the	O
lycogen	O
extract	O
of	O
the	O
present	O
invention	O
and	O
food	O
scientific	O
or	O
pharmaceutical	O
acceptable	O
carrier	O
is	O
also	O
presented	O
.	O

A	O
method	O
for	O
the	O
treatment	O
of	O
disease	O
in	O
need	O
of	O
the	O
lycogen	O
extract	O
which	O
comprises	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
lycogen	O
extract	O
of	O
the	O
present	O
invention	O
is	O
further	O
described	O
.	O

Lycogen	O
extract	O
,	O
composition	O
thereof	O
and	O
method	O
for	O
the	O
treatment	O
using	O
the	O
same	O

Disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
a	O
CIRP	O
inhibitor	O
.	O

A	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
an	O
inflammatory	O
condition	O
comprising	O
administering	O
to	O
said	O
subject	O
a	O
CIRP	O
inhibitor	O
is	O
also	O
described	O
herein	O
.	O

Treatment	O
of	O
Inflammatory	O
Diseases	O
by	O
Inhibiting	O
Cold	O
-	O
Inducible	O
RNA	O
-	O
Binding	O
Protein	O
(	O
CIRP	O
)	O

The	O
present	O
invention	O
relates	O
to	O
a	O
nano	O
-	O
carrier	O
for	O
an	O
anticancer	O
drug	O
,	O
which	O
comprises	O
:	O
a	O
metal	O
nanoparticle	O
;	O
and	O
a	O
polynucleotide	O
for	O
connecting	O
with	O
an	O
anticancer	O
drug	O
having	O
a	O
pyrimidine	B
group	O
or	O
a	O
purine	B
group	O
,	O
wherein	O
the	O
polynucleotide	O
connects	O
to	O
a	O
surface	O
of	O
the	O
metal	O
nanoparticle	O
,	O
and	O
the	O
anticancer	O
drug	O
binds	O
to	O
the	O
polynucleotide	O
through	O
the	O
pyrimidine	B
group	O
or	O
the	O
purine	B
group	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
also	O
provides	O
a	O
complex	O
of	O
an	O
anticancer	O
drug	O
and	O
a	O
nano	O
-	O
carrier	O
,	O
a	O
pharmaceutical	O
composition	O
thereof	O
,	O
a	O
method	O
for	O
manufacturing	O
the	O
complex	O
,	O
and	O
a	O
method	O
for	O
treating	O
a	O
cancer	O
by	O
using	O
the	O
pharmaceutical	O
composition	O
.	O

Nano	O
-	O
carrier	O
,	O
complex	O
of	O
anticancer	O
drug	O
and	O
nano	O
-	O
carrier	O
,	O
pharmaceutical	O
composition	O
thereof	O
,	O
method	O
for	O
manufacturing	O
the	O
complex	O
,	O
and	O
method	O
for	O
treating	O
cancer	O
by	O
using	O
the	O
pharmaceutical	O
composition	O

The	O
invention	O
provides	O
methods	O
for	O
the	O
administration	O
of	O
compounds	O
capable	O
of	O
prolonging	O
a	O
QTc	O
interval	O
and	O
methods	O
for	O
predicting	O
whether	O
an	O
individual	O
is	O
predisposed	O
to	O
such	O
QTc	O
prolongation	O
.	O

Method	O
of	O
treatment	O
based	O
on	O
polymorphisms	O
of	O
the	O
kcnq1	O
gene	O

Nitroxide	B
free	O
radicals	O
attached	O
to	O
antineoplastic	O
agents	O
can	O
synergize	O
their	O
potencies	O
to	O
cancer	O
cells	O
.	O

This	O
invention	O
relates	O
to	O
any	O
antineoplastic	O
agents	O
and	O
their	O
derivatives	O
chemically	O
attached	O
with	O
nitroxide	B
free	O
radicals	O
,	O
such	O
as	O
TEMPO	O
and	O
its	O
radical	O
derivatives	O
.	O

This	O
invention	O
also	O
relates	O
to	O
precursors	O
of	O
such	O
compounds	O
,	O
as	O
well	O
as	O
the	O
products	O
formed	O
from	O
the	O
adducts	O
after	O
administration	O
.	O

Nitroxide	B
Free	O
Radical	O
Synergized	O
Antineoplastic	O
Agents	O

The	O
invention	O
includes	O
compositions	O
and	O
methods	O
for	O
regulating	O
p110	O
delta	O
as	O
an	O
anti	O
-	O
influenza	O
virus	O
therapy	O
.	O

The	O
invention	O
includes	O
inhibiting	O
p110	O
delta	O
,	O
a	O
component	O
of	O
p110	O
delta	O
signaling	O
pathway	O
,	O
or	O
any	O
combination	O
thereof	O
in	O
a	O
cell	O
as	O
an	O
anti	O
-	O
influenza	O
viral	O
therapeutic	O
approach	O
for	O
treating	O
influenza	O
virus	O
infection	O
.	O

The	O
invention	O
includes	O
a	O
method	O
of	O
modulating	O
p110	O
delta	O
in	O
a	O
cell	O
by	O
contacting	O
the	O
cell	O
with	O
an	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
an	O
inhibitor	O
of	O
p110	O
delta	O
.	O

The	O
Role	O
of	O
p110	O
delta	O
Signaling	O
in	O
Morbidity	O
and	O
Lung	O
Pathology	O
Induced	O
by	O
Influenza	O
Virus	O
Infection	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
preparing	O
splice	O
variants	O
of	O
TNFalpha	O
receptor	O
(	O
TNFR	O
)	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
and	O
the	O
resulting	O
TNFR	O
protein	O
variants	O
.	O

Such	O
variants	O
may	O
be	O
prepared	O
by	O
controlling	O
the	O
splicing	O
of	O
pre	O
-	O
mRNA	O
molecules	O
and	O
regulating	O
protein	O
expression	O
with	O
splice	O
switching	O
oligonucleotides	O
or	O
splice	O
switching	O
oligomers	O
(	O
SSOs	O
)	O
.	O

The	O
preferred	O
SSOs	O
according	O
to	O
the	O
invention	O
target	O
exon	O
7	O
or	O
8	O
of	O
TNFR1	O
(	O
TNFRSF1A	O
)	O
or	O
TNFR2	O
(	O
TNFRSF1A	O
)	O
pre	O
-	O
mRNA	O
,	O
typically	O
resulting	O
in	O
the	O
production	O
of	O
TNFR	O
variants	O
which	O
comprise	O
a	O
deletion	O
in	O
part	O
or	O
the	O
entire	O
exon	O
7	O
or	O
8	O
respectfully	O
.	O

SSOs	O
targeting	O
exon	O
7	O
are	O
found	O
to	O
result	O
in	O
a	O
soluble	O
form	O
of	O
the	O
TNFR	O
,	O
which	O
has	O
therapeutic	O
benefit	O
for	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O

The	O
SSO	O
's	O
are	O
characterized	O
in	O
that	O
they	O
are	O
substantially	O
incapable	O
or	O
incapable	O
of	O
recruiting	O
RNaseH.	O
Splice	O
Switching	O
Oligomers	O
for	O
TNF	O
Superfamily	O
Receptors	O
and	O
Their	O
Use	O
in	O
Treatment	O
of	O
Disease	O

A	O
therapeutic	O
composition	O
for	O
treating	O
glaucoma	O
or	O
for	O
reducing	O
intraocular	O
pressure	O
containing	O
a	O
combination	O
of	O
pharmaceutically	O
effective	O
amounts	O
of	O
drugs	O
including	O
(	O
i	O
)	O
a	O
Rho	O
kinase	O
inhibitor	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
(	B
R	I
)	I
-	I
(	I
+	I
)	I
-N-	I
(	I
1H	I
-	I
pyrrolo	I
[	I
2,3-b	I
]	I
pyridin-4-yl	I
)	I
-4-	I
(	I
1-aminoethyl	I
)	I
benzamide	I
and	O
1-	B
(	I
5-isoquinolinesulfonyl	I
)	I
-homopiperazine	I
,	O
or	O
a	O
salt	O
thereof	O
and	O
(	O
ii	O
)	O
a	O
prostaglandin	B
which	O
is	O
latanoprost	B
or	O
a	O
salt	O
of	O
latanoprost	B
,	O
and	O
(	O
iii	O
)	O
optionally	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

A	O
therapeutic	O
composition	O
for	O
treating	O
glaucoma	O
or	O
for	O
reducing	O
intraocular	O
pressure	O
containing	O
a	O
combination	O
of	O
pharmaceutically	O
effective	O
amounts	O
of	O
drugs	O
comprising	O
(	O
i	O
)	O
a	O
Rho	O
kinase	O
which	O
is	O
(	B
R	I
)	I
-	I
(	I
+	I
)	I
-N-	I
(	I
1H	I
-	I
pyrrolo	I
[	I
2,3-b	I
]	I
pyridin-4-yl	I
)	I
-4-	I
(	I
1-aminoethyl	I
)	I
benzamide	I
or	O
a	O
slat	O
thereof	O
and	O
(	O
ii	O
)	O
a	O
prostaglandin	B
which	O
is	O
isopropyl	B
unoprostone	I
or	O
a	O
salt	O
thereof	O
,	O
and	O
(	O
iii	O
)	O
optionally	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

THERAPEUTIC	O
AGENT	O
FOR	O
GLAUCOMA	O
COMPRISING	O
Rho	O
KINASE	O
INHIBITOR	O
AND	O
PROSTAGLANDIN	B

The	O
invention	O
relates	O
to	O
Δ4,5	O
glycuronidase	O
,	O
related	O
compositions	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Delta	O
4	O
,	O
5	O
glycuronidase	O
compositions	O
and	O
methods	O
related	O
thereto	O

The	O
present	O
invention	O
relates	O
to	O
a	O
WT1	O
peptide	O
which	O
has	O
an	O
amino	O
acid	O
sequence	O
consisting	O
of	O
contiguous	O
amino	O
acids	O
derived	O
from	O
a	O
WT1	O
protein	O
and	O
induces	O
WT1-specific	O
helper	O
T	O
cells	O
by	O
binding	O
to	O
an	O
MHC	O
class	O
II	O
molecule	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
them	O
and	O
the	O
like	O
.	O

Cancer	O
antigen	O
helper	O
peptide	O

Pharmaceutical	O
formulations	O
comprising	O
multiple	O
drugs	O
,	O
for	O
treating	O
or	O
preventing	O
cardiovascular	O
disease	O
.	O

Embodiments	O
are	O
capsules	O
containing	O
individual	O
drugs	O
,	O
or	O
combinations	O
of	O
drugs	O
,	O
in	O
the	O
form	O
of	O
small	O
tablets	O
.	O

Fixed	O
dose	O
drug	O
combination	O
formulations	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
mixtures	O
containing	O
2-hydroxyphenylaldehyde	B
and	O
2-hydroxyphenylketone	B
heterocycloylhydrazone	B
compounds	O
and	O
copper	B
for	O
controlling	O
the	O
growth	O
of	O
fungi	O
and	O
algae	O
.	O

Synergistic	O
fungicidal	O
and	O
algicidal	O
compositions	O
including	O
2-hydroxyphenylaldehyde	B
and	O
2-hydroxyphenylketone	B
heterocycloylhydrazones	B
and	O
copper	B

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
mixtures	O
containing	O
7-hydroxy	B
-	I
indanone	I
benzoylhydrazone	I
compounds	O
and	O
copper	O
for	O
controlling	O
the	O
growth	O
of	O
fungi	O
and	O
algae	O
.	O

Synergistic	O
fungicidal	O
and	O
algicidal	O
compositions	O
including	O
7-hydroxy	B
-	I
indanone	I
benzoylhydrazones	I
and	O
copper	B

A	O
mosquito	O
repellent	O
solution	O
to	O
prevent	O
mosquito	O
bite	O
,	O
comprising	O
0.1	O
-	O
9.9	O
%	O
organic	O
acid	O
of	O
total	O
weight	O
as	O
active	O
principle	O
,	O
88	O
-	O
99.6	O
%	O
water	O
as	O
solvent	O
.	O

The	O
organic	O
acid	O
is	O
single	O
acid	O
or	O
mixed	O
composition	O
out	O
of	O
ethyl	B
butyrate	I
,	O
propionic	B
acid	I
,	O
n	B
-	I
butyric	I
acid	I
,	O
isobutyric	B
acid	I
,	O
isobutyric	B
,	O
valeric	B
acid	I
,	O
hexanoic	B
acid	I
,	O
n	B
-	I
Heptanoic	I
acid	I
,	O
L	B
-	I
Lactic	I
Acid	I
and	O
malic	B
acid	I
.	O

The	O
composition	O
solution	O
to	O
prevent	O
mosquito	O
bite	O
disturb	O
mosquitoes	O
'	O
olfactory	O
sensation	O
through	O
imitating	O
human	O
's	O
smell	O
of	O
skin	O
and	O
breath	O
;	O
all	O
raw	O
materials	O
base	O
on	O
the	O
standard	O
of	O
food	O
grade	O
,	O
so	O
the	O
composition	O
is	O
safe	O
to	O
human	O
beings	O
,	O
particularly	O
to	O
infant	O
,	O
pregnant	O
women	O
,	O
children	O
and	O
the	O
old	O
who	O
are	O
weaker	O
.	O

The	O
composition	O
solution	O
does	O
not	O
work	O
by	O
killing	O
mosquitoes	O
so	O
it	O
would	O
not	O
relate	O
to	O
resistance	O
and	O
ecology	O
risk	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
with	O
low	O
costs	O
;	O
there	O
is	O
no	O
three	O
wastes	O
and	O
friendly	O
to	O
the	O
environment	O
.	O

The	O
composition	O
solution	O
applies	O
to	O
the	O
preparation	O
of	O
preventing	O
mosquito	O
bite	O
,	O
relieving	O
itching	O
and	O
detumescence	O
,	O
and	O
air	O
sterilization	O
.	O

Mosquito	O
repellent	O
solution	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
semi	O
-	O
synthetic	O
macrolides	O
having	O
anti	O
-	O
inflammatory	O
activity	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
14-	O
and	O
15-membered	O
macrolides	O
substituted	O
at	O
the	O
4″	O
position	O
,	O
to	O
their	O
pharmaceutically	O
acceptable	O
derivatives	O
,	O
to	O
processes	O
and	O
intermediates	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
activity	O
and	O
use	O
in	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
and	O
conditions	O
in	O
humans	O
and	O
animals	O
,	O
especially	O
those	O
diseases	O
associated	O
with	O
excessive	O
secretion	O
of	O
TNF	O
-	O
α	O
,	O
IL-1	O
,	O
IL-8	O
,	O
IL-2	O
or	O
IL-5	O
;	O
and/or	O
inhibitor	O
of	O
excessive	O
lymphocyte	O
proliferation	O
;	O
and/or	O
excessive	O
granulocyte	O
degranulation	O
.	O

Macrolides	O
with	O
Anti	O
-	O
Inflammatory	O
Activity	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
related	O
disorders	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
combined	O
therapies	O
that	O
modulate	O
angiogenesis	O
for	O
treating	O
said	O
disease	O
.	O

Therapeutic	O
approaches	O
for	O
treating	O
alzheimer	O
disease	O
and	O
related	O
disorders	O
through	O
a	O
modulation	O
of	O
angiogenesis	O

A	O
method	O
of	O
inhibiting	O
the	O
inflammatory	O
process	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
a	O
mammal	O
suffering	O
from	O
inflammation	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
where	O
:	O
R	O
is	O
a	O
C1-C10	B
alkylene	I
group	O
,	O
in	O
which	O
,	O
when	O
the	O
number	O
of	O
carbon	B
atoms	O
is	O
at	O
least	O
2	O
,	O
there	O
are	O
optionally	O
1	O
or	O
2	O
non	O
-	O
adjacent	O
double	O
bonds	O
;	O
1	O
to	O
3	O
non	O
-	O
adjacent	O
methylene	B
groups	O
are	O
optionally	O
replaced	O
by	O
NR1	B
(	O
where	O
R1	O
is	O
H	B
,	O
alkyl	B
,	O
or	O
acyl	B
)	O
,	O
O	B
,	O
or	O
S	B
;	O
and	O
1	O
or	O
2	O
methylene	B
groups	O
are	O
optionally	O
replaced	O
by	O
a	O
carbonyl	B
or	O
hydroxymethylene	B
group	O
and	O
pharmaceutically	O
acceptable	O
esters	B
or	O
salts	O
of	O
the	O
compounds	O
and	O
wherein	O
the	O
inflammatory	O
process	O
results	O
from	O
a	O
disease	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ulcerative	O
colitis	O
,	O
endotoxic	O
shock	O
,	O
rheumatoid	O
arthritis	O
,	O
juvenile	O
arthritis	O
,	O
osteoarthritis	O
,	O
psoriasis	O
,	O
Crohn	O
's	O
disease	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
multiple	O
sclerosis	O
,	O
insulin	O
dependent	O
diabetes	O
mellitus	O
,	O
gout	O
,	O
psoriatic	O
arthritis	O
,	O
reactive	O
arthritis	O
,	O
vital	O
or	O
post	O
-	O
viral	O
arthritis	O
and	O
ankylosing	O
spondylarthritis	O
.	O

Compounds	O
,	O
Compositions	O
and	O
Methods	O
for	O
the	O
Treatment	O
of	O
Inflammatory	O
Diseases	O

Disclosed	O
are	O
diagnostic	O
and	O
therapeutic	O
methods	O
related	O
to	O
squamous	O
cell	O
carcinoma	O
.	O

In	O
particular	O
,	O
the	O
diagnostic	O
methods	O
relate	O
to	O
detecting	O
miRNA-205	O
,	O
thereby	O
diagnosing	O
an	O
aggressive	O
form	O
of	O
squamous	O
cell	O
carcinoma	O
.	O

The	O
therapeutic	O
methods	O
relate	O
to	O
inhibiting	O
the	O
function	O
of	O
miRNA-205	O
,	O
thereby	O
treating	O
an	O
aggressive	O
form	O
of	O
squamous	O
cell	O
carcinoma	O
.	O

METHODS	O
FOR	O
DIAGNOSING	O
AND	O
TREATING	O
SQUAMOUS	O
CELL	O
CARCINOMA	O
UTILIZING	O
miRNA-205	O
AND	O
INHIBITORS	O
THEREOF	O

Described	O
are	O
matrix	O
binders	O
comprising	O
copolymers	O
based	O
on	O
amino	B
-	O
containing	O
polymers	O
,	O
as	O
well	O
as	O
their	O
use	O
in	O
preparing	O
active	O
compound	O
-	O
containing	O
granules	O
and	O
administration	O
forms	O
The	O
copolymers	O
having	O
basic	O
amino	B
groups	O
can	O
be	O
obtained	O
by	O
radical	O
polymerization	O
of	O
:	O
a	O
)	O
N	B
,	I
N	I
-	I
diethylaminoethyl	I
methacrylate	I
,	O
and	O
b	O
)	O
at	O
least	O
one	O
radically	O
polymerizable	O
compound	O
,	O
selected	O
from	O
esters	B
of	O
α	O
,	O
β	O
-	O
ethylenically	O
unsaturated	O
mono-	O
and	O
dicarboxylic	B
acids	I
with	O
C1-C8	B
alkanols	I
.	O

Use	O
Of	O
Copolymers	O
Based	O
On	O
Amino	B
-	O
Containing	O
Polymers	O

As	O
Matrix	O
Binders	O
In	O
Preparing	O
Active	O
Compound	O
-	O
Containing	O
Granules	O
And	O
Administration	O
Forms	O

A	O
composition	O
for	O
promoting	O
wound	O
healing	O
comprises	O
a	O
bioadhesive	O
polymer	O
and	O
a	O
pharmaceutically	O
acceptable	O
liquid	O
medium	O
.	O

Such	O
a	O
composition	O
is	O
applied	O
to	O
a	O
wound	O
to	O
promote	O
healing	O
of	O
the	O
wound	O
.	O

The	O
bioadhesive	O
polymer	O
can	O
be	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
natural	O
or	O
synthetic	O
hydrophilic	O
polymers	O
and	O
hydrogels	O
.	O

Composition	O
and	O
Method	O
for	O
Promoting	O
Wound	O
Healing	O

A	O
method	O
for	O
inhibiting	O
formation	O
of	O
adhesions	O
following	O
abdominal	O
surgery	O
which	O
involves	O
application	O
of	O
an	O
anti	O
-	O
static	O
fatty	B
acid	I
ethoxylated	I
amide	I
(	O
Cocamide	B
DEA	I
)	O
in	O
a	O
matrix	O
that	O
is	O
placed	O
in	O
the	O
peritoneal	O
cavity	O
at	O
the	O
conclusion	O
of	O
an	O
abdominal	O
surgery	O
and	O
which	O
releases	O
this	O
anti	O
-	O
adhesive	O
chemical	O
over	O
a	O
predetermined	O
time	O
in	O
a	O
range	O
up	O
to	O
seven	O
days	O
.	O

Tests	O
conducted	O
on	O
laboratory	O
rats	O
established	O
that	O
the	O
method	O
reduced	O
the	O
incidence	O
of	O
adhesions	O
from	O
100	O
percent	O
(	O
100	O
%	O
)	O
in	O
a	O
test	O
model	O
to	O
near	O
zero	O
in	O
the	O
majority	O
of	O
treated	O
animals	O
.	O

In	O
an	O
alternative	O
embodiment	O
,	O
andrographalide	O
was	O
delivered	O
via	O
a	O
pump	O
with	O
similar	O
results	O
.	O

In	O
still	O
another	O
embodiment	O
,	O
an	O
effective	O
amount	O
of	O
50	O
%	O
phosphatidylchorene	B
and	O
propylene	B
glycol	I
was	O
delivered	O
,	O
via	O
a	O
pump	O
,	O
into	O
the	O
abdominal	O
cavity	O
,	O
again	O
with	O
similar	O
results	O
.	O

Apparatus	O
and	O
Method	O
for	O
Reducing	O
the	O
Occurrence	O
of	O
Post	O
-	O
Surgical	O
Adhesions	O

The	O
present	O
invention	O
pertains	O
to	O
methods	O
for	O
therapeutic	O
and	O
prophylactic	O
treatment	O
of	O
cats	O
against	O
FIV	O
infection	O
.	O

Methods	O
of	O
the	O
present	O
invention	O
utilize	O
a	O
combination	O
of	O
antiretroviral	O
compounds	O
to	O
treat	O
or	O
prevent	O
FIV	O
infection	O
in	O
a	O
feline	O
animal	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
method	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
AZT	B
and	O
another	O
nucleoside	O
analog	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
3TC	B
to	O
the	O
animal	O
.	O

In	O
another	O
embodiment	O
,	O
cats	O
are	O
given	O
an	O
effective	O
dose	O
(	O
s	O
)	O
of	O
AZT	B
,	O
3TC	B
,	O
and	O
a	O
retroviral	O
protease	O
inhibitor	O
.	O

Combination	O
therapy	O
for	O
treatment	O
of	O
fiv	O
infection	O

An	O
extended	O
regimen	O
for	O
treatment	O
of	O
HER-2	O
/	O
neu	O
overexpressed	O
/	O
amplified	O
cancer	O
is	O
described	O
,	O
with	O
involves	O
delivering	O
a	O
course	O
of	O
neratinib	B
therapy	O
to	O
HER-2	O
/	O
neu	O
overexpressed	O
/	O
amplified	O
cancer	O
patients	O
following	O
the	O
completion	O
of	O
surgical	O
and	O
adjuvant	O
therapy	O
.	O

The	O
neratinib	B
regimen	O
may	O
be	O
continued	O
for	O
upwards	O
of	O
twelve	O
months	O
to	O
five	O
years	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
kits	O
designed	O
to	O
facilitate	O
compliance	O
with	O
the	O
regimen	O
.	O

Treatment	O
regimen	O
utilizing	O
neratinib	B
for	O
breast	O
cancer	O

An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
marker	O
for	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
and	O
more	O
specifically	O
,	O
to	O
provide	O
a	O
marker	O
whose	O
expression	O
may	O
be	O
specifically	O
increased	O
or	O
decreased	O
in	O
RA	O
.	O

Another	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
confirm	O
whether	O
or	O
not	O
miRNA	O
serving	O
as	O
the	O
marker	O
is	O
involved	O
as	O
the	O
etiology	O
of	O
RA	O
,	O
and	O
to	O
provide	O
an	O
inspection	O
method	O
for	O
RA	O
and	O
a	O
therapeutic	O
agent	O
for	O
RA	O
each	O
using	O
the	O
miRNA	O
involved	O
.	O

The	O
marker	O
includes	O
miRNA	O
(	O
for	O
example	O
,	O
miR124a	O
)	O
whose	O
expression	O
is	O
specifically	O
increased	O
or	O
decreased	O
in	O
RA	O
synovial	O
cells	O
based	O
on	O
a	O
small	O
RNA	O
expression	O
profile	O
in	O
the	O
RA	O
synovial	O
cells	O
.	O

In	O
addition	O
,	O
the	O
therapeutic	O
agent	O
for	O
RA	O
includes	O
miRNA	O
(	O
for	O
example	O
,	O
miR124a	O
)	O
as	O
an	O
active	O
ingredient	O
.	O

Micro	O
-	O
RNA	O
Associated	O
With	O
Rheumatoid	O
Arthritis	O

This	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
highly	O
conserved	O
sequences	O
of	O
viral	O
genome	O
,	O
especially	O
from	O
a	O
highly	O
conserved	O
domain	O
of	O
enteroviral	O
genome	O
as	O
templates	O
to	O
design	O
target	O
small	O
ligand	O
RNAs	O
(	O
sliRNAs	O
)	O
.	O

The	O
resulting	O
sliRNAs	O
are	O
therapeutically	O
active	O
ingredients	O
in	O
the	O
treatment	O
of	O
the	O
related	O
diseases	O
caused	O
by	O
pathological	O
angiogenesis	O
.	O

Application	O
of	O
Highly	O
Conserved	O
Domain	O
Sequences	O
From	O
Viral	O
Genome	O
As	O
Template	O
To	O
Design	O
Therapeutic	O
Slirnas	O

Therapeutic	O
particles	O
contain	O
metal	O
ions	O
and	O
are	O
characterized	O
by	O
the	O
use	O
of	O
unique	O
ligand	O
sets	O
capable	O
of	O
making	O
the	O
metal	O
ion	O
complex	O
soluble	O
in	O
biological	O
media	O
to	O
induce	O
selective	O
toxicity	O
in	O
diseased	O
cells	O
.	O

The	O
particles	O
may	O
comprise	O
a	O
polymeric	O
base	O
particle	O
,	O
at	O
least	O
one	O
pharmaceutically	O
active	O
metal	O
ion	O
,	O
including	O
metal	O
ions	O
from	O
more	O
than	O
one	O
metal	O
element	O
,	O
a	O
ligand	O
that	O
is	O
covalently	O
attached	O
to	O
the	O
polymeric	O
base	O
particle	O
and	O
attached	O
to	O
the	O
metal	O
ion	O
via	O
a	O
stimuli	O
-	O
responsive	O
bond	O
,	O
and	O
a	O
cell	O
targeting	O
component	O
.	O

When	O
the	O
metal	O
ion	O
-	O
containing	O
particle	O
enters	O
a	O
pre	O
-	O
defined	O
environment	O
,	O
the	O
ligands	O
binding	O
the	O
metal	O
to	O
the	O
particle	O
are	O
broken	O
,	O
triggering	O
release	O
of	O
the	O
free	O
metal	O
ion	O
while	O
the	O
original	O
ligands	O
remain	O
covalently	O
bound	O
to	O
the	O
particle	O
.	O

Synthesis	O
and	O
use	O
of	O
therapeutic	O
metal	O
ion	O
containing	O
polymeric	O
particles	O

Modified	O
green	O
tea	O
polyphenols	B
and	O
methods	O
of	O
their	O
use	O
are	O
provided	O
.	O

One	O
aspect	O
provides	O
compounds	O
and	O
compositions	O
containing	O
green	O
tea	O
polyphenols	B
with	O
one	O
on	O
more	O
ester	O
-	O
linked	O
fatty	B
acids	I
.	O

Modified	O
green	O
tea	O
polyphenol	B
formulations	O

Described	O
herein	O
are	O
progenitor	O
cancer	O
cells	O
and	O
cell	O
lines	O
isolated	O
from	O
human	O
breast	O
ductal	O
carcinoma	O
in	O
situ	O
(	O
DCIS	O
)	O
lesions	O
and	O
the	O
uses	O
of	O
these	O
cells	O
or	O
cell	O
lines	O
in	O
drug	O
design	O
,	O
drug	O
screening	O
,	O
and	O
monitoring	O
in	O
vivo	O
therapy	O
.	O

The	O
DCIS	O
malignant	O
precursor	O
cells	O
or	O
cell	O
lines	O
are	O
epithelial	O
in	O
origin	O
,	O
are	O
positive	O
for	O
markers	O
of	O
autophagy	O
,	O
show	O
at	O
least	O
one	O
genetic	O
difference	O
from	O
normal	O
cells	O
of	O
said	O
fragment	O
,	O
form	O
3-D	O
tube	O
-	O
like	O
structures	O
or	O
ball	O
aggregates	O
,	O
or	O
are	O
inhibited	O
in	O
formation	O
of	O
3-D	O
structures	O
and	O
migration	O
by	O
treatment	O
with	O
chloroquine	O
.	O

Malignant	O
precursor	O
cells	O
from	O
ductal	O
carcinoma	O
in	O
situ	O
lesions	O

The	O
disclosure	O
features	O
crystalline	O
tripeptide	B
keto	I
epoxide	I
compounds	O
,	O
methods	O
of	O
their	O
preparation	O
,	O
and	O
related	O
pharmaceutical	O
compositions	O
.	O

Crystalline	O
tripeptide	B
epoxy	I
ketone	I
protease	O
inhibitors	O

This	O
invention	O
relates	O
to	O
a	O
prodrug	O
comprising	O
a	O
partial	O
structure	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
,	O
where	O
R1	O
and	O
R2	O
are	O
hydrogen	B
,	O
alkyl	B
,	O
or	O
aryl	B
radicals	I
.	O

Method	O
For	O
Improved	O
Bioactivation	O
Of	O
Pharmaceuticals	O

The	O
invention	O
provides	O
for	O
methods	O
of	O
upregulating	O
endogenous	O
GDNF	O
by	O
inhibiting	O
Shh	O
signaling	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
for	O
increasing	O
the	O
production	O
of	O
cholinergic	O
neurons	O
and	O
dopamine	B
neurons	O
by	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
neurogenesis	O
in	O
a	O
subject	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
for	O
treating	O
a	O
neurodegenerative	O
disorder	O
in	O
a	O
subject	O
.	O

SHH	O
Regulation	O
and	O
Methods	O
Thereof	O

Disclosed	O
is	O
a	O
cream	O
formulation	O
containing	O
calamine	O
,	O
an	O
H1	O
antihistamine	O
,	O
and	O
a	O
corticosteroid	O
for	O
the	O
reduction	O
of	O
inflammation	O
,	O
redness	O
and	O
itching	O
associated	O
with	O
acute	O
and	O
chronic	O
allergic	O
skin	O
disease	O
.	O

Allergic	O
skin	O
desease	O
topical	O
cream	O

Provided	O
herein	O
are	O
methods	O
for	O
treating	O
certain	O
conditions	O
,	O
including	O
fibrosis	O
,	O
inflammatory	O
,	O
and	O
autoimmune	O
conditions	O
,	O
with	O
conjugated	O
compounds	O
having	O
Toll	O
-	O
like	O
receptor	O
modulatory	O
activity	O
.	O

Treatment	O
of	O
conditions	O
by	O
toll	O
-	O
like	O
receptor	O
modulators	O

Certain	O
heterocyclic	B
amide	I
compounds	O
are	O
described	O
.	O

The	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
disease	O
states	O
,	O
disorders	O
,	O
and	O
conditions	O
mediated	O
by	O
TRPA1	O
activity	O
,	O
such	O
as	O
pain	O
,	O
arthritis	O
,	O
itch	O
,	O
cough	O
,	O
asthma	O
,	O
or	O
inflammatory	O
bowel	O
disease	O
.	O

Heterocyclic	B
amides	I
as	O
modulators	O
of	O
trpa1	O

The	O
use	O
of	O
5-	B
(	I
2,4-Dihydroxy-5-isopropyl	I
-	I
phenyl	I
)	I
-4-	I
(	I
4-morpholin-4-ylmethyl	I
-	I
phenyl	I
)	I
-isoxazole-3-carboxylic	I
acid	I
ethylamide	I
or	O
a	O
tautomer	O
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
a	O
hydrate	B
or	O
a	O
solvate	O
for	O
the	O
treatment	O
of	O
cancer	O
of	O
the	O
bladder	O
,	O
the	O
colon	O
,	O
the	O
liver	O
,	O
the	O
lung	O
,	O
the	O
breast	O
,	O
the	O
vagina	O
,	O
the	O
ovaries	O
,	O
the	O
pancreas	O
,	O
the	O
kidney	O
,	O
the	O
stomach	O
,	O
the	O
gastrointestinal	O
tract	O
,	O
the	O
prostate	O
,	O
the	O
head	O
and	O
neck	O
,	O
the	O
peritoneal	O
cavity	O
,	O
the	O
thyroid	O
,	O
the	O
bone	O
,	O
the	O
brain	O
,	O
the	O
central	O
nervous	O
system	O
and/or	O
the	O
blood	O
and/or	O
for	O
the	O
treatment	O
of	O
myelodysplastic	O
syndrome	O
,	O
systemic	O
mastocytosis	O
,	O
von	O
Hippel	O
-	O
Lindau	O
syndrome	O
,	O
multicentric	O
Castleman	O
disease	O
and/or	O
psioriasis	O
.	O

Isoxazole	B
compound	O
for	O
the	O
treatment	O
of	O
cancer	O

The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
identifying	O
host	O
cell	O
molecules	O
which	O
may	O
be	O
modulated	O
to	O
inhibit	O
viral	O
replication	O
and	O
method	O
of	O
testing	O
antiviral	O
compounds	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
compositions	O
,	O
methods	O
and	O
medicaments	O
for	O
treating	O
viral	O
infections	O
and/or	O
diseases	O
or	O
conditions	O
caused	O
or	O
contributed	O
to	O
by	O
viruses	O
.	O

Anti	O
viral	O
therapy	O

The	O
present	O
invention	O
relates	O
to	O
taste	O
-	O
masked	O
oral	O
formulations	O
of	O
influenza	O
antivirals	O
.	O

The	O
taste	O
-	O
masked	O
pharmaceutical	O
formulations	O
for	O
oral	O
administration	O
comprise	O
one	O
or	O
more	O
influenza	O
antivirals	O
,	O
at	O
least	O
one	O
taste	O
-	O
masking	O
agent	O
and	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

Further	O
,	O
the	O
taste	O
-	O
masked	O
influenza	O
antiviral	O
formulations	O
of	O
the	O
present	O
invention	O
are	O
provided	O
in	O
the	O
form	O
of	O
dispersible	O
tablets	O
,	O
effervescent	O
tablets	O
,	O
orally	O
disintegrating	O
tablets	O
,	O
chewable	O
tablets	O
,	O
bite	O
-	O
dispersion	O
tablets	O
or	O
the	O
like	O
,	O
wherein	O
the	O
bitter	O
taste	O
of	O
influenza	O
antivirals	O
is	O
masked	O
thereby	O
providing	O
palatable	O
formulations	O
.	O

Taste	O
-	O
masked	O
oral	O
formulations	O
of	O
influenza	O
antivirals	O

In	O
one	O
embodiment	O
a	O
layered	O
pharmaceutical	O
formulation	O
includes	O
two	O
or	O
more	O
pharmaceutical	O
layers	O
and	O
an	O
intermediate	O
layer	O
disposed	O
between	O
at	O
least	O
two	O
of	O
the	O
two	O
or	O
more	O
pharmaceutical	O
layers	O
,	O
the	O
intermediate	O
layer	O
configured	O
to	O
dissolve	O
in	O
vivo	O
to	O
thereby	O
leave	O
the	O
two	O
or	O
more	O
pharmaceutical	O
layers	O
substantially	O
intact	O
.	O

In	O
one	O
embodiment	O
,	O
an	O
active	O
pharmaceutical	O
ingredient	O
in	O
at	O
least	O
one	O
of	O
the	O
pharmaceutical	O
layers	O
is	O
selected	O
from	O
bupropion	B
,	O
zonisamide	B
,	O
naltrexone	B
,	O
topiramate	B
,	O
phentermine	B
,	O
metformin	B
,	O
olanzapine	B
and	O
fluoxetine	B
.	O

Layered	O
pharmaceutical	O
formulations	O

The	O
present	O
invention	O
provides	O
a	O
mangiferin	B
-	I
berberine	I
salt	O
and	O
manufacturing	O
method	O
thereof	O
.	O

Otherwise	O
,	O
the	O
present	O
invention	O
also	O
provides	O
the	O
use	O
of	O
mangiferin	B
-	I
berberine	I
salt	O
as	O
AMPK	O
activator	O
.	O

Mangiferin	B
-	I
Berberine	I
Salt	O
,	O
Manufacturing	O
Method	O
and	O
Use	O
Thereof	O

The	O
present	O
invention	O
includes	O
compositions	O
and	O
methods	O
for	O
inhibiting	O
kinase	O
activity	O
to	O
protect	O
against	O
neurodegeneration	O
including	O
diseases	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
or	O
Huntington	O
's	O
disease	O
,	O
and	O
conditions	O
such	O
as	O
ischemic	O
stroke	O
comprising	O
the	O
step	O
of	O
providing	O
the	O
subject	O
with	O
a	O
therapeutically	O
affective	O
amount	O
of	O
1,4-benzoxazine	B
compounds	O
and	O
derivatives	O
thereof	O
.	O

1	B
,	I
4-Benzoxazine	I
Compounds	O
and	O
Derivatives	O
Thereof	O
as	O
Therapeutic	O
Drugs	O
for	O
the	O
Treatment	O
of	O
Neurodegenerative	O
Conditions	O

A	O
porous	O
,	O
self	O
-	O
sustaining	O
body	O
useful	O
as	O
a	O
scaffold	O
for	O
bone	O
grafting	O
is	O
provided	O
.	O

The	O
scaffold	O
comprises	O
a	O
carbonaceous	O
matrix	O
comprising	O
a	O
continuous	O
phase	O
having	O
a	O
surface	O
and	O
defining	O
a	O
plurality	O
of	O
open	O
spaces	O
throughout	O
the	O
matrix	O
.	O

The	O
internal	O
and	O
external	O
surfaces	O
of	O
the	O
matrix	O
are	O
coated	O
with	O
a	O
layer	O
or	O
film	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
osteogenic	O
materials	O
,	O
therapeutic	O
agents	O
,	O
and	O
combinations	O
thereof	O
.	O

The	O
porous	O
body	O
comprises	O
organic	O
materials	O
and	O
is	O
substantially	O
free	O
of	O
metals	O
.	O

Methods	O
of	O
making	O
and	O
using	O
the	O
porous	O
self	O
-	O
sustaining	O
body	O
are	O
also	O
provided	O
,	O
along	O
with	O
kits	O
for	O
facilitating	O
the	O
same	O
.	O

Synthetic	O
bone	O
grafts	O
constructed	O
from	O
carbon	B
foam	O
materials	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
composition	O
for	O
treating	O
bacterial	O
skin	O
infections	O
,	O
along	O
with	O
skin	O
rejuvenation	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
cream	O
comprising	O
a	O
biopolymer	O
,	O
and	O
an	O
antibacterial	O
active	O
ingredient	O
.	O

It	O
discloses	O
a	O
composition	O
for	O
treating	O
fungal	O
skin	O
infections	O
along	O
with	O
skin	O
rejuvenation	O
containing	O
a	O
)	O
a	O
biopolymer	O
in	O
the	O
form	O
of	O
chitosan	O
,	O
b	O
)	O
an	O
active	O
pharmaceutical	O
ingredient	O
(	O
API	O
)	O
composition	O
in	O
the	O
form	O
of	O
framycetin	B
sulphate	I
used	O
in	O
treating	O
bacterial	O
skin	O
infections	O
,	O
c	O
)	O
a	O
cream	O
base	O
containing	O
primary	O
and	O
secondary	O
emulsifiers	O
,	O
waxy	O
materials	O
,	O
co	O
-	O
solvents	O
,	O
acids	O
,	O
preservatives	O
,	O
buffering	O
agents	O
,	O
anti	O
oxidants	O
,	O
chelating	O
agents	O
,	O
and	O
humectants	O
and	O
d	O
)	O
water	O
.	O

The	O
active	O
ingredients	O
,	O
namely	O
chitosan	O
,	O
and	O
an	O
anti	O
bacterial	O
agent	O
in	O
the	O
form	O
of	O
framycetin	B
sulphate	I
,	O
are	O
incorporated	O
in	O
cream	O
base	O
for	O
use	O
in	O
treating	O
bacterial	O
skin	O
infections	O
with	O
allergy	O
&	O
itching	O
,	O
&	O
wounds	O
on	O
human	O
skin	O
involving	O
contacting	O
human	O
skin	O
with	O
the	O
above	O
identified	O
composition	O
.	O

Medicinal	O
Cream	O
Made	O
Using	O
Framycetin	B
Sulphate	I
and	O
Chitosan	O
and	O
a	O
Process	O
to	O
Make	O
the	O
Same	O

Described	O
herein	O
are	O
methods	O
for	O
improving	O
engraftment	O
of	O
hematopoietic	O
cells	O
in	O
an	O
individual	O
following	O
hematopoietic	O
progenitor	O
cell	O
transplantation	O
(	O
e.g.	O
,	O
via	O
bone	O
marrow	O
or	O
cord	O
blood	O
transplantation	O
)	O
.	O

Methods	O
for	O
increasing	O
hematopoietic	O
progenitor	O
cell	O
proliferation	O
in	O
individuals	O
with	O
bone	O
marrow	O
aplasia	O
are	O
also	O
described	O
.	O

The	O
methods	O
involve	O
administering	O
an	O
agent	O
that	O
inhibits	O
adipogenesis	O
,	O
adipocyte	O
growth	O
,	O
adipocyte	O
differentiation	O
and/or	O
adipocyte	O
proliferation	O
.	O

Methods	O
for	O
enhancing	O
hematopoietic	O
progenitor	O
cell	O
engraftment	O

Novel	O
alkoxy	B
-	I
thienopyrimidine	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
have	O
the	O
meaning	O
according	O
to	O
claim	O
1	O
,	O
are	O
inhibitors	O
of	O
TGF	O
-	O
beta	O
receptor	O
I	O
kinase	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
tumors	O
.	O

Alkoxy	B
-	I
thienopyrimidines	I
as	O
tgf	O
-	O
beta	O
receptor	O
kinase	O
modulators	O

Improved	O
topical	O
gel	O
compositions	O
,	O
such	O
as	O
those	O
containing	O
brimonidine	B
,	O
for	O
the	O
treatment	O
of	O
skin	O
disorders	O
are	O
described	O
.	O

The	O
gel	O
compositions	O
contain	O
carbomer	O
and	O
paraben	O
,	O
and	O
are	O
substantially	O
free	O
of	O
paraben	O
crystalline	O
particles	O
after	O
an	O
extended	O
period	O
of	O
storage	O
.	O

Topical	O
gel	O
compositions	O
and	O
methods	O
of	O
use	O

The	O
instant	O
invention	O
relates	O
to	O
the	O
heptasaccharide	B
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
its	O
acid	O
form	O
or	O
in	O
the	O
form	O
of	O
any	O
one	O
of	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
and	O
to	O
its	O
process	O
of	O
preparation	O
.	O

The	O
oligosaccharide	B
of	O
formula	O
(	O
I	O
)	O
is	O
useful	O
as	O
an	O
antithrombotic	O
agent	O
.	O

Sulfated	B
heptasaccharide	I
and	O
its	O
use	O
as	O
an	O
antithrombotic	O
agent	O

The	O
present	O
disclosure	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
promoting	O
the	O
extension	O
of	O
a	O
neural	O
cell	O
by	O
increasing	O
the	O
expression	O
of	O
activity	O
of	O
cofilin	O
in	O
the	O
cell	O
.	O

The	O
increase	O
can	O
be	O
local	O
to	O
the	O
end	O
of	O
the	O
neural	O
cell	O
in	O
need	O
of	O
extension	O
and	O
the	O
neural	O
cell	O
can	O
be	O
a	O
cell	O
in	O
an	O
individual	O
.	O

By	O
extending	O
the	O
neural	O
cell	O
to	O
reach	O
its	O
synaptic	O
target	O
,	O
the	O
methods	O
and	O
compositions	O
of	O
the	O
present	O
disclosure	O
can	O
also	O
be	O
used	O
for	O
treating	O
neurological	O
diseases	O
characterized	O
by	O
damaged	O
or	O
degenerated	O
neurons	O
.	O

Accelerated	O
extension	O
of	O
axons	O

Methods	O
and	O
compositions	O
are	O
provided	O
for	O
treating	O
lung	O
diseases	O
,	O
including	O
but	O
not	O
limited	O
to	O
infections	O
and	O
small	O
cell	O
and	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
by	O
conjugating	O
a	O
drug	O
of	O
interest	O
to	O
glycerol	B
ethers	I
or	O
glycerol	B
phosphate	I
ethers	I
.	O

Lung	O
-	O
targeted	O
drugs	O

Methods	O
for	O
treating	O
respiratory	O
and	O
gastrointestinal	O
diseases	O
mediated	O
by	O
a	O
P2X3	O
and/or	O
a	O
P2X2	O
/	O
3	O
receptor	O
antagonist	O
,	O
the	O
methods	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
D	O
,	O
X	O
,	O
Y	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
herein	O
.	O

Methods	O
of	O
using	O
diaminopyrimidine	B
as	O
p2x3	O
and	O
p2x2	O
/	O
3	O
receptor	O
modulators	O
for	O
treatment	O
of	O
respiratory	O
and	O
gastrointestinal	O
diseases	O

One	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
two	O
or	O
more	O
active	O
agents	O
that	O
when	O
taken	O
together	O
can	O
be	O
used	O
to	O
treat	O
,	O
e.g.	O
,	O
insomnia	O
and/or	O
depression	O
.	O

The	O
first	O
component	O
of	O
the	O
pharmaceutical	O
composition	O
is	O
a	O
GABA	O
receptor	O
modulating	O
compound	O
.	O

The	O
second	O
component	O
of	O
the	O
pharmaceutical	O
composition	O
is	O
a	O
serotonin	B
reuptake	O
inhibitor	O
,	O
a	O
norepinephrine	B
reuptake	O
inhibitor	O
,	O
a	O
5-HT2A	O
modulator	O
,	O
or	O
dopamine	B
reuptake	O
inhibitor	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
pharmaceutical	O
composition	O
comprises	O
eszopiclone	B
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
pharmaceutical	O
composition	O
comprises	O
eszopiclone	B
and	O
fluoxetine	B
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treating	O
a	O
sleep	O
abnormality	O
,	O
treating	O
insomnia	O
,	O
treating	O
depression	O
,	O
augmenting	O
antidepressant	O
therapy	O
,	O
eliciting	O
a	O
dose	O
-	O
sparing	O
effect	O
,	O
reducing	O
depression	O
relapse	O
,	O
improving	O
the	O
efficacy	O
of	O
antidepressant	O
therapy	O
or	O
improving	O
the	O
tolerability	O
of	O
antidepressant	O
therapy	O
,	O
comprising	O
co	O
-	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
GABA	B
-	O
receptor	O
-	O
modulating	O
compound	O
;	O
and	O
a	O
SRI	O
,	O
NRI	O
,	O
5-HT2A	O
modulator	O
or	O
DRI	O
.	O

Combination	O
of	O
a	O
sedative	O
and	O
a	O
neurotransmitter	O
modulator	O
,	O
and	O
methods	O
for	O
treating	O
depression	O

Embodiments	O
disclosed	O
in	O
the	O
present	O
application	O
relate	O
to	O
a	O
composition	O
that	O
can	O
include	O
a	O
hepatitis	O
C	O
viral	O
polymerase	O
inhibitor	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
and	O
a	O
hepatitis	O
C	O
viral	O
protease	O
inhibitor	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
.	O

Additional	O
embodiments	O
disclosed	O
relate	O
to	O
methods	O
for	O
treating	O
a	O
disease	O
condition	O
such	O
as	O
a	O
hepatitis	O
C	O
virus	O
infection	O
,	O
liver	O
fibrosis	O
and/or	O
impaired	O
liver	O
function	O
with	O
a	O
hepatitis	O
C	O
viral	O
polymerase	O
inhibitor	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
and	O
a	O
hepatitis	O
C	O
viral	O
protease	O
inhibitor	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
prodrug	O
thereof	O
.	O

COMBINATION	O
OF	O
A	O
NUCLEOSIDE	O
POLYMERASE	O
INHIBITOR	O
WITH	O
A	O
MACROCYCLIC	O
PROTEASE	O
INHIBITOR	O
AND	O
USE	O
THEREOF	O
IN	O
THE	O
TREATMENT	O
OF	O
HEPATITIS	O
C	O
,	O
LIVER	O
FIBROSIS	O
AND	O
IMPAIRED	O
LIVER	O
FUNCTION	O
(	O
as	O
amended	O
)	O

The	O
present	O
invention	O
provides	O
deuterated	O
compounds	O
having	O
certain	O
biological	O
activities	O
that	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
inhibiting	O
cell	O
proliferation	O
,	O
modulating	O
protein	O
kinase	O
activity	O
and	O
modulating	O
polymerase	O
activity	O
.	O

The	O
deuterated	O
compounds	O
of	O
the	O
invention	O
can	O
modulate	O
casein	O
kinase	O
(	O
CK	O
)	O
activity	O
and/or	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
activity	O
.	O

The	O
invention	O
also	O
relates	O
in	O
part	O
to	O
methods	O
for	O
using	O
such	O
deuterated	O
compounds	O
as	O
therapeutic	O
agents	O
.	O

Deuterated	O
serine	B
-	O
threonine	B
protein	O
kinase	O
modulators	O

An	O
inhaler	O
includes	O
a	O
first	O
body	O
member	O
and	O
a	O
second	O
body	O
member	O
fit	O
closely	O
together	O
to	O
form	O
an	O
inhaler	O
body	O
,	O
and	O
an	O
outlet	O
.	O

The	O
first	O
body	O
member	O
has	O
a	O
medicament	O
chamber	O
containing	O
a	O
unit	O
dose	O
of	O
powdered	O
medicament	O
.	O

A	O
seal	O
such	O
as	O
a	O
foil	O
strip	O
seals	O
the	O
medicament	O
chamber	O
and	O
extends	O
outwardly	O
of	O
the	O
inhaler	O
body	O
.	O

In	O
use	O
,	O
one	O
end	O
of	O
the	O
seal	O
can	O
be	O
grasped	O
by	O
a	O
user	O
and	O
withdrawn	O
,	O
fully	O
or	O
partially	O
,	O
from	O
the	O
inhaler	O
body	O
,	O
to	O
release	O
the	O
powdered	O
medicament	O
from	O
the	O
medicament	O
chamber	O
.	O

The	O
second	O
body	O
member	O
includes	O
a	O
medicament	O
collection	O
well	O
in	O
which	O
the	O
medicament	O
is	O
collected	O
upon	O
its	O
release	O
from	O
the	O
medicament	O
chamber	O
.	O

The	O
medicament	O
collection	O
well	O
forms	O
part	O
of	O
an	O
airway	O
connecting	O
into	O
the	O
outlet	O
.	O

In	O
use	O
,	O
air	O
can	O
be	O
drawn	O
by	O
inhalation	O
at	O
the	O
outlet	O
to	O
entrain	O
the	O
powder	O
medicament	O
in	O
the	O
collection	O
well	O
for	O
inhalation	O
by	O
a	O
user	O
.	O

Unit	O
dose	O
dry	O
powder	O
inhaler	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
variables	O
for	O
Structural	O
Formula	O
I	O
are	O
defined	O
herein	O
.	O

Also	O
described	O
is	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
of	O
Structural	O
Formula	O
I	O
and	O
its	O
therapeutic	O
use	O
.	O

Tetracycline	B
Compounds	O

Microspheres	O
are	O
produced	O
by	O
contacting	O
a	O
solution	O
of	O
a	O
macromolecule	O
or	O
small	O
molecule	O
in	O
a	O
solvent	O
with	O
an	O
antisolvent	O
and	O
a	O
counterion	O
,	O
and	O
chilling	O
the	O
solution	O
.	O

The	O
microspheres	O
are	O
useful	O
for	O
preparing	O
pharmaceuticals	O
,	O
nutraceuticals	O
,	O
cosmetic	O
products	O
and	O
the	O
like	O
of	O
defined	O
dimensions	O
.	O

Technology	O
for	O
the	O
Preparation	O
of	O
Microparticles	O

Compositions	O
and	O
methods	O
are	O
provided	O
for	O
predicting	O
inhibitors	O
of	O
protein	O
targets	O
related	O
to	O
treatment	O
of	O
infectious	O
disease	O
,	O
for	O
example	O
,	O
bacterial	O
,	O
viral	O
,	O
or	O
parasitic	O
diseases	O
.	O

Methods	O
are	O
provided	O
for	O
predicting	O
inhibitors	O
of	O
protein	O
targets	O
related	O
to	O
treatment	O
infectious	O
disease	O
,	O
for	O
example	O
,	O
microbial	O
disease	O
,	O
utilizing	O
a	O
docking	O
with	O
dynamics	O
protocol	O
to	O
identify	O
inhibitors	O
,	O
or	O
utilizing	O
a	O
protein	O
structure	O
energy	O
function	O
to	O
identify	O
peptide	O
or	O
peptidomimetic	O
inhibitors	O
.	O

Compositions	O
And	O
Methods	O
For	O
Predicting	O
Inhibitors	O
Of	O
Protein	O
Targets	O

Compounds	O
having	O
drug	O
and	O
bio	O
-	O
affecting	O
properties	O
,	O
their	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
set	O
forth	O
.	O

In	O
particular	O
,	O
modified	O
C-3	O
and	O
C-28	O
betulinic	B
acid	I
derivatives	O
that	O
possess	O
unique	O
antiviral	O
activity	O
are	O
provided	O
as	O
HIV	O
maturation	O
inhibitors	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV	O
and	O
AIDS	O
.	O

C-28	O
amides	B
of	O
modified	O
c-3	O
betulinic	B
acid	I
derivatives	O
as	O
hiv	O
maturation	O
inhibitors	O

The	O
invention	O
relates	O
to	O
the	O
novel	O
materials	O
of	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
is	O
an	O
optionally	O
substituted	O
L	B
-	I
aryl	I
or	O
-heteroaryl	B
,	O
such	O
that	O
L	O
is	O
:	O
an	O
alkyl	B
or	O
CO	B
,	O
or	O
L	O
X	O
,	O
with	O
L	O
being	O
an	O
alkyl	B
and	O
X	O
being	O
O	B
or	O
S	B
;	O
R2	O
is	O
H	B
or	O
an	O
alkyl	B
;	O
R3	O
is	O
an	O
alkyl	B
optionally	O
substituted	O
by	O
Hal	O
;	O
and	O
R4	O
is	O
Hou	O
Hal	O
,	O
wherein	O
said	O
materials	O
are	O
in	O
any	O
isomeric	O
form	O
and	O
the	O
salts	O
thereof	O
,	O
to	O
be	O
used	O
as	O
drugs	O
.	O

Novel	O
2,3-dihydro-1h	B
-	I
imidazo	I
(	I
1,2-a	I
)	I
pyrimidin-5-one	I
derivatives	O
,	O
preparation	O
thereof	O
,	O
and	O
pharmaceutical	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
phenyl	B
oxadiazole	I
derivatives	O
,	O
processes	O
for	O
preparing	O
them	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
sphingosine-1-phosphate	B
receptors	O
.	O

Novel	O
phenyl	B
oxadiazole	I
derivatives	O
as	O
sphingosine	B
1-phosphate	I
(	O
s1p	O
)	O
receptor	O
modulators	O

This	O
invention	O
relates	O
to	O
a	O
stable	O
parenteral	O
aqueous	O
solutions	O
comprising	O
either	O
(	O
a	O
)	O
diclofenac	B
or	O
a	O
pharmaceutically	O
acceptable	O
diclofenac	B
salt	O
and	O
a	O
cyclodextrin	O
,	O
or	O
(	O
b	O
)	O
an	O
inclusion	O
complex	O
of	O
diclofenac	B
or	O
a	O
pharmaceutically	O
acceptable	O
diclofenac	B
salt	O
and	O
a	O
cyclodextrin	O
,	O
or	O
a	O
mixture	O
of	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
,	O
which	O
are	O
suitable	O
for	O
intramuscular	O
and	O
intravenous	O
administration	O
.	O

The	O
solutions	O
contain	O
diclofenac	B
or	O
diclofenac	B
salt	O
,	O
cyclodextrin	O
,	O
and	O
an	O
antioxidant	O
selected	O
from	O
monothioglycerol	B
,	O
or	O
a	O
combination	O
of	O
ethylene	B
diamine	I
tetra	I
-	I
acetic	I
acid	I
and	O
N	B
-	I
acetyl	I
-	I
cysteine	I
.	O

Stable	O
injectable	O
compositions	O

The	O
present	O
invention	O
is	O
directed	O
to	O
an	O
ophthalmic	O
lens	O
integrally	O
formed	O
with	O
a	O
hydrogel	O
,	O
the	O
hydrogel	O
including	O
a	O
copolymer	O
obtained	O
from	O
a	O
composition	O
containing	O
(	O
A	O
)	O
an	O
ionic	O
compound	O
including	O
a	O
cation	O
having	O
a	O
polymerizable	O
functional	O
group	O
,	O
and	O
a	O
fluorine	B
-	O
containing	O
anion	O
(	O
hereinafter	O
,	O
referred	O
to	O
as	O
(	O
A	O
)	O
ionic	O
compound	O
)	O
,	O
and	O
(	O
B	O
)	O
a	O
hydrophilic	O
compound	O
having	O
a	O
polymerizable	O
functional	O
group	O
.	O

Ophthalmic	O
lens	O

An	O
article	O
comprising	O
a	O
polyelectrolyte	O
complex	O
comprising	O
an	O
interpenetrating	O
network	O
of	O
at	O
least	O
one	O
predominantly	O
positively	O
charged	O
polyelectrolyte	O
polymer	O
and	O
at	O
least	O
one	O
predominantly	O
negatively	O
charged	O
polyelectrolyte	O
polymer	O
,	O
the	O
polyelectrolyte	O
complex	O
further	O
comprising	O
a	O
plurality	O
of	O
closed	O
-	O
shell	O
pores	O
,	O
the	O
plurality	O
of	O
pores	O
having	O
at	O
least	O
one	O
average	O
transverse	O
dimension	O
between	O
about	O
100	O
nanometer	O
and	O
about	O
1000	O
micrometers	O
.	O

Biocompatible	O
Polyelectrolyte	O
Complexes	O
and	O
Methods	O
of	O
Use	O

In	O
its	O
many	O
embodiments	O
,	O
the	O
present	O
invention	O
provides	O
provides	O
certain	O
pentafluorosulfur	B
imino	I
heterocyclic	I
compounds	O
,	O
including	O
compounds	O
Formula	O
(	O
I	O
)	O
:	O
and	O
tautomers	O
thereof	O
,	O
and	O
solvates	O
,	O
prodrugs	O
,	O
esters	B
,	O
and	O
deuterates	O
of	O
said	O
compounds	O
and	O
said	O
tautomers	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
said	O
compounds	O
,	O
tautomers	O
,	O
solvates	O
,	O
prodrugs	O
,	O
esters	B
,	O
and	O
deuterates	O
,	O
wherein	O
each	O
of	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R9	O
,	O
R11	O
,	O
ring	O
A	O
,	O
ring	O
B	O
,	O
m	O
,	O
n	O
,	O
p	O
,	O
q	O
,	O
r	O
,	O
-L1-	O
,	O
L2-	O
,	O
and	O
L3-	O
is	O
selected	O
independently	O
and	O
as	O
defined	O
herein	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
such	O
compounds	O
(	O
alone	O
and	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
active	O
agents	O
)	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
and	O
use	O
in	O
treating	O
pathologies	O
associated	O
with	O
amyloid	O
beta	O
(	O
Aβ	O
)	O
protein	O
,	O
including	O
Alzheimers	O
Disease	O
,	O
are	O
also	O
disclosed	O
.	O

Pentafluorosulfur	B
imino	I
heterocyclic	I
compounds	O
as	O
bace-1	O
inhibitors	O
,	O
compositions	O
,	O
and	O
their	O
use	O

The	O
invention	O
provides	O
a	O
method	O
of	O
treatment	O
of	O
cancer	O
,	O
wherein	O
a	O
individual	O
doses	O
of	O
picoplatin	B
,	O
each	O
of	O
less	O
than	O
about	O
200	O
mg	O
picoplatin	B
content	O
,	O
the	O
individual	O
doses	O
having	O
high	O
oral	O
bioavailability	O
,	O
are	O
administered	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

The	O
oral	O
bioavailability	O
can	O
be	O
greater	O
than	O
about	O
50	O
%	O
,	O
or	O
greater	O
than	O
about	O
75	O
%	O
,	O
or	O
greater	O
than	O
about	O
90	O
%	O
,	O
depending	O
upon	O
the	O
particular	O
dosage	O
form	O
and	O
dosing	O
regimen	O
used	O
.	O

The	O
invention	O
provides	O
a	O
quasi	O
-	O
metronomic	O
dosing	O
schedule	O
including	O
drug	O
dosing	O
intervals	O
and	O
drug	O
intermission	O
intervals	O
,	O
optionally	O
including	O
fasting	O
periods	O
prior	O
to	O
and	O
following	O
administration	O
of	O
each	O
individual	O
dose	O
of	O
picoplatin	B
.	O

High	O
bioavailability	O
oral	O
picoplatin	B
anti	O
-	O
cancer	O
therapy	O

The	O
present	O
invention	O
is	O
related	O
to	O
the	O
composition	O
and	O
methods	O
of	O
manufacture	O
of	O
orally	O
-	O
dissolvable	O
,	O
edible	O
films	O
as	O
a	O
vehicle	O
for	O
the	O
non	O
-	O
invasive	O
administration	O
of	O
active	O
drugs	O
through	O
the	O
mucosal	O
tissues	O
of	O
the	O
oral	O
cavity	O
.	O

The	O
films	O
include	O
a	O
water	O
soluble	O
film	O
-	O
forming	O
polymer	O
such	O
as	O
pullulan	O
.	O

Methods	O
for	O
producing	O
the	O
films	O
are	O
also	O
disclosed	O
.	O

Film	O
comprising	O
active	O
drugs	O

Disclosed	O
is	O
herein	O
a	O
composition	O
comprising	O
hexamidines	B
,	O
derivatives	O
thereof	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
and	O
retinoids	B
,	O
derivatives	O
thereof	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
has	O
effects	O
for	O
preventing	O
,	O
improving	O
or	O
treating	O
acne	O
;	O
controlling	O
sebum	O
;	O
pore	O
-	O
controlling	O
;	O
and	O
preventing	O
,	O
improving	O
or	O
treating	O
skin	O
pigmentation	O
.	O

Also	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
could	O
alleviate	O
skin	O
-	O
irritations	O
caused	O
with	O
retinoids	B
by	O
including	O
ceramides	O
.	O

Composition	O
for	O
skin	O
improvement	O
comprising	O
hexamidines	B
and	O
retinoids	B

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
preparing	O
a	O
comestible	O
product	O
comprising	O
xylitol	B
said	O
method	O
comprising	O
:	O
(	O
a	O
)	O
subjecting	O
a	O
composition	O
comprising	O
xylitol	B
in	O
an	O
amount	O
ranging	O
from	O
about	O
60	O
%	O
to	O
about	O
100	O
%	O
by	O
weight	O
to	O
extrusion	O
treatment	O
inside	O
an	O
extrusion	O
apparatus	O
under	O
conditions	O
sufficient	O
to	O
form	O
and	O
maintain	O
the	O
xylitol	B
in	O
a	O
slurry	O
and	O
(	O
b	O
)	O
then	O
shaping	O
the	O
extruded	O
slurry	O
and	O
cooling	O
the	O
product	O
to	O
form	O
a	O
solid	O
.	O

The	O
present	O
invention	O
additionally	O
is	O
directed	O
to	O
a	O
product	O
produced	O
therefrom	O
.	O

xylitol	B
containing	O
comestible	O
product	O

Described	O
are	O
estradiol	B
-	O
containing	O
pharmaceutical	O
compositions	O
and	O
,	O
and	O
methods	O
using	O
the	O
same	O
to	O
alleviate	O
menopause	O
-	O
related	O
symptoms	O
,	O
such	O
as	O
hot	O
flushes	O
,	O
by	O
topically	O
administering	O
estradiol	B
at	O
low	O
effective	O
doses	O
.	O

Treatment	O
of	O
menopause	O
-	O
associated	O
symptoms	O

This	O
invention	O
pertains	O
to	O
compositions	O
and	O
method	O
for	O
transdermal	O
administration	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
drugs	O
(	O
NSAID	O
)	O
for	O
the	O
treatment	O
of	O
inflammation	O
and	O
pain	O
caused	O
by	O
conditions	O
such	O
as	O
arthritis	O
,	O
degenerative	O
joint	O
disease	O
,	O
minor	O
strains	O
,	O
pains	O
,	O
and	O
contusions	O
.	O

This	O
invention	O
particularly	O
relates	O
to	O
transdermal	O
compositions	O
comprising	O
an	O
NSAID	O
,	O
a	O
bioadhesive	O
graft	O
copolymer	O
,	O
and	O
a	O
skin	O
penetration	O
enhancer	O
,	O
selected	O
from	O
pyrrolidone	B
or	O
its	O
derivatives	O
and	O
dialkyl	B
sulfoxides	I
and	O
combinations	O
thereof	O
.	O

Composition	O
for	O
transdermal	O
administration	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
flammatory	O
drug	O

Select	O
phytoestrogen	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
for	O
promoting	O
neurological	O
heath	O
and	O
prevention	O
of	O
age	O
-	O
related	O
neurodegeneration	O
,	O
such	O
as	O
AD	O
,	O
have	O
been	O
developed	O
.	O

These	O
select	O
phytoestrogen	O
formulations	O
are	O
composed	O
of	O
a	O
number	O
of	O
plant	O
-	O
derived	O
estrogenic	O
molecules	O
and/or	O
their	O
structural	O
analogues	O
and	O
exhibit	O
binding	O
preference	O
to	O
ERβ	O
over	O
ERα	O
and	O
agonist	O
activity	O
in	O
the	O
brain	O
.	O

These	O
ERβ	O
-	O
selective	O
phytoestrogen	O
formulations	O
cross	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
and	O
promote	O
estrogen	B
-	O
associated	O
neurotrophism	O
and	O
neuroprotections	O
mechanisms	O
in	O
the	O
brain	O
,	O
without	O
activating	O
proliferative	O
mechanisms	O
in	O
the	O
reproductive	O
tissues	O
and	O
are	O
therefore	O
devoid	O
of	O
other	O
estrogen	B
-	O
associated	O
problematic	O
aspects	O
.	O

These	O
are	O
administered	O
enterally	O
,	O
transdermally	O
,	O
transmucosally	O
,	O
intranasally	O
or	O
parenterally	O
,	O
in	O
a	O
dosage	O
effective	O
to	O
prevent	O
or	O
alleviate	O
neuronal	O
damage	O
,	O
effect	O
neuronal	O
regeneration	O
or	O
sustain	O
viability	O
,	O
increase	O
expression	O
of	O
anti	O
-	O
apoptotic	O
proteins	O
,	O
and/or	O
decrease	O
indicators	O
of	O
Alzheimer	O
's	O
Disease	O
.	O

Phytoestrogenic	O
formulations	O
for	O
alleviation	O
or	O
prevention	O
of	O
neurodegenerative	O
diseases	O

An	O
acidic	O
composition	O
for	O
external	O
use	O
which	O
contains	O
an	O
acidic	O
polysaccharide	O
and	O
water	O
as	O
essential	O
ingredients	O
,	O
and	O
an	O
agent	O
for	O
accelerating	O
the	O
penetration	O
into	O
skin	O
or	O
the	O
like	O
of	O
a	O
cosmetic	O
preparation	O
,	O
hair	O
-	O
growing	O
agent	O
or	O
preparation	O
for	O
external	O
use	O
,	O
each	O
containing	O
the	O
composition	O
.	O

The	O
composition	O
is	O
easy	O
to	O
manufacture	O
,	O
and	O
shows	O
a	O
stronger	O
cosmetic	O
or	O
therapeutic	O
effects	O
than	O
conventional	O
compositions	O
.	O

Acidic	O
composition	O
for	O
external	O
use	O
and	O
agent	O
for	O
accelerating	O
infiltration	O
of	O
cosmetic	O
preparation	O
,	O
hair	O
-	O
growing	O
agent	O
,	O
and	O
preparation	O
for	O
external	O
use	O
each	O
containing	O
the	O
composition	O
into	O
skin	O
or	O
the	O
like	O

6-amino	B
quinazoline	I
or	I
3-cyano	I
quinoline	I
derivatives	O
,	O
preparation	O
methods	O
and	O
pharmaceutical	O
uses	O
thereof	O
are	O
disclosed	O
.	O

Specifically	O
,	O
the	O
present	O
disclosure	O
discloses	O
novel	O
6-amino	B
quinazoline	I
or	I
3-cyano	I
quinoline	I
derivatives	O
presented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
or	O
tautomers	O
,	O
enantiomers	O
,	O
diastereomers	O
,	O
racemates	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
or	O
metabolites	O
,	O
metabolic	O
precursors	O
or	O
prodrugs	O
thereof	O
,	O
and	O
their	O
uses	O
as	O
treatment	O
agents	O
especially	O
as	O
protein	O
kinase	O
inhibitors	O
,	O
in	O
which	O
each	O
substitutent	O
group	O
of	O
general	O
formula	O
(	O
I	O
)	O
is	O
as	O
defined	O
in	O
the	O
specification	O
.	O

6-amino	B
quinazoline	I
or	I
3-cyano	I
quinoline	I
derivatives	O
,	O
preparation	O
methods	O
and	O
pharmaceutical	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
quinolinium	B
antiinfective	O
agents	O
in	O
which	O
the	O
qunolinium	B
nucleus	O
is	O
fused	O
to	O
an	O
indole	B
ring	O
or	O
the	O
qunolinium	B
nucleus	O
is	O
linked	O
to	O
a	O
cyclic	O
structure	O
through	O
an	O
opened	O
indole	B
or	O
a	O
benzothiophene	B
or	O
benzofuran	B
ring	O
.	O

The	O
compound	O
is	O
further	O
substituted	O
with	O
various	O
substituent	O
groups	O
.	O

The	O
compounds	O
are	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
and	O
(	O
III	O
)	O
:	O
Pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
also	O
included	O
.	O

3-SUBSTITUTED	B
QUINOLINIUM	I
AND	O
7H	B
-	I
INDOLO	I
[	I
2,3-c	I
]	I
QUINOLINIUM	I
SALTS	O
AS	O
NEW	O
ANTIINFECTIVES	O

Provided	O
is	O
a	O
stable	O
and	O
safe	O
oral	O
composition	O
that	O
acts	O
on	O
the	O
barrier	O
function	O
of	O
the	O
skin	O
for	O
alleviating	O
and/or	O
preventing	O
rough	O
skin	O
.	O

An	O
oral	O
composition	O
for	O
alleviating	O
rough	O
skin	O
and	O
an	O
oral	O
composition	O
for	O
preventing	O
rough	O
skin	O
are	O
provided	O
,	O
the	O
compositions	O
containing	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
D	B
-	I
glutamic	I
acid	I
and	O
derivatives	O
and/or	O
salts	O
thereof	O
.	O

Also	O
provided	O
are	O
a	O
pharmaceutical	O
composition	O
and/or	O
a	O
food	O
composition	O
containing	O
the	O
oral	O
composition	O
for	O
alleviating	O
rough	O
skin	O
or	O
the	O
oral	O
composition	O
for	O
preventing	O
rough	O
skin	O
.	O

Oral	O
composition	O
for	O
alleviating	O
rough	O
skin	O

The	O
present	O
invention	O
provides	O
use	O
of	O
protein	O
kinase	O
C	O
-	O
zeta	O
(	O
PKC	O
-	O
ζ	O
)	O
as	O
a	O
diagnostic	O
biomarker	O
for	O
breast	O
cancer	O
tumorigenesis	O
.	O

Also	O
provided	O
are	O
uses	O
of	O
PKC	O
-	O
zeta	O
inhibitors	O
for	O
inhibiting	O
breast	O
cancer	O
tumorigenesis	O
and	O
for	O
treatment	O
of	O
breast	O
cancer	O
.	O

Use	O
of	O
pkc	O
-	O
zeta	O
as	O
a	O
breast	O
cancer	O
tumorigenic	O
biomarker	O
as	O
well	O
as	O
a	O
target	O
for	O
treatment	O
of	O
breast	O
cancer	O

Formulations	O
and	O
methods	O
for	O
increasing	O
efficacies	O
and	O
flavors	O
of	O
jiaogulan	O
(	O
Gynostemma	O
pentaphyllum	O
and	O
related	O
species	O
)	O
by	O
combining	O
materials	O
derived	O
from	O
whole	O
plant	O
with	O
other	O
herbal	O
and	O
nutritional	O
materials	O
for	O
the	O
purpose	O
of	O
improving	O
general	O
well	O
-	O
being	O
in	O
mammals	O
by	O
increasing	O
metabolic	O
rate	O
through	O
fatigue	O
-	O
reducing	O
,	O
tonic	O
,	O
antioxidant	O
and	O
adaptogenic	O
effects	O
of	O
the	O
invention	O
.	O

Formulations	O
and	O
methods	O
for	O
increasing	O
efficacies	O
and	O
improving	O
flavors	O
of	O
formulations	O
containing	O
gynostemma	O
plant	O

During	O
clinical	O
trials	O
on	O
patients	O
suffering	O
from	O
neurological	O
disorders	O
,	O
it	O
has	O
been	O
observed	O
that	O
some	O
patients	O
obtain	O
dramatic	O
improvements	O
in	O
motor	O
control	O
and/or	O
higher	O
mental	O
functioning	O
,	O
when	O
they	O
receive	O
a	O
combination	O
of	O
dextromethorphan	B
and	O
quinidine	B
,	O
at	O
suitable	O
dosages	O
.	O

Improved	O
motor	O
control	O
has	O
been	O
exemplified	O
to	O
date	O
by	O
improved	O
ability	O
to	O
swallow	O
and/or	O
speak	O
,	O
among	O
victims	O
of	O
stroke	O
,	O
head	O
injury	O
,	O
or	O
ALS	O
.	O

Improved	O
higher	O
mental	O
functioning	O
has	O
been	O
exemplified	O
in	O
better	O
job	O
performance	O
,	O
increased	O
ability	O
to	O
analyze	O
and	O
solve	O
problems	O
,	O
and	O
increased	O
ability	O
to	O
have	O
successful	O
and	O
satisfying	O
interactions	O
with	O
other	O
people	O
.	O

These	O
types	O
of	O
effects	O
can	O
be	O
seen	O
in	O
a	O
relatively	O
brief	O
time	O
period	O
,	O
such	O
as	O
within	O
several	O
days	O
to	O
a	O
week	O
.	O

Enhancement	O
of	O
Impaired	O
Motor	O
and	O
Mental	O
Functions	O
,	O
Using	O
Dextromethorphan	B
and	O
Oxidase	O
Enzyme	O
Inhibitor	O

A	O
formulation	O
comprising	O
jasmonate	B
for	O
improving	O
skeletal	O
muscle	O
function	O
in	O
a	O
mammal	O
,	O
particularly	O
a	O
human	O
is	O
provided	O
.	O

This	O
may	O
be	O
accomplished	O
by	O
reducing	O
muscle	O
fatigue	O
and/or	O
increasing	O
skeletal	O
muscle	O
performance	O
.	O

Use	O
of	O
jasmonate	B
for	O
improving	O
skeletal	O
muscle	O
function	O

The	O
invention	O
concerns	O
nutritional	O
compositions	O
with	O
fucosyllactose	B
for	O
use	O
in	O
stimulation	O
of	O
NK	O
cells	O
.	O

The	O
composition	O
is	O
suitable	O
for	O
infants	O
.	O

Fucosyllactose	B
as	O
breast	O
milk	O
identical	O
non	O
-	O
digestible	O
oligosaccharide	B
with	O
new	O
functional	O
benefit	O

This	O
invention	O
relates	O
to	O
a	O
bipolar	O
antimicrobial	O
particle	O
for	O
use	O
in	O
laundry	O
detergent	O
compositions	O
,	O
fabric	O
conditioners	O
,	O
personal	O
care	O
and	O
cosmetic	O
compositions	O
and	O
a	O
process	O
for	O
making	O
the	O
same	O
.	O

In	O
view	O
of	O
the	O
foregoing	O
,	O
it	O
is	O
an	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
a	O
stabile	O
antimicrobial	O
agent	O
immobilised	O
on	O
a	O
carrier	O
particle	O
.	O

It	O
is	O
a	O
further	O
objective	O
to	O
provide	O
an	O
antimicrobial	O
particle	O
with	O
improved	O
retention	O
to	O
the	O
fabric	O
so	O
that	O
larger	O
amounts	O
of	O
antimicrobial	O
will	O
be	O
available	O
even	O
after	O
rinsing	O
.	O

Surprisingly	O
it	O
has	O
been	O
found	O
that	O
antimicrobial	O
molecules	O
tagged	O
by	O
surface	O
reaction	O
onto	O
naturally	O
occurring	O
asymmetric	O
clay	O
surfaces	O
,	O
act	O
as	O
an	O
antimicrobial	O
particle	O
with	O
improved	O
retention	O
properties	O
with	O
improved	O
stability	O
.	O

antimicrobial	O
particle	O
and	O
a	O
process	O
for	O
preparing	O
the	O
same	O

The	O
invention	O
provides	O
compounds	O
and	O
methods	O
for	O
inhibiting	O
proteases	O
.	O

One	O
aspect	O
of	O
the	O
invention	O
features	O
pro	O
-	O
soft	O
inhibitors	O
which	O
react	O
with	O
an	O
activating	O
protease	O
to	O
release	O
an	O
active	O
inhibitor	O
moiety	O
in	O
proximity	O
to	O
a	O
target	O
protease	O
.	O

In	O
certain	O
instances	O
,	O
compounds	O
inhibit	O
proteasomes	O
and/or	O
post	O
-	O
proline	O
cleaving	O
enzymes	O
(	O
PPCE	O
)	O
,	O
such	O
as	O
dipeptidyl	O
peptidase	O
IV	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
provide	O
a	O
better	O
therapeutic	O
index	O
,	O
owing	O
in	O
part	O
to	O
reduced	O
toxicity	O
and/or	O
improved	O
specificity	O
for	O
the	O
targeted	O
protease	O
.	O

Another	O
aspect	O
of	O
the	O
invention	O
provides	O
for	O
the	O
use	O
of	O
the	O
disclosed	O
compounds	O
for	O
treating	O
Type	O
II	O
diabetes	O
,	O
insulin	O
resistance	O
,	O
glucose	O
intolerance	O
,	O
hyperglycemia	O
,	O
hypoglycemia	O
,	O
hyperinsulinemia	O
,	O
obesity	O
,	O
hyperlipidemia	O
,	O
or	O
hyperlipoproteinemia	O
.	O

Soft	O
protease	O
inhibitors	O
,	O
and	O
pro	O
-	O
soft	O
forms	O
thereof	O

Stilbene	B
compounds	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
colon	O
cancer	O
or	O
colon	O
inflammation	O
and	O
methods	O
of	O
using	O
same	O
are	O
provided	O
.	O

Prevention	O
and	O
treatment	O
of	O
colon	O
cancer	O

In	O
accordance	O
with	O
the	O
present	O
invention	O
,	O
novel	O
methods	O
and	O
formulations	O
are	O
provided	O
for	O
treating	O
and	O
preventing	O
the	O
incidence	O
of	O
drug	O
-	O
induced	O
pro	O
-	O
arrhythmia	O
,	O
including	O
torsades	O
de	O
pointes	O
.	O

The	O
methods	O
and	O
formulations	O
comprise	O
a	O
combination	O
of	O
a	O
drug	O
that	O
induces	O
torsade	O
de	O
pointes	O
,	O
such	O
as	O
Class	O
III	O
antiarrhythmics	O
,	O
certain	O
antimicrobials	O
,	O
antihistamines	O
,	O
antidepressants	O
,	O
antipsychotics	O
,	O
diuretics	O
,	O
with	O
an	O
aspirin	O
and/or	O
a	O
statin	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
compositions	O
and	O
methods	O
for	O
treatment	O
comprise	O
azimilide	B
and	O
aspirin	B
and/or	O
a	O
statin	B
.	O

These	O
compositions	O
may	O
be	O
administered	O
by	O
different	O
routes	O
,	O
including	O
orally	O
.	O

In	O
certain	O
embodiments	O
where	O
the	O
antiarrhythmic	O
is	O
azimilide	B
it	O
may	O
be	O
administered	O
orally	O
in	O
a	O
dose	O
of	O
about	O
25	O
mg	O
to	O
about	O
300	O
mg	O
.	O

Compositions	O
for	O
Reducing	O
the	O
Incidence	O
of	O
Drug	O
Induced	O
Arrhythmia	O

Described	O
are	O
gastrointestinal	O
cancer	O
specific	O
biomarkers	O
comprising	O
the	O
nucleic	O
acid	O
sequence	O
of	O
the	O
Engrailed-2	O
(	O
EN2	O
)	O
gene	O
or	O
the	O
amino	B
acid	I
sequence	O
of	O
the	O
encoded	O
EN2	O
protein	O
.	O

Also	O
described	O
are	O
uses	O
of	O
the	O
biomarkers	O
in	O
the	O
treatment	O
,	O
diagnosis	O
,	O
monitoring	O
and	O
imaging	O
of	O
gastrointestinal	O
cancer	O
.	O

Biomarker	O

Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
modulate	O
apoptosis	O
including	O
IAP	O
antagonists	O
are	O
provided	O
herein	O
.	O

Compositions	O
including	O
mimetics	O
of	O
the	O
invention	O
and	O
,	O
optionally	O
,	O
secondary	O
agents	O
,	O
may	O
be	O
used	O
to	O
treat	O
proliferative	O
disorders	O
such	O
as	O
,	O
cancer	O
and	O
autoimmune	O
diseases	O
.	O

Dimeric	O
IAP	O
Inhibitors	O

Prodrugs	O
of	O
galantamine	B
or	O
its	O
3-hydroxy	B
metabolite	O
with	O
amino	B
acids	I
or	O
short	O
peptides	O
,	O
pharmaceutical	O
compositions	O
containing	O
such	O
prodrugs	O
and	O
methods	O
for	O
treating	O
a	O
memory	O
or	O
cognition	O
disorder	O
with	O
the	O
galantamine	B
prodrugs	O
are	O
provided	O
herein	O
.	O

Prodrugs	O
having	O
side	O
chains	O
of	O
valine	B
,	O
phenylalanine	B
,	O
tyrosine	B
or	O
para	B
amino	I
benzoic	I
acid	I
and	O
mono-	O
,	O
di-	O
and	O
tripeptides	O
thereof	O
are	O
preferred	O
.	O

Additionally	O
,	O
methods	O
for	O
avoiding	O
or	O
minimizing	O
the	O
adverse	O
gastrointestinal	O
side	O
effects	O
associated	O
with	O
galantamine	B
administration	O
,	O
as	O
well	O
as	O
improving	O
the	O
pharmacokinetics	O
of	O
galantamine	B
are	O
provided	O
herein	O
.	O

Galantamine	B
amino	B
acid	I
and	O
peptide	O
prodrugs	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
therapeutic	O
methods	O
,	O
compositions	O
and	O
uses	O
thereof	O
,	O
that	O
affect	O
,	O
directly	O
or	O
indirectly	O
,	O
the	O
behavior	O
of	O
LRP	O
receptors	O
.	O

These	O
compositions	O
and	O
methods	O
result	O
in	O
the	O
treatment	O
of	O
inflammatory	O
,	O
immunological	O
and	O
metabolic	O
conditions	O
.	O

More	O
particularly	O
,	O
the	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
are	O
directed	O
to	O
the	O
identification	O
of	O
small	O
molecules	O
,	O
drugs	O
and/or	O
pharmacological	O
agents	O
that	O
affect	O
the	O
Wnt	O
pathway	O
by	O
affecting	O
normal	O
complex	O
formation	O
among	O
various	O
signaling	O
receptors	O
,	O
the	O
LRP5	O
and	O
LRP6	O
receptor	O
,	O
and	O
related	O
ligands	O
.	O

Methods	O
for	O
treating	O
inflammation	O

This	O
invention	O
relates	O
to	O
complexes	O
of	O
certain	O
divalent	O
and	O
polyvalent	O
d	O
-	O
orbital	O
metals	O
of	O
first	O
transition	O
series	O
of	O
the	O
Periodic	O
Table	O
of	O
Elements	O
,	O
from	O
Group	O
IV	O
to	O
Group	O
VI	O
,	O
and	O
including	O
molybdenum	B
,	O
having	O
a	O
hydroxy	B
acid	I
[	O
HA	O
]	O
and	O
an	O
amino	B
acid	I
[	O
AA	O
]	O
moiety	O
concurrently	O
bound	O
to	O
a	O
single	O
said	O
metal	O
and	O
having	O
a	O
spirocyclic	B
,	O
bidentate	B
chelate	I
structure	O
of	O
formula	O
(	O
I	O
)	O
.	O

Upon	O
topical	O
application	O
said	O
metal	O
complexes	O
undergo	O
enhanced	O
skin	O
penetration	O
without	O
causing	O
skin	O
irritation	O
.	O

The	O
said	O
metal	O
complexes	O
are	O
useful	O
for	O
topical	O
conditions	O
that	O
includes	O
dry	O
skin	O
,	O
xerosis	O
,	O
ichthyosis	O
,	O
dandruff	O
,	O
brownish	O
spots	O
,	O
keratoses	O
,	O
melasma	O
,	O
lentigines	O
,	O
age	O
spots	O
,	O
dark	O
circles	O
around	O
eyes	O
,	O
skin	O
pigmentation	O
,	O
topical	O
inflammation	O
,	O
liver	O
spots	O
,	O
pigmented	O
spots	O
,	O
wrinkles	O
,	O
blemishes	O
,	O
skin	O
lines	O
,	O
oily	O
skin	O
,	O
acne	O
,	O
warts	O
,	O
eczema	O
,	O
pruritic	O
skin	O
,	O
psoriasis	O
,	O
inflammatory	O
dermatoses	O
,	O
disturbed	O
keratinization	O
,	O
dandruff	O
,	O
bacterial	O
infection	O
,	O
fungal	O
infection	O
,	O
wound	O
healing	O
,	O
body	O
odor	O
,	O
and	O
skin	O
changes	O
associated	O
with	O
aging	O
;	O
Hydroxy	B
Acid	I
Complexes	O
for	O
Skin	O
Renovation	O
and	O
Clarity	O

Organic	O
compounds	O
showing	O
the	O
ability	O
to	O
inhibit	O
viral	O
glycoprotein	O
(	O
GP	O
)	O
-mediated	O
entry	O
of	O
a	O
filovirus	O
into	O
a	O
host	O
cell	O
are	O
disclosed	O
.	O

The	O
disclosed	O
filovirus	O
entry	O
inhibitor	O
compounds	O
are	O
useful	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
reducing	O
the	O
spread	O
of	O
infections	O
by	O
filovirus	O
including	O
the	O
type	O
species	O
Marburg	O
virus	O
(	O
MARV	O
)	O
and	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
.	O

Preferred	O
inhibitors	O
of	O
the	O
invention	O
provide	O
therapeutic	O
agents	O
for	O
combating	O
the	O
Ivory	O
Coast	O
,	O
Sudan	O
,	O
Zaire	O
,	O
Bundibugyo	O
,	O
and	O
Reston	O
Ebola	O
virus	O
strains	O
.	O

Inhibitors	O
of	O
filovirus	O
entry	O
into	O
host	O
cells	O

The	O
present	O
application	O
is	O
directed	O
to	O
non	O
-	O
coding	O
RNA	O
motifs	O
that	O
are	O
used	O
in	O
conjunction	O
with	O
an	O
antigen	O
or	O
without	O
an	O
antigen	O
to	O
induce	O
,	O
enhance	O
or	O
modulate	O
an	O
immune	O
response	O
that	O
compromises	O
a	O
B	O
cell	O
and	O
a	O
T	O
cell	O
component	O
.	O

Compositions	O
and	O
methods	O
to	O
treat	O
and	O
control	O
tumors	O

A	O
liposome	O
comprising	O
a	O
phospholipid	O
,	O
a	O
hydrophobic	O
active	O
comprising	O
a	O
carboxylate	B
group	O
,	O
and	O
a	O
component	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
:	O
a	O
hydrophilic	O
adjuvant	O
comprising	O
a	O
positively	O
charged	O
group	O
,	O
a	O
complex	O
of	O
said	O
hydrophobic	O
active	O
with	O
said	O
hydrophilic	O
adjuvant	O
,	O
and	O
combinations	O
thereof	O
.	O

An	O
aqueous	O
liposome	O
dispersion	O
comprising	O
the	O
liposome	O
,	O
and	O
a	O
personal	O
care	O
composition	O
comprising	O
the	O
liposome	O
.	O

A	O
process	O
of	O
preparing	O
the	O
liposome	O
,	O
comprising	O
the	O
steps	O
of	O
:	O
forming	O
a	O
premix	O
by	O
dissolving	O
a	O
phospholipid	O
,	O
a	O
hydrophobic	O
active	O
comprising	O
a	O
carboxylate	B
group	O
in	O
an	O
organic	O
solvent	O
;	O
evaporating	O
off	O
said	O
organic	O
solvent	O
from	O
the	O
premix	O
to	O
form	O
a	O
phospholipid	O
film	O
;	O
and	O
hydrating	O
said	O
lipid	O
film	O
with	O
a	O
hydration	O
medium	O
comprising	O
a	O
hydrophilic	O
adjuvant	O
comprising	O
a	O
positively	O
charged	O
group	O
and	O
homogenize	O
the	O
medium	O
to	O
form	O
an	O
aqueous	O
liposome	O
dispersion	O
.	O

Liposome	O
and	O
Personal	O
Care	O
Composition	O
Comprising	O
Thereof	O

The	O
present	O
invention	O
provides	O
a	O
carrier	O
component	O
.	O

The	O
carrier	O
component	O
includes	O
a	O
carrier	O
core	O
body	O
including	O
a	O
dispersive	O
object	O
and	O
a	O
dualistic	O
self	O
-	O
assembly	O
material	O
for	O
encapsulating	O
the	O
dispersive	O
object	O
,	O
wherein	O
the	O
dualistic	O
self	O
-	O
assembly	O
material	O
has	O
an	O
electric	O
charge	O
;	O
and	O
a	O
first	O
shell	O
layer	O
having	O
an	O
electric	O
charge	O
opposite	O
to	O
the	O
electric	O
charge	O
of	O
the	O
dualistic	O
self	O
-	O
assembly	O
material	O
,	O
and	O
coating	O
the	O
carrier	O
core	O
body	O
,	O
and	O
thus	O
avoids	O
inactivation	O
of	O
a	O
medicine	O
,	O
eliminates	O
medicine	O
leakage	O
and	O
reduces	O
medicine	O
releasing	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
for	O
forming	O
a	O
carrier	O
component	O
.	O

Carrier	O
component	O
and	O
fabrication	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
novel	O
monomers	O
of	O
Formula	O
(	O
I	O
)	O
useful	O
for	O
preparation	O
of	O
phase	O
-	O
separated	O
biocompatible	O
polymers	O
or	O
polymer	O
compositions	O
.	O

These	O
polymers	O
or	O
polymer	O
compositions	O
may	O
be	O
bioresorbable	O
and/or	O
biodegradable	O
and	O
have	O
desirable	O
mechanical	O
properties	O
,	O
such	O
as	O
fracture	O
and/or	O
fatigue	O
toughness	O
,	O
which	O
have	O
not	O
been	O
a	O
primary	O
design	O
criteria	O
for	O
such	O
polymers	O
previously	O
.	O

The	O
polymers	O
or	O
polymer	O
compositions	O
are	O
useful	O
in	O
a	O
variety	O
of	O
medical	O
applications	O
,	O
such	O
as	O
in	O
the	O
fabrication	O
of	O
medical	O
devices	O
.	O

Therefore	O
,	O
methods	O
for	O
preparing	O
these	O
polymers	O
or	O
polymer	O
compositions	O
and	O
medical	O
devices	O
are	O
also	O
encompassed	O
by	O
this	O
disclosure	O
.	O

Monomers	O
and	O
phase	O
-	O
separated	O
biocompatible	O
polymer	O
compositions	O
prepared	O
therefrom	O
for	O
medical	O
uses	O

The	O
present	O
application	O
describes	O
selective	O
ligands	O
of	O
formula	O
(	O
I	O
)	O
for	O
neuronal	O
nicotinic	O
receptors	O
(	O
NNRs	O
)	O
,	O
more	O
specifically	O
for	O
the	O
α4β2	O
NNR	O
subtype	O
,	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
using	O
the	O
same	O
,	O
wherein	O
X	O
,	O
R1	O
,	O
X	O
,	O
R2	O
,	O
R3	O
,	O
L1	O
,	O
m	O
,	O
n	O
,	O
p	O
,	O
and	O
q	O
are	O
defined	O
in	O
the	O
specification	O
.	O

Selective	O
substituted	O
pyridine	B
ligands	O
for	O
neuronal	O
nicotinic	O
receptors	O

The	O
present	O
invention	O
relates	O
to	O
the	O
salts	O
of	O
(	B
+	I
)	I
-13a-	I
(	I
S	I
)	I
-deoxytylophorinine	I
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
the	O
preparation	O
method	O
thereof	O
,	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
use	O
as	O
medicaments	O
for	O
prevention	O
and/or	O
treatment	O
of	O
cancer	O
and/or	O
inflammation	O
disease	O
.	O

Salts	O
of	O
13a-	B
(	I
s	I
)	I
desoxytylophorinine	I
,	O
preparation	O
methods	O
and	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
is	O
directed	O
to	O
racemic	B
1-	I
(	I
3,4-dichlorophenyl	I
)	I
-3-azabicyclo	I
[	I
3.1.0	I
]	I
hexane	I
,	O
(	B
+	I
)	I
-1-	I
(	I
3,4-dichlorophenyl	I
)	I
-3-azabicyclo	I
[	I
3.1.0	I
]	I
hexane	I
,	O
racemic	B
1-	I
(	I
4-methylphenyl	I
)	I
-3-azabicyclo	I
[	I
3.1.0	I
]	I
hexane	I
,	O
and	O
(	B
+	I
)	I
-1-	I
(	I
4-methylphenyl	I
)	I
-3-azabicyclo	I
[	I
3.1.0	I
]	I
hexane	I
,	O
and	O
methods	O
of	O
their	O
use	O
for	O
treating	O
certain	O
nervous	O
system	O
disorders	O
and	O
conditions	O
,	O
including	O
,	O
inter	O
alia	O
,	O
vasomotor	O
symptoms	O
(	O
VMS	O
)	O
and	O
chronic	O
pain	O
.	O

Method	O
for	O
treating	O
nervous	O
system	O
disorders	O
and	O
conditions	O

Superior	O
buffered	O
formulations	O
and	O
their	O
kits	O
for	O
treating	O
lower	O
urinary	O
tract	O
symptoms	O
and	O
disorders	O
are	O
provided	O
in	O
the	O
invention	O
.	O

In	O
particular	O
superior	O
buffered	O
formulations	O
have	O
demonstrated	O
improvement	O
for	O
treating	O
lower	O
urinary	O
tract	O
symptoms	O
of	O
patients	O
experiencing	O
severe	O
pain	O
and/or	O
urgency	O
of	O
the	O
bladder	O
and	O
associated	O
areas	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O

Kits	O
and	O
improved	O
compositions	O
for	O
treating	O
lower	O
urinary	O
tract	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
hepcidin	O
antagonists	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
the	O
use	O
thereof	O
as	O
medicaments	O
,	O
in	O
particular	O
for	O
treatment	O
of	O
disorders	O
in	O
iron	O
metabolism	O
,	O
such	O
as	O
,	O
in	O
particular	O
,	O
iron	O
deficiency	O
diseases	O
and	O
anaemias	O
,	O
in	O
particular	O
anaemias	O
in	O
connection	O
with	O
chronic	O
inflammatory	O
diseases	O
(	O
ACD	O
:	O
anaemia	O
of	O
chronic	O
disease	O
and	O
AI	O
:	O
anaemia	O
of	O
inflammation	O
)	O
.	O

Novel	O
Quinoline	B
-	O
Hepcidine	O
Antagonists	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
neurodegenerative	O
disorders	O
,	O
e.g.	O
,	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
compositions	O
comprising	O
selective	O
antagonists	O
of	O
calcium	B
ion	O
channels	O
(	O
e.g.	O
,	O
cav1.3-type	O
ion	O
channels	O
)	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
to	O
treat	O
or	O
prevent	O
neurodegenerative	O
disorders	O
.	O

Selective	O
calcium	B
channel	O
antagonists	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
uses	O
of	O
antisense	O
oligolucleotides	B
targeted	O
to	O
the	O
coding	O
region	O
of	O
acetylcholinesterase	O
(	O
AChE	O
)	O
for	O
treating	O
inflammatory	O
disorders	O
other	O
than	O
inflammatory	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O
or	O
the	O
peripheral	O
nervous	O
system	O
innervating	O
voluntary	O
muscles	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
uses	O
of	O
antisense	O
oligodexoynucleotides	B
targeted	O
to	O
AChE	O
mRNA	O
for	O
treating	O
inflammatory	O
disease	O
of	O
the	O
gastroinstestinal	O
tract	O
including	O
inflammatory	O
bowel	O
disease	O
.	O

Antisense	O
oligonucleotides	B
against	O
acetylcholinesterase	O
for	O
treating	O
inflammatory	O
diseases	O

The	O
invention	O
provides	O
a	O
microsphere	O
formulation	O
for	O
the	O
sustained	O
delivery	O
of	O
an	O
aptamer	O
,	O
for	O
example	O
,	O
an	O
anti	O
-	O
Vascular	O
Endothelial	O
Growth	O
Factor	O
aptamer	O
,	O
to	O
a	O
preselected	O
locus	O
in	O
a	O
mammal	O
,	O
such	O
as	O
the	O
eye	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
making	O
such	O
formulations	O
,	O
and	O
methods	O
of	O
using	O
such	O
formulations	O
to	O
deliver	O
an	O
aptamer	O
to	O
a	O
preselected	O
locus	O
in	O
a	O
mammal	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
a	O
method	O
for	O
delivering	O
the	O
aptamer	O
to	O
an	O
eye	O
for	O
the	O
treatment	O
of	O
an	O
ocular	O
disorder	O
,	O
for	O
example	O
,	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

Drug	O
Delivery	O
Systems	O
and	O
Use	O
Thereof	O

This	O
invention	O
provides	O
methods	O
of	O
diagnosing	O
or	O
determining	O
a	O
cause	O
of	O
an	O
autoimmune	O
encephalitis	O
or	O
an	O
epilepsy	O
in	O
a	O
subject	O
and	O
of	O
diagnosing	O
a	O
tumor	O
in	O
a	O
subject	O
,	O
comprising	O
the	O
step	O
of	O
testing	O
a	O
biological	O
sample	O
of	O
the	O
subject	O
for	O
an	O
anti	O
-	O
body	O
to	O
a	O
GABAB	O
receptor	O
.	O

This	O
invention	O
further	O
provides	O
methods	O
of	O
treating	O
an	O
autoimmune	O
encephalitis	O
or	O
an	O
epilepsy	O
,	O
comprising	O
the	O
steps	O
of	O
detecting	O
an	O
antibody	O
to	O
a	O
GABAB	O
receptor	O
and	O
treating	O
a	O
tumor	O
associated	O
with	O
the	O
disease	O
.	O

Methods	O
for	O
diagnosing	O
and	O
treating	O
encephalitis	O
or	O
epilepsy	O

A	O
dental	O
curable	O
composition	O
comprises	O
(	O
A	O
)	O
a	O
polymerizable	O
monomer	O
and	O
(	O
B	O
)	O
an	O
organic	O
amine	O
-	O
based	O
polymerization	O
initiator	O
,	O
wherein	O
(	O
A′	O
)	O
a	O
long	O
-	O
chain	O
polymerizable	O
monomer	O
having	O
a	O
chain	O
length	O
of	O
17	O
or	O
more	O
atoms	O
is	O
contained	O
in	O
the	O
component	O
(	O
A	O
)	O
and/or	O
(	O
C	O
)	O
a	O
soft	O
resin	O
material	O
are	O
/	O
is	O
contained	O
in	O
the	O
composition	O
,	O
and	O
when	O
the	O
amount	O
(	O
parts	O
by	O
weight	O
)	O
based	O
on	O
100	O
parts	O
by	O
weight	O
of	O
the	O
component	O
(	O
A	O
)	O
of	O
the	O
component	O
(	O
A′	O
)	O
is	O
represented	O
by	O
[	O
a′	O
]	O
and	O
the	O
amounts	O
(	O
parts	O
by	O
weight	O
)	O
based	O
on	O
100	O
parts	O
by	O
weight	O
of	O
the	O
total	O
of	O
the	O
components	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
of	O
the	O
components	O
(	O
A	O
)	O
,	O
(	O
B	O
)	O
and	O
(	O
C	O
)	O
are	O
represented	O
by	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
and	O
(	O
c	O
)	O
,	O
respectively	O
,	O
70≦	O
(	O
a	O
)	O
≦99.99	O
,	O
0.01≦	O
(	O
b	O
)	O
≦5	O
30	O
,	O
1≦	O
[	O
a′	O
]	O
/	O
5+	O
(	O
c	O
)	O
/	O
1	O
,	O
0≦	O
[	O
a′	O
]	O
≦95	O
,	O
and	O
0≦	O
(	O
c	O
)	O
≦250	O
.	O

Removable	O
dental	O
curable	O
composition	O

Disclosed	O
are	O
methods	O
for	O
making	O
aldehydes	B
and	O
ketones	B
comprising	O
allowing	O
the	O
corresponding	O
primary	B
or	I
secondary	I
alcohol	I
to	O
react	O
in	O
the	O
presence	O
of	O
trichoroisocyanuric	B
acid	I
,	O
a	O
compound	O
of	O
formula	O
R1SR2	O
and	O
a	O
base	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
alcohol	B
is	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R3	O
is	O
a	O
protecting	O
group	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
making	O
3-O	B
-	I
protected	I
morphine	I
dienol	I
carboxylates	I
comprising	O
allowing	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
to	O
oxidize	O
in	O
the	O
presence	O
of	O
a	O
chlorine	B
-	O
containing	O
compound	O
and	O
a	O
compound	O
of	O
formula	O
R1SR2	O
;	O
and	O
allowing	O
the	O
product	O
of	O
the	O
oxidation	O
step	O
to	O
react	O
with	O
an	O
acylating	O
agent	O
.	O

Methods	O
for	O
making	O
3-o	B
-	I
protected	I
morphinones	I
and	O
3-o	B
-	I
protected	I
morphinone	I
dienol	I
carboxylates	I

The	O
present	O
invention	O
relates	O
to	O
the	O
expression	O
and	O
regulating	O
growth	O
factors	O
in	O
chrondrocytes	O
and	O
developing	O
cartilage	O
,	O
particularly	O
granulin	O
-	O
epithelin	O
precursor	O
(	O
GEP	O
)	O
.	O

The	O
invention	O
relates	O
to	O
the	O
modulation	O
and	O
manipulation	O
of	O
these	O
growth	O
factors	O
,	O
GEP	O
,	O
and/or	O
the	O
molecules	O
they	O
interact	O
with	O
,	O
for	O
instance	O
COMP	O
,	O
in	O
cartilage	O
disorders	O
,	O
including	O
arthritis	O
.	O

Assays	O
and	O
screening	O
methods	O
for	O
the	O
determination	O
of	O
the	O
expression	O
and	O
activity	O
of	O
GEP	O
,	O
or	O
of	O
GEP	O
-	O
COMP	O
,	O
are	O
provided	O
,	O
including	O
for	O
screening	O
for	O
the	O
presence	O
or	O
extent	O
of	O
cartilage	O
or	O
arthritic	O
disease	O
and	O
for	O
identifying	O
modulators	O
or	O
compounds	O
/	O
agents	O
for	O
treatment	O
or	O
prevention	O
of	O
cartilage	O
or	O
arthritic	O
diseases	O
.	O

GEP	O
,	O
a	O
novel	O
chondrogenic	O
growth	O
factor	O
and	O
target	O
in	O
cartilage	O
disorders	O

The	O
present	O
inventions	O
provides	O
crystalline	O
forms	O
of	O
(	B
3R,3aS,6aR	I
)	I
-hexahydrofuro	I
[	I
2,3-b	I
]	I
furan-3-yl	I
(	I
1S,2R	I
)	I
-	I
(	I
1-	I
{	I
4-	I
[	I
(	I
diethoxyphosphoryl	I
)	I
methoxy	I
]	I
phenyl	I
}	I
-3-hydroxy-4-	I
[	I
4-methoxy	I
-	I
N-	I
(	I
2-methylpropyl	I
)	I
benzenesulfonamido	I
]	I
butan-2-yl	I
)	I
carbamate	I
,	O
methods	O
of	O
preparing	O
the	O
crystalline	O
forms	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
crystalline	O
forms	O
,	O
and	O
therapeutic	O
uses	O
thereof	O
.	O

Crystalline	O
forms	O
of	O
(	B
3r	I
,	I
3as	I
,	I
6ar	I
)	I
-	I
hexahydrofuro	I
[	I
2,3-b	I
]	I
furan-3-yl	I
(	I
1s,2r	I
)	I
-	I
(	I
1-	I
{	I
4-	I
[	I
(	I
diethoxyphosphoryl	I
)	I
methoxy	I
]	I
pheny1	I
}	I
-3-hydroxy-4-	I
[	I
4-methoxy	I
-	I
n-	I
(	I
2-methylpropyl	I
)	I
benzenesul	I
-	I
fonamido	I
]	I
butan-2-yl	I
)	I
carbamate	I

A	O
method	O
of	O
inducing	O
mineralization	O
in	O
a	O
bone	O
cell	O
is	O
described	O
.	O

The	O
method	O
comprises	O
contacting	O
a	O
bone	O
cell	O
with	O
a	O
composition	O
comprising	O
nanoparticles	O
.	O

The	O
nanoparticles	O
can	O
be	O
single	O
-	O
walled	O
carbon	O
nanotubes	O
,	O
hydroxyapatite	O
nanoparticles	O
,	O
TiO2	O
nanoparticles	O
or	O
silver	O
nanoparticles	O
.	O

The	O
bone	O
cell	O
can	O
be	O
an	O
osteoblast	O
cell	O
.	O

A	O
method	O
for	O
increasing	O
bone	O
mass	O
,	O
bone	O
healing	O
or	O
bone	O
formation	O
is	O
also	O
described	O
which	O
comprises	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
nanoparticles	O
.	O

The	O
subject	O
can	O
suffer	O
from	O
a	O
bone	O
disease	O
such	O
as	O
osteoporosis	O
.	O

The	O
subject	O
can	O
suffer	O
from	O
a	O
bone	O
fracture	O
and	O
the	O
method	O
can	O
comprise	O
contacting	O
bone	O
cells	O
near	O
the	O
bone	O
fracture	O
site	O
with	O
the	O
composition	O
.	O

The	O
composition	O
can	O
further	O
comprise	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

NANOSTRUCTURAL	O
MATERIALS	O
THAT	O
INCREASE	O
MINERALIZATION	O
IN	O
BONE	O
CELLS	O
AND	O
AFFECT	O
GENE	O
EXPRESSION	O
THROUGH	O
miRNA	O
REGULATION	O
AND	O
APPLICATIONS	O
OF	O
SAME	O

There	O
is	O
disclosed	O
a	O
molecular	O
composition	O
(	O
s	O
)	O
of	O
a	O
novel	O
tissue	O
protective	O
erythropoietin	O
(	O
EPO	O
)	O
binding	O
receptor	O
protein	O
complex	O
,	O
termed	O
NEPOR	O
.	O

Presence	O
of	O
NEPOR	O
components	O
on	O
a	O
tumour	O
allows	O
EPO	O
to	O
impinge	O
on	O
the	O
survival	O
of	O
associated	O
cells	O
thereby	O
enhancing	O
tumour	O
progression	O
and	O
negatively	O
effecting	O
patient	O
survival	O
.	O

Presence	O
of	O
NEPOR	O
represents	O
a	O
prognostic	O
biomarker	O
for	O
poorer	O
patient	O
outcome	O
.	O

Thus	O
,	O
methods	O
are	O
provided	O
for	O
stratifying	O
patients	O
having	O
a	O
tumour	O
as	O
suitable	O
(	O
i.e.	O
NEPOR	O
not	O
present	O
)	O
or	O
non	O
-	O
suitable	O
(	O
i.e.	O
,	O
NEPOR	O
present	O
)	O
for	O
EPO	O
treatment	O
,	O
comprising	O
:	O
(	O
a	O
)	O
isolating	O
a	O
tissue	O
sample	O
from	O
an	O
individual	O
who	O
is	O
receiving	O
or	O
is	O
a	O
candidate	O
for	O
receiving	O
erythropoietin	O
,	O
(	O
b	O
)	O
determining	O
the	O
level	O
of	O
expression	O
of	O
the	O
NEPOR	O
gene	O
(	O
s	O
)	O
(	O
mRNA	O
)	O
and/or	O
the	O
presence	O
of	O
the	O
NEPOR	O
gene	O
product	O
(	O
protein	O
)	O
from	O
the	O
isolated	O
tissue	O
,	O
and	O
(	O
c	O
)	O
correlating	O
the	O
presence	O
of	O
an	O
NEPOR	O
gene	O
expression	O
product	O
or	O
the	O
presence	O
of	O
NEPOR	O
protein	O
to	O
a	O
physiological	O
response	O
to	O
the	O
treatment	O
with	O
erythropoietin	O
.	O

Furthermore	O
,	O
by	O
disclosing	O
the	O
molecular	O
compositions	O
of	O
NEPOR	O
species	O
,	O
there	O
are	O
disclosed	O
methods	O
for	O
rationally	O
identifying	O
/	O
designing	O
NEPOR	O
modulating	O
therapeutics	O
.	O

Methods	O
also	O
are	O
provided	O
for	O
treating	O
neurological	O
insults	O
such	O
as	O
stroke	O
(	O
via	O
enhancement	O
of	O
NEPOR	O
activity	O
)	O
and	O
cancer	O
(	O
via	O
down	O
-	O
regulation	O
of	O
cyto	O
-	O
protective	O
signaling	O
from	O
NEPOR	O
)	O
.	O

Novel	O
tissue	O
protective	O
erythropoietin	O
receptor	O
(	O
nepor	O
)	O
and	O
methods	O
of	O
use	O

A	O
composition	O
comprising	O
an	O
SL0101	O
[	O
kaempferol	B
3-O-	I
(	I
3″,4″-di	I
-	I
O	I
-	I
acetyl	I
-	I
α	I
-	I
L	I
-	I
rhamnopyranoside	I
)	I
]	O
derivative	O
compound	O
that	O
has	O
enhanced	O
ability	O
to	O
inhibit	O
RSK	O
activity	O
,	O
relative	O
to	O
the	O
parent	O
compound	O
is	O
provided	O
.	O

The	O
compounds	O
have	O
utility	O
for	O
treating	O
any	O
disease	O
or	O
conditions	O
characterized	O
or	O
associated	O
with	O
excess	O
or	O
undesirable	O
RSK	O
activity	O
.	O

For	O
example	O
the	O
RSK	O
inhibitors	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
to	O
reduce	O
the	O
proliferation	O
of	O
neoplastic	O
cells	O
or	O
for	O
inhibiting	O
the	O
establishment	O
or	O
maintenance	O
of	O
an	O
intracellular	O
pathogenic	O
infection	O
by	O
pathogens	O
whose	O
pathogenicity	O
derives	O
in	O
part	O
from	O
the	O
pathogen	O
's	O
ability	O
to	O
impede	O
endosomal	O
/	O
phagosomal	O
maturation	O
in	O
the	O
host	O
cell	O
.	O

Synthesis	O
and	O
identification	O
of	O
novel	O
rsk	O
-	O
specific	O
inhibitors	O

In	O
one	O
aspect	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
squamous	O
cell	O
lung	O
cancer	O
in	O
an	O
individual	O
comprising	O
administering	O
to	O
the	O
individual	O
having	O
lung	O
cancer	O
an	O
effective	O
amount	O
of	O
4-iodo-3-nitrobenzamide	B
or	O
a	O
metabolite	O
thereof	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
gemcitabine	B
;	O
and	O
carboplatin	B
.	O

Methods	O
of	O
treating	O
squamous	O
cell	O
lung	O
cancer	O
with	O
4-iodo-3-nitrobenzamide	B
in	O
combination	O
with	O
gemcitabine	B
and	O
carboplatin	B

The	O
disclosure	O
relates	O
to	O
(	B
heterocycle	I
-	I
fused	I
piperidine	I
)	I
-	I
(	I
piperazinyl	I
)	I
-1-alkanone	I
derivatives	O
and	O
(	B
heterocycle	I
-	I
fused	I
pyrrolidine	I
)	I
-	I
(	I
piperazinyI	I
)	I
-1-alkanone	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
A	O
,	O
W	O
,	O
R2	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
disclosure	O
,	O
to	O
the	O
method	O
of	O
preparation	O
thereof	O
and	O
the	O
therapeutic	O
use	O
thereof	O
.	O

NOVEL	O
(	O
HETEROCYCLE	B
/	I
CONDENSED	I
PIPERIDINE	I
)	I
-	I
(	I
PIPERAZINYL	I
)	I
-1-ALKANONE	I
OR	O
(	B
HETEROCYCLE	I
/	I
CONDENSED	I
PYRROLIDINE	I
)	I
-	I
(	I
PIPERAZINYL	I
)	I
-1-ALKANONE	I
DERIVATIVES	O
AND	O
USE	O
THEREOF	O
AS	O
p75	O
INHIBITORS	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
topical	O
pharmaceutical	O
composition	O
which	O
comprises	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
such	O
as	O
hydroxytyrosol	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
,	O
prodrug	O
or	O
isomer	O
thereof	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
take	O
different	O
values	O
,	O
and	O
the	O
use	O
of	O
said	O
composition	O
as	O
10	O
medicament	O
in	O
the	O
prevention	O
of	O
sexually	O
transmitted	O
diseases	O
(	O
STDs	O
)	O
,	O
such	O
as	O
HIV	O
-	O
infection	O
.	O

Topical	O
use	O
of	O
hydroxytyrosol	B
and	O
derivatives	O
for	O
the	O
prevention	O
of	O
hiv	O
infection	O

Provided	O
is	O
a	O
mosaic	O
mouse	O
model	O
for	O
use	O
in	O
determining	O
the	O
potency	O
of	O
an	O
shRNA	O
in	O
vivo	O
for	O
reducing	O
survival	O
of	O
cancer	O
cells	O
of	O
chemotherapy	O
-	O
resistant	O
leukemia	O
.	O

The	O
syngeneic	O
mouse	O
recipient	O
is	O
transplanted	O
with	O
tet	O
-	O
on	O
competent	O
leukemia	O
cells	O
carrying	O
a	O
bicistronic	O
nucleic	O
acid	O
construct	O
comprising	O
a	O
promoter	O
operably	O
linked	O
to	O
a	O
fusion	O
gene	O
associated	O
with	O
chemotherapy	O
-	O
resistant	O
leukemia	O
,	O
and	O
a	O
sequence	O
encoding	O
a	O
reverse	O
tet	O
-	O
transactivator	O
protein	O
,	O
such	O
that	O
both	O
coding	O
sequences	O
are	O
co	O
-	O
expressed	O
from	O
the	O
promoter	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
soft	O
tissue	O
cancers	O
.	O

Identification	O
of	O
rnai	O
targets	O
and	O
use	O
of	O
rnai	O
for	O
rational	O
therapy	O
of	O
chemotherapy	O
-	O
resistant	O
leukemia	O
and	O
other	O
cancers	O

The	O
present	O
invention	O
provides	O
aptamer	O
-	O
modified	O
polymers	O
and	O
materials	O
thereof	O
,	O
which	O
may	O
be	O
used	O
for	O
the	O
binding	O
of	O
factors	O
in	O
a	O
wound	O
bed	O
.	O

For	O
example	O
,	O
the	O
aptamer	O
-	O
modified	O
materials	O
can	O
be	O
polypeptides	O
conjugated	O
to	O
polymer	O
foam	O
materials	O
.	O

Such	O
materials	O
may	O
be	O
used	O
,	O
for	O
example	O
,	O
for	O
dressings	O
,	O
wound	O
inserts	O
,	O
or	O
pads	O
.	O

Aptamer	O
-	O
modified	O
polymeric	O
materials	O
for	O
the	O
binding	O
of	O
factors	O
in	O
a	O
wound	O
environment	O

The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
of	O
the	O
neuroactive	O
steroid	B
3α	B
-	I
hydroxy-3β	I
-	I
methoxymethyl-21-	I
(	I
1′-imidazolyl	I
)	I
-5α	I
-	I
pregnan-20-one	I
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
with	O
properties	O
desirable	O
for	O
use	O
in	O
treating	O
mood	O
disorders	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
compositions	O
provide	O
sustained	O
therapeutic	O
plasma	O
levels	O
of	O
3α	B
-	I
hydroxy-3β	I
-	I
methoxymethyl-21-	I
(	I
1′-imidazolyl	I
)	I
-5α	I
-	I
pregnan-20-one	I
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
these	O
disorders	O
by	O
administering	O
the	O
pharmaceutical	O
compositions	O
.	O

Pharmaceutical	O
Compositions	O
of	O
a	O
Neuroactive	O
Steroid	B
and	O
Methods	O
of	O
Use	O
Thereof	O

A	O
shampoo	O
composition	O
that	O
increases	O
the	O
deposition	O
and	O
retention	O
of	O
benefit	O
agent	O
containing	O
polyacrylate	B
microcapsules	O
onto	O
hair	O
during	O
the	O
cleansing	O
process	O
.	O

The	O
shampoo	O
composition	O
is	O
based	O
on	O
the	O
combination	O
of	O
anionic	O
charged	O
polyacrylate	B
microcapsules	O
,	O
cationic	O
deposition	O
polymers	O
,	O
detersive	O
surfactant	O
,	O
and	O
a	O
carrier	O
.	O

Shampoo	O
Compositions	O
with	O
Increased	O
Deposition	O
of	O
Polyacrylate	B
Microcapsules	O

Warmi	O
®	O
,	O
composed	O
of	O
glucosinolates	O
,	O
β	O
-	O
sitosterol	O
and	O
citrus	O
flavonoids	O
(	O
hesperidin	O
)	O
,	O
is	O
as	O
effective	O
as	O
HRT	O
in	O
reducing	O
menopausal	O
symptoms	O
,	O
Warmi	O
®	O
promotes	O
a	O
healthy	O
cardiovascular	O
system	O
,	O
supports	O
hormonal	O
balance	O
and	O
emotional	O
well	O
-	O
being	O
,	O
improving	O
the	O
quality	O
of	O
life	O
of	O
women	O
during	O
perimenopause	O
and	O
menopause	O
.	O

All	O
of	O
these	O
and	O
the	O
lack	O
of	O
side	O
effects	O
make	O
Warmi	O
®	O
an	O
ideal	O
natural	O
alternative	O
to	O
conventional	O
HRT	O
.	O

Warmi	O
®	O
,	O
natural	O
alternative	O
for	O
the	O
treatment	O
of	O
menopause	O

The	O
disclosure	O
relates	O
to	O
an	O
edible	O
energy	O
composition	O
that	O
provides	O
physical	O
and	O
mental	O
benefits	O
when	O
ingested	O
.	O

Edible	O
Energy	O
Composition	O

Cidofovir	B
is	O
obtained	O
in	O
different	O
forms	O
,	O
including	O
amorphous	O
cidofovir	B
,	O
crystalline	O
anhydrous	O
cidofovir	B
,	O
crystalline	O
cidofovir	B
monohydrate	I
,	O
and	O
crystalline	O
cidofovir	B
dihydrate	I
,	O
including	O
various	O
polymorphs	O
.	O

Forms	O
of	O
cidofovir	B

Use	O
of	O
the	O
N	B
-	I
phenyl-2-pyrimidine	I
-	I
amine	I
derivatives	O
of	O
formula	O
I	O
,	O
in	O
which	O
the	O
symbols	O
and	O
substituents	O
have	O
the	O
meaning	O
as	O
given	O
herein	O
in	O
free	O
form	O
or	O
in	O
pharmaceutically	O
acceptable	O
salt	O
form	O
in	O
the	O
manufacture	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
allergic	O
rhinitis	O
,	O
allergic	O
dermatitis	O
,	O
drug	O
allergy	O
or	O
food	O
allergy	O
,	O
angioedema	O
,	O
urticaria	O
,	O
sudden	O
infant	O
death	O
syndrome	O
,	O
bronchopulmonary	O
aspergillosis	O
,	O
multiple	O
sclerosis	O
or	O
mastocytosis	O
;	O
Use	O
of	O
N	B
-	I
Phenyl-2-pyrimidineamine	I
Derivatives	O
Against	O
Mast	O
Cell	O
-	O
based	O
Diseases	O
Like	O
Allergic	O
Disorders	O

There	O
may	O
be	O
provided	O
compositions	O
of	O
lipophilic	O
pharmaceutical	O
agents	O
with	O
improved	O
solubility	O
and	O
stability	O
.	O

For	O
example	O
,	O
there	O
may	O
be	O
provided	O
a	O
non	O
-	O
aqueous	O
composition	O
that	O
comprises	O
a	O
lipophilic	O
pharmaceutical	O
agent	O
,	O
and	O
an	O
amphiphilic	O
polymeric	O
solvent	O
such	O
as	O
PEG400	B
but	O
essentially	O
free	O
of	O
organic	O
solvents	O
and	O
non	O
-	O
solubilized	O
particles	O
.	O

The	O
composition	O
may	O
be	O
further	O
diluted	O
with	O
a	O
desired	O
aqueous	O
diluent	O
such	O
as	O
an	O
infusion	O
fluid	O
for	O
parenteral	O
administration	O
to	O
a	O
subject	O
such	O
as	O
a	O
human	O
.	O

The	O
compositions	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
for	O
diseases	O
or	O
conditions	O
that	O
are	O
sensitive	O
to	O
lipophilic	O
agents	O
,	O
such	O
as	O
infectious	O
diseases	O
,	O
malignant	O
or	O
autoimmune	O
diseases	O
.	O

Parenteral	O
formulations	O
of	O
lipophilic	O
pharmaceutical	O
agents	O
and	O
methods	O
for	O
preparing	O
and	O
using	O
the	O
same	O

There	O
is	O
provided	O
a	O
formulation	O
suitable	O
for	O
transmucosal	O
administration	O
comprising	O
a	O
short	O
acting	O
hypnotic	O
drug	O
,	O
which	O
formulation	O
provides	O
a	O
measurable	O
plasma	O
concentration	O
of	O
drug	O
within	O
10	O
minutes	O
of	O
administration	O
.	O

The	O
formulation	O
is	O
capable	O
of	O
providing	O
sleep	O
on	O
demand	O
,	O
and	O
preferably	O
comprises	O
particles	O
of	O
drug	O
,	O
for	O
example	O
zolpidem	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
and	O
a	O
mucoadhesion	O
promoting	O
agent	O
,	O
such	O
as	O
sodium	O
carboxymethylcellulose	O
,	O
which	O
particles	O
of	O
drug	O
and	O
mucoadhesive	O
are	O
presented	O
upon	O
the	O
surface	O
of	O
larger	O
carrier	O
particles	O
.	O

Pharmaceutical	O
formulations	O
useful	O
in	O
the	O
treatment	O
of	O
insomnia	O

The	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
an	O
extended	O
release	O
tablet	O
formulation	O
for	O
pramipexole	B
.	O

Modified	O
Release	O
Formulation	O

Disclosed	O
herein	O
are	O
methods	O
of	O
treating	O
a	O
condition	O
associated	O
with	O
elevated	O
cholesterol	B
levels	O
are	O
provided	O
,	O
comprising	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
of	O
such	O
treatment	O
a	O
safe	O
and	O
effective	O
amount	O
of	O
a	O
cholesterol	B
biosynthesis	O
inhibitor	O
and	O
a	O
soluble	O
fiber	O
.	O

Further	O
disclosed	O
herein	O
are	O
kits	O
comprising	O
a	O
first	O
composition	O
comprising	O
a	O
cholesterol	B
biosynthesis	O
inhibitor	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
HMG	O
CoA	O
reductase	O
inhibitors	O
,	O
HMG	O
CoA	O
synthase	O
inhibitors	O
,	O
and	O
mixtures	O
thereof	O
;	O
and	O
a	O
second	O
composition	O
comprising	O
a	O
soluble	O
fiber	O
.	O

Even	O
further	O
described	O
are	O
compositions	O
comprising	O
a	O
cholesterol	B
biosynthesis	O
inhibitor	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
HMG	O
CoA	O
reductase	O
inhibitors	O
,	O
HMG	O
CoA	O
synthase	O
inhibitors	O
,	O
and	O
mixtures	O
thereof	O
;	O
and	O
a	O
soluble	O
fiber	O
.	O

Compositions	O
,	O
Kits	O
,	O
and	O
Methods	O
for	O
the	O
Treatment	O
of	O
Conditions	O
Associated	O
with	O
Elevated	O
Cholesterol	B
Levels	O

Novel	O
metabolites	O
of	O
talarazole	B
of	O
formula	O
(	O
I	O
)	O
have	O
been	O
isolated	O
and	O
characterized	O
,	O
wherein	O
R	O
═	O
H	B
,	O
OH	B
,	O
OSO3H	B
or	O
O	B
-	I
gly	I
;	O
R1	O
,	O
═	O
H	B
,	O
OH	B
,	O
OSO3H	B
,	O
O	B
-	I
gly	I
or	O
=	B
0	I
;	O
and	O
gly	B
=	O
a	O
glucuronate	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

These	O
compounds	O
are	O
targeted	O
for	O
the	O
treatment	O
of	O
various	O
skin-	O
,	O
hair-	O
and	O
nail	O
-	O
associated	O
disorders	O
.	O

Talarazole	B
metabolites	O

This	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
substituted	O
macrocyclic	B
porphyrin	I
compounds	O
.	O

The	O
compounds	O
are	O
useful	O
as	O
peroxynitrite	B
decomposition	O
catalysts	O
.	O

Pharmaceutical	O
compositions	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	B
,	O
or	O
prodrug	O
thereof	O
are	O
also	O
described	O
.	O

Porphyrin	B
Catalysts	O
and	O
Methods	O
of	O
Use	O
Thereof	O

The	O
invention	O
relates	O
to	O
1H-	B
[	I
1,2,3	I
]	I
triazolo	I
[	I
4,5-c	I
]	I
pyridine-4-carbonitrile	I
derived	O
Cathepsin	O
S	O
inhibitors	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
H	B
or	O
(	B
C1	I
-	I
3	I
)	I
alkyl	I
;	O
R2	O
is	O
halogen	B
or	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
,	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
halogens	B
;	O
n	O
is	O
1	O
-	O
3	O
;	O
X	O
is	O
O	B
or	O
CH2	B
;	O
U	O
,	O
V	O
and	O
W	O
are	O
CH	B
;	O
or	O
one	O
of	O
U	O
,	O
V	O
and	O
W	O
is	O
N	B
;	O
Y	O
is	O
a	O
group	O
capable	O
of	O
interacting	O
with	O
the	O
Sn	B
.	O
.	O
.	O

S2	O
substites	O
of	O
the	O
active	O
site	O
of	O
Cathepsin	O
S	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
these	O
derivatives	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cathepsin	O
S	O
related	O
diseases	O
such	O
as	O
atherosclerosis	O
,	O
obesity	O
,	O
inflammation	O
and	O
immune	O
disorders	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
psoriasis	O
,	O
cancer	O
,	O
and	O
chronic	O
pain	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

1H-	B
[	I
1,2,3	I
]	I
TRIAZOLO	I
[	I
4,5-c	I
]	I
PYRIDINE-4-CARBONITRILE	I
DERIVATIVES	O

A	O
series	O
of	O
new	O
chemical	O
agents	O
that	O
demonstrate	O
anti	O
-	O
tumor	O
activity	O
are	O
described	O
herein	O
.	O

The	O
new	O
chemical	O
agents	O
exhibit	O
a	O
dual	O
mode	O
of	O
anti	O
-	O
tumor	O
action	O
:	O
blocking	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
mediated	O
signal	O
transduction	O
and	O
damaging	O
DNA	O
by	O
alkylation	O
.	O

Imidazotetrazinone	B
-	O
based	O
combi	O
-	O
molecules	O

Oligomeric	O
compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
eIF4E	O
.	O

The	O
antisense	O
compounds	O
may	O
be	O
single-	O
or	O
double	O
-	O
stranded	O
and	O
are	O
targeted	O
to	O
nucleic	O
acid	O
encoding	O
eIF4E	O
.	O

Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
eIF4E	O
expression	O
and	O
for	O
diagnosis	O
and	O
treatment	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
expression	O
of	O
eIF4E	O
are	O
provided	O
.	O

Modulation	O
of	O
eif4e	O
expression	O

The	O
present	O
invention	O
relates	O
to	O
the	O
preparation	O
of	O
poly	B
(	I
amino	I
oxalate	I
)	I
(	O
PAOX	B
)	O
using	O
oxalyl	B
chloride	I
,	O
1,4-cyclohexanedimethanol	B
,	O
and	O
piperazinediethanol	B
,	O
the	O
preparation	O
of	O
biodegradable	O
polymer	O
particles	O
using	O
the	O
PAOX	B
,	O
and	O
the	O
use	O
of	O
PAOX	B
particles	O
as	O
a	O
drug	O
delivery	O
vehicle	O
.	O

The	O
PAOX	B
according	O
to	O
the	O
present	O
invention	O
is	O
a	O
polymer	O
that	O
has	O
three	O
characteristics	O
of	O
biodegradability	O
,	O
biocompatibility	O
,	O
and	O
cationic	O
properties	O
at	O
the	O
same	O
time	O
with	O
appropriate	O
hydrophobicity	O
and	O
thus	O
can	O
be	O
prepared	O
as	O
particles	O
that	O
allow	O
rapid	O
drug	O
release	O
.	O

Moreover	O
,	O
the	O
particles	O
improve	O
the	O
delivery	O
efficiency	O
of	O
a	O
drug	O
into	O
cells	O
and	O
thus	O
can	O
be	O
efficiently	O
used	O
as	O
a	O
drug	O
delivery	O
vehicle	O
for	O
the	O
treatment	O
of	O
acute	O
inflammatory	O
diseases	O
such	O
as	O
acute	O
liver	O
failure	O
and	O
acute	O
lung	O
injury	O
.	O

Biodegradable	O
paox	B
polymer	O
particle	O
with	O
cationic	O
property	O

This	O
disclosure	O
provides	O
compositions	O
that	O
are	O
useful	O
combined	O
with	O
therapeutics	O
,	O
and	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
diseases	O
and	O
conditions	O
.	O

The	O
compositions	O
are	O
useful	O
for	O
delivery	O
of	O
agents	O
such	O
as	O
nucleic	O
acid	O
therapeutics	O
to	O
cells	O
,	O
tissues	O
,	O
organs	O
,	O
and	O
subjects	O
.	O

Compositions	O
comprising	O
cationic	O
amphiphiles	O
and	O
colipids	O
for	O
delivering	O
therapeutic	O
molecules	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
pancreatitis	O
and/or	O
organ	O
failure	O
comprising	O
administering	O
,	O
to	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
,	O
an	O
effective	O
amount	O
of	O
a	O
lipase	O
inhibitor	O
.	O

It	O
is	O
based	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
the	O
discoveries	O
that	O
lipotoxicity	O
contributes	O
to	O
inflammation	O
,	O
multisystem	O
organ	O
failure	O
,	O
necrotic	O
pancreatic	O
acinar	O
cell	O
death	O
and	O
in	O
acute	O
pancreatitis	O
,	O
and	O
that	O
inhibition	O
of	O
lipolysis	O
was	O
able	O
to	O
reduce	O
indices	O
associated	O
with	O
these	O
conditions	O
.	O

Accordingly	O
,	O
in	O
various	O
embodiments	O
,	O
the	O
present	O
invention	O
provides	O
for	O
methods	O
and	O
compositions	O
for	O
limiting	O
lipotoxicity	O
and	O
thereby	O
reducing	O
the	O
likelihood	O
of	O
poor	O
outcomes	O
associated	O
with	O
acute	O
pancreatitis	O
and	O
other	O
severe	O
systemic	O
conditions	O
,	O
especially	O
in	O
obese	O
individuals	O
.	O

Lipase	O
Inhibitors	O
for	O
the	O
Treatment	O
of	O
Pancreatitis	O
and	O
Organ	O
Failure	O

This	O
application	O
provides	O
methods	O
of	O
increasing	O
vascularization	O
,	O
muscle	O
performance	O
,	O
muscle	O
rehabilitation	O
,	O
and/or	O
mitochondrial	O
activity	O
in	O
subjects	O
in	O
need	O
thereof	O
,	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
agents	O
that	O
increases	O
ERRγ	O
activity	O
to	O
the	O
subject	O
.	O

Such	O
agents	O
can	O
include	O
one	O
or	O
more	O
ERRγ	O
agonists	O
.	O

In	O
some	O
examples	O
the	O
method	O
does	O
not	O
require	O
that	O
the	O
subject	O
exercise	O
,	O
and	O
as	O
such	O
,	O
the	O
subject	O
may	O
be	O
sedentary	O
(	O
such	O
as	O
bedridden	O
or	O
in	O
a	O
wheelchair	O
)	O
.	O

Modulation	O
of	O
estrogen	B
receptor	O
-	O
related	O
receptor	O
gamma	O
(	O
err	O
gamma	O
)	O
and	O
uses	O
therefor	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
characterized	O
by	O
the	O
following	O
Formula	O
I	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
X	O
,	O
and	O
Y	O
are	O
as	O
described	O
herein	O
.	O

Compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV-1	O
.	O

Derivatives	O
of	O
betulin	B

Pharmaceutical	O
compositions	O
of	O
the	O
invention	O
include	O
sulfamide	B
derivatives	O
having	O
a	O
disease	O
-	O
modifying	O
action	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
excitotoxicity	O
and	O
accompanying	O
oxidative	O
stress	O
that	O
include	O
epilepsy	O
,	O
Alzheimer	O
's	O
disease	O
,	O
and	O
any	O
neurodegenerative	O
disease	O
involving	O
glutamate	B
toxicity	O
.	O

Novel	O
sulfamides	B
exhibiting	O
neuroprotective	O
action	O
and	O
methods	O
for	O
use	O
thereof	O

Disclosed	O
is	O
a	O
sustained	O
release	O
preparation	O
which	O
releases	O
a	O
poorly	O
soluble	O
medicinal	O
agent	O
in	O
a	O
pH	O
-	O
independent	O
manner	O
.	O

Also	O
disclosed	O
is	O
a	O
sustained	O
release	O
preparation	O
which	O
is	O
capable	O
of	O
controlling	O
the	O
Cmax	O
of	O
a	O
medicinal	O
agent	O
to	O
an	O
adequate	O
amount	O
and	O
is	O
thus	O
capable	O
of	O
maintaining	O
the	O
level	O
of	O
the	O
medicinal	O
agent	O
in	O
the	O
blood	O
to	O
a	O
level	O
at	O
which	O
medicinal	O
effects	O
can	O
be	O
expected	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

Specifically	O
disclosed	O
is	O
a	O
sustained	O
release	O
preparation	O
which	O
is	O
characterized	O
by	O
containing	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
4-bromo-6-	B
[	I
3-	I
(	I
4-chlorophenyl	I
)	I
propoxy	I
]	I
-5-	I
(	I
3-pyridylmethylamino	I
)	I
-3	I
(	I
2H	I
)	I
-pyridazinone	I
,	O
and	O
hypromellose	O
.	O

An	O
organic	O
acid	O
is	O
blended	O
in	O
the	O
sustained	O
release	O
preparation	O
in	O
an	O
amount	O
of	O
less	O
than	O
1	O
%	O
by	O
mass	O
.	O

Extended	O
release	O
preparation	O

Embodiments	O
are	O
directed	O
to	O
compositions	O
and	O
methods	O
related	O
combination	O
therapy	O
with	O
HERV	O
inhibition	O
.	O

Combination	O
cancer	O
therapy	O
with	O
herv	O
inhibition	O

The	O
present	O
invention	O
relates	O
to	O
a	O
chewing	O
gum	O
having	O
a	O
high	O
Surface	O
Area	O
to	O
Volume	O
ratio	O
(	O
SAV	O
ratio	O
)	O
,	O
wherein	O
said	O
chewing	O
gum	O
comprises	O
a	O
water	O
insoluble	O
gum	O
base	O
matrix	O
,	O
a	O
water	O
soluble	O
bulk	O
portion	O
and	O
nicotine	O
,	O
wherein	O
the	O
gum	O
base	O
matrix	O
,	O
nicotine	B
and	O
the	O
bulk	O
portion	O
are	O
mixed	O
and	O
extruded	O
to	O
form	O
a	O
final	O
extruded	O
chewing	O
gum	O
product	O
having	O
a	O
SAV	O
ratio	O
above	O
0.7	O
,	O
and	O
wherein	O
sustained	O
release	O
of	O
nicotine	O
is	O
facilitated	O
by	O
adding	O
0.1	O
-	O
10	O
%	O
of	O
C8-C10	O
triglycerides	B
by	O
weight	O
of	O
the	O
chewing	O
gum	O
.	O

Chewing	O
gum	O
having	O
sustained	O
release	O
of	O
nicotine	B

The	O
present	O
invention	O
relates	O
to	O
a	O
nucleic	O
acid	O
encoding	O
a	O
polypeptide	O
and	O
the	O
use	O
of	O
the	O
nucleic	O
acid	O
or	O
polypeptide	O
in	O
preventing	O
and/or	O
treating	O
cancer	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
improved	O
vectors	O
for	O
the	O
insertion	O
and	O
expression	O
of	O
foreign	O
genes	O
encoding	O
tumor	O
antigens	O
for	O
use	O
in	O
immunotherapeutic	O
treatment	O
of	O
cancer	O
.	O

Tumor	O
Antigens	O
for	O
the	O
Prevention	O
and/or	O
Treatment	O
of	O
Cancer	O

A	O
nicotine	O
-	O
containing	O
chewing	O
gum	O
piece	O
packed	O
in	O
a	O
wrapping	O
of	O
laminate	O
,	O
where	O
the	O
laminate	O
comprises	O
at	O
least	O
an	O
inner	O
layer	O
facing	O
the	O
chewing	O
gum	O
and	O
a	O
nicotine	B
degradation	O
agent	O
barrier	O
layer	O
of	O
a	O
metal	O
foil	O
.	O

The	O
nicotine	B
-	O
containing	O
chewing	O
gum	O
piece	O
is	O
shaped	O
as	O
an	O
elongate	O
plate	O
having	O
two	O
ends	O
and	O
a	O
thickness	O
and	O
a	O
length	O
,	O
where	O
the	O
length	O
is	O
in	O
the	O
range	O
of	O
8	O
to	O
20	O
times	O
the	O
thickness	O
.	O

The	O
wrapping	O
has	O
two	O
elongate	O
edges	O
sealed	O
to	O
one	O
another	O
in	O
a	O
fin	O
area	O
extending	O
along	O
the	O
length	O
of	O
the	O
chewing	O
gum	O
piece	O
and	O
two	O
sealed	O
end	O
areas	O
extending	O
beyond	O
the	O
ends	O
of	O
the	O
chewing	O
gum	O
piece	O
.	O

Nicotine	B
-	O
containing	O
chewing	O
gum	O
piece	O
packed	O
in	O
a	O
wrapping	O
of	O
laminate	O

The	O
invention	O
relates	O
to	O
the	O
synthesis	O
of	O
a	O
second	O
-	O
generation	O
camptothecin	B
glucuronide	I
prodrug	O
(	O
BQC	B
-	I
G	I
)	O
of	O
a	O
potent	O
anticancer	O
camptothecin	B
derivative	O
5,6-dihydro-4H	B
-	I
benzo	I
[	I
de	I
]	I
quinoline	I
-	I
camptothecin	I
(	O
BQC	B
)	O
.	O

BQC	B
-	I
G	I
was	O
over	O
4000	O
times	O
more	O
water	O
soluble	O
than	O
BQC	B
,	O
displayed	O
good	O
stability	O
in	O
human	O
plasma	O
and	O
was	O
an	O
excellent	O
substrate	O
for	O
enzymatic	O
hydrolysis	O
by	O
bacterial	O
and	O
human	O
β	O
-	O
glucuronidases	O
.	O

BQC	B
-	I
G	I
was	O
about	O
30	O
times	O
less	O
toxic	O
than	O
BQC	B
,	O
but	O
was	O
as	O
toxic	O
as	O
BQC	B
after	O
hydrolysis	O
of	O
the	O
glucuronide	O
moiety	O
by	O
β	O
-	O
glucuronidase	O
.	O

In	O
the	O
presence	O
of	O
human	O
serum	O
albumin	O
,	O
BQC	B
-	I
G	I
displayed	O
lower	O
cytotoxicity	O
(	O
IC50=1080	O
nM	O
)	O
but	O
could	O
be	O
activated	O
by	O
β	O
-	O
glucuronidase	O
to	O
display	O
potent	O
activity	O
(	O
IC50=13.3	O
nM	O
)	O
.	O

Bqc	B
-	I
g	I
,	O
a	O
tumor	O
-	O
selective	O
anti	O
-	O
cancer	O
prodrug	O

A	O
method	O
of	O
identifying	O
cancer	O
or	O
an	O
associated	O
disorder	O
comprising	O
identifying	O
and	O
quantifying	O
STAT3	O
occurring	O
in	O
a	O
biological	O
sample	O
taken	O
from	O
a	O
subject	O
after	O
administering	O
a	O
SFK	O
inhibitor	O
to	O
said	O
subject	O
.	O

Biomarker	O
Identifying	O
the	O
Reactivation	O
of	O
STAT3	O
After	O
Src	O
Inhibition	O

The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
prasugrel	O
and	O
a	O
cyclodextrin	O
derivative	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
same	O
.	O

Pharmaceutical	O
Compositions	O
Comprising	O
Prasugrel	O
and	O
Cyclodextrin	O
Derivatives	O
and	O
Methods	O
of	O
Making	O
and	O
Using	O
the	O
Same	O

The	O
invention	O
provides	O
dosage	O
forms	O
and	O
methods	O
utilizing	O
nicotine	B
to	O
treat	O
symptoms	O
of	O
a	O
neurologic	O
disorder	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
invention	O
provides	O
compositions	O
for	O
treatment	O
of	O
gait	O
and	O
balance	O
problems	O
associated	O
with	O
Parkinson	O
's	O
Disease	O
.	O

Compositions	O
and	O
Methods	O
for	O
Treatment	O
of	O
Symptoms	O
in	O
Parkinson	O
's	O
Disease	O
Patients	O

The	O
subject	O
application	O
relates	O
to	O
novel	O
compositions	O
containing	O
a	O
diffusion	O
enhancing	O
compound	O
and	O
their	O
use	O
in	O
treating	O
a	O
variety	O
of	O
disorders	O
.	O

New	O
class	O
of	O
therapeutics	O
that	O
enhance	O
small	O
molecule	O
diffusion	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
including	O
a	O
testis	O
extract	O
serving	O
as	O
an	O
active	O
ingredient	O
for	O
treating	O
and	O
preventing	O
anemia	O
,	O
in	O
which	O
since	O
the	O
testis	O
extract	O
induces	O
proliferation	O
of	O
hematopoietic	O
stem	O
cell	O
,	O
an	O
increase	O
in	O
the	O
number	O
of	O
red	O
blood	O
cell	O
,	O
and	O
an	O
increase	O
in	O
the	O
amount	O
of	O
hemoglobin	O
,	O
it	O
is	O
effectively	O
used	O
as	O
a	O
therapeutic	O
agent	O
for	O
treating	O
anemia	O
related	O
to	O
red	O
blood	O
cell	O
and	O
hemoglobin	O
in	O
women	O
of	O
childbearing	O
age	O
,	O
post	O
-	O
childbearing	O
age	O
,	O
and	O
during	O
pregnancy	O
,	O
as	O
well	O
as	O
in	O
men	O
.	O

Pharmaceutical	O
composition	O
including	O
a	O
testis	O
extract	O
as	O
an	O
active	O
ingredient	O
for	O
treating	O
and	O
preventing	O
anemia	O

Based	O
on	O
the	O
present	O
disclosure	O
,	O
a	O
minimal	O
time	O
interval	O
can	O
be	O
achieved	O
between	O
the	O
last	O
ingestion	O
of	O
a	O
picosulfate	O
composition	O
and	O
the	O
performance	O
of	O
the	O
colonoscopy	O
.	O

For	O
example	O
,	O
the	O
present	O
disclosure	O
is	O
directed	O
to	O
a	O
method	O
of	O
timing	O
a	O
colonoscopy	O
procedure	O
performed	O
on	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
comprising	O
:	O
administering	O
,	O
to	O
the	O
patient	O
,	O
a	O
picosulfate	B
bowel	O
composition	O
kit	O
according	O
to	O
the	O
kit	O
's	O
instructions	O
;	O
performing	O
the	O
procedure	O
less	O
than	O
about	O
4	O
hours	O
after	O
the	O
administration	O
of	O
the	O
kit	O
.	O

Method	O
for	O
timing	O
a	O
colonoscopy	O

In	O
a	O
first	O
aspect	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
prevention	O
or	O
treating	O
memory	O
impairment	O
and/or	O
a	O
neurodegenerative	O
condition	O
,	O
disorder	O
or	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
targeting	O
a	O
miRNA	O
or	O
any	O
precursor	O
,	O
or	O
targeting	O
the	O
activity	O
of	O
said	O
miRNA	O
or	O
any	O
precursor	O
thereof	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
wherein	O
the	O
targeted	O
miRNA	O
is	O
miR-34	O
.	O

Moreover	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
improving	O
memory	O
functionality	O
in	O
a	O
subject	O
suffering	O
from	O
memory	O
loss	O
,	O
said	O
method	O
comprises	O
the	O
reduction	O
or	O
reducing	O
the	O
level	O
of	O
miR-34	O
levels	O
or	O
precursor	O
molecule	O
levels	O
in	O
brain	O
tissue	O
of	O
said	O
subject	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
targeting	O
miR-34	O
or	O
any	O
precursor	O
thereof	O
.	O

Moreover	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
inducing	O
memory	O
loss	O
in	O
an	O
individual	O
comprising	O
administering	O
to	O
said	O
individual	O
an	O
effective	O
amount	O
of	O
one	O
or	O
more	O
compounds	O
having	O
the	O
functionality	O
of	O
miR-34	O
,	O
in	O
particular	O
of	O
miR-34c	O
or	O
any	O
precursor	O
thereof	O
.	O

In	O
addition	O
,	O
a	O
method	O
for	O
diagnosing	O
or	O
predicting	O
memory	O
impairment	O
and/or	O
neurodegenerative	O
condition	O
,	O
disorder	O
or	O
disease	O
is	O
provided	O
.	O

Finally	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
compound	O
targeting	O
miR-34	O
or	O
precursor	O
molecules	O
thereof	O
.	O

Method	O
for	O
preventing	O
or	O
treating	O
memory	O
impairment	O
and	O
pharmaceutical	O
compositions	O
useful	O
therefore	O

Compounds	O
having	O
drug	O
and	O
bio	O
-	O
affecting	O
properties	O
,	O
their	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
set	O
forth	O
.	O

In	O
particular	O
,	O
C-17	O
and	O
C-3	O
modified	O
triterpenoids	B
that	O
possess	O
unique	O
antiviral	O
activity	O
are	O
provided	O
as	O
HIV	O
maturation	O
inhibitors	O
,	O
as	O
represented	O
by	O
compounds	O
of	O
Formulas	O
I	O
,	O
II	O
and	O
III	O
:	O
These	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV	O
and	O
AIDS	O
.	O

C-17	O
and	O
c-3	O
modified	O
triterpenoids	B
with	O
hiv	O
maturation	O
inhibitory	O
activity	O

There	O
is	O
provided	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
J	O
represents	O
(	O
A	O
)	O
:	O
or	O
(	O
B	O
)	O
:	O
compositions	O
comprising	O
same	O
,	O
processes	O
for	O
preparing	O
said	O
compounds	O
and	O
use	O
thereof	O
in	O
treatment	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
inflammatory	O
disease	O
,	O
such	O
as	O
asthma	O
,	O
COPD	O
and	O
15	O
rheumatoid	O
arthritis	O
.	O

P38	O
MAP	O
Kinase	O
Inhibitors	O

Provided	O
are	O
a	O
novel	O
pyridine	B
carboxylic	I
acid	I
based	O
compound	O
used	O
as	O
a	O
P2X1	O
and	O
P2X3	O
receptor	O
antagonist	O
,	O
a	O
production	O
method	O
for	O
the	O
same	O
and	O
a	O
composition	O
comprising	O
the	O
same	O
.	O

The	O
compound	O
according	O
to	O
the	O
present	O
invention	O
is	O
a	O
powerful	O
antagonist	O
of	O
P2X1	O
and	O
P2X3	O
receptors	O
,	O
and	O
hence	O
can	O
be	O
used	O
as	O
a	O
drug	O
for	O
treating	O
or	O
preventing	O
diseases	O
involving	O
neurological	O
pain	O
or	O
chronic	O
inflammatory	O
diseases	O
which	O
are	O
diseases	O
caused	O
by	O
P2X1	O
and	O
P2X3	O
receptor	O
activity	O
.	O

Novel	O
pyridine	B
carboxylic	I
acid	I
based	O
compound	O
used	O
as	O
a	O
p2x1	O
and	O
p2x3	O
receptor	O
antagonist	O
,	O
a	O
production	O
method	O
for	O
the	O
same	O
and	O
a	O
composition	O
comprising	O
the	O
same	O

The	O
present	O
invention	O
provides	O
therapeutic	O
nucleic	O
acids	O
such	O
as	O
interfering	O
RNA	O
(	O
e.g.	O
,	O
siRNA	O
)	O
that	O
target	O
the	O
expression	O
of	O
genes	O
associated	O
with	O
tumorigenesis	O
and/or	O
cell	O
transformation	O
,	O
lipid	O
particles	O
(	O
e.g.	O
,	O
nucleic	O
acid	O
-	O
lipid	O
particles	O
)	O
comprising	O
one	O
or	O
more	O
(	O
e.g.	O
,	O
a	O
cocktail	O
)	O
of	O
the	O
therapeutic	O
nucleic	O
acids	O
,	O
methods	O
of	O
making	O
the	O
lipid	O
particles	O
,	O
and	O
methods	O
of	O
delivering	O
and/or	O
administering	O
the	O
lipid	O
particles	O
,	O
e.g.	O
,	O
for	O
the	O
treatment	O
of	O
a	O
cell	O
proliferative	O
disorder	O
such	O
as	O
cancer	O
.	O

Compositions	O
and	O
methods	O
for	O
silencing	O
genes	O
expressed	O
in	O
cancer	O

This	O
invention	O
discloses	O
3-desoxy-2-methylene	B
-	I
vitamin	I
D	I
analogs	O
,	O
and	O
specifically	O
(	B
20S	I
)	I
-3-desoxy-1α,25-dihydroxy-2-methylene	I
-	I
vitamin	I
D3	I
and	O
(	B
20R	I
)	I
-3-desoxy-1α	I
,	I
25-dihydroxy-2-methylene	I
-	I
vitamin	I
D3	I
as	O
well	O
as	O
pharmaceutical	O
uses	O
therefor	O
.	O

These	O
compounds	O
exhibit	O
relatively	O
high	O
binding	O
activity	O
and	O
pronounced	O
activity	O
in	O
arresting	O
the	O
proliferation	O
of	O
undifferentiated	O
cells	O
and	O
inducing	O
their	O
differentiation	O
to	O
monocytes	O
thus	O
evidencing	O
use	O
as	O
anti	O
-	O
cancer	O
agents	O
especially	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
osteosarcoma	O
,	O
leukemia	O
,	O
colon	O
cancer	O
,	O
breast	O
cancer	O
,	O
skin	O
cancer	O
or	O
prostate	O
cancer	O
.	O

These	O
compounds	O
also	O
exhibit	O
relatively	O
high	O
calcemic	O
activity	O
evidencing	O
use	O
in	O
the	O
treatment	O
of	O
bone	O
diseases	O
.	O

3-Desoxy-2-Methylene	B
-	I
Vitamin	I
D	I
Analogs	O
and	O
Their	O
Uses	O

The	O
present	O
invention	O
is	O
correlated	O
with	O
a	O
derivative	O
of	O
18β	B
-	I
glycyrrhetinic	I
acid	I
apt	O
to	O
suppressing	O
cancer	O
cells	O
,	O
which	O
is	O
selected	O
from	O
a	O
group	O
comprising	O
of	O
structure	O
I	O
and	O
structure	O
II	O
:	O
wherein	O
residue	O
R1	O
is	O
selected	O
from	O
one	O
of	O
CH3	B
and	O
CH2C6H5	B
,	O
residue	O
R2	O
is	O
selected	O
from	O
one	O
of	O
COOCH3	B
,	O
COOCH2CH3	B
,	O
COOCH	B
(	I
CH3	I
)	I
2	I
,	O
CONHCH2CH3	B
,	O
CONHCH2CH2CH3	B
,	O
and	O
CONHCH2	B
(	I
CH3	I
)	I
2	I
,	O
and	O
residue	O
R3	O
is	O
selected	O
from	O
one	O
of	O
COOCH2CH3	B
,	O
COOCH	B
(	I
CH3	I
)	I
2	I
,	O
CONHCH2CH3	B
,	O
CONHCH2CH2CH3	B
,	O
and	O
CONHCH2	B
(	I
CH3	I
)	I
2	I
.	O

DERIVATIVE	O
OF	O
18beta	B
-	I
GLYCYRRHETINIC	I
ACID	I
APT	O
TO	O
SUPPRESS	O
CANCER	O
CELLS	O

Compositions	O
and	O
systems	O
for	O
topical	O
ophthalmic	O
application	O
,	O
which	O
include	O
an	O
aqueous	O
mixture	O
of	O
steroidal	O
and	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	O
in	O
a	O
flowable	O
mucoadhesive	O
polymer	O
,	O
for	O
treating	O
inflammation	O
and	O
inflammatory	O
conditions	O
of	O
the	O
eye	O
.	O

Combination	O
anti	O
-	O
inflammatory	O
ophthalmic	O
compositions	O

The	O
embodiments	O
herein	O
provide	O
a	O
composition	O
and	O
a	O
method	O
of	O
synthesizing	O
a	O
composition	O
comprising	O
an	O
aliphatic	B
amino	I
acid	I
biosynthesis	O
inhibitor	O
having	O
an	O
antifungal	O
activity	O
.	O

The	O
composition	O
comprises	O
2-oxo-2H	B
-	I
chromen-7-yl	I
propiolate	I
,	O
diethyl	B
-	I
hex-2-en-4-yne	I
-	I
dioate	I
and	O
dinonyl	B
-	I
hex-2-en-4-yne	I
-	I
dioate	I
.	O

The	O
composition	O
inhibits	O
a	O
biosynthesis	O
of	O
an	O
aliphatic	B
amino	I
acid	I
in	O
a	O
fungal	O
biological	O
system	O
.	O

The	O
aliphatic	B
amino	I
acid	I
is	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
leucine	B
,	O
isoleucine	B
and	O
valine	B
.	O

The	O
composition	O
is	O
used	O
with	O
a	O
concentration	O
of	O
0	O
-	O
200	O
μg	O
/	O
ml	O
.	O

The	O
method	O
comprises	O
mixing	O
solutions	O
of	O
dicyclohexylcarbodiimide	B
(	O
DCC	B
)	O
and	O
Dimethylaminopyridine	B
(	O
DMAP	B
)	O
with	O
alcohol	B
,	O
acetylene	B
carboxylic	I
acid	I
and	O
dichloromethane	B
to	O
obtain	O
a	O
mixture	O
which	O
is	O
stirred	O
filtered	O
and	O
washed	O
with	O
ether	O
.	O

The	O
solvents	O
are	O
evaporated	O
to	O
obtain	O
a	O
residue	O
that	O
is	O
dissolved	O
in	O
dichloromethane	B
and	O
stirred	O
with	O
a	O
catalyst	O
.	O

The	O
extra	O
solvents	O
are	O
evaporated	O
to	O
obtain	O
the	O
derivative	O
compound	O
and	O
purified	O
by	O
silica	B
gel	I
column	O
chromatography	O
.	O

Aliphatic	B
amino	I
acid	I
biosynthesis	O
inhibitors	O
and	O
a	O
method	O
of	O
synthesizing	O
the	O
same	O

A	O
method	O
of	O
providing	O
a	O
pet	O
with	O
a	O
benefit	O
relating	O
to	O
effective	O
assimilation	O
of	O
a	O
lipid	O
is	O
described	O
wherein	O
the	O
pet	O
is	O
administered	O
,	O
as	O
a	O
part	O
of	O
,	O
or	O
in	O
addition	O
to	O
its	O
regular	O
diet	O
,	O
an	O
edible	O
composition	O
that	O
contains	O
an	O
ingredient	O
that	O
maintains	O
,	O
promotes	O
or	O
enhances	O
the	O
capacity	O
of	O
the	O
pet	O
to	O
digest	O
lipid	O
efficiently	O
.	O

The	O
invention	O
extends	O
to	O
compositions	O
for	O
use	O
in	O
promoting	O
lipid	O
assimilation	O
in	O
pets	O
,	O
particularly	O
senior	O
or	O
elderly	O
pets	O
.	O

The	O
compositions	O
include	O
pancreatic	O
,	O
liver	O
and	O
intestinal	O
mucosa	O
function	O
-	O
promoters	O
.	O

In	O
embodiments	O
,	O
the	O
liver	O
function	O
-	O
promoter	O
may	O
be	O
selected	O
from	O
taurine	B
,	O
emulsifiers	O
,	O
vitamins	B
,	O
minerals	O
,	O
glutathione	B
and	O
glutathione	B
promoters	O
.	O

Method	O
of	O
improving	O
absorption	O
of	O
vitamin	B
e	I
by	O
a	O
pet	O
animal	O

The	O
current	O
invention	O
is	O
a	O
particle	O
comprising	O
an	O
assembly	O
of	O
lipid	O
-	O
enveloped	O
core	O
polypeptides	O
and	O
transmembrane	O
polypeptides	O
.	O

The	O
transmembrane	O
polypeptides	O
comprise	O
sequences	O
that	O
bind	O
to	O
phagocytes	O
through	O
indirect	O
or	O
direct	O
binding	O
by	O
surface	O
receptors	O
.	O

The	O
result	O
of	O
transmembrane	O
polypeptide	O
binding	O
is	O
engulfment	O
by	O
the	O
phagocyte	O
to	O
low	O
-	O
pH	O
compartments	O
.	O

The	O
low	O
pH	O
triggers	O
a	O
conformational	O
change	O
in	O
transmembrane	O
polypeptides	O
whereby	O
lipids	O
of	O
particles	O
and	O
phagocytes	O
are	O
fused	O
and	O
the	O
contents	O
of	O
the	O
particle	O
,	O
including	O
a	O
polypeptide	O
to	O
be	O
delivered	O
to	O
the	O
cell	O
,	O
are	O
released	O
into	O
the	O
phagocyte	O
.	O

Delivering	O
polypeptides	O
to	O
phagocytes	O

An	O
analgesic	O
medication	O
includes	O
an	O
oligonucleotide	B
being	O
a	O
double	O
strand	O
RNA	O
comprising	O
18	O
to	O
70	O
base	O
pairs	O
,	O
and	O
a	O
pharmaceutical	O
acceptable	O
vehicle	O
for	O
delivering	O
the	O
said	O
oligonucleotide	B
into	O
cells	O
,	O
wherein	O
a	O
dosage	O
of	O
the	O
oligonucleotide	B
in	O
the	O
analgesic	O
is	O
50	O
μg	O
to	O
200	O
μg	O
/	O
kg	O
per	O
time	O
,	O
and	O
the	O
pharmaceutical	O
acceptable	O
vehicle	O
is	O
selected	O
from	O
a	O
group	O
of	O
polyethyleneimine	B
,	O
lipofectamine	O
and	O
iFect	O
.	O

Analgesic	O
medication	O

A	O
topical	O
mixture	O
intended	O
to	O
reduce	O
undesirable	O
Iron	B
levels	O
in	O
the	O
cells	O
to	O
optimize	O
Mitochondrial	O
functioning	O
.	O

A	O
method	O
of	O
reducing	O
undesirable	O
levels	O
of	O
Iron	B
in	O
the	O
cells	O
to	O
optimize	O
Mitochondrial	O
functioning	O
.	O

Topical	O
mixture	O
and	O
method	O
for	O
dermal	O
application	O
to	O
remove	O
excess	O
iron	B
and	O
other	O
heavy	O
metals	O
from	O
cellular	O
tissue	O

The	O
invention	O
relates	O
to	O
compositions	O
containing	O
at	O
least	O
90	O
%	O
by	O
weight	O
of	O
dimer	O
diol	O
for	O
use	O
in	O
a	O
method	O
for	O
the	O
surgical	O
or	O
therapeutic	O
treatment	O
of	O
the	O
human	O
or	O
animal	O
body	O
,	O
and	O
in	O
particular	O
to	O
the	O
use	O
thereof	O
as	O
a	O
body	O
fluid	O
replacement	O
substance	O
.	O

Dimer	O
diol	B
compositions	O
as	O
substitutes	O
of	O
body	O
fluids	O

Novel	O
IL-17	O
like	O
polypeptides	O
and	O
nucleic	O
acid	O
molecules	O
encoding	O
the	O
same	O
.	O

The	O
invention	O
also	O
provides	O
vectors	O
,	O
host	O
cells	O
,	O
selective	O
binding	O
agents	O
,	O
and	O
methods	O
for	O
producing	O
IL-17	O
like	O
polypeptides	O
.	O

Also	O
provided	O
for	O
are	O
methods	O
for	O
the	O
treatment	O
,	O
diagnosis	O
,	O
amelioration	O
,	O
or	O
prevention	O
of	O
diseases	O
with	O
IL-17	O
like	O
polypeptides	O
,	O
agonists	O
,	O
or	O
antagonists	O
thereof	O
.	O

Methods	O
of	O
treatment	O
using	O
il-17e	O
antagonists	O

The	O
invention	O
is	O
the	O
compounds	O
2-	B
(	I
3,5-bis	I
-	I
trifluoromethyl	I
-	I
phenyl	I
)	I
-N-	I
[	I
6-	I
(	I
1,1-dioxo-1λ6-thiomorpholin-4-yl	I
)	I
-4-o	I
-	I
tolyl	I
-	I
pyridin-3-yl	I
]	I
-N	I
-	I
methyl	I
-	I
isobutyramide	I
and	O
2-	B
(	I
3,5-bis	I
-	I
trifluoromethyl	I
-	I
phenyl	I
)	I
-N-	I
[	I
6-	I
(	I
1,1-dioxo-1λ6-thiomorpholin-4-yl	I
)	I
-4-	I
(	I
4-fluoro-2-methyl	I
-	I
phenyl	I
)	I
-pyridin-3-yl	I
]	I
-N	I
-	I
methyl	I
-	I
isobutyramide	I
.	O

Compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
migraine	O
,	O
rheumatoid	O
arthritis	O
,	O
asthma	O
,	O
bronchial	O
hyperreactivity	O
,	O
inflammatory	O
bowel	O
disease	O
or	O
for	O
the	O
treatment	O
of	O
disorders	O
including	O
Parkinson	O
's	O
disease	O
,	O
anxiety	O
,	O
depression	O
,	O
pain	O
,	O
headache	O
,	O
Alzheimer	O
's	O
disease	O
,	O
multiple	O
sclerosis	O
,	O
edema	O
,	O
allergic	O
rhinitis	O
,	O
Crohn	O
's	O
disease	O
,	O
ocular	O
injury	O
,	O
ocular	O
inflammatory	O
diseases	O
,	O
psychosis	O
,	O
motion	O
sickness	O
,	O
induced	O
vomiting	O
,	O
emesis	O
,	O
urinary	O
incontinence	O
,	O
psychoimmunologic	O
or	O
psychosomatic	O
disorders	O
,	O
cancer	O
,	O
withdrawal	O
symptoms	O
of	O
addictive	O
drugs	O
from	O
opiates	O
or	O
nicotine	B
,	O
traumatic	O
brain	O
injury	O
or	O
benign	O
prostatic	O
hyperplasia	O
.	O

Headaches	O
;	O
antiarthritic	O
agents	O
;	O
respiratory	O
system	O
disorders	O
;	O
psychological	O
disorders	O

The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
promoting	O
production	O
gains	O
in	O
animals	O
,	O
and	O
of	O
enhancing	O
the	O
efficacy	O
of	O
therapeutic	O
agents	O
.	O

The	O
gains	O
are	O
achieved	O
through	O
reduction	O
in	O
stress	O
,	O
including	O
through	O
the	O
use	O
of	O
antistress	O
agents	O
.	O

Compositions	O
comprising	O
therapeutic	O
agents	O
such	O
as	O
anthelmintics	O
,	O
and	O
antistress	O
agents	O
are	O
provided	O
.	O

Agents	O
and	O
methods	O
for	O
promoting	O
production	O
gains	O
in	O
animals	O

A	O
solid	O
preparation	O
improved	O
in	O
oral	O
absorption	O
and	O
reduced	O
in	O
fluctuations	O
of	O
oral	O
absorption	O
can	O
be	O
obtained	O
by	O
incorporating	O
an	O
organic	O
acid	O
,	O
particularly	O
tartaric	B
acid	I
,	O
in	O
a	O
solid	O
preparation	O
having	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
high	O
content	O
of	O
a	O
quinolone	B
compound	O
,	O
particularly	O
sitafloxacin	B
,	O
having	O
poor	O
water	O
solubility	O
at	O
pH	O
around	O
neutrality	O
.	O

Highly	O
absorptive	O
solid	O
preparation	O

A	O
compound	O
of	O
the	O
formula	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
is	O
unsubstituted	O
,	O
mono-	O
,	O
di-	O
or	O
tri	O
-	O
substituted	O
(	B
C3-C11	I
)	I
cycloalkyl	I
or	O
(	O
C3-C11	O
)	O
cycloalkenyl	O
or	O
the	O
like	O
,	O
A	O
is	O
unsubstituted	O
(	B
C1-C7	I
)	I
alkyl	I
or	O
(	B
C2-C5	I
)	I
alkenyl	I
,	O
hydroxy-	B
(	I
C1-C4	I
)	I
alkyl	I
,	O
(	B
C1-C4	I
)	I
alkoxy-	I
(	I
C	I
═	I
O	I
)	I
,	O
or	O
unsubstituted	O
,	O
mono-	O
,	O
di-	O
or	O
tri	O
-	O
substituted	O
aryl	B
,	O
or	O
aromatic	B
-	I
heterocyclic	I
or	O
the	O
like	O
,	O
M	O
is	O
a	O
covalent	O
bond	O
O	B
,	O
S	B
,	O
NH	B
or	O
the	O
like	O
,	O
Y	O
is	O
4-	O
to	O
12-membered	O
bicyclic	B
-	I
carbocyclic	I
rings	O
or	O
4-	O
to	O
12-membered	O
bicyclic	B
-	I
heterocyclic	I
rings	O
,	O
or	O
5-	O
to	O
17	O
membered	O
spirocarbocyclic	O
rings	O
or	O
5-	O
to	O
17-membered	O
spiroheterocyclic	O
rings	O
or	O
the	O
like	O
,	O
Z1	O
,	O
Z2	O
,	O
Z3	O
and	O
Z4	O
are	O
hydrogen	O
or	O
the	O
like	O
,	O
is	O
disclosed	O
.	O

These	O
compounds	O
have	O
ORL1-receptor	O
agonist	O
activity	O
,	O
and	O
are	O
thus	O
useful	O
as	O
analgesics	O
or	O
the	O
like	O
in	O
mammalian	O
subjects	O
.	O

Benzimidazole	B
compounds	O
as	O
ORL1-receptor	O
agonists	O

Methods	O
of	O
modulating	O
the	O
activity	O
of	O
multidrug	O
transporters	O
are	O
disclosed	O
.	O

The	O
methods	O
of	O
modulating	O
the	O
activity	O
of	O
multidrug	O
transporters	O
use	O
compounds	O
that	O
selectively	O
increase	O
or	O
decrease	O
the	O
efflux	O
capabilities	O
of	O
the	O
multidrug	O
transporter	O
.	O

The	O
methods	O
can	O
be	O
used	O
therapeutically	O
to	O
enhance	O
performance	O
of	O
therapeutic	O
drugs	O
,	O
like	O
chemotherapeutic	O
drugs	O
and	O
antibiotics	O
;	O
to	O
promote	O
detoxification	O
of	O
cells	O
and	O
tissues	O
;	O
and	O
to	O
increase	O
or	O
decrease	O
the	O
efficacy	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
or	O
placental	O
barrier	O
.	O

Detoxification	O
of	O
cells	O
,	O
tissues	O

A	O
method	O
is	O
provided	O
for	O
producing	O
a	O
coenzyme	B
Q10	I
/	O
γ	O
-	O
cyclodextrin	O
complex	O
.	O

This	O
method	O
provides	O
that	O
a	O
mixture	O
of	O
γ	O
-	O
cyclodextrin	O
and	O
coenzyme	B
Q10	I
is	O
treated	O
by	O
homogenisation	O
and	O
inputting	O
energy	O
.	O

Method	O
for	O
producing	O
a	O
coenzyme	B
Q10	I
/	O
γ	O
-	O
cyclodextrin	O
complex	O

A	O
compound	O
comprising	O
a	O
target	O
cell	O
-	O
specific	O
portion	O
and	O
human	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	B
reductase	O
2	O
(	O
NQO2	O
)	O
or	O
a	O
variant	O
or	O
fragment	O
or	O
fusion	O
or	O
derivative	O
thereof	O
which	O
has	O
substantially	O
the	O
same	O
activity	O
as	O
NQO2	O
towards	O
a	O
given	O
prodrug	O
,	O
or	O
a	O
polynucleotide	O
encoding	O
said	O
NQO2	O
or	O
said	O
variant	O
or	O
fragment	O
or	O
fusion	O
or	O
derivative	O
.	O

A	O
recombinant	O
polynucleotide	O
comprising	O
a	O
target	O
cell	O
-	O
specific	O
promoter	O
operably	O
linked	O
to	O
a	O
polynucleotide	O
encoding	O
human	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	B
reductase	O
2	O
(	O
NQO2	O
)	O
or	O
a	O
variant	O
or	O
fragment	O
or	O
fusion	O
or	O
derivative	O
thereof	O
which	O
has	O
substantially	O
the	O
same	O
activity	O
as	O
NQO2	O
towards	O
a	O
given	O
prodrug	O
.	O

The	O
compounds	O
and	O
polynucleotides	O
are	O
useful	O
in	O
a	O
method	O
of	O
treating	O
a	O
patient	O
in	O
conjunction	O
with	O
a	O
suitable	O
prodrug	O
.	O

A	O
method	O
of	O
treating	O
a	O
human	O
patient	O
with	O
a	O
target	O
cell	O
to	O
be	O
destroyed	O
wherein	O
the	O
target	O
cell	O
expresses	O
NQO2	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
patient	O
a	O
prodrug	O
which	O
is	O
converted	O
to	O
a	O
substantially	O
cytotoxic	O
drug	O
by	O
the	O
action	O
of	O
NQO2	O
and	O
nicotinamide	B
riboside	I
(	O
reduced	O
)	O
(	O
NRH	O
)	O
or	O
an	O
analogue	O
thereof	O
which	O
can	O
pass	O
reducing	O
equivalents	O
to	O
NQO2	O
.	O

Therapeutic	O
systems	O

Fluorinated	O
oligopeptides	O
,	O
especially	O
those	O
having	O
4,4-difluoro-2-amino	B
butyric	I
acid	I
at	O
the	O
C	O
terminus	O
,	O
may	O
be	O
effective	O
inhibitors	O
of	O
hepatitis	O
C	O
virus	O
NS3	O
protease	O
.	O

Examples	O
of	O
hexapeptides	O
of	O
the	O
invention	O
,	O
optimized	O
for	O
binding	O
in	O
the	O
S1	O
specificity	O
pocket	O
of	O
the	O
enzyme	O
,	O
may	O
display	O
IC50s	O
at	O
the	O
sub	O
-	O
micromolar	O
level	O
.	O

Embodiments	O
of	O
tripeptides	O
of	O
the	O
invention	O
,	O
having	O
a	O
keto	O
-	O
acid	O
group	O
at	O
the	O
C	O
-	O
terminus	O
are	O
,	O
likewise	O
,	O
potent	O
inhibitors	O
of	O
NS3	O
protease	O
.	O

Fluorinated	O
oligopeptides	O
especially	O
those	O
having	O
4,4-difluoro-	B
2-amino	I
butyric	I
acid	I
at	O
the	O
C	O
terminus	O

Simple	O
carboxylic	B
acids	I
,	O
in	O
particular	O
dicarboxylic	B
acids	I
such	O
as	O
citric	B
acid	I
shows	O
an	O
unexpected	O
ability	O
to	O
enhance	O
the	O
antimicrobial	O
power	O
of	O
a	O
wide	O
range	O
of	O
disinfectant	O
and/or	O
antibiotic	O
agents	O
.	O

As	O
little	O
as	O
1	O
%	O
citrate	B
greatly	O
enhances	O
the	O
ability	O
of	O
antibiotics	O
to	O
kill	O
or	O
inhibit	O
a	O
wide	O
range	O
of	O
bacterial	O
species	O
including	O
antibiotic	O
resistant	O
strains	O
.	O

Citrate	B
alone	O
is	O
effective	O
in	O
preventing	O
bacterial	O
growth	O
in	O
platelet	O
concentrates	O
and	O
in	O
red	O
blood	O
cell	O
suspensions	O
.	O

Effective	O
concentrations	O
of	O
citrate	B
cause	O
little	O
if	O
any	O
damage	O
to	O
blood	O
cells	O
.	O

Besides	O
enhancing	O
the	O
power	O
of	O
antibiotics	O
citrate	B
also	O
enhances	O
the	O
antimicrobial	O
properties	O
of	O
disinfectant	O
organic	O
dyes	O
such	O
as	O
crystal	O
violet	O
and	O
methylene	B
blue	I
.	O

In	O
addition	O
citrate	O
enhances	O
the	O
antimicrobial	O
properties	O
of	O
polyphenols	B
of	O
plant	O
origin	O
.	O

Iodine	O
-	O
based	O
disinfectants	O
are	O
also	O
enhanced	O
without	O
enhancing	O
protein	O
denaturation	O
.	O

Enhancers	O
for	O
microbiological	O
disinfection	O

Compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
are	O
disclosed	O
.	O

Such	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alpha-1A	O
mediated	O
diseases	O
or	O
conditions	O
such	O
as	O
urinary	O
incontinence	O
.	O

Nitrogen	O
compounds	O
such	O
as	O
N-	O
(	O
4,5-dihydro-1H	O
-	O
imidazol-2-yl	O
-	O
methyl	O
)	O
-2-	O
(	O
methylsulfonyl	O
)	O
aniline	O
,	O
used	O
for	O
prophylaxis	O
of	O
incontinence	O

The	O
present	O
invention	O
provides	O
a	O
neurodegenerative	O
disease	O
therapeutic	O
agent	O
containing	O
as	O
its	O
active	O
ingredient	O
a	O
(	B
15R	I
)	I
-isocarbacycline	I
derivative	O
indicated	O
by	O
the	O
following	O
formula	O
[	O
I	O
]	O
or	O
a	O
15-deoxy	B
-	I
isocarbacycline	I
derivative	O
indicated	O
by	O
the	O
following	O
formula	O
[	O
III	O
]	O
:	O
(	O
wherein	O
,	O
R1	O
represents	O
a	O
C1-C6	B
alkylene	I
group	O
,	O
and	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1-C7	B
,	I
alkyl	I
group	O
or	O
protective	O
group	O
)	O
;	O
or	O
,	O
(	O
wherein	O
,	O
R1	O
and	O
R2	O
are	O
the	O
same	O
as	O
those	O
defined	O
in	O
formula	O
[	O
I	O
]	O
)	O
.	O

Administering	O
to	O
a	O
Alzheimer	O
's	O
patient	O
an	O
effective	O
amount	O
of	O
a	O
(	B
15R	I
)	I
-isocarbacycline	I
compound	O
to	O
treat	O
the	O
disease	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
-	O
acceptable	O
and	O
pharmaceutically	O
-	O
acceptable	O
and	O
-cleavable	O
esters	O
thereof	O
and	O
acid	O
addition	O
salts	O
thereof	O
,	O
wherein	O
the	O
symbols	O
are	O
as	O
defined	O
are	O
MAP	O
kinase	O
inhibitors	O
,	O
useful	O
pharmaceutically	O
for	O
treating	O
TNFα	O
and	O
IL-1	O
mediated	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
diseases	O
of	O
bone	O
metabolism	O
,	O
e.g.	O
osteoporosis	O
.	O

2-	B
(	I
4-Fluorophenyl	I
)	I
-1-	I
(	I
2-cyclopentylamino-4-pyrimidinyl	I
)	I
-5-	I
(	I
piperidino	I
-	I
N	I
-2-ethyl	I
)	I
imidazo	I
(	I
4,5-b	I
)	I
pyridine	I
,	O
for	O
example	O
;	O
MAP	O
kinase	O
inhibitors	O
,	O
for	O
Tumor	O
Necrosis	O
Factor	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
Interleukin-1	O
(	O
IL-1	O
)	O
disorders	O
such	O
as	O
osteoporosis	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
a	O
mammal	O
with	O
immunological	O
disorders	O
,	O
particularly	O
autoimmune	O
disease	O
,	O
and	O
most	O
preferably	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

The	O
method	O
includes	O
oral	O
administration	O
of	O
germination	O
activated	O
Ganoderma	O
lucidum	O
spores	O
(	O
""""	O
GLSs	O
""""	O
)	O
to	O
the	O
mammal	O
.	O

Additionally	O
,	O
a	O
corticosteroid	B
,	O
such	O
as	O
prednisolone	B
,	O
can	O
be	O
co	O
-	O
administered	O
with	O
the	O
GLSs	O
to	O
the	O
mammal	O
to	O
achieve	O
synergistic	O
effect	O
of	O
treatment	O
.	O

Ganoderma	O
lucidum	O
spores	O
for	O
treatment	O
of	O
autoimmune	O
diseases	O

Compounds	O
and	O
pharmaceutical	O
compositions	O
active	O
against	O
HIV	O
are	O
provided	O
,	O
as	O
is	O
a	O
method	O
for	O
the	O
treatment	O
of	O
HIV	O
infection	O
in	O
humans	O
and	O
other	O
host	O
animals	O
is	O
provided	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
β	B
-	I
L-	I
(	I
2′	I
or	I
3′-azido	I
)	I
-2′,3′-dideoxy-5-fluorocytosine	I
of	O
the	O
formula	O
wherein	O
R	O
is	O
H	B
,	O
acyl	B
,	O
monophosphate	B
,	O
diphosphate	B
,	O
or	O
triphosphate	B
,	O
or	O
a	O
stabilized	O
phosphate	B
derivative	O
(	O
to	O
form	O
a	O
stabilized	O
nucleotide	O
prodrug	O
)	O
,	O
and	O
R′	O
is	O
H	B
,	O
acyl	B
,	O
or	O
alkyl	B
.	O

β	O
-	O
L-2'-deoxy	O
-	O
nucleosides	O
for	O
the	O
treatment	O
of	O
HIV	O
infection	O

This	O
application	O
provides	O
human	O
H37	O
protein	O
having	O
an	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
1	O
or	O
NO	O
:	O
2	O
;	O
human	O
gene	O
encoding	O
the	O
protein	O
;	O
cDNA	O
of	O
the	O
human	O
gene	O
which	O
has	O
a	O
base	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
3	O
or	O
NO	O
:	O
4	O
;	O
DNA	O
fragment	O
comprising	O
a	O
partial	O
sequence	O
of	O
the	O
cDNA	O
;	O
recombinant	O
vector	O
having	O
the	O
cDNA	O
;	O
antibody	O
against	O
human	O
H37	O
protein	O
;	O
and	O
a	O
method	O
for	O
controlling	O
the	O
proliferation	O
of	O
cells	O
by	O
introducing	O
the	O
above	O
DNA	O
or	O
antibody	O
into	O
the	O
cells	O
.	O

For	O
controlling	O
in	O
vitro	O
cell	O
proliferation	O
;	O
genetic	O
engineering	O

Substituted	O
propanolamine	O
derivatives	O
,	O
their	O
pharmaceutically	O
tolerated	O
salts	O
and	O
physiologically	O
functional	O
derivatives	O
thereof	O
are	O
described	O
.	O

Also	O
described	O
are	O
compounds	O
of	O
formula	O

I	O
in	O
which	O
the	O
radicals	O
have	O
the	O
abovementioned	O
meanings	O
,	O
and	O
their	O
physiologically	O
tolerated	O
salts	O
,	O
physiologically	O
functional	O
derivates	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

The	O
compounds	O
are	O
suitable	O
as	O
,	O
for	O
example	O
,	O
hypolipidemics	O
.	O

Method	O
of	O
treatment	O
with	O
combinations	O
of	O
statin	O
and	O
aryl	O
-	O
substituted	O
propanolamine	O
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
polysaccharidic	O
esters	O
of	O
retinoic	B
acid	I
,	O
wherein	O
the	O
hydroxyl	B
groups	O
of	O
the	O
monosaccharidic	B
units	O
of	O
the	O
polysaccharide	O
are	O
partially	O
or	O
totally	O
esterified	O
with	O
retinoic	B
acid	I
.	O

A	O
process	O
to	O
obtain	O
these	O
esters	O
is	O
also	O
described	O
.	O

The	O
products	O
according	O
to	O
the	O
present	O
invention	O
can	O
be	O
used	O
in	O
the	O
pharmaceutical	O
and	O
cosmetic	O
field	O
.	O

Polysaccharidic	O
esters	O
of	O
retinoic	B
acid	I

The	O
invention	O
is	O
directed	O
to	O
physiologically	O
active	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
:	O
and	O
compositions	O
containing	O
such	O
compounds	O
;	O
and	O
their	O
prodrugs	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
of	O
such	O
compounds	O
and	O
their	O
prodrugs	O
,	O
as	O
well	O
as	O
to	O
novel	O
compounds	O
within	O
the	O
scope	O
of	O
formula	O
(	O
I	O
)	O
.	O

Such	O
compounds	O
and	O
compositions	O
have	O
valuable	O
pharmaceutical	O
properties	O
,	O
in	O
particular	O
the	O
ability	O
to	O
inhibit	O
kinases	O
.	O

Kinase	O
inhibitors	O
;	O
angiogenesis	O
inhibitors	O
,	O
anticancer	O
agents	O
,	O
antiinflammatory	O
agents	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
inhibitors	O

A	O
method	O
for	O
treating	O
the	O
psychiatric	O
disorders	O
known	O
as	O
oppositional	O
defiant	O
disorder	O
and	O
conduct	O
disorder	O
is	O
disclosed	O
.	O

The	O
method	O
comprises	O
the	O
administration	O
of	O
a	O
compound	O
according	O
to	O
Formula	O
I	O
or	O
II	O
to	O
a	O
patient	O
suffering	O
from	O
oppositional	O
defiant	O
disorder	O
and/or	O
conduct	O
disorder	O
.	O

The	O
compound	O
may	O
be	O
either	O
a	O
racemic	O
mixture	O
or	O
e.g.	O
the	O
levorotatory	O
form	O
.	O

It	O
may	O
be	O
short	O
acting	O
or	O
in	O
a	O
sustained	O
release	O
,	O
long	O
acting	O
form	O
.	O

Molindone	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
molindone	B
is	O
a	O
preferred	O
embodiment	O
.	O

Treatment	O
of	O
oppositional	O
defiant	O
disorder	O
and	O
conduct	O
disorder	O
with	O
5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones	B

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
process	O
for	O
preparing	O
8-methoxy-3-quinolonecarboxylic	B
acids	I
which	O
are	O
antibiotics	O
having	O
potent	O
antibacterial	O
action	O
.	O

Method	O
for	O
producing	O
8-methoxy	B
-	I
quinolinecarboxylic	I
acids	I

Crystalline	O
forms	O
of	O
Venlafaxine	B
hydrochloride	I
were	O
found	O
,	O
referred	O
to	O
hereinafter	O
as	O
polymorphic	O
Forms	O
A	O
,	O
B	O
and	O
D.	O
Furthermore	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
crystalline	O
forms	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
crystalline	O
forms	O
.	O

Antidepressant	O
;	O
storage	O
stability	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
various	O
substituent	O
groups	O
;	O
and	O
one	O
of	O
X1	O
and	O
X2	O
is	O
N	B
or	O
CR″	B
,	O
and	O
the	O
other	O
is	O
NR″	B
or	O
CHR″	B
wherein	O
R″	O
is	O
hydrogen	B
,	O
OH	B
,	O
C1	B
-	I
6alkyl	I
,	O
or	O
C3	B
-	I
7cycloalkyl	I
;	O
or	O
when	O
one	O
of	O
X1	O
and	O
X2	O
is	O
N	B
or	O
CR″	B
then	O
the	O
other	O
may	O
be	O
S	B
or	O
O	B
;	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

Kidney	O
disease	O
;	O
cardiovascular	O
disorders	O
;	O
antiscarring	O
agents	O
;	O
wound	O
healing	O
agents	O

Methods	O
of	O
treating	O
and	O
inhibiting	O
cancer	O
in	O
animals	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
pharmaceutical	O
composition	O
having	O
benzimidazole	B
of	O
the	O
general	O
formula	O
:	O
wherein	O
X	O
is	O
hydrogen	B
,	O
halogen	B
,	O
alkyl	B
of	O
less	O
than	O
7	O
carbon	B
atoms	O
or	O
alkoxy	B
of	O
less	O
than	O
7	O
carbon	B
atoms	O
;	O
n	O
is	O
a	O
positive	O
integer	O
of	O
less	O
than	O
4	O
;	O
Y	O
is	O
hydrogen	B
,	O
chlorine	B
,	O
oxychloro	B
,	O
nitro	B
,	O
methyl	B
or	O
ethyl	B
;	O
and	O
R	O
is	O
hydrogen	B
,	O
or	O
an	O
alkyl	B
group	O
of	O
from	O
1	O
to	O
8	O
carbon	B
atoms	O
and	O
R2	O
is	O
NHCOOR1	B
wherein	O
R1	O
is	O
aliphatic	B
hydrocarbon	I
of	O
less	O
than	O
7	O
carbon	B
atoms	O
,	O
and	O
preferably	O
an	O
alkyl	B
group	O
of	O
less	O
than	O
7	O
carbon	B
atoms	O
and	O
pharmaceutically	O
acceptable	O
derivatives	O
alone	O
,	O
or	O
in	O
combination	O
,	O
or	O
in	O
conduction	O
with	O
other	O
therapeutic	O
agents	O
such	O
as	O
other	O
cancer	O
inhibiting	O
compounds	O
,	O
and	O
operative	O
combinations	O
thereof	O
.	O

Inhibiting	O
metastasis	O
with	O
a	O
2-	B
(	I
alkoxycarbonylamino	I
)	I
benzimidazole	I
prodrug	O

Cyclic	B
glycerophosphates	I
and	O
analogs	O
thereof	O
(	O
CGs	O
)	O
are	O
shown	O
to	O
exert	O
neutral	O
promoting	O
activities	O
in	O
target	O
cells	O
.	O

Such	O
activities	O
include	O
promotion	O
of	O
neuronal	O
outgrowth	O
,	O
promotion	O
of	O
nerve	O
growth	O
,	O
provision	O
of	O
dopaminotrophic	O
supporting	O
envrionment	O
in	O
a	O
diseased	O
portion	O
of	O
the	O
brain	O
,	O
prevention	O
of	O
nerve	O
degeneration	O
and	O
nerve	O
rescue	O
.	O

These	O
activities	O
of	O
the	O
CGs	O
render	O
them	O
useful	O
for	O
treatment	O
of	O
various	O
disorders	O
including	O
but	O
not	O
limited	O
to	O
mental	O
disorders	O
such	O
as	O
,	O
for	O
example	O
,	O
schizophrenia	O
,	O
dementia	O
or	O
disorders	O
resulting	O
in	O
learning	O
disablities	O
.	O

In	O
addition	O
,	O
these	O
CGs	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
conditions	O
such	O
as	O
Altzheimer	O
's	O
diesease	O
,	O
Parkinson	O
's	O
disease	O
,	O
conditions	O
resulting	O
from	O
exposure	O
to	O
harmful	O
environmental	O
factors	O
or	O
resulting	O
from	O
a	O
mechanical	O
injury	O
.	O

The	O
CGs	O
may	O
also	O
be	O
used	O
to	O
treat	O
an	O
individual	O
suffering	O
from	O
a	O
primary	O
neurodengenerative	O
condition	O
in	O
order	O
to	O
prevent	O
or	O
reduce	O
the	O
appearance	O
of	O
secondary	O
degeneration	O
in	O
additional	O
nerves	O
(	O
""""	O
nerve	O
rescue	O
""""	O
)	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
cyclic	B
glycerophosphates	I
and	O
analogs	O
thereof	O
for	O
promoting	O
neural	O
cell	O
differentiation	O

The	O
invention	O
relates	O
to	O
new	O
α	B
-	I
arylethylpiperazine	I
of	O
the	O
formula	O
wherein	O
Z	O
represents	O
0	O
or	O
S	B
;	O
n′	O
represents	O
1	O
or	O
2	O
;	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
methyl	B
group	O
;	O
W	O
,	O
Ar1	O
and	O
Ar2	O
represent	O
various	O
substituents	O
as	O
defined	O
herein	O
;	O
or	O
non	O
-	O
toxic	O
pharmaceutically	O
acceptable	O
salt	O
,	O
individual	O
optical	O
isomer	O
,	O
or	O
individual	O
diastereoisomer	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
neurokinin	O
receptor	O
antagonists	O
(	O
NK1	O
antagonists	O
)	O
.	O

It	O
also	O
relates	O
to	O
processes	O
for	O
their	O
preparation	O
and	O
use	O
in	O
methods	O
for	O
treatment	O
of	O
asthma	O
and/or	O
allergic	O
rhinitis	O
.	O

α	B
-	I
arylethylpiperazine	I
derivatives	O
as	O
neurokinin	O
antagonists	O

This	O
invention	O
discloses	O
quinoxalinones	B
which	O
display	O
inhibitory	O
effects	O
on	O
serine	B
proteases	O
such	O
as	O
factor	O
Xa	O
,	O
thrombin	O
,	O
and/or	O
factor	O
VIIa	O
.	O

The	O
invention	O
also	O
discloses	O
pharmaceutically	O
acceptable	O
salts	O
and	O
prodrugs	O
of	O
the	O
compounds	O
,	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
,	O
their	O
salts	O
or	O
prodrugs	O
,	O
and	O
methods	O
of	O
using	O
them	O
as	O
therapeutic	O
agents	O
for	O
treating	O
or	O
preventing	O
disease	O
states	O
in	O
mammals	O
characterized	O
by	O
abnormal	O
thrombosis	O
.	O

Therapeutic	O
agents	O
for	O
treating	O
or	O
preventing	O
disease	O
states	O
in	O
mammals	O
characterized	O
by	O
abnormal	O
thrombosis	O

This	O
invention	O
provides	O
a	O
process	O
for	O
the	O
preparation	O
of	O
1	B
,	I
2	I
,	I
3	I
,	I
4	I
,	I
8	I
,	I
9	I
,	I
10	I
,	I
10a	I
-	I
octahydro-7bH	I
-	I
cyclopenta	I
[	I
b	I
]	I
[	I
1,4	I
]	I
diazepino	I
[	I
6,7,1-hi	I
]	I
indole	I
derivatives	O
of	O
the	O
general	O
formula	O
:	O
wherein	O
:	O
R	O
is	O
H	B
,	O
alkyl	B
,	O
cycloalkyl	B
,	O
—CH2-cycloalkyl	B
,	O
acyl	B
,	O
aryl	B
or	O
aroyl	B
;	O
R1	O
,	O
R2	O
,	O
R4	O
and	O
R5	O
are	O
H	B
,	O
hydroxy	B
,	O
alkyl	B
,	O
cycloalkyl	B
,	O
alkoxy	B
,	O
halogen	B
,	O
fluorinated	B
alkyl	I
,	O
—CN	B
,	O
—NH	B
—	I
SO2-alkyl	I
,	O
—SO2—NH	B
-	I
alkyl	I
,	O
alkyl	B
amide	I
,	O
amino	B
,	O
alkylamino	B
,	O
dialkylmino	B
,	O
fluorinated	B
alkoxy	I
,	O
acyl	B
,	O
aryl	B
or	O
aroyl	B
;	O
R3	O
is	O
H	B
,	O
alkyl	B
,	O
cycloalkyl	B
,	O
alkoxy	B
,	O
fluorinated	B
alkyl	I
,	O
alkyl	B
sulfonamide	I
,	O
alkyl	B
amide	I
,	O
amino	B
,	O
alkylamino	B
,	O
dialkylmino	B
,	O
fluorinated	B
alkoxy	I
,	O
acyl	B
,	O
aryl	B
or	O
aroyl	B
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
as	O
well	O
as	O
intermediates	O
for	O
their	O
synthesis	O
.	O

Acylating	O
a	O
cyclopentaindolemethylamine	B
and	O
cyclizing	O
and	O
reducing	O
the	O
product	O

Compounds	O
of	O
formulae	O
(	O
IA	O
)	O
and	O
(	O
IB	O
)	O
or	O
pharmaceutically	O
or	O
veterinarily	O
acceptable	O
salts	O
thereof	O
,	O
or	O
pharmaceutically	O
or	O
veterinarily	O
acceptable	O
solvates	O
of	O
either	O
entity	O
,	O
wherein	O
R1	O
is	O
C1	B
to	I
C3	I
alkyl	I
substituted	O
with	O
C3	B
to	I
C6	I
cycloalkyl	I
,	O
CONR5R6	B
or	O
a	O
N	B
-	O
linked	O
heterocyclic	B
group	O
;	O
(	B
CH2	I
)	I
nHet	I
or	O
(	B
CH2	I
)	I
nAr	I
,	O
R2	O
is	O
C1	B
to	I
C6	I
alkyl	I
;	O
R3	O
is	O
C1	B
to	I
C6	I
alkyl	I
optionally	O
substituted	O
with	O
C1	B
to	I
C4	I
alkoxy	I
;	O
R4	O
is	O
SO2NR7R8	B
;	O
R5	O
and	O
R6	O
are	O
each	O
independently	O
selected	O
from	O
H	B
and	O
C1	B
to	I
C4	I
alkyl	I
optionally	O
substituted	O
with	O
C1	B
to	I
C4	I
alkoxy	I
,	O
or	O
,	O
together	O
with	O
the	O
nitrogen	B
atom	O
to	O
which	O
they	O
are	O
attached	O
,	O
form	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	B
group	O
;	O
R7	O
and	O
R8	O
,	O
together	O
with	O
the	O
nitrogen	B
atom	O
to	O
which	O
they	O
are	O
attached	O
,	O
form	O
a	O
4-R10-piperazinyl	B
group	O
;	O
R10	O
is	O
H	B
or	O
C1	B
to	I
C4	I
alkyl	I
optionally	O
substituted	O
with	O
OH	B
,	O
C1	B
to	I
C4	I
alkoxy	I
or	O
CONH2	B
;	O
Het	O
is	O
an	O
optionally	O
substituted	O
C	O
-	O
linked	O
5-	O
or	O
6-membered	O
heterocyclic	B
group	O
;	O
Ar	B
is	O
optionally	O
substituted	O
phenyl	B
;	O
and	O
n	O
is	O
0	O
or	O
1	O
;	O
are	O
potent	O
and	O
selective	O
cGMP	B
PDE5	O
inhibitors	O
useful	O
in	O
the	O
treatment	O
of	O
,	O
inter	O
alia	O
,	O
male	O
erectile	O
dysfunction	O
and	O
female	O
sexual	O
dysfunction	O
Pyrazolopyrimidinones	B
which	O
inhibit	O
type	O
5	B
cyclic	I
guanosine	I
3′,5′-monophosphate	I
phosphodiesterase	O
(	O
cGMP	B
-	O
PDE5	O
)	O
for	O
the	O
treatment	O
of	O
sexual	O
dysfunction	O

The	O
present	O
invention	O
provides	O
compounds	O
that	O
elevate	O
cellular	O
expression	O
of	O
the	O
ABCA-1	O
gene	O
,	O
promoting	O
cholesterol	B
efflux	O
from	O
cells	O
and	O
increasing	O
HDL	O
levels	O
in	O
the	O
plasma	O
of	O
a	O
mammal	O
,	O
in	O
particular	O
humans	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
treating	O
coronary	O
artery	O
disease	O
.	O

ABCA-1	O
elevating	O
compounds	O

Derivatives	O
of	O
C2-substituted	O
indan-1-ol	B
compounds	O
of	O
formula	O
I	O
:	O
its	O
physiologically	O
acceptable	O
salts	O
,	O
and	O
its	O
physiologically	O
functional	O
derivatives	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
obesity	O
are	O
disclosed	O
herein	O
.	O

Compositions	O
comprising	O
the	O
same	O
,	O
methods	O
for	O
preparing	O
the	O
instant	O
compounds	O
,	O
and	O
methods	O
for	O
reducing	O
weight	O
in	O
mammals	O
and	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
obesity	O
are	O
also	O
described	O
.	O

Carbocyclic	B
esters	I
such	O
as	O
5-chloro-2-methanesulfonylindan-1	B
-	I
-yl-4-chlorobenzoate	I
,	O
used	O
as	O
anorexigenic	O
agents	O
;	O
dietetics	O

This	O
invention	O
relates	O
to	O
piperazine	B
derivatives	O
of	O
the	O
formula	O
:	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salt	O
,	O
to	O
processes	O
for	O
preparation	O
thereof	O
,	O
to	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
,	O
and	O
to	O
a	O
use	O
of	O
the	O
same	O
for	O
treating	O
or	O
preventing	O
Tachykinin	O
-	O
mediated	O
diseases	O
in	O
human	O
being	O
or	O
animals	O
.	O

Heterocyclic	B
carboxy	I
amines	I
such	O
as	O
(	B
2R	I
)	I
-1-	I
[	I
3,5-Bis	I
(	I
trifluoromethyl	I
)	I
benzoyl	I
]	I
-4-	I
[	I
4-	I
(	I
(	I
3S	I
)	I
-3-ethylmorpholino	I
)	I
-2-butynyl	I
]	I
-2-	I
[	I
(	I
1H	I
-	I
indol-3-yl	I
)	I
methyl	I
]	I
piperazine	I
,	O
used	O
as	O
substance	B
P	I
and	O
neurokinin	O
antagonist	O
for	O
prophylaxis	O
of	O
diseases	O

Novel	O
compounds	O
that	O
are	O
potent	O
inhibitors	O
of	O
HIV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
are	O
described	O
in	O
the	O
invention	O
.	O

Thes	O
novel	O
compounds	O
also	O
inhibit	O
replication	O
of	O
a	O
retrovirus	O
,	O
such	O
as	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
.	O

The	O
novel	O
compounds	O
of	O
the	O
invention	O
include	O
analogs	O
and	O
derivatives	O
of	O
phenethylthiazolylthiourea	B
(	O
PETT	B
)	O
,	O
of	O
dihydroalkoxybenzyloxopyrimidine	B
(	O
DABO	B
)	O
,	O
and	O
of	O
1-	B
[	I
(	I
2-hydroxyethoxy	I
)	I
methyl	I
]	I
-6-	I
(	I
phenylthio	I
)	I
thymine	I
(	O
HEPT	B
)	O
.	O

The	O
invention	O
additionally	O
provides	O
a	O
composite	O
HIV	O
reverse	O
-	O
transcriptase	O
(	O
RT	O
)	O
nonnucleoside	O
inhibitor	O
(	O
NNI	O
)	O
binding	O
pocket	O
constructed	O
from	O
a	O
composite	O
of	O
multiple	O
NNI	O
-	O
RT	O
complexes	O
.	O

The	O
composite	O
RT	O
-	O
NNI	O
binding	O
pocket	O
provides	O
a	O
unique	O
and	O
useful	O
tool	O
for	O
designing	O
and	O
identifying	O
novel	O
,	O
potent	O
inhibitors	O
of	O
reverse	O
transcriptase	O
.	O

Heterocyclic	B
nonnucleoside	O
inhibitors	O
of	O
reverse	O
transcriptase	O

N	B
-	I
substituted	I
3-hydroxy-4-pyridinones	I
and	O
metal	O
chelates	O
,	O
methods	O
of	O
preparing	O
N	B
-	I
substituted	I
3-hydroxy-4-pyridinones	I
and	O
metal	O
chelates	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
new	O
N	B
-	I
substituted	I
3-hydroxy-4-pyridinones	I
and/or	O
their	O
metal	O
chelates	O
.	O

Use	O
of	O
N	B
-	I
substituted	I
3-hydroxy-4-pyridinones	I
and	O
their	O
metal	O
chelates	O
as	O
pharmaceutical	O
agents	O
for	O
the	O
treatment	O
of	O
diseases	O
,	O
such	O
as	O
parasitic	O
and	O
viral	O
infections	O
,	O
conditions	O
associated	O
with	O
inflammation	O
and	O
infection	O
,	O
and	O
conditions	O
mediated	O
by	O
cell	O
-	O
proliferation	O
or	O
collagen	O
formation	O
.	O

Complexes	O
with	O
radionuclides	O
;	O
for	O
use	O
as	O
contrast	O
agent	O
in	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
;	O
as	O
parasiticide	O
,	O
viricide	O
,	O
or	O
as	O
chelation	O
therapy	O
of	O
iron	B
overload	O
such	O
as	O
thalassemia	O
;	O
optimal	O
combination	O
of	O
lipophilicity	O
and	O
hydrophilicity	O

The	O
present	O
invention	O
provides	O
compositions	O
for	O
treating	O
pain	O
using	O
an	O
atypical	O
antipsychotic	O
compound	O
that	O
is	O
seroquel	O
in	O
combination	O
with	O
another	O
Drug	O
Used	O
in	O
the	O
Treatment	O
of	O
Pain	O
.	O

Psychological	O
disorders	O
;	O
synergistic	O
mixture	O

The	O
present	O
invention	O
provides	O
a	O
composition	O
for	O
treating	O
pain	O
.	O

The	O
composition	O
includes	O
a	O
pharmaceutically	O
acceptable	O
analgesic	O
and	O
a	O
GABAergic	O
agent	O
,	O
such	O
as	O
gamma	B
vinyl	I
GABA	I
,	O
effective	O
in	O
reducing	O
or	O
eliminating	O
the	O
addictive	O
liability	O
of	O
the	O
analgesic	O
.	O

The	O
invention	O
also	O
includes	O
a	O
method	O
for	O
reducing	O
or	O
eliminating	O
the	O
addictive	O
Mixture	O
of	O
analgesic	O
and	O
addition	O
reducting	O
compound	O
of	O
a	O
gamma	B
-	I
aminobutyric	I
acid	I

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
dibenzoxazepine	B
derivative	O
,	O
its	O
synthesis	O
,	O
and	O
its	O
use	O
as	O
an	O
αv	O
integrin	O
receptor	O
antagonist	O
.	O

More	O
particularly	O
,	O
the	O
compound	O
of	O
the	O
present	O
invention	O
is	O
an	O
antagonist	O
of	O
the	O
integrin	O
receptors	O
αvβ3	O
and	O
αvβ5	O
and	O
therefor	O
useful	O
for	O
inhibiting	O
bone	O
resorption	O
,	O
treating	O
and/or	O
preventing	O
osteoporosis	O
,	O
and	O
inhibiting	O
vascular	O
restenosis	O
,	O
diabetic	O
retinopathy	O
,	O
macular	O
degeneration	O
,	O
angiogenesis	O
,	O
artheroscietosis	O
,	O
inflammatory	O
arthritis	O
,	O
cancer	O
and	O
metastatic	O
tumor	O
growth	O
.	O

3-	B
(	I
5,6,7,8-Tetrahydro-	I
(	I
1,8	I
)	I
naphthyridin-2-yl	I
)	I
-ethoxy	I
)	I
-11H	I
-	I
di	I
-	I
b	I
enzo	I
(	I
1,4	I
)	I
oxazepin-10-yl	I
)	I
-acetic	I
acid	I
;	O
inhibiting	O
bone	O
resorption	O
;	O
vascular	O
restenosis	O
;	O
osteoporosis	O
;	O
angiogenesis	O
inhibitors	O
;	O
diabetic	O
retinopathy	O
;	O
anticarcinogenic	O
agents	O

The	O
present	O
invention	O
provides	O
novel	O
5-substituted	B
tetralones	I
of	O
Formulas	O
I	O
,	O
II	O
,	O
III	O
,	O
and	O
IV	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
esters	B
,	O
amides	B
,	O
and	O
prodrugs	O
thereof	O
,	O
which	O
are	O
useful	O
for	O
treating	O
and	O
preventing	O
uncontrolled	O
or	O
abnormal	O
proliferation	O
of	O
tissues	O
,	O
such	O
as	O
cancer	O
,	O
atherosclerosis	O
,	O
restenosis	O
,	O
and	O
psoriasis	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
inhibit	O
the	O
farnesyl	B
transferase	O
enzyme	O
Antiproliferative	O
agnets	O
;	O
anticancer	O
agents	O
;	O
skin	O
disorders	O
;	O
restenosis	O

The	O
use	O
of	O
low	O
molecular	O
weight	O
amino	B
alcohols	I
in	O
ophthalmic	O
compositions	O
is	O
described	O
.	O

These	O
compounds	O
have	O
been	O
found	O
to	O
enhance	O
the	O
efficacy	O
of	O
anti	O
-	O
microbial	O
preservatives	O
.	O

Use	O
of	O
low	O
molecular	O
weight	O
amino	B
alcohols	I
in	O
ophthalmic	O
compositions	O

The	O
present	O
application	O
describes	O
monocyclic	B
or	I
bicyclic	I
carbocycles	I
and	I
heterocycles	I
and	O
derivatives	O
thereof	O
of	O
Formula	O
I	O
:	O
or	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
inhibitors	O
of	O
factor	O
Xa	O
.	O

Monocyclic	B
or	I
bicyclic	I
carbocycles	I
and	I
heterocycles	I
as	O
factor	O
Xa	O
inhibitors	O

The	O
invention	O
relates	O
to	O
fluorobenzamide	B
derivatives	O
of	O
the	O
formula	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
herein	O
.	O
=	O
,	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
selective	O
monoamine	B
oxidase	O
B	O
inhibitors	O
and	O
therefore	O
they	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
monoamine	B
oxidase	O
B	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
or	O
senile	O
dementia	O
.	O

Fluorobenzamides	B
and	O
uses	O
thereof	O

Methods	O
and	O
compositions	O
are	O
disclosed	O
utilizing	O
optically	O
pure	O
(	B
−	I
)	I
pantoprazole	I
for	O
the	O
treatment	O
of	O
ulcers	O
in	O
humans	O
while	O
substantially	O
reducing	O
the	O
concomitant	O
liability	O
of	O
adverse	O
effects	O
associated	O
with	O
the	O
racemic	O
mixture	O
of	O
pantoprazole	B
.	O

The	O
optically	O
pure	O
(	O
−	O
)	O
isomer	O
is	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
gastroesophageal	O
reflux	O
.	O

(	B
−	I
)	I
Pantoprazole	I
is	O
an	O
inhibitor	O
of	O
H+	O
release	O
and	O
is	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
other	O
conditions	O
related	O
to	O
gastric	O
hypersecretion	O
such	O
as	O
Zollinger	O
-	O
Ellison	O
Syndrome	O
.	O

Method	O
for	O
treating	O
gastric	O
disorders	O
using	O
optically	O
pure	O
(	B
−	I
)	I
pantoprazole	I

Compounds	O
of	O
formulae	O
(	O
IA	O
)	O
and	O
(	O
IB	O
)	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
Ar1	O
and	O
X	O
are	O
as	O
defined	O
above	O
,	O
are	O
endothelin	O
antagonists	O
.	O

The	O
compounds	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
mediated	O
by	O
endothelin	O
,	O
such	O
as	O
restenosis	O
,	O
renal	O
failure	O
and	O
systemic	O
and	O
pulmonary	O
hypertension	O
.	O

Pyrazole	B
compositions	O

A	O
1,3-thiazole	B
compound	O
substituted	O
at	O
the	O
5-position	O
by	O
a	O
pyridyl	B
group	O
optionally	O
having	O
substituent	O
(	O
s	O
)	O
has	O
a	O
superior	O
p38	O
MAP	O
kinase	O
inhibitory	O
activity	O
and	O
TNF	O
-	O
α	O
production	O
inhibitory	O
activity	O
.	O

cerebral	O
hemorrhage	O
/	O
infarction	O
,	O
head	O
trauma	O
,	O
spinal	O
cord	O
injury	O
,	O
brain	O
edema	O
,	O
multiple	O
sclerosis	O
,	O
Alzheimer's	O
/	O
Parkinson	O
's	O
disease	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
diabetes	O
,	O
osteoporosis	O
,	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
or	O
virus	O
infections	O

The	O
present	O
invention	O
is	O
directed	O
to	O
non	O
-	O
peptidic	O
factor	O
Xa	O
inhibitors	O
which	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
arterial	O
and	O
venous	O
thrombotic	O
occlusive	O
disorders	O
,	O
inflammation	O
,	O
cancer	O
,	O
and	O
neurodegenerative	O
diseases	O
.	O

The	O
factor	O
Xa	O
inhibitors	O
provide	O
compounds	O
having	O
Formula	O
I	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
wherein	O
Q	O
is	O
phenyl	B
,	O
benzyl	B
,	O
pyridyl	B
,	O
thienyl	B
,	O
indolyl	B
,	O
quinolinyl	B
,	O
benzothienyl	B
,	O
biphenylyl	B
,	O
or	O
imidazolyl	B
;	O
any	O
of	O
which	O
can	O
include	O
one	O
or	O
more	O
optional	O
substituents	O
independently	O
selected	O
from	O
halo	B
,	O
trifluoromethyl	B
,	O
hydroxy	B
,	O
amino	B
,	O
nitro	B
,	O
cyano	B
,	O
C1	B
alkoxy	I
,	O
C1	B
-	I
3	I
alkyl	I
,	O
methylenedioxy	B
,	O
carboxamido	B
,	O
acetamido	B
,	O
or	O
amidino	B
;	O
X	O
is	O
methylene	B
,	O
carbonyl	B
,	O
or	O
sulfonyl	B
;	O
Z	O
is	O
methylene	B
,	O
ethylene	B
,	O
or	O
propylene	B
;	O
M	O
is	O
methylene	B
or	O
ethylene	B
;	O
and	O
R1	O
R2	O
and	O
R3	O
are	O
independently	O
hydrogen	B
or	O
C1	B
-	I
3	I
alkyl	I
.	O

Azacycloalkanone	B
serine	B
protease	O
inhibitors	O

The	O
invention	O
provides	O
new	O
triazolo	B
[	I
4,5-d	I
]	I
pyrimidine	I
compounds	O
,	O
their	O
use	O
as	O
medicaments	O
,	O
compositions	O
containing	O
them	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

A	O
6-	B
(	I
7-	I
(	I
(	I
2-	I
(	I
phenyl	I
)	I
cyclopropyl	I
)	I
amino	I
)	I
-5-	I
(	I
propylthio	I
)	I
-3H-1,2	I
,	I
3-triazolo	I
(	I
4,5-d	I
)	I
pyrimidin-3-yl	I
)	I
-tetrahydro-2,2-dimethyl-4H	I
-	I
cyclopentane-1,2-diol	I
derivative	O
;	O
anticoagulants	O
;	O
myocardial	O
infarction	O
,	O
strokes	O
;	O
thrombolytic	O
and	O
antiischemic	O
agents	O
;	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
human	O
protein	O
called	O
Cytokine	O
Receptor	O
Common	O
Gamma	O
Chain	O
Like	O
,	O
and	O
isolated	O
polynucleotides	O
encoding	O
this	O
protein	O
.	O

Also	O
provided	O
are	O
vectors	O
,	O
host	O
cells	O
,	O
antibodies	O
,	O
and	O
recombinant	O
methods	O
for	O
producing	O
this	O
human	O
protein	O
.	O

The	O
invention	O
further	O
relates	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
useful	O
for	O
diagnosing	O
and	O
treating	O
disorders	O
related	O
to	O
this	O
novel	O
human	O
protein	O
.	O

Cytokine	O
receptor	O
common	O
gamma	O
chain	O
like	O

The	O
present	O
invention	O
comprises	O
crystalline	O
forms	O
of	O
3R,4R	B
)	I
-4-	I
[	I
3-	I
(	I
S	I
)	I
-hydroxy-3-	I
(	I
6-methoxyquinolin-4-yl	I
)	I
propyl	I
]	I
-1-	I
[	I
2-	I
(	I
2-thienylthio	I
)	I
ethyl	I
]	I
piperidine-3-carboxylic	I
acid	I
,	O
represented	O
by	O
the	O
structure	O
:	O
and	O
as	O
characterized	O
herein	O
by	O
powder	O
X	O
-	O
ray	O
diffraction	O
patterns	O
as	O
form	O
A	O
and	O
form	O
B	O
,	O
processes	O
for	O
preparing	O
form	O
A	O
from	O
the	O
purified	O
amorphous	O
form	O
of	O
(	B
3R,4R	I
)	I
-4-	I
[	I
3-	I
(	I
S	I
)	I
-hydroxy-3-	I
(	I
6-methoxyquinolin-4-yl	I
)	I
propyl	I
]	I
-1-	I
[	I
2-	I
(	I
2-thienylthio	I
)	I
ethyl	I
]	I
piperidine-3-carboxylic	I
acid	I
,	O
a	O
processes	O
for	O
preparing	O
form	O
A	O
by	O
heating	O
monohydrated	O
form	O
C	O
of	O
(	B
3R,4R	I
)	I
-4-	I
[	I
3-	I
(	I
S	I
)	I
-hydroxy-3-	I
(	I
6-methoxyquinolin-4-yl	I
)	I
propyl	I
]	I
-1-	I
[	I
2-	I
(	I
2-thienylthio	I
)	I
ethyl	I
]	I
piperidine-3-carboxylic	I
acid	I
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
form	O
A	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
form	O
A	O
and	O
form	O
B	O
or	O
monohydrated	O
form	O
C	O
,	O
a	O
pharmaceutical	O
composition	O
comprising	O
form	O
A	O
,	O
form	O
B	O
and	O
monohydrated	O
form	O
C	O
,	O
a	O
method	O
for	O
treating	O
a	O
bacterial	O
infection	O
with	O
form	O
A	O
,	O
a	O
method	O
for	O
treating	O
a	O
bacterial	O
infection	O
with	O
form	O
A	O
and	O
form	O
B	O
or	O
monohydrated	O
form	O
C	O
,	O
and	O
a	O
method	O
for	O
treating	O
a	O
bacterial	O
infection	O
with	O
form	O
A	O
and	O
form	O
B	O
and	O
monohydrated	O
form	O
C.	O
Crystalline	O
form	O
of	O
(	B
3R,4R	I
)	I
-4-	I
[	I
3-	I
(	I
S	I
)	I
-hydroxy-3-	I
(	I
6-methoxyquinolin-4-yl	I
)	I
propyl	I
]	I
-1-	I
[	I
2-	I
(	I
2-thienylthio	I
)	I
ethyl	I
]	I
piperindine-3-carboxylic	I
acid	I

Compounds	O
of	O
general	O
formula	O
in	O
which	O
X	O
represents	O
an	O
oxygen	B
atom	O
or	O
a	O
group	O
of	O
formula	O
NZ	O
in	O
which	O
Z	O
represents	O
a	O
hydrogen	B
atom	O
or	O
an	O
alkyl	B
group	O
,	O
n	O
represents	O
a	O
number	O
0	O
,	O
1	O
or	O
2	O
,	O
and	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
each	O
represent	O
a	O
hydrogen	B
or	O
halogen	B
atom	O
or	O
a	O
trifluoromethyl	B
,	O
trifluoromethoxy	B
,	O
cyano	B
,	O
hydroxyl	B
,	O
alkyl	B
,	O
alkoxy	B
,	O
phenoxy	B
or	O
phenyl	B
group	O
optionally	O
substituted	O
with	O
a	O
halogen	B
atom	O
or	O
a	O
trifluoromethyl	B
,	O
cyano	B
,	O
hydroxyl	B
,	O
alkyl	B
or	O
alkoxy	B
group	O
,	O
or	O
alternatively	O
R2	O
and	O
R3	O
together	O
form	O
a	O
group	O
of	O
formula	O
—OCH2O—	B
or	O
—CH2CH2CH2CH2—.	B
Application	O
in	O
therapy	O
.	O

Nootropic	O
agents	O
;	O
Alzheimer	O
's	O
Disease	O
,	O
Schizophrenia	O
;	O
ligands	O
for	O
the	O
a7	O
subunits	O
of	O
the	O
nicotinic	O
receptor	O
;	O
4-Bromophenyl-1,4-diazabicyclo	B
[	I
3.2.2	I
]	I
nonane-4-carboxylate	I

Once	O
daily	O
pharmaceutical	O
compositions	O
containing	O
lithium	B
carbonate	I
in	O
the	O
form	O
of	O
coated	O
granules	O
.	O

Pharmaceutical	O
compositions	O
containing	O
lithium	B
carbonate	I

The	O
present	O
invention	O
has	O
disclosed	O
the	O
use	O
of	O
N	B
-	I
acetyl	I
-	I
D	I
-	I
glucosamine	I
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
cervical	O
erosion	O
.	O

N	B
-	I
acetyl	I
-	I
D	I
-	I
glucosamine	I
can	O
resist	O
the	O
field	O
planting	O
of	O
microorganism	O
and	O
control	O
microorganism	O
infection	O
,	O
and	O
improve	O
the	O
symptoms	O
of	O
local	O
exudation	O
,	O
tissue	O
inflammatory	O
oedema	O
and	O
pain	O
and	O
the	O
like	O
.	O

Use	O
of	O
N	B
-	I
acetyl	I
-	I
D	I
-	I
glucosamine	I
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
cervical	O
erosion	O

A	O
compound	O
selected	O
from	O
those	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
Ra	O
represents	O
linear	O
or	O
branched	O
(	B
C1–C6	I
)	I
alkylene	I
,	O
X	O
represents	O
a	O
group	O
selected	O
from	O
W1	O
,	O
—C	O
(	O
W1	O
)	O
—W2—	O
,	O
—W2—C	O
(	O
W1	O
)	O
—	O
,	O
—W2—C	B
(	I
W1	I
)	I
W2—	I
,	O
—W2—Ra—	O
and	O
—CH	B
(	I
OR1	I
)	I
—	I
wherein	O
W1	O
,	O
W2	O
and	O
R1	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
when	O
Y	O
represents	O
aryl	B
or	O
heteroaryl	B
,	O
or	O
X	O
represents	O
a	O
group	O
selected	O
from	O
single	O
bond	O
,	O
—C	B
(	I
W1	I
)	I
—	I
,	O
—W2—C	B
(	I
W1	I
)	I
—	I
,	O
—W2—Ra	O
and	O
—CH	B
(	I
OR1	I
)	I
—	I
wherein	O
W1	O
,	O
W2	O
,	O
Ra	O
and	O
R1	O
are	O
as	O
defined	O
hereinbefore	O
,	O
when	O
Y	O
represents	O
a	O
fused	O
bicyclic	O
group	O
,	O
of	O
formula	O
:	O
wherein	O
:	O
A	O
represents	O
nitrogen	O
-	O
containing	O
heterocycle	B
having	O
from	O
4	O
to	O
7	O
ring	O
members	O
that	O
is	O
unsaturated	O
or	O
partially	O
saturated	O
and	O
optionally	O
contains	O
a	O
second	O
hetero	O
atom	O
,	O
B	O
represents	O
phenyl	B
ring	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
as	O
defined	O
in	O
the	O
description	O
,	O
its	O
isomers	O
,	O
and	O
addition	O
salts	O
thereof	O
with	O
a	O
pharmaceutically	O
acceptable	O
acid	O
or	O
base	O
,	O
medicinal	O
products	O
containing	O
the	O
same	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
cognitive	O
deficiencies	O
.	O

Octahydro-2H	B
-	I
pyrido	I
[	I
1,2-a	I
]	I
pyrazine	I
compounds	O

The	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
wherein	O
:	O
R1-R5	O
,	O
""""	O
a	O
""""	O
and	O
X	O
have	O
any	O
of	O
the	O
meanings	O
defined	O
in	O
the	O
specification	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
I	O
,	O
processes	O
for	O
preparing	O
compounds	O
of	O
formula	O
I	O
,	O
intermediates	O
useful	O
for	O
preparing	O
compounds	O
of	O
formula	O
I	O
,	O
and	O
therapeutic	O
methods	O
for	O
treating	O
cancer	O
using	O
compounds	O
of	O
formula	O
I.	O
Tetracyclic	B
or	O
pentacyclic	B
cytotoxic	O
agents	O
,	O
enzyme	O
inhibitors	O
,	O
anticarcinogenic	O
agents	O
,	O
bactericides	O
,	O
fungicides	O

The	O
subject	O
-	O
matter	O
of	O
the	O
invention	O
is	O
the	O
B	O
form	O
of	O
ethyl	B
[	I
(	I
7S	I
)	I
-7-	I
[	I
(	I
2R	I
)	I
-2-	I
(	I
3-chlorophenyl	I
)	I
-2-hydroxyethylamino	I
]	I
-5,6,7,8-tetrahydronaphth-2-yloxy	I
]	I
acetate	I
hydrochloride	I
,	O
of	O
use	O
as	O
a	O
medicament	O
,	O
which	O
exhibits	O
in	O
particular	O
the	O
following	O
physical	O
characteristics	O
:	O
characteristic	O
IR	O
absorption	O
peaks	O
(	O
cm−1	O
)	O
:	O
2780	O
,	O
2736	O
,	O
1722	O
,	O
1211	O
;	O
melting	O
point	O
:	O
129+	O
/	O
−2	O
°	O
C.	O
;	O
characteristic	O
lines	O
of	O
the	O
powder	O
X	O
-	O
ray	O
diffraction	O
diagram	O
(	O
to	O
within	O
0.1	O
(	O
2θ	O
)	O
)	O
:	O
7.69	O
,	O
9.83	O
,	O
13.95	O
,	O
16.58	O
,	O
18.70	O
,	O
20.40	O
,	O
21.57	O
,	O
23.40	O
,	O
24.15	O
and	O
25.64	O
.	O

The	O
product	O
can	O
be	O
obtained	O
by	O
salification	O
of	O
the	O
base	O
or	O
recrystallization	O
of	O
the	O
salt	O
from	O
an	O
alcohol	B
.	O

Crystalline	O
form	O
of	O
phenylethanolamine	B
,	O
the	O
preparation	O
thereof	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O

The	O
invention	O
concerns	O
a	O
composition	O
containing	O
,	O
in	O
a	O
physiologically	O
acceptable	O
medium	O
:	O
(	O
a	O
)	O
at	O
least	O
a	O
DHEA	B
derivative	O
selected	O
among	O
7-hydroxy	B
DHEA	I
and	O
7-keto	B
DHEA	I
,	O
and	O
(	O
b	O
)	O
at	O
least	O
a	O
carotenoid	O
.	O

The	O
invention	O
also	O
concerns	O
cosmetic	O
and	O
dermatological	O
uses	O
of	O
said	O
composition	O
,	O
in	O
particular	O
for	O
preventing	O
or	O
treating	O
actinic	O
skin	O
ageing	O
symptoms	O
.	O

Cosmetics	O
for	O
dermatological	O
treatment	O
and	O
prevention	O
of	O
skin	O
aging	O
due	O
to	O
actinic	O
radiation	O

There	O
is	O
disclosed	O
an	O
isolated	O
or	O
substantially	O
pure	O
form	O
of	O
a	O
nucleic	O
acid	O
molecule	O
encoding	O
a	O
human	O
5-HT4	O
(	O
h	O
)	O
receptor	O
,	O
which	O
5-HT4	O
(	O
h	O
)	O
receptor	O
preferably	O
comprises	O
the	O
sequence	O
illustrated	O
in	O
FIG	O
.	O

1B	O
.	O

Also	O
provided	O
by	O
the	O
invention	O
are	O
expression	O
vectors	O
incorporating	O
said	O
nucleic	O
acid	O
molecule	O
in	O
addition	O
to	O
transgenic	O
cells	O
,	O
tissues	O
or	O
organisms	O
transfected	O
with	O
the	O
nucleic	O
acid	O
molecule	O
.	O

contacting	O
a	O
cell	O
transformed	O
or	O
transfected	O
with	O
an	O
expression	O
vector	O
capable	O
of	O
expressing	O
5-HT4	O
receptor	O
with	O
a	O
compound	O
in	O
presence	O
of	O
a	O
ligand	O
,	O
monitoring	O
CAMP	O
formation	O
in	O
the	O
cell	O
,	O
a	O
change	O
indicates	O
compund	O
as	O
an	O
antagonist	O
or	O
agonist	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
Formula	O
I	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
,	O
and	O
to	O
the	O
method	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
associated	O
with	O
a	O
dysfunction	O
of	O
the	O
nicotinic	O
receptors	O
.	O

cognition	O
activators	O
;	O
prevention	O
of	O
nicotinic	O
receptors	O
dysfunction	O
,	O
central	O
nervous	O
system	O
;	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
Huntington	O
's	O
chorea	O
,	O
neurodegenerative	O
diseases	O

The	O
present	O
application	O
describes	O
6–5	B
,	I
6—6	I
,	I
or	I
6–7	I
heterobicycles	I
of	O
Formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
:	O
wherein	O
ring	O
P	O
is	O
a	O
6-membered	O
heteroaromatic	B
and	O
ring	O
M	O
is	O
a	O
5-	B
,	I
6-	I
,	I
or	I
7-membered	I
non	I
-	I
aromatic	I
carbocycle	I
or	I
heterocycle	I
.	O

Compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
inhibitors	O
of	O
trypsin	O
-	O
like	O
serine	B
proteases	O
,	O
specifically	O
factor	O
Xa	O
.	O

6	B
-	I
5	I
,	I
6	I
-	I
6	I
,	I
or	I
6	I
-	I
7	I
Heterobicycles	I
as	O
factor	O
Xa	O
inhibitors	O

A	O
benzene	B
-	I
fused	I
heteroring	I
derivative	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
all	O
symbols	O
are	O
the	O
same	O
as	O
described	O
in	O
the	O
specification	O
,	O
and	O
a	O
non	O
-	O
toxic	O
salt	O
thereof	O
.	O

The	O
compound	O
of	O
formula	O
(	O
I	O
)	O
has	O
an	O
inhibitory	O
activity	O
against	O
cysteine	B
protease	O
and	O
therefore	O
it	O
is	O
useful	O
as	O
an	O
agent	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
immune	O
diseases	O
(	O
autoimmune	O
diseases	O
,	O
infectious	O
diseases	O
,	O
etc	O
.	O
)	O
,	O
inflammatory	O
diseases	O
(	O
inflammatory	O
bowel	O
diseases	O
,	O
multiple	O
cerebrosclerosis	O
,	O
arthritis	O
,	O
etc	O
.	O
)	O
,	O
nerve	O
degeneration	O
diseases	O
(	O
Alzheimer	O
's	O
disease	O
,	O
muscular	O
dystrophy	O
,	O
etc	O
.	O
)	O
,	O
bone	O
resorption	O
diseases	O
(	O
osteoporosis	O
,	O
etc	O
.	O
)	O
,	O
respiratory	O
system	O
diseases	O
,	O
diabetes	O
,	O
shock	O
,	O
etc	O
.	O

Benzene	B
-	I
fused	I
heteroring	I
derivatives	O
and	O
pharmaceutical	O
agents	O
comprising	O
the	O
same	O
as	O
active	O
ingredient	O

Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
where	O
the	O
variables	O
R1	O
,	O
R2	O
,	O
A	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R6′	O
,	O
n	O
,	O
and	O
W	O
are	O
defined	O
herein	O
.	O

These	O
compounds	O
bind	O
to	O
the	O
benzodiazepine	B
site	O
of	O
GABAA	B
receptors	O
are	O
provided	O
and	O
,	O
therefore	O
can	O
be	O
used	O
to	O
modulate	O
ligand	O
binding	O
to	O
GABAA	B
receptors	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
and	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
in	O
humans	O
,	O
domesticated	O
companion	O
animals	O
and	O
livestock	O
animals	O
.	O

Use	O
to	O
treat	O
anxiety	O
,	O
depression	O
,	O
a	O
sleep	O
disorder	O
such	O
as	O
primary	O
insomnia	O
,	O
circadian	O
rhythm	O
sleep	O
disorder	O
,	O
dyssomnia	O
NOS	O
,	O
nightmare	O
disorder	O
,	O
or	O
attention	O
deficit	O
disorder	O

Described	O
are	O
recombinant	O
DNA	O
molecules	O
comprising	O
the	O
regulatory	O
sequences	O
of	O
an	O
intron	O
of	O
the	O
Endothelial	O
Growth	O
Factor	O
(	O
VFGF	O
)	O
receptor-2	O
gene	O
(	O
Flk-1	O
)	O
or	O
of	O
a	O
gene	O
homologous	O
to	O
the	O
Flk-1	O
gene	O
,	O
being	O
capable	O
of	O
conferring	O
expression	O
of	O
a	O
heterologous	O
DNA	O
sequence	O
in	O
endothelial	O
cells	O
,	O
preferably	O
in	O
vivo	O
.	O

Vectors	O
comprising	O
said	O
DNA	O
molecules	O
as	O
well	O
as	O
host	O
cells	O
containing	O
the	O
same	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
and	O
diagnostic	O
compositions	O
comprising	O
such	O
recombinant	O
DNA	O
molecules	O
and	O
vectors	O
.	O

Furthermore	O
,	O
cells	O
and	O
transgenic	O
non	O
-	O
human	O
animals	O
,	O
comprising	O
the	O
aforementioned	O
recombinant	O
DNA	O
molecules	O
or	O
vectors	O
stably	O
integrated	O
into	O
their	O
genome	O
and	O
their	O
use	O
for	O
the	O
identification	O
of	O
substances	O
capable	O
of	O
suppressing	O
or	O
activating	O
transcription	O
of	O
a	O
gene	O
in	O
endothelial	O
cells	O
are	O
described	O
.	O

Described	O
is	O
further	O
the	O
use	O
of	O
the	O
before	O
described	O
recombinant	O
DNA	O
molecules	O
and	O
vectors	O
for	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
for	O
treating	O
,	O
preventing	O
,	O
and/or	O
delaying	O
a	O
vascular	O
or	O
tumorous	O
disease	O
in	O
a	O
subject	O
.	O

Furthermore	O
,	O
uses	O
of	O
the	O
recombinant	O
DNA	O
molecules	O
and	O
vectors	O
of	O
the	O
invention	O
for	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
for	O
inducing	O
a	O
vascular	O
or	O
tumorous	O
disease	O
in	O
a	O
non	O
-	O
human	O
animal	O
are	O
provided	O
.	O

recombinant	O
DNA	O
molecules	O
comprising	O
regulatory	O
sequences	O
of	O
an	O
intron	O
of	O
the	O
Vascular	O
Endothelial	O
Growth	O
Factor	O
receptor-2	O
gene	O
or	O
of	O
a	O
gene	O
homologous	O
to	O
the	O
Flk-1	O
gene	O
,	O
being	O
capable	O
of	O
conferring	O
expression	O
of	O
a	O
heterologous	O
DNA	O
sequence	O

The	O
present	O
invention	O
relates	O
to	O
ion	O
channel	O
modulating	O
agents	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
particular	O
class	O
of	O
chemical	O
compounds	O
that	O
has	O
proven	O
useful	O
as	O
modulators	O
of	O
SK	O
Ca	O
,	O
IK	O
Ca	O
and	O
BK	O
Ca	O
channels	O
.	O

In	O
further	O
aspects	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
SK	O
/	O
IK	O
/	O
BK	O
channel	O
modulating	O
agents	O
for	O
the	O
manufacture	O
of	O
medicaments	O
,	O
for	O
methods	O
of	O
therapy	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
SK	O
/	O
IK	O
/	O
BK	O
channel	O
modulating	O
agents	O
.	O

The	O
SK	O
/	O
IK	O
/	O
BK	O
channel	O
modulating	O
agents	O
of	O
the	O
invention	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
alleviation	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
the	O
SK	O
/	O
IK	O
/	O
BK	O
channels	O
.	O

Modulators	O
of	O
all	O
three	O
classes	O
of	O
calcium	B
channel	O
blocker	O
subtypes	O
(	O
Small	O
,	O
Intermediate	O
and	O
Big	O
conductance	O
K	O
channel	O
(	O
SK	O
,	O
IK	O
and	O
BK	O
)	O
)	O
comprising	O
malonate	B
esters	I
and	O
nitriles	B
;	O
respiratory	O
,	O
brain	O
,	O
cardiovascular	O
,	O
urogenital	O
disorders	O

The	O
invention	O
relates	O
to	O
cross	O
-	O
linked	O
copolymers	O
based	O
on	O
non	O
cross	O
-	O
linked	O
polycarboxylic	O
copolymers	O
,	O
said	O
non	O
cross	O
-	O
linked	O
copolymers	O
containing	O
at	O
least	O
one	O
polysaccharide	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
these	O
copolymers	O
and	O
their	O
use	O
in	O
particular	O
as	O
a	O
support	O
in	O
pharmaceutical	O
compositions	O
.	O

copolymer	O
of	O
a	O
polysaccharide	O
and	O
a	O
vinyl	B
or	I
acrylic	I
polymer	I
crosslinked	O
with	O
a	O
diamine	B
,	O
amino	B
acid	I
or	O
polypeptide	O
;	O
sustained	O
release	O
;	O
as	O
the	O
polysaccharide	O
is	O
degraded	O
by	O
intestinal	O
bacteria	O
,	O
an	O
active	O
steroidal	O
or	O
nonsteroidal	O
drug	O
is	O
released	O
for	O
effective	O
absorption	O

This	O
invention	O
provides	O
a	O
vaccine	O
for	O
stimulating	O
or	O
enhancing	O
in	O
a	O
subject	O
to	O
which	O
the	O
vaccine	O
is	O
administered	O
,	O
production	O
of	O
an	O
antibody	O
which	O
recognizes	O
a	O
ganglioside	B
,	O
comprising	O
an	O
amount	O
of	O
ganglioside	B
or	O
oligosaccharide	B
portion	O
thereof	O
conjugated	O
to	O
an	O
immunogenic	O
protein	O
effective	O
to	O
stimulate	O
or	O
enhance	O
antibody	O
production	O
in	O
the	O
subject	O
,	O
an	O
effective	O
amount	O
of	O
adjuvant	O
and	O
a	O
pharmaceutically	O
acceptable	O
vehicle	O
.	O

for	O
stimulating	O
or	O
enhancing	O
production	O
of	O
an	O
antibody	O
which	O
recognizes	O
a	O
ganglioside	B
;	O
comprises	O
a	O
ganglioside	B
or	O
oligosaccharide	O
portion	O
conjugated	O
to	O
an	O
immunogenic	O
protein	O
with	O
a	O
carrier	O
and/or	O
vehicle	O
;	O
cancer	O
treatment	O

The	O
present	O
invention	O
provides	O
novel	O
tricyclic	B
diazepine	I
compounds	O
and	O
methods	O
and	O
pharmaceutical	O
compositions	O
utilizing	O
them	O
for	O
the	O
treating	O
or	O
preventing	O
disorders	O
including	O
diabetes	O
insipidus	O
,	O
nocturnal	O
enuresis	O
,	O
nocturia	O
,	O
urinary	O
incontinence	O
,	O
bleeding	O
and	O
coagulation	O
disorders	O
,	O
congestive	O
heart	O
failure	O
or	O
for	O
inducing	O
temporary	O
delay	O
of	O
urination	O
,	O
and	O
in	O
conditions	O
with	O
increased	O
vascular	O
resistance	O
and	O
coronary	O
vasoconstriction	O
;	O
and	O
for	O
the	O
treating	O
or	O
preventing	O
disorders	O
remedied	O
or	O
alleviated	O
by	O
oxytocin	B
antagonist	O
activity	O
,	O
including	O
suppression	O
of	O
preterm	O
labor	O
,	O
dysmenorrhea	O
,	O
endometritis	O
,	O
and	O
for	O
suppressing	O
labor	O
at	O
term	O
prior	O
to	O
caesarean	O
delivery	O
.	O

These	O
compounds	O
are	O
also	O
useful	O
in	O
enhancing	O
fertility	O
rates	O
,	O
enhancing	O
survival	O
rates	O
and	O
synchronizing	O
estrus	O
in	O
farm	O
animals	O
;	O
and	O
treatment	O
of	O
disfunctions	O
of	O
the	O
oxytocin	B
system	O
in	O
the	O
central	O
nervous	O
system	O
including	O
obsessive	O
compulsive	O
disorder	O
(	O
OCD	O
)	O
and	O
neuropsychiatric	O
disorders	O
.	O

Cyclohexenyl	B
phenyl	I
diazepines	I
vasopressin	I
and	O
oxytocin	B
receptor	O
modulators	O

This	O
invention	O
provides	O
a	O
class	O
of	O
androgen	O
receptor	O
targeting	O
agents	O
(	O
ARTA	O
)	O
.	O

The	O
agents	O
define	O
a	O
new	O
subclass	O
of	O
compounds	O
,	O
which	O
are	O
selective	O
androgen	B
receptor	O
modulators	O
(	O
SARM	O
)	O
.	O

Several	O
of	O
the	O
SARM	O
compounds	O
have	O
been	O
found	O
to	O
have	O
an	O
unexpected	O
androgenic	O
and	O
anabolic	O
activity	O
of	O
a	O
nonsteroidal	O
ligand	O
for	O
the	O
androgen	B
receptor	O
.	O

Other	O
SARM	O
compounds	O
have	O
been	O
found	O
to	O
have	O
an	O
unexpected	O
antiandrogenic	O
activity	O
of	O
a	O
nonsteroidal	O
ligand	O
for	O
the	O
androgen	B
receptor	O
.	O

The	O
SARM	O
compounds	O
,	O
either	O
alone	O
or	O
as	O
a	O
composition	O
,	O
are	O
useful	O
for	O
a	O
)	O
male	O
contraception	O
;	O
b	O
)	O
treatment	O
of	O
a	O
variety	O
of	O
hormone	O
-	O
related	O
conditions	O
,	O
for	O
example	O
conditions	O
associated	O
with	O
Androgen	B
Decline	O
in	O
Aging	O
Male	O
(	O
ADAM	O
)	O
,	O
such	O
as	O
fatigue	O
,	O
depression	O
,	O
decreased	O
libido	O
,	O
sexual	O
dysfunction	O
,	O
erectile	O
dysfunction	O
,	O
hypogonadism	O
,	O
osteoporosis	O
,	O
hair	O
loss	O
,	O
anemia	O
,	O
obesity	O
,	O
sarcopenia	O
,	O
osteopenia	O
,	O
osteoporosis	O
,	O
benign	O
prostate	O
hyperplasia	O
,	O
alterations	O
in	O
mood	O
and	O
cognition	O
and	O
prostate	O
cancer	O
;	O
c	O
)	O
treatment	O
of	O
conditions	O
associated	O
with	O
Androgen	O
Decline	O
in	O
Female	O
(	O
ADIF	O
)	O
,	O
such	O
as	O
sexual	O
dysfunction	O
,	O
decreased	O
sexual	O
libido	O
,	O
hypogonadism	O
,	O
sarcopenia	O
,	O
osteopenia	O
,	O
osteoporosis	O
,	O
alterations	O
in	O
cognition	O
and	O
mood	O
,	O
depression	O
,	O
anemia	O
,	O
hair	O
loss	O
,	O
obesity	O
,	O
endometriosis	O
,	O
breast	O
cancer	O
,	O
uterine	O
cancer	O
and	O
ovarian	O
cancer	O
;	O
d	O
)	O
treatment	O
and/or	O
prevention	O
of	O
acute	O
and/or	O
chronic	O
muscular	O
wasting	O
conditions	O
;	O
e	O
)	O
preventing	O
and/or	O
treating	O
dry	O
eye	O
conditions	O
;	O
f	O
)	O
oral	O
androgen	B
replacement	O
therapy	O
;	O
and/or	O
g	O
)	O
decreasing	O
the	O
incidence	O
of	O
,	O
halting	O
or	O
causing	O
a	O
regression	O
of	O
prostate	O
cancer	O
.	O

Antidepressants	O
;	O
sexual	O
disorders	O
;	O
anticancer	O
agnets	O
;	O
hormone	O
replacement	O
therapy	O

Compounds	O
of	O
the	O
formula	O
where	O
the	O
symbols	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
have	O
retinoid	O
agonist	O
,	O
antagonist	O
or	O
negative	O
hormone	O
-	O
like	O
biological	O
activity	O
.	O

Amines	O
substituted	O
with	O
a	O
dihydronaphthalenyl	B
,	O
chromenyl	B
,	O
or	O
thiochromenyl	B
group	O
,	O
a	O
pyridyl	B
group	O
and	O
an	O
alkyl	B
group	O
,	O
having	O
retinoid	O
-	O
like	O
biological	O
activity	O

Novel	O
isothiazole	B
and	O
isoxazole	B
compounds	O
,	O
including	O
derivatives	O
thereof	O
,	O
to	O
intermediates	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
medicinal	O
use	O
are	O
described	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
potent	O
inhibitors	O
of	O
transforming	O
growth	O
factor	O
(	O
""""	O
"TGF"""	O
)	O
-β	O
signaling	O
pathway	O
.	O

They	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
TGF	O
-	O
related	O
disease	O
states	O
including	O
,	O
for	O
example	O
,	O
cancer	O
,	O
and	O
fibrotic	O
diseases	O
.	O

useful	O
in	O
the	O
treatment	O
of	O
TGF-	O
beta	O
related	O
disease	O
states	O
including	O
,	O
for	O
example	O
,	O
cancer	O
and	O
fibrotic	O
diseases	O

Disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
brimondine	B
and	O
timolol	B
for	O
topical	O
ophthalmic	O
delivery	O
and	O
a	O
method	O
of	O
treatment	O
comprising	O
administering	O
said	O
composition	O
when	O
indicated	O
for	O
glaucoma	O
and	O
associated	O
conditions	O
such	O
as	O
elevated	O
intraocular	O
pressure	O
in	O
the	O
eyes	O
of	O
humans	O
.	O

Combination	O
of	O
brimonidine	B
timolol	B
for	O
topical	O
ophthalmic	O
use	O

Cartridges	O
useful	O
in	O
regenerating	O
or	O
purifying	O
dialysis	O
solutions	O
are	O
described	O
as	O
well	O
as	O
methods	O
to	O
regenerate	O
or	O
purify	O
spent	O
dialysis	O
solutions	O
.	O

Dialysis	O
systems	O
using	O
the	O
sorbent	O
cartridges	O
of	O
the	O
present	O
invention	O
are	O
further	O
described	O
.	O

Sorbent	O
cartridge	O
comprising	O
at	O
least	O
sodium	B
zirconium	I
carbonate	I

This	O
invention	O
provides	O
isolated	O
nucleic	O
acids	O
encoding	O
mammalian	O
SNORF36	O
receptors	O
,	O
purified	O
mammalian	O
SNORF36	O
receptors	O
,	O
vectors	O
comprising	O
nucleic	O
acid	O
encoding	O
mammalian	O
SNORF36	O
receptors	O
,	O
cells	O
comprising	O
such	O
vectors	O
,	O
antibodies	O
directed	O
to	O
mammalian	O
SNORF36	O
receptors	O
,	O
nucleic	O
acid	O
probes	O
useful	O
for	O
detecting	O
nucleic	O
acid	O
encoding	O
mammalian	O
SNORF36	O
receptors	O
,	O
antisense	O
oligonucleotides	O
complementary	O
to	O
unique	O
sequences	O
of	O
nucleic	O
acid	O
encoding	O
mammalian	O
SNORF36	O
receptors	O
,	O
transgenic	O
,	O
nonhuman	O
animals	O
which	O
express	O
DNA	O
encoding	O
normal	O
or	O
mutant	O
mammalian	O
SNORF36	O
receptors	O
,	O
methods	O
of	O
isolating	O
mammalian	O
SNORF36	O
receptors	O
,	O
methods	O
of	O
treating	O
an	O
abnormality	O
that	O
is	O
linked	O
to	O
the	O
activity	O
of	O
the	O
mammalian	O
SNORF36	O
receptors	O
,	O
as	O
well	O
as	O
methods	O
of	O
determining	O
binding	O
of	O
compounds	O
to	O
mammalian	O
SNORF36	O
receptors	O
,	O
methods	O
of	O
identifying	O
agonists	O
and	O
antagonists	O
of	O
SNORF36	O
receptors	O
,	O
and	O
agonists	O
and	O
antagonists	O
so	O
identified	O
.	O

Compositions	O
comprising	O
SNORF36	O
receptor	O
compounds	O

The	O
invention	O
provides	O
methods	O
and	O
compositions	O
relating	O
to	O
vertebrate	O
UNC-5	O
proteins	O
which	O
function	O
as	O
receptor	O
proteins	O
for	O
netrins	O
,	O
a	O
family	O
of	O
cell	O
guidance	O
proteins	O
.	O

The	O
proteins	O
may	O
be	O
produced	O
recombinantly	O
from	O
transformed	O
host	O
cells	O
from	O
the	O
disclosed	O
vertebrate	O
UNC-5	O
encoding	O
nucleic	O
acid	O
or	O
purified	O
from	O
human	O
cells	O
.	O

The	O
invention	O
provides	O
specific	O
hybridization	O
probes	O
and	O
primers	O
capable	O
of	O
specifically	O
hybridizing	O
with	O
the	O
disclosed	O
vertebrate	O
unc-5	O
gene	O
,	O
vertebrate	O
UNC-5-specific	O
binding	O
agents	O
such	O
as	O
specific	O
antibodies	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
subject	O
compositions	O
in	O
diagnosis	O
,	O
therapy	O
and	O
in	O
the	O
biopharmaceutical	O
industry	O
.	O

Netrin	O
receptors	O

The	O
present	O
invention	O
concerns	O
the	O
use	O
of	O
glutathione	B
-	O
reductase	O
(	O
GSSG	O
reductase	O
)	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
HIV	O
-	O
infected	O
patients	O
,	O
seropositive	O
or	O
already	O
affected	O
by	O
AIDS	O
,	O
both	O
for	O
prophylactic	O
and	O
therapeutic	O
use	O
.	O

Glutathione	B
reductase	O
for	O
therapy	O
and	O
prophylaxis	O
of	O
aids	O

The	O
present	O
invention	O
relates	O
to	O
use	O
of	O
peptide	O
to	O
which	O
G	O
-	O
protein	O
coupled	O
receptor	O
protein	O
recognizes	O
as	O
a	O
ligand	O
.	O

Since	O
the	O
ligand	O
polypeptide	O
of	O
the	O
present	O
invention	O
has	O
a	O
stimulating	O
action	O
on	O
oxytocin	B
secretion	O
,	O
it	O
is	O
useful	O
as	O
a	O
drug	O
for	O
ameliorating	O
,	O
preserving	O
or	O
treating	O
various	O
diseases	O
related	O
to	O
oxytocin	B
secretion	O
such	O
as	O
uterine	O
inertia	O
,	O
atonic	O
hemorrhage	O
,	O
placental	O
expulsion	O
,	O
subinvolution	O
and	O
the	O
like	O
.	O

Use	O
of	O
peptide	O

The	O
invention	O
concerns	O
a	O
ligand	O
comprising	O
(	O
I	O
)	O
wherein	O
n	O
is	O
an	O
integer	O
from	O
1	O
to	O
5	O
Y	O
is	O
CO2H	B
or	O
PO3H2	O
T	O
represents	O
—X	O
or	O
-phenyl	O
-	O
X	O
,	O
wherein	O
X	O
represents	O
NO2	B
,	O
NH2	B
,	O
NCS	B
,	O
NHCOCH2-Z	B
,	O
NHCO	B
—	I
W	I
—	I
COCNHS	I
,	O
—NH	B
-	I
Q	I
,	O
—NHCS	B
-	I
Q	I
,	O
—NHCOCH2-Q	B
,	O
or	O
NHCO	B
(	I
CH2	I
)	I
m	I
-	I
Q	I
where	O
Q	O
is	O
a	O
hapten	O
chosen	O
from	O
the	O
group	O
consisting	O
of	O
steroids	B
,	O
enzymes	O
,	O
proteins	O
,	O
monoclonal	O
antibodies	O
,	O
chimeric	O
antibodies	O
,	O
or	O
fragments	O
thereof	O
or	O
any	O
activated	O
linker	O
ready	O
for	O
coupling	O
reaction	O
,	O
W	O
is	O
—	B
(	I
CH2	I
)	I
m-	I
m	O
is	O
an	O
integer	O
from	O
1	O
to	O
10	O
Z	O
is	O
chloride	B
,	O
bromide	B
or	O
iodine	B
Chelate	O
compound	O
containing	O
ligand	O
with	O
steroids	B
,	O
enzymes	O
,	O
hapten	O
and	O
antibodies	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
a	O
process	O
for	O
their	O
menufacture	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
to	O
their	O
use	O
in	O
therapy	O
,	O
in	O
particular	O
their	O
use	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
respiratory	O
diseases	O
prophylaxis	O
and	O
treatment	O
of	O
respiratory	O
diseases	O
;	O
phenethanolamine	O
derivatives	O

A	O
polymorphic	O
form	O
of	O
9-nitrocamptothecin	O
is	O
provided	O
,	O
the	O
polymorph	O
being	O
characterizable	O
as	O
having	O
,	O
by	O
differential	O
scanning	O
calorimetry	O
,	O
an	O
endotherm	O
at	O
between	O
273.9	O
to	O
275.9	O
°	O
C.	O
,	O
and	O
an	O
exotherm	O
at	O
between	O
279.3	O
and	O
281.3	O
°	O
C.	O
Compositions	O
and	O
formulations	O
of	O
9-nitrocamptothecin	O
polymorphs	O
and	O
methods	O
of	O
use	O
therefor	O

An	O
N	B
-	I
aminoimidazole	I
or	O
N	B
-	I
aminoimidazolethione	I
derivative	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
a	O
tautomer	O
,	O
an	O
isomer	O
,	O
an	O
ester	O
or	O
glycosylation	O
product	O
thereof	O
,	O
said	O
derivative	O
being	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
m	O
=	O
zero	O
or	O
1	O
,	O
n	O
=	O
zero	O
or	O
1	O
,	O
R1	O
is	O
selected	O
from	O
hydrogen	B
,	O
methyl	B
or	O
ethyl	B
,	O
R2	O
is	O
selected	O
from	O
hydrogen	B
,	O
SH	B
or	O
—SR0	O
wherein	O
R0	O
is	O
methyl	B
,	O
benzyl	B
or	O
glucose	B
residue	O
;	O
Q	O
is	O
selected	O
from	O
1-naphtyl	B
,	O
2-naphtyl	B
,	O
biphenyl	B
,	O
2-pyridyl	B
,	O
3-pyridyl	B
,	O
4-pyridyl	B
,	O
2-pyrimidyl	B
,	O
4-pyrimidyl	B
,	O
5-pyrimidyl	B
,	O
thienyl	B
,	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	B
ring	O
,	O
wherein	O
the	O
substitution	O
is	O
understood	O
as	O
being	O
one	O
or	O
two	O
substituents	O
selected	O
from	O
H	B
,	O
F	B
,	O
Cl	B
,	O
Br	B
,	O
I	B
,	O
methyl	B
,	O
ethyl	B
or	O
isopropyl	B
;	O
L	O
is	O
selected	O
from	O
1-naphtyl	B
,	O
2-naphtyl	B
,	O
biphenyl	B
,	O
2-pyridyl	B
,	O
3-pyridyl	B
,	O
4-pyridyl	B
,	O
2-pyrimidyl	B
,	O
4-pyrimidyl	B
,	O
5-pyrimidyl	B
,	O
thienyl	B
,	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	B
ring	O
wherein	O
the	O
substitution	O
is	O
understood	O
as	O
being	O
one	O
or	O
two	O
substituents	O
selected	O
from	O
H	B
,	O
F	B
,	O
Cl	B
,	O
Br	B
,	O
I	B
,	O
methyl	B
,	O
ethyl	B
or	O
isopropyl	B
.	I

This	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
agents	O
having	O
biological	O
activity	O
,	O
especially	O
against	O
viral	O
infections	O
.	O

Effective	O
against	O
mutations	O
;	O
such	O
as	O
2,3-Dihydro-4-ethyl-1-	B
(	I
3-methylphenylamino	I
)	I
-5-phenyl-1H	I
-	I
imidazole-2-thione	I

The	O
present	O
invention	O
provides	O
novel	O
pyrrolo-	B
[	I
2,1-c	I
]	I
[	I
1,4	I
]	I
benzodiazepine	I
hybrids	O
useful	O
as	O
anti	O
-	O
tumour	O
agents	O
and	O
a	O
process	O
for	O
the	O
preparation	O
thereof	O
.	O

for	O
example	O
,	O
7-methoxy-8-	B
[	I
n'-	I
(	I
4''-acridonylcarboxyamido	I
)	I
alkyl	I
]	I
-oxy-	I
(	I
11aS	I
)	I
-1,2,3,11a	I
-	I
tetraydro-5H	I
-	I
pyrrolo	I
[	I
2,1-c	I
]	I
[	I
1,4	I
]	I
benzodiazepin-5-one	I
;	O
antitumor	O
agents	O

The	O
invention	O
provides	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
in	O
which	O
:	O
R1	O
and	O
R2	O
are	O
independently	O
selected	O
from	O
H	B
,	O
or	O
C1	B
-	I
6alkyl	I
;	O
R3	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
C1	B
-	I
6alkyl	I
,	O
NH2	B
and	O
R6CONH	B
;	O
R4	O
is	O
H	B
or	O
C1	B
-	I
6alkyl	I
;	O
R5	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
CH2F	B
,	O
CHF2	B
,	O
CF3CH2	B
,	O
CF3CHF	B
and	O
CF3CF2	B
;	O
A	O
is	O
a	O
5-	O
or	O
6-membered	O
aryl	B
,	O
or	O
a	O
5-	O
or	O
6-membered	O
aryl	B
substituted	O
by	O
one	O
or	O
more	O
R7	O
;	O
R6	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
H	B
,	O
C1	B
-	I
6alkyl	I
,	O
C1	B
-	I
6alkoxy	I
,	O
C1	B
-	I
6alkylOC1	I
-	I
6alkyl	I
,	O
phenyl	B
,	O
HO2CC1	B
-	I
6alkyl	I
,	O
C1	B
-	I
6alkylOCOC1	I
-	I
6alkyl	I
,	O
C1	B
-	I
6alkylOCO	I
,	O
H2NC1	B
-	I
6alkyl	I
,	O
C1	B
-	I
6alkylOCONHC1	I
-	I
6alkyl	I
and	O
C1	B
-	I
6alkylCONHC1	I
-	I
6alkyl	I
;	O
R7	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	B
,	O
C1	B
-	I
6alkyl	I
,	O
C1	B
-	I
6alkyl	I
substituted	O
by	O
one	O
or	O
more	O
F	B
,	O
C1	B
-	I
6alkoxy	I
,	O
C1	B
-	I
6alkoxy	I
substitued	O
by	O
one	O
or	O
more	O
F	B
,	O
SO2NH2	B
or	O
SO2C1	B
-	I
6alkyl	I
;	O
and	O
n	O
is	O
1	O
to	O
4	O
.	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
potent	O
and	O
selective	O
inhibitors	O
of	O
COX-2	O
and	O
are	O
of	O
use	O
in	O
the	O
treatment	O
of	O
the	O
pain	O
,	O
fever	O
,	O
inflammation	O
of	O
a	O
variety	O
of	O
conditions	O
and	O
diseases	O
.	O

anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
pyretic	O
and	O
analgesic	O
properties	O
,	O
without	O
the	O
potential	O
side	O
effects	O
associated	O
with	O
inhibition	O
of	O
COX-1	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
hydroxycitric	B
acid	I
(	O
HCA	B
)	O
in	O
combination	O
with	O
either	O
one	O
or	O
both	O
of	O
garcinol	B
and	O
anthocyanin	B
,	O
and	O
its	O
use	O
as	O
a	O
weight	O
-	O
loss	O
therapy	O
in	O
animal	O
subjects	O
,	O
preferably	O
humans	O
.	O

The	O
therapeutic	O
effects	O
for	O
the	O
composition	O
observed	O
in	O
murine	O
and	O
human	O
studies	O
include	O
a	O
reduction	O
in	O
total	O
body	O
weight	O
and	O
body	O
mass	O
index	O
,	O
a	O
reduction	O
in	O
body	O
fat	O
,	O
an	O
increase	O
in	O
lean	O
body	O
mass	O
and	O
content	O
of	O
body	O
water	O
,	O
and	O
a	O
reduction	O
in	O
perceived	O
appetite	O
level	O
.	O

Another	O
composition	O
for	O
use	O
in	O
weight	O
-	O
loss	O
therapy	O
is	O
also	O
described	O
relating	O
to	O
forskolin	B
in	O
combination	O
with	O
either	O
one	O
or	O
both	O
of	O
garcinol	B
and	O
anthocyanin	B
.	O

The	O
anti	O
-	O
oxidant	O
properties	O
of	O
garcinol	B
are	O
described	O
as	O
being	O
enhanced	O
in	O
the	O
presence	O
of	O
HCA	B
and	O
anthocyanin	B
,	O
and	O
the	O
combination	O
of	O
HCA	B
,	O
garcinol	B
and	O
anthocyanin	B
is	O
also	O
shown	O
to	O
exert	O
greater	O
citrate	B
lyase	O
inhibiting	O
properties	O
than	O
either	O
compound	O
alone	O
.	O

Methods	O
of	O
obtaining	O
HCA	B
,	O
garcinol	B
or	O
anthocyanin	B
,	O
or	O
a	O
composition	O
containing	O
all	O
three	O
compounds	O
,	O
are	O
described	O
.	O

Bioavailable	O
composition	O
of	O
natural	O
and	O
synthetic	O
HCA	O

Methods	O
to	O
obtain	O
genetic	O
modifications	O
of	O
cells	O
in	O
histoculture	O
are	O
described	O
.	O

Modification	O
is	O
assisted	O
by	O
treating	O
the	O
histoculture	O
with	O
collagenase	O
prior	O
to	O
contacting	O
the	O
histoculture	O
with	O
the	O
delivery	O
vehicle	O
for	O
the	O
desired	O
gene	O
.	O

Hair	O
follicles	O
and	O
other	O
organized	O
tissues	O
can	O
be	O
modified	O
in	O
this	O
was	O
and	O
then	O
transplanted	O
into	O
intact	O
recipients	O
.	O

Transplanting	O
into	O
dermis	O
,	O
least	O
one	O
hair	O
follicle	O
that	O
has	O
been	O
modified	O
ex	O
vivo	O
to	O
contain	O
nucleic	O
acid	O
molecule	O
to	O
introduce	O
nucleic	O
acid	O
molecule	O
into	O
mammal	O

The	O
present	O
invention	O
relates	O
to	O
a	O
bi	O
-	O
specific	O
antibody	O
or	O
antibody	O
fragment	O
having	O
at	O
least	O
one	O
arm	O
that	O
specifically	O
binds	O
a	O
targeted	O
tissue	O
and	O
at	O
least	O
one	O
other	O
arm	O
that	O
specifically	O
binds	O
a	O
targetable	O
conjugate	O
.	O

The	O
targetable	O
conjugate	O
comprises	O
a	O
carrier	O
portion	O
which	O
comprises	O
or	O
bears	O
at	O
least	O
one	O
epitope	O
recognizable	O
by	O
at	O
least	O
one	O
arm	O
of	O
said	O
bi	O
-	O
specific	O
antibody	O
or	O
antibody	O
fragment	O
.	O

The	O
targetable	O
conjugate	O
further	O
comprises	O
one	O
or	O
more	O
therapeutic	O
or	O
diagnostic	O
agents	O
or	O
enzymes	O
.	O

The	O
invention	O
provides	O
constructs	O
and	O
methods	O
for	O
producing	O
the	O
bi	O
-	O
specific	O
antibodies	O
or	O
antibody	O
fragments	O
,	O
as	O
well	O
as	O
methods	O
for	O
using	O
them	O
.	O

antibody	O
binds	O
target	O
tissue	O
and	O
conjugate	O
carrying	O
epitope	O
(	O
haptens	O
)	O

A	O
method	O
for	O
the	O
preparation	O
of	O
compositions	O
,	O
preferably	O
pharmaceutical	O
compositions	O
,	O
in	O
form	O
of	O
expanded	O
,	O
mechanically	O
stable	O
,	O
lamellar	O
,	O
porous	O
,	O
sponge	O
-	O
like	O
or	O
foam	O
structures	O
out	O
of	O
solutions	O
and	O
dispersions	O
results	O
in	O
a	O
favored	O
pharmaceutical	O
product	O
.	O

This	O
method	O
comprises	O
the	O
steps	O
of	O
a	O
)	O
preparing	O
a	O
solution	O
or	O
a	O
homogeneous	O
dispersion	O
of	O
a	O
liquid	O
and	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
one	O
or	O
more	O
pharmaceutically	O
active	O
compounds	O
,	O
one	O
or	O
more	O
pharmaceutically	O
suitable	O
excipients	O
,	O
and	O
mixtures	O
thereof	O
,	O
followed	O
by	O
b	O
)	O
the	O
expansion	O
of	O
the	O
solution	O
or	O
the	O
homogeneous	O
dispersion	O
without	O
boiling	O
.	O

Expanding	O
the	O
homogeneous	O
solution	O
by	O
exposing	O
it	O
to	O
a	O
change	O
in	O
pressure	O
under	O
conditions	O
such	O
that	O
the	O
solution	O
or	O
homogeneous	O
dispersion	O
does	O
not	O
boil	O

Disclosed	O
are	O
compounds	O
,	O
which	O
are	O
bradykinin	O
antagonists	O
and	O
are	O
useful	O
to	O
treat	O
diseases	O
or	O
relieve	O
adverse	O
symptoms	O
associated	O
with	O
disease	O
conditions	O
in	O
mammals	O
mediated	O
by	O
bradykinin	O
.	O

Certain	O
of	O
the	O
compounds	O
exhibit	O
increased	O
potency	O
and	O
are	O
expected	O
to	O
also	O
exhibit	O
an	O
increased	O
duration	O
of	O
action	O
.	O

Analgesics	O
;	O
central	O
nervous	O
system	O
disorders	O
;	O
asthma	O
;	O
rhinitis	O
;	O
antiarthritic	O
agents	O
;	O
inflammatory	O
bowel	O
disorders	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
I	O
and	O
the	O
use	O
thereof	O
for	O
the	O
therapeutic	O
treatment	O
of	O
disorders	O
relating	O
to	O
or	O
affected	O
by	O
the	O
5-HT6	O
receptor	O
.	O

antiserotonine	O
agents	O
;	O
central	O
nervous	O
system	O
disorders	O
;	O
Alzheimer	O
's	O
disease	O

Vascular	O
damaging	O
agents	O
composed	O
of	O
substituted	O
5	B
(	I
6	I
)	I
-substituted	I
benzimidazole-2-carbamates	I
are	O
provided	O
.	O

These	O
agents	O
are	O
useful	O
in	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
diseases	O
involving	O
neovascularisation	O
,	O
particularly	O
for	O
the	O
treatment	O
of	O
solid	O
tumors	O
,	O
macular	O
degeneration	O
,	O
diabetic	O
retinopathy	O
,	O
rheumatoid	O
arthritis	O
,	O
psoriasis	O
,	O
and	O
atherosclerosis	O
.	O

Embodiments	O
include	O
a	O
5	B
(	I
6	I
)	I
-substituted	I
benzimidazole-2-carbamate	I
of	O
formula	O
I	O
wherein	O
A	O
represents	O
a	O
multi	O
-	O
substituted	O
alkyl	B
group	O
or	O
aromatic	B
ring	O
.	O

Therapy	O
for	O
neovascularization	O
;	O
antitumor	O
agents	O
;	O
vision	O
defects	O
;	O
antidiabetic	O
agents	O
;	O
antiarthritic	O
agents	O

The	O
present	O
invention	O
provides	O
a	O
low	O
-	O
molecular	O
inhibitor	O
of	O
GIP	O
functions	O
and	O
,	O
further	O
,	O
an	O
agent	O
for	O
preventing	O
/	O
ameliorating	O
obesity	O
based	O
on	O
inhibition	O
of	O
GIP	O
functions	O
,	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
wherein	O
R1	O
represents	O
hydrogen	B
,	O
halogen	B
,	O
a	O
nitro	B
group	O
or	O
a	O
cyano	B
group	O
,	O
R2	O
and	O
R3	O
each	O
represent	O
hydrogen	B
or	O
halogen	B
,	O
hydrogen	B
or	O
a	O
methoxy	B
group	O
,	O
or	O
both	O
R2	O
and	O
R3	O
may	O
form	O
an	O
optionally	O
substituted	O
benzene	B
or	O
pyrrole	B
ring	O
,	O
and	O
A	O
represents	O
nitrogen	B
or	O
C	B
—	I
R4	I
whereupon	O
R4	O
represents	O
hydrogen	B
,	O
an	O
optionally	O
substituted	O
C1	O
to	O
C6	O
alkyl	B
group	O
,	O
—OR7	O
,	O
—NR8R9	B
,	O
—NHCO	B
—	I
R10	I
or	O
—SO2—R11	B
or	O
may	O
,	O
together	O
with	O
R3	O
,	O
form	O
an	O
optionally	O
substituted	O
benzene	B
or	O
pyrrole	B
ring	O
,	O
R7	O
,	O
R8	O
and	O
R9	O
each	O
represent	O
hydrogen	B
or	O
an	O
optionally	O
substituted	O
C1	O
to	O
C6	B
alkyl	I
group	O
,	O
R10	O
represents	O
a	O
C1	O
to	O
C6	O
alkyl	B
group	O
or	O
the	O
like	O
,	O
and	O
R1	O
represents	O
an	O
optionally	O
substituted	O
morpholyl	B
group	O
or	O
the	O
like	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Glucose	B
dependent	O
-	O
insulinotropic	O
polypeptide	O
,	O
or	O
gastric	O
inhibitory	O
polypeptide	O
(	O
GIP	O
)	O
inhibitors	O
;	O
p	B
-	I
methylidene	I
hydrizide	I
phenols	I

The	O
invention	O
relates	O
to	O
novel	O
5-Ethyl	B
-	I
imidazotriazinones	I
,	O
processes	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
medicaments	O
,	O
esp	O
.	O

for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
inflammatory	O
processes	O
and/or	O
immune	O
diseases	O
.	O

5-Ethyl	B
-	I
imidazotriazinones	I

Polycation	O
bioconjugates	O
and	O
a	O
method	O
for	O
producing	O
them	O
.	O

The	O
polycations	O
are	O
capable	O
of	O
transporting	O
active	O
substances	O
of	O
different	O
types	O
.	O

The	O
polycations	O
function	O
as	O
carrier	O
molecules	O
that	O
transport	O
enhancer	O
molecules	O
,	O
thereby	O
enhancing	O
the	O
biological	O
effectiveness	O
of	O
the	O
transported	O
molecules	O
.	O

The	O
polycation	O
bioconjugates	O
of	O
the	O
present	O
invention	O
may	O
inhibit	O
malignant	O
cell	O
proliferation	O
,	O
possess	O
antimicrobial	O
effect	O
,	O
or	O
be	O
configured	O
for	O
gene	O
transport	O
.	O

Method	O
for	O
preparing	O
polycation	O
based	O
bioconjugates	O
suitable	O
for	O
transporting	O
different	O
kinds	O
of	O
active	O
substances	O
within	O
the	O
body	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
2,5-disubstituted	O
pyrimidine	O
derivatives	O
which	O
stimulate	O
soluble	O
guanylate	O
cyclase	O
,	O
to	O
processes	O
for	O
the	O
preparation	O
thereof	O
,	O
and	O
to	O
the	O
use	O
thereof	O
for	O
producing	O
medicaments	O
,	O
in	O
particular	O
medicaments	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
diseases	O
.	O

2,5-disubstituted	O
pyrimidine	O
derivatives	O

The	O
invention	O
relates	O
to	O
novel	O
aryl	B
-	I
alkane	I
-	I
sulfonamides	I
and	O
their	O
use	O
as	O
active	O
ingredients	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
.	O

The	O
invention	O
also	O
concerns	O
related	O
aspects	O
including	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
those	O
compounds	O
and	O
especially	O
their	O
use	O
as	O
endothelin	O
receptor	O
antagonists	O
.	O

Arylalkane	B
-	I
sulfonamides	I
having	O
endothelin	O
-	O
antagonist	O
activity	O

The	O
present	O
invention	O
relates	O
to	O
biphenyl	B
and	O
biphenyl	B
-	O
analogous	O
compounds	O
,	O
their	O
preparation	O
and	O
use	O
as	O
pharmaceutical	O
compositions	O
,	O
as	O
integrin	O
antagonists	O
and	O
in	O
particular	O
for	O
the	O
production	O
of	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
cancer	O
,	O
arteriosclerosis	O
,	O
restenosis	O
,	O
osteolytic	O
disorders	O
such	O
as	O
osteoporosis	O
and	O
ophthalmic	O
diseases	O
.	O

The	O
compounds	O
according	O
to	O
the	O
invention	O
have	O
the	O
formula	O
(	O
1	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
U	O
,	O
V	O
,	O
A	O
,	O
B	O
,	O
W	O
,	O
R3	O
,	O
C	O
and	O
R4	O
have	O
the	O
meaning	O
as	O
defined	O
in	O
the	O
claims	O
.	O

Biphenyl	B
and	O
biphenyl	B
-	O
analogous	O
compounds	O
as	O
integrin	O
antagonists	O

Indole	B
derivatives	O
represented	O
by	O
formula	O
(	O
I	O
)	O
:	O
(	O
wherein	O
all	O
symbols	O
are	O
described	O
in	O
the	O
description	O
)	O
,	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O
and	O
a	O
DP	O
receptor	O
antagonist	O
comprising	O
it	O
as	O
an	O
active	O
ingredient	O
.	O

Since	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
binds	O
to	O
and	O
are	O
antagonistic	O
to	O
a	O
DP	O
receptor	O
,	O
they	O
are	O
useful	O
in	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
diseases	O
,	O
for	O
example	O
,	O
allergic	O
diseases	O
(	O
allergic	O
rhinitis	O
,	O
allergic	O
conjunctivitis	O
,	O
atopic	O
dermatitis	O
,	O
bronchial	O
asthma	O
,	O
food	O
allergy	O
,	O
etc	O
.	O
,	O
systemic	O
mastocytosis	O
;	O
disorders	O
due	O
to	O
systemic	O
mastocyte	O
activation	O
,	O
anaphylactic	O
shock	O
,	O
bronchoconstriction	O
,	O
urticaria	O
,	O
eczema	O
,	O
etc	O
.	O
)	O
,	O
diseases	O
accompanied	O
with	O
itching	O
(	O
atopic	O
dermatitis	O
,	O
urticaria	O
,	O
etc	O
.	O
)	O
,	O
secondary	O
diseases	O
caused	O
by	O
behaviors	O
(	O
scratching	O
behaviors	O
,	O
beating	O
,	O
etc	O
.	O
)	O
(	O
cataract	O
,	O
retinal	O
detachment	O
,	O
inflammation	O
,	O
infection	O
,	O
sleep	O
disorder	O
,	O
etc	O
.	O
)	O
,	O
inflammation	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
ischemic	O
reperfusion	O
disorder	O
,	O
cerebrovascular	O
disorder	O
,	O
pleuritis	O
complicated	O
by	O
rheumatoid	O
arthritis	O
,	O
ulcerative	O
colitis	O
,	O
and	O
the	O
like	O
.	O

Indole	B
derivatives	O
,	O
process	O
for	O
preparation	O
of	O
the	O
same	O
and	O
use	O
thereof	O

Compositions	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
,	O
for	O
use	O
as	O
blood	O
substitute	O
products	O
comprise	O
aqueous	O
mixtures	O
of	O
oxygen	B
-	O
carrying	O
and	O
non	O
-	O
oxygen	B
carrying	O
plasma	O
expanders	O
and	O
methods	O
for	O
the	O
use	O
thereof	O
.	O

The	O
oxygen	B
-	O
carrying	O
component	O
may	O
consist	O
of	O
any	O
hemoglobin	O
-	O
based	O
oxygen	B
carrier	O
,	O
while	O
the	O
non	O
-	O
oxygen	B
carrying	O
plasma	O
expander	O
my	O
consist	O
of	O
any	O
suitable	O
diluent	O
.	O

Methods	O
and	O
compositions	O
for	O
optimization	O
of	O
oxygen	B
transport	O
by	O
cell	O
-	O
free	O
systems	O

The	O
present	O
invention	O
relates	O
to	O
a	O
class	O
of	O
compounds	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutical	O
acceptable	O
salt	O
,	O
prodrug	O
or	O
ester	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
and	O
methods	O
of	O
selectively	O
inhibiting	O
or	O
antagonizing	O
αvβ3	O
integrin	O
.	O

Substituted	O
benzoxazines	B
as	O
integrin	O
antagonists	O

Bicyclic	B
carbohydrates	I
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
herpseviridae	O
,	O
and	O
in	O
particular	O
cytomegalovirus	O
.	O

The	O
invention	O
consists	O
of	O
the	O
novel	O
bicyclic	B
carbohydrates	I
the	O
generic	O
structure	O
of	O
which	O
is	O
:	O
wherein	O
R1	O
is	O
either	O
-Bn	O
or	O
-Ph	O
;	O
R2	O
and	O
R3	O
are	O
either	O
-alkyl	O
,	O
-aryl	O
,	O
-allyl	O
,	O
or	O
—H	B
;	O
R4	O
and	O
R5	O
form	O
a	O
ring	O
and	O
are	O
either	O
—CH	B
(	I
Ph	I
)	I
-	I
or	O
—CH	B
(	I
aryl	I
)	I
-	I
and	O
X	O
is	O
either	O
O	B
,	O
N	B
or	O
S.	B
Nontoxic	O
treatment	O
for	O
infections	O
from	O
cytomegalovirus	O

Method	O
of	O
making	O
an	O
alpha	B
-	I
amino	I
acid	I
compound	O
having	O
the	O
structure	O
of	O
Formula	O
32	O
:	O
comprising	O
treating	O
under	O
hydrolyzing	O
conditions	O
a	O
hydantoin	B
compound	O
having	O
the	O
structure	O
of	O
Formula	O
33	O
:	O
where	O
the	O
substituents	O
are	O
described	O
herein	O
.	O

Treating	O
under	O
hydrolyzing	O
conditions	O
a	O
hydantoin	B
compound	O
to	O
form	O
an	O
alpha	B
-	I
amino	I
acid	I
derivative	O

Compounds	O
represented	O
by	O
formula	O

I	O
:	O
wherein	O
R1	O
is	O
H	B
,	O
halogen	B
,	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
,	O
O	B
(	I
C1	I
-	I
4	I
)	I
alkyl	I
,	O
and	O
haloalkyl	B
;	O
R2	O
is	O
H	B
or	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
;	O
R3	O
is	O
H	B
or	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
;	O
R4	O
is	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
,	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
(	I
C3	I
-	I
7	I
)	I
cycloalkyl	I
,	O
or	O
(	B
C3	I
-	I
7	I
)	I
cycloalkyl	I
;	O
and	O
Q	O
is	O
a	O
fused	O
phenyl-5	B
or	O
6-membered	O
saturated	O
heterocycle	B
having	O
one	O
to	O
two	O
heteroatoms	O
selected	O
from	O
O	B
and	O
N	B
,	O
said	O
Q	O
being	O
optionally	O
substituted	O
with	O
hydroxy	B
,	O
or	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
which	O
in	O
turn	O
maybe	O
optionally	O
substituted	O
with	O
pyridinyl	B
-	I
N	I
-	I
oxide	I
or	O
C	B
(	I
O	I
)	I
OR	I
wherein	O
R	O
is	O
H	B
or	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
;	O
or	O
a	O
salt	O
thereof	O
.	O

The	O
compounds	O
have	O
inhibitory	O
activity	O
against	O
Wild	O
Type	O
,	O
and	O
single	O
and	O
double	O
mutants	O
strains	O
,	O
of	O
HIV	O
.	O

dipyrido	B
[	I
1,4	I
]	I
diazepine	I
derivatives	O
;	O
treating	O
and	O
preventing	O
hiv	O

Phenylalanine	B
derivatives	O
of	O
the	O
following	O
formulae	O
and	O
analogues	O
thereof	O
have	O
an	O
antagonistic	O
activity	O
to	O
α4	O
integrin	O
.	O

They	O
are	O
used	O
as	O
therapeutic	O
agents	O
for	O
various	O
diseases	O
concerning	O
α4	O
integrin	O
Alpha	O
4	O
integrin	O
antagonists	O

The	O
use	O
of	O
the	O
reduction	O
products	O
of	O
hyperforin	B
and	O
adhyperforin	B
,	O
pharmaceutically	O
acceptable	O
salts	O
or	O
esters	O
thereof	O
,	O
in	O
the	O
pharmaceutical	O
and/or	O
nutritional	O
field	O
,	O
in	O
particular	O
in	O
the	O
treatment	O
of	O
depression	O
and	O
Alzheimer	O
's	O
disease	O
.	O

E.g.	O
,	O
dodecahydroadhyperforin	B
and	O
acetyloctahydroadhyperforin	B
,	O
for	O
use	O
in	O
the	O
treatment	O
of	O
depression	O
and	O
Alzheimer	O
's	O
disease	O

New	O
thyroid	O
receptor	O
ligands	O
are	O
provided	O
which	O
have	O
the	O
general	O
formula	O
in	O
which	O
:	O
X	O
is	O
—O—	B
,	O
—S—	B
,	O
—CH2—	B
,	O
—CO—	B
,	O
or	O
—NH—	B
;	O
Y	O
is	O
—	B
(	I
CH2	I
)	I
n—	I
where	O
n	O
is	O
an	O
integer	O
from	O
1	O
to	O
5	O
,	O
or	O
cis-	B
or	I
trans	I
-	I
ethylene	I
;	O
R1	O
is	O
halogen	B
,	O
trifluoromethyl	B
,	O
or	O
alkyl	B
of	O
1	O
to	O
6	O
carbons	B
or	O
cycloalkyl	B
of	O
3	O
to	O
7	O
carbons	B
;	O
R2	O
and	O
R3	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
hydrogen	B
,	O
halogen	B
,	O
alkyl	B
of	O
1	O
to	O
4	O
carbons	B
or	O
cycloalkyl	B
of	O
3	O
to	O
6	O
carbons	B
,	O
at	O
least	O
one	O
of	O
R2	O
and	O
R3	O
being	O
other	O
than	O
hydrogen	B
;	O
R4	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
R5	O
is	O
hydrogen	O
or	O
lower	O
alkyl	B
;	O
R6	O
is	O
carboxylic	B
acid	I
,	O
or	O
esters	B
or	O
prodrugs	O
;	O
R7	O
is	O
hydrogen	B
or	O
an	O
alkanoyl	B
or	O
an	O
aroyl	B
.	O

In	O
addition	O
,	O
a	O
method	O
is	O
provided	O
for	O
preventing	O
,	O
inhibiting	O
or	O
treating	O
a	O
disease	O
associated	O
with	O
metabolism	O
dysfunction	O
or	O
which	O
is	O
dependent	O
upon	O
the	O
expression	O
of	O
a	O
T3	O
regulated	O
gene	O
,	O
wherein	O
a	O
compound	O
as	O
described	O
above	O
is	O
administered	O
in	O
a	O
therapeutically	O
effective	O
amount	O
.	O

Examples	O
of	O
such	O
diseases	O
associated	O
with	O
metabolism	O
dysfunction	O
or	O
are	O
dependent	O
upon	O
the	O
expression	O
of	O
a	O
T3	O
regulated	O
gene	O
include	O
obesity	O
,	O
hypercholesterolemia	O
,	O
atherosclerosis	O
,	O
cardiac	O
arrhythmias	O
,	O
depression	O
,	O
osteoporosis	O
,	O
hypothyroidism	O
,	O
goiter	O
,	O
thyroid	O
cancer	O
as	O
well	O
as	O
glaucoma	O
,	O
congestive	O
heart	O
failure	O
and	O
skin	O
disorders	O
.	O

Administering	O
compounds	O
such	O
as	O
3-	B
[	I
[	I
3,5-dibromo-	I
[	I
4-hydroxy-3-	I
(	I
1-methylethyl	I
)	I
phenoxy	I
]	I
-phenyl	I
]	I
amino	I
]	I
-3-oxopropanoic	I
acid	I
for	O
therapy	O
of	O
obesity	O
,	O
hypercolesterolemia	O
atherosclerosis	O
,	O
depression	O
,	O
osteoporosis	O
,	O
hypothyroidism	O
,	O
goiter	O
,	O
glaucoma	O
,	O
cardiac	O
arrhythmia	O
,	O
congestive	O
heart	O
failure	O
,	O
or	O
a	O
skin	O
disorder	O

This	O
invention	O
provides	O
novel	O
tricyclic	B
diazepine	I
compounds	O
as	O
well	O
as	O
methods	O
and	O
pharmaceutical	O
compositions	O
utilizing	O
these	O
compounds	O
for	O
the	O
treatment	O
and/or	O
prevention	O
and/or	O
suppression	O
of	O
disorders	O
which	O
may	O
be	O
remedied	O
or	O
alleviated	O
by	O
oxytocin	B
antagonist	O
activity	O
,	O
including	O
treatment	O
of	O
preterm	O
labor	O
,	O
dysmenorrhea	O
,	O
endometritis	O
,	O
and	O
for	O
suppressing	O
labor	O
prior	O
to	O
caesarean	O
delivery	O
.	O

These	O
compounds	O
are	O
also	O
useful	O
in	O
enhancing	O
fertility	O
rates	O
,	O
enhancing	O
survival	O
rates	O
and	O
synchronizing	O
estrus	O
in	O
farm	O
animals	O
;	O
and	O
may	O
be	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
disfunctions	O
of	O
the	O
oxytocin	B
system	O
in	O
the	O
central	O
nervous	O
system	O
including	O
obsessive	O
compulsive	O
disorder	O
(	O
OCD	O
)	O
and	O
neuropsychiatric	O
disorders	O
.	O

Tricyclic	B
diazepines	I
tocolytic	O
oxytocin	B
receptor	O
antagonists	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
a	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
medicaments	O
are	O
described	O
.	O

Substituted	B
2-thio-3,5-dicyano-4-phenyl-6-aminopyridines	I
and	O
the	O
use	O
of	O
the	O
same	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O

I	O
and	O
their	O
use	O
for	O
the	O
production	O
of	O
pharmaceutical	O
agents	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
diseases	O
that	O
coincide	O
with	O
inflammatory	O
,	O
allergic	O
and/or	O
proliferative	O
processes	O
.	O

Antiinflammatory	O
agents	O
;	O
antiarthritic	O
agents	O
;	O
antiallergens	O
;	O
antiinflammatory	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
N	O
-	O
alkylated	O
GABA	B
(	O
Gamma	B
-	I
aminobutyric	I
acid	I
)	O
compounds	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
their	O
use	O
in	O
therapy	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

More	O
particularly	O
these	O
compounds	O
are	O
useful	O
for	O
treatment	O
of	O
disorders	O
of	O
the	O
central	O
and/or	O
peripheral	O
nervous	O
system	O
.	O

Of	O
particular	O
interest	O
is	O
their	O
potent	O
anticonvulsant	O
activity	O
.	O

N	O
-	O
alkylated	O
GABA	B
compounds	O
,	O
processes	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
medicaments	O

The	O
present	O
invention	O
relates	O
to	O
variant	O
forms	O
of	O
human	O
prolactin	O
which	O
act	O
as	O
antagonists	O
at	O
the	O
prolactin	O
receptor	O
,	O
and	O
to	O
the	O
use	O
of	O
such	O
variants	O
in	O
the	O
treatment	O
of	O
human	O
cancers	O
and	O
proliferative	O
disorders	O
,	O
including	O
both	O
benign	O
and	O
malignant	O
diseases	O
of	O
the	O
breast	O
and	O
prostate	O
.	O

Use	O
of	O
anti	O
-	O
prolactin	O
agents	O
to	O
treat	O
proliferative	O
conditions	O

The	O
present	O
inventions	O
relates	O
to	O
a	O
novel	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
the	O
use	O
and	O
manufacture	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
.	O

For	O
therapy	O
of	O
hypertension	O
,	O
congestive	O
heart	O
failure	O
,	O
cardiac	O
hypertrophy	O
,	O
cardiac	O
fibrosis	O
,	O
cardiomyopathy	O
postinfarction	O
,	O
complications	O
resulting	O
from	O
diabetes	O
,	O
such	O
as	O
nephropathy	O
,	O
vasculopathy	O
and	O
neuropathy	O
,	O
diseases	O
of	O
the	O
coronary	O
vessels	O
,	O
restenosis	O
following	O
angioplasty	O

A	O
controlled	O
release	O
formulation	O
of	O
lipoic	B
acid	I
is	O
disclosed	O
.	O

The	O
lipoic	B
acid	I
is	O
combined	O
with	O
excipient	O
materials	O
in	O
such	O
a	O
way	O
that	O
those	O
materials	O
provide	O
for	O
gradual	O
release	O
of	O
the	O
lipoic	B
acid	I
in	O
a	O
manner	O
which	O
makes	O
it	O
possible	O
to	O
substantially	O
increase	O
the	O
period	O
of	O
time	O
over	O
which	O
therapeutic	O
levels	O
of	O
lipoic	B
acid	I
are	O
maintained	O
relative	O
to	O
a	O
quick	O
release	O
formulation	O
.	O

These	O
features	O
make	O
it	O
possible	O
to	O
use	O
lipoic	B
acid	I
to	O
reduce	O
serum	O
glucose	B
levels	O
and	O
maintain	O
those	O
levels	O
over	O
time	O
thereby	O
obtaining	O
a	O
range	O
of	O
desired	O
therapeutic	O
results	O
.	O

Controlling	O
,	O
stabilization	O
blood	O
,	O
glucose	B
concentration	O

A	O
drug	O
effective	O
for	O
prevention	O
and	O
therapy	O
of	O
endometriosis	O
and	O
hysteromyoma	O
is	O
disclosed	O
.	O

The	O
drug	O
for	O
prevention	O
and/or	O
therapy	O
of	O
endometriosis	O
and/or	O
hysteromyoma	O
according	O
to	O
the	O
present	O
invention	O
comprises	O
as	O
an	O
effective	O
ingredient	O
a	O
macrolide	B
antibiotic	O
.	O

Administering	O
macrolide	B
antibiotic	O

Phenothiazine	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
.	O

The	O
compounds	O
are	O
inhibitors	O
of	O
the	O
mitotic	O
kinesin	O
KSP	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
cellular	O
proliferative	O
diseases	O
,	O
such	O
as	O
cancer	O
,	O
hyperplasias	O
,	O
restenosis	O
,	O
cardiac	O
hypertrophy	O
,	O
immune	O
disorders	O
and	O
inflammation	O
.	O

Phenothiazine	B
kinesin	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
derived	O
from	O
indazoles	B
or	O
indoles	B
of	O
formula	O
(	O
1	O
)	O
or	O
formula	O
(	O
2	O
)	O
,	O
to	O
methods	O
for	O
treating	O
tumors	O
or	O
cancerous	O
cells	O
with	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
or	O
formula	O
(	O
2	O
)	O
and	O
to	O
pharmacaetutical	O
compositions	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
a	O
compound	O
of	O
formula	O
(	O
1	O
)	O
or	O
formula	O
(	O
2	O
)	O
For	O
therapy	O
of	O
treating	O
tumors	O
or	O
cancerous	O
cells	O

The	O
present	O
invention	O
is	O
directed	O
to	O
humanized	O
antibodies	O
which	O
bind	O
human	O
gp39	O
and	O
their	O
use	O
as	O
therapeutic	O
agents	O
.	O

These	O
humanized	O
antibodies	O
are	O
especially	O
useful	O
for	O
treatment	O
of	O
autoimmune	O
diseases	O
;	O
and	O
an	O
immunosuppressant	O
during	O
transplantation	O
of	O
heterologous	O
cells	O
,	O
tissues	O
or	O
organs	O
,	O
cell	O
therapy	O
,	O
and	O
gene	O
therapy	O
.	O

Treating	O
autoimmune	O
diseases	O
with	O
humanized	O
anti	O
-	O
CD40L	O
antibody	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
an	O
asthma	O
-	O
associated	O
gene	O
,	O
designated	O
AAGA	O
,	O
the	O
protein	O
molecule	O
encoded	O
by	O
AAGA	O
and	O
related	O
molecules	O
in	O
diagnostic	O
and	O
prognostic	O
screening	O
of	O
patient	O
populations	O
,	O
to	O
polymorphisms	O
in	O
AAGA	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
protein	O
encoded	O
by	O
AAGA	O
or	O
a	O
variant	O
thereof	O
as	O
a	O
therapeutic	O
target	O
.	O

Diagnosing	O
respiratory	O
disorder	O
;	O
obtain	O
cells	O
,	O
monitor	O
expression	O
of	O
marker	O
gene	O
,	O
determine	O
sequence	O
,	O
compare	O
to	O
control	O
,	O
detect	O
polymorphism	O
in	O
polypeptide	O
or	O
nucleotide	O
,	O
presence	O
of	O
polymorphism	O
indicates	O
respiratory	O
disorders	O

Nitric	B
acid	I
salts	O
with	O
medicines	O
active	O
in	O
the	O
respiratory	O
system	O
pathology	O
treatment	O
.	O

lower	O
gastrointestinal	O
and	O
cardiovascular	O
side	O
effects	O
;	O
use	O
in	O
treatment	O
of	O
respiratory	O
system	O
disorders	O
,	O
as	O
tokolitics	O
and	O
as	O
antiallergics	O
,	O
for	O
eye	O
applications	O
.	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O

I	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

These	O
compounds	O
are	O
inhibitors	O
of	O
protein	O
kinases	O
,	O
particularly	O
inhibitors	O
of	O
JAK	O
and	O
CDK2	O
mammalian	O
protein	O
kinases	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compounds	O
and	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
protein	O
kinase	O
mediated	O
disorders	O
.	O

Antiallergens	O
;	O
autoimmune	O
diseases	O
;	O
antiproliferative	O
agents	O
;	O
controlling	O
signal	O
transduction	O

Compounds	O
useful	O
as	O
inhibitors	O
of	O
cyclooxygenase-2	O
activity	O
have	O
the	O
formulae	O
I	O
or	O
Ia	O
:	O

wherein	O
:	O
Q1	O
,	O
Q2	O
,	O
n	O
,	O
m	O
,	O
X	O
,	O
Y	O
and	O
R	O
are	O
as	O
defined	O
herein	O
.	O

Substituted	O
hydrazones	B
as	O
inhibitors	O
of	O
cyclooxygenase-2	O

The	O
present	O
invention	O
involves	O
the	O
discovery	O
that	O
synthetic	O
thyroid	O
hormones	O
can	O
be	O
used	O
as	O
compositions	O
to	O
reduce	O
intraocular	O
pressure	O
in	O
vivo	O
.	O

Methods	O
of	O
screening	O
synthetic	O
thyroid	O
hormones	O
for	O
effect	O
on	O
intraocular	O
pressure	O
,	O
aqueous	O
pressure	O
,	O
hydraulic	O
conductivity	O
,	O
hyaluronic	B
acid	I
secretion	O
,	O
and	O
extracellular	O
matrix	O
assembly	O
are	O
provided	O
.	O

Methods	O
of	O
treating	O
glaucoma	O
and	O
treating	O
excess	O
intraocular	O
pressure	O
with	O
synthetic	O
thyroid	O
hormones	O
and	O
compositions	O
therefore	O
are	O
also	O
provided	O
.	O

Eye	O
treatments	O
using	O
synthetic	O
thyroid	O
hormone	O
compositions	O

This	O
invention	O
provides	O
compounds	O
which	O
are	O
represented	O
by	O
a	O
general	O
formula	O
[	O
I	O
]	O
[	O
in	O
which	O
X	O
stands	O
for	O
hydrogen	B
or	O
halogen	B
;	O
B	O
stands	O
for	O
halogen	B
,	O
cyano	B
or	O
optionally	O
fluorine	B
-	I
substituted	I
lower	I
alkyl	I
;	O
D	O
stands	O
for	O
a	O
3–10	O
membered	O
aliphatic	O
nitrogen	B
-	O
containing	O
heterocyclic	B
group	O
;	O
R3	O
,	O
R4	O
and	O
R5	O
may	O
be	O
same	O
or	O
different	O
,	O
and	O
each	O
stands	O
for	O
hydrogen	B
,	O
lower	B
alkyl	I
optionally	O
having	O
substituent	O
group	O
(	O
s	O
)	O
and	O
the	O
like	O
;	O
and	O
a	O
is	O
0	O
or	O
1	O
]	O
.	O

These	O
compounds	O
exhibit	O
high	O
affinity	O
to	O
nociceptin	B
receptors	O
and	O
whereby	O
inhibit	O
actions	O
of	O
nociceptin	B
,	O
and	O
are	O
useful	O
as	O
an	O
analgesic	O
,	O
antiobestic	O
,	O
agent	O
for	O
ameliorating	O
brain	O
function	O
,	O
treating	O
agents	O
for	O
Alzheimer	O
's	O
disease	O
and	O
dementia	O
,	O
and	O
therapeutic	O
agents	O
for	O
schizophrenia	O
,	O
neurodegenerative	O
diseases	O
,	O
depression	O
,	O
diabetes	O
insipidus	O
,	O
polyuria	O
,	O
hypotension	O
and	O
the	O
like	O
.	O

Brain	O
disorders	O
;	O
psychological	O
disorders	O
;	O
central	O
nervous	O
system	O
disorders	O
;	O
antidiabetic	O
agents	O
;	O
hypotensive	O
agents	O

This	O
invention	O
concerns	O
HIV	O
replication	O
inhibitors	O
of	O
formula	O
(	O
I	O
)	O
the	O
N	B
-	I
oxides	I
,	O
the	O
pharmaceutically	O
acceptable	O
addition	O
salts	O
,	O
the	O
quaternary	B
amines	I
and	O
the	O
stereochemically	O
isomeric	O
forms	O
thereof	O
,	O
wherein	O
the	O
ring	O
containing	O
−a1	O
=	O
a2−a3	O
=	O
a4—and	O
−b1	O
=	O
b2−b3	O
=	O
b4represents	O
pheynl	B
,	O
pyridyl	B
,	O
pyrimidinyl	B
,	O
pirazinyl	B
,	O
pyridazinyl	B
;	O
n	O
is	O
0	O
to	O
5	O
;	O
m	O
is	O
1	O
to	O
4	O
;	O
R1	O
is	O
hydrogen	B
;	O
aryl	B
;	O
formyl	O
;	O
C1	B
-	I
6alkylcarbonyl	I
;	O
C1	B
-	I
6alkyl	I
;	O
C1	B
-	I
6alkyloxycarbonyl	I
,	O
substituted	O
C1	B
-	I
6alkyl	I
,	O
C1	B
-	I
6alkylcarbonyl	I
;	O
R2	O
is	O
hydroxy	B
,	O
halo	B
,	O
optionally	O
substituted	O
C1	B
-	I
6alkyl	I
,	O
C3	B
-	I
7cycloalkyl	I
,	O
optionally	O
substituted	O
C2	B
-	I
6alkenyl	I
,	O
optionally	O
substituted	O
C2	B
-	I
6alkynyl	I
,	O
C1	B
-	I
6alkyloxy	I
,	O
C1	B
-	I
6alkyloxycarbonyl	I
,	O
carboxyl	B
,	O
cyano	B
,	O
nitro	B
,	O
amino	B
,	O
mono-	B
or	I
di	I
(	I
C1	I
-	I
6alkyl	I
)	I
amino	I
,	O
polyhalomethyl	B
,	O
polyhalomethyloxy	B
,	O
polyhalomethylthio	B
,	O
—S	O
(	B
═	I
O	I
)	I
pR6	I
,	O
—NH	B
—	I
S	I
(	I
═	I
O	I
)	I
pR6	I
,	O
—C	B
(	I
═	I
O	I
)	I
R6	I
,	O
—NHC	B
(	I
═	I
O	I
)	I
H	I
,	O
—C	B
(	I
═	I
O	I
)	I
NHNH?2	I
?	I
,	O
—NHC	B
(	I
═	I
O	I
)	I
R6	I
,	O
—C	B
(	I
═	I
NH	I
)	I
R6	I
or	O
a	O
5-membered	O
hetrocycl	B
;	O
X1	O
is	O
—NR5—	B
,	O
—NH	B
—	I
NH—	I
,	O
—N	B
═	I
N—	I
,	O
—O—	B
,	O
—C	B
(	I
═	I
O	I
)	I
—	I
,	O
C1	B
-	I
4alkanediyl	I
,	O
—CHOH—	B
,	O
—S—	B
,	O
—S	B
(	I
═	I
O	I
)	I
p—	I
,	O
—X2—C1	B
-	I
4alkanediyl-	I
or	O
—C1	B
-	I
4alkanediyl	I
-	I
X2—	I
;	O
R3	O
is	O
NHR13	B
,	O
NR13R14	B
;	O
—C	B
(	I
═	I
O	I
)	I
—NHR13	I
;	O
—C	B
(	I
═	I
O	I
)	I
—NR13R14	I
;	O
—C	B
(	I
═	I
O	I
)	I
—R15	I
;	O
—CH	B
═	I
N	I
—	I
NH	I
—	I
C	I
(	I
═	I
O	I
)	I
—R16	I
;	O
substituted	O
C1	B
-	I
6alkyl	I
;	O
optionally	O
substituted	O
C1	B
-	I
6alkyloxyC1	I
-	I
6alkyl	I
;	O
substituted	O
C2	B
-	I
6alkenyl	I
;	O
substituted	O
C2	B
-	I
6alkynyl	I
;	O
substituted	O
C2	B
-	I
6alkylenyl	I
;	O
C1	B
-	I
6alkyl	I
substituted	O
with	O
hydroxy	B
and	O
a	O
second	O
substituent	O
;	O
—C	B
(	I
═	I
N	I
—	I
O	I
—	I
R8	I
)	I
—C1	I
-	I
4alkyl	I
;	O
R7	O
;	O
or	O
—X3—R7	O
;	O
R4	O
is	O
halo	B
,	O
hydroxy	B
,	O
C1	B
-	I
6alkyl	I
,	O
C3	B
-	I
7cycloalkyl	I
,	O
C1	B
-	I
6alkyloxy	I
,	O
cyano	B
,	O
nitro	B
,	O
polyhaloC1	B
-	I
6alkyl	I
,	O
polyhaloC1	B
-	I
6alkyloxy	I
,	O
aminocarbonyl	B
,	O
C1	B
-	I
6alkyloxycarbonyl	I
,	O
C1	B
-	I
6alkylcarbonyl	I
,	O
formyl	B
,	O
amino	B
,	O
mono-	B
or	I
di	I
(	I
C1	I
-	I
4alkyl	I
)	I
amino	I
;	O
their	O
use	O
as	O
a	O
medicine	O
,	O
their	O
processes	O
for	O
preparation	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
Prevention	O
reproduction	O
of	O
virus	O

Imidazopyridine	B
compounds	O
that	O
contain	O
an	O
ether	O
or	O
thioether	O
functionality	O
at	O
the	O
1-position	O
are	O
useful	O
as	O
immune	O
response	O
modifiers	O
.	O

The	O
compounds	O
and	O
compositions	O
of	O
the	O
invention	O
can	O
induce	O
the	O
biosynthesis	O
of	O
various	O
cytokines	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
including	O
viral	O
diseases	O
and	O
neoplastic	O
diseases	O
.	O

Methods	O
of	O
preparing	O
the	O
compounds	O
and	O
intermediates	O
useful	O
in	O
the	O
preparation	O
of	O
the	O
compounds	O
are	O
also	O
disclosed	O
.	O

Immunology	O
for	O
viral	O
diseases	O
and	O
biosynthesis	O
of	O
cytokines	O
of	O
anticancer	O
drugs	O
for	O
tumors	O

The	O
invention	O
relates	O
to	O
a	O
clusianon	O
isomer	O
and	O
to	O
the	O
use	O
thereof	O
,	O
in	O
particular	O
as	O
a	O
pharmaceutical	O
or	O
medical	O
active	O
ingredient	O
,	O
in	O
particular	O
for	O
producing	O
medicaments	O
for	O
the	O
prophylactic	O
and/or	O
therapeutic	O
(	O
curative	O
)	O
treatment	O
of	O
tumor	O
or	O
cancer	O
diseases	O
as	O
well	O
as	O
viral	O
diseases	O
.	O

The	O
aforementioned	O
compound	O
can	O
be	O
used	O
in	O
cytostatics	O
and	O
antiviral	O
agents	O
(	O
virostatics	O
)	O
.	O

Said	O
compound	O
acts	O
,	O
in	O
particular	O
,	O
as	O
a	O
topoisomerase	O
and	O
telomerase	O
inhibitor	O
and	O
as	O
a	O
regulator	O
in	O
the	O
MAP	O
kinase	O
signal	O
transduction	O
.	O

Said	O
compound	O
can	O
thus	O
intervene	O
at	O
the	O
cellular	O
level	O
in	O
the	O
proliferation	O
mechanism	O
of	O
tumor	O
or	O
cancer	O
cells	O
and	O
viruses	O
.	O

Clusianon	O
isomers	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
is	O
an	O
orally	O
administered	O
liquid	O
pharmaceutical	O
composition	O
that	O
demonstrates	O
excellent	O
physical	O
stability	O
while	O
delivering	O
concentrated	O
levels	O
of	O
the	O
pharmaceutical	O
active	O
(	O
s	O
)	O
.	O

Specifically	O
,	O
these	O
compositions	O
for	O
extended	O
periods	O
do	O
not	O
allow	O
the	O
active	O
to	O
precipitate	O
or	O
settle	O
out	O
of	O
solution	O
.	O

Among	O
the	O
advantages	O
of	O
this	O
invention	O
is	O
that	O
the	O
compositions	O
do	O
not	O
require	O
agitation	O
/	O
shaking	O
prior	O
to	O
use	O
as	O
a	O
method	O
to	O
re	O
-	O
suspend	O
or	O
dissolve	O
active	O
drug	O
material	O
to	O
insure	O
even	O
and	O
consistent	O
dosing	O
.	O

Orally	O
administered	O
liquid	O
compositions	O

A	O
composition	O
and	O
therapeutic	O
methods	O
therefore	O
for	O
pharmacologically	O
strong	O
acid	O
solutions	O
comprising	O
a	O
mixture	O
of	O
strong	O
and	O
weak	O
acids	O
.	O

Pharmacologically	O
active	O
strong	O
acid	O
solutions	O

A	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
remove	O
dryness	O
and	O
unpleasantness	O
in	O
eyes	O
of	O
contact	O
lens	O
wearers	O
and	O
to	O
obtain	O
favorable	O
moist	O
feel	O
and	O
wearing	O
feel	O
by	O
stabilizing	O
a	O
lacrimal	O
fluid	O
layer	O
on	O
the	O
surface	O
of	O
eyeballs	O
of	O
the	O
wearers	O
.	O

By	O
using	O
an	O
ophthalmic	O
composition	O
containing	O
polyvinyl	B
pyrrolidone	I
,	O
the	O
lacrimal	O
fluid	O
layer	O
existing	O
on	O
ionic	O
contact	O
lenses	O
can	O
be	O
stabilized	O
via	O
adsorption	O
of	O
polyvinyl	B
pyrrolidone	I
on	O
the	O
ionic	O
contact	O
lenses	O
.	O

By	O
adding	O
a	O
viscosity	O
-	O
increasing	O
agent	O
to	O
the	O
ophthalmic	O
composition	O
,	O
the	O
lacrimal	O
fluid	O
layer	O
can	O
be	O
maintained	O
in	O
a	O
stable	O
state	O
over	O
a	O
long	O
period	O
of	O
time	O
.	O

System	O
for	O
stabilizing	O
lacrimal	O
fluid	O
layer	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
inhibit	O
tyrosine	B
kinase	O
activity	O
of	O
growth	O
factor	O
receptors	O
such	O
as	O
HER1	O
,	O
HER2	O
and	O
HER4	O
thereby	O
making	O
them	O
useful	O
as	O
antiproliferative	O
agents	O
.	O

The	O
compounds	O
are	O
also	O
useful	O
for	O
the	O
treatment	O
of	O
other	O
diseases	O
associated	O
with	O
signal	O
transduction	O
pathways	O
operating	O
through	O
growth	O
factor	O
receptors	O
.	O

5-	B
[	I
(	I
4-aminopiperidin-1-yl	I
)	I
methyl	I
]	I
-N-	I
[	I
(	I
1R	I
)	I
-1-phenylethyl	I
]	I
pyrrolo	I
[	I
2,1-f	I
]	I
[	I
1,2,4	I
]	I
triazin-4-amine	I
for	O
example	O
;	O
antiproliferative	O
agents	O
;	O
inhibit	O
tyrosine	B
kinase	O
activity	O
of	O
growth	O
factor	O
receptors	O
such	O
as	O
HER1	O
,	O
HER2	O
and	O
HER4	O

Cyclic	O
peptide	O
antibiotics	O
including	O
the	O
loloatins	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
rosacea	O
,	O
particularly	O
when	O
administered	O
in	O
conjunction	O
with	O
an	O
antibiotic	O
such	O
as	O
metronidazole	B
that	O
is	O
effective	O
against	O
anaerobic	O
bacteria	O
.	O

Cyclic	O
peptide	O
antibiotics	O
including	O
the	O
loloatins	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
rosacea	O
,	O
particularly	O
when	O
administered	O
in	O
conjunction	O
with	O
an	O
antibiotic	O
such	O
as	O
metronidazole	B
that	O
is	O
effective	O
against	O
anaerobic	O
bacteria	O
.	O

Phthalocyanine	B
analogues	O
having	O
an	O
active	O
group	O
able	O
to	O
link	O
the	O
phthalocyanine	O
t	O
carriers	O
molecules	O
and	O
phthalocyanine	B
to	O
carriers	O
molecules	O
and	O
phthalocyanine	B
analogues	O
as	O
phthalocyanine	B
-	O
carrier	O
conjugates	O
showing	O
enhanced	O
photodynamic	O
properties	O
,	O
red	O
shifted	O
absorption	O
characteristic	O
,	O
all	O
useful	O
for	O
photodynamic	O
therapy	O
,	O
are	O
described	O
.	O

Photosensitizers	O
themselves	O
or	O
the	O
photosensitizers	O
-	O
carriers	O
conjugates	O
are	O
useful	O
compounds	O
either	O
for	O
treatment	O
of	O
various	O
infectious	O
diseases	O
,	O
the	O
in	O
vivo	O
eradication	O
of	O
micro	O
-	O
organisms	O
as	O
well	O
as	O
diseases	O
characterized	O
by	O
cellular	O
hyperproliferation	O
,	O
in	O
particular	O
tumours	O
psoriasis	O
,	O
actinic	O
keratosis	O
,	O
atheromas	O
,	O
endoarterial	O
hyperplasia	O
and	O
prostate	O
hyperplasia	O
.	O

The	O
above	O
compounds	O
can	O
be	O
also	O
useful	O
for	O
blood	O
and	O
blood	O
derivatives	O
sterilization	O
and	O
in	O
vivo	O
/	O
vitro	O
diagnostics	O
.	O

Conjugates	O
with	O
carriers	O
;	O
red	O
shifted	O
absorption	O
;	O
antiproliferative	O
and	O
antitumor	O
agents	O
;	O
benign	O
prostatic	O
hyperplasia	O
;	O
diagnosis	O

The	O
present	O
invention	O
relates	O
to	O
pharmacological	O
methods	O
for	O
the	O
amelioration	O
of	O
sleep	O
-	O
related	O
breathing	O
disorders	O
via	O
administration	O
of	O
agents	O
or	O
combinations	O
of	O
agents	O
that	O
possess	O
serotonin	B
-	O
related	O
pharmacological	O
activity	O
.	O

Pharmacological	O
treatment	O
for	O
sleep	O
apnea	O

Inhalation	O
particles	O
incorporating	O
,	O
in	O
an	O
individual	O
particle	O
,	O
a	O
combination	O
of	O
a	O
βhd	O
2-agonist	O
and	O
a	O
glucocorticosteroid	B
in	O
a	O
predetermined	O
and	O
constant	O
ratio	O
,	O
a	O
process	O
for	O
the	O
preparation	O
thereof	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhalation	O
particles	O
.	O

The	O
particles	O
have	O
a	O
narrow	O
particle	O
size	O
distribution	O
and	O
are	O
preferably	O
in	O
the	O
form	O
of	O
spherical	O
crystalline	O
particles	O
with	O
a	O
rough	O
surface	O
.	O

The	O
particles	O
are	O
particularly	O
useful	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
respiratory	O
disorders	O
.	O

Synergistic	O
mixture	O
of	O
antiserotonine	O
agents	O
and	O
glucocorticoids	B
;	O
inhalation	O

The	O
present	O
invention	O
relates	O
,	O
generally	O
,	O
to	O
a	O
polyvalent	O
immunogen	O
and	O
,	O
more	O
particularly	O
,	O
to	O
a	O
method	O
of	O
inducing	O
neutralizing	O
antibodies	O
against	O
HIV	O
and	O
to	O
a	O
polyvalent	O
immunogen	O
suitable	O
for	O
use	O
in	O
such	O
a	O
method	O
.	O

Polyvalent	O
immunogen	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
1,4-benzothiepine	B
1,1-dioxide	I
compound	O
of	O
formula	O
I	O
in	O
which	O
the	O
radicals	O
have	O
the	O
meanings	O
defined	O
herein	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
physiologically	O
functional	O
derivative	O
thereof	O
,	O
with	O
at	O
least	O
one	O
other	O
active	O
ingredient	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
physiologically	O
functional	O
derivative	O
thereof	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
the	O
use	O
of	O
the	O
combination	O
product	O
,	O
pharmaceutical	O
composition	O
comprising	O
the	O
combination	O
product	O
and	O
method	O
for	O
preparing	O
the	O
pharmaceutical	O
composition	O
.	O

Combination	O
product	O
of	O
a	O
1,4-benzothiepine	B
1,1-dioxide	I
compound	O
with	O
at	O
least	O
one	O
other	O
active	O
ingredient	O
and	O
the	O
use	O
of	O
the	O
product	O

Compounds	O
having	O
Formula	O
I	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
and	O
solvates	O
thereof	O
:	O
are	O
selective	O
inhibitors	O
of	O
the	O
11β	O
-	O
HSD1	O
enzyme	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
such	O
as	O
noninsulin	O
-	O
dependent	O
diabetes	O
(	O
NIDDM	O
)	O
,	O
hyperglycemia	O
,	O
obesity	O
,	O
insulin	O
resistance	O
,	O
dylsipidernia	O
,	O
hyperlipidemia	O
,	O
hypertension	O
,	O
Syndrome	O
X	O
,	O
and	O
other	O
symptoms	O
associated	O
with	O
NIDDM	O
.	O

reducing	O
the	O
risk	O
of	O
developing	O
a	O
condition	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hypercholesterolemia	O
,	O
atherosclerosis	O
,	O
low	O
HDL	O
levels	O
,	O
high	O
LDL	O
levels	O
,	O
hyperlipidemia	O
,	O
hypertriglyceridemia	O
and	O
dyslipidemia	O

Substituted	O
thienoimidazoles	B
with	O
a	O
backbone	O
structure	O
of	O
formula	O
I	O
or	O
II	O
:	O
These	O
substituted	O
thienoimidazoles	B
are	O
useful	O
in	O
prevention	O
or	O
treatment	O
of	O
various	O
disorders	O
,	O
including	O
respiratory	O
disorders	O
.	O

Such	O
as	O
2-	B
(	I
4-methyl-3-thienylamino	I
)	I
-1H	I
-	I
thieno	I
[	I
3,4-d	I
]	I
imidazole	I
for	O
treatment	O
of	O
repiratory	O
disorders	O
,	O
sleep	O
apnea	O

The	O
present	O
invention	O
provides	O
antitumor	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
and	O
antitumor	O
methods	O
For	O
therapy	O
of	O
neoplastic	O
diseases	O

Novel	O
conformationally	O
restricted	O
polyamine	O
analogs	O
are	O
provided	O
,	O
as	O
well	O
as	O
compositions	O
comprising	O
these	O
novel	O
polyamine	O
analogs	O
.	O

Methods	O
of	O
using	O
the	O
novel	O
polyamine	O
analogs	O
in	O
treatment	O
of	O
diseases	O
such	O
as	O
cancer	O
are	O
also	O
provided	O
.	O

Also	O
provided	O
is	O
a	O
method	O
of	O
delivering	O
these	O
analogs	O
specifically	O
to	O
tumor	O
cells	O
by	O
covalently	O
attaching	O
polyamine	O
analogs	O
to	O
porphyrin	O
compounds	O
,	O
along	O
with	O
novel	O
polyamine	O
-	O
porphyrin	O
covalent	O
conjugates	O
.	O

Polyamines	O
for	O
treatment	O
of	O
diseases	O
such	O
as	O
cancer	O
or	O
treatment	O
of	O
tumors	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
for	O
use	O
in	O
the	O
treatment	O
of	O
diseases	O
,	O
in	O
a	O
mammal	O
,	O
in	O
which	O
inappropriate	O
,	O
excessive	O
or	O
undesirable	O
angiogenesis	O
has	O
occurred	O
and/or	O
where	O
excessive	O
Tie2	O
receptor	O
activity	O
has	O
occurred	O
.	O

For	O
use	O
in	O
therapy	O
of	O
diseases	O
,	O
in	O
a	O
mammal	O
,	O
in	O
which	O
inappropriate	O
,	O
excessive	O
or	O
undesirable	O
angiogenesis	O
has	O
occurred	O
and/or	O
where	O
excessive	O
Tie2	O
receptor	O
activity	O
has	O
occurred	O
,	O
cytokine	O
antagonist	O
,	O
antiarthritic	O
agent	O
,	O
for	O
therapy	O
of	O
diabetic	O
retinopathy	O

Conditions	O
such	O
as	O
kidney	O
stones	O
,	O
which	O
are	O
characterized	O
by	O
undesired	O
absorption	O
of	O
oxalate	B
from	O
the	O
intestinal	O
tract	O
are	O
conveniently	O
treated	O
using	O
nontoxic	O
salts	O
of	O
rare	O
earth	O
metal	O
ions	O
.	O

Administering	O
to	O
the	O
gastrointestinal	O
tract	O
salt	O
of	O
a	O
rare	O
earth	O
metal	O
and	O
one	O
or	O
more	O
nontoxic	O
counterions	O
,	O
which	O
salt	O
is	O
hydrated	O
,	O
in	O
an	O
amount	O
effective	O
to	O
inhibit	O
the	O
absorption	O
of	O
oxalate	B
from	O
the	O
gastrointestinal	O
tract	O

The	O
present	O
invention	O
provides	O
compounds	O
having	O
formula	O
(	O
I	O
)	O
:	O
and	O
additionally	O
provides	O
methods	O
for	O
the	O
synthesis	O
thereof	O
and	O
methods	O
for	O
the	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
cancer	O
,	O
wherein	O
R1–R7	O
,	O
X1	O
,	O
X2	O
,	O
R	O
,	O
Q	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O

Prevention	O
of	O
restenosis	O
of	O
blood	O
vessels	O
after	O
trauma	O
,	O
angioplasty	O
or	O
stenting	O
;	O
piperidin-2-amide	B
derivatives	O
;	O
anticarcinogenic	O
agents	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
I	O
wherein	O
W	O
,	O
Q	O
,	O
E	O
,	O
D	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
Y	O
,	O
K	O
,	O
R9	O
,	O
R10	O
,	O
R12	O
,	O
G	O
,	O
and	O
the	O
double	O
bond	O
denoted	O
""""	O
*	O
""""	O
have	O
any	O
of	O
the	O
values	O
defined	O
therefore	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
that	O
are	O
useful	O
as	O
agents	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
conditions	O
,	O
including	O
inflammatory	O
diseases	O
,	O
cardiovascular	O
diseases	O
,	O
and	O
cancers	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
compounds	O
of	O
Formula	O
I.	O
such	O
as	O
4-	B
(	I
4-tert	I
-	I
Butyl	I
-	I
benzyl	I
)	I
-6-	I
(	I
4-oxo-2-thioxo	I
-	I
thiazolidin-5-ylidenemethyl	I
)	I
-4H-1,4-benzoxazin-3-one	I
;	O
phosphoinositide-3-kinases	O
(	O
PI3Ks	O
)	O
;	O
for	O
treatment	O
/	O
prevention	O
of	O
inflammatory	O
diseases	O
,	O
cardiovascular	O
diseases	O
,	O
and	O
cancers	O

A	O
method	O
for	O
transfection	O
of	O
DNA	O
or	O
RNA	O
encoding	O
apo	O
A1	O
into	O
the	O
liver	O
to	O
regulate	O
lipid	O
metabolism	O
comprises	O
injection	O
of	O
a	O
solution	O
containing	O
the	O
DNA	O
or	O
RNA	O
gene	O
into	O
the	O
liver	O
in	O
combination	O
with	O
gas	O
microbubbles	O
or	O
microspheres	O
and	O
using	O
ultrasound	O
to	O
induce	O
the	O
transfection	O
of	O
the	O
DNA	O
or	O
RNA	O
in	O
the	O
liver	O
.	O

Controlling	O
lipid	O
metabolism	O
;	O
injecting	O
a	O
solution	O
of	O
Dna	O
,	O
Rna	O
gene	O
using	O
gas	O
microbubbles	O
using	O
ultrasonic	O
frequency	O
;	O
gene	O
expression	O

The	O
administration	O
of	O
cytotoxic	O
agents	O
followed	O
by	O
the	O
administration	O
of	O
heat	O
shock	O
protein	O
90	O
inhibitors	O
,	O
such	O
as	O
ansamycins	B
,	O
has	O
a	O
synergistic	O
effect	O
on	O
the	O
growth	O
inhibition	O
of	O
cells	O
.	O

This	O
synergy	O
occurs	O
at	O
doses	O
of	O
each	O
cytotoxic	O
agent	O
that	O
normally	O
only	O
causes	O
minimal	O
growth	O
inhibition	O
of	O
cells	O
.	O

Such	O
combination	O
therapy	O
thus	O
allows	O
one	O
to	O
use	O
lower	O
doses	O
of	O
cytotoxic	O
agents	O
to	O
avoid	O
or	O
reduce	O
their	O
respective	O
toxicity	O
to	O
patients	O
without	O
compromising	O
their	O
growth	O
inhibitory	O
effects	O
.	O

Thus	O
,	O
these	O
combinations	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
an	O
animal	O
,	O
preferably	O
a	O
mammal	O
,	O
that	O
has	O
a	O
cell	O
proliferative	O
disorder	O
,	O
whether	O
the	O
cells	O
have	O
wild	O
-	O
type	O
Rb	O
or	O
are	O
Rb	O
deficient	O
or	O
Rb	O
negative	O
.	O

One	O
such	O
method	O
,	O
directed	O
to	O
treating	O
cell	O
proliferative	O
disorders	O
includes	O
the	O
step	O
of	O
administering	O
a	O
therapeutic	O
effective	O
amount	O
of	O
a	O
cytotoxic	O
agent	O
followed	O
by	O
administering	O
a	O
therapeutic	O
effective	O
amount	O
of	O
a	O
heat	O
shock	O
protein	O
90	O
inhibitor	O
.	O

The	O
cytotoxic	O
agent	O
may	O
be	O
a	O
microtubule	O
-	O
affecting	O
agent	O
,	O
topoisomerase	O
II	O
inhibitor	O
,	O
a	O
platinum	B
complex	O
,	O
paclitaxel	B
,	O
or	O
a	O
paclitaxel	B
derivative	O
.	O

The	O
HSP90	O
inhibitor	O
may	O
be	O
an	O
ansamycin	B
,	O
radicicol	B
or	O
a	O
synthetic	O
compound	O
that	O
binds	O
to	O
the	O
ATP	O
-	O
binding	O
site	O
of	O
HSP90	O
.	O

cytotoxic	O
agents	O
followed	O
by	O
a	O
heat	O
shock	O
protein	O
90	O
inhibitor	O
,	O
has	O
a	O
synergistic	O
effect	O
on	O
the	O
growth	O
inhibition	O
of	O
cells	O
;	O
destroying	O
cells	O
having	O
a	O
cell	O
proliferative	O
disorder	O
with	O
wild	O
-	O
type	O
retinoblastoma	O
gene	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
to	O
P2X7	O
inhibitors	O
of	O
formula	O

I	O
and	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
intermediates	O
useful	O
in	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
use	O
in	O
therapy	O
.	O

The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
potent	O
inhibitors	O
of	O
P2X7	O
and	O
as	O
such	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
inflammation	O
,	O
osteoarthritis	O
,	O
rheumatoid	O
arthritis	O
,	O
cancer	O
,	O
reperfusion	O
or	O
ischemia	O
in	O
stroke	O
or	O
heart	O
attack	O
,	O
autoimmune	O
diseases	O
and	O
other	O
disorders	O
.	O

Benzamide	B
,	O
heteroarylamide	B
and	O
reverse	O
amides	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
tachykinin	O
antagonists	O
,	O
including	O
substance	B
P	I
antagonists	O
and	O
other	O
neurokinin	O
antagonists	O
,	O
in	O
the	O
treatment	O
of	O
emesis	O
.	O

Also	O
described	O
are	O
novel	O
tachykinin	O
antagonists	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
medical	O
use	O
.	O

wherein	O
R	O
represents	O
the	O
ring	O
A	O
or	O
2-pyridinyl	B
or	O
2-pyridinyl	B
-	I
N	I
-	I
oxide	I
;	O
R1	O
is	O
selected	O
from	O
halogen	B
atoms	O
and	O
C1	B
-	I
4alkyl	I
,	O
C1	B
-	I
4alkoxy	I
,	O
trifluoromethyl	B
,	O
and	O
S	B
(	I
O	I
)	I
nC1	I
-	I
4alkyl	I
groups	O
;	O
R2	O
and	O
R3	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
each	O
independently	O
are	O
selected	O
from	O
hydrogen	B
and	O
halogen	B
atoms	O
and	O
C1	B
-	I
4alkyl	I
,	O
C1	B
-	I
4alkoxy	I
,	O
trifluoromethyl	B
and	O
cyano	B
groups	O
;	O
n	O
represents	O
zero	O
,	O
1	O
or	O
2	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
.	O

Medical	O
use	O
for	O
tachykinin	O
antagonists	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
prodrugs	O
of	O
chemotherapeutic	O
agents	O
and	O
method	O
of	O
use	O
thereof	O
.	O

Permeable	O
,	O
water	O
soluble	O
,	O
non	O
-	O
irritating	O
prodrugs	O
of	O
chemotherapeutic	O
agents	O
with	O
oxaalkanoic	B
acids	I

A	O
hydroxyformamidine	B
compound	O
represented	O
by	O
the	O
following	O
formula	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
[	O
wherein	O
R1	O
represents	O
a	O
substituted	O
morpholino	B
group	O
,	O
a	O
substituted	O
piperidino	B
group	O
,	O
a	O
piperazin-1-yl	B
group	O
,	O
a	O
substituted	O
piperazin-1-yl	B
group	O
,	O
a	O
thiomorpholin-1-yl	B
group	O
,	O
a	O
perhydroazepin-1-yl	B
group	O
,	O
a	O
perhydroazocin-1-yl	B
group	O
,	O
a	O
tetrahydropyridin-1-yl	B
group	O
,	O
a	O
pyrrolin-1-yl	B
group	O
,	O
etc	O
.	O
;	O
X	O
represents	O
a	O
nitrogen	B
atom	O
or	O
a	O
group	O
represented	O
by	O
CR5	B
;	O
and	O
R2	O
to	O
R5	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1	B
-	I
4	I
alkyl	I
group	O
,	O
a	O
C1	B
-	I
4	I
alkoxy	I
group	O
,	O
a	O
trifluoromethyl	B
group	O
or	O
a	O
halogen	B
atom	O
.	O
]	O

There	O
is	O
provided	O
a	O
drug	O
which	O
inhibits	O
an	O
enzyme	O
producing	O
20-HETE	B
participating	O
in	O
a	O
contracting	O
or	O
dilating	O
action	O
for	O
microvessels	O
and	O
an	O
inducing	O
action	O
for	O
cell	O
proliferation	O
in	O
main	O
organs	O
such	O
as	O
kidney	O
and	O
cerebrovascular	O
vessels	O
.	O

for	O
treatment	O
of	O
renal	O
diseases	O
,	O
cerebrovascular	O
diseases	O
and	O
circulatory	O
diseases	O

4-	B
(	I
2-Fluorophenyl	I
)	I
-6-Methyl-2-	I
(	I
1-Piperazinyl	I
)	I
-Thieno	I
(	I
2,3-D	I
)	I
pyrimidine	I
or	O
a	O
salt	O
thereof	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
urinary	O
incontinence	O
.	O

Administering	O
,	O
to	O
a	O
patient	O
in	O
need	O
of	O
such	O
treatment	O
,	O
an	O
effective	O
amount	O
of	O
4-	B
(	I
2-fluorophenyl	I
)	I
-6-methyl-2-	I
(	I
1-piperazinyl	I
)	I
thieno	I
[	I
2,3-D	I
]	I
pyrimidine	I
or	O
a	O
salt	O
thereof	O

Mono	B
-	I
ester	I
and	O
asymmetrically	O
substituted	O
diesters	B
of	I
dihydrexidine	I
,	O
dinapsoline	B
and	O
A-86929	O
and	O
substituted	O
derivatives	O
thereof	O
are	O
described	O
.	O

The	O
novel	O
ester	B
/	O
diester	B
derivatives	O
exhibit	O
improved	O
pharmacokinetic	O
characteristics	O
relative	O
to	O
their	O
unesterified	O
parent	O
compounds	O
and	O
can	O
be	O
formulated	O
into	O
pharmaceutical	O
compositions	O
useful	O
for	O
the	O
treatment	O
of	O
a	O
wide	O
variety	O
of	O
dopamine	B
related	O
disorders	O
.	O

Mono	B
-	I
ester	I
and	O
asymmetrically	O
substatuted	O
di	B
-	I
ester	I
pro	O
-	O
drugs	O
of	O
dopamide	O
D1	O
receptor	O
agonists	O

The	O
present	O
invention	O
is	O
directed	O
to	O
the	O
use	O
of	O
agents	O
that	O
induce	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
to	O
provide	O
targets	O
for	O
immunotoxins	O
directed	O
against	O
the	O
same	O
cell	O
surface	O
molecules	O
.	O

A	O
specific	O
example	O
is	O
given	O
in	O
which	O
all	B
-	I
trans	I
-	I
retinoic	I
acid	I
(	O
RA	B
)	O
is	O
used	O
to	O
induce	O
high	O
levels	O
of	O
CD38	O
cell	O
surface	O
antigen	O
expression	O
in	O
several	O
myeloid	O
and	O
lymphoid	O
leukemia	O
cells	O
.	O

CD38	O
was	O
then	O
used	O
as	O
target	O
for	O
delivering	O
plant	O
toxin	O
(	O
gelonin	O
)	O
to	O
leukemia	O
cells	O
.	O

Treatment	O
of	O
leukemia	O
cells	O
with	O
RA	O
induced	O
high	O
levels	O
of	O
CD38	O
in	O
those	O
cells	O
that	O
otherwise	O
had	O
low	O
CD38	O
expression	O
.	O

The	O
RA	O
-	O
induced	O
leukemia	O
cells	O
then	O
became	O
exquisitely	O
sensitive	O
to	O
an	O
immunotoxin	O
constructed	O
from	O
an	O
anti	O
-	O
CD38	O
monoclonal	O
antibody	O
conjugated	O
to	O
the	O
plant	O
toxin	O
gelonin	O
.	O

Administering	O
an	O
agent	O
which	O
upregulates	O
the	O
expression	O
of	O
a	O
cellular	O
target	O
;	O
administering	O
a	O
dose	O
of	O
an	O
immunotoxin	O
directed	O
against	O
the	O
upregulated	O
cellular	O
target	O

The	O
present	O
invention	O
concerns	O
a	O
tablet	O
comprising	O
two	O
distinct	O
segments	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
combinations	O
of	O
two	O
pharmaceutical	O
substances	O
and	O
methods	O
of	O
treatment	O
of	O
allergic	O
disorders	O
.	O

segmented	O
;	O
sustained	O
release	O
;	O
for	O
treatment	O
of	O
allergies	O

A	O
method	O
for	O
treating	O
a	O
disease	O
associated	O
with	O
the	O
estrogen	B
receptor	O
-	O
β	O
,	O
comprising	O
the	O
step	O
of	O
administiering	O
a	O
therapeutically	O
-	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
satifies	O
the	O
equation	O
:	O
KiαA	O
/	O
KiβA>25	O
,	O
optionally	O
having	O
general	O
structure	O
(	O
I	O
)	O
.	O

Estrogen	B
receptor	O
-	O
β	O
ligands	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
nimesulide	B
and	O
structurally	O
related	O
compounds	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
neurodegenerative	O
conditions	O
.	O

It	O
is	O
based	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
the	O
discovery	O
that	O
nimesulide	B
exhibits	O
a	O
neuroprotective	O
effect	O
against	O
β	O
-	O
amyloid	O
induced	O
cell	O
death	O
.	O

Without	O
being	O
bound	O
to	O
any	O
particular	O
theory	O
,	O
it	O
appears	O
that	O
nimesulide	B
inhibits	O
a	O
non	O
-	O
inflammatory	O
mechanism	O
of	O
neurodegeneration	O
.	O

Treatment	O
of	O
neurodegenerative	O
conditions	O
with	O
nimesulide	B

The	O
present	O
invention	O
provides	O
a	O
process	O
for	O
the	O
production	O
of	O
hyaluronic	B
acid	I
(	O
HA	B
)	O
derivatives	O
cross	O
-	O
linked	O
with	O
another	O
polymer	O
,	O
in	O
particular	O
multiple	O
e.g.	O
double	O
cross	O
-	O
linked	O
hyaluronic	B
acid	I
derivatives	O
.	O

The	O
invention	O
also	O
provides	O
novel	O
cross	O
-	O
linked	O
derivatives	O
,	O
products	O
containing	O
them	O
and	O
their	O
uses	O
in	O
cosmetic	O
,	O
medical	O
and	O
pharmaceutical	O
applications	O
.	O

Cosmetics	O
,	O
drugs	O

Aspirin	B
(	O
ASA	B
)	O
triggers	O
a	O
switch	O
in	O
the	O
biosynthesis	O
of	O
lipid	O
mediators	O
,	O
inhibiting	O
prostanoid	O
production	O
and	O
initiating	O
15-epi	B
-	I
lipoxin	I
generation	O
,	O
through	O
the	O
acetylation	O
of	O
cyclooxygenase	O
II	O
.	O

Aspirin	B
-	O
triggered	O
lipoxins	O
as	O
modulators	O
of	O
diseases	O
associated	O
with	O
polymorphoneutrophil	B
inflammation	O
;	O
antiinflammatory	O
agents	O

Substituted	O
3,4-dihydropyrido	B
[	I
1,2-a	I
]	I
pyrimidines	I
of	O
formula	O

I	O
and	O
processes	O
for	O
the	O
production	O
thereof	O
Also	O
disclosed	O
are	O
substance	O
libraries	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
,	O
and	O
methods	O
of	O
treatment	O
for	O
pain	O
,	O
urinary	O
incontinence	O
,	O
pruritus	O
,	O
tinnitus	O
and/or	O
diarrhoea	O
using	O
the	O
pharmaceutical	O
composition	O
.	O

Substituted	O
3,4-dihydropyrido	B
[	I
1,2-a	I
]	I
pyrimidines	I

Selective	O
PDE4	O
inhibition	O
is	O
achieved	O
by	O
4-	B
(	I
substituted	I
-	I
phenyl	I
)	I
-2-pyrrolidinone	I
compounds	O
.	O

The	O
compounds	O
exhibit	O
improved	O
PDE4	O
inhibition	O
as	O
compared	O
to	O
compounds	O
like	O
rolipram	B
and	O
show	O
selectivity	O
with	O
regard	O
to	O
inhibition	O
of	O
other	O
classes	O
of	O
PDEs	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
of	O
formula	O
I	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
and	O
R3	O
are	O
as	O
defined	O
herein	O
.	O

Antiinflammatory	O
agents	O
;	O
antidepressants	O
;	O
respiratory	O
system	O
disorders	O
;	O
cognition	O
activators	O

The	O
invention	O
provides	O
hyaluronic	O
acid	O
compounds	O
and	O
derivatives	O
thereof	O
for	O
preventing	O
urogenital	O
infections	O
by	O
a	O
variety	O
of	O
pathogens	O
,	O
as	O
well	O
as	O
compositions	O
,	O
articles	O
and	O
methods	O
for	O
treating	O
and	O
preventing	O
urogenital	O
infections	O
.	O

Prevention	O
of	O
urogenital	O
infections	O

Disclosed	O
are	O
novel	O
A2B	O
adenosine	B
receptor	O
antagonists	O
of	O
Formula	O
I	O
:	O
A	O
compound	O
of	O
the	O
formula	O
:	O
wherein	O
:	O
R1	O
is	O
optionally	O
substituted	O
alkyl	B
or	O
a	O
group	O
—Y	O
-	O
Z	O
,	O
in	O
which	O
Y	O
is	O
a	O
covalent	O
bond	O
or	O
optionally	O
substituted	O
alkylene	B
,	O
and	O
Z	O
is	O
optionally	O
substituted	O
cycloalkyl	B
,	O
optionally	O
substituted	O
aryl	B
,	O
optionally	O
substituted	O
heteroaryl	B
,	O
optionally	O
substituted	O
heterocyclyl	B
,	O
optionally	O
substituted	O
alkenyl	B
or	O
optionally	O
substituted	O
alkynyl	B
,	O
with	O
the	O
proviso	O
that	O
when	O
Y	O
is	O
a	O
covalent	O
bond	O
Z	O
can	O
not	O
be	O
alkenyl	B
or	O
alkynyl	B
;	O
and	O
X	O
is	O
oxygen	B
,	O
sulfur	B
,	O
or	O
NH—	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
,	O
or	O
prodrug	O
thereof	O
.	O

The	O
compounds	O
are	O
particularly	O
useful	O
for	O
treating	O
asthma	O
and	O
diabetic	O
retinopathy	O
.	O

A2B	O
adenosine	B
receptor	O
antagonists	O

Pharmaceutical	O
compositions	O
and	O
methods	O
are	O
described	O
comprising	O
at	O
least	O
a	O
parathyroid	O
hormone	O
peptide	O
(	O
PTH	O
)	O
preferably	O
PTH1	O
-	O
34	O
and	O
one	O
or	O
more	O
mucosal	O
delivery	O
-	O
enhancing	O
agents	O
for	O
enhanced	O
nasal	O
mucosal	O
delivery	O
of	O
PTH	O
,	O
for	O
treating	O
or	O
preventing	O
osteoporosis	O
or	O
osteopenia	O
in	O
a	O
mammalian	O
subject	O
,	O
preferably	O
a	O
human	O
.	O

comprising	O
an	O
aqueous	O
mixture	O
of	O
parathyroid	O
hormone	O
,	O
a	O
cyclodextran	O
and	O
didecanoylphosphatidylcholine	B
at	O
concentrations	O
sufficient	O
to	O
enhance	O
permeation	O
across	O
the	O
cellular	O
layer	O
,	O
wherein	O
the	O
formulation	O
consists	O
of	O
droplets	O
,	O
of	O
which	O
less	O
than	O
10	O
%	O
are	O
less	O
than	O
10	O
microns	O
in	O
diameter	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	B
antagonists	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
comprising	O
said	O
antagonists	O
of	O
the	O
corticotropin	B
releasing	O
factor	O
receptor	O
(	O
""""	O
CRF	O
receptor	O
""""	O
)	O
useful	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
anxiety	O
,	O
affective	O
disorders	O
,	O
feeding	O
disorders	O
,	O
post	O
-	O
traumatic	O
stress	O
disorder	O
,	O
headache	O
,	O
drug	O
addiction	O
,	O
inflammatory	O
disorders	O
,	O
drug	O
or	O
alcohol	B
withdrawal	O
symptoms	O
and	O
other	O
conditions	O
the	O
treatment	O
of	O
which	O
can	O
be	O
effected	O
by	O
the	O
antagonism	O
of	O
the	O
CRF-1	O
receptor	O
.	O

Imidazolyl	B
derivatives	O
as	O
corticotropin	B
releasing	O
factor	O
inhibitors	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
D	O
,	O
R1	O
,	O
R2	O
and	O
n	O
are	O
defined	O
in	O
Claim	O
1	O
,	O
are	O
potent	O
5-HT1A	O
agonists	O
and	O
5-HT	B
reuptake	O
inhibitors	O
and	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
anxiety	O
states	O
,	O
panic	O
attacks	O
,	O
obsessive	O
-	O
compulsive	O
disorders	O
,	O
psychiatric	O
illnesses	O
,	O
cerebral	O
infarction	O
,	O
cerebral	O
ischaemia	O
,	O
tension	O
states	O
,	O
side	O
-	O
effects	O
in	O
the	O
treatment	O
of	O
high	O
blood	O
pressure	O
,	O
for	O
the	O
prophylaxis	O
and	O
therapy	O
of	O
cerebral	O
illnesses	O
,	O
acromegaly	O
,	O
hypogonadism	O
,	O
secondary	O
amenorrhoea	O
,	O
premenstrual	O
syndrome	O
,	O
undesired	O
puerperal	O
lactation	O
,	O
pain	O
,	O
sleep	O
disorders	O
,	O
narcolepsy	O
,	O
bipolar	O
illnesses	O
,	O
mania	O
,	O
dementia	O
,	O
addiction	O
illnesses	O
,	O
sexual	O
dysfunction	O
,	O
eating	O
disorders	O
,	O
obesity	O
or	O
fibromyalgia	O
Substituted	O
benzofuran-2-carboxamides	B
derivatives	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
R1	O
represents	O
hydroxy	B
or	O
RCO	B
—	I
O—	I
,	O
R2	O
represents	O
hydrogen	B
,	O
halogen	B
,	O
hydroxy	B
or	O
R′CO	B
—	I
O	I
,	O
R	O
,	O
R′	O
,	O
which	O
may	O
be	O
identical	O
or	O
different	O
,	O
represent	O
linear	O
or	O
branched	O
(	B
C1-C6	I
)	I
alkyl	I
optionally	O
substituted	O
by	O
aryl	B
,	O
linear	O
or	O
branched	O
(	B
C2-C6	I
)	I
alkenyl	I
optionally	O
substituted	O
by	O
aryl	B
,	O
linear	O
or	O
branched	O
(	B
C1-C6	I
)	I
perhaloalkyl	I
,	O
(	B
C3-C7	I
)	I
cycloalkyl	I
,	O
adamantyl	B
,	O
aryl	B
or	O
heteroaryl	B
,	O
R3	O
represents	O
hydrogen	B
,	O
linear	O
or	O
branched	O
(	B
C1-C6	I
)	I
alkyl	I
or	O
(	B
C3-C7	I
)	I
cycloalkyl	I
,	O
A	O
represents	O
CR4R5	O
or	O
NR4	O
,	O
R4	O
represents	O
hydrogen	B
or	O
linear	O
or	O
branched	O
(	B
C1-C6	I
)	I
alkyl	I
,	O
their	O
isomers	O
and	O
also	O
their	O
addition	O
salts	O
with	O
a	O
pharmaceutically	O
acceptable	O
acid	O
or	O
base	O
.	O

Medicaments	O
.	O

Benzothiazine	B
and	O
benzothiadiazine	B
compounds	O

Compounds	O
of	O
the	O
current	O
invention	O
relate	O
to	O
rifamycin	B
derivatives	O
having	O
antimicrobial	O
activities	O
,	O
including	O
activities	O
against	O
drug	O
-	O
resistant	O
microorganisms	O
.	O

More	O
specifically	O
,	O
compounds	O
of	O
the	O
current	O
invention	O
relate	O
to	O
C-25	B
carbamate	I
derivatives	O
of	O
rifamycin	O
having	O
another	O
functional	O
group	O
or	O
pharmacophore	O
covalently	O
attached	O
to	O
this	O
position	O
through	O
a	O
carbamate	B
linkage	O
.	O

The	O
resulting	O
compounds	O
exert	O
their	O
antimicrobial	O
activity	O
through	O
a	O
dual	O
-	O
function	O
mechanism	O
and	O
therefore	O
exhibit	O
reduced	O
frequency	O
of	O
resistance	O
.	O

C-25	B
carbamate	I
rifamycin	I
derivatives	O
with	O
activity	O
against	O
drug	O
-	O
resistant	O
microbes	O

Compounds	O
and	O
compositions	O
of	O
azacytosine	B
analogs	O
and	O
derivatives	O
are	O
provided	O
.	O

In	O
one	O
aspect	O
of	O
the	O
invention	O
,	O
analogs	O
or	O
derivatives	O
of	O
decitabine	B
and	O
azacitidine	B
are	O
provided	O
with	O
modification	O
at	O
the	O
4-	O
and	O
6-position	O
of	O
the	O
triazine	B
ring	O
,	O
at	O
the	O
1′–6′	O
position	O
of	O
the	O
ribose	B
ring	O
,	O
or	O
combinations	O
thereof	O
.	O

Methods	O
of	O
synthesizing	O
and	O
manufacturing	O
these	O
analogs	O
and	O
derivatives	O
are	O
also	O
provided	O
.	O

These	O
compounds	O
can	O
be	O
formulated	O
into	O
pharmaceutical	O
compositions	O
that	O
can	O
be	O
used	O
for	O
treating	O
any	O
disease	O
that	O
is	O
sensitive	O
to	O
the	O
treatment	O
with	O
decitabine	B
or	O
azacitidine	B
,	O
such	O
as	O
hematological	O
disorders	O
and	O
cancer	O
.	O

Alkyl	B
,	O
substituted	O
or	O
unsubstituted	O
ribose	B
,	O
or	O
2'-deoxyribose	B
substituted	I
1,3,5-triazin-2	I
(	I
1H	I
)	I
-ones	I
,	O
which	O
may	O
be	O
additionally	O
substituted	O
with	O
alkyl	B
,	O
aryl	B
,	O
halo	B
,	O
amino	B
,	O
oxy	B
,	O
thio	B
,	O
and/or	O
hydrazine	B
groups	O
;	O
used	O
for	O
treating	O
diseases	O
such	O
as	O
hematological	O
disorders	O
and	O
cancer	O

A	O
method	O
of	O
treating	O
or	O
preventing	O
chronic	O
organ	O
transplant	O
rejection	O
comprising	O
administering	O
a	O
compound	O
of	O
the	O
formula	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
above	O
.	O

Using	O
a	O
pyrrolo	B
(	I
2,3-d	I
)	I
pyrimidine	I
compound	O

This	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
is	O
—S	B
(	I
O	I
)	I
p	I
-	I
A	I
,	O
—S—	B
(	I
O	I
)	I
q	I
-	I
B	I
or	O
—O	B
-	I
D	I
,	O
wherein	O
p	O
and	O
q	O
,	O
which	O
are	O
the	O
same	O
or	O
different	O
,	O
each	O
represent	O
an	O
integer	O
from	O
0	O
to	O
2	O
,	O
A	O
is	O
a	O
straight	O
chain	O
C1-C10	B
alkyl	I
group	O
which	O
may	O
be	O
substituted	O
by	O
R10	O
,	O
and	O
B	O
and	O
D	O
each	O
independently	O
represent	O
R12	O
which	O
may	O
be	O
substituted	O
by	O
R10	O
;	O
R2	O
is	O
a	O
hydrogen	B
atom	O
,	O
a	O
halogen	B
atom	O
,	O
or	O
a	O
straight	O
chain	O
or	O
branched	O
C1-C6	B
alkyl	I
group	O
which	O
may	O
be	O
substituted	O
by	O
R10	O
;	O
X1	O
and	O
X2	O
each	O
independently	O
represent	O
N	B
or	O
CH	B
,	O
but	O
can	O
not	O
both	O
be	O
N	B
;	O
the	O
formula	O
(	O
II	O
)	O
:	O
shows	O
a	O
monocyclic	B
or	I
bicyclic	I
heteroaryl	I
group	O
which	O
has	O
a	O
nitrogen	B
atom	O
adjacent	O
to	O
the	O
carbon	B
atom	O
bonded	O
to	O
the	O
amide	B
group	O
,	O
and	O
the	O
heteroaryl	B
group	O
may	O
be	O
substituted	O
by	O
R10	O
;	O
R10	O
is	O
R11	O
,	O
or	O
a	O
hydrocarbon	B
group	O
which	O
may	O
be	O
substituted	O
by	O
R11	O
;	O
R11	O
is	O
,	O
for	O
example	O
,	O
a	O
hydrogen	B
atom	O
or	O
amino	B
;	O
and	O
R12	O
is	O
,	O
for	O
example	O
,	O
phenyl	B
,	O
thiazolyl	B
,	O
pyridyl	B
or	O
methylene	B
dioxyphenyl	I
.	O

The	O
compound	O
according	O
to	O
this	O
invention	O
has	O
a	O
glucokinase	O
activation	O
effect	O
,	O
and	O
for	O
example	O
,	O
is	O
useful	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
diabetes	O
mellitus	O
,	O
and	O
in	O
the	O
prevention	O
of	O
its	O
complications	O
such	O
as	O
diabetic	O
nephropathy	O
,	O
diabetic	O
retinopathy	O
,	O
diabetic	O
neuropathy	O
and	O
diabetic	O
arteriosclerosis	O
.	O

Aminobenzamide	B
derivative	O

Tetrazole	B
compounds	O
substituted	O
directly	O
,	O
or	O
by	O
a	O
bridge	O
,	O
with	O
a	O
heteroaryl	B
moiety	O
containing	O
N	B
adjacent	O
to	O
the	O
point	O
of	O
connection	O
of	O
the	O
heteroaryl	B
,	O
are	O
mGluR5	O
modulators	O
useful	O
in	O
the	O
treatment	O
of	O
psychiatric	O
and	O
mood	O
disorders	O
such	O
as	O
,	O
for	O
example	O
,	O
schizophrenia	O
,	O
anxiety	O
,	O
depression	O
,	O
and	O
panic	O
,	O
as	O
well	O
as	O
in	O
the	O
treatment	O
of	O
pain	O
and	O
other	O
diseases	O
.	O

G	O
protein	O
-	O
coupled	O
receptors	O
activators	O
such	O
as	O
2-	B
[	I
2-	I
(	I
3-chlorophenyl	I
)	I
-2H	I
-	I
tetrazol-5-yl	I
]	I
pyridine	I
,	O
used	O
as	O
analgesics	O
,	O
anxiolytic	O
,	O
antidepressants	O
,	O
and	O
for	O
prophylaxis	O
of	O
psychological	O
disorders	O

The	O
present	O
invention	O
is	O
directed	O
to	O
1,2,3,4,10,10a	B
,-	I
hexahydropyrazino	I
[	I
1,2-a	I
]	I
indole	I
derivatives	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
and	O
esters	B
thereof	O
,	O
wherein	O
R1	O
to	O
R8	O
have	O
the	O
significance	O
given	O
in	O
claim	O
1	O
be	O
used	O
in	O
the	O
form	O
of	O
pharmaceutical	O
preparations	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O
,	O
damage	O
to	O
the	O
central	O
nervous	O
system	O
,	O
cardiovascular	O
disorders	O
,	O
gastrointestinal	O
disorders	O
,	O
diabetes	O
insipidus	O
,	O
obesity	O
and	O
sleep	O
apnea	O
.	O

2-	B
(	I
9-bromo-3,4,10,10a	I
-	I
tetrahydro-1H	I
-	I
pyrazino	I
[	I
1,2-a	I
]	I
indol-2-yl	I
)	I
-cyclobutanone	I
;	O
treating	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O
,	O
damage	O
to	O
the	O
central	O
nervous	O
system	O
,	O
cardiovascular	O
disorders	O
,	O
gastrointestinal	O
disorders	O
,	O
diabetes	O
insipidus	O
,	O
obesity	O
and	O
sleep	O
apnea	O

Compounds	O
represented	O
by	O
the	O
following	O
general	O
formula	O
:	O
[	O
wherein	O
X1	O
,	O
X2	O
,	O
X3	O
and	O
X4	O
each	O
independently	O
represent	O
a	O
single	O
bond	O
,	O
C1	O
-	O
6	O
alkylene	O
,	O
etc	O
.	O
;	O
A2	O
represents	O
optionally	O
substituted	O
phenyl	O
,	O
etc	O
.	O
;	O
A1	O
represents	O
an	O
optionally	O
substituted	O
5-	O
to	O
7-membered	O
heterocyclic	O
group	O
containing	O
—C	O
(	O
=Q1	O
)	O
-	O
(	O
wherein	O
Q1	O
represents	O
oxygen	O
,	O
sulfur	O
or	O
═	O
N	O
—	O
R11	O
(	O
wherein	O
R11	O
represents	O
hydrogen	O
or	O
C1	O
-	O
6	O
alkyl	O
)	O
)	O
and	O
nitrogen	O
,	O
etc	O
.	O
;	O
and	O
Z1	O
represents	O
piperidin	O
-	O
diyl	O
,	O
etc	O
.	O
]	O
,	O
salts	O
thereof	O
and	O
hydrates	O
of	O
the	O
foregoing	O
.	O

For	O
example	O
,	O
6-	O
[	O
2-	O
[	O
4-	O
(	O
2-fluorophenoxymethyl	O
)	O
piperidino	O
]	O
ethyl	O
]	O
-1H	O
-	O
pyrazin-2-one	O
;	O
therapeutic	O
or	O
prophylactic	O
agent	O
for	O
diabetic	O
neuralgia	O
,	O
HIV	O
neuralgia	O
,	O
postherpetic	O
neuralgia	O
,	O
nerve	O
system	O
disorders	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
n	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R7	O
are	O
disclosed	O
herein	O
,	O
are	O
useful	O
in	O
treating	O
disease	O
-	O
states	O
associated	O
with	O
nuclear	O
receptor	O
activity	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
and	O
methods	O
of	O
using	O
said	O
compounds	O
are	O
also	O
disclosed	O
herein	O
.	O

For	O
therapy	O
of	O
disease	O
-	O
states	O
associated	O
with	O
nuclear	O
receptor	O
activity	O

An	O
extract	O
of	O
the	O
Minari	O
plant	O
containing	O
a	O
component	O
which	O
prevents	O
cancer	O
and	O
cancer	O
metastasis	O
.	O

A	O
Minari	O
extract	O
which	O
is	O
useful	O
for	O
the	O
prevention	O
of	O
cancer	O
and	O
cancer	O
metastasis	O
induced	O
by	O
urethane	B
(	O
EC	B
(	O
ethylcarbamate	B
)	O
)	O
,	O
which	O
is	O
a	O
carcinogen	O
present	O
in	O
fermented	O
foods	O
or	O
alcoholic	O
beverages	O
,	O
or	O
by	O
NNK	B
[	O
{	O
(	B
4-N	I
-	I
methyl	I
-	I
N	I
-	I
nitrosoamino	I
)	I
-1-	I
(	I
3-pyridyl	I
)	I
-1-buta	I
none	I
)	I
}	O
]	O
,	O
which	O
is	O
a	O
carcinogen	O
present	O
in	O
cigarette	O
smoke	O
.	O

Minari	O
extract	O
for	O
preventing	O
the	O
induction	O
and	O
metastasis	O
of	O
cancer	O
by	O
carcinogens	O
contained	O
in	O
cigarette	O
smoke	O
,	O
fermented	O
foods	O
or	O
alcoholic	O
drinks	O

Substituted	O
phenylpiperidines	B
and	O
phenylpyrrolidines	B
of	O
formula	O
(	O
I	O
)	O
,	O
compositions	O
containing	O
them	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
them	O
to	O
treat	O
histamine	B
-	O
mediated	O
conditions	O
.	O

Phenylpiperidines	B
and	O
phenylpyrrolidines	B

Preparation	O
of	O
(	B
S	I
)	I
-2-	I
[	I
[	I
3-	I
[	I
N-	I
[	I
4-	I
[	I
(	I
4-fluorophenoxy	I
)	I
phenyl	I
]	I
methyl	I
]	I
carbamoyl	I
]	I
-4-methoxyphenyl	I
]	I
methyl	I
]	I
butanoic	I
acid	I
(	O
referred	O
to	O
as	O
compound	O
(	O
I	O
)	O
)	O
on	O
an	O
industrial	O
scale	O
lies	O
in	O
the	O
finding	O
of	O
crystals	O
homogeneous	O
and	O
excellent	O
in	O
the	O
stability	O
and	O
the	O
establishment	O
of	O
a	O
preparative	O
process	O
thereof	O
.	O

Novel	O
crystals	O
of	O
compound	O
(	O
I	O
)	O
homogeneous	O
and	O
excellent	O
in	O
the	O
stability	O
characterized	O
by	O
exhibiting	O
the	O
diffraction	O
angles	O
(	O
2θ	O
)	O
at	O
at	O
least	O
17.7	O
°	O
,	O
19.0	O
°	O
and	O
24.1	O
°	O
in	O
the	O
X	O
-	O
ray	O
powder	O
diffraction	O
are	O
provided	O
by	O
recrystallizing	O
from	O
an	O
alcoholic	O
solvent	O
and	O
purifying	O
by	O
acid	O
-	O
base	O
treatment	O
.	O

Stable	O
crystals	O
of	O
substituted	O
phenylpropionic	B
acid	I
derivative	O
and	O
process	O
for	O
producing	O
the	O
same	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
;	O
pharmaceutically	O
acceptable	O
salts	O
and	O
N	B
-	I
oxides	I
thereof	O
in	O
which	O
A	O
,	O
B	O
,	O
D	O
and	O
E	O
are	O
C	B
or	O
N	B
with	O
the	O
proviso	O
that	O
one	O
or	O
more	O
are	O
N	B
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
simple	O
substituents	O
,	O
n	O
is	O
0	O
-	O
3	O
and	O
y	O
is	O
an	O
aryl	B
,	O
heteroaryl	B
,	O
carbocyclyl	B
or	O
fused	B
-	I
carbocyclyl	I
group	O
;	O
as	O
VR-1	O
antagonists	O
for	O
treating	O
conditions	O
or	O
diseases	O
in	O
which	O
pain	O
and/or	O
inflammation	O
predominates	O
;	O
the	O
use	O
of	O
the	O
same	O
for	O
manufacturing	O
medicaments	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
methods	O
of	O
treatment	O
utilizing	O
them	O
e.g.	O
N	B
-	I
Benzyl	I
-	I
N'-isoquinolin-5-ylurea	I
;	O
treatment	O
of	O
pain	O
and	O
other	O
conditions	O
ameliorated	O
by	O
the	O
modulation	O
of	O
the	O
function	O
of	O
the	O
vanilloid-1	O
receptor	O
(	O
VR1	O
)	O

A	O
process	O
for	O
the	O
preparation	O
of	O
L	B
-	I
ribavirin	I
on	O
an	O
industrial	O
scale	O
is	O
described	O
which	O
comprises	O
the	O
reaction	O
of	O
glycosylation	O
of	O
3-substituted	B
triazoles	I
in	O
the	O
presence	O
of	O
a	O
Lewis	B
acid	I
.	O

Said	O
process	O
comprises	O
:	O
a	O
)	O
the	O
reaction	O
of	O
a	O
triazole	B
of	O
the	O
formula	O
with	O
a	O
protected	O
ribofuranose	B
of	O
the	O
formula	O
(	O
II	O
)	O
b	O
)	O
the	O
removal	O
of	O
the	O
Pg	O
groups	O
and	O
,	O
optionally	O
,	O
the	O
conversion	O
into	O
a	O
carboxyamide	B
group	O
of	O
the	O
R2	O
group	O
of	O
the	O
compound	O
obtained	O
of	O
the	O
formula	O
(	O
III	O
)	O
Process	O
for	O
the	O
preparation	O
of	O
L	B
-	I
ribavirin	I

Pharmaceutical	O
compositions	O
containing	O
plant	O
essential	O
oils	O
,	O
natural	O
or	O
synthetic	O
,	O
or	O
mixtures	O
or	O
derivatives	O
thereof	O
,	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
soft	O
tissue	O
cancer	O
in	O
mammals	O
.	O

Breast	O
cancer	O
;	O
therapy	O
containing	O
plant	O
extracts	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
AA	O
)	O
(	O
I	O
)	O
and	O
(	O
X	O
)	O
:	O
useful	O
in	O
treating	O
Alzheimer	O
's	O
disease	O
and	O
other	O
similar	O
diseases	O
.	O

These	O
compounds	O
include	O
inhibitors	O
of	O
the	O
beta	O
-	O
secretase	O
enzyme	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
other	O
diseases	O
characterized	O
by	O
deposition	O
of	O
A	O
beta	O
peptide	O
in	O
a	O
mammal	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
to	O
reduce	O
A	O
beta	O
peptide	O
formation	O
.	O

1,3-Diamino-2-hydroxypropane	B
pro	O
-	O
drug	O
derivatives	O

The	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
wherein	O
R1	O
to	O
R4	O
and	O
n	O
have	O
any	O
of	O
the	O
meanings	O
defined	O
in	O
the	O
specification	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
I	O
,	O
processes	O
for	O
preparing	O
compounds	O
of	O
formula	O
I	O
,	O
intermediates	O
useful	O
for	O
preparing	O
compounds	O
of	O
formula	O
I	O
,	O
and	O
therapeutic	O
methods	O
for	O
treating	O
pain	O
and	O
treating	O
other	O
conditions	O
which	O
involve	O
,	O
for	O
example	O
,	O
binding	O
opioid	O
receptors	O
using	O
compounds	O
of	O
formula	O
I.	O
N3-	B
(	I
hydroxy-	I
or	I
alkoxyphenyl	I
)	I
amidrazone	I
,	O
e.g.	O
,	O
N3-	B
[	I
3-Methoxyphenyl	I
]	I
-p	I
-	I
tert	I
-	I
butyl	I
-	I
benzamidrazone	I
,	O
are	O
intermediates	O
for	O
preparing	O
phenyl-1,2,4-triazoles	B
,	O
e.g.	O
,	O
1-	B
{	I
3-	I
[	I
4-	I
(	I
tert	I
-	I
Butyl	I
)	I
phenyl	I
]	I
-	I
(	I
1,2,4-triazol-4-yl	I
)	I
}	I
-3-methoxybenzene	I

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
which	O
are	O
useful	O
for	O
elevating	O
the	O
plasma	O
level	O
of	O
growth	O
hormone	O
in	O
a	O
mammal	O
as	O
well	O
as	O
for	O
the	O
treatment	O
of	O
growth	O
hormone	O
secretion	O
deficiency	O
,	O
growth	O
retardation	O
in	O
child	O
and	O
metabolic	O
disorders	O
associated	O
with	O
growth	O
hormone	O
secretion	O
deficiency	O
.	O

For	O
use	O
in	O
therapy	O
of	O
growth	O
metabolic	O
disorders	O

This	O
invention	O
relates	O
to	O
a	O
novel	O
crystalline	O
diphosphate	B
salt	O
of	O
(	B
2R,3S,4R,5R,8R,10R,11R,12S,13S,14R	I
)	I
-13-	I
[	I
[	I
2,6-dideoxy-3-C	I
-	I
methyl-3-O	I
-	I
methyl-4-C-	I
[	I
(	I
propylamino	I
)	I
methyl	I
]	I
-α	I
-	I
L	I
-	I
ribo	I
-	I
hexopryanosyl	I
]	I
oxy	I
]	I
-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-	I
[	I
[	I
3,4,6-trideoxy-3-	I
(	I
dimethylamino	I
)	I
-β	I
-	I
D	I
-	I
xylo	I
-	I
hexopyranosyl	I
]	I
oxy	I
]	I
-1-oxa-6-azacyclopentadecan-15-one	I
that	O
is	O
useful	O
as	O
an	O
antibacterial	O
and	O
antiprotozoal	O
agent	O
in	O
mammals	O
.	O

This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
free	O
base	O
of	O
the	O
diphosphate	B
salt	O
and	O
the	O
methods	O
of	O
treating	O
bacterial	O
and	O
protozoal	O
infections	O
in	O
mammals	O
by	O
administering	O
the	O
free	O
base	O
of	O
the	O
diphosphate	B
to	O
mammals	O
requiring	O
such	O
treatment	O
.	O

The	O
free	O
base	O
of	O
the	O
diphosphate	B
salt	O
of	O
the	O
present	O
invention	O
possesses	O
potent	O
activity	O
against	O
various	O
bacterial	O
and	O
protozoal	O
infections	O
when	O
given	O
by	O
parenteral	O
application	O
to	O
mammals	O
.	O

liquid	O
crystal	O
diphosphate	B
polymorph	O
;	O
antibacterial	O
and	O
antiprotozoal	O
agents	O

Compounds	O
having	O
the	O
general	O
structure	O
and	O
compositions	O
containing	O
them	O
,	O
for	O
the	O
treatment	O
of	O
acute	O
,	O
inflammatory	O
and	O
neuropathic	O
pain	O
,	O
dental	O
pain	O
,	O
general	O
headache	O
,	O
migraine	O
,	O
cluster	O
headache	O
,	O
mixed	O
-	O
vascular	O
and	O
non	O
-	O
vascular	O
syndromes	O
,	O
tension	O
headache	O
,	O
general	O
inflammation	O
,	O
arthritis	O
,	O
rheumatic	O
diseases	O
,	O
osteoarthritis	O
,	O
inflammatory	O
bowel	O
disorders	O
,	O
inflammatory	O
eye	O
disorders	O
,	O
inflammatory	O
or	O
unstable	O
bladder	O
disorders	O
,	O
psoriasis	O
,	O
skin	O
complaints	O
with	O
inflammatory	O
components	O
,	O
chronic	O
inflammatory	O
conditions	O
,	O
inflammatory	O
pain	O
and	O
associated	O
hyperalgesia	O
and	O
allodynia	O
,	O
neuropathic	O
pain	O
and	O
associated	O
hyperalgesia	O
and	O
allodynia	O
,	O
diabetic	O
neuropathy	O
pain	O
,	O
causalgia	O
,	O
sympathetically	O
maintained	O
pain	O
,	O
deafferentation	O
syndromes	O
,	O
asthma	O
,	O
epithelial	O
tissue	O
damage	O
or	O
dysfunction	O
,	O
herpes	O
simplex	O
,	O
disturbances	O
of	O
visceral	O
motility	O
at	O
respiratory	O
,	O
genitourinary	O
,	O
gastrointestinal	O
or	O
vascular	O
regions	O
,	O
wounds	O
,	O
burns	O
,	O
allergic	O
skin	O
reactions	O
,	O
pruritus	O
,	O
vitiligo	O
,	O
general	O
gastrointestinal	O
disorders	O
,	O
gastric	O
ulceration	O
,	O
duodenal	O
ulcers	O
,	O
diarrhea	O
,	O
gastric	O
lesions	O
induced	O
by	O
necrotising	O
agents	O
,	O
hair	O
growth	O
,	O
vasomotor	O
or	O
allergic	O
rhinitis	O
,	O
bronchial	O
disorders	O
or	O
bladder	O
disorders	O
.	O

N-	B
(	I
2-	I
(	I
6	I
-	I
7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-ylamino	I
)	I
pyrimidin-4-yl	I
)	I
-5-	I
(	I
trifluoromethyl	I
)	I
phenyl	I
)	I
-1-isopropylpyrrolidine-2-carboxamide	I
hydrochloride	I
;	O
antiinflammatory	O
agents	O
,	O
analgesics	O
,	O
antiarthritic	O
agents	O
,	O
antiulcer	O
agents	O

The	O
present	O
invention	O
is	O
directed	O
towards	O
novel	O
cyclic	B
phosph	I
(	I
oramid	I
)	I
ate	I
prodrugs	O
of	O
alcohol-	B
,	O
amine-	B
,	O
and	O
thiol	B
-	O
containing	O
drugs	O
,	O
their	O
preparation	O
,	O
their	O
synthetic	O
intermediates	O
,	O
and	O
their	O
uses	O
.	O

Another	O
aspect	O
of	O
the	O
invention	O
is	O
the	O
use	O
of	O
the	O
prodrugs	O
to	O
treat	O
diseases	O
that	O
benefit	O
from	O
enhanced	O
drug	O
distribution	O
to	O
the	O
liver	O
and	O
like	O
tissues	O
and	O
cells	O
that	O
express	O
cytochrome	O
P450	O
,	O
including	O
hepatitis	O
,	O
cancer	O
,	O
liver	O
fibrosis	O
,	O
malaria	O
,	O
other	O
viral	O
and	O
parasitic	O
infections	O
,	O
and	O
metabolic	O
diseases	O
where	O
the	O
liver	O
is	O
responsible	O
for	O
the	O
overproduction	O
of	O
the	O
biochemical	O
end	O
product	O
,	O
e.g.	O
glucose	B
(	O
diabetes	O
)	O
;	O
cholesterol	B
,	O
fatty	B
acids	I
and	O
triglycerides	B
(	O
hyperlipidemia	O
)	O
(	O
atherosclerosis	O
)	O
(	O
obesity	O
)	O
.	O

In	O
one	O
aspect	O
,	O
the	O
invention	O
is	O
directed	O
towards	O
the	O
use	O
of	O
the	O
prodrugs	O
to	O
enhance	O
oral	O
drug	O
delivery	O
.	O

In	O
another	O
aspect	O
,	O
the	O
prodrugs	O
are	O
used	O
to	O
prolong	O
pharmacodynamic	O
half	O
-	O
life	O
of	O
the	O
drug	O
.	O

In	O
addition	O
,	O
the	O
prodrug	O
methodology	O
of	O
the	O
current	O
invention	O
is	O
used	O
to	O
achieve	O
sustained	O
delivery	O
of	O
the	O
parent	O
drug	O
.	O

In	O
another	O
aspect	O
,	O
the	O
prodrugs	O
are	O
used	O
to	O
increase	O
the	O
therapeutic	O
index	O
of	O
the	O
drug	O
.	O

In	O
another	O
aspect	O
of	O
the	O
invention	O
,	O
a	O
method	O
of	O
making	O
these	O
prodrugs	O
is	O
described	O
.	O

In	O
another	O
aspect	O
,	O
the	O
prodrugs	O
are	O
also	O
useful	O
in	O
the	O
delivery	O
of	O
diagnostic	O
imaging	O
agents	O
to	O
the	O
liver	O
.	O

Cyclic	B
phosph	I
(	I
oramid	I
)	I
ate	I
prodrugs	O
having	O
alcohol	B
,	O
amine	B
,	O
orthiol	O
groups	O
attached	O
to	O
phosphorus	B
;	O
camptothecins	B
;	O
pharmacodynamic	O
half	O
-	O
life	O
;	O
diagnostic	O
imaging	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
represented	O
by	O
the	O
structural	O
Formula	O
I	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
which	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
and	O
eating	O
disorders	O
such	O
as	O
obesity	O
and	O
hyperphagia	O
,	O
and	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
associated	O
disorders	O
.	O

Piperidinyl-	B
and	I
pyrimidinyl	I
-	I
ureas	I
:	O
N-	B
(	I
1-acetyl-4-piperidinyl	I
)	I
-N	I
-	I
methyl	I
-	I
N'-	I
(	I
5-	I
(	I
3,5-difluorophenyl	I
)	I
-2-pyrimidinyl	I
)	I
urea	I
;	O
metabolic	O
disorders	O
,	O
eating	O
disorders	O
,	O
disorders	O
associated	O
with	O
obesity	O
:	O
type	O
II	O
diabetes	O
,	O
insulin	O
resistance	O
,	O
hyperlipidemia	O
or	O
hypertension	O
.	O

The	O
present	O
invention	O
provides	O
a	O
stabilized	O
pharmaceutical	O
preparation	O
of	O
a	O
4-amino-3-substituted	B
-	I
butanoic	I
acid	I
derivative	O
which	O
can	O
be	O
obtained	O
by	O
incorporating	O
an	O
amino	B
acid	I
as	O
a	O
stabilizer	O
.	O

Stabilized	O
pharmaceutical	O
preparation	O
of	O
gamma	B
-	I
aminobutyric	I
acid	I
derivatives	O
and	O
process	O
for	O
preparing	O
the	O
same	O

Compounds	O
having	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R3	O
is	O
selected	O
from	O
H	B
,	O
OH	B
and	O
NH2	B
;	O
R30	O
is	O
selected	O
from	O
═	B
O	I
and	O
═	B
S	I
;	O
W	O
is	O
—C	B
(	I
═	I
O	I
)	I
—	I
,	O
—S	B
(	I
═	I
O	I
)	I
—	I
,	O
or	O
—S	B
(	I
O	I
)	I
2—	I
;	O
or	O
W	O
may	O
be	O
—CH2—	B
if	O
X	O
is	O
—C	B
(	I
═	I
O	I
)	I
—	I
;	O
X	O
is	O
selected	O
from	O
—CH2—	B
,	O
—N	B
(	I
R4	I
)	I
—	I
,	O
and	O
—O—	B
,	O
except	O
that	O
when	O
W	O
is	O
—CH2—	B
,	O
X	O
is	O
—C	B
(	I
═	I
O	I
)	I
—	I
;	O
Y	O
is	O
a	O
bond	O
or	O
—C	B
(	I
R40	I
)	I
(	I
R45	I
)	I
—	I
;	O
Q	O
is	O
a	O
linker	O
;	O
Z	O
is	O
optionally	O
substituted	O
alkyl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
cycloalkyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
or	O
heterocyclyl	B
;	O
and	O
R1	O
,	O
R2	O
,	O
R24	O
,	O
and	O
R25	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

An	O
immunosuppressants	O
for	O
treating	O
allograft	O
rejection	O
,	O
transplant	O
rejection	O
,	O
psoriasis	O
,	O
and	O
rheumatoid	O
arthritis	O
,	O
a	O
9,10-dihydro-9-oxo	B
-	I
acridine-3-yl-	I
derivatives	O

A	O
compound	O
or	O
a	O
salt	O
thereof	O
having	O
the	O
atom	O
corresponding	O
to	O
N3	O
and	O
the	O
two	O
or	O
more	O
atoms	O
selected	O
from	O
N1	O
,	O
N2	O
,	O
N4	O
and	O
N5	O
,	O
said	O
atoms	O
constitute	O
the	O
pharmacophore	O
represented	O
by	O
the	O
following	O
formula	O
:	O
and	O
inhibits	O
the	O
activity	O
of	O
transcription	O
factor	O
AP-1	O
and	O
is	O
useful	O
as	O
an	O
agent	O
for	O
preventing	O
and	O
treating	O
the	O
diseases	O
into	O
which	O
over	O
expression	O
of	O
AP-1	O
participates	O
and	O
as	O
an	O
AP-1	O
inhibitor	O
.	O

2-	B
{	I
5-	I
[	I
(	I
2,4-diisobutoxyphenyl	I
)	I
(	I
hydroxy	I
)	I
methyl	I
]	I
-2-isobutoxyphenyl	I
}	I
-acetic	I
acid	I
;	O
inhibits	O
the	O
activity	O
of	O
transcription	O
factor	O
AP-1	O

The	O
use	O
of	O
adenosine-5′-triphosphate-2′,3′-dialdehyde	B
(	O
oATP	B
)	O
as	O
a	O
medicament	O
useful	O
for	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O
is	O
disclosed	O
.	O

The	O
use	O
of	O
adenosine-5'-triphosphate-2',3'-dialdehyde	B
(	O
oATP	B
)	O
as	O
a	O
medicament	O
useful	O
for	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O

Fluoro	O
substituted	O
cycloalkanoindole	B
derivatives	O
are	O
antagonists	O
of	O
prostaglandins	B
,	O
and	O
as	O
such	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
prostaglandin	B
mediated	O
diseases	O
.	O

Prostaglandins	B
for	O
prostaglandin	B
mediated	O
diseases	O
such	O
as	O
antihistamines	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
treatment	O
or	O
prevention	O
of	O
neoplasia	O
disorders	O
using	O
protein	O
tyrosine	B
kinase	O
inhibitors	O
of	O
the	O
formula	O
I	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
and	O
R7	O
are	O
defined	O
herein	O
,	O
in	O
combination	O
with	O
cyclooxygenase	O
inhibitors	O
,	O
in	O
particular	O
cyclooxygenase-2	O
selective	O
inhibitors	O
.	O

Administering	O
to	O
a	O
cancer	O
patient	O
an	O
indole-2-one	B
derivative	O
containing	O
pyrrole	B
ring	O
as	O
protein	O
kinase	O
inhibitor	O
together	O
with	O
a	O
cyclooxygenase	O
inhibitor	O
to	O
treat	O
the	O
cancer	O

The	O
invention	O
relates	O
to	O
new	O
4-amino-5-phenyl-7-cyclobutyl	O
-	O
pyrrolo	O
[	O
2,3-d	O
]	O
pyrimidine	O
derivatives	O
,	O
processes	O
for	O
the	O
preparation	O
thereof	O
,	O
the	O
application	O
thereof	O
in	O
a	O
process	O
for	O
the	O
treatment	O
of	O
the	O
human	O
or	O
animal	O
body	O
,	O
the	O
use	O
thereof	O
-	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds	O
-	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
,	O
especially	O
a	O
proliferative	O
disease	O
,	O
such	O
as	O
a	O
tumour	O
disease	O
,	O
a	O
method	O
for	O
the	O
treatment	O
of	O
such	O
diseases	O
in	O
mammals	O
,	O
especially	O
in	O
humans	O
,	O
and	O
the	O
use	O
of	O
such	O
a	O
compound	O
-	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds	O
-	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
(	O
medicament	O
)	O
for	O
the	O
treatment	O
especially	O
of	O
a	O
proliferative	O
disease	O
,	O
such	O
as	O
a	O
tumour	O
.	O

4-Amino-5-phenyl-7-cyclobutyl	O
-	O
pyrrolo	O
(	O
2,3-d	O
)	O
pyrimidine	O
derivatives	O

Pyridin	B
[	I
1,2-a	I
]	I
pyrimidinyl	I
compounds	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
and	O
prodrugs	O
thereof	O
;	O
compositions	O
that	O
include	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
one	O
or	O
more	O
of	O
the	O
pyridino	B
[	I
1,2-a	I
]	I
pyrimidinyl	I
compounds	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
therapeutic	O
agent	O
.	O

Methods	O
of	O
using	O
the	O
pyridino	B
[	I
1,2-a	I
]	I
pyrimidinyl	I
compounds	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
therapeutic	O
agent	O
,	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
proliferative	O
diseases	O
.	O

Antiproliferative	O
agents	O
for	O
humans	O
,	O
animals	O

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R11	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
are	O
novel	O
effective	O
iNOS	O
inhibitors	O
.	O

2-	B
[	I
3-	I
(	I
4-Methoxypyridin-2-yl	I
)	I
prop-2-yl	I
]	I
-3H	I
-	I
imidazo	I
[	I
4,5-b	I
]	I
pyridine	I
hydrochloride	I
;	O
transcriptional	O
activation	O
of	O
the	O
iNOS	O
-	O
promoter	O
,	O
tissue	O
and	O
organ	O
damage	O
,	O
cytotoxicity	O
reduction	O

The	O
invention	O
provides	O
a	O
method	O
of	O
increasing	O
expression	O
of	O
p21WAF1	O
/	O
Cip	O
1	O
in	O
cells	O
to	O
decrease	O
proliferation	O
of	O
the	O
cells	O
,	O
the	O
method	O
comprising	O
decreasing	O
levels	O
of	O
PP5	O
protein	O
in	O
the	O
cells	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
an	O
abnormal	O
condition	O
resulting	O
from	O
a	O
defect	O
in	O
a	O
tumor	O
suppressor	O
gene	O
in	O
a	O
subject	O
that	O
results	O
in	O
decreased	O
induction	O
of	O
p21WAF1	O
/	O
Cip	O
1	O
in	O
the	O
cells	O
of	O
the	O
subject	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
amount	O
of	O
a	O
compound	O
effective	O
to	O
decrease	O
levels	O
of	O
PP5	O
protein	O
in	O
the	O
cells	O
of	O
the	O
subject	O
.	O

Increasing	O
expression	O
of	O
p21WAF1	O
/	O
Cip	O
1	O
in	O
cells	O
to	O
decrease	O
proliferation	O
of	O
the	O
cells	O
by	O
decreasing	O
levels	O
of	O
PP5	O
protein	O
in	O
the	O
cells	O
.	O

Disclosed	O
are	O
novel	O
tricyclic	O
compounds	O
represented	O
by	O
the	O
formula	O
(	O
1.0	O
)	O
:	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
inhibiting	O
farnesyl	O
protein	O
transferase	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
formula	O
1.0	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
cancer	O
using	O
the	O
compounds	O
of	O
formula	O
1.0	O
.	O

Benzo	B
(	I
5,6	I
)	I
cyclohepta	I
(	I
1,2-b	I
)	I
pyridine	I
derivatives	O
;	O
use	O
in	O
combination	O
with	O
antineoplastic	O
agents	O
such	O
as	O
cisplatin	B

The	O
present	O
invention	O
relates	O
to	O
a	O
double	O
-	O
stranded	O
ribonucleic	O
acid	O
(	O
dsRNA	O
)	O
having	O
a	O
nucleotide	O
sequence	O
which	O
is	O
less	O
that	O
30	O
nucleotides	O
in	O
length	O
and	O
which	O
is	O
substantially	O
identical	O
to	O
at	O
least	O
a	O
part	O
of	O
a	O
3′-untranslated	O
region	O
(	O
3′-UTR	O
)	O
of	O
a	O
(	O
+	O
)	O
strand	O
RNA	O
virus	O
,	O
such	O
as	O
HCV	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
the	O
dsRNA	O
,	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
pharmaceutical	O
compositions	O
are	O
useful	O
for	O
treating	O
infections	O
and	O
diseases	O
caused	O
by	O
the	O
replication	O
or	O
activity	O
of	O
the	O
(	O
+	O
)	O
strand	O
RNA	O
virus	O
,	O
as	O
well	O
as	O
methods	O
for	O
inhibiting	O
viral	O
replication	O
.	O

Double	O
-	O
stranded	O
ribonucleic	O
acid	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
antiobesity	O
and	O
hypocholesterolemic	O
compounds	O
,	O
their	O
derivatives	O
,	O
their	O
analogs	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
polymorphs	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
novel	O
β	B
-	I
aryl	I
-	I
α	I
-	I
oxysubstituted	I
alkylcarboxylic	I
acids	I
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
their	O
analogs	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
polymorphs	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
Substituted	B
bicyclic	I
heterocycles	I
,	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
antiobesity	O
and	O
hypocholesterolemic	O
agents	O

A	O
formulation	O
is	O
disclosed	O
for	O
the	O
treatment	O
of	O
diseases	O
caused	O
by	O
an	O
infectious	O
agent	O
which	O
acquires	O
host	O
membranes	O
protein	O
during	O
its	O
life	O
cycle	O
.	O

The	O
formulation	O
is	O
a	O
targeting	O
pharmaceutical	O
composition	O
.	O

It	O
comprises	O
a	O
ligand	O
capable	O
of	O
binding	O
the	O
host	O
membrane	O
proteins	O
coupled	O
to	O
a	O
lipid	O
-	O
comprising	O
vesicle	O
,	O
which	O
may	O
comprise	O
or	O
not	O
a	O
drug	O
effective	O
in	O
the	O
treatment	O
of	O
the	O
disease	O
.	O

Specific	O
liposomes	O
bearing	O
anti	O
-	O
HLA	O
-	O
DR	O
or	O
anti	O
-	O
CD4	O
antibodies	O
comprising	O
or	O
not	O
antiviral	O
drugs	O
,	O
namely	O
anti	O
-	O
HIV	O
drugs	O
,	O
are	O
disclosed	O
and	O
claimed	O
.	O

A	O
method	O
of	O
formulation	O
as	O
well	O
as	O
a	O
method	O
of	O
using	O
the	O
formulation	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
are	O
also	O
disclosed	O
.	O

Methods	O
and	O
formulations	O
for	O
targeting	O
infectious	O
agents	O
bearing	O
host	O
cell	O
proteins	O

Compounds	O
having	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
A	O
represents	O
a	O
group	O
such	O
as	O
a	O
cyclic	O
group	O
,	O
R1	O
and	O
R2	O
represent	O
groups	O
such	O
as	O
alkyl	B
groups	O
or	O
hydroxymethyl	B
groups	O
,	O
and	O
n	O
represents	O
1	O
or	O
2	O
,	O
or	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
or	O
pharmacologically	O
acceptable	O
esters	B
thereof	O
have	O
superior	O
activity	O
and	O
stability	O
,	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diabetes	O
mellitus	O
,	O
or	O
the	O
like	O
.	O

Oligosaccharide	B
derivative	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
the	O
formula	O
I	O
wherein	O
J1	O
,	O
J2	O
,	O
R0	O
,	O
R1	O
,	O
R2	O
,	O
Q	O
,	O
V	O
,	O
G	O
and	O
M	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compounds	O
of	O
the	O
formula	O
I	O
are	O
valuable	O
pharmacologically	O
active	O
compounds	O
.	O

They	O
exhibit	O
a	O
strong	O
antithrombotic	O
effect	O
and	O
are	O
suitable	O
,	O
for	O
example	O
,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
cardiovascular	O
disorders	O
like	O
thromboembolic	O
diseases	O
or	O
restenoses	O
.	O

They	O
are	O
reversible	O
inhibitors	O
of	O
the	O
blood	O
clotting	O
enzymes	O
factor	O
Xa	O
(	O
FXa	O
)	O
and/or	O
factor	O
VIIa	O
(	O
FVIIa	O
)	O
,	O
and	O
can	O
in	O
general	O
be	O
applied	O
in	O
conditions	O
in	O
which	O
an	O
undesired	O
activity	O
of	O
factor	O
Xa	O
and/or	O
factor	O
VIIa	O
is	O
present	O
or	O
for	O
the	O
cure	O
or	O
prevention	O
of	O
which	O
an	O
inhibition	O
of	O
factor	O
Xa	O
and/or	O
factor	O
VIIa	O
is	O
intended	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
formula	O
I	O
,	O
their	O
use	O
,	O
in	O
particular	O
as	O
active	O
ingredients	O
in	O
pharmaceuticals	O
,	O
and	O
pharmaceutical	O
preparations	O
comprising	O
them	O
.	O

Indazole	B
-	O
derivatives	O
as	O
factor	O
Xa	O
inhibitors	O

The	O
present	O
invention	O
provides	O
compounds	O
represented	O
by	O
the	O
structural	O
formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
isomers	O
,	O
salts	O
,	O
solvates	O
or	O
esters	O
of	O
the	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
each	O
of	O
the	O
substituents	O
is	O
as	O
specified	O
herein	O
,	O
formulations	O
iucluding	O
the	O
above	O
compounds	O
,	O
processes	O
for	O
preparing	O
the	O
same	O
and	O
methods	O
for	O
treating	O
vascular	O
conditions	O
,	O
such	O
as	O
atherosclerosis	O
or	O
hypercholesterolemia	O
,	O
diabetes	O
,	O
obesity	O
,	O
stroke	O
,	O
demyelination	O
and	O
lowering	O
plasma	O
levels	O
of	O
sterols	O
and/or	O
stanols	O
.	O

Treatment	O
of	O
atherosclerosis	O
,	O
hypercholesterolemia	O
diabetes	O
,	O
obesity	O
,	O
stroke	O
,	O
alzheimer	O
's	O
,	O
demyelination	O
and	O
lowering	O
plasma	O
levels	O
of	O
sterols	O

Use	O
for	O
the	O
diabetes	O
treatment	O
of	O
compounds	O
or	O
salts	O
thereof	O
,	O
having	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
:	O
A-	B
(	I
B	I
)	I
b0—	I
(	I
C	I
)	I
c0—NO2	I
wherein	O
A	O
contains	O
the	O
radical	O
of	O
a	O
drug	O
having	O
an	O
antiinflammatory	O
or	O
analgesic	O
activity	O
,	O
B	O
is	O
a	O
bivalent	O
linking	O
group	O
wherein	O
the	O
precursor	O
must	O
meet	O
the	O
tests	O
described	O
in	O
the	O
application	O
,	O
C	O
is	O
a	O
a	O
bivalent	O
linking	O
group	O
as	O
defined	O
in	O
the	O
invention	O
.	O

Use	O
for	O
the	O
diabetes	O
treatment	O
of	O
compounds	O
or	O
salts	O
thereof	O
,	O
having	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
:	O
A-	B
(	I
B	I
)	I
b0-	I
(	I
C	I
)	I
c0-NO2	I
wherein	O
A	O
contains	O
the	O
radical	O
of	O
a	O
drug	O
having	O
an	O
antiiflammatory	O
or	O
analgesic	O
activity	O
,	O
B	O
is	O
a	O
bivalen	O
:	O
linking	O

This	O
invention	O
provides	O
an	O
isolated	O
nucleic	O
acid	O
encoding	O
a	O
human	O
MCH1	O
receptor	O
,	O
a	O
purified	O
human	O
MCH1	O
receptor	O
,	O
vectors	O
comprising	O
isolated	O
nucleic	O
acid	O
encoding	O
a	O
human	O
MCH1	O
receptor	O
,	O
cells	O
comprising	O
such	O
vectors	O
,	O
antibodies	O
directed	O
to	O
a	O
human	O
MCH1	O
receptor	O
,	O
nucleic	O
acid	O
probes	O
useful	O
for	O
detecting	O
nucleic	O
acid	O
encoding	O
human	O
MCH1	O
receptors	O
,	O
antisense	O
oligonucleotides	B
complementary	O
to	O
unique	O
sequences	O
of	O
nucleic	O
acid	O
encoding	O
human	O
MCH1	O
receptors	O
,	O
transgenic	O
,	O
nonhuman	O
animals	O
which	O
express	O
DNA	O
encoding	O
a	O
normal	O
or	O
mutant	O
human	O
MCH1	O
receptor	O
,	O
methods	O
of	O
isolating	O
a	O
human	O
MCH1	O
receptor	O
,	O
methods	O
of	O
treating	O
an	O
abnormality	O
that	O
is	O
linked	O
to	O
the	O
activity	O
of	O
a	O
human	O
MCH1	O
receptor	O
,	O
as	O
well	O
as	O
methods	O
of	O
determining	O
binding	O
of	O
compounds	O
to	O
mammalian	O
MCH1	O
receptors	O
.	O

Nucleotide	O
sequences	O
coding	O
cyclic	O
peptide	O
receptor	O
for	O
use	O
in	O
identifying	O
modulators	O
for	O
treatment	O
of	O
pituitary	O
hormone	O
,	O
epinephrine	B
release	O
,	O
gastrointestinal	O
,	O
cardiovascular	O
,	O
electrolyte	O
balance	O
,	O
hypertensive	O
,	O
diabetic	O
and	O
respiratory	O
system	O
disorder	O

The	O
present	O
invention	O
provides	O
a	O
medical	O
device	O
,	O
preferably	O
a	O
contact	O
lens	O
,	O
which	O
comprises	O
an	O
antimicrobial	O
coating	O
including	O
at	O
least	O
one	O
layer	O
of	O
polyquat	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
.	O

The	O
antimicrobial	O
coating	O
on	O
the	O
medical	O
device	O
of	O
the	O
invention	O
has	O
a	O
high	O
antimicrobial	O
efficacy	O
against	O
microorganisms	O
including	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacterial	O
,	O
a	O
low	O
toxicity	O
,	O
low	O
coefficient	O
of	O
friction	O
,	O
and	O
increased	O
hydrophilicity	O
while	O
maintaining	O
the	O
desired	O
bulk	O
properties	O
such	O
as	O
oxygen	O
permeability	O
and	O
ion	O
permeability	O
of	O
lens	O
material	O
.	O

Such	O
lenses	O
are	O
useful	O
as	O
extended	O
-	O
wear	O
contact	O
lenses	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
a	O
method	O
for	O
making	O
a	O
medical	O
device	O
,	O
preferably	O
a	O
contact	O
lens	O
,	O
having	O
an	O
antimicrobial	O
coating	O
thereon	O
.	O

Medical	O
devices	O
having	O
antimicrobial	O
coatings	O
thereon	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treating	O
the	O
epithelial	O
toxicity	O
caused	O
by	O
administering	O
to	O
a	O
human	O
cancer	O
patient	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
inhibitor	O
.	O

The	O
pharmaceutical	O
composition	O
preferably	O
comprises	O
an	O
EGFR	O
inhibitor	O
and	O
a	O
keratinocyte	O
growth	O
factor	O
(	O
KGF	O
)	O
in	O
a	O
pharmaceutically	O
-	O
acceptable	O
carrier	O
.	O

The	O
method	O
of	O
treatment	O
comprises	O
co	O
-	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
KGF	O
with	O
the	O
EGFR	O
inhibitor	O
.	O

Reducing	O
epithelial	O
toxicity	O
such	O
as	O
a	O
skin	O
rash	O
or	O
diarrhea	O
during	O
cancer	O
therapy	O
,	O
by	O
coadministering	O
KGF	O
with	O
erlotinib	B
(	B
N-	I
(	I
3-ethynylphenylamino	I
)	I
-6,7-bis	I
(	I
2-methoxyethoxy	I
)	I
-4-quinazoline	I
amine	I
)	I

The	O
present	O
invention	O
concerns	O
compounds	O
of	O
formula	O
:	O
where	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
defined	O
in	O
the	O
specification	O
.	O

(	B
Diaryl	I
-	I
methyl	I
)	I
-malononitriles	I
and	O
their	O
use	O
as	O
estrogen	B
receptor	O
ligands	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
to	O
a	O
process	O
for	O
their	O
manufacture	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
to	O
their	O
use	O
in	O
therapy	O
,	O
in	O
particular	O
their	O
use	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
respiratory	O
diseases	O
.	O

Methods	O
using	O
phenethanolamine	B
derivatives	O
for	O
treatment	O
of	O
respiratory	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
heteroaromate	B
OSC	O
inhibitors	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
2,3-oxidosqualene	O
-	O
lanosterol	O
cyclase	O
such	O
as	O
hypercholesterolemia	O
,	O
hyperlipemia	O
,	O
arteriosclerosis	O
,	O
vascular	O
diseases	O
,	O
mycoses	O
,	O
gallstones	O
,	O
tumors	O
and/or	O
hyperproliferative	O
disorders	O
,	O
and	O
treatment	O
and/or	O
prophylaxis	O
of	O
impaired	O
glucose	O
tolerance	O
and	O
diabetes	O
.	O

e.g.	O
2-	B
(	I
Ethyl-	I
{	I
4-	I
[	I
2-methyl-3-	I
(	I
4-trifluoromethyl	I
-	I
phenyl	I
)	I
-benzo	I
[	I
b	I
]	I
thiophen-6-yl	I
]	I
-butyl	I
}	I
-amino	I
)	I
-ethanol	I
;	O
2,3-oxidosqualene	O
-	O
lanosterol	O
cyclase	O
inhibitor	O
;	O
antidiabetic	O
,	O
antitumor	O
,	O
antiproliferative	O
agent	O
;	O
hypercholesterolemia	O
,	O
hyperlipemia	O
,	O
arteriosclerosis	O
,	O
vascular	O
diseases	O
,	O
mycoses	O
,	O
gallstones	O

A	O
44-bp	O
region	O
that	O
confers	O
vitamin	B
D3-responsiveness	I
to	O
the	O
human	O
p27Kip1	O
promoter	O
in	O
the	O
human	O
p27Kip1	O
transcriptional	O
regulatory	O
mechanism	O
was	O
revealed	O
.	O

This	O
region	O
also	O
conferred	O
vitamin	B
D3-responsiveness	I
to	O
a	O
heterogenous	O
promoter	O
.	O

Moreover	O
,	O
it	O
was	O
found	O
that	O
vitamin	B
D3	I
enhances	O
the	O
binding	O
between	O
the	O
CCAAT	O
box	O
existing	O
in	O
the	O
region	O
and	O
the	O
NF	O
-	O
Y	O
protein	O
and	O
also	O
the	O
binding	O
between	O
the	O
Sp1	O
sequence	O
(	O
also	O
existing	O
in	O
the	O
region	O
)	O
and	O
the	O
Sp1	O
protein	O
,	O
thus	O
inducing	O
human	O
p27Kip1	O
transcription	O
.	O

Also	O
revealed	O
were	O
methods	O
of	O
screening	O
for	O
pharmaceutical	O
agents	O
that	O
regulate	O
the	O
expression	O
of	O
the	O
p27Kip1	O
gene	O
using	O
these	O
molecular	O
mechanisms	O
.	O

Vitamin	B
D3-responsive	I
sequences	O
located	O
5′-upstream	O
of	O
p27	O
/	O
kip	O
1	O
gene	O
and	O
methods	O
of	O
screening	O
for	O
pharmaceutical	O
agents	O
using	O
the	O
sequences	O

This	O
invention	O
pertains	O
to	O
certain	O
carbamic	B
acid	I
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
which	O
inhibit	O
HDAC	O
(	O
histone	O
deacetylase	O
)	O
activity	O
:	O
wherein	O
:	O
J	O
is	O
a	O
linking	O
functional	O
group	O
and	O
is	O
independently	O
:—	O
O	B
—C	I
(	I
═	I
O	I
)	I
—	I
or	O
—C	B
(	I
═	I
O	I
)	I
—O	I
—	I
or	O
—C	B
(	I
═	I
O	I
)	I
—	I
;	O
Cy	B
is	O
a	O
cyclyl	B
group	O
and	O
is	O
independently	O
:	O
C3	B
-	I
20carbocyclyl	I
,	O
C3	B
-	I
20heterocyclyl	I
,	O
or	O
C5	B
-	I
20aryl	I
;	O
and	O
is	O
optionally	O
substituted	O
;	O
Q1	O
is	O
a	O
cyclyl	B
leader	O
group	O
,	O
and	O
is	O
independently	O
a	O
divalent	O
bidentate	O
group	O
obtained	O
by	O
removing	O
two	O
hydrogen	B
atoms	O
from	O
a	O
ring	O
carbon	B
atom	O
of	O
a	O
saturated	O
monocyclic	O
hydrocarbon	B
having	O
from	O
4	O
to	O
7	O
ring	O
atoms	O
,	O
or	O
by	O
removing	O
two	O
hydrogen	B
atoms	O
from	O
a	O
ring	O
carbon	B
atom	O
of	O
saturated	O
monocyclic	B
heterocyclic	I
compound	O
having	O
from	O
4	O
to	O
7	O
ring	O
atoms	O
including	O
1	O
nitrogen	B
ring	O
atom	O
or	O
1	O
oxygen	B
ring	O
atom	O
;	O
and	O
is	O
optionally	O
substituted	O
;	O
Q2	O
is	O
an	O
acid	O
leader	O
group	O
,	O
and	O
is	O
independently	O
:	O
C1	B
-	I
8alkylene	I
;	O
and	O
is	O
optionally	O
substituted	O
;	O
or	O
:	O
Q2	O
is	O
an	O
acid	O
leader	O
group	O
,	O
and	O
is	O
independently	O
:	O
C5	B
-	I
20arylene	I
;	O
C5	B
-	I
20arylene	I
-	O
C1	B
-	I
7alkylene	I
;	O
C1	B
-	I
7alkylene	I
-	O
C5	B
-	I
20arylene	I
;	O
or	O
C1	B
-	I
7alkylene	I
-	O
C5	B
-	I
20aryleneC1	I
-	B
7alkylene	I
;	O
and	O
is	O
optionally	O
substituted	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
amides	B
,	O
esters	B
,	O
ethers	B
,	O
chemically	O
protected	O
forms	O
,	O
and	O
prodrugs	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
to	O
inhibit	O
HDAC	O
,	O
and	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
HDAC	O
,	O
cancer	O
,	O
proliferative	O
conditions	O
,	O
psoriasis	O
,	O
etc	O
.	O

e.g.	O
4-	B
{	I
[	I
(	I
Benzyloxy	I
)	I
amino	I
]	I
carbonyl	I
}	I
phenyl	I
1-	I
(	I
4-methoxyphenyl	I
)	I
cyclohexanecarboxylate	I
;	O
histone	O
deacetylase	O
inhibitor	O
;	O
anticarcinogenic	O
,	O
antiproliferative	O
agent	O
;	O
neurodegenerative	O
diseases	O
;	O
bactericide	O
;	O
psoriasis	O
,	O
osteoarthritis	O
;	O
rheumatoid	O
arthritis	O
,	O
malaria	O
,	O
protozoal	O
infection	O
,	O
Alzheimer	O
's	O
;	O
Parkinson	O
's	O

An	O
azole	B
derivative	O
of	O
formula	O
(	O
I	O
)	O
a	O
medicament	O
that	O
contains	O
the	O
azole	B
derivative	O
of	O
formula	O
(	O
I	O
)	O
,	O
a	O
method	O
of	O
treating	O
a	O
disease	O
with	O
the	O
azole	B
derivative	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
method	O
of	O
preparing	O
the	O
azole	B
derivative	O
of	O
formula	O
(	O
I	O
)	O
.	O

e.g.	O
(	B
2-chloropyrimidin-4-yl	I
)	I
-	I
(	I
4-ethyl-3H	I
-	I
thiazol-2ylidene	I
)	I
-acetonitrile,	I
[	B
4-	I
(	I
4-chlorophenyl	I
)	I
-1,3-thiazol-2	I
(	I
3H	I
)	I
-ylidene	I
]	I
(	I
2-chloropyrimidin-4-yl	I
)	I
acetonitrile	I
;	O
Jun	O
N	O
-	O
terminal	O
kinase	O
and	O
Glycogen	O
Synthase	O
Kinase	O
3	O
inhibitor	O
;	O
antidiabetic	O
,	O
antiinflammatory	O
,	O
anticarcinogenic	O
agent	O
;	O
neurodegenerative	O
diseases	O

Pyrimidone	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
are	O
inhibitors	O
of	O
the	O
enzyme	O
Lp	O
-	O
PLA2	O
and	O
are	O
of	O
use	O
in	O
treating	O
atheroscelerosis	O
.	O

Treating	O
atherosclerosis	O
by	O
administering	O
1-	B
(	I
N-	I
(	I
2-	I
(	I
diethylamino	I
)	I
ethyl	I
)	I
-N-	I
(	I
4-	I
(	I
4-trifluoromethylphenyl	I
)	I
benzyl	I
)	I
aminocarbonylmethyl	I
)	I
-2-	I
(	I
4-fluorobenzyl	I
)	I
thio-5,6-trimethylenepyrimidin-4-one	I
or	O
a	O
salt	O
;	O
coadministering	O
an	O
anticholesterol	O
agent	O
;	O
inhibitor	O
of	O
platlet	O
activating	O
factor	O
acetylhydrolase	O

The	O
present	O
invention	O
discloses	O
a	O
pharmaceutical	O
method	O
comprising	O
urea	O
,	O
a	O
hydrophilic	O
film	O
-	O
forming	O
agent	O
,	O
water	O
and/or	O
a	O
water	O
-	O
alcohol	B
mixture	O
that	O
is	O
suitable	O
for	O
the	O
removal	O
of	O
abnormal	O
keratinous	O
material	O
.	O

Composition	O
for	O
removing	O
abnormal	O
keratinous	O
material	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
novel	O
haemopoietin	O
receptors	O
,	O
or	O
components	O
or	O
parts	O
thereof	O
and	O
to	O
a	O
method	O
for	O
cloning	O
genetic	O
sequences	O
encoding	O
same	O
.	O

More	O
particularly	O
,	O
the	O
subject	O
invention	O
is	O
directed	O
to	O
recombinant	O
or	O
synthetic	O
haemopoietin	O
receptors	O
or	O
components	O
or	O
parts	O
thereof	O
.	O

The	O
receptor	O
molecules	O
or	O
components	O
or	O
parts	O
thereof	O
and	O
their	O
genetic	O
sequences	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
development	O
of	O
a	O
wide	O
range	O
agonists	O
,	O
antagonists	O
and	O
therapeutics	O
and	O
diagnostic	O
reagents	O
based	O
on	O
ligand	O
interaction	O
with	O
its	O
receptor	O
.	O

Nucleic	O
acid	O
encoding	O
α	O
chain	O
of	O
human	O
IL-11	B
receptor	O

The	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
each	O
of	O
R2	O
and	O
R3	O
is	O
,	O
same	O
or	O
different	O
,	O
C2-C4	B
alkyl	I
or	O
the	O
like	O
;	O
or	O
R2	O
and	O
R3	O
are	O
taken	O
together	O
with	O
the	O
adjacent	O
carbon	B
atom	O
to	O
form	O
a	O
5	O
to	O
8	O
membered	O
non	O
-	O
aromatic	B
carbocyclic	I
ring	O
;	O
R4	O
is	O
C1-C6	B
alkyl	I
or	O
the	O
like	O
;	O
X	O
is	O
an	O
oxygen	B
atom	O
or	O
a	O
sulfur	B
atom	O
;	O
A	O
is	O
the	O
group	O
of	O
the	O
formula	O
:	O
wherein	O
R1	O
is	O
,	O
same	O
or	O
different	O
,	O
alkyl	B
or	O
the	O
like	O
;	O
W	O
is	O
C2-C6	B
alkylene	I
which	O
may	O
contain	O
an	O
optionally	O
substituted	O
heteroatom	O
(	O
s	O
)	O
or	O
the	O
like	O
;	O
n	O
is	O
an	O
integer	O
of	O
0	O
to	O
7	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
or	O
a	O
solvate	O
thereof	O
.	O

Cannabinoid	B
receptor	O
agonists	O
;	O
antipruritic	O
agents	O
,	O
analgesics	O
,	O
bronchodilator	O
agents	O

An	O
oral	O
pharmaceutical	O
dosage	O
form	O
comprising	O
an	O
acid	O
susceptible	O
proton	O
pump	O
inhibitor	O
and	O
one	O
or	O
more	O
NSAIDs	O
in	O
a	O
fixed	O
formulation	O
,	O
wherein	O
the	O
proton	O
pump	O
inhibitor	O
is	O
protected	O
by	O
an	O
enteric	O
coating	O
layer	O
.	O

The	O
fixed	O
formulation	O
is	O
in	O
the	O
form	O
of	O
an	O
enteric	O
coating	O
layered	O
tablet	O
,	O
a	O
capsule	O
or	O
a	O
multiple	O
unit	O
tableted	O
dosage	O
form	O
.	O

The	O
multiple	O
unit	O
dosage	O
forms	O
are	O
most	O
preferred	O
.	O

The	O
new	O
fixed	O
formulation	O
is	O
especially	O
useful	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
side	O
-	O
effects	O
associated	O
with	O
NSAID	O
treatment	O
.	O

Oral	O
pharmaceutical	O
dosage	O
forms	O
comprising	O
a	O
proton	O
pump	O
inhibitor	O
and	O
a	O
NSAID	O

The	O
present	O
application	O
describes	O
a	O
large	O
circular	O
target	O
-	O
specific	O
antisense	O
molecule	O
that	O
is	O
effective	O
in	O
ablating	O
RNA	O
and	O
protein	O
expression	O
.	O

The	O
large	O
circular	O
antisense	O
molecule	O
is	O
used	O
to	O
treat	O
any	O
human	O
disease	O
in	O
which	O
modulation	O
of	O
gene	O
expression	O
can	O
be	O
beneficial	O
to	O
intervene	O
in	O
the	O
disease	O
initiation	O
and	O
progression	O
.	O

Large	O
circular	O
target	O
-	O
specific	O
antisense	O
nucleic	O
acid	O
compounds	O

This	O
invention	O
is	O
directed	O
to	O
selective	O
antagonists	O
of	O
A2A	O
and/or	O
A2B	O
adenosine	B
receptors	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
;	O
to	O
processes	O
for	O
their	O
preparation	O
;	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
;	O
and	O
to	O
their	O
use	O
in	O
therapy	O
.	O

potent	O
and	O
selective	O
antagonists	O
of	O
adenosine	B
receptors	O
;	O
Parkinson	O
's	O
disease	O
,	O
asthma	O
,	O
allergies	O
,	O
inflammation	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
gastrointestinal	O
disorders	O
,	O
cell	O
proliferation	O
and	O
autoimmune	O
diseases	O
;	O
sulfonamidation	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
a	O
glomerular	O
disease	O
comprising	O
as	O
an	O
active	O
ingredient	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
:	O
or	O
a	O
salt	O
thereof	O
.	O

The	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
glomerular	O
diseases	O
is	O
useful	O
for	O
preventing	O
or	O
treating	O
a	O
variety	O
of	O
glomerular	O
diseases	O
including	O
chronic	O
glomerular	O
nephritis	O
.	O

Therapeutic	O
agent	O
for	O
glomerular	O
disease	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
:	O
R	O
is	O
an	O
amino	O
or	O
guanidino	O
group	O
;	O
R2	O
is	O
acetyl	O
or	O
trifluoroacetyl	O
;	O
n	O
and	O
q	O
are	O
either	O
the	O
same	O
or	O
different	O
and	O
selected	O
from	O
0	O
,	O
1	O
or	O
2	O
;	O
and	O
X	O
is	O
an	O
optionally	O
substituted	O
phenyl	O
,	O
optionally	O
substituted	O
naphthyl	O
or	O
optionally	O
substituted	O
phenyl	O
-	O
Y	O
-	O
optionally	O
substituted	O
phenyl	O
in	O
which	O
Y	O
is	O
selected	O
from	O
a	O
covalent	O
bond	O
,	O
CH2	O
,	O
CH2CH2	O
,	O
O	O
or	O
SO2	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
with	O
the	O
proviso	O
that	O
when	O
X	O
is	O
phenyl	O
or	O
naphthyl	O
,	O
n	O
and	O
q	O
are	O
both	O
2	O
and	O
when	O
X	O
is	O
phenyl	O
-	O
Y	O
-	O
phenyl	O
in	O
which	O
Y	O
is	O
a	O
covalent	O
bond	O
,	O
then	O
n	O
and	O
q	O
are	O
not	O
both	O
0	O
,	O
methods	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
formulations	O
containing	O
them	O
or	O
their	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
viral	O
infection	O
.	O

3-	O
(	O
acetylamino	O
)	O
-4-	O
{	O
[	O
amino	O
(	O
imino	O
)	O
methyl	O
]	O
amino	O
}	O
-6-carboxy-3,4-dihydro-2H	O
-	O
pyran-2-yl	O
)	O
-dimer	O
;	O
viricide	O
;	O
influenza	O
A	O
or	O
B	O
infection	O
,	O
parainfluenza	O
,	O
mumps	O
or	O
Newcastle	O
disease	O
,	O
myxovirus	O
infections	O
;	O
stability	O
;	O
long	O
time	O
in	O
lungs	O

Process	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
R	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
Patent	O
claim	O
1	O
,	O
and	O
compounds	O
of	O
the	O
formula	O
IV	O
in	O
which	O
R	O
and	O
R1	O
are	O
as	O
defined	O
in	O
Patent	O
claim	O
1	O
,	O
are	O
intermediates	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
I.	O
Method	O
for	O
the	O
production	O
of	O
pyrrolidine-1,2-dicarboxylic	B
acid-1-	I
(	I
phenyl	I
(	I
-amide	I
)	I
)	I
-2	I
(	I
phenyl	I
(	I
-amide	I
)	I
)	I
derivatives	O
and	O
1-	B
(	I
phenylcarbamoyl	I
)	I
-pyrrolidine-2-carboxylic	I
acid	I
derivatives	O
as	O
intermediate	O
products	O

Novel	O
heterocyclic	B
dihydropyrimidine	I
compounds	O
useful	O
as	O
inhibitors	O
of	O
potassium	B
channel	O
function	O
(	O
especially	O
inhibitors	O
of	O
the	O
Kv1	O
subfamily	O
of	O
voltage	O
gated	O
K+	B
channels	O
,	O
especially	O
inhibitors	O
Kv1.5	O
which	O
has	O
been	O
linked	O
to	O
the	O
ultra	O
-	O
rapidly	O
activating	O
delayed	O
rectifier	O
,	O
which	O
have	O
the	O
structure	O
stereoisomers	O
including	O
enantiomers	O
thereof	O
and	O
diastereomers	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
Q	O
is	O
alkyl	B
,	O
substituted	O
alkyl	B
,	O
cycloalkyl	B
,	O
substituted	O
cycloalkyl	B
,	O
cycloheteroalkyl	B
,	O
substituted	O
cycloheteroalkyl	B
or	O
which	O
is	O
aryl	B
,	O
substituted	O
aryl	B
,	O
heteroaryl	B
or	O
substituted	O
heteroaryl	B
;	O
R3	O
is	O
wherein	O
R1	O
,	O
R2	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
and	O
R10	O
are	O
defined	O
herein	O
.	O

Methods	O
of	O
using	O
such	O
compounds	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
arrhythmia	O
and	O
IKur	O
-	O
associated	O
conditions	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
are	O
also	O
provided	O
.	O

Substituted	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidines	I
as	O
potassium	B
channel	O
activators	O

Sequences	O
and	O
partial	O
sequences	O
for	O
three	O
types	O
of	O
mammalian	O
(	O
human	O
and	O
rat	O
sequences	O
identified	O
)	O
T	O
-	O
type	O
calcium	B
channel	O
subunits	O
which	O
we	O
have	O
labeled	O
as	O
the	O
α1	O
G	O
,	O
α1H	O
and	O
α1I	O
subunits	O
are	O
provided	O
.	O

Knowledge	O
of	O
the	O
sequence	O
of	O
these	O
calcium	B
channel	O
permits	O
the	O
localization	O
and	O
recovery	O
of	O
the	O
complete	O
sequence	O
from	O
human	O
cells	O
,	O
and	O
the	O
development	O
of	O
cell	O
lines	O
which	O
express	O
the	O
novel	O
calcium	O
channels	O
of	O
the	O
invention	O
.	O

These	O
cells	O
may	O
be	O
used	O
for	O
identifying	O
compounds	O
capable	O
of	O
acting	O
as	O
agonists	O
or	O
antagonists	O
to	O
the	O
calcium	B
channels	O
.	O

Nucleic	O
acids	O
encoding	O
mammalian	O
T	O
-	O
type	O
calcium	B
channels	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
the	O
specific	O
inhibition	O
of	O
kinase	O
suppressor	O
of	O
Ras	O
(	O
KSR	O
)	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
genetic	O
approaches	O
and	O
nucleic	O
acids	O
for	O
the	O
specific	O
inhibition	O
of	O
KSR	O
,	O
particularly	O
of	O
KSR	O
expression	O
.	O

The	O
invention	O
relates	O
to	O
antisense	O
oligonucleotides	B
and	O
the	O
expression	O
of	O
nucleic	O
acid	O
which	O
is	O
substantially	O
complementary	O
to	O
KSR	O
RNA	O
.	O

Oligonucleotide	B
and	O
nucleic	O
acid	O
compositions	O
are	O
provided	O
.	O

The	O
invention	O
provides	O
methods	O
to	O
inhibit	O
KSR	O
,	O
including	O
inhibition	O
of	O
KSR	O
expression	O
.	O

Methods	O
for	O
blocking	O
gf	O
Ras	O
mediated	O
tumorigenesis	O
,	O
metastasis	O
,	O
and	O
for	O
cancer	O
therapy	O
are	O
provided	O
.	O

Kinase	O
suppressor	O
of	O
Ras	O
inactivation	O
for	O
therapy	O
of	O
Ras	O
mediated	O
tumorigenesis	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
preventing	O
or	O
reducing	O
oxytocin	B
-	O
mediated	O
action	O
by	O
using	O
a	O
thiazolidinedione	B
,	O
such	O
as	O
troglitazone	B
,	O
or	O
thiazolidinedione	B
-	O
like	O
compounds	O
.	O

These	O
methods	O
describe	O
the	O
employment	O
of	O
these	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
other	O
agent	O
,	O
such	O
as	O
a	O
tocolytic	O
agent	O
.	O

This	O
offers	O
a	O
novel	O
therapeutic	O
regimen	O
for	O
the	O
treatment	O
of	O
oxytocin	B
-	O
mediated	O
actions	O
,	O
for	O
example	O
induction	O
of	O
uterine	O
contractions	O
,	O
prostaglandin	O
release	O
,	O
and	O
milk	O
letdown	O
.	O

Accordingly	O
,	O
conditions	O
such	O
as	O
preterm	O
labor	O
and	O
labor	O
prior	O
to	O
Caesarian	O
delivery	O
can	O
be	O
treated	O
by	O
these	O
methods	O
.	O

Use	O
of	O
thiazolidinediones	B
derivatives	O
for	O
preventing	O
uterine	O
contractions	O
in	O
premature	O
labour	O
or	O
lactation	O

Bipolar	O
lipids	O
are	O
described	O
which	O
are	O
able	O
to	O
form	O
complexes	O
with	O
polyanions	O
.	O

The	O
lipids	O
comprise	O
a	O
cationic	O
head	O
linked	O
to	O
a	O
hydrophobic	O
backbone	O
and	O
a	O
hydrophilic	O
tail	O
and	O
are	O
capable	O
of	O
self	O
assembly	O
to	O
form	O
stable	O
complexes	O
in	O
aqueous	O
solutions	O
.	O

The	O
lipids	O
are	O
of	O
particular	O
use	O
for	O
the	O
delivery	O
of	O
bioactive	O
substances	O
such	O
as	O
nucleic	O
acids	O
to	O
cells	O
in	O
vitro	O
and	O
especially	O
in	O
vivo	O
.	O

Bipolar	O
;	O
cationic	O
head	O
linked	O
to	O
a	O
hydrophobic	O
backbone	O
and	O
a	O
hydrophilic	O
tail	O
;	O
capable	O
of	O
self	O
assembly	O
to	O
form	O
stable	O
complexes	O
in	O
aqueous	O
solutions	O
;	O
use	O
for	O
the	O
delivery	O
of	O
bioactive	O
substances	O
such	O
as	O
nucleic	O
acids	O
to	O
cells	O
in	O
vitro	O
and	O
especially	O
in	O
vivo	O

The	O
present	O
invention	O
relates	O
to	O
an	O
Akt	O
inhibitor	O
comprising	O
a	O
compound	O
represented	O
by	O
formula	O
I	O
:	O
wherein	O
R	O
is	O
C4	O
-	O
30	O
linear	O
or	O
branched	O
acyl	B
,	O
which	O
may	O
be	O
substituted	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
screening	O
for	O
a	O
substance	O
inhibiting	O
acylated	O
homoserine	B
lactone	I
by	O
culturing	O
animal	O
cells	O
with	O
a	O
test	O
substance	O
in	O
the	O
presence	O
of	O
acylated	O
homoserine	B
lactone	I
represented	O
by	O
the	O
above	O
formula	O
I	O
,	O
and	O
then	O
detecting	O
inhibition	O
of	O
Akt	O
activity	O
or	O
inhibition	O
of	O
the	O
survival	O
signalling	O
pathway	O
in	O
which	O
Akt	O
is	O
involved	O
in	O
the	O
cells	O
.	O

inhibition	O
of	O
Akt	O
activity	O
or	O
inhibition	O
of	O
the	O
survival	O
signalling	O
pathway	O
in	O
which	O
Akt	O
is	O
involved	O
in	O
the	O
cells	O
,	O
akt	O
is	O
a	O
kinase	O

Bicyclo	B
-	I
pyrazole	I
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
as	O
defined	O
in	O
the	O
specification	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
combinatorial	O
libraries	O
comprising	O
a	O
plurality	O
of	O
them	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
are	O
herewith	O
disclosed	O
:	O
the	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
,	O
in	O
therapy	O
,	O
as	O
protein	O
kinase	O
inhibitors	O
,	O
for	O
instance	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

tert	B
-	I
butyl	I
3-amino-1H	I
-	I
thieno	I
[	I
2,3-c	I
]	I
pyrazole-5-carboxylate	I
;	O
N	B
-	I
benzyl-3-	I
[	I
(	I
4-fluorobenzoyl	I
)	I
amino	I
]	I
-1H	I
-	I
thieno	I
[	I
2,3-c	I
]	I
pyrazole-5-carboxamide	I
;	O
treats	O
a	O
disease	O
caused	O
associated	O
with	O
an	O
altered	O
(	O
disregulated	O
)	O
protein	O
kinase	O
activity	O
e.g	O
cancer	O
,	O
cell	O
proliferative	O
disorders	O
,	O
Alzheimer	O
's	O
disease	O
,	O
viral	O
infections	O

β	O
-	O
lactamases	O
are	O
the	O
most	O
widespread	O
resistance	O
mechanism	O
to	O
β	B
-	I
lactam	I
antibiotics	O
,	O
such	O
as	O
penicillins	B
and	O
cephalosporins	B
.	O

In	O
response	O
to	O
these	O
enzymes	O
,	O
inhibitors	O
have	O
been	O
introduced	O
.	O

Unfortunately	O
,	O
these	O
inhibitors	O
are	O
also	O
β	B
-	I
lactams	I
,	O
and	O
resistance	O
to	O
them	O
has	O
developed	O
rapidly	O
.	O

Consequently	O
,	O
the	O
present	O
invention	O
provides	O
a	O
novel	O
structure	O
-	O
based	O
approach	O
to	O
inhibitors	O
of	O
these	O
enzymes	O
.	O

Sulfur	B
compounds	O
such	O
as	O
3-	B
(	I
(	I
4-chloroanilino	I
)	I
sulfonyl	I
)	I
thio	I
-	I
phene-2-carboxylic	I
acid	I
,	O
used	O
as	O
enzymes	O
inhibitors	O
for	O
prophylaxis	O
of	O
antibiotic	O
resistant	O
bacterial	O
infections	O

This	O
invention	O
relates	O
to	O
a	O
benzimidazole	B
derivative	O
of	O
the	O
general	O
formula	O
[	O
I	O
]	O
[	O
wherein	O
B1	O
,	O
B2	O
,	O
and	O
B3	O
represent	O
hydrogen	B
atom	O
or	O
lower	O
alkyl	B
;	O
R1	O
and	O
R2	O
are	O
same	O
or	O
different	O
and	O
represent	O
lower	O
alkyl	B
,	O
etc	O
.	O
;	O
R3	O
and	O
R4	O
represent	O
hydrogen	B
atom	O
,	O
etc	O
.	O
;	O
W	O
represents	O
a	O
3	O
to	O
8-membered	O
aromatic	B
or	O
alphatic	B
heterocycle	I
,	O
etc	O
.	O
;	O
and	O
Ar	B
represents	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	B
heterocycle	I
,	O
etc	O
.	O
]	O

This	O
compound	O
functions	O
as	O
an	O
antagonist	O
to	O
melanin	O
-	O
concentrating	O
hormone	O
receptor	O
and	O
is	O
useful	O
as	O
a	O
drug	O
for	O
central	O
diseases	O
,	O
circulatory	O
diseases	O
and	O
metabolic	O
diseases	O
.	O

hormone	O
inhibitor	O
5-	B
(	I
4-fluorophenyl	I
)	I
-N-	I
{	I
2-	I
[	I
isopropyl	I
(	I
methyl	I
)	I
amino	I
]	I
-1H	I
-	I
benzimidazol-6-yl	I
}	I
-2-pyridinecarboxamide	I
;	O
treating	O
the	O
disorders	O
of	O
cardiovascular	O
system	O
,	O
nervous	O
system	O
,	O
metabolic	O
systems	O
,	O
reproductive	O
system	O
,	O
respiratory	O
system	O
,	O
digestive	O
system	O

Compositions	O
,	O
methods	O
of	O
making	O
the	O
compositions	O
,	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
are	O
provided	O
for	O
an	O
enhanced	O
magnetic	O
resonance	O
imaging	O
agent	O
and	O
a	O
hematinic	O
agent	O
,	O
the	O
agents	O
comprising	O
carboxyalkylated	O
reduced	O
polysaccharides	O
coated	O
ultrasmall	O
superparamagnetic	O
iron	O
oxides	O
.	O

Methods	O
of	O
use	O
of	O
the	O
carboxymethyl	B
reduced	O
dextran	B
as	O
a	O
plasma	O
extender	O
are	O
provided	O
.	O

Heat	O
stable	O
colloidal	O
iron	B
oxides	I
coated	O
with	O
reduced	O
carbohydrates	B
and	O
uses	O
thereof	O

The	O
present	O
invention	O
is	O
related	O
to	O
compositions	O
containing	O
chitosan	O
conjugated	O
CLA	O
(	O
conjugated	O
linoleic	B
acid	I
)	O
and	O
a	O
chitosan	O
conjugated	O
Vitamin	B
A	I
or	O
a	O
β	O
-	O
cyclodextrin	O
conjugated	O
vitamin	B
A.	I
The	O
invention	O
also	O
concerns	O
the	O
preparation	O
of	O
the	O
compositions	O
.	O

The	O
compositions	O
according	O
to	O
the	O
invention	O
can	O
be	O
used	O
as	O
topical	O
and	O
cosmetic	O
compositions	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
for	O
treatment	O
of	O
atopical	O
dermatitis	O
,	O
psoriasis	O
eczema	O
as	O
well	O
as	O
eczema	O
of	O
different	O
origins	O
and	O
solar	O
dermatitis	O
.	O

Complex	O
of	O
chitosan	O
,	O
conjugated	O
linoleic	B
acid	I
,	O
vitamin	B
a	I
and	O
cyclodextrin	O

A	O
compound	O
having	O
GSK-3	O
inhibitory	O
activity	O
.	O

A1	O
and	O
A3	O
are	O
a	O
single	O
bond	O
,	O
an	O
aliphatic	O
hydrocarbon	B
group	O
;	O
A2	O
and	O
A4	O
are	O
a	O
single	O
bond	O
,	O
CO	B
,	O
COO	B
,	O
CONR	B
,	O
O	B
,	O
OCO	B
,	O
NR	B
,	O
NRCO	B
,	O
NRCOO	B
,	O
etc	O
.	O
;	O
G1	O
is	O
a	O
single	O
bond	O
,	O
an	O
aliphatic	B
hydrocarbon	I
,	O
aromatic	B
hydrocarbon	I
,	O
heterocyclic	B
;	O
G2	O
is	O
H	B
,	O
an	O
aliphatic	B
hydrocarbon	I
,	O
an	O
alicyclic	B
hydrocarbon	I
,	O
an	O
aromatic	B
hydrocarbon	I
,	O
heterocyclic	B
;	O
A5	O
is	O
a	O
single	O
bond	O
,	O
NR	O
;	O
R2	O
is	O
H	B
,	O
halogen	B
,	O
an	O
aliphatic	B
hydrocarbon	I
,	O
alicyclic	B
hydrocarbon	I
,	O
aromatic	B
hydrocarbon	I
,	O
heterocyclic	B
;	O
A6	O
is	O
a	O
single	O
bond	O
,	O
NR	B
,	O
CO	B
,	O
NRCO	B
,	O
NRCONR	B
,	O
CONR	B
,	O
COO	B
,	O
O	B
,	O
etc	O
.	O
;	O
R3	O
is	O
H	B
,	O
halogen	B
,	O
nitro	B
,	O
saturated	O
aliphatic	B
hydrocarbon	I
,	O
alicyclic	B
hydrocarbon	I
,	O
aromatic	B
hydrocarbon	I
,	O
heterocyclic	B
;	O
and	O
R3	O
may	O
be	O
a	O
trimethylsilyl	B
,	O
formyl	B
,	O
acyl	B
,	O
carboxyl	B
,	O
alkoxylcarbonyl	B
,	O
carbamoyl	B
,	O
alkylcarbamoyl	B
,	O
or	O
cyano	B
group	O
when	O
A6	O
is	O
CR	B
═	I
CR	I
or	O
C≡C	B
,	O
wherein	O
R	O
is	O
H	B
or	O
an	O
lower	O
aliphatic	O
hydrocarbon	B
group	O
.	O

5-	B
{	I
2-	I
[	I
(	I
t	I
-	I
butoxy	I
)	I
carbonylamino	I
]	I
ethyl	I
}	I
-6-	I
{	I
3-chloro	I
(	I
2-thienyl	I
)	I
}	I
-4-oxo-3-hydr-	I
opyrrolo	I
[	I
3,2-d	I
]	I
pyrimidin-7-carboxyamide	I
;	O
GSK-3	O
inhibitor	O
;	O
diabetes	O
,	O
diabetic	O
complications	O
,	O
Alzheimer	O
's	O
,	O
neurodegenerative	O
,	O
manic	O
depression	O
,	O
traumatic	O
cerebrospinal	O
injury	O
,	O
alopecia	O
,	O
inflammatory	O
diseases	O
,	O
cancer	O
,	O
immunodeficienc	O

It	O
is	O
intended	O
to	O
provide	O
a	O
composition	O
containing	O
isoflavones	B
which	O
has	O
a	O
high	O
purity	O
and	O
yet	O
is	O
highly	O
soluble	O
in	O
water	O
in	O
a	O
natural	O
state	O
without	O
adding	O
any	O
solubilizers	O
or	O
subjecting	O
to	O
chemically	O
modification	O
.	O

It	O
is	O
found	O
out	O
that	O
a	O
composition	O
containing	O
isoflavones	B
with	O
a	O
high	O
purity	O
and	O
a	O
high	O
solubility	O
in	O
water	O
can	O
be	O
obtained	O
by	O
extracting	O
soybean	O
hypocotyls	O
with	O
a	O
water	O
-	O
containing	O
alcohol	B
within	O
a	O
specific	O
temperature	O
range	O
,	O
then	O
allowing	O
a	O
synthetic	O
adsorbent	O
resin	O
to	O
adsorb	O
the	O
obtained	O
extract	O
and	O
eluting	O
with	O
a	O
water	O
-	O
containing	O
alcohol	B
at	O
a	O
specific	O
concentration	O
.	O

High	O
solubility	O
composition	O
with	O
high	O
isoflavone	B
concentration	O
and	O
process	O
of	O
producing	O
same	O

The	O
use	O
of	O
(	B
R	I
)	I
-ibuprofen	I
methanesulfonamide	I
is	O
described	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
functional	O
injury	O
resulting	O
from	O
rejection	O
reactions	O
of	O
transplanted	O
organs	O
.	O

In	O
particular	O
,	O
the	O
use	O
of	O
non	O
-	O
toxic	O
salts	O
of	O
(	B
R	I
)	I
-ibuprofen	I
methanesulfonamide	I
,	O
such	O
as	O
the	O
(	B
L	I
)	I
-lysine	I
salt	O
,	O
is	O
described	O
for	O
the	O
prevention	O
and	O
the	O
treatment	O
of	O
rejection	O
reactions	O
of	O
transplanted	O
kidneys	O
.	O

In	O
particular	O
,	O
kidneys	O

The	O
present	O
invention	O
has	O
been	O
made	O
based	O
on	O
the	O
finding	O
that	O
a	O
compound	O
acting	O
on	O
the	O
ORL-1	O
receptor	O
as	O
an	O
agonist	O
acts	O
as	O
a	O
non	O
-	O
photic	O
entrainment	O
factor	O
,	O
and	O
advances	O
the	O
circadian	O
rhythm	O
phase	O
,	O
and	O
provides	O
a	O
novel	O
therapeutic	O
agent	O
for	O
a	O
sleep	O
disorder	O
such	O
as	O
circadian	O
rhythm	O
sleep	O
disorder	O
,	O
more	O
particularly	O
,	O
an	O
agent	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
a	O
sleep	O
disorder	O
,	O
which	O
contains	O
an	O
ORL-1	O
receptor	O
agonist	O
,	O
and	O
a	O
novel	O
compound	O
useful	O
as	O
such	O
agent	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
.	O

Advance	O
circadian	O
rhythm	O
disorders	O
;	O
using	O
opioid	O
receptor	O
antagonist	O

Substituted	O
3-carbonyl-1H	B
-	I
indol-1-yl	I
acetic	I
acid	I
derivatives	O
of	O
formula	O
I	O
are	O
provided	O
:	O
wherein	O
:	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
as	O
defined	O
herein	O
which	O
are	O
useful	O
as	O
inhibitors	O
of	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
for	O
treating	O
conditions	O
resulting	O
from	O
fibrinolytic	O
disorders	O
,	O
such	O
as	O
deep	O
vein	O
thrombosis	O
and	O
coronary	O
heart	O
disease	O
,	O
and	O
pulmonary	O
fibrosis	O
.	O

Substituted	O
3-carbonyl-1h	B
-	I
indol-1yl	I
acetic	I
acid	I
derivatives	O
as	O
inhibitors	O
of	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O

Substituted	O
indoles	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
physiologically	O
acceptable	O
derivatives	O
and	O
salts	O
thereof	O
,	O
in	O
which	O
R1	O
,	O
D	O
,	O
E	O
,	O
R12	O
,	O
p	O
,	O
X1	O
,	O
E	O
,	O
G	O
,	O
X2	O
and	O
Z	O
are	O
as	O
defined	O
in	O
claim	O
1	O
,	O
exhibit	O
particular	O
actions	O
on	O
the	O
central	O
nervous	O
system	O
,	O
especially	O
5HT	O
reuptake	O
-	O
inhibiting	O
and	O
5	O
HTx	O
-	O
agonistic	O
and/or	O
-antagonistic	O
actions	O
and	O
in	O
particular	O
serotonin	B
-	O
agonistic	O
and	O
-antagonistic	O
properties	O
and	O
can	O
be	O
employed	O
as	O
antipsychotics	O
,	O
neuroleptics	O
,	O
antidepressants	O
,	O
anxiolytics	O
and/or	O
antihypertonics	O
.	O

They	O
can	O
furthermore	O
be	O
employed	O
as	O
excitatory	O
amino	B
acid	I
antagonists	O
for	O
combating	O
neurodegenerative	O
diseases	O
,	O
including	O
cerebrovascular	O
diseases	O
,	O
epilepsy	O
,	O
schizophrenia	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
Huntington	O
's	O
disease	O
,	O
cerebral	O
ischaemia	O
,	O
infarction	O
or	O
psychoses	O
.	O

excitatory	O
amino	B
acid	I
antagonists	O
for	O
treating	O
neurodegenerative	O
diseases	O
as	O
cerebrovascular	O
diseases	O
,	O
epilepsy	O
,	O
schizophrenia	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
Huntington	O
's	O
disease	O
,	O
cerebral	O
ischaemia	O
,	O
infarction	O
,	O
psychoses	O
;	O
6-	B
{	I
3-	I
[	I
4-	I
(	I
4-fluorobenzyl	I
)	I
-1-piperidyl	I
]	I
propyl	I
}	I
-1H	I
-	I
indole-3-carbonitrile	I

The	O
present	O
invention	O
pertains	O
to	O
certain	O
ketones	B
and	O
reduced	O
ketones	B
and	O
derivatives	O
thereof	O
which	O
,	O
inter	O
alia	O
,	O
inhibit	O
osteoclast	O
survival	O
,	O
formation	O
,	O
and/or	O
activity	O
;	O
and/or	O
inhibit	O
bone	O
resorption	O
,	O
and	O
more	O
particularly	O
to	O
compounds	O
of	O
the	O
formulae	O
:	O
(	O
1	O
)	O
(	O
2	O
)	O
wherein	O
:	O
Ar1	O
is	O
independently	O
a	O
biphenyl	B
,	O
phenanthryl	B
,	O
fluorenyl	B
,	O
or	O
carbazolyl	B
,	O
and	O
is	O
optionally	O
substituted	O
;	O
Ralk	O
is	O
independently	O
a	O
C2	B
-	I
10alkylene	I
group	O
,	O
and	O
is	O
optionally	O
substituted	O
;	O
—ORO	B
,	O
if	O
present	O
,	O
is	O
independently	O
—OH	B
or	O
—ORK	B
;	O
—ORK	B
,	O
if	O
present	O
,	O
is	O
independently	O
selected	O
from	O
:	O
—O	B
—	I
RK1	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
RK2	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
ORK3	I
;	O
—O	B
—	I
S	I
(	I
═	I
O	I
)	I
2ORK4	I
;	O
Q	O
is	O
independently	O
—OH	B
or	O
—OROT	B
;	O
wherein	O
:	O
—OROT	B
,	O
if	O
present	O
,	O
is	O
independently	O
selected	O
from	O
:	O
—O	B
—	I
RE1	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
—RE2	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
—O	I
—	I
RE3	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
—O	I
—	I
SO3RE4	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
—O—	I
(	I
CH2	I
)	I
n	I
—	I
COORE5	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
—	I
(	I
CH2	I
)	I
n	I
—	I
NRN1RN2	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
—	I
(	I
CH2	I
)	I
n	I
—	I
NH	I
—	I
C	I
(	I
═	I
O	I
)	I
RE6	I
;	O
—O	B
—	I
C	I
(	I
═	I
O	I
)	I
—	I
(	I
CH2	I
)	I
n	I
—	I
C	I
(	I
═	I
O	I
)	I
—NRN3RN4	I
;	O
—O	B
—	I
P	I
(	I
═	I
O	I
)	I
(	I
ORE7	I
)	I
(	I
ORE8	I
)	I
;	O
—O	B
—	I
RPA	I
;	O
RPA	O
,	O
if	O
present	O
,	O
is	O
an	O
organic	O
group	O
which	O
incorporates	O
a	O
phosphonic	B
acid	I
group	O
;	O
with	O
the	O
proviso	O
that	O
if	O
—OROT	B
is	O
—O	B
—	I
RE1	I
,	O
then	O
RE1	O
is	O
not	O
a	O
phenyl	B
group	O
substituted	O
with	O
a	O
sulfonyl	B
group	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
amides	B
,	O
esters	B
,	O
ethers	B
,	O
chemically	O
protected	O
forms	O
,	O
or	O
prodrugs	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
to	O
inhibit	O
osteoclast	O
survival	O
,	O
formation	O
,	O
and/or	O
activity	O
,	O
and	O
to	O
inhibit	O
conditions	O
mediated	O
by	O
osteoclasts	O
and/or	O
characterised	O
by	O
bone	O
resorption	O
,	O
in	O
the	O
treatment	O
of	O
bone	O
disorders	O
such	O
as	O
osteoporosis	O
,	O
rheumatoid	O
arthritis	O
,	O
cancer	O
associated	O
bone	O
disease	O
,	O
Paget	O
's	O
disease	O
,	O
aseptic	O
loosening	O
of	O
prosthetic	O
implants	O
,	O
and	O
the	O
like	O
;	O
and/or	O
in	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
inflammation	O
or	O
activation	O
of	O
the	O
immune	O
system	O
.	O

4-	B
(	I
t	I
-	I
Butyldiphenylsiloxy	I
)	I
pentyl	I
-	I
p	I
-	I
toluene	I
sulfonate	I
;	O
2,2-	B
[	I
4-Biphenyl-5-	I
(	I
t	I
-	I
butyldiphenylsiloxy	I
)	I
pentyl	I
)	I
]	I
-1,3-propanedithiane	I
;	O
osteoporosis	O
,	O
rheumatoid	O
arthritis	O
,	O
cancer	O
associated	O
bone	O
disease	O
,	O
Paget	O
's	O
disease	O
,	O
aseptic	O
loosening	O
of	O
prosthetic	O
implants	O
;	O
inflammation	O

Delayed	O
release	O
oral	O
pharmaceutical	O
formulations	O
and	O
methods	O
for	O
enhanced	O
intestinal	O
drug	O
absorption	O
.	O

The	O
formulation	O
comprises	O
a	O
first	O
population	O
of	O
carrier	O
particles	O
comprising	O
a	O
drug	O
and	O
a	O
penetration	O
enhancer	O
which	O
are	O
released	O
at	O
a	O
first	O
location	O
in	O
the	O
intestine	O
,	O
and	O
a	O
second	O
population	O
of	O
carrier	O
particles	O
comprising	O
a	O
penetration	O
enhancer	O
and	O
a	O
delayed	O
release	O
coating	O
or	O
matrix	O
.	O

This	O
penetration	O
enhancer	O
is	O
released	O
at	O
a	O
second	O
location	O
in	O
the	O
intestine	O
downstream	O
from	O
the	O
first	O
location	O
and	O
enhances	O
absorption	O
of	O
the	O
drug	O
when	O
it	O
reaches	O
the	O
second	O
location	O
.	O

Pulsatile	O
release	O
compositions	O
and	O
methods	O
for	O
enhanced	O
intestinal	O
oligonucleotide	B
drug	O
absorption	O

The	O
present	O
invention	O
provides	O
compounds	O
for	O
modulating	O
receptor	O
kinase	O
activity	O
,	O
particularly	O
ephrin	O
and	O
EGFR	O
,	O
and	O
methods	O
of	O
treating	O
diseases	O
mediated	O
by	O
receptor	O
kinase	O
activity	O
utilizing	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

Diseases	O
mediated	O
by	O
receptor	O
kinase	O
activity	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
diseases	O
characterized	O
in	O
part	O
by	O
abnormal	O
levels	O
of	O
cell	O
proliferation	O
(	O
i.e.	O
tumor	O
growth	O
)	O
,	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
,	O
cell	O
migration	O
and	O
invasion	O
and	O
angiogenesis	O
associated	O
with	O
tumor	O
growth	O
.	O

Compounds	O
of	O
the	O
invention	O
include	O
""""	O
spectrum	O
selective	O
""""	O
kinase	O
modulators	O
,	O
compounds	O
that	O
inhibit	O
,	O
regulate	O
and/or	O
modulate	O
signal	O
transduction	O
across	O
subfamilies	O
of	O
receptor	O
-	O
type	O
tyrosine	B
kinases	O
,	O
including	O
ephrin	O
and	O
EGFR	O
.	O

Receptor	O
-	O
type	O
kinase	O
modulators	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
formula	O
I	O
:	O
wherein	O
X1	O
,	O
X2	O
,	O
X3	O
,	O
X4	O
,	O
X5	O
,	O
X6	O
,	O
X7	O
,	O
X8	O
,	O
X9	O
,	O
X10	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
and	O
n	O
are	O
as	O
defined	O
for	O
formula	O
I	O
in	O
the	O
description	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
and	O
to	O
new	O
intermediates	O
employed	O
in	O
the	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
in	O
therapy	O
.	O

9-	B
{	I
[	I
5-	I
(	I
3-Chlorophenyl	I
)	I
-1,2,4-oxadiazol-3-yl	I
]	I
methyl	I
}	I
-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-	I
[	I
1,2,4	I
]	I
triazolo	I
[	I
4,3-a	I
]	I
[	I
1,3	I
]	I
diazepine	I
;	O
Group	O
1	O
receptor	O
subtype	O
;	O
analgesics	O
;	O
psychological	O
disorders	O
;	O
gastroesophageal	O
reflux	O
;	O
neuroprotectans	O
;	O
antiischemic	O
agents	O
;	O
hyperglycemic	O
agents	O
;	O
neurodegenerative	O
disease	O

The	O
present	O
invention	O
is	O
generally	O
drawn	O
to	O
novel	O
isolated	O
therapeutic	O
agents	O
,	O
termed	O
resolvins	O
,	O
generated	O
from	O
the	O
interaction	O
between	O
a	O
dietary	O
omega-3	B
polyunsaturated	I
fatty	I
acid	I
(	O
PUFA	B
)	O
such	O
as	O
eicosapentaenoic	B
acid	I
(	O
EPA	B
)	O
or	O
docosahexaenoic	B
acid	I
(	O
DHA	B
)	O
,	O
cyclooxygenase	O
-	O
II	O
(	O
COX-2	O
)	O
and	O
an	O
analgesic	O
,	O
such	O
as	O
aspirin	B
(	O
ASA	B
)	O
.	O

Surprisingly	O
,	O
careful	O
isolation	O
of	O
compounds	O
generated	O
from	O
the	O
combination	O
of	O
components	O
in	O
an	O
appropriate	O
environment	O
provide	O
di-	B
and	I
tri	I
-	I
hydroxy	I
EPA	I
or	I
DHA	I
compounds	O
having	O
unique	O
structural	O
and	O
physiological	O
properties	O
.	O

The	O
present	O
invention	O
therefore	O
provides	O
for	O
many	O
new	O
useful	O
therapeutic	O
di-	B
or	I
tri	I
-	I
hydroxy	I
derivatives	I
of	I
EPA	I
or	I
DHA	I
(	O
resolvins	B
)	O
that	O
diminish	O
,	O
prevent	O
,	O
or	O
eliminate	O
inflammation	O
or	O
PMN	O
migration	O
,	O
for	O
example	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
use	O
,	O
methods	O
of	O
preparation	O
,	O
and	O
packaged	O
pharmaceuticals	O
for	O
use	O
as	O
medicaments	O
for	O
the	O
compounds	O
disclosed	O
throughout	O
the	O
specification	O
.	O

Resolvins	B
:	O
Biotemplates	O
for	O
novel	O
therapeutic	O
interventions	O

The	O
present	O
invention	O
relates	O
to	O
use	O
of	O
certain	O
antiviral	O
fragrances	O
for	O
reduction	O
of	O
viruses	O
,	O
in	O
particular	O
vira	O
causing	O
common	O
cold	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
an	O
antiviral	O
fragrance	O
,	O
preferably	O
menthol	B
.	O

Said	O
compositions	O
preferably	O
also	O
comprise	O
one	O
or	O
more	O
flavonoids	B
.	O

The	O
invention	O
also	O
relates	O
to	O
treatment	O
of	O
common	O
cold	O
using	O
said	O
compositions	O
.	O

One	O
or	O
more	O
purified	O
flavonoids	B
and	O
purified	O
menthol	B
,	O
in	O
a	O
state	O
of	O
purity	O
such	O
that	O
the	O
purified	O
menthol	B
has	O
a	O
direct	O
antiviral	O
effect	O
in	O
vitro	O
on	O
rhinovirus	O
in	O
WISH	O
cells	O
,	O
or	O
potentiates	O
the	O
antiviral	O
effect	O
in	O
vitro	O
of	O
human	O
interferon	O
-	O
alpha	O
-2b	O
(	O
Intron	O
A	O
)	O
on	O
rhinovirus	O
in	O
WISH	O
cells	O

This	O
invention	O
provides	O
a	O
process	O
for	O
efficient	O
production	O
of	O
folic	B
acid	I
derivatives	O
suitable	O
for	O
forming	O
conjugates	O
of	O
anticancer	O
drug	O
with	O
folic	B
acid	I
.	O

It	O
discloses	O
a	O
process	O
comprising	O
a	O
step	O
of	O
reacting	O
2-amino	B
-	I
protected	O
pteroylimidazole	B
with	O
γ	O
-	O
lower	O
alkyl	B
glutamate	I
;	O
and	O
a	O
step	O
of	O
reacting	O
the	O
resulting	O
product	O
with	O
an	O
amino	B
compound	O
having	O
a	O
reactive	O
group	O
which	O
is	O
readily	O
reactable	O
with	O
a	O
functional	O
group	O
of	O
the	O
drug	O
.	O

chemical	O
synthesis	O
for	O
forming	O
a	O
conjugate	O
of	O
anticancer	O
drug	O
with	O
folic	B
acid	I
;	O
chemotherapy	O
drug	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
to	O
the	O
salts	O
,	O
solvates	O
and	O
prodrugs	O
thereof	O
,	O
wherein	O
the	O
meanings	O
of	O
the	O
various	O
substituents	O
are	O
as	O
disclosed	O
in	O
the	O
description	O
.	O

Said	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
psoriasis	O
and	O
other	O
immune	O
diseases	O
.	O

2-acetoxy-4-	B
(	I
2,2,3,3,3-pentafluoropropoxy	I
)	I
benzoic	I
acid	I
;	O
methyl	B
2-hydroxy-4-	I
(	I
2,2,3,3,3-pentafluoropropoxy	I
)	I
benzoate	I
;	O
psoriasis	O
and	O
other	O
immune	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
isatin	B
derivatives	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
isatin	B
derivatives	O
of	O
the	O
invention	O
,	O
methods	O
of	O
preparing	O
the	O
isatin	B
derivatives	O
of	O
the	O
invention	O
,	O
their	O
use	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases	O
and	O
for	O
the	O
regeneration	O
or	O
prevention	O
of	O
degeneration	O
of	O
lesioned	O
and	O
damaged	O
neurons	O
,	O
and	O
methods	O
of	O
treatment	O
of	O
neurodegenerative	O
diseases	O
and	O
for	O
the	O
regeneration	O
or	O
prevention	O
of	O
degeneration	O
of	O
lesioned	O
and	O
damaged	O
neurons	O
.	O

Isatine	B
derivatives	O
with	O
neurotrophic	O
activity	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
eliciting	O
an	O
immune	O
response	O
and	O
the	O
prevention	O
and	O
treatment	O
of	O
primary	O
and	O
metastatic	O
neoplastic	O
diseases	O
and	O
infectious	O
diseases	O
.	O

The	O
methods	O
of	O
the	O
invention	O
comprise	O
administering	O
a	O
composition	O
comprising	O
an	O
effective	O
amount	O
of	O
a	O
complex	O
,	O
in	O
which	O
the	O
complex	O
consists	O
essentially	O
of	O
a	O
heat	O
shock	O
protein	O
(	O
hsp	O
)	O
noncovalently	O
bound	O
to	O
an	O
antigenic	O
molecule	O
.	O
""""	O
Antigenic	O
molecule	O
""""	O
as	O
used	O
herein	O
refers	O
to	O
the	O
peptides	O
with	O
which	O
the	O
hsps	O
are	O
endogenously	O
associated	O
in	O
vivo	O
as	O
well	O
as	O
exogenous	O
antigens	O
/	O
immunogens	O
(	O
i.e.	O
,	O
with	O
which	O
the	O
hsps	O
are	O
not	O
complexed	O
in	O
vivo	O
)	O
or	O
antigenic	O
/	O
immunogenic	O
fragments	O
and	O
derivatives	O
thereof	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
complex	O
is	O
autologous	O
to	O
the	O
individual	O
.	O

The	O
effective	O
amounts	O
of	O
the	O
complex	O
are	O
in	O
the	O
range	O
of	O
10	O
-	O
600	O
micrograms	O
for	O
complexes	O
comprising	O
hsp70	O
,	O
50	O
-	O
1000	O
micrograms	O
for	O
hsp90	O
,	O
and	O
10	O
-	O
600	O
micrograms	O
for	O
gp96	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
measuring	O
tumor	O
rejection	O
in	O
vivo	O
in	O
an	O
individual	O
,	O
preferably	O
a	O
human	O
,	O
comprising	O
measuring	O
the	O
generation	O
by	O
the	O
individual	O
of	O
MHC	O
Class	O
I	O
-	O
restricted	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocytes	O
specific	O
to	O
the	O
tumor	O
.	O

Methods	O
of	O
purifying	O
hsp70-peptide	O
complexes	O
are	O
also	O
provided	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
primary	O
and	O
metastatic	O
neoplastic	O
diseases	O
and	O
infectious	O
diseases	O
with	O
heat	O
shock	O
/	O
stress	O
proteins	O

Compounds	O
of	O
formula	O
Ia	O
or	O
Ib	O
:	O
wherein	O
A	O
,	O
W	O
,	O
X	O
,	O
Y	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
herein	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
for	O
treatment	O
of	O
p38	O
MAP	O
kinase	O
-	O
mediated	O
diseases	O
.	O

Substituted	O
pyrazolo	B
[	I
3,4-d	I
]	I
pyrimidines	I
as	O
p38	O
MAP	O
kinase	O
inhibitors	O

Pyrido	B
[	I
2,3-d	I
]	I
pyrimidine	I
phosphodiesterase	O
7	O
(	O
PDE	O
7	O
)	O
inhibitors	O
are	O
provided	O
which	O
are	O
useful	O
in	O
treating	O
T	O
-	O
cell	O
mediated	O
diseases	O
,	O
said	O
inhibitors	O
include	O
:	O
(	O
i	O
)	O
2-	B
[	I
[	I
4-	I
[	I
[	I
[	I
4-	I
(	I
Aminosulfonyl	I
)	I
phenyl	I
]	I
methyl	I
]	I
amino	I
]	I
pyrido	I
[	I
2,3-d	I
]	I
pyrimidin-2-yl	I
]	I
amino	I
]	I
-4-methyl-5-thiazolecarboxylic	I
acid	I
,	O
ethyl	B
ester	I
;	O
and	O
4-Methyl-2-	B
[	I
[	I
4-	I
[	I
[	I
[	I
4-	I
(	I
methylsulfonyl	I
)	I
phenyl	I
]	I
methyl	I
]	I
amino	I
]	I
pyrido	I
[	I
2,3-d	I
]	I
pyrimidin-2-yl	I
]	I
amino	I
]	I
-5-thiazolecarboxylic	I
acid	I
,	O
ethyl	B
ester	I
;	O
or	O
(	O
ii	O
)	O
an	O
enantiomer	O
,	O
diastereomer	O
,	O
tautomer	O
or	O
pharmaceutically	O
acceptable	O
salt	O
of	O
(	O
i	O
)	O
.	O

Pyrido	B
[	I
2,3-D	I
]	I
pyrimidine	I
inhibitors	O
of	O
phosphodiesterase	O
(	O
PDE	O
)	O
7	O

A	O
bisphosphonate	B
for	O
the	O
treatment	O
of	O
osteonecrosis	O
and/or	O
osteonecrosis	O
dissecans	O
.	O

The	O
drug	O
may	O
further	O
he	O
used	O
to	O
prevent	O
the	O
onset	O
of	O
osteonecrosis	O
and/or	O
osetonecrosis	O
dissecans	O
and	O
any	O
complications	O
associated	O
with	O
both	O
diseases	O
.	O

Via	O
bisphosphonate	B
drug	O
;	O
for	O
prophylaxis	O
of	O
cartilage	O
destruction	O
or	O
chondrolysis	O
associated	O
with	O
osteonecrosis	O
and/or	O
osteochondritis	O
dissecans	O

The	O
present	O
invention	O
provides	O
compositions	O
,	O
therapeutic	O
combinations	O
and	O
methods	O
including	O
:	O
(	O
a	O
)	O
at	O
least	O
one	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
activator	O
;	O
and	O
(	O
b	O
)	O
at	O
least	O
one	O
substituted	O
azetidinone	O
or	O
substituted	O
β	B
-	I
lactam	I
sterol	I
absorption	O
inhibitor	O
which	O
can	O
be	O
useful	O
for	O
treating	O
vascular	O
conditions	O
,	O
diabetes	O
,	O
obesity	O
and	O
lowering	O
plasma	O
levels	O
of	O
sterols	B
.	O

Administering	O
1-	B
(	I
4-fluorophenyl	I
)	I
-3	I
(	I
R	I
)	I
-	I
[	I
3	I
(	I
S	I
)	I
-	I
(	I
4-fluorophenyl	I
)	I
-3-hydroxypropyl	I
)	I
]	I
-4	I
(	I
S	I
)	I
-	I
[	I
4-	I
(	I
phenylmethoxy	I
)	I
phenyl	I
]	I
-2-azetidinone	I
;	O
and	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
activator	O
;	O
obesity	O
,	O
antidiabetic	O
agents	O

Compounds	O
are	O
disclosed	O
with	O
the	O
general	O
formula	O
in	O
which	O
the	O
groups	O
are	O
as	O
defined	O
in	O
the	O
description	O
here	O
below	O
and	O
characterized	O
by	O
the	O
presence	O
of	O
polyamine	B
substituents	O
on	O
the	O
imine	B
/	O
oxime	B
residue	O
,	O
such	O
amine	B
groups	O
being	O
in	O
turn	O
protected	O
by	O
suitable	O
protective	O
groups	O
.	O

Said	O
compounds	O
are	O
endowed	O
with	O
potent	O
topoisomerase	O
I	O
inhibiting	O
activity	O
and	O
therefore	O
are	O
useful	O
as	O
medicaments	O
for	O
the	O
treatment	O
of	O
tumors	O
and	O
viral	O
and	O
parasite	O
infections	O
.	O

Such	O
as	O
tert	B
-	I
butylester	I
of	O
20S-	B
(	I
4-	I
{	I
[	I
3-	I
(	I
7-camptothecinylidene	I
-	I
amino	I
)	I
-propyl	I
]	I
-tert	I
-	I
butoxycarbonyl	I
-	I
amino	I
}	I
-butyl	I
)	I
-	I
(	I
3-tert	I
-	I
butoxycarbonylaminopropyl	I
)	I
-carbamic	I
acid	I
;	O
topoisomerase	O
I	O
inhibiting	O
activity	O
and	O
useful	O
for	O
treatment	O
of	O
tumors	O
and	O
viral	O
and	O
parasite	O
infections	O

Compounds	O
of	O
formula	O
wherein	O
R1	O
and	O
R1′	O
are	O
hydrogen	O
or	O
deuterium	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
hydrogen	B
or	O
deuterium	B
,	O
R5	O
is	O
the	O
residue	O
of	O
an	O
amino	B
acid	I
,	O
X	O
is	O
S	B
or	O
N	B
-	I
ALK	I
,	O
is	O
piperidinyl	B
or	O
tetrahydropyridinyl	B
,	O
ALK	O
is	O
(	B
C1	I
-	I
4	I
)	I
alkyl	I
,	O
and	O
R6	O
is	O
hydrogen	B
,	O
hydroxy	B
or	O
(	B
C2	I
-	I
12	I
)	I
acyloxy	I
,	O
and	O
their	O
use	O
as	O
antimicrobials	O
.	O

Such	O
as	O
14-O-	B
[	I
4-hydroxy	I
-	I
N	I
-	I
valyl	I
-	I
piperidin-3-yl	I
]	I
-sulfanylacetylmutilin	I

Methods	O
and	O
compositions	O
for	O
modulating	O
the	O
FGF	O
effect	O
on	O
the	O
sensitivity	O
of	O
malignant	O
and	O
normal	O
cells	O
to	O
anticancer	O
agents	O
are	O
provided	O
.	O

In	O
particular	O
,	O
methods	O
and	O
compositions	O
for	O
inhibiting	O
FGF	O
-	O
induced	O
resistance	O
to	O
a	O
broad	O
spectrum	O
of	O
anticancer	O
agents	O
in	O
solid	O
and	O
soft	O
-	O
tissue	O
tumors	O
,	O
metastatic	O
lesions	O
,	O
leukemia	O
and	O
lymphoma	O
are	O
provided	O
.	O

Preferably	O
,	O
the	O
compositions	O
include	O
at	O
least	O
one	O
FGF	O
inhibitor	O
in	O
combination	O
with	O
a	O
cytotoxic	O
agents	O
,	O
e.g.	O
,	O
antimicrotubule	O
agents	O
,	O
topoisomerase	O
I	O
inhibitors	O
,	O
topoisomerase	O
II	O
inhibitors	O
,	O
antimetabolites	O
,	O
mitotic	O
inhibitors	O
,	O
alkylating	O
agents	O
,	O
intercalating	O
agents	O
,	O
agents	O
capable	O
of	O
interfering	O
with	O
a	O
signal	O
transduction	O
pathway	O
(	O
e.g.	O
,	O
g.	O
,	O
a	O
protein	O
kinase	O
C	O
inhibitor	O
,	O
e.g.	O
,	O
an	O
anti	O
-	O
hormone	O
,	O
e.g.	O
,	O
an	O
antibody	O
against	O
growth	O
factor	O
receptors	O
)	O
,	O
an	O
agent	O
that	O
promotes	O
apoptosis	O
and/or	O
necrosis	O
,	O
an	O
interferon	O
,	O
an	O
interleukin	O
,	O
a	O
tumor	O
necrosis	O
factor	O
,	O
and	O
radiation	O
.	O

In	O
other	O
embodiments	O
,	O
methods	O
and	O
composition	O
for	O
protecting	O
a	O
cell	O
in	O
a	O
subject	O
,	O
from	O
one	O
or	O
more	O
of	O
killing	O
,	O
inhibition	O
of	O
growth	O
or	O
division	O
or	O
other	O
damage	O
caused	O
,	O
e.g.	O
,	O
by	O
a	O
cytotoxic	O
agent	O
,	O
are	O
provided	O
.	O

Preferably	O
,	O
the	O
method	O
includes	O
:	O
administering	O
,	O
to	O
the	O
subject	O
,	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
FGF	O
agonist	O
,	O
thereby	O
treating	O
the	O
cell	O
,	O
e.g.	O
,	O
protecting	O
or	O
reducing	O
the	O
damage	O
to	O
the	O
dividing	O
cell	O
from	O
said	O
cytotoxic	O
agent	O
.	O

Administering	O
a	O
combination	O
of	O
a	O
cytotoxic	O
agent	O
and	O
a	O
fibroblastic	O
growth	O
factor	O
antagonist	O
,	O
wherein	O
the	O
FGF	O
antagonist	O
enhances	O
the	O
efficacy	O
of	O
the	O
cytotoxic	O
agent	O

Use	O
for	O
the	O
treatment	O
of	O
diseases	O
having	O
an	O
inflammatory	O
basis	O
of	O
compounds	O
or	O
salts	O
thereof	O
,	O
Having	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
:	O
A	O
—	O
X1—L—	O
(	O
W	O
)	O
p	O
—	O
NO2	B
wherein	O
A	O
contains	O
the	O
radical	O
of	O
a	O
drug	O
,	O
X1	O
and	O
W	O
are	O
bivalent	O
radicals	O
,	O
L	O
is	O
a	O
covalent	O
bond	O
or	O
oxygen	B
,	O
sulphur	B
,	O
NR1e	O
wherein	O
R1e	O
is	O
H	B
or	O
a	O
C1-C5	O
linear	O
or	O
branched	O
alkyl	B
.	O

Nitroderivatives	B
as	O
drugs	O
for	O
diseases	O
having	O
an	O
inflammatory	O
basis	O

The	O
present	O
invention	O
concerns	O
the	O
use	O
of	O
biologically	O
active	O
MP52	O
or	O
/	O
and	O
MP121	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
diseases	O
of	O
the	O
nervous	O
system	O
or	O
/	O
and	O
for	O
the	O
treatment	O
of	O
neuropathological	O
situations	O
which	O
are	O
caused	O
by	O
ageing	O
of	O
the	O
nervous	O
system	O
.	O

A	O
pharmaceutical	O
agent	O
according	O
to	O
the	O
invention	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
diseases	O
of	O
the	O
nervous	O
system	O
or	O
/	O
and	O
for	O
treating	O
neuropathological	O
situations	O
which	O
are	O
caused	O
by	O
ageing	O
of	O
the	O
nervous	O
system	O
therefore	O
contains	O
biologically	O
active	O
MP52	O
or	O
/	O
and	O
MP121	O
as	O
the	O
active	O
substance	O
.	O

Use	O
of	O
MP52	O
or	O
MP121	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
diseases	O
of	O
the	O
nervous	O
system	O

A	O
pharmaceutical	O
composition	O
and	O
a	O
product	O
which	O
includes	O
an	O
acryloyl	B
distamycin	I
derivative	O
,	O
an	O
antimicrotubule	O
agent	O
and/or	O
an	O
antimetabolite	O
useful	O
in	O
the	O
treatment	O
of	O
tumors	O
.	O

Synergistic	O
antineoplastic	O
effect	O
;	O
side	O
effect	O
reduction	O

A	O
process	O
for	O
preparing	O
a	O
processed	O
ginseng	O
extract	O
with	O
enhanced	O
pharmacological	O
effects	O
due	O
to	O
subsequent	O
treatment	O
is	O
disclosed	O
.	O

The	O
subsequent	O
treatment	O
includes	O
an	O
acid	O
-	O
treatment	O
of	O
ginseng	O
and	O
a	O
bio	O
-	O
converting	O
treatment	O
,	O
such	O
as	O
a	O
lactic	B
acid	I
bacterial	O
fermenting	O
and	O
an	O
intestinal	O
bacterial	O
fermenting	O
process	O
.	O

Includes	O
acid	O
-	O
treatment	O
of	O
ginseng	O
and	O
bio	O
-	O
converting	O
treatment	O
,	O
such	O
as	O
lactic	B
acid	I
bacterial	O
fermenting	O
and	O
intestinal	O
bacterial	O
fermenting	O
process	O
,	O
extracting	O
acid	O
treated	O
ginseng	O
with	O
organic	O
solvent	O
to	O
obtain	O
organic	O
extract	O
,	O
fermenting	O
organic	O
extract	O
with	O
lactic	B
-	I
acid	I
bacteria	O
Bifidobacterium	O
KK-1	O

Novel	O
salicylic	B
anilides	I
are	O
chemical	O
uncouplers	O
useful	O
e.g.	O
for	O
the	O
treatment	O
of	O
obesity	O
.	O

5-tert	B
-	I
Butyl-4-hydroxy-2-methyl	I
-	I
biphenyl-3-carboxylic	I
acid	I
(	I
2-chloro-4-nitro	I
-	I
phenyl	I
)	I
-amide	I
;	O
chemical	O
uncouplers	O
like	O
for	O
the	O
treatment	O
of	O
obesity	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
tetracyclic	B
arylsulfonyl	I
indoles	I
,	O
their	O
derivatives	O
,	O
their	O
analogues	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
polymorphs	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutically	O
acceptable	O
solvates	O
,	O
novel	O
intermediates	O
described	O
herein	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

This	O
invention	O
particularly	O
relates	O
to	O
novel	O
tetracyclic	B
arylsulfonyl	I
indoles	I
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
their	O
analogues	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
polymorphs	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutically	O
acceptable	O
solvates	O
,	O
novel	O
intermediates	O
described	O
herein	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

This	O
invention	O
also	O
relates	O
to	O
process	O
/	O
es	O
for	O
preparing	O
such	O
compound	O
/	O
s	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
composition	O
/	O
s	O
containing	O
effective	O
amount	O
/	O
s	O
of	O
such	O
a	O
compound	O
and	O
the	O
use	O
of	O
such	O
a	O
compound	O
/	O
composition	O
in	O
therapy	O
.	O

Tetracyclic	B
arylsulfonyl	I
indoles	I
having	O
serotonin	B
receptor	O
affinity	O
useful	O
as	O
therapeutic	O
agents	O
,	O
process	O
for	O
their	O
preparation	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O

This	O
invention	O
relates	O
to	O
novel	O
lactams	O
of	O
Formula	O
(	O
I	O
)	O
:	O
having	O
drug	O
and	O
bio	O
-	O
affecting	O
properties	O
,	O
their	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
inhibit	O
the	O
processing	O
of	O
amyloid	O
precursor	O
protein	O
and	O
,	O
more	O
specifically	O
,	O
inhibit	O
the	O
production	O
of	O
Aβ	O
-	O
peptide	O
,	O
thereby	O
acting	O
to	O
prevent	O
the	O
formation	O
of	O
neurological	O
deposits	O
of	O
amyloid	O
protein	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
neurological	O
disorders	O
related	O
to	O
β	O
-	O
amyloid	O
production	O
such	O
as	O
Alzheimer	O
's	O
disease	O
and	O
Down	O
's	O
Syndrome	O
.	O

3-	B
[	I
(	I
1-oxo-2-cyclopropylmethyl	I
-	I
heptyl	I
)	I
]	I
amino-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one	I
;	O
amyloid	O
precursor	O
protein	O
and	O
beta	O
-peptide	O
inhibitor	O
;	O
beta	O
or	O
gamma	O
secretases	O
inhibitor	O
;	O
amyloid	O
plaques	O
and	O
neurofibrillar	O
tangles	O
;	O
neurodegenerative	O
diseases	O
:	O

Alzheimer	O
's	O
disease	O
;	O
Down	O
syndrome	O

Substituted	O
5,6,7,8-tetrahydro	B
-	I
pyrido	I
[	I
4,3-d	I
]	I
pyrimidin-2-yl	I
and	O
5,6,7,8-tetrahydro	B
-	I
quinazolin-2-yl	I
compounds	O
,	O
corresponding	O
to	O
formula	O
I	O
processes	O
for	O
the	O
production	O
thereof	O
,	O
pharmaceutical	O
preparations	O
containing	O
these	O
compounds	O
the	O
use	O
thereof	O
for	O
the	O
production	O
of	O
pharmaceutical	O
preparations	O
and	O
related	O
method	O
of	O
treating	O
or	O
inhibiting	O
certain	O
disorders	O
or	O
conditions	O
,	O
including	O
pain	O
.	O

Substituted	O
5,6,7,8-tetrahydropyrido	B
[	I
4,3-d	I
]	I
pyrimidine-2-yl	I
compounds	O
and	O
5,6,7,8-tetrahydroquinazoline-2-yl	B
compounds	O

This	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
4-	B
[	I
(	I
4-thiazolyl	I
)	I
phenoxyl	I
]	I
alkoxy	I
-	I
benzamidine	I
derivatives	O
expressed	O
by	O
the	O
following	O
formula	O
1	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
osteoporosis	O
and	O
more	O
particularly	O
,	O
to	O
the	O
use	O
of	O
4-	B
{	I
5-	I
[	I
4-	I
(	I
5-isopropyl-2-methyl-1,3-thiazol-4-yl	I
)	I
phenoxyl	I
]	I
pentoxy	I
}	I
-benzamidine	I
or	O
N	B
-	I
hydroxy-4-	I
{	I
5-	I
[	I
4-	I
(	I
5-iso	I
-	I
propyl-2-methyl-1,3-thiazol-4-yl	I
)	I
phenoxyl	I
]	I
pentoxy	I
}	I
-benzamidine	I
expressed	O
by	O
the	O
following	O
formula	O
1	O
,	O
which	O
is	O
known	O
as	O
an	O
antagonist	O
of	O
leukotriene	B
-	I
B4	I
receptor	O
,	O
as	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
osteoporosis	O
.	O

[	O
Formula	O
1	O
]	O
,	O
wherein	O
,	O
R	O
is	O
a	O
hydrogen	B
atom	O
or	O
a	O
hydroxy	B
group	O
.	O

4-	B
{	I
5-	I
[	I
4-	I
(	I
5-Isopropyl-2-methyl-1,3-thiazol-4-yl	I
)	I
phenoxy	I
]	I
pentoxy	I
}	I
-benzamidine	I
or	O
N	B
-	I
hydroxy-4-	I
{	I
5-	I
[	I
4-	I
(	I
5-isopropyl-2-methyl-1,3-thiazol-4-yl	I
)	I
phenoxy	I
]	I
pentoxy	I
}	I
-benzamidine	I
(	O
DW-1350	O
)	O
;	O
a	O
leukotriene	O
-	O
B4	O
receptor	O
antangonist	O
;	O
inhibiting	O
osteoclastic	O
bone	O
absorption	O

The	O
present	O
invention	O
provides	O
a	O
novel	O
bioactive	O
substance	O
having	O
an	O
antitumor	O
activity	O
and	O
a	O
process	O
for	O
producing	O
it	O
,	O
and	O
a	O
medical	O
use	O
thereof	O
.	O

Namely	O
,	O
it	O
provides	O
a	O
12-membered	O
ring	O
macrolide	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
obtained	O
from	O
the	O
incubation	O
solution	O
of	O
Streptomyces	O
sp.	O
Mer	O
.	O

11107	O
or	O
a	O
variant	O
thereof	O
,	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
hydrate	B
of	O
them	O
,	O
and	O
a	O
process	O
for	O
producing	O
it	O
.	O

Bioactive	O
substance	O

A	O
method	O
is	O
described	O
for	O
the	O
diagnosis	O
of	O
an	O
ovarian	O
or	O
endometrial	O
tumor	O
or	O
for	O
a	O
prognosis	O
,	O
characterized	O
in	O
that	O
the	O
L1	O
level	O
is	O
determined	O
in	O
a	O
patient	O
sample	O
,	O
preferably	O
via	O
an	O
anti	O
L1	O
antibody	O
,	O
the	O
presence	O
of	O
L1	O
being	O
an	O
indication	O
of	O
the	O
presence	O
of	O
an	O
ovarian	O
or	O
endometrial	O
tumor	O
or	O
a	O
predisposition	O
for	O
such	O
a	O
tumor	O
.	O

Furthermore	O
,	O
methods	O
for	O
treating	O
of	O
ovarian	O
or	O
endometrial	O
tumors	O
are	O
provided	O
.	O

Using	O
uterine	O
tumor	O
specific	O
marker	O
as	O
diagnostic	O
tool	O
in	O
detection	O
of	O
urogenital	O
specific	O
cell	O
proliferative	O
disorders	O

Compositions	O
and	O
methods	O
of	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
psoriasis	O
and	O
related	O
skin	O
ailments	O
are	O
disclosed	O
.	O

The	O
compositions	O
include	O
topical	O
skin	O
formulations	O
of	O
glucosamine	B
in	O
an	O
emollient	O
base	O
such	O
as	O
moisturizing	O
cream	O
.	O

In	O
addition	O
to	O
glucosamine	B
,	O
the	O
formulations	O
may	O
include	O
keratolytic	O
substances	O
such	O
as	O
coal	O
tar	O
extract	O
or	O
salicylic	B
acid	I
.	O

The	O
formulations	O
may	O
also	O
include	O
glucosamine	B
and	O
antioxidant	O
anti	O
-	O
inflammatory	O
herbal	O
extracts	O
such	O
as	O
oleuropein	O
and	O
berberine	O
in	O
an	O
emollient	O
base	O
.	O

Topical	O
composition	O
for	O
the	O
treatment	O
of	O
psoriasis	O
and	O
related	O
skin	O
disorders	O

Heterocyclic	B
amidines	I
with	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
activity	O
that	O
inhibit	O
nitrogen	B
oxide	I
production	O
,	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
:	O
G1	O
and	O
G2	O
are	O
hydrogen	B
,	O
halogen	B
,	O
hydroxyl	B
,	O
C1-C4	B
alkoxy	I
,	O
C1-C4	B
alkyl	I
,	O
and	O
an	O
amidino	B
substituent	O
of	O
formula	O
Q	O
,	O
provided	O
that	O
,	O
for	O
each	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
only	O
one	O
of	O
the	O
two	O
substituents	O
G1	O
or	O
G2	O
is	O
an	O
amidino	B
substituent	O
of	O
formula	O
Q	O
:	O
and	O
in	O
which	O
the	O
substituents	O
W	O
,	O
Y	O
and	O
X	O
are	O
combined	O
to	O
form	O
9-	O
or	O
10-membered	O
bicyclic	B
heteroaromatic	I
derivatives	O
containing	O
up	O
to	O
2	O
hetero	O
atoms	O
in	O
the	O
same	O
ring	O
;	O
and	O
Z	O
is	O
an	O
aryl	B
or	I
heteroaryl	I
group	O
,	O
a	O
linear	O
or	O
branched	O
C1-C6	B
alkyl	I
or	O
alkenyl	B
chain	O
,	O
a	O
C1-C4	B
alkyl	I
-	I
aryl	I
group	O
or	O
a	O
C1-C4	B
alkyl	I
-	I
heteroaryl	I
group	O
.	O

Anti	O
-	O
inflammatory	O
and	O
analgesic	O
heterocyclic	B
amidines	I
that	O
inhibit	O
nitrogen	B
oxide	I
(	O
NO	B
)	O
production	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
1,2,4-oxadiazole	B
derivatives	O
which	O
are	O
inhibitors	O
of	O
the	O
dipeptidyl	O
peptidase	O
-	O
IV	O
enzyme	O
(	O
""""	O
DP	O
-	O
IV	O
inhibitors	O
""""	O
)	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
dipeptidyl	O
peptidase	O
-	O
IV	O
enzyme	O
is	O
involved	O
,	O
such	O
as	O
diabetes	O
and	O
particularly	O
type	O
2	O
diabetes	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
the	O
dipeptidyl	O
peptidase	O
-	O
IV	O
enzyme	O
is	O
involved	O
.	O

1,2,4-Oxadiazole	B
derivatives	O
as	O
dipeptidyl	O
peptidase	O
-	O
IV	O
inhibitors	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
diabetes	O

The	O
invention	O
relates	O
to	O
substituted	O
quinazolines	B
and	O
to	O
methods	O
for	O
the	O
production	O
thereof	O
,	O
in	O
addition	O
to	O
the	O
use	O
thereof	O
in	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
especially	O
for	O
use	O
as	O
antiviral	O
agents	O
,	O
especially	O
against	O
cytomegaloviruses	O
.	O

{	B
8-Fluoro-2-	I
(	I
4'-fluoro-1,1'-biphenyl-4-yl	I
)	I
-3-	I
[	I
3-trifluoromethyl	I
)	I
phenyl	I
]	I
-3,4-dihydro-4-quinazolinyl	I
}	I
acetic	I
acid	I
;	O
have	O
high	O
antiviral	O
activity	O

The	O
invention	O
provides	O
proteins	O
from	O
Neisseria	O
meningitidis	O
(	O
strains	O
A	O
&	O
B	O
)	O
,	O
including	O
amino	B
acid	I
sequences	O
,	O
the	O
corresponding	O
nucleotide	O
sequences	O
,	O
expression	O
data	O
,	O
and	O
serological	O
data	O
.	O

The	O
proteins	O
are	O
useful	O
antigens	O
for	O
vaccines	O
,	O
immunogenic	O
compositions	O
,	O
and/or	O
diagnostics	O
.	O

Protein	O
for	O
vaccines	O
;	O
immunology	O
response	O
;	O
medical	O
diagnosis	O
;	O
antibody	O
binding	O
to	O
protein	O

An	O
ophthalmic	O
pharmaceutical	O
composition	O
comprising	O
trehalose	B
as	O
an	O
effective	O
ingredient	O
and	O
a	O
pharmaceutically	O
-	O
acceptable	O
carrier	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
a	O
safe	O
,	O
long	O
-	O
term	O
continuously	O
-	O
administrable	O
,	O
therapeutic	O
and/or	O
prophylactic	O
agent	O
for	O
the	O
ophthalmologic	O
clinical	O
symptoms	O
and	O
signs	O
in	O
Sjögren	O
syndrome	O
.	O

Comprises	O
trehalose	B
;	O
for	O
treatment	O
of	O
Gougerot	O
-	O
Sjogren	O
Syndrome	O

The	O
invention	O
concerns	O
a	O
pharmaceutical	O
composition	O
comprises	O
trimegestone	B
optionally	O
associated	O
with	O
an	O
oestrogen	B
,	O
characterized	O
in	O
that	O
it	O
comprises	O
a	O
buffer	O
solution	O
whereof	O
the	O
pH	O
,	O
when	O
it	O
is	O
introduced	O
in	O
the	O
composition	O
,	O
ranging	O
essentially	O
between	O
2	O
and	O
5.5	O
.	O

The	O
invention	O
also	O
concerns	O
the	O
methods	O
for	O
making	O
such	O
a	O
composition	O
and	O
the	O
primary	O
package	O
containing	O
them	O
.	O

for	O
inducing	O
contraception	O
;	O
for	O
treating	O
menopause	O
;	O
thermoformed	O
packages	O

A	O
composition	O
for	O
potentiating	O
glutathione	B
,	O
which	O
contains	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
2-	B
(	I
3,4-dihydroxyphenyl	I
)	I
ethanol	I
or	O
a	O
glycoside	B
thereof	O
,	O
a	O
plant	O
containing	O
2-	B
(	I
3,4-dihydroxyphenyl	I
)	I
ethanol	I
or	O
a	O
glycoside	B
thereof	O
,	O
an	O
extract	O
of	O
said	O
plant	O
,	O
a	O
hydrolysate	O
of	O
said	O
plant	O
,	O
and	O
a	O
hydrolysate	O
of	O
the	O
extract	O
of	O
said	O
plant	O
(	O
excluding	O
Olea	O
europaea	O
and	O
an	O
extract	O
thereof	O
)	O
,	O
and	O
which	O
further	O
contains	O
at	O
least	O
one	O
member	O
selected	O
from	O
among	O
an	O
S	O
-	O
containing	O
compound	O
that	O
is	O
a	O
supply	O
source	O
of	O
cysteine	B
,	O
a	O
protein	O
that	O
contains	O
cysteine	B
and/or	O
cystine	B
,	O
a	O
yeast	O
that	O
contains	O
cysteine	B
and/or	O
cystine	B
,	O
and	O
a	O
vitamin	O
.	O

Compositions	O
for	O
potentiating	O
glutathione	B

Compounds	O
of	O
the	O
formula	O

I	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
Claim	O
1	O
,	O
are	O
ligands	O
of	O
the	O
nicotinic	B
acetylcholine	I
receptor	O
and/or	O
serotonergic	O
ligands	O
and	O
are	O
suitable	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
psychoses	O
,	O
schizophrenia	O
,	O
depression	O
,	O
anxiety	O
states	O
,	O
dementia	O
,	O
in	O
particular	O
Alzheimer	O
's	O
disease	O
and	O
Lewy	O
bodies	O
dementia	O
,	O
neurodegenerative	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
Huntington	O
's	O
disease	O
,	O
Tourette	O
's	O
syndrome	O
,	O
learning	O
and	O
memory	O
restrictions	O
,	O
bulimia	O
,	O
anorexia	O
nervosa	O
or	O
other	O
eating	O
disorders	O
,	O
compulsive	O
behavior	O
,	O
premenstrual	O
syndrome	O
,	O
age	O
-	O
induced	O
memory	O
impairment	O
,	O
amelioration	O
of	O
withdrawal	O
symptoms	O
in	O
nicotine	O
dependence	O
,	O
strokes	O
or	O
brain	O
damage	O
by	O
toxic	O
compounds	O
,	O
and	O
for	O
the	O
treatment	O
of	O
disorders	O
which	O
are	O
characterized	O
by	O
an	O
excess	O
of	O
circulating	O
serotonin	B
or	O
by	O
serotonergic	O
hyperactivity	O
.	O

6H	B
-	I
oxazolo	I
[	I
4,5	I
e	I
]	I
indole	I
derivatives	O
as	O
nicotinic	B
acetylcholine	I
receptor	O
ligands	O
and/or	O
serotonergic	O
ligands	O

The	O
invention	O
relates	O
to	O
3-	O
,	O
5-	O
,	O
7-trisubstituted	O
pyrazolo	O
[	O
4,3-d	O
]	O
pyrimidines	O
represented	O
by	O
the	O
general	O
formula	O

I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
R3	O
is	O
an	O
optionally	O
substituted	O
alkyl	O
,	O
cycloalkyl	O
,	O
cycloheteroalkyl	O
,	O
cycloalkyl	O
alkyl	O
,	O
aryl	O
or	O
alkylaryl	O
group	O
;	O
R5	O
is	O
halogen	O
,	O
—NHNH2	O
,	O
—NHOH	O
,	O
NHCONH2	O
,	O
guanylo	O
(	O
NH	O
—	O
C	O
(	O
NH	O
)	O
NH2	O
)	O
an	O
optionally	O
substituted	O
C1-C6	O
alkyl	O
,	O
alkenyl	O
,	O
alkynyl	O
,	O
C3-C15	O
cycloalkyl	O
,	O
Rf	O
(	O
C3-C15	O
cycloalkyl	O
)	O
,	O
heterocyclyl	O
,	O
heteroalkyl	O
,	O
aryl	O
,	O
heteroaryl	O
,	O
arylalkylene	O
,	O
arylalkenylene	O
,	O
arylalkynylene	O
,	O
cycloheteroalkyl	O
,	O
cycloheteroalkyl	O
alkyl	O
,	O
heteroarylalkylene	O
,	O
heteroarylalkenylene	O
,	O
heteroarylalkynylene	O
group	O
,	O
the	O
group	O
—C	O
(	O
O	O
)	O
—Ra	O
,	O
—C	O
(	O
O	O
)	O
NRbRc	O
,	O
—SO3Rd	O
,	O
or	O
—NHC	O
(	O
O	O
)	O
Re	O
,	O
wherein	O
Ra	O
and	O
Rf	O
are	O
an	O
optionally	O
substituted	O
C1-C6	O
alkyl	O
,	O
alkenyl	O
,	O
or	O
alkynyl	O
group	O
,	O
Rb	O
,	O
Rc	O
,	O
and	O
Rd	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
H	O
,	O
optionally	O
substituted	O
C1-C6	O
alkyl	O
,	O
alkenyl	O
,	O
or	O
alkynyl	O
group	O
,	O
and	O
Re	O
is	O
a	O
hydroxy	O
,	O
amino	O
,	O
alkoxy	O
,	O
alkylamino	O
,	O
optionally	O
substituted	O
C1-C6	O
alkyl	O
,	O
alkenyl	O
or	O
alkynyl	O
group	O
;	O
or	O
the	O
group	O
—X	O
—	O
R5′	O
,	O
wherein	O
X	O
is	O
—NH—	O
,	O
—O—	O
,	O
—S—	O
or	O
—N	O
(	O
alkyl	O
)	O
-	O
and	O
R5′	O
is	O
hydrogen	O
,	O
an	O
optionally	O
substituted	O
C1-C6	O
alkyl	O
,	O
alkenyl	O
,	O
alkynyl	O
,	O
C3-C15	O
cycloalkyl	O
,	O
Rf	O
(	O
C3-C15	O
cycloalkyl	O
)	O
,	O
aryl	O
,	O
heterocyclyl	O
,	O
hetero	O
C1-C6	O
alkyl	O
,	O
arylalkylene	O
,	O
arylalkenylene	O
,	O
arylalkynylene	O
,	O
heteroaryl	O
,	O
cycloheteroalkyl	O
,	O
cycloheteroalkyl	O
alkyl	O
,	O
or	O
heteroarylalkylene	O
,	O
heteroarylalkenylene	O
,	O
heteroarylalkynylene	O
group	O
,	O
the	O
group	O
—C	O
(	O
O	O
)	O
—Ra	O
,	O
—C	O
(	O
O	O
)	O
NRbRc	O
,	O
—SO3Rd	O
,	O
or	O
—NHC	O
(	O
O	O
)	O
Re	O
,	O
wherein	O
Ra	O
,	O
Rb	O
,	O
Rc	O
,	O
Rd	O
,	O
Re	O
and	O
Rf	O
have	O
the	O
above	O
meaning	O
,	O
and	O
R7	O
is	O
halogen	O
,	O
—NHNH2	O
,	O
NHOH	O
,	O
NHCONH2	O
,	O
guanylo	O
(	O
NH	O
—	O
C	O
(	O
NH	O
)	O
NH2	O
)	O
or	O
the	O
group	O
—X	O
—	O
R7′	O
,	O
wherein	O
X	O
has	O
the	O
above	O
meaning	O
and	O
the	O
meaning	O
of	O
R7′	O
is	O
as	O
defined	O
for	O
R5′.	O
5-	O
[	O
1-	O
(	O
hydroxymethyl	O
)	O
propyl	O
]	O
amino-7-benzylamino-3-isopropyl	O
(	O
methyl	O
,	O
ethyl	O
)	O
pyrazolo	O
[	O
4,3-d	O
]	O
pyrimidine	O
for	O
inhibiting	O
cell	O
proliferation	O
,	O
cancer	O
,	O
or	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
lupus	O
,	O
diabetes	O
,	O
multiple	O
sclerosis	O
,	O
restenosis	O
,	O
polycystic	O
kidney	O
disease	O
,	O
graft	O
rejection	O
,	O
and	O
neurodegerative	O
diseases	O

There	O
is	O
provided	O
a	O
compound	O
of	O
Formula	O
I	O
wherein	O
each	O
T	O
is	O
independently	O
selected	O
from	O
H	B
,	O
hydrocarbyl	B
,	O
—F	B
—	I
R	I
,	O
and	O
a	O
bond	O
with	O
one	O
of	O
D	O
,	O
E	O
,	O
P	O
or	O
Q	O
,	O
or	O
together	O
with	O
one	O
of	O
P	O
and	O
Q	O
forms	O
a	O
ring	O
;	O
Z	O
is	O
a	O
suitable	O
atom	O
the	O
valency	O
of	O
which	O
is	O
m	O
;	O
D	O
,	O
E	O
and	O
F	O
are	O
each	O
independently	O
of	O
each	O
other	O
an	O
optional	O
linker	O
group	O
,	O
wherein	O
when	O
Z	O
is	O
nitrogen	O
E	O
is	O
other	O
than	O
CH2	B
and	O
C	B
═	I
O	I
;	O
P	O
,	O
Q	O
and	O
R	O
are	O
independently	O
of	O
each	O
other	O
a	O
ring	O
system	O
;	O
and	O
at	O
least	O
Q	O
comprises	O
a	O
sulphamate	B
group	O
.	O

Dimethylsulfamic	B
Acid	I
2-bromo-4-	I
{	I
[	I
(	I
4-cyano	I
-	I
phenyl	I
)	I
-	I
[	I
1,2,4	I
]	I
triazol-4-ylamino	I
]	I
methyl	I
}	I
phenyl	I
Ester	I
,	O
used	O
as	O
effective	O
sulfatase	O
and/or	O
aromatase	O
inhibitors	O
,	O
and	O
as	O
modulators	O
of	O
cell	O
cycling	O
and	O
modulators	O
of	O
apoptosis	O
;	O
therapy	O
of	O
breast	O
,	O
prostate	O
,	O
ovarian	O
or	O
endometrial	O
cancer	O

The	O
topical	O
application	O
of	O
an	O
azalide	B
antibiotic	O
such	O
as	O
azithromycin	B
to	O
the	O
eye	O
is	O
useful	O
in	O
treating	O
or	O
preventing	O
ocular	O
infections	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
azalide	B
antibiotic	O
is	O
supplied	O
to	O
the	O
eye	O
in	O
a	O
depot	O
for	O
sustained	O
release	O
.	O

A	O
more	O
convenient	O
dosing	O
regimen	O
can	O
also	O
be	O
provided	O
by	O
the	O
use	O
of	O
an	O
appropriate	O
depot	O
.	O

Furthermore	O
,	O
a	O
composition	O
containing	O
a	O
combination	O
of	O
medicaments	O
is	O
also	O
provided	O
.	O

Application	O
of	O
an	O
azalide	B
antibiotic	O
such	O
as	O
azithromycin	B

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
I	O
:	O
I	O
(	O
where	O
A1	O
,	O
A2	O
,	O
B1	O
,	O
B2	O
,	O
B3	O
,	O
B4	O
,	O
D1	O
,	O
D2	O
,	O
T	O
,	O
U	O
,	O
V	O
,	O
W	O
,	O
X	O
,	O
Y	O
,	O
Z	O
,	O
R4	O
,	O
R5a	O
?	O
,	O
R5b	O
,	O
R5c	O
,	O
R6	O
,	O
m	O
and	O
n	O
are	O
defined	O
herein	O
)	O
useful	O
as	O
antagonists	O
of	O
CGRP	O
receptors	O
and	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
CGRP	O
is	O
involved	O
,	O
such	O
as	O
headache	O
,	O
migraine	O
and	O
cluster	O
headache	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
CGRP	O
is	O
involved	O
.	O

2-	B
(	I
2,5-Dioxo-5,6-dihydro-4H	I
-	I
imidazo	I
[	I
1,5,4-de	I
]	I
quinoxalin-1	I
(	I
2H	I
)	I
-yl	I
)	I
-N-	I
(	I
3-methyl	I
-	I
spiro	I
[	I
imidazolidine-4,2'-indane	I
]	I
-2,5-dione	I
)	I
acetamide	I
,	O
used	O
as	O
Calcitonin	O
Gene	O
-	O
Related	O
Peptide	O
(	O
CGRP	O
)	O
,	O
ligands	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
headaches	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
modulating	O
the	O
inflammatory	O
response	O
of	O
respiratory	O
tract	O
cells	O
using	O
an	O
agent	O
that	O
increases	O
ceramide	B
levels	O
in	O
the	O
cells	O
of	O
the	O
respiratory	O
tract	O
.	O

reducing	O
pro	O
-	O
inflammatory	O
response	O
in	O
diseased	O
cell	O
of	O
respiratory	O
tract	O
by	O
contacting	O
cell	O
with	O
an	O
agent	O
that	O
increases	O
ceramide	O
levels	O
in	O
cell	O
thereby	O
reducing	O
pro	O
-	O
inflammatory	O
response	O
in	O
cell	O
,	O
wherein	O
agent	O
is	O
fenretinide	B
and	O
diseased	O
cell	O
is	O
representative	O
of	O
disease	O
state	O
of	O
cystic	O
fibrosis	O

The	O
invention	O
relates	O
to	O
a	O
formulation	O
comprising	O
formoterol	B
and	O
budesonide	B
for	O
use	O
in	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O

The	O
composition	O
further	O
contains	O
HFA	O
227	O
,	O
PVP	B
and	O
PEG	B
,	O
preferably	O
PVP	B
K25	I
and	O
PEG	B
1000	I
.	O

Formeratol	B
and	O
budesonide	B
for	O
treatment	O
of	O
respiratory	O
system	O
disorders	O
such	O
as	O
chronc	O
obstructive	O
pulmonary	O
disease	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
modified	O
forms	O
of	O
therapeutic	O
agents	O
.	O

A	O
typical	O
prodrug	O
compound	O
of	O
the	O
invention	O
comprises	O
a	O
therapeutic	O
agent	O
,	O
an	O
oligopeptide	O
,	O
a	O
stabilizing	O
group	O
and	O
,	O
optionally	O
,	O
a	O
linker	O
group	O
.	O

The	O
prodrug	O
is	O
cleavable	O
by	O
the	O
CD10	O
enzyme	O
.	O

Methods	O
of	O
treatment	O
using	O
the	O
prodrug	O
and	O
methods	O
of	O
designing	O
the	O
prodrug	O
are	O
also	O
disclosed	O
.	O

screening	O
for	O
a	O
therapeutic	O
oligopeptide	O
for	O
treatment	O
of	O
tumor	O
disorders	O
;	O
contacting	O
the	O
tumor	O
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
CD10	O
cleavable	O
prodrug	O
,	O
wherein	O
tumor	O
is	O
comprised	O
of	O
one	O
or	O
more	O
target	O
cells	O
which	O
express	O
CD10	O
for	O
at	O
least	O
a	O
portion	O
of	O
the	O
target	O
cell	O
life	O
cycle	O

Methods	O
for	O
preventing	O
or	O
treating	O
damage	O
to	O
sensory	O
hair	O
cells	O
and	O
cochlear	O
neurons	O
are	O
disclosed	O
.	O

The	O
methods	O
comprise	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I	O
or	O
Formula	O
II	O
.	O

The	O
method	O
provides	O
for	O
the	O
prevention	O
/	O
treatment	O
of	O
both	O
hearing	O
loss	O
and	O
loss	O
of	O
the	O
sense	O
of	O
balance	O
.	O

Methods	O
for	O
preventing	O
/	O
treating	O
damage	O
to	O
sensory	O
hair	O
cells	O
and	O
cochlear	O
neurons	O

A	O
method	O
for	O
treating	O
irritable	O
bowel	O
syndrome	O
in	O
a	O
mammalian	O
subject	O
includes	O
administering	O
an	O
effective	O
amount	O
of	O
13,14-dihydro-15-keto-16,16-difluoro-18-methyl	B
-	I
prostaglandin	I
E1	I
or	O
13,14-dihydro-15-keto-16,16-difluoro	B
-	I
prostaglandin	I
E1	I
,	O
or	O
a	O
salt	O
,	O
ether	B
,	O
ester	B
or	O
amide	B
thereof	O
,	O
to	O
the	O
subject	O
.	O

A	O
method	O
for	O
treating	O
abdominal	O
discomfort	O
associated	O
with	O
irritable	O
bowel	O
syndrome	O
in	O
a	O
mammalian	O
subject	O
includes	O
administering	O
an	O
effective	O
amount	O
of	O
13,14-dihydro-15-keto-16,16-difluoro-18-methyl	B
-	I
prostaglandin	I
E1	I
or	O
13,14-dihydro-15-keto-16,16-difluoro	O
-	B
prostaglandin	I
E1	I
,	O
or	O
a	O
salt	O
,	O
ether	O
,	O
ester	O
or	O
amide	O
thereof	O
,	O
to	O
the	O
subject	O
.	O

FDA	O
Orange	O
book	O
listed	O
patent	O
for	O
lubiprostone	B
;	O
treating	O
irritable	O
bowel	O
syndrome	O
with	O
a	O
13,14-dihydro-15-keto-16,16-difluoro-18-methyl	B
-	I
prostaglandin	I
E1	I
,	O
or	O
a	O
salt	O
,	O
ether	B
,	O
ester	B
or	O
amide	B
thereof	O

The	O
present	O
invention	O
provides	O
novel	O
pyrimidinyl	B
-	I
thiophene	I
kinase	O
modulators	O
and	O
methods	O
of	O
using	O
the	O
novel	O
pyrimidinyl	B
-	I
thiophene	I
kinase	O
modulators	O
to	O
treat	O
diseases	O
mediated	O
by	O
kinase	O
activity	O
.	O

protein	O
kinase	O
inhibitors	O
such	O
as	O
1-	B
{	I
3-	I
[	I
4-	I
(	I
5-Bromo	I
-	I
thiophen-2-yl	I
)	I
-pyrimidin-2-ylamino	I
]	I
-phenyl	I
}	I
-ethanol	I
,	O
used	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O
or	O
rheumatoid	O
arthritis	O

A	O
novel	O
polypeptide	O
,	O
osteoprotegerin	O
binding	O
protein	O
,	O
involved	O
in	O
osteoclast	O
maturation	O
has	O
been	O
identified	O
based	O
upon	O
its	O
affinity	O
for	O
osteoprotegerin	O
.	O

Nucleic	O
acid	O
sequences	O
encoding	O
the	O
polypeptide	O
,	O
or	O
a	O
fragment	O
,	O
analog	O
,	O
or	O
derivative	O
thereof	O
,	O
vectors	O
and	O
host	O
cells	O
for	O
production	O
,	O
and	O
binding	O
assays	O
are	O
described	O
.	O

Antibodies	O
specifically	O
binding	O
osteoprotegerin	O
binding	O
protein	O
are	O
also	O
described	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
bone	O
diseases	O
such	O
as	O
osteoporosis	O
,	O
bone	O
loss	O
due	O
to	O
arthritis	O
or	O
metastasis	O
,	O
hypercalcemia	O
,	O
and	O
Paget	O
's	O
disease	O
are	O
also	O
provided	O
.	O

Antibodies	O
to	O
osteoprotegerin	O
binding	O
proteins	O

An	O
oral	O
,	O
immunostimulating	O
material	O
for	O
mammals	O
,	O
birds	O
,	O
fish	O
,	O
and	O
reptiles	O
comprising	O
an	O
immunostimulating	O
amount	O
of	O
an	O
alginate	O
having	O
a	O
M	O
content	O
of	O
at	O
least	O
40	O
%	O
and	O
an	O
acceptable	O
carriers	O
.	O

Oral	O
immunostimulation	O
of	O
fish	O
from	O
(	O
1	O
-	O
4	O
)	O
linked	O
β	B
-	I
D	I
-	I
mannuronic	I
acid	I

Long	O
chain	O
N	B
-	I
alkyl	I
amino	I
and	I
imino	I
compounds	O
,	O
oxa	B
-	O
substituted	O
derivatives	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
including	O
such	O
compounds	O
are	O
described	O
.	O

The	O
long	O
chain	O
N	B
-	I
alkyl	I
group	O
is	O
a	O
C8-C16	B
alkyl	I
group	O
.	O

The	O
long	O
chain	O
N	B
-	I
alkyl	I
compounds	O
and	O
oxa	B
-	O
substituted	O
derivatives	O
thereof	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
viral	O
infections	O
,	O
in	O
particular	O
hepatitis	O
B	O
virus	O
or	O
hepatitis	O
C	O
virus	O
,	O
in	O
a	O
cell	O
or	O
an	O
individual	O
.	O

For	O
example	O
,	O
the	O
long	O
chain	O
N	B
-	I
alkyl	I
compounds	O
or	O
oxa	B
-	O
substituted	O
derivatives	O
thereof	O
can	O
be	O
derived	O
from	O
piperidines	B
,	O
pyrrolidines	B
,	O
phenylamines	B
,	O
pyridines	B
,	O
pyrroles	B
,	O
or	O
amino	B
acids	I
.	O

N	B
-	I
nonyl-1,5,6-trideoxy-1,5-imino	I
-	I
D	I
-	I
galactitol	I
;	O
N-	B
(	I
7-oxa	I
-	I
nonyl	I
)	I
-1,5,6-trideoxy-1,5-imino	I
-	I
D	I
-	I
galactito	I
;	O
viricide	B
;	O
for	O
treating	O
hepatitis	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
licochalcone	B
A	I
for	O
the	O
treatment	O
of	O
rosacea	O
.	O

Use	O
of	O
licochalcone	B
A	I
against	O
rosacea	O

A	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
diabetes	O
complications	O
,	O
which	O
comprises	O
as	O
an	O
effective	O
ingredient	O
a	O
cyclohexenone	B
long	O
-	O
chain	O
alcoholic	O
derivative	O
represented	O
by	O
the	O
following	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
each	O
independently	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
methyl	B
group	O
and	O
X	O
represents	O
a	O
linear	O
or	O
branched	O
C10	B
-	I
28	I
alkylene	I
or	O
alkenylene	B
group	O
.	O

The	O
cyclohexenone	B
long	O
-	O
chain	O
alcoholic	O
derivative	O
of	O
the	O
present	O
invention	O
significantly	O
suppresses	O
a	O
reduction	O
in	O
a	O
peripheral	O
nerve	O
conduction	O
rate	O
and	O
alleviates	O
the	O
hypofunction	O
of	O
the	O
bladder	O
so	O
that	O
it	O
is	O
useful	O
as	O
a	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
diabetes	O
complications	O
,	O
particularly	O
,	O
for	O
diabetic	O
neuropathy	O
.	O

Suppresses	O
reduction	O
in	O
peripheral	O
nerve	O
conduction	O
rate	O
and	O
alleviates	O
hypofunction	O
of	O
bladder	O
so	O
that	O
it	O
is	O
useful	O
as	O
a	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
,	O
particularly	O
,	O
diabetic	O
neuropathy	O

Novel	O
synthetic	O
gangliosides	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
synthetic	O
gangliosides	O
are	O
described	O
.	O

Methods	O
of	O
making	O
the	O
novel	O
synthetic	O
ganglioside	O
compounds	O
and	O
compositions	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
field	O
of	O
neuroprotection	O
and	O
cancer	O
treatment	O
is	O
also	O
described	O
.	O

use	O
in	O
the	O
field	O
of	O
neuroprotection	O
and	O
cancer	O
treatment	O
(	O
neuroblastoma	O
tumors	O
)	O

The	O
present	O
invention	O
relates	O
to	O
CGRP	O
receptor	O
antagonists	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
therewith	O
for	O
treating	O
CGRP	O
receptor	O
-	O
mediated	O
diseases	O
and	O
conditions	O
.	O

Calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
receptor	O
antagonists	O
,	O
such	O
as	O
2-	B
(	I
2-Butyl-3-oxo-2H	I
-	I
benzo	I
[	I
b	I
]	I
[	I
1,4	I
]	I
thiazin-4	I
(	I
3H	I
)	I
-yl	I
)	I
-N-	I
(	I
2,5-dioxo-1',3'-dihydrospiro	I
[	I
imidazolidine-4,2'-indene	I
]	I
-5'-yl	I
)	I
acetamide	I
,	O
used	O
as	O
analgesics	O

The	O
present	O
invention	O
relates	O
to	O
cosmetic	O
compositions	O
and	O
more	O
particularly	O
to	O
skin	O
-	O
whitening	O
cosmetic	O
compositions	O
comprising	O
senkyunolide	B
A	I
as	O
an	O
active	O
ingredient	O
.	O

The	O
present	O
invention	O
discloses	O
the	O
novel	O
inhibitory	O
function	O
of	O
senkyunolide	B
A	I
isolated	O
from	O
Cnidium	O
officinale	O
and	O
Ligusticum	O
chuanxiong	O
on	O
the	O
melanocyte	O
-	O
stimulating	O
hormone	O
(	O
MSH	O
)	O
,	O
and	O
provides	O
MSH	O
-	O
inhibitory	O
compositions	O
and	O
skin	O
-	O
whitening	O
cosmetic	O
compositions	O
comprising	O
the	O
senkyunolide	B
A.	I
The	O
compositions	O
of	O
the	O
present	O
invention	O
show	O
significantly	O
enhanced	O
skin	O
-	O
whitening	O
effect	O
owing	O
to	O
its	O
efficient	O
inhibition	O
of	O
MSH	O
even	O
in	O
lower	O
concentration	O
.	O

isolated	O
from	O
Cnidium	O
officinale	O
and	O
Ligusticum	O
chuanxiong	O
;	O
inhibiting	O
melanocyte	O
-	O
stimulating	O
hormone	O

Use	O
of	O
hydroxyoleic	B
acid	I
and	O
its	O
analogous	O
compounds	O
in	O
the	O
manufacture	O
of	O
drugs	O
.	O

Describes	O
the	O
use	O
of	O
hydroxyoleic	B
acid	I
and	O
its	O
analogs	O
of	O
general	O
formula	O

I	O
:	O
COOH	B
—	I
CHR—	I
(	I
CH2	I
)	I
m	I
—	I
CH	I
═	I
CH—	I
(	I
CH2	I
)	I
n	I
—	I
CH3	I
,	O
in	O
which	O
m	O
and	O
n	O
have	O
,	O
independently	O
,	O
a	O
value	O
of	O
0	O
-	O
15	O
and	O
R	O
can	O
be	O
any	O
residue	O
with	O
molecular	O
weight	O
below	O
200	O
Da	O
,	O
in	O
the	O
manufacture	O
of	O
drugs	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
cancer	O
,	O
hypertension	O
,	O
obesity	O
or	O
diseases	O
mediated	O
by	O
alteration	O
of	O
the	O
membrane	O
structure	O
and	O
the	O
consequent	O
regulation	O
of	O
G	O
-	O
proteins	O
or	O
of	O
the	O
receptors	O
coupled	O
to	O
them	O
.	O

Administering	O
to	O
a	O
lung	O
cancer	O
patient	O
2-hydroxyoleic	B
acid	I
in	O
an	O
amount	O
effective	O
to	O
inhabit	O
proliferation	O
of	O
the	O
cancer	O
;	O
leukemia	O
,	O
brain	O
metastasis	O

A	O
method	O
for	O
treating	O
fungal	O
infections	O
in	O
a	O
mammal	O
that	O
includes	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
substantially	O
pure	O
amphotericin	B
B	I
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Amphotericin	B
BHP	I
is	O
associated	O
with	O
decreased	O
toxicity	O
in	O
mammals	O
and	O
cells	O
measured	O
by	O
cell	O
viability	O
and	O
expression	O
of	O
cytokine	O
markers	O
.	O

Thus	O
,	O
this	O
method	O
allows	O
for	O
reduced	O
adverse	O
reactions	O
when	O
using	O
amphotericin	B
B	I
products	O
.	O

Compositions	O
comprising	O
highly	O
purified	O
amphotericin	B
B	I

The	O
present	O
invention	O
describes	O
organophosphorus	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
their	O
preparation	O
and	O
their	O
uses	O
in	O
the	O
activation	O
of	O
gamma	O
/	O
delta	O
T	O
-	O
cells	O
,	O
in	O
the	O
screening	O
of	O
GcpE	O
and	O
LytB	O
enzyme	O
inhibitors	O
and	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
in	O
humans	O
and	O
animals	O
.	O

antiallergen	O
,	O
viricide	O
,	O
herbicide	O
,	O
autoimmune	O
diseases	O
;	O
screening	O
procedure	O
for	O
the	O
identification	O
of	O
enzymes	O
GcpE	O
and	O
LytB	O
inhibitor	O
;	O
4-hydroxy-3-methyl-2-butenyl	B
1-pyrophosphate	I
;	O
precursor	O
of	O
higher	O
isoprenoids	B
in	O
2-methyl	B
-	I
D	I
-	I
erythritol	I
pathway	O
(	O
MEP	O
)	O

Racemic	B
norketotifen	I
,	O
racemic	B
10-hydroxy	I
-	I
ketotifen	I
,	O
racemic	B
10-hydroxy	I
-	I
nor	I
-	I
ketotifen	I
and	O
optically	O
active	O
isomers	O
of	O
ketotifen	B
,	O
norketotifen	B
,	O
10-hydroxy	B
-	I
ketotifen	I
and	O
10-hydroxy	B
-	I
norketotifen	I
were	O
found	O
to	O
have	O
antiallergic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
while	O
being	O
devoid	O
of	O
the	O
severe	O
dose	O
-	O
limiting	O
sedative	O
side	O
effects	O
of	O
Ketotifen	B
.	O

Optically	O
active	O
isomers	O
of	O
ketotifen	B
and	O
therapeutically	O
active	O
metabolites	O
thereof	O

The	O
invention	O
relates	O
to	O
arylcycloalkyl	B
-	I
substituted	I
alkanoic	I
acid	I
derivatives	O
and	O
to	O
their	O
physiologically	O
acceptable	O
salts	O
and	O
physiologically	O
functional	O
derivatives	O
.	O

What	O
is	O
described	O
are	O
compounds	O
of	O
the	O
formula	O
I	O
,	O
in	O
which	O
the	O
radicals	O
are	O
as	O
defined	O
,	O
and	O
their	O
physiologically	O
acceptable	O
salts	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

The	O
compounds	O
are	O
suitable	O
,	O
for	O
example	O
,	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
disorders	O
of	O
the	O
fatty	B
acid	I
metabolism	O
and	O
glucose	O
utilization	O
disorders	O
and	O
also	O
disorders	O
in	O
which	O
insulin	O
resistance	O
is	O
involved	O
.	O

Arylcycloalkyl	B
-	I
substituted	I
alkanoic	I
acid	I
derivatives	O
,	O
processes	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
pharmaceuticals	O

Disclosed	O
is	O
a	O
composition	O
and	O
methods	O
of	O
treating	O
a	O
skin	O
condition	O
.	O

The	O
ester	B
includes	O
an	O
ester	B
and	O
a	O
dermatologically	O
acceptable	O
carrier	O
.	O

The	O
ester	B
is	O
represented	O
by	O
the	O
general	O
formula	O
1	O
:	O
idebenone	B
octanoate	I
;	O
idebenone	B
conjugated	I
linoleate	I
,	O
idebenone	B
linoleate	I
;	O
dematology	O
;	O
skin	O
roughness	O
,	O
skin	O
wrinkles	O
,	O
photodamaged	O
skin	O
,	O
skin	O
hyperpigmentation	O
,	O
skin	O
irritation	O
and	O
skin	O
inflammatory	O
reaction	O

The	O
invention	O
relates	O
to	O
crystalline	O
barium	B
salt	O
of	O
(	B
S	I
)	I
-omeprazole	I
,	O
which	O
is	O
(	B
S	I
)	I
-5-methoxy-2-	I
[	I
[	I
(	I
4-methoxy-3,5-dimethyl-2-pyridinyl	I
)	I
-methyl	I
]	I
sulfinyl	I
]	I
-1H	I
-	I
benzimidazole	I
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
preparing	O
crystalline	O
barium	B
salt	O
of	O
(	B
S	I
)	I
-omeprazole	I
and	O
pharmaceutical	O
compositions	O
that	O
include	O
the	O
crystalline	O
barium	B
salt	O
of	O
(	B
S	I
)	I
-omeprazole	I
so	O
prepared	O
.	O

contacting	O
(	B
S	I
)	I
-omeprazole	I
freebase	O
or	O
its	O
sodium	B
/	O
potassium	B
salt	O
with	O
inorganic	O
or	O
organic	B
acid	I
salt	O
of	O
the	O
barium	B
(	O
barium	B
chloride	I
,	O
barium	B
sulfate	I
,	O
barium	B
oxalate	I
,	O
barium	B
acetate	I
)	O
in	O
a	O
suitable	O
solvent	O
(	O
methanol	B
)	O
in	O
presence	O
of	O
a	O
base	O
(	O
NaOH	B
)	O
to	O
form	O
(	B
S	I
)	I
-omeprazole	I
barium	I
;	O
helicobacter	O
infections	O

Disclosed	O
is	O
a	O
method	O
of	O
treating	O
a	O
non	O
-	O
topical	O
infection	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ear	O
infections	O
,	O
skin	O
and	O
soft	O
tissue	O
infections	O
,	O
acne	O
,	O
infected	O
wounds	O
,	O
bacteremia	O
,	O
in	O
a	O
useful	O
warm	O
blooded	O
mammal	O
who	O
is	O
in	O
need	O
of	O
such	O
treatment	O
which	O
comprises	O
topical	O
administration	O
of	O
a	O
pharmaceutical	O
formulation	O
containing	O
a	O
transdermally	O
effective	O
amount	O
of	O
an	O
Oxazolidinone	B
.	O

Topical	O
administration	O
of	O
oxazolidinones	B
for	O
transdermal	O
delivery	O

The	O
present	O
invention	O
aims	O
at	O
providing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
,	O
irrespective	O
of	O
the	O
kind	O
of	O
virus	O
,	O
of	O
viral	O
myocarditis	O
or	O
viral	O
diseases	O
induced	O
by	O
viral	O
myocarditis	O
,	O
by	O
the	O
treatment	O
or	O
prevention	O
of	O
the	O
onset	O
of	O
cytotoxicity	O
in	O
various	O
organs	O
,	O
and	O
a	O
method	O
of	O
the	O
prophylaxis	O
or	O
treatment	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
viral	O
myocarditis	O
or	O
viral	O
diseases	O
induced	O
by	O
viral	O
myocarditis	O
,	O
which	O
contains	O
2-amino-2-	B
(	I
2-	I
(	I
4-octylphenyl	I
)	I
ethyl	I
)	I
propane-1,3-diol	I
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
method	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
viral	O
myocarditis	O
or	O
viral	O
diseases	O
induced	O
by	O
viral	O
myocarditis	O
,	O
which	O
includes	O
administering	O
an	O
effective	O
amount	O
of	O
the	O
aforementioned	O
compound	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Use	O
of	O
fingolimod	B
or	O
salt	O

Compositions	O
comprising	O
first	O
and	O
second	O
oligomers	B
are	O
provided	O
wherein	O
at	O
least	O
a	O
portion	O
of	O
the	O
first	O
oligomer	B
is	O
capable	O
of	O
hybridizing	O
with	O
at	O
least	O
a	O
portion	O
of	O
the	O
second	O
oligomer	B
,	O
at	O
least	O
a	O
portion	O
of	O
the	O
first	O
oligomer	B
is	O
complementary	O
to	O
and	O
capable	O
of	O
hybridizing	O
to	O
a	O
selected	O
target	O
nucleic	O
acid	O
,	O
and	O
at	O
least	O
one	O
of	O
the	O
first	O
or	O
second	O
oligomers	B
includes	O
a	O
modified	O
sugar	B
and/or	O
backbone	O
modification	O
.	O

In	O
some	O
embodiments	O
the	O
modification	O
is	O
a	O
2′	O
substituent	O
group	O
on	O
a	O
sugar	B
moiety	O
that	O
is	O
not	O
H	B
or	O
OH	B
.	O

Oligomer	B
/	O
protein	O
compositions	O
are	O
also	O
provided	O
comprising	O
an	O
oligomer	B
complementary	O
to	O
and	O
capable	O
of	O
hybridizing	O
to	O
a	O
selected	O
target	O
nucleic	O
acid	O
and	O
at	O
least	O
one	O
protein	O
comprising	O
at	O
least	O
a	O
portion	O
of	O
an	O
RNA	O
-	O
induced	O
silencing	O
complex	O
(	O
RISC	O
)	O
,	O
wherein	O
at	O
least	O
one	O
nucleotide	O
of	O
the	O
oligomer	O
has	O
a	O
modified	O
sugar	B
and/or	O
backbone	O
modification	O
.	O

Comprises	O
modified	O
nucleotide	O
sequences	O
for	O
use	O
in	O
gene	O
expression	O
inhibition	O
,	O
viral	O
defense	O
,	O
transposon	O
silencing	O
and	O
treatment	O
of	O
metabolic	O
disorders	O
;	O
antisense	O
agents	O

Intraorally	O
rapidly	O
disintegrating	O
tablets	O
which	O
,	O
when	O
ingested	O
,	O
disintegrates	O
in	O
the	O
oral	O
cavity	O
rapidly	O
without	O
presenting	O
unpleasant	O
taste	O
,	O
can	O
be	O
quickly	O
absorbed	O
in	O
the	O
digestive	O
tract	O
and	O
express	O
efficacy	O
are	O
provided	O
.	O

The	O
intraorally	O
rapidly	O
disintegrating	O
tablets	O
contain	O
a	O
drug	O
being	O
hardly	O
water	O
-	O
soluble	O
under	O
neutral	O
or	O
alkaline	O
conditions	O
and	O
being	O
highly	O
water	O
-	O
soluble	O
under	O
acidic	O
conditions	O
yet	O
presenting	O
unpleasant	O
taste	O
,	O
which	O
tablets	O
can	O
be	O
prepared	O
by	O
combining	O
the	O
medicinal	O
substance	O
with	O
a	O
water	O
-	O
soluble	O
acidic	O
substance	O
,	O
coating	O
either	O
or	O
both	O
of	O
the	O
substances	O
with	O
a	O
water	O
-	O
soluble	O
coating	O
agent	O
being	O
insoluble	O
in	O
alcoholic	O
solvent	O
,	O
further	O
adding	O
a	O
water	O
-	O
soluble	O
binding	O
agent	O
being	O
soluble	O
in	O
alcoholic	O
solvent	O
and	O
a	O
water	O
-	O
soluble	O
saccharide	O
,	O
subjecting	O
the	O
resultant	O
mixture	O
to	O
compression	O
,	O
and	O
treating	O
the	O
products	O
with	O
an	O
alcoholic	O
solvent	O
.	O

Pleasant	O
taste	O
;	O
bioabsorbable	O
;	O
overcoated	O
water	O
insoluble	O
drug	O
in	O
alcohol	B
solvent	O
and	O
water	O
soluble	O
binder	O
;	O
mixing	O
,	O
compression	O

Ethyl	B
3-	I
[	I
(	I
2-	I
{	I
[	I
4-	I
(	I
hexyloxycarbonylaminoiminomethyl	I
)	I
phenylamino	I
]	I
methyl	I
}	I
-1-methyl-1H	I
-	I
benzimidazole-5-carbonyl	I
)	I
pyridin-2-ylamino	I
]	I
propionate	I
methanesulfonate	I
in	O
the	O
crystalline	O
modifications	O
I	O
and	O
II	O
and	O
as	O
the	O
hemihydrate	O
and	O
the	O
use	O
thereof	O
as	O
a	O
pharmaceutical	O
composition	O
.	O

3-	B
[	I
(	I
2-	I
{	I
[	I
4-	I
(	I
hexyloxycarbonylaminoiminomethyl	I
)	I
phenylamino	I
]	I
methyl	I
}	I
-1-methyl-1H	I
-	I
benzimidazol-5-carbonyl	I
)	I
pyridin-2-ylamino	I
]	I
propionic	I
acid	I
ethylester	I
methansulfonate	I
and	O
its	O
use	O
as	O
a	O
medicament	O

The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
developing	O
a	O
main	O
proteinase	O
SARS	O
inhibitor	O
.	O

Human	O
coronaviruses	O
are	O
major	O
causes	O
of	O
upper	O
respiratory	O
tract	O
illnesses	O
in	O
humans	O
,	O
in	O
particular	O
,	O
the	O
common	O
cold	O
.	O

Recent	O
investigations	O
have	O
shown	O
that	O
a	O
novel	O
coronavirus	O
causes	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
,	O
a	O
disease	O
that	O
is	O
characterized	O
by	O
high	O
fever	O
,	O
malaise	O
,	O
rigor	O
,	O
headache	O
,	O
non	O
-	O
productive	O
cough	O
or	O
dyspnea	O
,	O
which	O
is	O
rapidly	O
spreading	O
.	O

Within	O
the	O
scope	O
of	O
the	O
invention	O
,	O
based	O
on	O
the	O
structural	O
analysis	O
of	O
the	O
binding	O
mode	O
of	O
the	O
SARS	O
Mpro	O
enzyme	O
,	O
a	O
group	O
of	O
prototype	O
inhibitors	O
is	O
provided	O
that	O
acts	O
as	O
suitable	O
drugs	O
targeting	O
a	O
majority	O
of	O
viral	O
infections	O
of	O
the	O
respiratory	O
tract	O
,	O
including	O
SARS	O
.	O

Crystal	O
structure	O
of	O
human	O
coronavirus	O
229E	O
main	O
proteinase	O
and	O
uses	O
for	O
developing	O
SARS	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
useful	O
as	O
inhibitors	O
of	O
voltage	O
-	O
gated	O
sodium	O
channels	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
.	O

Compositions	O
useful	O
as	O
inhibitors	O
of	O
voltage	O
-	O
gated	O
ion	O
channels	O

The	O
subject	O
invention	O
relates	O
to	O
the	O
identification	O
of	O
several	O
genes	O
involved	O
in	O
the	O
elongation	O
of	O
polyunsaturated	O
fatty	B
acids	I
(	O
i.e.	O
,	O
""""	O
elongases	O
""""	O
)	O
and	O
to	O
uses	O
thereof	O
.	O

At	O
least	O
two	O
of	O
these	O
genes	O
are	O
also	O
involved	O
in	O
the	O
elongation	O
of	O
monounsaturated	O
fatty	B
acids	I
.	O

In	O
particular	O
,	O
elongase	O
is	O
utilized	O
in	O
the	O
conversion	O
of	O
gamma	B
linolenic	I
acid	I
(	O
GLA	B
)	O
to	O
dihomogamma	B
linolenic	I
acid	I
(	O
DGLA	B
)	O
and	O
in	O
the	O
conversion	O
of	O
AA	B
to	O
adrenic	B
acid	I
(	O
ADA	B
)	O
,	O
or	O
eicosapentaenoic	B
acid	I
(	O
EPA	B
)	O
to	O
ω3-docosapentaenoic	B
acid	I
(	O
DPA	B
)	O
.	O

DGLA	B
may	O
be	O
utilized	O
in	O
the	O
production	O
of	O
polyunsaturated	O
fatty	B
acids	I
,	O
such	O
as	O
arachidonic	B
acid	I
(	O
AA	B
)	O
,	O
docosahexaenoic	B
acid	I
(	O
DHA	B
)	O
,	O
EPA	B
,	O
adrenic	B
acid	I
,	O
ω6-docosapentaenoic	B
acid	I
or	O
ω3-docosapentaenoic	B
acid	I
which	O
may	O
be	O
added	O
to	O
pharmaceutical	O
compositions	O
,	O
nutritional	O
compositions	O
,	O
animal	O
feeds	O
,	O
as	O
well	O
as	O
other	O
products	O
such	O
as	O
cosmetics	O
.	O

Nutrients	O
,	O
animal	O
feeds	O
,	O
cosmetics	O
;	O
elongation	O
of	O
polyunsaturated	O
fatty	B
acid	I

A	O
subject	O
of	O
the	O
present	O
invention	O
is	O
to	O
find	O
utility	O
of	O
a	O
combination	O
of	O
a	O
Rho	O
kinase	O
inhibitor	O
having	O
a	O
novel	O
action	O
and	O
a	O
β	O
-	O
blocker	O
as	O
a	O
therapeutic	O
agent	O
for	O
glaucoma	O
.	O

Actions	O
of	O
reducing	O
intraocular	O
pressure	O
are	O
complemented	O
and/or	O
enhanced	O
each	O
other	O
by	O
combining	O
the	O
Rho	O
kinase	O
inhibitor	O
with	O
the	O
β	O
-	O
blocker	O
.	O

For	O
the	O
administration	O
mode	O
,	O
each	O
drug	O
can	O
be	O
administered	O
in	O
combination	O
or	O
in	O
mixture	O
.	O

Remedy	O
for	O
glaucoma	O
comprising	O
Rho	O
kinase	O
inhibitor	O
and	O
β	O
-	O
blocker	O

Immunization	O
of	O
human	O
antibody	O
-	O
producing	O
transgenic	O
mice	O
,	O
which	O
have	O
been	O
created	O
using	O
genetic	O
engineering	O
techniques	O
,	O
with	O
AILIM	O
molecule	O
as	O
an	O
antigen	O
resulted	O
in	O
various	O
human	O
monoclonal	O
antibodies	O
capable	O
of	O
binding	O
to	O
AILIM	O
and	O
capable	O
of	O
controlling	O
a	O
variety	O
of	O
biological	O
reactions	O
(	O
for	O
example	O
,	O
cell	O
proliferation	O
,	O
cytokine	O
production	O
,	O
immune	O
cytolysis	O
,	O
cell	O
death	O
,	O
induction	O
of	O
ADCC	O
,	O
etc	O
.	O
)	O
associated	O
with	O
AILIM	O
-	O
mediated	O
costimulatory	O
signal	O
(	O
secondary	O
signal	O
)	O
transduction	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
revealed	O
that	O
the	O
human	O
monoclonal	O
antibody	O
is	O
effective	O
to	O
treat	O
and	O
prevent	O
various	O
diseases	O
associated	O
with	O
AILIM	O
-	O
mediated	O
costimulatory	O
signal	O
transduction	O
,	O
being	O
capable	O
of	O
inhibiting	O
the	O
onset	O
and/or	O
advancement	O
of	O
the	O
diseases	O
.	O

Methods	O
of	O
treating	O
systemic	O
lupus	O
erythematosus	O
with	O
an	O
antibody	O
against	O
costimulatory	O
signal	O
transduction	O
molecule	O
ailim	O

The	O
invention	O
relates	O
to	O
an	O
assay	O
to	O
select	O
a	O
candidate	O
drug	O
for	O
the	O
treatment	O
of	O
inflammatory	O
disease	O
due	O
to	O
cytokine	O
production	O
.	O

The	O
assay	O
comprises	O
:	O
a	O
)	O
exposing	O
said	O
candidate	O
drug	O
to	O
intestinal	O
cells	O
;	O
and	O
b	O
)	O
analysing	O
the	O
effect	O
of	O
the	O
said	O
candidate	O
drug	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
the	O
variation	O
of	O
nuclear	O
export	O
or	O
import	O
of	O
transcription	O
factors	O
from	O
the	O
NF	O
-	O
κB	O
family	O
the	O
disruption	O
of	O
transcriptional	O
activity	O
of	O
transcription	O
factors	O
from	O
the	O
NF	O
-	O
κB	O
family	O
,	O
the	O
differential	O
histone	O
acetylation	O
of	O
p65	O
(	O
RelA	O
)	O
;	O
the	O
variation	O
of	O
the	O
amount	O
of	O
PPARγ	O
/	O
RelA	O
complexes	O
in	O
the	O
cytosol	O
of	O
the	O
cells	O
;	O
and	O
a	O
combination	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
methods	O
for	O
the	O
treatment	O
of	O
inflammatory	O
cytokine	O
production	O
associated	O
diseases	O
and	O
to	O
the	O
use	O
of	O
a	O
therapeutically	O
effective	O
dose	O
of	O
Bacteroides	O
thetaiotaomicron	O
or	O
a	O
component	O
thereof	O
.	O

Methods	O
for	O
treating	O
an	O
inflammatory	O
disease	O
of	O
the	O
bowel	O

The	O
invention	O
relates	O
to	O
a	O
nasally	O
applied	O
,	O
film	O
-	O
shaped	O
,	O
bioadhesive	O
pharmaceutical	O
form	O
of	O
administration	O
containing	O
at	O
least	O
one	O
agent	O
-	O
containing	O
layer	O
that	O
is	O
based	O
on	O
crosslinked	O
hydrophilic	O
polymers	O
comprising	O
up	O
to	O
60	O
percent	O
by	O
weight	O
of	O
Lidocaine	B
,	O
the	O
percentage	O
being	O
in	O
relation	O
to	O
the	O
total	O
quantity	O
of	O
crosslinked	O
hydrophilic	O
polymers	O
.	O

Also	O
disclosed	O
is	O
the	O
use	O
thereof	O
for	O
controlling	O
primary	O
headaches	O
,	O
preferably	O
migraine	O
.	O

Form	O
of	O
administration	O
for	O
controlling	O
primary	O
headaches	O

There	O
are	O
disclosed	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
L	O
,	O
R1	O
,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
together	O
with	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
.	O

The	O
compounds	O
are	O
inhibitors	O
of	O
the	O
enzyme	O
MPO	O
and	O
are	O
thereby	O
particularly	O
useful	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
neuroinflammatory	O
disorders	O
,	O
cardio-	O
and	O
cerebrovascular	O
atherosclerotic	O
disorders	O
and	O
peripheral	O
artery	O
disease	O
and	O
respiratory	O
disorders	O
.	O

Thioxanthine	B
derivatives	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
MPO	O

Lysine	B
mimetic	O
compounds	O
having	O
useful	O
pharmacological	O
activity	O
such	O
as	O
antiarrhythmic	O
activity	O
and	O
desirable	O
bioavailability	O
properties	O
are	O
disclosed	O
.	O

Modified	O
lysine	B
-	O
mimetic	O
compounds	O

The	O
invention	O
relates	O
to	O
bisphosphonates	B
,	O
in	O
particular	O
more	O
potent	O
N	B
-	I
bisphosphonates	I
such	O
as	O
zoledronic	B
acid	I
and	O
derivatives	O
,	O
and	O
to	O
methods	O
of	O
treatment	O
using	O
bisphosphonates	B
.	O

These	O
bisphosphonates	B
are	O
used	O
with	O
satisfactory	O
results	O
for	O
prolonged	O
inhibition	O
of	O
bone	O
resorption	O
in	O
conditions	O
of	O
abnormally	O
increased	O
bone	O
turnover	O
,	O
e.g.	O
osteoporosis	O
,	O
by	O
intermittent	O
administration	O
,	O
the	O
periods	O
between	O
bisphosphonate	B
administrations	O
are	O
longer	O
than	O
was	O
previously	O
considered	O
appropriate	O
,	O
e.g.	O
a	O
dosing	O
interval	O
of	O
at	O
least	O
about	O
6	O
months	O
or	O
less	O
frequently	O
.	O

Intermittently	O
administering	O
a	O
bisphosphonate	B
to	O
patient	O
,	O
wherein	O
period	O
between	O
administrations	O
of	O
bisphosphonate	B
is	O
at	O
least	O
6	O
months	O
;	O
treatment	O
of	O
osteoporosis	O

Peptide	O
compositions	O
are	O
described	O
.	O

In	O
particular	O
,	O
peptide	O
compositions	O
are	O
described	O
which	O
include	O
at	O
least	O
two	O
peptides	O
which	O
are	O
selected	O
from	O
among	O
the	O
following	O
peptides	O
:	O
a	O
peptide	O
A	O
having	O
at	O
least	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
N	O
°	O
1	O
,	O
a	O
peptide	O
B	O
having	O
at	O
least	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
N	O
°	O
45	O
,	O
a	O
peptide	O
C	O
having	O
at	O
least	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
N	O
°	O
127	O
,	O
and	O
a	O
peptide	O
D	O
having	O
at	O
least	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
N	O
°	O
174	O
.	O

The	O
compositions	O
can	O
be	O
used	O
,	O
in	O
particular	O
,	O
in	O
the	O
preparation	O
of	O
active	O
pharmaceutical	O
compositions	O
against	O
the	O
hepatitis	O
C	O
virus	O
.	O

Nucleic	O
acid	O
compositions	O
and	O
their	O
use	O
against	O
the	O
hepatitic	O
C	O
virus	O

This	O
invention	O
relates	O
to	O
a	O
use	O
of	O
hederagenin	B
3-O	I
-	I
α	I
-	I
L	I
-	I
rhamnopyranosyl	I
(	I
(	I
1→2	I
)	I
-	I
[	I
β	I
-	I
D	I
-	I
glucopyranosyl	I
(	I
1→4	I
)	I
]	I
-α	I
-	I
L	I
-	I
arabinopyranoside	I
or	O
a	O
Pulsatillae	O
radix	O
extract	O
containing	O
the	O
same	O
as	O
a	O
therapeutic	O
agent	O
for	O
solid	O
tumors	O
.	O

Also	O
,	O
this	O
invention	O
relates	O
to	O
a	O
method	O
of	O
preparing	O
a	O
therapeutic	O
agent	O
for	O
solid	O
tumors	O
by	O
using	O
hederagenin	B
3	I
-	I
0-α	I
-	I
L	I
-	I
rhamnopyranosyl	I
(	I
1→2	I
)	I
-	I
[	I
β	I
-	I
D	I
-	I
glucopyranosyl	I
(	I
1→4	I
)	I
]	I
-α	I
-	I
L	I
-	I
arabinopyranoside	I
,	O
or	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
solid	O
tumors	O
,	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
dose	O
of	O
hederagenin	B
3	I
-	I
0-α	I
-	I
L	I
-	I
rhamnopyranosyl	I
(	I
1→2	I
)	I
-	I
[	I
β	I
-	I
D	I
-	I
glucopyranosyl	I
(	I
1→4	I
)	I
]	I
-α	I
-	I
L	I
-	I
arabinopyranoside	I
.	O

Use	O
of	O
hederagenin	B
3-O	I
-	I
α	I
-	I
L	I
-	I
rhamnopyranosyl	I
(	I
1→2	I
)	I
-	I
(	I
β	I
-	I
D	I
-	I
glucopyranosyl	I
(	I
1→4	I
)	I
-α	I
-	I
L	I
-	I
arabinopyranoside	I
or	O
an	O
extract	O
from	O
pulsatillae	O
radix	O
containing	O
the	O
same	O
as	O
a	O
therapeutic	O
agent	O
for	O
solid	O
tumors	O

The	O
use	O
of	O
nanoparticles	O
of	O
inorganic	O
materials	O
(	O
e.g.	O
,	O
synthetic	O
smectite	O
clays	O
)	O
in	O
ophthalmic	O
compositions	O
is	O
described	O
.	O

The	O
nanoparticles	O
are	O
utilized	O
as	O
biologically	O
inert	O
carriers	O
or	O
depots	O
for	O
biocides	O
.	O

The	O
nanoparticles	O
are	O
particularly	O
useful	O
in	O
preventing	O
or	O
reducing	O
the	O
uptake	O
of	O
biocides	O
from	O
ophthalmic	O
compositions	O
by	O
contact	O
lenses	O
,	O
when	O
the	O
compositions	O
are	O
applied	O
to	O
the	O
lenses	O
.	O

Use	O
of	O
nanoparticles	O
as	O
carriers	O
for	O
biocides	O
in	O
ophthalmic	O
compositions	O

Dermatological	O
methods	O
of	O
cosmetic	O
,	O
therapeutic	O
,	O
prophylactic	O
,	O
and/or	O
diagnostic	O
treatment	O
by	O
topically	O
applying	O
compositions	O
comprising	O
a	O
multiplicity	O
of	O
particles	O
,	O
at	O
least	O
one	O
of	O
the	O
particles	O
comprising	O
porous	O
and/or	O
polycrystalline	O
silicon	B
.	O

Included	O
are	O
methods	O
and	O
compositions	O
for	O
sun	O
protection	O
applications	O
.	O

The	O
use	O
of	O
porous	O
silicon	B
,	O
polycrystalline	O
silicon	B
,	O
and	O
porous	O
silicon	B
oxide	I
mirrors	O
is	O
disclosed	O
.	O

Method	O
of	O
protecting	O
skin	O
from	O
UV	O
radiation	O
using	O
a	O
dermatological	O
composition	O
having	O
porous	O
silicon	B

The	O
invention	O
relates	O
to	O
a	O
combined	O
pharmaceutical	O
preparation	O
comprising	O
parathyroid	O
hormone	O
and	O
a	O
bone	O
resorption	O
inhibitor	O
,	O
said	O
preparation	O
being	O
adapted	O
for	O
(	O
a	O
)	O
the	O
administration	O
of	O
parathyroid	O
hormone	O
during	O
a	O
period	O
of	O
approximately	O
6	O
to	O
24	O
months	O
;	O
(	O
b	O
)	O
after	O
the	O
administration	O
of	O
parathyroid	O
hormone	O
has	O
been	O
terminated	O
,	O
the	O
administration	O
of	O
a	O
bone	O
resorption	O
inhibitor	O
during	O
a	O
period	O
of	O
approximately	O
12	O
to	O
36	O
months	O
.	O

Methods	O
useful	O
in	O
the	O
treatment	O
of	O
bone	O
resorption	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
following	O
general	O
formula	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
are	O
fatty	O
acyl	O
groups	O
,	O
a	O
process	O
to	O
extract	O
them	O
from	O
Mycobacterium	O
tuberculosis	O
,	O
and	O
their	O
use	O
in	O
the	O
treatment	O
or	O
the	O
prophylaxis	O
of	O
tuberculosis	O
.	O

T	O
cell	O
clones	O
;	O
drug	O
screening	O

This	O
invention	O
comprises	O
the	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
n	O
,	O
m	O
,	O
t	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
L	O
,	O
Q	O
,	O
X	O
,	O
Y	O
,	O
Z	O
and	O
have	O
defined	O
meanings	O
,	O
having	O
histone	B
deacetylase	O
inhibiting	O
enzymatic	O
activity	O
;	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
a	O
medicine	O
.	O

Sulfonylamino	B
-	O
derivatives	O
as	O
novel	O
inhibitors	O
of	O
histone	O
deacetylase	O

Compounds	O
of	O
formula	O
I	O
:	O
wherein	O
variables	O
A1	O
,	O
A2	O
,	O
B	O
,	O
m	O
,	O
n	O
,	O
J	O
,	O
R4	O
,	O
G1	O
,	O
G2	O
,	O
G3	O
and	O
Y	O
are	O
as	O
described	O
herein	O
,	O
which	O
are	O
antagonists	O
of	O
CGRP	O
receptors	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
in	O
which	O
the	O
CGRP	O
is	O
involved	O
,	O
such	O
as	O
migraine	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
CGRP	O
is	O
involved	O
.	O

Tricyclic	B
anilide	I
heterocyclic	I
CGRP	O
receptor	O
antagonists	O

The	O
invention	O
relates	O
to	O
a	O
combination	O
comprising	O
the	O
renin	O
inhibitor	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Combination	O
comprising	O
a	O
renin	O
inhibitor	O
and	O
an	O
angiotensin	B
receptor	O
inhibitor	O
for	O
hypertension	O

The	O
compounds	O
of	O
formula	O
I	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R31	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
have	O
the	O
meanings	O
as	O
indicated	O
in	O
the	O
description	O
,	O
are	O
novel	O
effective	O
PDE4	O
inhibitors	O
.	O

3-hydroxy-6-phenylphenanthridines	B
as	O
PDE4	O
inhibitors	O

A	O
compound	O
of	O
Formula	O
I	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
or	O
solvate	O
thereof	O
:	O
complexes	O
with	O
metals	O
such	O
as	O
rhenium	B
,	O
technetium	B
,	O
and	O
others	O
to	O
provide	O
a	O
complex	O
for	O
imaging	O
tissues	O
or	O
treating	O
disease	O
,	O
particularly	O
where	O
the	O
metal	O
is	O
radioactive	O
.	O

Such	O
complexes	O
are	O
specific	O
to	O
PSMA	O
protein	O
and	O
can	O
therefore	O
be	O
used	O
in	O
imaging	O
or	O
treating	O
cancer	O
of	O
the	O
prostate	O
and	O
other	O
tissue	O
where	O
the	O
protein	O
is	O
expressed	O
.	O

Technetium-	B
and	I
rhenium	I
-	I
bis	I
(	I
heteroaryl	I
)	I
complexes	O
and	O
methods	O
of	O
use	O
thereof	O
for	O
inhibiting	O
PSMA	O

A	O
composition	O
for	O
the	O
intranasal	O
delivery	O
of	O
fentanyl	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
an	O
animal	O
includes	O
an	O
aqueous	O
solution	O
of	O
fentanyl	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutically	O
acceptable	O
additive	O
selected	O
from	O
(	O
i	O
)	O
a	O
pectin	O
and	O
(	O
ii	O
)	O
a	O
poloxamer	O
and	O
chitosan	O
or	O
a	O
salt	O
or	O
derivative	O
thereof	O
;	O
provided	O
that	O
when	O
the	O
composition	O
comprises	O
a	O
pectin	O
it	O
is	O
substantially	O
free	O
of	O
divalent	O
metal	O
ions	O
;	O
and	O
which	O
,	O
in	O
comparison	O
to	O
a	O
simple	O
aqueous	O
solution	O
of	O
fentanyl	B
administered	O
intranasally	O
at	O
the	O
same	O
dose	O
,	O
provides	O
a	O
peak	O
plasma	O
concentration	O
of	O
fentanyl	B
(	O
Cmax	O
)	O
that	O
is	O
from	O
10	O
to	O
80	O
%	O
of	O
that	O
achieved	O
using	O
a	O
simple	O
aqueous	O
solution	O
of	O
fentanyl	B
administered	O
intranasally	O
at	O
an	O
identical	O
fentanyl	B
dose	O
.	O

A	O
method	O
for	O
treating	O
or	O
managing	O
pain	O
by	O
intranasally	O
administering	O
the	O
composition	O
is	O
also	O
disclosed	O
.	O

Intranasally	O
administering	O
aqueous	O
solution	O
offentanyl	O
or	O
salt	O
thereof	O
and	O
pectin	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
pharmaceutical	O
compositions	O
of	O
the	O
compound	O
2-	B
(	I
R	I
)	I
-	I
(	I
1-	I
(	I
R	I
)	I
-	I
(	I
3,5-bis	I
(	I
trifluoromethyl	I
)	I
phenyl	I
)	I
ethoxy	I
)	I
-3-	I
(	I
S	I
)	I
-	I
(	I
4-fluoro	I
)	I
phenyl-4-	I
(	I
3-	I
(	I
5-oxo-1H,4H-1,2,4-triazolo	I
)	I
methylmorpholine	I
.	O

The	O
pharmaceutical	O
compositions	O
of	O
this	O
invention	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
such	O
as	O
psychiatric	O
disorders	O
including	O
depression	O
and	O
anxiety	O
,	O
inflammatory	O
diseases	O
and	O
emesis	O
.	O

Pharmaceutical	O
composition	O
of	O
a	O
tachykinin	O
receptor	O
antagonist	O

Disclosed	O
is	O
a	O
method	O
of	O
administering	O
an	O
interleukin-2	O
receptor	O
(	O
IL-2R	O
)	O
antagonist	O
to	O
a	O
subject	O
to	O
treat	O
an	O
autoimmune	O
disease	O
.	O

In	O
particular	O
embodiments	O
,	O
the	O
IL-2R	O
antagonist	O
is	O
an	O
anti	O
-	O
IL-2R	O
monoclonal	O
antibody	O
specific	O
for	O
one	O
or	O
more	O
chains	O
of	O
the	O
IL-2R	O
,	O
such	O
as	O
the	O
alpha	O
-	O
chain	O
,	O
for	O
example	O
daclizumab	B
.	O

In	O
other	O
particular	O
embodiments	O
the	O
autoimmune	O
disease	O
is	O
multiple	O
sclerosis	O
.	O

In	O
certain	O
embodiments	O
administration	O
of	O
interferon	O
-	O
beta	O
is	O
combined	O
with	O
administration	O
of	O
an	O
antagonist	O
of	O
the	O
IL-2R	O
to	O
provide	O
significant	O
clinical	O
improvement	O
in	O
a	O
subject	O
with	O
an	O
autoimmune	O
disease	O
.	O

Method	O
of	O
treating	O
multiple	O
sclerosis	O
with	O
interferon	O
-	O
beta	O
and	O
an	O
IL-2R	O
antagonist	O

A	O
novel	O
sulfur	B
containing	O
heteroaryl	B
-	O
pyrazole	B
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
effective	O
as	O
a	O
cannabinoid	B
CB1	O
receptor	O
inverse	O
agonist	O
or	O
antagonist	O
,	O
which	O
is	O
useful	O
for	O
preventing	O
or	O
treating	O
obesity	O
and	O
obesity	O
-	O
related	O
metabolic	O
disorders	O
.	O

The	O
prevention	O
also	O
provide	O
a	O
method	O
for	O
preparing	O
same	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
same	O
,	O
and	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
obesity	O
and	O
obesity	O
-	O
related	O
metabolic	O
disorders	O
.	O

Sulfur	B
containing	I
pyrazole	I
-	I
heterocycle	I
derivatives	O
as	O
cannabinoid	B
CB1	O
receptor	O
antagonists	O

The	O
present	O
invention	O
pertains	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
novel	O
substituted	O
tetracycline	B
compounds	O
.	O

These	O
tetracycline	B
compounds	O
can	O
be	O
used	O
to	O
treat	O
numerous	O
tetracycline	B
compound	O
-	O
responsive	O
states	O
,	O
such	O
as	O
bacterial	O
infections	O
and	O
neoplasms	O
.	O

Substituted	O
tetracycline	B
compounds	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
novel	O
macrocyclic	B
compounds	O
of	O
Formula	O
I	O
,	O
wherein	O
the	O
variables	O
Q	O
,	O
Q1	O
,	O
Q2	O
,	O
Q3	O
,	O
and	O
Q4	O
are	O
defined	O
as	O
described	O
herein	O
,	O
which	O
inhibit	O
JAK	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
auto	O
-	O
immune	O
and	O
inflammatory	O
diseases	O
.	O

Macrocyclic	B
inhibitors	O
of	O
JAK	O

A	O
mitotic	O
kinesin	O
Eg5	O
inhibitor	O
which	O
comprises	O
a	O
thiadiazoline	B
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
:	O
[	O
wherein	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
and	O
the	O
like	O
,	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
—C	B
(	I
═	I
W	I
)	I
R6	I
(	O
wherein	O
W	O
represents	O
an	O
oxygen	B
atom	O
or	O
a	O
sulfur	B
atom	O
,	O
and	O
R6	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
and	O
the	O
like	O
)	O
and	O
the	O
like	O
,	O
R3	O
represents	O
—C	B
(	I
═	I
Z	I
)	I
R19	I
(	O
wherein	O
Z	O
represents	O
an	O
oxygen	B
atom	O
or	O
a	O
sulfur	B
atom	O
,	O
and	O
R19	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
and	O
the	O
like	O
)	O
and	O
the	O
like	O
,	O
R4	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
and	O
the	O
like	O
,	O
and	O
R5	O
represents	O
substituted	O
or	O
unsubstituted	O
aryl	B
and	O
the	O
like	O
]	O
and	O
the	O
like	O
are	O
provided	O
.	O

Mitotic	O
kinesin	O
inhibitor	O

Methods	O
of	O
treating	O
cancer	O
using	O
compounds	O
according	O
to	O
Formula	O
(	O
I	O
)	O
are	O
disclosed	O
herein	O
,	O
wherein	O
X	O
,	O
X1	O
,	O
X2	O
,	O
Ra	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
g	O
,	O
M	O
,	O
y	O
,	O
a	O
,	O
b	O
,	O
d	O
,	O
e	O
,	O
V	O
,	O
W	O
,	O
Z	O
and	O
Q	O
are	O
as	O
defined	O
herein	O
.	O

Treatment	O
of	O
proliferative	O
disorders	O
with	O
amino	B
-	I
substituted	I
(	I
E	I
)	I
-2,6-	I
dialkoxystyryl	I
4-substituted	I
benzylsulfones	I

A	O
process	O
for	O
inhibiting	O
development	O
of	O
allergic	O
disease	O
comprises	O
exposing	O
a	O
neonatal	O
or	O
immature	O
mammal	O
or	O
bird	O
to	O
irradiation	O
-	O
detoxified	O
lipopolysaccharide	O
derived	O
from	O
microbial	O
,	O
protozoan	O
and/or	O
fungal	O
endotoxin	O
.	O

Processes	O
for	O
inhibiting	O
development	O
of	O
allergic	O
disease	O

A	O
cut	O
-	O
point	O
in	O
the	O
quantitative	O
measurement	O
of	O
PTEN	O
protein	O
expression	O
that	O
accurately	O
identifies	O
tumors	O
with	O
two	O
inactivated	O
alleles	O
of	O
the	O
PTEN	O
gene	O
.	O

Patients	O
with	O
a	O
normalized	O
PTEN	O
score	O
of	O
PTEN	O
null	O
will	O
be	O
treated	O
with	O
a	O
pan	O
-	O
ErbB	O
tyrosine	O
kinase	O
inhibitor	O
.	O

A	O
normalized	O
PTEN	O
protein	O
expression	O
score	O
is	O
obtained	O
by	O
comparing	O
the	O
tumor	O
PTEN	O
OD	O
expression	O
value	O
with	O
the	O
non	O
-	O
malignant	O
PTEN	O
OD	O
expression	O
value	O
.	O

Cut	O
-	O
point	O
in	O
PTEN	O
protein	O
expression	O
that	O
accurately	O
identifies	O
tumors	O
and	O
is	O
predictive	O
of	O
drug	O
response	O
to	O
a	O
pan	O
-	O
ErbB	O
inhibitor	O

Compounds	O
exhibiting	O
3alpha	B
-	I
hydroxy-5alpha	I
/	I
beta	I
-	I
steroid	I
blocking	O
action	O
with	O
no	O
or	O
only	O
low	O
antagonism	O
against	O
the	O
gamma	B
-	I
aminobutyric	I
acid	I
(	O
A	O
)	O
receptor	O
(	O
GABA	B
-	O
A	O
)	O
,	O
and	O
compounds	O
exhibiting	O
partial	O
antagonism	O
against	O
said	O
receptor	O
are	O
presented	O
.	O

Methods	O
for	O
the	O
prevention	O
,	O
treatment	O
and/or	O
alleviation	O
of	O
various	O
CNS	O
-	O
disorders	O
are	O
suggested	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
for	O
such	O
use	O
.	O

GABA	B
-	O
steroid	O
antagonists	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
CNS	O
disorders	O

Articles	O
of	O
clothing	O
treated	O
with	O
bacteria	O
adapted	O
to	O
metabolize	O
a	O
component	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ammonia	B
,	O
ammonium	B
salts	O
,	O
or	O
urea	B
into	O
any	O
of	O
nitric	B
oxide	I
,	O
nitric	B
oxide	I
precursors	O
,	O
and	O
combinations	O
thereof	O
are	O
provided	O
.	O

Articles	O
of	O
clothing	O
treated	O
with	O
ammonia	O
oxidizing	O
bacteria	O
to	O
produce	O
nitric	B
oxide	I

The	O
invention	O
relates	O
to	O
a	O
primary	O
composition	O
in	O
which	O
at	O
least	O
one	O
lipophilic	O
bioactive	O
compound	O
is	O
mixed	O
with	O
a	O
whey	O
protein	O
,	O
present	O
in	O
an	O
amount	O
effective	O
to	O
increase	O
the	O
bioavailability	O
of	O
the	O
lipophilic	O
bioactive	O
compound	O
.	O

The	O
invention	O
also	O
relates	O
to	O
an	O
oral	O
composition	O
that	O
contains	O
the	O
primary	O
composition	O
in	O
a	O
foodstuff	O
,	O
in	O
a	O
food	O
supplement	O
,	O
or	O
in	O
a	O
pharmaceutical	O
preparation	O
,	O
and	O
to	O
a	O
cosmetic	O
preparation	O
that	O
contains	O
the	O
primary	O
composition	O
.	O

Methods	O
for	O
increasing	O
the	O
bioavailability	O
of	O
the	O
lipophilic	O
bioactive	O
compound	O
and	O
providing	O
increased	O
photostability	O
and	O
oxidation	O
resistance	O
are	O
also	O
provided	O
.	O

Primary	O
composition	O
comprising	O
a	O
lipophilic	O
bioactive	O
compound	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
selective	O
phosphodiesterase	O
9A	O
(	O
PDE9A	O
)	O
inhibitors	O
for	O
producing	O
medicaments	O
for	O
improving	O
perception	O
,	O
concentration	O
,	O
cognitive	O
processes	O
,	O
learning	O
and/or	O
memory	O
.	O

Selective	O
phosphodiesterase	O
9A	O
inhibitors	O
as	O
medicaments	O
for	O
improving	O
cognitive	O
processes	O

Described	O
herein	O
are	O
chlorite	B
formulations	O
having	O
a	O
pH	O
between	O
about	O
7	O
and	O
about	O
8.5	O
,	O
wherein	O
the	O
chlorite	B
formulations	O
are	O
substantially	O
free	O
of	O
deleterious	O
non	O
-	O
chlorite	B
components	O
.	O

Described	O
herein	O
are	O
chlorite	B
formulations	O
,	O
including	O
pharmaceutical	O
formulations	O
,	O
which	O
are	O
formulated	O
for	O
systemic	O
,	O
parenteral	O
,	O
or	O
intravenous	O
administration	O
.	O

Described	O
herein	O
are	O
methods	O
of	O
preparing	O
and	O
methods	O
of	O
using	O
the	O
chlorite	B
formulations	O
described	O
herein	O
.	O

Chlorite	O
formulations	O
and	O
methods	O
of	O
preparation	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
provides	O
heteroaryl	B
-	I
cyclohexyl	I
-	I
tetraazabenzo	I
[	I
e	I
]	I
azulenes	I
of	O
formula	O
I	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
described	O
herein	O
.	O

The	O
compounds	O
according	O
to	O
the	O
invention	O
act	O
as	O
V1a	O
receptor	O
modulators	O
,	O
and	O
in	O
particular	O
as	O
V1a	O
receptor	O
antagonists	O
,	O
their	O
manufacture	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
.	O

The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
therapeutics	O
acting	O
peripherally	O
and	O
centrally	O
in	O
the	O
conditions	O
of	O
dysmenorrhea	O
,	O
male	O
or	O
female	O
sexual	O
dysfunction	O
,	O
hypertension	O
,	O
chronic	O
heart	O
failure	O
,	O
inappropriate	O
secretion	O
of	O
vasopressin	O
,	O
liver	O
cirrhosis	O
,	O
nephrotic	O
syndrome	O
,	O
anxiety	O
,	O
depressive	O
disorders	O
,	O
obsessive	O
compulsive	O
disorder	O
,	O
autistic	O
spectrum	O
disorders	O
,	O
schizophrenia	O
,	O
and	O
aggressive	O
behavior	O
.	O

Heteroaryl	B
-	I
cyclohexyl	I
-	I
tetraazabenzo	I
[	I
E	I
]	I
azulenes	I

Novel	O
methods	O
of	O
treating	O
proliferative	O
disorders	O
characterized	O
by	O
elevated	O
Her-2	O
,	O
and	O
the	O
patient	O
is	O
then	O
administered	O
an	O
effective	O
amount	O
of	O
an	O
HSP90	O
inhibitor	O
.	O

Method	O
of	O
treatment	O
for	O
cancers	O
associated	O
with	O
elevated	O
HER2	O
levels	O

The	O
present	O
invention	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
azelastine	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
including	O
azelastine	B
hydrochloride	I
,	O
and	O
optionally	O
one	O
or	O
more	O
additional	O
active	O
agents	O
.	O

Preferred	O
such	O
compositions	O
further	O
comprise	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
carriers	O
or	O
excipients	O
that	O
reduce	O
the	O
amount	O
of	O
post	O
-	O
nasal	O
drip	O
,	O
and/or	O
that	O
minimize	O
or	O
mask	O
the	O
unpleasant	O
bitter	O
taste	O
associated	O
with	O
post	O
-	O
nasal	O
drip	O
,	O
of	O
the	O
compositions	O
into	O
the	O
oral	O
cavity	O
,	O
upon	O
intranasal	O
or	O
ocular	O
administration	O
of	O
the	O
compositions	O
.	O

Especially	O
effective	O
excipients	O
used	O
in	O
the	O
compositions	O
of	O
the	O
present	O
invention	O
are	O
hypromellose	O
as	O
a	O
viscosity	O
modifier	O
and	O
sucralose	O
as	O
a	O
taste	O
-	O
masking	O
agent	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
or	O
preventing	O
certain	O
disorders	O
,	O
or	O
symptomatic	O
relief	O
therefrom	O
,	O
by	O
administering	O
the	O
compositions	O
of	O
the	O
invention	O
to	O
a	O
patient	O
,	O
e.g.	O
,	O
for	O
the	O
symptomatic	O
relief	O
of	O
allergic	O
rhinitis	O
,	O
non	O
-	O
allergic	O
vasomotor	O
rhinitis	O
,	O
allergic	O
conjunctivitis	O
,	O
as	O
well	O
as	O
other	O
disorders	O
.	O

Compositions	O
comprising	O
azelastine	B
and	O
methods	O
of	O
use	O
thereof	O

The	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
wherein	O
n	O
,	O
A	O
,	O
R	O
,	O
R′	O
,	O
R″	O
,	O
RO	O
,	O
X	O
and	O
Y	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
and	O
their	O
preparation	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
useful	O
as	O
pharmaceuticals	O
.	O

Acetylene	B
derivatives	O
having	O
MGluR	O
5	O
antagonistic	O
activity	O

A	O
novel	O
method	O
for	O
improving	O
the	O
meat	O
quality	O
of	O
an	O
animal	O
is	O
provided	O
.	O

The	O
method	O
comprises	O
feeding	O
the	O
animal	O
a	O
diet	O
supplemented	O
with	O
oleic	B
acid	I
and	O
selected	O
tocols	O
in	O
amounts	O
effective	O
to	O
improve	O
the	O
meat	O
quality	O
.	O

The	O
method	O
may	O
be	O
practiced	O
on	O
non	O
-	O
ruminants	O
and	O
ruminants	O
.	O

Method	O
of	O
improving	O
animal	O
tissue	O
quality	O
by	O
supplementing	O
the	O
animal	O
diet	O
with	O
oleic	B
acid	I
and	O
selected	O
tocols	O

Anxiety	O
disorders	O
,	O
such	O
as	O
panic	O
disorder	O
,	O
agoraphobia	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
social	O
phobia	O
,	O
post	O
-	O
traumatic	O
stress	O
disorder	O
,	O
generalized	O
anxiety	O
disorder	O
,	O
specific	O
phobia	O
,	O
or	O
the	O
like	O
,	O
are	O
treated	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
adenosine	B
A2A	O
receptor	O
antagonist	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
optionally	O
in	O
combination	O
with	O
an	O
anxiolytic	O
(	O
s	O
)	O
other	O
than	O
the	O
adenosine	B
A2A	O
receptor	O
antagonist	O
.	O

Method	O
of	O
treating	O
an	O
anxiety	O
disorder	O

The	O
invention	O
provides	O
immunomodulatory	O
compounds	O
and	O
methods	O
for	O
immunomodulation	O
of	O
individuals	O
using	O
the	O
immunomodulatory	O
compounds	O
.	O

Chimeric	O
immunomodulatory	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
same	O
-	O
IV	O

Dermatological	O
conditions	O
/	O
afflictions	O
such	O
as	O
rosacea	O
,	O
common	O
acne	O
,	O
seborrheic	O
dermatitis	O
,	O
perioral	O
dermatitis	O
,	O
acneform	O
rashes	O
,	O
transient	O
acantholytic	O
dermatosis	O
,	O
and	O
acne	O
necrotica	O
milliaris	O
,	O
most	O
notably	O
rosacea	O
,	O
are	O
treated	O
by	O
topically	O
applying	O
onto	O
the	O
affected	O
skin	O
area	O
of	O
an	O
individual	O
in	O
need	O
of	O
such	O
treatment	O
,	O
a	O
topical	O
pharmaceutical	O
composition	O
which	O
comprises	O
a	O
thus	O
effective	O
amount	O
of	O
ivermectin	B
.	O

Topical	O
application	O
of	O
ivermectin	B
for	O
the	O
treatment	O
of	O
dermatological	O
conditions	O
/	O
afflictions	O

Provided	O
is	O
a	O
modified	O
human	O
tumor	O
necrosis	O
factor	O
receptor-1	O
polypeptide	O
or	O
a	O
fragment	O
thereof	O
that	O
binds	O
to	O
a	O
tumor	O
necrosis	O
factor	O
in	O
vivo	O
or	O
ex	O
vivo	O
.	O

The	O
modified	O
human	O
tumor	O
necrosis	O
factor	O
receptor-1	O
polypeptide	O
or	O
fragment	O
exhibits	O
improved	O
ability	O
to	O
bind	O
tumor	O
necrosis	O
factor	O
and	O
resistance	O
to	O
proteases	O
.	O

Modified	O
human	O
tumor	O
necrosis	O
factor	O
receptor-1	O
polypeptide	O
or	O
fragment	O
thereof	O
,	O
and	O
method	O
for	O
preparing	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
increasing	O
the	O
sensitivity	O
of	O
neoplastic	O
cells	O
to	O
chemotherapeutic	O
agents	O
by	O
using	O
a	O
virus	O
,	O
a	O
method	O
of	O
treating	O
proliferative	O
disorders	O
with	O
a	O
virus	O
and	O
chemotherapeutic	O
agents	O
,	O
and	O
a	O
method	O
for	O
preventing	O
a	O
neoplasm	O
from	O
developing	O
drug	O
resistance	O
to	O
chemotherapeutic	O
agents	O
.	O

The	O
virus	O
is	O
preferably	O
a	O
reovirus	O
.	O

Sensitization	O
of	O
chemotherapeutic	O
agent	O
resistant	O
neoplastic	O
cells	O
with	O
a	O
virus	O

A	O
method	O
for	O
providing	O
antisense	O
therapy	O
which	O
reduces	O
the	O
expression	O
of	O
clusterin	O
to	O
provide	O
therapeutic	O
benefits	O
in	O
the	O
treatment	O
of	O
cancer	O
comprising	O
administering	O
from	O
40	O
to	O
640	O
mg	O
anti	O
-	O
clusterin	O
antisense	O
oligonucleotide	B
to	O
a	O
patient	O
in	O
need	O
of	O
treatment	O
for	O
a	O
cancer	O
expressing	O
clusterin	O
is	O
provided	O
.	O

The	O
method	O
may	O
include	O
administering	O
chemotherapeutic	O
agent	O
or	O
agents	O
,	O
radiotherapy	O
,	O
and/or	O
hormone	O
ablation	O
therapy	O
.	O

The	O
invention	O
also	O
encompasses	O
pharmaceutical	O
compositions	O
formulated	O
to	O
provide	O
a	O
dosage	O
of	O
40	O
to	O
640	O
mg	O
,	O
and	O
use	O
of	O
antisense	O
in	O
formulating	O
a	O
medicament	O
.	O

Clusterin	O
antisense	O
therapy	O
for	O
treatment	O
of	O
cancer	O

Pharmaceutical	O
formulations	O
are	O
provided	O
which	O
are	O
in	O
the	O
form	O
of	O
capsules	O
or	O
tablets	O
for	O
oral	O
use	O
and	O
which	O
include	O
a	O
medicament	O
dapagliflozin	B
or	O
its	O
propylene	B
glycol	I
hydrate	I
and	O
a	O
pharmaceutical	O
acceptable	O
carrier	O
therefor	O
,	O
which	O
formulation	O
is	O
designed	O
for	O
immediate	O
release	O
.	O

Pharmaceutical	O
formulations	O
containing	O
an	O
SGLT2	O
inhibitor	O

Utilization	O
of	O
a	O
contact	O
device	O
placed	O
on	O
the	O
eye	O
in	O
order	O
to	O
detect	O
physical	O
and	O
chemical	O
parameters	O
of	O
the	O
body	O
as	O
well	O
as	O
the	O
non	O
-	O
invasive	O
delivery	O
of	O
compounds	O
according	O
to	O
these	O
physical	O
and	O
chemical	O
parameters	O
,	O
with	O
signals	O
being	O
transmitted	O
continuously	O
as	O
electromagnetic	O
waves	O
,	O
radio	O
waves	O
,	O
infrared	O
and	O
the	O
like	O
.	O

One	O
of	O
the	O
parameters	O
to	O
be	O
detected	O
includes	O
non	O
-	O
invasive	O
blood	O
analysis	O
utilizing	O
chemical	O
changes	O
and	O
chemical	O
products	O
that	O
are	O
found	O
in	O
the	O
conjunctiva	O
and	O
in	O
the	O
tear	O
film	O
.	O

A	O
transensor	O
mounted	O
in	O
the	O
contact	O
device	O
laying	O
on	O
the	O
cornea	O
or	O
the	O
surface	O
of	O
the	O
eye	O
is	O
capable	O
of	O
evaluating	O
and	O
measuring	O
physical	O
and	O
chemical	O
parameters	O
in	O
the	O
eye	O
including	O
non	O
-	O
invasive	O
blood	O
analysis	O
.	O

The	O
system	O
utilizes	O
eye	O
lid	O
motion	O
and/or	O
closure	O
of	O
the	O
eye	O
lid	O
to	O
activate	O
a	O
microminiature	O
radio	O
frequency	O
sensitive	O
transensor	O
mounted	O
in	O
the	O
contact	O
device	O
.	O

The	O
signal	O
can	O
be	O
communicated	O
by	O
wires	O
or	O
radio	O
telemetered	O
to	O
an	O
externally	O
placed	O
receiver	O
.	O

The	O
signal	O
can	O
then	O
be	O
processed	O
,	O
analyzed	O
and	O
stored	O
.	O

Several	O
parameters	O
can	O
be	O
detected	O
including	O
a	O
complete	O
non	O
-	O
invasive	O
analysis	O
of	O
blood	O
components	O
,	O
measurement	O
of	O
systemic	O
and	O
ocular	O
blood	O
flow	O
,	O
measurement	O
of	O
heart	O
rate	O
and	O
respiratory	O
rate	O
,	O
tracking	O
operations	O
,	O
detection	O
of	O
ovulation	O
,	O
detection	O
of	O
radiation	O
and	O
drug	O
effects	O
,	O
diagnosis	O
of	O
ocular	O
and	O
systemic	O
disorders	O
and	O
the	O
like	O
.	O

Device	O
for	O
generating	O
a	O
detectable	O
signal	O
based	O
upon	O
concentration	O
of	O
at	O
least	O
one	O
substance	O

This	O
invention	O
features	O
betulinic	B
acid	I
derivatives	O
having	O
the	O
formula	O
:	O
wherein	O
the	O
variables	O
are	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
provides	O
related	O
compounds	O
and	O
intermediates	O
thereof	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
,	O
kits	O
,	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
compounds	O
.	O

Treatment	O
methods	O
and	O
methods	O
of	O
manufacture	O
are	O
also	O
provided	O
.	O

Betulinic	B
acid	I
derivatives	O
and	O
methods	O
of	O
use	O
thereof	O

This	O
invention	O
provides	O
Chelating	O
Complex	O
Micelles	O
as	O
a	O
drug	O
carrier	O
.	O

The	O
Chelating	O
Complex	O
Micelles	O
can	O
load	O
drugs	O
without	O
changing	O
their	O
structure	O
,	O
and	O
therefore	O
extend	O
the	O
half	O
-	O
life	O
of	O
drugs	O
in	O
the	O
human	O
body	O
.	O

The	O
chelating	O
complex	O
micelles	O
contain	O
a	O
metal	O
ion	O
core	O
,	O
at	O
least	O
one	O
polymer	O
,	O
and	O
at	O
least	O
one	O
drug	O
molecule	O
.	O

The	O
metal	O
ion	O
is	O
considered	O
as	O
a	O
Lewis	B
acid	I
while	O
polymer	O
chain	O
and	O
drug	O
molecules	O
are	O
referred	O
to	O
as	O
Lewis	B
bases	I
.	O

The	O
drug	O
molecule	O
is	O
linked	O
to	O
the	O
polymer	O
via	O
forming	O
coordinate	O
bonds	O
with	O
metal	O
ion	O
,	O
and	O
then	O
self	O
-	O
assembled	O
to	O
form	O
chelating	O
complex	O
micelles	O
as	O
a	O
drug	O
carrier	O
.	O

Drug	O
carrier	O
with	O
chelating	O
complex	O
micelles	O
and	O
the	O
application	O
thereof	O

This	O
disclosure	O
relates	O
to	O
sphingosine-1-phosphate	B
(	O
S1P	B
)	O
receptor	O
antagonists	O
,	O
compositions	O
comprising	O
the	O
S1P	B
receptor	O
antagonists	O
and	O
methods	O
for	O
using	O
and	O
processes	O
for	O
making	O
the	O
S1P	O
receptor	O
antagonists	O
.	O

In	O
particular	O
,	O
this	O
disclosure	O
relates	O
to	O
sphingosine-1-phosphate	B
1	I
(	O
S1P1	B
)	O
receptor	O
antagonists	O
,	O
compositions	O
comprising	O
the	O
S1P1	O
receptor	O
antagonist	O
and	O
methods	O
for	O
using	O
the	O
S1P1	B
receptor	O
antagonist	O
,	O
such	O
as	O
in	O
the	O
treatment	O
of	O
cancer	O
,	O
and	O
processes	O
for	O
making	O
the	O
S1P1	B
receptor	O
antagonists	O
.	O

Acetanilide	B
sphingosine-1-phosphate	I
receptor	O
antagonists	O

The	O
invention	O
concerns	O
a	O
system	O
for	O
biocompatible	O
drug	O
release	O
comprising	O
:	O
(	O
i	O
)	O
a	O
polymer	O
matrix	O
;	O
(	O
ii	O
)	O
an	O
inorganic	O
component	O
located	O
inside	O
said	O
matrix	O
and	O
characterized	O
by	O
a	O
lamellar	O
structure	O
with	O
a	O
net	O
positive	O
or	O
negative	O
charge	O
able	O
to	O
intercalate	O
(	O
iii	O
)	O
a	O
pharmacologically	O
active	O
principle	O
into	O
said	O
lamellar	O
structure	O
,	O
by	O
establishing	O
an	O
ionic	O
type	O
of	O
bond	O
with	O
it	O
and	O
thereby	O
obtaining	O
an	O
intercalation	O
compound	O
.	O

The	O
preparation	O
process	O
for	O
the	O
release	O
system	O
comprises	O
the	O
stages	O
of	O
:	O
treating	O
the	O
lamellar	O
solid	O
in	O
such	O
a	O
way	O
as	O
to	O
give	O
it	O
a	O
net	O
positive	O
or	O
negative	O
charge	O
,	O
then	O
combining	O
it	O
with	O
the	O
chosen	O
active	O
principle	O
,	O
also	O
in	O
an	O
ionic	O
form	O
,	O
to	O
obtain	O
an	O
intercalation	O
compound	O
which	O
is	O
then	O
mixed	O
with	O
the	O
polymer	O
matrix	O
.	O

The	O
release	O
system	O
can	O
be	O
employed	O
in	O
making	O
medical	O
devices	O
,	O
like	O
sutures	O
,	O
membranes	O
,	O
osteosynthesis	O
plaques	O
,	O
multilayered	O
devices	O
,	O
gels	O
and	O
drug	O
delivery	O
systems	O
.	O

Controlled	O
-	O
delivery	O
system	O
of	O
pharmacologically	O
active	O
substances	O
,	O
preparation	O
process	O
and	O
medical	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
azacyclyl	B
-	I
substituted	I
arylthienopyrimidinones	I
and	O
their	O
derivatives	O
,	O
of	O
the	O
Formula	O
(	O
I	O
)	O
;	O
and	O
their	O
physiologically	O
tolerated	O
salts	O
and	O
physiologically	O
functional	O
derivatives	O
,	O
their	O
preparation	O
,	O
medicaments	O
comprising	O
at	O
least	O
one	O
azacyclyl	B
-	I
substituted	I
arylthienopyrimidinone	I
according	O
to	O
Formula	O
(	O
I	O
)	O
or	O
its	O
derivative	O
,	O
and	O
the	O
use	O
of	O
the	O
azacyclyl	B
-	I
substituted	I
arylthienopyrimidinones	I
according	O
to	O
Formula	O
(	O
I	O
)	O
and	O
their	O
derivatives	O
as	O
MCH	O
antagonists	O
.	O

Azacyclyl	B
-	I
substituted	I
arylthienopyrimidinones	I
,	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
medicaments	O

The	O
invention	O
relates	O
to	O
new	O
unsaturated	O
14,15-cyclopropano	B
-	I
androstanes	I
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
to	O
their	O
synthesis	O
and	O
to	O
pharmaceutical	O
compositions	O
,	O
containing	O
these	O
compounds	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
have	O
gestagenic	O
and/or	O
androgenic	O
activity	O
.	O

Unsaturated	O
14	B
,	I
15-cyclopropanoandrostanes	I
,	O
a	O
method	O
for	O
their	O
production	O
and	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O

The	O
use	O
of	O
diaryl	B
acid	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
N	B
-	I
oxides	I
,	O
hydrates	B
or	O
solvates	O
thereof	O
,	O
wherein	O
the	O
variables	O
shown	O
are	O
defined	O
in	O
the	O
disclosure	O
,	O
and	O
their	O
pharmaceutical	O
compositions	O
as	O
PPAR	O
ligand	O
receptor	O
binders	O
.	O

The	O
PPAR	O
ligand	O
receptor	O
binders	O
of	O
this	O
invention	O
are	O
useful	O
as	O
agonists	O
or	O
antagonists	O
of	O
the	O
PPAR	O
receptor	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptors	O
agonists	O
/	O
antagonists	O
;	O
2-methyl-6-	B
[	I
3-	I
(	I
quinolin-2-ylmethoxy	I
)	I
-propoxymethyl	I
]	I
-benzoic	I
acid	I
;	O
eating	O
diorders	O
;	O
physiological	O
detrimental	O
blood	O
level	O
of	O
insulin	O
,	O
glucose	B
,	O
free	O
fatty	B
acids	I
,	O
or	O
triglycerides	O
;	O
hyperlipemia	O
;	O
atherosclerosis	O
;	O
antidiabetic	O
agent	O

This	O
invention	O
provides	O
the	O
use	O
of	O
a	O
combination	O
of	O
CCI-779	O
and	O
EKB-569	O
in	O
the	O
treatment	O
of	O
neoplasms	O
.	O

Rapamycin	B
42-ester	O
with	O
3-hydroxy-2-	B
(	I
hydroxymethyl	I
)	I
-2-methyl	I
propionic	I
acid	I
(	O
CCI-779	O
)	O
and	O
4-dimethylamino	B
-	I
but-2-enoic	I
acid	I
(	I
4-	I
(	I
3-chloro-4-fluoro	I
-	I
phenylamino	I
)	I
-3-cyano-7-ethoxy	I
-	I
quinol	I
in-6-yl	I
)	I
amide	I
(	O
EKB-569	O
)	O
;	O
synergistic	O
;	O
antitumor	O
agents	O

Provided	O
is	O
,	O
among	O
other	O
things	O
,	O
a	O
method	O
of	O
treating	O
in	O
an	O
animal	O
infection	O
or	O
neoplasm	O
of	O
cerebrospinal	O
tissue	O
characterized	O
by	O
a	O
risk	O
of	O
death	O
,	O
the	O
method	O
comprising	O
:	O
(	O
a	O
)	O
injecting	O
a	O
physiologically	O
acceptable	O
fluid	O
for	O
cerebrospinal	O
perfusion	O
into	O
a	O
first	O
catheter	O
into	O
the	O
cerebrospinal	O
pathway	O
,	O
which	O
fluid	O
for	O
cerebrospinal	O
perfusion	O
has	O
an	O
therapeutically	O
effective	O
amount	O
an	O
agent	O
,	O
the	O
agent	O
selected	O
for	O
effectiveness	O
against	O
the	O
infection	O
as	O
identified	O
or	O
diagnosed	O
;	O
(	O
b	O
)	O
withdrawing	O
fluid	O
at	O
a	O
second	O
catheter	O
into	O
the	O
cerebrospinal	O
pathway	O
to	O
create	O
a	O
flow	O
and	O
flow	O
pathway	O
between	O
the	O
first	O
and	O
second	O
catheters	O
;	O
and	O
(	O
c	O
)	O
maintaining	O
the	O
flow	O
for	O
a	O
period	O
of	O
time	O
adapted	O
to	O
perfuse	O
at	O
least	O
1	O
CSF	O
volume	O
.	O

Treatment	O
of	O
neurological	O
disease	O

The	O
invention	O
relates	O
to	O
phenyl	O
oxazolidinone	O
derivatives	O
.	O

More	O
particularly	O
,	O
it	O
relates	O
to	O
polymorphic	O
forms	O
of	O
(	O
S	O
)	O
-N-	O
[	O
[	O
3-fluoro-4-	O
[	O
N-1	O
[	O
4-	O
{	O
2-furyl-	O
(	O
5-nitro	O
)	O
methyl	O
}	O
]	O
piperazinyl	O
]	O
-phenyl	O
]	O
-2-oxo-5-oxazolidinyl	O
]	O
-methyl	O
]	O
acetamide	O
hydrochloride	O
having	O
the	O
Formula	O
I.	O
Further	O
,	O
the	O
invention	O
relates	O
to	O
methods	O
of	O
using	O
such	O
compounds	O
as	O
antimicrobials	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
novel	O
polymorphic	O
forms	O
,	O
and	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
polymorphic	O
forms	O
.	O

Polymorphic	O
forms	O
of	O
phenyl	O
oxazolidinone	O
derivatives	O

The	O
invention	O
provides	O
objective	O
methods	O
for	O
detecting	O
and	O
diagnosing	O
colorectal	O
cancers	O
and	O
pre	O
-	O
malignant	O
lesions	O
.	O

For	O
example	O
,	O
the	O
methods	O
disclosed	O
herein	O
can	O
reliably	O
detect	O
very	O
early	O
-	O
stage	O
colorectal	O
cancers	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
diagnostic	O
method	O
involves	O
the	O
scoring	O
of	O
gene	O
expression	O
profiles	O
that	O
discriminate	O
between	O
adenomas	O
and	O
carcinomas	O
.	O

The	O
profile	O
score	O
calculated	O
acts	O
as	O
diagnostic	O
indicator	O
that	O
can	O
objectively	O
indicate	O
whether	O
a	O
sample	O
tissue	O
is	O
non	O
-	O
cancerous	O
,	O
pre	O
-	O
cancerous	O
,	O
or	O
cancerous	O
.	O

The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
diagnosing	O
colorectal	O
tumors	O
in	O
a	O
subject	O
,	O
methods	O
of	O
screening	O
for	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
colorectal	O
tumors	O
,	O
methods	O
of	O
treating	O
colorectal	O
tumors	O
and	O
method	O
of	O
vaccinating	O
a	O
subject	O
against	O
colorectal	O
tumors	O
.	O

Method	O
for	O
diagnosis	O
of	O
colorectal	O
tumors	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
neurotoxic	O
substances	O
which	O
have	O
a	O
toxic	O
effect	O
,	O
particularly	O
for	O
the	O
axons	O
and	O
nociceptive	O
nerve	O
endings	O
and	O
to	O
the	O
production	O
of	O
a	O
means	O
for	O
the	O
treatment	O
of	O
joint	O
pain	O
.	O

Use	O
of	O
neurotoxic	O
substances	O
for	O
the	O
production	O
of	O
a	O
means	O
for	O
the	O
treatment	O
of	O
joint	O
pain	O
and	O
method	O
for	O
application	O
of	O
said	O
means	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
diagnosing	O
mental	O
disorders	O
such	O
as	O
mood	O
disorders	O
,	O
including	O
bipolar	O
disorder	O
I	O
and	O
II	O
and	O
major	O
depression	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
identifying	O
modulators	O
of	O
such	O
mental	O
disorders	O
as	O
well	O
as	O
methods	O
of	O
using	O
these	O
modulators	O
to	O
treat	O
patients	O
suffering	O
from	O
such	O
mental	O
disorders	O
.	O

Compositions	O
and	O
methods	O
for	O
diagnosing	O
and	O
treating	O
mood	O
disorders	O

The	O
invention	O
provides	O
nucleic	O
acid	O
therapeutic	O
compositions	O
capable	O
of	O
binding	O
to	O
cytokines	O
,	O
growth	O
factors	O
and	O
cell	O
surface	O
proteins	O
,	O
individually	O
or	O
in	O
combinations	O
of	O
two	O
or	O
more	O
,	O
and	O
methods	O
for	O
delivering	O
these	O
nucleic	O
acid	O
therapeutics	O
in	O
the	O
treatment	O
of	O
glaucoma	O
and	O
other	O
proliferative	O
diseases	O
of	O
the	O
eye	O
.	O

Aptamer	O
therapeutics	O
useful	O
in	O
ocular	O
pharmacotherapy	O

Polynucleotides	O
and	O
polypeptides	O
which	O
participate	O
in	O
influenza	O
virus	O
infection	O
of	O
cells	O
and	O
nucleic	O
acid	O
molecules	O
,	O
which	O
include	O
a	O
polynucleotide	O
sequence	O
capable	O
of	O
specifically	O
binding	O
the	O
polypeptides	O
of	O
the	O
present	O
invention	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
using	O
such	O
nucleic	O
acid	O
molecules	O
,	O
polynucleotides	O
and	O
antibodies	O
directed	O
thereagainst	O
for	O
diagnosing	O
,	O
treating	O
and	O
preventing	O
influenza	O
virus	O
infection	O
.	O

Compositions	O
of	O
nucleic	O
acids	O
for	O
treating	O
and	O
detecting	O
influenza	O
virus	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
P	O
,	O
P	O
'	O
,	O
W	O
,	O
R1	O
,	O
R2	O
,	O
n	O
,	O
p	O
,	O
q	O
,	O
r	O
,	O
s	O
and	O
t	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
processes	O
for	O
preparing	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
their	O
use	O
as	O
vanilloid	B
receptor	O
(	O
VR1	O
)	O
antagonists	O
in	O
the	O
treatment	O
of	O
pain	O
.	O

Urea	O
derivatives	O
and	O
their	O
use	O
as	O
vanilloid	B
receptor	O
antagonists	O
in	O
the	O
treatment	O
of	O
pain	O

The	O
present	O
invention	O
relates	O
to	O
carbacephem	B
antibiotics	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
useful	O
for	O
the	O
treatment	O
of	O
bacterial	O
infections	O
,	O
in	O
particular	O
infections	O
caused	O
by	O
methicillin	B
-	O
resistant	O
Staphylococcus	O
spp	O
.	O

bacteria	O
.	O

CARBACEPHEM	B
ss	I
-	I
LACTAM	I
ANTIBIOTICS	O

The	O
invention	O
relates	O
to	O
(	B
+	I
)	I
-pantoprazole	I
magnesium	I
hydrates	I
and	O
to	O
medicaments	O
comprising	O
these	O
compounds	O
.	O

Novel	O
salt	O
of	O
(	B
r	I
)	I
-	I
pantoprazole	I

[	O
PROBLEMS	O
]	O
To	O
confirm	O
the	O
presence	O
of	O
a	O
solubilized	O
human	O
IL-18	O
receptor	O
-	O
α	O
by	O
a	O
novel	O
ELISA	O
method	O
and	O
provide	O
an	O
assay	O
kit	O
and	O
a	O
medicinal	O
composition	O
containing	O
the	O
solubilized	O
human	O
IL-18	O
receptor	O
-	O
α	O
as	O
the	O
active	O
ingredient	O
.	O

[	O
MENAS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
A	O
solubilized	O
human	O
interleukin-18	O
receptor	O
-	O
α	O
,	O
a	O
method	O
of	O
assaying	O
the	O
solubilized	O
human	O
interleukin-18	O
receptor	O
-	O
α	O
by	O
an	O
enzyme	O
immunoassay	O
method	O
characterized	O
by	O
using	O
the	O
following	O
antibody	O
(	O
A	O
)	O
,	O
a	O
kit	O
for	O
assaying	O
the	O
solubilized	O
human	O
interleukin-18	O
receptor	O
-	O
α	O
and	O
a	O
medicinal	O
composition	O
containing	O
the	O
solubilized	O
human	O
IL-18	O
receptor	O
-	O
α	O
.	O

(	O
A	O
)	O
An	O
anti	O
-	O
human	O
interleukin-18	O
receptor	O
-	O
α	O
monoclonal	O
antibody	O
capable	O
of	O
recognizing	O
the	O
same	O
epitope	O
as	O
an	O
H44	O
mouse	O
anti	O
-	O
human	O
interleukin-18	O
receptor	O
-	O
α	O
monoclonal	O
antibody	O
.	O

SOLUBLE	O
HUMAN	O
INTERLEUKIN	O
18	O
RECEPTOR	O
-	O
α	O
,	O
METHOD	O
OF	O
ASSAYING	O
THE	O
SAME	O
,	O
ASSAY	O
KIT	O
AND	O
MEDICINAL	O
COMPOSITION	O

There	O
are	O
disclosed	O
novel	O
pyridyl	B
piperazinyl	I
ureas	I
that	O
are	O
potent	O
antagonists	O
of	O
vanilloid	B
receptor	O
,	O
VR1	O
,	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
i	O
)	O
acute	O
or	O
chronic	O
pain	O
or	O
itch	O
;	O
ii	O
)	O
inflammation	O
;	O
iii	O
)	O
gastrointestinal	O
and	O
urinary	O
tract	O
disorders	O
;	O
and	O
iv	O
)	O
tracheobronchial	O
and	O
diaphragmatic	O
dysfunction	O
in	O
humans	O
.	O

Pyridyl	B
piperazinyl	I
ureas	I

Compounds	O
of	O
formula	O
(	O
A	O
)	O
and	O
formula	O
(	O
B	O
)	O
:	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
compositions	O
comprising	O
them	O
,	O
methods	O
for	O
their	O
use	O
,	O
and	O
their	O
use	O
in	O
the	O
preparation	O
of	O
medicaments	O
.	O

The	O
compounds	O
are	O
antagonists	O
of	O
MCP-1	O
function	O
,	O
and	O
are	O
useful	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
chronic	O
or	O
acute	O
inflammatory	O
or	O
autoimmune	O
diseases	O
,	O
such	O
as	O
multiple	O
sclerosis	O
,	O
and	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
allergic	O
hypersensitivity	O
diseases	O
.	O

Antagonists	O
of	O
mcp-1	O
function	O
and	O
methods	O
of	O
use	O
thereof	O

This	O
invention	O
relates	O
to	O
substituted	O
tetrahydroquinoline	B
phenylacetic	I
acids	I
and	I
benzoic	I
acids	I
that	O
bind	O
to	O
and/or	O
modulate	O
hepatocyte	O
factor	O
4α	O
receptors	O
and	O
to	O
methods	O
for	O
making	O
and	O
using	O
such	O
compounds	O
.	O

Substituted	O
tetrahydroquinolines	B
,	O
phenylacetic	B
acids	I
and	O
benzoic	B
acids	I
as	O
hepatocyte	O
nuclear	O
factor	O
4	O
(	O
hnf-4	O
)	O
modulator	O
compounds	O

Imidazo	B
-	O
containing	O
compounds	O
(	O
e.g.	O
,	O
imidazoquinolines	B
,	O
imidazonaphthyridines	B
,	O
imidazopyridines	B
)	O
with	O
a	O
hydroxylamine	B
substituent	O
at	O
the	O
1-position	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
intermediates	O
,	O
and	O
methods	O
of	O
use	O
of	O
these	O
compounds	O
as	O
immunomodulators	O
,	O
for	O
inducing	O
cytokine	O
biosynthesis	O
in	O
animals	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
including	O
viral	O
and	O
neoplastic	O
diseases	O
are	O
disclosed	O
.	O

Hydroxylamine	B
substituted	I
imidazo	I
-	O
containing	O
compounds	O

A	O
process	O
for	O
producing	O
2-	B
(	I
4-acetylpiperazin-1-yl	I
)	I
-6-	I
[	I
3,5-bis	I
(	I
trifluoromethyl	I
)	I
phenylmethyl	I
]	I
-4-	I
(	I
2-methylphenyl	I
)	I
-6,7,8,9-tetrahydro-5H	I
-	I
pyrimido	I
[	I
4,5-b	I
]	I
[	I
1,5	I
]	I
oxazocin-5-one	I
(	O
compound	O
1	O
)	O
for	O
industrial	O
production	O
of	O
a	O
compound	O
having	O
excellent	O
antagonism	O
against	O
tachykinin	O
receptor	O
,	O
especially	O
NK1	O
receptor	O
antagonism	O
.	O

The	O
process	O
is	O
characterized	O
by	O
comprising	O
causing	O
a	O
chlorinating	O
agent	O
to	O
act	O
on	O
4-	B
(	I
2-methylphenyl	I
)	I
-2-methylthio-6-oxo-1,6-dihydro-5-pyrimidinecarboxylic	I
acid	I
(	O
7	O
)	O
as	O
an	O
intermediate	O
;	O
reacting	O
the	O
product	O
with	O
3-	B
[	I
3,5-bis	I
(	I
trifluoromethyl	I
)	I
benzylamino	I
]	I
-1-propanol	I
;	O
causing	O
a	O
base	O
to	O
act	O
on	O
the	O
product	O
to	O
thereby	O
effect	O
cyclization	O
;	O
effecting	O
oxidation	O
thereof	O
;	O
and	O
reacting	O
the	O
oxide	B
with	O
N	B
-	I
acetylpiperazine	I
.	O

Process	O
for	O
producing	O
compound	O
having	O
nk1	O
receptor	O
antagonism	O
and	O
production	O
intermediate	O
thereof	O

An	O
electric	O
drug	O
transport	O
preparation	O
in	O
which	O
stability	O
of	O
a	O
drug	O
is	O
enhanced	O
during	O
storage	O
and	O
a	O
variation	O
in	O
appearance	O
(	O
coloring	O
)	O
of	O
a	O
drug	O
holding	O
layer	O
due	O
to	O
metal	O
ions	O
derived	O
from	O
an	O
electrode	O
can	O
be	O
prevented	O
during	O
preparation	O
under	O
such	O
a	O
state	O
that	O
the	O
drug	O
holding	O
layer	O
containing	O
a	O
drug	O
unstable	O
under	O
dissolved	O
state	O
adjoins	O
a	O
nonpolarizable	O
electrode	O
,	O
and	O
a	O
high	O
biological	O
utilization	O
rate	O
of	O
a	O
drug	O
can	O
be	O
attained	O
by	O
preventing	O
adhesion	O
of	O
the	O
electrode	O
component	O
to	O
skin	O
.	O

The	O
electric	O
drug	O
transport	O
preparation	O
(	O
1	O
)	O
comprises	O
an	O
electrode	O
supporting	O
substrate	O
(	O
5	O
)	O
,	O
an	O
electrode	O
layer	O
(	O
2	O
)	O
arranged	O
on	O
the	O
electrode	O
supporting	O
substrate	O
(	O
5	O
)	O
,	O
a	O
drug	O
holding	O
layer	O
(	O
3	O
)	O
arranged	O
on	O
the	O
electrode	O
layer	O
(	O
2	O
)	O
,	O
and	O
a	O
cover	O
material	O
(	O
4	O
)	O
covering	O
the	O
drug	O
holding	O
layer	O
(	O
3	O
)	O
.	O

The	O
drug	O
holding	O
layer	O
(	O
3	O
)	O
contains	O
an	O
electrolyte	O
reacting	O
with	O
a	O
metal	O
chelating	O
agent	O
and/or	O
the	O
electrode	O
layer	O
(	O
2	O
)	O
to	O
form	O
a	O
hard	O
-	O
to	O
-	O
dissolve	O
compound	O
.	O

Electric	O
drug	O
transport	O
preparation	O

[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
method	O
of	O
diagnosing	O
caner	O
with	O
the	O
use	O
of	O
Nox1	O
gene	O
relating	O
to	O
mutated	O
Ras	O
oncogen	O
,	O
a	O
method	O
of	O
screening	O
a	O
cancer	O
growth	O
inhibitor	O
and	O
a	O
medicinal	O
composition	O
to	O
be	O
used	O
in	O
treating	O
cancer	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
A	O
polypeptide	O
encoded	O
by	O
Nox1	O
gene	O
,	O
its	O
homolog	O
,	O
a	O
composition	O
for	O
producing	O
an	O
antibody	O
containing	O
such	O
a	O
peptide	O
fragment	O
,	O
an	O
antibody	O
against	O
the	O
polypeptide	O
encoded	O
by	O
Nox1	O
gene	O
,	O
and	O
a	O
method	O
of	O
detecting	O
mRNA	O
expressing	O
such	O
an	O
antibody	O
or	O
Nox1	O
.	O

ANTIBODY	O
AGAINST	O
Nox1	O
POLYPEPTIDE	O
,	O
METHOD	O
OF	O
DIAGNOSING	O
CANCER	O
WITH	O
THE	O
USE	O
OF	O
Nox1	O
GENE	O
AND	O
METHOD	O
OF	O
SCREENING	O
CANCER	O
GROWTH	O
INHIBITOR	O

This	O
invention	O
relates	O
to	O
a	O
novel	O
series	O
of	O
chemical	O
compounds	O
useful	O
as	O
Human	O
immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
protease	O
inhibitors	O
and	O
to	O
the	O
use	O
of	O
such	O
compounds	O
as	O
antiviral	O
agents	O
.	O

The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
antiviral	O
agents	O
,	O
and	O
their	O
uses	O
and	O
materials	O
for	O
their	O
synthesis	O
Hiv	O
protease	O
inhibitors	O
,	O
compositions	O
containing	O
the	O
same	O
and	O
their	O
pharmaceutical	O
uses	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
substituted	O
indoles	O
such	O
as	O
substituted	O
1H	B
-	I
indole-2-carboxylic	I
acid	I
derivatives	O
,	O
and	O
methods	O
of	O
using	O
them	O
.	O

Heterocyclic-	B
or	O
aryloxy	B
,	O
-thio	B
or	I
-amino	I
substituted	I
indoles-2-carboxylic	I
acids	I
or	I
esters	I
as	O
pai-1	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
promoting	O
collagen	O
synthesis	O
and	O
a	O
composition	O
for	O
external	O
application	O
to	O
skin	O
which	O
includes	O
the	O
collagen	O
synthesis	O
promoting	O
composition	O
.	O

The	O
collagen	O
synthesis	O
promoting	O
composition	O
includes	O
,	O
as	O
an	O
effective	O
component	O
,	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
compounds	O
represented	O
as	O
:	O
wherein	O
R	O
is	O
hydrogen	B
,	O
a	O
methoxy	B
group	O
,	O
or	O
a	O
3-methyl-2-butenyl	B
group	O
.	O

The	O
composition	O
for	O
external	O
application	O
to	O
skin	O
includes	O
at	O
least	O
one	O
collagen	O
synthesis	O
promoting	O
component	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
compounds	O
represented	O
by	O
above	O
.	O

Composition	O
for	O
promoting	O
synthesis	O
of	O
collagen	O
,	O
and	O
composition	O
for	O
external	O
preparation	O
for	O
skin	O
comprising	O
the	O
same	O

This	O
invention	O
relates	O
to	O
a	O
group	O
of	O
novel	O
dammarane	B
sapogenin	B
compounds	O
and	O
their	O
use	O
in	O
anti	O
-	O
cancer	O
applications	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
pertains	O
to	O
a	O
novel	O
group	O
of	O
dammarane	B
sapogenin	B
:	O
PPD	B
derivative	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
PPT	O
derivative	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
.	O

This	O
invention	O
also	O
includes	O
a	O
novel	O
application	O
of	O
the	O
said	O
sapogenins	B
for	O
anti­cancer	O
treatment	O
by	O
using	O
them	O
separately	O
or	O
together	O
,	O
and/or	O
jointly	O
with	O
other	O
drugs	O
.	O

Said	O
novel	O
dammarane	O
sapogenins	B
show	O
surprising	O
anti	O
-	O
cancer	O
effect	O
when	O
applied	O
.	O

Novel	O
dammarane	B
sapogenins	B
and	O
their	O
use	O
as	O
anti	O
-	O
cancer	O
agents	O

The	O
invention	O
relates	O
to	O
pharmaceuticals	O
,	O
in	O
particular	O
to	O
a	O
composition	O
which	O
exhibits	O
anti	O
-	O
inflammatory	O
,	O
regenerating	O
and	O
antimicrobial	O
action	O
and	O
comprises	O
1,3	B
diethyl	I
-	I
menzimidasole	I
thriiodide	I
as	O
an	O
active	O
compound	O
,	O
an	O
organic	O
dipolar	O
dissociating	O
(	O
polar	O
)	O
basic	O
soft	O
aprotic	O
solvent	O
and	O
a	O
base	O
.	O

The	O
inventive	O
composition	O
also	O
comprised	O
a	O
medicinal	O
low	O
-	O
molecular	O
polyvinyl	B
-	I
pirrolydone	I
in	O
the	O
form	O
of	O
the	O
active	O
compound	O
solubiliser	O
and	O
stabiliser	O
,	O
dimethyl	B
-	I
sulphoxide	I
(	O
dimexide	B
)	O
or	O
a	O
medicinal	O
ethyl	B
alcohol	I
in	O
the	O
form	O
of	O
the	O
organic	O
dipolar	O
dissociating	O
(	O
polar	O
)	O
basic	O
soft	O
aprotic	O
solvent	O
and	O
a	O
medicinal	O
vaseline	O
or	O
cleaned	O
water	O
in	O
the	O
form	O
of	O
a	O
base	O
at	O
a	O
certain	O
component	O
ratio	O
.	O

Said	O
invention	O
makes	O
it	O
possible	O
to	O
increase	O
the	O
efficiency	O
of	O
burn	O
and	O
wound	O
treatment	O
and	O
facilitates	O
the	O
access	O
of	O
the	O
active	O
compound	O
into	O
invaded	O
tissues	O
by	O
excluding	O
the	O
crystallisation	O
thereof	O
in	O
the	O
hydrophilic	O
medium	O
of	O
moist	O
wounds	O
and	O
burns	O
.	O

Anti	O
-	O
inflammatory	O
,	O
regenerating	O
and	O
antimicrobial	O
composition	O

Compounds	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
;	O
salts	O
thereof	O
,	O
solvates	O
thereof	O
,	O
prodrugs	O
thereof	O
or	O
cyclodextrin	O
clathrates	O
thereof	O
.	O

Because	O
of	O
having	O
a	O
potent	O
agonism	O
to	O
EP2	O
and	O
a	O
potent	O
effect	O
of	O
lowering	O
ocular	O
tension	O
while	O
little	O
irritating	O
the	O
eye	O
,	O
these	O
compounds	O
are	O
useful	O
in	O
treating	O
eye	O
diseases	O
such	O
as	O
glaucoma	O
,	O
ocular	O
hypertension	O
,	O
macular	O
edema	O
,	O
macular	O
degeneration	O
,	O
blood	O
flow	O
loss	O
in	O
retinal	O
and	O
optic	O
nerve	O
papillae	O
,	O
retinal	O
and	O
optic	O
nerve	O
hypertension	O
,	O
myopia	O
,	O
hyperopia	O
,	O
astigma	O
,	O
dry	O
eye	O
,	O
retinal	O
detachment	O
,	O
cataract	O
and	O
so	O
on	O
.	O

Nitrogen	B
-	O
containing	O
heterocyclic	B
compounds	O
and	O
drugs	O
comprising	O
the	O
same	O
as	O
the	O
active	O
ingredient	O

It	O
is	O
intended	O
to	O
provide	O
an	O
ABCA1	O
stabilizer	O
focusing	O
on	O
the	O
HDL	O
neogenesis	O
system	O
which	O
is	O
pharmacologically	O
useful	O
as	O
a	O
preventive	O
/	O
remedy	O
for	O
low	O
HDL	O
cholesterolemia	O
.	O

Namely	O
,	O
an	O
ABCA1	O
stabilizer	O
,	O
which	O
comprises	O
a	O
bisphenol	B
compound	O
selected	O
from	O
among	O
probucol	B
spiroquinone	I
,	O
probucol	B
diphenoquinone	I
and	O
probucol	B
bisphenol	I
as	O
the	O
active	O
ingredient	O
,	O
enables	O
the	O
continuous	O
and	O
stable	O
express	O
of	O
ABCA1	O
by	O
a	O
mechanism	O
completely	O
different	O
from	O
those	O
in	O
the	O
conventional	O
art	O
,	O
thereby	O
increasing	O
blood	O
HDL	O
level	O
.	O

Therefore	O
,	O
it	O
is	O
useful	O
as	O
a	O
preventive	O
/	O
remedy	O
for	O
low	O
HDL	O
cholesterolemia	O
,	O
arteriosclerosis	O
,	O
etc	O
.	O

Abca1	O
stabilizer	O

[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
preventive	O
means	O
or	O
a	O
therapeutic	O
means	O
efficacious	O
against	O
liver	O
fibrosis	O
and	O
to	O
provide	O
a	O
liver	O
fibrosis	O
inhibitor	O
,	O
a	O
medicinal	O
composition	O
,	O
a	O
food	O
and	O
a	O
drink	O
usable	O
as	O
the	O
therapeutic	O
means	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
It	O
is	O
intended	O
to	O
provide	O
a	O
liver	O
fibrosis	O
inhibitor	O
which	O
contains	O
a	O
shiitake	O
mushroom	O
mycelium	O
extract	O
or	O
a	O
fraction	O
thereof	O
.	O

It	O
is	O
also	O
intended	O
to	O
provide	O
a	O
liver	O
protecting	O
agent	O
having	O
an	O
effect	O
of	O
inhibiting	O
liver	O
fibrosis	O
which	O
contains	O
a	O
shiitake	O
mushroom	O
mycelium	O
extract	O
or	O
a	O
fraction	O
thereof	O
.	O

It	O
is	O
also	O
intended	O
to	O
provide	O
a	O
medicinal	O
composition	O
,	O
a	O
food	O
,	O
a	O
drink	O
and	O
so	O
on	O
containing	O
the	O
above	O
-	O
described	O
fraction	O
.	O

Liver	O
fibrosis	O
inhibitor	O

The	O
present	O
invention	O
provides	O
novel	O
combinations	O
comprising	O
a	O
topical	O
anticholinergic	O
drug	O
alone	O
or	O
in	O
combination	O
with	O
topically	O
administered	O
antihistamines	O
,	O
topically	O
or	O
orally	O
administered	O
phosphodiesterase	O
4	O
inhibitors	O
or	O
topical	O
corticosteroids	O
for	O
the	O
treatment	O
of	O
rhinitis	O
of	O
various	O
origins	O
.	O

It	O
further	O
comprises	O
presentation	O
of	O
these	O
combinations	O
in	O
locally	O
applied	O
formulations	O
and	O
includes	O
various	O
pharmaceutical	O
formulations	O
suitable	O
for	O
topical	O
application	O
,	O
e.g.	O
nasal	O
sprays	O
,	O
nasal	O
drops	O
,	O
emulsions	O
,	O
pastes	O
,	O
creams	O
and	O
gels	O
.	O

Treatment	O
of	O
rhinitis	O
with	O
anticholinergics	O
alone	O
in	O
combination	O
with	O
antihistamines	B
phosphodiesterase	O
4	O
inhibitors	O
,	O
or	O
corticosteroids	O

This	O
invention	O
provides	O
a	O
pharmaceutical	O
agent	O
containing	O
,	O
in	O
combination	O
,	O
a	O
sulfonamide	B
compound	O
and	O
other	O
therapeutic	O
agent	O
,	O
preferably	O
,	O
at	O
least	O
one	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
R1-SO2-NH	B
-	I
CO	I
-	I
A1-CH2-R2	I
[	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
at	O
least	O
one	O
pharmaceutical	O
agent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
α	O
-	O
glucosidase	O
inhibitor	O
,	O
an	O
insulin	O
secretagogue	O
,	O
a	O
sulfonylurea	B
and	O
a	O
biguanide	B
,	O
which	O
has	O
a	O
superior	O
therapeutic	O
effect	O
.	O

Concomitant	O
drugs	O
of	O
a	O
sulfonamide	B
and	O
another	O
therapeutic	O
agent	O

A	O
high	O
through	O
-	O
put	O
in	O
situ	O
hybridization	O
system	O
process	O
has	O
been	O
applied	O
to	O
an	O
epidermis	O
of	O
mouse	O
sole	O
in	O
order	O
to	O
identify	O
a	O
novel	O
gene	O
participating	O
in	O
epidermal	O
differentiation	O
.	O

As	O
a	O
result	O
,	O
about	O
100	O
types	O
of	O
unique	O
mRNA	O
expression	O
patterns	O
in	O
the	O
epidermis	O
have	O
been	O
detected	O
.	O

Two	O
novel	O
secreted	O
proteins	O
,	O
dermokine	O
-	O
α	O
and	O
-β	O
,	O
expressed	O
in	O
the	O
epidermal	O
layer	O
resulting	O
from	O
differentiation	O
of	O
a	O
superstratum	O
of	O
basal	O
layer	O
have	O
been	O
successfully	O
identified	O
therefrom	O
.	O

Further	O
,	O
it	O
has	O
been	O
found	O
that	O
the	O
genes	O
coding	O
for	O
these	O
proteins	O
construct	O
a	O
novel	O
gene	O
complex	O
(	O
SSC	O
)	O
.	O

Novel	O
gene	O
participating	O
in	O
epidermal	O
differentiation	O
and	O
use	O
thereof	O

A	O
compound	O
having	O
the	O
activity	O
of	O
glucokinase	O
activation	O
and	O
being	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diabetes	O
,	O
etc	O
.	O
,	O
represented	O
by	O
the	O
formula	O
:	O
(	O
I	O
)	O
[	O
wherein	O
X	O
is	O
a	O
nitrogen	B
atom	O
,	O
etc	O
.	O
;	O
Y	O
is	O
an	O
oxygen	B
atom	O
,	O
etc	O
.	O
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
5	O
to	O
6-membered	O
heteroaryl	B
group	O
,	O
etc	O
.	O

;	O
R2	O
is	O
a	O
hydrogen	B
atom	O
or	O
a	O
fluorine	B
atom	O
;	O
and	O
the	O
ring	O
A	O
is	O
an	O
optionally	O
substituted	O
monocyclic	O
or	O
bicyclic	O
heteroaryl	B
group	O
of	O
the	O
formula	O
:	O

(	O
II	O
)	O
]	O
,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Substituted	O
quinazoline	B
or	O
pyridopyrimidine	B
derivative	O

The	O
invention	O
provides	O
a	O
medical	O
composition	O
which	O
can	O
increase	O
the	O
medicine	O
safety	O
,	O
the	O
composition	O
comprises	O
adequate	O
emetic	O
,	O
low	O
dose	O
main	O
constituent	O
and	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
excipient	O
,	O
the	O
said	O
main	O
constituent	O
selected	O
from	O
any	O
one	O
of	O
the	O
hypnotics	O
,	O
sedatives	O
or	O
contraceptives	O
and	O
combination	O
thereof	O
,	O
the	O
composition	O
can	O
avoid	O
taking	O
the	O
overdose	O
main	O
constituent	O
or	O
increasing	O
the	O
dosage	O
without	O
authorization	O
;	O
the	O
said	O
main	O
constituent	O
also	O
can	O
be	O
the	O
pesticides	O
or	O
caustic	O
chemical	O
drugs	O
,	O
when	O
the	O
composition	O
be	O
wrong	O
taken	O
,	O
because	O
of	O
the	O
emetic	O
can	O
be	O
quickly	O
released	O
to	O
cause	O
nausea	O
and	O
vomiting	O
,	O
so	O
only	O
the	O
minor	O
constituent	O
would	O
stay	O
in	O
vivo	O
,	O
thus	O
can	O
attain	O
the	O
purpose	O
to	O
lower	O
the	O
nocuity	O
.	O

A	O
medical	O
composition	O
for	O
increasing	O
the	O
medicine	O
safety	O

The	O
present	O
invention	O
relates	O
to	O
an	O
active	O
substance	O
combination	O
comprising	O
at	O
least	O
one	O
substituted	O
carbinol	B
compound	O
and	O
at	O
least	O
one	O
opioid	B
,	O
a	O
medicament	O
comprising	O
said	O
active	O
substance	O
combination	O
,	O
a	O
pharmaceutical	O
formulation	O
comprising	O
said	O
active	O
substance	O
combination	O
and	O
the	O
use	O
of	O
said	O
active	O
substance	O
combination	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
.	O

Active	O
substance	O
combination	O
of	O
a	O
carbinol	B
compound	O
and	O
an	O
opioid	B

An	O
edible	O
composition	O
having	O
effects	O
of	O
promoting	O
the	O
production	O
and	O
release	O
of	O
a	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
.	O

Namely	O
,	O
an	O
edible	O
composition	O
comprising	O
isoflavone	B
and	O
capsaicin	O
as	O
the	O
essential	O
components	O
and	O
having	O
effects	O
of	O
promoting	O
the	O
production	O
and	O
release	O
of	O
a	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
;	O
and	O
an	O
edible	O
composition	O
comprising	O
the	O
above	O
-	O
described	O
edible	O
composition	O
for	O
preventing	O
and	O
treating	O
gastric	O
mucosal	O
injury	O
,	O
life	O
style	O
-	O
related	O
diseases	O
,	O
obesity	O
,	O
malignant	O
tumor	O
and	O
osteoporosis	O
,	O
relieving	O
rejection	O
accompanying	O
organ	O
transplantation	O
,	O
preventing	O
and	O
relieving	O
organ	O
injury	O
caused	O
by	O
vital	O
invasion	O
reactions	O
against	O
invasive	O
factors	O
such	O
as	O
infection	O
,	O
and	O
stimulating	O
hair	O
(	O
for	O
example	O
,	O
head	O
hair	O
)	O
growth	O
.	O

This	O
edible	O
composition	O
exerts	O
effects	O
of	O
preventing	O
and	O
treating	O
gastric	O
mucosal	O
injury	O
and	O
so	O
on	O
and	O
these	O
effects	O
are	O
mild	O
without	O
any	O
risk	O
of	O
side	O
effect	O
.	O

Edible	O
composition	O
having	O
effects	O
of	O
promoting	O
the	O
production	O
and	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
podophyllotoxin	B
derivatives	O
substituted	O
in	O
the	O
4-position	O
by	O
a	O
substituted	O
(	B
poly	I
)	I
aminoalkylaminoacetamide	I
chain	O
,	O
to	O
their	O
process	O
of	O
preparation	O
and	O
to	O
their	O
use	O
as	O
medicament	O
as	O
anticancer	O
agents	O
.	O

(	O
poly	O
)	O
aminoacetamide	B
derivatives	O
of	O
epipodophyllotoxin	B
their	O
process	O
of	O
preparation	O
and	O
their	O
applications	O
in	O
therapeutics	O
as	O
anticancer	O
agents	O

The	O
invention	O
relates	O
to	O
a	O
combination	O
preparation	O
,	O
effective	O
against	O
cancer	O
cells	O
,	O
comprising	O
,	O
as	O
active	O
substance	O
,	O
at	O
least	O
one	O
1-diethylaminoethyl-3-quinoxalin-2-one	B
derivative	O
of	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
and	O
R2	O
independently	O
=	O
H	B
,	O
methyl	B
,	O
ethyl	B
,	O
propyl	B
,	O
butyl	B
,	O
or	O
R1	O
and	O
R2	O
together	O
=	O
a	O
cycloalkyl	B
compound	O
,	O
R3	O
=	O
methoxy	B
,	O
ethoxy	B
,	O
hydroxy	B
,	O
H	B
,	O
C1-C4	B
alkyl	I
,	O
or	O
halogen	B
and	O
n=	O
1	O
,	O
2	O
or	O
3	O
,	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
of	O
said	O
derivatives	O
and	O
an	O
effective	O
amount	O
of	O
a	O
cytostatic	O
anti	O
-	O
cancer	O
agent	O
,	O
such	O
as	O
a	O
compound	O
of	O
the	O
oxysterol	B
or	O
polyphenol	B
classes	O
,	O
or	O
a	O
mixture	O
comprising	O
selenium	O
and	O
L	B
-	I
cysteine	I
and/or	O
L	B
-	I
glutathione	I
,	O
or	O
a	O
mixture	O
comprising	O
B	O
-	O
complex	O
vitamins	O
,	O
in	O
particular	O
with	O
the	O
vitamins	B
B1	I
,	I
and/or	I
B6	I
and/or	I
B12	I
,	O
with	O
the	O
exception	O
of	O
cis-	B
or	I
oxaliplatin	I
and	O
irinotecan	B
.	O

Preparation	O
for	O
the	O
treatment	O
of	O
cancer	O

It	O
is	O
intended	O
to	O
provide	O
an	O
agent	O
for	O
removing	O
a	O
factor	O
causing	O
circulatory	O
dysfunction	O
which	O
is	O
efficacious	O
in	O
ameliorating	O
circulatory	O
dysfunction	O
(	O
in	O
particular	O
,	O
heart	O
dysfunction	O
)	O
and	O
efficacious	O
in	O
preventing	O
or	O
treating	O
circulatory	O
diseases	O
such	O
as	O
heart	O
diseases	O
(	O
for	O
example	O
,	O
heart	O
failure	O
or	O
congestive	O
heart	O
failure	O
)	O
and	O
venous	O
thrombosis	O
.	O

This	O
agent	O
for	O
removing	O
a	O
factor	O
causing	O
circulatory	O
dysfunction	O
comprises	O
spherical	O
active	O
carbon	B
as	O
the	O
active	O
ingredient	O
.	O

Agent	O
for	O
removing	O
factor	O
causing	O
circulatory	O
dysfunction	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
are	O
independently	O
from	O
each	O
other	O
hydrogen	B
or	O
Cl	B
-	I
C6-alkyl	I
;	O
R3	O
,	O
R4	O
are	O
independently	O
from	O
each	O
other	O
hydrogen	B
or	O
C1-C6-alkyl	B
;	O
R5	O
is	O
halogen	B
,	O
CN	B
,	O
(	B
C1-C6	I
)	I
-alkyl	I
or	O
(	B
C1-C6	I
)	I
-alkoxy	I
;	O
n	O
,	O
m	O
or	O
o	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
as	O
well	O
as	O
to	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

The	O
compounds	O
may	O
be	O
used	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
Alzheimer	O
's	O
disease	O
or	O
senile	O
dementia	O
.	O

New	O
mao	O
-	O
b	O
inhibitors	O

Antitumor	O
compounds	O
based	O
on	O
the	O
α1-adrenoceptor	O
antagonist	O
,	O
doxazosin	B
,	O
as	O
well	O
as	O
compositions	O
and	O
methods	O
of	O
use	O
.	O

The	O
disclosed	O
compounds	O
induce	O
apoptosis	O
in	O
cancer	O
cells	O
.	O

Amino	B
-	I
quinazoline	I
derivatives	O
as	O
antitumor	O
agents	O

The	O
invention	O
pertains	O
to	O
inhibitors	O
of	O
various	O
kinases	O
(	O
e.g.	O
S	O
/	O
T	O
kinases	O
,	O
Tyr	B
kinases	O
,	O
etc	O
.	O
)	O
,	O
which	O
inhibitors	O
are	O
previously	O
known	O
as	O
cyclin	O
dependent	O
kinase	O
inhibitors	O
(	O
CDKs	O
)	O
.	O

As	O
described	O
herein	O
,	O
the	O
inhibitors	O
of	O
this	O
invention	O
are	O
capable	O
of	O
inhibiting	O
various	O
wild	O
-	O
type	O
and	O
mutant	O
form	O
kinases	O
,	O
including	O
drug	O
resistant	O
forms	O
of	O
mutant	O
kinases	O
.	O

Thus	O
the	O
subject	O
kinase	O
inhibitors	O
are	O
useful	O
in	O
treating	O
a	O
wide	O
range	O
of	O
diseases	O
/	O
conditions	O
associated	O
with	O
abnormal	O
functions	O
/	O
excessive	O
activities	O
of	O
the	O
target	O
kinases	O
,	O
including	O
mutant	O
kinases	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
for	O
treating	O
cancers	O
,	O
tumors	O
and	O
patients	O
which	O
are	O
resistant	O
or	O
refractory	O
to	O
other	O
therapeutic	O
agents	O
.	O

Pharmaceutical	O
compositions	O
and	O
packaged	O
pharmaceuticals	O
with	O
instructions	O
of	O
these	O
inhibitors	O
,	O
and	O
methods	O
of	O
using	O
these	O
inhibitors	O
are	O
also	O
provided	O
.	O

Kinase	O
inhibitors	O
for	O
treating	O
cancers	O

The	O
present	O
invention	O
generally	O
relates	O
to	O
a	O
series	O
of	O
compounds	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
and	O
to	O
use	O
of	O
the	O
compounds	O
and	O
compositions	O
as	O
therapeutic	O
agents	O
.	O

More	O
specifically	O
,	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
hexahydroazepinoindole	B
and	O
octahydroazepinoindole	B
compounds	O
.	O

These	O
compounds	O
are	O
serotonin	B
receptor	O
(	O
5-HT	B
)	O
ligands	O
and	O
are	O
useful	O
for	O
treating	O
diseases	O
,	O
disorders	O
,	O
and	O
conditions	O
wherein	O
modulation	O
of	O
the	O
activity	O
of	O
serotonin	B
receptors	O
(	O
5-HT	B
)	O
is	O
desired	O
(	O
e.g.	O
anxiety	O
,	O
depression	O
and	O
obesity	O
)	O
.	O

Substituted	O
azepine	B
derivatives	O
as	O
serotonin	O
receptor	O
modulators	O

The	O
invention	O
concerns	O
a	O
stable	O
foaming	O
pharmaceutical	O
composition	O
for	O
topical	O
use	O
for	O
treating	O
psoriasis	O
,	O
comprising	O
a	O
hydrophilic	O
phase	O
,	O
at	O
least	O
one	O
hydrophobic	O
phase	O
,	O
a	O
surfactant	O
,	O
and	O
as	O
active	O
principle	O
a	O
combination	O
of	O
vitamin	B
D	I
analogue	O
and	O
corticosteroid	B
and	O
at	O
least	O
one	O
propellant	O
gas	O
.	O

Pressurized	O
foaming	O
composition	O
for	O
topical	O
treatment	O
of	O
psoriasis	O

A	O
therapeutic	O
method	O
for	O
the	O
treatment	O
of	O
patients	O
suffering	O
from	O
a	O
gastrin­-promoted	O
tumor	O
;	O
a	O
tumor	O
comprising	O
cells	O
bearing	O
a	O
gastrin	O
receptor	O
;	O
or	O
a	O
tumor	O
of	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
,	O
a	O
pancreatic	O
tumor	O
,	O
a	O
medullary	O
thyroid	O
carcinoma	O
(	O
MTC	O
)	O
,	O
a	O
tumor	O
of	O
the	O
lung	O
,	O
a	O
glioblastoma	O
,	O
an	O
ovarian	O
tumor	O
,	O
or	O
a	O
tumor	O
of	O
neuroendocrine	O
origin	O
is	O
provided	O
.	O

The	O
method	O
includes	O
administering	O
to	O
a	O
patient	O
a	O
DNA	O
molecule	O
comprising	O
a	O
gastrin	O
anti	O
-	O
sense	O
sequence	O
operatively	O
linked	O
to	O
a	O
regulatory	O
sequence	O
that	O
expresses	O
gastrin	O
anti	O
-	O
sense	O
RNA	O
to	O
the	O
patient	O
,	O
and	O
also	O
administering	O
a	O
chemotherapeutic	O
agent	O
.	O

The	O
method	O
is	O
especially	O
useful	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	O
stage	O
disease	O
,	O
and	O
for	O
patients	O
having	O
undergone	O
prior	O
surgery	O
,	O
radiotherapy	O
or	O
chemotherapy	O
treatment	O
.	O

Anti	O
-	O
sense	O
polynucleotide	O
therapy	O
for	O
gastrin	O
-	O
promoted	O
tumors	O

Stabilized	O
pharmaceutical	O
compositions	O
containing	O
Pravastatin	B
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
are	O
disclosed	O
.	O

The	O
composition	O
comprises	O
of	O
pravastatin	B
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
,	O
stabilized	O
by	O
synergistic	O
combination	O
of	O
substantially	O
low	O
amount	O
of	O
alkalizing	O
agent	O
and	O
nonionic	O
surfactant	O
,	O
to	O
impart	O
a	O
pH	O
between	O
8	O
to	O
8.75	O
to	O
an	O
aqueous	O
solution	O
or	O
dispersion	O
of	O
the	O
said	O
composition	O
.	O

Stabilized	O
pharmaceutical	O
compositions	O
of	O
pravastatin	B

Disclosed	O
are	O
a	O
compound	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
below	O
.	O

(	O
In	O
the	O
formula	O
(	O
1	O
)	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
X	O
are	O
the	O
same	O
as	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
X	O
defined	O
in	O
the	O
description	O
.	O
)	O
5-substituted-2-phenylamino	B
-	I
benzamide	I
as	O
mek	O
inhibitor	O

An	O
isovaleramide	B
analog	O
having	O
at	O
least	O
one	O
of	O
an	O
increased	O
potency	O
,	O
an	O
increased	O
half	O
-	O
life	O
,	O
and	O
an	O
increased	O
stability	O
compared	O
to	O
isovaleramide	B
.	O

The	O
isovaleramide	B
analog	O
is	O
a	O
cyclic	O
analog	O
or	O
a	O
noncyclic	O
analog	O
.	O

The	O
isovaleramide	B
analog	O
is	O
formulated	O
into	O
a	O
pharmaceutical	O
composition	O
.	O

A	O
method	O
of	O
treating	O
a	O
central	O
nervous	O
system	O
condition	O
or	O
disease	O
is	O
also	O
disclosed	O
.	O

The	O
method	O
comprises	O
administering	O
an	O
isovaleramide	B
analog	O
to	O
a	O
patient	O
suffering	O
from	O
the	O
central	O
nervous	O
system	O
condition	O
or	O
disease	O
.	O

Analogs	O
of	O
isovaleramide	B
,	O
a	O
pharmaceutical	O
composition	O
including	O
the	O
same	O
,	O
and	O
a	O
method	O
of	O
treating	O
central	O
nervous	O
system	O
conditions	O
or	O
diseases	O

A	O
peroral	O
solid	O
preparation	O
of	O
the	O
quick	O
-	O
acting	O
short	O
-	O
lasting	O
type	O
which	O
gives	O
no	O
feeling	O
of	O
bitterness	O
and	O
retains	O
properties	O
of	O
nateglinide	B
.	O

The	O
peroral	O
solid	O
preparation	O
reduced	O
in	O
bitterness	O
contains	O
nateglinide	B
and	O
a	O
water	O
-	O
soluble	O
polymer	O
,	O
and	O
is	O
characterized	O
by	O
containing	O
the	O
water	O
-	O
soluble	O
polymer	O
in	O
an	O
amount	O
of	O
0.3	O
-	O
6	O
parts	O
by	O
weight	O
,	O
in	O
terms	O
of	O
solid	O
amount	O
,	O
per	O
part	O
by	O
weight	O
of	O
the	O
nateglinide	B
.	O

Nateglinide	B
-	O
containing	O
preparation	O
reduced	O
in	O
bitterness	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
public	O
health	O
and	O
,	O
in	O
particular	O
,	O
to	O
a	O
preparation	O
containing	O
ionic	O
iron	B
and	O
haem	O
iron	B
in	O
powder	O
form	O
,	O
which	O
can	O
be	O
administered	O
orally	O
in	O
the	O
form	O
of	O
tablets	O
or	O
an	O
aqueous	O
suspension	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
iron	B
deficiency	O
.	O

The	O
powder	O
preparation	O
contains	O
between	O
6	O
and	O
26	O
%	O
ferrous	B
fumarate	I
and	O
between	O
74	O
and	O
94	O
%	O
haemoderivative	O
in	O
powder	O
form	O
,	O
with	O
an	O
ionic	O
iron	B
/	O
haem	O
iron	B
ratio	O
of	O
between	O
30	O
and	O
70	O
%	O
and	O
an	O
amino	B
acid	I
concentration	O
of	O
between	O
20	O
and	O
30	O
µmol	O
/	O
100µmol	O
of	O
proteins	O
.	O

In	O
a	O
10	O
%	O
aqueous	O
suspension	O
,	O
the	O
preparation	O
contains	O
a	O
total	O
iron	B
concentration	O
of	O
between	O
11	O
and	O
22	O
mg	O
/	O
mL.	O
In	O
tablets	O
with	O
a	O
mass	O
of	O
between	O
500	O
and	O
700	O
mg	O
,	O
the	O
preparation	O
contains	O
between	O
13	O
and	O
30	O
mg	O
total	O
iron	B
,	O
between	O
0.2	O
and	O
0.25	O
mg	O
folic	B
acid	I
and	O
between	O
45	O
and	O
55	O
mg	O
ascorbic	B
acid	I
.	O

In	O
addition	O
,	O
the	O
preparation	O
can	O
be	O
used	O
as	O
a	O
restorative	O
remedy	O
in	O
convalescent	O
states	O
and	O
as	O
a	O
therapeutic	O
adjuvant	O
.	O

Preparation	O
comprising	O
ionic	O
iron	B
and	O
haem	O
iron	B
and	O
variants	O
thereof	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
iron	O
deficiency	O

The	O
invention	O
relates	O
to	O
a	O
stable	O
,	O
non	O
hygroscopic	O
alpha	O
crystalline	O
form	O
of	O
methane	B
sulfonic	I
acid	I
addition	O
salt	O
of	O
4-	B
(	I
4-methyl	I
piperazin	I
-	I
lyl	I
methyl	I
)	I
-N-	I
[	I
4-methyl-3-	I
(	I
4-pyridin-3-yl	I
)	I
pyrimidin-2-yl	I
amino	I
)	I
phenyl	I
]	I
-benzamide	I
(	O
imatinib	B
mesylate	I
)	O
.	O

A	O
process	O
for	O
the	O
preparation	O
of	O
the	O
crystalline	O
form	O
is	O
also	O
described	O
.	O

Stable	O
crystal	O
form	O
of	O
imatinib	B
mesylate	I
and	O
process	O
for	O
the	O
preparation	O
thereof	O

Methods	O
and	O
intermediates	O
for	O
synthesizing	O
triethylenetetramine	B
and	O
salts	O
thereof	O
,	O
as	O
well	O
as	O
novel	O
triethylenetetramine	B
salts	O
and	O
their	O
crystal	O
structure	O
,	O
and	O
triethylenetetramine	B
salts	O
of	O
high	O
purity	O
.	O

Synthesis	O
of	O
triethylenetetramines	B

The	O
invention	O
concerns	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
in	O
base	O
,	O
hydrate	B
or	O
solvate	O
state	O
,	O
in	O
the	O
form	O
of	O
cis	O
/	O
trans	O
isomers	O
or	O
mixtures	O
thereof	O
3-spiro	B
-	I
indolin-2-one	I
derivatives	O
as	O
vasopressin	O
receptor	O
ligand	O

A	O
drug	O
having	O
anti	O
-	O
HIV	O
activity	O
,	O
especially	O
a	O
drug	O
having	O
integrase	O
inhibitory	O
activity	O
.	O

Also	O
provided	O
is	O
a	O
quinolizinone	B
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
[	O
I	O
]	O
:	O
[	O
I	O
]	O
(	O
wherein	O
the	O
symbols	O
are	O
the	O
same	O
as	O
defined	O
in	O
the	O
description	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
drug	O
is	O
an	O
anti	O
-	O
HIV	O
agent	O
containing	O
the	O
compound	O
or	O
salt	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
compound	O
has	O
the	O
function	O
of	O
inhibiting	O
HIV	O
integrase	O
activity	O
and	O
is	O
useful	O
as	O
an	O
anti	O
-	O
HIV	O
agent	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
AIDs	O
.	O

The	O
anti	O
-	O
HIV	O
agent	O
can	O
be	O
a	O
more	O
effective	O
one	O
when	O
used	O
in	O
combination	O
with	O
other	O
anti	O
-	O
HIV	O
agent	O
such	O
as	O
a	O
protease	O
inhibitor	O
or	O
reverse	O
transcriptase	O
inhibitor	O
.	O

The	O
anti	O
-	O
HIV	O
agent	O
has	O
high	O
inhibitory	O
activity	O
specific	O
for	O
integrases	O
and	O
can	O
hence	O
be	O
a	O
drug	O
safe	O
for	O
the	O
human	O
body	O
and	O
reduced	O
in	O
side	O
effects	O
.	O

Quinolizinone	B
compound	O
and	O
use	O
thereof	O
as	O
hiv	O
integrase	O
inhibitor	O

A	O
novel	O
immune	O
stimulating	O
oligonucleotide	O
having	O
the	O
activity	O
of	O
inducing	O
strong	O
immune	O
responses	O
;	O
a	O
pharmaceutical	O
product	O
comprising	O
this	O
immune	O
stimulating	O
oligonucleotide	O
;	O
and	O
use	O
thereof	O
.	O

This	O
immune	O
stimulating	O
oligonucleotide	O
,	O
for	O
example	O
,	O
consists	O
of	O
an	O
oligonucleotide	O
having	O
the	O
sequence	O
of	O
ggtgccgatcggcagggggg	O
.	O

This	O
oligonucleotide	O
can	O
be	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
pharmaceuticals	O
,	O
such	O
as	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
allergoses	O
.	O

As	O
this	O
immune	O
stimulating	O
oligonucleotide	O
has	O
a	O
strong	O
immune	O
stimulating	O
activity	O
,	O
the	O
use	O
thereof	O
renders	O
it	O
promising	O
to	O
attain	O
enhanced	O
treating	O
,	O
preventive	O
and	O
remedial	O
effects	O
and	O
to	O
through	O
reduction	O
of	O
administration	O
frequency	O
,	O
attain	O
side	O
effect	O
suppression	O
and	O
QOL	O
remedy	O
.	O

Immune	O
stimulating	O
oligonucleotide	O
and	O
use	O
thereof	O
in	O
pharmaceutical	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
ketone	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
having	O
Asp2	O
(	O
β	O
-	O
secretase	O
,	O
BACE1	O
or	O
Memapsin-2	O
)	O
inhibitory	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
the	O
treatment	O
of	O
diseases	O
characterised	O
by	O
elevated	O
β-	O
amyloid	O
levels	O
or	O
β	O
-	O
amyloid	O
deposits	O
,	O
particularly	O
Alzheimer	O
's	O
disease	O
.	O

Tricyclic	B
indole	I
derivatives	O
for	O
use	O
in	O
the	O
treatment	O
of	O
alzheimer	O
's	O
disease	O

A	O
highly	O
efficient	O
method	O
of	O
screening	O
drugs	O
for	O
diabetes	O
treatment	O
;	O
and	O
novel	O
compounds	O
for	O
treatment	O
and	O
prevention	O
of	O
PPAR	O
-	O
associated	O
diseases	O
.	O

There	O
is	O
provided	O
a	O
method	O
of	O
identifying	O
a	O
compound	O
capable	O
of	O
regulating	O
peroxisome	O
proliferator	O
activated	O
receptor	O
(	O
PPAR	O
)	O
,	O
which	O
compound	O
has	O
at	O
least	O
one	O
activity	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
the	O
activity	O
of	O
promoting	O
the	O
insulin	O
secretion	O
of	O
pancreatic	O
β	O
-	O
cells	O
and	O
the	O
activity	O
of	O
promoting	O
peripheral	O
insulin	O
sensitivity	O
.	O

This	O
method	O
comprises	O
the	O
steps	O
of	O
(	O
A	O
)	O
providing	O
candidate	O
compounds	O
;	O
(	O
B	O
)	O
with	O
respect	O
to	O
the	O
candidate	O
compounds	O
,	O
measuring	O
at	O
least	O
one	O
activity	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
the	O
activity	O
of	O
promoting	O
the	O
insulin	O
secretion	O
of	O
pancreatic	O
β	O
-	O
cells	O
and	O
the	O
activity	O
of	O
promoting	O
peripheral	O
insulin	O
sensitivity	O
;	O
(	O
C	O
)	O
subjecting	O
the	O
candidate	O
compounds	O
to	O
an	O
assay	O
for	O
measuring	O
the	O
activity	O
of	O
PPAR	O
;	O
and	O
(	O
D	O
)	O
identifying	O
those	O
judged	O
as	O
having	O
an	O
activity	O
in	O
each	O
of	O
the	O
steps	O
(	O
B	O
)	O
and	O
(	O
C	O
)	O
as	O
lead	O
compounds	O
.	O

Novel	O
ppar	O
regulating	O
agent	O
and	O
method	O
of	O
screening	O
the	O
same	O

A	O
compound	O
with	O
p38MAP	O
kinase	O
inhibiting	O
activity	O
useful	O
as	O
a	O
pharmaceutical	O
,	O
represented	O
by	O
the	O
general	O
formula	O
:	O
(	O
I	O
)	O
[	O
wherein	O
all	O
the	O
characters	O
are	O
as	O
defined	O
in	O
the	O
description	O
]	O
,	O
or	O
its	O
salt	O
,	O
N	B
-	I
oxide	I
or	O
solvate	O
,	O
or	O
a	O
prodrug	O
thereof	O
.	O

Further	O
,	O
there	O
are	O
provided	O
a	O
process	O
for	O
producing	O
the	O
same	O
and	O
usage	O
thereof	O
.	O

The	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
has	O
a	O
p38MAP	O
kinase	O
inhibiting	O
activity	O
and	O
is	O
useful	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
diseases	O
in	O
which	O
an	O
abnormal	O
production	O
of	O
cytokine	O
,	O
such	O
as	O
inflammatory	O
cytokine	O
or	O
chemokine	O
,	O
or	O
an	O
over	O
-	O
reaction	O
thereto	O
would	O
be	O
instrumental	O
in	O
the	O
cause	O
and	O
aggravation	O
of	O
pathologic	O
condition	O
thereof	O
,	O
namely	O
,	O
cytokine	O
-	O
mediated	O
diseases	O
,	O
for	O
example	O
,	O
inflammatory	O
diseases	O
,	O
respiratory	O
diseases	O
,	O
circulatory	O
diseases	O
,	O
central	O
nervous	O
system	O
diseases	O
,	O
etc	O
.	O

Nitrogenous	B
heterocyclic	I
compound	O
and	O
pharmaceutical	O
use	O
thereof	O

Disclosed	O
herein	O
is	O
a	O
regioselective	O
synthesis	O
of	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
salt	O
,	O
solvate	O
,	O
clathrate	O
,	O
or	O
prodrug	O
thereof	O
,	O
wherein	O
X	O
,	O
Y	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
,	O
m	O
and	O
n	O
are	O
defined	O
as	O
within	O
.	O

Process	O
for	O
preparing	O
trisubstituted	B
pyrimidine	I
compounds	O

The	O
present	O
invention	O
provides	O
for	O
pyrazolopurine	B
-	O
based	O
tricyclic	O
compounds	O
having	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R6	O
are	O
as	O
described	O
herein	O
.	O

The	O
present	O
invention	O
further	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
such	O
compounds	O
for	O
treating	O
inflammatory	O
and	O
immune	O
diseases	O
.	O

IMIDAZO	B
-	I
FUSED	I
THIAZOLO	I
[	I
4,5-b	I
]	I
PYRIDINE	I
BASED	O
TRICYCLIC	O
COMPOUNDS	O
AND	O
PHARMACEUTICAL	O
COMPOSITIONS	O
COMPRISING	O
SAME	O

A	O
nutraceutical	O
composition	O
including	O
one	O
or	O
more	O
extracts	O
of	O
one	O
or	O
more	O
plant	O
components	O
,	O
the	O
one	O
or	O
more	O
extracts	O
providing	O
a	O
combination	O
of	O
phytonutrient	O
materials	O
,	O
the	O
type	O
and	O
amount	O
of	O
which	O
are	O
in	O
excess	O
of	O
a	O
minimum	O
value	O
predetermined	O
to	O
provide	O
a	O
therapeutically	O
or	O
prophylactically	O
desirable	O
effect	O
.	O

Improved	O
nutraceutical	O
composition	O

Substituted	O
caprolactames	B
,	O
method	O
for	O
the	O
preparation	O
thereof	O
,	O
compositions	O
containing	O
them	O
and	O
use	O
thereof	O
.	O

The	O
invention	O
relates	O
to	O
the	O
preparation	O
of	O
substituted	O
caprolactames	B
,	O
a	O
method	O
for	O
the	O
preparation	O
thereof	O
,	O
compositions	O
containing	O
them	O
and	O
the	O
use	O
thereof	O
as	O
a	O
medicament	O
,	O
particularly	O
as	O
anti	O
-	O
canceral	O
agents	O
.	O

Bengamides	B
with	O
a	O
substituted	O
caprolactame	B
cycle	O
,	O
method	O
for	O
the	O
preparation	O
thereof	O
,	O
compositions	O
containing	O
them	O
and	O
use	O
thereof	O

A	O
use	O
and	O
a	O
composition	O
based	O
on	O
chitosan	O
are	O
provided	O
for	O
stimulating	O
bone	O
healing	O
and	O
bone	O
formation	O
.	O

Chitosan	O
is	O
demonstrated	O
to	O
be	O
a	O
potent	O
osteoinductor	O
and	O
substantially	O
accelerates	O
new	O
bone	O
formation	O
through	O
the	O
endochondrial	O
ossification	O
pathway	O
,	O
by	O
forming	O
cartilage	O
which	O
is	O
subsequently	O
vascularised	O
and	O
mineralized	O
and	O
transformed	O
into	O
a	O
normal	O
healthy	O
bone	O
tissue	O
.	O

Use	O
of	O
chitosan	O
for	O
stimulating	O
bone	O
healing	O
and	O
bone	O
formation	O

This	O
invention	O
discloses	O
2α	B
-	I
methyl-19-nor	I
-	I
vitamin	I
D	I
analogs	O
,	O
and	O
specifically	O
2α	B
-	I
methyl-19-nor-1α	I
-	I
hydroxy	I
-	I
homopregnacalciferol	I
and	O
pharmaceutical	O
uses	O
therefor	O
.	O

This	O
compound	O
exhibits	O
pronounced	O
activity	O
in	O
arresting	O
the	O
proliferation	O
of	O
undifferentiated	O
cells	O
and	O
inducing	O
their	O
differentiation	O
to	O
the	O
monocyte	O
thus	O
evidencing	O
use	O
as	O
an	O
anti	O
-	O
cancer	O
agent	O
and	O
for	O
the	O
treatment	O
of	O
skin	O
diseases	O
such	O
as	O
psoriasis	O
as	O
well	O
as	O
skin	O
conditions	O
such	O
as	O
wrinkles	O
,	O
slack	O
skin	O
,	O
dry	O
skin	O
and	O
insufficient	O
sebum	O
secretion	O
.	O

This	O
compound	O
also	O
has	O
little	O
,	O
if	O
any	O
,	O
calcemic	O
activity	O
and	O
therefore	O
may	O
be	O
used	O
to	O
treat	O
autoimmune	O
disorders	O
or	O
inflammatory	O
diseases	O
in	O
humans	O
as	O
well	O
as	O
renal	O
osteodystrophy	O
.	O

This	O
compound	O
may	O
also	O
be	O
used	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
obesity	O
.	O

2alpha	B
-	I
methyl-19-nor-1alpha	I
-	I
hydroxy	I
-	I
homopregnacalciferol	I
and	O
its	O
uses	O

The	O
present	O
invention	O
relates	O
to	O
new	O
pharmaceutical	O
uses	O
of	O
4-azasteroid	B
compounds	O
,	O
in	O
particular	O
of	O
Finasteride	B
and	O
Dutasteride	B
and	O
its	O
pharmaceutically	O
acceptable	O
derivatives	O
,	O
and	O
combinations	O
comprising	O
said	O
compounds	O
.	O

The	O
invention	O
also	O
features	O
generally	O
the	O
use	O
of	O
a	O
modulator	O
compound	O
of	O
neuroprotective	O
conditions	O
via	O
beta	O
subunits	O
of	O
shaker-	O
type	O
voltage	O
-	O
gated	O
potassium	B
channels	O
and/or	O
via	O
members	O
of	O
solute	O
carriers	O
family	O
25	O
,	O
in	O
particular	O
Aralar	O
(	O
member	O
12	O
)	O
and	O
adenine	B
-nucleotide	O
translocators	O
1	O
&	O
2	O
(	O
member	O
4	O
&	O
5	O
)	O
and/or	O
via	O
a	O
4-nitrophenylphosphatase	O
domain	O
and	O
non	O
-	O
neurona	O
SNAP25-like	O
protein	O
homolog	O
1	O
(	O
NIPSNAP	O
1	O
)	O
as	O
a	O
neuroprotective	O
medicament	O
,	O
particularly	O
as	O
a	O
medicament	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
neurological	O
diseases	O
such	O
as	O
dementia	O
,	O
Parkinson	O
,	O
Alzheimer	O
,	O
schizophrenia	O
or	O
epilepsy	O
.	O

The	O
demonstrated	O
inhibition	O
of	O
the	O
MPTP	O
appears	O
to	O
constitute	O
a	O
novel	O
principle	O
applicable	O
to	O
all	O
pathological	O
conditions	O
which	O
have	O
underlying	O
excitotoxic	O
/	O
mitochondrial	O
mechanisms	O
,	O
like	O
:	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
Alzheimer	O
's	O
disease	O
,	O
depression	O
,	O
epilepsy	O
,	O
multiple	O
sclerosis	O
,	O
pain	O
,	O
Parkinson	O
's	O
disease	O
,	O
schizophrenia	O
,	O
traumatic	O
brain	O
and	O
spinal	O
chord	O
injury	O
,	O
stroke	O
and	O
other	O
ischemic	O
conditions	O
in	O
the	O
brain	O
.	O

Finasteride	B
,	O
dutasteride	B
and	O
related	O
compounds	O
for	O
preventing	O
/	O
treating	O
neurologically	O
-	O
associated	O
disorders	O

A	O
medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
adhesion	O
which	O
contains	O
a	O
CCR8	O
inhibitor	O
as	O
the	O
active	O
ingredient	O
.	O

The	O
CCR8	O
inhibitor	O
is	O
preferably	O
a	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
antibody	O
binding	O
to	O
CCR8	O
,	O
a	O
neutralizing	O
antibody	O
against	O
a	O
CCR8	O
ligand	O
CCL1	O
,	O
aptamers	O
to	O
CCR8	O
and	O
CCL1	O
,	O
an	O
antagonist	O
to	O
CCR8	O
,	O
antisense	O
oligonucleotides	B
to	O
CCR8	O
and	O
CCL1	O
genes	O
and	O
siRNAs	O
thereto	O
.	O

A	O
method	O
of	O
diagnosing	O
adhesion	O
which	O
comprises	O
detecting	O
the	O
expression	O
of	O
a	O
CCR8	O
gene	O
or	O
a	O
CCL1	O
gene	O
in	O
test	O
cells	O
or	O
detecting	O
the	O
content	O
of	O
CCR8	O
or	O
CCL1	O
in	O
the	O
test	O
cells	O
.	O

A	O
method	O
of	O
screening	O
a	O
substance	O
which	O
is	O
useful	O
in	O
preventing	O
and	O
treating	O
adhesion	O
.	O

Agent	O
for	O
diagnosing	O
,	O
preventing	O
and	O
treating	O
adhesion	O
with	O
the	O
use	O
of	O
ccr8	O
inhibitor	O

Selected	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
effective	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
,	O
such	O
as	O
HGF	O
mediated	O
diseases	O
such	O
as	O
cancer	O
and	O
the	O
like	O
.	O

The	O
subject	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
making	O
such	O
compounds	O
as	O
well	O
as	O
to	O
intermediates	O
useful	O
in	O
such	O
processes	O
.	O

R	O
-	O
X	O
-	O
W	O
-	O
A	O
-	O
Y	O
-	O
R	O
Formula	O
(	O
I	O
)	O
wherein	O
R	O
is	O
X	O
is	O
O	B
,	O
S	B
,	O
NR2	B
or	O
CR3R4	B
W	O
is	O
an	O
substituted	O
or	O
unsubstituted	O
aryl	B
or	O
substituted	O
or	O
unsubstituted	O
5-	O
or	O
6-	O
membered	O
heteroaryl	B
.	O

Quinolines	B
and	O
quinazoline	B
analogs	O
and	O
their	O
use	O
as	O
medicaments	O
for	O
treating	O
cancer	O

The	O
invention	O
relates	O
to	O
novel	O
analogues	O
of	O
the	O
hormonally	O
active	O
metabolite	O
of	O
vitamin	B
D3	I
,	O
and	O
more	O
specifically	O
provides	O
7-	B
(	I
2-cyclohexylidene	I
-	I
ethylidene	I
)	I
-spiro	I
[	I
5.5	I
]	I
undecanes	I
and	O
methods	O
for	O
making	O
them	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
which	O
comprise	O
said	O
7-	B
(	I
2-cyclohexylidene	I
-	I
ethylidene	I
)	I
-spiro	I
[	I
5.5	I
]	I
undecanes	I
,	O
and	O
methods	O
for	O
treating	O
and	O
preventing	O
diseases	O
,	O
illnesses	O
and	O
disorders	O
in	O
humans	O
,	O
in	O
particular	O
conditions	O
related	O
to	O
cell	O
proliferation	O
and	O
bone	O
disorders	O
such	O
a	O
osteoporosis	O
,	O
by	O
the	O
administration	O
of	O
effective	O
amounts	O
of	O
said	O
compounds	O
.	O

7-	B
(	I
2-cyclohexylidene	I
-	I
ethylidene	I
)	I
-spiro	I
[	I
5.5	I
]	I
undecanes	I
useful	O
for	O
making	O
pharmaceutical	O
compositions	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
non	O
-	O
ionic	O
surfactant	O
,	O
preferably	O
a	O
polyoxyethylene	B
fatty	I
acid	I
glyceride	I
,	O
and	O
a	O
steroid	B
,	O
particularly	O
ethinylestradiol	B
and/or	O
desogestrel	B
.	O

The	O
inventive	O
composition	O
is	O
characterized	O
by	O
an	O
increased	O
shelf	O
life	O
of	O
the	O
steroid	B
that	O
is	O
contained	O
therein	O
.	O

Stable	O
,	O
hormone	O
-	O
containing	O
(	O
intermediate	O
)	O
product	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
GABAA	B
receptor	O
agonist	O
,	O
such	O
as	O
an	O
agonist	O
or	O
partial	O
agonist	O
of	O
the	O
2	O
GABAA	B
receptors	O
and/or	O
3	O
GABAA	B
receptors	O
,	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
neuropathic	O
,	O
inflammatory	O
and	O
migraine	O
associated	O
pain	O
,	O
and	O
to	O
a	O
method	O
of	O
prevention	O
and	O
treatment	O
of	O
neuropathic	O
,	O
inflammatory	O
and	O
migraine	O
associated	O
pain	O
using	O
a	O
GABAA	B
receptor	O
agonist	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
such	O
a	O
use	O
,	O
wherein	O
the	O
GABAA	B
receptor	O
agonist	O
is	O
an	O
anxiolytic	O
compound	O
acting	O
at	O
the	O
GABAA	B
receptor	O
benzodiazepine	B
binding	O
sites	O
,	O
and	O
preferably	O
having	O
less	O
binding	O
affinity	O
to	O
1	O
or	O
less	O
efficacy	O
of	O
receptor	O
activation	O
at	O
1	O
GABAA	B
receptors	O
compared	O
to	O
2	O
and/or	O
3	O
GABAA	B
receptors	O
.	O

Particular	O
compounds	O
considered	O
are	O
1,2,4-triazolo	B
[	I
4,3-b	I
]	I
pyridazines	I
,	O
e.g.	O
L-838,417	O
,	O
TPA	O
023	O
or	O
CL-218,872	O
,	O
1H-	B
pyrido	I
[	I
3,4-b	I
]	I
indole	I
derivatives	O
,	O
e.g.	O
SL	O
651498	O
,	O
and	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidines	I
,	O
e.g.	O
ocinaplon	B
.	O

Gaba	B
-	O
a	O
alpha	O
2	O
and	O
alpha	O
3	O
receptor	O
agonists	O
for	O
treating	O
neuropathic	O
,	O
inflammatory	O
and	O
migraine	O
associated	O
pain	O

An	O
anthranilic	B
acid	I
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
X	O
)	O
[	O
wherein	O
R1	O
represents	O
hydrogen	B
or	O
a	O
carboxy	B
-	O
protecting	O
group	O
;	O
R2	O
represents	O
optionally	O
substituted	O
phenyl	B
,	O
a	O
heterocyclic	B
group	O
,	O
etc	O
.	O
;	O
R3	O
represents	O
optionally	O
substituted	O
phenyl	B
,	O
a	O
monocyclic	B
heterocyclic	I
group	O
,	O
etc	O
.	O
;	O
X1	O
represents	O
carbonyl	B
,	O
etc	O
.	O
;	O
X2	O
represents	O
optionally	O
substituted	O
alkylene	B
,	O
a	O
bond	O
,	O
etc	O
.	O
;	O
X3	O
represents	O
oxygen	B
,	O
a	O
bond	O
,	O
etc	O
.	O
;	O
and	O
X4	O
represents	O
a	O
group	O
represented	O
by	O
the	O
general	O
formula	O
-X5-X6-	O
or	O
-X6-X5-	O
(	O
wherein	O
X5	O
means	O
oxygen	B
,	O
a	O
bond	O
,	O
etc	O
.	O
;	O
and	O
X6	O
means	O
optionally	O
substituted	O
alkylene	B
,	O
a	O
bond	O
,	O
etc	O
.	O
)	O
]	O
or	O
a	O
salt	O
of	O
the	O
derivative	O
.	O

The	O
derivative	O
or	O
salt	O
has	O
an	O
MMP-13	O
production	O
inhibitory	O
activity	O
and	O
is	O
hence	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
articular	O
rheumatisum	O
,	O
osteoarthritis	O
,	O
cancer	O
,	O
etc	O
.	O

Novel	O
anthranilic	B
acid	I
derivative	O
or	O
salt	O
thereof	O

The	O
present	O
invention	O
pertains	O
to	O
certain	O
pyrazines	B
and	O
pyridines	B
,	O
and	O
dervatives	O
thereof	O
,	O
which	O
,	O
inter	O
alia	O
,	O
inhibit	O
RAF	O
(	O
e.g.	O
,	O
B	O
RAF	O
)	O
activity	O
,	O
inhibit	O
cell	O
proliferation	O
,	O
treat	O
cancer	O
,	O
etc	O
.	O
,	O
and	O
more	O
particularly	O
to	O
compounds	O
of	O
the	O
formulae	O
:	O

(	O
I	O
)	O
wherein	O
:	O
Q	O
is	O
independently	O
-N=	B
or	O
-CH=	B
;	O
one	O
of	O
RP2	O
and	O
RP3	O
is	O
independently	O
a	O
group	O
of	O
the	O
formula	O
-J1-L1-Z	O
;	O
wherein	O
:	O
if	O
Q	O
is	O
-N=	B
,	O
then	O
-J1-L1-Z	O
is	O
independently	O
:	O
-NH	B
-	I
Z	I
;	O
-O	B
-	I
Z	I
;	O
or	O
S	O
-	O
Z	O
;	O
if	O
Q	O
is	O
-CH=	B
,	O
then	O
-J1-L1-Z	O
is	O
independently	O
:	O
-NH-	B
(	I
CH2	I
)	I
n	I
-	I
Z	I
,	O
wherein	O
n	O
is	O
independently	O
0	O
or	O
1	O
;	O
-O	B
-	I
Z	I
;	O
or	O
-S	B
-	I
Z	I
;	O
Z	O
is	O
independently	O
:	O
C6	B
-	I
14	I
carboaryl	I
,	O
C5	B
-	I
14	I
heteroaryl	I
,	O
C3	B
-	I
12carbocyclic	I
,	O
C3	B
-	I
12	I
heterocyclic	I
;	O
and	O
is	O
independently	O
unsubstituted	O
or	O
substituted	O
;	O
the	O
other	O
of	O
RP2	O
and	O
RP3	O
is	O
independently	O
-H	B
,	O
-NHRN1	B
,	O
or	O
-NHC	B
(	I
=O	I
)	I
RN2	I
;	O
wherein	O
:	O
RN1	B
,	O
if	O
present	O
,	O
is	O
independently	O
-H	B
or	O
aliphatic	O
saturated	O
C1	B
-	I
4alkyl	I
;	O
RN2	B
,	O
if	O
present	O
,	O
is	O
independently	O
-H	B
or	O
aliphatic	B
saturated	O
C1	B
-	I
4alkyl	I
;	O
one	O
of	O
RP5	O
and	O
RP6	O
is	O
independently	O
a	O
group	O
of	O
the	O
formula	O
-W	O
-	O
Y	O
;	O
wherein	O
:	O
W	O
is	O
independently	O
:	O
a	O
covalent	O
bond	O
;	O
-NRN4-	B
,	O
-O-	B
,	O
-S-	B
,	O
-C	B
(	I
=O	I
)	I
-	I
,	O
-CH2-	B
;	O
-NRN4-CH2-	B
,	O
-O	B
-	I
CH2-	I
,	O
-S	B
-	I
CH2-	I
,	O
-C	B
(	I
=O	I
)	I
-CH2-	I
,	O
-	B
(	I
CH2	I
)	I
2-	I
;	O
-CH2-NRN4-	B
,	O
-CH2-O-	B
,	O
-CH2-S-	B
,	O
or	O
-CH2-C	B
(	I
=O	I
)	I
-	I
;	O
wherein	O
RN4	B
,	O
if	O
present	O
,	O
is	O
independently	O
-H	B
or	O
aliphatic	B
saturated	O
C1	B
-	I
4alkyl	I
;	O
Y	O
is	O
independently	O
:	O
C6	B
-	I
14carboaryl	I
,	O
C5	B
-	I
14heteroaryl	I
,	O
C3	B
-	I
12carbocyclic	I
,	O
C3	B
-	I
12heterocyclic	I
;	O
and	O
is	O
independently	O
unsubstituted	O
or	O
substituted	O
;	O
the	O
other	O
of	O
RP5	O
and	O
RP6	O
is	O
independently	O
-H	B
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
amides	B
,	O
esters	B
,	O
ethers	B
,	O
N	B
-	I
oxides	I
,	O
chemically	O
protected	O
forms	O
,	O
and	O
prodrugs	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
e.g.	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
to	O
inhibit	O
RAF	O
(	O
e.g.	O
,	O
B	O
-	O
RAF	O
)	O
activity	O
,	O
to	O
inhibit	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
activity	O
,	O
to	O
inhibit	O
cell	O
proliferation	O
,	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
conditions	O
that	O
are	O
ameliorated	O
by	O
the	O
inhibition	O
of	O
RAF	O
,	O
RTK	O
,	O
etc	O
.	O
,	O
proliferative	O
conditions	O
such	O
as	O
cancer	O
(	O
e.g.	O
,	O
colorectal	O
cancer	O
,	O
melanoma	O
)	O
,	O
etc	O
.	O

Pyrazines	B
and	O
pyridines	B
and	O
derivatives	O
thereof	O
as	O
therapeutic	O
compounds	O

A	O
microorganism	O
(	O
Streptomyces	O
sp.	O
K03	O
-	O
0132	O
,	O
FERM	O
ABP-10148	O
)	O
,	O
which	O
belongs	O
to	O
Streptomyces	O
sp.	O
and	O
is	O
capable	O
of	O
producing	O
active	O
substances	O
K03	O
-	O
0132A	O
and/or	O
K03	O
-	O
0132B	O
,	O
is	O
cultured	O
in	O
a	O
medium	O
to	O
thereby	O
accumulate	O
the	O
active	O
substances	O
K03	O
-	O
0132A	O
and/or	O
K03	O
-	O
0132B	O
in	O
the	O
culture	O
medium	O
.	O

Then	O
the	O
active	O
substances	O
K03	O
-	O
0132A	O
and/or	O
K03	O
-	O
0132B	O
are	O
collected	O
from	O
the	O
culture	O
medium	O
.	O

Because	O
of	O
having	O
an	O
effect	O
of	O
elevating	O
the	O
activity	O
of	O
azole	B
-	O
type	O
fungicides	O
,	O
the	O
obtained	O
active	O
substances	O
act	O
on	O
a	O
large	O
number	O
of	O
fungal	O
infections	O
such	O
as	O
deep	O
-	O
seated	O
mycosis	O
in	O
a	O
low	O
dose	O
within	O
a	O
short	O
period	O
of	O
time	O
and	O
are	O
useful	O
in	O
lowering	O
the	O
frequency	O
of	O
the	O
appearance	O
of	O
resistant	O
strains	O
.	O

It	O
is	O
also	O
expected	O
that	O
these	O
substances	O
are	O
useful	O
in	O
overcoming	O
resistance	O
.	O

Active	O
substances	O
k03	O
-	O
0132	O
and	O
method	O
of	O
producing	O
the	O
same	O

Solid	O
dispersion	O
of	O
glibenclamide	B
,	O
as	O
well	O
as	O
its	O
oral	O
composition	O
and	O
preparative	O
methods	O
of	O
the	O
solid	O
dispersion	O
.	O

It	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
.	O

The	O
solid	O
dispersion	O
containing	O
glibenclamide	B
2	O
-	O
60	O
%	O
and	O
disperse	O
medium	O
98	O
-	O
40	O
%	O
by	O
the	O
ratio	O
of	O
weight	O
.	O

The	O
glibenclamide	B
disperse	O
in	O
the	O
disperse	O
medium	O
by	O
the	O
form	O
of	O
unformed	O
,	O
molecule	O
or	O
microcrystal	O
.	O

The	O
solid	O
dispersion	O
can	O
be	O
prepared	O
by	O
the	O
methods	O
of	O
triturate	O
,	O
fusion	O
or	O
spray	O
drying	O
.	O

According	O
to	O
the	O
preparative	O
methods	O
of	O
said	O
,	O
the	O
solid	O
dispersion	O
of	O
glibenclamide	B
is	O
harmless	O
and	O
pollution	O
-	O
free	O
.	O

And	O
the	O
operation	O
of	O
methods	O
is	O
conveniently	O
.	O

The	O
solid	O
dispersion	O
can	O
improve	O
the	O
solubility	O
materially	O
,	O
improve	O
the	O
bioavailability	O
and	O
the	O
stability	O
of	O
thermodynamics	O
of	O
preparation	O
of	O
glibenclamide	B
.	O

Solid	O
dispersion	O
of	O
glibenclamide	B
,	O
its	O
oral	O
composition	O
and	O
methods	O

The	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
salt	O
,	O
tautomer	O
,	O
N	B
-	I
oxide	I
or	O
solvate	O
thereof	O
;	O
wherein	O
A	O
is	O
selected	O
from	O
a	O
bond	O
,	O
CH2	B
and	O
CH	B
(	I
CN	I
)	I
;	O
Rl	O
is	O
selected	O
from	O
:	O
(	O
i	O
)	O
a	O
cycloalkyl	B
group	O
of	O
3	O
to	O
6	O
ring	O
members	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
selected	O
from	O
methyl	B
,	O
ethyl	B
,	O
hydroxy	B
,	O
methoxy	B
,	O
ethoxy	B
,	O
fluorine	B
,	O
amino	B
and	O
cyano	B
;	O
(	O
ii	O
)	O
a	O
phenyl	B
group	O
optionally	O
substituted	O
by	O
up	O
to	O
three	O
substituents	O
selected	O
from	O
methyl	B
,	O
ethyl	B
,	O
fluorine	B
,	O
chlorine	B
,	O
methoxy	B
,	O
ethoxy	B
and	O
methylsulphonyl	B
,	O
but	O
excluding	O
2,6-difluorophenyl	B
,	O
2-fluoro-6-methoxy	B
and	O
5-chloro-2-methoxyphenyl	B
;	O
(	O
iii	O
)	O
a	O
monocyclic	B
heterocyclic	I
group	O
selected	O
from	O
furyl	B
and	O
isoxazolyl	B
,	O
the	O
heterocyclic	B
group	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
groups	O
selected	O
from	O
methyl	B
,	O
ethyl	B
,	O
and	O
a	O
group	O
CH2R2	B
where	O
R2	O
is	O
a	O
five	O
or	O
six	O
membered	O
saturated	O
heterocyclic	B
ring	O
containing	O
one	O
or	O
two	O
heteroatom	O
ring	O
members	O
selected	O
from	O
O	B
and	O
N	B
,	O
the	O
heterocyclic	B
ring	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
methyl	B
groups	O
;	O
and	O
(	O
iv	O
)	O
a	O
bicyclic	B
heterocyclic	I
group	O
selected	O
from	O
2,3-dihydrobenzofuranyl	B
and	O
benzo	B
[	I
c	I
]	I
isoxazolyl	I
,	O
the	O
bicyclic	B
group	O
being	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
substituents	O
selected	O
from	O
methyl	B
,	O
ethyl	B
,	O
hydroxy	B
,	O
methoxy	B
,	O
ethoxy	B
,	O
fluorine	B
,	O
amino	B
,	O
cyano	B
and	O
chlorine	B
,	O
the	O
bicyclic	B
heterocyclic	I
group	O
being	O
other	O
than	O
a	O
2,2-dimethyl-2,3-dihydrobenzofuran-7-yl	B
group	O
.	O

Pyrazole	B
derivatives	O
having	O
kinase	O
modulating	O
activity	O

The	O
invention	O
relates	O
to	O
novel	O
macrocyclic	O
compounds	O
of	O
the	O
formula	O
in	O
which	O
R1	O
,	O
R3	O
,	O
V1	O
,	O
V2	O
,	O
X1	O
,	O
X2	O
,	O
Y	O
,	O
Z	O
,	O
Ar	B
,	O
AA	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
the	O
number	O
of	O
ring	O
atoms	O
included	O
in	O
the	O
macrocyclic	O
ring	O
being	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
or	O
18	O
,	O
in	O
free	O
base	O
form	O
or	O
in	O
acid	O
addition	O
salt	O
form	O
,	O
to	O
their	O
preparation	O
,	O
to	O
their	O
use	O
as	O
medicaments	O
and	O
to	O
medicaments	O
comprising	O
them	O
.	O

Macrocyclic	O
compounds	O
and	O
compositions	O
useful	O
as	O
bace	O
inhibitors	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
substituted	O
cyclopentanes	B
or	O
cyclopentanones	B
as	O
ocular	O
hypotensives	O
.	O

New	O
Compounds	O
are	O
also	O
provided	O
.	O

Substituted	O
cyclopentanes	B
or	O
cyclopentanones	B
for	O
the	O
treatment	O
of	O
ocular	O
hypertensive	O
conditions	O

The	O
present	O
invention	O
provides	O
a	O
Traditional	O
Chinese	O
Medicament	O
for	O
treating	O
injuries	O
from	O
falls	O
,	O
rheumatism	O
and	O
ostealgia	O
and	O
method	O
for	O
manufacture	O
thereof	O
.	O

The	O
present	O
medicament	O
is	O
manufactured	O
from	O
21	O
TCM	O
materials	O
,	O
such	O
as	O
Radices	O
saussureae	O
,	O
Radices	O
sileris	O
,	O
Herba	O
schizeneptae	O
,	O
Herba	O
asari	O
,	O
Cortex	O
acanthopanacis	O
,	O
Ramulus	O
,	O
Radix	O
achyranthis	O
,	O
Rhizoma	O
ligustici	O
,	O
etc	O
.	O

Zoological	O
studies	O
and	O
clinical	O
trials	O
indicate	O
that	O
the	O
present	O
medicament	O
is	O
capable	O
of	O
being	O
effective	O
in	O
relieving	O
arthralgia	O
caused	O
by	O
rheumatism	O
,	O
periomitis	O
,	O
injuries	O
from	O
falls	O
,	O
such	O
as	O
acute	O
sprain	O
and	O
contusion	O
,	O
anonymous	O
intumescence	O
,	O
parotitis	O
.	O

Traditional	O
chinese	O
medicament	O
for	O
treating	O
injuries	O
from	O
falls	O
,	O
rheumatism	O
and	O
ostealgia	O
and	O
method	O
for	O
manufacture	O
thereof	O

The	O
invention	O
concerns	O
benzamide	B
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1a	O
,	O
R1b	O
,	O
R1c	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
integer	O
m	O
,	O
integer	O
n	O
and	O
W	O
have	O
any	O
of	O
the	O
meanings	O
defined	O
in	O
the	O
description	O
;	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
as	O
an	O
antiproliferative	O
agent	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
tumours	O
or	O
other	O
proliferative	O
conditions	O
which	O
are	O
sensitive	O
to	O
the	O
inhibition	O
of	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
.	O

Novel	O
benzamide	B
derivatives	O

Compounds	O
and	O
compositions	O
are	O
provided	O
for	O
modulating	O
the	O
activity	O
of	O
protein	O
tyrosine	B
phosphatases	O
.	O

The	O
compounds	O
for	O
use	O
in	O
the	O
compositions	O
and	O
methods	O
provided	O
herein	O
have	O
formulae	O
(	O
I	O
)	O
Protein	O
tyrosine	B
hosaphatase	O
,	O
including	O
PTB-1B	O
,	O
mediated	O
diseases	O
and	O
disorders	O
include	O
diabetes	O
including	O
Type	O
1	O
and	O
Type	O
2	O
diabetes	O
(	O
and	O
associated	O
complications	O
such	O
as	O
hypertension	O
,	O
ischemic	O
diseases	O
of	O
the	O
large	O
and	O
small	O
blood	O
vessels	O
,	O
blindness	O
,	O
circulatory	O
problems	O
,	O
kidney	O
failure	O
and	O
atherosclerosis	O
)	O
,	O
syndrome	O
X	O
,	O
methabolic	O
syndrome	O
,	O
glucose	O
intolerance	O
,	O
insulin	O
resistance	O
,	O
obesity	O
,	O
cancer	O
,	O
neurodegenerative	O
diseases	O
.	O

2-imidazolone	B
and	O
2-imidazolidinone	B
heterocyclic	B
inhibitors	O
of	O
tyrosine	B
phosphatases	O

The	O
present	O
invention	O
relates	O
to	O
2-phenylquinoxaline	B
derivatives	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
at	O
least	O
one	O
of	O
these	O
2-phenylquinoxaline	B
derivatives	O
together	O
with	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
excipient	O
and/or	O
diluents	O
.	O

Said	O
2-phenylquinoxaline	B
derivatives	O
have	O
been	O
identified	O
as	O
specific	O
inhibitors	O
of	O
the	O
mitotic	O
kinesin	O
MPP1	O
,	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
cancers	O
and	O
proliferative	O
diseases	O
including	O
tumor	O
growth	O
and	O
metastases	O
.	O

2-phenylquinoxalines	B
as	O
inhibitors	O
for	O
mpp1	O

Compounds	O
of	O
a	O
certain	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
,	O
are	O
novel	O
effective	O
compounds	O
with	O
anti	O
-	O
proliferative	O
and/or	O
apoptosis	O
inducing	O
activity	O
.	O

Novel	O
indolopyridines	B
,	O
benzofuranopyridines	B
and	O
benzothienopyridines	B

A	O
method	O
of	O
inhibiting	O
or	O
effecting	O
the	O
activity	O
of	O
an	O
integral	O
receptor	O
which	O
comprises	O
contacting	O
an	O
integrin	O
with	O
a	O
compound	O
of	O
formula	O
I	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
General	O
Formula	O

I	O
Wherein	O
the	O
ring	O
may	O
be	O
of	O
any	O
configuration	O
;	O
Z	O
is	O
sulphur	B
,	O
oxygen	B
,	O
CH2	B
,	O
NH	B
,	O
NRA	O
or	O
hydrogen	B
,	O
in	O
the	O
case	O
where	O
Z	O
is	O
hydrogen	B
then	O
R1	O
is	O
not	O
present	O
,	O
RA	O
is	O
selected	O
from	O
the	O
set	O
defined	O
for	O
R1	O
to	O
R5	O
,	O
X	O
is	O
oxygen	B
or	O
NRA	O
providing	O
that	O
at	O
least	O
one	O
X	O
of	O
General	O
Formula	O

I	O
is	O
NRA	O
,	O
X	O
may	O
also	O
combine	O
independently	O
with	O
one	O
of	O
R1	O
to	O
R5	O
to	O
form	O
an	O
azide	B
,	O
R1	O
to	O
R5	O
are	O
independently	O
selected	O
from	O
the	O
group	O
comprising	O
H	B
,	O
-	B
(	I
CO	I
)	I
R6	I
or	O
an	O
alkyl	B
,	O
acyl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
heteroalkyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
arylalkyl	B
or	O
heteroarylalkyl	B
substituent	O
of	O
1	O
to	O
20	O
atoms	O
,	O
which	O
is	O
optionally	O
substituted	O
,	O
and	O
can	O
be	O
branched	O
or	O
linear	O
wherein	O
substituents	O
may	O
optionally	O
be	O
further	O
substituted	O
,	O
wherein	O
R6	O
is	O
selected	O
from	O
the	O
group	O
comprising	O
an	O
alkyl	B
,	O
acyl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
heteroalkyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
arylalkyl	B
or	O
heteroarylalkyl	B
substituent	O
of	O
1	O
to	O
20	O
atoms	O
,	O
which	O
is	O
optionally	O
substituted	O
,	O
and	O
can	O
be	O
branched	O
or	O
linear	O
wherein	O
substituents	O
may	O
optionally	O
be	O
further	O
substituted	O
,	O
with	O
the	O
proviso	O
that	O
XR2	O
or	O
XR3	O
or	O
XR4	O
or	O
XR5	O
is	O
not	O
NH2	B
,	O
with	O
the	O
further	O
proviso	O
that	O
not	O
more	O
than	O
one	O
of	O
R2	O
to	O
R5	O
is	O
hydrogen	B
,	O
where	O
the	O
group	O
X	O
is	O
NRA	O
and	O
RA	O
is	O
not	O
hydrogen	B
,	O
the	O
groups	O
RA	O
and	O
the	O
corresponding	O
group	O
R2	O
to	O
R5	O
may	O
combine	O
to	O
form	O
a	O
cycle	O
.	O

Classes	O
of	O
compounds	O
that	O
interact	O
with	O
integrins	O

Use	O
of	O
Idazoxan	B
or	O
an	O
active	O
enantiomer	O
thereof	O
,	O
and	O
treatment	O
of	O
patients	O
receiving	O
therapy	O
with	O
selective	O
serotonin	B
uptake	O
inhibitor	O
(	O
s	O
)	O
,	O
such	O
as	O
Fluoxetine	B
,	O
Citalopram	B
,	O
Paroxetine	B
,	O
Sertraline	B
and	O
Fluvoxamine	B
,	O
are	O
described	O
.	O

The	O
patients	O
being	O
treated	O
are	O
in	O
particular	O
those	O
who	O
are	O
suffering	O
from	O
severe	O
depression	O
,	O
anxiety	O
-	O
depression	O
,	O
PTSD	O
(	O
Post	O
Traumatic	O
Stress	O
Disorder	O
)	O
,	O
or	O
ADHD	O
(	O
Attention	O
Deficit	O
Hyperactive	O
Disorder	O
)	O
.	O

Antidepressant	O
medicament	O
comprising	O
idazoxan	B
and	O
a	O
selective	O
serotonin	B
reuptake	O
inhibitor	O

A	O
substance	O
for	O
use	O
as	O
a	O
medicament	O
,	O
comprises	O
a	O
solid	O
mixed	O
metal	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O

Mll	O
1-a	O
Mlll	O
aObAn-	O
c.zH2O	O
(	O
I	O
)	O
where	O
Mll	O
is	O
at	O
least	O
one	O
bivalent	O
metal	O
:	O

Mlll	O
bis	O
at	O
least	O
one	O
trivalent	O
metal	O
;	O
An-	O
is	O
at	O
least	O
one	O
n	O
-	O
valent	O
anion	O
;	O
2+a	O
=	O
2b+Σcn	O
;	O
and	O
Σcn	O
<	O
0.9a	O
.	O

The	O
substance	O
may	O
be	O
made	O
by	O
heating	O
at	O
a	O
temperature	O
of	O
from	O
200	O
°	O
C	O
to	O
600	O
°	O
C	O
,	O
preferably	O
from	O
250	O
°	O
C	O
to	O
500	O
°	O
C	O
of	O
a	O
substance	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
II	O
)	O
:	O
Mll1-xMlll	O
x	O
(	O
OH	O
)	O
2An-	O
y.mH2O	O
(	O
II	O
)	O
where	O
Mll	O
is	O
at	O
least	O
one	O
bivalent	O
metal	O
;	O
Mlll	O
is	O
at	O
least	O
one	O
trivalent	O
metal	O
;	O
An-	O
is	O
at	O
least	O
one	O
n	O
-	O
valent	O
anion	O
;	O
x	O
=	O
Σyn	O
0	O
<	O
x	O
≤	O
0.5	O
,	O
0	O
<	O
y≤	O
1	O
and	O
0	O
<	O
m	O
≤	O
10	O
.	O

Pharmaceutically	O
active	O
phosphate	B
binders	O
,	O
their	O
manufacture	O
,	O
compositions	O
containing	O
them	O
and	O
their	O
use	O

Therapeutically	O
active	O
heteroaryl	B
carboxylic	I
acid	I
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
W	O
,	O
X	O
,	O
Y	O
and	O
Z	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
processes	O
for	O
the	O
preparation	O
of	O
said	O
derivatives	O
,	O
pharmaceutical	O
formulations	O
containing	O
the	O
active	O
compounds	O
and	O
the	O
use	O
of	O
the	O
compounds	O
in	O
therapy	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
under	O
-	O
activation	O
of	O
the	O
HM74A	O
receptor	O
contributes	O
to	O
the	O
disease	O
or	O
in	O
which	O
activation	O
of	O
the	O
receptor	O
will	O
be	O
beneficial	O
,	O
are	O
disclosed	O
.	O

2-substituted	B
5-membered	I
heteroaryl	I
carboxylates	I
as	O
hm74a	O
receptor	O
agonists	O

A	O
flowable	O
composition	O
suitable	O
for	O
forming	O
in	O
situ	O
a	O
controlled	O
release	O
implant	O
system	O
for	O
the	O
treatment	O
of	O
nail	O
diseases	O
,	O
the	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
biocompatible	O
thermoplastic	O
polymer	O
that	O
is	O
at	O
least	O
substantially	O
insoluble	O
in	O
aqueous	O
medium	O
or	O
body	O
fluid	O
;	O
a	O
pharmaceutically	O
acceptable	O
biocompatible	O
solvent	O
that	O
is	O
water	O
soluble	O
;	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
active	O
ingredient	O
,	O
wherein	O
the	O
thermoplastic	O
polymer	O
and	O
biocompatible	O
solvent	O
are	O
present	O
in	O
concentrations	O
effective	O
to	O
form	O
the	O
implant	O
in	O
situ	O
periungually	O
or	O
subungually	O
.	O

Methods	O
,	O
implants	O
,	O
uses	O
,	O
kits	O
and	O
systems	O
are	O
likewise	O
provided	O
.	O

Compositions	O
for	O
treatment	O
of	O
diseases	O
of	O
the	O
nail	O
unit	O

The	O
invention	O
provides	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
substituents	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
processes	O
and	O
intermediates	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
in	O
the	O
treatment	O
of	O
disorders	O
mediated	O
by	O
mGluR5	O
.	O

Pyrrolidine	B
and	O
piperidine	B
acetylene	I
derivatives	O
for	O
use	O
as	O
mglur5	O
antagonists	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
a	O
metastatic	O
prostate	O
cancer	O
patient	O
by	O
administering	O
to	O
said	O
patient	O
an	O
effective	O
amount	O
of	O
a	O
bicalutamide	B
(	O
4'-cyano	B
-	I
α',α',α'-trifluoro-3-	I
(	I
4-fluorophenylsulphonyl	I
)	I
-2-hydroxy-2-methylpropiono	I
-	I
m	I
-	I
toluidide	I
)	O
containing	O
formulation	O
capable	O
of	O
delivering	O
at	O
least	O
a	O
mean	O
steady	O
state	O
plasma	O
level	O
of	O
(	B
R	I
)	I
-bicalutamide	I
enantiomer	O
of	O
40	O
µg	O
/	O
ml	O
;	O
and	O
to	O
bicalutamide	B
containing	O
products	O
and	O
formulations	O
capable	O
of	O
delivering	O
the	O
at	O
least	O
mean	O
steady	O
state	O
plasma	O
level	O
of	O
(	B
R	I
)	I
-bicalutamide	I
enantiomer	O
of	O
40	O
µg	O
/	O
ml	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

Bicalutamide	B
for	O
delivering	O
increasing	O
steady	O
state	O
plasma	O
levels	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
diosmetin	B
in	O
order	O
to	O
obtain	O
pharmaceutical	O
compositions	O
that	O
are	O
intended	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
thrombotic	O
pathologies	O
as	O
well	O
as	O
pathologies	O
with	O
thrombotic	O
risk	O
.	O

Diosmetin	B
derivatives	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
thrombotic	O
pathologies	O

The	O
instant	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
a	O
PDE7	O
inhibitor	O
and	O
an	O
alpha-2-delta	O
ligand	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
pain	O
,	O
particularly	O
inflammatory	O
,	O
neuropathic	O
,	O
visceral	O
and	O
nociceptive	O
pain	O
.	O

Use	O
of	O
combinations	O
of	O
pde7	O
inhibitors	O
and	O
alpha-2-delty	O
ligands	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O

Crystalline	O
polymorphous	O
forms	O
of	O
the	O
rifaximin	B
(	O
INN	O
)	O
antibiotic	O
named	O
rifaximin	B
δ	O
and	O
rifaximin	B
ϵ	O
useful	O
in	O
the	O
production	O
of	O
medicinal	O
preparations	O
containing	O
rifaximin	O
for	B
oral	I
and	O
topical	O
use	O
and	O
obtained	O
by	O
means	O
of	O
a	O
crystallization	O
process	O
carried	O
out	O
by	O
hot	O
-	O
dissolving	O
the	O
raw	O
rifaximin	O
in	B
ethyl	I
alcohol	B
and	I
by	I
causing	O
the	O
crystallization	O
of	O
the	O
product	O
by	O
addition	O
of	O
water	O
at	O
a	O
determinate	O
temperature	O
and	O
for	O
a	O
determinate	O
period	O
of	O
time	O
,	O
followed	O
by	O
a	O
drying	O
carried	O
out	O
under	O
controlled	O
conditions	O
until	O
reaching	O
a	O
settled	O
water	O
content	O
in	O
the	O
end	O
product	O
,	O
are	O
the	O
object	O
of	O
the	O
invention	O
.	O

New	O
polymorphous	O
forms	O
of	O
rifaximin	O
,	B
processes	I
for	O
their	O
production	O
and	O
use	O
thereof	O
in	O
the	O
medicinal	O

Provided	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
modulating	O
the	O
activity	O
of	O
sirtuin	O
deacetylase	O
protein	O
family	O
members	O
;	O
p53	O
activity	O
;	O
apoptosis	O
;	O
lifespan	O
and	O
sensitivity	O
to	O
stress	O
of	O
cells	O
and	O
organisms	O
.	O

Exemplary	O
methods	O
comprise	O
contacting	O
a	O
cell	O
with	O
an	O
activating	O
compound	O
,	O
such	O
as	O
a	O
flavone	B
,	O
stilbene	B
,	O
flavanone	B
,	O
isoflavone	B
,	O
catechin	B
,	O
chalcone	B
,	O
tannin	B
or	O
anthocyanidin	B
;	O
or	O
an	O
inhibitory	O
compound	O
,	O
such	O
as	O
a	O
sphingolipid	O
,	O
e.g.	O
,	O
sphingosine	B
.	O

Also	O
disclosed	O
herein	O
are	O
methods	O
for	O
treating	O
,	O
preventing	O
or	O
diagnosing	O
a	O
disease	O
associated	O
with	O
neuronal	O
cell	O
death	O
,	O
e.g.	O
,	O
a	O
neurodegenerative	O
disease	O
.	O

Sirtuin	O
related	O
therapeutics	O
and	O
diagnostics	O
for	O
neurodegenerative	O
diseases	O

Methods	O
of	O
treating	O
an	O
SCD	O
-	O
mediated	O
disease	O
or	O
condition	O
in	O
a	O
mammal	O
,	O
preferebly	O
a	O
human	O
,	O
are	O
disclosed	O
,	O
wherein	O
the	O
methods	O
comprise	O
administering	O
to	O
a	O
mammal	O
in	O
need	O
thereof	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
where	O
x	O
,	O
y	O
,	O
G	O
,	O
J	O
,	O
K	O
,	O
L	O
,	O
M	O
,	O
W	O
,	O
R2	O
,	O
R3	O
,	O
R5	O
,	O
R5a	O
,	O
R6	O
,	O
R6a	O
,	O
R7	O
,	O
R7a	O
,	O
R8	O
and	O
R8a	O
are	O
difined	O
herein	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
also	O
disclosed	O
.	O

Heterocyclic	B
derivatives	O
and	O
their	O
use	O
as	O
stearoyl	O
-	O
coa	O
desaturase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
which	O
:	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
while	O
being	O
identical	O
or	O
different	O
,	O
each	O
represent	O
an	O
atom	O
or	O
group	O
selected	O
among	O
H	B
,	O
halogen	B
,	O
alkyl	B
,	O
alkoxy	B
,	O
phenyl	B
and	O
cyano	B
;	O
X	O
represents	O
a	O
bond	O
,	O
an	O
oxygen	B
atom	O
or	O
a	O
group	O
selected	O
among	O
-	B
(	I
CH2	I
)	I
m-	I
,	O
-OCH2-	B
and	O
-NR5-	B
;	O
m	O
represents	O
1	O
or	O
2	O
;	O
R5	O
is	O
as	O
defined	O
in	O
the	O
description	O
;	O
Y	O
represents	O
an	O
oxygen	B
atom	O
or	O
a	O
group	O
selected	O
among	O
NR7	B
and	O
CHR8	B
,	O
whereby	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
in	O
the	O
description	O
;	O
Z	O
represents	O
a	O
nitrogen	B
atom	O
or	O
a	O
CH	B
group	O
;	O
n	O
represents	O
1	O
or	O
2	O
;	O
Ak	B
represents	O
an	O
alkylene	B
chain	O
;	O
Ar	B
represents	O
an	O
aryl	B
or	O
heteroaryl	B
group	O
,	O
its	O
optical	O
isomers	O
as	O
well	O
as	O
its	O
addition	O
salts	O
to	O
a	O
pharmaceutically	O
acceptable	O
acid	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
serotonin	B
reuptake	O
inhibitors	O
or	O
as	O
neurokinin	O
antagonists	O
NK1	O
,	O
in	O
particular	O
,	O
for	O
treating	O
depressive	O
states	O
.	O

Piperazine	B
derivatives	O
and	O
use	O
thereof	O
as	O
serotonin	B
reuptake	O
inhibitors	O
or	O
as	O
neurokinin	O
antagonists	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
with	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
Formula	O
(	O
I	O
)	O
;	O
wherein	O
R1	O
is	O
an	O
optionally	O
fused	O
pyridine	B
ring	O
and	O
R2	O
and	O
R3	O
together	O
form	O
a	O
heterocyclic	B
ring	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
treating	O
a	O
condition	O
that	O
is	O
mediated	O
by	O
the	O
modulation	O
of	O
the	O
11-β	O
-	O
hsd-1	O
enzyme	O
.	O

Amino	B
sulfonyl	I
derivatives	O
as	O
inhibitors	O
of	O
human	O
11-.beta	B
.-	I
hydrosysteroid	I
dehydrogenase	O

Disclosed	O
is	O
a	O
compound	O
having	O
an	O
inhibitory	O
effect	O
on	O
both	O
EGF	O
receptor	O
tyrosine	B
kinase	O
and	O
HER2	O
tyrosine	B
kinase	O
.	O

Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
below	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
solvate	O
of	O
either	O
of	O
them	O
.	O

[	O
In	O
the	O
formula	O
(	O
I	O
)	O
,	O
R1	O
represents	O
a	O
C1	B
-	I
3	I
alkyl	I
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
group	O
represented	O
by	O
the	O
following	O
formula	O
:	O
(	O
wherein	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen	B
atom	O
,	O
an	O
optionally	O
substituted	O
alkyl	B
group	O
or	O
the	O
like	O
;	O
Ar1	O
represents	O
an	O
allylene	B
or	O
heteroallylene	B
;	O
R6	O
represents	O
an	O
optionally	O
substituted	O
alkyl	B
group	O
,	O
an	O
alkoxycarbonyl	B
group	O
or	O
the	O
like	O
;	O
R	O
's	O
independently	O
represent	O
an	O
optionally	O
substituted	O
alkyl	B
group	O
,	O
an	O
alkyloxy	B
group	O
or	O
the	O
like	O
;	O
and	O
n	O
represents	O
an	O
integer	O
of	O
0	O
-	O
2	O
)	O
;	O
Y	O
represents	O
-O-	B
,	O
-S-	B
,	O
-N	B
(	I
R20	I
)	I
-	I
or	O
the	O
like	O
;	O
R20	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
alkyl	B
group	O
,	O
an	O
acyl	B
group	O
or	O
the	O
like	O
;	O
and	O
R3	O
represents	O
an	O
optionally	O
substituted	O
phenyl	B
group	O
or	O
the	O
like	O
.	O
]	O

Pyrimidine	B
derivative	O
having	O
tyrosine	B
kinase	O
inhibitory	O
effect	O

Disclosed	O
is	O
an	O
excellent	O
LXR	O
modulator	O
.	O

A	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
:	O
H	B
,	O
an	O
alkyl	B
which	O
may	O
be	O
substituted	O
,	O
OH	B
,	O
an	O
alkoxy	B
which	O
may	O
be	O
substituted	O
,	O
an	O
amino	B
which	O
may	O
be	O
substituted	O
,	O
a	O
halogeno	B
,	O
a	O
phenyl	B
or	O
the	O
like	O
;	O
R5	O
:	O
H	B
or	O
an	O
alkyl	B
;	O
R6	O
:	O
-COR8	B
(	O
wherein	O
R8	O
:	O
an	O
alkoxy	B
which	O
may	O
be	O
substituted	O
,	O
a	O
phenyloxy	B
which	O
may	O
be	O
substituted	O
,	O
an	O
amino	B
which	O
may	O
be	O
substituted	O
,	O
or	O
the	O
like	O
)	O
,	O
-SO2R9	B
(	O
wherein	O
R9	O
:	O
an	O
alkyl	B
which	O
may	O
be	O
substituted	O
,	O
a	O
phenyl	B
which	O
may	O
be	O
substituted	O
or	O
a	O
heterocyclyl	B
which	O
may	O
be	O
substituted	O
)	O
,	O
or	O
an	O
alkyl	B
which	O
may	O
be	O
substituted	O
;	O
R7	O
:	O
-X2R10	O
[	O
wherein	O
R10	O
:	O
-COR11	B
(	O
where	O
R11	O
:	O
OH	B
,	O
an	O
alkoxy	B
which	O
may	O
be	O
substituted	O
or	O
an	O
amino	B
which	O
may	O
be	O
substituted	O
)	O
,	O
-SO2R12	B
(	O
where	O
R12	O
:	O
an	O
alkyl	B
which	O
may	O
be	O
substituted	O
or	O
amino	B
which	O
may	O
be	O
substituted	O
)	O
,	O
-N	B
(	I
R13	I
)	I
COR14	I
(	O
where	O
R13	O
:	O
H	B
or	O
an	O
alkyl	B
which	O
may	O
be	O
substituted	O
;	O
R14	O
:	O
H	B
or	O
an	O
alkyl	B
which	O
may	O
be	O
substituted	O
)	O
,	O
-N	B
(	I
R13	I
)	I
SO2R15	I
(	O
where	O
R13	O
:	O
as	O
defined	O
above	O
;	O
R15	O
:	O
an	O
alkyl	B
which	O
may	O
be	O
substituted	O
)	O
or	O
tetrazol-5-yl	B
;	O
and	O
X2	O
:	O
a	O
single	O
bond	O
or	O
an	O
alkylene	B
which	O
may	O
be	O
substituted	O
]	O
;	O
X1	O
:	O
a	O
methylene	B
which	O
may	O
be	O
substituted	O
;	O
Y1	O
:	O
a	O
phenyl	B
which	O
may	O
be	O
substituted	O
or	O
a	O
heterocyclyl	B
which	O
may	O
be	O
substituted	O
;	O
and	O
Y2	O
:	O
an	O
aryl	O
which	O
may	O
be	O
substituted	O
,	O
a	O
heterocyclyl	B
which	O
may	O
be	O
substituted	O
or	O
the	O
like	O
]	O
,	O
or	O
the	O
like	O
.	O

Substituted	O
indole	B
compound	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
screening	O
for	O
compounds	O
that	O
modulate	O
the	O
expression	O
of	O
the	O
cannabinoid	B
CBl	O
and	O
CB2	O
receptors	O
,	O
and	O
methods	O
for	O
modulating	O
receptor	O
activity	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
CB	O
1	O
and	O
CB2	O
receptors	O
and/or	O
binding	O
partners	O
for	O
identification	O
of	O
pharmacologically	O
active	O
agents	O
,	O
and	O
their	O
use	O
for	O
enhancing	O
wound	O
healing	O
and	O
treating	O
wound	O
healing	O
disorders	O
.	O

Methods	O
for	O
identifying	O
modulators	O
of	O
cb1	O
and	O
cb2	O
cannabinoid	B
receptors	O
and	O
their	O
use	O
in	O
wound	O
healing	O

Disclosed	O
herein	O
are	O
novel	O
and	O
stable	O
polymorphic	O
form	O
of	O
Donepezil	B
Hydrochloride	I
,	O
wherein	O
said	O
polymorphic	O
form	O
is	O
designated	O
as	O
J	O
and	O
are	O
characterized	O
by	O
their	O
powder	O
X	O
-	O
ray	O
diffraction	O
patterns	O
,	O
Infrared	O
absorption	O
spectrums	O
,	O
thermo	O
gravimetric	O
analysis	O
and	O
differential	O
scanning	O
calorimetry	O
.	O

The	O
processes	O
for	O
preparing	O
said	O
polymorphic	O
form	O
and	O
use	O
thereof	O
to	O
prepare	O
another	O
forms	O
is	O
also	O
disclosed	O
.	O

NOVEL	O
POLYMORPHIC	O
FORM	O
OF	O
(	B
l	I
-	I
BENZYL-4-	I
[	I
(	I
5,6-DIMETHOXY	I
-	I
l-	I
INDANONE	I
)	I
-2-YL	I
]	I
METHYL	I
PIPERIDINE	I
HYDROCHLORIDE	I
AND	O
PROCESS	O
FOR	O
PREPARING	O
THE	O
SAME	O

An	O
object	O
of	O
the	O
invention	O
is	O
to	O
provide	O
a	O
peritoneal	O
dialysis	O
fluid	O
,	O
which	O
is	O
excellent	O
in	O
a	O
water	O
removal	O
ability	O
,	O
has	O
high	O
biocompatibility	O
,	O
and	O
is	O
excellent	O
in	O
storage	O
stability	O
.	O

The	O
object	O
is	O
solved	O
by	O
a	O
peritoneal	O
dialysis	O
fluid	O
containing	O
one	O
or	O
more	O
substances	O
selected	O
from	O
cyclonigerosyl	O
nigerose	O
,	O
cyclomaltosyl	B
maltose	I
and	O
L	B
-	I
ascorbic	I
acid	I
2-glucoside	I
.	O

Peritoneal	O
dialysis	O
fluid	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
pyrrolidine	B
and	O
thiazolidine	B
DPP	O
-	O
IV	O
inhibitor	O
compounds	O
.	O

The	O
present	O
invention	O
also	O
provides	O
synthetic	O
methods	O
for	O
preparation	O
of	O
such	O
compounds	O
,	O
methods	O
of	O
inhibiting	O
DPP	O
-	O
IV	O
using	O
such	O
compounds	O
and	O
pharmaceutical	O
formulations	O
containing	O
them	O
for	O
treatment	O
of	O
DPP	O
-	O
IV	O
mediated	O
diseases	O
,	O
in	O
particular	O
,	O
Type-2	O
diabetes	O
.	O

Dipeptidyl	O
peptidase	O
-	O
iv	O
inhibitors	O

Tanaproget	B
polymorph	O
Form	O
II	O
,	O
processes	O
for	O
preparing	O
tanaproget	B
polymorph	O
Form	O
II	O
,	O
pharmaceutical	O
compositions	O
including	O
tanaproget	B
polymorph	O
Foπn	O
II	O
,	O
micronized	O
tanaproget	B
polymorph	O
Form	O
II	O
,	O
and	O
processes	O
for	O
converting	O
Form	O
II	O
to	O
tanaproget	B
Form	O
I	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
contraception	O
,	O
hormone	O
replacement	O
therapy	O
,	O
stimulation	O
of	O
food	O
intake	O
and	O
treating	O
or	O
preventing	O
uterine	O
myometrial	O
fibroids	O
,	O
benign	O
prostatic	O
hypertrophy	O
,	O
benign	O
and	O
malignant	O
neoplastic	O
disease	O
,	O
dysfunctional	O
bleeding	O
,	O
uterine	O
leiomyomata	O
,	O
endometriosis	O
,	O
polycystic	O
ovary	O
syndrome	O
,	O
or	O
carcinomas	O
and	O
adenocarcinomas	O
comprising	O
administering	O
polymorph	O
Form	O
II	O
to	O
a	O
mammalian	O
subject	O
.	O

Polymorph	O
form	O
ii	O
of	O
tanaproget	B

Provided	O
are	O
quinazoline	B
derivatives	O
of	O
the	O
compound	O
(	O
I	O
)	O
,	O
and	O
its	O
preparation	O
process	O
and	O
application	O
as	O
a	O
medicine	O
of	O
inhibit	O
tumor	O
growth	O
.	O

The	O
group	O
X	O
,	O
Y	O
,	O
Z	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
of	O
compound	O
(	O
I	O
)	O
are	O
defined	O
in	O
the	O
description	O
.	O

Compounds	O
of	O
the	O
invention	O
can	O
specially	O
inhibit	O
tyrosine	B
kinase	O
activity	O
,	O
adjust	O
VEGF	O
secretion	O
,	O
thus	O
to	O
achieve	O
the	O
purpose	O
of	O
treating	O
malignant	O
tumor	O
.	O

The	O
preparation	O
process	O
of	O
quinazoline	B
derivatives	O
and	O
application	O
for	O
the	O
manufacture	O
for	O
the	O
treatment	O
of	O
tumor	O
disease	O

The	O
invention	O
provides	O
methods	O
of	O
treating	O
cancer	O
using	O
a	O
compound	O
of	O
formula	O
(	O
1	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
particularly	O
a	O
malate	B
salt	I
,	O
in	O
combination	O
with	O
various	O
additional	O
therapeutic	O
agents	O
.	O

The	O
invention	O
also	O
provides	O
therapeutic	O
dosing	O
regimens	O
,	O
using	O
the	O
compound	O
of	O
formula	O
(	O
1	O
)	O
and	O
an	O
additional	O
therapeutic	O
agent	O
.	O

Anticancer	O
combination	O
therapy	O
using	O
sunitinib	B
malate	I

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
to	O
R3	O
are	O
as	O
described	O
herein	O
,	O
processes	O
for	O
preparing	O
the	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
use	O
of	O
the	O
compounds	O
and	O
compositions	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
GHSR	O
receptor	O
-	O
related	O
disorder	O
.	O

Examples	O
of	O
such	O
disorders	O
are	O
obesity	O
and	O
related	O
disorders	O
such	O
as	O
diabetes	O
type	O
II	O
,	O
dyslipidemia	O
and	O
the	O
metabolic	O
syndrome	O
Prader	O
-	O
Willi	O
syndrome	O
,	O
cardiovascular	O
diseases	O
such	O
as	O
atherosclerotic	O
vascular	O
disease	O
,	O
angina	O
pectoris	O
,	O
myocardial	O
infarction	O
and	O
stroke	O
,	O
intestinal	O
inflammation	O
that	O
is	O
associated	O
with	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
such	O
as	O
Crohn	O
's	O
disease	O
and	O
ulcerative	O
colitis	O
,	O
acromegaly	O
and	O
cancer	O
,	O
in	O
particular	O
breast	O
,	O
lung	O
,	O
prostate	O
,	O
thyroid	O
and	O
endocrine	O
pituary	O
carcinomas	O
.	O

Beta	B
-	I
carboline	I
derivatives	O
and	O
theri	O
use	O
as	O
ghsr	O
modulators	O

Disclosed	O
are	O
methods	O
for	O
detecting	O
adriamycin	B
resistance	O
in	O
a	O
test	O
neoplastic	O
cell	O
from	O
a	O
non	O
-	O
hematological	O
cancer	O
.	O

The	O
methods	O
include	O
detecting	O
a	O
level	O
of	O
pl6	O
expression	O
in	O
the	O
test	O
neoplastic	O
cell	O
of	O
a	O
given	O
origin	O
or	O
cell	O
type	O
,	O
and	O
comparing	O
the	O
level	O
of	O
pl6	O
expression	O
detected	O
in	O
the	O
test	O
neoplastic	O
cell	O
to	O
the	O
level	O
of	O
pl6	O
expression	O
in	O
a	O
nonresistant	O
neoplastic	O
cell	O
of	O
the	O
same	O
origin	O
or	O
cell	O
type	O
,	O
wherein	O
the	O
test	O
neoplastic	O
cell	O
is	O
adriamycin	B
resistant	O
if	O
the	O
level	O
of	O
pl6	O
expression	O
is	O
greater	O
than	O
the	O
level	O
of	O
pl6	O
expression	O
in	O
the	O
nonresistant	O
neoplastic	O
cell	O
of	O
the	O
same	O
origin	O
or	O
cell	O
type	O
.	O

Also	O
disclosed	O
are	O
therapeutic	O
compositions	O
comprising	O
an	O
agent	O
that	O
inhibits	O
pl6	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Methods	O
for	O
identifying	O
chemotherapeutic	O
resistance	O
in	O
non	O
-	O
hematopoietic	O
tumors	O

This	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
anti	O
-	O
cancer	O
compounds	O
which	O
comprises	O
a	O
)	O
an	O
orally	O
effective	O
taxane	B
,	O
and	O
b	O
)	O
a	O
thymidylate	O
synthase	O
inhibitor	O
,	O
and	O
optionally	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
carrier	O
for	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
use	O
.	O

Combination	O
therapy	O
comprising	O
a	O
taxane	B
and	O
a	O
thymidylate	O
synthase	O
inhibitor	O

[	O
PROBLEMS	O
]	O
Although	O
fucoxanthin	B
extracted	O
from	O
wakame	O
(	O
Undaria	O
pinnatifida	O
)	O
is	O
efficacious	O
as	O
an	O
agent	O
having	O
an	O
antiobesity	O
activity	O
,	O
fucoxanthin	B
is	O
contained	O
in	O
only	O
a	O
small	O
amount	O
in	O
a	O
matured	O
brown	O
alga	O
body	O
and	O
,	O
therefore	O
,	O
it	O
takes	O
a	O
long	O
time	O
and	O
a	O
large	O
cost	O
to	O
obtain	O
a	O
practically	O
usable	O
amount	O
of	O
fucoxanthin	B
.	O

Moreover	O
,	O
it	O
has	O
been	O
required	O
to	O
develop	O
an	O
agent	O
having	O
an	O
enhanced	O
antiobesity	O
activity	O
.	O

Thus	O
,	O
it	O
is	O
intended	O
to	O
specify	O
a	O
carotenoid	B
having	O
a	O
stronger	O
antiobesity	O
activity	O
than	O
fucoxanthin	B
and	O
provide	O
an	O
agent	O
having	O
an	O
antiobesity	O
activity	O
and	O
a	O
method	O
of	O
inhibiting	O
obesity	O
by	O
using	O
the	O
same	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
As	O
the	O
results	O
of	O
intensive	O
studies	O
for	O
finding	O
a	O
carotenoid	B
having	O
a	O
stronger	O
antiobesity	O
activity	O
than	O
fucoxanthin	B
and	O
a	O
material	O
for	O
economically	O
obtaining	O
the	O
same	O
,	O
it	O
is	O
found	O
out	O
that	O
these	O
problems	O
can	O
be	O
solved	O
by	O
using	O
ascidian	O
.	O

Ascidian	O
is	O
a	O
general	O
name	O
involving	O
marine	O
animals	O
belonging	O
to	O
the	O
phylum	O
Chordata	O
,	O
the	O
subphylum	O
Urochordata	O
,	O
and	O
the	O
class	O
Ascidiacea	O
and	O
these	O
animals	O
widely	O
occur	O
throughout	O
the	O
country	O
.	O

Fucoxanthinol	B
is	O
extracted	O
from	O
,	O
in	O
particular	O
,	O
the	O
internal	O
organs	O
and	O
shell	O
of	O
ascidian	O
and	O
it	O
is	O
clarified	O
that	O
this	O
substance	O
has	O
a	O
strong	O
antiobesity	O
activity	O
.	O

Agent	O
having	O
antiobesity	O
activity	O
and	O
method	O
of	O
inhibiting	O
obesity	O

A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
salt	O
:	O
(	O
I	O
)	O
wherein	O
Y	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
(	O
II	O
)	O
below	O
,	O
provided	O
that	O
Y	O
is	O
not	O
a	O
phenyl	B
which	O
is	O
substituted	O
by	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
-CR9R10X3	O
in	O
para	O
-	O
position	O
and	O
which	O
may	O
have	O
a	O
substituent	O
;	O
R1	O
to	O
R10	O
independently	O
represent	O
a	O
halogen	B
,	O
a	O
hydroxy	B
,	O
a	O
lower	O
alkyl	B
which	O
may	O
have	O
a	O
substituent	O
,	O
an	O
aryl	B
which	O
may	O
have	O
a	O
substituent	O
or	O
the	O
like	O
;	O
and	O
X1	O
represents	O
-O-	B
,	O
-S-	B
or	O
the	O
like	O
:	O
(	O
II	O
)	O
wherein	O
the	O
ring	O
A	O
represents	O
an	O
aryl	B
which	O
may	O
have	O
a	O
substituent	O
or	O
a	O
heteroaryl	B
which	O
may	O
have	O
a	O
substituent	O
;	O
and	O
X3	O
represents	O
COOR17	B
or	O
the	O
like	O
.	O

Arylacetate	B
derivative	O
having	O
isoxazole	B
skeleton	O

Provided	O
is	O
amorphous	O
cinacalcet	B
hydrochloride	I
,	O
processes	O
for	O
the	O
preparation	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
therewith	O
.	O

Amorphous	O
cinacalcet	B
hydrochloride	I
and	O
preparation	O
thereof	O

Vaccines	O
against	O
Chlamydia	O
are	O
formulated	O
based	O
on	O
the	O
peptidoglycan	O
-	O
associated	O
lipoprotein	O
(	O
PaL	O
)	O
.	O

The	O
vaccines	O
contain	O
PaL	O
sequences	O
from	O
various	O
Chlamydia	O
strains	O
,	O
the	O
sequences	O
sharing	O
immunologically	O
significant	O
epitopes	O
.	O

Pal	O
-	O
based	O
chlamydia	O
vaccine	O

A	O
pharmaceutical	O
composition	O
comprising	O
ganoderic	B
acid	I
T	O
and/or	O
ganoderic	B
acid	I
Me	B
,	O
as	O
well	O
as	O
its	O
application	O
for	O
inhibiting	O
tumor	O
growth	O
or	O
proliferation	O
.	O

Ganoderic	O
acid	O
T	O
and/or	O
ganoderic	B
acid	I
Me	B
have	O
obvious	O
action	O
for	O
inhibiting	O
human	O
tumor	O
cell	O
growth	O
or	O
proliferation	O
,	O
at	O
the	O
same	O
time	O
its	O
toxicity	O
for	O
normal	O
cells	O
is	O
low	O
.	O

Use	O
of	O
ganoderic	B
acid	I
in	O
treating	O
tumour	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
anti	O
-	O
inflammatory	O
and/or	O
anti	O
-	O
edematous	O
agent	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
prevention	O
and/or	O
treatment	O
of	O
inflammatory	O
/	O
edematous	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
or	O
increased	O
intracranial	O
pressure	O
wherein	O
the	O
agent	O
is	O
administered	O
intrathecally	O
and	O
preparations	O
useful	O
therefore	O
.	O

Anti	O
-	O
inflammatory	O
preparations	O
and	O
their	O
intrathecal	O
use	O
in	O
the	O
therapy	O
of	O
inflammatory	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O

The	O
object	O
is	O
to	O
prepare	O
a	O
2-naphthylimino-5,5-disubstituted-1,3-thiazin	B
derivative	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
as	O
an	O
active	O
ingredient	O
and	O
to	O
provide	O
an	O
analgesic	O
agent	O
,	O
a	O
therapeutic	O
agent	O
for	O
pain	O
,	O
an	O
anti	O
-	O
pruritic	O
agent	O
or	O
a	O
bronchodilator	O
.	O

A	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
an	O
optically	O
active	O
form	O
or	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
,	O
optically	O
active	O
form	O
or	O
salt	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
independently	O
represents	O
an	O
alkyl	B
or	O
the	O
like	O
;	O
R2	O
and	O
R3	O
are	O
different	O
from	O
each	O
other	O
and	O
represent	O
a	O
C1-C6	B
alkyl	I
or	O
the	O
lie	O
,	O
or	O
R2	O
and	O
R3	O
may	O
together	O
form	O
a	O
5-	O
to	O
8-membered	O
cycloalkane	B
which	O
has	O
a	O
adjacent	O
carbon	B
atom	O
and	O
is	O
substituted	O
by	O
a	O
C1-C4	B
alkyl	I
,	O
or	O
the	O
like	O
;	O
R4	O
represents	O
a	O
C1-C4	B
alkyl	I
or	O
the	O
like	O
;	O
X	O
represents	O
an	O
oxygen	B
or	O
sulfur	O
atom	O
;	O
W	O
represents	O
-CH	B
=	I
CH	I
-	I
CH	I
=	I
CH-	I
or	O
the	O
like	O
;	O
and	O
n	O
is	O
an	O
integer	O
of	O
0	O
to	O
7	O
.	O

2-naphthylimino-5,5-disubstituted-1,3-thiazin	B
derivative	O

A	O
prophylactic	O
and/or	O
therapeutic	O
agent	O
for	O
a	O
motor	O
disorder	O
comprising	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
triazolopyrimidine	B
derivative	O
having	O
an	O
adenosine	B
A2A	O
receptor	O
antagonistic	O
effect	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
aryl	B
group	O
or	O
a	O
substituted	O
or	O
unsubstituted	O
heterocyclic	B
group	O
;	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
R3	O
represents	O
-WR4	O
or	O
the	O
like	O
;	O
and	O
Q1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
3,4-dimethoxybenzyl	B
;	O
and	O
others	O
.	O

Prophylactic	O
and/or	O
therapeutic	O
agent	O
for	O
motor	O
disorder	O

The	O
present	O
invention	O
relates	O
to	O
improved	O
methods	O
for	O
treating	O
anemia	O
.	O

Compounds	O
which	O
stabilise	O
HIF	O
-	O
alpha	O
useful	O
for	O
treating	O
anemia	O
,	O
wherein	O
the	O
anemia	O
treatment	O
is	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
thrombosis	O
or	O
hypertension	O
compared	O
to	O
that	O
observed	O
with	O
rhEPO	O
therapy	O
,	O
are	O
provided	O
.	O

Improved	O
treatment	O
for	O
anemia	O
using	O
a	O
hif	O
-	O
alpha	O
stabilising	O
agent	O

The	O
present	O
invention	O
uses	O
NF	O
-	O
κB	O
as	O
target	O
point	O
,	O
and	O
utilizes	O
the	O
NF	O
-	O
κB	O
inhibitor	O
to	O
treat	O
several	O
diseases	O
of	O
mammal	O
,	O
e.g.	O
virusinfection	O
,	O
cancer	O
,	O
chronic	O
inflammation	O
and	O
autoimmune	O
diseases	O
.	O

The	O
said	O
inhibitor	O
includes	O
the	O
compounds	O
and	O
derivates	O
which	O
can	O
inhibit	O
NF	O
-	O
κB	O
,	O
such	O
as	O
quinazoline	B
derivative	O
,	O
celastrol	B
,	O
phenylethyl	B
caffeiatc	I
,	O
(	B
E	I
)	I
3-	I
(	I
(	I
4-methylphenyl	I
)	I
ulfonyl	I
)	I
-2-acrylonitrile	I
,	O
Rocaglamide	B
and	O
7-methoxy-5,11,12-trihydroxy	B
-	I
benzofuran	I
coumarin	I
.	O

They	O
can	O
be	O
used	O
alonely	O
or	O
be	O
combined	O
with	O
known	O
clinical	O
treatment	O
to	O
treat	O
viral	O
diseases	O
,	O
especially	O
viral	O
infection	O
caused	O
by	O
retrovirus	O
and	O
AIDS	O
caused	O
by	O
HIV	O
,	O
cancer	O
,	O
chronic	O
inflammation	O
and	O
autoimmune	O
diseases	O
.	O

USE	O
OF	O
NF	O
-	O
κB	O
INHIBITOR	O
FOR	O
TREATING	O
SEVERAL	O
DISEASES	O

The	O
present	O
invention	O
includes	O
the	O
treatment	O
of	O
psoriasis	O
in	O
a	O
human	O
comprising	O
the	O
intralesional	O
administration	O
of	O
a	O
phenothiazine	B
,	O
preferably	O
fluphenazine	B
,	O
to	O
a	O
psoriatic	O
plaque	O
in	O
the	O
patient	O
.	O

Intralesional	O
treatment	O
of	O
psoriasis	O

A	O
pharmaceutical	O
for	O
use	O
in	O
the	O
treatment	O
of	O
Perkinson	O
's	O
disease	O
which	O
comprises	O
a	O
vector	O
having	O
a	O
mediatophore	O
-	O
encoding	O
gene	O
integrated	O
therein	O
and	O
which	O
can	O
express	O
mediatophore	O
in	O
the	O
brain	O
.	O

Pharmaceutical	O
for	O
treatment	O
of	O
parkinson	O
's	O
disease	O

The	O
invention	O
relates	O
to	O
dicarbonic	B
acid	I
derivatives	O
,	O
in	O
particular	O
to	O
monooximides	B
and	O
dicarbonic	B
acid	I
dioxydiamides	I
which	O
are	O
physiologically	O
active	O
substances	O
and	O
can	O
be	O
used	O
in	O
the	O
form	O
of	O
low	O
-	O
toxic	O
and	O
non	O
-	O
toxic	O
agents	O
for	O
enhancing	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
metastasis	O
effects	O
of	O
known	O
cytostatics	O
(	O
cyclophosphane	B
and	O
cisplatin	B
)	O
in	O
cytostatic	O
chemotherapy	O
of	O
tumors	O
.	O

The	O
aim	O
of	O
said	O
invention	O
is	O
to	O
extend	O
the	O
variety	O
of	O
agents	O
acting	O
on	O
a	O
live	O
organism	O
for	O
enhancing	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
metastasis	O
effects	O
of	O
known	O
cytostatics	O
.	O

Said	O
aim	O
is	O
attained	O
by	O
the	O
properties	O
of	O
monooximides	B
and	O
dicarbonic	B
acid	I
dioxydiamides	B
.	O

The	O
invention	O
is	O
characterised	O
by	O
the	O
use	O
of	O
dicarbonic	B
acid	I
derivatives	O
in	O
the	O
form	O
of	O
agents	O
for	O
enhancing	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
metastasis	O
effects	O
of	O
cytostatics	O
of	O
formulas	O
given	O
in	O
a	O
description	O
.	O

The	O
inventive	O
compounds	O
can	O
be	O
used	O
in	O
medicine	O
in	O
the	O
form	O
of	O
low	O
-	O
toxic	O
means	O
for	O
enhancing	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
metastasis	O
effects	O
of	O
known	O
cytostatics	O
and	O
for	O
reducing	O
the	O
cytostatic	O
therapeutic	O
dose	O
by	O
four	O
times	O
.	O

The	O
use	O
of	O
the	O
inventive	O
compounds	O
in	O
combination	O
with	O
cisplatin	B
minimum	O
doses	O
makes	O
it	O
possible	O
to	O
totally	O
inhibit	O
the	O
metastasis	O
process	O
of	O
experimental	O
melanoma	O
B-16	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
minimum	O
doses	O
of	O
the	O
inventive	O
compounds	O
in	O
combination	O
with	O
the	O
cytostatic	O
minimum	O
doses	O
(	O
when	O
said	O
preparations	O
are	O
individually	O
inefficient	O
)	O
makes	O
it	O
possible	O
to	O
attain	O
a	O
high	O
therapeutic	O
effect	O
for	O
treating	O
(	O
the	O
survival	O
of	O
test	O
group	O
of	O
animals	O
having	O
leukaemia	O
P-338	O
is	O
equal	O
to	O
100	O
%	O
)	O
Dicarbonic	B
acid	I
derivatives	O
,	O
metastasis	O
inhibitors	O
and	O
agents	O
increasing	O
chemotherapeutic	O
activity	O
of	O
anti	O
-	O
tumor	O
preparations	O
,	O
method	O
for	O
enhancing	O
the	O
cytostatic	O
efficiency	O
and	O
metastasis	O
process	O
inhibiting	O
method	O

This	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
forms	O
thereof	O
useful	O
as	O
inhibitors	O
of	O
cPLA2	O
and	O
a	O
method	O
for	O
preventing	O
,	O
treating	O
or	O
ameliorating	O
a	O
cPLA2	O
mediated	O
inflammatory	O
related	O
disease	O
,	O
disorder	O
or	O
condition	O
using	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
and	O
,	O
more	O
particularly	O
,	O
for	O
preventing	O
,	O
treating	O
or	O
ameliorating	O
a	O
cPLA2	O
mediated	O
inflammatory	O
related	O
disease	O
,	O
disorder	O
or	O
condition	O
which	O
results	O
from	O
the	O
cellular	O
secretion	O
of	O
TXB2	O
or	O
LTB4	O
.	O

Substituted	O
isothiazolones	B
as	O
inhibitors	O
of	O
cytosolic	O
phospholipase	O
a2	O

The	O
invention	O
relates	O
to	O
novel	O
medicinal	O
combinations	O
preferably	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
groups	O
X	O
,	O
Ra	O
,	O
Rb	O
,	O
R1	O
,	O
R1	O
'	O
,	O
R2	O
,	O
R2	O
'	O
,	O
R2	O
'	O
'	O
,	O
R2	O
'	O
'	O
'	O
,	O
V	O
and	O
n	O
can	O
have	O
a	O
significance	O
specified	O
in	O
claims	O
and	O
in	O
a	O
description	O
,	O
or	O
several	O
of	O
said	O
compounds	O
and	O
at	O
least	O
one	O
type	O
of	O
other	O
active	O
substance	O
2	O
.	O

Methods	O
for	O
the	O
production	O
of	O
the	O
inventive	O
compounds	O
and	O
the	O
use	O
thereof	O
in	O
the	O
form	O
of	O
drugs	O
are	O
also	O
disclosed	O
.	O

Novel	O
medicinal	O
combinations	O
which	O
are	O
used	O
for	O
treating	O
respiratory	O
tract	O
diseases	O
and	O
contain	O
beta-2	O
long	O
-	O
acting	O
agonists	O
and	O
at	O
least	O
one	O
other	O
type	O
of	O
active	O
substance	O
.	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
as	O
antibacterial	O
agents	O
.	O

Oxazolidiones	B
containing	O
cyclobutane	B
as	O
antibacterial	O
agents	O

An	O
antibody	O
directed	O
against	O
a	O
protein	O
having	O
an	O
amino	B
acid	I
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:3	O
,	O
5	O
,	O
7	O
,	O
13	O
,	O
19	O
,	O
25	O
,	O
27	O
,	O
29	O
,	O
31	O
,	O
33	O
or	O
35	O
,	O
a	O
compound	O
capable	O
of	O
inhibiting	O
the	O
activity	O
or	O
function	O
of	O
the	O
protein	O
or	O
a	O
salt	O
thereof	O
,	O
a	O
compound	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
the	O
protein	O
or	O
a	O
salt	O
thereof	O
or	O
the	O
like	O
is	O
useful	O
as	O
a	O
prophylactic	O
/	O
therapeutic	O
agent	O
and	O
(	O
or	O
)	O
a	O
recurrence	O
-	O
preventive	O
agent	O
for	O
non	O
-	O
small	O
cell	O
lung	O
.	O

A	O
protein	O
having	O
an	O
amino	B
acid	I
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:1	O
,	O
9	O
,	O
11	O
,	O
15	O
,	O
17	O
,	O
21	O
,	O
23	O
or	O
37	O
,	O
DNA	O
encoding	O
the	O
protein	O
,	O
a	O
compound	O
capable	O
of	O
promoting	O
the	O
activity	O
or	O
function	O
of	O
the	O
protein	O
or	O
a	O
salt	O
thereof	O
,	O
a	O
compound	O
capable	O
of	O
promoting	O
the	O
expression	O
of	O
the	O
protein	O
or	O
a	O
salt	O
thereof	O
or	O
the	O
like	O
is	O
also	O
useful	O
as	O
a	O
prophylactic	O
/	O
therapeutic	O
agent	O
and	O
(	O
or	O
)	O
a	O
recurrence	O
-	O
preventive	O
agent	O
for	O
non	O
-	O
small	O
cell	O
lung	O
.	O

An	O
antibody	O
directed	O
against	O
the	O
protein	O
,	O
DNA	O
encoding	O
the	O
protein	O
or	O
the	O
like	O
is	O
also	O
useful	O
as	O
a	O
diagnostic	O
agent	O
for	O
the	O
grade	O
of	O
malignancy	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Prophylactic	O
/	O
therapeutic	O
agent	O
and	O
diagnostic	O
agent	O
for	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
:	O
R1	O
is	O
independently	O
H1	B
-OR3	I
,	O
-NHR4	B
;	O
C1-C4	B
alkyl	I
;	O
or	O
,	O
when	O
n	O
is	O
2	O
,	O
adjacent	O
R1	O
together	O
define	O
an	O
olefin	B
ic	O
bond	O
;	O
R2	O
is	O
H	B
;	O
or	O
when	O
the	O
gem	O
R1	O
is	O
C1-C4	B
alkyl	I
,	O
that	O
R2	O
may	O
also	O
be	O
C1-C4	B
alkyl	I
;	O
or	O
when	O
the	O
gem	O
R1	O
is	O
-OR3	B
,	O
that	O
R2	O
may	O
also	O
be	O
-C	B
(	I
=O	I
)	I
OH	I
or	O
a	O
pharmaceutically	O
acceptable	O
ester	O
thereof	O
;	O
R3	O
is	O
independently	O
H	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
ester	O
thereof	O
;	O
R4	O
is	O
independently	O
H	B
or	O
a	O
pharmaceutically	O
acceptable	O
amide	B
thereof	O
;	O
R5	O
and	O
R6	O
are	O
H	B
or	O
an	O
amine	B
prodrug	O
moiety	O
n	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
have	O
utility	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
HIV	O
,	O
especially	O
reverse	O
transcriptase	O
mutants	O
which	O
allow	O
an	O
obligate	O
chain	O
terminating	O
nucleoside-	O
or	O
nucleotide	O
phosphate	O
to	O
be	O
excised	O
from	O
the	O
nascent	O
DNA	O
strand	O
by	O
ATP-	O
or	O
pyrophosphate	O
-	O
mediated	O
excision	O
.	O

1-	B
[	I
2	I
'	I
,	I
3	I
'	I
-dideoxy-3	I
'	I
c-	I
(	I
hydroxymethyl	I
)	I
-	I
beta	I
-	I
d	I
-	I
erythro	I
-	I
pentofuranosyl	I
]	I
cytosine	I
derivatives	O
as	O
hiv	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
substituted	O
pyrazoline	B
compounds	O
for	O
the	O
treatment	O
of	O
food	O
disorders	O
,	O
including	O
obesity	O
or	O
metabolic	O
syndrome	O
in	O
patients	O
with	O
developed	O
diabetes	O
.	O

Use	O
of	O
substituted	O
pyrazoline	B
compounds	O
for	O
the	O
treatment	O
of	O
food	O
disorders	O
,	O
including	O
obesity	O
or	O
metabolic	O
syndrome	O
in	O
patients	O
with	O
developed	O
diabetes	O

The	O
present	O
invention	O
relates	O
to	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
process	O
for	O
their	O
preparation	O
,	O
their	O
use	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
tachykinins	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Piperidine	B
carboxamide	I
derivate	O
suitable	O
as	O
tachykinin	O
receptor	O
antagonist	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
phosphodiesterase	O
(	O
PDE	O
)	O
type	O
5	O
inhibitors	O
or	O
their	O
pharmaceutically	O
compatible	O
salts	O
for	O
producing	O
a	O
medicament	O
for	O
preventing	O
and/or	O
treating	O
diseases	O
or	O
health	O
disorders	O
,	O
which	O
are	O
associated	O
with	O
an	O
excessive	O
proliferation	O
of	O
adipose	O
tissue	O
in	O
the	O
body	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
phosphodiesterase	O
type	O
5	O
inhibitors	O
for	O
preventing	O
and	O
treating	O
adiposity	O
.	O

In	O
addition	O
,	O
the	O
invention	O
relates	O
to	O
special	O
dispensing	O
systems	O
for	O
the	O
vaginal	O
and	O
sub	O
-	O
cutaneous	O
administration	O
of	O
PDE5	O
inhibitors	O
.	O

Use	O
of	O
phosphodiesterase	O
type	O
5	O
inhibitors	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
diseases	O
or	O
health	O
disorders	O
and	O
dispensing	O
system	O
for	O
said	O
inhibitors	O

It	O
is	O
intended	O
to	O
provide	O
an	O
agent	O
for	O
relieving	O
a	O
wound	O
and	O
promoting	O
wound	O
recovery	O
which	O
contains	O
a	O
pine	O
bark	O
extract	O
.	O

This	O
agent	O
for	O
relieving	O
a	O
wound	O
and	O
promoting	O
wound	O
recovery	O
has	O
an	O
effect	O
of	O
relieving	O
skin	O
injury	O
due	O
to	O
a	O
wound	O
(	O
in	O
particular	O
,	O
a	O
burn	O
wound	O
and	O
a	O
chemical	O
wound	O
)	O
and	O
an	O
effect	O
of	O
promoting	O
the	O
recovery	O
therefrom	O
.	O

Moreover	O
,	O
the	O
agent	O
for	O
relieving	O
a	O
wound	O
and	O
promoting	O
wound	O
recovery	O
thus	O
obtained	O
is	O
usable	O
as	O
a	O
material	O
for	O
oral	O
compositions	O
such	O
as	O
foods	O
and	O
drugs	O
as	O
well	O
as	O
a	O
material	O
for	O
transdermal	O
compositions	O
such	O
as	O
cosmetics	O
.	O

Agent	O
for	O
relieving	O
wound	O
and	O
promoting	O
wound	O
recovery	O

Single	O
strand	O
deoxynucleosides	O
useful	O
for	O
viral	O
infective	O
disease	O
treatment	O
.	O

These	O
single	O
strand	O
deoxynucleosides	O
could	O
stimulate	O
the	O
human	O
cells	O
to	O
produce	O
antiviral	O
substance	O
,	O
which	O
could	O
inhibit	O
the	O
replication	O
of	O
the	O
virus	O
.	O

Also	O
the	O
composition	O
containing	O
the	O
deoxynucleosides	O
,	O
the	O
kit	O
and	O
the	O
use	O
for	O
viral	O
infective	O
disease	O
treatment	O
thereof	O
is	O
disclosed	O
.	O

Viral	O
infection	O
resistent	O
single	O
strand	O
deoxynucleosides	O

The	O
present	O
invention	O
relates	O
to	O
benzylpiperazine	B
derivatives	O
such	O
as	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
have	O
activity	O
as	O
agonists	O
of	O
the	O
GPR38	O
receptor	O
and	O
the	O
use	O
of	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
thereof	O
in	O
the	O
preparation	O
of	O
medicaments	O
suitable	O
for	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
.	O

Benzylpiperazine	B
derivates	O
and	O
their	O
medical	O
use	O

The	O
invention	O
concerns	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
:	O
n	O
represents	O
an	O
integer	O
between	O
1	O
and	O
6	O
inclusive	O
;	O
R1	O
and	O
R2	O
represent	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1-C6	B
alkyl	I
or	O
C1-C6	B
arylalkyl	I
group	O
;	O
R3	O
and	O
R4	O
represent	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1-C6	B
alkyl	I
group	O
;	O
R5	O
and	O
R6	O
represent	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1-C6	B
alkyl	I
group	O
,	O
halogen	B
,	O
hydroxy	B
,	O
C1-C6	B
alkoxy	I
,	O
cyano	B
,	O
nitro	B
,	O
C2-C6	B
acyl	I
,	O
C1-C6	B
alkoxycarbonyl	I
,	O
C1-C6	B
trihalogenoalkyl	I
,	O
C1-C6	B
triahalogenoalkoxy	I
or	O
amino	B
group	O
optionally	O
substituted	O
.	O

The	O
invention	O
is	O
useful	O
for	O
making	O
drugs	O
.	O

Novel	O
polysubstituted	O
1,1-pyridinyloxycyclopropanamine	B
compounds	O
,	O
method	O
for	O
preparing	O
same	O
and	O
pharmaceutical	O
compositions	O
containing	O
same	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
Formula	O
(	O
I	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
a	O
solvate	O
,	O
or	O
a	O
prodrug	O
thereof	O
,	O
wherein	O
m	O
,	O
n	O
,	O
Ar1	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
and	O
R5	O
are	O
those	O
defined	O
herein	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
5	O
for	O
using	O
and	O
preparing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
.	O

Cathepsin	O
k	O
inhibitors	O

The	O
invention	O
relates	O
to	O
methods	O
for	O
preventing	O
or	O
treating	O
metabolic	O
disorders	O
,	O
for	O
improving	O
glycemic	O
control	O
,	O
for	O
preventing	O
progression	O
from	O
impaired	O
glucose	B
tolerance	O
,	O
insulin	O
resistance	O
and/or	O
from	O
metabolic	O
syndrome	O
to	O
type	O
2	O
diabetes	O
mellitus	O
,	O
for	O
preventing	O
or	O
treating	O
of	O
complications	O
of	O
diabetes	O
mellitus	O
,	O
for	O
reducing	O
the	O
weight	O
,	O
for	O
preventing	O
or	O
treating	O
the	O
degeneration	O
of	O
pancreatic	O
beta	O
cells	O
,	O
for	O
treating	O
hyperinsulinemia	O
and	O
insulin	O
resistance	O
and	O
diabetes	O
type	O
1	O
,	O
in	O
patients	O
in	O
need	O
thereof	O
by	O
administering	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
pyrazole	B
-	I
O	I
-	I
glycoside	I
as	O
defined	O
in	O
claim	O
1	O
,	O
or	O
a	O
prodrug	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Methods	O
for	O
preventing	O
and	O
treating	O
metabolic	O
disorders	O
and	O
new	O
pyrazole	B
-	I
o	I
-	I
glycoside	I
derivatives	O

The	O
crystalline	O
form	O
III	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
is	O
characterised	O
by	O
the	O
X	O
diffraction	O
diagram	O
thereof	O
on	O
a	O
powder	O
.	O

Can	O
be	O
used	O
for	O
drugs	O
Novel	O
crystalline	O
iii	O
form	O
of	O
agomelatine	B
,	O
method	O
of	O
the	O
preparation	O
thereof	O
and	O
pharmaceutical	O
compositions	O
containing	O
said	O
form	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
corresponding	O
enantiomeric	O
,	O
diastereomeric	O
and/or	O
tautomeric	O
forms	O
thereof	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
the	O
prodrugs	O
of	O
said	O
compounds	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compounds	O
as	O
binding	O
partners	O
for	O
5-HT5	O
receptors	O
for	O
treating	O
diseases	O
that	O
are	O
modulated	O
by	O
a	O
5-HT5	O
receptor	O
activity	O
,	O
in	O
particular	O
,	O
for	O
treating	O
neurodegenerative	O
and	O
neuropsychiatric	O
disorders	O
as	O
well	O
as	O
signs	O
,	O
symptoms	O
and	O
dysfunctions	O
.	O

Heterocyclic	B
compounds	O
and	O
their	O
use	O
as	O
binding	O
partners	O
for	O
5-ht5	O
receptors	O

The	O
invention	O
relates	O
to	O
pyrrolopyridine	B
derivative	O
compounds	O
having	O
general	O
formula	O
(	O
I	O
)	O
as	O
defined	O
in	O
the	O
claims	O
and	O
to	O
the	O
pharmaceutically	O
-	O
acceptable	O
addition	O
salts	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
method	O
of	O
preparing	O
the	O
aforementioned	O
compounds	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
same	O
and	O
to	O
the	O
use	O
thereof	O
as	O
a	O
pharmacologically	O
-	O
active	O
substance	O
,	O
for	O
example	O
in	O
the	O
treatment	O
of	O
hypertriglyceridaemias	O
,	O
hyperlipidemias	O
,	O
hypercholesterolemias	O
,	O
diabetes	O
,	O
endothelial	O
dysfunction	O
,	O
cardiovascular	O
and	O
inflammatory	O
diseases	O
and	O
neurodegeneration	O
.	O

Pyrrolopyridine	B
derivatives	O
and	O
use	O
of	O
same	O
as	O
ppar	O
receptor	O
modulators	O

A	O
pharmaceutical	O
composition	O
comprising	O
10	O
-	O
120	O
mg	O
lamivudine	B
,	O
1	O
-	O
30	O
mg	O
stavudine	B
and	O
50	O
-	O
170	O
mg	O
nevirapine	B
for	O
paediatric	O
treatment	O
of	O
viral	O
infections	O
.	O

One	O
particularly	O
preferred	O
composition	O
comprises	O
a	O
tablet	O
containing	O
12	O
mg	O
stavudine	B
,	O
60	O
mg	O
lamivudine	B
and	O
l00	O
mg	O
nevirapine	B
.	O

Another	O
particularly	O
preferred	O
composition	O
comprises	O
a	O
second	O
tablet	O
containing	O
6	O
mg	O
stavudine	B
,	O
30	O
mg	O
lamivudine	B
and	O
500	O
mg	O
nevirapine	B
.	O

These	O
compositions	O
are	O
suitable	O
for	O
treating	O
children	O
having	O
a	O
body	O
weight	O
from	O
5	O
to	O
30	O
kg	O
.	O

Pharmaceutical	O
combinations	O
containing	O
lamivudine	B
,	O
stavudine	B
and	O
nevirapine	B

A	O
heterocyclic	B
compound	O
or	O
a	O
salt	O
thereof	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
:	O
where	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
lower	O
alkyl	B
group	O
;	O
A	O
represents	O
a	O
lower	O
alkylene	B
group	O
or	O
lower	O
alkenylene	B
group	O
;	O
and	O
R1	O
represents	O
an	O
aromatic	B
group	O
or	O
a	O
heterocyclic	B
group	O
.	O

The	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
wide	O
treatment	O
spectrum	O
for	O
mental	O
disorders	O
including	O
central	O
nervous	O
system	O
disorders	O
,	O
no	O
side	O
effects	O
and	O
high	O
safety	O
.	O

Derivatives	O
of	O
4-piperazin-1-yl-4-benz0	B
[	I
b	I
]	I
thiophene	I
suitable	O
for	O
the	O
treatment	O
of	O
cns	O
disorders	O

The	O
present	O
application	O
has	O
disclosed	O
carzole	B
sulphamide	I
derivatives	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
compounds	O
can	O
be	O
used	O
as	O
small	O
molecular	O
anti	O
-	O
mitotic	O
agent	O
.	O

The	O
compounds	O
not	O
only	O
can	O
inhibit	O
tumor	O
cell	O
in	O
the	O
first	O
mitosis	O
,	O
but	O
also	O
have	O
remarkable	O
antitumor	O
activity	O
.	O

They	O
have	O
the	O
advantage	O
of	O
small	O
molecular	O
and	O
simple	O
synthesis	O
without	O
drug	O
resistance	O
problems	O
.	O

The	O
present	O
application	O
also	O
provides	O
pharmaceutical	O
composition	O
containing	O
the	O
carzole	B
sulphamide	I
derivatives	O
as	O
active	O
ingredient	O
.	O

Carzole	B
sulphamide	I
derivatives	O
and	O
their	O
preparation	O
method	O

Disclosed	O
is	O
an	O
effective	O
therapeutic	O
agent	O
for	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
.	O

The	O
therapeutic	O
agent	O
comprises	O
chloperastine	B
,	O
caramiphen	B
,	O
tipepidine	B
,	O
or	O
a	O
salt	O
thereof	O
.	O

Therapeutic	O
agent	O
for	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
production	O
of	O
1,2,4-triazoles	B
.	O

The	O
process	O
comprises	O
the	O
reaction	O
of	O
a	O
disubstituted	O
amide	B
and	O
a	O
hydrazide	O
in	O
the	O
presence	O
of	O
POCl3	O
.	O

Process	O
for	O
synthesizing	O
1,2,4-triazoles	B

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
where	O
R1	O
to	O
R4	O
are	O
as	O
defined	O
herein	O
which	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
an	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
,	O
or	O
treating	O
AIDS	O
or	O
ARC	O
.	O

The	O
invention	O
further	O
provides	O
for	O
methods	O
of	O
treating	O
or	O
preventing	O
HIV	O
infection	O
with	O
compounds	O
according	O
to	O
formula	O
(	O
I	O
)	O
and	O
compositions	O
containing	O
the	O
same	O
.	O

The	O
invention	O
still	O
further	O
provides	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R4	O
is	O
A1	O
and	O
X1	O
is	O
NH	B
or	O
O.	B
Nnrt	O
inhibitors	O

The	O
invention	O
provides	O
a	O
method	O
of	O
treatment	O
of	O
a	O
female	O
human	O
or	O
non	O
-	O
human	O
subject	O
to	O
enhance	O
cervical	O
mucus	O
penetrability	O
by	O
spermatozoa	O
,	O
which	O
method	O
comprises	O
vaginally	O
applying	O
to	O
said	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
spermicide	O
-	O
free	O
,	O
physiologically	O
tolerable	O
oligouronate	O
.	O

Use	O
of	O
oligouronates	B
for	O
treating	O
mucus	O
hyperviscosity	O

A	O
method	O
of	O
normalizing	O
microalbuminuria	O
in	O
a	O
patient	O
,	O
comprising	O
administering	O
to	O
the	O
patient	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
angiotensin	O
II	O
antagonist	O
.	O

Normalization	O
or	O
remission	O
of	O
microalbuminuria	O

It	O
is	O
intended	O
to	O
provide	O
an	O
agent	O
for	O
treating	O
diabetes	O
,	O
particularly	O
an	O
agent	O
for	O
treating	O
diabetes	O
capable	O
of	O
being	O
administered	O
orally	O
,	O
which	O
has	O
high	O
safety	O
even	O
if	O
it	O
is	O
administered	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
or	O
preventing	O
diabetes	O
comprising	O
an	O
anionic	O
polyamino	B
acid	I
,	O
preferably	O
a	O
metal	B
-	I
polyamino	I
acid	I
complex	O
which	O
can	O
be	O
produced	O
from	O
poly	B
-	I
gamma	I
-	I
glutamic	I
acid	I
and	O
a	O
metal	O
compound	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
composition	O
for	O
treating	O
or	O
preventing	O
diabetes	O
comprising	O
an	O
anionic	O
polyamino	B
acid	I
,	O
preferably	O
a	O
metal	B
-	I
polyamino	I
acid	I
complex	O
which	O
can	O
be	O
produced	O
from	O
poly	B
-	I
gamma	I
-	I
glutamic	I
acid	I
and	O
a	O
metal	O
compound	O
and	O
having	O
at	O
least	O
one	O
action	O
of	O
a	O
hypoglycemic	O
action	O
,	O
a	O
glucose	B
tolerance	O
improving	O
action	O
,	O
a	O
blood	O
pressure	O
-	O
lowering	O
action	O
and	O
an	O
insulin	O
resistance	O
improving	O
action	O
.	O

Further	O
,	O
the	O
invention	O
relates	O
to	O
a	O
food	O
composition	O
comprising	O
an	O
anionic	O
polyamino	B
acid	I
,	O
preferably	O
a	O
metal	B
-	I
polyamino	I
acid	I
complex	O
which	O
can	O
be	O
produced	O
from	O
poly	B
-	I
gamma	I
-	I
glutamic	I
acid	I
and	O
a	O
metal	O
compound	O
.	O

Antidiabetic	O
agent	O
comprising	O
anionic	O
polyamino	B
acid	I
-	I
metal	I
complex	O

The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
Liver	O
X	O
Receptor	O
(	O
LXR	O
)	O
modulators	O
that	O
have	O
been	O
identified	O
to	O
downregulate	O
5-lipoxygenase	O
gene	O
expression	O
in	O
order	O
to	O
treat	O
various	O
diseases	O
and	O
disorders	O
that	O
involve	O
the	O
function	O
of	O
the	O
5-LO	O
protein	O
in	O
intracellular	O
signaling	O
(	O
or	O
other	O
cellular	O
processes	O
)	O
or	O
the	O
function	O
of	O
protein	O
products	O
downstream	O
of	O
5-LO	O
in	O
intracellular	O
signaling	O
(	O
i.e.	O
,	O
leukotrienes	O
)	O
.	O

5-lipoxygenase	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
combination	O
of	O
cannabinoids	B
in	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
,	O
in	O
particular	O
peripheral	O
neuropathic	O
pain	O
.	O

A	O
combination	O
of	O
cannabidiol	B
(	O
CBD	B
)	O
and	O
delta-9-tetrahydrocannabinol	B
(	O
THC	B
)	O
may	O
be	O
used	O
,	O
wherein	O
the	O
ratio	O
of	O
CBD	B
:	O
THC	B
by	O
weight	O
is	O
between	O
10:1	O
and	O
1:10	O
.	O

A	O
combination	O
of	O
cannabinoids	B
for	O
the	O
treatment	O
of	O
peripheral	O
neurophatic	O
pain	O

The	O
invention	O
relates	O
to	O
6-	B
[	I
2-	I
(	I
1-Isopropyl	I
-	I
piperidin-4-yloxy	I
)	I
-7,8-dihydro-5H-	I
[	I
1	I
,	I
6	I
]	I
naphthyridin-6-yl	I
]	I
-	I
nicotinamide	I
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
,	O
compositions	O
containing	O
and	O
the	O
uses	O
of	O
,	O
the	O
compound	O
.	O

The	O
compound	O
is	O
an	O
H3	O
ligand	O
and	O
is	O
useful	O
in	O
numerous	O
diseases	O
,	O
disorders	O
and	O
conditions	O
,	O
in	O
particular	O
inflammatory	O
,	O
allergic	O
and	O
respiratory	O
diseases	O
,	O
disorders	O
and	O
conditions	O
.	O

Tetrahydronaphthyridine	B
derivative	O

The	O
invention	O
relates	O
to	O
a	O
depigmenting	O
composition	O
for	O
the	O
skin	O
,	O
comprising	O
,	O
in	O
a	O
physiologically	O
acceptable	O
medium	O
,	O
adapalene	B
,	O
at	O
least	O
one	O
depigmenting	O
agent	O
and	O
at	O
least	O
one	O
anti-	O
inflammatory	O
agent	O
,	O
and	O
to	O
its	O
pharmaceutical	O
or	O
cosmetic	O
use	O
.	O

Depigmenting	O
composition	O
for	O
the	O
skin	O
,	O
comprising	O
adapalene	B
,	O
at	O
least	O
one	O
depigmenting	O
agent	O
and	O
at	O
least	O
one	O
anti	O
-	O
inflammatory	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
a	O
dosage	O
form	O
for	O
hormonal	O
contraception	O
comprising	O
a	O
defined	O
number	O
of	O
progestogen	B
-	O
containing	O
daily	O
units	O
A	O
and	O
a	O
defined	O
number	O
of	O
progestogen	B
-	O
containing	O
daily	O
units	O
B	O
for	O
uninterrupted	O
daily	O
oral	O
administration	O
of	O
daily	O
units	O
A	O
and	O
,	O
immediately	O
subsequent	O
thereto	O
,	O
of	O
daily	O
units	O
B	O
,	O
where	O
the	O
daily	O
units	O
A	O
in	O
each	O
case	O
comprise	O
not	O
more	O
than	O
200	O
μg	O
of	O
folic	B
acid	I
and	O
the	O
daily	O
units	O
B	O
comprise	O
>	O
200	O
μg	O
up	O
to	O
the	O
maximum	O
permissible	O
amount	O
for	O
women	O
of	O
folic	B
acid	I
.	O

Dosage	O
form	O
for	O
hormonal	O
contraception	O

(	O
The	O
disclosure	O
relates	O
to	O
compositions	O
for	O
and	O
methods	O
of	O
inhibiting	O
the	O
mammalian	O
Hedgehog	O
signaling	O
pathway	O
.	O

Mammalian	O
hedgehog	O
signaling	O
inhiabitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
I	O
:	O
[	O
(	O
C	O
)	O
-	O
(	O
L'	O
)	O
]	O
n-	O
(	O
A	O
)	O
-	O
[	O
(	O
L	O
)	O
-	O
(	O
B	O
)	O
]	O
m	O
wherein	O
(	O
A	O
)	O
is	O
a	O
thioglycosylated	O
cysteine	B
of	O
formula	O
IIa	O
or	O
IIb	O
:	O
IIa	O
IIb	O
;	O
(	O
B	O
)	O
is	O
a	O
melanogenosis	O
-	O
inhibiting	O
peptide	O
comprising	O
peptide	O
sequence	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
:	O
(	O
i	O
)	O
.	O

Glu	B
-	I
Asp	I
-	I
Tyr	I
-	I
His	I
-	I
Ser	I
-	I
Leu	I
-	I
Tyr	I
-	I
Gln	I
-	I
Ser	I
-	I
His	I
-	I
Leu	I
;	O
(	O
ii	O
)	O
.	O

Ser	B
-	I
Gly	I
-	I
Gly	I
-	I
Tyr	I
-	I
Leu	I
-	I
Pro	I
-	I
Pro	I
-	I
Leu	I
;	O
and	O
(	O
iii	O
)	O
.	O

His	B
-	I
Ser	I
-	I
C	I
(	I
O	I
)	I
-NH-	I
(	I
CH2	I
)	I
k	I
-	I
CH2-C	I
(	I
O	I
)	I
-NH	I
-	I
Ser	I
-	I
His	I
;	O
(	O
C	O
)	O
is	O
a	O
tyrosinase	O
inhibitor	O
;	O
n	O
is	O
0	O
or	O
1	O
;	O
m	O
is	O
0	O
or	O
1	O
;	O
m	O
+	O
n	O
is	O
1	O
or	O
2;k	O
is	O
2	O
-	O
10	O
;	O
X1	O
is	O
O	B
or	O
NH	B
;	O
R1	O
,	O
R2	O
,	O
R7	O
,	O
and	O
R8	O
are	O
each	O
,	O
independently	O
,	O
selected	O
from	O
H	B
,	O
and	O
a	O
bond	O
in	O
a	O
linkage	O
group	O
between	O
(	O
A	O
)	O
and	O
(	O
L	O
)	O
;	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R9	O
,	O
R10	O
,	O
R11	O
,	O
and	O
R12	O
are	O
each	O
,	O
independently	O
,	O
selected	O
from	O
H	B
,	O
a	O
saccharide	B
,	O
and	O
a	O
bond	O
in	O
a	O
linkage	O
group	O
between	O
(	O
A	O
)	O
and	O
(	O
L	O
'	O
)	O
;	O
(	O
L	O
)	O
is	O
a	O
linker	O
which	O
forms	O
linkage	O
groups	O
with	O
thioglycosylated	O
cysteine	B
(	O
A	O
)	O
and	O
melanogenosis	O
-	O
inhibiting	O
peptide	O
(	O
B	O
)	O
;	O
and	O
(	O
L	O
'	O
)	O
is	O
a	O
linker	O
which	O
forms	O
linkage	O
groups	O
with	O
thioglycosylated	O
cysteine	B
(	O
A	O
)	O
and	O
tyrosinase	O
inhibitor	O
(	O
C	O
)	O
.	O

Method	O
and	O
composition	O
for	O
skin	O
depigmentation	O

The	O
invention	O
provides	O
alpha	O
-mimetic	O
structure	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
A	O
is	O
-	B
(	I
C	I
=	I
O	I
)	I
-CHR3-	I
,	O
or	O
-	B
(	I
C	I
=	I
O	I
)	I
,	O
B	O
is	O
N	B
-	I
R3-	I
or	O
-CHR6-	B
,	O
D	O
is	O
-	B
(	I
C	I
=	I
O	I
)	I
-	I
(	I
CHR7	I
)	I
-	I
or	O
-	B
(	I
C	I
=	I
O	I
)	I
E	O
is	O
-	O
(	O
ZR8	O
)	O
-	O
or	O
(	B
C	I
=	I
O	I
)	I
,	O
G	O
is	O
-	O
(	O
XR9	O
)	O
n-	O
,	O
-	B
(	I
CHR10	I
)	I
-	I
(	I
NR6	I
)	I
-	I
,	O
-	B
(	I
C	I
=	I
O	I
)	I
-	I
(	I
XR12	I
)	I
-	I
,	O
-	B
(	I
C	I
=	I
N	I
-	I
W	I
-	I
R1	I
)	I
-	I
,	O
-	B
(	I
C	I
=	I
O	I
)	I
-	I
,	O
X-	B
(	I
C	I
=	I
O	I
)	I
-R13	I
,	O
X-	B
(	I
C	I
=	I
O	I
)	I
-NR13R14	I
,	O
X-	B
(	I
SO2	I
)	I
-R13	I
,	O
or	O
X-	B
(	I
C	I
=	I
O	I
)	I
-OR13	I
,	O
W	O
is	O
-Y	B
(	I
C	I
=	I
O	I
)	I
-	I
,	O
-	B
(	I
C	I
=	I
O	I
)	I
NH-	I
,	O
-	B
(	I
SO2	I
)	I
-	I
,	O
-CHR14	B
,	O
(	B
C	I
=	I
O	I
)	I
-	I
(	I
NR15	I
)	I
-	I
,	O
substituted	O
or	O
unsubstituted	O
oxadiazole	B
,	O
substituted	O
or	O
unsubstituted	O
triazole	B
,	O
substituted	O
or	O
unsubstituted	O
thiadiazole	B
,	O
substituted	O
or	O
unsubstituted	O
4,5	B
dihydrooxazole	I
,	O
substituted	O
or	O
unsubstituted	O
4,5	B
dihydrothiazole	I
,	O
substituted	O
or	O
unsubstituted	O
4,5	B
dihydroimidazole	I
,	O
or	O
nothing	O
,	O
Y	O
is	O
oxygen	B
or	O
sulfur	B
,	O
X	O
and	O
Z	O
is	O
independently	O
nitrogen	B
or	O
CH	B
,	O
n=0	O
or	O
1	O
;	O
and	O
R1	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
R10	O
,	O
R11	O
,	O
R12	O
,	O
R13	O
,	O
R14	O
,	O
and	O
R15	O
are	O
the	O
same	O
or	O
different	O
and	O
independently	O
selected	O
from	O
an	O
amino	B
acid	I
side	O
chain	O
moiety	O
or	O
derivative	O
thereof	O
,	O
the	O
remainder	O
of	O
the	O
molecule	O
,	O
a	O
linker	O
and	O
a	O
solid	O
support	O
,	O
and	O
stereoisomers	O
,	O
salts	O
,	O
and	O
prodrugs	O
thereof	O
,	O
provided	O
that	O
where	O
B	O
is	O
CHR6	B
and	O
W	O
is	O
-Y	B
(	I
C	I
=	I
O	I
)	I
-	I
,	O
-	B
(	I
C	I
=	I
O	I
)	I
NH-	I
,	O
-	B
(	I
SO2	I
)	I
,	O
-CHR14	B
,	O
or	O
(	B
C	I
=	I
O	I
)	I
-	I
(	I
NR15	I
)	I
-	I
,	O
G	O
can	O
not	O
be	O
CHR9	B
,	O
NR9	B
,	O
(	B
C	I
=	I
O	I
)	I
-CHR12	I
,	O
(	B
C	I
=	I
O	I
)	I
-NR12	I
,	O
or	O
no	O
atom	O
at	O
all	O
.	O

Additionally	O
,	O
the	O
invention	O
provides	O
methods	O
wherein	O
α	O
-	O
mimetic	O
compounds	O
are	O
used	O
to	O
treat	O
cancer	O
stem	O
cells	O
.	O

α	O
-	O
HELIX	O
MIMETICS	O
AND	O
METHOD	O
RELATING	O
TO	O
THE	O
TREATMENT	O
OF	O
CANCER	O
STEM	O
CELLS	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
cancers	O
;	O
which	O
have	O
acquired	O
resistance	O
to	O
a	O
KIT	O
inhibitor	O
by	O
administering	O
effective	O
amounts	O
of	O
sorafenib	B
.	O

Treatment	O
of	O
cancers	O
with	O
acquired	O
resistance	O
to	O
kit	O
inhibitors	O

A	O
bicyclic	B
cinnamide	I
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
(	O
II	O
)	O
indicates	O
a	O
single	O
bond	O
or	O
double	O
bond	O
;	O
Ar1	O
represents	O
phenyl	B
or	O
pyridinyl	B
optionally	O
substituted	O
by	O
one	O
to	O
three	O
substituents	O
;	O
R1	O
and	O
R2	O
each	O
represents	O
C1	B
-	I
6	I
alkyl	I
,	O
hydroxy	B
,	O
etc	O
.	O
;	O
Z1	O
represents	O
optionally	O
substituted	O
methylene	B
or	O
vinylene	B
,	O
oxygen	B
,	O
or	O
imino	B
optionally	O
substituted	O
by	O
C1	B
-	I
6	I
alkyl	I
or	O
C1	B
-	I
6	I
acyl	I
;	O
and	O
p	O
,	O
q	O
,	O
and	O
r	O
each	O
is	O
an	O
integer	O
of	O
0	O
-	O
2	O
]	O
.	O

It	O
functions	O
to	O
reduce	O
the	O
production	O
of	O
Aβ40	O
and	O
Aβ42	O
.	O

It	O
is	O
hence	O
useful	O
especially	O
as	O
a	O
preventive	O
or	O
remedy	O
for	O
neurodegenerative	O
diseases	O
of	O
which	O
Aβ	O
is	O
causative	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
and	O
Down	O
's	O
syndrome	O
.	O

Bicyclic	B
cinnamide	I
compound	O

A	O
taxane	B
-	O
liposome	O
composition	O
and	O
its	O
industrial	O
preparing	O
process	O
,	O
said	O
composition	O
comprises	O
taxane	B
,	O
phospholipid	B
,	O
cholesterol	B
,	O
cyclodextrin	O
and	O
lyophilized	O
excipients	O
.	O

It	O
exhibits	O
enhanced	O
reconstitution	O
and	O
stability	O
.	O

Lyophilized	O
taxane	B
-	O
liposome	O
composition	O
and	O
its	O
preparing	O
process	O

Processes	O
for	O
obtaining	O
lignan	O
extracts	O
from	O
plant	O
materials	O
are	O
disclosed	O
.	O

Compositions	O
including	O
lignan	O
extracts	O
as	O
well	O
as	O
uses	O
of	O
the	O
lignan	O
extracts	O
are	O
also	O
disclosed	O
.	O

Processes	O
for	O
obtaining	O
lignan	O
extracts	O
and	O
compositions	O
containing	O
the	O
lignan	O
extracts	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
protein	O
tyrosine	B
phosphatases	O
(	O
PTPases	O
)	O
and	O
,	O
thus	O
,	O
may	O
be	O
employed	O
for	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
PTPase	O
activity	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
also	O
be	O
employed	O
as	O
inhibitors	O
of	O
other	O
enzymes	O
characterized	O
with	O
a	O
phosphotyrosine	B
binding	O
region	O
such	O
as	O
the	O
SH2	B
domain	O
.	O

Accordingly	O
,	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
may	O
be	O
employed	O
for	O
prevention	O
and/or	O
treatment	O
of	O
insulin	O
resistance	O
associated	O
with	O
obesity	O
,	O
glucose	B
intolerance	O
,	O
diabetes	O
mellitus	O
,	O
hypertension	O
and	O
ischemic	O
diseases	O
of	O
the	O
large	O
and	O
small	O
blood	O
vessels	O
,	O
conditions	O
that	O
accompany	O
type-2	O
diabetes	O
,	O
including	O
hyperlipidemia	O
,	O
hypertriglyceridemia	O
,	O
atherosclerosis	O
,	O
vascular	O
restenosis	O
,	O
irritable	O
bowel	O
syndrome	O
,	O
pancreatitis	O
,	O
adipose	O
cell	O
tumors	O
and	O
carcinomas	O
such	O
as	O
liposarcoma	O
,	O
dyslipidemia	O
,	O
and	O
other	O
disorders	O
where	O
insulin	O
resistance	O
is	O
indicated	O
.	O

In	O
addition	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
be	O
employed	O
to	O
treat	O
and/or	O
prevent	O
cancer	O
,	O
osteoporosis	O
,	O
neurodegenerative	O
and	O
infectious	O
diseases	O
,	O
and	O
diseases	O
involving	O
inflammation	O
and	O
the	O
immune	O
system	O
.	O

1-orthofluorophenyl	B
substituted	I
1	I
,	I
2	I
,	I
5-thiazolidinedione	I
derivatives	O
as	O
ptp	O
-	O
as	O
inhibitors	O

The	O
object	O
is	O
to	O
isolate	O
phosphatidylglucoside	B
(	O
a	O
hysiologically	O
active	O
glycolipid	O
)	O
and	O
an	O
acetylated	O
form	O
of	O
the	O
glycolipid	O
from	O
the	O
brain	O
of	O
a	O
fetal	O
rat	O
,	O
determining	O
the	O
structures	O
of	O
these	O
compounds	O
and	O
evaluating	O
the	O
physiological	O
activities	O
of	O
these	O
compounds	O
.	O

Thus	O
,	O
disclosed	O
is	O
a	O
glycolipid	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
.	O

Physiologically	O
active	O
glycolipid	O

The	O
present	O
invention	O
is	O
concerned	O
with	O
isoxazol-4-yl	B
-	I
oxadiazole	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen	B
,	O
halogen	B
,	O
aryl	B
,	O
heterocyclyl	B
,	O
heteroaryl	B
,	O
cyano	B
,	O
lower	O
alkyl	B
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
cycloalkyl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
N	I
(	I
R	I
)	I
2	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
O	I
-	I
lower	I
alkyl	I
or	O
-	B
(	I
CH2	I
)	I
n	I
-	I
OH	I
;	O
n	O
is	O
0,1	O
or	O
2	O
R	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
R2	O
is	O
cycloalkyl	B
,	O
aryl	B
,	O
heteroaryl	B
or	O
heterocyclyl	B
,	O
which	O
are	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
,	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	B
,	O
cyano	B
,	O
nitro	B
,	O
lower	O
alkyl	B
,	O
lower	O
alkoxy	B
,	O
lower	O
alkoxy	B
substituted	O
by	O
halogen	B
,	O
lower	O
alkyl	B
substituted	O
by	O
halogen	B
,	O
C	B
(	I
O	I
)	I
O	I
-	I
lower	I
alkyl	I
,	O
lower	O
alkylsulfonyl	B
,	O
-NRaRb	B
,	O
-C	B
(	I
O	I
)	I
-NRaRb	I
,	O
-C	B
(	I
O	I
)	I
-heterocyclyl	I
,	O
benzyloxy	B
,	O
heterocyclyl	B
optionally	O
substituted	O
by	O
hydroxy	B
,	O
halogen	B
or	O
lower	O
alkyl	B
,	O
or	O
is	O
heteroaryl	B
optionally	O
substituted	O
by	O
lower	O
alkyl	B
;	O
Ra	O
and	O
Rb	O
are	O
independently	O
hydrogen	B
,	O
lower	O
alkylsulfonyl	B
,	O
-C	B
(	I
O	I
)	I
H	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
N	I
(	I
R	I
)	I
2	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
O	I
-	I
lower	I
alkyl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
S	I
-	I
lower	I
alkyl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
S	I
(	I
O	I
)	I
2-lower	I
alkyl	I
,	O
heteroarylsulfonyl	B
,	O
lower	O
alkyl	B
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
heterocyclyl	I
,	O
optionally	O
substituted	O
by	O
lower	O
alkyl	B
,	O
or	O
is	O
-	B
(	I
CH2	I
)	I
n	I
-	I
cycloalkyl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
heteroaryl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
OH	I
,	O
-	B
(	I
CO	I
)	I
-R	I
'	I
,	O
wherein	O
R	O
'	O
is	O
lower	O
alkyl	B
,	O
cycloalkyl	B
or	O
heteroaryl	B
;	O
R3	O
is	O
aryl	B
or	O
heteroaryl	B
,	O
which	O
are	O
optionally	O
substituted	O
by	O
halogen	B
or	O
lower	O
alkyl	B
substituted	O
by	O
halogen	B
;	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O

It	O
has	O
been	O
found	O
that	O
this	O
class	O
of	O
compounds	O
show	O
high	O
affinity	O
and	O
selectivity	O
for	O
GABA	B
α5	O
receptor	O
binding	O
sites	O
and	O
might	O
be	O
useful	O
as	O
cognitive	O
enhancer	O
or	O
for	O
the	O
treatment	O
of	O
cognitive	O
disorders	O
like	O
Alzheimer	O
's	O
disease	O
.	O

Aryl	B
-	I
isoxazolo-4-yl	I
-	I
oxadiazole	I
derivatives	O

The	O
present	O
invention	O
is	O
concerned	O
with	O
aryl	B
-	I
isoxazol-4-yl	I
-	I
imidazo	I
[	I
1,5-a	I
]	I
pyridine	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
:	O
R1	O
is	O
hydrogen	B
,	O
halogen	B
,	O
hydroxy	B
,	O
lower	O
alkyl	B
,	O
benzyloxy	B
or	O
-O-	B
(	I
CH2	I
)	I
-	I
(	I
CO	I
)	I
-5	I
or	O
6	O
membered	O
heteroaryl	B
optionally	O
substituted	O
by	O
aryl	B
and	O
lower	O
alkyl	B
;	O
R2	O
is	O
hydrogen	B
,	O
lower	O
alkyl	B
,	O
or	O
-	B
(	I
CO	I
)	I
-Ra	I
;	O
R3	O
is	O
hydrogen	B
,	O
halogen	B
,	O
cyano	B
,	O
lower	O
alkyl	B
,	O
or	O
-	B
(	I
CO	I
)	I
-Ra	I
;	O
Ra	O
is	O
hydroxy	B
,	O
lower	O
alkoxy	B
,	O
NR'R	B
'	I
'	I
,	O
wherein	O
R	O
'	O
and	O
R	O
'	O
'	O
are	O
each	O
independently	O
hydrogen	B
,	O
cycloalkyl	B
,	O
5	O
or	O
6-membered	O
heterocycloalkyl	B
or	O
lower	O
alkyl	B
optionally	O
substituted	O
by	O
cycloalkyl	B
,	O
cyano	B
,	O
5	O
or	O
6-membered	O
heterocycloalkyl	B
or	O
5	O
or	O
6-membered	O
heteroaryl	B
;	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O

It	O
has	O
been	O
found	O
that	O
this	O
class	O
of	O
compounds	O
show	O
high	O
affinity	O
and	O
selectivity	O
for	O
GABA	O
A	O
α5	O
receptor	O
binding	O
sites	O
and	O
might	O
be	O
useful	O
as	O
cognitive	O
enhancer	O
or	O
for	O
the	O
treatment	O
of	O
cognitive	O
disorders	O
like	O
Alzheimer	O
's	O
disease	O
.	O

Aryl	B
-	I
isoxazol-4-yl	I
-	I
imidazo	I
[	I
1	I
,	I
5-a	I
]	I
pyridine	I
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
dihydro-2,3-benzodiazepine	B
compounds	O
of	O
high	O
enantiomeric	O
purity	O
according	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
contain	O
an	O
asymmetric	O
centre	O
at	O
the	O
position	O
4	O
of	O
the	O
dihydro-2,3-benzodiazepine	B
compound	O
,	O
and	O
the	O
preparation	O
thereof	O
and	O
the	O
used	O
intermediates	O
as	O
well	O
.	O

These	O
compounds	O
have	O
anti	O
-	O
convulsiveA	O
muscle	O
relaxant	O
and	O
neuroprotective	O
effect	O
due	O
their	O
non	O
-	O
competitive	O
AMPA	O
antagonistic	O
properties	O
.	O

Optical	O
isomers	O
of	O
dihydro-2,3-benzodiazepines	B
and	O
their	O
stereoselective	O
synthesis	O

The	O
present	O
invention	O
is	O
concerned	O
with	O
co	O
-	O
crystalline	O
forms	O
of	O
sildenafil	B
,	O
processes	O
of	O
preparing	O
such	O
co	O
-	O
crystalline	O
forms	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
therapeutic	O
uses	O
thereof	O
and	O
methods	O
of	O
treatment	O
employing	O
the	O
same	O
.	O

Pharmaceutically	O
acceptable	O
co	O
-	O
crystalline	O
forms	O
of	O
sildenafil	B

A	O
quinazoline	B
derivative	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
formula	O
(	O
I	O
)	O
for	O
use	O
in	O
treatment	O
of	O
prevention	O
of	O
a	O
flaviviridae	O
infection	O
.	O

Triazoloanilinopyrimidine	B
derivatives	O
for	O
use	O
as	O
antiviral	O
agents	O

The	O
present	O
invention	O
includes	O
the	O
use	O
of	O
at	O
least	O
one	O
agent	O
which	O
induces	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
together	O
with	O
at	O
least	O
one	O
agent	O
which	O
gives	O
rise	O
to	O
inhibition	O
of	O
protein	O
disulfide	O
isomerase	O
(	O
PDI	O
)	O
or	O
GRP78	O
function	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
,	O
more	O
particularly	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cancer	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
agent	O
which	O
induces	O
ER	O
stress	O
together	O
with	O
at	O
least	O
one	O
agent	O
which	O
gives	O
rise	O
to	O
inhibition	O
of	O
PDI	O
or	O
GRP78	O
function	O
,	O
and	O
which	O
together	O
provide	O
a	O
therapeutic	O
effect	O
.	O

Use	O
in	O
an	O
alternative	O
treatment	O
of	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
hydrogen	B
,	O
tritium	B
,	O
hydroxy	B
,	O
amino	B
,	O
lower	O
alkyl	B
,	O
cycloalkyl	B
,	O
lower	O
alkoxy	B
,	O
halogen	B
,	O
cyano	B
,	O
lower	O
alkyl	B
substituted	O
by	O
halogen	B
,	O
lower	O
alkoxy	B
substituted	O
by	O
halogen	B
,	O
phenyl	B
,	O
O	B
-	I
phenyl	I
,	O
-S	B
-	I
phenyl	I
,	O
optionally	O
substituted	O
by	O
halogen	B
,	O
or	O
is	O
benzyl	B
,	O
benzyloxy	B
,	O
NHC	B
(	I
O	I
)	I
-lower	I
alkyl	B
or	O
pyridin-2,3	B
or	I
4-yl	I
;	O
R1	O
is	O
hydrogen	O
,	O
hydroxy	B
or	O
lower	O
alkyl	B
;	O
R2	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
aryl	B
is	O
an	O
aromatic	B
group	O
,	O
selected	O
from	O
phenyl	B
,	O
naphthalen-1-yl	B
or	O
naphthalen-2-yl	B
;	O
hetaryl	B
is	O
an	O
aromatic	B
group	O
,	O
containing	O
at	O
least	O
one	O
O	B
,	O
N	B
or	O
S	B
ring	O
atom	O
,	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
pyridine-3-yl	B
,	O
pyrazolyl	B
,	O
benzofuran-3-yl	B
,	O
benzofuran-4-yl	B
,	O
benzofuran-5-yl	B
,	O
benzofuran-6-yl	B
,	O
benzofuran-7-yl	B
,	O
thiophen-2-yl	B
,	O
thiophen-3-yl	B
,	O
benzo	B
[	I
b	I
]	I
thiophen-3-yl	I
or	O
indol-3-yl	B
;	O
n	O
is	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
or	O
5	O
;	O
when	O
n	O
is	O
2	O
,	O
3	O
,	O
4	O
or	O
5	O
,	O
R	O
may	O
be	O
the	O
same	O
or	O
not	O
;	O
the	O
dotted	O
line	O
may	O
be	O
a	O
bond	O
or	O
not	O
;	O
and	O
to	O
their	O
pharmaceutically	O
active	O
salts	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
anxiety	O
disorders	O
,	O
bipolar	O
disorder	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
stress	O
-	O
related	O
disorders	O
,	O
psychotic	O
disorders	O
such	O
as	O
schizophrenia	O
,	O
neurological	O
diseases	O
such	O
as	O
Parkinson	O
's	O
disease	O
,	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
epilepsy	O
,	O
migraine	O
,	O
hypertension	O
,	O
substance	O
abuse	O
and	O
metabolic	O
disorders	O
such	O
as	O
eating	O
disorders	O
,	O
diabetes	O
,	O
diabetic	O
complications	O
,	O
obesity	O
,	O
dyslipidemia	O
,	O
disorders	O
of	O
energy	O
consumption	O
and	O
assimilation	O
,	O
disorders	O
and	O
malfunction	O
of	O
body	O
temperature	O
homeostasis	O
,	O
disorders	O
of	O
sleep	O
and	O
circadian	O
rhythm	O
,	O
and	O
cardiovascular	O
disorders	O
.	O

Use	O
of	O
substituted	O
2-imidazole	B
of	O
imidazoline	B
derivatives	O

Disclosed	O
is	O
a	O
novel	O
process	O
for	O
production	O
of	O
lasofoxifene	B
,	O
nafoxidine	B
or	O
an	O
analogue	O
thereof	O
,	O
which	O
comprises	O
reduced	O
number	O
of	O
reaction	O
steps	O
,	O
has	O
a	O
high	O
efficiency	O
,	O
and	O
is	O
practically	O
advantageous	O
.	O

For	O
the	O
production	O
of	O
lasofoxifene	B
or	O
an	O
analogue	O
thereof	O
,	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
4	O
)	O
is	O
used	O
as	O
an	O
intermediate	O
.	O

The	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
4	O
)	O
can	O
be	O
produced	O
using	O
compounds	O
represented	O
by	O
the	O
formulae	O
(	O
1	O
)	O
to	O
(	O
3	O
)	O
as	O
starting	O
compounds	O
by	O
performing	O
the	O
coupling	O
of	O
the	O
three	O
components	O
in	O
one	O
step	O
.	O

Process	O
for	O
production	O
of	O
lasofoxifene	B
or	O
analogue	O
thereof	O

It	O
is	O
known	O
that	O
a	O
conventional	O
anticholinergic	O
agent	O
for	O
inhalation	O
administration	O
is	O
antagonistic	O
to	O
muscarinic	O
receptor	O
in	O
the	O
airway	O
smooth	O
muscle	O
and	O
further	O
migrates	O
from	O
airway	O
to	O
blood	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
concerned	O
that	O
there	O
is	O
a	O
possibility	O
that	O
dysuria	O
is	O
aggravated	O
by	O
prostatic	O
hyperplasia	O
via	O
blood	O
.	O

A	O
long	O
-	O
acting	O
inhaled	O
anticholinergic	O
agent	O
with	O
no	O
possibility	O
of	O
such	O
a	O
side	O
effect	O
has	O
been	O
demanded	O
.	O

A	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
(	O
wherein	O
all	O
symbols	O
represent	O
the	O
same	O
meaning	O
as	O
in	O
the	O
description	O
)	O
,	O
a	O
salt	O
thereof	O
or	O
a	O
solvate	O
thereof	O
exerts	O
an	O
effect	O
in	O
a	O
target	O
region	O
,	O
is	O
inactivated	O
rapidly	O
and	O
is	O
excellent	O
in	O
long	O
-	O
acting	O
property	O
,	O
therefore	O
,	O
it	O
is	O
useful	O
as	O
a	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
a	O
muscarinic	O
receptor	O
-	O
mediated	O
disease	O
with	O
fewer	O
side	O
effects	O
.	O

Tropane	B
compound	O
and	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
as	O
active	O
ingredient	O

The	O
invention	O
relates	O
to	O
new	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
and	O
methods	O
for	O
the	O
preparation	O
thereof	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
instant	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
combinations	O
comprising	O
flibanserin	B
as	O
one	O
active	O
ingredient	O
in	O
combination	O
with	O
at	O
least	O
one	O
additional	O
active	O
ingredient	O
for	O
the	O
treatment	O
ADHD	O
and	O
methods	O
for	O
the	O
preparation	O
thereof	O
.	O

Pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
attention	O
deficit	O
hyperactivity	O
disorder	O
comprising	O
flibanserin	B

An	O
agent	O
for	O
improving	O
the	O
hepatic	O
function	O
comprising	O
orniplabin	B
as	O
an	O
active	O
ingredient	O
.	O

Agent	O
for	O
improvement	O
of	O
hepatic	O
function	O

It	O
is	O
intended	O
to	O
provide	O
a	O
cancer	O
inhibitor	O
and	O
a	O
cancer	O
inhibitor	O
-	O
containing	O
product	O
capable	O
of	O
enhancing	O
the	O
potency	O
of	O
cancer	O
inhibitor	O
containing	O
fucoxanthin	B
and	O
providing	O
an	O
immediate	O
effect	O
,	O
and	O
a	O
process	O
for	O
producing	O
the	O
cancer	O
inhibitor	O
.	O

The	O
cancer	O
inhibitor	O
is	O
characterized	O
by	O
containing	O
cis	B
-	I
fucoxanthin	I
as	O
an	O
active	O
ingredient	O
.	O

The	O
cis	B
-	I
fucoxanthin	I
can	O
be	O
added	O
to	O
foods	O
,	O
supplements	O
,	O
feeds	O
for	O
pets	O
,	O
sanitary	O
products	O
,	O
cosmetics	O
,	O
or	O
drugs	O
.	O

Further	O
,	O
the	O
cis	B
-	I
fucoxanthin	I
can	O
be	O
one	O
obtained	O
by	O
combination	O
of	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
one	O
obtained	O
by	O
extraction	O
from	O
a	O
natural	O
product	O
followed	O
by	O
purification	O
,	O
one	O
obtained	O
by	O
organic	O
synthesis	O
and	O
one	O
obtained	O
by	O
synthesis	O
with	O
the	O
use	O
of	O
a	O
microorganism	O
.	O

Cancer	O
inhibitor	O
,	O
cancer	O
inhibitor	O
-	O
containing	O
product	O
and	O
process	O
for	O
producing	O
cancer	O
inhibitor	O

The	O
invention	O
relates	O
to	O
a	O
new	O
class	O
of	O
compounds	O
with	O
inhibitory	O
action	O
on	O
carnitine	O
palmitoyl	O
transferase	O
(	O
CPT	O
)	O
in	O
the	O
central	O
nervous	O
system	O
(	O
SNC	O
)	O
,	O
derived	O
from	O
trimetazidine	B
and	O
perhexiline	B
,	O
preferentially	O
selective	O
for	O
the	O
hepatic	O
form	O
of	O
CPT1	O
(	O
CPT1L	O
)	O
,	O
pharmaceutical	O
compounds	O
which	O
contain	O
at	O
least	O
one	O
new	O
compound	O
according	O
to	O
the	O
invention	O
,	O
and	O
their	O
therapeutic	O
use	O
in	O
the	O
treatment	O
and/or	O
in	O
the	O
prevention	O
of	O
obesity	O
,	O
hyperglycaemia	O
,	O
diabetes	O
and	O
disorders	O
associated	O
with	O
them	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
diabetic	O
retinopathy	O
,	O
diabetic	O
neuropathy	O
and	O
cardiovascular	O
disorders	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
also	O
used	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
heart	O
disorders	O
such	O
as	O
CHF	O
(	O
congestive	O
heart	O
failure	O
)	O
.	O

Inhibitors	O
of	O
cpt	O
in	O
the	O
central	O
nervous	O
system	O
as	O
antidiabetic	O
and/or	O
anti	O
-	O
obesity	O
drugs	O

Provided	O
are	O
methods	O
and	O
compositions	O
for	O
treating	O
ocular	O
conditions	O
characterized	O
by	O
the	O
presence	O
of	O
unwanted	O
choroidal	O
neovasculature	O
,	O
for	O
example	O
,	O
neovascular	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

The	O
selectivity	O
and	O
sensitivity	O
of	O
,	O
for	O
example	O
,	O
a	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
-based	O
approach	O
can	O
be	O
enhanced	O
by	O
combining	O
the	O
PDT	O
with	O
an	O
ansamycin	B
analog	O
or	O
heat	O
shock	O
protein	O
90	O
inhibitor	O
,	O
for	O
example	O
,	O
17-allylamino-17-demethoxygeldanamycin	B
.	O

Ansamycin	B
analogs	O
or	O
heat	O
shock	O
90	O
inhibitors	O
in	O
combination	O
with	O
pdt	O
treatin	O
conditions	O
of	O
the	O
eye	O

The	O
object	O
is	O
to	O
provide	O
:	O
a	O
microcapsule	O
which	O
contains	O
an	O
antibiotic	O
and	O
is	O
excellent	O
in	O
sustained	O
release	O
properties	O
,	O
biodegradability	O
and	O
adhesion	O
properties	O
;	O
a	O
method	O
for	O
production	O
of	O
the	O
microcapsule	O
;	O
and	O
a	O
stable	O
pasty	O
composition	O
comprising	O
the	O
microcapsule	O
.	O

Disclosed	O
are	O
:	O
an	O
adhesive	O
microcapsule	O
which	O
comprises	O
a	O
particle	O
and	O
an	O
adhesive	O
substance	O
layer	O
coated	O
on	O
the	O
surface	O
of	O
the	O
particle	O
,	O
wherein	O
the	O
particle	O
comprises	O
a	O
biodegradable	O
polymer	O
containing	O
an	O
antibiotic	O
;	O
a	O
method	O
for	O
production	O
of	O
the	O
microcapsule	O
;	O
and	O
a	O
composition	O
comprising	O
the	O
microcapsule	O
.	O

Adhesive	O
microcapsule	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
RA	O
in	O
subjects	O
in	O
need	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
kits	O
and	O
pharmaceutical	O
packs	O
comprising	O
compositions	O
and	O
dosage	O
forms	O
.	O

Use	O
of	O
vx-702	O
for	O
treating	O
rheumatoid	O
arthritis	O

This	O
invention	O
is	O
directed	O
to	O
treating	O
disease	O
states	O
or	O
conditions	O
associated	O
with	O
the	O
treatment	O
and	O
prevention	O
of	O
neurodegeneration	O
and	O
neurodegenerative	O
disease	O
states	O
,	O
and	O
treatment	O
of	O
radiation	O
damage	O
.	O

The	O
invention	O
relates	O
to	O
novel	O
phytonutrient	O
compositions	O
and	O
compounds	O
comprising	O
L	B
-	I
ergothioneine	I
and/or	O
selenium	B
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
of	O
administering	O
these	O
compositions	O
and	O
combinations	O
to	O
humans	O
or	O
animals	O
in	O
need	O
thereof	O
.	O

Phytonutrient	O
compositions	O
from	O
mushrooms	O
or	O
filamentous	O
fungi	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
describes	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
W	O
,	O
X	O
,	O
Y	O
,	O
Z	O
,	O
and	O
Q	O
are	O
defined	O
herein	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
the	O
prophylaxis	O
,	O
or	O
treatment	O
of	O
diseases	O
and	O
conditions	O
related	O
to	O
thrombin	O
activity	O
in	O
a	O
mammal	O
.	O

Pyridines	B
and	O
pyridine	B
n	I
-	I
oxides	I
as	O
modulators	O
of	O
thrombin	O

Disclosed	O
are	O
a	O
novel	O
oxazolidinone	B
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
and	O
an	O
antibacterial	O
agent	O
containing	O
the	O
oxazolidinone	B
derivative	O
.	O

(	O
I	O
)	O
[	O
In	O
the	O
formula	O
,	O
ring	O
A	O
may	O
be	O
substituted	O
or	O
fused	O
and	O
represents	O
(	O
A-1	O
)	O
at	O
least	O
7-membered	O
monocyclic	B
heterocyclic	I
ring	O
containing	O
at	O
least	O
three	O
N	B
atoms	O
,	O
(	O
A-2	O
)	O
at	O
least	O
6-membered	O
monocyclic	B
heterocyclic	I
ring	O
containing	O
at	O
least	O
two	O
N	B
atoms	O
and	O
at	O
least	O
one	O
O	B
atom	O
,	O
or	O
(	O
A-3	O
)	O
at	O
least	O
7-membered	O
monocyclic	B
heterocyclic	I
ring	O
containing	O
at	O
least	O
two	O
N	B
atoms	O
and	O
at	O
least	O
one	O
S	B
atom	O
;	O
X1	O
represents	O
a	O
single	O
bond	O
,	O
-O-	B
,	O
-S-	B
,	O
-NR2-	B
,	O
-CO-	B
,	O
-CS-	B
,	O
-CONR3-	B
,	O
-NR4CO-	B
,	O
-SO2NR5-	B
,	O
-NR6SO2-	B
(	O
wherein	O
R2-R6	O
independently	O
represent	O
a	O
hydrogen	B
or	O
a	O
lower	O
alkyl	B
)	O
,	O
or	O
a	O
lower	O
alkylene	B
or	O
lower	O
alkenylene	B
in	O
which	O
one	O
of	O
the	O
preceding	O
groups	O
may	O
intervene	O
;	O
ring	O
B	O
represents	O
an	O
optionally	O
substituted	O
carbon	B
ring	O
or	O
heterocyclic	B
ring	O
;	O
R1	O
represents	O
a	O
hydrogen	B
or	O
an	O
organic	O
residue	O
which	O
can	O
be	O
bonded	O
to	O
the	O
5-position	O
of	O
an	O
oxazolidinone	B
ring	O
of	O
an	O
oxazolidinone	B
antibacterial	O
agent	O
.	O
]	O

Novel	O
compound	O
having	O
heterocyclic	B
ring	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
a	O
method	O
of	O
modulating	O
β	O
amyloid	O
peptide	O
production	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
modulating	O
β	O
amyloid	O
peptide	O
production	O
by	O
downregulating	O
cleavage	O
of	O
the	O
β	O
amyloid	O
precursor	O
protein	O
to	O
produce	O
the	O
β	O
amyloid	O
protein	O
.	O

The	O
method	O
of	O
the	O
present	O
invention	O
is	O
useful	O
,	O
inter	O
alia	O
,	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
conditions	O
characterised	O
by	O
aberrant	O
,	O
unwanted	O
or	O
otherwise	O
inappropriate	O
Aβ	O
amyloidosis	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Down	O
's	O
Syndrome	O
and	O
cerebral	O
amyloid	O
angiopathy	O
.	O

A	O
method	O
of	O
modulating	O
beta	O
-	O
amyloid	O
peptide	O
production	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
G	O
and	O
R	O
to	O
R	O
and	O
R	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
claims	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
which	O
are	O
associated	O
with	O
the	O
modulation	O
of	O
H3	O
receptors	O
.	O

5-amido-2-carboxamide	B
indoles	I

This	O
invention	O
relates	O
to	O
17α	B
-	I
substituted	I
4-	I
(	I
3-oxoestra-4,9-dien-11β	I
-	I
yl	I
)	I
-benzoic	I
acids	I
and	O
derivatives	O
thereof	O
,	O
a	O
process	O
for	O
the	O
production	O
of	O
these	O
compounds	O
,	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
production	O
of	O
pharmaceutical	O
agents	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
that	O
contain	O
these	O
compounds	O
.	O

17α	B
-	I
SUBSTITUTED	I
4-	I
(	I
3-OXOESTRA-4,9-DIEN-11β	I
-	I
YL	I
)	I
-BENZOIC	I
ACID	I
,	O
ITS	O
DERIVATIVES	O
AND	O
PROCESS	O
FOR	O
ITS	O
PRODUCTION	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
obesity	O
,	O
eating	O
disorders	O
,	O
and	O
sexual	O
dysfunction	O
.	O

The	O
methods	O
comprise	O
administering	O
to	O
a	O
mammalian	O
host	O
suffering	O
from	O
obesity	O
,	O
an	O
eating	O
disorder	O
,	O
or	O
sexual	O
dysfunction	O
an	O
effective	O
dose	O
of	O
a	O
compound	O
of	O
the	O
invention	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
potentiating	O
the	O
effect	O
of	O
an	O
MC4	O
receptor	O
agonist	O
in	O
a	O
mammalian	O
host	O
.	O

In	O
some	O
cases	O
the	O
methods	O
comprise	O
administering	O
to	O
the	O
host	O
a	O
compound	O
that	O
lowers	O
the	O
EC50	O
of	O
the	O
agonist	O
.	O

In	O
other	O
cases	O
the	O
methods	O
comprise	O
administering	O
to	O
the	O
host	O
a	O
compound	O
that	O
increases	O
the	O
maximum	O
effect	O
of	O
the	O
agonist	O
.	O

Piperidine	B
and	O
piperazine	B
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
obesity	O
,	O
eating	O
disorders	O
and	O
sexual	O
dysfunction	O
by	O
potentiation	O
of	O
mc4	O
receptor	O
activity	O

Methods	O
and	O
compositions	O
for	O
modulating	O
blood	O
-	O
neural	O
barrier	O
(	O
BNB	O
)	O
for	O
the	O
treatment	O
of	O
CNS	O
conditions	O
such	O
as	O
edema	O
,	O
and	O
for	O
increased	O
drug	O
delivery	O
efficacy	O
across	O
the	O
BNB	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
improved	O
tPA	O
treatment	O
of	O
ischemic	O
cerebrovascular	O
and	O
related	O
diseases	O
in	O
combination	O
with	O
antagonism	O
of	O
the	O
PDGF	O
signaling	O
pathway	O
.	O

The	O
inventive	O
method	O
and	O
composition	O
is	O
particularly	O
suitable	O
for	O
conjunctive	O
therapy	O
of	O
ischemic	O
stroke	O
using	O
tPA	O
and	O
an	O
anti	O
-	O
PDGF	O
-	O
C	O
antagonist	O
or	O
an	O
anti	O
-	O
PDGFR	O
-	O
α	O
antagonist	O
.	O

Methods	O
and	O
compositions	O
for	O
modulation	O
of	O
blood	O
-	O
neural	O
barrier	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
functional	O
muscarinic	O
M1	O
/	O
M4	O
receptor	O
agonist	O
such	O
as	O
the	O
functional	O
muscarinic	O
M1	O
/	O
M4	O
receptor	O
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
particular	O
sabcomeline	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
for	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
schizophrenia	O
and	O
to	O
combination	O
therapies	O
for	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
schizophrenia	O
which	O
the	O
functional	O
muscarinic	O
M1	O
/	O
M4	O
receptor	O
agonist	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
particular	O
sabcomeline	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
at	O
least	O
one	O
other	O
neuroprotective	O
agent	O
and/or	O
neuroleptic	O
and/or	O
atypical	O
antipsyhcotic	O
agent	O
are	O
administered	O
adjunctively	O
or	O
simultaneously	O
.	O

The	O
invention	O
provides	O
methods	O
of	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
schizophrenia	O
utilising	O
such	O
therapies	O
and	O
such	O
adjunctive	O
or	O
simultaneous	O
therapeutic	O
combination	O
therapies	O
,	O
therapeutic	O
combinations	O
for	O
use	O
therein	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

Mono	O
and	O
combination	O
therapy	O
with	O
a	O
m1	O
/	O
m4	O
muscarinic	O
agonist	O
(	O
sabcomeline	B
)	O
for	O
treatment	O
of	O
cognitive	O
disorders	O
in	O
schizophrenia	O

Co	O
-	O
administration	O
of	O
alovudine	B
and	O
zidovudine	B
at	O
ratios	O
considerably	O
in	O
excess	O
of	O
the	O
prior	O
art	O
completely	O
or	O
substantially	O
abolishes	O
the	O
mitochondrial	O
toxicity	O
of	O
alovudine	B
in	O
mitochondrial	O
DNA	O
depletion	O
experiments	O
.	O

The	O
invention	O
thus	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
alovudine	B
and	O
zidovudine	B
in	O
a	O
molar	O
ratio	O
in	O
the	O
range	O
1	O
:	O
100	O
to	O
1	O
:	O
350	O
and	O
methods	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
multiply	O
resistant	O
HIV	O
comprising	O
the	O
simultaneous	O
or	O
consequential	O
administration	O
of	O
alovudine	B
and	O
zidovudine	B
in	O
the	O
characteristic	O
molar	O
ratio	O
.	O

Combination	O
of	O
alovudine	B
and	O
zidovudine	B
in	O
a	O
molar	O
ratio	O
of	O
1:100	O
to	O
1:350	O
.	O

The	O
present	O
invention	O
provides	O
intraocular	O
polymer	O
delivery	O
compositions	O
based	O
on	O
biodegradable	O
polyester	B
amide	I
(	O
PEA	B
)	O
,	O
polyester	B
urethane	I
(	O
PEUR	B
)	O
,	O
and	O
polyester	B
urea	I
(	O
PEU	B
)	O
polymers	O
,	O
which	O
contain	O
amino	B
acids	I
.	O

The	O
compositions	O
can	O
be	O
formulated	O
as	O
an	O
implantable	O
solid	O
or	O
as	O
a	O
liquid	O
dispersion	O
of	O
polymer	O
particles	O
for	O
sustained	O
delivery	O
of	O
ophthalmologic	O
agents	O
dispersed	O
therein	O
or	O
incorporated	O
into	O
the	O
backbone	O
of	O
the	O
polymers	O
.	O

Methods	O
of	O
delivering	O
an	O
ophthalmologic	O
agent	O
to	O
the	O
exterior	O
or	O
interior	O
of	O
the	O
eye	O
by	O
implanting	O
the	O
composition	O
in	O
the	O
eye	O
of	O
a	O
subject	O
are	O
also	O
included	O
.	O

Delivery	O
of	O
ophthalmologic	O
agents	O
to	O
the	O
exterior	O
or	O
interior	O
of	O
the	O
eye	O

Ubiquitin	O
-	O
proteasome	O
system	O
dysfunction	O
related	O
disorders	O
are	O
treated	O
by	O
administering	O
to	O
a	O
mammalian	O
patient	O
an	O
effective	O
amount	O
of	O
phosphatidylglycerol	B
presenting	O
bodies	O
of	O
a	O
size	O
resembling	O
that	O
of	O
an	O
apoptotic	O
cell	O
or	O
apoptotic	O
body	O
.	O

Said	O
phosphatidylglycerol	B
presenting	O
body	O
may	O
be	O
liposomal	O
while	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
dysfunction	O
related	O
disorders	O
include	O
dementia	O
with	O
Lewy	O
bodies	O
,	O
Pick	O
's	O
disease	O
,	O
progressive	O
supranuclear	O
palsy	O
,	O
corticobasal	O
degeneration	O
,	O
argyrophilic	O
grain	O
disease	O
,	O
frontotemporal	O
dementia	O
,	O
Gerstmann	O
-	O
Straussler	O
-	O
Scheinker	O
disease	O
,	O
spinocerebellar	O
ataxias	O
,	O
spinal	O
and	O
bulbar	O
muscular	O
ataxia	O
,	O
dentatorubal	O
and	O
pallidouysian	O
ataxia	O
and	O
Lafora	O
disease	O
.	O

Treatment	O
of	O
ubiquitin	O
-	O
proteasome	O
system	O
dysfunction	O
related	O
disorders	O

It	O
is	O
intended	O
to	O
provide	O
an	O
animal	O
model	O
which	O
contributes	O
to	O
the	O
clarification	O
of	O
a	O
disease	O
causing	O
a	O
decrease	O
in	O
bone	O
mass	O
and	O
bone	O
strength	O
such	O
as	O
osteoporosis	O
and	O
a	O
disease	O
causing	O
an	O
increase	O
in	O
bone	O
mass	O
and	O
bone	O
strength	O
,	O
utilization	O
thereof	O
and	O
so	O
on	O
.	O

More	O
specifically	O
,	O
a	O
transgenic	O
animal	O
having	O
an	O
osteoblast	O
-	O
specific	O
promoter	O
and	O
a	O
gene	O
encoding	O
Bcl	O
-	O
xL	O
which	O
have	O
been	O
transferred	O
thereinto	O
;	O
a	O
method	O
of	O
screening	O
a	O
substance	O
capable	O
of	O
increasing	O
bone	O
mass	O
and/or	O
bone	O
strength	O
with	O
the	O
use	O
of	O
this	O
transgenic	O
animal	O
;	O
a	O
method	O
of	O
screening	O
a	O
substance	O
capable	O
of	O
decreasing	O
bone	O
mass	O
and/or	O
bone	O
strength	O
with	O
the	O
use	O
of	O
this	O
transgenic	O
animal	O
;	O
and	O
an	O
agent	O
for	O
increasing	O
bone	O
mass	O
and	O
bone	O
strength	O
which	O
contains	O
a	O
gene	O
encoding	O
Bcl	O
-	O
xL	O
or	O
Bcl	O
-	O
xL.	O
Bcl	O
-	O
xL	O
TRANSGENIC	O
ANIMAL	O
AND	O
UTILIZATION	O
OF	O
THE	O
SAME	O

Modified	O
-	O
release	O
multimicroparticulate	O
pharmaceutical	O
form	O
capable	O
of	O
maintaining	O
the	O
modified	O
release	O
of	O
the	O
active	O
ingredient	O
in	O
an	O
alcoholic	O
solution	O
and	O
of	O
withstanding	O
attempts	O
at	O
misuse	O
.	O

Sustained	O
-	O
release	O
alcohol	B
-	O
resistant	O
multimicroparticulate	O
oral	O
pharmaceutical	O
form	O
comprising	O
anti	O
-	O
misuse	O
means	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
com-	O
prising	O
an	O
inhibitor	O
of	O
the	O
enzyme	O
7-dehydrocholesterol	B
reductase	O
(	O
DHCR7	O
)	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
ex-	O
cipient	O
.	O

This	O
pharmaceutical	O
composition	O
is	O
active	O
against	O
various	O
types	O
of	O
cancer	O
,	O
in	O
particular	O
but	O
not	O
limited	O
to	O
adenocarcinomas	O
of	O
the	O
upper	O
gastro	O
-	O
intestinal	O
tract	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
preparing	O
a	O
pharmaceutical	O
composition	O
suitable	O
for	O
the	O
treatment	O
of	O
an	O
adenocarcinoma	O
.	O

A	O
pharmaceutical	O
composition	O
suitable	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
method	O
of	O
preparing	O
said	O
pharmaceutical	O
composition	O

The	O
present	O
invention	O
relates	O
to	O
crystalline	O
forms	O
of	O
5-chloro-6-	B
{	I
2,6-difluoro-4-	I
[	I
3-	I
(	I
methylamino	I
)	I
propoxy	I
]	I
phenyl	I
}	I
-N-	I
[	I
(	I
1S	I
)	I
-2,2,2-	I
trifluoro-	I
1	I
-	I
methylethyl	I
]	I
[	I
l,2,4	I
]	I
triazolo	I
[	I
l,5-a	I
]	I
pyrimidin-7-amine	I
salts	O
;	O
processes	O
for	O
the	O
production	O
thereof	O
;	O
pharmaceutical	O
compositions	O
thereof	O
;	O
and	O
methods	O
for	O
inhibiting	O
tumor	O
growth	O
therewith	O
.	O

Crystalline	O
forms	O
of	O
5-chloro-6-	B
(	I
2	I
,	I
6-difluoro-4-	I
[	I
3-	I
(	I
methylamino	I
)	I
propoxy	I
]	I
phenyl	I
)	I
-n-	I
(	I
(	I
1s	I
)	I
-2	I
,	I
2	I
,	I
2,-trifluoro-1-methylethyl	I
]	I
[	I
1,2,4	I
]	I
triazolo	I
[	I
1,5-a	I
]	I
pyrimidin-7-amine	I
salts	O

Disclosed	O
herein	O
are	O
small	O
molecule	O
modulators	O
hormone	O
receptors	O
,	O
including	O
agonists	O
and	O
antagonists	O
of	O
luteinizing	O
hormone	O
/	O
choriogonadotropin	O
,	O
follicle	O
stimulating	O
hormone	O
and	O
thyroid	O
stimulating	O
hormone	O
receptors	O
.	O

Exemplary	O
disclosed	O
compounds	O
include	O
those	O
of	O
the	O
formula	O
wherein	O
X	O
is	O
-S	B
(	I
O	I
)	I
nR5	I
;	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
Y	O
is	O
-OR6	B
or	O
-NR7R8	B
R1	O
and	O
R2	O
independently	O
are	O
selected	O
from	O
optionally	O
substituted	O
lower	O
aliphatic	B
,	O
alkoxy	B
,	O
aralkyl	B
,	O
halogen	B
,	O
H	B
and	O
-OR5	B
,	O
wherein	O
R5	O
is	O
selected	O
from	O
lower	O
alkyl	B
,	O
H	B
,	O
aralkyl	B
,	O
acyl	B
,	O
alkoxycarbonyl	B
and	O
aminocarbonyl	B
;	O
R3	O
and	O
R4	O
independently	O
are	O
selected	O
from	O
acyl	B
,	O
alkoxycarbonyl	B
,	O
aminocarbonyl	B
,	O
aralkyl	B
,	O
H	B
,	O
lower	O
alkyl	B
and	O
cycloalkyl	B
;	O
R5	O
is	O
selected	O
from	O
lower	O
alkyl	B
,	O
aralkyl	B
,	O
cycloalkyl	B
and	O
haloalkyl	B
;	O
R6	O
is	O
selected	O
from	O
H	B
,	O
lower	O
alkyl	B
and	O
aralkyl	B
;	O
R7	O
and	O
R8	O
independently	O
are	O
selected	O
from	O
H	B
,	O
lower	O
alkyl	B
,	O
aralkyl	B
and	O
cycloalkyl	B
.	O

Pyrimidine	B
low	O
molecular	O
weight	O
ligands	O
for	O
modulating	O
hormone	O
receptors	O

The	O
invention	O
relates	O
to	O
substituted	O
heterocycles	B
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
their	O
use	O
for	O
treatment	O
and/or	O
prophylaxis	O
of	O
disorders	O
and	O
to	O
their	O
use	O
for	O
producing	O
medicaments	O
for	O
treatment	O
and/or	O
prophylaxis	O
of	O
disorders	O
,	O
especially	O
of	O
thromboembolic	O
disorders	O
.	O

Substituted	O
heterocycles	B
and	O
use	O
thereof	O

A	O
process	O
for	O
production	O
of	O
a	O
piperidine	B
compound	O
having	O
a	O
syn	O
-	O
configuration	O
represented	O
by	O
the	O
general	O
formula	O
[	O
I	O
]	O
or	O
a	O
salt	O
thereof	O
,	O
comprising	O
reducing	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
[	O
II	O
]	O
.	O

[	O
I	O
]	O
wherein	O
the	O
solid	O
bold	O
line	O
represents	O
such	O
a	O
bond	O
that	O
each	O
of	O
the	O
substituents	O
at	O
position-2	O
and	O
position-4	O
in	O
the	O
piperidine	B
ring	O
can	O
have	O
a	O
syn	O
-	O
configuration	O
;	O
and	O
other	O
variable	O
symbols	O
are	O
as	O
defined	O
above	O
.	O

[	O
II	O
]	O
wherein	O
the	O
ring	O
A	O
represents	O
a	O
benzene	O
ring	O
which	O
may	O
have	O
a	O
substituent	O
;	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
hydroxyl	B
group	O
which	O
may	O
have	O
a	O
substituent	O
,	O
an	O
amino	B
group	O
which	O
may	O
have	O
a	O
substituent	O
,	O
an	O
alkyl	B
groupwhich	O
may	O
have	O
a	O
substituent	O
,	O
a	O
carbonyl	B
group	O
which	O
has	O
a	O
substituent	O
,	O
or	O
a	O
halogen	B
atom	O
;	O
and	O
M	O
represents	O
an	O
alkali	B
metal	I
or	O
a	O
hydrogen	B
atom	O
.	O

Process	O
for	O
production	O
of	O
optically	O
active	O
piperidine	B
compound	O

Compounds	O
of	O
formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
:	O
[	O
Chemical	O
formula	O
should	O
be	O
inserted	O
here	O
.	O

Please	O
see	O
paper	O
copy	O
]	O

I	O
wherein	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
specification	O
as	O
well	O
as	O
salts	O
and	O
pharmaceutical	O
compositions	O
including	O
the	O
compounds	O
are	O
prepared	O
.	O

They	O
are	O
useful	O
in	O
therapy	O
,	O
in	O
particular	O
in	O
the	O
management	O
of	O
pain	O
.	O

Isoindole	B
derivatives	O
useful	O
for	O
treating	O
pain	O
,	O
gastrointestinal	O
diseases	O
and	O
cancer	O

A	O
pharmaceutical	O
preparation	O
comprising	O
as	O
an	O
active	O
ingredient	O
micron	O
-	O
sized	O
sulphur	O
particles	O
[	O
-	O
(	O
300	O
microns	O
]	O
.	O

The	O
pharmaceutical	O
preparation	O
further	O
comprises	O
an	O
excipient	O
,	O
i.e.	O
a	O
sodium	B
lignin	I
sulphate	I
or	O
other	O
suitable	O
agents	O
.	O

The	O
preparation	O
is	O
used	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
pathogenic	O
disorders	O
in	O
humans	O
and	O
animals	O
,	O
in	O
a	O
nutritional	O
and/or	O
supplemental	O
regime	O
,	O
as	O
well	O
as	O
,	O
to	O
improve	O
feed	O
and	O
reproductive	O
performance	O
.	O

A	O
variety	O
of	O
conditions	O
were	O
treated	O
including	O
:	O
pneumonia	O
,	O
arthritis	O
,	O
ulcers	O
,	O
diabetes	O
mellitus	O
,	O
GI	O
cancer	O
,	O
lupus	O
,	O
herpes	O
,	O
psoriasis	O
and	O
early	O
menopause	O
.	O

Pathogenic	O
attenuation	O
via	O
the	O
administration	O
of	O
an	O
equilibiotic	O
compound	O

A	O
series	O
of	O
5,6-dihydro-1-benzothiophen-7	B
(	I
4H	I
)	I
-one	I
derivatives	O
,	O
and	O
analogues	O
thereof	O
,	O
which	O
are	O
substituted	O
in	O
the	O
2-position	O
by	O
an	O
optionally	O
substituted	O
morpholin-4-yl	B
moiety	O
,	O
being	O
selective	O
inhibitors	O
of	O
PI3	O
kinase	O
enzymes	O
,	O
are	O
accordingly	O
of	O
benefit	O
in	O
medicine	O
,	O
for	O
example	O
in	O
the	O
treatment	O
of	O
inflammatory	O
,	O
autoimmune	O
,	O
cardiovascular	O
,	O
neurodegenerative	O
,	O
metabolic	O
,	O
oncological	O
,	O
nociceptive	O
or	O
ophthalmic	O
conditions	O
.	O

Fused	B
thiophene	I
derivatives	O
as	O
kinase	O
inhibitors	O

A	O
method	O
of	O
treating	O
a	O
patient	O
suffering	O
from	O
a	O
cancer	O
,	O
such	O
as	O
ovarian	O
,	O
renal	O
,	O
head	O
&	O
neck	O
,	O
hepatocellular	O
,	O
thyroid	O
,	O
esophageal	O
,	O
large	O
bowel	O
,	O
pancreatic	O
,	O
mesothelioma	O
,	O
carcinoma	O
,	O
sarcoma	O
and	O
melanoma	O
,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Definitions	O
for	O
the	O
variables	O
are	O
provided	O
herein	O
.	O

Compounds	O
for	O
treating	O
cancers	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
hot	O
flashes	O
by	O
administering	O
a	O
muscarinic	O
receptor	O
antagonist	O
.	O

The	O
method	O
is	O
useful	O
for	O
treating	O
peri-	O
and	O
post	O
-	O
menopausal	O
women	O
,	O
including	O
women	O
who	O
have	O
undergone	O
surgically	O
induced	O
menopause	O
.	O

Treatment	O
of	O
hot	O
flashes	O
using	O
muscarinic	O
receptor	O
antagonists	O
such	O
as	O
oxybutynin	B

The	O
present	O
invention	O
relates	O
to	O
antimicrobial	O
carbon	B
and	O
to	O
its	O
use	O
,	O
especially	O
for	O
treating	O
diseases	O
and	O
toxications	O
of	O
the	O
gastrointestinal	O
tracts	O
,	O
in	O
particular	O
diarrhoea	O
.	O

Antimicrobial	O
carbon	B

An	O
aqueous	O
ophthalmic	O
composition	O
comprising	O
a	O
branched	O
glycerol	B
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
branched	O
,	O
glycerol	B
monoalkyl	I
ether	I
,	O
a	O
branched	O
,	O
glycerol	B
monoalkyl	I
amine	I
,	O
a	O
branched	O
,	O
glycerol	B
monoalkyl	I
sulfide	I
,	O
or	O
any	O
mixture	O
thereof	O
,	O
present	O
in	O
a	O
total	O
amount	O
of	O
from	O
0.05	O
ppm	O
to	O
1,000	O
ppm	O
;	O
a	O
cationic	O
antimicrobial	O
component	O
,	O
and	O
having	O
an	O
osmolality	O
in	O
a	O
range	O
from	O
200	O
mOsmol	O
/	O
kg	O
to	O
400	O
mOsmol	O
/	O
kg	O
.	O

The	O
presence	O
of	O
the	O
branched	O
glycerol	B
compound	O
enhances	O
the	O
biocidal	O
efficacy	O
of	O
the	O
aqueous	O
ophthalmic	O
composition	O
containing	O
one	O
or	O
more	O
cationic	O
antimicrobial	O
components	O
.	O

Ophthalmic	O
compositions	O
comprising	O
a	O
branched	O
,	O
glycerol	B
compound	O
and	O
a	O
cationic	O
antimicrobial	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
salts	O
and	O
solvates	O
thereof	O
are	O
provided	O
:	O
wherein	O
either	O
1	O
)	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
and	O
all	O
methyl	B
,	O
or	O
2	O
)	O
R1	O
and	O
R2	O
form	O
a	O
pyrrolidinyl	B
group	O
and	O
R3	O
and	O
R4	O
are	O
both	O
methyl	B
,	O
or	O
3	O
)	O
R1	O
and	O
R2	O
are	O
both	O
methyl	B
and	O
R3	O
and	O
R4	O
together	O
form	O
a	O
cyclopentyl	B
group	O
.	O

Uses	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
treating	O
neurological	O
and	O
neuropsychiatric	O
disorders	O
,	O
such	O
as	O
psychoses	O
,	O
dementia	O
or	O
attention	O
deficit	O
disorder	O
,	O
and	O
processes	O
to	O
make	O
these	O
compounds	O
and	O
pharmaceutical	O
formulations	O
thereof	O
are	O
also	O
disclosed	O
.	O

Glycine	B
transporter	O
inhibiting	O
compounds	O
and	O
uses	O
in	O
medicine	O

The	O
invention	O
encompasses	O
therapeutic	O
compositions	O
containing	O
a	O
pentavalent	O
antimonial	O
composition	O
.	O

The	O
pentavalent	O
antimonial	O
can	O
be	O
sodium	B
stibogluconate	I
and	O
pentamidine	B
and	O
biological	O
equivalents	O
of	O
said	O
compounds	O
.	O

The	O
therapeutic	O
composition	O
of	O
this	O
embodiment	O
contains	O
an	O
effective	O
amount	O
of	O
pentavalent	O
antimonial	O
that	O
can	O
be	O
used	O
in	O
treating	O
infectious	O
diseases	O
.	O

The	O
types	O
of	O
diseases	O
that	O
can	O
be	O
treated	O
with	O
the	O
present	O
invention	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
the	O
following	O
:	O
diseases	O
associated	O
with	O
PTPase	O
activity	O
,	O
immune	O
deficiency	O
,	O
cancer	O
,	O
infections	O
(	O
such	O
as	O
viral	O
infections	O
)	O
,	O
hepatitis	O
B	O
,	O
and	O
hepatitis	O
C.	O
The	O
therapeutic	O
composition	O
enhances	O
cytokine	O
activity	O
.	O

The	O
therapeutic	O
composition	O
may	O
include	O
a	O
cytokine	O
,	O
such	O
as	O
interferon	O
α	O
,	O
interferon	O
β	O
,	O
interferon	O
γ	O
,	O
or	O
granulocyte	O
/	O
macrophage	O
colony	O
stimulating	O
factor	O
.	O

The	O
composition	O
may	O
also	O
include	O
a	O
second	O
agent	O
for	O
treating	O
hepatitis	O
.	O

Therapeutic	O
compositions	O
and	O
methods	O
useful	O
in	O
treating	O
hepatitis	O

Disclosed	O
herein	O
are	O
non	O
-	O
competitive	O
NMDA	O
receptor	O
antagonists	O
having	O
chemical	O
structures	O
similar	O
to	O
that	O
of	O
phencyclidine	B
(	O
PCP	O
)	O
.	O

These	O
antagonists	O
contain	O
a	O
polycyclic	O
ring	O
structure	O
in	O
place	O
of	O
the	O
cycloalkyl	B
ring	O
of	O
PCP	O
.	O

The	O
antagonists	O
also	O
differ	O
from	O
PCP	O
in	O
that	O
they	O
include	O
an	O
electron	O
withdrawing	O
group	O
,	O
a	O
hydroxyl	B
group	O
,	O
or	O
an	O
amine	B
group	O
at	O
the	O
para	O
position	O
of	O
the	O
phenyl	B
ring	O
.	O

The	O
antagonists	O
disclosed	O
herein	O
are	O
useful	O
for	O
treating	O
or	O
ameliorating	O
a	O
symptom	O
of	O
ailments	O
associated	O
with	O
over	O
excitation	O
of	O
cells	O
(	O
e.g.	O
,	O
neurons	O
)	O
that	O
express	O
NMDA	O
receptors	O
.	O

Examples	O
of	O
ailments	O
that	O
can	O
be	O
treated	O
and	O
for	O
which	O
symptoms	O
can	O
be	O
ameliorated	O
include	O
epilepsy	O
,	O
neurodegenerative	O
disease	O
(	O
e.g.	O
,	O
Alzheimer	O
's	O
and	O
Parkinson	O
's	O
diseases	O
)	O
,	O
drug	O
addiction	O
,	O
neuropathic	O
pain	O
,	O
and	O
neuronal	O
and	O
glutamate-	B
dependent	O
tumors	O
.	O

Non	O
-	O
competitive	O
nmda	O
receptor	O
antagonists	O

The	O
subject	O
invention	O
provides	O
stereoisomeric	O
compounds	O
of	O
formula	O
(	O
X	O
)	O
:	O
wherein	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
,	O
and	O
compositions	O
for	O
the	O
safe	O
and	O
effective	O
treatment	O
of	O
various	O
gastrointestinal	O
disorders	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
gastroparesis	O
,	O
gastroesophageal	O
reflux	O
and	O
related	O
conditions	O
.	O

The	O
compounds	O
of	O
the	O
subject	O
invention	O
are	O
also	O
useful	O
in	O
treating	O
a	O
variety	O
of	O
conditions	O
involving	O
the	O
central	O
nervous	O
system	O
.	O

Piperidine	B
derivatives	O
for	O
the	O
treatment	O
of	O
gastrointestinal	O
and	O
cns	O
disorders	O

[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
novel	O
anion	O
adsorbent	O
with	O
extremely	O
high	O
anion	O
adsorption	O
capacity	O
,	O
composed	O
mainly	O
of	O
iron	O
being	O
a	O
metal	O
excelling	O
in	O
biological	O
safety	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
There	O
is	O
provided	O
an	O
anion	O
adsorbent	O
characterized	O
by	O
containing	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
amorphous	O
ferric	B
hydroxide	I
produced	O
in	O
the	O
presence	O
of	O
ferrous	O
species	O
.	O

Anion	O
adsorbent	O
,	O
water	O
or	O
soil	O
cleanup	O
agent	O
and	O
process	O
for	O
producing	O
the	O
same	O

A	O
method	O
and	O
composition	O
for	O
cleaning	O
and	O
topical	O
treatment	O
of	O
the	O
scalp	O
in	O
psoriasis	O
.	O

The	O
composition	O
includes	O
oli	O
oil	O
and	O
vinegar	O
with	O
optional	O
essential	O
oils	O
.	O

The	O
method	O
includes	O
topical	O
application	O
optionally	O
followed	O
by	O
combing	O
.	O

A	O
method	O
and	O
composition	O
for	O
treating	O
the	O
scalp	O

The	O
invention	O
pertains	O
to	O
heteroaromatic	B
compounds	O
of	O
the	O
formula	O
I	O
,	O
as	O
defined	O
herein	O
,	O
that	O
serve	O
as	O
effective	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibitors	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
said	O
compounds	O
which	O
are	O
selective	O
inhibitors	O
of	O
PDE10	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
;	O
and	O
the	O
use	O
of	O
said	O
compounds	O
in	O
a	O
method	O
for	O
treating	O
certain	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
or	O
other	O
disorders	O
.	O

Selective	O
azole	B
pde10a	O
inhibitor	O
compounds	O

Methods	O
for	O
identifying	O
subjects	O
who	O
could	O
benefit	O
therapeutically	O
from	O
administration	O
of	O
a	O
high	O
specificity	O
cytokine	O
inhibitor	O
are	O
provided	O
.	O

Subjects	O
that	O
are	O
identified	O
include	O
those	O
that	O
are	O
eligible	O
,	O
based	O
on	O
pre	O
-	O
determined	O
criteria	O
,	O
for	O
a	O
spinal	O
device	O
or	O
fusion	O
procedure	O
,	O
such	O
as	O
the	O
implantation	O
of	O
a	O
nucleus	O
replacement	O
device	O
,	O
an	O
annular	O
repair	O
device	O
,	O
or	O
a	O
fusion	O
device	O
.	O

Methods	O
of	O
preventing	O
such	O
procedures	O
or	O
improving	O
the	O
outcome	O
of	O
such	O
procedures	O
are	O
also	O
provided	O
,	O
and	O
include	O
administering	O
a	O
TAT	O
to	O
the	O
subject	O
by	O
any	O
route	O
or	O
regimen	O
of	O
administration	O
,	O
including	O
the	O
regimens	O
described	O
herein	O
.	O

Methods	O
for	O
preventing	O
,	O
postponing	O
or	O
improving	O
the	O
outcome	O
of	O
spinal	O
device	O
and	O
fusion	O
procedures	O

The	O
use	O
of	O
substituted	O
amides	B
for	O
modulating	O
the	O
activity	O
of	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
(	O
11βHSD1	O
)	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
pharmaceutical	O
compositions	O
,	O
are	O
described	O
.	O

Also	O
a	O
novel	O
class	O
of	O
substituted	O
amides	B
,	O
of	O
the	O
general	O
formula	O
I.	O
Their	O
use	O
in	O
therapy	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
as	O
well	O
as	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
medicaments	O
are	O
described	O
.	O

The	O
present	O
compounds	O
are	O
modulators	O
and	O
more	O
specifically	O
inhibitors	O
of	O
the	O
activity	O
of	O
11βHSDI	O
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
range	O
of	O
medical	O
disorders	O
where	O
a	O
decreased	O
intracellular	O
concentration	O
of	O
active	O
glucocorticoid	B
is	O
desirable	O
.	O

11beta	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
active	O
compounds	O

The	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
breast	O
cancer	O
which	O
comprises	O
administration	O
of	O
fulvestrant	B
and	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
treatment	O
with	O
an	O
aromatase	O
inhibitor	O
,	O
for	O
example	O
anastrozole	B
,	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
wherein	O
the	O
patient	O
has	O
hormone	O
receptor	O
positive	O
early	O
breast	O
cancer	O
.	O

Use	O
of	O
fulvestrant	B
and	O
an	O
aromatase	O
inhibitor	O
for	O
treating	O
breast	O
cancer	O

The	O
present	O
invention	O
concerns	O
a	O
method	O
of	O
enhancing	O
the	O
numbers	O
and	O
activity	O
of	O
naturally	O
occurring	O
CD4+CD25	O
+	O
regulatory	O
T	O
cells	O
using	O
statins	B
,	O
e.g.	O
atorvastatin	B
.	O

Treatment	O
with	O
statins	O
increases	O
the	O
number	O
of	O
Tregs	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
concomitant	O
upregulation	O
of	O
their	O
master	O
transcriptional	O
activator	O
foxp3	O
.	O

The	O
invention	O
further	O
concerns	O
a	O
method	O
of	O
treatment	O
of	O
diseases	O
which	O
are	O
characterized	O
by	O
an	O
impaired	O
function	O
of	O
Tregs	O
.	O

Enhancement	O
of	O
regulatory	O
t	O
cells	O
'	O
activity	O
using	O
statins	O

The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
formulations	O
comprising	O
an	O
anti	O
-	O
inflammatory	O
glucocorticoid	B
compound	O
of	O
formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
,	O
(	O
V	O
)	O
or	O
a	O
solvate	O
thereof	O
and	O
a	O
compound	O
for	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
or	O
solvate	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
therapeutic	O
uses	O
thereof	O
,	O
particularly	O
for	O
the	O
treatment	O
of	O
inflammatory	O
and	O
allergic	O
conditions	O
,	O
specifically	O
rhinitis	O
.	O

Pharmaceutical	O
formulations	O
comprising	O
azelastine	B
and	O
a	O
corticosteroid	B
for	O
the	O
treatment	O
of	O
inflammatory	O
or	O
allergic	O
conditions	O

The	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
and	O
formula	O
II	O
,	O
their	O
preparation	O
,	O
a	O
their	O
use	O
as	O
pharmaceutically	O
active	O
immunosuppressive	O
agents	O
for	O
the	O
treatment	O
of	O
autoimmune	O
disorders	O
,	O
organ	O
transplant	O
rejection	O
,	O
disorders	O
associated	O
with	O
an	O
activated	O
immune	O
system	O
,	O
as	O
well	O
as	O
other	O
disorders	O
modulated	O
by	O
lymphopenia	O
or	O
SlP	O
receptors	O
.	O

Agonists	O
of	O
the	O
sphingosine-	B
1-	I
phosphate	I
receptor	O
(	O
slp	O
)	O

Provided	O
herein	O
are	O
deuterated	O
amphetamines	B
,	O
processes	O
of	O
preparation	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
management	O
of	O
trauma	O
associated	O
with	O
a	O
terminal	O
disease	O
,	O
a	O
post	O
-	O
traumatic-	O
stress	O
-	O
disorder	O
,	O
or	O
a	O
psychological	O
disorder	O
.	O

Preparation	O
and	O
utility	O
of	O
deuterated	O
amphetamines	B

The	O
present	O
invention	O
provides	O
an	O
antiretroviral	O
solid	O
oral	O
composition	O
comprising	O
one	O
or	O
more	O
antiretroviral	O
drugs	O
,	O
for	O
example	O
protease	O
inhibitors	O
such	O
as	O
lopinavir	B
,	O
ritonavir	B
or	O
a	O
combination	O
thereof	O
with	O
one	O
or	O
more	O
excipients	O
.	O

The	O
invention	O
provides	O
a	O
composition	O
which	O
is	O
smaller	O
for	O
a	O
given	O
amount	O
of	O
said	O
active	O
substance	O
and	O
possesses	O
taste	O
masking	O
property	O
and	O
a	O
process	O
for	O
preparing	O
the	O
composition	O
.	O

The	O
present	O
invention	O
also	O
provides	O
an	O
antiretroviral	O
solid	O
oral	O
composition	O
comprising	O
one	O
or	O
more	O
antiretroviral	O
drugs	O
,	O
for	O
example	O
protease	O
inhibitors	O
such	O
as	O
lopinavir	B
,	O
ritonavir	B
or	O
a	O
combination	O
thereof	O
with	O
at	O
least	O
one	O
water	O
insoluble	O
polymer	O
,	O
wherein	O
the	O
ratio	O
of	O
drug	O
to	O
polymer	O
in	O
the	O
composition	O
ranges	O
from	O
about	O
1	O
:1	O
to	O
about	O
1	O
:	O
6	O
,	O
and	O
a	O
process	O
for	O
preparing	O
the	O
composition	O
.	O

Antiretroviral	O
solid	O
oral	O
composition	O
with	O
at	O
least	O
one	O
water	O
insoluble	O
polymer	O

It	O
is	O
intended	O
to	O
provide	O
a	O
therapeutic	O
agent	O
effective	O
in	O
a	O
pigmented	O
skin	O
lesion	O
.	O

The	O
therapeutic	O
agent	O
for	O
a	O
pigmented	O
skin	O
lesion	O
containing	O
artocarpin	B
as	O
an	O
active	O
ingredient	O
.	O

Examples	O
of	O
the	O
pigmented	O
skin	O
lesion	O
includes	O
not	O
only	O
a	O
cafe	O
-	O
au	O
-	O
lait	O
spot	O
of	O
Von	O
Recklinghausen	O
disease	O
,	O
a	O
small	O
Recklinghausen	O
spot	O
and	O
neurofibroma	O
,	O
but	O
also	O
seborrheic	O
keratosis	O
and	O
senile	O
pigmented	O
spot	O
which	O
are	O
basically	O
caused	O
by	O
hypermorphosis	O
by	O
the	O
age	O
-	O
related	O
change	O
of	O
epidermis	O
but	O
clinically	O
considered	O
as	O
a	O
pigmented	O
lesion	O
of	O
skin	O
,	O
nevoid	O
pigmentation	O
disorders	O
such	O
as	O
nevus	O
spilus	O
,	O
melanocytic	O
nevus	O
,	O
Ota	O
's	O
nevus	O
,	O
blue	O
nevus	O
and	O
ectopic	O
mongolian	O
spot	O
,	O
postinflammatory	O
pigmentation	O
and	O
the	O
like	O
.	O

Therapeutic	O
agent	O
for	O
pigmented	O
skin	O
lesion	O

Disclosed	O
is	O
a	O
pharmaceutical	O
product	O
having	O
sugar	B
production	O
inhibiting	O
activity	O
,	O
which	O
is	O
useful	O
for	O
prevention	O
and	O
treatment	O
of	O
diabetes	O
.	O

This	O
pharmaceutical	O
product	O
contains	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

(	O
I	O
)	O
(	O
II	O
)	O
[	O
In	O
the	O
formula	O
(	O
I	O
)	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
represent	O
a	O
hydrogen	B
atom	O
,	O
an	O
optionally	O
substituted	O
lower	O
alkoxy	B
or	O
the	O
like	O
;	O
R5	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
n	O
represents	O
an	O
integer	O
such	O
as	O
4	O
;	O
and	O
A	O
represents	O
a	O
group	O
represented	O
by	O
the	O
formula	O
(	O
II	O
)	O
above	O
or	O
the	O
like	O
.	O

(	O
In	O
the	O
formula	O
(	O
II	O
)	O
,	O
p	O
represents	O
0	O
or	O
the	O
like	O
;	O
q	O
represents	O
1	O
or	O
the	O
like	O
;	O
and	O
X	O
represents	O
a	O
sulfur	B
atom	O
,	O
-N	B
(	I
R6	I
)	I
,	O
or	O
-C	B
(	I
R7	I
)	I
(	I
R8	I
)	I
-	I
,	O
wherein	O
R6	O
represents	O
an	O
optionally	O
substituted	O
lower	O
alkyl	B
or	O
the	O
like	O
;	O
R7	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
and	O
R8	O
represents	O
a	O
hydroxy	B
,	O
an	O
optionally	O
substituted	O
lower	O
alkyl	B
or	O
the	O
like	O
.	O
)	O
]	O
Phthalide	B
derivative	O
and	O
salt	O
thereof	O

Methods	O
and	O
compositions	O
for	O
promoting	O
coupling	O
between	O
bone	O
formation	O
and	O
bone	O
resorption	O
are	O
provided	O
.	O

The	O
method	O
related	O
to	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
rho	O
inhibitor	O
,	O
a	O
Transforming	O
Growth	O
Factor	O
ß	O
receptor	O
I	O
(	O
TßRI	O
)	O
inhibitor	O
or	O
a	O
combination	O
thereof	O
to	O
a	O
subject	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
useful	O
,	O
for	O
example	O
,	O
in	O
a	O
subject	O
with	O
a	O
disorder	O
linked	O
to	O
an	O
imbalance	O
between	O
bone	O
formation	O
and	O
bone	O
resorption	O
.	O

Methods	O
for	O
promoting	O
coupling	O
between	O
bone	O
formation	O
and	O
resorption	O

The	O
present	O
invention	O
relates	O
to	O
a	O
propellant	O
-	O
gas	O
-	O
free	O
aerosol	O
formulation	O
which	O
comprises	O
one	O
or	O
more	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
in	O
which	O
the	O
radicals	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
X	O
'	O
can	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
in	O
the	O
description	O
for	O
inhalation	O
.	O

Aerosol	O
formulation	O
for	O
the	O
inhalation	O
of	O
beta	O
-	O
agonists	O

Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
,	O
which	O
selectively	O
accelerates	O
biosynthesis	O
of	O
a	O
proteoglycan	O
,	O
particularly	O
a	O
chondroitin	B
sulfate	I
proteoglycan	O
or	O
a	O
heparan	B
sulfate	I
proteoglycan	O
.	O

Also	O
disclosed	O
is	O
a	O
pharmaceutical	O
product	O
containing	O
such	O
a	O
compound	O
as	O
an	O
active	O
ingredient	O
.	O

(	O
I	O
)	O
(	O
In	O
the	O
formula	O
,	O
R	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
optionally	O
substituted	O
alkyl	B
,	O
an	O
optionally	O
substituted	O
aryl	B
,	O
an	O
optionally	O
substituted	O
heteroaryl	B
,	O
or	O
a	O
peptide	O
residue	O
composed	O
of	O
a	O
natural	O
or	O
non	O
-	O
natural	O
amino	B
acid	I
;	O
and	O
X	O
and	O
Y	O
represent	O
a	O
halogen	B
atom	O
,	O
a	O
hydroxy	B
group	O
or	O
an	O
alkoxy	B
group	O
.	O

In	O
this	O
connection	O
,	O
at	O
least	O
one	O
of	O
X	O
and	O
Y	O
represents	O
a	O
hydroxy	B
group	O
,	O
but	O
both	O
X	O
and	O
Y	O
are	O
not	O
hydroxy	B
groups	O
at	O
the	O
same	O
time	O
.	O
)	O

Proteoglycan	O
production	O
accelerator	O

Disclosed	O
are	O
compounds	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
A	O
,	O
R7	O
,	O
X1	O
,	O
X2	O
,	O
X3	O
,	O
Y	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O

Compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
and/or	O
conditions	O
related	O
to	O
cell	O
proliferation	O
,	O
such	O
as	O
cancer	O
,	O
inflammation	O
,	O
arthritis	O
,	O
angiogenesis	O
,	O
or	O
the	O
like	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
treating	O
the	O
aforementioned	O
conditions	O
using	O
such	O
compounds	O
.	O

Piperazine	B
-	I
substituted	I
benzothiophenes	I
for	O
treatment	O
of	O
mental	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
bind	O
to	O
the	O
NRl	O
H4	O
receptor	O
(	O
FXR	O
)	O
and	O
act	O
as	O
agonists	O
or	O
partial	O
agonists	O
of	O
the	O
NRl	O
H4	O
receptor	O
(	O
FXR	O
)	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
diseases	O
and/or	O
conditions	O
through	O
binding	O
of	O
said	O
nuclear	O
receptor	O
by	O
said	O
compounds	O
,	O
and	O
to	O
a	O
process	O
for	O
the	O
synthesis	O
of	O
said	O
compounds	O
,	O
and	O
an	O
enantiomer	O
,	O
diasterecmer	O
,	O
tautomer	O
,	O
solvate	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
X	O
is	O
(	O
a	O
)	O
or	O
(	O
b	O
)	O
or	O
(	O
c	O
)	O
or	O
(	O
d	O
)	O
,	O
and	O
the	O
rest	O
of	O
the	O
variables	O
are	O
as	O
specified	O
in	O
claim	O
1	O
.	O

Heterocyclic	B
fxr	O
binding	O
compounds	O

The	O
inventor	O
found	O
for	O
the	O
first	O
time	O
that	O
renal	O
fibrosis	O
can	O
be	O
efficiently	O
inhibited	O
by	O
inhibiting	O
the	O
formation	O
or	O
accumulation	O
of	O
chondroitin	B
sulfate	I
proteoglycan	O
.	O

That	O
is	O
,	O
by	O
administering	O
chondroitinase	O
ABC	O
which	O
is	O
an	O
enzyme	O
degrading	O
chondroitin	B
sulfate	I
proteoglycan	O
and	O
inhibiting	O
the	O
expression	O
of	O
C4ST-1	O
,	O
C6ST-1	O
or	O
C6ST-2	O
,	O
which	O
is	O
a	O
chondroitin	B
sulfate	I
proteoglycan	O
sulfotransferase	O
,	O
using	O
siRNA	O
,	O
fibrosis	O
in	O
renal	O
tissue	O
could	O
be	O
inhibited	O
.	O

A	O
compound	O
such	O
as	O
a	O
nucleic	O
acid	O
to	O
be	O
used	O
for	O
such	O
an	O
siRNA	O
can	O
be	O
used	O
as	O
an	O
agent	O
for	O
inhibiting	O
renal	O
fibrosis	O
.	O

Further	O
,	O
this	O
makes	O
it	O
possible	O
to	O
find	O
the	O
agent	O
for	O
inhibiting	O
renal	O
fibrosis	O
by	O
screening	O
a	O
compound	O
inhibiting	O
the	O
formation	O
or	O
accumulation	O
of	O
chondroitin	B
sulfate	I
proteoglycan	O
.	O

Remedy	O
for	O
kidney	O
disease	O

We	O
provide	O
a	O
composition	O
comprising	O
a	O
first	O
agent	O
which	O
is	O
an	O
antagonist	O
of	O
mTOR	O
activity	O
,	O
together	O
with	O
a	O
second	O
agent	O
comprising	O
an	O
angiogenesis	O
inhibitor	O
.	O

The	O
first	O
agent	O
may	O
comprise	O
rapamycin	B
,	O
and	O
the	O
second	O
agent	O
may	O
comprise	O
an	O
inhibitor	O
of	O
VEGF	O
activity	O
such	O
as	O
Bevacizumab	B
(	O
Avastin	B
)	O
.	O

Such	O
a	O
composition	O
may	O
be	O
used	O
for	O
preventing	O
the	O
growth	O
or	O
proliferation	O
,	O
or	O
both	O
,	O
of	O
a	O
cell	O
or	O
tissue	O
.	O

The	O
composition	O
may	O
also	O
be	O
used	O
to	O
treat	O
or	O
prevent	O
cancer	O
,	O
such	O
as	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

Combination	O
of	O
mtor	O
antagonist	O
and	O
angiogenesis	O
inhibitor	O
for	O
the	O
treatment	O
of	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
imidazopyridine	B
and	O
imidazopyrimidine	B
derivatives	O
that	O
act	O
as	O
cannabinoid	B
receptor	O
ligands	O
,	O
e.g.	O
,	O
CB2	O
ligands	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
the	O
compounds	O
,	O
compositions	O
containing	O
the	O
compounds	O
,	O
and	O
to	O
methods	O
of	O
treatment	O
using	O
the	O
compounds	O
.	O

Imidazopyridine	B
and	O
imidazopyrimidine	B
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
thiophene	B
containing	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
in	O
,	O
n	O
,	O
p	O
,	O
q	O
,	O
r	O
,	O
s	O
,	O
Rl	O
,	O
R2	O
,	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

Included	O
also	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
methods	O
for	O
treating	O
pain	O
using	O
such	O
compounds	O
and	O
pharmaceutical	O
compositions	O
.	O

Compounds	O
as	O
cb2	O
cannabinoid	O
receptor	O
ligands	O

Provided	O
herein	O
is	O
a	O
novel	O
treatment	O
for	O
HIV	O
-	O
associated	O
adipose	O
redistribution	O
syndrome	O
(	O
HARS	O
)	O
comprising	O
combination	O
of	O
agents	O
,	O
said	O
combination	O
of	O
agents	O
comprising	O
a	O
first	O
agent	O
which	O
binds	O
to	O
and	O
initiates	O
signaling	O
of	O
the	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
receptor	O
or	O
a	O
substance	O
which	O
stimulates	O
release	O
or	O
potentiates	O
the	O
activity	O
of	O
endogenous	O
hGH	O
;	O
and	O
a	O
second	O
agent	O
which	O
increases	O
insulin	O
sensitivity	O
in	O
said	O
patient	O
.	O

Novel	O
combination	O
of	O
agents	O
for	O
the	O
treatment	O
of	O
hiv	O
-	O
associated	O
adipose	O
redistribution	O
syndrome	O
(	O
hars	O
)	O

This	O
invention	O
relates	O
to	O
a	O
new	O
process	O
for	O
preparation	O
of	O
enantiomerically	O
pure	O
dapoxetine	B
or	O
an	O
acid	O
addition	O
salt	O
thereof	O
i.e.	O
S	B
(	I
+	I
)	I
-N	I
,	I
N	I
-	I
dimethyl-2-	I
[	I
2-	I
(	I
naphthalenyl	I
oxy	I
)	I
ethyl	I
]	I
benzenemethanamine	I
hydrochoride	I
,	O
a	O
potent	O
serotonin	O
re	O
-	O
uptake	O
inhibitor	O
(	O
SSRI	O
)	O
,	O
which	O
comprises	O
resolving	O
racemic	B
(	I
±	I
)	I
-dapoxetine	I
i.e.	O
(	B
±	I
)	I
-	I
N	I
,	I
N	I
-	I
dimethyl-2-	I
[	I
2-	I
(	I
naphthalenyloxy	I
)	I
ethyl	I
]	I
benzene	I
methanamine	I
with	O
a	O
chiral	O
acid	O
so	O
as	O
to	O
obtain	O
salt	O
of	O
the	O
chiral	O
acid	O
and	O
(	B
+	I
)	I
-dapoxetine	I
,	O
substantially	O
free	O
from	O
(	B
-	I
)	I
-dapoxetine	I
.	O

Process	O
for	O
preparing	O
dapoxetine	B

The	O
present	O
invention	O
discloses	O
oximinophenoxyalkanoic	B
acid	I
and	O
phenylalkanoic	B
acid	I
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
methods	O
for	O
their	O
preparation	O
,	O
use	O
of	O
these	O
compounds	O
in	O
medicine	O
and	O
the	O
intermediates	O
involved	O
in	O
their	O
preparation	O
.	O

Oximinophenoxyalkanoic	B
acid	I
and	O
phenylalkanoic	B
acid	I
derivatives	O

This	O
invention	O
provides	O
novel	O
methods	O
of	O
treatment	O
to	O
ameliorate	O
or	O
prevent	O
cognitive	O
disorder	O
/	O
dysfunction	O
in	O
pre-	O
or	O
asymptomatic	O
subject	O
having	O
one	O
or	O
more	O
mutations	O
in	O
the	O
Huntington	O
gene	O
.	O

The	O
methods	O
involve	O
increasing	O
the	O
expression	O
or	O
activity	O
of	O
the	O
neurotrophin	O
BDNS	O
in	O
the	O
brain	O
of	O
said	O
subject	O
.	O

Upregulating	O
activity	O
or	O
expression	O
of	O
bdnf	O
to	O
mitigate	O
cognitive	O
impairment	O
in	O
asymptomatic	O
huntington	O
's	O
subjects	O

Compounds	O
are	O
provided	O
which	O
are	O
useful	O
as	O
platelet	O
ADP	O
receptor	O
inhibitors	O
,	O
for	O
treating	O
thrombosis	O
and	O
for	O
reducing	O
the	O
likelihood	O
and/or	O
severity	O
of	O
a	O
secondary	O
ischemic	O
event	O
in	O
a	O
patient	O
.	O

Nitrogen	B
containing	I
substituted	I
heterocycles	I
as	O
platelet	O
adp	O
receptor	O
inhibitors	O

New	O
isoindolo	B
[	I
2,1-a	I
]	I
quinoxaline	I
derivatives	O
of	O
general	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
R	O
represents	O
H	B
or	O
OH	B
and	O
R5	O
represents	O
H	B
or	O
CN	B
,	O
have	O
been	O
prepared	O
with	O
simple	O
procedures	O
starting	O
from	O
known	O
intermediates	O
and	O
resulted	O
to	O
posses	O
potent	O
in	O
vitro	O
antitumor	O
activity	O
against	O
a	O
panel	O
of	O
about	O
60	O
different	O
human	O
tumor	O
cell	O
lines	O
belonging	O
to	O
several	O
kinds	O
of	O
tumors	O
,	O
both	O
hematological	O
and	O
solid	O
.	O

Preparations	O
containing	O
such	O
derivatives	O
as	O
active	O
ingredients	O
are	O
proposed	O
as	O
drugs	O
to	O
be	O
employed	O
in	O
cancer	O
therapy	O
both	O
alone	O
and	O
in	O
combination	O
with	O
other	O
chemotherapeutics	O
.	O

Isoindolo	B
-	I
quinoxaline	I
derivatives	O
having	O
antitumor	O
activity	O
,	O
process	O
for	O
their	O
production	O
and	O
their	O
use	O

This	O
invention	O
relates	O
to	O
the	O
field	O
of	O
protein	O
tyrosine	B
kinases	O
and	O
inhibitors	O
thereof	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
inhibitors	O
of	O
JAK-2	O
,	O
pharmaceutical	O
compositions	O
of	O
the	O
compounds	O
for	O
inhibiting	O
JAK-2	O
,	O
methods	O
of	O
inhibiting	O
JAK-2	O
in	O
a	O
cell	O
,	O
comprising	O
contacting	O
a	O
cell	O
in	O
which	O
inhibition	O
of	O
JAK-2	O
is	O
desired	O
with	O
a	O
compound	O
or	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
according	O
to	O
the	O
invention	O
.	O

The	O
also	O
comprises	O
methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
that	O
involves	O
JAK-2	O
comprising	O
administering	O
to	O
a	O
patient	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
compound	O
according	O
to	O
the	O
invention	O
.	O

Imidazole-4	B
,	I
5-dicarboxamide	I
derivatives	O
as	O
jak-2	O
modulators	O

Disclosed	O
herein	O
are	O
methods	O
for	O
treating	O
energy	O
metabolism	O
disorders	O
by	O
administering	O
a	O
composition	O
containing	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
fatty	B
acid	I
amide	I
hydrolase	O
inhibitor	O
.	O

The	O
composition	O
can	O
also	O
be	O
administered	O
to	O
reduce	O
body	O
fat	O
,	O
body	O
weight	O
,	O
or	O
caloric	O
intake	O
.	O

Fatty	B
acid	I
amide	I
hydrolase	O
inhibitors	O
for	O
energy	O
metabolism	O
disorders	O

The	O
present	O
invention	O
provides	O
novel	O
purines	B
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
autoimmune	O
diseases	O
,	O
inflammatory	O
disease	O
,	O
mast	O
cell	O
mediated	O
disease	O
and	O
transplant	O
rejection	O
.	O

The	O
compounds	O
are	O
of	O
the	O
general	O
formula	O
I.	O
8-substituted	B
2-	I
(	I
benzimidazolyl	I
)	I
purine	I
derivatives	O
for	O
immunosuppression	O

Use	O
of	O
hydrochloric	B
acid	I
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
the	O
disease	O
caused	O
by	O
fouling	O
of	O
transport	O
tract	O
,	O
wherein	O
the	O
disease	O
comprises	O
diabetes	O
and	O
prostate	O
disease	O
.	O

Use	O
of	O
hydrochloric	B
acid	I
in	O
manufacture	O
of	O
medicament	O
for	O
treating	O
disease	O
caused	O
by	O
fouling	O
of	O
transport	O
tract	O

An	O
antidepressant	O
agent	O
comprising	O
at	O
least	O
one	O
compound	O
selected	O
from	O
a	O
branched	O
amino	B
acid	I
,	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
derivative	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

Antidepressant	O
agent	O

Compounds	O
having	O
formula	O
I	O
:	O
where	O
A1	O
,	O
A2	O
,	O
L	O
,	O
V	O
,	O
W	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
as	O
described	O
herein	O
,	O
compositions	O
thereof	O
,	O
and	O
their	O
use	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
type	O
2	O
diabetes	O
and	O
type	O
2	O
diabetes	O
-	O
related	O
conditions	O
are	O
provided	O
herein	O
.	O

N	B
-	I
aryl	I
pyrazole	I
compounds	O
for	O
use	O
against	O
diabetes	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
EGFR	O
kinase	O
inhibitor	O
and	O
at	O
least	O
one	O
additional	O
active	O
compound	O
selected	O
from	O
beta-2	O
mimetics	O
,	O
steroids	O
,	O
PDE	O
-	O
IV	O
inhibitors	O
,	O
p38	O
MAP	O
kinase	O
inhibitors	O
,	O
NK1	O
antagonists	O
,	O
anticholinergics	O
and	O
endothelin	O
antagonists	O
,	O
processes	O
for	O
preparing	O
the	O
compositions	O
and	O
the	O
use	O
thereof	O
as	O
medicament	O
in	O
the	O
treatment	O
of	O
respiratory	O
or	O
gastrointestinal	O
complaints	O
,	O
as	O
well	O
as	O
inflammatory	O
diseases	O
of	O
the	O
joints	O
,	O
the	O
skin	O
or	O
the	O
eyes	O
.	O

Egfr	O
kinase	O
inhibitor	O
combinations	O
for	O
the	O
treatment	O
of	O
respiratory	O
and	O
gastrointestinal	O
disorders	O

Use	O
of	O
a	O
combination	O
of	O
Aloe	O
Vera	O
and	O
Spermine	B
for	O
the	O
manufacture	O
of	O
a	O
remedy	O
for	O
topic	O
application	O
on	O
the	O
skin	O
for	O
treatment	O
of	O
different	O
skin	O
conditions	O
as	O
wrinkles	O
,	O
stressed	O
skin	O
,	O
ageing	O
skin	O
and	O
eczema	O
and	O
psoriasis	O
.	O

Skin	O
cream	O
comprising	O
a	O
combination	O
of	O
aloe	O
vera	O
and	O
spermine	B

The	O
present	O
application	O
provides	O
nitrogen	B
-	O
containing	O
heterocycle	B
derivatives	O
that	O
are	O
antiviral	O
compounds	O
that	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
viral	O
infection	O
.	O

Compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
may	O
be	O
administered	O
to	O
a	O
subject	O
for	O
antiviral	O
therapy	O
or	O
prophylaxis	O
.	O

Formula	O
:	O
(	O
I	O
)	O
Nitrogen	B
-	O
containing	O
heterocycle	B
derivatives	O
,	O
pharmaceutical	O
compositions	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
as	O
antiviral	O
agents	O

The	O
present	O
invention	O
is	O
a	O
method	O
for	O
the	O
treatment	O
of	O
Pervasive	O
Developmental	O
Disorders	O
(	O
PDDs	O
)	O
including	O
;	O
Autistic	O
Disorder	O
,	O
Asperger	O
's	O
Disorder	O
,	O
Childhood	O
Disintegrative	O
Disorder	O
(	O
CDD	O
)	O
,	O
Rett	O
's	O
Disorder	O
,	O
and	O
PDD	O
-	O
Not	O
Otherwise	O
Specified	O
(	O
PDD	O
-	O
NOS	O
)	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
carbamate	B
compounds	O
of	O
Formula	O
1	O
and/or	O
Formula	O
2	O
as	O
herein	O
defined	O
and	O
shown	O
below	O
.	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
for	O
the	O
treatment	O
of	O
Pervasive	O
Developmental	O
Disorders	O
(	O
PDDs	O
)	O
including	O
;	O
Autistic	O
Disorder	O
,	O
Asperger	O
's	O
Disorder	O
,	O
Childhood	O
Disintegrative	O
Disorder	O
(	O
CDD	O
)	O
,	O
Rett	O
's	O
Disorder	O
,	O
and	O
PDD	O
-	O
Not	O
Otherwise	O
Specified	O
(	O
PDD	O
-	O
NOS	O
)	O
,	O
which	O
includes	O
mono	O
-	O
therapy	O
and	O
alternatively	O
,	O
co	O
-	O
therapy	O
with	O
at	O
least	O
one	O
additional	O
psychoactive	O
medication	O
.	O

Treatment	O
of	O
pervasive	O
developmental	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
the	O
polymorph	O
III	O
of	O
4-	B
[	I
4-	I
(	I
{	I
[	I
4-chloro-3-	I
(	I
trifluoromethyl	I
)	I
phenyl	I
]	I
carbamoyl	I
}	I
amino	I
)	I
-3-fluorophenoxy	I
]	I
-N	I
-	I
methylpyridine-2-carboxamide	I
,	O
to	O
processes	O
for	O
its	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
it	O
and	O
to	O
its	O
use	O
in	O
the	O
control	O
of	O
disorders	O
.	O

Polymorph	O
iii	O
of	O
4-	B
[	I
4-	I
(	I
{	I
[	I
4-chloro-3-	I
(	I
trifluoromethyl	I
)	I
phenyl	I
]	I
carbamoyl	I
}	I
amino	I
)	I
-3-fluorophenoxy	I
]	I
-n	I
-	I
methylpyridine-2-carboxamide	I

Disclosed	O
is	O
a	O
medicament	O
containing	O
a	O
compound	O
of	O
formula	O
(	O
Ia	O
)	O
or	O
(	O
Ib	O
)	O
,	O
wherein	O
Z	O
is	O
selected	O
from	O
among	O
a	O
group	O
comprising	O
a	O
covalent	O
bond	O
,	O
at	O
least	O
one	O
at	O
least	O
bivalent	O
heteroatom	O
,	O
a	O
saturated	O
,	O
unsaturated	O
,	O
branched	O
,	O
linear	O
and/or	O
cyclic	O
,	O
substituted	O
or	O
unsubstituted	O
hydrocarbon	B
chain	O
,	O
a	O
saturated	O
or	O
unsaturated	O
,	O
branched	O
,	O
linear	O
and/or	O
cyclic	O
,	O
substituted	O
or	O
unsubstituted	O
hydrocarbon	B
chain	O
containing	O
heteroatoms	O
,	O
or	O
combinations	O
thereof	O
,	O
R`1	O
to	O
R`4	O
and	O
R``1	O
to	O
R``5	O
each	O
independently	O
represents	O
H	B
,	O
at	O
least	O
one	O
heteroatom	O
,	O
a	O
saturated	O
,	O
unsaturated	O
,	O
branched	O
,	O
linear	O
and/or	O
cyclic	O
,	O
substituted	O
or	O
unsubstituted	O
hydrocarbon	B
chain	O
,	O
a	O
saturated	O
or	O
unsaturated	O
,	O
branched	O
,	O
linear	O
and/or	O
cyclic	O
,	O
substituted	O
or	O
unsubstituted	O
hydrocarbon	B
chain	O
containing	O
heteroatoms	O
,	O
or	O
combinations	O
thereof	O
,	O
the	O
cyclopentadienyl	O
rings	O
are	O
optionally	O
linked	O
by	O
means	O
of	O
any	O
of	O
the	O
radicals	O
R``1	O
to	O
R``5	O
,	O
R1	O
and	O
R2	O
independently	O
represent	O
H	O
,	O
a	O
heteroatom	O
,	O
a	O
saturated	O
,	O
unsaturated	O
,	O
branched	O
,	O
linear	O
and/or	O
cyclic	O
,	O
substituted	O
or	O
unsubstituted	O
hydrocarbon	B
chain	O
,	O
a	O
saturated	O
or	O
unsaturated	O
,	O
branched	O
,	O
linear	O
and/or	O
cyclic	O
,	O
substituted	O
or	O
unsubstituted	O
hydrocarbon	B
chain	O
containing	O
heteroatoms	O
,	O
or	O
combinations	O
thereof	O
,	O
A	O
`	O
,	O
A	O
`	O
`	O
independently	O
represent	O
F	B
,	O
Cl	B
,	O
BR	B
,	O
I	B
,	O
and/or	O
a	O
physically	O
acceptable	O
acid	O
radical	O
of	O
an	O
organic	O
or	O
inorganic	O
acid	O
,	O
n	O
represents	O
a	O
positive	O
integer	O
,	O
particularly	O
1	O
,	O
2	O
,	O
3	O
,	O
X	O
=	O
O	B
,	O
S	B
,	O
NH	B
,	O
NR3	B
,	O
NR4R5	B
,	O
wherein	O
R3	O
,	O
R4	O
,	O
and	O
R5	O
independently	O
have	O
the	O
meanings	O
indicated	O
for	O
R`1	O
to	O
R`4	O
,	O
Y	O
=	O
a	O
covalent	O
bond	O
,	O
O	B
,	O
S	B
,	O
or	O
NR6	B
,	O
wherein	O
R6	O
has	O
the	O
meaning	O
indicated	O
for	O
R`1	O
to	O
R`4	O
.	O

Carbonyl	B
-	I
substituted	I
titanocenes	I

It	O
is	O
intended	O
to	O
provide	O
a	O
method	O
by	O
which	O
a	O
polysaccharide	O
can	O
be	O
degraded	O
while	O
sustaining	O
the	O
effect	O
of	O
the	O
polysaccharide	O
and	O
a	O
degraded	O
polysaccharide	O
.	O

A	O
method	O
of	O
degrading	O
a	O
polysaccharide	O
which	O
comprises	O
irradiating	O
the	O
polysaccharide	O
with	O
a	O
light	O
in	O
the	O
visible	O
range	O
in	O
the	O
presence	O
of	O
titanium	B
dioxide	I
.	O

In	O
this	O
method	O
,	O
it	O
is	O
preferable	O
that	O
the	O
polysaccharide	O
contains	O
at	O
least	O
one	O
of	O
chondroitin	B
sulfate	I
,	O
heparin	B
and	O
hyaluronic	B
acid	I
.	O

It	O
is	O
also	O
preferable	O
that	O
the	O
energy	O
of	O
the	O
light	O
in	O
the	O
visible	O
range	O
for	O
the	O
irradiation	O
is	O
1	O
MJ	O
or	O
more	O
but	O
not	O
more	O
than	O
20	O
MJ	O
.	O

Furthermore	O
,	O
it	O
is	O
preferable	O
that	O
titanium	B
dioxide	I
is	O
employed	O
in	O
an	O
amount	O
of	O
0.1	O
g	O
or	O
more	O
but	O
not	O
more	O
than	O
10	O
g	O
per	O
gram	O
of	O
the	O
polysaccharide	O
as	O
described	O
above	O
.	O

Method	O
of	O
degrading	O
polysaccharide	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
fragile	O
X	O
syndrome	O
and/or	O
other	O
neurodevelopmental	O
disorders	O
by	O
administering	O
small	O
molecule	O
p21	O
-activated	O
kinase	O
(	O
PAK	O
)	O
inhibitors	O
to	O
a	O
patient	O
suffering	O
from	O
,	O
susceptible	O
to	O
,	O
and/or	O
exhibiting	O
one	O
or	O
more	O
symptoms	O
of	O
FXS	O
and/or	O
other	O
neurodevelopmental	O
disorders	O
.	O

The	O
present	O
invention	O
provides	O
specific	O
small	O
molecule	O
PAK	O
inhibitors	O
and	O
pharmaceutical	O
compositions	O
comprising	O
small	O
molecule	O
PAK	O
inhibitors	O
.	O

Small	O
molecule	O
pak	O
inhibitors	O

The	O
presently	O
disclosed	O
subject	O
matter	O
is	O
directed	O
to	O
metallo	O
-	O
oxidoreductase	O
inhibitors	O
having	O
metal	O
binding	O
moities	O
linked	O
to	O
a	O
targeting	O
moiety	O
through	O
a	O
linking	O
group	O
or	O
a	O
direct	O
bond	O
,	O
methods	O
for	O
screening	O
for	O
metallo	O
-	O
oxidoreductase	O
inhibitors	O
,	O
and	O
methods	O
of	O
treating	O
an	O
oxidoreductase	O
related	O
disorder	O
by	O
administering	O
a	O
metallo-	O
oxidoreductase	O
inhibitor	O
to	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
thereof	O
.	O

Metallo	O
-	O
oxidoreductase	O
inhibitors	O
using	O
metal	O
binding	O
moieties	O
in	O
combination	O
with	O
targeting	O
moieties	O

The	O
present	O
invention	O
relates	O
to	O
controlled	O
-	O
release	O
beads	O
comprising	O
diquinoline-	O
substituted	O
piperazine	B
-	O
piperidine	B
compounds	O
,	O
such	O
as	O
5-fluoro-8-	B
{	I
4-	I
[	I
4-	I
[	I
(	I
6-methoxyquinolin-	I
8-yl	I
)	I
piperazin	I
-	I
l	I
-	I
yl	I
]	I
piperidin	I
-	I
l	I
-	I
yl	I
}	I
quinoline	I
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
;	O
to	O
multiple	O
particulate	O
formulations	O
comprising	O
such	O
beads	O
;	O
to	O
methods	O
of	O
preparing	O
such	O
beads	O
;	O
and	O
to	O
methods	O
of	O
treating	O
5-HTiA	O
-	O
related	O
disorders	O
using	O
such	O
beads	O
and/or	O
multiple	O
particulate	O
formulations	O
.	O

Controlled	O
-	O
release	O
multi	O
-	O
layer	O
formulation	O
of	O
piperazine	B
-	O
piperidine	B
antagonists	O
and	O
agonists	O
of	O
the	O
5-th1a	O
receptor	O
having	O
enhanced	O
intestinal	O
dissolution	O

Disclosed	O
is	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
below	O
,	O
while	O
having	O
improved	O
storage	O
stability	O
.	O

Specifically	O
disclosed	O
is	O
a	O
film	O
-	O
coated	O
preparation	O
having	O
excellent	O
storage	O
stability	O
,	O
which	O
contains	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
,	O
while	O
having	O
a	O
film	O
layer	O
containing	O
one	O
or	O
more	O
film	O
coating	O
base	O
agents	O
selected	O
from	O
polyvinyl	B
alcohols	I
,	O
sodium	O
carboxymethylcelluloses	O
and	O
pullulans	O
.	O

[	O
chemical	O
formula	O
1	O
]	O
(	O
I	O
)	O
Film	O
-	O
coated	O
preparation	O
having	O
improved	O
stability	O

Method	O
and	O
composition	O
of	O
Carboxyamidotriazole	B
orotate	I
for	O
treating	O
age	O
-	O
related	O
macular	O
degeneration	O
and	O
other	O
angiogenesis	O
-	O
dependent	O
diseases	O
.	O

Use	O
of	O
carboxyamidotriazole	B
(	O
cai	B
)	O
orotate	O
in	O
macular	O
degeneration	O

Disclosed	O
is	O
an	O
iron	B
metabolism	O
-	O
improving	O
agent	O
for	O
improving	O
the	O
iron	B
metabolism	O
in	O
the	O
body	O
of	O
a	O
patient	O
having	O
chronic	O
renal	O
failure	O
who	O
is	O
receiving	O
a	O
blood	O
purification	O
therapy	O
such	O
as	O
hemodialysis	O
,	O
hemofiltration	O
and	O
hemodialysis	O
filtration	O
.	O

The	O
iron	B
metabolism	O
-	O
improving	O
agent	O
does	O
not	O
contain	O
acetic	B
acid	I
and/or	O
an	O
acetic	B
acid	I
salt	O
as	O
an	O
electrolyte	O
,	O
comprises	O
citric	B
acid	I
and/or	O
a	O
citric	B
acid	I
salt	O
,	O
and	O
further	O
comprises	O
other	O
electrolyte	O
(	O
s	O
)	O
and	O
glucose	B
alone	O
or	O
in	O
combination	O
.	O

The	O
iron	B
metabolism	O
-	O
improving	O
agent	O
is	O
in	O
the	O
form	O
of	O
a	O
dialysis	O
fluid	O
and/or	O
a	O
substitution	O
fluid	O
for	O
dialysis	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
for	O
improving	O
the	O
iron	B
metabolism	O
in	O
a	O
living	O
body	O
by	O
using	O
the	O
dialysis	O
fluid	O
and/or	O
the	O
substitution	O
fluid	O
for	O
dialysis	O
.	O

Further	O
disclosed	O
is	O
a	O
blood	O
purification	O
method	O
including	O
hemodialysis	O
and	O
hemodialysis	O
filtration	O
for	O
a	O
patient	O
having	O
chronic	O
renal	O
failure	O
.	O

Iron	B
metabolism	O
-	O
improving	O
agent	O

A	O
composition	O
for	O
the	O
treatment	O
of	O
aging	O
skin	O
,	O
and	O
a	O
method	O
of	O
treating	O
aging	O
or	O
stressed	O
skin	O
,	O
is	O
disclosed	O
.	O

The	O
composition	O
comprises	O
a	O
hydroxycinnamic	B
acid	I
or	O
a	O
methoxycinnamic	B
acid	I
and	O
a	O
suitable	O
carrier	O
for	O
topical	O
application	O
of	O
the	O
composition	O
to	O
human	O
skin	O
.	O

The	O
composition	O
demonstrates	O
antiaging	O
effects	O
on	O
skin	O
tone	O
and	O
firmness	O
.	O

Composition	O
for	O
treating	O
aging	O
skin	O
comprising	O
a	O
hydroxycinnamic	B
acid	I
such	O
as	O
p	B
-	I
coumaric	I
acid	I

The	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
a	O
neuronal	O
nicotinic	O
receptor	O
ligand	O
and	O
an	O
α4β2	O
positive	O
allosteric	O
modulator	O
,	O
a	O
method	O
of	O
using	O
the	O
same	O
,	O
and	O
a	O
related	O
article	O
of	O
manufacture	O
.	O

Pharmaceutical	O
compositions	O
and	O
their	O
methods	O
of	O
use	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
to	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
,	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
glaucoma	O
,	O
ocular	O
hypertension	O
,	O
age	O
-	O
related	O
macular	O
degeneration	O
,	O
diabetic	O
macular	O
edema	O
,	O
diabetic	O
retinopathy	O
,	O
hypertensive	O
retinopathy	O
,	O
retinal	O
vasculopathies	O
and	O
intraocular	O
pressure	O
in	O
mammals	O
by	O
administering	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
which	O
contain	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
for	O
such	O
treatments	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

Tricyclic	O
inhibitors	O
of	O
carbonic	O
anhydrase	O

This	O
invention	O
provides	O
pyrido	B
(	I
3,2-d	I
)	I
pyrimidine	I
derivatives	O
represented	O
by	O
the	O
structural	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
R1	O
is	O
amino	B
,	O
R4	O
is	O
hydrogen	B
,	O
and	O
R2	O
and	O
R3	O
together	O
provide	O
a	O
specific	O
substitution	O
pattern	O
,	O
pharmaceutical	O
acceptable	O
addition	O
salts	O
,	O
stereochemical	O
isomeric	O
forms	O
,	O
N	B
-	I
oxides	I
,	O
solvates	O
and	O
pro	O
-	O
drugs	O
thereof	O
,	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
hepatitis	O
C.	O
Pyrido	B
(	I
3,2-d	I
)	I
pyrimidines	I
useful	O
for	O
treating	O
viral	O
infections	O

Compounds	O
active	O
on	O
protein	O
kinases	O
are	O
described	O
,	O
as	O
well	O
as	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
and	O
conditions	O
associated	O
with	O
aberrant	O
activity	O
of	O
protein	O
kinases	O
.	O

Pyrrolo	B
[	I
2,3-b	I
]	I
pyridines	I
as	O
kinase	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
to	O
treat	O
and/or	O
prevent	O
increased	O
intraocular	O
pressure	O
in	O
a	O
subject	O
by	O
administering	O
a	O
protein	O
kinase	O
C	O
-	O
delta	O
(	O
PKCδ	O
)	O
inhibitor	O
.	O

In	O
further	O
embodiments	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
to	O
treat	O
and/or	O
prevent	O
glaucoma	O
by	O
administering	O
a	O
PKCδ	O
inhibitor	O
.	O

Inhibitors	O
of	O
protein	O
kinase	O
c	O
-	O
delta	O
for	O
the	O
treatment	O
of	O
glaucoma	O

The	O
invention	O
relates	O
to	O
1-	O
(	O
2-deoxy	O
-	O
alpha	O
-	O
D	O
-	O
erythro	O
-	O
pentofuranosyl	O
)	O
-5-azacytosine	O
of	O
formula	O
(	O
I	O
)	O
for	O
use	O
as	O
a	O
hypomethylating	O
drug	O
applicable	O
for	O
epigenetic	O
therapy	O
of	O
cancer	O
and	O
other	O
epigenetically	O
determined	O
diseases	O
and	O
further	O
includes	O
the	O
use	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
for	O
manufacturing	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
epigenetic	O
therapy	O
of	O
cancer	O
and	O
other	O
epigenetically	O
determined	O
diseases	O
.	O

1-	O
(	O
2-deoxy	O
-	O
alpha	O
-	O
d	O
-	O
erythro	O
-	O
pentofuranosyl	O
)	O
-5-azacytosine	O
for	O
use	O
as	O
drug	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
2-substituted	B
pyridines	I
of	O
the	O
formulaI	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
2-substituted	B
pyridines	I
of	O
formula	O
I	O
in	O
therapy	O
,	O
in	O
particular	O
in	O
therapy	O
or	O
treatment	O
of	O
cancerous	O
diseases	O
:	O
in	O
which	O
the	O
indices	O
and	O
the	O
substituents	O
are	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
specification	O
.	O

2-substituted	B
5-phenylpyrimidines	I
for	O
the	O
treatment	O
of	O
proliferative	O
disorders	O

A	O
forsythoside	B
injection	O
and	O
preparation	O
thereof	O
,	O
wherein	O
the	O
injection	O
is	O
essentially	O
manufactured	O
by	O
the	O
forsythoside	B
and	O
the	O
pharmaceutic	O
adjuvants	O
in	O
weight	O
ratio	O
of	O
1	O
:	O
(	O
0	O
-	O
5	O
)	O
,	O
are	O
disclosed	O
.	O

A	O
forsythoside	B
injection	O
and	O
preparation	O
thereof	O

This	O
invention	O
relates	O
to	O
novel	O
semicarbazide	B
and	O
carbonylhydrazide	B
derivatives	O
that	O
are	O
found	O
to	O
be	O
potent	O
modulators	O
of	O
potassium	B
channels	O
and	O
,	O
as	O
such	O
,	O
they	O
are	O
valuable	O
candidates	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
which	O
are	O
responsive	O
to	O
modulation	O
of	O
potassium	B
channels	O
.	O

Novel	O
semicarbazide	B
and	O
carbonylhydrazide	B
derivatives	O
useful	O
as	O
potassium	B
channel	O
modulators	O

Compositions	O
with	O
improved	O
stability	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
11-	B
(	I
4-aminophenyl	I
)	I
-19-noφregna-4,9	I
(	I
10	I
)	I
-diene-	I
3,20-dione	I
derivatives	O
are	O
provided	O
Pharmaceutically	O
acceptable	O
salts	O
of	O
11-	B
(	I
4-aminophenyl	I
)	I
-19-n0rpregna-4,9	I
(	I
10	I
)	I
-diene-3	I
,	I
20-dione	I
derivatives	O

The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
dopamine	B
transporters	O
and	O
noradrenaline	B
transporters	O
dual	O
inhibitors	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
treating	O
neural	O
degeneration	O
diseases	O
in	O
central	O
nervous	O
system	O
,	O
wherein	O
the	O
inhibitors	O
include	O
bakuchiols	B
compounds	O
,	O
such	O
as	O
bakuchiol	B
and	O
13-hydroxyisobakuchiol	B
.	O

The	O
present	O
invention	O
also	O
discloses	O
the	O
compositions	O
comprising	O
the	O
inhibitors	O
.	O

The	O
use	O
of	O
dopamine	B
transporters	O
and	O
noradrenaline	B
transporters	O
dual	O
inhibitors	O

A	O
matrix	O
is	O
described	O
for	O
the	O
intra	O
-	O
intestinal	O
release	O
of	O
a	O
drug	O
,	O
and	O
an	O
oral	O
form	O
of	O
a	O
preparation	O
containing	O
sodium	B
butyrate	I
protected	O
in	O
a	O
triglyceride	B
matrix	O
at	O
a	O
concentration	O
of	O
200	O
-	O
400	O
mg	O
/	O
g	O
,	O
or	O
sodium	B
butyrate	I
at	O
a	O
concentration	O
of	O
200	O
-	O
400	O
mg	O
/	O
g	O
along	O
with	O
short	O
-	O
chained	O
organic	O
acids	O
at	O
a	O
concentration	O
of	O
0	O
-	O
100	O
mg	O
/	O
g	O
,	O
or	O
sodium	B
butyrate	I
at	O
a	O
concentration	O
of	O
200	O
-	O
400	O
mg	O
/	O
g	O
along	O
with	O
an	O
extract	O
from	O
Yucca	O
Schidigeri	O
at	O
a	O
concentration	O
of	O
0	O
-	O
25	O
mg	O
/	O
g	O
,	O
or	O
sodium	B
butyrate	I
at	O
a	O
concentration	O
of	O
200	O
-	O
400	O
mg	O
/	O
g	O
along	O
with	O
short	O
-	O
chained	O
organic	O
acids	O
at	O
concentrations	O
of	O
0	O
-	O
100	O
mg	O
/	O
g	O
,	O
along	O
with	O
an	O
extract	O
from	O
Yucca	O
Schidigeri	O
at	O
a	O
concentration	O
of	O
0	O
-	O
25	O
mg	O
/	O
g	O
,	O
in	O
a	O
triglyceride	B
matrix	O
up	O
to	O
1	O
g	O
for	O
oral	O
administration	O
in	O
the	O
human	O
in	O
the	O
form	O
of	O
a	O
granulate	O
,	O
capsules	O
or	O
tablets	O
.	O

The	O
produced	O
medicinal	O
product	O
may	O
be	O
applied	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
inflammatory	O
bowel	O
diseases	O
and	O
of	O
colorectal	O
cancer	O
.	O

A	O
preparation	O
containing	O
sodium	B
butyrate	I
and	O
the	O
application	O
of	O
a	O
preparation	O
containing	O
sodium	B
butyrate	I

The	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
A	O
:	O
(	O
A	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
,	O
hydrate	B
,	O
or	O
prodrug	O
thereof	O
.	O

The	O
compounds	O
of	O
Formula	O
A	O
are	O
TGR5	O
modulators	O
useful	O
for	O
the	O
treatment	O
of	O
various	O
diseases	O
,	O
including	O
obesity	O
,	O
insulin	O
sensitivity	O
,	O
inflammation	O
,	O
cholestasis	O
,	O
and	O
bile	O
desaturation	O
.	O

23-substituted	O
bile	B
acids	I
as	O
tgr5	O
modulators	O
and	O
methods	O
of	O
use	O
thereof	O

Compounds	O
of	O
Formula	O
(	O
IA	O
)	O
or	O
(	O
IB	O
)	O
modulate	O
ghrelin	O
receptor	O
activity	O
,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
,	O
for	O
example	O
,	O
obesity	O
and	O
eating	O
disorders	O
:	O
wherein	O
W	O
is	O
,	O
in	O
either	O
orientation	O
,	O
-C	B
(	I
=O	I
)	I
N	I
(	I
R3	I
)	I
-	I
,	O
or	O
-C	B
(	I
=O	I
)	I
O-	I
;	O
R	O
is	O
hydrogen	B
or	O
C1-C4	B
alkyl	I
;	O
R1	O
is	O
selected	O
from	O
hydrogen	B
,	O
(	B
C1-C4	I
)	I
alkyl	I
,	O
cycloalkyl	B
,	O
fully	O
or	O
partially	O
fluorinated	B
(	I
C1-C4	I
)	I
alkyl	I
,	O
or	O
-OR10	B
;	O
and	O
R2	O
is	O
selected	O
from	O
(	O
i	O
)	O
hydrogen	B
and	O
(	O
ii	O
)	O
(	B
C1-C4	I
)	I
alkyl	I
,	O
cycloalkyl	B
,	O
cycloalkenyl	B
,	O
and	O
non	O
aromatic	B
heterocyclyl	I
,	O
each	O
optionally	O
substituted	O
by	O
-F	B
,	O
-CN	B
,	O
C1-C4	B
alkyl	I
,	O
cyclopropyl	B
,	O
-NR7COR0	B
,	O
-NR7SO2R0	B
,	O
-COR0	B
,	O
-COOH	B
,	O
-SOR9	B
,	O
-SO2R0	B
,	O
-OR10	B
,	O
-NR7R8	B
,	O
or	O
-NR7COOR8	B
;	O
and	O
(	O
iii	O
)	O
aryl	B
,	O
aryl-	B
(	I
C1-C2	I
)	I
alkyl-	I
,	O
heteroaryl	B
and	O
heteroaryl-	B
(	I
C1-C2	I
alkyl	I
)	I
-	I
each	O
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
or	O
R1	O
and	O
R2	O
,	O
together	O
with	O
the	O
nitrogen	B
to	O
which	O
they	O
are	O
attached	O
,	O
form	O
an	O
optionally	O
substituted	O
cyclic	B
amino	I
group	O
;	O
R3	O
is	O
selected	O
from	O
hydrogen	B
,	O
(	B
C1-C4	I
)	I
alkyl	I
,	O
cycloalkyl	B
,	O
fully	O
or	O
partially	O
fluorinated	B
(	I
C1-C4	I
)	I
aIkyl	I
,	O
or	O
-OR10	B
;	O
and	O
R4	O
is	O
selected	O
from	O
(	O
iv	O
)	O
hydrogen	B
and	O
(	O
v	O
)	O
(	B
C1-C4	I
)	I
alkyl	I
,	O
cycloalkyl	B
,	O
and	O
non	O
aromatic	B
heterocyclyl	I
,	O
each	O
optionally	O
substituted	O
by	O
-F	B
,	O
-CN	B
,	O
-NR7COR0	B
,	O
-NR7SO2R0	B
,	O
-COR0	B
,	O
-	B
COOH	I
,	O
-SOR9	B
,	O
-SO2R0	B
,	O
-OR10	B
,	O
-NR7R8	B
,	O
or	O
-NR7COOR8	B
;	O
and	O
(	O
vi	O
)	O
aryl	B
,	O
aryl-	B
(	I
C1-C2	I
)	I
alkyl-	I
,	O
heteroaryl	B
and	O
heteroaryl-	B
(	I
C1-C2	I
alkyl	I
)	I
-	I
each	O
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
thereof	O
;	O
or	O
R3	O
and	O
R4	O
,	O
together	O
with	O
the	O
nitrogen	B
to	O
which	O
they	O
are	O
attached	O
,	O
form	O
an	O
optionally	O
substituted	O
cyclic	B
amino	I
group	O
;	O
L	O
is	O
a	O
linker	O
radical	O
of	O
formula	O
-	B
(	I
CR11R13	I
)	I
aB	I
(	I
CR12R14	I
)	I
b-	I
as	O
defined	O
in	O
the	O
specification	O
;	O
R0	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
and	O
R10	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Ghrelin	O
receptor	O
modulators	O

Chronic	O
Otitis	O
Media	O
with	O
Effusion	O
(	O
COME	O
)	O
,	O
Recurrent	O
Acute	O
Otitis	O
Media	O
(	O
RAOM	O
)	O
,	O
cholesteatoma	O
,	O
chronic	O
rhinosinusitis	O
and	O
other	O
bacterial	O
ear	O
,	O
nose	O
or	O
throat	O
conditions	O
may	O
be	O
treated	O
by	O
applying	O
a	O
solvating	O
system	O
to	O
a	O
bacterial	O
biofilm	O
attached	O
or	O
adhered	O
to	O
the	O
treatment	O
site	O
.	O

The	O
biofilm	O
is	O
disrupted	O
and	O
a	O
protective	O
layer	O
of	O
a	O
polymeric	O
film	O
-	O
forming	O
medical	O
sealant	O
is	O
applied	O
to	O
the	O
treatment	O
site	O
.	O

Solvating	O
system	O
and	O
sealant	O
for	O
medical	O
use	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
their	O
enantiomers	O
,	O
diastereoisomers	O
,	O
and	O
N	B
-	I
oxides	I
,	O
as	O
well	O
as	O
to	O
their	O
addition	O
salts	O
to	O
a	O
pharmaceutically	O
acceptable	O
acid	O
or	O
base	O
.	O

The	O
compounds	O
according	O
to	O
the	O
invention	O
are	O
powerful	O
tyrosine	B
hydroxylase	O
inducers	O
.	O

Novel	O
triazabenzo	B
[	I
α	I
]	I
naphtho	I
[	I
2,l,8-cde	I
]	I
azulene	I
derivatives	O
,	O
method	O
for	O
preparing	O
the	O
same	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
suppressing	O
lipid	O
peroxidation	O
in	O
erythrocytes	O
,	O
which	O
contains	O
xanthophyll	B
or	O
an	O
ester	B
thereof	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
composition	O
for	O
preventing	O
or	O
treating	O
dementia	O
and	O
a	O
diagnostic	O
method	O
for	O
dementia	O
including	O
measuring	O
the	O
concentration	O
of	O
xanthophyll	B
or	O
an	O
ester	B
thereof	O
in	O
erythrocytes	O
of	O
a	O
mammal	O
.	O

Composition	O
and	O
method	O
for	O
suppressing	O
lipid	O
peroxidation	O
in	O
erythrocytes	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
phenylmorpholine	B
and	O
phenyl	B
thiomorpholine	I
compounds	O
useful	O
as	O
alpha2C	O
adrenergic	O
receptor	O
agonists	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
and	O
methods	O
of	O
treatment	O
,	O
prevention	O
,	O
inhibition,-	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
diseases	O
associated	O
with	O
the	O
alpha2C	O
adrenergic	O
receptor	O
agonists	O
,	O
such	O
as	O
allergic	O
rhinitis	O
,	O
congestion	O
,	O
pain	O
,	O
diarrhea	O
,	O
glaucoma	O
,	O
congestive	O
heart	O
failure	O
,	O
cardiac	O
ischemia	O
,	O
manic	O
disorders	O
,	O
depression	O
,	O
anxiety	O
and	O
schizophrenia	O
.	O

3,4-dihydr0-l,4-benz0xazine	B
,	I
3	I
,	I
4-dihydr0	I
-	I
1	I
,	I
4-benzothiazine	I
and	O
1,2,3,4-tetrahydro	B
-	I
quinoxaline	I
derivatives	O
as	O
alpha2c	O
adrenoreceptor	O
agonists	O

The	O
present	O
disclosure	O
provides	O
compounds	O
having	O
affinity	O
for	O
the	O
5-HT6	O
receptor	O
which	O
are	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1-R4	O
A	O
,	O
B	O
,	O
D	O
,	O
E	O
,	O
and	O
G	O
are	O
as	O
defined	O
herein	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
such	O
compounds	O
,	O
compositions	O
containing	O
such	O
compounds	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

6	B
'	I
substituted	I
indole	I
and	I
indazole	I
derivatives	O
having	O
5-ht6	O
receptor	O
affinity	O

Novel	O
derivatives	O
of	O
cannabidiol	B
,	O
having	O
one	O
or	O
two	O
of	O
the	O
hydroxyl	B
groups	O
substituted	O
,	O
exhibiting	O
improved	O
production	O
yield	O
,	O
solubility	O
,	O
stability	O
and	O
bioavailability	O
,	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
same	O
and	O
uses	O
thereof	O
as	O
anti	O
-	O
inflammatory	O
agents	O
.	O

Novel	O
cannabidiol	B
derivatives	O
and	O
their	O
use	O
as	O
anti	O
-	O
inflammatory	O
agents	O

Bridged	O
phenanthridine	B
compounds	O
having	O
the	O
structure	O
of	O
formula	O
I	O
or	O
of	O
formula	O
II	O
are	O
provided	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
cannabinoid	B
receptor	O
ligands	O
and	O
can	O
be	O
prepared	O
as	O
pharmaceutical	O
compositions	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
variety	O
of	O
diseases	O
,	O
disorders	O
and	O
conditions	O
including	O
inflammatory	O
pain	O
,	O
visceral	O
pain	O
,	O
postoperative	O
pain	O
,	O
cancer	O
pain	O
,	O
neuropathic	O
pain	O
,	O
musculoskeletal	O
pain	O
,	O
dysmenorrhea	O
,	O
menstrual	O
pain	O
,	O
migraine	O
,	O
headache	O
as	O
well	O
as	O
inflammatory	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
Crohn	O
's	O
disease	O
,	O
psoriasis	O
,	O
eczema	O
,	O
multiple	O
sclerosis	O
,	O
diabetes	O
and	O
thyroiditis	O
.	O

The	O
compounds	O
can	O
also	O
be	O
used	O
in	O
the	O
treatment	O
of	O
skin	O
disorders	O
,	O
lung	O
disorders	O
,	O
ophthalmic	O
disorders	O
,	O
gastrointestinal	O
disorders	O
,	O
cardiovascular	O
disorders	O
,	O
as	O
well	O
as	O
neurodegenerative	O
,	O
neuroinflammatory	O
and	O
certain	O
psychiatric	O
disorders	O
.	O

Bridged	O
phenanthridines	B

The	O
present	O
disclosure	O
provides	O
meroduplex	O
ribonucleic	O
acid	O
molecules	O
(	O
mdRNA	O
)	O
capable	O
of	O
decreasing	O
or	O
silencing	O
BCR	O
-	O
ABL	O
gene	O
expression	O
.	O

An	O
mdRNA	O
of	O
this	O
disclosure	O
comprises	O
at	O
least	O
three	O
strands	O
that	O
combine	O
to	O
form	O
at	O
least	O
two	O
non	O
-	O
overlapping	O
double	O
-	O
stranded	O
regions	O
separated	O
by	O
a	O
nick	O
or	O
gap	O
wherein	O
one	O
strand	O
is	O
complementary	O
to	O
a	O
BCR	O
-	O
ABL	O
mRNA	O
.	O

In	O
addition	O
,	O
the	O
meroduplex	O
may	O
have	O
at	O
least	O
one	O
uridine	B
substituted	O
with	O
a	O
5-methyluridine	B
,	O
a	O
nucleoside	O
replaced	O
with	O
a	O
locked	O
nucleic	O
acid	O
,	O
or	O
optionally	O
other	O
modifications	O
,	O
and	O
any	O
combination	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
decreasing	O
expression	O
of	O
a	O
BCR	O
-	O
ABL	O
gene	O
in	O
a	O
cell	O
or	O
in	O
a	O
subject	O
to	O
treat	O
a	O
BCR	O
-	O
ABL	O
-	O
related	O
disease	O
.	O

Nucleic	O
acid	O
compounds	O
for	O
inhibiting	O
bcr	O
-	O
abl	O
gene	O
expression	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
and	O
methods	O
useful	O
for	O
treating	O
cancer	O
and	O
for	O
amelioration	O
of	O
cellular	O
stress	O
response	O
triggered	O
by	O
chemotherapy	O
.	O

Amelioration	O
of	O
cellular	O
stress	O
response	O

A	O
CPT	O
inhibitor	O
compound	O
is	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

A	O
pharmaceutical	O
composition	O
comprises	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

A	O
method	O
of	O
treating	O
a	O
subject	O
having	O
cancer	O
comprises	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Inhibitors	O
of	O
carnitine	B
palmitoyltransferase	O
and	O
treating	O
cancer	O

Provided	O
herein	O
are	O
novel	O
polypeptides	O
,	O
polynucleotides	O
and	O
compositions	O
containing	O
such	O
,	O
and	O
to	O
methods	O
useful	O
in	O
treating	O
diseases	O
,	O
disorders	O
,	O
or	O
conditions	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
associated	O
with	O
demyelination	O
.	O

The	O
novel	O
polypeptides	O
,	O
polynucleotides	O
stimulate	O
oligodendrocyte	O
precursor	O
cell	O
(	O
OPC	O
)	O
,	O
and	O
are	O
capable	O
of	O
promoting	O
myelination	O
or	O
remyelination	O
in	O
a	O
subject	O
.	O

Compositions	O
and	O
methods	O
for	O
treating	O
diseases	O
,	O
disorders	O
or	O
conditions	O
characterized	O
by	O
myelin	O
degeneration	O
,	O
myelin	O
deficiency	O
or	O
loss	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
chronic	O
pain	O
,	O
in	O
particular	O
,	O
neuropathic	O
pain	O
,	O
chronic	O
visceral	O
pain	O
,	O
chronic	O
inflammatory	O
pain	O
and	O
pain	O
resulting	O
from	O
fibromyalgia	O
syndrome	O
,	O
in	O
a	O
subject	O
by	O
administering	O
Dimebon	O
™	O
antihistamine	O
agent	O
(	O
DETCD	O
)	O
to	O
the	O
subject	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
chronic	O
pain	O
in	O
a	O
subject	O
by	O
administering	O
a	O
combination	O
of	O
DETCD	O
and	O
one	O
or	O
more	O
additional	O
agents	O
,	O
such	O
as	O
an	O
antidepressant	O
agent	O
,	O
an	O
anticonvulsant	O
agent	O
,	O
an	O
antiarrhythmic	O
agent	O
,	O
an	O
anesthetic	O
agent	O
,	O
an	O
NMDA	O
antagonist	O
,	O
or	O
a	O
narcotic	O
.	O

2	B
,	I
8-dimethyl-5-	I
[	I
2-	I
(	I
6-methylpyridin-3-yl	I
)	I
-ethyl	I
]	I
-2,3,4	I
,	I
5-tetrahydro-	I
ih-	I
pyrido	I
[	I
4	I
,	I
3	I
-b	I
]	I
indole	I
dihydrochloride	I
(	O
dimebon	B
)	O
for	O
the	O
treatment	O
of	O
chronic	O
pain	O

The	O
invention	O
relates	O
to	O
substituted	O
imidazopyrimidines	B
and	O
triazolopyrimidines	B
,	O
to	O
methods	O
for	O
the	O
production	O
thereof	O
,	O
and	O
to	O
the	O
use	O
of	O
same	O
for	O
producing	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
especially	O
haematological	O
diseases	O
,	O
preferably	O
leucopenia	O
and	O
neutropenia	O
.	O

Substituted	O
imidazopyrimidines	B
and	O
triazolopyrimidines	B

The	O
present	O
invention	O
provides	O
PLK1	O
inhibitor	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

Useful	O
in	O
the	O
treatment	O
or	O
control	O
of	O
cell	O
proliferative	O
disorders	O
,	O
particularly	O
oncological	O
disorders	O
.	O

These	O
compounds	O
and	O
formulations	O
containing	O
such	O
compounds	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
or	O
control	O
of	O
solid	O
tumors	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
breast	O
,	O
colon	O
,	O
lung	O
and	O
prostate	O
tumors	O
and	O
other	O
oncological	O
diseases	O
such	O
as	O
non	O
-	O
Hodgkin	O
's	O
lymphomas	O
.	O

Substituted	O
pyrimidodiazepines	B
useful	O
as	O
plk1	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
XI	O
)	O
or	O
(	O
CI	O
)	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
said	O
compounds	O
and	O
to	O
the	O
use	O
of	O
said	O
compounds	O
in	O
therapy	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
XI	O
)	O
or	O
(	O
CI	O
)	O
and	O
to	O
new	O
intermediates	O
used	O
in	O
the	O
preparation	O
thereof	O
.	O

4	B
,	I
5-dihydro-1,3-thiazol-2-amine	I
derivatives	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
respiratory	O
,	O
cardiovascular	O
,	O
neurological	O
or	O
gastrointestinal	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
pyrazoloanthrones	B
or	O
functional	O
derivatives	O
or	O
functional	O
analogues	O
thereof	O
to	O
activate	O
MIS	O
receptor	O
-	O
mediated	O
downstream	O
effects	O
in	O
a	O
cell	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
method	O
to	O
prevent	O
and	O
treat	O
cancer	O
that	O
expresses	O
MIS	O
receptor	O
type	O
II	O
(	O
MISRII	O
)	O
by	O
administering	O
to	O
a	O
subject	O
at	O
least	O
one	O
pyrazoloanthrone	B
or	O
a	O
functional	O
derivative	O
or	O
a	O
functional	O
analogue	O
thereof	O
.	O

Another	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
to	O
lower	O
plasma	O
androgen	B
levels	O
in	O
a	O
subject	O
,	O
and/or	O
for	O
the	O
treatment	O
of	O
a	O
subject	O
with	O
a	O
disease	O
characterized	O
by	O
excess	O
androgen	B
,	O
whereby	O
the	O
subject	O
is	O
administered	O
at	O
least	O
one	O
pyrazoloanthrone	B
or	O
a	O
functional	O
derivative	O
or	O
a	O
functional	O
analogue	O
thereof	O
.	O

Another	O
aspect	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
pyrazoloanthrone	B
or	O
functional	O
a	O
derivative	O
or	O
a	O
functional	O
analogue	O
thereof	O
,	O
and	O
optionally	O
with	O
one	O
or	O
more	O
additional	O
agents	O
such	O
as	O
chemotherapeutic	O
agents	O
.	O

Another	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
to	O
decrease	O
the	O
dose	O
of	O
a	O
chemotherapeutic	O
agent	O
by	O
administering	O
the	O
chemotherapeutic	O
agent	O
with	O
a	O
pyrazoloanthrone	B
or	O
a	O
functional	O
derivative	O
or	O
a	O
functional	O
analogue	O
thereof	O
that	O
lowers	O
the	O
effective	O
dose	O
of	O
the	O
chemotherapeutic	O
agent	O
,	O
such	O
as	O
for	O
example	O
,	O
paclitaxel	B
.	O

Pyrazoloanthrone	B
and	O
derivatives	O
thereof	O
for	O
the	O
treatment	O
of	O
cancer	O
expressing	O
'	O
mullerian	O
inhibiting	O
substance	O
'	O
type	O
ii	O
receptor	O
(	O
misrii	O
)	O
and	O
of	O
excess	O
androgen	O
states	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
,	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
provide	O
a	O
treatment	O
for	O
myeloproliferative	O
disorders	O
and	O
cancer	O
.	O

Pyrazolyl	B
-	I
amino	I
-	I
substituted	I
pyrazines	I
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
cancer	O

Novel	O
heterocyclic	B
compounds	O
of	O
formula	O

I	O
:	O

A	O
-	O
B	O
-	O
D	O
Formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
:	O
A	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
moiety	O
having	O
general	O
Formula	O
II	O
and	O
a	O
moiety	O
having	O
general	O
Formula	O
III	O
:	O

Formula	O
II	O
Formula	O
III	O
B	O
is	O
a	O
moiety	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
O	O
D	O
is	O
a	O
moiety	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
N	B
and	O
which	O
exhibit	O
a	O
dopamine	B
receptor	O
(	O
preferably	O
a	O
D4	O
receptor	O
)	O
and/or	O
a	O
serotonine	B
receptor	O
(	O
preferably	O
5HTAi	O
agonistic	O
activity	O
)	O
,	O
processes	O
of	O
preparing	O
same	O
,	O
pharmaceutical	O
compositions	O
containing	O
same	O
and	O
uses	O
thereof	O
in	O
the	O
treatment	O
of	O
medical	O
conditions	O
associated	O
with	O
the	O
dopaminergic	O
and/or	O
serotonergic	O
systems	O
(	O
e.g.	O
,	O
sexual	O
disorders	O
,	O
dyskinesia	O
,	O
anxiety	O
)	O
are	O
disclosed	O
.	O

Heterotri	B
cyciii	I
c	I
compounds	O
as	O
serotonergic	O
and/or	O
dopaminergic	O
agents	O
and	O
uses	O
thereof	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
are	O
provided:	O
(	O
I	O
)	O
wherein	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
Q	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

Uses	O
of	O
the	O
compounds	O
as	O
medicaments	O
and	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
treating	O
psychotic	O
disorders	O
and	O
cognitive	O
impairments	O
are	O
disclosed	O
.	O

The	O
invention	O
further	O
discloses	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
.	O

Substituted	O
benzimidazolone	B
compounds	O
which	O
have	O
activity	O
at	O
m1	O
receptor	O
and	O
their	O
uses	O
in	O
medicine	O

A	O
quinoline-3-carboxyderivative	B
of	O
formula	O
(	O
I	O
)	O
,	O
a	O
method	O
for	O
preparing	O
it	O
and	O
use	O
ofthe	O
derivativein	O
therapy	O
,	O
in	O
particular	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cell	O
proliferative	O
disorders	O
or	O
cell	O
differentiation	O
disorders	O
.	O

Quinoline	B
-	I
s	I
-	I
carboxylic	I
acid	I
derivatives	O
as	O
tyrosine	B
kinase	O
inhibitors	O

The	O
present	O
invention	O
provides	O
novel	O
benzophenone	B
hybrids	O
as	O
potential	O
anticancer	O
agents	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
N1-	B
[	I
4-chloro-	I
2-	I
(	I
2-chlorøbenzoyl	I
)	I
phenyl	I
]	I
-2-	I
[	I
4-	I
(	I
aryl	I
)	I
piperazinojacetamide	I
with	O
aliphatic	O
chain	O
length	O
variations	O
of	O
formula	O
(	O
A	O
)	O
.	O

Novel	O
benzophenone	B
hybrids	O
as	O
potential	O
anticancer	O
agents	O
and	O
a	O
process	O
for	O
the	O
preparation	O
thereof	O

A	O
composition	O
to	O
inhibit	O
the	O
formation	O
of	O
adhesions	O
that	O
may	O
arise	O
at	O
a	O
surgical	O
site	O
.	O

The	O
composition	O
includes	O
an	O
antioxidant	O
in	O
a	O
carrier	O
.	O

The	O
carrier	O
is	O
comprised	O
of	O
cocamide	B
diethanolamine	I
,	O
diethanolamine	B
and	O
glycerin	B
.	O

The	O
composition	O
may	O
include	O
additional	O
additives	O
,	O
such	O
as	O
euricamide	O
and	O
a	O
compound	O
including	O
a	O
polyethylene	B
resin	O
,	O
calcium	B
carbonate	I
and	O
a	O
concentrated	O
form	O
of	O
the	O
carrier	O
.	O

The	O
composition	O
is	O
produced	O
by	O
heating	O
the	O
carrier	O
to	O
a	O
temperature	O
,	O
preferably	O
about	O
375	O
°	O
F	O
and	O
then	O
adding	O
the	O
additives	O
.	O

The	O
mixture	O
is	O
heated	O
at	O
temperature	O
long	O
enough	O
to	O
cause	O
the	O
antioxidant	O
to	O
leach	O
into	O
the	O
liquid	O
.	O

The	O
mixture	O
is	O
then	O
cooled	O
at	O
room	O
temperature	O
and	O
maintained	O
in	O
liquid	O
form	O
for	O
ease	O
of	O
application	O
to	O
the	O
surgical	O
site	O
where	O
adhesion	O
formation	O
inhibition	O
is	O
desired	O
.	O

The	O
composition	O
is	O
preferably	O
degradable	O
in	O
vivo	O
.	O

Fluid	O
composition	O
for	O
inhibiting	O
surgical	O
adhesion	O
formation	O
and	O
related	O
method	O
of	O
production	O

The	O
present	O
invention	O
provides	O
a	O
new	O
forms	O
of	O
(	B
R	I
)	I
-N	I
-	I
methylnaltrexone	I
,	O
and	O
compositions	O
thereof	O
,	O
useful	O
as	O
a	O
peripheral	O
mu	O
opioid	O
receptor	O
antagonist	O
.	O

Crystal	O
forms	O
of	O
(	O
r	O
)	O
-n	O
-	O
methylnaltrexone	O
bromide	O
and	O
uses	O
thereof	O

The	O
instant	O
invention	O
is	O
directed	O
towards	O
steroid	B
compounds	O
and	O
compositions	O
,	O
methods	O
of	O
inhibiting	O
Tdpl	O
activity	O
,	O
and	O
methods	O
of	O
treating	O
Tdpl	O
-associated	O
disorders	O
including	O
cancer	O
,	O
using	O
steroid	B
derivatives	O
.	O

Steroid	B
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
treatment	O

The	O
present	O
invention	O
relates	O
to	O
non	O
-	O
steroidal	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

A	O
representative	O
example	O
of	O
these	O
compounds	O
is	O
formula	O
(	O
III	O
)	O
.	O

Non	O
-	O
steroidal	O
compounds	O

The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
product	O
and	O
a	O
process	O
for	O
bone	O
regeneration	O
and	O
neoformation	O
,	O
which	O
uses	O
sirtuin	O
modulators	O
such	O
as	O
resveratrol	B
and/or	O
trans	B
-	I
resveratrol	I
.	O

Among	O
the	O
several	O
advantages	O
of	O
the	O
invention	O
,	O
worth	O
of	O
notice	O
is	O
the	O
substantial	O
acceleration	O
in	O
the	O
process	O
of	O
integration	O
of	O
biomaterials	O
to	O
the	O
body	O
,	O
substantially	O
shortening	O
the	O
recovery	O
period	O
of	O
the	O
injured	O
or	O
lost	O
organ	O
.	O

Resveratrol	B
-	O
containing	O
composition	O
for	O
modulating	O
bone	O
formation	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
modulating	O
,	O
disrupting	O
or	O
enhancing	O
the	O
clearance	O
of	O
copper	B
/	O
zinc	B
superoxide	I
dismutase	O
1	O
(	O
SOD1	O
)	O
aggregates	O
in	O
astrocytes	O
or	O
motor	O
neurons	O
in	O
a	O
subject	O
,	O
by	O
administering	O
a	O
medicament	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
cyclohexanehexol	B
derivative	O
.	O

In	O
another	O
aspect	O
,	O
the	O
invention	O
provides	O
a	O
medicament	O
comprising	O
at	O
least	O
one	O
cyclohexanehexol	B
derivative	O
of	O
formula	O
III	O
or	O
IV	O
useful	O
in	O
preventing	O
or	O
treating	O
amyothropic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
improving	O
motor	O
neuron	O
function	O
and	O
slowing	O
the	O
degeneration	O
or	O
death	O
of	O
motor	O
neurons	O
in	O
brain	O
stem	O
,	O
spinal	O
cord	O
or	O
motor	O
cortex	O
.	O

These	O
medicaments	O
may	O
be	O
administered	O
orally	O
,	O
intravenously	O
,	O
intraperitoneal	O
,	O
subcutaneous	O
,	O
intramuscular	O
,	O
intranasal	O
or	O
transdermal	O
.	O

Use	O
of	O
cyclohexanehexol	B
derivatives	O
in	O
the	O
treatment	O
of	O
amyotrophic	O
lateral	O
sclerosis	O

The	O
present	O
study	O
has	O
demonstrated	O
that	O
heparanase	O
expression	O
and	O
activity	O
was	O
increased	O
in	O
human	O
microvascular	O
endothelial	O
cells	O
and	O
rat	O
kidney	O
epithelial	O
cells	O
growing	O
under	O
hyperglycemia	O
condition	O
,	O
as	O
found	O
in	O
diabetic	O
nephropathy	O
disease	O
.	O

Oligotide	O
was	O
able	O
to	O
:	O
-downregulate	O
the	O
heparanase	O
gene	O
expression	O
;	O
-downregulate	O
the	O
cell	O
surface	O
protein	O
expression	O
;	O
-decrease	O
the	O
heparanase	O
enzymatic	O
activity	O
.	O

Since	O
heparanase	O
is	O
a	O
critical	O
factor	O
in	O
maintaining	O
glomerular	O
basement	O
membrane	O
integrity	O
and	O
is	O
elevated	O
in	O
renal	O
diseases	O
,	O
as	O
for	O
instance	O
diabetic	O
nephropathies	O
,	O
Oligotide	O
should	O
be	O
considered	O
for	O
the	O
management	O
of	O
these	O
diseases	O
.	O

Use	O
of	O
oligotide	O
for	O
the	O
treatment	O
of	O
renal	O
diseases	O

The	O
invention	O
provides	O
compounds	O
which	O
are	O
pyrimidines	B
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
a	O
group	O
-NR-	B
(	I
CHR	I
)	I
m	I
-	I
X	I
;	O
R2	O
is	O
a	O
substituted	O
indolyl	B
group	O
;	O
R	O
is	O
H	B
or	O
C1-C6	B
alkyl	I
;	O
m	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
and	O
X	O
is	O
a	O
pyridyl	B
ring	O
;	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

These	O
compounds	O
are	O
inhibitors	O
of	O
PI3	O
K	O
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth	O
,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	O
kinase	O
such	O
as	O
cancer	O
,	O
immune	O
disorders	O
,	O
cardiovascular	O
disease	O
,	O
viral	O
infection	O
,	O
inflammation	O
,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O

2-morpholin-4-yl	B
-	I
pyrimidines	I
as	O
pi3k	O
inhibitors	O

Provided	O
herein	O
are	O
compounds	O
that	O
modulate	O
the	O
activity	O
of	O
a	O
bacterial	O
peptidyl	O
tRNA	O
hydrolase	O
,	O
including	O
compositions	O
and	O
dosage	O
forms	O
comprising	O
the	O
compounds	O
.	O

Further	O
provided	O
herein	O
are	O
methods	O
for	O
preventing	O
or	O
inhibiting	O
bacterial	O
proliferation	O
as	O
well	O
as	O
methods	O
for	O
preventing	O
,	O
treating	O
,	O
and/or	O
managing	O
a	O
bacterial	O
infection	O
using	O
such	O
compounds	O
and	O
compositions	O
.	O

Pyrrolinone	B
compounds	O
as	O
inhibitors	O
of	O
bacterial	O
peptidyl	O
trna	O
hydrolase	O
and	O
uses	O
thereof	O

Methods	O
and	O
compositions	O
for	O
contributing	O
to	O
the	O
treatment	O
of	O
cancers	O
,	O
especially	O
ovarian	O
tumors	O
,	O
are	O
disclosed	O
.	O

The	O
methods	O
and	O
compositions	O
utilize	O
an	O
endothelin	O
B	O
agonist	O
(	O
ETB	O
)	O
to	O
enhance	O
the	O
delivery	O
and	O
resulting	O
efficacy	O
of	O
chemotherapeutic	O
agent	O
(	O
s	O
)	O
(	O
e.g.	O
,	O
cisplatin	B
and/or	O
cyclophosphamide	B
)	O
.	O

Methods	O
and	O
compositions	O
for	O
contributing	O
to	O
the	O
treatment	O
of	O
cancers	O

Provided	O
is	O
a	O
process	O
for	O
preparing	O
gemcitabine	B
or	O
a	O
salt	O
thereof	O
,	O
which	O
preferably	O
includes	O
selectively	O
precipitating	O
the	O
β	O
-	O
anomer	O
of	O
a	O
3',5'-di	B
-	I
O	I
-	I
protected	I
-	I
N4-trimethylsilyl-2'-deoxy-2',2'-difluorocytidine	I
,	O
removing	O
the	O
protecting	O
groups	O
to	O
produce	O
gemcitabine	B
,	O
and	O
,	O
optionally	O
,	O
converting	O
the	O
gemcitabine	B
into	O
a	O
salt	O
.	O

Preferably	O
,	O
the	O
3	O
'	O
and	O
5	O
'	O
protecting	O
groups	O
are	O
the	O
same	O
or	O
different	O
,	O
and	O
at	O
least	O
one	O
of	O
the	O
3	O
'	O
and	O
5	O
'	O
protecting	O
groups	O
is	O
cinnamoyl	B
,	O
naphthoyl	B
,	O
naphthylmethylcarbonyl	B
,	O
2-methylbenzylcarbonyl	B
,	O
4-methylbenzylcarbonyl	B
or	O
9-fluorenylmethyloxycarbonyl	B
.	O

Also	O
provided	O
are	O
methods	O
for	O
enriching	O
the	O
β	O
-	O
anomer	O
from	O
an	O
anomeric	O
mixture	O
of	O
a	O
3',5'-di	B
-	I
O	I
-	I
protected	I
-	I
N4-trimethylsilyl-2'-deoxy-2',2'-difluorocytidine	I
,	O
e.g.	O
,	O
a	O
N4-trimethylsilyl-2'-deoxy-2',2'-difluoro	B
-	I
cytidine-3',5'-diester	I
,	O
e.g.	O
,	O
3',5'-dicinnamoyl	B
-	I
N4-trimethylsilyl-2'-deoxy-2',2'-difluorocytidine	I
,	O
using	O
a	O
slurrying	O
process	O
,	O
and	O
methods	O
for	O
converting	O
the	O
β	O
-	O
anomer	O
-	O
enriched	O
product	O
into	O
gemcitabine	B
or	O
a	O
salt	O
thereof	O
.	O

Gemcitabine	B
production	O
process	O

Formation	O
of	O
adhesions	O
,	O
which	O
is	O
a	O
process	O
in	O
which	O
adjacent	O
tissues	O
or	O
organs	O
bind	O
to	O
each	O
other	O
,	O
can	O
be	O
caused	O
by	O
infections	O
,	O
inflammation	O
diseases	O
,	O
surgery	O
procedures	O
or	O
trauma	O
.	O

Following	O
abdominal	O
surgery	O
,	O
the	O
incidence	O
of	O
the	O
formation	O
of	O
adhesions	O
may	O
be	O
as	O
high	O
as	O
90	O
%	O
.	O

Pain	O
,	O
discomfort	O
,	O
immobility	O
and	O
retarded	O
wound	O
healing	O
are	O
common	O
complications	O
due	O
to	O
adhesions	O
formation	O
;	O
moreover	O
,	O
depending	O
on	O
the	O
tissues	O
involved	O
,	O
adhesions	O
can	O
cause	O
various	O
disorders	O
.	O

In	O
the	O
eye	O
,	O
adhesion	O
of	O
the	O
iris	O
to	O
the	O
lens	O
can	O
lead	O
to	O
glaucoma	O
.	O

In	O
the	O
intestines	O
,	O
adhesions	O
can	O
cause	O
partial	O
or	O
complete	O
bowel	O
obstruction	O
which	O
is	O
life	O
threatening	O
.	O

Intrauterine	O
adhesions	O
are	O
known	O
as	O
the	O
Asherman	O
syndrome	O
.	O

Pelvic	O
adhesions	O
can	O
lead	O
to	O
infertility	O
and	O
reproductive	O
problems	O
.	O

Problems	O
associated	O
with	O
adhesions	O
often	O
require	O
a	O
further	O
operative	O
procedure	O
in	O
order	O
to	O
remove	O
the	O
adhesions	O
.	O

This	O
could	O
have	O
the	O
major	O
drawback	O
of	O
leading	O
to	O
new	O
adhesion	O
formation	O
.	O

A	O
wide	O
variety	O
of	O
adjunctive	O
treatments	O
have	O
been	O
investigated	O
to	O
reduce	O
or	O
prevent	O
post	O
surgical	O
adhesions	O
.	O

Most	O
of	O
these	O
treatments	O
,	O
however	O
,	O
show	O
inconsistent	O
results	O
.	O

In	O
an	O
attempt	O
to	O
reduce	O
the	O
inflammatory	O
reaction	O
at	O
the	O
wounded	O
site	O
following	O
surgery	O
,	O
the	O
use	O
of	O
corticosteroids	O
,	O
NSAIDS	O
,	O
histamine	O
antagonists	O
and	O
calcium	O
channel	O
blockers	O
have	O
been	O
investigated	O
.	O

More	O
recently	O
,	O
barrier	O
materials	O
have	O
been	O
suggested	O
for	O
the	O
prevention	O
of	O
post	O
surgical	O
adhesions	O
.	O

These	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
Hyskon	O
®	O
,	O
Ringer	O
's	O
lactate	O
,	O
Interceed	O
®	O
(	O
oxidized	O
regenerated	O
cellulose	O
)	O
,	O
Polaxamer	O
407	O
®	O
(	O
temperature	O
dependent	O
polymer	O
)	O
,	O
Gore	O
-	O
Tex	O
®	O
(	O
expanded	O
polytetrafluorethylene	O
)	O
and	O
SepraFilm	O
®	O
(	O
hyaluronic	O
acid	O
derivative	O
film	O
)	O
.	O

Composition	O
,	O
methods	O
and	O
kits	O
for	O
prevention	O
of	O
adhesion	O

Disclosed	O
is	O
a	O
method	O
for	O
improving	O
the	O
activity	O
of	O
a	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
-scavenging	O
enzyme	O
,	O
which	O
has	O
a	O
mechanism	O
of	O
action	O
based	O
on	O
scientific	O
grounds	O
,	O
is	O
highly	O
safe	O
,	O
is	O
inexpensive	O
,	O
and	O
is	O
widely	O
applicable	O
.	O

An	O
organism	O
having	O
an	O
ROS	O
-	O
scavenging	O
enzyme	O
(	O
e.g.	O
,	O
superoxide	O
dismutase	O
,	O
catalase	O
,	O
peroxidase	O
)	O
is	O
administered	O
with	O
one	O
or	O
more	O
substances	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
erythritol	B
,	O
mannitol	B
,	O
sorbitol	B
and	O
xylitol	B
at	O
a	O
dosage	O
concentration	O
of	O
0.01	O
to	O
10	O
%	O
to	O
thereby	O
induce	O
the	O
increase	O
in	O
the	O
amount	O
or	O
the	O
enhancement	O
of	O
the	O
activity	O
of	O
the	O
ROS	O
-	O
scavenging	O
enzyme	O
in	O
the	O
organism	O
.	O

Method	O
for	O
improvement	O
in	O
activities	O
of	O
reactive	O
oxygen	B
species	O
-	O
scavenging	O
enzymes	O

The	O
present	O
invention	O
is	O
directed	O
to	O
benzoxazole	B
compounds	O
which	O
are	O
ltgands	O
at	O
the	O
NPY	O
Y5	O
receptor	O
.	O

The	O
invention	O
further	O
provides	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

This	O
invention	O
also	O
provides	O
a	O
method	O
of	O
treating	O
a	O
subject	O
suffering	O
from	O
depression	O
,	O
anxiety	O
or	O
obesity	O
which	O
comprises	O
administering	O
to	O
the	O
subject	O
an	O
amount	O
of	O
a	O
compound	O
of	O
the	O
subject	O
invention	O
.	O

Furthermore	O
,	O
this	O
invention	O
also	O
provides	O
uses	O
of	O
a	O
compound	O
of	O
the	O
invention	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
depression	O
,	O
anxiety	O
or	O
obesity	O
.	O

Benzoxazole	B
compounds	O

A	O
proliferation	O
of	O
cells	O
can	O
be	O
reduced	O
by	O
contacting	O
the	O
cells	O
with	O
a	O
compound	O
having	O
formula	O
(	O
I	O
)	O
.	O

where	O
R	O
and	O
R	O
are	O
each	O
alkyl	B
groups	O
,	O
R	O
'	O
is	O
hydrogen	O
or	O
an	O
alkyl	B
group	O
and	O
X3	O
,	O
X4	O
and	O
X5	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
benzyl	B
,	O
t	B
-	I
butyldimethylsiloxy	I
radical	I
and	O
triphenylmethyl	B
.	O

Accordingly	O
,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
used	O
for	O
treatment	O
of	O
tumors	O
including	O
melanoma	O
.	O

Also	O
a	O
secretion	O
of	O
a	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
enzyme	O
by	O
cells	O
can	O
be	O
reduced	O
by	O
contacting	O
the	O
cells	O
with	O
the	O
compound	O
having	O
formula	O
(	O
I	O
)	O
.	O

Accordingly	O
,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
can	O
be	O
used	O
for	O
treatment	O
physiological	O
conditions	O
associated	O
with	O
an	O
elevated	O
MMP	O
level	O
,	O
such	O
as	O
tumors	O
.	O

Iminosugar	B
for	O
treatment	O
of	O
tumors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
(	O
a	O
)	O
ICA512	O
,	O
pro	O
-	O
ICA512	O
,	O
ICA512-TMF	O
or	O
ICA512-CCF	O
,	O
each	O
devoid	O
of	O
the	O
C	O
-	O
terminus	O
or	O
PHOGRIN	O
devoid	O
of	O
the	O
C	O
-	O
terminus	O
,	O
wherein	O
said	O
ICA512	O
,	O
pro	O
-	O
ICA512	O
,	O
ICA512-	O
TMF	O
,	O
ICA512-CCF	O
or	O
PHOGRIN	O
does	O
not	O
comprise	O
a	O
functional	O
domain	O
involved	O
in	O
the	O
binding	O
to	O
the	O
PDZ	O
domain	O
of	O
β2-syntrophin	O
,	O
or	O
a	O
mimetic	O
of	O
the	O
C	O
-	O
terminus	O
of	O
ICA512	O
,	O
pro	O
-	O
ICA512	O
,	O
ICA512-TMF	O
,	O
ICA512-CCF	O
or	O
PHOGRIN	O
;	O
(	O
b	O
)	O
a	O
compound	O
promoting	O
the	O
presence	O
or	O
activity	O
of	O
a	O
protease	O
that	O
cleaves	O
the	O
C	O
-	O
terminus	O
of	O
ICA512	O
,	O
pro	O
-	O
ICA512	O
,	O
ICA512-TMF	O
or	O
ICA512-CCF	O
or	O
PHOGRIN	O
,	O
wherein	O
the	O
removed	O
C	O
-	O
terminal	O
fragment	O
includes	O
the	O
functional	O
domain	O
involved	O
in	O
the	O
binding	O
to	O
the	O
PDZ	O
domain	O
of	O
β2-syntrophin	O
or	O
a	O
portion	O
of	O
said	O
functional	O
domain	O
wherein	O
said	O
portion	O
is	O
sufficient	O
to	O
hinder	O
binding	O
of	O
ICA512	O
,	O
pro	O
-	O
ICA512	O
,	O
ICA512-TMF	O
or	O
ICA512-CCF	O
or	O
PHOGRIN	O
to	O
β2-syntrophin	O
;	O
(	O
c	O
)	O
a	O
compound	O
promoting	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine	B
/	O
threonine	B
kinase	O
which	O
phosphorylates	O
β2-	O
syntrophin	O
on	O
serine	B
residue	O
95	O
;	O
(	O
d	O
)	O
a	O
compound	O
interfering	O
with	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine	B
/	O
threonine	B
phosphatase	O
which	O
dephosphorylates	O
β2-syntrophin	O
on	O
serine	B
residue	O
95	O
;	O
(	O
e	O
)	O
a	O
compound	O
promoting	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine	B
/	O
threonine	B
phosphatase	O
which	O
dephosphorylates	O
β2-syntrophin	O
on	O
serine	B
residue	O
110	O
;	O
or	O
(	O
f	O
)	O
a	O
compound	O
interfering	O
with	O
the	O
presence	O
or	O
activity	O
of	O
a	O
serine	B
/	O
threonine	B
kinase	O
which	O
phosphorylates	O
β2-syntrophin	O
on	O
serine	B
residue	O
110	O
.	O

PHARMACEUTICAL	O
COMPOSITION	O
FOR	O
INCREASING	O
INSULIN	O
SECRETION	O
FROM	O
PANCREATIC	O
β	O
-	O
CELLS	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
,	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
,	O
intermediates	O
used	O
in	O
the	O
preparation	O
of	O
,	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
uses	O
of	O
such	O
compounds	O
for	O
the	O
treatment	O
of	O
pain	O
.	O

N-	B
[	I
6-amino-5-	I
(	I
phenyl	I
)	I
pyrazin-2-yl	I
]	I
-isoxazole-4-carboxamide	I
derivatives	O
and	O
related	O
compounds	O
as	O
nav1.8	O
channel	O
modulators	O
for	O
the	O
treatment	O
of	O
pain	O

Disclosed	O
are	O
a	O
substance	O
and	O
a	O
pharmaceutical	O
product	O
inhibiting	O
activation	O
of	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
.	O

Specifically	O
disclosed	O
is	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
inhibitor	O
containing	O
a	O
specific	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
1	O
)	O
.	O

G	O
protein	O
-	O
coupled	O
receptor	O
inhibitor	O
and	O
pharmaceutical	O
product	O

It	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
microtubule	O
-	O
disrupting	O
agent	O
and	O
use	O
of	O
this	O
microtubule	O
-	O
disrupting	O
agent	O
.	O

Namely	O
,	O
a	O
microtubule	O
-	O
disrupting	O
agent	O
which	O
comprises	O
an	O
α	O
,	O
β	O
-	O
unsaturated	O
carbonyl	O
compound	O
as	O
the	O
active	O
ingredient	O
is	O
provided	O
.	O

Further	O
,	O
a	O
cancer	O
cell	O
proliferation	O
inhibitor	O
which	O
contains	O
this	O
microtubule	O
-	O
disrupting	O
agent	O
is	O
provided	O
.	O

As	O
the	O
α	O
,	O
β	O
-	O
unsaturated	O
carbonyl	O
compound	O
,	O
it	O
is	O
preferable	O
to	O
use	O
6-shogaol	O
.	O

Microtubule	O
-	O
disrupting	O
agent	O
and	O
cancer	O
cell	O
proliferation	O
inhibitor	O
containing	O
the	O
same	O

Disclosed	O
is	O
a	O
novel	O
aralkyl	B
carboxylic	I
acid	I
compound	O
which	O
has	O
an	O
agonistic	O
activity	O
on	O
GPR-120	O
and/or	O
GPR-40	O
,	O
particularly	O
GPR-120	O
,	O
and	O
is	O
therefore	O
useful	O
as	O
an	O
appetite	O
regulator	O
,	O
an	O
anti	O
-	O
obesity	O
agent	O
,	O
a	O
therapeutic	O
agent	O
for	O
diabetes	O
,	O
a	O
pancreatic	O
beta	O
differentiating	O
cell	O
growth	O
enhancer	O
,	O
a	O
therapeutic	O
agent	O
for	O
metabolic	O
syndrome	O
,	O
a	O
therapeutic	O
agent	O
for	O
a	O
gastrointestinal	O
disease	O
,	O
a	O
therapeutic	O
agent	O
for	O
a	O
neuropathy	O
,	O
a	O
therapeutic	O
agent	O
for	O
a	O
mental	O
disorder	O
,	O
a	O
therapeutic	O
agent	O
for	O
a	O
pulmonary	O
disease	O
,	O
a	O
therapeutic	O
agent	O
for	O
a	O
pituitary	O
hormone	O
secretion	O
disorder	O
or	O
a	O
lipid	O
flavoring	O
/	O
seasoning	O
agent	O
.	O

The	O
aralkyl	B
carboxylic	I
acid	I
compound	O
is	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
.	O

(	O
I	O
)	O
wherein	O
the	O
ring	O
Q	O
represents	O
a	O
pyridyl	B
or	O
the	O
like	O
;	O
R1	O
represents	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1	B
-	I
4	I
alkyl	I
group	O
or	O
a	O
C1	B
-	I
4	I
alkoxy	I
group	O
;	O
m	O
and	O
n	O
independently	O
represent	O
an	O
integer	O
of	O
1	O
to	O
5	O
;	O
and	O
X	O
represents	O
an	O
oxygen	B
atom	O
,	O
a	O
sulfur	B
atom	O
or	O
-NR3-	B
[	O
wherein	O
R3	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
C1	B
-	I
4	I
alkyl	I
group	O
]	O
.	O

G	O
-	O
protein	O
-	O
conjugated	O
receptor	O
agonist	O

The	O
present	O
invention	O
relates	O
to	O
pyrimidine	B
compounds	O
that	O
are	O
useful	O
as	O
agents	O
for	O
the	O
treatment	O
of	O
kinase	O
related	O
disorders	O
such	O
as	O
proliferative	O
disorders	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
heterocycloalkyl	B
substituted	I
pyrimidine	I
compounds	O
,	O
methods	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders	O
.	O

These	O
compounds	O
may	O
be	O
useful	O
as	O
medicaments	O
for	O
the	O
treatment	O
of	O
a	O
number	O
of	O
kinase	O
related	O
disorders	O
such	O
as	O
proliferative	O
disorders	O
including	O
tumours	O
and	O
cancers	O
as	O
well	O
as	O
other	O
disorders	O
or	O
conditions	O
related	O
to	O
or	O
associated	O
with	O
kinases	O
.	O

Heterocycloalkyl	B
substituted	I
pyrimidine	I
derivatives	O

Dietary	O
formulations	O
in	O
the	O
form	O
of	O
an	O
oil	O
emulsion	O
providing	O
total	O
enteral	O
or	O
parenteral	O
nutrition	O
,	O
or	O
in	O
the	O
form	O
of	O
food	O
oil	O
suitable	O
for	O
oral	O
administration	O
is	O
provided	O
.	O

The	O
formulations	O
include	O
about	O
2	O
-	O
60	O
%	O
by	O
calories	O
of	O
a	O
C20	B
or	O
longer	O
omega-3	B
fatty	I
acid	I
and	O
about	O
0.05	O
%	O
to	O
1	O
%	O
by	O
calories	O
of	O
arachidonic	B
acid	I
,	O
where	O
the	O
formulation	O
provides	O
less	O
than	O
1	O
%	O
of	O
total	O
calories	O
from	O
linoleic	B
acid	I
and	O
alpha	B
-	I
linolenic	I
acid	I
,	O
and	O
where	O
the	O
fatty	B
acids	I
provide	O
5	O
-	O
60	O
%	O
of	O
the	O
total	O
calories	O
of	O
said	O
dietary	O
formulation	O
.	O

Methods	O
for	O
treatment	O
of	O
diseases	O
and	O
disorders	O
using	O
the	O
dietary	O
formulations	O
are	O
also	O
provided	O
.	O

Dietary	O
formulations	O
and	O
methods	O
for	O
treatment	O
of	O
inflammation	O
and	O
other	O
disorders	O

The	O
composition	O
containing	O
cycloartenol	B
ferulic	I
acid	I
ester	I
and	O
24-methylenecycloaltanol	B
ferulic	I
acid	I
ester	I
as	O
the	O
active	O
components	O
and	O
pharmaceutical	O
preparation	O
and	O
application	O
thereof	O
are	O
provided	O
.	O

The	O
weight	O
percent	O
of	O
the	O
two	O
active	O
components	O
is	O
above	O
over	O
90	O
%	O
in	O
the	O
composition	O
.	O

The	O
said	O
composition	O
can	O
be	O
injections	O
,	O
freeze	O
-	O
dried	O
powders	O
or	O
oral	O
solid	O
preparation	O
,	O
and	O
can	O
be	O
used	O
to	O
treat	O
vegetative	O
dystonie	O
syndrome	O
,	O
climacteric	O
period	O
syndrome	O
,	O
essential	O
dysmenorrhea	O
,	O
premenstrual	O
tension	O
,	O
periodic	O
psychosis	O
,	O
vascular	O
headache	O
,	O
head	O
injury	O
syndrome	O
,	O
stomach	O
intestine	O
nerve	O
detuning	O
syndrome	O
and	O
hyperlipoidemia	O
etc	O
.	O

A	O
composition	O
for	O
treating	O
vegetative	O
dystonine	O
syndrome	O
and	O
pharmaceutical	O
preparation	O
and	O
application	O
thereof	O

Compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
salts	O
thereof	O
are	O
provided	O
:	O
wherein	O
X	O
,	O
Y	O
,	O
Z	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Processes	O
for	O
preparation	O
,	O
pharmaceutical	O
compositions	O
,	O
and	O
uses	O
thereof	O
as	O
a	O
medicament	O
,	O
for	O
example	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
a	O
reduction	O
or	O
imbalance	O
in	O
glutamate	B
receptor	O
function	O
,	O
such	O
as	O
schizophrenia	O
or	O
cognition	O
impairment	O
,	O
are	O
also	O
disclosed	O
.	O

Compounds	O
which	O
potentiate	O
ampa	O
receptor	O
and	O
uses	O
therof	O
in	O
medicine	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
polymorphic	O
forms	O
of	O
the	O
oxalate	O
salt	O
of	O
tegaserod	O
,	O
and	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
novel	O
polymorphic	O
forms	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
novel	O
polymorphs	O
,	O
and	O
to	O
uses	O
of	O
said	O
compositions	O
for	O
treating	O
patients	O
suffering	O
from	O
gastrointestinal	O
disorders	O
.	O

Tegaserod	B
oxalate	I
and	O
polymorphic	O
forms	O

The	O
present	O
invention	O
comprises	O
a	O
new	O
class	O
of	O
compounds	O
capable	O
of	O
modulating	O
the	O
activity	O
of	O
Raf	O
kinase	O
and	O
,	O
accordingly	O
,	O
useful	O
for	O
treatment	O
of	O
Raf	O
kinase	O
mediated	O
diseases	O
,	O
including	O
melanomas	O
,	O
tumors	O
and	O
other	O
cancer	O
-	O
related	O
conditions	O
.	O

The	O
compounds	O
have	O
a	O
general	O
Formula	O
(	O
I	O
)	O
wherein	O
each	O
of	O
A1	O
,	O
A2	O
,	O
A3	O
,	O
A4	O
,	O
A5	O
,	O
A6	O
,	O
A7	O
,	O
A8	O
,	O
A9	O
,	O
bond	O
B	O
,	O
X	O
,	O
rings	O
Z1	O
and	O
Z2	O
,	O
R1	O
and	O
R3	O
are	O
defined	O
herein	O
.	O

The	O
invention	O
further	O
comprises	O
pharmaceutical	O
compositions	O
,	O
methods	O
for	O
treatment	O
of	O
Raf	O
kinase	O
mediated	O
diseases	O
,	O
and	O
intermediates	O
and	O
processes	O
useful	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
invention	O
.	O

Heterocyclic	B
compounds	O
as	O
raf	O
kinase	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
as	O
defined	O
in	O
claim	O
1	O
or	O
a	O
salt	O
or	O
N	B
-	I
oxide	I
thereof	O
and	O
their	O
use	O
in	O
methods	O
for	O
the	O
control	O
and/or	O
prevention	O
of	O
fungal	O
infection	O
,	O
particularly	O
in	O
plants	O
.	O

Substituted	O
aromatic	B
heterocyclic	I
compounds	O
as	O
fungicides	O

This	O
invention	O
provides	O
potassium	B
channel	O
modulators	O
which	O
are	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
formula	O
I	O
)	O
,	O
where	O
at	O
least	O
one	O
of	O
W	O
and	O
Z	O
is	O
N	B
;	O
where	O
the	O
moiety	O
(	O
formula	O
II	O
)	O
,	O
is	O
one	O
of	O
Groups	O
A	O
or	O
B	O
below	O
(	O
formula	O
A	O
)	O
,	O
where	O
Ar	B
is	O
a	O
1,2-fused	O
,	O
six	O
membered	O
ring	O
aromatic	B
group	O
,	O
bearing	O
substituents	O
R1	O
and	O
R2	O
as	O
defined	O
below	O
,	O
and	O
containing	O
zero	O
or	O
one	O
ring	O
nitrogen	B
atom	O
;	O
and	O
where	O
other	O
substituents	O
are	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
provides	O
a	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
at	O
least	O
one	O
of	O
the	O
following	O
:	O
i	O
)	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I	O
and	O
ii	O
)	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
,	O
or	O
prodrug	O
thereof	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
a	O
disease	O
or	O
disorder	O
which	O
is	O
affected	O
by	O
activities	O
of	O
potassium	B
channels	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
I	O
or	O
a	O
salt	O
,	O
ester	O
,	O
or	O
prodrug	O
thereof	O
.	O

Derivatives	O
of	O
4-	B
(	I
n	I
-	I
azacycloalkyl	I
)	I
anilides	I
as	O
potassium	B
channel	O
modulators	O

Antrodia	O
camphorata	O
cyclohexenone	B
compounds	O
used	O
for	O
decreasing	O
physiological	O
fatigue	O
,	O
in	O
particular	O
4-hydroxy-2,3-dimethoxy-6-methy-5	B
[	I
3,7,11-trimethy-	I
dodeca-2,6,10-trienyl	I
]	I
-cyclohex-2-enone	I
isolated	O
from	O
extract	O
of	O
Antrodia	O
camphorata	O
,	O
are	O
capable	O
of	O
decreasing	O
physiological	O
fatigue	O
effectively	O
.	O

In	O
the	O
present	O
invention	O
,	O
administration	O
of	O
said	O
compounds	O
immediately	O
after	O
highly	O
intensive	O
prostrate	O
physical	O
exercises	O
with	O
80	O
%	O
maximal	O
oxygen	B
uptake	O
can	O
increase	O
the	O
metabolism	O
of	O
creatine	O
kinase	O
and	O
blood	O
ammonia	B
and	O
militate	O
to	O
recover	O
their	O
concentration	O
,	O
thus	O
to	O
achieve	O
the	O
effect	O
of	O
decreasing	O
physiological	O
fatigue	O
.	O

An	O
antrodia	O
camphorata	O
cyclohexenone	B
compound	O
used	O
for	O
decreasing	O
physiological	O
fatigue	O

Disclosed	O
is	O
an	O
aqueous	O
liquid	O
agent	O
characterized	O
by	O
containing	O
(	O
a	O
)	O
a	O
prostaglandin	B
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
below	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
hydrate	B
of	O
any	O
of	O
them	O
,	O
and	O
(	O
b	O
)	O
at	O
least	O
one	O
polyhydric	B
alcohol	I
selected	O
from	O
glycerin	B
,	O
propylene	B
glycol	I
,	O
dipropylene	B
glycol	I
and	O
1,3-butylene	B
glycol	I
.	O

Prostaglandin	B
derivative	O
-	O
containing	O
aqueous	O
liquid	O
agent	O

Methods	O
for	O
treating	O
certain	O
cancers	O
in	O
patients	O
,	O
such	O
as	O
mammals	O
,	O
using	O
certain	O
17α	O
-	O
hydroxylase	O
/	O
C17	O
,	O
20-lyase	O
inhibitors	O
are	O
discussed	O
herein	O
.	O

More	O
particularly	O
,	O
methods	O
for	O
treating	O
cancers	O
comprising	O
administering	O
a	O
17α	O
-	O
hydroxylase	O
/	O
C17	O
,	O
20-lyase	O
inhibitor	O
,	O
such	O
as	O
abiraterone	O
acetate	O
(	O
i.e.	O
3β	O
-	O
acetoxy-17-	O
(	O
3-pyridyl	O
)	O
androsta-5	O
,	O
16-diene	O
)	O
and	O
metabolites	O
thereof	O
are	O
described	O
.	O

In	O
addition	O
,	O
methods	O
for	O
treating	O
cancers	O
that	O
are	O
refractory	O
to	O
hormone	O
therapy	O
or	O
that	O
are	O
refractory	O
to	O
chemotherapy	O
are	O
also	O
discussed	O
.	O

Finally	O
novel	O
dosing	O
regimens	O
and	O
novel	O
uses	O
of	O
the	O
compounds	O
discussed	O
herein	O
are	O
disclosed	O
.	O

Use	O
of	O
17alpha	O
-	O
hydroxylase	O
/	O
c17	O
,	O
20-lyase	O
inhibitors	O
for	O
the	O
treatment	O
of	O
cancer	O

The	O
invention	O
relates	O
to	O
the	O
chemical	O
and	O
pharmaceutical	O
industry	O
,	O
in	O
particular	O
to	O
agents	O
for	O
washing	O
the	O
nasal	O
cavity	O
,	O
rhinopharynx	O
and	O
the	O
mouth	O
cavity	O
.	O

The	O
inventive	O
composition	O
for	O
washing	O
the	O
nasal	O
cavity	O
,	O
rhinopharynx	O
and	O
the	O
mouth	O
cavity	O
contains	O
mineral	O
salt	O
,	O
carnallite	B
,	O
sodium	B
bicarbonate	I
,	O
a	O
dry	O
wild	O
rose	O
extract	O
and	O
a	O
dry	O
licorice	O
extract	O
at	O
the	O
following	O
component	O
ratio	O
(	O
in	O
%	O
by	O
weight	O
)	O
:	O
70.0	O
mineral	O
salt	O
,	O
25.0	O
carnallite	B
,	O
2.0	O
sodium	B
bicarbonate	I
,	O
1.5	O
dry	O
wild	O
rose	O
extract	O
and	O
1.5	O
dry	O
licorice	O
extract	O
.	O

The	O
use	O
of	O
the	O
composition	O
in	O
the	O
form	O
of	O
a	O
solution	O
improves	O
the	O
nasal	O
mucosa	O
and	O
rhinopharynx	O
nutrition	O
by	O
means	O
of	O
useful	O
microelements	O
of	O
K	B
,	O
Na	B
,	O
Mg	B
and	O
Cl	B
.	O

Moreover	O
,	O
it	O
reduces	O
the	O
nasal	O
mucosa	O
and	O
rhinopharynx	O
irritation	O
and	O
contributed	O
in	O
the	O
mucosa	O
reparation	O
in	O
the	O
case	O
of	O
different	O
types	O
of	O
rhinitis	O
,	O
rhinopharingitis	O
(	O
infectious	O
,	O
allergic	O
and	O
atrophic	O
)	O
.	O

Composition	O
for	O
washing	O
the	O
nasal	O
cavity	O
,	O
rhinopharynx	O
and	O
the	O
mouth	O
cavity	O

The	O
invention	O
discloses	O
use	O
of	O
aniline	B
quinazoline	I
compounds	O
of	O
formula	O
I	O
,	O
especially	O
N-	B
{	I
4-	I
[	I
3-chloro-4-	I
(	I
3-fluoro	I
-	I
benzyloxy	I
)	I
phenylamino	I
]	I
-quinazoline-6-yl	I
}	I
-acrylamide	I
and	O
N-	B
{	I
4-	I
[	I
3-chloro-4-	I
(	I
3-fluoro	I
-	I
benzyloxy	I
)	I
phenylamino	I
]	I
-7-methoxyl-	I
quinazoline-6-	I
yl	I
}	I
-acrylamide	I
,	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
cancer	O
with	O
high	O
expression	O
of	O
erb	O
-	O
B1	O
and/or	O
erb	O
-	O
B2	O
,	O
such	O
as	O
lung	O
cancer	O
,	O
ovarian	O
cancer	O
,	O
and	O
breast	O
cancer	O
.	O

Use	O
of	O
4-aniline	B
quinazoline	I
derivative	O
for	O
preparing	O
medicaments	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
multimers	O
thereof	O
are	O
inhibitors	O
of	O
human	O
neutrophil	O
elastase	O
activity	O
,	O
and	O
of	O
utility	O
in	O
the	O
treatment	O
of	O
,	O
e.g.	O
,	O
COPD	O
:	O
wherein	O
all	O
the	O
substituents	O
are	O
as	O
defined	O
in	O
claim	O
1	O
.	O

Tetrahydropyrrolopyrimidinediones	B
and	O
their	O
use	O
as	O
human	O
neutrophil	O
elastase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
novel	O
ethers	O
of	O
substituted	O
1H	B
-	I
indol-3-carboxylic	I
acids	I
exhibiting	O
antiviral	O
activity	O
,	O
to	O
the	O
use	O
thereof	O
as	O
active	O
ingredients	O
for	O
pharmaceutical	O
compositions	O
and	O
to	O
the	O
use	O
of	O
said	O
compositions	O
for	O
producing	O
medicinal	O
preparations	O
used	O
for	O
preventing	O
and	O
treating	O
viral	O
diseases	O
,	O
in	O
particular	O
generated	O
by	O
influenza	O
viruses	O
A	O
and	O
B	O
,	O
acute	O
respiratory	O
diseases	O
,	O
infectious	O
hepatitis	O
(	O
HVC	O
,	O
HBV	O
)	O
,	O
human	O
immunodeficiency	O
(	O
HIV	O
)	O
,	O
atipical	O
pneumonia	O
(	O
SARS	O
)	O
and	O
bird	O
flu	O
.	O

The	O
invention	O
discloses	O
the	O
use	O
,	O
in	O
the	O
form	O
of	O
biologically	O
active	O
substances	O
exhibiting	O
antiviral	O
action	O
,	O
of	O
ethers	B
of	O
substituted	O
5-hydrixy-1h	B
-	I
indol-3-carboxylic	I
acids	I
of	O
general	O
formula	O
(	O
I	O
)	O
or	O
the	O
racemates	O
thereof	O
,	O
or	O
the	O
optical	O
isomers	O
thereof	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
and/or	O
hydrates	B
thereof	O
,	O
wherein	O
R1	O
is	O
an	O
amino	B
-	O
group	O
substitute	O
selected	O
from	O
hydrogen	B
,	O
optionally	O
substituted	O
alkyl	B
,	O
optionally	O
substituted	O
cycloalkyl	B
,	O
optionally	O
substituted	O
aryl	B
or	O
optionally	O
substituted	O
heterocyclyl	B
;	O
R2	O
is	O
an	O
alkyl	B
substitute	O
selected	O
from	O
hydrogen	B
,	O
an	O
optionally	O
substituted	O
hydroxy	B
group	O
,	O
an	O
optionally	O
substituted	O
mercaptan	B
group	O
,	O
an	O
optionally	O
substituted	O
arylsulphonyl	B
group	O
,	O
an	O
optionally	O
substituted	O
amino	B
-	O
group	O
,	O
optionally	O
substituted	O
saturated	O
or	O
unsaturated	O
N	O
heterocyclyl	B
;	O
R3	O
is	O
hydrogen	B
and	O
optionally	O
substituted	O
lower	O
alkyl	B
;	O
R14	O
and	O
R24	O
independently	O
from	O
each	O
other	O
are	O
a	O
substitute	O
selected	O
form	O
a	O
hydrogen	B
atom	O
,	O
halogen	B
,	O
cyan	B
group	O
,	O
trifluoromethyl	B
,	O
optionally	O
substituted	O
aryl	B
or	O
optionally	O
substituted	O
heterocyclyl	B
.	O

Ethers	B
of	O
substituted	O
5-hydrixy-1h	B
-	I
indol-3-carboxylic	I
acids	I
,	O
a	O
pharmaceutical	O
composition	O
and	O
a	O
method	O
for	O
the	O
production	O
and	O
use	O
thereof	O

In	O
its	O
many	O
embodiments	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
class	O
of	O
6-substituted	B
sulfonyl-1,3,3-trialkyl-6-azabicyclo	I
[	I
3.2.1	I
]	I
octane	I
compounds	O
useful	O
to	O
inhibit	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
-	O
I	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
and	O
methods	O
of	O
treatment	O
,	O
prevention	O
,	O
inhibition	O
,	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
conditions	O
associated	O
with	O
the	O
expression	O
of	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
-	O
I	O
using	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
.	O

6-SUBSTITUTED	B
SULFONYL	I
AZABICYCLO	I
[	I
3.2.1	I
]	I
OCTANES	I
USEFUL	O
TO	O
INHIBIT	O
11β	B
-	I
HYDROXYSTEROID	I
DEHYDROGENASE	O
TYPE-1	O

The	O
invention	O
concerns	O
pyrazine	B
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
each	O
of	O
G1	O
,	O
G2	O
,	O
Ring	O
A	O
,	O
R1	O
,	O
m	O
,	O
R2	O
,	O
R3	O
,	O
n	O
and	O
R4	O
has	O
any	O
of	O
the	O
meanings	O
defined	O
hereinbefore	O
in	O
the	O
description	O
;	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositionscontaining	O
them	O
and	O
their	O
use	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
cell	O
proliferative	O
disorders	O
.	O

2-pyrazinylbenzimidazole	B
derivatives	O
as	O
receptor	O
tyrosine	B
kinase	O
inhibitors	O

The	O
present	O
invention	O
related	O
to	O
a	O
combination	O
of	O
(	O
a	O
)	O
a	O
compound	O
which	O
is	O
a	O
MPO	O
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
b	O
)	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
which	O
is	O
used	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
PD	O
or	O
Multiple	O
Sclerosis	O
.	O

The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
combination	O
and	O
to	O
methods	O
of	O
treating	O
Neuroinflammatory	O
and	O
Neurodegenerative	O
Disorder	O
(	O
s	O
)	O
,	O
such	O
as	O
PD	O
and	O
Multiple	O
Sclerosis	O
in	O
mammals	O
by	O
administrating	O
said	O
combination	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
kit	O
comprising	O
the	O
combination	O
and	O
use	O
of	O
said	O
kit	O
in	O
treatment	O
of	O
Neuroinflammatory	O
Disorder	O
(	O
s	O
)	O
.	O

Combinations	O
containing	O
mpo	O
inhibitors	O
against	O
neuroinflammatory	O
disorders	O

A	O
pharmaceutical	O
composition	O
for	O
treating	O
hepatitis	O
B	O
virus	O
infection	O
.	O

Said	O
composition	O
comprises	O
crystal	O
entecavir	O
as	O
the	O
active	O
ingredient	O
and	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Crystal	O
entecavir	B
fomulation	O
and	O
the	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
generally	O
to	O
crystalline	O
polymorphic	O
forms	O
of	O
O-	B
desmethylvenlafaxine	I
base	O
,	O
designated	O
herein	O
as	O
O	B
-	I
desmethylvenlafaxine	I
base	O
Forms	O
A	O
and	O
B	O
,	O
and	O
methods	O
for	O
preparing	O
and	O
obtaining	O
the	O
same	O
.	O

New	O
crystalline	O
solid	O
forms	O
of	O
o	B
-	I
desvenlafaxine	I
base	O

The	O
invention	O
relates	O
to	O
novel	O
heterocyclic	B
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
in	O
which	O
all	O
of	O
the	O
variables	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
in	O
free	O
form	O
or	O
in	O
salt	O
form	O
,	O
to	O
their	O
preparation	O
,	O
to	O
their	O
use	O
as	O
medicaments	O
and	O
to	O
medicaments	O
comprising	O
them	O
.	O

Dihydroindole	B
derivatives	O
useful	O
in	O
parkinson	O
's	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
new	O
pomegranate	O
extracts	O
,	O
combined	O
or	O
not	O
with	O
soluble	O
fiber	O
,	O
compositions	O
free	O
of	O
any	O
kind	O
of	O
organic	O
solvent	O
,	O
soluble	O
in	O
cold	O
water	O
in	O
high	O
concentration	O
,	O
with	O
very	O
low	O
sugar	O
content	O
and	O
specially	O
standardized	O
to	O
punicalagins	O
,	O
and	O
its	O
addition	O
to	O
foods	O
to	O
provide	O
nutritional	O
products	O
and	O
beverages	O
with	O
increased	O
antioxidant	O
capacity	O
to	O
be	O
used	O
as	O
a	O
source	O
of	O
punicalagins	O
for	O
preventing	O
or	O
treating	O
cardiovascular	O
diseases	O
,	O
plaque	O
build	O
-	O
up	O
in	O
the	O
arteries	O
,	O
arterial	O
hypertension	O
,	O
and	O
metabolic	O
syndrome	O
.	O

Pomegranate	O
extracts	O
,	O
nutritional	O
products	O
containing	O
them	O
and	O
their	O
uses	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O

A	O
composition	O
effective	O
in	O
inhibiting	O
the	O
growth	O
of	O
human	O
cancer	O
cells	O
,	O
characterized	O
by	O
containing	O
as	O
an	O
essential	O
ingredient	O
a	O
flavonone	B
compound	O
monomer	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
.	O

[	O
Chemical	O
formula	O
1	O
]	O
When	O
administered	O
in	O
a	O
significant	O
amount	O
,	O
the	O
composition	O
can	O
inhibit	O
the	O
growth	O
of	O
human	O
liver	O
cancer	O
cells	O
(	O
SMMC7721	O
)	O
,	O
human	O
lung	O
cancer	O
cells	O
(	O
A549	O
)	O
,	O
human	O
gastric	O
cancer	O
cells	O
(	O
SGC7901	O
)	O
,	O
human	O
poorly	O
differentiating	O
gastric	O
adenocarcinoma	O
cells	O
(	O
BGC-823	O
)	O
,	O
human	O
colon	O
cancer	O
cells	O
(	O
LOVO	O
)	O
,	O
human	O
early	O
-	O
infancy	O
granular	O
leukemic	O
cells	O
(	O
HL-60	O
)	O
,	O
etc	O
.	O

Composition	O
containing	O
flavanone	B
compound	O
monomer	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
substituted	O
indolyl	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
above	O
said	O
novel	O
compounds	O
,	O
their	O
derivatives	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

This	O
invention	O
also	O
relates	O
to	O
the	O
novel	O
intermediates	O
involved	O
therein	O
and	O
process	O
of	O
their	O
preparation	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
that	O
are	O
related	O
to	O
5-HT6	O
receptor	O
functions	O
.	O

Substituted	O
indolyl	B
compounds	O
and	O
their	O
use	O
as	O
5-ht6	O
ligands	O

The	O
invention	O
provides	O
a	O
glucocorticoid	B
receptor	O
agonist	O
consisting	O
of	O
a	O
1,3,3-trimethyl-7-phenyl-3,4-dihydro-1H	B
-quinoxalin-2-one	I
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
and	O
novel	O
pharmacological	O
effects	O
of	O
the	O
agonist	O
:	O
[	O
Chemical	O
formula	O
1	O
]	O
(	O
1	O
)	O
(	O
2a	O
)	O
(	O
4a	O
)	O
(	O
3a	O
)	O
(	O
5a	O
)	O
wherein	O
R1	O
is	O
a	O
group	O
represented	O
by	O
the	O
general	O
formula	O
(	O
2a	O
)	O
,	O
(	O
3a	O
)	O
,	O
(	O
4a	O
)	O
or	O
(	O
5a	O
)	O
;	O
R2	O
and	O
R3	O
may	O
be	O
the	O
same	O
or	O
different	O
from	O
each	O
other	O
and	O
are	O
each	O
hydrogen	B
,	O
halogeno	B
,	O
lower	O
alkyl	B
,	O
hydroxy	B
,	O
esterified	O
hydroxy	B
,	O
or	O
the	O
like	O
;	O
R4	O
is	O
lower	O
alkyl	B
;	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
each	O
halogeno	B
,	O
lower	O
alkyl	B
,	O
hydroxy	B
,	O
lower	O
alkoxy	B
,	O
or	O
the	O
like	O
;	O
and	O
m	O
,	O
n	O
,	O
p	O
and	O
q	O
are	O
each	O
0	O
,	O
1	O
or	O
2	O
.	O

Glucocorticoid	B
receptor	O
agonists	O
consisting	O
of	O
1,3,3-tri-	B
methyl-7-phenyl-3,4-dihydro-1h	I
-	I
quinoxalin-2-one	I
derivatives	O

The	O
present	O
application	O
relates	O
to	O
naphtyl	B
substituted	I
sulfonamides	I
according	O
to	O
general	O
formula	O
(	O
I	O
)	O
with	O
5-HT6	O
receptor	O
affinity	O
,	O
a	O
medicament	O
comprising	O
a	O
said	O
compound	O
,	O
and	O
the	O
use	O
of	O
one	O
of	O
said	O
compounds	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
.	O

Naphtyl	B
-	I
substituted	I
sulfonamides	I

Provided	O
herein	O
are	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	B
thereof	O
,	O
wherein	O
the	O
substituents	O
are	O
as	O
those	O
disclosed	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
,	O
and	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
obesity	O
,	O
hyperlipidemia	O
,	O
hypercholesterolemia	O
and	O
diabetes	O
and	O
other	O
related	O
disorders	O
and	O
diseases	O
,	O
and	O
may	O
be	O
useful	O
for	O
other	O
diseases	O
such	O
as	O
NASH	O
,	O
atherosclerosis	O
,	O
cardiovascular	O
diseases	O
,	O
hypothyroidism	O
,	O
thyroid	O
cancer	O
and	O
other	O
disorders	O
and	O
diseases	O
related	O
thereto	O
.	O

Prodrugs	O
to	O
thyroid	O
hormone	O
analogs	O

(	B
S	I
)	I
-2-	I
(	I
3-tert	I
-	I
Butylureido	I
)	I
-3,3-dimethylbutanoic	I
acid	I
is	O
conveniently	O
prepared	O
in	O
a	O
single	O
reaction	O
vessel	O
from	O
commercially	O
available	O
starting	O
materials	O
in	O
a	O
process	O
that	O
can	O
be	O
run	O
on	O
a	O
kilogram	O
or	O
larger	O
scale	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
(	B
s	I
)	I
-2-	I
(	I
3-tert	I
-	I
butylureido	I
)	I
-3,3-dimethylbutanoic	I
acid	I

The	O
present	O
invention	O
relates	O
to	O
specific	O
compounds	O
for	O
use	O
in	O
controlling	O
inflammatory	O
cell	O
function	O
and	O
their	O
potential	O
use	O
in	O
modulating	O
an	O
immune	O
response	O
or	O
inflammation	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
identification	O
of	O
an	O
alternative	O
RSK	O
pathway	O
in	O
,	O
for	O
example	O
,	O
dendritic	O
cells	O
and	O
the	O
development	O
of	O
assays	O
for	O
the	O
identification	O
of	O
compounds	O
capable	O
of	O
modulating	O
the	O
alternative	O
RSK	O
associated	O
pathway	O
in	O
dendritic	O
cells	O
/	O
macrophage	O
cells	O
and	O
their	O
potential	O
use	O
in	O
enhancing	O
,	O
or	O
controlling	O
an	O
immune	O
response	O
or	O
in	O
treating	O
inflammation	O
.	O

Modulation	O
of	O
rsk	O

The	O
invention	O
concerns	O
the	O
use	O
of	O
L	B
-	I
kynurenine	I
amino	B
acid	I
and	O
derivatives	O
thereof	O
,	O
both	O
natural	O
and	O
synthetic	O
,	O
for	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
pathologies	O
like	O
,	O
for	O
example	O
,	O
chronic	O
granulomatous	O
disease	O
(	O
CGD	O
)	O
and	O
allergies	O
.	O

Use	O
of	O
amino	B
acid	I
l	B
-	I
kynurenine	I
and	O
derivatives	O
thereof	O
for	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
pathologies	O

To	O
provide	O
an	O
external	O
preparation	O
for	O
free	O
radical	O
diseases	O
which	O
is	O
excellent	O
in	O
transdermal	O
and	O
transmucosal	O
absorption	O
properties	O
.	O

An	O
external	O
preparation	O
is	O
obtained	O
by	O
combining	O
3-methyl-1-phenyl-2-pyrazolin-5-one	B
with	O
a	O
metabolic	O
inhibitor	O
inhibiting	O
the	O
drug	O
metabolism	O
thereof	O
in	O
the	O
skin	O
and/or	O
mucous	O
membranes	O
.	O

External	O
preparation	O
for	O
free	O
radical	O
diseases	O

Provided	O
herein	O
are	O
alkylthio	B
substituted	I
pyrimidine	I
compounds	O
having	O
CRTH2	O
(	O
G-	O
protein	O
-	O
coupled	O
chemoattractant	O
receptor	O
,	O
expressed	O
on	O
Th2	O
cells	O
)	O
antagonistic	O
activity	O
,	O
useful	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
diseases	O
associated	O
with	O
CRTH2	O
activity	O
,	O
including	O
the	O
treatment	O
of	O
allergic	O
diseases	O
,	O
eosinophil	O
-	O
related	O
diseases	O
and	O
basophil	O
-	O
related	O
diseases	O
.	O

Alkylthio	B
pyrimidines	I
as	O
crth2	O
antagonists	O

This	O
application	O
describes	O
quinone	B
derivatives	O
which	O
target	O
the	O
redox	O
site	O
of	O
Ape1	O
/	O
Ref1	O
.	O

Also	O
included	O
in	O
the	O
invention	O
are	O
pharmaceutical	O
formulations	O
containing	O
the	O
derivatives	O
and	O
therapeutic	O
uses	O
of	O
the	O
derivatives	O
.	O

Quinone	B
derivatives	O
,	O
pharmaceutical	O
compositions	O
,	O
and	O
uses	O
thereof	O

The	O
use	O
of	O
Kit	O
Ligand	O
and	O
,	O
optionally	O
,	O
a	O
steroid	O
such	O
as	O
Dexamethasone	B
in	O
the	O
treatment	O
of	O
β	O
-	O
Thalassaemias	O
is	O
provided	O
,	O
as	O
are	O
methods	O
of	O
treating	O
β	O
-	O
Thalassaemias	O
.	O

Kit	O
ligand	O
for	O
use	O
in	O
the	O
treatment	O
of	O
beta	O
-	O
thalassaemia	O

Internally	O
masked	O
neopentyl	B
sulfonyl	I
ester	I
prodrugs	O
of	O
acamprosate	B
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
prodrugs	O
,	O
and	O
methods	O
of	O
using	O
such	O
prodrugs	O
and	O
compositions	O
thereof	O
for	O
treating	O
diseases	O
are	O
disclosed	O
.	O

In	O
particular	O
,	O
acamprosate	B
prodrugs	O
exhibiting	O
enhanced	O
oral	O
bioavailability	O
and	O
methods	O
of	O
using	O
acamprosate	B
prodrugs	O
to	O
treat	O
neurodegenerative	O
disorders	O
,	O
psychotic	O
disorders	O
,	O
mood	O
disorders	O
,	O
anxiety	O
disorders	O
,	O
somatoform	O
disorders	O
,	O
movement	O
disorders	O
,	O
substance	O
abuse	O
disorders	O
,	O
binge	O
eating	O
disorder	O
,	O
cortical	O
spreading	O
depression	O
related	O
disorders	O
,	O
tinnitus	O
,	O
sleeping	O
disorders	O
,	O
multiple	O
sclerosis	O
,	O
and	O
pain	O
are	O
disclosed	O
.	O

Internally	O
masked	O
neopentyl	B
sulfonyl	I
ester	I
cyclization	O
release	O
prodrugs	O
of	O
acamprosate	B
,	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
amorphous	O
and	O
crystalline	O
forms	O
of	O
the	O
tartrate	B
salt	O
of	O
tegaserod	B
,	O
and	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
novel	O
forms	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
novel	O
forms	O
,	O
and	O
to	O
uses	O
of	O
said	O
compositions	O
to	O
provide	O
methods	O
of	O
treatingpatients	O
suffering	O
from	O
gastrointestinal	O
disorders	O
.	O

Novel	O
crystalline	O
and	O
amorphous	O
forms	O

The	O
invention	O
relates	O
to	O
the	O
study	O
on	O
the	O
synthesis	O
of	O
novel	O
indole	B
derivatives	O
and	O
also	O
relates	O
to	O
the	O
application	O
of	O
the	O
compounds	O
for	O
medical	O
purposes	O
.	O

Thus	O
,	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
[	O
in	O
the	O
formula	O
,	O
X	O
represents	O
O	B
,	O
S	B
or	O
N	B
-	I
R4	I
;	O
R1	O
represents	O
an	O
aryl	B
group	O
,	O
an	O
aromatic	B
heterocyclic	I
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
an	O
aryl	B
group	O
,	O
an	O
aromatic	B
heterocyclic	I
group	O
or	O
the	O
like	O
;	O
R3	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
alkyl	B
group	O
,	O
an	O
alkylcarbonyl	B
group	O
or	O
the	O
like	O
;	O
and	O
R4	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
alkyl	B
group	O
or	O
the	O
like	O
.	O

(	O
I	O
)	O
Novel	O
indole	B
derivative	O
having	O
anti	O
-	O
angiogenic	O
activity	O

The	O
subject	O
matter	O
of	O
the	O
instant	O
invention	O
is	O
pertinent	O
to	O
the	O
field	O
of	O
hormone	O
therapy	O
.	O

More	O
specifically	O
,	O
the	O
subject	O
matter	O
of	O
the	O
instant	O
invention	O
concerns	O
methods	O
of	O
treating	O
dysfunctional	O
uterine	O
bleeding	O
.	O

The	O
instant	O
invention	O
is	O
also	O
relevant	O
to	O
the	O
treatment	O
and/or	O
prevention	O
of	O
anemia	O
in	O
patients	O
with	O
dysfunctional	O
uterine	O
bleeding	O
.	O

Compositions	O
for	O
practicing	O
the	O
methods	O
,	O
comprising	O
progesterone	B
antagonists	O
are	O
also	O
disclosed	O
.	O

Embodiments	O
of	O
the	O
instant	O
invention	O
also	O
disclose	O
methods	O
for	O
identifying	O
new	O
selective	O
progesterone	B
receptor	O
modulators	O
for	O
practicing	O
disclosed	O
methods	O
of	O
treatment	O
.	O

Compositions	O
and	O
methods	O
for	O
treating	O
dysfunctional	O
uterine	O
bleeding	O

New	O
pharmaceutical	O
uses	O
of	O
1-	B
[	I
2-	I
(	I
2,4-dimethylphenylsulfanyl	I
)	I
phenyl	I
]	I
piperazine	I
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
are	O
provided	O
.	O

Therapeutic	O
uses	O
of	O
compounds	O
having	O
combined	O
sert	O
,	O
5-ht3	O
and	O
5-ht1a	O
activity	O

The	O
invention	O
is	O
concerned	O
with	O
novel	O
substituted	O
benzimidazole	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R10	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
in	O
the	O
claims	O
,	O
as	O
well	O
as	O
physiologically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
.	O

These	O
compounds	O
can	O
be	O
used	O
as	O
medicaments	O
.	O

Benzimidazole	B
derivatives	O
and	O
their	O
use	O
as	O
fxr	O
agonists	O

This	O
invention	O
relates	O
to	O
novel	O
4,5-dihydroisoxazoles	B
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
their	O
use	O
as	O
estrogen	B
receptor	O
modulators	O
,	O
and	O
to	O
methods	O
of	O
their	O
preparation	O
.	O

Novel	O
4,5-dihydroisoxazoles	B
with	O
estrogenic	O
activity	O

Morpholino	B
pyrimidines	I
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
selected	O
from	O
-Y	O
-	O
R6	O
and	O
-NR4R5	B
;	O
R2	O
is	O
a	O
N	O
-	O
containing	O
monocyclic	B
heteroaryl	I
group	O
which	O
is	O
selected	O
from	O
pyridyl	B
,	O
isoxazolyl	B
,	O
imidazolyl	B
,	O
pyrazolyl	B
,	O
pyrrolyl	B
,	O
thiazolyl	B
,	O
pyridazinyl	B
,	O
pyrimidinyl	B
,	O
pyrazinyl	B
,	O
oxazolyl	B
,	O
furanyl	B
,	O
thienyl	B
,	O
triazolyl	B
and	O
tetrazolyl	B
and	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
by	O
halo	B
,	O
-CN	B
,	O
-NR10R11	B
,	O
-OR10	B
,	O
-C	B
(	I
O	I
)	I
R10	I
,	O
-NR10C	B
(	I
O	I
)	I
R11	I
,	O
-	B
N	I
(	I
C	I
(	I
O	I
)	I
R11	I
)	I
2	I
,	O
-NR10C	B
(	I
O	I
)	I
NR10R11	I
,	O
-SO2R10R11	B
,	O
-SO2NR10R11	B
,	O
-C	B
(	I
=O	I
)	I
OR10	I
,	O
-C	B
(	I
=O	I
)	I
NR10R11	I
,	O
halo	B
-	I
C1	I
-C6	I
alkyl	I
and	O
unsubstituted	O
C1-C12	B
alkyl	I
;	O
R3	O
is	O
selected	O
from	O
H	O
,	O
C1-C6	O
alkyl	O
and	O
C1-C6	O
alkoxy	O
;	O
Y	O
is	O
selected	O
from	O
a	O
direct	O
bond	O
,	O
-	O
(	O
CR2	O
)	O
m-	O
,	O
C2-C6	O
alkenylene	O
,	O
C2-C6	O
alkynylene	O
,	O
-	O
(	O
CR2	O
)	O
p	O
-	O
O-	B
(	I
CR2	I
)	I
t-	I
,	O
-	B
(	I
CR2	I
)	I
p	I
-	I
NR-	I
(	I
CR2	I
)	I
t	I
,	O
-	B
(	I
CR2	I
)	I
p	I
-	I
NR-	I
(	I
CR2	I
)	I
n	I
-	I
C	I
(	I
O	I
)	I
-	I
,	O
-	B
(	I
CR2	I
)	I
p	I
-	I
NR	I
-	I
C	I
(	I
O	I
)	I
-	I
(	I
CR2	I
)	I
n-	I
,	O
-	B
(	I
CR2	I
)	I
p	I
-	I
C	I
(	I
O	I
)	I
-NR-	I
(	I
CR2	I
)	I
t	I
,	O
-	B
(	I
CR2	I
)	I
p	I
-	I
C	I
(	I
O	I
)	I
-	I
(	I
CR2	I
)	I
n	I
-	I
NR-	I
(	I
CR2	I
)	I
t,-	I
and	O
-	B
(	I
CR2	I
)	I
p-	I
C	I
(	I
O	I
)	I
-	I
(	I
CR2	I
)	I
n-	I
;	O
R6	O
is	O
selected	O
from	O
an	O
unsaturated	O
5-	O
to	O
12-membered	O
carbocyclic	B
or	O
heterocyclic	B
ring	O
,	O
a	O
saturated	O
5-	O
,	O
6-	O
or	O
7-	O
membered	O
N	O
-	O
containing	O
heterocyclic	B
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
,	O
C1-C6	B
alkyl	I
,	O
-NR2	B
,	O
-OR	B
,	O
-NR	B
(	I
CO	I
)	I
R	I
and	O
-	B
C	I
(	I
O	I
)	I
NR2	I
;	O
R4	O
and	O
R5	O
,	O
which	O
are	O
the	O
same	O
or	O
different	O
,	O
are	O
both	O
C1-C6	O
alkyl	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
,	O
or	O
R4	O
and	O
R5	O
together	O
form	O
,	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
,	O
a	O
saturated	O
5-	O
,	O
6-	O
or	O
7-	O
membered	O
N	O
-	O
containing	O
heterocyclic	O
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
each	O
R	O
,	O
which	O
are	O
the	O
same	O
or	O
different	O
when	O
more	O
than	O
one	O
is	O
present	O
in	O
a	O
given	O
group	O
,	O
is	O
independently	O
H	B
,	O
C1-C6	B
alkyl	I
which	O
is	O
unsubstituted	O
or	O
substituted	O
or	O
a	O
5-	O
to	O
12-membered	O
aryl	B
or	O
heteroaryl	B
group	O
which	O
is	O
unsubstituted	O
or	O
substituted	O
;	O
R10	O
and	O
R11	O
,	O
which	O
are	O
the	O
same	O
or	O
different	O
,	O
are	O
independently	O
selected	O
from	O
H	B
,	O
C1-C6	B
alkyl	I
,	O
C2-C6	B
alkenyl	I
,	O
C2-C6	B
alkynyl	I
and	O
C3-C8	B
cycloalkyl	I
;	O
n	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
6	O
;	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
6	O
;	O
p	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
6	O
;	O
and	O
t	O
is	O
0	O
or	O
an	O
integer	O
of	O
1	O
to	O
6	O
,	O
with	O
the	O
proviso	O
that	O
t	O
is	O
an	O
integer	O
of	O
2	O
to	O
6	O
when	O
R6	O
is	O
linked	O
to	O
Y	O
through	O
a	O
constituent	O
O	B
or	O
N	B
atom	O
of	O
R6	O
;	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
subject	O
to	O
various	O
provisos	O
,	O
have	O
activity	O
as	O
inhibitors	O
of	O
PI3	O
K	O
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth	O
,	O
function	O
or	O
behaviour	O
,	O
particularly	O
that	O
associated	O
with	O
PI3	O
kinase	O
such	O
as	O
cancer	O
,	O
immune	O
disorders	O
,	O
cardiovascular	O
disease	O
,	O
viral	O
infection	O
,	O
inflammation	O
,	O
metabolism	O
/	O
endocrine	O
disorders	O
and	O
neurological	O
disorders	O
.	O

Processes	O
for	O
synthesizing	O
the	O
compounds	O
are	O
also	O
described	O
.	O

2	B
-morpholinopyrimidines	I
and	O
their	O
use	O
as	O
pi3	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
an	O
improved	O
process	O
for	O
preparation	O
of	O
the	O
non	O
-	O
steroidal	O
aromatase	O
inhibitor	O
drug	O
,	O
Letrozole	B
of	O
formula	O
(	O
I	O
)	O
and	O
its	O
intermediates	O
,	O
4-	B
[	I
1-	I
(	I
1,2,4-triazolyl	I
)	I
methyl	I
]	I
-benzonitrile	I
of	O
formula	O
(	O
IV	O
)	O
and	O
4-	B
[	I
1-	I
(	I
1,2,4-triazolyl	I
)	I
methyl	I
]	I
-benzonitrile	I
hydrochloride	I
of	O
formula	O
(	O
VII	O
)	O
,	O
all	O
having	O
a	O
purity	O
of	O
≥99	O
%	O
,	O
which	O
is	O
simple	O
,	O
convenient	O
,	O
economical	O
,	O
does	O
not	O
use	O
hazardous	O
chemicals	O
and	O
industrially	O
viable	O
.	O

An	O
improved	O
process	O
for	O
preparation	O
of	O
letrozole	B
and	O
its	O
intermediates	O

It	O
is	O
intended	O
to	O
amplify	O
CD34-positive	O
cells	O
in	O
vitro	O
more	O
efficiently	O
and	O
in	O
a	O
shorter	O
time	O
than	O
conventional	O
by	O
using	O
a	O
low	O
-	O
molecular	O
compound	O
which	O
can	O
be	O
produced	O
biologically	O
safely	O
at	O
low	O
cost	O
.	O

It	O
is	O
also	O
intended	O
to	O
provide	O
an	O
amplification	O
agent	O
for	O
CD34-positive	O
cells	O
useful	O
as	O
a	O
method	O
for	O
treating	O
various	O
hematopoietic	O
diseases	O
accompanying	O
dysfunction	O
of	O
hematopoietic	O
stem	O
cells	O
and/or	O
hematopoietic	O
progenitor	O
cells	O
.	O

An	O
amplification	O
method	O
for	O
CD34-positive	O
cells	O
characterized	O
by	O
culturing	O
CD34-positive	O
cells	O
in	O
vitro	O
in	O
the	O
presence	O
of	O
a	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
(	O
wherein	O
A	O
,	O
B	O
,	O
L1	O
,	O
L2	O
,	O
L3	O
,	O
L4	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
X	O
,	O
and	O
Y	O
are	O
defined	O
in	O
the	O
specification	O
)	O
,	O
a	O
tautomer	O
thereof	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
solvate	O
thereof	O
.	O

Amplification	O
method	O
for	O
hematopoietic	O
stem	O
cells	O
with	O
heterocyclic	B
compound	O

A	O
stable	O
crystal	O
(	O
I	O
-	O
form	O
crystal	O
)	O
of	O
(	B
4R,5S,6S	I
)	I
-6-	I
[	I
(	I
1R	I
)	I
-1-hydroxyethyl	I
]	I
-4-methyl-3-	I
(	I
{	I
4-	I
[	I
(	I
5S	I
)	I
-5-	I
methyl-2,5-dihydro-1H	I
-	I
pyrrol-3-yl	I
]	I
-1,3-thiazol-2-yl	I
}	I
thio	I
)	I
-7-oxo-1-azabicyclo	I
[	I
3.2.0	I
]	I
hept-2-ene-2-carboxylic	I
acid	I
that	O
has	O
desirable	O
characteristics	O
as	O
the	O
active	O
ingredient	O
of	O
drugs	O
,	O
and	O
a	O
method	O
of	O
producing	O
the	O
I	O
-	O
form	O
crystal	O
characterized	O
by	O
comprising	O
desolvating	O
the	O
solvated	O
crystal	O
of	O
the	O
above	O
compound	O
.	O

Stable	O
crystal	O
of	O
β	B
-	I
lactam	I
compound	O

The	O
present	O
invention	O
pertains	O
generally	O
to	O
the	O
field	O
of	O
therapeutic	O
compounds	O
,	O
and	O
mor	O
specifically	O
to	O
certain	O
3-substituted-4-dihydro	B
-	I
imidazo	I
[	I
5	I
,	I
1-d	I
]	I
[	I
1,2,3,5	I
]	I
tetrazine-8-	I
carboxylic	I
acid	I
amide	I
(	O
collectively	O
referred	O
to	O
herein	O
as	O
3TM	O
compounds	O
)	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
to	O
inhibit	O
cell	O
proliferation	O
,	O
and	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders	O
such	O
as	O
cancer	O
,	O
etc	O
..	O
and	O
methods	O
of	O
preparing	O
such	O
compounds	O
.	O

3-substituted-4	B
-	I
0x0	I
-	I
3	I
,	I
4-dihydro	I
-	I
imidazo-	I
[	I
5	I
,	I
1-d	I
]	I
[	I
1,2,3,5	I
]	I
-tetrazine-8-carboxylic	I
acid	I
amides	I
as	O
anticancer	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
Acetyl	B
Coenzyme	O
A	O
Carboxylase	O
(	O
ACC	O
)	O
inhibitors	O
according	O
to	O
formula	O
(	O
I	O
)	O
,	O
or	O
an	O
enantiomer	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
where	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
E	O
,	O
L	O
,	O
Z	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
to	O
processes	O
for	O
preparing	O
such	O
compounds	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
to	O
the	O
use	O
of	O
such	O
inhibitors	O
and	O
to	O
methods	O
for	O
th	O
eir	O
therapeutic	O
use	O
,	O
particularly	O
in	O
the	O
treatments	O
of	O
obesity	O
and	O
diabetes	O
mellitus	O
.	O

New	O
acetyl	B
coenzyme	O
a	O
carboxylase	O
(	O
acc	O
)	O
inhibitors	O
and	O
uses	O
in	O
treatments	O
of	O
obesity	O
and	O
diabetes	O
mellitus	O
-	O
087	O

The	O
invention	O
relates	O
to	O
steroid-17	B
,	I
17-lactol	I
-	O
derivatives	O
with	O
the	O
chemical	O
formula	O
(	O
I	O
)	O
and	O
the	O
tautomer	O
forms	O
thereof	O
with	O
general	O
chemical	O
formula	O
(	O
Ia	O
)	O
wherein	O
R4	O
,	O
R6a	O
,	O
R6b	O
,	O
R7	O
,	O
R15	O
,	O
R16a	O
,	O
R16b	O
,	O
R18	O
,	O
R22and	O
Z	O
have	O
the	O
designations	O
given	O
in	O
claim	O
1	O
,	O
and	O
to	O
the	O
solvates	O
,	O
hydrates	B
,	O
stereoisomers	O
and	O
salts	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
derivatives	O
for	O
producing	O
a	O
medicament	O
for	O
oral	O
contraception	O
and	O
for	O
the	O
treatment	O
of	O
premenopausal	O
,	O
perimenopausal	O
and	O
postmenopausal	O
troubles	O
,	O
and	O
medicaments	O
containing	O
said	O
derivatives	O
.	O

The	O
derivatives	O
according	O
to	O
the	O
invention	O
have	O
a	O
gestagen	O
effect	O
,	O
and	O
in	O
preferred	O
cases	O
,	O
also	O
an	O
anti	O
-	O
mineral	O
corticoid	O
and	O
neutral	O
to	O
lightly	O
androgenous	O
effect	O
.	O

Steroid-17,17-lactol	B
derivative	O
,	O
use	O
thereof	O
,	O
and	O
medicament	O
containing	O
said	O
derivative	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
chondroitin	O
sulphate	B
and	O
mannosamine	B
or	O
a	O
derivative	O
thereof	O
.	O

The	O
mannosamine	B
derivative	O
is	O
preferably	O
N	B
-	I
acetylmannosamine	I
.	O

The	O
compositions	O
may	O
comprise	O
glucosamine	B
.	O

Said	O
compositions	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
degenerative	O
joint	O
diseases	O
,	O
preferably	O
of	O
osteoarthritis	O
,	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
tendon	O
or	O
ligament	O
diseases	O
,	O
disorders	O
or	O
injuries	O
and	O
of	O
immune	O
system	O
diseases	O
,	O
preferably	O
of	O
rheumatoid	O
arthritis	O
.	O

Composition	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O

Provided	O
herein	O
are	O
compounds	O
which	O
are	O
CDC2-Like	O
Kinase	O
(	O
CLK	O
)	O
inhibiting	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

The	O
CLK	O
-	O
inhibiting	O
compounds	O
may	O
be	O
used	O
for	O
increasing	O
the	O
lifespan	O
of	O
a	O
cell	O
,	O
and	O
treating	O
and/or	O
preventing	O
a	O
wide	O
variety	O
of	O
diseases	O
and	O
disorders	O
including	O
,	O
for	O
example	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
aging	O
or	O
stress	O
,	O
diabetes	O
,	O
obesity	O
,	O
neurodegenerative	O
diseases	O
,	O
cardiovascular	O
disease	O
,	O
blood	O
clotting	O
disorders	O
,	O
inflammation	O
,	O
ocular	O
disorders	O
,	O
and/or	O
flushing	O
as	O
well	O
as	O
diseases	O
or	O
disorders	O
that	O
would	O
benfit	O
from	O
increased	O
mitochondrial	O
activity	O
.	O

Also	O
provided	O
are	O
compositions	O
comprising	O
a	O
Clk	O
-	O
inhibiting	O
compound	O
in	O
combination	O
with	O
another	O
therapeutic	O
agent	O
.	O

Inhibitors	O
of	O
cdc2-like	O
kinases	O
(	O
clks	O
)	O
and	O
methods	O
of	O
use	O
thereof	O

This	O
invention	O
relates	O
generally	O
to	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidine	I
-	O
based	O
modulators	O
of	O
Liver	O
X	O
receptors	O
(	O
LXRs	O
)	O
having	O
formula	O
(	O
I	O
)	O
and	O
related	O
methods	O
:	O
Formula	O
(	O
I	O
)	O
wherein	O
R2	O
is	O
C6-C10	B
aryl	I
or	O
heteroaryl	B
including	O
5	O
-	O
10	O
atoms	O
,	O
each	O
of	O
which	O
is	O
:	O
(	O
i	O
)	O
substituted	O
with	O
1	O
R6	O
,	O
and	O
(	O
ii	O
)	O
optionally	O
substituted	O
with	O
from	O
1	O
-	O
5	O
Re	O
;	O
and	O
R1	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
Re	O
are	O
defined	O
herein	O
.	O

Pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidine	I
compounds	O

Novel	O
uses	O
of	O
administering	O
ixabepilone	B
are	O
provided	O
,	O
namely	O
,	O
the	O
oral	O
administration	O
of	O
ixabepilone	B
with	O
surprising	O
efficacy	O
to	O
safety	O
profiles	O
,	O
comprising	O
splitting	O
the	O
oral	O
dose	O
into	O
to	O
or	O
more	O
daily	O
unit	O
dosages	O
administered	O
on	O
an	O
intermittent	O
dosing	O
cycle	O
.	O

Oral	O
administration	O
of	O
ixabepilone	B

The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
therapy	O
for	O
the	O
treatment	O
of	O
immune	O
-	O
related	O
disorders	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
oral	O
or	O
mucosal	O
synergistic	O
compositions	O
combining	O
beta	O
-	O
glycolipids	O
,	O
preferably	O
,	O
β	O
-	O
glycosphingolipids	O
with	O
immunoglobulin	O
molecules	O
specific	O
for	O
at	O
least	O
one	O
antigen	O
derived	O
from	O
a	O
component	O
of	O
the	O
immune	O
system	O
,	O
specifically	O
an	O
anti	O
-	O
CD3	O
antibody	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
kits	O
and	O
uses	O
of	O
the	O
combined	O
compositions	O
of	O
the	O
invention	O
for	O
immuno-	O
modulation	O
and	O
thereby	O
for	O
the	O
treatment	O
of	O
immune	O
-	O
related	O
disorders	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
anti	O
-	O
CD3	O
antibody	O
(	O
OKT3	O
)	O
is	O
orally	O
administered	O
in	O
combination	O
with	O
β	B
-	I
glucosylceramide	I
(	O
also	O
known	O
as	O
glycocerebroside	B
)	O
in	O
an	O
animal	O
model	O
of	O
type	O
2	O
diabetes	O
.	O

Combination	O
therapy	O
of	O
beta	O
-	O
glycolipids	O
and	O
antibodies	O
for	O
the	O
treatment	O
of	O
immune	O
-	O
related	O
disorders	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
skin	O
disorders	O
(	O
e.g.	O
,	O
genetic	O
skin	O
disorders	O
)	O
are	O
provided	O
.	O

The	O
methods	O
and	O
compositions	O
include	O
an	O
EGFR	O
inhibitor	O
.	O

For	O
genetic	O
skin	O
disorders	O
that	O
exhibit	O
a	O
high	O
percentage	O
of	O
penetrance	O
,	O
or	O
complete	O
penetrance	O
,	O
such	O
as	O
Darier	O
's	O
disease	O
,	O
the	O
methods	O
and	O
compositions	O
provided	O
herein	O
can	O
be	O
used	O
to	O
prevent	O
or	O
reduce	O
manifestation	O
of	O
symptoms	O
of	O
the	O
disease	O
.	O

Treatment	O
of	O
skin	O
disorders	O
with	O
egfr	O
inhibitors	O

Disclosed	O
is	O
a	O
process	O
for	O
producing	O
a	O
carbapenem	B
compound	O
represented	O
by	O
Formula	O
[	O
1	O
]	O
,	O
which	O
is	O
characterized	O
by	O
allowing	O
a	O
base	O
and	O
a	O
Lewis	O
-	O
acidic	O
metal	O
salt	O
to	O
coexist	O
in	O
the	O
reaction	O
of	O
a	O
compound	O
represented	O
by	O
Formula	O
[	O
2	O
]	O
with	O
a	O
compound	O
represented	O
by	O
Formula	O
[	O
3	O
]	O
.	O

According	O
to	O
the	O
process	O
,	O
a	O
side	O
-	O
chain	O
mercaptothiazole	B
can	O
be	O
introduced	O
into	O
a	O
β	B
-	I
lactam	I
skeleton	O
efficiently	O
in	O
the	O
production	O
of	O
a	O
β	B
-	I
lactam	I
compound	O
having	O
an	O
excellent	O
antibacterial	O
activity	O
against	O
a	O
Gram	O
-	O
positive	O
bacterium	O
.	O

[	O
3	O
]	O
[	O
2	O
]	O
[	O
1	O
]	O
wherein	O
R1	O
represents	O
a	O
lower	O
alkyl	B
group	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
R3	O
represents	O
a	O
protective	O
group	O
for	O
a	O
carboxyl	B
group	O
;	O
L	O
represents	O
an	O
active	O
ester	O
of	O
a	O
hydroxy	B
group	O
;	O
R4	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
and	O
R5	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
.	O

PROCESS	O
FOR	O
PRODUCTION	O
OF	O
β	B
-	I
LACTAM	I
COMPOUND	O

The	O
object	O
is	O
to	O
discover	O
a	O
pharmaceutical	O
composition	O
having	O
an	O
excellent	O
anti	O
-	O
tumor	O
effect	O
and	O
a	O
therapeutic	O
method	O
for	O
cancer	O
.	O

4-	B
(	I
3-Chloro-4-	I
(	I
cyclopropylaminocarbonyl	I
)	I
aminophenoxy	I
)	I
-7-	I
methoxy-6-quinolinecarboxamide	I
,	O
an	O
analogous	O
compound	O
or	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
analogous	O
compound	O
or	O
pharmacologically	O
acceptable	O
salt	O
can	O
exhibit	O
an	O
excellent	O
anti	O
-	O
tumor	O
effect	O
when	O
used	O
in	O
combination	O
with	O
a	O
taxane	O
.	O

Combined	O
use	O
of	O
angiogenesis	O
inhibitor	O
and	O
taxane	B

The	O
present	O
invention	O
comprises	O
a	O
new	O
combination	O
or	O
association	O
of	O
substances	O
for	O
treating	O
infections	O
and	O
diseases	O
caused	O
by	O
strict	O
or	O
facultative	O
intracellular	O
microorganisms	O
.	O

According	O
to	O
the	O
present	O
invention	O
,	O
the	O
combination	O
or	O
association	O
of	O
substances	O
is	O
used	O
in	O
the	O
treatment	O
of	O
bacterial	O
,	O
parasitic	O
,	O
fungal	O
and	O
viral	O
diseases	O
.	O

The	O
components	O
of	O
the	O
combination	O
or	O
association	O
of	O
substances	O
of	O
the	O
invention	O
,	O
the	O
immunomodulator	O
(	O
proteic	O
aggregate	O
of	O
ammonium	O
and	O
magnesium	O
phospholinoleate	O
-	O
palmitoleate	O
anhydride	O
)	O
and	O
at	O
least	O
one	O
substance	O
with	O
antimicrobial	O
properties	O
can	O
be	O
administered	O
either	O
jointly	O
,	O
simultaneously	O
,	O
consecutively	O
or	O
sequentially	O
,	O
in	O
an	O
appropriate	O
form	O
,	O
according	O
to	O
their	O
chemical	O
properties	O
,	O
and	O
in	O
a	O
dose	O
effective	O
against	O
microorganisms	O
in	O
human	O
and	O
animals	O
.	O

Combination	O
of	O
immunomodulator	O
and	O
anti	O
-	O
pathogenic	O
agent	O

Methods	O
are	O
provided	O
for	O
treating	O
conditions	O
characterized	O
by	O
dysfunction	O
in	O
protein	O
homeostasis	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

A	O
method	O
for	O
treating	O
a	O
condition	O
characterized	O
by	O
dysfunction	O
in	O
protein	O
homeostasis	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
is	O
provided	O
which	O
comprises	O
administering	O
to	O
the	O
patient	O
a	O
proteostasis	O
regulator	O
in	O
an	O
amount	O
effective	O
to	O
improve	O
or	O
restore	O
protein	O
homeostasis	O
,	O
and	O
to	O
reduce	O
or	O
eliminate	O
the	O
condition	O
in	O
the	O
patient	O
or	O
to	O
prevent	O
its	O
occurrence	O
or	O
recurrence	O
.	O

The	O
condition	O
can	O
be	O
a	O
loss	O
of	O
function	O
disorder	O
such	O
as	O
a	O
lysosomal	O
storage	O
disease	O
,	O
or	O
a	O
gain	O
of	O
function	O
disorder	O
such	O
as	O
an	O
aging	O
associated	O
disease	O
.	O

Methods	O
for	O
treating	O
a	O
condition	O
characterized	O
by	O
dysfunction	O
in	O
protein	O
homeostasis	O

The	O
invention	O
discloses	O
a	O
product	O
made	O
of	O
O	B
-	I
acylated	I
hydroxycarboxylic	I
acid	I
and	O
amino	B
acid	I
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
where	O
AS	O
is	O
a	O
proteinogenic	O
or	O
synthetically	O
produced	O
amino	B
acid	I
of	O
the	O
general	O
formula	O
(	O
II	O
)	O
,	O
which	O
is	O
preferably	O
D	O
,	O
L	O
,	O
or	O
racemically	O
configured	O
,	O
where	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and/or	O
R4	O
,	O
R5	O
have	O
the	O
meanings	O
stated	O
in	O
the	O
claims	O
and	O
the	O
description	O
,	O
and	O
to	O
the	O
production	O
and	O
use	O
thereof	O
.	O

Products	O
made	O
of	O
o	B
-	I
acylated	I
hydroxycarboxylic	I
acids	I
and	O
amino	B
acids	I
,	O
the	O
production	O
,	O
biological	O
activities	O
,	O
cosmetically	O
or	O
pharmaceutically	O
effective	O
compositions	O
and	O
use	O
thereof	O
,	O
particularly	O
as	O
food	O
additives	O
,	O
and	O
as	O
cosmetic	O
additives	O

It	O
is	O
intended	O
to	O
provide	O
a	O
composition	O
,	O
which	O
has	O
an	O
excellent	O
suppressive	O
effect	O
on	O
fat	O
accumulation	O
,	O
is	O
safe	O
without	O
side	O
effects	O
,	O
can	O
be	O
conveniently	O
taken	O
continuously	O
,	O
and	O
can	O
prevent	O
and/or	O
improve	O
a	O
disease	O
and/or	O
symptom	O
associated	O
with	O
excess	O
fat	O
accumulation	O
,	O
for	O
example	O
,	O
obesity	O
or	O
metabolic	O
syndrome	O
.	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
suppressing	O
fat	O
accumulation	O
containing	O
1-deoxynojirimycin	B
.	O

Composition	O
and	O
method	O
for	O
suppressing	O
fat	O
accumulation	O

The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
formulation	O
containing	O
choline	B
alfoscerate	I
with	O
improved	O
stability	O
and	O
convenient	O
administration	O
.	O

Additionally	O
the	O
invention	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
pharmaceutical	O
formulation	O
containing	O
choline	B
alfoscerate	I
which	O
can	O
be	O
easily	O
and	O
conveniently	O
prepared	O
with	O
conventional	O
production	O
equipment	O
.	O

Pharmaceutical	O
formulation	O
containing	O
choline	B
alfoscerate	I

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
3-	B
(	I
4-hydroxy-3-methoxyphenyl	I
)	I
-1-	I
(	I
4-hydroxyphenyl	I
)	I
-propane-1-on	I
in	O
cosmetic	O
or	O
dermatological	O
preparations	O
for	O
treating	O
and	O
preventing	O
hyperpigmentation	O
and	O
for	O
alleviating	O
post	O
-	O
inflammatory	O
pigmentation	O
disorders	O
.	O

Use	O
of	O
3-	B
(	I
4-hydroxy-3-methoxyphenyl	I
)	I
-1	I
(	I
4-hydroxyphenyl	I
)	I
-propane-1-on	I
against	O
hyperpigmentation	O

Use	O
of	O
tea	O
polyphenols	O
in	O
preparing	O
medicaments	O
for	O
prevention	O
or	O
treatment	O
of	O
tumors	O
is	O
provided	O
.	O

The	O
tea	O
polyphenols	O
are	O
an	O
extract	O
of	O
tea	O
comprising	O
EGCG	B
,	O
EGC	B
and	O
ECG	B
,	O
or	O
Tegreen	O
97	O
®	O
,	O
a	O
green	O
tea	O
capsule	O
of	O
PHARMANEX	O
,	O
INC	O
.	O

Use	O
of	O
tea	O
polyphenols	O
in	O
preparing	O
medicaments	O
for	O
prevention	O
or	O
treatment	O
of	O
tumors	O

The	O
present	O
invention	O
is	O
concerned	O
with	O
2-Aminoquinoline	B
derivatives	O
as	O
5-HT5A	O
receptor	O
antagonists	O
,	O
their	O
manufacture	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
medicaments	O
.	O

The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
depression	O
,	O
anxiety	O
disorders	O
,	O
schizophrenia	O
,	O
panic	O
disorders	O
,	O
agoraphobia	O
,	O
social	O
phobia	O
,	O
obsessive	O
compulsive	O
disorders	O
,	O
post	O
-	O
traumatic	O
stress	O
disorders	O
,	O
pain	O
,	O
memory	O
disorders	O
,	O
dementia	O
,	O
disorders	O
of	O
eating	O
behaviors	O
,	O
sexual	O
dysfunction	O
,	O
sleep	O
disorders	O
,	O
abuse	O
of	O
drugs	O
,	O
motor	O
disorders	O
such	O
as	O
Parkinson	O
's	O
disease	O
,	O
psychiatric	O
disorders	O
or	O
gastrointestinal	O
disorders	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
is	O
concerned	O
with	O
compounds	O
of	O
the	O
general	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
-Z	O
-	O
Ar1	O
are	O
as	O
described	O
herein	O
.	O

2-aminoquinoline	B
derivatives	O
as	O
5-ht	B
(	O
5a	O
)	O
receptor	O
antagonists	O

Described	O
herein	O
are	O
bismethylene-17α	B
carbolactone	I
derivatives	O
having	O
progestational	O
and/or	O
antimineralocorticoid	O
and/or	O
aldosterone	B
antagonistic	O
activity	O
.	O

Also	O
described	O
herein	O
are	O
methods	O
of	O
preparing	O
and	O
using	O
these	O
novel	O
compounds	O
.	O

BISMETHYLENE-17α	B
CARBOLACTONES	I
AND	O
RELATED	O
USES	O

The	O
present	O
invention	O
provides	O
a	O
compounds	O
of	O
general	O
formula	O
IXa	O
-	O
d	O
,	O
useful	O
as	O
potential	O
antitumour	O
agents	O
and	O
pharmaceutical	O
composition	O
comprising	O
these	O
compounds	O
exhibits	O
binding	O
affinity	O
with	O
calf	O
thymus	O
(	O
CT	O
)	O
DNA	O
at	O
a	O
molar	O
ratio	O
of	O
1:5	O
in	O
aqueous	O
sodium	B
phosphate	I
buffer	O
at	O
pH	O
of	O
7.00	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
process	O
for	O
the	O
preparation	O
of	O
C2-Fluoro	B
substituted	I
piperazine	I
linked	O
pyrrolo	B
[	I
2,1c	I
]	I
[	I
1	I
-	I
4	I
]	I
,	I
benzodiazepine	I
of	O
formula	O
(	O
IX	O
)	O
.	O

C2-fluoro	B
substituted	I
piperazine	I
linked	O
pyrrolo	B
[	I
2,1-c	I
]	I
[	I
1,4	I
]	I
benzodiazepine	I
dimers	O
and	O
a	O
process	O
for	O
the	O
preparation	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
compounds	O
of	O
general	O
formula	O
(	O
8)	O
,	O
(	O
11	O
)	O
and	O
(	O
14	O
)	O
,	O
useful	O
as	O
potential	O
antitumour	O
agents	O
against	O
human	O
cancer	O
cell	O
lines	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
process	O
for	O
the	O
preparation	O
of	O
pyrrolo	B
[	I
2,1-c	I
]	I
[	I
1,4	I
]	I
benzodiazepine	I
hybrids	O
of	O
general	O
formula	O
(	O
8)	O
,	O
(	O
11	O
)	O
and	O
(	O
14	O
)	O
.	O

Novel	O
benzimidazole	B
linked	O
pyrrolo	B
[	I
2,1-q	I
[	I
1,4	I
]	I
benzodiazepine	I
hybrids	O
as	O
potential	O
antitumour	O
agents	O
and	O
process	O
for	O
the	O
preparation	O
thereof	O

A	O
sugar	B
derivative	O
preparation	O
which	O
contains	O
an	O
Aphanothece	O
sacrum	O
-	O
derived	O
specific	O
sugar	B
derivative	O
G1	O
or	O
G2	O
as	O
an	O
active	O
ingredient	O
and	O
is	O
used	O
for	O
various	O
functional	O
purposes	O
such	O
as	O
water	O
absorption	O
,	O
antimicrobial	O
use	O
,	O
anticancer	O
use	O
,	O
promotion	O
of	O
health	O
for	O
food	O
and	O
increase	O
of	O
viscosity	O
as	O
a	O
cosmetic	O
composition	O
,	O
a	O
food	O
composition	O
,	O
a	O
pharmaceutical	O
composition	O
,	O
a	O
material	O
composition	O
and	O
the	O
like	O
.	O

Accordingly	O
,	O
a	O
novel	O
and	O
useful	O
sugar	B
derivative	O
preparation	O
containing	O
an	O
Aphanothece	O
sacrum	O
-	O
derived	O
sugar	B
derivative	O
is	O
provided	O
.	O

Sugar	B
derivative	O
preparation	O

Disclosed	O
is	O
a	O
prophylactic	O
/	O
ameliorating	O
agent	O
for	O
functional	O
gastrointestinal	O
disorders	O
,	O
which	O
comprises	O
glutamic	B
acid	I
or	O
a	O
salt	O
thereof	O
and	O
arginine	B
or	O
a	O
salt	O
thereof	O
(	O
excluding	O
glutamic	B
acid	I
arginine	B
salt	O
)	O
as	O
active	O
ingredients	O
.	O

The	O
prophylactic	O
/	O
ameliorating	O
agent	O
can	O
be	O
produced	O
conveniently	O
at	O
a	O
low	O
cost	O
,	O
is	O
highly	O
safe	O
,	O
and	O
is	O
effective	O
particularly	O
for	O
upper	O
gastrointestinal	O
functional	O
disorders	O
such	O
as	O
functional	O
dyspepsia	O
(	O
FD	O
)	O
including	O
abdominal	O
pain	O
,	O
heavy	O
stomach	O
feeling	O
and	O
burning	O
pain	O
and	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
.	O

Agent	O
and	O
food	O
for	O
prevention	O
/	O
amelioration	O
of	O
functional	O
gastrointestinal	O
disorders	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
producing	O
a	O
remineralizing	O
saliva	O
substitute	O
,	O
comprising	O
the	O
steps	O
:	O
f	O
)	O
complete	O
dissolution	O
of	O
at	O
least	O
one	O
organic	O
calcium	B
salt	O
,	O
selected	O
from	O
the	O
group	O
of	O
physiologically	O
acceptable	O
organic	O
acids	O
,	O
in	O
warm	O
water	O
at	O
35	O
-	O
80	O
°	O
C	O
;	O
g	O
)	O
concentrating	O
the	O
solution	O
under	O
reduced	O
pressure	O
at	O
a	O
hot	O
bath	O
temperature	O
of	O
50	O
-	O
150	O
°	O
C	O
;	O
h	O
)	O
expanding	O
to	O
standard	O
pressure	O
and	O
then	O
adding	O
at	O
least	O
one	O
organic	O
acid	O
at	O
constant	O
temperature	O
;	O
i	O
)	O
concentrating	O
the	O
solution	O
under	O
reduced	O
pressure	O
at	O
a	O
hot	O
bath	O
temperature	O
of	O
50	O
-	O
150	O
°	O
C	O
;	O
j	O
)	O
expanding	O
the	O
hot	O
,	O
free	O
-	O
flowing	O
calcium	B
salt	O
hydrate	O
melt	O
to	O
standard	O
pressure	O
;	O
aa	O
)	O
producing	O
a	O
base	O
saliva	O
substitute	O
compound	O
comprising	O
:	O
55	O
-	O
97,8	O
weight	O
%	O
water	O
;	O
1	O
-	O
15	O
weight	O
%	O
humectant	O
agent	O
;	O
0.2	O
-	O
10	O
weight	O
%	O
binding	O
and	O
thickening	O
agent	O
;	O
bb	O
)	O
producing	O
a	O
mixture	O
of	O
the	O
base	O
saliva	O
substitute	O
compound	O
while	O
heating	O
to	O
a	O
temperature	O
range	O
from	O
40	O
to	O
70	O
°	O
C	O
;	O
cc	O
)	O
adding	O
the	O
calcium	B
salt	I
hydrate	I
melt	O
to	O
the	O
base	O
compound	O
tempered	O
to	O
40	O
to	O
70	O
°	O
C	O
and	O
stirring	O
until	O
a	O
homogenous	O
saliva	O
substitute	O
mixture	O
is	O
produced	O
,	O
wherein	O
the	O
proportion	O
of	O
the	O
calcium	B
salt	I
hydrate	I
melt	O
relative	O
to	O
the	O
total	O
weight	O
of	O
the	O
saliva	O
substitute	O
mixture	O
is	O
between	O
1	O
and	O
20	O
weight	O
%	O
,	O
and	O
the	O
sum	O
of	O
the	O
amounts	O
of	O
the	O
components	O
from	O
step	O
aa	O
)	O
adds	O
up	O
to	O
100	O
%	O
.	O

dd	O
)	O
cooling	O
the	O
saliva	O
substitute	O
mixture	O
.	O

Remineralizing	O
saliva	O
substitute	O
and	O
method	O
for	O
the	O
production	O
thereof	O

Disclosed	O
is	O
a	O
mineral	O
-	O
enriched	O
soybean	O
protein	O
drink	O
such	O
as	O
a	O
soy	O
milk	O
which	O
can	O
be	O
prepared	O
without	O
using	O
any	O
troublesome	O
step	O
such	O
as	O
a	O
pretreatment	O
for	O
preventing	O
aggregation	O
caused	O
by	O
the	O
addition	O
of	O
a	O
calcium	O
compound	O
and	O
has	O
a	O
good	O
taste	O
.	O

It	O
is	O
found	O
out	O
that	O
when	O
a	O
soybean	O
protein	O
material	O
in	O
which	O
the	O
content	O
of	O
glycinine	O
,	O
i.e.	O
,	O
one	O
of	O
the	O
major	O
components	O
of	O
soybean	O
protein	O
has	O
been	O
reduced	O
is	O
used	O
as	O
a	O
starting	O
material	O
in	O
the	O
case	O
of	O
adding	O
a	O
calcium	O
compound	O
being	O
highly	O
reactive	O
with	O
soybean	O
protein	O
and	O
highly	O
water	O
soluble	O
,	O
the	O
starting	O
material	O
is	O
stable	O
to	O
the	O
addition	O
of	O
the	O
calcium	O
compound	O
at	O
a	O
higher	O
concentration	O
than	O
in	O
using	O
a	O
commonly	O
employed	O
soybean	O
material	O
.	O

It	O
is	O
also	O
found	O
out	O
that	O
the	O
addition	O
of	O
a	O
chelating	O
agent	O
allows	O
the	O
addition	O
of	O
the	O
calcium	O
compound	O
at	O
a	O
still	O
higher	O
concentration	O
.	O

The	O
above	O
-	O
described	O
object	O
has	O
been	O
achieved	O
based	O
on	O
these	O
findings	O
.	O

Mineral	O
-	O
enriched	O
soybean	O
protein	O
solution	O

This	O
invention	O
relates	O
to	O
novel	O
polymorphs	O
of	O
(	B
HO	I
)	I
2NO2	I
(	I
C6H	I
)	I
-	I
(	I
C2N2O	I
)	I
-	I
(	I
C5N	I
)	I
(	I
CH3	I
)	I
2Cl2O	I
,	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
said	O
novel	O
polymorphs	O
as	O
active	O
pharmaceutical	O
ingredient	O
.	O

Crystal	O
forms	O
of	O
5-	B
[	I
3-	I
(	I
2	I
,	I
5-dichloro-4	I
,	I
6-dimethyl-1-oxy	I
-	I
pyridine-3-yl	I
)	I
[	I
1,2,3	I
]	I
oxadiazol-5-yl	I
]	I
-3-nit	I
robenzene-1	I
,	I
2-diol	I

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
maslinic	B
acid	I
or	O
natural	O
,	O
synthetic	O
or	O
semi	O
-	O
synthetic	O
maslinic	O
-	O
rich	O
mixtures	O
or	O
of	O
a	O
composition	O
containing	O
said	O
acid	O
for	O
the	O
treatment	O
of	O
pathological	O
processes	O
associated	O
with	O
COX-2	O
activation	O
,	O
intended	O
,	O
inter	O
alia	O
,	O
for	O
the	O
symptomatic	O
and/or	O
regenerative	O
treatment	O
of	O
arthrosis	O
,	O
rheumatoid	O
arthritis	O
,	O
fibromyalgia	O
,	O
sciatica	O
and	O
other	O
articular	O
disorders	O
that	O
are	O
difficult	O
to	O
diagnose	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
topical	O
administration	O
thereof	O
.	O

Use	O
of	O
maslinic	B
acid	I
for	O
the	O
treatment	O
of	O
diseases	O
and	O
the	O
symptoms	O
thereof	O
by	O
means	O
of	O
cox-2	O
inhibition	O

Disclosed	O
are	O
:	O
a	O
therapeutic	O
agent	O
for	O
respiratory	O
diseases	O
including	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
pulmonary	O
adenomatosis	O
;	O
a	O
therapeutic	O
agent	O
for	O
allergic	O
diseases	O
including	O
bronchial	O
asthma	O
,	O
atopic	O
dermatitis	O
and	O
allergic	O
rhinitis	O
;	O
a	O
novel	O
inhibitor	O
of	O
an	O
IL-13-induced	O
reaction	O
;	O
a	O
novel	O
inhibitor	O
of	O
the	O
production	O
of	O
eotaxin	O
;	O
a	O
novel	O
therapeutic	O
or	O
prophylactic	O
agent	O
for	O
IL-13-induced	O
interstitial	O
lung	O
disease	O
;	O
a	O
novel	O
therapeutic	O
agent	O
for	O
tumors	O
;	O
and	O
an	O
IL-17	O
production	O
promoter	O
,	O
a	O
Th2	O
differentiation	O
inhibitor	O
and	O
a	O
therapeutic	O
agent	O
for	O
asthma	O
,	O
each	O
of	O
which	O
comprises	O
siRNA	O
as	O
an	O
active	O
ingredient	O
and	O
can	O
induce	O
RNA	O
interference	O
.	O

Specifically	O
disclosed	O
are	O
:	O
a	O
therapeutic	O
agent	O
for	O
respiratory	O
diseases	O
and	O
others	O
,	O
each	O
of	O
which	O
comprises	O
SOCS1	O
as	O
an	O
active	O
ingredient	O
;	O
and	O
an	O
agent	O
and	O
others	O
,	O
each	O
of	O
which	O
comprises	O
siRNA	O
for	O
SOCS3	O
as	O
an	O
active	O
ingredient	O
.	O

Therapeutic	O
agent	O
for	O
respiratory	O
diseases	O
or	O
allergic	O
diseases	O

Disclosed	O
is	O
a	O
ketone	B
accumulation	O
inhibitor	O
which	O
can	O
inhibit	O
the	O
accumulation	O
of	O
ketones	B
which	O
is	O
caused	O
by	O
exercising	O
.	O

The	O
ketone	B
accumulation	O
inhibitor	O
comprises	O
isomaltulose	O
as	O
an	O
active	O
ingredient	O
.	O

Ketone	B
accumulation	O
inhibitor	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
preventive	O
and	O
therapeutic	O
veterinary	O
medicine	O
.	O

In	O
particular	O
,	O
it	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
sweet	O
itch	O
in	O
equine	O
species	O
,	O
horses	O
,	O
ponies	O
,	O
donkeys	O
.	O

Provided	O
is	O
the	O
use	O
of	O
ubiquitin	O
,	O
or	O
ubiquitin	O
-	O
related	O
molecule	O
,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
sweet	O
itchin	O
an	O
equine	O
mammal	O
.	O

Also	O
provided	O
is	O
a	O
composition	O
comprising	O
pharmaceutically	O
active	O
quantities	O
of	O
ubiquitin	O
or	O
ubiquitin-	O
related	O
molecule	O
and	O
tocopherol	B
,	O
together	O
with	O
an	O
acceptable	O
carrier	O
.	O

Ubiquitin	O
alone	O
or	O
in	O
combination	O
for	O
use	O
in	O
the	O
treatment	O
of	O
sweet	O
itch	O

The	O
present	O
invention	O
provides	O
a	O
photosensitising	O
composition	O
comprising	O
a	O
mixture	O
of	O
at	O
least	O
one	O
oxygen	B
carrier	O
,	O
at	O
least	O
one	O
oxidising	O
agent	O
and	O
at	O
least	O
one	O
surfactant	O
,	O
and	O
its	O
uses	O
.	O

The	O
ratio	O
of	O
the	O
at	O
least	O
one	O
oxygen	B
carrier	O
to	O
the	O
at	O
least	O
one	O
oxidising	O
agent	O
to	O
the	O
at	O
least	O
one	O
surfactant	O
may	O
be	O
in	O
the	O
range	O
of	O
50:40:10	O
to	O
80:19.8:0.2	O
.	O

The	O
photosensitising	O
composition	O
may	O
be	O
used	O
for	O
treating	O
and/or	O
preventing	O
conditions	O
caused	O
by	O
microorganisms	O
.	O

A	O
photosensitising	O
composition	O
and	O
its	O
uses	O

Methods	O
of	O
treating	O
patients	O
with	O
an	O
HDAC	O
inhibitor	O
and	O
an	O
HMT	O
inhibitor	O
are	O
provided	O
.	O

Administration	O
of	O
an	O
inhibitor	O
of	O
hdac	O
and	O
an	O
hmt	O
inhibitor	O

A	O
conjugated	O
linoleic	B
acid	I
(	O
CLA	O
)	O
derivative	O
having	O
the	O
structure	O
(	O
I	O
)	O
wherein	O
n	O
is	O
an	O
integer	O
from	O
1	O
to	O
10	O
;	O
and	O
wherein	O
the	O
broken	O
lines	O
at	O
positions	O
9	O
and	O
11	O
,	O
or	O
at	O
positions	O
10	O
and	O
12	O
,	O
are	O
each	O
double	O
bonds	O
separated	O
by	O
a	O
single	O
bond	O
,	O
and	O
wherein	O
the	O
remaining	O
broken	O
line	O
is	O
a	O
single	O
bond	O
.	O

Conjugated	O
linoleic	B
acid	I
derivatives	O

Effective	O
treatments	O
of	O
pain	O
and/or	O
inflammation	O
are	O
provided	O
.	O

Through	O
the	O
administration	O
of	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
beta	O
adrenergic	O
agonist	O
at	O
or	O
near	O
a	O
target	O
site	O
,	O
one	O
can	O
reduce	O
,	O
prevent	O
or	O
treat	O
pain	O
and/or	O
inflammation	O
.	O

Beta	O
adrenergic	O
receptor	O
agonists	O
for	O
treatment	O
of	O
pain	O
and/or	O
inflammation	O

A	O
kind	O
of	O
substituted	O
five	B
-	I
membered	I
heterocyclic	I
compounds	O
represented	O
by	O
the	O
following	O
formula	O
I	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
esters	O
,	O
salvates	O
,	O
metal	O
complex	O
or	O
prodrug	O
with	O
the	O
same	O
biological	O
activity	O
thereof	O
.	O

The	O
uses	O
of	O
those	O
compounds	O
as	O
GLP-1	O
receptor	O
signaling	O
transoluction	O
positive	O
modulators	O
,	O
and	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
relating	O
to	O
metabolic	O
diseases	O
(	O
including	O
but	O
not	O
limited	O
to	O
type-2	O
diabetes	O
,	O
insulin	O
resistance	O
and	O
obesity	O
etc	O
.	O
)	O
,	O
cardiovascular	O
disease	O
and	O
neuro	O
degenerative	O
diseases	O
(	O
such	O
as	O
Alzheimer	O
's	O
Disease	O
,	O
AD	O
,	O
also	O
said	O
Alzheimer	O
's	O
dememtia	O
)	O
.	O

A	O
kind	O
of	O
receptor	O
signaling	O
transoluction	O
positive	O
modulators	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O

The	O
invention	O
provides	O
for	O
new	O
methods	O
for	O
treatment	O
and	O
diagnosis	O
of	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

In	O
particular	O
,	O
there	O
is	O
disclosed	O
the	O
use	O
of	O
a	O
Chlamydia	O
activating	O
agent	O
and	O
one	O
or	O
several	O
antibiotics	O
selected	O
from	O
macroildes	O
and	O
benzoxazinorifamycins	B
in	O
the	O
preparation	O
of	O
combination	O
agent	O
for	O
simultaneous	O
,	O
concomitant	O
or	O
sequential	O
administration	O
for	O
the	O
treatment	O
of	O
IBS	O
.	O

New	O
therapy	O
of	O
treatment	O
of	O
the	O
irritable	O
bowel	O
syndrome	O
.	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
for	O
the	O
regulation	O
of	O
phosphoinositides	O
3-kinases	O
activity	O
and	O
related	O
diseases	O
.	O

Fused	B
bicyclic	I
compounds	O
and	O
use	O
thereof	O
as	O
pi3k	O
inhibitors	O

The	O
present	O
invention	O
provides	O
novel	O
non	O
-	O
hydrolyzable	O
and	O
permeable	O
cyclic	B
bis-	I
[	I
nucleotide	I
monophosphate	I
]	I
derivatives	O
and	O
pharmaceutical	O
compositions	O
comprising	O
thereof	O
.	O

The	O
cyclic	B
bis-	I
[	I
nucleotide	I
monophosphate	I
]	I
derivatives	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
treatment	O
of	O
bacterial	O
infections	O
,	O
in	O
particular	O
,	O
for	O
disruption	O
of	O
bacterial	O
regulation	O
and/or	O
signal	O
transduction	O
,	O
disruption	O
or	O
reduction	O
of	O
bacterial	O
pathogenicity	O
,	O
and/or	O
disruption	O
or	O
reduction	O
of	O
a	O
bacterial	O
pathogenicity	O
related	O
activity	O
such	O
as	O
biofilm	O
formation	O
.	O

Non	O
-	O
hydrolyzable	O
and	O
permeable	O
cyclic	B
bis-	I
[	I
nucleotide	I
monophosphate	I
]	I
derivatives	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
a	O
novel	O
LXRβ	O
agonist	O
which	O
is	O
useful	O
as	O
a	O
prophylactic	O
and/or	O
therapeutic	O
agent	O
for	O
arteriosclerosis	O
such	O
as	O
atherosclerosis	O
and	O
arteriosclerosis	O
associated	O
with	O
diabetes	O
,	O
dyslipidemia	O
,	O
hypercholesterolemia	O
,	O
lipid	O
-	O
related	O
diseases	O
,	O
inflammatory	O
diseases	O
induced	O
by	O
an	O
inflammatory	O
cytokine	O
,	O
skin	O
diseases	O
such	O
as	O
allergic	O
skin	O
diseases	O
,	O
diabetes	O
or	O
Alzheimer	O
's	O
disease	O
.	O

Specifically	O
disclosed	O
is	O
a	O
quinoline	B
compound	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
,	O
a	O
salt	O
thereof	O
,	O
or	O
a	O
solvate	O
of	O
the	O
quinoline	B
compound	O
or	O
the	O
salt	O
.	O

Quinoline	B
compound	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
administering	O
compositions	O
comprising	O
a	O
progesterone	O
receptor	O
antagonist	O
for	O
use	O
in	O
treating	O
estrogen	B
-	O
dependent	O
conditions	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
methods	O
for	O
treating	O
pain	O
associated	O
with	O
endometriosis	O
.	O

The	O
compositions	O
may	O
be	O
administered	O
to	O
females	O
with	O
endometriosis	O
as	O
well	O
as	O
to	O
females	O
undergoing	O
estrogen	B
and/or	O
selective	O
estrogen	B
receptor	O
modulator	O
(	O
SERM	O
)	O
therapy	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
invention	O
provides	O
a	O
method	O
for	O
suppressing	O
endometrial	O
proliferation	O
.	O

Progesterone	B
antagonists	O
such	O
as	O
cdb-4124	O
in	O
the	O
treatment	O
of	O
endometriosis	O
,	O
uterine	O
fibroids	O
,	O
dysmenorrhea	O
,	O
breast	O
cancer	O
etc	O

A	O
compound	O
which	O
is	O
a	O
quaternary	B
ammonium	I
salt	O
derivative	O
of	O
an	O
opioid	B
,	O
for	O
use	O
in	O
therapy	O
.	O

Use	O
of	O
opioid	B
compounds	O
in	O
peripheral	O
pain	O
,	O
wound	O
healing	O
and	O
scar	O
formation	O

A	O
combination	O
,	O
comprising	O
4-	B
(	I
3-chloro-2-fluoroanilino	I
)	I
-7-methoxy-6-	I
{	I
[	I
l-	I
(	I
N-	I
methylcarbamoylmethyl	I
)	I
piperidin-4-yl	I
]	I
oxy	I
}	I
quinazoline	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
an	O
endocrine	O
agent	O
suitable	O
for	O
use	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
is	O
described	O
.	O

Also	O
described	O
is	O
the	O
use	O
of	O
the	O
combination	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

Combination	O
comprising	O
4-	B
(	I
3-chloro-2-fluoroanilino	I
)	I
-7-meth0xy-6-	I
{	I
[	I
1-	I
(	I
n	I
-	I
methylcarbamoylmethyl	I
)	I
piperidin-	I
4-yl	I
]	I
oxyjquinazoline	I

Disclosed	O
is	O
a	O
10a	B
-	I
azalide	I
compound	O
which	O
is	O
effective	O
against	O
a	O
bacterium	O
Haemophilus	O
influenzae	O
(	O
an	O
influenza	O
bacterium	O
)	O
or	O
an	O
erythromycin	B
-	O
resistant	O
bacterium	O
(	O
e.g.	O
,	O
resistant	O
pneumococcus	O
or	O
streptococcus	O
)	O
and	O
has	O
a	O
novel	O
structure	O
.	O

The	O
10a	B
-	I
azalide	I
compound	O
is	O
represented	O
by	O
formula	O
(	O
I	O
)	O
and	O
has	O
a	O
4-membered	O
ring	O
structure	O
cross	O
-	O
linked	O
at	O
position-10a	O
and	O
position-12	O
.	O

10a	B
-	I
azalide	I
compound	O
having	O
4-membered	O
ring	O
structure	O

Disclosed	O
is	O
a	O
novel	O
pharmaceutical	O
composition	O
for	O
external	O
application	O
for	O
increasing	O
the	O
permeation	O
of	O
prochlorperazine	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
through	O
the	O
skin	O
to	O
allow	O
prochlorperazine	B
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
exhibit	O
its	O
excellent	O
pharmacological	O
activity	O
.	O

Specifically	O
disclosed	O
is	O
a	O
novel	O
pharmaceutical	O
composition	O
for	O
external	O
application	O
,	O
which	O
contains	O
prochlorperazine	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
and	O
further	O
contains	O
menthol	B
.	O

The	O
composition	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
prochlorperazine	B
which	O
has	O
been	O
widely	O
used	O
clinically	O
as	O
the	O
first	O
-	O
line	O
drug	O
of	O
a	O
therapeutic	O
agent	O
for	O
nausea	O
or	O
vomiting	O
before	O
or	O
after	O
a	O
surgery	O
or	O
the	O
like	O
,	O
and	O
is	O
extremely	O
highly	O
useful	O
as	O
a	O
transdermally	O
absorbable	O
antiemetic	O
agent	O
that	O
has	O
excellent	O
efficacy	O
and	O
can	O
be	O
used	O
safely	O
over	O
a	O
long	O
period	O
.	O

Pharmaceutical	O
composition	O
for	O
external	O
application	O
containing	O
prochlorperazine	B

The	O
present	O
invention	O
provides	O
a	O
use	O
of	O
tanshinone	B
IIA	I
,	O
physiologically	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	B
or	O
mixtures	O
thereof	O
in	O
preparing	O
medicine	O
for	O
treating	O
obesity	O
and	O
insulin	O
resistance	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
losing	O
weight	O
by	O
using	O
tanshinone	B
IIA	I
or	O
a	O
composition	O
thereof	O
,	O
and	O
a	O
medical	O
use	O
of	O
a	O
composition	O
which	O
includes	O
tanshinone	B
IIA	I
and	O
other	O
materials	O
,	O
said	O
materials	O
could	O
prevent	O
,	O
control	O
or	O
treat	O
diabetes	O
and/or	O
symptoms	O
or	O
diseases	O
associated	O
with	O
obesity	O
.	O

The	O
use	O
of	O
tanshinone	B
iia	I
in	O
preparing	O
medicine	O
for	O
treating	O
obesity	O
and	O
insulin	O
resistance	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
useful	O
as	O
inhibitors	O
of	O
protein	O
kinases	O
,	O
such	O
as	O
inhibitors	O
of	O
GSK-3	O
.	O

The	O
invention	O
provides	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
.	O

The	O
invention	O
provides	O
processes	O
for	O
preparing	O
compounds	O
of	O
the	O
invention	O
.	O

The	O
invention	O
provides	O
methods	O
of	O
identifying	O
compounds	O
useful	O
for	O
treatment	O
of	O
diabetes	O
,	O
diabetic	O
neuropathy	O
,	O
osteoporosis	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Huntington	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
AIDS	O
-	O
associated	O
dementia	O
,	O
bipolar	O
disorder	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
multiple	O
sclerosis	O
,	O
schizophrenia	O
,	O
leukocytopenia	O
,	O
cardiomyocyte	O
hypertrophy	O
,	O
stroke	O
,	O
post	O
-	O
stroke	O
,	O
spinal	O
cord	O
injury	O
,	O
traumatic	O
brain	O
injury	O
,	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
,	O
peripheral	O
nerve	O
regeneration	O
,	O
and	O
rheumatoid	O
arthritis	O
.	O

Pyrimidines	B
and	O
pyridines	B
useful	O
as	O
inhibitors	O
of	O
protein	O
kinases	O

Provided	O
herein	O
is	O
a	O
highly	O
pure	O
deferasirox	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
substantially	O
free	O
of	O
hydrazine	B
impurity	O
,	O
4-hydrazinobenzoic	B
acid	I
,	O
processes	O
for	O
the	O
preparation	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
highly	O
pure	O
deferasirox	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
substantially	O
free	O
of	O
hydrazine	B
impurity	O
.	O

Substantially	O
pure	O
deferasirox	B
and	O
processes	O
for	O
the	O
preparation	O
thereof	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
specific	O
dosing	O
regimens	O
of	O
telaprevir	B
in	O
combination	O
with	O
peg	O
-	O
IFN	O
and	O
RBV	O
in	O
the	O
treatment	O
of	O
HCV	O
patients	O
,	O
wherein	O
the	O
treatment	O
comprises	O
(	O
a	O
)	O
a	O
lead	O
-	O
in	O
phase	O
of	O
administering	O
to	O
the	O
subject	O
pegylated	O
interferon	O
and	O
ribavirin	B
,	O
and	O
(	O
b	O
)	O
a	O
treatment	O
phase	O
of	O
administering	O
to	O
the	O
subject	O
a	O
combination	O
of	O
telaprevir	B
,	O
pegylated	O
interferon	O
and	O
ribavirin	B
.	O

Telaprevir	B
dosing	O
regimen	O

Histone	O
deacetylase	O
inhibitors	O
and	O
uses	O
thereof	O
.	O

The	O
histone	O
deacetylase	O
inhibitors	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
malignant	O
tumor	O
and	O
the	O
diseases	O
associated	O
with	O
differentiation	O
and	O
proliferation	O
.	O

The	O
histone	O
deacetylase	O
inhibitors	O
are	O
the	O
compounds	O
or	O
salts	O
thereof	O
represented	O
as	O
the	O
formula	O
illustrated	O
below	O
.	O

Histone	O
deacetylase	O
inhibitors	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
,	O
Y	O
,	O
Z	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
are	O
as	O
defined	O
in	O
claim	O
1	O
,	O
including	O
pharmaceutical	O
compositions	O
thereof	O
and	O
for	O
their	O
use	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diabetes	O
,	O
metabolic	O
syndrome	O
,	O
obesity	O
,	O
cancer	O
,	O
inflammation	O
.	O

Quinoxalinedione	B
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
hydrogen	B
,	O
halogen	B
,	O
cyano	B
or	O
lower	O
alkyl	B
;	O
n	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
R2	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
R3	O
is	O
an	O
aryl-	B
or	O
a	O
heteroaryl	B
ring	O
,	O
wherein	O
the	O
rings	O
are	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
substituents	O
R	O
'	O
;	O
R	O
'	O
is	O
selected	O
from	O
hydrogen	B
,	O
halogen	B
,	O
lower	O
alkyl	B
,	O
lower	O
alkoxy	B
,	O
lower	O
alkyl	B
substituted	O
by	O
halogen	B
,	O
lower	O
alkoxy	B
substituted	O
by	O
halogen	B
,-	O
S	B
(	I
O	I
)	I
2-lower	I
alkyl	I
,	O
CN	B
,	O
-NR4R5	B
,	O
-C	B
(	I
O	I
)	I
-lower	I
alkyl	I
,	O
heterocyclyl	B
or	O
heteroaryl	B
;	O
R4	O
/	O
R5	O
are	O
independently	O
from	O
each	O
other	O
hydrogen	B
,	O
-	O
(	O
CO	O
)	O
CF3	O
or	O
lower	O
alkyl	B
or	O
is	O
a	O
non	O
aromatic	B
heterocyclic	B
group	O
(	O
II	O
)	O
wherein	O
X	O
is	O
N	B
or	O
CH	B
;	O
Y	O
is	O
-CH	O
(	B
R7	I
)	I
-	I
;	O
-N	B
(	I
R7'	I
)	I
-	I
,	O
or	O
O	B
or	O
can	O
be	O
SO2	B
;	O
R6	O
is	O
hydrogen	B
,	O
lower	O
alkyl	B
or	O
hydroxy	B
;	O
R7	O
is	O
hydrogen	B
,	O
hydroxy	B
,	O
=	B
0	I
,	O
lower	O
alkyl	B
,	O
lower	O
alkoxy	B
,	O
-S	B
(	I
O	I
)	I
2-lower	I
alkyl	I
,	O
-C	O
(	B
O	I
)	I
-lower	I
alkyl	I
,	O
-C	B
(	I
O	I
)	I
CH2O	I
-	I
lower	I
alkyl	I
,	O
-CH2CN	B
,	O
-C	B
(	I
O	I
)	I
CH2CN	I
,	O
-C	B
(	I
O	I
)	I
-cycloalkyl	I
wherein	O
the	O
cycloalkyl	B
group	O
is	O
optionally	O
substituted	O
by	O
cyano	B
,	O
lower	O
alkyl	B
,	O
one	O
or	O
two	O
halogen	B
atoms	O
,	O
=	B
0	I
or	O
by	O
amino	B
,	O
or	O
is	O
-C	B
(	I
O	I
)	I
O	I
-	I
lower	I
alkyl	I
,	O
-NH	B
-	I
lower	I
alkyl	I
,	O
-NRC	B
(	I
O	I
)	I
O	I
-	I
lower	I
alkyl	I
,	O
-NRC	B
(	I
O	I
)	I
-lower	I
alkyl	I
or	O
-CH2O	B
-	I
lower	I
alkyl	I
;	O
and	O
R7	O
'	O
is	O
hydrogen	B
,	O
lower	O
alkyl	B
,	O
-	B
(	I
CH2	I
)	I
q	I
-	I
S	I
(	I
O	I
)	I
2-lower	I
alkyl	I
,	O
-	B
(	I
CH2	I
)	I
q	I
-	I
S	I
(	I
O	I
)	I
2-cycloalkyl	I
,	O
-C	B
(	I
O	I
)	I
-lower	I
alkyl	I
,	O
-	B
(	I
CH2	I
)	I
q	I
-	I
cycloalkyl	I
,	O
-C	B
(	I
O	I
)	I
CH2-O	I
-	I
lower	I
alkyl	I
,	O
-	B
(	I
CH2	I
)	I
qCN	I
,	O
-C	B
(	I
O	I
)	I
CN	I
,	O
-C	B
(	I
O	I
)	I
CH2CN	I
,	O
lower	O
alkyl	B
substituted	O
by	O
halogen	B
,	O
lower	O
alkenyl	B
substituted	O
by	O
halogen	B
,	O
-C	B
(	I
O	I
)	I
-cycloalkyl	I
wherein	O
the	O
cycloalkyl	B
group	O
is	O
optionally	O
substituted	O
by	O
cyano	B
,	O
lower	O
alkyl	B
,	O
one	O
or	O
two	O
halogen	B
atoms	O
,	O
=	B
0	I
or	O
by	O
amino	B
,	O
or	O
is	O
-C	B
(	I
O	I
)	I
O	I
-	I
lower	I
alkyl	I
or	O
-	B
(	I
CH2	I
)	I
qO	I
-	I
lower	I
alkyl	I
and	O
q	O
is	O
O	O
-	O
3	O
;	O
or	O
R6	O
and	O
R7	O
may	O
form	O
together	O
with	O
the	O
carbon	B
atoms	O
to	O
which	O
they	O
are	O
attach	O
a	O
five	O
or	O
six-	O
membered	O
non	O
aromatic	B
ring	O
or	O
R6	O
and	O
R7	O
may	O
form	O
together	O
with	O
the	O
nitrogen	B
and	O
carbon	B
atoms	O
to	O
which	O
they	O
are	O
attach	O
a	O
five	O
or	O
six	O
-	O
membered	O
non	O
aromatic	B
ring	O
;	O
p	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
Ar	B
is	O
aryl-	B
or	O
heteroaryl	B
,	O
wherein	O
the	O
rings	O
are	O
optionally	O
substituted	O
by	O
one	O
or	O
two	O
substituents	O
R	O
""""	O
;	O
R	O
'	O
'	O
is	O
selected	O
from	O
hydrogen	B
,	O
halogen	B
,	O
lower	O
alkyl	B
,	O
lower	O
alkyl	B
substituted	O
by	O
halogen	B
,	O
lower	O
alkoxy	B
,	O
lower	O
alkoxy	B
substituted	O
by	O
halogen	B
,	O
-O	B
-	I
CH2-cycloalkyl	I
,	O
-NR4R5	B
,	O
-CN	B
,	O
-CH	B
(	I
CH3	I
)	I
CN	I
,	O
-CH2O	B
-	I
lower	I
alkyl	I
or	O
pyrrolyl	B
;	O
m	O
is	O
0	O
,	O
1	O
or	O
2	O
and	O
o	O
is	O
0	O
;	O
o	O
is	O
0	O
,	O
1	O
or	O
2	O
and	O
m	O
is	O
1	O
or	O
pharmaceutically	O
active	O
salts	O
,	O
racemic	O
mixtures	O
,	O
enantiomers	O
,	O
optical	O
isomers	O
or	O
tautomeric	O
forms	O
thereof	O
.	O

The	O
compounds	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
anxiety	O
or	O
schizophrenia	O
.	O

Pyrrolidine	B
derivatives	O
as	O
nk2	O
receptor	O
antagonists	O

The	O
invention	O
relates	O
to	O
bi-	O
and	O
polycyclic	O
substituted	O
isoquinoline	B
and	O
isoquinolinones	B
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R12	O
are	O
as	O
defined	O
in	O
the	O
application	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
associated	O
with	O
Rho	O
-	O
kinase	O
and/or	O
Rho	O
-	O
kinase	O
mediated	O
phosphorylation	O
of	O
myosin	O
light	O
chain	O
phosphatase	O
,	O
and	O
compositions	O
containing	O
such	O
compounds	O
.	O

Bi	O
-	O
and	O
polycyclic	O
substituted	O
isoquinoline	B
and	O
isoquinoline	B
derivatives	O
as	O
rho	O
kinase	O
inhibitors	O

Compounds	O
having	O
drug	O
and	O
bio	O
-	O
affecting	O
properties	O
,	O
their	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
are	O
set	O
forth	O
.	O

In	O
particular	O
,	O
diketopiperidine	B
derivatives	O
that	O
possess	O
unique	O
antiviral	O
activity	O
are	O
provided	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV	O
and	O
AIDS	O
.	O

Diketopiperidine	B
derivatives	O
as	O
hiv	O
attachment	O
inhibitors	O

Disclosed	O
are	O
methods	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
cancer	O
such	O
as	O
a	O
liver	O
cancer	O
or	O
a	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
in	O
a	O
subject	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
andrographolide	B
(	O
AND	B
)	O
or	O
a	O
composition	O
comprising	O
AND	B
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
use	O
thereof	O
.	O

Disclosed	O
also	O
are	O
methods	O
for	O
preventing	O
,	O
treating	O
and/or	O
reducing	O
liver	O
damage	O
in	O
a	O
subject	O
comprising	O
administering	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
AND	B
or	O
a	O
composition	O
comprising	O
AND	B
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
use	O
thereof	O
.	O

Methods	O
for	O
treatment	O
and/or	O
prevention	O
of	O
cancer	O
with	O
andrographolide	B
(	O
and	B
)	O
and	O
use	O
thereof	O

The	O
subject	O
of	O
the	O
invention	O
is	O
novel	O
compositions	O
having	O
,	O
in	O
particular	O
,	O
antiviral	O
properties	O
,	O
characterized	O
in	O
that	O
they	O
contain	O
,	O
in	O
combination	O
,	O
at	O
least	O
one	O
phenolic	B
derivative	O
and	O
propolis	O
,	O
said	O
phenolic	B
derivative	O
corresponding	O
to	O
the	O
following	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
in	O
which	O
R	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1-C5	B
alkyl	I
radical	O
or	O
an	O
‑N	B
(	I
R1	I
,	I
R2	I
)	I
group	O
,	O
with	O
R1	O
and	O
R2	O
,	O
which	O
are	O
identical	O
or	O
different	O
,	O
representing	O
a	O
hydrogen	B
atom	O
or	O
a	O
C1-C5	B
alkyl	I
radical	O
.	O

Compositions	O
containing	O
a	O
combination	O
of	O
propolis	O
and	O
a	O
phenolic	B
derivative	O
and	O
biological	O
applications	O
thereof	O

Disclosed	O
is	O
an	O
oligonucleotide	B
structure	O
which	O
can	O
distinguish	O
between	O
a	O
normal	O
cell	O
and	O
an	O
abnormal	O
cell	O
such	O
as	O
a	O
cancer	O
cell	O
and	O
can	O
act	O
only	O
in	O
an	O
abnormal	O
cell	O
.	O

The	O
oligonucleotide	B
structure	O
comprises	O
three	O
oligonucleotide	B
chains	O
,	O
i.e.	O
,	O
a	O
trigger	O
chain	O
,	O
an	O
effector	O
chain	O
and	O
a	O
support	O
chain	O
,	O
wherein	O
each	O
of	O
the	O
three	O
oligonucleotide	B
chains	O
is	O
bound	O
to	O
the	O
other	O
two	O
chains	O
so	O
as	O
to	O
form	O
a	O
structure	O
like	O
a	O
three	O
-	O
way	O
joint	O
,	O
and	O
wherein	O
the	O
trigger	O
chain	O
has	O
a	O
site	O
capable	O
of	O
recognizing	O
the	O
sequences	O
of	O
other	O
polynucleotide	O
chains	O
on	O
the	O
outside	O
of	O
a	O
site	O
that	O
is	O
bound	O
to	O
the	O
support	O
chain	O
.	O

Oligonucleotide	B
structure	O
,	O
and	O
method	O
for	O
regulation	O
of	O
gene	O
expression	O

The	O
subject	O
invention	O
concerns	O
compounds	O
having	O
activity	O
as	O
inhibitors	O
of	O
proteasomes	O
and	O
methods	O
of	O
using	O
the	O
subject	O
compounds	O
.	O

In	O
one	O
embodiment	O
,	O
a	O
compound	O
of	O
the	O
invention	O
has	O
the	O
chemical	O
structure	O
shown	O
in	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
an	O
organic	O
cyclic	B
ring	O
structure	O
bonded	O
to	O
a	O
sulfonamide	B
structure	O
;	O
R2	O
is	O
H	B
,	O
halogen	B
,	O
alkyl	B
,	O
-NR6R7	B
,	O
or	O
heteroalkyl	B
;	O
R3	O
is	O
H	B
,	O
halogen	B
,	O
-OH	B
,	O
-O	B
-	I
alkyl	I
,	O
alkyl	B
,	O
cycloalkyl	B
,	O
heterocycloalkyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
-NO2	B
,	O
-NH2	B
or	O
substituted	O
amines	B
;	O
R4	O
is	O
H	B
,	O
alkyl	B
,	O
heteroalkyl	B
,	O
aryl	B
,	O
or	O
heteroaryl	B
,	O
any	O
of	O
which	O
can	O
be	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
of	O
-NO2	B
,	O
alkyl	B
,	O
heteroalkyl	B
,	O
aryl	B
,	O
or	O
heteroaryl	B
,	O
or	O
halogen	B
;	O
R5	O
is	O
H	B
,	O
-OH	B
,	O
halogen	B
,	O
alkyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
cycloalkyl	B
,	O
heterocycloalkyl	B
,	O
-O	B
-	I
alkyl	I
,	O
-O-	B
aryl	I
,	O
heteroalkyl	B
,	O
-NO2	B
,	O
-NH2	B
,	O
or	O
substituted	O
amine	B
;	O
and	O
R6	O
and	O
R7	O
are	O
independently	O
H	B
,	O
O	B
,	O
alkyl	B
,	O
aryl	B
,	O
heterocycloalkyl	B
,	O
or	O
heteroaryl	B
,	O
or	O
together	O
can	O
form	O
a	O
heterocycloalkyl	B
or	O
a	O
heteroaryl	B
,	O
any	O
of	O
which	O
can	O
be	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
of	O
-NO2	B
,	O
alkyl	B
,	O
heteroalkyl	B
,	O
aryl	B
,	O
or	O
halogen	B
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	B
thereof	O
.	O

In	O
another	O
embodiment	O
,	O
a	O
compound	O
of	O
the	O
invention	O
has	O
the	O
chemical	O
structure	O
shown	O
in	O
Formula	O
(	O
II	O
)	O
,	O
wherein	O
Q	O
,	O
W	O
,	O
X	O
,	O
Y	O
,	O
Z	O
are	O
each	O
independently	O
carbon	B
,	O
oxygen	B
,	O
or	O
nitrogen	B
;	O
R1	O
is	O
H	B
,	O
or	O
X1R8	O
;	O
R2	O
is	O
heteroalkyl	B
,	O
which	O
can	O
be	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
of	O
-OH	B
,	O
halogen	B
,	O
-C	B
(	I
O	I
)	I
OR4	I
,	O
alkyl	B
,	O
heteroalkyl	B
,	O
heterocycloalkyl	B
,	O
or	O
heteroaryl	B
;	O
R3	O
is	O
heterocycloalkyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
any	O
of	O
which	O
can	O
be	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
of	O
a	O
halogen	B
or	O
-OH	B
;	O
and	O
R4	O
is	O
H	B
or	O
alkyl	B
;	O
R5	O
is	O
halogen	B
,	O
alkyl	B
or	O
nitro	B
;	O
R6	O
is	O
nitro	B
,	O
X2R9	O
or	O
a	O
halogen	B
;	O
R7	O
is	O
H	B
or	O
alkyl	B
;	O
R8	O
is	O
H	B
,	O
alkyl	B
,	O
aryl	B
,	O
CH2-alkyl	B
-	I
aryl	I
,	O
-alkyl	B
-	I
C	I
(	I
O	I
)	I
OH	I
,	O
or	O
alkyl	B
-	I
tetrazole	I
(	O
aromatic	O
and	O
aliphatic	O
heterocyclic	B
groups	O
)	O
;	O
R9	O
is	O
H	B
or	O
alkyl	B
;	O
X1	O
is	O
oxygen	B
,	O
nitrogen	B
,	O
or	O
sulfur	B
;	O
X2	O
is	O
oxygen	B
,	O
nitrogen	B
,	O
or	O
sulfur	B
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	B
thereof	O
.	O

Proteasome	O
inhibitors	O
for	O
selectively	O
inducing	O
apoptosis	O
in	O
cancer	O
cells	O

The	O
present	O
disclosure	O
generally	O
relates	O
to	O
therapeutic	O
nanoparticles	O
.	O

Exemplary	O
nanoparticles	O
disclosed	O
herein	O
may	O
include	O
about	O
1	O
to	O
about	O
20	O
weight	O
percent	O
of	O
a	O
vinca	O
alkaloid	B
;	O
and	O
about	O
50	O
to	O
about	O
99	O
weight	O
percent	O
biocompatible	O
polymer	O
.	O

Therapeutic	O
polymeric	O
nanoparticles	O
comprising	O
vinca	O
alkaloids	B
and	O
methods	O
of	O
making	O
and	O
using	O
same	O

An	O
immune	O
composition	O
containing	O
Globo	O
H	O
or	O
its	O
fragment	O
(	O
e.g.	O
,	O
SSEA3	O
)	O
and	O
an	O
adjuvant	O
,	O
e.g.	O
,	O
α	O
-GalCer	O
,	O
for	O
eliciting	O
immune	O
responses	O
against	O
Globo	O
H	O
or	O
its	O
fragment	O
and	O
uses	O
thereof	O
in	O
cancer	O
treatment	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
of	O
treating	O
cancer	O
by	O
inhibiting	O
the	O
activity	O
of	O
one	O
of	O
FUT1	O
and	O
FUT2	O
,	O
both	O
of	O
which	O
involve	O
in	O
Globo	O
H	O
biosynthesis	O
.	O

Compositions	O
for	O
inducing	O
immune	O
responses	O
specific	O
to	O
globo	O
h	O
and	O
ssea3	O
and	O
uses	O
thereof	O
in	O
cancer	O
treatment	O

This	O
invention	O
discloses	O
2-methylene-19,26-dinor-	B
(	I
20S,22E,25R	I
)	I
-	I
vitamin	I
D	I
analogs	O
,	O
and	O
specifically	O
2-methylene-19,26-dinor-	B
(	I
20S,22E,25R	I
)	I
-lα,25-	I
dihydroxyvitamin	I
D3	I
,	O
and	O
pharmaceutical	O
uses	O
therefor	O
.	O

This	O
compound	O
exhibits	O
transcription	O
activity	O
as	O
well	O
as	O
pronounced	O
activity	O
in	O
arresting	O
the	O
proliferation	O
of	O
undifferentiated	O
cells	O
and	O
inducing	O
their	O
differentiation	O
to	O
the	O
monocyte	O
thus	O
evidencing	O
use	O
as	O
an	O
anti	O
-	O
cancer	O
agent	O
and	O
for	O
the	O
treatment	O
of	O
skin	O
diseases	O
such	O
as	O
psoriasis	O
as	O
well	O
as	O
skin	O
conditions	O
such	O
as	O
wrinkles	O
,	O
slack	O
skin	O
,	O
dry	O
skin	O
and	O
insufficient	O
sebum	O
secretion	O
.	O

This	O
compound	O
also	O
shows	O
no	O
activity	O
in	O
vivo	O
on	O
bone	O
calcium	O
mobilization	O
and	O
relatively	O
low	O
intestinal	O
calcium	O
transport	O
activity	O
compared	O
to	O
the	O
native	O
hormone	O
lα,25-dihydroxyvitamin	B
D3	I
,	O
and	O
therefore	O
may	O
be	O
used	O
to	O
treat	O
autoimmune	O
disorders	O
or	O
inflammatory	O
diseases	O
in	O
humans	O
as	O
well	O
as	O
renal	O
osteodystrophy	O
.	O

This	O
compound	O
may	O
also	O
be	O
used	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
obesity	O
.	O

2-methylene-19	B
,	I
26-dinor-	I
(	I
20s	I
,	I
22e	I
,	I
25r	I
)	I
-vitamin	I
d	I
analogs	O

The	O
invention	O
relates	O
to	O
the	O
novel	O
products	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
:	O
n	O
=	O
0,1	O
or	O
2	O
;	O
X	O
is	O
H	B
,	O
Hal	B
or	O
alk	B
;	O
R	O
is	O
H	B
,	O
NH2	B
,	O
NHalk	B
or	O
N	B
(	I
alk	I
)	I
2	I
;	O
Ra	O
is	O
H	B
,	O
Hal	B
,	O
-O	B
-	I
cycloalkyl	I
,	O
-O	B
-	I
alkyl	I
,	O
-O	B
-	I
aryl	I
,	O
-O	B
-	I
heteroaryl	I
,	O
‑NRd	B
(	I
cycloalkyl	I
)	I
,	O
‑NRd	B
(	I
alkyl	I
)	I
,	O
-NRd	B
(	I
aryl	I
)	I
,	O
-NRd	B
(	I
heteroaryl	I
)	I
,	O
alkyl	B
,	O
cycloalkyl	B
,	O
heterocycloalkyl	B
,	O
aryl	B
or	O
heteroaryl	B
,	O
all	O
optionally	O
substituted	O
;	O
Rb	O
is	O
H	B
,	O
Rc	O
,	O
-COORc	B
-	I
CO	I
-	I
Rc	I
or	O
-CO	B
-	I
NRcRd	I
;	O
where	O
Rc	O
is	O
alkyl	B
,	O
cycloalkyl	B
,	O
heterocycloalkyl	B
,	O
aryl	B
and	O
heteroaryl	B
,	O
all	O
optionally	O
substituted	O
;	O
Rd	O
is	O
H	B
,	O
alk	B
or	O
cycloalkyl	B
;	O
these	O
products	O
being	O
in	O
all	O
the	O
isomer	O
forms	O
and	O
the	O
salts	O
,	O
as	O
medicaments	O
,	O
in	O
particular	O
as	O
MET	O
inhibitors	O
.	O

Imidazo	B
[	I
1	I
,	I
2-a	I
]	I
pyrimidine	I
derivatives	O
method	O
for	O
the	O
production	O
thereof	O
application	O
thereof	O
as	O
medicaments	O
pharmaceutical	O
compositions	O
and	O
use	O
thereof	O
as	O
met	O
inhibitors	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
for	O
thalidomide	B
,	O
involving	O
the	O
inhibition	O
of	O
osteoclast	O
-	O
activating	O
factors	O
which	O
promote	O
the	O
formation	O
of	O
osteoclasts	O
and	O
cause	O
bone	O
pain	O
and	O
fracture	O
symptoms	O
.	O

The	O
treatment	O
of	O
patients	O
with	O
multiple	O
myeloma	O
using	O
a	O
pharmaceutical	O
thalidomide	B
composition	O
has	O
demonstrated	O
a	O
reduction	O
in	O
the	O
number	O
of	O
fractures	O
and	O
reduced	O
localised	O
pain	O
.	O

Use	O
of	O
thalidomide	B
to	O
inhibit	O
the	O
osteoclast	O
-	O
activation	O
process	O
associated	O
with	O
multiple	O
myeloma	O
disease	O

Provided	O
herein	O
is	O
a	O
method	O
of	O
treating	O
postangiplasty	O
or	O
instent	O
restenosis	O
in	O
an	O
individual	O
in	O
need	O
of	O
such	O
treatment	O
,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
individual	O
an	O
effective	O
dose	O
of	O
morelloflavone	B
.	O

Also	O
provided	O
is	O
a	O
method	O
of	O
treating	O
postangiplasty	O
or	O
instent	O
restenosis	O
in	O
an	O
individual	O
in	O
need	O
of	O
such	O
treatment	O
,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
individual	O
an	O
effective	O
dose	O
of	O
morelloflavone	B
and	O
an	O
HMG	O
-	O
CoA	O
reductase	O
inhibitor	O
.	O

Uses	O
of	O
morelloflavone	B

The	O
present	O
invention	O
relates	O
to	O
indoline	B
-	I
sulfonamide	I
compounds	O
according	O
to	O
general	O
structural	O
formula	O
(	O
I	O
)	O
,	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
the	O
invention	O
.	O

Further	O
provided	O
is	O
the	O
use	O
of	O
a	O
compound	O
or	O
a	O
composition	O
according	O
to	O
the	O
invention	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease	O
,	O
in	O
particular	O
the	O
treatment	O
of	O
cancer	O
.	O

6-substituted	B
1-sulfonyl-2	I
,	I
3-dihydro	I
-	I
indole	I
derivatives	O
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O

Compositions	O
and	O
methods	O
are	O
provided	O
having	O
unexpected	O
anti	O
-	O
inflammatory	O
and	O
other	O
properties	O
based	O
on	O
unprecedented	O
synergistic	O
effects	O
of	O
administering	O
two	O
or	O
more	O
of	O
(	O
i	O
)	O
an	O
opiate	O
antagonist	O
,	O
partial	O
antagonist	O
,	O
or	O
reverse	O
agonist	O
,	O
(	O
ii	O
)	O
a	O
cAMP	O
-	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibitor	O
,	O
(	O
iii	O
)	O
an	O
adenylate	O
cyclase	O
activator	O
,	O
and	O
(	O
iv	O
)	O
a	O
nicotinamide	B
adenine	I
dinucleotide	I
(	O
phosphate	B
)	O
(	O
NAD	O
(	O
P	O
)	O
H	O
)	O
oxidase	O
inhibitor	O
.	O

Invention	O
embodiments	O
are	O
useful	O
for	O
treating	O
or	O
reducing	O
one	O
or	O
more	O
of	O
tissue	O
inflammation	O
,	O
inflammation	O
-	O
associated	O
cellular	O
proliferation	O
,	O
oxidative	O
stress	O
or	O
neuronal	O
death	O
or	O
dysfunction	O
,	O
or	O
for	O
treating	O
or	O
preventing	O
gray	O
hair	O
or	O
restoring	O
hair	O
color	O
.	O

Synergizing	O
active	O
compounds	O
for	O
treating	O
inflammation	O
and	O
other	O
conditions	O

Disclosed	O
herein	O
are	O
cannabinoid	B
receptor	O
ligands	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Y	O
,	O
X1	O
,	O
X2	O
,	O
X3	O
,	O
R1	O
,	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
methods	O
for	O
treating	O
conditions	O
and	O
disorders	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
also	O
disclosed	O
.	O

Imine	B
derivatives	O
as	O
cannabinoid	B
receptor	O
ligands	O

The	O
present	O
invention	O
pertains	O
to	O
cannabinoid	B
(	O
CB	B
)	O
receptor	O
and	O
cannabinoid	B
-	O
like	O
receptor	O
neutral	O
antagonists	O
,	O
and	O
especially	O
CB1	O
neutral	O
antagonists	O
of	O
Formula	O
(	O
I	O
)	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
these	O
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
diseases	O
and	O
disorders	O
that	O
are	O
ameliorated	O
by	O
treatment	O
with	O
a	O
neutral	O
antagonist	O
of	O
the	O
cannabinoid	B
type	O
1	O
(	O
CB1	O
)	O
receptor	O
or	O
a	O
non	O
-	O
CB1	O
/	O
non	O
-	O
CB2	O
cannabinoid	B
-	O
like	O
receptor	O
,	O
for	O
example	O
:	O
an	O
eating	O
disorder	O
;	O
obesity	O
;	O
cardiovascular	O
disease	O
;	O
a	O
disease	O
or	O
disorder	O
characterised	O
by	O
an	O
addiction	O
component	O
;	O
addiction	O
;	O
withdrawal	O
;	O
smoking	O
addiction	O
;	O
smoking	O
withdrawal	O
;	O
drug	O
addiction	O
;	O
drug	O
withdrawal	O
;	O
smoking	O
cessation	O
therapy	O
;	O
a	O
bone	O
disease	O
or	O
disorder	O
;	O
osteoporosis	O
,	O
Paget	O
'	O
s	O
disease	O
of	O
bone	O
;	O
bone	O
related	O
cancer	O
;	O
breast	O
cancer	O
;	O
breast	O
cancer	O
metastases	O
;	O
breast	O
cancer	O
which	O
has	O
metastasised	O
to	O
bone	O
;	O
cancer	O
associated	O
with	O
activation	O
or	O
inactivation	O
of	O
a	O
non	O
-	O
CB1	O
/	O
non	O
-	O
CB2	O
cannabinoid	O
-	O
like	O
receptor	O
,	O
1,5-diaryl	B
-	I
pyrazoles	I
and	O
their	O
use	O
as	O
cannabinoid	B
receptor	O
neutral	O
antagonists	O

Disclosed	O
is	O
a	O
therapeutic	O
agent	O
for	O
uremia	O
that	O
contains	O
carbon	B
nanotubes	O
possessing	O
apertures	O
in	O
the	O
surface	O
layer	O
thereof	O
where	O
portions	O
of	O
the	O
carbon	B
skeleton	O
are	O
missing	O
.	O

The	O
present	O
therapeutic	O
agent	O
for	O
uremia	O
is	O
able	O
to	O
absorb	O
the	O
uremic	O
toxin	O
with	O
high	O
efficiency	O
.	O

Therapeutic	O
agent	O
for	O
uremia	O

Methods	O
and	O
compositions	O
containing	O
huperzine	B
for	O
direct	O
delivery	O
to	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
tissue	O
are	O
used	O
to	O
alleviate	O
pain	O
and	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
seizures	O
and	O
epilepsy	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
methods	O
and	O
compositions	O
for	O
using	O
huperzine	B
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
neuropathic	O
pain	O
and	O
orthostatic	O
hypotension	O
.	O

Treatment	O
of	O
neurological	O
disorders	O
using	O
huperzine	B

Novel	O
bicyclic	O
compounds	O
,	O
stereoisomers	O
,	O
and/or	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
novel	O
bicyclic	O
compounds	O
,	O
and/or	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
stereoisomers	O
of	O
the	O
novel	O
bicyclic	O
compounds	O
are	O
provided	O
.	O

Additionally	O
,	O
methods	O
of	O
forming	O
novel	O
bicyclic	O
compounds	O
,	O
stereoisomers	O
,	O
and/or	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
novel	O
bicyclic	O
compounds	O
,	O
and/or	O
pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
stereoisomers	O
of	O
the	O
novel	O
bicyclic	O
compounds	O
are	O
provided	O
.	O

Novel	O
biccyclic	O
compounds	O
as	O
gata	O
modulators	O

The	O
present	O
invention	O
in	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
provides	O
a	O
type	O
of	O
pleuromutilin	B
phosphate	I
according	O
to	O
formula	O
(	O
I	O
)	O
,	O
its	O
pharmaceutical	O
composition	O
,	O
its	O
preparation	O
method	O
and	O
uses	O
thereof	O
.	O

The	O
pleuromutilin	B
phosphate	I
of	O
the	O
present	O
invention	O
has	O
good	O
water	O
-	O
solubility	O
,	O
releases	O
the	O
parent	O
drug	O
quickly	O
after	O
intravenous	O
injection	O
,	O
can	O
achieve	O
a	O
very	O
high	O
plasma	O
concentration	O
,	O
and	O
has	O
excellent	O
anti	O
-	O
infectious	O
activity	O
.	O

The	O
medicine	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
infectious	O
diseases	O
,	O
especially	O
infectious	O
diseases	O
caused	O
by	O
multidrug	O
-	O
resistant	O
bacteria	O
.	O

Pleuromutilin	B
phosphate	I
,	O
its	O
pharmaceutical	O
composition	O
,	O
preparation	O
method	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
a	O
simple	O
method	O
for	O
producing	O
a	O
plant	O
containing	O
sapogenin	B
,	O
which	O
contains	O
a	O
large	O
quantity	O
of	O
sapogenin	B
and	O
has	O
outstanding	O
taste	O
and	O
safety	O
,	O
using	O
a	O
plant	O
containing	O
saponin	B
as	O
the	O
raw	O
material	O
.	O

The	O
method	O
for	O
producing	O
a	O
plant	O
containing	O
sapogenin	B
is	O
a	O
method	O
for	O
producing	O
a	O
composition	O
with	O
a	O
high	O
content	O
of	O
sapogenin	B
,	O
in	O
which	O
a	O
plant	O
containing	O
saponin	B
is	O
subjected	O
to	O
hydrolysis	O
treatment	O
by	O
the	O
action	O
of	O
an	O
aqueous	O
solution	O
of	O
a	O
strong	O
acid	O
with	O
a	O
concentration	O
of	O
0.01	O
mol	O
/	O
L	O
to	O
4	O
mol	O
/	O
L	O
,	O
the	O
liquid	O
obtained	O
after	O
hydrolysis	O
treatment	O
is	O
neutralized	O
and	O
then	O
filtered	O
,	O
and	O
the	O
residue	O
is	O
dried	O
.	O

The	O
hydrolysis	O
treatment	O
is	O
preferably	O
carried	O
out	O
,	O
for	O
example	O
,	O
in	O
the	O
presence	O
of	O
a	O
lower	O
alcohol	B
.	O

Method	O
for	O
producing	O
a	O
composition	O
with	O
a	O
high	O
content	O
of	O
sapogenin	B

In	O
its	O
many	O
embodiments	O
,	O
the	O
present	O
invention	O
provides	O
a	O
novel	O
class	O
of	O
azanitrile	B
compounds	O
as	O
inhibitors	O
of	O
α2C	O
adrenergic	O
receptor	O
agonists	O
,	O
methods	O
of	O
preparing	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
such	O
compounds	O
,	O
methods	O
of	O
preparing	O
pharmaceutical	O
formulations	O
comprising	O
one	O
or	O
more	O
such	O
compounds	O
,	O
and	O
methods	O
of	O
treatment	O
,	O
prevention	O
,	O
inhibition	O
,	O
or	O
amelioration	O
of	O
one	O
or	O
more	O
conditions	O
associated	O
with	O
the	O
α2C	O
adrenergic	O
receptors	O
using	O
such	O
compounds	O
or	O
pharmaceutical	O
compositions	O
.	O

Functionally	O
selective	O
azanitrile	B
alpha2c	O
adrenoreceptor	O
agonists	O

Compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
through	O
the	O
inhibition	O
of	O
sodium	B
ion	I
flux	O
through	O
voltage	O
-	O
gated	O
sodium	O
channels	O
.	O

Sulfonamide	B
derivatives	O
as	O
inhibitors	O
of	O
ion	O
channels	O

The	O
present	O
invention	O
relates	O
to	O
GCH1	O
(	O
GTP	O
cyclohydrolase	O
1	O
)	O
-targeted	O
siRNA	O
,	O
a	O
recombinant	O
vector	O
containing	O
the	O
siRNA	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
recombinant	O
vector	O
for	O
treating	O
and	O
preventing	O
neuropathic	O
pain	O
.	O

The	O
GCH1-targeted	O
siRNA	O
of	O
the	O
present	O
invention	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
GCH1	O
,	O
and	O
the	O
recombinant	O
vector	O
containing	O
the	O
siRNA	O
may	O
deliver	O
siRNA	O
to	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
.	O

Thus	O
,	O
neuropathic	O
pain	O
caused	O
by	O
nerve	O
injury	O
can	O
be	O
inhibited	O
,	O
and	O
inflammatory	O
response	O
at	O
the	O
spine	O
caused	O
by	O
nerve	O
injury	O
can	O
also	O
be	O
inhibited	O
by	O
using	O
the	O
recombinant	O
vector	O
.	O

GCH1-TARGETED	O
si	O
RNA	O
,	O
RECOMBINANT	O
VECTOR	O
CONTAINING	O
si	O
RNA	O
,	O
AND	O
PHARMACEUTICAL	O
COMPOSITION	O
CONTAINING	O
RECOMBINANT	O
VECTOR	O
FOR	O
TREATING	O
AND	O
PREVENTING	O
NEUROPATHIC	O
PAIN	O

Esters	B
of	I
4,5-disubstituted	I
-	I
oxy-2-rnethyl-3,6-dioxo	I
-	I
cyclohexa-1,4-dienyl	I
alkyl	I
acids	I
were	O
prepared	O
chemically	O
and/or	O
enzymatically	O
.	O

Depending	O
upon	O
the	O
ester	O
,	O
improved	O
melanocyte	O
cytotoxicity	O
was	O
achieved	O
.	O

Improved	O
cytotoxicity	O
characteristics	O
are	O
consistent	O
with	O
ester	O
analogs	O
being	O
more	O
physiologically	O
compatible	O
and	O
less	O
irritating	O
to	O
skin	O
than	O
their	O
corresponding	O
acids	O
.	O

Esters	B
of	I
4,5-disubstituted	I
-	I
oxy-2-methyl-3,6-dioxo	I
-	I
cyclohexa-1,4-dienyl	I
alkyl	I
acids	I
and	O
preparation	O
thereof	O

Combinations	O
of	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
microcrystalline	O
cellulose	O
,	O
polyvinylpyrrolidone	B
,	O
cyclodextrin	O
,	O
and	O
disaccharide	B
or	O
derivatives	O
thereof	O
and	O
acomposition	O
of	O
sunitinib	B
base	O
and	O
L	B
-	I
malic	I
acid	I
were	O
prepared	O
.	O

Amorphous	O
compositions	O
of	O
sunitinib	B
base	O
and	O
l	B
-	I
malic	I
acid	I

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
the	O
treatment	O
of	O
skin	O
wounds	O
or	O
lesions	O
,	O
and	O
connective	O
tissue	O
damage	O
or	O
injury	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
glucan	B
composition	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
the	O
promotion	O
of	O
wound	O
healing	O
and	O
tissue	O
regeneration	O
.	O

Methods	O
of	O
treatment	O
utilising	O
glucan	O
formulations	O

The	O
present	O
invention	O
relates	O
to	O
N	B
-	I
acyl	I
hydrazine	I
compounds	O
capable	O
of	O
promoting	O
vascular	O
smooth	O
muscle	O
relaxation	O
by	O
activation	O
of	O
the	O
biosynthesis	O
of	O
nitric	B
oxide	I
(	O
NO	B
)	O
and	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
to	O
the	O
method	O
for	O
producing	O
same	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
same	O
,	O
to	O
uses	O
thereof	O
and	O
methods	O
for	O
treatment	O
of	O
dysfunctions	O
related	O
to	O
NO	B
synthesis	O
in	O
human	O
and	O
non	O
-	O
human	O
mammals	O
,	O
and	O
to	O
the	O
treatment	O
of	O
muscle	O
disorders	O
.	O

N	B
-	I
acyl	I
hydrazine	I
derivatives	O
,	O
method	O
for	O
producing	O
n	B
-	I
acyl	I
hydrazine	I
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
same	O
,	O
uses	O
thereof	O
and	O
methods	O
for	O
treatment	O

Disclosed	O
are	O
ethoxy	B
diphenyl	I
ethane	I
derivates	O
,	O
preparation	O
processes	O
and	O
uses	O
thereof	O
.	O

Diphenyl	B
ethane	I
is	O
chemically	O
modified	O
by	O
ethoxy	B
substituted	O
on	O
the	O
4'-position	O
of	O
its	O
B	O
aryl	B
ring	O
and	O
is	O
changed	O
into	O
their	O
soluble	O
prodrugs	O
of	O
phosphates	B
or	O
the	O
like	O
by	O
modifying	O
the	O
hydroxyl	B
on	O
the	O
3'-position	O
of	O
their	O
B	O
aryl	B
ring	O
.	O

Similarly	O
,	O
side	O
chain	O
of	O
amino	B
acid	I
can	O
be	O
introduced	O
to	O
3'-amino	B
to	O
form	O
soluble	O
prodrug	O
of	O
amino	B
acidamide	I
.	O

The	O
structure	O
of	O
the	O
said	O
compounds	O
is	O
showed	O
as	O
formula	O
(	O
I	O
)	O
.	O

Ethoxy	B
diphenyl	I
ethane	I
derivates	O
and	O
prodrugs	O
thereof	O
are	O
characterized	O
by	O
the	O
following	O
:	O
possessing	O
potent	O
tubulin	O
polymerizaion	O
inhibitory	O
activity	O
;	O
possessing	O
obvious	O
target	O
damage	O
of	O
tumour	O
vessel	O
;	O
resulting	O
in	O
dysfunction	O
and	O
structural	O
damage	O
of	O
tumour	O
vessel	O
selectively	O
;	O
evoking	O
die	O
of	O
vessel	O
endothelium	O
cell	O
;	O
making	O
the	O
tumor	O
cell	O
lose	O
nourishment	O
and	O
oxygen	B
;	O
and	O
killing	O
tumor	O
cell	O
or	O
inhibiting	O
tumor	O
metastasis	O
.	O

Ethoxy	B
diphenyl	I
ethane	I
derivates	O
,	O
preparation	O
processes	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
a	O
compound	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
associated	O
with	O
abnormal	O
plasma	O
uric	O
acid	O
levels	O
and	O
the	O
like	O
.	O

Specifically	O
disclosed	O
are	O
:	O
a	O
phenylisonicotinic	B
acid	I
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
a	O
prodrug	O
thereof	O
,	O
or	O
a	O
salt	O
thereof	O
,	O
which	O
has	O
a	O
xanthine	B
oxidase	O
inhibiting	O
activity	O
and	O
an	O
URAT1	O
inhibiting	O
activity	O
and	O
is	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
associated	O
with	O
abnormal	O
plasma	O
uric	B
acid	I
levels	O
;	O
and	O
others	O
.	O

In	O
formula	O
(	O
I	O
)	O
,	O
R1	O
represents	O
a	O
cyano	B
,	O
a	O
trifluoromethyl	B
,	O
or	O
the	O
like	O
;	O
R2	O
represents	O
H	B
,	O
a	O
fluorine	B
,	O
or	O
the	O
like	O
;	O
and	O
R3	O
represents	O
W	O
,	O
or	O
a	O
group	O
represented	O
by	O
formula	O
-X	O
-	O
Y	O
-	O
Z	O
(	O
wherein	O
W	O
represents	O
H	B
,	O
a	O
halogen	B
,	O
a	O
hydroxy	B
group	O
,	O
a	O
cycloalkyl	B
,	O
a	O
heterocycloalkyl	B
,	O
or	O
the	O
like	O
;	O
X	O
represents	O
a	O
single	O
bond	O
,	O
-NH-	B
,	O
-O-	B
,	O
or	O
the	O
like	O
;	O
Y	O
represents	O
an	O
alkylene	B
,	O
or	O
the	O
like	O
;	O
Z	O
represents	O
H	B
,	O
a	O
haloalkyl	B
,	O
a	O
hydroxy	B
group	O
,	O
an	O
alkoxy	B
,	O
a	O
cycloalkyl	B
,	O
a	O
heterocycloalkyl	B
,	O
an	O
aryl	B
,	O
or	O
the	O
like	O
)	O
.	O

Phenylisonicotinic	B
acid	I
derivative	O
and	O
use	O
thereof	O
for	O
medical	O
purposes	O

The	O
invention	O
features	O
a	O
method	O
for	O
treating	O
a	O
patient	O
diagnosed	O
with	O
,	O
or	O
at	O
risk	O
of	O
developing	O
,	O
a	O
dermal	O
immunoinflammatory	O
disorder	O
by	O
topically	O
administering	O
to	O
the	O
patient	O
loratadine	B
and	O
nortriptyline	B
.	O

The	O
invention	O
also	O
features	O
a	O
topical	O
dosage	O
forms	O
containing	O
loratadine	B
and	O
nortriptyline	B
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
immunoinflammatory	O
disorders	O

The	O
response	O
of	O
immunotherapy	O
in	O
the	O
treatment	O
of	O
cancer	O
is	O
enhanced	O
by	O
use	O
of	O
an	O
oligonucleotide	B
in	O
a	O
dose	O
effective	O
to	O
induce	O
at	O
least	O
one	O
of	O
endogenous	O
production	O
of	O
cytokines	O
,	O
and	O
the	O
regulation	O
of	O
the	O
expression	O
of	O
one	O
or	O
more	O
of	O
the	O
cell	O
surface	O
antigens	O
(	O
Figure	O
1	O
)	O
.	O

Increased	O
expression	O
of	O
specific	O
antigens	O

A	O
method	O
for	O
preventing	O
stroke	O
in	O
a	O
patient	O
suffering	O
from	O
atrial	O
fibrillation	O
,	O
wherein	O
the	O
patient	O
has	O
no	O
risk	O
factors	O
for	O
major	O
bleeding	O
events	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
patient	O
150	O
mg	O
b.i.d	O
.	O

of	O
dabigatran	B
etexilate	I
,	O
optionally	O
in	O
the	O
form	O
of	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Method	O
for	O
treating	O
or	O
preventing	O
thrombosis	O
using	O
dabigatran	B
etexilate	I
or	O
a	O
salt	O
thereof	O
with	O
improved	O
efficacy	O
over	O
conventional	O
warfarin	O
therapy	O

6-morpholin-4-yl	B
-	I
pyrazolo	I
[	I
3,4-d	I
]	I
pyrimidine	I
and	I
2-morpholin-4-yl-7H-	I
pyrrolo	I
[	I
2,3-d	I
]	I
pyrimidine	I
derivatives	O
have	O
unexpected	O
drug	O
properties	O
as	O
inhibitors	O
of	O
PI3	O
and/or	O
mTOR	O
kinases	O
and	O
are	O
useful	O
in	O
treating	O
disorders	O
related	O
to	O
abnormal	O
PI3K	O
/	O
mT0R	O
activities	O
such	O
as	O
cancer	O
,	O
immune	O
disorders	O
,	O
cardiovascular	O
disease	O
,	O
viral	O
infection	O
,	O
inflammation	O
,	O
metabolism	O
/	O
endocrine	O
disorders	O
and	O
neurological	O
disorders	O
.	O

Pi3k	O
/	O
mtor	O
kinase	O
inhibitors	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
,	O
Z	O
,	O
A	O
,	O
B	O
,	O
D	O
,	O
E	O
,	O
R1-R4	O
and	O
m	O
are	O
as	O
defined	O
in	O
the	O
claims	O
,	O
exhibit	O
alpha2C	O
antagonistic	O
activity	O
and	O
are	O
thus	O
useful	O
as	O
alpha2C	O
antagonists	O
.	O

Aryl	B
piperazine	I
and	O
their	O
use	O
as	O
alpha2c	O
antagonists	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
Rimcazole	B
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
associated	O
with	O
vessel	O
oedema	O
and/or	O
leakage	O
,	O
for	O
example	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
Rimcazole	B
is	O
administered	O
orally	O
.	O

Use	O
of	O
rimcazole	B
for	O
the	O
treatment	O
of	O
ocular	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
inhibiting	O
virus	O
and	O
target	O
cell	O
interaction	O
.	O

The	O
composition	O
comprises	O
turmerone	B
.	O

Turmerones	B
can	O
include	O
arturmerone	B
,	O
α	B
-	I
turmerone	I
and	O
β	B
-	I
turmerone	I
.	O

Extracts	O
from	O
Curcuma	O
longa	O
which	O
contain	O
turmerones	B
are	O
also	O
shown	O
to	O
demonstrate	O
inhibitory	O
effect	O
on	O
virus	O
and	O
target	O
cell	O
interaction	O
.	O

Process	O
or	O
method	O
for	O
extracting	O
turmerone	B
from	O
Curcuma	O
longa	O
is	O
provided	O
.	O

The	O
composition	O
for	O
inhibiting	O
virus	O
and	O
target	O
cell	O
interaction	O
can	O
be	O
used	O
for	O
counteracting	O
H5N1	O
AI	O
virus	O
infection	O
and	O
protecting	O
one	O
against	O
H5N1	O
AI	O
virus	O
infection	O
.	O

The	O
composition	O
can	O
also	O
be	O
mixed	O
with	O
chicken	O
feed	O
to	O
protect	O
chicken	O
from	O
viruses	O
such	O
as	O
H5N1	O
AI	O
virus	O
.	O

Virus	O
and	O
target	O
cell	O
interaction	O
inhibition	O

The	O
invention	O
concerns	O
compounds	O
DLBS1425E2.2	O
and	O
DLBS1425F1	O
isolated	O
and	O
identified	O
from	O
the	O
extract	O
of	O
the	O
plant	O
Phaleria	O
macrocarpa	O
(	O
Scheff	O
.	O
)	O

Boerl	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compounds	O
,	O
either	O
as	O
a	O
single	O
active	O
compound	O
or	O
in	O
combination	O
,	O
in	O
a	O
pharmaceutical	O
dosage	O
form	O
that	O
has	O
anti	O
-	O
proliferative	O
activity	O
of	O
cancer	O
cells	O
,	O
and	O
its	O
use	O
relating	O
to	O
female	O
related	O
diseases	O
.	O

Formula	O
(	O
I	O
)	O
.	O

Isolated	O
compounds	O
from	O
phaleria	O
macrocarpa	O
as	O
anti	O
-	O
cancer	O
agents	O

A	O
treatment	O
for	O
glomerulonephritis	O
,	O
and	O
other	O
renal	O
dysfunctions	O
is	O
disclosed	O
,	O
using	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
.	O

Treatment	O
for	O
glomerulonephritis	O
with	O
2	B
-	I
[	I
4-	I
(	I
-7-ethyl-5h	I
-	I
pyrrolo	I
[	I
2,3-b	I
]	I
-pyrazin-	I
6	I
-yl	I
)	I
propan-2-ol	I

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
radicals	O
R1	O
to	O
R6	O
have	O
the	O
meaning	O
according	O
to	O
claim	O
1	O
,	O
and/or	O
physiologically	O
acceptable	O
salts	O
thereof	O
,	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
treatment	O
and/or	O
monitoring	O
of	O
physiological	O
and/or	O
pathological	O
conditions	O
that	O
are	O
associated	O
with	O
the	O
activity	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

Another	O
object	O
of	O
the	O
invention	O
concerns	O
the	O
use	O
of	O
said	O
compounds	O
for	O
enhancing	O
glucose	B
homeostasis	O
,	O
improving	O
podocytopathy	O
and/or	O
decreasing	O
the	O
production	O
of	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
in	O
-	O
vitro	O
diagnosing	O
diabetic	O
nephropathy	O
and	O
a	O
method	O
for	O
screening	O
compounds	O
that	O
reduce	O
podocytopathy	O
,	O
in	O
each	O
case	O
by	O
applying	O
synaptopodin	O
as	O
biomarker	O
.	O

Tetrahydrotriazine	B
compounds	O
for	O
treating	O
diseases	O
associated	O
with	O
ampk	O
activity	O

The	O
present	O
invention	O
provides	O
compounds	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
thereof	O
,	O
and	O
methods	O
for	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
any	O
of	O
a	O
number	O
of	O
conditions	O
or	O
diseases	O
in	O
which	O
hepatocyte	O
growth	O
factor	O
/	O
scatter	O
factor	O
(	O
HGF	O
/	O
SF	O
)	O
or	O
the	O
activities	O
thereof	O
,	O
or	O
agonists	O
or	O
antagonists	O
thereof	O
,	O
have	O
a	O
therapeutically	O
useful	O
role	O
.	O

Small	O
molecule	O
modulators	O
of	O
hepatocyte	O
growth	O
factor	O
(	O
scatter	O
factor	O
)	O
activity	O

The	O
present	O
invention	O
is	O
directed	O
to	O
stable	O
polymorphic	O
forms	O
of	O
the	O
compound	O
of	O
formula	O
Il	O
and	O
hydrates	B
thereof	O
:	O
i.	O
e.	O
,	O
a	O
solvent	O
free	O
polymorph	O
""""	O
C	O
""""	O
of	O
4-	B
[	I
(	I
4-methoxyphenyl	I
)	I
methyl	I
]	I
-5-	I
(	I
trifluoromethyl	I
)	I
-	I
1H	I
-	I
pyrazole-3-yl	I
]	I
-4-deoxy-4-fluoro	I
-	I
beta	I
-	I
D	I
-	I
glucopyranoside	I
;	O
a	O
monohydrate	B
form	O
""""	O
D	O
""""	O
;	O
and	O
a	O
dihydrate	B
form	O
""""	O
B	O
""""	O
,	O
each	O
substantially	O
free	O
of	O
residual	O
organic	O
solvent	O
contaminants	O
and	O
impurities	O
.	O

Novel	O
polymorphic	O
forms	O
of	O
4-	B
[	I
(	I
4-methoxyphenyl	I
)	I
methyl	I
]	I
-5-	I
(	I
trifluoromethyl	I
)	I
-1h	I
-	I
pyrazole-3-yl	I
]	I
4-deoxy-4-fluoro	I
-	I
beta	I
-	I
d	I
-	I
glucopyranoside	I
including	O
hydrates	B
thereof	O
and	O
the	O
preparations	O
thereof	O

The	O
use	O
of	O
a	O
combination	O
of	O
photodynamic	O
therapy	O
and	O
an	O
anti	O
-	O
VEGF	O
agent	O
in	O
the	O
treatment	O
of	O
conditions	O
characterized	O
by	O
unwanted	O
choroidal	O
neovasculature	O
is	O
described	O
.	O

These	O
conditions	O
include	O
wet	O
age	O
-	O
related	O
macular	O
degeneration	O
Preferred	O
anti	O
-	O
VEGF	O
agents	O
are	O
antibodies	O
such	O
as	O
bevacizumab	O
or	O
ranibizumab	O
Photosensitizers	O
may	O
be	O
selected	O
from	O
green	O
porphyrins	O
such	O
as	O
BPD	B
-	I
MA	I
(	O
verteporfin	B
)	O
and	O
the	O
photodynamic	O
activation	O
of	O
the	O
photosensitizer	O
may	O
be	O
accomplished	O
using	O
a	O
reduced	O
fluence	O
rate	O
.	O

The	O
use	O
may	O
further	O
comprises	O
an	O
anti	O
-	O
inflammatory	O
agent	O
such	O
a	O
dexamethasone	B
.	O

Combination	O
of	O
photodynamic	O
therapy	O
and	O
anti	O
-	O
vegf	O
agents	O
in	O
the	O
treatment	O
of	O
unwanted	O
choroidal	O
neovasculature	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
anti	O
-	O
cancer	O
treatments	O
and	O
compositions	O
using	O
combinations	O
of	O
at	O
least	O
one	O
agonist	O
of	O
the	O
RXR	O
-	O
PPARγ	O
heterodimer	O
complex	O
selected	O
in	O
the	O
group	O
consisting	O
of	O
a	O
RXRα	O
agonist	O
,	O
a	O
RXRβ	O
agonist	O
,	O
a	O
RXRγ	O
agonist	O
,	O
a	O
PPARγ	O
agonist	O
or	O
a	O
RXR	O
-	O
PPARγ	O
heterodimer	O
agonist	O
and	O
a	O
growth	O
factor	O
inhibitor	O
.	O

Rxr	O
-	O
ppargamma	O
agonist	O
/	O
growth	O
factor	O
inhibitor	O
combination	O
therapy	O
for	O
inducing	O
apoptosis	O
and	O
the	O
treatment	O
of	O
cancer	O

Pyrazolo	B
[	I
1,5-a	I
]	I
pyridine	I
derivatives	O
of	O
formula	O
I	O
,	O
wherein	O
the	O
meaning	O
for	O
R1	O
,	O
R2	O
and	O
R3	O
is	O
as	O
disclosed	O
in	O
the	O
description	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
JAK3	O
kinase	O
inhibitors	O
.	O

PYRAZOLE	B
[	I
1,5a	I
]	I
PYRIDINE	I
DERIVATIVES	O

Disclosed	O
is	O
a	O
method	O
which	O
can	O
predict	O
the	O
therapeutic	O
effectiveness	O
of	O
a	O
chemotherapy	O
comprising	O
a	O
5-fluorouracil	B
anti	O
-	O
tumor	O
agent	O
in	O
a	O
cancer	O
patient	O
with	O
high	O
accuracy	O
.	O

Specifically	O
disclosed	O
is	O
a	O
method	O
for	O
predicting	O
the	O
therapeutic	O
effectiveness	O
of	O
a	O
chemotherapy	O
comprising	O
a	O
5-fluorouracil	B
anti	O
-	O
tumor	O
agent	O
in	O
a	O
cancer	O
patient	O
by	O
employing	O
,	O
as	O
a	O
measure	O
,	O
the	O
expression	O
level	O
of	O
at	O
least	O
one	O
miRNA	O
selected	O
from	O
miR-17	O
,	O
miR-17	O
*	O
,	O
miR-20a	O
,	O
miR-20a	O
*	O
,	O
miR-20b	O
,	O
miR-92a	O
,	O
miR-106a	O
,	O
miR-126	O
*	O
,	O
miR-142	O
-	O
3p	O
,	O
miR-223	O
,	O
miR-630	O
and	O
let-7a	O
*	O
contained	O
in	O
a	O
biological	O
sample	O
collected	O
from	O
the	O
patient	O
.	O

Prediction	O
of	O
effectiveness	O
of	O
preoperative	O
chemoradiotherapy	O
on	O
rectal	O
cancer	O
using	O
micro	O
-	O
rna	O

The	O
invention	O
relates	O
to	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
new	O
biologically	O
active	O
substances	O
(	O
BAS	O
)	O
and	O
to	O
the	O
properties	O
thereof	O
,	O
namely	O
,	O
to	O
creatine	O
derivatives	O
of	O
general	O
formula	O
:	O
NH	O
=	O
C	O
(	O
NH2	O
)	O
-N	O
(	O
CH3	O
)	O
-	O
CH2-CO	O
-	O
NH	O
-	O
R٠X	O
,	O
wherein	O
R	O
is	O
an	O
amino	O
-	O
acid	O
residue	O
or	O
a	O
substituted	O
amino	O
-	O
acid	O
residue	O
;	O
X	O
is	O
a	O
low	O
-	O
molecular	O
organic	O
or	O
mineral	O
acid	O
or	O
water	O
.	O

The	O
new	O
substances	O
are	O
produced	O
by	O
interacting	O
guanidyl	O
agents	O
with	O
sarcosine	O
amides	O
in	O
polar	O
organic	O
solvents	O
at	O
a	O
temperature	O
equal	O
to	O
or	O
less	O
than	O
50	O
°	O
C	O
.	O

The	O
new	O
substances	O
exhibit	O
a	O
neuroprotective	O
action	O
and	O
can	O
be	O
used	O
in	O
the	O
form	O
of	O
an	O
agent	O
promising	O
for	O
preventing	O
and	O
treating	O
brain	O
ischemia	O
.	O

Creatine	O
amides	O
,	O
a	O
method	O
for	O
the	O
production	O
thereof	O
and	O
an	O
agent	O
exhibiting	O
a	O
neuroprotective	O
action	O

The	O
present	O
invention	O
relates	O
to	O
ethanamine	B
compounds	O
,	O
namely	O
1-	B
(	I
3-f	I
luorophenyl	I
)	I
-2-methyl-2-	I
(	I
pyridine-2-yl	I
)	I
propan-1-amine	I
and	O
2-methyl	B
-	I
l	I
-	I
phenyl-2-	I
(	I
pyridine-2yl	I
)	I
propan-1-amine	I
,	O
the	O
enantiomers	O
and	O
salts	O
thereof	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
depression	O
.	O

Ethanamine	B
compounds	O
and	O
their	O
use	O
for	O
treating	O
depression	O

Provided	O
are	O
3-substituted	B
oxindole	I
derivatives	O
which	O
are	O
agonists	O
of	O
the	O
CB2	O
receptor	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
methods	O
of	O
treatment	O
related	O
to	O
CB2-mediated	O
disorders	O
(	O
e.g.	O
,	O
pain	O
,	O
cancer	O
etc	O
.	O
)	O
using	O
the	O
3-substituted	B
oxindole	I
derivatives	O
and	O
compositions	O
described	O
herein	O
.	O

Substituted	O
oxindol	B
cb2	O
agonists	O
for	O
pain	O
treatment	O

The	O
present	O
invention	O
relates	O
to	O
an	O
eyesight	O
-	O
protecting	O
composition	O
having	O
preventive	O
and	O
therapeutic	O
efficacy	O
in	O
diabetes	O
or	O
diabetes	O
complications	O
.	O

In	O
particular	O
,	O
the	O
eyesight	O
-	O
protecting	O
composition	O
essentially	O
comprises	O
functional	O
components	O
such	O
as	O
calcium	B
,	O
vitamin	B
A	I
,	O
vitamin	B
C	I
and	O
vitamin	B
D	I
,	O
and	O
additionally	O
at	O
least	O
one	O
plant	O
extract	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
lycii	O
fructus	O
extract	O
,	O
astragalus	O
extract	O
,	O
cassia	O
tora	O
extract	O
,	O
polygonatum	O
odoratum	O
extract	O
and	O
rubus	O
coreanus	O
extract	O
.	O

A	O
composition	O
containing	O
functional	O
components	O
of	O
the	O
present	O
invention	O
significantly	O
inhibits	O
the	O
expression	O
of	O
inflammatory	O
factors	O
,	O
inhibits	O
/	O
regulates	O
the	O
expression	O
of	O
cytokines	O
of	O
Th1	O
/	O
Th2	O
cells	O
via	O
a	O
JAK	O
-	O
STAT	O
pathway	O
,	O
and	O
also	O
significantly	O
inhibits	O
the	O
expression	O
of	O
STAT3	O
in	O
diabetic	O
retinopathy	O
,	O
which	O
is	O
one	O
of	O
the	O
complications	O
of	O
diabetes	O
,	O
such	O
that	O
the	O
composition	O
can	O
advantageously	O
be	O
used	O
as	O
an	O
eyesight	O
-	O
protecting	O
composition	O
efficacious	O
for	O
prevention	O
and	O
treatment	O
of	O
diabetes	O
complications	O
.	O

Eyesight	O
-	O
protecting	O
composition	O
containing	O
functional	O
components	O
having	O
preventive	O
and	O
therapeutic	O
efficacy	O
in	O
diabetes	O
or	O
diabetes	O
complications	O

The	O
present	O
invention	O
related	O
to	O
a	O
combination	O
of	O
(	O
a	O
)	O
a	O
α4β2	O
nicotinic	O
agonist	O
and	O
(	O
b	O
)	O
a	O
Second	O
Therapeutic	O
Agent	O
,	O
as	O
defined	O
under	O
group	O
A	O
or	O
group	O
B.	O
The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
combination	O
and	O
to	O
methods	O
of	O
treating	O
CNS	O
disorders	O
in	O
mammals	O
by	O
administrating	O
said	O
combination	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
kit	O
comprising	O
the	O
combination	O
and	O
use	O
of	O
said	O
kits	O
in	O
treatment	O
of	O
CNS	O
disorders	O
,	O
such	O
as	O
cognitive	O
dysfunction	O
in	O
schizophrenia	O
,	O
dementia	O
and/or	O
Alzheimer	O
's	O
disease	O
or	O
those	O
disorders	O
defined	O
below	O
.	O

Combinations	O
with	O
an	O
alpha-4beta-2	O
nicotinic	O
agonist	O

Various	O
anticancer	O
compounds	O
are	O
disclosed	O
,	O
including	O
a	O
series	O
of	O
carbohydrate	B
-	I
cyclopamine	I
conjugates	O
.	O

These	O
compounds	O
include	O
pyranose	B
,	O
furanose	B
,	O
and	O
mannitol	B
conjugates	O
,	O
linked	O
through	O
a	O
1,2,3-triazine	B
ring	O
to	O
the	O
nitrogen	B
of	O
cyclopamine	B
.	O

Methods	O
for	O
preparing	O
these	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
and	O
their	O
use	O
as	O
anticancer	O
agents	O
are	O
also	O
disclosed	O
.	O

Carbohydrate	B
-	I
cyclopamine	I
conjugates	O
as	O
anticancer	O
agents	O

Inhibitors	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
having	O
a	O
structure	O
of	O
Formula	O
(	O
I	O
)	O
,	O
ways	O
to	O
make	O
them	O
and	O
methods	O
of	O
treating	O
patients	O
using	O
them	O
are	O
disclosed	O
.	O

Benzthiazole	B
inhibitors	O
of	O
poly	O
(	O
adp	O
-	O
ribose	O
)	O
polymerase	O

ABSTRACT	O
This	O
invention	O
provides	O
for	O
certain	O
bridged	O
and	O
fused	O
compounds	O
of	O
the	O
formula	O
G	O
-	O
L	O
-	O
A	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
of	O
solvate	O
thereof	O
wherein	O
:	O
A	O
is	O
:	O
(	O
I	O
)	O
and	O
the	O
other	O
variables	O
are	O
defined	O
herein	O
;	O
the	O
inventive	O
compounds	O
are	O
agonists	O
of	O
the	O
G	O
-	O
protein	O
coupled	O
receptor	O
40	O
(	O
GPR40	O
,	O
also	O
known	O
as	O
free	O
fatty	O
acid	O
receptor	O
FFAR	O
)	O
.	O

This	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
and	O
the	O
use	O
of	O
these	O
compounds	O
to	O
regulate	O
insulin	O
levels	O
in	O
a	O
mammal	O
.	O

The	O
compounds	O
may	O
be	O
used	O
,	O
for	O
example	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
Type	O
2	O
diabetes	O
mellitus	O
and	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
conditions	O
related	O
to	O
Type	O
2	O
diabetes	O
mellitus	O
,	O
such	O
as	O
insulin	O
resistance	O
,	O
obesity	O
and	O
lipid	O
disorders	O
.	O

Bridged	O
and	O
fused	O
antidiabetic	O
compounds	O

The	O
present	O
invention	O
relates	O
to	O
Inclusion	O
complexes	O
comprising	O
cyclodextrin	O
,	O
preferably	O
gamma	O
-	O
cyclodextrin	O
and	O
cinacalcet	B
,	O
wherein	O
the	O
molar	O
ratio	O
of	O
cyclodextrin	O
to	O
cinacalcet	B
is	O
1	O
:	O
1	O
to	O
5	O
:	O
1	O
,	O
preferably	O
about	O
1	O
:	O
2	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
process	O
for	O
producing	O
said	O
cinacalcet	B
inclusion	O
complexes	O
and	O
to	O
pharmaceutical	O
composition	O
comprising	O
said	O
complexes	O
.	O

Finally	O
,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
gamma	O
-	O
cyclodextrin	O
for	O
producing	O
cinacalcet	O
containing	O
pharmaceutical	O
formulations	O
.	O

Inclusion	O
complex	O
comprising	O
cinacalcet	B
and	O
cyclodextrin	O

A	O
low	O
-	O
molecular	O
polysulfated	O
hyaluronic	B
acid	I
derivative	O
useful	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
allergic	O
diseases	O
.	O

Provided	O
is	O
a	O
preventive	O
and/or	O
therapeutic	O
agent	O
for	O
an	O
allergic	O
disease	O
selected	O
from	O
pollinosis	O
,	O
allergic	O
rhinitis	O
,	O
allergic	O
conjunctivitis	O
,	O
atopic	O
dermatitis	O
,	O
and	O
asthma	O
,	O
the	O
agent	O
containing	O
either	O
a	O
low	O
-	O
molecular	O
polysulfated	O
hyaluronic	B
acid	I
derivative	O
represented	O
by	O
general	O
formula	O
(	O
IA	O
)	O
or	O
(	O
IB	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

[	O
In	O
the	O
formulae	O
,	O
n	O
is	O
a	O
number	O
of	O
0	O
-	O
15	O
,	O
and	O
Rs	O
each	O
independently	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
SO3H	B
group	O
,	O
etc	O
.	O
]	O

Low	O
-	O
molecular	O
polysulfated	O
hyaluronic	B
acid	I
derivative	O
and	O
medicine	O
containing	O
same	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
whole	O
grain	O
products	O
high	O
in	O
resistant	O
starch	O
content	O
to	O
increase	O
satiety	O
in	O
mammals	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
management	O
of	O
weight	O
by	O
increasing	O
such	O
satiety	O
.	O

The	O
whole	O
grain	O
products	O
may	O
be	O
added	O
to	O
foods	O
,	O
and	O
the	O
enhancement	O
may	O
be	O
achieved	O
while	O
not	O
significantly	O
sacrificing	O
organoleptic	O
quality	O
characteristics	O
of	O
the	O
food	O
,	O
including	O
texture	O
and	O
flavor	O
yet	O
increasing	O
the	O
nutritional	O
value	O
.	O

Use	O
of	O
whole	O
grain	O
materials	O
with	O
high	O
resistant	O
starch	O
for	O
satiety	O
,	O
reduction	O
of	O
food	O
intake	O
and	O
weight	O
management	O

Certain	O
embodiments	O
disclosed	O
herein	O
are	O
directed	O
to	O
a	O
method	O
of	O
producing	O
endoderm	O
cells	O
,	O
such	O
as	O
definitive	O
endoderm	O
cells	O
by	O
exposing	O
stem	O
cells	O
such	O
as	O
embryonic	O
stem	O
cells	O
or	O
induced	O
pluripotent	O
stem	O
(	O
iPS	O
)	O
cells	O
to	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
described	O
herein	O
to	O
differentiate	O
the	O
stem	O
cells	O
into	O
the	O
endoderm	O
cells	O
such	O
as	O
definitive	O
endoderm	O
cells	O
.	O

Differentated	O
endoderm	O
cells	O
produced	O
by	O
the	O
methods	O
disclosed	O
herein	O
can	O
be	O
differentiated	O
into	O
pancreatic	O
epithelium	O
,	O
and	O
other	O
endoderm	O
derivatives	O
such	O
as	O
thymus	O
,	O
liver	O
,	O
stomach	O
,	O
intestine	O
and	O
lung	O
.	O

Another	O
aspect	O
of	O
the	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
producing	O
pancreatic	O
progenitor	O
cells	O
,	O
such	O
as	O
Pdx1-positive	O
pancreatic	O
progenitor	O
cells	O
by	O
exposing	O
endoderm	O
cells	O
,	O
such	O
as	O
definitive	O
endoderm	O
cells	O
to	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
described	O
herein	O
to	O
differentiate	O
the	O
definitive	O
endoderm	O
cells	O
into	O
Pdx1-positive	O
pancreatic	O
progenitor	O
cells	O
.	O

Kits	O
and	O
compositions	O
comprising	O
Pdx1-positive	O
pancreatic	O
progenitor	O
produced	O
using	O
the	O
methods	O
are	O
also	O
described	O
.	O

Compositions	O
and	O
methods	O
for	O
promoting	O
the	O
generation	O
of	O
definitive	O
endoderm	O

The	O
present	O
invention	O
relates	O
to	O
CXCR2	O
receptor	O
antagonists	O
or	O
inhibitors	O
of	O
CXCR2	O
receptor	O
gene	O
expression	O
for	O
the	O
treatment	O
or	O
the	O
prevention	O
of	O
insulin	O
resistance	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
diagnosing	O
and/or	O
prognosing	O
insulin	O
resistance	O
in	O
a	O
subject	O
comprising	O
detecting	O
the	O
presence	O
and/or	O
quantifying	O
CXCL5	O
in	O
a	O
biological	O
sample	O
obtained	O
from	O
said	O
subject	O
.	O

Cxcr2	O
receptor	O
antagonists	O
for	O
the	O
treatment	O
or	O
the	O
prevention	O
of	O
insulin	O
resistance	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
N2-	B
(	I
1-oxohexadecyl	I
)	I
-lysyl	I
-	I
valyl-	I
lysine	I
or	O
a	O
salt	O
thereof	O
,	O
spent	O
grain	O
wax	O
and	O
/	O
or	O
conjugated	O
linoleic	B
acid	I
.	O

The	O
compositions	O
are	O
particularly	O
useful	O
for	O
the	O
treatment	O
or	O
co	O
-	O
treatment	O
of	O
rosacea	O
and	O
its	O
symptoms	O
.	O

Furthermore	O
the	O
invention	O
relates	O
to	O
a	O
stable	O
W	O
/	O
O	O
emulsion	O
pre	O
-	O
mix	O
comprising	O
the	O
composition	O
according	O
to	O
the	O
invention	O
.	O

Composition	O
comprising	O
n2	B
-	I
(	I
1-oxohexadecyl	I
)	I
-	I
lysyl	I
-	I
valyl	I
-	I
lysine	I
for	O
treating	O
rosacea	O
and	O
its	O
symptoms	O

The	O
present	O
invention	O
relates	O
to	O
a	O
product	O
that	O
contains	O
sucrose	O
and	O
a	O
berry	O
polyphe-	O
nolic	O
compound	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
use	O
of	O
a	O
polyphenolic	B
compound	O
for	O
controlling	O
postprandial	O
blood	O
glucoseand	O
/	O
or	O
insulinconcentration	O
in	O
a	O
subject	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
use	O
of	O
the	O
product	O
for	O
controlling	O
postprandial	O
blood	O
glucoseand	O
/	O
or	O
insulinconcentration	O
in	O
a	O
subject	O
.	O

In	O
addition	O
,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
of	O
controlling	O
postprandial	O
blood	O
glucoseand	O
/	O
or	O
insulinconcentration	O
in	O
a	O
subject	O
by	O
administering	O
a	O
polyphenolic	O
compound	O
and	O
/	O
or	O
the	O
product	O
to	O
the	O
subject	O
.	O

Sugar	B
product	O

New	O
use	O
of	O
patchouli	B
alcohol	I
,	O
CO2	B
supercritical	O
extracts	O
of	O
herba	O
pogostemonis	O
or	O
patchouli	O
oil	O
in	O
medicament	O
preparation	O
is	O
disclosed	O
.	O

Patchouli	B
alcohol	I
,	O
having	O
distinct	O
inhibiting	O
and	O
killing	O
effect	O
on	O
influenza	O
virus	O
H1N1	O
,	O
influenza	O
virus	O
B	O
and	O
avian	O
influenza	O
virus	O
H5N1	O
,	O
can	O
be	O
found	O
in	O
both	O
CO2	B
supercritical	O
extracts	O
of	O
herba	O
pogostemonis	O
and	O
patchouli	O
oil	O
.	O

Use	O
of	O
patchouli	B
alcohol	I
in	O
medicament	O
preparation	O

Disclosed	O
are	O
a	O
compound	O
having	O
an	O
antibacterial	O
activity	O
and	O
a	O
derivative	O
thereof	O
,	O
more	O
preferably	O
an	O
antibacterial	O
nucleoside	O
compound	O
that	O
can	O
inhibit	O
the	O
activity	O
of	O
MraY	O
to	O
exert	O
an	O
antibacterial	O
activity	O
and	O
a	O
derivative	O
of	O
the	O
nucleoside	O
compound	O
,	O
particularly	O
a	O
novel	O
derivative	O
of	O
Muraymycin	B
that	O
is	O
an	O
MraY	O
inhibitor	O
.	O

Specifically	O
disclosed	O
is	O
a	O
novel	O
derivative	O
of	O
Muraymycin	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
compound	O
has	O
good	O
intracellular	O
penetration	O
properties	O
and	O
a	O
potent	O
antibacterial	O
activity	O
.	O

The	O
compound	O
also	O
has	O
resistance	O
against	O
enzymes	O
such	O
as	O
an	O
esterase	O
occurring	O
in	O
blood	O
.	O

A	O
preferred	O
embodiment	O
of	O
the	O
compound	O
has	O
an	O
inhibitory	O
activity	O
on	O
MraY.	O
The	O
preferred	O
embodiment	O
of	O
the	O
compound	O
is	O
effective	O
against	O
resistant	O
bacteria	O
such	O
as	O
VRE	O
and	O
MRSA	O
.	O

Nucleoside	O
-	O
type	O
antibiotic	O

The	O
present	O
invention	O
relates	O
to	O
pyridine-2-yl	B
-	I
carboxylic	I
acid	I
amides	I
which	O
act	O
as	O
metabotropic	O
glutamate	B
receptor	O
antagonists	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
pyridine-2-yl	B
-	I
carboxylic	I
acid	I
amides	I
of	O
formula	O
I	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O

Pyridine-2-yl	B
-	I
carboxylic	I
acid	I
amides	I

The	O
present	O
invention	O
relates	O
to	O
novel	O
prodrugs	O
of	O
metformin	B
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
prodrugs	O
,	O
and	O
methods	O
of	O
using	O
the	O
prodrugs	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
prodrugs	O
wherein	O
sulfur	O
-	O
containing	O
promoieties	O
are	O
attached	O
to	O
metformin	B
to	O
form	O
novel	O
bioreversible	O
sulfenyl	B
guanidine	I
(	O
N	B
-	I
S	I
)	O
prodrugs	O
of	O
metformin	B
with	O
improved	O
oral	O
absorption	O
,	O
and	O
consequently	O
promoted	O
bioavailability	O
.	O

Novel	O
prodrugs	O
of	O
metformin	B

The	O
invention	O
provides	O
novel	O
prodrug	O
compounds	O
comprising	O
a	O
kinase	O
inhibitor	O
and	O
a	O
reductively	O
-	O
activated	O
fragmenting	O
aromatic	B
nitroheterocycle	I
or	I
aromatic	I
nitrocarbocycle	I
trigger	O
,	O
where	O
the	O
compound	O
carries	O
a	O
positive	O
charge	O
.	O

In	O
preferred	O
embodiments	O
,	O
the	O
compounds	O
are	O
of	O
Formula	O
I	O
:	O
where	O
:	O
X	O
is	O
any	O
negatively	O
charged	O
counterion	O
;	O
R1	O
is	O
a	O
group	O
of	O
the	O
formula	O
—	B
(	I
CH2	I
)	I
nTr	I
,	O
where	O
Tr	O
is	O
an	O
aromatic	B
nitroheterocycle	I
or	I
aromatic	I
nitrocarbocycle	I
and	O
—	B
(	I
CH2	I
)	I
nTr	I
acts	O
as	O
a	O
reductively	O
-	O
activated	O
fragmenting	O
trigger	O
;	O
and	O
n	O
is	O
an	O
integer	O
from	O
0	O
to	O
6	O
;	O
R2	O
,	O
R3	O
and	O
R4	O
may	O
each	O
independently	O
be	O
selected	O
from	O
aliphatic	B
or	I
aromatic	I
groups	O
of	O
a	O
tertiary	B
amine	I
kinase	O
inhibitor	O
(	B
R2	I
)	I
(	I
R3	I
)	I
(	I
R4	I
)	I
N	I
,	O
or	O
two	O
of	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
may	O
form	O
an	O
aliphatic	B
or	I
aromatic	I
heterocyclic	I
amine	I
ring	O
of	O
a	O
kinase	O
inhibitor	O
,	O
or	O
one	O
of	O
R2	O
,	O
R3	O
and	O
R4	O
may	O
be	O
absent	O
and	O
two	O
of	O
R2	O
,	O
R3	O
and	O
R4	O
form	O
an	O
aromatic	B
heterocyclic	I
amine	I
ring	O
of	O
a	O
kinase	O
inhibitor	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
treating	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
.	O

Prodrug	O
forms	O
of	O
kinase	O
inhibitors	O
and	O
their	O
use	O
in	O
therapy	O

The	O
present	O
invention	O
relates	O
to	O
solid	O
dispersions	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
co	O
-	O
processed	O
carbohydrates	B
with	O
different	O
solubilities	O
and	O
concentrations	O
,	O
which	O
have	O
a	O
microcrystalline	O
plate	O
structure	O
.	O

The	O
solid	O
dispersions	O
,	O
excipient	O
systems	O
and	O
formulations	O
of	O
the	O
present	O
invention	O
are	O
highly	O
compactable	O
and	O
durable	O
and	O
when	O
compressed	O
into	O
solid	O
dosage	O
forms	O
demonstrate	O
uniform	O
densification	O
,	O
low	O
friability	O
at	O
low	O
pressures	O
,	O
and	O
and/or	O
relatively	O
constant	O
low	O
disintegration	O
times	O
at	O
various	O
hardnesses	O
.	O

The	O
solid	O
dosage	O
forms	O
of	O
the	O
present	O
invention	O
demonstrate	O
superior	O
organoleptics	O
,	O
disintegration	O
,	O
and/or	O
robustness	O
.	O

Highly	O
compactable	O
and	O
durable	O
direct	O
compression	O
excipients	O
and	O
excipient	O
systems	O

The	O
present	O
application	O
discloses	O
novel	O
prodrugs	O
of	O
substituted	O
3-	B
(	I
4-hydroxy	I
-	I
phenyl	I
)	I
-indolin-2-one	I
compounds	O
(	O
oxindole	B
compounds	O
)	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
mammal	O
.	O

The	O
prodrug	O
compounds	O
are	O
of	O
the	O
formula	O
(	O
I	O
)	O
.	O

Prodrugs	O
of	O
substituted	O
3-	B
(	I
4-hydroxyphenyl	I
)	I
-indolin-2-ones	I

Disclosed	O
is	O
a	O
substance	O
capable	O
of	O
inhibiting	O
the	O
excessive	O
production	O
of	O
nitrogen	B
monoxide	I
(	O
NO	B
)	O
.	O

Also	O
disclosed	O
is	O
a	O
therapeutic	O
agent	O
for	O
diseases	O
associated	O
with	O
the	O
excess	O
production	O
or	O
expression	O
of	O
NO	B
(	O
e.g.	O
,	O
inflammations	O
,	O
allergic	O
diseases	O
)	O
.	O

A	O
cembrane	O
diterpene	O
represented	O
by	O
formula	O
(	O
A	O
)	O
which	O
is	O
isolated	O
from	O
coral	O
can	O
inhibit	O
the	O
production	O
of	O
nitrogen	B
monoxide	I
by	O
cells	O
,	O
and	O
is	O
therefore	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
inflammations	O
and	O
allergic	O
diseases	O
.	O

Coral	O
-	O
derived	O
therapeutic	O
agent	O
for	O
inflammations	O
and	O
allergic	O
diseases	O

The	O
present	O
invention	O
provides	O
a	O
novel	O
transdermal	O
patch	O
containing	O
high	O
concentration	O
of	O
riluzole	B
and	O
being	O
able	O
to	O
administer	O
transdermally	O
and	O
quantitatively	O
the	O
drug	O
to	O
the	O
ALS	O
patients	O
having	O
difficulties	O
taking	O
the	O
drug	O
orally	O
.	O

Furthermore	O
,	O
the	O
transdermal	O
patch	O
of	O
the	O
present	O
invention	O
can	O
prevent	O
adverse	O
effects	O
which	O
have	O
become	O
problem	O
in	O
the	O
oral	O
administration	O
and	O
improved	O
the	O
compliance	O
and	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
of	O
the	O
patients	O
and	O
various	O
problems	O
can	O
be	O
solved	O
,	O
then	O
the	O
transdermal	O
patch	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
ALS	O
.	O

Preferably	O
,	O
such	O
patch	O
provided	O
by	O
the	O
present	O
invention	O
contains	O
20	O
to	O
60	O
%	O
by	O
weight	O
of	O
riluzole	B
based	O
on	O
the	O
drug	O
-	O
containing	O
layer	O
and	O
the	O
area	O
of	O
the	O
patch	O
is	O
15	O
to	O
60	O
cm2	O
.	O

Riluzole	B
-	O
containing	O
transdermal	O
patch	O

Provided	O
is	O
an	O
agent	O
for	O
amelioration	O
or	O
prevention	O
of	O
metabolic	O
syndrome	O
,	O
said	O
agent	O
containing	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
β-1,3	O
-	O
1,4-glucan	O
having	O
a	O
weight	O
-	O
average	O
molecular	O
weight	O
from	O
50,000	O
to	O
500,000	O
Da	O
.	O

Said	O
agent	O
has	O
a	O
high	O
level	O
of	O
safety	O
with	O
respect	O
to	O
living	O
organisms	O
,	O
can	O
be	O
taken	O
daily	O
and	O
continually	O
,	O
and	O
can	O
be	O
used	O
as	O
an	O
ingredient	O
in	O
pharmaceuticals	O
,	O
foods	O
,	O
drinks	O
,	O
and	O
the	O
like	O
.	O

Agent	O
for	O
amelioration	O
or	O
prevention	O
of	O
metabolic	O
syndrome	O

Disclosed	O
is	O
a	O
novel	O
and	O
excellent	O
method	O
for	O
preventing	O
and/or	O
treating	O
cannabinoid-2	B
receptor	O
-	O
related	O
diseases	O
,	O
which	O
is	O
based	O
on	O
an	O
agonist	O
action	O
on	O
cannabinoid-2	B
receptors	O
.	O

Specifically	O
disclosed	O
is	O
a	O
heterocyclic	B
derivative	O
mainly	O
having	O
two	O
substituents	O
,	O
for	O
example	O
,	O
a	O
pyrimidine-5-carboxylic	B
acid	I
amide	I
derivative	O
having	O
a	O
substituted	O
amino	B
group	O
at	O
the	O
2-position	O
,	O
which	O
has	O
a	O
strong	O
agonist	O
action	O
on	O
cannabinoid-2	B
receptors	O
.	O

The	O
derivative	O
can	O
be	O
an	O
agent	O
for	O
preventing	O
and/or	O
treating	O
diseases	O
related	O
to	O
cannabinoid-2	B
receptors	O
,	O
such	O
as	O
inflammatory	O
diseases	O
and	O
pains	O
.	O

Pyrimidine	B
compound	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
bone	O
regeneration	O
including	O
a	O
hyaluronic	O
acid	O
and	O
a	O
mesenchymal	O
stem	O
cell	O
into	O
which	O
a	O
bone	O
regeneration	O
inducing	O
factor	O
is	O
introduced	O
,	O
and	O
a	O
manufacturing	O
method	O
thereof	O
.	O

The	O
composition	O
for	O
bone	O
regeneration	O
can	O
include	O
a	O
stem	O
cell	O
into	O
which	O
a	O
gene	O
coding	O
a	O
protein	O
with	O
a	O
bone	O
formation	O
function	O
is	O
introduced	O
or	O
cells	O
differentiated	O
from	O
the	O
stem	O
cell	O
and	O
the	O
hyaluronic	O
acid	O
.	O

The	O
protein	O
with	O
the	O
bone	O
formation	O
function	O
can	O
be	O
a	O
bone	O
morphogenic	O
protein	O
(	O
BMP	O
)	O
.	O

The	O
stem	O
cell	O
can	O
be	O
a	O
mesenchymal	O
stem	O
cell	O
,	O
and	O
it	O
can	O
be	O
a	O
stem	O
cell	O
into	O
which	O
a	O
suicide	O
gene	O
is	O
additionally	O
introduced	O
.	O

An	O
average	O
molecular	O
weight	O
of	O
the	O
hyaluronic	O
acid	O
can	O
be	O
from	O
50,000	O
to	O
300,000	O
daltons	O
.	O

Composition	O
for	O
bone	O
regeneration	O

EphB3	O
kinase	O
inhibitor	O
compounds	O
,	O
including	O
certain	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyridine	I
and	O
imidazo	B
[	I
1,2-a	I
]	I
pyridine	I
compounds	O
,	O
inhibit	O
EphB3	O
kinase	O
.	O

The	O
EphB3	O
kinase	O
inhibitor	O
compounds	O
can	O
have	O
greater	O
potency	O
for	O
the	O
inhibition	O
of	O
EphB3	O
kinase	O
than	O
general	O
kinase	O
inhibitors	O
.	O

Pharmaceutical	O
compositions	O
,	O
such	O
as	O
neuroprotective	O
agents	O
,	O
comprising	O
the	O
EphB3	O
kinase	O
inhibitor	O
compounds	O
are	O
also	O
provided	O
.	O

The	O
EphB3	O
kinase	O
inhibitor	O
compounds	O
and	O
pharmaceutical	O
compositions	O
are	O
useful	O
,	O
for	O
example	O
,	O
to	O
provide	O
neuroprotection	O
and/or	O
repair	O
of	O
neuronal	O
tissue	O
damaged	O
during	O
an	O
ischemic	O
event	O
,	O
such	O
as	O
a	O
stroke	O
.	O

Inhibiting	O
eph	O
b-3	O
kinase	O

The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
decreasing	O
the	O
level	O
of	O
pro-	O
AD	O
AM	O
10	O
and/or	O
BACE	O
protein	O
in	O
a	O
subject	O
,	O
the	O
method	O
comprising	O
administering	O
a	O
heterocyclic	B
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	B
or	O
prodrug	O
thereof	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

Method	O
of	O
decreasing	O
pro	O
-	O
adam10	O
secretase	O
and/or	O
beta	O
secretase	O
levels	O

A	O
combination	O
of	O
compounds	O
is	O
described	O
that	O
target	O
protein	O
kinases	O
and	O
is	O
more	O
effective	O
than	O
the	O
individual	O
compounds	O
against	O
cancer	O
where	O
EGFR	O
is	O
upregulated	O
and	O
c	O
-	O
met	O
is	O
activated	O
,	O
for	O
example	O
,	O
epithelial	O
cell	O
tumors	O
,	O
and	O
particularly	O
,	O
non	O
small	O
cell	O
lung	O
carcinomas	O
(	O
NSCLC	O
)	O
.	O

Combination	O
targeted	O
therapy	O
for	O
lung	O
cancer	O

Oxalato	O
complexes	O
of	O
platinum	O
in	O
the	O
oxidation	O
state	O
+	O
II	O
and	O
their	O
crystal	O
-	O
solvates	O
including	O
the	O
structural	O
motif	O
(	O
I	O
)	O
or	O
having	O
the	O
general	O
formula	O
(	O
II	O
)	O
expressed	O
by	O
the	O
structural	O
formula	O
[	O
Pt	O
(	O
L	O
)	O
2	O
(	O
ox	O
)	O
]	O
(	O
II	O
)	O
or	O
the	O
general	O
formula	O
(	O
III	O
)	O
expressed	O
by	O
the	O
structural	O
formula	O
[	O
Pt	O
(	O
L	O
)	O
(	O
L'	O
)	O
(	O
ox	O
)	O
]	O
(	O
III	O
)	O
,	O
where	O
the	O
symbols	O
L	O
and	O
L	O
'	O
stand	O
for	O
N6-	O
benzyladenine	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
IV	O
)	O
bound	O
to	O
the	O
platinum	O
atom	O
of	O
the	O
basic	O
motif	O
(	O
V	O
)	O
through	O
any	O
adenine	O
nitrogen	O
atom	O
independently	O
chosen	O
from	O
the	O
N1	O
,	O
N3	O
,	O
N6	O
,	O
N7	O
or	O
N9	O
atoms	O
,	O
depending	O
on	O
the	O
substitution	O
rate	O
of	O
the	O
molecules	O
(	O
IV	O
)	O
,	O
where	O
the	O
substituents	O
R1	O
,	O
R2	O
a	O
R3	O
are	O
independently	O
chosen	O
from	O
the	O
group	O
of	O
:	O
hydrogen	O
atom	O
,	O
halogen	O
,	O
alkyl	O
,	O
substituted	O
alkyl	O
,	O
alkenyl	O
,	O
substituted	O
alkenyl	O
,	O
alkynyl	O
,	O
substituted	O
alkynyl	O
,	O
cycloalkyl	O
,	O
substituted	O
cycloalkyl	O
,	O
cycloheteroalkyl	O
,	O
substituted	O
cycloheteroalkyl	O
,	O
cycloalkenyl	O
,	O
substituted	O
cycloalkenyl	O
,	O
cycloheteroalkenyl	O
,	O
substituted	O
cycloheteroalkenyl	O
,	O
aryl	O
,	O
substituted	O
aryl	O
,	O
heteroaryl	O
,	O
substituted	O
heteroaryl	O
,	O
functional	O
group	O
and	O
N	O
-	O
R'R	O
""""	O
group	O
,	O
where	O
R	O
'	O
and	O
R	O
""""	O
independently	O
symbolize	O
hydrogen	O
atom	O
,	O
alkyl	O
,	O
substituted	O
alkyl	O
,	O
alkenyl	O
,	O
substituted	O
alkenyl	O
,	O
alkynyl	O
,	O
substituted	O
alkynyl	O
,	O
cycloalkyl	O
,	O
substituted	O
cycloalkyl	O
,	O
cycloheteroalkyl	O
,	O
substituted	O
cycloheteroalkyl	O
,	O
cycloalkenyl	O
,	O
substituted	O
cycloalkenyl	O
,	O
cycloheteroalkenyl	O
,	O
substituted	O
cycloheteroalkenyl	O
,	O
aryl	O
,	O
substituted	O
aryl	O
,	O
heteroaryl	O
,	O
substituted	O
heteroaryl	O
and	O
functional	O
group	O
.	O

Oxalato	O
complexes	O
of	O
platinum	O

This	O
invention	O
relates	O
to	O
3-azabicyclo	B
[	I
4.1.0	I
]	I
heptane	I
derivatives	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
orexin	O
receptor	O
antagonists	O
.	O

3	B
-azabicyclo	I
[	I
4.1.0	I
]	I
heptanes	I
used	O
as	O
orexin	O
antagonists	O

This	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
formula	O
I	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Such	O
compounds	O
possess	O
both	O
muscarinic	O
receptor	O
antagonist	O
and	O
β2	O
adrenergic	O
receptor	O
agonist	O
activities	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
processes	O
and	O
intermediates	O
for	O
preparing	O
such	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
as	O
bronchodilating	O
agents	O
to	O
treat	O
pulmonary	O
disorders	O
.	O

DIAMIDE	B
COMPOUNDS	O
HAVING	O
MUSCARINIC	O
RECEPTOR	O
ANTAGONIST	O
AND	O
β2	O
ADRENERGIC	O
RECEPTOR	O
AGONIST	O
ACTIVITY	O

The	O
invention	O
features	O
compositions	O
,	O
methods	O
,	O
and	O
kits	O
for	O
the	O
administration	O
of	O
an	O
oxidatively	O
transformed	O
carotenoid	B
,	O
or	O
a	O
fractionated	O
component	O
thereof	O
,	O
for	O
treating	O
inflammatory	O
conditions	O
.	O

Methods	O
,	O
compositions	O
,	O
and	O
kits	O
for	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O

A	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
,	O
which	O
has	O
a	O
β2	O
adrenergic	O
receptor	O
agonist	O
activity	O
and	O
a	O
muscarin	O
receptor	O
antagonist	O
activity	O
.	O

R1	O
is	O
H	B
or	O
a	O
C1	B
-	I
8	I
alkyl	I
.	O

R4	O
is	O
a	O
C1	B
-	I
10	I
alkylene	I
.	O

R2	O
is	O
a	O
single	O
bond	O
,	O
a	O
(	O
substituted	O
)	O
C1	B
-	I
8	I
alkylene	I
,	O
a	O
C2	B
-	I
4	I
alkenylene	I
,	O
or	O
an	O
O-	B
(	I
C1	I
-	I
4	I
alkylene	I
)	I
.	O

X	O
is	O
a	O
single	O
bond	O
,	O
O	B
,	O
CONR3	B
,	O
NR3CO	B
,	O
or	O
NR3COCH2O	B
(	O
wherein	O
R3	O
is	O
H	B
or	O
a	O
C1	B
-	I
8	I
alkyl	I
)	O
.	O

A1	O
is	O
a	O
single	O
bond	O
,	O
a	O
(	O
substituted	O
)	O
C6	B
-	I
10	I
arylene	I
,	O
etc	O
.	O

R8	O
and	O
R9	O
each	O
is	O
X	O
,	O
CN	B
,	O
a	O
C1	B
-	I
6	I
alkyl	I
,	O
etc	O
.	O

a	O
and	O
b	O
each	O
is	O
0	O
-	O
3	O
.	O

W-	O
is	O
an	O
anion	O
.	O

Y	O
is	O
any	O
of	O
formulae	O
(	O
1	O
)	O
to	O
(	O
9	O
)	O
.	O

Q	O
is	O
any	O
of	O
formulae	O
(	O
10	O
)	O
to	O
(	O
12	O
)	O
(	O
wherein	O
R6	O
and	O
R7	O
each	O
is	O
a	O
(	O
substituted	O
)	O
C1	B
-	I
6	I
alkyl	I
or	O
a	O
(	O
substituted	O
)	O
C8	B
-	I
10	I
phenoxyalkyl	I
;	O
n	O
is	O
0	O
-	O
2	O
;	O
m	O
is	O
0	O
-	O
3	O
;	O
and	O
R5	O
is	O
a	O
(	O
substituted	O
)	O
C1	B
-	I
6	I
alkyl	I
(	O
two	O
of	O
R5	O
to	O
R8	O
may	O
form	O
a	O
ring	O
structure	O
)	O
)	O
.	O

Quaternary	B
ammonium	I
salt	O
compound	O

Disclosed	O
are	O
:	O
a	O
compound	O
represented	O
by	O
structural	O
formula	O
(	O
1	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
;	O
a	O
histone	O
acetylase	O
inhibitor	O
;	O
a	O
nuclear	O
receptor	O
transcription	O
activation	O
inhibitor	O
;	O
a	O
deuteromycetes	O
belonging	O
to	O
the	O
genus	O
Penicillium	O
,	O
which	O
can	O
produce	O
the	O
compound	O
;	O
a	O
process	O
for	O
producing	O
the	O
compound	O
,	O
which	O
comprises	O
a	O
culturing	O
step	O
of	O
culturing	O
the	O
microorganism	O
and	O
a	O
collection	O
step	O
of	O
collecting	O
the	O
compound	O
from	O
a	O
culture	O
produced	O
in	O
the	O
culturing	O
step	O
;	O
and	O
others	O
.	O

Novel	O
compound	O
,	O
histone	O
acetylase	O
inhibitor	O
,	O
nuclear	O
receptor	O
transcription	O
activation	O
inhibitor	O
,	O
deuteromycetes	O
belonging	O
to	O
genus	O
penicillium	O
,	O
and	O
production	O
process	O

Disclosed	O
is	O
an	O
excellent	O
therapeutic	O
agent	O
for	O
prostate	O
cancer	O
,	O
which	O
comprises	O
a	O
combination	O
of	O
leuprorelin	B
acetate	I
and	O
lapatinib	B
and	O
can	O
inhibit	O
the	O
change	O
from	O
hormone	O
-	O
dependent	O
prostate	O
cancer	O
to	O
hormone	O
-	O
independent	O
prostate	O
cancer	O
.	O

Combined	O
drug	O

A	O
nano	O
-	O
emulsion	O
injection	O
of	O
Vinca	O
alkaloids	B
and	O
its	O
preparation	O
method	O
are	O
disclosed	O
.	O

The	O
injection	O
is	O
an	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
injection	O
comprising	O
Vinca	O
alkaloids	B
or	O
their	O
salts	O
,	O
injectable	O
oil	O
,	O
surfactant	O
(	O
s	O
)	O
and	O
injectable	O
water	O
,	O
wherein	O
the	O
average	O
diameter	O
of	O
the	O
droplets	O
of	O
the	O
emulsion	O
is	O
less	O
than	O
100	O
nm	O
and	O
the	O
pH	O
of	O
the	O
emulsion	O
is	O
7	O
-	O
9	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
preparing	O
the	O
oil	O
phase	O
and	O
the	O
aqueous	O
phase	O
respectively	O
,	O
homogeneously	O
mixing	O
the	O
oil	O
phase	O
and	O
the	O
aqueous	O
phase	O
with	O
high	O
speed	O
,	O
adding	O
the	O
active	O
ingredient	O
,	O
adjusting	O
the	O
pH	O
to	O
7	O
-	O
9	O
,	O
adding	O
water	O
to	O
constant	O
volume	O
,	O
and	O
homogenizing	O
the	O
emulsion	O
till	O
the	O
average	O
diameter	O
of	O
the	O
droplets	O
being	O
less	O
than	O
100	O
nm	O
.	O

The	O
alternative	O
method	O
comprises	O
the	O
steps	O
of	O
homogeneously	O
mixing	O
the	O
oil	O
phase	O
and	O
the	O
aqueous	O
phase	O
,	O
homogenizing	O
the	O
obtained	O
emulsion	O
under	O
high	O
pressure	O
till	O
the	O
average	O
diameter	O
of	O
the	O
droplets	O
being	O
less	O
than	O
100	O
nm	O
,	O
adding	O
the	O
active	O
ingredient	O
,	O
adjusting	O
the	O
pH	O
to	O
7	O
-	O
9	O
,	O
stirring	O
,	O
and	O
adding	O
water	O
to	O
constant	O
volume	O
.	O

A	O
nano	O
-	O
emulsion	O
injection	O
of	O
vinca	O
alkaloids	B
and	O
the	O
preparation	O
method	O
thereof	O

A	O
topical	O
composition	O
containing	O
an	O
alkoxylated	B
diphenylacrylate	I
compound	O
and	O
an	O
aryl	B
carboxylic	I
ester	I
is	O
provided	O
.	O

Preferably	O
,	O
the	O
topical	O
composition	O
is	O
a	O
sunscreen	O
composition	O
containing	O
α	B
-	I
ethylhexyl	I
α	I
-	I
cyano	I
-	I
β-	I
(	I
4-methoxyphenyl	I
)	I
-β	I
-	I
phenylacrylate	I
and	O
2-phenylethyl	B
benzoate	I
,	O
and	O
optionally	O
further	O
containing	O
4,4'-t	B
-	I
butyl	I
methoxydibenzoylmethane	I
,	O
which	O
is	O
characterized	O
by	O
improved	O
photo	O
-	O
protection	O
of	O
the	O
skin	O
and	O
is	O
effective	O
in	O
preventing	O
/	O
reducing	O
photo	O
-	O
damage	O
of	O
the	O
skin	O
upon	O
exposure	O
to	O
sunlight	O
or	O
other	O
sources	O
of	O
light	O
in	O
the	O
ultraviolet	O
(	O
UV	O
)	O
,	O
visible	O
,	O
and	O
infrared	O
(	O
IR	O
)	O
ranges	O
.	O

Topical	O
compositions	O
comprising	O
an	O
alkoxylated	B
diphenylacrylate	I
compound	O
and	O
an	O
aryl	B
carboxylic	I
ester	I

The	O
invention	O
relates	O
generally	O
to	O
optical	O
agents	O
for	O
biomedical	O
applications	O
,	O
including	O
phototherapy	O
.	O

The	O
invention	O
includes	O
optical	O
agents	O
,	O
and	O
related	O
therapeutic	O
methods	O
,	O
comprising	O
compounds	O
with	O
an	O
acyclic	B
N	B
-	O
N	B
bond	O
having	O
at	O
least	O
one	O
aromatic	O
and/or	O
heterocyclic	B
aromatic	O
group	O
providing	O
phototherapeutic	O
agents	O
,	O
including	O
Type	O
1	O
phototherapeutic	O
agents	O
.	O

In	O
some	O
embodiments	O
,	O
for	O
example	O
,	O
the	O
invention	O
provides	O
compounds	O
for	O
phototherapeutic	O
methods	O
having	O
one	O
or	O
more	O
photolabile	O
acyclic	B
N	B
-	O
N	B
bonds	O
capable	O
of	O
undergoing	O
photoactivated	O
cleavage	O
to	O
produce	O
reactive	O
species	O
,	O
such	O
as	O
radicals	O
,	O
ions	O
,	O
etc	O
.	O
,	O
that	O
achieve	O
a	O
desired	O
therapeutic	O
effect	O
,	O
such	O
as	O
selective	O
and/or	O
localized	O
tissue	O
damage	O
and/or	O
cell	O
death	O
.	O

Compounds	O
containing	O
acyclic	B
n	B
-	O
n	B
bonds	O
for	O
phototherapy	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
represented	O
by	O
Structural	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
variables	O
for	O
Structural	O
Formula	O
(	O
I	O
)	O
are	O
defined	O
herein	O
.	O

Also	O
described	O
is	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
of	O
Structural	O
Formula	O
(	O
I	O
)	O
and	O
its	O
therapeutic	O
use	O
.	O

Pentacycline	B
compounds	O

Diastereomeric	O
pyrrolidine	B
compounds	O
and	O
methods	O
of	O
preparation	O
,	O
as	O
can	O
be	O
used	O
en	O
route	O
to	O
the	O
preparation	O
of	O
a	O
range	O
of	O
nitric	B
oxide	I
synthase	O
inhibitors	O
.	O

Chiral	O
pyrrolidine	B
core	O
compounds	O
en	O
route	O
to	O
inhibitors	O
of	O
nitric	B
oxide	I
synthase	O

The	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
highly	O
pathogenic	O
infectious	O
diseases	O
,	O
such	O
as	O
highly	O
pathogenic	O
influenza	O
A	O
(	O
in	O
particular	O
,	O
subtypes	O
H5	O
and	O
H7	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
caused	O
by	O
the	O
genotype	O
4	O
coronavirus	O
.	O

The	O
agent	O
is	O
in	O
the	O
form	O
of	O
glutaryl	B
histamine	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
based	O
on	O
glutaryl	B
histamine	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
to	O
a	O
method	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
highly	O
pathogenic	O
infectious	O
diseases	O
.	O

Agent	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
highly	O
pathogenic	O
infectious	O
diseases	O

This	O
invention	O
provides	O
compounds	O
and	O
methods	O
of	O
imaging	O
amyloid	O
deposits	O
using	O
radiolabeled	O
compounds	O
.	O

This	O
invention	O
also	O
provides	O
a	O
method	O
of	O
inhibiting	O
the	O
aggregation	O
of	O
amyloid	O
proteins	O
to	O
form	O
amyloid	O
plaques	O
or	O
deposits	O
,	O
a	O
method	O
of	O
determining	O
a	O
therapeutic	O
compound	O
's	O
ability	O
to	O
inhibit	O
aggregation	O
of	O
amyloid	O
protein	O
,	O
and	O
a	O
method	O
of	O
delivering	O
a	O
therapeutic	O
agent	O
to	O
amyloid	O
deposits	O
.	O

Alzheimer	O
's	O
disease	O
imaging	O
agents	O

The	O
present	O
invention	O
provides	O
compositions	O
comprising	O
isolated	O
elastin	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
wherein	O
the	O
human	O
elastin	O
is	O
substantially	O
insoluble	O
in	O
water	O
with	O
a	O
molecular	O
weight	O
greater	O
than	O
100	O
kDa	O
.	O

The	O
present	O
invention	O
further	O
provides	O
methods	O
and	O
kits	O
for	O
soft	O
tissue	O
augmentation	O
.	O

Elastin	O
for	O
soft	O
tissue	O
augmentation	O

Provided	O
herein	O
are	O
pharmaceutical	O
formulations	O
,	O
methods	O
,	O
and	O
systems	O
for	O
the	O
cosmetic	O
alteration	O
of	O
fat	O
deposits	O
.	O

Methods	O
comprise	O
administering	O
a	O
pharmaceutical	O
formulation	O
of	O
a	O
long	O
-	O
acting	O
beta-2	O
adrenergic	O
receptor	O
agonist	O
,	O
for	O
example	O
,	O
salmeterol	B
,	O
that	O
is	O
suitable	O
for	O
subcutaneous	O
administration	O
.	O

Methods	O
further	O
comprise	O
administering	O
a	O
pharmaceutical	O
formulation	O
that	O
is	O
suitable	O
for	O
subcutaneous	O
injection	O
comprising	O
:	O
(	O
a	O
)	O
a	O
lipophilic	O
long	O
-	O
acting	O
selective	O
beta-2	O
adrenergic	O
receptor	O
agonist	O
and/or	O
glucocorticosteroid	B
,	O
or	O
a	O
salt	O
,	O
optical	O
isomer	O
,	O
racemate	O
,	O
solvate	O
,	O
or	O
polymorph	O
thereof	O
;	O
and	O
(	O
b	O
)	O
at	O
least	O
one	O
subcutaneously	O
acceptable	O
inactive	O
ingredient	O
Methods	O
for	O
administration	O
and	O
formulations	O
for	O
the	O
treatment	O
of	O
regional	O
adipose	O
tissue	O

The	O
present	O
invention	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
crystalline	O
N-	B
(	I
2-chloro-6-methylphenyl	I
)	I
-2-	I
[	I
[	I
6-	I
[	I
4-	I
(	I
2-hydroxyethyl	I
)	I
-1-piperazinyl	I
]	I
-2-methyl-4-pyrimidinyl	I
]	I
amino	I
]	I
-5-	I
thiazolecarboxamide	I
(	I
dasatinib	I
)	I
monohydrate	I
.	O

The	O
invention	O
further	O
relates	O
to	O
pure	O
polymorphs	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
polymorphs	O
and	O
to	O
uses	O
thereof	O
.	O

Process	O
for	O
preparing	O
crystalline	O
dasatinib	B
monohydrate	I

The	O
present	O
invention	O
pertains	O
to	O
4-	B
(	I
4-methylpiperazin-1-ylmethyl	I
)	I
-N-	I
[	I
4-methyl-3-	I
(	I
4-pyridin-3-yl	I
)	I
pyrimidin-2-ylamino	I
)	I
phenyl	I
]	I
-benzamide	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
4-methyl-3-	B
[	I
[	I
4-	I
(	I
3-pyridinyl	I
)	I
-2-pyrimidinyl	I
]	I
amino	I
]	I
-Λ	I
/	I
-	I
[	I
5-	I
(	I
4-methyl-1	I
H	I
-	I
imidazol-1-yl	I
)	I
-3-	I
(	I
trifluoro-	I
methyl	I
)	I
phenyl	I
]	I
benzamide	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
the	O
treatment	O
of	O
ophthalmologic	O
disorders	O
mediated	O
by	O
alpha	O
-	O
carbonic	O
anhydrase	O
isoforms	O
.	O

Treatment	O
of	O
ophthalmologic	O
disorders	O
mediated	O
by	O
albha	O
-	O
carbonic	O
anhydrase	O
isoforms	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
steroid	B
compounds	O
having	O
the	O
formula	O
(	O
I	O
)	O
Wherein	O
R1	O
is	O
H	B
or	O
halogen	B
;	O
R2	O
is	O
H	B
,	O
(	B
1C-4C	I
)	I
alkyl	I
,	O
(	B
1C-4C	I
)	I
acyl	I
,	O
glucuronyl	B
or	O
sulfamoyl	B
;	O
R3	O
is	O
H	B
or	O
halogen	B
;	O
R4	O
is	O
H	B
,	O
(	B
1C-4C	I
)	I
alkyl	I
,	O
(	B
2C-4C	I
)	I
alkenyl	I
or	O
(	B
2C-4C	I
)	I
alkynyl	I
;	O
R5	O
is	O
methyl	B
or	O
ethyl	B
;	O
R6	O
is	O
H	B
or	O
methyl	B
;	O
R7	O
is	O
H	B
or	O
methyl	B
;	O
R8	O
is	O
H	B
or	O
acyl	B
for	O
use	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
endometriosis	O
,	O
for	O
contraception	O
,	O
for	O
hormonal	O
therapy	O
in	O
perimenopausal	O
and	O
post	O
-	O
menopausal	O
women	O
,	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
and	O
for	O
the	O
treatment	O
uterine	O
fibroids	O
and	O
other	O
menstrual	O
-	O
related	O
disorders	O
,	O
such	O
as	O
dysfunctional	O
uterine	O
bleeding	O
.	O

Substituted	O
16,17-annellated	O
steroid	O
compounds	O
for	O
use	O
in	O
women	O
's	O
healthcare	O

A	O
novel	O
C	B
-	I
aryl	I
glucoside	I
compound	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
a	O
prodrug	O
thereof	O
having	O
an	O
inhibitory	O
activity	O
against	O
sodium	B
-	O
dependent	O
glucose	B
cotransporter	O
2	O
(	O
SGLT2	O
)	O
being	O
present	O
in	O
the	O
intestine	O
and	O
kidney	O
;	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
,	O
which	O
is	O
useful	O
for	O
preventing	O
or	O
treating	O
metabolic	O
disorders	O
,	O
particularly	O
,	O
diabetes	O
,	O
are	O
provided	O
.	O

Novel	O
c	B
-	I
aryl	I
glucoside	I
sglt2	O
inhibitors	O
and	O
pharmaceutical	O
composition	O
comprising	O
same	O

Use	O
of	O
puerarin	B
in	O
preparing	O
medicine	O
for	O
treating	O
P2X3-mediated	O
pain	O
and	O
nervous	O
system	O
disease	O
.	O

Experiment	O
verified	O
that	O
puerarin	B
treats	O
acute	O
or	O
chronic	O
pain	O
by	O
blocking	O
transfer	O
of	O
pain	O
sensation	O
information	O
mediated	O
by	O
primary	O
sensory	O
neuron	O
P2X3	O
receptor	O
.	O

Puerarin	B
has	O
antagonistic	O
effect	O
on	O
P2X3	O
receptor	O
and	O
therefore	O
can	O
prevent	O
and	O
treat	O
P2X3	O
receptor	O
-	O
mediated	O
nervous	O
system	O
disease	O
.	O

Use	O
of	O
puerarin	B
in	O
preparing	O
medicine	O
for	O
treating	O
p2x3-mediated	O
pain	O
/	O
nervous	O
system	O
disease	O

Anti	O
-	O
acne	O
formulation	O
containing	O
(	O
i	O
)	O
3.5	O
%	O
w	O
/	O
v	O
or	O
greater	O
of	O
a	O
dialkyl	B
sulpho	I
succinate	I
(	O
DAS	B
)	O
such	O
as	O
a	O
dioctyl	B
sulpho	I
succinate	I
and	O
(	O
ii	O
)	O
salicylic	B
acid	I
or	O
a	O
derivative	O
thereof	O
(	O
other	O
than	O
a	O
halogenated	B
salicylanilide	I
)	O
,	O
which	O
is	O
suitable	O
for	O
application	O
as	O
a	O
topical	O
leave	O
-	O
on	O
formulation	O
.	O

The	O
salicylic	B
acid	I
or	O
derivative	O
may	O
be	O
present	O
at	O
a	O
concentration	O
of	O
0.5	O
%	O
w	O
/	O
w	O
.	O

The	O
formulation	O
may	O
contain	O
,	O
in	O
addition	O
to	O
the	O
DAS	B
and	O
the	O
salicylic	B
acid	I
or	O
derivative	O
,	O
(	O
a	O
)	O
a	O
polyoxyalkylene	O
-	O
based	O
solubilising	O
agent	O
and	O
(	O
b	O
)	O
an	O
organic	O
solvent	O
,	O
in	O
particular	O
an	O
alcohol	B
,	O
optionally	O
together	O
with	O
a	O
thickening	O
agent	O
and/or	O
water	O
.	O

It	O
may	O
contain	O
an	O
antioxidant	O
such	O
as	O
AO	O
2246	O
or	O
AO	O
425	O
.	O

It	O
may	O
be	O
applied	O
once	O
daily	O
over	O
a	O
period	O
of	O
several	O
weeks	O
.	O

Anti	O
-	O
acne	O
formulations	O
containing	O
a	O
dialkyl	B
sulphosuccinate	I
and	O
salicylic	B
acid	I

The	O
invention	O
relates	O
to	O
the	O
treatment	O
and	O
prevention	O
of	O
viral	O
and	O
bacterial	O
infections	O
using	O
vitamin	B
E	I
,	O
including	O
all	O
isoforms	O
of	O
tocopherol	B
,	O
tocomonoenol	B
,	O
tocodienol	B
,	O
tocotrienol	B
,	O
and	O
their	O
derivates	O
.	O

Compositions	O
,	O
methods	O
,	O
and	O
kits	O
for	O
treating	O
viral	O
and	O
bacterial	O
infections	O
by	O
tocotrienols	B
,	O
tocomonoenols	B
,	O
tocodienols	B
,	O
tocopherols	B
,	O
and	O
their	O
derivates	O

Provided	O
is	O
a	O
crystalline	O
form	O
of	O
the	O
ethylenediamine	B
salt	O
of	O
[	B
4,6-bis	I
(	I
dimethylamino	I
)	I
-2-	I
(	I
4-	I
{	I
[	I
4-	I
(	I
trifluoromethyl	I
)	I
benzoyl	I
]	I
amino	I
}	I
benzyl	I
)	I
pyrimidin-5-yl	I
]	I
acetic	I
acid	I
,	O
processes	O
for	O
its	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
it	O
,	O
and	O
methods	O
of	O
its	O
use	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
CRTH2-mediated	O
disorder	O
or	O
disease	O
.	O

Polymorph	O
of	O
[	B
4,6-bis	I
(	I
dimethylamino	I
)	I
-2-	I
(	I
4-	I
{	I
[	I
4-	I
(	I
trifluoromethyl	I
)	I
benzoyl	I
]	I
amino	I
}	I
benzyl	I
)	I
pyrimidin-5-yl	I
]	I

The	O
present	O
invention	O
is	O
directed	O
to	O
improve	O
the	O
usefulness	O
of	O
zeolite	O
and	O
sericite	O
in	O
various	O
medical	O
fields	O
.	O

To	O
achieve	O
this	O
purpose	O
,	O
a	O
composition	O
for	O
medical	O
or	O
medical	O
assisting	O
uses	O
,	O
which	O
contains	O
zeolite	O
and	O
sericite	O
,	O
is	O
provided	O
based	O
on	O
,	O
as	O
the	O
most	O
important	O
characteristic	O
,	O
the	O
finding	O
that	O
zeolite	O
and	O
sericite	O
can	O
exert	O
a	O
synergistic	O
effect	O
when	O
used	O
in	O
combination	O
.	O

It	O
is	O
confirmed	O
that	O
the	O
aforesaid	O
composition	O
containing	O
zeolite	O
and	O
sericite	O
exerts	O
an	O
advantageous	O
synergistic	O
effect	O
in	O
the	O
following	O
cases	O
.	O

When	O
externally	O
applied	O
,	O
the	O
aforesaid	O
composition	O
is	O
particularly	O
efficacious	O
in	O
,	O
for	O
example	O
,	O
treating	O
skin	O
itching	O
,	O
sore	O
and	O
pain	O
caused	O
by	O
burn	O
injury	O
,	O
skin	O
diseases	O
,	O
miliaria	O
,	O
etc	O
.	O
,	O
atopic	O
dermatitis	O
,	O
cut	O
,	O
scratch	O
,	O
nail	O
slipping	O
,	O
inflammatory	O
diseases	O
,	O
sunburn	O
inflammation	O
,	O
muscle	O
fragmentation	O
,	O
muscular	O
pain	O
,	O
contusion	O
,	O
bruise	O
,	O
sprain	O
,	O
athlete	O
's	O
foot	O
,	O
urticaria	O
and	O
cancerous	O
pain	O
,	O
as	O
a	O
substitute	O
for	O
ice	O
in	O
cooling	O
,	O
as	O
an	O
additive	O
to	O
hair	O
dyes	O
and	O
perming	O
agents	O
for	O
preventing	O
itching	O
and	O
sore	O
,	O
and	O
so	O
on	O
.	O

When	O
orally	O
administered	O
,	O
the	O
aforesaid	O
composition	O
is	O
particularly	O
efficacious	O
in	O
,	O
for	O
example	O
,	O
healing	O
bronchitis	O
,	O
asthma	O
,	O
stomach	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
gastritis	O
,	O
stomatitis	O
,	O
chronic	O
gastritis	O
,	O
periodontal	O
disease	O
,	O
chronic	O
liver	O
disease	O
,	O
pollen	O
allergy	O
,	O
oral	O
dysodia	O
,	O
cancer	O
,	O
etc	O
.	O
,	O
overcoming	O
fatigue	O
and	O
exhaustion	O
,	O
and	O
so	O
on	O
.	O

Zeolite	O
and	O
sericite	O
-	O
containing	O
composition	O
for	O
medical	O
or	O
medical	O
assisting	O
uses	O

Disclosed	O
are	O
:	O
a	O
composition	O
comprising	O
a	O
double	O
-	O
stranded	O
nucleic	O
acid	O
molecule	O
and	O
a	O
liposome	O
in	O
which	O
the	O
double	O
-	O
stranded	O
nucleic	O
acid	O
molecule	O
is	O
encapsulated	O
;	O
and	O
others	O
.	O

In	O
the	O
composition	O
,	O
the	O
double	O
-	O
stranded	O
nucleic	O
acid	O
molecule	O
comprises	O
an	O
antisense	O
strand	O
and	O
a	O
sense	O
strand	O
,	O
wherein	O
the	O
antisense	O
strand	O
is	O
a	O
polynucleotide	O
which	O
contains	O
a	O
nucleotide	O
sequence	O
complementary	O
to	O
a	O
sequence	O
composed	O
of	O
contiguous	O
17	O
nucleotides	O
contained	O
in	O
mRNA	O
for	O
a	O
target	O
gene	O
and	O
which	O
has	O
a	O
length	O
of	O
17	O
to	O
30	O
nucleotides	O
,	O
the	O
sense	O
strand	O
is	O
a	O
polynucleotide	O
which	O
contains	O
a	O
nucleotide	O
sequence	O
complementary	O
to	O
a	O
sequence	O
lying	O
between	O
the	O
1st	O
nucleotide	O
and	O
the	O
17th	O
nucleotide	O
numbered	O
from	O
the	O
5'-terminal	O
toward	O
the	O
3'-terminal	O
in	O
the	O
antisense	O
strand	O
and	O
which	O
has	O
a	O
length	O
of	O
17	O
to	O
30	O
nucleotides	O
,	O
each	O
of	O
sugars	O
respectively	O
bound	O
to	O
a	O
nucleotide	O
located	O
at	O
a	O
specific	O
position	O
in	O
the	O
antisense	O
strand	O
and	O
a	O
nucleotide	O
located	O
at	O
a	O
specific	O
position	O
in	O
the	O
sense	O
strand	O
is	O
a	O
deoxyribose	B
or	O
a	O
ribose	B
in	O
which	O
a	O
hydroxy	B
group	O
at	O
position-2	O
'	O
is	O
substituted	O
by	O
a	O
modifying	O
group	O
,	O
and	O
the	O
deoxyribose	B
and	O
the	O
ribose	B
are	O
contained	O
at	O
a	O
specific	O
ratio	O
.	O

In	O
the	O
composition	O
,	O
the	O
liposome	O
has	O
a	O
lipid	O
bilayer	O
membrane	O
comprising	O
a	O
lipid	O
derivative	O
,	O
fatty	B
acid	I
derivative	O
or	O
aliphatic	B
hydrocarbon	I
derivative	O
of	O
a	O
water	O
-	O
soluble	O
substance	O
as	O
a	O
component	O
.	O

Composition	O
for	O
inhibiting	O
the	O
expression	O
of	O
target	O
gene	O

Disclosed	O
is	O
an	O
agent	O
for	O
inhibiting	O
increase	O
in	O
postprandial	O
blood	O
insulin	O
level	O
,	O
which	O
contains	O
a	O
polyglutamic	B
acid	I
as	O
an	O
active	O
ingredient	O
.	O

Agent	O
for	O
inhibiting	O
increase	O
in	O
postprandial	O
blood	O
insulin	O
level	O

Methods	O
,	O
uses	O
,	O
compositions	O
,	O
combinations	O
and	O
kits	O
relating	O
to	O
the	O
decrease	O
of	O
Tau	O
protein	O
levels	O
,	O
and	O
prevention	O
and/or	O
treatment	O
of	O
diseases	O
or	O
disorders	O
associated	O
with	O
Tau	O
protein	O
(	O
Tauophathies	O
)	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
using	O
a	O
curcuminoid	B
and	O
a	O
mammalian	O
target	O
of	O
rapamycin	B
(	O
mTOR	O
)	O
inhibitor	O
,	O
are	O
described	O
.	O

Combinations	O
of	O
curcuminoids	B
and	O
mtor	O
inhibitors	O
for	O
the	O
treatment	O
of	O
tauopathies	O

The	O
invention	O
relates	O
to	O
17-hydroxy-17-pentafluorethyl	B
-	I
estra-4,9	I
(	I
10	I
)	I
-dien-11-ethyinylphenyl	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
and	O
X	O
are	O
defined	O
as	O
in	O
the	O
claims	O
and	O
in	O
the	O
description	O
,	O
to	O
a	O
method	O
for	O
the	O
production	O
thereof	O
and	O
to	O
the	O
use	O
thereof	O
as	O
medicaments	O
.	O

17-hydroxy-17-pentafluorethyl	B
-	I
estra-4,9	I
(	I
10	I
)	I
-dien-11-ethinylphenyl	I
derivatives	O
,	O
methods	O
for	O
the	O
production	O
thereof	O
and	O
use	O
thereof	O
for	O
treating	O
diseases	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
tautomers	O
and	O
salts	O
thereof	O
wherein	O
R1	O
is	O
methyl	B
or	O
ethyl	B
,	O
R2	O
is	O
n	B
-	I
butyl	I
or	O
o	B
-	I
methoxyphenyl	I
,	O
R3	O
is	O
hydrogen	B
or	O
hydroxy	B
;	O
and	O
R4	O
is	O
hydrogen	B
or	O
methyl	B
.	O

These	O
compounds	O
are	O
receptor	O
tyrosine	B
kinase	O
EphB4	O
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
angiogenesis	O
dependent	O
cancers	O
and	O
intraocular	O
neovascular	O
syndromes	O
.	O

New	O
anti	O
-	O
angiogenic	O
compounds	O

Disclosed	O
is	O
a	O
therapeutic	O
pharmaceutical	O
composition	O
comprising	O
a	O
thrombolytic	O
agent	O
and	O
an	O
inhibitor	O
capable	O
of	O
inhibiting	O
a	O
signaling	O
that	O
is	O
mediated	O
by	O
a	O
receptor	O
of	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

The	O
therapeutic	O
pharmaceutical	O
composition	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
severe	O
ischemic	O
events	O
including	O
cerebral	O
infarction	O
,	O
cardiac	O
infarction	O
and	O
pulmonary	O
embolism	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
of	O
ischemic	O
events	O

The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
obesity	O
or	O
disorders	O
related	O
to	O
diabetes	O
or	O
obesity	O
.	O

The	O
compositions	O
comprise	O
a	O
combination	O
of	O
a	O
selective	O
PPARγ	O
modulator	O
and	O
an	O
incretin	O
.	O

The	O
methods	O
include	O
the	O
administration	O
of	O
the	O
combination	O
of	O
a	O
selective	O
PPARγ	O
modulator	O
and	O
an	O
incretin	O
.	O

Combination	O
of	O
a	O
selective	O
ppar	O
-	O
gamma	O
modulator	O
and	O
an	O
incretin	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
obesity	O

Compositions	O
comprising	O
compounds	O
of	O
Formula	O
IA	O
and	O
IB	O
and	O
cancer	O
therapeutics	O
are	O
provided	O
.	O

Uses	O
of	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
provided	O
for	O
the	O
modulation	O
of	O
autophagy	O
.	O

In	O
particular	O
,	O
compounds	O
and	O
compositions	O
may	O
be	O
for	O
use	O
in	O
early	O
stage	O
autophagy	O
inhibition	O
and	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

Furthermore	O
,	O
the	O
treatment	O
may	O
be	O
in	O
combination	O
with	O
a	O
cancer	O
therapeutics	O
agent	O
.	O

Autophagy	O
inhibitor	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
the	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
cancer	O

The	O
invention	O
provides	O
,	O
in	O
part	O
,	O
polyhydroxylated	O
bile	O
acids	O
for	O
treating	O
biliary	O
disorders	O
,	O
for	O
example	O
,	O
biliary	O
disorders	O
arising	O
out	O
of	O
cholestasis	O
or	O
portal	O
hypertesion	O
.	O

The	O
invention	O
also	O
provides	O
,	O
in	O
part	O
,	O
polyhydroxylated	O
bile	O
acids	O
for	O
stimulating	O
bile	O
flow	O
.	O

New	O
compounds	O
2α,3α,7α,12α	B
-	I
tetrahydroxy-5β	I
-	I
cholanoic	I
acid	I
and	I
3α,4α,7α,12α	I
-	I
tetrahydroxy-5β	I
-	I
cholanoic	I
acid	I
are	O
disclosed	O
,	O
uses	O
thereof	O
and	O
synthesis	O
thereof	O
.	O

Polyhydroxylated	O
bile	O
acids	O
for	O
treatment	O
of	O
biliary	O
disorders	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
are	O
described	O
.	O

Processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
their	O
use	O
as	O
medicaments	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O
are	O
also	O
described	O
.	O

Heterocyclic	B
urea	I
derivatives	O
useful	O
for	O
treatment	O
of	O
bacterial	O
infection	O

Processes	O
for	O
preparing	O
sitagliptin	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
and	O
process	O
intermediates	O
.	O

Preparation	O
of	O
sitagliptin	O
and	O
salts	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
polymorphic	O
Forms	O
B	O
and	O
P	O
of	O
atazanavir	B
sulfate	I
and	O
methods	O
for	O
their	O
preparation	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
towards	O
pharmaceutical	O
compositions	O
comprising	O
the	O
novel	O
polymorphs	O
of	O
atazanavir	B
sulfate	I
and	O
methods	O
of	O
treating	O
HIV	O
infection	O
by	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
polymorphic	O
Forms	O
B	O
and	O
P	O
of	O
atazanavir	B
sulfate	I
.	O

The	O
present	O
invention	O
also	O
describes	O
process	O
for	O
preparation	O
of	O
amorphous	O
atazanavir	B
sulfate	I
.	O

Polymorphic	O
forms	O
of	O
atazanavir	B
sulfate	I

The	O
present	O
invention	O
relates	O
to	O
combined	O
compositions	O
comprising	O
a	O
combination	O
of	O
at	O
least	O
one	O
natural	O
or	O
synthetic	O
beta	O
-	O
glycolipid	O
and	O
at	O
least	O
one	O
tocopherol	B
(	O
vitamin	B
E	I
)	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
and	O
kits	O
using	O
said	O
combined	O
compositions	O
for	O
treating	O
and	O
preventing	O
hepatic	O
disorders	O
,	O
specifically	O
,	O
liver	O
insult	O
cause	O
by	O
hepatotoxic	O
drugs	O
or	O
caused	O
by	O
any	O
one	O
of	O
infectious	O
,	O
metabolic	O
,	O
toxic	O
,	O
immune	O
,	O
or	O
perfusion	O
or	O
blood	O
flow	O
related	O
hepatic	O
injury	O
.	O

Combination	O
of	O
vitamin	B
e	I
and	O
beta	O
-	O
glycosphingolipids	O
in	O
compositions	O
and	O
methods	O
for	O
preventing	O
and	O
treating	O
hepatic	O
disorders	O

Disclosed	O
are	O
a	O
diamide	B
-	I
phenyl	I
derivative	O
which	O
inhibits	O
soluble	O
epoxy	B
hydrolase	O
(	O
sEH	O
)	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
diamide	B
-	I
phenyl	I
derivative	O
.	O

Specifically	O
disclosed	O
are	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O

(	O
In	O
the	O
formula	O
,	O
A	O
represents	O
a	O
group	O
represented	O
by	O
formula	O
(	O
a	O
)	O
(	O
wherein	O
Ra1	O
,	O
Ra2	O
and	O
Ra3	O
each	O
independently	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
R1	O
represents	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
(	O
which	O
is	O
substituted	O
by	O
a	O
C1	B
-	I
4	I
alkoxy	I
group	O
(	O
which	O
may	O
be	O
substituted	O
by	O
a	O
C1	B
-	I
4	I
alkoxy	I
group	O
)	O
,	O
a	O
C1	B
-	I
4	I
alkylsulfonyl	I
group	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
and	O
R2	O
represents	O
an	O
optionally	O
substituted	O
C1	B
-	I
6	I
alkyl	I
group	O
or	O
an	O
optionally	O
substituted	O
C3	B
-	I
6	I
cycloalkyl	I
group	O
.	O
)	O

Diamide	B
-	I
phenyl	I
derivative	O
and	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O

Alternative	O
forms	O
of	O
Compound	O
I	O
,	O
processes	O
to	O
reproducibly	O
make	O
them	O
and	O
methods	O
of	O
treating	O
patients	O
using	O
them	O
.	O

Novel	O
forms	O
of	O
a	O
multicyclic	O
compound	O

Fused	B
heteroaryl	I
compounds	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
defined	O
as	O
in	O
the	O
description	O
are	O
disclosed	O
.	O

The	O
method	O
for	O
preparing	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
as	O
phosphoinositide	O
3-kinase	O
(	O
PI3	O
K	O
)	O
inhibitors	O
and	O
anticancer	O
agents	O
are	O
also	O
disclosed	O
.	O

Fused	B
heteroaryl	I
compounds	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

Novel	O
substituted	O
carbonyl	B
compounds	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
salts	O
thereof	O
,	O
which	O
exhibit	O
excellent	O
bronchodilating	O
effect	O
that	O
relies	O
on	O
potent	O
EP2	O
agonist	O
activity	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
.	O

In	O
general	O
formula	O
(	O
I	O
)	O
,	O
R1	O
is	O
-OR5	B
,	O
-O	B
(	I
CH2CH2O	I
)	I
mR6	I
or	O
-NR7R8	B
(	O
wherein	O
R5	O
is	O
C7	B
-	I
22	I
alkyl	I
or	O
the	O
like	O
;	O
R6	O
is	O
H	B
or	O
benzyl	B
;	O
m	O
is	O
1	O
to	O
4	O
;	O
and	O
R7	O
and	O
R8	O
are	O
each	O
H	B
,	O
C1	B
-	I
12	I
alkyl	I
,	O
or	O
the	O
like	O
)	O
;	O
R2	O
and	O
R3	O
are	O
each	O
H	B
or	O
C1	B
-	I
6	I
alkyl	I
;	O
Y	O
is	O
a	O
(	O
substituted	O
)	O
bicyclic	B
heteroaromatic	I
ring	O
,	O
-Q1-Q2	O
,	O
or	O
the	O
like	O
(	O
wherein	O
Q1	O
is	O
arylene	B
or	O
the	O
like	O
;	O
and	O
Q2	O
is	O
a	O
(	O
substituted	O
)	O
5-	O
or	O
6-memebred	O
heterocycle	B
,	O
or	O
the	O
like	O
)	O
;	O
and	O
Z	O
is	O
(	O
substituted	O
)	O
aryl	B
or	O
a	O
(	O
substituted	O
)	O
5-	O
or	O
6-memeberd	O
heteroaromatic	B
ring	O
.	O

Substituted	O
carbonyl	B
compounds	O

Disclosed	O
are	O
methods	O
and	O
compositions	O
for	O
treating	O
gliomas	O
that	O
involve	O
quinacrine	B
and	O
other	O
acridine	B
analogs	O
.	O

Acridine	B
analogs	O
in	O
the	O
treatment	O
of	O
gliomas	O

A	O
phosphoproteomic	O
method	O
termed	O
SH2	B
profiling	O
to	O
characterize	O
phosphotyrosine	B
(	O
pTyr	O
)	O
signaling	O
in	O
lung	O
cancer	O
.	O

This	O
method	O
provides	O
quantitative	O
values	O
for	O
the	O
phosphorylated	O
binding	O
sites	O
for	O
Src	O
Homology	O
2	O
(	O
SH2	B
)	O
domains	O
,	O
which	O
the	O
cell	O
uses	O
to	O
relay	O
signals	O
from	O
tyrosine	O
kinases	O
.	O

Lung	O
cancer	O
cell	O
lines	O
with	O
known	O
mutational	O
status	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
and	O
Ras	O
were	O
profiled	O
.	O

Changes	O
in	O
SH2	B
domain	O
binding	O
were	O
characterized	O
in	O
response	O
to	O
the	O
EGFR	O
inhibitor	O
erlotinib	B
,	O
and	O
the	O
SRC	O
/	O
multi	O
-	O
kinase	O
inhibitor	O
dasatinib	B
.	O

Cell	O
lines	O
grouped	O
based	O
on	O
SH2	B
binding	O
patterns	O
.	O

Clusters	O
correlated	O
with	O
EGFR	O
mutation	O
status	O
or	O
MET	O
activation	O
.	O

Binding	O
of	O
specific	O
SH2	B
domains	O
correlated	O
with	O
EGFR	O
mutation	O
and	O
erlotinib	O
sensitivity	O
.	O

SH2	B
domain	O
profiling	O
identifies	O
subsets	O
of	O
lung	O
cancer	O
cells	O
with	O
distinct	O
patterns	O
of	O
pTyr	O
signaling	O
and	O
provides	O
a	O
powerful	O
molecular	O
diagnostic	O
tool	O
for	O
classification	O
and	O
biomarker	O
identification	O
.	O

This	O
analysis	O
has	O
therapeutic	O
importance	O
for	O
personalized	O
use	O
of	O
tyrosine	B
kinase	O
inhibitors	O
in	O
cancer	O
.	O

Sh2	O
domain	O
profiling	O
to	O
characterize	O
tyrosine	B
phosphorylation	O
signaling	O
in	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
a	O
quinolone	B
antibiotic	O
compound	O
of	O
formula	O
(	O
1	O
)	O
capable	O
of	O
promoting	O
the	O
production	O
of	O
G	O
-	O
CSF	O
in	O
the	O
body	O
,	O
and	O
the	O
medicament	O
for	O
treatment	O
of	O
neutropenia	O
and	O
early	O
recovery	O
of	O
immunocytes	O
,	O
comprising	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
.	O

Use	O
of	O
a	O
quinolone	B
derivative	O
containing	O
7-	B
(	I
4-aminomethyl-3-oxime	I
)	I
pyrrolidine	I
group	O
that	O
is	O
capable	O
of	O
inducing	O
granulocyte	O
colony	O
stimulating	O
factor	O
for	O
treatment	O
of	O
neutropenia	O
and	O
recovery	O
of	O
hematopoiesis	O

The	O
present	O
invention	O
discloses	O
the	O
uses	O
of	O
CRISPLD2	O
protein	O
and	O
agonists	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
septicemia	O
and	O
septic	O
shock	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
and	O
pharmaceutical	O
compositions	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
septicemia	O
and	O
septic	O
shock	O
,	O
and	O
kits	O
for	O
the	O
prediction	O
of	O
susceptibility	O
to	O
septicemia	O
and	O
septic	O
shock	O
.	O

Methods	O
and	O
kits	O
for	O
the	O
prediction	O
,	O
prevention	O
and	O
treatment	O
of	O
septicemia	O
and	O
septic	O
shock	O

Provided	O
are	O
compositions	O
and	O
uses	O
of	O
the	O
benzimidazole	B
pyridyl	I
ether	I
{	I
1-methyl-5-	I
[	I
2-	I
(	I
5-tri	I
-	I
fluoromethyl-1H	I
-	I
imidazol-2-yl	I
)	I
-pyridin-4-yloxy	I
]	I
-1H	I
-	I
benzoimidazol-2-yl	I
}	I
-	I
(	I
4-trifluoromethylphenyl	I
)	I
-amine	I
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
in	O
combination	O
with	O
an	O
activator	O
of	O
AMPK	O
(	O
AMP	O
-	O
activated	O
protein	O
kinase	O
)	O
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
.	O

Combination	O
of	O
raf-265	O
and	O
an	O
activator	O
of	O
ampk	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
using	O
RNA	O
-	O
binding	O
protein	O
modulating	O
agents	O
to	O
treat	O
of	O
cancer	O
,	O
particularly	O
patients	O
that	O
are	O
susceptible	O
to	O
or	O
diagnosed	O
with	O
estrogen	B
receptor	O
-	O
negative	O
breast	O
cancer	O
,	O
such	O
as	O
methods	O
of	O
inhibiting	O
the	O
growth	O
or	O
metastasis	O
of	O
cancer	O
cells	O
comprising	O
contacting	O
cells	O
with	O
a	O
therapeutically	O
-	O
effective	O
amount	O
of	O
an	O
HuR	O
-	O
modulating	O
agent	O
.	O

The	O
invention	O
also	O
relates	O
to	O
compositions	O
comprising	O
therapeutically	O
-	O
effective	O
amounts	O
of	O
an	O
HuR	O
-	O
modulating	O
agent	O
.	O

Modulating	O
levels	O
of	O
rna	O
-	O
binding	O
proteins	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O

Disclosed	O
are	O
:	O
an	O
antisense	O
nucleotide	O
which	O
contains	O
a	O
sequence	O
complementary	O
to	O
IFN	O
-	O
α	O
mRNA	O
,	O
especially	O
a	O
sequence	O
complementary	O
to	O
a	O
base	O
sequence	O
in	O
the	O
SL1	O
and/or	O
SL2	O
region	O
of	O
IFN	O
-	O
α	O
mRNA	O
,	O
and	O
which	O
is	O
capable	O
of	O
enhancing	O
the	O
expression	O
of	O
IFN	O
-	O
α	O
;	O
an	O
IFN	O
-	O
α	O
expression	O
enhancer	O
and	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
viral	O
infectious	O
diseases	O
or	O
cancer	O
,	O
each	O
containing	O
the	O
antisense	O
nucleotide	O
;	O
a	O
sense	O
oligonucleotide	O
which	O
contains	O
a	O
sequence	O
complementary	O
to	O
endogenous	O
asRNA	O
for	O
IFN	O
-	O
α	O
mRNA	O
,	O
especially	O
a	O
sequence	O
homologous	O
to	O
a	O
base	O
sequence	O
in	O
the	O
SL1	O
or	O
SL2	O
region	O
of	O
IFN	O
-	O
α	O
mRNA	O
,	O
and	O
which	O
is	O
capable	O
of	O
modulating	O
the	O
expression	O
of	O
IFN	O
-	O
α	O
;	O
and	O
an	O
IFN	O
-	O
α	O
expression	O
modulator	O
which	O
contains	O
the	O
sense	O
oligonucleotide	O
.	O

INTERFERON	O
-	O
α	O
MODULATOR	O

Small	O
tablets	O
for	O
use	O
in	O
procedural	O
sedation	O
,	O
anxiolysis	O
and	O
analgesia	O
comprising	O
the	O
combination	O
sufentanil	B
and	O
triazolam	B
administered	O
via	O
the	O
oral	O
transmucosal	O
route	O
and	O
methods	O
for	O
using	O
the	O
same	O
are	O
provided	O
.	O

Compositions	O
and	O
methods	O
for	O
mild	O
sedation	O
,	O
anxiolysis	O
and	O
analgesia	O
in	O
the	O
procedural	O
setting	O

The	O
present	O
application	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
intermediates	O
useful	O
in	O
the	O
manufacture	O
of	O
oseltamivir	B
and	O
the	O
H3PO4	B
salt	O
of	O
oseltamivir	B
,	O
Tamiflu	B
®	O
.	O

The	O
application	O
further	O
relates	O
to	O
novel	O
intermediate	O
and	O
compounds	O
and	O
oseltamivir	B
analogs	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
said	O
analog	O
compounds	O
.	O

The	O
application	O
further	O
relates	O
to	O
a	O
method	O
of	O
using	O
the	O
novel	O
analogs	O
of	O
oseltamivir	B
to	O
treat	O
or	O
prevent	O
influenza	O
.	O

Process	O
and	O
compounds	O
for	O
the	O
manufacture	O
of	O
oseltamivir	B
and	O
analogs	O
thereof	O
,	O
and	O
new	O
antiviral	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
use	O
of	O
benzo	B
-	I
heterocycle	I
derivatives	O
,	O
and	O
more	O
particularly	O
,	O
to	O
a	O
composition	O
for	O
preventing	O
and	O
treating	O
cancer	O
,	O
comprising	O
benzo	B
-	I
heterocycle	I
derivatives	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
as	O
active	O
ingredients	O
.	O

The	O
inventors	O
of	O
the	O
present	O
invention	O
have	O
found	O
that	O
KRS	O
interacts	O
with	O
67LR	O
to	O
promote	O
the	O
migration	O
of	O
cancer	O
(	O
or	O
tumor	O
)	O
cells	O
and	O
thus	O
affects	O
the	O
metastasis	O
of	O
cancer	O
,	O
and	O
also	O
have	O
identified	O
that	O
the	O
substance	O
which	O
inhibits	O
the	O
interaction	O
between	O
the	O
KRS	O
and	O
67LR	O
suppresses	O
the	O
metastasis	O
of	O
cancer	O
cells	O
,	O
and	O
thus	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
cancer	O
.	O

Accordingly	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
suppresses	O
the	O
metastasis	O
of	O
cancer	O
,	O
and	O
therefore	O
provides	O
a	O
novel	O
means	O
for	O
preventing	O
and	O
treating	O
cancer	O
.	O

Use	O
of	O
benzo	B
-	I
heterocycle	I
derivatives	O
for	O
preventing	O
and	O
treating	O
cancer	O
or	O
for	O
inhibiting	O
cancer	O
metastasis	O

The	O
present	O
invention	O
provides	O
medicaments	O
,	O
their	O
methods	O
of	O
preparation	O
,	O
as	O
well	O
as	O
methods	O
of	O
diagnosis	O
and	O
imaging	O
of	O
mammalian	O
tumors	O
with	O
[	B
131I	I
]	I
-MIBG	I
and/or	O
[	B
123I	I
]	I
-MIBG	I
.	O

A	O
method	O
for	O
treating	O
a	O
mammalian	O
tumor	O
which	O
comprises	O
administering	O
to	O
a	O
mammal	O
having	O
a	O
tumor	O
,	O
a	O
composition	O
comprising	O
a	O
histone	O
deacetylase	O
inhibitor	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	B
,	O
or	O
solvate	O
thereof	O
,	O
in	O
an	O
effective	O
amount	O
for	O
at	O
least	O
about	O
forty	O
-	O
eight	O
hours	O
,	O
and	O
followed	O
by	O
administering	O
to	O
the	O
mammal	O
a	O
composition	O
comprising	O
an	O
effective	O
amount	O
of	O
[	B
131I	I
]	I
-MIBG	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	B
,	O
or	O
solvate	O
thereof	O
is	O
also	O
disclosed	O
.	O

Diagnosis	O
and	O
treatment	O
of	O
cancer	O
using	O
histone	O
deacetylase	O
inhibitors	O
and	O
radiolabeled	O
metaiodobenzylguanidine	B

The	O
present	O
disclosure	O
is	O
directed	O
to	O
a	O
two	O
-	O
part	O
cytocompatible	O
system	O
for	O
preparing	O
a	O
cytocompatible	O
composition	O
for	O
use	O
in	O
repairing	O
tissue	O
of	O
a	O
subject	O
.	O

The	O
system	O
comprises	O
an	O
admixture	O
of	O
a	O
first	O
-	O
part	O
liquid	O
solution	O
of	O
a	O
polysaccharide	O
,	O
such	O
as	O
chitosan	O
and	O
a	O
second	O
-	O
part	O
liquid	O
solution	O
of	O
a	O
salt	O
,	O
such	O
as	O
glycerol	B
phosphate	I
.	O

When	O
the	O
chitosan	O
and	O
glycerol	B
phosphate	I
solutions	O
are	O
combined	O
,	O
a	O
cytocompatible	O
composition	O
is	O
produced	O
which	O
is	O
free	O
of	O
polymer	O
precipitation	O
at	O
room	O
temperature	O
.	O

The	O
composition	O
also	O
promotes	O
non	O
-	O
covalent	O
complex	O
formation	O
between	O
chitosan	O
and	O
therapeutic	O
anionic	O
proteins	O
with	O
a	O
pl	O
<	O
6	O
78	O
.	O

Formulation	O
and	O
method	O
for	O
rapid	O
preparation	O
of	O
isotonic	O
and	O
cytocompatible	O
chitosan	O
solutions	O
without	O
inducing	O
chitosan	O
precipitation	O

The	O
invention	O
relates	O
to	O
novel	O
polymorphs	O
of	O
raltegravir	B
,	O
to	O
a	O
method	O
for	O
the	O
production	O
thereof	O
,	O
and	O
to	O
pharmaceutical	O
formulations	O
comprising	O
the	O
novel	O
polymorphs	O
.	O

Raltegravir	B
polymorphs	O

The	O
invention	O
relates	O
to	O
the	O
composition	O
and	O
use	O
of	O
a	O
medicament	O
comprising	O
a	O
fixed	O
dose	O
combination	O
of	O
droloxifene	O
and	O
clopidogrel	O
.	O

Combination	O
of	O
droloxifene	O
and	O
clopidogrel	O

Provided	O
are	O
compounds	O
having	O
prophylactic	O
and/or	O
therapeutic	O
effect	O
on	O
chronic	O
rheumatoid	O
arthritis	O
,	O
multiple	O
sclerosis	O
,	O
inflammatory	O
bowel	O
diseases	O
such	O
as	O
Crohn	O
diseases	O
and	O
ulcerative	O
colitis	O
,	O
autoimmune	O
diseases	O
typified	O
by	O
psoriasis	O
,	O
rejection	O
of	O
a	O
transplanted	O
organ	O
,	O
allergic	O
diseases	O
and	O
so	O
on	O
;	O
medicinal	O
compositions	O
comprising	O
these	O
compounds	O
;	O
and	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
an	O
autoimmune	O
disease	O
characterized	O
by	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
medicinal	O
composition	O
to	O
a	O
mammal	O
.	O

A	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
of	O
the	O
same	O
.	O

Bicyclic	B
nitrogen	I
-	O
containing	O
saturated	O
heterocyclic	B
derivatives	O

The	O
present	O
invention	O
provides	O
a	O
diagnostic	O
kit	O
of	O
molecular	O
markers	O
in	O
blood	O
for	O
diagnosing	O
colorectal	O
cancer	O
,	O
and/or	O
monitoring	O
the	O
therapeutic	O
effect	O
for	O
treating	O
colorectal	O
cancer	O
.	O

The	O
kit	O
comprises	O
a	O
plurality	O
of	O
nucleic	O
acid	O
molecules	O
,	O
and	O
each	O
nucleic	O
acid	O
molecule	O
encodes	O
a	O
microRNA	O
biomarker	O
,	O
wherein	O
one	O
or	O
more	O
of	O
the	O
plurality	O
of	O
nucleic	O
acid	O
molecules	O
are	O
differentially	O
expressed	O
in	O
plasma	O
of	O
patient	O
and	O
healthy	O
control	O
,	O
and	O
wherein	O
the	O
one	O
or	O
more	O
differentially	O
expressed	O
nucleic	O
acid	O
molecules	O
together	O
represent	O
a	O
nucleic	O
acid	O
expression	O
biomarker	O
that	O
is	O
indicative	O
for	O
the	O
presence	O
of	O
colorectal	O
cancer	O
.	O

The	O
invention	O
further	O
provides	O
corresponding	O
methods	O
using	O
such	O
nucleic	O
acid	O
expression	O
biomarkers	O
for	O
identifying	O
colorectal	O
cancer	O
as	O
well	O
as	O
for	O
preventing	O
or	O
treating	O
such	O
a	O
condition	O
.	O

Finally	O
,	O
the	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
colorectal	O
cancer	O
.	O

Plasma	O
-	O
based	O
micro	O
-	O
rna	O
biomarkers	O
and	O
methods	O
for	O
early	O
detection	O
of	O
colorectal	O
cancer	O

The	O
invention	O
relates	O
to	O
pyrrolopyridinyl	B
-	I
pyrimidin-2-ylamine	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
-	O
R6	O
and	O
R1	O
have	O
the	O
meanings	O
given	O
in	O
claim	O
1	O
,	O
and	O
are	O
cell	O
proliferation	O
/	O
cell	O
vitality	O
inhibitors	O
and	O
can	O
be	O
employed	O
for	O
the	O
treatment	O
of	O
tumours	O
.	O

Pyrrolopyridinyl	B
-	I
pyrimidin-2-ylamine	I
derivatives	O

Aminoalkyipyrimidine	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
meaning	O
of	O
the	O
different	O
substituents	O
are	O
those	O
indicated	O
in	O
the	O
description	O
.	O

These	O
compounds	O
are	O
useful	O
as	O
histamine	B
H4	O
receptor	O
antagonists	O
.	O

Aminoalkylpyrimidine	B
derivatives	O
as	O
histamine	B
h4	O
receptor	O
antagonists	O

Disclosed	O
is	O
a	O
novel	O
compound	O
which	O
has	O
excellent	O
IκB	O
kinase	O
inhibitory	O
activity	O
and	O
TNFα	O
production	O
inhibitory	O
activity	O
,	O
and	O
is	O
used	O
as	O
an	O
active	O
ingredient	O
for	O
an	O
agent	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
associated	O
with	O
NF	O
-	O
κB	O
and	O
TNFα	O
.	O

Specifically	O
disclosed	O
is	O
a	O
novel	O
dihydrothieno	B
[	I
2,3-e	I
]	I
indazole	I
compound	O
represented	O
by	O
formula	O
(	O
1	O
)	O
.	O

Also	O
specifically	O
disclosed	O
are	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
dihydrothieno	B
[	I
2,3-e	I
]	I
indazole	I
compound	O
,	O
and	O
use	O
of	O
the	O
dihydrothieno	B
[	I
2,3-e	I
]	I
indazole	I
compound	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
.	O

Dihydrothieno	B
[	I
2,3-e	I
]	I
indazole	I
compound	O

The	O
present	O
invention	O
relates	O
herein	O
to	O
compounds	O
and	O
compositions	O
for	O
the	O
treatment	O
and	O
amelioration	O
of	O
inflammatory	O
disease	O
.	O

Specifically	O
the	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
having	O
a	O
tryptase	O
inhibition	O
activity	O
and	O
the	O
intermediates	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
a	O
method	O
of	O
treating	O
subjects	O
suffering	O
from	O
a	O
condition	O
disease	O
or	O
disorder	O
that	O
can	O
be	O
ameliorated	O
by	O
the	O
administration	O
of	O
an	O
inhibitor	O
of	O
tryptase	O
including	O
but	O
not	O
limited	O
to	O
for	O
example	O
asthma	O
and	O
other	O
inflammatory	O
diseases	O
including	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

[	B
4	I
[	I
4-	I
(	I
5-aminomethyl-2-fluoro	I
-	I
phenyl	I
)	I
-piperidin-1-yl	I
]	I
-	I
(	I
1h	I
-	I
pyrrolo	I
-	I
pyridin	I
-	I
yl	I
)	I
-methanones	I
and	O
synthesis	O
thereof	O

The	O
instant	O
invention	O
relates	O
to	O
new	O
chemical	O
entities	O
which	O
comprise	O
corticosteroids	B
,	O
phosphorylated	O
β	O
-	O
agonists	O
and	O
muscarinic	O
(	O
M3	O
)	O
antagonists	O
for	O
use	O
in	O
therapy	O
and	O
compositions	O
comprising	O
and	O
processes	O
for	O
preparing	O
the	O
same	O
.	O

Corticosteroid	B
-	O
beta	O
-	O
agonist	O
-	O
muscarinic	O
antagonist	O
compounds	O
for	O
use	O
in	O
therapy	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
where	O
A	O
,	O
Cy	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
NURR-1	O
nuclear	O
receptor	O
modulators	O
.	O

Novel	O
benzoic	B
pyrrolopyridine	I
derivatives	O

Methods	O
and	O
materials	O
useful	O
for	O
applying	O
moxifloxacin	B
to	O
the	O
ear	O
are	O
described	O
.	O

The	O
methods	O
involve	O
delivering	O
a	O
composition	O
that	O
contains	O
at	O
least	O
one	O
viscogenic	O
agent	O
and	O
moxifloxacin	B
or	O
a	O
salt	O
thereof	O
to	O
the	O
epidermal	O
surface	O
of	O
the	O
tympanic	O
membrane	O
via	O
the	O
ear	O
canal	O
.	O

The	O
composition	O
is	O
delivered	O
to	O
the	O
tympanic	O
membrane	O
in	O
a	O
flowable	O
form	O
and	O
,	O
after	O
delivery	O
to	O
the	O
tympanic	O
membrane	O
,	O
becomes	O
sufficiently	O
viscous	O
such	O
that	O
the	O
moxifloxacin	B
is	O
localized	O
against	O
the	O
tympanic	O
membrane	O
.	O

Such	O
compositions	O
can	O
be	O
used	O
to	O
prophylactically	O
and/or	O
therapeutically	O
treat	O
middle	O
and	O
inner	O
ear	O
conditions	O
,	O
including	O
otitis	O
media	O
.	O

Methods	O
and	O
compositions	O
for	O
applying	O
moxifloxacin	B
to	O
the	O
ear	O

The	O
present	O
disclosure	O
relates	O
to	O
methods	O
of	O
using	O
fatty	O
acid	O
amide	O
hydrolase	O
(	O
FAAH	O
)	O
inhibitors	O
to	O
treat	O
aspects	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
restless	O
legs	O
syndrome	O
(	O
RLS	O
)	O
and	O
periodic	O
limb	O
movement	O
disorder	O
(	O
PLMD	O
)	O
,	O
the	O
use	O
of	O
FAAH	O
inhibitors	O
for	O
the	O
manufacture	O
of	O
medicaments	O
for	O
use	O
in	O
the	O
treatment	O
of	O
PD	O
,	O
RLS	O
and	O
PLMD	O
,	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
compositions	O
comprising	O
FAAH	O
inhibitors	O
for	O
use	O
in	O
the	O
treatment	O
of	O
PD	O
,	O
RLS	O
and	O
PLMD	O
.	O

Use	O
of	O
faah	O
inhibitors	O
for	O
treating	O
parkinson	O
's	O
disease	O
and	O
restless	O
legs	O
syndrome	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
and	O
wound	O
dressing	O
for	O
delivering	O
a	O
composition	O
comprising	O
povidone	B
-	I
iodine	I
and	O
sucrose	B
mixture	O
.	O

The	O
composition	O
is	O
gelled	O
and	O
,	O
in	O
one	O
embodiment	O
,	O
is	O
impregnated	O
on	O
a	O
gauze	O
or	O
other	O
like	O
material	O
for	O
application	O
to	O
an	O
exuding	O
or	O
non	O
-	O
exuding	O
wound	O
.	O

Povidone	B
-	I
iodine	I
and	O
sucrose	B
wound	O
healing	O
dressing	O

The	O
invention	O
relates	O
to	O
novel	O
chromium	B
-	I
carbonyl	I
complexes	O
and	O
a	O
method	O
for	O
the	O
preparation	O
of	O
the	O
latter	O
as	O
well	O
as	O
use	O
of	O
the	O
inventive	O
chromium	B
-	I
carbonyl	I
complexes	O
to	O
inhibit	O
NOD1	O
and/or	O
NOD2	O
in	O
the	O
immune	O
system	O
of	O
vertebrates	O
.	O

In	O
a	O
further	O
aspect	O
,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
inventive	O
chromium	B
-	I
carbonyl	I
complexes	O
as	O
pharmaceutical	O
active	O
ingredients	O
in	O
a	O
pharmaceutical	O
composition	O
.	O

Arene	B
chromium	I
-	I
carbonyl	I
complexes	O
,	O
a	O
method	O
for	O
the	O
preparation	O
of	O
and	O
us	O
of	O
as	O
pharmaceutical	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
ciprofloxacin	B
or	O
salts	O
of	O
thereof	O
and	O
amoxycillin	B
or	O
salts	O
of	O
thereof	O
and	O
other	O
pharmaceutical	O
excipients	O
.	O

The	O
present	O
invention	O
provides	O
more	O
reliable	O
effect	O
against	O
all	O
bacteria	O
,	O
including	O
the	O
most	O
commonly	O
causative	O
streptococci	O
,	O
responsible	O
for	O
especially	O
respiratory	O
tract	O
infections	O
.	O

The	O
invention	O
makes	O
up	O
for	O
the	O
weakness	O
of	O
ciprofloxacin	B
against	O
streptococci	O
.	O

A	O
pharmaceutical	O
composition	O
for	O
treatment	O
of	O
respiratory	O
tract	O
infections	O

A	O
process	O
for	O
the	O
preparation	O
of	O
a	O
granular	O
oral	O
complex	O
comprising	O
the	O
steps	O
of	O
mixing	O
5	O
to	O
10	O
%	O
polyvinylpyrrolidone	B
iodine	I
powder	O
,	O
a	O
soluble	O
diluent	O
with	O
20	O
to	O
25	O
%	O
effervescent	O
agent	O
and	O
17	O
to	O
25	O
%	O
acidifying	O
agent	O
having	O
moisture	O
content	O
less	O
then	O
0.2	O
%	O
w	O
/	O
w	O
and	O
particle	O
size	O
less	O
then	O
250	O
micron	O
;	O
granulating	O
the	O
above	O
mixture	O
with	O
80	O
%	O
isopropyl	B
alcohol	I
;	O
granulating	O
with	O
1:1	O
hydro	O
alcoholic	O
solution	O
;	O
drying	O
the	O
granules	O
obtained	O
at	O
a	O
temperature	O
not	O
exceeding	O
40	O
°	O
C	O
;	O
and	O
micronizing	O
the	O
granules	O
to	O
size	O
less	O
than	O
175	O
micron	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
a	O
granular	O
oral	O
composition	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
cinchonine	B
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
and	O
treating	O
obesity	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
,	O
or	O
insulin	O
resistance	O
syndrome	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
containing	O
cinchonine	B
as	O
an	O
active	O
ingredient	O
may	O
inhibit	O
the	O
differentiation	O
of	O
fat	O
cells	O
,	O
reduce	O
body	O
fat	O
mass	O
,	O
reduce	O
visceral	O
fat	O
,	O
reduce	O
a	O
total	O
cholesterol	B
concentration	O
,	O
reduce	O
plasma	O
triglyceride	O
and	O
liver	O
triglyceride	B
,	O
normalize	O
liver	O
function	O
marker	O
enzyme	O
expression	O
,	O
and	O
eventually	O
promote	O
the	O
prevention	O
or	O
treatment	O
of	O
obesity	O
,	O
dyslipidemia	O
,	O
or	O
fatty	O
liver	O
.	O

In	O
addition	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
may	O
induce	O
a	O
significant	O
reduction	O
in	O
the	O
fasting	O
blood	O
sugar	B
level	O
and	O
blood	O
insulin	O
concentration	O
level	O
resulting	O
in	O
the	O
effect	O
of	O
improving	O
type	O
2	O
diabetes	O
or	O
insulin	O
resistance	O
,	O
in	O
addition	O
to	O
the	O
metabolic	O
diseases	O
closely	O
related	O
thereto	O
.	O

Composition	O
containing	O
cinchonine	B
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
and	O
treating	O
obesity	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
,	O
or	O
insulin	O
resistance	O
syndrome	O

There	O
are	O
described	O
4-difluoromethoxyphenyl	B
pyrazolo	I
[	I
5.1-b	I
]	I
oxazole	I
derivatives	O
useful	O
as	O
corticotropin	O
releasing	O
factor	O
(	O
CRF1	O
)	O
receptor	O
antagonists	O
.	O

Pyrazolo	B
[	I
5,1b	I
]	I
oxazole	I
derivatives	O
as	O
crf-1	O
receptor	O
antagonists	O

This	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
inhibitors	O
of	O
S100	O
protein	O
binding	O
interactions	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
annexin	O
A2-S100A10	O
protein	O
binding	O
interaction	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
concerns	O
certain	O
substituted	O
pyrrole	B
derivatives	O
of	O
the	O
general	O
formula	O
I	O
or	O
II	O
as	O
defined	O
herein	O
,	O
as	O
well	O
as	O
processes	O
for	O
preparing	O
these	O
derivatives	O
,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
derivatives	O
and	O
their	O
use	O
in	O
the	O
treatment	O
,	O
prevention	O
or	O
delay	O
of	O
progression	O
of	O
diseases	O
in	O
which	O
S100	O
protein	O
binding	O
interactions	O
are	O
implicated	O
(	O
such	O
as	O
cancer	O
)	O
.	O

S100	O
protein	O
binding	O
interaction	O
inhibitors	O

Disclosed	O
is	O
a	O
therapeutic	O
agent	O
for	O
Crohn	O
's	O
disease	O
which	O
is	O
a	O
disease	O
of	O
unknown	O
cause	O
and	O
has	O
no	O
radical	O
therapeutic	O
agent	O
.	O

Specifically	O
disclosed	O
is	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
Crohn	O
's	O
disease	O
,	O
which	O
comprises	O
an	O
organic	O
acid	O
polymer	O
represented	O
by	O
the	O
following	O
formula	O
:	O
[	B
(	I
O1	I
/	I
2	I
)	I
3Ge	I
-	I
A	I
-	I
CO2H	I
]	I
n	I
(	O
wherein	O
n	O
represents	O
a	O
numeral	O
value	O
of	O
100	O
to	O
1000	O
;	O
and	O
A	O
represents	O
a	O
lower	O
alkyl	B
group	O
)	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
organic	O
acid	O
polymer	O
is	O
preferably	O
one	O
in	O
which	O
A	O
in	O
the	O
formula	O
is	O
a	O
lower	O
alkyl	B
group	O
having	O
1	O
to	O
3	O
carbon	B
atoms	O
and	O
which	O
has	O
a	O
polymerization	O
degree	O
(	O
n	O
)	O
of	O
200	O
to	O
900	O
.	O

The	O
organic	O
acid	O
polymer	O
is	O
effective	O
as	O
a	O
therapeutic	O
agent	O
for	O
Crohn	O
's	O
disease	O
.	O

Prophylactic	O
or	O
therapeutic	O
agent	O
for	O
crohn	O
's	O
disease	O
comprising	O
organic	O
acid	O
polymer	O
as	O
active	O
ingredient	O

An	O
ultrasound	O
-	O
mediated	O
gene	O
transfer	O
method	O
named	O
Ultrasound	O
Targeted	O
Microbubble	O
Destruction	O
(	O
UTMD	O
)	O
for	O
the	O
delivery	O
of	O
human	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
hVEGF	O
)	O
gene	O
to	O
transplanted	O
islets	O
and	O
the	O
surrounding	O
tissue	O
is	O
described	O
herein	O
.	O

The	O
delivery	O
of	O
hVEGF	O
promotes	O
islet	O
revascularization	O
and	O
survival	O
.	O

The	O
inventors	O
,	O
first	O
transplanted	O
human	O
islets	O
were	O
transplanted	O
into	O
diabetic	O
nude	O
mice	O
liver	O
followed	O
by	O
the	O
induction	O
of	O
non	O
-	O
viral	O
plasmid	O
vectors	O
encoding	O
hVEGF	O
or	O
Green	O
Fluorescent	O
Protein	O
(	O
GFP	O
)	O
gene	O
in	O
the	O
host	O
liver	O
by	O
UTMD	O
.	O

Transplantation	O
without	O
gene	O
delivery	O
was	O
also	O
performed	O
as	O
a	O
control	O
.	O

Blood	O
glucose	B
,	O
serum	O
human	O
insulin	O
,	O
C	O
-	O
peptide	O
levels	O
and	O
the	O
revascularization	O
in	O
graft	O
islets	O
were	O
evaluated	O
.	O

The	O
findings	O
of	O
the	O
method	O
of	O
the	O
present	O
invention	O
indicated	O
that	O
hVEGF	O
gene	O
delivery	O
to	O
host	O
liver	O
using	O
UTMD	O
promoted	O
islet	O
revascularization	O
after	O
islet	O
transplantation	O
and	O
improved	O
the	O
restoration	O
of	O
euglycemia	O
.	O

In	O
-	O
vivo	O
non	O
-	O
viral	O
gene	O
delivery	O
of	O
human	O
vascular	O
endothelial	O
growth	O
factor	O
following	O
islet	O
transplantation	O

The	O
invention	O
relates	O
to	O
a	O
double	O
-	O
stranded	O
ribonucleic	O
acid	O
(	O
ds	O
RNA	O
)	O
for	O
inhibiting	O
the	O
expression	O
of	O
an	O
IKK2	O
gene	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
ds	O
RNA	O
or	O
nucleic	O
acid	O
molecules	O
or	O
vectors	O
encoding	O
the	O
same	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
;	O
methods	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
expression	O
of	O
an	O
IKK2	O
gene	O
using	O
said	O
pharmaceutical	O
composition	O
;	O
and	O
methods	O
for	O
inhibiting	O
the	O
expression	O
of	O
IKK2	O
in	O
a	O
cell	O
.	O

Compositions	O
and	O
methods	O
for	O
inhibiting	O
expression	O
of	O
ikk2	O
genes	O

The	O
present	O
invention	O
relates	O
to	O
an	O
indirubin-3'-oxime	B
derivative	O
as	O
potent	O
cyclin	O
dependent	O
kinase	O
inhibitor	O
with	O
anti	O
-	O
cancer	O
activity	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
relates	O
to	O
an	O
indirubin-3'-oxime	B
derivative	O
as	O
potent	O
cyclin	O
dependent	O
kinase	O
inhibitor	O
having	O
excellent	O
anti	O
-	O
cancer	O
activity	O
against	O
human	O
lung	O
cancer	O
cell	O
,	O
human	O
fibro	O
sarcoma	O
cell	O
,	O
human	O
colon	O
cancer	O
cell	O
,	O
human	O
leukemia	O
cell	O
,	O
human	O
stomach	O
cancer	O
cell	O
,	O
human	O
nasopharyngeal	O
cancer	O
cell	O
and/or	O
human	O
breast	O
cancer	O
cell	O
.	O

Indirubin-3'-oxime	B
derivatives	O
as	O
potent	O
cyclin	O
dependent	O
kinase	O
inhibitors	O

Methods	O
for	O
improving	O
the	O
functionality	O
and/or	O
fertility	O
of	O
sperm	O
,	O
for	O
example	O
,	O
by	O
enhancing	O
motility	O
and	O
extending	O
the	O
lifespan	O
of	O
sperm	O
in	O
the	O
female	O
reproductive	O
tract	O
,	O
by	O
adding	O
PEG	B
to	O
the	O
surface	O
of	O
the	O
sperm	O
are	O
provided	O
.	O

Such	O
methods	O
may	O
be	O
used	O
in	O
artificial	O
insemination	O
to	O
reduce	O
the	O
number	O
of	O
sperm	O
needed	O
for	O
insemination	O
and	O
to	O
improve	O
conception	O
rates	O
.	O

Methods	O
for	O
improving	O
sperm	O
functionality	O

The	O
Stable	O
Pharmaceutical	O
Preparation	O
Containing	O
Clindamycin	B
And	O
Benzoyl	B
Peroxide	I
comprises	O
of	O
Benzoyl	B
peroxide	I
,	O
Clindamycin	B
or	O
its	O
pharmaceutically	O
accepted	O
salts	O
and	O
esters	B
,	O
Cellulose	O
derivative	O
or	O
Cyclic	O
derivative	O
or	O
glycerol	B
derivative	O
and/or	O
combination	O
of	O
them	O
and	O
Effective	O
amounts	O
of	O
excipients	O
like	O
antioxidants	O
,	O
preservatives	O
,	O
pH	O
modifiers	O
,	O
suspending	O
agents	O
and	O
pharmaceutical	O
acceptable	O
barrier	O
by	O
which	O
the	O
compositions	O
of	O
the	O
present	O
invention	O
are	O
maintained	O
at	O
the	O
desired	O
pH	O
,	O
the	O
tendency	O
of	O
benzoyl	B
peroxide	I
to	O
oxidize	O
and	O
degrade	O
Clindamycin	B
can	O
be	O
largely	O
overcome	O
with	O
,	O
and	O
the	O
product	O
,	O
during	O
storage	O
at	O
room	O
temperature	O
,	O
remains	O
stable	O
for	O
extended	O
periods	O
and	O
when	O
maintained	O
at	O
temperature	O
between	O
2	O
to	O
8	O
degree	O
C	O
,	O
remains	O
stable	O
for	O
at	O
least	O
24	O
months	O
.	O

Stable	O
pharmaceutical	O
preparations	O
containing	O
clindamycin	B
and	O
benzoyl	B
peroxide	I
and	O
method	O
thereof	O

Taxane	B
pro	O
-	O
emulsion	O
formulations	O
are	O
provided	O
.	O

Pro	O
-	O
emulsion	O
formulations	O
are	O
dried	O
powders	O
that	O
include	O
a	O
taxane	B
,	O
oil	O
,	O
surfactant	O
and	O
sugar	B
alcohol	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
making	O
and	O
using	O
the	O
pro	O
-	O
emulsion	O
formulations	O
,	O
as	O
well	O
as	O
kits	O
that	O
include	O
the	O
pro	O
-	O
emulsion	O
formulations	O
.	O

Taxane	B
pro	O
-	O
emulsion	O
formulations	O
and	O
methods	O
making	O
and	O
using	O
the	O
same	O

The	O
present	O
invention	O
is	O
directed	O
to	O
an	O
emulsion	O
comprising	O
an	O
emulsifϊer	O
,	O
an	O
isotonic	O
agent	O
and	O
a	O
docosahexaenoic	B
acid	I
ethyl	I
ester	I
(	O
DHA	B
-	I
EE	I
)	O
wherein	O
the	O
emulsion	O
is	O
substantially	O
free	O
of	O
eicosapentaenoic	B
acid	I
(	O
EPA	B
)	O
and	O
is	O
suitable	O
for	O
parenteral	O
administration	O
.	O

Dha	B
ester	I
emulsions	O

A	O
functional	O
molecule	O
involved	O
in	O
the	O
regulation	O
of	O
cancer	O
stem	O
cells	O
is	O
newly	O
identified	O
.	O

Thus	O
,	O
disclosed	O
are	O
:	O
a	O
technique	O
for	O
detecting	O
cancer	O
stem	O
cells	O
accurately	O
;	O
and	O
a	O
technique	O
for	O
inducing	O
the	O
apoptosis	O
of	O
cancer	O
stem	O
cells	O
to	O
completely	O
cure	O
cancer	O
.	O

CD13	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
an	O
active	O
oxygen	B
species	O
removal	O
pathway	O
in	O
a	O
cancer	O
stem	O
cell	O
,	O
and	O
is	O
therefore	O
a	O
molecule	O
essential	O
to	O
the	O
maintenance	O
of	O
cancer	O
stem	O
cells	O
.	O

Therefore	O
,	O
cancer	O
stem	O
cells	O
can	O
be	O
detected	O
accurately	O
using	O
CD13	O
as	O
an	O
indicator	O
.	O

Further	O
,	O
the	O
radical	O
treatment	O
of	O
cancer	O
(	O
particularly	O
liver	O
cancer	O
and	O
gastrointestinal	O
cancer	O
)	O
can	O
be	O
achieved	O
using	O
a	O
CD13	O
inhibitor	O
and	O
an	O
anti	O
-	O
cancer	O
agent	O
or	O
a	O
radiation	O
therapy	O
in	O
combination	O
.	O

Method	O
for	O
detection	O
of	O
cancer	O
stem	O
cell	O
,	O
and	O
therapeutic	O
agent	O
or	O
recurrence	O
-	O
preventing	O
agent	O
for	O
cancer	O

Disclosed	O
is	O
a	O
dried	O
plant	O
tissue	O
or	O
a	O
plant	O
tissue	O
extract	O
having	O
a	O
nonconventional	O
significant	O
ameliorating	O
effect	O
on	O
central	O
nervous	O
system	O
degenerative	O
diseases	O
,	O
particularly	O
Alzheimer	O
's	O
disease	O
and	O
Parkinson	O
's	O
disease	O
.	O

Specifically	O
disclosed	O
are	O
a	O
dried	O
plant	O
tissue	O
and	O
a	O
plant	O
tissue	O
extract	O
each	O
having	O
a	O
nonconventional	O
significant	O
anti	O
-	O
Alzheimer	O
's	O
disease	O
activity	O
and/or	O
a	O
nonconventional	O
significant	O
anti	O
-	O
Parkinson	O
's	O
disease	O
activity	O
.	O

Also	O
disclosed	O
is	O
a	O
pharmaceutical	O
agent	O
and	O
a	O
food	O
or	O
beverage	O
for	O
ameliorating	O
central	O
nervous	O
system	O
degenerative	O
diseases	O
,	O
particularly	O
for	O
enhancing	O
the	O
ability	O
of	O
acquiring	O
,	O
maintaining	O
and	O
recalling	O
memory	O
,	O
which	O
comprises	O
the	O
dried	O
plant	O
tissue	O
or	O
the	O
plant	O
tissue	O
extract	O
.	O

Dried	O
plant	O
tissue	O
and	O
plant	O
tissue	O
extract	O
for	O
ameliorating	O
central	O
nervous	O
system	O
degenerative	O
diseases	O
accompanied	O
by	O
learning	O
/	O
memory	O
disorders	O
,	O
movement	O
disorders	O
and	O
the	O
like	O
,	O
and	O
pharmaceutical	O
agent	O
and	O
food	O
or	O
beverage	O
each	O
comprising	O
the	O
dried	O
plant	O
tissue	O
and	O
the	O
plant	O
tissue	O
extract	O

A	O
treatment	O
for	O
a	O
dermatological	O
allergic	O
condition	O
is	O
disclosed	O
,	O
using	O
a	O
compound	O
:	O
as	O
[	B
4-	I
(	I
5-Aminomethyl-2-fluorophenyl	I
)	I
piperidine-1-yl	I
]	I
[	I
7-fluoro-1-	I
(	I
2-methoxyethyl	I
)	I
-4-trifluoromethoxy-1H	I
-	I
indol-3-yl	I
]	I
methanone	I
.	O

Treatment	O
of	O
dermatological	O
allergic	O
conditions	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
isoquinolones	B
for	O
preparing	O
drugs	O
,	O
including	O
novel	O
isoquinolones	B
.	O

The	O
invention	O
also	O
relates	O
to	O
said	O
novel	O
isoquinolones	B
as	O
well	O
as	O
to	O
the	O
method	O
for	O
synthesising	O
same	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
isoquinolone	B
derivatives	O
used	O
in	O
the	O
treatment	O
of	O
pathological	O
angiogeneses	O
,	O
specifically	O
cancer	O
.	O

Use	O
of	O
isoquinolones	B
for	O
preparing	O
drugs	O
,	O
novel	O
isoquinolones	B
and	O
method	O
for	O
synthesising	O
same	O

Disclosed	O
is	O
a	O
solid	O
pharmaceutical	O
composition	O
which	O
contains	O
(	O
A	O
)	O
a	O
propionic	B
acid	I
or	O
acetic	B
acid	I
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
(	O
B	O
)	O
an	O
aminoalkyl	B
methacrylate	I
copolymer	O
E	O
,	O
and	O
(	O
C	O
)	O
silicon	B
dioxide	I
.	O

The	O
mass	O
ratio	O
of	O
the	O
component	O
(	O
B	O
)	O
relative	O
to	O
the	O
component	O
(	O
A	O
)	O
expressed	O
as	O
(	O
B	O
)	O
/	O
(	O
A	O
)	O
is	O
0.5	O
-	O
2	O
,	O
and	O
the	O
mass	O
ratio	O
of	O
the	O
component	O
(	O
C	O
)	O
relative	O
to	O
the	O
component	O
(	O
A	O
)	O
expressed	O
as	O
(	O
C	O
)	O
/	O
(	O
A	O
)	O
is	O
0.5	O
-	O
2	O
.	O

Solid	O
pharmaceutical	O
composition	O
and	O
pharmaceutical	O
preparation	O

A	O
therapeutic	O
composition	O
having	O
at	O
least	O
one	O
botanical	O
active	O
ingredient	O
,	O
carvone	B
,	O
derived	O
from	O
plants	O
such	O
as	O
mint	O
Mentha	O
sp.	O
,	O
caraway	O
Carum	O
carvi	O
or	O
dill	O
Anethum	O
graveolens	O
.	O

Carvone	B
is	O
capable	O
of	O
anesthetizing	O
teleost	O
,	O
elasmobranch	O
,	O
and	O
agnathan	O
fishes	O
as	O
well	O
as	O
amphibians	O
by	O
contact	O
with	O
skin	O
and/or	O
gills	O
.	O

Carvone	B
has	O
two	O
natural	O
enantiomers	O
;	O
both	O
have	O
anesthetic	O
properties	O
on	O
these	O
fishes	O
and	O
amphibians	O
.	O

Carvone	B
in	O
combinations	O
with	O
other	O
sodium	B
channel	O
blockers	O
such	O
as	O
methyl	B
salicylate	I
have	O
a	O
synergistic	O
effect	O
and	O
are	O
more	O
efficient	O
at	O
anesthetizing	O
teleosts	O
,	O
elasmobranchs	O
and	O
agnathan	O
fishes	O
than	O
carvone	B
alone	O
.	O

This	O
invention	O
has	O
value	O
because	O
it	O
offers	O
an	O
opportunity	O
to	O
forumulate	O
fish	O
anesthetizing	O
drugs	O
with	O
a	O
compound	O
that	O
is	O
also	O
documented	O
to	O
be	O
safe	O
for	O
human	O
consumption	O
.	O

Oil	O
composition	O
containing	O
carvone	B
for	O
use	O
on	O
aquatic	O
creatures	O
and	O
amphibians	O

The	O
disclosure	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
including	O
their	O
salts	O
,	O
as	O
well	O
as	O
compositions	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O

The	O
compounds	O
have	O
activity	O
against	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
and	O
may	O
be	O
useful	O
in	O
treating	O
those	O
infected	O
with	O
HCV	O
.	O

Compounds	O
for	O
the	O
treatment	O
of	O
hepatitis	O
c	O

This	O
invention	O
relates	O
crystalline	O
hydrates	B
of	I
N-	I
[	I
3-fluoro-4-	I
(	I
{	I
6-	I
(	I
methyloxy	I
)	I
-7-	I
[	I
(	I
3-	I
morpholin-4-ylpropyl	I
)	I
oxy	I
]	I
quinolin-4-yl	I
}	I
oxy	I
)	I
phenyl	I
]	I
-N'-	I
(	I
4-fluorophenyl	I
)	I
cyclopropane-1,1-dicarboxamide	I
,	O
Compound	O
(	O
I	O
)	O
.	O

The	O
invention	O
provides	O
methods	O
for	O
treatment	O
of	O
cancer	O
by	O
exploiting	O
the	O
modulation	O
of	O
protein	O
kinase	O
activity	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
containing	O
a	O
crystalline	O
hydrate	O
of	O
Compound	O
(	O
I	O
)	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

Hydrated	O
crystalline	O
forms	O
of	O
n-	B
[	I
3-fluoro-4-	I
(	I
{	I
6-	I
(	I
methyloxy	I
)	I
-7-	I
[	I
(	I
3-morpholin-4-ylpropyl	I
)	I
oxy	I
]	I
-quinolin-4-yl	I
}	I
oxy	I
)	I
phenyl	I
]	I
-n'-	I
(	I
4-fluorophenyl	I
)	I
cyclopropane-1,1-dicarboxamide	I

Shikonin	O
naphthazarin	B
derivatives	O
represented	O
by	O
formula	O
I	O
and	O
their	O
preparation	O
method	O
are	O
disclosed	O
,	O
wherein	O
Ri	O
~	O
R4	O
and	O
R	O
are	O
defined	O
as	O
in	O
the	O
description	O
.	O

The	O
antitumor	O
use	O
of	O
the	O
compounds	O
is	O
also	O
disclosed	O
.	O

Shikonin	O
naphthazarin	B
derivatives	O
,	O
preparation	O
method	O
and	O
antitumor	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
small	O
molecule	O
compounds	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O
,	O
in	O
particular	O
Tuberculosis	O
.	O

Anti	O
-	O
infective	O
compounds	O

The	O
invention	O
relates	O
to	O
nucleic	O
acid	O
molecules	O
and	O
compositions	O
for	O
specific	O
post	O
-	O
transcriptional	O
inhibition	O
of	O
PKM2	O
expression	O
.	O

Methods	O
for	O
specific	O
inhibition	O
of	O
PKM2	O
expression	O
in	O
a	O
target	O
cell	O
,	O
for	O
example	O
a	O
cancer	O
cell	O
,	O
are	O
also	O
provided	O
.	O

Isoform	O
-	O
specific	O
rnai	O
based	O
on	O
codon	O
redundancy	O
/	O
degeneracy	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
general	O
formulae	O
A	O
useful	O
as	O
potential	O
antitumour	O
agents	O
against	O
human	O
cancer	O
cell	O
lines	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
process	O
for	O
the	O
preparation	O
of	O
pyrrolo	B
[	I
2	I
,	I
l	I
-	I
c	I
]	I
[	I
l,4	I
]	I
benzodiazepine	I
hybrids	O
of	O
general	O
formulae	O
6a	O
-	O
g	O
,	O
10a	O
-	O
o	O
,	O
14a	O
-	O
g	O
and	O
18a	O
-	O
o	O
.	O

Carbazole	B
linked	O
pyrrolo	B
[	I
2,1-c	I
]	I
[	I
1,4	I
]	I
benzodiazepine	I
hybrids	O
as	O
potential	O
anticancer	O
agents	O
and	O
process	O
for	O
the	O
preparation	O
thereof	O

Novel	O
compounds	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
thrombosis	O
or	O
a	O
thrombosis	O
-	O
associated	O
disease	O
.	O

Thrombin	O
inhibiting	O
compositions	O

The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
L	B
-	I
oxiracetam	I
in	O
the	O
manufacture	O
of	O
the	O
medicaments	O
for	O
preventing	O
or	O
treating	O
cognitive	O
dysfunction	O
.	O

L	B
-	I
oxiracetam	I
with	O
the	O
purity	O
of	O
more	O
greater	O
than	O
99.3	O
%	O
is	O
used	O
in	O
the	O
present	O
invention	O
,	O
which	O
effectively	O
excludes	O
toxic	O
hazards	O
caused	O
by	O
the	O
inactive	O
ingredients	O
in	O
the	O
medicaments	O
.	O

Meanwhile	O
L	B
-	I
oxiracetam	I
in	O
the	O
medicaments	O
of	O
the	O
present	O
invention	O
is	O
used	O
as	O
single	O
active	O
ingredient	O
,	O
which	O
makes	O
the	O
medicaments	O
quality	O
much	O
easier	O
to	O
control	O
.	O

Use	O
of	O
l	B
-	I
oxiracetam	I
in	O
manufacture	O
of	O
medicaments	O
for	O
preventing	O
or	O
treating	O
cognitive	O
dysfunction	O

The	O
present	O
invention	O
relates	O
to	O
identification	O
of	O
a	O
compound	O
which	O
inhibits	O
the	O
enzyme	O
NMPRTase	O
and	O
glioma	O
cancer	O
cell	O
growth	O
and	O
further	O
used	O
for	O
glioma	O
therapy	O
.	O

Pre	O
-	O
B-	O
cell	O
colony	O
enhancing	O
factor	O
1	O
gene	O
(	O
PBEF1	O
)	O
encodes	O
nicotinamide	B
phosphoribosyltransferase	O
(	O
NMPRTase	O
)	O
,	O
which	O
catalyses	O
the	O
rate	O
limiting	O
step	O
in	O
the	O
salvage	O
pathway	O
of	O
NAD	O
metabolism	O
in	O
mammalian	O
cells	O
.	O

PBEF1	O
transcript	O
and	O
protein	O
levels	O
have	O
been	O
shown	O
to	O
be	O
elevated	O
in	O
glioblastoma	O
and	O
a	O
chemical	O
inhibitor	O
of	O
NMPRTase	O
has	O
been	O
shown	O
to	O
specifically	O
inhibit	O
cancer	O
cells	O
.	O

Here	O
a	O
structure	O
based	O
drug	O
discovery	O
approach	O
has	O
been	O
reported	O
with	O
an	O
aim	O
to	O
develop	O
novel	O
inhibitors	O
for	O
glioblastoma	O
therapy	O
.	O

Present	O
invention	O
relates	O
to	O
virtual	O
screening	O
using	O
docking	O
of	O
ligands	O
from	O
a	O
large	O
library	O
of	O
13,000	O
compounds	O
against	O
NMPRTase	O
as	O
the	O
macromolecular	O
target	O
resulting	O
in	O
short	O
listing	O
of	O
34	O
possible	O
ligands	O
,	O
of	O
which	O
six	O
were	O
tested	O
experimentally	O
,	O
using	O
the	O
NMPRTase	O
enzyme	O
inhibition	O
assay	O
and	O
further	O
with	O
the	O
glioma	O
cell	O
viability	O
assays	O
.	O

Of	O
these	O
,	O
two	O
compounds	O
were	O
found	O
to	O
be	O
significantly	O
efficacious	O
in	O
inhibiting	O
the	O
conversion	O
of	O
nicotinamide	B
to	O
NAD	O
,	O
and	O
out	O
of	O
which	O
one	O
compound	O
,	O
3-amino-2-benzyl-7-nitro-4-	B
(	I
2-quinolyl-	I
)	I
-l,2-	I
dihydroisoquinolin	I
-	I
l	I
-one	I
,	O
was	O
found	O
to	O
inhibit	O
the	O
growth	O
of	O
a	O
PBEF1	O
over	O
expressing	O
glioma	O
derived	O
cell	O
line	O
U87	O
also	O
.	O

NICOTINAMIDE	B
PHOSPHORIBOSYLTRANSFERASE	O
(	O
NMPRTase	O
)	O
INHIBITOR	O
FOR	O
GLIOMA	O
THERAPY	O

Disclosed	O
is	O
a	O
novel	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
inflammatory	O
diseases	O
.	O

Specifically	O
disclosed	O
is	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
inflammatory	O
bowel	O
diseases	O
or	O
autoimmune	O
peripheral	O
neuropathy	O
,	O
which	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
or	O
general	O
formula	O
(	O
II	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
solvate	O
thereof	O
.	O

(	O
In	O
general	O
formula	O
(	O
I	O
)	O
,	O
n	O
represents	O
an	O
integer	O
of	O
1	O
-	O
10	O
;	O
X1	O
represents	O
-CHY	B
-	I
C	I
(	I
CH3	I
)	I
2Z	I
(	O
wherein	O
Y	O
and	O
Z	O
each	O
independently	O
represents	O
-H	B
or	O
-OH	B
,	O
or	O
alternatively	O
Y	O
and	O
Z	O
combine	O
together	O
to	O
form	O
a	O
single	O
bond	O
)	O
;	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
residue	O
of	O
a	O
pharmaceutically	O
acceptable	O
ester	O
;	O
and	O
R2s	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
protecting	O
group	O
of	O
a	O
hydroxyl	B
group	O
.	O
)	O

(	O
In	O
general	O
formula	O
(	O
II	O
)	O
,	O
X2	O
represents	O
-CHY	B
-	I
C	I
(	I
CH3	I
)	I
2Z	I
(	O
wherein	O
Y	O
and	O
Z	O
each	O
independently	O
represents	O
-H	B
or	O
-OH	B
,	O
or	O
alternatively	O
Y	O
and	O
Z	O
combine	O
together	O
to	O
form	O
a	O
single	O
bond	O
)	O
;	O
R4s	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
protecting	O
group	O
of	O
a	O
hydroxyl	B
group	O
;	O
and	O
R3	O
represents	O
a	O
six	O
-	O
membered	O
ring	O
group	O
or	O
a	O
fused	O
ring	O
group	O
thereof	O
.	O
)	O

Prophylactic	O
or	O
therapeutic	O
agent	O
for	O
inflammatory	O
bowel	O
diseases	O
or	O
autoimmune	O
peripheral	O
neuropathy	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
the	O
selective	O
silencing	O
of	O
neurons	O
in	O
pain	O
pathway	O
by	O
using	O
a	O
combination	O
of	O
inhibitory	O
light	O
-	O
sensitive	O
protein	O
gene	O
transfer	O
and	O
wavelength	O
specific	O
illumination	O
.	O

Methods	O
and	O
compositions	O
for	O
decreasing	O
chronic	O
pain	O

Methods	O
for	O
improving	O
the	O
health	O
of	O
the	O
skin	O
of	O
a	O
subject	O
by	O
the	O
oral	O
administration	O
of	O
a	O
composition	O
comprising	O
resveratrol	B
,	O
a	O
proanthocyanidin	B
,	O
grape	O
skin	O
extract	O
and	O
vitamin	B
C	I
are	O
described	O
.	O

Method	O
for	O
improving	O
the	O
health	O
of	O
skin	O

The	O
present	O
invention	O
describes	O
a	O
pharmaceutical	O
composition	O
and	O
a	O
method	O
for	O
preventing	O
and/or	O
reducing	O
hepatotoxicity	O
associated	O
with	O
a	O
treatment	O
for	O
tuberculosis	O
,	O
reducing	O
the	O
duration	O
of	O
the	O
treatment	O
and	O
avoiding	O
the	O
creation	O
of	O
resistant	O
Mycobacterium	O
tuberculosis	O
strains	O
.	O

The	O
pharmaceutical	O
formulation	O
according	O
to	O
the	O
present	O
invention	O
contains	O
resveratrol	O
,	O
a	O
tuberculostatic	O
agent	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
pertains	O
to	O
the	O
fields	O
of	O
chemistry	O
,	O
pharmacy	O
and	O
medicine	O
.	O

Pharmaceutical	O
formulation	O
and	O
method	O
for	O
reducing	O
hepatotoxicity	O

The	O
invention	O
relates	O
to	O
an	O
N-	B
(	I
aminoacyl	I
)	I
-amino	I
compound	O
or	O
N-	B
(	I
aminoacyl	I
)	I
-amino	I
salt	O
,	O
of	O
the	O
following	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
is	O
hydrogen	B
,	O
lower	O
alkyl	B
or	O
carbonyl	B
and	O
N1	O
is	O
a	O
NH	B
group	O
and	O
R2	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
-	I
phenyl	I
or	O
aralkyl	B
or	O
imidazolyl	B
alkyl	I
or	O
indolyl	B
alkyl	I
,	O
which	O
may	O
be	O
substituted	O
by	O
lower	O
alkyl	B
or	O
hydroxy	B
or	O
alkylhydroxy	B
or	O
methylene	B
dioxy	I
or	O
mercapto	B
or	O
alkylmercapto	B
or	O
amino	B
or	O
guanidino	B
or	O
carboxa	B
and	O
R1	O
and	O
R2	O
together	O
can	O
complete	O
a	O
pyrrolidine	B
or	O
piperidine	B
or	O
thiazolidine	B
ring	O
,	O
and	O
each	O
ring	O
may	O
be	O
substituted	O
by	O
a	O
lower	O
alkyl	B
or	O
aralkyl	B
or	O
phenyl	B
or	O
furyl	B
or	O
thienyl	B
or	O
pyridyl	B
or	O
naphthyl	B
,	O
which	O
in	O
turn	O
may	O
be	O
substituted	O
by	O
a	O
lower	O
alkyl	B
or	O
hydroxy	B
lower	O
alkyl	B
or	O
mercapto	B
lower	O
alkyl	B
or	O
hydroxy	B
or	O
lower	O
alkoxy	B
or	O
alkylene	B
dioxy	I
or	O
halogen	B
or	O
nitro	B
or	O
amino	B
or	O
lower	O
alkylamino	B
or	O
acylamino	B
,	O
and	O
R3	O
is	O
hydrogen	B
or	O
methyl	B
or	O
lower	O
alkyl	B
and	O
R4	O
is	O
hydrogen	B
or	O
alkyl	B
or	O
is	O
the	O
group	O
remaining	O
upon	O
exclusion	O
of	O
R4	O
from	O
the	O
formula	O
and	O
Z	O
is	O
a	O
straight	O
-	O
chain	O
or	O
branched	O
alkylene	B
that	O
can	O
contain	O
up	O
to	O
3	O
carbon	B
atoms	O
and	O
R5	O
is	O
nitrogen	B
or	O
sulphur	B
or	O
oxygen	B
or	O
salts	O
and	O
ester	O
compounds	O
thereof	O
,	O
where	O
A	O
is	O
an	O
ester	O
or	O
A	O
is	O
a	O
sodium	B
or	O
potassium	B
salt	O
of	O
arginate	B
and/or	O
of	O
ornitrate	B
and/or	O
of	O
asparaginate	B
,	O
that	O
is	O
,	O
a	O
sodium	B
arginate	I
and/or	O
a	O
potassium	B
arginate	I
and/or	O
a	O
sodium	B
ornitrate	I
and/or	O
a	O
potassium	B
ornitrate	I
and/or	O
a	O
sodium	B
asparaginate	I
and/or	O
a	O
potassium	B
asparaginate	I
or	O
A	O
is	O
an	O
amino	B
acid	I
.	O

N-	B
(	I
aminoacyl	I
)	I
-amino	I
compound	O

Provided	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
inhibiting	O
apoptosis	O
of	O
neurons	O
or	O
neurodegeneration	O
.	O

The	O
pharmaceutical	O
composition	O
effectively	O
prevents	O
or	O
treats	O
diseases	O
related	O
to	O
apoptosis	O
of	O
neurons	O
or	O
neurodegeneration	O
.	O

Pharmaceutical	O
composition	O
for	O
inhibiting	O
apoptosis	O
of	O
neuron	O
or	O
neurodegeneration	O

The	O
invention	O
provides	O
Saxagliptin	B
Schiff	I
bases	I
,	O
polymorphs	O
of	O
Saxagliptin	B
and	O
(	B
1	I
S,3S,5S	I
)	I
-2-	I
[	I
(	I
2S	I
)	I
-2-propan-2-y	I
lideneamino-2-	I
(	I
3-hydroxy-	I
1	I
-adamanty	I
l	I
)	I
acetyl	I
]	I
-	I
2-azabicyclo	I
[	I
3.1.0	I
]	I
hexane-3-carbonitrile	I
,	O
processes	O
for	O
preparing	O
Saxagliptin	B
hydrates	I
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

Saxagliptin	B
intermediates	O
,	O
saxagliptin	B
polymorphs	O
,	O
and	O
processes	O
for	O
preparation	O
thereof	O

An	O
atomizing	O
formulation	O
comprising	O
plant	O
extract	O
and	O
its	O
preparation	O
method	O
are	O
disclosed	O
.	O

The	O
atomizing	O
formulation	O
consists	O
of	O
tea	O
polyphenol	B
,	O
vitamin	B
E	I
,	O
essence	O
and	O
diluent	O
.	O

Its	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
crushing	O
green	O
tea	O
,	O
reflux	O
extracting	O
the	O
green	O
tea	O
with	O
ethanol	B
solution	O
,	O
filtering	O
the	O
extract	O
solution	O
,	O
decompress	O
distilling	O
the	O
filtrate	O
to	O
obtain	O
the	O
liquid	O
extract	O
;	O
mixing	O
the	O
liquid	O
extract	O
with	O
chloroform	B
,	O
agitating	O
the	O
solution	O
,	O
standing	O
until	O
precipitate	O
is	O
formed	O
and	O
collecting	O
supernatant	O
;	O
clarifying	O
the	O
supernatant	O
by	O
plate	O
ultrafiltration	O
equipment	O
into	O
the	O
clarified	O
solution	O
;	O
freezing	O
and	O
drying	O
the	O
clarified	O
solution	O
to	O
obtain	O
tea	O
polyphenol	B
powder	O
;	O
and	O
mixing	O
the	O
tea	O
polyphenol	B
with	O
vitamin	B
E	I
,	O
essence	O
and	O
diluent	O
.	O

Atomizing	O
formulation	O
comprising	O
plant	O
extract	O
and	O
its	O
preparation	O
method	O

Two	O
new	O
compounds	O
with	O
anticancer	O
effects	O
of	O
N-	B
[	I
4-chloro-3-	I
(	I
trifluoromethyl	I
)	I
phenyl	I
]	I
-	I
[	I
4-	I
(	I
N	I
-	I
methyl	I
-	I
formamide	I
)	I
(	I
4-pyridyloxy	I
)	I
phenyl	I
]	I
-thiourea	I
and	O
N-	B
[	I
4-chloro-3-	I
(	I
trifluoromethyl	I
)	I
phenyl	I
]	I
-	I
[	I
4-	I
(	I
N	I
-	I
methyl	I
-	I
formamide	I
)	I
(	I
4-pyridylthio	I
)	I
phenyl	I
]	I
-thiourea	I
,	O
and	O
salts	O
thereof	O
are	O
disclosed	O
.	O

Preparation	O
methods	O
of	O
the	O
two	O
new	O
compounds	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
new	O
compounds	O
are	O
further	O
disclosed	O
.	O

Experimental	O
studies	O
show	O
that	O
the	O
two	O
new	O
compounds	O
can	O
effectively	O
inhibit	O
the	O
activity	O
of	O
Raf	O
and	O
VEGFR	O
protein	O
kinase	O
,	O
widely	O
inhibit	O
growth	O
of	O
various	O
types	O
of	O
human	O
tumor	O
cell	O
lines	O
and	O
further	O
induce	O
apoptosis	O
of	O
tumor	O
cells	O
.	O

Human	O
tumor	O
heterograft	O
model	O
investigation	O
proves	O
that	O
the	O
two	O
new	O
compounds	O
are	O
effective	O
antineoplastic	O
agents	O
,	O
and	O
can	O
sharply	O
inhibit	O
growth	O
of	O
human	O
liver	O
cancer	O
cells	O
,	O
lung	O
cancer	O
cells	O
and	O
intestinal	O
cancer	O
cells	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
anticancer	O
effects	O
of	O
the	O
compounds	O
are	O
much	O
better	O
than	O
that	O
of	O
sorafenib	B
.	O

Anticancer	O
compounds	O
and	O
preparation	O
methods	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
tricarbonyl	B
technetium-99	I
m	I
or	O
rhenium-188	B
label	O
ring	O
RGD	O
derivative	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
derivative	O
as	O
an	O
active	O
ingredient	O
for	O
use	O
in	O
the	O
diagnosis	O
or	O
treatment	O
of	O
angiogenesis	O
-	O
related	O
diseases	O
.	O

The	O
tricarbonyl	B
technetium-99	I
m	I
or	O
rhenium-188	B
label	O
ring	O
RGD	O
derivative	O
of	O
the	O
present	O
invention	O
has	O
a	O
high	O
subnanomolar	O
affinity	O
to	O
αvβ3	O
integrin	O
(	O
also	O
called	O
as	O
a	O
vitronectin	O
receptor	O
that	O
is	O
activated	O
in	O
an	O
angiogenic	O
action	O
induced	O
by	O
a	O
tumor	O
,	O
reflects	O
a	O
high	O
tumor	O
image	O
after	O
an	O
animal	O
in	O
which	O
cancer	O
cells	O
are	O
transplanted	O
received	O
an	O
initial	O
intake	O
of	O
the	O
tricarbonyl	B
technetium-99	I
m	I
label	O
ring	O
RGD	O
derivative	O
,	O
and	O
acts	O
exclusively	O
upon	O
cancer	O
cells	O
having	O
selectively	O
activated	O
αvβ3	O
integrin	O
because	O
of	O
a	O
substantially	O
low	O
intake	O
into	O
the	O
liver	O
and	O
intestines	O
,	O
compared	O
to	O
existing	O
known	O
radioactive	O
isotope	O
label	O
ring	O
RGD	O
derivatives	O
.	O

These	O
results	O
show	O
that	O
the	O
rhenium-188	B
label	O
derivative	O
,	O
a	O
therapeutic	O
nuclide	O
using	O
the	O
same	O
precursor	O
as	O
used	O
in	O
the	O
technetium-99	B
m	I
label	O
,	O
effectively	O
inhibits	O
the	O
growth	O
of	O
a	O
tumor	O
and	O
demonstrates	O
therapeutic	O
efficacy	O
when	O
administered	O
via	O
tail	O
vein	O
injection	O
to	O
an	O
animal	O
model	O
of	O
a	O
tumor	O
,	O
compared	O
to	O
a	O
case	O
where	O
only	O
saline	O
has	O
been	O
injected	O
,	O
thereby	O
making	O
it	O
useful	O
as	O
a	O
medicine	O
for	O
the	O
diagnosis	O
or	O
treatment	O
of	O
angiogenesis	O
-	O
related	O
diseases	O
.	O

Tricarbonyl	B
technetium-99	I
m	I
or	O
rhenium-188	B
label	O
ring	O
rgd	O
derivative	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
derivative	O
as	O
an	O
active	O
ingredient	O
for	O
use	O
in	O
the	O
diagnosis	O
or	O
treatment	O
of	O
angiogenesis	O
-	O
related	O
diseases	O

Disclosed	O
are	O
a	O
sympatholytic	O
agent	O
which	O
can	O
suppress	O
the	O
activity	O
of	O
a	O
sympathetic	O
nerve	O
more	O
effectively	O
,	O
a	O
cosmetic	O
,	O
a	O
food	O
and	O
a	O
sundry	O
.	O

Ethyl	B
4-methoxybenzoate	I
can	O
calm	O
down	O
the	O
activity	O
of	O
a	O
sympathetic	O
nerve	O
.	O

The	O
sympatholytic	O
agent	O
,	O
the	O
cosmetic	O
,	O
the	O
food	O
and	O
the	O
sundry	O
can	O
suppress	O
the	O
activity	O
of	O
a	O
sympathetic	O
nerve	O
effectively	O
.	O

Sympatholytic	O
agent	O
,	O
and	O
cosmetic	O
,	O
food	O
and	O
sundry	O
containing	O
same	O

The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
platinum	B
-	O
sensitive	O
recurrent	O
ovarian	O
cancer	O
in	O
a	O
patient	O
,	O
comprising	O
administering	O
to	O
the	O
patient	O
an	O
effective	O
amount	O
of	O
4-iodo-3-nitrobenzamide	B
or	O
a	O
metabolite	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
gemcitabine	B
;	O
and	O
carboplatin	B
.	O

Methods	O
of	O
treating	O
platinum	B
-	O
sensitive	O
recurrent	O
ovarian	O
cancer	O
with	O
4-iodo-3-nitrobenzamide	B
in	O
combination	O
with	O
an	O
anti	O
-	O
metabolite	O
and	O
platinum	B
compound	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
(	B
4R,6S	I
)	I
-	I
(	I
E	I
)	I
-6-	I
[	I
2-	I
(	I
2-cyclopropyl	I
)	I
-4-	I
(	I
4-Fluorophenyl	I
)	I
quinoline-3-yl	I
]	I
-vinyl-2,2-dimethyl-1,3-dioxane-4-yl	I
]	I
acetic	I
acid	I
ester	I
derivative	O
,	O
which	O
is	O
an	O
intermediate	O
of	O
pitavastatin	B
or	O
of	O
the	O
salt	O
thereof	O
,	O
into	O
a	O
crystalline	O
solid	O
form	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
solvate	O
of	O
the	O
intermediate	O
and	O
to	O
a	O
method	O
for	O
preparing	O
pitavastatin	B
or	O
the	O
salt	O
thereof	O
using	O
the	O
intermediate	O
.	O

Method	O
for	O
preparing	O
an	O
intermediate	O
of	O
pitavastatin	B
or	O
of	O
the	O
salt	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
(	B
11β,17α	I
)	I
-11-	I
(	I
4-	I
(	I
2	I
-	I
11C	I
-	I
acetyl	I
)	I
phenyl	I
)	I
-17,23-	I
epoxy-19,24-dinorchola-4,9,20-trien-3-one	I
,	O
an	O
11C	O
-	O
labelled	O
ORG	O
33628	O
;	O
a	O
process	O
for	O
the	O
preparation	O
thereof	O
,	O
intermediates	O
used	O
in	O
this	O
process	O
and	O
the	O
use	O
of	O
this	O
compound	O
as	O
a	O
PET	O
tracer	O
for	O
the	O
detection	O
of	O
breast	O
cancer	O
.	O

(	B
11β,17α	I
)	I
-11-	I
(	I
4-	I
(	I
2	I
-	I
11C	I
-	I
ACETYL	I
)	I
PHENYL	I
)	I
-17,23-EPOXY-	I
19,24-DINORCHOLA-4,9,20-TRIEN-3-ONE	I

A	O
sialic	B
acid	I
-	O
containing	O
sugar	B
chain	O
complex	O
characterized	O
by	O
comprising	O
a	O
C14	B
-	I
18	I
fatty	I
acid	I
,	O
excluding	O
a	O
sphingolipid	B
,	O
that	O
is	O
bonded	O
,	O
via	O
an	O
amide	B
bond	O
,	O
to	O
an	O
end	O
other	O
than	O
the	O
sialic	B
acid	I
end	O
of	O
a	O
sialic	B
acid	I
-	O
containing	O
sugar	B
chain	O
,	O
which	O
contains	O
sialic	B
acid	I
at	O
one	O
end	O
,	O
and	O
having	O
a	O
molecular	O
weight	O
of	O
400	O
-	O
1,400	O
;	O
an	O
anti	O
-	O
influenza	O
virus	O
agent	O
which	O
comprises	O
said	O
complex	O
as	O
the	O
active	O
ingredient	O
;	O
and	O
a	O
filter	O
which	O
carries	O
said	O
anti	O
-	O
influenza	O
virus	O
agent	O
.	O

Sialic	B
acid	I
-	O
containing	O
sugar	B
chain	O
complex	O
and	O
method	O
for	O
producing	O
same	O
,	O
anti	O
-	O
influenza	O
virus	O
agent	O
and	O
filter	O

Described	O
herein	O
is	O
the	O
LPAl	O
antagonist	O
{	B
4'-	I
[	I
3-methyl-4-	I
(	I
(	I
R	I
)	I
-l	I
-	I
phenyl	I
-	I
ethoxycarbonylamino	I
)	I
-isoxazol-5-yl	I
]	I
-biphenyl-4-yl	I
}	I
-acetic	I
acid	I
(	O
Compound	O
1	O
)	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

Also	O
described	O
are	O
methods	O
of	O
preparing	O
the	O
LPAl	O
antagonist	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
suitable	O
for	O
administration	O
to	O
a	O
mammal	O
that	O
include	O
the	O
LPAl	O
antagonist	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
methods	O
of	O
using	O
such	O
pharmaceutical	O
compositions	O
for	O
treating	O
LPA	O
-	O
dependent	O
or	O
LPA	O
-	O
mediated	O
diseases	O
or	O
conditions	O
.	O

Lysophosphatidic	B
acid	I
receptor	O
antagonist	O
and	O
uses	O
thereof	O

Organic	O
acid	O
salts	O
of	O
Penehyclidine	B
optical	O
isomer	O
,	O
specifically	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
crystals	O
,	O
solvates	O
or	O
pro	O
-	O
drugs	O
thereof	O
are	O
disclosed	O
,	O
in	O
which	O
n	O
and	O
HX	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

The	O
methods	O
for	O
preparing	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
crystals	O
,	O
solvates	O
or	O
pro	O
-	O
drugs	O
thereof	O
,	O
their	O
pharmaceutical	O
use	O
,	O
methods	O
for	O
treating	O
diseases	O
or	O
disorders	O
using	O
them	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
also	O
disclosed	O
.	O

The	O
organic	O
acid	O
salts	O
of	O
Penehyclidine	B
optical	O
isomer	O
possess	O
the	O
character	O
of	O
high	O
stability	O
.	O

Organic	O
acid	O
salts	O
of	O
penehyclidine	B
optical	O
isomer	O

The	O
present	O
invention	O
is	O
related	O
to	O
the	O
use	O
of	O
uleine	B
or	O
a	O
plant	O
extract	O
comprising	O
uleine	B
or	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
in	O
the	O
prevention	O
and/or	O
the	O
treatment	O
of	O
an	O
infectious	O
disease	O
in	O
a	O
mammal	O
subject	O
.	O

Use	O
of	O
uleine	B
for	O
the	O
prevention	O
and/or	O
the	O
treatment	O
of	O
infectious	O
diseases	O

A	O
composition	O
comprising	O
:	O
a	O
core	O
which	O
comprises	O
of	O
metformin	B
,	O
rosiglitazone	B
,	O
and	O
pharmaceutically	O
acceptable	O
excipients	O
and	O
permeable	O
coating	O
.	O

The	O
invention	O
further	O
involves	O
a	O
composition	O
comprising	O
a	O
core	O
which	O
comprises	O
of	O
metformin	B
,	O
rosiglitazone	B
,	O
and	O
pharmaceutically	O
acceptable	O
excipients	O
and	O
permeable	O
coating	O
comprising	O
ammonio	B
methacrylate	I
copolymer	O
.	O

A	O
process	O
of	O
manufacturing	O
a	O
tablet	O
comprising	O
metformin	B
and	O
rosiglitazone	B
wherein	O
the	O
process	O
comprises	O
of	O
preparing	O
granules	O
of	O
rosiglitazone	B
by	O
mixing	O
rosiglitazone	B
with	O
molten	O
carrier	O
,	O
preparing	O
granules	O
of	O
metformin	B
,	O
mixing	O
and	O
compression	O
of	O
granules	O
followed	O
by	O
coating	O
with	O
permeable	O
coating	O
.	O

Compositions	O
comprising	O
metformin	B
and	O
rosiglitazone	B

Provided	O
is	O
a	O
compound	O
preparation	O
which	O
comprises	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ω3	O
polyvalent	O
unsaturated	O
fatty	B
acids	I
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
,	O
and	O
comprises	O
at	O
least	O
one	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
statin	O
compounds	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compound	O
preparation	O
has	O
a	O
capsule	O
film	O
pH	O
of	O
7.0	O
to	O
9.5	O
and	O
is	O
in	O
the	O
form	O
of	O
a	O
soft	O
capsule	O
.	O

The	O
compound	O
preparation	O
inhibits	O
decomposition	O
of	O
the	O
statin	O
compounds	O
and/or	O
degeneration	O
/	O
insolubilization	O
of	O
the	O
capsule	O
film	O
.	O

A	O
medical	O
use	O
for	O
the	O
compound	O
preparation	O
,	O
a	O
method	O
for	O
producing	O
the	O
compound	O
preparation	O
,	O
and	O
a	O
method	O
for	O
using	O
the	O
compound	O
preparation	O
are	O
also	O
provided	O
.	O

ω3	B
FATTY	I
ACID	I
COMPOUND	O
PREPARATION	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
general	O
formula	O
:	O
(	O
I	O
)	O
wherein	O
A	O
is	O
selected	O
from	O
the	O
groups	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
or	O
(	O
c	O
)	O
:	O
formula	O
(	O
II	O
)	O
or	O
formula	O
(	O
III	O
)	O
(	O
b	O
)	O
or	O
is	O
cycloalkyl	B
,	O
(	O
c	O
)	O
optionally	O
substituted	O
by	O
lower	O
alkyl	B
(	O
c	O
)	O
;Ar1	O
is	O
phenyl	O
or	O
a	O
six	O
membered	O
heteroaryl;X1	B
is	O
N	B
or	O
CH	B
;	O
X2	O
is	O
N	B
-	I
R1	I
or	O
O	B
;	O
R1	O
is	O
S	B
(	I
O	I
)	I
2-lower	I
alkyl	I
,	O
C	B
(	I
O	I
)	I
-cycloalkyl	I
substituted	O
by	O
lower	O
alkyl	B
,	O
or	O
is	O
C	B
(	I
O	I
)	I
-lower	I
alkyl	I
,	O
lower	O
alkyl	B
,	O
cyano	B
,	O
cycloalkyl	B
or	O
is	O
a	O
six	O
membered	O
heteroaryl	B
substituted	O
by	O
lower	O
alkyl	B
,	O
cyano	B
,	O
C	B
(	I
O	I
)	I
-lower	I
alkyl	I
,	O
halogen	B
,	O
lower	O
alkyl	B
substituted	O
by	O
halogen	O
or	O
lower	O
alkoxy	O
;	O
or	O
is	O
phenyl	O
substituted	O
by	O
cyano	O
or	O
halogen	O
;	O
R2	O
is	O
lower	O
alkyl	O
,	O
halogen	O
,	O
pyrazolyl	O
,	O
3-methyl-	O
[	O
1,2,4	O
]	O
oxazolyl	O
,	O
5-methyl-	O
[	B
1,2,4	I
]	I
oxadiazol-3-yl	I
,	O
pyridyl	B
substituted	O
by	O
cyano	B
,	O
or	O
is	O
phenyl	B
substituted	O
by	O
halogen	B
,	O
or	O
is	O
cyano	B
,	O
lower	O
alkoxy	B
,	O
or	O
is	O
piperidin-2-one	B
;	O
or	O
to	O
pharmaceutically	O
active	O
salts	O
,	O
sterioisomeric	O
forms	O
,	O
including	O
individual	O
diastereoisomers	O
and	O
enantiomers	O
of	O
the	O
compound	O
of	O
formula	O
I	O
as	O
well	O
as	O
racemic	O
and	O
non	O
-	O
racemic	O
mixtures	O
thereof	O
..	O

It	O
has	O
been	O
found	O
that	O
the	O
present	O
compounds	O
are	O
high	O
potential	O
NK-3	O
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
pain	O
,	O
psychosis	O
,	O
Parkinsons	O
disease	O
,	O
schizophrenia	O
,	O
anxiety	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O

(	B
3	I
-methylpyrrolidin-	I
3	I
-	I
yl	I
)	I
methyl	I
pyridinyl	I
ether	I
derivatives	O
and	O
their	O
use	O
as	O
nk-3	O
receptor	O
antagonists	O

The	O
invention	O
relates	O
to	O
substituted	O
pyridine	B
compounds	O
of	O
Formula	O
I	O
:	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
,	O
or	O
solvate	O
thereof	O
,	O
wherein	O
A1	O
,	O
X	O
,	O
A2	O
,	O
R1a	O
,	O
R1b	O
,	O
R1c	O
,	O
G	O
,	O
and	O
z	O
are	O
defined	O
as	O
set	O
forth	O
in	O
the	O
specification	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
I	O
to	O
treat	O
a	O
disorder	O
responsive	O
to	O
the	O
blockade	O
of	O
sodium	B
channels	O
.	O

Compounds	O
of	O
the	O
present	O
invention	O
are	O
especially	O
useful	O
for	O
treating	O
pain	O
.	O

Pyridine	B
compounds	O
as	O
sodium	B
channel	O
blockers	O

Disclosed	O
is	O
a	O
crystal	O
of	O
carboprost	B
tromethamine	B
as	O
represented	O
by	O
Formula	O
(	O
I	O
)	O
.	O

The	O
crystal	O
has	O
in	O
the	O
X	O
-	O
ray	O
diffraction	O
pattern	O
at	O
angle	O
2θ	O
the	O
following	O
characteristic	O
peaks	O
:	O
6.6±0.2	O
,	O
9.9±0.2	O
,	O
18.5±0.2	O
°	O
,	O
and	O
20.1±0.2	O
°	O
.	O

Furthermore	O
,	O
also	O
disclosed	O
are	O
a	O
preparation	O
method	O
and	O
use	O
of	O
the	O
crystal	O
.	O

Preparation	O
method	O
for	O
and	O
uses	O
of	O
carboprost	B
tromethamine	B
crystal	O

Disclosed	O
is	O
a	O
lipid	O
metabolism	O
improving	O
agent	O
which	O
is	O
characterized	O
by	O
containing	O
an	O
α	O
-	O
glucosidase	O
inhibitor	O
and	O
being	O
administered	O
in	O
combination	O
with	O
at	O
least	O
one	O
kind	O
of	O
bacterium	O
that	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
bifidus	O
bacterium	O
,	O
a	O
lactic	O
acid	O
bacterium	O
,	O
a	O
saccharification	O
bacterium	O
and	O
a	O
butyric	B
acid	I
bacterium	O
.	O

Lipid	O
metabolism	O
improving	O
agent	O
,	O
agent	O
for	O
enhancing	O
lipid	O
metabolism	O
improving	O
action	O
,	O
anti	O
-	O
obesity	O
agent	O
,	O
and	O
agent	O
for	O
enhancing	O
anti	O
-	O
obesity	O
action	O

Compositions	O
containing	O
one	O
or	O
more	O
derivatives	O
of	O
essential	O
oil	O
compounds	O
for	O
use	O
in	O
personal	O
care	O
compositions	O
,	O
such	O
as	O
compositions	O
for	O
oral	O
,	O
throat	O
and	O
skin	O
care	O
are	O
disclosed	O
.	O

These	O
derivatives	O
include	O
acetals	B
of	O
parent	O
essential	O
oil	O
aldehydes	B
and	O
ketones	B
;	O
esters	B
or	O
ethers	B
of	O
parent	O
essential	O
oil	O
alcohols	B
and	O
phenolics	O
;	O
and	O
esters	B
of	O
parent	O
essential	O
oil	O
acids	O
.	O

Examples	O
of	O
parent	O
essential	O
oil	O
aldehydes	B
and	O
ketones	B
include	O
citral	O
,	O
cinnamic	B
aldehyde	I
,	O
ρ	B
-	I
anisaldehyde	I
,	O
vanillin	B
,	O
ethyl	B
vanillin	I
,	O
heliotropin	B
,	O
carvone	B
,	O
and	O
menthone	B
.	O

Examples	O
of	O
parent	O
essential	O
oil	O
alcohols	B
and	O
phenolics	O
include	O
thymol	B
,	O
eugenol	B
,	O
isoeugenol	B
,	O
dihydroeugenol	B
,	O
carvacrol	B
,	O
carveol	B
,	O
geraniol	B
,	O
nerol	B
,	O
vanillyl	B
alcohol	I
,	O
heliotropyl	B
alcohol	I
,	O
ρ	B
-	I
anisyl	I
alcohol	I
,	O
cinnamyl	B
alcohol	I
and	O
β	B
-	I
ionol	I
.	O

Examples	O
of	O
parent	O
essential	O
oil	O
acids	O
include	O
ρ	B
-	I
anisic	I
acid	I
,	O
cinnamic	B
acid	I
,	O
vanillic	B
acid	I
and	O
geranic	B
acid	I
.	O

The	O
present	O
compositions	O
comprising	O
essential	O
oil	O
derivatives	O
are	O
useful	O
as	O
base	O
flavor	O
or	O
base	O
perfume	O
for	O
incorporation	O
into	O
personal	O
care	O
products	O
and	O
to	O
provide	O
other	O
benefits	O
including	O
antimicrobial	O
efficacy	O
.	O

Optionally	O
the	O
compositions	O
will	O
contain	O
additional	O
antimicrobially-	O
or	O
anti	O
-	O
inflammatory	O
-	O
effective	O
components	O
including	O
those	O
also	O
derived	O
from	O
plant	O
essential	O
oils	O
or	O
synthetic	O
versions	O
thereof	O
.	O

Compositions	O
comprising	O
derivatives	O
of	O
essential	O
oil	O
compounds	O
and	O
use	O
in	O
personal	O
care	O
products	O

Metal	O
particulates	O
capable	O
of	O
generating	O
low	O
levels	O
of	O
corrosion	O
current	O
beneficial	O
for	O
pharmaceutical	O
,	O
cosmetic	O
and	O
other	O
medical	O
uses	O
are	O
provided	O
.	O

Corrosion	O
current	O
-	O
generating	O
metal	O
particulates	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
extracts	O
and	O
compositions	O
from	O
Gnetum	O
africanum	O
and	O
methods	O
for	O
obtaining	O
the	O
extracts	O
,	O
wherein	O
the	O
extracts	O
comprise	O
resveratrol	B
and	O
have	O
anti	O
-	O
inflammatory	O
activity	O
.	O

Methods	O
of	O
using	O
the	O
extracts	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
inflammatory	O
diseases	O
,	O
and	O
compositions	O
which	O
comprise	O
the	O
extracts	O
including	O
cosmetic	O
compositions	O
are	O
also	O
encompassed	O
.	O

Compounds	O
and	O
extracts	O
from	O
gnetum	O
africanum	O
and	O
anti	O
-	O
inflammatory	O
activity	O
related	O
thereto	O

The	O
invention	O
relates	O
,	O
in	O
one	O
aspect	O
,	O
to	O
a	O
tablet	O
having	O
an	O
internal	O
core	O
and	O
external	O
coating	O
,	O
both	O
comprising	O
melatonin	B
and	O
separated	O
by	O
an	O
internal	O
coating	O
which	O
does	O
not	O
comprise	O
melatonin	B
.	O

The	O
tablet	O
is	O
useful	O
as	O
a	O
medicinal	O
product	O
,	O
dietetic	O
or	O
food	O
supplements	O
for	O
the	O
treatment	O
or	O
as	O
adjunctive	O
therapy	O
in	O
sleep	O
disorders	O
.	O

Three	O
-	O
phase	O
controlled	O
-	O
release	O
tablet	O
comprising	O
melatonin	B
and	O
process	O
of	O
preparation	O

[	O
Problem	O
]	O

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
pharmaceutical	O
preparation	O
for	O
preventing	O
and/or	O
treating	O
various	O
diseases	O
,	O
which	O
comprises	O
a	O
compound	O
capable	O
of	O
increasing	O
a	O
translation	O
initiation	O
factor	O
or	O
a	O
transcription	O
elongation	O
factor	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

[	O
Solution	O
]	O

The	O
present	O
inventors	O
made	O
extensive	O
studies	O
for	O
the	O
purpose	O
of	O
solving	O
the	O
problem	O
,	O
and	O
it	O
is	O
found	O
for	O
the	O
first	O
time	O
that	O
the	O
increase	O
in	O
a	O
translation	O
initiation	O
factor	O
(	O
e.g.	O
,	O
eIF4A1	O
)	O
or	O
a	O
translation	O
elongation	O
factor	O
(	O
e.g.	O
,	O
eEF1A1	O
)	O
is	O
involved	O
in	O
the	O
NGF	O
-	O
induced	O
neurite	O
elongation	O
potentiating	O
activity	O
of	O
minocycline	B
or	O
cilostazol	B
,	O
and	O
the	O
invention	O
has	O
been	O
accomplished	O
.	O

Agent	O
for	O
increasing	O
translation	O
initiation	O
factor	O
or	O
translation	O
elongation	O
factor	O
,	O
and	O
use	O
thereof	O
for	O
medical	O
purposes	O

Pharmaceutical	O
composition	O
for	O
treating	O
hemorrhage	O
caused	O
by	O
blood	O
clotting	O
disorder	O
and	O
use	O
thereof	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
(	O
per	O
unit	O
)	O
:	O
L	B
-	I
ornithine	I
0.5	O
-	O
8	O
g	O
,	O
aspartic	B
acid	I
1	O
-	O
5	O
g	O
,	O
arginine	B
3	O
-	O
10	O
g	O
,	O
vitamin	B
B6	I
3	O
-	O
10	O
g	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
treat	O
hemorrhage	O
caused	O
by	O
blood	O
clotting	O
disorder	O
effectively	O
and	O
is	O
very	O
appropriate	O
for	O
treating	O
patient	O
at	O
stake	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
hemorrhage	O
caused	O
by	O
blood	O
clotting	O
disorder	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
specific	O
solid	O
forms	O
of	O
(	B
S	I
)	I
-pyrrolidine	I
-	I
l,2-dicarboxylic	I
acid	I
2-amide	I
l-	I
(	I
4-methyI-5-	I
[	I
2-	I
(	I
2,2,2-trifluoro	I
-	I
l	I
,	I
l	I
-	I
dimethyl	I
-	I
ethyl	I
)	I
-pyridin-4-yl	I
]	I
-thiazol-2-yl	I
)	I
-amide	I
,	O
(	O
I	O
)	O
,	O
and	O
its	O
hydrates	B
and	O
solvates	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
processes	O
for	O
preparing	O
said	O
solid	O
forms	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
solid	O
forms	O
,	O
and	O
methods	O
of	O
using	O
said	O
solid	O
forms	O
and	O
pharmaceutical	O
compositions	O
to	O
treat	O
disease	O
.	O

A	O
crystalline	O
form	O
of	O
(	B
s	I
)	I
-pyrrolidine-1,2-dicarboxylic	I
acid	I
2-amide	I
1-	I
(	I
4	I
-methyl-5-	I
[	I
2-	I
(	I
2,2,2-trifluoro-1,1-dimethyl	I
-	I
ethyl	I
)	I
-pyridin-4-yl	I
]	I
-thiazol-2-yl	I
)	I
-amide	I
and	O
its	O
use	O
as	O
pi3k	O
inhibitor	O

A	O
sustained	O
release	O
preparation	O
containing	O
a	O
semaphorin	O
3A	O
inhibitor	O
as	O
an	O
active	O
ingredient	O
,	O
which	O
is	O
a	O
solid	O
preparation	O
that	O
comprises	O
the	O
semaphorin	O
3A	O
inhibitor	O
and	O
a	O
carrier	O
comprising	O
a	O
silicone	B
containing	O
a	O
pharmaceutically	O
acceptable	O
poorly	O
water	O
-	O
soluble	O
solid	O
substance	O
.	O

Preparation	O
for	O
treatment	O
of	O
spinal	O
cord	O
injury	O

Disclosed	O
herein	O
are	O
compounds	O
,	O
in	O
particular	O
phenanthrene	B
and	O
naphthalene	B
compounds	O
,	O
useful	O
as	O
modulators	O
of	O
an	O
NMDA	O
receptor	O
.	O

Further	O
disclosed	O
are	O
methods	O
of	O
modulating	O
an	O
NMDA	O
receptor	O
using	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
treating	O
various	O
NMDA-	O
receptor	O
disorders	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
schizophrenia	O
,	O
post	O
-	O
traumatic	O
stress	O
disorder	O
,	O
Alzheimer	O
's	O
disease	O
,	O
and	O
pain	O
.	O

Compounds	O
for	O
use	O
in	O
modulating	O
the	O
nmda	O
receptor	O

Benzohydrol	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
a	O
preparation	O
method	O
,	O
pharmaceutical	O
compositions	O
and	O
pharmaceutical	O
use	O
thereof	O
are	O
disclosed	O
in	O
the	O
invention	O
.	O

The	O
derivatives	O
can	O
be	O
used	O
as	O
rennin	O
inhibitors	O
to	O
prepare	O
the	O
drugs	O
for	O
the	O
treatment	O
of	O
the	O
diseases	O
related	O
with	O
rennin	O
,	O
such	O
as	O
antihypertensive	O
drugs	O
.	O

Benzohydrol	B
derivatives	O
,	O
a	O
preparation	O
process	O
and	O
pharmaceutical	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
granulate	O
containing	O
95	O
-	O
99	O
%	O
of	O
imatinib	B
mesylate	I
and	O
1	O
-	O
5	O
%	O
of	O
a	O
volatile	O
liquid	O
to	O
a	O
process	O
of	O
making	O
a	O
granulate	O
of	O
imatinib	B
mesylate	I
,	O
which	O
process	O
comprises	O
wetting	O
imatinib	B
mesylate	I
with	O
a	O
granulation	O
liquid	O
,	O
and	O
granulating	O
the	O
mixture	O
in	O
a	O
granulator	O
,	O
followed	O
by	O
drying	O
,	O
and	O
optionally	O
sieving	O
and/or	O
milling	O
of	O
the	O
produced	O
population	O
of	O
granules	O
,	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
,	O
and	O
for	O
use	O
in	O
medicine	O
.	O

Pharmaceutical	O
granulate	O
comprising	O
imatinib	B
mesylate	I

The	O
compound	O
N-	B
(	I
4-	I
{	I
[	I
4-amino-2-butyl-1H	I
-	I
imidazo	I
[	I
4,5-c	I
]	I
quinolin-1-yl	I
]	I
oxy	I
}	I
butyl	I
)	I
octadecanamide	I
is	O
a	O
useful	O
drug	O
compound	O
for	O
enhancing	O
immune	O
response	O
and	O
can	O
be	O
used	O
,	O
for	O
example	O
,	O
as	O
a	O
vaccine	O
adjuvant	O
and	O
a	O
cancer	O
treatment	O
.	O

Lipidated	O
immune	O
response	O
modifier	O
compound	O
compositions	O
,	O
formulations	O
,	O
and	O
methods	O

Provided	O
are	O
a	O
hydrochloride	B
of	O
a	O
tricyclic	B
pyrazolopyrimidine	I
compound	O
that	O
inhibits	O
the	O
action	O
of	O
Hsp90	O
and	O
a	O
crystal	O
thereof	O
.	O

The	O
present	O
invention	O
provides	O
a	O
hydrochloride	B
of	O
2-	B
{	I
4-amino-2-	I
[	I
(	I
3-chloro-4-methoxy-5-methylpyridine-2-yl	I
)	I
methyl	I
]	I
-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo	I
[	I
cd	I
]	I
azulene-8-yl	I
}	I
-N	I
-	I
methylacetamide	I
that	O
inhibits	O
the	O
activity	O
of	O
Hsp90	O
ATPase	O
and	O
has	O
antitumor	O
activity	O
,	O
a	O
crystal	O
thereof	O
,	O
and	O
a	O
medicine	O
,	O
anticancer	O
agent	O
,	O
and	O
the	O
like	O
containing	O
the	O
same	O
.	O

Crystal	O
of	O
tricyclic	B
pyrazolopyrimidine	I
derivative	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
BUPROPION	B
(	B
±	I
)	I
-2-	I
(	I
tert	I
-	I
butylamino	I
)	I
-1	I
-	I
(	I
3-	I
chlorophenyl	I
)	I
propan-1-one	I
and	O
its	O
(	O
+	O
+	O
)	O
and	O
(	O
--	O
)	O
isomeric	O
forms	O
or	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof	O
,	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
sexual	O
desire	O
,	O
especially	O
,	O
though	O
not	O
limited	O
to	O
,	O
patients	O
of	O
the	O
female	O
gender	O
.	O

The	O
invention	O
relates	O
to	O
the	O
physical	O
improvement	O
of	O
orgasm	O
in	O
patients	O
who	O
until	O
now	O
may	O
have	O
had	O
difficulty	O
in	O
achieving	O
sexual	O
satisfaction	O
.	O

Use	O
of	O
bupropion	B
in	O
treating	O
sexual	O
dysfunction	O

An	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
composition	O
containing	O
a	O
poorly	O
-	O
soluble	O
drug	O
:	O
has	O
a	O
solubility	O
in	O
water	O
of	O
less	O
than	O
1	O
mg	O
/	O
mL	O
;	O
contains	O
a	O
poorly	O
soluble	O
drug	O
with	O
a	O
molecular	O
weight	O
of	O
at	O
least	O
500	O
,	O
an	O
oil	O
constituent	O
in	O
an	O
amount	O
of	O
more	O
than	O
6	O
mass	O
%	O
but	O
not	O
more	O
than	O
25	O
mass	O
%	O
with	O
respect	O
to	O
the	O
mass	O
of	O
the	O
entire	O
composition	O
,	O
and	O
containing	O
medium	O
-	O
chain	O
triglycerides	B
in	O
an	O
amount	O
of	O
more	O
than	O
80	O
mass	O
%	O
but	O
not	O
more	O
than	O
100	O
mass	O
%	O
,	O
and	O
a	O
surfactant	O
constituent	O
containing	O
phospholipids	O
in	O
an	O
amount	O
of	O
not	O
less	O
than	O
50	O
mass	O
%	O
and	O
not	O
more	O
than	O
100	O
mass	O
%	O
;	O
and	O
which	O
has	O
emulsified	O
particles	O
with	O
an	O
average	O
particle	O
diameter	O
of	O
less	O
than	O
500	O
nm	O
.	O

Oil	O
-	O
in	O
-	O
water	O
emulsion	O
composition	O
containing	O
poorly	O
-	O
soluble	O
drug	O
,	O
and	O
method	O
for	O
manufacturing	O
same	O

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
medicinal	O
agent	O
for	O
controlling	O
and/or	O
preventing	O
cramps	O
induced	O
by	O
hemodialysis	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
.	O

Provided	O
are	O
an	O
agent	O
for	O
controlling	O
hemodialysis	O
-	O
induced	O
cramps	O
comprising	O
as	O
an	O
active	O
ingredient	O
a	O
coenzyme	O
,	O
such	O
as	O
biotin	B
and/or	O
thiamine	B
pyrophosphate	I
,	O
that	O
functions	O
in	O
the	O
citric	B
acid	I
cycle	O
,	O
as	O
well	O
as	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
agent	O
.	O

The	O
agent	O
for	O
controlling	O
hemodialysis	O
-	O
induced	O
cramps	O
and	O
the	O
pharmaceutical	O
composition	O
effectively	O
and	O
immediately	O
control	O
hemodialysis	O
-	O
induced	O
cramps	O
and	O
also	O
prevent	O
the	O
same	O
.	O

Agent	O
for	O
controlling	O
hemodialysis	O
-	O
induced	O
cramps	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
polymorphs	O
and	O
salts	O
of	O
a	O
compound	O
which	O
is	O
an	O
inhibitor	O
of	O
kinase	O
activity	O
.	O

Polymorphs	O
and	O
salts	O
of	O
n-	B
[	I
5-	I
[	I
4-	I
(	I
5-	I
{	I
[	I
(	I
2r,6s	I
)	I
-2	I
,	I
6	I
-	I
dimethyl	I
-	I
4	I
-morpholinyl	I
]	I
methyl	I
}	I
-	I
1	I
,	I
3	I
-	I
oxazol	I
-	I
2	I
-	I
yl	I
)	I
-	I
1h-	I
inda	I
zol-6-yl	I
]	I
-2-	I
(	I
methyloxy	I
)	I
-	I
3	I
-	I
pyridinyl	I
]	I
methanesulfonamide	I

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
sepsis	O
,	O
containing	O
genipin	B
or	O
a	O
derivative	O
thereof	O
.	O

While	O
being	O
far	O
short	O
of	O
an	O
effective	O
method	O
or	O
medicine	O
for	O
treating	O
sepsis	O
,	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
can	O
be	O
useful	O
for	O
preventing	O
or	O
treating	O
sepsis	O
or	O
septic	O
shock	O
.	O

In	O
addition	O
,	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
is	O
a	O
therapeutic	O
agent	O
based	O
on	O
natural	O
products	O
,	O
and	O
thus	O
it	O
is	O
possible	O
to	O
reduce	O
side	O
effects	O
which	O
frequently	O
appear	O
using	O
chemical	O
materials	O
in	O
addition	O
to	O
having	O
a	O
wide	O
range	O
of	O
therapeutic	O
effects	O
.	O

Pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
sepsis	O
,	O
containing	O
genipin	B
or	O
derivative	O
thereof	O

Provided	O
is	O
an	O
inhibitor	O
of	O
HMGB	O
protein	O
-	O
mediated	O
immune	O
response	O
activation	O
,	O
comprising	O
one	O
or	O
more	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
phosphorothioate	O
oligonucleotides	O
and	O
derivatives	O
thereof	O
.	O

Also	O
provided	O
is	O
a	O
method	O
for	O
screening	O
an	O
inhibitor	O
or	O
promoter	O
of	O
HMGB	O
protein	O
-	O
mediated	O
immune	O
response	O
activation	O
,	O
comprising	O
:	O
a	O
mixing	O
step	O
of	O
mixing	O
an	O
HMGB	O
protein	O
and	O
a	O
labeled	O
nucleic	O
acid	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
test	O
substance	O
;	O
a	O
assaying	O
step	O
of	O
assaying	O
the	O
HMGB	O
protein	O
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
;	O
and	O
a	O
determination	O
step	O
of	O
determining	O
that	O
the	O
test	O
substance	O
is	O
an	O
inhibitor	O
of	O
HMGB	O
protein	O
-	O
mediated	O
immune	O
response	O
activation	O
in	O
the	O
case	O
that	O
the	O
quantity	O
of	O
the	O
HMGB	O
protein	O
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
presence	O
of	O
the	O
test	O
substance	O
is	O
less	O
than	O
the	O
quantity	O
of	O
the	O
HMGB	O
protein	O
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
,	O
and	O
determining	O
that	O
the	O
test	O
substance	O
is	O
a	O
promoter	O
of	O
HMGB	O
protein	O
-	O
mediated	O
immune	O
response	O
activation	O
in	O
the	O
case	O
that	O
the	O
quantity	O
of	O
the	O
HMGB	O
protein	O
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
presence	O
of	O
the	O
test	O
substance	O
is	O
greater	O
than	O
the	O
quantity	O
of	O
the	O
HMGB	O
protein	O
bound	O
to	O
the	O
labeled	O
nucleic	O
acid	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
.	O

Inhibitor	O
of	O
hmgb	O
protein	O
-	O
mediated	O
immune	O
response	O
activation	O
,	O
and	O
screening	O
method	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicine	O
,	O
in	O
particular	O
to	O
pharmacology	O
,	O
and	O
specifically	O
to	O
remedies	O
used	O
for	O
administering	O
first	O
aid	O
for	O
burns	O
in	O
emergency	O
medicine	O
and	O
can	O
be	O
used	O
for	O
topical	O
treatment	O
of	O
wounds	O
at	O
all	O
stages	O
of	O
a	O
combination	O
treatment	O
in	O
patients	O
with	O
I	O
-	O
IIIA	O
-	O
degree	O
radiation	O
,	O
thermal	O
and	O
solar	O
radiation	O
burns	O
,	O
as	O
well	O
as	O
treatment	O
of	O
granulating	O
wounds	O
of	O
different	O
etiology	O
for	O
treating	O
insect	O
bites	O
and	O
stings	O
.	O

The	O
technical	O
result	O
arising	O
from	O
the	O
use	O
of	O
the	O
invention	O
consists	O
in	O
extending	O
the	O
range	O
of	O
possible	O
uses	O
for	O
administering	O
first	O
aid	O
for	O
topical	O
burns	O
of	O
different	O
etiology	O
including	O
radiation	O
burns	O
at	O
all	O
stages	O
in	O
the	O
provision	O
of	O
medical	O
aid	O
.	O

The	O
hydrogel	O
composition	O
for	O
the	O
treatment	O
of	O
burns	O
comprises	O
an	O
active	O
ingredient	O
,	O
auxiliary	O
ingredients	O
and	O
a	O
gel	O
-	O
forming	O
component	O
.	O

The	O
active	O
ingredient	O
in	O
the	O
composition	O
is	O
the	O
medicinal	O
substance	O
2-allyloxyethanol	B
in	O
a	O
quantity	O
of	O
from	O
0.1	O
to	O
10.0	O
(	O
mass%	O
)	O
.	O

The	O
auxiliary	O
ingredients	O
in	O
the	O
composition	O
are	O
the	O
medicinal	O
substances	O
lidocaine	B
or	O
anilocaine	B
in	O
a	O
quantity	O
of	O
from	O
0.1	O
to	O
5.0	O
(	O
mass%	O
)	O
.	O

The	O
auxiliary	O
ingredients	O
in	O
the	O
composition	O
are	O
the	O
medicinal	O
substances	O
lidocaine	B
or	O
anilocaine	B
in	O
a	O
quantity	O
of	O
from	O
0.1	O
to	O
5.0	O
(	O
mass%	O
)	O
and	O
deoxynatum	O
in	O
a	O
quantity	O
of	O
from	O
0.1	O
to	O
5.0	O
(	O
mass%	O
)	O
.	O

The	O
gel	O
-	O
forming	O
component	O
in	O
the	O
composition	O
is	O
hydroxypropyl	O
cellulose	O
in	O
a	O
quantity	O
of	O
from	O
0.1	O
to	O
5.0	O
(	O
mass%	O
)	O
.	O

Immobilized	O
active	O
and	O
auxiliary	O
ingredients	O
are	O
used	O
.	O

The	O
hydrogel	O
composition	O
also	O
comprises	O
at	O
least	O
one	O
of	O
the	O
following	O
substrates	O
:	O
a	O
textile	O
or	O
a	O
nonwoven	O
material	O
,	O
a	O
mesh	O
fabric	O
with	O
a	O
ratio	O
by	O
mass	O
of	O
said	O
at	O
least	O
one	O
substrate	O
to	O
the	O
gel	O
-	O
forming	O
component	O
of	O
1:3	O
to	O
1:8	O
.	O

Hydrogel	O
composition	O
for	O
the	O
treatment	O
of	O
burns	O

[	O
insert	O
compound	O
of	O
Formula	O
I	O
]	O

This	O
invention	O
relates	O
to	O
novel	O
substituted	O
azaindoles	B
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
compound	O
showing	O
selective	O
inhibitory	O
activity	O
of	O
oncogenic	O
B	O
-	O
RafV600E	O
protein	O
kinase	O
.	O

Substituted	O
azaindoles	B

The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
lung	O
cancer	O
by	O
cyclohexenone	B
compounds	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
lung	O
cancer	O

There	O
is	O
provided	O
an	O
antidiabetic	O
enolic	O
glucoside	B
of	O
phenylpyruvic	B
acid	I
and	O
derivatives	O
thereof	O
for	O
use	O
as	O
medicaments	O
,	O
especially	O
normoglycemic	O
agents	O
,	O
i.e.	O
for	O
lowering	O
blood	O
glucose	B
levels	O
to	O
normal	O
levels	O
in	O
mammals	O
that	O
are	O
obese	O
,	O
pre	O
-	O
diabetic	O
or	O
have	O
diabetes	O
,	O
obesity	O
and/or	O
syndrome	O
X.Hence	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
help	O
to	O
manage	O
blood	O
sugar	B
levels	O
,	O
i.e.	O
helping	O
the	O
body	O
by	O
balancing	O
the	O
blood	O
sugar	B
levels	O
;	O
helping	O
to	O
keep	O
balanced	O
blood	O
glucose	B
levels	O
,	O
particularly	O
in	O
humans	O
with	O
diabetes	O
;	O
aiding	O
by	O
enhancing	O
the	O
glucose	B
uptake	O
by	O
the	O
cells	O
and	O
by	O
reducing	O
sugar	B
levels	O
,	O
thus	O
improving	O
or	O
restoring	O
the	O
glucose	B
tolerance	O
;	O
optimizing	O
the	O
glycemic	O
response	O
;	O
normalizing	O
the	O
glucose	O
tolerance	O
.	O

Antidiabetic	O
enolic	O
glucoside	B
of	O
phenylpyruvic	B
acid	I

The	O
present	O
invention	O
provides	O
a	O
novel	O
compound	O
having	O
an	O
excellent	O
antitumor	O
effect	O
,	O
stability	O
and	O
metabolic	O
stability	O
.	O

The	O
compound	O
of	O
the	O
present	O
invention	O
is	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
wherein	O
R1	O
represents	O
a	O
halogen	B
atom	O
,	O
an	O
aryl	B
group	O
,	O
an	O
aryloxy	B
group	O
or	O
a	O
lower	O
alkyl	B
group	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
halogen	B
atoms	O
;	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
halogen	B
atom	O
,	O
a	O
lower	O
alkyl	B
group	O
or	O
a	O
lower	O
alkoxy	B
group	O
;	O
and	O
;	O
m	O
represents	O
an	O
integer	O
of	O
1	O
to	O
3	O
;	O
provided	O
that	O
when	O
m	O
represents	O
2	O
or	O
3	O
,	O
R1s	O
are	O
the	O
same	O
or	O
different	O
.	O

4-	B
(	I
methylaminophenoxy	I
)	I
pyrdin-	I
3	I
-	I
yl	I
-	I
benzamide	I
derivatives	O
for	O
treating	O
cancer	O

Compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
ocular	O
bacterial	O
infections	O
,	O
or	O
disorders	O
associated	O
with	O
such	O
infections	O
,	O
are	O
disclosed	O
.	O

The	O
compositions	O
include	O
rifalazil	B
or	O
rifalazil	B
derivatives	O
,	O
and	O
optionally	O
include	O
other	O
antimicrobial	O
agents	O
and/or	O
anti	O
-	O
inflammatory	O
agents	O
.	O

The	O
compositions	O
can	O
be	O
used	O
to	O
treat	O
bacterial	O
infections	O
and	O
associated	O
ocular	O
disorders	O
.	O

Trachoma	O
and	O
bacterial	O
conjunctivitis	O
are	O
representative	O
bacterial	O
disorders	O
that	O
can	O
be	O
treated	O
.	O

Use	O
of	O
rifazil	B
and	O
analogues	O
thereof	O
to	O
treat	O
ocular	O
disorders	O

The	O
invention	O
relates	O
to	O
organic	O
chemistry	O
,	O
more	O
specifically	O
to	O
novel	O
biologically	O
active	O
compounds	O
in	O
the	O
form	O
of	O
5-amino-1,2,4-thiadiazole	B
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
where	O
X	O
may	O
be	O
ONO2	B
or	O
NHR3	B
;	O
R1	O
,	O
R2	O
,	O
R3	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
independently	O
represent	O
hydrogen	B
,	O
alkyl	B
,	O
aryl	B
,	O
aralkyl	B
,	O
heteroaryl	B
,	O
heteroaralkyl	B
or	O
cycloakyl	B
and	O
R1	O
+	O
R2	O
may	O
represent	O
a	O
heterocycle	B
(	O
for	O
example	O
,	O
optionally	O
substituted	O
pyrrolidine	B
,	O
piperidine	B
,	O
azepane	B
,	O
piperazine	B
,	O
morpholine	B
,	O
etc	O
.	O
)	O
provided	O
that	O
when	O
R1	O
=	O
H	B
,	O
R2	O
is	O
different	O
from	O
hydrogen	B
or	O
methyl	B
.	O

The	O
5-amino-1,2,4-thiadiazole	B
derivatives	O
are	O
of	O
particular	O
interest	O
as	O
drugs	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
neurodegenerative	O
diseases	O
,	O
for	O
example	O
Alzheimer	O
's	O
disease	O
.	O

5-amino-1,2,4-thiadiazole	B
derivatives	O

The	O
present	O
invention	O
provides	O
treating	O
LAL	O
deficiency	O
(	O
e.g.	O
Wolman	O
's	O
disease	O
,	O
CESD	O
)	O
comprising	O
administering	O
to	O
a	O
mammal	O
a	O
therapeutically	O
effective	O
amount	O
o	O
lysosomal	O
acid	O
lipase	O
with	O
an	O
effective	O
dosage	O
frequency	O
.	O

Methods	O
of	O
improving	O
growth	O
and	O
liver	O
function	O
,	O
increasing	O
LAL	O
tissue	O
concentration	O
,	O
and	O
increasing	O
LAL	O
activity	O
in	O
a	O
human	O
patient	O
suffering	O
from	O
LAL	O
deficiency	O
are	O
also	O
provided	O
Use	O
of	O
lysosomal	O
acid	O
lipase	O
for	O
treating	O
lysosomal	O
acid	O
lipase	O
deficiency	O
in	O
patients	O

The	O
invention	O
relates	O
to	O
bicyclic	B
aminocyclitols	I
and	O
to	O
the	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
lysosomal	O
diseases	O
,	O
such	O
as	O
Gaucher	O
's	O
disease	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
method	O
for	O
the	O
synthesis	O
of	O
said	O
compounds	O
.	O

Bicyclic	B
aminocyclitols	I
and	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
lysosomal	O
diseases	O

The	O
present	O
invention	O
refers	O
to	O
2-mercaptoethane	B
sulfonate	I
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
it	O
for	O
epidural	O
use	O
in	O
the	O
treatment	O
of	O
lumbar	O
pain	O
.	O

Sodium	B
2	I
-mercaptoethane	I
sulfonate	I
for	O
use	O
in	O
the	O
treatment	O
of	O
lumbar	O
pain	O

Disclosed	O
are	O
a	O
compound	O
inhibitory	O
of	O
HIF-1	O
activity	O
,	O
a	O
method	O
for	O
preparing	O
the	O
same	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
compound	O
has	O
anticancer	O
activity	O
which	O
is	O
attributable	O
to	O
its	O
inhibitory	O
activity	O
against	O
HIF-1	O
,	O
but	O
not	O
to	O
non	O
-	O
selective	O
cellular	O
toxicity	O
.	O

Thus	O
,	O
having	O
inhibitory	O
activity	O
against	O
HIF-1	O
,	O
the	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
can	O
be	O
used	O
as	O
an	O
ingredient	O
in	O
an	O
anticancer	O
agent	O
for	O
various	O
cancers	O
including	O
large	O
intestine	O
cancer	O
,	O
hepatic	O
cancer	O
,	O
stomach	O
cancer	O
and	O
breast	O
cancer	O
.	O

Further	O
,	O
the	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
is	O
applicable	O
to	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	O
or	O
arthritis	O
which	O
is	O
aggravated	O
upon	O
the	O
activation	O
of	O
VEGFA	O
by	O
HIF-1	O
.	O

Aryloxyphenoxyacetyl	B
-	O
based	O
compound	O
having	O
hif-1	O
inhibition	O
activity	O
,	O
preparation	O
method	O
thereof	O
and	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
as	O
an	O
active	O
ingredient	O

A	O
method	O
for	O
treating	O
an	O
ATP	B
analog	O
-	O
induced	O
side	O
effect	O
in	O
a	O
subject	O
comprises	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
adenosine	B
receptor	O
antagonist	O
to	O
the	O
subject	O
.	O

A	O
method	O
for	O
treating	O
cancer	O
in	O
a	O
subject	O
comprises	O
administering	O
a	O
nucleobase	O
and/or	O
nucleoside	O
prior	O
to	O
administering	O
an	O
ATP	B
analog	O
.	O

Combination	O
comprising	O
an	O
atp	B
analog	O
and	O
an	O
adenosine	B
receptor	O
antagonist	O
or	O
a	O
nucleobase	O
/	O
nucleoside	O
analog	O
for	O
the	O
treatment	O
of	O
cancer	O

Compounds	O
of	O
Formula	O
I	O
are	O
disclosed	O
:	O
wherein	O
L	O
,	O
A	O
,	O
R1	O
,	O
R2	O
,	O
R3A	O
,	O
R3B	O
,	O
R4A	O
,	O
R4B	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
defined	O
herein	O
.	O

The	O
compounds	O
encompassed	O
by	O
Formula	O
I	O
include	O
compounds	O
which	O
are	O
HIV	O
protease	O
inhibitors	O
and	O
other	O
compounds	O
which	O
can	O
be	O
metabolized	O
in	O
vivo	O
to	O
HIV	O
protease	O
inhibitors	O
.	O

The	O
compounds	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
are	O
useful	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
infection	O
by	O
HIV	O
and	O
the	O
prophylaxis	O
,	O
treatment	O
,	O
or	O
delay	O
in	O
the	O
onset	O
of	O
AIDS	O
.	O

The	O
compounds	O
and	O
their	O
salts	O
can	O
be	O
employed	O
as	O
ingredients	O
in	O
pharmaceutical	O
compositions	O
,	O
optionally	O
in	O
combination	O
with	O
other	O
antivirals	O
,	O
immunomodulators	O
,	O
antibiotics	O
or	O
vaccines	O
.	O

Sulfonamides	B
as	O
hiv	O
protease	O
inhibitors	O

Disclosed	O
are	O
novel	O
diphosphonate	B
compounds	O
,	O
and	O
method	O
for	O
preparing	O
the	O
novel	O
diphosphonate	B
compounds	O
.	O

The	O
novel	O
diphosphonate	B
compounds	O
provided	O
in	O
the	O
present	O
invention	O
show	O
an	O
almost	O
equivalent	O
activity	O
in	O
inhibiting	O
the	O
activity	O
of	O
osteoclasts	O
as	O
compared	O
to	O
alendronate	B
sodium	I
and	O
a	O
relatively	O
high	O
activity	O
in	O
influencing	O
the	O
proliferation	O
of	O
osteoblasts	O
as	O
compared	O
to	O
positive	O
control	O
drugs	O
having	O
a	O
relatively	O
weak	O
influence	O
on	O
the	O
proliferation	O
of	O
osteoblasts	O
.	O

In	O
the	O
test	O
examples	O
,	O
dosing	O
regimens	O
for	O
using	O
the	O
diphosphonate	B
compounds	O
according	O
to	O
the	O
present	O
invention	O
are	O
provided	O
.	O

Diphosphonate	B
compounds	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
,	O
processes	O
for	O
making	O
said	O
compounds	O
,	O
and	O
their	O
use	O
as	O
medicaments	O
for	O
treatment	O
and/or	O
prevention	O
of	O
Αβ	O
-	O
related	O
diseases	O
.	O

COMPOUNDS	O
AND	O
THEIR	O
USE	O
FOR	O
TREATMENT	O
OF	O
Αβ	O
-	O
RELATED	O
DISEASES	O

The	O
invention	O
generally	O
relates	O
to	O
methods	O
of	O
improving	O
thyroid	O
hormone	O
sensitivity	O
or	O
treating	O
a	O
thyroid	O
hormone	O
resistance	O
related	O
disorder	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
comprising	O
administering	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
a	O
MetAP-2	O
inhibitor	O
.	O

Such	O
methods	O
may	O
include	O
administering	O
a	O
MetAP-2	O
inhibitor	O
at	O
a	O
dose	O
that	O
does	O
not	O
substantially	O
modulate	O
angiogenesis	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
thyroid	O
hormone	O
related	O
disorders	O

Disclosed	O
are	O
methods	O
to	O
treat	O
allergic	O
conditions	O
,	O
including	O
pulmonary	O
and	O
non-	O
pulmonary	O
conditions	O
,	O
in	O
a	O
subject	O
by	O
administering	O
a	O
composition	O
that	O
inhibits	O
Pirn	O
kinase	O
.	O

Also	O
disclosed	O
are	O
methods	O
to	O
treat	O
allergic	O
conditions	O
in	O
a	O
subject	O
by	O
administering	O
a	O
composition	O
that	O
induces	O
expression	O
of	O
Runx3	O
.	O

Methods	O
to	O
test	O
allergic	O
conditions	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
styraxlignolide	B
A	I
or	O
the	O
aglycone	B
thereof	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
or	O
treating	O
asthma	O
.	O

More	O
particularly	O
,	O
the	O
styraxlignolide	B
A	I
compound	O
is	O
separated	O
from	O
the	O
stem	O
and	O
bark	O
of	O
Styrax	O
japonica	O
,	O
and	O
the	O
styraxlignolide	B
A	I
or	O
homoegonol	B
,	O
which	O
is	O
the	O
aglycone	B
of	O
styraxlignolide	B
A	I
and	O
which	O
has	O
improved	O
safety	O
,	O
has	O
the	O
effect	O
of	O
attenuating	O
weight	O
loss	O
and	O
hypersensitivity	O
of	O
the	O
airway	O
,	O
inhibiting	O
the	O
generation	O
of	O
active	O
oxygen	B
in	O
the	O
airway	O
,	O
inhibiting	O
the	O
generation	O
of	O
IgE	O
,	O
TGF	O
-	O
â1	O
,	O
and	O
IL-17	O
in	O
the	O
serum	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
inhibiting	O
inflammatory	O
cell	O
infiltration	O
in	O
the	O
bronchial	O
tubes	O
,	O
and	O
inhibiting	O
the	O
formation	O
of	O
a	O
mucous	O
plug	O
and	O
subepithelial	O
fibrosis	O
in	O
an	O
asthmatic	O
mouse	O
model	O
.	O

Therefore	O
,	O
the	O
above	O
-	O
described	O
styraxlignolide	B
or	O
homoegonol	B
can	O
be	O
effectively	O
used	O
as	O
the	O
active	O
ingredient	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
or	O
treating	O
bronchial	O
asthma	O
in	O
which	O
airway	O
remodeling	O
has	O
progressed	O
.	O

Composition	O
containing	O
styraxlignolide	B
a	O
or	O
the	O
aglycone	B
thereof	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
or	O
treating	O
asthma	O

Provided	O
is	O
an	O
insulin	O
secretagogue	O
which	O
is	O
effective	O
in	O
preventing	O
diabetes	O
and	O
the	O
like	O
and	O
which	O
is	O
very	O
safe	O
and	O
free	O
of	O
concern	O
of	O
side	O
effects	O
even	O
when	O
ingested	O
continuously	O
.	O

This	O
insulin	O
secretagogue	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
any	O
of	O
a	O
phospholipid	O
,	O
a	O
sucrose	B
fatty	I
acid	I
ester	I
,	O
an	O
HLB-4	O
to	O
15	O
polyglycerin	B
fatty	I
acid	I
ester	I
,	O
or	O
glycerin	B
mono	I
fatty	I
acid	I
ester	I
,	O
and	O
is	O
therefore	O
very	O
safe	O
and	O
free	O
of	O
concern	O
of	O
side	O
effects	O
even	O
when	O
ingested	O
continuously	O
.	O

The	O
phospholipid	O
is	O
preferably	O
lecithin	O
derived	O
from	O
soybeans	O
.	O

The	O
HLB	O
of	O
the	O
sucrose	B
fatty	I
acid	I
ester	I
is	O
preferably	O
4	O
to	O
16	O
.	O

The	O
carbon	O
number	O
of	O
the	O
constituent	O
fatty	B
acid	I
of	O
the	O
glycerin	B
mono	I
fatty	I
acid	I
ester	I
is	O
preferably	O
8	O
to	O
12	O
.	O

Insulin	O
secretagogue	O

Disclosed	O
are	O
bispecific	O
aptamers	O
binding	O
with	O
high	O
specifity	O
to	O
a	O
tumour	O
specific	O
antigen	O
(	O
TSA	O
)	O
and	O
a	O
effector	O
cell	O
specific	O
antigen	O
(	O
ESA	O
)	O
for	O
treatment	O
of	O
cancer	O
.	O

Bispecific	O
aptamers	O
mediating	O
tumour	O
cell	O
lysis	O

The	O
present	O
invention	O
relates	O
to	O
synthetic	O
retinoid	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
use	O
in	O
the	O
control	O
of	O
cell	O
differentiation	O
or	O
apoptosis	O
.	O

Synthetic	O
retinoids	B
for	O
control	O
of	O
cell	O
differentiation	O

The	O
invention	O
relates	O
to	O
thieno	B
[	I
3,4-b	I
]	I
pyrazine	I
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
treating	O
,	O
preventing	O
and/or	O
managing	O
diseases	O
,	O
disorders	O
,	O
syndromes	O
or	O
conditions	O
associated	O
with	O
inadequate	O
insulin	O
secretion	O
such	O
as	O
diabetes	O
,	O
related	O
disorders	O
and	O
metabolic	O
syndrome	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
treating	O
,	O
preventing	O
and/or	O
managing	O
diseases	O
,	O
disorders	O
,	O
syndromes	O
or	O
conditions	O
which	O
are	O
affected	O
or	O
facilitated	O
by	O
the	O
modulation	O
of	O
GLP-1	O
receptor	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
.	O

Substituted	O
thieno	B
[	I
3,4-b	I
]	I
pyrazine	I
compounds	O

A	O
process	O
for	O
preparation	O
of	O
montelukast	B
sodium	I
through	O
novel	O
montelukast	B
amine	I
salts	O
is	O
provided	O
,	O
wherein	O
the	O
amine	B
is	O
selected	O
from	O
1-	B
(	I
l	I
-	I
naphthyl	I
)	I
ethylamine	I
,	O
S	B
-	I
methyl	I
-	I
L	I
-	I
cysteine	I
,	O
diallylamine	B
or	O
isomers	O
thereof	O
.	O

A	O
process	O
for	O
purification	O
of	O
2-	B
(	I
2-	I
(	I
3-	I
(	I
S	I
)	I
-	I
(	I
3-	I
(	I
7-chloro-2-quinolinyl	I
)	I
-ethenyl	I
)	I
phenyl	I
)	I
-3-hydroxylpropyl	I
)	I
-phenyl-2-propanol	I
is	O
also	O
provided	O
,	O
which	O
uses	O
a	O
halogenated	B
hydrocarbon	I
and	O
a	O
nitrile	B
as	O
solvent	O
.	O

Processes	O
for	O
preparation	O
of	O
montelukast	B
sodium	I
and	O
purification	O
of	O
diol	B
intermediate	O

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
inflammatory	O
diseases	O
,	O
which	O
can	O
inhibit	O
the	O
function	O
of	O
an	O
inflammatory	O
cytokine	O
and	O
therefore	O
can	O
exhibit	O
an	O
anti	O
-	O
inflammatory	O
effect	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
inflammatory	O
diseases	O
,	O
which	O
contains	O
2-deoxy	B
-	I
D	I
-	I
glucose	I
or	O
a	O
derivative	O
thereof	O
as	O
an	O
active	O
ingredient	O
and	O
can	O
inhibit	O
the	O
function	O
of	O
an	O
inflammatory	O
cytokine	O
.	O

Therapeutic	O
agent	O
for	O
inflammatory	O
diseases	O
,	O
which	O
can	O
inhibit	O
function	O
of	O
inflammatory	O
cytokine	O

The	O
invention	O
provides	O
a	O
process	O
for	O
producing	O
a	O
composition	O
comprising	O
natural	O
alumino	B
-	I
silicate	I
minerals	O
having	O
improved	O
reactivity	O
for	O
use	O
in	O
methods	O
of	O
animal	O
husbandry	O
,	O
veterinary	O
and	O
pharmaceutical	O
treatment	O
,	O
comprising	O
irradiating	O
natural	O
alumino	B
-	I
silicate	I
minerals	O
in	O
a	O
liquid	O
suspension	O
with	O
transverse	O
electromagnetic	O
wave	O
radiation	O
in	O
the	O
range	O
of	O
1,800	O
MHz	O
to	O
3,000	O
MHz	O
,	O
the	O
liquid	O
suspension	O
having	O
a	O
boiling	O
temperature	O
of	O
below	O
120	O
°	O
C	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
of	O
treating	O
digestive	O
ailments	O
in	O
animals	O
comprising	O
administering	O
to	O
an	O
animal	O
in	O
need	O
of	O
same	O
an	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
at	O
least	O
one	O
natural	O
alumina	B
-	I
silicate	I
mineral	O
which	O
has	O
been	O
irradiated	O
with	O
transverse	O
electromagnetic	O
wave	O
radiation	O
in	O
the	O
range	O
of	O
1,800	O
MHz	O
to	O
3,000	O
MHz	O
.	O

Improved	O
mineral	O
based	O
composition	O
and	O
methods	O
of	O
use	O

A	O
solid	O
oral	O
pharmaceutical	O
composition	O
comprises	O
greater	O
than	O
100	O
mg	O
of	O
imatinib	B
,	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

A	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
comprising	O
than	O
greater	O
than	O
100	O
mg	O
of	O
imatinib	B
,	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
comprises	O
manufacturing	O
a	O
solid	O
oral	O
pharmaceutical	O
composition	O
by	O
granulating	O
imatimib	B
with	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

A	O
solid	O
oral	O
pharmaceutical	O
composition	O
for	O
use	O
in	O
medicine	O
comprises	O
greater	O
than	O
100	O
mg	O
of	O
imatinib	B
,	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Pharmaceutical	O
composition	O
comprising	O
imatinib	B

The	O
invention	O
provides	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
and	O
the	O
use	O
of	O
the	O
compound	O
in	O
therapy	O
.	O

Imidazo	B
[	I
4	I
,	I
5	I
-c	I
]	I
quinolin-	I
1	I
-yl	I
derivative	O
useful	O
in	O
therapy	O

Provided	O
is	O
a	O
lactam	B
compound	O
or	O
a	O
salt	O
thereof	O
indicated	O
by	O
formula	O
(	O
1	O
)	O
,	O
which	O
is	O
a	O
compound	O
with	O
a	O
lactam	B
skeleton	O
or	O
a	O
salt	O
thereof	O
useful	O
as	O
a	O
PPAR	O
activator	O
.	O

[	O
In	O
the	O
formula	O
,	O
the	O
ring	O
Z	O
indicates	O
a	O
condensed	O
hydrocarbon	B
ring	I
or	O
a	O
heterocyclic	B
ring	I
;	O
R1	O
indicates	O
the	O
same	O
or	O
different	O
halogen	B
atoms	O
,	O
alkyl	B
groups	O
that	O
can	O
have	O
a	O
substituted	O
group	O
,	O
hydroxyl	B
groups	O
,	O
or	O
alkoxy	B
groups	O
that	O
can	O
have	O
a	O
substituted	O
group	O
;	O
R2	O
indicates	O
an	O
alkylene	B
group	O
that	O
can	O
have	O
a	O
direct	O
bond	O
or	O
a	O
substituted	O
group	O
;	O
R3	O
indicates	O
a	O
alkoxy	B
group	O
that	O
can	O
have	O
a	O
hydroxyl	B
group	O
or	O
a	O
substituted	O
group	O
;	O
the	O
linker	O
(	O
X	O
)	O
has	O
1	O
-	O
10	O
atoms	O
in	O
the	O
main	O
chain	O
selected	O
from	O
carbon	B
atoms	O
and	O
hetero	O
atoms	O
and	O
the	O
main	O
chain	O
can	O
have	O
a	O
substituted	O
group	O
;	O
Y	O
indicates	O
a	O
direct	O
bond	O
,	O
an	O
oxygen	B
atom	O
,	O
or	O
a	O
sulfur	B
atom	O
;	O
and	O
k	O
is	O
an	O
integer	O
between	O
0	O
and	O
5	O
.	O
]	O

Lactam	B
compound	O
or	O
a	O
salt	O
thereof	O
,	O
and	O
ppar	O
activator	O

In	O
one	O
aspect	O
,	O
the	O
invention	O
provides	O
an	O
ophthalmic	O
composition	O
comprising	O
active	O
Vitamin	B
D	I
and	O
at	O
least	O
one	O
topical	O
steroid	O
in	O
a	O
formulation	O
suitable	O
for	O
topical	O
administration	O
to	O
the	O
eye	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
composition	O
comprises	O
an	O
amount	O
of	O
active	O
Vitamin	B
D	I
and	O
at	O
least	O
one	O
topical	O
steroid	O
in	O
an	O
amount	O
effective	O
to	O
provide	O
at	O
least	O
one	O
of	O
:	O
relief	O
of	O
symptoms	O
of	O
dry	O
eyes	O
and	O
ocular	O
surface	O
disease	O
,	O
reduction	O
in	O
ocular	O
vascular	O
injection	O
(	O
redness	O
)	O
,	O
enhancement	O
of	O
corneal	O
clarity	O
,	O
structural	O
integrity	O
and/or	O
refractive	O
ability	O
,	O
and/or	O
inhibition	O
of	O
steroid	O
-	O
induced	O
rise	O
in	O
intraocular	O
pressure	O
when	O
administered	O
topically	O
to	O
the	O
eye	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
composition	O
comprises	O
calcitriol	B
and	O
difluprednate	O
.	O

Compositions	O
and	O
methods	O
for	O
improving	O
ocular	O
surface	O
health	O
,	O
corneal	O
clarity	O
,	O
optical	O
function	O
and	O
maintaining	O
visual	O
acuity	O

Provided	O
is	O
a	O
carrier	O
which	O
prevents	O
decomposition	O
of	O
a	O
medical	O
agent	O
and	O
is	O
capable	O
of	O
delivering	O
the	O
medical	O
agent	O
specifically	O
to	O
an	O
in	O
vivo	O
target	O
cell	O
with	O
excellent	O
safety	O
.	O

A	O
carrier	O
-	O
producing	O
cell	O
is	O
obtained	O
by	O
introducing	O
an	O
expression	O
vector	O
,	O
which	O
comprises	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
a	O
peptide	O
that	O
is	O
capable	O
of	O
binding	O
to	O
a	O
membrane	O
protein	O
of	O
a	O
target	O
cell	O
,	O
into	O
a	O
membrane	O
vesicle	O
-	O
producing	O
cell	O
.	O

The	O
carrier	O
-	O
producing	O
cell	O
is	O
capable	O
of	O
producing	O
a	O
membrane	O
vesicle	O
which	O
has	O
,	O
as	O
a	O
membrane	O
peptide	O
,	O
a	O
binding	O
peptide	O
that	O
is	O
capable	O
of	O
binding	O
to	O
a	O
membrane	O
protein	O
of	O
a	O
target	O
cell	O
.	O

Since	O
the	O
membrane	O
vesicle	O
is	O
bound	O
to	O
the	O
membrane	O
protein	O
of	O
the	O
target	O
cell	O
,	O
a	O
medical	O
agent	O
can	O
be	O
specifically	O
administered	O
to	O
the	O
target	O
cell	O
by	O
having	O
the	O
membrane	O
vesicle	O
contain	O
the	O
medical	O
agent	O
.	O

Expression	O
vector	O
,	O
method	O
for	O
producing	O
carrier	O
using	O
same	O
,	O
and	O
use	O
of	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
tape	O
for	O
body	O
slimming	O
which	O
is	O
to	O
be	O
used	O
for	O
body	O
slimming	O
by	O
means	O
of	O
taping	O
,	O
and	O
more	O
particularly	O
,	O
to	O
a	O
caffeine	B
tape	O
for	O
body	O
slimming	O
in	O
which	O
caffeine	B
is	O
mixed	O
with	O
an	O
adhesive	O
,	O
and	O
the	O
mixture	O
is	O
applied	O
to	O
the	O
surface	O
of	O
a	O
fabric	O
sheet	O
to	O
form	O
an	O
adhesive	O
layer	O
.	O

Caffeine	B
tape	O
for	O
body	O
slimming	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
one	O
of	O
X	O
and	O
Y	O
is	O
N	O
and	O
the	O
other	O
is	O
an	O
optionally	O
substituted	O
carbon	O
atom	O
,	O
and	O
Z2-Z5	O
represent	O
one	O
or	O
two	O
nitrogen	B
atoms	O
,	O
as	O
further	O
described	O
herein	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
,	O
enantiomers	O
,	O
stereoisomers	O
,	O
rotamers	O
,	O
tautomers	O
,	O
diastereomers	O
,	O
or	O
racemates	O
thereof	O
.	O

These	O
compounds	O
inhibit	O
the	O
activity	O
of	O
CDK9	O
and	O
are	O
thus	O
useful	O
as	O
pharmaceuticals	O
and	O
as	O
components	O
of	O
pharmaceutical	O
compositions	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
mediated	O
by	O
CDK9	O
using	O
the	O
compounds	O
described	O
herein	O
or	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O

N	B
-	I
acyl	I
pyrimidine	I
biaryl	I
compounds	O
as	O
protein	O
kinase	O
inhibitors	O

Provided	O
is	O
an	O
anti	O
-	O
Trichophyton	O
agent	O
having	O
as	O
an	O
active	O
ingredient	O
a	O
compound	O
having	O
a	O
2-	B
(	I
1H	I
-	I
pyrazol-1-yl	I
)	I
phenol	I
backbone	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
,	O
or	O
a	O
salt	O
of	O
the	O
compound	O
.	O

Topical	O
antifungal	O
agent	O

Disclosed	O
are	O
nitrogen	B
-	O
containing	O
artemisinin	B
dimers	O
represented	O
by	O
formula	O
(	O
1	O
)	O
below	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
X	O
is	O
NR	B
,	O
NR	B
(	I
CH2	I
)	I
nNR	I
,	O
or	O
formula	O
(	O
2	O
)	O
,	O
wherein	O
R	O
is	O
H	B
or	O
C1	B
-	I
4	I
alkyl	I
;	O
Y	O
and	O
Z	O
are	O
separately	O
independently	O
(	B
CH2	I
)	I
m	I
,	O
(	O
CH2	O
)	O
n	O
(	O
OCH2CH2	O
)	O
m	O
,	O
OC	B
(	I
CH2	I
)	I
nCO	I
,	O
or	O
COAr	B
;	O
wherein	O
Ar	B
is	O
phenyl	B
,	O
naphthyl	B
,	O
or	O
heterocyclyl	B
;	O
n	O
is	O
an	O
integer	O
between	O
2	O
and	O
8	O
;	O
m	O
is	O
an	O
integer	O
between	O
1	O
and	O
11	O
;	O
the	O
said	O
heterocyclyl	B
is	O
a	O
5	O
-	O
6	O
membered	O
heterocyclyl	B
containing	O
1	O
-	O
2	O
heteroatoms	O
selected	O
from	O
N	B
,	O
O	B
or	O
S.	B
Also	O
disclosed	O
are	O
the	O
preparation	O
methods	O
of	O
these	O
compounds	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
uses	O
thereof	O
in	O
the	O
manufacture	O
of	O
drugs	O
for	O
the	O
treatment	O
of	O
cancers	O
,	O
especially	O
endometrial	O
cancer	O
,	O
ovarian	O
cancer	O
,	O
cervical	O
cancer	O
,	O
breast	O
cancer	O
,	O
colorectal	O
cancer	O
,	O
lung	O
cancer	O
,	O
prostatic	O
cancer	O
,	O
liver	O
cancer	O
and/or	O
gastric	O
cancer	O
.	O

Nitrogen	B
-	O
containing	O
artemisinin	B
dimers	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
the	O
aqueous	O
concentrated	O
formulation	O
of	O
linezolid	B
,	O
more	O
particularly	O
,	O
the	O
aqueous	O
concentrated	O
formulation	O
of	O
linezolid	B
comprising	O
at	O
least	O
one	O
solubilizer	O
,	O
wherein	O
the	O
formulation	O
is	O
preferably	O
administered	O
intravenously	O
.	O

Aqueous	O
concentrated	O
formulation	O
of	O
linezolid	B

The	O
present	O
invention	O
refers	O
to	O
a	O
method	O
of	O
treating	O
a	O
disease	O
or	O
disorder	O
associated	O
with	O
the	O
expression	O
of	O
at	O
least	O
one	O
transgluaminase-2	O
and	O
a	O
method	O
of	O
identifying	O
a	O
candidate	O
transglutaminase-2	O
inhibitor	O
.	O

Transglutaminase-2	O
inhibitors	O
and	O
uses	O
thereof	O

A	O
dual	O
H1	O
/	O
5-HT2A	O
receptor	O
antagonist	O
of	O
the	O
formula	O
:	O
,	O
its	O
uses	O
,	O
and	O
methods	O
for	O
its	O
preparation	O
are	O
described	O
.	O

SUBSTITUTED	B
[	I
(	I
5H	I
-	I
PYRROLO	I
[	I
2,1-c	I
]	I

[	B
1,4	I
]	I
BENZODIAZEPIN-11-YL	I
)	I
PIPERAZIN-1-YL	I
]	I
-2,2-DIMETHYLPROPANOIC	I
ACID	I
COMPOUNDS	O
AS	O
DUAL	O
ACTIVITY	O
H1	O
INVERSE	O
AGONISTS	O
/	O
5-HT2A	O
ANTAGONISTS	O

The	O
present	O
invention	O
is	O
directed	O
to	O
benzimidazole	B
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
modulated	O
by	O
TRP	O
M8	O
,	O
including	O
for	O
example	O
,	O
inflammatory	O
pain	O
,	O
inflammatory	O
hyperalgesia	O
,	O
inflammatory	O
hypersensitivity	O
condition	O
,	O
neuropathic	O
pain	O
,	O
neuropathic	O
cold	O
allodynia	O
,	O
inflammatory	O
somatic	O
hyperalgesia	O
,	O
inflammatory	O
visceral	O
hyperalgesia	O
,	O
cardiovascular	O
disease	O
aggravated	O
by	O
cold	O
and	O
pulmonary	O
disease	O
aggravated	O
by	O
cold	O
.	O

Substituted	O
benzimdazole	B
derivatives	O
useful	O
as	O
trpm8	O
receptor	O
modulators	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
producing	O
a	O
dietetic	O
or	O
pharmaceutical	O
preparation	O
,	O
comprising	O
the	O
following	O
steps	O
:	O
a	O
)	O
a	O
preparation	O
containing	O
rutin	O
,	O
in	O
particular	O
ground	O
Tartary	O
buckwheat	O
,	O
is	O
mixed	O
with	O
a	O
protein	O
solution	O
at	O
a	O
weight	O
ratio	O
of	O
protein	O
solution	O
to	O
buckwheat	O
of	O
1	O
to	O
100	O
(	O
or	O
vice	O
versa	O
)	O
,	O
wherein	O
the	O
protein	O
solution	O
has	O
been	O
heated	O
above	O
room	O
temperature	O
before	O
the	O
buckwheat	O
is	O
added	O
;	O
b	O
)	O
the	O
mixture	O
from	O
step	O
a	O
)	O
is	O
kept	O
at	O
a	O
temperature	O
>	O
50	O
°	O
C	O
for	O
a	O
duration	O
of	O
at	O
least	O
10	O
-	O
1000	O
s	O
;	O
and	O
c	O
)	O
following	O
step	O
b	O
)	O
the	O
mixture	O
is	O
cooled	O
to	O
a	O
temperature	O
below	O
45	O
°	O
C	O
.	O

The	O
invention	O
further	O
relates	O
to	O
preparations	O
that	O
can	O
be	O
obtained	O
in	O
such	O
a	O
way	O
and	O
to	O
the	O
uses	O
thereof	O
.	O

Dietetic	O
or	O
pharmaceutical	O
preparation	O
containing	O
tartary	O
buckwheat	O

Embodiments	O
of	O
the	O
invention	O
relate	O
to	O
a	O
composition	O
containing	O
zinc	B
and	O
copper	B
and	O
methods	O
of	O
using	O
the	O
same	O
in	O
treatment	O
of	O
exposure	O
to	O
a	O
pore	O
-	O
forming	O
toxin	O
(	O
PFT	O
)	O
in	O
a	O
subject	O
or	O
membrane	O
perturbant	O
(	O
MP	O
)	O
.	O

Compositions	O
and	O
multi	O
-	O
step	O
methods	O
of	O
using	O
the	O
same	O
for	O
the	O
treatment	O
of	O
jellyfish	O
stings	O

The	O
present	O
invention	O
provides	O
a	O
new	O
class	O
of	O
compounds	O
useful	O
for	O
the	O
modulation	O
of	O
beta	O
-	O
secretase	O
enzyme	O
(	O
BACE	O
)	O
activity	O
.	O

The	O
compounds	O
have	O
a	O
general	O
Formula	O
I	O
,	O
wherein	O
variables	O
A1	O
,	O
A3	O
,	O
A4	O
,	O
A5	O
,	O
A6	O
,	O
A8	O
,	O
R2	O
,	O
R7	O
,	O
X	O
,	O
Y	O
and	O
Z	O
of	O
Formula	O

I	O
are	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
corresponding	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
for	O
treatment	O
of	O
disorders	O
and/or	O
conditions	O
related	O
to	O
plaque	O
formation	O
and	O
deposition	O
,	O
resulting	O
from	O
the	O
activity	O
of	O
BACE	O
.	O

Such	O
BACE	O
mediated	O
disorders	O
include	O
,	O
for	O
example	O
,	O
Alzheimer	O
's	O
Disease	O
,	O
cognitive	O
deficits	O
and	O
impairments	O
,	O
schizophrenia	O
and	O
other	O
central	O
nervous	O
system	O
conditions	O
and	O
disorders	O
.	O

The	O
invention	O
further	O
provides	O
compounds	O
of	O
Formulas	O
II	O
and	O
III	O
,	O
and	O
of	O
sub	O
-	O
formulas	O
of	O
Formulas	O
I	O
,	O
II	O
and	O
III	O
,	O
intermediates	O
and	O
processes	O
and	O
methods	O
useful	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
Formulas	O
I	O
-	O
III	O
.	O

Spiro	B
-	I
amino	I
-	I
imidazo	I
-	I
fused	I
heterocyclic	I
compounds	O
as	O
beta	O
-	O
secretase	O
modulators	O
and	O
methods	O
of	O
use	O

Methods	O
for	O
treating	O
cancer	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
represented	O
by	O
the	O
following	O
structural	O
formula	O
a	O
tautomer	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
combination	O
with	O
radiotherapy	O
.	O

The	O
variables	O
depicted	O
in	O
the	O
structural	O
formula	O
are	O
defined	O
herein	O
.	O

Combination	O
therapy	O
of	O
hsp90	O
inhibitory	O
compounds	O
with	O
radiotherapy	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
central	O
nervous	O
system	O
disorders	O
,	O
such	O
as	O
mood	O
disorders	O
(	O
e.g.	O
,	O
depression	O
)	O
and	O
neurodegenerative	O
diseases	O
using	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
subject	O
disclosure	O
enables	O
the	O
manufacture	O
of	O
medicaments	O
as	O
well	O
as	O
compositions	O
containing	O
same	O
for	O
use	O
in	O
methods	O
of	O
therapy	O
and	O
prophylaxis	O
of	O
central	O
nervous	O
system	O
disorders	O
.	O

Methods	O
of	O
treating	O
a	O
disease	O
or	O
condition	O
of	O
the	O
central	O
nervous	O
system	O

The	O
present	O
invention	O
relates	O
to	O
the	O
crystalline	O
substance	O
comprising	O
Tiotropium	B
bromide	I
and	O
process	O
that	O
shall	O
be	O
used	O
in	O
production	O
of	O
the	O
said	O
substance	O
.	O

Anhydrous	O
crystalline	O
form	O
of	O
tiotropium	B
bromide	I

Provided	O
herein	O
are	O
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
-trauma	O
related	O
disorders	O
like	O
spinal	O
cord	O
injuries	O
.	O

Pharmaceutical	O
compositions	O
,	O
single	O
unit	O
dosage	O
forms	O
,	O
and	O
kit	O
suitable	O
for	O
use	O
for	O
the	O
treatment	O
of	O
(	O
CNS	O
)	O
-trauma	O
related	O
disorders	O
are	O
also	O
disclosed	O
.	O

Novel	O
use	O
of	O
benzofuranylsulfonates	B

The	O
application	O
describes	O
methods	O
for	O
screening	O
subjects	O
with	O
breast	O
cancer	O
to	O
determine	O
if	O
the	O
breast	O
cancer	O
will	O
be	O
responsive	O
to	O
a	O
breast	O
cancer	O
therapy	O
including	O
an	O
anthracycline	B
.	O

The	O
application	O
also	O
describes	O
methods	O
for	O
treating	O
subjects	O
with	O
breast	O
cancer	O
by	O
screening	O
them	O
for	O
the	O
likelihood	O
of	O
the	O
effectiveness	O
of	O
treating	O
the	O
cancer	O
with	O
a	O
therapy	O
including	O
anthracycline	B
and	O
administering	O
the	O
therapy	O
in	O
subjects	O
when	O
it	O
is	O
found	O
that	O
anthracycline	B
is	O
likely	O
to	O
be	O
effective	O
.	O

Methods	O
of	O
treating	O
breast	O
cancer	O
with	O
anthracycline	B
therapy	O

The	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
containing	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
m-3M3FBS	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
preventing	O
or	O
treating	O
inflammatory	O
diseases	O
or	O
infectious	O
diseases	O
.	O

Further	O
,	O
another	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
functional	O
health	O
food	O
containing	O
m-3M3FBS	O
for	O
preventing	O
or	O
treating	O
inflammatory	O
diseases	O
or	O
infectious	O
diseases	O
.	O

The	O
m-3M3FBS	O
of	O
the	O
present	O
invention	O
exhibits	O
germicidal	O
effects	O
,	O
apoptosis	O
-	O
inhibiting	O
effects	O
,	O
and	O
effects	O
of	O
inhibiting	O
LPS	O
-	O
related	O
signaling	O
,	O
and	O
thus	O
enables	O
the	O
effective	O
treatment	O
or	O
prevention	O
of	O
inflammatory	O
diseases	O
or	O
infectious	O
diseases	O
.	O

Therefore	O
,	O
the	O
m-3M3FBS	O
of	O
the	O
present	O
invention	O
can	O
be	O
effectively	O
used	O
in	O
a	O
pharmaceutical	O
product	O
or	O
functional	O
health	O
food	O
for	O
treating	O
or	O
preventing	O
inflammatory	O
diseases	O
or	O
infectious	O
diseases	O
.	O

Pharmaceutical	O
composition	O
containing	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
m-3m3fbs	O
,	O
which	O
is	O
an	O
activator	O
of	O
phospholipase	O
c	O
,	O
for	O
preventing	O
or	O
treating	O
inflammatory	O
diseases	O
or	O
infectious	O
diseases	O

A	O
method	O
of	O
treating	O
NSCLC	O
comprising	O
in	O
some	O
aspects	O
administering	O
OSI-906	O
and	O
an	O
EGFR	O
inhibitor	O
to	O
a	O
patient	O
having	O
NSCLC	O
having	O
an	O
activating	O
EGFR	O
mutation	O
,	O
as	O
disclosed	O
herein	O
.	O

Nsclc	O
combination	O
therapy	O

The	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
human	O
RPT4	O
protein	O
/	O
gene	O
can	O
function	O
as	O
a	O
therapeutic	O
target	O
for	O
solid	O
tumour	O
type	O
cancers	O
,	O
especially	O
solid	O
tumours	O
of	O
the	O
colon	O
,	O
and	O
that	O
reducing	O
the	O
abundance	O
of	O
RPT4	O
in	O
tumour	O
cells	O
causes	O
a	O
significant	O
increase	O
in	O
cancer	O
cell	O
death	O
,	O
and	O
potently	O
decreases	O
the	O
survival	O
and	O
proliferation	O
of	O
cancer	O
cells	O
in	O
tumour	O
growth	O
assays	O
(	O
Figs	O
3	O
and	O
4	O
)	O
.	O

A	O
further	O
,	O
but	O
linked	O
,	O
aspect	O
of	O
the	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
inhibitors	O
of	O
RPT4	O
significantly	O
decrease	O
the	O
viability	O
of	O
chemotherapeutic	O
-	O
resistant	O
tumours	O
,	O
especially	O
solid	O
tumours	O
,	O
especially	O
colorectal	O
solid	O
tumours	O
(	O
Fig.	O
5	O
)	O
.	O

A	O
further	O
,	O
but	O
linked	O
,	O
aspect	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
efficacy	O
of	O
conventional	O
chemotherapeutic	O
therapy	O
,	O
for	O
example	O
5-FU	B
/	O
oxaliplatin	B
therapy	O
,	O
is	O
significantly	O
improved	O
when	O
combined	O
with	O
treatment	O
with	O
a	O
RPT4	O
inhibitor	O
(	O
Fig.	O
6	O
)	O
.	O

A	O
further	O
,	O
but	O
linked	O
,	O
aspect	O
of	O
the	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
levels	O
of	O
RPT4	O
in	O
solid	O
tumours	O
such	O
as	O
colorectal	O
cancer	O
can	O
function	O
as	O
a	O
prognostic	O
variable	O
of	O
outcome	O
/	O
survival	O
(	O
Fig.	O
2	O
)	O
.	O

Treatment	O
and	O
prognosis	O
of	O
solid	O
tumour	O
cancers	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
group	O
of	O
sulphamide	O
derivatives	O
with	O
neuroprotective	O
capacity	O
that	O
are	O
of	O
use	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
associated	O
with	O
cell	O
death	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
(	O
sporadic	O
forms	O
and	O
hereditary	O
forms	O
)	O
,	O
cerebral	O
ischaemia	O
,	O
lateral	O
amyotrophic	O
sclerosis	O
,	O
post	O
encephalitic	O
parkinsonism	O
,	O
and	O
also	O
other	O
rare	O
diseases	O
involving	O
neurodegeneration	O
,	O
such	O
as	O
Huntington	O
's	O
disease	O
and	O
spino	O
-	O
cerebellar	O
ataxias	O
.	O

Use	O
of	O
sulphamide	O
derivatives	O
as	O
neuroprotectors	O

The	O
present	O
invention	O
discloses	O
novel	O
crystalline	O
and	O
non	O
-	O
crystalline	O
forms	O
of	O
3-	B
(	I
(	I
3R	I
,	I
4R	I
)	I
-4-methyl-3-	I
[	I
methyl-	I
(	I
7H	I
-	I
pyrrolo	I
[	I
2	I
,	I
3-d	I
]	I
pyrimidin-4-yl	I
)	I
-amino	I
]	I
-piperidin-1-yl	I
)	I
-3-oxopropionitrile	I
,	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
,	O
preparations	O
thereof	O
and	O
the	O
uses	O
thereof	O
.	O

Crystalline	O
and	O
non-	O
crystalline	O
forms	O
of	O
tofacitinib	B
,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
tofacitinib	B
and	O
a	O
penetration	O
enhancer	O

A	O
sustained	O
-	O
release	O
preparation	O
of	O
compound	O
methoxyphenamine	B
,	O
with	O
methoxyphenamine	B
or	O
hydrochloride	B
thereof	O
,	O
noscapine	B
,	O
aminophylline	B
and	O
chlorpheniramine	B
maleate	I
as	O
active	O
components	O
,	O
wherein	O
a	O
ratio	O
of	O
the	O
active	O
components	O
to	O
a	O
sustained	O
-	O
release	O
adjuvant	O
is	O
1:0.03	O
to	O
1:30	O
,	O
and	O
the	O
sustained	O
-	O
release	O
preparation	O
is	O
a	O
sustained	O
-	O
release	O
tablet	O
,	O
a	O
sustained	O
-	O
release	O
capsule	O
or	O
a	O
sustained	O
-	O
release	O
suspensoid	O
.	O

Sustained	O
-	O
release	O
preparation	O
of	O
compound	O
methoxyphenamine	B

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
yessotoxins	B
and	O
the	O
derivatives	O
thereof	O
for	O
producing	O
a	O
medicament	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
metabolic	O
diseases	O
and	O
preferably	O
metabolic	O
syndrome	O
or	O
diabetes	O
mellitus	O
type	O
2	O
,	O
inter	O
alia	O
.	O

Use	O
of	O
yessotoxins	B
and	O
the	O
derivatives	O
thereof	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
metabolic	O
diseases	O

Provided	O
are	O
a	O
Tigecycline	B
crystalline	O
hydrate	B
,	O
and	O
a	O
preparation	O
method	O
therefor	O
and	O
use	O
thereof	O
.	O

The	O
crystalline	O
hydrate	B
has	O
high	O
stability	O
for	O
storage	O
,	O
and	O
is	O
applicable	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
treating	O
or	O
preventing	O
Gram	O
-	O
positive	O
or	O
negative	O
bacterium	O
sensitive	O
bacterium	O
or	O
diseases	O
in	O
human	O
or	O
animal	O
caused	O
by	O
Gram	O
-	O
positive	O
or	O
negative	O
bacterium	O
sensitive	O
bacterium	O
,	O
such	O
as	O
infection	O
of	O
respiratory	O
system	O
,	O
liver	O
and	O
gall	O
system	O
,	O
five	O
sense	O
organs	O
and	O
urogenital	O
system	O
,	O
bone	O
and	O
joint	O
infection	O
,	O
skin	O
soft	O
tissue	O
infection	O
and	O
endocarditis	O
,	O
septicemia	O
,	O
meningitis	O
.	O

Tigecycline	B
crystalline	O
hydrate	B
and	O
preparation	O
method	O
therefor	O
and	O
use	O
thereof	O

A	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
oral	O
administration	O
for	O
chronic	O
hepatic	O
diseases	O
associated	O
with	O
a	O
hepatitis	O
-	O
C	O
virus	O
(	O
an	O
HCV	O
)	O
,	O
alcoholic	O
hepatitis	O
or	O
non	O
-	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
,	O
which	O
contains	O
deferoxamine	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
prophylactic	O
or	O
therapeutic	O
agent	O
is	O
effective	O
as	O
a	O
chronic	O
hepatic	O
diseases	O
therapeutic	O
agent	O
for	O
oral	O
administration	O
.	O

Chronic	O
hepatic	O
diseases	O
therapeutic	O
agent	O
for	O
oral	O
administration	O

The	O
invention	O
relates	O
to	O
acidic	O
cannabinoids	B
as	O
defined	O
in	O
the	O
specification	O
for	O
use	O
in	O
increasing	O
the	O
natural	O
resistance	O
of	O
an	O
animal	O
,	O
for	O
use	O
in	O
enhancing	O
cellular	O
resistance	O
,	O
for	O
use	O
in	O
therapy	O
of	O
diabetes	O
,	O
for	O
use	O
in	O
therapy	O
of	O
atherosclerosis	O
,	O
reduce	O
the	O
decline	O
in	O
stress	O
response	O
found	O
in	O
ageing	O
or	O
for	O
use	O
in	O
decreasing	O
the	O
necessity	O
for	O
antibiotic	O
treatment	O
.	O

Preferably	O
said	O
acidic	O
cannabinoid	B
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Δ9-tetrahydrocannabinolic	B
acid	I
or	O
THC	B
acid	I
(	O
THCA	B
)	O
,	O
cannabidiolic	B
acid	I
(	O
CBD	B
-	I
A	I
)	O
,	O
cannabidiol	B
(	O
CBD	B
)	O
,	O
cannabigerolic	B
acid	I
(	O
CBGA	B
)	O
,	O
cannabigerol	B
(	O
CBG	B
)	O
,	O
cannabinolic	B
acid	I
(	O
CBN	B
-	I
A	I
)	O
and	O
cannabinol	B
(	O
CBN	B
)	O
,	O
cannabichromenic	B
acid	I
(	O
CBC	B
-	I
A	I
)	O
and	O
cannabichromene	B
(	O
CBC	B
)	O
.	O

Medical	O
use	O
for	O
acidic	O
cannabinoids	B

A	O
method	O
of	O
treating	O
neuropathic	O
pain	O
in	O
a	O
subject	O
is	O
provided	O
.	O

The	O
method	O
comprises	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
A3AR	O
agonist	O
.	O

Use	O
of	O
adenosine	B
a3	O
receptor	O
agonists	O
for	O
treatment	O
of	O
neuropathic	O
pain	O

TRPVl	O
antagonists	O
and	O
associated	O
methods	O
are	O
provided	O
.	O

A	O
TRPVl	O
channel	O
antagonist	O
can	O
have	O
the	O
structure	O
:	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
can	O
be	O
-CH3	B
,	O
-	B
(	I
CH2	I
)	I
X	I
(	I
CH	I
)	I
YCH3	I
where	O
x	O
+	O
y	O
=	O
1	O
-	O
20	O
,	O
an	O
aromatic	B
,	O
a	O
(	B
CH2	I
)	I
n	I
aromatic	B
where	O
n	O
can	O
be	O
less	O
than	O
or	O
equal	O
to	O
6	O
,	O
a	O
lipid	O
,	O
or	O
a	O
linker	O
,	O
and	O
wherein	O
R2	O
can	O
be	O
either	O
Formula	O
(	O
II	O
)	O
or	O
Formula	O
(	O
III	O
)	O
Additionally	O
,	O
R3	O
can	O
be	O
-O	B
-	I
R4	I
or	O
-NH	B
-	I
R4	I
and	O
R4	O
can	O
be	O
-H	B
,	O
-CH3	B
,	O
an	O
ester	B
,	O
a	O
cyclic	B
ester	I
,	O
or	O
an	O
amide	B
.	O

Antagonists	O
of	O
trpv1	O
receptor	O

A	O
formulation	O
,	O
composition	O
or	O
combination	O
of	O
substances	O
comprising	O
jasmonate	O
for	O
modulating	O
melatonin	B
production	O
and/or	O
calcification	O
of	O
a	O
pineal	O
gland	O
and/or	O
modulation	O
and/or	O
treatment	O
of	O
age	O
-	O
related	O
neurodegeneration	O
in	O
a	O
subject	O
,	O
particularly	O
in	O
a	O
mammalian	O
subject	O
and	O
more	O
particularly	O
in	O
a	O
human	O
subject	O
and	O
use	O
of	O
jasmonate	B
for	O
modulating	O
melatonin	B
production	O
and/or	O
calcification	O
of	O
a	O
pineal	O
gland	O
and/or	O
modulation	O
and/or	O
treatment	O
of	O
age	O
-	O
related	O
neurodegeneration	O
is	O
provided	O
.	O

Use	O
of	O
jasmonates	O
for	O
modulating	O
melatonin	O
production	O
and	O
calcification	O
of	O
the	O
pineal	O
gland	O

The	O
present	O
invention	O
addresses	O
the	O
problem	O
of	O
providing	O
a	O
wrinkle	O
-	O
improving	O
composition	O
having	O
a	O
moisturizing	O
effect	O
and	O
having	O
excellent	O
wrinkle	O
-	O
improving	O
efficacy	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
wrinkle	O
-	O
improving	O
composition	O
containing	O
a	O
liquid	O
fraction	O
of	O
a	O
high	O
-	O
pressure	O
-	O
treated	O
product	O
of	O
placenta	O
or	O
a	O
treated	O
product	O
of	O
the	O
fraction	O
,	O
in	O
particular	O
,	O
to	O
a	O
wrinkle	O
-	O
improving	O
composition	O
for	O
imparting	O
moisture	O
to	O
the	O
skin	O
and	O
for	O
obscuring	O
wrinkles	O
caused	O
by	O
dryness	O
.	O

Wrinkle	O
-	O
improving	O
composition	O
containing	O
placenta	O
-	O
derived	O
component	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
transdermal	O
administration	O
with	O
improved	O
storage	O
stability	O
,	O
containing	O
rivastigmine	B
or	O
a	O
salt	O
thereof	O
.	O

The	O
composition	O
for	O
transdermal	O
administration	O
of	O
the	O
present	O
invention	O
uses	O
gentisic	O
acid	O
as	O
a	O
stabilizer	O
of	O
rivastigmine	B
,	O
wherein	O
gentisic	O
acid	O
has	O
greater	O
rivastigmine	B
stability	O
than	O
tocopherol	B
,	O
a	O
formulation	O
used	O
on	O
the	O
market	O
,	O
is	O
easy	O
to	O
handle	O
and	O
is	O
commercially	O
cheap	O
.	O

According	O
to	O
the	O
present	O
invention	O
,	O
the	O
composition	O
has	O
improved	O
stability	O
,	O
and	O
thus	O
can	O
be	O
stored	O
for	O
a	O
long	O
time	O
as	O
a	O
drug	O
for	O
transdermal	O
administration	O
.	O

Composition	O
for	O
transdermal	O
administration	O
,	O
containing	O
rivastigmine	B
or	O
salt	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
2'-Fluoro-6'-methylene	B
carbocyclic	I
nucleosides	I
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
nucleosides	O
and	O
their	O
use	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
number	O
of	O
viral	O
infections	O
and	O
secondary	O
disease	O
states	O
and	O
conditions	O
thereof	O
,	O
especially	O
including	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
secondary	O
disease	O
states	O
and	O
conditions	O
thereof	O
(	O
cirrhosis	O
and	O
liver	O
cancer	O
)	O
,	O
Heptatitis	O
C	O
virus	O
(	O
HCV	O
)	O
,	O
Herpes	O
Simplex	O
virus	O
I	O
and	O
II	O
(	O
HSV-1	O
and	O
HSV-2	O
)	O
,	O
cytomegalovirus	O
(	O
CMV	O
)	O
,	O
Varicella	O
-	O
Zoster	O
Virus	O
(	O
VZV	O
)	O
and	O
Epstein	O
Barr	O
virus	O
(	O
EBV	O
)	O
and	O
secondary	O
cancers	O
which	O
occur	O
thereof	O
(	O
lymphoma	O
,	O
nasopharyngeal	O
cancer	O
,	O
including	O
drug	O
resistant	O
(	O
especially	O
including	O
lamivudine	B
and/or	O
adefovir	B
resistant	O
)	O
and	O
other	O
mutant	O
forms	O
of	O
these	O
viruses	O
,	O
especially	O
HBV	O
.	O

2'-fluoro-6'-methylene	B
carbocyclic	I
nuceosides	I
and	O
methods	O
of	O
treating	O
viral	O
infections	O

This	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
CFTR	O
potentiator	O
.	O

Deuterated	O
derivatives	O
of	O
ivacaftor	O

Methods	O
and	O
compositions	O
for	O
enhancing	O
fertility	O
and/or	O
inhibiting	O
pregnancy	O
failure	O
,	O
restoring	O
glucose	B
tolerance	O
and/or	O
preventing	O
glucose	B
intolerance	O
and/or	O
maintaining	O
glucose	B
homeostasis	O
and/or	O
inducing	O
or	O
enhancing	O
weight	O
loss	O
,	O
treating	O
dyslipidemia	O
,	O
treating	O
hypertestosteronism	O
or	O
hyperandrogenism	O
,	O
and/or	O
treating	O
type	O
2	O
diabetes	O
in	O
an	O
individual	O
in	O
need	O
thereof	O
are	O
provided	O
.	O

These	O
involve	O
compositions	O
that	O
inhibit	O
expression	O
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
γ	O
)	O
or	O
a	O
downstreamIFN	O
-	O
γ	O
-	O
stimulated	O
gene	O
,	O
which	O
is	O
preferably	O
a	O
macrolide	O
immunosuppressant	O
compound	O
.	O

Methods	O
and	O
compositions	O
for	O
enhancing	O
fertility	O
and/or	O
inhibiting	O
pregnancy	O
failure	O
and	O
restoring	O
glucose	B
tolerance	O

The	O
present	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
and	O
relates	O
to	O
a	O
pyridothiazepine	B
derivative	O
and	O
a	O
preparation	O
method	O
and	O
uses	O
therefor	O
.	O

Pyridothiazepine	B
derivatives	O
have	O
a	O
wide	O
range	O
of	O
antineoplastic	O
activity	O
,	O
said	O
compounds	O
exhibiting	O
excellent	O
inhibitive	O
effect	O
on	O
various	O
human	O
carcinoma	O
cell	O
lines	O
in	O
in	O
vitro	O
cell	O
tests	O
;	O
said	O
cell	O
lines	O
include	O
human	O
leukemia	O
cell	O
line	O
OP-1	O
,	O
human	O
colon	O
carcinoma	O
cell	O
line	O
HT29	O
,	O
human	O
lung	O
carcinoma	O
cell	O
line	O
H460	O
,	O
paclitaxel	O
-	O
resistant	O
human	O
lung	O
carcinoma	O
cell	O
line	O
H460TaxR	O
,	O
and	O
doxorubicin	B
-	O
resistant	O
human	O
breast	O
carcinoma	O
cell	O
line	O
MCF-7	O
/	O
Adr	O
.	O

The	O
compounds	O
can	O
independently	O
or	O
together	O
with	O
active	O
ingredients	O
of	O
other	O
anticancer	O
drugs	O
be	O
mixed	O
with	O
pharmaceutical	O
excipients	O
to	O
form	O
a	O
pharmaceutical	O
formulation	O
that	O
can	O
be	O
used	O
to	O
treat	O
various	O
carcinomas	O
.	O

Pyridothiazepine	B
derivative	O
,	O
preparation	O
method	O
and	O
uses	O
therefor	O

Provided	O
herein	O
are	O
antibacterial	O
compounds	O
,	O
wherein	O
the	O
compounds	O
in	O
some	O
embodiments	O
have	O
broad	O
spectrum	O
bioactivity	O
.	O

The	O
compounds	O
provided	O
herein	O
can	O
in	O
other	O
embodiments	O
overcome	O
the	O
resistance	O
conferred	O
by	O
single	O
amino	B
acid	I
mutations	O
at	O
defined	O
positions	O
of	O
bacterial	O
Signal	O
Peptidases	O
(	O
SPases	O
)	O
and	O
in	O
other	O
embodiments	O
provide	O
for	O
a	O
broader	O
spectrum	O
of	O
antibiotic	O
bioactivity	O
compared	O
to	O
the	O
natural	O
product	O
.	O

Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treatment	O
using	O
the	O
compounds	O
described	O
herein	O
are	O
also	O
provided	O
.	O

Broad	O
spectrum	O
antibiotics	O

The	O
present	O
invention	O
generally	O
relates	O
to	O
methods	O
,	O
assays	O
,	O
compositions	O
and	O
kits	O
related	O
to	O
a	O
subpopulation	O
of	O
ovarian	O
cancer	O
stem	O
cells	O
which	O
are	O
selected	O
or	O
enriched	O
by	O
chemotherapeutic	O
agents	O
and	O
inhibited	O
by	O
MIS	O
(	O
Mullerian	O
Inhibiting	O
Substance	O
)	O
and	O
MIS	O
mimetics	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
population	O
of	O
CD44+	O
/	O
CD24+	O
/	O
EpCam+	O
/	O
ECad-	O
subpopulation	O
of	O
ovarian	O
cancer	O
stem	O
cells	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
to	O
screen	O
a	O
subject	O
with	O
ovarian	O
cancer	O
to	O
identify	O
if	O
they	O
have	O
an	O
ovarian	O
cancer	O
comprising	O
CD44+	O
/	O
CD24+	O
/	O
EpCam+	O
/	O
ECad-	O
ovarian	O
cancer	O
stem	O
cells	O
,	O
and	O
methods	O
to	O
identify	O
and	O
enrich	O
or	O
isolate	O
for	O
such	O
ovarian	O
cancer	O
cell	O
populations	O
.	O

Ovarian	O
cancer	O
stem	O
cells	O
and	O
methods	O
of	O
isolation	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
heterocyclic	O
[	B
b	I
]	I
pyridone	I
compound	O
of	O
the	O
following	O
formula	O
(	O
I	O
)	O
.,and	O
the	O
heterocyclic	O
[	B
b	I
]	I
pyridone	I
compound	O
is	O
used	O
as	O
tyrosine	O
kinase	O
inhibitors	O
,	O
particularly	O
as	O
the	O
c	O
-	O
Met	O
inhibitors	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
intermediates	O
of	O
the	O
preparation	O
of	O
the	O
heterocyclic	O
[	B
b	I
]	I
pyridone	I
compound	O
as	O
well	O
as	O
the	O
method	O
of	O
preparation	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
pharmaceutical	O
composition	O
containing	O
such	O
compounds	O
as	O
the	O
active	O
ingredient	O
,	O
and	O
disclose	O
the	O
purpose	O
of	O
heterocyclic	O
[	B
b	I
]	I
pyridone	I
compound	O
as	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
the	O
disease	O
associated	O
with	O
tyrosine	O
kinase	O
,	O
especially	O
cancer	O
associated	O
with	O
c	O
-	O
Met	O
.	O

A	O
heterocyclic	O
[	B
b	I
]	I
pyridone	I
compound	O
,	O
intermediates	O
thereof	O
,	O
method	O
of	O
preparation	O
and	O
uses	O

A	O
core	O
-	O
shell	O
nanoparticle	O
for	O
drug	O
delivery	O
comprising	O
a	O
polymeric	O
shell	O
encapsulating	O
core	O
comprising	O
a	O
drug	O
and	O
an	O
imaging	O
agent	O
.	O

A	O
core	O
-	O
shell	O
nanoparticle	O

Provided	O
is	O
a	O
therapeutic	O
agent	O
capable	O
of	O
treating	O
allergic	O
rhinitis	O
in	O
a	O
safe	O
,	O
simple	O
,	O
and	O
noninvasive	O
manner	O
substantially	O
without	O
side	O
effects	O
and	O
physical	O
pain	O
to	O
a	O
patient	O
.	O

Provided	O
is	O
a	O
therapeutic	O
agent	O
for	O
allergic	O
rhinitis	O
for	O
ALA	O
-	O
PDT	O
that	O
contains	O
5-aminolevulinic	B
acid	I
(	O
ALA	B
)	O
,	O
a	O
derivative	O
thereof	O
,	O
or	O
a	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
that	O
is	O
used	O
in	O
5-aminolevulinic	B
acid	I
-	O
based	O
photodynamic	O
therapy	O
(	O
ALA	O
-	O
PDT	O
)	O
in	O
which	O
light	O
having	O
a	O
wavelength	O
of	O
400	O
-	O
700	O
nm	O
is	O
irradiated	O
;	O
and	O
more	O
particularly	O
provided	O
is	O
a	O
locally	O
applied	O
solution	O
,	O
a	O
dissolving	O
-	O
type	O
water	O
-	O
soluble	O
ointment	O
,	O
a	O
dissolving	O
-	O
type	O
jelly	O
agent	O
,	O
or	O
another	O
therapeutic	O
agent	O
for	O
allergic	O
rhinitis	O
.	O

This	O
therapeutic	O
agent	O
does	O
not	O
require	O
5-aminolevulinic	B
acid	I
-	O
based	O
photodynamic	O
diagnosis	O
(	O
ALA	O
-	O
PDD	O
)	O
for	O
detecting	O
areas	O
of	O
protoporphyrin	B
IX	I
(	O
PpIX	B
)	O
accumulation	O
in	O
which	O
light	O
having	O
a	O
wavelength	O
of	O
610	O
-	O
650	O
nm	O
is	O
emitted	O
under	O
irradiation	O
of	O
excitation	O
light	O
having	O
a	O
wavelength	O
of	O
380	O
-	O
420	O
nm	O
prior	O
to	O
ALA	O
-	O
PDT	O
.	O

Therapeutic	O
agent	O
for	O
allergic	O
rhinitis	O

Synthesis	O
and	O
purification	O
of	O
deoxycholic	B
acid	I
and	O
its	O
salts	O
are	O
provided	O
.	O

Methods	O
for	O
the	O
synthesis	O
and	O
purification	O
of	O
deoxycholic	B
acid	I

The	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
cancers	O
including	O
hematologic	O
malignancies	O
comprising	O
administering	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
:	O
in	O
combination	O
with	O
one	O
or	O
both	O
of	O
bendamustine	B
and	O
rituximab	B
.	O

Combination	O
therapies	O
for	O
treating	O
hematologic	O
malignancies	O
using	O
pyridopyrimidinone	B
inhibitors	O
of	O
pi3k	O
/	O
mtor	O
with	O
bendamustine	B
and/or	O
rituximab	B

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
preparative	O
methods	O
and	O
the	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
their	O
pharmaceutical	O
acceptable	O
salts	O
as	O
antitumor	O
agents	O
can	O
be	O
used	O
to	O
treat	O
cancers	O
or	O
tumors	O
.	O

A	O
series	O
of	O
ecteinascidins	B
analogs	O
with	O
anti	O
-	O
tumor	O
effect	O

The	O
present	O
invention	O
provides	O
an	O
N	B
-	I
substituted	I
isopropyldimethyl	I
azulene	I
sulfonamide	I
derivative	O
as	O
represented	O
by	O
formula	O
(	O
1	O
)	O
,	O
and	O
preparation	O
method	O
and	O
uses	O
thereof	O
.	O

R1	O
is	O
an	O
alkyl	B
,	O
cycloalkyl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
amino	B
,	O
or	O
a	O
substituted	O
alkyl	B
,	O
cycloalkyl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
and	O
amino	B
.	O

The	O
N	B
-	I
substituted	I
isopropyldimethyl	I
azulene	I
sulfonamide	I
derivative	O
can	O
be	O
used	O
in	O
treating	O
gastric	O
ulcer	O
.	O

N	B
-	I
substituted	I
isopropyldimethyl	I
azulene	I
sulfonamide	I
derivatives	O
,	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O

A	O
combined	O
therapy	O
which	O
utilizes	O
hydroxychloroquine	B
and	O
GNS-227	O
:	O
GNS-227	O
,	O
for	O
the	O
treatment	O
of	O
an	O
HCV	O
-	O
related	O
disease	O
,	O
including	O
HCV	O
chronic	O
infection	O
,	O
is	O
disclosed	O
.	O

Further	O
disclosed	O
is	O
pharmaceutical	O
composition	O
(	O
e.g.	O
,	O
as	O
a	O
unit	O
dosage	O
form	O
)	O
comprising	O
hydroxychloroquine	B
and	O
GNS-227	O
.	O

Treatment	O
of	O
hepatitis	O
c	O
virus	O

[	O
Problem	O
]	O
To	O
provide	O
a	O
novel	O
substance	O
which	O
can	O
exert	O
a	O
sedating	O
effect	O
safely	O
and	O
effectively	O
through	O
being	O
vaporized	O
and	O
inhaled	O
.	O

[	O
Solution	O
]	O
A	O
sedative	O
agent	O
for	O
vaporization	O
and	O
inhalation	O
,	O
which	O
comprises	O
3-methoxy-5-methylphenol	B
as	O
an	O
active	O
ingredient	O
.	O

Sedative	O
agent	O
for	O
vaporization	O
and	O
inhalation	O
,	O
and	O
sedative	O
perfume	O
composition	O
containing	O
same	O

The	O
present	O
disclosure	O
relates	O
to	O
regulation	O
of	O
macrophage	O
activation	O
by	O
delivering	O
of	O
miRNAs	O
,	O
for	O
example	O
miR-125b	O
or	O
anti	O
-	O
miR-125b	O
,	O
to	O
macrophages	O
.	O

For	O
example	O
,	O
in	O
some	O
embodiments	O
,	O
macrophage	O
activation	O
can	O
be	O
elevated	O
or	O
reduced	O
by	O
administering	O
miR-125b	O
or	O
anti	O
-	O
miR-125b	O
oligonucleotides	B
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
promoting	O
T	O
cell	O
activation	O
and	O
method	O
for	O
treating	O
various	O
disorders	O
such	O
as	O
tumor	O
and	O
autoimmune	O
diseases	O
.	O

Regulation	O
of	O
macrophage	O
activation	O
using	O
mir	O
-	O
125b	O

The	O
present	O
invention	O
concerns	O
paiiperidone	B
oleate	I
,	O
a	O
solid	O
state	O
form	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
paiiperidone	B
oleate	I
,	O
the	O
use	O
of	O
paiiperidone	B
oleate	I
for	O
the	O
treatment	O
of	O
schizophrenia	O
,	O
and	O
processes	O
for	O
preparing	O
paiiperidone	B
oleate	I
and	O
a	O
solid	O
state	O
form	O
of	O
paiiperidone	B
oleate	I
.	O

Formula	O
(	O
I	O
)	O
Paliperidone	B
oleate	I

The	O
invention	O
relates	O
to	O
novel	O
amidoalkylpiperazinyl	B
derivatives	O
of	O
tricyclic	B
heterocyclic	I
systems	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Z	O
represents	O
-NH-	B
and	O
X	O
represents	O
-S-	B
,	O
or	O
Z	O
represents	O
-S-	B
and	O
X	O
represents	O
>	B
C	I
=	I
C	I
<	I
;	O
R1	O
represents	O
H	B
or	O
-CH3	B
,	O
R6	O
and	O
R7	O
both	O
represent	O
H	B
,	O
n	O
is	O
an	O
integer	O
from	O
0	O
to	O
4	O
inclusive	O
,	O
G	O
represents	O
a	O
cyclic	O
amide	B
or	O
imide	B
moiety	O
,	O
and	O
optical	O
isomers	O
,	O
geometric	O
isomers	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
the	O
central	O
nervous	O
system	O
disorders	O
.	O

Amidoalkylpiperazinyl	B
derivatives	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
as	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
is	O
H	B
,	O
hydroxyl	B
or	O
methoxyl	B
;	O
R2	O
is	O
hydroxyl	B
;	O
R3	O
is	O
heteroatom	O
-	O
substituted	O
or	O
unsubstituted	O
organic	O
matter	O
,	O
and	O
the	O
heteroatom	O
is	O
one	O
or	O
more	O
of	O
halogens	B
,	O
N	B
,	O
O	B
and	O
S	B
;	O
R4	O
is	O
H	B
,	O
carbobenzoxy	B
,	O
benzoyl	B
or	O
acetyl	B
.	O

The	O
compound	O
of	O
the	O
present	O
invention	O
as	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
is	O
an	O
antibacterial	O
agent	O
,	O
and	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
various	O
bacteria	O
and	O
protozoan	O
infections	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
use	O
of	O
the	O
compound	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
a	O
composition	O
formed	O
therewith	O
.	O

C-3	B
substituted-9-deoxidized-9a	I
-	I
aza-9a	I
-	I
erythromycin	I
a	O
derivative	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
useful	O
in	O
therapy	O
,	O
to	O
compositions	O
comprising	O
said	O
compounds	O
,	O
and	O
to	O
methods	O
of	O
treating	O
diseases	O
comprising	O
administration	O
of	O
said	O
com-	O
pounds	O
.	O

The	O
compounds	O
referred	O
to	O
are	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
of	O
the	O
nicotinic	B
acetylcholine	I
α7	O
receptor	O
.	O

Pyrazolopyridines	B
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
of	O
the	O
central	O
nervous	O
system	O

The	O
present	O
invention	O
relates	O
to	O
crystalline	O
forms	O
of	O
(	B
1r,4r	I
)	I
-6'-fluoro	I
-	I
N	I
,	I
N	I
-	I
dimethyl-4-phenyl-4',9'-dihydro-3'l	I
-	I
l	I
-	I
spiro	I
[	I
cyclohexane-1,1	I
'	I
-pyrano	I
[	I
3,4,b	I
]	I
indol	I
]	I
-4-amine	I
,	O
pharmaceutical	O
compositions	O
and	O
medicaments	O
comprising	O
these	O
modifications	O
,	O
the	O
use	O
of	O
these	O
modifications	O
as	O
well	O
as	O
to	O
a	O
process	O
for	O
the	O
enrichment	O
of	O
them	O
.	O

Crystalline	O
(	B
1r,4r	I
)	I
-6'-fluoro	I
-	I
n	I
,	I
n	I
-	I
dimethyl-4-phenyl-4',9'-dihydro-3'h	I
-	I
spiro	I
[	I
cyclohexane-1,1'-pyrano	I
[	I
3,4,b	I
]	I
indol	I
]	I
-4-amine	I

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
therapeutic	O
agent	O
or	O
a	O
prophylactic	O
agent	O
for	O
fibrosis	O
,	O
which	O
has	O
no	O
phototoxicity	O
and	O
reduced	O
hepatotoxicity	O
and	O
digestive	O
disorders	O
and	O
is	O
highly	O
safe	O
.	O

The	O
present	O
invention	O
provides	O
a	O
lactam	O
derivative	O
represented	O
by	O
chemical	O
formula	O
(	O
I	O
)	O
.	O

Lactam	B
derivative	O
and	O
use	O
thereof	O
for	O
medical	O
purposes	O

Therapeutic	O
agents	O
targeted	O
to	O
voltage	O
gated	O
calcium	B
channels	O
and	O
compositions	O
comprising	O
such	O
therapeutic	O
agents	O
are	O
provided	O
,	O
as	O
is	O
the	O
use	O
of	O
such	O
agents	O
and	O
compositions	O
to	O
modulate	O
the	O
function	O
of	O
haematopoietic	O
cells	O
expressing	O
the	O
voltage	O
gated	O
calcium	B
channel	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
screening	O
for	O
agents	O
that	O
target	O
a	O
given	O
voltage	O
gated	O
calcium	B
channel	O
that	O
are	O
suitable	O
for	O
use	O
as	O
therapeutics	O
to	O
modulate	O
the	O
activity	O
of	O
cells	O
expressing	O
the	O
targeted	O
voltage	O
gated	O
calcium	B
channel	O
.	O

The	O
agent	O
can	O
be	O
,	O
for	O
example	O
,	O
an	O
antibody	O
,	O
an	O
aptamer	O
,	O
a	O
peptide	O
or	O
a	O
small	O
molecule	O
capable	O
of	O
binding	O
to	O
an	O
ectodomain	O
of	O
the	O
target	O
voltage	O
gated	O
calcium	B
channel	O
and	O
thus	O
of	O
modulating	O
the	O
function	O
of	O
the	O
calcium	B
channel	O
.	O

Methods	O
and	O
compositions	O
for	O
modulating	O
voltage	O
-	O
gated	O
calcium	B
channel	O
function	O

A	O
method	O
for	O
treating	O
a	O
p62-mediated	O
disease	O
(	O
e.g.	O
,	O
multiple	O
myeloma	O
)	O
in	O
a	O
subject	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
p62-ZZ	O
inhibitor	O
compound	O
.	O

P62-zz	O
chemical	O
inhibitor	O

Use	O
of	O
a	O
polysaccharide	O
polymer	O
obtained	O
from	O
the	O
seeds	O
of	O
the	O
tamarind	O
tree	O
for	O
use	O
in	O
protecting	O
the	O
epithelial	O
cells	O
of	O
the	O
respiratory	O
tract	O
by	O
damages	O
induced	O
by	O
tobacco	O
smoke	O
.	O

Use	O
of	O
a	O
polysaccharide	O
polymer	O
from	O
the	O
seeds	O
of	O
the	O
tamarind	O
tree	O
in	O
protecting	O
against	O
tobacco	O
-	O
associated	O
damages	O

A	O
series	O
of	O
monocyclic	O
or	O
bicyclic	O
diamine	B
-	I
substituted	I
thieno	I
[	I
2,3-d	I
]	I
pyrimidine	I
and	I
isothiazolo	I
[	I
5,4-d	I
]	I
pyrimidine	I
derivatives	O
are	O
beneficial	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
various	O
human	O
ailments	O
,	O
including	O
inflammatory	O
,	O
autoimmune	O
and	O
oncological	O
disorders	O
;	O
viral	O
diseases	O
;	O
and	O
organ	O
and	O
cell	O
transplant	O
rejection	O
.	O

Therapeutically	O
active	O
fused	O
pyrimidine	B
derivatives	O

The	O
present	O
invention	O
provides	O
a	O
sepsis	O
treatment	O
drug	O
which	O
is	O
useful	O
in	O
preventing	O
and	O
treating	O
sepsis	O
.	O

A	O
prophylactic	O
agent	O
and/or	O
therapeutic	O
agent	O
for	O
sepsis	O
,	O
the	O
agent	O
containing	O
as	O
an	O
active	O
ingredient	O
5-aminolevulinic	B
acid	I
(	O
5-ALA	B
)	O
,	O
a	O
derivative	O
thereof	O
,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
,	O
is	O
prepared	O
.	O

Preferably	O
,	O
the	O
ALA	B
contains	O
sodium	B
ferrous	I
citrate	I
or	O
another	O
metal	O
-	O
containing	O
compound	O
.	O

Appropriate	O
examples	O
of	O
the	O
ALA	B
include	O
:	O
ALA	B
;	O
methyl	B
,	O
ethyl	B
,	O
propyl	B
,	O
butyl	B
,	O
pentyl	B
,	O
and	O
other	O
esters	B
thereof	O
;	O
hydrochlorides	B
,	O
phosphates	B
,	O
and	O
sulfates	B
thereof	O
;	O
and	O
the	O
like	O
.	O

Prophylactic	O
agent	O
and/or	O
therapeutic	O
agent	O
for	O
sepsis	O

The	O
primary	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
heterocyclic	B
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Examples	O
of	O
the	O
present	O
invention	O
can	O
include	O
a	O
heterocyclic	B
compound	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
,	O
a	O
tautomer	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

(	O
In	O
the	O
formula	O
,	O
R1	O
and	O
R2	O
are	O
identical	O
or	O
different	O
and	O
represent	O
an	O
aromatic	O
ring	O
or	O
the	O
like	O
,	O
and	O
the	O
ring	O
(	O
A	O
)	O
represents	O
a	O
heterocycle	O
.	O
)	O

This	O
compound	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
has	O
high	O
mPGES-1	O
inhibitory	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
prophylactic	O
agent	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
involving	O
mPGES-1	O
,	O
e.g.	O
,	O
rheumatoid	O
arthritis	O
,	O
osteoarthritis	O
,	O
temporomandibular	O
joint	O
disease	O
,	O
low	O
back	O
pain	O
,	O
endometriosis	O
,	O
dysmenorrhea	O
,	O
overactive	O
bladder	O
,	O
malignancy	O
,	O
or	O
neurodegenerative	O
disease	O
.	O

Heterocyclic	B
derivative	O
and	O
pharmaceutical	O
drug	O

Conventional	O
fragranced	O
products	O
and	O
perfumes	O
often	O
form	O
potent	O
allergens	O
and	O
may	O
also	O
have	O
irritant	O
properties	O
.	O

The	O
invention	O
relates	O
to	O
compounds	O
,	O
compositions	O
,	O
formulations	O
and	O
methods	O
for	O
reducing	O
,	O
avoiding	O
or	O
eliminating	O
allergic	O
contact	O
dermatitis	O
reactions	O
to	O
the	O
oxidation	O
products	O
of	O
odorous	O
chemicals	O
conventionally	O
used	O
in	O
fragranced	O
products	O
and	O
perfumes	O
.	O

Methods	O
and	O
compounds	O
for	O
reducing	O
allergic	O
reactions	O
to	O
fragranced	O
products	O
and	O
perfumes	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
predicting	O
if	O
a	O
squamous	O
cell	O
neoplasm	O
in	O
a	O
subject	O
will	O
be	O
susceptible	O
to	O
treatment	O
with	O
a	O
PI3	O
K	O
inhibitor	O
,	O
a	O
method	O
for	O
selecting	O
a	O
subject	O
with	O
a	O
squamous	O
cell	O
neoplasm	O
for	O
PI3	O
K	O
inhibitor	O
treatment	O
,	O
and	O
a	O
method	O
for	O
treating	O
a	O
squamous	O
cell	O
neoplasm	O
in	O
a	O
subject	O
,	O
and	O
to	O
kits	O
related	O
to	O
said	O
methods	O
.	O

Method	O
for	O
predicting	O
treatment	O
responsiveness	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
including	O
less	O
than	O
600	O
picomoles	O
,	O
in	O
particular	O
less	O
than	O
400	O
picomoles	O
,	O
of	O
biologically	O
-	O
active	O
polyamines	B
per	O
gram	O
of	O
composition	O
,	O
to	O
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
patient	O
,	O
in	O
particular	O
a	O
human	O
being	O
or	O
an	O
animal	O
,	O
for	O
skin	O
or	O
mucosa	O
conditions	O
induced	O
by	O
radiotherapy	O
.	O

Use	O
of	O
compositions	O
having	O
a	O
low	O
polyamine	B
content	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
adverse	O
effects	O
linked	O
to	O
cancer	O
treatment	O

[	O
Problem	O
]	O
To	O
provide	O
a	O
composition	O
for	O
improving	O
an	O
in	O
vivo	O
metabolism	O
parameter	O
.	O

[	O
Solution	O
]	O
A	O
composition	O
containing	O
D	B
-	I
psicose	I
as	O
an	O
active	O
ingredient	O
,	O
which	O
can	O
be	O
used	O
for	O
giving	O
D	B
-	I
psicose	I
at	O
a	O
dose	O
of	O
5	O
g	O
or	O
more	O
for	O
each	O
time	O
continuously	O
for	O
the	O
purpose	O
of	O
decreasing	O
an	O
in	O
vivo	O
metabolism	O
parameter	O
,	O
i.e.	O
,	O
a	O
uric	B
acid	I
level	O
and/or	O
a	O
level	O
of	O
a	O
hepatic	O
function	O
indicator	O
component	O
.	O

The	O
level	O
of	O
15	O
g	O
γ	B
-	I
GTP	I
is	O
significantly	O
decreased	O
from	O
week	O
4	O
of	O
the	O
ingestion	O
of	O
the	O
composition	O
.	O

When	O
the	O
composition	O
is	O
given	O
continuously	O
at	O
a	O
dose	O
of	O
5	O
g	O
or	O
more	O
in	O
terms	O
of	O
D	B
-	I
psicose	I
content	O
three	O
times	O
a	O
day	O
,	O
the	O
level	O
of	O
γ	B
-	I
GTP	I
is	O
significantly	O
decreased	O
from	O
week	O
4	O
of	O
the	O
ingestion	O
of	O
the	O
composition	O
and	O
the	O
level	O
of	O
ALP	O
is	O
significantly	O
decreased	O
from	O
week	O
2	O
of	O
the	O
ingestion	O
of	O
the	O
composition	O
.	O

Composition	O
for	O
improving	O
in	O
vivo	O
metabolism	O
parameter	O

The	O
present	O
invention	O
relates	O
to	O
betulinic	B
acid	I
exhibiting	O
anti	O
-	O
aging	O
activity	O
,	O
wherein	O
the	O
betulinic	B
acid	I
according	O
to	O
the	O
invention	O
,	O
functional	O
foods	O
containing	O
the	O
betulinic	B
acid	I
,	O
or	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
betulinic	B
acid	I
has	O
effects	O
of	O
prolonging	O
one	O
's	O
life	O
and	O
improving	O
overall	O
health	O
and	O
is	O
thus	O
very	O
useful	O
in	O
a	O
functional	O
food	O
or	O
medicine	O
field	O
.	O

Betulinic	B
acid	I
having	O
anti	O
-	O
aging	O
activity	O
and	O
derivatives	O
thereof	O
,	O
and	O
composition	O
containing	O
same	O

Polymorphs	O
of	O
N-	B
(	I
(	I
S	I
)	I
-3-amino-1-	I
(	I
hydroxyamino	I
)	I
-3-methyl-1-oxobutan-2-yl	I
)	I
-4-	I
(	I
(	I
(	I
1R,2R	I
)	I
-2-	I
(	I
hydroxymethyl	I
)	I
cyclopropyl	I
)	I
buta-1,3-diynyl	I
)	I
benzamide	I
(	O
Compound	O
I	O
)	O
are	O
provided	O
.	O

Processes	O
for	O
making	O
the	O
same	O
,	O
as	O
well	O
as	O
related	O
compositions	O
and	O
methods	O
,	O
are	O
also	O
disclosed	O
,	O
particularly	O
with	O
regard	O
to	O
the	O
treatment	O
of	O
bacterial	O
infections	O
.	O

Polymorphs	O
of	O
n-	B
(	I
(	I
s	I
)	I
-3-amino-1-	I
(	I
hydroxyamino	I
)	I
-3-methyl-1-oxobutan-2-yl	I
)	I
-4-	I
(	I
(	I
(	I
1r,2r	I
)	I
-2-	I
(	I
hydroxymethyl	I
)	I
cyclopropyl	I
)	I
buta-1,3-diynyl	I
)	I
benzamide	I

The	O
present	O
application	O
relates	O
to	O
:	O
(	O
a	O
)	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
,	O
and	O
salts	O
thereof	O
,	O
wherein	O
Z	O
'	O
,	O
Z	O
""""	O
,	O
L2	O
,	O
G2	O
,	O
R1	O
,	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
specification	O
;	O
(	O
b	O
)	O
compositions	O
comprising	O
such	O
compounds	O
and	O
salts	O
;	O
and	O
(	O
c	O
)	O
methods	O
of	O
use	O
of	O
such	O
compounds	O
,	O
salts	O
,	O
and	O
compositions	O
,	O
particularly	O
use	O
as	O
calcium	B
channel	O
blockers	O
.	O

Substituted	O
octahydropyrrolo	B
[	I
1,2-a	I
]	I
pyrazine	I
sulfonamides	I
as	O
calcium	B
channel	O
blockers	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inducing	O
an	O
immune	O
response	O
to	O
influenza	O
virus	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
an	O
effective	O
amount	O
of	O
a	O
glycolipid	O
,	O
thereby	O
inducing	O
a	O
T	O
cell	O
response	O
,	O
and	O
treating	O
or	O
preventing	O
influenza	O
infection	O
;	O
and	O
methods	O
of	O
identifying	O
a	O
glycolipid	O
that	O
will	O
induce	O
an	O
immune	O
response	O
in	O
a	O
subject	O
upon	O
administration	O
to	O
the	O
subject	O
,	O
the	O
method	O
comprising	O
identifying	O
the	O
glycolipids	O
isolated	O
from	O
a	O
sample	O
isolated	O
from	O
the	O
subject	O
,	O
and	O
which	O
have	O
been	O
increased	O
in	O
the	O
subject	O
as	O
a	O
result	O
of	O
infection	O
by	O
an	O
influenza	O
virus	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
activating	O
iNKT	O
cells	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
glycolipid	O
thereby	O
activating	O
iNKT	O
cells	O
in	O
the	O
subject	O
.	O

Novel	O
vaccination	O
strategies	O
or	O
therapeutic	O
treatment	O
for	O
influenza	O
virus	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
cysteinyl	O
leukotriene	O
(	O
specifically	O
LTD4	O
)	O
antagonists	O
,	O
mainly	O
to	O
quinolin	B
,	O
quinoxaline	B
or	O
benz	B
[	I
c	I
]	I
thiazole	I
derivatives	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
process	O
of	O
preparation	O
thereof	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
for	O
the	O
therapeutic	O
treatment	O
of	O
disorders	O
related	O
to	O
cysteinyl	O
leukotriene	O
,	O
in	O
mammals	O
,	O
more	O
specially	O
in	O
humans	O
.	O

Quinoline-	B
,	O
quinoxaline	B
or	O
benzothiazole	B
based	O
cysteinyl	O
leukotriene	O
antagonists	O
(	O
ltc4	O
)	O

Provided	O
is	O
a	O
promoter	O
capable	O
of	O
promoting	O
the	O
inhibition	O
of	O
the	O
expression	O
of	O
mRNA	O
by	O
RNA	O
interference	O
.	O

The	O
promoter	O
according	O
to	O
the	O
present	O
invention	O
is	O
characterized	O
by	O
comprising	O
at	O
least	O
one	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
resveratrol	B
,	O
a	O
resveratrol	B
derivative	O
,	O
a	O
tautomer	O
,	O
a	O
geometric	O
isomer	O
and	O
a	O
stereoisomer	O
of	O
resveratrol	B
or	O
the	O
resveratrol	B
derivative	O
,	O
and	O
salts	O
thereof	O
,	O
wherein	O
the	O
active	O
ingredient	O
can	O
promote	O
the	O
transcription	O
of	O
a	O
nucleic	O
acid	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
mRNA	O
by	O
RNA	O
interference	O
and/or	O
the	O
expression	O
of	O
Argonaute-2	O
(	O
Ago2	O
)	O
.	O

The	O
nucleic	O
acid	O
is	O
preferably	O
miRNA	O
.	O

The	O
promoter	O
according	O
to	O
the	O
present	O
invention	O
is	O
applicable	O
to	O
,	O
for	O
example	O
,	O
a	O
method	O
for	O
treating	O
a	O
disease	O
utilizing	O
RNA	O
interference	O
,	O
a	O
medicinal	O
agent	O
,	O
a	O
food	O
additive	O
,	O
the	O
analysis	O
of	O
a	O
gene	O
by	O
means	O
of	O
knock	O
down	O
,	O
and	O
others	O
Promoter	O
capable	O
of	O
promoting	O
inhibition	O
of	O
expression	O
of	O
mrna	O
by	O
rna	O
interference	O
,	O
and	O
use	O
thereof	O

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
orally	O
administered	O
adsorbent	O
comprising	O
activated	O
carbon	O
fiber	O
having	O
high	O
adsorption	O
performance	O
or	O
removal	O
performance	O
,	O
whereby	O
a	O
toxic	O
substance	O
inside	O
the	O
body	O
can	O
be	O
adsorbed	O
or	O
removed	O
rapidly	O
and	O
in	O
large	O
quantity	O
.	O

The	O
present	O
invention	O
is	O
an	O
orally	O
administered	O
adsorbent	O
comprising	O
activated	O
carbon	O
fiber	O
,	O
wherein	O
the	O
orally	O
administered	O
adsorbent	O
is	O
a	O
drug	O
for	O
treating	O
or	O
preventing	O
kidney	O
disease	O
,	O
or	O
a	O
drug	O
for	O
treating	O
or	O
preventing	O
dialysis	O
complications	O
.	O

Orally	O
administered	O
adsorbent	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
used	O
for	O
production	O
of	O
effervescent	O
formulations	O
comprising	O
diclofenac	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
effervescent	O
formulations	O
obtained	O
by	O
said	O
method	O
.	O

Production	O
method	O
for	O
effervescent	O
formulations	O
comprising	O
diclofenac	B

Disclosed	O
herein	O
are	O
methods	O
and	O
compositions	O
related	O
to	O
therapeutic	O
use	O
of	O
aminopyridines	B
in	O
patients	O
with	O
a	O
stroke	O
-	O
related	O
impairment	O
,	O
in	O
particular	O
,	O
in	O
patients	O
with	O
a	O
stroke	O
-	O
related	O
sensorimotor	O
impairment	O
.	O

Methods	O
for	O
treating	O
a	O
stroke	O
-	O
related	O
sensorimotor	O
impairment	O
using	O
aminopyridines	B

The	O
invention	O
describes	O
compounds	O
for	O
cleaning	O
contact	O
lenses	O
containing	O
D	B
-	I
limonene	I
as	O
a	O
biocidal	O
agent	O
and	O
degreasing	O
,	O
further	O
containing	O
other	O
biocides	O
and	O
surfactants	O
as	O
well	O
as	O
auxiliary	O
agents	O
to	O
control	O
pH	O
,	O
viscosity	O
and	O
preservatives	O
.	O

The	O
present	O
invention	O
promotes	O
the	O
reduction	O
of	O
bacterial	O
total	O
amount	O
of	O
one	O
log	O
in	O
one	O
hour	O
.	O

Cleaning	O
solution	O
for	O
contact	O
lenses	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
compound	O
3,12-di	B
-	I
O	I
-	I
acetyl-8-O	I
-	I
tigloilingol	I
(	O
hereafter	O
referred	O
to	O
as	O
ELAF	B
)	O
or	O
a	O
pharmacologically	O
active	O
salt	O
thereof	O
in	O
order	O
to	O
promote	O
the	O
proliferation	O
of	O
neural	O
precursors	O
or	O
neural	O
stem	O
cells	O
in	O
culture	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compound	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
affecting	O
the	O
central	O
nervous	O
system	O
and	O
associated	O
with	O
neuronal	O
loss	O
.	O

Composition	O
capable	O
of	O
promoting	O
the	O
proliferation	O
of	O
neural	O
stem	O
cells	O

Disclosed	O
are	O
hybrid	O
compounds	O
that	O
release	O
both	O
nitric	B
oxide	I
and	O
a	O
moiety	O
that	O
inhibits	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
,	O
e.g.	O
,	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
-	O
4	O
and	O
m	O
-	O
p	O
are	O
as	O
described	O
herein	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
including	O
treating	O
cancer	O
and	O
enhancing	O
the	O
chemotherapeutic	O
treatment	O
of	O
chemotherapeutic	O
agents	O
and	O
high	O
energy	O
radiation	O
.	O

Hybrid	O
diazeniumdiolated	O
compounds	O
,	O
pharmaceutical	O
compositions	O
,	O
and	O
method	O
of	O
treating	O
cancer	O

Compounds	O
having	O
methyltransferase	O
inhibitory	O
activity	O
are	O
disclosed	O
.	O

The	O
compounds	O
are	O
amino	B
acids	I
,	O
esters	B
and	O
amides	B
having	O
a	O
common	O
core	O
based	O
on	O
adenosine	B
or	O
deazaadenosine	B
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
similar	O
diseases	O
associated	O
with	O
inappropriate	O
methyltransferase	O
activity	O
.	O

Methyltransferase	O
inhibitors	O
for	O
treating	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
all	O
variable	O
substituents	O
are	O
defined	O
as	O
described	O
herein	O
,	O
which	O
are	O
SYK	O
inhibitors	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
auto	O
-	O
immune	O
and	O
inflammatory	O
diseases	O
.	O

Imidazopyridazine	B
compounds	O

[	O
Problem	O
]	O
To	O
provide	O
a	O
compound	O
having	O
sEH	O
inhibitory	O
activity	O
and	O
to	O
provide	O
a	O
pharmaceutical	O
that	O
actualizes	O
a	O
therapeutic	O
effect	O
based	O
on	O
the	O
mechanism	O
against	O
hypertension	O
and	O
other	O
such	O
cardiovascular	O
diseases	O
.	O

[	O
Solution	O
]	O

The	O
invention	O
provides	O
a	O
diazaspirourea	B
derivative	O
represented	O
by	O
the	O
following	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Diazaspirourea	B
derivative	O
and	O
pharmaceutical	O
use	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
combination	O
of	O
rebamipide	B
and	O
a	O
tear	O
-	O
retaining	O
agent	O
as	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
anterior	O
eye	O
diseases	O
.	O

A	O
medicament	O
for	O
treating	O
anterior	O
eye	O
disease	O
comprising	O
rebamipide	B
and	O
a	O
tear	O
-	O
retaining	O
agent	O

The	O
invention	O
relates	O
to	O
a	O
cosmetic	O
composition	O
,	O
in	O
particular	O
a	O
composition	O
for	O
making	O
up	O
and/or	O
caring	O
for	O
keratin	O
materials	O
,	O
preferably	O
a	O
nail	O
makeup	O
,	O
comprising	O
the	O
compound	O
of	O
chemical	O
formula	O
(	O
I	O
)	O
below	O
:	O
(	O
I	O
)	O
in	O
which	O
:	O
n	O
is	O
between	O
1	O
and	O
8	O
,	O
m	O
is	O
between	O
1	O
and	O
20	O
,	O
m	O
'	O
is	O
equal	O
to	O
0	O
or	O
1	O
,	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
methyl	B
group	O
,	O
R2	O
and	O
R2	O
'	O
independently	O
represent	O
a	O
hydrogen	B
atom	O
or	O
a	O
group	O
(	B
C1-C20	I
)	I
alkyl	I
or	O
an	O
aryl	B
group	O
,	O
or	O
alternatively	O
R2	O
and	O
R2	O
'	O
are	O
linked	O
to	O
form	O
a	O
(	B
C1-C6	I
)	I
alkylene	I
chain	O
,	O
R3	O
and	O
R4	O
independently	O
represent	O
an	O
ethoxy	B
group	O
,	O
a	O
group	O
(	B
C1-C20	I
)	I
alkyl	I
or	O
a	O
(	B
C1-C4	I
)	I
aminoalkyl	I
group	O
,	O
Y	O
represents	O
a	O
polyether	B
or	O
a	O
polyester	B
or	O
a	O
polyurethane	B
or	O
a	O
polyurea	B
,	O
or	O
alternatively	O
a	O
hydrocarbon	B
-	O
based	O
group	O
comprising	O
from	O
2	O
to	O
1500	O
carbon	B
atoms	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
cosmetic	O
process	O
,	O
in	O
particular	O
a	O
makeup	O
or	O
hair	O
shaping	O
process	O
,	O
preferably	O
a	O
process	O
for	O
making	O
up	O
keratin	O
materials	O
,	O
in	O
particular	O
the	O
nails	O
and/or	O
the	O
hair	O
,	O
characterized	O
in	O
that	O
it	O
comprises	O
at	O
least	O
one	O
step	O
which	O
consists	O
in	O
applying	O
a	O
cosmetic	O
composition	O
as	O
above	O
defined	O
to	O
keratin	O
materials	O
.	O

Cosmetic	O
composition	O
comprising	O
an	O
alpha	B
-	I
alkoxysilane	I
obtained	O
from	O
an	O
acrylate	B

The	O
present	O
invention	O
is	O
related	O
to	O
Nox4	O
inhibitors	O
,	O
pharmaceutical	O
composition	O
thereof	O
and	O
to	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
osteoporosis	O
or	O
an	O
osteoclastogenesis	O
dysfunction	O
,	O
in	O
particular	O
osteoporotic	O
and	O
pre	O
-	O
osteoporotic	O
osteoclastogenesis	O
dysfunction	O
.	O

Nadph	O
oxidase	O
4	O
inhibitors	O
and	O
use	O
thereof	O

Provided	O
is	O
a	O
puncture	O
pain	O
alleviating	O
external	O
preparation	O
which	O
causes	O
little	O
pain	O
and	O
which	O
can	O
be	O
easily	O
used	O
.	O

The	O
puncture	O
pain	O
alleviating	O
external	O
preparation	O
of	O
the	O
present	O
invention	O
is	O
to	O
be	O
applied	O
in	O
the	O
vicinity	O
of	O
the	O
site	O
to	O
be	O
punctured	O
,	O
and	O
comprises	O
:	O
at	O
least	O
one	O
aliphatic	O
alcohol	O
selected	O
from	O
methanol	B
,	O
ethanol	B
,	O
isopropanol	B
,	O
and	O
normal	O
propanol	B
;	O
menthol	B
;	O
and	O
at	O
least	O
one	O
or	O
more	O
substance	O
that	O
stimulates	O
the	O
TRPM8	O
receptor	O
activation	O
channel	O
selected	O
from	O
the	O
group	O
of	O
compounds	O
represented	O
by	O
the	O
following	O
chemical	O
formula	O
.	O

(	O
In	O
the	O
formula	O
,	O
R1	O
and	O
R2	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
hydrogen	B
or	O
halogen	B
atom	O
;	O
a	O
hydroxy	B
,	O
cyano	B
,	O
nitro	B
,	O
mercapto	B
,	O
carbonyl	B
,	O
sulfone	B
,	O
or	O
carboxy	B
group	O
;	O
or	O
an	O
optionally	O
substituted	O
alkyl	B
,	O
alkenyl	B
,	O
alkoxy	B
,	O
alkylthio	B
,	O
aryl	B
,	O
aryloxy	B
,	O
arylthio	B
,	O
amino	B
,	O
siloxy	B
,	O
ester	B
,	O
or	O
heterocycle	B
group	O
.	O
)	O

Puncture	O
pain	O
alleviating	O
external	O
preparation	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
the	O
chemical	O
and	O
pharmaceutical	O
industry	O
and	O
medicine	O
and	O
concerns	O
compounds	O
which	O
can	O
be	O
used	O
to	O
produce	O
agents	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
diseases	O
.	O

A	O
novel	O
compound	O
of	O
formula	O
I	O
is	O
proposed	O
which	O
exhibits	O
the	O
properties	O
of	O
an	O
exogenous	O
nitric	B
oxide	I
donor	O
and	O
thus	O
a	O
thrombocyte	O
aggregation	O
inhibitor	O
,	O
as	O
well	O
as	O
displaying	O
antihypertensive	O
activity	O
and	O
activating	O
activity	O
towards	O
the	O
enzyme	O
soluble	O
guanylyl	O
cyclase	O
.	O

Variants	O
of	O
methods	O
for	O
synthesizing	O
the	O
above	O
compound	O
are	O
also	O
proposed	O
.	O

Novel	O
antithrombotic	O
and	O
antiatherosclerotic	O
agent	O
and	O
method	O
for	O
producing	O
same	O
(	O
variants	O
)	O

Disclosed	O
is	O
the	O
use	O
of	O
five	O
normal	O
bases	O
in	O
humans	O
for	O
preparation	O
of	O
tumour	O
drugs	O
including	O
using	O
the	O
five	O
normal	O
bases	O
in	O
the	O
field	O
of	O
tumour	O
treatment	O
,	O
making	O
same	O
into	O
oral	O
formulations	O
,	O
injections	O
,	O
sustained	O
-	O
release	O
formulations	O
or	O
targeted	O
formulations	O
,	O
and	O
by	O
comparing	O
with	O
the	O
anti	O
-	O
tumour	O
effect	O
of	O
the	O
corresponding	O
standard	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
five	O
normal	O
bases	O
involved	O
in	O
the	O
metabolism	O
of	O
the	O
body	O
will	O
have	O
varying	O
degrees	O
of	O
inducing	O
tumour	O
cell	O
apoptosis	O
and	O
anti	O
-	O
angiogenic	O
effects	O
when	O
reaching	O
a	O
certain	O
concentration	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O

The	O
advantages	O
of	O
the	O
present	O
invention	O
are	O
:	O
comparing	O
the	O
five	O
bases	O
with	O
other	O
anti	O
-	O
tumour	O
drugs	O
,	O
the	O
five	O
bases	O
have	O
a	O
broad	O
spectrum	O
and	O
a	O
low	O
toxicity	O
anti	O
-	O
tumour	O
effect	O
,	O
the	O
greatest	O
advantage	O
of	O
which	O
is	O
the	O
absence	O
of	O
a	O
cytotoxicity	O
effect	O
.	O

The	O
five	O
bases	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
malignant	O
tumour	O
such	O
as	O
gastric	O
cancer	O
,	O
lung	O
cancer	O
,	O
liver	O
cancer	O
,	O
colon	O
cancer	O
,	O
breast	O
cancer	O
and	O
reproductive	O
system	O
cancer	O
etc	O
.	O
;	O
the	O
anti	O
-	O
tumour	O
effects	O
thereof	O
are	O
obvious	O
;	O
conventional	O
dosage	O
is	O
without	O
bone	O
marrow	O
suppression	O
and	O
vital	O
organic	O
damage	O
;	O
and	O
compared	O
with	O
normal	O
nucleosides	O
,	O
the	O
anti	O
-	O
tumour	O
effects	O
thereof	O
are	O
enhanced	O
.	O

Use	O
of	O
five	O
normal	O
bases	O
in	O
humans	O
for	O
preparation	O
of	O
tumour	O
drugs	O

The	O
present	O
invention	O
provides	O
2-	B
[	I
(	I
3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-	I
yl	I
)	I
amino	I
]	I
nicotinic	I
acid	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
N	B
-	I
oxide	I
or	O
solvate	O
or	O
deuterated	O
derivative	O
thereof	O
,	O
for	O
use	O
in	O
the	O
treatment	O
of	O
psoriasis	O
.	O

2-	B
[	I
(	I
3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl	I
)	I
amino	I
]	I
nicotinic	I
acid	I
for	O
the	O
treatment	O
of	O
psoriasis	O

Disclosed	O
are	O
compounds	O
of	O
formulas	O
I	O
,	O
II	O
,	O
and	O
III	O
:	O
Formulas	O
I	O
,	O
II	O
,	O
and	O
III	O
wherein	O
R1-R19	O
and	O
n	O
are	O
as	O
described	O
herein	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
or	O
an	O
enantiomer	O
thereof	O
or	O
a	O
conjugate	O
thereof	O
wherein	O
the	O
conjugate	O
comprises	O
a	O
marker	O
group	O
,	O
for	O
use	O
in	O
treating	O
or	O
preventing	O
a	O
disease	O
or	O
disorder	O
responsive	O
to	O
reduction	O
of	O
lipid	O
storage	O
droplets	O
in	O
an	O
animal	O
in	O
need	O
thereof	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
neurodegenerative	O
diseases	O
and	O
disorders	O
.	O

Modulators	O
of	O
lipid	O
storage	O

Disclosed	O
are	O
a	O
phthalic	B
hydrazide	I
(	O
phthalazine	B
ketone	I
)	O
compound	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
same	O
.	O

As	O
a	O
DNA	O
repair	O
enzyme	O
poly	O
(	O
ADP	O
-	O
ribozyme	O
)	O
polymerase	O
inhibitor	O
,	O
the	O
compound	O
and	O
the	O
pharmaceutical	O
composition	O
can	O
effectively	O
treat	O
diseases	O
involving	O
PARP	O
enzymatic	O
activity	O
,	O
including	O
cancer	O
,	O
neural	O
degenerative	O
diseases	O
,	O
inflammation	O
and	O
the	O
like	O
.	O

Poly	O
(	O
adp	O
-	O
ribose	O
)	O
polymerase	O
inhibitor	O

Benzotriazine	B
doxides	I
are	O
disclosed	O
as	O
drugs	O
targeting	O
mycobacterium	O
tuberculosis	O
,	O
including	O
novel	O
compounds	O
of	O
formula	O
I	O
:	O
(	O
Formula	O
(	O
I	O
)	O
Benzotriazine	B
oxides	I
as	O
drugs	O
targeting	O
mycobacterium	O
tuberculosis	O

Provided	O
is	O
a	O
compound	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
.	O

Compared	O
to	O
prior	O
art	O
,	O
the	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
dual	O
structure	O
of	O
sulfonylurea	B
and	O
aminoguanidine	B
;	O
the	O
sulfonylurea	B
can	O
reduce	O
blood	O
sugar	B
level	O
by	O
enhancing	O
the	O
secretion	O
of	O
endogenous	O
insulin	O
,	O
and	O
the	O
aminoguanidine	B
structure	O
has	O
significant	O
prevention	O
and	O
treatment	O
effects	O
for	O
various	O
complications	O
of	O
diabetic	O
patients	O
.	O

Each	O
substituent	O
of	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
is	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Sulfonylurea	B
guanidine	I
,	O
preparation	O
method	O
and	O
use	O
thereof	O

Provided	O
herein	O
are	O
use	O
of	O
polymeric	O
excipients	O
,	O
specifically	O
polyvinyl	B
alcohols	I
,	O
optionally	O
in	O
conjunction	O
with	O
sugars	B
,	O
as	O
cryoprotectants	O
to	O
prevent	O
aggregation	O
of	O
PEG-	B
containing	O
particles	O
.	O

Also	O
provided	O
are	O
PEG	B
-	O
containing	O
particles	O
comprising	O
such	O
polymeric	O
excipients	O
.	O

Use	O
of	O
polymeric	O
excipients	O
for	O
lyophilization	O
or	O
freezing	O
of	O
particles	O

A	O
pharmacological	O
treatment	O
of	O
both	O
familial	O
early	O
onset	O
and	O
sporadic	O
late	O
onset	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
AD	O
-	O
related	O
disorders	O
and	O
Down	O
's	O
syndrome	O
-	O
coupled	O
neuropathies	O
involves	O
the	O
use	O
of	O
a	O
class	O
of	O
drugs	O
,	O
the	O
calcilytics	O
,	O
which	O
by	O
inhibiting	O
the	O
calcium	O
-	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
signaling	O
in	O
all	O
types	O
of	O
brain	O
cells	O
prevent	O
:	O
(	O
i	O
)	O
the	O
overproduction	O
of	O
cell	O
-	O
harming	O
nitric	B
oxide	I
(	O
NO	B
)	O
and	O
peroxynitrite	B
(	O
ONOO-	B
)	O
,	O
and	O
most	O
importantly	O
(	O
ii	O
)	O
the	O
intracellular	O
overproduction	O
,	O
accumulation	O
,	O
and	O
secretion	O
of	O
Amyloid	O
β	O
(	O
Aβ	O
)	O
peptides	O
in	O
response	O
to	O
the	O
extracellular	O
presence	O
of	O
exogenous	O
Aβpeptides	O
and/or	O
proinflammatory	O
cytokines	O
,	O
and	O
(	O
iii	O
)	O
the	O
Aβ	O
peptide	O
-	O
related	O
hyperphosphorylation	O
of	O
the	O
Tau	O
(	O
τ	O
)	O
protein	O
on	O
the	O
part	O
of	O
an	O
Aβ	O
/	O
Ca	O
SR	O
-	O
signaling	O
activated	O
glycogen	O
synthase	O
kinase-	O
(	O
GSK	O
)	O
-3β	O
w	O
i	O
t	O
h	O
the	O
resulting	O
formation	O
of	O
neurofibrillary	O
tangles	O
(	O
NTFs	O
)	O
,	O
the	O
latter	O
known	O
to	O
cause	O
such	O
severe	O
dysfunctioning	O
of	O
the	O
microtubular	O
cytoskeleton	O
as	O
to	O
eventually	O
favor	O
(	O
iv	O
)	O
the	O
death	O
of	O
human	O
cerebral	O
cortex	O
neurons	O
.	O

Use	O
of	O
calcilytic	O
drugs	O
as	O
a	O
pharmacological	O
approach	O
to	O
the	O
treatment	O
and	O
prevention	O
of	O
alzheimer	O
's	O
disease	O
,	O
alzheimer	O
's	O
disease	O
-	O
related	O
disorders	O
,	O
and	O
down	O
's	O
syndrome	O
neuropathies	O

Composition	O
comprising	O
at	O
least	O
one	O
active	O
principle	O
,	O
at	O
least	O
one	O
vehicle	O
for	O
said	O
active	O
principle	O
and	O
particles	O
of	O
porous	O
silica	O
,	O
in	O
which	O
the	O
active	O
principle	O
is	O
contained	O
in	O
at	O
least	O
one	O
pore	O
of	O
at	O
least	O
a	O
first	O
portion	O
of	O
such	O
silica	O
particles	O
and	O
in	O
that	O
vehicle	O
,	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
of	O
a	O
mucous	O
membrane	O
.	O

Compositions	O
for	O
the	O
treatment	O
of	O
mucous	O
membrane	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
in	O
effervescent	O
form	O
comprising	O
pregabalin	B
and	O
use	O
of	O
this	O
composition	O
in	O
the	O
treatment	O
of	O
epilepsy	O
,	O
central	O
nervous	O
system	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
;	O
Huntington	O
's	O
disease	O
;	O
tardive	O
dyskinesia	O
;	O
spasticity	O
;	O
cerebral	O
ischemia	O
;	O
postherpetic	O
neuralgia	O
;	O
social	O
phobia	O
;	O
fibromyalgia	O
and	O
spinal	O
cord	O
injury	O
induced	O
chronic	O
pains	O
;	O
neuropathic	O
pains	O
associated	O
with	O
diabetic	O
peripheral	O
neuropathy	O
and	O
common	O
anxiety	O
disorder	O
.	O

Effervescent	O
pregablin	B
formulation	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
corresponding	O
to	O
formula	O
(	O
I	O
)	O
in	O
which	O
R2	O
and	O
R3	O
together	O
form	O
,	O
with	O
the	O
carbon	B
atoms	O
of	O
the	O
phenyl	B
nucleus	O
to	O
which	O
they	O
are	O
attached	O
,	O
a	O
6-membered	O
nitrogenous	B
heterocycle	I
corresponding	O
to	O
one	O
of	O
the	O
formulae	O
(	O
A	O
)	O
,	O
(	O
B	O
)	O
and	O
(	O
C	O
)	O
in	O
which	O
the	O
wavy	O
lines	O
represent	O
the	O
phenyl	B
nucleus	O
to	O
which	O
R2	O
and	O
R3	O
are	O
attached	O
,	O
or	O
of	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
preparing	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
bladder	O
cancer	O
.	O

Therapeutic	O
use	O
of	O
imidazopyridine	B
derivatives	O

Provision	O
of	O
a	O
TRPA1	O
activity	O
inhibitor	O
capable	O
of	O
reducing	O
sensory	O
irritation	O
to	O
skin	O
or	O
mucous	O
membrane	O
and	O
an	O
agent	O
for	O
reduction	O
of	O
sensory	O
irritation	O
for	O
skin	O
or	O
mucous	O
membrane	O
.	O

A	O
TRPA1	O
inhibitor	O
and	O
an	O
agent	O
for	O
reduction	O
of	O
sensory	O
irritation	O
for	O
skin	O
or	O
mucous	O
membrane	O
comprising	O
as	O
an	O
active	O
ingredient	O
a	O
compound	O
represented	O
by	O
the	O
following	O
formula	O
(	O
1	O
)	O
wherein	O
R1	O
and	O
R3	O
each	O
independently	O
represent	O
a	O
hydrogen	B
atom	O
or	O
an	O
alkyl	B
group	O
having	O
1	O
to	O
3	O
carbon	B
atoms	O
,	O
R2	O
represents	O
an	O
alkyl	B
group	O
having	O
1	O
to	O
6	O
carbon	B
atoms	O
,	O
R4	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
methyl	B
group	O
or	O
an	O
ethyl	B
group	O
,	O
and	O
a	O
double	O
line	O
composed	O
of	O
a	O
dotted	O
line	O
and	O
a	O
solid	O
line	O
represents	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
.	O

Agent	O
for	O
reduction	O
of	O
sensory	O
irritation	O

Bivalent	O
ligands	O
that	O
contain	O
two	O
pharmacophores	O
linked	O
through	O
a	O
spacer	O
,	O
one	O
of	O
which	O
interacts	O
with	O
the	O
μ	O
-	O
opioid	B
receptor	O
(	O
MOR	O
)	O
and	O
the	O
other	O
of	O
which	O
interacts	O
with	O
the	O
co	O
-	O
receptor	O
CC	O
chemokine	O
receptor	O
5	O
(	O
CCR5	O
)	O
,	O
are	O
used	O
for	O
the	O
treatment	O
of	O
neurological	O
disorders	O
such	O
as	O
those	O
associated	O
with	O
AIDS	O
.	O

Bivalent	O
ligands	O
for	O
the	O
treatment	O
of	O
neurological	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
indoleamine-2	O
,	O
3-dioxygenase	O
(	O
IDO	O
)	O
inhibitor	O
,	O
a	O
preparation	O
method	O
therefor	O
,	O
and	O
the	O
uses	O
thereof	O
.	O

The	O
inhibitor	O
is	O
a	O
compound	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
a	O
solvate	O
,	O
a	O
polymorph	O
,	O
an	O
enantiomer	O
,	O
or	O
a	O
racemic	O
mixture	O
pharmaceutically	O
acceptable	O
thereto	O
.	O

R1	O
or	O
R2	O
is	O
independently	O
selected	O
from	O
hydrogen	B
,	O
a	O
C1-C5	B
alkyl	I
group	O
,	O
a	O
halogen	B
,	O
and	O
a	O
substituent	O
group	O
as	O
represented	O
by	O
formula	O
(	O
II	O
)	O
,	O
and	O
one	O
of	O
the	O
R1	O
and	O
the	O
R2	O
is	O
the	O
substituent	O
group	O
as	O
represented	O
by	O
formula	O
(	O
II	O
)	O
.	O

R3	O
is	O
selected	O
from	O
an	O
aryl	B
group	O
,	O
and	O
n=0	O
,	O
1	O
,	O
2	O
,	O
or	O
3	O
.	O

Compared	O
with	O
a	O
known	O
IDO	O
inhibitor	O
,	O
the	O
novel	O
inhibitor	O
has	O
a	O
more	O
powerful	O
IDO	O
inhibitory	O
effect	O
,	O
and	O
can	O
be	O
used	O
to	O
treat	O
diseases	O
having	O
a	O
pathological	O
feature	O
of	O
an	O
IDO	O
-	O
mediated	O
tryptophan	B
metabolic	O
pathway	O
,	O
for	O
example	O
,	O
tumors	O
,	O
cancers	O
,	O
Alzheimer	O
disease	O
,	O
autoimmune	O
diseases	O
,	O
cataract	O
,	O
mental	O
disorders	O
,	O
depression	O
,	O
and/or	O
anxiety	O
disorders	O
.	O

The	O
preparation	O
method	O
therefor	O
has	O
the	O
advantages	O
of	O
easy	O
operation	O
and	O
a	O
mild	O
reaction	O
condition	O
,	O
and	O
saves	O
the	O
solvent	O
and	O
reduces	O
pollution	O
,	O
thereby	O
facilitating	O
industrial	O
production	O
.	O

Novel	O
indoleamine-2	O
,	O
3-dioxygenase	O
inhibitor	O
,	O
preparation	O
method	O
therefor	O
and	O
uses	O
thereof	O

This	O
invention	O
is	O
based	O
on	O
an	O
exclusive	O
pharmaceutical	O
formulation	O
to	O
reduce	O
inflammation	O
bones	O
and	O
joint	O
friction	O
with	O
improve	O
cartilage	O
quality	O
,	O
comprising	O
Glucosamine	B
,	O
MSM	B
(	O
Methyl	B
Suphonil	I
Methane	I
)	O
,	O
Taurine	B
and	O
RacemetMonin	O
.	O

The	O
concentration	O
of	O
following	O
ingredients	O
are	O
Glucosamine	B
500	O
mg	O
/	O
capsule	O
,	O
Methyl	B
sulfonyl	I
methane	I
25	O
mg	O
/	O
capsule	O
,	O
Taurine	B
500	O
mg	O
/	O
capsule	O
and	O
racemethionin	B
100	O
mg	O
/	O
capsule	O
.	O

Pharmaceutical	O
formulation	O
to	O
reduce	O
inflammation	O
of	O
bones	O
and	O
joint	O
friction	O
with	O
improved	O
cartilage	O
quality	O

The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
and/or	O
therapeutic	O
agent	O
for	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
which	O
contains	O
an	O
anacardic	O
acid	O
derivative	O
,	O
and	O
a	O
method	O
of	O
screening	O
for	O
a	O
prophylactic	O
and/or	O
therapeutic	O
drug	O
for	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
utilizing	O
an	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
from	O
a	O
patient	O
with	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

Prophylactic	O
and	O
therapeutic	O
drug	O
for	O
amyotrophic	O
lateral	O
sclerosis	O
and	O
method	O
of	O
screening	O
therefor	O

The	O
present	O
invention	O
relates	O
to	O
topical	O
trisodium	B
diethylenetriamine	I
pentaacetic	I
acid	I
(	O
DTPA	B
)	O
prodrug	O
formulations	O
and	O
methods	O
of	O
using	O
the	O
same	O
.	O

Topical	O
dtpa	O
prodrug	O
formulations	O
and	O
methods	O
of	O
using	O
the	O
same	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
in	O
which	O
R1	O
and	O
R2	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
GCN2	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Triazolo	B
[	I
4,5-d	I
]	I
pyrimidine	I
derivatives	O

The	O
present	O
invention	O
describes	O
and	O
claims	O
stable	O
pharmaceutical	O
compositions	O
and/or	O
food	O
supplements	O
based	O
on	O
phosphatidylserine	B
(	O
PS	B
)	O
and	O
curcumin	B
,	O
which	O
are	O
consequently	O
devoid	O
of	O
degradation	O
products	O
,	O
for	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
disorders	O
associated	O
with	O
brain	O
aging	O
,	O
and	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
osteoporosis	O
and/or	O
osteoarthritis	O
.	O

Pharmaceutical	O
compositions	O
containing	O
phosphatidylserine	B
and	O
curcumin	B

The	O
present	O
invention	O
relates	O
methods	O
to	O
increase	O
the	O
expression	O
of	O
fatty	B
acid	I
desaturases	O
(	O
FADS	O
)	O
and	O
increase	O
cellular	O
and	O
tissue	O
levels	O
of	O
highly	O
unsaturated	O
fatty	B
acids	I
(	O
HUFA	O
)	O
by	O
modulating	O
one	O
or	O
more	O
of	O
the	O
FADS	O
via	O
the	O
action	O
of	O
specific	O
classes	O
of	O
drugs	O
(	O
e.g.	O
,	O
statins	O
and	O
LXR	O
agonists	O
)	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
treating	O
conditions	O
(	O
e.g.	O
,	O
tumor	O
and	O
cancer	O
)	O
involving	O
deficient	O
function	O
of	O
FADS	O
by	O
administering	O
statins	O
and/or	O
LXR	O
agonists	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
determining	O
the	O
need	O
for	O
statins	O
or	O
dietary	O
LCPUFA	O
in	O
subjects	O
.	O

Fads	O
regulation	O

Modified	O
release	O
formulations	O
of	O
viloxazine	B
and	O
methods	O
of	O
administering	O
the	O
same	O
are	O
disclosed	O
.	O

High-	O
drug	O
load	O
formulations	O
of	O
viloxazine	O
are	O
further	O
disclosed	O
.	O

Modified	O
release	O
formulations	O
of	O
viloxazine	B

The	O
present	O
invention	O
regards	O
compositions	O
and	O
methods	O
for	O
the	O
modulation	O
of	O
amidases	O
capable	O
of	O
hydrolysing	O
N	B
-	I
acylethanolamines	I
useable	O
in	O
the	O
therapy	O
of	O
inflammatory	O
diseases	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
regards	O
a	O
compound	O
of	O
general	O
formula	O
(	O
I	O
)	O
:	O
enantiomers	O
,	O
diastereoisomers	O
,	O
racemes	O
and	O
mixtures	O
,	O
polymorphs	O
,	O
salts	O
,	O
solvates	O
thereof	O
,	O
wherein	O
:	O
(	O
a	O
)	O
R	O
is	O
a	O
linear	O
alkyl	B
radical	O
having	O
13	O
to	O
19	O
carbon	B
atoms	O
or	O
alkenyl	B
radical	O
having	O
13	O
to	O
19	O
carbon	B
atoms	O
carrying	O
a	O
double	O
bond	O
;	O
(	O
b	O
)	O
X	O
is	O
0	B
or	O
S	B
;	O
(	O
c	O
)	O
Y	O
is	O
a	O
2	O
or	O
3	O
carbon	B
atom	O
alkylene	B
residue	O
,	O
optionally	O
substituted	O
with	O
one	O
or	O
two	O
groups	O
equal	O
or	O
different	O
from	O
each	O
other	O
and	O
selected	O
from	O
among	O
the	O
group	O
consisting	O
of	O
:	O
-CH3	B
,	O
-CH2OH	B
,	O
-COOCH3	B
,	O
-COOH	B
.	O

Y	O
may	O
preferably	O
be	O
:	O
-CH2-CH2-	B
,	O
-CH2-CH2-CH2-	B
,	O
CH	B
(	I
CH3	I
)	I
-CH2-	I
,	O
-CH2-CH	B
(	I
CH3	I
)	I
-	I
,	O
-CH2-C	B
(	I
CH3	I
)	I
2-	I
,	O
-CH2-CH	B
(	I
CH2OH	I
)	I
-	I
,	O
-CH2-C	B
(	I
(	I
CH2OH	I
)	I
2	I
)	I
-	I
,	O
-CH	B
=	I
CH-	I
,	O
-CH2-CH	B
(	I
COOCH3	I
)	I
-	I
,	O
-CH2-CH	B
(	I
COOH	I
)	I
-	I
,	O
for	O
use	O
as	O
a	O
medicine	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
modulation	O
of	O
specific	O
amidases	O
for	O
n	B
-	I
acylethanolamines	I
for	O
use	O
in	O
the	O
therapy	O
of	O
inflammatory	O
diseases	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
I	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
that	O
are	O
inhibitors	O
of	O
voltage	O
-	O
gated	O
sodium	B
channels	O
,	O
in	O
particular	O
Nav	O
1.7	O
.	O

The	O
compounds	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
treatable	O
by	O
inhibition	O
of	O
sodium	O
channels	O
such	O
as	O
pain	O
disorders	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
the	O
present	O
invention	O
.	O

Dihydrobenzoxazine	B
and	O
tetrahydroquinoxaline	B
sodium	B
channel	O
inhibitors	O

A	O
process	O
for	O
the	O
manufacture	O
of	O
an	O
extract	O
of	O
the	O
skin	O
of	O
Goji	O
berries	O
containing	O
zeaxanthin	B
and/or	O
its	O
esters	B
,	O
comprises	O
the	O
following	O
steps	O
:	O
a	O
)	O
obtaining	O
dried	O
skin	O
of	O
Goji	O
berries	O
or	O
the	O
size	O
reduced	O
pieces	O
thereof	O
;	O
and	O
b	O
)	O
extracting	O
the	O
dried	O
skin	O
of	O
Goji	O
berries	O
or	O
the	O
size	O
reduced	O
pieces	O
thereof	O
obtained	O
in	O
step	O
a	O
)	O
with	O
a	O
solvent	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ethyl	B
acetate	I
,	O
hexane	B
,	O
heptane	B
,	O
petroleum	B
ether	I
,	O
acetone	B
,	O
butane	B
,	O
ethyl	B
methyl	I
ketone	I
,	O
methanol	B
,	O
propan-2-ol	B
and	O
mixtures	O
thereof	O
;	O
and	O
c	O
)	O
removing	O
the	O
solvent	O
from	O
the	O
extracts	O
obtained	O
in	O
step	O
b	O
)	O
;	O
and	O
d	O
)	O
optionally	O
cleaving	O
the	O
esters	B
in	O
the	O
dried	O
extracts	O
obtained	O
in	O
step	O
c	O
)	O
;	O
and	O
e	O
)	O
optionally	O
crystallizing	O
the	O
dried	O
extracts	O
obtained	O
in	O
step	O
c	O
)	O
or	O
d	O
)	O
in	O
an	O
aliphatic	B
straight	O
or	O
branched	O
CH	B
alcohol	I
.	O

Preferably	O
the	O
process	O
consists	O
only	O
of	O
the	O
step	O
a	O
)	O
to	O
e	O
)	O
given	O
above	O
.	O

Process	O
for	O
manufacture	O
of	O
extract	O
containing	O
zeaxanthin	B
and/or	O
its	O
esters	B

The	O
present	O
invention	O
relates	O
to	O
new	O
thiadiazolidmediones	B
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
any	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
and	O
its	O
use	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
in	O
which	O
glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK-3	O
)	O
is	O
involved	O
,	O
particularly	O
neurodegenerative	O
diseases	O
,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
cardiovascular	O
disorders	O
.	O

Additionally	O
,	O
there	O
is	O
provided	O
a	O
process	O
for	O
preparing	O
such	O
compounds	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

Thiadiazolidinediones	B
as	O
gsk-3	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
thiobenzyl	B
and	O
sulfinylbenzyl	B
derivatives	O
,	O
processes	O
for	O
preparing	O
them	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
sphingosine-1-phosphate	B
receptors	O
.	O

Sulfinylbenzyl	B
and	O
thiobenzyl	B
derivatives	O
as	O
sphingosine	B
1-phosphate	I
(	O
s1p	B
)	O
receptor	O
modulators	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
a	O
patient	O
undergoing	O
multi	O
-	O
cycle	O
chemotherapy	O
that	O
provides	O
significantly	O
improved	O
platelet	O
counts	O
in	O
the	O
patients	O
,	O
and	O
facilitates	O
retention	O
of	O
dose	O
intensity	O
from	O
cycle	O
to	O
cycle	O
of	O
the	O
chemotherapy	O
.	O

Methods	O
for	O
treating	O
patients	O
undergoing	O
multi	O
-	O
cycle	O
chemotherapy	O

Use	O
of	O
dietary	O
fibre	O
material	O
extracted	O
from	O
sugar	O
cane	O
in	O
the	O
manufacture	O
of	O
a	O
food	O
product	O
that	O
is	O
formulated	O
to	O
ameliorate	O
the	O
effects	O
of	O
diabetes	O
in	O
pet	O
animals	O
.	O

Dietary	O
supplement	O
for	O
pet	O
mammals	O

A	O
method	O
for	O
isolating	O
flavonoid	B
Dihydroquercetin	I
(	O
taxifolin	B
)	O
from	O
wood	O
parts	O
including	O
lower	O
portions	O
of	O
the	O
trunk	O
,	O
referred	O
to	O
as	O
butt	O
logs	O
,	O
bark	O
and	O
roots	O
.	O

The	O
method	O
includes	O
extracting	O
either	O
the	O
particle	O
-	O
reduced	O
chip	O
fraction	O
obtained	O
by	O
chipping	O
or	O
subdividing	O
into	O
chips	O
the	O
butt	O
logs	O
and	O
roots	O
,	O
or	O
dry	O
cork	O
fraction	O
of	O
the	O
bark	O
or	O
powdered	O
bark	O
obtained	O
as	O
a	O
residue	O
in	O
finishing	O
of	O
mechanical	O
wood	O
products	O
with	O
a	O
polar	O
solvent	O
.	O

The	O
method	O
further	O
includes	O
recovering	O
the	O
extract	O
.	O

The	O
wood	O
used	O
in	O
the	O
method	O
is	O
a	O
hardwood	O
or	O
a	O
coniferous	O
wood	O
selected	O
from	O
wood	O
of	O
Larix	O
genus	O
,	O
spruce	O
wood	O
of	O
the	O
genus	O
Picea	O
,	O
fir	O
wood	O
of	O
the	O
genus	O
Abies	O
,	O
pine	O
wood	O
of	O
the	O
genus	O
Pinus	O
,	O
and	O
wood	O
of	O
Pseudotsuga	O
genus	O
.	O

The	O
isolated	O
prime	O
substance	O
from	O
all	O
of	O
the	O
above	O
genus	O
is	O
a	O
flavonoid	B
such	O
as	O
Dihydroquercetin	B
(	O
taxifolin	B
)	O
.	O

Method	O
for	O
isolating	O
flavonoid	B
dihydroquercetin	I
(	O
taxifolin	B
)	O
from	O
conifer	O
wood	O
species	O

Provided	O
is	O
a	O
treated	O
platy	O
substrate	O
,	O
a	O
method	O
of	O
making	O
it	O
,	O
and	O
methods	O
of	O
using	O
it	O
.	O

The	O
substrate	O
can	O
be	O
synthetic	O
mica	O
,	O
optionally	O
comprising	O
metal	O
-	O
oxide	O
layers	O
.	O

The	O
treated	O
platy	O
substrate	O
is	O
useful	O
in	O
cosmetic	O
compositions	O
.	O

Treated	O
platy	O
substrates	O

The	O
present	O
invention	O
relates	O
in	O
one	O
embodiment	O
to	O
a	O
pharmaceutical	O
combination	O
of	O
a	O
metabotropic	O
glutamate	B
receptor	O
5	O
(	O
mGluR5	O
)	O
negative	O
allosteric	O
modulator	O
and	O
levodopa	B
or	O
a	O
dopamine	B
agonist	O
,	O
and	O
at	O
least	O
one	O
of	O
a	O
dopa	B
decarboxylase	O
inhibitor	O
or	O
a	O
catechol	O
-	O
O	O
-	O
methyl	O
transferase	O
inhibitor	O
for	O
the	O
treatment	O
of	O
PD	O
-	O
LID	O
.	O

In	O
this	O
exemplary	O
pharmaceutical	O
combination	O
,	O
the	O
mGluR5	O
negative	O
allosteric	O
modulator	O
will	O
have	O
similar	O
pharmacokinetic	O
parameters	O
to	O
levodopa	B
or	O
to	O
a	O
dopamine	B
agonist	O
.	O

Pharmaceutical	O
combination	O
products	O
for	O
parkinson	O
's	O
disease	O

The	O
present	O
invention	O
is	O
directed	O
to	O
taste	O
-	O
masked	O
Ibuprofen	B
granules	O
and	O
to	O
a	O
process	O
for	O
preparation	O
thereof	O
.	O

Still	O
further	O
,	O
the	O
present	O
invention	O
is	O
also	O
directed	O
to	O
an	O
oral	O
dosage	O
form	O
comprising	O
said	O
granules	O
and	O
to	O
the	O
use	O
of	O
said	O
granules	O
in	O
an	O
oral	O
dosage	O
form	O
.	O

Taste	O
-	O
masked	O
ibuprofen	B
granules	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
compositions	O
with	O
a	O
health	O
benefit	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
treatment	O
or	O
prevention	O
of	O
liver	O
disorders	O
.	O

A	O
subject	O
matter	O
of	O
the	O
invention	O
is	O
a	O
composition	O
comprising	O
4-oxo-2-pentenoic	B
acid	I
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
liver	O
disorders	O
.	O

A	O
further	O
subject	O
matter	O
of	O
the	O
invention	O
is	O
a	O
composition	O
comprising	O
4-oxo-2-pentenoic	B
acid	I
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
liver	O
disorders	O
linked	O
to	O
an	O
insufficient	O
activity	O
of	O
phase	O
II	O
enzymes	O
in	O
the	O
liver	O
.	O

4-oxo-2-pentenoic	B
acid	I
and	O
liver	O
disorders	O

[	O
Problem	O
]	O
To	O
provide	O
a	O
novel	O
technology	O
with	O
which	O
elution	O
performance	O
of	O
a	O
pharmaceutical	O
active	O
ingredient	O
can	O
be	O
improved	O
in	O
a	O
solid	O
pharmaceutical	O
preparation	O
containing	O
as	O
the	O
pharmaceutical	O
active	O
ingredient	O
a	O
compound	O
that	O
gels	O
on	O
contact	O
with	O
water	O
.	O

[	O
Means	O
]	O
A	O
capsule	O
pharmaceutical	O
preparation	O
comprises	O
a	O
capsule	O
and	O
,	O
filled	O
into	O
the	O
capsule	O
,	O
a	O
composition	O
for	O
filling	O
the	O
capsule	O
containing	O
a	O
pharmaceutical	O
active	O
ingredient	O
and	O
a	O
monosaccharide	B
alcohol	I
,	O
wherein	O
the	O
pharmaceutical	O
active	O
ingredient	O
is	O
a	O
water	O
-	O
gelling	O
compound	O
,	O
which	O
is	O
a	O
compound	O
having	O
the	O
property	O
of	O
gelling	O
on	O
contact	O
with	O
water	O
,	O
and	O
the	O
monosaccharide	B
alcohol	I
is	O
a	O
monosaccharide	B
alcohol	I
having	O
a	O
solubility	O
in	O
water	O
at	O
25ºC	O
of	O
25	O
%	O
or	O
higher	O
.	O

Capsule	O
preparation	O

The	O
present	O
invention	O
provides	O
:	O
a	O
composition	O
which	O
has	O
an	O
effect	O
of	O
preventing	O
or	O
improving	O
skin	O
conditions	O
including	O
the	O
formation	O
of	O
small	O
wrinkles	O
and	O
the	O
sagging	O
of	O
the	O
skin	O
;	O
and	O
an	O
external	O
preparation	O
for	O
the	O
skin	O
or	O
a	O
functional	O
food	O
,	O
each	O
of	O
which	O
contains	O
the	O
composition	O
.	O

The	O
present	O
invention	O
relates	O
to	O
:	O
a	O
composition	O
comprising	O
carotenoid	O
and	O
pterostilbene	O
;	O
and	O
an	O
external	O
preparation	O
for	O
the	O
skin	O
or	O
a	O
functional	O
food	O
,	O
each	O
of	O
which	O
contains	O
the	O
composition	O
.	O

Composition	O
,	O
and	O
external	O
preparation	O
for	O
the	O
skin	O
or	O
functional	O
food	O
each	O
containing	O
said	O
composition	O

The	O
present	O
invention	O
is	O
a	O
cocrystal	O
of	O
3-	B
(	I
15-hydroxypentadecyl	I
)	I
-2,4,4-trimethyl-2-cyclohexen-1-one	I
and	O
a	O
C14	B
-	I
17	I
fatty	I
acid	I
.	O

Cocrystal	O
of	O
3-	B
(	I
15-hydroxypentadecyl	I
)	I
-2,4,4-trimethyl-2-cyclohexen-1-one	I

Compounds	O
useful	O
as	O
kinase	O
inhibitors	O
are	O
provided	O
herein	O
,	O
as	O
well	O
as	O
salts	O
,	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
medical	O
treatment	O
and	O
methods	O
of	O
synthesis	O
thereof	O
.	O

Lactam	B
kinase	O
inhibitors	O

The	O
invention	O
provides	O
novel	O
compounds	O
and	O
compositions	O
and	O
methods	O
for	O
making	O
and	O
using	O
the	O
compounds	O
and	O
compositions	O
.	O

In	O
particular	O
,	O
the	O
use	O
of	O
organic	O
acid	O
salts	O
promotes	O
solubility	O
.	O

These	O
more	O
soluble	O
forms	O
are	O
suitable	O
for	O
use	O
in	O
various	O
diseases	O
,	O
notably	O
diseases	O
of	O
lung	O
,	O
muscle	O
,	O
metabolism	O
and	O
eyesight	O
.	O

Anti	O
-	O
inflammatory	O
macrolides	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
cancer	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
neuroblastoma	O
,	O
Ewing	O
's	O
Sarcoma	O
,	O
or	O
rhabdomyosarcoma	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
defined	O
herein	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
a	O
subject	O
,	O
preferably	O
a	O
human	O
,	O
in	O
need	O
thereof	O
;	O
to	O
use	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
for	O
the	O
manufacture	O
of	O
pharmaceutical	O
compositions	O
for	O
use	O
in	O
the	O
treatment	O
of	O
cancer	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
neuroblastoma	O
,	O
Ewing	O
's	O
Sarcoma	O
,	O
or	O
rhabdomyosarcoma	O
;	O
and	O
to	O
use	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
the	O
treatment	O
of	O
cancer	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
neuroblastoma	O
,	O
Ewing	O
's	O
Sarcoma	O
,	O
or	O
rhabdomyosarcoma	O
.	O

Compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
neuroblastoma	O
,	O
ewing	O
's	O
sarcoma	O
or	O
rhabdomyosarcoma	O

Methods	O
and	O
compositions	O
for	O
treating	O
various	O
indications	O
by	O
lessening	O
oxidative	O
stress	O
in	O
a	O
patient	O
are	O
provided	O
.	O

A	O
pharmaceutical	O
composition	O
comprises	O
between	O
about	O
0.001	O
%	O
to	O
about	O
10.0	O
%	O
)	O
,	O
or	O
more	O
specifically	O
between	O
about	O
0.015	O
%	O
to	O
about	O
5	O
%	O
,	O
sodium	B
iodine	I
or	O
catalase	O
by	O
weight	O
.	O

The	O
iodine	B
ion	O
or	O
the	O
catalase	O
dissociates	O
hydrogen	B
peroxide	I
into	O
water	O
and	O
molecular	O
oxygen	B
to	O
interrupt	O
biological	O
events	O
that	O
result	O
in	O
negative	O
side	O
effects	O
.	O

The	O
pharmaceutical	O
composition	O
further	O
comprises	O
in	O
some	O
cases	O
a	O
reducing	O
agent	O
or	O
various	O
carrier	O
materials	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
in	O
some	O
cases	O
formulated	O
for	O
a	O
variety	O
of	O
delivery	O
methods	O
.	O

Compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
diseases	O
associated	O
with	O
oxidative	O
stress	O

The	O
present	O
disclosure	O
relates	O
generally	O
to	O
compounds	O
and	O
methods	O
for	O
inhibiting	O
centrosomal	O
clustering	O
in	O
a	O
cell	O
harboring	O
supernumerary	O
centrosomes	O
by	O
,	O
for	O
example	O
,	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
general	O
chemical	O
formula	O
(	O
I	O
)	O
:	O
Formula	O
(	O
I	O
)	O
Where	O
X	O
is	O
optionally	O
substituted	O
alkyl	B
,	O
n	O
is	O
an	O
integer	O
from	O
1	O
to	O
10	O
and	O
R1	O
is	O
optionally	O
substituted	O
aryl	B
or	O
cycloalkyl	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

5-nitrofuran-2-carboxamide	B
derivatives	O
for	O
inhibiting	O
centrosomal	O
clustering	O

The	O
present	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
EPl	O
receptor	O
ligands	O
.	O

More	O
specifically	O
it	O
refers	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
having	O
great	O
affinity	O
and	O
selectivity	O
for	O
the	O
EPl	O
receptor	O
.	O

The	O
invention	O
also	O
refers	O
to	O
the	O
process	O
for	O
their	O
preparation	O
,	O
to	O
their	O
use	O
as	O
medicament	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
or	O
disorders	O
mediated	O
by	O
the	O
EPl	O
receptor	O
as	O
well	O
as	O
to	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

Substituted	B
tricyclic	I
compounds	O
with	O
activity	O
towards	O
ep1	O
receptors	O

The	O
invention	O
provides	O
indole	B
and	O
indoline	B
derivatives	O
and	O
slats	O
thereof	O
,	O
compositions	O
comprising	O
them	O
and	O
uses	O
thereof	O
for	O
the	O
treatment	O
of	O
diseases	O
and	O
disorders	O
.	O

Indole	B
,	O
indoline	B
derivatives	O
,	O
compositions	O
comprising	O
them	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
amidopyridine	B
derivative	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
provides	O
a	O
medicinal	O
agent	O
which	O
is	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
diseases	O
,	O
which	O
is	O
based	O
on	O
the	O
production	O
of	O
cytokines	O
from	O
T	O
cells	O
,	O
and	O
which	O
has	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
the	O
amidopyridine	B
derivative	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Provided	O
are	O
the	O
amidopyridine	B
derivative	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
(	O
in	O
general	O
formula	O
(	O
I	O
)	O
,	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
)	O
.	O

Amidopyridine	B
derivative	O
,	O
and	O
use	O
thereof	O

Compounds	O
disclosed	O
herein	O
including	O
compounds	O
of	O
formula	O
(	O
I	O
'	O
)	O
and	O
salts	O
thereof	O
are	O
provided	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
compounds	O
disclosed	O
herein	O
,	O
processes	O
for	O
preparing	O
compounds	O
disclosed	O
herein	O
,	O
intermediates	O
useful	O
for	O
preparing	O
compounds	O
disclosed	O
herein	O
and	O
therapeutic	O
methods	O
for	O
treating	O
an	O
HIV	O
infection	O
using	O
compounds	O
disclosed	O
herein	O
are	O
also	O
provided	O
.	O

Benzothiazol-	B
6	I
-yl	I
acetic	I
acid	I
derivatives	O
and	O
their	O
use	O
for	O
treating	O
an	O
hiv	O
infection	O

Various	O
embodiments	O
are	O
described	O
herein	O
related	O
to	O
an	O
assay	O
,	O
method	O
and	O
apparatus	O
for	O
performing	O
an	O
RNA	O
Disruption	O
Assay	O
(	O
RDA	O
)	O
for	O
cellular	O
RNA	O
optionally	O
in	O
response	O
to	O
a	O
cytotoxic	O
treatment	O
such	O
as	O
chemotherapy	O
and/or	O
radiation	O
treatment	O
.	O

The	O
method	O
comprises	O
obtaining	O
at	O
least	O
one	O
electropherogram	O
dataset	O
corresponding	O
to	O
a	O
unique	O
biological	O
sample	O
comprising	O
the	O
cellular	O
RNA	O
at	O
a	O
time	O
point	O
,	O
optionally	O
during	O
or	O
after	O
the	O
treatment	O
;	O
determining	O
values	O
for	O
features	O
from	O
at	O
least	O
two	O
shifted	O
regions	O
of	O
the	O
at	O
least	O
one	O
electropherogram	O
dataset	O
,	O
the	O
shifting	O
being	O
due	O
to	O
the	O
treatment	O
;	O
and	O
optionally	O
determining	O
an	O
RDA	O
score	O
based	O
on	O
a	O
combination	O
of	O
the	O
values	O
of	O
the	O
features	O
.	O

Assays	O
,	O
methods	O
and	O
apparatus	O
for	O
assessing	O
rna	O
disruption	O

This	O
deuterated	O
nitrogen	B
-	O
containing	O
heterocyclic	B
carboxamide	I
derivative	O
represented	O
by	O
general	O
formula	O
(	O
1	O
)	O
(	O
in	O
the	O
formula	O
,	O
D	O
represents	O
a	O
deuterium	B
atom	O
,	O
and	O
R	O
represents	O
a	O
hydrogen	B
atom	O
or	O
deuterium	B
atom	O
)	O
,	O
or	O
a	O
salt	O
thereof	O
,	O
exhibits	O
excellent	O
pharmacokinetics	O
,	O
such	O
as	O
maintenance	O
of	O
a	O
high	O
blood	O
concentration	O
and/or	O
increase	O
in	O
AUC	O
,	O
and	O
is	O
useful	O
as	O
an	O
antiviral	O
agent	O
.	O

Deuterated	O
nitrogen	B
-	O
containing	O
heterocyclic	B
carboxamide	I
derivative	O

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
composition	O
for	O
controlling	O
a	O
chromatin	O
structure	O
.	O

A	O
composition	O
of	O
the	O
present	O
invention	O
contains	O
:	O
(	O
1	O
)	O
a	O
polymer	O
which	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
amphoteric	O
polymers	O
,	O
anionic	O
polymers	O
and	O
nonionic	O
polymers	O
having	O
a	O
specific	O
main	O
chain	O
skeleton	O
;	O
or	O
(	O
2	O
)	O
a	O
carrier	O
which	O
encloses	O
two	O
or	O
more	O
kinds	O
of	O
substances	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
expression	O
vectors	O
containing	O
a	O
gene	O
such	O
as	O
a	O
gene	O
encoding	O
histone	O
acetyltransferase	O
and	O
inhibitors	O
such	O
as	O
histone	O
acetylation	O
inhibitors	O
.	O

Composition	O
for	O
controlling	O
chromatin	O
structure	O

The	O
present	O
invention	O
comprises	O
a	O
method	O
for	O
detoxification	O
or	O
measurement	O
of	O
the	O
concentration	O
of	O
at	O
least	O
one	O
compound	O
in	O
a	O
host	O
body	O
,	O
wherein	O
said	O
host	O
body	O
comprises	O
a	O
sorption	O
material	O
of	O
at	O
least	O
one	O
phase	O
over	O
a	O
certain	O
period	O
of	O
time	O
,	O
where	O
sorption	O
of	O
said	O
at	O
least	O
one	O
compound	O
in	O
at	O
least	O
one	O
phase	O
of	O
said	O
sorption	O
material	O
is	O
effected	O
and	O
the	O
content	O
of	O
the	O
at	O
least	O
one	O
compound	O
in	O
said	O
sorption	O
material	O
is	O
optionally	O
analysed	O
.	O

Use	O
of	O
a	O
sorption	O
material	O
for	O
providing	O
an	O
estimate	O
of	O
the	O
concentration	O
of	O
compounds	O
present	O
in	O
a	O
host	O
body	O
,	O
use	O
of	O
a	O
sorption	O
material	O
for	O
detoxification	O
and	O
sorption	O
material	O
for	O
diagnostic	O
use	O
is	O
also	O
comprised	O
in	O
the	O
present	O
application	O
.	O

Method	O
for	O
detoxification	O
or	O
measurement	O
of	O
at	O
least	O
one	O
compound	O
or	O
at	O
least	O
one	O
fluid	O
in	O
a	O
host	O
body	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
described	O
herein	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
acceptable	O
salts	O
thereof	O
,	O
which	O
modulate	O
the	O
activity	O
of	O
calcium	B
release-	O
activated	O
calcium	B
(	O
CRAC	O
)	O
channel	O
.	O

The	O
invention	O
also	O
describes	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
thereof	O
for	O
treating	O
,	O
managing	O
,	O
and/or	O
lessening	O
the	O
severity	O
of	O
diseases	O
,	O
disorders	O
,	O
syndromes	O
or	O
conditions	O
associated	O
with	O
the	O
modulation	O
of	O
calcium	B
release	O
-	O
activated	O
calcium	B
(	O
CRAC	O
)	O
channel	O
.	O

Substituted	O
pyrazole	B
compounds	O
as	O
crac	O
modulators	O

The	O
present	O
invention	O
discloses	O
agonists	O
of	O
the	O
G	O
protein	O
-	O
coupled	O
receptor	O
TGR5	O
,	O
compositions	O
comprising	O
them	O
,	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
compositions	O
and	O
using	O
them	O
,	O
methods	O
of	O
making	O
the	O
compounds	O
and	O
compositions	O
and	O
using	O
them	O
for	O
the	O
treatment	O
of	O
diseases	O
TGR5	O
mediates	O
or	O
is	O
implicated	O
in	O
.	O

Heterocyclic	B
compounds	O
and	O
their	O
use	O
for	O
treatment	O
of	O
diabetes	O
,	O
obesity	O
or	O
related	O
disorders	O

Methods	O
,	O
systems	O
,	O
devices	O
,	O
and	O
medicaments	O
are	O
provided	O
for	O
locally	O
administering	O
to	O
a	O
pelvic	O
-	O
area	O
organ	O
or	O
tissue	O
structure	O
in	O
a	O
patient	O
at	O
least	O
one	O
drug	O
continuously	O
or	O
continually	O
over	O
a	O
treatment	O
period	O
of	O
24	O
hours	O
or	O
more	O
in	O
an	O
amount	O
effective	O
to	O
achieve	O
a	O
therapeutic	O
effect	O
in	O
another	O
organ	O
or	O
tissue	O
structure	O
by	O
means	O
of	O
shared	O
or	O
convergent	O
pelvic	O
afferent	O
pathways	O
.	O

The	O
methods	O
systems	O
,	O
devices	O
,	O
and	O
medicaments	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
IC	O
/	O
BPS	O
,	O
chronic	O
pelvic	O
pain	O
,	O
vulvodynia	O
,	O
orchialgia	O
,	O
urethral	O
syndrome	O
,	O
dysparenia	O
,	O
chronic	O
prostatitis	O
,	O
chronic	O
pelvic	O
pain	O
,	O
levator	O
ani	O
syndrome	O
,	O
irritative	O
bowel	O
syndrome	O
,	O
or	O
a	O
combination	O
thereof	O
.	O

The	O
drug	O
may	O
include	O
anesthetic	O
agents	O
,	O
analgesic	O
agents	O
,	O
antispasmodic	O
agents	O
,	O
antimuscarinic	O
agents	O
,	O
and	O
combinations	O
thereof	O
.	O

The	O
drug	O
may	O
be	O
released	O
from	O
a	O
drug	O
delivery	O
device	O
or	O
a	O
sustained	O
release	O
composition	O
deployed	O
inside	O
the	O
bladder	O
.	O

Methods	O
for	O
treatment	O
of	O
pelvic	O
pain	O
and	O
/	O
or	O
comorbid	O
conditions	O

Provided	O
are	O
compounds	O
,	O
pharmaceutical	O
acceptable	O
salts	O
,	O
polymorphs	O
,	O
solvates	O
,	O
enantiomers	O
,	O
stereoisomers	O
and	O
hydrates	B
thereof	O
.	O

The	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
may	O
be	O
formulated	O
for	O
oral	O
,	O
buccal	O
,	O
rectal	O
,	O
topical	O
,	O
transdermal	O
,	O
transmucosal	O
,	O
intravenous	O
,	O
parenteral	O
administration	O
,	O
syrup	O
or	O
injection	O
,	O
and	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
neurologic	O
diseases	O
,	O
such	O
as	O
depression	O
,	O
Alzheimer	O
's	O
disease	O
,	O
multiple	O
sclerosis	O
,	O
Batten	O
disease	O
,	O
Parkinson	O
's	O
disease	O
and	O
restless	O
legs	O
syndrome	O
.	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
neurologic	O
diseases	O

The	O
present	O
invention	O
provides	O
solid	O
state	O
forms	O
of	O
Fidaxomycin	B
,	O
processes	O
for	O
preparing	O
the	O
solid	O
state	O
forms	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
formulations	O
comprising	O
one	O
or	O
more	O
of	O
the	O
solid	O
state	O
forms	O
of	O
Fidaxomycin	B
,	O
and	O
processes	O
for	O
the	O
preparation	O
of	O
of	O
the	O
compositions	O
and	O
formulations	O
.	O

The	O
solid	O
state	O
forms	O
of	O
the	O
present	O
invention	O
exhibit	O
advantageous	O
properties	O
such	O
as	O
improved	O
reliability	O
and	O
reproducibility	O
manufacturing	O
and	O
processing	O
and	O
stability	O
in	O
formulations	O
.	O

Solid	O
state	O
forms	O
of	O
fidaxomycin	B
and	O
processes	O
for	O
preparation	O
thereof	O

Methods	O
of	O
improving	O
muscle	O
energetics	O
,	O
muscle	O
blood	O
flow	O
,	O
and	O
muscle	O
health	O
in	O
humans	O
,	O
and	O
specifically	O
in	O
adults	O
and	O
older	O
adults	O
,	O
use	O
nutritional	O
compositions	O
including	O
a	O
combination	O
of	O
beta	B
-	I
hydroxy	I
-	I
beta	I
-	I
methylbutyrate	I
and	O
beta	B
-	I
alanine	I
.	O

The	O
combination	O
of	O
beta	B
-	I
hydroxy	I
-	I
beta	I
-	I
methylbutyrate	I
and	O
beta	B
-	I
alanine	I
increases	O
muscle	O
vasculature	O
and	O
blood	O
flow	O
,	O
resulting	O
in	O
increased	O
heme	O
concentration	O
.	O

Increased	O
heme	O
concentration	O
increases	O
oxygen	B
supply	O
to	O
the	O
muscle	O
thereby	O
improving	O
muscle	O
aerobic	O
capacity	O
,	O
strength	O
,	O
performance	O
,	O
and	O
endurance	O
.	O

Combination	O
of	O
beta	B
-	I
hydroxy	I
-	I
beta	I
-	I
methylbutyrate	I
and	O
beta	B
-	I
alanine	I
for	O
increasing	O
muscle	O
blood	O
flow	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
first	O
pharmacologically	O
active	O
ingredient	O
selected	O
from	O
(	B
1r,4r	I
)	I
-6'-fluoro	I
-	I
N	I
,	I
N	I
-	I
dimethyl-4-phenyl-4',9'-dihydro-3'H	I
-	I
spiro	I
[	I
cyclohexane-1,1'-pyrano	I
[	I
3,4,b	I
]	I
indol	I
]	I
-4-amine	I
and	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
a	O
second	O
pharmacologically	O
active	O
ingredient	O
which	O
is	O
an	O
anticonvulsant	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
retigabin	B
,	O
lamotrigine	B
,	O
lacosamide	B
,	O
levetiracetam	B
,	O
carbamazepine	B
,	O
sultiame	B
,	O
phenacemide	B
,	O
felbamate	B
,	O
topiramate	B
,	O
pheneturide	B
,	O
brivaracetam	B
,	O
selectracetam	B
,	O
zonisamide	B
,	O
stiripentol	B
,	O
beclamide	B
,	O
mexiletin	B
,	O
ralfinamide	B
,	O
methyl-	B
phenobarbital	I
,	O
phenobarbital	B
,	O
primidone	B
,	O
barbexaclone	B
,	O
metharbital	B
,	O
ethotoin	B
,	O
phenytoin	B
,	O
amino	B
(	I
diphenylhydantoin	I
)	I
valeric	I
acid	I
,	O
mephenytoin	B
,	O
fosphenytoin	B
,	O
paramethadione	B
,	O
trimethadione	B
,	O
ethadione	B
,	O
ethosuximide	B
,	O
phensuximide	B
,	O
mesuximide	B
,	O
clonazepam	B
,	O
lorazepam	B
,	O
diazepam	B
,	O
clobazam	B
,	O
oxcarbazepine	B
,	O
eslicarbazepine	B
,	O
rufinamide	B
,	O
valproic	B
acid	I
,	O
valpromide	B
,	O
aminobutyric	B
acid	I
,	O
progabide	B
,	O
tiagabine	B
,	O
and	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
.	O

Pharmaceutical	O
composition	O
comprising	O
(	B
1r,4r	I
)	I
-6'-fluoro	I
-	I
n	I
,	I
n	I
-	I
dimethyl-4-phenyl-4',9'-dihydro-3'h	I
-	I
spiro	I
[	I
cyclohexane-1,1'-pyrano	I
[	I
3,4,b	I
]	I
indol	I
]	I
-4-amine	I
and	O
an	O
anticonvulsant	O

The	O
present	O
disclosure	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
as	O
modulator	O
of	O
retinoid	B
-	O
related	O
orphan	O
receptor	O
gamma	O
t	O
(	O
RORϒt	O
)	O
.	O

These	O
compounds	O
prevent	O
,	O
inhibit	O
,	O
or	O
suppress	O
the	O
action	O
of	O
RORϒt	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
RORϒt	O
mediated	O
disease	O
,	O
disorder	O
,	O
syndrome	O
or	O
condition	O
such	O
as	O
pain	O
,	O
inflammation	O
,	O
COPD	O
,	O
asthma	O
,	O
rheumatoid	O
arthritis	O
,	O
colitis	O
,	O
multiple	O
sclerosis	O
,	O
neurodegenerative	O
diseases	O
or	O
cancer	O
.	O

Aryl	B
and	O
heteroaryl	B
amide	I
compounds	O
as	O
ror	O
gamma	O
t	O
modulator	O

The	O
invention	O
is	O
related	O
to	O
anti	O
-	O
viral	O
compounds	O
,	O
compositions	O
containing	O
such	O
compounds	O
,	O
and	O
therapeutic	O
methods	O
that	O
include	O
the	O
administration	O
of	O
such	O
compounds	O
,	O
as	O
well	O
as	O
to	O
processes	O
and	O
intermediates	O
useful	O
for	O
preparing	O
such	O
compounds	O
.	O

Antiviral	O
compounds	O
with	O
an	O
imidazole	B
-	I
biphenyl	I
-	I
imidazole	I
core	O

Isolated	O
metabolites	O
of	O
(	B
1	I
R	I
-	I
trans	I
)	I
-N-	I
[	I
[	I
2-	I
(	I
2,3-dihydro-4-benzofuranyl	I
)	I
cyclopropyl	I
]	I
-	I
methyl	I
]	I
propanamide	I
,	O
methods	O
for	O
their	O
use	O
,	O
and	O
compositions	O
containing	O
the	O
metabolites	O
.	O

Metabolites	O
of	O
(	B
1r	I
-	I
trans	I
)	I
-n-	I
[	I
[	I
2-	I
(	I
2,3-dihydro-4-benzofuranyl	I
)	I
cyclopropyl	I
]	I
methyl	I
]	I
propanamide	I

The	O
invention	O
provides	O
a	O
dinucleoside	O
polyphosphate	B
analogue	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
use	O
in	O
the	O
inhibition	O
(	O
or	O
down	O
-	O
regulation	O
)	O
of	O
a	O
pain	O
,	O
via	O
a	O
transducing	O
ATP	O
-gated	O
P2X3	O
receptor	O
,	O
often	O
by	O
means	O
of	O
high	O
-	O
affinity	O
desensitisation	O
(	O
HAD	O
)	O
mechanism	O
.	O

Dinuceloside	O
polyphosphates	B
for	O
the	O
treatment	O
of	O
pain	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicine	O
and	O
the	O
pharmaceutical	O
-	O
chemical	O
industry	O
,	O
and	O
specifically	O
to	O
the	O
field	O
of	O
neurology	O
,	O
and	O
concerns	O
new	O
compositions	O
containing	O
memantine	B
and	O
melatonin	B
.	O

It	O
has	O
been	O
established	O
that	O
a	O
strengthening	O
of	O
the	O
effect	O
of	O
memantine	B
takes	O
place	O
when	O
it	O
is	O
combined	O
with	O
melatonin	B
.	O

The	O
invention	O
may	O
be	O
realized	O
through	O
the	O
preparation	O
of	O
a	O
finished	O
pharmaceutical	O
product	O
such	O
as	O
capsules	O
,	O
preferably	O
hard	O
gelatin	O
capsules	O
.	O

Pharmaceutical	O
composition	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
psychological	O
,	O
behavioral	O
and	O
cognitive	O
disorders	O

This	O
application	O
is	O
directed	O
to	O
α	O
-	O
neuronal	O
nicotinic	O
receptor	O
agonists	O
selective	O
for	O
α7-subtype	O
that	O
are	O
useful	O
for	O
improving	O
cognition	O
impairment	O
in	O
patients	O
having	O
schizophrenia	O
,	O
a	O
schizophreniform	O
disorder	O
or	O
a	O
related	O
schizophrenia	O
spectrum	O
psychotic	O
disorder	O
.	O

Compounds	O
and	O
compositions	O
containing	O
such	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
such	O
compound	O
and	O
compositions	O
are	O
described	O
herein	O
.	O

Neuronal	O
nicotinic	O
receptor	O
agonists	O
for	O
treating	O
schizophrenia	O
in	O
patients	O
with	O
variants	O
of	O
comt	O
gene	O

The	O
present	O
disclosure	O
is	O
directed	O
in	O
part	O
to	O
heterocycles	O
,	O
and	O
their	O
use	O
in	O
treating	O
medical	O
disorders	O
,	O
such	O
as	O
immune	O
inflammatory	O
disorders	O
such	O
as	O
Crohn	O
's	O
disease	O
,	O
ulcerative	O
colitis	O
,	O
rheumatic	O
disorders	O
,	O
psoriasis	O
,	O
and	O
allergies	O
.	O

The	O
compounds	O
are	O
contemplated	O
to	O
modulate	O
T	O
-	O
Cell	O
responses	O
.	O

Heterocycles	O
capable	O
of	O
modulating	O
t	O
-	O
cell	O
responses	O
,	O
and	O
methods	O
of	O
using	O
same	O

The	O
present	O
invention	O
is	O
related	O
to	O
the	O
use	O
of	O
compounds	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
that	O
modulate	O
astrocytic	O
release	O
of	O
substances	O
through	O
connexin	O
and	O
pannexin	O
hemichannels	O
,	O
for	O
the	O
treatment	O
of	O
psychiatric	O
disorders	O
.	O

Compounds	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
comprise	O
any	O
compound	O
that	O
differentially	O
modulates	O
,	O
blocks	O
,	O
opens	O
,	O
inhibits	O
,	O
and/or	O
activates	O
connexin	O
and/or	O
pannexin	O
hemichannels	O
from	O
astrocytes	O
while	O
not	O
affecting	O
gap	O
junctions	O
.	O

The	O
invention	O
is	O
also	O
related	O
to	O
a	O
method	O
for	O
treating	O
psychiatric	O
disorders	O
,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
that	O
modulates	O
astrocytic	O
release	O
of	O
substances	O
through	O
connexin	O
and	O
pannexin	O
hemichannels	O
.	O

Pharmaceutical	O
compositions	O
and	O
a	O
screening	O
method	O
are	O
also	O
provided	O
.	O

Examples	O
are	O
shown	O
for	O
connexin	O
43	O
,	O
connexin	O
30	O
and	O
pannexin	O
1	O
hemichannel	O
modulators	O
shown	O
not	O
to	O
affect	O
gap	O
junctions	O
,	O
which	O
were	O
tested	O
in	O
different	O
models	O
for	O
psychiatric	O
disorders	O
,	O
comprising	O
PTSD	O
,	O
memory	O
,	O
anxiety	O
and	O
depression	O
.	O

Compounds	O
modulating	O
astrocytic	O
release	O
of	O
substances	O
through	O
connexins	O
and	O
pannexins	O
and	O
treatment	O
of	O
psychiatric	O
disorders	O

The	O
main	O
purpose	O
of	O
the	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
aromatic	B
heterocyclic	I
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Examples	O
of	O
the	O
invention	O
include	O
aromatic	B
heterocyclic	I
derivatives	O
represented	O
by	O
general	O
formula	O
[	O
1	O
]	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

In	O
formula	O
[	O
1	O
]	O
,	O
R1	O
represents	O
phenyl	O
optionally	O
substituted	O
with	O
one	O
or	O
two	O
groups	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogens	B
,	O
as	O
well	O
as	O
alkyls	B
and	O
alkoxys	B
optionally	O
substituted	O
by	O
halogens	B
;	O
R2	O
represents	O
a	O
hydrogen	B
,	O
an	O
alkyl	B
,	O
cycloalkyl	B
,	O
or	O
alkoxy	B
optionally	O
substituted	O
by	O
a	O
halogen	B
,	O
or	O
a	O
heteroaryl	B
optionally	O
substituted	O
by	O
an	O
alkyl	B
;	O
X	O
represents	O
CR3	O
,	O
and	O
Y	O
represents	O
N	B
or	O
CR4	O
,	O
or	O
X	O
represents	O
N	B
,	O
and	O
Y	O
represents	O
CR4	O
;	O
and	O
Z	O
represents	O
CR5	O
or	O
N.	B
Aromatic	B
heterocyclic	I
derivative	O
and	O
pharmaceutical	O

Provided	O
is	O
a	O
screening	O
method	O
with	O
which	O
it	O
is	O
possible	O
to	O
determine	O
the	O
cause	O
of	O
a	O
decrease	O
or	O
an	O
increase	O
in	O
the	O
amount	O
of	O
a	O
target	O
protein	O
that	O
is	O
expressed	O
by	O
a	O
cell	O
.	O

One	O
or	O
a	O
plurality	O
of	O
embodiments	O
include	O
:	O
cultivation	O
of	O
a	O
culture	O
including	O
an	O
assay	O
cell	O
brought	O
into	O
contact	O
with	O
a	O
test	O
substance	O
,	O
and	O
measurement	O
of	O
the	O
relative	O
amount	O
of	O
the	O
target	O
protein	O
(	O
A	O
)	O
in	O
relation	O
to	O
an	O
internal	O
standard	O
;	O
cultivation	O
of	O
a	O
culture	O
in	O
which	O
an	O
assay	O
cell	O
is	O
not	O
contacted	O
with	O
a	O
test	O
substance	O
,	O
and	O
measurement	O
of	O
the	O
relative	O
amount	O
(	O
B	O
)	O
in	O
relation	O
to	O
an	O
internal	O
standard	O
;	O
comparison	O
of	O
the	O
relative	O
amount	O
(	O
A	O
)	O
and	O
the	O
relative	O
amount	O
(	O
B	O
)	O
;	O
and	O
,	O
based	O
on	O
the	O
comparison	O
,	O
selection	O
of	O
a	O
candidate	O
substance	O
that	O
induces	O
instability	O
and/or	O
stability	O
in	O
the	O
target	O
protein	O
.	O

The	O
assay	O
cell	O
is	O
a	O
cell	O
that	O
is	O
able	O
to	O
express	O
the	O
mRNA	O
of	O
the	O
target	O
protein	O
and	O
the	O
mRNA	O
of	O
the	O
internal	O
standard	O
protein	O
under	O
identical	O
regulation	O
of	O
expression	O
,	O
or	O
a	O
cell	O
having	O
a	O
means	O
for	O
expressing	O
the	O
mRNA	O
of	O
the	O
target	O
protein	O
and	O
the	O
mRNA	O
of	O
the	O
internal	O
standard	O
protein	O
under	O
conditions	O
where	O
the	O
gene	O
expression	O
control	O
is	O
identical	O
.	O

Screening	O
method	O
,	O
protein	O
instability	O
and/or	O
stability	O
inducers	O
,	O
and	O
protein	O
activity	O
assesment	O

The	O
invention	O
relates	O
to	O
the	O
chemical	O
-	O
pharmaceutical	O
industry	O
,	O
to	O
the	O
field	O
of	O
psychoneurology	O
and	O
specifically	O
to	O
means	O
for	O
treating	O
multiple	O
sclerosis	O
.	O

The	O
composition	O
(	O
in	O
a	O
solid	O
oral	O
dosage	O
form	O
)	O
is	O
suitable	O
for	O
sublingual	O
or	O
buccal	O
administration	O
or	O
for	O
administration	O
via	O
the	O
gingival	O
mucosa	O
,	O
and	O
contains	O
(	B
Z	I
)	I
-2-cyano-3-hydroxy	I
-	I
but-2-enoic	I
acid-	I
(	I
4'-trifluoromethylphenyl	I
)	I
-amide	I
(	O
Teriflunomide	B
)	O
as	O
active	O
agent	O
.	O

Composition	O
for	O
treating	O
multiple	O
sclerosis	O
(	O
variants	O
)	O

The	O
invention	O
features	O
methods	O
,	O
compositions	O
,	O
dosing	O
regimens	O
,	O
and	O
infusion	O
pumps	O
for	O
subcutaneously	O
infusing	O
acidic	O
solutions	O
of	O
L	B
-	I
DOPA	I
prodrugs	O
,	O
such	O
as	O
esters	B
and	O
amides	B
of	O
L	B
-	I
DOPA	I
,	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

The	O
methods	O
and	O
acidic	O
compositions	O
of	O
the	O
invention	O
can	O
reduce	O
the	O
severity	O
and	O
rate	O
of	O
occurrence	O
of	O
transient	O
local	O
swelling	O
,	O
erythema	O
,	O
and	O
persistent	O
subcutaneous	O
granulomas	O
associated	O
with	O
subcutaneous	O
delivery	O
of	O
certain	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

Dosing	O
regimens	O
for	O
subcutaneously	O
infusible	O
acidic	O
compositions	O

Vilazodone	B
hydrochloride	I
benzyl	B
alcohol	I
solvates	O
are	O
provided	O
as	O
well	O
as	O
processes	O
for	O
the	O
preparation	O
thereof	O
.	O

Forms	O
of	O
vilazodone	B
and	O
processes	O
for	O
the	O
preparation	O
thereof	O

Provided	O
are	O
benzothiazine-4-one	B
derivatives	O
and	O
preparation	O
method	O
therefor	O
and	O
use	O
thereof	O
.	O

The	O
benzothiazine-4-one	B
derivatives	O
represented	O
by	O
the	O
formula	O
I	O
have	O
activity	O
of	O
anti	O
-	O
mycobacterium	O
tuberculosis	O
.	O

Benzothiazine-4-one	B
derivatives	O
,	O
preparation	O
method	O
therefor	O
and	O
use	O
thereof	O

Treatment	O
of	O
pouchitis	O
with	O
a	O
solid	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
comprising	O
metronidazole	B
,	O
which	O
composition	O
delivers	O
metronidazole	B
to	O
an	O
ileal	O
pouch	O
.	O

Formulations	O
of	O
metronidazole	B
for	O
the	O
treatment	O
of	O
pouchitis	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
which	O
includes	O
at	O
least	O
one	O
hyaluronic	B
acid	I
,	O
optionally	O
cross	O
-	O
linked	O
,	O
or	O
one	O
of	O
the	O
salts	O
thereof	O
,	O
and	O
at	O
least	O
one	O
sucrose	B
octasulphate	I
water	O
-	O
soluble	O
salt	O
,	O
to	O
the	O
methods	O
for	O
manufacturing	O
said	O
composition	O
as	O
well	O
as	O
to	O
the	O
use	O
of	O
said	O
composition	O
for	O
the	O
formulation	O
of	O
a	O
viscosupplementation	O
composition	O
,	O
for	O
the	O
formulation	O
of	O
a	O
composition	O
for	O
filling	O
wrinkles	O
or	O
for	O
the	O
formulation	O
a	O
cosmetic	O
composition	O
.	O

Composition	O
,	O
in	O
an	O
aqueous	O
medium	O
,	O
including	O
at	O
least	O
one	O
hyaluronic	B
acid	I
and	O
at	O
least	O
one	O
sucrose	B
octasulphate	I
water	O
-	O
soluble	O
salt	O

The	O
invention	O
relates	O
to	O
a	O
feijoa	O
fruit	O
extract	O
.	O

In	O
particular	O
the	O
invention	O
relates	O
to	O
therapeutic	O
uses	O
of	O
a	O
feijoa	O
fruit	O
extract	O
,	O
processes	O
for	O
preparing	O
the	O
extract	O
,	O
and	O
compositions	O
comprising	O
the	O
extract	O
.	O

The	O
feijoa	O
fruit	O
extract	O
of	O
the	O
invention	O
can	O
be	O
used	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
rheumatoid	O
arthritis	O
and	O
Type-2	O
diabetes	O
.	O

Feijoa	O
fruit	O
extract	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
composition	O
for	O
the	O
treatment	O
of	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
.	O

The	O
pharmaceutical	O
composition	O
in	O
accordance	O
with	O
the	O
present	O
invention	O
is	O
a	O
novel	O
liquid	O
composition	O
that	O
improves	O
the	O
ease	O
of	O
administration	O
,	O
simplifies	O
the	O
manufacturing	O
process	O
,	O
facilitates	O
sterilization	O
,	O
and	O
forms	O
a	O
floating	O
gel	O
of	O
structurally	O
superior	O
strength	O
enabling	O
treatment	O
of	O
GERD	O
.	O

Novel	O
composition	O
for	O
the	O
treatment	O
of	O
gastroesophageal	O
reflux	O
disease	O

The	O
invention	O
relates	O
to	O
substantially	O
pure	O
Desfesoterodine	B
salts	O
,	O
Desfesoterodine	B
salts	O
,	O
solid	O
state	O
forms	O
thereof	O
and	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
of	O
the	O
Desfesoterodine	B
salts	O
and/or	O
solid	O
state	O
forms	O
thereof	O
.	O

Desfesoterodine	B
salts	O

The	O
present	O
invention	O
relates	O
to	O
the	O
compound	O
of	O
formula	O
I	O
,	O
a	O
pharmaceutical	O
composition	O
thereof	O
and	O
the	O
use	O
thereof	O
as	O
an	O
anti	O
-	O
tumour	O
drug	O
.	O

Compound	O
of	O
camptothecin	B
and	O
preparation	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
heterocyclyl	B
-	I
substituted	I
-	I
phenyl	I
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
A	O
is	O
a	O
compound	O
selected	O
from	O
the	O
following	O
group	O
:	O
n	O
is	O
selected	O
from	O
0	O
or	O
1	O
,	O
for	O
use	O
in	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
and	O
the	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

Heterocyclyl	B
-	I
substituted	I
-	I
phenyl	I
derivatives	O
for	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O

The	O
invention	O
relates	O
to	O
polymer	O
-	O
drug	O
conjugate	O
for	O
delivering	O
a	O
substituted	O
alkanoic	O
acid	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
drug	O
delivery	O
systems	O
comprising	O
the	O
polymer	O
-	O
NSAID	O
conjugate	O
.	O

The	O
polymer	O
-	O
NSAID	O
conjugates	O
comprise	O
a	O
substituted	O
alkanoic	O
acid	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
conjugated	O
to	O
a	O
biodegradable	O
polymer	O
backbone	O
by	O
an	O
ester	O
linkage	O
.	O

Polymer	O
-	O
nsaid	O
conjugate	O

5-Azaindazole	B
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
including	O
stereoisomers	O
,	O
geometric	O
isomers	O
,	O
tautomers	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
are	O
useful	O
for	O
inhibiting	O
Pim	O
kinase	O
,	O
and	O
for	O
treating	O
disorders	O
such	O
as	O
cancer	O
mediated	O
by	O
Pim	O
kinase	O
.	O

Methods	O
of	O
using	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
for	O
in	O
vitro	O
,	O
in	O
situ	O
,	O
and	O
in	O
vivo	O
diagnosis	O
,	O
prevention	O
or	O
treatment	O
of	O
such	O
disorders	O
in	O
mammalian	O
cells	O
,	O
or	O
associated	O
pathological	O
conditions	O
,	O
are	O
disclosed	O
.	O

5-azaindazole	B
compounds	O
and	O
methods	O
of	O
use	O

Provided	O
in	O
the	O
present	O
invention	O
are	O
antibiotic	O
Tetrathiazomycin	B
A	I
and	O
the	O
preparation	O
method	O
thereof	O
and	O
the	O
use	O
in	O
the	O
preparation	O
of	O
an	O
antitumour	O
drug	O
.	O

The	O
structural	O
formula	O
of	O
Tetrathiazomycin	B
A	I
is	O
shown	O
as	O
formula	O
(	O
I	O
)	O
.	O

The	O
present	O
invention	O
isolated	O
a	O
novel	O
compound	O
Tetrathiazomycin	B
A	I
having	O
an	O
antitumour	O
activity	O
from	O
a	O
fermentation	O
culture	O
of	O
Marinactinospora	O
thermotolerans	O
SCSIO	O
00652	O
of	O
the	O
genus	O
Actinomyces	O
,	O
providing	O
a	O
new	O
way	O
of	O
preparing	O
compound	O
Tetrathiazomycin	B
A	I
,	O
and	O
the	O
compound	O
Tetrathiazomycin	B
A	I
of	O
the	O
present	O
invention	O
has	O
a	O
better	O
antitumour	O
activity	O
,	O
so	O
it	O
can	O
be	O
used	O
in	O
an	O
antitumour	O
drug	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
leading	O
compound	O
for	O
the	O
development	O
of	O
antitumour	O
drugs	O
.	O

Antibiotic	O
tetrathiazomycin	B
a	I
and	O
preparation	O
method	O
thereof	O
and	O
use	O
in	O
preparation	O
of	O
antitumour	O
drug	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
preparing	O
substituted	O
triazolopyridine	B
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
as	O
described	O
and	O
defined	O
herein	O
,	O
as	O
well	O
as	O
to	O
intermediate	O
compounds	O
useful	O
in	O
the	O
preparation	O
of	O
said	O
compounds	O
.	O

Method	O
for	O
preparing	O
substituted	O
triazolopyridines	B

The	O
invention	O
relates	O
to	O
AKR1C3	O
inhibitors	O
and	O
methods	O
for	O
the	O
production	O
thereof	O
,	O
the	O
use	O
thereof	O
for	O
treating	O
and/or	O
preventing	O
diseases	O
,	O
and	O
the	O
use	O
thereof	O
for	O
producing	O
medicaments	O
for	O
treating	O
and/or	O
preventing	O
diseases	O
,	O
in	O
particular	O
menstrual	O
pain	O
and	O
endometriosis	O
.	O

3-substituted	B
estra-1,3,5	I
(	I
10	I
)	I
,16-tetraene	I
derivatives	O
,	O
methods	O
for	O
the	O
production	O
thereof	O
,	O
pharmaceutical	O
preparations	O
containing	O
same	O
,	O
and	O
use	O
thereof	O
for	O
the	O
production	O
of	O
medicaments	O

A	O
composition	O
comprising	O
i	O
)	O
oligomeric	B
lactic	I
acid	I
with	O
the	O
following	O
formula	O
(	O
I	O
)	O
wherein	O
n	O
is	O
an	O
integer	O
from	O
2	O
to	O
20	O
,	O
from	O
2	O
to	O
19	O
,	O
or	O
from	O
2	O
to	O
18	O
,	O
and	O
wherein	O
from	O
about	O
10	O
to	O
about	O
20	O
%	O
w	O
/	O
w	O
of	O
the	O
total	O
weight	O
of	O
the	O
oligomeric	B
lactic	I
acid	I
is	O
a	O
trimer	O
,	O
HL3	O
,	O
having	O
n	O
equal	O
to	O
2	O
,	O
wherein	O
the	O
number	O
average	O
molecular	O
weight	O
Mn	O
of	O
the	O
oligomeric	B
lactic	I
acid	I
is	O
from	O
about	O
200	O
to	O
about	O
500	O
,	O
and	O
ii	O
)	O
a	O
mucoadhesive	O
agent	O
.	O

Pharmaceutical	O
compositions	O
containing	O
oligomeric	B
lactic	I
acid	I

This	O
invention	O
is	O
related	O
to	O
the	O
use	O
of	O
inhibitors	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
3	O
for	O
treating	O
hepatocellular	O
carcinoma	O
.	O

Use	O
of	O
vegfr-3	O
inhibitors	O
for	O
treating	O
hepatocellular	O
carcinoma	O

The	O
invention	O
provides	O
fatty	B
acid	I
derivatives	O
for	O
use	O
in	O
a	O
method	O
of	O
treatment	O
of	O
at	O
least	O
one	O
disease	O
,	O
disorder	O
or	O
condition	O
selected	O
from	O
anxiety	O
,	O
depression	O
,	O
conditions	O
associated	O
menopause	O
,	O
stress	O
,	O
bipolar	O
disorder	O
,	O
neuropathic	O
pain	O
and	O
fibromyalgia	O
.	O

Fatty	B
acid	I
derivatives	O
for	O
use	O
in	O
a	O
method	O
of	O
treating	O
depression	O
and	O
associated	O
conditions	O

Provided	O
is	O
a	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
influenza	O
virus	O
infection	O
,	O
which	O
can	O
exert	O
the	O
effect	O
thereof	O
prior	O
to	O
the	O
infection	O
with	O
an	O
influenza	O
virus	O
,	O
in	O
an	O
early	O
phase	O
of	O
the	O
infection	O
,	O
and	O
in	O
a	O
middle	O
and	O
late	O
phase	O
of	O
the	O
infection	O
and	O
is	O
highly	O
safe	O
for	O
human	O
bodies	O
.	O

A	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
influenza	O
virus	O
infection	O
,	O
which	O
comprises	O
5-aminolevulinic	B
acid	I
(	O
5-ALA	B
)	O
,	O
a	O
derivative	O
of	O
the	O
compound	O
or	O
a	O
salt	O
of	O
the	O
compound	O
or	O
the	O
derivative	O
and	O
an	O
iron	O
compound	O
as	O
active	O
ingredients	O
,	O
is	O
prepared	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
can	O
be	O
used	O
for	O
improving	O
(	O
or	O
preventing	O
)	O
the	O
decrease	O
in	O
the	O
amount	O
of	O
a	O
food	O
ingested	O
,	O
the	O
amount	O
of	O
water	O
taken	O
and	O
a	O
body	O
weight	O
,	O
for	O
improving	O
the	O
increase	O
in	O
(	O
or	O
reducing	O
)	O
the	O
amount	O
of	O
a	O
ketone	O
body	O
,	O
which	O
is	O
a	O
causative	O
substance	O
for	O
ketosis	O
,	O
in	O
the	O
blood	O
,	O
for	O
improving	O
(	O
or	O
preventing	O
)	O
the	O
decrease	O
in	O
the	O
amount	O
of	O
ATP	O
in	O
the	O
blood	O
,	O
or	O
for	O
improving	O
the	O
decrease	O
in	O
(	O
or	O
increasing	O
)	O
a	O
survival	O
rate	O
or	O
the	O
temperature	O
on	O
the	O
surface	O
of	O
the	O
body	O
.	O

Prophylactic	O
/	O
therapeutic	O
agent	O
for	O
influenza	O
virus	O
infection	O

Provided	O
herein	O
are	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
:	O
(	O
I	O
)	O
(	O
II	O
)	O
harmaceutically	O
acceptable	O
salts	O
,	O
tautomers	O
,	O
prodrugs	O
,	O
and	O
stereoisomers	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
wherein	O
X	O
,	O
RN	O
,	O
R1	O
,	O
R3	O
,	O
R4	O
,	O
p	O
,	O
and	O
m	O
are	O
as	O
defined	O
herein	O
.	O

Such	O
compounds	O
and	O
compositions	O
have	O
been	O
found	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
viral	O
infections	O
,	O
e.g.	O
,	O
polyomaviral	O
infections	O
,	O
and	O
are	O
further	O
envisioned	O
useful	O
in	O
treatment	O
or	O
prevention	O
of	O
other	O
pathogenic	O
conditions	O
associated	O
with	O
endosomal	O
trafficking	O
.	O

Methods	O
of	O
treating	O
or	O
preventing	O
an	O
infection	O
by	O
a	O
pathogen	O
secreting	O
an	O
AB5	O
toxin	O
is	O
also	O
contemplated	O
.	O

Compounds	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
infections	O

The	O
invention	O
provides	O
a	O
method	O
of	O
preventing	O
or	O
treating	O
hearing	O
loss	O
in	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O

The	O
method	O
involves	O
administering	O
to	O
the	O
mammal	O
an	O
agent	O
that	O
increases	O
intracellular	O
NAD+	O
in	O
the	O
mammal	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
of	O
determining	O
if	O
a	O
compound	O
acts	O
as	O
a	O
neuroprotective	O
agent	O
.	O

Nicotinamide	B
riboside	I
to	O
treat	O
hearing	O
loss	O

Disclosed	O
in	O
the	O
present	O
invention	O
is	O
a	O
bulk	O
drug	O
of	O
meropenem	B
,	O
characterized	O
in	O
that	O
the	O
meropenem	B
content	O
in	O
the	O
bulk	O
drug	O
is	O
98.5%~101.0	O
%	O
based	O
on	O
the	O
anhydrous	O
substances	O
;	O
the	O
impurities	O
A	O
and	O
B	O
in	O
the	O
related	O
substances	O
of	O
the	O
bulk	O
drug	O
are	O
both	O
no	O
more	O
than	O
0.25	O
%	O
;	O
any	O
single	O
unknown	O
impurity	O
is	O
no	O
more	O
than	O
0.05	O
%	O
;	O
the	O
sum	O
of	O
the	O
other	O
impurities	O
in	O
addition	O
to	O
A	O
and	O
B	O
is	O
no	O
more	O
than	O
0.2	O
%	O
;	O
the	O
residue	O
of	O
acetone	B
is	O
no	O
more	O
than	O
400ppm	O
,	O
preferably	O
no	O
more	O
than	O
100ppm	O
.	O

Also	O
disclosed	O
in	O
the	O
present	O
invention	O
is	O
a	O
meropenem	B
pharmaceutical	O
composition	O
with	O
very	O
good	O
stability	O
for	O
injection	O
using	O
the	O
meropenem	B
bulk	O
drug	O
provided	O
by	O
the	O
present	O
invention	O
as	O
the	O
active	O
ingredient	O
.	O

The	O
meropenem	B
bulk	O
drug	O
provided	O
by	O
the	O
present	O
invention	O
has	O
high	O
purity	O
,	O
well	O
-	O
defined	O
impurity	O
levels	O
,	O
low	O
residual	O
solvent	O
content	O
,	O
good	O
solubility	O
,	O
and	O
good	O
stability	O
for	O
long	O
-	O
term	O
storage	O
,	O
so	O
it	O
ensures	O
that	O
the	O
drug	O
is	O
effective	O
and	O
safe	O
.	O

The	O
present	O
invention	O
has	O
a	O
simple	O
process	O
,	O
a	O
very	O
low	O
cost	O
,	O
a	O
compact	O
process	O
,	O
and	O
is	O
easy	O
to	O
control	O
,	O
so	O
it	O
is	O
suitable	O
for	O
the	O
production	O
of	O
sterile	O
meropenem	O
bulk	O
drug	O
and	O
pharmaceutical	O
preparations	O
on	O
an	O
industrial	O
scale	O
.	O

Meropenem	B
bulk	O
drug	O
,	O
preparation	O
method	O
thereof	O
and	O
pharmaceutical	O
composition	O
containing	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
at	O
least	O
one	O
sucrose	B
octasulphate	I
,	O
or	O
a	O
salt	O
thereof	O
,	O
and	O
at	O
least	O
one	O
emollient	O
.	O

Composition	O
comprising	O
a	O
sucrose	B
octasulphate	I
and	O
a	O
specific	O
emollient	O

[	O
Problem	O
]	O
To	O
find	O
a	O
therapeutic	O
method	O
for	O
increasing	O
the	O
drug	O
effect	O
of	O
a	O
taxan	B
antitumor	O
agent	O
against	O
various	O
types	O
of	O
tumors	O
.	O

[	O
Solution	O
]	O

As	O
a	O
result	O
of	O
studying	O
methods	O
for	O
potentiation	O
of	O
the	O
antitumor	O
effect	O
of	O
taxan	B
antitumor	O
drugs	O
,	O
the	O
inventors	O
completed	O
the	O
present	O
invention	O
upon	O
confirming	O
that	O
a	O
pharmaceutical	O
composition	O
for	O
cancer	O
therapy	O
comprising	O
as	O
the	O
active	O
ingredient	O
an	O
NO	B
production	O
inhibitor	O
potentiates	O
the	O
antitumor	O
effect	O
of	O
a	O
taxan	B
antitumor	O
drug	O
.	O

That	O
is	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
cancer	O
therapy	O
comprising	O
as	O
the	O
active	O
ingredient	O
an	O
NO	B
production	O
inhibitor	O
that	O
is	O
for	O
co	O
-	O
administration	O
with	O
a	O
taxan	B
antitumor	O
drug	O
.	O

Method	O
for	O
treating	O
cancer	O
by	O
anticancer	O
agent	O
co	O
-	O
administration	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
,	O
and	O
salts	O
thereof	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
invention	O
relates	O
to	O
inhibitors	O
or	O
modulators	O
of	O
Pim-1	O
and/or	O
Pim-2	O
,	O
and/or	O
Pim-3	O
protein	O
kinase	O
activity	O
or	O
enzyme	O
function	O
.	O

In	O
still	O
further	O
embodiments	O
,	O
the	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
disclosed	O
herein	O
,	O
and	O
their	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
Pim	O
kinase	O
related	O
conditions	O
and	O
diseases	O
,	O
preferably	O
cancer	O
.	O

Macrocycles	O
as	O
pim	O
inhibitors	O

The	O
present	O
invention	O
provides	O
a	O
trinuclear	O
platinum	B
complex	O
(	O
ZD028	O
)	O
capable	O
of	O
inhibiting	O
telomerase	O
activity	O
with	O
high	O
efficiency	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
same	O
as	O
an	O
antitumor	O
drug	O
.	O

The	O
complex	O
(	O
ZD028	O
)	O
of	O
the	O
present	O
invention	O
has	O
a	O
low	O
toxicity	O
on	O
normal	O
cells	O
,	O
thereby	O
reducing	O
side	O
effects	O
on	O
other	O
organs	O
or	O
systems	O
.	O

The	O
complex	O
has	O
a	O
simple	O
and	O
easy	O
preparation	O
method	O
,	O
is	O
low	O
in	O
costs	O
,	O
can	O
be	O
completed	O
in	O
a	O
common	O
chemical	O
laboratory	O
,	O
and	O
has	O
no	O
environmental	O
pollution	O
during	O
the	O
production	O
process	O
.	O

High	O
efficiency	O
telomerase	O
inhibitor	O
and	O
application	O
of	O
same	O
in	O
antitumor	O
drug	O

The	O
present	O
invention	O
relates	O
to	O
certain	O
pyrrolopyrimidine	B
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
methods	O
of	O
using	O
them	O
,	O
including	O
methods	O
for	O
the	O
treatment	O
of	O
proliferation	O
disorders	O
and	O
other	O
diseases	O
related	O
to	O
the	O
dysregulation	O
of	O
kinase	O
(	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
EGFR	O
(	O
including	O
HER	O
)	O
,	O
Alk	O
,	O
PDGFR	O
,	O
BLK	O
,	O
BMX	O
/	O
ETK	O
,	O
BTK	O
,	O
FLT3	O
(	O
D835Y	O
)	O
,	O
ITK	O
,	O
JAKl	O
,	O
JAK2	O
,	O
JAK3	O
,	O
TEC	O
and	O
TXK	O
)	O
and/or	O
the	O
respective	O
pathways	O
.	O

Novel	O
pyrrolopyrimidine	B
compounds	O
as	O
inhibitors	O
of	O
protein	O
kinases	O

Provided	O
herein	O
are	O
curcumin	B
analogues	O
that	O
are	O
able	O
to	O
interact	O
with	O
amyloid	O
β	O
(	O
Aβ	O
)	O
and	O
to	O
attenuate	O
the	O
copper	B
-	O
induced	O
crosslinking	O
of	O
Aβ	O
.	O

Also	O
provided	O
herein	O
are	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
or	O
a	O
related	O
disorder	O
.	O

Curcumin	B
analogs	O

The	O
invention	O
provide	O
herein	O
provides	O
for	O
a	O
targeted	O
drug	O
delivery	O
vehicle	O
compositions	O
,	O
methods	O
of	O
manufacture	O
,	O
and	O
methods	O
of	O
treatment	O
for	O
therapeutic	O
applications	O
.	O

Drug	O
delivery	O
vehicle	O
comprising	O
conjugates	O
between	O
targeting	O
polyamino	B
acids	I
and	O
fatty	B
acids	I

The	O
present	O
invention	O
concerns	O
the	O
combination	O
of	O
pullulan	O
or	O
one	O
of	O
the	O
derivatives	O
of	O
same	O
with	O
a	O
polysaccharide	O
chosen	O
from	O
hyaluronic	O
acid	O
,	O
one	O
of	O
the	O
salts	O
or	O
derivatives	O
of	O
same	O
,	O
alginic	O
acid	O
,	O
one	O
of	O
the	O
salts	O
or	O
derivatives	O
of	O
same	O
,	O
and	O
a	O
mixture	O
of	O
said	O
polysaccharides	O
.	O

It	O
further	O
concerns	O
a	O
mixture	O
of	O
cosmetic	O
or	O
pharmaceutical	O
ingredients	O
,	O
a	O
cosmetic	O
or	O
pharmaceutical	O
composition	O
and	O
a	O
detergent	O
or	O
hygiene	O
product	O
comprising	O
said	O
combination	O
.	O

It	O
further	O
concerns	O
the	O
use	O
of	O
this	O
combination	O
to	O
reduce	O
imperceptible	O
water	O
losses	O
and/or	O
to	O
increase	O
the	O
water	O
content	O
of	O
the	O
skin	O
and/or	O
of	O
the	O
mucosa	O
and/or	O
to	O
increase	O
and/or	O
prolong	O
the	O
content	O
of	O
active	O
cosmetic	O
and/or	O
pharmaceutical	O
ingredients	O
in	O
the	O
skin	O
and/or	O
the	O
mucosa	O
and/or	O
maintain	O
it	O
over	O
time	O
,	O
the	O
use	O
of	O
this	O
cosmetic	O
composition	O
to	O
maintain	O
or	O
increase	O
the	O
state	O
of	O
hydration	O
of	O
the	O
skin	O
and/or	O
to	O
prevent	O
or	O
slow	O
down	O
the	O
appearance	O
of	O
signs	O
of	O
dry	O
skin	O
and/or	O
mucosal	O
dryness	O
and/or	O
for	O
the	O
treatment	O
of	O
dry	O
skin	O
conditions	O
and/or	O
to	O
prevent	O
or	O
reduce	O
the	O
appearance	O
of	O
wrinkles	O
linked	O
to	O
dry	O
skin	O
,	O
and/or	O
to	O
improve	O
the	O
comfort	O
of	O
dry	O
skin	O
and/or	O
mucosa	O
,	O
and/or	O
for	O
the	O
treatment	O
of	O
skin	O
and/or	O
mucosa	O
that	O
has	O
/	O
have	O
a	O
rough	O
appearance	O
and/or	O
feel	O
,	O
and	O
the	O
use	O
of	O
the	O
pharmaceutical	O
composition	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
chapping	O
and/or	O
flaws	O
or	O
eczematid	O
achromians	O
and/or	O
cracks	O
and/or	O
atopic	O
dermatitis	O
and/or	O
ichthyosis	O
and/or	O
states	O
of	O
dryness	O
of	O
the	O
skin	O
or	O
mucosa	O
that	O
accompany	O
skin	O
conditions	O
.	O

Cosmetic	O
or	O
pharmaceutical	O
moisturising	O
ingredient	O

A	O
composition	O
in	O
the	O
form	O
of	O
microparticles	O
primarily	O
made	O
up	O
of	O
:	O
a	O
)	O
an	O
inert	O
core	O
;	O
b	O
)	O
a	O
layer	O
of	O
active	O
principle	O
formed	O
by	O
spraying	O
onto	O
the	O
inert	O
core	O
,	O
and	O
c	O
)	O
optionally	O
,	O
a	O
second	O
coating	O
comprising	O
one	O
or	O
more	O
layers	O
of	O
pharmaceutically	O
acceptable	O
excipient	O
(	O
s	O
)	O
and/or	O
drug	O
(	O
s	O
)	O
.	O

Said	O
composition	O
may	O
be	O
used	O
to	O
treat	O
conditions	O
resulting	O
from	O
excessive	O
retention	O
of	O
water	O
and/or	O
electrolytes	O
,	O
cardiovascular	O
disease	O
,	O
renovascular	O
disease	O
,	O
diabetes	O
,	O
endothelial	O
dysfunction	O
,	O
cirrhosis	O
,	O
preeclampsia	O
,	O
nephropathy	O
,	O
peripheral	O
vascular	O
disease	O
and	O
hypertension	O
,	O
among	O
others	O
.	O

Oral	O
pharmaceutical	O
composition	O
in	O
the	O
form	O
of	O
microspheres	O
and	O
preparation	O
method	O

A	O
compound	O
represented	O
by	O
general	O
formula	O
[	O
1D	O
]	O
(	O
in	O
the	O
formula	O
,	O
R1A	O
,	O
R1B	O
,	O
R2A	O
,	O
R2B	O
,	O
R3A	O
and	O
R3B	O
each	O
denote	O
a	O
hydrogen	B
atom	O
,	O
an	O
optionally	O
substituted	O
C1	B
-	I
6	I
alkyl	I
group	O
,	O
and	O
the	O
like	O
)	O
is	O
useful	O
as	O
an	O
intermediate	O
for	O
producing	O
a	O
thionucleoside	B
,	O
and	O
this	O
production	O
method	O
is	O
useful	O
as	O
a	O
method	O
for	O
producing	O
a	O
thionucleoside	B
.	O

INTERMEDIATE	O
FOR	O
SYNTHESIS	O
OF	O
1-	B
(	I
2-DEOXY-2-FLUORO-4-THIO	I
-	I
β	I
-	I
D	I
-	I
ARABINOFURANOSYL	I
)	I
CYTOSINE	I
,	O
INTERMEDIATE	O
FOR	O
SYNTHESIS	O
OF	O
THIONUCLEOSIDE	B
,	O
AND	O
METHODS	O
FOR	O
PRODUCING	O
THESE	O
INTERMEDIATES	O

Prostate	O
cancer	O
is	O
treated	O
by	O
administration	O
of	O
N	B
6-benzyladenosine-5'-	I
monophosphate	I
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Treatment	O
of	O
prostate	O
cancer	O

Disclosed	O
herein	O
is	O
use	O
of	O
one	O
or	O
more	O
aminopyridines	B
in	O
methods	O
and	O
compositions	O
for	O
improving	O
walking	O
capacity	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
.	O

Methods	O
for	O
improving	O
walking	O
capacity	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
using	O
an	O
aminopyridine	B

Novel	O
compounds	O
of	O
the	O
structural	O
formula	O
(	O
I	O
)	O
are	O
activators	O
of	O
AMP	O
-	O
protein	O
kinase	O
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
the	O
AMPK	O
activated	O
protein	O
kinase	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Type	O
2	O
diabetes	O
,	O
hyperglycemia	O
,	O
metabolic	O
syndrome	O
,	O
obesity	O
,	O
hypercholesterolemia	O
,	O
and	O
hypertension	O
.	O

Novel	O
azabenzimidazole	B
hexahydrofuro	I
[	I
3,2-b	I
]	I
furan	I
derivatives	O

Inhibitors	O
of	O
HBV	O
replication	O
of	O
Formula	O
(	O
I	O
)	O
including	O
stereochemically	O
isomeric	O
forms	O
,	O
and	O
salts	O
,	O
hydrates	B
,	O
solvates	O
thereof	O
,	O
wherein	O
B	O
,	O
R1	O
,	O
R2	O
and	O
R4	O
have	O
the	O
meaning	O
as	O
defined	O
herein	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
preparing	O
said	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
HBV	O
inhibitors	O
,	O
in	O
HBV	O
therapy	O
.	O

Sulfamoyl	B
-	I
arylamides	I
and	O
the	O
use	O
thereof	O
as	O
medicaments	O
for	O
the	O
treatment	O
of	O
hepatitis	O
b	O

[	O
Problem	O
]	O
To	O
provide	O
a	O
novel	O
therapeutic	O
agent	O
or	O
preventive	O
agent	O
for	O
photosensitivity	O
or	O
a	O
cosmetic	O
.	O

[	O
Solution	O
]	O
A	O
compound	O
represented	O
by	O
general	O
formula	O
;	O
and	O
a	O
medicinal	O
composition	O
or	O
cosmetic	O
composition	O
having	O
therapeutic	O
and/or	O
preventive	O
effects	O
on	O
photosensitivity	O
,	O
said	O
composition	O
containing	O
the	O
aforesaid	O
compound	O
as	O
an	O
active	O
ingredient	O
.	O

In	O
the	O
formula	O
:	O
one	O
of	O
R1	O
to	O
R3	O
is	O
a	O
2-methylbut-2-enoyl	B
group	O
and	O
the	O
two	O
remainders	O
are	O
hydrogen	B
atoms	O
;	O
and	O
one	O
of	O
R4	O
to	O
R6	O
is	O
a	O
2-methylbut-2-enoyl	B
group	O
and	O
the	O
two	O
remainders	O
are	O
hydrogen	B
atoms	O
.	O

Trehangelin	B
compounds	O
as	O
novel	O
photosensitivity	O
inhibitors	O
and	O
method	O
for	O
producing	O
same	O

The	O
present	O
disclosure	O
relates	O
to	O
the	O
prevention	O
and/or	O
treatment	O
of	O
metastatic	O
cancer	O
.	O

Certain	O
example	O
embodiments	O
of	O
the	O
present	O
disclosure	O
provide	O
a	O
method	O
for	O
preventing	O
and/or	O
treating	O
a	O
metastatic	O
cancer	O
in	O
a	O
subject	O
.	O

The	O
method	O
comprises	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
inhibitor	O
of	O
a	O
chemokine	O
receptor	O
CCX	O
-	O
CKR	O
.	O

Methods	O
and	O
products	O
for	O
preventing	O
and/or	O
treating	O
metastatic	O
cancer	O

Process	O
for	O
manufacturing	O
a	O
product	O
for	O
treating	O
psoriasis	O
and	O
product	O
for	O
treating	O
psoriasis	O
,	O
presented	O
in	O
the	O
present	O
patent	O
application	O
,	O
comprising	O
a	O
manufacturing	O
process	O
and	O
a	O
product	O
that	O
,	O
by	O
the	O
innocuous	O
nature	O
of	O
the	O
components	O
thereof	O
,	O
constitutes	O
no	O
risk	O
whatsoever	O
to	O
the	O
health	O
of	O
patients	O
and	O
offers	O
a	O
good	O
cost	O
/	O
benefit	O
ratio	O
;	O
said	O
process	O
and	O
product	O
for	O
treating	O
psoriasis	O
comprise	O
the	O
following	O
compounds	O
:	O
alpha	B
-	I
bisabolol	I
,	O
vitamin	B
A	I
,	O
vitamin	B
E	I
,	O
salicylic	B
acid	I
,	O
allantoin	B
,	O
camomile	O
,	O
copaiba	O
oil	O
,	O
aloe	O
vera	O
,	O
non‑ionic	O
Polawax	O
base	O
lotion	O
and	O
,	O
optionally	O
,	O
arnica	O
extract	O
,	O
sunflower	O
oil	O
and	O
liquid	O
paraffin	O
.	O

Process	O
for	O
manufacturing	O
a	O
product	O
for	O
treating	O
psoriasis	O
and	O
product	O
for	O
treating	O
psoriasis	O

The	O
present	O
disclosure	O
is	O
directed	O
generally	O
to	O
cosmetic	O
compositions	O
comprising	O
eicosapentaenoic	O
free	O
acid	O
and	O
gamma	O
-	O
linolenic	O
free	O
acid	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
cosmetic	O
compositions	O
have	O
a	O
cosmetically	O
acceptable	O
odor	O
.	O

Cosmetic	O
compositions	O
comprising	O
eicosapentaeninic	O
free	O
acid	O
and	O
gamma	O
-	O
linopenic	O
free	O
acid	O
and	O
methods	O
of	O
making	O
and	O
using	O
same	O

The	O
present	O
invention	O
addresses	O
the	O
problem	O
of	O
providing	O
a	O
method	O
and	O
the	O
like	O
for	O
efficiently	O
growing	O
kidney	O
-	O
derived	O
somatic	O
stem	O
cells	O
.	O

This	O
production	O
method	O
for	O
kidney	O
-	O
derived	O
somatic	O
stem	O
cells	O
comprises	O
the	O
following	O
steps	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
:	O
a	O
step	O
(	O
A	O
)	O
in	O
which	O
a	O
group	O
of	O
cells	O
including	O
cells	O
that	O
constitute	O
the	O
kidneys	O
are	O
made	O
to	O
pass	O
through	O
the	O
G0	O
phase	O
or	O
the	O
G1	O
phase	O
,	O
and	O
a	O
gene	O
for	O
a	O
protein	O
that	O
is	O
active	O
in	O
causing	O
the	O
transition	O
to	O
the	O
S	O
phase	O
are	O
expressed	O
;	O
and	O
a	O
step	O
(	O
B	O
)	O
in	O
which	O
the	O
cells	O
obtained	O
at	O
the	O
step	O
(	O
A	O
)	O
are	O
cultivated	O
in	O
the	O
presence	O
of	O
an	O
extracellular	O
growth	O
factor	O
.	O

Production	O
method	O
for	O
kidney	O
-	O
derived	O
somatic	O
stem	O
cells	O

Bolaamphiphilic	O
compounds	O
are	O
provided	O
according	O
to	O
formula	O
(	O
I	O
)	O
:	O
where	O
HG1	O
,	O
HG2	O
and	O
L1	O
are	O
as	O
defined	O
herein	O
.	O

Provided	O
bolaamphilphilic	O
compounds	O
and	O
the	O
pharmaceutical	O
compositions	O
thereof	O
are	O
useful	O
for	O
delivering	O
HIV	O
active	O
drugs	O
into	O
animal	O
or	O
human	O
brain	O
.	O

Bolaamphiphilic	O
compounds	O
,	O
compositions	O
and	O
uses	O
thereof	O

This	O
invention	O
is	O
directed	O
to	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
patient	O
,	O
particularly	O
a	O
patient	O
with	O
lung	O
adenocarcinoma	O
,	O
and	O
more	O
particularly	O
a	O
patient	O
with	O
KIF5B	O
-	O
RET	O
fusion	O
-	O
positive	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
with	O
an	O
inhibitor	O
of	O
MET	O
,	O
VEGF	O
,	O
and	O
RET	O
which	O
is	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Inhibitors	O
of	O
met	O
,	O
vegfr	O
and	O
ret	O
for	O
use	O
in	O
the	O
treatment	O
of	O
lung	O
adenocarcinoma	O

In	O
an	O
embodiment	O
of	O
the	O
present	O
disclosure	O
there	O
is	O
provided	O
a	O
method	O
of	O
inactivating	O
enveloped	O
DNA	O
virus	O
particles	O
in	O
a	O
biological	O
sample	O
.	O

In	O
an	O
embodiment	O
,	O
such	O
a	O
method	O
comprises	O
contacting	O
the	O
biological	O
sample	O
with	O
an	O
effective	O
amount	O
of	O
an	O
antiviral	O
composition	O
comprising	O
PD	O
404,182	O
In	O
some	O
embodiments	O
,	O
the	O
DNA	O
virus	O
is	O
the	O
Herpes	O
Simplex	O
virus-	O
1	O
(	O
HSV-1	O
)	O
or	O
the	O
Herpes	O
Simplex	O
Virus-2	O
(	O
HSV-2	O
)	O
.	O

In	O
another	O
embodiment	O
of	O
the	O
present	O
disclosure	O
,	O
there	O
is	O
provided	O
a	O
method	O
of	O
treating	O
,	O
preventing	O
,	O
or	O
reducing	O
a	O
viral	O
infection	O
caused	O
by	O
an	O
enveloped	O
DNA	O
virus	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

In	O
yet	O
another	O
embodiment	O
,	O
there	O
is	O
provided	O
a	O
method	O
of	O
preventing	O
transmission	O
of	O
a	O
viral	O
infection	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

In	O
an	O
embodiment	O
,	O
such	O
a	O
method	O
comprises	O
contacting	O
a	O
mucus	O
membrane	O
of	O
the	O
subject	O
with	O
a	O
topical	O
formulation	O
comprising	O
an	O
effective	O
amount	O
of	O
PD	O
404,182	O
in	O
combination	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
A	O
virucidal	O
small	O
molecule	O
and	O
uses	O
thereof	O

Disclosed	O
are	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
formula	O
(	O
II	O
)	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
as	O
well	O
as	O
polymorphs	O
,	O
solvates	O
,	O
enantiomers	O
,	O
stereoisomers	O
and	O
hydrates	B
thereof	O
.	O

The	O
pharmaceutical	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
formula	O
(	O
II	O
)	O
are	O
also	O
disclosed	O
.	O

Such	O
compositions	O
may	O
be	O
used	O
for	O
treating	O
diabetes	O
related	O
renal	O
complications	O
,	O
hypertension	O
,	O
albuminuria	O
,	O
heart	O
diseases	O
,	O
ESRD	O
,	O
kidney	O
GFR	O
complications	O
,	O
vascular	O
disease	O
,	O
ventricular	O
septal	O
defect	O
,	O
vascular	O
dilation	O
,	O
high	O
blood	O
pressure	O
,	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
,	O
post	O
-	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

Compounds	O
and	O
compositions	O
for	O
treatment	O
of	O
hypertension	O
and	O
management	O
of	O
diabetic	O
kidney	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
process	O
for	O
the	O
preparation	O
of	O
crystalline	O
etoricoxib	B
Process	O
for	O
preparation	O
of	O
crystalline	O
etoricoxib	B

Disclosed	O
are	O
compositions	O
,	O
such	O
as	O
liquid	O
and	O
solid	O
nutritional	O
compositions	O
,	O
that	O
contain	O
beta	B
-	I
hydroxy	I
-	I
beta	I
-	I
methylbutyric	I
acid	I
and	O
optionally	O
at	O
least	O
one	O
protein	O
,	O
carbohydrate	B
,	O
fat	O
,	O
or	O
a	O
combination	O
of	O
protein	O
,	O
carbohydrate	B
,	O
and	O
fat	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
the	O
compositions	O
for	O
improving	O
physical	O
endurance	O
,	O
locomotion	O
,	O
mobility	O
and	O
cognition	O
in	O
an	O
individual	O
,	O
including	O
a	O
pediatric	O
individual	O
.	O

Beta	B
-	I
hydroxy	I
-	I
beta	I
-	I
methylbutryic	I
acid-	I
containing	O
compositions	O
and	O
uses	O
thereof	O

Pan	O
-	O
genotypic	O
HCV	O
inhibitors	O
are	O
described	O
.	O

This	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
using	O
these	O
inhibitors	O
to	O
treat	O
HCV	O
infection	O
.	O

Methods	O
for	O
treating	O
hepatitis	O
c	O

Disclosed	O
are	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
wherein	O
:	O
R2	O
is	O
phenyl	B
,	O
fluorophenyl	B
,	O
chlorophenyl	B
,	O
trifluorophenyl	B
,	O
methylisoxazolyl	B
,	O
or	O
pyridinyl	B
;	O
R3	O
is	O
H	B
,	O
CH3	B
,	O
CH2	B
(	I
cyclopropyl	I
)	I
,	O
pyridinyl	B
,	O
chloropyridinyl	B
,	O
or	O
methoxypyridinyl	B
:	O
and	O
Ra	O
,	O
Rb	O
,	O
y	O
,	O
and	O
z	O
are	O
defined	O
herein	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
inhibit	O
the	O
Notch	O
receptor	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
treating	O
,	O
preventing	O
,	O
or	O
slowing	O
the	O
progression	O
of	O
diseases	O
or	O
disorders	O
in	O
a	O
variety	O
of	O
therapeutic	O
areas	O
,	O
such	O
as	O
cancer	O
.	O

Fluoroalkyl-1,4-benzodiazepinone	B
compounds	O

The	O
invention	O
relates	O
to	O
novel	O
AMPK	O
agonist	O
containing	O
compositions	O
that	O
are	O
adapted	O
for	O
localised	O
use	O
in	O
treating	O
inflammation	O
and/or	O
pain	O
due	O
to	O
disease	O
or	O
injury	O
in	O
a	O
human	O
or	O
animal	O
.	O

The	O
novel	O
compositions	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
including	O
osteoarthritis	O
(	O
OA	O
)	O
,	O
synovitis	O
,	O
tendonitis	O
,	O
desmitis	O
,	O
cystitis	O
,	O
osteitis	O
and	O
laminitis	O
.	O

Routes	O
of	O
administration	O
include	O
intra	O
-	O
articular	O
,	O
direct	O
injection	O
into	O
tissues	O
,	O
instillation	O
,	O
retrograde	O
perfusion	O
and	O
topical	O
.	O

AMPK	O
agonists	O
which	O
can	O
be	O
used	O
include	O
AICAR	B
,	O
metformin	B
,	O
phenformin	B
,	O
A-769662	O
,	O
resveratrol	B
,	O
berberine	B
and	O
polyphenols	B
.	O

Novel	O
ampk	O
agonist	O
compositions	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
aging	O
or	O
skin	O
moisturizing	O
composition	O
.	O

The	O
composition	O
according	O
to	O
the	O
present	O
invention	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
material	O
for	O
controlling	O
the	O
expression	O
of	O
ABH	O
antigen	O
,	O
and	O
therefore	O
,	O
has	O
superior	O
anti	O
-	O
aging	O
and	O
skin	O
moisturizing	O
effects	O
.	O

Further	O
,	O
the	O
composition	O
of	O
the	O
preset	O
invention	O
may	O
inhibit	O
the	O
expression	O
of	O
MMP-1	O
,	O
and	O
therefore	O
,	O
can	O
be	O
effectively	O
used	O
in	O
reducing	O
wrinkles	O
or	O
improving	O
the	O
appearance	O
thereof	O
.	O

Composition	O
comprising	O
material	O
for	O
controlling	O
expression	O
of	O
abh	O
antigen	O

The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
industry	O
and	O
medicine	O
and	O
can	O
be	O
used	O
in	O
the	O
creation	O
and	O
administration	O
of	O
solid	O
dosage	O
forms	O
having	O
a	O
choleretic	O
effect	O
.	O

The	O
present	O
invention	O
addresses	O
the	O
problem	O
of	O
creating	O
an	O
effective	O
solid	O
dosage	O
form	O
having	O
a	O
choleretic	O
effect	O
.	O

In	O
the	O
description	O
,	O
two	O
variants	O
of	O
the	O
invention	O
are	O
claimed	O
which	O
solve	O
the	O
problem	O
of	O
interest	O
in	O
that	O
the	O
solid	O
dosage	O
form	O
contains	O
dried	O
bile	O
,	O
mineral	O
substances	O
and	O
a	O
pharmaceutically	O
acceptable	O
carbon	B
-	O
containing	O
additional	O
substance	O
with	O
carbon-13	B
isotopes	O
.	O

The	O
invention	O
achieves	O
the	O
technical	O
results	O
of	O
a	O
greater	O
and	O
more	O
rapid	O
therapeutic	O
effect	O
in	O
the	O
treatment	O
of	O
liver	O
and	O
gall	O
bladder	O
diseases	O
without	O
decreasing	O
the	O
duration	O
of	O
said	O
therapeutic	O
effect	O
or	O
increasing	O
the	O
concentration	O
of	O
bile	O
.	O

Solid	O
dosage	O
form	O
having	O
a	O
choleretic	O
effect	O
(	O
variants	O
)	O

Novel	O
protein	O
tyrosine	B
phosphatase	O
(	O
PTP	O
)	O
inhibitor	O
compounds	O
synthesized	O
from	O
phosphonodifluoromethyl	B
phenylalanine	I
(	O
F2Pmp	O
)	O
are	O
provided	O
.	O

Use	O
of	O
these	O
compounds	O
for	O
inhibiting	O
a	O
PTP	O
enzyme	O
(	O
such	O
as	O
PTP	O
-	O
MEG2	O
)	O
,	O
as	O
well	O
as	O
treating	O
a	O
disease	O
,	O
disorder	O
,	O
or	O
condition	O
associated	O
with	O
inappropriate	O
activity	O
of	O
a	O
PTP	O
(	O
such	O
as	O
type	O
2	O
diabetes	O
)	O
,	O
is	O
also	O
provided	O
.	O

Inhibitors	O
of	O
protein	O
tyrosine	B
phosphatases	O

Disclosed	O
are	O
a	O
double	O
-	O
bond	O
substituted	O
tripterygium	O
wilfordii	O
lactone	O
derivative	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
or	O
hydrate	B
thereof	O
,	O
or	O
optical	O
isomer	O
thereof	O
,	O
wherein	O
R1	O
=	O
OH	B
,	O
R2	O
=	O
H	B
,	O
or	O
R1	O
=	O
H	B
,	O
R2	O
=	O
OH	B
.	O

Also	O
disclosed	O
are	O
a	O
preparation	O
method	O
and	O
uses	O
thereof	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
treating	O
cancers	O
and	O
cancer	O
-	O
related	O
diseases	O
.	O

Double	O
-	O
bond	O
substituted	O
tripterygium	O
wilfordii	O
lactone	O
derivative	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
one	O
or	O
more	O
endocannabinoids	B
,	O
cannabinoids	B
and/or	O
modified	O
versions	O
thereof	O
complexed	O
with	O
one	O
or	O
more	O
lipoproteins	O
,	O
wherein	O
said	O
one	O
or	O
more	O
endocannabinoids	B
are	O
selected	O
from	O
N	B
-	I
acylethanolamides	I
,	O
N	B
-	I
acyl	I
dopamines	I
,	O
2-acyl	B
glycerols	I
and	O
2-glyceryl	B
ethers	I
and	O
wherein	O
said	O
one	O
or	O
more	O
cannabinoids	B
are	O
selected	O
from	O
cannabinols	B
,	O
cannabidiols	B
and	O
tetrahydrocannabinols	B
.	O

Further	O
,	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
said	O
pharmaceutical	O
composition	O
in	O
the	O
treatment	O
of	O
a	O
tumour	O
in	O
a	O
mammal	O
.	O

Also	O
,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
for	O
modulating	O
the	O
activity	O
of	O
the	O
hedgehog	O
signaling	O
pathway	O
in	O
a	O
mammalian	O
cell	O
and	O
the	O
use	O
of	O
one	O
or	O
more	O
endocannabinoids	B
,	O
cannabinoids	B
and	O
modified	O
versions	O
thereof	O
in	O
the	O
differentiation	O
of	O
embryonic	O
stem	O
cells	O
,	O
progenitor	O
cells	O
and/or	O
induced	O
stem	O
cells	O
.	O

Cannabinoids	B
for	O
the	O
treatment	O
of	O
cancers	O
dependent	O
on	O
hedgehog	O
mechanisms	O

The	O
present	O
invention	O
relates	O
to	O
[	O
ortho	O
bi-	O
(	O
hetero-	O
)	O
aryl	O
]	O
-	O
[	O
2-	O
(	O
meta	O
bi-	O
(	O
hetero-	O
)	O
aryl	O
)	O
-pyrrolidin-1-yl	O
]	O
-	O
methanone	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
,	O
and	O
the	O
rings	O
A1	O
A2	O
and	O
A3	O
are	O
as	O
described	O
in	O
the	O
description	O
,	O
to	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
to	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
to	O
their	O
use	O
as	O
pharmaceuticals	O
,	O
especially	O
to	O
their	O
use	O
as	O
orexin	O
receptor	O
antagonists	O
.	O

Orexin	O
receptor	O
antagonists	O
which	O
are	O
[	O
ortho	O
bi	O
(	O
hetero	O
)	O
aryl	O
]	O
-	O
[	O
2-	O
(	O
meta	O
bi	O
(	O
hetero	O
)	O
aryl	O
)	O
-pyrrolidin-1-yl	O
]	O
-methanone	O
derivatives	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
R1	O
is	O
a	O
hydrogen	B
atom	O
,	O
a	O
hydroxy	B
or	O
methoxy	B
group	O
,	O
a	O
halogen	B
atom	O
,	O
or	O
an	O
NO2	B
group	O
;	O
R2	O
is	O
a	O
hydrogen	B
atom	O
,	O
a	O
hydroxy	B
or	O
methoxy	B
group	O
,	O
or	O
an	O
acyl	B
or	O
aroyl	B
group	O
;	O
R3	O
is	O
hydrogen	B
,	O
trifluoroacetyl	B
(	B
C	I
(	I
=O	I
)	I
CF3	I
)	I
,	O
or	O
p	B
-	I
nitrobenzoyl	I
(	B
C	I
(	I
=O	I
)	I
PhNO2	I
)	I
,	O
and	O
in	O
each	O
case	O
the	O
wavy	O
line	O
represents	O
both	O
possible	O
configurations	O
of	O
-OR3	B
relative	O
to	O
the	O
skeleton	O
;	O
Y	O
is	O
[	B
C	I
(	I
=O	I
)	I
]	I
,	O
[	B
C	I
(	I
=N	I
)	I
-OH	I
]	I
,	O
[	B
CH	I
-	I
OH	I
]	I
,	O
or	O
[	B
CH	I
-	I
NR5R6	I
]	I
in	O
the	O
two	O
possible	O
stereoisomer	O
arrangements	O
,	O
wherein	O
R5	O
and	O
R6	O
either	O
each	O
represent	O
a	O
hydrogen	B
atom	O
or	O
a	O
hydrogen	B
atom	O
and	O
a	O
trifluoroacetyl	B
group	O
(	O
TFA	B
)	O
;	O
X	O
=	O
O	B
,	O
S	B
,	O
or	O
NR	B
,	O
in	O
which	O
R	O
=	O
hydrogen	B
or	O
a	O
C1	B
to	I
C4	I
alkyl	I
group	O
;	O
and	O
R4	O
is	O
an	O
unbranched	O
or	O
branched	O
alkyl	B
or	O
heteroalkyl	B
chain	O
with	O
a	O
chain	O
length	O
of	O
1	O
to	O
19	O
elements	O
,	O
maximally	O
6	O
heteroatoms	B
(	O
O	B
,	O
N	B
,	O
S	B
)	O
being	O
separated	O
from	O
one	O
another	O
in	O
any	O
combination	O
by	O
at	O
least	O
two	O
carbon	B
atoms	O
.	O

The	O
invention	O
further	O
relates	O
to	O
,	O
among	O
others	O
,	O
methods	O
for	O
producing	O
the	O
compounds	O
according	O
to	O
formula	O
(	O
I	O
)	O
,	O
to	O
pharmaceutical	O
compositions	O
,	O
to	O
a	O
pharmaceutical	O
kit	O
,	O
and	O
to	O
the	O
use	O
thereof	O
as	O
a	O
medicament	O
for	O
treating	O
proliferative	O
diseases	O
or	O
conditions	O
,	O
preferably	O
cancer	O
.	O

Anthracyline	B
derivatives	O
for	O
treating	O
tumor	O
diseases	O

Provided	O
is	O
a	O
novel	O
cancer	O
marker	O
that	O
is	O
useful	O
for	O
the	O
diagnosis	O
of	O
urothelial	O
cancer	O
.	O

According	O
to	O
the	O
present	O
invention	O
,	O
ubiquilin	O
2	O
is	O
used	O
as	O
a	O
cancer	O
marker	O
for	O
urothelial	O
cancer	O
(	O
renal	O
pelvic	O
cancer	O
,	O
ureteral	O
cancer	O
,	O
bladder	O
cancer	O
)	O
.	O

By	O
detecting	O
ubiquilin	O
2	O
in	O
a	O
urine	O
sample	O
,	O
the	O
risk	O
of	O
urothelial	O
cancer	O
can	O
be	O
easily	O
and	O
exactly	O
diagnosed	O
.	O

The	O
present	O
invention	O
is	O
also	O
applicable	O
to	O
the	O
diagnosis	O
of	O
squamous	O
cancer	O
(	O
esophageal	O
cancer	O
,	O
cervical	O
cancer	O
,	O
etc	O
.	O
)	O
.	O

Novel	O
cancer	O
marker	O
and	O
utilization	O
thereof	O

The	O
present	O
disclosure	O
relates	O
generally	O
to	O
alpha	O
-	O
helix	O
mimetic	O
structures	O
and	O
specifically	O
to	O
alpha	O
-	O
helix	O
mimetic	O
structures	O
that	O
are	O
inhibitors	O
of	O
β	O
-	O
catenin	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
applications	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
and	O
pre	O
-	O
cancerous	O
skin	O
conditions	O
including	O
actinic	O
keratosis	O
and	O
psoriasis	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
alpha	O
helix	O
mimetic	O
β	O
-	O
catenin	O
inhibitors	O
.	O

Treatment	O
of	O
hyperproliferative	O
and	O
pre	O
-	O
cancerous	O
skin	O
diseases	O
using	O
an	O
inhibitor	O
of	O
cbp	O
/	O
catenin	O

The	O
therapeutically	O
effective	O
,	O
medicated	O
wound	O
-	O
healing	O
aid	O
for	O
wounds	O
and	O
burns	O
relates	O
to	O
medicine	O
and	O
can	O
be	O
used	O
in	O
the	O
production	O
of	O
medicated	O
remedies	O
which	O
stimulate	O
the	O
healing	O
of	O
wounds	O
and	O
burns	O
of	O
diverse	O
etiology	O
.	O

The	O
aid	O
for	O
wounds	O
and	O
burns	O
comprises	O
an	O
absorbent	O
material	O
constituting	O
a	O
nonwoven	O
perforated	O
material	O
impregnated	O
by	O
a	O
medicament	O
which	O
constitutes	O
a	O
gel	O
-	O
like	O
mixture	O
of	O
boric	B
acid	I
,	O
hydroxypropylmethyl	O
cellulose	O
,	O
lidocaine	B
hydrochloride	I
and	O
purified	O
water	O
,	O
with	O
the	O
following	O
ratio	O
of	O
components	O
:	O
0.001	O
-	O
20.0	O
%	O
by	O
mass	O
of	O
boric	B
acid	I
,	O
0.001	O
-	O
10.0	O
%	O
by	O
mass	O
of	O
hydroxypropylmethyl	O
cellulose	O
,	O
0.001	O
-	O
10.0	O
%	O
by	O
mass	O
of	O
lidocaine	B
hydrochloride	I
,	O
with	O
the	O
remainder	O
being	O
purified	O
water	O
.	O

The	O
aid	O
additionally	O
comprises	O
0.0001	O
-	O
1.0	O
%	O
by	O
mass	O
of	O
betamethasone	B
,	O
or	O
recombinant	O
interferon	O
selected	O
from	O
the	O
group	O
:	O
alpha	O
,	O
beta	O
or	O
gamma	O
recombinant	O
interferon	O
in	O
an	O
amount	O
of	O
100	O
-	O
1000000	O
ME	O
,	O
or	O
heparin	O
in	O
an	O
amount	O
of	O
10	O
-	O
100000	O
ME	O
.	O

The	O
aid	O
is	O
in	O
the	O
form	O
of	O
medicated	O
wipes	O
,	O
bandages	O
or	O
applied	O
patches	O
applications	O
.	O

Medicated	O
wound	O
-	O
healing	O
aid	O
for	O
treating	O
wounds	O
and	O
burns	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
benzene	B
compounds	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
methods	O
of	O
treating	O
cancer	O
by	O
administering	O
these	O
compounds	O
and	O
pharmaceutical	O
compositions	O
to	O
subjects	O
in	O
need	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
research	O
or	O
other	O
non	O
-	O
therapeutic	O
purposes	O
.	O

Substituted	O
benzene	B
compounds	O

The	O
present	O
invention	O
provides	O
novel	O
compounds	O
(	O
e.g.	O
,	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
hydrates	B
,	O
polymorphs	O
,	O
co	O
-	O
crystals	O
,	O
tautomers	O
,	O
stereoisomers	O
,	O
isotopically	O
labeled	O
derivatives	O
,	O
prodrugs	O
,	O
and	O
compositions	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
and	O
kits	O
comprising	O
the	O
inventive	O
compounds	O
,	O
or	O
compositions	O
thereof	O
,	O
for	O
treating	O
and/or	O
preventing	O
a	O
fungal	O
or	O
protozoan	O
infection	O
,	O
inhibiting	O
the	O
activity	O
of	O
a	O
fungal	O
or	O
protozoan	O
enzyme	O
,	O
killing	O
a	O
fungus	O
or	O
protozoan	O
,	O
or	O
inhibiting	O
the	O
growth	O
of	O
a	O
fungus	O
or	O
protozoan	O
.	O

The	O
fungus	O
may	O
be	O
a	O
Candida	O
species	O
,	O
Sacchawmyces	O
species	O
,	O
or	O
other	O
pathogenic	O
fungal	O
species	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
may	O
inhibit	O
the	O
activity	O
of	O
fungal	O
or	O
protozoan	O
mitochondrial	O
phosphate	O
carrier	O
protein	O
.	O

Thiohydantoin	B
derivatives	O
and	O
uses	O
thereof	O

Provided	O
are	O
bifunctional	O
small	O
molecules	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
M	O
represents	O
a	O
small	O
organic	O
molecule	O
which	O
binds	O
,	O
covalently	O
or	O
non	O
-	O
covalently	O
,	O
a	O
kinase	O
,	O
such	O
as	O
Her3	O
protein	O
kinase	O
;	O
L1	O
represents	O
a	O
linker	O
;	O
and	O
RH	O
represents	O
a	O
hydrophobic	O
group	O
.	O

An	O
example	O
of	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
is	O
a	O
compound	O
of	O
Formula	O
(	O
II	O
)	O
:	O
Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
for	O
treating	O
proliferative	O
diseases	O
.	O

Hydrophobically	O
tagged	O
small	O
molecules	O
as	O
inducers	O
of	O
protein	O
degradation	O

The	O
invention	O
provides	O
novel	O
substituted	O
2-aminopyridine	B
compounds	O
according	O
to	O
Formula	O
(	O
I	O
)	O
,	O
their	O
manufacture	O
and	O
use	O
for	O
the	O
treatment	O
of	O
hyperproliferative	O
diseases	O
such	O
as	O
cancer	O
,	O
inflammatory	O
or	O
degenerative	O
diseases	O
.	O

2-aminopyridine	B
compounds	O

The	O
invention	O
provides	O
a	O
conjugate	O
comprising	O
(	O
i	O
)	O
a	O
nucleic	O
acid	O
which	O
is	O
complementary	O
to	O
a	O
target	O
nucleic	O
acid	O
sequence	O
and	O
which	O
expression	O
prevents	O
or	O
reduces	O
expression	O
of	O
the	O
target	O
nucleic	O
acid	O
and	O
(	O
ii	O
)	O
a	O
selectivity	O
agent	O
which	O
is	O
capable	O
of	O
binding	O
with	O
high	O
affinity	O
to	O
a	O
receptor	O
which	O
can	O
be	O
internalised	O
by	O
the	O
cell	O
in	O
response	O
to	O
the	O
binding	O
of	O
said	O
selectivity	O
agent	O
.	O

The	O
conjugates	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
the	O
delivery	O
of	O
the	O
nucleuc	O
acid	O
to	O
cell	O
of	O
interests	O
and	O
thus	O
,	O
for	O
the	O
treatment	O
of	O
diseases	O
which	O
require	O
a	O
down	O
-	O
regulation	O
of	O
the	O
protein	O
encoded	O
by	O
the	O
target	O
nucleic	O
acid	O
as	O
well	O
as	O
for	O
the	O
delivery	O
of	O
contrast	O
agents	O
to	O
the	O
cells	O
for	O
diagnostic	O
purposes	O
.	O

Compositions	O
and	O
methods	O
for	O
selective	O
delivery	O
of	O
oligonucleotide	B
molecules	O
to	O
cell	O
types	O

Provided	O
are	O
a	O
nerve	O
growth	O
inhibitor	O
and	O
a	O
cutaneous	O
-	O
sensory	O
-	O
irritation	O
inhibitor	O
,	O
with	O
which	O
cutaneous	O
-	O
sensory	O
irritation	O
and	O
nerve	O
growth	O
based	O
on	O
newly	O
found	O
nerve	O
growth	O
mechanisms	O
can	O
be	O
effectively	O
inhibited	O
.	O

This	O
nerve	O
growth	O
inhibitor	O
or	O
cutaneous	O
-	O
sensory	O
-	O
irritation	O
inhibitor	O
comprises	O
one	O
or	O
more	O
selected	O
from	O
:	O
(	O
1	O
)	O
a	O
specific	O
flavonoid	B
;	O
(	O
2	O
)	O
a	O
tannin	B
;	O
(	O
3	O
)	O
chlorogenic	B
acid	I
;	O
(	O
4	O
)	O
a	O
specific	O
stilbenoid	B
,	O
and	O
either	O
(	O
5	O
)	O
a	O
specific	O
crude	O
drug	O
extract	O
,	O
or	O
a	O
glycoside	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
(	O
1	O
)	O
-	O
(	O
4	O
)	O
;	O
and	O
(	O
6	O
)	O
a	O
walnut	O
polyphenol	B
.	O

Nerve	O
growth	O
inhibitor	O
,	O
cutaneous	O
-	O
sensory	O
-	O
irritation	O
inhibitor	O
,	O
and	O
marker	O
for	O
cutaneous	O
-	O
sensory	O
-	O
irritation	O
detection	O

1	O
.	O

Subject	O
matter	O
of	O
the	O
invention	O
:	O
Chitoplast	O
-	O
derma	O
and	O
a	O
method	O
for	O
the	O
use	O
of	O
a	O
composition	O
thereof	O
as	O
a	O
wound	O
dressing	O
.	O

2	O
.	O

Field	O
of	O
use	O
:	O

Medicine	O
and	O
the	O
chemical	O
and	O
pharmaceutical	O
industry	O
;	O
the	O
invention	O
can	O
be	O
used	O
as	O
a	O
therapeutic	O
agent	O
for	O
healing	O
wounds	O
of	O
various	O
etiologies	O
and	O
2nd	O
and	O
3rd	O
degree	O
burns	O
,	O
preventing	O
scarring	O
,	O
stopping	O
bleeding	O
(	O
haemostasis	O
)	O
etc	O
.	O

3	O
.	O

Essence	O
of	O
the	O
invention	O
:	O
The	O
use	O
of	O
chitosan	O
,	O
a	O
natural	O
polymer	O
,	O
to	O
create	O
a	O
hydrogel	O
composition	O
containing	O
chitosan	O
and/or	O
chitosan	O
derivatives	O
,	O
particularly	O
chitosan	O
iodide	O
,	O
glycerin	B
,	O
sodium	B
hydroxide	I
,	O
acetic	B
acid	I
,	O
biologically	O
active	O
substances	O
,	O
silver	B
nanoparticles	O
,	O
and	O
water	O
.	O

4	O
.	O

Technical	O
result	O
:	O
The	O
creation	O
of	O
the	O
optimum	O
micro	O
environment	O
for	O
wound	O
healing	O
,	O
a	O
high	O
capacity	O
for	O
absorbing	O
wound	O
exudate	O
,	O
an	O
absence	O
of	O
pyrogenic	O
,	O
antigenic	O
and	O
toxic	O
activity	O
,	O
the	O
capacity	O
for	O
creating	O
a	O
broad	O
range	O
of	O
surgical	O
dressings	O
for	O
healing	O
wounds	O
of	O
various	O
etiologies	O
and	O
agents	O
for	O
stopping	O
bleeding	O
.	O

Agent	O
for	O
healing	O
wounds	O
of	O
various	O
etiologies	O
and	O
method	O
for	O
the	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
novel	O
substituted	O
imidazo	B
[	I
1,2-a	I
]	I
pyridino-3-carboxamides	I
of	O
formula	O
(	O
I	O
)	O
in	O
which	O
R3	O
is	O
a	O
group	O
of	O
the	O
formula	O
,	O
to	O
methods	O
for	O
their	O
production	O
,	O
their	O
use	O
alone	O
or	O
in	O
combination	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
and	O
their	O
use	O
for	O
producing	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
especially	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
cardiovascular	O
diseases	O
.	O

Carboxy	B
-	I
substituted	I
imidazo	I
[	I
1,2-a	I
]	I
pyridinecarboxamides	I
and	O
their	O
use	O
as	O
soluble	O
guanylate	O
cyclase	O
stimulants	O

The	O
invention	O
relates	O
to	O
the	O
compounds	O
of	O
formula	O
I	O
or	O
its	O
pharmaceutical	O
acceptable	O
salts	O
,	O
as	O
well	O
as	O
polymorphs	O
,	O
solvates	O
,	O
enantiomers	O
,	O
stereoisomers	O
and	O
hydrates	B
thereof	O
.	O

The	O
pharmaceutical	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
compounds	O
of	O
formula	O
I	O
,	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
inflammation	O
and	O
metabolic	O
disorders	O
may	O
be	O
formulated	O
for	O
oral	O
,	O
buccal	O
,	O
rectal	O
,	O
topical	O
,	O
transdermal	O
,	O
transmucosal	O
,	O
intravenous	O
,	O
parenteral	O
administration	O
,	O
syrup	O
,	O
or	O
injection	O
.	O

Such	O
compositions	O
may	O
be	O
used	O
to	O
treatment	O
of	O
diabetes	O
,	O
lipid	O
disorders	O
,	O
cardiovascular	O
diseases	O
,	O
pain	O
and	O
inflammation	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
inflammation	O
and	O
metabolic	O
disorders	O

A	O
novel	O
amine	B
derivative	O
expressed	O
by	O
general	O
formula	O
(	O
1	O
)	O
(	O
in	O
the	O
formula	O
:	O
G1	O
,	O
G2	O
,	O
and	O
G3	O
are	O
the	O
same	O
or	O
different	O
and	O
represent	O
CH	B
or	O
a	O
nitrogen	B
atom	O
;	O
R1	O
represents	O
a	O
chlorine	B
atom	O
,	O
an	O
optionally	O
-	O
substituted	O
C3	B
-	I
8	I
cycloalkyl	I
group	O
,	O
or	O
the	O
like	O
;	O
R2	O
represents	O
-COOR5	B
(	O
in	O
the	O
formula	O
,	O
R5	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
carboxyl	B
protective	O
group	O
)	O
,	O
or	O
the	O
like	O
;	O
R3	O
represents	O
a	O
hydrogen	B
atom	O
,	O
or	O
the	O
like	O
;	O
and	O
R4	O
represents	O
an	O
optionally	O
-	O
substituted	O
condensed	O
bicyclic	B
hydrocarbon	I
group	O
,	O
an	O
optionally	O
-	O
substituted	O
bicyclic	B
heterocyclic	I
group	O
,	O
or	O
the	O
like	O
)	O
,	O
or	O
a	O
salt	O
thereof	O
is	O
useful	O
in	O
procedures	O
such	O
as	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
related	O
to	O
excessive	O
keratinocyte	O
proliferation	O
.	O

Novel	O
amine	B
derivative	O
or	O
salt	O
thereof	O

Disclosed	O
herein	O
are	O
compositions	O
comprising	O
a	O
galectin-1	O
-targeting	O
compound	O
in	O
a	O
therapeutically	O
effective	O
composition	O
for	O
treating	O
cancer	O
.	O

In	O
an	O
aspect	O
,	O
a	O
galectin-1	O
-targeting	O
compound	O
is	O
OTX-008	O
.	O

Also	O
disclosed	O
herein	O
are	O
methods	O
of	O
making	O
and	O
using	O
such	O
compositions	O
.	O

Anti	O
-	O
tumor	O
agent	O
otx-008	O
targets	O
human	O
galectin-1	O

The	O
present	O
invention	O
provides	O
tricyclic	O
fused	O
thiophene	B
derivatives	O
,	O
as	O
well	O
as	O
their	O
compositions	O
and	O
methods	O
of	O
use	O
,	O
that	O
modulate	O
the	O
activity	O
of	O
Janus	O
kinase	O
(	O
JAK	O
)	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
the	O
activity	O
of	O
JAK	O
including	O
,	O
for	O
example	O
,	O
inflammatory	O
disorders	O
,	O
autoimmune	O
disorders	O
,	O
cancer	O
,	O
and	O
other	O
diseases	O
.	O

Tricyclic	O
fused	O
thiophene	B
derivatives	O
as	O
jak	O
inhibitors	O

The	O
invention	O
relates	O
to	O
a	O
co	O
-	O
micronisation	O
product	O
comprising	O
:	O
an	O
active	O
principle	O
selected	O
from	O
the	O
group	O
containing	O
ulipristal	B
acetate	I
,	O
a	O
metabolite	O
thereof	O
and	O
mixtures	O
of	O
same	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
solid	O
surfactant	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
co	O
-	O
micronisation	O
product	O
and	O
to	O
the	O
therapeutic	O
uses	O
thereof	O
.	O

Co	O
-	O
micronisation	O
product	O
comprising	O
ulipristal	B
acetate	I

The	O
present	O
invention	O
relates	O
to	O
a	O
fixed	O
dose	O
pharmaceutical	O
composition	O
comprising	O
iron	O
chelating	O
agents	O
.	O

Fixed	O
dose	O
pharmaceutical	O
composition	O
comprising	O
deferasirox	B
and	O
deferipone	B

Vanadium	B
complexes	O
of	O
the	O
general	O
formula	O
M	O
[	O
VX	O
(	O
ONO	O
)	O
y	O
(	O
L	O
)	O
n	O
]	O
-mS	O
,	O
wherein	O
X	O
is	O
oxygen	B
or	O
is	O
absent	O
,	O
L	O
is	O
L1or	O
L2	O
,	O
wherein	O
Li	B
represents	O
a	O
halogen	B
anion	O
or	O
a	O
neutral	O
molecule	O
or	O
deprotonated	O
solvent	O
selected	O
from	O
the	O
group	O
comprising	O
C1-C12	O
alcohols	B
and/or	O
water	O
,	O
and	O
L2	O
is	O
a	O
neutral	O
or	O
anionic	O
NN	B
,	O
NO	B
or	O
OO	B
-	O
donor	O
ligand	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
polypyridine	B
,	O
1,10-phenanthroline	B
,	O
pyrones	B
,	O
quinoline	B
or	I
pyridine	I
carboxylic	I
acids	I
,	O
S	O
is	O
a	O
neutral	O
solvent	O
molecule	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
C	B
1-C4	I
alcohols	I
,	O
water	O
or	O
sulfuric	B
acid	I
,	O
M	O
may	O
be	O
absent	O
,	O
and	O
when	O
present	O
it	O
is	O
monocharged	O
alkali	B
metal	I
cation	I
,	O
ammonium	B
cation	I
,	O
alkylammonium	B
cation	I
,	O
and	O
the	O
letters	O
O	B
and	O
N	B
represent	O
atom	O
,	O
by	O
which	O
the	O
ligand	O
is	O
bound	O
to	O
vanadium	B
.	O

The	O
invention	O
also	O
includes	O
a	O
method	O
for	O
making	O
vanadium	B
complexes	O
,	O
pharmaceutical	O
preparations	O
containing	O
these	O
complexes	O
and	O
the	O
use	O
of	O
the	O
complexes	O
.	O

Vanadium	B
complexes	O
with	O
hydrazide	B
-	O
hydrazones	B
,	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
formulations	O
and	O
the	O
use	O
of	O
thereof	O
.	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutics	O
and	O
medicine	O
,	O
and	O
more	O
particularly	O
to	O
agents	O
used	O
in	O
the	O
case	O
of	O
various	O
spastic	O
states	O
of	O
smooth	O
muscle	O
,	O
particularly	O
in	O
the	O
case	O
of	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

A	O
medicinal	O
composition	O
in	O
the	O
form	O
of	O
an	O
orodispersible	O
tablet	O
for	O
pain	O
management	O
in	O
the	O
case	O
of	O
smooth	O
muscle	O
spasm	O
,	O
characterized	O
in	O
that	O
it	O
contains	O
a	O
combination	O
of	O
hyoscine	B
butylbromide	I
and	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
in	O
therapeutically	O
effective	O
quantities	O
as	O
active	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

The	O
tablets	O
have	O
increased	O
effectiveness	O
and	O
improved	O
bioavailability	O
of	O
the	O
active	O
ingredient	O
.	O

New	O
medicinal	O
composition	O
for	O
pain	O
management	O
in	O
the	O
case	O
of	O
smooth	O
muscle	O
spasm	O

The	O
instant	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
which	O
are	O
PI3K	O
-	O
delta	O
inhibitors	O
,	O
and	O
as	O
such	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
PI3K	O
-	O
delta	O
-	O
mediated	O
diseases	O
such	O
as	O
inflamation	O
,	O
asthma	O
,	O
COPD	O
and	O
cancer	O
.	O

Purine	B
inhibitors	O
of	O
human	O
phosphatidylinositol	B
3-kinase	O
delta	O

Disclosed	O
herein	O
are	O
oxiran	B
amines	I
useful	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
diseases	O
.	O

The	O
oxiran	B
amines	I
are	O
useful	O
in	O
the	O
manufacture	O
of	O
pharmaceutical	O
compositions	O
.	O

The	O
pharmaceutical	O
composition	O
may	O
be	O
used	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
a	O
disease	O
caused	O
by	O
a	O
virus	O
having	O
a	O
lipid	O
membrane	O
or	O
the	O
pharmaceutical	O
composition	O
may	O
be	O
used	O
for	O
diseases	O
requiring	O
cell	O
proliferation	O
or	O
immune	O
-	O
regulation	O
.	O

Oxiran	B
amines	I

The	O
present	O
invention	O
relates	O
to	O
disubstituted	O
N-	B
(	I
pyridin-2-yl	I
)	I
pyrimidin-4-amine	I
derivatives	O
containing	O
a	O
sulfoximine	B
group	O
of	O
general	O
formula	O
(	O
I	O
)	O
as	O
described	O
and	O
defined	O
herein	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
,	O
their	O
use	O
for	O
the	O
treatment	O
and	O
/	O
or	O
prophylaxis	O
of	O
disorders	O
,	O
in	O
particular	O
of	O
hyper-	O
proliferative	O
disorders	O
and/or	O
virally	O
induced	O
infectious	O
diseases	O
and/or	O
of	O
cardiovascular	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
intermediate	O
compounds	O
useful	O
in	O
the	O
preparation	O
of	O
said	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
.	O

N-	B
(	I
pyridin-2-yl	I
)	I
pyrimidin-4-amine	I
derivatives	O
containing	O
a	O
sulfoximine	B
group	O

The	O
gist	O
of	O
the	O
invention	O
is	O
a	O
new	O
pharmaceutical	O
composition	O
which	O
contains	O
a	O
lipid	O
phase	O
,	O
composed	O
as	O
follows	O
:	O
1.0	O
-	O
40.0	O
%	O
solid	O
lipids	O
;	O
0.1	O
-10.0	O
%	O
roxithromycin	B
;	O
1.0	O
-	O
10.0	O
%	O
surfactants	O
,	O
and	O
optionally	O
0	O
-	O
20.0	O
%	O
of	O
preservatives	O
,	O
plus	O
complementing	O
water	O
to	O
make	O
100	O
%	O
.	O

The	O
invention	O
further	O
concerns	O
application	O
of	O
the	O
pharmaceutical	O
composition	O
to	O
produce	O
medicinal	O
products	O
targeted	O
at	O
treating	O
androgenic	O
hair	O
loss	O
and/or	O
common	O
acne	O
.	O

The	O
preparation	O
method	O
of	O
the	O
pharmaceutical	O
composition	O
comprises	O
the	O
following	O
stages	O
:	O
the	O
aqueous	O
phase	O
and	O
components	O
of	O
the	O
lipid	O
phase	O
are	O
heated	O
separate	O
to	O
the	O
temperature	O
of	O
75	O
-	O
85	O
°	O
C	O
;	O
both	O
phases	O
are	O
combined	O
and	O
homogenised	O
,	O
and	O
the	O
obtained	O
microemulsion	O
is	O
cooled	O
down	O
to	O
the	O
room	O
temperature	O
;	O
after	O
the	O
cooling	O
,	O
preservatives	O
are	O
added	O
.	O

Solid	O
lipid	O
nanoparticles	O
of	O
roxithromycin	B
for	O
hair	O
loss	O
or	O
acne	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
:	O
or	O
a	O
stereoisomer	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
all	O
of	O
the	O
variables	O
are	O
as	O
defined	O
herein	O
.	O

These	O
compounds	O
are	O
GPR40	O
G	O
protein	O
-	O
coupled	O
receptor	O
modulators	O
which	O
may	O
be	O
used	O
as	O
medicaments	O
.	O

Dihydropyrazole	B
gpr40	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
crystal	O
forms	O
of	O
4-	B
{	I
[	I
4-	I
(	I
{	I
[	I
4-	I
(	I
2,2,2-trifluoroethoxy	I
)	I
-1,2-benzisoxazol-3-yl	I
]	I
oxy	I
}	I
methyl	I
)	I
piperidin-1-yl	I
]	I
methyl	I
}	I
-tetrahydro-2H	I
-	I
pyran-4-carboxylic	I
acid	I
.	I

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
polymorph	O
forms	O
(	O
Polymorph	O
Form	O
I	O
,	O
Polymorph	O
Form	O
II	O
,	O
Polymorph	O
Form	O
III	O
,	O
Polymorph	O
Form	O
IV	O
,	O
Polymorph	O
Form	O
V	O
,	O
and	O
Polymorph	O
Form	O
VI	O
)	O
,	O
and	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
,	O
compositions	O
containing	O
and	O
to	O
uses	O
of	O
,	O
such	O
polymorph	O
forms	O
.	O

Polymorph	O
forms	O

The	O
inhibitory	O
oligonucleotides	O
(	O
ODNs	O
)	O
which	O
strongly	O
block	O
NF-	O
κ	O
B	O
activation	O
induced	O
by	O
TLR9	O
agonists	O
and	O
TLR7	O
agonists	O
are	O
provided	O
.	O

The	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
interleukin-6	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
is	O
inhibited	O
by	O
the	O
inhibitory	O
-	O
ODNs	O
.	O

Interferon	O
production	O
from	O
human	O
PBMC	O
induced	O
by	O
TLR9	O
agonist	O
is	O
prevented	O
by	O
the	O
inhibitory	O
-	O
ODNs	O
.	O

These	O
ODNs	O
can	O
be	O
used	O
as	O
a	O
remedy	O
for	O
the	O
treatment	O
of	O
immune	O
-	O
mediated	O
disorders	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
sepsis	O
,	O
multiple	O
organ	O
dysfunction	O
syndromes	O
.	O

Inhibitory	O
oligonucleotide	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
combinations	O
of	O
metformin	B
or	O
related	O
biguanides	O
such	O
as	O
phenformin	B
,	O
buformin	B
or	O
proguanil	B
,	O
with	O
particular	O
metformin	O
sensitizing	O
compounds	O
that	O
have	O
the	O
capability	O
to	O
sensitize	O
rapidly	O
proliferating	O
cells	O
to	O
metformin	O
or	O
related	O
biguanides	O
in	O
such	O
a	O
way	O
that	O
combinations	O
cause	O
cell	O
lethality	O
at	O
concentrations	O
where	O
neither	O
metformin	B
alone	O
nor	O
such	O
metformin	B
sensitizing	O
compounds	O
alone	O
exert	O
appreciable	O
cell	O
lethality	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
such	O
combinations	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
for	O
achieving	O
immunosuppression	O
.	O

Combinations	O
of	O
metformin	B
with	O
other	O
compounds	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
for	O
immunosuppression	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
of	O
preparation	O
of	O
Crystal	O
Forms	O
of	O
4-	B
(	I
cyclopropylmethoxy	I
)	I
-N-	I
(	I
3,5-dichloro-1-oxidopyridin-4-yl	I
)	I
-5-methoxypyridine-2-	I
carboxamide	I
of	O
formula	O
(	O
I	O
)	O
,	O
said	O
Crystal	O
Forms	O
which	O
are	O
designated	O
as	O
Crystal	O
Forms	O
A	O
to	O
I	O
A	O
and	O
their	O
use	O
as	O
a	O
medicament	O
.	O

METHOD	O
OF	O
PREPARATION	O
OF	O
CRYSTAL	O
FORMS	O
OF	O
4-	B
(	I
CYCLOPROPYLMETHOXY	I
)	I
-N-	I
(	I
3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl	I
)	I
-5-METHOXYPYRIDINE-2-CARBOXAMIDE	I
AND	O
CRISTAL	O
FORMS	O
THEREOF	O

The	O
present	O
invention	O
relates	O
to	O
a	O
knot	O
-	O
wood	O
extract	O
comprising	O
at	O
least	O
one	O
lignan	B
selected	O
from	O
the	O
list	O
comprising	O
(	B
-	I
)	I
-hydroxymatairesinol	I
(	O
two	O
epimers	O
;	O
7S	O
,	O
8R	O
,	O
8'R	O
and	O
7R	O
,	O
8R	O
,	O
8'R	O
)	O
,	O
(	B
-	I
)	I
(	I
7S	I
,	I
8R	I
,	I
8'R	I
)	I
-hydroxymatairesinol	I
,	O
(	B
+	I
)	I
-lariciresinol	I
,	O
(	B
-	I
)	I
-secoisolariciresinol	I
,	O
liovil	B
and	O
any	O
epimers	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
activating	O
a	O
β2	O
adrenergic	O
receptor	O
,	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
knot	O
-	O
wood	O
extract	O
of	O
the	O
invention	O
or	O
of	O
at	O
least	O
one	O
lignan	B
selected	O
from	O
the	O
list	O
comprising	O
(	B
-	I
)	I
-hydroxymatairesinol	I
(	O
two	O
epimers	O
;	O
7S	O
,	O
8R	O
,	O
8'R	O
and	O
7R	O
,	O
8R	O
,	O
8'R	O
)	O
,	O
(	B
-	I
)	I
(	I
7S	I
,	I
8R	I
,	I
8'R	I
)	I
-hydroxymatairesinol	I
,	O
(	B
+	I
)	I
-lariciresinol	I
,	O
(	B
-	I
)	I
-secoisolariciresinol	I
,	O
liovil	B
and	O
any	O
epimers	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treating	O
a	O
β2	O
adrenergic	O
receptor	O
related	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
knot-	O
wood	O
extract	O
of	O
the	O
invention	O
or	O
of	O
at	O
least	O
one	O
lignan	B
selected	O
from	O
the	O
list	O
comprising	O
(	B
-	I
)	I
-hydroxymatairesinol	I
(	O
two	O
epimers	O
;	O
7S	O
,	O
8R	O
,	O
8'R	O
and	O
7R	O
,	O
8R	O
,	O
8'R	O
)	O
,	O
(	B
-	I
)	I
(	I
7S	I
,	I
8R	I
,	I
8'R	I
)	I
-hydroxymatairesinol	I
,	O
(	B
+	I
)	I
-lariciresinol	I
,	O
(	B
-	I
)	I
-secoisolariciresinol	I
,	O
liovil	B
and	O
any	O
epimers	O
thereof	O
.	O

Natural	O
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
beta-2	O
adrenergic	O
receptor	O
related	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
stabilizing	O
a	O
fusion	O
protein	O
of	O
a	O
bioactive	O
protein	O
and	O
an	O
Fc	O
domain	O
,	O
and	O
relates	O
to	O
a	O
method	O
for	O
stabilizing	O
a	O
fusion	O
protein	O
of	O
a	O
protein	O
and	O
an	O
Fc	O
domain	O
by	O
using	O
a	O
composition	O
containing	O
an	O
ammonium	B
salt	O
,	O
or	O
an	O
ammonium	B
salt	O
and	O
a	O
succinate	B
.	O

The	O
composition	O
containing	O
an	O
ammonium	B
salt	O
,	O
or	O
an	O
ammonium	B
salt	O
and	O
a	O
succinate	O
,	O
according	O
to	O
the	O
present	O
invention	O
,	O
effectively	O
inhibits	O
the	O
aggregation	O
of	O
an	O
Fc	O
-	O
fusion	O
protein	O
,	O
thereby	O
enabling	O
the	O
fusion	O
protein	O
to	O
be	O
stored	O
for	O
a	O
long	O
time	O
,	O
and	O
thus	O
can	O
be	O
widely	O
used	O
in	O
the	O
medical	O
field	O
using	O
an	O
Fc	O
-	O
fusion	O
protein	O
.	O

Composition	O
for	O
stabilizing	O
fusion	O
protein	O
in	O
which	O
protein	O
and	O
fc	O
domain	O
are	O
fused	O

A	O
TARP	O
γ8	O
dependant	O
AMPA	O
receptor	O
antagonist	O
of	O
the	O
formula	O
:	O
(	O
I	O
)	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
uses	O
,	O
and	O
methods	O
for	O
its	O
preparation	O
are	O
described	O
.	O

6-	B
(	I
(	I
s	I
)	I
-1-	I
{	I
1-	I
[	I
5-	I
(	I
2-hydroxy	I
-	I
ethoxy	I
)	I
-pyridin-2-yl	I
]	I
-1h	I
-	I
pyrazol-3-yl	I
}	I
-ethyl	I
)	I
-3h-1,3-benzothiazol-2-one	I
as	O
a	O
tarp	O
-	O
gamma	O
8	O
dependent	O
ampa	O
receptor	O
antagonist	O

In	O
one	O
aspect	O
,	O
the	O
invention	O
provides	O
a	O
stabilized	O
lipid	O
-	O
based	O
glycopeptide	O
antibiotic	O
composition	O
and	O
a	O
process	O
for	O
producing	O
the	O
same	O
.	O

In	O
another	O
aspect	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
treating	O
a	O
bacterial	O
pulmonary	O
infection	O
by	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
stabilized	O
lipid	O
-	O
based	O
glycopeptide	O
antibiotic	O
composition	O
.	O

Stabilized	O
vancomycin	B
formulations	O

Disclosed	O
in	O
the	O
invention	O
are	O
a	O
deuterated	B
3-cyano	I
quinoline	I
compound	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
prodrugs	O
,	O
stereoisomers	O
,	O
tautomers	O
,	O
polymorphic	O
substances	O
,	O
metabolites	O
etc	O
.	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
these	O
compounds	O
or	O
compositions	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
treating	O
or	O
preventing	O
tumours	O
,	O
especially	O
drugs	O
such	O
as	O
protein	O
kinase	O
inhibitors	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
have	O
the	O
clear	O
advantages	O
of	O
properties	O
such	O
as	O
plasma	O
drug	O
concentration	O
,	O
half	O
-	O
life	O
,	O
clearance	O
,	O
microsomal	O
stability	O
,	O
bioavailability	O
or	O
enzyme	O
inhibition	O
and	O
the	O
like	O
,	O
and	O
thus	O
can	O
more	O
effectively	O
inhibit	O
the	O
activities	O
of	O
more	O
than	O
one	O
protein	O
kinase	O
and/or	O
inhibit	O
the	O
growth	O
of	O
tumuor	O
cells	O
.	O

Deuterated	B
3-cyano	I
quinoline	I
compound	O
,	O
pharmaceutical	O
composition	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

Methods	O
,	O
compositions	O
of	O
matter	O
,	O
medical	O
devices	O
,	O
and	O
kits	O
useful	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
conditions	O
are	O
disclosed	O
comprising	O
of	O
administering	O
cells	O
and/or	O
nucleic	O
acids	O
into	O
the	O
cardiac	O
venous	O
system	O
in	O
a	O
retrograde	O
manner	O
so	O
as	O
to	O
obtain	O
tissue	O
perfusion	O
of	O
said	O
cells	O
and/or	O
nucleic	O
acids	O
.	O

In	O
one	O
embodiment	O
,	O
administration	O
of	O
endometrial	O
regenerative	O
cells	O
in	O
a	O
retrograde	O
manner	O
is	O
disclosed	O
.	O

Additionally	O
,	O
nucleic	O
acids	O
capable	O
of	O
suppressing	O
inflammation	O
and/or	O
inhibition	O
of	O
pathological	O
remodeling	O
may	O
be	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
said	O
cells	O
.	O

Retrograde	O
delivery	O
of	O
cells	O
and	O
nucleic	O
acids	O
for	O
treatment	O
of	O
cardiovascular	O
diseases	O

Disclosed	O
herein	O
are	O
maytansinoid	O
drug	O
linker	O
derivatives	O
which	O
can	O
be	O
linked	O
to	O
a	O
antigen	O
binding	O
unit	O
(	O
Abu	O
)	O
,	O
and	O
maytansinoid	B
drugs	O
linked	O
with	O
an	O
antigen	O
binding	O
unit	O
(	O
Drug-	O
Linker	O
-	O
Antigen	O
binding	O
Unit	O
:	O
D	O
-	O
L	O
-	O
Abu	O
)	O
,	O
for	O
targeted	O
delivery	O
to	O
disease	O
tissues	O
.	O

D	B
-	I
L	I
-	I
Abu	I
,	O
D	B
-	I
L-	I
Abu	I
derivatives	O
,	O
and	O
methods	O
relating	O
to	O
the	O
use	O
of	O
such	O
drug	O
conjugates	O
to	O
treat	O
antigen	O
positive	O
cells	O
in	O
cancers	O
and	O
immunological	O
disorders	O
are	O
provided	O
.	O

Maytansinoid	B
derivatives	O

This	O
invention	O
relates	O
to	O
novel	O
ALK	O
inhibitors	O
of	O
Formula	O
I	O
:	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
ALK	O
inhibitors	O
.	O

Deuterated	O
alk	O
inhibitors	O

The	O
invention	O
relates	O
to	O
a	O
DNA	O
aptamer	O
that	O
can	O
inhibit	O
the	O
enzymatic	O
activity	O
of	O
tyrosinase	O
for	O
the	O
conversion	O
of	O
tyrosine	B
into	O
L	B
-	I
DOPA	I
and	O
dopaquinone	B
,	O
and	O
to	O
the	O
dermatological	O
and	O
cosmetic	O
uses	O
thereof	O
.	O

Aptamers	O
inhibiting	O
the	O
enzymatic	O
activity	O
of	O
tyrosinase	O

Disclosed	O
is	O
use	O
of	O
glycyrrhetinic	B
acid	I
or	O
glycyrrhizic	B
acid	I
in	O
preventing	O
or	O
treating	O
radiation	O
injury	O
of	O
soft	O
tissue	O
.	O

Therefore	O
,	O
glycyrrhetinic	B
acid	I
or	O
glycyrrhizic	B
acid	I
can	O
be	O
used	O
for	O
preparing	O
medicaments	O
for	O
preventing	O
or	O
treating	O
radiation	O
injury	O
of	O
soft	O
tissue	O
.	O

The	O
medicament	O
prepared	O
from	O
glycyrrhetinic	B
acid	I
or	O
glycyrrhizic	B
acid	I
has	O
advantages	O
of	O
low	O
cost	O
,	O
good	O
curative	O
effect	O
,	O
low	O
toxicity	O
and	O
side	O
effect	O
during	O
administration	O
in	O
long	O
term	O
and	O
so	O
on	O
.	O

Glycyrrhetinic	B
acid	I
or	O
glycyrrhizic	B
acid	I
can	O
also	O
be	O
used	O
for	O
preparing	O
health	O
care	O
products	O
,	O
foods	O
or	O
food	O
additives	O
for	O
preventing	O
or	O
treating	O
radiation	O
injury	O
of	O
soft	O
tissue	O
.	O

Use	O
of	O
glycyrrhetinic	B
acid	I
or	O
glycyrrhizic	B
acid	I
in	O
preparing	O
medicaments	O
for	O
preventing	O
or	O
treating	O
radiation	O
injury	O
of	O
soft	O
tissue	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
protecting	O
nerve	O
cells	O
from	O
nerve	O
cell	O
death	O
induced	O
by	O
kainic	B
acid	I
by	O
pretreating	O
nerve	O
cells	O
with	O
anthocyanin	B
,	O
and	O
to	O
a	O
composition	O
comprising	O
anthocyanin	B
,	O
as	O
an	O
active	O
ingredient	O
,	O
for	O
protecting	O
nerve	O
cells	O
from	O
death	O
induced	O
by	O
kainic	B
acid	I
.	O

Since	O
anthocyanin	B
of	O
the	O
present	O
invention	O
has	O
the	O
effect	O
of	O
protecting	O
nerve	O
cells	O
from	O
nerve	O
cell	O
death	O
induced	O
by	O
kainic	B
acid	I
,	O
anthocyanin	B
can	O
be	O
used	O
to	O
study	O
and	O
develop	O
a	O
drug	O
related	O
to	O
preventing	O
neurodegenerative	O
diseases	O
associated	O
with	O
nerve	O
cell	O
death	O
.	O

Use	O
of	O
anthocyanin	B
for	O
protecting	O
nerve	O
cells	O

The	O
present	O
invention	O
provides	O
for	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
various	O
embodiments	O
thereof	O
,	O
and	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
various	O
embodiments	O
thereof	O
.	O

(	O
I	O
)	O
In	O
compounds	O
of	O
Formula	O
I	O
,	O
the	O
groups	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
have	O
the	O
meaning	O
as	O
described	O
herein	O
.	O

The	O
present	O
invention	O
also	O
provides	O
for	O
methods	O
of	O
using	O
compounds	O
of	O
Formula	O
I	O
and	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
as	O
DLK	O
inhibitors	O
and	O
for	O
treating	O
neurodegeneration	O
diseases	O
and	O
disorders	O
.	O

3-substituted	B
pyrazoles	I
and	O
use	O
as	O
dlk	O
inhibitors	O

Disclosed	O
is	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
m	O
are	O
as	O
described	O
herein	O
,	O
as	O
a	O
modulator	O
of	O
nicotinic	O
acetylcholine	B
receptors	O
particularly	O
α7	O
subtype	O
,	O
its	O
tautomeric	O
forms	O
,	O
its	O
stereoisomers	O
,	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
its	O
pharmaceutical	O
composition	O
,	O
and	O
its	O
combinations	O
with	O
suitable	O
medicaments	O
.	O

Also	O
disclosed	O
are	O
a	O
process	O
of	O
preparation	O
of	O
the	O
compounds	O
and	O
the	O
intended	O
uses	O
thereof	O
in	O
therapy	O
,	O
particularly	O
in	O
the	O
prophylaxis	O
and	O
therapy	O
of	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
mild	O
cognitive	O
impairment	O
,	O
senile	O
dementia	O
,	O
and	O
the	O
like	O
.	O

Pyrrole	B
derivatives	O
as	O
alpha	O
7	O
nachr	O
modulators	O

This	O
disclosure	O
provides	O
compositions	O
,	O
kits	O
,	O
and	O
methods	O
useful	O
for	O
treating	O
or	O
preventing	O
viral	O
and	O
bacterial	O
infection	O
and	O
reducing	O
or	O
preventing	O
the	O
effects	O
of	O
toxins	O
.	O

The	O
methods	O
comprise	O
administering	O
to	O
a	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
liposomal	O
composition	O
.	O

Multivalent	O
liposome	O
formulations	O

The	O
invention	O
relates	O
to	O
novel	O
substituted	O
condensed	O
pyrimidine	B
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
in	O
which	O
the	O
chemical	O
groupings	O
,	O
substituents	O
and	O
indices	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
and	O
to	O
their	O
use	O
as	O
medicaments	O
,	O
in	O
particular	O
as	O
medicaments	O
for	O
the	O
treatment	O
of	O
conditions	O
and	O
diseases	O
that	O
can	O
be	O
treated	O
by	O
inhibition	O
of	O
the	O
PDE4	O
enzyme	O
.	O

Novel	O
substituted	O
condensed	O
pyrimidine	B
compounds	O

The	O
disclosure	O
provides	O
compositions	O
and	O
methods	O
for	O
counteracting	O
the	O
effects	O
of	O
direct	O
activated	O
Factor	O
X	O
(	O
FXa	O
)	O
inhibitors	O
in	O
a	O
subject	O
by	O
administering	O
a	O
variant	O
of	O
FXa	O
.	O

Compositions	O
and	O
methods	O
for	O
counteracting	O
factor	O
xa	O
inhibition	O

The	O
invention	O
is	O
a	O
method	O
and	O
composition	O
for	O
treating	O
a	O
topical	O
microbial	O
infection	O
in	O
a	O
subject	O
.	O

The	O
method	O
includes	O
the	O
step	O
of	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
polyether	B
ionophore	I
,	O
or	O
a	O
therapeutically	O
acceptable	O
salt	O
thereof	O
,	O
to	O
the	O
subject	O
.	O

Methods	O
of	O
treating	O
topical	O
microbial	O
infections	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
quinoxaline	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
as	O
positive	O
allosteric	O
modulators	O
for	O
modulating	O
metabotropic	O
glutamate	B
receptor	O
subtype	O
4	O
(	O
mGluR4	O
)	O
and/or	O
altering	O
glutamate	B
level	O
or	O
glutamatergic	O
signalling	O
.	O

Substituted	O
quinoxaline	B
derivatives	O
and	O
their	O
use	O
as	O
positive	O
allosteric	O
modulators	O
of	O
mglur4	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrazoles	B
,	O
processes	O
for	O
preparing	O
them	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
as	O
modulators	O
of	O
sphingosine-1-	B
phosphate	I
receptors	O
.	O

Claimed	O
are	O
compounds	O
of	O
Markush	O
formula	O
(	O
I	O
)	O
:	O

[	O
Formula	O
should	O
be	O
inserted	O
here	O
]	O

A	O
typical	O
example	O
for	O
a	O
Markush	O
formula	O
(	O
I	O
)	O
compound	O
is	O
example	O
7	O
:	O
Example	O
7	O
[	O
Formula	O
should	O
be	O
inserted	O
here	O
]	O
Substituted	O
4,5-dihydropyrazole-1,2,4-oxadiazole	B
derivatives	O
as	O
sphingosine	B
receptor	O
modulators	O

Compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
salts	O
thereof	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
associated	O
with	O
aberrant	O
activity	O
of	O
the	O
protein	O
kinases	O
ΙΚΚε	O
and/or	O
TBK-1	O
in	O
which	O
one	O
of	O
V	O
and	O
W	O
is	O
N	B
,	O
and	O
the	O
other	O
of	O
V	O
and	O
W	O
is	O
C	B
-	I
H	I
;	O
and	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
provides	O
uses	O
of	O
the	O
compounds	O
and	O
compositions	O
containing	O
them	O
.	O

Pyrimidine	B
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
ikke	O
and/or	O
tbk1	O
mechanisms	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
containing	O
piroxicam	B
in	O
a	O
carrier	O
substance	O
,	O
for	O
use	O
in	O
the	O
prophylactic	O
and	O
therapeutic	O
treatment	O
of	O
CMV	O
infections	O
.	O

Piroxicam	B
for	O
use	O
in	O
the	O
prophylactic	O
and	O
therapeutic	O
treatment	O
of	O
cmv	O
infections	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
chroman-6-yloxy	B
-	I
cycloalkanes	I
of	O
the	O
formula	O
(	O
I	O
)	O
in	O
which	O
Ar	O
,	O
R1	O
to	O
R4	O
,	O
p	O
and	O
q	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O

The	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
are	O
inhibitors	O
of	O
the	O
sodium	B
-	O
calcium	B
exchanger	O
(	O
NCX	O
)	O
,	O
especially	O
of	O
the	O
sodium	B
-	O
calcium	B
exchanger	O
of	O
subtype	O
1	O
(	O
NCX1	O
)	O
,	O
and	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diverse	O
disorders	O
in	O
which	O
intracellular	O
calcium	B
homeostasis	O
is	O
disturbed	O
,	O
such	O
as	O
arrhythmias	O
,	O
heart	O
failure	O
and	O
stroke	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
their	O
use	O
as	O
pharmaceuticals	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
.	O

Substituted	O
chroman-6-yloxy	B
-	I
cycloalkanes	I
and	O
their	O
use	O
as	O
pharmaceuticals	O

The	O
invention	O
provides	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
10	O
)	O
.	O

The	O
cyclometallating	O
ligand	O
of	O
compound	O
(	O
10	O
)	O
includes	O
an	O
N	O
-	O
donor	O
heterocyclic	B
ligand	O
(	O
2	O
)	O
where	O
at	O
least	O
one	O
X	O
is	O
nitrogen	B
and	O
which	O
is	O
directly	O
bonded	O
to	O
a	O
phenyl	B
group	O
.	O

The	O
phenyl	B
group	O
is	O
orthometallated	O
to	O
the	O
platinum	B
.	O

The	O
donor	O
atoms	O
(	O
Y	O
)	O
of	O
the	O
bidentate	O
stabilizing	O
ligand	O
are	O
N	B
or	O
O.	B
The	O
invention	O
further	O
provides	O
methods	O
of	O
producing	O
photoluminescence	O
and	O
electroluminescence	O
,	O
methods	O
of	O
applying	O
the	O
compounds	O
in	O
thin	O
film	O
,	O
and	O
uses	O
of	O
the	O
compounds	O
of	O
the	O
invention	O
in	O
a	O
light	O
emitting	O
device	O
,	O
a	O
luminescent	O
probe	O
,	O
a	O
sensor	O
,	O
and/or	O
an	O
electroluminescent	O
device	O
.	O

Luminescent	O
compounds	O
and	O
methods	O
of	O
using	O
same	O

Methods	O
of	O
altering	O
microenvironmental	O
levels	O
of	O
Vascular	O
Endothelial	O
Growth	O
Factor	O
in	O
a	O
subject	O
are	O
disclosed	O
.	O

The	O
methods	O
include	O
providing	O
a	O
Granzyme	O
B	O
(	O
GzmB	O
)	O
inhibitor	O
to	O
an	O
area	O
of	O
inflammation	O
.	O

The	O
area	O
of	O
inflammation	O
can	O
be	O
associated	O
with	O
conditions	O
that	O
have	O
an	O
associated	O
increase	O
in	O
vascular	O
permeability	O
,	O
including	O
for	O
example	O
,	O
rheumatoid	O
arthritis	O
,	O
myocardial	O
infarction	O
,	O
ocular	O
disease	O
,	O
skin	O
conditions	O
,	O
such	O
as	O
psoriasis	O
,	O
and	O
dermatitis	O
,	O
cancer	O
,	O
transplantation	O
,	O
and/or	O
arthrosclerosis	O
,	O
and	O
the	O
like	O
.	O

The	O
Granzyme	O
B	O
inhibitor	O
can	O
be	O
comprised	O
of	O
,	O
but	O
not	O
limited	O
to	O
,	O
a	O
nucleic	O
acid	O
,	O
a	O
polypeptide	O
,	O
a	O
Granzyme	O
B	O
specific	O
antibody	O
,	O
a	O
Granzyme	O
B	O
antibody	O
derivative	O
,	O
or	O
a	O
small	O
molecule	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
inhibition	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
activity	O
and	O
vascular	O
permeability	O

The	O
invention	O
provides	O
novel	O
compounds	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
Y	O
,	O
A	O
,	O
W	O
,	O
R2	O
,	O
m	O
,	O
n	O
,	O
p	O
and	O
q	O
are	O
as	O
described	O
herein	O
,	O
compositions	O
including	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O

New	O
octahydro	B
-	I
pyrrolo	I
[	I
3,4-c	I
]	I
-pyrrole	I
derivatives	O
and	O
analogs	O
thereof	O
as	O
autotaxin	O
inhibitors	O

The	O
use	O
of	O
PRX933	O
for	O
the	O
acute	O
treatment	O
of	O
hypertension	O
.	O

Prx933	O
(	O
prx-00933	O
)	O
,	O
a	O
5ht2c	O
agonist	O
,	O
for	O
use	O
in	O
the	O
treatment	O
of	O
hypertension	O

The	O
invention	O
relates	O
to	O
methods	O
of	O
inducing	O
insulin	O
production	O
in	O
non	O
-	O
beta	O
-	O
cells	O
or	O
converting	O
non	O
-	O
beta	O
-	O
cells	O
into	O
insulin	O
producing	O
cells	O
,	O
as	O
well	O
as	O
methods	O
of	O
preventing	O
and/or	O
treating	O
diabetes	O
and	O
methods	O
of	O
predicting	O
the	O
susceptibility	O
of	O
a	O
diabetic	O
subject	O
to	O
a	O
treatment	O
.	O

Use	O
of	O
insulin	O
signaling	O
antagonists	O
,	O
optionally	O
in	O
combination	O
of	O
transfection	O
of	O
non	O
-	O
beta	O
cells	O
,	O
for	O
inducing	O
insulin	O
production	O

A	O
compound	O
represented	O
by	O
formula	O
(	O
J	O
)	O
or	O
crystals	O
thereof	O
,	O
or	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
Q	O
)	O
or	O
crystals	O
thereof	O
.	O

Hydrate	B
of	O
fluorine	B
compound	O
,	O
and	O
crystals	O
thereof	O

Tetrahydroisoquinolin-2-yl-	B
(	I
quinazolin-4-yl	I
)	I
methanone	I
derivatives	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
pharmacologically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
compositions	O
containing	O
such	O
compounds	O
are	O
described	O
.	O

Methods	O
for	O
treating	O
hyperproliferative	O
disorders	O
by	O
administering	O
the	O
compounds	O
are	O
also	O
described	O
.	O

1,2,3,4-tetrahydroisoquinoline	B
derivatives	O
for	O
making	O
tetrahydroisoquinolin-2-yl-	B
(	I
quinazolin-4-yl	I
)	I
methanone	I
compounds	O
are	O
also	O
described	O
.	O

Tetrahydroisoquinolin-2-yl-	B
(	I
quinazolin-4-yl	I
)	I
methanone	I
compounds	O
as	O
cancer	O
cell	O
growth	O
inhibitors	O

The	O
disclosure	O
provides	O
crystalline	O
Sovaprevir	B
forms	O
.	O

The	O
crystalline	O
forms	O
of	O
Sovaprevir	B
comprise	O
a	O
Form	O
A	O
polymorph	O
,	O
a	O
Form	O
B	O
polymorph	O
,	O
a	O
Form	O
C	O
polymorph	O
,	O
a	O
Form	O
D	O
polymorph	O
,	O
and	O
a	O
Form	O
E	O
polymorph	O
.	O

The	O
Form	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
,	O
and	O
E	O
polymorphs	O
exhibit	O
X	O
-	O
ray	O
powder	O
diffraction	O
patterns	O
having	O
peak	O
locations	O
in	O
accordance	O
with	O
Figs.	O
1	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
and	O
13	O
,	O
respectively	O
.	O

Sovaprevir	B
polymorphs	O
and	O
methods	O
of	O
manufacture	O
thereof	O

Provided	O
are	O
compounds	O
of	O
Formula	O
I	O
,	O
a	O
JAK	O
inhibitor	O
,	O
and	O
use	O
thereof	O
for	O
the	O
treatment	O
of	O
JAK	O
-	O
mediated	O
diseases	O
by	O
the	O
application	O
.	O

N-	O
(	O
2-cyano	O
heterocyclyl	O
)	O
pyrazolo	O
pyridones	O
as	O
janus	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicinal	O
chemistry	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
β	B
-	I
aminocarbonyl	I
compound	O
as	O
represented	O
by	O
general	O
formula	O
I	O
,	O
or	O
tautomer	O
,	O
enantiomer	O
,	O
racemate	O
and	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
preparation	O
method	O
and	O
pharmaceutical	O
composition	O
thereof	O
,	O
and	O
use	O
thereof	O
as	O
a	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPP-4	O
)	O
inhibitor	O
.	O

The	O
compound	O
or	O
pharmaceutical	O
composition	O
thereof	O
can	O
be	O
used	O
as	O
a	O
DPP-4	O
inhibitor	O
to	O
treat	O
type	O
II	O
diabetes	O
,	O
hyperglycaemia	O
,	O
obesity	O
,	O
or	O
insulin	O
-	O
resistance	O
syndromes	O
.	O

Β	B
-	I
aminocarbonyl	I
compound	O
,	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
use	O
in	O
the	O
treatment	O
of	O
metabolic	O
oxidative	O
alterations	O
in	O
non	O
-	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
,	O
wherein	O
said	O
composition	O
comprises	O
silybin	B
and	O
wherein	O
the	O
treatment	O
is	O
administered	O
to	O
patients	O
having	O
an	O
altered	O
lipidomic	O
profile	O
.	O

Patients	O
having	O
altered	O
lipidomic	O
profile	O
show	O
an	O
high	O
TBARS	O
value	O
in	O
TBARS	O
test	O
(	O
lipid	O
peroxidation	O
marker	O
)	O
with	O
respect	O
to	O
healthy	O
subjects	O
.	O

Silybin	B
for	O
the	O
treatment	O
of	O
metabolic	O
oxidative	O
alterations	O
in	O
patients	O
with	O
non	O
-	O
alcoholic	O
steatohepatitis	O
(	O
nash	O
)	O

The	O
present	O
invention	O
relates	O
to	O
an	O
isolated	O
EGF	O
receptor	O
agonist	O
for	O
use	O
in	O
the	O
treatment	O
of	O
chronic	O
liver	O
diseases	O
associated	O
with	O
a	O
low	O
hepcidin	O
expression	O
such	O
as	O
alcoholic	O
liver	O
disease	O
,	O
chronic	O
hepatitis	O
C	O
,	O
or	O
genetic	O
hemochromatosis	O
.	O

Method	O
and	O
pharmaceutical	O
composition	O
for	O
use	O
in	O
the	O
treatment	O
of	O
chronic	O
liver	O
diseases	O
associated	O
with	O
a	O
low	O
hepcidin	O
expression	O

Phenylephrine	B
particles	O
suitable	O
for	O
solid	O
,	O
semi	O
solid	O
or	O
liquid	O
dosage	O
forms	O
are	O
disclosed	O
.	O

Phenylephrine	B
resinate	O
particles	O
and	O
use	O
thereof	O
in	O
pharmaceutical	O
formulations	O

Sequestrants	O
of	O
AGE	O
precursors	O
comprise	O
amines	O
separated	O
by	O
2	O
,	O
3	O
or	O
4	O
carbons	O
.	O

Sequestrants	O
of	O
AGE	O
precursors	O
can	O
be	O
used	O
as	O
pharmaceutical	O
agents	O
and	O
in	O
pharmaceutical	O
compositions	O
.	O

The	O
sequestrants	O
of	O
AGE	O
precursors	O
are	O
particularly	O
useful	O
binding	O
AGE	O
precursors	O
and	O
dietary	O
dicarbonyls	O
in	O
mammals	O
in	O
the	O
gastrointestinal	O
tract	O
for	O
the	O
treatment	O
of	O
ailments	O
such	O
as	O
diabetic	O
nephropathy	O
,	O
chronic	O
renal	O
disease	O
,	O
atherosclerosis	O
,	O
stroke	O
,	O
cataracts	O
,	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Sequestrants	O
of	O
advanced	O
glycation	O
end	O
product	O
(	O
age	O
)	O
precursors	O

Methods	O
of	O
treating	O
,	O
managing	O
or	O
preventing	O
psoriatic	O
arthritis	O
are	O
disclosed	O
.	O

Specific	O
methods	O
encompass	O
the	O
administration	O
of	O
apremilast	B
,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
second	O
active	O
agent	O
.	O

Treatment	O
of	O
psoriatic	O
arthritis	O
using	O
apremilast	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
(	O
I	O
)	O
and	O
solvates	O
,	O
hydrates	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
ring	O
A	O
,	O
R1	O
,	O
R5	O
and	O
R6	O
are	O
as	O
defined	O
herein	O
,	O
useful	O
as	O
FLAP	O
modulators	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
.	O

Methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
also	O
within	O
the	O
scope	O
of	O
the	O
invention	O
.	O

1,2,5-substituted	B
benzimidazoles	I
as	O
flap	O
modulators	O

Treating	O
Sonic	O
Hedgehog	O
-	O
Associated	O
Medulloblastoma	O
comprises	O
inhibiting	O
the	O
synthesis	O
or	O
biologic	O
activity	O
of	O
leukotrienes	B
that	O
drive	O
Nestin	O
expression	O
in	O
cancerous	O
or	O
precancerous	O
granule	O
neuron	O
precursors	O
and	O
that	O
further	O
drive	O
growth	O
and	O
proliferation	O
of	O
medulloblastoma	O
cells	O
through	O
Nestin	O
-	O
mediated	O
aberrant	O
Sonic	O
Hedgehog	O
signaling	O
.	O

Inhibition	O
of	O
leukotriene	B
synthesis	O
and	O
activity	O
in	O
the	O
treatment	O
of	O
sonic	O
hedgehog	O
-	O
associated	O
medulloblastoma	O

The	O
present	O
invention	O
encompasses	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
groups	O
ring	O
A	O
and	O
Cy	O
are	O
defined	O
herein	O
,	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
BTK	O
,	O
process	O
of	O
making	O
,	O
pharmaceutical	O
preparations	O
which	O
contain	O
compounds	O
and	O
their	O
methods	O
of	O
use	O
.	O

5-thiazolecarboxamide	B
dervatives	O
and	O
their	O
use	O
as	O
btk	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
salt	O
forms	O
of	O
(	B
S	I
)	I
-Quinuclidin-3-yl	I
(	I
2-	I
(	I
2-	I
(	I
4-fluorophenyl	I
)	I
thiazol-4-yl	I
)	I
propan-2-yl	I
)	I
carbamate	I
useful	O
as	O
an	O
inhibitor	O
of	O
glucosylceramide	O
synthase	O
(	O
GCS	O
)	O
and	O
for	O
the	O
treatment	O
metabolic	O
diseases	O
,	O
such	O
as	O
lysosomal	O
storage	O
diseases	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
enzyme	O
replacement	O
therapy	O
,	O
and	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

SALT	O
FORMS	O
OF	O
(	B
S	I
)	I
-Quinuclidin-3-yl	I
(	I
2-	I
(	I
2-	I
(	I
4-fluorophenyl	I
)	I
thiazol-4-yl	I
)	I
propan-2-yl	I
)	I
carbamate	I

Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
can	O
modulate	O
the	O
activity	O
of	O
one	O
or	O
more	O
SIP	B
receptors	O
and/or	O
the	O
activity	O
of	O
autotaxin	O
(	O
ATX	O
)	O
.	O

Formula	O
(	O
1	O
)	O
S1p	B
and/or	O
atx	O
modulating	O
agents	O

The	O
present	O
invention	O
concerns	O
a	O
process	O
for	O
obtaining	O
(	B
±	I
)	I
-cis-2-dimethylaminomethyl-1-	I
(	I
3-methoxyphenyl	I
)	I
-	I
cyclohexanol	I
comprising	O
the	O
following	O
steps	O
:	O
a	O
)	O
extraction	O
from	O
roots	O
of	O
Nauclea	O
Latifolia	O
with	O
an	O
appropriate	O
solvent	O
,	O
leading	O
to	O
a	O
crude	O
residue	O
,	O
and	O
b	O
)	O
purification	O
of	O
said	O
crude	O
residue	O
to	O
obtain	O
a	O
purified	O
residue	O
containing	O
(	B
±	I
)	I
-cis-2-dimethylaminomethyl-1-	I
(	I
3-methoxyphenyl	I
)	I
cyclohexanol	I
.	O

Extraction	O
of	O
tramadol	B
from	O
nauclea	O
latifolia	O
smith	O

The	O
invention	O
refers	O
to	O
an	O
oligonucleotide	B
consisting	O
of	O
10	O
to	O
18	O
nucleotides	O
of	O
selected	O
regions	O
of	O
the	O
TGF	O
-	O
beta2	O
nucleic	O
acid	O
sequence	O
,	O
which	O
comprises	O
modified	O
nucleotides	O
such	O
as	O
LNA	O
,	O
ENA	O
,	O
polyalkylene	B
oxide-	I
,	O
2'-fluoro	B
,	O
2'-O	B
-	I
methoxy	I
and/or	O
2'-O	B
-	I
methyl	I
modified	O
nucleotides	O
.	O

The	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
such	O
oligonucleotide	B
,	O
wherein	O
the	O
composition	O
or	O
the	O
oligonucleotide	B
is	O
used	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
a	O
malignant	O
and/or	O
benign	O
tumor	O
,	O
an	O
immunologic	O
disease	O
,	O
fibrosis	O
,	O
or	O
an	O
ophthalmic	O
disease	O
such	O
as	O
dry	O
eye	O
,	O
glaucoma	O
or	O
posterior	O
capsular	O
opacification	O
(	O
PCO	O
)	O
.	O

Modified	O
tgf	O
-	O
beta2	O
oligonucleotides	B

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
25-hydroxyvitamin	B
D3	I
(	O
25-OH	B
D3	I
)	O
to	O
increase	O
or	O
maintain	O
or	O
alternatively	O
,	O
to	O
lessen	O
the	O
decrease	O
of	O
the	O
cognitive	O
element	O
known	O
as	O
executive	O
functioning	O
in	O
healthy	O
individuals	O
.	O

Optionally	O
,	O
25-OH	B
D3	I
may	O
be	O
administered	O
in	O
combination	O
with	O
Vitamin	B
D	I
or	O
other	O
ingredients	O
.	O

Use	O
of	O
25-hydroxyvitamin	B
d3	I
to	O
enhance	O
executive	O
functions	O

A	O
propellane	B
derivative	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
(	O
wherein	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
,	O
a	O
cycloalkylalkyl	B
group	O
(	O
wherein	O
the	O
number	O
of	O
carbon	B
atoms	O
in	O
a	O
cycloalkyl	B
moiety	O
is	O
3	O
to	O
6	O
and	O
the	O
number	O
of	O
carbon	B
atoms	O
in	O
an	O
alkylene	B
moiety	O
is	O
1	O
to	O
5	O
)	O
,	O
an	O
aralkyl	B
group	O
(	O
wherein	O
the	O
number	O
of	O
carbon	B
atoms	O
in	O
an	O
aryl	B
moiety	O
is	O
6	O
to	O
10	O
and	O
the	O
number	O
of	O
carbon	B
atoms	O
in	O
an	O
alkylene	B
moiety	O
is	O
1	O
to	O
5	O
)	O
or	O
the	O
like	O
;	O
R2	O
represents	O
a	O
hydroxy	B
group	O
,	O
a	O
C1	B
-	I
6	I
alkoxy	I
group	O
or	O
the	O
like	O
;	O
V	O
represents	O
CH	B
or	O
N	B
;	O
W	O
,	O
X	O
,	O
Y	O
and	O
Z	O
independently	O
represent	O
CR3	B
or	O
N	B
,	O
wherein	O
a	O
case	O
in	O
which	O
each	O
of	O
W	O
,	O
X	O
,	O
Y	O
and	O
Z	O
represents	O
N	B
is	O
excluded	O
,	O
and	O
W	O
,	O
X	O
,	O
Y	O
and	O
Z	O
may	O
be	O
the	O
same	O
as	O
or	O
different	O
from	O
one	O
another	O
when	O
each	O
of	O
at	O
least	O
two	O
of	O
W	O
,	O
X	O
,	O
Y	O
and	O
Z	O
represents	O
CR3	B
;	O
and	O
R3	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
halogen	B
atom	O
,	O
a	O
nitro	B
group	O
,	O
a	O
C1	B
-	I
6	I
alkyl	I
group	O
or	O
the	O
like	O
)	O
,	O
a	O
tautomer	O
,	O
stereoisomer	O
or	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
tautomer	O
,	O
stereoisomer	O
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
which	O
can	O
be	O
used	O
as	O
an	O
analgesic	O
agent	O
or	O
the	O
like	O
.	O

Propellane	B
derivative	O

Small	O
molecule	O
LRRK2	O
and	O
ERK5	O
inhibitors	O
are	O
provided	O
,	O
as	O
well	O
as	O
methods	O
for	O
their	O
use	O
in	O
treating	O
or	O
preventing	O
cancer	O
and/or	O
neurodegenerative	O
disorders	O
.	O

Small	O
molecule	O
lrrk2	O
and	O
erk5	O
inhibitors	O

Provided	O
herein	O
are	O
solid	O
forms	O
comprising	O
(	O
a	O
)	O
4-amino	B
-	I
l	I
-	I
β	I
-	I
D	I
-	I
ribofuranosyl-1,3,5-triazin-2	I
(	I
1	I
H	I
)	I
-one	I
(	O
known	O
as	O
5-azacytidine	B
)	O
and	O
(	O
b	O
)	O
a	O
coformer	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
the	O
solid	O
forms	O
(	O
e.g.	O
,	O
cocrystals	O
)	O
and	O
methods	O
for	O
treating	O
,	O
preventing	O
and	O
managing	O
various	O
disorders	O
are	O
also	O
disclosed	O
.	O

SOLID	O
FORMS	O
COMPRISING	O
4-AMINO	B
-	I
I	I
-	I
β	I
-	I
D	I
-	I
RIBOFURANOSYL-1,3,5-TRIAZIN-2	I
(	I
1H	I
)	I
-ONE	I
AND	O
A	O
COFORMER	O
,	O
COMPOSITIONS	O
AND	O
METHODS	O
OF	O
USE	O
THEREOF	O

The	O
present	O
invention	O
relates	O
to	O
SGLT2	O
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
form	O
thereof	O
for	O
use	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
a	O
metabolic	O
disorder	O
of	O
an	O
equine	O
animal	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
relates	O
the	O
SGLT2	O
inhibitor	O
or	O
a	O
pharmaceutically	O
acceptable	O
form	O
thereof	O
for	O
use	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
insulin	O
resistance	O
,	O
hyperinsulinemia	O
,	O
impaired	O
glucose	O
tolerance	O
,	O
dyslipidemia	O
,	O
dysadipokinemia	O
,	O
subclinical	O
inflammation	O
,	O
systemic	O
inflammation	O
,	O
low	O
grade	O
systemic	O
inflammation	O
,	O
obesity	O
,	O
and/or	O
regional	O
adiposity	O
in	O
an	O
equine	O
animal	O
.	O

Treatment	O
of	O
metabolic	O
disorders	O
in	O
equine	O
animals	O

There	O
are	O
provided	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
to	O
R5	O
,	O
Ak	O
and	O
X1	O
to	O
X3	O
have	O
meanings	O
given	O
in	O
the	O
description	O
,	O
which	O
compounds	O
have	O
antiinflammatory	O
activity	O
(	O
e.g.	O
through	O
inhibition	O
of	O
one	O
or	O
more	O
of	O
members	O
of	O
:	O
the	O
family	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
enzymes	O
;	O
Syk	O
kinase	O
;	O
and	O
members	O
of	O
the	O
Src	O
family	O
of	O
tyrosine	O
kinases	O
)	O
and	O
have	O
use	O
in	O
therapy	O
,	O
including	O
in	O
pharmaceutical	O
combinations	O
,	O
especially	O
in	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
,	O
including	O
inflammatory	O
diseases	O
of	O
the	O
lung	O
,	O
eye	O
and	O
intestines	O
.	O

Kinase	O
inhibitors	O
based	O
upon	O
n	B
-	I
alkyl	I
pyrazoles	I

This	O
invention	O
is	O
directed	O
to	O
compositions	O
having	O
synergistic	O
combinations	O
of	O
omega-3	B
fatty	I
acid	I
such	O
as	O
OMEGA-3	O
with	O
a	O
tomato	O
extract	O
lycopene	B
,	O
and	O
optionally	O
with	O
carnosic	B
acid	I
and/or	O
lutein	B
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
provides	O
compositions	O
having	O
synergistic	O
combinations	O
of	O
the	O
aforementioned	O
compounds	O
,	O
which	O
may	O
be	O
used	O
,	O
inter	O
alia	O
,	O
to	O
inhibit	O
/	O
suppress	O
inflammation	O
via	O
the	O
suppression	O
of	O
the	O
expression	O
of	O
anti	O
-	O
inflammatory	O
mediators	O
or	O
via	O
the	O
suppression	O
of	O
the	O
secretion	O
of	O
anti	O
-	O
inflammatory	O
mediators	O
from	O
macrophages	O
at	O
a	O
site	O
of	O
inflammation	O
.	O

Anti	O
-	O
inflammatory	O
synergistic	O
combinations	O
comprising	O
omega-3	B
fatty	I
acid	I
and	O
tomato	O
lycopene	B

Compounds	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
a	O
Flavivirus	O
infection	O
in	O
a	O
subject	O
are	O
provided	O
.	O

The	O
methods	O
comprise	O
administering	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
as	O
described	O
herein	O
.	O

The	O
methods	O
are	O
useful	O
in	O
treating	O
and/or	O
preventing	O
Flavivirus	O
infections	O
such	O
as	O
,	O
for	O
example	O
,	O
West	O
Nile	O
Virus	O
,	O
Dengue	O
Virus	O
,	O
and	O
Japanese	O
Encephalitis	O
Virus	O
.	O

Methods	O
of	O
inhibiting	O
a	O
Flavivirus	O
protease	O
in	O
a	O
cell	O
are	O
also	O
provided	O
.	O

Dengue	O
and	O
west	O
nile	O
virus	O
protease	O
inhibitors	O

